ÃÄ«~¥N½X,ÃÄ«~¾Ç¦W,ÃÄ«~¦WºÙ,ÃÄ«~¤ÀÃþ,¾AÀ³¯g,¸T§Ò,°Æ§@¥Î,Àx¦s,¥Îªk¥Î¶q,¨x¥\¯à²§±`(Y/N),¨x¥\¯à²§±`»¡©ú,µÇ¥\¯à²§±`(Y/N),Ãh¥¥¥ÎÃÄ¦MÀI¤À¯Å,¥¥´Á¥ÎÃÄ«ØÄ³,¥¥´Áªþ±a»¡©ú,­÷¨Å´Á¥ÎÃÄ«ØÄ³,­÷¨Å´Áªþ±a»¡©ú,µ¹ÃÄ³~®|,°®¯»µ}ÄÀ²G,¿éª`ÂIºw²G,IVP¥Îªk«ØÄ³,IVD¥Îªk«ØÄ³,ª`·N¨Æ¶µ
OEZE,Ezetimibe,Ezetrol 10mg,CAVS,,¾AÀ³¯g:¬°­°¦å¯×ÃÄ(B024058100),,RT,10 mg once daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OELME,Dihydroergotoxine,Elmesatt 2mg,CAVS,,¾AÀ³¯g:Adjunct in treating symptoms of mild to moderate dementia in the elderly °Æ§@¥Î: Abdominal cramps¡A nausea¡A vomiting¡A headache¡A blurred vision¡A skin rashes¡A nasal congestion¡A flushing of the skin¡A dizziness¡A bradycardia¡A & orthostatic hypotension ¸T§Ò: Severe bradycardia.,,«Ç·Å,Should be taken with food 1 tab tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OCHA1,Varenicline,CHAMPIX 1mg,ZADT,Aid to smoking cessation treatment.,,Nausea¡A sleep disturbance¡A constipation¡A flatulence¡A vomiting. Diarrhea¡A gingivitis¡A chest pain¡A flu-like illness¡A edema¡A thirst¡A abnormal liver function test¡A increased weight¡A arthralgia¡A back pain¡A muscle cramp¡A musculoskeletal pain¡A myalgia¡A attention disturbance¡A dizziness¡A sensory disturbance¡A anxiety¡A depression¡A emotional disorder¡A irritability¡A restlessness¡A polyuria¡A menstrual disorder¡A epistaxis¡A respiratory disorders¡A hyperhidrosis¡A hot flush¡A HTN. Gastrointestinal: Constipation (5% to 8% )¡A Flatulence (6% to 9% )¡A Nausea (16% to 40% )¡A Vomiting (1% to 5% ) Neurologic: Dream disorder (9% to 13% )¡A Headache (15% to 19% )¡A Insomnia (18% to 19% ),25¢J,"Days 1-3: 0.5 mg once daily.Days 4-7: 0.5 mg twice daily.Days 8 and later (maintenance): 1 mg twice daily. Continue maintenance dose for at least 11 weeks to 1 year (for a total of at least 12 weeks of treatment).Approaches to selecting a tobacco quit date: May either choose a fixed quit date (ie¡A start varenicline¡A then quit on day 8) or a flexible quit date (ie¡A start varenicline¡A then quit between days 8-35). Alternatively¡A consider a gradual quit date (ie¡A start varenicline and reduce smoking 50% by week 4¡A reduce an additional 50% by week 8¡A and continue reducing with a goal of complete abstinence by week 12) followed by a maintenance dose for 12 weeks (for a total of at least 24 weeks of treatment).",µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EAZE,Azelastine,Azela nasal spray 100dose,TENT,,¾AÀ³¯g: Allergic rhinitis. °Æ§@¥Î: Rarely¡A irritation of inflamed nasal mucosa on spraying. Improper administration may produce a taste disturbance. Gastrointestinal: Abnormal taste in mouth¡A Bitter (nasal¡A 4% to 19.7%; ophthalmic¡A approximately 10% ) Neurologic: Headache (nasal¡A 1% to 14.8%; ophthalmic¡A approximately 15% )¡A Somnolence (up to 11.5% ) Ophthalmic: Burning sensation in eye (ophthalmic¡A 30% ) Respiratory: Epistaxis (1% to 7% )¡A Nasal irritation (nasal¡A 1% to 4% )¡A Pharyngitis (nasal¡A 3.8%; ophthalmic¡A 1% to 10% )¡A Rhinitis (adults nasal¡A 2.3%; children nasal¡A 17%; ophthalmic¡A 1% to 10% )¡A Sneezing (3.1% ) Other: Fatigue (nasal¡A 2% to 2.3%; ophthalmic¡A 1% to 10% ),,«Ç·Å,>6 ys 1 puff into each nostril bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EPAT,NaCl + KCl + Boric Acid,Patear eye lotion 10mL,TOPH,Dry eyes¡A eye wash solution.,People with a history of allergy to the ingredients of this medicine.,Occasional eye redness¡A swelling¡A burning¡A and stinging sensation.,25¢J¥H¤U,Usually 2-3 drops at a time¡A apply 5-6 times a day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
OCON1,Bisoprolol,Concor 1.25mg±dªÖ¿õ,CAVS,1.25 mg & 2.5 mg tab Stable chronic moderate to severe heart failure. 5 mg & 10 mg tab Management of hypertension¡A angina pectoris & stable¡A chronic moderate to severe heart failure (NYHA class III¡A IV).,Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy¡A cardiogenic shock¡A AV block of grades II & III (without pacemaker)¡A sick sinus syndrome¡A SA block¡A bradycardia with < 60 beats/min; severe bronchial asthma or severe COPD¡A hypotension (systolic BP < 100 mmHg)¡A advanced stages of peripheral arterial circulatory disturbance & Raynaud's syndrome¡A untreated pheochromocytoma¡A metabolic acidosis.,Feeling of coldness or numbness in the extremities¡A nausea¡A vomiting¡A diarrhea¡A constipation. Tiredness¡A exhaustion¡A dizziness¡A headache (occur at the beginning of the therapy & usually disappear within 1-2 weeks). Gastrointestinal: Diarrhea (2.6% to 3.5% ) Neurologic: Headache (8.8% to 10.9% ) Respiratory: Rhinitis (2.9% to 4% )¡A Upper respiratory infection (4.8% to 5% .) Other: Fatigue (6.6% to 8.2%),25¢J¥H¤U,Stable mild to server chronic heart failure: Patient must be treated at optimal dose with an ACE inhibitor¡A a diuretic¡A & optionally cardiac glycosides¡A prior to the administration of bisoprolol. Titrate gradually as follows: Week 1: 1.25 mg QD. Week 2: 2.5 mg QD. Week 3: 3.75 mg QD. Week 4-7: 5 mg QD. Week 8-11: 7.5 mg QD. Week 12 and beyond: 10 mg QD as maintenance therapy. Maximum: 10 mg daily.,µL»Ý½Õ¾ã¾¯¶q,«ØÄ³ªì©l¾¯¶q: 2.5 mg ORALLY once daily ³Ì°ª¾¯¶q:10 mg ORALLY once daily,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] Ãh¥¥´Á¶¡¡A±dªÖ¥²¶·¸g¹LÂå®v¤p¤ßµû¦ô¨ä§Q¯q»P­·ÀI«á¤~¯à¨Ï¥Î¡C¤@¯ë»¡¨Ó¡A£]-ªýÂ_¾¯·|­°§C­L½Lªº¦å¬y¶q¡A¦]¦¹¦³¥i¯à·|¼vÅT­L¨àªºµo¨|¡C¦b³oºØ±¡ªp¤U¡AÀ³ºÊ´ú­L½L¤Î¤l®cªº¦å¬y¶q»P­L¨àªº¥Íªøµo¨|ª¬ªp¡A­Y¹ïÃh¥¥¤Î­L¨à³y¦¨¤£¨}¼vÅT¡A«hÀ³¦Ò¼{§ï¥Î¨ä¥Lªº´À¥N©ÊªvÀø¡C ·s¥ÍÀ¦¨à¦b¥X¥Í«áÀ³¤©¥HÄY±KºÊ´ú¡C³q±`¦å¿}­°§C¤Î¯ß·i´î½wªº¯gª¬¦³¥i¯à¦b¥X¥Í«áªº 3 ¤Ñ¤º¥X²{¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e©|µL¦³Ãö bisoprolol fumarate ¤Àªc©ó¥À¨Å¤ÎÀ¦¨àÄá¨ú bisoprolol fumarate ªº¦w¥þ©Ê¼Æ¾Ú¡C ¦]¦¹¡A¤£«ØÄ³©ó±Â¨Å´Á¶¡ªA¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
IHEP,Heparin,Heparin inj 25KIU/5mL,HEMT,,¾AÀ³¯g: Unstable angina; Venous thromboembolism; Peripheral arterial embolism¡A Prevention of re-occlusion of the coronary arteries following thrombolytic therapy ¡A Venous thromboembolism ¡AProphylaxis of post-op venous thromboembolism¡A Prevention of mural thrombosis °Æ§@¥Î:Slight fever¡A headache¡A chills¡A nausea¡A vomiting¡A constipation¡A epistaxis¡A bruising¡A slight haematuria¡A skin necrosis (SC inj)¡A osteoporosis¡A alopecia. Hypersensitivity reactions include urticaria¡A conjunctivitis¡A rhinitis¡A asthma¡A angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding Dermatologic: Erythema¡A Injection site ulcer¡A After deep subcutaneous injection Hematologic: Hematoma¡A Heparin-induced thrombocytopenia (up to 30% ) Neurologic: Pain (Mild) Other: Irritation symptom¡A Local ¸T§Ò: Patients predisposed to active bleeding including thrombocytopenia¡A peptic ulcer disease¡A cerebrovascular disorders¡A haemorrhagic blood disorders¡A bacterial endocarditis¡A severe hypertension¡A oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage¡A abdominal or thoracic bleeding into closed space¡A severe traumatic bleed¡A hepatic¡A renal¡A splenic or arterial injury¡A severe haemostatic defect¡A arterial thrombosis with heparin-associated thrombocytopenia. IM admin.,,15-30¢J,IV Unstable angina; Venous thromboembolism; Peripheral arterial embolism Loading dose: 5¡A000 u¡A then 1¡A000-2¡A000 u/hr. Prevention of re-occlusion of the coronary arteries following thrombolytic therapy in MI 5¡A000 u¡A then 1¡A000 u/hr w/ alteplase. SC Venous thromboembolism 15¡A000 u 12 hrly. Prophylaxis of post-op venous thromboembolism 5¡A000 u 2 hr before surgery¡A then 8-12 hrly for 7 days or until patient is ambulant. Prevention of mural thrombosis 12¡A500 u 12 hrly for at least 10 days,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IHBIG,Hepatitis B Immune Globulin,HBIG (B¨x§K¬Ì²y³J¥Õ¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Prophylaxis of hepatitis B.,Severe platelet deficiency or other coagulation disorders.,Occasionally temporary tenderness at inj site¡A skin reactions & elevations of temperature.,2-8¢JÁ×§K§N­á,IM¡A acute exposure to blood containing HBsAg 0.06 mL/kg within 24 hours. Prophylaxis of infants born to HBsAg & HBeAg postive mothers 0.5 mL to be given within 12 hours of birth. Sexual exposure to an HBsAg postive person 0.06 mL/kg as a single dose within 14 days of sexual contact. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ]¥¥°ü¨Ï¥Î«á¬O§_·|¶Ë®`­L¨à¡B©Î¼vÅT¥Í´Þ¯à¤O¤]¤£¤Ó²M·¡¡A°ß¦³©ú½T»Ý­n®É¤~¥i§ë»P¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
ODAL3,Flurazepam,Dalmadorm 30mg,CNEU,,,,,,,,,,,,,,,,,,,
OPROG,Progesterone,Progeffik 100mg,HM,,¾AÀ³¯g: Progesterone eficiency¡A Luteal insufficiency: premenstrual syndrome¡A benign mastopathy¡A menstrual irregularities¡A Prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogen HRT ¡A Oocyte donation programme from the day of transfer till pregnancy is confirmed¡A Luteal support in IVF or embryo transfer starting with the day of inj of hCG up to the 12th week of pregnancy¡A Repeated abortions up to the 12th week of pregnancy. °Æ§@¥Î: Abdominal pain¡A perineal pain¡A headache¡A constipation¡A diarrhea¡A nausea¡A joint pain¡A depression¡A decreased libido¡A nervousness¡A somnolence¡A breast tenderness & pain¡A dyspareunia¡A nocturia¡A allergy¡A bloating¡A cramps¡A fatigue¡A pain¡A dizziness¡A vomiting¡A genital moniliasis & pruritus¡A aggressive reactions¡A forgetfulness¡A vag dryness¡A cystitis¡A UTI¡A vag discharge. Gastrointestinal: Abdominal pain (oral¡A 10% to 20%; vaginal gel¡A 5% to 12%; vaginal insert¡A 12% )¡A Constipation (vaginal gel¡A 27%; vaginal insert¡A 2% to 3% )¡A Nausea (oral¡A 8%; vaginal gel¡A 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral¡A 7% to 12% ) Musculoskeletal: Cramp (vaginal gel¡A 15% to 26% ) Neurologic: Dizziness (oral¡A 15% to 24%; vaginal gel¡A 5% )¡A Headache (oral¡A 10% to 31%; vaginal gel¡A 13% to 19%¡A vaginal insert¡A 3% to 4% )¡A Sleep disorder (vaginal gel¡A 18% )¡A Somnolence (vaginal gel¡A 27% ) Psychiatric: Depression (oral¡A 19%; vaginal gel¡A 11% to 19% )¡A Feeling nervous (vaginal gel¡A 16% )¡A Mood swings (oral¡A 6%; vaginal gel¡A 22% to 23% ) Reproductive: Breast tenderness (oral¡A 16% to 27% )¡A Large breast (vaginal gel¡A 40% )¡A Pain¡A Post-oocyte retrieval (vaginal insert¡A 25% to 28% )¡A Pain of breast (oral¡A 6% to 16%; vaginal gel¡A 13% )¡A Perineal pain (vaginal gel¡A 17% ) Other: Fatigue (oral¡A 8% to 9%; vaginal gel¡A 21% to 22%; vaginal insert¡A 2% to 3% ) ¸T§Ò: Undiagnosed vag bleeding; known or suspected malignancy of breast or genital organs; severe liver dysfunction or disease; thrombophlebitis¡A thromboembolic disorders¡A cerebral apoplexy or patients with a history of these conditions; missed abortion; as a diagnostic test for pregnancy.,,«Ç·Å,Revention: 200-400 mg q8h on the 1st day¡A then 100-200 mg q8h afterward till 36th week of pregnancy. Supplement: 100-200 mg hs x 10-14 days (may give an extra 100 mg in the morning if needed) starting from the 12th day of the menstrual cycle.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ESER1,Salmeterol + Fluticasone,SERETIDE 125 EVOHALER,ERSP,Regular treatment of reversible obstructive airways disease (ROAD)¡A including asthma in adult & children¡A where combination therapy (bronchodilator & inhaled corticosteroid) is appropriate. Seretide Accuhaler 250/Seretide Evohaler 125/Seretide Evohaler 250 Maintenance treatment of COPD including chronic bronchitis & emphysema.,History of hypersensitivity to any of the ingredients of Seretide.,Hoarseness or dysphonia¡A throat irritation¡A headache¡A candidiasis of mouth & throat¡A palpitations¡A tremor¡A paradoxical bronchospasm¡A arthralgia. Gastrointestinal: Nausea (COPD¡A above 5% )¡A Oral candidiasis (asthma¡A 1% to 4%; COPD¡A 10% ) Musculoskeletal: Musculoskeletal pain (asthma¡A 2% to 7%; COPD¡A 9% ) Neurologic: Dizziness (asthma¡A 1% to 4%; COPD¡A 4% and greater )¡A Headache (9% to 21% ) Respiratory: Bronchitis (asthma¡A 2% to 8% )¡A Cough (asthma¡A 3% to 6% )¡A Difficulty speaking¡A Hoarse¡A Pharyngitis (asthma¡A 10% to 13% )¡A Throat irritation (7% to 9% )¡A Upper respiratory infection (asthma¡A 16% to 27%; COPD¡A greater than 5% )¡A Viral lower respiratory infection (3% to 6% ),°®ÀêÁ×ÅÎ30¢J¥H¤U,Asthma: Adults and adolescents 12 years and older: Two inhalations of 25 mcg salmeterol and 125 mcg fluticasone propionate twice daily. or Two inhalations of 25 mcg salmeterol and 250 mcg fluticasone propionate twice daily. Children 4 years and older: 2 inhalation of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily. There are no recommended doses available in children aged under 4 years. Chronic Obstructive Pulmonary Disease (COPD): For adult patients the recommended dose is 2 inhalation 50/250 micrograms to 50/500 micrograms salmeterol/fluticasone propionate twice daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,SALMETEROL PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible FLUTICASONE PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,SALMETEROL BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible FLUTICASONE BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IH;INHL;,,,,,
IRECB,Epoetin beta,Recormon inj 2000IU(­­¬~µÇ«Ç¥Î),HEMT,Treatment of anaemia associated w/ chronic renal failure (CRF) in patients on dialysis; treatment of symptomatic renal anaemia in patient not yet undergoing dialysis. Treatment of symptomatic anaemia in adult patients w/ non-myeloid malignancies receving chemotherapy. Increasing the yield of autologous blood from patients in pre-donation programmes. Prevention of anaemia in premature infant (<34 wk; 750-1¡A500 g birth wt).,Hypersensitivity. Poorly controlled HTN. Patients¡A who in the mth preceding treatment¡A have suffered a MI or stroke. Unstable angina pectoris. Patients at risk of DVT.,Increased BP¡A increased platelet count¡A encephalopathy-like symptoms¡A thromboembolic event¡A rash¡A pruritus¡A urticaria or inj site reactions.,2-8¢JÁ×¥ú,Anaemia with CRF: (Initially)SC¡A 3 x 20 IU/kg/week ¡A if the increase of hemoglobin level is inadequate (<0.25g/dL per week)¡A may be increased every 4 week by 3 x 20 IU/kg/week; IV¡A 3 x 40 IU/kg¡A may up to 80 IU/kg after 4 weeks¡A 3 times a week. (Maintenance) Half of initial dose¡A depend on individuals. Symptomatic anemia in patients with tumors/Multiple myeloma/Low grade non-Hodgkin¡¦s lymphoma/Chronic lymphocytic leukemia: Initial dose of 450 IU/kg/week¡A may up to 900 IU/kg/week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,EPOETIN ALFA: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk ¥é³æ¸ê®Æ¡G °Êª«¬ã¨s¨Ã¥¼Åã¥Ü¥»«~·|¹ïÃh¥¥¡B­F­L/­L¨àµo¨|¡B¤À®Y©Î¥X¥Í«áµo¨|³y¦¨ª½±µ©Î¶¡±µªº¶Ë®`¡C ´Nepoetin beta¦Ó¨¥¡A¦bÃh¥¥´Á¶¡±µÄ²¨ì®e¥i°Ò¦³Ãöªº©Ò¦³¦w¥þ©Ê¸ê®Æ¡A³£¬O·½¦Û¤W¥««áªº¨Ï¥Î¸gÅç¡C ¦b¤@¶µ°w¹ï²{¦³¤§¤W¥««á¸ê®Æ©Ò¶i¦æªº±´°Q¤¤¡A¨Ã¥¼µo²{¥ô¦óÃÒ¾ÚÅã¥ÜÃh¥¥¡B­F­L/­L¨àµo¨|©Î¥X¥Í«á µo¨|¤è­±ªº¶Ë®`§@¥Î©M¨Ï¥Î®e¥i°ÒªvÀø¤§¶¡¦³¦]ªG¤WªºÃöÁp©Ê¡C ¤£¹L¡A¥Ñ©ó¯Ê¥FÁ{§É¬ã¨sªº¸ê®Æ¡A¹ïÃh¥¥°ü¤k³B¤è¥»«~®É¤´À³ÂÔ·V±q¨Æ¡C,Unknown ¨S¦³¸ê®Æ,EPOETIN ALFA: Compatible ¥é³æ¸ê®Æ¡G ¦b¤HÃþ±Â¨Å´Á¶¡¨Ï¥Î¥»«~¥Ø«e¶È¦³¦³­­ªº¸gÅç¡C¤º·½©Ê¬õ¦å²y¥Í¦¨¯À·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¨Ã¥B «Ü®e©ö¬°·s¥Í¨àªº­G¸z¹D©Ò§l¦¬¡CÀ³¿Å¶qÁý­÷¥À¨Å¹ï¨àµ£ªº®Ä¯q¥H¤Î¨Ï¥Îepoetin betaªvÀø¹ï°ü¤kªº ®Ä¯q¡A¦A°µ¥X¬O§_­nÄ~Äò©Î°±¤îÁý­÷¥À¨Å¡A©Î¬O§_­nÄ~Äò©Î°±¤î¨Ï¥Îepoetin betaªvÀø¤§¨M©w¡C,IVD;IVPUSH;SC;,,,ª`®gÃÄ¾¯ªº®É¶¡­n¤j©ó¨â¤ÀÄÁ¡A¦å²G³zªR¯f¤H¥i¥H¦b¬~µÇµ²§ô®É¸g¥Ñ°Ê-ÀR¯ß°úºÞ¶i¦æª`®g¡C,ÀR¯ßª`®g®É¡Aª`®gÃÄ¾¯ªº®É¶¡­n¤j©ó¨â¤ÀÄÁ¡A¦å²G³zªR¯f¤H¥i¥H¦b¬~µÇµ²§ô®É¸g¥Ñ°Ê-ÀR¯ß°úºÞ¶i¦æª`®g¡C,1.¦b¨S¦³¬Û®e©Ê¬ã¨sªº±¡ªp¤U¡A¥»«~¤£¥i»P¨ä¥¦ÃÄª«²V¦X¨Ï¥Î¡C 2.°t»s¦n·»²G¥i¥H¸g¥Ñ¥Ö¤U©Î¬OÀR¯ßª`®g¨Ï¥Î¡C·í¨Ï¥ÎÀR¯ßª`®g®É¡Aª`®gÃÄ¾¯ªº®É¶¡­n¤j©ó¨â¤ÀÄÁ¡AÄ´¦p»¡¡A¦å²G³zªR¯f¤H¥i¥H¦b¬~µÇµ²§ô®É¸g¥Ñ°Ê-ÀR¯ß°úºÞ¶i¦æª`®g¡C
IRIF,Rifamycin SV,Rifocin inj 500mg/10mL,QANB,,,,,,,,,,,,,,,,,,,
EASA,Mesalazine,Asacol 500mg suppository,ALIM,Treatment of mildly to moderately active ulcerative proctitis¡A colitis¡A or proctosigmoiditis.,Patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any ingredients in the suppository vehicle. Severe renal impairment: eGFR<30mL/min/1.73m2. Severe liver impairment. Age <2 years.,Common Dermatologic: Rash (Up to 6% ; pediatrics¡A 5% ) Gastrointestinal: Abdominal pain (Adult¡A 2.2% to 18% ; pediatrics 5% or more )¡A Burping (16% )¡A Diarrhea (Adults¡A up to 8% ; pediatrics¡A 5% )¡A Nausea (Up to 4% )¡A Vomiting (Less than 1% to 5% ; pediatric¡A 5% or more ) Musculoskeletal: Arthralgia (Less than 3% to greater than 5% ) Neurologic: Asthenia (Less than 1% to greater than 5% )¡A Headache (Adults¡A 2.9% to 14% ; pediatrics¡A 5% or more ) Respiratory: Nasopharyngitis (Adults¡A 1.4% to 4% ; pediatrics¡A 15% )¡A Rhinitis (5% or more ) Other: Pain (Up to 14% ) Serious Cardiovascular: Myocarditis¡A Pericarditis Dermatologic: Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Exacerbation of ulcerative colitis (Pediatrics¡A 12% )¡A Gastrointestinal hemorrhage (2% or greater )¡A Pancreatitis (Less than 1% )¡A Rectal hemorrhage (Less than 3% to 2% or greater.) Hematologic: Agranulocytosis¡A Aplastic anemia¡A Leukopenia¡A Neutropenia¡A Pancytopenia¡A Thrombocytopenia (Less than 1% ) Hepatic: Cholestatic hepatitis (Less than 3% )¡A Hepatotoxicity¡A Liver failure¡A Sclerosing cholangitis Immunologic: Anaphylaxis¡A Angioedema¡A Drug reaction with eosinophilia and systemic symptoms¡A Edema of face (Less than 1% )¡A Hypersensitivity reaction Renal: Renal impairment Other: Infectious disease¡A Intolerance to drug¡A Syndrome,°®Àê³±²D(15-25¢J)³B,1-2 suppository TID¡A after a bowel movement. The dose depends on the response.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ÄY­«¨x·l¶ËªÌ¸T¥Î¡C³ø§iÅã¥Ü¯f¤HªA¥Î§t¦³mesalazineÃÄª«¡A¨ä¨x»Ã¯À¼Æ­È·|¤É°ª¡A«ØÄ³¨x¥\¯à¤£¥þ¤§¯f¤HÀ³¤p¤ß¨Ï¥Î¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,MESALAMINE: Compatible [¥é³æ] Mesalazine¥Î©óÃh¥¥°ü¤k¤§Á{§É¬ã¨s«D±`¦³­­¡C¦³­­ªº¬ã¨s¤¤(627¦ì)¨Ã¥¼µo²{¹ïÃh¥¥°ü¤k ©Î°·±d­L¨à/·s¥Í¨à³y¦¨¶Ë®`¡C¨´¤µ¬°¤îÁÙ¥¼¦³¨ä¥L¬ÛÃöªº¬y¦æ¯f¾Ç¼Æ¾Ú¡C´¿¦³¤@¨Ò³ø§iÅã¥Ü ¡A¦bÃh¥¥´Á¶¡ªø´ÁªA¥Î°ª¾¯¶q¡]2-4 g¡A ¤fªA¡^ªºmesalazine¡A¾É­P·s¥Í¨àªºµÇ¥\¯à°IºÜ¡C ¥HMesalazine§@°Êª«¤fªA¸ÕÅç¡A¹ïÃh¥¥¡B­F­L/­L¨àªºµo®i¨ÃµLª½±µ©Î¶¡±µ¶Ë®`¡A ¯S§O¬O²£«áµo®i¡CÃh¥¥´Á¶¡¡AmesalazineÀ³¶È­­©óÂå®v§PÂ_ªvÀø»Ý­n©Ê¤j©ó¥i¯àµo¥Í¤§­·ÀI¡A ¥BÀ³ÂÔ·V¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,MESALAMINE: Limited Human Data¡XPotential Toxicity [¥é³æ] N-acetyl-5-aminosalicylic acid¤Î¤Ö¶qmesalazine³Q±Æ¦Ü¨Å¥Ä¡AÁö¨äÁ{§É·N¸q¤£½T©w¡C ¨´¤µ¬°¤î­÷¨Å¤§¬ÛÃö¬ã¨s¦³­­¡CÀ¦¥®¨àµLªk±Æ°£¤§¹L±Ó¤ÏÀ³¡A¦p¡G¸¡Âm¡C¦]¦¹¡A ­÷¨Å´Á¶¡¨Ï¥ÎmesalazineÀ³§PÂ_ªvÀø»Ý­n©Ê¤j©ó¥i¯àµo¥Í¤§­·ÀI¡C °²¦p¯f¤H¦bªvÀø´Á¶¡¥X²{À¦¥®¨à¸¡Âm¯gª¬¡AÀ³¥ß§Y°±¤î­÷¨Å¡C,R;RECT;,,,,,1. Àx¦s©ó°®Àê³±²D(15-25¢J)³B¡C 2. ½ÐÀx¦s©ó­ì¥]¸Ë¤¤Á×¥ú«O¦s¡A¨Ï¥Î«e»Ý©î¶}¶ì½¦¥]¸Ë.
ODEL,Dexchlorpheniramine,Delamin 2mg,HIMM,Palliative treatment of allergic reaction.,Acute attack of asthma. Premature infants.,Drowsiness¡A dizziness; dry mouth. GIT disturbances. Hypotension¡A muscular weakness¡A tinnitus¡A euphoria¡A headache. CNS stimulation. Allergic reaction. Blood disorders.,25¢J¥H¤U,Adult: 1 TAB. TID-QID. Children : 6-12 years 1/2 TAB. 3-6 years 1/4 TAB. TID-QID.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OBCO,Vitamin B complex,Betacom(B complex) ­­¦Û¶O,NUTR,,¾AÀ³¯g: Prevention & treatment of vit B deficiency.,,«Ç·Å,Adult 2-3 tab daily¡A children 8-12 years 1 tab daily¡A 5-7 years 1/2 tab daily.,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
YGLU,Glucosamine 150m,¾¾¥ß³ß¼Ö¸²Ói300'S,NUTR,,,,,,,,,,,,,,,,,,,
OCELA,Pergolide,CELANCE 0.25mg,CNEU,,¾AÀ³¯g:±±¨î¶g´Á©ÊªÏÅéÅ¸°Ê¡B¸£¯«¸g¿E¯À½Õ¾ãµ¥(B019552100),,,Initially 0.05 mg daily for the first 2 days¡A gradually increased by 0.1 or 0.15 mg daily every 3rd day over the next 12 days . Then increase by 0.25 mg daily every 3rd day until optimal response. Max: 5 mg daily. Usually administered in divided dose 3 times/day. Dosage of concurrent l-dopa/carbidopa may be cautiously decreased during dosage titration.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OLOD,Zotepine,Lodopin 25mg,CNEU,,¾AÀ³¯g: Schizophrenia. °Æ§@¥Î: Sleepiness¡A weakness¡A malaise¡A insomnia¡A thirst¡A constipation¡A dizziness. ¸T§Ò:Patients with coma or circulatory collapse¡A patients on epinephrine¡A hypersensitivity to phenothiazines¡A suspected subcortical lesions (eg encephalitis¡A cerebral tumor & sequelae of brain trauma).,,«Ç·Å,Adult: 75-150 mg daily in divided doses¡A up to 450 mg/day,,,,¨S¦³¸ê®Æ,,,,,,,,,,
INOV3,Insulin Aspart 30 + NPH 70,Novomix 30 penfill 3mL,META,,¾AÀ³¯g:Treatment of patients with diabetes mellitus. °Æ§@¥Î:Hypoglycaemia¡A edema¡A refraction anomalies¡A hypersensitivity reactions¡A lipodystrophy ¸T§Ò:Hypoglycaemia.,,2-8¢J,Individualised dosage. Administered by SC inj. Penfill should be used with NovoPen 4 & NovoFine Needles,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OFOX,Flavoxate,FOXate 200 mg,SGU,,¾AÀ³¯g: Symptomatic relief of prostatitis¡A urinary frequency. °Æ§@¥Î: GI disturbances; hypersensitivity reactions; headache¡A sedation¡A vertigo¡A confusion; intraocular pressure. Rarely¡A leukopenia. ¸T§Ò: GI hemorrhage; obstructive uropathies of the lower urinary tract. Children <12 years. Pyloric or duodenal obstruction¡A obstructive intestinal lesions of ileus.,,«Ç·Å,Adult:1 tab tid.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IFIB,Sodium Tetradecyl Sulphate,FIBRO-VEIN inj 3%¡A 5mL,ZOTH,,,,,,,,,,,,,,,,,,,
IPUR3,Follitropin beta,PUREGON cartridge 300IU,HM,,¾AÀ³¯g:Treatment of female infertility due to anovulation in women who have been unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs. °Æ§@¥Î:Ovarian hyperstimulation¡A bruising¡A pain¡A redness¡A swelling & itching¡A ectopic pregnancy¡A multiple gestations¡A arterio-thromboembolisms. ¸T§Ò:Ovarian¡A breast¡A uterine¡A pituitary or hypothalamic tumours. Pregnancy or lactation. Undiagnosed vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries¡A not related to polycystic ovarian disease (PCOD). Sexual organ malformations incompatible with pregnancy. Uterine fibroid tumours incompatible with pregnancy.,,2 ~ 8 ¢XC,Anovulation 50 iu daily¡A maintained for at least 7 days. Controlled ovarian hyperstimulation in medically assisted reproduction programs Starting dose of 100-225 iu for at least the 1st 4 days,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,SC;,,,,,1. ¥»ÃÄ«~¬Oª`®g§X³]­p¡A»Pª`®gµ§°t¦X¨Ï¥Î¡C
IDEX,Low Molecular Dextran Dextrose,Dextran (¦å½ç¦h®Ôºw) inj 500mL,HEMT,As plasma expander in haemorrhage.,Hypersensitivity. Severe renal disease with oliguria or anuria. Marked cardiac decompensation. Pregnancy.,GI disturbances; headache¡A dizziness; allergic reactions; raised liver enzyme values; alopecia; bone marrow suppression.,30¢J¥H¤U,Normally IV 500mL one time. IV 20 mL/kg on the first 24 hours. For treatment or prevention of thrombosis¡A 10mL/kg daily in 5 days.,µL»Ý½Õ¾ã¾¯¶q,Use with extreme caution.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,"ª`®g³t²v:20~40mL/mins¡AMax:20mL/kg/day",1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î 2.Max:20mL/kg/day
EGENO,Gentamicin,Gentamicin ²´ÃÄ»I 0.3%¡A 5gm,TOPH,,¾AÀ³¯g: Treatment of ocular infections due to susceptible organisms. °Æ§@¥Î: Rarely¡A transient stinging. ¸T§Ò: Hypersensitivity.,,«Ç·Å,Apply bid-tid to the affected eye(s).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EGEN,Gentamicin,Gentamycin OPH sol 0.3%¡A 3mL,TOPH,,¾AÀ³¯g: Bacterial inflammations of conjunctiva¡A cornea¡A lid margin & lacrimal sac; styes¡A corneal ulcers¡A corneal infections. °Æ§@¥Î: Irritation¡A pain¡A stinging & burning.,,«Ç·Å,1-2 drop 3-8 times daily.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IGW250A,Glucose,°tÃÄ¥Î Glucose inj 5% 250mL,MSIV,,,,,°tÃÄ¥Î¤lÂå¥O,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
ETOPC,Fluocinonide,Topsym ³n»I5gm (¦Û¶O),TDER,,¾AÀ³¯g: Eczema; dermatitis; psoriasis; vitiligo; alopecia; pustulosis; prurigo. °Æ§@¥Î: Burning¡A itching¡A irritation¡A dryness; perioral dermatitis; allergic contact dermatitis; skin atrophy. ¸T§Ò: Vaccinia & varicella.,,«Ç·Å,Apply once-tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OAVA2,Rosiglitazone + Metformin,AvandaMet 2mg/500mg,META,,¾AÀ³¯g: Type 2 DM. °Æ§@¥Î:Upper resp tract infection¡A headache¡A back pain¡A hyperglycemia¡A fatigue¡A sinusitis¡A diarrhea¡A viral infection¡A arthralgia. Anaemia. Rosiglitazone: Hypoglycaemia¡A oedema¡A anaemia¡A hypercholesterolaemia¡A dose-related wt gain¡A CHF¡A pulmonary oedema¡A pleural effusions. Metformin: Nausea¡A vomiting¡A diarrhoea¡A abdominal pain¡A loss of appetite¡A metallic taste. Cardiovascular: Edema (6% to 25% ) Endocrine metabolic: Hypoglycemia (12% ) Gastrointestinal: Diarrhea (12.7% to 14%) Hematologic: Anemia (4% to 7.1% ) ¸T§Ò: ketoacidosis or pre-coma¡A renal failure. ½Ã¥Í¸p¤½§i(99.10.14) 1.¤£«ØÄ³¸Ó¦¨¤À(rosiglitazone)¨Ï¥Î©ó¯Ê¦å©Ê¤ßÅ¦¯f¤§¯f¤H¡C 2.¤£«ØÄ³¸Ó¦¨¤À¨Ï¥Î©ó¤ßÅ¦°IºÜ¤§¯f¤H¡C 3.¸T¥Î©ó¤ß°IºÜ²Ä3¯Å©Î²Ä4¯Å(NYHA Class III or IV cardiac status )¯f¤H,,«Ç·Å,starting does : 2/ 500 mg daily. max daily dose: 8 / 2000 mg.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ETRI,Fluocinolone + Hydroquinone + Tretinoin,TRI-LUMA cream 15gm,TDER,,¾AÀ³¯g: Short-term treatment of moderate to severe melasma of the face¡A in the presence of measures for sun avoidance¡A including the use of sunscreens. °Æ§@¥Î: Erythema¡A desquamation¡A burning¡A dryness & pruritus at the site of application. ¸T§Ò: Individuals with a history of hypersensitivity¡A allergy¡A or intolerance to Tri-Luma or any of its components.,,«Ç·Å,Apply a thin film of cream to hyperpigmented areas of melasma including about 0.5 inch of normal appearing skin surrounding each lesion. Rub lightly & uniformly into the skin. Apply once daily at night 30 minutes before bedtime.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OSES,Timepidium,Sesden 30mg,ALIM,,¾AÀ³¯g: Pain associated with smooth muscle spasm eg. gastritis¡A peptic ulcer¡A enteritis¡A gallbladder & bile-duct diseases; lithangiuria¡A pancreatitis. °Æ§@¥Î: Rarely shock; photophobia¡A visual disturbances; headache¡A dizziness¡A lightheadedness¡A drowsiness; dry mouth¡A nausea¡A vomiting¡A constipation¡A anorexia¡A abdominal distention; palpitation¡A tachycardia; hypersensitivity reactions; difficulty in micturition¡A dysuria; flushing & lassitude. ¸T§Ò: Glaucoma; dysuria; severe cardiac disease; paralytic ileus.,,«Ç·Å,30 mg tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IGS5A,Dextrose + Sodium Chloride,°tÃÄ¥Î 5%Dextrose in 0.9% NaCl 500mL,MSIV,,,,,,,,,,,,,,IVD;,,,,,
OARC,Etoricoxib,Arcoxia 60mg,CNEU,Acute & chronic treatment of the signs & symptoms of osteoarthritis (OA) & rheumatoid arthritis (RA); acute gouty arthritis; primary dysmenorrhea.,CHF (NYHA II-IV)¡A established ischemic heart disease &/or cerebrovascular disease (including those who have recently undergone coronary artery bypass graft surgery or angioplasty). Patient with coronary artery bypass graft (CABG) in 14 days.,Asthenia/fatigue¡A dizziness¡A lower extremity edema¡A hypertension¡A dyspepsia¡A heartburn¡A nausea¡A headache¡A increased ALT & AST levels. Also¡A hypersensitivity reactions¡A dysgeusia¡A CHF¡A abdominal pain¡A peptic ulceration & bleeding¡A vomiting¡A angioedema¡A pruritus¡A rash¡A urticaria¡A renal insufficiency.,30¢J¥H¤U,Osteoarthritis: 30mg or 60mg QD Rheumatoid arthritis: 60mg or 90mg QD Ankylosing spondylitis: 60mg or 90mg QD Acute gouty arthritis: 120mg QD¡A treatment should not exceed 8 days Primary menstrual pain: 120mg QD¡A treatment should not exceed 8 days Pain relief after dental surgery: 90mg¡A treatment should not exceed 3 days Pain relief after gynecological surgery: 90mg or 120mg QD¡A treatment should not exceed 5 days No dose adjustment is required based on age¡A gender or race.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ(Child-pugh B)¤§¯f±w¡AÀ³­°§C°_©l¾¯¶q¡A¤£¥i¶W¹L¨C¨â¤é60mg¾¯¶q ­««×¨x¥\¯à¤£¥þ(Child-pugh C)¤§¯f±w¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F§³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C [¥é³æ] ©M¨ä¥L¤wª¾·|§í¨î«e¦C¸¢¯À¦X¦¨ªºÃÄª«¤@¼Ë¡A¦bÃh¥¥¬ù30¶g©Î¤§«áÀ³Á×§K¨Ï¥ÎARCOXIA¡A¦]¬°¥i¯à·|¾É­P°Ê¯ß¾ÉºÞ¹L¦­³¬Âê¡C¦bÃh¥¥20¶g©Î¤§«á±µ¨üNSAIDsªvÀøªº¥¥°ü´¿³Q³ø¾É¦³­L¨àµÇ¥\¯à²§±`¾É­P¦Ï¤ô¶q´î¤Ö(¦Ï¤ô¹L¤Ö)¡C¦b¬Y¨Ç±¡ªp¤U¡A³o¥i¯à·|¾É­P·s¥Í¨àµÇ¥\¯à²§±`¡C¥­§¡¦Ó¨¥¡A¦¹Ãþ§@¥Î¥i¯à¦bNSAIDªvÀø¶}©l¼Æ¤Ñ¦Ü¼Æ¶g«áµo¥Í¡A¦ý¦bÀW²v·¥§Cªº±¡ªp¤U´¿³q³ø©ó¶}©l¨Ï¥ÎNSAID«á48¤p®É¤º¡F¦Ï¤ô¹L¤Ö³q±`(¦ý¨Ã«DÁ`¬O¦p¦¹)¥i©óªvÀø¤¤Â_«á°fÂà¡Cªø®É¶¡¦Ï¤ô¹L¤Öªº¨Öµo¯g¥i¯à¥]¬A¨Ò¦pªÏÅéÅËÁY©M©µ¿ðªÍ¦¨¼ô¡C¦b¬Y¨Ç¤W¥««á·s¥Í¨àµÇ¥\¯à¤£¥þªº­Ó®×¤¤¡A»Ý­n¶i¦æ«I¤J©Êµ{§Ç¡A¨Ò¦p¥æ´«¿é¦å©Î³zªR¡C¤£«ØÄ³Ãh¥¥20¶g¤§«áªº¥¥°ü¨Ï¥ÎARCOXIA¡F¦pªGµo¥Í¦Ï¤ô¹L¤Ö¡A½Ð°±¥ÎARCOXIA¡A¨Ã®Ú¾ÚÁ{§É¹ê°È¶i¦æ°lÂÜ¡C ¥H¨ß¤l©Ò¶i¦æªº¥Í´Þ¬ã¨sÅã¥Ü¡A¦b°ª¹F15 mg/kg/dayªº¾¯¶q¤U(¥þ¨­ ¼ÉÃÄ¶q¬ù¬°¤HÃþ¾¯¶q[90²@§J]ªº1.5­¿)¡A¨Ã¥¼¥X²{¥ô¦óµo¨|²§±`ªº ¸ñ¶H¡C¦b¥þ¨­¼ÉÃÄ¶q¬ù¬°2­¿¦¨¤H¾¯¶q(90²@§J)ªºetoricoxibªvÀøªº »Û¨ß¡AÆ[¹î¨ì¨ä¤ß¦åºÞ·î§Î¦ýµo¥Í²v§C¡A¥ç¨£¼W¥[µÛ§É«á¬y²£(post implantation loss)¡C¦Ó¥H¥þ¨­¼ÉÃÄ¶q¬ùµ¥©ó©Î¤p©ó¤HÃþ¨C¤é¾¯¶q(90 ²@§J)¡A¥¼Æ[¹î¨ì¹ïµo¨|¦³¼vÅT¡C¤£¹L¡A°Êª«¥Í´Þ¬ã¨s¨Ã¤£¤@©w¯à¹w ´ú¤HÃþªº¤ÏÀ³¡C¥Ø«e¨ÃµL¥ô¦ó¾A·í¥B±±¨î¨}¦nªº¥¥°ü¬ã¨s¡C¥u¦³¦b ¼ç¦b®Ä¯q½T©w¶W¶V¹ï­L¨àªº¼ç¦b¦MÀI®É¡A¤~¥i©óÃh¥¥ªº³Ìªì20¶g´Á ¶¡¨Ï¥ÎARCOXIA¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Etoricoxib ·|¤Àªc¶i¤J±Â¨Å¤j¹«ªº¨Å¥Ä¤¤¡A¥Ø«e©|¤£½Tª¾¥»ÃÄ¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C¥Ñ©ó³\¦hÃÄª«³£·|¤Àªc¶i¤J¤HÃþ¨Å¥Ä¡A¦Ó¥BÁý­÷¥À¨ÅªºÀ¦¨à¥i¯à·|¦]¥»ÃÄ§í¨î«e¦C¸¢¯À¦X¦¨¦Ó²£¥Í°Æ§@¥Î¡A¦]¦¹¡AÀ³ÂÔ·V¦Ò¼{¥»ÃÄ¹ï¥À¿Ëªº­«­n©Ê¡A¨Ã¾Ú¥H¨M©w­n°±¤îÁý­÷¥À¨Å©Î¬O°±¥Î¥»ÃÄ¡C,AC;AC15;PC;PO;WM;,,,,,
EIND,Indomethacin,Indomethacin supp 50mg,CNEU,,¾AÀ³¯g: Alleviation of pain. °Æ§@¥Î: GI upsets¡A headache¡A dizziness¡A tinnitus¡A lightheadedness¡A depression¡A insomnia¡A psychiatric disturbances¡A peripheral neuropathy¡A blurred vision¡A confusion; hyperglycaemia¡A hyperkalaemia. Gastrointestinal: Abdominal pain (1% to 3% )¡A Constipation (1% to 3% )¡A Diarrhea (1% to 3% )¡A Indigestion (3% to 9% )¡A Nausea (3% to 9% ) Neurologic: Dizziness¡A Headache¡A Somnolence Otic: Tinnitus Psychiatric: Depression Other: Fatigue ¸T§Ò: Active peptic ulcer; pregnancy (3rd trimester)¡A hypersensitivity to aspirin and other NSAIDs; treatment of perioperative pain in CABG surgery; severe renal impairment; rectal admin in patients with proctitis and haemorrhoids; neonates with necrotizing enterocolitis¡A active bleeding¡A thrombocytopenia¡A coagulation defects and untreated infections.,,«Ç·Å,50-100 mg qd.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,RECT;,,,,,
ODIVI,Estradiol + Medroxyprogesterone,Diviseq 28's/pk,HM,,I: Signs & symptoms of naturally or surgically induced estrogen deficiency due to monopause. °Æ§@¥Î: GI disturbances¡A nausea¡A vomiting¡A weight gain¡A breast tenderness¡A decreased libido¡A headache¡A chloasma¡A itching. CI: known¡A suspected or past history of breast carcinoma¡A pregnancy. Undiagnosed abnormal gentital bleeding. Known or suspected estrogen-dependent neoplasia. Active thrombophlebitis or thromboembolic disorders. Application on the breast & vulvar mucosa areas. Acute or chronic liver disease¡A porphyria.,,«Ç·Å,1 tab daily in a 28-day cycle.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OACEO,Acemetacin,ACEO 90mg,CNEU,,Analgesia¡A antipyresis¡A anti-inflammatory¡A actue gout.,,,1-2 tab daily Acute gout: 180 mg (1 tab BID) until pain is relieved.,,,,,,,,,,,,,,
OPAN3,Nefopam,Panagesic 30mg,CNEU,,¾AÀ³¯g: Acute & chronic pain including post-op¡A dental¡A musculoskeletal¡A acute traumatic & cancer pain. °Æ§@¥Î: Nausea¡A vomiting¡A nervousness¡A dry mouth & light-headedness¡A blurred vision¡A drowsiness¡A sweating¡A insomnia¡A headache¡A tachycardia. ¸T§Ò: History of convulsive disorders or those taking MAOI. Pregnancy.,,«Ç·Å,Adult: 1 tab tid-qid In severe pain¡A single dose can be increased to 90 mg. Max recommanded dose in 24 hr: 300 mg,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IGEL,Succinylated Gelatin,Gelofusine 500mL¡A 4%,HEMT,Primary vol replacement in hypovolaemia & shock due to acute blood or fluid loss¡A burns & sepsis; prophylaxis of hypotension during epidural or spinal anaesth; haemodilution & autologous transfusion; extracorporeal circulation (haemodialysis¡A heart lung machine).,Hypervolemia; hyperhydration; severe cardiac insufficiency; severe bleeding disorders; severe renal insufficiency.,As with all colloidal vol substitutes¡A allergic¡A (anaphylactic or anaphylactoid) reactions of varying severity can occur after infusion of Gelafundin/Gelofusine.,25¢J¥H¤U,Compensation of minor losses of blood or plasma¡A pre- & intraoperative routine prophylaxis 500-1¡A000 mL infused over 1-3 hr. Major losses of blood or plasma Average dose is between 1¡A000 & 2¡A000 mL. Emergency situations or shock conditions Initially 500 mL administered by forced infusion over 5-10 mins. Thereafter¡A the infusion can be continued with doses corresponding to actual losses of blood or plasma. During extracorporal circulation Normally¡A between 500-1¡A000 mL.,µL»Ý½Õ¾ã¾¯¶q,Use with extreme caution,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,500~1000 mL ºwª`¶W¹L 1-3 hs,¦¹²£«~¼t°Ó¥¼°µ¬Û®e©Ê¸ÕÅç¡A¬G¤£«ØÄ³µ}ÄÀ¨Ï¥Î
ICRA,Levofloxacin,Cravit °w¾¯ 500mg/100mL,QANB,,¾AÀ³¯g: Respiratory tract¡A ENT¡A GUT infection. Intrauterine infections¡A cervicitis¡A uterine adnesxitis¡A folliculitis. GIT infections¡A lymphangitis¡A mild to moderate skin & skin tissue infections. °Æ§@¥Î: Dizziness¡A GI disturbances¡A rash¡A pruritus¡A vaginitis¡A genital moniliasis¡A taste perversion¡A insomnia¡A tendinitis. Rarely¡A anaphylactic reactions¡A Lyell's syndrome¡A Stevens-Johnson's syndrome. Gastrointestinal: Diarrhea (ophthalmic¡A 1% to 2%; oral or intravenous¡A 5% )¡A Nausea (ophthalmic¡A 1% to 2%; oral or intravenous¡A 7% ) Neurologic: Headache (ophthalmic¡A 8% to 10% ; oral and intravenous¡A 6% ) ¸T§Ò: Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.,,«Ç·Å,adult: by slow IV infusion. Community-acquired pneumonia 500 mg once-bid. Complicated UTI 250 mg once daily Skin and soft tissue infections 500 mg bid. Dosage may be increased if necessary in severe infections. Max treatment duration: 14 days,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LAUG3,Amoxicillin + Clavulanic Acid,Augmentin¿}¼ß 457mg/5mL¡A 35mL,QANB,Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI¡A pelvic¡A head & neck¡A cardiac¡A renal¡A joint replacement & biliary tract.,Hypersensitivity to penicillins¡A possible cross sensitivity with other £]-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction.,Common: Diaper rash (3.5-6%)¡A Rash (1.1-3%)¡A Urticaria¡A Diarrhea (2.9-14.5%)¡A Loose stool (1.6-9%)¡A Nausea (up to 3%)¡A Vomiting (up to 2.2%)¡A Mycosis (3.3%)¡A Vaginitis (1%)¡A Candidiasis (1.4%) Serious: Drug reaction with eosinophilia and systemic symptoms¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Cholestasis¡A Hepatitis¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Angioedema¡A Serum sickness due to drug,30¢J¥H¤U¥B¸m©ó°®Àê³B¡Cªw»s¦¨·»²G«á½ÐÀx¦s©ó2-8¢J¥B¤£¨Ï¥Î¶W¹L¤C¤Ñ¡C¤£¥i§N­á¡C,(Amoxicillin 400mg + Clavulanic Acid 57mg/ 5mL) Usual dose (amoxicillin/clavulanate): 25/3.6-45/6.4 mg/kg/day. Children 2 years and over: 2-6 years (13-21 kg): 2.5-5 mL twice daily; 7-12 years (22-40 kg): 5-10 mL twice daily. Children aged 2 months to under 2 years: dose according to body weight: 2 kg: 0.3-0.6 mL every 12 hours¡A 3 kg: 0.5-0.8 mL every 12 hours¡A 4 kg: 0.6-1.1 mL every 12 hours¡A 5 kg: 0.8-1.4 mL every 12 hours¡A 6 kg: 0.9-1.7 mL every 12 hours¡A 7 kg: 1.1-2.0 mL every 12 hours¡A 8 kg: 1.3-2.3 mL every 12 hours¡A 9 kg: 1.4-2.5 mL every 12 hours¡A 10 kg: 1.6-2.8 mL every 12 hours¡A 11 kg: 1.7-3.1 mL every 12 hours¡A 12 kg: 1.9-3.4 mL every 12 hours¡A 13 kg: 2.0-3.7 mL every 12 hours¡A 14 kg: 2.2-3.9 mL every 12 hours¡A 15 kg: 2.3-4.2 mL every 12 hours. The following Pediatric dose recommendation is from Sanford Guide to Antimicrobial Therapy.(2022/11/08): Age>28 days: 25-100mg/kg/day divided Q8-12H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st and 3 rd trimesters,AMOXICILLIN PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters CLAVULANATE¡A POTASSIUM PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,WHO: Compatible with breastfeeding Micromedex: Infant AMOXICILLIN BREASTFEEDING RECOMMENDATION: Compatible CLAVULANATE¡A POTASSIUM BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,AC;AC15;PC;PO;WM;,,,,,
OAUG1,Amoxicillin + Clavulanic Acid,AUGMENTIN 1gm,QANB,Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis.,Hypersensitivity to amoxicillin¡A clavulanate¡A or other beta-lactam antibacterials (eg¡A penicillins and cephalosporins). Concomitant use of extended-release tablets with hemodialysis. History of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate potassium. Severe renal impairment (ie¡A CrCl less than 30 mL/min) when administering extended-release tablets.,Common: Diaper rash (3.5-6%)¡A Rash (1.1-3%)¡A Urticaria¡A Diarrhea (2.9-14.5%)¡A Loose stool (1.6-9%)¡A Nausea (up to 3%)¡A Vomiting (up to 2.2%)¡A Mycosis (3.3%)¡A Vaginitis (1%)¡A Candidiasis (1.4%) Serious: Drug reaction with eosinophilia and systemic symptoms¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Cholestasis¡A Hepatitis¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Angioedema¡A Serum sickness due to drug,«Ç·Å,(Amoxicillin 875 mg and clavulanate 125 mg per Tab) Acute otitis media: (immediate-release tablets¡A suspension) severe infections¡A 875 mg ORALLY every 12 hr Infection of skin AND/OR subcutaneous tissue: (immediate-release tablets¡A suspension) severe infections¡A 875 mg ORALLY every 12 hr Lower respiratory tract infection: (immediate-release tablets¡A suspension) 875 mg ORALLY every 12 hr Sinusitis: (initial empiric therapy) 875 mg/125 mg ORALLY twice daily for 5 to 7 days Urinary tract infectious disease: (immediate-release tablets¡A suspension) severe infections¡A 875 mg ORALLY every 12 hr Acute otitis media: severe infections or treatment failure¡A 90 mg/kg/day (amoxicillin component) ORALLY in 2 divided doses for 10 days Acute otitis media:3 months and older and under 40 kg¡A 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hr for 10 days¡A depending on severity of infection Acute otitis media: (immediate-release tablets¡A suspension) severe infections¡A 40 kg and greater; 875 mg ORALLY every 12 hr Infection of skin AND/OR subcutaneous tissue: 3 months and older and under 40 kg¡A 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hr¡A depending on severity of infection Infection of skin AND/OR subcutaneous tissue: (immediate-release tablets¡A suspension) severe infections¡A 40 kg and greater; 875 mg ORALLY every 12 hr Lower respiratory tract infection:3 months and older and under 40 kg¡A 25 to 45 mg/kg/day (based on amoxicillin component) ORALLY divided every 12 hr¡A depending on severity of infection Lower respiratory tract infection: 40 kg and greater; 875 mg ORALLY every 12 hr Sinusitis: (initial empiric therapy) 45 mg/kg/day (amoxicillin component) ORALLY twice daily for 10 to 14 days Sinusitis: (second-line¡A high-dose) 90 mg/kg/day (amoxicillin component) ORALLY twice daily Sinusitis: 3 months and older and under 40 kg¡A 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hours¡A depending on severity of infection Sinusitis: severe infections¡A 40 kg and greater; 875 mg (amoxicillin component) ORALLY every 12 hr Urinary tract infectious disease: 3 months and older and under 40 kg¡A 25 to 45 mg/kg/day (amoxicillin component) ORALLY divided every 12 hr¡A depending on severity of infection Urinary tract infectious disease: severe infections¡A 40 kg and greater; 875 mg ORALLY every 12 hr,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,WHO: Compatible with breastfeeding Micromedex: Infant,,,,,,
OHEPS,Adefovir Dipivoxil,Hepsera 10mg,QANB,,¾AÀ³¯g:Treatment of chronic hepatitis B in adults with evidence of hepatitis B viral replication. °Æ§@¥Î¡G Neurologic: Asthenia (13% ) Renal: Serum creatinine raised,,«Ç·Å,Adult 18-65 years 10 mg once daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Contraindicated (HIV),,,,,,
OCRE,Rosuvastatin,Crestor 10mg,CAVS,Treatment of primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet & other non-pharmacological measures are inadequate. Treatment of homozygous familial hypercholesterolaemia¡A either alone or as an adjunct to diet & other non-pharmacological (e.g. exercise¡A weight reduction) is inadequate. Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.,Active liver disease including unexplained¡A persistent elevations of serum transaminases & any serum transaminase elevation exceeding 3 times the upper limit of normal; severe renal impairment (creatinine clearance <30 mL/min)¡A myopathy; patients on concomitant cyclosporin; pregnancy & lactation.,Constipation¡A nausea¡A abdominal pain¡A headache¡A dizziness¡A myalgia¡A asthenia. Gastrointestinal: Abdominal pain (2.4% )¡A Nausea (2% to 3.4% ) Musculoskeletal: Arthralgia (10.1% )¡A Myalgia (2.8% to 12.7% ¡A ) Neurologic: Asthenia (0.9% to 4.7% )¡A Headache (3.1% to 5.5% ) Renal: Urinary tract infectious disease (2.3% .),30¢J¥H¤U,Adult and children (10-17 years): 5-20 mg orally once daily with or without food.,»Ý½Õ¾ã¾¯¶q,ALT©ÎAST«ùÄò¶W¹LUTN¤§3­¿¥H¤W¡A«h«ØÄ³­°§C¾¯¶q©Î°±ÃÄ,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,[¥é³æ] Ãh¥¥©Î¥i¯àÃh¥¥ªº°ü¤k¡AHMG-CoAÁÙ­ìžJ§í¨î¾¯·|´î¤ÖÁx©T¾Jªº¦X¦¨¡A¥i¯à¤]·|´î¤Ö¨ä¥L¥ÑÁx©T¾J­l¥Í¤§¥Íª«¬¡©Êª«½èªº¦X¦¨¡A¦]¦¹¥¥°ü¨Ï¥Î¦¹ÃþÃÄª«¥i¯à¹ï­L¨à³y¦¨¶Ë®`¡A¦Ó¥B¦bÃh¥¥´Á¶¡¨S¦³ÅãµÛªºªvÀø¯q³B¡A¥¥°ü¨Ï¥Î¤§¦w¥þ©Ê¤]©|¥¼½T¥ß¡F¯f¤H­Y¦bªA¥Î¥»ÃÄ´Á¶¡Ãh¥¥¡AÀ³§iª¾¦o¥»ÃÄ¹ï­L¨àªº¼ç¦b¦MÀI¡A¥H¤Î¦bÃh¥¥´Á¶¡Ä~Äò¨Ï¥Î¬O§_¦³¦n³B¤´ÄÝ¥¼ª¾¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ±Â¨Å°ü¡A³o¤@ÃþÃÄª«¤¤ªº¤@­ÓÃÄª«·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¤S¦]HMG-CoAÁÙ­ìžJ§í¨î¾¯¥i¯à¹ï¦Y¥À¥¤ªºÀ¦¨à³y¦¨ÄY­«ªº¤£¨}¤ÏÀ³¡A©Ò¥HÀ³¸Ó­n«ØÄ³»Ý­n¥ÎCRESTORªvÀøªº°ü¤k¤£­nÁý¥À¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
OAMD,Alum Hydroxide + Mag Hydroxide + Dimethylpolysilox,A.M.D.,ALIM,,I: Hyperacidity¡A functional gastric bloating¡A gastritis¡A flatulence.,,RT,2 tab tid~qid pc 1hr.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OGOW,Dihydroxyalumium Allantoinate + Metamagnesium Alum,Gowell,ALIM,,I: Hyperacidity¡A peptic and doudenal ulcer¡A gastritis¡A flatulence.,,RT,2 tab tid pc 1hr.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OMEI,Diclofenac,Meitifen SR 75mg,CNEU,,I: An analgesic¡A antipyretic¡A anti-inflammatory agents used in RA. and other rheumatic disorders. ADR: Occasionally¡A GI disorders; edema; headache¡A dizziness¡A vertigo; rash. Rarely¡A peptic ulcer¡A GI bleeding; hepatitis. Blood disorders. CI: Peptic ulcer. Hypersensitivity to diclofenac¡A aspirin and other prostaglanding-synthetase inhibiting drugs.,,RT,75 mg qd - bid,,,,¥i¯à¦w¥þ,,,,,,,,,,
IINF,Combined DPT+ Inactivated Polio + Hib,Infanrix-IPV+Hib(¤­¦X¤@¬Ì­]),HIMM,,I: Active immunization against diphtheria¡A tetanus¡A pertussis¡A po-liomyelitis and Haemophilus influenzae type b caused diseases. CI: Acute febrile illness. Encephalopathy of unknown aetiology¡A occurring within 7 days following previous vaccination with per-tussis-containing vaccination. Hypersensitive to neomycin or any other components of this product. ADR: Redness¡A swelling and pain at injection site. Fever¡A unusual crying¡A vomitting diarrhea¡A loss of appetite¡A restlessness.,,2 ~ 8 ¢XC,Deep IM. Primary immunization: complete all 3 doses before the first 6 mth of life¡A start from the age of 2 mth¡A subsequent doses at intervals > 1 mth. A reinforcing 4th dose is recommended to be given in the 2nd yr of life.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OEXE,Rivastigmine,Exelon 3mg,CNEU,Mild to moderately severe dementia of the Alzheimer type.,Serious hypersensitivity to other carbamate derivatives.,Nausea¡A vomiting¡A diarrhea¡A abdominal pain¡A loss of appetite¡A dyspepsia¡A dizziness¡A headache. Gastrointestinal: Diarrhea (6% )¡A Nausea (7% )¡A Vomiting (6% ),30¢J¥H¤U,Initially 1.5 mg BID for 2 weeks. If well tolerated¡A increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks. Maintenance: 3-12 mg daily. Maximun: 12 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] Exelon¦bÃh¥¥°ü¤k¨­¤W¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C ©óÃh¥¥¤j¹«¤Î¨ß¤l¶i¦æªº¤fªA¥Í´Þ¸ÕÅç¡AÅã¥ÜµL­P·î­L©Ê¡C¦bÃh¥¥°Êª«¤¤¡Arivastigmine¤Î/©Î¨ä¥NÁÂª«·|³q¹L­L½L¡F©|¥¼©úÁA¬O§_·|µo¥Í©ó¤HÃþ¡C °Êª«¥Í´Þ©Ê¸ÕÅç¨Ã¤£¯à§¹¥þ¥Î¨Ó¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹Ãh¥¥´Á¶¡¥u¦³¦b¼ç¦bªº®Ä¯q¤j©ó¹ï­L¨àªº¦M®`±¡ªp¤U¤è¥i¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Exelon·|¤£·|³Q¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡A¨Ã¤£²M·¡¡C©ó¤j¹«¤fªA§ë¤©rivastigmine«á¡Arivastigmine»P¨ä¥NÁÂª«·|¤Àªc¦Ü¨Å¥Ä·í¤¤¡A¦b¨Å¥Ä¤¤ªºrivastigmine¤Î¨ä¥NÁÂª«ªº¿@«×¬ù¬°¥ÀÅé¦å¼ß¿@«×ªº¤G­¿¡C ¦]¦¹¯f¤HªA¥ÎExelon®É¤£¥i¥H­÷¨Å¡C,PC;PO;WM;,,,,,
EARTI,Hydroxypropylmethylcellulose,Artificial tear 10mL,TOPH,,¾AÀ³¯g:¤H¤u²\²G(A034503429),,RT,D: 1-2 gtt as needed.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ETIL5,Timolol,Timolast 0.5%¡A 5mL,TOPH,,,,,,,,,,,,,,,,,,,
ETIL2,Timolol,Timolast 0.25%¡A 5mL,TOPH,,,,,,,,,,,,,,,,,,,
OACET,Acetazolamide,Acetazolamide 250mg,CAVS,Management of glaucoma; edema¡A epilepsy.,Na or K depletion; marked kidney or liver dysfunction; suprarenal gland failure; hyper-chloremic acidosis; hepatic cirrhosis. Long-term administration in patients with chronic non-congestive angle-closure glaucoma.,Frequency not defined: Flushing¡A Allergic skin reaction¡A skin photosensitivity¡A Electrolyte disorder¡A glycosuria¡A hyperglycemia¡A hypoglycemia¡A hypokalemia¡A hyponatremia¡A Decreased appetite¡A diarrhea¡A dysgeusia¡A melena¡A nausea¡A vomiting¡A Crystalluria¡A hematuria¡A Immune thrombocytopenia¡A leukopenia¡A Abnormal hepatic function tests¡A cholestatic jaundice¡A fulminant hepatic necrosis¡A hepatic insufficiency¡A Pain at injection site¡A Ataxia¡A confusion¡A depression¡A dizziness¡A drowsiness¡A excitement¡A fatigue¡A flaccid paralysis¡A headache¡A malaise¡A Auditory disturbance¡A tinnitus¡A Polyuria¡A Fever. Postmarketing: Acute generalized exanthematous pustulosis¡A maculopapular rash¡A Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A urticaria¡A Growth retardation (children)¡A metabolic acidosis¡A Agranulocytosis¡A aplastic anemia¡A thrombocytopenia¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Paresthesia ¡A Acute angle-closure glaucoma¡A choroidal effusion¡A myopia¡A Renal failure syndrome.,15-30¢J,Adult usual dosage: Glaucoma¡A open-angle: Initial¡A 250 mg QD-QID. Glaucoma¡A secondary or preoperative treatment to reduce intraocular pressure: 250 mg BID to Q4H¡A or 500 mg initial dose followed by 125 or 250 mg every 4 hours. Epilepsy: 8-30 mg/kg daily in divided doses¡A optimum range: 375-1000 mg daily. Edema: 5 mg/kg (usual dosage: 250 to 375 mg) QD in the morning for 1 or 2 days¡A alternating with a day of rest. [Micromedex 2021/06/17] Acute mountain sickness; Treatment and Prophylaxis: 500-1000 mg daily¡A in divided doses; during rapid ascent¡A 1000 mg/day is recommended; initiate 24-48 hours before ascent and continue for 48 hours or longer while at high altitude. Pediatric usual dosage: Glaucoma: 8-30 mg/kg (usual dosage: 10-15 mg/kg) or 300-900 mg/m2 daily in divided doses. Epilepsy: 8-30 mg/kg daily in divided doses. Edema: 5 mg/kg or 150 mg/m2 QD in the morning for 1 or 2 days¡A alternating with a day of rest.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IOLI2,TPN Solution,Oliclinomel N7-1000E 1500mL,NUTR,,¾AÀ³¯g: Parenteral nutrition for adults and children > 2 years when oral or enteral nutrition is impossible¡A insufficient or contraindicated. °Æ§@¥Î:Hyperthermia¡A excessive sweating¡A tremors¡A nause¡A headaches¡A dyspnea. ¸T§Ò:Use in premature neonates¡A infants & children < 2 years. Severe renal failure without the possibility of hemofiltration or dialysis. Severe hepatic insufficiency¡A blood coagulation disorder or hyperlipidemia. Congenital abnormalities of amino acid metabolism. Hyperglycemia which requires >6 u insulin/hr.,,RT,By IV administration through a central vein. Adult Average nitrogen requirements: 0.16-0.35 g/kg/day (approximately 1-2 g of amino acids/kg/day). Average energy requirements: 25-40 kcal/kg/day. Max daily dose: 40 mL/kg. Children > 2 years Average nitrogen requirements: 0.35-0.45 g/kg/day (approximately 2-3 g of amino acids/kg/day). Average energy requirements: 60-110 kCal/kg/day. Max daily dose: 75 mL/kg.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OEME,Domperidone,Emetrol (DMP) 10 mg,ALIM,,¾AÀ³¯g: Nausea¡A vomiting & flatulence. °Æ§@¥Î: Rarely¡A transient abdominal cramps. Raised prolactin levels,,«Ç·Å,,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OMOB1,Meloxicam,Mobic 15mg,CNEU,,¾AÀ³¯g: Painful osteoarthritis¡A rheumatoid arthritis¡A ankylosing spondylitis. °Æ§@¥Î: Dyspepsia¡A nausea¡A vomiting¡A abdominal pain¡A constipation¡A flatulence¡A diarrhoea¡A anaemia¡A pruritus¡A rash¡A lightheadedness¡A headache¡A oedema. Cardiovascular: Edema (0.6% to 4.5% ) Gastrointestinal: Abdominal pain (1.9% to 4.7% )¡A Constipation (0.8% to 2.6% )¡A Diarrhea (1.9% to 7.8% )¡A Flatulence (3.2% )¡A Indigestion (3.8% to 9.5% )¡A Nausea (2.4% to 7.2% )¡A Vomiting Neurologic: Dizziness (1.1% to 3.8% )¡A Headache (2.4% to 8.3% ) Respiratory: Upper respiratory infection (up to 8.3% ) Other: Fever ¸T§Ò: Hypersensitivity to NSAIDs or aspirin. Active peptic ulceration¡A severe hepatic insufficiency¡A non-dialysed severe renal insufficiency. Children < 15 years. Pregnancy & lactation.,,«Ç·Å,Osteoarthritis 7.5 mg/day. May be increased to 15 mg/day. RA 15 mg/day. May be reduced to 7.5 mg/day. Ankylosing spondylitis 15 mg/day. Max: 15 mg/day.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
LWEM,Domperidone,Wempty 1mg/mL¡A 60mL suspension,ALIM,Symptomatic treatment of nausea & vomiting¡A diabetic gastroparesis.,Prolactinoma; co-administration with ketoconazole; GI hemorrhage¡A mechanical obstruction¡A perforation.,Rarely hypersensitivity reactions¡A raised serum prolactin levels¡A extrapyramidal reactions; GI abnormalities¡A urticaria¡A galactorrhea¡A gynecomastia¡A menstrual irregularity.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Adult & > 12 years with > 35 kg: 10 mg before meal or before bed time 15~30 minuts. up to 3 times a day. Children < 12 years or body weight < 35 kg: 0.25 mg/kg each time. up to 3 times a day.,µL»Ý½Õ¾ã¾¯¶q,¤¤«×©Î­««×ÄY­«¨x¥\¯à»ÙÃªªÌ¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OCEF1,Cefixime,Cefspan 100mg,QANB,,¾AÀ³¯g: ²Óµß©Ê·P¬V(A033225100) Bronchitis¡A infected bronchiectasis¡A secondary infections of chronic respiratory tract diseases¡A pneumonia; pyelonephritis¡A cystitis¡A gonococcal urethritis; otitis media¡A sinusitis. °Æ§@¥Î: Shock¡A hypersensitivity¡A haematologic disorders¡A GI disorders¡A vit K deficiency. ¸T§Ò: Hypersensitivity to cephalosporins. Infant <6 months.,,«Ç·Å,Adult & child over 30 kg: 50-100 mg q12h¡A up to 200 mg q12h. Child: 3-9.9 mg/kg/day devide 2~3 times¡A up to 6 mg/kg q12h Gonorrhea a) uncomplicated¡A 400 mg ORALLY as one-time dose,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OCLE,Clindamycin,Cleocin 150mg,QANB,,Serious clindamycin-sensitive infections.,,,Adult: 150-450 mg q6h. Child: 8-25 mg/kg/day in 3-4 divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OKLA,Clarithromycin,Klaricid 250mg,QANB,,Upper & lower resp tract¡Auncomplicated skin & skin structure infections.Eradication of H. pylori in patient with duodenal ulcer when use with omeprazole.,,,250-500 mg bid. Eradication of H. pylori inpatient with duodenal ulcer: Adult& elderly 250mg bid for 14 days. Klaricid should be given with oral omeprazole 40 mg qd. Renal impairment if adjustment is necessary¡Atotal daily dose shoud be reduced by 1/2.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OLUC,Silymarin,Luckyhepa 70mg (½Æ¤è),ALIM,,¾AÀ³¯g: Chronic liver diseases¡A liver cirrhosis¡A fatty liver. °Æ§@¥Î: GI disturbance¡A nausea¡A vomiting¡A flatulence¡A diarrhea¡A diuresis ¸T§Ò: Hypersensitivity to any ingredients of the capsule.,,«Ç·Å,1-2 cap three times a days after meals. Each cap contains: Siymarin 70mg¡A Niacinamide 12mg¡A Thiamine HCl 4mg¡A Riboflavin 4mg¡A Pyridoxine HCl 4 mg¡A Cyanocobalamin 1.2mcg¡A Pantothenate Calcium 8 mg,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OMUCS,Ambroxol,Mucosolvan 30mg,ERSP,,¾AÀ³¯g:¬°¤Æ·ð¾¯(A028453100) ADR: Mild GI effects & Allergic reactions.,,RT,Adult or child over 6 yrs.: 1 tab tid. Child under 5 yrs.: 1.2-1.6 mg/kg bid-tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OCRA5,Levofloxacin,Cravit F.C. 500mg,QANB,Respiratory tract¡A ENT¡A GUT infection. Intrauterine infections¡A cervicitis¡A uterine adnesxitis¡A folliculitis. GIT infections¡A lymphangitis¡A mild to moderate skin & skin tissue infections.,Hypersensitivity to quinolones. Epilepsy. History of tendon disorders related to fluoroquinolone administration. Children or growing adolescents. Pregnancy & lactation.,Common Gastrointestinal: Diarrhea (oral or intravenous¡A 5% )¡A Nausea (oral or intravenous¡A 7% ) Neurologic: Dizziness (3% )¡A Headache (6% to 10% )¡A Insomnia (4% ) Serious Cardiovascular: Aortic aneurysm¡A Or dissection¡A Cardiac arrest (0.1% to 1% )¡A Prolonged QT interval¡A Torsades de pointes¡A Ventricular tachycardia (0.1% to 1% ) Dermatologic: Erythema multiforme¡A Stevens-Johnson syndrome Endocrine metabolic: Hypoglycemia (0.1% to 1% ) Hematologic: Aplastic anemia¡A Pancytopenia¡A Thrombocytopenic purpura Hepatic: Hepatitis¡A Liver failure Immunologic: Hypersensitivity reaction (0.1% to 1% )¡A Non-allergic anaphylaxis Musculoskeletal: Myasthenia gravis¡A Exacerbation¡A Rupture of tendon¡A Tendinitis (0.1% to 1% ) Neurologic: Disorientated¡A Disturbance of attention¡A Guillain-Barre syndrome¡A Memory impairment¡A Peripheral neuropathy¡A Pseudotumor cerebri¡A Raised intracranial pressure¡A Seizure (0.1% to 1% ) Ophthalmic: Retinal detachment Psychiatric: Delirium¡A Depression (0.1% to 1% )¡A Hallucinations (0.1% to 1% )¡A Paranoid disorder¡A Psychotic disorder¡A Suicidal Renal: Acute renal failure (0.1% to 1% )¡A Tubulointerstitial nephritis,25¢J¥H¤U,(¥é³æ) Adult: 250-500 mg po/IV 1-2 times daily. Administer 250 mg injection over 30 minutes¡A 500 mg injection over 60 minutes. (¼ö¯f) Adult: 250-750 mg po/IV Q24H (depends on indication). For most indications¡A in patients with normal renal function¡A the 750 mg dose is preferred. Pediatric (age > 28 days): 16-20 mg/kg/day (divided Q12H) (maximum: 750 mg/day) For oral therapy¡A avoid concomitant exposure to multivalent cations (Ca¡A Fe¡A Al¡A Mg¡A Zn) in dairy products¡A multivitamins and antacids. Cations chelate the drug and prevent absorption.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,LEVOFLOXACIN: Contraindicated (Use only if no other alternatives) [¥é³æ] Ãö©óÃh¥¥°ü¤k¨Ï¥Îlevofloxacinªº¸ê®Æ¡A¨ä¼Æ¶q¬Û·í¦³­­¡A¦Ó°Êª«¹êÅç¨Ã¨S¦³µo²{ª½±µ©Î¶¡±µªº¥Í´Þ¬r©Ê¡C ¤£¹L¦b¯Ê¥F¤HÃþ¸ê®Æ¡A¥B¹êÅç«Çªº¸ê®Æ»¡©úFluoroquinolones¨ã¦³¯}Ãa¦¨ªø¥Íª«©Ó­«³n°©ªº­·ÀI¡A levofloxacin¤£À³¥Î©óÃh¥¥¤k©Ê¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Cravit¿õ¾¯¸T¥Î©ó­÷¨Å¤¤ªº°ü¤k¡C¥Ø«e¨S¦³¨¬°÷ªº¸ê°T¥H¤F¸Ñlevofloxacin¬O§_·|¶i¤J¤HÃþ¥À¨Å¤¤¡F ¤£¹L¨ä¥LfluoroquinoloneÃþªºÃÄª«·|¶i¤J¥À¨Å¤¤¡C ¦b¯Ê¥F¤HÃþ¸ê®Æ¡A¥BFluoroquinolones¨ã¦³¯}Ãa¦¨ªø¥Íª«©Ó­«³n°©ªº¥i¯à¹êÅç­·ÀIªº±¡ªp¤U¡A levofloxacin¤£À³¥Î©ó­÷¨Å¤k©Ê¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¶·¾ã²É§]ªA¡A¥i­é¥b¦ý¤£­n©CÄZ©ÎÀ£¸H¡C¦]¼t°Ó¥¼¦³¬ÛÃö¦w©w©Ê¤ÎÀø®Ä¼Æ¾Ú¡A­Y¦³¿i¯»»Ý¨D½Ð±K¤ÁºÊ´ú¯f±wÁ{§É¤ÏÀ³¡C
ITHYR,Thyrotropin alfa,Thyrogen inj 1.1mg,META,Adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer. Adjunctive diagnostic tool for serum Tg testing w/ or w/o radioiodine imaging.,Hypersensitivity to thyrotropin alfa or any component of the formulation.,Nausea¡A vomiting¡A headache¡A asthenia¡A chills¡A fever¡A flu syndrome¡A dizziness¡A paresthesia.,2-8¢XCÁ×¥ú,IM¡A 2 injection regimen¡A initial 0.9 mg followed by second 0.9 mg 24 hours later.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,IM: 1.2 mL D/W,,,,°t»s»Pµ¹ÃÄ 1.¬°­á´¹¯»¥½¡A¥H1.2 mLªºµLµßª`®g¥Î¤ô¥[¤J§t¦³THYROGEN­á´¹¯»¥½ªºª`®g²~¤¤¡C 2.Âà°Êª`®g²~ª½¨ì¤º®eª«·»¸Ñ¡A¤£¥i·n®Ì·»²G¡A°t»s«áªºTHYROGEN ·»²G¿@«×¬°¨CmL§tthyrotropin alfa 0.9 mg¡C 3.°t»s«áªº·»²GÀ³¸Ó¬O³z©úµL¦âªº¡A­Y·»²G¦³Âø½è©Î²V¿B¤£²M¤Á¤Å¨Ï¥Î¡C 4.©â¥X1 mLªºTHYROGEN°t»s·»²G(§tthyrotropin alfa 0.9 mg)¶i¦æÁv³¡¦Ù¦×ª`®g¡C 5.°t»s«áªºTHYROGEN·»²G­YµL§NÂÃ¡A«h¥²¶·¦b3¤p®É¤º§¹¦¨ª`®g¡A­Y¦³§NÂÃ¡A³Ì¦h¥i©ñ¸m24¤p®É¡C 6.¥¼¥Î§¹ªº³¡¤À¥²¶·¥á±ó¡A¤£¥i»P¨ä¥LÃÄª«²V¦X¨Ï¥Î¡C
IAHIB,Haemophilus b Conjugate Vaccine,Act-HIB inj 0.5 mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
OTAK,Lansoprazole,Takepron OD 30mg,ALIM,Treatment of gastric ulcers¡A duodenal ulcers¡A gastroesophageal reflux disease - erosive esophagitis¡A symptomatic treatment of gastroesophageal reflux disease. Zollinger-Ellison syndrome¡A combined with antibiotics for Helicobacter pylori-related peptic ulcers¡A and treatment of stomach ulcers caused by NSAIDs.,Known hypersensitivity including anaphylaxis¡A anaphylactic shock¡A angioedema¡A bronchospasm¡A acute tubulointerstitial nephritis¡A and urticaria to any component of the product. Concomitant use with rilpivirine-containing products.,Common: Abdominal pain (Up to 5%)¡A Constipation (1-5%)¡A Diarrhea (Up to 7.4%)¡A Nausea (1.3-3%)¡A Headache (1%) Serious: Cutaneous lupus erythematosus¡A Erythema multiforme¡A Acute generalized exanthematous pustulosis¡A Acute generalized exanthematous pustulosis¡A Stevens-Johnson syndrome (SJS)¡A Toxic epidermal necrolysis (TEN)¡A Hypomagnesemia¡A Clostridium difficile diarrhea¡A Fundic gland polyposis of stomach¡A Pancreatitis¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms (DRESS)¡A Fracture of bone¡A Rhabdomyolysis¡A Acute tubulointerstitial nephritis,¶J¦s©ó 25¢XC,Take Takepron 1 hour before meals¡A do not crush or chew. Avoid use in children aged 1-17 for over 12 weeks. Adult: - Ulcer of duodenum¡A short-term treatment: 15 mg PO QD up to 4 weeks. - Gastric ulcer¡A short-term treatment of active ulcer: 30 mg PO QD up to 8 weeks. - Gastric ulcer¡A treatment of NSAID-associated gastropathy: 30 mg PO QD for 8 weeks. - Gastroesophageal reflux disease (GERD): 15 mg PO QD up to 8 weeks. - Erosive esophagitis¡A short-term treatment: 30 mg PO QD for 8 weeks. - Zollinger-Ellison syndrome: 60 mg PO QD up to 90 mg BID.- Pediatric: - Erosive esophagitis: (1-11 years¡A <=30 kg or less) 15 mg PO QD for 8-12 weeks. (1-11 years¡A >30 kg) 30 mg PO QD for 8-12 weeks. (12-17 years) 30 mg PO QD for up to 8 weeks. - Gastroesophageal reflux disease: (1-11 years¡A less than or equal-30 kg) 15 mg PO QD for up to 12 weeks. (1-11 years¡A greater than 30 kg) 30 mg PO QD for up to 12 weeks. (12-17 years) 15 mg PO QD for up to 8 weeks.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¹ï©óÄY­«¨x¥\¯à¤£¥þ¯f¤H(Child-Pugh C¯Å)«ØÄ³¨C¤Ñ¤fªA15²@§J¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ] ±q¤wµoªíªºÆ[¹î©Ê¬ã¨s©ÒÀò±oªº¼Æ¾Ú¡A¹ï©ólansoprazoleªvÀø©M¤£¨}§³®Wµ²ªG¡A¨äÁ`Åé ¤W¨Ã¨S¦³Åã¥Ü¬ÛÃö©Ê¡C¦b°Êª«¥Í´Þ¬ã¨s¤¤¡A¹ï¾¹©x§Î¦¨´Á¦Ü­÷¨Å´Áªº¤j¹«¡A¤fªAµ¹¤©¬Û·í©ó ¤HÅé³Ì¤j«ØÄ³¾¯¶q6.4­¿ªºlansoprazole¡A¾É­P¨ä«á¥N©ó²£«á21¤Ñ¦bªÑ°©­«¶q¡BªÑ°©ªø«×¡BÀYÁv ªø©M¥ÍªøªO«p«×(¶È­­¶¯©Ê)ªº´î¤Ö¡C³o¨Ç¼vÅT»PÅé­«¼W¥[ªº´î¤Ö¦³Ãö¡CÀ³§iª¾¥¥°ü¨ä¹ï©ó­L¨àªº¼ç¦b­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¨S¦³lansoprazole¥X²{¦b¤HÃþ¨Å¥Ä¡B¹ï­÷¨ÅÀ¦¨à¼vÅT¡B©Î¹ï¨Å¥Ä¤Àªc¼vÅTªº¸ê°T¡CµM¦Ó lansoprazole©M¨ä¥NÁÂ²£ª«¦³¥X²{¦b¤j¹«¨Å¥Ä¡AÀ³¦Ò¼{­÷¨Å¹ï©óµo¨|»P°·±dªº¯q³B©M¥À¿ËªºÁ{ §É»Ý¨D¡A¥H¤Î¦Ò¶q¹ïÁý¥À¨ÅªºÀ¦¨à©Î¥ÀÅé¼ç¦bª¬ªp¹ïÁý¥À¨ÅªºÀ¦¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT¡C,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O] ¥»ÃÄ¬°¤f·»¿õ¡C¥i·»¤ô±Y¸Ñ«áºÞÄé¡C
IHIB,Haemophilus b Conjugate Vaccine,Hiberix inj 0.5 mL,HIMM,,Active immunisation of all infants > 6 weeks against disease caused by Haemophilus influenza type b,,2-8,Primary vaccination 3 doses by IM in the 1st 6 months of life. Maybe starting from the age of 6 weeks. booster dose: in 2nd years of life. Previously unvaccinated children 1-5 years 1 dose¡A children 6-12 months 2 dose 1 month apart¡A followed by 1 booster dose in 2nd years of life,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OCOU2,Warfarin,Coumadin 2.5mg,HEMT,,,,,,,,,,,,,,,,,,,
IERY,Erythromycin,Erythrocin I.V. 500mg,QANB,,,,,,,,,,,,,,,,,,,
OLEV,Vardenafil,Levitra F.C. 20mg¡A 4's/box,SGU,,¾AÀ³¯g: Treatment of erectile dysfunction. °Æ§@¥Î: Headache¡A flushing¡A dyspepsia¡A nausea¡A dizziness¡A rhinitis. Dermatologic: Flushing (7.6% to 11% ) Neurologic: Dizziness (2% to 2.3% )¡A Headache (14.4% to 15% ) Respiratory: Rhinitis (9% ) ¸T§Ò: Coadministration with nitrates or nitric oxide donors. Concomitant use of vardenafil with HIV protease inhibitors such as indinavir or ritonavir.,,«Ç·Å,Adult 10 mg approximately 25-60 mins before sexual activity. Max: 20 mg once daily. A max dose of 5 mg should not be exceeded when used in combination with an £\-blocker¡A erythromycin¡A ketoconazole or itraconazole. Starting dose of 5 mg is recommended for elderly (over 65 years).,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OMON1,Fosinopril,Monopril 10mg,CAVS,,,,,,,,,,,,,,,,,,,
OMODI,Flunitrazepam,Modipanol 2mg,CNEU,,¾AÀ³¯g: Insomnia. °Æ§@¥Î: Drowsiness & lightheadedness the next day; confusion & ataxia; dependence. ¸T§Ò: Respiratory depression; acute pulmonary insufficiency; severe hepatic impairment¡A myasthenia gravis¡A sleep apnoea syndrome.,,«Ç·Å,Adult 0.5-1 mg at bedtime. Max: 2 mg/day. Elderly or debilitated patients Initially 0.5 mg at bedtime. Max: 1 mg/day.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IBUR,Bumetanide,Burinex inj 2mg/4mL,CAVS,,¾AÀ³¯g: Edema associated with CHF¡A liver cirrhosis¡A renal diseases. Acute pulmonary edema¡A drug-induced fluid retention¡A drug poisoning that can be treated by forced diuresis. Hypertension. °Æ§@¥Î: Hypokalemia & hypochloremic alkalosis (long-term therapy); muscular cramps in patients with severe chronic renal failure; asymptomatic hyperuricemia. Rarely¡A skin rashes¡A depression of formed elements in the blood; abdominal discomfort. ¸T§Ò: Hepatic coma¡A severe electrolyte depletion¡A concurrent administration with lithium¡A anuria.,,«Ç·Å,adult: Edema: 0.5-2 mg ORALLY daily¡A maximum 10 mg/day Edema: 0.5-1 mg IV or IM¡A given over 1-2 min; can give a second and third dose at intervals of 2-3 hr to maximum of 10 mg/day pediatric: Not FDA-approved in children less than 18 years of age Edema: (over 6 months) 0.015-0.1 mg/kg/dose ORALLY¡A IV¡A or IM every 6-24 hrs; max dose 10 mg/day Edema: (neonates) 0.01-0.05 mg/kg/dose ORALLY¡A IV¡A OR IM every 24 to 28 hrs.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OMOP,Mosapride,Mopride 5mg,ALIM,Treatment of GI motility disorders e.g. heartburn¡A nausea &/or vomiting.,GI hemorrhage¡A mechanical obstruction¡A or perforation.,Hypersensitivity reactions¡A rash¡A urticaria¡A hematological changes¡A GI disturbances¡A increased hepatic enzyme levels. Palpitation¡A dizziness¡A headache¡A fatigue¡A hypertriglyceridemia¡A tremor.,25¢J¥H¤U,Adult 15 mg/day in 3 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;,,,,,
OSB,Benzoate,Sod. Benzoate 250 mg,META,,¾AÀ³¯g: Nonketotic hyperglycinemia. °Æ§@¥Î: GI discomfort.,,«Ç·Å,initial dose: 250 mg/kg/day divided into 3-6 times up to 750 mg/kg/day if necessary max dose: 10 gm/day,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OONEH,Alfacalcidol,Onealfa 0.5mcg(µÇÅ¦¤º¬ì¨Ï¥Î),META,,¾AÀ³¯g:¬°ºû¥L©RD3»s¾¯(B018274100)(B023031100),,RT,Osteoporosis: Adult: 0.5-1 mcg qd. Child: 0.01-0.03 mcg/kg qd. Hypoparathyroidism: 1-4 mcg qd.,,,,¦w¥þ,,,,,,,,,,
OOSC5,Ca Carbonate from Oyster Shell,Stanley Calcium(Ca= 500mg),ALIM,,Calcium supplement.,,,1-2 cap tid.,,,,,,,,,,,,,,
OPER,Dipyridamole,Persantin S.C. 50mg,HEMT,,¾AÀ³¯g: Coronary insufficiency¡A Inhibition of platelet aggregation. °Æ§@¥Î: Worsening of angina¡A flushing¡A dizziness¡A palpitations. Lightheadedness¡A headache¡A asthenia¡A hypersensitivity reactions. GI disturbances. Cardiovascular: Electrocardiogram abnormal (15.9%)¡A Hypotension¡A IV (4.6%) Gastrointestinal: Abdominal discomfort¡A Oral (6.1%)¡A Nausea¡A IV (4.6%) Neurologic: Dizziness (12%)¡A Headache¡A IV (12.2%)¡A Headache¡A Oral (2.3%),,«Ç·Å,Adult: Coronary insufficiency :150-225mg daily in divided doses. Inhibition of platelet aggregation : 300- 450mg daily in divided doses. Childn in general¡A 5-10mg/kg body weight.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OPZAT,Pyrazinamide,Pyrazinamide 500mg,QANB,,¾AÀ³¯g: Treatment of pulmonary & extrapulmonary TB. °Æ§@¥Î: Hepatotoxicity¡A jaundice¡A hyperuricemia leading to attacks of gout¡A anorexia¡A nausea¡A vomiting¡A arthralgia¡A malaise¡A fever¡A sideroblastic anemia¡A difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea¡A Vomiting Musculoskeletal: Arthralgia (40%) ¸T§Ò: Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage,,«Ç·Å,Always administer in combination with other antitubercular drugs. 20-35 mg/kg daily in 3-4 divided doses. (max. 3 gm/day).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OPON,Mefenamic Acid,Ponstan 250mg,CNEU,Mild to moderate pain¡A RA¡A osteoarthritis¡A dysmenorrhea¡A menorrhagia¡A Still's disease¡A pyrexia.,Patients in whom aspirin and/or other NSAIDs have induced symptoms of bronchospasm¡A allergic rhinitis or urticaria. Active ulceration or chronic inflammation of GIT. Kidney disease. Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Severe renal¡A hepatic & heart failure.,Hematologic disorders; hypersensitivity reactions; glucose intolerance in diabetic patients¡A hyponatremia; nervousness; aseptic meningitis¡A blurred vision¡A convulsion¡A dizziness¡A drowsiness¡A headache¡A insomnia; eye irritation¡A reversible loss of color vision; ear pain; palpitation; hypotension; asthma¡A dyspnea; abdominal pain¡A diarrhea¡A nausea with or without vomiting; skin & SC tissue disorders; dysuria¡A hematuria¡A renal failure including papillary necrosis. Cardiovascular: Edema Hepatic: Increased liver function test (up to 15%),15-30¢J,Adult and teenagers >14 years old: 500 mg TID. Still's Disease or antipyretic therapy for children of 6 months to 14 years old: 19.5-25mg/kg/day divided into 3 doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] ¦]µL¨¬°÷¥B±±¨î¨}¦nªº¬ã¨s¡A©Ò¥H¥u¦³¦b¹ï¥À¿Ëªº¼ç¦b®Ä¯q¶W¹L¹ï­L¨à¥i¯à³y¦¨ªº¦MÀI®É¡A¤è¥i¦bÃh¥¥´Á¶¡¨Ï¥Î¥»ÃÄ¡C Mefenamic acid©Î¥¦ªº¥NÁÂ²£ª«¯à¤£¯à³q¹L­L½L¤´¥¼ª¾¡C¥Ñ©ó¦¹ÃþÃÄª«·|¼vÅT­L¨àCV¨t²Î¡]¨Ò¦p¦­µo©Ê°Ê¯ß¾ÉºÞ³¬Âê¡^¡A©Ò¥H¤£«ØÄ³¦bÃh¥¥´Á¶¡¨Ï¥Î¥»ÃÄ¡A¥BÀ³Á×§K¦bÃh¥¥«á´Á¨Ï¥Î¡C Mefenamic acid§í¨î«e¦C¸¢¯À¦X¦¨¡A¦bÃh¥¥«á´Áµ¹ÃÄ¥i¯à·|³y¦¨Ãh¥¥´Á©µªø¡A¦Ó¥B§«Ãª¤À®Y¡C¬y¦æ¯f¾Ç¬ã¨sªº¼Æ¾ÚÅã¥Ü¦bÃh¥¥ªì´Á¨Ï¥Î«e¦C¸¢¯À¦X¦¨§í¨î¾¯«á¾É­P¦ÛµM¬y²£ªº¦MÀI©Ê¼W¥[¡C NSAID­Y¨Ï¥Î©óÃh¥¥¤¤´Á©Î«á´Á¡A¥i¯à·|¤Þ°_­L¨àµÇÅ¦¥\¯à¤£¥þ¡AÄY­«®É·|³y¦¨¦Ï¤ô¶q´î¤Ö©Î¦Ï¤ô¹L¤Ö¡C¦¹Ãþ§@¥Î·|µo¥Í©ó¶}©lªvÀø«á¤£¤[¡A°±ÃÄ«á¤@¯ë¨ã¥i°f©Ê¡CÃh¥¥¤k©Ê±µ¨ümefenamic acidªvÀø®É¡AÀ³±K¤ÁºÊ´ú¦Ï¤ô¶q¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ·L¶qªºmefenamic acid¥i¯à·|¤Àªc¦Ü¨Å¥Ä¤¤¡A¦Ó¶i¤J¦Y¥À¥¤ªºÀ¦¨àÅé¤º¡A ¦]¦¹±Â¨Åªº¥À¿Ë¤£¥i¥HªA¥Î¥»ÃÄ¡C,PC;PO;WM;,,,,,
IBCG0,BCG Vaccine,BCG (¥d¤¶­]¡A¬F©²´£¨Ñ) 0.5mg/mL,HIMM,Active immunisation against TB.,Individuals who are tuberculin +ve. Congenital or acquired immunodeficiencies¡A including treatment w/ immunosuppressive drugs or radiation.,Ulceration of the inoculation site¡A lymphadenitis¡A keloid formation. Rarely¡A enlargement of the regional lymph glands.,8¢J¥H¤UÁ×¥ú,By intradermal inj. Adult & children >1 year 0.1 mL.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]µL¬ÛÃö¸ê°T¡C,SC;,,,,,
EATRU,Ipratropium,Atrovent U.D.V.0.5mg,ERSP,,¾AÀ³¯g:¥DªvºC©Êªý¶ë©Ê®ðºÞª¢¡B¤ä®ðºÞ®ð³Ýµ¥(B018863412) AR: Dry mouth¡A throat irritation or allergic reactions¡A cough¡A rise of intraocular pressure may occur if substance accidentally enters eyes in patients with narrow-angle glaucoma. CI: Hyperseneitivity of atropine-like substances.Chronic obstructive bronchitis¡A bronchial¡A asthma.,,RT,Oral inhalation: Inhaler: Over 12 yrs: 1-2 inhalations tid-qid¡A Nebulizer Soln: Adult: 2 ml¡A Child: 1 ml¡A q4-6h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OSERQ,Quetiapine,SEROQUEL 200 mg,CNEU,,¾AÀ³¯g¡G¨­¤ß¬ì¥ÎÃÄ¡C(B022544100),,RT,Day 1: 50 mg Day 2: 100 mg Day 3: 200 mg Day 4: 300 mg From day 4 onwards¡A the dose should be titrated to 400800 mg/day,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OELM,Pentosan Polysulfate,Elmiron 100mg,SGU,,¾AÀ³¯g: ¨Ï¥Î©ó¦]¶¡½è©Ê»H¯Öª¢¤Þ°_ªº»H¯Ö¯kµh©Î¤£¾Aªº¸Ñ°£¡C °Æ§@¥Î: Alopecia¡A diarrhea¡A nausea¡A headache¡A rash¡A dyspepsia¡A abdominal pain¡A liver function abnormalities¡A dizziness¡A increased bleeding time. Dermatologic: Alopecia (4%) Gastrointestinal: Abdominal pain (2%)¡A Diarrhea (4%)¡A Indigestion (2%)¡A Nausea (4%) Neurologic: Headache (3%) ¸T§Ò: ¤wª¾¹ï¦¹ÃÄª«¡B¤Æ¾Çµ²ºc¬ÛÃöªº¤Æ¦Xª«©Î½á§Î¾¯¹L±Óªº¯f±w¤£¥i¨Ï¥Î¡C,,«Ç·Å,100 mg tid.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ECOL,Dexamethasone + Neomycin,Colsamin eye oint 3.5gm,TOPH,,¾AÀ³¯g: Non-infectious forms of conjunctivitis¡A keratitis & blepharitis¡A especially of allergic origin¡A inflammation of the anterior uvea¡A scleritis¡A episcleritis & orbital myositis. Sympathetic ophthalmia. °Æ§@¥Î:Glaucoma¡A cataract¡A transient blurred vision. Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin¡A Finding of skin healing¡A Impaired Endocrine metabolic: Cushing's syndrome¡A Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )¡A Raised intraocular pressure (25% ) Psychiatric: Depression¡A Euphoria Respiratory: Pulmonary tuberculosis ¸T§Ò: Herpes cornea superficialis; injuries & ulcerous processes of the cornea; ocular TB; ophth mycosis; ulcerous lesions of the cornea; narrow- & open-angle glaucoma.,,«Ç·Å,Once to several times daily.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EAGNO3P,Silver Nitrate,Silver nitrate powder 25gm,AGENT,,,,,,,,,,,,,,,,,,,
LALU,Oxethazaine+Aluminum Hydroxide+Magnesium Hydroxid,Aluzaine susp 360mL,ALIM,,¾AÀ³¯g: Gastro duodenal ulcer & esophagitis. °Æ§@¥Î: Anorexia¡A dry mouth¡A constipation¡A diarrhea; phosphate depletion; headache¡A drowsiness¡A dizziness¡A weakness. ¸T§Ò: Renal failure; hypophosphatemia.,,«Ç·Å,Adult 5-10 mL taken 15 minutes before meals & at bedtime.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OTANL,Nabumetone,Tanleeg F.C. 500mg,CNEU,,,,,,,,,,,,,,,,,,,
IBONV,Ibandronate,Bonviva inj 3mg/3mL,META,Treatment of osteoporosis in postmenopausal women.,Uncorrected hypocalcaemia. Severe renal impairment.,Back pain¡A pain in extremity¡A infection¡A asthenia¡A allergic reaction; GI disturbances; hypercholesterolemia; myalgia¡A joint disorder; arthritis; headache¡A dizziness¡A vertigo¡A nerve root lesion; upper resp infection¡A bronchitis¡A pneumonia¡A pharyngitis; UTI. Cardiovascular: Hypertension (5.3% to 7.3% ) Gastrointestinal: Abdominal pain (5.1% to 7.8% )¡A Diarrhea (2.4% to 6.8% )¡A Indigestion (3.6% to 11.9% )¡A Nausea (2.1% to 5.1% ) Musculoskeletal: Backache (4.3% to 13.5% ) Neurologic: Headache (2.6% to 6.5% ) Respiratory: Bronchitis (2.1% to 10% )¡A Upper respiratory infection (2% to 33.7% ),15-30¢J,3 mg IV every 3 months.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,IV over 15-30 seconds,,1.¤£¥i»P§t¶t·»²G©Î¨ä¥LÀR¯ß¿éª`ÃÄª«²V¦X¨Ï¥Î 2.¥H15-30¬íªº®É¶¡ÀR¯ß±Àª`3mgÃÄª«¡A¨Ï¥Î®É°È¥²¤p¤ß¡A¡u¤£¥i¡v±NBonvivaª`¤J°Ê¯ß©ÎÀR¯ß®Ç°¼¡A§_«h¥i¯à³y¦¨²ÕÂ´¶Ë®`¡C
OLOE,Levonorgestrel + Ethinylestradiol,Loette (28's/pk),HM,,,,,,,,,,,,,,,,,,,
OBAC5,Baclofen,Baclospas 5mg,CNEU,Alleviation of signs & symptoms of painful spasticity resulting from cerebral & spinal cord injuries¡A multiple sclerosis¡A cerebral palsy¡A trigeminal neuralgia¡A low back syndrome¡A flexor spasm¡A tardive dyskinesia.,Epilepsy or convulsive disorders.,Common: Hypotension (0-9%)¡A Constipation (intrathecal bolus¡A 0.2%; intrathecal titration¡A 1.5%; intrathecal maintenance¡A 5.1% ; oral¡A 2-6%)¡A Nausea (Intrathecal bolus¡A 1.4%¡A intrathecal titration¡A 3.3%¡A intrathecal maintenance¡A 7.3% ; oral¡A 4-12%)¡A Vomiting (intrathecal bolus¡A 6.2%; intrathecal titration¡A 8.5%; intrathecal maintenance¡A 4%)¡A Poor muscle tone (intrathecal bolus¡A 2.4-5.4%; intrathecal titration¡A 13.5-14.4%; intrathecal maintenance¡A 25.3-34.7%)¡A Asthenia (0.7-15%)¡A Dizziness (Intrathecal bolus¡A 1.7-2.4%; intrathecal titration¡A 1.9-2.6%; intrathecal maintenance¡A 7.9-8% ; oral¡A 5-15%)¡A Headache (intrathecal bolus¡A 1.6-6.6%; intrathecal titration¡A 2.5-7.8%; intrathecal maintenance¡A 5.1-10.7% ; oral¡A 4-8%)¡A Somnolence (Intrathecal bolus¡A 5.7-7.6%; intrathecal titration¡A 5.9-10.5%; intrathecal maintenance¡A 18.7-20.9% ; oral¡A 10-63%)¡A Urinary complication (2-6%)¡A Fatigue (2-4%)¡A Shivering (0.5-1.3%) Serious: Gastrointestinal hemorrhage¡A Aseptic meningitis¡A with intrathecal administration¡A Coma (0.5-1.5%)¡A Seizure (Intrathecal bolus¡A 0.5-0.9%; intrathecal titration¡A 1.3-3.3%; intrathecal maintenance¡A 4.7-10%)¡A Pneumonia (0.2-2%)¡A Substance withdrawal,25¢J¥H¤U°®Àê³BÁ×§K¶§¥ú·Ó®g,Adult: Initially 5-15 mg daily divided in 1-3 doses. May increase dosage by 15 mg/day increments every 3 days until optimum effect is achieved. Usual daily dose is 30 mg. (MicroMedex maximum: 80mg/day) Children: Initially 5 mg daily in 2 divided doses. Usual daily dose: 4-6 years old¡A 5-15 mg; 7-11 years old¡A 5-20 mg; 12-15 years old¡A 5-25 mg.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;,,,,,
LSTR,Fenoterol,Strolin liquid 0.5mg/mL¡A 60mL,ERSP,Prophylaxis & treatment of symptoms of reversible obstructive pulmonary disease (including asthma & acute bronchospasm)¡A chronic bronchitis¡A emphysema.,Hypertrophic obstructive cardiomyopathy¡A tachyarrhythmias.,Fine tremor of skeletal muscles & nervousness. Less frequently¡A tachycardia¡A dizziness¡A palpitations or headache. Very rarely¡A local irritation or allergic reactions; cough¡A paradoxical bronchospasm. Potentially serious hypokalemia may result from £]2-agonist therapy.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Age >14 years: 5-10 mL TID. Age 6-14 years: 5 mL TID. Age 1-6 years 2.5-5 mL TID. Age <1 year: 2.5 mL BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T§Ò¡G¥¥´Á¤p©ó22¶gªÌ¡C·íÄ~ÄòÃh¥¥©Î¦w­L³Q»{¬°¬O¦MÀIªº±¡ªp(¨Ò¦p:ÄY­«§³®W¬r¦å¯g¡B¤l®c¤º·P¬V¡B«e¸m­L½L³y¦¨¤§³±¹D¥X¦å¡B¤lÅöíw¯g©Î­««×¤lÅöíw¯g«e¥ü¡B­L½L¦­´Á­éÂ÷¡BÂÀ±aÀ£­¢µ¥)¡C¦º­L¤Î¤wª¾­P¦º©Ê­L¨à·î§Î©Î¬V¦âÅé²§±`¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¨S¦³¬ÛÃö±Ô­z¡C,AC;AC15;PC;PO;WM;,,,,,
OMEPE,Mepenzolate,Mepenzolate 7.5mg,ALIM,,¾AÀ³¯g: Diarrhea¡A abdominal pain & flatulence due to irritable colon¡A colitis¡A acute enterocolitis¡A diverticulitis. °Æ§@¥Î: GI disturbances¡A dry mouth¡A mental confusion¡A dizziness¡A weakness¡A drowsiness¡A headache¡A nervousness¡A increased ocular pressure¡A cycloplegia¡A blurred vision¡A dilation of the pupil¡A hypersensitivity reactions¡A tachycardia¡A palpitations¡A urinary retention¡A decreased sweating¡A drowsiness¡A insomnia¡A impotence¡A suppression of lactation. ¸T§Ò: Glaucoma¡A obstructive uropathy¡A urinary or GI obstruction¡A paralytic ileus¡A intestinal atony of the elderly or debilitated patient¡A unstable CV status in acute GI hemorrhage¡A toxic megacolon complicating ulcerative colitis¡A myasthenia gravis.,,«Ç·Å,2 tab tid,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OMYLI,Ginkgo Biloba,Mylin 40mg,CAVS,,¾AÀ³¯g: Disturbed cerebral performance. Supporting treatment in reduced hearing capacity due to cervical syndrome. Peripheral arterial circulatory disturbances with saved circulatory reserve.,,«Ç·Å,1 tab tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EFLUR,Flurbiprofen,Flurbi PAP(4¤ù/¥]),CNEU,Analgesics and anti-inflammatory for arthrosis deformans¡A scapulohumural periarthritis¡A tenosynovitis¡A perimyositis¡A muscle pain¡A post-trauma swelling.,Hypersensitivity to flurbiprofen.,Local irritation,Àx¦s©ó³±²D°®Àê³B,Apply 1 patch daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] ¥Ø«e©|µL¸ê®Æ¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¥Ø«e©|µL¸ê®Æ¡C,EXT;,,,,,
OUROT,Propiverine,Urotrol 15mg,SGU,,¾AÀ³¯g:¬°±Æ§¿¾÷¯à§ïµ½¾¯(A045700100),,RT,15 mg bid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OFERI,Iron,Ferich 150mg,NUTR,,¾AÀ³¯g:¹w¨¾¤ÎªvÀøÅK½è¯Ê¥F¯g¡B¯ÊÅK©Ê³h¦å¯g(A045855100),,RT,1 tab daily. If required¡A 1 tab. bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EEVR,Norelgestromin + Estradiol,Evra patch 3's/box,HM,,¾AÀ³¯g: Female contraception. °Æ§@¥Î: Fluid retention¡A change in body wt¡A reduced glucose tolerance¡A mood changes¡A depression¡A irritability¡A changes in libido¡A estrogen-induced chorea¡A alteration in contact lens tolerance¡A slight rise in BP¡A GI disturbances¡A bloating¡A erythema nodosum¡A rash¡A pruritus¡A chloasma¡A melasma¡A erythema multiforme¡A acne¡A seborrhea¡A alopecia¡A intermenstrual bleeding¡A amenorrhea¡A absence of withdrawal bleeding¡A change in size of uterine fibromyomata¡A vag candidosis¡A dysmenorrhoea¡A breast tenderness¡A galactorrhea¡A breast pain¡A application site reaction¡A headache. ¸T§Ò: Thrombophlebitis¡A thromboembolic disorders or a past history of these conditions; cerebro-vascular or coronary artery disease; valvular heart disease with complications; severe hypertension; diabetes with vascular involvement; migraine with focal aura; known or suspected carcinoma of the breast¡A endometrium or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use; acute or chronic hepatocellular disease with abnormal liver function; hepatic adenomas or carcinomas; known or suspected pregnancy.,,«Ç·Å,Apply 1 patch weekly for 3 weeks¡A followed by a patch-free interval of 1 week to clean¡A dry¡A hairless¡A intact healthy skin on the buttock¡A abdomen¡A upper outer arm or upper torso (excluding the breast).,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OVIA1,Glucosamine Sulphate,Viartril-S powder 1.5gm,CNEU,,¾AÀ³¯g: All forms of degenerative osteoarticular disease. Primary & secondary osteoarthrosis such as: cervical arthrosis¡A coxofemoral arthrosis¡A gonarthrosis¡A dorsal arthrosis¡A lumbosacral arthrosis¡A scapulohumeral arthrosis¡A periarthritis¡A lumbago¡A fractures¡A osteoarticular dystrophies¡A chronic & subacute arthritis. °Æ§@¥Î: Headache¡A fatigue¡A drowsiness¡A flushing. ¸T§Ò: Hypersensitivity to glucosamine and shellfish.,,«Ç·Å,Sachet 0.5 sachet once daily for 3 mth. Repeat at an interval of 2 mth.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þªÌ¡AÀ³¦bÂåÅ@ºÊ·þ¤Uµ¹»P,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OADA1,Nifedipine,Adalat 10mg,CAVS,,¾AÀ³¯g: Hypertension¡A chronic stable angina pectoris °Æ§@¥Î: Initially mild & transient vasodilatation¡A hypotension¡A rarely GI¡A skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established¡A discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia¡A gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )¡A Palpitations (up to 7% )¡A Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )¡A Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough¡A Dyspnea ¸T§Ò: CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,,«Ç·Å,Usually 1 cap tid¡A can be increased to 2 cap tid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OFUG,Flutamide,Fuferel 250mg,RACA,,,,,,,,,,,,,,,,,,,
OCONQ,Mebendazole,Conquer 100mg,QANP,Whipworm¡A pinworm¡A hookworm¡A roundworm¡A tapeworm¡A strongyloides infestations.,Pregnancy.,Transient abdominal pain¡A diarrhea. At high doses¡A Allergic reactions¡A raised liver enzyme values¡A leukopenia¡A alopecia.,25¢J¥H¤UÁ×¥ú,Trichuriasis (whipworm)¡A ascariasis (roundworm)¡A ancylostoma duodenale or necator americanus (hookworm): 100 mg orally twice daily for 3 days; repeat in 3 weeks if not cured with initial treatment. Enterobiasis (pinworm): 100 mg orally as a single dose.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st trimester,PREGNANCY RECOMMENDATION: Compatible (2nd & 3rd Trimesters),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ECUT,Fluticasone,Cutivate cream 5gm,TDER,,¾AÀ³¯g: Relief of the inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses such as: eczema including atopic¡A infantile & discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses including lichen simplex; lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus; an adjunct to systemic steroid therapy in generalised erythroderma; insect bite reactions; prickly heat. °Æ§@¥Î: Local burning¡A pruritus¡A local atrophic skin changes. Secondary infection¡A exacerbation of the signs & symptoms of the dermatoses¡A hypercorticism. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ) ¸T§Ò: Rosacea¡A acne vulgaris¡A perioral dermatitis; primary cutaneous viral infections (eg. Herpes simplex¡A chickenpox; perianal & genital pruritus¡A dermatoses in infant < 3 month including dermatitis & napkin eruptions. Primarily infected skin lesions caused by infection with fungi or bacteria.,,«Ç·Å,Inflammatory dermatoses Adult¡A children¡A infants >=3 months Apply thinly to the affected skin areas once-bid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IDPT1,Diphtheria + Tetanus + Pertussis,Infanrix (DTPa) inj 0.5mL,HIMM,,Active immunization against diphtheria¡A tetanus and pertussis,,§NÂÃ,IM¡A for child 6 wks-6 yrs¡A 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1 yr later. Booster dose: Given at 4-6 yrs.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IDIG2,Digoxin,Lanoxin inj 0.5mg/2mL (Digoxin),CAVS,Emergency heart failure.,Digitalis toxicity¡A ventricular tachycardia/fibrillation¡A obstructive cardiomyopathy. Arrhythmias due to accessory pathways (e.g. Wolff-Parkinson-White syndrome).,Extra beats¡A anorexia¡A nausea and vomiting. Diarrhoea in elderly¡A confusion¡A dizziness¡A drowsiness¡A restlessness¡A nervousness¡A agitation and amnesia¡A visual disturbances¡A gynaecomastia¡A local irritation (IM/SC inj)¡A rapid IV admin may lead to vasocostriction and transient hypertension.,25¢J¥H¤UÁ×¥ú,Adults and children over 10 years old: Loading dose: ""Totally"" 500-1000 mcg (0.5-1 mg). Fist dose: half of full dose. Remaining dose: in divided doses at 4-8 hour intervals. Each dose should be given by IV infusion at a rate of 10-20 minutes. Maintenance dose: Based on the percentage of peak body storage lost through daily loss. Maintenance dose = peak body storage (loading dose) * daily loss/100 daily loss% = 14 + Ccr/5 Ccr (Corrected to 70 kg body weight or 1.73 m2 body surface area creatinine clearance rate) = (140-age)/Scr(mg/100mL) Newborns¡A infants and children under 10 years of age: Loading dose¡A should be divided. (Fist dose: half of full dose. Remaining dose: in divided doses at 4-8 hour intervals. Pre-term newborns less than 1.5 kg: 20 mcg/kg within 24 hours. 1.5 to 2.5 kg preterm newborns: 30 mcg/kg within 24 hours. Full-term newborns to 2-year-old child: 35 mcg/kg within 24 hours. Children 2 to 5 years old: 35 mcg/kg within 24 hours. Children 5 to 10 years old: 25 mcg/kg within 24 hours. Each dose should be given by IV infusion at a rate of 10-20 minutes. Maintenance dose: Adjust the dose according to the serum digoxin concentration.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iH/S¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,May be administered undiluted or diluted. Inject slowly over ?5 minutes.,IV infusion over 10-20 mins,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IPAN4,Pantoprazole,Pantoloc I.V. inj 40 mg,ALIM,Maintenance therapy of Erosive esophagitis. Gastroesophageal reflux disease. Gastric hypersecretion¡A Pathological. Zollinger-Ellison syndrome.,Known hypersensitivity including anaphylaxis¡A anaphylactic shock¡A angioedema¡A bronchospasm¡A acute tubulointerstitial nephritis¡A and urticaria to substituted benzimidazoles or any component of the product. Concomitant use with rilpivirine-containing products.,Common Gastrointestinal: Abdominal pain (3% )¡A Diarrhea (4% )¡A Flatulence (4% ) Neurologic: Headache (5% ) Serious Dermatologic: Cutaneous lupus erythematosus Gastrointestinal: Atrophic gastritis¡A Clostridium difficile diarrhea¡A Fundic gland polyposis of stomach Hematologic: Thrombocytopenia (less than 1% ) Immunologic: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Musculoskeletal: Disorder of muscle¡A Fracture of bone¡A Osteoporosis-related¡A Hip fracture¡A Rhabdomyolysis Renal: Tubulointerstitial nephritis¡A acute,25¢J¥H¤UÁ×¥ú,Peptic or duodenal ulcer¡A Gastric ulcer & GERD: 40 mg IV infusion once daily Zollinger-Ellison syndrome Initial¡A 80 mg IV infusion QD- Q12H,»Ý½Õ¾ã¾¯¶q,[¥é³æ]±w¦³ÄY­«¨x¥\¯à¤£¥þªº¯f¤H¨C¤é¾¯¶q¶·­°¦ÜPantoprazole 20mg¡A¨Ã¥B¦bªvÀø´Á¶¡¡A©w´ÁºÊ´ú¨x»Ã¯À¡A­Y¨x»Ã¯À«ü¼Æ¤É°ª¡AÀ³°±¤î¨Ï¥ÎPantoloc i.v.¡C [Micromedex 20201228]Hepatic impairment (mild to moderate¡A Child-Pugh A to C): No dosage adjustments necessary; doses above 40 mg/day have not been studied.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ]¦³ÃöÃh¥¥°ü¤k¤§¥R¨¬¼Æ¾Ú (300 ¡V 1000 ¥óÃh¥¥µ²ªG®×¨Ò ) Åã¥Ü¡APantoloc i.v. µL­P·î­L©Î­L¨à / ·s¥Í¨à¬r©Ê¡C °Êª«¸ÕÅç«hÆ[¹î¨ì¥Í´Þ¬r©Ê¡C¬°¥H¨¾¸U¤@¡AÃh¥¥´Á¶¡³Ì¦nÁ×§K¨Ï¥Î Pantoloc i.v.¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]°Êª«¸ÕÅçÃÒ¹ê pantoprazole ·|¤Àªc¦Ü¨Å¥Ä¤º¡C ¥Ø«e¦³Ãö pantoprazole ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤º¤§¸ê®Æ¤£¨¬¡A¦ýªº½T´¿µo¥ÍÃÄª«¤Àªc¦Ü¤HÃþ¨Å¥Ä¤º¤§®×¨Ò¡C µLªk±Æ°£¥i¯à¹ï·s¥Í¨à / À¦¨à³y¦¨­·ÀI¤§¥i¯à©Ê¡C ¦]¦¹¨M©w¬O§_°±¤î­÷¨Å©Î°±¤î / ¸T¥ÎPantoloc i.v. ªvÀø®É¡AÀ³±N­÷¨Å¹ï«Äµ£¤§®Ä¯q¥H¤ÎPantoloc i.v. ªvÀø¹ï¯f¤H¤§®Ä¯q¯Ç¤J¦Ò¶q¡C,IVD;IVPUSH;,¨C¤@¤p²~¤ºª`¤J 10mL ª`®g¥Î¥Í²z­¹ÆQ¤ô sodium chloride 9mg/mL (0.9%) ·»¸Ñ¡C,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,administer over a period of at least 2 minutes,Reconstitute 1 vial (40 mg) with 10 mL of Normal Saline injection and then dilute to a total volume of 100 mL to a final concentration of approximately 0.4 mg/mL for a 40-mg dose. Administer IV over a period of 15 minutes at a rate of approximately 7 mL/min.,°t»s«áªº·»²G¥iª½±µª`®g§ë¤©©Î¥H100mLª`®g¥Î¥Í²z­¹ÆQ¤ô0.9% sodium chloride 9 mg/mL©Î5%¸²µå¿}ª`®g²G²V¦Xºwª`¡CÀ³¨Ï¥Î¬Á¼þ©Î¶ì½¦®e¾¹¶i¦æµ}ÄÀ¡C°t»s«á¡A©Î°t»s¥Bµ}ÄÀ«á¡A¨Ï¥Î´Á¤§¤Æ¾Ç»Pª«²zÃ­©w©Ê¬°25¢XC¤U¥iºû«ù12¤p®É¡C¨Ì¾Ú·L¥Íª«Æ[ÂI¡AÀ³¥ß§Y¨Ï¥Î²£«~¡C°£¯S©w·»¾¯¥~¡APantoloc i.v. ¤£¥i»P«D«ü©w·»¾¯¶i¦æ°t»s©Î²V©M¡C¨Ï¥ÎÀR¯ßª`®g§ë¤©¡A©ó2¡V15¤ÀÄÁ¤ºª`®g§¹²¦¡C
OHYP,Barnidipine HCL,Hypoca 15mg,CAVS,,I: Hypertension¡A renal parenchymatous hypertension & renovas-cular hypertension. CI: Pregnancy¡A lactation¡A children. ADR: Headache¡A dizziness.,,,D: Adult: initially 5 ~ 10 mg daily¡A may be increased to 10 ~ 15 mg daily.,,,,,,,,,,,,,,
ONEU,Gabapentin,Neurontin 300mg,CNEU,Adjunctive treatment of partial seizures in adults & children ? 3 years with epilepsy. Post-herpetic neuralgia.,Patients who are hypersensitive to gabapentin and other components of Neurontin.,Somnolence¡A dizziness¡A ataxia¡A fatigue¡A nystagmus¡A headache¡A tremor¡A diplopia¡A nausea &/or vomiting¡A rhinitis¡A amblyopia. Cardiovascular: Peripheral edema (1.7% to 8.3% ) Gastrointestinal: Nausea (3.9% )¡A Vomiting (3.3% ) Immunologic: Viral disease (10.9% ) Neurologic: Ataxia (3.3% to 12.5% )¡A Dizziness (adults¡A 17.1% to 28%; pediatrics¡A 2.5% )¡A Nystagmus (0.1% to 8.3% )¡A Somnolence (8.4% to 21.4% ) Psychiatric: Hostile behavior (1% to 7.6% ) Other: Fatigue (3.4% to 11% )¡A Fever (10.1% ),15-30¢J,Epilepsy: Adult & children > 12 years 900-1800 mg/day in 3 divided doses. May be increased to 1800 mg/day. On the other long term clinical trials¡Abeing increased to 2400 mg/day ¡Asome patient may be in the good tolerance .Children 3-12 years Initially 10- 15 mg/kg/day in 3 divided doses¡A then titrated upward over a period of about 3 days to the effective dose of 25-35 mg/kg/day for children over 5 years. May require up to 40 mg/kg/day for children over 3-5 years.Not recommand that over 12 hrs of maximum interval when dosage up to 50 mg/kg/day.Post-herpetic neuralgia :Adult Initially 900 mg TID. May titrate dosage up to 1800 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OUNA,Sultamicillin,Unasyn 375mg,QANB,,I: Infection caused by G(+) & G(-) bacteria including some an-aerobes. ADR: GI disturbance¡A skin rashes¡A itching¡A blood disorders¡A ana-phylaxis & superinfection. CI: History of allergic reaction to any penicillins.,,,D: Adult 750 ~ 1500 mg/day 12 hrly. Children¡A infants & neonate 25 ~ 50 mg/kg/day 12 hrly.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OGAL,Zinc Acetate,Galzin 25mg,META,,I: Maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent. CI: In patients with known hypersensitivity to any of the components of this formulation. ADR: gastric irritation; elevations of serum alkaline phosphatase¡AAmylase & lipase lasting from weeks to months suggesting,,,D: Adults : recommended dose is 50mg as zinc 3 times daily. Children 10 years of age or older or in women who are pregnant: 25 mg 3 times a day . The dose can be raised to 50 mg tid if monitoring indicates a lessening control.,,,,¦w¥þ,,,,,,,,,,
EJMC,Naftifine,Jia mei cream 1% 5gm,TDER,,¾AÀ³¯g: Mycotic infections of skin & skin folds; onychomycosis; Candida infections of the skin; pityriasis versicolor; dermatomycosis (with or without pruritus). °Æ§@¥Î: Burning¡A stinging¡A dryness¡A redness. Dermatologic: Dry skin (3%)¡A Erythema¡A Pruritus¡A Sensation of burning of skin¡A Local (5%) Other: Irritation symptom (2%),,«Ç·Å,1% applied topically once or bid. Continue for at least 2 weeks after clinical healing.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
LZYR,Cetirizine,Zyrtec soln 0.1%¡A 60mL,HIMM,,¾AÀ³¯g: Symptomatic treatment of seasonal rhinitis & conjunctivitis¡A perennial allergic rhinitis as well as pruritus & urticaria of allergic origin. °Æ§@¥Î: Headache¡A dizziness¡A drowsiness¡A agitation¡A dry mouth¡A GI discomfort¡A skin reactions & angioedema. ¸T§Ò: Lactation.,,«Ç·Å,Children 2-5years: initial dose: 2.5mg qd¡A may be increased to 2.5mg every 12 hours or up to 5 mg/day. Children >6 years and Adults: 5-10 mg once daily¡A depending upon symptom severity.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EPIL1,Pilocarpine,Pilocarpine oph soln 1%¡A 15mL,TOPH,,¾AÀ³¯g: Control of intraocular pressure. °Æ§@¥Î: Burning¡A itching & smarting of the eyes¡A blurred vision¡A conjunctival vascular congestion¡A myopia¡A lens changes (chronic use)¡A vitreous haemorrhage¡A pupillary block¡A headache. Dermatologic: Flushing¡A Oral formulation (8-13%)¡A Sweating symptom¡A Oral formulation (29-68%) Endocrine metabolic: Shivering¡A Oral formulation (3-15%) Gastrointestinal: Nausea¡A Oral formulation (6-15%) Neurologic: Dizziness¡A Oral formulation (5-12%) Ophthalmic: Blurred vision¡A Ophthalmic formulation¡A Burning sensation in eye¡A Ophthalmic formulation¡A Itching of eye¡A Ophthalmic formulation¡A Scotopic sensitivity¡A Difficulty¡A with ophthalmic formulation Renal: Increased frequency of urination¡A Oral formulation (9-12%) Respiratory: Rhinitis¡A Oral formulation (5-14%) ¸T§Ò: Acute iritis¡A anterior uveitis¡A acute inflammatory disease of the anterior segment.,,«Ç·Å,1 drop up to qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EPIL2,Pilocarpine,PILOCARPINE 2% oph soln 15mL,TOPH,,¾AÀ³¯g: Control of intraocular pressure. °Æ§@¥Î: Burning¡A itching & smarting of the eyes¡A blurred vision¡A conjunctival vascular congestion¡A myopia¡A lens changes (chronic use)¡A vitreous haemorrhage¡A pupillary block¡A headache. Dermatologic: Flushing¡A Oral formulation (8-13%)¡A Sweating symptom¡A Oral formulation (29-68%) Endocrine metabolic: Shivering¡A Oral formulation (3-15%) Gastrointestinal: Nausea¡A Oral formulation (6-15%) Neurologic: Dizziness¡A Oral formulation (5-12%) Ophthalmic: Blurred vision¡A Ophthalmic formulation¡A Burning sensation in eye¡A Ophthalmic formulation¡A Itching of eye¡A Ophthalmic formulation¡A Scotopic sensitivity¡A Difficulty¡A with ophthalmic formulation Renal: Increased frequency of urination¡A Oral formulation (9-12%) Respiratory: Rhinitis¡A Oral formulation (5-14%) ¸T§Ò: Acute iritis¡A anterior uveitis¡A acute inflammatory disease of the anterior segment.,,«Ç·Å,1 drop up to qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EPRED,Prednisolone,Pred Forte 1% 5mL ophthalmic suspension,TOPH,The treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva¡A cornea¡A and anterior segment of the globe.,Acute untreated purulent ocular infections¡A in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis)¡A vaccinia¡A and varicella¡A and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Hypersensitivity to any of the ingredients of this preparation.,Increased intraocular pressure with optic nerve damage¡A visual field defects. Posterior subcapsular cataract formation (heavy or protracted use)¡A secondary ocular infection from fungi or viruses liberated from ocular tissues & perforation of the globe when there is thinning of the cornea or sclera. Systemic side effects may occur with extensive use of steroids.,«Ç·Å¤U(15-25¢J)¶J¦s¡A¤£»Ý§NÂÃ©Î§N­á¡C,Shake well before using. Instill 1-2 drops BID-QID into the conjunctival sac. During the initial 24 to 48 hours¡A the dosing frequency may be increased to 2 drops every hour if necessary. Care should be taken not to discontinue therapy prematurely.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Prednisolone: Human Data Suggest Risk [¥é³æ] §³®W´Á¶¡¤§ªø´Á¨Ï¥Î©Î¼W¥[¾¯¶q®Éªº¦w¥þ©Ê¤´¥¼½T©w¡C ¦]¦¹¡A³B¤è¥»«~©ó¥¥°ü¯f¤H¡A¶È­­¹ï­L¨àÀø®Ä¯q³B¦h©óÃa³B®É¡C©ó°Êª«¸ÕÅç¤¤¡AÃþ©T¾Jªº¨Ï¥ÎÅã¥Ü¦³·î­L¤ÏÀ³¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,Prednisolone: Compatible [¥é³æ] ¹ï©ó§½³¡Ãþ©T¾J¤§¨Ï¥Î¬O§_·|¾É­P¨¬¥H²£¥Í¥þ¨­©Ê§l¦¬¡A¨Ã©ó¨Å¥Ä¤¤²£¥Í¥i°»´úªº¶q¡A¦Ü¤µ¤´¥¼ª¾¡C ¦]¦¹¡A¤£«ØÄ³±Â¨Å°ü¤k¨Ï¥Î¥»«~¡C·í§ë»P¥»«~©ó±Â¨Å°ü¤k®É¡AÀ³¼f·V¦Ò¼{¥»«~¹ï¨ä¤§ªº­«­n©Ê¡C,OD;OL;OU;,,,,,
EXAL2,Latanoprost + Timolol,Xalacom eye drops 2.5mL,TOPH,,,,,,,,,,,,,,,,,,,
OANG,Drospirenone + Estradiol,Angeliq 28's/pk,HM,,¾AÀ³¯g: ªvÀø°±¸g¤@¦~¥H¤W°ü¤k¤§§ó¦~´Á¯g­Ô¸s °Æ§@¥Î: Enlarged abdomen¡A abdominal pain¡A diarrhoea¡A dyspepsia¡A gastroenteritis¡A nausea¡A tooth disorder¡A vomiting¡A wt gain. Depression¡A dizziness¡A emotional lability¡A fever¡A headache¡A migraine¡A nervousness¡A pain. Acne¡A pruritus¡A rash. Amenorrhoea¡A breast pain¡A dysmenorrhoea¡A hyperlipidaemia¡A intermenstrual bleeding¡A reduced libido¡A irregular menstrual cycles. Bronchitis¡A cough¡A pharyngitis¡A rhinitis¡A sinusitis¡A upper respiratory infection. ¸T§Ò: Undiagnosed abnormal genital bleeding. Renal insufficiency¡A hepatic dysfunction or tumor. Adrenal insufficiency¡A cholestatic jaundice of pregnancy¡A jaundice with prior oral contraceptive use. Major surgery with prolonged immobilisation. Heavy smoking (>=15 cigarettes/day) in patients >35 y. History of or current thrombophlebitis or venous thromboembolic disorders. Active or recent (within 1 yr) arterial thromboembolic disease; cerebral vascular disease¡A coronary artery disease¡A severe hypertension¡A valvular heart disease with thrombogenic complications. Diabetes with vascular involvement; headache with focal neurological symptoms. Known or suspected breast carcinoma¡A endometrial cancer¡A oestrogen-dependent neoplasms. Pregnancy.,,«Ç·Å,1 tab/day,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IFLUO,5-Fluorouracil,Fluorouracil inj 1000mg/20mL,RACA,,¾AÀ³¯g: Palliative management of carcinoma of the colon¡A rectum¡A breast¡A stomach & pancreas. °Æ§@¥Î: Stomatitis¡A esophagopharyngitis¡A diarrhea¡A anorexia¡A nausea¡A vomiting¡A enteritis¡A cramps¡A abdominal pain & ulceration¡A glossitis¡A pharyngitis¡A leukopenia¡A alopecia¡A dermatitis¡A ocular irritation¡A central neurotoxicity (acute cerebellar syndrome)¡A myocardial ischemia & angina. ¸T§Ò: Patients in a poor nutritional state; with depressed bone marrow function or potentially serious infections.,,«Ç·Å,IV inj Initial dosage 12 mg/kg once daily (to a max of 800 mg daily) for 4 days. If no toxicity is observed¡A this may be followed by 6 mg/kg on the 6th¡A 8th¡A 10th & 12th days¡A unless toxicity occurs. Poor risk patients or those in a poor nutritional state 6 mg/kg/day (to a max of 400 mg daily) for 3 days. If no toxicity is observed¡A 3 mg/kg is given on the 5th¡A 7th & 9th days¡A unless toxicity occurs. Maintenance therapy Repeat the dosage of the 1st course every 30 days after the last day of the previous course of treatment. Alternatively¡A administer a maintenance dose of 10-15 mg/kg/week (to a max of 1 g/week) as a single dose. IV infusion 15 mg/kg/day (to a max of 1 g daily) being infused in 500 mL of 5% dextrose or 0.9% NaCl over 4 hours & repeated on successive days until toxicity occurs or a total of 12-15 g has been given. Continuous infusion may also be used. The course may be repeated after 4-6 weeks.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¦å¿}ÅÜ¤Æ (DM¯f¤H)¡C
IACE,Amikacin,Acemycin inj 500mg/2mL,QANB,Respiratory tract infection¡A UTI¡A bacteremia¡A septicemia¡A skin & soft tissue infection¡A intra-abdominal¡A burns¡A post-op infection.,Hypersensitivity to aminoglycosides. Pregnancy. Myasthenia gravis,Frequency not defined: Neurotoxicity (including muscle twitching¡A numbness¡A seizure¡A tingling of skin)¡A Auditory ototoxicity¡A vestibular ototoxicity¡A Nephrotoxicity¡A Respiratory paralysis. Postmarketing: Hypotension¡A Skin rash¡A Albuminuria¡A hypomagnesemia¡A Clostridium difficile-associated diarrhea¡A nausea¡A vomiting¡A Azotemia¡A hematuria¡A oliguria¡A toxic nephrosis¡A Anemia¡A eosinophilia¡A leukocyturia¡A Drug reaction with eosinophilia and systemic symptoms¡A Drug fever¡A headache¡A paresthesia¡A tremor¡A Arthralgia¡A state of neuromuscular blockade¡A Acute kidney injury¡A casts in urine¡A increased serum creatinine.,25¢J¥H¤U,Adults and children: 7.5-15 mg/kg/day divided into 2 doses infused over 30-60 minutes; neonates and premature infants: 10-15 mg/kg/day divided into 2 doses infused over 1-2 hours. For adults with life-threatening infections: 500 mg every 8 hours (Maximum dose 1.5 g/day; duration < or = 10 days). Amikacin in concentrations 0.25% (2.5 mg/ml) may be used as an irrigating solution in abscess cavities¡A the pleural space¡A the peritoneum (adults: 0.5 g/dose) and the cerebral ventricles. Intraventricular injection: 1-5 mg/day in concentrations 1 mg/mL for 3 days. *****NEONATE ANTIBIOTICS DOSE***** Amikacin: Draw peak 30 min after completion infusion; draw trough just before next dose (©ó²Ä4­Ódoseµ¹ÃÄ«e) PMA <=29 week Postnatal 0 to 7 days dose : 18mg/kg Q48h PMA <=29 week Postnatal 8 to 28 days dose : 15mg/kg Q36 h PMA <=29 week Postnatal >=29 days dose :15mg/kg Q24 h PMA 30 ¡V 34 week Postnatal 0 to 7 days dose : 18mg/kg Q36 h PMA 30 ¡V 34 week Postnatal >= 8 days dose : 15mg/kg Q24 h PMA 35 - 44 week ¡A dose : 15mg/kg Q24 h,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;IH;IM;INS;IVD;IVI;SCI;SUBCI;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C,,¦¨¤H:¨C500 mg ºwª`®É¶¡¤j©ó 30 ~ 60 ¤ÀÄÁ¡CInfant:ºwª`®É¶¡À³¤j©ó1 ~ 2 ¤p®É¡CPediatrics: ºwª`®É¶¡À³¤j©ó30 ~ 60 ¤ÀÄÁ¡C,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C 2. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C
EEXT6,Nystatin+Neomycin+Gramicidin+Triamcinolone,Extracomb cream 6gm,TDER,,¾AÀ³¯g:Àã¯l¡B¹L±Ó©Ê©Mµoª¢©Ê¥Ö½§¯f¡A¨Ã§í¨î²Óµß¡BÅðµß¤§·P¬V¯g(A023133323),,,,,,,,,,,,,,,,,
OIWE,Aluminum Dihydroxyallantoinate+magnesium silicate,Iwell 50/450mg,ALIM,,¾AÀ³¯g: Relief of gastric hyperacidity¡A gastric & duodenal ulcer¡A acute & chronic gastritis. °Æ§@¥Î: Constipation or diarrhea.,,«Ç·Å,1 tab TID ~ QID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
LIDO,Ibuprofen,Idofen susp 20mg/mL¡A 60 mL,CNEU,,¾AÀ³¯g: Relief of pain¡A inflammation & fever. °Æ§@¥Î: GI effects including ulceration; rashes; bronchospasm. Rarely¡A thrombocytopenia. ¸T§Ò: Peptic ulceration; patients in whom attacks of asthma¡A angioedema¡A urticaria or rhinitis are precipitated by aspirin & other NSAIDs.,,«Ç·Å,Adult Initially 80 mL daily in 3-4 divided doses. Juvenile RA Children > 7 kg body wt 1.5-2 mL/kg daily in 3-4 divided doses. Fever & pain in children Children > 7 kg 0.25-0.5 mL/kg daily in divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
YSIC,Sea salt,SiccOral spray 50mL,ZOTH,,,,,,,,,,,,,,,,,,,
ENIC2,Nicotine,Nicotinell TTS 20,ZADT,To aid smoking cessation.,Non-smokers¡A children & occasional smokers. Acute MI¡A unstable or worsening angina pectoris¡A severe cardiac arrhythmias¡A recent CVA¡A skin diseases. Pregnancy¡A lactation.,Most frequent: Reaction at application site (usually erythema or pruritus)¡A headache¡A cold & flu-like symptoms¡A insomnia¡A nausea¡A myalgia & dizziness. Less common: BP changes¡A other CNS effects & GI disturbances. Also see lit.,«Ç·Å,(Uptodate) Nicotinell TTS 10: 10 cm2 (7 mg/day); TTS 20: 20 cm2 (14 mg/day); TTS 30: 30 cm2 (21 mg/day). Transdermal patch: Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced). Patients smoking > 10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks¡A followed by step 2 (14 mg/day) for 2 weeks; finish with step 3 (7 mg/day) for 2 weeks. Patients smoking < or = 10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks¡A followed by step 3 (7 mg/day) for 2 weeks. Do not exceed more than 3 months of treatment.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,NICOTINE REPLACEMENT THERAPY: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk Contraindicated (with any use of tobacco),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,NICOTINE REPLACEMENT THERAPY: Limited Human Data¡XPotential Toxicity,EXT;SKIN;,,,,,
ENIC3,Nicotine,Nicotinell TTS 30,ZADT,To aid smoking cessation.,Non-smokers¡A children & occasional smokers. Acute MI¡A unstable or worsening angina pectoris¡A severe cardiac arrhythmias¡A recent CVA¡A skin diseases. Pregnancy¡A lactation.,Most frequent: Reaction at application site (usually erythema or pruritus)¡A headache¡A cold & flu-like symptoms¡A insomnia¡A nausea¡A myalgia & dizziness. Less common: BP changes¡A other CNS effects & GI disturbances. Also see lit.,25¢J¥H¤U,(Uptodate) Nicotinell TTS 10: 10 cm2 (7 mg/day); TTS 20: 20 cm2 (14 mg/day); TTS 30: 30 cm2 (21 mg/day). Transdermal patch: Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced). Patients smoking > 10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks¡A followed by step 2 (14 mg/day) for 2 weeks; finish with step 3 (7 mg/day) for 2 weeks. Patients smoking ? 10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks¡A followed by step 3 (7 mg/day) for 2 weeks. Do not exceed more than 3 months of treatment.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,NICOTINE REPLACEMENT THERAPY: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk Contraindicated (with any use of tobacco),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,NICOTINE REPLACEMENT THERAPY: Limited Human Data¡XPotential Toxicity,EXT;,,,,,
OHALC,Triazolam,Halcion 0.25 mg,CNEU,,¾AÀ³¯g: Transient & short-term insomnia¡A short-term adjunctive treatment in long-term insomnia. °Æ§@¥Î: Drowsiness¡A dizziness¡A lightheadedness¡A impaired coordination. Occasionally¡A anterograde amnesia¡A confusion¡A agitation. ¸T§Ò: Patients with known sensitivity to benzodiazepines.,,«Ç·Å,Adult 0.25 mg before retiring. Elderly &/or debilitated patient 0.125-0.25 mg (therapy initiated at 0.125 mg) before retiring.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OLIPS,Fenofibrate,Lipanthyl 160mg,CAVS,Hypercholesterolaemia¡A hypertriglyceridaemia & mixed dyslipidaemias (types IIa¡A IIb¡A III¡A IV¡A & V).,Children. Pregnant & breastfeeding women. Severe liver dysfunction¡A including unexplained persistent liver function abnormalities; patients with active liver disease¡A including primary biliary cirrhosis. Gallbladder disease. Severe chronic kidney disease¡A including end-stage renal disease or those receiving dialysis. Chronic or acute pancreatitis (except for acute pancreatitis caused by severe hypertriglyceridemia). Hypersensitivity to fibrates or ketoprofen¡A especially if there's a history of photosensitivity or phototoxic reactions. Hypersensitivity to fenofibrate or its excipients. Hypersensitivity to peanuts¡A peanut oil¡A or legume phospholipids.,Common: Abdominal pain (4.6%)¡A Nausea (2.3%)¡A Aspartate aminotransferase serum level above reference range (3.4%)¡A Liver function tests outside reference range (7.5%; 3x ULN or greater¡A 13% with fenofibrate 87-130 mg¡A 0% with fenofibrate 43 mg or less)¡A Backache (3.4%)¡A Rhinitis (2.3%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis due to drug¡A Pancreatitis¡A Cholestatic hepatitis¡A Injury of liver¡A drug-induced¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Acute¡A Delayed hypersensitivity reaction¡A Rhabdomyolysis Serum creatinine above reference range (12-27%)¡A Angioedema,30¢J¥H¤U,Adults: one 160mg tablet daily¡A taken with a main meal. Monitoring treatment response through blood lipid measurements is recommended. If there's inadequate response after a few months (e.g.¡A 3 months)¡A consider supplementation or an alternative treatment.,µL»Ý½Õ¾ã¾¯¶q,¤£«ØÄ³¨Ï¥Î¦b¨x¥\¯à¤£¥þªº¯f¤H,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ] °Êª«¸ÕÅç¤¤¨Ã¥¼Åã¥Ü¥ô¦ó­P·î§@¥Î¡C¦b³y¦¨¥ÀÅé¬r©Ê¤§¾¯¶q½d³ò¤U¤wÅã¥Ü¦³­F­L¬r©Ê¡C ¹ï¤HÃþ¤§¼ç¦b­·ÀI¥¼ª¾¡C¤£¥i¨Ï¥Î¦bÃh¥¥ªº°ü¤k¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e¨S¦³fenofibrate©M/©Î¨ä¥NÁÂª«±q¥ÀÅéÂà²¾¦Ü¥À¨Å¤¤ªº¬ÛÃö¸ê®Æ¡C¤£¥i¦b±Â¨Å´Á¶¡¨Ï¥Î¡C ¥¼ª¾fenofibrate¬O§_·|±Æªn¤Î/©Î¥¦ªº¥NÁÂª«¨ì¤HÃþ¨Å¥Ä¤¤¡C¤£¯à±Æ°£¹ï³Ü¥À¥¤¤§¨àµ£ªº­·ÀI¡C ¦]¦¹¡Afenofibrate¤£À³©ó±Â¨Å´Á¶¡¨Ï¥Î¡C,PO;WM;,,,,,
ICAM,Irinotecan,Campto inj 100mg/5mL,RACA,,¾AÀ³¯g¡G±ß´Á©Ê¤j¸zª½¸zÀù¤§²Ä¤@½uªvÀøÃÄª«¡A»P5-FU¤Îfolinic acid¦X¨Ö¡A¨Ï¥Î©ó¥¼´¿±µ¨ü¹L¤Æ¾ÇªvÀø¤§±wªÌ¡A³æ¿W¨Ï¥Î©ó´¿±µ¨ü5-FUÀøµ{ªvÀøµL®Ä¤§±wªÌ¡C(B022473221) ¸T§Ò¯g¡G(1)±w¦³ºC©Êµoª¢©Ê¸z¯e¯f©Î¸z¹Dªý¶ë¤§¯f¤H¡C (2)¹ïCampto¥ô¤@¦¨¥÷¹L±Ó¤§¯f±w¡C (3)Ãh¥¥´Á»P­÷¨Å´Á¡C (4)Áx¬õ¯À > 1.5 ­¿¥¿±`­È¤W­­ªº¯f±w¡C (5)ÄY­«°©Åè¥\¯à°IºÜ¤§¯f±w¡C (6) WHO°·±dª¬ºA > 2 ¤§¯f±w¡C,,12 hrs at room temp.,Monotherapy : 300 ~ 350 mg / m2¡A iv infusion for 30 ~ 90 minutes¡A every 3 weekly. Combined Therapy : 180 mg / m2 Campto¡A iv infusion for 30 ~ 90 minutes¡A followed by folinic acid and 5-FU¡A every 2 weekly.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IETO,Etoposide,Eposin inj 100mg/5mL,RACA,,¾AÀ³¯g:Small cell carcinoma of lung¡A In combination with other approved chemotherapeutic agents as first line¡A Testicular cancer¡A In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical¡A chemotherapeutic¡A and radiotherapeutic therapy °Æ§@¥Î:Alopecia¡A Shivering¡A Diarrhea¡A Inflammatory disease of mucous membrane¡A Loss of appetite¡A Nausea¡A Vomiting¡A Asthenia¡A Fever¡A Malaise ¸T§Ò:Hypersensitivity to etoposide phosphate or etoposide.,,«Ç·Å,Small cell carcinoma of lung¡A In combination with other approved chemotherapeutic agents as first line: range¡A 35 mg/m(2)/day IV for 4 days¡A to 50 mg/m(2)/day IV for 5 days; in combination with other approved chemotherapeutic agents; repeat at 3 to 4 wk intervals Testicular cancer¡A In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical¡A chemotherapeutic¡A and radiotherapeutic therapy: range¡A 50-100 mg/m(2)/day IV days 1-5¡A to 100 mg/m(2)/day IV on days 1¡A 3¡A 5; in combination with other approved chemotherapeutic agents; repeat at 3-4 wk intervals,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.2 - 0.4 mg/mL¡A¨Ï¥Î«eÀ³¦A¦¸¥ØµøÀË¬d¬O§_¦³Áû²É¨I¾ý©ÎÅÜ¦â¡C 3. ¿éª`¹L§Ö¥i¯àµo¥Í§C¦åÀ£¡C 4. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
IGEM,Gemcitabine,Gemzar inj 200mg,RACA,1-line treatment of metastatic breast cancer (in combination with paclitaxel) after failure of adjuvant chemotherapy which contained an anthracycline (unless contraindicated). 1-line treatment (in combination with cisplatin) of inoperable¡A locally advanced (stage IIIA or IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC). Treatment of advanced ovarian cancer¡A pancreatic cancer (locally advanced or metastatic).,Patients with a known hypersensitivity to gemcitabine.,Myelosuppression with anemia¡A leukopenia or thrombocytopenia; nausea & vomiting¡A diarrhea & stomatitis; transient elevations in serum transminases; mild proteinuria & hematuria¡A hemolytic uremic syndrome (discontinue); fever & flu-like symptoms; rash¡A pruritus; dyspnea¡A occasionally accompanied by bronchospasm¡A pulmonary toxicity (discontinue); edema; infections¡A sepsis (rare); alopecia; paresthesia; inj site reactions; allergic reactions; CV events (rare). Cardiovascular: Peripheral edema (20% ) Dermatologic: Alopecia (15% to 90% )¡A Rash (10% to 30% ) Endocrine metabolic: Hyperglycemia (30% )¡A Hypomagnesemia (30% ) Gastrointestinal: Constipation (10% to 42%)¡A Diarrhea (14% to 25% )¡A Nausea and vomiting (64% to 96% )¡A Stomatitis Hematologic: Anemia¡A All grade (65% to 89% )¡A Leukopenia¡A All grade (21% to 86% )¡A Neutropenia¡A All grade (62% to 90% )¡A Thrombocytopenia¡A All grade (24% to 85% ) Hepatic: Alkaline phosphatase raised (16% to 71% )¡A ALT/SGPT level raised (6% to 72% )¡A AST/SGOT level raised (3% to 72% ) Immunologic: Infectious disease (8 to 28% ) Musculoskeletal: Arthralgia (24% )¡A Myalgia (33% ) Neurologic: Paresthesia (2% to 38% )¡A Peripheral motor neuropathy (15% to 35% )¡A Sensory neuropathy (23% to 64% ) Otic: Hearing disorder (25% ) Renal: Hematuria (13% to 35% )¡A Proteinuria (10% to 45% )¡A Serum creatinine raised (2% to 38% ) Respiratory: Dyspnea (1% to 23% ) Other: Fatigue (40% )¡A Fever (6% to 41% )¡A Pain (10% to 48% ),30¢J¥H¤U,[Ovarian Cancer] 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle¡A in combination with carboplatin AUC 4 intravenously after Gemzar administration on Day 1 of each 21-day cycle. [Breast Cancer] 1250 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle that includes paclitaxel. Paclitaxel should be administered at 175 mg/m2 on Day 1 as a 3-hour intravenous infusion before Gemzar. [Non-Small Cell Lung Cancer] Every 4-week schedule: 1000 mg/m2 over 30 minutes on Days 1¡A 8¡A and 15 in combination with cisplatin 100 mg/m2 on Day 1 after Gemzar. Every 3-week schedule: 1250 mg/m2 over 30 minutes on Days 1 and 8 in combination with cisplatin 100 mg/m2 on Day 1 after Gemzar. [Pancreatic Cancer] 1000 mg/m2 over 30 minutes intravenously.The recommended treatment schedule:¡E Weeks 1-8: weekly dosing for the first 7 weeks followed by one week rest.¡E After Week 8: weekly dosing on Days 1¡A 8¡A and 15 of 28-day cycles. [Bladder cancer] 1000 mg/m2 over 30 minutes on days 1¡A 8¡A and 15 in combination with cisplatin 70 mg/m2 on day 1; repeat cycle every 28 days. [Biliary tract cancer] 1000 mg/m2 as a single agent over 30 minutes once weekly for 3 weeks followed by 1 week rest; repeat cycle every 28 days. 1000 mg/m2 over 30 minutes in combination with cisplatin 25 mg/m2 on Days 1 and 8; repeat cycle every 21 days.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à·l¶ËªÌÀ³°±ÃÄ,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Micromedex:Infant risk cannot be reled out.,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. °t»s¦nªº¿éª`·»²G¿@«×¬ù 0.1 mg/mL¡A«Ç·Å¦w©w©Êºû«ù 24 ¤p®É¡C¥»ÃÄ«~¤£¥i§NÂÃ¡AÃÄª«·|²£¥Íµ²´¹¡C 3. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
IMIT,Mitomycin C,Mitomycin-C inj 2mg,RACA,,Gastrointestinal¡A breast¡A lung¡A cervix and bladder carcinomas.,,,IV (through a running IV infusion): 10-20 mg/m2 (max. 20mg/m2) as a single dose every 6-8 wks; or 2 mg/m2/day for 5 days and after 2 drug-free days for a further 5 days¡A repeated every 6-8 wks. Bladder instillation: prevention: 4-10 mg/day¡A treatment: 10-40 mg/day.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IONC,Vincristine,Oncovin inj 1mg,RACA,,Hodgkin's disease¡A leukemia¡A neuroblastoma¡A rhabdomyosarcoma¡A Wilms' tumor.,,,IV (injected carefully or through a running IV infusion): Adult: 0.4-1.4 mg/m2 (max. 2 mg/m2 as a single dose over 1 min once weekly.) Child over 1 yr: 1.5-2 mg/m2 once weekly. Under 10 kg: 0.05 mg/kg once weekly.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IPLA5,Cisplatin,Platinex inj 50mg/100mL,RACA,,¾AÀ³¯g:¬°§Ü¸~½FÃÄ(B022602255),,RT,IV infusion over 6-8 hrs¡A As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin¡A 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin¡A 50 mg/mL once every 3 wks.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
ICAL1,Calcitriol,Calcijex 1mcg,META,,¾AÀ³¯g: Management of hypocalcemia in patients undergoing chronic renal dialysis. °Æ§@¥Î: Weakness¡A headache¡A somnolence; nausea¡A vomiting¡A dry mouth¡A constipation; muscle pain¡A bone pain & metallic taste. ¸T§Ò: Hypercalcemia or evidence of vit D toxicity.,,«Ç·Å,Initially 1 mcg (0.02 mcg/kg) administered 3 times weekly¡A approximately every other day. Dose may be increased by 0.5-1 mcg at 2-4 weeks intervals.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OAZO,Acetazolamide,Azol 250mg,CAVS,,,,,,,,,,,,,,,,,,,
IDAN,Dantrolene,Dantrolene inj 20mg (±M®×¶i¤f),CNEU,Treatment of malignant hyperthermia.,Hypersensitivity to Dantrolene.,Common: Flushing (27%)¡A Diarrhea¡A Nausea (10%)¡A Somnolence (17%)¡A Fatigue¡A Malaise Serious: Heart failure¡A Tachycardia (3%)¡A Dysphagia (10%)¡A Gastrointestinal hemorrhage¡A Aplastic anemia¡A Leukopenia¡A Small lymphocytic lymphoma¡A Thrombocytopenia¡A Anaphylaxis¡A Muscle weakness (3-21.7%)¡A Decreased vital capacity¡A inspiratory¡A Dyspnea¡A Muscle weakness¡A respiratory,20-25¢JÁ×¥ú,Malignant hyperthermia: (FDA dosage) Minimum 1 mg/kg IV push; if physiologic and metabolic abnormalities continue¡A administer additional IV boluses to a MAX cumulative dose of 10 mg/kg; if abnormalities reappear¡A repeat dosing starting with 1 mg/kg IV push. (Guideline dosage) Initially¡A give 2-3 mg/kg IV push¡A then 1 mg/kg every 5 minutes as needed with active cooling until CO2 levels are <6 kPa¡A normal ventilation¡A and core temperature is <38.5¢XC. Additional doses may be required for rebound increases in CO2 and temperature¡A typically within 14 hours of initial control. If rebound occurs within 6 hours¡A use 1 mg/kg; if >6 hours since the last dose¡A administer 2-3 mg/kg. After a cumulative dose of 10 mg/kg¡A reevaluate the diagnosis; if malignant hyperthermia is still likely¡A continue dantrolene administration. Obese patients: Use actual body weight for initial dose calculation Malignant hyperthermia¡A Post-crisis follow-up: Individualize dose starting with 1 mg/kg IV or more as the clinical situation dictates. Malignant hyperthermia; Prophylaxis: 2.5 mg/kg IVD over 1 hour¡A starting approximately 1.25 hours before anesthesia.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,,Hold Breast Feeding ¼È°±­÷¨Å,,IVD;IVP;IVPUSH;,¼t°Ó´£¨Ñ¤§ª`®g¥Î¤ô (¨C²~ÃÄª«§t20mg Dantrolene¡A¥²¶·»P60²@¤Éªºª`®g¥Î¤ô²V¦X¡C),,°_©l¾¯¶q¡G2~3²@§J/¤½¤ç§Ö³t¿é¤J¡Aµø¯gª¬½w¸Ñµ{«× (¨Ò¦pHypercarbia¡A rigidity¡A tachycardia¡A fever) ¨C5¤ÀÄÁ°l¥[¡AÁ`¾¯¶q¥i¦Ü10 ²@§J/¤½¤ç¡C (¨C²~ÃÄª«§t20mg Dantrolene¡A¥²¶·»P60²@¤Éªºª`®g¥Î¤ô²V¦X¡C),°_©l¾¯¶q¡G2~3²@§J/¤½¤ç§Ö³t¿é¤J¡Aµø¯gª¬½w¸Ñµ{«× (¨Ò¦pHypercarbia¡A rigidity¡A tachycardia¡A fever) ¨C5¤ÀÄÁ°l¥[¡AÁ`¾¯¶q¥i¦Ü10 ²@§J/¤½¤ç¡C (¨C²~ÃÄª«§t20mg Dantrolene¡A¥²¶·»P60²@¤Éªºª`®g¥Î¤ô²V¦X¡C),1. µ}ÄÀ«áªºÃÄ²G¶W¹L6¤p®ÉÀ³¥á±ó¤£¥Î¡C 2. ª`®g³¡¦ì¡G³Ì¦n¬O¤¤¥¡ÀR¯ß¡A¥HÁ×§K©PÃä¦åºÞ®ê¶ë¡C 3. ÃÄª«µ}ÄÀ¡G¨C²~ÃÄª«§t20mg Dantrolene¡A¥²¶·»P60²@¤Éªºª`®g¥Î¤ô²V¦X¡C 4. °_©l¾¯¶q¡G2~3²@§J/¤½¤ç§Ö³t¿é¤J¡Aµø¯gª¬½w¸Ñµ{«× (¨Ò¦pHypercarbia¡A rigidity¡A tachycardia¡A fever) ¨C5¤ÀÄÁ°l¥[¡AÁ`¾¯¶q¥i¦Ü10 ²@§J/¤½¤ç¡C 5. ¦p¤wª`®g Dantrolene¡Aµ´¹ïÁ×§K¨Ï¥Î¶tÂ÷¤lªýÂ_¾¯¡C 6. ¨C²~ Dantrolene ¤w§t3 §J mannitol¡A³Ì¦n¦³¤¤¥¡ÀR¯ß¾ÉºÞ©ÎªÍ°Ê¯ß¾ÉºÞºÊ´úÅé²Gª¬ºA¡C
YSDE,µÎ¼¯¨à¾L»ÄÄé¬~²G133mL/twin,µÎ¼¯¨à¾L»ÄÄé¬~²G133mL/twin,MSGO,,,,,,,,,,,,,,,,,,,
IXY15,Lidocaine,Xylocaine inj 1% 5mL§½³Â,ZANE,For the production of local or regional anesth by infiltration¡A IV regional anesth¡A minor & major nerve blocks¡A epidural block & subarachnoid block.,Epidural or spinal anesth in patients with uncorrected hypotension or with coagulation disorders or receiving anti-coagulation treatment; inflammation &/or sepsis in the region of proposed inj or in the presence of septicemia; general contraindications related to epidural anesth should also be taken into account.,CNS reactions¡A either excitatory or depressant. CV reactions¡A mainly depressant. Maternal hypotension. Rarely allergic reactions.,25¢J¥H¤U,Maximum recommended single dose of lidocaine is 3 mg/kg (plain solution) or 7 mg/kg (solution with adrenaline). Adult¡A 70 kg: Infiltration: 20 mL of 1% solution (200 mg). Paravertebral nerve block: 3-5 mL of 1% solution (30-50 mg). Pudendal block: 10 mL of 1% solution (100 mg) on each side. Paracervical block: 10 mL of 1% solution (100 mg). Stellate ganglion block¡A Cervical: 5 mL of 1% solution (50 mg). Stellate ganglion block¡A Lumbar: 10 mL of 1% solution (100 mg). Epidural anesthesia¡A Thoracic: 10-20 mL of 1% solution (100-200 mg). Lumbar or caudal epidural analgesia: 10-20 mL of 1% solution (100-200 mg).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;LA;LI;,,,,,
OGLI,Glibenclamide,Gliben 5mg,META,,¾AÀ³¯g:¬°­°¦å¿}ÃÄ(A002863100) ADR: Hypoglycaemia¡A temporary visual impairment esp at the start of treatment¡A GI disturbance. Rarely¡A mild to severe thrombocytopenia. Isolated cases of haemolytic anemia¡A hypersensitivity reactions. CI: Type I IDDM¡A diabetic ketoacidosis¡A diabetic precoma or coma. Severe renal or hepatic dysfunction. Pregnancy & lactation.,,RT,Initial¡A 2.5-5 mg/day with breakfast¡A increased as needed; (max daily dose: 20 mg ).,,,,¥i¯à¦w¥þ,,,,,,,,,,
YCAL,,¾¾¥ß³ß¼Ö 90'S/²~,NUTR,,,,,,,,,,,,,,,,,,,
EFRA,Fradiomycin,Framycin gauze dressing 10x10cm,TDER,Wounds¡A burns¡A ulcers & other infections skin conditions.,Hypersensitivity to any component of the formulation.,Possible ototoxicity.,25¢J¥H¤U,Apply the paraffin gauze dressing directly to the cleaned wound QD-BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;SKIN;,,,,,
IVANC,Vancomycin,Vanco inj 1gm,QANB,Endocarditis¡A osteomyelitis¡A pneumonia¡A septicemia¡A soft tissue infections¡A enteritis caused by Staphylococcus aureus infections¡A and pseudomembranous colitis caused by Clostridium difficile infections.,Hypersensitivity to vancomycin.,Anaphylactoid reactions following rapid infusion. Nephrotoxicity¡A ototoxicity¡A reversible neutropenia¡A pseudomembranous colitis; chemical peritonitis following intraperitoneal administration.,,Adult 500 mg Q6H or 1 g Q12H by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses Q8H for patients undergoing GI or GU procedures. Children 10 mg/kg body weight Q6H. Neonates initial 15 mg/kg followed by 10 mg/kg Q12H in 1st weeks of life & Q8H up to 1 month of age. *****NEONATE ANTIBIOTICS DOSE***** Vancomycin: Dilute to a final concentration <=5 mg/mL; IV infusion over 90 minutes Draw trough level within 30 mins before the fourth dose. peak level 60 mins after end of infusion Sepsis PMA <=29 week Postnatal 0-14 days¡A dose: 10mg/kg Q18H PMA <=29 week Postnatal >=15 days¡A dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days¡A dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days¡A dose: 10mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days¡A dose 10mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days¡A dose 10mg/kg Q8H PMA >=45 week: 10mg/kg Q6H Meningitis PMA<=29 week Postnatal 0-14 days dose: 15mg/kg Q18H PMA <=29 week Postnatal >=15 days¡A dose: : 15mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days¡A dose: 15mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days¡A dose: 15mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days¡A dose: 15mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days¡A dose: 15mg/kg Q8H PMA >=45 week: 15mg/kg Q6H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IMP;INS;IRR;IS;IVD;IVI;SCI;SUBCI;,IVD: 20 mL D/W (water for injection),¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,µ¹ÃÄ¿@«× 2.5~5mg/mL¡A¿éª`³t²v< 10 mg/min¡A¨àµ£¦Ü¤Ö¥H¶W¹L60¤ÀÄÁ¥H¤W®É¶¡½wºCºwª`¡C,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C 2. ª`·N¿éª`¹L§Ö®Éªº¤£¨}¤ÏÀ³¡G§C¦åÀ£¡B©I§l§xÃø¡BëC³Â¯l¡C 3. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C 4. µ¹ÃÄ¿@«×: 2.5~5mg/mL¡A§Q¥Î¿éª`²Gµ¹ÃÄ¡A¿@«×¤£¥i¶W¹L 5mg/mL¡C 5. ½Õ°t¤Î©âÃÄ®É«ØÄ³¨Ï¥ÎG21¸¹°wÀY(¥~®|0.8mm)¡A¨Ã¥B©ó¾ó½¦¶ë¤¤¥¡¦ì¸m°wÀY90«×¦V¤U¬ï¨ë¡AÁ×§K²£¥Í¾ó½¦¶ë¸H®h¡C 6. ¥[¤J10 mL·Àµßª`®g¥Î¤ô©ó500 mgµLµßvancomycin°®¯»¤§¤p²~¤º¡C¥H¦¹ªk½Õ±o50 mg/ mLªº·»²G¡A¶·¶i¤@¨Bµ}ÄÀ¡C·»²G½Õ°t¤§«á»Ý§NÂÃ¡A¥i©ó¦B½c¤¤«O¦s14¤Ñ¦Ó¤£·|©úÅã­°§C¤O»ù¡C
OMID,Pyrazinamide,Mide 500mg,QANB,,¾AÀ³¯g: Treatment of pulmonary & extrapulmonary TB. °Æ§@¥Î: Hepatotoxicity¡A jaundice¡A hyperuricemia leading to attacks of gout¡A anorexia¡A nausea¡A vomiting¡A arthralgia¡A malaise¡A fever¡A sideroblastic anemia¡A difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea¡A Vomiting Musculoskeletal: Arthralgia (40%) ¸T§Ò: Liver damage.,,«Ç·Å,20-35 mg/kg daily in 3-4 divided doses. (max. 3 g/day).,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
YAMS,N-acetyl-D-glucosamine,Amsun nasal spray,ZOTH,,,,,,,,,,,,,,,,,,,
IFIB0,Sodium Tetradecyl Sulphate,Fibro-Vein 3%¡A 0.5 mL,ZOTH,,¾AÀ³¯g: As a sclerosant in the treatment of varicose veins of the leg by compression sclerotherapy. °Æ§@¥Î: Local pain or burning¡A skin pigmentation¡A tissue necrosis & ulceration may occur with extravasation. paraesthesia & anesth may occur if an inj effects a cutaneous nerve. Superficial thrombophlebitis. ¸T§Ò: Patients unable to walk due to any cause. Patients currently taking OCs. Significant obesity. Acute superficial thrombophlebitis. Local or systemic infection. Varicosities caused by pelvic or abdominal tumours. Uncontrolled systemic disease eg. DM. Significant valvular incompetence requiring surgical treatment.,,«Ç·Å,Adult 0.5-1 mL IV into the lumen of an isolated superficial vein¡A followed by immediate continuous compression. Max. 4 sites may be injected during 1 treatment session.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,­­¥ÑÂå®v¨Ï¥Î
OANG0,Drospirenone + Estradiol,Angeliq 28's/pk (Á{§É¸ÕÅçÃÄ),HM,,,,,,,,,,,,,,,,,,,
EMEN,Butenafine,Mentax cream 1% 15gm,TDER,Dermatophytoses eg interdigital tinea pedis¡A tinea corporis¡A tinea cruris,Burning¡A stinging & itching at application site.,Individuals who have known or suspected sensitivity to butenafine HCl or to any of the components of Mentax. Patients who are known to be sensitive to allylamine antifungals should use Mentax with caution¡A since cross-sensitivity may occur.,25¢J¥H¤U,Tinea corporis¡A tinea cruris: Topical: Apply once daily for 2 weeks Tinea versicolor: Topical: Apply once daily for 2 weeks Tinea pedis: Topical: Apply twice daily for 1 week or once daily for 4 weeks to affected skin between and around the toes,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
IAMI2,Amino Acids,Amiparen inj 10% 200mL,NUTR,Nutritional support for patients with hypoproteinemia¡A malnutrition,Hepatic coma¡A severely impaired renal function¡A abnormal amino acid metabolism.,Hypersensitivity¡A GI upsets¡A chest discomfort¡A palpitations¡A occasional chills¡A hot flushes¡A fever¡A headache¡A increase of GOT¡AGPT & BUN level.,30¢J¥H¤U,Central vein infusion: The usual adult dosage is 400-800 mL per day by drip infusion. Peripheral vein infusion: The usual adult dosage is 200-400 mL per dose by drip infusion. A typical infusion rate in adults is 100 mL over 60 minutes The dosage and the rate may be increased or decreased depending on the patient's age¡A symptoms and body weight.,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,IVF:100mL/60min,1. ¤¤¥¡ÀR¯ß§ë»P¡G¦¨¤H¤@¤é400-800mL¬I¦æ°ª¼ö¶q¿é²Gªk¡C 2. ©PÃäÀR¯ß§ë»P¡G¦¨¤H¤@¤é200-400mL¬I¦æ°ª¼ö¶q¿é²Gªk¡C¦¨¤H¼Ð·Ç§ë»P³t«×¬°60¤ÀÄÁ¤º¿éª`100mL¡C¤p«Ä¡B¦Ñ¤H»P­«¯g±wªÌÀç½wºCª`®g¡C
OHYD,Hydroxyurea,Hydrea 500mg,RACA,Chronic myeloid leukemia¡A malignant neoplastic disease.,Hypersensitivity. Bone marrow depression eg leukopenia¡A thrombocytopenia or severe anemia. Pregnancy & lactation.,Bone-marrow suppression; rarely¡A GI disorders¡A skin rash¡A headache¡A disorientation¡A pulmonary edema¡A dysuria¡A renal tubular function impairment.,25¢J¥H¤U¡AÁ×§K°ª·Å,[Solid tumor] Intermittent therapy: 80 mg/kg once every 3 days; Continuous therapy: 20-30 mg/kg once daily [Squamous cell carcinoma of head and neck or cervical cancer¡A in combination with radiation therapy] 80 mg/kg once every 3 days [Chronic myeloid leukemia] 20-30 mg/kg once daily,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
YPHY,Isoflavones,Phyto Soya 60's/box,NUTR,,,,,ªA¥Î¤è¦¡: ¨C¤é¦­±ß¶º«áªA¥Î1-2²É¡A¥H¤ô§]ªA¡A¦h­¹µL¯q ¨C½¦Ån§t(8ºØ)-- ¤j¨§²§¶Àà¬¯À: 17.5²@§J(¥h¿}°ò¤j¨§²§¶Àà¬¯À11²@§J) Áâ: 40²@§J ¾N: 7.5²@§J Ö´: 25·L§J ºû¥Í¯ÀB6: 1²@§J ºû¥Í¯ÀB9: 100·L§J ºû¥Í¯ÀB12: 0.5·L§J ºû¥Í¯ÀE: 5²@§J,,,,,,,,,,,,,,
YSOY,Isoflavones,SOYGERM C,NUTR,,,,,,,,,,,,,,,,,,,
IPCT,Penicillin G,Penicillin test reagent 300U/0.1mL/dose,TEST,,,,,For penicillin skin testing.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,ID;,,,,,For Penicillin Skin Test use only
OIRE,Gefitinib,Iressa 250mg,RACA,Treatment of patients with locally advanced or metastatic adenocarcinoma of the lung who have previously received chemotherapy.,Patients with known severe hypersensitivity to gefinitib or to any of the excipients of Iressa.,Diarrhoea¡A nausea¡A skin rash¡A dry skin¡A vomiting¡A anorexia¡A stomatitis¡A liver function abnormalities¡A nail disorder¡A alopecia¡A asthenia¡A conjunctivitis & blepharitis. Dermatologic: Acne (25% to 33% )¡A Dry skin (13% to 26% )¡A Pruritus (8% to 9% )¡A Rash (43% to 54% ) Endocrine metabolic: Weight loss (3% to 5% ) Gastrointestinal: Diarrhea (48% to 67% )¡A Loss of appetite (7% to 10% )¡A Nausea (13% to 18% )¡A Vomiting (9% to 12% ) Neurologic: Asthenia (4% to 6% ),30¢J¥H¤U,250 mg orally once daily with or without food.,»Ý½Õ¾ã¾¯¶q,Severe hepatic impairment: Permanently discontinue.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OSTA,Nateglinide,Starlix 120mg,META,,¾AÀ³¯g: Treatment of type 2 diabetes¡A as monotherapy or in combination with metformin. °Æ§@¥Î: Hypoglycaemic symptoms¡A GI disturbances¡A headache. Rarely: raised liver enzymes¡A hypersensitivity reactions. Endocrine metabolic: Hypoglycemia (1.3% to 3%% ) Respiratory: Upper respiratory infection (10.5% ) ¸T§Ò: Type 1 diabetes¡A diabetic ketoacidosis. Pregnancy¡A lactation.,,«Ç·Å,120 mg before meals,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OCATI,Calcium Citrate,Catin 950mg,NUTR,,¾AÀ³¯g:¸É¥R¶t½è,,«Ç·Å,1-2 Tab bid,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OTONE,Aceclofenac,Tonec 100mg,CNEU,Relief of pain & inflammation in osteoarthritis¡A rheumatoid arthritis & ankylosing spondylitis.,Hypersensitivity to aspirin or other NSAIDs; previous or active peptic ulceration or GI bleeding; moderate to severe renal impairment.,GI disturbances¡A ulceration or bleeding; dizziness; hypersensitivity reactions including skin rash¡A angioedema or bronchospasm; headache¡A nervousness¡A depression¡A drowsiness¡A insomnia¡A vertigo¡A tinnitus¡A photosensitivity reactions¡A hematuria¡A blood disorders¡A fluid retention¡A disturbances in renal function.,25¢J¥H¤UÁ×¥ú,100 mg BID,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à·l¶Ëªº¯f±w¶·´î§C¾¯¶q¡Aªì©l¾¯¶q¬°¨C¤é 100 mg,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,¥é³æ:¥»ÃÄµL¥¥°ü¨Ï¥Îªº¬ÛÃö¸ê°T¡A¬G¤£«ØÄ³¨Ï¥Î¡A¥B©ó²Ä¤T¥¥´Á¨Ï¥ÎNSAIDs¥i¯à¼W¥[¤l®c±i¤O¡A«P¶i¤l®c¦¬ÁY.¥i¯à¨Ï­L¨à°Ê¯ß¾ÉºÞ¦­´Á³¬Âê¡A³y¦¨·s¥Í¨àªÍ°Ê¯ß°ªÀ£.¤À®Y©µ¿ð©M®É¶¡©µªø. [20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,Unknown ¨S¦³¸ê®Æ,¥é³æ:¥»ÃÄµL±Â¨Å°ü¨Ï¥Îªº¬ÛÃö¸ê°T¡A¬G¤£«ØÄ³¨Ï¥Î.¦ý¬O¹«¹êÅç¤¤ÃÄ«~¤£·|¶i¤J¨Å¥Ä.,PC;PO;WM;,,,,,
OKAS,S-Carboxymethylcysteine,Kasteine 375mg,ERSP,,¾AÀ³¯g:¤Æ·ð¾¯(A028142100),,RT,500 mg tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ICHI,Levobupivacaine,Chirocaine inj 0.5%¡A10mL,ZANE,,¾AÀ³¯g:Adult Surgical anesth & pain management. Children Infiltration analgesia. °Æ§@¥Î:Hypotension¡A nausea¡A post-op pain¡A fever¡A vomiting¡A anemia¡A pruritis¡A pain¡A headache¡A constipation¡A dizziness¡A fetal distress. ¸T§Ò: Hypersensitivity to local anesth amide agents. IV regional anesth (eg Bier block)¡A obstetric procedures¡A paracervical blocks in obstetrics.,,«Ç·Å,Adult a) Local anesthesia: local anesthetic¡A 60 mL of 0.25% solution (150 mg) b) Obstetric pain: 10-20 mL of 0.25% solution EPIDURAL bolus (25-50 mg) c) Postoperative pain: 4-10 mL/hr of 0.125% or 0.25% solution EPIDURAL infusion (5-25 mg/hour) ; 0.125% used only in combination with fentanyl or clonidine d) Regional anesthesia: 1) peribulbar infiltration¡A 5-15 mL of 0.75% solution (37.5-112.5 mg) 2) peripheral block¡A 30 mL or 0.4 mL/kg of 0.25%-0.5% solution (75-150 mg (1-2 mg/kg)) 3) epidural (surgical)¡A 10-20 mL of 0.5-0.75% solution (50-150 mg) 4) epidural (cesarean section) 20-30 mL of 0.5% solution (100-150 mg),,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,¥~¬ì³Â¾K¡Gµw½¤¥~ªýÂ_³Â¾K¥H¶i¦æ¥~¬ì¤â³N¡A¥]¬A­å¸¡²£¤Î°Ï°ìªýÂ_¡C «æ©Ê¯kµh³B²z¡G«ùÄò©Êµw½¤¥~¿éª`©Î¶¡·²©Ê¤§¤@¦¸ª`®gµ¹ÃÄ¡A¦p¡G¤â³N«á©Î²£«á¯kµh¡C ¨àµ£¾A¥Î©ó®û¼í³Â¾K¡C ¥»«~¶È¨Ñ¦³³Â¾K¸gÅçªºÁ{§ÉÂå¥Í©Î¦b¨ä«ü¾É¤U¨Ï¥Î¡C
OURO1,Potassium Citrate,UROCIT-K 10meq,SGU,,Renal tubular acidosis (RTA) with calcium stones¡A hypocitraturic calcium oxalate nephrolithiasis of any etiology¡A and uric acid lithiasis with or without calcium stones.,,,Mild to moderate hypocitraturia: 2 tab tid. Do not exceed 100 mEq/day. Severe hypocitraturia: 4 tab tid or 3 tab qid with meals.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OFUC,Fusidate,Fucidin 250mg,QANB,Treatment of infections caused by susceptible organisms especially Staph eg osteomyelitis¡A septicaemia¡A endocarditis¡A pneumonia¡A cutaneous infections¡A surgical & traumatic wound infections. Also other Staph infections including MRSA.,Hypersensitivity to Fusidate.,GI disturbances.,,Adult: 2 TAB TID Skin & soft tissue infection 1-2 TAB BID,µL»Ý½Õ¾ã¾¯¶q,¨xÅ¦¥\¯à»ÙÃªªÌ¨Ï¥Î¡AÀ³¹ï¨ä¨x¥\¯à¶i¦æºÊ´ú¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,,,,,,
IARE,Pamidronate,Aredia inj 15mg/5mL,META,,¾AÀ³¯g:Treatment of conditions associated with increased osteoclast activity such as predominantly lytic bone metastases & multiple myeloma; tumor-induced hypercalcemia; Paget's disease of bone. °Æ§@¥Î: Mild transient pyrexia & lymphocytopenia may occur at start of treatment. Hypocalcaemia mostly asymptomatic & transient. Also see lit. ¸T§Ò: Known hypersensitivity to Aredia or other bisphosphonates.,,«Ç·Å,should be diluted in a Ca-free infusion soln (e.g. 0.9 % sodium chloride or 5 % glucose) & infused slowly via cannula in a relatively large vein. The infusion rate should not exceed 60 mg/hr (1 mg/min)¡A & the concentration of Aredia in the infusion solution should not exceed 90 mg/250 mL. Adults & elderly Lytic bone metastases of malignancy 90 mg administered as a single infusion every 4 weeks (or every 3 weeks in patients who receive chemotherapy at 3-weekly intervals). Tumor-induced hypercalcemia Total dose of 15-90 mg according to the initial serum Ca concentration. The dose may be administered either in a single infusion or in multiple infusions over 2-4 consecutive days. Max dose per treatment course (for both initial and repeated courses): 90 mg. Paget's disease of bone Either 6 unit doses of 30 mg once weekly (total dose 180 mg)¡A OR initial dose of 30 mg followed by 3 unit doses of 60 mg every other week (total dose 210 mg). The latter regimen¡A omitting the initial dose¡A may be repeated after 6 months until remission of disease or relapse occurs.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OBET1,Betahistine,Betaserc 16mg,CNEU,,¾AÀ³¯g:ªvÀø¯t·w¡BÅ¥¤O»ÙÃª(B023041100),,RT,1 tab tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODOX4,Doxazosin,Doxaben XL 4mg,CAVS,Hypertension. Benign prostatic hyperplasia.(B023711100),Patients with known hypersensitivity to quinazolines¡A doxazosin or any of the excipients of Doxaben/Doxaben XL.,Dizziness¡A headache¡A fatigue¡A vertigo¡A edema & asthenia. Cardiovascular: Edema (2.7% to 4%)¡A Hypotension (1.7%-10%) Gastrointestinal: Nausea (1.2% to 4.3%) Neurologic: Dizziness (5.3% to 19%)¡A Headache (4% to 15.8%)¡A Somnolence (1.2% to 5%)¡A Vertigo (1.5% to 7%) Other: Fatigue (8% to 12%),30¢J¥H¤U,Extended release tablet should be swallowed whole; do not crush¡A cut¡A chew¡A or divide. Adult usual dosage: 4 mg QD¡A may increase if necessary at the 4-week interval to a maximum 8 mg QD.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª(Child-Pugh C)¤§¯f±w¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ] ¦bdoxazosinªº°Êª«¹êÅç¤¤¡AÁöµM¨S¦³µo²{·î­L²{¶H¡A¦ý¥H°Êª«¸ÕÅç¹ï¨ü¸Õ°Êª«¨Ï¥Î¤j¬ù¤HÅé³Ì°ª«ØÄ³¾¯¶q¤§300­¿¤§¸ÕÅç¾¯¶q·|´î§C¨ü¸Õ°Êª«­L¨àªº¦s¬¡²v¡C ¥Ø«e°w¹ï¥¥°ü©Î±Â¨Å°ü¤kÁÙ¨S¦³¥R¤À¥BÄY®æªº¹ï·Ó¬ã¨s¡A¦]¦¹¦bÃh¥¥©Î±Â¨Å´Á¶¡¨Ï¥Î¥i¨³«ùÄòÃÄ®Ä¿õªº¦w¥þ©Ê©|¥¼½T¥ß¡C©Ò¥H¡A¥u¦³¦bÂå®vµû¦ô§Q¤j©ó¹ú®É¡A¥¥°ü¤Î±Â¨Å°ü¤k¤è¥i¨Ï¥Î¥»ÃÄ¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ³æ¤@­Ó®×³ø§i´¿ÃÒ©údoxazosin¥i¤Àªc¦Ü¤H¨Å¤¤¡A¦Ó¥B°Êª«¬ã¨sÅã¥Ü¡A¦¹ÃÄª«·|»W¿n¦b¨Å¥Ä¤¤¡C ¥Ø«e°w¹ï¥¥°ü©Î±Â¨Å°ü¤kÁÙ¨S¦³¥R¤À¥BÄY®æªº¹ï·Ó¬ã¨s¡A¦]¦¹¦bÃh¥¥©Î±Â¨Å´Á¶¡¨Ï¥Î¥i¨³«ùÄòÃÄ®Ä¿õªº¦w¥þ©Ê©|¥¼½T¥ß¡C©Ò¥H¡A¥u¦³¦bÂå®vµû¦ô§Q¤j©ó¹ú®É¡A¥¥°ü¤Î±Â¨Å°ü¤k¤è¥i¨Ï¥Î¥»ÃÄ¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½wÄÀ¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C­Y¦³¿i¯»ºÞÄé»Ý¨D¥i§ï¥Î°|¤º¨ä¥¦Alpha-Blockers¡C
OTEM,Buprenorphine,Temgesic Sublingual 0.2mg,CNEU,,Moderate to severe pain,,,1-2 tab 6-8 hrly or as required,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EFDF,Flurbiprofen,´I«Òªâ¶K¤ù(4¤ù/¥]),CNEU,,RA¡A osteoarthritis,,,apply twice daily in adequate size,,,,¥i¯à¦w¥þ,,,,,,,,,,
OCIS,Carbocysteine,Cisdyne 250mg,ERSP,,¾AÀ³¯g:¤Æ·ð¾¯(A040125100)(B020459100),,RT,2 tab tid,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IETOM,Etomidate,Etomidate-Lipuro 20mg/10mL,ZANE,Induction of general anesthesia¡A Maintenance of general anesthesia; Adjunct,Hypersensitivity to etomidate products,:njection site pain ¡A Nausea¡A Vomiting,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Dosage should be individualized¡A for IV use only. Adult dosage: IV 0.15-0.3 mg/kg (equivalent to 0.075 to 0.15 mL/kg Etomidate-Lipuro) over 30 to 60 seconds for induction of anesthesia. Children under 15 years old and the elderly: Single dose IV 0.15- 0.2 mg/kg (equivalent to 0.075-0.15 ml/kg Etomidate-Lipuro). In patients with liver cirrhosis and patients having been premedicated with neuroleptics¡A the dose has to be reduced. In the special case of narcosis to terminate a status epilepticus or serial epilepticus seizures a sufficient dose of etomidate (0.3 mg/kg) should be injected quickly (within 10 seconds). This dose may be repeated several times¡A if required.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVP;IVPUSH;,,,±Àª`®É¶¡>30¬í Administer IV push over 30 to 60 seconds.,,1. Etomidate-Lipuro¥¼§@¬Û®e©Ê´ú¸Õ«e¡A¤£±o»P¨ä¥L¿éª`²G²V¦X¡C¦¹¥~¡A°£«D¤w½T»{¬Û®e©Ê¡A§_«hEtomidate-Lipuro¤£±o¦P®É»P¨ä¥Lª`®g²G¥H¦P¤@¿éª`ºÞµ¹¤©¡F»Ý­n¦X¨Öµ¹¤©¤§ÃÄª«¦p¤îµh¾¯¡A¥H¦P¤@¿éª`ºÞ©Î­Ó§OÀR¯ß´¡ºÞ±µÄòµ¹ÃÄ¡C 2. Etomidate-Lipuro¤£§t§Üµß¨¾»G¾¯¡C¦]¬°¯×ªÕ¨Å¾¯·|«P¶i·L¥Íª«¥Íªø¡A¦wÞÀ¶}²~«áÀ³©óµLµßª¬ºA¤U¥ß§Y¥Hª`®g¾¹©â¥X¨Ã¿éª`¡C³Ñ¾l³¡¥÷À³¥á±ó¡C 3. §ë¤©Etomidate-Lipuro«eÀ³¾A«×«eÅXµ¹ÃÄ¥HÁ×§K¦Ù°}µjªºµo¥Í¡C«ØÄ³©ó§ëÃÄ«e1¤p®ÉIMµ¹¤©©Î10¤ÀÄÁ«eIVµ¹¤©BZDÃþÃÄª«¡C
YISO,Isoflavones,Isoflavone 30's/box,NUTR,,,,«Ç·Å,ªA¥Î¤è¦¡: ¨C¤é1-3¦¸¡A¨C¦¸1²É¡A¦h­¹µL¯q ¨C½¦Ån§t(15ºØ)-- ¤j¨§µÑ¨úª«(§t²§¶Àà¬¯À40%): 120²@§J(²§¶Àà¬¯À: 48²@§J) ¸Á¤ý¨Å: 60²@§J ªá¯»: 60²@§J ªx»Ä¶t: 50²@§J ºû¥Í¯ÀD3: 250IU ºû¥Í¯ÀE: 50²@§J ºû¥Í¯ÀB1: 0.5²@§J ºû¥Í¯ÀB2: 0.5²@§J ºû¥Í¯ÀB6: 0.5²@§J ºû¥Í¯ÀB12: 50·L§J ¸­»Ä: 250·L§J ¤p³Á­FªÞªo: 110²@§J ©ú½¦: 170²@§J ¥Ìªo: 60²@§J ¯Â¤ô: 15²@§J,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSINC,Levodopa + Carbidopa,SINEMET CR(«ùÄò¿õ) 50/200MG,CNEU,,¾AÀ³¯g: Symptomatic treatment of Parkinsonism. °Æ§@¥Î: Dyskinesia including choreiform¡A dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% ) ¸T§Ò: Narrow-angle glaucoma. Undiagnosed skin lesions or history of melanoma. Hypersensitivity to any component of this product.,,«Ç·Å,Patient who has not received prior L-dopa therapy Initially 1 tab bid or tid. Max 600 mg/day of L-dopa.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IALB1,Albumin,Human Albumin 20% 100mL,HEMT,,,,,,,,,,,,,,,,,,,
IVAX2,Purified Split Inactivated Influenza Virus,¦Û¶O¬y·P¬Ì­]( <¤T·³) 0.25mL/¤ä,HIMM,,I: Prophylaxis against influenza. ADR: Erythema (rash)¡A swelling¡A pain¡A ecchymosis¡A induration¡A fever¡A dizziness¡A shivering¡A tiredness¡A headaches¡A sweating¡A muscle pain¡A joint pains. CI: Allergy to eggs¡A chicken protein or any constituents of the vaccine. Febrile illness or acute infection.,,2 ~ 8 ¢XC,Children 6 ~ 35 mth 0.25ml IV or deep SC. Chidren have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EALBS,Policresulen,Albothyl solution,SGU,,¾AÀ³¯g: Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis¡A cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration. °Æ§@¥Î: Occasionally¡A mild local discomfort at beginning of treatment which disappears on discontinuation. ¸T§Ò: Concomitant use of other topical agents in treating the affected areas.,,«Ç·Å,Concentrate Undiluted for cauterization 1-2 times weekly; diluted for vag douches.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EDUA2,Budesonide,Duasma MDI 200mcg/puff,ERSP,,¾AÀ³¯g: Chronic control of bronchial asthma. °Æ§@¥Î: Mild irritation of the throat¡A coughing¡A reversible hoarseness of voice¡A bad taste¡A dryness of the throat. Candidiasis of the mouth & throat. Paradoxical bronchoconstriction. Gastrointestinal: Diarrhea (inhalation¡A 4%; oral¡A 10% )¡A Nausea (inhalation¡A 1.8% to 6%; oral¡A 11% ) Musculoskeletal: Arthralgia (inhalation¡A 6%; oral¡A 5% ) Neurologic: Headache (inhalation¡A 3%; oral¡A 21% ) Respiratory: Epistaxis (intranasal¡A 8%; inhalation¡A 2% to 4% )¡A Nasal stinging/burning (intranasal¡A greater than 1% )¡A Respiratory tract infection (inhalation¡A 3% to 38%; oral¡A 11% )¡A Sinusitis (inhalation¡A 3% to 16%; oral¡A 8% ) ¸T§Ò: Moderate to severe bronchiectasis.,,«Ç·Å,Adult & children > 12 years Initially 400-1600 mcg daily. Maintenance: 200-400 mcg bid¡A up to 2000 mcg/day. Children 6-12 years Initially 200-400 mcg daily.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IMETR,Metronidazole,Metronidazole inj 500mg/100mL,QANB,Infections with anaerobic causative agents. Infections of the GIT¡A after colon surgery¡A in peritonitis¡A purulent diseases of the pelvic cavity¡A infections of the female genital tract as well as puerperal fever.,Hypersensitivity. Blood dyscrasias.,GI disturbances¡A somnolence¡A vertigo¡A headache¡A ataxia¡A darkening of urine¡A itch¡A cutaneous eruption¡A peripheral neuropathy. Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction,25¢J¥H¤UÁ×¥ú,(¥é³æ) Anaerobic infections: Adults and children >= 12 years: 500 mg Q8H IV at a rate of 25 mg/minute (5 mL/minute) or 22.5 mg/kg/day; children < 12 years: 22.5 mg/kg/day once daily. Pre- and post-operation: 500-1500 mg at a rate of 25 mg/minute (5 mL/minute). *****NEONATE ANTIBIOTICS DOSE***** Metronidazole: Loading dose: 15 mg/kg; (°Ñ¦Ò °¨°º)¡A IV drip> 0.5-1hour¡A at conc < 8mg/ml Maintenance dose: as below Body weight <1kg ge<=7day 7.5mg/kg QD  Age 8-14 day 7.5mg/kg QD  Age 15-28 day 7.5 mg/kg QD Body weight 1-2kg ge<=7day 7.5mg/kg Q12H  Age 8-14 day 7.5 mg/kg Q12H  Age 15-28 day 7.5 mg/kg Q12H Body weight >2kg Age<=7day 7.5mg/kg Q8H  Age 8-14 day 10 mg/kg Q8H  Age 15-28 day 10mg/kg Q8H,»Ý½Õ¾ã¾¯¶q,[¥é³æ] µL»¡©ú [Micromedex-20200728] Hepatic impairment¡A severe (Child-Pugh C): Reduce dose of IV by 50%; for treatment of trichomoniasis with 375-mg capsules¡A increase dosing interval to once every 24 hours.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,,Hold Breast Feeding ¼È°±­÷¨Å,,IVD;,,,,< 5mL/min,1. ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡Aª`·N¤ß´¼»P¯«¸g¥\¯àÅÜ¤Æ¡C 2. Àøµ{«ØÄ³¤£¶W¹L10¤Ñ¡C
OTAN,Imidapril,Tanatril 10mg,CAVS,,¾AÀ³¯g: Hypertension. °Æ§@¥Î: Cough¡A dizziness¡A hypotension¡A headache¡A pharynx discomfort¡A rash. Rarely angioedema¡A thrombocytopenia¡A acute renal failure. Pancytopenia¡A pancreatitis. ¸T§Ò: History of angioedema due to an ACE inhibitor¡A patients who undergo LDL apheresis using dextran cellulose sulfate or hemodialysis with acrylonitrile methallyl sulfonate Na membrane. Pregnancy¡A lactation.,,«Ç·Å,Adult: 5-10 mg once daily Severe hypertension: initially 2.5 mg once daily,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
YPAR,Multivitamin,Paragon 30's(³tÄR±d),NUTR,,,,,,,,,,,,,,,,,,,
ORE15,Sibutramine,REDUCTIL 15mg 28's/box,META,,¾AÀ³¯g: Adjunctive therapy within a weight management programme for obese patients with BMI >= 30 kg/m2¡A overweight patients with BMI >= 27 kg/m2 or above who have obesity-related risk factors like type 2 diabetes or dyslipidemia. °Æ§@¥Î: Loss of appetite¡A constipation; dry mouth¡A insomnia; tachycardia¡A palpitations¡A hypertension; dizziness¡A paresthesia¡A headache¡A anxiety; sweating; taste disturbances. ¸T§Ò: Bulimia nervosa¡A psychiatric illness¡A Gilles de la Tourette's syndrome¡A coronary artery disease¡A CHF¡A tachycardia¡A occlusive artery disease¡A heart rhythm disorder¡A cerebrovascular disease¡A inadequately controlled hypertension¡A hyperthyroidism¡A severely hepatic/renal impairment¡A benign prostatic hyperplasia¡A pheochromocytoma¡A narrow angle glaucoma¡A pregnancy¡A lactation¡A children < 16¡A elderly ? 65. Concomitant use of MAOIs or other CNS active drugs for the treatment of mental disorders (such as antidepressants or antipsychotics)¡A for sleep disorders (tryptophan) or for weight reduction. Misuse of drugs¡A medicines or alcohol.,,«Ç·Å,D: Initial dose is 10 mg qd; if weight loss < 2 kg in 4 weeks and well-toleranted patients can increased to 15 mg qd.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IOXY,Oxytocin,Oxytocin inj 10 IU/1mL,SGU,Induction of labor for medical reasons; stimulation or reinforcement of labor in hypotonic uterine inertia; during caesarean section¡A following delivery of the child; adjunctive therapy in the management of incomplete¡A inevitable¡A or missed abortion; prevention & treatment of postpartum uterine atony & haemorrhage.,Significant cephalopelvic disproportion or unfavorable presentation of the fetus¡A placenta praevia or vasa praevia¡A cord presentation or prolapse¡A mechanical obstruction to delivery¡A fetal distress or hypertonic uterine contractions; multiple pregnancy or high parity¡A polyhydramnios¡A or the presence of a uterine scar from previous caesarean section. Avoid prolonged administration in patients with oxytocin-resistant uterine inertia¡A severe pre-eclampsia or severe CV disorders.,Uterine spasm¡A uterine overstimulation (usually with excessive doses); water intoxication associated with maternal & neonatal hyponatraemia; nausea¡A vomiting¡A arrhythmias; rashes & anaphylactoid reactions. Rapid IV bolus inj may result in an acute short-lasting drop in BP.,25¢J¥H¤U,Induction or stimulation of labor: 3 IU (0.3mL) IM or SC. Or 10 IU(1mL) in 0.9% NaCl or 5% glucose solution IV infusion 15 drops/minutes. Treatment and prophylaxis of postpartum haemorrhage: 0.6-2 IU(0.06-0.2mL) in 3-5mL 0.9% NaCl intravenously slowly. [Micromedex 2021/08/04] Induction of labor¡A Medically indicated: initial¡A 0.5 to 1 milliunit/min IV (3 to 6 mL/h of a 10 units/1000 mL dilute oxytocin solution); gradually increase dose in increments of 1 to 2 milliunits/min every 30 to 60 min until desired contraction pattern has been established; once desired frequency of contractions has been reached and labor progressed to 5 to 6 cm dilation¡A the dose may be reduced by similar increments. Postpartum hemorrhage 10 to 40 units of oxytocin added to running IV infusion (maximum 40 units to 1000 mL IV solution); adjust infusion rate to sustain uterine contractions and control uterine atony. 10 units IM given after delivery of the placenta.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IM;IVD;IVP;IVPUSH;SC;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,Slow IV injections (5 or 10 units over 1 minute) are preferred for women without cardiovascular risk factors; very slow injections (?5 minutes) are preferred for women with cardiovascular risk factors.,ª`®g³t²v:10~20 milliunit/min (postpartum bleeding) ¿éª`³t²v< 9~10 milliunit/min Maximum 40 units to 1000 mL IV solution.,
OSTR2,Atomoxetine,Strattera 25mg,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI¡A narrow-Angle Glaucoma.,Nausea¡A vomiting¡A fatigue¡A decreased appetite¡A abdominal pain¡A somnolence. Endocrine metabolic: Weight loss (pediatrics¡A 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults¡A 7%; pediatrics¡A 17% to 18% )¡A Constipation (adults¡A 9%; pediatric¡A 1% to 2%)¡A Decrease in appetite (adult¡A 11%; pediatrics¡A 16% ¡A)¡A Nausea (adults¡A 21%; pediatrics¡A 7% to 13% )¡A Vomiting (adults¡A 3%; pediatrics¡A 11%)¡A Xerostomia (adults¡A 21% ) Neurologic: Headache (pediatrics¡A 19% )¡A Insomnia (adults¡A 16%; pediatrics¡A at least 2%; )¡A Somnolence (adult¡A 4%; pediatrics¡A 11% ) Renal: Delay when starting to pass urine (adults¡A 5.6% )¡A Urinary retention (adults¡A 1.7% ) Reproductive: Dysmenorrhea (adults¡A 6% )¡A Erectile dysfunction (adults¡A 9% ) Other: Menopausal flushing (adults¡A 8% ),25¢J¥H¤U,Adult¡A adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg¡A whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult¡A adolescent & children>70 kg maximum dose is 100 mg total daily .,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh B): Initial and target doses should be reduced to 50% of the normal dose ­««×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh C): Initial and target doses should be reduced to 25% of the normal dose,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OREB,Ribavirin,Rebetol 200mg,QANB,,¾AÀ³¯g: In combination with interferon £\-2b for the treatment of chronic hepatitis C in adult patients who are £\-interferon-naive or who have relapsed following £\-interferon therapy. °Æ§@¥Î: Haemolysis¡A anaemia¡A neutropenia¡A dry mouth¡A hyperhidrosis¡A asthenia¡A chest pain¡A fatigue¡A fever¡A headache¡A flu-like symptoms¡A malaise¡A rigors¡A weight loss¡A dizziness¡A paresthesia¡A GI disturbances¡A arthralgia¡A myalgia¡A CNS effects¡A viral infection¡A cough¡A dyspnoea¡A pharyngitis¡A rhinitis¡A alopecia¡A pruritus¡A rash¡A dry skin¡A parageusia¡A blurred vision. ¸T§Ò: History of severe pre-existing cardiac disease; haemoglobinopathies; severe¡A debilitating medical conditions; chronic renal failure or CrCl < 50 mL/minute. Pregnancy & lactation.,,«Ç·Å,Adult > 18 years >75 kg 600 mg bid as morning & evening doses. <=75 kg 400 mg in the morning; 600 mg in the evening. To be given in combination with interferon £\-2b soln for SC inj at a dose of 3 million IU three times a weeks for 24 weeks.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IPRE0,Pneumococcal Vaccine Polyvalent,Prevenar (¥_¥«´£¨Ñ¡A13»ùªÍª¢) 0.5mL/dose,HIMM,,¾AÀ³¯g:Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1¡A 3¡A 4¡A 5¡A 6A¡A 6B¡A 7F¡A 9V¡A 14¡A 18C¡A 19A¡A 19F and 23F in infants and children from 2 month-5 years. °Æ§@¥Î:Decreased appetite¡A irritability¡A drowsiness/increased sleep¡A restless sleep/decreased sleep¡A fever¡A inj site erythema¡A induration/swelling or pain/tenderness¡A rash. ¸T§Ò:Hypersensitivity.,,2-8¢J,0.5 mL/dose via IM inj. Infant 6 week-6 months Recommended 3-dose schedule: 1st dose at 2 month but can be given as young as 6 week with 1-month interval between doses¡A followed by a 4th (booster) dose to be administered at 12-15 months. Unvaccinated children 2-5 years 1 dose¡A 12-23 months 2 doses with at least 2-months interval between doses¡A Infant 7-11 months 2 doses with at least 1 month interval between doses¡A 3rd dose by 2nd year.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;,,,,,1. À³¥H¦Ù¦×ª`®g¤è¦¡§ë¤©¡A³Ì¦nª`®g¦bÀ¦¨à¤j»L«e¥~°¼ªºªÑ¥~°¼¦Ù¡A©Î¬O¥®µ£¤WÁuªº¤T¨¤¦Ù¡C
IPAM,Pralidoxime,PAM inj 500mg/10mL,ZADT,,¾AÀ³¯g:Organic phosphorus intoxication °Æ§@¥Î:Dizziness¡A hallucination¡A blurred vision¡A tachycardia¡A headache¡A vomiting¡A nausea¡A hypernea¡A myasthenia.,,RT,Adult 500 mg-1 g slow IV/inj. Children 20-40 mg/kg/inj,,,,°£«DªvÀø¤W»Ý­n,,,Hold Breast Feeding ¼È°±­÷¨Å,,,,,,,
OKLA5,Clarithromycin,Klaricid 500mg,QANB,Upper & lower respiratory tract. Eradication of H. pylori when used with omeprazole.,Known hypersensitivity to macrolides. Concomitant administration with astemizole¡A terfenadine¡A pimozide or cisapride.,Diarrhea¡A vomiting¡A abdominal pain¡A dyspepsia¡A nausea¡A headache¡A taste perversion¡A transient elevation of liver enzymes. Allergic reactions ranging from urticaria & mild skin eruptions to anaphylaxis & Stevens-Johnson syndrome/toxic epidermal necrolysis. Transient CNS effects including dizziness¡A vertigo¡A anxiety¡A insomnia¡A bad dreams¡A tinnitus¡A confusion¡A disorientation¡A hallucination¡A psychosis & depersonalization. Alteration of sense of smell with taste perversion. Glossitis¡A stomatitis¡A oral monilia¡A tongue discoloration¡A tooth discoloration. Gastrointestinal: Abdominal pain (adults¡A 2%; pediatrics 3% )¡A Diarrhea (adults¡A 3% to 6%¡A pediatrics¡A 6% )¡A Disorder of taste (3% to 18.9% )¡A Indigestion (2% )¡A Nausea (3% )¡A Vomiting (6% ) Neurologic: Headache (2% up to 9%),15-30¢JÁ×¥ú,Adults and children > 12 years of age: 250-500 mg orally Q12H. (¼ö¯f) Pediatric age > 28 days: 15 mg/kg/day¡A divided Q12H (maximum 1 gm/day),»Ý½Õ¾ã¾¯¶q,if renal function normal¡A dose adjustment not necessar,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ODES,Potassium Citrate,Destone 540mg (5mEq),SGU,,¾AÀ³¯g: Prevention of uric acid nephrolithiasis; prevention of Ca renal stones in patients with hypocitraturia; avoidance of the complication of Ca stone formation in uric lithiasis. °Æ§@¥Î: Abdominal pain; dyspepsia; gastroenteritis; hyperkinesia; nervousness. ¸T§Ò: Hyperkalemia¡A peptic ulcer¡A abnormal renal function¡A anuria.,,«Ç·Å,Sever hypocitraturia 60 mEq/day. Mild to moderate hypocitraturia 30 mEq/day. Do not exceed 100 mEq/day.,,,,¦w¥þ,,,,,,,,,,
IWIN,Cefazolin,Winzolin inj 1gm,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(A021012209)(B014405221),,RT,Adult 1 g in 2 divided doses¡A increase to 1.5-3 g in 3 divided doses; dose may be increased up to 5 g/day in individed doses. Childn 20-40 mg/kg daily in 2 divided doses¡A increase to 50 mg/kg in 3 divided doses; dose may be increased to100 mg/kg/day.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OZEL,Tegaserod,Zelmac 6mg,ALIM,,Treatment of abdominal pain & discomfort¡A bloating & altered bowel function in patients w/ irritable bowel syndrome (IBS) whose main symptoms are pain/discomfort & constipation.,,RT,6 mg bid,,,,¥i¯à¦w¥þ,,,,,,,,,,
ESTE,Diazepam,Stesolid rectal tubes 10mg,CNEU,Convulsions¡A including febrile convulsions in children. As sedative before exploratory examination & treatment.,Myasthenia gravis¡A sleep apnoea¡A severe hepatic insufficiency¡A acute respiratory depression.,Common: Rash (Rectal gel¡A 3%)¡A Taste sense altered (Nasal spray¡A 2%)¡A Ataxia (Rectal gel¡A 3%)¡A Dizziness (Rectal gel¡A 3%)¡A Headache (Rectal gel¡A 5%)¡A Incoordination (Rectal gel¡A 3%)¡A Somnolence (Rectal gel¡A 23%)¡A Euphoria (Rectal gel¡A 3%)¡A Bleeding from nose (Nasal spray¡A 3%)¡A Nasal congestion (Nasal spray¡A 3%)¡A Nasal irritation (Nasal spray¡A 6%) Serious: Central nervous system depression¡A Suicidal thoughts,25¢J¥H¤U,Adult & children 0.25-1 mg/kg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] ¦b°Êª«¸ÕÅç¤¤µo²{¡A¦bÃh¥¥®É´Á§ë¤© benzodiazepine ·|¤Þ°_ÃEµõ¡B¤¤¼Ï¯«¸g¨t²Îªº¤£¥¿±`¡A¥H¤Î¦b­L¨à¥X²{¥Ã¤[©Êªº¥\¯à»ÙÃª¡C¦b«á¨Ó¸û¤jªºÁ{§É¬ã¨s³ø§i¡A¨Ã¥¼½T»{Ãh¥¥«e¤T­Ó¤ë¨Ï¥Î diazepam ·|­P·î§Îªº¦MÀI©Ê¡C °ü¤k¦b¨ã¥Í¨|¤Oªº¦~ÄÖ¶¥¬q¡A­Y¥¿¦b±µ¨ü¥»«~¤§ªvÀø¥B±ýÃh¥¥ªÌ¡A«hÀ³¬¢¸ßÂå®v¬O§_°±¤îªvÀø¡C ¥Ñ©ó diazepam ªºÃÄ²z§@¥Î¡A­Y¦bÃh¥¥¥½¤T­Ó¤ë¦]­¢¤Á»Ý­n¦Ó¨Ï¥Î¥»«~¡A©Î¤À®Y®É¨Ï¥Î°ª¾¯¶q¥»«~¡A«h·s¥Í¨à¥i¯à·|¥X²{§CÅé·Å¡B±i¤O´î°h¡B¤¤«×©I§l§xÃø¤§²{¶H¡C¥¥°ü¦bÃh¥¥«á´Á­Y®É±`¨Ï¥Î benzodiazepine ©Î benzodiazepine-like ÃÄª«¡A¥i¯à·|¤ÞµoÀ¦¨à¨­Åéªº¨Ì¿à¡A¦b¥X¥Í«á¥X²{§ÙÂ_¯gª¬¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ñ©ó¦b¨Å¥Ä¤¤µo²{ benzodiazepine ©Î benzodiazepine-like ÃÄª«¡A¬G±Â¨Å°ü¤£¥i¨Ï¥Î¥»«~¡C,R;RECT;,,,,,
EBRU,Ciclopiroxolamine,Brumixol cream 10gm,TDER,,¾AÀ³¯g:ªí¥ÖÅðµß·P¬V(B021515329),,RT,Apply once daily to the affected skin area and its vicinity after thorough cleaning and drying. To prevent recurrent infection continue treatment for at least 2 weeks after clinical healing.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OLEXA,Escitalopram,LexaPRO 10mg,CNEU,,¾AÀ³¯g: Treatment of major depressive episodes. Treatment of social anxiety disorder (social phobia). Treatment of generalised anxiety disorder. Treatment of obsessive-compulsive disorder (OCD). °Æ§@¥Î: Appetite decreased¡A libido decreased¡A anorgasmia (female)¡A insomnia¡A somnolence¡A dizziness¡A sinusitis¡A yawning¡A nausea¡A diarrhoea¡A constipation¡A sweating increased¡A ejaculation disorder¡A impotence¡A fatigue¡A pyrexia. Rarely¡A hyponatraemia¡A seizures¡A ecchymoses. Cardiovascular: Hypertension (1% or greater )¡A Palpitations (1% or greater ) Dermatologic: Diaphoresis (4% to 5% )¡A Rash (1% or greater ) Endocrine metabolic: Weight increased (1% or greater ) Gastrointestinal: Constipation (3% to 6% )¡A Diarrhea (6% to 14% )¡A Gastroenteritis (1% or greater )¡A Heartburn (1% or greater )¡A Indigestion (2% to 6% )¡A Nausea (15% to 18% )¡A Xerostomia (4% to 9% ) Musculoskeletal: Arthralgia (1% or greater )¡A Myalgia (1% or greater ) Neurologic: Dizziness (4% to 7% )¡A Headache (24% )¡A Insomnia (7% to 14% )¡A Lightheadedness (1% or greater )¡A Somnolence (4% to 9% ) Reproductive: Disorder of ejaculation (9% to 14%)¡A Impotence (3% )¡A Orgasm incapacity (females¡A 2% to 6% )¡A Reduced libido (males¡A 6%; females¡A 3%) Other: Fatigue (2% to 6% ) ¸T§Ò: Concomitant treatment with non-selective¡A irreversible MAOIs.,,«Ç·Å,Social anxiety disorder 10 mg once daily for 2-4 weeks. Dose may be adjusted to 5 mg or max 20 mg daily. Treatment for 3 months is recommended. Generalised anxiety disorder 10 mg once daily; may be increased to max 20 mg daily. Obsessive-compulsive disorder 10 mg once daily; may be increased to max 20 mg daily. Duration may be several months or longer.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªº±wªÌ«ØÄ³¾¯¶q¬°10 mg/day orally,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OVGR1,Sildenafil,VIAGRA 100mg (4 tablets/box),SGU,Treatment of erectile dysfunction.,Patients who use nitric oxide donors or nitrates. Viagra should not be used in men for whom sexual activity is inadvisable (patients with severe CV disorders eg unstable angina or severe cardiac failure). Severe hepatic impairment¡A hypotension (< 90/50 mm Hg) or hypertension (> 170/100 mm Hg)¡A recent history of stroke or MI¡A known hereditary degenerative retinal disorders such as retinitis pigmentosa. Not indicated for women.,Common: Flushing (9-19%)¡A Indigestion (3-17%)¡A Headache (Erectile dysfunction¡A 16-28% ; pulmonary arterial hypertension¡A 46%)¡A Insomnia (erectile dysfunction¡A less than 2%)¡A Visual disturbance (erectile dysfunction¡A 1-11%)¡A Bleeding from nose (pulmonary arterial hypertension¡A 3-9%)¡A Nasal congestion (erectile dysfunction¡A 4-9%) Serious: Cardiovascular morbidity¡A Myocardial infarction¡A Sickle cell anemia with vasoocclusive crisis¡A Non-arteritic ischemic optic neuropathy¡A Retinal hemorrhage¡A Decreased hearing¡A Sudden onset (erectile dysfunction¡A less than 2%)¡A Sudden hearing loss (erectile dysfunction¡A less than 2%)¡A Priapism¡A Prolonged erection of penis,30¢J¥H¤U,Erectile dysfunction: Sildenafil 25 to 100 mg (50 mg usual dose) orally 1 hour (range 0.5 to 4 hours) prior to sexual activity; the maximum frequency of administration once daily.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¨ü·l¤§±wªÌ(¦p¨xµw¤Æ)±wªÌªº²M°£²v·|¤U­°¡A¦]¦¹À³¦Ò¼{¨Ï¥Î25 mgªº°_©l¾¯¶q¡C°ò©óÃÄ®Ä¤Î­@¨üªº¦Ò¶q¡A¾¯¶q¥i´£°ª¦Ü50 mg©Î100 mg,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] Ãh¥¥¨Ï¥Î¤ÀÃþB1¡CVIAGRA¨Ã¤£¾A¥Î©ó¤k©Ê¡C ¹ï©ó¾¹©x§Î¦¨´Áªº¤j¥Õ¹«¤Î¨ß¤l§ë»P°ª¹F200 mg/kg/dayªº¾¯¶q«á¡A¨ÃµL¥ô¦óÃÒ¾ÚÅã¥Ü¦³­P·î­Lªº°Æ§@¥Î¡A©Î¹ï­F­L­L¨à¦³¥ô¦ó¤£¨}¼vÅT¡C¦¹¾¯¶q200mg/kg/day¤U©Ò´ú±o¤§¥¼µ²¦XºA¤Î¥D­n¥NÁÂª«¤§¿@«×¡A¬°¤HÃþ³Ì°ª«ØÄ³¾¯¶q100mg©Ò´ú±o¿@«×¤§60­¿¡C©ó¤j¥Õ¹«¥Í²£«e«á¤§µo¨|ª¬ºA¬ã¨s¤¤¡A30mg/kg/dayªº¾¯¶q§ë»P36¤Ñ«á¡A¨ÃµLµo²{¥ô¦óªº°Æ§@¥Î¡C¦b¥¼Ãh¥¥¤j¥Õ¹«¡A¦¹¾¯¶q¤UªºAUC¬O¤HÃþAUCªº20­¿¡C ¹ï©ó¥¥°ü¨Ï¥Îsildenafil¨ÃµL¨¬°÷¥B¸g¦³®Ä±±¨îªº¬ã¨s¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] VIAGRA¤£¾A¥Î©ó¤k©Ê¡A¥Ø«e¨Ã¨S¦³¥ô¦ó¦³Ãö¨ä·|¤Àªc¶i¤J¥À¨Å¤¤ªº¸ê®Æ¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¤£À³¥Î©óºÞÄé¯f±w¡C
OCIA,Tadalafil,Cialis 20mg 4's/box,SGU,,Erectile dysfunction,,RT,Erectile dysfunction a) ONCE-DAILY DOSING 1) Once-daily doses of 50 milligrams (mg) have been effective in nondiabetic patients with mild or moderate erectile dysfunction; doses were taken each morning (Porst¡A 2002b). The longest duration of once-daily treatment has been 3 weeks. 2) This dose regimen provides "round-the-clock coverage¡A" eliminating the need for planning of sexual activity and enhancing spontaneity; however¡A it has not been evaluated as extensively as on-demand dosing. b) ON-DEMAND DOSING 1) For on-demand dosing¡A the manufacturer recommends an initial dose of 10 milligrams (mg) prior to sexual activity. The dose may be increased to 20 mg or decreased to 5 mg depending upon individual efficacy and tolerability. The maximum recommended dosing frequency is once daily. Tadalafil has been shown to improve erectile function for up to 36 hours after administration. Tadalafil may be taken with or without food (Prod Info Cialis(R)¡A 2003n). 2) In patients taking concomitant potent inhibitors of CYP3A4 (eg¡A ketoconazole¡A ritonavir)¡A the maximum recommended dose of tadalafil is 10 milligrams¡A not to exceed once every 72 hours (Prod Info Cialis(R)¡A 2003n). 3) Studies indicate that doses of 10 to 25 milligrams are effective in mild-to-severe erectile dysfunction¡A including diabetics (Anon¡A 2001a; Porst¡A 2002b; Padma-Nathan et al¡A 2001b; Sorbera et al¡A 2001b; Saenz de Tejada et al¡A 2001a). 4) Successful erections upon sexual stimulation have been achieved as early as 15 minutes postdosing (Anon¡A 2001a; Brock¡A 2001a); most responding patients will achieve an adequate erection within 30 to 45 minutes (Brock¡A 2001a). Thus¡A administration 30 to 60 minutes prior to sexual activity would appear sufficient. The duration of effect is up to 36 hours (Porst et al¡A 2003; Brock¡A 2001a; Porst¡A 2002b; Anon¡A 2001a) and only one dose per 24 hours (as needed) is indicated (Padma-Nathan et al¡A 2001b). The longest duration of on-demand treatment has been 12 weeks.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OGAS,Metoclopramide,Gastro-Timelets 30mg,ALIM,,¾AÀ³¯g:ªvÀø®ø¤Æ¨t²Î²§±`©Î¹w¨¾¹Ã¦R(B019538100),,RT,1 tab daily,,,,¥i¯à¦w¥þ,,,,,,,,,,
ORISU,Amezinium,Risumic 10mg,CAVS,,Essential & orthostatic hypotension¡A hypotension during hemodialysis,,RT,Essential & orthostatic hypotension: 10 mg bid Hypotension during hemodialysis: 10 mg at start,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OCOU1,Warfarin,Coumadin 1mg,HEMT,,I: Thrombolic conditions. CI: Pregnancy; haemorrhagic tendency or blood dyscrasias; recent or contemplated surgery of CNS¡A eye; traumatic surgery resulting in large open surfaces; bleeding tendencies associated with active ulceration or overt bleeding; threatened abortion; spinal puncture.,,RT,Initial: 40-60 mg/day. Maintenance: 2-10 mg/day,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OASP,Acetylsalicylic Acid,Aspirin protect 100mg,HEMT,Reducing the risk of mortality in patients with a suspected acute MI or a history of MI; secondary prevention of stroke; reducing the risk of transient ischaemic attacks (TIA) & stroke in patients with TIA; reducing the risk of morbidity & death in patients with stable & unstable angina pectoris; prevention of thromboembolism after vascular surgery or interventions (e.g. PTCA¡A CABG¡A carotid endarterectomy¡A arteriovenous shunts); prophylaxis of deep vein thrombosis & lung embolism after longer-term immobilisation (e.g. after major surgery); reducing the risk of first MI in patients with CV risk factors (e.g. diabetes mellitus¡A hyperlipidaemia¡A hypertension¡A obesity¡A smoking¡A old age).,Active peptic ulcers; haemorrhagic diathesis; a history of asthma induced by acetylsalicylic acid or other NSAIDs; combination with methotrexate at doses of ? 15 mg/week; last trimester of pregnancy.,Frequency not defined: Cardiac arrhythmia¡A hypotension¡A tachycardia¡A Dehydration¡A hyperglycemia¡A hyperkalemia¡A hypoglycemia (children)¡A increased thirst¡A metabolic acidosis¡A Abdominal pain¡A dyspepsia¡A gastrointestinal perforation¡A gastrointestinal ulcer¡A heartburn¡A nausea¡A vomiting¡A Postpartum hemorrhage¡A post-term pregnancy¡A prolonged labor¡A proteinuria¡A stillborn infant¡A Disorder of hemostatic components of blood¡A disseminated intravascular coagulation¡A hemorrhage¡A prolonged bleeding time¡A prolonged prothrombin time¡A thrombocytopenia¡A Hepatitis¡A increased liver enzymes¡A Agitation¡A brain edema¡A coma¡A confusion¡A dizziness¡A headache¡A hypothermia¡A lethargy¡A seizure¡A Increased blood urea nitrogen¡A increased serum creatinine¡A interstitial nephritis¡A renal failure syndrome¡A renal insufficiency¡A renal papillary necrosis¡A Hyperventilation¡A laryngeal edema¡A pulmonary edema¡A respiratory alkalosis¡A tachypnea¡A Fever¡A low birth weight. Postmarketing: Urticaria¡A Hyperuricemia (doses ?325 mg/day)¡A Gastrointestinal hemorrhage¡A pancreatitis¡A Anaphylaxis¡A angioedema¡A Drug reaction with eosinophilia and systemic symptoms¡A Intracranial hemorrhage¡A Reye's syndrome¡A Rhabdomyolysis¡A Macular degeneration (age-related)¡A Hearing loss¡A tinnitus¡A Asthma¡A bronchospasm.,25¢J¥H¤U,Take 100-200 mg every day or 300 mg every other day: Reduce the mortality of patients who may have acute myocardial infarction¡A Prevent deep vein thrombosis and pulmonary embolism caused by long-term immobility¡A Reduce the risk of first myocardial infarction in patients with cardiovascular risk factors¡A such as diabetes¡A hyperlipidemia¡A hypertension¡A obesity¡A smoking¡A and the elderly. Take 100-300 mg every day: Reduce the recurrence rate and mortality of patients with myocardial infarction¡A Prevent secondary-stroke¡A Reduce the recurrence of transient ischemic attack and stroke in patients with transient ischemic attack¡A Reduce the incidence and mortality of patients with stable and unstable angina¡A Prevent thromboembolism caused by vascular surgery or invasive treatment¡A such as percutaneous coronary angioplasty¡A coronary artery separation¡A flow transplantation¡A carotid endarterectomy¡A arteriovenous catheter.,»Ý½Õ¾ã¾¯¶q,Avoid use in severe liver disease.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,1.Compatible (Low Dose) 40~150mg/day 2.PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters (Full Dose),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»¿õ¡A½Ð¾ã²É§]ªA¡A¤£¥i¼·¥b©Î¿i¯»¡C
IARA,Darbepoetin alfa,Aranesp 25mcg/mL (­­¦Û¶O-¬~µÇ«Ç¥Î),HEMT,,¾AÀ³¯g:Treatment of anemia associated with chronic renal failure (CRF)¡A including patients either on or not on dialysis. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. °Æ§@¥Î:Vascular access thrombosis¡A CHF¡A sepsis¡A cardiac arrhythmia¡A infections¡A hypertension¡A hypotension¡A myalgia¡A headache¡A diarrhea¡A fever¡A nausea¡A chest pain ¸T§Ò: Uncontrolled hypertension.,,2-8¢J,CRF patients Starting dose: 0.45 mcg/kg body weight as a single weekly IV or SC inj. Cancer patients receiving chemotherapy Starting dose: 2.25 mcg/kg as a weekly SC inj. Doses should be titrated to not exceed a target hemoglobin concentration of 12 g/dL or cause a rapid rise in hemoglobin levels (e.g. >1 g/dL in any 2-week period).,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
LCAR,Digoxin,Cardiacin elixir 0.05mg/mL,CAVS,,¾AÀ³¯g: Heart failure¡A atrial fibrillation &/or flutter & supraventricular tachycardia. °Æ§@¥Î: Anorexia¡A nausea¡A vomiting. Rarely psychosis¡A verbal & visual disturbances including hallucinations. GI disturbances¡A arrhythmia¡A tachycardia¡A bradycardia¡A dizziness¡A headache¡A confusion. Hypersensitivity reactions. ¸T§Ò: Intermittent complete heart block or 2nd degree AV block; arrhythmias caused by cardiac glycoside intoxication.,,«Ç·Å,Oral digitalizing dose Children 4-6 years Initially 10-12 mL (0.5-0.6 mg). Maintenance: 3-4 mL (0.15-0.2 mg); 2-3 years Initially 8 mL (0.4 mg). Maintenance: 2-3 mL (0.1-0.15 mg); >12 months Initially 6-8 mL (0.3-0.4 mg). Maintenance: 2 mL (0.1 mg); >3 months Initially 4-6 mL (0.2-0.3 mg). Maintenance: 1.5-2 mL (0.075-0.1 mg); >1 month Initially 2-4 mL (0.1-0.2 mg). Maintenance: 1 mL (0.05 mg). To be taken daily in 3-4 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EELE1,Carteolol,Elebloc 1%¡A 5mL,TOPH,,¾AÀ³¯g: Glaucoma¡A ocular hypertension. °Æ§@¥Î: Burning or transient ocular itching¡A blepharoconjunctivitis¡A decreased corneal sensitivity¡A decreased tear secretion. ¸T§Ò: Bronchial asthma¡A significant bradycardia (< 45-50 beats/min)¡A 2nd or 3rd degree AV block or uncontrolled CHF¡A Raynaud's disease.,,«Ç·Å,Initially 1 drop of 1% soln bid (morning & evening) into each affected eye. Dose may be increased to 1 drop of 2% soln bid. Max: 2 drops daily. If intraocular pressure is controlled¡A 1 drop daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
EELE2,Carteolol,Elebloc 2%¡A 5mL,TOPH,,¾AÀ³¯g: Glaucoma¡A ocular hypertension. °Æ§@¥Î: Burning or transient ocular itching¡A blepharoconjunctivitis¡A decreased corneal sensitivity¡A decreased tear secretion. ¸T§Ò: Bronchial asthma¡A significant bradycardia (< 45-50 beats/min)¡A 2nd or 3rd degree AV block or uncontrolled CHF¡A Raynaud's disease.,,«Ç·Å,Initially 1 drop of 1% soln bid (morning & evening) into each affected eye. Dose may be increased to 1 drop of 2% soln bid. Max: 2 drops daily. If intraocular pressure is controlled¡A 1 drop daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IKA1,Triamcinolone Acetonide,Kenacort-A 10mg/1mL,HM,,¾AÀ³¯g¡GÃö¸`ª¢(A034743209),,RT,Intra-articular: 2.5-15 mg. Intradermal or intralesional: less than 1 mg/site.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IVAX4,Purified Split Inactivated Influenza Virus,§K¶O¦¨¤H¬y·P 0.5mL/dose (12~64·³ÂX¤j¹ï¶H),HIMM,,I: Prophylaxis against influenza. ADR: Erythema (rash)¡A swelling¡A pain¡A ecchymosis¡A induration¡A fever¡A dizziness¡A shivering¡A tiredness¡A headaches¡A sweating¡A muscle pain¡A joint pains. CI: Allergy to eggs¡A chicken protein or any constituents of the vaccine. Febrile illness or acute infection.,,2 ~ 8 ¢XC,Adult & Children >= 36 mth 0.5ml IV or deep SC. Chidren <= 8 yr who have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LMUS,Ambroxol,Musco soln 3mg/mL¡A 60mL,ERSP,,,,,,,,,,,,,,,,,,,
OACT3,Pioglitazone,Actos 30mg,META,Monotherapy or in combination with sulphonylureas¡A metformin or insulin in patients with type II diabetes.,Type 1 diabetes¡A diabetic ketoacidosis. Active hepatic disease or ALT levels > 2.5 times the upper limit of normal. NYHA class III or IV heart failure.,Edema¡A upper respiratory tract infection¡A headache¡A myalgia. Cardiovascular: Edema (4.8% to 15.3% ) Endocrine metabolic: Weight gain Hematologic: Anemia (less than or equal to 2% ) Musculoskeletal: Fracture of bone (5.1% )¡A Myalgia (5.4%) Neurologic: Headache (9.1% ) Respiratory: Pharyngitis (5.1% )¡A Sinusitis (6.3% )¡A Upper respiratory infection (13.2% ),15-30¢J¡A25¢J¬°¨Î,15-30 mg once daily¡A maximum: 45 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OMINE,Gestodene + Ethinylestradiol,Minesse F.C 28's/box,HM,,I: Oral contraceptive. CI: Defects of coagulation system¡A valvular heart disease¡A atrial fibrillation¡A acute & chronic liver function disturbance¡A sex ster-oid dependent neoplasia¡A sickle cell anemia¡A severe diabetes with vascular changes¡A herpes gestations¡A undiagnosed vag bleeding¡A pregnancy¡A disorders of lipometabolism. ADR: Headache¡A pain¡A asthenia¡A elevated BP¡A nausea¡A flatulence¡A vomiting¡A edema¡A hypercholesterolemia¡A wt gain¡A depression¡A dizziness/vertigo¡A emotional lability¡A nervousness¡A acne pruritus¡A breast pain¡A dysmenorrhea¡A metrorrhagia¡A amenorrhea¡A breast engorgement¡A breast enlargement¡A beast neoplasm¡A cervix dis-order¡A leukorrhea¡A menorrhea¡A vag moniliasis¡A vaginitis.,,RT,D: 1 tab daily¡A starting on day 1 of menstrual cycle. Tab: 28's (24 tab with ethinylestradiol 15ug & gestodene 60ug¡A plus 4 inactive tab),,,,¤£¥i¨Ï¥Î,,,,,,,,,,
ESERE,Salmeterol + Fluticasone,Seretide 50 evohaler,ERSP,Regular treatment of reversible obstructive airways disease (ROAD)¡A including asthma in adult & children¡A where combination therapy (bronchodilator & inhaled corticosteroid) is appropriate. Seretide Accuhaler 250/Seretide Evohaler 125/Seretide Evohaler 250 Maintenance treatment of COPD including chronic bronchitis & emphysema.,History of hypersensitivity to any of the ingredients of Seretide.,Hoarseness or dysphonia¡A throat irritation¡A headache¡A candidiasis of mouth & throat¡A palpitations¡A tremor¡A paradoxical bronchospasm¡A arthralgia. Gastrointestinal: Nausea (COPD¡A above 5% )¡A Oral candidiasis (asthma¡A 1% to 4%; COPD¡A 10% ) Musculoskeletal: Musculoskeletal pain (asthma¡A 2% to 7%; COPD¡A 9% ) Neurologic: Dizziness (asthma¡A 1% to 4%; COPD¡A 4% and greater )¡A Headache (9% to 21% ) Respiratory: Bronchitis (asthma¡A 2% to 8% )¡A Cough (asthma¡A 3% to 6% )¡A Difficulty speaking¡A Hoarse¡A Pharyngitis (asthma¡A 10% to 13% )¡A Throat irritation (7% to 9% )¡A Upper respiratory infection (asthma¡A 16% to 27%; COPD¡A greater than 5% )¡A Viral lower respiratory infection (3% to 6% ),°®ÀêÁ×ÅÎ30¢J¥H¤U,Asthma: Adults and adolescents 12 years and older: Two inhalations of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily. Children 4 years and older: 2 inhalation of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily. There are no recommended doses available in children aged under 4 years.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,SALMETEROL PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible FLUTICASONE PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,SALMETEROL BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible FLUTICASONE BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IH;,,,,,
OENTE,Entecavir,Entecavir 0.5mg,QANB,,,,,,,,,,,,,,,,,,,
OGAB,Glibenclamide,Gabemid (Glibenclamide) 5 mg,META,,¾AÀ³¯g: Diabetes mellitus. °Æ§@¥Î: Mild or severe hypoglycaemia¡A GI distress; dizziness¡A edema & hyponatraemia¡A urticaria¡A pruritus¡A rash¡A photosensitivity¡A cholestatic jaundice¡A hepatic porphyria. ¸T§Ò: Insulin-dependent diabetes¡A hepatic or renal dysfunction¡A uraemia¡A acidosis¡A ketosis¡A coma¡A pregnancy¡A severe cases of stress¡A fever¡A infection¡A trauma¡A juvenile onset or unstable diabetes.,,«Ç·Å,Initially 2.5 mg daily for 3-5 days. Adjust dose by 2.5 mg increment if required. Max: 15 mg daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OBAR,Entecavir,Baraclude 0.5mg,QANB,Treatment of chronic active type B viral hepatitis or reactivation of hepatitis B viral hepatitis in adults and children over 2 years of age.,Hypersensitivity to entecavir or any component of the formulation.,Common: Nausea (Adult¡A <1%; Pediatric¡A >1%)¡A Dizziness (<1%)¡A Headache (2-4%)¡A Fatigue (1-3%) Serious: Lactic acidosis¡A Hepatomegaly (Severe)¡A With steatosis¡A Recurrent hepatitis,30¢J¥H¤UÁ×¥ú,Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive¡A compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]¦b¥¥°ü¤¤¨ÃµL¾A·í¥B¨ã¦³¨}¦n¹ï·ÓªºBARACLUDE¬ã¨s¡C¦]¬°°Êª«¥Í´Þ¬ã¨s¥¼¥²¯à¹w´ú¤HÅéªº¤ÏÀ³¡A©Ò¥H¥u¦³¦b¼ç¦b®Ä¯q°ª©ó¹ï­L¨àªº¼ç¦b­·ÀI®É¡A¤è¯à©óÃh¥¥´Á¶¡¨Ï¥ÎBARACLUDE(entecavir)¡C¦b°Êª«¥Í´Þ¬ã¨s¤¤¡Aentecavir¹F¨ìÁ{§É·N¸q¼ÉÅS®É¡A¨Ã¥¼Æ[¹î¨ì¤£¨}µo¨|¼vÅT¡C¥þ¨­¼ÉÅS¶q(AUC)¬ù¬°¤HÃþ³Ì¤j«ØÄ³¾¯¶q(MRHD)¨C¤é1mgªº25­¿(¤j¹«)»P200­¿(¨ß¤l)®É¡A¨Ã¥¼Æ[¹î¨ìµo¨|¬r©Ê¡C¦b­L¨à¾¹©x§Î¦¨´Á¶¡(§³®W²Ä6¦Ü15¤Ñ[¤j¹«]»P§³®W²Ä6¦Ü18¤Ñ[¨ß¤l])¡A¹ïÃh¥¥ªº¤j¹«(¨C¤é¨C¤½¤çÅé­«2¡B20¤Î200²@§J)»P¨ß¤l(¨C¤é¨C¤½¤çÅé­«1¡B4¤Î16²@§J)¤fªA¬I¥Îentecavir¡C¦b¤j¹«¤¤¡A·í¥ÀÅé¥þ¨­¼ÉÅS(AUC)¬°MRHDªº3100­¿®É¡AÆ[¹î¨ì­F­L¡Ð­L¨à¬r©Ê¡A¥]¬AµÛ§É«á¬y²£¡B­F­L¦A§l¦¬¡B§À¤Ú»P¯á´Õ·î§Î¡B°©ÀfÅÜ¤Æ¡A¥]¬A¦¨°©¤£¥þ(¯á´Õ¡B¯Ý°©¸`»P«ü°©)¡B¦h¾lªº¸y´Õ»P¦Ø°©¡B­L¨àÅé­«¸û»´¡C¦b¸Ó¾¯¶q¿@«×¤]Æ[¹î¨ì¥ÀÅé¬r©Ê¡C¦b¨ß¤l¤¤¡A·í¥ÀÅé¥þ¨­¼ÉÅS(AUC)¬°MRHDªº883­¿®É¡AÆ[¹î¨ì­F­L¡Ð­L¨à¬r©Ê¡A¥]¬AµÛ§É«á¬y²£¡B­F­L¦A§l¦¬¤Î°©ÀfÅÜ¤Æ¡A¥]¬A¦¨°©¤£¥þ(¦Þ°©)¡B²Ä13¦Ø°©ªºµo¥Í²v¼W¥[¡C·íÃh¥¥°Êª«¤fªA¬I¥Îªºentecavir¬ù¬°28­¿(¤j¹«)»P212­¿(¨ß¤l)¤§MRHD¤HÅé¼ÉÅS¶q(AUC)®É¡A¨ÃµL­F­L¡Ð­L¨à¬r©Êªº²{¶H¡C¦b²£«e¤Î²£«áµo¨|¸ÕÅç¤¤¡A±q§³®W²Ä6¤Ñ¦Ü­÷¨Å´Á/²£«á20¤Ñ¡A¹ïÃh¥¥¤j¹«¤fªA¬I¥Îentecavir¡A¾¯¶q¬°¨C¤é¨C¤½¤çÅé­«0.3¡B3¤Î30²@§J¡C¦bµû¦ôªº³Ì°ª¾¯¶q¤U¡A¼ÉÅS¶q(AUC)°ª©óMRHD94­¿¡A¨Ã¥¼¹ï«á¥N²£¥Í¤£¨}¼vÅT¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Breastfeeding Recommendation: Contraindicated (HIV) ; No Human Data¡XProbably Compatible (Hepatitis B) [¥é³æ]¥Ø«e©|¤£²M·¡BARACLUDE¬O§_·|±Æ¤J¤HÃþ¨Å¥Ä¡B¼vÅT¥À¨Å¤Àªc¡A©Î¹ï­÷¨ÅÀ¦¨à³y¦¨¼vÅT¡C¦b¤j¹«­÷¨Å´Á¬I¥Î®É¡Aentecavir·|¥X²{¦b¨Å¥Ä¤¤(½Ð¨£¸ê®Æ)¡C¦b¦Ò¶q­÷Áý¥À¨Å¹ïµo¨|©M°·±d®Ä¯q®É¡AÀ³¤@¨Ö¦Ò¶q²£°ü¹ïBARACLUDEªºÁ{§É»Ý¨D¡A¥H¤ÎBARACLUDE©Î²£°üªº¨­Åéª¬ªp¹ïÁý­÷¥À¨ÅÀ¦¨àªº©Ò¦³¥i¯à¤£¨}¤ÏÀ³¡C¦b¤j¹«­÷¨Å²Ä7¤Ñ¤fªA³æ¾¯entecavir 10mg/kg«á¡Aentecavir·|¤Àªc¦Ü¤j¹«ªº¨Å¥Ä¤¤¡C¨Å¥Ä¤¤ªºentecavir¬ù¬°¥ÀÅé¦å¼ß¤¤ªº25%(®Ú¾ÚAUC)¡C,AC;AC15;PO;,,,,,
ITRA9,Atosiban,Tractocile inj 7.5mg/mL¡A 0.9mL,SGU,,¾AÀ³¯g: Delay imminent preterm birth in pregnant women with regular uterine contractions of at least 30 seconds duration at a rate of >=4 per 30 mins; cervical dilation of 1-3 cm (0-3 for nulliparas) & effacement of >=50%¡A age >=18 years; gestational age of 24-33 weeks¡A normal fetal heart rate. °Æ§@¥Î: Very common (>10%): nausea. Common (1-10%): headache¡A dizziness¡A hot flushes¡A vomiting¡A tachycardia¡A hypotension¡A inj site reactions¡A hyperglycemia. Uncommon (0.1%-1%): fever¡A insomnia¡A pruritus¡A rash. Rare (<0.1%): incidental cases of uterine haemorrhage/uterine atony and one case of allergic reaction were reported. ¸T§Ò: Gestation ages <24 weeks or >33 weeks premature rupture of the membranes > 30 weeks of gestation¡A intrauterine growth retardation & abnormal fetal heart rate¡A antepartum uterine hemorrhage requiring immediate delivery¡A eclampsia & severe pre-eclampsia requiring delivery¡A intrauterine fetal death¡A suspected intrauterine infection¡A placenta praevia¡A abruptio placenta¡A abnormal or high-risk pregnancy.,,2-8¢J,Initially 6.75 mg via slow IV over 1 min¡A followed by continuous IV infusion at 18 mg/ hr for 3 hrs. Thereafter¡A administer 6 mg / hr via continuous IV infusion up to 45 hr.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ONIL,Betahistine,Nilasen 16mg,CNEU,,¾AÀ³¯g: Vertigo & hearing impairment associated with Meniere's syndrome. Treatment of vestibular vertigo. °Æ§@¥Î: Mild gastric complaints. Very rarely¡A rash¡A pruritus¡A urticaria.,,«Ç·Å,Adult 24-48 mg daily in divided doses.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OSPI,Spironolactone,Spironolactone 25mg,CAVS,Edematous disorders¡A Congestive cardiac failure¡A Liver cirrhosis¡A Nephrotic syndrome¡A Idiopathic edema¡A Hypertension.,Acute renal insufficiency; significant impairment of renal function; anuria; hyperkalaemia; hypersensitivity.,GI symptoms; drowsiness; lethargy; headache; cutaneous eruptions; urticaria; mental confusion; drug fever; ataxia; impotence; amenorrhea; post-menopausal bleeding; gynecomastia; rarely agranulocytosis.,³±²D(15-30¢J) °®Àê³B©Ò,Diuretic-induced hypokalemia: 25-100 mg/day in 2-4 divided doses. Congestive cardiac failure/Liver cirrhosis/Nephrotic syndrome¡A Edematous disorders: Initially¡A 25-200 mg/day in 2-4 divided doses¡A administer for at least 5 days before increasing dose to obtain desired effect. Maintenance dose: 75-400 mg/day in 2-4 divided doses. Hypertension: 50-100 mg/day given in divided doses or as a single daily dose. For difficult or severe cases¡A gradually increased at 2-weekly intervals up to 200 mg/day. Hyperaldosteronism: Preparation for surgery: 100-400 mg/day in 2-4 divided doses. Long-term therapy for patients unsuitable for surgery: use lowest effective dosage. Children: Initial daily dose approximately 1-3 mg/kg in a single or divided doses¡A administer for at least 5 days before increasing dose to obtain desired effect.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,No reports linking spironolactone with human congenital defects have been located. Some have commented¡A however¡A that spironolactone may be contraindicated during pregnancy based on the known antiandrogenic effects in humans and the feminization observed in male rat fetuses. Other investigators consider diuretics in general to be contraindicated in pregnancy¡A except for patients with cardiovascular disorders¡A because they do not prevent or alter the course of toxemia and they may decrease placental perfusion. In general¡A diuretics are not recommended for the treatment of gestational hypertension because of the maternal hypovolemia characteristic of this disease.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ILOF1,Cephradine,LofaDine °w¾¯ 1gm,QANB,,¾AÀ³¯g: Treatment of infections of the respiratory tract¡A urinary tract¡A skin & soft tissue¡A bones & joints; septicaemia; endocarditis. °Æ§@¥Î: Pain at inj site¡A thrombophlebitis¡A GI disturbances¡A hypersensitivity reactions including skin rashes¡A overgrowth of non-susceptible organisms¡A transient increases in hepatic enzyme levels. Rarely¡A pseudomembranous colitis¡A nephrotoxicity. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult: 0.5-1 g q4-6h¡A (max. 8 g/day). Child over 1 yr: 50-100 mg/kg/day in 4 divided doses; max. daily dose should not exceed the recommended adult dose.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IBAY5,Hepatitis B Immune Globulin,Bay Hep B 5mL,HIMM,,¾AÀ³¯g:Post-exposure prophylaxis of hepatitis. Acute exposure to blood containing HBsAg¡A perinatal exposure of infants born to HBsAg +ve mothers¡A sexual exposure to an HBsAg +ve person¡A household exposure to persons with acute HBV infection. °Æ§@¥Î: Local pain & tenderness at the inj site¡A urticaria & angioedema¡A anaphylactic reactions.,,2-8¢J,By IM inj only. Acute exposure to blood containing HBsAg 0.06 mL/kg body weight within 24 hr. Prophylaxis of infants born to HBsAg & HBeAg +ve mothers 0.5 mL to be given within 12 hr of birth. Sexual exposure to an HBsAg +ve person 0.06 mL/kg as a single dose within 14 days of sexual contact. Give together with 1st dose of 1 mL IM of vaccine. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OAMZ,Dihydroxyalumium allantoinate + Metamagnesium alum,A.M.Z,ALIM,,¾AÀ³¯g: Relief of gastric hyperacidity¡A gastric & duodenal ulcer¡A acute & chronic gastritis. °Æ§@¥Î: Constipation or diarrhea.,,«Ç·Å,1 tab TID ~ QID,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OALUS,Aldioxa,Alusa 100mg,ALIM,,¾AÀ³¯g:Acute & chronic gastritis¡A indigestion¡A hyperacidity & symptomatic relief of pain due to peptic or duodenal ulceration. °Æ§@¥Î:Constipation. ¸T§Ò:Hypophosphatemia,,«Ç·Å,100mg TID ~ QID,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OZIN,Zinc Acetate,Zinca 50 mg,META,,,,,,,,,,,,,,,,,,,
IPREV,Pneumococcal Vaccine Polyvalent,Prevenar (¤C»ùªÍª¢¬Ì­]) 0.5mL/dose,HIMM,,¾AÀ³¯g: Active immunisation of infants & toddlers against invasive disease caused by Strep pneumoniae serotypes (4¡A 6B¡A 9V¡A 14¡A 18C¡A 19F & 23F) at 2¡A 4¡A 6 & 12-15 months of age. Active immunisation of infants & toddlers < 2 years against otitis media caused by Strep pneumoniae serotypes (4¡A 6B¡A 9V¡A 14¡A 18C¡A 19F & 23F). °Æ§@¥Î: Decreased appetite¡A vomiting¡A diarrhoea¡A injection site reactions (e.g. erythema¡A induration/swelling¡A pain/tenderness)¡A tenderness interfering with movement¡A fever¡A irritability¡A drowsiness¡A restless sleep.,,2-8¢J,Children 24 months-9 years A single dose of 0.5 mL IM¡A 12-23 months 2 doses of 0.5 mL with an interval of at least 2 months. Infants 7-11 months 2 doses of 0.5 mL with an interval of at least 1 month. A 3rd dose is recommended in the 2nd year of life¡A 2-6 months 3 doses of 0.5 mL with the 1st dose given at 2 months of age & with an interval of at least 1 month between doses. A 4th dose is recommended in the 2nd year of life.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EVID,Carbomer,Vidisic gel 10gm,TOPH,Substitute for lacrimal fluid in deficiency of tear production or dry eye.,Hypersensitivity to cetrimide.,Transient blurring in vision.,25¢J¥H¤U,Instill 1 drop into conjunctival sac 3-5 times daily or more frequently during the day & before bed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
OWIT1,Memantine,Witgen 10mg,CNEU,Alzheimer's disease (Moderate to Severe),Hypersensitivity to memantine hydrochloride or any other components of the product,Common Gastrointestinal: Constipation (3% to 5% )¡A Diarrhea (5% )¡A Vomiting (2% to 3% ) Neurologic: Confusion (6% )¡A Dizziness (5% to 7% )¡A Headache (adults¡A 6% ; pediatrics¡A 8% ) Serious Neurologic: Cerebrovascular accident¡A Seizure (up to 0.3% ) Renal: Acute renal failure Respiratory: Pneumonia,25¢XC¥H¤U,Initial¡A 5 mg orally once daily; titrate in 5-mg increments at intervals of at least 1 week to 10 mg/day (5 mg twice daily)¡A 15 mg/day (5 mg and 10 mg in separate doses)¡A and 20 mg/day (10 mg twice daily); target daily dose is 20 mg/day,µL»Ý½Õ¾ã¾¯¶q,Hepatic impairment¡A mild to moderate: No adjustment necessary Hepatic impairment¡A severe: Administer with caution,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,¥é³æ¥¼¦³»¡©ú,Unknown ¨S¦³¸ê®Æ,¥é³æ¥¼¦³»¡©ú,AC;PO;WM;,,,,,
OMIZ,Mizolastine,Mizollen 10mg (¦Û¶O),HIMM,,¡iI¡jSymptomatic treatment of seasonal & perennial allergic rhinoconjunctivitis & urticaria..,,RT,¡iD¡jAdult & childn > 12 yr 1 tab once daily,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OKYT,Granisetron,Kytril 1mg,CNEU,Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation.,Hypersensitivity to granisetron or related substances.,Headache¡A constipation. Gastrointestinal: Constipation (5.4% ),30¢J¥H¤U,Chemotherapy-induced nausea and vomiting; Prophylaxis: Adult: 1 mg BID or 2 mg once daily start from 1 hour before chemotherapy. Radiation-induced nausea and vomiting; Prophylaxis: Adult: 2mg QD for 7 days at most¡A start from 1 hour before radiotherapy. Children: There is not enough suggested information.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IREC2,Propofol,RECOFOL 20mg/mL¡A10mL,ZANE,,,,,,,,,,,,,,,,,,,
ONOV,Prochlorperazine,Novamin 5mg,CNEU,Pyschosis¡A nausea¡A vomiting.,Bone-marrow depression.,CV & haematological changes¡A GI disturbances. Hepatic dysfunction¡A Malin syndrome¡A extrapyrimidal reactions¡A visual disturbances¡A weight increase¡A breast enlargement changes in libido¡A dysmenorrhoea¡A CNS disorders¡A photosensitivity.,30¢J¥H¤U°®ÀêÁ×¥ú,Adult: 5-10 mg TID-QID (maximum: 150 mg/day). Children > 2 years or > 9 kg: 0.1 mg/kg or 2.5mg/m2 QID. Antiemetic: Body weight 9-13 kg: 2.5mg QD-BID¡A maximum: 7.5mg/day. Body weight 14-17 kg: 2.5mg BID-TID¡A maximum: 10 mg/day. Body weight 18-39 kg: 2.5mg TID or 5mg BID¡A maximum: 15 mg/day. For antipsychotic or sedation (2-12 years): 2.5mg BID-TID. Note: 1. Not recommended for children under 9 kg. Maximum dosage: first day¡A 10 mg; thereafter (2-5 years) 20mg/day; (6 to 12 years) 25 mg/day. 2. Children with an acute illness or dehydration are at increased risk of extrapyramidal syndrome.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]µL¬ÛÃö°O¸ü,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]µL¬ÛÃö°O¸ü,AC;AC15;PC;PO;WM;,,,,,
OPARL,Bromocriptine,Volbro 2.5mg,CNEU,Galactorrhea &/or prolactin-dependent amenorrhea¡A female infertility¡A Suppression of lactation¡A Pre-menstrual syndrome¡A Male hypogonadism¡A Acromegaly¡A Parkinson's disease.,Hypersensitivity to bromocriptine or ergot alkaloids¡A uncontrolled hypertension during pregnancy¡A post-partum or puerperal period.,Slight nausea¡A dizziness¡A fatigue¡A vomiting¡A orthostatic hypotension¡A constipation¡A drowsiness. Cardiovascular: Hypotension (type 2 diabetes¡A 2.2% ) Gastrointestinal: Constipation (acromegaly¡A 14%; hyperprolactinemic indications¡A 3%; type 2 diabetes¡A 5.8% to 11.3% )¡A Diarrhea (hyperprolactinemic indications¡A 3%; type 2 diabetes¡A 8.1% to 8.8% )¡A Indigestion (acromegaly¡A 4%; type 2 diabetes¡A 7.5% )¡A Nausea (acromegaly¡A 18%; hyperprolactinemic indications¡A 49%; type 2 diabetes¡A 25.4% to 32.5% )¡A Vomiting (acromegaly¡A 2%; hyperprolactinemic indications¡A 5%; type 2 diabetes¡A 5.3% to 8.1% ) Neurologic: Asthenia (type 2 diabetes¡A 12.5% to 18.9% )¡A Dizziness (hyperprolactinemic indications¡A 17%; type 2 diabetes¡A 11.9% to 14.8% )¡A Headache (hyperprolactinemic indications¡A 19%; type 2 diabetes¡A 11.4% to 16.8% )¡A Somnolence ( 3% to 6.6% ) Ophthalmic: Amblyopia (type 2 diabetes¡A 5.3% to 7.5% ) Respiratory: Rhinitis (type 2 diabetes 10.7% to 13.8% )¡A Sinusitis (type 2 diabetes¡A 7.4% to 10% ) Other: Fatigue (hyperprolactinemia indications¡A 7%; type 2 diabetes¡A 13.9% ),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Galactorrhea/hyperprolactinemia related amenorrhea or female infertility: 2.5 mg BID-TID. If the effect is not significant¡A can slowly increased to 5mg BID-TID. Inhibition of lactation: 5 mg BID for 14 days to maximum of 21 days. Premenstrual syndrome: 2.5 mg once daily from day 14 of the cycle¡A increment of 2.5mg every day to 2.5 mg twice daily¡A continue use until menstruation. Prolactin induced male hypogonadism: 10-20 mg daily. Prolactinoma: 2.5 mg BID-TID initially¡A slowly increase dose until optimal therapeutic response achieved. Acromegaly: 5mg daily and slowly increased to 20-40mg/day in 4 divided doses. Parkinsonism: start from 1.25 mg QD-BID¡A increased by 2.5 mg daily in 3-day or longer intervals as tolerated. Usual dose: 20-40mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,PC;PO;WM;,,,,,
OSIL,Silymarin,Silimin 150mg,ALIM,,¾AÀ³¯g:Chronic hepatitis¡A liver cirrhosis¡A fatty liver.,,«Ç·Å,150 mg bid-tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OLOF,Cephalexin,Lofaxin 250mg,QANB,,¾AÀ³¯g: Infections caused by Staph¡A Strep¡A pneumococci & other susceptible bacteria. °Æ§@¥Î: Diarrhea; superinfection; hypersensitivity reactions; eosinophilia; neutropenia¡A thrombopenia; rarely erythema multiforme¡A anaphylaxis; pseudomembranous colitis. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult: 250 mg q6h¡A (max. 4g/day). Child: 6.25-12.5 mg/kg q6h¡A up to 25 mg/kg q6h.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ODDA,Desmopressin,Minirin (DDAVP) 0.1mg,HM,,¾AÀ³¯g: ¥Dªv§¿±Y¯g¡B©]§¿¯g(B020826100) Central Diabetes Insipidus¡A Primary Nocturnal Enuresis¡A Renal Concentrating Capacity Test¡ASymptomatic treatment of nocturia in adults associated with nocturnal polyuria ie¡A nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease °Æ§@¥Î: Nausea¡A abdominal pain¡A headache¡A nasal congestion/rhinitis¡A nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea¡A Will respond to dosage decrease Neurologic: Fatigue (10% )¡A Headache (22.5% ) ¸T§Ò:Habitual & psychogenic polydipsia¡A syndrome of inappropriate ADH secretion (SIADH)¡A known hyponatremia¡A known or suspected cardiac decompensation & other conditions that require diuretics¡A moderate & severe renal impairment.,,«Ç·Å,Central diabetes insipidus:0.1-0.2mg tid. Primary nocturnal enuresis:0.2-0.4mg at bedtime.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OVIO,Rofecoxib,Vioxx 25mg,CNEU,,I: Relief of the signs & symptoms of osteoarthritis. Pain relief. Treatment of primary dysmenorrhoea. AR: Abdominal pain¡A asthenia¡A dizziness¡A influenza-like disease¡A lower extremity edema¡A upper respiratory infection¡A hypertension¡A GI effects¡A sinusitis¡A back pain¡A headache¡A bronchitis¡A urinary tract infection¡A post-dental extraction alveolitis¡A fever. Rarely¡A serious GI ulceration & bleeding. CI: Patients who have experienced asthma¡A urticaria of allergic-type reactions after taking aspirin or other NSAIDs. Late pregnacy.,,,D: Osteoarthritis: 12.5 mg once daily. Max: 25 mg daily. Management of acute pain & treatment of primary dysmenorrhoea: 50 mg once daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
YSWS,''µÎ¼¯¨à''¯D¼äÅS 237mL,µÎ¼¯¨à¯D¼äÅS 237mL,MSGO,,,,,,,,,,,,,,,,,,,
YSFM,''µÎ¼¯¨à''½Ã¥Í²M¼ä¼Q¾¯ 118mL,µÎ¼¯¨à½Ã¥Í²M¼ä¼Q¾¯ 118mL,MSGO,,,,,,,,,,,,,,,,,,,
YSFB,''µÎ¼¯¨à''¨N¯D¾®½¦ 340mL,µÎ¼¯¨à¨N¯D¾®½¦ 340mL,MSGO,,,,,,,,,,,,,,,,,,,
YSLJ,water¡A propylene glycol¡A methycelluose,µÎ¼¯¨à³±¹D¼í¿A¾®½¦ 113gm,MSGO,,,,,,,,,,,,,,,,,,,
OTS11,Tegafur + Gimeracil + Oteracil K,TS-1 capsules 25mg,RACA,,¾AÀ³¯g:Post-op adjuvant chemotherapy for locally advanced [stage II (excluding T1)¡A IIIA or IIIB) gastric cancer.Treatment for advanced Inoperable or recurrent gastric cancer. °Æ§@¥Î:Leukopenia¡A decreased Hb¡A thrombocytopenia¡A decreased neutrophil count; increased AST/ALT¡A bilirubin & creatinine; glycosuria¡A stomatitis¡A anorexia¡A nausea¡A vomiting¡A diarrhea¡A abdominal pain¡A constipation¡A rash¡A pigmentation¡A lacrimation¡A taste abnormality¡A dizziness¡A decreased weight¡A pyrexia¡A nasopharyngitis & fatigue. ¸T§Ò:Severe bone marrow depression¡A renal & hepatic disorder. Treatment with other fluoropyrimidine-group anticancer drugs (including combination therapies) & flucytosine. Pregnancy & lactation.,,«Ç·Å,Adult <1.25 m2 BSA Initially 40 mg; 1.25- <1.5 m2 BSA Initially 50 mg; >=1.5 m2 BSA Initially 60 mg. All doses are to be taken bid¡A for 28 consecutive days followed by a 14-day rest.,,,,¤£¥i¨Ï¥Î,,,Hold Breast Feeding ¼È°±­÷¨Å,,,,,,,
YSMP,"µÎ¼¯¨à"²n¨­¯» 198G,µÎ¼¯¨à²n¨­¯» 198gm,MSGO,,,,,,,,,,,,,,,,,,,
ODIZ,Diazepam,Diazepam 2mg,CNEU,,¾AÀ³¯g: µJ¼{¡B¥¢¯v¡B¦Ù¦×µjÅË¡BÀ°§U¤º¦Õ´`Àô¤Î¨ä¥L(A001646100) Short-term use in anxiety or insomnia. °Æ§@¥Î: Drowsiness¡A lightheadedness¡A confusion¡A ataxia¡A amnesia¡A dependence¡A muscle weakness. Cardiovascular: Hypotension Dermatologic: Rash (3%¡A rectal gel ) Gastrointestinal: Diarrhea (4%¡A rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia¡A Incoordination (3%¡A rectal gel )¡A Somnolence Psychiatric: Euphoria (3%¡A rectal gel ) Respiratory: Respiratory depression Other: Fatigue ¸T§Ò: Respiratory depression; acute pulmonary insufficiency; sleep apnoea; severe hepatic impairment; chronic psychosis; myasthenia gravis.,,«Ç·Å,Adult: Antianxiety: 2-10 mg bid-qid. Sedative-hypnotic (acute alcohol withdrawal): 10 mg tid-qid during the first 24 hrs¡A then 5 mg tid-qid as needed. Anticonvulsant and skeletal muscle relaxant: 2-10 mg bid-qid. Child 6 months of age and over: 0.04-0.2 mg/kg tid-qid.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
EOEK,Estriol,Oekolp forte ovula®ê¾¯ 0.5mg,SGU,,¾AÀ³¯g: Vag or cervical inflammation¡A atrophic vaginitis. °Æ§@¥Î: Local irritation or itch¡A breast tenderness¡A fluid retention.,,«Ç·Å,Atrophic vaginitis Insert 1-2 ovules daily for 3 weeks. A maintenance dose of 1 ovule twice a week may be used after restoration of the vaginal mucosa has been achieved. Pre- & post-operative treatment related to vaginal surgery in women with estrogen deficiency Insert 1-2 ovules daily for 2 weeks prior to surgery & 2 ovules/week after surgery.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EGYN,Clotrimazole,Gynox VT 500mg,SGU,,¾AÀ³¯g: Vulvovaginal candidiasis °Æ§@¥Î: Erythema¡A stinging¡A irritation; hypersensitivity reactions. ¸T§Ò: Hypersensitivity.,,«Ç·Å,1 vag. tab every three days at sleeping time.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,VAG;,,,,,
EEXT1,Nystatin+Neomycin+Gramicidin+Triamcinolone,Extracomb cream 15gm,TDER,,¾AÀ³¯g: Treatment of inflammatory skin lesions where bacterial or candidal infections are suspected. °Æ§@¥Î: Skin atrophy; ototoxicity; nephrotoxicity. ¸T§Ò: Tuberculous & most viral lesions of skin¡A especially herpes simplex¡A vaccinia¡A varicella.,,«Ç·Å,apply bid or tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OERAF,Oseltamivir,Eraflu 75mg (¬F©²´£¨Ñ),QANB,Prophylaxis & treatment of influenza in adult & children.,Hypersensitivity.,Common: Nausea (8-10%)¡A Vomiting (Adult and adolescent¡A 2-8%; pediatric¡A 8-16%)¡A Headache (Influenza treatment¡A 2%; influenza prophylaxis¡A 17%) Serious: Cardiac dysrhythmia¡A Erythema multiforme (Rare)¡A Facial swelling¡A Stevens-Johnson syndrome (Rare)¡A Toxic epidermal necrolysis (Rare)¡A Gastrointestinal hemorrhage¡A Hemorrhagic colitis¡A Hepatitis¡A Anaphylaxis (Rare)¡A Seizure¡A Abnormal behavior¡A Delirium,25¢J¥H¤U,(¥é³æ) Influenza: Treatment (for patients > 1 year): - Adult: Usual Dose for uncomplicated influenza of <48 hrs duration: 75 mg po BID x 5 days; complicated influenza in immunocompromised patients even if ill over 48 hrs: 75 mg po BID x 10 or more days. - Children > 40 kg: 75 mg BID x 5 days - Children > 23-40 kg: 60 mg BID x 5 days - Children > 15-23 kg: 45 mg BID x 5 days - Children <= 15 kg: 30 mg BID x 5 days - Infant 0-12 months: 3 mg/kg BID x 5 days Prophylaxis (for patients > 1 year): - Adults: 75 mg orally once daily for 10 days to 6 weeks. - Children > 40 kg: 75 mg QD x 10 days - Children > 23-40 kg: 60 mg QD x 10 days - Children > 15-23 kg: 45 mg QD x 10 days - Children <= 15 kg: 30 mg QD x 10 days - Infants 3-11 months: 3 mg/kg once daily (¼ö¯f),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCOD,Valsartan + Hydrochlorothiazide,Co-Diovan 80/12.5mg,CAVS,2nd-line therapy for HTN in patients whose BP is not adequately controlled by monotherapy.,Severe hepatic impairment¡A biliary cirrhosis & cholestasis. Anuria¡A severe renal impairment. Refractory hypokalemia¡A hyponatremia¡A hypercalcemia & symptomatic hyperuricemia. Pregnancy.,Headache¡A dizziness¡A nasopharyngitis¡A fatigue¡A upper respiratory tract infection¡A cough¡A diarrhea¡A arthralgia¡A back pain. Cardiovascular: Hypotension Gastrointestinal: Diarrhea (3%) Neurologic: Dizziness (9%)¡A Headache (2%) Renal: Serum blood urea nitrogen raised (15% )¡A Serum creatinine raised (2% ) Respiratory: Cough (3%) Other: Fatigue (5%),30¢J¥H¤U°®Àê³B,HTN adult: initial therapy 1-2 tablet QD. Maximum dose: Valsartan 320 mg/hydrochlorothiazide 25 mg per day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 2nd and 3 rd trimesters,Valsartan: Human Data Suggest Risk in 2nd and 3rd Trimesters Hydrochlorothiazide: (See Chlorothiazide.) Compatible [¥é³æ] ¸T§Ò: Ãh¥¥¡C¦p¦P¨ä¥Lª½±µ§@¥Î©óRAAS¤§ÃÄª«¡ACo-Diovan ¤£À³¥Î©óÃh¥¥¤¤¤§¤k©Ê¡C¥Ñ©ó¦åºÞ¥[À£¯À II «ú§ÜÅéªº§@¥Î¾÷Âà¡A¤£¯à±Æ°£¹ï­L¨àªº¦MÀI©Ê¡CÁöµM©|µL Co-Diovan ¨Ï¥Î¦bÃh¥¥°ü¤kªº¸gÅç¡A¦ý´¿¦³³ø§iµ¹¤©²Ä¤G¤Î²Ä¤T´ÁÃh¥¥°ü¤k¦åºÞ¥[À£¯ÀÂà¤ÆžJ(ACE) §í¨î¾¯·|³y¦¨µo®i¤¤ªº­F­L·l¶Ë©Î¦º¤`¡C¦¹¥~¡A¦^·¹©Ê¸ê®Æ«ü¥X²Ä¤@´ÁÃh¥¥°ü¤k¨Ï¥ÎACE§í¨î¾¯»Pµo¥Í¼ç¦b¥X¥Í¯Ê³´ªº­·ÀI¬ÛÃö¡C·íÃh¥¥°ü¤k¤£ª`·N¦aªA¥Îvalsartan¡A´¿¥X²{¦Ûµo©Ê¬y²£¡B¦Ï¤ô¹L¤Ö(oligohydramnios) ©M·s¥Í¨àµÇ¥\¯à¤£¥þªº®×¨Ò³ø§i¡C©ó¤l®c¤º±µÄ²¨ì thiazide §Q§¿¾¯(¥]¬A hydrochlorothiazide) ·|¾É­P­L¨à©Î·s¥Í¨à¶À¯n©Î¦å¤pªO´î¤Ö¯g¡A¦Ó¥B¥i¯à¤]·|¾É­P¨ä¥L´¿µo¥Í©ó¦¨¤H¯f¤Hªº¤£¨}¤ÏÀ³¡C ­Y¦bªvÀø´Á¶¡ÀË¬d¥X¤wÃh¥¥¡AÀ³ºÉ§Ö¤¤¤î¨Ï¥ÎCo-Diovan¡C ¦pªG·N¥~¼ÉÅS©óARBªvÀø¡AÀ³¦Ò¼{¶i¦æ¾A·íªº­L¨àºÊ´ú¡C¥À¿Ë±µ¨ü¹LARBªvÀøªºÀ¦¨à¡AÀ³±K¤ÁÆ[¹î¨ä§C¦åÀ£ªºµo¥Í¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Valsartan: No Human Data¡XProbably Compatible Hydrochlorothiazide: (See Chlorothiazide.) Compatible [¥é³æ] ©|¥¼ª¾ valsartan ¬O§_·|¤Àªc¨Å¥Ä¤¤¡CValsartan ·|¤Àªc©ó­÷¨Å¤¤¦Ñ¹«ªº¨Å¥Ä¤¤¡CHydrochlorothiazide«h·|³q¹L­L½L¨Ã¤Àªc©ó¤HÃþªº¨Å¥Ä¤¤¡C ©Ò¥H¨Ã¤£«ØÄ³¹ï­÷¨Å¤¤ªº¥À¿Ë¨Ï¥ÎCo-Diovan¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¥»ÃÄ¤£¥i¤À³Î¡C
OKEP,Levetiracetam,Keppra 500mg,CNEU,Monotherapy for focal seizures (with or without secondary generalized seizures) in patients above 16 years of age. Adjunctive therapy for (1) focal seizures (with or without secondary generalized seizures) in children aged 4 years and above¡A (2) in adolescents and adults aged 12 years and above for myoclonic seizures and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy.,Hypersensitivity to levetiracetam.,Common: Loss of appetite (3-8%)¡A Vomiting (15%)¡A Infectious disease (13%)¡A Decreased bone mineral density (70%)¡A Neck pain (2-8%)¡A Asthenia (15%)¡A Dizziness (5-9%)¡A Headache (14-19%)¡A Abnormal behavior (7-37.6%)¡A Irritability (6-12%)¡A Cough (2-9%)¡A Nasopharyngitis (7-15%)¡A Fatigue (10-11%) Serious: Stevens-Johnson syndrome (SJS)¡A Toxic epidermal necrolysis (TEN)¡A Decreased erythrocyte production¡A Decreased white blood cell count (2.4-3.2%)¡A Eosinophil count above reference range (8.6%)¡A Neutropenia ( 2.4%)¡A Pancytopenia¡A Thrombocytopenia¡A Liver failure¡A Anaphylaxis¡A Somnolence (8-45%)¡A Suicidal intent (0.5%)¡A Suicide¡A Angioedema,30¢J¥H¤U,Monotherapy: Adults¡A 16 Years and Older: Initial¡A 250 mg twice daily IV/orally; titration¡A may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum: 3000 mg/day. Adjunctive therapy: Adults¡A 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily¡A increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily. Child >6 years and dosage <250mg should use solution of Levetiracetam.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ]¦b¤@¤j¶q¤W¥««á¸ê®Æ¤¤¡A±µ¨ü levetiracetam ³æ¤@ªvÀøªº¥¥°ü¡]¶W¹L 1800 ¨Ò¡A¨ä¤¤¶W¹L 1500 ¨Òµo¥Í¦bÃh¥¥ªº«e¤T­Ó¤ë´Á¶¡¡^¥D­n¥ý¤Ñ©Ê·î§Îªº­·ÀI¨Ã¥¼¼W¥[¡C Ãö©ó¦b¤l®c¤º±µ¨ü levetiracetam ³æ¤@ªvÀøªº¨àµ£¯«¸gµo¨|¡A¥Ø«e¶È¦³¦³­­ªºÃÒ¾Ú¡C¦ý¥Ø«e¬y¦æ¯f¾Ç¬ã¨s¡]¬ù 100 ¦W¨àµ£¡^¨Ã¥¼¦³¯«¸gµo¨|»ÙÃª©Î©µ¿ðªº­·ÀI¼W¥[¡C Levetiracetam ¦pªG¦b¸g¥J²Óµû¦ô«á»{¬°¥¦¬OÁ{§É¤W©Ò»Ý­n®É¡A¤~¥i¥H¦bÃh¥¥´Á¶¡¨Ï¥Î¡C ¦b³oºØ±¡ªp¤U¡A«ØÄ³¨Ï¥Î³Ì§C¦³®Ä¾¯¶q¡CÃh¥¥´Á¶¡ªº¥Í²zÅÜ¤Æ¤]¥i¯à·|¼vÅT levetiracetam ªº¿@«×¡C ´¿¦³¦bÃh¥¥´Á¶¡¥X²{¦å¼ß¤¤ levetiracetam ¿@«×­°§C²{¶Hªº³ø§i¡C³oºØ¿@«×­°§Cªº²{¶H¦b²Ä¤T¥¥´Á·|§ó¬°ÅãµÛ(­°§Cµ{«×³Ì°ª¥i¹FÃh¥¥«e¤§°òÂ¦¿@«×ªº 60%)¡C ½Ð°È¥²¬°±µ¨üªvÀøªºÃh¥¥°ü¤k¶i¦æ¾A·íªºÁ{§É³B¸m¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Levetiracetam ·|±Æªn¦Ü¤HÃþ¨Å¥Ä¤¤¡A¬G¤£«ØÄ³±Â¨Å¡C ¦ý¦pªG¦b±Â¨Å´Á¶¡»Ý­nªA¥Îlevetiracetam¡A¶·µû¦ôªvÀø®Ä¯q¤Î­·ÀI»P±Â¨Åªº­«­n©Ê¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³µLªk§]ªAÃÄ¿õ¤§¯f¤H¡AÀ³¨Ï¥ÎLevetiracetam¤fªA²G¾¯¡C¥»°|Á{±Ä²M³æ¥]§tKeppra solution¡C
ODUP1,Dydrogesterone,Duphaston 10mg,HM,Treatment of progesterone deficiencies; counteract unopposed estrogen in hormone replacement therapy. Luteal support as part of assisted reproductive technology.,Hypersensitivity¡A progestogen dependent neoplasm to prevent endometrial hyperplasia¡A abnormal vag bleeding.,Migraines/headache¡A jaundice¡A asthenia (weakness) or malaise¡A abdominal pain¡A rash¡A pruritus¡A urticaria¡A metrorrhagia¡A breast pain/tenderness.,30¢J¥H¤U,Hormone replacement therapy :In combination with continuous sequential therapy: 10 mg daily during 14 consecutive days per cycle of 28 days.In combination with cyclical oestrogen therapy: 10 mg daily during 14 consecutive days per cycle of 28 days.If the endometrial section or ultrasound shows an inappropriate progestational response¡A should give 20mg.Primary dysmenorrhea: 10 mg BID from day 5-25 of the cycle.Endometriosis: 10 mg BID-TID from day 5-25 of the cycle or continuously. Dysfunction bleeding: 10mg BID 5-7 days.Secondary amenorrhea: An oestrogen once daily from day 1-25 of the cycle and then with 10 mg dydrogesterone BID from day 11-25 of the cyclePremenstrual syndrome¡A Irregular menstuation: 10 mg BID from day 11-25 of the cycle.Threatened abortion: 40 mg at once then 10 mg 8 hourly until symptoms remit.Habitual abortion: 10 mg BID until the 20th week of pregnancyInfertility: 10 mg QD from day 14-25 of the cycle.Luteal support as part of assisted reproductive technology: 10 mg TID starting at the day of oocyte retrieval & continuing for 10 weeks if pregnancy is confirmed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Use of vaginal progesterone may be considered to decrease the risk of recurrent spontaneous preterm birth in women with a singleton pregnancy and prior spontaneous preterm singleton birth (therapy may begin at 16 to 24 weeks¡A regardless of cervical length). It may also be used to prevent spontaneous preterm birth in women with a singleton pregnancy who have a cervix <20 mm before or at 24 weeks' gestation. Use is not recommended as an intervention for women with multiple gestations (ACOG 2012) .(UpToDate)2021/0125,Unknown ¨S¦³¸ê®Æ,Breastfeeding recommendations vary by manufacturer; the decision to breastfeed during therapy should consider the risk of infant exposure¡A the benefits of breastfeeding to the infant¡A and the benefits of treatment to the mother. (UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡C
OPZA,Pyrazinamide,Pyramide 250mg,QANB,,I: Tuberculosis. ADR: nausea¡A vomiting¡A anorexia¡A thrombocytopenia¡A sideroblastic anemia with erythroid hyperplasia¡A vacuolation of erythrocytes¡A increased serum iron concentration and adverse effects on blood clotting mechanisms (rare)¡A hepatotoxicity (dose-related)¡A mild arthralgia and myalgia (frequent)¡A hypersensitivity reactions including rashes¡A urticaria¡A pruritus. Photosensitivity¡A porphyria¡A dysuria¡A interstitial nephritis (rare). CI: severe hepatic damage¡A hypersensitivity¡A acute gout.,,Room Temp,20-35 mg/kg daily in 3-4 divided doses. (max. 3 g/day).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OROC,Calcitriol,Rocaltrol 0.25mcg,META,,I: Hypoparathyroidism & rickets; Renal osteodystroghy; Postmenopausal osteoporosis. ADR: Hypercalcemia syndrome¡A Ca intoxication. CI: Hypercalcemia. Vit D containing prep.,,,Initially 0.25 mcg/day Adults: 0.5-3 mcg/day or more. Childn: 0.5-2 mcg/day. Hypoparathyroidism: Adults: 0.25-207 mcg/day. Childn: 0.04-0.08 mcg/kg/day. Renal osteodystroghy: Adults: 0.25 mcg qod to 3 mcg/day or more. Childn: 0.014-0.041 mcg/kg/day.,,,,,,,,,,,,,,
INS100,Sodium Chloride,0.9% NaCl inj 100mL,MSIV,¤ô¥÷¸É¥R(A001085255),Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus¡A hypernatremia¡A fluid retention,Cardiovascular: Cardiac failure¡A hypotension¡A localized phlebitis¡A thrombosis. Central nervous system: Osmotic demyelination syndrome (due to rapid correction of hyponatremia) Endocrine & metabolic: Electrolyte disturbance (dilution of electrolytes)¡A hypernatremia¡A hypervolemia¡A hypokalemia¡A water intoxication Gastrointestinal: Nausea¡A vomiting (oral administration) Respiratory: Bronchospasm (inhalation with hypertonic solutions)¡A pulmonary edema,«Ç·Å,Individualized dosage.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
IGW100,Dextrose,Glucose inj 5% 100mL,MSIV,Treatment of carbohydrate & fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,30¢J¥H¤UÁ×¥ú,Individualise dosage. Adult 500-1000 mL each time IV drip.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
OORF3,Warfarin,Orfarin 3mg,HEMT,,¾AÀ³¯g: Treatment & prophylaxis of thromboembolic disorders. °Æ§@¥Î: Alopecia¡A skin rashes of various kinds¡A hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ) ¸T§Ò: Severe hepatic or renal disease¡A actual or potential haemorrhagic conditions¡A severe hypertension¡A endocarditis¡A ulceration of the GI & urinary tract¡A visceral carcinoma¡A endocarditis¡A neurosurgery¡A recent surgery on the eye¡A brain or spinal cord. Pregnancy.,,«Ç·Å,Initially¡A 10-15 mg daily¡A adjusted with relation to the result of control tests. Maintenance dosage adjusted according to INR.,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,WHO:Compatible with breast-feeding.,,,,,,
OGASD,Famotidine,Gaster D 20mg,ALIM,,¾AÀ³¯g: ¥Dªv¼ìºÅ¡B°f¬y©Ê­¹¹Dª¢(A022903100)(B024185100) Gastric¡A duodenal & anastomotic ulcers¡A upper GI hemorrhage¡A reflux esophagitis¡A Zollinger-Ellison syndrome °Æ§@¥Î: Infrequently¡A rash; constipation¡A diarrhea; dry mouth¡A nausea. Rarely¡A leukopenia¡A thrombocytopenia; tinnitus¡A increased pulse & BP; reversible mental confusion. Gastrointestinal: Constipation (1.2% )¡A Diarrhea (1.7% ),,«Ç·Å,Adult 20 mg bid or 40 mg at bedtime. Micromedex: Gastric hypersecretion: 20 to 160 mg ORALLY every 6 h,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IPPD1,Tuberculin PPD RT,PPD 2TU/0.1mL/dose (­­°·¶E¥Î),HIMM,Skin test in diagnosis of tuberculosis,Hypersensitivity to tuberculin purified protein derivative (PPD) or any component of the formulation; previous severe reaction to tuberculin PPD skin test (TST),Dermatologic: Rash Local: Injection site reactions: Bleeding¡A bruising¡A discomfort¡A erythematous reaction¡A hematoma¡A necrosis¡A pain¡A pruritus¡A redness¡A scarring¡A ulceration¡A vesiculation Miscellaneous: Anaphylaxis,2-8¢JÁ×¥úÁ×§K§N­á,ID¡A 0.1 mL¡A in the middle third of the forearm.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,WHO:Compatible with breastfeeding.,ID;,,,,,
OZIN2,Zinc Acetate,Zinca 25mg,META,Maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.,Hypersensitivity to any component of the formulation.,Gastric irritation.,25¢J¥H¤U³±²D°®Àê³B¡AÁ×§K¶§¥úª½±µ·Ó®g,Adult 50 mg TID. Children 1-6 years 25 mg BID¡A 6-16 years¡A < 57 kg 25 mg TID¡A > 57 kg 50 mg TID¡A 16-18 years 50 mg TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;PO;,,,,,
IRIS,Risperidone,Risperdal Consta 25mg,CNEU,,¾AÀ³¯g:Treatment of acute & chronic schizophrenic psychoses & other psychotic conditions in which +ve &/or -ve symptoms are prominent. Alleviates affective symptoms associated with schizophrenia °Æ§@¥Î:Wt gain¡A depression¡A fatigue¡A extrapyramidal symptoms. Uncommonly¡A hypotension¡A tardive dyskinesia¡A neuroleptic malignant syndrome¡A seizures¡A impaired concentration. ¸T§Ò:Patients with a known hypersensitivity to Risperdal Consta or any of the components,,2-8¢J,Adult 25 mg IM every 2 weeks. Some patients may benefit from higher doses of 37.5 mg or 50 mg. Max: 50 mg every 2 weeks. Upward dose adjustments should not be made more frequently than every 4 weeks. Elderly 25 mg IM every 2 weeks.,µL»Ý½Õ¾ã¾¯¶q,«ØÄ³°_©l¾¯¶q¬O²Ä¤@¶g¨C¤éªA¥Îrisperidone 0.5 mg ¨â¦¸¡A²Ä¤G¶g«h¼W¥[¬°¨C¤é¤fªA1 mg ¨â¦¸©Î¨C¤éªA¥Î2 mg ¤@¦¸¡C­Y¯f¤H¹ï¨C¤éªA¥Î¦Ü¤Ö2 mg ªº­@¨ü«×¨Î¡A§Y¥i¨C¨â¶gª`®gRISPERDAL CONSTAR 25 mg,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;,,,,,
ODIP,Diphenidol,Dinidol 25mg,CNEU,Vertigo caused by inner ear disturbance.,Renal failure,Thirst¡A anorexia¡A heartburn.,25¢J¥H¤U,Adult: 25-50mg QID (maximum: 300mg/day). Child over 6 months or over 12kg: 0.9mg/kg¡A may be repeated in 1hr with subsequent doses of Q4H as needed¡A (maximum: 5.5mg/kg/day).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,
LPHO,Sodium Phosphate,Phospho-Soda 90mL,ALIM,,¾AÀ³¯g: Relief of occasional constipation. For use as part of a bowel cleansing regimen in preparing the patient for surgery or for preparing the colon for X-ray or endoscopic exam. °Æ§@¥Î: Nausea¡A vomiting¡A bloating. ¸T§Ò: Congenital megacolon¡A intestinal obstruction or CHF. Children < 5 years.,,«Ç·Å,Prep for diagnostic procedures & pre-op 45 mL the evening before & repeat on the morning of the procedure. Constipation Adult & children >= 12 years Dilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 45 mL/24 hr. Children 10-11 yearsDilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 15 mL/24 hr. 5-9 years Dilute 7.5 mL in 240 mL liqd & drink at least 240 mL. Max: 7.5 mL/24 hr. Take 120 ml cool water with half (45 ml) of the Fleet phospho-soda to drink¡A and follow up more than 240 ml of cool water. Twice a day.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OKON,Psyllium hydrophilic mucilloid,Konsyl 6gm,ALIM,,¾AÀ³¯g: Treatment of constipation °Æ§@¥Î:Flatulence & abdominal distension ¸T§Ò: Intestinal obstruction or colonic atony¡A fecal impaction.,,«Ç·Å,Adult: 1 sachet 1-3 times daily Child >= 6.5 yr : adult dose or less,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ODIT,Oxybutynin,Ditropan 2.5mg,SGU,,¾AÀ³¯g: ¬°±Æ§¿¾÷¯à§ïµ½¾¯(A030803100) Relief of symptoms associated with voiding in patients with uninhibited neurogenic & reflex neurogenic bladder. °Æ§@¥Î: Dose-related anticholinergic effects; dry mouth¡A blurred vision¡A tachycardia¡A dizziness¡A impotence; allergic reactions. Dermatologic: Application site erythema (5.6% to 8.3% )¡A Application site rash (3.3% )¡A Pruritus (14% to 16.8% ) Gastrointestinal: Constipation (3.3% )¡A Diarrhea (3.2% )¡A Xerostomia (4.1% to 9.6% ) ¸T§Ò: Glaucoma; GI obstruction¡A paralytic ileus¡A intestinal atony¡A megacolon¡A severe colitis; myasthenia gravis; acute haemorrhage.,,«Ç·Å,Adult: 1 tab bid-tid Child > 5 yr: 1 tab bid,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OGEO,Ziprasidone,Geodon 40mg,CNEU,,¾AÀ³¯g: Management of schizophrenia and acute bipolar mania. °Æ§@¥Î: Asthenia¡A extrapyramidal syndrome¡A nausea¡A somnolence¡A respiratory disorder. ¸T§Ò: QT-interval prolongation¡A acute MI¡A uncompensated heart failure¡A cardiac arrhythmias requiring treatment with Class I & III antiarrhythmic drugs.,,«Ç·Å,Adult Initially 40 mg bid. Recommended dosage: 60 mg bid¡A up to max 80 mg bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ENS2,Sodium Chloride,0.9%NaCl irrigation 2000mL,MSIV,Wound cleansing¡A irrigation & flushing.,Not to be used to induce emesis.,,«Ç·Å,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds¡A and for washing¡A rinsing medical device.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;G;GAR;IH;IN;INHL;IRR;IRRI;RT;SHA;SKIN;TOPI;,,,,,
ENS3,Sodium Chloride,0.9%NaCl irrigation 3000mL,MSIV,Wound cleansing¡A irrigation & flushing.,Not to be used to induce emesis.,,«Ç·Å,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds¡A and for washing¡A rinsing medical device.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;G;GAR;IH;IN;INHL;IRR;IRRI;SKIN;TOPI;,,,,,
OEVI,Raloxifene,Evista 60mg¡A 28's/¥],META,,¾AÀ³¯g:¥Dªv°©½è²¨ÃP¯g(B022717100),,RT,1 tab daily,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OSIM,Polysiloxane + Co-dried Gel,Simagal,ALIM,,Hyperacidity¡A heartburn¡A flatulence.,,,Adult: 1-2 tab tid-qid. Child 5-12yrs: 1 tab bid-tid. Under 5yrs: 1/2 tab bid-tid.,,,,,,,,,,,,,,
OSPO,Itraconazole,Sporanox 100mg,QANB,,,,RT,PO¡A take with meals. Dermatomycosis: 100-200 mg/day x 7-30 days. Fungal keratitis: 200mg qd x 21 days. Oral candidiasis: 100mg qd x 15 days. Vaginal candidiasis: 200mg bid x 1 day or 200mg/day x 3 days.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTON,Allopurinol,Tonsaric 100mg,CNEU,Reduces urate conc¡A manifestations of urate/uric acid deposition. Prevention & treatment of Ca oxalate/phosphate renal stones. Manifestations of hyperuricaemia &/or hyperuricosuria.,GI intolerance.,Common: Maculopapular eruption (1% or greater)¡A Rash (1% or greater)¡A Diarrhea (1% or greater)¡A Nausea (1% or greater)¡A Alkaline phosphatase above reference range (1% or greater)¡A ALT/SGPT level raised (1% or greater)¡A Aspartate aminotransferase serum level above reference range (1% or greater)¡A Gout¡A acute (1% or greater) Serious: Pruritus (< 1%)¡A Stevens-Johnson syndrome (< 1%)¡A Toxic epidermal necrolysis (< 1%)¡A Loss of appetite (< 1%)¡A Weight loss¡A Agranulocytosis (< 1%)¡A Aplastic anemia (< 1%)¡A Leukopenia (< 1%)¡A Myelosuppression¡A Thrombocytopenia (< 1%)¡A Granulomatous hepatitis (< 1%)¡A Hepatic necrosis (< 1%)¡A Hepatotoxicity¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Dizziness (< 1%)¡A Somnolence (< 1%)¡A Acute renal failure¡A Renal failure (< 1%),ºò±K®e¾¹¤¤¡A«Ç·Å¤U¥BÁ×¥ú«O¦s,Adults: Antigout agent: Initial dose:100mg QD¡A increase by 100 mg/day during one-week intervals until the required serum uric acid concentration is reached. maximum:800mg/day. Maintenance dose:100mg-200mg BID-TID¡A or 300mg QD. The general maintenance dose for people with mild gout is 200 to 300 mg per day. In moderately severe Tophaceaus gout¡A the general maintenance dose is 400 to 600 mg per day. Neoplastic disease therapy:12 hours to 3 days (preferably 2 to 3 days) before the start of chemotherapy or radiotherapy¡A 600 mg to 800 mg per day. Antiurolithic(Uric acid caliculi):100-200mg QD. maximum dose: each dose 300mg¡A 800mg/day Children: Neoplastic disease therapy:<6 years old:50mg TID 6-12 years old: 100mg TID or 300mg QD. After 48 hours of treatment¡A adjust the dose according to the patient's condition.,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OVERM,Mebendazole,Vermox 100mg,QANP,,Treament of pinworm¡A whipworm¡A roundworm¡A hookworm¡A in single or mixed infections.,,,Pinworm infestation: Adult & child: 100 mg as a single dose. Roundworm¡A whipworm & hookworm infestations: Adult & child: 100 mg bid for 3 days. Tapeworm infestation: Adult: 200 mg bid for 3 days. Child: 100 mg bid for 3 days. If necessary¡A a second course may be given after 2-3 wks.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OZYR,Cetirizine,Zyrtec 10mg,HIMM,,Symptomatic treatment of seasonal rhinitis & conjunctivte perennial allergic rhinitis as well as pruritus & urticaria of allergic origin.,,,Adult or under 6 year is 10mg/day or 5mg bid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EPRO1,Tacrolimus,Protopic oint 0.1%¡A10gm,TDER,,¾AÀ³¯g: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. °Æ§@¥Î: Burning sensation¡A pruritus¡A flu-like symptoms & headache. ¸T§Ò: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15-30¢J,Adult & children 2-15 years Apply thinly & rub in bid¡A continue for 1 week after signs & symptoms clear.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IKAT,Phytonadione,Katimin"1" inj 10mg/1mL,HEMT,Vit K deficiency due to drugs or malabsorption¡A Over-anticoagulation.,Hypersensitivity.,Anaphylaxis¡A dyspnoea¡A cyanosis¡A pain¡A swelling¡A phloebitis at the Inj site¡A diaphoresis¡A dizziness¡A hypotension (rare)¡A allergic reactions after SC and IM inj.,¦s©ó§N·t³B,Prevention and controlling bleeding of infant: IM 1-2 mg¡A increased if needed. Prevention of hypoprothrombinemia in infant: IM 10 mg daily 1-2 weeks before delivery or slow IV 1-2 mg before delivery. Antagonistic anticoagulant: IM 5-10mg¡A up to 20mg if needed. Control bleeding & Severe bleeding: slow IV 10-15mg.(do not exceed 1mg/min) Prevention of bleeding during surgery: IM 25-50mg before surgery.(do not exceed 25mg at same site),µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment provided in manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVP;IVPUSH;,,,Slow IV¡A±Àª`³t²v < 1mg/min,,
IAMP,Ampicillin,Ampolin inj 0.5gm,QANB,Respiratory tract infections¡A UTI¡A gonorrhea¡A enteric infections¡A meningitis¡A septicemia¡A bacillary dysentery¡A shigellosis¡A salmonellosis.,Hypersensitivity to penicillins. Infectious mononucleosis.,Common: Rash¡A Urticaria¡A Diarrhea Serious: Erythema multiforme¡A Erythroderma¡A Toxic epidermal necrolysis¡A Clostridium difficile colitis¡A Agranulocytosis¡A Thrombocytopenia¡A Anaphylaxis,25¢J¥H¤U,Usually¡A adults: 250-500 mg IM 2-4 times daily¡A children weighing < 20 kg: 25-60 mg/kg/day IM/IV in 3-4 divided doses. Infection of respiratory tract¡A skin or soft tissue and genitourinary tract: adults 250-500 mg every 6 hours; children weighing < 40 kg: 25-50 mg/kg/day in 4 divided doses. Urinary tract infection due to N. Gonorrhea: adults 500 mg every 12 hours. Bacterial meningitis: adults 8-14 g/day; children 100-200 mg/kg/day. Administer in equally divided doses every 3-4 hours. Treatment may be initiated with intravenous drip therapy and continued with intramuscular injections. *****NEONATE ANTIBIOTICS DOSE***** Ampicillin: Total dose: General infection: 100 mg/kg/day Group B streptococcal bacteremia (GBS) sepsis: 200mg/kg/day PMA (postmenstrual age ) = gestational age plus postnatal age Drug Interval: PMA <=29 week Postnatal 0-28 days Q12H PMA <=29 week Postnatal >= 29 days Q8H PMA 30 to 36 week Postnatal 0-14 days Q12H PMA 30 to 36 week Postnatal >=15 days Q8H PMA 37 to 44 week Postnatal 0-7 days Q12H PMA 37 to 44 week Postnatal >= 8 days Q8H PMA >=45 week Q6H GBS meningitis: total dose 0-7 days: 200 to 300 mg/kg/day divided Q8H 8 days and older: 300 mg/kg/day divided Q6H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st trimester,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,IM: 1.8 mL D/W IV: 5mL D/W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¡C,over 3 to 5 minutes,IV infusion: ¥H50 ~ 100 mL¾A·í¿éª`²Gµ}ÄÀ¡A¿@«× < 30mg/mL¡C¨C1gm¾¯¶q¥H¦Ü¤Ö10 ~ 15¤ÀÄÁ®É¶¡½wºCºwª`¡A¨àµ£ªººwª`³t²v«ØÄ³¶W¹L30¤ÀÄÁ¡C NeoFax«ØÄ³¡GDoses 500 mg or less should be administered slowly over 3 to 5 minutes IV and over at least 10 to 15 minutes for doses 1 g or greater. Recommended concentrations are 30¡A 40¡A 50¡A and 100 mg/mL for intermittent IV. For ampicillin 100 mg/mL¡A consider central line administration due to potential osmolality greater than 600 mOsm/kg.,1. ª`®g«eÀË¬d¯f±w¬O§_¦³PCN¹L±Ó¥v¡C 2. µ}ÄÀ²G»Ý¦b¤@¤p®É¤º¥Î§¹¡C 3. °®¯»µ}ÄÀ¡G(IM) 0.5gm/vial °®¯»¥[¤J1.8 mL D/Wªw»s¡A(IV bolus) 0.5gm/vial °®¯»¥[¤J5 mL D/Wªw»s¡C 4. IV infusion: ¥H50 ~ 100 mL¾A·í¿éª`²Gµ}ÄÀ¡A¿@«× < 30mg/mL¡C¨C1gm¾¯¶q¥H¦Ü¤Ö10 ~ 15¤ÀÄÁ®É¶¡½wºCºwª`¡A¨àµ£ªººwª`³t²v«ØÄ³¶W¹L30¤ÀÄÁ¡C
LMUS1,Ambroxol,Musco soln 3mg/mL¡A 100mL,ERSP,,¾AÀ³¯g: Expectorant. °Æ§@¥Î: Mild GI effects & Allergic reactions.,,«Ç·Å,Adult & children >10 years 10 mL tid¡A 5-10 years 5 mL tid. < 2 years 2.5 mL bid. Reduce dose in long-term therapy.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EFUB,Flurbiprofen,Fubifen PAP (4¤ù/¥]),CNEU,,¾AÀ³¯g: Relief of pain & inflammation in rheumatic disease & other musculoskeletal disorders e.g. ankylosing spondylitis¡A osteoarthritis¡A sprains & strains¡A post-op pain. °Æ§@¥Î: Occasionally¡A redness¡A rashes¡A pruritus¡A dryness¡A irritation¡A edema¡A photosensitivity. ¸T§Ò: Patients with a history of hypersensitivity to aspirin & other NSAIDs.,,«Ç·Å,Apply 1 sheet to the affected area bid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ILIPI,Iodine¡A combined ethyl ester of fatty acid oil,Lipiodol ultra-fluid 4800mg/10mL,SCAN,Diagnostic radiology: Lymphography¡A hysterosalpingography¡A sialography. Interventional radiology: Visualisation¡A localisation & vectorisation during trans-arterial chemo-embolisation (TACE) of hepatocellular carcinoma at intermediate stage¡A in adults.,Hypersensitivity to iodine-containing products or ethyl esters of iodised fatty acids of poppy seed oil. Acute pelvic inflammation. Confirmed hyperthyroidism or pulmonary insufficiency. Traumatic lesions¡A haemorrhage or recent bleeding (risk of extravasation or embolism). Bronchography. Pregnancy. Administration in liver areas w/ dilated bile ducts (specific for use in interventional radiology).,Increase temp followed by a fever (38-39¢XC)¡A fat microembolism. Post embolisation syndrome (fever¡A abdominal pain¡A nausea¡A vomiting) and transitory changes in liver function tests. Hypersensitivity¡A anaphylactic reaction; hyperthyroidism; cerebral embolism; pulmonary embolism; vomiting¡A diarrhoea¡A nausea; pain; fat embolism. Spinal cord injury.,«Ç·Å,Diagnostic radiology adult: Lymphography: Unilateral lymphography of upper extremities: 2 to 4 mL. Unilateral lymphography of lower extremities: 6 to 8 mL. Penile lymphography: 2 to 3 mL. Cervical lymphography: 1 to 2 mL. child: 1-6 mL¡A max: =<0.25mL/kg. Hysterosalpingography: Inject in 2 mL increments into the endometrial cavity until tubal patency is observed. Selective hepatic intra-arterial injection: 1.5 to 15 mL administered slowly under continuous radiologic monitoring; discontinue administration when stagnation or reflux is evident¡A maximum total dose: 20 mL.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,METRONIDAZOLE: Human Data Suggest Low Risk,Compatible ­÷¨Å®É¥i¨Ï¥Î,METRONIDAZOLE: Hold Breastfeeding (Oral/IV Single Dose) Limited Human Data¡XPotential Toxicity (Oral/IV Divided Dose) Compatible (Topical/Intravaginal),IA;LI;,,,,,Lipiodol ultra-fluid ¤£¥i¥ÑÀR¯ß¤º¡B°Ê¯ß¤º(°£¤F¿ï¾Ü©Ê´¡ºÞ)©Î¸£¯áÅè½¤¤ºªº³~®|µ¹ÃÄ¡C
ITRI4,Triamcinolone,4% TRIAMCINOLONE 40mg/1mL,HM,Inflammatory skin conditions.,Untreated systemic fungal¡A bacterial¡A viral or parasitic infection¡A hypersensitivity. Neonates (Parenteral),HPA axis supression¡A intracranial hypertension¡A Cushing's syndrome¡A growth retardation in children; osteoporosis¡A fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas¡A broken skin or under occlusive dressing.,25¢J¥H¤UÁ×¥ú,Adult: INS 2.5-40mg or IM 40-60mg per time¡A could inject 2-3 times if symptoms reappear. Children > 6 years: IM 30-200mcg daily to weekly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,ID;IM;INS;IVI;SKIN;SUBCI;,,,,,
EZAD,Ketotifen,Zaditen eye drops 5mL,TOPH,,¾AÀ³¯g: Treatment of signs & symptoms of allergic conjunctivitis. °Æ§@¥Î: Ocular: Burning/stinging¡A punctate corneal epithelial erosion¡A blurring of vision¡A dry eyes¡A eyelid disorder¡A conjunctivitis¡A eye pain¡A photophobia¡A subconjunctival hemorrhage. Systemic: Headache¡A somnolence¡A skin rash¡A eczema¡A urticaria¡A dry mouth & allergic reaction. Neurologic: Headache (10%-25%) Ophthalmic: Dry eyes¡A Eye irritation¡A Conjunctival (10%-25%)¡A Pain in eye Respiratory: Pharyngitis¡A Rhinitis (10%-25%) Other: Influenza ¸T§Ò: Hypersensitivity to ketotifen or to any of the excipients of Zaditen eye drops.,,«Ç·Å,Adult¡A elderly & children >=3 years Instill 1 drop bid into the conjunctival sac.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSTR8,Atomoxetine,Strattera 18mg,CNEU,,¾AÀ³¯g:Treatment of attention-deficit/hyperactivity disorder (ADHD). °Æ§@¥Î: Nausea¡A vomiting¡A fatigue¡A decreased appetite¡A abdominal pain¡A somnolence. Endocrine metabolic: Weight loss (pediatrics¡A 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults¡A 7%; pediatrics¡A 17% to 18% )¡A Constipation (adults¡A 9%; pediatric¡A 1% to 2%)¡A Decrease in appetite (adult¡A 11%; pediatrics¡A 16% ¡A)¡A Nausea (adults¡A 21%; pediatrics¡A 7% to 13% )¡A Vomiting (adults¡A 3%; pediatrics¡A 11%)¡A Xerostomia (adults¡A 21% ) Neurologic: Headache (pediatrics¡A 19% )¡A Insomnia (adults¡A 16%; pediatrics¡A at least 2%; )¡A Somnolence (adult¡A 4%; pediatrics¡A 11% ) Renal: Delay when starting to pass urine (adults¡A 5.6% )¡A Urinary retention (adults¡A 1.7% ) Reproductive: Dysmenorrhea (adults¡A 6% )¡A Erectile dysfunction (adults¡A 9% ) Other: Menopausal flushing (adults¡A 8% ) ¸T§Ò: with a MAOI or within 2 weeks after discontinuing a MAOI¡A narrow-Angle Glaucoma.,,«Ç·Å,Adult¡A adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses; max: 1.4 mg/kg or 100 mg¡A whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approx 80 mg administered as single or divided doses. Dose may be increased to a max of 100 mg after 2-4 additional weeks. Max: 100 mg.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh B): Initial and target doses should be reduced to 50% of the normal dose ­««×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh C): Initial and target doses should be reduced to 25% of the normal dose,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OSTR1,Atomoxetine,Strattera 10mg,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI¡A narrow-Angle Glaucoma.,Nausea¡A vomiting¡A fatigue¡A decreased appetite¡A abdominal pain¡A somnolence. Endocrine metabolic: Weight loss (pediatrics¡A 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults¡A 7%; pediatrics¡A 17% to 18% )¡A Constipation (adults¡A 9%; pediatric¡A 1% to 2%)¡A Decrease in appetite (adult¡A 11%; pediatrics¡A 16% ¡A)¡A Nausea (adults¡A 21%; pediatrics¡A 7% to 13% )¡A Vomiting (adults¡A 3%; pediatrics¡A 11%)¡A Xerostomia (adults¡A 21% ) Neurologic: Headache (pediatrics¡A 19% )¡A Insomnia (adults¡A 16%; pediatrics¡A at least 2%; )¡A Somnolence (adult¡A 4%; pediatrics¡A 11% ) Renal: Delay when starting to pass urine (adults¡A 5.6% )¡A Urinary retention (adults¡A 1.7% ) Reproductive: Dysmenorrhea (adults¡A 6% )¡A Erectile dysfunction (adults¡A 9% ) Other: Menopausal flushing (adults¡A 8% ),25¢J¥H¤U,Adult¡A adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approximate 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg¡A whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult¡A adolescent & children>70 kg maximum dose is 100 mg total daily .,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh B): Initial and target doses should be reduced to 50% of the normal dose ­««×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh C): Initial and target doses should be reduced to 25% of the normal dose,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½Ð¾ãÁû½¦Ån§]ªA¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¥»ÃÄ¯»¥½¨ã¦³²´³¡¨ë¿E©Ê¡C
OHAV,Estradiol + Norethisterone,Havina 28's/pk,HM,,¾AÀ³¯g:¬°²üº¸»X¸É¥R¾¯(A044203100),,RT,D: 1 tab daily,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OINDI,Estradiol + Medroxyprogesterone,Indivina (1/2.5) 28's/box,HM,,¾AÀ³¯g: Hormone replacement therapy (HRT) for estrogen deficiency symptoms & prophylaxis of osteoporosis in women with an intact uterus. °Æ§@¥Î: Breast tenderness & enlargement¡A uterine bleeding¡A increase in size of uterine fibroids¡A headache¡A GI discomfort¡A weight changes¡A edema¡A mood changes including anxiety & depressive mood¡A changes in libido. ¸T§Ò: Pregnancy & lactation. Known¡A suspected or past history of breast cancer or estrogen-dependent tumour¡A undiagnosed vag bleeding¡A confirmed active venous thromboembolism (VTE) within the last 2 years. History of recurrent VTE or known thrombophilic disease in patients not on anticoagulant¡A acute or chronic liver diseases or a history of liver disease.,,«Ç·Å,1 tab daily. Women w/ amenorrhoea & not taking HRT or women switching from another continuous combined HRT regimen Indivina may be started on any day. Women switching from cyclic HRT Start Indivina 1 wk after completion of cyclic HRT regimen.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IESO,Isosorbide Dinitrate,Esokit 0.1% 10 mL,CAVS,,,,«Ç·Å,Adult 2-12 mg/hr by IV infusion; some patients may require up to 20 mg/hr. Administration during percutaneous transluminal coronary angioplasty By the intracoronary route: 1 mg as a bolus before balloon inflation. Max recommended dose: 5 mg within a 30-min period.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ¤@¯ëµ}ÄÀ¿@«×¡G50 mL Angidil 0.1 % ¥H¾A·í·»²Gµ}ÄÀ¦Ü500 mL¡A¨CmL§t¦³100 mcg isosorbide dinitrate¡C 2. µ}ÄÀ®ÉÀ³¨Ï¥Î¬Á¼þ©Î«DPVC¤§µw¶ì½¦§÷½è®e¾¹ªºµ}ÄÀ·»²G¡C 3. ª`®g®É«ØÄ³¨Ï¥Î»E¤A²m(PE)§÷½èªº¿éª`®M©Îµw¶ì½¦§÷½èªº°wµ©À°®ú¡C 4. §ëÃÄ´Á¶¡À³ÄY±KºÊ´ú¯ß·i»P¦åÀ£¡C
IDIPE,Alanine 8.2% + glutamine 13.64%,Dipeptiven inj 100mL,NUTR,Part of an IV parenteral nutrition regimen as a supplement to amino acid soln,Severe renal insufficiency (CrCl <25 mL/min)¡A severe hepatic insufficiency. Pregnancy¡A lactation¡A childn.,None known when correctly administered.,25¢J¥H¤U,1.5-2.5 mL/kg body weight/day for maximum 3 weeks. Maximum dose: 2.5 mL/kg body weight/day. Rate of infusion should not exceed 0.1g amino acids/kg body weight/hr. Should be mixed with a compatible amino acid carrier solution or an amino acid containing infusion regimen and proportion of amino acid supplied through Dipeptiven should not exceed 30% of total amino acid.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þªÌ¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,¡iD10W¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,< 0.1 g amino acid/kg/hr (dilution:Dipeptiven 100 mL + Compatible solution 500 mL),1.Dipeptiven should be mixed with a compatible amino acid carrier solution or an amino acid-containing infusion regimen prior to administration. 2.One part volume of Dipeptiven is to be mixed with at least 5 parts volume of carrier solution (eg¡A Dipeptiven 100 mL + amino acid solution at least 500 mL). Water rationing:dilute Dipeptiven to an osmolarity =< 800 mosmol/l (e.g. 100 ml Dipeptiven + 100 mL saline.) 3.The maximum concentration < 3.5%. The duration of use should not exceed 3 weeks.
OMEC,Meclizine,Meclizine 25mg,CNEU,Prophylaxis & symptomatic relief of nausea¡A vomiting¡A vertigo.,Hypersensitivity to any component of the formulation.,Drowsiness; dry mouth¡A fatigue¡A vomiting; rarely¡A blurred vision.,25¢J¥H¤Uºò±K®e¾¹¡AÁ×¥úÀx¦s,Adult and children over 12 years: for motion sickness¡A take 30-60 minutes before boarding¡A 50 mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OAND4,Testosterone,Andriol 40mg,HM,,¾AÀ³¯g: Testosterone replacement therapy in male hypogonadal disorders. Osteoporosis due to androgen deficiency. °Æ§@¥Î: Priapism¡A signs of excessive sexual stimulation; oligospermia¡A decreased ejaculatory vol; fluid & salt retention. In prepubertal boys¡A precocious sexual development¡A increased frequency of erections¡A phallic enlargement & premature epiphyseal closure. ¸T§Ò: Known or suspected prostatic or mammary carcinoma.,,«Ç·Å,Initially 120-160 mg daily for 2-3 weeks. Maintenance 40-120 mg daily.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
ITAZ,Piperacillin + Tazobactam,Tazocin inj 2.25gm,QANB,,,,,,,,,,,,,,,,,,,
ENEU,Rotigotine,Neupro patch 6mg/24h,CNEU,Parkinson's disease,Hypersensitivity to rotigotine or any component of the product.,(Common) Cardiovascular: Orthostatic hypotension (up to 18% )¡A Peripheral edema (2% to 9% ) Dermatologic: Application site reaction (21% to 46% )¡A Diaphoresis (Parkinson disease¡A 3% to 11%; restless leg syndrome¡A 1% to 5% )¡A Pruritus (3% to 9% ) Endocrine metabolic: Weight increased (2% to 9% ) Gastrointestinal: Loss of appetite (2% to 8% )¡A Nausea (Parkinson disease¡A 28% to 48%; restless leg syndrome¡A 15% to 23% )¡A Vomiting (Parkinson disease¡A 10% to 20%; restless leg syndrome¡A 2% to 4% )¡A Xerostomia (3% to 7% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (7% to 14%)¡A Dizziness (Parkinson disease¡A 14% to 23%; restless leg syndrome¡A 5% to 9% )¡A Dysesthesia (5% )¡A Dyskinesia (7% to 14% )¡A Headache (Parkinson disease¡A 8% to 14%; restless leg syndrome¡A 15% to 21% )¡A Insomnia (5% to 11% )¡A Paresthesia (5%)¡A Sleep disorder (2% to 10% )¡A Somnolence (Parkinson disease¡A 12% to 32%; restless leg syndrome¡A 5% to 10% ) (Serious) Cardiovascular: Syncope Neurologic: Sleep attack (1% to 2% ) Psychiatric: Compulsive behavior¡A Hallucinations (4% to 7% )¡A Impulse control disorder,30¢J¥H¤U,Apply a new patch to a new site daily¡A wear continually for 24 hours and apply a new patch at approximately the same time every day. Parkinson's disease: Early-stage¡A the recommended initial dose is 2 mg/24 hr intradermally. Depending on clinical response and tolerability¡A doses may be increased weekly in 2 mg/24 hr increments to a minimum effective dose of 4 mg/24 hr or further to the highest recommended dose of 8 mg/24 hr. Advanced-stage¡A the recommended initial dose is 4 mg/24 hours. Doses may be increased weekly in 2 mg/24 hour increments to the highest recommended dose of 8 mg/24 hours. When discontinuing therapy¡A reduce the dose by a maximum of 2 mg/24 hour increments everyday.,µL»Ý½Õ¾ã¾¯¶q,Severe hepatic impairment: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL rotigotine ¨Ï¥Î©óÃh¥¥°ü¤kªº¾A·í¸ê®Æ¡C°Êª«¬ã¨sÅã¥Ü¡AÃÄª«¹ï¤j¹«¤Î¨ß¤l¤£·|»¤µo·î­L¡A¦ý¦b¹ï¥ÀÅé¨ã¬r©Êªº¾¯¶q¤U¡Aµo²{¹ï¤j¹«¤Î¤p¹«§¡¦³­F­L¬r©Ê¡C ¥Ø«e¨Ã¤£²M·¡ÃÄª«¹ï¤HÃþªº¼ç¦b­·ÀI¡A¦]¦¹¡AÃh¥¥´Á¶¡¤£À³¨Ï¥Î rotigotine¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ñ©ó rotigotine ·|¨Ï¤HÅé­°§Cªc¨Å¿E¯Àªº¤Àªc¶q¡A¦]¦¹¹w´Á¨Å¥Äªº¤Àªc¤]·|¨ü¨ì§í¨î¡C¤j¹«¬ã¨sÃÒ¹ê¡Arotigotine¤Î/©Î¨ä¥NÁÂª«·|ÀH¨Å¥Ä¤Àªc¡C ¥Ñ©ó¯Ê¤Ö¤HÃþªº¸ê®Æ¡A¦]¦¹À³°±¤î­÷¨Å©Î¼È°±rotigotineªvÀø¡C,EXT;,,,,,¨C±i30cm2¶K¤ù§t¦³13.5mg¡A¨C24¤p®ÉÄÀ©ñ6mg¥D¦¨¤À¡C
OKLE1,Polyethylene Glycol,Klean-Prep (¸zÀù±M®×),ALIM,,Bowel prep before colonoscopy¡A colonic surgery¡A radiological exam & other related procedures.,,RT,Adult including elderly & renal insufficiency patient 1 sachet In 1 L water . 250ml to be drunk rapidly every 10-15 mins until all soln has been consumed. Repeat procedure with 2-4 sachets or until the rectal effuent is clear.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ENEOE,Phenylephrine,Neosinicin eye drop 5%,TOPH,,,,,,,,,,,,,,,,,,,
EBNO,Bacitracin + Neomycin,Bacitracin neomycin oint 30gm,TDER,,¾AÀ³¯g:¥Ö½§¥~¶Ë¡B¼ìºÅ¡BÁw¥Ö¯fµ¥²Óµß·P¬V¯g(A022990343),,,,,,,,,,,,,,,,,
LBIS,Bromhexine,Bisolvon solution 2mg/mL¡A 50mL,ERSP,As expectorant.,Rare hereditary problems of galactose intolerance eg. galactosemia.,Diarrhea¡A nausea¡A vomiting & other mild GI disturbances. Allergic reactions include skin rashes¡A urticaria¡A bronchospasm¡A angio-edema & anaphylaxis.,30¢J¥H¤U,Oral: Age > 14 years old and Adult: 4-8mL TID. Age 6-14 years old: 4mL TID. Age < 6 years old: 2mL TID. Recommended doses of Adult: Maximum: 48mL/day. Inhaleration: Age > 6 years old and Adult: 4mL BID. Age 2-6 years old: 2-4mL BID. Age < 2 years old: 2mL BID. Needs to be diluted with 0.9% sodium chloride at a ratio of 1:1.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;IH;INHL;PC;PO;WM;,,,,,
EMAX,Dexamethasone + Neomycin + Polymyxin B,Maxitrol oph oint 3.5g,TOPH,,¾AÀ³¯g: SInflammatory ocular conditions: Management of corticosteroid-responsive inflammatory ocular conditions where bacterial infection or a risk of bacterial infection exists. °Æ§@¥Î: Hypersensitivity: Hypersensitivity reaction Infection: Secondary infection Ophthalmic: Glaucoma¡A increased intraocular pressure¡A optic nerve damage (infrequent)¡A subcapsular posterior cataract Miscellaneous: Wound healing impairment ¸T§Ò: Hypersensitivity to neomycin¡A polymyxin B¡A dexamethasone¡A or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis]¡A vaccinia¡A varicella); mycobacterial ophthalmic infection; fungal diseases of ocular structures.,,«Ç·Å,Apply a small amount into the conjunctival sac up to tid or qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OXYZ,Levocetirizine,Xyzal 5mg,HIMM,To treat allergy symptoms in adults and children aged six and above caused by allergic rhinitis¡A chronic urticaria¡A and other allergic conditions. This includes various symptoms caused by persistent allergic rhinitis.,Hypersensitivity to levocetirizine¡A cetirizine¡A or any component of the product; reactions ranging from urticaria to anaphylaxis have been observed. End-stage renal disease with a CrCl less than 10 mL/min or requiring dialysis. Pediatric patients between 6 months and 11 years old with renal impairment.,Common: Dry mouth¡A Headache¡A Somnolence¡A Abdominal pain¡A Migraine¡A Constipation (Infants¡A 7%)¡A Diarrhea (Infants¡A 13%; pediatrics¡A 4%)¡A Painful teething (Infants¡A 6.7%)¡A Vomiting (Pediatrics¡A 4%)¡A Xerostomia (Adults and adolescents¡A 2-3%)¡A Otitis media (Pediatric¡A 3%)¡A Nasopharyngitis (Adults and adolescents¡A 4-6%)¡A Pharyngitis (Adults and adolescents¡A 1-2%)¡A Fever (Pediatric¡A 4%) Serious: Asthenia¡A Somnolence (4.4-6%)¡A Urinary retention¡A Fatigue (Adults and adolescents¡A 1-4%),30¢J¥H¤U°®Àêªº³õ©Ò,Adult & children >= 6 years 5 mg once daily¡A before or after meals. Not recommended for children under six.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¥Ø«e¨ÃµL©Î¦³­­(¤Ö©ó300­ÓÃh¥¥®×¨Ò)ªº¥¥°ü¨Ï¥Îlevocetirizineªº¼Æ¾Ú¸ê®Æ¡CµM¦Ó¡Alevocetirizineªº®ø±Ûª«cetirizine«h¦³¤j¶q(1000¨Ò¥H¤W)¥¥°ü¨Ï¥Î¸ê®Æ¡AÅã¥Ü¨äµL·î­L©Î­L¨à/·s¥Í¨à¬r©Ê¡C ¦pªG¥²­nªº¸Ü¡AÃh¥¥´Á¶¡¥i¥H¦Ò¼{¨Ï¥Îlevocetirizine¡C °Êª«¸ÕÅçÅã¥Ülevocetirizine¤£·|ª½±µ©Î¶¡±µ¹ïÃh¥¥ªÌ¡B¥Íªø¤¤ªº­F­L¡A¤Î¥X¥Í«áªº­L¨à³y¦¨¶Ë®`¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ·í³B¤è¥»ÃÄµ¹±Â¨Å°ü¤k¨Ï¥Î®É¡A¶·¯S§O¤p¤ß¡C Cetirizine (levocetirizineªº®ø±Ûª«)¤wÅã¥Ü·|³Q¤HÅé±Æªn¡A¦]¦¹levocetirizine¦³¥i¯à·|¸g¥Ñ¨Å¥Ä¤Àªc¡C»Plevocetirizine¦³Ãöªº¤£¨}¤ÏÀ³«h¥i¯à·|¥X²{¦b­÷Áý¥À¨ÅªºÀ¦¨à¨­¤W¡C,AC;AC15;PC;PO;WM;,,,,,
IGON4,Follitropin Alpha,GONAL-F ª`®gµ§ 450 IU/ 0.75mL,HM,Female: - Induction of ovulation in women who are still unable to ovulate after treatment with Clomiphene Citrate (including polycystic ovary disease¡A PCOD). - Used together with lutein-stimulating hormone (LH) to stimulate the development of multiple follicles in patients with severe deficiencies of lutein-stimulating hormone and follicle-stimulating hormone. - For stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)¡A gamete intra fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT). Male: Induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure.,Pregnancy & lactation¡A ovarian enlargement or cyst not due to polycystic ovarian disease¡A gynaecological haemorrhages of unknown aetiology¡A ovarian¡A uterine or mammary carcinoma¡A case of tumours of the hypothalamus & pituitary gland¡A hypersensitivity to follitropin £\¡A FSH or to any of the excipients. When an effective response cannot be obtained¡A such as primary ovarian failure¡A malformation of sexual organs incompatible with pregnancy¡A fibroid tumours of the uterus incompatible with pregnancy.,Local reactions at the inj site. Fever¡A arthralgia¡A pain in the lower abdominal region¡A nausea¡A vomiting¡A weight gain.,2-8¢JÁ×¥úÁ×§K§N­á,Women with anovulation (including PCOD) 75-150 IU daily & increased by 37.5 or 75 IU at 7 or 14 day intervals. Maximum daily dose: 225 IU. When an optimal response is obtained a single injection of up to 5¡A000 IU¡A up to 10¡A000 IU hCG should be given 24-48 hr after the last Gonal-F injection. The patient is recommended to have coitus on the day of¡A & the day after hCG administration. Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other ART 150-225 IU of Gonal-F daily¡A commencing on day 2 or 3 of the cycle. When an optimal response is obtained a single injection of up to 5¡A000 IU¡A up to 10¡A000 IU hCG should be given 24-48 hour after the last Gonal-F injection. Dose adjustment should not exceed 450 IU daily. A single inj of up to 10¡A000 IU hCG is administered 24-48 hour after the last Gonal-f inj to induce final follicular maturation. Women with anovulation resulting from severe LH and FSH deficiency usually is starting as dose of GONAL-f 75-150 IU together with 75 IU of lutropin alfa¡A dose increased should be after 7-14 day intervals and preferablt by 37.5-75 IU. When an optimal response is obtained a single injection of up to 5¡A000 IU¡A up to 10¡A000 IU hCG should be given 24-48 hr after the last Gonal-F injection. Men with hypogonadotrophic hypogonadism should be given at a dose of 150 IU three times a week¡A together with hCG¡A for minimum of 4 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Micromedex: Fetal harm has been demonstrated. (MDX) [¥é³æ] Ãh¥¥´Á¶¡¤£¾A¥Î¡C¦³­­ªº¬ÛÃöÃh¥¥®×¨Ò¼Æ¾ÚÅã¥Ü(¤Ö©ó300­ÓÃh¥¥®×¨Ò )¡Afollitropin alfa ¨S¦³·î­L©Î­L¨à/·s¥Í¨à¬r©Ê¡C°Êª«¸ÕÅç¨Ã¥¼µo²{­P·î­L§@¥Î¡A¦ýÁ{§É¼Æ¾Ú¤´¤£¨¬¥H±Æ°£Ãh¥¥´Á¶¡¼ÉÅS©óGONAL-f ¦Ó³y¦¨­P·î­L§@¥Îªº¥i¯à©Ê¡C,Unknown ¨S¦³¸ê®Æ,Micromedex: Infant risk cannot be ruled out. [¥é³æ] GONAL-f ¤£¾A¦X±Â¨Å´Á¶¡¨Ï¥Î¡C¦b±Â¨Å´Á¶¡ prolactin ªº¤Àªc·|¹ï¨ë¿E±Æ§Z²£¥Í¤£¨}¹w«á¡C,SC;,,,,,
IHBIG1,Hepatitis B Immune Globulin,HBIG 1 mL (¦Û¶O),HIMM,,,,,,,,,,,,,,,,,,,
OTOP1,Alginic Acid+Colloidal Al(OH)3+MgHCO3,Topaal chewable Tab (¦Û¶O),ALIM,,,,,,,,,,,,,,,,,,,
OEUP,Theophylline,Euphyllin Retard 250mg,ERSP,,I: Bronchitic syndrome¡A spastic conditions of the bronchial system¡A bronchial & cardiac asthma¡A pulmonary emphysema¡A conditions of dyspnea¡A Cheyne-Stokes resp¡A cor pulmonale. CI: Recent MI. ADR: Occasional GI disturbances¡A overstimulation of CNS¡A ver-tigo & convulsions in high doses. Hypersensitivity.,,,D:Adult > 50 kg :1 Tab bid ~ tid¡A 45 ~ 50 kg :1/2 Tab bid ~ tid. Children: 10 ~ 15 mg/kg/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OMEQ,Mequitazine,Mequitazine 5mg,HIMM,Allergic & vasomotor rhinitis¡A hay fever¡A urticaria¡A ocular allergies & other allergic reactions.,Coadministration with MAOIs.,Drowsiness¡A headache¡A psychomotor impairment¡A urinary retention¡A dry mouth¡A blurred vision¡A GI disturbances.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adult: PO 5 mg twice daily. Children 0.25 mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
EWAR,Podophyllotoxin,Wartec cream 0.15%¡A 5gm,TDER,,I: Topical treatment of anogenital warts. CI: Not for use on open wounds. Pregnancy¡A lactation. ADR: Itching¡A irritation¡A tenderness¡A smarting.,,RT,Apply bid for 3 days¡A followed by 4 treatment-free days at wkly intervals.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
EVIR,Tromantadine,Viru-Merz 5gm,TDER,,I: Herpes simplex infection of skin & semimucous membranes; Eczema herpeticum¡A dermal manifestations of herpes zoster.,,RT,Apply tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OFOS7,Alendronate,Fosamax 70mg,META,,¾AÀ³¯g:¥Dªv°©½è²¨ÃP¯g(B023167100) °Æ§@¥Î: Esophagitis¡A esophageal erosions¡A esophageal ulcers¡A abdominal distension. Rash¡A erythema; bone¡A muscle & joint pain; constipation¡A diarrhea¡A flatulence¡A headache¡A urticaria¡A angioedema¡A nausea¡A vomiting¡A oropharyngeal ulceration¡A gastric or duodenal ulcer. ¸T§Ò: (1) Abnormalities of the oesophagus which delay oesophageal emptying eg stricture or achalasia. Inability to stand or sit upright for at least 30 mins. (2) Hypocalcemia. (3) Hypersensitivity.,,«Ç·Å,70mg once weekly.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IHIG3,Human Immunoglobulin,Human Immunoglobulin 3gm/60mL,HIMM,,,,,,,,,,,,,,,,,,,
IMIXTI,Human Insulin Regular/NPH 30/70,Mixtard insulin 30/70 (IU) 100IU/mL,META,,,,,,,,,,,,,,,,,,,
IHUMRI,Insulin Regular Human,Humulin R inj100IU/mL (IU),META,,¾AÀ³¯g:¬°µu®Ä«¬¯Ø®q¯À¡A¿}§¿¯f¥ÎÃÄ(A034983299)(K000663299),,,,,,,,,,,,,,,,,
IHUMNI,Human NPH Insulin,Humulin N inj100IU/mL (IU),META,,¾AÀ³¯g:¬°¤¤®Ä«¬¯Ø®q¯À¡A¿}§¿¯f¥ÎÃÄ(A034984299)(K000657299),,,,,,,,,,,,,,,,,
OFOSR,Lanthanum carbonate,Fosrenol Chewable 750mg,META,Second-line treatment for hyperphosphatemia in patients with chronic renal failure undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Second-line treatment of adult patients with stage 5 chronic kidney disease who are not on dialysis¡A with serum phosphate concentrations ?5.5 mg/dl (1.78 mmol/L) and who have not been adequately controlled by diet alone.,Bowel obstruction¡A fecal impaction¡A ileus. Hypersensitivity to lanthanum carbonate or any component of the formulation; hypophosphatemia.,Common: Abdominal pain (5%)¡A Diarrhea¡A Nausea (11%)¡A Vomiting (9%) Serious: Vascular graft occlusion¡A Dialysis¡A Bowel obstruction¡A Fecal impaction¡A Gastrointestinal obstruction¡A Gastrointestinal perforation¡A Ileus,25¢J¥H¤U,The daily dose in divided doses with meals or immediately after meals. Control of serum phosphate level has been demonstrated at doses starting from 750 mg per day. Then titrate at intervals of 2 to 3 weeks until an acceptable serum phosphate level is reached. The recommended maximum dosage: 3750mg/day. [Micromedex 20210731] Initial dosage: 1500 mg per day¡A then titrate in increments of 750 mg/day at intervals of 2 to 3 weeks until an acceptable serum phosphate level is reached. Maintenance dosage: 1500 to 3000 mg per day is usually required to achieve plasma phosphate levels less than 6 mg/dL. Maximum dosage: 4500 mg/day was evaluated in ESRD patients.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,upper table (according to up to date of Pregnancy Risk Factor and Lactation ),PC;PO;WM;,,,,,
OMETH,Methyldopa,MethylDOPA 250mg,CAVS,Hypertension.,Active hepatic disease.,Sedation¡A headache¡A asthenia¡A weakness¡A fever¡A bradycardia¡A hypotension¡A GI disturbances¡A sore or 'black' tongue¡A liver disorders¡A +ve Coombs test¡A nasal congestion¡A anxiety¡A depression¡A arthralgia¡A rash.,«Ç·Å«O¦s,HTN Adult: initial 250 mg BID¡A titrate up to 2-4 tablets/day (maximum: 6 tablets/day),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PO;WM;,,,,,
OTIN5,Tinidazole,Tinidazole 500mg,QANB,,,,,,,,,,,,,,,,,,,
OVYT,Ezetimibe + Simvastatin,Vytorin 10/20mg,CAVS,Primary hypercholesterolemia: Adjunctive therapy to diet for the reduction of elevated total-C¡A LDL-C¡A Apo B¡A TG & non-HDL-C¡A & to increase HDL-C in patients with primary (heterozygous familial & non-familial) hypercholesterolemia or mixed hyperlipidemia. Homozygous familial hypercholesterolemia (HoFH): For the reduction of elevated total-C & LDL-C levels in patients with HoFH¡A as an adjunct to other lipid-lowering treatments (eg LDL apheresis) or if such treatments are unavailable.,Active liver disease or unexplained persistent elevations of serum transaminases. Pregnancy¡A lactation.,Flatulence¡A abdominal pain¡A diarrhea¡A myalgia¡A headache¡A fatigue¡A thrombocytopenia¡A hepatitis¡A increased CPK¡A elevations of liver transaminases. Gastrointestinal: Diarrhea (2.8% ) Neurologic: Headache (5.8% ) Respiratory: Upper respiratory infection (3.6% ),30¢J¥H¤U±K³¬Àx¦s,Adult: usual dosage range: 10/10 mg/day to 10/40 mg/day. Usual starting dose: 10/10 mg/day or 10/20 mg/day. Take as a single daily dose in the evening¡A with or without food.,µL»Ý½Õ¾ã¾¯¶q,¤¤«×©Î­««×¨x¥\¯à»ÙÃª(Child-Pugh B&C)¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,Ezetimibe - Limited Human Data¡XAnimal Data Suggest Moderate Risk Simvastatin - Contraindicated 1st Trimester,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Ezetimibe - Contraindicated Simvastatin - Contraindicated,,,,,,
ILID2E,Lidocaine + Epinephrine,Lidophrine inj (2%+E) 20mL,ZANE,For production of local anesth by nerve block or infiltration inj.,Thyrotoxicosis¡A hypertension¡A severe heart disease (particularly when tachycardia is present)¡A diabetes; hypovolaemia¡A shock¡A heart block; when inflammation or sepsis is present in the region of the proposed inj. Soln containing epinephrine should not be used for local anesth inj in digits & appendages.,Common: Nervousness¡A dizziness¡A blurred vision¡A tremor¡A drowsiness¡A tinnitus¡A numbness¡A disorientation¡A nausea & vomiting. Less common: Convulsions¡A unconsciousness¡A respiratory depression or arrest¡A hypotension¡A CV collapse & bradycardia which may lead to cardiac arrest.,Á×¥ú,Each mL contains 20mg Lidocaine and 0.02mg Epinephrine. Maximum dose of lidocaine when given with epinephrine is 500 mg in a normal healthy adult. Dental local anesthesia is according to the patient's physical condition and inject the minimum dose that can obtain effective local anesthetic effect. Oral infiltration or mandibular block: Initial dose: 1-2 mL. Children < 10 years usually need no more than 10 mL of Lidophrine 2%+E.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,[17] due to epinephrine [1] lidocain,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[4] due to epinephrine [3] lidocain,LA;LI;,,,,,
OSUT,Sunitinib,Sutent 12.5mg,RACA,Treatment of GI stromal tumor after disease progression on or intolerance to imatinib mesylate. Treatment of advanced or metastatic renal cell carcinoma (clear cell carcinoma in pathology).,Pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment.,Fatigue¡A asthenia¡A diarrhea¡A nausea¡A mucositis/stomatitis¡A vomiting¡A dyspensia¡A abdominal pain¡A constipation¡A hypertension¡A rash¡A hand-foot syndrome¡A skin discoloration¡A altered taste¡A anorexia & bleeding. Potentially serious adverse reactions of LV dysfunction¡A QT interval prolongation¡A hemorrhage¡A hypertension & adrenal dysfunction. Dermatologic: Discoloration of skin¡A Yellow (GIST¡A 30%; MRCC¡A 19% )¡A Dry skin (MRCC¡A 18% )¡A Rash (GIST¡A 14%; MRCC¡A 27% ) Endocrine metabolic: Hypothyroidism (GIST¡A 4% to 36%; MRCC¡A 3% ) Gastrointestinal: Abdominal pain (MRCC¡A 22% )¡A Constipation (GIST¡A 20%; MRCC¡A 16% )¡A Diarrhea (GIST¡A 40%; MRCC¡A 58% )¡A Increased serum lipase level (GIST¡A 25%; MRCC¡A 52% )¡A Indigestion (MRCC¡A 28% )¡A Inflammatory disease of mucous membrane (GIST¡A 29%; MRCC¡A 43% )¡A Loss of appetite (GIST¡A 33%; MRCC¡A 38% )¡A Nausea (MRCC¡A 49% )¡A Pain of oral cavity structure (GIST¡A 6%; MRCC¡A 10% )¡A Taste sense altered (GIST¡A 21%; MRCC¡A 44% )¡A Vomiting (MRCC¡A 28% ) Hematologic: Anemia (GIST¡A 26%; MRCC¡A 71% )¡A Bleeding (GIST¡A 18%; MRCC¡A 30% )¡A Leukopenia (MRCC¡A 78% )¡A Lymphocytopenia (GIST¡A 38%; MRCC¡A 59% )¡A Neutropenic disorder (GIST¡A 53%; MRCC¡A 72% ) Hepatic: Liver function tests abnormal (GIST¡A 10% to 39%; MRCC¡A 13% to 56% ) Neurologic: Asthenia (GIST¡A 22%; MRCC¡A 21% ) Renal: Increased uric acid level (MRCC¡A 41% ),Àx¦s©ó25 oC,[Gastrointestinal Stromal Tumor (GIST) and Advanced Renal Cell Carcinoma (RCC)] 50 mg orally with or without food once daily¡A on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). [Pancreatic neuroendocrine tumors (pNET)] 37.5 mg orally with or without food once daily continuously without a scheduled off-treatment period. [Adjuvant Treatment of RCC] 50 mg orally with or without food once daily¡A on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2)¡A for nine 6-week cycles.,µL»Ý½Õ¾ã¾¯¶q,Hepatotoxicity during treatment: Hepatic adverse events ? grade 3 or 4: Withhold treatment; discontinue if hepatotoxicity does not resolve. Do not reinitiate in patients with severe changes in liver function tests or other signs/symptoms of liver failure.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ] ®Ú¾Ú°Êª«¥Í´Þ¬ã¨s»P¨ä§@¥Î¾÷¨î¡A¹ï¥¥°ü§ë¤© SUTENT¥i¯à·|³y¦¨­L¨à¶Ë®`¡C¨S¦³¨Ï¥Î ©ó¥¥°üªº¸ê®Æ¥H§iª¾ÃÄ«~¬ÛÃöªº­·ÀI¡C¦b°Êª«µo¨|»P¥Í´Þ¬r²z¾Ç¬ã¨s¤¤¡A©ó¾ã­Ó¾¹©x§Î¦¨´Á ¶¡¡A¤À§O¤fªAµ¹¤©Ãh¥¥¤j¹«©M¨ß¤lsunitinib¹F¯f¤H¨C¤é«ØÄ³¾¯¶q50 mg¤§AUCÁ`©M5.5­¿»P0.3­¿®É ¤Þ°_­P·î©Ê(­F­L­P¦º¡BÆ`­±©M°©Àf·î§Î)¡C§iª¾¦³¥Í¨|¯à¤O°ü¤k¹ï­L¨àªº¼ç¦b­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ¨S¦³Ãö©ósunitinib»P¨ä¥NÁÂª«·|¦s¦b©ó¤HÃþ¨Å¥Äªº¸ê°T¡CSunitinib»P¨ä¥NÁÂª«·|¤Àªc ¦Ü¤j¹«¨Å¥Ä¤¤¡A¿@«×°ª¹F¦å¼ß¿@«×ªº12­¿(¨£¸ê®Æ)¡C¦]¥i¯à·|¨Ï­÷Áý¤§À¦¨à²£¥ÍÄY­«ªº ¤£¨}¤ÏÀ³¡A«ØÄ³°ü¤k©ó SUTENTªvÀø´Á¶¡¦Ü³Ì«á¤@¦¸ªAÃÄ«á¦Ü¤Ö4¶g¤º¤£­n­÷¨Å¡C,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
ODIP5,Valproic Acid,Dipachro S.R. 500mg,CNEU,,,,«Ç·Å,Adult & >15 yr or wt. >25 kg: 20-30 mg/kg/day. Child: 30 mg/kg/day.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OPREL,Estrogen + Medroxyprogesterone,Premelle LITE 0.3/1.5mg 28's,HM,,¾AÀ³¯g: Moderate-to-severe vasomotor symptoms associated with estrogen deficiency. Prevention & treatment of osteoporosis associated with estrogen deficiency. Atrophic vaginitis & atrophic urethritis. °Æ§@¥Î: Abdominal pain¡A back pain¡A flu syndrome¡A headache¡A infection¡A pain¡A nausea & other GI disturbances¡A pharyngitis¡A pruritus¡A breast pain. Also reported¡A changes in vag bleeding pattern & abnormal withdrawal bleeding or flow¡A breakthrough bleeding¡A change in amount of cervical secretion¡A breast tenderness & enlargement¡A venous thromboembolism¡A cholestatic jaundice¡A increased incidence of gallbladder disease¡A pancreatitis¡A enlargement of hepatic hemangiomas¡A chloasma or melasma¡A neuro-ocular lesions¡A CNS disturbances¡A wt changes¡A edema¡A changes in libido¡A reduced carbohydrate tolerance¡A aggravation of porphyria¡A pyrexia¡A hypocalcemia¡A exacerbation of asthma¡A increased triglycerides. ¸T§Ò: Undiagnosed abnormal genital bleeding. Known¡A suspected or history of breast cancer. Known or suspected estrogen-dependent neoplasia. Active or history of deep vein thrombosis¡A pulmonary embolism. Active or recent arterial thromboembolic disease e.g. stroke¡A MI. Liver dysfunction. Known or suspected pregnancy.,,«Ç·Å,1 tab once dialy.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ITD,Diphtheria + Tetanus,Td (¥Õ³ï¯}¶Ë­·¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
OTAM0,Oseltamivir,Tamiflu 75mg (¦X¬ù±M®×),QANB,,¾AÀ³¯g: 30 mg cap Prophylaxis & treatment of influenza in adult & children >= 1 yr. 75 mg cap Prophylaxis & treatment of influenza in adult & children >= 13 yr. °Æ§@¥Î: Nausea¡A vomiting¡A abdominal pain¡A headache. Insomnia¡A diarrhea. ¸T§Ò: Hypersensitivity.,,«Ç·Å,Treatment of influenza Begin treatment within the 1st or 2nd day of onset of symptoms. Adult & adolescent >= 13 years 75 mg¡A children > 1 year¡A > 40 kg 75 mg¡A > 23-40 kg 60 mg¡A >15-23 kg 45 mg¡A <= 15 kg 30 mg. Doses to be given bid for 5 days. Prophylaxis of influenza Adult & adolescent > 13 years 75 mg once daily for 10 days¡A children > 1 year¡A > 40 kg 75 mg¡A > 23-40 kg 60 mg¡A >15-23 kg 45 mg¡A <= 15 kg 30 mg. Doses to be given once daily for 10 days.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IHCG5,Chorionic Gonadotropin,Pregnyl (HCG) 5000 IU,HM,,¾AÀ³¯g: Male Hypogonadotrophic hypogonadism¡A Delayed puberty associated with insufficiency gonadotrophic pituitary function¡ACryptorchism Female Sterility due to absence of ovulation °Æ§@¥Î:Fluid & salt retention (occasionally). Skin rash (rare ¸T§Ò:Known or suspected androgen-dependent tumours. Precocious puberty.,,2-8¢J,Male Hypogonadotrophic hypogonadism 500-1000 iu 2-3 times/wk. Delayed puberty associated with insufficiency gonadotrophic pituitary function 1500 iu 2 times/wk for >= 6 months. Cryptorchism 6 years 1000 iu¡A <6 years 500 iu; to be given 2 times/wk for 6 weeks. Sterility 3000 iu/wk in combination with FSH or HMG prep. Female Sterility due to absence of ovulation 5000-10¡A000 iu for 1 or 3 days. Repeat inj of 5000 iu 7 days later to prevent corpus luteum insufficiency.,,,,¤£¥i¨Ï¥Î,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ECOMU,Ipratropium + Salbutamol,Combivent UDV 2.5mL,ERSP,Management of reversible bronchospasm associated with obstructive airways diseases in patients who require more than a single bronchodilator.,Hypertrophic obstructive cardiomyopathy or tachyarrhythmia,Headache¡A dizziness¡A nervousness¡A tachycardia¡A fine tremor¡A palpitations. Potentially serious hypokalaemia may result from £]2 agonist therapy. Dry mouth¡A dysphonia¡A ocular complications¡A allergic-type reactions.,30¢J¥H¤UÀx¦s,Adult 1-2 inhalations BID-QID. [Micromedexs 2021/06/11] Asthma: >12years moderate to severe asthma every 4- 6hours 1 unit dose¡A severe asthma every 20 minutes use 1 unit dose for 3 times as needed for up to 3hours. 0-12year severe asthma every 20 minutes use 0.5- 1 unit dose for 3 times as needed for up to 3hours. COPD requring second bronchodilator 1 inhalation QID. Maximum: 6 inhalations in 24 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,IPRATROPIUM PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk ALBUTEROL PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,IPRATROPIUM BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible ALBUTEROL BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IH;INHL;,,,,,
YCIM,polysiloxanes,Cimeosil scar gel 14gm,TDER,,,,,,,,,,,,,,,,,,,
OANL,Lactobacillus + Bifidobacterium,Anlorin 5's/pk,ALIM,,¾AÀ³¯g: Symptomatic treatment of mild diarrhea & abdominal pain.,,2-8¢J,1 CAP TID,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OARI1,Donepezil,Aricept 10mg,CNEU,,¾AÀ³¯g: Treatment of mild to moderate dementia of the Alzheimer's type. °Æ§@¥Î:Nausea¡A diarrhea¡A insomnia¡A vomiting¡A muscle cramp¡A fatigue & anorexia. Syncopal episodes have been reported. Cardiovascular: Hypertension (3% )¡A Syncope (2% ) Endocrine metabolic: Weight decreased (3% to 5% ) Gastrointestinal: Diarrhea (5% to 15% )¡A Loss of appetite (2% to 8% )¡A Nausea (3% to 19% )¡A Vomiting (3% to 9% ) Hematologic: Contusion (2% )¡A Ecchymosis (4% to 5% ) Musculoskeletal: Cramp (3% to 8% )¡A Increased creatine kinase level (3% ) Neurologic: Asthenia (1% to 2% )¡A Dizziness (2% to 8% )¡A Headache (3% to 4% )¡A Insomnia (2% to 14% )¡A Somnolence (1% to 2% ) Psychiatric: Depression (2% to 3% )¡A Dream disorder (3% ) Renal: Urinary incontinence (1% to 3% ) Other: Fatigue (1% to 8% ) ¸T§Ò:Patients with a known hypersensitivity to donepezil HCl¡A piperidine derivatives or to any excipients used in Aricept. Use in children: Aricept is not recommended for use in children.,,«Ç·Å,Adult 5 mg once daily in the evening just prior to retiring. Dose may be increased to 10 mg once daily following 4-6 weeks of clinical assessment.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IGCS,Filgrastim,Gcsf 150mcg/0.6mL (Filgrastim),HEMT,Mobilization of hematopoietic progenitor cells to peripheral blood¡A Acceleration of an increase in the number of neutrophils following hematopoietic progenitor cells transplantation¡A Neutropenia caused by cancer chemotherapy¡A Neutropenia accompanying MDS¡A Congenital idiopathic neutropenia.,Hypersensitivity to any component of the formulation.,Mainly bone pain¡A fever¡A redness¡A nausea & vomiting¡A headache. Gastrointestinal: Nausea and vomiting (57% ) Musculoskeletal: Bone pain (22% to 33% ),Á×¥ú§NÂÃ (<10¢J),Mobilization of hematopoietic progenitor cells to peripheral blood: Adult & children Administer 400 mcg/m2 once daily or 200mcg/m2 twice daily SC.Acceleration of an increase in the number of neutrophils following hematopoietic progenitor cells transplantation:Adult & children Administer 300 mcg/m2 once daily IV. Neutropenia caused by cancer chemotherapy:Acute leukemia: Adult & children Administer 200 mcg/m2 once daily IV.Malignant lymphoma¡A Small Cell Lung Cancer¡A Germ cell tumors¡A Neuroblastoma and Pediatric cancer: 50 mcg/m2 SC or 100 mcg/m2 IV once daily after the next day of chemotherapy.Other cancer: Neutrophil count ¡Ø 1000/mm3 and fever¡A or Neutrophil count ¡Ø 500/mm3¡A 50 mcg/m2 SC or 100 mcg/m2 IV once daily.When neutrophil count ¡Ù 5000/mm3¡A consideration monitor and discontinue therapy.Neutropenia accompanying myelodysplastic syndrome: Neutrophil count ¡Ø 1000/mm3¡A 100 mcg/m2 once daily IV.Congenital idiopathic neutropenia:Adult & children: Neutrophil count ¡Ø 1000/mm3¡A 50 mcg/m2 SC once daily. When neutrophil count ¡Ù 5000/mm3¡A close observation is needed & consideration should be made to either decrease dosage or discontinue therapy.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¬s labeling,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;SC;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,IV¿éª`®É¥i¨Ï¥Î D5Wµ}ÄÀ¡A¿@«×¤Å§C©ó 5 mcg/mL¡C,1. IV¿éª`®É¥i¨Ï¥Î D5Wµ}ÄÀ¡A¿@«×¤Å§C©ó 5 mcg/mL¡C
IMIT1,Mitomycin C,Mitomycin-C inj 10mg,RACA,Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.,Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders¡A or other increased bleeding tendency,Leukopenia¡A thrombocytopenia¡A anorexia¡A nausea/vomiting¡A malaise¡A weight loss¡A bleeding tendency & anemia. Haemolytic-uremic syndrome¡A microangiopathic hemolytic anemia¡A nephropathy¡A bone marrow depression¡A interstitial pneumonia¡A liver & biliary tract disorders.,25¢XC¥H¤U,Intermittent therapy Adult 4-6 mg IV once or twice weekly. Consecutive therapy Adult 2 mg IV once daily. Large dose intermittent therapyAdult 10-30 mg IV at 1-3 (or more) weeks intervals. Combined use with other antineoplastic agent Adult 2-4 mg once or twice weekly. Bladder cancer Prophylaxis of recurrence: 4-10 mg intravesically once daily or every 2 days. Treatment: 10-40 mg intravesically once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest high risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;IRR;IVD;,¥H25mLµLµßª`®g¥Î¤ô·»¸Ñ,¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡BµÇ¥\¯à¡C
EMYDP,Tropicamide + Phenylephrine,Mydrin-P 10mL,TOPH,Mydriasis & cycloplegia for diagnosis,Narrow-angle glaucoma.,Transient stinging¡A dry mouth¡A Allergic reactions,1-30¢J,For pupil dilation¡A usually 1-2 drops per time¡A or 1 drop each time at an interval of 3 to 5 minutes and 2 attempts in total. For cycloplegia¡A usually 1 drop each time at an interval of 3 to 5 minutes and 2 to 3 attempts in total. The dosage may be increased or decreased as appropriate depending on the symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,Tropicamide Ophthalmic: No Human Data¡XProbably Compatible Phenylephrine Ophthalmic: No Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Tropicamide Ophthalmic: No Human Data¡XProbably Compatible Phenylephrine Ophthalmic: No Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
OANTI,Lactobacillus Casei,Antibiophilus 250mg,ALIM,Temporary relief of mild diarrhea¡A abdominal pain¡A constipation. Regulate bowel movement & soften stool.,When used for self-medication¡A do not use if sensitive to milk protein (product specific).,Bloating (intestinal)¡A flatulence.,25¢J¥H¤U,Adult & children >12 years: PO 1~2 CAP TID-QID. (Better to take between meals) 6-12 years: one half dose of Adult. 3-6 years: one quarter dose of Adult.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IINFE,Interferon alfacon-1,Infergen 9mcg,QANB,,¾AÀ³¯g: Chronic hepatitis C. °Æ§@¥Î: Insomnia¡A nervousness¡A depression¡A dizziness¡A anxiety¡A emotional lability; alopecia¡A pruritus¡A rash; hot flushes; GI disturbances; blood dyscrasia; inj site reactions; myalgia¡A arthralgia¡A pain¡A paraesthesia; flu-like symptoms; upper respiratory tract infection; chest pain¡A arrhythmia¡A MI; hypersensitivity reaction; blurred or loss of vision; hepatomegaly¡A liver tenderness. ¸T§Ò: Hypersensitivity. Hepatic decompensation¡A autoimmune hepatitis.,,2-8¢XC,SC 9 mcg 3 times/wk for 24 wk¡A then 15 mcg 3 times/wk for up to 48 wk if needed.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OKET,Ketorolac,Keto 10mg,CNEU,For the short-term management of moderate-severe acute pain¡A including pain following major abdominal¡A orthopedic & gynecological operative procedures.,Hypersensitivity to aspirin or other NSAIDs.,Nausea¡A abdominal discomfort¡A peptic ulceration¡A GI bleeding¡A drowsiness¡A dizziness. Cardiovascular: Edema (1% to 10% )¡A Hypertension (1% to 10% ) Dermatologic: Injection site pain (injection¡A 1% to 10% )¡A Pruritus (1% to 10% )¡A Rash (1% to 10% )¡A Sweating (1% to 10% ) Gastrointestinal: Abdominal pain (1% to 10% )¡A Diarrhea¡A Indigestion (1% to 10% )¡A Nausea (greater than 10% ) Hematologic: Anemia (1% to 10% )¡A Purpura (1% to 10% ) Neurologic: Dizziness (1% to 10% )¡A Headache (greater than 10% )¡A Somnolence (1% to 10% ) Ophthalmic: Burning sensation in eye¡A Transient (ophthalmic¡A 20% to 40% )¡A Corneal edema (ophthalmic¡A 1% to 10% )¡A Eye irritation (ophthalmic¡A 1% to 10% )¡A Iritis (ophthalmic¡A 1% to 10% )¡A Keratitis (ophthalmic¡A 1% to 10% ) Respiratory: Nasal irritation (nasal¡A 15% )¡A Pain¡A Rhinalgia (nasal¡A 13% ),25¢J¥H¤UÁ×¥ú,10mg(1 capsule) every 4-6 hours,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C [¥é³æ] ¥»ÃÄ·|§í¨î«e¦C¸¢¯À(prostaglandin)¤§¦X¦¨¡A¼vÅT­L¨à´`Àô¤Î§í¨î¤l®c¦¬ÁY¡A¼W¥[¤l®c¥X¦åªº¦MÀI©Ê¡A¬G¸T¥Î©ó¤À®Y¤ÎÁ{¬Öªº°ü¤k¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ¥»ÃÄ·|§í¨î·s¥Í¨à¤§«e¦C¸¢¯À¡A¾É­P¼ç¦b©Êªº°Æ§@¥Î¡A¬G¸T¥Î©ó±Â¨Å°ü¤k¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»½¦Ån¡A¥i©î½¦Ån«áªA¥Î¡C¦ý¤£¥i±N½¦Ån¤ºªº¸z·»·L²É¬ã¿i©ÎÀ£¸H¡C
OFERS,Ferrous Fumarate,Ferall soft cap 460mg¡A100's,NUTR,,I: Treatment all anemias responsive to oral iron therapy.,,RT,1-2 cap daily.,,,,,,,,,,,,,,
ESILK,Calcitriol,Silkis oint 30gm,TDER,,¾AÀ³¯g:°®Å~¡B´M±`©ÊÚµ½H(B023403343),,RT,Apply bid. A maxium of 30 g of ointment is applied per day to up to 35% body surface.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EDAIV,Calcipotriol + Betamethasone,Daivobet ointment 30gm,TDER,Psoriasis vulgaris.,Disorders of Ca metabolism¡A viral¡A fungal or bacterial skin infections¡A parasitic infections¡A skin manifestations in relation to TB or syphilis¡A rosacea¡A acne rosacea¡A perioral dermatitis¡A acne vulgaris¡A skin atrophy¡A striae atrophicae¡A fragility of skin veins¡A ichthyosis¡A ulcers¡A wounds¡A perianal & genital pruritus; guttate¡A erythrodermic¡A exfoliative & pustular psoriasis¡A severe renal insufficiency or severe hepatic disorders.,Pruritus¡A local transient irritation¡A dermatitis¡A erythema¡A aggravation of psoriasis¡A photosensitivity & hypersensitivity reactions. Dermatologic: Atrophic condition of skin (1.9% )¡A Pruritus (3.1% to 7.2% )¡A Psoriasis (1.2 to 3.4% )¡A Rash¡A scaly (1.2% ) Neurologic: Headache (2.8% ),30¢J¥H¤U,Psoriasis Apply to the affected area once daily for 4 weeks. After this period¡A repeated treatment can be initiated under medical supervision. Maximum daily dose: 15 g. Maximum weekly dose: 100 g. Maximum treated area: 30% of the body surface.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,Calcipotriol¡A See Calcipotriene CALCIPOTRIENE: No Human Data¡XProbably Compatible BETAMETHASONE: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Calcipotriol¡A See Calcipotriene CALCIPOTRIENE: No Human Data¡XProbably Compatible BETAMETHASONE: No Human Data¡XProbably Compatible,EXT;SKIN;TOPI;,,,,,
IPEG1,Peginterferon alfa-2b,PEG-INTRON 100mcg,QANB,,¾AÀ³¯g:Treatment of chronic hepatitis C in patients ? 18 years with compensated liver disease. °Æ§@¥Î:Headache¡A myalgia¡A pain/inflammation at inj site¡A fatigue¡A rigors¡A fever¡A depression¡A arthralgia¡A nausea¡A alopecia¡A musculoskeletal pain¡A irritability¡A flu-like symptoms¡A insomnia¡A diarrhea¡A abdominal pain¡A asthenia¡A pharyngitis¡A weight decrease¡A anorexia¡A anxiety¡A impaired concentration¡A dizziness¡A local reactions at inj site. ¸T§Ò:Hypersensitivity to interferon. Pregnancy. Men whose female partners are pregnant. Autoimmune hepatitis or a history of autoimmune disease. Decompensated liver disease or severe renal dysfunction.,,2-8¢J,Adult¡Ù18 years Monotherapy 0.5 or 1 mcg/kg SC once weekly for at least 6 months. Combination therapy 1.5 mcg/kg SC once weekly in combination with ribavirin,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
EPRO,Tacrolimus,Protopic 0.03%³n»I¡A10gm,TDER,,¾AÀ³¯g: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. °Æ§@¥Î: Burning sensation¡A pruritus¡A flu-like symptoms & headache. ¸T§Ò: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15 ~ 30 ¢XC,Adult & children 2-15 years Apply thinly & rub in bid¡A continue for 1 week after signs & symptoms clear.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODOR,Mephenoxalone,Dorsiflex 200mg,CNEU,,¾AÀ³¯g: ¬°¦Ù¦×ÃP¦¢¾¯Muscle spasms(A044318100)(B022801100) °Æ§@¥Î: Drowsiness; GI disturbances¡A paraesthesia¡A weakness; headache¡A dizziness¡A ataxia¡A paradoxical excitement; visual disturbances; arrhythmias¡A hypotension; hypersensitivity reactions; blood dyscrasias. ¸T§Ò: Porphyria; pregnancy and lactation,,«Ç·Å,Adult: 1-2 tab. tid. Child 6-15 yr: 1/2 tab tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OEFE,Venlafaxine,Efexor 37.5mg,CNEU,,¾AÀ³¯g:¸Ñ°£¼~Æ{µJ¼{ª¬ºA(B022328100) ADR: Dizziness¡A dry mouth¡A insomnia¡A nervousness¡A somnolence¡A anorexia¡A constipation¡A nausea¡A abnormal ejaculation/orgasm¡A sweating¡A asthenia. CI: Concomitant use in patient taking MAOIs. Pregnancy¡A lactation. Children < 18 yr.,,«Ç·Å,75 mg once daily. After 2 weeks¡A the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OEUC,Nicametate,Euclidan 50mg,CAVS,,Peripheral vascular disorders¡A cerebral insufficiency.,,,50-100 mg tid.,,,,,,,,,,,,,,
OHEA,Dihydroergotoxine Mesylate,Headgen 1.5mg,CAVS,,Cerebral arteriosclerosis and other cerebral vascular disorders.,,,1 tab tid.,,,,,,,,,,,,,,
OIMD,Isosorbide 5-Mononitrate,Imdur 60mg,CAVS,Prophylaxis of angina pectoris.,Cardiogenic shock¡A head trauma¡A cerebral hemorrhage¡A severe hypotension & severe hypovolemia.,Headache¡A dizziness¡A nausea. Neurologic: Dizziness (8% to 11% )¡A Headache (38% to 57% ),«Ç·Å,60 mg in the morning. Dose may be increased to 120 mg QD. Start from 30 mg QD in the initial 2-4 days to prevent headache occur.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ICLI2,TPN Solution,CLINOLEIC 20% 250mL emulsion,NUTR,,,,,,,,,,,,,,,,,,,
ICLI1,TPN Solution,Clinoleic 20% 100mL emulsion,NUTR,,,,,,,,,,,,,,,,,,,
OKAL,Calcium Polystyrene Sulfonate,Kalimate powder 5 gm/pk,ZADT,,,,,,,,,,,,,,,,,,,
OSTR4,Atomoxetine,STRATTERA 40MG,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI¡A narrow-Angle Glaucoma.,Nausea¡A vomiting¡A fatigue¡A decreased appetite¡A abdominal pain¡A somnolence. Endocrine metabolic: Weight loss (pediatrics¡A 7.1% to 29.1% ) Gastrointestinal: Abdominal pain (adults¡A 7%; pediatrics¡A 17% to 18% )¡A Constipation (adults¡A 9%; pediatric¡A 1% to 2%)¡A Decrease in appetite (adult¡A 11%; pediatrics¡A 16% ¡A)¡A Nausea (adults¡A 21%; pediatrics¡A 7% to 13% )¡A Vomiting (adults¡A 3%; pediatrics¡A 11%)¡A Xerostomia (adults¡A 21% ) Neurologic: Headache (pediatrics¡A 19% )¡A Insomnia (adults¡A 16%; pediatrics¡A at least 2%; )¡A Somnolence (adult¡A 4%; pediatrics¡A 11% ) Renal: Delay when starting to pass urine (adults¡A 5.6% )¡A Urinary retention (adults¡A 1.7% ) Reproductive: Dysmenorrhea (adults¡A 6% )¡A Erectile dysfunction (adults¡A 9% ) Other: Menopausal flushing (adults¡A 8% ),25¢J¥H¤U,Adult¡A adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg¡A whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult¡A adolescent & children>70 kg maximum dose is 100 mg total daily .,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh B): Initial and target doses should be reduced to 50% of the normal dose ­««×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh C): Initial and target doses should be reduced to 25% of the normal dose,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½Ð¾ãÁû½¦Ån§]ªA¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¥»ÃÄ¯»¥½¨ã¦³²´³¡¨ë¿E©Ê¡C
OSTR6,Atomoxetine,Strattera 60mg,CNEU,Treatment of attention-deficit/hyperactivity disorder (ADHD).,with a MAOI or within 2 weeks after discontinuing a MAOI¡A narrow-Angle Glaucoma.,Common: Increased heart rate (Adult¡A 10.2-22.4%; pediatric¡A 12.2-23.4%)¡A Weight decreased (Adult¡A 2%; pediatric¡A 3%)¡A Abdominal pain (Adult¡A 7%; pediatric¡A 18%)¡A Constipation (Adult¡A 8%; pediatric¡A 1-2%)¡A Decrease in appetite (Adult¡A 16%; pediatric¡A 16%)¡A Nausea (Adult¡A 26%; pediatric¡A 10%)¡A Vomiting (Adult¡A 4%; pediatric¡A 11%)¡A Xerostomia (Adult¡A 20%)¡A Dizziness (Adult¡A 8%; pediatric¡A 5%)¡A Headache (Pediatric¡A 19%)¡A Insomnia (Adult¡A 15%; pediatric¡A at least 2%)¡A Somnolence (Adult¡A 8%; pediatric¡A 11%)¡A Delay when starting to pass urine (Adult¡A 6%)¡A Dysmenorrhea (Adult¡A 3%)¡A Erectile dysfunction (Adult¡A 8%)¡A Fatigue (Adult¡A 10%; pediatric¡A 8%) Serious: Increased diastolic arterial pressure (Adult¡A 4.8-12.6%; pediatric¡A 9.3-21.5%)¡A Increased systolic arterial pressure (Adult¡A 4.2-12.4%; pediatric¡A 4.9-12.5%)¡A Myocardial infarction¡A Sudden cardiac death¡A Tachycardia (Adult¡A 1.5%; pediatric¡A 0.3%)¡A Injury of liver (Severe)¡A Liver failure¡A Cerebrovascular accident¡A Aggressive behavior¡A Hostile behavior¡A Mania¡A Psychotic disorder¡A Suicidal thoughts (Pediatric¡A 0.4%)¡A Priapism,«Ç·Å,Adult¡A adolescent & children <70 kg Total daily dose of 0.5 mg/kg & increased after a min of 3 days to approx 1.2 mg/kg administered as single or divided doses(BID);For adolescent & children maximum: 1.4 mg/kg or 100 mg¡A whichever is less. >70 kg Total daily dose of 40 mg & increased after 3 days to approximate 80 mg administered as single or divided doses(BID). Dose may be increased to a maximum of 100 mg after 2-4 additional weeks. Adult¡A adolescent & children>70 kg maximum dose is 100 mg total daily .,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
YDER,Polysiloxane,Dermatix gel 15gm,TDER,,,,,,,,,,,,,,,,,,,
YORI,¾¾¥ß³ß¼Ö¸Á½¦,¾¾¥ß³ß¼Ö¸Á½¦240'S,NUTR,,,,,,,,,,,,,,,,,,,
EATRI,Ipratropium,Atrovent MDI 200pff/10mL,ERSP,,¾AÀ³¯g: Chronic obstructive bronchitis¡A bronchial asthma. Assisted respiration in patients with bronchospasm in intensive care & anaesthesiology. °Æ§@¥Î: GI motility disorders¡A dry mouth¡A headache¡A tachycardia¡A palpitations¡A supraventricular tachycardia¡A atrial fibrillation¡A ocular accomodation disturbances¡A nausea¡A urinary retention¡A cough¡A local irritation¡A inhalation-induced bronchospasm¡A allergic reactions. ¸T§Ò: Hypersensitivity to atropine or its derivatives.,,«Ç·Å,Metered inhaler Intermittent & long-term treatment 2-6 puffs several times daily (ave: 4 puffs 3-4 times daily). Treatment of attacks 2-3 metered doses¡A may be repeated after 2 hr.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OEXE1,Rivastigmine,Exelon 1.5mg,CNEU,§ïµ½»{ª¾¤Î°O¾Ð¯g(B022861100),,,,Initially 1.5 mg BID for 2 weeks. If well tolerated¡A increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks. Maintenance: 3-12 mg daily. Maximun: 12 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] Exelon¦bÃh¥¥°ü¤k¨­¤W¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C ©óÃh¥¥¤j¹«¤Î¨ß¤l¶i¦æªº¤fªA¥Í´Þ¸ÕÅç¡AÅã¥ÜµL­P·î­L©Ê¡C¦bÃh¥¥°Êª«¤¤¡Arivastigmine¤Î/©Î¨ä¥NÁÂª«·|³q¹L­L½L¡F©|¥¼©úÁA¬O§_·|µo¥Í©ó¤HÃþ¡C °Êª«¥Í´Þ©Ê¸ÕÅç¨Ã¤£¯à§¹¥þ¥Î¨Ó¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹Ãh¥¥´Á¶¡¥u¦³¦b¼ç¦bªº®Ä¯q¤j©ó¹ï­L¨àªº¦M®`±¡ªp¤U¤è¥i¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Exelon·|¤£·|³Q¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡A¨Ã¤£²M·¡¡C©ó¤j¹«¤fªA§ë¤©rivastigmine«á¡Arivastigmine»P¨ä¥NÁÂª«·|¤Àªc¦Ü¨Å¥Ä·í¤¤¡A¦b¨Å¥Ä¤¤ªºrivastigmine¤Î¨ä¥NÁÂª«ªº¿@«×¬ù¬°¥ÀÅé¦å¼ß¿@«×ªº¤G­¿¡C ¦]¦¹¯f¤HªA¥ÎExelon®É¤£¥i¥H­÷¨Å¡C,,,,,,
OINDO2,Indomethacin,Indoy 25mg,CNEU,Inflammation¡A pain in the musculoskeletal system¡A swelling after dental surgery,1. Disabled for active gastric ulcers; should also be used with caution in patients with past gastric ulcers. 2. Patients with asthma caused by allergic to Aspirin are banned. 3. Disabled for children under the age of fourteen; use caution for patients who are pregnant or breastfeeding. 4. Patients with epilepsy¡A Parkinson's disease and mental illness should also pay attention to use. 5. The drug was banned within 14 days after the Coronary artery bypass graft (CABG).,>10%:Headache (12% to 16%)¡A Vomiting (<=12%)¡A Postoperative hemorrhage (<=11%) 1% to 10%:Presyncope (<=3%)¡A syncope (<=2%)¡A Dizziness (3% to 9%)¡A depression (1% to 3%)¡A drowsiness (1% to 3%)¡A fatigue (1% to 3%)¡A malaise (1% to 3%)¡A vertigo (1% to 3%)¡A Pruritus (1% to 4%)¡A hyperhidrosis (2%)¡A skin rash (1% to 2%)¡A Hot flash (2%)¡A Epigastric pain (3% to 9%)¡A heartburn (3% to 9%)¡A nausea (3% to 9%)¡A dyspepsia (2% to 9%)¡A constipation (?6%)¡A abdominal distress (1% to 3%)¡A abdominal pain (<3%)¡A diarrhea (<3%)¡A decreased appetite (>=2%)¡A Tinnitus (>1%)¡A Swelling (3%; postprocedural),25¢J¥H¤U,Depending on the patient's response and tolerance¡A 25mg(1 capsule) twice or three times a day for adults¡A with or after meal.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling; use with caution.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 1st and 3 rd trimesters,Indomethacin use during the latter part of pregnancy may cause severe fetal toxicity. Short-term use¡A such as 24¡V48 hours¡A lessens the risk. Based on animal data¡A prostaglandin synthesis inhibitors¡A including indomethacin¡A might block blastocyst implantation. Nonsteroidal anti-inflammatory agents (NSAIDs) also have been associated with spontaneous abortions (SABs) and congenital malformations¡A but the absolute risk appears to be low. [20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;WM;,,,,,
INOVO,Insulin Aspart,NovoRapid 100u/mL 3mL,META,,¾AÀ³¯g:Treatment of patients with diabetes mellitus. °Æ§@¥Î:Hypoglycaemia¡A edema¡A refraction anomalies¡A hypersensitivity reactions¡A lipodystrophy. ¸T§Ò: Hypoglycaemia.,,2-8¢J,Individualised dosage. Administered by SC inj. Normally combined with basal insulins (intermediate or long acting insulins). Penfill should be used with NovoPen 4 & NovoFine Needles,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IINS,Insulin Monocomponent Isophane (NPH),Insulatard HM penfill 3mL(100IU/mL),META,,¾AÀ³¯g:Insulin-requiring diabetes mellitus. °Æ§@¥Î:Rare incidence of allergy & lipoatrophy. ¸T§Ò:Hypoglycaemia¡A insulinoma.,,2-8¢J,Administer once or twice daily by SC inj. Duration of action: Onset after 1 1/2 hr¡A peak between 4th-12th hr¡A terminates after approximately 24 hr. Penfill should be used with NovoPen 4 & NovoFine Needles.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OYAS,Drospirenone + Ethinylestradiol,Yasmin 21's/box,HM,,¾AÀ³¯g: Oral Contraceptives °Æ§@¥Î: Breast tenderness¡A pain¡A secretion; headache; migraine; changes in libido; depressive moods; contact lens intolerance; nausea; vomiting; changes in vaginal secretion; various skin disorders; fluid retention; change in body weight; hypersensitivity reaction. Rarely¡A benign or malignant liver tumors which may lead to life-threatening intra-abdominal hemorrhage have been observed. ¸T§Ò: Venous or arterial thromboembolic events including MI & CVA. Prodromi of thrombosis (transient ischemic attack¡A angina pectoris)¡A diabetes mellitus with vascular involvement. Severe or multiple risk factors for venous or arterial thrombosis. Severe hepatic disease¡A benign or malignant liver tumours. Malignant conditions of the genital organs or breasts¡A if sex steroid-influenced. Undiagnosed vag bleeding. Pregnancy.,,«Ç·Å,1 tab daily for 21 consecuive days¡A starting on the 1st day of the cycle¡A then 7 tab-free days.,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ODEN,Desloratadine,Denosin 5mg,HIMM,,¾AÀ³¯g:Symptomatic relief of seasonal allergic rhinitis & chronic idiopathic urticaria. °Æ§@¥Î: Pharyngitis¡A dry mouth¡A myalgia¡A fatigue¡A somnolence¡A dysmenorrhea¡A headache¡A nausea¡A dizziness¡A dyspepsia.,,«Ç·Å,Adult & children > 12 years 5 mg once daily,»Ý½Õ¾ã¾¯¶q,Mild to severe impairment: 5 mg every other day.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OCARD,Sotalol,Cardol 160mg,CAVS,,¾AÀ³¯g: Management of ventricular & supraventricular arrhythmias; hypertension; angina pectoris. °Æ§@¥Î: Fatigue¡A bradycardia¡A dyspnoea¡A proarrhythmia¡A asthenia¡A dizziness. Cardiovascular: Bradyarrhythmia ( 12.3% to 16% )¡A Chest pain (2.5% to 16% )¡A Lightheadedness (12% )¡A Palpitations (14% ) Dermatologic: Rash (5% ) Gastrointestinal: Nausea (5.7% to 10% ) Neurologic: Disturbance of consciousness (4% )¡A Dizziness ( 13.1% to 20% )¡A Headache (3.3% to 11.5% ) Respiratory: Dyspnea (9.2% to 21% ) Other: Fatigue (18.9% to 20% ) ¸T§Ò:Sick sinus syndrome; 2nd or 3rd degree AV heart block (unless a functioning pacemaker is present); congenital or acquired long QT syndromes; symptomatic sinus bradycardia; uncontrolled CHF; cardiogenic shock;history of COPD or bronchial asthma.,,«Ç·Å,Initial dose is 80 mg bid. This dose may be increased if necessary¡A after appropriate evaluation¡A to 240 or 320 mg/day. In most patients¡A a therapeutic response is obtained at total daily dose of 160 to 320 mg/day¡A given in two or three divided doses. Because of the long terminal elimination half-life of sotalol¡A dosing on more than a twice-daily regimen is usually not nessary.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OINF,Lactobacillus + Bifidobacterium,Infloran 250mg (20 capsules/box),ALIM,Restoration of the eubiotic intestinal flora. Prophylaxis against antibiotic-induced enterocolitis. Acute non-specific enterocolitis after treatment with antibiotics.Digestive disorders in infants on an artificial diet. Chronic constipation.,Hypersensitivity,No significant side effects in normal dosage.,2-8¢J,Adult & children >12 years: PO 1 CAP TID-QID 6-12 years: PO 0.5 CAP TID-QID 3-6 years: PO 0.25 CAP TID-QID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥¡B¥i¯àÃh¥¥°ü¤k¤Î­÷¨Å°ü¡A¨Ï¥Î«e½Ð¥ý¿Ô¸ßÂå®v¡BÃÄ®v¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥¡B¥i¯àÃh¥¥°ü¤k¤Î­÷¨Å°ü¡A¨Ï¥Î«e½Ð¥ý¿Ô¸ßÂå®v¡BÃÄ®v¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¦¨¥÷¤£©y¹J¼ö¡A¬G¤£©y¨Ï¥Î¿i¯»¤À¥]¾÷¡C¥i¦Û¦æ©î½¦Ån¨Ï¥Î¡C
OINH,Isoniazid,Duracrin (INH) 100mg,QANB,,¾AÀ³¯g: TB. °Æ§@¥Î: Peripheral neuropathy¡A elevated hepatic enzyme levels¡A bilirubinemia¡A bilirubinuria¡A jaundice¡A hepatitis¡A GI disturbances¡A hematologic reactions¡A hypersensitivity reactions. ¸T§Ò: Drug-induced hepatitis.,,,Adult 3-5 mg/kg/day in divided doses for 4-16 weeks. Infants and Children: Treatment of active infection: 10-15 mg/kg/day given once daily as part of a multidrug regimen; maximum dose: 300 mg/day Treatment of latent infection: 10-20 mg/kg/day given once daily¡A not to exceed 300 mg/day,»Ý½Õ¾ã¾¯¶q,Advanced disease or AST greater than 3 times ULN and not due to TB: Isoniazid-based regimens are preferred if possible; expert consultation and dosage adjustments may be necessary. If isoniazid cannot be used¡A consider treatment regimens with fewer potentially hepatotoxic drugs.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IRI,Insulin Regular,Insulin actrapid (RI) HM Penfill,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,,According to individual requirements.,,,,,,,,,,,,,,
IGENT,Gentamicin,Gentamicin inj 80mg/2mL,QANB,,¾AÀ³¯g: Susceptible infections¡A Surgical prophylaxis. °Æ§@¥Î: Dizziness or vertigo; acute renal failure¡A interstitial nephritis¡A acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea¡A vomiting; convulsions¡A mental depression¡A hallucinations. Atrophy or rat necrosis at inj sites. ¸T§Ò: History of hypersensitivity to aminoglycoside; pregnancy; perforated ear drum.,,,Adult: 3-5 mg/kg/day in 3 equal dose q8h. Child: 6-7.5 mg/kg/day q8h. Infant and neonate: 7.5 mg/kg/day q8h. 1 wk of age or less: 5 mg/kg/day q12h. *****NEONATE ANTIBIOTICS DOSE***** Gentamicin: Draw peak 30 min after completion infusion; draw trough just before the next dose (©ó²Ä4­Ódoseµ¹ÃÄ«e) PMA <=29 week Postnatal 0 to 7 days dose : 5mg/kg Q48h PMA <=29 week Postnatal 8 to 28 days dose : 4mg/kg Q36 h PMA <=29 week Postnatal >=29 days dose : 4mg/kg Q24 h PMA 30 ¡V 34 week Postnatal 0 to 7 days dose : 4.5mg/kg Q36 h PMA 30 ¡V 34 week Postnatal >= 8 days dose : 4mg/kg Q24 h PMA 35 - 44 week Postnatal all dose : 4mg/kg Q24 h,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IH;IM;IMP;IRR;IVD;IVI;SCI;SUBCI;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,,µ¹ÃÄ¿@«×< 1 mg/mL (IV infuse over 30 minutes to 2 hours)¡C NeoFax«ØÄ³¡GInfuse over a period of 30 to 120 minutes using a concentration of 2 mg/mL or 10 mg/mL.,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡B¦å¶t¡B¦å¹[¡B¦å¶u¡B¦åÁâ¡BÅ¥Ä±¥\¯à¡C 2. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C
ESWI,Sterile Water,Sterile water for irrigation 2000mL,MSIV,Wound cleansing¡A irrigation & flushing.,,,«Ç·Å25¢J¤Å§N­á,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds¡A and for washing¡A rinsing medical device.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;G;GAR;IH;INHL;IRR;IRRI;NA;ORO;RT;SKIN;TOPI;,,,,,
YALDA,Imiquimod,Aldara cream 5%,TDER,Topical treatment of external genital & perianal warts.,Known allergy to imiquimod or to any of the excipients of Aldara.,Local skin reactions including erythema¡A erosion¡A excoriation¡A flaking & edema.,¦s©ñ¦b³±²D¥B°®²nªº¦a¤è¡A·Å«×«O«ù25¢J¥H¤U¡A¦ý¤Á¤Å§N­á,Molluscum contagiosum infection¡A Condyloma acuminatum of the anogenital region Apply 3 times weekly before sleep. Leave on skin for 6-10 hr¡A then wash off with mild soap & water.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,IMIQUIMOD: Limited Human Data Suggest Low Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,IMIQUIMOD: No Human Data¡XProbably Compatible,EXT;SKIN;TOPI;,,,,,
OCONC,Methylphenidate,Concerta 18mg,CNEU,,¾AÀ³¯g:For treatment of attention deficit hyperactivity disorder. °Æ§@¥Î:Headache¡A stomach ache¡A loss of appetite¡A insomnia¡A aggravation reaction¡A asthenia¡A hypertension¡A nausea &/or vomiting¡A dyspepsia¡A weight loss¡A twitching (tics)¡A dizziness¡A emotional lability¡A somnolence¡A anxiety¡A depression¡A nervousness¡A hostility¡A rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )¡A Loss of appetite (5% )¡A Nausea (12% )¡A Vomiting (10% ) Neurologic: Headache¡A Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )¡A Nasopharyngitis (5% ) ¸T§Ò: Patients with marked anxiety¡A tension & agitation¡A glaucoma¡A Tourette's syndrome¡A & patients on MAOI therapy.,,«Ç·Å,Attention deficit disorder: Child over 6 yrs: Initial¡A 18 mg qd¡A max. 54 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IVIN,Vinblastin,Vinblastin 10mg/10mL,RACA,,¾AÀ³¯g: Histiocytic lymphoma; Hodgkin's disease; Kaposi's sarcoma; Letterer-Siwe disease; Lymphocytic lymphoma; Mycosis fungoides; Testicular cancer. °Æ§@¥Î: Alopecia¡A constipation¡A malaise¡A stomatitis¡A dose-limiting bone marrow suppression (e.g. granulocytopenia¡A thrombocytopenia¡A anaemia)¡A hypertension¡A central and peripheral neurotoxicity¡A 8th cranial nerve damage resulting in vestibular and auditory toxicity¡A ischaemic cardiac toxicity¡A breathlessness¡A bone¡A tumour or jaw pain. Nausea¡A vomiting¡A GI bleed¡A syndrome of inappropriate antidiuretic hormone. Necrosis¡A cellulitis if extravasation occurs. ¸T§Ò: Severe bone marrow suppression; presence of bacterial infection; maglignant cell infiltration of bone marrow; Inj into extremity with poor circulation; porphyria; granulocytopenia. Elderly with cachexia or extreme skin ulcerations. Pregnancy; lactation. Intrathecal use may result in death.,,2-8¢XC.,IV Histiocytic lymphoma; Hodgkin's disease; Kaposi's sarcoma; Letterer-Siwe disease; Lymphocytic lymphoma; Mycosis fungoides; Testicular cancer Initial: 3.7 mg/m2¡A increase dose wkly in increments based on WBC counts until leukocyte count decreases to about 3¡A000/mm3¡A or max dose of 18.5 mg/m2/wk is reached. Usual dose: 5.5-7.4 mg/m2/wk.,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,,,IVD;,,,,,
Indocin,Indomethacin,Indocin IV 1mg,CNEU,,,,,,,,,,,,,,,,,,,
ENIC,Nicotine,Smokfree Nicotine TDDS 15,ZADT,To aid smoking cessation.,Non-somkers¡A children & occasional smokers. Acute MI¡A unstable or worsening angina pectoris¡A severe cardiac arrhythmias¡A recent CVA¡A skin diseases¡A pregnancy¡A lactation.,Withdrawal symptoms with smoking cessation. Frequently: Reaction at application site ( usually erythema or pruitus )¡A headache¡A cold & flu-like symptoms¡A insomnia¡A nausea¡A myalgia¡A & dizziness. Less common: BP changes¡A other CNS effects & GI disturbances.,«Ç·Å,1 patch/day. Treatment =/<3 months. Smokfree Nicotine TDDS 15 for those smoking >20 cigarettes/day. Smokfree Nicotine TDDS 10 for those smoking <20 cigarettes/day. Smokfree Nicotine TDDS 5 is designed to reduce nicotine replacement towards the end of therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,NICOTINE REPLACEMENT THERAPY: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk Contraindicated (with any use of tobacco),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,NICOTINE REPLACEMENT THERAPY: Limited Human Data¡XPotential Toxicity,EXT;SKIN;,,,,,
ENOG,NO Gravid IUD,NO Gravid IUD,HM,,intrauterine contraception.,,RT,Inserted into uterus.,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EINTD,Cromolyn,Intal eye drop 10mL,TOPH,,I: Allergic conjunctivitis. AR: Ocular stinging. CI: Soft contact lenses.,,,1-2 gtt qid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ENOV,NOVA T,NOVA T,HM,,Intrauterine contraception.,,,Inserted into uterus.,,,,,,,,,,,,,,
ENTG,Nitroglycerin,Nitrolingual spray 0.4mg/dose,CAVS,,¾AÀ³¯g:¤ßµ±µh¤§ªvÀø©Î¹w¨¾(B020941153)(B020941153) CI: Severe hypotension¡A hypotensive shock¡A severe anemia¡A constrictive pericarditis¡A extreme bradycardia¡A G6PD deficiency¡A cerebral hemorrhage & brain trauma¡A aortic &/or mitral stenosis & angina caused by hypertrophic obstructive cardiomyopathy¡A circulatory collapse¡A cardiogenic shock¡A toxic pulmonary edema. Avoid coadministration with sildenafil.,,RT,Spray: Acute attack 1-2 doses. Max: 3 doses at any one time. Prevention of exercise-induced angina 1-2 doses before exercise.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EOES,Estradiol,Oestrogel gel 30gm,HM,,¾AÀ³¯g: Natural or surgical menopause¡A estrogen deficiencies; vasomotor disorders associated with menopause; tropic disorders caused by disturbances in ovarian secretions as in vag atrophy¡A kraurosis vulvae¡A female hypogonadism¡A castration in women¡A primary ovarian deficiency. ¸T§Ò: Malignant tumors of the breast or uterus. Pituitary tumors. °Æ§@¥Î¡G Cardiovascular: Edema (transdermal system¡A 0.5% to 13% ) Dermatologic: Application site irritation (transdermal spray¡A 1.3% ; transdermal system¡A 5.7% to 56.7% )¡A Chloasma¡A Hirsutism¡A Persistent erythema of skin (transdermal patch¡A 17% )¡A Pruritus (topical emulsion¡A 4% ; topical gel¡A 4.8% ) Endocrine metabolic: Weight change finding Gastrointestinal: Bloating symptom¡A Nausea¡A Vomiting Neurologic: Migraine Psychiatric: Depression (transdermal system¡A 1% to 8% )¡A Disturbance in mood Reproductive: Breast tenderness (topical gel¡A 2.5% to 8.8% ; transdermal spray¡A 5% to 7% ; transdermal system¡A 6.5% to 17.0% )¡A Disorder of menstruation¡A Leukorrhea¡A Swelling of breast¡A Vaginal discomfort (vaginal cream¡A 5% ; vaginal ring¡A 5% )¡A Withdrawal bleeding,,«Ç·Å,Apply 2.5 g daily (preferably on the abdomen) for 24 successive days¡A stop for 1 week (25th-end of the months)¡A then combine therapy with an oral progesterone from 13th-24th day of the cycle. A depletion in bleeding is generally seen during the weeks of interruption.,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EOTO,Polymyxin B + Neomycin + Lidocaine.,Otozambon ear drops 8mL,TENT,,¾AÀ³¯g: Otitis externa & media¡A furunculosis of auricular tube¡A allergic dermatoses of exudative¡A seborrheic & eczematous type¡A suppurative complications following ear & mastoid surgery¡A otalgia. ¸T§Ò: Infected TB lesions of ear; chickenpox; live vaccine; herpes simplex.,,«Ç·Å,4-5 drop bid-qid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EOVEC,Estriol,Ovestin cream 0.1%¡A 15gm,SGU,,¾AÀ³¯g:µäÁY©Ê³±¹Dª¢¤Î¬ÛÃö¯gª¬(B020830535) AR: Initially local irritation or itching. Occasional mastodynia. CI: Pregnancy¡A thrombosis¡A known or suspected estrogen-dependent tumors¡A undiagnosis vag bleeding.,,RT,Cream: 1 application/day for 2-3 wks.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
EPAN,Benzoyl Peroxide,Panoxyl 5 acne gel,TDER,,Acne vulgaris.,,,Apply once daily initially. Increase strength as required.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
INOV,Prochlorperazine,Novamin inj 5mg/1mL,CNEU,Pyschosis¡A nausea¡A vomiting.,CNS depression¡A comatose patients. Bone marrow depression¡A phaechromocytoma¡A prolactin-dependent tumours¡A hypersensitivity. Childn <2 yr. Pregnancy and lactation.,Cholestatic jaundice¡A cardiac arrhythmias¡A orthostatic hypotension¡A leucopaenia¡A thrombocytopaenia¡A dry mouth¡A blurring of vision¡A glaucoma¡A urinary retention¡A constipation¡A galactorrhoea¡A gynaecomastia¡A amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue. Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration,25¢J¥H¤UÁ×¥ú,Usual dose: IM¡A 5 to 10 mg (1 to 2 mL)¡A may repeat every 3 to 4 hours as needed; maxium daily dose: 40 mg. surgery: IM¡A 5 to 10 mg (1 to 2 mL) 1 to 2 hours prior to anesthesia; may repeat after 30 minutes.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ]¥¥°ü©Î¥i¯àÃh¥¥¤§°ü¤k½Ð¤Åµ¹ÃÄ¡C°Êª«¸ÕÅç( ¤p¹«¡B¤j¹«)¡A¦³¶Ê·î­L§@¥Î( ®BÃEµõ¼W¥[) ¤§³ø§i),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]­÷Áý¥À¨Å¤§°ü¤k¡AÀ³Á×§Kµ¹»P¥»¾¯¡C,IM;,,,,,
INPHI,Insulin NPH,Insulin Protaphane 100IU/mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,,According to individual requirements.,,,,,,,,,,,,,,
OPRA1,Multivitamins + Minerals,Pramet F.A 100'S/BOT,NUTR,,Pregnancy nutrition supplement.,,,1 Tab daily,,,,,,,,,,,,,,
IPRO5,Oxacillin,Prostaphlin inj 500mg,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(B017520277),,RT,IM¡A slow IV or IV infusion. Adult: 250 mg-1g q4-6h¡A (max. 20 g/day). Child under 40 kg: 12.5-25 mg/kg q4-6h¡A 300 mg/kg/day. Neonate: 25 mg/kg q6-12h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EPOSU,Epinephrine,Posumin (¥~¥Î),CAVS,,¾AÀ³¯g: Open-angle glaucoma; Ocular HTN¡A Inhalation Asthmatic attacks¡A hemorrhage¡A nasal decongestants. °Æ§@¥Î: CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness¡A tremors; coldness of extremities; hypokalaemia. Gangrene¡A tissue necrosis and sloughing (extravasation) when used in addition to local anaesthetics. Eye drops: Severe smarting¡A blurred vision¡A photophobia; naso-lachrymal ducts obstruction. Oedema¡A hyperaemia and inflammation of the eyes with repeated administration. ¸T§Ò: Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics: Procedures involving digits¡A ears¡A nose¡A penis or scrotum.,,«Ç·Å,As hemostatic agent in surgery Apply as original concentration or 5 times more concentrated soln with cotton or gauze to the skin. Add 2-5 drops when use as local anesth. Ophthalmology Apply as 5-10 times more concentrated soln as eye drops.ENT Apply as original concentration or 5 times more concentrated soln as ear/nose drops. Asthma¡A whooping cough Add 2-3 mL to 100 mL salt water. Inhale daily in 2-3 divided dose.Coughing spasm 1-3 drops.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
TEST,TEST_PHR_NAME,test,TEST,¾AÀ³¯g,¸T§Ò,°Æ§@¥Î,,,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,
YCON,Heparin Na¡A allantoin,Contractubex gel 20gm,TDER,,,,,,,,,,,,,,,,,,,
IKYT,Granisetron,Kytril °w¾¯ 3mg/3mL,CNEU,,¾AÀ³¯g: Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation. °Æ§@¥Î: Headache¡A constipation. ¸T§Ò: Hypersensitivity to granisetron or related substances.,,«Ç·Å,Prevention & treatment of nausea & vomiting due to cytostatic therapy & radiation Adult 3 mg either in 15 mL infusion fluid as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid & administered over 5 mins. Max dose over 24 hr: 9 mg. Children 10-40 mcg/kg body weight (up to 3 mg) diluted in 10-30 mL infusion fluid & administered over 5 mins. Max dose: 1 additional dose of 40 mcg/kg (up to 3 mg) within 24 hr if necessary. Max: 9 mg/day. For prevention¡A administration should be completed prior to the start of cytostatic therapy and anesth induction.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EVORS,Diclofenac,Voren ®ê¾¯ 12.5mg,CNEU,Rheumatism¡A acute musculoskeletal disorders¡A post-traumatic & post-op inflammation & swelling.,Patients sensitive to aspirin or other NSAIDs.,GI disturbances. Peptic ulceration. GI bleeding. Headache¡A dizziness¡A nervousness¡A skin rash¡A pruritus¡A tinnitus¡A edema¡A depression¡A drowsiness¡A insomnia¡A & blurred vision. Hypersensitivity. Impairment of liver & kidney function. Agranulocytosis & thrombopenia. Dermatologic: Application site reaction (gel: all reactions¡A 7%; dermatitis¡A 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )¡A Keratitis (up to 28% )¡A Lacrimation and lacrimal drainage - finding (up to 30% )¡A Raised intraocular pressure (up to 15% ),25¢J¥H¤U³±²D³B,Adult: 75-100mg/day in 2 or 3 divided doses. Children >1year old: 0.5-2mg/kg/day in 2 or 3 divided doses. Juvenile rheumatoid arthritis(JRA) can increase to 3 mg/kg/day in divided doses.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling; however¡A may require dosage adjustment due to extensive hepatic metabolism.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C [¥é³æ] ¸T§Ò: Ãh¥¥²Ä¤T¯Å°ü¤k¸T¥Î¥»ÃÄ¡C ¹ï¥¥°ü¤Î±Â¨Å°ü¤H¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C¹ï©ó¥¥°ü¤Î¥i¯àÃh¥¥¤§°ü¤k©Î±Â¨Å¤§°ü¤H¡A¶·§PÂ_¨äªvÀø ®Ä¯q¶W¹L¦MÀI©Ê®É¡A¤è¤©§ë»P¡C Ãh¥¥³Ì«á3­Ó¤ëªº°ü¤k¨Ï¥Î¥»«~¶·¯S§Oª`·N(¦]¥i¯à³y¦¨¤l®c¦¬ÁYµL¤O¤Î/©Î­L¨à°Ê¯ß³¬Âê¹L¦­)¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¹ï¥¥°ü¤Î±Â¨Å°ü¤H¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C¹ï©ó¥¥°ü¤Î¥i¯àÃh¥¥¤§°ü¤k©Î±Â¨Å¤§°ü¤H¡A¶·§PÂ_¨äªvÀø ®Ä¯q¶W¹L¦MÀI©Ê®É¡A¤è¤©§ë»P¡C,RECT;,,,,,
EXAL,Latanoprost,Xalatan 0.005%¡A 2.5mL ophthalmic solution,TOPH,Reduction of elevated intraocular pressure in patients with glaucoma & ocular hypertension.,Known hypersensitivity to any component of Xalatan.,Slight discomfort¡A mild to moderate conjunctival hyperaemia¡A transient punctate epithelial erosions¡A increased pigmentation of iris¡A rash.,2-8¢J,1 drop in affected eye once daily in the evening.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
EXYL41,Xylocaine,Xylocaine 4% 30mL,ZANE,,¾AÀ³¯g: Local anesth in bronchoscopy¡A bronchography¡A laryngoscopy¡A oesophagoscopy¡A endotracheal intubation¡A & biopsy in the mouth & throat. °Æ§@¥Î: Rarely¡A allergic reactions¡A CNS excitation or depression¡A hypotension¡A bradycardia. ¸T§Ò: Previously known hypersensitivity to local anaesthetics of amide type.,,«Ç·Å,Adult 2-7.5 mL (80-300 mg lidocaine); up to 400 mg may be administered during prolonged (> 5 mins) procedures. With applications mainly to the larynx¡A trachea & bronchi¡A the dose should not exceed 5 mL (200 mg lidocaine). When inhaled from a nebulizer¡A 5-10 mL (200-400 mg lidocaine HCl) may be used.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OMIND,Glipizide,Minidiab 5mg,META,,NIDDM.,,,2.5 mg-20 mg daily; in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OMOB,Meloxicam,Mobic 7.5mg,CNEU,,¾AÀ³¯g:¬°¤îµh®øª¢ÃÄ(A041913100),,RT,Rheumatoid arthritis:15mg/day.According to the therapeutic response¡A the dose may be reduced to 7.5 mg/day. Osteoarthritis:7.5 mg/day.If necessary¡A the dose may be increase to 15 mg/day. In patient with increase risks of adverse reaction: Start treatment at the dose of 7.5 mg/day. In dialysis patients with severe renal failure¡Gthe dose should not exceed 7.5 mg/day.Max:15 mg.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LGEL,Colloidal Aluminum Phosphate,Gelfos 20gm/pk,ALIM,,¾AÀ³¯g:­G»Ä¹L¦h¡B­G©Î¤Q¤G«ü¸z¼ìºÅ(B018641138),,,20-40gm bid-tid,,,,,,,,,,,,,,
OMOR,Morphine,Morphine 10mg,CNEU,,¾AÀ³¯g: Relief of moderate to severe pain. Pre-op anesth. °Æ§@¥Î: Nausea¡A vomiting¡A constipation¡A drowsiness¡A palpitations¡A headache¡A disorientation¡A vertigo¡A mood changes¡A decreased libido¡A ureteric spasm¡A urinary retention¡A rash¡A sweating¡A facial flushing¡A miosis. Cardiovascular: Peripheral edema (5% to 10% ) Dermatologic: Pruritus (up to 80% )¡A Rash (5% to 10% )¡A Sweating (5% to 10% ) Gastrointestinal: Abdominal pain (5% to 10% )¡A Constipation (> 10% )¡A Diarrhea (5% to 10% )¡A Loss of appetite (5% to 10% )¡A Nausea and vomiting (7% to 70% )¡A Xerostomia (5% to 10% ) Hepatic: Liver function tests abnormal (< 5% ) Musculoskeletal: Backache (5% to 10% ) Neurologic: Asthenia (5% to 10% )¡A Dizziness (6% )¡A Headache (>10% )¡A Insomnia (5% to 10% )¡A Lightheadedness¡A Paresthesia (5% to 10% )¡A Somnolence (> 10% ) Ophthalmic: Amblyopia (< 5% )¡A Miosis Psychiatric: Anxiety (6% )¡A Depression (5% to 10% ) Renal: Urinary retention (oral: < 5% ; epidural/intrathecal: 15% to 70% ) Other: Fever (5% to 10% )¡A Hiccoughs (< 5% ) ¸T§Ò: Respiratory depression¡A head injury¡A obstructive airways disease¡A paralytic ileus¡A GI obstruction¡A delayed gastric emptying¡A acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,,«Ç·Å,5-20 mg every 4 hr.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OMORBAD,Morphine,Morphine 10mg ´Ý¾l¾PÀì,CNEU,,Relief of visceral pain¡A preanesthetic medication¡A sedation and hypnosis when pain is present¡A dyspneic seizures of acute left ventricular failure and pulmonary edema.,,,Adult: PO: Initial¡A 10-30 mg q4h. IM or SC:5-20 mg (usually 10 mg) q4h as needed. IV (only rarely): 2.5-10 mg diluted in 4-5 ml of water for injection¡A administered slowly over 4-5 mins. Child: SC:0.1-0.2 mg/kg¡A not to exceed 15 mg/dose.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IDOP,Dopamine,Dopamine 200mg(DBL),CAVS,,¾AÀ³¯g:¥ð§J¯g­Ô¸s¤Î¤ß°IºÜµ¥(B021687221) CI: Phaeochromocytoma; uncorrected hypovolaemia; uncorrected tachyarrhythmia or ventricular fibrillation.,,RT,IV infusion¡A initially 1-5 mcg/kg/min¡A increased by 5-10 mcg/kg/min¡A up to 20-50 mcg/kg/min.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IEPH,Ephedrine,Ephedrine inj 40mg/1mL,CAVS,Diabetic neuropathic oedema ¡A Reversal of spinal or epidural anesth-induced hypotension,Hypersensitivity. Hypertension¡A thyrotoxicosis¡A BPH. Lactation.,Anxiety¡A tachycardia¡A tremor¡A dry mouth¡A hypertension¡A cardiac arrhythmias¡A impaired circulation to the extremities¡A nervousness¡A insomnia¡A palpitations. Difficulty in micturition in patients with prostatic enlargement. Nasal drops: Local irritation¡A rebound nasal congestion and drug-induced rhinitis on prolonged use. Potentially Fatal: Delusions¡A hallucinations. Seen with hypersensitivity and overdosage. Acute CNS and CVS stimulation presenting as vomiting¡A fever¡A hypertension¡A psychosis. Cardiac arrhythmias.,15-30¢JÁ×¥úÁ×§K§N­á,Adult usual dosage: IM/SC 25-50mg¡A repeat if necessary. IV 5-25mg slowly inject¡A repeat after 5-10 minutes if necessary. Maximum: 150mg/24 hours. Children usual dosage: IM/SC 500 mcg/kg (0.5 mg/kg) Q4H-Q6H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;IVP;IVPUSH;SC;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,µ}ÄÀ¨ì5-10mg/mL¡A½wºCÀR¯ß±Àª`,,1.IV: µ}ÄÀ¨ì 5 - 10 mg/mL¡A½wºCÀR¯ß±Àª`¡C 2. ºÊ´ú¦åÀ£¡B¤ß¸õÅÜ¤Æ¡C
IEUD,Clindamycin,Eudamycin inj 300mg/2mL,QANB,,¾AÀ³¯g: Infections caused by susceptible strains of strep¡A staph¡A pneumococci¡A anaerobic bacteria. °Æ§@¥Î: Abdominal pain¡A nausea¡A vomiting¡A diarrhoea¡A urticaria¡A maculopapular reactions¡A jaundice¡A blood disorders. ¸T§Ò: Hypersensitivity¡A meningitis.,,«Ç·Å,Adult 600-1200 mg IM daily in 2-4 doses. Severe infections: 1200-2700 mg daily in 2-4 doses. Children > 1 month 15-25 mg/kg/day in 3-4 doses. Severe infections: 25-40 mg/kg/day in 3-4 doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IEUJ,Prostaglandin F2 Alpha,Eujum 5mg/mL(PGF2),SGU,,¾AÀ³¯g: Induction of labour. Therapeutic termination of pregnancy. °Æ§@¥Î: Nausea¡A vomiting¡A diarrhoea¡A local tissue reaction¡A flushing¡A shivering¡A headache¡A dizziness¡A temporary pyrexia & elevated WBC. Foetal distress¡A uterine hypertonus¡A tetonic contractions. Bronchoconstriction (in asthmatic patients). Rarely¡A uterine rupture. ¸T§Ò: Acute pelvic inflammation¡A history of major uterine surgery; previous caesarean section. Patients with active cardiac¡A pulmonary¡A renal or hepatic disease. Difficult labour or traumatic delivery; significant cephalopelvic disproportion; grand multiparity; preexisting foetal distress; foetal malpresentation. History of previous difficult labor &/or traumatic delivery; unexplained vag bleeding during the 2nd or 3rd trimester of the present pregnancy.,,2-8¢J,Induction of labour Initially 2.5 mcg/min for 30 min. May be increased to 10 mcg/min if needed. Foetal death in utero Initially 5 mcg/min. May increase to 40 mcg/min. Therapeutic termination of pregnancy IV Initially 50 mcg/min for 30 min. May increase up to 100 mcg/min. Intra-amniotic route Initially 40 mg administered intra-amniotically by slowly injecting 8 mL of a solution containing 5 mg/mL into the amniotic sac. A further dose of 10-40 mg after 24 hr may be given.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OIMO,Loperamide,Ufunin (Imodium) 2mg,ALIM,,¾AÀ³¯g: Acute & chronic diarrhea °Æ§@¥Î: Flatulence¡A constipation¡A nausea¡A abdominal pain¡A dry mouth; giddiness. ¸T§Ò: Diarrhea associated with organisms which penetrate the mucosa; pseudomembranous colitis or diarrhea associated with broad spectrum antibiotics.,,«Ç·Å,Acute & chronic diarrhea Adult Initially 4 mg then 2 mg after each loose stool. Usual daily dose: 6-8 mg. Max: 16 mg daily. Initial dose: Children 8-12 years 6 mg¡A 5-8 years 4 mg¡A 2-5 years 3 mg. To be given in divided doses¡A followed by 1 mg/10 kg body wt¡A administered only after a loose stool. Chronic diarrhea Adult Initially 4-8 mg daily in divided doses¡A subsequently adjusted as necessary. Usual daily dose: 4-8 mg.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OMACA,1¡A25-Dihydroxycholecalciferol,Macalol 0.25mcg,META,Management of vit D deficiency states & hypocalcaemia associated with disorders such as hypoparathyroidism & secondary hyperparathyroidism.,Hypercalcemia or evidence of vit D toxicity.,Hypercalcemia.,25¢J¥H¤U³±²D°®Àê³B,Initial 1 capsule daily¡A dosage may be gradually increased to 2-4 capsule daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦ÅnÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©ÎÀ£¸H¡AµLªk§]ªA±wªÌ¥i¥H·Å¤ô·»¸Ñ«áªA¥Î¡C
IFRAX,Nadroparin,Fraxiparine inj 3800u/0.4mL,HEMT,,¾AÀ³¯g:¹w¨¾¦å®ê(B016271218),,§NÂÃ,Prophylaxis: 0.3 mL or 0.4 mL SC/day. General surgery: 0.3 mL or 0.4 mL SC 2-4 hr prior to operation¡A duration of treatment is at least 7 days. Treatment: 0.1 mL/10 kg bid for 7-10 days.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OCLIM,Estradiol Valerate + Cyproterone Acetate,Climen 21 tab/pk,HM,,¾AÀ³¯g:§ó¦~´Á«á¤§¶Pº¸»X¸É¥R(B022443100),,RT,1 tab. daily from the 5th to the 25th day of the cycle¡A then 7 tab-free days.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IDDA,Desmopressin,Minirin inj 4mcg/1mL (DDAVP),HM,Central Diabetes Insipidus¡A Primary Nocturnal Enuresis¡A Renal Concentrating Capacity Test¡ASymptomatic treatment of nocturia in adults associated with nocturnal polyuria ie¡A nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease,Habitual & psychogenic polydipsia¡A syndrome of inappropriate ADH secretion (SIADH)¡A known hyponatremia¡A known or suspected cardiac decompensation & other conditions that require diuretics¡A moderate & severe renal impairment.,Nausea¡A abdominal pain¡A headache¡A nasal congestion/rhinitis¡A nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea¡A Will respond to dosage decrease Neurologic: Fatigue (10% )¡A Headache (22.5% ),¦B½c2-8¢J§NÂÃ¡A«Ç·Å(25¢J)¥H¤U¥i4¶g¡A¶W¹L4¶g¶·¥á±ó¡A¤@¸g«Ç·Å¦s©ñ«á«h¤£¥i¦A©ñ¦^¦B½c,Central diabetes insipidus: Adult: 1-4mcg(0.25-1mL) ; Children > 1 year 0.4-1mcg(0.1-0.25mL) ; Children < 1 year 0.2-0.4mcg(0.05-0.1mL)¡A 1-2 times per day .Patients with mild to severe hemophilia or drug-induced platelet dysfunction: 0.3mcg/kg diluted with normal saline to 50-100mL¡A IV infusion for over 15-30 minutes¡A could repeat after 6-12 hours.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¡C,,Infuse over 15-30 min. Adult: IV: 0.3 mcg/kg by slow infusion¡A Maximum IV dose: 20 mcg.,Adminisration (Intravenous) 1.dilute in sterile physiological saline (diluent); use 10 mL diluent if patient 10 kg or less; use 50 mL diluent if patient more than 10 kg 2.infuse over 15-30 min 3.give 30 min prior to surgical procedures if need to give preoperatively 4.fluid restriction recommended ¶·©ó¦B½c2-8¢J§NÂÃÀx¦s¡A¦pªGÀx¦s©ó«Ç·Å25¢J¥H¤UÀx¦s¡A³Ì¦h¥i«O¦s4¶g¡A¶W¹L4¶g¶·¥á±ó¡A¤@¸g«Ç·Å¦s©ñ«á«h¤£¥i¦A©ñ¦^¦B½c§NÂÃÀx¦s¡C
ODEXA,Dexamethasone,Dexamethasone 0.5mg,HM,,¾AÀ³¯g:®ð³Ý¡BÃö¸`ª¢¡B¹L±Ó©Ê¯e¯fµ¥(A014183100),,RT,Adul: Initial daily dose: 1.5-3 mg in 2-4 divided doses. Maintenance dose: 0.5-0.75 mg/day. Child: According to age.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
INS2,Sodium Chloride,Isotonic NaCl inj 20mL,NUTR,¬°¥Í²z­¹ÆQ¤ô(N009997238),,,«Ç·Å,20-1000 mL SC/IV/IV infusion. May use as diluent.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;IH;IM;IRR;IVD;IVI;IVPUSH;LI;SC;,,,,,
INS250,Sodium Chloride,0.9% NaCl inj 250mL(µw²~),MSIV,¬°¥Í²z­¹ÆQ¤ôª`®g²G(A001085265),,,«Ç·Å,Individualized dosage.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IRR;IRRI;IVD;,,,,,
INS3,Sodium Chloride,3% NaCl inj 500mL,NUTR,¡½Corneal edema ¡½Hyponatremia ¡½Hypovolemic shock,Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus¡A hypernatremia¡A fluid retention,common ¡½Cardiovascular: Phlebitis ¡½Dermatologic: Injection site extravasation¡A Injection site reaction ¡½Endocrine metabolic: Hypervolemia serious ¡½Cardiovascular: Congestive heart failure ¡½Endocrine metabolic: Hypernatremia¡A Overhydration ¡½Hematologic: Disseminated intravascular coagulation ¡½Respiratory: Respiratory distress,25¢J¥H¤U,Adult Parenteral nutrition: Sodium maintenance electrolyte requirement: IV: 1 to 2 mEq/kg/24 hours; customize amounts based on individual patient needs. Acute hyponatremia (serum sodium <130 mEq/L): Asymptomatic: IV 50 mL bolus over at least 5 minutes; monitor serum sodium every 1-2 hrs to assess need for additional treatment. Symptomatic: IV 100 mL over 10 minutes; if symptoms persist¡A may repeat up to a total of 3 doses over a period of 30 minutes; monitor serum sodium hourly to assess need for repeat treatment. Chronic hyponatremia Asymptomatic or mild to moderate symptoms¡A severe hyponatremia (serum sodium <120 mEq/L): IV Initial: 15 to 30 mL/hr with frequent (eg¡A every 2 to 4 hrs) serum sodium monitoring; or alternatively¡A 1 mL/kg bolus (maximum bolus: 100 mL) over 10 minutes every 6 hrs as needed. Severe symptoms (eg¡A seizures¡A obtundation¡A coma¡A respiratory arrest) or known intracranial pathology: IV 100 mL over 10 minutes; if symptoms persist¡A may repeat up to a total of 3 doses over a period of 30 minutes¡A Alternatively¡A some experts recommend 150 mL over 20 minutes¡A up to a total of 2 doses while measuring serum sodium between infusions. Hyponatremia in neonate: 3%NaCl infusion rate about 0.1-1 ml/kg/hour (max infusion rate 1 ml/kg/hour) and a central line is preferred for administration for 3% NaCl.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,micromedex: Pregnancy category:C,IH;IVD;LI;,,,,,1. ¥»ÃÄ«~¬°°ª±i¿éª`²G¡A¶·¯S§Oª`·Nµ¹ÃÄ³t²v¡C
IOCT,Human Immunoglobulin,Octagam Human 2.5gm/50mL,HIMM,,Immunoglobulin deficiency¡A bacterial infections¡A idiopathic thrombocytopenic purpura¡A Kawasaki disease.,,,IV infusion (not exceeding 20 drops/min). Immunoglobulin deficiency: Adult: 0.1-0.15 g/kg; child: 0.15 g/kg; Infant: 0.2 g/kg¡A (max. 0.4 g/kg); repeated every 3-4 wks. Serious bacterial infections including sepsis: As above¡A repeated every 1-2 days if needed. Idiopathic thrombocytopenic purpura & Kawasaki disease: 0.4 g/kg/day for 5 consecutive days.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IORA,Dexamethasone,Oradexon inj 5mg/1mL,HM,,¾AÀ³¯g:Treatment in immuno-allergology¡A rheumatology¡A endocrinology¡A dermatology¡A ophthalmology¡A gastroenterology¡A cardiology¡A pulmonology¡A hematology & oncology¡A neurology; prevention of inflammatory edema & adhesions in surgery; tuberculous meningitis¡A pericarditis¡A peritonitis & pleuritis; severe trichinosis¡A hypercalcemia associated with neoplastic diseases¡A hypervitaminosis-D¡A idiopathic infantile hypercalcemia¡A dexamethasone suppression test; prevention of neonatal respiratory distress syndrome. °Æ§@¥Î:GI disorders; skin atrophy¡A acne; psychic disturbances¡A convulsions; glaucoma¡A increased intraocular pressure¡A posterior subcapsular cataracts; fluid & electrolyte disturbances; Cushing-like syndrome¡A premature epiphyseal closure¡A menstrual irregularities; myopathy¡A abdominal distension¡A osteoporosis¡A aseptic necrosis of femoral & humeral heads; following IV inj of large doses¡A transient burning or tingling sensation. ¸T§Ò:Systemic therapy: peptic ulcers; systemic fungal infection; varicella & herpes genitalia infection; glaucoma. Local therapy: septic arthritis from gonorrhea or TB¡A instability of the joints. Hypersensitivity to glucocorticoids,,rt,IV or IM: 0.5-9 mg/day (max. 80 mg/day). Cerebral edema: IV 10 mg¡A then IM 4 mg q6h. Shock: 2-6 mg/kg as a single IV inj. Intra-articular or soft-tissue inj: 0.2-6 mg.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IPAN,Cefotiam,Pansporin inj 0.5gm,QANB,,Active against E. coli¡A Klebsiella¡A Proteus¡A P. mirabilis¡A Citrobacter¡A Indole (+) proteus¡A H. influenza.,,,IV¡A IV infusion or IM (with Lidocaine) Adult: 0.5-2 g/day in 2-4 divided doses¡A (max. 4 g/day). Child: 40-80 mg/kg/day in 3-4 divided doses¡A (max. 160 mg/kg/day).,,,,,,,,,,,,,,
IURO6,Urokinase,Urokinase-GCC 6000 IU,HEMT,,¾AÀ³¯g: Acute coronary embolism¡A clearance of occluded catheters & shunts¡A acute pulmonary embolism¡A peripheral arterial or venous thromboembolism. °Æ§@¥Î: Bleeding tendency. Fever¡A chills¡A headache & malaise may occur. Rarely¡A shock¡A sweating¡A disturbed pulse & dyspnea; rash¡A urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria. Hematologic: Decreased hematocrit level (37%) ¸T§Ò: Intracranial hemorrhage¡A hemoptysis¡A difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.,,«Ç·Å,Cerebral thrombosis (within 5 days after onset of symptoms & without hemorrhage) 60¡A000 iu once daily for 7 days. Peripheral arterial/venous occlusion 60¡A000 to 240¡A000 iu on first day of treatment followed by tapered doses for about 7 days. Acute coronary embolism 26¡A000-52¡A000 iu daily for 7 days. Deep vein thrombosis or acute pulmonary embolism IV loading 250¡A000 iu/hr¡A then 1¡A000 iu/kg/hr (or 60¡A000 -100¡A000 iu/hr) for 72 hr.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr
EZOVC,Acyclovir,Zovirax cream 5%¡A 2gm,TDER,,¾AÀ³¯g: Herpes simplex virus infection of the skin including initial & recurrent genital herpes & herpes labialis. °Æ§@¥Î: Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction¡A Topical Preparation (5% )¡A Contact dermatitis¡A Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )¡A Nausea (2.4% to 4.8% )¡A Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ) ¸T§Ò: Patients known to be hypersensitive to acyclovir or propylene glycol.,,«Ç·Å,Adult & children Apply 5 times daily at approximately 4 hr interval for 5-10 days.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IABM,B. Multicinctus antivenin + N. Naja atra antivenin,§Ü«B³Ê¸`¤Î¶º°Í­Å³D¬r¦å²M,HIMM,,¾AÀ³¯g:Therapy for the bite of B. multicintus and N.atra snakes. °Æ§@¥Î:allergic phenomena including anaphylaxis¡A hypotension¡A serum sickness. ¸T§Ò: Hypersensitivity to antivenin.,,2-8¢J,Adult 1 dose.(SC: 0.5 dose near bite; 0.5 dose IV or IM),,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. µ}ÄÀªk¡G¨úµ}ÄÀ·»²G10 mLª`¤J­á´¹»s¾¯¤¤¡AÁ×§K¥Î¤O®¶·n¡AÀ³©ó2¤p®É¤º¥Î§¹¡C 2. ©y¾¨¦­ª`®g¡A³Q«r¶Ë«á4¤p®É¤ºª`®g³Ì¦³®Ä¡C 3. ª`®g³¡¦ì¡G«r¶Ë®É¶¡¤G¤p®É¤º¡A¥i±N¤@¥b¾¯¶qª`®g¦b«r¶Ë³¡¦ì©P³ò¥Ö¤U¡A¥t¤@¥b«hIV©ÎIM¡C 4. ª`®g³t²v¡GIV: ²Ä1 mL¼Æ¤ÀÄÁª`§¹¡A¥H«á¨C1 mL¤£§Ö©ó¤@¤ÀÄÁ (30-60¤ÀÄÁ¤º¥´§¹)¡CIVD: ¤@¾¯§Ü³D¬r¦å²Mµ}ÄÀ©ó300mL N/S¡C 5. ª`®g¾¯¶q¡G¦¨¤H¬°¤@¾¯¶q¡A10·³¥H¤U¨àµ£¥[­¿¡C¦p¯gª¬Ä~Äò´c¤Æ¹j30¤ÀÄÁ¦Ü¤@¤p®É«á¥i¦A¥´¤@¾¯¡C 6. ³D¬r¦å²M¬°°¨ªº¦å²M»s¾¯¡A¬°¨¾¹L±Ó¤ÏÀ³¡A¥i¥ý°µ¥Ö½§¸ÕÅç¨Ã·Ç³Æ1:1000 Epinephrine³Æ¥Î¡C
IADR1,Epinephrine,Adrenalin inj 1mg/mL,CAVS,Anaphylactic shock¡A respiratory tract spasm¡A laryngeal edema¡A cardiac arrest¡A bronchial asthma.,Hypersensitivity to other sympathomimetics eg. Amphetamine¡A ephedrine¡A isoproterenol¡A metaproterenol¡A norepinephrine¡A levarterenol¡A phenylephedrine¡A phenylpropanolamine¡A pseudoephrine¡A terbutaline. Labor¡A lactation.,Chest pain¡A arrhythmia; headache¡A nervousness¡A restlessness¡A palpitation¡A dizziness¡A face flush¡A nausea¡A vomiting¡A tremor¡A insomnia¡A dysnea¡A increased adnormal perspiration¡A adnormal pallor & debilitation.,15~30¢J,Adult Hypersensitivity reactions: 0.2-0.5 mg IM/SC at 10-15 minute-interval if necessary. Maximum: 1 mg/dose. Relief of bronchospasm: 0.2-0.5 mg SC at 20 minutes to 4 hours interval if necessary. Maximum: 1 mg/dose. Cardiac arrest: 0.1-1 mg intracardiac/IV at 5 minutes interval. As vasoconstrictor: Administer 0.2-0.4 mg with anesthetic spinal fluid mixture. Administration with local anesthetics 0.1-0.2 mg as 1:200000-1:20000 solution. Anaphylactic shock: Initially 0.5 mg IM/SC at a rate of 25-50 mcg per 5-15 minutes; 0.1-0.25 mg slow IV at 5-15 minutes interval if necessary. Children dosage: Hypersensitivity reactions or to relieve bronchospasm: 0.01 mg/kg or 0.3 mg/m2 SC. Maximum: 0.5 mg. Administer at 15 minutes interval¡A repeat twice. May be given every 4 hours. Cardiac arrest: 0.005-0.01 mg/kg or 0.15-0.3 mg/m2 intracardiac/IV. As vasoconstrictor as per adult dose. Anaphylactic shock: Initially 0.3 mg IM/SC at 15 minutes interval¡A repeated 3-4 times if necessary.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,EXT;IH;IM;IRR;IVD;IVPUSH;LI;SC;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,IV push for cardiac resuscitation management.,IVD: 1-15 mcg/min,1. ªvÀøAnaphylaxis¤ÏÀ³: 0.2 to 0.5 mg IM ©Î SC¡A¥iµø±¡ªp¨C 5 ¤ÀÄÁ§ë¤©¡C 2. ªvÀøAnaphylaxis¤ÏÀ³: : (IV infusion) µ}ÄÀ1 mg in 250 mL D5W (4 mcg/mL) ¡Aµ¹ÃÄ³t²v 1 mcg/min (15 mL/hr) ¦Ü 10 mcg/min ¡A©Îµ}ÄÀ¬° 1 mg in 100 mL NS (10 mcg/mL) ¡Aµ¹ÃÄ³t²v 5 to 15 mcg/min (30 to 100 mL/hr)¡C
IALBB,Albumin,Albumin 25% 50mL(Buminate),HEMT,,¾AÀ³¯g:§C¥Õ³J¥Õ¦å¯g(K000271248),,,IV infusion. Hypoproteinemia: 1 ml/lb/day¡A the rate should not exceed 2-3 ml/min. Burns: Depend on extent of burn. Shock: If initial dose is a inadequate¡A additional case give 15- 30' later¡A in normal blood volume not exceeding 1ml/min.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IALI,TTFD + B12,Alinamin F-B12 inj 20mg/2mL,NUTR,,Vit. B1 deficiency¡A alinamin supplement.,,,Inj.: 1 amp qd SC¡A IM or IV for 5-10 days,,,,¦w¥þ,,,,,,,,,,
ITEM,Buprenorphine,Temgesic inj 0.3mg/mL,CNEU,,Moderate to severe pain.,,,Adult 300-600ug IM or slow IV 6-8 hrly.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ITIE5,Imipenem + Cilastatin Sodium,Tienam inj 500mg,QANB,,¾AÀ³¯g: Intra-abdominal¡A lower respiratory tract¡A gynecological¡A GUT¡A bone & joint¡A skin & soft tissue & mixed infections¡A endocarditis¡A septicemia. Prophylaxis of post-op infections. °Æ§@¥Î: Thrombophlebitis¡A pain¡A induration¡A erythema & tenderness following inj. Rash¡A urticaria¡A pruritus¡A GI disturbances¡A pseudomembranous colitis¡A haematological disturbances¡A increase in liver enzymes¡A taste perversion. Myoclonic activity¡A seizures¡A psychic disturbances¡A confusional states. Dermatologic: Injection site pain Gastrointestinal: Diarrhea (1.8% )¡A Nausea (2% )¡A Vomiting (1.5% ) Hematologic: Thrombophlebitis (3.1% ) ¸T§Ò: Hypersensitivity to amide-type local anaesth¡A severe shock or heart block.,,,IV infusion Adult with normal renal function & body weight >= 70 kg 1-2 g imipenem daily in 3-4 divided doses. Moderate infection 1 g imipenem bid. Infections due to less susceptible organisms Max: 4 g imipenem daily or 50 mg/kg/day (whichever is lower). Post-op prophylaxis 1 g imipenem IV on induction of anesth & 1 g 3 hr later. High-risk surgery: 2 additional 500 mg doses may be given at 8 & 16 hr after induction. Children >= 40 kg Administer adult dose. Children & infant < 40 kg & >= 3 months 15 mg/kg every 6 hr. Max: 2 g imipenem daily. IM inj 500-750 mg imipenem every 12 hr. Max: 1.5 g imipenem daily. Urethritis or cervicitis due to non-penicillinase producing Neisseria gonorrhoeae Single dose of 500 mg imipenem.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,N/S¡A D5W¡A D10W¡A D5NS,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¾¯¶q¡Ø500 mg®É¡Aºwª`®É¶¡¬ù20 ~ 30¤ÀÄÁ¡A§ó¤j¾¯¶qªººwª`®É¶¡¬ù40 ~ 60¤ÀÄÁ¡C,1. ­Y¯f±w¦³äú¤ß·P®ÉÀ³´îºCºwª`³t²v¡C 2. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡Aª`·N¬O§_¦³¦Ù¦×¾_Å¸©ÎÅöíwµo§@¼xª¬¡C
ITIG1,Tetanus Immune Globulin Human,BayTet 250 IU,HIMM,,Passive immunization tetanus¡A treatment of active tetanus infection.,,,Deep IM¡A Prophylaxis: Adult & child: 250 U as a single dose. Treatment: Adult: 3000-5000 U. Child: 500-3000 U,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
´º¦¬ÁY,Hexoprenaline,Ipradol inj 5mcg/2mL,ERSP,,,,,,,,,,,,,,,,,,,
IKET,Ketamine,Ketalar inj 500mg/10mL,ZANE,,For diagnostic and surgical procedures that do not require skeletal muscle relaxation¡A induction of anesthesia prior to the administration of other general anesthetics.,,,Induction: IV (over 1 min)¡A 1-4.5 mg/kg or IV infusion¡A at a rate of 0.5 mg/kg/min; IM¡A 6.5-13 mg/kg. Maintenance: 1/2 of the full induction dose¡A repeated as needed.,,,,,,,,,,,,,,
IKETO,Ketorolac,Keto°w¾¯ 30mg/1mL,CNEU,For the short-term management of moderate-severe acute pain¡A including pain following major abdominal¡A orthopedic & gynecological operative procedures.,Hypersensitivity to aspirin or other NSAIDs.,Nausea¡A abdominal discomfort¡A peptic ulceration¡A GI bleeding¡A drowsiness¡A dizziness. Cardiovascular: Edema (1% to 10% )¡A Hypertension (1% to 10% ) Dermatologic: Injection site pain (injection¡A 1% to 10% )¡A Pruritus (1% to 10% )¡A Rash (1% to 10% )¡A Sweating (1% to 10% ) Gastrointestinal: Abdominal pain (1% to 10% )¡A Diarrhea¡A Indigestion (1% to 10% )¡A Nausea (greater than 10% ) Hematologic: Anemia (1% to 10% )¡A Purpura (1% to 10% ) Neurologic: Dizziness (1% to 10% )¡A Headache (greater than 10% )¡A Somnolence (1% to 10% ) Ophthalmic: Burning sensation in eye¡A Transient (ophthalmic¡A 20% to 40% )¡A Corneal edema (ophthalmic¡A 1% to 10% )¡A Eye irritation (ophthalmic¡A 1% to 10% )¡A Iritis (ophthalmic¡A 1% to 10% )¡A Keratitis (ophthalmic¡A 1% to 10% ) Respiratory: Nasal irritation (nasal¡A 15% )¡A Pain¡A Rhinalgia (nasal¡A 13% ),«Ç·Å,Single dose: IM: deep inject slowly¡A < 65 years old: 60mg¡A>= 65 years old:30mg IV: inject > 15 seconds¡A < 65 years old: 30mg¡A >=65 years old:15mg Continuous dose¡A IV/IM: < 65 years old: 30mg q6h (maximum:120mg/day)¡A >= 65 years old¡A renal dysfunction and body weight <50kg: 15mg q6h(maximum:60mg/day),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;IV;IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö 15¬í,,1. IM: ½wºC¤Î²`³¡§ë¤© 2. ¥é³æÄµ»y¡G¡]1¡^Ketorolac¤£¥i¥Î©ó°h¿N¡A¥B¸T¤î¨Ï¥Î©ó²£¬ì¬ÛÃö¤îµh¡C¡]2¡^»OÆW´¿¦³¯f±w¨Ï¥ÎKetorolac¾É­P¹L±Ó©Ê¥ð§J¡A¬Æ¦Ü¦º¤`¤§®×¨Òµo¥Í¡AÀ³¤p¤ß¨Ï¥Î¥»ÃÄ«~¡C¡]3¡^¨Ï¥Îª`®g¾¯«¬¤§Ketorolac¦¨¤ÀÃÄ«~®É¡A»Ý¦³«æ±Ï³]³Æ³Æ¥Î¡Aª`®g«á¥b¤p®É¤ºÀ³¦³¤HºÊ±±¯f±w¤§¦w¥þ©Ê¡C
ILIPO,Soyean oil + MCT+ Egg Yolk Phospholipids+ Glycerol,Lipofundin 10% 250mL,NUTR,In parenteral nutrition for energy & essential fatty acids.,Disturbances in fat metabolism; ketoacidosis¡A hypoxia¡A thromboembolism & acute shock states.,Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea¡A cyanosis¡A allergic reactions¡A hyperlipaemia¡A hypercoagulability¡A nausea¡A vomiting¡A headache¡A flushing¡A hyperthermia¡A sweating¡A chills¡A sleepiness¡A chest and back pain. Delayed Reactions: Hepatomegaly¡A jaundice due to central lobular cholestasis¡A splenomegaly¡A thrombocytopenia¡A leucopenia¡A transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system¡A the so-called "IV Fat Pigment"¡A has also been reported. The cause and the significance of this phenomenon are unknown.,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Dosage Adult: 0.7-1.5g lipids/kg body weight/day¡A maximum: 2g lipids/kg body weight/day. For home TPN apply>6 months or Short Bowel Syndrome: < 1g lipids/kg body weight/day. Children and adolescents: 2-3g lipids/kg body weight/day. Preterm neonatal infants¡A term newborn infants¡A infants and toddlers: <3g lipids/kg body weight/day. (Maximum: 4g lipids/kg body weight/day). Maximum infusion rate Adults: Up to 0.15 g lipids/kg body weight/hr. Children and adolescents: Up to 0.13 g lipids/kg body weight/hr. Preterm neonatal infants¡A term newborn infants¡A infants and toddlers: Up to 0.17 g lipids/kg body weight/hr.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] µ¹ÃÄ´Á¶¡­Y¦¨¤H¦å²M¤T»Ä¥Ìªo¯×¿@«×¶W¹L4.6 mmol/L (407.1 mg/dL) «ØÄ³­°§C¿éª`³t²v¡A¶W¹L11.4 mmol/L (1008.9 mg/dL) °±¤î¿éª`¡C­YÀ¦¨à¦å²M¤T»Ä¥Ìªo¯×¿@«×¶W¹L2.8 mmol/L (247.8 mg/dL) À³¦Ò¼{­°§C¾¯¶q¡A¦~ÄÖ¸û¤j¨àµ£¦å²M¤T»Ä¥Ìªo¯×¿@«×¶W¹L4.5 mmol/L (398.2 mg/dL) À³¦Ò¼{­°§C¾¯¶q¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,¿éª`«e15¤ÀÄÁ¡A¿éª`³t²v: 0.5 - 1 mL/kg/hr¡A³Ì¤j¿éª`³t²v: 1.5 mL/kg/hr,1. ¥»¯×ªÕ¨Å¾¯¥i¸g¥Ñ¶gÃäÀR¯ß©Î¤¤¥¡ÀR¯ß¾ÉºÞ¿éª`¡A­Y¨Ï¥Î§t¹LÂo¾¹¤§¿éª`®M¡A¥²¶·¿ï¾Ü¾A¦X¯×ªÕ¨Å¾¯ªÌ¡C 2. ¯×ªÕ¨Å¾¯À³¥HºC³t¿éª`¬°­ì«h¡A¤×¨ä¿éª`¶}©lªº¤Q¤­¤ÀÄÁ¡A¨C¤p®É¨C¤½¤çÅé­«0.5-1mL¡C 3. ³Ì¤j¿éª`³t«×¨C¤p®É¨C¤½¤çÅé­«1.5mL¡C
ILIS,Cephradine,Licef-A 1gm inj,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(A035929209) Infection of the respiratory tract¡A GUT¡A skin & skin structure¡A bone & joints; septicemia. °Æ§@¥Î:GI disturbances¡A hypersensitivity reactions. ¸T§Ò:Hypersensitivity to cephalosporins.,,RT,Adult: 0.5-1 g q4-6h¡A (max. 8 g/day). Child over 1 yr: 50-100 mg/kg/day in 4 divided doses; max. daily dose should not exceed the recommended adult dose.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡C
IMAR5,Bupivacaine,Marcaine 0.5% inj 100mg/20mL,ZANE,,¾AÀ³¯g:¬°§½³¡³Â¾K¾¯(B017201238),,RT,Marcaine: Caudal¡A epidural or peripheral nerve block: 25-175 mg (5-35 ml)as a 0.5% soln¡A repeated q3h as needed¡A (max. 175 mg (35 ml)/dose or 400 mg (80 ml)/day). Marcaine Spinal Heavy: Obstetrical: Vaginal delivery¡A 6 mg; cesarean section¡A 7.5-10.5 mg. Surgical: Lower extremity and perineal procedures¡A 7.5 mg; lower abdominal procedures¡A 12 mg. (Max. 400 mg/day)¡A dosing intervals>= 3 hrs.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ICEF,Cefazolin,Cefamezin inj 1gm,QANB,,G(+) (not enterococci¡A methicillin-resistant staph.)¡A G(-)(esp. E. coli¡A proteus¡A Klebsiella¡A H. influenzae¡A not indole positive proteus¡A enterobacter¡A pseudomonas¡A seriatia¡A acinetobacter).,,,Adult: Antibacterial: IM or IV 250 mg-1 g q6-8h. Acute uncomplicated UTI: IM¡A IV 1 g q12h. Pneumococcal pneumonia: IM¡A IV 500 mg q12h. Perioperative prophylaxis: IM¡A IV 1 g 30 mins-1hr prior to the start of surgery¡A 500 mg-1 g during surgery¡A and 500mg-1 g q6-8h following surgery. Infant and child: IM¡A IV 6.25-25 mg/kg q6h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ICEFO,Cefoperazone,Cefobid 0.5gm,QANB,,,,,,,,,,,,,,,,,,,
ICHL,Chlorpromazine,Chlorpromazine 50mg/2mL,CNEU,,¾AÀ³¯g:ÂíÀR¡B¤î¦Rµ¥§@¥Î(N000662212),,RT,Deep IM: 10-50 mg¡A repeated 3-4 times in 24 hrs if necessary. Child over 6 months. IM: 0.5 mg/kg q6-8h as needed.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IHIK,Sodium Hyaluronate,Hikamilon Dispo syringe,CNEU,,¾AÀ³¯g:Treatment of pain in osteoarthritis in knee in patients who have failed simple analgesics (e.g. acetaminophen) & nonpharmacologic treatment. °Æ§@¥Î:Transient swelling¡A pain¡A heat & redness may occur sporadically at the injection site. ¸T§Ò:1. Hypersensitivity to the product components. 2. Infections or skin diseases at injection site.,,«Ç·Å,Inject 1 syringe once weekly for 5 weeks.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IS;,,,,,
IOVI,Choriogonadotropin alfa,Ovidrel inj 250mcg,HM,Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilisation (IVF) ¡AAnovulatory or oligo-ovulatory women,Hypothalamic & pituitary tumours; ovarian enlargement or cyst due to reasons other than polycystic ovarian disease; gynaecological haemorrhage of unknown aetiology; ovarian¡A uterine or mammary carcinoma; extrauterine pregnancy in the previous 3 months; active thromboembolic disorders; primary ovarian failure¡A sexual organ malformations incompatible with pregnancy; fibroid uterine tumours incompatible with pregnancy; postmenopausal women. Pregnancy & lactation.,Local inj site reactions¡A headache¡A fatigue¡A GI disturbances¡A mild or moderate ovarian hyperstimulation syndrome. Ectopic pregnancy¡A ovarian torsion & other complications in some patients after hCG administration. Uncommonly¡A depression¡A irritability¡A restlessness¡A diarrhoea¡A severe ovarian hyperstimulation syndrome¡A breast pain. Rarely¡A thromboembolism.,­ì¥]¸Ë«O¦s©ó2-8¢J;¦bÃÄ«~¦³®Ä´Á­­¤º¥i¥H©ñ¦b25¢J¥H¤U30¤Ñ¡A¦ý¶W¹L30¤ÑÀ³±NÃÄ«~¥á±ó,Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilisation (IVF) 250 mcg SC 24-48 hr after the last administration of an FSH or hMG prep¡A when optimal stimulation of follicular growth is achieved Anovulatory or oligo-ovulatory women 250 mcg SC 24-48 hr after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of¡A & the day after inj.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G·»¸Ñ,,,,
YMEP,Mepiform,MEPIFORM 4x30cm,ZOTH,,,,,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;SKIN;,,,,,
OPROT,Pancrelipase,Protase 280mg enteric coated,ALIM,Cystic fibrosis¡A post-pancreatectomy¡A total gastrectomy¡A or chronic pancreatitis¡A ductal obstruction from neoplasm.,Early stages of acute pancreatitis.,Nausea¡A vomiting¡A bloating¡A cramping¡A constipation or diarrhea.,25¢J¥H¤U,Adult & children >6 years: Initially 1 CAP with meals. Fibrocyst:1500-3000 USP Lipase Units/kg¡A with every meals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»·L²É½¦Ån¡AÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©ÎÀ£¸H¡CµLªk§]ªA¯f±w¥i©î½¦Ån«áªA¥Î¡C¦ý¤£¥i±N½¦Ån¤ºªº¸z·»·L²É¬ã¿i©ÎÀ£¸H¡C
YMEP5,Mepiform,Mepiform 5x7.5cm,ZOTH,,,,,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;SKIN;,,,,,
OMED4,Methylprednisolone,Mednin 4mg,HM,,¾AÀ³¯g: RA¡A acute & subacute bursitis¡A exfoliative dermatitis¡A allergic rhinitis¡A bronchial asthma¡A contact dermatitis & allergic conjunctivitis. °Æ§@¥Î:Fluid & electrolyte disturbances; muscle weakness¡A aseptic osteonecrosis¡A osteoporosis; peptic ulcer with perforation¡A hemorrhage¡A abdominal distention¡A impaired wound healing; increased intraocular pressure; Cushingoid state¡A growth suppression¡A menstrual irregularities¡A posterior subcapsular cataracts. ¸T§Ò: Systemic fungal infection; immunization. Lactation,,«Ç·Å,Should be taken with food 4-48 mg once-qid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OCLOX,Cloxacillin,Cloxacillin 250 mg,QANB,,¾AÀ³¯g: Treatment of infections due to staphylococci resistant to benzylpenicillin including skin & soft tissue infections¡A bone & joint infections¡A endocarditis¡A pneumonia¡A septicemia °Æ§@¥Î: GI disturbances¡A rash¡A urticaria¡A purpura. Rarely¡A hepatitis¡A cholestatic jaundice¡A Stevens-Johnson syndrome¡A interstitial nephritis. ¸T§Ò: Hypersensitivity; history of cloxacillin-associated jaundice/hepatic dysfunction.,,«Ç·Å,Adult 250-500 mg every 6 hr. Children over 40 kg Use adult dose¡A <40 kg 25-50 mg/kg/day in divided doses every 6 hr.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ODIF,Fluconazole,Diflucan 150mg,QANB,Dermatomycosis including tinea pedis¡A tinea corporis¡A tinea cruris¡A tinea versicolor and candidal infections.,Patients with known hypersensitivity to fluconazole or to related azole compounds.,Common: Nausea (2.3-7%)¡A Vomiting (1.7%)¡A Headache (1.9-13%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Agranulocytosis¡A Anaphylaxis¡A Seizure,30¢J¥H¤U,Adult: Cryptococcal meningitis: 400 mg on day 1¡A followed by 200 mg once daily for 10-12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of cryptococcal meningitis in patients with AIDS: 100-200 mg once daily. Oropharyngeal candidiasis: 100 mg on day 1¡A followed by 50 mg once daily for at least 2-3 weeks; 150 mg once weekly for oropharyngeal candidiasis prophylxis in patients with HIV. Esophageal candidiasis: 200 mg on day 1¡A followed by 100 mg once daily for a 2-3 weeks. Candidiasis¡A life-threatening: 400 mg on day 1¡A followed by 200-400 mg once daily for at least 4 weeks. Vaginal/vulvovaginal candidiasis: 150 mg as a single dose. Tinea corporis or cruris/Tinea pedis: 150 mg once weekly for 4 weeks. Children: 6-12 mg/kg/dose on day 1¡A followed by 3-12 mg/kg/dose once daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,PREGNANCY RECOMMENDATION: Human Data Suggest Risk (¤j©ó400 mg/day),Compatible ­÷¨Å®É¥i¨Ï¥Î,,PO;,,,,,
ODIL,Phenytoin,Dilantin 100mg,CNEU,Control of generalized tonic-clonic (grand mal) and complex partial (psychomotor¡A temporal lobe) seizures. Prevention and treatment of seizures occurring during or following neurosurgery.,Sinus bradycardia¡A sino-atrial block¡A 2nd and 3rd degree AV block or in patients with Adams-Stokes sybdrome.,GI disturbances; ataxia¡A slurred speech; diplopia¡A nystagmus and mental confusion with headache¡A dizziness¡A gingival hyperplasia¡A hirsutism¡A hyperglycemia¡A osteomalacia.,25¢J¥H¤U,Seizure¡A During and following neurosurgery; Treatment and Prophylaxis Oral: Adult: 100 mg BID or TID¡A adjusted as needed; (maximum loading dose: 1000 mg/day in 3 divided doses). Child: Initial¡A 5 mg/kg/day in 2-3 divided doses; maintenance¡A 4-8 mg/kg/day; (maximum: 300 mg/day).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,Phenytoin: Compatible¡XMaternal Benefit and Embryo¡VFetal Risk [¥é³æ] Phenytoin¥i¬ï¹L¤HÅé­L½L¡C¤w¦³«Ü¦h³ø§i«ü¥X¡AÅöíw°ü¤kªA¥Î§ÜµjÅËÃÄ»P¨ä©Ò¥Í¤p«Ä¤§°ª¥X¥Í¯Ê³´µo¥Í²v¤§¶¡¦³Ãö¡C¤Ö¼Æ¨t²Î©Ê³ø§i©Î­Ó®×³ø§i«ü¥X¡A³oºØ¬ÛÃö©Ê¥i¯à¾A¥Î©ó©Ò¦³¤wª¾§ÜµjÅËÃÄ¡C Áö¦³³ø§i«ü¥X¡A±µ¨üÃÄª«ªvÀøªºÅöíw°ü¤k©Ò¥Íªº¤p«Ä¯Ê³´µo¥Í²v¸û°ª¡A¦ý³o¨Ã¤£¨¬¥H¥R¤ÀÃÒ©ú¨ä¶¡¦³½T©wªº¦]ªGÃö«Y¡C¦b°w¹ïÃÄª«©ó¤HÅé¤¤ªº­P·î©Ê¨ú±o¥R¤À¸ê®Æ¤è­±¡A¦³©T¦³ªº¤èªk¾Ç¤Wªº°ÝÃD¡C¿ò¶Ç¦]¤l©ÎÅöíwª¬ºA¥»¨­¹ï¾É­P¥X¥Í¯Ê³´ªº¼vÅT¡A¥i¯à¤ñÃÄª«ªvÀø§ó­«­n¡Aµ´¤j¦h¼Æ¨Ï¥Î§ÜµjÅËÃÄªvÀøªº¥À¿Ë³£¯à¥Í¥X¥¿±`ªºÀ¦¨à¡C »Ýª`·Nªº¬O¡A·í¯f¤H¨Ï¥Î§ÜµjÅËÃÄ¬O¬°¤F¨¾¤î¥i¯à¦]®ñ®ð¤£¨¬¦Ó¦M¤Î¥Í©Rªº³sÄòÅöíwª¬ºA®É¡A¤£¥i°±¥Î§ÜµjÅËÃÄ¡CPhenytoin¹ï©ó¤j¹«¡B¤p¹«»P®a¨ß¨ã¦³­P·î­L©Ê¡C ¹ï¸û»´·L¥B¸û¤£±`µo§@ªº¯f¤H¡A¦p°±ÃÄ¤£·|¹ï¯f¤H²£¥ÍÄY­«¤§«Â¯Ù¡A¥i¦Ò¼{¦bÃh¥¥«e¤ÎÃh¥¥´Á¶¡°±ÃÄ¡A¦ýµLªk«OÃÒµL¥Í©R¦MÀI¤§µo§@¤£·|¦M¤Îµo¨|¤¤ªº­F­L©Î­L¨à¡C ³B¤èÂå®v¦bªvÀø©ÎÄU¾É¦³¥Í²£¥i¯à©Ê¤§Åöíw°ü¤k®É¡A»Ýµû¦ô¨Ã§iª¾¨ä­·ÀI®Ä¯q¡C À³¶È¹ï©ó¦³¥Í¨|¯à¤Oªº°ü¤k©M¥¥°ü¤§¼ç¦b®Ä¯q©úÅã¤j©ó­·ÀI®É¤~¥i¨Ï¥Îphenytoin¡C¾A·í®É¡A¦V¥¥°ü¤Î¦³¥Í¨|¯à¤Oªº°ü¤k«ØÄ³¨ä¥L´À¥NªvÀø¤è®×¡C ¦b±µ¨üphenobarbital©M/©ÎphenytoinªºÅöíw¤k©Ê¯f¤H©Ò²£¤UªºÀ¦¨à¤¤¡A¹L¥h´¿³q³ø¦b³Ìªì24¤p®É¤ºµo¥Í·s¥Í¨à¾®¦å¯Ê³´¡CVitamin K¥i¹w¨¾©ÎªvÀø¦¹ºØ±¡§Î¡A¦]¦¹«ØÄ³¦b¥À¿Ë¤À®Y«e¤Î·s¥Í¨à¥X¥Í«áµ¹¤©vitamin K¡C À³«ØÄ³©|µLÃh¥¥­p¹º¦ý¦³¥Í¨|¯à¤Oªº°ü¤k©óªvÀø´Á¶¡¨Ï¥Î¦³®ÄªºÁ×¥¥¤èªk¡CPhenytoin¥i¯à·|¾É­P²üº¸»X¿E¯ÀÃþÁ×¥¥ÃÄ(hormonal contraceptives)ªvÀø§@¥Î¥¢®Ä¡C Phenytoin¹ï©ó¤j¹«¡B¤p¹«»P®a¨ß¨ã¦³­P·î­L©Ê¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¤£«ØÄ³ªA¥Î¥»ÃÄªº°ü¤k­÷¨Å¡A¦]§C¿@«×phenytoin·|¤Àªc©ó¨Å¥Ä¤¤¡CPhenytoin¦b¨Å¥Ä¤¤ªº¿@«×¬ù¬°¬Û¹ïÀ³¥ÀÅé¦å¼ß¿@«×ªº¤T¤À¤§¤@¡C,PC;PO;WM;,,,,,
ODIM,Gestrinone,Dimetriose 2.5mg¡A 8's/box,HM,,¾AÀ³¯g: ¥Dªv¤l®c¤º½¤²§¦ìEndometriosis(B021526100) °Æ§@¥Î: Spotting¡A mild acne¡A oily skin¡A fluid retention¡A weight gain; hirsutism¡A voice changes. Transient increases in liver transaminases¡A headache¡A GI disturbances¡A libido changes¡A hot flushes¡A breast size reduction¡A nervousness & depression¡A cramp & appetite changes¡A arthralgia & isolated cases of benign intra-cranial hypertension. ¸T§Ò: Pregnancy¡A lactation; severe cardiac¡A renal or hepatic insufficiency; metabolic &/or vascular disorders during previous oestrogen &/or progestogen therapy.,,«Ç·Å,2 cap/wk. Initial dose must be taken on day 1 of the menstrual cycle¡A 2nd dose on day 4. Continue treatment for 6 months.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODIV,Estradiol + Medroxyprogesterone,Divina 21's/pk,HM,,¾AÀ³¯g:°±¸g¯g­Ô¸s²üº¸»X¤§¸É¥R(B019190100),,RT,1 tab. daily in 21 days cycle.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
ODMP,Domperidone,Domperidone (D.M.P) 10mg,ALIM,,¾AÀ³¯g:¥Dªv¸z­GÄ¯°Ê²§±`¤Î­G¸zµÈ®ð(A030619100),,RT,Adult: 1-2 tab tid-qid. Child: 0.3-0.6 mg/kg tid-qid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODOG5,Sulpiride,Dogmatyl 50mg,CNEU,Treatment of psychotic disorders. Management of gastric and duodenal ulcers.,Pheochromocytoma. Acute involuntary porphyria. prolactin-dependent tumors¡A such as pituitary prolactinoma and breast cancer.,Neuroleptic malignant syndrome. Extrapyramidal symptoms¡A parkinsonism and endocrine side effects. Perspiration¡A nausea¡A dry mouth¡A lowered BP¡A agitated state¡A difficulty in falling asleep¡A sexual stimulation¡A dysopia¡A profuse salivation¡A increase in weight and allergy.,¾B¥ú±K«Ê«Ç·Å25¢J¤UÀx¦s,Adults: Schizophrenia: 300-600mg/day oral in divided doses. Adjust according to age and symptoms. maximum: 1200mg/day. Depression: 150-300mg/day oral in divided doses. Adjust according to age and symptoms. maximum: 600mg/day. Gastric ulcer: 150/day¡A in 3 divided doses. Adjust according to symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IAZA,Aztreonam,Azactam inj 1gm,QANB,,¾AÀ³¯g:UTI¡A lower respiratory tract¡A skin & soft tissue¡A intra-abdominal¡A bone & joint¡A gynecological infections¡A septicemia. °Æ§@¥Î:Thrombophlebitis¡A GI disturbances¡A haematologic disorders¡A hepatitis. Rarely¡A anaphylaxis ¸T§Ò:Hypersensitivity to £]-lactams.,,«Ç·Å,UTI 500 mg-1 g 8-12 hrly. Moderately severe systemic infection 1-2 g 8-12 hrly. Life threatening infection 2 g 6-8 hrly. Children >1 weeks 30 mg/kg/dose 6 or 8 hrly.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ODOXA,Doxazosin,Doxaben 2mg,CAVS,,I: Hypertension or Benign prostatic hyperplasia.,,,Hypertension: 1-16mg qd. or qhs. initially 1mg qhs¡A increase every1 or 2 wk of therapy to 2mg & thereafter at similar intervals to 4¡A8 & 16mg as determined by patient's response to achieve the desired BP reduction. Benign prostatic hyperplasia: Initially 1 mg once daily¡A may be increased to 2 mg & thereafter to 4 mg & 8 mg once daily. Recommened titration interval is 1-2WK.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTRAC,Mepenzolate,Trancolon 7.5mg,ALIM,,Adjunctive therapy of peptic ulcer¡A visceral spasms¡A spasmodic condition of the colon.,,,Adult: 15 mg tid ac¡A increased if needed. Child 6-12 yrs: 12.5 mg in 3-4 divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ITNL,Tinidazole,TNL inj 500mg/100mL,QANB,,Prophylaxis and treatment of infections due to anaerobes.,,,IV infusion 100 ml q8h¡A infusion rate: 5 ml/min.,,,,,,,,,,,,,,
ITPN1,TPN Solution,TPN-1 Solution,NUTR,,¾AÀ³¯g:¬°10%ÀR¯ßÀç¾i¿éª`²G(TPN0501209),,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITPN3,TPN Solution,TPN-3 Solution,NUTR,,¾AÀ³¯g:¬°30%ÀR¯ßÀç¾i¿éª`²G(TPN05032CS),,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITPNH,TPN Solution,TPN-H Solution,NUTR,,¾AÀ³¯g:¬°ÀR¯ßÀç¾i¿éª`²G(TPN0505297),,,,,,,,,,,,,,,,,
ITPNP1,TPN Solution,TPN-P1 Solution (Ped.),NUTR,,¾AÀ³¯g:¬°ÀR¯ßÀç¾i¿éª`²G(TPN0506255),,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITPNP2,TPN Solution,TPN-P2 Solution (Ped.),NUTR,,¾AÀ³¯g:¬°ÀR¯ßÀç¾i¿éª`²G(TPN0507255),,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITPNP3,TPN Solution,TPN-P3 Solution (Ped.),NUTR,,¾AÀ³¯g:¬°ÀR¯ßÀç¾i¿éª`²G(TPN0508255),,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITPNR,TPN Solution,TPN-R Solution,NUTR,,¾AÀ³¯g:¬°ÀR¯ßÀç¾i¿éª`²G(TPN05042CT),,,,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITRA,Zn + Cu + Mn + Cr + Iodide,Trace Element inj 10mL,NUTR,,¾AÀ³¯g: Supplement of trace elements¡A diluted in TPN soln. °Æ§@¥Î: Hypersensitivity reactions of iodide. ¸T§Ò: Never be injected into peripheral veins with undiluted soln¡A hypersensitivity to trace elements especially iodide.,,2-8¢J,Individualised dosage.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVA;,,,,,
ITRAD,Labetalol,Trandate °w¾¯ 25mg/5mL,CAVS,Hypertension.,2nd or 3rd degree heart block¡A cardiogenic shock¡A severe & prolonged hypotension or severe bradycardia. Hypertensive episodes after acute MI when peripheral vasoconstriction suggests low cardiac output.,Pronounced postural hypotension¡A nasal congestion. Rarely hypersensitivity¡A rash¡A pruritus¡A angioedema & dyspnea; raised liver function tests¡A jaundice¡A hepatitis & hepatitis necrosis; bradycardia¡A heart block. Cardiovascular: Orthostatic hypotension (1%¡A oral ; 58%¡A IV ) Dermatologic: Has tingling sensation (7% .) Gastrointestinal: Nausea (14% ) Neurologic: Dizziness (9% to 20% ) Respiratory: Nasal congestion (3% ) Other: Fatigue (11% ),30¢J¥H¤UÁ×¥ú,IV bolus: Given 50 mg over 1 minute and may repeat every 5 minutes until desired blood pressure is achieved or up to a total maximum of 200 mg. IV infusion: Diluted with saline or 5% Dextrose solution to 1 mg/mL¡A administered 2 mg/minute initially. Gestational hypertension: Initial¡A 20mg/hour as an IV infusion¡A then double the dose in every 30 minutes until desired blood pressure is achieved or up to 160mg/hours. May give higher dosage when necessary. Blood pressure management in acute myocardial infarction: Initially give 15 mg/hour via infusion then increase gradually to maximum 120 mg/hour adjusted by blood pressure. Hypertension due to other causes: Initially give 2 mg/minute via infusion then adjust infusion rate to blood pressure response. The effective dose usually around 50-200 mg. Higher dosage may be required in particular patients¡A especially with pheochromocytoma. The infusion rate can be adjusted by the doctor according to the reaction. Blood pressure management in operative procedure: Initially IV 10-20 mg¡A add supplemental dose 5-10 mg every 5 minutes until target blood pressure is reached. (use with halothane) Patients with contraindications for halothane usually need the higher initial dose (25-30 mg).,»Ý½Õ¾ã¾¯¶q,Average required dose is 50% of usual dosing,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD2.5HS¡j¥i¿ï ¡C,Administer IV over 1 minutes,Micromedex Adult Dosing :Add 40 mL of labetalol (200 mg) to 250 mL of a compatible IV fluid for a final concentration of approximately 2 mg/3 mL. Pediatric Dosing: 1.General Dosage Information:Safety and efficacy not established in pediatric patients. 2.Hypertension: (1 year or older) (1 year or older) Infusion: 0.25 to 3 mg/kg/hour IV infusion (guideline dosage).,1. Do not dilute in 5% sodium bicarbonate. 2. Patient should remain supine during and for up to 3 hours following injection.
OINDO,Indomethacin,Indocid 25mg,CNEU,,Analgesia¡A antipyresis¡A anti-inflammatory¡A actue gout.,,,Antirheumatic and antipyretic: Oral¡A 25-50 mg bid-tid. Rectal¡A 50-100 mg qd-bid. Acute gout: 100 mg initially¡A then 50 mg tid until pain is relieved. For patent ductus arteriosus closure in neonate: Oral(via a nasogastric tube)¡A 0.2 mg/kg initially. If necessary¡A 1-2 additional doses of 0.1-0.25 mg/kg may be given at 12 hrs intervals.,,,,,,,,,,,,,,
ICIT,Thiamylal,Citosol inj 0.5gm,ZANE,,¾AÀ³¯g: Anaesth for diagnostic & surgical procedures; induction of anaesth or to supplement low potency agent °Æ§@¥Î:Induced-asthma. ¸T§Ò: Liver disease.,,«Ç·Å,IV test dose 3 mL¡A if no problems¡A then 1 mL/5 sec or by continuous infusion titrated to response.,,,,¨S¦³¸ê®Æ,,,,,,,,,,1. ¥»ÃÄ«~¬°³Â¾K»¤¾ÉÃÄ«~¡A­­¥ÑÂå®v¨Ï¥Î¡C 2. 500mg ¯»¾¯¥[¤J©Òªþ·»¸Ñ²G20 mL¡Aµ}ÄÀ«áÃÄª«¿@«× 2.5 % (¤j©ó5 % ·|¤Þ°_ÀR¯ßª¢)¡C 3. ¥»ÃÄ«~¤§³Ì¤j¶q¬°¤@¦¸ 1 gmÀR¯ß¤º§ë»P¡C
ICLA1,Cefotaxime,Claforan inj 1gm,QANB,Respiratory tract¡A ENT¡A skin & soft tissue¡A bone & joints¡A genital organs¡A abdominal infections¡A UTI; septicemia¡A endocarditis¡A meningitis.,Hypersensitivity to cephalosporins.,Thrombocytopenia¡A eosinophilia¡A leukopenia; hypersensitivity reactions; GI effects; anaphylactic shock (rare). Dermatologic: Injection site pain¡A Injection site phlebitis¡A Rash (2.2% ) Gastrointestinal: Diarrhea¡A Vomiting,25¢J¥H¤UÁ×¥ú,Adults and children > 50 kg: 1-2 g IV/IM Q8-12H; serious infection: 2 g IV Q6-8H (maximum 12 g/day); gonorrhea: 0.5-1 g IM as single dose. Children < 50 kg: 50-100 mg/kg/day IV/IM (divided Q6-12H); 150-200 mg/kg/day for severe infections. Preterm infants: 50 mg/kg/day (divided Q12H). *****NEONATE ANTIBIOTICS DOSE***** Cefotaxime (Claforan): General infection: total dose : 100-150 mg/kg/day Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 0mg/kg Q12H  Age 15-28 day 0 mg/kg Q8H Body weight 1-2kg ge<=7day 0mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H meningitis; total dose : 200 mg/kg/day ; interval ¤ñ·Ó¤W­zªí®æ©Ò¥Ü (°Ñ¦Ò°¨°º)¡C Neofax: But if Body weight <2kg Age<=7days total dose : 100-150mg/kg/day Q12-Q8H Age 8-28 days total dose: 150-200mg/kg/day Q8H-Q6H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,"IM: 4 mL D/W;IV: 10mL D/W",¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ,«ØÄ³¥H20~60¤ÀÄÁ½wºCºwª`¡C NeoFax«ØÄ³¡GFor IV push¡A a concentration of 50 to 100 mg/mL may be used. For intermittent IV infusion¡A dilute to a concentration of 10 to 40 mg/mL and infuse over 10 to 30 minutes.,1. ª`®g«e¸ß°Ý¯f±w¬O§_¦³£]-ñQÓiÃþ§Ü¥Í¯À¹L±Ó¥v¡C 2. ºÊ´úÅé·Å¡BCBC (¤×¨ä¨Ï¥Î¶W¹L10¤Ñ)¡B¨xµÇ¥\¯à¡BPT­È¡Aª`·N¬O§_µo¥Í§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 3. (IM) 1 gm/vial °®¯»¥[¤J4 mL D/Wªw»s¡C 4. (IV bolus) 1 gm/vial °®¯»¥[¤J10 mL D/Wªw»s¡A¨àµ£¨Ï¥ÎªºÃÄ²G¿@«× < 50 mg/mL¡A±Àª`¦Ü¤Ö3 ~ 5¤ÀÄÁ¡C 5. (IV infusion) 1 - 2gm °®¯»µ}ÄÀ¦¨40 ~ 100 mL¡A¥H20 ~ 60¤ÀÄÁ½wºCºwª` ¤p¨àµ¹ÃÄ«ØÄ³¡GIV push¡A200 mg/mL via central catheter and 60 mg/mL via peripheral vein over3-5 minutes. Intermittent infusion¡A10-60 mg/mL over10-30 minutes.
ICLE,Clindamycin,Cleocin inj 300mg/2mL,QANB,,,,,,,,,,,,,,,,,,,
ICOD,Codeine,Codeine phosphate inj 15mg/1mL,CNEU,,Relief of mild to moderate pain and cough.,,,Adult: Analgesia: 15-60 mg q4h. Antitussive: 10-20 mg q4-6h.(max. 120 mg ). Child:Analgesia: 3 mg/kg/day in 6 divided dose. Antitussive: 2.5-10 mg q4-6h. (max. 60 mg ).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ICODBAD,Codeine,Codeine inj 15mg/1mL´Ý¾l¾PÀì,CNEU,,,,,,,,,,,,,,,,,,,
ICOR,A.C.T.H.,Cortrosyn depot,HM,,Collagen diseases¡A chronic skin disorders¡A GI diseases¡A nephrotic syndrome¡A acute neurological conditions; palliative therapy in terminal stage of cancer; exceptional cases of asthma.,,,Adult: 0.5-1 mg 2 times/week & for acute cases 1 mg daily for 3 days. Child 6-12 yrs: 1/2 adult dose. Child < 6 yrs: 1/4 adult dose.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IBON,Clodronate,Bonefos inj 300mg/5mL,META,,¾AÀ³¯g:Treatment of osteolysis of malignant origin & malignant hypercalcaemia °Æ§@¥Î: Mild GI irritation¡A asymptomatic hypocalcemia¡A elevations of aminotransferases. Rarely¡A respiratory disorders¡A renal impairment. ¸T§Ò: Coadministration with other bisphosphonates.,,,Infusion concentrate 3-5 mg/kg by IV infusion during 3-5 consecutive days. To be given in 300-500ml normal saline(0.9%)in slow infusion(in 2-3 hr daily),,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,Slow infusion 300 mg over at least 2 hours once daily.,Multiple infusions: 300 mg over at least 2 hours once daily; continue until plasma calcium levels return to normal (usually 2 to 5 days); treatment duration should not exceed 7 days. ¤£¥i¨Ï¥Î§t¶t·»²G©Î¨â»ù¶§Â÷¤l
IDES,Deferoxamine Methansulphonate,DesFERAL inj 500mg,ZADT,Transfusional hemosiderosis especially in thalassemia major; idiopathic hemochromatosis; porphyria cutanea tarda. Acute Fe poisoning. Chronic Al overload with Al-related disease &/or encephalopathy. Test for Fe & Al overload.,Known hypersensitivity to the active substance¡A except where desensitisation proves possible.,Rarely¡A allergic skin reactions¡A anaphylactic reactions; local irritation at inj site; audiovisual disturbances¡A lens opacities; GI disturbances; leg cramps; renal or hepatic impairment; reddish brown urine discoloration; thrombocytopenia; CV & neurological disturbances.,µL¯S§O«ü¥Ü,If the patient is normotensive¡A Desferal is usually given in a single IM dose: 2 g for an adult and 1 g for a child. If the patient is hypotensive¡A the IV route is recommended. The maximum rate for administration IV is 15 mg/kg/hr and is reduced after 4-6 hrs so that the total IV dose in general does not exceed 80 mg/kg/24 hrs. In an adult patient with severe iron poisoning even infusion of 37.1 g Desferal over 52 hrs has been tolerated without apparent unwanted effects. Therapy should be continued until the serum iron levels are less than the total iron-binding capacity.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;SC;,»Ý¥ý¥H5mlª`®g¥Î¤ôµ}ÄÀ¦¨10% Desferal¡A¤è¥i¨Ï¥Î¡C,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,ª`®g³t²v < 15mg/kg/hr,1.­­¥Î5mLª`®g¥Î¤ô·»¸Ñ°®¯»¡A ¤£¥i¥Î 0.9% N/S§@¬°°®¯»ÃÄ¾¯¤§·»¾¯ 2.·»¸Ñ«á¥i¥Î0.9% N/S°µ¶i¤@¨Bªºµ}ÄÀ
LHAL,Haloperidol,Haldol drops 2mg/mL¡A 15 mL,CNEU,,¾AÀ³¯g:äú¤ß¹Ã¦R©Îºë¯«»ÙÃª¤§ªvÀø(B019337135),,,Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially¡A adjusted as needed. Child: 3-12 yrs¡A 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LKEF,Cefaclor,Keflor syr 25mg/mL¡A 60mL,QANB,,Active against some beta-lactamase producing Haemophilus influenza.,,,Adult: 250-500 mg q8h¡A (max. 4 g/day). Child: 6.7-13.4 mg/kg q8h¡A (max. 1 g/day).,,,,¥i¯à¦w¥þ,,,,,,,,,,
LKI,Potassium Iodide,3% KI solution,ERSP,,¾AÀ³¯g: Pre-op reduction of the vascularity of the thyroid gland¡A Thyrotoxicosis¡A Cutaneous or lymphocutaneous sporotrichosis¡A Cough. °Æ§@¥Î: Hypersensitivity reactions¡A gastric irritation¡A diarrhoea. Iodism (large doses). Potentially Fatal: Periarteritis. ¸T§Ò: Hypersensitivity. Acute bronchitis.,,«Ç·Å,Pre-op reduction of the vascularity of the thyroid gland: 250 mg 3 times/day for 10-14 days pre-op. Thyrotoxicosis: 500 mg 4 hrly. Given 1 hr after an antithyroid agent. Cutaneous or lymphocutaneous sporotrichosis: As 1 g/mL soln: 1 mL 3 times/day. Duration: >=1 mth after the disappearance or stabilisation of the lesions. Cough 300-650 mg 3-4 times/day.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IMAG2,Magnesium Sulfate,Mg Sulfate inj 10%¡A 200mL,NUTR,Hypomagnesemia; emergency treatment of life-threatening arrhythmias; prevention of recurrent seizures in eclampsia or pre-eclampsia.,Patients with heart block¡A myocardial damage or severe renal impairment.,Hypermagnesaemia characterized by loss of tendon reflexes & respiratory depression¡A flushing¡A thirst¡A hypotension¡A drowsiness¡A nausea¡A vomiting¡A confusion¡A muscle weakness¡A cardiac arrhythmias¡A coma & cardiac arrest.,«Ç·Å,Each mL contains: 0.1g magnesium sulfate salt=0.81mEq of elemental magnesium=0.405 mmol of elemental magnesium. Eclampsia¡BPreeclampsia: 1-10gm/day IV or IM¡A Initial 4 gm and follow with 5mL (0.5gm) every half hour. Hypomagnesemia: only for TPN¡A not to injection via peripheral intravenous directly. [UpToDate 20210731] Eclampsia/preeclampsia¡A seizure prophylaxis and treatment: IV: Initial: 4 to 6 g loading dose over 15 to 30 minutes at onset of labor or induction/cesarean delivery¡A followed by 1 to 2 g/hour continuous infusion for at least 24 hours after delivery; maximum infusion rate: 3 g/hour. If seizure occurs while receiving magnesium¡A an additional bolus of 2 to 4 g may be administered over ?5 minutes with frequent monitoring for toxicity (ACOG 2020; Eclampsia Trial Collaborative Group 1995; Kraft 2005; Norwitz 2020). IM (50% concentration): Initial: 10 g loading dose administered as 5 g in each buttock at onset of labor or induction/cesarean delivery¡A followed by 5 g every 4 hours for at least 24 hours after delivery. Note: Use IM route when unable to establish venous access (ACOG 2020; Altman 2002; Norwitz 2020).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IH;IM;IVD;IVP;IVPUSH;,D5W¡A N/S¡A L/R,,¿éª`³t²v: < 1.5 mL/min¡ASevere hypomagnesemia (<1 mg/dL) with polymorphic VT (including torsade de pointes): IV push 1 to 2 g (10-20 mL),¿éª`³t²v: < 1.5 mL/min,1.¦³µÇ¥\¯à»Ù®`¤§±wªÌ¡F°ªÁâ¦å¯g±wªÌ¡F¸z¤º¦³±H¥ÍÂÎ¤§¤p«Ä±wªÌ¤Î¦³¤ßÅ¦¯e¯f±wªÌ¥²¶·¼f·V§ë»P¡A¥H§K³y¦¨¦MÀI¡C 2.§³®W°ü§ë»P®É¡A¥Ñ©ó²¸»ÄÁâ«Ü®e©ö³q¹L­L½L¡A´¿¸g¦³¤Þ°_·¥¤Ö¼Æ·s¥Í¨à¤§°ªÁâ¦å¯g¡A¬GÀ³¤p¤ß§ë»P¡C 3.¥»¾¯»P§t¦³ÁDÓi¾¯¡BÆP©ÊºÒ»ÄÆQ¡BºÒ»Ä²BÆQ¡B°s¥Û»ÄÆQ¡B¥i·»©ÊÁC»ÄÆQ¡B¯~»ÄÆQ¡B·Í¤Æ¹[¡B·Í¤Æ»Ïµ¥»s¾¯¤@°_²V¦X¨Ï¥Î®É·|¦³¨I¾ý²£¥Í¡A°t¦X®É¥²¶·ª`·N¡C 4.¥»¾¯­Y»P¨ä¥L¥þÀR¯ßÀç¾i¿éª`²G½Õ°t²V¦X«á¡A½Ð¾¨³t¨Ï¥Î¡C 5.²¸»ÄÁâ¤¤¬r®É±`¤Þ°_©I§l°±¤î¡AÀ³ÀH®Éª`·N¦å¤¤¿@«×¨Ãµ¹¤©¶t¾¯ª`®g¸Ñ¬r¡C
IINF6,DTaP-IPV-HIB-HBV,INFANRIX Hexa (¤»¦X¤@¬Ì­]) 0.5 mL/dose,HIMM,,¾AÀ³¯g:Primary immunisation against diphtheria¡A tetanus¡A pertussis¡A hepatitis B¡A poliomyelitis & Haemophilus influenzae type b in infants from the age of 6 week & in infants who received a 1st dose of hepatitis B vaccine at birth. °Æ§@¥Î:Pain¡A redness¡A swelling¡A loss of appetite¡A fever¡A drowsiness¡A irritability. ¸T§Ò: Hypersensitivity. Encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine.,,2-8¢J,Deep IM inj Primary immunisation: 3 doses of 0.5 mL with an interval of at least 1 mth between doses. If it is intended to administer according to the EPI schedule (Expanded Program on Immunisation: 6¡A 10¡A 14 weeks)¡A then the vaccinee must receive a dose of hepatitis B vaccine at birth. Booster dose at 15-18 months.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OBET,Betahistine,Betaserc 8mg,CNEU,,Meniere's disease & Meniere-like syndrome & peripheral vertigo.,,,1 or 2 tab tid .,,,,,,,,,,,,,,
OBRI2,Terbutaline,Bricanyl 2.5mg,ERSP,,Bronchial asthma¡A bronchitis¡A emphysema.,,,Oral: Adult: 5 mg tid¡A Child 12-15 yrs: 2.5 mg tid. Nebulizing soln: Adult & child over 20 kg: 5 mg¡A Child under 20 kg: 2.5 mg¡A qid. Turbuhaler: Adult & childn > 12yr: 1 inhalation 6 hrly¡A may be increased to 3 inhalations. Max: 12 inhalation/24 hr. Childn 5-12 yr 1 inhalation 6 hrly¡A may be increased to 2 inhalation to 2 inhalations. Max: 8 inhalation/24 hr.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OADA3,Nifedipine,Adalat OROS 30mg,CAVS,,¾AÀ³¯g: Hypertension¡A chronic stable angina pectoris °Æ§@¥Î: Initially mild & transient vasodilatation¡A hypotension¡A rarely GI¡A skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established¡A discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia¡A gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )¡A Palpitations (up to 7% )¡A Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )¡A Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough¡A Dyspnea ¸T§Ò: CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,,«Ç·Å,30-60 mg once daily. Max 120 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OATI5,Lorazepam,Ativan 0.5mg,CNEU,Relief of anxiety. Insomnia due to anxiety or transient situational stress. Pre-surgical medication.,Sleep apnoea¡A severe respiratory insufficiency. Pregnancy¡A lactation.,Daytime drowsiness¡A dizziness¡A muscle weakness¡A ataxia¡A confusion¡A depression¡A appetite changes¡A headache¡A sleep disturbance¡A agitation¡A dermatological symptoms¡A libido changes¡A decreased alertness¡A numbed emotions¡A eye function disturbance¡A GI symptoms¡A blood dyscrasias¡A elevated liver enzymes. Paradoxical reactions eg stimulation & rage (rare). Hypotension. Neurologic: Asthenia (4.2% )¡A Dizziness (6.9% )¡A Sedated (15.9% )¡A Unsteadiness present (3.4% )¡A Vertigo Psychiatric: Depression,25¢J¥H¤UÁ×¥ú¥BÁ×¼ö,Anxiety:1-3mg/day in 2~3 divided doses. Insomnia:2-4mg HS. Elderly or frail patients:1-2mg in divided doses. Medication before surgery:2-4mg one or two hours before surgery¡A or the night before surgery.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible1 1 Potential toxicity if combined with other CNS depressants.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OCIP,Citalopram,Cipram 20mg,CNEU,,Depression. Panic disorders.,,,Initially 20mg once a day. Max: 60mg daily. Elderly > 65 yr 20¡Ag daily¡A increased to max of 40mg qd.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTRAZ,Trazodone,Mesyrel 50mg,CNEU,Depression.,Serious hepatic impairment.,Dry mouth¡A constipation¡A nausea & vomiting¡A blurred vision¡A fatigue¡A restlessness¡A dizziness¡A hypotension. Gastrointestinal: Constipation (7% to 8% )¡A Diarrhea (up to 9% )¡A Nausea (21% )¡A Vomiting (at least 1% )¡A Xerostomia (14% to 33.8% ) Musculoskeletal: Backache (5% ) Neurologic: Confusion (up to 5.7% )¡A Dizziness (25% )¡A Headache (9.9% to 33% )¡A Insomnia (6.4% to 9.9% )¡A Somnolence (23.9% to 46% ) Ophthalmic: Blurred vision (5% to 14.7% ) Psychiatric: Dream disorder (up to 5.1% )¡A Feeling nervous (6.4% to 14.8% ) Other: Fatigue (5.7% to 15% ),25¢J¥H¤U,Initial dose: 150 mg/day. Dose may be gradually increased by 50mg/day at adjustment interval of 3-4 days. maximum dose(in divided doses): Out-patient 400 mg/day¡A in-patient 600 mg/day.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]ÄY­«¨x¥\¯à»ÙÃª¤§¯f¤H¬°¸T§Ò¡C,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ñ©ó¯Ê¥F¸gÅç¡A¥»«~¤£±ÀÂË¨Ï¥Î¦bÃh¥¥°ü¤k¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ñ©ó¯Ê¥F¸gÅç¡A¥»«~¤£±ÀÂË¨Ï¥Î¦b­÷¨Å¤¤°ü¤k¡C,PC;PO;WM;,,,,,
OTRE4,Pentoxifylline,Trental 400mg,CAVS,,¾AÀ³¯g:¥½±é¦åºÞ´`Àô»ÙÃª(A028470100) CI: Severe cerebral hemorrhage; recent MI; massive retinal hemorrhage.,,RT,Cerebrovascular disease:Initial¡A 200 mg tid; maintenance¡A 100 mg tid¡A pc. Peripheral vascular disorders: Initial 400 mg tid; maintenance 400 mg bid¡A pc; swallowed whole.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTRYN,Amitriptyline,Trynol 10mg,CNEU,Endogenic depression¡A manic depressive psychosis¡A involution melancholia¡A climacteric & reactive melancholia¡A melancholia senilis¡A nervous depression¡A depressive state¡A depression due to neurasthenia & psychosis.,Concomitant use with MAOI. Immediate recovery phase after MI¡A heart block. Mania.,Common: Weight gain¡A Constipation¡A Xerostomia¡A Dizziness¡A Extrapyramidal movements¡A Headache¡A Somnolence¡A Blurred vision Serious: Atrioventricular conduction disorder¡A Cardiac dysrhythmia¡A Electrocardiogram abnormal¡A Heart block¡A Myocardial infarction¡A Prolonged QT interval¡A Sudden cardiac death¡A Bone marrow depression¡A Cholestasis¡A Hepatitis¡A Cerebrovascular accident¡A Coma¡A Seizure¡A Depression¡A Worsening¡A Hypomania¡A Mania¡A Suicidal thoughts,³±²D(15-30¢J) °®Àêªººò±K®e¾¹¡AÁ×¥ú«O¦s,Adults: Outpatient initial dose: 75mg/day in divided doses. If necessary¡A the dose can be gradually increased to 150mg/day. Inpatient initial dose: 100mg/day. If necessary¡A the dose can be gradually increased to 200-300mg/day. The elderly: 50mg/day in divided doses. Single dose should be at night or before bed. Maintenance dose: 50-100mg/day Children with enuresis: under 6 years old:10mg HS 6-10 years old: 10-20mg/day 11-16 years old: 25-50mg/day,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OUCE,Cefadroxil,Ucefa 500mg,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(A025083100),,RT,Adult: 1-2 g/day in 1-2 divided doses¡A (max. 6 g/day). Child: 15 mg/kg q12h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OUROC,Potassium Citrate,Urocit K 5meq,SGU,,Renal tubular acidosis (RTA) with calcium stones¡A hypocitraturic calcium oxalate nephrolithiasis of any etiology¡A and uric acid lithiasis with or without calcium stones.,,,Mild to moderate hypocitraturia: 2 tab tid. Do not exceed 100 mEq/day. Severe hypocitraturia: 4 tab tid or 3 tab qid with meals.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OUROP,Phenazopyridine,Uroprin 100mg,SGU,,¾AÀ³¯g: Symptomatic relief of pain¡A burning and urinary urgency and/or frequency caused by irritation of the lower urinary tract mucosa. °Æ§@¥Î: GI disturbances¡A headache; rash; hepatotoxicity; haemolytic anaemia¡A methaemoglobinaemia; discolouration of urine and other body fluids; staining of contact lens; crystal deposits in urinary tract. Potentially Fatal: Acute renal failure. Common: Neurologic - Headache Serious: Hematologic: Hemolytic anemia Hepatic: Hepatotoxicity Immunologic: Anaphylactoid reaction Renal: Nephrotoxicity ¸T§Ò: Hypersensitivity to phenazopyridine products¡Arenal insufficiency.,,«Ç·Å,Urinary analgesic: Adult: 200 mg tid¡A pc. Child: 4 mg/kg tid. - Micromedex 2.0 ¡½ Dysuria¡A Symptomatic relief: 200 mg ORALLY 3 times a day after meals; use should not exceed 2 days when used concomitantly with an antibiotic ¡½ renal impairment: mild renal failure (GFR greater than 50 mL/min)¡A increase dosing interval to every 8 to 16 hours; do not use if GFR less than 50 mL/min ¡½ geriatrics: increased risk of accumulation and toxicity; age-related renal function impairment,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Infant risk cannot be ruled out,,,,,,
OURS,Ursodeoxycholic Acid,Ursolic tab 100 mg,ALIM,,Dissolution of radiolucent cholesterol gallstones.,,,8-10 mg/kg/day in 2-3 divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OVB1,Thiamine,Vitamin B1 100mg,NUTR,,Vit. B1 deficiency or beriberi disease.,,,Oral¡A 10 mg tid.,,,,¦w¥þ,,,,,,,,,,
OVC,Ascorbic Acid,Vitamin C 200mg,NUTR,,¾AÀ³¯g: Prevention & treatment of vit C deficiency.,,«Ç·Å,Usual dose: 40-1000 mg/day.,,,,¦w¥þ,,,,,,,,,,
EGENV,Gentian Violet,Gentian violet soln,TDER,,Skin disinfection.,,RT,Apply directly or on a dressing as often as needed.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OJOL,Iodized Lecithin,Jolethin 0.75mg (Iodine 0.05mg),META,,¾AÀ³¯g: Pre-op management of hyperthyroidism. °Æ§@¥Î: Hypersensitivity reaction.,,«Ç·Å,Adult 6-12 tab daily. Children 1-6 tab daily.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OJUM,Selegiline,Jumexal 5mg,CNEU,,¾AÀ³¯g:»²§UªvÀø©¬ª÷´Ë¤ó¯g(B021941100),,RT,5 ~ 10 mg. ( max: 10 mg/day ),,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OKAY,Sodium polystyrene sulfonate,Resonium-A powder 5gm/PK,ZADT,,¾AÀ³¯g: Hyperkalemia. °Æ§@¥Î: Gastric irritation¡A anorexia¡A nausea¡A vomiting¡A constipation¡A occasional diarrhea; hypokalemia¡A hypocalcemia¡A Na retention. ¸T§Ò: Patients with hypokalemia or those who are hypersensitive to Resonium-A.,,«Ç·Å,Adult: 15 g ORALLY 1 to 4 times daily as a slurry in water or syrup. Or 30 to 50 g RECTALLY every 6 hr as a warm emulsion in 100 mL aqueous vehicle (sorbitol)¡A retain 30-60 min and follow with a cleansing enema. Smaller children & infant: Use lower dose at a rate of 1 g/kg body wt.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OKEF,Cephalexin,Keflex 250mg,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(B023139100)(N003905100) G(+) (not enterococci¡A variable against beta-lactamase + staph. & Neissria¡A not methicillin-resistant staphylococcus aureus) G(-)(urinary infections due to most E. coli¡A Pr. mirabilis¡A & some klebsiella¡A variable against samonella and shigella¡A not enterobacter¡A pseudomonas¡A acinetobacter),,RT,Adult: 250 mg q6h¡A (max. 4g/day). Child: 6.25-12.5 mg/kg q6h¡A up to 25 mg/kg q6h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OKLE,Polyethylene Glycol,Klean-Prep powder,ALIM,,¾AÀ³¯g: Bowel prep before colonoscopy¡A colonic surgery¡A radiological exam & other related procedures. °Æ§@¥Î: Nausea¡A bloatedness¡A abdominal pain¡A vomiting. Rarely rectal irritation. ¸T§Ò: GI obstruction or perforation¡A ileus¡A gastric retention¡A acute intestinal or gastric ulceration¡A toxic colitis or megacolon.,,«Ç·Å,Adult including elderly & renal insufficiency patient 1 sachet In 1 L water . 250ml to be drunk rapidly every 10-15 mins until all soln has been consumed. Repeat procedure with 2-4 sachets or until the rectal effuent is clear. ¥ÎÃÄ«e2¤p®É¥H¬yÅé­¹ª«¬°¥D,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OKLI,Estradiol 2 mg/tab + Norethisterone 1mg/tab,Kliogest (28tab/box),HM,,,,,,,,,,,,,,,,,,,
OKNO,Piracetam,Knowful 400mg,CNEU,,¾AÀ³¯g:¬°¸£¥NÁÂ§ïµ½¾¯(A017508100) CI: Severe renal insufficiency¡A creatinine clearance < 20 ml/min.,,RT,Initial¡A 800 mg tid; maintenance¡A 400 mg tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OSUR2,Sulpiride,Surin 200mg,CNEU,,Acute or chronic schizophrenia.,,,Neurosis¡A migraine¡A function intestinal spasm: 100-200 mg/day. Gastric and duodenal ulcers:150-300 mg/day. Anxiety with depression: 150-300mg/day in divided doses¡A up to 600mg/day. Psychotic disorder: Adult: initially¡A 200-400mg bid; maintenance¡A 600-1200mg/day in 2-3 doses; max. 1200mg bid. Child: 3-5mg/kg/day.,,,,,,,,,,,,,,
LLUG,Strong Iodine Solution,Lugol's soln 10%,META,,Thyroid disorder due to iodine deficiency.,,,0.1-0.3 ml tid,,,,ºÉ¶qÁ×§K,,,,,,,,,,
LMAC,Ibuprofen,Mac safe susp 60mL,CNEU,,,,,,,,,,,,,,,,,,,
LMAG,Magnesium Citrate,Magvac solution 250mL,ALIM,,,,,,,,,,,,,,,,,,,
LMEP6,Procaterol,Meptin liquid 5mcg/mL¡A 60mL,ERSP,Bronchial asthma¡A chronic bronchitis & pulmonary emphysema.,Hypersensitivity to any component of the formulation.,Infrequent palpitations & tremors.,30¢J¥H¤UÁ×¥ú,Adult: 10 mL HS or 10 mL BID (in the morning and bedtime). Age >6 years: 5 mL HS or 5 mL BID (in the morning and bedtime). Age <6 years 0.25 mL/kg BID (in the morning and bedtime) or TID (morning¡A evening and bedtime.),µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
LOPV,Poliovirus Vaccine,¨F»«¬Ì­](§K¶O),HIMM,,¾AÀ³¯g: Active immunization against poliomyelitis. °Æ§@¥Î: Rarely¡A allergic & anaphylactic reactions & vaccine-associated poliomyelitis. ¸T§Ò: Immunosuppressed & immunodeficient patients; during acute feverish illnesses¡A hypersensitivity to neomycin. Vomiting & diarrhea. Debilitated states.,,§N­á,3 oral doses¡A (1 dose=2 drops). Separated by 2 months. Oral¡A 0.5 ml/dose. Primary immunization: 3 doses given at 8 wks intervals and a reinforcing 4th dose given 1 yr later. Booster dose: Given at 4-6 yrs.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
LPEA,Triprolidine + Pseudoephedrine,Peace syrup 60mL (0.5+6 mg/mL),HIMM,Nasal congestion¡A allergic rhinitis.,Hypersensitivity to any component of the formulation.,Insomnia.,25¢J¥H¤UÁ×¥ú,TID-QID¡A Adult and children >12 years 10 mL¡A Children 6-12 years 5 mL¡A < 6 years as doctors' order.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,Triprolidine- Compatible Pseudoephedrine Human Data Suggest Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Triprolidine- Limited Human Data¡XProbably Compatible Pseudoephedrine -Limited Human Data¡XProbably Compatible,AC;AC15;PC;PO;WM;,,,,,
ODILA,Carvedilol,Dilatrend 25mg,CAVS,Hypertention¡A congestive heart failure.,Hypersensitivity to any component of the formulation.,Dizziness¡A headaches¡A fatigue¡A bradycardia¡A postural hypotension¡A hypotension¡A GI disturbances¡A flu-like symptoms¡A respiratory effects. Cardiovascular: Bradyarrhythmia (3% to 10% )¡A Hypotension (1.8% to 20.2% )¡A Peripheral edema (1% to 7% ) Endocrine metabolic: Abnormal weight gain (10% to 12% )¡A Hyperglycemia (5% to 12% ) Gastrointestinal: Diarrhea (2% to 12% ) Neurologic: Dizziness (6% to 33% ) Reproductive: Erectile dysfunction (13.5% ) Other: Fatigue (24% ) CI: Decompensated heart failure requiring IV inotropic support; asthma; COPD with bronchospastic component; clinically manifested liver dysfunction; 2nd & 3rd degree AV block; severe bradycardia; cardiogenic shock; sick sinus syndrome; severe hypotension.,30¢J¥H¤UÁ×¥ú,Essential hypertension: Initially 12.5mg QD for 2 days¡A then 25 mg QD¡A and over the interval of 2 weeks to maximum 50 mg QD (may divide to 2 doses). Symptomatic¡A stable¡A chronic heart failure: Initially 3.125mg BID for 2 weeks¡A then increase to 6.25 mg¡A 12.5 mg¡A and 25 mg BID over successive intervals of at least 2 weeks if the initial dose is well-tolerated titration. Sever chronic heart failure and mild to moderate chronic heart failure < 85 kg: Maximum 25 mg BID. Mild to moderate chronic heart failure > 85 kg: Maximum 50mg BID.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¯f¤H¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] °Êª«¬ã¨sÅã¥Ü¨ã¦³¥Í´Þ¬r©Ê¡C¥Ø«e¤£²M·¡¨ä¹ï¤HÃþªº¼ç¦b­·ÀI¡Cbeta-ªýÂ_¾¯´î¤Ö­L½LÄé¬y(placental perfusion)¡A¨ä¥i¯à¾É­P¤l®c¤º¦º­L¡B©M¥¼¦¨¼ôªº¤Î¦­²£¨àªº¤À®Y¡C¥t¥~¡A¤£¨}§@¥Î(¤×¨ä¬O¦å¿}¹L§C©M¤ß¸õ¹LºC)¥i¯àµo¥Í¦b­L¨à©M·s¥Í¨à¡C¦b²£«á´Á¶¡¤ºªº·s¥Í¨à¡A¤ßÅ¦©MªÍÅ¦¨Öµo¯gªº­·ÀI¥i¯à·|¼W¥[¡C°Êª«¬ã¨s¤¤µLÃÒ¾ÚÅã¥Ücarvedilol¦³¥ô¦ó­P·î­L§@¥Î¡C ¥¥°üªA¥Îcarvedilol©|µL¨¬°÷ªºÁ{§É¸gÅç¡C Carvedilol¤£À³¦bÃh¥¥´Á¶¡¨Ï¥Î°£«D¼ç¦bªvÀø®Ä¯q¤j©ó¼ç¦b­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] °Êª«¬ã¨sÅã¥Ücarvedilol©M/©Î¨ä¥NÁÂª«·|¤Àªc©ó¤j¹«¨Å¥Ä¤¤¡C ¥Ø«e©|¥¼½T»{carvedilol·|³Q¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡C¤£¹L¡A¤j¦h¼Æªºbeta-ªýÂ_¾¯·|¶i¤J¤HÃþ¨Å¥Ä¤¤¡A¤×¨ä¬O¿Ë¯×©Ê¤Æ¦Xª«¡A¦ý¨Å¥Ä¤¤§t¶q¨ÌÃÄ¦Ó²§¡C ¦]¦¹¤£«ØÄ³©ó§ë¤©carvedilol¤§«á­÷Áý¥À¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
LPRE,Cisapride,Prepulsid susp 1mg/mL¡A 100mL,ALIM,,,,,,,,,,,,,,,,,,,
OCOUM,Warfarin,Coumadin 5 MG,HEMT,,I: Thrombolic conditions. CI: Pregnancy; haemorrhagic tendency or blood dyscrasias; recent or contemplated surgery of CNS¡A eye; traumatic surgery resulting in large open surfaces; bleeding tendencies associated with active ulceration or overt bleeding; threatened abortion; spinal puncture.,,,Initial: 40-60 mg/day. Maintenance: 2-10 mg/day,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
ODEX,Simethicone,Dexicone 40mg,ALIM,,¾AÀ³¯g: Abdominal distension caused by GI disorders. Elimination of gas in GI tract prior to radiography.,,«Ç·Å,Adult: 40 mg qid¡A Child: Individualized by physician.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OTHA,Thalidomide,Thado 50mg,HIMM,,I: Erythema nodosum leprosum.,,,D: Initial dose is 100-300 mg hs¡A max.dose is 400 mg/day.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
EPEN,NovoPen,NovoPen 3,ZOTH,,«DÃÄ«~,,RT,«DÃÄ«~,,,,,,,,,,,,,,
IIG3,Human Immunoglobulin,Human Immunoglobulin 3gm/50mL,HIMM,Replacement IgG therapy in primary immunodeficiency¡A myeloma & chronic lymphatic leukamia with severe secondary hypogammaglobulinemia & recurrent infections¡A congenital or AIDS with recurrent infections. Immunomodulatory therapy in idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery¡A allogeneic bone marrow transplantation¡A Kawasaki disease.,Hypersensitivity to human Ig.,Malaise¡A abdominal pain¡A headache¡A chest tightness¡A facial flushing or pallor¡A erythema¡A hot sensations¡A dyspnea or respiratory difficulty¡A non-urticarial skin rash¡A cutaneous vasculitis¡A pompholyx on hands/palms¡A itching¡A tissue swelling¡A change in BP¡A nausea¡A vomiting.,2-8¢J,IVD¡A Replacement therapy 0.2-0.6 g/kg/month as a single dose or 2 divided doses at fortnightly intervals. Idiopathic Thrombocytopenic Purpura (ITP) Up to max total cumulative dose of 2 g/kg over 2-5 days. Kawasaki disease 1.6-2 g/kg in divided doses over 2-5 days or 2 g/kg as single dose. Allogeneic bone marrow transplantation Initially 0.5 g/kg/week. Guillain Barre Syndrome (GBS) 0.4 g/kg/day for 5 days.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ]¥Ø«eÁÙ¨S¦³°w¹ïÃh¥¥°ü¤k¡B­÷¨Å´Á¶¡¤§¹ï·ÓÁ{§É¸ÕÅç¡A¦]¦¹¹ï¥¥°ü¡B­÷¨Å°ü¤k ¬I¥Î®É­n¯S§O¤p¤ß¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«eÁÙ¨S¦³°w¹ïÃh¥¥°ü¤k¡B­÷¨Å´Á¶¡¤§¹ï·ÓÁ{§É¸ÕÅç¡A¦]¦¹¹ï¥¥°ü¡B­÷¨Å°ü¤k ¬I¥Î®É­n¯S§O¤p¤ß¡C,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¿éª`³t²v< 4 mL/min;­è¶}©l¥H1 mL/min¡A«ùÄò15¤ÀÄÁ¥H¤W¡A¤§«á³t²v¥iº¥¼W¡A³Ì°ª 3-4 mL/min¡C,1. ¥»ª`®g²G¥i¤£µ}ÄÀª½±µÀR¯ß¿éª`¡A¤]¥i¥ÎN/S©ÎD5Wµ}ÄÀ«áª`®g¡C 2. ª`®g³t²v±q 1 mL/min¶}©l¡A«ùÄò15¤ÀÄÁ¥H¤W¡A¤§«á³t²v¥iº¥¼W¡A³Ì°ª 3-4 mL/min¡C 3. °ªÄÖ¯f¤H¤ÎµÇÅ¦¯f¯f±wÀ³¦Ò¼{¨Ï¥Î¸û§C³t²vµ¹ÃÄ¡C 4. ¦pµo²{ª`®g²G¦³²V¿B©Î¨I¾ý¡A©Î¬O´¿³Q§N­á¹L¡A¤Á¤Å¨Ï¥Î¡C
EELI,Pimecrolimus,Elidel cream 1% 15gm,TDER,Second-line therapy for the short- term & non-continuous chronic treatment of mild to moderate atopic dermatitis in non- immunocompromised adults & children > 2 years.,Hypersensitivity to pimecrolimus or to any of the excipients of Elidel.,Feeling of warmth &/or burning sensation¡A irritation¡A pruritus & erythema¡A folliculitis. Dermatologic: Sensation of burning of skin Immunologic: At risk for infection¡A Viral Neurologic: Headache (7% to 25.4% ) Other: Fever,25¢XC¥H¤U,Apply thin layer to affected area twice daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,¨´¤µElidel 1%¨Å»I¨Ï¥Î©ó¥¥°üªº¸gÅç¤´¦³­­¡C¥H°Êª«¥Ö½§¨Ï¥ÎElidel 1%¨Å»Iªº¸ÕÅç¤¤¡A¨ÃµLÅã¥ÜElidel 1%¨Å»I·|ª½±µ©Î¶¡±µ¹ïÃh¥¥¡B­F­L/­L¨àµo¨|¡B¤À®Y©Î²£«á³y¦¨¶Ë®`(½Ð¨£¡§Á{§É«eÅé¥~¸ÕÅç¤§¦w¥þ©Ê¸ê®Æ¡¨³¡¥÷)¡C ·í¨Ï¥ÎFlidel 1%¨Å»I©ó¥¥°ü®É¡A¥²¶·¤Q¤À¤p¤ß¡FµM¦Ó¡A¥Ñ©ópimecrolimus¦b§½³¡¨Ï¥Î«áªº§l¦¬©Ê·¥¤p(½Ð¨£¡§ÃÄª«°Ê¤O¾Ç¡¨³¡¥÷)¡A¦]¦¹¹ï©ó¤HÅé¥i¯àµo¥Íªº¦MÀI©Ê¦³­­¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,§½³¡¨Ï¥ÎElidel1%¨Å»I¹ï©ó­÷¨Å¤¤ªº°Êª«¸ÕÅç©|¥¼¶i¦æ¹L¡A¦]¦¹¤´¥¼ª¾¨Ï¥Îpimecrolimus«á·|¤£·|¤Àªc¦Ü¨Å¥Ä¤¤¡C¤wª¾³\¦hÃÄª«§¡·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡A¦]¦¹­÷¨Å°ü¤k¨Ï¥ÎElidel 1%¨Å»I®É¥²¶·¤Q¤À¤p¤ß¡CµM¦Ó¡A¥Ñ©ó§½³¡¨Ï¥ÎElidel 1%¨Å»I«á(½Ð¨£¡§ÃÄª«°Ê¤O¾Ç¡¨³¡¥÷) ¨ä¥D¦¨¥÷pimecrolimusªº§l¦¬²v·¥¤p¡A¹ï¤HÅé³y¦¨ªº¦MÀI©Ê¥ç¦³­­¡C ­÷¨Å°ü¤k¤£À³¨Ï¥Î©óElidel 1%¨Å»I©ó¨Å©Ð¤W¡C,EXT;SKIN;TOPI;,,,,,
IGON6,Follitropin,Gonal-F 1200iu/val,HM,,,,,,,,,,,,,,,,,,,
EGLYC,Glycerin,Glycerin liquid (mL),TDER,As a moisturizer to prevent dry skin and minor skin irritations.,Hypersensitivity to any component of the formulation.,,«Ç·Å,60 mL¡A 120 mL/BOT.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
EILO,Erythromycin,Erythromycin oph oint 0.5%¡A 3.5gm,TOPH,,¾AÀ³¯g: Treatment of bacterial infections of the eye involving the conjunctiva &/or cornea caused by susceptible organisms. °Æ§@¥Î: Rarely¡A hypersensitivity reactions¡A ocular irritation or redness. ¸T§Ò: Hypersensitivity.,,«Ç·Å,Apply up to 6 times daily.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EINT5,Sod Cromoglycate,Intal 5 inhalerªù¶E­­¤@¤ä,ERSP,,I: Prophylaxis & treatment of bronchial asthma due to allergy¡A exercise¡A cold air or chemical & occupational irritants. AR: Mild throat irritation¡A coughing & transient brochospasm. Very rarely¡A severe bronchospasm necessitating withdrowal of treatment may occur.,,,1-2 puffs qid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EINTS,Indomethacin,Intocin supp 100mg,CNEU,,¾AÀ³¯g:¸Ñ¼ö¡B®øª¢¡BÂíµh(A005949500),,RT,Antirheumatic and antipyretic: Oral¡A 25-50 mg bid-tid. Rectal¡A 50-100 mg qd-bid. Acute gout: 100 mg initially¡A then 50 mg tid until pain is relieved. For patent ductus arteriosus closure in neonate: Oral(via a nasogastric tube)¡A 0.2 mg/kg initially. If necessary¡A 1-2 additional doses of 0.1-0.25 mg/kg may be given at 12 hrs intervals.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EISA,Iodine + Salicylic Acid Alcohol,I.S.A spirit 30mL,TDER,,A keratolytics and a slight antiseptics.,,«Ç·Å,Topical use when necessary.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EISO1,Pilocarpine,Isopto carpine 1%¡A 15mL,TOPH,,¾AÀ³¯g:±±¨îºC©Ê«C¥ú²´¤§²´À£(B016354435) AR: Slight ciliary spasm¡A conjunctival vascular congestion¡A temporal or supraorbital headache¡A myopia. CI: Where constriction is undesirable eg in acute iritis¡A pupillary block glaucoma.,,RT,2 drops tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EISO4,Pilocarpine,Isopto carpine 4% 15mL,TOPH,,I: Control of intraocular pressure. AR: Slight ciliary spasm¡A conjunctival vascular congestion¡A temporal or supraorbital headache¡A myopia. CI: Where constriction is undesirable eg in acute iritis¡A pupillary block glaucoma.,,,2 drops tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EKIN,N6-furfuryladerine,Kinerase cream 0.1%,TDER,,Skin condition improvement,,,Apply to face and neck twice daily.,,,,,,,,,,,,,,
EKLA,Phenyl Mercuric Acetate,Klargine soln 20mL,TENT,,Bacteriostatic and antifungal.,,«Ç·Å,1-2 drops qd-qid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ELAT,Tetracycline,Latycin eye oint 5gm,TOPH,,I: External ocular infections such as acute¡Achronic or purulent conjunctiveitis¡A nordeolum¡A acute and chronic lepharitis¡Ablepharo-conjunctivitis¡Acorneal ulcers¡A secondary infections in patients with herpes corneae and trachoma.It is also useful for preventing infections in patients undergoing ophthalmic surgery. AR: Superinfection. CI: Photodermatosis.,,,Apply into the lower conjunctival sac every 2 hours. Treatment should be continued for 2 to 3 days after symptoms have subsided.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ELOC,Flumethasone + Salicylic Acid,Locasalen oint 5gm,TDER,,¾AÀ³¯g: Seborrheic eczema¡A contact eczema¡A atopic dermatitis¡A localized neurodermatitis¡A psoriasis vulgaris¡A lichen planus¡A hyperkeratosis of the palms & soles. °Æ§@¥Î: Mild transient burning sensation¡A itching; in isolated cases¡A mild skin atrophy; changes in skin pigmentation¡A telangiectasia¡A purpura¡A steroid acne particularly after prolonged application. ¸T§Ò: Tuberculous¡A syphilitic & fresh viral skin affections¡A vaccination reactions. Perioral dermatitis¡A acne vulgaris.,,«Ç·Å,Apply the ointment to the affected areas in a thin film once or twice daily and gently rubbed-in. An occlusive dressing may also be used.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OFLU,Trichlormethiazide,Fluitran 2mg,CAVS,As diuretics¡A antihypertensive.,Anuria¡A hypersensitivity to sulfonamides.,Arrhythmias¡A orthostatic hypotension¡A dizziness¡A headache¡A paresthesias¡A vertigo¡A xanthopsia¡A hyperglycemia¡A hyperuricemia¡A hypercalcemia¡A hypokalemia¡A hyponatremia¡A anorexia¡A cramping¡A constipation¡A diarrhea¡A gastric irritation¡A jaundice¡A pancreatitis¡A nausea & vomiting¡A glycosuria¡A muscle weakness¡A muscle spasm¡A necrotizing angiitis¡A photosensitivity¡A purpura¡A rash¡A urticaria¡A agranulocytosis¡A aplastic anemia¡A leukopenia¡A thrombocytopenia.,30¢XC¥H¤UÁ×¥ú,Antihypertensive: 2-4 mg once daily. Initial dose: 2-4 mg BID. Maintenance: 2 mg once daily. Diuretic: 4 mg once daily. Initial dose: 4 mg BID. Maintenance: 2 mg BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Chlorothiazide: Compatible [¥é³æ] §³®W«á´Á¡A¥u¦³¦b»{¬°ªvÀø®Ä¯q¤j©ó­·ÀI®É¤~¥i¥ÎÃÄ¡C´¿¦³®×¨Ò«ü¥X¡AThiazideÃþÃÄª«¥i¯à·|¨Ï·s¥Í¨à©ÎÀ¦¨à²£¥Í°ªÁx¬õ¯À¦å¯g¡B¦å¤pªO´î¤Öµ¥¡C¥t¥~¡A§Q§¿®ÄªG¥i¯à·|³y¦¨¦å¼ß¶q´î¤Ö¡B¦å²G¿@ÁY¡B¤l®c¡H­L½L¦å¬y¶q´î¤Ö¡C,Unknown ¨S¦³¸ê®Æ,Chlorothiazide: Compatible [¥é³æ] ¤£«ØÄ³­÷Áý¥À¨Å¡C´¿¦³³ø§i«ü¥X¡A¦b¤HÅé¤º¦PÃþÃÄª«·|¤Àªc¨ì¨Å¥Ä¡C,AC;AC15;PC;PO;WM;,,,,,
ISHI,Triamcinolone,Shincort 40mg/1mL,HM,,¾AÀ³¯g:¨ã§Üµoª¢§@¥Î(A011475209) ADR: Local atrophy (temporary). IA: post-inj flare¡A pigmentation changes¡A sterile abscess¡A charcot-like arthropathy. Systemically: Na and fluid retention¡A peptic ulcer with possible perforation¡A decreaswd carbohydrate tolerance¡A impaired wound healing¡A thin fragile skin¡A purpura¡A striae¡A muscle weakness¡A steroid myopathy¡A osteoporosis¡A aseptic necrosis¡A cataracts¡A increased intraocular or intracranial pressure¡A protein catabolism¡A Cushingoid state¡A growth retardation¡A aggravation of preexisting psychiatric conditions. CI: Systemic fungal infection¡A unstable or infected joints¡A lactation,,RT,Intra-articular: 2.5-15 mg. Intradermal or intralesional: less than 1 mg/site.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ORES,Testosterone,Restandol 40mg,HM,,,,,,,,,,,,,,,,,,,
EMIR,Levonorgestrel Implants,Mirena 20mcg/24hours intrauterine system,HM,Contraception¡A idiopathic menorrhagia¡A Protection from endometrial hyperplasia during ERT.,Known or suspected pregnancy; genital infection; confirmed or suspected uterine or cervical malignancy; Undiagnosed abnormal uterine bleeding; Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity; acute liver disease or liver tumor; active thrombophlebitis or thromboembolic disorder.,Menstrual changes¡A lower abdominal pain¡A acne or other skin problems¡A back pain¡A mastalgia¡A headache¡A vag discharge¡A mood changes¡A nausea¡A edema¡A weight gain¡A decreased libido¡A sweating¡A hair loss¡A greasy hair. Ectopic pregnancy¡A pelvic inflammatory disease¡A perforation of the uterine wall¡A enlarged follicles (functional ovarian cysts) may develop.,30¢J¥H¤U,1 unit inserted into the uterine cavity within 7 days of the onset of menstruation or immediately after first trimester abortion. Postpartum insertions should be postponed until 6 weeks after delivery.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,INU;IUS;,,,,,
EMYD1,Tropicamide,Mydriacyl 1% 5mL,TOPH,,I: Mydriasis and cycloplegia for diagnostic purposes. AR: Increased intraocular pressure. Psychotic reactions¡A behavioral disturbances¡A cardioresp collapse in children & some adults; transient stinging¡A dry mouth¡A blurred vision¡A photophobia with or without corneal staining¡A tachycardia¡A headache¡A parasympathetic stimulation¡A allergic reactions. CI: Primary glaucoma or a tendency toward glaucoma.,,,For refraction: 1 drop followed by a second drop 5 mins later. If examination can't be performed within 20-35 mins¡A a third drop must be instilled.,,,,,,,,,,,,,,
EULT,Sevoflurane,Ultane 250mL,ZANE,,¾AÀ³¯g: Induction & maintenance of general anesth. °Æ§@¥Î: Dose-dependent cardio-respiratory depression¡A nausea¡A vomiting¡A hypotension. ¸T§Ò: Known or suspected genetic susceptibility to malignant hyperthermia.,,15-30¢XC,Individualized dosage. Adult Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (25 years) Sevoflurane in oxygen: 2.6%¡A Sevoflurane in 65% N20/35% oxygen: 1.4% (40 years) Sevoflurane in oxygen: 2.1%¡A Sevoflurane in 65% N20/35% oxygen: 1.1% (60 years) Sevoflurane in oxygen: 1.7%¡A Sevoflurane in 65% N20/35% oxygen: 0.9% (80 years) Sevoflurane in oxygen: 1.4%¡A Sevoflurane in 65% N20/35% oxygen: 0.7% Pediatric Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (0 to 1 month old full-term neonates) Sevoflurane in oxygen: 3.3% (1 to <6 months) Sevoflurane in oxygen: 3% (6 months to <1 year) Sevoflurane in oxygen: 2.8%¡A Sevoflurane in 65% N20/35% oxygen: 2% (1 to <3 years) Sevoflurane in oxygen: 2.8%¡A Sevoflurane in 60% N20/40% oxygen: 2% (3-12 years) Sevoflurane in oxygen: 2.5%,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,1. ¥u¦³¨ü¹L¥þ¨­³Â¾K¾Þ§@°V½mªÌ¤~¥i¬I¥Îsevoflurane¡Cºû«ù®ð¹D³qºZªº³]³Æ¡B¤H¤u©I§l¾¹¡B®ñ®ðµ©¡B¤Î´`Àô´_µd¾¹¥²¶·ÀH®É³Æ¥Î¡C 2. À³ºë½T¦aª¾¹D¦Û³Â¾K´§µo¾¹ÄÀ¥Xªºsevoflurane ªº¿@«×¡C¦]¬°´§µo©Ê³Â¾K¾¯ªºª«©Ê¬Ò¤£¬Û¦P¡A¥u¥i¨Ï¥Î¯S§O¬°sevoflurane©w¶q®Õ¥¿ªº³Â¾K´§µo¾¹¡CÀ³¨Ì¾Ú¯f±wªº¤ÏÀ³¨Ó­Ó®×½Õ¾ã¥þ¨­³Â¾K¾¯ªº¨Ï¥Î¶q¡C·í³Â¾K²`«×·U²`®É¡A§C¦åÀ£©M©I§l§í¨î·|¼W¥[¡C
EURE,Urea,Urea cream 10%¡A 20gm,TDER,Ichthyosis and hyperkeratotic skin disorders.,Hypersensitivity to any component of the formulation.,Occasionally local stinging¡A pain¡A redness and itch.,25¢J¥H¤U,Apply QD-TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
EXYLS,Lidocaine,Xylocaine spray 80mg/gm,ZANE,,¾AÀ³¯g:¬°§½³¡³Â¾K¾¯(B003456353),,,Infiltration¡A caudal¡A epidural or peripheral nerve block: Up to 30 ml as a 1% soln or 15 ml as a 2% soln. Surface anesthesia: Nose¡A nasopharynx and respiratory tract: 1-5 ml of 1%-4% soln is sprayed¡A 8% spray may be needed. Mouth¡A pharynx and upper digestive tract: 5-15 ml of 2% viscous soln. Urethral catheterization: Men¡A 5-10 ml; women¡A 3-5 ml of 2% jelly.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EXYSP,Lidocaine,Xylocaine spray 10%¡A 50mL,ZANE,Local anesthesia.,Allergic history to local anesthetics of the amide class or other ingredients in the spray solution.,Local irritation¡A allergic reactions¡A acute systemic toxicity.,25¢XC¥H¤U,Each press of the plunger releases 10mg of Lidocaine. No need to dry the sprayed area before use. For mucosal surface anesthesia¡A effect lasts 10-15 minutes. Anesthesia occurs within 1-5 minutes¡A depending on the area of use. - ENT procedures: 3 sprays for maxillary sinus puncture or minor surgery. - Pleural fluid drainage: 3 sprays. - Labor and delivery: Up to 20 sprays (200mg Lidocaine) at most. - Respiratory or digestive procedures: Up to 20 sprays (200mg Lidocaine)¡A with a maximum of 400mg Lidocaine for prolonged procedures. Total dosage should not exceed 400mg when combined with other Lidocaine products. - Dental procedures: 1-5 mucosal sprays. Special Patients: Elderly¡A children above 12 years¡A acutely ill¡A or septic patients should receive appropriate doses based on their age¡A weight¡A and condition.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] °²©w¤w¦³¬Û·í¦h¤§¥¥°ü¤Î¨|ÄÖ°ü¤k¤w¨Ï¥Î¹Llidocaine¬O«Ü¦X²zªº¡C ¨´¤µ©|µL¹ï¥Í´Þ¹Lµ{·|²£¥Í©ú½TªýÃªªº³ø§i¡A¨Ò¦p·î§Îªºµo¥Í²v¨ÃµL¼W¥[¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¦p¦P¨ä¥L§½³¡³Â¾K¾¯¡ALidocaine¥i¶i¤J¥À¿Ë¤§¨Å¥Ä¡A¦ý¦b³o»ò¤pªº¾¯¶q¤U¡A ³q±`¨ÃµL¹ï·s¥Í¨à³y¦¨¼vÅTªº¦MÀI©Ê¡C,EXT;LA;SKIN;TOPI;,,,,,1. Àx¦s©ó8 ¢XC¥H¤U®É¥i¯àµo¥Í¨I¾ý¡A¥i¦b«Ç·Å¤U¦^·Å®É·»¸Ñ¡C 2. ¤£¯à±N¼Q¼L§Ëµu¡A¤£¥i­«½Æ¨Ï¥Î¼Q¼L¡A¨Ï¥Î«áÀ³¥ß§Y¥á±ó¡C
ETAR,Ofloxacin,Tarivid otic solution 0.3%¡A 5mL,TENT,Otitis media¡A otitis externa caused by ofloxacin-susceptible pathogen: Staph¡A Strep¡A Proteus sp¡A Pseudomonas aeruginosa¡A & haemophilus influenzae.,Hypersensitivity to quinolones; pregnancy and lactation; prolongation of the QT interval; uncorrected hypokalaemia.,Infrequently¡A earache¡A superinfection. Dermatologic: Pruritus¡A Rash Gastrointestinal: Diarrhea¡A Nausea (up to 3.5% )¡A Vomiting Neurologic: Dizziness (up to 8% )¡A Headache (up to 8% )¡A Insomnia (up to 13% ) Ophthalmic: Burning sensation in eye¡A Pain in eye,«Ç·Å,Otitis media¡A chronic suppurative (with perforated tympanic membranes): Otic: Instill 6-10 drops into affected ear(s) twice daily for 14 days,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AD;AS;AU;,,,,,
OMUS,Tolperisone,MusCalm S 50mg,CNEU,,¾AÀ³¯g: Spastic paralysis due to sequelae to stroke¡A cerebral palsy¡A subacute myelo-opticoneuropathy¡A spastic spinal paralysis¡A amyotrophic lateral sclerosis¡A cerebrospinal degeneration¡A multiple sclerosis¡A cervical spondylosis¡A ossification of the posterior longitudinal ligament¡A sequelae to injury¡A sequelae to operation. For improvement of increased muscular tension in cervical syndrome¡A lumbago. °Æ§@¥Î: Shock¡A hepatic disorder¡A rashes; chest distress¡A respiratory disorders; lightheadedness¡A weakness¡A lassitude¡A dizziness¡A dull headache¡A drowsiness; anorexia¡A abdominal pain¡A nausea¡A vomiting¡A diarrhea & thirst; rarely¡A constipation¡A meteorism¡A gastric oppression & pyrosis; itching¡A sensation of weakness of lower extremity.,,«Ç·Å,Adult Usually 300 mg daily in 3 divided doses.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OMYK,Metolazone,Mykrox 0.5mg,CAVS,,¾AÀ³¯g: Hypertension. °Æ§@¥Î: Dizziness¡A headache¡A muscle cramps¡A fatigue¡A joint pain¡A swelling¡A chest pain. ¸T§Ò: Anuria¡A hepatic coma or pre-coma; allergy or hypersensitivity to metolazone.,,«Ç·Å,1 tab once daily¡A usually in the morning. may be increased to 2 tab once daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OMYL,Busulphan,Myleran (Busulphan) 2mg,RACA,,,,,,,,,,,,,,,,,,,
ONAT,Indapamide,Natrilix SR 1.5mg,CAVS,Hypertension.,Hypersensitivity to sulfonamides; severe hepatic or renal failure¡A hypokalemia & hepatic encephalopathy.,Fatigue¡A orthostatic hypotension¡A hypokalemia¡A hyponatremia¡A allergic manifestations. Cardiovascular: Orthostatic hypotension¡A Vasculitis Dermatologic: Flushing¡A Hives¡A Pruritus¡A Rash Endocrine metabolic: Hyperuricemia¡A Hypochloremia (less than 5% )¡A Hypokalemia (3% to 7% )¡A Hyponatremia (less than 5% ) Neurologic: Dizziness¡A Fatigue¡A Headache¡A Paresthesia,30¢J¥H¤U,1.5 mg once daily in the morning.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä½¤¦ç¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
ONEG,Nalidixic Acid,Negram 500mg,QANB,,Acute and chronic urinary tract infection.,,,Adult: Initial¡A 1 g q6h for 1-2 wks; maintenance¡A 500 mg q6h(max. 4 g/day). Child over 3 months: Initial¡A 13.75 mg/kg q6h for 1-2 wks; maintenance¡A 8.25 mg/kg q6h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ONEO,Neomycin,Neomycin 250mg,QANB,Bowel sterilisation before surgery; to reduce the bacterial population of the colon in hepatic failure.,Intestinal obstruction; myasthenia gravis.,Vestibular & auditory damage¡A nephrotoxicity¡A GI disturbances.,25¢J¥H¤U¡AÁ×¥ú±K«Ê«O¦s,(¥é³æ) Adults: Intestinal infection: 500 mg orally Q6H. Bowel preparation¡A pre-GI surgery: 1 g orally Q6H for 1-3 days. (¼ö¯f) Hepatic encephalopathy: 500-2000 mg Q6-8H for 5-6 days; seek safer alternative for longer use.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,¥H¤WÃh¥¥¤À¯Å°Ñ¦Òmicromedex,AC;AC15;PC;PO;WM;,,,,,
ONEW,Multivitamins + Minerals + Fe,New Prenatal 30's/bot,NUTR,,¾AÀ³¯g: Nutritional supplement for vits & minerals during pregnancy & lactation.,,«Ç·Å,1 tab daily or as directed by the physician.,,,,¦w¥þ,,,,,,,,,,
IIG5,Human Immunoglobulin,Gammar-P 5gm,HIMM,,I: Primary defective antibody synthesis such as hypogammaglobulinemia or gammaglobulinemia. Unlabeled use: Bacterial infections¡A idiopathic thrombocytopenic purpura¡A Kawasaki disease. ADR: Headache¡A myalgia¡A hypotension¡A nausea¡A abdominal pain¡A chills¡A pyrexia¡A palpitation¡A edema¡A flushing¡A diaphoresis¡A rash¡A pruritus¡A wheezing are often related to infusion rate. Increases in creatinine and BUN¡A oligouria or other types of severe renal adverse reactions has been observed. CI: Isolated IgA deficiency. Allergic to Ig or human albumin.,,< 25¢XC,Primary defective antibody synthesis: 100 ~ 200 mg/kg¡A up to 400 mg/kg. To be repeated every 3 ~ 4 wk at a level titrated to the individual¡A but in case of acute illness¡A it may be given as frequently as once a week or even daily. Serious bacterial infections including sepsis: As above¡A repeated every 1-2 days if needed. Idiopathic thrombocytopenic purpura & Kawasaki disease: 0.4 g/kg/day for 5 consecutive days.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ILIP2,Soyean Oil + MCT+ Egg Yolk Phospholipids+ Glycerol,Lipofundin 20%¡A 250ml(¦¨¤H),NUTR,,¾AÀ³¯g: In parenteral nutrition for energy & essential fatty acids. °Æ§@¥Î: Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea¡A cyanosis¡A allergic reactions¡A hyperlipaemia¡A hypercoagulability¡A nausea¡A vomiting¡A headache¡A flushing¡A hyperthermia¡A sweating¡A chills¡A sleepiness¡A chest and back pain. Delayed Reactions: Hepatomegaly¡A jaundice due to central lobular cholestasis¡A splenomegaly¡A thrombocytopenia¡A leucopenia¡A transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system¡A the so-called "IV Fat Pigment"¡A has also been reported. The cause and the significance of this phenomenon are unknown. ¸T§Ò: Disturbances in fat metabolism; ketoacidosis¡A hypoxia¡A thromboembolism & acute shock states.,,«Ç·Å,Adult 1-2 g of fat/kg/day by IV infusion. Infusion rate of 1st 15 mins should not exceed 0.05-1.0 g/kg/hr. Max infusion rate up to 0.15 g/kg/hr.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IOXA,Oxaliplatin,Oxalip inj 50mg/10mL,RACA,Used in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for (1) Adjuvant therapy following complete resection of the primary tumor in stage III colon cancer (Duke's C); (2) Treatment of metastatic colorectal cancer. The combination of oxaliplatin and fluoropyrimidine class drugs can be used for locally advanced¡A recurrent¡A or metastatic gastric cancer. The combination with 5-fluorouracil¡A leucovorin¡A and irinotecan (FOLFIRINOX) as a first-line treatment for metastatic pancreatic cancer.,Patients with known hypersensitivity to oxaliplatin. Breastfeeding. Patients with pre-existing bone marrow suppression (myelosuppression) prior to initiation of therapy (neutrophil counts < 2 x10^9/L or platelet counts < 100 x 10^9/L). Patients with pre-existing peripheral sensory neuropathies with functional impairment prior to initiation of therapy. Patients with severe renal impairment (creatinine clearance <30ml/min).,Common: Abdominal pain (Monotherapy¡A 31%; combination therapy¡A up to 39%)¡A Constipation (Combination therapy¡A up to 32%)¡A Diarrhea (Monotherapy¡A 46%; combination therapy¡A up to 76%)¡A Loss of appetite (Monotherapy¡A 20%; combination therapy¡A up to 35%)¡A Nausea (Monotherapy¡A 64%; combination therapy¡A 64-83%)¡A Stomatitis (Monotherapy¡A 14%; combination therapy¡A up to 42%)¡A Vomiting (Monotherapy¡A 37%; combination therapy¡A 40-64%)¡A Anemia¡A All grades (Monotherapy¡A 64%; combination therapy¡A 25-81%)¡A Granulocytopenic disorder¡A Grade 3 and 4 (39-45%)¡A Leukopenia¡A All grades (Monotherapy¡A 13%; combination therapy¡A up to 85%)¡A Neutropenia¡A All grades (Monotherapy¡A 7%; combination therapy¡A 71-81%)¡A Thrombocytopenia¡A All grades (Monotherapy¡A 30%; combination therapy¡A 44-77%)¡A Abnormal alkaline phosphatase (Combination therapy¡A 14-16%)¡A ALT/SGPT level abnormal (Monotherapy¡A 36%; combination therapy¡A 5-31%)¡A Serum aspartate aminotransferase level outside reference range (Monotherapy¡A 54%; combination therapy¡A 11-47%)¡A Backache (Monotherapy¡A 11%; combination therapy¡A 19%)¡A Paresthesia (62-77%)¡A Cough (Monotherapy¡A 11%; combination therapy¡A up to 35%)¡A Fatigue (Monotherapy¡A 61%; combination therapy¡A up to 70%)¡A Fever (Monotherapy¡A 25%; combination therapy¡A 29%) Serious: Edema (Monotherapy¡A 5%; combination therapy¡A up to 15%)¡A Prolonged QT interval¡A Torsades de pointes¡A Metabolic acidosis¡A Bowel obstruction¡A Colitis¡A Including clostridium difficile diarrhea¡A Pancreatitis¡A acute¡A Anemia¡A Grade 3 or 4 (Monotherapy¡A 1%; combination therapy¡A 1-3%)¡A Febrile neutropenia (Combination therapy¡A up to 12%)¡A Hemolytic anemia¡A Immuno-allergic¡A Leukopenia¡A Grade 3 or 4 (Combination therapy¡A 13-24%)¡A Neutropenia¡A Grade 3 or 4 (Combination therapy¡A 36-53%)¡A Thrombocytopenia¡A Grade 3 or 4 (Monotherapy¡A 3%; combination therapy¡A 2-5%)¡A Thrombocytopenia¡A Immuno-allergic¡A Increased liver function test (Combination therapy¡A 57%)¡A Veno-occlusive disease of the liver¡A Anaphylaxis¡A Hypersensitivity reaction (Monotherapy¡A grade 3 or 4¡A 1-3% ; combination therapy¡A all grades¡A 6-12%)¡A Infusion reaction¡A Rhabdomyolysis¡A Dysesthesia¡A Pharyngolaryngeal (1-38%)¡A Neuropathy¡A Acute or persistent (Overall neuropathy¡A 69-92%; acute neuropathy¡A 56%; persistent neuropathy¡A 21-60%)¡A Posterior reversible encephalopathy syndrome (less than 0.1%)¡A Transient visual loss¡A Hearing loss¡A Hemolytic uremic syndrome¡A Tubulointerstitial nephritis¡A acute¡A Dyspnea (Monotherapy¡A 13%; combination therapy¡A up to 20%)¡A Pneumonitis (Severe)¡A Pulmonary fibrosis (Less than 1%)¡A Angioedema¡A Sepsis,25¢J¥H¤U,Adjuvant therapy post-surgery: 85 mg/m2 IVD every 2 weeks for a total of 12 cycles (6 months). Metastatic colorectal cancer: 85 mg/m2 IVD every 2 weeks. Locally advanced and recurrent/metastatic gastric cancer: 130 mg/m2 (given as 65 mg/m2 on days 1 and 8 of each 3-week cycle or 130 mg/m2 on day 1 only) IVD every 3 weeks. FOLFIRINOX: oxaliplatin (85mg/m2) IVD over 2 hours¡A followed by leucovorin (400mg/m2) IVD over 2 hours. Begin irinotecan (180mg/m2) 90 minutes into the leucovorin infusion via a Y-line. Immediately follow with an IV bolus of fluorouracil (400mg/m2). Then administer a 46-hour continuous infusion of fluorouracil (2400mg/m2). Repeat every 2 weeks for 6 months. Oxaliplatin is generally diluted in 250-500mL of 5% dextrose injection (50mg/mL) to a concentration between 0.2 to 0.70 mg/mL. The infusion is administered over 2-6 hours. For an oxaliplatin dose of 85 mg/m2¡A the maximum concentration for dilution is 0.70 mg/mL. Combination with fluoropyrimidines¡A oxaliplatin should be administered prior to fluoropyrimidine administration.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] Oxaliplatin ©|¥¼¹ï­««×¨x¥\¯à¤£¨}ªº¯f¤H¶i¦æ¬ã¨s¡C¹ï©ó¨x¥\¯à²§±`ªº¯f¤H¨Ï¥Î oxaliplatin «á¨Ã¥¼Æ[¹î¨ì¦³«æ©Ê¨x¬r©Ê¥[¼@ªº²{¶H¡A¦bÁ{§É¸ÕÅç®É¹ï©ó¨x¥\¯à²§±`ªº¯f±w¨ÃµL½Õ¾ã¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated ¡V 1st trimester,[¥é³æ] ¨ì¥Ø«e¬°¤î¡A¥»ÃÄ©|µL¥¥°ü¨Ï¥Îªº¦w¥þ©Ê¸ê®Æ¡C°Êª«¸ÕÅçÅã¥Ü¦³¥Í´Þ¬r©Ê¡A¦]¦¹ oxaliplatin ¤£«ØÄ³¨Ï¥Î©óÃh¥¥©M¡H¦³¶i¦æÁ×¥¥ªº¥¥ÄÖ°ü¤k¡C¶È¦³¦b³qª¾¯f¤H¦¹ÃÄ¹ï­L¨àªº¦MÀI¨ÃÀò±o¥¥°ü¦P·Nªº¯S®í±¡ªp¤U¡A¤~¥i¦Ò¼{¨Ï¥Î¥»ÃÄ¡C ªvÀø´Á¶¡¶·¶i¦æ¾A·íªºÁ×¥¥¡AªvÀø«á¤k©Ê±wªÌÀ³«ùÄòÁ×¥¥ 4 ­Ó¤ë¦Ó¨k©Ê±wªÌÀ³«ùÄò 6 ­Ó¤ë¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] Oxaliplatin ¬O§_·|¥Ñ¨Å¥Ä±Æ°£©|¥¼³Q¬ã¨s¡A¦]¦¹±Â¨Å°ü¸T¥Î¥»ÃÄ¡C,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Dilute oxaliplatin in 250-500mL of 5% dextrose solution to a concentration of 0.2-0.7 mg/mL. The diluted oxaliplatin infusion must be administered through a central venous line or peripheral vein as a 2-6 hour infusion. Oxaliplatin must be infused prior to 5-FU administration.,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gªº¾¹¨ã¤£¥i§t¦³¾T¡C¥»ÃÄ«~¤£¥i¨Ï¥Î§t¦³´âªºµ}ÄÀ·»²G (¨Ò¦p¡GN/S)¡Aµ¹ÃÄ®ÉÁ×§K©MÆP©ÊÃÄª«(¨Ò¦p¡G5-FU)¨Ï¥Î¬Û¦PºÞ¸ô¡C 3. µ}ÄÀ«áªº¿éª`·»²G¦b«Ç·Å¤U¦w©w©Êºû«ù24¤p®É¡C¦b 2-8¢J¤U¥i«O¦s 48 ¤p®É¡C 4. ºÊ´úCBC¡BµÇ¥\¯à¡Aª`·N¯f¤H¬O§_¦³©I§l¤è­±ªº²§±`¯gª¬¡C 5. ©w´Á¯«¸g¾ÇÀË´ú¡C 6. Oxaliplatin ¤@©w­n¦b 5-FU ¤§«e¥ý¿éª`¡C
OHYP1,Barnidipine,Hypoca 10mg,CAVS,,¾AÀ³¯g:°ª¦åÀ£(B023235100),,RT,¡iD¡jInitially 5-10 mg daily¡A may be increased to 10-15 mg daily.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ILIPD1,Doxorubicin,Lipo-Dox inj 20mg (°·«O¥Î),RACA,Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa¡A skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer¡A where there is an increased cardiac risk.,Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal¡A conventional doxorubicin¡A or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic £\-interferon,Infusion-associated acute reactions¡A stomatitis¡A Palmar-plantar erythrodysesthesia¡A cardiac toxicity. Nausea¡A leukopenia¡A neutropenia¡A anemia & thrombocytopenia. Asthenia¡A alopecia¡A fever¡A diarrhea. Resp infections¡A laboratory abnormalities. Dermatologic: Alopecia¡A Hand-foot syndrome due to cytotoxic therapy (ovarian cancer¡A 50.6% AIDS-related Kaposi's sarcoma¡A 3.4% multiple myeloma¡A 19% )¡A Rash (ovarian cancer¡A 28.5%AIDS-related Kaposi's sarcoma¡A 1% to 5% multiple myeloma¡A 22% ) Gastrointestinal: Constipation (multiple myeloma¡A 31% )¡A Diarrhea (ovarian cancer¡A 20.9%AIDS-related Kaposi's sarcoma¡A 7.8%multiple myeloma¡A 46% )¡A Loss of appetite (ovarian cancer¡A 20.1% AIDS-related Kaposi's sarcoma¡A 1% to 5%multiple myeloma¡A 19% )¡A Nausea (ovarian cancer¡A 46% AIDS-related Kaposi's sarcoma¡A 16.9%multiple myeloma¡A 48% )¡A Stomatitis (ovarian cancer¡A 41.4% AIDS-related Kaposi's sarcoma¡A 6.8%multiple myeloma¡A 20% )¡A Vomiting (ovarian cancer¡A 32.6%AIDS-related Kaposi's sarcoma¡A 7.8%multiple myeloma¡A 32%) Hematologic: Decreased platelet count (ovarian cancer¡A 13% to 24.2%; AIDS-related Kaposi's sarcoma¡A 60.9%; multiple myeloma¡A 33%)¡A Hemoglobin low (ovarian cancer¡A 40.2% to 52.6%; AIDS-related Kaposi's sarcoma¡A 55.4%; multiple myeloma¡A 25% )¡A Neutrophil count abnormal (ovarian cancer¡A 19% to 35.1%; AIDS-related Kaposi's sarcoma¡A 48.9%; multiple myeloma¡A 36%) Neurologic: Asthenia (ovarian cancer¡A 40.2% AIDS-related Kaposi's sarcoma¡A 9.9% multiple myeloma¡A 22% ) Psychiatric: Fatigue (multiple myeloma¡A 36%; ) Other: Drug fever (ovarian cancer¡A 21.3%AIDS-related Kaposi's sarcoma¡A 9.1%multiple myeloma¡A 31% ),2-8¢JÁ×§K§N­á,[Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment. [Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1¡A 4¡A 8¡A and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days.,»Ý½Õ¾ã¾¯¶q,¦pªGÁx¬õ¯À­È¤¶©ó1.2-3.0mg/dl¡A²Ä¤@¦¸µ¹ÃÄ¾¯¶qÀ³­°§C25%¡F¦pªGÁx¬õ¯À­È¤j©ó3.0mg/dl ²Ä¤@¦¸µ¹ÃÄ¾¯¶qÀ³­°§C50%¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C 3.Pegylatedliposomal doxorubicinªº²Ö­p¾¯¶q¨ì450mg/m2®É¡A»Ý§@¥ª¤ß«Ç¥\¯àµû¦ô¡A¨Ã¥B¦b¨C¼W¥[100mg/m2µ¹ÃÄ«e¦A¦¸µû¦ô. 450-600mg/m2¨Ã¤£·|¼W¥[¤ßÅ¦¬r©Êªº¦MÀI©Ê.
ETOBO,Tobramycin + Dexamethasone,Tobradex ²´ÃÄ»I 3.5gm,TOPH,Steroid-responsive inflammatory ocular conditions.,Epithelial herpes simplex keratitis (dendritic keratitis)¡A vaccinia¡A varicella & many other viral diseases of the cornea & conjunctiva. Mycobacterial eye infection. Fungal diseases of ocular structures. After uncomplicated removal of a corneal foreign body.,Localized ocular toxicity & hypersensitivity including lid itching & swelling & conjunctival erythema. Secondary infection.,8-27¢J¤Å§NÂÃ,Apply a 1-1.5 cm into the conjunctival sac up to three or four times daily or may be used adjunctively with drops at bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,TOBRAMYCIN OPHTHALMIC:No Human Data¡XProbably Compatible DEXAMETHASONE: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,TOBRAMYCIN OPHTHALMIC:No Human Data¡XProbably Compatible DEXAMETHASONE: No Human Data¡XProbably Compatible,EXT;OD;OL;OU;SKIN;TOPI;,,,,,
IENL,Edrophonium,Enlon inj 150mg/15mL,CNEU,,Enlon is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action¡A it is not recommended for maintenance therapy in myasthenia gravis.,,RT,Enlon Test for Evaluation of Treatment Requirements in Myasthenia Gravis: The recommended dose is 0.1 mL to 0.2 mL (1 mg to 2 mg) of EnlonR¡A administered intravenously one hour after oral intake of the drug being used in treatment. 1-5 Response will be myasthenic in the undertreated patient¡A adequate in the controlled patient¡A and cholinergic in the overtreated patient.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ESIL,Silver Sulphadiazine,Siliverzine cream 1%¡A 20gm,TDER,Adjunct for the prevention & treatment of wound sepsis in patients with 2nd & 3rd degree burns.,Pregnancy¡A premature & newborn infants during 1st months of life.,Burning¡A rash¡A itching¡A interstitial nephritis.,Á×¥ú,Burn treatment: Topical: Apply to a thickness of 1/16 inch QD -BID; reapply as needed to areas where the cream is removed by patient activity as the burned area should be covered with cream at all times. Continue use until healing has occurred.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,°Ñ·Ó Sulfonamide¡G Taken in sum¡A sulfonamides¡A as single agents¡A do not appear to pose a significant teratogenic risk. One study has found associations with birth defects¡A but a causative association cannot be determined with this type of study¡A and they may have been due to other factors¡A particularly if trimethoprim was combined with the sulfonamide. Confirmation is required. Because of the potential toxicity to the newborn¡A these agents should be avoided near term.,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,°Ñ·Ó Sulfonamide,EXT;SKIN;TOPI;,,,,,
IPAP1,Papaverine,Paparin inj 30mg/mL,CAVS,,¾AÀ³¯g:½w¸Ñ¸£¦åºÞ©M¥½µy¯Ê¦å£¿½w¸Ñ¥­·Æ¦ÙµjÅËµ¥(A029287209),,,,,,,,,,,,,,,,,
IAMISA,Procainamide,Amisalin 200mg/2mL,CAVS,,Ventricular arrhythmia¡A atrial arrhythmia¡A atrial fibrilation.,,,Loading dose: 1 g over 2 hrs in 2 divided doses. Maintenance dose: 1-9 g/day in 4-6 divided doses. Child: 15-50 mg/kg/day¡A (max. 4 g/day).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IPARB,Electrolyte + Dextrose,Paramental B inj 400mL,NUTR,,¾AÀ³¯g: Fluid¡A electrolytes & calories supplement¡A especially for those who are poor-oral absorption or malnutrition °Æ§@¥Î:Hyperglycemia. At high dose or rapid administration: pulmonary & peripheral edema¡A acidosis. ¸T§Ò:Hyperkalemia¡A hyperphosphatemia¡A hypermagnesemia¡A hypocalcemia¡A hepatic coma¡Asevere renal insufficiency¡A disturbances in amino acid metabolism¡A peripheral parenteral administration.,,«Ç·Å,Mixed with 10-12% amino acid 200ml. Adult 1200-2400 mL daily IV infusion.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. °ª±i¿éª`²G¡A­­¥Ñ¤¤¥¡ÀR¯ß¾ÉºÞµ¹ÃÄ¡C 2. ¥»«~±M¨ÑÃÄ¾¯¬ì½Õ°tTPN»s¾¯¨Ï¥Î¡C
IPAV,Pancuronium,Pavulon inj 4mg/2mL,CNEU,,Adjunct to anesthesia to induce skeletal muscle relaxation¡A to facilitate the management of patients undergoing mechanical ventilation.,,,Adult and child: 0.04-0.1 mg/kg¡A later incremental doses starting at 0.01 mg/kg may be used. Neonate: 30-40 mcg/kg¡A then 10-20 mcg/kg.,,,,,,,,,,,,,,
IPCN3,Penicillin G,Penicillin G Sod inj 3¦Ê¸U³æ¦ì,QANB,,¾AÀ³¯g:Bacterial endocarditis¡AIntrapartum prophylaxis against group B Streptoccocal infection in neonates¡A Meningococcal meningitis¡APneumococcal meningitis¡ASusceptible infection °Æ§@¥Î:Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis. Potentially Fatal: Anaphylaxis. ¸T§Ò:Hypersensitivity to penicillins,,,Staphylococcal/Streptococcal Endocarditis: Usual dosage: 5 to 24 million units/day IM in equally divided doses every 4 to 6 hours. Erysipeloid Endocarditis: Usual dosage: 12 to 20 million units/day IM in equally divided doses every 4 to 6 hours for 4 to 6 weeks. Listeria Endocarditis: Usual dosage: 15 to 20 million units/day IM in equally divided doses every 4 to 6 hours for 4 weeks. Sepsis: Meningococcal/Neisseria meningitidis: 2 million units IM every 2 hours; Streptococcus or Staphylococcus: 5 to 24 million units/day IM in equally divided doses every 4 to 6 hours. Actinomycotic infection: For abdominal or thoracic actinomycosis in adults¡A the recommended dose of penicillin G sodium 10 million to 20 million units IM per day¡A in divided doses every 4 to 6 hours. For cervicofacial infections¡A the recommended dose is 1 to 6 million units IM per day in divided doses every 4 to 6 hours. Anthrax: The recommended dose of penicillin G sodium for the treatment of anthrax in adults is a minimum of 8 million units IM daily in divided doses every 6 hours. Higher doses may be required based on the susceptibility of the pathogen. Diphtheria: Treatment and Prophylaxis - The recommended dosage of penicillin G sodium is 2 to 3 million units/day IM in divided doses every 4 to 6 hours for 10 to 12 days. Clostridial infection: The recommended dose of penicillin G sodium as adjunctive treatment for clostridial infection in adults is 20 million units per day IM in divided doses every 4 to 6 hours. Fusospirochetosis: For the treatment of susceptible strains of Fusospirochetosis in adults¡A the recommended dosage of penicillin G sodium is 5 to 10 million units IM daily in divided doses every 4 to 6 hours. Pasteurella infection: For the treatment of susceptible strains of Pasteurella infection¡A including bacteremia or meningitis in adults¡A the recommended dose of penicillin G sodium is 4 to 6 million units/day IM in divided doses every 4 to 6 hours for 2 weeks. Rat bite fever: For the treatment of rat-bite fever in adults¡A the recommended dose of penicillin G sodium is 12 million to 20 million units IM per day in divided doses every 4 to 6 hours for 3 to 4 weeks. Neurosyphilis: Usual dosage: 2 to 4 million units IM every 4 hours for 10 to 14 days. NEONATE ANTIBIOTICS DOSE Penicillin G: General infection ( IU/kg/dose) Body weight <1kg Age <=7 day 5¸UIU/kg Q12H      Age 8-14 day 5¸UIU/kg Q12H   Age 15-28 day 5¸UIU/kg Q8H Body weight 1-2kg Age<=7 day 5¸UIU/kg Q12H  Age 8-14 day 5¸UIU/kg Q8H   Age 15-28 day 5¸UIU/kg Q8H Body weight >2kg Age<=7 day 5¸UIU/kg Q8H  Age 8-14 day 5¸UIU/kg Q6H  Age 15-28 day 5¸UIU/kg Q6H Meningitis: Body weight <1kg ge<=7 day 2.5¸UIU/kg Q12H  Age 8-14 day 2.5¸UIU/kg Q12H  Age 15-28 day 2.5¸UIU/kg Q12H Body weight 1-2kg ge<=7 day 2.5¸UIU/kg Q12H  Age 8-14 day 2.5¸UIU/kg Q8H  Age 15-28 day 2.5¸UIU/kg Q8H Body weight >2kg ge <=7 day  2.5¸UIU/kg Q8H  Age 8-14 day 2.5¸UIU/kg Q6H  Age 15-28 day 2.5¸UIU/kg Q6H Congenital Syphilis: 5¸UIU/kg/dose Q12H during the first 7 days of life¡A and thereafter 5¸UIU/kg/dose Q8H¡A for a total of 10 days GBS meningitis: 50-60¸UIU/kg/day (°Ñ¦Ò°¨°º) Age<= 7 days: 25- 45¸UIU/kg/day divided Q8H; Age 8-28 days : 45-50¸UIU/kg/day divided Q6H (°Ñ¦Ò NeoFax),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,ID;IM;IVD;,IM: 3 mL D/W¡A N/S IV: 3 mL D/W¡A N/S,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¡C,,«ØÄ³¥H15 ~ 30¤ÀÄÁ½wºCºwª`,1. ª`®g«eÀË¬d¯f±w¬O§_¦³PCN¹L±Ó¥v¡C 2. ª`®g°ª¾¯¶q (¨C¤é¤j©ó1¤d¸U³æ¦ì) ®É¡AÀ³´îºCª`®g³t²v¨ÃºÊ´ú¹q¸Ñ½èª¬ºA¡C 3. Penicillin G sodium §t¶u¶q¡G1.68 mEq/100¸U³æ¦ì (¨C²~§t¦³5.04 mEq ¶u)¡C 4. (IV infusion) ¥H¾A·í¿éª`²Gµ}ÄÀ¦¨ 50¡A000-100¡A000 unit/mL¡A½wºCºwª`15 ~ 30¤ÀÄÁ¡C 5. º¯³zÀ£»P©PÃäÀR¯ßµ¹ÃÄ³Ì¤jµ}ÄÀ¿@«×¡G154000 units/mL in D/W¡A76000 units/mL in N/S¡A85000 units/mL in D5W¡C
IPED,Haemophilus b Conjugate Vaccine,°ö©w«_,HIMM,,Routine immunization against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age.,,,IM only. 2 to 14 months of age: 0.5 ml dose of vaccine ideally beginning at 2 months of age followed by a 0.5 ml dose 2 months later. When the primary 2-dose egimen is completed before 12 monthsof age¡A a booster dose is required. 15 months of age and older: Children 15 months of age and older previously unvaccinated against Haemophilus B disease should receive a single 0.5ml dose of vaccine. Booster dose: In infants completing the primary 2-dose regimen before 12 months of age ¡A a booster dose (0.5ml) should be administered at 12 to 15 months of age but not earlier than 2 months after the second dose.,,,,,,,,,,,,,,
IPEN0,Thiopental,Pentothal inj 0.5mg,ZANE,,,,,,,,,,,,,,,,,,,
IPENV,Thiopental,Pentothal 2.5gm,ZANE,,¾AÀ³¯g:Anaesth for brief surgical procedures¡A induction of anaesth prior to administration of other anaesth agents¡A control of convulsive states¡A supplement to regional anaesth or low potency agents¡A aid in diagnosis & treatment of psychiatric disorders. °Æ§@¥Î:Drowsiness; tolerance¡A dependence¡A withdrawal effects including seizures. ¸T§Ò:Absence of suitable veins; status asthmaticus; porphyria,,RT,Induction of anesthesia & induce hypnosis Adult test dose 25-75 mg¡A then 50-75 mg at 20-40 sec intervals IV. Children IV 3-5 mg/kg initially¡A followed by 1 mg/kg if needed Convulsions Adult IV 75-125 mg. Narcoanalysis IV 100 mg/min until confusion occurs.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IPETBAD,Meperidine,Pethidine inj 50mg/1mL´Ý¾l¾PÀì,CNEU,Relief of pain¡A preoperative medication anesthesia support.,,,,Analgesic: Adult: IM or SC 50-150 mg q3-4h. Child: 1.1-1.76 mg/kg q3-4h. Obstetrical analgesia: IM or SC¡A 50-100 mg¡A administered when pains become regular¡A may be repeated at 1-3 hrs intervals. Preoperative: Adult: IM or SC¡A 50-100 mg 30'-90' prior to anesthesia. Child: 1-2.2 mg/kg. Adjunct to anesthesia: IV: Slow injection of fractional doses of a soln diluted to 10 mg/ml. IVF: As a soln diluted to 1 mg/ml.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,,,,
IPHA,Epirubicin,Pharmorubicin inj 10mg,RACA,,¾AÀ³¯g:Adjuvant therapy component for primary breast cancer in patients with evidence of axillary node involvement following tumor resection. °Æ§@¥Î:Myelosuppression¡A cardiotoxicity¡A alopecia¡A mucositis¡A GI disturbances¡A hyperpyrexia. ¸T§Ò:Hypersensitivity to epirubicin¡A other anthracyclines¡A anthracenediones¡A or any component of the formulation; cardiomyopathy and/or heart failure¡A recent myocardial infarction¡A severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose. Marked persistent myelosuppression induced by prior treatment with other chemotherapy agents or by radiotherapy; severe hepatic impairment.,,«Ç·Å,Breast cancer¡A adjuvant treatment: IV: Usual dose: 100 to 120 mg/m2 per 3- or 4-week treatment cycle as follows: 60 mg/m2 on days 1¡A 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil or 100 mg/m2 on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨xÅ¦¥\¯à¤£¨}ªº¯f¤H(Áx¬õ¯À¡G1.4-3²@§J/100²@¤É)»Ý­n­°§C50%ªº¾¯¶q¡CÄY­«¨xÅ¦¥\¯à¤£¨} ªº¯f¤H(Áx¬õ¯À¡G¤j©ó3²@§J/100²@¤É)»Ý­n­°§C75%ªº¾¯¶q¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,IA;IRR;IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C
IPHA1,Epirubicin,Pharmorubicin inj 1mg,RACA,,,,,,,,,,,,,,IVD;,,,,,
ETES,Testosterone + K-Y,Testoviron K-Y,HM,,,,,,,,,,,,,,,,,,,
EINTC,Indomethacin,InteBan cream 1%¡A 25gm,CNEU,,¾AÀ³¯g: Alleviation of pain. °Æ§@¥Î: GI upsets¡A headache¡A dizziness¡A tinnitus¡A lightheadedness¡A depression¡A insomnia¡A psychiatric disturbances¡A peripheral neuropathy¡A blurred vision¡A confusion; hyperglycaemia¡A hyperkalaemia. Gastrointestinal: Abdominal pain (1% to 3% )¡A Constipation (1% to 3% )¡A Diarrhea (1% to 3% )¡A Indigestion (3% to 9% )¡A Nausea (3% to 9% ) Neurologic: Dizziness¡A Headache¡A Somnolence Otic: Tinnitus Psychiatric: Depression Other: Fatigue ¸T§Ò: Active peptic ulcer; pregnancy (3rd trimester)¡A hypersensitivity to aspirin and other NSAIDs; treatment of perioperative pain in CABG surgery; severe renal impairment; rectal admin in patients with proctitis and haemorrhoids; neonates with necrotizing enterocolitis¡A active bleeding¡A thrombocytopenia¡A coagulation defects and untreated infections.,,«Ç·Å,Antirheumatic and antipyretic: Oral¡A 25-50 mg bid-tid. Rectal¡A 50-100 mg qd-bid. Acute gout: 100 mg initially¡A then 50 mg tid until pain is relieved. For patent ductus arteriosus closure in neonate: Oral(via a nasogastric tube)¡A 0.2 mg/kg initially. If necessary¡A 1-2 additional doses of 0.1-0.25 mg/kg may be given at 12 hrs intervals.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ETIM2,Timolol,Timoptol 0.25% 5mL,TOPH,,¾AÀ³¯g:«C¥ú²´(B019247421),,RT,Initial: 1 gtt bid Maintenance: 1 gtt qd.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ETIM5,Timolol,Timoptol 0.5% 5mL,TOPH,Glucoma.,Bronchial asthma or a history of bronchial asthma¡A severe COPD. Sinus bradycardia¡A 2nd and 3rd degree AV block¡A overt cardiac failure¡A cardiogenic shock.,Transient blurred vision¡A burning and stinging¡A conjunctival infection¡A discharge¡A foreign body sensation¡A itching. Ocular irritation and visual disturbances. Bradycardia¡A arrhythmia¡A hypotension¡A syncope¡A heart block¡A CVA¡A cerebral ischaemia¡A CHF¡A palpitation¡A cardiac arrest¡A oedema¡A claudication¡A Raynaud's syndrome¡A cold hands and feet. Bronchospasm¡A respiratory failure¡A dyspnoea¡A cough. Headache¡A asthenia¡A fatigue¡A chest pain. Alopecia¡A psoriasiform rash or exacerbation of psoriasis. Allergic reactions. Dizziness¡A depression¡A insomnia¡A nightmares¡A memory loss¡A paraesthesia. Increase in signs and symptoms of myasthenia gravis. Nausea¡A diarrhoea¡A dyspepsia¡A dry mouth. Decreased libido¡A Peyronie's disease. SLE. Ocular irritation¡A visual disturbances¡A bradycardia¡A arrhythmia¡A hypotension¡A syncope¡A heart block¡A CVA¡A cerebral ischemia¡A CHF; palpitation¡A cardiac arrest¡A bronchospasm in patients with pre-existing bronchospastic disease; respiratory failure¡A dyspnea¡A hypersensitivity reactions.,Á×¥ú¥B30¢J¥H¤U,Adult: Initial: 0.25% Timoptol 1 drop BID then titrate to 0.5% Timoptol 1 drop BID with poor efficacy. Maintenance: 1 drop QD. Child: Initial: 0.25% Timoptol 1 drop Q12H then titrate to 0.5% Timoptol 1 drop Q12H when necessary. Do not suggest using Timoptol to premature Infant or infant.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;OD;OL;OU;,,,,,
ETRU,Dorzolamide,Trusopt 2%¡A 5mL ophthalmic solution,TOPH,Raised intraocular pressure¡A open-angle glaucoma,Hypersensitivity to dorzolamide or any product component. CrCl < 30 mL/min.,Bitter taste in mouth¡A hypersensitivity reaction (ocular)¡A burning sensation in eye¡A superficial punctate keratitis¡A visual discomfort. Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A metabolic acidosis¡A aplastic anemia¡A thrombocytopenia¡A choroidal detachment¡A corneal decompensation¡A urolithiasis¡A angioedema.,30¢J¥H¤UÁ×¥ú,Raised intraocular pressure¡A In patients with ocular hypertension or open-angle glaucoma: 1 drop into affected eye(s) 3 times daily. As an adjuvant therapy with an ophthalmic beta-blocker: 1 drop into affected eye(s) 2 times daily.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¥Ø«e©|¥¼¹ï¨x¥\¯à¤£¨}¤§¯f¤H¶i¦æ¨Ï¥ÎTRUSOPTªº¬ã¨s¡A¦]¦¹¨Ï¥Î©ó¦¹Ãþ¯f¤H®É¶·ª`·N¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]Ãh¥¥´Á¶¡¤£¥i¨Ï¥ÎTRUSOPT¡C¥Ø«eµLÃh¥¥¤k©Ê¨Ï¥ÎÃÄª«ªºÁ{§É¸ê®Æ¡C ¦b¨ß¤lÅé¤º¡A§ë¤©¨ã¥ÀÅé¬r©Ê¾¯¶qªºTRUSOPT·|²£¥Í­P·î­L§@¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨Ã¤£²M·¡TRUSOPT¬O§_·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C©ó­÷¨Å¤j¹«¤¤¡A µo²{¤l¹«ªºÅé­«¼W¥[´T«×´î¤Ö¡C¦pªG¥²¶·¥HTRUSOPT¶i¦æªvÀø¡A«h¤£«ØÄ³­÷¨Å¡C,OD;OL;OU;,,,,,1. §tbenzalkonium chloride¨¾»G¾¯¡A¥i¯à·|³y¦¨²´·ú¨ë¿E¡CÂIÃÄ«eÀ³¥ýºK°£Áô§Î²´Ãè¨Ã¦Ü¤Öµ¥«Ý15¤ÀÄÁ¤~¥i­«·s°tÀ¹¡CBenzalkonium chloride¤wª¾·|³y¦¨³n©ÊÁô§Î²´ÃèÅÜ¦â¡C
EVENN,Salbutamol,Ventolin Nebule 5mg/2.5mL,ERSP,,¾AÀ³¯g: Routine management of bronchospasm unresponsive to conventional therapy; acute severe asthma. °Æ§@¥Î: Fine tremor of skeletal muscle¡A feelings of tension¡A peripheral vasodilation¡A a compensatory small increase in heart rate¡A headaches¡A transient muscle cramps¡A hypersensitivity reactions¡A potentially serious hypokalaemia¡A hyperactivity in children¡A tachycardia¡A cardiac arrhythmias. Mouth & throat irritations (inhalers). ¸T§Ò: Threatened abortion. Inhaled prep not appropriate for managing premature labour.,,«Ç·Å,Initially 2.5-5 mg¡A may be repeated up to qid via a nebuliser.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
EVENR,Salbutamol,Ventolin respirator soln 1mL,ERSP,,¾AÀ³¯g: Routine management of bronchospasm unresponsive to conventional therapy; acute severe asthma. °Æ§@¥Î: Fine tremor of skeletal muscle¡A feelings of tension¡A peripheral vasodilation¡A a compensatory small increase in heart rate¡A headaches¡A transient muscle cramps¡A hypersensitivity reactions¡A potentially serious hypokalaemia¡A hyperactivity in children¡A tachycardia¡A cardiac arrhythmias. Mouth & throat irritations (inhalers). ¸T§Ò: Threatened abortion. Inhaled prep not appropriate for managing premature labour.,,«Ç·Å,Intermittent administration Adult 0.5-1 mL diluted to a final vol of 2-2.5 mL nebulised & administered over 10 mins. Or 2 mL of undiluted soln over 3-5 mins. Children <12 years 0.5 mL diluted to a final vol of 2-2.5 mL. Some children may require higher doses up to 1 mL. Continuous administration Dilute soln to contain 50-100 mcg salbutamol/mL & administer as an aerosol at rate of 1-2 mg/hr.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EVOR,Diclofenac,Voren-G gel 10mg/gm 30gm,CNEU,,An analgesic¡A antipyretic¡A anti-inflammatory agents used in RA. and other rheumatic disorders.,,,Adult: 50 mg qd-bid. Child: 0.5-1 mg/kg qd-bid.,,,,,,,,,,,,,,
ITRI,Nitroglycerin,Tridil inj 25mg/5mL,CAVS,,I: Treatment and prophylaxis of angina pectoris. CI: Severe hypotension¡A severe anemia¡A constrictive pericarditis¡A extreme bradycardia¡A G6PD deficiency¡A cerebral hemorrhage & brain trauma¡A circulatory collapse¡A cardiogenic shock¡A toxic pulmonary edema. Avoid coadministration with sildenafil.,,,IV infusion: Initially¡A 5 mcg/min; may be increased by 5 mcg/min q3-5 mins until a response is noted.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IXYL10,Lidocaine,Xylocaine 10% inj 10mL,ZANE,,Ventricular arrhythmias in connection with myocardial infarction.,,,Antiarrhythmic: IV (loading dose): 1 mg/kg at a rate of 25-50 mg/min¡A repeated after 5 mins if necessary¡A up to 300 mg/hr. IV continuous infusion: Diluted with 5% dextrose¡A at a rate of 1-4 mg/min. IM: 4.3 mg/kg¡A repeated after 60-90 mins if necessary. Anticonvulsant (status epilepticus): IV continuous infusion: 1-3 mg/min following a usual loading dose.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IZIN2,Cefuroxime,Zinacef 250mg,QANB,,Respiratory tract and soft tissue infections¡A serious infections pending bacteriology¡A Meningitis¡A Prophylaxis against infection in surgical procedures¡A UTI and gonorrhoea.,,,IV¡A IV infusion or IM¡A Adult: 0.75-1.5 g q8h¡A up to 1.5 g q6h. For bacterial meningitis: Max. 3-6 g/day in 3-4 divided doses. Child & infant over 3 Months: 30-100 mg/kg/day in 3-4 divided doses. For bacterial meningitis: 150-250 mg/kg/day in 3-4 divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
LUPE,Ibuprofen,U-Pedia 20mg/mL¡A 60mL,CNEU,,Analgesic¡A antipyretic & anti-inflammatory.,,,Adult:20-30ml tid. Child: 0.75-2ml / kg / day,,,,,,,,,,,,,,
LXYLV,Lidocaine,Xylocaine viscous 2%¡A 100mL,ZANE,,¾AÀ³¯g: Oropharynx¡A larynx¡A esophageal¡A bronchial & gastric exam. Local anaesth. °Æ§@¥Î: Intoxication¡A cutaneous & hypersensitivity symptoms. Drowsiness¡A anxiety¡A excitement¡A blurred vision¡A nausea¡A dizziness & vomiting. ¸T§Ò: Known history of hypersensitivity to local anaesthetics of the amide type or other components of Xylocaine Viscous¡A eg methyl and propyl parahydroxybenzoate.,,«Ç·Å,Adult 5-15 mL once-tid.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ORIV5,Clonazepam,Rivotril 0.5mg,CNEU,Majority of clinical forms of epileptic disease in infants & children especially typical or atypical petit mal epilepsy¡A tonic-clonic seizures¡A status epilepticus. Adult epilepsies & in focal seizures.,,Tiredness¡A sleepiness¡A lassitude¡A muscular hypotonia¡A muscle weakness¡A dizziness¡A lightheadedness¡A ataxia¡A slowed reaction¡A poor conc.¡A restlessness¡A confusion¡A disorientation; anterograde amnesia¡A depression. Increased production of saliva or of bronchial secretions in infants & young children.,©ó30¢J¥H¤U¡CÁ×§K¥ú·Ó¡C,Adult 4-8 mg. Children >6 years 3-6 mg¡A Small children 1.5-3 mg. Infant 0.5-1 mg. Divided into 3 or 4 doses daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ]±qÁ{§É«e¬ã¨s¤¤¡A¨Ã¤£¯à±Æ°£clonazepam¨ã¦³²£¥Í¥ý¤Ñ©Ê·î§Îªº¥i¯à©Ê¡C±q¬y¦æ¯f¾Çªº¸ê®Æµû¦ô¡A¥çÅã¥Ü§ÜµjÅËÃÄ¥i¯à¬°­P·î­L­ì¡FµM¦Ó¡A±qµoªíªº¬y¦æ¯f¾Ç³ø§i¤¤¡A«ÜÃø¥h¨M©w¬O¨º¤@­ÓÃÄª«©Î¨º¤@¸s¨Ö¥ÎÃÄª«³y¦¨·s¥Í¨àªº¯Ê³´¡C¨ä¥L¦]¯À¦p¿ò¶Ç¦]¤l©ÎÅöíwª¬ªp¥»¨­¥i¯à¦b¾É­P¥ý¤Ñ¯Ê³´ªº¹Lµ{¤¤¸ûÃÄª«§êºt§ó­«­n¨¤¦âªº¥i¯à©Ê¤]¤´µM¦s¦b¡C¦b³o¨Ç«e´£¤U¡A¥u¦³·í¥i¯àªº®Ä¯q³Ó¹L¹ï­L¨àªº¦MÀI©Ê®É¡A¤~¥iµ¹¤©¥¥°ü¦¹ÃÄ¡C¦bÃh¥¥´Á¡A¥u¦³·í¥²»Ý­n¨Ï¥ÎRivotril®É¡A¤~¥iµ¹¤©¡C¦bÃh¥¥ªº³Ì«á¤T­Ó¤ë©Î¤À®Y®Éµ¹¤©°ª¾¯¶qRivotril¡A¥i¯à³y¦¨¥¼¥X¥Í¨àªº¤ß¸õ¤£³W«h¡A·s¥Í¨àªºÅé·Å¹L§C¡B¦Ù±i¤O¹L§C¡B»´«×©I§l§í¨î©MÁý­¹§xÃø¡C¦¹¥~¡A¥çÀ³¤Á°OÃh¥¥¥»¨­©M¬ðµM°±ÃÄ¨âªÌ¬Ò¥i¯à¥[­«Åöíwªº¯f±¡¡CBenzodiazepines³y¦¨·s¥Í¨àµo¥Í§ÙÂ_¯gª¬°¸º¸·|³Q³q³ø¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]ÁöµM¤wµo²{Rivotrilªº¬¡©Ê¦¨¤À¥u¦³¤p³¡¤À·|¶i¤J¥À¨Å¤¤¡A¶i¦æ¦¹ÃÄªvÀøªº¥À¿Ë¤´¤£À³¸Ó±Â¨Å¡C¦pªG¥²¶·­n¨Ï¥ÎRivotril¡A«hÀ³°±¤î±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
ODIC1,Diclofenac,Diclofenac 100mg S.R. F.C.,CNEU,Rheumatism¡A acute musculoskeletal disorders¡A post-traumatic & post-op inflammation & swelling.,Patients sensitive to aspirin or other NSAIDs.,GI disturbances. Peptic ulceration. GI bleeding. Headache¡A dizziness¡A nervousness¡A skin rash¡A pruritus¡A tinnitus¡A edema¡A depression¡A drowsiness¡A insomnia¡A & blurred vision. Hypersensitivity. Impairment of liver & kidney function. Agranulocytosis & thrombopenia. Dermatologic: Application site reaction (gel: all reactions¡A 7%; dermatitis¡A 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )¡A Keratitis (up to 28% )¡A Lacrimation and lacrimal drainage - finding (up to 30% )¡A Raised intraocular pressure (up to 15% ),25¢J¥H¤UÁ×¥ú,100 mg QD¡A swallowed whole,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling; however¡A may require dosage adjustment due to extensive hepatic metabolism.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] ¸T§Ò¡GÃh¥¥²Ä¤T´Á°ü¤k¸T¥Î¥»ÃÄ¡C ¹ï¥¥°ü¤Î±Â¨Å°ü¤H¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C¹ï©ó¥¥°ü¤Î¥i¯àÃh¥¥¤§°ü¤k©Î±Â¨Å¤§°ü¤H¡A¶·§PÂ_¨äªvÀø®Ä¯q¶W¹L¦MÀI©Ê®É¡A¤è¤©§ë»P¡CÃh¥¥³Ì«á3 ­Ó¤ëªº°ü¤k¨Ï¥Î¥»«~¶·¯S§Oª`·N(¦]¥i¯à³y¦¨¤l®c¦¬ÁYµL¤O¤Î/©Î ­L¨à°Ê¯ß³¬Âê¹L¦­)¡C FDAPregnancy Category (Ãh¥¥¥ÎÃÄ¯Å¼Æ)¡GC [20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¹ï¥¥°ü¤Î±Â¨Å°ü¤H¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½wÄÀ¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C­Y¦³¿i¯»ºÞÄé»Ý¨D¥i§ï¥Î°|¤º¦P¦¨¤ÀCataflam 25mg¡C
IDIG,Digoxin,Digosin °w¾¯ 0.25mg/1mL,CAVS,,I: CHF¡A artrial fibrilation¡A atrial flutter¡A paroxysmal atrial tachycardia. CI: AV block¡A SA block¡A digitalis intoxication¡A obstructive cardiomyopathy.,,,Adult and child over 10 yrs: IV slowly: Digitalization: 0.25-0.5 mg followed by 0.25 mg q4-6h as needed¡A not exceeding 1 mg/day. Maintenance: 0.125-0.5 mg/day. Infant and child under 10 yrs: IV slowly: Digitialization: 1/4-1/2 of the total digitalizing dose given initially¡A followed by 1/4 dose q6h for 2-3 doses. 2-10 yrs: 0.025-0.04 mg/kg. 2 wks-2 yrs: 0.035-0.05 mg/kg. Under 2 wks: 0.025-0.04 mg/kg. Maintenance: 1/5-1/3 of the total digitalizing dose¡A qd.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IANX,Lorazepam,Anxicam inj 2mg/1mL,CNEU,Insomnia¡A anxiety & tension.,Sleep apnea; severe respiratory insufficiency; not for primary treatment of psychosis or depressive disorders,Sedation; dizziness; muscle weakness; ataxia; disorientation; depression; change in appetite; headache; sleep disturbance; agitation; dermatological symptoms¡A eye function disturbance; minor GI symptoms; autonomic manifestations; blood dyscrasias; elevated liver enzymes. Paradoxical reactions eg stimulation & rage (rare). Hypotension. Neurologic: Asthenia (4.2% )¡A Dizziness (6.9% )¡A Sedated (15.9% )¡A Unsteadiness present (3.4% )¡A Vertigo Psychiatric: Depression,2-8¢J,Adults: IM: 0.05mg/kg¡A maximum dose: 4mg. 2 hours before surgery. Direct deep intramuscular injection without dilution. IV: 0.044mg/kg or totally 2mg¡A 15-20 minutes before surgery. Dilute with an equal volume of saline or water for injection. Slow injection¡A limited to a rate of 2 mg/min. Excluding those over 50 years old. Children: Dose not determined.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iN/S¡j¥i¿ï ¡C,IVª`®g³t²vÀ³2mg/¤ÀÄÁ¥H¤U¡A¥Îµ¥Åé¿n¥Í²z­¹ÆQ¤ô©Îª`®g¥Î¤ôµ}ÄÀ¡C,À³¨Ï¥Înon-PVC§÷½è¡A¥Îµ¥Åé¿n¥Í²z­¹ÆQ¤ô©Îª`®g¥Î¤ôµ}ÄÀ¡C,1.¥¼µ}ÄÀ¥ideep IM¡C 2.IV±`¥Î¾¯¶q:0.044mg/kg©ÎÁ`¶q2mg¡C 3.À³¨Ï¥Înon-PVC§÷½è¡C 4.dilute with an equal volume of compatible solution immediately prior to use; mix thoroughly by gently inverting the container until homogenous; do not shake vigorously. 5.diluted solution may be injected directly into a vein or into the tubing of an existing IV infusion.
EZOR,Tazarotene,Zorac cream 0.1%¡A 30gm,TDER,,¾AÀ³¯g: Stable plaque psoriasis¡A acne vulgaris. °Æ§@¥Î: Pruritus¡A burning/stinging¡A erythema¡A worsening of psoriasis¡A irritation¡A pain¡A rash¡A desquamation¡A irritation¡A contact dermatitis. ¸T§Ò: Pregnancy.,,«Ç·Å,Apply once daily at night.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OAMO2,Amoxicillin,Amoxicillin 250mg,QANB,G(+) & G(-) infections. Ear¡A nose¡A and throat infection. Helicobacter pylori gastrointestinal tract infection. Infection of skin and/or subcutaneous tissue. Infectious disease of genitourinary system. Lower respiratory tract infection. Pharyngitis - Tonsillitis. Sinusitis.,Serious hypersensitivity reactions¡A such as anaphylaxis and Stevens-Johnson syndrome¡A to amoxicillin or other beta-lactam antibiotics (eg¡A penicillins¡A cephalosporins),Common: Rash (greater than 1%)¡A Diarrhea (overall¡A greater than 1%; Helicobacter pylori therapy¡A 7-8%)¡A Nausea (greater than 1%)¡A Vomiting (greater than 1%)¡A Headache (Helicobacter pylori therapy¡A 6-7%; extended-release tablets¡A 1%)¡A Vulvovaginitis¡A Mycotic (extended-release¡A 2%) Serious: Shock¡A Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Angioedema,«Ç·ÅÁ×¥ú,Infection of upper respiratory tract¡A genitourinary tract and skin/soft tissue: Adult: 250-500 mg orally once every 8 hours; children: 20-40 mg/kg/day in divided doses every 8 hours. Lower respiratory tract infection: Adult: 500 mg every 8 hours; children: 40 mg/kg/day in divided doses every 8 hours. Children > 20 kg should be dosed according to the adult recommendations. Gonorrhea¡A acute uncomplicated genitourinary tract infections caused by N. gonorrhoeae in males and females: Adult: 3 g as single oral dose. All patients with gonorrhea should be evaluated for syphilis. The following Pediatric dose recommendation is from Sanford Guide to Antimicrobial Therapy.(2022/11/08): Age>28 days: 25-100mg/kg/day divided Q8-12H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ILIPO2,Soybean Oil,Lipovenoes 20% 100mL(¤p¨àTPN¥Î),NUTR,,,,,,,,,,,,,,IVD;,,,,,
OISM,Isosorbide 5-Mononitrate,Ismo 20mg,CAVS,,¾AÀ³¯g: Prophylaxis of angina pectoris. °Æ§@¥Î: Transient headache¡A nausea¡A dizziness¡A weakness¡A vomiting¡A tachycardia¡A decreased BP¡A possible formation of methemoglobin¡A rarely allergic skin reactions. Neurologic: Dizziness (8% to 11% )¡A Headache (38% to 57% ) ¸T§Ò: Marked hypotension¡A hypertrophic obstructive cardiomyopathy¡A constrictive pericarditis¡A aortic & mitral stenosis¡A increased intracranial pressure¡A MI with low filling pressure. Avoid sildenafil¡A tadalafil¡A vardenafil.,,«Ç·Å,20 mg bid. Dose may be increased to 20 mg tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IPHA5,Epirubicin,PHARMORUBICIN inj 50mg,RACA,,¾AÀ³¯g:Adjuvant therapy component for primary breast cancer in patients with evidence of axillary node involvement following tumor resection. °Æ§@¥Î:Myelosuppression¡A cardiotoxicity¡A alopecia¡A mucositis¡A GI disturbances¡A hyperpyrexia. ¸T§Ò:Hypersensitivity to epirubicin¡A other anthracyclines¡A anthracenediones¡A or any component of the formulation; cardiomyopathy and/or heart failure¡A recent myocardial infarction¡A severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose. Marked persistent myelosuppression induced by prior treatment with other chemotherapy agents or by radiotherapy; severe hepatic impairment.,,«Ç·Å,Breast cancer¡A adjuvant treatment: IV: Usual dose: 100 to 120 mg/m2 per 3- or 4-week treatment cycle as follows: 60 mg/m2 on days 1¡A 8 every 28 days for 6 cycles in combination with cyclophosphamide and fluorouracil or 100 mg/m2 on day 1 every 21 days for 6 cycles in combination with cyclophosphamide and fluorouracil.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨xÅ¦¥\¯à¤£¨}ªº¯f¤H(Áx¬õ¯À¡G1.4-3²@§J/100²@¤É)»Ý­n­°§C50%ªº¾¯¶q¡CÄY­«¨xÅ¦¥\¯à¤£¨} ªº¯f¤H(Áx¬õ¯À¡G¤j©ó3²@§J/100²@¤É)»Ý­n­°§C75%ªº¾¯¶q¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,IA;IRR;IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C
IPITA,Piperacillin,Pitamycin inj 2gm,QANB,,Systemic and local infections caused by G(+) (NOT resistant staphy. and enterococci)¡A G(-) (includes klebsiella¡A enterobacter¡A Pseudomonas anaerobes cluding B. fragilis.,,,IV or IM (under 2g per injection site). Max. 24 g/day. Severe Infection: IM or IV¡A 200-300 mg/kg/day in 4-6 divided doses. Complicated UTI: IV¡A 125-200 mg/kg/day in 3-4 divided doses. Uncomplicated UTI: IM or IV¡A 100-125 mg/kg/day in 2-4 divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ODOXY,Doxycycline,Doxymycin 100mg enteric coated,QANB,Rickettsial¡A chlamydial¡A mycoplasmal infection.,Pregnancy. Children <12 years. SLE.,Gastrointestinal effects; photosensitivity; enamel hypoplasia¡A tooth discoloration; hypersensitivity reactions. Rarely¡A bone marrow depression; oesophagitis & oesophageal ulceration.,25¢J¥H¤UÁ×¥ú,(¥é³æ) Adults: 200 mg in 1-2 divided doses on day 1¡A followed by 100-200 mg/day since day 2. (¼ö¯f) Pediatric: usual dose: 2-4.4 mg/kg/day¡A divided Q12H (maximum: 200 mg/day; maximum duration : 21 days),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 2nd and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»½¦Ån¡A¥i©î½¦Ån«áªA¥Î¡C¦ý¤£¥i±N½¦Ån¤ºªº¸z·»·L²É¬ã¿i©ÎÀ£¸H¡C
ODUP,Dydrogesterone,Duphaston 5mg,HM,,¾AÀ³¯g: Infertility ¡Aendometriosis ¡Aamenorrhea ¡Auterine bleeding ¡APostmenopausal complaints °Æ§@¥Î: During the clinical use of Duphaston¡A side effects eg¡A virilization were never seen. However¡A breakthrough bleeding does occur occasionally. ¸T§Ò:None known.,,RT,Dysmenorrhoea: 10 mg twice daily from day 5 to day 25 of the cycle. Endometriosis: 10 mg 2 or 3 times daily from day 5 to day 25 of the cycle or continuously. Dysfunctional Bleeding: To Arrest bleeding: 10 mg twice daily with an oestrogen once daily for 5-7 days. Tto Regulate Bleeding: 10 mg twice daily together with an oestrogen once daily from day 11 to day 25 of the cycle¡A together with 10 mg dydrogesterone twice daily from day 11 to day 25 of the cycle. Premenstrual Syndrome: 10 mg twice daily from day 11 to day 25 of the cycle. Infertility or Irregular Cycles: 10 mg twice daily from day 11 to day 25 of the cycle. Threatened Abortion: 40 mg at once¡A then 10 mg every 8 hrs until symptoms remit. Habitual Abortion: 10 mg twice daily until the 20th week of pregnancy. Postmenopausal Complaints (HRT): In combination with continuous oestrogen therapy¡A 10-20 mg dydrogesterone daily during the last 12-14 days of each cycle. In combination with cyclical oestrogen therapy¡A 10-20 mg dydrogesterone daily during the last 12-14 days of oestrogen therapy.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OERGO,Ergometrine,Ergometrine 0.2mg,SGU,Postpartum haemorrhage caused by uterine atony.,Threatened spontaneous abortion¡A vascular diseases¡A impaired renal or hepatic function¡A pregnancy¡A induction of labor.,Nausea¡A vomiting¡A headache¡A dizziness¡A abdominal pain¡A hypertension¡A bradycardia¡A dyspnea¡A ergotism.,25¢J¥H¤UÁ×¥ú,Adult 1 tablet TID. the maximum dose: 2 mg/day. [Micromedex 2021/08/04] Postpartum hemorrhage; Treatment and Prophylaxis: Minimization of late postpartum hemorrhage¡A 0.2 to 0.4 mg (1 or 2 tablets ) orally or sublingually every 6 to 12 hours until the danger of uterine atony has passed¡A usually 48 hours.,µL»Ý½Õ¾ã¾¯¶q,¦³¨x¯e¯f¤ÎµÇ¯e¯f±wªÌÀ³ÂÔ·V§ë»P,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Micromedex: Fetal risk cannot be ruled out. METHYLERGONOVINE MALEATE PREGNANCY RECOMMENDATION: Contraindicated,Unknown ¨S¦³¸ê®Æ,Micromedex: Infant risk has been demonstrated. METHYLERGONOVINE MALEATE BREASTFEEDING RECOMMENDATION: Compatible,AC;AC15;PC;PO;WM;,,,,,
OERI,Fludiazepam,Erispan 0.25mg,CNEU,,¾AÀ³¯g: Anxiety¡A insomnia & muscle spasm. °Æ§@¥Î:Dependence¡A irritability¡A excitation¡A confusion¡A dizziness¡A dull headache¡A tremor¡A ataxia¡A visual disturbances¡A dizziness on standing up¡A delirium¡A amnesia¡A insomnia¡A vivid dreams¡A dyslalia¡A increased AST/ALT¡A dry mouth¡A anorexia¡A GI discomfort¡A rash¡A pruritus¡A fatigue¡A malaise¡A muscle weakness¡A decreased libido¡A dysuria¡A yawning¡A closed pharynx sensation¡A numbness of tongue & hands¡A diaphoresis¡A slight fever¡A enlarged axillary glands¡A urinary incontinence¡A premenstrual tension¡A alopecia. ¸T§Ò: Acute narrow angle glaucoma¡A serious myasthenia,,«Ç·Å,May be taken with or without food Adult 0.75 mg in 3 divided doses¡A adjusted according to age & symptoms.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OEUG,Glibenclamide,Euglucon 5mg(Glibenclamide),META,,I: Diabetes mellitus. (NIDDM) ADR: Hypoglycaemia¡A temporary visual impairment esp at the start of treatment¡A GI disturbance. Rarely¡A mild to severe thrombocytopenia. Isolated cases of haemolytic anemia¡A hypersensitivity reactions. CI: Type I IDDM¡A diabetic ketoacidosis¡A diabetic precoma or coma. Severe renal or hepatic dysfunction. Pregnancy & lactation.,,RT,Initial¡A 2.5-5 mg/day with breakfast¡A increased as needed; (max daily dose: 20 mg ).,,,,¥i¯à¦w¥þ,,,,,,,,,,
OEUR,Estazolam,Eurodin 2mg,CNEU,Insomnia.,Myasthenia gravis. Pregnancy¡A lactation.,Dependence¡A somnolence¡A confusion¡A dizziness¡A coordination abnormal¡A headache¡A dull headache & other psychotic disturbances. Respiratory depression. Anemia¡A leukopenia. Hypotension. Nausea¡A dry mouth. Fatigue¡A edema.,15-30¢Jºò±K®e¾¹,2mg-4mg(1- 2 TAB) at bedtime. Increase or decrease according to age and medical condition.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
ITT2,Electrolytes + Water,¥x¤j No.2 500mL,MSIV,Fluid¡A electrolytes & calories supplement.,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30¢J¥H¤U,Central vein or peripheral vein infusion¡A as needed. Taita No.1: Na 25mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 20mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 38g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.2: Na 40mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 26mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 33g/L¡A 500mL/Bot¡A 287mOsm/L. Taita No.3: Na 75mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 61mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 20g/L¡A 500mL/Bot¡A 285mOsm/L. Taita No.4: Na 110mEq/L¡A K 20mEq/L¡A Mg 0mEq/L¡A Cl 102mEq/L¡A Acetate 16mEq/L¡A Phosphate 12mM/L¡A Glucose 8g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.5: Na 36mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 17mEq/L¡A Acetate 28mEq/L¡A Phosphate 12mM/L¡A Glucose 100g/L¡A 400mL/Bot¡A 669mOsm/L.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¯SÂI¤Î¾AÀ³¯g Taita No.1: Na¡BCl ¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì§C¡F¤p¨à¥Îºû«ù²G¡B¹q¸Ñ½è¡B¤ô¥÷¡B¾i¥÷¸É¥R Taita No.2: ¦¨¤À»PTaita No.1¬Û¦ü¦ýNa¡BCl¸û¦h;¼ö¶q¤ÎK§t¶q¸û§C¡A¥i§@¬°¤p¨à©Î¦¨¤H¥Îºû«ù²G Taita No.3: NaCl§t¶q¦ü0.45 %N/S¡A¥i¥Î©óµ¥±i©Ê²æ¤ô¡B¿}§¿¯f©Ê»Ä¤¤¬r Taita No.4: Na¡BK¡BCl¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì°ª¡A¥i¥Î©ó§C±i©Ê²æ¤ô¡B§CÁC¦å¯g Taita No.5: ¥x¤j¹q¸Ñ½è¿é²G¨t¦C¤¤¡A§tAcetate¤Î¼ö¶q³Ì°ª¡A¥i¥Î©ó°ª¼ö¶q¹q¸Ñ½è¸É¥R²G¡B§CÁC¦å¯g
ITT3,Electrolytes + Water,¥x¤j No.3 500mL,MSIV,Supplement of water¡A electrolytes and nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30¢J¥H¤U,Central vein or peripheral vein infusion¡A as needed. Taita No.1: Na 25mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 20mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 38g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.2: Na 40mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 26mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 33g/L¡A 500mL/Bot¡A 287mOsm/L. Taita No.3: Na 75mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 61mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 20g/L¡A 500mL/Bot¡A 285mOsm/L. Taita No.4: Na 110mEq/L¡A K 20mEq/L¡A Mg 0mEq/L¡A Cl 102mEq/L¡A Acetate 16mEq/L¡A Phosphate 12mM/L¡A Glucose 8g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.5: Na 36mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 17mEq/L¡A Acetate 28mEq/L¡A Phosphate 12mM/L¡A Glucose 100g/L¡A 400mL/Bot¡A 669mOsm/L.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¯SÂI¤Î¾AÀ³¯g Taita No.1: Na¡BCl ¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì§C¡F¤p¨à¥Îºû«ù²G¡B¹q¸Ñ½è¡B¤ô¥÷¡B¾i¥÷¸É¥R Taita No.2: ¦¨¤À»PTaita No.1¬Û¦ü¦ýNa¡BCl¸û¦h;¼ö¶q¤ÎK§t¶q¸û§C¡A¥i§@¬°¤p¨à©Î¦¨¤H¥Îºû«ù²G Taita No.3: NaCl§t¶q¦ü0.45 %N/S¡A¥i¥Î©óµ¥±i©Ê²æ¤ô¡B¿}§¿¯f©Ê»Ä¤¤¬r Taita No.4: Na¡BK¡BCl¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì°ª¡A¥i¥Î©ó§C±i©Ê²æ¤ô¡B§CÁC¦å¯g Taita No.5: ¥x¤j¹q¸Ñ½è¿é²G¨t¦C¤¤¡A§tAcetate¤Î¼ö¶q³Ì°ª¡A¥i¥Î©ó°ª¼ö¶q¹q¸Ñ½è¸É¥R²G¡B§CÁC¦å¯g
IV2112Z,Insulin Syringe,1mL ¯Ø®q¯ÀªÅ°w,ZOTH,,¾AÀ³¯g:¬°¯Ø®q¯ÀªÅ°w(NCS030510NBD),,,,,,,,,,,,,,,,,
IVAL,Diazepam,Valium inj 10mg/2mL,CNEU,,Anxiety¡A acute alcohol withdrawal¡A anticonvulsant.,,RT,IM or IV¡A 2-10 mg may be repeated after 4 hrs.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IVAR1,Varicella Virus Vaccine,§K¶O¤ôµk¬Ì­](¥_¥«),HIMM,,¾AÀ³¯g: Active immunisation against varicella of healthy infants from 12 months onwards¡A susceptible high-risk patients & their susceptible healthy close contacts. °Æ§@¥Î: Fever. Occasionally¡A papulovesicular eruptions. ¸T§Ò: Pregnancy. Acute febrile illness. Total lymphocyte count < 1200/mm3. Hypersensitivity to neomycin.,,2-8¢J,intradermal¡A 0.5ml / dose (children > 12 months¡A < 12 yrs),,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IVC5,Ascorbic Acid,Vitamin C (Vitacicol) inj 100mg/2mL,NUTR,Scurvy¡A adjunct in treatment of wounds and infections.,Hypersensitivity to any component of the preparation. (Vitacicol contains Benzyl Alcohol 10mg per mL),Common Dermatologic: Injection site pain¡A Swelling at injection site Serious Hematologic: Hemolysis Renal: Oxalate nephropathy,25¢J¥H¤U¡AÁ×§K¥ú½u·Ó®g,1-2mL per day. Maybe more times a day in severe cases. [Uptodate 20210731] Ascorbic acid deficiency: IM¡A IV¡A SC: 70 to 150 mg daily is an average protective dose; doses 3 to 5 times the recommended dietary allowance may be adequate for conditions with increased requirements. Burns: IM¡A IV¡A SC: 1 to 2 g daily for severe burns; dose may be determined by extent of tissue injury. Parenteral nutrition¡A maintenance requirement: IV: 200 mg/day (ASPEN 2019). Scurvy: IM¡A IV¡A SC: 300 to 1¡A000 mg daily; dose and duration of therapy should be individualized; doses up to 6 g per day have been administered. Ascor: IV: 200 mg once daily for up to a maximum of 7 days. If no improvement after one week of treatment¡A retreat until resolution of symptoms is observed. Wound healing: IM¡A IV¡A SC: 300 to 500 mg daily for 7 to 10 days pre-and post-operatively; larger doses have also been used.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ]¥¼¦³»¡©ú¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¥¼¦³»¡©ú¡C,IM;IVD;SC;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¥H³Ì¤Öµ¥¶qÅé¿nªº¿éª`²Gµ}ÄÀ«á¡A½wºC¿éª`¶W¹L10¤ÀÄÁ,1. ¥»ÃÄ¾¯·|¼vÅT¦UºØ§¿¿}ÀË¬d­È¡A¥i¯à³y¦¨°²³±©Ê¤ÏÀ³¡C 2. IVª`®g¤Ó§Ö¥i¯à¤Þ°_·w¯t¤£¨}¤ÏÀ³¡CÀR¯ßª`®g®É¡A«ØÄ³¥H³Ì¤Öµ¥¶qÅé¿nªº¿éª`²Gµ}ÄÀ«á¡A½wºC¿éª`¶W¹L10¤ÀÄÁ¡C 3. µ}ÄÀ«áªºª`®g·»²G«ØÄ³Á×¥ú¦s©ñ¨ÃºÉ§Ö¨Ï¥Î§¹²¦¡C 4. ¥»ÃÄ¾¯§tBenzyl Alcohol¡A¤£«ØÄ³¥Î©ó·s¥Í¨à¡C
IDIL,Diphenylhydantoin,Dilantin inj 100mg/2mL,CNEU,,I: Status epilepticus of the grand mal type¡A prevention and treatment of seizure occuring during neurosurgery¡A arrhythmia. CI: Sinus bradycardia¡A sino-atrial block¡A 2nd and 3rd degree AV block or in patients with Adams-Stokes sybdrome.,,,Oral: Adult: 100 mg tid¡A adjusted as needed; (max. 600 mg/day). Child: Initial¡A 5 mg/kg/day in 2-3 divided doses; maintenance¡A 4-8 mg/kg/day;(max. 300 mg/day). Slow IV (not exceeding 50 mg/min): Anticonvulsant (for status epilepticus): Adult & child¡A loading dose¡A 15 mg/kg then 5 mg/kg given after 12hrs. Alternatively¡A 20 mg/kg as a full loading dose. Antiarrhythmic: 100 mg q5mins as needed; (max.1g).,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IDIP,Propofol,Diprivan 200mg/20mL,ZANE,,,,,,,,,,,,,,,,,,,
IDIPI,Propofol,Diprivan inj 200mg/20mL,ZANE,,,,,,,,,,,,,,,,,,,
IDOB,Dobutamine,Dobuject inj 250mg/5mL,CAVS,,¾AÀ³¯g: Short-term treatment of cardiac decompensation due to depressed contractility resulting from heart disease or cardiac surgery. °Æ§@¥Î: Tachycardia¡A nausea¡A non-specific chest pain & palpitation. ¸T§Ò: Obstructive cardiomyopathy.,,«Ç·Å,Usually 2.5-10 mcg/kg/min as IV infusion.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1.¤Å¥[¤JÆP©ÊÃÄ«~
IDPT,Diphtheria + Tetanus + Pertussis,DPT vaccine §K¶O 0.5 mL/dose,HIMM,,Active immunization against diphtheria¡A tetanus and pertussis.,,2-8,IM¡A for child 6 wks-6 yrs¡A 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1yr later. Booster dose: Given at 4-6 yrs.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IDPT0,Diphtheria + Tetanus + Pertussis,¥Õ³ï¡B¦Ê¤é«y¡B¯}¶Ë­·¬Ì­](¦Û¶O),HIMM,,Active immunization against diphtheria¡A tetanus and pertussis.,,,IM¡A for child 6 wks-6 yrs¡A 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1yr later. Booster dose: Given at 4-6 yrs.,,,,,,,,,,,,,,
IDT2,Diphtheria + Tetanus,DT vaccine (child),HIMM,,Active immunization against diphtheria and tetanus.,,,IM¡A for child 6 wks-6 yrs¡A 0.5 ml/dose. Primary immunization: Child 6 wks-1 yrs: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months 1 yr later. Child over 1 yrs: 2 doses given at 4-8 wks intervals and a reinforcing 3th dose given 6 months-1 yr later. Booster dose: Given at 4-6 yrs.,,,,,,,,,,,,,,
IDW5,Water for injection,Water for inj 500mL (TPN½Õ°t¨Ï¥Î),NUTR,Solvent for parenteral preparations.,,,µL¯S§O«ü¥Ü,As TPN material.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IRR;IVD;,,,,,
IEPO,Recombinant Human Erythropoietin,Eprex (EPO 4000IU),HEMT,,¾AÀ³¯g:Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy °Æ§@¥Î:Increased BP¡A thrombotic or vascular events. Flu-like symptoms¡A bone pain & chills after inj. Seizures. Skin reactions¡A palpebral edema. Rarely¡A erythroblastopenia. ¸T§Ò:Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,,2-8¢J,Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally¡A children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ¥»ÃÄ«~¬°¹w¥ý¥R¶ñªº°wµ©¡A­­³æ¦¸¨Ï¥Î¡Aµ¹ÃÄ«e¶·¥ýÀË¬d½T©w·»²GµLÂø½è©ÎÅÜ¦â¡C 2. ¥Ö¤Uª`®g¨C¦¸Åé¿n¤£¥i¶W¹L1 mL¡C¦p»Ýª`®g¸û¤j¶q¡AÀ³©ó¤£¦P³¡¦ìµ¹ÃÄ¡C 3. ÀR¯ßª`®g®É¶¡¦Ü¤Ö¶·¶W¹L 1-5 ¤ÀÄÁ¡C¦å²G³zªR¯f¤H¦b³zªR´Á¶¡¡A¥i¸g¥Ñ³zªR½u¤º¤@­Ó¾A·íªºÀR¯ß¤J¤f¶i¦æ¤j¶qª`®g¡C 4. ¥»ÃÄ«~¡u¤£¥i¥H¡vÀR¯ßÂIºw¿éª`©Î»P¨ä¥LÃÄª«²V¥Î¡C
IEPO10,Erythropoietin,EPO 1000 IU (¬~µÇ«Ç¥Î),HEMT,,¾AÀ³¯g:Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy °Æ§@¥Î:Increased BP¡A thrombotic or vascular events. Flu-like symptoms¡A bone pain & chills after inj. Seizures. Skin reactions¡A palpebral edema. Rarely¡A erythroblastopenia. ¸T§Ò:Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,,2-8¢J,Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally¡A children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ¥»«~­­³æ¦¸¨Ï¥Î¡Aµ¹ÃÄ«e¶·¥ýÀË¬d½T©w·»²GµLÂø½è©ÎÅÜ¦â¡C 2. ¥Ö¤Uª`®g¨C¦¸Åé¿n¤£¥i¶W¹L1 mL¡C¦p»Ýª`®g¸û¤j¶q¡AÀ³©ó¤£¦P³¡¦ìµ¹ÃÄ¡C 3. ÀR¯ßª`®g®É¶¡¦Ü¤Ö¶·¶W¹L 1-5 ¤ÀÄÁ¡C¦å²G³zªR¯f¤H¦b³zªR´Á¶¡¡A¥i¸g¥Ñ³zªR½u¤º¤@­Ó¾A·íªºÀR¯ß¤J¤f¶i¦æ¤j¶qª`®g¡C 4. ¥»ÃÄ«~¡u¤£¥i¥H¡vÀR¯ßÂIºw¿éª`©Î»P¨ä¥LÃÄª«²V¥Î¡C
LPRE1,Cisapride,Prepulsid susp 1mg/mL,ALIM,,,,,,,,,,,,,,,,,,,
OWIN,Cefadroxil,Wincef 500mg,QANB,,¾AÀ³¯g: Susceptible infections. °Æ§@¥Î: Nausea¡A vomiting¡A diarrhoea¡A abdominal discomfort; skin rash¡A angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida. Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult: 1-2 g/day in 1-2 divided doses¡A (max. 6 g/day). Child: 15 mg/kg q12h.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IFOR1,Paclitaxel,Formoxol inj 102mg/17mL,RACA,,¾AÀ³¯g: After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma. °Æ§@¥Î: Bone marrow suppression¡A peripheral neuropathy¡A GI disturbances¡A alopecia¡A hypersensitivity. ¸T§Ò: Baseline neutropenia¡A severe hepatic impairment.,,«Ç·Å,135-175 mg/m2 IV over 3 hr every 3 weeks. Patients must be premedicated dexamethasone¡A diphenhydramine & cimetidine prior to administration.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OULE,Cephalexin,Ulex 250mg,QANB,,G(+) (not enterococci¡A variable against beta-lactamase + staph. & Neissria¡A not methicillin-resistant staphylococcus aureus) G(-)(urinary infections due to most E. coli¡A Pr. mirabilis¡A & some klebsiella¡A variable against samonella and shigella¡A not enterobacter¡A pseudomonas¡A acinetobacter),,RT,Adult: 250 mg q6h¡A (max. 4g/day). Child: 6.25-12.5 mg/kg q6h¡A up to 25 mg/kg q6h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IINT3,Leucovorin,Antrex inj 30mg/10mL,ZADT,,,,,,,,,,,,,,,,,,,
ORED,Sibutramine,Reductil 10mg 28's/box,META,,¾AÀ³¯g: Adjunctive therapy within a weight management programme for obese patients with BMI >= 30 kg/m2¡A overweight patients with BMI >= 27 kg/m2 or above who have obesity-related risk factors like type 2 diabetes or dyslipidemia. °Æ§@¥Î: Loss of appetite¡A constipation; dry mouth¡A insomnia; tachycardia¡A palpitations¡A hypertension; dizziness¡A paresthesia¡A headache¡A anxiety; sweating; taste disturbances. ¸T§Ò: Bulimia nervosa¡A psychiatric illness¡A Gilles de la Tourette's syndrome¡A coronary artery disease¡A CHF¡A tachycardia¡A occlusive artery disease¡A heart rhythm disorder¡A cerebrovascular disease¡A inadequately controlled hypertension¡A hyperthyroidism¡A severely hepatic/renal impairment¡A benign prostatic hyperplasia¡A pheochromocytoma¡A narrow angle glaucoma¡A pregnancy¡A lactation¡A children < 16¡A elderly ? 65. Concomitant use of MAOIs or other CNS active drugs for the treatment of mental disorders (such as antidepressants or antipsychotics)¡A for sleep disorders (tryptophan) or for weight reduction. Misuse of drugs¡A medicines or alcohol.,,«Ç·Å,D: Initial dose is 10 mg qd; if weight loss < 2 kg in 4 weeks and well-toleranted patients can increased to 15 mg qd.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ETAZ,Tazarotene,Zorac gel 0.1%¡A 30gm,TDER,,I: Stable plaque psoriasis¡A acne vulgaris. AR: Prurtus¡A burning/stinging¡A erythema¡A worsening of psoriasis¡A irritation¡A pain¡A rash¡A desquamation¡A contact dermatitis. CI: Pregnancy.,,,D: Apply once daily at night.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OFA,Folic Acid,Folic acid 5mg,NUTR,Pernicious anemia¡A pregnancy¡A megaloblastic anemia¡A aplastic anemia.,Hypersensitivity to any component of the formulation.,GI upset at high doses.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,1 TAB contains 5 mg folic acid. Adult: Initially 1 TAB TID for 14 days. Maintenance: 1 TAB daily for 1-7 days. Children 6-12 years: Initially 2 TAB/day. Maintenance: As half of initial dose. Children 1-5 years: Initially 1 TAB /day. Maintenance: As half of initial dose. Children <1 years: 0.5 mg/kg body weight/day. Maintenance: As half of initial dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OVEN,Coumarin + Troxerutin,Venalot depot,HEMT,,¾AÀ³¯g: Congestive symptoms due to venous (chronic venous insufficiency) & lymphatic lymphedema) flow impairments such as edemas¡A skin & tissue changes( dermatosiderosis¡A dematoliposclerosis)¡A ulcus cruris venosum. Superficial phlebitis. Hemorrhoids. Swelling after sports & accidental injuries (e.g. contusions & sprains) & after operations. Drug- or radiation-induced xerostomia. °Æ§@¥Î: Elevations of liver enzymes. Rarely¡A hepatitis with or without jaundice. ¸T§Ò: Liver disease or a past history of liver diseases.,,«Ç·Å,1-2 tab tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OWEL,Aluminum Hydroxide,Wellpin,ALIM,,I:Hyperacidity¡A flatulence¡A indigestion¡A abdominal pain. AR:Nausea¡A vomiting.,,,Adult (>12 yr) : 2 tab. tid ~ qid. Children (6 ~12 yr): 1 tab. tid ~ qid.,,,,,,,,,,,,,,
OXAN,Alprazolam,Xanax 0.5mg,CNEU,Anxiety states¡A Anxiety with symptoms of depression.,Acute narrow angle glaucoma.,Common: Decrease in appetite (7.3-27.8%)¡A Increased appetite (7-32.7%)¡A Weight increased (2.7-27.2%)¡A Constipation (8.1-26.2%)¡A Reduced salivation (32.8%)¡A Xerostomia (10.2-14.7%)¡A Cognitive disorder (28.8%)¡A Confusion (1.5-10.4%)¡A Dysarthria (10.9-23.3%)¡A Incoordination (9.4-40.1%)¡A Lightheadedness (20.8%)¡A Memory impairment (15.4-33.1%)¡A Sedated (45.2%)¡A Somnolence (23-76.8%)¡A Irritability (immediate-release¡A 33.1%; extended-release 1% or more)¡A Reduced libido (6-14.4%)¡A Fatigue (13.9-48.6%) Serious: Stevens-Johnson syndrome¡A Liver failure¡A Seizure co-occurrent and due to substance withdrawal,25¢J¥H¤U,Adults: General dose: 0.25-0.5mg TID¡A dosage range:0.5-4mg/day. Slowly reduce the dose when stopping the drug. The reduction should not exceed 0.5mg every three days. Elderly or frail patients: Elderly patients who have not used psychotropic drugs should be treated with the lowest effective dose. Children: Safety and efficacy have not been established.,»Ý½Õ¾ã¾¯¶q,Advanced liver disease: Immediate release tablet: 0.25 mg 2 to 3 times daily.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OXAT1,Alfuzosin,Xatral XL 10mg,SGU,,¾AÀ³¯g:¨}©Ê«e¦C¸¢ªÎ¤j¡C(B022917100),,RT,1 tab after dinner.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OKRE,PSK,Krestin 1gm,RACA,Cancer chemotherapy adjunct¡A used in neoplastic diseases as immunomodulator.,Hypersensitivity to Coriolus versicolor,Dark colored stools¡A nail pigmentation¡A diarrhea¡A abnormal liver functions,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,3 g daily administered in 1 to 3 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IIPR,Hexoprenaline,Ipradol inj 5mcg/2mL,ERSP,,¾AÀ³¯g:¹w¨¾¤ä®ðºÞµjÅË(B000656212),,RT,IM¡A slow IV. Adult: Acute asthmatic 1 amp; severe dyspnea 1.5-2 amp; status asthmaticus 1 amp tid-qid. Child: 1-3 mcg qd-tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IHBV1,Hepatitis B Vaccine,Engerix-B (B¨x¬Ì­]¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Active immunisation against hepatitis B virus infection.,Severe allergic reaction after a previous dose of any hepatitis B-containing vaccine or to any vaccine component¡A including yeast.,Common: Injection site disorder¡A Diarrhea¡A Nausea¡A Asthenia (>1%)¡A Headache (1-10%)¡A Fatigue (14%)¡A Fever¡A Malaise Serious: Pancytopenia¡A Anaphylaxis,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A > or = 20 years 20 mcg/1mL/dose¡A < or = 19 years 10 mcg/0.5 mL/dose¡A 3 doses at 0¡A 1¡A and 6 months or 4 doses at 0¡A 1¡A 2¡A and 12 months. > or = 20 years rapid immunization 3 doses at 0¡A 7¡A and 21 days with a booster at 12 months. Renal insufficiency > or = 16 years 4 double doses (20 mcg x 2) at 0¡A 1¡A 2¡A and 6 months. 11-15 years 2 doses (20 mcg) at 0 and 6 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] ¥Ø«e¨ÃµL¨¬°÷ªº©ó¤HÃþÃh¥¥´Á¶¡¨Ï¥Î¤§¸ê®Æ¤Î°Êª«¥Í´Þ¬ã¨s¡CµM¦Ó¡A»P¨ä¥¦¥h¬¡©Ê¯f¬r¬Ì­]¤@¼Ë¡A§Ú­Ì¨Ã¤£§Æ±æ­L¨à¨ü¨ì¥ô¦ó¶Ë®`¡C ¦]¦¹¡A¥u¦³¦b©ú½T¥²­n¥B¨ä¼ç¦b®Ä¯q¶W¶V¹ï­L¨àªº¼ç¦b¦MÀI©Ê®É¡A¤~¥i¦bÃh¥¥´Á¶¡¨Ï¥ÎEngerix-B¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«e¨ÃµL¨¬°÷ªº©ó¤HÃþ±Â¨Å´Á¶¡¨Ï¥Î¤§¸ê®Æ¤Î°Êª«¥Í´Þ¬ã¨s¡C ©|¥¼½T»{¦³¥ô¦óªº¸T§Ò¡C,IM;,,,,,1. ¥H¦Ù¦×ª`®g©ó¦¨¤H©Î¨àµ£ªº¤âÁu¤T¨¤¦Ù³¡¦ì¡A©Î·s¥Í¨à¡BÀ¦¨à¡B¥®µ£ªº¤j»L«e¥~°¼¡C 2. ¦å¤pªO´î¤Ö¯g©Î¥X¦å©Ê¯e¯f±wªÌ¥i¥H¥Ö¤Uª`®g¤è¦¡§ë»P¡C
OLAD,Danazol,Ladogal 200mg,HM,,¾AÀ³¯g:¥Dªv¤l®c¤º½¤²§¦ì(B022413100),,RT,Endometriosis: 400 mg bid for 3-6 months up to 9 months. Hereditary angioedema: 1-2 cap bid-tid. Fibrocystic breast cancer: 100-400 mg bid.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OLAMC,Lamotrigine,Lamictal 50mg,CNEU,Monotherapy in adult and children >12 year or as add-on therapy in adult and children > 2 year for the treatment of epilepsy (partial seizures and generalised seizures)¡A including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Prevention of depressive episodes in patients with bipolar disorder.,Hypersensitivity to any component of the formulation.,Skin rash¡A irritability¡A headache¡A drowsiness¡A insomnia¡A dizziness¡A tremor¡A nystagmus¡A ataxia¡A diplopia¡A blurred vision¡A nausea¡A vomiting¡A diarrhoea¡A tiredness¡A arthralgia¡A pain¡A back pain. Dermatologic: Rash (immediate-release¡A 10% or less (adult); 14% (pediatric) ) Gastrointestinal: Abdominal pain (immediate-release¡A 5% to 10% )¡A Diarrhea (immediate-release¡A 6% to 11%; extended-release¡A 5% )¡A Indigestion (immediate-release¡A 2% to 7% )¡A Nausea (immediate-release¡A 7% to 25%; extended-release¡A 7% )¡A Vomiting (immediate-release¡A 5% to 20%; extended-release¡A 6%)) Neurologic: Asthenia (immediate-release¡A 2% to 8%; extended-release¡A 6% )¡A Ataxia (immediate-release¡A 2% to 11% )¡A Coordination problem (immediate-release¡A 6% to 7%; extended-release¡A 3% )¡A Dizziness (immediate-release¡A 7% to 54% ; extended release¡A 14% )¡A Headache (immediate-release¡A 29% )¡A Insomnia (immediate-release¡A 5% to 10% )¡A Somnolence (immediate-release¡A 9% to 17%; extended-release¡A 5% )¡A Tremor (immediate-release¡A 4% to 10%; extended-release¡A 6% )¡A Vertigo (immediate-release¡A 2%; extended-release¡A 3% ) Ophthalmic: Blurred vision (immediate-release¡A 11% to 25% (adults) and 4% (children); extended-release¡A 3%)¡A Diplopia (immediate-release¡A 24% to 49% (adults) and 5% (children); extended-release¡A 5%) Psychiatric: Anxiety (immediate-release¡A 4%; extended-release¡A 3%)¡A Depression (immediate-release¡A 4%; extended-release¡A 3% ) Reproductive: Dysmenorrhea (immediate-release¡A 5% to 7% ) Respiratory: Rhinitis (immediate-release¡A 7% to 14% ) Other: Pain (immediate-release¡A 5%),30¢J¥H¤U¡AÁ×¥ú¥B«O«ù°®Àê,Adult & childn > 12yrs for mono therapy: Initially 25 mg once a day for 2 weeks¡A and 50 mg once a day for next 2 weeks¡A then increasing up to 50-100 mg every 1-2 weeks to achieve the desired effect. Maitenance: 100-500 mg/day in 1-2 divided doses. With valproate or without other antiepileptic drugs: the initial dose of Lamictal is 25 mg every other day for 2 weeks; then 25 mg daily for the next 2 weeks. Then increase 25-50 mg at most every 1-2 weeks to achieve an appropriate response. Maintenance: 100-200 mg/day QD or BID. With other Antiepileptic drugs or other drugs that induce lamotrigine aldose: Initially 50 mg QD for 2weeks¡A and 100 mg BID for the next 2 weeks. then increasing to 100 mg every 1-2 weeks to achieve the desired effect. Maintenance: 200-700 mg/day in 1-2 divided doses. With other drugs that do not significantly inhibit or induce lamotrigine aldose: Initially 25 mg QD for 2weeks¡A and 50 mg BID for the next 2 weeks. then increasing to 50-100 mg every 1-2 weeks to achieve the desired effect. Maintenance: 100-200 mg/day in 1-2 divided doses.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh B)­°§C¾¯¶q¬ù50%¡A¼W¥[©Mºû«ù¾¯¶q¶·®Ú¾Ú¯f±wªºÁ{§É¤ÏÀ³½Õ¾ã ­««×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh C)­°§C¾¯¶q¬ù75%¡A¼W¥[©Mºû«ù¾¯¶q¶·®Ú¾Ú¯f±wªºÁ{§É¤ÏÀ³½Õ¾ã,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¶·¾ã²É§]ªA¡A¤£­n©CÄZ¡C¦]¼t°ÓµL¬ÛÃö¦w©w©Ê´ú¸Õ¡C
OLE15,Folinic Acid,Leucovorin 15mg,ZADT,,An antidote or rescue after treatment with high dose of methotrexate. To diminish oxicity and counteract effect of overdosage of folic acid antagonist. For treatment of megaloblastic anemias.,,,For megaloblastic anemia: 1-15mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OLEUC,Leucomycin,Leucomycin 250mg,QANB,,Tonsillitis¡A pharyngitis¡A pertussis¡A bronchitis¡A pneumonia¡A pyothorax¡A mastitis¡A osteomyelitis¡A gonorrhea¡A urethritis¡A syphilis¡A otitis media¡A septicemia¡A bacteria endocarditis¡A scarlet fever¡A scrub typhus & diphtheria.,,,1-2 cap every 6 hrs.,,,,,,,,,,,,,,
OLIB,Chlordiazepoxide,Librium 5mg,CNEU,,¾AÀ³¯g: Tension¡A fear & anxiety. Muscular spasm of psychogenic¡A neurogenic or myogenic origin¡A acute alcohol withdrawal. °Æ§@¥Î: May affect psychomotor performances. Ataxia & drowsiness.,,«Ç·Å,Adult 20-40 mg daily; severe cases: 50-100 mg daily. Elderly or debilitated patient 5-10 mg daily & only in exceptional cases more. Children 5-10 mg daily¡A may be increased to 20-30 mg or in special cases more¡A daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OLIM,Tramadol,Limadol 50mg,CNEU,,safety and efficacy <16 y/o have not been established FDA label use: Cancer pain¡A chronic pain: moderate to moderately severe contraindication: a)Rasagiline (theoretical); Selegiline (theoretical) b)situations where opioids are contraindicated¡A( including intoxication with alcohol¡A hypnotics¡A narcotics¡A centrally acting analgesics¡A opioids¡A or psychotropic drugs; may worsen CNS and respiratory depression) Commen side effect: a)Dermatologic: Flushing (7.7% to 15.8% )¡A Pruritus (6.2% to 11.9% ) b)Gastrointestinal: Constipation (12.2% to 29.7% )¡A Diarrhea (3.7% to 8.5% )¡A Nausea (15.1% to 26.2% )¡A Vomiting (5% to 9.4% )¡A Xerostomia (5% to 9.8% ) c)Neurologic: Asthenia (3.5% to 6.5% )¡A Dizziness (15.9% to 28.2% )¡A Headache (11.5% to 15.8% )¡A Insomnia (6.5% to 10.9% )¡A Somnolence (7.3% to 20.3% ) severe side effect: a)Cardiovascular: Myocardial infarction (0.5% to less than 1% )¡A Palpitations (0.5% to less than 1% ) b)Gastrointestinal: Pancreatitis (0.5% to less than 1% ) c)Hepatic: Liver function tests abnormal (0.5% to less than 1% ) d)Immunologic: Anaphylactoid reaction Neurologic: Seizure Respiratory: Dyspnea (1% to less than 5%,,,safety and efficacy <16 y/o have not been established Usual dose: 50-100mg q 4-6 h¡A max 400mg/day Dosage in renal impairment: Clcr< 30 ml/min¡A increase dosing interval to 12 h ; max. 200 mg/day dose for patients with cirrhosis: 50 mg q 12 h Thomson: Infant risk cannot be ruled out,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OLIP,Etofibrate,Lipo-Merz retard 500mg,CAVS,,¾AÀ³¯g:¬°­°¦å¯×ÃÄ(B010330100) CI: Liver diseases¡A gallbladder diseases¡A severe renal insufficiency¡A decompensated heart failure¡A acute cardiac infarct¡A acute bleedings. Pregnancy & lactation.,,RT,1 cap daily.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
LSEC,Chlorpheniramine + Guaifenesin + Methylephedrine,Secorine syrup 120mL,ERSP,Relief of cold symptoms (runny nose¡A nasal congestion¡A sneezing and phlegm).,Hypersensitivity to any component of the formulation.,Dizziness¡A palpitations¡A nausea¡A vomiting¡A skin rash,25¢J¥H¤U¡A¤£»Ý¦B¦s,Adult and >12 years children 20 mL TID. Children 9-12 years 10 mL(1/2 adult dose) TID. Children 6-9 years 6.7 mL(1/3 adult dose ) TID. Children < 6 years depended on doctor.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,CHLORPHENIRAMINE PREGNANCY RECOMMENDATION: Compatible GUAIFENESIN PREGNANCY RECOMMENDATION: Compatible Methylephedrine¨S¦³¸ê®Æ,Unknown ¨S¦³¸ê®Æ,CHLORPHENIRAMINE BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible GUAIFENESIN BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible Methylephedrine¨S¦³¸ê®Æ,AC;AC15;PC;PO;WM;,,,,,
LTRIM,Sulfamethoxazole + Trimethoprim,Trimerin syr 60mL,QANB,,,,,Antimicrobial: Adult: 2 tab q12h. Child over 2 months under 40 kg: 20 mg/kg syr & 4 mg/kg tab q12h. Antiprotozoal (Pneumocystis carinii pneumonia): Adult & child over 2 months: 18.75-25 mg/kg syr. & 3.75-5 mg/kg tab q6h for 2 wks.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LULO,Erythromycin,Ulosina(Erythromycin) susp 25mg/mL¡A 60mL,QANB,,¾AÀ³¯g: Prophylaxis of endocarditis; syphilis; otitis media; diphtheria; pertussis; Legionnaires' disease; enteritis¡A chancroid¡A severe acne vulgaris; M pneumoniae & chlamydia trachomatis infections. °Æ§@¥Î: Abdominal discomfort; Allergic reactions; hepatotoxicity; reversible hearing loss. ¸T§Ò: Liver impairment.,,«Ç·Å,Adult 1 g daily in 2-4 divided doses; 2-4 g daily in severe infection. Children 30-50 mg/kg body weight daily¡A may be doubled in severe infection.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
LZIT,Azithromycin,Zithromax 200mg/5mL suspension¡A 15mL,QANB,Upper & lower respiratory tract infections; skin & soft tissue infections; otitis media; uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrheae.,Cholestatic jaundice with prior azithromycin therapy. Hepatic dysfunction with prior azithromycin therapy. Hypersensitivity to azithromycin or to any product component¡A erythromycin¡A or any macrolide or ketolide antibiotic.,Common: Injection site disorder (3.1-6.5%)¡A Abdominal pain (adult¡A 1.9-14%; pediatric¡A 2-4%)¡A Diarrhea (Adult¡A 4.3-12%; pediatric¡A 7-10%)¡A Flatulence (5%)¡A Nausea (Adult¡A 3-14%; pediatric¡A 4%)¡A Vomiting (Adult¡A up to 13%; pediatric¡A 11-14%)¡A Increased liver enzymes (<1-6%)¡A Headache (up to 5%)¡A Abnormal vision (5%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Congenital hypertrophic pyloric stenosis¡A Hepatic necrosis¡A Hepatitis (<1%)¡A Liver failure¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Eaton-Lambert syndrome¡A Myasthenia gravis¡A Exacerbation of¡A Myasthenic crisis¡A Corneal erosion (<1%),30¢J¥H¤U,Adults and children weighing > or = 45 kg: 500 mg orally once daily with or without food for 3 days. Sexually transmitted diseases caused by Chlamydia trachomatis: 1 g as single oral dose. Children 10 mg/kg once daily for 3 days.,µL»Ý½Õ¾ã¾¯¶q,¨Ö¦³»´(A¯Å)¦Ü¤¤«×(B¯Å)¨x¥\¯à·l®`ªº±wªÌ¡AµL¶·½Õ¾ã,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;PC;PO;WM;,,,,,
MS0330,Alcohol,Alcohol 1mL °sºë,ZOTH,,,,,,,,,,,,,,,,,,,
MS2200,,3x12cm Silicone Gel Sheet¦w½§¾A¬Í²ªª¿½¦¤ù,ZOTH,,,,,,,,,,,,,,,,,,,
MS2201,,4x15cm Silicone Gel Sheet¦w½§¾A¬Í²ªª¿½¦¤ù,ZOTH,,,,,,,,,,,,,,,,,,,
MS2202,,4x12 Silk ª¿½¦¤ù,ZOTH,,,,,,,,,,,,,,,,,,,
MS2203,,4x18 Silk ª¿½¦¤ù,ZOTH,,,,,,,,,,,,,,,,,,,
OROB,Ribavirin,Robatrol 200mg,QANB,,¾AÀ³¯g: In combination with interferon £\ for the treatment of chronic hepatitis C in adult patients who are £\-interferon-naive or who have relapsed following £\-interferon therapy. °Æ§@¥Î: Haemolysis¡A anaemia¡A neutropenia¡A dry mouth¡A hyperhidrosis¡A asthenia¡A chest pain¡A fatigue¡A fever¡A headache¡A flu-like symptoms¡A malaise¡A rigors¡A weight loss¡A dizziness¡A paresthesia¡A GI disturbances¡A arthralgia¡A myalgia¡A CNS effects¡A viral infection¡A cough¡A dyspnoea¡A pharyngitis¡A rhinitis¡A alopecia¡A pruritus¡A rash¡A dry skin¡A parageusia¡A blurred vision. Dermatologic: Pruritus¡A Rash Gastrointestinal: Indigestion¡A Loss of appetite¡A Nausea Hematologic: Neutropenia (8% to 40% ) Neurologic: Headache Other: Fatigue ¸T§Ò: History of severe pre-existing cardiac disease; haemoglobinopathies; severe¡A debilitating medical conditions; severe hepatic dysfunction or decompensated liver cirrhosis; autoimmune hepatitis or a history of autoimmune disease; pre-existing thyroid disease. Pregnancy & lactation.,,«Ç·Å,Adult >= 18 years 1000-1200 mg daily in 2 divided doses¡A in combination with interferon £\ soln for inj administered SC at a dose of 3MIU 3 times/wk.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OLIP2,Fenofibrate,LIPANTHYL 200M,CAVS,,I: Endogenous hypercholesterolaemia (type IIa) & hypertriglyceridaemia¡A either in isolation (type IV) or in association (type IIb & III). AR: GI disturbances¡A allergic skin reactions¡A elevation of transaminases¡A muscular pains. CI: Serious hepatic & renal insufficiency¡A children.,,Room Temperature,200 mg qd with meal.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OZYP,Olanzapine,Zyprexa 5mg,CNEU,,¾AÀ³¯g¡GOlanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment¡A olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. °Æ§@¥Î: Somnolence¡A weight gain¡A dizziness¡A akathisia¡A parkinsonism¡A dyskinesia¡A increased appetite¡A elevated glucose & triglyceride levels¡A asthenia¡A edema¡A orthostatic hypotension¡A dry mouth¡A constipation¡A eosinophilia¡A elevated prolactin levels (but clinical manifestations rare). May affect ability to operate machinery or drive motor vehicles. Elderly patients with dementia: a higher incidence of death and cerebrovascular adverse events; abnormal gait and falls; Pneumonia and urinary incontinence. Cardiovascular: Orthostatic hypotension (1% to 5% )¡A Peripheral edema (3% to 6% ) Endocrine metabolic: Hypercholesterolemia (up to 24% )¡A Hyperglycemia (0.1% to 17.4% )¡A Increased appetite (3% to 24% )¡A Increased prolactin level (31.2% to 61.1% )¡A Serum triglycerides raised (up to 40% )¡A Weight gain (up to 57% ) Gastrointestinal: Constipation (4% to 11% )¡A Xerostomia (3% to 32% ) Neurologic: Akathisia (3% to 27% )¡A Asthenia (2% to 20% )¡A Dizziness (1.6% to 18% )¡A Somnolence (6% to 52% )¡A Tremor (1% to 23% ) Psychiatric: Personality disorder (8% ) Other: Accidental injury (4% to 12% )¡A Fever (up to 4% ) ¸T§Ò: Patients with known risk of narrow-angle glaucoma. Neuroleptic malignant syndrome.,,«Ç·Å,Adult Schizophrenia Starting dose: 10 mg/day. Manic episodes Starting dose: 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in patients whose manic episodes have responded previously to olanzapine Starting dose: 10 mg daily. Dose range for all indications: 5-20 mg daily. A lower starting dose (5 mg/day) should be considered for elderly patients (> 65 years) & in renal or hepatic impairment.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OPRE5,Estrogen + Medroxyprogesterone,Premelle cycle 5,HM,,I: Moderate-to-severe vasomotor symptoms associated with estrogen deficiency. Prevention & management of osteoporosis associated with estrogen deficiency. Atrophic vaginitis & atrophic urethritis. AR: Increased risk of breast cancer¡A gallbladder disease¡A thrombophlebitis and/or thromboembolic disease. Increase in BP¡A fluid retention¡A changes in glucose tolerance¡A vag. bleeding¡A breast pain¡A tenderness & enlargement. GI effects¡A alopecia¡A rash¡A hirsutism¡A pruritus¡A visual disturbances¡A headache¡A nervousness. CI: Konwn or suspected cancer of the breast¡A estrogen-dependent neoplasia¡A pregnency. Undiagnosed abnormal genital bleeding. Active thrombophlebitis or thromboembolic disorders. Liver dysfunction or disease.,,,D: 1 maroon tab daily for the 1st 14 days¡A followed 1 blue tab daily for the next 14 days.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IMIXT,Human Insulin Regular/NPH 30/70,Mixtard insulin 30/70 10mL,META,,Insulin-requiring diabetes mellitus.,,,Administer SC once or bid.Duration of action:Onset 1/2 hr¡A peak between 2nd-8th hr¡Aterminates after approx 24 hr. Vial:Soluble human monocomponent insulin 30% & Isophane human monocomponent insulin 70% ¡A100 IU/ml x10ml.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EPULN,Budesonide,Pulmicort »ó¼Q¾¯ 64mcg/dose,TENT,,¾AÀ³¯g: Seasonal & perennial rhinitis¡A vasomotor rhinitis. Prevention of nasal polyps after polypectomy. °Æ§@¥Î: Local irritation¡A slight hemorrhagic secretion¡A epistaxis. Hypersensitivity reactions. Gastrointestinal: Diarrhea (inhalation¡A 4%; oral¡A 10% )¡A Nausea (inhalation¡A 1.8% to 6%; oral¡A 11% ) Musculoskeletal: Arthralgia (inhalation¡A 6%; oral¡A 5% ) Neurologic: Headache (inhalation¡A 3%; oral¡A 21% ) Respiratory: Epistaxis (intranasal¡A 8%; inhalation¡A 2% to 4% )¡A Nasal stinging/burning (intranasal¡A greater than 1% )¡A Respiratory tract infection (inhalation¡A 3% to 38%; oral¡A 11% )¡A Sinusitis (inhalation¡A 3% to 16%; oral¡A 8% ) ¸T§Ò: Hypersensitivity to budesonide or any of the ingredients.,,«Ç·Å,Rhinitis Adult & children >= 6 years Initially 256 mcg daily as single (2 sprays of 64 mcg in each nostril) or in 2 divided doses (1 spray of 64 mcg in each nostril). Maintenance: 32 mcg in each nostril once daily in the morning. Treatment or prevention of nasal polyps 256 mcg daily as single or in 2 divided doses.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IMAX,Sulbactam,Maxtam inj 500mg,QANB,,¾AÀ³¯g: To be combined with ampicillin to treat the moderate to severe bacterial infection. °Æ§@¥Î: Blood disorders¡A hypersensitivity¡A GI disturbances¡A chronic nephritis¡A dizziness¡A headache. ¸T§Ò: Hypersensitivity to £]-lactam antibiotics.,,«Ç·Å,Adult 0.5-1 g 6¡A 8 or 12 hrly IM/IV. Max: 4 g/day. Children 50 mg/kg/day given 6¡A8 or 12 hrly. Max: 80 mg/kg/day.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. IM: µ¹ÃÄ«á3 ~ 5¤ÀÄÁ¡Aª`®g¨Ö¥Î§Ü¥Í¯À¡C 2. IVF: ¥»ÃÄ¥i©óª`®g¨Ö¥Î§Ü¥Í¯À«e3 ~ 5¤ÀÄÁ¬I¥´¡A©Î»P¨Ö¥Î¤§ampicillin²V¦X«á½wºCºwª`¡C
ODIA3,Gliclazide,Diamicron MR 30mg,META,,¾AÀ³¯g: ²Ä¤G«¬¿}§¿¯f(B023503100) °Æ§@¥Î: Hypoglycaemia¡A nausea¡A dyspepsia¡A diarrhoea¡A constipation. ¸T§Ò: Type 1 diabetes¡A diabetic keto-acidosis or diabetic pre-coma¡A severe renal or hepatic insufficiency¡A co-administration with miconazole¡A pregnancy¡A lactation. Avoid coadministration with phenylbutazone or danazol.,,«Ç·Å,1-4 tab taken once daily at breakfast. Max : 120 mg daily.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OXEN1,Orlistat,Xenical 120mg,META,,,,,,,,,,,,,,,,,,,
EPOD,Podophylline,Podophylline extract,TDER,,,,,,,,,,,,,,,,,,,
EPOL,Tar + Cade Oil + Coal Tar Soln,Polytar liquid 1% 150mL,TDER,,¾AÀ³¯g: Seborrhea¡A psoriasis. Dandruff & itching scalp. °Æ§@¥Î: Skin irritation¡A rash¡A mild photosensitivity.,,«Ç·Å,Use as scalp cleanser once or twice weekly.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EPOS,Hydrocortisone + Polyvalent Colibacilli,Posterisan forte oint 10gm,ALIM,,¾AÀ³¯g:¥Dªvµi½H(B012133329),,RT,Apply to affected areas several times daily.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EPP,Potassium Permanganate,Pot permanganate 1gm,AGENT,,,,,,,,,,,,,,,,,,,
EPRE4,Conjugated Estrogen,Premarin vag cream 42.5gm(¤j¾¯¶q),SGU,,¾AÀ³¯g: Atrophic vaginitis. Post-menopausal atrophic urethritis. °Æ§@¥Î: Rarely nausea¡A vomiting. Breakthrough bleeding¡A spotting¡A change in menstrual flow¡A amenorrhea. Breast tenderness¡A enlargement¡A secretion. GI effects¡A cholestatic jaundice. Chloasma or melasma. Steepening of the corneal curvature; intolerance to contact lenses. Headache¡A migraine¡A dizziness; chorea. Wt changes; edema; changes in libido. Cardiovascular: Edema¡A Vasodilatation (vaginal cream¡A 21 days on/7 off regimen¡A 3.5%; 2 times/wk regimen¡A 5% ) Dermatologic: Chloasma¡A Hirsutism¡A Injection site reaction¡A Pruritus (5% ) Endocrine metabolic: Weight change finding Gastrointestinal: Abdominal pain (vaginal cream¡A 21 days on/7 off regimen¡A 7.7%; 2 times/wk regimen¡A 6.4% )¡A Bloating symptom¡A Diarrhea (vaginal cream¡A 21 days on/7 off regimen¡A 2.8%; 2 times/wk regimen¡A 7.1% )¡A Flatulence (7% )¡A Nausea (oral¡A 9% ; vaginal cream¡A 21 days on/7 off regimen¡A 3.5%; 2 times/wk regimen¡A 2.1% )¡A Stomach cramps¡A Vomiting Musculoskeletal: Backache (vaginal cream¡A 21 days on/7 off regimen¡A 4.9%; 2 times/wk regimen¡A 9.3% )¡A Leg cramp Neurologic: Asthenia (vaginal cream¡A 21 days on/7 off regimen¡A 5.6%; 2 times/wk regimen¡A 1.4% )¡A Headache (vaginal cream¡A 21 days on/7 off regimen¡A 11.2%; 2 times/wk regimen¡A 17.9% )¡A Migraine Psychiatric: Depression¡A Disturbance in mood Reproductive: Disorder of menstruation¡A Pain of breast (oral¡A 12% ; vaginal cream¡A 21 days on/7 off regimen¡A 5.6%; 2 times/wk regimen¡A 2.9% )¡A Swelling of breast¡A Vaginitis (vaginal cream¡A 21 days on/7 off regimen¡A 5.6%; 2 times/wk regimen¡A 5% )¡A Withdrawal bleeding Respiratory: Increasing frequency of cough (vaginal cream¡A 21 days on/7 off regimen¡A 0%; 2 times/wk regimen¡A 5% )¡A Pharyngitis (vaginal cream¡A 21 days on/7 off regimen¡A 2.1%; 2 times/wk regimen¡A 5% ) Other: Accidental injury (vaginal cream¡A 21 days on/7 off regimen¡A 2.8%; 2 times/wk regimen¡A 6.4% )¡A Disorder of skin appendage (vaginal cream¡A 21 days on/7 off regimen¡A 8.4%; 2 times/wk regimen¡A 11.4% )¡A Infectious disease (vaginal cream¡A 21 days on/7 off regimen¡A 4.9%; 2 times/wk regimen¡A 11.4% )¡A Pain (vaginal cream¡A 21 days on/7 off regimen¡A 7%; 2 times/wk regimen¡A 2.9% ) ¸T§Ò: Known or suspected breast cancer¡A estrogen-dependent neoplasia¡A active thromboembolic disease¡A undiagnosed abnormal genital bleeding. Pregnancy.,,«Ç·Å,Intravaginally or topically¡A 0.5-2 g daily depending on severity of condition. Max: 4 g/day. Cyclic administration (3 weeks on & 1 week off) should be used.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EPROO,Hydrocortisone + Cinchocaine,Proctosedyl oint 15gm,ALIM,,,,RT,Rectal or applied topically¡A bid & after each stool.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EQUI,Azapentacene Polysulfonate Sodium,Quinax 15mL,TOPH,,¾AÀ³¯g: Senile cataract¡A traumatic cataract.,,§NÂÃ2-8¢J,Instill 2 gtt 3-5 times daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EREG,Minoxidil,Regain(Minoxidil) 5%¡A 60mL,TDER,,I: Alopecia androgenetica. AR: Scaling¡A dry skin¡A burning sensation¡A rash¡A erythema/flushing¡A dermaitis¡A hypertrichosis¡A infrequent allergic reactions¡A dizziness¡A tingling reaction¡Aheadache¡A weakness¡A neuritis¡A edema¡A eye irritation¡A altered taste¡A eye infection¡A visual disturbances¡A rarely alopecia¡A hair abnormalities¡A chest pain¡A BP changes¡A hepatitis¡A kidney calculi. CI: Pregnancy¡A lactation.,,RT,Applied bid,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
INAHCO3,Sodium Bicarbonate,Sod. Bicarbonate inj 7% 20mL,NUTR,,¾AÀ³¯g:Metabolic acidosis arising from a variety of disorders¡A eg diabetic ketoacidosis¡A diarrhoea¡A kidney disturbances & shock. To correct hyperkalaemia. Acute poisoning from weakly acidic drugs¡A eg phenobarbitone & salicylates. °Æ§@¥Î:Metabolic alkalosis; shortness of breath & muscle weakness; muscle hypertonicity¡A twitching & tetany; Na overloading & hyperosmolality. Stomach cramps & flatulence. Tissue necrosis at inj site. ¸T§Ò:Metabolic or respiratory alkalosis¡A hypocalcaemia¡A hypochlorhydria. Avoid overtreatment.,,«Ç·Å,Metabolic acidosis IV 2-5 mEq/kg over 4-8 hr. Cardiac arrest IV 1 mEq initially¡A then 0.5 mEq/kg every 10 min if needed.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IPEN2,Penicillin G Benzathine,Penadur LA (Retarpen)2.4MIU,QANB,,¾AÀ³¯g:Treatment & prophylaxis of infections caused by highly penicillin-sensitive organisms °Æ§@¥Î:Allergic reactions¡A stomatitis¡A glossitis¡A hemolytic anaemia¡A leucopenia¡A thrombocytopenia¡A agranulocytosis¡A neuropathy¡A nephropathy¡A Jarisch-Herxheimer reactions secondary to bacteriolysis. ¸T§Ò:Hypersensitivity to penicillins & cephalosporins. Severe pneumonia¡A empyema¡A sepsis¡A pericarditis¡A meningitis¡A peritonitis or arthritis requiring high penicillin levels¡A allergic diathesis¡A bronchial asthma.,,«Ç·Å,Retarpen 2.4 MIU is intended for use in adults only. Therapy: Syphilis: Primary Stage: 1 x 1 Retarpen 2.4 MIU given at 2 injection sites. Secondary Stage: 1 x 2 Retarpen 2.4 MIU given at 2 injection sites. Treatment should be repeated if clinical symptoms recur or if laboratory values remain highly positive. Late Syphilis: 1-2 x Retarpen 2.4 MIU at weekly intervals over 3-5 weeks. Therapy of Streptococcal Infections¡A eg Tonsillitis¡A Scarlet Fever¡A Erysipelas: Treatment is commenced in the acute phase of infection with a rapidly absorbed penicillin preparation (eg¡A penicillin G) and continued with Retarpen. 1 x 1 Retarpen 2.4 MIU at weekly intervals. Prophylaxis: Rheumatic Fever: 1 x 1 Retarpen 2.4 MIU every 4 weeks.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ª`®g«eÀË¬d¯f±w¬O§_¦³PCN¹L±Ó¥v¡C 2. ¥»ÃÄ«~­­¦Ù¦×ª`®g¡I
IPENT,Thiopental,Pentothal inj 0.5gm,ZANE,,Control of convulsive states¡A narcoanalysis and narcosynthesis in psychiatrist disorders¡A induction of anesthesia¡A supplementation of other anesthetic agents.,,,IV only Anesthesia: 50-75 mg (2.5% soln) at interval of 20'-40'¡A additional injection of 20-25mg can be given whenever the patient moves. Convulsive states: 75-250 mg (2.5% soln) over a period of 10'. Induction: 3~5mg/kg,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IPITS,Oxytocin,Piton-S inj 10iu/mL,SGU,,¾AÀ³¯g:«P¶i¤l®c¦¬ÁY£¿ ¶Ê²£¤§¥Î(B022279229),,2-8,Induction of labor & oxytocin challenge test: IV infusion: 5 U in 500 ml of normal saline or 5% dextrose (10 mU/ml)¡A initial¡A 0.5-2 mU/min¡A increased by 1-2 mU/min q 15-30 mins; (max. 20 mU/min)¡A Control of postpartum uterine bleeding: IV infusion: 10-20 U in 500 ml (20-40 mU/ml) given at a rate of 20-40 mU/min. IM: 3-10 U.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OSERE,Haloperidol,Serenace 0.5mg,CNEU,,Antidyskinetic (in Gilles de la Tourette's disease)¡A antipsychotic.,,,Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially¡A adjusted as needed. Child: 3-12 yrs¡A 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTIC,Ticlopidine,PanalDine 100mg,HEMT,,¾AÀ³¯g: To reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors or who have had a completed thrombotic stroke¡A & are intolerant or allergic to or who have failed aspirin therapy. As adjunctive therapy with aspirin to reduce incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation. °Æ§@¥Î: GI disturbances; skin rashes. Blood dyscrasias; vertigo; jaundice. ¸T§Ò: Hemorrhagic diathesis¡A GI ulcers¡A severe liver dysfunction¡A leukopenia.,,«Ç·Å,200 - 300 mg daily.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OVIA,Glucosamine Sulphate,Viartril-S 250mg,CNEU,,Vertebral artrosis¡A coxofemoral¡A scapulo-humeral¡A gonarthrosis¡A periarthritis¡A lumbosciatalgies¡A arthrosis of any etiology.,,RT,4-6 cap daily for 30-60 days.,,,,,,,,,,,,,,
OXEN2,Orlistat,Xenical 120mg 21'S/BOX,META,,I: Long-term treatment of obese & overweight patients w/ risk factors associated w/ obesity¡A in conjunction w/ a mildly hypocaloric diet. ADR: Oily spotting¡A flatus with discharge¡A fecal urgency¡A fatty/oily stool¡A oily evacuation¡A increased defecation¡A fecal incontinence (incidence of these increases the higher the fat content of the diet). CI: Chronic malabsorption syndrome.,,RT,1 cap 3 times daily w/ meals,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IDES1,Iron-Dextran,DesMAN inj 100mg/2mL,NUTR,,¾AÀ³¯g: Treatment of Fe-deficiency anemia¡A where oral Fe is intolerable or ineffective. °Æ§@¥Î: Dyspnea¡A nausea & vomiting¡A abdominal pain¡A flushing¡A puritus¡A rash¡A blurred vision¡A feeling hot¡A cramps¡A numbness. ¸T§Ò: Non-Fe deficiency anemia; Fe overload or disturbances in utilization of Fe; patients with a history of asthma¡A eczema or other atopic allergy (IV inj only); decompensated liver cirrhosis¡A hepatitis; acute or chronic infection; active RA; acute renal failure.,,«Ç·Å,Individualized dosage based on patients body wt & iron deficit. Slow IV or deep IM¡A Adult : not exceed 100 mg / day. Children < 10 kg : not exceed 50 mg / day. Infants < 5 kg : not exceed 25 mg / day.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ONORE,Ethinylestradiol + Levonorgestrel,Nordette 21's/pk,HM,,Oral contraceptive & treatment of dysmenorrhea & menstrual irregularities.,,,1 tab daily for 21 days¡A followed by 7 tab-free days.,,,,,,,,,,,,,,
ONORM,Sterculia + Frangula,Normacol plus granules 7gm/pack,ALIM,Treatment of constipation. The initiating and maintenance of bowel action after rectal surgery and haemorrhoidectomy.,Intestinal obstruction. Faecal impaction. Total atony of the colon. Hypersensitivity to the active substances or to any of the excipients. Pregnancy and lactation. Children under 12 years of age.,Abdominal distension¡A intestinal obstruction if overdosage or inadequate fluid intake.,25¢J³±²D³B,1 pack= 7g granules (62% w/w Sterculia and 8% w/w Frangula). Adult: 1-2 sachets QD-BID. After meal. (Put the granules directly into your mouth¡A do not chew or crush¡A and swallow with plenty of water or cold drinks),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]©|µLSterculia»PFrangula¨Ö¥Î©óÃh¥¥°ü¤kªº¸ê®Æ¡A¥Ø«e¤wª¾Frangula·|³q¹L­L½L¡A ¥B«DÁ{§É¸ê®ÆÅã¥Ü¼Æ­Ó»PFrangula¬ÛÃö¤§Anthranoids¥i¯à¨ã¦³°ò¦]¬r©Ê¡A¦]¦¹Ãh¥¥´Á¸T¤î¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]µLÃÒ¾ÚÅã¥ÜSterculia·|¤Àªc¦Ü¨Å¥Ä¡FFrangula©Î¨ä¥NÁÂª«¬O§_·|¤Àªc¶i¤J¤HÅé¨Å¥Ä¥ç¥¼ª¾¡A ¦ý¦³¬ã¨sÅã¥Ü¨ä¥LAnthranoids¤§¬¡©Ê¥NÁÂª«·|¤Àªc¦Ü¨Å¥Ä¡A ¬GµLªk±Æ°£¥¼Â_¥¤¤p«Äªº­·ÀI¡A°ü¤k­÷¨Å´Á¸T¤î¨Ï¥Î¡C,PC;,,,,,
ONORV,Amlodipine,Norvasc 5mg,CAVS,Hypertension & angina pectoris.,Known hypersensitivity to dihydropyridines.,Common: Flushing (0.7-2.6%)¡A Palpitations (Up to 4.5%)¡A Peripheral edema (Up to 10.8%)¡A Abdominal pain (1.6%)¡A Nausea (2.9% .)¡A Dizziness (Up to 3.4%)¡A Headache (7.3%)¡A Somnolence (1.4%)¡A Fatigue (4.5%) Serious: Acute myocardial infarction¡A Angina pectoris¡A Angioedema,25¢J¥H¤U,Initially 5 mg once daily which may be increased to a maximum dose of 10 mg depending on the patient's response.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment with angina: 5 mg orally once daily Hepatic impairment with hypertension: Initial or when adding to other antihypertensive therapy¡A 2.5 mg orally once daily,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,[¥é³æ] ¶tÂ÷¤l³q¹DªýÂ_¾¯¦³¥i¯à¨Ï±o¥ÀÅé¦åÀ£¹L§C¦Ó¾É­P­L¨à¯Ê®ñ¡A¦]¦¹°£¤F¹w´Á®Ä¯q¤ñ­L¨à­·ÀIÁÙ°ª®É¡A¥¥°ü¤£À³¨Ï¥Î¥»ÃÄª«¡C¯ßÀu¹ï¤HÃþÃh¥¥©Î±Â¨Åªº¦w¥þ©Ê©|¥¼½T¥ß¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] §Q¥Î¯ßÀu¶i¦æªvÀø®ÉÀ³°±¤î±Â¨Å¡C¤HÅé¨Ï¥Î¸gÅçªí©úamlodipine¥i¤Àªc¦Ü¤H¨Å¤¤¡C,AC;AC15;PC;PO;WM;,,,,,
ONOVO,Repaglinide,NovoNorm (Repaglinide) 1mg,META,,I: Type 2 diabetes(NIDDM) whose hyperglycaemia is not controlled satisfactorily by diet¡A wt reduction & exercise. ADR: (>10 %) Headache¡A hypoglycemia. (1 ~ 10 %) Cheast pain¡A nausea¡A heartburn¡A vomiting¡A constipation¡A diarrhea¡A tooth disorder¡A arthralgia¡A back pain¡A paresthesia¡A allergy. (<1 %) Alopecia¡A anaphylactoid reaction¡A hemolytic anemia¡A hepatic dysfunction¡A leukopenia¡A liver function tests increased¡A pancreatitis¡A Stevens-Johnson sundrome¡A thrombocytopenia. CI: Type 1 diabetes. Diabetic ketoacidosis with or without coma. Pregnancy¡A lactation. Childn < 12 yr. Severe renal or hepatic function disorders. Concomitant therapy with medicinal products which are CYP3A4 inhibitors or inducers.,,RT,Initially 0.5mg¡A max single dose: 4mg with main meals. Max: 16mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OOLB,Acipimox,Olbetam 250mg,CAVS,,hyperlipoproteinemia.,,,Treatment of type IV hyperlipoproteinemia 1 cap bid. Type ¢ºa¡A¢ºb¡A¢»¡AV 1 cap tid. Daily dose should be adjusted according to plasma triglyceride & cholesterol levels.,,,,,,,,,,,,,,
OONE,Alfacalcidol,Onealfa 0.5mcg,META,,¾AÀ³¯g:¬°ºû¥L©RD3»s¾¯(B018274100)(B023031100),,RT,Osteoporosis: Adult: 0.5-1 mcg qd. Child: 0.01-0.03 mcg/kg qd. Hypoparathyroidism: 1-4 mcg qd.,,,,¦w¥þ,,,,,,,,,,
OOVE,Estriol,Ovestin 1mg,HM,,¾AÀ³¯g:¬°¤k©Ê¶Pº¸»X¸É¥R¾¯(B019326100),,RT,Tab: Climacteric symptoms & complaints: 4-8 mg/day for 7 days¡A Maintance dose: 1-2 mg day. Supportive therapy of vag or cervical infection & Inflammation :0.5-2mg/day until regeneration.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OPAN,Acetaminophen,Panamax 500mg,CNEU,,¾AÀ³¯g: Relief of painful disorders such as headache¡A dysmenorrhea¡A conditions involving musculoskeletal pain¡A myalgias & neuralgias. After dental work¡A tooth extractions & in teething. As an analgesic & antipyretic in conditions accompanied by discomfort & fever¡A such as common cold & viral infections. °Æ§@¥Î: Acetaminophen has rarely been found to produce any side effects. It is usually well tolerated by aspirin-sensitive patients. Severe recurrent pain or high continued fever may indicate a serious conditions. Under these circumstances consult a physician.,,«Ç·Å,Adult:500 mg q4h as needed¡A (max. 4 g/day). For long term therapy¡A not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed¡A (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period. 6-10 yrs.:20 ml qid.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³´î§C¨C¤é¾¯¶q ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OPANA,Acetaminophen,Panadol for Children 80mg,CNEU,,¾AÀ³¯g:¨ã¸Ñ¼ö¡BÂíµh§@¥Î(A028474100)(B023602100),,RT,Adult:500 mg q4h as needed¡A (max. 4 g/day). For long term therapy¡A not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed¡A (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period. Syrup: 3 months-1 yr.:2.5-5 ml qid. 1-6 yrs.:5-10 ml qid. 6-10 yrs.:20 ml qid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OPANT,Terfenadine,Pantadin 60mg,HIMM,,,,,,,,,,,,,,,,,,,
OANTA,Magaldrate,Antashin(·R§J­G·s) 400mg,ALIM,,I : Hyperacidity,,,1-2 tab qid,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LEUF,Dimemorfan Phosphate,Eufan 2.5mg/mL¡A 120mL,ERSP,,¾AÀ³¯g:Âí«y(A044509157) SP: Diabetes mellitus AP: Infrequently¡A change in glucose tolerance; dizziness¡A drowsiness; dry mouth¡A nausea¡A vomiting. Rarely¡A malaise; tachycardia¡A palpitations¡A hot flushes.,,,D: children 7-14 yr: 12-14 ml 6-4 yr: 8-11 ml 2-3 yr: 5-8 ml <2 yr: 3-4.5 ml tid,,,,,,,,,,,,,,
EPAR,Chlorhexidine gluconate,Parmason gargle 0.2%¡A 200mL,TENT,Cleansing & disinfection of mouth infections¡A eg gingivitis & oral candidiasis.,Hypersensitivity to any component of the formulation.,Conjunctival irritation. Discolouration of the tongue & teeth. Taste disturbances¡A burning sensation of the tongue. Oral desquamation.,25¢J¥H¤U,Oral infection; Prophylaxis 10-20 mL BID rinse for 30-60 sec then spit it out,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,GAR;,,,,,
OLIV,Tibolone,Livial 2.5mg (28 tablets/box),HM,Complaints resulting from natural or surgical menopause.,Pregnancy. Known or suspected hormone dependent tumours. CV or cerebrovascular disorders¡A vag bleeding of unknown etiology; severe liver disorders.,Change in body wt¡A dizziness¡A seborrhoeic dermatosis¡A vaginal bleeding¡A headache¡A GI upset¡A changes in liver parameters¡A increased facial hair growth¡A pretibial edema.,2-25¢J,1 tablet QD.,µL»Ý½Õ¾ã¾¯¶q,Contraindications: Acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Tibolone is approved for use in postmenopausal women; use is contraindicated during pregnancy. Discontinue immediately if pregnancy occurs.(UpToDate)2021/0125,Unknown ¨S¦³¸ê®Æ,It is not known if tibolone or its metabolites are present in breast milk. Use is contraindicated in women who are breastfeeding.(UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡C
OQUE,Cholestyramine,Questran 4gm/pk,CAVS,,¾AÀ³¯g: Hypercholesterolemia¡A Pruritus associated with partial biliary obstruction¡A Intractable diarrhea¡A Acute diarrhea. °Æ§@¥Î: Commonly¡A GI disturbances. Constipation may be accompanied by fecal impaction &/or hemorrhoids. ¸T§Ò: Complete biliary obstruction.,,«Ç·Å,Hypercholesterolemia: 12-16 g/day¡A (max. 16-32 g/day)¡A ac. Pruritis of cholestasis: 4 g tid-qid. Diarrhea: Infant and child: 2-8 g/day in 3-4 divided doses. Adult: 4 g tid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ORIT,Methylphenidate,Ritalin 10mg,CNEU,,¾AÀ³¯g: Attention-deficit hyperactivity disorder; narcolepsy. °Æ§@¥Î: Frequent: nervousness¡A insomnia¡A decreased appetite. Occasional: headache¡A drowsiness¡A dizziness¡A dry mouth¡A tachycardia¡A palpitations¡A arrhythmias¡A changes in BP & heart rate; GI disturbances¡A skin reactions¡A fever¡A arthralgia. Rare: blurred vision¡A moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )¡A Loss of appetite (5% )¡A Nausea (12% )¡A Vomiting (10% ) Neurologic: Headache¡A Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )¡A Nasopharyngitis (5% ) ¸T§Ò: Anxiety & tension states¡A agitation¡A tics¡A tics in siblings¡A family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias¡A severe angina pectoris.,,«Ç·Å,20-30 mg daily. Children >= 6 years Initially 5 mg once-bid with gradual increments of 5-10 mg weekly. Max: 60 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,,,,,,
OSOT,Sotalol,Sotalex 80mg,CAVS,,I: Ventricular arrhythmias. CI: Bronchial asthma¡A sinus bradycardia; 2nd and 3rd degree AV block; congenital or acquired long QT syndromes; cardiogenic shock; uncontrolled CHF; concurrent use of cisapride¡A gatifloxacin¡A moxifloxacin¡A or sparfloxacin.,,RT,Initial dose is 80 mg bid. This dose may be increased if necessary¡A after appropriate evaluation¡A to 240 or 320 mg/day. In most patients¡A a therapeutic response is obtained at total daily dose of 160 to 320 mg/day¡A given in two or three divided doses.Because of the long terminal elimination half-life of sotalol¡A dosing on more than a twice-daily regimen is usually not nessary.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OTAM,Tamoxifen,Nolvadex 10mg,RACA,Breast cancer.,Pregnancy¡A concomitant coumarin-type anticoagulant therapy; when used for the reduction in breast cancer incidence in high risk women¡A deep vein thrombosis¡A history; when used for the reduction in breast cancer incidence in high risk women¡A hypersensitivity to tamoxifen citrate or any component of the product¡A pulmonary embolus¡A history; when used for the reduction in breast cancer incidence in high risk women.,Hot flushes¡A vag bleeding¡A vag discharge & pruritus vulvae; GI intolerance¡A tumour flare¡A light-headedness; fluid retention¡A skin rash¡A alopecia. A small number of patients with bony metastases have developed hypercalcaemia on initiation of therapy. Falls in platelet count. Visual disturbance including corneal changes¡A cataracts & retinopathy. Cystic ovarian swellings occasionally in pre-menopausal women. Infrequently¡A thromboembolic events. An increased incidence of endometrial changes¡A including hyperplasia¡A polyps & cancer have been reported. Dermatologic: Menopausal flushing (33% to 64% ) Reproductive: Amenorrhea¡A Disorder of menstruation¡A Irregular periods¡A Vaginal discharge,Àx¦s½Ð¤Å¶W¹L30¢J,20-40 mg once daily (with doses >20 mg administered in 2 divided doses),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
ERET,Tretinoin,Retin-A cream 20gm,TDER,,,,,,,,,,,,,,,,,,,
ERHE,Etofenamate,Rheumon gel 20gm,CNEU,,,,,,,,,,,,,,,,,,,
ERIN5,Betamethasone,Rinderon eye soln 0.1%¡A 5mL,TOPH,,¾AÀ³¯g: Short-term treatment of steroid responsive inflammatory conditions of the eye. °Æ§@¥Î: Local burning & irritation¡A raised intraocular pressure¡A thinning of cornea (possibly perforation); rarely¡A cataracts (prolonged use). ¸T§Ò: Bacterial¡A viral¡A fungal¡A tuberculous or purulent conditions of the eye; glaucoma; herpetic keratitis.,,«Ç·Å,1-2 drops tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ERINO,Betamethasone + Fradiomycin,Rinderon-A ²´ÃÄ»I3gm,TOPH,,¾AÀ³¯g: Inflammatory conditions of the eye when secondary bacteria infection is present. °Æ§@¥Î: Allergic reactions¡A superinfection¡A delayed wound healing¡A raised intraocular pressure¡A thinning of cornea (possible perforation). ¸T§Ò: Viral¡A fungal or TB conditions; glaucoma¡A herpetic keratitis.,,«Ç·Å,3-5 times daily.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IPLA1,Cisplatin,Platinex inj 10mg/20mL,RACA,,Testicular cancer¡A ovarian cancer¡A head and neck¡A Hogkin's and non-Hogkin's lymphoma¡A sarcomas¡A bladder¡A gastric¡A lung¡A esophageal¡A cervical¡A prostate¡A myeloma¡A breast¡A melanoma¡A mesothelioma¡A and osteosarcoma.,,RT,IV infusion over 6-8 hrs¡A As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin¡A 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin¡A 50 mg/mL once every 3 wks.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IPPD,Tuberculin purified protein derivative,Tuberculin PPD (µ²®Öµß¯À¸Õ¾¯) 0.1mL/dose,HIMM,Skin test as an aid in the diagnosis of tuberculosis.,Hypersensitivity to any component of the formulation.,Injection site reactions (pain¡A pruritus¡A redness¡A ulceration¡A scarring),2-8¢JÁ×¥úÁ×§K§N­á,ID¡A 0.1 mL¡A in the middle third of the forearm.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,WHO:Compatible with breastfeeding.,ID;,,,,,
IPRE,Estrogen + Medroxyprogesterone,Premarin inj 25mg,HM,,Menopausal and post-menopausal oestrogen replacement¡A postmenopausal osteoporosis¡A atrophic vaginitis or urethritis.,,,IM¡A IV: 25 mg¡A repeated in 6-12hrs if needed.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IPROS,Oxacillin,Prostaphlin inj 250mg,QANB,,,,,,,,,,,,,,,,,,,
IPUR,Follitropin beta,Puregon 100 IU/0.5mL,HM,,¾AÀ³¯g:Treatment of female infertility due to anovulation in women who have been unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs. °Æ§@¥Î:Ovarian hyperstimulation¡A bruising¡A pain¡A redness¡A swelling & itching¡A ectopic pregnancy¡A multiple gestations¡A arterio-thromboembolisms ¸T§Ò:Ovarian¡A breast¡A uterine¡A pituitary or hypothalamic tumours. Pregnancy or lactation. Undiagnosed vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries¡A not related to polycystic ovarian disease (PCOD). Sexual organ malformations incompatible with pregnancy. Uterine fibroid tumours incompatible with pregnancy,,2-8¢J,Anovulation 50 iu daily¡A maintained for at least 7 days. Controlled ovarian hyperstimulation in medically assisted reproduction programs Starting dose of 100-225 iu for at least the 1st 4 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,SC;,,,,,
IPROA,Protamine sulphate,Protamine sulphate inj 50mg/5mL,ZADT,Treatment of overdosage or haemorrhage during heparin or Low Molecular Weight Heparin (LMWH) therapy. To counteract the anticoagulant effects of heparin or LMWH before emergency surgery. To reverse the anticoagulant effects of heparin in cardiopulmonary bypass procedures.,Hypersensitivity to the active substance or to any of the excipients.,Common: Flushing¡A Nausea¡A Vomiting¡A Dyspnea Serious: Bradyarrhythmia¡A Hypotension¡A Anaphylaxis¡A Non-allergic anaphylaxis¡A Circulatory collapse¡A capillary leak¡A noncardiogenic pulmonary edema,30¢J¥H¤U,Administered as a slow intravenous injection over 10 minutes or as a slow intravenous infusion. Bolus dose not to exceed 5 mL. Dose ideally guided by blood coagulation studies¡A such as APTT¡A ACT¡A anti-Xa¡A and protamine neutralization test. Coagulation tests performed 5-15 minutes after administration. Additional doses may be required due to rapid clearance from the blood. - For heparin neutralization: 1 mL of Protamine sulphate neutralizes approximately 1400 IU of heparin. - For LMWH neutralization: consult manufacturer guidelines; 1 mL per 1000 anti Xa IU is recommended. Repeat administrations may be necessary¡A especially for subcutaneously administered LMWH. - In cardiopulmonary bypass procedures: 0.1-0.2 mL for each 100 units of heparin given. Doses should be guided by blood coagulation studies.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,PREGNANCY RECOMMENDATION: Compatible¡XMaternal Benefit and Embryo¡VFetal Risk [¥é³æ] ¥Ø«e¨S¦³©Î¦³­­¼Æ¶qªºÃh¥¥°ü¤k¨Ï¥Î²¸»Ä³½ºë³J¥Õprotamine sulphateªº¸ê®Æ¡C¥¼´¿¶i¦æ ¥ô¦ó°Êª«ªº¥Í´Þ¬r©Ê¬ã¨s¡C¥Ø«e¥¼¦³Ãö©ó°Êª«¸ÕÅç¥Í´Þ¬r©Êªº¥R¤À¸ê®Æ¡C Protamine Sulphate LEOR¤£«ØÄ³¨Ï¥Î©óÃh¥¥´Á¶¡»P¥¼Á×¥¥ªº¨ã¥Í¨|¯à¤O¤k©Ê¡A°£«D¸Ó¤k©Êªº Á{§É±¡ªp·¥»Ý­n±µ¨üprotamine sulphateªvÀø¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«e©|¤£ª¾¹D²¸»Ä³½ºë³J¥Õprotamine sulphate¬O§_·|¤Àªc¨ì¥À¨Å·í¤¤¡C,IVD;,,¡iN/S¡j¥i¿ï ¡C,,IV infused over 10 minutes,1. ¸gÀR¯ßª`®g«á¡A¹ï¨x¯Àªº¤¤©M§@¥Î¦b5-15¤ÀÄÁ¤ºµo¥Í¡C 2. µ¹ÃÄ¹L§Ö¥i¯à¤Þ°_§C¦åÀ£¡]µu¼È©ÎÄY­«¡^©Î¤ß·i¹LºC¡A¼W¥[¹L±Ó¤ÏÀ³ªº­·ÀI¡C 3. 1 mL§t¦³²¸»Ä³½ºë³J¥Õ 1400 §Ü¨x¯À°ê»Ú³æ¦ì anti-heparin IU (10mg )¡C 4. ³Ì¤j³æ¤@ª`®g¾¯¶q¤£À³¶W¹L50mg/5mL¡C
IROB,Glycopyrrolate,Robinul inj 0.2mg/mL,ALIM,,¾AÀ³¯g:Preoperatively to inhibit salivation & excessive secretions of the respiratory tract; reversal of neuromuscular blockade; control of upper airway secretions; adjunct in treatment of peptic ulcer. °Æ§@¥Î:Dry mouth; urinary hesitancy & retention; blurred vision. Increased ocular tension; tachycardia; palpitations; decreased sweating¡A loss of taste¡A headache¡A nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reaction¡A drug idiosyncrasies; urticaria; mental confusion. ¸T§Ò:In management of peptic ulcer¡A may be C/I in glaucoma; obstructive uropathy; achalasia; pyloroduodenal stenosis; paralytic ileus; intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Inj Newborn infant <1 mth.,,,Preoperative Adult & children 1 month-12 years 0.002 mg/pound body weight (0.01 mL) IM 30-60 mins before procedure or to be administered with pre-anesth narcotic & sedative. Intraoperative Adult 0.1 mg (0.5 mL) IV. May repeat at intervals of 2-3 mins. Children 0.002 mg/pound body weight (0.01 mL) IV. Max: 0.1 mg (0.5 mL)/dose. May repeat at intervals of 2-3 mins. Reversal of neuromuscular blockade Adult & children 0.2 mg (1 mL) IV for each 1 mg of neostigmine or 5 mg of pyridostigmine.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IALL,Allergy Skin Test,Allergy skin test,ZOTH,,,,,,,,,,,,,,,,,,,
IAMH,Amino Acids,Aminopoly-H 500 mL,NUTR,,,,,,,,,,,,,,,,,,,
IAMIK,Amino Acids + Xylitol,Aminol-K inj 500mL,NUTR,,¾AÀ³¯g:¬°¦¨¤HÓi°ò»Ä¸É¥R²G(A011723277),,RT,IV infusion 500-2000 ml/daily.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IAMIL,Aminophylline,Aminophylline°w¾¯250mg/10mL,ERSP,,¾AÀ³¯g: Bronchospasm. °Æ§@¥Î: GI disturbances¡A visual disturbances¡A insomnia¡A nervousness¡A psychotic disturbances¡A dizziness. ¸T§Ò: Hypersensitivity to xanthines.,,«Ç·Å,Amp Adult 250-500 mg 6 hrly¡A children 5 mg/kg 6 hrly.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IAMIN,Amino Acids Infusion Soln,Aminosteril N Hepa 8% 500mL,NUTR,,¾AÀ³¯g: Parenteral amino acid supply in severe forms of hepatic failure with & without encephalopathy¡A therapy of hepatic coma. °Æ§@¥Î: May lead to an increased production of gastric acid & to stress ulcer. ¸T§Ò: Disturbed amino acid metabolism¡A conditions following hyperhydration¡A hyponatremia¡A hypokalemia¡A renal insufficiency¡A severe cardiac insufficiency.,,«Ç·Å,1.3-1.5 mL/kg body weight/hr. Max: 1.5 g amino acids/kg body weight/day.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ¿éª`³t²v¡G 1.3-1.5mL/kg BW/Hour¡A³Ì¤j¾¯¶q¡G1.5 ¤½§JÓi°ò»Ä/kg BW/¤Ñ¡C
IAMIO,Amiodarone,Amiodarone (Cordarone) inj 150mg/3mL,CAVS,Wolff-Parkinson-White syndrome¡A supraventricular & ventricular tachycardia¡A atrial & ventricular fibrillation.,AV or SA block¡A sinus bradycardia¡A sick sinus syndrome except when used in conjunction with a pacemaker; history of thyroid dysfunction; iodine intolerance¡A severe arterial hypotension¡A CV collapse¡A acute cardiac insufficiency. Combined therapy with drugs which may induce torsades de pointes. Pregnancy¡A lactation.,Common: Hypotension (Oral¡A less than 1%; IV¡A 15.6%)¡A Photodermatitis (2-24%)¡A Photosensitivity (3-10%)¡A Thyroid dysfunction¡A Constipation (4-9%)¡A Loss of appetite (4-9%)¡A Nausea (10-33%)¡A Vomiting (10-33%)¡A Increased liver enzymes¡A Abnormal gait (4-9%)¡A Coordination problem (4-9%)¡A Dizziness (4-9%)¡A Involuntary movement (4-9%)¡A Movement disorder (4-9%)¡A Paresthesia (4-9%)¡A Peripheral neuropathy¡A Corneal deposit¡A Microdeposits¡A Visual disturbance (4-9%)¡A Malaise and fatigue (4-9%) Serious: Bradyarrhythmia¡A Cardiac dysrhythmia¡A Congestive heart failure¡A High threshold for implanted defibrillator¡A Prolonged QT interval¡A Sinus arrest¡A Torsades de pointes (Less than 2%)¡A Vasculitis¡A Ventricular arrhythmia¡A Injection site extravasation¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hyperthyroidism (2%)¡A Hypothyroidism (Up to 10% .)¡A Thyroid cancer¡A Thyrotoxicosis¡A Thrombocytopenia¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Lupus erythematosus¡A Low back pain¡A acute¡A Rhabdomyolysis¡A Pseudotumor cerebri¡A Raised intracranial pressure¡A Blindness AND/OR vision impairment level¡A Optic neuritis¡A Toxic optic neuropathy¡A Renal impairment¡A Acute respiratory distress syndrome (2%)¡A Pulmonary fibrosis¡A Pulmonary toxicity (Up to 17%),25¢J¥H¤U,Must be administered using a volumetric infusion pump preferably via a central venous catheter. Initially 5 mg/kg in 250 mL of dextrose 5% IV infusion for 20 minutes to 2 hours. May repeat 2-3 times in 24 hours. Maintenance dose: 10-20 mg/kg (usually 600-800 mg/24 hours¡A maximum: 1.2 gm/24 hours) in 250 mL dextrose IV infusion. Cardiopulmonary resuscitation¡A Ventricular fibrillation/pulseless ventricular tachycardia: 300 mg IV by rapid infusion; a single dose of 150 mg IV may be repeated if Ventricular fibrillation/pulseless ventricular tachycardia recurs.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C,administer according the ACLS guidelines for ventricular fibrillation/pulseless ventricular tachycardia (300mg ¥H20mLªº5%¸²µå¿}·»²Gµ}ÄÀ«á§Ö³tª`®g),µ}ÄÀ¿@«×¤£¥i§C©ó 600mg/L(2 Amp in 500 mL D5W)¡A¾¨¥i¯à±q¤¤¥¡ÀR¯ß¾ÉºÞÂIºwµ¹ÃÄ(¿@«×¤j©ó2mg/mL»Ý¥ÑCVPµ¹ÃÄ)¡Aµ¹ÃÄ®e¾¹»PºÞ¸ôÀ³¨Ï¥Î«DPVC§÷½è¡C,1.µ}ÄÀ¿@«×¤£¥i§C©ó 600mg/L(2 Amp in 500 mL D5W)¡Aµ}ÄÀ²G¥u¯à¨Ï¥Îµ¥±iªº¸²µå¿}·»²G¡C½Ð¤Å±N¥ô¦ó¨ä¥Lªº²£«~¥[¤J¦¹¿éª`·»²G¤¤¡C 2.¾¨¥i¯à±q¤¤¥¡ÀR¯ß¾ÉºÞÂIºwµ¹ÃÄ¡A¿@«×¤j©ó2mg/mL¶·¥ÑCVPµ¹ÃÄ¡C 3.µ¹ÃÄ®e¾¹»PºÞ¸ôÀ³¨Ï¥Î«DPVC§÷½è(Á×§KDEHP¶ì¤Æ¾¯·»¥X»P10%ÃÄª«³Q§lªþ)¡C 4.¤£¥i²V¤JSodium Bicarbonate¡A·|¨I¾ý¡C 5.«ØÄ³¨Ï¥Î0.22micron fillter¹LÂo¡C
IAMIP,Amikacin,Amikin inj 500mg/2mL,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(A034956212)(B017767212),,RT,IM or intermittent infusion over 30-60 mins (preferred)¡A Adult and child: 7.5 mg/kg q12h or 5 mg/kg q8h¡A (max.15mg/kg/day not to exceed 1.5 g/day). Neonate: 10 mg/kg initially¡A then 7.5 mg/kg q12h.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OGIN,Ginkgo Biloba,Gina'ex F.C. 40mg,CAVS,,Peripheral circulatory or cerebrovascular disorders,,,1 Tab tid ~ qid,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OUFU,Tegafur + Uracil,UFUR 100/224mg,RACA,Colorectal cancer¡A gastric cancer¡A breast cancer¡A head & neck cancer¡A lung cancer.,Hypersensitivity to 5-fluorouracil. Pregnancy¡A lactation. Severe hepatic impairment or impairment of the cytochrome P450 3A system. Bone marrow suppression. Severe diarrhia. Severe infection.,Anorexia¡A diarrhea¡A nausea¡A vomiting¡A itch.,«Ç·Å 30¢J¥H¤U«O¦s,(1 UFUR capsule = tegafur 100 mg and uracil 224 mg)300-600 mg/day (300 mg/m2/day) tegafur administered in 2-3 doses one hour before or one hour after meals for 28 consecutive days. If the total number of UFUR capsules cannot be evenly divided¡A the highest dose should be given in the morning and lower doses in the afternoon or evening. Courses may be repeated every 35 days.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à»ÙÃª¤§±wªÌÀ³Äµ·V§ë»P (¨x¥\¯à¥i¯à·|´c¤Æ),µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
EFLIN,Fluticasone,Flixonase nasal spray 0.05%,TENT,,¾AÀ³¯g:¹L±Ó©Ê»óª¢(B021477423) ADR: Nasal irritation¡A burning¡A dryness¡A mild naso-pharyngeal irritation¡A rhinorrhea¡A dry mucous membranes¡A nasal septum perforation¡A localized infections of the nose and pharynx with Candida albicans¡A alterations in taste and smell. CI: Hypersensitivity to any components of this product.,,< 30 ¢J,D: Adult & childn > 12 yr : 2 sprays into each nostril once daily in the morning¡A in some severe cases¡A 2 sprays each nostril bid may be required. (Max : 4 sprays / nostril / day) Childn 4 - 11 yr : 1 spray into each nostril qd. (Max : 2 sprays / nostril / day),,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ONIC,Nitroxoline,Nice 100mg,QANB,,¾AÀ³¯g: Infection of the lower urinary tract. Infection related to urinary tract malformations & lithiasis.,,«Ç·Å,Adult : 100 mg tid ~ qid. Childn : 5 ~ 7 mg / kg / day divided into 4 doses.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OTRIO,Ethinylestradiol + Levonorgestrel,Trinordiol 21's/pk,HM,,I: Oral contraceptive. ADR: Chloasma¡A melasma¡A headache¡A nausea¡A vomiting¡A weight gain¡A breast pain¡A changes in menstrual flow¡A changes in libido¡A spotting¡A depression. CI: 1. History of thrombophlebitis 2. Cerebral vessel or coronary artery disease 3. Severe hepatic function impairment 4. Breast cancer 5. Estrogen-dependent neoplasia 6. Undiagnosed abnormal genital bleeding 7. Pregnancy,,RT,1 tab daily for 21 days beginning on Day 5 of menstruation¡A fallowed by 7 tab-free days.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IATO,Ferric Chloride Hexahydrate,Atofen inj 40mg/10mL,NUTR,,,,,,,,,,,,,,,,,,,
ENAC,Diclofenac,Naclof 0.1%¡A 5mL,TOPH,,¾AÀ³¯g:¥Õ¤º»Ù¤â³N«á¤§²´³¡µoª¢¥Î(B019625429) AR: Mild transient burning sensation. CI: Hypersensitivity.,,RT,Pre-operation: Up to 5 drops over the 3 hrs preceding surgery. Post-operation: 3 drops immediately after surgery¡A thereafter 3-5 drops daily. Other indication: 4-5 drops daily.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OBAS,Methimazole,Based 5mg,META,,¾AÀ³¯g: Hyperthyroidism. °Æ§@¥Î:Skin rash¡A urticaria¡A nausea¡A vomiting¡A epigastric distress¡A hair loss¡A myalgia¡A edema¡A jaundice¡A sialadenopathy¡A lymphadenopathy & much less frequency of inhibition of myelopoiesis. ¸T§Ò: Pregnancy¡A lactation.,,«Ç·Å,Adult: Initial¡A 5-10 mg q8h; maintenance¡A 5-15 mg/day. Child: Initial¡A 0.4 mg/kg/day¡A maintenance¡A 0.2 mg/kg/day.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OATR,Atropine,Atropine 1mg (Tromine),ALIM,,Cycloplegia and mydriasis¡A reduce salivation and bronchial secretion¡A spastic conditions of the GI tract.,,,0.4-0.6mg.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EALC4,Alcohol,75% Alcohol 4000mL/bot,TDER,,,,,,,,,,,,,,,,,,,
ECRI,Progesterone,Crinone vaginal gel 8%,SGU,Treatment of disorders associated with progesterone deficiency¡A such as infertility due to inadequate luteal phase; for use during IVF¡A where infertility is mainly due to tubal¡A idiopathic or endometriosis linked sterility associated with normal ovulatory cycles.,Undiagnosed vag bleeding¡A breast or genital organ malignancy¡A acute porphyria¡A thrombophlebitis¡A thromboembolic disorder¡A cerebral apoplexy¡A missed abortion. Lactation.,Abdominal pain¡A perineal pain¡A headache¡A constipation¡A diarrhea¡A nausea¡A joint pain¡A depression¡A decreased libido¡A nervousness¡A somnolence¡A breast tenderness & pain¡A dyspareunia¡A nocturia¡A allergy¡A bloating¡A cramps¡A fatigue¡A pain¡A dizziness¡A vomiting¡A genital moniliasis & pruritus¡A aggressive reactions¡A forgetfulness¡A vag dryness¡A cystitis¡A UTI¡A vag discharge. Gastrointestinal: Abdominal pain (oral¡A 10% to 20%; vaginal gel¡A 5% to 12%; vaginal insert¡A 12% )¡A Constipation (vaginal gel¡A 27%; vaginal insert¡A 2% to 3% )¡A Nausea (oral¡A 8%; vaginal gel¡A 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral¡A 7% to 12% ) Musculoskeletal: Cramp (vaginal gel¡A 15% to 26% ) Neurologic: Dizziness (oral¡A 15% to 24%; vaginal gel¡A 5% )¡A Headache (oral¡A 10% to 31%; vaginal gel¡A 13% to 19%¡A vaginal insert¡A 3% to 4% )¡A Sleep disorder (vaginal gel¡A 18% )¡A Somnolence (vaginal gel¡A 27% ) Psychiatric: Depression (oral¡A 19%; vaginal gel¡A 11% to 19% )¡A Feeling nervous (vaginal gel¡A 16% )¡A Mood swings (oral¡A 6%; vaginal gel¡A 22% to 23% ) Reproductive: Breast tenderness (oral¡A 16% to 27% )¡A Large breast (vaginal gel¡A 40% )¡A Pain¡A Post-oocyte retrieval (vaginal insert¡A 25% to 28% )¡A Pain of breast (oral¡A 6% to 16%; vaginal gel¡A 13% )¡A Perineal pain (vaginal gel¡A 17% ) Other: Fatigue (oral¡A 8% to 9%; vaginal gel¡A 21% to 22%; vaginal insert¡A 2% to 3% ),25¢J¥H¤U,Treatment of infertility due to inadequate luteal phase : one application (1.125 g 8 % gel) every day¡A starting after documented ovulation or arbitrarily on the day18 to day21 of the cycle. When used during in-vitro fertilisation¡A daily application of CrinoneR 8 % gel should be continued for 30 days if there is laboratory evidence of pregnancy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st trimester,HYDROXYPROGESTERONE PREGNANCY RECOMMENDATION: Human Data Suggest Risk (0¡V16 weeks) Compatible (after 16 weeks),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,HYDROXYPROGESTERONE BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,VAG;,,,,,
EEFE,Fluorometholone + Tetryzoline,Efemoline eye drops 0.1%¡A 5mL,TOPH,,¾AÀ³¯g:Acute & chronic allergic non-infectious conjunctivitis & keratitis with severe swelling & intravascular inj. Non-infectious inflammation of the anterior segment of the eye. Post-op states after strabotomy; cataract & glaucoma operations. °Æ§@¥Î:Mild burning sensation; reversible increase in intraocular pressure¡A reactive hyperemia/rebound effect¡A cataract & corneal defects¡A glaucoma¡A systemic effects (chronic use). ¸T§Ò:Herpes corneal superficialis¡A mycosis of the cornea & conjunctiva¡A tuberculous affections¡A ulcerous processes of the cornea.,,«Ç·Å,1 drop bid-tid. Increasing to 1 drop hrly in the 1st 24-48 hr if required.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OFER4,Ferrous Fumarate,Ferall ³n½¦Ån 460mg,NUTR,,Treatment all anemias responsive to oral iron therapy.,,RT,1-2 cap daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ECLOC,Clobetasol,Clobetasol cream 0.05%¡A 5gm,TDER,,¾AÀ³¯g:¥Dªv°®Å~¡B«ó¥­­aÅ~¡B¥Ö½§·kÄoµ¥¹L±Ó¯gª¬(A028562321),,RT,Apply bid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IANT,Folinic Acid,Antrex inj 30mg/10mL,ZADT,,¾AÀ³¯g: Megaloblastic anemia due to folic acid deficiency¡A Intoxication & side-effects of folic acid antagonists¡A associated with high-dose methotrexate. °Æ§@¥Î:Occasionally Allergic reactions. Pyrexia may occur after inj ¸T§Ò: Untreated vit B12 deficiency. Never given alone or in conjunction with inadequate amounts of hydroxocobalamin.,,2-8¢J,Megaloblastic anemia due to folic acid deficiency Initially¡A 9-12 mg IM or 1 tab daily for 10-15 days. Then adjust dose according to clinical response. Intoxication & side-effects of folic acid antagonists 3-6 mg 1-2 times daily IM. Associated with high-dose methotrexate Individualised dosage,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
LROT3,Human Rotavirus,RotaTeq (MSD ½üª¬¯f¬r¬Ì­]) 2mL/dose,HIMM,Prevention of rotavirus gastroenteritis in infant & children caused by the serotypes G1¡A G2¡A G3¡A G4 & G-serotypes that contain P1 (such as G9).,Hypersensitivity.,Diarrhea¡A vomiting¡A irritability¡A fever.,2-8¢JÁ×¥ú,2 mL¡A 3 doses administered orally starting at 6-12 weeks of age¡A the subsequent doses administered at 4- to 10-weeks intervals. The third dose should be given before 32 weeks of age.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡C ¦¹¬Ì­]¤£¾A¥Î©ó¦¨¤H¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡C ¦¹¬Ì­]¤£¾A¥Î©ó¦¨¤H¡C,PO;,,,,,
EENT,Tyrothricin,ENT oint 5gm,TENT,,¾AÀ³¯g: Acute & chronic forms of rhinitis & treatment of bacterial infection of the nasal mucosa. °Æ§@¥Î: Rarely¡A hypersensitivity reactions. ¸T§Ò: Acute & congestive glaucoma. Children <= 2 years.,,«Ç·Å,Apply to the nasal mucosa several times daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IREC,Epoetin-B 5000 I.U.,Recormon 5000 inj,HEMT,,,,,,,,,,,,,,,,,,,
IRECO,Propofol,Recofol inj 10mg/mL¡A 20mL,ZANE,,A short-acting intravenous anaesthetic agent suitable for induction and maintenance of general anesthesia.,,,Induction: IV¡A 2-2.5 mg/kg. Maintenance: IV infusion¡A 6-12 mg/kg/hr or intermittent IV bolus¡A 25-50 mg.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IREL,Succinylcholine,Relaxin inj 500mg,CNEU,Muscle relaxation.,Genetically determined disorders of plasma pseudocholinesterase; history of malignant hyperthermia; penetrating eye injuries.,Bronchial spasm; arrhythmia; hypotension; myotonia¡A raised intraocular pressure & hypersensitivity,25¢J¥H¤U,IV injection for endotracheal intubation: 10-60 mg. Continuous IV infusion: dilute with normal saline or 5% dextrose to 0.1-0.2% solution¡A with rate of 2.5 mg/min. Infants and children: 1 mg/kg/dose intravenously or 2 to 3 mg/kg/dose intramuscularly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVPUSH;,N/S or D5W¡A 250mL or 500mL. Final concentration of 1 or 2 mg/mL. (0.1% or 0.2% solution),¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,for Intubation: Adult dose - 0.6 mg/kg (range: 0.3 to 1.1 mg/kg),IVD: (continuous infusion) a solution diluted to 1 mg/mL in D5W or N/S may be administered at a rate of 0.5 to 10 mg/min depending on patient specific factors.,Do not mix with alkaline solutions having a pH greater than 8.5 (eg¡A barbiturate solutions). Add 1 g succinylcholine to 1000 or 500 mL sterile solution (eg¡A D5W or NS) for a final concentration of 1 or 2 mg/mL. (0.1% or 0.2% solution)
IRHO,Rho D Immune Globulin,Rho (D) Immune Globulin [HyperRHO],HIMM,Prevention of Rh haemolytic disease of the newborn by its administration to the Rho (D)-ve mother¡A within 72 hr after birth of her 1st Rho (D)+ve infant or after an abortion.,Rho (D)+ve mother.,Pain at inj site. Slight temp elevation. Hypersensitivity (rare),2-8¢JÁ×§K§N­á,IM¡A full dose¡A Postpartum prophylaxis within 72 hours. Antenatal prophylaxis 1 full dose at 28 weeks gestation¡A followed by 1 more full dose within 72 hours postpartum. Threatened abortion at any stage of gestation 1 full dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,[UpToDate2021/01/25]Available evidence suggests that Rho(D) immune globulin administration during pregnancy does not harm the fetus or affect future pregnancies.(UpToDate)2021/01/25 [¥é³æ]¨Ï§_¼vÅT¥Í´Þ¯à¤O¡B©Î¥¥°ü¨Ï¥Î«á¬O§_·|¶Ë®`­L¨à¤£²M·¡¡A°ß¦³©ú½T»Ý­n®É¤~ ¥i¹ï¥¥°ü§ë¤©¡C,Unknown ¨S¦³¸ê®Æ,[UpToDate2021/01/25]Adverse events in the breastfeeding infant have not been observed when administered to women for the suppression of RhD isoimmunization.,IM;,,,,,
IRII,Insulin Regular,Insalin Actrapid (R) 100IU/mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,,According to individual requirements.,,,,,,,,,,,,,,
OFAR,Medroxyprogesterone,Farlutal 500mg,RACA,,¾AÀ³¯g:Palliative treatment of breast cancer; endometrial carcinoma¡A hypernephroma¡A prostate carcinoma; prostate hypertrophy. Anorexia cachexia. °Æ§@¥Î:Mastodynia¡A galactorrhea¡A vag bleeding¡A amenorrhea; modification to cervical erosions & secretions; changes in menstrual flow; edema; weight variation; cholestatic jaundice; rash; mental depression. ¸T§Ò:Thrombophlebitis; thromboembolic disorders; severe hepatic impairment; hypercalcemia; pregnancy; missed abortion.,,«Ç·Å,Breast CA: 1 g / day. Other hormone dependent CA: 200 ~ 500 mg / day.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OFLAM,Diclofenac,Flamquit 50mg,CNEU,,An analgesic¡A antipyretic¡A anti-inflammatory agents used in RA. and other rheumatic disorders.,,,Oral: 25mg tid-qid¡A "Adefuronic". 100 mg qd¡A swallowed whole¡A "Grofenac Retard".,,,,,,,,,,,,,,
OFT207,Futraful,FT 207 200mg,RACA,,Malignant neoplasms of the breast and G-I tract.,,,800-1200 mg/day in 2-4 divided doses. 750mg-2g rectally once or in 2 divided dose daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OFYB,Ispaghula Husk,Fybogel,ALIM,,Diverticular disease¡Aspastic & irritable colon. Constipation due to insufficient fibre.,,,Adult 1 sachet bid.Childn 2.5-5 ml bid.,,,,,,,,,,,,,,
IANP,Ritodrine,Anpo °w¾¯ 50mg/5mL,SGU,Prevention of preterm labour¡A Acute fetal distress¡A Prevention of preterm labour after operation.,Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor¡A nausea¡A vomiting¡A headache or erythema¡A nervousness¡A restlessness¡A jitteriness¡A emotional upset¡A anxiety or malaise. Infrequently cardiac symptoms¡A eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment.,25¢J¥H¤U¡AÁ×§K§N­á,Uncomplicated premature labour: IV infusion¡A initially 0.05 mg/min. Increase by 0.05 mg/minute every 10 min until patient responds. Usual rate: 0.15-0.35 mg/minute. Maintain for 12-48 hour after the contractions have stopped. As IM injection: initially 10 mg for 1 hour. then 10-20mg every 2-6 hours maintain for 12-48 hours. Increase or decrease the dose depending on the response.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IM;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,°_©l: 0.05 mg/min¡Aºû«ù:0.15~0.35 mg/min¡A¿éª`²G«ØÄ³¨Ï¥ÎD5W¡A­Y¨Ï¥ÎN/Sµ}ÄÀ¡A±N¼W¥[µo¥ÍªÍ¤ô¸~¤§¥i¯à©Ê¡C,1. ¿éª`²G«ØÄ³¨Ï¥ÎD5W¡C­Y¨Ï¥ÎN/Sµ}ÄÀ¡A±N¼W¥[µo¥ÍªÍ¤ô¸~¤§¥i¯à©Ê¡C(½Ã¥Í¸p¤½¤å¡GFDAÃÄ¦r²Ä1001409159¸¹)
IART,Sodium Hyaluronate,ARTZDispo 2.5mL,CNEU,,Degenerative osteoarthritis failed to common analgesics.,,,25mg weekly for 5 weeks intraarticular use.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IVFDRUG,»¤µo±Æ§ZÃÄª«¶O,»¤µo±Æ§ZÃÄª«¶O,PHR,,,,,,,,,,,,,,,,,,,
IWAT,Water for injection,Water for injection 20mL,NUTR,Solvent for parenteral preparations.,,,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,It is for use only as a sterile solvent or diluent vehicle for drugs or solutions suitable for parenteral administration.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,ID;IH;IM;IRR;IVD;IVPUSH;,,,,,
IXYL1,Lidocaine,Xylocaine 1% inj 20mL,ZANE,,1%/20 ml/vial: For local anesthesia¡A acute management of cardiac rrhythmia.,,,Infiltration¡A caudal¡A epidural or peripheral nerve block: Up to 30 ml as a 1% soln or 15 ml as a 2% soln. Surface anesthesia: Nose¡A nasopharynx and respiratory tract: 1-5 ml of 1%-4% soln is sprayed¡A 8% spray may be needed. Mouth¡A pharynx and upper digestive tract: 5-15 ml of 2% viscous soln. Urethral catheterization: Men¡A 5-10 ml; women¡A 3-5 ml of 2% jelly.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IXYL1E1,Lidocaine + Epinephrine,Xylocaine 1% + E inj 1mL,ZANE,,,,,,,,,,,,,,,,,,,
IXYL21,Lidocaine,Xylocaine 2% inj 1mL§½³Â,ZANE,For the production of local or regional anesth by infiltration¡A IV regional anesth¡A minor & major nerve blocks¡A epidural block & subarachnoid block.,Epidural or spinal anesth in patients with uncorrected hypotension or with coagulation disorders or receiving anti-coagulation treatment; inflammation &/or sepsis in the region of proposed inj or in the presence of septicemia; general contraindications related to epidural anesth should also be taken into account.,CNS reactions¡A either excitatory or depressant. CV reactions¡A mainly depressant. Maternal hypotension. Rarely allergic reactions.,«Ç·Å,Maximum recommended single dose of lidocaine is 3 mg/kg (plain solution) or 7 mg/kg (solution with adrenaline). Adult¡A 70 kg: Retrobulbar or peribulbar: 4 mL of 2% solution (80 mg). Sciatic nerve block: 15-20 mL of 2% solution (300-400 mg). Epidural anesthesia¡A Lumbar: 15-25 mL of 2% solution (300-500 mg). Epidural anesthesia¡A Thoracic: 15-20 mL of 2% solution (300-400 mg).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,LA;LI;,,,,,
IXYL2E1,Lidocaine + Epinephrine,Xylocaine 2% + E inj 1mL,ZANE,,Local anesthesia.,,,Infiltration¡A caudal¡A epidural or peripheral nerve block: As needed¡A up to 50 ml.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IXYL2V,Lidocaine,Xylocaine IV 2% 100mg/5mL,ZANE,Emergency treatment of ventricular arrhythmia.,Complete AV block. Amide local anesthetic hypersensitivity.,Conduction block¡A shock. Rarely malignant hyperthermia. Confusion¡A dizziness¡A drowsiness¡A nervousness¡A euphoria¡A vomiting¡A numbness.,25¢J¥H¤U,Adult IV 50-100 mg (1-2 mg/kg) slow IV within 1-2 mins. If no effect is observed after the 1st inj¡A the same dose may be repeated after 5 mins. May repeat at 10-20 min intervals but not > 300 mg during a 1 hr period. IV infusion 1-2 mg/min.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à±wªÌ·|¦]¥NÁÂ¿ð½w¦Ó¤Þ°_¦å¼ß¤¤¿@«×¤W¤É¡A¬GÂÔ·V¨Ï¥Î¤§,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,,Slow IV 50~100 mg/1~2 min (¤@¤p®É¤º³Ì°ª°ò·Çµ¹ÃÄ¶q300mg),I.V. infusion: 1000 mg in 250 mL (concentration: 4 mg/mL) or 2000 mg in 250 mL (concentration: 8 mg/mL) of D5W,Usual Infusion Concentrations: Adult I.V. infusion: 1000 mg in 250 mL (concentration: 4 mg/mL) or 2000 mg in 250 mL (concentration: 8 mg/mL) of D5W ¤£¥i»PÆP©ÊÃÄ«~²V¦X¡A·|¦³¨I¾ýªR¥X¡C Usual Infusion Concentrations: Pediatric Note: Premixed solutions available I.V. infusion: 8000 mcg/mL Compatibility Stable in D5LR¡A D51/2NS¡A D5NS¡A D5W¡A LR¡A 1/4NS¡A NS.
IEPO4,Recombinant Human Erythropoiet,Eprex (EPO 4000 IU),HEMT,,¾AÀ³¯g:Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy °Æ§@¥Î:Increased BP¡A thrombotic or vascular events. Flu-like symptoms¡A bone pain & chills after inj. Seizures. Skin reactions¡A palpebral edema. Rarely¡A erythroblastopenia. ¸T§Ò:Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,,2-8¢J,Chronic renal failure Adult patients Correction phase: 50 iu/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 iu/kg. Pediatric patients Correction phase: 50 iu/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 iu/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally¡A children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 iu/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 iu/kg for an additional 4 weeks.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ¥»ÃÄ«~¬°¹w¥ý¥R¶ñªº°wµ©¡A­­³æ¦¸¨Ï¥Î¡Aµ¹ÃÄ«e¶·¥ýÀË¬d½T©w·»²GµLÂø½è©ÎÅÜ¦â¡C 2. ¥Ö¤Uª`®g¨C¦¸Åé¿n¤£¥i¶W¹L1 mL¡C¦p»Ýª`®g¸û¤j¶q¡AÀ³©ó¤£¦P³¡¦ìµ¹ÃÄ¡C 3. ÀR¯ßª`®g®É¶¡¦Ü¤Ö¶·¶W¹L 1-5 ¤ÀÄÁ¡C¦å²G³zªR¯f¤H¦b³zªR´Á¶¡¡A¥i¸g¥Ñ³zªR½u¤º¤@­Ó¾A·íªºÀR¯ß¤J¤f¶i¦æ¤j¶qª`®g¡C 4. ¥»ÃÄ«~¡u¤£¥i¥H¡vÀR¯ßÂIºw¿éª`©Î»P¨ä¥LÃÄª«²V¥Î¡C
IEPOC,Ceftizoxime,Epocelin 0.5gm,QANB,,Useful in the treatment of meningitis due to susceptible G(-) bacilli¡A including betalactamase positive H. influenzae¡A active against Enterobacteriaceae and modest activity vs. Ps. aeruginosa.,,,IV¡A IV infusion or IM. Adult: 0.5-2g/day in 2-4 divided doses. increased up to 4g/day. Childn 40-80mg/kg/day in 2-4 divided doses; max. 120mg/kg/day.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IFEN1,Fentanyl,Fentanyl inj 0.05mg/1mL,CNEU,,¾AÀ³¯g: Premed prior to surgery¡A Adjunct to general anesth induction¡A Adjunct to regional anesth¡A Post-operatively . °Æ§@¥Î: Respiratory depression¡A apnoea¡A muscle rigidity & bradycardia. ¸T§Ò: Children <2 years¡A bronchial asthma¡A respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,,«Ç·Å,Premed 50-100 mcg IM 30-60 mins prior to surgery. Adjunct to general anesth induction 50-100 mcg IV & repeated at 2-3 mins intervals until the desired effect is achieved. Adjunct to regional anesth 50-100 mcg IM or slow IV inj. Post-operatively 50-100 mcg IM repeated in 1-2 hr as needed. Induction & maintenance of anaesth Children 2-12 years 20-30 mcg/10 kg body wt.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IFENBAD,Fentanyl,Fentanyl inj 0.05mg/mL´Ý¾l¾PÀì,CNEU,,1. For analgesic action of short duration during the anesthetic period¡A premedication¡A induction¡A maintenance¡A and in the immediate post-operative period. 2. It is also as the only agent in diagnostic procedure such as arteriograms¡A and pneumonence-phalograms.,,,Adult dosage: 1.Premedication:50 -100mcg im. 2.Adjunct to general anaesthesia induction:50-100mcg iv and repeated at 2-3min intervals¡A until the desired effect is achieved. 3.Adjunct to regional anaesthesia:50-100mcg im or slow iv injection. 4.Postoperatively:50-100mcg im repeated in 1-2 hours as needed.,,,,,,,,,,,,,,
IATI,Lorazepam,Ativan inj 2mg/mL,CNEU,,Insomnia associated with anxiety¡A neurosis and transiet situational disturbance.,,,Anxiolytic:1-3 mg bid-tid¡A (max. 10 mg/day). Sedative-hypnotic:2-4 mg hs. For elderly or debilitated patients: Initial¡A 0.5-2 mg/day in divided doses. Inj Premed IV: 44£gg/kg (max 2mg)15-20 mins before procedure.Premed IM:50£gg/kg(max 4 mg)¡Ù2 hr before procedure.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IFLU,Acetylcysteine,Fluimucil inj 300mg/3mL,ZADT,,Reduce the viscosity of pulmonary secretions in cystic fibrosis of the pancreas¡A paracetamol poisoning.,,,IM 1 Amp. Qd~bid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IFOY,Gabexate Mesilate,FOY 100mg,HEMT,,Acute pancreatitis¡A chronic recurrent pancreatitis with acute exacerbation¡A postoperative acute pancreatitis.,,,Pancreatitis: 100-300mg in 500-1500ml soln/day Disseminated intravascular coagulation: 20-39 mg/kg/day IV drip in 24 hrs.,,,,,,,,,,,,,,
IFRA,Dalteparin,FRAGMIN 10000 IU(Anti-Xa)/4mL(¬~µÇ«Ç±M¥Î),HEMT,Treatment of acute deep venous thrombosis. Prevention of clotting in the extracorporeal system during hemodialysis & hemofiltration.,Confirmed or suspected history of immunologically-mediated heparin-induced thrombocytopenia. Active¡A clinically significant bleeding (eg. GI ulceration or bleeding or cerebral hemorrhage). Severe coagulation disorders¡A septic endocarditis. Recent injury to¡A or surgical procedures of¡A the CNS¡A eyes &/or ears.,Reversible non-immunologically-mediated thrombocytopenia (type 1)¡A transient elevation of liver transaminases¡A bleeding¡A hematoma at inj site¡A allergic reactions¡A pain at inj site. Dermatologic: Hematoma¡A Injection site (7% to 35%)¡A Injection site pain (4.5% to 12% ) Hematologic: Hematoma Other: Irritation symptom¡A Local,25¢J¥H¤U,Thrombolysis or treatment of acute deep vein thrombosis and pulmonary embolism not suitable for surgical treatment: SC once daily 200 IU/kg or twice daily 100 IU/kg¡A up to 18000 IU. Prophylaxis of coagulation during hemodialysis and hemofiltration¡A IV initial dose of 30-40 IU/kg then 10-15 IU/kg every hour. Prophylaxis to patients with substantially increased risk of venous thromboembolism & that are temporarily immobilized due to acute illness such as cardiac/respiratory insufficiency¡A severe infections 5000 IU SC once daily for 12-14 days or longer in patients with restricted mobility. Treatment of acute deep venous thrombosis & pulmonary embolism & extended thromboprophylaxis in cancer patients 200 IU/kg SC once daily for first month of treatment. Maximum daily dose: 18¡A000 IU . 150 IU/kg SC once daily for months 2-6.,»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling. Use with caution in patients with severe hepatic impairment; accumulation may occur with repeated dosing¡A increasing the risk for bleeding.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;SC;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. Dalteparin ¤£¥i¸g¥Ñ¦Ù¦×ª`®gµ¹ÃÄ¡C 2. ¥H·»¸Ñ¦å®ê©Î¤â³NªvÀø¤£¾A¦X¤§«æ©Ê²`³¡ÀR¯ß¦å®ê»PªÍ®ê¶ëªvÀø¡ADalteparin¥i±Ä¨C¤Ñ¤@¦¸©Î¨C¤Ñ¨â¦¸ªº¤è¦¡¡A¸g¥Ñ¥Ö¤Uª`®g(SC)µ¹ÃÄ¡C 3. ¹w¨¾¦å²G³zªR(hemodialysis)»P¦å²Gº¯ªR(hemofiltration)´Á¶¡ªº¾®¦å¡A¸g¥ÑÀR¯ßª`®g(IV)§ë»Pdalteparin¡C 4. ¥»ª`®g²G¥i»P¸Ë©ó¬Á¼þ©Î¶ì½¦®e¾¹¤¤ªº¥Í²z­¹ÆQ¤ô·»²G(0.9% NaCl)©Îµ¥±i¸²µå¿}·»²G(5%)²V¦X¡CFragmin»P¨ä¥LÃÄª«ªº¬Û®e©Ê¦Ü¤µ©|¥¼¶i¦æ¬ã¨s¡A¦]¦¹¤£¥i»P¨ä¥LÃÄª«²V¦X¨Ï¥Î¡C
IFUN,Amphotericin B,Fungizone inj 50mg,QANB,,Treatment of cryptococcosis¡A North American blastomycosis¡A disseminated moniliasis¡A coccidioidomycosis¡A histoplasmosis¡A mucormycosis¡A sporotrichosis and spergillosis.,,«Ç·Å,IV infusion over 6 hrs with a conc. of 0.1 mg/ml¡A Initially: 0.25 mg/kg/day. Gradually increased: by 5-10 mg/day or q2d to 0.4-0.6mg/kg/day (max. 1 mg/kg qd or 1.5 mg/kg q2d).,,,,¥i¯à¦w¥þ,,,,,,,,,,
IGAS,Famotidine,Gaster °w¾¯ 20mg/2mL,ALIM,,¾AÀ³¯g: Upper GI hemorrhage¡A Zollinger-Ellison syndrome. °Æ§@¥Î: Infrequently¡A rash; constipation¡A diarrhea; dry mouth¡A nausea. Rarely¡A leukopenia¡A thrombocytopenia; tinnitus¡A increased pulse & BP; reversible mental confusion. Gastrointestinal: Constipation (1.2% )¡A Diarrhea (1.7% ),,«Ç·Å,Upper GI hemorrhage¡A Zollinger-Ellison syndrome Adult 20 mg dissolved in 20 mL physiological saline or glucose soln by slow IV. Premed Adult 20 mg dissolved in 1-1.5 mL distilled water for inj IM or dissolved in 20 mL physiological saline or glucose soln by slow IV¡A 1 hr before anesthetization.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Famotidine is excreted into breast milk with peak concentrations occurring ~6 hours after the maternal dose. According to the manufacturer¡A the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.,,,,,,I.V. push: Inject over at least 2 minutes. Solution for infusion: Administer over 15-30 minutes.
IGCSF75,Filgrastim,GCSF 75mcg(FILGRASTIM),HEMT,,Increase in absolute neutrophil count after bone marrow transplantation; Neutropenia induced by cancer chemotherapy; Neutropenia accompanying MDS; Neutropenia accompanying aplastic anemia; Congenital idiopathic neutropenia:,,,Increase in absolute neutrophil count after bone marrow transplantation : Adult & childn administer 1 or 5 days after BMT; 300 mcg/m2 once daily IV. Neutropenia induced by cancer chemotherapy: Adult: Neutrophil count <= 1000/mml after chemotherapy 50 mcg/m2 once daily SC. Child: Neutrophil count <= 500/mml after chemotherapy 50 mcg/m2 once daily SC. When SC inj is not possible¡A 400 mcg/m2 once daily can be given IV. Neutropenia accompanying MDS: Adult¡A Neutrophil count <= 1000/mml¡A 200 mcg/m2 IV once daily. Neutropenia accompanying aplastic anemia: Adult & childn¡A Neutrophil count <=1000/mml 100 mcg/m2 IV once daily. Congenital idiopathic neutropenia: Adult & childn¡A Neutrophil count <=1000/mml¡A 50 mcg/m2 SC once daily. When neutrophil count >= 5000/mml¡A close observation is needed & consideration should be made to either decrease dosage or discontinue therapy.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ODIMR,Metoclopramide + Pancreatin,Dimotil Repe-Tab 5/212mg,ALIM,,¾AÀ³¯g: Digestant¡A improve digestive tract function Management of GI disorders (e.g. nausea¡A vomiting¡A bloatedness). °Æ§@¥Î: Rarely¡A extrapyramidal reactions¡A tardive dyskinesia¡A raised serum prolactin levels¡A sedation. ¸T§Ò: Whenever stimulation of GI motility might be dangerous (e.g. in the presence of mechanical obstruction or perforation); pheochromocytoma; seizure disorders; children < 14 years,,«Ç·Å,1-2 tab tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IROL,Cephalexin,Roles inj 1gm,QANB,,¾AÀ³¯g:Respiratory tract infections¡A skin & soft tissue infections¡A bone & joint infections °Æ§@¥Î:GI disturbances¡A hypersensitivity reactions¡A superinfection. Rarely¡A pseudomembranous colitis. ¸T§Ò:Hypersensitivity to cephalosporins.,,«Ç·Å,IM/IV inj. Adult 2-8 g/day in divided doses¡A children 50-100 mg/kg/day.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ÀR¯ß¤j¶q§ë»P·|¤Þ°_¦åºÞµh¡B¦å®êÀR¯ßª¢¡C 2. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡C
IDPT2,Diphtheria + Tetanus + Pertussis,Tripacel 0.5mL/dose,HIMM,,Active immunization against diphtheria¡A tetanus and pertussis.,,2-8,IM¡A for child 6 wks-6 yrs¡A 0.5 ml/dose. Primary immunization: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months-1yr later. Booster dose: Given at 4-6 yrs.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IDPTA,,Tripacel+Act-Hib (¥|¦X¤@),HIMM,,,,,,,,,,,,,,,,,,,
LROT2,Human Rotavirus,Rotarix (gsk ½üª¬¯f¬r¬Ì­]) 1.5mL/dose,HIMM,Prevention of gastroenteritis caused by rotavirus¡A G1 & certain non-G1 serotypes.,Hypersensitivity¡A uncorrected congenital malformation of the GIT¡A known or suspected immunodeficiency.,Irritability¡A loss of appetite¡A diarrhoea¡A vomiting¡A flatulence¡A abdominal pain¡A regurgitation of food¡A fever¡A fatigue.,2-8¢JÁ×¥úÁ×§K§N­á,1.5 mL¡A 2 doses administered orally starting at 6 weeks of age¡A the subsequent doses administered at intervals of at least 4 weeks. Th second dose should be given before 24 weeks of age.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡C ¦¹¬Ì­]¤£¾A¥Î©ó¦¨¤H¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡C ¦¹¬Ì­]¤£¾A¥Î©ó¦¨¤H¡C,PO;,,,,,
OCEL2,Celecoxib,Celebrex 200mg,CNEU,Relief of the signs and symptoms of osteoarthritis and RA. Management of acute pain and treatment of primary dysmenorrhea. To reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP)¡A as an adjunct to usual care. Ankylosing spondylitis.,Hypersensitivity to sulfonamides. Patients in whom aspirin or other NSAIDs induce symptoms of asthma¡A urticaria or allergic-type reactions.,Abdominal pain¡A diarrhea¡A dyspepsia¡A flatulence¡A peripheral edema¡A dizziness¡A pharyngitis¡A rhinitis¡A sinusitis¡A upper respiratory tract infection¡A rash. Cardiovascular: Hypertension (arthritis¡A 2.4% ; familial adenomatous polyposis¡A 12.5% ) Gastrointestinal: Diarrhea (arthritis¡A 5.6%; familial adenomatous polyposis¡A 10.5%; juvenile rheumatoid arthritis¡A 4% to 5% )¡A Nausea (arthritis¡A 3.5%; familial adenomatous polyposis¡A 6.8%; juvenile rheumatoid arthritis¡A 4% to 7% ) Neurologic: Headache (arthritis¡A 15.8%; juvenile rheumatoid arthritis¡A 10% to 13% ),25¢J¥H¤U,Osteoarthritis: 200mg QD¡A or 100mg BID Rheumatoid arthritis: 100-200mg BID Ankylosing Spondylitis (AS):200mg/day in single (once a day) or divided (twice a day) dose. If it doesn't work after six weeks¡A try 400 mg/day. If there is no effect after another 6 weeks¡A there will be no therapeutic response¡A and other treatments should be considered. Relieve acute pain and treat primary dysmenorrhea: initial dose: 400mg¡A then 200 mg twice a day when needed.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ(Child-pugh B)¤§¯f±w:Reduce daily dose by 50% ­««×¨x¥\¯à¤£¥þ(Child-pugh C)¤§¯f±w¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] Á×§KÅýÃh¥¥30¶g¤Î§ó±ßªº¥¥°ü¨Ï¥Î¡C¦b¬ù¦¹Ãh¥¥¶g¼Æ¨Ï¥Î·|¼W¥[­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦X­·ÀI¡C Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥Î¥i¯à·|¾É­P­L¨àµÇ¥\¯à²§±`¡A³y¦¨¦Ï¤ô¹L¤Ö¡A¾É­P·s¥Í¨àµÇ¥\¯à¤£¥þ¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EEMA,Emedastine,Emadine 0.05%¡A 5mL oph soln,TOPH,,¾AÀ³¯g:Symptomatic relief of allergic conjunctivitis. °Æ§@¥Î:Headache¡A abnormal dreams¡A asthenia¡A dysgeusia¡A blurred vision¡A burning or stinging¡A corneal infiltrates¡A corneal staining¡A dermatitis¡A discomfort¡A dry eye¡A foreign body sensation¡A hyperemia¡A keratitis¡A pruritus¡A rhinitis¡A sinusitis¡A tearing. ¸T§Ò: hypersensitivity,,«Ç·Å,Allergic conjunctivitis As 0.05% soln: Instill 1 drop twice daily. If needed¡A up to qid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,¥H¤WÃh¥¥¤À¯Å°Ñ¦ÒUpToDate Pregnancy Risk Factor: B,,,,,,
OFERC,Iron (III) hydroxide polymaltose complex,Ferrum Hausmann 100mg Chewable,NUTR,,¾AÀ³¯g: Treatment or prevention of iron deficiency and/or anemia °Æ§@¥Î:GI irritation¡A nausea¡A constipation¡A diarrhea. ¸T§Ò:All cases of Fe overload or disturbances in utilization of Fe.,,«Ç·Å,Chewable tab: May be taken with food or immediately after a meal. PO Doses equivalent to 100 mg elemental Fe/day¡A up to 300 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Unknown ¨S¦³¸ê®Æ,,,,,,,
OGLUB,Acarbose,Glucobay 50mg,META,,¾AÀ³¯g: NIDDM. °Æ§@¥Î: Flatulence¡A diarrhea¡A GI & abdominal pains. Gastrointestinal: Abdominal pain (19% )¡A Diarrhea (31% )¡A Flatulence (74% ) ¸T§Ò: Chronic intestinal disorders associated with distinct disturbances of digestion & absorption. States which may deteriorate as a result of increased gas formation in the intestine (eg. Roemheld's syndome¡A major hernias¡A intestinal obstructions¡A & intestinal ulcers). Severe renal impairment (CrCl < 25 mL/min).,,«Ç·Å,Diabetes mellitus type 2: initial¡A 25 mg ORALLY 3 times a day with the first bite of each main meal; may initiate at 25 mg ORALLY once daily with gradual dose titration to 25 mg ORALLY 3 times a day in some patients to minimize gastrointestinal side effects Diabetes mellitus type 2: maintenance¡A dose may be increased at 4- to 8-week intervals to 50 to 100 mg ORALLY 3 times a day with the first bite of each main meal; MAX 50 mg three times daily for patients weighing 60 kg or less and MAX 100 mg three times daily for those weighing more than 60 kg,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OGLUR,Gliquidone,Glurenorm 30mg,META,,,,,,,,,,,,,,,,,,,
OMOM,Magnisum Hydroxide,Mag Mag 500mg,ALIM,,,,,,,,,,,,,,,,,,,
OYUT,Ritodrine,Yutopar 10mg,SGU,,¾AÀ³¯g: Prevention of preterm labour¡A Acute fetal distress¡A Prevention of preterm labour after operation Follow treatment for preterm labour. °Æ§@¥Î: Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor¡A nausea¡A vomiting¡A headache or erythema¡A nervousness¡A restlessness¡A jitteriness¡A emotional upset¡A anxiety or malaise. Infrequently cardiac symptoms¡A eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment. ¸T§Ò: Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,,«Ç·Å,Tab 1-2 tab 2-6 hrly. Max: 120 mg daily. Usually 80-120 mg equally divided over the day.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OZAD,Ketotifen,Zaditen 1mg,HIMM,,¾AÀ³¯g: Long-term prevention of bronchial asthma¡A allergic bronchitis¡A asthmatic symptoms associated with hay fever. Treatment of multi-system allergies¡A allergic rhinitis & skin conditions. °Æ§@¥Î: Sedation¡A dry mouth & slight dizziness; weight gain. Neurologic: Headache (10%-25%) Ophthalmic: Dry eyes¡A Eye irritation¡A Conjunctival (10%-25%)¡A Pain in eye Respiratory: Pharyngitis¡A Rhinitis (10%-25%) Other: Influenza,,«Ç·Å,Adult 1-2 mg¡A in susceptible patients start with 0.5 mg. Children over 3 years 1 mg¡A 6 months-3 years 0.5 mg. To be taken bid.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OZEF,Lamivudine,Zeffix 100mg,QANB,,¾AÀ³¯g: Treatment of patients with chronic hepatitis B & evidence of hepatitis B virus replication. °Æ§@¥Î: Malaise¡A fatigue¡A respiratory tract infections¡A headache¡A abdominal discomfort¡A pain¡A nausea¡A vomiting¡A diarrhoea. Pancreatitis & peripheral neuropathy in patients with HIV infection. Lactic acidosis associated with severe hepatomegaly & hepatic steatosis. ¸T§Ò: Patients with known hypersensitivity to lamivudine or to any ingredient of Zeffix.,,«Ç·Å,Adult & children <= 12 years 100 mg once daily. Childn 2-11 yr 3 mg/kg once daily¡A up to max 100 mg daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OZIT,Azithromycin,Zithromax 250mg,QANB,Upper & lower respiratory tract infections; skin & soft tissue infections; otitis media; uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrheae.,Cholestatic jaundice with prior azithromycin therapy. Hepatic dysfunction with prior azithromycin therapy. Hypersensitivity to azithromycin or to any product component¡A erythromycin¡A or any macrolide or ketolide antibiotic.,Common: Injection site disorder (3.1-6.5%)¡A Abdominal pain (adult¡A 1.9-14%; pediatric¡A 2-4%)¡A Diarrhea (Adult¡A 4.3-12%; pediatric¡A 7-10%)¡A Flatulence (5%)¡A Nausea (Adult¡A 3-14%; pediatric¡A 4%)¡A Vomiting (Adult¡A up to 13%; pediatric¡A 11-14%)¡A Increased liver enzymes (<1-6%)¡A Headache (up to 5%)¡A Abnormal vision (5%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Congenital hypertrophic pyloric stenosis¡A Hepatic necrosis¡A Hepatitis (<1%)¡A Liver failure¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Eaton-Lambert syndrome¡A Myasthenia gravis¡A Exacerbation of¡A Myasthenic crisis¡A Corneal erosion (<1%),30¢J¥H¤U,Adults: usual dose: 500 mg orally once daily + or - food for 3 days or 500 mg on day 1 then 250 mg on days 2-5; Chlamydia trachomatis infection of the cervix¡A urethra: 1 g as single oral dose; conjunctivitis or trachoma due to Chlamydia trachomatis infection: 1 g once weekly for ? 3 weeks; community-acquired pneumonia following IV therapy: 500 mg once daily for 7-10 days; primary prophylaxis for disseminated disease due to Mycobacterium avium complex (MAC) infection in patients with HIV: 1.2 g once weekly.,µL»Ý½Õ¾ã¾¯¶q,¨Ö¦³»´(A¯Å)¦Ü¤¤«×(B¯Å)¨x¥\¯à·l®`ªº±wªÌ¡AµL¶·½Õ¾ã,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OZOC2,Simvastatin,Zocor 20mg,CAVS,,I: Reduction of elevated total & LDL-cholesterol levels in patients primary hypercholesterloemia. Reduction of elevated cholesterol levels in patients hypercholesterolemia & hypertriglyceridemia. CI: Active liver disease or unexplained persistent elevations of serum transaminases. Pregnancy & lactation.,,RT,Patient should be placed on standard cholesterol-lowering diet before & during treatment. Usual starting dose: 10mg daily. Max: 40mg. Adjusted at 4wk intervals as required.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IXYL3,Lidocaine,Xylocaine 3% inj 3.5mL,ZANE,,¾AÀ³¯g:¬°§½³¡³Â¾K¾¯(B013896217),,RT,Infiltration¡A caudal¡A epidural or peripheral nerve block: Up to 30 ml as a 1% soln or 15 ml as a 2% soln. Surface anesthesia: Nose¡A nasopharynx and respiratory tract: 1-5 ml of 1%-4% soln is sprayed¡A 8% spray may be needed. Mouth¡A pharynx and upper digestive tract: 5-15 ml of 2% viscous soln. Urethral catheterization: Men¡A 5-10 ml; women¡A 3-5 ml of 2% jelly.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IZIN7,Cefuroxime,Zinacef inj 750mg,QANB,,¾AÀ³¯g: Infections of resp tract¡A ENT¡A GUT¡A skin & soft tissue¡A bone & joint¡A gonorrhoea¡A septicaemia¡A meningitis¡A peritonitis. Prophylaxis against infections in abdominal¡A pelvic¡A orthopaedic¡A cardiac¡A pulmonary¡A oesophageal & vascular surgery. °Æ§@¥Î: Hypersensitivity¡A GI disturbances including very rarely pseudomembranous colitis. Haematological changes. Superinfection. Transient pain at IM inj site. Occasionally¡A thrombophlebitis (IV inj). ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult 750 mg tid IM or IV. Severe infections: 1.5 g tid IV. Total dose: 3-6 g/day. Infants & children 30-100 mg/kg/day in 3-4 divided doses. Neonates 30-100 mg/kg/day in 2-3 divided doses. Gonorrhoea 1.5 g as a single dose (as 2 x 750 mg IM with different sites eg each buttock). Meningitis Adult 3g IV 8 hrly. Infants & children 150-250 mg/kg/day IV in 3-4 divided doses. Neonates 100 mg/kg/day IV. Prophylaxis Abdominal¡A pelvic & orthopaedic operations 1.5 g IV with induction of anaeth¡A may be supplemented with two 750 mg IM doses 8 & 16 hrs later. Cardiac¡A pulmonary¡A oesophageal & vascular operations 1.5 g IV with induction of anaesth¡A continuing with 750 mg IM tid for a further 24-48 hrs. Total joint replacement 1.5 g cefuroxime powder may be mixed dry with each pack of methyl methacrylate cement polymer before adding the liquid monomer.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IZOL,Goserelin,Zoladex Depot 3.6mg,RACA,Breast cancer¡A advanced. Endometrial thinning. Endometriosis. Prostate cancer¡A advanced. Prostate cancer¡A stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males. Artificial assisted reproduction.,Hypersensitivity to goserelin¡A gonadotropin releasing hormone (GnRH)¡A GnRH agonist analogues¡A or any component of the product. Pregnancy in females with endometriosis or endometrial thinning¡A as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation.,Common Cardiovascular: Peripheral edema (21% ) Dermatologic: Acne (42% )¡A Seborrhea (26% )¡A Sweating (1% to 45% ) Endocrine metabolic: Atrophy of breast (33% ) Neurologic: Headache (men¡A greater than 1% to less than 5%; women¡A 32% to 75% ) Psychiatric: Depression (men¡A greater than 1% to less than 5%; women¡A 54% )¡A Mood swings (60% ) Reproductive: Erectile dysfunction (18% )¡A Flushing (46% to 96% )¡A Reduced libido (47.7% to 61% )¡A Sexual dysfunction (21% )¡A Vaginitis (5% to 75% ) Other: Pain (8% to 17% ) Serious Cardiovascular: Cardiovascular event risk¡A Congestive heart failure (5% )¡A Hemorrhagic shock¡A Myocardial infarction (greater than 1% to less than 5% )¡A Prolonged QT interval Dermatologic: Injection site hemorrhage Endocrine metabolic: Diabetes mellitus (10.9% to 22.2% )¡A Pituitary apoplexy (rare )¡A Pituitary tumor (rare )¡A Tumor flare (23% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis¡A Hypersensitivity reaction (1% or greater ) Neurologic: Cerebrovascular accident (greater than 1% to less than 5% ) Renal: Renal impairment (greater than 1% to less than 5% ) Respiratory: Chronic obstructive pulmonary disease (5% ) Other: Tumor flare (23% ),25¢J¥H¤U,3.6 mg SC every 28 days [Endometriosis] 3.6 mg SC every 28 days for up to 6 months [Endometrial thinning] Two 3.6 mg SC injections given 4 weeks apart with endometrial ablation surgery performed within 2 weeks of the second injection [Uterine fibroid with anemia] 3.6 mg SC with supplementary iron for up to 3 months before surgery,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]ÁöµM¦b°Êª«¤§¥Í´Þ¬r©Ê¹êÅç¤¤¨Ã¥¼¦³³y¦¨·î­L¤§ÃÒ¾Ú¡A¦ý²z½×¤WLHRH¨ó¦P¦³³y¦¨¬y¡H©Î­L¨à¤£¥¿±`ªº­·ÀI¡A ¬G Zoladex3.6mg¤£À³¨Ï¥Î©óÃh¥¥¤¤ªº°ü¤k¡C ¥i¯àÃh¥¥ªº¡H¤k¦b¨Ï¥Î¥»ÃÄ«eÀ³¥J²ÓÀËÂ¾¡A¥H±Æ°£¤wÃh¥¥ªº¥i¯à¡C ¥H Zoladex3.6mgªvÀø½¤²§¦ì¯g¤§¯f¨Ò«h¶·Á×¥¥¦Ü¤ë¸g«ì´_¬°¤î¡C®É¡AÀ³±Ä¨ú²üº¸»X¥H¥~¤§Á×¥¥¤èªk¡F¹ï©ó¤l®c¤º Zoladex3.6mg¦b¥Î©ó¤H¤u¨ó§U¥Í´Þ«e¡AÀ³¥ý±Æ°£§³®W¤§ª¬ªp¡CÁöµM¨Ó¦Û³o­Ó­I´º¤§Á{§É¸ê®Æ¦³ ­­¡A¦ý¥Ø«e©Ò¦³ªº¸ê®Æ¥Ü Zoladex3.6mg»P§Z¤lµo¨|©Î§³®W¤Îµ²ªG¤§¥ô¦óÄ~°_ªº¤£¥¿±`¡A¨S¦³¦]ªG«Y¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¤£±ÀÂË¨Ï¥Î¦b­÷¨Å´Á¶¡¨Ï¥Î¡C,SC;,,,,,
OLAT,Lurasidone,Latuda 40mg,CNEU,Schizophrenia.,Hypersensitivity. Concomitant w/ strong CYP3A4 inhibitors (eg¡A ketoconazole¡A clarithromycin¡A ritonavir¡A voriconazole) & inducers (eg¡A rifampin¡A St. John's wort¡A phenytoin¡A carbamazepine).,Akathisia¡A somnolence. Hypersensitivity; increased wt; insomnia¡A agitation¡A anxiety¡A restlessness; parkinsonism¡A dizziness¡A dystonia¡A dyskinesia; nausea¡A vomiting¡A dyspepsia¡A salivary hypersecretion¡A upper abdominal pain¡A stomach discomfort; rash¡A pruritus; musculoskeletal stiffness¡A increased blood creatine phoshokinase; increased serum creatinine; fatigue.,25¢J¥H¤U,Should be taken with food (at least 350 kcal). Schizophrenia: 40mg QD. maximum: 160mg/day. Depressive episodes of type 1 bipolar disorder: 20mg QD¡A the dose can be increased based on clinical response after one week of treatment. maximum: 80mg/day.,»Ý½Õ¾ã¾¯¶q,Moderate impairment (Child-Pugh class B): Initial: 20 mg daily; maximum: 80 mg/day Severe impairment (Child-Pugh class C): Initial: 20 mg daily; maximum: 40 mg/day,»Ý½Õ¾ã¾¯¶q,,Human data suggest risk in 3 rd trimester,No Human Data¡XPotential Risk in 3rd Trimester,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IZOV,Acyclovir,Zovirax inj 250mg,QANB,Herpes simplex (except Herpes encephalitis) or Varicella zoster infections¡A Immuno-compromised patient with Varicella zoster infections or patient with Herpes encephalitis¡A Prophylaxis of CMV infection in bone marrow transplant recipients.,Hypersensitivity to valaciclovir or aciclovir.,Common: Injection site inflammation (Approximately 9%)¡A Nausea¡A Vomiting¡A Serum blood urea nitrogen raised¡A Transient¡A Serum creatinine above reference range¡A Transient Serious: Injection site extravasation¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Thrombotic thrombocytopenic purpura¡A Neurotoxicity¡A Hemolytic uremic syndrome¡A Renal failure,25¢J¥H¤U,Zovirax should be administered by slow IV infusion over 1 hour period. Usual treatment course: 5-10 days. Use ideal body weight for obese patients. Adults: 5-10 mg/kg every 8 hours; children aged between 3 months to 12 years: 250-500 mg/m2 every 8 hours; neonates: 20 mg/kg every 8 hours for 14 or 21 days. *****NEONATE ANTIBIOTICS DOSE***** Acyclovir: this dosage for herpes simplex virus infection Treat localized infections for 14 days; disseminated or CNS infections for 21 days. Dilute to a final concentration<=7 mg /mL; IV infusion over 60 minutes Body weight <1kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20mg/kg Q12H  Age 15-28 day  20 mg/kg Q8H Body weight 1-2kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20 mg/kg Q8H  Age 15-28 day 20 mg/kg Q8H Body weight >2kg Age<=7day 20 mg/kg Q8H  Age 8-14 day 20mg/kg Q8H  Age 15-28 d ay 20mg/kg Q8H PMA (postmenstrual age ) = gestational age plus postnatal age,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,IVD: 10mL D/W¡A N/S,¡iH/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5NS¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,,> 60¤ÀÄÁ¥H¤W®É¶¡½wºCºwª`¡C ¥[¤J¾A·í¿éª`²Gµ}ÄÀ¡A¿@«×¤£¥i¶W¹L 5 mg/mL¡C,1. ¥»«~¤£§t§Üµß¾¯¡Aµ}ÄÀ«áÀ³¥ß§Y¨Ï¥Î¡C 2.¥H1¤p®Éªº®É¶¡½wºCÀR¯ß¿éª`¡C 3.µ}ÄÀ¤èªk¡G¨C¤p²~ 250 mg °®¯»¥[¤J 10 mL ª`®g¥Î¤ô©Î0.9%ª`®g¥Î¥Í²z­¹ÆQ¤ô·»¸Ñ¡C¨ú¥XÂåÅñ©Ò»Ý¾¯¶q¡A¥[¤J¾A·í¿éª`²Gµ}ÄÀ¡A¿@«×¤£¥i¶W¹L 5 mg/mL¡C 4. ¨Ì·Ó«ü¥Ü°t»s«áªºZoviraxÀR¯ß¿éª`²G pH­È¬ù 11¡A¤£¥i§NÂÃ¡AÀ³Àx¦s©ó 25 ¢J¥H¤U¡C«Ç·Å¤U(15-25¢J)«O«ù12¤p®ÉÃ­©w©Ê 5. ­Y©ó¿éª`«e¡B¿éª`¤¤µo²{ÃÄ²G¥X²{µ²´¹©Î²V¿B¡AÀ³¥ß§Y©ß±ó¤£¥i¨Ï¥Î¡C 6. ºÊ´ú¯f¤HÅé·Å¡BCBC¡BµÇ¥\¯à¡C
OLISA,Cephradine,Lisacef 500mg,QANB,,¾AÀ³¯g: Infection of the respiratory tract¡A GUT¡A skin & skin structure¡A bone & joints; septicemia. °Æ§@¥Î: GI disturbances¡A hypersensitivity reactions. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult: 0.5-1 g q4-6h¡A (max. 8 g/day). Child over 1 yr: 50-100 mg/kg/day in 4 divided doses; max. daily dose should not exceed the recommended adult dose.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OLISE,Metergoline,Liserdol 4mg (­­¦Û¶O),HM,,,,,,,,,,,,,,,,,,,
OLIT,Lithium,Lithonate 300mg,CNEU,,Treatment of manic episodes of manic depressive illness.,,,Acute mania: Initial 600 mg tid¡A Mintenance: 300 mg tid.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OLOS,Omeprazole,Losec 20mg,ALIM,,Gastric and peptic ulcer¡A gastroesophageal reflex.,,,Active ulcer: 20 mg qd. Pathological hypersecretory conditions: Initial¡A 60 mg qd. Zollinger-Ellison syndrome: 20~40mg qd. S/P: 1. In elderly patients¡A the daily dose usually should not exceed 20 mg. 2. Swallow capsule whole.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OLUVO,Fluvoxamine,Luvox 50mg,CNEU,Treatment of symptoms of depressive illness. Obsessive compulsive disorder in children & adolescents.,None.,Nausea¡A vomiting¡A asthenia¡A headache¡A malaise¡A palpitations/tachycardia¡A abdominal pain¡A anorexia¡A constipation¡A diarrhoea¡A dry mouth¡A dyspepsia¡A agitation¡A anxiety¡A dizziness¡A insomnia¡A nervousness¡A somnolence¡A tremor¡A sweating¡A (postural) hypotension¡A arthralgia¡A myalgia¡A ataxia¡A confusion¡A extrapyramidal symptoms¡A hallucinations¡A abnormal (delayed) ejaculation¡A cutaneous hypersensitivity reactions (including rash¡A pruritus¡A angioedema)¡A liver dysfunction¡A convulsions¡A mania¡A galactorrhoea¡A photosensitivity¡A weight gain/loss¡A serotonin syndrome¡A neuroleptic malignant syndrome-like events¡A hyponatremia & SIADH¡A withdrawal reactions¡A haemorrhage¡A paresthesia¡A anorgasmy & taste perversion. Dermatologic: Sweating (immediate-release¡A 7%; extended-release (social anxiety disorder)¡A 6%; extended-release (obsessive-compulsive disorder)¡A 7% ) Gastrointestinal: Diarrhea (immediate-release¡A 11%; extended-release (social anxiety disorder)¡A 14%; extended-release (obsessive-compulsive disorder)¡A 18% )¡A Indigestion (immediate-release¡A 10%; extended-release (social anxiety disorder)¡A 10%; extended-release (obsessive-compulsive disorder)¡A 8% )¡A Loss of appetite (immediate-release¡A 6%; extended-release (social anxiety disorder)¡A 14%; extended-release (obsessive-compulsive disorder)¡A 13% )¡A Nausea (immediate-release¡A 40%; extended-release (social anxiety disorder)¡A 39%; extended-release (obsessive-compulsive disorder)¡A 34% )¡A Xerostomia (immediate-release¡A 14%; extended-release (social anxiety disorder)¡A 11%; extended-release (obsessive-compulsive disorder)¡A 10% ) Neurologic: Asthenia (immediate-release¡A 14%; extended-release (social anxiety disorder)¡A 24%; extended-release (obsessive-compulsive disorder)¡A 26% )¡A Dizziness (immediate-release¡A 11%; extended-release (social anxiety disorder)¡A 15%; extended-release (obsessive-compulsive disorder)¡A 12% )¡A Insomnia (immediate-release¡A 21%; extended-release (social anxiety disorder)¡A 32%; extended-release (obsessive-compulsive disorder)¡A 35% )¡A Somnolence (immediate-release¡A 22%; extended-release (social anxiety disorder)¡A 26%; extended-release (obsessive-compulsive disorder)¡A 27% )¡A Tremor (immediate-release¡A 5%; extended-release (social anxiety disorder)¡A 8%; extended-release (obsessive-compulsive disorder)¡A 6% ) Psychiatric: Agitation (immediate-release¡A 2%; extended-release (social anxiety disorder)¡A 3%; extended-release (obsessive-compulsive disorder)¡A 2% )¡A Anxiety (immediate-release¡A 5%; extended-release (social anxiety disorder)¡A 8%; extended-release (obsessive-compulsive disorder)¡A 6% )¡A Feeling nervous (immediate-release¡A 12%; extended-release (social anxiety disorder)¡A 10% ) Reproductive: Abnormal ejaculation (immediate-release¡A 8%; extended-release (social anxiety disorder)¡A 11%; extended-release (obsessive-compulsive disorder)¡A 10% )¡A Orgasm incapacity (immediate-release¡A 2%; extended-release¡A 5% ),25¢J¥H¤U,May be taken with or without food 100-200 mg daily. Maximum: 300 mg daily. The minimum recommended starting dose is 100 mg/day and can be given as a single dose; preferably in the evening.It is advisable that a total daily dose over 150 mg be given in 2 or 3 divided doses.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³ A lower initial dose¡A longer dosing interval¡A or slower titration may be necessary,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OMAC,Mag Hydroxide + Alum Hydroxide,Macgel,ALIM,,Hyperacidity¡A peptic and doudenal ulcer¡A gastritis¡A flatulence.,,RT,2-4 tab qid pc 1hr.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OACC,Zafirlukast,Accolate 20mg,ERSP,,¾AÀ³¯g:¥Dªv¤ä®ðºÞ­ý³Ý(B022398100),,«Ç·Å,20mg twice daily in adults and children 12 years and older. Since food reduces the bioavailability of zafirlukast¡AAccolate should be taken at least 1 hour before or 2 hours after meals.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OACE,Perindopril,Acertil 4mg,CAVS,,,,RT,Hypertension 4mg daily as single dose¡A may be increased to a single 8mg dose. Elderly Start treatment 2mg dose. In renal insufficiency¡A dose has to be adapted according to creatinine clearance.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OACT,Acetylcysteine,Actein 100mg/pk Áû²É¾¯,ERSP,,¾AÀ³¯g: Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis¡A emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms. °Æ§@¥Î: Bronchospasm¡A GI upsets¡A stomatitis; rhinorrhea¡A fever¡A hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )¡A Rash (4% to 5% )¡A Urticaria Gastrointestinal: Diarrhea¡A Nausea (2% to 7% )¡A Vomiting (9% to 12% ) ¸T§Ò: Effervescent tab Phenylketonuria.,,«Ç·Å,Effervescent tab Adult & children > 6 years 1 effervescent tab daily. Granules Adult 200 mg. Children 100 mg. To be taken tid.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OAKI,Biperiden,Akineton 2mg,CNEU,,¾AÀ³¯g: Parkinsonism. °Æ§@¥Î: Fatigue¡A dizziness¡A drowsiness. Restlessness¡A confusion at higher doses. Occasionally¡A impairment of memory. In rare cases¡A hallucinations. Dry mouth¡A accommodation impairment¡A hypohydrosis¡A constipation¡A gastric discomfort¡A tachycardia. Very rarely¡A bradycardia. Skin allergy¡A dyskinesia. Rarely¡A urine retention. ¸T§Ò: Untreated narrow-angle glaucoma¡A intestinal stenoses or obstruction¡A megacolon¡A prostatic hypertrophy¡A life-threatening tachycardia.,,«Ç·Å,Initially¡A 1 mg bid. Maintenance: 3-16 mg/day(or 1-4 mg tid-qid) Max: 16 mg/day,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OALDA,Spironolactone,Aldactone 25mg,CAVS,,¾AÀ³¯g: Edematous disorders¡A Congestive cardiac failure¡A Liver cirrhosis¡A Nephrotic syndrome¡A Hypertension °Æ§@¥Î: GI symptoms; drowsiness; lethargy; headache; cutaneous eruptions; urticaria; mental confusion; drug fever; ataxia; impotence; amenorrhea; post-menopausal bleeding; gynecomastia; rarely agranulocytosis. ¸T§Ò: Acute renal insufficiency; significant impairment of renal function; anuria; hyperkalaemia; hypersensitivity.,,«Ç·Å,Edematous disorders: Daily dose given in divided doses or as single dose. Congestive cardiac failure: Initially¡A 100 mg/day; gradually increased up to 200 mg/day; usual maintenance dose¡A 25-200 mg/day. Liver cirrhosis Urinary Na/K ratio >1: recommended dose 100 mg/day¡A ratio <1: recommended dose 200-400 mg/day; maintenance dose individually determined. Nephrotic syndrome 100-200 mg/day. Idiopathic edema Usual dose 100 mg/day. Children Initial daily dose approximately 3.3 mg/kg body wt. Hypertension 50-100 mg/day given in divided doses or as a single daily dose. For difficult or severe casses¡A gradually increased at 2-wkly intervals up to 200 mg/day.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OALDO,Methyldopa,Aldomet 250mg,CAVS,,I: Moderate to severe hypertension. CI: Active hepatic disease.,,,Adult: Initial: 250 mg bid-tid. Maintenance: 500 mg-2g/day in 2-4 divided doses¡A Max. 3 g/day Child: Initial: 10 mg/kg/day in 2-4 divided doses¡A up to 65 mg/kg/day.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OALK,Melphalan,Alkeran(Melphalan) 2mg,RACA,,Multiple myeloma¡A advanced ovarian aderocarcinoma¡A advanced breast carcinoma¡A polycythemia vera.,,,Multiple myeloma: 0.15 mg/kg/day with 40mg prednisolone daily in divided doses for 4 days. Repeat 6 weekly. Ovarian adenocarcinoma: 0.2 mg/kg/day for 5 days. Repeat 4-8 weekly. Advanced breast carcinoma: 0.15/kg/day for 5 weekly. Polycythemia vera: Induction: 6-10 mg daily for 5-7 days. Maintenance: 2-6 mg/week.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OALM,Diclofenac,Almiral 100mg(Voren),CNEU,,An analgesic¡A antipyretic¡A anti-inflammatory agents used in RA. and other rheumatic disorders.,,,100 mg qd¡A swallowed whole¡A,,,,,,,,,,,,,,
EZAL,Sertaconazole,Zalain cream 2%¡A 15gm,TDER,Topical treatment of skin mycoses eg dermophytosis¡A tinea pedis¡A tinea cruris¡A tinea corporis¡A tinea barbae¡A tinea manus¡A candidiasis & Pityriasis versicolor.,Hypersensitivity to any component of the formulation.,Slight local & transient erythematous reaction.,25¢XC ¥H¤U,Apply to affected area once-bid. Clinical improvement within 2-4 weeks of treatment.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
ESYM,Budesonide + Formoterol,Symbicort Turbuhaler 160/4.5mcg,ERSP,Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting £]2-agonist) is appropriate. Symptomatic treatment of severe COPD & history of repeated exacerbation symptoms despite regular therapy with long-acting bronchodilators.,Hypersensitivity to any component of the formulation.,Palpitation¡A oral candidiasis¡A headache¡A tremor¡A mild throat irritation¡A cough¡A hoarseness.,30¢J¥H¤U»\ºò²~»\,Anti-Inflammatory Reliever Therapy (patients with mild persistent asthma)¡A Adults and adolescents (12 years and older): 1 inhalation as needed in response to symptoms to control asthma. If symptoms persist after a few minutes¡A 1 additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion. The maximum recommended total daily dose is 8 inhalations. Anti-inflammatory Reliever plus Maintenance Therapy (patients with moderate or severe asthma)¡A Adults and adolescents (12 years and older): 1 or 2 inhalations twice daily or 2 inhalations once daily. Additional doses can be used as needed to provide rapid symptom relief and improved asthma control. Patients should take 1 additional inhalation as needed in response to symptoms to control asthma. If symptoms persist after a few minutes¡A 1 additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion. The maximum recommended total daily dose is 8 inhalations. Maintenance Therapy (patients with moderate or severe asthma)¡A Adults and adolescents (12 years and older): 1 or 2 inhalations once or twice daily. The maximum recommended daily maintenance dose is 4 inhalations.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,BUDESONIDE: Compatible (Inhaled/Nasal) No Human Data¡XAnimal Data Suggest Risk (Oral) FORMOTEROL: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BUDESONIDE: Limited Human Data¡XProbably Compatible FORMOTEROL: No Human Data¡XProbably Compatible,IH;,,,,,
ITARI,Ofloxacin,Tarivid IV 200mg,QANB,,I: UTI including sexually transmitted diseases¡A biliary tract¡A GIT¡A ENT¡A phthalmological¡A resp. tract¡A gynaecological¡A skin & soft tissue infections. AR: GI disturbances¡A headache¡A giddiness¡A sleep disorders¡A hypersensitivty reactions. CI: Hypersensitivty. Pregnancy & lactation. Epileptics with pre-existing CNS lesions involving a lowered threshold. Children or adolescents in the growth phase.,,,D: UTI: 200 mg once daily or 200 mg bid. Infections of the kidneys & reproductive organs: 200 mg bid. RTI¡A infections of ENT¡A infections of the skin & soft tissues¡A abdominal cavity or septicaemia: 200 mg bid¡A maybe increased to 400 mg bid in severe cases. IV infusion rate < 200 mg / 30 mins.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ETRA,Travoprost,Travatan 0.004%¡A 2.5mL,TOPH,,¾AÀ³¯g: Reduction of intraocular pressure in patients with open-angle glaucoma or ocular HTN. °Æ§@¥Î: Ocular hyperemia¡A decreased visual acuity¡A eye discomfort¡A itch & pain¡A blepharitis¡A blurred vision¡A conjunctivitis¡A dry eye¡A foreign body sensation¡A iris discoloration¡A keratitis¡A photophobia & tearing. Neurologic: Foreign body sensation (5%-10%) Ophthalmic: Blepharitis¡A Blurred vision¡A Itching of eye (5%-10%)¡A Ocular hyperemia (35%-50%)¡A Pain in eye¡A Reduced visual acuity ¸T§Ò: Hypersensitivity to travoprost¡A benzalkonium chloride. Pregnancy & women who are attempting to get pregnant.,,«Ç·Å,1 drop in the affected eye(s) once every evening.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OBUW,Hyoscyamine,Buwecon 0.125mg,ALIM,,¾AÀ³¯g: Control gastric secretion¡A visceral spasm & hypermotility in spastic colitis¡A spastic bladder¡A cystitis¡A pylorospasm & associated abdominal cramps °Æ§@¥Î: Dry mouth¡A urinary hesitancy & retention¡A blur vision¡A tachycardia. ¸T§Ò: Glaucoma¡A obstructive uropathy¡A GI obstruction¡A paralytic ileus¡A severe ulcerative colitis¡A myasthenia gravis.,,«Ç·Å,Adult & children > 12 years 1-2 tab 4 hrly. Max: 12 tab/day. Children 2-12 years 1/2-1 tab 4 hrly. Max: 6 tab/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OFAR6,Toremifene,Fareston 60mg,RACA,,¾AÀ³¯g:Metastatic breast cancer in postmenopausal patients. °Æ§@¥Î:Hot flush¡A sweating¡A nausea¡A leukorrhea¡A dizziness¡A edema¡A pain¡A vomiting¡A vag bleeding¡A fatigue¡A skin discoloration¡A insomnia¡A dyspnea¡A pruritus¡A anorexia¡A reversible cornea¡A verticillata¡A asthenia. Thromboembolic events¡A endometrial hypertrophy. ¸T§Ò:Pre-existing endometrial hyperplasia¡A severe hepatic failure.,,«Ç·Å,D : 60 mg daily,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IJEV1,Japanese Encephalitis Vaccine,JEV (¦Û¶O¤é¥»¸£ª¢¬Ì­]) 0.5-1mL/dose,HIMM,,¾AÀ³¯g: Active immunisation against encephalitis due to Japanese encephalitis virus. °Æ§@¥Î: Local reactions eg redness¡A swelling¡A tenderness or systemic reactions eg fever¡A chill¡A headache¡A lassitude. Rarely¡A severe adverse reactions manifesting as generalized urticaria or angioedema may occur. ¸T§Ò: Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV¡A renal or hepatic diseases in acute¡A exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,,2-8¢J,Adult Initially 2 inj of 1 mL SC at an interval of 7-14 days¡A with an additional 1 mL after 1 yr. Children <3 yr 3 doses of 0.5 mL.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OZOV,Acyclovir,Zovirax 200mg,QANB,,¾AÀ³¯g:¯f¬r·P¬V(B012736100),,RT,Oral: 200 mg 5 times daily at 4 hrs intervals for 5days. Adult or child with impaired renal function: 200 mg q12h.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
SK1002,,§³®W²Ó¯¾×¶°£Á÷,TDER,,,,,,,,,,,,,,,,,,,
SK1004,,¯Ý³¡¯S§OÅ@«ùÁ÷,TDER,,,,,,,,,,,,,,,,,,,
SK1006,,»L³¡¯h³Ò³t¸ÑÁ÷,TDER,,,,,,,,,,,,,,,,,,,
ESA,Salicylic Acid,Salicylic Acid 5% 20mL,TDER,,¾AÀ³¯g: Hyperkeratotic and scaling skin conditions¡A Warts and calluses . °Æ§@¥Î: Irritation¡A sensitivity¡A excessive drying; systemic effects on prolonged use.,,«Ç·Å,Hyperkeratotic and scaling skin conditions As 2-6% preparation: Apply <=3 times/day. Warts and calluses As 60% preparation: Apply as directed.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ESAN,Cyanocobalamin,Sancoba 0.02%¡A 5mL ophthalmic solution,TOPH,Relief of fatigue of ocular muscle.,Hypersensitivity to cyanocobalamin or any component of the formulation.,Transient stinging & burning¡A ocular irritation¡A allergic reactions.,Á×¥ú¤Î30¢J¥H¤U,Instill 1-2 drops TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,Cyanocobalamin¡A See Vitamin B12,Compatible ­÷¨Å®É¥i¨Ï¥Î,Cyanocobalamin¡A See Vitamin B12,OD;OL;OU;,,,,,
ESER,Salmeterol,Serevent Accuhaler 50mcg(³æ¤è),ERSP,,I: Adult long-term regular treatment of reversible airways obstruction¡A in asthma & chronic bronchitis¡A emphyema. Childn¡Ù4 yr regular treatment of reversible airway obstruction in asthma including long lasting prevention of exercise-induced bronchospasm. AR: Tremor¡A paradoxical brochospasm¡A headache¡A palpitations¡A muscle cramps¡A tachycardia¡A hypersensitiviy reactions.,,,Accuhaler:adult 1 rotadisk blister bid. In patients with more severe airways obstruction¡A up to 2 rotadisk blister bid. Inhaler:adult: 2 inhalation bid. Child ¡Ù4 yr: 2 inhalation bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ESERI,Salmeterol,Serevent inhaler 25mcg/dose,ERSP,,I: Adult long-term regular treatment of reversible airways obstruction¡A in asthma & chronic bronchitis¡A emphyema. Childn¡Ù4 yr regular treatment of reversible airway obstruction in asthma including long lasting prevention of exercise-induced bronchospasm. AR: Tremor¡A paradoxical brochospasm¡A headache¡A palpitations¡A muscle cramps¡A tachycardia¡A hypersensitiviy reactions.,,,Accuhaler:adult 1 rotadisk blister bid. In patients with more severe airways obstruction¡A up to 2 rotadisk blister bid. Inhaler:adult: 2 inhalation bid. Child ¡Ù4 yr: 2 inhalation bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ESIL1,Silver Sulphadiazine,Silvazine cream 1gm,TDER,,I: Prevention of infectios in burns. CI: Pregnancy¡A premature & newborn infants.,,RT,Apply topically once daily,,,,¥i¯à¦w¥þ,,,,,,,,,,
ESKI,Azelaic Acid,Skinoren cream 30gm,TDER,Acne vulgaris.,Hypersensitivity to azelaic acid or any component of the formulation,Occasionally¡A local skin irritation.,30¢J¥H¤U,Acne vulgaris adult¡A apply BID. In the event of excessive skin irritation¡A reduce amount of cream/application or reduce application to once a day until irritation ceases or interrupt treatment temporarily for a few days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
ESOFT,Framycetin + Lanoparaffin Gauz,Sofra-tulle 10x10,TDER,,I: Wounds¡A burns¡A ulcers and other infected skin conditions. AR: Possible ototoxicity ( open wounds¡A large areas¡A renal impairment on prolonged use ). CI: Known allergy to framycetin or where organisms are known to be resistant to framycetin.,,Room Temp,Apply the paraffin gauze dressing directly to the cleaned wound qd-bid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OMEDA,Dextromethorphan+Lysozyme+K Cresolsulfonate,Medicon-A 20/20/90mg,ERSP,,¾AÀ³¯g: Symptomatic relief of coughs caused by the common cold or inhaled irritants. °Æ§@¥Î: Central nervous system: Confusion¡A excitement¡A irritability¡A nervousness¡A serotonin syndrome. ¸T§Ò: Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor.,,«Ç·Å,Adult :10-20 mg ORALLY every 4hrs or 30 mg ORALLY every 6-8hrs maximum dose¡A 120 mg/day Pediatric : (6-12yrs) 5-10 mg ORALLY every 4hrs or 15 mg ORALLY every 6-8hrs; maximum dose: 60 mg/day (2-6yrs) 2.5-5 mg ORALLY every 4hrs or 7.5 mg ORALLY every 6-8hrs; maximum dose: 30 mg/day,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OMEG,Magestrol,Megace 20mg,RACA,,,,,,,,,,,,,,,,,,,
OMEL,Thioridazine,Melleril 25mg,CNEU,,Anxiolytic & antidepressants; Neuroleptic.,,,Anxiolytic & antidepressants: Adult 10-75 mg daily. Childn 0.5-2 mg/kg body weight daily. Neuroleptic: Adult: 25-600 mg daily .Max:800mg daily. Childn: 1-4 mg/kg body weight daily.To be taken in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OMEL1,Thioridazine,Melleril 100mg,CNEU,,Anxiolytic & antidepressants; Neuroleptic.,,,Anxiolytic & antidepressants: Adult 10-75 mg daily. Childn 0.5-2 mg/kg body weight daily. Neuroleptic: Adult: 25-600 mg daily .Max:800mg daily. Childn: 1-4 mg/kg body weight daily.To be taken in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OSELA,Naproxen,Seladin 250mg,CNEU,RA¡A osteoarthritis¡A ankylosing spondylitis¡A acute gout¡A musculoskeletal disorders.,Hypersensitivity to aspirin or other NSAID¡A bleeding tendencies¡A peptic ulcer.,GI disturbances & bleeding¡A peptic ulceration. Headache¡A dizziness¡A nervousness¡A drowsiness; skin rash¡A blurred vision; hypersensitivity¡A hepatic & renal impairment¡A hematological reactions. Cardiovascular: Edema (3% to 9% ) Dermatologic: Pruritus (3% to 9% )¡A Rash (3% to 9% ) Gastrointestinal: Abdominal pain (3% to 9% )¡A Constipation (3% to 9% )¡A Diarrhea (1% to 10% )¡A Heartburn (3% to 9% )¡A Indigestion (1% to 10% )¡A Nausea (3% to 9% )¡A Stomatitis (less than 1% to 10% ) Neurologic: Dizziness (3% to 9% )¡A Headache (3% to 9% )¡A Lightheadedness (less than 3% )¡A Somnolence (3% to 9% )¡A Vertigo (less than 3% ) Otic: Tinnitus (3% to 9% ) Respiratory: Dyspnea (3% to 9% ),25¢J¥H¤UÁ×¥ú,250mg(1 Tablet) BID for adult. Adjust the dose according to the patient's clinical response.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à·l¶Ëªº¯f±w«ØÄ³±q³Ì§C¦³®Ä¾¯¶q¶}©l¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;,,,,,
OISOR,Isosorbide,Isordil 10mg (Sorbitrate),CAVS,,¾AÀ³¯g:¥D­n¹w¨¾¯U¤ß¯g¤§µo§@(B018987100) CI: Cardiogenic shock; circulatory collapse; severe hypotension; marked anemia; head trauma; cerebral hemorrhage; severe hypovolemia.,,RT,Oral: 2.5-10 mg tid-qid¡A ac,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LOPV0,Oral Poliovirus Vaccine,Polio Sabin (¦Û¶O),HIMM,,¾AÀ³¯g: Active immunization against poliomyelitis. °Æ§@¥Î: Rarely¡A allergic & anaphylactic reactions & vaccine-associated poliomyelitis. ¸T§Ò: Immunosuppressed & immunodeficient patients; during acute feverish illnesses¡A hypersensitivity to neomycin. Vomiting & diarrhea. Debilitated states.,,§N­á,3 oral doses¡A (1 dose=2 drops). Separated by 2 months. Oral¡A 0.5 ml/dose. Primary immunization: 3 doses given at 8 wks intervals and a reinforcing 4th dose given 1 yr later. Booster dose: Given at 4-6 yrs.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IKET1,Ketamine,Ketalar inj 50mg/mL¡A 10mL,ZANE,Induction & maintenance of anaesth.,Patients at risk of complications of hypertension.,Respiratory depression; hypotension¡A bradycardia¡A arrhythmia; emergent reactions. Occasionally¡A laryngospasms; diplopia¡A nystagmus; tonic/clonic movement.,25¢J¥H¤UÁ×¥ú,Induction of general anesthesia: Adult: IV: Initial¡A 1-4.5 mg/kg as a single dose. The average amount required to produce 5-10 minutes of surgical anesthesia is 2 mg/kg¡A administer slowly (over 60 seconds); dose may be administered as an IV infusion at a rate of 0.5 mg/kg/minutes. In addition¡A diazepam in 2-5 mg doses¡A administered in a separate syringe over 60 seconds¡A may be used. In most cases¡A 15 mg or less of diazepam IV is enough. Adult: IM: initially 6.5-13 mg/kg as a single dose. Dosage of 10 mg/kg usually produce the surgical anesthetic effect lasting 12-25 minutes. Maintenance of anesthesia: Increments of 1/2 to the full induction dose may be repeated for maintenance of anesthesia. Adult patients induced with ketamine augmented with intravenous diazepam¡A may be maintanined with slow microdrip infusion ketamine at a dose of 0.1-0.5 mg/minute¡A and augmented with diazepam 2 to 5 mg administered intravenously as needed. In many cases 20 mg or less of intravenous diazepam total for combined induction and maintenance will suffice. For pediatric procedural sedation: Initial dose: 1-2mg/kg. When given with propofol: reduce to 0.5mg/kg. Repeat dose:0.5-1mg/kg repeat every 5-10 minutes¡A titrating to desired level of sedation.,»Ý½Õ¾ã¾¯¶q,¹ï©ó¦³¨xµw¤Æ©Î¨ä¥L¨x¥\¯à»ÙÃªªº±wªÌ¡AÀ³¦Ò¼{­°§C¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö 60¬í,µ}ÄÀ©ó¾A·í¿éª`²G¡Aµ¹ÃÄ¿@«×1-2 mg/mL¡A¥H¿éª`³t²v 0.1 - 0.5 mg/min ºwª`,1. IV infusion: µ}ÄÀ©ó¾A·í¿éª`²G¡A¿@«×1-2 mg/mL¡A³t²v 0.1 - 0.5 mg/min ¡C
IKETBAD,Ketamine,Ketalar 50mg/mL ´Ý¾l¾PÀì,ZANE,,,,,,,,,,,,,,IM;IV;IVD;IVP;IVPUSH;,,,,,
OAMA,Glimepiride,AmaRyl 2mg,META,Type 2 diabetes mellitus.,Insulin-dependent (type 1) diabetes mellitus; diabetic ketoacidosis; diabetic precoma or coma; serious renal or hepatic dysfunction. Pregnancy¡A lactation.,Hypoglycaemia; adrenergic counter-regulation; temporary visual impairment; GI symptoms. Rarely thrombopenia¡A haemolytic anaemia¡A erythrocytopenia¡A leucopenia¡A agranulocytosis. Common: Hypoglycemia (4-19.7%)¡A Nausea (5%)¡A Asthenia¡A Dizziness (5%)¡A Headache (8.2%) Serious: Cutaneous hypersensitivity (<1%)¡A Lichenoid drug eruption,30¢J¥H¤U,1-2 mg once daily at breakfast¡A maximum: 8 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] Ãh¥¥´Á¶¡À³¸T¥Îglimepiride¡A§_«h·|¦³¶Ë®`­L¨àªº­·ÀI¡AÃh¥¥±wªÌÀ³§ï¥Î¯Ø®q¯À¡C ­Y¦³­pµeÃh¥¥ªº¯f±w¡AÀ³¥ý³qª¾ªvÀøªºÂå®v¡C«ØÄ³¦¹Ãþ±wªÌ§ï¥Î¯Ø®q¯ÀªvÀø¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Glimepiride: No Human Data¡XProbably Compatible [¥é³æ] Glimepiride¬O§_·|¸g¥Ñ¤HÃþªº¨Å¥Ä±Æ°£©|¤£±o¦Óª¾¡C¦ý¬Oglimepiride·|±Æ°£©ó¦Ñ¹«ªº¨Å¥Ä¤¤¡C¦]¬°¨ä¥Lªºsulfonylureas·|±Æ°£©ó¤HÃþ¨Å¥Ä¡A¦]¦¹§l§m¥À¨ÅªºÀ¦¨à·|¦³§C¦å¿}ªº­·ÀI¡C ¬°Á×§K¥i¯à±q¥À¨ÅÄá¨ú¨ì¦Ó¶Ë®`À¦¨à¡A±Â¨Å´Á¶¡À³¸T¥Îglimepiride¡C­Y¦³¥²­n¡A±wªÌ»Ý§ï¥Î¯Ø®q¯ÀªvÀø©Î°±¤î§ë¨Å¡C,AC;AC15;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¤£¥i©CÄZ©ÎÀ£¸H¡C¼t°Ó¥çµL¬ÛÃö¦w©w©Ê¸ÕÅç¡C
OPCN,Penicillin V,Penicillin V 240mg,QANB,,¾AÀ³¯g: Treatment of mild to moderate respiratory tract infections¡A otitis media¡A sinusitis¡A skin & UTI; prophylaxis in rheumatic fever. °Æ§@¥Î: Diarrhea¡A nausea¡A vomiting¡A hypersensitivity reactions. ¸T§Ò: Hypersensitivity.,,«Ç·Å,Adult: 125-500 mg q6-8h. (max. 7.2 g/day). Child under 12 yrs: 15-56 mg/kg/day in 3-4 divided doses. To prevent recurrences of rheumatic fever 1 tab bid.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OPEA,Triprolidine + Pseudoephedrine,Peace 2.5/60mg,HIMM,Nasal congestion¡A allergic rhinitis.,Hypersensitivity to any component of the formulation.,Cardiovascular: Tachycardia Central nervous system: Dizziness¡A drowsiness¡A fatigue¡A headache¡A insomnia¡A nervousness¡A transient stimulation Gastrointestinal: Abdominal pain¡A appetite increase¡A diarrhea¡A nausea¡A weight gain¡A xerostomia Genitourinary: Dysuria Neuromuscular & skeletal: Arthralgia¡A weakness Respiratory: Pharyngitis¡A thickening of bronchial secretions Miscellaneous: Diaphoresis,25¢J¥H¤UÁ×¥ú,TID-QID¡A Adult and children >12 years 1 TAB¡A Children 6-12 years 0.5 TAB¡A 3-6 years 0.25 TAB¡A < 3 years as doctors' order.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Triprolidine- Compatible Pseudoephedrine Human Data Suggest Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Triprolidine- Limited Human Data¡XProbably Compatible Pseudoephedrine -Limited Human Data¡XProbably Compatible,AC;AC15;PC;PO;WM;,,,,,
OPER2,Dipyridamole,Persantin 25mg,HEMT,,,,,,,,,,,,,,,,,,,
OPERD,Nicardipine,Perdipine 20mg,CAVS,,¾AÀ³¯g:Cerebral blood flow disturbances¡A Essential hypertension. °Æ§@¥Î: Infrequently¡A anorexia¡A nausea¡A vomiting; flushing; palpitation; headache. Rarely¡A granulocytopenia; dry mouth¡A constipation¡A diarrhea; peripheral edema; rash. Cardiovascular: Hypotension (5.6% )¡A Peripheral edema (5.9% )¡A Tachyarrhythmia (3.5% ) Gastrointestinal: Nausea (1.9% to 4.9% )¡A Vomiting (0.6% to 4.9%) Neurologic: Headache (6.2% to 14.6% ) ¸T§Ò: Incomplete hemostasis following intracranial hemorrhage; acute cerebral apoplexy¡A elevated intracranial pressure.,,«Ç·Å,Cerebral blood flow disturbances Adult 20 mg tid. Essential hypertension Adult 10-20 mg tid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OPHE,Phenobarbital,Phenobarbital 30mg,CNEU,Generalised tonic-clonic seizures¡A Partial seizures¡A Sedation¡A Hypnotic.,Severe renal and hepatic disorders. Severe respiratory depression¡A dyspnoea or airway obstruction; porphyria. Pregnancy.,Bradycardia¡A hypotension¡A syncope; drowsiness¡A lethargy¡A CNS excitation or depression¡A impaired judgment¡A hangover effect¡A confusion¡A somnolence¡A agitation¡A hyperkinesia¡A ataxia¡A nervousness¡A headache¡A insomnia¡A nightmares¡A hallucinations¡A anxiety¡A dizziness; rash¡A exfoliative dermatitis; nausea¡A vomiting¡A constipation; agranulocytosis¡A thrombocytopenia¡A megaloblastic anaemia; pain at inj site¡A thrombophlebitis (IV); oliguria: laryngospasm¡A respiratory depression¡A apnoea (especially with rapid IV admin)¡A hypoventilation. Potentially Fatal: Stevens-Johnson syndrome. Neurologic: Somnolence (1% to 3% ),³±²D(15-30¢J) °®Àê³B©Ò,Adult: For anticonvulsant or ataxia: Oral: 100-200 mg HS or TID. For hypnotic: 100-200 mg HS. For CYP450 inducer: 30-60 mg TID. For sedative: 15-32 mg BID-TID. Child:For anticonvulsant or ataxia: Oral: 3-5 mg/kg HS or TID. For hypnotic: following doctor instruction. For CYP450 inducer¡Aneonatel: 5-10 mg/kg. For CYP450 inducer¡A Child under 12 years : 1-4 mg/kg TID. For sedative: 2mg/kg or 60mg/BSA(m2) TID.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ¯f±w¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;P1;P2;P3;P4;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OPIM,Pimozied,Pimozide(Orap)4mg,CNEU,,Chronic psychotics¡A responsive specific antipsychotic effects of neuroleptics. Borderline psychosis.,,,Adult initally 1-2mg once daily. Optimum daily maintenance dose:2-6 mg in one intake.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OPLA,Hydroxychloroquine,Plaquenil 200mg,QANP,RA¡A Juvenile chronic arthritis¡A Systemic or discoid lupus erythematosus¡A Light-sensitive disease¡A Suppression of malaria.,Retinal or visual field changes. Long-term therapy in children.,Headache¡A GI complaints; skin reactions; psychic stimulation¡A bleaching of hair¡A alopecia¡A blurred vision¡A difficulty in focusing or accommodation¡A corneal changes¡A retinal changes; blood dyscrasias.,Á×Àã¡AÀx¦s©ó25¢J¥H¤U,Other indications except malaria:Adults:Generally treated with lowest effective dose. 200mg or 400mg daily¡A maximum dose:6.5mg/kg/day(calculated with ideal body weight).Children:Should be treated with lowest effective dose¡A maximum dose:6.5mg/kg/day(calculated with ideal body weight).For children ideal body weight < 31kg¡A should avoid dose of 200mg tablet each time.Suppression of malaria:Adult 400 mg on the same day of each weeks. Children & infant 6.5 mg/kg body weight. Maximum: Adult dose regardless of wt. Suppressive therapy should begin 2 weeks prior to exposure. Failing this¡A in adults an initial double (loading) dose of 800 mg¡A or in children 12.9 mg/kg (maximum: 800 mg)¡A may be taken in 2 divided doses¡A 6 hr apart. The suppressive therapy should be continued for 8 weeks after leaving the endemic area. Treatment of acute attack of malaria: Adult Initially 800 mg followed by 400 mg in 6-8 hours & 400 mg on each of 2 consecutive days. Alternatively¡A 800 mg as single dose. Infant & children first dose: 12.9 mg/kg (but not exceeding a single dose of 800 mg); 2nd dose: 6.5 mg/kg (but not exceeding 400 mg) 6 hours after first dose; 3rd dose: 6.5 mg/kg (but not exceeding 400 mg) 18 hours after 2nd dose; 4th dose: 6.5 mg/kg (but not exceeding 400 mg) 24 hours after 3rd dose. Total dose of 32 mg/kg body weight (not exceeding 2 g) over 3 days,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;WM;,,,,,
OPOL2,Chlorpheniramine,Polaramine 2mg,HIMM,,i: Allergic and vasomotor rhinitis¡A allergic conjunctivitis¡A mild and uncomplicated allergic skin manifestations of urticaria and angioedema. ADR: Drowsiness¡A urticaria¡A drug rash¡A anaphylactic shock¡A photosensitivity¡A excessive perspiration¡A chills¡A dry mouth¡A nose & throat. CI: Newborn & premature infants. MAOI therapy.,,RT,Adult: 2mg tid-qid. Child: 1mg tid-qid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OPLET,Cilostazol,Pletaal 50mg,HEMT,,¾AÀ³¯g: Reduction of symptoms of intermittent claudication¡A as indicated by an increased walking distance. °Æ§@¥Î: Abdominal pain¡A back pain¡A headache¡A infection¡A palpitation¡A tachycardia¡A GI effects¡A peripheral edema¡A myalgia¡A dizziness¡A vertigo¡A cough¡A pharyngitis¡A rhinitis. Cardiovascular: Palpitations (5% to 10% )¡A Peripheral edema (7% to 9% )¡A Tachyarrhythmia (4% ) Gastrointestinal: Abdominal pain (4% to 5% )¡A Diarrhea (12% to 19% )¡A Feces contents abnormal (12% to 15% )¡A Indigestion (6% ) Hematologic: Decreased platelet aggregation Musculoskeletal: Backache (6% to 7% )¡A Myalgia (2% to 3% ) Neurologic: Dizziness (9% to 10% )¡A Headache (27% to 34% ) Respiratory: Increasing frequency of cough (3% to 4% )¡A Pharyngitis (7% to 12% )¡A Rhinitis (7% to 12% ) Other: Infectious disease (10% to 14% ) ¸T§Ò: Patients with CHF of any severity.,,«Ç·Å,100 mg BID,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OSOL,Amisulpride,Solian 200mg,CNEU,,¾AÀ³¯g:Treatment of psychoses¡A particularly acute or chronic schizophrenic disorders¡A characterized by +ve symptoms (e.g. delirium¡A hallucinations¡A thought disorders) &/or -ve symptoms (eg blunted emotions¡A emotional & social withdrawal)¡A including when the -ve symptoms predominate. °Æ§@¥Î:Insomnia¡A anxiety¡A agitation¡A extrapyramidal symptoms; galactorrhea¡A amenorrhea¡A gynecomastia¡A swollen breasts¡A impotence¡A frigidity¡A weight gain; GI disturbances. Occasionally¡A daytime drowsiness. ¸T§Ò:Known or suspected pheochromocytoma carriers. Children < 15 years. Lactation. Known or suspected prolactin-dependent tumour¡A eg prolactin-secreting pituitary adenoma & breast cancer. Severe renal insufficiency. Congenital galactosemia¡A glucose or galactose malabsorption syndrome or lactase deficiency (due to lactose content). In combination with sultopride; dopaminergic agonists except L-dopa (amantadine¡A apomorphine¡A bromocriptine¡A cabergoline¡A entacapone¡A lisuride¡A pergolide¡A piribedil¡A pramipexole¡A quinagolide¡A ropinirole¡A selegiline)¡A except in the case of patients with Parkinson's disease.,,«Ç·Å,<=400 mg daily dose¡A single intake. >400 mg¡A in 2 divided doses. Predominant -ve episode 50-300 mg/day as individualized dosage. Optimum dosage: 100 mg/day. Mixed episodes w/ +ve & -ve symptoms 400-800 mg/day as individualized dosage to maintain min effective dose. Acute psychotic episodes Initiate with max 400 mg/day IM¡A replaced thereafter with 400-800 mg orally¡A max dosage: 1200 mg. Renal insufficiency CrCl 30-60 mL/min: reduce dose by 1/2. CrCl 10-30 mL/min: reduce dose to 1/3.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ENS5,Sodium Chloride,0.9%NaCl irrigation (Normal Saline) 500mL(¨R¬~¥Î),MSIV,Wound cleansing¡A irrigation & flushing.,Not to be used to induce emesis.,,«Ç·Å,For Irrigation Only. Not for Injection. As sterile irrigation of tissues or wounds¡A and for washing¡A rinsing medical device.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;G;GAR;IH;IN;INHL;IRR;IRRI;NA;ORO;RT;SKIN;TOPI;,,,,,
ENS1,Sodium Chloride,Normal Saline irrigation 1000mL,NUTR,,¾AÀ³¯g: Wound cleansing¡A irrigation & flushing. ¸T§Ò: Not to be used to induce emesis.,,,,,,,,,,,,IRR;IRRI;,,,,,
EULE,Crotamiton,Ulex À¿²G 10%¡A 30gm,TDER,Non-atopic allergy¡A urticaria¡A eczema.,Hypersensitivity to any component of the formulation.,Local skin irritations.,25¢J¥H¤U,Scabies¡A Apply several times daily for 5 days Pruritus¡A Apply several times daily,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
OZYB,Bupropion,Zyban SR 150 mg,ZADT,,¾AÀ³¯g:·ÏÅ}»²§U§Ùªv¾¯(B023941100),,RT,Adult Start treatment while patient is still smoking & set a "target stop date" w/in 1st 2 wk of treatment. Initially 150 mg daily for 3 days increasing to 150 mg bid¡A at least 8 hr between successive dose. Max: 150 mg/dose¡A 300 mg/day. Treat for at least 7 wk.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IGLYT,Nitroglycerin,Glyceryl trinitrate inj 50mg/10mL,CAVS,,,,RT,IV infusion: Initially¡A 5 mcg/min; may be increased by 5 mcg/min q3-5 mins until a response is noted.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ICHL1,Chloramphenicol,Chloramphenicol inj 1gm,QANB,,¾AÀ³¯g:Streptococcal¡A pneumococcal¡A H. influenzae infection¡A whooping cough¡A pneumonia¡A brucellosis¡A UTI¡A enteritis¡A peritonitis¡A salmonellosis¡A rickettsiosis¡A granuloma inguinale¡A typhus¡A cholera¡A actinomycetes. °Æ§@¥Î:Reversible bone marrow depression¡A leukopenia¡A reticulocytopenia¡A thrombopenia & anemia. ¸T§Ò: Pregnancy & lactation¡A hypersensitivity¡A anemia.,,«Ç·Å,Adult 1g 12 hrly by IM or IV.,,,,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡B¨xµÇ¥\¯à¡C 2. ·s¥Í¨à©Î¦­²£¨à¨Ï¥Î»Ýª`·N¡¨gray syndrome¡¨¡C 3. µ}ÄÀ¿@«×¡G100 mg/mL
EGLYQ,Hydroquinon,Glyquin XM cream 4% ¡A1oz,TDER,,Chloasma¡A melasma¡A freckles¡A senile lentigines¡A & other unwanted areas of melanin hyperpigmentation.,,RT,Apply to the affected area bid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ESPED,Antazoline + Tetryzoline,Spersallerg eye drop 10mL,TOPH,,¾AÀ³¯g: Irritant conjunctivitis¡A allergic inflammatory conditions of the conjunctiva¡A particularly hay fever conjunctivitis & vernal conjunctivitis. °Æ§@¥Î: Mild burning sensation; headache¡A sleepiness¡A tachycardia. ¸T§Ò: Narrow-angle glaucoma.,,«Ç·Å,Acute stage: 1 drop 3 hrly. Continuous use: 1 drop 2-3 times daily. Severe cases: Use hrly. Infant Max: 1-2 drop daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EGEND,Gentamicin,Garamycin eye drop 5mL,TOPH,,I: Treatment of superficial bacterial infection of the conjunctive¡A cornea¡A eyelids¡A tear ducts¡A and skin adjacent to the eyes. CI: Garamycin solution should never be injected subconjunctivally¡A nor directly introduced into the anterior chamber of the eye.,,RT,Oph. oint.: tid-qid. Oph. soln: 1-2 gtt tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ESUP,Desflurane,Suprane 240mL,ZANE,Inhalation agent for induction & maintenance of general anesth.,Patient in whom general anaesth is contraindicated. Sensitivity to halogenated agents. Genetic susceptibility to malignant hyperthermia.,Dose-dependent hypotension & respiratory depression. Cough¡A breath holding¡A salivation¡A apnoea & laryngospasm. Post-op nausea & vomiting. Transient increase of WBC count¡A malignant hyperthermia.,15-30¢J,Induction: Adult Initially 3%¡A increased by 0.5-1% every 2-3 breaths. Inspired concentration of 4-11% produces surgical anesthesia in 2-4 minutes. Maintenance: Adult whether mix nitrous oxide or not¡A 2.5-8.5% Suprane. Children 5.2-10% Suprane.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,1.Suprane (desflurane) should be administered only by persons trained in the administration of general anesthesia. It should only be administered using a vaporizer specifically designed and designated for use with Suprane. 2.The administration of general anesthesia must be individualized based on the patient¡¦s response¡A including cardiovascular and pulmonary changes. 3.Suprane (desflurane) should not be used as the sole agent for anesthetic induction in patients with coronary artery disease
ETAL,Tetracycline + Amphotericin B,Talsutin VT 100/50mg,SGU,,¾AÀ³¯g:©À¯]µß¡BºwÂÎ©Î²Óµß·P¬V©Ò¤Þ°_¤§³±¹Dª¢(A034794500),,RT,Intravaginal¡A 1-2 vag. tab/day for 2 wks.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IRIN,Betamethasone Disodium Phosphate,Rinderon inj 2mg/0.5mL,HM,,Emergency use in conditions or situations where a rapid and intense hormonal effect is necessary or desirable.,,,Initial: 1-2 ml to be repeated at 3 or 4 hrs interval. Maintenance: 0.5-1 ml.,,,,,,,,,,,,,,
OGLU,Metformin,Glucomine F.C. 500mg,META,,,,RT,250 - 1000 mg tid pc ( max: 3 g/day ).,,,,¥i¯à¦w¥þ,,,,,,,,,,
EALC9,Alcohol,95% Alcohol,TDER,Antiseptics and disinfectants.,Hypersensitivity to any component of the formulation.,Mild local discomfort.,¶J¦s¦b³±²D¡B°®Àê¡B¹jÂ÷¥B³q­·¨}¦nªº¦a°Ï¡A »·Â÷¼ö¡B¤Þ¿U·½¤Î¤£¬Û®eª«¡C,95% Alcohol contains 95% ethyl alcohol¡A can be diluted with purified water to the effective disinfecting strength of 70%.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,EXT;,,,,,
ISAN1,Octreotide,Sandostatin inj 0.1mg/1mL,HM,Symptomatic control & reduction of growth hormone & somatomedin C plasma levels in acromegaly; relief of symptoms associated with gastroenteropancreatic endocrine (GEP) tumors & carcinoid tumors including VIPomas¡A glucagonomas¡A gastrinomas/Zollinger-Ellison syndrome¡A insulinomas¡A GRFomas. Prevention of complications following pancreatic surgery. Bleeding gastro-oesophageal varices.,Known hypersensitivity to octreotide or one of the excipients (see Description) of Sandostatin,Anorexia¡A nausea¡A vomiting¡A crampy abdominal pain¡A abdominal bloating¡A flatulence¡A loose stools¡A steatorrhea¡A rarely progressive abdominal distension¡A severe epigastric pain¡A gallstones. Dermatologic: Injection site pain Endocrine metabolic: Hyperglycemia (1.5% to 16%)¡A Hypoglycemia (1.5% to 3%)¡A Hypothyroidism Gastrointestinal: Abdominal discomfort¡A Cholelithiasis (22% to 33% )¡A Constipation¡A Diarrhea¡A Flatulence¡A Nausea¡A Pancreatitis Hepatic: Disorder of biliary tract Neurologic: Dizziness¡A Headache,2-8¢J,Acromegaly: Initially IM 0.05-0.1mg every 8-12 hour¡A could increased up to 1.5mg. Functional gastrointestinal pancreatic endocrine tumor: Initially IM 0.05mg 1-2 times per day¡A followed by 0.1-0.2mg three times per day. Complications after pancreatic surgery: IM 0.1mg three times per day for 7 days. Bleeding esophageal varices: diluted in normal saline and IV infusion 25mcg per hour for 5 days.,µL»Ý½Õ¾ã¾¯¶q,¿©±w¨xµw¤Æªº¯f±w¥Ñ©óÃÄª«¥b°I´Á¥i¯à©µªø¡A©Ò¥H»Ý­n½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;SC;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Bleeding gastro-oesophageal varices 50 mcg/hr by IV infusion for max 5 days.,
ISAN2,Octreotide,Sandostatin LAR 20mg,HM,,Symptomatic control and reduction of growth hormone and somatomedin C plasma levels¡A gastroenteropancreatic endocrine tumors & carcinoid tumors. Acute pancreatitis¡A enteric fistula.,,,Adult: (max. 750 mcg/day). Carcinoid tumors: SC¡A 100-600 mcg/day in 2-4 divided doses. VIPomas & acromegaly: SC¡A 200-300 mcg/day in 2-4 divided doses. Initial: 100 mcg. Maintenance: 25 mcg/hr for 24 hrs. Acute pancreatitis: SC¡A 100 mcg q6h for 3-7 days. Child over 1 month: SC¡A 1-10 mcg/kg/day.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ISEP,Sulfamethoxazole + Trimethoprim,Septrin 400/80 for infusion,QANB,,Acute exacerbation of chronic obstructive pulmonary disease Acute otitis media Pneumocystis carinii pneumonia Pneumocystis carinii pneumonia; Prophylaxis Shigellosis Traveler's diarrhea Urinary tract infectious disease,,RT,Adult: Acute exacerbation of chronic obstructive pulmonary disease: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 14 days Granuloma inguinale: 1 double-strength tablet ORALLY twice a day for at least 3 weeks and lesions are healed completely Pneumocystis carinii pneumonia: 15-20 mg/kg TMP component/day ORALLY or IV divided every 6 hr for 14-21 days Pneumocystis carinii pneumonia; Prophylaxis: 1 double-strength tablet ORALLY once a day; alternative regimens¡A 1 double-strength tablet ORALLY 3 times a week or 1 single-strength tablet ORALLY once a day Shigellosis: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 5 days Toxoplasma encephalitis; Prophylaxis: 1 double-strength tablet or 1 single-strength tablet ORALLY once a day Traveler's diarrhea: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 5 days Urinary tract infectious disease: 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hr for 10-14 days Pediatric: Acute otitis media: (2 months of age and older) 8 mg/kg TMP component/day ORALLY divided every 12 hr for 10 days Pneumocystis carinii pneumonia: (2 months of age and older) 15-20 mg/kg TMP component/day ORALLY or IV divided every 6 hr for 14-21 days Pneumocystis carinii pneumonia; Prophylaxis: (1 month of age and older) 150 mg/m(2) TMP component/day in 2 divided doses 3 times a week on consecutive days; alternative regimens¡A 150 mg/m(2) TMP component once daily 3 times a week on consecutive days or 150 mg/m(2) TMP component/day in 2 divided doses every day or 3 times a week on alternate days Shigellosis: 8-10 mg/kg TMP component/day IV divided every 6-12 hr for up to 5 days Toxoplasma encephalitis; Prophylaxis: (2 months of age and older) 150 mg/m(2) TMP component/day in 2 divided doses Urinary tract infectious disease: (2 months of age and older) 8 mg/kg TMP component/day ORALLY divided every 12 hr for 10 days,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ISOLC,Hydrocortisone,Solu-Cortef inj 100mg,HM,,¾AÀ³¯g:Endocrine¡A rheumatic & hematologic disorders; collagen¡A dermatologic¡A ophth¡A GI¡A respiratory & neoplastic diseases; allergic & edematous states; acute exacerbation of multiple sclerosis; tuberculous meningitis with subarachnoid block; trichinosis with neurologic or myocardial involvement. °Æ§@¥Î:Fluid & electrolyte disturbances; decreased carbohydrate tolerance; impaired wound healing¡A thin fragile skin; muscle weakness¡A steroid myopathy¡A osteoporosis¡A aseptic necrosis; peptic ulceration with possible perforation; cataracts¡A increased intraocular & intracranial pressure; growth retardation; Cushingoid state; protein catabolism; psychic derangements. ¸T§Ò:Systemic fungal infection. Lactation,,20-25¢J,Initially 100-500 mg depending on severity of condition¡A repeated at interval of 2¡A 4 or 6 hr.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
ODET,Tolterodine,Detrusitol 2mg,SGU,Overactive bladder¡A With symptoms of urinary frequency¡A urgency¡A or urge incontinence.,Hypersensitivity to the drug¡A tolterodine¡A or its ingredients. Uncontrolled narrow-angle glaucoma. Urinary retention.,Common Gastrointestinal: Abdominal pain (3% to 5% )¡A Constipation (6% to 7% )¡A Xerostomia (23% to 35% ) Neurologic: Headache (immediate-release¡A 7%) Serious Immunologic: Anaphylaxis Other: Angioedema,«Ç·Å¡A§C©ó25¢J,Adult: Initial¡A 2 mg BID; may decreasing to 1 mg BID depending on tolerability and response. Children: Safety and efficacy in pediatric patients has not been established on label. Pediatric Dosing recommedion from micromedex: 4 to 12 years: 1 mg twice daily(study dosage). Or younger than 5 years: 0.1 mg/kg/day¡A divided into 2 doses(study dosage).,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ:«ØÄ³¾¯¶q¬O¨C¦¸1²@§J¡B¤@¤Ñ¨â¦¸,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]©|µL¥¥°üªºÁ{§É¸ÕÅç¡C¦]¦¹Ãh¥¥´Á¶¡¡Atolterodine À³¥u¥Î©ó¹ï¥ÀÅéªº¯q³B¤j©ó¹ï­L¨à¥i¯à ¤§¦MÀIªºÁ{§Éª¬ªp¡C,Human Data Suggest Potential Toxicity,[¥é³æ]¨Ï¥Îtolterodine ®É¥²¶·Á×§K±Â¨Å¡A¦]¬°©|¤£ª¾tolterodine ¬O§_·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C,AC;AC15;PC;PO;WM;,,,,,1. ¥»ÃÄ¹ï©ó¶}¨®¤Î¾÷±ñ¾Þ§@¯à¤O¥i¯à¦³­t­±ªº¼vÅT¡CÀ³Äµ§i¯f¤HÀ³Á×§K±q¨Æ¬ÛÃö¬¡°Ê¡C 2. ¨Ö¥Î¨ä¥L±j®ÄCYP3A4 §í¨î¾¯¤§±wªÌ¡A¦p¥¨ÀôÃþ§Ü¥Í¯À¡]Erythromycin ©MClarithromycin¡^©ÎAzole Ãþ§ÜÅðµß¾¯¡]Ketoconazole¡A Itraconazole ©MMiconazole¡^®É¡ATolterodine ¨C¤é«ØÄ³Á`¾¯¶q¬°2 ²@§J¡C
ECOM,Ipratropium + Salbutamol,Combivent Metered Aerosol,ERSP,,¾AÀ³¯g: Management of reversible bronchospasm associated with obstructive airways diseases in patients who require more than a single bronchodilator. °Æ§@¥Î: Headache¡A dizziness¡A nervousness¡A tachycardia¡A fine tremor¡A palpitations. Potentially serious hypokalaemia may result from £]2 agonist therapy. Dry mouth¡A dysphonia¡A ocular complications¡A allergic-type reactions. ¸T§Ò: Hypertrophic obstructive cardiomyopathy or tachyarrhythmia,,«Ç·Å,Shake well before use. Adult 2 inhalations qid. Max: 12 inhalations in 24 hr.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OLIP10,Atorvastatin,Lipitor 10mg,CAVS,,¾AÀ³¯g: Hyperlipidemia. °Æ§@¥Î: Constipation¡A flatulence¡A dyspepsia¡A abdominal pain¡A headache¡A nausea¡A myalgia¡A asthenia¡A diarrhea¡A insomnia. Gastrointestinal: Diarrhea (up to 14.1% ) Musculoskeletal: Arthralgia (up to 11.7% ) Renal: Urinary tract infectious disease (up to 8% ) Respiratory: Nasopharyngitis (8.3% ) Other: Pain¡A In extremity (up to 9.3% ) ¸T§Ò: Active liver disease or persistent elevations of serum transaminases > 3 times the upper limit of normal. Pregnancy & lactation.,,«Ç·Å,Initial dose: 10 mg / day Dose range: 10 ~ 80 mg / day¡A atorvastatin can be administered as a single dose at any time of the day¡A with or without food.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,
IATR,Atropine,Atropine sulfate °w¾¯1mg/1mL,ALIM,Bradycardia¡A Organophosphorus poisoning¡A Premed in anesth¡A Poisoning or overdosage w/ compd having muscarinic actions.,Glaucoma¡A chronic respiratory disease¡A sick sinus syndrome¡A thyrotoxicosis¡A cardiac failure¡A pyloric stenosis¡A prostatic hypertrophy.,Common: Palpitations¡A Flushing¡A Abdominal pain¡A Constipation¡A Nausea¡A Swollen abdomen¡A Vomiting¡A Xerostomia¡A Confusion¡A Dizziness¡A Headache¡A Blurred vision¡A Finding of lacrimation¡A Decreased¡A Pain in eye¡A Photophobia¡A Superficial keratitis¡A Delay when starting to pass urine¡A Difficulty passing urine¡A Urinary retention¡A Erectile dysfunction¡A Lack of libido Serious: Asystole¡A Cardiac dysrhythmia¡A Cardiac syncope¡A Electrocardiogram abnormal¡A Hypotension¡A Myocardial infarction¡A Tachycardia¡A Ventricular fibrillation¡A Ventricular tachycardia¡A Anhidrosis¡A Anaphylaxis¡A Hypersensitivity reaction¡A Laryngeal spasm¡A Coma¡A Angle-closure glaucoma¡A acute¡A Respiratory depression¡A Hyperpyrexia,15-30¢JÁ×§K¦B­á,Adult : IV/IM/SC Antimuscarinic 400-600mcg every 4-6 hours. IV Anti-arrhythmia 400 mcg-1mg every 1-2 hours. Maximum: 2 mg. IM Premedication in anesthesia 200-600 mcg 30-60 minutes before anesthesia. IM Gastrointestinal endoscopy: 1 mg. IV/IM Organophosphorus poisoning: 1-2 mg every 20-30 minutes until cyanosis disappear or atropine toxicity appears. IV/IM Poisoning or overdosage with compound having muscarinic actions 1-2 mg¡A repeat 1 hourly until the breathing effect occurs. Children: SC Antimuscarinic 10mcg/kg or 0.3mg/m2 (Body surface area) every 4-6 hours. Maximum: 400mcg. IV Anti-arrhythmia 10-30mcg/kg. SC before anesthesia: <3 kg: 100mcg¡A 7-9 kg: 200mcg¡A 12-16 kg: 300mcg¡A 20-27 kg: 400mcg¡A 32 kg: 500mcg¡A 41 kg: 600mcg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;SC;,,¡iN/S¡j¥i¿ï ¡C,Administer undiluted by rapid IV injection.,1. ¤£«ØÄ³¥[¦b¤j«¬ÀR¯ßª`®g²G¤º¡C,1. ¤£«ØÄ³¥[¦b¤j«¬ÀR¯ßª`®g²G¤º¡C 2. UpToDate:IV: Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia. In bradycardia¡A atropine administration should not delay treatment with external pacing.
IATRA,Atracurium Besylate,Atracurium inj 25mg,CNEU,,Used in anesthesia to relax skeletal muscles during surgical procedures and to facilitate controlled ventilation¡A endotracheal intubation.,,,IV: Initial dose: 0.4-0.5 mg/kg. Subsequent doses: 0.08-0.1 mg/kg as needed.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IAUG,Amoxicillin + Clavulanic Acid,Augmentin°w¾¯ 600mg,QANB,,¾AÀ³¯g:Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI¡A pelvic¡A head & neck¡A cardiac¡A renal¡A joint replacement & biliary tract. °Æ§@¥Î:Diarrhea¡A indigestion¡A nausea¡A vomiting¡A pseudomembranous colitis and candidiasis have been reported. Nausea¡A although uncommon¡A is more often associated with higher oral dosages. If gastrointestinal side effects occur with oral therapy¡A they may be reduced by taking Augmentin at the start of meals. ¸T§Ò:Hypersensitivity to penicillins¡A possible cross sensitivity with other £]-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction,,«Ç·Å,Treatment of infections Adult & children >12 years 1.2 g 8 hrly¡A increasing to 6 hrly in more serious infections. Children 3 months-12 years 30 mg/kg 8 hrly¡A increasing to 6 hrly in more serious infections¡A 0-3 months 30 mg/kg 12 hrly in premature infants & in full-term infants during the perinatal period¡A increasing to 8 hrly thereafter. Surgical prophylaxis Adult 1.2 g at the induction of anesth. Where there is a high risk of infection¡A 3-4 doses of 1.2 g may be needed in a 24-hr period. Continue regimen for several days if procedure has significantly increased risk of infection,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ª`®g«eÀË¬d¯f±w¬O§_¦³ penicillin ¹L±Ó¥v¡C 2. µ}ÄÀ«áÀ³¾¨§Ö¨Ï¥Î¡A¦w©w©Ê»Pµ}ÄÀ¿@«×»P«O¦s±ø¥ó¦³Ãö¡C
EFLU,Halothane,Fluothane 250mL,ZANE,,¾AÀ³¯g: Induction and maintenance of general anesth. °Æ§@¥Î: Bradycardia¡A hypotension¡A cardiac arrhythmias¡A respiratory depression¡A shivering during recovery (occasional)¡A hepatitis (multiple exposure). ¸T§Ò: Obstetrics; malignant hyperthermia; porphyria.,,15-25¢XC.,Inhalation Induction: 2-4% v/v in O2 or mixtures of nitrous oxide and O2. Maintenance: 0.5-2% v/v depending on the flow rate used.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IBAY1,Hepatitis B Immune Globulin,HyperHep B 1mL,HIMM,,¾AÀ³¯g: Post-exposure prophylaxis of hepatitis. Acute exposure to blood containing HBsAg¡A perinatal exposure of infants born to HBsAg +ve mothers¡A sexual exposure to an HBsAg +ve person¡A household exposure to persons with acute HBV infection. °Æ§@¥Î: Local pain & tenderness at the inj site¡A urticaria & angioedema¡A anaphylactic reactions.,,2-8¢J,Prophylaxis of infants born to HBsAg and HBeAg +ve mothers: 0.5ml to be given w/in 12 hr of birth. Sexual exposure to an HBsAg +ve person: 0.06ml/mg of HBIG IM as a single dose w/in 14 days of sexual contact.Give together with 1st dose of 1mL IM of vaccine. Household exposure to persons w/ acute HBV infection: infants<12mth 0.5mL.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IBCG,BCG Vaccine,BCG vaccine 2.5mg/mL,HIMM,,Persons who have negative tubercullin skin test.,,,Neonate against tuberculosis:0.1 ml intrademally¡A 0.05 ml may be given to newborn infants.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OPOLI0,B1+ B12 + FA + Fe + Cu + Mg + Lysine,Polichinon,NUTR,,Aplastic anemias¡A iron deficiency anemias¡A macrocytic hyperchromic anemias.,,,1-3 cap daily¡A after meals.,,,,,,,,,,,,,,
EAAS,Sodium Oleate,Alcos-Anal ®ê¾¯,ALIM,Hemorrhoids,Hypersensitivity to any component of the formulation.,Local irritation,¦s©ñ¦b³±²D³B,Insert 1 suppository in the morning¡A evening and after defecations,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,RECT;,,,,,
EACN,Sulfur Precipitated,Acne lotion 4% 100mL,TDER,,¾AÀ³¯g: Acne¡A subacute & chronic dermatitis.,,«Ç·Å,Apply tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EAGNO3,Silver Nitrate,Silver nitrate 10%¡A 10mL,TDER,,I: An astringent and caustic.,,«Ç·Å,Topcial use when necessary.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;,,,,,
EAIR,Tretinoin,Airol cream 0.05% 20gm,TDER,,I: Acne vulgaris esp. forms with comedones. AR: Transient skin irritation.,,,Apply qd-bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EAL0C9,95% Alcohol,95% Alcohol,TDER,,,,,,,,,,,,,,,,,,,
EALB,Policresulen,Albothyl vag supp 90mg,SGU,,¾AÀ³¯g: Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis¡A cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration. °Æ§@¥Î: Occasionally¡A mild local discomfort at beginning of treatment which disappears on discontinuation. ¸T§Ò: Concomitant use of other topical agents in treating the affected areas.,,«Ç·Å,1 to be inserted on alternate days.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EALC5,Alcohol,75% Alcohol 500mL,TDER,,,,,,,,,,,,,,,,,,,
EALCA,Proparacaine,Alcaine 0.5%¡A 15mL,TOPH,,¾AÀ³¯g: Procedures in which a rapid & short-acting topical ophth anesth is indicated eg tonometry¡A gonioscopic exam¡A removal of foreign bodies & sutures from the cornea¡A conjunctival scraping in diagnosis¡A cataract extraction or other surgical procedures. °Æ§@¥Î: Transient stinging & burning¡A conjunctival redness.,,2-8 ¢XC,Tonometry & other exam of short duration Instill 1-2 drops prior to evaluation. Minor surgical procedures eg foreign body or suture removal Instill 1-2 drops every 5-10 mins for 1-3 doses. Prolonged anesth Instill 1-2 drops every 5-10 mins for 3-5 times.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EALD,Beclomethason Dipronate,Aldecin Inhaler(50mcg/puff),ERSP,,,,,,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EART1,Carteolol,Arteoptic 1% oph sol 5mL,TOPH,,¾AÀ³¯g: Glaucoma & ocular hypertension. ¸T§Ò: Unsatisfactorily controlled cardiac insufficiency; risk of bronchial asthma & bronchospasm; sinus bradycardia; AV block (II & III); cardiogenic shock; right ventricular insufficiency due to pulmonary hypertension & CHF.,,«Ç·Å,1 gtt qd-bid.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OMOD,Hydrochlorothiazide + Amiloride,Moduretic 50/5mg,CAVS,,¾AÀ³¯g: Hypertension¡A edema of cardiac origin & hepatic cirrhosis with ascites & edema. °Æ§@¥Î: Headache¡A weakness¡A nausea¡A anorexia¡A rash & dizziness; orthostatic effects. Dermatologic: Rash (3% to 8% ) Gastrointestinal: Nausea Neurologic: Asthenia (3% to 8% )¡A Dizziness (3% to 8% )¡A Headache (3% to 8% ) ¸T§Ò: Hyperkalemia¡A other concomitant antikaliuretic therapy or K supplementation¡A renal insufficiency.,,«Ç·Å,Initially 1-2 tab daily.Max: 4 tab.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OGLU2,Glimepiride,Glusafe 2mg,META,,¾AÀ³¯g: Type 2 diabetes mellitus. °Æ§@¥Î: Hypoglycaemia; adrenergic counter-regulation; temporary visual impairment; GI symptoms. Rarely thrombopenia¡A haemolytic anaemia¡A erythrocytopenia¡A leucopenia¡A agranulocytosis. Endocrine metabolic: Hypoglycemia [0.9% to 1.7% (adults); 4% (pediatrics) ] Gastrointestinal: Nausea (1.1% ) Neurologic: Asthenia (1.6% )¡A Dizziness (1.7% )¡A Headache (1.5% ) ¸T§Ò: Insulin-dependent (type 1) diabetes mellitus; diabetic ketoacidosis; diabetic precoma or coma; serious renal or hepatic dysfunction. Pregnancy¡A lactation.,,«Ç·Å,Starting dose: 1 mg/day. Dosage may be adjusted at 1-2 wk interval to 2¡A 3 or 4 mg/day. Max: 8 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OHIC,Ca Carbonate from Oyst,Hi-Cal 250mg( ­­¦Û¶O),NUTR,,Calcium supplement.,,RT,1-2 tab tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODIO,Valsartan,Diovan 80mg,CAVS,Hypertension¡A heart failure and heart disease.,Pregnancy.,Headache¡A dizziness¡A viral infection¡A upper respiratory tract infection¡A diarrhea¡A coughing¡A fatigue¡A rhinitis¡A sinusitis¡A back pain¡A abdominal pain¡A nausea¡A pharyngitis¡A arthralgia. Cardiovascular: Hypotension Neurologic: Dizziness¡A Headache Renal: Serum blood urea nitrogen raised (heart failure¡A 16.6%; hypertension and post-myocardial infarction¡A not reported )¡A Serum creatinine raised (hypertension¡A 0.8%; heart failure¡A 3.9%; post-myocardial infarction¡A 4.2% ) Respiratory: Cough Other: Fatigue,30¢J¥H¤U°®Àê³B,HTN Initial: 80 -160 mg QD; slowly titrate up to maximum 320 mg QD CHF with reduced ejection fraction 20 -40 mg BID; doubling dose¡A every 1 to 2 weeks to 160mg BID Acute coronary syndromes: initial: 20mg BID may tolerance up to 160mg BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] ¦p¦P©Ò¦³ª½±µ§@¥Î©óRAASªºÃÄª«¡ADiovan¤£À³¨Ï¥Î©óÃh¥¥¡C±q¤wª¾¦åºÞ¥[À£¯ÀII«ú§Ü¾¯ªº§@¥Î¾÷Âà¨Ó±ÀÂ_¡A¹ï©ó­L¨à¥i¯à³y¦¨ªº¼vÅT¤´¬O¤£®e©¿µøªº¡C ´¿¦³³ø§iµ¹¤©²Ä¤G´Á¤Î²Ä¤T´ÁªºÃh¥¥¥¥°ü¨Ï¥Î¦åºÞ¦¬ÁY¯ÀÂà¤ÆžJ(ACE)ªýÂ_¾¯(¤@ºØ§@¥Î©óRAASªºÃÄª«)¡A³y¦¨µo®i¤¤ªº­L¨à·l¶Ë©Î¦º¤`ªº³ø§i¡C´¿¦³Ãh¥¥°ü¤k¤£ª`·N¤UªA¥ÎValsartanµo¥Í¦Ûµo©Ê¬y²£¡B¦Ï¤ô¹L¤Ö¡B·s¥Í¨àµÇ¤£¥þªº³ø§i¡C¦bªvÀø´Á¶¡ÀË¬d¥X¤wÃh¥¥¡AÀ³¥ß§Y°±ÃÄ¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ©|¥¼ª¾Valsartan¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡A¦ý¤wª¾ Valsartan ·|¤Àªc¦Ü¤j¥Õ¹«¨Å¥Ä¤¤¡C ¦]¦¹¡A±Â¨Å´Á¶¡¤£«ØÄ³¨Ï¥Î Diovan¡C,AC;AC15;PC;PO;WM;,,,,,
ECUS2,Timolol,Cusimolol 0.25%¡A 5mL,TOPH,,¾AÀ³¯g: Reduction of increased intraocular pressure in conditions such as ocular hypertension¡A chronic open-angle glaucoma (including aphakic patients) & certain instances of secondary glaucoma. °Æ§@¥Î: Conjunctivitis¡A blepharitis¡A keratitis. Rarely hypersensitivity¡A urticaria¡A local or general eruptions. Mild bradycardia¡A hypotension¡A bronchospasm¡A congestive cardiac insufficiency & masking of hypoglycemic symptoms of IDDM patients. Cardiovascular: Angina¡A Bradyarrhythmia (9%)¡A Heart failure¡A Hypotension Dermatologic: Pruritus¡A Rash¡A Urticaria Gastrointestinal: Abdominal pain¡A Diarrhea¡A Indigestion¡A Nausea¡A Vomiting Musculoskeletal: Cramp Neurologic: Confusion (13%)¡A Dizziness (2%-10%)¡A Headache (2%-12%) Ophthalmic: Blurred vision¡A Burning sensation in eye (15%-20%)¡A Cataract¡A Conjunctival hyperemia¡A Corneal anesthesia (15%-20%)¡A Dry eyes (15%-20%)¡A Reduced visual acuity¡A Ophthalmic Psychiatric: Depression (12%)¡A Hallucinations (11%)¡A Psychotic disorder (3%) Respiratory: Cough¡A Dyspnea Other: Fatigue (3%-11%)¡A Infectious disease,,«Ç·Å,1 drop of 0.25 % soln in affected eye bid. If responseis not satisfactory¡A use 1 drop of 0.5 % soln in the affected eye bid.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ODANZ,Serratiopeptidase,Danzen 5mg,CNEU,,¾AÀ³¯g:¤Æ·ð¡B®ø¸~¤§¥Î(A001001100),,RT,1-2 tab tid-qid¡A to be swallowed whole with warm drinking water¡A pc.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODAR,Sotalol,Darobb 80mg,CAVS,,,,,,,,,,,,,,,,,,,
ODEA,Flupentixol + Melitracen,Deanxit 0.5/10mg,CNEU,,¾AÀ³¯g: µJ¼{¯g¡B¼~Æ{¯g(B011315100) Anxiety¡A depression¡A asthenia. °Æ§@¥Î: Transient restlessness¡A insomnia. ¸T§Ò:Immediate recovery phase after MI. Defects in bundle-branch conduction. Untreated narrow-angle glaucoma. Acute alcohol¡A barbiturates & opiate intoxications. Patients who have received MAOIs within 2 weeks. Excitable or overactive patients.,,«Ç·Å,2 tab bid. Maintenance: 1 tab qd. Max: 6 tab/daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ISOLM,Methylprednisolone,Solu-Medrol inj 40mg,HM,Adjunctive therapy in life-threatening conditions ¡ARheumatic disorders ¡A Multiple sclerosis ¡AGlomerulonephritis¡A lupus nephritis¡ASLE,Systemic fungal infection,GI upsets¡A aseptic necrosis of femoral & humeral heads; peptic ulceration with possible perforation & hemorrhage; manifestations of latent diabetes mellitus; anaphylactic reactions with or without circulatory collapse¡A cardiac arrest or arrhythmias¡A bronchospasm. Fluid & electrolyte disturbances. Also see lit.,25¢J¥H¤U,For large dose¡A IV 30mg/kg for 10-20 minutes¡A could repeat every 4-6 hours in 48 hours. In other indication¡A 10-40mg for the first dose¡A adjusted by patient's condition from second dose. For multiple sclerosis¡A 160mg daily for one week¡A then 80mg every two days for one month.,µL»Ý½Õ¾ã¾¯¶q,pulsed IV methylprednisolone(³q±`¾¯¶q¬°¨C¤é1 G )¥i¯à·|¾É­PÃÄª«©Ê¨x·l¶Ë¦p«æ©Ê¨xª¢,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,Methylprednisolone is classified as a nonfluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders¡A nonfluorinated corticosteroids are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,Unknown ¨S¦³¸ê®Æ,Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however¡A monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders¡A low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,IM;IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,IV push over 1 minute,Low dose (eg¡A <1.8 mg/kg or <125 mg/dose): Administer over 3 to 15 minutes Moderate dose (eg¡A >2 mg/kg or 250 mg/dose): Administer over 15 to 30 minutes High dose (eg¡A >15 mg/kg or >500 mg/dose): Administer over 30 to 60 minutes,UpToDate:Do not administer moderate- or high-dose IV push; severe adverse effects¡A including hypotension¡A cardiac arrhythmia¡A and sudden death¡A have been reported in patients receiving high-dose methylprednisolone IV push over <20 minutes. µ}ÄÀ«á·»²G­Y¦s©ñ©ó20-25¢J¶·©ó3¤p®É¤º¨Ï¥Î¡A2-8¢J¶·©ó24¤p®É¤º¨Ï¥Î.
ISOMA,Somatostatin,Somatosan 3mg,HM,,¾AÀ³¯g: Severe acute hemorrhage from esophageal varices. Severe acute hemorrhage from gastric or duodenal ulcers or accompanying acute erosive or hemorrhagic gastritis. Prophylaxis & treatment of post-op complications following pancreatic surgery. Adjuvant treatment of intestinal & pancreatic fistule. °Æ§@¥Î: GI symptoms (nausea¡A vomiting¡A diarrhea)¡A rarely skin rash. ¸T§Ò: Pregnancy¡A peri & postnatal period¡A lactation. Spurting arterial bleeding must be treated by surgery.,,«Ç·Å,250 mcg IV in initial 3 mins¡A then continue with 250 mcg/hr by IV infusion.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ISPAR,Sparteine Sulfate (JP),Sparteine inj 100mg/1mL,SGU,,,,,,,,,,,,,,,,,,,
OGAST,Famotidine,Gaster 20mg,ALIM,,1. Duodenal and benign gastric ulcer. 2. Prevention of relapse of duodenal ulceration. 3. Zollinger-Ellison syndrome.,,,Oral: Adult: Benign gastric and duodenal ulcer: 40 mg at night for 6-8 wks. Prophylaxis of duodenal ulcer relapse: 20 mg at night. Zollinger-Ellison syndrome: Initially 20 mg q6h¡A adjust as necessary (max. 480 mg/day). Inj: Slow IV: 20 mg q12h¡A IV inj must be diluted to 20 ml and given over 2 mins. IV infusion: 20 mg q12h over 15-30 mins.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ISUN25,5% Dextrose in 0.9% Sodium,Suntose 2.5% 500mL,NUTR,,,,,,,,,,,,,,,,,,,
ITAX,Paclitaxel,Taxol inj 30mg/5mL,RACA,,After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast cancer.,,,135 mg/ m^2 IV over 24 hr every 3 wk. Patients must be premedicated prior to administration eg dexamehtasone 20 mg orally (or its equiv) 12 & 6 hr before Taxol¡A diphenhydramine (or its equiv) 50 mg IV 30-60 mins before Taxol.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OHARN,Tamsulosin,Harnalidge 0.2mg,SGU,,¾AÀ³¯g:¥Dªv¨}©Ê«e¦C¸¢ªÎ¤j(B022095100),,RT,0.2mg once daily.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OHER,Diltiazem,Herbesser 30mg,CAVS,Angina pectoris¡A mild to moderate essential hypertension.,Sick-sinus syndrome; 2nd or 3rd AV block; porphyria. Severe congestive cardiac failure; marked bradycardia. Pregnancy & lactation. Serious Cardiovascular: Congestive heart failure (less than 2% )¡A Heart block¡A Myocardial infarction Hepatic: Hepatotoxicity,Dizziness¡A bradycardia¡A facial flushing¡A AV block. Fatigue¡A headache¡A lightheadedness. Skin rash; GI disturbances¡A constipation¡A abdominal pain¡A heartburn¡A dyspepsia. Cardiovascular: Bradyarrhythmia (1.7% to 3.6% )¡A Peripheral edema (4.6% to 8% ) Neurologic: Dizziness (3.5% to 6.4% )¡A Headache (4.6% ) Respiratory: Cough (2% ) Other: Fatigue (4.8% ),25¢J¥H¤U,Angina: 30 mg TID. May be increased to 60 mg TID. HTN: (mild to moderate): 30-60 mg TID. Maximum dose: 360mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest low risk,[¥é³æ] ¸T§Ò¡G¤Å¹ï¥¥°ü©Î¥i¯àÃh¥¥ªº°ü¤k§ëÃÄ¡C °Êª«¹êÅç¤¤¥X²{­P·î§@¥Î(¤p¹«:°©Àf²§±`¡B¥~Æ[²§±`)¤Î­L¨à¬r©Ê(¤p¹«¡B¤jÆU:­P¦º)ªº³ø§i®×¨Ò¡FÃh¥¥©Î¥i¯àÃh¥¥°ü¤k¨Ï¥Î¥»ÃÄ¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C FDA Pregnancy Category (Ãh¥¥¥ÎÃÄ¯Å¼Æ):C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] «ØÄ³Á×§K¹ï­÷¨Å¤¤ªº°ü¤k§ëÃÄ¡A¦ýµLªkÁ×§K¤´¶·§ëÃÄ®É¡A¥²¶·°±¤î­÷¨Å¡C[¦³³ø§i«ü¥X¥»ÃÄ¾¯·|Âà²¾¦Ü¥À¨Å¤¤]¡F­÷¨Å°ü¤k¨Ï¥Î¥»ÃÄ¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C,AC;AC15;PC;PO;WM;,,,,,
OHYT,Terazosin,Hytrin 2mg,CAVS,,¾AÀ³¯g:Hypertension¡A benign prostatic hyperplasia (BPH). °Æ§@¥Î: Dizziness¡A nasal congestion¡A drowsiness¡A nausea¡A peripheral edema¡A asthenia¡A postural hypotension. Cardiovascular: Edema (3%)¡A Hypotension (3%-7%)¡A Lightheadedness¡A Palpitations (4%)¡A Syncope (1%)¡A Tachyarrhythmia (2%) Gastrointestinal: Nausea (2%-4%) Neurologic: Asthenia (2%-13%)¡A Dizziness (4%-26%)¡A Headache (2.5%)¡A Somnolence (3%-5%) Reproductive: Impotence (1%-2%) Respiratory: Dyspnea (2%-3%)¡A Nasal congestion (6%-12%)¡A Rhinitis (2%)¡A Sinusitis (3%) Other: Fatigue ¸T§Ò: Pregnancy.,,«Ç·Å,BPH initially 1 mg at bedtime¡A increase dose in a stepwise fasion to 2 mg¡A 5 mg or 10 mg once daily to achieve desired improvement. Hypertension initially 1 mg at bedtime. Recommended dose range: 1~ 5 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OILO2,Erythromycin,Ilosone 250mg,QANB,,Active against Mycoplasma pneumonia¡A Legionella pneumophilia.,,,Oral: Take on an empty stomach. Adult: 250 mg q6h¡A (max. 4 g/day). Child: 30-50 mg/kg/day in 3-4 divided doses; dosage may be doubled in severe infections.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IBER,Immune Globulin,Beriglobin P 320mg/2mL,HIMM,,Immunoglobulin deficiency¡A Hepatitis A measles¡A Hepatitis B¡A other viral diseases.,,2-8,IM¡AImmunoglobulin deficiency: 0.66 ml/kg monthly¡A using multiple inj sites (max. 5 ml/site). Hepatitis A: Prophylaxis¡A 0.02 ml/kg; for travel longer than 3 months¡A 0.06 ml/kg. Measles: Prevention or modification¡A 0.25 ml/kg; max. 15 ml given within 6 days after exposure.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IBLT,Dextrose,Bluton 500mL (50% glucose),NUTR,,¾AÀ³¯g:Treatment of carbohydrate & fluid depletion; hypoglycaemia. °Æ§@¥Î: Fever¡A phlebitis¡A thrombosis¡A pain at inj site. ¸T§Ò:Anuria¡A intracranial or intraspinal haemorrhage.,,«Ç·Å,Individualised dosage¡A depending on the deficit or the daily maintenance requirements.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,50 % Glucose Solution¡A°ª±i¸²µå¿}²G¡A­­ÃÄ¾¯¬ì½Õ°tTPN¨Ï¥Î
IBRE,Esmolol,Brevibloc 100mg,CAVS,,¾AÀ³¯g: Rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in peri-op¡A post-op or other emergent circumstances. Noncompensatory sinus tachycardia. Treatment of tachycardia & hypertension that occur during induction¡A tracheal intubation¡A during surgery¡A on emergence from anesth & in the post-op period. °Æ§@¥Î: Hypotension¡A dizziness¡A somnolence¡A confusion¡A headache¡A agitation¡A fatigue; nausea¡A vomiting. ¸T§Ò: Sinus bradycardia¡A heart block > 1st degree¡A cardiogenic shock or overt heart failure.,,«Ç·Å,Supraventricular tachycardia 50-200 mcg/kg/min. Intra-op & post-op tachycardia &/or hypertension Immediate control: 80 mg bolus dose over 30 seconds followed by a 150 mcg/kg/min infusion. Gradual control: Initially 50 mcg/kg/min for 1 min followed by a 4-min maintenance infusion of 500 mcg/kg/min.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IBRI,Methohexital,Brietal inj 500mg,ZANE,,¾AÀ³¯g: Anesth. °Æ§@¥Î: Cardiorespiratory depression¡A tachycardia¡A hypotension¡A myocardial depression¡A bronchospasm¡A hiccups¡A laryngeal spasm¡A hypersensitivity reactions¡A inj-site reactions¡A skeletal muscle hyperactivity¡A convulsions¡A nausea¡A abdominal pain¡A abnormal liver function tests. ¸T§Ò: Porphyria.,,20-25¢XC,IV Induction: 50-120 mg at rate of 10 mg every 5 sec. Maintenance: 20-40 mg via inj every 4-7 min or via continuous infusion using a 0.2% soln at 3 mL/min.,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IBUS,Hyoscin-Butylbromide,Buscopan inj 20mg/1mL,ALIM,,,,«Ç·Å,,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
L,Liq Dispensing,Liq Dispensing,PHR,,,,,,,,,,,,,,,,,,,
LANT,Acetaminophen,Anti-phen 24mg/mL¡A 60mL,CNEU,Analgesic & antipyretic.,When used for self-medication¡A do not use with other drug products containing acetaminophen or if allergic to acetaminophen or any of the inactive ingredients.,Common: Pruritus (5% or greater)¡A Constipation (5% or greater)¡A Nausea (adult¡A 34%; pediatric¡A 5% or greater)¡A Vomiting (adult¡A 15%; pediatric¡A 5% or greater)¡A Headache (1-10%)¡A Insomnia (1-7%)¡A Agitation (5% or greater)¡A Atelectasis (5% or greater) Serious: Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Liver failure¡A Pneumonitis,25¢J¥H¤U¡A¤£»Ý¦B¦s,¡Ö12 years old:20-30mL(480mg-720mg) Q4H-Q6H¡A 6-12 years old: 10-15mL(240mg-360mg) Q4H-Q6H¡A 3-6 years old: 5-7.5mL(120mg-180mg) Q4H-Q6H¡A,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LAUG,Amoxicillin + Clavulanic Acid,Augmentin syr 100mL,QANB,,,,,,,,,,,,,,,,,,,
LAUG1,Amoxicillin + Clavulanic Acid,Augmentin syr 100mL,QANB,,Respiratory tract infections¡A skin and soft tissue infections¡A genito-urinary tract infections¡A osteomyelitis.,,,Adult & child over 40 kg: 250-500 mg q8h. Child under 40 kg: 20-40 mg/kg/day in 3 divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
LBER,Fenoterol,Berotec liq 0.5 mg/mL,ERSP,,Bronchospasm¡A bronchitis¡A emphysema.,,,Oral: Adult: 2.5-5 mg tid. Child: Up to 1 yr: 1.25 mg bid-tid. 1-6 yrs: 1.25 mg-2.5 mg tid. 6-14 yrs: 2.5 mg tid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
LBM,Opium Tincture + Glycyrrhiza + Antimony K tartrate,Brown mixture 200mL,ERSP,,¾AÀ³¯g: Expectorant & antitussive.,,«Ç·Å,Adult 5 mL tid-qid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,ÃÄ«~¥é³æ:Ãh¥¥¤Î­÷¨Å¤£«ØÄ³¨Ï¥Î,,,,,,
OCYM,Duloxetine,Cymbalta 30mg,CNEU,Treatment of major depressive disorder.,Coadministration with MAOIs; uncontrolled narrow-angle glaucoma.,Nausea¡A dry mouth¡A constipation¡A diarrhea¡A vomiting¡A decreased appetite¡A wt loss¡A fatigue¡A dizziness¡A somnolence¡A tremor¡A increased sweating¡A hot flushes¡A blurred vision¡A insomnia¡A anxiety¡A sexual dysfunction. Infrequently¡A urinary hesitation. Dermatologic: Diaphoresis (6% to 8% ) Gastrointestinal: Constipation (5% to 15% )¡A Decrease in appetite¡A Diarrhea (7% to 13% )¡A Nausea (14% to 30% )¡A Xerostomia (5% to 18% ) Neurologic: Dizziness (6% to 17% )¡A Insomnia (8% to 16% )¡A Somnolence (7% to 21% ) Other: Fatigue (2% to 15% ),30¢J¥H¤U,Major Depression: Initial dose:40-60mg/day. Maintenance dose: 60mg/day. maximum dose: 120mg/day. Generalized Anxiety Disorder: Initial dose:30mg/day. Maintenance dose: 60mg/day. maximum dose: 120mg/day. Diabetic peripheral neuropathy: 60mg/day. maximum dose: 60mg/day. Fibromyalgia: Initial dose:30mg/day. Maintenance dose: 60mg/day. maximum dose: 60mg/day.",µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ(chronic liver disease or cirrhosis)¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã¿õ§]ªA¡A¤£¥i«r¸H©Î©î¶}½¦Ån¡C
ISOO,Amoxicillin + Clavulanic Acid,Soonmelt inj 600mg,QANB,Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI¡A pelvic¡A head & neck¡A cardiac¡A renal¡A joint replacement & biliary tract.,Hypersensitivity to penicillins¡A possible cross sensitivity with other £]-lactam antibiotics. History of penicillin-associated cholestatic jaundice/hepatic dysfunction,Common: Diaper rash (3.5-6%)¡A Rash (1.1-3%)¡A Urticaria¡A Diarrhea (2.9-14.5%)¡A Loose stool (1.6-9%)¡A Nausea (up to 3%)¡A Vomiting (up to 2.2%)¡A Mycosis (3.3%)¡A Vaginitis (1%)¡A Candidiasis (1.4%) Serious: Drug reaction with eosinophilia and systemic symptoms¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Cholestasis¡A Hepatitis¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Angioedema¡A Serum sickness due to drug,³±²D³BÀx¦s¡A»Ý§C©ó25¢J,Adults and children > 12 years: 1.2 g IV every 6-8 hours for 30-40 minutes; children 3 months to 12 years: 30 mg/kg IV every 6-8 hours; infants 0-3 months: 30 mg/kg IV every 8-12 hours. Surgical prophylaxis: 1.2 g at induction of anesthesia then 1.2 g 3-4 times within 24 hours.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,AMOXICILLIN PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk CLAVULANATE¡A POTASSIUM PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,AMOXICILLIN BREASTFEEDING RECOMMENDATION: Compatible CLAVULANATE¡A POTASSIUM BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IVD;IVP;IVPUSH;,10 mL D/W (µ}ÄÀ²G»Ý¦b20¤ÀÄÁ¤º¨Ï¥Î),¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 4¤ÀÄÁ,¥H30 ~ 40¤ÀÄÁ½wºCºwª`,1. ª`®g«eÀË¬d¯f±w¬O§_¦³ penicillin ¹L±Ó¥v¡C 2. µ}ÄÀ«áÀ³¾¨§Ö¨Ï¥Î¡A¦w©w©Ê»Pµ}ÄÀ¿@«×»P«O¦s±ø¥ó¦³Ãö¡C 3. ¨C¤p²~ªºSoonmelt inj. 600mg¤¤¡A§t¦³0.5 mmol ªº¹[»P 1.55 mmol ªº¶u (¦ô­p­È)¡C 4. ¥»²£«~¤£¾A¥Î©ó¦Ù¦×ª`®gµ¹ÃÄ¡C 5.¤£¥i¥H¦å²G»s¾¯¡B¨ä¥L³J¥Õ²G©ÎÀR¯ßª`®g¥Î¯×ªÕ¨Å¾¯²V¦X¨Ï¥Î¡C 5. IV bolus: Amoxycillin 500mg + Clavulanic acid 100mg/vial °®¯»¥[¤J10 mL D/Wªw»s¡C 6. IV infusion: ¨C¤p²~¥H50 mL¾A·í¿éª`²Gµ}ÄÀ¡A¥H30 ~ 40¤ÀÄÁ½wºCºwª`¡C ¥»ÃÄ«~¤£¥i¥[¤J§t¦³¸²µå¿}¡B»E¸²µå¿}©Î­«ºÒ»ÄÆQªº¿éª`·»²G¡C
IPEGI,Peginterferon alfa-2b,Peg-Intron inj 80mcg,QANB,,¾AÀ³¯g:Treatment of chronic hepatitis C in patients ? 18 years with compensated liver disease. °Æ§@¥Î:Headache¡A myalgia¡A pain/inflammation at inj site¡A fatigue¡A rigors¡A fever¡A depression¡A arthralgia¡A nausea¡A alopecia¡A musculoskeletal pain¡A irritability¡A flu-like symptoms¡A insomnia¡A diarrhea¡A abdominal pain¡A asthenia¡A pharyngitis¡A weight decrease¡A anorexia¡A anxiety¡A impaired concentration¡A dizziness¡A local reactions at inj site. ¸T§Ò:Hypersensitivity to interferon. Pregnancy. Men whose female partners are pregnant. Autoimmune hepatitis or a history of autoimmune disease. Decompensated liver disease or severe renal dysfunction.,,2-8¢J,Adult¡Ù18 years Monotherapy 0.5 or 1 mcg/kg SC once weekly for at least 6 months. Combination therapy 1.5 mcg/kg SC once weekly in combination with ribavirin,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
IARI,Fondaparinux,Arixtra 2.5mg/0.5mL pre-filled syringe,HEMT,Deep venous thrombosis¡A acute¡A In conjunction with warfarin sodium ¡EPostoperative deep vein thrombosis¡A Hip repair or replacement¡A knee replacement¡A or abdominal surgery; Prophylaxis ¡EPulmonary embolism¡A acute¡A In conjunction with warfarin sodium when initial therapy is administered in a hospital,¡EActive major bleeding ¡EBacterial endocarditis ¡EBody weight less than 50 kg in patients requiring prophylaxis for venous thromboembolism ¡EHistory of serious hypersensitivity reaction (eg¡A angioedema¡A anaphylactoid or anaphylactic reactions) ¡ESevere renal impairment (ie¡A CrCl less than 30 mL/minute) ¡EThrombocytopenia associated with positive in vitro test for antiplatelet antibody in the presence of fondaparinux sodium,Common ¡EDermatologic: Injection site reaction¡A Rash (7.5% ) ¡EOther: Fever (13.6% ) Serious ¡EHematologic: Anemia (perioperative prophylaxis¡A 19.6%; extended prophylaxis¡A 1.5% )¡A Hemorrhage (2.2% to 3.4% )¡A Thrombocytopenia (0.04% to 0.2% (less than 50¡A000/mm(3)); 0.5% to 3% (50¡A000 to 100¡A000/mm(3)) ) ¡EImmunologic: Anaphylaxis¡A Hypersensitivity reaction ¡ENeurologic: Extradural intracranial hematoma¡A Non-traumatic spinal subdural hematoma,25¢J¥H¤U¡C¤Á¤Å§N­á,For patients undergoing lower extremity surgery or abdominal surgery¡A SC 2.5mg once daily for 5-9 days. The first dose must be gievn 6 hours after surgery and stop bleeding. For UA/NSTEMI¡A SC 2.5mg daily for 8 days or discharge. Maximum 8 days. For STEMI¡A IV 2.5mg as first dose¡A followed by SC 2.5mg once daily to 8 days or dischrage. Maximum 8 days. For DVT and PE¡A SC once daily with dose of 5mg for weight < 50kg¡A 7.5mg for weight between 50-100 kg and 10mg for weight beyond 100 kg¡A combination with warfarin sodium within 72 hours¡A for at least 5 days¡A up to 9 days.,»Ý½Õ¾ã¾¯¶q,Severe impairment (Child-Pugh class C): There are no dosage adjustment provided in the manufacturer's labeling (has not been studied). Use with caution; monitor closely for signs of bleeding.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;SC;,,¡iN/S¡j¥i¿ï ¡C,,¦¨¤H:·í­º¦¸¾¯¶q¨Ï¥ÎIVD¤è¦¡§ë¤©®É¡A±NÃÄ«~¥[¤J25~50²@¤Éªº0.9%¥Í²z­¹ÆQ¤ô¡AÀR¯ßª`®g»Ý¶W¹L2¤ÀÄÁ¡C,1.·í¦å¤pªO¼Æ­È§C©ó100¡A000/mm¡A¤£¥i¨Ï¥Î¥»ÃÄ 2.¥»ÃÄ¤£¥i¥Î©ó¦Ù¦×ª`®g
IDOR,Midazolam,Dormicum inj 5mg/1mL,CNEU,Conscious sedation before diagnostic therapeutic procedures with or without local anesthesia (IV administration). Premedication before induction of anesthesia (IM or rectal administration in children). Induction and maintenance of anesthesia. As an induction agent in inhalation anesthesia or a sedative component in combined anesthesia¡A including total IV anesthesia (IV injection and infusion). Ataralgesia in combination with ketamine in children (IM administration). Long-term sedation in intensive care units (IV administration as bolus injection or continuous infusion).,Hypersensitivity to benzodiazepines.,Drowsiness¡A numbed emotions¡A reduced alertness¡A confusion¡A fatigue¡A headache¡A dizziness¡A muscle weakness¡A ataxia or double vision. GI disturbances¡A changes in libido¡A skin reactions. Anterograde amnesia¡A depression¡A psychiatric & 'paradoxical' reactions (eg restlessness¡A agitation¡A irritability)¡A physical dependence. Gastrointestinal: Nausea (2.8%)¡A Vomiting (2.6%) Neurologic: Excessive somnolence (1.6%)¡A Headache (1.5%)¡A Somnolence (1.2%) Respiratory: Cough (1.3%) Other: Hiccoughs (3.9%),Á×¥ú,Conscious sedation: Adult < 60 years old: IV: Initial dose: 2-2.5 mg¡A titration dose: 1mg¡A total dose: 3.5-7.5mg Adult >= 60 years old: IV: Initial dose: 0.5-1 mg¡A titration dose: 0.5-1mg¡A total dose: <3.5mg Pediatrics: IV: 6 months - 5 years: Initial dose: 0.05-0.1 mg/kg¡A repeat after 2-5 minutes and titrating to disired level of sedation as 0.2mg/kg/dose¡A total dose: <6mg. IV: 6-12 years: Initial dose: 0.025-0.05 mg/kg¡A repeat after 2-5 minutes and titrating to disired level of sedation as 0.1mg/kg/dose¡A total dose: <10mg. IV:13-16 years: As adults. Rectal:>6 montHS: 0.3-0.5 mg/kg IM: 1-15 years: 0.05-0.15 mg/kg Anaesthesia premedication: Adult < 60 years old: IV: 1-2 mg repeated¡A IM: 0.07-0.1mg/kg Adult >= 60 years old: IV: Initial dose:0.5mg slow uptitration as need¡A IM: 0.025-0.05 mg/kg Paediatrics:Rectal:>6 montHS: 0.3-0.5 mg/kg¡A IM: 1-15 years: 0.08-0.2 mg/kg Anaesthesia induction: Adult < 60 years old: IV: 0.2mg/kg(0.2-0.35 mg/kg without premedication) Adult >= 60 years old: IV: 0.05-0.15 mg/kg(0.15-0.2 mg/kg without premedication) Sedative component in combined anaesthesia: Adult < 60 years old: IV: Intermittent doses of 0.03-0.1 mg/kg or continuous infusion of 0.03-0.1 mg/kg/hr Adult >= 60 years old: IV: Lower doses than recommended for adults < 60 years old Sedation in ICUs: Adult: IV: Loading dose:0.03-0.3 mg/kg in increment of 1-2.5mg. Maintenance dose: 0.03-0.2 mg/kg/hr. <=32 weeks gestational age: IV 0.03mg/kg/hr >32 weeks gestational age up to 6 montHS: IV 0.06 mg/kg/hr >6 montHS of age: IV: Loading dose: 0.05-0.2 mg/kg. Maintenance dose: 0.06-0.12 mg/kg/hr.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¨ü·l·|­°§Cmidazolamªº²M°£²v¡A¶i¦Ó¼W¥[³Ì²×¥b°I´Á¡A¦]¦¹Á{§É®ÄªG¥i¯à·|¼W±j©Î©µªø¡A¥i¯à¶·­°§Cmidazolam¾¯¶q¡A¨Ã¾A·íºÊ±±¥Í©R¸ñ¶H,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Potential Toxicity If Combined With Other CNS Depressants,IM;IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C,½wºC±Àª`¡A¦¨¤Hª`®g20-30 ¬í¡A«Äµ£ª`®g>2-3¤ÀÄÁ¡C¤U¦¸§ëÃÄ«e¦Ü¤Öµ¥«Ý 2 ¤ÀÄÁ¡AÆ[¹î¬O§_¤wµo´§¨¬°÷ÃÄ®Ä¡C,¦¨¤H0.03-0.1 mg/kg/hour¡A«Äµ£0.06-0.12 mg/kg/hour¡A>32¶g·s¥Í¨à0.06 mg/kg/hour¡A<32¶g·s¥Í¨à0.03 mg/kg/hour¡C,1. IM: ª`®g©ó¤j«¬¦Ù¦×¤§²`³¡¡C 2. IV: ½wºC±Àª`¡A¦¨¤Hª`®g20-30 ¬í¡A«Äµ£ª`®g>2-3¤ÀÄÁ¡C¤U¦¸§ëÃÄ«e¦Ü¤Öµ¥«Ý 2 ¤ÀÄÁ¡AÆ[¹î¬O§_¤wµo´§¨¬°÷ÃÄ®Ä¡C 3. «ùÄò IV infusion: ¦¨¤H0.03-0.1 mg/kg/hour¡A«Äµ£0.06-0.12 mg/kg/hour¡A>32¶g·s¥Í¨à0.06 mg/kg/hour¡A<32¶g·s¥Í¨à0.03 mg/kg/hour¡C 4. Dormicum inj 5mg/1mL¥i¨Ï¥Î¾A·í·»²Gµ}ÄÀ¬°0.015-0.15mg/mL¿@«×¡C 5. Dormicum inj 5mg/1mL¤£¥i»PÆP©Ê·»²G²V¦X¡A·|²£¥Í¨I¾ý¡C
OAVA,Rosiglitazone,Avandia F.C. 4mg,META,,¾AÀ³¯g:²Ä¤G«¬¿}§¿¯f(B022818100) ¸T§Ò:.Patients with known "NYHA"Class III or Class IV cardiac status. Patients with known hypersensitivity to this product or any of its components. °Æ§@¥Î: Anaemia and edema have been reported as adverse events of mild to moderate in severity. Cardiovascular: Edema (4.8% to 14.7% ) Endocrine metabolic: Weight gain ½Ã¥Í¸p¤½§i(99.10.14) 1.¤£«ØÄ³¸Ó¦¨¤À(rosiglitazone)¨Ï¥Î©ó¯Ê¦å©Ê¤ßÅ¦¯f¤§¯f¤H¡C 2.¤£«ØÄ³¸Ó¦¨¤À¨Ï¥Î©ó¤ßÅ¦°IºÜ¤§¯f¤H¡C 3.¸T¥Î©ó¤ß°IºÜ²Ä3¯Å©Î²Ä4¯Å(NYHA Class III or IV cardiac status )¯f¤H,,«Ç·Å,Monotherapy or combination therapy with metformin:4mg once daily or in 2 divided doses¡A may be increased to 8mg in 1 or 2 divided doses after 12 wk. Combination therapy with sulfonylurea:4mg once daily or in 2 divided doses¡A may be increased to 8mg in 1 or 2 divided doses after 8-12 wk.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ONEX,Esomeprazole,Nexium 40mg (­@¾A®¦),ALIM,Erosive reflux esophagitis¡A Long-term management of patients with healed esophagitis¡A Symptomatic treatment of GERD¡A Treatment and prevention of H. pylori associated ulcers with amoxicillin and clarithromycin.,Hypersensitivity to benzimidadazoles.,Headache¡A abdominal pain¡A diarrhea¡A flatulence¡A nausea¡A vomiting¡A constipation. Rarely¡A dermatitis¡A pruritus¡A urticaria¡A dizziness¡A dry mouth. Dermatologic: Injection site reaction (1.7%) Gastrointestinal: Abdominal pain (5.8%%)¡A Constipation (2.5%)¡A Diarrhea (3.9%)¡A Flatulence (10.3%)¡A Indigestion (6.4%)¡A Nausea (6.4%)¡A Xerostomia (3.9%) Neurologic: Dizziness (2.5%)¡A Headache (10.9%),30¢J¥H¤UÁ×§K¼éÀã,Erosive esophagitis - Gastroesophageal reflux disease treatment¡A 20 to 40 mg ORALLY once daily for 4 to 8 weeks; an additional 4 to 8 weeks may be considered if healing is not complete maintenance¡A 20 mg ORALLY once daily Gastroesophageal reflux disease - Heartburn 20 mg orally once daily for 4 weeks; an additional 4 weeks may be considered if symptoms do not completely resolve Helicobacter pylori gastrointestinal tract infection - Ulcer of duodenum Triple therapy¡A 40 mg orally once daily in combination with amoxicillin 1000 mg twice daily plus clarithromycin 500 mg twice daily for 10 days Gastric ulcer; Prophylaxis - NSAID-associated gastropathy; Prophylaxis 20 mg once daily 4-8 weeks Zollinger-Ellison syndrome 40 mg twice daily,»Ý½Õ¾ã¾¯¶q,Severe impairment (Child-Pugh class C): Maximum: 20 mg daily.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»¿õ¾¯À³¾ã²É¥H²GÅé§]ªA¡A¤£¥iÄZ¯}©ÎÀ£¯}¥»¿õ¾¯¡CµLªk§]ªAªº¯f¤H¡A¥i±NÃÄ¿õ¸m¤J¥bªM«DºÒ»ÄÃþªº¤ô¤¤¡AÅÍ©Õª½¨ìÃÄ¿õ±Y´²¡A±N¤ô³s¦P¤pÃÄ²y³Ü¤U©ÎºÞÄé¡C¦A±N¥bªM¤ô¥[¤JªM¤¤¨R¬~¨ÃªA¥Î¡A¦ý¤pÃÄ²y¤£¥i«r¸H©ÎÀ£¸H¡C
IV2113Z,Insulin Syringe,0.5mL ¯Ø®q¯ÀªÅ°w,ZOTH,¬°¯Ø®q¯ÀªÅ°w(NCS030510NBD),,,Á×§K·¥ºÝªº·Å«×»PÀã«×,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,,,,,,
ETIMX,Timolol,Timoptol-XE 0.5% 2.5mL,TOPH,,I:Reduction of elevated intraocular pressure. AR:Transient blurred vision¡A burning¡A stinging¡A conjunctival infection¡A discharge¡A foreign body sensation¡A itching. Ocular irritation & visual disturbances. Bradycardia¡A arrhythmia¡A hypotension¡A syncope¡A heart block¡A CVA¡A cereral ischemia¡A CHF¡A palpitation¡A cardiac arrest¡A edema¡A bronchospasm¡A resp. failure etc. CI:Bronchial assthma or a hisory of bronchial asthma¡A severe COPD.Sinus bradycardia¡A 2nd & 3rd degree AV block¡A overt cardiac failure¡A cardiogenic shock.,,,1 drop once daily.,,,,,,,,,,,,,,
ODEC,Levamisole,Decaris 50mg,QANP,,¾AÀ³¯g: ¥Î©ó¼W±j§K¬Ì¤O(B005827100) Ascariasis & ankylostomiasis. °Æ§@¥Î: Headache¡A vertigo¡A palpitation & GI disturbances. ¸T§Ò: Patients with a known hypersensitivity to Decaris or its components. There are no absolute contraindications to the use of Decaris.,,«Ç·Å,Anthelmintic: 2.5 mg/kg as a single dose. Immunostimulant: 2.5 mg/kg/day in 1-3 divided doses¡A for 2 consecutive days every week or 3 consecutive days every 2 wks.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ODEU,Benzbromarone,Deuron 50mg,CNEU,,¾AÀ³¯g:Hyperuricemia. °Æ§@¥Î:Rarely¡A diarrhoea¡A mild GI disturbances ¸T§Ò:Severe renal disease¡A nephrolithiasis; pregnancy & lactation,,«Ç·Å,1 tab qd to tid,,,,¨S¦³¸ê®Æ,,,,,,,,,,
ODIAM,Acetazolamide,Diamox 250mg,CAVS,,I: Edema¡A open angle glaucoma. CI: Depressed Na or K blood serum levels; marked kidney or liver disease; suprarenal gland failure; hyperchloremic acidosis; cirrhosis. Long-term administration in patients with chronic non-congestive angle-closure glaucoma.,,,0.25-1.5 g/day in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ODIAN,Cyproterone Acetate + Ethinylestradiol,Diane 35 (21 tablets/box),HM,Treatment of androgen dependent diseases in women¡A such as acne¡A especially pronounced forms & those which are accompanied by seborrhea or by inflammation or formation of nodes (acne papulopustulosa¡A acne nodulocystica)¡A mild forms of hirsutism. As OC.,Presence or a history of venous or arterial thrombotic/thromboembolic events (e.g. deep venous thrombosis¡A pulmonary embolism¡A MI) angina pectoris). History of migraine with focal neurological symptoms. DM with vascular involvement. Presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication. Pancreatitis or a history thereof if associated with severe hypertriglyceridemia. Presence or history of severe hepatic disease. Presence or history of liver tumors (benign or malignant). Known or suspected sex-steroid influenced malignancies (eg. of the genital organs or the breasts). Undiagnosed vag bleeding. Known or suspected pregnancy. Lactation.,Nausea¡A abdominal pain; weight increased; headache; depressed mood¡A mood altered; breast pain¡A breast tenderness.,³±²D(15-30¢J) °®Àê³B©Ò,1 tablet daily for 21 days¡A starting on the 1st day of the cycle¡A then 7 tablet-free days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,Cyproterone Acetate [18] Micromedex Pregnancy Rating: Fetal risk cannot be ruled out Ethinylestradil [18] by book . micromedex : Teratogenicity/Effects in Pregnancy,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Cyproterone Acetate [8] Micromedex Lactation Rating: Infant risk cannot be ruled out Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OSUR,Tiaprofenic Acid,Surgam 200mg,CNEU,,¾AÀ³¯g:¬°¤îµh®øª¢ÃÄ(B022728100),,RT,Initial: 600 mg/day in 2-3 divided doses. Maintenance: 300-400 mg/day.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OSYN,Allopurinol,Synorid 100mg,CNEU,,,,,,,,,,,,,,,,,,,
OTAG4,Cimetidine,Tagamet 400mg,ALIM,,Active duodenal ulcer¡A pathological hypersecretory conditions¡A enhance pancreatic replacemant by reducing peptic acid deactivation¡A benign gastric ulcer¡A reflux esophagitis¡A upper GI bleeding.,,,,,,,¥i¯à¦w¥þ,,,,,,,,,,
OTAPL,Acetylsalicylic Acid,Tapal 100mg (Aspirin),HEMT,,Fever¡A pain¡A rheumatic arthritis.,,RT,Antipyretic & analgesic: Adult: 325-650 mg q4h as needed. Child:10-15 mg/kg q4h. Arthritis:Adult:3.6-5.4 g/day. Child: 65 mg/kg/day in divided doses q6h. Acute rheumatic fever: Up to 7.8 g/day. Transient ischemic attacks: 1300 mg/day.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OIMIN,Methisoprinol,Imin 500mg,QANB,Viral disease¡A immunomodulator.,Hypersensitivity to any component of the formulation.,GI discomfort. Transient rise in serum & uric acid levels.,25¢J¥H¤UÁ×¥ú,Adult: 500 mg q3-4h. Children: 50 mg/kg/day in divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
EAZO,Brinzolamide,Azopt 1%¡A 5mL ophthalmic suspension,TOPH,Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.,Hypersensitivity to sulphonamides. Severe renal impairment¡A hyperchloremic acidosis.,Taste perversion¡A temporary blurred vision¡A ocular discomfort¡A foreign body sensation¡A ocular hyperemia. Gastrointestinal: Abnormal taste in mouth¡A Bitter (5-10%) Neurologic: Headache (5-10%) Ophthalmic: Blurred vision (5-10%),Àx¦s©ó4¢J -30¢J,Instill 1 drop BID-TID into the conjunctival sac. Age <18 years: Not recommend use. Shake well before using.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,BRINZOLAMIDE OPHTHALMIC: No Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BRINZOLAMIDE OPHTHALMIC: No Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
OIMP,Lacatol Monohydrate,Importal powder,ALIM,,,,,,,,,,,,,,,,,,,
OIMU,Azathioprine,Imuran 50mg,HIMM,As an adjunct for the prevention of rejection in renal homotransplantation. Treatment of SLE¡A severe RA¡A acute & chronic leukemia.,Hypersensitivity to 6-mercaptopurine. Pregnancy or patients who are likely to become pregnant in the near future.,Common: Nausea and vomiting (12%) Serious: Pericarditis¡A Skin cancer¡A Pancreatitis¡A Hypersensitivity¡A Acute myeloid leukemia¡A Hematologic toxicity¡A Leukopenia (Renal transplant¡A more than 50%; rheumatoid arthritis¡A 28%)¡A Leukopenia (Severe)¡A <2500 cells/mm[3] (renal transplant¡A 16%; rheumatoid arthritis¡A 5.3%)¡A Macrocytic anemia¡A Myelodysplastic syndrome¡A Myelosuppression (5%)¡A Pancytopenia¡A Thrombocytopenia¡A Hepatotoxicity (<1%)¡A Lymphoma involves liver¡A Veno-occlusive disease of the liver¡A Hypersensitivity reaction¡A Malignant lymphoma (0.5%)¡A T-cell lymphoma¡A Hepatosplenic¡A Progressive multifocal leukoencephalopathy¡A Adenocarcinoma of lung¡A Infectious disease (renal transplant¡A 20%; rheumatoid arthritis¡A <1%)¡A Neoplastic disease (0.5-11.9%),25¢J¥H¤UÁ×¥ú,Adult Transplantation initial dose 5 mg/kg/day¡A maintenance dose 1-4 mg/kg/day. Other conditions 1-3 mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°§K¬Ì§í¨î¾¯¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
EBSS5,Balanced Salt Soln,BSS plus 500mL,TOPH,,¾AÀ³¯g: B.S.S. Irrigation during various surgical procedures of the eyes¡A ears¡A nose &/or throat. BSS Plus Intraocular irrigating soln during intraocular surgical procedures involving perfusion of the eye. °Æ§@¥Î: When the corneal endothelium is abnormal¡A irrigation or any other trauma may result in bullous keratopathy.,,«Ç·Å,For irrigation during operations of the eyes¡A ears¡A nose and throat.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IPOL,Inactivated poliovirus vaccine,Imovax polio 0.5mL (¦Û¶O),HIMM,,Prophylaxis of poliomyelitis,,,SC/IM inj Primary immunization At least 2 inj of 0.5ml min 1mth apart.Boosters 1 yr after the last inj¡A then every 10 yr.,,,,,,,,,,,,,,
OALL6,Fexofenadine,Allegra 60mg,HIMM,Symptomatic relief of seasonal allergic rhinitis & uncomplicated skin manifestations of chronic idiopathic urticaria in adult & children over 6 years.,Patients with known hypersensitivity to any of the ingredients of Allegra,Viral infection¡A nausea¡A dysmenorrhoea¡A drowsiness¡A dyspepsia¡A fatigue¡A headache¡A back pain¡A coughing¡A fever¡A pain¡A otitis media¡A upper respiratory tract infection. Central nervous system: Headache (5% to 11%) Gastrointestinal: Vomiting (children 6 months to 5 years: 4% to 12%),20-25¢JÁ×§K¹L°ªÀã®ð,Seasonal allergic rhinitis Adult & children > 12 years 60 mg BID or 180 mg QD. 6-11 years 30 mg BID. Chronic idiopathic urticaria Adult & children > 12 years 60 mg BID. 6-11 years 30-60 mg BID.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LCOFS,Platycodon Fluid Extract,Cough mixture 120mL,ERSP,Antitussive¡A expectorant.,Hypersensitivity to any component of the formulation.,Poor appetite¡A GI disturbance,25¢J¥H¤U,May be taken with or without food 5-15 mL TID.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
LDEP,Valproate Sodium,Depakine oral solution 200mg/mL¡A 40mL,CNEU,Epilepsy particularly of grand mal combined with petit mal & myoclonic petit mal types.,Acute or chronic hepatitis¡A personal or family history of severe hepatitis¡A hepatic porphyria.,GI disturbances¡A ataxia¡A tremor¡A increased appetite & weight gain¡A edema¡A thrombocytopenia¡A inhibition of platelet aggregation; impaired hepatic function¡A rashes¡A sedation. Rarely¡A pancreatitis (discontinue).,25¢J¥H¤UÁ×§K¶§¥úª½®g,Giving with food to decrease gastrointestinal irritation. Children 6 years and below: syrup or oral liquid is recommended for administration. DEPAKINE 500mg Chrono Tablet is only recommended for adult and children > 17 kg. Average daily dose (per 24 hours): Adult and adolescents: 20-30 mg/kg/day in 2 or 3 divided doses. Children: 30 mg/kg/day in 2 or 3 divided doses. (< 1 year old: in 2 divided doses),µL»Ý½Õ¾ã¾¯¶q,Valproic acid should not be administered to patients with hepatic disease or significant hepatic insufficiency,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest low risk,[¥é³æ]Ãh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÄ¼Æ{¯g¡C °£«DÅöíwªvÀø¨S¦³¦X¾Aªº´À¥NÃÄª«¡A§_«hÃh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÅöíw¡C °£«D¯à½T¹ê°õ¦æÁ×¥¥­pµe¡A§_«h¨ã¥Í¨|¯à¤Oªº°ü¤k¸T¥Î valproate¡C ¨Ï¥Î¥»«~¥i¯à·|¾É­P­«¤jªº¥ý¤Ñ©Ê·î§Î¡A¯S§O¬O¯«¸gºÞ·î§Î¡]¦p¡G¯á¬Wµõ¡A spina bifida¡^¡A ¥B¥i¯à·|¾É­P­L¨à´¼°Ó¤U­°¡A¬G¥»«~À³¶È­­¥Î©óµLªk¥H¨ä¥LÃÄª«±±¨î¯gª¬¡A ©Î¦³¨ä¥¦­ì¦]µLªk¨Ï¥Î¨ä¥LÃÄª«ªvÀø¤§¥¥°ü¡C ¦Ò¶q¨Ï¥Î¥»«~¥i¯à·|¦³¨Ï«Äµ£´¼°Ó­°§C¡Bµo¥Í¯«¸gºÞ¯Ê³´¤Î¨ä¥LÄY­«¥ý¤Ñ©Ê·î§Î¤§­·ÀI¡A ¥B¸Óµ¥­·ÀI¥i¯àµo¥Í©óÃh¥¥¦­´Á¡A¬G°£«D¥²­n¨Ï¥Î¡A§_«h¤£À³¨Ï¥Î©ó¨ã¥Í¨|¯à¤O©Î¦³Ãh¥¥¥i¯à¤§°ü¤k¡C Á×¥¥­pµe¡G Valproate¦³°ª«×ªº­P·î©Ê¡A¥B­L¨à¦b¤l®c¤¤ÃnÅS©óvalproate¦³¾É­P¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº°ª «×­·ÀI¡C ¥»«~¸T¥Î©ó¥H¤U±¡ªp¡G ªvÀøÅöíw ¡E ¦bÃh¥¥ª¬ºA¤U¡A°£«D¨S¦³¾A¦Xªº´À¥NÀøªk ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe ªvÀøÄ¼Æ{¯g ¡E ¦bÃh¥¥ª¬ºA¤U ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe Á×¥¥­pµe±ø¥ó¡G ³B¤èÂå®vÀ³½T«O ¡E ¨Ì¯f¤H­Ó§Oª¬ªp¶i¦æµû¦ô¨Ã»P¤§°Q½×¡C³o¬O¬°¤F«OÃÒ¯f¤H¯à½T¹ê°t¦X¨Ã¤F¸ÑªvÀø¿ï¾Ü¤Î¨ä­·ÀI¡A ¥H¤Î¬°¤F­°§C­·ÀI¦Ó±Ä¨úªº±¹¬I¡C ¡E ©Ò¦³¤k©Ê¯f¤H³£À³°w¹ïÃh¥¥ªº¥i¯à©Ê¶i¦æµû¦ô¡C ¡E ¯f¤HÀ³¤F¸Ñ¨Ã»{ª¾¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº­·ÀI¡A¥]¬A­L¨à¦b¤l®c¤¤ÃnÅS©óvalproateªº­·ÀIµ{«×¡C ¡E ¯f¤HÀ³¤F¸Ñ¡AªvÀø«e¤ÎªvÀø´Á¶¡(¥²­n®É)¥²¶·¶i¦æÃh¥¥ÀË´ú¡C ¡E À³§i¶D¯f¤H¥²¶·Á×¥¥¡A¥B¯f¤H¦b¾ã­ÓvalproateªvÀø´Á¶¡¥²¶·¤£¶¡Â_¦a±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I ¡E ¯f¤HÀ³¤F¸Ñ¡AÅý¦³Åöíw©ÎÄ¼Æ{¯gªvÀø¸gÅçªº±M¬ìÂå®v©w´Á(¦Ü¤Ö¨C¦~¤@¦¸)µû¦ôªvÀøµ²ªG¦³¨ä¥²­n©Ê¡C ¡E ¤k©Ê¯f¤HÀ³¤F¸Ñ¡A·í¨ä­pµeÃh¥¥®É¡AÀ³ºÉ§Ö¿Ô¸ßÂå®v¡A¥H½T«O¯à¤Î®É°Q½×¨Ã¦bÃh¥¥«e¤Î°±¤îÁ×¥¥«e§ó´«ªvÀøÃÄª«¡C ¡E ¯f¤HÀ³¤F¸Ñ¡A·íµo²{Ãh¥¥®ÉÀ³ºò«æ³qª¾Âå®v¡C ¡E ¯f¤H¤w¦¬¨ì¯f¤H¥ÎÃÄ«ü«n¡C ¡E ¤k©Ê¯f¤H¤w½T»{¤F¸Ñ¡A¨Ï¥Îvalproate¤§¬ÛÃö­·ÀI©MÀ³ª`·N¨Æ¶µ (¦~«×­·ÀI½T»{ªí)¡C ³o¨Ç±ø¥ó¥ç¾A¥Î©ó¥Ø«eµL©Ê¦æ¬°ªº°ü¤k¡A°£«D³B¤èÂå®v¥R¤À¤§²z¥Ñ»{¬°¨äµLÃh¥¥­·ÀI¡C ÃÄ®v©Î¨ä¥LÂåÀø±M·~¤H­ûÀ³½T«O ¡E ¨C¦¸½Õ°tvalproate®É³£¦³¥æ¥I¯f¤H¥d¡AÅý¯f¤H¤F¸Ñ¨ä¤º®e¡C ¡E §iª¾¯f¤H·í­pµeÃh¥¥©ÎºÃ¦üÃh¥¥®É¡Avalproate¤£À³¾Õ¦Û°±ÃÄ¡AÀ³¥ß¨è³sµ¸±M¬ìÂå®v¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]valproate ¤Àªc¨ì¨Å¥Ä¤¤ªº¶q«Ü§C¡A¿@«×¤j¬ù¬O¥ÀÅé¦å²M¿@«×ªº 1%¦Ü 10%¤§¶¡¡C ®Ú¾Ú¤åÄm©MÁ{§É¸gÅç¡A­Y­n­÷¨Å¡A»Ý¦Ò¼{¥»«~ÃÄª«¦w¥þ©Ê¡A¯S§O¬O¦å²G¬ÛÃöªº¯e¯f¡C µM¦Ó¡AÃh¥¥´Á¶¡¼ÉÅS©ó sodium valproate ªº¥®¨à¡A¥i¯à­°§C»y¨¥¯à¤O¡A«ØÄ³ªvÀø®É¤£­n±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
LDIG,Digoxin,Digosin ÔA¾¯ 0.05mg/mL,CAVS,,I: CHF¡A artrial fibrilation¡A atrial flutter¡A paroxysmal atrial tachycardia. CI: AV block¡A SA block¡A digitalis intoxication¡A obstructive cardiomyopathy.,,,Adult and child over 10 yrs: Oral: Rapid digitalization: A total of 1-1.5 mg divided into 2 or more doses given q6-8h. Slow digitalization: 0.125-0.5 mg qd for 7 days. Maintenance: 0.125-0.5 mg qd. Infant and child under 10 yrs: Oral: Digitalization: The following amounts divided into 2 or more doses given q6-8h. 2-10 yrs: 0.04-0.06 mg/kg. 1 month-2 yrs: 0.06-0.08 mg/kg. Under 1 month: 0.04-0.06 mg/kg. Maintenance: 1/5-1/3 of the total digitalizing dose¡A qd.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LDUP,Lactulose,Duphalac 300mL(667mg/mL) oral solution,ALIM,,¾AÀ³¯g: Chronic portal systemic encephalopathy¡A hepatic pre coma¡A hepatic coma °Æ§@¥Î: Flatulence¡A nausea¡A vomiting¡A abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). ¸T§Ò: Galactosemia¡A bowel obstruction.,,«Ç·Å,Chronic constipation: adult: Initial: 10-45 mL; Maintain dose: 10-25 mL. 7-14 years: Initial: 15 mL; Maintain dose: 10-15 mL. 1-6 years: Initial: 5-10 mL; Maintain dose: 5-10 mL. infant: Initial: 5 mL; Maintain dose: 5 mL. Orally once daily in the morning. It takes about 48 hours for a normal bowel movement if there is no response after taking the medicine for two days¡A should consider increasing the dose. Hepatic encephalopathy: adult: Initial dosage: 30-50 mL orally 3 times daily. Maintenance dosage: Adjust every day to achieve 2 to 3 soft formed stools daily. <6years old Children & infant: Initial: 5ml orally 4 times daily for10-12 days. The second and third course of treatment will adjust the dose according to individual conditions. [Micromedex 20210101] Rectal route: Treatment and Prophylaxis of Hepatic encephalopathy: Usual dosage: Mix lactulose 300 mL with 700 mL water or NS and administer rectally via rectal balloon catheter; retain for 30 to 60 minutes. Repeat dosages: Enema may be repeated every 4 to 6 hours for reversal of coma stage; if inadvertently evacuated too promptly¡A repeat immediately. Conversion to oral: When the oral route is viable¡A initiate oral administration before rectal administration is terminated.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,,Excretion in breast milk unknown/use caution,AC;AC15;PC;PO;R;RECT;WM;,,,,,
LGAS0,Simethicone,Gascon drop 20mg/mL,ALIM,,,,,,,,,,,,,,,,,,,
OMES,Pyridostigmine,Mestinon 60mg,CNEU,Myasthenia gravis.,Mechanical intestinal or urinary obstruction.,Muscarinic: Nausea¡A vomiting¡A diarrhea¡A abdominal cramps¡A increased peristalsis¡A increased salivation¡A increased bronchial secretions¡A headache¡A miosis and diaphoresis. Nicotinic: Muscle cramps¡A fasciculation and weakness.,25¢J¥H¤U,Myasthenia gravis: 60-180 mg BID-QID. Severe cases may require up to 1500 mg daily. (MicroMedex),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OMET,Penicillamine,Metalcaptase 300mg,ZADT,,¾AÀ³¯g: Chelating agent in treatment of Wilson's disease¡A cystinuria where high fluid regimens are not adequate or in conjunction with them. °Æ§@¥Î: Anorexia¡A nausea & vomiting; oral ulceration & stomatitis; pruritus¡A urticaria & fever. Glomerulonephritis or nephrotic syndrome. Rarely¡A hematuria; myasthenia gravis. ¸T§Ò: Lupus erythematosus; history of penicillamine-induced agranulocytosis¡A aplastic anemia or severe thrombocytopenia. History of hepatic encephalopathy or bleeding varices.,,«Ç·Å,Adult Initially 150-300 mg daily for 2 weeks. Max: 1.8 g daily. Maintenance: 300-600 mg daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OMETY,Mecobalamin,Methycobal 250mcg,CNEU,Megaloblastic anemia due to vit B12 deficiency & peripheral neuropathies.,Hypersensitivity to any component of the formulation.,Infrequently: Anorexia¡A nausea¡A diarrhea¡A pain & induration at IM inj site. Rarely: Skin rash¡A headache¡A sweating or hot sensation.,30¢J¥H¤U,Adult: 1500 mcg daily in 3 divided doses. May adjust dosage according to patient's age and synptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
YPOL,,Saugella poligyn 250mL,SGU,,,,,,,,,,,,,,,,,,,
YATT,,Saugella attiva 250mL,SGU,,,,,,,,,,,,,,,,,,,
YINT,,Saugella intilac 7¤ä/box,SGU,,,,,,,,,,,,,,,,,,,
INAV,Vinorelbine,Navelbine inj 50mg/5mL,RACA,,¾AÀ³¯g:¬°§Ü¸~½FÃÄ(B022215221) CI: Patients with pretreatment granulocyte counts < 1000 cells/mm3. Adverse Reactions: Chest pain (5%)¡A paresthesia¡A loss of deep tendon reflexes (< 5 %)¡A severe peripheral neuropathy (< 1 %)¡A alopecia (12 %)¡A injection site irritation¡A chemical phlebitis¡A mild or moderate nausea (34 %)¡A constipation (29 %)¡A paralytic ileus (1 %)¡A vomiting diarrhea¡A anorexia¡A stomatitis (< 20 %)¡A granulocytopenia ( the major dose-limiting toxicity)¡A grade 3 and 4 anemia (1 %)¡A transient liver enzyme elevation¡A shortness of breath (3 %)¡A fatigue (27 %)¡A jaw pain¡A myalgia¡A arthralgia¡A rash (< 5 %)¡A hemorrhagic cystitis¡A syndrome of inappropriate ADH secretion (< 1 %).,,2 ~ 8 ¢J¡A,Dilute Navelbine to a concentration to 0.5 ~ 2 mg / ml with 5 % Dextrose or 0.9 % NaCl bofore administration. The recommemded method of administration is an IV injection over 6 ~ 10 minutes. The usual initial dose is 30 mg / m2 administered weekly¡A and the single-agent vinorelbine can be continued until progression or dose-limited toxicity. When Navelbine is used in combination wuth 120 mg / m2 of cisplatin¡A it can be used at the same dose and given on days 1 and 29¡A then every 6 weeks.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OCOM,Lipase + Protease + Amylase,Combizym,ALIM,,¾AÀ³¯g:À°§U®ø¤Æ(B014461100) CI: Peptic ulcer.,,RT,2 tab during meals,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OACTI,Estradiol Hemihydrate + Norethisterone,Activelle,HM,,,,,,,,,,,,,,,,,,,
IALE,Phenytoin,Aleviatin inj 250mg/5mL,CNEU,Control of status epilepticus of the tonic-clonic (grand mal) type; prevention & treatment of seizures which occur during or following neurosurgery &/or severe head injury,Sinus bradycardia¡A heart block¡A Stokes-Adams syndrome.,Nystagmus¡A ataxia¡A slurred speech¡A decreased coordination¡A mental confusion¡A paraesthesia¡A drowsiness¡A vertigo; severe cardiotoxic reactions & fatalities; GI disturbances¡A scarlatiniform or measles-like rashes; pain & inflammation at inj site; gingival hypertrophy¡A coarse facies¡A acne & hirsutism¡A fever & hepatitis. Rarely¡A haematological effects¡A including megaloblastic anaemia¡A thrombocytopenia¡A leucopenia¡A granulocytopenia¡A agranulocytosis & aplastic anaemia.,30¢J¥H¤U,Continuous epileptic state: The initial dose for adults (loading dose) is 10-15 mg/kg¡A and slowly intravenous injection at a rate of no more than 50 mg/min. Then use a maintenance dose of 100 mg orally or intravenously every 6-8 hours. Newborns and children: After an initial dose of 15-20 mg/kg body weight intravenously¡A the usual therapeutic concentration (10-20 mcg/mL) is usually reached.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¡C,½wºCª`®g¡A¨C¤ÀÄÁ¤£¶W¹L50²@§J¡C(¤£¶W¹L1mL/minute),1.¥H50¨ì100²@¤Éªº¥Í²z­¹ÆQ¤ô±NPhenytoinª`®g¾¯¿@«×µ}ÄÀ¨ì¤£¶W¹L10 mg/mLªº¿éª`²G¡C 2.¦¨¤HªºÀR¯ßª`®g³t«×¨C¤ÀÄÁ¤£¥i¶W¹L50²@§J¡A·s¥Í¨à¤Î«Äµ£¨C¤ÀÄÁ¤£¥i¶W¹L¨C¤½¤çÅé­«1-3²@§J¡C 3.À³¨Ï¥Î0.22-0.50 micron fillter¹LÂo¡C 4.Dilute in normal saline¡A to a final concentration no less than 5 mg/mL. [Micromedex 20211206],1.¥»«~¬°±jÆP©Ê¡A¬GµLªk»P¨ä¥LÃÄ«~°t¦X¡A»P»Ä©ÊÃÄ«~²V¦X·|²£¥Í¤£¬Û®e©Ê¡CPH­È­°§C·|ªR¥Xµ²´¹¡C 2.°t»s§¹¦¨«áÀ³¥ß§Y¶}©lµ¹ÃÄ¡A¥B¥²¶·¦b¤@¤p®É¤º¿éª`§¹²¦¡]¿éª`²V¦X²G¤£¥i§NÂÃ¡^¡C 3.À³¨Ï¥Î0.22-0.50 micronsªº½u¤º¡]in-line¡^Âo¾¹¡C 4.¨C¦¸ÀR¯ßª`®gPhenytoin«e¡AÀ³¥ý¥H¥Í²z­¹ÆQ¤ô¨R¬~¡Fµ¹ÃÄ«á¡A¦A¥H¦P¤@ª`®g°w©ÎÀR¯ß¾ÉºÞª`®gµLµß¥Í²z­¹ÆQ¤ô¡A¥HÀ°§U´î¤Ö·»²GªºÆP©Ê©Ò³y¦¨ªº§½³¡ÀR¯ß¨ë¿E¡C
IDPTH,Infanrix + Hiberix,Infanrix+Hiberix(¥|¦X¤@),HIMM,,I: Active immunization against diphtheria¡A tetanus¡A pertussis and Haemophilus influenzae type b caused diseases. CI: Children > 7 yr¡A adult. ADR: Erythema & swelling at the inj. site¡A Fever¡A irritability¡A drowsiness¡A decreased feeding¡A diarrhea. Vomiting¡A pallor¡A listlessness.,,2 ~ 8 ¢XC,IM or SC. Primary immunization: complete all 3 doses before the first 6 mth of life¡A start from the age of 2 mth¡A subsequent doses at intervals of 1 ~ 2 mth. A reinforcing 4th dose is recommended to be given 1 yr after the 3rd dose.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IMIX3,Insulin RI 30 NPH 70,Mixtard 30 HM Penfill,META,,I: Insulin-requiring diabetes mellitus. CI: Hypoglycemia. ADR : Lipodistrophy¡A local and generalized allergic reactions.,,2 ~ 8 ¢XC,Administer SC once or bid.Duration of action:Onset 1/2 hr¡A peak between 2nd-8th hr¡Aterminates after approx 24 hr. Vial:Soluble human monocomponent insulin 30% & Isophane human monocomponent insulin 70% ¡A100 IU/ml x10ml.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OTAPZ,Methimazole,Tapazole 5mg,META,,Hyperthyroidism.,,,Adult: Initial¡A 5-10 mg q8h; maintenance¡A 5-15 mg/day. Child: Initial¡A 0.4 mg/kg/day¡A maintenance¡A 0.2 mg/kg/day.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OTEG1,Carbamazepine,Tegretol 100mg ''Chewable'',CNEU,,Relief of pain associated with trigeminal neuralgia and used to control grand mal and psychomotor or partial seizure.,,,Anticonvulsant: Adult: Initial¡A 200 mg bid; maintenance¡A 800 mg-1.2 g/day;(max. 2 g/day). Child 6-12 yrs: Initial¡A 100 mg bid; Maintenance¡A 400-800 mg/day¡A (max. 1 g/day). Analgesic (for trigeminal neuralgia): Initial: 100 mg bid¡A increased by 100 mg q12h until pain is relieved. Maintenance: 400-800 mg/day¡A (max. 1.2 g/day).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTEG2,Carbamazepine,Tegretol 200mg,CNEU,,Relief of pain associated with trigeminal neuralgia and used to control grand mal and psychomotor or partial seizure.,,RT,Anticonvulsant: Adult: Initial¡A 200 mg bid; maintenance¡A 800 mg-1.2 g/day;(max. 2 g/day). Child 6-12 yrs: Initial¡A 100 mg bid; Maintenance¡A 400-800 mg/day¡A (max. 1 g/day). Analgesic (for trigeminal neuralgia): Initial: 100 mg bid¡A increased by 100 mg q12h until pain is relieved. Maintenance: 400-800 mg/day¡A (max. 1.2 g/day).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OTENO,Atenolol,Tenormin 100mg,CAVS,,¾AÀ³¯g: Antihypertension¡A anti angina. °Æ§@¥Î: Cold extremities¡A fatigue¡A GI disturbances¡A bradycardia. Occasionally¡A headache¡A mood changes¡A dizziness & deterioration of heart failure. Rarely¡A sleep disturbances¡A alopecia¡A thrombocytopenia¡A purpura¡A psoriasiform skin reactions¡A exacerbation of psoriasis¡A visual disturbances¡A psychoses¡A hallucinations¡A heart block¡A postural hypotension which may be associated with syncope. Intermittent claudication. Raynaud's phenomenon. Bronchospasm. Rashes & dry eyes¡A paraesthesia. Cardiovascular: Bradyarrhythmia (3% to 18% )¡A Cold extremities (12% )¡A Hypotension (4% to 25% ) Neurologic: Dizziness (13% ) Psychiatric: Depression (up to 12% ) Other: Fatigue (up to 26% ) ¸T§Ò: Presence of 2nd or 3rd degree heart block; cardiogenic shock. Bradycardia¡A hypotension¡A metabolic acidosis¡A severe peripheral circulatory disturbances¡A sick sinus syndrome¡A untreated phaeochromocytoma¡A uncontrolled heart failure.,,«Ç·Å,50-100 mg daily.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OTRA2,Tranexamic Acid,Transamin 250mg,HEMT,Hemorrhage¡A abnormal bleeding¡A genital & renal bleeding¡A bleeding due to prostatectomy.,Hypersensitivity to any component of the formulation.,GI disturbances. Gastrointestinal: Abdominal pain (oral¡A 19.8% ) Hematologic: Anemia (oral¡A 5.6% ) Musculoskeletal: Arthralgia (oral¡A 6.9% )¡A Backache (oral¡A 20.7% )¡A Cramp (oral¡A 6.5% )¡A Musculoskeletal pain (oral¡A 11.2% ) Neurologic: Headache (oral¡A 50.4% )¡A Migraine (oral¡A 6% ) Respiratory: Nasal sinus problem (oral¡A 25.4% ) Other: Fatigue (oral¡A 5.2% ),25¢J¥H¤U,750-2000 mg/day divide 3-4 times a day.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment is necessary.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EMET,Metronidazole,Metrogel 0.75%¡A 15gm,TDER,,¾AÀ³¯g: Topical treatment of inflammatory papules¡A pustules & erythema of rosacea. °Æ§@¥Î: Transient redness¡A mild dryness¡A burning & skin irritation. Watery (tearing) eyes if applied too near the eyes Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction ¸T§Ò: Hypersensitivity to metronidazole.,,«Ç·Å,Apply and rub a thin film of Metrogel topical gel twice daily¡A morning and evening¡A to the entire affected areas after washing. Significant therapeutic results should be noticed within 3 weeks. Clinical studies have demonstrated continuing improvement through 9 weeks of therapy. Areas to be treated should be cleansed before application of Metrogel. Patients may use cosmetics after application of Metrogel.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Hold Breastfeeding (Single Dose) Limited Human Data¡XPotential Toxicity (Divided Dose),,,,,,
EMIN,Liquid Paraffin,Mineral oil,TDER,,Stool softeners,,«Ç·Å,Adult: 15-45 ml hs¡A up to 90 ml/day. 6 yrs and over: 10-15 ml hs.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EMYDM,Tropicamide,Mydrin-M oph soln 5mL,TOPH,,,,,,,,,,,,,,,,,,,
EMYDPO,Tropicamide + Phenylephrine,Mydrin-P oph soln,TOPH,,I: Mydriasis & cycloplegia for diagnosis¡A pseudomyopia. AR: Transient stinging¡A dry mouth¡A allergic reactions. CI: Narrow-angle glaucoma.,,,Ophthalmoscopy: 1-2 gtt 15-20 mins prior to examination. Pseudomyopia: 1-2 gtt hs.,,,,,,,,,,,,,,
INEP,Amino Acids (Essential & Nonessential ),Nephrosteril inj 250mL¡A 7%,NUTR,Supply of protein elements in acute & chronic renal insufficiency as well as during peritoneal & hemodialysis treatment.,Disturbances in amino acid metabolism; liver failure¡A cardiac insufficiency; hyperhydration; hypokalemia; hyponatremia,Nausea¡A chills & vomiting (when rate of infusion is too rapid).,25¢J¥H¤UÁ×¥ú,Acute & chronic renal insufficiency without dialysis. 0.5 g amino acids/kg body weight/day (= 500 mL/day at 70 kg body weight). Acute & chronic renal insufficiency under hemodialysis¡A hemofiltration or peritoneal dialysis. 1 g amino acids/kg body weight/day (= 1000 mL/day at 70 kg body weight). Maximum: 1.5 g amino acids/kg body weight/day (= 1500 mL/day at 70 kg body weight). Duration of Application: In case of acute renal insufficiency¡A the duration of use should be a few days to a maximum of 2 weeks. In chronic renal insufficiency not treated by hemodialysis¡A Nephrosteril can be used until a sufficient oral administration of protein is possible again.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤U­°ªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,1. ¨C¤é¨C¤½¤çÅé­«³Ì°ª1.5¤½§JÓi°ò»Ä¡Aºw³t¤£¯à¶W¹L¨C¤ÀÄÁ20ºw¡Cºw³t¹L§Ö¥i¯à³y¦¨äú¤ß¡B´HÅ¸©M¹Ã¦Rªº¯gª¬¡C 2. ¥¼±µ¨ü¦å²G³zªRªvÀøªº«æ©Ê©MºC©ÊµÇ¥\¯à¤£¨¬¯f¤H¡A¨C¤é¨C¤½¤çÅé­«³Ì°ª0.5¤½§JÓi°ò»Ä¡C
INIM,Nimodipine,Nimotop°w¾¯10mg/ 50mL,CAVS,Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasms following subarachnoid haemorrhage.,Must not be administered to patients with severely impaired liver function,Hypotension¡A GI disturbances.,Á×¥ú,Subarachnoid hemorrhage¡A From ruptured intracranial berry aneurysms prophylaxis: initial¡A 0.5 mg/hr (hemadynamics unstable patient) to 1mg/hr (15mcg/kg/hr) for 2hr¡A then slowly titrate to 2mg/hr. (usually start drug within 4 days¡A then keep therapy for10-14days. if Craniotomy: continue IVD for at least 5 days after craniotomy. Then switch to orally 60mg Q4H for 7 days. treatment: initial¡A 1mg/hr (15mcg/kg/hr) for 2hr¡A then slowly titrate to 2mg/hr for 5-14days. after that¡A switch to orally 60mg Q4H for 7 days.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¯f±w(especially liver cirrhosis)¡A«ØÄ³30 mg ORALLY every 4 hours ©Î¦Ò¼{°±¤îªvÀø,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,CVC;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,°_©l³t²v:15 mcg/kg/hr¿éª`³t²v < 2mg/hr (¥»ÃÄÀ³»P¤U¦C¬Û®e·»²G¥H¤@¤ñ¥|¤ñ¨Ò¸g¥Ñ¤T¦V¬¡¶ëµ¹¤©¡A¥]¬AD5W¡B0.9% NaCl¡BLactated Ringer¡¦s solution¡B§t¦³Áâªº¨Å»ÄÆQªL®æ¤ó²G¡Bdextran40 solution¡BHAESR poly (O-2-hydroxyethyl) starch 6%¡B¥ÌÅS¾J(mannitol)¡B¤HÃþ¥Õ³J¥Õ(human albumin)¥H¤Î¦å²G¡C),1. Nimotop¿éª`²G»Ý¨Ï¥Î¿éª`À°®ú¥H³sÄòÀR¯ß¿éª`¸g¥Ñ¤¤¥¡ÀR¯ß¾ÉºÞ(central catheter) ª`¤JÅé¤º¡C 2. ¥Ñ©óÃÄ«~ªº¦³®Ä¦¨¤À·|³Q»E´â¤A²m(PVC)§lªþ¡A¦]¦¹¥u¯à¨Ï¥Î»E¤A²m(PE)ªº¿éª`ºÞ¡C 3. ÃÄ«~¤Åª½±µ¥[¤JÂIºw¡AÀ³¥Ñ¤T¦V¬¡¶ë(three-way stopcock)»P¬Û®e·»²G¥H¤@¤ñ¥|ªº¤ñ¨Ò¤@¦Pµ¹¤©¡C
OCLOP,Clozapine,Clopine 100mg,CNEU,,¾AÀ³¯g¡Gºë¯«¬ì¥ÎÃÄ¡C(A042448100) Treatment-resistant schizophrenic patients. °Æ§@¥Î:Initially drowsiness¡A hypersalivation¡A granulocytopenia & agranulocytosis¡A palpitation¡A fatigue. Dry mouth¡A blurred vision¡A orthostatic hypotension¡A disturbance in temp regulation. Tachycardia¡A ECG changes. Rarely: delirium¡A extrapyramidal reactions. Cardiovascular: Hypotension¡A Tachyarrhythmia (25%) Dermatologic: Rash (2%)¡A Sweating symptom (6%) Endocrine metabolic: Excessive salivation (31% )¡A Weight gain (4%) Gastrointestinal: Constipation (14% )¡A Excessive salivation (31% )¡A Nausea (5% )¡A Xerostomia (6% ) Musculoskeletal: Motor function behavior finding (4%)¡A Muscle rigidity (3%) Neurologic: Akathisia (3%)¡A Confusion (3%)¡A Dizziness (19%)¡A Headache (7%)¡A Insomnia (2%)¡A Somnolence (39%)¡A Tremor (6%)¡A Vertigo (19%) Ophthalmic: Visual disturbance (5%) Psychiatric: Agitation (4%)¡A Dyssomnia¡A Nightmares (4%)¡A Restlessness (4%) Other: Fatigue (2%)¡A Fever (5%) Tachycardia¡A ECG changes. Rarely: delirium¡A extrapyramidal reactions. ¸T§Ò:History of drug-induced granulocytopenia¡A agranulocytosis. Impaired bone marrow function¡A comatose¡A severe hepatic & renal disease.,,«Ç·Å,300-450 mg daily in divided doses. Max: 900 mg daily.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OCOC,Cocaine,Cocaine HCl Powder,ZANE,,,,,,,,,,,,,,,,,,,
OCODI,Codeine,Codeine 30mg,CNEU,Symptomatic relief of mild to moderate severe pain¡A suppress hyperactive or nonproductive cough.,Hypersensitivity to opiates¡A acute respiratory depression¡A acute asthma¡A increased intracranial pressure¡A COPD¡A head injury¡A paralytic ileus¡A acute alcoholism¡A hepatic or renal dysfunction¡A phaeochromocytoma.,Common: Sweating¡A Constipation¡A Nausea¡A Vomiting¡A Dizziness¡A Lightheadedness¡A Sedated¡A Somnolence¡A Dyspnea Serious: Cardiac arrest¡A Disorder of cardiovascular system¡A Circulatory Depression¡A Shock¡A Adrenal insufficiency¡A Pancreatitis¡A Deficiency of testosterone biosynthesis¡A Respiratory arrest¡A Respiratory depression¡A Serotonin syndrome,25¢J¥H¤UÁ×¥ú,Analgesic: Adult 15-60 mg qid. Children and Adolescents: Pain management; analgesia: 0.5-1 mg/kg/dose every 4-6 hours as needed; maximum single dose: 60 mg. Note: Do not use for postoperative tonsillectomy and/or adenoidectomy pain management. Antitussive: Adult Oral: 7.5 to 120 mg/day as a single dose or in divided doses; Note: The American College of Chest Physicians does not recommend the routine use of codeine as an antitussive in patients with upper respiratory infections.,µL»Ý½Õ¾ã¾¯¶q,Initiate with a lower dosage or longer dosing interval and titrate slowly,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,Human Data Suggest Potential Toxicity,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C The FDA is currently investigating the safety of using codeine-containing medicines to treat coughs and colds in children younger than 18 years.
OCODIBAD,Codeine,Codeine 30mg ´Ý¾l¾PÀì,CNEU,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
OCOLC,Colchicine,Colchicine 0.5mg,CNEU,Gout.,Serious GI¡A renal/cardiac disorders¡A blood dyscrasias.,Diarrhea¡A N/V¡A abdominal pain¡A bone marrow depression¡A peripheral neuritis¡A myopathy¡A alopecia¡A rashes¡A reversible azoospermia. Gastrointestinal: Diarrhea (high dose¡A 77%; low-dose¡A 23% )¡A Nausea (high dose¡A 17%; low-dose¡A 4% )¡A Vomiting (17% ),30¢J¥H¤UÁ×¥ú,Not recommended for use in children and adolescents Adults(>16 years old): Prevent gout:0.5mg QD or BID. maximum:1mg/day. Treat gout: Initial dose:1mg¡A take another 0.5 mg one hour later¡A or 0.5mg TID. maximum:1.5mg/day. After the next day¡A 0.5 mg 1-2 times a day until the onset of symptoms is relieved. Repeat courses of treatment should be separated by at least 3 days. For patients who have used the preventive dose¡A if necessary¡A 1 mg colchicine can be used to treat gout attacks¡A and then 0.5 mg one hour later. Wait 12 hours and then resume the preventive dose.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ¯f±w»Ý¦Ò¼{­°§C¾¯¶q (for gout flare: Do not repeat course more than once every 2 weeks),»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCOR,Cortisone,Cortisone acetate 25mg,HM,,,,,,,,,,,,,,,,,,,
OCOUG,Bromhexine,Coughxin 8mg,ERSP,,Tracheobronchitis¡A emphysema with bronchitis¡A pneumoconiosis¡A chronic inflammatory pulmonary conditions¡A bronchiectasis¡A bronchitis with bronchospasm¡A asthma.,,,Adult: 8-16 mg tid-qid. 5-10 yrs: 4mg qid. Under 5 yrs: 4 mg bid.,,,,,,,,,,,,,,
OCOV,Estradiol + Norethisterone,Covina 28tab/pk,HM,,Estrogen deficiency.,,,1 tab qd.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IDPT3,Diphtheria + Tetanus + Pertussis,Adacel (¤T¦X¤@¸É°l¬Ì­]) 0.5mL/dose,HIMM,Active booster immunization for the prevention of tetanus diphtheria & pertussis in children¡A adolescents & adults 4-64 years.,Hypersensitivity. Progressive neurological disorders¡A uncontrolled epilepsy or progressive encephalopathy. Encephalopathy not attributable to identifiable cause. Pregnancy.,Pain¡A swelling¡A erythema at inj site. Tiredness¡A headache¡A fever (> 38¢XC). Axillary lymph node swelling¡A rash¡A body ache or muscle weakness¡A sore or swollen joints. Nausea¡A diarrhea¡A vomiting. Demyelinating CNS diseases¡A peripheral mononeuropathies¡A cranial mononeuropathies & EEG disturbances with encephalopathy (with or without permanent intellectual &/or motor function impairment).,2-8¢JÁ×§K§N­á,IM¡A 0.5mL¡A > or = 4 years as a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]²Ä¤G¡B¤T¥¥´Á¥i¨Ï¥Î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,Up to date: Pregnancy Risk Factor B/C [¥é³æ]±Â¨Å´Á¶¡±µºØªº¼vÅT©|¥¼°µ¹Lµû¦ô¡C,IM;,,,,,
EDUOT,Travoprost + Timolol,Duotrav eye drops 2.5mL,TOPH,Decrease of intraocular pressure in patient with open-angle glaucoma or ocular HTN who are insufficiently responsive to topical £]-blockers or prostaglandin analogues.,Bronchial asthma¡A a history of bronchial asthma or severe COPD. Sinus bradycardia¡A 2nd or 3rd degree AV block¡A overt cardiac failure or cardiogenic shock. Severe allergic rhinitis & bronchial hypersensitivity; corneal dystrophies; hypersensitivity to other £]-blockers. Pregnancy or women who may become pregnant.,Nervousness¡A dizziness¡A headache¡A eye irritation¡A ocular hyperemia¡A punctate keratitis¡A anterior chamber cells¡A anterior chamber flare¡A eye pain¡A photophobia¡A eye swelling¡A conjunctival hemorrhage¡A corneal staining¡A ocular discomfort¡A abnormal sensation in the eye¡A reduced visual acuity¡A visual disturbance¡A blurred vision¡A dry eye¡A eye pruritus¡A allergic conjunctivitis¡A increased lacrimation¡A eyelid irritation¡A eyelid erythema¡A eyelid dermatitis¡A asthenopia¡A growth of eyelashes¡A irregular or decreased heart rate¡A increased or decreased BP¡A bronchospasm¡A urticaria¡A skin hyperpigmentation (periocular)¡A pain in extremity. Neurologic: Foreign body sensation (5%-10%) Ophthalmic: Blepharitis¡A Blurred vision¡A Itching of eye (5%-10%)¡A Ocular hyperemia (35%-50%)¡A Pain in eye¡A Reduced visual acuity,25¢J¥H¤U,Adult including the elderly: 1 drop in the conjunctival sac of the affected eye(s) once daily in the morning or evening. Age <18 years: Not recommend use.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,Travoprost ophthalmic: No Human Data¡XProbably Compatible Timolol ophthalmic: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] Ãh¥¥°ü¤k¨Ï¥ÎDUOTRAVÂI²´²G©Î¹ï¨ä­Ó§O¦¨¤Àªº¸ê®Æ¦³­­¡C °£«D½T¹ê»Ý­n¡A§_«h¤£¥i±NDUOTRAVÂI²´²G¥Î©óÃh¥¥°ü¤k¡C¦ý¬O¦pªGÃh¥¥´Á¶¡«ùÄò§ë¤©DUOTRAVÂI²´²Gª½¨ì¤À®Y®É¡A«h¶·¦b¥X¥Í«áªº«e´X¤ÑÂÔ·VºÊ´ú·s¥Í¨à¡C ¦b¤j¹«©M¤p¹«¾¹©x§Î¦¨´Á¶¡¡A¥Ö¤U(s.c.)µ¹¤©travoprostªº¬ã¨sÅã¥Ü¨ã¦³¥Í´Þ¬r©Ê¡A¨ä¾¯¶q¤À§O¬O®Ú¾ÚÅéªí­±¿n (body surface area¡A BSA) ­pºâ¡A¬Û·í©ó¤HÃþ²´³¡µ¹ÃÄ³Ì°ª¾¯¶q (maximum recommended ocular human dose¡A MROHD) ªº34­¿©M1.7­¿¡C¤fªAtimololªº¤p¹«¡B¤j¹«©M¨ß¤lªº¥Í´Þ¬ã¨sÅã¥Ü¡A®Ú¾ÚÅéªí­±¿n­pºâ¡A°ª¹F¤HÃþ²´³¡µ¹ÃÄ³Ì°ª¾¯¶qªº675­¿®É¡A¨Ã¥¼µo¥Í·î§Î¡C ¬y¦æ¯f¾Ç¬ã¨s©|¥¼µo²{¦³­P·î­Lªº§@¥Î¡A¦ýÅã¥Ü·í¥H¤fªA¤A«¬ªýÂ_¾¯®É¡A«h¦³¤l®c¤ºµo¨|¿ð½wªº­·ÀI¡C¦¹¥~¡A·í¥¥°üª½¦Ü¤À®Y®É¤´¨Ï¥Î¤A«¬ªýÂ_¾¯¡A¥i¦b·s¥Í¨àÆ[¹î¨ì¤A«¬ªýÂ_¾¯ªº¼x¥ü©M¯gª¬¡]¦p¤ß·i¹L½w¡B§C¦åÀ£¡B©I§lµ~­¢¤Î§C¦å¿}¡^¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Travoprost ophthalmic: No Human Data¡XProbably Compatible Timolol ophthalmic: Limited Human Data¡XProbably Compatible [¥é³æ] ¤£«ØÄ³±NDUOTRAVÂI²´²G¥Î©ó­÷¨Å°ü¤k¡C­÷¨Å°ü¤k¨Ï¥ÎDUOTRAVÂI²´²Gªº¸ê®Æ¦³­­¡C²´³¡§½³¡µ¹ÃÄ«á¡ATimolol·|Âà²¾¦Ü¤HÃþ¨Å¥Ä¤¤¡C¤fªA¤A«¬ªýÂ_¾¯¦³¥i¯à¦b¥À¨Å­÷ÁýªºÀ¦¨à¤¤¤Þ°_ÄY­«ªº¤£¨}¤ÏÀ³¡C¦ý¬O¡A¦b²´³¡µ¹¤©ªvÀø¾¯¶qªº±¡ªp¤U¡A¥À¨Å¤¤¦s¦³timololªº¶q¤£¤Ó¥i¯à¦bÀ¦¨à¤¤²£¥Í¤A«¬ªýÂ_ªºÁ{§É¯gª¬¡C ¥Ø«e¤´¥¼ª¾²´³¡µ¹¤©travoprost«á¬O§_·|Âà²¾¦Ü¤HÃþ¨Å¥Ä¤¤¡C¤@¶µ°Êª«¬ã¨sÅã¥Ü¡A¥Ö¤Uµ¹ÃÄ«átravoprost©M/©Î¥NÁÂª«·|Âà²¾¦Ü¨Å¥Ä¤¤¡C,OD;OL;OU;,,,,,
LCEN,Theophylline,Centertheo 60mL (5.34mg/mL) liquid,ERSP,Treatment of reversible airways obstruction associated with asthma¡A chronic bronchitis & related conditions,Allergy to theophylline¡A aminophylline or other xanthines.,GI disturbances¡A nervousness¡A headache¡A palpitations¡A insomnia¡A agitation¡A tachycardia¡A CNS stimulation,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Theophylline 5.34mg/ml Adult 200-250 mg Children 6-12 years 125-250 mg. To be taken every 6 hr.,»Ý½Õ¾ã¾¯¶q,Oral: There are no specific dosage adjustments provided in manufacturer's labeling. Dose reduction and frequent monitoring of serum theophylline concentration are required; risk of severe and potentially fatal toxicity may occur. Maximum dose: 400 mg/day,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OIMI5,Sumatriptan,Imigran FDT 50mg,CNEU,Acute relief of migraine attacks with or without aura.,Previous MI¡A ischaemic heart disease (IHD)¡A Prinzmetal's angina/coronary vasospasm¡A peripheral vascular disease or patients who have symptoms or signs consistent with IHD; history of previous CVA or transient ischaemic attack (TIA); uncontrolled HTN; severe hepatic impairment. Concomitant use of ergotamine or its derivatives (including methysergide)¡A MAOIs or use within 2 wk of MAOI therapy.,Tingling¡A dizziness¡A drowsiness; transient increase in BP¡A flushing¡A nausea & vomiting; sensations of heaviness¡A heat¡A pressure or tightness; pain¡A feelings of weakness¡A fatigue.,30¢J¥H¤U°®Àê³B,Migraine¡A acute:Adult: 50-100 mg as single dose. Further doses at 2 hours interval may be given in the next 24 hours. Maximum: 300 mg/24 hours.,»Ý½Õ¾ã¾¯¶q,»´«×¨ì¤¤«×¨x¥\¯à¤£¥þ¯f±w«ØÄ³ MAX single dose 50 mg orally,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³t·»¿õ¡A¥é³æ«ØÄ³¶·¾ã²É¥H¤ô§]ªA¡A¤£­n©CÄZ¡C
OSUZ,Flunarizine,Suzin 5mg,CAVS,Prophylaxis of migraine¡A maintenance treatment of cerebral circulation disorders.,Hypersensitivity to flunarizine or any component of the formulation; history of depression; preexisting symptoms of Parkinson disease¡A or other extrapyramidal disorders.,Occasionally¡A transient fatigue & somnolence; weight gain. Exceptionally¡A depression or extrapyramidal reactions.,25¢J¥H¤UÁ×¥ú,5-10 mg once daily in the evening (at bedtime),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OGES,Gestrinone,Gestrin 2.5mg (8 capsules/box),HM,Endometriosis.,Pregnancy¡A lactation; cardiac¡A renal or hepatic diseases. Experience adverse reactions during previous hormonal therapy,Menstrual disturbances. Acne¡A oily skin¡A fluid retention¡A wt gain¡A hirsutism¡A voice change¡A headache¡A GI disturbances¡A altered libido¡A hot flushes¡A breast size reduction¡A nervousness¡A change in appetite¡A muscle cramp¡A depression¡A arthralgia¡A isolated cases of benign intracranial hypertension.,25¢J¥H¤U±K«ÊÁ×¥ú,2 capsule every week. First capsule must be taken on day 1 of the menstrual cycle¡A 2nd dose after 3 days. From then¡A take on the same 2 days per week.,µL»Ý½Õ¾ã¾¯¶q,±w¦³¨xÅ¦¯e¯f±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OELT1,Levothyroxine,100mcg ELTROXIN,META,,¾AÀ³¯g: Hypothyroidism. °Æ§@¥Î: Following excessive dosage: Anginal pain¡A cardiac arrhythmias¡A palpitation & cramps in skeletal muscle¡A tachycardia¡A diarrhoea¡A vomiting¡A tremors¡A restlessness¡A excitability¡A insomnia¡A headache¡A flushing¡A sweating¡A excessive weight loss & muscular weakness ¸T§Ò: Thyrotoxicosis.,,«Ç·Å,Adult Initially 50-100 mcg daily¡A adjusted 3-4 weekly by 50 mcg until normal metabolism is maintained. This may require doses of 100-200 mcg daily. Adult >50 yr <50 mcg/day¡A with cardiac disease 25 mcg/day or 50 mcg on alternate days. This may be increased by 25 mcg at intervals of 4 week. Congenital hypothyroidism Infant Initially 25 mcg¡A increase by 25 mcg 2-4 weekly until mild toxic symptoms appear. Juvenile myxoedema Children >1 yr 2.5-5 mcg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;PO;,,,,,
OFLUV,Fluvoxamine,Fluvoxin 50mg,CNEU,,¾AÀ³¯g: Treatment of symptoms of depressive illness. Obsessive compulsive disorder in children & adolescents. °Æ§@¥Î: Nausea¡A vomiting¡A asthenia¡A headache¡A malaise¡A palpitations/tachycardia¡A abdominal pain¡A anorexia¡A constipation¡A diarrhoea¡A dry mouth¡A dyspepsia¡A agitation¡A anxiety¡A dizziness¡A insomnia¡A nervousness¡A somnolence¡A tremor¡A sweating¡A (postural) hypotension¡A arthralgia¡A myalgia¡A ataxia¡A confusion¡A extrapyramidal symptoms¡A hallucinations¡A abnormal (delayed) ejaculation¡A cutaneous hypersensitivity reactions (including rash¡A pruritus¡A angioedema)¡A liver dysfunction¡A convulsions¡A mania¡A galactorrhoea¡A photosensitivity¡A weight gain/loss¡A serotonin syndrome¡A neuroleptic malignant syndrome-like events¡A hyponatremia & SIADH¡A withdrawal reactions¡A haemorrhage¡A paresthesia¡A anorgasmy & taste perversion. Dermatologic: Sweating (immediate-release¡A 7%; extended-release (social anxiety disorder)¡A 6%; extended-release (obsessive-compulsive disorder)¡A 7% ) Gastrointestinal: Diarrhea (immediate-release¡A 11%; extended-release (social anxiety disorder)¡A 14%; extended-release (obsessive-compulsive disorder)¡A 18% )¡A Indigestion (immediate-release¡A 10%; extended-release (social anxiety disorder)¡A 10%; extended-release (obsessive-compulsive disorder)¡A 8% )¡A Loss of appetite (immediate-release¡A 6%; extended-release (social anxiety disorder)¡A 14%; extended-release (obsessive-compulsive disorder)¡A 13% )¡A Nausea (immediate-release¡A 40%; extended-release (social anxiety disorder)¡A 39%; extended-release (obsessive-compulsive disorder)¡A 34% )¡A Xerostomia (immediate-release¡A 14%; extended-release (social anxiety disorder)¡A 11%; extended-release (obsessive-compulsive disorder)¡A 10% ) Neurologic: Asthenia (immediate-release¡A 14%; extended-release (social anxiety disorder)¡A 24%; extended-release (obsessive-compulsive disorder)¡A 26% )¡A Dizziness (immediate-release¡A 11%; extended-release (social anxiety disorder)¡A 15%; extended-release (obsessive-compulsive disorder)¡A 12% )¡A Insomnia (immediate-release¡A 21%; extended-release (social anxiety disorder)¡A 32%; extended-release (obsessive-compulsive disorder)¡A 35% )¡A Somnolence (immediate-release¡A 22%; extended-release (social anxiety disorder)¡A 26%; extended-release (obsessive-compulsive disorder)¡A 27% )¡A Tremor (immediate-release¡A 5%; extended-release (social anxiety disorder)¡A 8%; extended-release (obsessive-compulsive disorder)¡A 6% ) Psychiatric: Agitation (immediate-release¡A 2%; extended-release (social anxiety disorder)¡A 3%; extended-release (obsessive-compulsive disorder)¡A 2% )¡A Anxiety (immediate-release¡A 5%; extended-release (social anxiety disorder)¡A 8%; extended-release (obsessive-compulsive disorder)¡A 6% )¡A Feeling nervous (immediate-release¡A 12%; extended-release (social anxiety disorder)¡A 10% ) Reproductive: Abnormal ejaculation (immediate-release¡A 8%; extended-release (social anxiety disorder)¡A 11%; extended-release (obsessive-compulsive disorder)¡A 10% )¡A Orgasm incapacity (immediate-release¡A 2%; extended-release¡A 5% ),,«Ç·Å,May be taken with or without food 100-200 mg daily. Max: 300 mg daily. The minimum recommended starting dose is 100 mg/day and can be given as a single dose; preferably in the evening.It is advisable that a total daily dose over 150 mg be given in 2 or 3 divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IVAX9,Purified Split Inactivated Influenza Virus,§K¶O¤p¨à¬y·P¬Ì­](4~10·³),HIMM,,I: Prophylaxis against influenza. ADR: Erythema (rash)¡A swelling¡A pain¡A ecchymosis¡A induration¡A fever¡A dizziness¡A shivering¡A tiredness¡A headaches¡A sweating¡A muscle pain¡A joint pains. CI: Allergy to eggs¡A chicken protein or any constituents of the vaccine. Febrile illness or acute infection.,,2 ~ 8 ¢XC,¥»¾¯¬°¦¨¤H¾¯«¬¡A­Y¥Î©ó¤p¨à¾¯¶q»Ý´î¥b Adult & Children >= 36 mth 0.5ml IV or deep SC. Chidren <= 8 yr who have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
LFERH,Ferric Hydroxide Polymaltose Complex,Ferrum hausmann 50mg/20drops/mL 30mL,NUTR,Treatment of latent Fe deficiency & Fe deficiency anaemia (manifest iron deficiency). Prophylactic therapy of Fe deficiency during pregnancy,Fe overload (eg haemochromatosis¡A hemosiderosis) or disturbances in Fe utilisation (eg lead anaemia¡A sideroachrestic anaemia¡A thalassaemia) & anaemia not caused by Fe deficiency (eg haemolytic anaemia).,GI irritations such as a sensation of repletion¡A pressure in the epigastric region¡A nausea¡A constipation or diarrhoea.,30¢J¥H¤UÁ×§K·Ó¥ú,1 mL = 20 drops = 50 mg Iron as Iron(lll)-Hydroxide polymaltose complex. Iron deficiency anemia Pregnant women: 80-120 drops daily with meal. Adult & children > 12 years: 40-120 drops daily with meal. Children 1-12 years: 20-40 drops daily with meal. Infants < 1 year: 10-20 drops daily with meal. Premature infants: 1-2 drops/kg of body weight/day with meal. Iron deficiency Pregnant women: 40 drops daily with meal. Adult and children > 12 years: 20-40 drops daily with meal. Children 1-12 years: 10-20 drops daily with meal. Infants < 1 year: 6-10 drops daily with meal.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
LPEC,Kaolin + Pectin,Pecolin 200/10 mg/mL¡A 120mL suspension,ALIM,,¾AÀ³¯g: Diarrhea. °Æ§@¥Î: Constipation. ¸T§Ò: Intestinal obstruction.,,«Ç·Å,Adult 30 mL qid¡A Children > 6 years 15 mL qid¡A 2-5 years 7.5 mL qid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;PO;,,,,,
LSUR,Beractant,Survanta 25mg/mL¡A 8mL,ERSP,Prevention & treatment of respiratory distress syndrome in premature infants.,Hypersensitivity to any component of the formulation.,Transient bradycardia. O2 desaturation.,2-8¢J»ÝÁ×¥ú,4 mL/kg (100 mg phospholipids/kg) as soon as possible after birth¡A preferably within 15 minutes; as many as 4 doses may be administered during the first 48 hours of life¡A no more frequently than 6 hours apart. following is the recommended doses according body weight: 600-650g: 2.6mL¡A 651-700g: 2.8mL¡A 701-750g: 3.0mL¡A 751-800g: 3.2mL¡A 801-850g: 3.4mL¡A 851-900g: 3.6mL¡A 901-950g: 3.8mL¡A 951-1000g: 4.0mL¡A 1001-1050g: 4.2mL¡A 1051-1100g: 4.4mL¡A 1101-1150g: 4.6mL¡A 1151-1200g: 4.8mL¡A 1201-1250g: 5.0mL¡A 1251-1300g: 5.2mL¡A 1301-1350g: 5.4mL¡A 1351-1400g: 5.6mL¡A 1401-1450g: 5.8mL¡A 1451-1500g: 6.0mL¡A 1501-1550g: 6.2mL¡A 1551-1600g: 6.4mL¡A 1601-1650g: 6.6mL¡A 1651-1700g: 6.8mL¡A 1701-1750g: 7.0mL¡A 1751-1800g: 7.2mL¡A 1801-1850g: 7.4mL¡A 1851-1900g: 7.6mL¡A 1901-1950g: 7.8mL¡A 1951-2000g: 8.0mL.,»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,INHL;,,,,,
ECER,Sod Bicarbonate + Glycerin,Cerum water 4%/20%¡A 20mL,TENT,To soften earwax,Hypersensitivity to any component of the formulation.,Local irritation,,Ear Drop: 3-4 drops twice a day for 5 days for each affected ear to soften dry or hardened earwax.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AD;AS;AU;,,,,,
OART2,Trihexyphenidyl,Artane 2mg,CNEU,,¾AÀ³¯g: Parkinsonism. °Æ§@¥Î: GI disturbances; glaucoma¡A mydriasis; urinary retention¡A mental disturbances¡A excitement. ¸T§Ò: Closed-angle glaucoma¡A paralytic ileus¡A prostatic hypertrophy.,,«Ç·Å,1-2 mg the first day¡A the dosage being increased by an additional 2 mg at 3-4days intervals until the desired response is obtained or until the dose reaches 10-15 mg/day¡A usually in 3-4 doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OASA,Mesalazine,Asacol 400mg,ALIM,,¾AÀ³¯g:¥Dªv¼ìºÅ©Êµ²¸zª¢(B017428100)(B023232100) Tab: Treatment & maintenance of remission of ulcerative colitis. Supp: Ulcerative colitis¡A mild to moderate proctitis¡A proctosigmoiditis. °Æ§@¥Î:Nausea¡A diarrhea¡A abdominal pain¡A headache¡A exacerbation of symptoms of colitis; rarely¡A blood disorders¡A pancreatitis¡A hepatitis. Gastrointestinal: Diarrhea (up to 8% )¡A Flatulence (0.7% to 4% )¡A Nausea (2.8% to 4% )¡A Upper abdominal pain (5%) Neurologic: Headache (3.4% to 11% ) Respiratory: Nasopharyngitis (1.4% to 4% ) ¸T§Ò: Infant <2 years. Severe renal impairment.,,«Ç·Å,1-2 tab tid.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OPRA,Multivitamins + Minerals,Pramet F.A 30's/bot,NUTR,,¾AÀ³¯g: Nutritional supplement for vit & mineral deficiency. °Æ§@¥Î: Hypersensitivity reactions reported with folic acid.,,«Ç·Å,1 Tab daily,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OPRED,Prednisolone,Prednisolone 5mg,HM,,¾AÀ³¯g: RA¡A lupus erythematosus¡A periarthritis nodosum¡A allergic & inflammatory skin disorders. °Æ§@¥Î: Fluid & salt retention¡A edema¡A hypertension; amenorrhea¡A hyperhidrosis¡A mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; local atrophy; increased appetite; growth retardation. ¸T§Ò: Peptic ulcer¡A osteoporosis¡A psychoses or severe neuropsychosis; active or doubtfully quiescent TB; acute infection; live vaccines.,,«Ç·Å,Allergic and inflammatory disorders 5-60 mg/day¡A in 2-4 divided doses. Rheumatoid arthritis Initial: 5-7.5 mg/day¡A adjust dose if needed. Multiple sclerosis 200 mg/day for 1 wk¡A then 80 mg every other day for 1 mth.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OPREM,Estrogen + Medroxyprogesterone,Premelle 2.5¡A 28's/pk,HM,,¾AÀ³¯g: Moderate-to-severe vasomotor symptoms associated with estrogen deficiency. Prevention & treatment osteoporosis associated with estrogen deficiency. Atrophic vaginitis & atrophic urethritis. °Æ§@¥Î: Increased risk of breast cancer¡A gallbladder disease¡A thrombophlebitis &/or thromboembolic disease. Increase in BP¡A fluid retention¡A changes in glucose tolerance¡A vag bleeding¡A breast pain¡A tenderness & enlargement. GI effects¡A alopecia¡A rash¡A hirsutism¡A pruritus¡A visual disturbances¡A headache¡A nervousness. ¸T§Ò: Known or suspected cancer of the breast¡A estrogen-dependent neoplasia¡A pregnancy. Undiagnosed abnormal genital bleeding. Active thrombophlebitis or thromboembolic disorders. Liver dysfunction or disease.,,«Ç·Å,1 tab qd.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OPRIN,Norethisterone,Primolut-Nor 5mg,HM,,¾AÀ³¯g: Dysfunctional bleeding¡A primary & secondary amenorrhea¡A premenstrual syndrome¡A mastopathy¡A timing of menstruation¡A endometriosis¡A progressive breast carcinoma. °Æ§@¥Î: Rarely¡A nausea. ¸T§Ò: Pregnancy; severe liver dysfunction; Dubin-Johnson syndrome & Rotor syndrome; previous or existing liver tumors; history of jaundice or severe pruritus during pregnancy¡A history of herpes of pregnancy; thromboembolic processes.,,«Ç·Å,Dysfunctional bleeding 5 mg/day for 10 day. Primary & secondary amenorrhea Estrogen first¡A then 1 tab bid from day 19-26 of the cycle. Premenstrual syndrome & mastopathy 1 tab qd-bid from day 19-26 of the cycle. Endometriosis 1 tab bid from day 5 of the cycle. Duration: 4-6 months.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OPRIP,Metoclopramide,Primperan 5mg,ALIM,Prevention of nausea & vomiting¡A GERD & diabetic gastroparesis.,GI hemorrhage¡A mechanical obstruction or digestive perforation; Pheochromocytoma; previous history of tardive dyskinesia with neuroleptics. Epilepsy.,Syndrome malin. Occasionally GI disturbances¡A headache¡A lightheadedness¡A drowsiness. Rarely¡A endocrinal disorders eg. amenorrhea¡A hyperprolactinemia¡A gynecomastia in males¡A breast enlargement in women; extrapyrimidal symptoms¡A hypotension¡A tachycardia¡A arrhythmia. Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )¡A Vomiting (1.4% to 2.1% ) Neurologic: Asthenia (10% )¡A Headache (4.2% to 5.2% .)¡A Somnolence (oral¡A 2.1% to 10%; IV¡A 70%) Other: Fatigue (2.1% to 2.8% ),25¢J¥H¤U,Adult: 10-30 mg daily in 2-3 divided doses¡A AC.,»Ý½Õ¾ã¾¯¶q,¤¤«×©Î­««×¨x¥\¯à¤£¥þ(Child-Pugh B or C)¯f±w ¥Î¨ÓªvÀøGERD¡A«ØÄ³³Ì°ªÁ`¾¯¶q30 mg/day ¥Î¨ÓªvÀødiabetic gastroparesis¡A«ØÄ³³Ì°ªÁ`¾¯¶q20 mg/day,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OCOZ,Losartan,Cozaar 50mg,CAVS,,Hypertension,,,Initial & maintence dose : 50 mg once daily. May increase to 100mg once daily.,,,,,,,,,,,,,,
IKAN,Kanamycin,Kanamycin 1g inj (¬F©²´£¨Ñ),QANB,,¾AÀ³¯g: Susceptible infections. °Æ§@¥Î: Pain¡A inflammation¡A bruising¡A haematoma at inj site; GI disturbances; malabsorption of fat. ¸T§Ò: Hypersensitivity.,,«Ç·Å,IV/IM Susceptible infections 15 mg/kg/day. Max: 1.5 g/day in 2-4 divided doses. Max cumulative dose: 10 g. IM Penicillin-resistant gonorrhoea 2 g as a single dose. Irrigation Irrigation of body cavities As 0.25% soln: Instill into abscess cavities¡A pleural space¡A or peritoneal or ventricular cavities as directed. Intraperitoneal Peritonitis or peritoneal contamination during surgery Instill 500 mg into the peritoneal cavity. Inhalation Susceptible infections 250 mg 2-4 times/day.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OGIN9,Ginkgo Biloba,Gincare 9.6mg film coated,CAVS,Peripheral circulatory disorders,Caution should be exercised with ginkgo in patients with bleeding disorders or those who take anticoagulant drugs.,GI disturbance¡A headache¡A skin rash¡A dizzy¡A palpitation.,25¢J¥H¤UÁ×¥ú,1 TAB TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¥»ÃÄ«~¨Ï¥Î©ó¥¥°ü¡B±Â¨Å°ü¤§¦w¥þ©Ê©|¥¼½T¥ß¡A¦]¦¹¹ï¥¥°ü¤Î¥i¯àÃh¥¥ªº°ü¤k»P±Â¨Å°ü¦b¨Ï¥Î¤§«e©y¥ýÅv¿ÅªvÀø¤§¥²­n©Ê¤è©l§ë»P¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥»ÃÄ«~¨Ï¥Î©ó¥¥°ü¡B±Â¨Å°ü¤§¦w¥þ©Ê©|¥¼½T¥ß¡A¦]¦¹¹ï¥¥°ü¤Î¥i¯àÃh¥¥ªº°ü¤k»P±Â¨Å°ü¦b¨Ï¥Î¤§«e©y¥ýÅv¿ÅªvÀø¤§¥²­n©Ê¤è©l§ë»P¡C,AC;AC15;PC;PO;WM;,,,,,
EREL,Zanamivir,Relenza inhalation 5mg/dose (¬F©²´£¨Ñ),QANB,Treatment of influenza A and B in adults and children >=5 year.,Hypersensitivity to any of the ingredients of Relenza.,Common: Cough (influenza prophylaxis in pediatric patients¡A 16%)¡A Nasal symptom (influenza prophylaxis in pediatric patients¡A 20%)¡A Pain in throat (influenza prophylaxis in pediatric patients¡A 11%)¡A Respiratory depression¡A Fever with chills (influenza prophylaxis¡A 5%) Serious: Cardiac dysrhythmia¡A Rash¡A Anaphylaxis¡A Hypersensitivity reaction¡A Seizure¡A Abnormal behavior¡A Delirium¡A Bronchospasm¡A Edema of pharynx,30¢J¥H¤U,(¥é³æ+¼ö¯f) Zanamivir is used for treatment of influenza A or B in patients age > or = 7 years or for prophylaxis in patients age > or = 5 years. Treatment: 2 oral inhalations (10 mg) twice daily for 5 days; therapy should begin within 48 hours from onset of signs or symptoms. Prophylaxis: 2 oral inhalations (10 mg) once daily for 10 days or up to 28 days.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;INHL;,,,,,
HE5004,Dianeal 1500cc 4.25% (PD 2 Âù³U),Dianeal 1500mL 4.25% (PD 2 Âù³U),NUTR,,,,,Select mode of therapy¡A frequency of treatment¡A formulation¡A fill volume¡A duration of dwell¡A and length of dialysis based on the patient¡¦s clinical condition¡A fluid¡A electrolyte and specific needs. The fill volume depends on body size¡A usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5010,Dianeal 2000cc 1.5% (PD 2Âù³U),Dianeal 2000mL 1.5% (PD 2Âù³U),NUTR,,,,,Select mode of therapy¡A frequency of treatment¡A formulation¡A fill volume¡A duration of dwell¡A and length of dialysis based on the patient¡¦s clinical condition¡A fluid¡A electrolyte and specific needs. The fill volume depends on body size¡A usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5011,Dianeal 2L 1.5% (PD 4 Âù³U),Dianeal 2L 1.5% (PD 4 Âù³U),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
IALB,Albumin,Albumin 25% 50mL(Albutein),HEMT,,¾AÀ³¯g: Hypovolemic shock¡A conditions when there is severe hypoalbuminemia¡A as an adjunct in hemodialysis & in cardiopulmonary bypass procedures. In conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia. °Æ§@¥Î: Allergic reactions¡A nausea¡A vomiting¡A increased salivation¡A fever and chills; vascular overload¡A haemodilution and pulmonary oedema. Potentially Fatal: Anaphylactic shock. ¸T§Ò:Cardiac failure¡A severe anaemia¡A history of hypersensitivity¡A parenteral nutrition.,,,Adult: IV Acute hypovolaemic shock Initial: 25 g¡A adjust according to response. Usual rate: Up to 5 mL/min using 5% soln. Hypoproteinaemia Up to 2 g/kg/day. Usual rate: Up to 5 mL/min using 5% soln.,µL»Ý½Õ¾ã¾¯¶q,There are no dosing adjustments provided in the manufacturer's labeling; use with caution.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,1.¦pªG¬O¥Î©óªvÀø¦³ÄY­«¦å¶q´î¤Öªº¥ð§J¯f¤H®É¡AÀ³¾¨¥i¯à¦a±Ä°ª¬y³t¨Ï¥Î¡C 2.¹ï©ó¦å¶q¥¿±`©Îµy´îªº¯f¤H¡A¿éª`³t²v¬ù¬° 1 mL/min¡C 3.¿éª`³t²v¹L§Ö·|³y¦¨ªÍ¤ô¸~±¡§Î¡A¶·ª`·N¯f¤HÀR¯ßÀ£¬O§_¤É°ª,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
ICEFA,Cefazolin,Cefazolin inj 1gm,QANB,,¾AÀ³¯g: Susceptible infections¡A Surgical prophylaxis. °Æ§@¥Î: Superinfection; nausea¡A vomiting¡A abdominal pain¡A anorexia¡A diarrhoea; rash¡A leukopenia¡A thrombocytopaenia¡A haemorrhage¡A elevated transaminases. ¸T§Ò: Hypersensitivity.,,«Ç·Å,Adult: IV/IM Susceptible infections 0.5-1 g 6-12 hrly. Max: 6 g/day¡A up to 12 g/day in severe infections. Surgical prophylaxis 1 g 30-60 mins pre-op¡A followed by 0.5-1 g during surgery for lengthy procedures. Continue w/ 0.5-1 g 6-8 hrly post-op for 24 hr. Children: (1 month of age and older): 25-50 mg/kg/day IV/IM divided into 3 or 4 equal doses¡A depending on severity of infection; dose may be increased to 100 mg/kg/day for severe infections.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,,,,,,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡BPT­È¡C 2. ª`·N¬O§_µo¥Í§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 3. (IM) 1gm/vial °®¯»¥[¤J2.5 mL D/W ªw»s¡C 4. (IV bolus) 1gm/vial °®¯»¥[¤J2.5 mL D/W ªw»s¡A¦A¥[¤J5 mLµ}ÄÀ²G¡A½wºC±Àª`¦Ü¤Ö3 ~ 5¤ÀÄÁ¡C
IKAB,Glucose + Amino Acid + lipid,Kabiven PI inj 1440mL,NUTR,,,,,,,,,,,,,,,,,,,
OINV6,Paliperidone,INVEGA ER 6mg (Á{§É¸ÕÅç¥Î),CNEU,,Indication: schizophrenia. Contraindication: Hypersensitivity to paliperidone or risperidone.,,«Ç·Å,3-12 mg daily¡A max. dose: 12mg / day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ONAV2,Vinorelbine,Navelbine 20mg (Á{±Ä),RACA,Non-small cell lung cancer. Metastatic breast cancer.,Disease significantly affecting absorption; previous significant surgical resection of stomach or small bowel. Severe hepatic impairment; pregnancy & lactation; patients requiring long-term O2 therapy. Coadministration with meningocococal conjugate vaccine or other live virus vaccines¡A phenytoin & itraconazole. Pretreatment granulocyte counts <1000/mm3,Neutropenia¡A anemia¡A thrombocytopenia; nausea & vomiting¡A diarrhea¡A anorexia¡A stomatitis¡A esophagitis; loss of tendon reflexes¡A neuromotor disorders¡A neuroconstipation (rarely progressing to paralytic ileus); alopecia; fatigue¡A fever¡A arthralgia including jaw pain¡A myalgia¡A pain including pain at tumor site. Vial Ischemic cardiac disease (rare)¡A abnormal liver function tests¡A dyspnea¡A bronchospasm¡A generalized cutaneous reactions (rare).,2-8¢J,As a single agent¡A first three administrations: 60 mg/m2 once weekly. Beyond the third administration¡A it is recommended to increase the dose to 80mg/m2 once weekly except in those patients for whom the neutrophil count dropped once < 500/mm3 or 500-1000/mm3 during the first three administrations at 60mg/m2,»Ý½Õ¾ã¾¯¶q,»´«×¨x¥\¯à¤£¥þ±wªÌ(Áx¬õ¯À<1.5­¿¡A¥BALAT ©Î/©M ASAT ¬°1.5¦Ü2.5­¿ULN):¨C©P¥iµ¹¤©60mg/m^2 ¼Ð·Ç¾¯¶q ¤¤«×¨x¥\¯à¤£¥þ±wªÌ(Áx¬õ¯À¬°1.5 ~ 3 ­¿¡A¥BµL½×ALAT ©M ASAT ¼Æ­È¬°¦ó):¨C©PÀ³µ¹50mg/m^2¼Ð·Ç¾¯¶q ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦Ån»Ý¥H¤ô¾ãÁû§]ªA¡C
ISEV,Sulfamethoxazole + Trimethoprim,Sevatrim inj(400mg+80mg),QANB,Infections of respiratory tract¡A GIT due to gm+ve & gm-ve bacteria.,Liver parenchymal damage¡A blood dyscrasias; severe renal insufficiency. Pregnancy¡A lactation. Porphyria.,Allergic skin reactions; hallucinations¡A depression¡A apathy¡A nervousness. Arthralgia¡A myalgia. Neurologic reactions.,25¢J¥H¤U,Trimethoprim-sulfamethoxazole (TMP-SMX)Adult and children > 12 years: 160/800-240/1200 mg (10-15 mL) twice daily. Children (6-12 years): 80/400 mg (5 mL) twice daily. Children (6 months-6 years): 40/200 mg (2.5 mL) twice daily. Children (6 weeks-5 months): 20/100 mg (1.25 mL) twice daily. Pediatric dose is calculated based on TPM 6 mg/kg/day and SMX 30 mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,¸T§Ò©ó¨xÅ¦¹ê½è¶Ë®`ªº¯f¤H¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Trimethoprim:Human and Animal Data Suggest Risk Sulfamethoxazole(Sulfonamides):Human Data Suggest Risk in 3rd Trimester,Unknown ¨S¦³¸ê®Æ,Trimethoprim:Compatible Sulfamethoxazole(Sulfonamides):Limited Human Data¡XPotential Toxicity,IVD;,,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,
OINV3,Paliperidone,Invega ER 3mg (Á{§É¸ÕÅç¥Î),CNEU,,Indication: schizophrenia. Contraindication: Hypersensitivity to paliperidone or risperidone.,,«Ç·Å,3-12 mg daily¡A max. dose: 12mg / day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ROHER,·íÂk/¤tË|/¨¢ÃÄ/¼ô¦a¶À/¥ÌÓi»Ä¨ÈÅK,Herbiron 50ml/bot(Á{§É¸ÕÅç),NUTR,,,,,,,,,,,,,,,,,,,
OAMT,Amlodipine + Benazepril,AmTrel 5/10mg,CAVS,Hypertension,Concomitant use with aliskiren in patients with diabetes mellitus. Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2),Cough¡A edema¡A headache¡A dizziness. Other effects include angioedema¡A asthenia & fatigue; Insomnia¡A nervousness¡A anxiety¡A tremor & decreased libido; flushing¡A hot flashes¡A rash¡A skin nodule¡A & dermatitis; GI disturbances; hypokalemia; musculoskeletal pain & cramps; pharyngitis; impotence¡A polyuria. Cardiovascular: Edema Neurologic: Dizziness¡A Headache Respiratory: Cough (3.3%),25¢J¥H¤UÁ×¥ú,HTN Initial: 1 tablet QD¡A amlodipine 2.5-10 mg daily¡A benazepril 10-80 mg daily.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªº¯f¤H·|±Æ°£¥b°I´Á·|©µªø¡AªA¥Î¾¯¶q»Ý½Õ¾ã¨ÃÂÔ·V¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 2nd and 3 rd trimesters,Amlodipine: Human Data Suggest Low Risk Benazepril: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] Ãh¥¥¤ÀÃþC(²Ä¤@´Á)¤ÎD(²Ä¤G¤Î¤T´Á),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Amlodipine: Compatible Benazepril: No Human Data¡XProbably Compatible [¥é³æ] ¥HbenazeprilªvÀø¤§±Â¨Å°ü¡A¶È·¥¤Ö¶qªº benazepril©Mbenazeprilat·|±q¨Å¥Ä¤Àªc¡A¦]¦¹­Y·s¥Í¨à¶È­¹¥Î¥À¨Å¡A¥u·|±µ¨ü¨ì¤Ö©ó¥À¿Ë±µ¨ü¾¯¶qªº0.1%¡C ¥Ø«e¨Ã¤£²M·¡¬O§_amlodipine·|±q¤HÅé¨Å¥Ä¤Àªc¡A¦]¦¹«ØÄ³·í±Â¨Å°ü»Ý±µ¨ü¥»«~ªvÀø®É¡AÀ³°±¤î­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
ICLEX,Enoxaparin,Clexane inj 60mg/0.6mL,HEMT,Prophylactic treatment of venous thromboembolic disease¡A particularly in orthopaedic & general surgery. Treatment of established DVT. Unstable angina¡A Non-Q-wave myocardial infarction.,History of thrombocytopenia during enoxaparin therapy. Hemorrhagic tendencies¡A organic lesion with tendency to bleed¡A major blood clotting disorder. Acute infectious endocarditis¡A hemorrhagic stroke syndrome¡A acute GI ulcer.,Hemorrhagic symptoms¡A thrombocytopenia (rare)¡A hematomas & skin necrosis at inj site; skin allergies or systemic allergic reactions. Gastrointestinal: Diarrhea (2.2% )¡A Nausea (2.5% to 3% ) Hematologic: Anemia (up to 16% )¡A Bleeding¡A Major (up to 4% )¡A Thrombocytopenia (less than 3% ) Hepatic: Increased liver function test (5.9% to 6.1% ) Other: Fever (up to 8% ),«Ç·Å25¢J¥H¤U,For non-severe symptom DVT¡A SC 100 IU/kg twice daily¡A for less than 10 days. For unstable angina/ non-Q-wave MI¡A SC 100 IU/kg twice daily¡A for 2-8 days until stable¡A combination with aspirin (loading dose160mg then 75~325mg) could be considerated. For elevated ST-wave AMI¡A (only for patient < 75 years old¡A Clcr >60 mL/min) IV 3000 IU and SC 100 IU/kg within 15 minutes¡A then SC every 12 hours for 8 days or discharge. (stay at hospital less then 8 days)¡A combined with aspirin 75-325mg. The total dose of two initial injection should be less than 10000 IU. If patient > 75 years old ¡A SC 75 IU/kg every 12 hours¡A (first 2 doses can't exceed 7500IU.),»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling (has not been studied); use with caution.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVP;IVPUSH;SC;,,,ST-ªi¬q¤É°ªªº«æ©Ê¤ß¦Ù±ð¶ë±wªÌ¤Î¶i¦æ¦å²G³zªRªvÀøªº±wªÌ¤~«ØÄ³¬I¥HÀR¯ßª`®g¡A¥H30 IU/kgµ¹¤©,,1. ¥Ö¤Uª`®gµ¹ÃÄ¡]ST-ªi¬q¤É°ªªº«æ©Ê¤ß¦Ù±ð¶ë±wªÌ¤Î¶i¦æ¦å²G³zªRªvÀøªº±wªÌ°£¥~¡A³o¨Ç±wªÌÀ³¬I¥HÀR¯ßª`®g¡^¡C 2. ¥»ÃÄª«¤£¥i¥H¦Ù¦×ª`®gµ¹ÃÄ¡C
IPRO,Progesterone,Progesterone inj 50mg/1mL,HM,,¾AÀ³¯g:Amenorrhoea; Dysfunctional uterine bleeding¡ARecurrent miscarriage w/ progesterone deficiency¡A °Æ§@¥Î:GI disturbances¡A appetite/wt change¡A fluid retention¡A oedema¡A acne¡A skin rash¡A urticaria¡A depression¡A headache¡A fever¡A fatigue¡A breast changes¡A hirsutism¡A changes in libido¡A altered menstrual cycles or irregular menstrual bleeding (rare). Gastrointestinal: Abdominal pain (oral¡A 10% to 20%; vaginal gel¡A 5% to 12%; vaginal insert¡A 12% )¡A Constipation (vaginal gel¡A 27%; vaginal insert¡A 2% to 3% )¡A Nausea (oral¡A 8%; vaginal gel¡A 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral¡A 7% to 12% ) Musculoskeletal: Cramp (vaginal gel¡A 15% to 26% ) Neurologic: Dizziness (oral¡A 15% to 24%; vaginal gel¡A 5% )¡A Headache (oral¡A 10% to 31%; vaginal gel¡A 13% to 19%¡A vaginal insert¡A 3% to 4% )¡A Sleep disorder (vaginal gel¡A 18% )¡A Somnolence (vaginal gel¡A 27% ) Psychiatric: Depression (oral¡A 19%; vaginal gel¡A 11% to 19% )¡A Feeling nervous (vaginal gel¡A 16% )¡A Mood swings (oral¡A 6%; vaginal gel¡A 22% to 23% ) Reproductive: Breast tenderness (oral¡A 16% to 27% )¡A Large breast (vaginal gel¡A 40% )¡A Pain¡A Post-oocyte retrieval (vaginal insert¡A 25% to 28% )¡A Pain of breast (oral¡A 6% to 16%; vaginal gel¡A 13% )¡A Perineal pain (vaginal gel¡A 17% ) Other: Fatigue (oral¡A 8% to 9%; vaginal gel¡A 21% to 22%; vaginal insert¡A 2% to 3% ) ¸T§Ò:Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding¡A incomplete abortion¡A hormone-dependent carcinoma¡A as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease.,,«Ç·Å,IM Amenorrhoea; Dysfunctional uterine bleeding 5-10 mg/day for 5-10 days until 2 days before expected onset of menstruation Recurrent miscarriage w/ progesterone deficiency 25-100 mg twice wkly from the 15th day of pregnancy until 8-16 wk. May increase to daily inj if needed. Vag Amenorrhoea; Dysfunctional uterine bleeding 45 mg every other day from the 15th-25th day of the cycle. Rectal/Vag Premenstrual syndrome 200 mg/day¡A up to 400 mg twice daily. Start on days 12-14 of the cycle and continue till onset of menstruation. Intrauterine Contraception As device containing progesterone 38 mg: Insert into the uterine cavity,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ICRA2,Levofloxacin,Cravit °w¾¯ 250mg/50mL,QANB,Respiratory tract¡A ENT¡A GUT infection. Intrauterine infections¡A cervicitis¡A uterine adnesxitis¡A folliculitis. GIT infections¡A lymphangitis¡A mild to moderate skin & skin tissue infections.,Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.,Dizziness¡A GI disturbances¡A rash¡A pruritus¡A vaginitis¡A genital moniliasis¡A taste perversion¡A insomnia¡A tendinitis. Rarely¡A anaphylactic reactions¡A Lyell's syndrome¡A Stevens-Johnson's syndrome. Gastrointestinal: Diarrhea (ophthalmic¡A 1% to 2%; oral or intravenous¡A 5% )¡A Nausea (ophthalmic¡A 1% to 2%; oral or intravenous¡A 7% ) Neurologic: Headache (ophthalmic¡A 8% to 10% ; oral and intravenous¡A 6% ),30¢J¥H¤UÁ×¥ú,(¥é³æ) Adult: 250-500 mg po/IV 1-2 times daily. Administer 250 mg injection over 30 minutes¡A 500 mg injection over 60 minutes. (¼ö¯f) Adult: 250-750 mg po/IV Q24H (depends on indication). For most indications¡A in patients with normal renal function¡A the 750 mg dose is preferred. Pediatric (age > 28 days): 16-20 mg/kg/day (divided Q12H) (maximum 750 mg/day) For oral therapy¡A avoid concomitant exposure to multivalent cations (Ca¡A Fe¡A Al¡A Mg¡A Zn) in dairy products¡A multivitamins and antacids. Cations chelate the drug and prevent absorption.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,Infuse 250 mg IV solution over 30 minutes; infuse 500 mg IV solution over 60 minutes; infuse 750 mg IV solution over 90 minutes. Too rapid of infusion can lead to hypotension.,1. »ÝÁ×¥úÀx¦s¡A¥ú·Ó¤UÃÄ®Ä¥u¯àºû«ù3¤Ñ¡C 2. ¿éª`®ÉºÊ´úBP¡A¿éª`¹L§Ö¥i¯àµo¥Í§C¦åÀ£¡C 3. ºÞ¸ôÁ×§K»P§t¶t¡BÁâÂ÷¤l·»²G±µÄ²¡C 4. ¨Ì2016¦~²Ä2¦¸ADR·|Ä³¨MÄ³: ¦]QuinolonesÃþÃÄª«±`¨£¤Þ°_ÀR¯ßª¢¡A«ØÄ³¿éª`®É¶¡À³¶W¹L60¤ÀÄÁ¡C
OONG,Saxagliptin,Onglyza 5mg,META,,¾AÀ³¯g: Type 2 DM. °Æ§@¥Î: Upper respiratory tract infection¡A UTI¡A headache¡A sinusitis¡A abdominal pain¡A gastroenteritis¡A vomiting¡A hypersensitivity. ¸T§Ò: Treatment of type 1 diabetes mellitus or diabetic ketoacidosis,,below 30¢XC.,2.5-5 mg once daily as monotherapy or as combination therapy with metformin¡A a sulfonylurea¡A a PPAR£^ agonist.,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Micromedex: Infant risk cannot be ruled out.,,,,,,
IGLYP,Terlipressin,Glypressin inj 1mg,HM,Treatment of bleeding esophageal varices¡A and type 1 hepatorenal syndrome¡A characterised by spontaneous acute renal insufficiency¡A in patients suffering from severe cirrhosis with ascites.,Pregnancy.,Infrequently¡A acrocyanosis¡A diarrhea¡A abdominal cramps¡A headache.,25¢J¥H¤UÁ×¥ú,Bleeding oesophageal varices: Adults: Initially an IV injection of 2 ampoules of GLYPRESSINR solution for injection (2 mg terlipressin acetate¡A equivalent to 1.7 mg terlipressin) is given every 4 hours. The treatment should be maintained until bleeding has been controlled but up to a maximum of 48 hours. The dose can be adjusted to 1 ampoule of GLYPRESSINR solution for injection (1 mg terlipressin acetate¡A equivalent to 0.85 mg terlipressin) IV every 4 hours in patients with body weight < 50 kg. For maintenance dosage (if necessary)¡A bolus injection of 1 ampoule of GLYPRESSINR solution for injection every 4 hours for a maximum of 3 days. Duration of treatment must not exceed 5 days. In type 1 hepatorenal syndrome: 3 to 4 ampoules of GLYPRESSINR solution for injection (3 to 4 mg terlipressin acetate¡A equivalent to 2.55 to 3.4 mg terlipressin) every 24 hours as 3 or 4 administrations. In the absence of any reduction of the serum creatinine after 3 days of treatment¡A cessation of GLYPRESSINR treatment is advised. In the other cases¡A GLYPRESSINR treatment is to be pursued until the obtaining either of a serum creatinine less than 130 mmol/L or of a drop of at least 30 % in the serum creatinine with respect to the value measured at the time of diagnosis of hepatorenal syndrome. The standard average duration of treatment is 10 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVP;IVPUSH;,¨Ï¥Î¼t°Ó¤ºªþµ}ÄÀ·»²G,,2 mg ±Àª`®É¶¡¶·¶W¹L 1 ¤ÀÄÁ,,
OPROA,Cloxacillin,Prostaphlin-A 250mg,QANB,,¾AÀ³¯g:²Óµß©Ê·P¬V(N006998100) Infections caused by penicillinase producing bacterias¡A upper and lower respiratory tract infection¡A skin and soft-tissue infections¡A G(+) infections¡A except Staphylococcus.,,RT,Adult: 250-500 mg q6h up to 6 g/day. Child: 12.5-25 mg/kg q6h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OPROP,Finasteride,Propecia 1mg (28 tablets/box),TDER,Treatment of male pattern hair loss (androgenetic alopecia) in men only. Not indicated in women & children.,Pregnancy (or may potentially be pregnant). Hypersensitivity to any component of this product.,Decreased libido (placebo 1.3% vs Propecia 1.8%); erectile dysfunction (placebo 0.7% vs Propecia 1.3%); decreased vol of ejaculate (placebo 0.4% vs Propecia 0.8%).,30¢J¥H¤U,Androgenetic alopecia (male pattern hair loss): Males: Oral: 1 mg once daily. Continue for at least 12 months to assess the full effect,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ¡BÀ£¸H¡C¥»ÃÄ¶È¥Î©ó¨k©Ê¡A¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C¿õ¾¯ÂÐ¦³½¤¦ç¡A­YµL¯}·l¥i¨¾¤î¥­±`Ä²ºN®Éª½±µ±µÄ²¦³®Ä¦¨¥÷¡C
OPROS,Dinoprostone,Prostarmon-E 0.5mg,SGU,,¾AÀ³¯g: Induction & augmentation of labor near term. °Æ§@¥Î: Hypercontractions & fetal distress; nausea¡A vomiting¡A diarrhea¡A facial flush¡A heaviness in the head¡A headache¡A dizziness & slight elevation or fall of BP may occasionally occur. Gastrointestinal: Diarrhea (vaginal insert¡A less than 1%; vaginal suppository¡A approximately 40% )¡A Nausea (vaginal insert¡A less than 1%; vaginal suppository¡A 33% )¡A Vomiting (vaginal insert¡A less than 1%; vaginal suppository¡A approximately 66% ) Musculoskeletal: Backache (cervical gel¡A 3.1% ) Neurologic: Headache (vaginal suppository¡A approximately 10% ) Reproductive: Irregular uterine contractions (cervical gel¡A 6.6% ) Other: Fever (cervical gel¡A 1.4%; vaginal insert¡A less than 1% )¡A Shivering (vaginal suppository¡A approximately 10% ) ¸T§Ò: Contracted pelvis¡A cephalopelvic disproportion & fetal malpresentation; obstet complications which may threaten the life of the fetus; early or mid-pregnancy.,,«Ç·Å,1 tab hrly. If no effect is observed after 6 tab refrain from further dosing & resume the administration on the next day or later. Discontinue the administration when onset of uterine contractions or progression of parturition is observed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EBSS2,Balanced salt solution,BSS sterile irrigation solusion 500ml/Bottle,TOPH,B.S.S. Irrigation during various surgical procedures of the eyes¡A ears¡A nose or throat. BSS Plus Intraocular irrigating soln during intraocular surgical procedures involving perfusion of the eye.,Hypersensitivity to any component of the formulation.,When the corneal endothelium is abnormal¡A irrigation or any other trauma may result in bullous keratopathy.,«Ç·Å,For irrigation during operations of the eyes¡A ears¡A nose and throat.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AD;AL;AS;AU;EXT;G;GAR;IN;IRR;IRRI;LI;NA;OD;OL;ORO;OU;SKIN;TOPI;,,,,,
ECAN,Clotrimazole,Canesten 20gm,TDER,,I: Dermatomycoses¡A pityriasis versicolor¡A erythrasma¡A Candidal vulvitis. AR: Skin reactions.,,,1-2 times daily.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ECH4,Chloral hydrate,Chloral hydrate 4%,CNEU,,,,,,,,,,,,,,,,,,,
ECHL,Chloramphenicol,Chloramphenicol 0.25% 10mL,TOPH,,¾AÀ³¯g:Superficial bacterial eye infections °Æ§@¥Î: Transient stinging.,,2-8 ¢XC,Apply 1 drop every 2 hr & reduce frequency as infection is controlled; continue for 48 hr after healing.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ECLI,Estradiol 17B,Climara 50 patch,HM,,¾AÀ³¯g:¸É¥R¤k©Ê¶Pº¸»X(B022702318),,,,,,,,,,,,,,,,,
HE5012,Dianeal 2000cc 2.5% (PD 2Âù³U),Dianeal 2000mL 2.5% (PD 2Âù³U),NUTR,,,,,Select mode of therapy¡A frequency of treatment¡A formulation¡A fill volume¡A duration of dwell¡A and length of dialysis based on the patient¡¦s clinical condition¡A fluid¡A electrolyte and specific needs. The fill volume depends on body size¡A usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5013,Dianeal 2L 2.5% (PD 4Âù³U),Dianeal 2L 2.5% (PD 4Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5014,Dianeal 2000cc 4.25%(PD 2Âù³U),Dianeal 2000mL 4.25% (PD 2Âù³U),NUTR,,,,,Select mode of therapy¡A frequency of treatment¡A formulation¡A fill volume¡A duration of dwell¡A and length of dialysis based on the patient¡¦s clinical condition¡A fluid¡A electrolyte and specific needs. The fill volume depends on body size¡A usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5015,Dianeal 2000cc 4.25% (PD 4Âù³U),Dianeal 2000mL 4.25% (PD 4Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5020,Dianeal 2500cc 1.5% (PD 2 ³æ³U),Dianeal 2500mL 1.5% (PD 2 ³æ³U),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD¡A the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period¡A the access device is opened¡A the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night¡A the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5021,Dianeal 2500cc 1.5% (PD 2 Âù³U),Dianeal 2500mL 1.5% (PD 2 Âù³U),NUTR,,,,,Select mode of therapy¡A frequency of treatment¡A formulation¡A fill volume¡A duration of dwell¡A and length of dialysis based on the patient¡¦s clinical condition¡A fluid¡A electrolyte and specific needs. The fill volume depends on body size¡A usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5022,Dianeal 2.5L 1.5% (PD 4 ³æ³U),Dianeal 2.5L 1.5% (PD 4 ³æ³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
ESPI,Tiotropium,Spiriva inhaler 18mcg 30's/set,ERSP,,¾AÀ³¯g: Maintenance treatment of patients with COPD (including chronic bronchitis & emphysema). °Æ§@¥Î: GI disturbances¡A cough & local irritation¡A dysuria¡A urinary retention (in men)¡A tachycardia¡A allergic reactions. Gastrointestinal: Constipation (4% )¡A Xerostomia (12% to 16% ) Respiratory: Pharyngitis (7% to 9% )¡A Sinusitis (3% to 11% )¡A Upper respiratory infection (41% to 43% ) ¸T§Ò: Patients with a history of hypersensitivity to atropine or its derivatives eg¡A ipratropium or oxitropium¡A or to any component of Spiriva.,,«Ç·Å,Inhale the contents of 1 cap once daily with the HandiHaler inhalation device at the same time of day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
RIMMR,Measles & Mumps & Rubella & Varicella,Priorix-Tetra (Á{§É¸ÕÅçÃÄ),HIMM,,,,,,,,,,,,,,,,,,,
HE5023,Dianeal 2500cc 1.5% (PD 4 Âù³U),Dianeal 2500mL 1.5% (PD 4 Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
ROFER,Ferrous sulfate,Ferrous sulfate 324mg(Á{§É¸ÕÅç),NUTR,,,,,,,,,,,,,,,,,,,
EAAO,Sod Oleate + Poldocanol + Chlorocarvacrol,Alcos-Anal oint 20gm,ALIM,,¾AÀ³¯g: Hemorrhoids. °Æ§@¥Î: Local irritation.,,«Ç·Å,Apply once-bid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,RECT;,,,,,
OIXE,Milnacipran,Ixel 50mg,CNEU,,¾AÀ³¯g: Treatment of major depressive episodes in adults. °Æ§@¥Î: Dizziness¡A increased sweating¡A anxiety¡A hot flushes¡A dysuria¡A GI disturbances¡A dry mouth¡A constipation¡A tremors¡A palpitations. ¸T§Ò: Children < 15 years; concomitant administration with non-selective MAOI¡A MAO-B inhibitors¡A digoxin or 5-HT1 agonists (e.g. sumatriptan); use with parenteral adrenaline or noradrenaline¡A clonidine & related substances¡A MAO-A inhibitors; prostatic hypertrophy or urinary retention; pregnancy & lactation.,,«Ç·Å,50 mg bid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
YSLJ2,water¡A propylene glycol¡A methycelluose,µÎ¼¯¨à¼í¿A¾®ÅS 2 Oz (57gm),MSGO,,,,,,,,,,,,,,,,,,,
OGLUM,Glyburide + Metformin,GlucoMET 5/500mg(¾Tºä/¿üºä),META,As initial or 2nd-line therapy in the treatment of type 2 diabetes.,Renal disease or renal dysfunction¡A CHF requiring pharmacologic treatment¡A acute or chronic metabolic acidosis¡A including diabetic ketoacidosis with or without coma. Treatment should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials.,GI disturbances¡A headache¡A abdominal pain¡A dizziness. Rarely¡A lactic acidosis. Endocrine metabolic: Cobalamin deficiency (7% )¡A Hypoglycemia Gastrointestinal: Abdominal pain (6.9% )¡A Diarrhea (17% )¡A Nausea and vomiting (7.6% ) Neurologic: Dizziness (5.5% )¡A Headache (8.9% ) Respiratory: Upper respiratory infection (17.3% ),25¢J¥H¤U¡A¤£³z¥ú®e¾¹¤º,Initial 0.5-1 TAB once daily¡A max 4 TAB (20 mg glyburide and 2000 mg metformin).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PO;WM;,,,,,
ELOCO,Hydrocortisone,Locoid cream 0.1%¡A 5gm,TDER,,¾AÀ³¯g: Treatment of all conditions for which corticosteroid therapy is indicated. °Æ§@¥Î: Electrolyte imbalance with edema & hypertension¡A increased insulin requirements in diabetic patients¡A delayed wound healing. Cushingoid symptoms¡A amenorrhoea¡A hyperhidrosis¡A skin thinning¡A ocular changes¡A mental & neurological disturbances¡A intracranial hypertension¡A acute pancreatitis¡A aseptic necrosis of the bone¡A muscle weakness & wasting¡A hypersensitivity reactions. ¸T§Ò: Peptic ulcer¡A osteoporosis¡A psychoses¡A severe psychoneuroses¡A acute infections¡A concurrent administration with live vaccines.,,«Ç·Å,Apply several times a day.,,,,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IKCL1A,Potassium Chloride,¤lÂå¥O KCl inj 15% 10mL,NUTR,,,,,¤lÂå¥O,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,½Õ°t»s¾¯¤§¤lÂå¥O¡A­p»ù¥Î¡C
IFEN2BAD,Fentanyl,Fentanyl inj 0.1mg/2mL´Ý¾l¾P·´,CNEU,,,,,,,,,,,,,,IM;IV;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦¨¤H > 1-2¤ÀÄÁ¡A¨àµ£ > 2-5¤ÀÄÁ,,
IFEN2,Fentanyl,Fentanyl inj 0.1mg/2mL,CNEU,Premed prior to surgery¡A Adjunct to general anesth induction¡A Adjunct to regional anesth¡A Post-operatively .,Children <2 years¡A bronchial asthma¡A respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,Respiratory depression¡A apnoea¡A muscle rigidity & bradycardia.,25¢J¥H¤UÁ×¥ú,As a general anesthesia analgesic aid: Low dose: 2 mcg/kg IV (Minor surgery) Medium dose: 2-20 mcg/kg IV (Complex surgery) High dose: 20-50 mcg/kg IV (Prolonged major surgery. Use with Oxygen¡A Nitrous Oxide to avoid body's stress response) IV injection 25-250 mcg/kg (0.5-5mL) can be given to extend the action time until the completion of the operation. As an anesthetic: When it is important to reduce the stress response during surgery¡A fentanyl can be administered intravenously 50-100 mcg/kg¡A combined with Oxygen and Muscle Relaxants without adding additional anesthetics. This method is often used for heart surgery and other needs to protect the myocardium from hypoxia. As an analgesic for acute severe pain: Epidural injection: single dose 5-100 mcg; continuous infusion: 25-100 mcg per hour. Elderly patients: similar to other opioids¡A the dose of the elderly and frail patients should be lowered. Children: The induction and maintenance of anesthesia for children between 2-12 years old¡A the dose should be reduced to 2-3 mcg/kg IV.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]§h©Z¥§·|±Æªn¨ì¤HÅé¨Å¥Ä¤¤¡A¦]¦¹§ë»P¥»ÃÄ«áªº24¤p®É¤º¤£«ØÄ³±Â¨Å¡C»Ý¦Ò¶q¦b§h©Z¥§µ¹ÃÄ«á¶i¦æ­÷¨Åªº§Q¹ú¡C,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦¨¤H > 1-2¤ÀÄÁ¡A¨àµ£ > 2-5¤ÀÄÁ,,
OSWI,Trihexyphenidyl,Switane 2mg,CNEU,Parkinsonism.,Closed-angle glaucoma¡A paralytic ileus¡A prostatic hypertrophy.,GI disturbances; glaucoma¡A mydriasis; urinary retention¡A mental disturbances¡A excitement.,25¢J¥H¤U,Parkinsonism: 1 mg on the 1st day¡A increment of 2 mg every 3-5 days until 6-10 mg/day in 3 divided doses. Medication induced parkinsonism: 5-15 mg/day¡A start from 1 mg/day. Postencephalitic parkinsonism: 12-15 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EACUL,Ketorolac,Acular 0.5%¡A 5mL ophthalmic solution,TOPH,Temporary relief of ocular itching due to seasonal allergic conjunctivitis. Treatment of postop inflammation in patients who have undergone cataract extraction.,Patients who have previously demonstrated hypersensitivity to any of the ingredients of Acular.,Transient stinging & burning¡A ocular irritation¡A allergic reactions¡A superficial ocular infections¡A superficial keratitis. Cardiovascular: Edema (1% to 10% )¡A Hypertension (1% to 10% ) Dermatologic: Injection site pain (injection¡A 1% to 10% )¡A Pruritus (1% to 10% )¡A Rash (1% to 10% )¡A Sweating (1% to 10% ) Gastrointestinal: Abdominal pain (1% to 10% )¡A Diarrhea¡A Indigestion (1% to 10% )¡A Nausea (greater than 10% ) Hematologic: Anemia (1% to 10% )¡A Purpura (1% to 10% ) Neurologic: Dizziness (1% to 10% )¡A Headache (greater than 10% )¡A Somnolence (1% to 10% ) Ophthalmic: Burning sensation in eye¡A Transient (ophthalmic¡A 20% to 40% )¡A Corneal edema (ophthalmic¡A 1% to 10% )¡A Eye irritation (ophthalmic¡A 1% to 10% )¡A Iritis (ophthalmic¡A 1% to 10% )¡A Keratitis (ophthalmic¡A 1% to 10% ) Respiratory: Nasal irritation (nasal¡A 15% )¡A Pain¡A Rhinalgia (nasal¡A 13% ),Á×¥úÀx¦s©ó15¢J- 25¢J,Relief of ocular itching due to seasonal allergic conjunctivitis: Instill 1 drop QID. Treatment of inflammation in patients who have undergone cataract extraction: Instill 1 drop QID (above 24 hrs post-operation)¡A and use constantly until 2 weeks after surgery.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
OALI,Thiaine Tetrahydrofurfuryl Disulfide + Riboflavin,Alinamin-F 50mg,NUTR,Neuralgia¡A neuritis¡A eye's fatigue¡A nervous cystitis; post-op intestinal paralysis¡A vit B1 deficiency.,Hypersensitivity,Rarely¡A nausea¡A vomiting & rumbling; shock¡A hypersensitivity¡A headache or pollakiuria (decrease dose or stop use).,«O¦s©ó°®Àê³±²D¥BÁ×§K¶§¥úª½®g,Oral: 1 tab QD-TID PC.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OAMI,Aminophylline,Aminophylline 100mg,ERSP,,¾AÀ³¯g:Bronchospasm. °Æ§@¥Î:Nausea¡A vomiting¡A abdominal pain¡A diarrhoea¡A headache¡A insomnia¡A dizziness¡A anxiety¡A restlessness; tremor¡A palpitations. ¸T§Ò: Hypersensitivity to xanthines.,,«Ç·Å,Oral: Adult: 100-300 mg tid-qid. Child: 13-24 mg/kg/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ECLO,Clotrimazole,Clomazole VT 100mg,SGU,,Fungal and G(+) bacterial infection of the skin and nails.,,,1-2 times daily.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ECLT,Clindamycin,Cleocin T gel 1% 30gm,TDER,Acne vulgaris.,Individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin¡A a history of regional enteritis or ulcerative colitis¡A or a history of antibiotic-associated colitis.,Skin dryness¡A skin irritation¡A oiliness¡A contact dermatitis¡A gm-ve folliculitis¡A stinging of the eye.,Àx¦s©ó20¢J -25¢J,Apply a thin film of Cleocin T twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
ECU375,Cu375,Cu 375,HM,,¾AÀ³¯g: Intrauterine contraception °Æ§@¥Î: Uterine cramps &/or abdominal pain; syncope¡A bradycardia¡A other neurovascular episodes during or immediately after insertion or removal of IUDs; breakthrough bleeding¡A prolongation of menstruation¡A dysmenorrhea; back & leg pain¡A dyspareunia; pelvic inflammatory disease; abnormal vag discharge; perforated uterus or cervix; spontaneous abortion; septicemia; ectopic pregnancy. Urticarial allergic skin reactions. ¸T§Ò: Pregnancy; ectopic pregnancy or predisposing factors; malformations or distortions of uterus or cervix; active pelvic inflammatory disease¡A presence or history of venereal disease¡A infected abortion within 3 months; undiagnosed vag bleeding; coagulopathy¡A treatment with anticoagulant; disorders of copper metabolism; severe anemia. Large or multiple uterine fibromyomata with heavy menstrual periods.,,«Ç·Å,Individualised dosage. Inserted into uterus.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EDAI,Calcipotriol,Daivonex ointment,TDER,,,,,,,,,,,,,,,,,,,
EDAIS,Calcipotriol,Daivonex scalp soln 30mL,TDER,,¾AÀ³¯g: Scalp psoriasis. °Æ§@¥Î: Transient local irritation & very rarely¡A facial dermatitis may occur. Scalp soln Transient burning¡A stinging¡A rash¡A dry skin¡A skin irritation¡A worsening of psoriasis. ¸T§Ò: Known disorder of Ca metabolism.,,«Ç·Å,Oint Apply bid. Maintenance therapy may be achieved with less frequent application. Weekly dose should not exceed 100 g. Scalp soln Apply bid. Weekly dose should not exceed 60 mL. When used together with oint/cream¡A the total dose of calcipotriol should not exceed 5 mg/week corresponding to 100 g of oint/cream.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IHBVA,Hepatitis B Vaccine,Engerix-B vaccine 20mcg/mL/DOS,HIMM,,Prevention of hepatitis B in healthy individuals exposed to risk of contamination.,,,IM (preferred) or SC¡A 20 mcg purified antigen protein. Standard 3-dose schedule: Given at 1 and 6 months after 1st dose. Alternative 4-dose schedule:Given at 1¡A2 and 12 months after 1st dose.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IHCG1,Chorionic Gonadotropin,Gona Hormon(Pregnyl)1500U,HM,,,,,,,,,,,,,,,,,,,
IHCG2,Human Chorionic Gonadotrophin,Profasi (HCG) 2000IU,HM,,¾AÀ³¯g:¬°¤£¥¥¯g¥ÎÃÄ(B022773212),,2-8,Prepubertal cryptorchidism: 5000U every second day for 4 injections. Hypogonadism in males: 500-1000U 3 times/week for 3 wks¡A then twice/week for 3 wks. Induction of ovulation: 5000-10000U one day following the last dose of menotropins.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IHD10,House Dust Mite,HD 10,ZOTH,,,,,,,,,,,,,,,,,,,
HE5024,Dianeal 2500cc 2.5% (PD 2 ³æ³U),Dianeal 2500mL 2.5% (PD 2 ³æ³U),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD¡A the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period¡A the access device is opened¡A the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night¡A the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
HE5025,Dianeal 2500cc 2.5% (PD 2 Âù³U),Dianeal 2500mL 2.5% (PD 2 Âù³U),NUTR,,,,,Select mode of therapy¡A frequency of treatment¡A formulation¡A fill volume¡A duration of dwell¡A and length of dialysis based on the patient¡¦s clinical condition¡A fluid¡A electrolyte and specific needs. The fill volume depends on body size¡A usually from 2.0 to 2.5 liters per 1.73m2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD).,,,,,,,,,,,,,,
HE5026,Dianeal 2.5L 2.5% (PD 4 ³æ³U),Dianeal 2.5L 2.5% (PD 4 ³æ³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5027,Dianeal 2500cc 2.5% (PD 4 Âù³U),Dianeal 2500mL 2.5% (PD 4 Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5028,Dianeal 2500cc 4.25% (PD 4 ³æ³U),Dianeal 2500mL 4.25% (PD 4 ³æ³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5029,Dianeal 2500cc 4.25% (PD 4Âù³U),Dianeal 2500mL 4.25% (PD 4Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5040,Dianeal 5000cc 1.5% (PD2³æ³U),Dianeal 5000mL 1.5% (PD2³æ³U),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD¡A the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period¡A the access device is opened¡A the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night¡A the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5041,Dianeal 5L1.5% (PD 4³æ³U),Dianeal 5L1.5% (PD 4³æ³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5042,Dianeal 5000cc 2.5% (PD 2³æ³U),Dianeal 5000mL 2.5% (PD 2³æ³U),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week . For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD¡A the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period¡A the access device is opened¡A the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night¡A the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5043,Dianeal 5L 2.5% (PD 4³æ³U),Dianeal 5L 2.5% (PD 4³æ³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
ETOP1,Fluocinonide,Topsym ¨Å»I0.05%¡A 10gm,TDER,Eczema; dermatitis; psoriasis; vitiligo; alopecia; pustulosis; prurigo.,Vaccinia & varicella.,urning¡A itching¡A irritation¡A dryness; perioral dermatitis; allergic contact dermatitis; skin atrophy. Dermatologic: Dry skin¡A Pruritus¡A Sensation of burning of skin Neurologic: Headache¡A with 0.1% cream (4%) Other: Irritation symptom,Àx¦s©ó³±²D³B,Apply QD-TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,EXT;,,,,,
IDEXA,Dexamethasone,Dexamethasone inj 5mg/1mL,HM,Conditions where the anti-inflammatory & immunosuppressive effects of the corticosteroids are desirable¡A especially for intensive treatment during shorter periods.,Systemic fungal infection¡A hypersensitivity. Administration of live virus vaccine¡A unstable or infected joint¡A diagnosed sepsis.,Common: Body fluid retention¡A Hypertension¡A Skin irritation¡A Cushing's syndrome¡A Decreased body growth¡A Depression¡A Euphoria¡A Pulmonary tuberculosis Serious: Cardiac rupture due to and following acute myocardial infarction¡A Cardiomyopathy¡A Thromboembolic disorder¡A Hyperglycemia¡A Pancreatitis¡A Perforation of large intestine¡A Perforation of small intestine¡A Non-allergic anaphylaxis¡A Compression fracture of vertebral column¡A Osteoporosis¡A Cerebrovascular accident¡A Infarction of spinal cord¡A Nerve injury¡A Paraplegia¡A Raised intracranial pressure¡A Seizure¡A Tetraplegia¡A Blindness AND/OR vision impairment level¡A Cortical blindness,µL¯S§O«ü¥Ü,IM and IV: 2-10 mg (0.4-2 mL). INS : 4-6 mg (0.8-1.2 mL) on large joint and 0.8-1 mg (0.16-0.2 mL) for smaller joint. Soft tissue: 2-6 mg (0.4-1.2 mL). Subconjectival or retrobulbar injection: 0.4-2 mg (0.08-0.4 mL). ID: diluted 1/5 of Dexamethasone with normal saline¡A then inject 0.1mL. Eye drops: diluted 1/25 of Dexamethasone with normal saline.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,ID;IM;INS;IRR;IS;IVD;IVI;IVP;IVPUSH;LI;SCI;SUBCI;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,ÀR¯ß±Àª`»Ý¤j©ó¤@¤ÀÄÁ,Consider further dilution and administration by IV intermittent infusion over 5 to 15 minutes. (UpToDate),¤@¤éÁ`§ë»P¶q¤£¥i¶W¹L80mg;¥Î©ó¥Ö¤º³q±`±N¤§¥Î¥Í²z­¹ÆQ¤ôµ}ÄÀ5­¿«á¨ú¬ù0.1mL;ÂI²´³q±`µ}ÄÀ25­¿«á¨Ó¨Ï¥Î Adult: May administer 4 mg/mL or 10 mg/mL concentration undiluted over >1 minute. (UpToDate)
IMTX1,Methotrexate,Abitrexate inj 50mg/2mL,RACA,,¾AÀ³¯g: Gestational choriocarcinoma¡A acute lymphocytic leukemia¡A meningeal leukemia¡A chorioadenoma destruens¡A hydatidiform mole¡A epidermoid cancers of the head & neck¡A lung cancer¡A bladder cancer & lymphosarcoma. °Æ§@¥Î: Ulcerative stomatitis¡A leukopenia¡A nausea & abdominal distress. malaise¡A fatigue¡A chills & fever¡A dizziness & decreased resistance to infection. Erythematous rashes¡A pruritus¡A urticaria¡A photosensitivity¡A depigmentation¡A alopecia¡A ecchymosis¡A telangiectasia¡A acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes¡A precipitating diabetes¡A osteoporosis¡A conjunctivitis¡A abnormal tissue cell changes¡A anaphylaxis. ¸T§Ò: Pregnant psoriatic patients. Psoriatic patients with severe renal or hepatic disorders¡A preexisting blood dyscrasias.,,«Ç·Å,Choriocarcinoma: Oral or IM¡A 15-30 mg/day for a 5 day course. Acute leukemia: Induction¡A oral or IV¡A 3.3 mg/m2/day with prednisolone; maintenance¡A oral or IM¡A 30 mg/mL twice a week¡A or IV¡A 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal¡A 0.2-0.5 mg/kg or 12 mg/mL (max. 15mg) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma (stage I & II): Oral¡A 10-25 mg/day for 4-8 days. Psoriasis: Oral¡A IM or IV¡A 10-25 mg/week. Rheumatoid arthritis: Oral¡A 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral¡A 2.5-10 mg/day for weeks or months; IM¡A 50mg/week.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C 3. Methotrexate¥HÀR¯ß¤è¦¡µ¹ÃÄ»Ý½wºC±Àª`¡A¤]¥i¥Hµu®É¶¡ÀR¯ß¿éª`©ÎÀR¯ß«ùÄò¿éª`µ¹ÃÄ¡C¨ÌªvÀø²Õ¦X»PÂåÅñ¨M©w¡C
IERB,Cetuximab,Erbitux inj 100mg/50mL,RACA,,¾AÀ³¯g¡GTreatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Treatment of locally advanced oropharyngeal cancer¡A hypopharyngeal cancer¡A laryngeal cancer in combination with radiation therapy. °Æ§@¥Î¡GMild or moderate infusion-related reactions eg fever¡A chills¡A nausea¡A vomiting¡A headache¡A dizziness or dyspnoea; mild to moderate mucositis. Severe infusion-related reactions eg rapid onset of airway obstruction¡A urticaria¡A hypotension¡A loss of consciousness &/or stenocardia may occur during or within 1 hr of initial infusion. Skin reactions¡A mainy as acne-like rash. Renal impairment. Conjunctivitis. Mild to moderate increase in liver enzyme levels. Dermatologic: Acneiform eruption¡A Any grade (76% to 88% )¡A Application site reaction (squamous cell carcinoma of the head and neck (with radiation)¡A 18% )¡A Dry skin (metastatic colorectal cancer (monotherapy)¡A 49% )¡A Nail changes (colorectal cancer (monotherapy)¡A 21% )¡A Pruritus (squamous cell carcinoma of the head and neck (with radiation)¡A 16%; colorectal cancer (monotherapy)¡A 40% )¡A Radiation dermatitis¡A Any grade (squamous cell carcinoma of the head and neck (with radiation)¡A 86% )¡A Rash (squamous cell carcinoma of the head and neck (with radiation)¡A 87%; colorectal cancer (monotherapy)¡A 89% ) Endocrine metabolic: Dehydration (squamous cell carcinoma of the head and neck (with radiation)¡A 25% )¡A Hypomagnesemia¡A Any grade (55% )¡A Weight loss (squamous cell carcinoma of the head and neck (with radiation)¡A 84% ) Gastrointestinal: Abdominal pain (colorectal cancer (monotherapy)¡A 59% )¡A Constipation (colorectal cancer (monotherapy)¡A 46% )¡A Diarrhea (squamous cell carcinoma of the head and neck (with radiation)¡A 19%; colorectal cancer (monotherapy)¡A 39%; colorectal cancer (with irinotecan)¡A 72% )¡A Nausea (squamous cell carcinoma of the head and neck (with radiation)¡A 49%; colorectal cancer (with irinotecan)¡A 55% )¡A Stomatitis (colorectal cancer (monotherapy)¡A 25% )¡A Vomiting (squamous cell carcinoma of the head and neck (with radiation)¡A 29%; colorectal cancer (monotherapy)¡A 37% ) Immunologic: Infectious disease (squamous cell carcinoma of the head and neck (with radiation)¡A 13%; colorectal cancer (monotherapy)¡A 35% ) Neurologic: Asthenia¡A Any grade (squamous cell carcinoma of the head and neck (with radiation)¡A 56%; colorectal carcinoma (with irinotecan)¡A 73% )¡A Confusion (colorectal cancer¡A 15% )¡A Headache (squamous cell carcinoma of the head and neck (with radiation)¡A 19%; colorectal cancer (monotherapy)¡A 33% )¡A Insomnia (colorectal cancer (monotherapy)¡A 30% ) Psychiatric: Anxiety (colorectal cancer (monotherapy)¡A 14% )¡A Depression (colorectal cancer (monotherapy)¡A 13% ) Respiratory: Cough (colorectal cancer (monotherapy)¡A 29% )¡A Dyspnea (colorectal cancer (monotherapy)¡A 48% )¡A Pharyngitis (squamous cell carcinoma of the head and neck (with radiation)¡A 26% ) Other: Complication of infusion¡A Any grade (15% to 21% )¡A Fatigue (colorectal cancer (monotherapy)¡A 89% )¡A Fever (squamous cell carcinoma of the head and neck (with radiation)¡A 29%; colorectal cancer (monotherapy)¡A 30% )¡A Late effect of radiation¡A Pain (colorectal cancer (monotherapy)¡A 51% ),,2-8¢J,Prior to infusion¡A patients must receive premedication with an antihistamine. Initial dose: 400 mg/m2 once weekly. Subsequent doses: 250 mg/m2 once weekly. Colorectal cancer Same dose of irinotecan is administered in the last cycles of the prior irinotecan-containing regimen. Irinotecan must not be administered earlier than 1 hr after the end of Erbitux infusion. Oropharyngeal cancer¡A hypopharyngeal cancer¡A laryngeal cancer Start therapy 1 week before the radiotherapy & continue until the end of the radiotherapy period.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
LMUS2,Ambroxol,Musco solution 3mg/mL¡A 120mL,ERSP,Expectorant.,Hypersensitivity to any component of the formulation.,Contact dermatitis¡A Pruritus¡A Rash¡A Skin finding¡A Urticaria¡A Constipation¡A Diarrhea¡A Excessive salivation¡A Gastrointestinal tract finding¡A Nausea and vomiting¡A Xerostomia¡A Dysuria¡A Urogenital finding¡A Nasal discharge¡A Respiratory finding¡A Fatigue,25¢J¥H¤U,Adult & children >10 years 10 mL TID. 5-10 years 5 mL TID. 2-5 years 2.5 mL TID. < 2 years 2.5 mL BID. Reduce dose in long-term therapy. Recommended doses of Children: 1.2-1.6mg/Kg/day.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
LLAC6,Lactulose,Lacoly soln 60mL(667mg/mL),ALIM,,¾AÀ³¯g: Chronic portal systemic encephalopathy¡A hepatic pre coma¡A hepatic coma °Æ§@¥Î: Flatulence¡A nausea¡A vomiting¡A abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). ¸T§Ò: Galactosemia¡A bowel obstruction.,,«Ç·Å,Chronic constipation:  Starting dose(for 3 days) aintenance -------------------- ---------------------------------- --------------------- Severe cases 0-45 ml 15-25 ml Moderate cases 5-30 ml 10-15 ml Mild cases 5ml 10 ml 6-14yr 15 ml 10 ml 1-6yr 5-10 ml 5-10 ml Infant 1-12mth 5 ml 5 ml All doses to be taken daily preferably as single doses. Precoma & hepatic coma: Starting doses: approx 30-50 ml tid. In acute cases a retention enema is given in a proportion of 300ml Duphalac to 700 ml water.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
INEB,Testosterone,Nebido inj 1000mg/4mL,HM,Testosterone replacement therapy for primary or secondary male hypogonadism < 65 years.,Androgen-dependent carcinoma of the prostate or male mammary gland; hypercalcemia accompanying malignant tumors; past or present liver tumors. Women.,Diarrhea¡A leg pain¡A arthralgia¡A dizziness¡A increased sweating¡A headache¡A dyspnea¡A acne¡A breast pain¡A gynecomastia¡A pruritus¡A skin reactions¡A testicular pain¡A inj site pain¡A SC hematoma at inj site. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation¡A Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ),30¢J¥H¤U,1000 mg every 10-12 weeks.,µL»Ý½Õ¾ã¾¯¶q,´¿¦³©Î¥Ø«e¿©±w¨x¸~½Fªº¨k©Ê¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;,,,,,1. ¥»ÃÄ«~­­¦Ù¦×ª`®g¡A¶·¥H·¥½wºC³t«×¬I¥´¡A¨Ã¤p¤ßÁ×§Kª`®g¤J¦åºÞ¤º¡C
OSPAS,Alverine,Spasmonal 60mg,ALIM,,¾AÀ³¯g: Irritable bowel syndrome. °Æ§@¥Î: Rarely fatigue¡A dizziness¡A headache¡A allergic reactions¡A rash¡A itch. ¸T§Ò: Paralytic ileus. Pregnancy¡A lactation.,,«Ç·Å,Adult & elderly 60-120 mg once-tid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OAMIO,Amiodarone,Cordarone 200mg,CAVS,Wolff-Parkinson-White syndrome¡A supraventricular & ventricular tachycardia¡A atrial & ventricular fibrillation.,AV or SA block¡A sinus bradycardia¡A sick sinus syndrome except when used in conjunction with a pacemaker; history of thyroid dysfunction; iodine intolerance¡A severe arterial hypotension¡A CV collapse¡A acute cardiac insufficiency. Combined therapy with drugs which may induce torsades de pointes. Pregnancy¡A lactation.,Common: Hypotension (Oral¡A less than 1%; IV¡A 15.6%)¡A Photodermatitis (2-24%)¡A Photosensitivity (3-10%)¡A Thyroid dysfunction¡A Constipation (4-9%)¡A Loss of appetite (4-9%)¡A Nausea (10-33%)¡A Vomiting (10-33%)¡A Increased liver enzymes¡A Abnormal gait (4-9%)¡A Coordination problem (4-9%)¡A Dizziness (4-9%)¡A Involuntary movement (4-9%)¡A Movement disorder (4-9%)¡A Paresthesia (4-9%)¡A Peripheral neuropathy¡A Corneal deposit¡A Microdeposits¡A Visual disturbance (4-9%)¡A Malaise and fatigue (4-9%) Serious: Bradyarrhythmia¡A Cardiac dysrhythmia¡A Congestive heart failure¡A High threshold for implanted defibrillator¡A Prolonged QT interval¡A Sinus arrest¡A Torsades de pointes (Less than 2%)¡A Vasculitis¡A Ventricular arrhythmia¡A Injection site extravasation¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hyperthyroidism (2%)¡A Hypothyroidism (Up to 10% .)¡A Thyroid cancer¡A Thyrotoxicosis¡A Thrombocytopenia¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Lupus erythematosus¡A Low back pain¡A acute¡A Rhabdomyolysis¡A Pseudotumor cerebri¡A Raised intracranial pressure¡A Blindness AND/OR vision impairment level¡A Optic neuritis¡A Toxic optic neuropathy¡A Renal impairment¡A Acute respiratory distress syndrome (2%)¡A Pulmonary fibrosis¡A Pulmonary toxicity (Up to 17%),30¢J¥H¤U,Initial dose: 600mg/day in divided doses for 8-10 days. Maintenance dose: dosage range from 100mg daily (200 mg every other day) to 400 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,Ãh¥¥²Ä¤G´Á(²Ä4-6¤ë)°_¸T¥Î(¥é³æ),Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¨ã¦³­W¨ý¡A¤£«ØÄ³¿i¯»¤fªA¡C
IADIF,Purified Split Inactivated Influenza Virus,4»ù¦Û¶O¬y·P AdimFlu-S 0.5mL/dose,HIMM,,¾AÀ³¯g: Active immunisation against influenza. °Æ§@¥Î: Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome. ¸T§Ò: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 ¢XC,Adult & Children >= 36 mth 0.5ml IM Chidren(>= 3yr¡A < 9 yr who have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,
OARIM,Anastrozole,Arimidex 1mg,RACA,Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. Treatment of advanced breast cancer in postmenopausal women. Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2-3 years of adjuvant tamoxifen.,Hypersensitivity to anastrozole or any component of the formulation; use in women who are or may become pregnant. Lactating women.,Common: Hypertension (2-13%)¡A Peripheral edema (5-10%)¡A Vasodilatation (25-36%)¡A Rash (6-11%)¡A Menopausal flushing (12-36%)¡A Diarrhea (8-9%)¡A Disorder of gastrointestinal tract (29-34%)¡A Nausea (11-19%)¡A Vomiting (8-9%)¡A Lymphedema (10%)¡A Arthralgia (2-15%)¡A Arthritis (17%)¡A Arthropathy¡A Backache (10-12%)¡A Bone pain (6-11%)¡A Osteoporosis (11%)¡A Asthenia (16-19%)¡A Headache (adult¡A 9-13%; pediatric¡A 7%)¡A Insomnia (2-10%)¡A Depression (5-13%)¡A Disturbance in mood (19%)¡A Dyspnea (8-10%)¡A Increasing frequency of cough (8-11%)¡A Pharyngitis (6-14%)¡A Pain (11-17%) Serious: Cerebral infarction¡A Cerebrovascular accident¡A Chest pain (5-7%)¡A Ischemic heart disease (4%)¡A Myocardial infarction (1.2%)¡A Myocardial ischemia¡A Thrombophlebitis (2-5%)¡A Venous thromboembolism¡A Blister¡A Erythema multiforme¡A Skin lesion¡A Skin ulcer¡A Stevens-Johnson syndrome¡A Breast cancer (5%)¡A Serum cholesterol above reference range (2-9%)¡A Deep venous thrombosis (1.6%)¡A Thromboembolic disorder (2-4%)¡A Hepatitis¡A Liver function tests outside reference range (0.01%)¡A Hypersensitivity reaction (0.01%)¡A Decreased bone mineral density¡A Fracture of bone (10-15%)¡A Cerebral ischemia (2%)¡A Thrombosis of retinal vein¡A Abnormal vaginal bleeding (1-5%)¡A Endometrial cancer (0.2%)¡A Pulmonary embolism¡A Breast cancer (5%)¡A Neoplasm of endometrium (0.2%)¡A Neoplastic disease (5-13.7%)¡A Tumor flare (3%),25¢J¥H¤U,1 mg once daily,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤­««×¨x¯fªÌ¸T§Ò [Micromedex 20210504]Hepatic impairment¡A mild to moderate: No dosage adjustment necessary; monitor closely.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OARO,Exemestane,Aromasin 25mg,RACA,Adjuvant treatment of postmenopausal women with oestrogen receptor +ve invasive early breast cancer¡A following at least 2 year of initial adjuvant tamoxifen therapy. Treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.,Pregnancy¡A lactation. Women with premenopausal endocrine status.,Anorexia¡A insomnia¡A depression¡A headache¡A dizziness¡A carpal tunnel syndrome¡A hot flushes¡A nausea¡A abdominal pain¡A vomiting¡A constipation¡A dyspepsia¡A diarrhea¡A increased sweating¡A rash¡A alopecia¡A joint & musculoskeletal pain¡A fatigue¡A pain¡A peripheral oedema. Rarely¡A hepatitis including cholestatic hepatitis. Endocrine metabolic: Diaphoresis (6% to 17.8% )¡A Hot sweats (13% to 32.9% ) Gastrointestinal: Nausea (8.5% to 18% ) Musculoskeletal: Arthralgia (14.6% to 28.8% ) Neurologic: Headache (6.9% to 13.1% )¡A Insomnia (11% to 13.7% ) Psychiatric: Fatigue (11% to 22% ),30¢J¥H¤U,25 mg administered orally once daily after a meal.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OBAM,Bambuterol,Bambec 10mg,ERSP,,¾AÀ³¯g:¹w¨¾¤ÎªvÀø¤ä®ðºÞµjÅË(B020058100) Bronchial asthma¡A chronic bronchitis¡A emphysema. °Æ§@¥Î: Tremor¡A headache¡A tonic muscle cramps¡A palpitations. ¸T§Ò: Hypersensitivity to any of the ingredients of Bambec or to terbutaline.,,«Ç·Å,10 mg once daily at night¡A may be increased to 20 mg once daily after 1-2 wk.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OBENS,Benzonatate,Bensau 100mg,ERSP,,¾AÀ³¯g:¤î«y§@¥Î(A042435100) Symptomatic relief of cough. °Æ§@¥Î: Sedation¡A headache¡A dizziness¡A itch¡A skin eruption¡A nasal congestion¡A constipation¡A GI upset¡A chills¡A chest tightness¡A allergy. ¸T§Ò: Children < 14 yr.,,«Ç·Å,Adult 1-2 cap tid MAX dose is 600 mg/day,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IHD100,House Dust Mite,HD 100,ZOTH,,,,,,,,,,,,,,,,,,,
IHD1000,House Dust Mite,HD 1000,ZOTH,,,,,,,,,,,,,,,,,,,
IHEA,Amino Acids,8% Hepatamine 500mL,NUTR,,,,,,,,,,,,,,,,,,,
IHEP1,Heparin,Heparin inj 1KIU/0.2mL,HEMT,,¾AÀ³¯g: Unstable angina; Venous thromboembolism; Peripheral arterial embolism¡A Prevention of re-occlusion of the coronary arteries following thrombolytic therapy ¡A Venous thromboembolism ¡AProphylaxis of post-op venous thromboembolism¡A Prevention of mural thrombosis °Æ§@¥Î:Slight fever¡A headache¡A chills¡A nausea¡A vomiting¡A constipation¡A epistaxis¡A bruising¡A slight haematuria¡A skin necrosis (SC inj)¡A osteoporosis¡A alopecia. Hypersensitivity reactions include urticaria¡A conjunctivitis¡A rhinitis¡A asthma¡A angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding ¸T§Ò: Patients predisposed to active bleeding including thrombocytopenia¡A peptic ulcer disease¡A cerebrovascular disorders¡A haemorrhagic blood disorders¡A bacterial endocarditis¡A severe hypertension¡A oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage¡A abdominal or thoracic bleeding into closed space¡A severe traumatic bleed¡A hepatic¡A renal¡A splenic or arterial injury¡A severe haemostatic defect¡A arterial thrombosis with heparin-associated thrombocytopenia. IM admin.,,15-30¢J,IV Unstable angina; Venous thromboembolism; Peripheral arterial embolism Loading dose: 5¡A000 u¡A then 1¡A000-2¡A000 u/hr. Prevention of re-occlusion of the coronary arteries following thrombolytic therapy in MI 5¡A000 u¡A then 1¡A000 u/hr w/ alteplase. SC Venous thromboembolism 15¡A000 u 12 hrly. Prophylaxis of post-op venous thromboembolism 5¡A000 u 2 hr before surgery¡A then 8-12 hrly for 7 days or until patient is ambulant. Prevention of mural thrombosis 12¡A500 u 12 hrly for at least 10 days,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IHMG,FSH75IU + LH75IU,Humegon,HM,,,,,,,,,,,,,,,,,,,
IHUMN,Insulin NPH Human,Humulin N inj100IU/mL 10mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,2-8,According to individual requirements.,,,,¦w¥þ,,,,,,,,,,
OASV,Tipepidine,Asverin 20mg,ERSP,Relief of cough and difficulty in expectoration of sputum accompanying common cold¡A pharyngitis¡A laryngitis¡A acute bronchitis¡A chronic bronchitis¡A bronchiectasis.,Hypersensitivity to any component of the formulation.,Dizziness¡A insomnia; GI disturbances; skin itch.,25¢J¥H¤U,Adult & children >12 years: 20mg TID. Children 6-12 years: 10mg TID. Children 3-6 years: 5 mg TID. Children < 3 years old: reduce dose depended on doctor.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OATO,Formoterol,Atock 40 mcg,ERSP,,Alleviation of various symptoms egdyspnea due to airway obstructive disturbances in bronchial asthma¡A acute/chronic bronchitis¡A asthmatic bronchitis¡A pulmonary emphysema.,,,Adult 160 mg bid. Childn 4 mg/kg daily bid~tid.,,,,,,,,,,,,,,
OAUG,Amoxicillin + Clavulanic Acid,Augmentin 375mg,QANB,,Respiratory tract infections¡A skin and soft tissue infections¡A genito-urinary tract infections¡A osteomyelitis.,,,Adult & child over 40 kg: 250-500 mg q8h. Child under 40 kg: 20-40 mg/kg/day in 3 divided doses.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OAUR,Moclobemide,Aurorix 150mg,CNEU,,¾AÀ³¯g:¬°§Ü¼~Æ{¾¯¡A½w¸ÑªÀ¥æ¬ÈÄß(B019040100),,RT,300-600mg /day¡A depending on severity of depression¡A in 2-3 divided doses¡A taken after meal.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OBACC,Norfloxacin,Baccidal 100mg,QANB,,All G(+) and G(-) pathogens sensitive to norfloxacin such as urinary tract infections¡A gastrointestinal infection & gonorrhoea.,,,Urinary tract infection: Adult: 400-800 mg/day in 2-4 divided doses¡A (max. 800 mg/day). Gastrointestinal infection: 400 mg bid-tid. Gonorrhoea: 800 mg single dose.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OLEV5,Levofloxacin,Levofloxacin 500mg (¬F©²´£¨Ñ),QANB,Respiratory tract¡A ENT¡A GUT infection. Intrauterine infections¡A cervicitis¡A uterine adnesxitis¡A folliculitis. GIT infections¡A lymphangitis¡A mild to moderate skin & skin tissue infections,Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.,Dizziness¡A GI disturbances¡A rash¡A pruritus¡A vaginitis¡A genital moniliasis¡A taste perversion¡A insomnia¡A tendinitis. Rarely¡A anaphylactic reactions¡A Lyell's syndrome¡A Stevens-Johnson's syndrome.,«Ç·Å,100 mg tab Adult 100 mg bid-tid. Severe case: 200 mg tid. 500 mg tab Adult Skin & soft tissue infections 250 mg once daily or 500 mg once-bid for 7-14 days. Chronic bacterial prostatitis 500 mg once daily for 28 days. Complicated UTI including pyelonephritis 250 mg once daily for 7-10 days. Community-acquired pneumonia 500 mg once-bid for 7-14 days. Acute exacerbations of chronic bronchitis 250-500 mg once daily for 7-10 days. Acute sinusitis 500 mg once daily for 10-14 days. Infusion Adult By slow IV infusion. Community-acquired pneumonia 500 mg once-bid. Complicated UTI 250 mg once daily. Skin & soft tissue infections 500 mg bid. Dosage may be increased if necessary in severe infections. Max treatment duration: 14 days.,,,,°£«DªvÀø¤W»Ý­n,,,,,AC;PO;,,,,,
ISM1,Streptomycin,SM inj 1gm (¬F©²´£¨Ñ),QANB,,¾AÀ³¯g:Tuberculosis. Bacterial endocarditis. Plague¡A tularemia & brucellosis. Mycetoma & Whipple's disease. °Æ§@¥Î:Vestibular & auditory damage¡A nephrotoxicity¡A paraesthesia of face¡A rash¡A fever¡A urticaria¡A angioneurotic edema¡A eosinophilia. ¸T§Ò:Hypersensitivity.,,«Ç·Å,TB Adult 15-20 mg/kg body weight/day. Max: 1 g/day. Adult > 40 years & < 50 kg Max: 500-750 mg/day. May be given as part of intermittent regimen 2 or 3 times weekly. Children 15-20 mg/kg/day. Max: 1 g/day. Non-tuberculous infections Adult 1-2 g/day in divided doses. Children Up to 40 mg/kg daily in divided doses. Max: 1 g/day. Course of treatment (except TB) should be limited to 7-14 days,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OGLIV,Imatinib,Glivec 100mg,RACA,,¾AÀ³¯g: Adult & pediatrics with newly diagnosed chronic myeloid leukemia (CML)¡A CML in blast crisis¡A accelerated phase or chronic phase after failure of interferon-£\ therapy. Adult with newly diagnosed Philadelphia chromosome +ve acute lymphoblastic leukemia (Ph+ALL) integrated with chemotherapy; with relapsed or refractory Ph+ALL as montherapy; myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; systemic mastocytosis (SM) without D816V c-Kit mutation or with c-Kit mutation status unknown; hypereosinophilic syndrome (HES) &/or chronic eosinophilic leukemia (CEL); unresectable &/or metastatic¡A malignant GI stromal tumors (GIST); unresectable¡A recurrent &/or dermatofibrosarcoma protuberans (DFSP). °Æ§@¥Î: GI disturbances¡A anorexia¡A gastro-esophageal reflux¡A mouth ulceration¡A myalgia¡A muscle cramps¡A joint swelling¡A headache¡A dizziness¡A taste disturbance¡A paraesthesia¡A insomnia¡A conjunctivitis¡A increased lacrimation¡A blurred vision¡A epistaxis¡A dyspnea¡A weight gain¡A periorbital edema¡A dermatitis¡A rash¡A face & eyelid edema¡A pruritus¡A erythema¡A dry skin¡A alopecia¡A night sweats¡A fluid retention & edema¡A fatigue; pyrexia¡A weakness¡A rigors; neutropenia & febrile neutropenia¡A thrombocytopenia¡A anemia. Cardiovascular: Edema (1.1% to 86.1% ) Dermatologic: Night sweats (13% to 17% )¡A Rash (up to 49.8% ) Endocrine metabolic: Weight gain (up to 32% ) Gastrointestinal: Diarrhea (3% to 58.2% )¡A Nausea (3% to 73% )¡A Vomiting (2% to 58% ) Musculoskeletal: Arthralgia (12.3% to 40% )¡A Cramp (up to 62% )¡A Musculoskeletal pain (up to 49% )¡A Myalgia (9% to 32.2% ) Neurologic: Asthenia (15% to 21% )¡A Dizziness (12% to 16% )¡A Headache (up to 36% )¡A Insomnia (10% to 14% ) Respiratory: Cough (14% to 27% )¡A Nasopharyngitis (10% to 30.5% )¡A Pain¡A Pharyngolaryngeal (18.1% )¡A Pharyngitis (10% to 15% ) Other: Fatigue (25% to 48% )¡A Fever (16.7% to 41% )¡A Influenza (0.8% to 13.8% )¡A Rigor (10% to 12% ) ¸T§Ò: Hypersensitivity to imatinib or any component of the formulation,,«Ç·Å,Ph+ CML chronic phase 400mg qd¡A may be increase to 600mg qd Accelerated phase or blast crisis: 600mg qd increase to 800mg daily divided in two Ph+ ALL : 600mg once daily Kit+ GIST: adjuvant therapy¡A 400 mg qd; unresectable/metastatic¡A 400 mg qd; may increase up to 400 mg bid Dosage adjustment for hepatic impairment: Mild to moderate impairment : 400mg/day Severe impairment: 300mg/day ¡iLactation¡jInfant risk cannot be ruled out,»Ý½Õ¾ã¾¯¶q,Severe impairment: Reduce dose by 25%.,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,
INOV6,Eptacog alfa,Novo Seven for inj 60K IU,HEMT,,¾AÀ³¯g:Treatment of bleeding episodes & prevention of excessive bleeding in those undergoing surgery or invasive procedure in patients with congenital hemophilia with inhibitors¡A acquired hemophilia¡A Factor VII (FVII) deficiency¡A Glanzmann's thrombathenia. °Æ§@¥Î:Rarely rash¡A itching¡A fever¡A nausea¡A headache¡A general discomfort¡A perspiration or changes in BP ¸T§Ò:Hypersensitivity to mouse¡A hamsters or bovine protein.,,2-8¢J,Hemophilia with inhibitors or acquired hemophilia 90 mcg/kg 2-3 hrly or 270 mcg/kg as single IV bolus. May increase dosing frequency to 4¡A 6¡A 8 or 12 hrly. FVII deficiency 15-30 mcg/kg 4-6 hrly by IV bolus. Glanzmann's thrombasthenia 90 mcg/kg body wt (80-120 mcg/kg body wt) 2 hrly (1.5-2.5 hr) at least 3 doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IVAR0,Varicella Vaccine,¤ôµk¬Ì­](­û¤u¥Î) 0.5mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
IADA0,Diphtheria + Tetanus + Pertussis,Adacel 0.5mL (±M®×),HIMM,,,,,,,,,,,,,,,,,,,
HE5044,Dianeal 5000cc 4.25% (PD 2³æ³U),Dianeal 5000mL 4.25%(PD 2³æ³U),NUTR,,,,,DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients on CAPD typically perform 4 cycles per day (24 hours). In CAPD¡A the solution remains in the cavity for dwell times of 4 to 6 hours during the day and approximately 8 hours overnight. At the conclusion of each dwell period¡A the access device is opened¡A the solution drained and fresh solution instilled. Automated Peritoneal Dialysis (APD) Patients on APD typically perform 3-5 cycles at night and up to 2 cycles during the day. After the last outflow during the night¡A the equipment is then disconnected from the patient and the dialysate remains in the peritoneum until the next cycle. Additional exchanges can be infused by the cycler machine into the peritoneum during the daytime. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5045,Dianeal 5000cc 4.25%(PD 4³æ³U),Dianeal 5000mL 4.25% (PD 4³æ³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous administration. Intermittent Peritoneal Dialysis (IPD) For dialysis of acute renal failure patients and maintenance dialysis of chronic renal failure patients¡A the cycle of instillation¡A dwell and removal of dialysis fluid is repeated sequentially over a period of hours (8 to 36 hours) as many times per week. For chronic renal failure patients who have residual renal function¡A maintenance dialysis is often accomplished by periodic dialysis (3 to 5 times weekly) for shorter time periods (8 to 14 hours per session) Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
HE5050,Nutrineal 2000cc 1.1% (PD 4Âù³U),Nutrineal 2000mL 1.1% (PD 4Âù³U),NUTR,,,,,The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Note that the recommended daily total intake of proteins is greater than or equal to 1.2-1.3 g/kg body weight for adult dialysis patients. A 2.0L bag of Nutrineal contains 22 g of amino acids which corresponds to 0.30 g/kg body weight/24 h (approximately 25% of the daily protein requirements) for an adult dialysis patient of 70 kg body weight.,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,,,
ECOS,Dorzolamide + Timolol,Cosopt 2/0.5%¡A 5ml ophthalmic solution,TOPH,Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension¡A open-angle glaucoma¡A pseudoexfoliative glaucoma or other secondary open-angle glaucomas when concomitant therapy is appropriate.,Bronchial asthma or a history of bronchial asthma¡A or severe COPD¡A sinus bradycardia¡A 2nd or 3rd degree AV block¡A overt cardiac failure¡A cardiogenic shock.,Taste perversion¡A ocular burning &/or stinging¡A conjunctival hyperemia¡A blurred vision¡A superficial punctate keratitis or eye itching. Cardiovascular: Angina¡A Bradyarrhythmia¡A Heart failure¡A Hypertension¡A Hypotension Gastrointestinal: Nausea (less than 5%)¡A Taste sense altered (8%-42%)¡A Vomiting (less than 5%)¡A Xerostomia (less than 5%) Neurologic: Dizziness (less than 5%)¡A Headache (less than 5%) Ophthalmic: Blepharitis (5%)¡A Blurred vision (5% to 15%)¡A Burning sensation in eye (12%-30%)¡A Conjunctival hyperemia (5% to 15%)¡A Excessive tear production (15%)¡A Itching of eye (5% to 15%)¡A Light intolerance (5% to 15%)¡A Pain in eye (1%-14%) Psychiatric: Depression (less than 5%) Respiratory: Bronchitis¡A Dyspnea¡A Nasal congestion (less than 5%)¡A Upper respiratory infection (less than 5%),30¢J¥H¤UÀx¦s,Instill 1 drop BID into the conjunctival sac. Limited data available with child under 2 years old. Shake well before using.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 2nd and 3 rd trimesters,Dorzolamide ophthalmic: Limited Human Data¡XProbably Compatible Timolol ophthalmic: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] Ãh¥¥´Á¶¡¤£¥i¨Ï¥Î<COSOPT>¡C Dorzolamide ¥Ø«eµLÃh¥¥¤k©Ê¨Ï¥ÎÃÄª«ªº¾A·íÁ{§É¸ê®Æ¡C¦b¨ß¤lÅé¤º¡A§ë¤©¨ã¥ÀÅé¬r©Ê¾¯¶qªºdorzolamide·|²£¥Í­P·î­L§@¥Î¡C Timolol ¥Ø«e¨ÃµLÃö©óÃh¥¥¤k©Ê¨Ï¥ÎTimololªº¾A·í¸ê®Æ¡CÃh¥¥´Á¶¡¤£±o¨Ï¥Îtimolol¡A°£«D¦³©ú½T¥²­n©Ê¡C ¬y¦æ¯f¾Ç¬ã¨s©|¥¼ÃÒ¹ê¸g¤fªA³~®|§ë¤©BªýÂ_¾¯¥i¯à³y¦¨­P·î­L§@¥Î¡A¦ýÅã¥Ü¥i¯à¦³¤l®c¤º¥Íªø¿ðº¢ªº­·ÀI¡C¦¹¥~¡A«ùÄò¹ï¥ÀÅé§ë¤©BªýÂ_¾¯¦Ü¥Í²£«á¡A·|©ó·s¥Í¨à¨­¤WÆ[¹î¨ìBªýÂ_§@¥Î(¦p¤ß·i®}½w¡B§C¦åÀ£¡B©I§lµ~­¢¥H¤Î§C¦å¿}¯g)ªº¼x¥ü»P¯gª¬¡C¦pªG«ùÄò§ë¤©¥»ÃÄ«~¦Ü¥Í²£«á¡A·s¥Í¨à¥X¥Í«áÀY´X¤ÑÀ³¶i¦æ±K¤ÁÆ[¹î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Dorzolamide ophthalmic: No Human Data¡XProbably Compatible Timolol ophthalmic: Limited Human Data¡XProbably Compatible [¥é³æ] ¥Ø«e¨Ã¤£²M·¡dorzolamide¬O§_·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C©ó±µ¨üdorzolamide¤§­÷¨Å¤j¹«¤¤¡Aµo²{¤l¹«ªºÅé­«¼W¥[¤U­°¡CBªýÂ_¾¯·|¤Àªc¦Ü¨Å¥Ä¤º¡CµM¦Ó¡AÂI²´²G¤º¨ãªvÀø¾¯¶q¤§timolol¥i¯à¤£¨¬¥H¤Àªc¦Ü¨Å¥Ä¤º¡A¨Ã©ó·s¥Í¨àÅé¤º³y¦¨BªýÂ_§@¥ÎªºÁ{§É¯gª¬¡C ¦pªG¥²¶·¥H<COSOPT>¶i¦æªvÀø¡A«h¤£«ØÄ³­÷¨Å¡C,OD;OL;OU;,,,,,
EPER,Test Strips,Performa test strips¡A 50strips(Ã¹¤ó),ZOTH,,,,2-30¢J,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EULTR,Test Strips,Ultra test strips(§§¥Í),ZOTH,,,,,,,,,,,,,,,,,,,
INES,Darbepoetin alfa,NESP inj 20mcg(­­¦Û¶O-¬~µÇ¥Î),HEMT,,¾AÀ³¯g: Treatment of anemia associated with chronic renal failure (CRF)¡A including patients either on or not on dialysis. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. °Æ§@¥Î: Vascular thrombosis¡A CHF¡A sepsis¡A cardiac arrhythmia¡A infections¡A HTN¡A hypotension¡A myalgia¡A headache¡A diarrhea¡A fever¡A nausea¡A chest pain. ¸T§Ò: Uncontrolled HTN.,,2-8¢J,CRF patients Administered either IV/SC as a single weekly injection. Dose should be started & slowly adjusted to achieve & maintain a target Hb 10-12 g/dL. Reduce dose by 25% if rise in Hb is > 1 g/dL in 2 weeks. Correction of anemia Adult Initially 0.45 mcg/kg as single SC/IV once weekly. Maintain a target Hb 10-12 g/dL. Conversion From epoetin £\ to NESP Starting weekly dose should be estimated on the basis of the weekly epoetin £\ dose at the time of substitution. Administer once weekly if a patient was receiving epoetin £\ 2-3 times weekly. Administer once every 2 weeks if a patient was receiving epoetin £\ once weekly. Cancer patients receiving chemotherapy 2.25 mcg/kg once weekly. Increase dose to 4.5 mcg/kg if the rise in Hb is > 1 g/dL after 6 weeks. Refer full prescribing information for dosage adjustment.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IADEN,Adenosine,Adenozer inj 6mg/2mL,CAVS,,¾AÀ³¯g: Treatment of paroxysmal supraventricular tachycardias. Diagnostic in narrow & broad-complex tachycardias °Æ§@¥Î: >10%: Cardiovascular: Cardiac arrhythmia (transient and new arrhythmia after cardioversion; eg¡A atrial premature contractions¡A atrial fibrillation¡A premature ventricular contractions; 55%)¡A chest pressure (and discomfort; 7% to 40%) Central nervous system: Headache (2% to 18%)¡A dizziness (?12%) Dermatologic: Facial flushing (18% to 44%) Gastrointestinal: Gastrointestinal distress (13%) Neuromuscular & skeletal: Neck discomfort (includes throat¡A jaw; <1% to 15%) Respiratory: Dyspnea (12% to 28%) 1% to 10%: Cardiovascular: Atrioventricular block (infusion 6%; third-degree <1%)¡A depression of ST segment on ECG (3%)¡A hypotension (<1% to 2%)¡A chest pain¡A palpitations Central nervous system: Nervousness (2%)¡A paresthesia (?2%)¡A numbness (1%)¡A apprehension Dermatologic: Diaphoresis Gastrointestinal: Nausea (3%) Neuromuscular & skeletal: Upper extremity discomfort (?4%) Respiratory: Hyperventilation <1%¡A postmarketing¡A and/or case reports: Asystole (prolonged)¡A atrial fibrillation¡A blurred vision¡A bradycardia¡A bronchospasm¡A burning sensation¡A cardiac arrest (fatal and nonfatal)¡A increased intracranial pressure¡A injection site reaction¡A loss of consciousness¡A metallic taste¡A myocardial infarction¡A respiratory arrest¡A seizure¡A torsades de pointes¡A transient hypertension¡A ventricular arrhythmia¡A ventricular fibrillation¡A ventricular tachycardia ¸T§Ò: Hypersensitivity to adenosine or any component of the formulation; second- or third-degree AV block¡A sick sinus syndrome¡A or symptomatic bradycardia; known or suspected bronchoconstrictive or bronchospastic lung disease¡A asthma.,,«Ç·Å,Initially 3 mg by rapid IV bolus inj over 2 seconds. If required¡A a 2nd dose of 6 mg & 3rd dose of 12 mg at 1-2 min intervals may be given.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVP;,,,§Ö³tÀR¯ßª`®g (3mg > 2¬í)¡C,,
EAVA,Fluticasone,Avamys 27.5mcg/dose¡A 120dose nasal spray,TENT,Treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.,Hypersensitivity to any ingredients of Avamys.,Headache¡Adizziness¡A epistaxis¡A pharyngitis¡A nausea¡A vomiting¡A asthma symptoms¡A nasal ulceration. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ),30¢J¥H¤UÀx¦s,Allergic rhinitis (fluticasone furoate): Intranasal adult¡A two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg/day). Children 2 to 11 years: Initial: 1 spray per nostril once daily (total daily dose: 55 mcg/day),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IN;,,,,,
ILUC,Ranibizumab,Lucentis inj 3mg/0.3mL,TOPH,,Treatment of neovascular (wet) age-related macular degeneration (AMD). ¸T§Ò: Patients with active or suspected ocular or periocular infections. Patients with active intraocular inflammation. ¤£¨}¤ÏÀ³:Nasopharyngitis¡A influenza; anemia; anxiety; headache¡A stroke; intraocular inflammation¡A vitritis¡A vitreous detachment¡A retinal hemorrhage¡A visual disturbance¡A eye pain¡A vitreous floaters¡A conjunctival hemorrhage¡A eye irritation¡A foreign body sensation in eyes¡A lacrimation increased¡A blepharitis¡A dry eye¡A ocular hyperemia¡A eye pruritus; retinal degeneration¡A retinal disorder¡A retinal detachment¡A retinal tear¡A detachment of retinal pigment epithelium¡A retinal pigment epithelium tear¡A visual acuity reduced¡A vitreous hemorrhage¡A vitreous disorder¡A uveitis¡A iritis¡A iridacyclitis¡A cataract¡A calaract subcapsular¡A posterior capsule opacification¡A punctuate keratitis¡A corneal abrasion¡A anterior chamber flare¡A vision blurred¡A inj site hemorrhage¡A eye hemorrhage¡A conjunctivitis¡A conjunctivitis allergic¡A eye discharge¡A photopsia¡A photophobia¡A ocular discomfort¡A eyelid edema¡A eyelid pain¡A conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased.,,,0.5 mg (0.05 mL) by intravitreous inj¡A initiated with a loading phase of 1 inj/mth for 3 consecutive months followed by a maintenance phase in which patients should be monitored for visual acuity on a monthly basis. Interval between 2 doses should not be < 1 month.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OMYC,Metolazone,Mycros 0.5mg,CAVS,,¾AÀ³¯g: Hypertension. °Æ§@¥Î: Dizziness¡A headache¡A muscle cramps¡A fatigue¡A joint pain¡A swelling¡A chest pain. ¸T§Ò: Anuria¡A hepatic coma or pre-coma; allergy or hypersensitivity to metolazone.,,,1 tab once daily¡A usually in the morning. may be increased to 2 tab once daily.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ODUL,Bisacodyl,Dulcolax 5mg,ALIM,,¾AÀ³¯g: ¬°Âm¾¯(A028503100) Constipation. Preparation of diagnostic procedures¡A in pre- & post-op treatment & in conditions which require defecation to be facilitated. °Æ§@¥Î: Rarely¡A abdominal cramps¡A abdominal pain & diarrhea. ¸T§Ò: Ileus¡A intestinal obstruction¡A acute abdominal conditions including appendicitis¡A acute inflammatory bowel diseases & severe abdominal pain associated with nausea & vomiting. Severe dehydration. Rare hereditary conditions of galactose intolerance eg. galactosemia or fructose intolerance.,,«Ç·Å,Oral: Adult: 10-15 mg qn. Child Over 4 yrs: 5 mg¡A as one dose only.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OEBI,Memantine,Ebixa 10mg,CNEU,Treatment of adult patients with moderate to severe Alzheimer¡¦s disease.,Hypersensitivity to the active substance or to any of the excipients.,Common Gastrointestinal: Constipation (3% to 5% )¡A Diarrhea (5% )¡A Vomiting (2% to 3% ) Neurologic: Confusion (6% )¡A Dizziness (5% to 7% )¡A Headache (adults¡A 6% ; pediatrics¡A 8% ) Serious Neurologic: Cerebrovascular accident¡A Seizure (up to 0.3% ) Renal: Acute renal failure Respiratory: Pneumonia,«Ç·Å,Initial¡A 5 mg orally once daily; titrate in 5-mg increments at intervals of at least 1 week to 10 mg/day (5 mg twice daily)¡A 15 mg/day (5 mg and 10 mg in separate doses)¡A and 20 mg/day (10 mg twice daily); target daily dose is 20 mg/day.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]»´·L©Î¤¤«×¨ü·l±wªÌ(Child-Pugh A and B)¤£»Ý½Õ¾ã¾¯¶q¡CÄY­«¨ü·l±wªÌ¤£«ØÄ³¨Ï¥Î¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]µLmemantine¥Î©ó¥¥°ü¤§Á{§É¸ê®Æ¡C°Êª«¹êÅç«ü¥X¡A¼ÉÅS©ó¦X¤HÅé¤@­P©Îµy°ªªº¿@«×¤U¡A·|©µ´î½w­L¨à¤§¤l®c¤º¥Íªø¡C¨Ï¥Î©ó¤HÅé¤§¼ç¦b©Ê­·ÀI¥¼ª¾¡A°£«D©ú½T»Ý­n¡A§_«hmemantine¤£À³¥Î©ó¥¥°ü¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¨Ã¥¼ª¾memantine¬O§_·|±Æªn¦Ü¨Å¥Ä¡A¦ý¦Ò¼{¨ì¥»«~ªº¿Ë¯×©Ê¡A¦¹±¡ªp¥i¯àµo¥Í¡C¦]¦¹ªA¥Îmemantine¤§°ü¤k¤£À³±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
OCAD,Amlodipine + Atorvastatin,Caduet 5/20mg,CAVS,Primary prevention of cardiovascular disease (high-risk for cardiovascular disease [CVD]): To reduce the risk of MI¡A stroke¡A and revascularization procedures and angina in adults without clinically evident coronary heart disease (CHD).,Active liver disease; unexplained persistent elevations of serum transaminases; pregnancy or women who may become pregnant; breastfeeding. Hypersensitivity to amlodipine¡A atorvastatin¡A or to other dihydropyridine calcium channel blockers; severe hypotension (systolic <90 mm Hg).,Amlodipine: Headache¡A dizziness¡A fatigue¡A somnolence¡A peripheral oedema¡A flushing¡A palpitations¡A nausea¡A abdominal pain; rarely pruritus¡A rash¡A dyspnoea¡A asthenia and muscle cramps. Atorvastatin: Nasopharyngitis¡A arthralgia¡A diarrhoea¡A pain in extremity¡A UTI¡A dyspepsia¡A nausea¡A musculoskeletal pain¡A muscle spasms¡A myalgia¡A insomnia¡A increased transaminases¡A abnormal liver function test¡A increased creatinine phosphokinase¡A thrombocytopenia¡A malaise¡A hepatitis¡A cholestasis¡A bullous rashes. Potentially Fatal: Rhabdomyolysis with acute renal failure.,15-30¢J,Amlodipine: Initial¡A 5-10 mg orally once daily¡A titrate after 7-14 days to clinical response; if needed¡A titration may proceed more rapidly; Atorvastatin: Initial¡A 10-20 mg orally once daily; titrate within 2-4 weeks according to laboratory values; maintenance¡A 10-80 mg once daily.,»Ý½Õ¾ã¾¯¶q,May initiate Amlodipine component at 2.5 mg once daily. Use is contraindicated in active liver disease or unexplained persistent elevations of serum transaminases.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,Amlodipine: Human Data Suggest Low Risk Atorvastatin: Contraindicated 1st Trimester [¥é³æ] Atorvastatin¸T¥Î©óÃh¥¥¤k©Ê¡A¦]¬°¦bÃh¥¥¤k©Ê¤¤ªº¦w¥þ©Ê©|¥¼½T¥ß¡A¦Ó¥B­°¦å¯×ÃÄª«¦bÃh¥¥´Á¶¡¨S¦³©úÅãªº®Ä¯q¡C¥Ñ©óHMG-CoAÁÙ­ìžJ§í¨î¾¯·|´î¤ÖÁx©T¾J¦X¦¨¡AÁÙ¥i¯à´î¤Ö¥ÑÁx©T¾J­l¥Í¤§¨ä¥L¥Íª«¬¡©Êª«½èªº¦X¦¨¡A¦]¦¹atorvastatin¥Î©óÃh¥¥¤k©Ê®É¥i¯à¹ï­L¨à³y¦¨¦M®`¡C CADUETÀ³©óµo²{Ãh¥¥«á¥ß§Y°±¥Î¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Amlodipine: Compatible Atorvastatin: Contraindicated [¥é³æ] CADUET¤£±o¦b­÷Áý¥À¨Å´Á¶¡¨Ï¥Î¡C Atorvastatin¤£±o¦b­÷Áý¥À¨Å´Á¶¡¨Ï¥Î¡CÃö©ó¦¹ÃÄ¹ï­÷¨ÅÀ¦¨àªº¼vÅT¡A©Î¦¹ÃÄ¹ï¨Å¥Ä¥Í¦¨ªº¼vÅT¡A¨S¦³¬ÛÃö¸ê°T¡C¥Ø«e¨Ã¤£²M·¡atorvastatin¬O§_¦s¦b©ó¤HÃþ¨Å¥Ä¡A¦ý¬ã¨sÅã¥Ü¦¹Ãþ§O¤¤¥t¤@ºØÃÄª«¥i¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¥Batorvastatin¦s¦b©ó¤j¹«¨Å¥Ä¤¤¡C¥Ñ©ó¥i¯à¦b­÷¨ÅÀ¦¨à¤¤³y¦¨ÄY­«¤£¨}¤ÏÀ³¡A¦]¦¹½Ð§iª¾¤k©Ê¤£«ØÄ³¦bCADUETªvÀø´Á¶¡­÷Áý¥À¨Å¡C Amlodipine¥Ñ¤wµoªíªºÁ{§É±Â¨Å¬ã¨s±o¨ìªº¦³­­²{¦³¸ê®Æ«ü¥X¡Aamlodipine¥H¦ôºâ¬°4.2%ªº¤¤¦ì¬Û¹ïÀ¦¨à¾¯¶q¦s¦b©ó¤HÃþ¨Å¥Ä¤¤¡C¥¼´¿Æ[¹î¨ìamlodipine¹ï­÷¨ÅÀ¦¨à³y¦¨¤£¨}¤ÏÀ³¡CÃö©óamlodipine¹ï¨Å¥Ä¥Í¦¨ªº¼vÅT¡A¥Ø«e¨S¦³¬ÛÃö¸ê°T¡C,AC;AC15;PC;PO;WM;,,,,,
OENZ,Serratiopeptidase,Enzdase EC 5mg,CNEU,,¾AÀ³¯g: Inflammation after operation & traumatic injury¡A inadequate expectoration of sputum in respiratory disease. °Æ§@¥Î:Skin rash; diarrhoea¡A anorexia¡A GI disturbances¡A epistaxis (rare). ¸T§Ò: Blood coagulation disorders.,,«Ç·Å,15-30 mg/day.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OERY,Erythromycin,Erythromycin 250mg,QANB,Susceptible infections ¡AProphylaxis against pneumococcal infections; Prevention of streptococcal infections in patients w/ rheumatic fever or heart disease.,Hypersensitivity. Patient receiving astemizole¡A terfenadine¡A cisapride¡A pimozide¡A ergotamine or dihydroergotamine.,Rash¡A urticaria; nausea¡A vomiting¡A GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis. Potentially Fatal: Hepatotoxicity¡A cholestatic jaundice; raised serum transaminases; eosinophilia.,25¢J¥H¤U,Adult 250-500 mg orally Q6H. Children 20-40 mg/pound/day¡A divided Q6H. (¼ö¯f) Pediatric dose: 40-50 mg/kg/day¡A divided Q6H.,»Ý½Õ¾ã¾¯¶q,drug may accumulate in patients with severe liver disease; no specific dosing recommendations available,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Drugs in Pregnancy and Lactation µL¥¥°ü¨Ï¥Î estolate salt¸ê®Æ¡C (2020.12.02§ó·s),Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OBACL,Baclofen,Baclon 10mg,CNEU,,¾AÀ³¯g:¬°¦Ù¦×ÃP¦¢¾¯(B019346100)(B020226100),,RT,5 mg tid for 3 days¡A 10 mg tid for 3 days¡A 15 mg tid for 3 days¡A 20 mg tid for 3 days. Max daily dose: 80 mg.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OBAE,Methylcobalamin,Baesukang 500mcg,CNEU,,¾AÀ³¯g:¥½µy©Ê¯«¸g»ÙÃª(A029759100) Peripheral neuropathies¡A megaloblastic anaemia caused by vit B12 deficiency. °Æ§@¥Î:Anorexia¡A nausea¡A vomiting and diarrhoea. Parenteral: Rash¡A headache¡A hot sensation.,,«Ç·Å,Adult: PO Peripheral neuropathies 1¡A500 mcg/day in 3 divided doses. IV/IM Peripheral neuropathies 500 mcg/day 3 times/wk. Megaloblastic anaemia caused by vit B12 deficiency 500 mcg/day 3 times/wk for about 2 mth. Maintenance: 500 mcg 1-3 mthly.,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OBAK,Sulfamethoxazole + Trimethoprim,Baktar(Trimerin) 400 / 80,QANB,,,,RT,Antimicrobial: Adult: 2 tab q12h. Child over 2 months under 40 kg: 20 mg/kg syr & 4 mg/kg tab q12h. Antiprotozoal (Pneumocystis carinii pneumonia): Adult & child over 2 months: 18.75-25 mg/kg syr. & 3.75-5 mg/kg tab q6h for 2 wks.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OBEC,Sodium Dibunate,Becantex S.C. 30mg,ERSP,,¾AÀ³¯g:¤î«y§@¥Î(A035817100) Cough. °Æ§@¥Î: GI discomfort.,,«Ç·Å,1 tab tid-qid.Childn:4~8mg/kg. Adult 90-240 mg/day. Children 7-15 years 60-120 mg/day¡A 2-7 years 60-90 mg/day¡A < 2 years 22-38 mg/day. Divided in 3 or 4 doses.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OPRS,Finasteride,Proscar 5mg,SGU,Treatment & control of benign prostatic hyperplasia (BPH) to cause regression of enlarged prostate¡A improve urine flow & improve the symptoms of BPH.,Women & paediatric patients.,Impotence¡A decreased libido & volume of ejaculate.,30¢J¥H¤UÁ×¥ú,5mg daily.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à²§±`±wªÌÀ³¤p¤ß§ë»P¡A(¦]Finasteride¥D­n¬O¦b¨xÅ¦¥NÁÂ),µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C¿õ¾¯ÂÐ¦³½¤¦ç¡A­YµL¯}·l¥i¨¾¤î¥­±`Ä²ºN®Éª½±µ±µÄ²¦³®Ä¦¨¥÷¡C
OPTU,Propylthiouracil,Procil 50mg,META,,¾AÀ³¯g: Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy; treatment of hyperthyroidism in patients intolerant of methimazole and not candidates for surgical/radiotherapy °Æ§@¥Î: Cardiovascular: Periarteritis¡A vasculitis (ANCA-positive¡A cutaneous¡A leukocytoclastic) Central nervous system: Drowsiness¡A drug fever¡A fever¡A headache¡A neuritis¡A vertigo Dermatologic: Alopecia¡A erythema nodosum¡A exfoliative dermatitis¡A pruritus¡A skin pigmentation¡A skin rash¡A skin ulcers¡A urticaria Endocrine & metabolic: Goiter¡A weight gain Gastrointestinal: Constipation¡A loss of taste¡A nausea¡A sialoadenopathy¡A splenomegaly¡A stomach pain¡A taste perversion¡A vomiting Hematologic: Agranulocytosis¡A aplastic anemia¡A bleeding¡A granulopenia¡A hypoprothrombinemia¡A leukopenia¡A thrombocytopenia Hepatic: Acute liver failure¡A cholestatic jaundice¡A hepatitis Neuromuscular & skeletal: Arthralgia¡A myalgia¡A paresthesia Renal: Acute renal failure¡A glomerulonephritis¡A nephritis Respiratory: Alveolar hemorrhage¡A interstitial pneumonitis Miscellaneous: Lymphadenopathy¡A SLE-like syndrome ¸T§Ò:Hypersensitivity to propylthiouracil or any component of the formulation,,RT,Dosing: Adult --Hyperthyroidism: Oral: Initial: 300 mg/day in 3 divided doses¡A usual maintenance: 100-150 mg/day --Graves¡¦ disease (off-label use): Oral: Initial: 50-150 mg (depending on severity) 3 times daily to restore euthyroidism; maintenance: 50 mg 2-3 times daily for a total of 12-18 months¡A then tapered or discontinued if TSH is normal at that time Thyrotoxic crisis/thyroid storm (off-label use): Oral: Typical dosing is 800-1200 mg/day given as 200-300 mg every 4-6 hours; maintenance dosage (100-600 mg/day in divided doses) Dosing: Pediatric --Hyperthyroidism: Oral: Children: Initial: 5-7 mg/kg/day or 150-200 mg/m2/day in divided doses every 8 hours or 6-10 years: 50-150 mg/day >10 years: 150-300 mg/day,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OREL,Buspirone,Relac 5mg,CNEU,,¾AÀ³¯g: Anxiety. °Æ§@¥Î: Dizziness¡A nausea¡A headache¡A nervousness¡A lightheadedness¡A excitement; rarely tachycardia¡A palpitations¡A chest pain¡A drowsiness¡A tinnitus. Gastrointestinal: Nausea (3%) Neurologic: Asthenia (2%)¡A Confusion (2%)¡A Dizziness (9%)¡A Excitement (2%)¡A Headache (3%)¡A Numbness (2%) Ophthalmic: Blurred vision (2%) Psychiatric: Feeling angry (2%)¡A Feeling nervous (4%)¡A Hostile behavior (2%) ¸T§Ò: Epilepsy¡A severe hepatic or renal impairment¡A pregnancy & lactation. Breast feeding.,,«Ç·Å,Initially 5 mg bid-tid¡A increase as necessary every 2-3 days; usual range 15-30 mg daily in divided doses; max: 60 mg daily.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OREN2,Enalapril,Renitec 20mg,CAVS,,,,,,,,,,,,,,,,,,,
HE5060,Extraneal 2L 7.5% 3.5meq/LÂù³U,Extraneal 2L 7.5% 3.5meq/LÂù³U,NUTR,,,,,Adults By intraperitoneal administration limited to a single exchange in each 24 hour-period¡A as part of a CAPD or APD regimen. The volume to be instilled should be given over a period of approximately 10 to 20 minutes at a rate which the patient finds comfortable. For adult patients of normal body size the instilled volume should not exceed 2.0 L. If the instilled volume causes discomfort due to abdominal tension the instilled volume should be reduced to 1.5 L. The recommended dwell time is between 6 and 12 hours in CAPD and 14-16 hours in APD. Drainage of the fluid is by gravity at a rate comfortable for the patient.,µL»Ý½Õ¾ã¾¯¶q,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
HE5061,Extraneal 2L 7.5% 3.5meq/L³æ³U,Extraneal 2L 7.5% 3.5meq/L³æ³U,NUTR,,,,,Adults By intraperitoneal administration limited to a single exchange in each 24 hour-period¡A as part of a CAPD or APD regimen. The volume to be instilled should be given over a period of approximately 10 to 20 minutes at a rate which the patient finds comfortable. For adult patients of normal body size the instilled volume should not exceed 2.0 L. If the instilled volume causes discomfort due to abdominal tension the instilled volume should be reduced to 1.5 L. The recommended dwell time is between 6 and 12 hours in CAPD and 14-16 hours in APD. Drainage of the fluid is by gravity at a rate comfortable for the patient.,µL»Ý½Õ¾ã¾¯¶q,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ELID4,Lidocaine,Lidocaine solution 4% 30mL,ZANE,,¾AÀ³¯g: Local anesth in bronchoscopy¡A bronchography¡A laryngoscopy¡A oesophagoscopy¡A endotracheal intubation¡A & biopsy in the mouth & throat. °Æ§@¥Î: Rarely¡A allergic reactions¡A CNS excitation or depression¡A hypotension¡A bradycardia. ¸T§Ò: Previously known hypersensitivity to local anaesthetics of amide type.,,«Ç·Å,Adult 2-7.5 mL (80-300 mg lidocaine); up to 400 mg may be administered during prolonged (> 5 mins) procedures. With applications mainly to the larynx¡A trachea & bronchi¡A the dose should not exceed 5 mL (200 mg lidocaine). When inhaled from a nebulizer¡A 5-10 mL (200-400 mg lidocaine HCl) may be used.,,,,¥i¯à¦w¥þ,,,,,,,,,,
IMIL,Nitroglycerin,Millisrol inj 5mg/10mL,CAVS,Control of peri-op hypertension; CHF associated with acute MI. Treatment of angina pectoris unresponsive to recommended doses of organic nitrates &/or a £]- blocker. Production of controlled hypotension during neurosurgical & orthopedic surgical procedures.,Glaucoma¡A severe anemia.,Tachycardia¡A arrhythmia¡A sudden drop of BP¡A deterioration of cardiac output¡A methemoglobinemia¡A headache¡A nausea¡A vomiting. Cardiovascular: Hypotension Dermatologic: Erythroderma¡A Flushing¡A Rash Neurologic: Headache (63% )¡A Lightheadedness (6% ),Á×¥ú¡A«Ç·ÅÀx¦s,Diluted to 0.005-0.05% (50-500 mcg/mL)¡A IV infusion rate: 0.05-5 mcg/kg/minute according to indications and responses. Maintenance of reduced blood pressure during surgery: 1-5 mcg/kg/minute. Emergent treatment for hypertension during surgery: 0.5-5 mcg/kg/minute. Acute heart failure (including the acute exacerbation period of chronic heart failure): Initially 0.05-0.1 mcg/kg/minute¡A then increase drip rate to 0.1-0.2 mcg/kg/minute every 5-15 minutes until desired response is obtained.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5NS¡j¥i¿ï ¡C,,µ}ÄÀ¦¨0.005 ~ 0.05% (50 ~ 500 mcg/mL)¡AIV infusion rate: 0.05 - 5 mcg/kg/min¨Ì¾AÀ³¯g¤£¦P¡AÀ³¨Ï¥Î¬Á¼þ©Înon-PVC§÷½è¡C,1. À³¨Ï¥Î¬Á¼þ©Înon-PVC§÷½è 2. ÂIºw³t«×¸û§C¤Î¿éª`ºÞ¸ûªø¡A¬Ò·|¼W¥[¿éª`®ÉÃÄ«~³Q§lªþªº¤ñ²v¡C 3. ¨Ï¥Î¥»¾¯À³ºÊ´ú¦åÀ£¡C
ICIT3,Thiamylal,Citosol inj 300mg,ZANE,Anaesth for diagnostic & surgical procedures; induction of anaesth or to supplement low potency agent,Shock & circulatory insufficiency due to severe hemorrhage¡A severe cardiac insufficiency¡A acute & intermittent porphyria¡A Addison's disease¡A severe bronchial asthma. Hypersensitivity to barbiturates.,During anesth: respiratory arrest or depression¡A laryngospasm¡A hypotensin¡A arrhythmia¡A rash. After anesth: nausea¡A vomiting¡A headache¡A dizziness¡A tearing eyes¡A tremor¡A spasm¡A excitation¡A face flush¡A diplopia¡A numbness¡A urinary retention¡A drowsiness.,25¢J¥H¤U,Use 2.5% solution for IV injection. Induction of general anesthesia: 50-100mg (2.5% solution¡A 2-4 mL) Anesthesia of short duration: 50-75mg (2.5% solution¡A 2-3mL) IV over 10-15 seconds initially¡A monitor the reaction for 30 seconds¡A if necessary¡A may readminister 50-75mg to produce anesthesia state. For maintaining the depth of anesthesia when the operation is not completed¡A give 25-100mg (2.5% solution¡A 1-4 mL). Maximum: 1000 mg for each time. Anesthesia for psychological electroconvulsive therapy: 300mg over 25-35 seconds (2.5% solution¡A 12 mL). Combine use with local or inhaled anesthetics: 50-100mg IV drip intermittently (2.5% solution¡A 2-4mL). Seizure: 50-200mg IV slowly (2.5% solution¡A 2-8mL).,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃªªÌÀ³ÂÔ·V¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ²G(300mg powder + 12mLµ}ÄÀ²G¡A¨Ï¥Î¿@«×¬°2.5%¡A¤j©ó5%·|¤Þ°_ÀR¯ßª¢),,IV test dose: 3mL¡A¨S°ÝÃD«á¥H1mL/5 sec³t²vµ¹ÃÄ¡AMax:1g/¦¸ (300mg ¯»¾¯¥[¤J©Òªþ·»¸Ñ²G12 mL¡Aµ}ÄÀ«áÃÄª«¿@«× 2.5 %),IV test dose: 3mL¡A¨S°ÝÃD«á¥H1mL/5 sec³t²vµ¹ÃÄ¡AMax:1g/¦¸ (300mg ¯»¾¯¥[¤J©Òªþ·»¸Ñ²G12 mL¡Aµ}ÄÀ«áÃÄª«¿@«× 2.5 %),1. ¥»ÃÄ«~¬°³Â¾K»¤¾ÉÃÄ«~¡A­­¥ÑÂå®v¨Ï¥Î¡C 2. 300mg ¯»¾¯¥[¤J©Òªþ·»¸Ñ²G12 mL¡Aµ}ÄÀ«áÃÄª«¿@«× 2.5 % (¤j©ó5 % ·|¤Þ°_ÀR¯ßª¢)¡C 3. ¥»ÃÄ«~¤§³Ì¤j¶q¬°¤@¦¸ 1 gmÀR¯ß¤º§ë»P¡C
OSYNS,Estradiol + Medroxyprogesterone,Synseq (28 tablets/box),HM,Treat menopause symptoms such as hot flashes and vaginal changes¡A and to prevent osteoporosis (bone loss) in menopausal women.,Unusual vaginal bleeding that has not been checked by a doctor; liver disease; a history of heart attack¡A stroke¡A or blood clot; an increased risk of having blood clots due to a heart problem or a hereditary blood disorder; or a history of hormone-related cancer¡A or cancer of the breast¡A uterus/cervix¡A or vagina.,Heart attack symptoms: chest pain or pressure¡A pain spreading to your jaw or shoulder¡A nausea¡A sweating; signs of a stroke: sudden numbness or weakness (especially on one side of the body)¡A sudden severe headache¡A slurred speech¡A problems with vision or balance; signs of a blood clot: sudden vision loss¡A stabbing chest pain¡A feeling short of breath¡A coughing up blood¡A pain or warmth in one or both legs; swelling or tenderness in your stomach; jaundice (yellowing of the skin or eyes); memory problems¡A confusion¡A unusual behavior; unusual vaginal bleeding¡A pelvic pain; a lump in your breast; or high levels of calcium in your blood: nausea¡A vomiting¡A constipation¡A increased thirst or urination¡A muscle weakness¡A bone pain¡A lack of energy. Common side effects may include: nausea¡A gas¡A stomach pain; headache¡A back pain; depression¡A weakness; breast pain; itching¡A thinning scalp hair; or vaginal itching or discharge¡A changes in your menstrual periods¡A breakthrough bleeding.,25¢J¥H¤U³±²D°®Àêªº¦a¤è,1 tablet daily.,µL»Ý½Õ¾ã¾¯¶q,«æºC©Ê¨x¯f±w©Î´¿±w¨x¯f¡A¥B¨ä¨x¥\¯à©|¥¼«ì´_¥¿±`ªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
ONIL2,Betahistine,Nilasen 24mg,CNEU,Vertigo & hearing impairment associated with Meniere's syndrome. Treatment of vestibular vertigo.,Hypersensitivity to any component of the formulation.,Mild gastric complaints. Very rarely¡A rash¡A pruritus¡A urticaria.,25¢J¥H¤U°®Àê³õ©Ò,Adult: 24mg BID. It is recommended that the drug be taken with meals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IKCL2,Potassium Chloride,20mEq KCl in 0.9%NaCl 500mL,NUTR,Hypokalaemia,Hyperkalemia.,Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg¡A heart block¡A ventricular arrhythmias¡A asystole).,30¢J¥H¤UÁ×¥úÁ×§K§N­á,Adult: Initial loading dose: 40~60 mEq¡A with ECG monitoring then based on serum potassium levels¡A Serum K>2.5 mEq/L: concentration < 30 mEq/L¡A with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia¡A treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
YHYA,Hyaluronic acid,Hyalofemme Lubricant 30gm,MSGO,¥Dªv³±¹DµäÁY¯g¡A°®Àß.,¹ï²£«~¹L±Ó,,,Use applicator scale 2.5gm gel to apply vagina BIW for vaginal atrophy. No need to stop medication during menstrual cycle.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,VAG;,,,,,
ONIC4,Nicotine,Nicorette ©CÄZ¿õ 4mg (Á¡²ü¨ý),ZADT,,,,,(Uptodate) Gum: If strong or frequent cravings are present after 1 piece of gum¡A may use a second piece within the hour (do not continuously use one piece after the other). Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. The 12-week dosing schedule (max 24 pieces/day): Weeks 1-6: Chew 1 piece of gum Q1-2H; chew at least 9 pieces/day during the first 6 weeks. Weeks 7-9: Chew 1 piece of gum Q2-4H. Weeks 10-12: Chew 1 piece of gum Q4-8H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,NICOTINE REPLACEMENT THERAPY Central Nervous System (Smoking Deterrent) PREGNANCY RECOMMENDATION: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk Contraindicated (with any use of tobacco),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,NICOTINE REPLACEMENT THERAPY Central Nervous System (Smoking Deterrent) BREASTFEEDING RECOMMENDATION: Limited Human Data¡XPotential Toxicity,,,,,,
ONIC2,Nicotine,Nicorette ©CÄZ¿õ 2mg (Á¡²ü¨ý),ZADT,,,,,(Uptodate) Gum: If strong or frequent cravings are present after 1 piece of gum¡A may use a second piece within the hour (do not continuously use one piece after the other). Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. The 12-week dosing schedule (maximum: 24 pieces/day): Weeks 1-6: Chew 1 piece of gum Q1-2H; chew at least 9 pieces/day during the first 6 weeks. Weeks 7-9: Chew 1 piece of gum Q2-4H. Weeks 10-12: Chew 1 piece of gum Q4-8H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,
ONIQ2,Nicotine,NiQuitin §ÙµÒ¤f§t¿õ 2mg,ZADT,,,,,,,,,,,,,,,,,,,
ONIQ4,Nicotine,NiQuitin §ÙµÒ¤f§t¿õ4mg (24's/Bot),ZADT,,,,,,,,,,,,,,,,,,,
OJANM,Sitagliptin + Metformin,JanuMET 50/500mg,META,,¾AÀ³¯g: Diabetes mellitus type 2 °Æ§@¥Î: Diarrhea¡A nausea¡A vomiting¡A flatulence¡A abdominal discomfort¡A indigestion¡A asthenia & headache. Hypoglycemia. Hypersensitivity reactions. Musculoskeletal: Asthenia (greater than 5% ) Neurologic: Headache (greater than 5% ) Respiratory: Nasopharyngitis (greater than 5% ) ¸T§Ò: Renal disease or dysfunction¡A abnormal CrCl which may result from CV collapse¡A acute MI & septicemia. Acute or chronic metabolic acidosis including diabetic ketoacidosis¡A with or without coma. Temporarily discontinue treatment in patients undergoing radiologic studies. Type 1 diabetes¡A diabetic ketoacidosis.,,«Ç·Å,should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis Diabetes mellitus type 2: dosage should be individualized based on patient's current regimen¡A effectiveness¡A and tolerability; MAX sitagliptin 100 mg and metformin 2000 mg per day (given twice a day in divided doses with meals) Diabetes mellitus type 2: (inadequately controlled on metformin monotherapy) initial¡A sitagliptin 50 mg plus current dose of metformin ORALLY twice daily Diabetes mellitus type 2: (inadequately controlled on metformin 850 mg twice daily) initial¡A sitagliptin 50 mg/metformin 1000 mg ORALLY twice daily Diabetes mellitus type 2: (inadequately controlled on sitagliptin monotherapy) initial¡A sitagliptin 50 mg/metformin 500 mg ORALLY twice daily Diabetes mellitus type 2: (switching from sitagliptin co-administered with metformin) initial¡A same as current doses of sitagliptin and metformin Diabetes mellitus type 2: when administered with a sulfonylurea or with insulin¡A a lower dose of sulfonylurea or insulin may be required,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IAMIF,Amino Acid + Dextrose,Aminofluid 1000mL,NUTR,,¾AÀ³¯g:Provision of electrolytes¡A glucose & amino acids in inadequate oral intake before & after surgery. ¸T§Ò:Hepatic coma or risk of hepatic coma; severe renal disorder or azotemia; CHF; severe acidosis; abnormal electrolyte metabolism¡A hyperpotassemia¡A hyperphosphatemia¡A hypermagnesemia¡A hypercalcemia; reduced urine output; abnormal amino acid metabolism °Æ§@¥Î: Rash¡A chest discomfort¡A palpitation¡A cerebral¡A pulmonary & peripheral edema¡A hyperpotassemia¡A acidosis¡A water intoxication¡A vascular pain¡A phlebitis¡A chills¡A fever¡A feeling of warmth¡A headache.,,«Ç·Å,Adult Usual dose: 500 mL infused via peripheral vein. Max: 2500 mL/day. Infusion rate: 500 mL/120 min¡A slowed in elderly & critically ill patients,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ¨C¤é³Ì¤j§ë»P¾¯¶q 2500mL 2. ¨Ï¥Î«e¡A¥ÎÂù¤âÀ£¤W«Ç©Î¤U«Ç¥H¥´³q¨â«Ç¶¡ªº³sµ²³B¡A¨Ï¤G«Ç·»²G§¹¥þ²V¦X¡C 3.¦¨¤H¼Ð·Ç¿éª`³t«×¬°120¤ÀÄÁ¤ºª`®g500mL¡C¦Ñ¤H¤Î­«¯g±wªÌÀ³´î½w¿éª`³t«×¡C
OIND1,Propranolol,Inderal 10mg,CAVS,Adult HTN¡A Angina¡A migraine & essential tremor¡A Arrhythmias¡A anxiety tachycardia¡A thyrotoxicosis¡A Pheochromocytoma.,History of bronchial asthma or bronchospasm¡A bradycardia¡A cardiogenic shock¡A hypotension¡A metabolic acidosis¡A after prolonged fasting¡A severe peripheral arterial circulatory disturbances¡A 2nd or 3rd degree heart block¡A sick sinus syndrome¡A untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma¡A uncontrolled heart failure¡A Prinzmetal's angina.,Cold extremities¡A GI & sleep disturbances¡A fatigue¡A lassitude. Deterioration in heart failure¡A mood changes. Isolated cases of paresthesia. Rarely bradycardia¡A dizziness¡A postural hypotension which may be associated with syncope¡A heart block¡A alopecia¡A thrombocytopenia¡A purpura¡A psoriasiform skin reactions¡A exacerbation of psoriasis¡A visual disturbances¡A CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication¡A Raynaud's phenomenon¡A bronchospasm¡A increased antinuclear antibodies. Dermatologic: Dermatitis¡A Pruritus¡A Urticaria Neurologic: Dizziness (4% to 7% ) Other: Fatigue (5% to 7% ),Àx¦s©óºò±K®e¾¹¡A³±²D15-30¢J°®ÀêÁ×¥ú,Adult: Angina: Initially 10-20 mg TID-QID¡A may titrate every 3 to 7 days gradually to 320 mg/day. Arrhythmia: 10-30mg TID-QID. Migraine prophylaxis: Initially 20mg QID; then up to 160-240 mg/day in divided doses. Hypertension: 120-240 mg/day¡A may increase to 640mg based on response and tolerability. Thyrotoxicosis: 10-40mg TID-QID. Pheochromocytoma: 20mg TID for 3 days prior to surgery¡A with alpha-adrenergic blocker. (Do not start propranolol before the effect of the alpha-blocker is established) Child: Limited data available. Supraventricular tachycardia: 0.5 to 1 mg/kg/day in 3-4 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,1) American Academy of Pediatrics Rating: Maternal medication usually compatible with breastfeeding. 2) World Health Organization Rating: Compatible with breastfeeding. 3) Micromedex Lactation Rating: Infant risk is minimal. 4) Clinical Management a) Propranolol is excreted in human milk and the manufacturer advises caution if propranolol is administered to a nursing woman. However¡A propranolol is considered compatible with breastfeeding by the American Academy of Pediatrics and the World Health Organization (WHO) [888][889]. Although propranolol appears in breast milk¡A the concentration is too low to be pharmacologically significant to the infant. WHO recommends monitoring the infant for bradycardia¡A hypoglycemia¡A and cyanosis,AC;AC15;PC;PO;WM;,,,,,
OISO2,Verapamil,Isoptin SR 240mg,CAVS,HTN.,CV shock¡A complicated acute MI¡A severe conduction disorders (2nd & 3rd degree AV block¡A SA block)¡A sick-sinus syndrome¡A heart failure¡A atrial fibrillation/flutter & simultaneous pre-excitation syndrome. Myasthenia gravis.,Bradycardiac arrhythmias eg. sinus bradycardia¡A asystole¡A 2nd/3rd degree AV blockade¡A hypotension¡A heart failure. Constipation. Rarely nausea¡A vomiting¡A dizziness¡A headache¡A flushing¡A fatigue¡A nervousness¡A ankle edema¡A inflammation of extremities¡A paresthesia¡A myalgia¡A rheumatism. Cardiovascular: Edema (up to 3.7% )¡A Hypotension (1.5% to 3% ) Gastrointestinal: Constipation (7.3% to 13% ) Neurologic: Dizziness (3% to 5.9% )¡A Headache (2.2% to 12.1% ) Respiratory: Pharyngitis (3% )¡A Sinusitis (3% ) Other: Influenza-like symptoms (3.7% ),25¢J¥H¤UÁ×¥ú,HTN: 120-240mg/day with food in the morning.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¤§¯f±w«ØÄ³ Use 30% of dose given to patients with normal hepatic function,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,The use of verapamil in any stage of pregnancy appears to be low risk. The drug was not teratogenic in two animal species¡A but did cause death and growth restriction in one species.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©Ê½¤¦ç¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
OKIN,Sertraline,Kinloft 50mg,CNEU,,¾AÀ³¯g: Depression¡A obsessive-compulsive disorder (OCD)¡A panic disorder. °Æ§@¥Î: Nausea¡A diarrhoea¡A dyspepsia¡A tremor¡A dizziness¡A insomnia¡A drowsiness¡A increased sweating¡A dry mouth¡A delay in ejaculation (males).,,«Ç·Å,50 mg daily. Dosage may be increased in 50 mg increments to max 200 mg over a period of 2-4 wks.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OMEX,Mexiletine,Mexitil 100mg,CAVS,,¾AÀ³¯g: Ventricular arrhythmia. °Æ§@¥Î: Indigestion; hiccups; unpleasant taste¡A nausea¡A vomiting; joint pains; drowsiness¡A dizziness; confusion; disarticulated speech; blurred vision; nystagmus; tremor; paresthesia¡A ataxia; convulsions; hypotension¡A sinus bradycardia¡A atrial fibrillation¡A palpitations. Gastrointestinal: Heartburn¡A Nausea¡A Vomiting Neurologic: Coordination problem (approximately 10% )¡A Dizziness¡A Lightheadedness¡A Tremor (13.2% ) Ophthalmic: Blurred vision¡A Visual disturbance Psychiatric: Feeling nervous (5% to 11.3% ),,«Ç·Å,Initially¡A 400 mg. Maintenance¡A should be given 2-6 hr after initial dose: 400-800 mg in divided doses; max: 1200 mg daily in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OMGO,Magnesium Oxide,MgO 250mg,ALIM,,¾AÀ³¯g: Treatment of various GI problems associated with hyperacidity; as a laxative. °Æ§@¥Î: Diarrhea¡A abdominal cramps¡A nausea¡A hypermagnesemia¡A renal stones,,«Ç·Å,Antacids 250-1500 mg with water or milk¡A qid. Laxative 2-4 g with water or milk hs. Magnesium supplement 500-1200 mg/day.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OMIDO,Midodrine,Midorine 2.5mg,CAVS,Treatment of symptomatic orthostatic hypotension. Adjunct in the management of urinary incontinence.,Severe organic heart disease¡A acute renal disease¡A urinary retention¡A pheochromocytoma¡A thyrotoxicosis.,Supine hypertension (discontinue)¡A paresthesia¡A pruritus¡A goosebumps¡A chills¡A dysuria.,25¢J¥H¤UÁ×¥ú,Hypotensive states Adult & children > 12 years: Initially 1 tab BID-TID Urinary incontinence Adult 1-2 tablet BID to TID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OREN5,Enalapril,Renitec 5mg,CAVS,,I: All grades of essential hypertension¡A renovascular hypertension¡A congestive heart failure. CI: History of angioneurotic edema related to previous treatment with an ACE inhibitor.,,,Initial: Patients without diuretic therapy: 5 mg qd. Patients with diuretic therapy: An initial dose of 2.5 mg should be used to determine the magnitude of hypotensive effect. Maintenance: 10-40 mg/day in 1-2 divided doses.(max. 40 mg/day).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ORIF3,Rifampicin,Rifampicin 300mg,QANB,,¾AÀ³¯g: TB & meningococcal carriers. °Æ§@¥Î: Skin reactions; GI discomfort; hepatitis; thrombopenia; flu-syndrome; reddish discoloration of urine¡A sputum & tears; stains soft contact lenses. ¸T§Ò: Jaundice. Hypersensitivity to rifampicin.,,,Adult 8-12 mg/kg body weight daily; children 10-20 mg/kg to a max daily dose of 600 mg.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌ¨C¤é¨C¤½¤çÅé­«¤£¯à¶W¹L8mg¡C(¥é³æ) Dosage reductions of rifampin have been suggested in patients with serum bilirubin levels exceeding 50 mcmol/L. Rifampin 6 to 8 mg/kg biweekly should not be exceeded in patients with severe liver impairment.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ORIFA,Isoniazid + Pyrazinamide + Rifampicin,(½Æ¤è) RifaTER 80/250/120mg,QANB,Initial intensive phase treatment (usually 2 months) for short course chemotherapy of TB. When indicated other anti-TB drugs may be added. After the intensive phase treatment¡A therapy should be continue with Rifinah for a further 4 months min.,Hypersensitivity; presence of jaundice.,Staining of contact lenses¡A reddish coloration of urine¡A sputum & lachrymal fluid. Irregular dosing may result in immunological side effects eg 'flu syndrome'.,30¢J¥H¤U,Take Rifater tablet 1-2 hours before one meal. Weight > or = 50 kg: 5 tablets; weight < 50 kg: 4 tablets. Alternative dosing: weight > or = 50 kg: 5 tablets; weight 40-49 kg: 4 tablets; weight 30-39 kg: 3 tablets.,»Ý½Õ¾ã¾¯¶q,INH: Hepatic impairment (advanced disease or AST greater than 3 times ULN and not due to TB): Isoniazid-based regimens are preferred if possible; expert consultation and dosage adjustments may be necessary. Rifampicin: Dosage reductions of rifampin have been suggested in patients with serum bilirubin levels exceeding 50 mcmol/L. Rifampin 6 to 8 mg/kg biweekly should not be exceeded in patients with severe liver impairment.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OROCH,Calcitriol,Rocaltrol 0.25mcg(Hemodialysis,META,,I: Hypoparathyroidism & rickets; Renal osteodystroghy; Postmenopausal osteoporosis. ADR: Hypercalcemia syndrome¡A Ca intoxication. CI: Hypercalcemia. Vit D containing prep.,,,Initially 0.25 mcg/day Adults: 0.5-3 mcg/day or more. Childn: 0.5-2 mcg/day. Hypoparathyroidism: Adults: 0.25-207 mcg/day. Childn: 0.04-0.08 mcg/kg/day. Renal osteodystroghy: Adults: 0.25 mcg qod to 3 mcg/day or more. Childn: 0.014-0.041 mcg/kg/day.,,,,,,,,,,,,,,
EATR5,Atropine,Atropine oph soln 0.5%,TOPH,,Long acting mydriatic and cycloplegic for use in uveitis and for use in treatment of myopia,,,1 gtt hs:for treatment of myopia.(0.1%¡A 0.25% and 0.5%) 1 gtt qid :for use in uveitis.(1.0%),,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EATRC,Atropine,Colircusi ATROPINE 0.5%¡A10mL,TOPH,,¾AÀ³¯g: Mydriasis & cycloplegia for ocular refraction examination. Acute inflammatory conditions of the anterior uveal tract. Treatment of iritis¡A iridocyclitis¡A corneal ulcer conditions¡A suppurated ulcers with hypopyon & accommodative spasm. Post-op treatment of extra or intracapsular lens extraction where an anticholinergic effect is required. °Æ§@¥Î: Dryness of the mouth¡A blurred vision¡A sensitivity to light¡A local irritation¡A hypotension with progressive respiratory depression. ¸T§Ò: Primary glaucoma or narrow-angle glaucoma.,,«Ç·Å,Sustained anticholinergic effect Adult 2 drops tid. Children 1 drop tid. Refraction exam 1-2 drops to each eye bid¡A 1-3 days prior to exam.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EATRD,Atropine,Atropine 1% ÂI²´²G¡A 5mL,TOPH,,¾AÀ³¯g: Topical mydriatic & cycloplegic; uveitis. °Æ§@¥Î: Stinging¡A increased intraocular pressure¡A conjunctivitis. May precipitate glaucoma. ¸T§Ò: Closed- & narrow-angle glaucoma.,,«Ç·Å,1 gtt hs: for treatment of myopia. (0.1 %¡A 0.25 % and 0.5%) 1 gtt qid: for use in uveitis. (1.0 %),,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IDT1,Diphtheria + Tetanus,Td Adult (¦Û¶O¦¨¤H¯}¶Ë­·¥Õ³ï²V¦X¬Ì­]) 0.5mL/dose,HIMM,,Active immunization against diphtheria and tetanus.,,2-8¢J,IM¡A for child 6 wks-6 yrs¡A 0.5 ml/dose. Primary immunization: Child 6 wks-1 yrs: 3 doses given at 4-8 wks intervals and a reinforcing 4th dose given 6 months 1 yr later. Child over 1 yrs: 2 doses given at 4-8 wks intervals and a reinforcing 3th dose given 6 months-1 yr later. Booster dose: Given at 4-6 yrs.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
ITTA,Tetanus Toxid Alum Precipitate,Tetanus Toxoid (¯}¶Ë­·Ãþ¬r¯À) 0.5mL/dose¡A 3mL/vial,HIMM,,¾AÀ³¯g: Active immunization of tetanus. °Æ§@¥Î: Drowsiness¡A malaise¡A hypersensitivity. ¸T§Ò¡GHypersensitivity to tetanus toxoid or any component of the formulation,,2-8¢J,IM¡A 0.5 mL/dose. Primary immunization: I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose Routine booster dose: Recommended every 10 years Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated¡A the immunization status of the patient¡A proper use of tetanus toxoid and/or tetanus immune globulin (TIG)¡A wound cleaning¡A and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,,,,,,
RIMEN,Meningococcal vaccine,¸£½¤ª¢¬Ì­](Á{§É¸ÕÅç),HIMM,,,,,,,,,,,,,,,,,,,
RIPRE,Pneumococcal vaccine,ªÍª¢Ãì²yµß¬Ì­](Á{§É¸ÕÅç),HIMM,,,,,,,,,,,,,,,,,,,
RIPED,DTaP5-IPV-HIB,¤­¦X¤@¬Ì­](Á{§É¸ÕÅç),HIMM,,,,,,,,,,,,,,,,,,,
IH1N1,Inactivated H1N1 Influenza Virus,H1N1·s«¬¬y·P(>3·³) 0.5mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
OACE5,Perindopril,Acertil 5mg,CAVS,Hypertension¡A CHF¡A stable coronary artery disease.,Pregnancy¡A lactation; children. Bilateral or unilateral renal artery stenosis.,GI disorders; dizziness¡A headaches¡A mood &/or sleep disorders¡A asthenia; taste disorder; cramps¡A localized rash; dry cough; angioneurotic edema. Gastrointestinal: Intestinal angioedema Hepatic: Liver failure (rare) Other: Angioedema¡A More frequent in black patients (0.1%)¡A Angioedema of lips¡A More frequent in black patients (0.1%)¡A Angioedema of throat¡A More frequent in black patients (0.1%),30¢J¥H¤U,HTN Initial: 5 mg QD before meal¡A maximum 16mg/day CHF: Initial: 2.5 mg QD before meal slow titrate up¡A maximum to 8-16mg QD Stable coronary artery disease: Initial: 5 mg QD before meal for 2 weeks; titrate up to10 mg QD if needed.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;PO;,,,,,
OKNO1,Piracetam,KNOWFUL 1200mg,CNEU,,I: Treatment of cerebrovascular insufficiency & age-related cognitive impairment. CI: Hepatic & severe renal impairment.,,«Ç·Å,Adult: initially 800 mg tid. Maintenance: 400mg tid. Children: 30-50 mg / kg / day,,,,¨S¦³¸ê®Æ,,,,,,,,,,
LMEG,Megestrol,Megest 40mg/mL¡A120mL suspension,HM,Cachexia associated with AIDS or cancer.,Known or suspected pregnancy. History of hypersensitivity to megestrol acetate or any component of the formulation.,Common Cardiovascular: Hypertension Dermatologic: Rash¡A Sweating symptom Endocrine metabolic: Hot sweats¡A Weight gain Gastrointestinal: Diarrhea¡A Flatulence¡A Indigestion¡A Nausea¡A Vomiting Neurologic: Insomnia Psychiatric: Mood swings Reproductive: Erectile dysfunction Serious Endocrine metabolic: Adrenal insufficiency Hematologic: Anemia¡A Deep venous thrombosis¡A Thrombophlebitis Respiratory: Pulmonary embolism,«Ç·Å,Initial¡A 400-800 mg (10-20 mL) orally daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,[¥é³æ],Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,
YCYS,Hyaluronate,Cystistat 40mg/50mL,MEDD,Temporary replacement of the glycosaminoglycan layer in the bladder.,Hypersensitivity to sodium hyaluronate or avian proteins.,Hypersensitivity,25¢J¥H¤U,[MIMS 2021/08/05] Instill the entire vol into the bladder after any residual urine has been removed. Alleviation of cystitis Instill into the bladder each week for 4-12 treatments & then mthly until symptoms resolve.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IRRI;,,,,,
ISYNA,Palivizumab,Synagis inj 50mg,HIMM,,¾AÀ³¯g: Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease¡A including infants with bronchopulmonary dysplasia¡A a history of premature birth (<=35 weeks gestational age)¡A & children with hemodynamically significant congenital heart disease. °Æ§@¥Î: Upper respiratory infections¡A otitis media¡A rhinitis¡A rash¡A pain¡A hernia¡A increased SGOT¡A pharyngitis. ¸T§Ò: Hypersensitivity to palivizumab or humanized monoclonal antibodies.,,2-8 C,Recommended Dose: 15 mg/kg IM (preferably in anterolateral thigh)¡A given once a month during anticipated periods of RSV risk in the community,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;,,,,,1.½Õ°t«e¡A¥ý²¾°£²~»\©ÔÀô³¡¥÷¡A¥H70%°sºë©Îµ¥®Ä«~²M¼ä¾ó½¦²~¶ë 2.½wºC¥[¤J0.6²@¤ÉµLµßª`®g¥Î¤ô©ó50²@§J¤§¤p²~¡A»´»´±ÛÂà30¬í¡AÁ×§K²£¥Íªwªj¡C¤Á¤Å·n®Ì²~Åé 3.½Õ°t«áªºpalivizumabÀ³©ó«Ç·Å¤UÀR¸m¦Ü¤Ö20¤ÀÄÁ¡Aª½¦Ü·»²G¼á²M¡C 4.½Õ°t«áªºpalivizumab¥¼§t¦³¨¾»G¾¯¡AÀ³©ó½Õ°t«á¤»¤p®É¤º¨Ï¥Î¡C 5.¦¹¤p²~¶È¨Ñ³æ¦¸¨Ï¥Î¡C¥¼¨Ï¥Î³¡¥÷½Ð¥á±ó¡C
OMET4,Methylprednisolone,Metisone 4mg,HM,,¾AÀ³¯g: RA¡A acute & subacute bursitis¡A exfoliative dermatitis¡A allergic rhinitis¡A bronchial asthma¡A contact dermatitis & allergic conjunctivitis. °Æ§@¥Î:Fluid & electrolyte disturbances; muscle weakness¡A aseptic osteonecrosis¡A osteoporosis; peptic ulcer with perforation¡A hemorrhage¡A abdominal distention¡A impaired wound healing; increased intraocular pressure; Cushingoid state¡A growth suppression¡A menstrual irregularities¡A posterior subcapsular cataracts. ¸T§Ò: Systemic fungal infection; immunization. Lactation,,«Ç·Å,Should be taken with food 4-48 mg once-qid.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ODIA6,Gliclazide,DIAMICRON MR 60mg,META,,¾AÀ³¯g: ²Ä¤G«¬¿}§¿¯f(B023503100) °Æ§@¥Î: Hypoglycaemia¡A nausea¡A dyspepsia¡A diarrhoea¡A constipation. ¸T§Ò: Type 1 diabetes¡A diabetic keto-acidosis or diabetic pre-coma¡A severe renal or hepatic insufficiency¡A co-administration with miconazole¡A pregnancy¡A lactation. Avoid coadministration with phenylbutazone or danazol.,,«Ç·Å,1-4 tab taken once daily at breakfast. Max : 120 mg daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ECAR,Carbenoxolone,Carboxe orabase 100mg/5gm,TENT,,¾AÀ³¯g: Aphthous¡A herpes inflammation & traumatic mucosal lesions of the lips & oral cavity.,,«Ç·Å,Apply about 1 mm thick to affected areas after meals & before bedtime.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EMYC,Triamcinolone + Neomycin + Gramicidin + Nystatin,Mycomb otic drops 5mL,TENT,Inflammation of the outer and middle ear.,Acute herpes simplex¡A vaccinia¡A varicella; perforated eardrum.,Long term use: acne or oily skin; increased hair growth¡A especially on the face.,25¢J¥H¤U,Instill2-3 drops into affected ear(s) TID to QID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Triamcinolone - Compatible (Inhaled) Neomycin - Human Data Suggest Low Risk Gramicidin - Unknown Nystatin - Compatible,Unknown ¨S¦³¸ê®Æ,Triamcinolone - No Human Data¡XProbably Compatible Neomycin - No Human Data¡XProbably Compatible Gramicidin - Unknown Nystatin - Compatible,AD;AS;AU;,,,,,
IDOBU,Dobutamine,DOBUha inj 250mg/20mL,CAVS,,¾AÀ³¯g: Short-term treatment of cardiac decompensation due to depressed contractility resulting from heart disease or cardiac surgery. °Æ§@¥Î: Tachycardia¡A nausea¡A non-specific chest pain & palpitation. Cardiovascular: Angina (1% to 3% )¡A Hypertension (7.5% )¡A Tachyarrhythmia (approximately 10% ) Neurologic: Headache (1% to 3% ) ¸T§Ò: Obstructive cardiomyopathy.,,«Ç·Å,Usually 2.5-10 mcg/kg/min as IV infusion.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1.¤Å¥[¤JÆP©ÊÃÄ«~
LLAC3,Lactulose,LACOLY soln 300mL(667mg/mL),ALIM,,¾AÀ³¯g: Chronic portal systemic encephalopathy¡A hepatic pre coma¡A hepatic coma °Æ§@¥Î: Flatulence¡A nausea¡A vomiting¡A abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). ¸T§Ò: Galactosemia¡A bowel obstruction.,,«Ç·Å,Chronic constipation:  Starting dose(for 3 days) aintenance -------------------- ---------------------------------- --------------------- Severe cases 0-45 ml 15-25 ml Moderate cases 5-30 ml 10-15 ml Mild cases 5ml 10 ml 6-14yr 15 ml 10 ml 1-6yr 5-10 ml 5-10 ml Infant 1-12mth 5 ml 5 ml All doses to be taken daily preferably as single doses. Precoma & hepatic coma: Starting doses: approx 30-50 ml tid. In acute cases a retention enema is given in a proportion of 300ml Duphalac to 700 ml water.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IGLUC,Glucagon,Glucagen inj 1mg/1mL,META,Treatment of severe hypoglycemia. Use as a diagnostic aid. Assessing of beta cell function.,Hypersensitivity to glucagon or any components of the product. Insulinoma. Pheochromocytoma. Glucagonoma when used as a diagnostic aid.,Common Gastrointestinal: Nausea¡A Vomiting Serious Dermatologic: Necrolytic migratory erythema Immunologic: Anaphylaxis,2-8¢JÁ×¥ú,IM¡A SC¡A IVP¡A Hypoglycemia(severe) 1 mg IM¡A SC¡A child < 25 kg or < 8 years 0.5 mg IM¡A SC. Diagnostic aid: Radiologic examinations of gastrointestinal tract 0.2-0.5 mg IVP 1 min before procedure¡A 1-2 mg IM 5-15 min before procedure. £]cell secretion function test 1 mg IVP.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]ª@¿}¯À¤£·|¬ï³z¤HÃþ­L½L«Ì»Ù¡C ¦³³ø§i«ü¥X±w¦³¿}§¿¯fªº¥¥°ü¨Ï¥Îª@¿}¯À¡A¹ï©óÃh¥¥¹Lµ{¥H¤Î·s¥Í¨à¥¼ª¾¦³¥ô¦ó¦³®`ªº¼vÅT¡C GlucaGenR¥i¦bÃh¥¥®É¨Ï¥Î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]ª@¿}¯À¦b¦å¬y¤¤²M°£ªº³t²v«D±`ªº§Ö³t¡A¥D­n¥Ñ¨xÅ¦liver (¥b°I´Át¡H= 3-6¤ÀÄÁ)¡F ¦]¦¹¹ï©ó¨º¨Ç¦]ÄY­«§C¦å¿}¦Óµ¹¤©ªvÀøªº­÷¨Å°ü¤k¨Ó»¡¡A¤Àªc¨ì¨Å¥Äªº¶q¬O«D±`¤Öªº¡C ¥Ñ©óª@¿}¯À·|¦b®ø¤Æ¹D¤¤³Q¤À¸Ñ¡A¦Ó¥BµLªk¥H¨ä­ì§Î§Î¦¡³Q§l¦¬¡A¦]¦¹¤£·|¹ï¨àµ£¦³¥ô¦ó¥NÁÂ¤Wªº¼vÅT¡C GlucaGenR¥i¦b­÷¨Å®É¨Ï¥Î¡C,IM;IVP;IVPUSH;SC;,,,¨Ï¥Î¦bHypoglycemia: 1 mg (1 unit)¡AChildren BW < 25 Kg: 0.5 mg (0.5 unit),,1. °t»s¦nªº·»²GÀ³¥ß§Y¨Ï¥Î¡A­Y¦³ÂHµÛª¬©Î¤£®eª«½è¥X²{¡AÀ³¥á±ó¤£¥Î¡C 2. ÄY­«§C¦å¿}¯g¯f¤H­Y¦bµ¹¤©Glucagon¤Q¤ÀÄÁ¤º¨S¦³¤ÏÀ³¡A¶·¥HÀR¯ßª`®g¤è¦¡µ¹¤©¸²µå¿}¡C 3. Glucagon©ó¶EÂ_¥Î³~¥ÑIVµ¹¤©¡A±`¨£äú¤ß¡B¹Ã¦Rªº°Æ§@¥Î¡C 4. ­Y¤j¶q§ë¤©³y¦¨ÃÄª«¹L¶q¡A¥i¯à­°§C¦å¹[¡A¥²¶·¥[¥HºÊ´ú¡A¥²­n®Éµ¹¤©®Õ¥¿ªvÀø¡C
OBLO,Candesartan,Blopress 8mg,CAVS,Heart failure¡A (NYHA class II to IV¡A ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations. Hypertension.,Concomitant use with aliskiren in diabetic patients. Hypersensitivity to candesartan. Severe hepatic impairment &/or cholestasis. Lactating women and women in the second and third trimesters of pregnancy. Children under one year old.,Common Cardiovascular: Hypotension (18.8% ) Musculoskeletal: Backache (3% .) Neurologic: Dizziness (less than 5% ) Respiratory: Pharyngitis (2% )¡A Rhinitis (2% )¡A Upper respiratory infection (6% ),25¢J¥H¤U,HTN:initial: 8mg QD¡A may titrate up to 16mg¡A maximum 32mg.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¹ï»´«×¨ì¤¤«×¨x¥\¯à¤£¥þªÌ¡A«ØÄ³¨äªì¾¯¶q¥Ñ2mg¶}©l¡A¤@¤Ñ¤@¦¸¡A¦A¨Ì¨äÁ{§É¤ÏÀ³¨Ó½Õ¾ã¾¯¶q¡C¹ï­««×¨x¥\¯à¤£¥þªÌ¡A¨ÃµLÁ{§É¨Ï¥Î¸gÅç¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ]¬y¦æ¯f¾Ç¸ê®Æ©|¥¼¯àÃÒ¹êÃh¥¥ªì´Á¼ÉÅS©óACEI¥i¯à¼W¥[·î­Lªº­·ÀI¡F¦ýµLªk±Æ°£¦³»´·L´£¤Éªº¥i¯à¡C Áö¥¼¦³AIIRAs¦b¬y¦æ¯f¾Çªº¸ê®Æ¡A¦ý¦]ÄÝ¦PÃþ²£«~¡A¤´¦³¬Û¦Pªº­·ÀI¡C °£«DÄ~Äò¨Ï¥ÎAIIRAÃÄ«~¬O¥²­nªº¡A§_«h·í¯f¤H¦³­pµe­nÃh¥¥¡A´NÀ³§ï¦¨¨ä¥L¹ï©ó¨Ï¥Î¦bÃh¥¥¯f¤H¨­¤W¦³¦w¥þÀø®Äªº­°¦åÀ£ÃÄ«~¡C ¤@¥¹¶EÂ_Ãh¥¥¡A«hÀ³¥ß§Y°±¤î¨Ï¥ÎAIIRAÃÄ«~¨Ã¶}©l¨Ï¥Î¨ä¥L¦X¾AªºªvÀø¤è¦¡¡C ¤wª¾­YÃh¥¥²Ä¤G¤Î²Ä¤T´Á¶¡¼ÉÅS¦bAIIRAªvÀø±N¾É­P·î­L¡C(µÇ¥\¯à­°§C¡A¦Ï¤ô¹L¤Ö¡AÆ`°©µo¨|¿ð­P)¤Î­L¨à¬r¦å¯g(µÇ°IºÜ¡A§C¦åÀ£¡A°ª¦å¹[) ·íµo¥ÍAIIRA¨Ï¥Î©óÃh¥¥²Ä¤G´Á¡A«ØÄ³¨Ï¥Î¶W­µªi½T»{µÇ¥\¯à¤ÎÆ`³¡¡CÄY±KÆ[¹î¥À¿Ë¨Ï¥Î¤FAIIRAªºÀ¦¨à´Á§C¦åÀ£±¡§Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ñ©ó¯Ê¥F­÷¨Å´Á¶¡¨Ï¥ÎBlopressªº¸ê°T¡A¬G­÷¨Å®É¤£«ØÄ³¨Ï¥Î ¡A «ØÄ³§ï¥Î¨ä¥L¦w¥þ©Ê¸û½T¥ßªºÃÄª«¡A¤×¨ä¬O¬°·s¥Í¨à©Î¦­²£¨à­÷¨Å´Á¶¡¡C,AC;AC15;PC;PO;WM;,,,,,
OCAL,Calcium Carbonate + Vit D3,Caltrate chewable 28's,NUTR,,¾AÀ³¯g:¸É¥R¶t½è(A031828100) ADR: Constipation. CI: Hypercalcaemia & hypercalciuria¡A severe renal failure.,,«Ç·Å,Adult: 2 Tab bid ~ tid Children: 1 Tab bid ~ tid,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OCAR4,Metergoline,Carry 4mg,HM,,¾AÀ³¯g: Hyperprolactinaemia°ªªc¨Å¯À¯g(A044600100) °Æ§@¥Î: Nausea¡A vomiting¡A insomnia¡A drowsiness¡A anxiety¡A dizziness¡A weakness. ¸T§Ò: Lactation (discontinue from the 1st day of treatment).,,«Ç·Å,1 tab once-tid¡A increased gradually at meals.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EBBL,Benzyl benzoate,B.B. lotion 25%¡A100mL,TDER,,¾AÀ³¯g: Treatment of scabies¡A head lice. °Æ§@¥Î: Skin irritation¡A burning sensation.,,«Ç·Å,Scabies Apply over the whole body; repeat without bathing on the following day & wash off 24 hr later. A repeat application may be required in some cases. Head lice Apply 10 mL to the affected area & repeat as often as necessary.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EBEC,Beclomethason,Beclomet nasal aqua 100mcg/dose,TENT,,Seasonal & perennial obstinate allergic rhinitis. Vasomotoric rhinitis require corticosteroids.,,,Adult: 1 spray qid into both nostrils. Max: 10 sprays. Child: 1 spray bid-qid daily into both nostrils. Max: 5 sprays.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EBIAQ,Povidone-iodine,Povidone-Iodine solution 200mL,TDER,Post-op infections¡A bacterial or fungal skin infections. surgical scrub Antiseptic cleanser for pre-op scrubbing & washing by surgeons & theatre staff¡A & pre-op preparation of patients' skin.,Hypersensitivity to any component of the formulation.,Local irritation (discontinue).,25¢J¥H¤UÀx¦s,Aqueous soln As directed. Surgical disinfection Use 5 mL undiluted & allow to work for 5 mins¡A rinse off & repeat. Pre-op antiseptic skin cleanser Use undiluted.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 2nd and 3 rd trimesters,Four studies have shown the potential hazard resulting from the use of povidone¡Viodine during pregnancy. In each case¡A significant absorption of iodine occurred in the mother and fetus following topical¡A vaginal¡A or perineal use before delivery. Transient hypothyroidism was demonstrated in some newborns.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
EBOR,Boric Acid,Boric acid 2% 20mL,TDER,,¾AÀ³¯g: Relief of chapped skin¡A chafed skin¡A diaper rash¡A dry skin¡A abrasion¡A sunburn¡A windburn¡A insect bites and other skin irritations.,,«Ç·Å,Apply directly or on a dressing as often as needed.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EBRIT,Terbutaline,Bricanyl Turbuhaler 0.5mg/dose,ERSP,,I: Relief of bronchospasm in bronchial asthma¡A chronic brochitis¡A emphysema & other bronchopulmonary conditions when bronchoconstriction is a complicating factor. AR: Tremor¡A tonic cramp & palpitations. Tachycardia¡A arrhythmia. Urticaria & exanthema may occur. CI: Thyrotoxicosis.,,,Oral: Adult: 5 mg tid¡A Child 12-15 yrs: 2.5 mg tid. Nebulizing soln: Adult & child over 20 kg: 5 mg¡A Child under 20 kg: 2.5 mg¡A qid. Turbuhaler: Adult & childn > 12yr: 1 inhalation 6 hrly¡A may be increased to 3 inhalations. Max: 12 inhalation/24 hr. Childn 5-12 yr 1 inhalation 6 hrly¡A may be increased to 2 inhalation to 2 inhalations. Max: 8 inhalation/24 hr.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EBSM,Boric Acid + NaHCO3 + Menthol,Boric acid+NaHCO3+Menthol,TDER,Antiseptics,Hypersensitivity to any component of the formulation.,Local irritation,«Ç·Å,1pk boric acid + 1pk NaHCO3 + few Methol to some warm water for topical infection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
IHUMR,Insulin Regular Human,Humulin R inj100IU/mL 10mL,META,,IDDM and NIDDM that can not be properly controlled by diet and oral hypoglycemia agents.,,2-8,According to individual requirements.,,,,¦w¥þ,,,,,,,,,,
IINT,Interferon alfa,Intron A inj 3MIU,QANB,,Multiple myeloma¡A hairy cell leukaemia¡A chronic myelogenous leukaemia¡A AIDS-related kaposi's sarcoma¡A condyloma acuminatum¡A chronic hepatitis B¡A chronic non-A¡A non-B hepatitis (hepatitis C) & non-Hodgkin's lymphoma.,,,Hairly cell leukemia: 3 million iu SC or IM daily for 16-24 wk. Maintenance: 3 million IU 3 times wkly. AIDS-related Kaposi's sarcoma: 36 million IU SC or IM daily for 4-10 wk. Maintenance: 36 million iu 3 times wkly.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IISOK,Isosorbide Dinitrate,Isoket inj 10mg/10mL,CAVS,,I: Unresponsive left ventricular failure secondary to acute MI¡A unresponsive left ventricular failure of various etiology & severe or unstable angina pectoris. CI: Cardiogenic shock; circulatory collapse; severe hypotension; marked anemia; head trauma; cerebral hemorrhage; severe hypovolemia.,,,2-10 mg/hr by IV infusion after dilution.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IJEV,Japanese Encephalitis Vaccine,JEV (¤é¥»¸£ª¢¡A¬F©²´£¨Ñ) 0.5-1mL/dose,HIMM,Active immunisation against encephalitis due to Japanese encephalitis virus,Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV¡A renal or hepatic diseases in acute¡A exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,Local reactions eg redness¡A swelling¡A tenderness or systemic reactions eg fever¡A chill¡A headache¡A lassitude. Rarely¡A severe adverse reactions manifesting as generalized urticaria or angioedema may occur.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 2 months - < 3 years 0.25 mL¡A > 3 years 0.5 mL¡A 2 doses primary immunization at intervals of 28 days. A booster dose: Age > or = 18 years: after primary immunization 6 months¡A Age < 18 years: after primary immunization 1 year.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,,,,,,,,
IBLE1,Bleomycin,BLEOCIN inj 15mg,RACA,Carcinoma of the skin¡A head & neck¡A lung¡A oesophagus¡A uterine cervix & thyroid¡A malignant lymphomas¡A glioma.,Severe pulmonary¡A renal or cardiac dysfunction.,Severe interstitial pneumonia & pulmonary fibrosis¡A hypersensitivity¡A fever¡A haemorrhage¡A scleroderma-like changes in skin¡A anorexia¡A diarrhea¡A GI upsets; renal¡A urinary & neuropsychic disturbances¡A hypertrophy of venous wall¡A narrowing of venous lumen & induration around administration site. Phlebalgia with IV administration. Dermatologic: Alopecia (1-10%)¡A Skin reaction - finding¡A Erythema¡A rash¡A striae¡A vesiculation¡A hyperpigmentation¡A skin tenderness (50%) Endocrine metabolic: Shivering Gastrointestinal: Nausea and vomiting¡A Stomatitis Psychiatric: Confusion Other: Fever,2-8¢J,15-30 mg IV¡A IM or SC twice weekly; 5-15 mg IA twice weekly.May adjust dosing frequency to once daily to once weekly.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,,,,1. ¤Å¨Ï¥ÎD5W©Î¨ä¥L§t¦³dextroseªºµ}ÄÀ²G¡C 2. IM¡BSQµ¹ÃÄ¡G15 mg·»©ó1 mL¨ì 5 mLªºNS©Îª`®g¥Î¤ô¡C 3. IV µ¹ÃÄ¡G15 mg·»©ó 5 mLªºNS¡A½wºCÀR¯ßª`®g¶W¹L10¤ÀÄÁ¡C 4. Intrapleuralµ¹ÃÄ¡G·»©ó50 ¨ì100 mL ªºNS ¡A¸g¥Ñthoracostomy tube§ëÃÄ¡C 5. ºÊ´ú¶µ¥Ø¡GPulmonary function tests (total lung volume¡A forced vital capacity¡A carbon monoxide diffusion)¡A renal function¡A liver function¡A chest x-ray¡A temperature initially; check body weight at regular intervals
OEST6,Conjugated Estrogen,Estromon 0.625mg,HM,Primary ovarian failure¡A primary amenorrhea¡A management of menopause syndrome.,Malignant neoplastic disease of the breast or genital tract (unless indicated for the treatment of the neoplasm); previous thromboembolic disorders¡A CV disease¡A thrombophlebitis; undiagnosed vag bleeding; liver impairment; pregnancy.,Fluid & salt retention¡A edema; weight gain; breast tenderness¡A gynecomastia; altered liver function¡A jaundice; depression; GI upsets¡A dizziness¡A chloasma¡A rash¡A urticaria¡A erythema multiforme; endometrial hyperplasia.,ºò±K«O¦s©ó25¢J¥H¤U°®Àê³B,Continue administetion or cyclic administration (3 weeks on & 1 week off) should be used.Atrophic vaginitis and atrophic urethritis caused by lack of estrogen: 0.3-1.25mg daily. Osteoporosis: 0.625mg daily. Protection of the cardiovascular system: 0.625-1.25mg daily. Low of feminine estrogen: 0.3-1.25mg daily. Promote the development of secondary sexual characteristics: 0.15mg.,µL»Ý½Õ¾ã¾¯¶q,¬¡°Ê©Ê©ÎºC©Ê¨xÅ¦¤£¥þ©Î¨xÅ¦¯e¯f±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Use is contraindicated during pregnancy.(UpToDate)2021/0125,Unknown ¨S¦³¸ê®Æ,Estrogens can be detected in breast milk. Estrogen has been shown to decrease the quantity and quality of human milk. The manufacturer recommends that caution be used if administered to a breastfeeding woman. (UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OSE200,Quetiapine,SEROQUEL XR 200mg,CNEU,Schizophrenia¡A manic episodes associated with bipolar disorder.,,Dry mouth¡A somnolence¡A dizziness ¡A & dyspepsia. Heart rate increased¡A hypotension¡A weight increased¡A tremor¡A akathisia¡A increased appetite¡A blurred vision¡A postural dizziness¡A pyrexia¡A dysarthria¡A dystonia¡A drooling¡A syncope¡A tardive dyskinesia¡A dysphagia¡A leukopenia & rash. Anaphylactic reaction¡A peripheral edema¡A rhinitis¡A eosinophilia¡A hypersensitivity¡A elevations in £^- GT levels & restless legs syndrome have also been reported. Cardiovascular: Hypertension (1% to 2% (adults); 15.2 to 40.6% (children and adolescents) )¡A Orthostatic hypotension (4% to 7% (adults); less than 1% (children and adolescents) )¡A Tachycardia (0.5% to 7% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )¡A Serum triglycerides raised (8% to 22% )¡A Weight gain (3% to 23% ) Gastrointestinal: Abdominal pain (4% to 7% )¡A Constipation (2% to 11% )¡A Increased appetite (2% to 12% )¡A Indigestion (2% to 7% )¡A Vomiting (1% to 11% )¡A Xerostomia (4.1% to 44% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (2% to 10% )¡A Dizziness (9% to 18% )¡A Extrapyramidal disease (3% to 12.9% )¡A Headache (7.4% to 21% )¡A Insomnia (8% to 12% )¡A Lethargy (1% to 5% )¡A Somnolence (16% to 57% )¡A Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )¡A Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )¡A Pain (1% to 7% ),«Ç·Å,Seroquel XR Schizophrenia Initially 300 mg once daily preferably in the evening. Patients should be titrated within a dose range of 400-800 mg daily. Dose increases can be made at intervals as short as 1 day & in increments of up to 300 mg daily.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OLOX,Ambroxol,Loxol SR 75mg,ERSP,Expectorant.,Hypersensitivity to any component of the formulation.,Contact dermatitis¡A Pruritus¡A Rash¡A Skin finding¡A Urticaria¡A Constipation¡A Diarrhea¡A Excessive salivation¡A Gastrointestinal tract finding¡A Nausea and vomiting¡A Xerostomia¡A Dysuria¡A Urogenital finding¡A Nasal discharge¡A Respiratory finding¡A Fatigue,«Ç·Å,Adult 1 TAB once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] °Êª«¸ÕÅç¤Î¼sªxªºÁ{§É¹êÅç©Ò±o¡A¥ô®W´Á¶¡ªA­¹Ambroxol hydrochloride¡A¦b²Ä28¶g«áÃÒ¹ê¨ÃµL¤£¨}°Æ§@¥Î¡C µM¦Ó¡A¦bÃh¥¥´Á¶¡ªA­¹¥ô¦óÃÄª«³£À³¤p¤ß¡A¯S§O¦bÃh¥¥ªì´Á¤T­Ó¤ë¤º¡AÀ³µ¹¤©¤p¤ßÆ[¹î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ÃÄª«·|¶i¤J¥À¨Å¤º¡A¦ÓÂåÀø¾¯¶qªº¨Ï¥Î¦Ü¥Ø«e¬°¤î¡A©|¥¼µo²{¹ïÀ¦¨à¦³³y¦¨¶Ë®`ªº±¡§Î¥X²{¡C,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°ªø®Ä¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C°|¤º¥t¦³¦P¦¨¥÷Musco solution¥i¨Ï¥Î¡C
IMID1,Midazolam,Midazo inj 5mg/1mL,CNEU,,¾AÀ³¯g: Sedation with amnesia; sedation in intensive care; premed¡A induction of anaesth. °Æ§@¥Î: Rarely cardio-resp adverse events¡A nausea¡A vomiting¡A headache¡A hiccoughs¡A laryngospasm¡A dyspnoea¡A hallucination¡A oversedation drowsiness¡A ataxia¡A paradoxical reactions¡A amnesic episodes. ¸T§Ò: Premature infants. Myasthenia gravis.,,«Ç·Å,Premed before an operation 20-30 mins before induction of anaesth¡A alone or in combination with anticholinergics. Adult 0.07-0.1 mg/kg IM. Children 0.15-0.2 mg/kg body weight by IM. Sedation in interventions under local anaesth 2.5-5 mg IV 5-10 mins before start of operation. Elderly > 60 years 1-3.5 mg IV slowly. Induction agent in inhalation anesth or sleep-inducing component in combined anesth 10-15 mg IV in combination with analgesics. Maintenance of anesth Further small doses should be injected IV or by continuous infusion. Sedation in ICU Dosage should be individualised & titrated to the desired state of sedation. Loading dose: 0.03-0.3 mg/kg. Maintenance dose: 0.03-0.2 mg/kg/hr.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
ETRI3,Fluocinolone + Hydroquinone + Tretinoin,Tri-Luma cream 3gm,TDER,,¾AÀ³¯g: Short-term treatment of moderate to severe melasma of the face¡A in the presence of measures for sun avoidance¡A including the use of sunscreens. °Æ§@¥Î: Erythema¡A desquamation¡A burning¡A dryness & pruritus at the site of application. ¸T§Ò: Individuals with a history of hypersensitivity¡A allergy¡A or intolerance to Tri-Luma or any of its components.,,«Ç·Å,Apply a thin film of cream to hyperpigmented areas of melasma including about 0.5 inch of normal appearing skin surrounding each lesion. Rub lightly & uniformly into the skin. Apply once daily at night 30 minutes before bedtime.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OEXJ,Deferasirox,Exjade 125mg,ZADT,,¾AÀ³¯g:Treatment of chronic ion overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (?2 years). °Æ§@¥Î:Headache¡A diarrhoea¡A constipation¡A vomiting¡A nausea¡A abdominal pain¡A abdominal distension¡A dyspepsia¡A elevated transaminases¡A rash¡A pruritus¡A proteinuria¡A increased serum creatinine.,,,initial daily dose: 20 mg/kg once daily. Dose adjustments should be made in steps 5-10 mg/kg. Max daily dose: 30 mg/kg. Should be taken on an empty stomach (Take on an empty stomach at least 30 mins before meals¡A preferably at the same time daily. Disperse the tab by stirring in 100-200 mL of water or orange juice until a fine susp is obtained.,,,,¥i¯à¦w¥þ,,,,,,,,,,
EVIM,Clobetasol,Vimax foaming solution 25mL,TDER,Psoriasis¡A recalcitrant eczema.,Bacterial infections (eg. impetigo¡A furuncle¡A boils¡A cellulitis)¡A candidiasis¡A dermatophytes infection¡A herpes simplex or herpes zoster infections. Avoid application near the eyes. Rosacea¡A perioral dermatitis & acne.,Local skin reactions: burning sensation¡A itch¡A rash¡A folliculitis¡A hypertrichosis¡A hypopigmentation¡A perioral dermatitis¡A allergic dermatitis¡A wrinkles¡A miliaria. HPA axis suppression¡A Cushing syndrome¡A hyperglycemia¡A DM. Cataract & glaucoma¡A skin atrophy¡A telangiectasia & purpura on prolonged use.,25¢J¥H¤U³±²D°®Àê³B,Plaque psoriasis Apply sparingly to the affected area once or BID. Treatment should be stopped if the condition improves after treatment for more than four weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
ODON5,Prednisolone,DONIson 5mg,HM,,¾AÀ³¯g: RA¡A lupus erythematosus¡A periarthritis nodosum¡A allergic & inflammatory skin disorders. °Æ§@¥Î: Fluid & salt retention¡A edema¡A hypertension; amenorrhea¡A hyperhidrosis¡A mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; local atrophy; increased appetite; growth retardation. ¸T§Ò: Peptic ulcer¡A osteoporosis¡A psychoses or severe neuropsychosis; active or doubtfully quiescent TB; acute infection; live vaccines.,,«Ç·Å,Allergic and inflammatory disorders 5-60 mg/day¡A in 2-4 divided doses. Rheumatoid arthritis Initial: 5-7.5 mg/day¡A adjust dose if needed. Multiple sclerosis 200 mg/day for 1 wk¡A then 80 mg every other day for 1 mth.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OVIRO,Tenofovir,Viread 300mg (¤Å¥Î),QANB,,¾AÀ³¯g¡G Management of HIV infections in combination with at least two other antiretroviral agents; treatment of chronic hepatitis B virus (HBV) in patients with compensated or decompensated liver disease °Æ§@¥Î¡GDiarrhoea¡A nausea¡A vomiting¡A abdominal pain¡A flatulence¡A dyspepsia¡A anorexia¡A skin rash¡A peripheral neuropathy¡A headache¡A dizziness¡A insomnia¡A depression¡A dyspnoea¡A asthenia¡A sweating¡A myalgia¡A myopathy¡A body fat redistribution¡A osteomalacia. Hypophosphataemia¡A raised amylase and liver enzymes¡A hepatitis¡A hypertriglyceridaemia¡A hyperglycaemia¡A neutropenia¡A nephritis¡A nephrogenic diabetes insipidus¡A renal impairment¡A proximal tubulopathy¡A Fanconi syndrome¡A immune reconstitution syndrome. Potentially Fatal: Lactic acidosis with severe hepatomegaly with steatosis; severe acute exacerbations of hepatitis B. Acute renal failure. ¸T§Ò¡GLactation. Not for treatment for chronic hepatitis B virus infection. Do not co-administer with fixed dose combinations containing tenofovir.,,«Ç·Å,Adult: PO HIV infection; Chronic hepatitis B over18 yr: 300 mg once daily. Click to view tenofovir disoproxil fumarate Dosage by Indications,,,,¥i¯à¦w¥þ,,,,,,,,,,
IKCL3,Potassium Chloride,10mEq KCl in 5% D/W 500mL,NUTR,,¾AÀ³¯g: Hypokalaemia. °Æ§@¥Î: Hyperkalemia¡A pain or phlebitis at injection site. ¸T§Ò: Hyperkalemia.,,2-8«×C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr¡A with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
ROVIR,Tenofovir,Viread 300mg(Á{§É¸ÕÅç),QANB,,¾AÀ³¯g¡G Management of HIV infections in combination with at least two other antiretroviral agents; treatment of chronic hepatitis B virus (HBV) in patients with compensated or decompensated liver disease °Æ§@¥Î¡GDiarrhoea¡A nausea¡A vomiting¡A abdominal pain¡A flatulence¡A dyspepsia¡A anorexia¡A skin rash¡A peripheral neuropathy¡A headache¡A dizziness¡A insomnia¡A depression¡A dyspnoea¡A asthenia¡A sweating¡A myalgia¡A myopathy¡A body fat redistribution¡A osteomalacia. Hypophosphataemia¡A raised amylase and liver enzymes¡A hepatitis¡A hypertriglyceridaemia¡A hyperglycaemia¡A neutropenia¡A nephritis¡A nephrogenic diabetes insipidus¡A renal impairment¡A proximal tubulopathy¡A Fanconi syndrome¡A immune reconstitution syndrome. Potentially Fatal: Lactic acidosis with severe hepatomegaly with steatosis; severe acute exacerbations of hepatitis B. Acute renal failure. ¸T§Ò¡GLactation. Not for treatment for chronic hepatitis B virus infection. Do not co-administer with fixed dose combinations containing tenofovir.,,30¢J¥H¤U,Adults and children > 12 years (> 35 kg): 300 mg orally once daily. (¼ö¯f) Pediatric: age 2 to < 12 years: 8 mg/kg (maximum: 300 mg) Q24H. Weight based tablet recommendations: 17 to <22 kg: 150 mg Q24H; 22 to <28 kg: 200 mg Q24H; 28 to <35 kg: 250 mg Q24H; > or = 35 kg: 300 mg Q24H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OZYPZ,Olanzapine,ZYPREXA Zydis 5mg,CNEU,,¾AÀ³¯g¡GOlanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment¡A olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. °Æ§@¥Î: Somnolence¡A weight gain¡A dizziness¡A akathisia¡A parkinsonism¡A dyskinesia¡A increased appetite¡A elevated glucose & triglyceride levels¡A asthenia¡A edema¡A orthostatic hypotension¡A dry mouth¡A constipation¡A eosinophilia¡A elevated prolactin levels (but clinical manifestations rare). May affect ability to operate machinery or drive motor vehicles. Elderly patients with dementia: a higher incidence of death and cerebrovascular adverse events; abnormal gait and falls; Pneumonia and urinary incontinence. Cardiovascular: Orthostatic hypotension (1% to 5% )¡A Peripheral edema (3% to 6% ) Endocrine metabolic: Hypercholesterolemia (up to 24% )¡A Hyperglycemia (0.1% to 17.4% )¡A Increased appetite (3% to 24% )¡A Increased prolactin level (31.2% to 61.1% )¡A Serum triglycerides raised (up to 40% )¡A Weight gain (up to 57% ) Gastrointestinal: Constipation (4% to 11% )¡A Xerostomia (3% to 32% ) Neurologic: Akathisia (3% to 27% )¡A Asthenia (2% to 20% )¡A Dizziness (1.6% to 18% )¡A Somnolence (6% to 52% )¡A Tremor (1% to 23% ) Psychiatric: Personality disorder (8% ) Other: Accidental injury (4% to 12% )¡A Fever (up to 4% ) ¸T§Ò: Patients with known risk of narrow-angle glaucoma. Neuroleptic malignant syndrome.,,«Ç·Å,Adult Schizophrenia Starting dose: 10 mg/day. Manic episodes Starting dose: 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in patients whose manic episodes have responded previously to olanzapine Starting dose: 10 mg daily. Dose range for all indications: 5-20 mg daily. A lower starting dose (5 mg/day) should be considered for elderly patients (> 65 years) & in renal or hepatic impairment.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IMAB1,Rituximab,Mabthera inj 100mg/10mL,RACA,Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment¡A after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.,Hypersensitivity to rituximab or murine proteins. Pregnancy¡A lactation. Active hepatits B disease,Fever¡A chills or rigor¡A flushing¡A angioedema¡A nausea¡A urticaria/rash¡A fatigue¡A headache¡A pruritus¡A dyspnea¡A throat irritation¡A rhinitis¡A vomiting. Cardiovascular: Hypertension (all grades¡A 6%; grades 3 and 4¡A 1% )¡A Hypotension (all grades¡A 10%; grades 3 and 4¡A 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% )¡A Diarrhea (10% )¡A Nausea (23% )¡A Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma¡A all grades¡A 26%; grades 3 and 4¡A 1%; rheumatoid arthritis¡A 2% )¡A Dizziness (all grades¡A 10%; grades 3 and 4¡A 1% )¡A Headache (all grades¡A 19%; grades 3 and 4¡A 1% )¡A Sensory neuropathy (30% ) Other: Fever (all grades¡A 53%; grades 3 and 4¡A 1% )¡A Shivering (all grades¡A 33%; grades 3 and 4¡A 3% ),2-8¢JÁ×¥úÁ×§K§N­á,Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction¡A increase the rate by 50 mg/hour increments every 30 minutes¡A to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion¡A start at 100 mg/hour; if there is no infusion-related reaction¡A increase the rate by 100 mg/hour increments every 30 minutes¡A to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin¡¦s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide¡A doxorubicin¡A prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1¡A then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation)¡A but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,,,,1. ²Ä¤@¦¸¨Ï¥Î¡Gµ¹ÃÄ³t²v«ØÄ³±q50 mg/¤p®É¶}©l¡A¤§«áµø¯f¤H­@¨üµ{«×¥i¨C30 ¤ÀÄÁ´£°ª50 mg/¤p®É¡A³Ì¤j³t²v¤£¥i¶W¹L 400 mg/¤p®É¡C 2. ²Ä¤G¦¸¥H«á¨Ï¥Î¡Gµ¹ÃÄ³t²v«ØÄ³±q100 mg/¤p®É¶}©l¡A¤§«á¥i¨C30 ¤ÀÄÁ´£°ª100 mg/¤p®É¡A³Ì¤j³t²v¤£¥i¶W¹L 400 mg/¤p®É¡C­Y¯f¤H­@¨üµ{«×¨}¦n¡A§Ö³tµ¹ÃÄ¤§µ¹ÃÄ®É¶¡À³ > 60 ¤ÀÄÁ¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¬ù 1 -4 mg/mL¡A«Ç·Å¦w©w©Êºû«ù 12 ¤p®É¡C 4.±w¦³¤ß«ß¤£¾ã¡B¤ßµ±µh¡BªÍ¯e±wªº¯f¤H¡A ¿éª`®É¥[±jºÊ´ú¤ßªÍ¥\¯à¡C 5. ºÊ´úCBC¡BµÇ¥\¯à¡C
IMAB5,Rituximab,MABTHERA infusion 500mg/50mL,RACA,Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment¡A after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.,Hypersensitivity to rituximab or murine proteins. Pregnancy¡A lactation. Active hepatits B disease.,Fever¡A chills or rigor¡A flushing¡A angioedema¡A nausea¡A urticaria/rash¡A fatigue¡A headache¡A pruritus¡A dyspnea¡A throat irritation¡A rhinitis¡A vomiting. Cardiovascular: Hypertension (all grades¡A 6%; grades 3 and 4¡A 1% )¡A Hypotension (all grades¡A 10%; grades 3 and 4¡A 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% )¡A Diarrhea (10% )¡A Nausea (23% )¡A Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma¡A all grades¡A 26%; grades 3 and 4¡A 1%; rheumatoid arthritis¡A 2% )¡A Dizziness (all grades¡A 10%; grades 3 and 4¡A 1% )¡A Headache (all grades¡A 19%; grades 3 and 4¡A 1% )¡A Sensory neuropathy (30% ) Other: Fever (all grades¡A 53%; grades 3 and 4¡A 1% )¡A Shivering (all grades¡A 33%; grades 3 and 4¡A 3% ),2-8¢JÁ×¥úÁ×§K§N­á,Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction¡A increase the rate by 50 mg/hour increments every 30 minutes¡A to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion¡A start at 100 mg/hour; if there is no infusion-related reaction¡A increase the rate by 100 mg/hour increments every 30 minutes¡A to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin¡¦s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide¡A doxorubicin¡A prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1¡A then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation)¡A but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,,,,1. ²Ä¤@¦¸¨Ï¥Î¡Gµ¹ÃÄ³t²v«ØÄ³±q50 mg/¤p®É¶}©l¡A¤§«áµø¯f¤H­@¨üµ{«×¥i¨C30 ¤ÀÄÁ´£°ª50 mg/¤p®É¡A³Ì¤j³t²v¤£¥i¶W¹L 400 mg/¤p®É¡C 2. ²Ä¤G¦¸¥H«á¨Ï¥Î¡Gµ¹ÃÄ³t²v«ØÄ³±q100 mg/¤p®É¶}©l¡A¤§«á¥i¨C30 ¤ÀÄÁ´£°ª100 mg/¤p®É¡A³Ì¤j³t²v¤£¥i¶W¹L 400 mg/¤p®É¡C­Y¯f¤H­@¨üµ{«×¨}¦n¡A§Ö³tµ¹ÃÄ¤§µ¹ÃÄ®É¶¡À³ > 60 ¤ÀÄÁ¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¬ù 1 -4 mg/mL¡A«Ç·Å¦w©w©Êºû«ù 12 ¤p®É¡C 4.±w¦³¤ß«ß¤£¾ã¡B¤ßµ±µh¡BªÍ¯e±wªº¯f¤H¡A ¿éª`®É¥[±jºÊ´ú¤ßªÍ¥\¯à¡C 5. ºÊ´úCBC¡BµÇ¥\¯à¡C
IMIR,Methoxy Polyethylene Glycol- Epoetin £],Mircera inj 50mcg/0.3mL,HEMT,Treatment of symptomatic anemia associated with chronic kidney disease (CKD). Not indicated for the treatment of anemia due to cancer chemotherapy.,Uncontrolled hypertension.Neonates: injections containing benzyl alcohol.,Hypertension¡A diarrhea¡A nasopharyngitis¡A headache & upper respiratory tract infections. Increased mortality¡A serious cardiovascular & thromboembolic events; Increased mortality and/or tumor progression; seizures; pure red cell aplasia.,2-8¢JÁ×¥úÁ×§K§N­á,Adult without treated with an ESA before¡A initially IV/SC 0.6 mcg/kg as a single dose every 2 weeks. Once Hb has been maintained between 10-12 g/dL¡A one time per month could be considerated¡A with double dose of initial dose. Adult currently treated with an ESA¡A IV/SC every 2 weeks or once monthly. Previous dose of Epoetin £\ or £] < 4000 u/week or Darbepoetin £\ < 20 mcg/week: 80 mcg/month or 40 mcg every 2 weeks. Previous dose of Epoetin £\ or £] 4000-< 8000 u/week or Darbepoetin £\ 20-< 40 mcg/week: 120 mcg/month or 60 mcg every 2 weeks. Previous dose of Epoetin £\ or £] 8000-16000 u/week or Darbepoetin £\ 40-80 mcg/week: 200 mcg/month or 100 mcg every 2 weeks. Previous dose of Epoetin £\ or £] > 16000 u/week or Darbepoetin £\ > 80 mcg/week: 360 mcg/month or 180 mcg every 2 weeks. Dose adjustments should not be made more than once per month.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,EPOETIN ALFA: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk ¥é³æ¸ê°T¡GÃh¥¥¤À¯Å C ¹ï¤j¹«©M¨ß¤l©óÃh¥¥´Á¶¡¥H¥Ö¤Uª`®gªº¤è¦¡§ë¤©Mircera¤§«á¡A¨âºØª«ºØ¦b¨C¤T¤Ñ§ë¤©¤@¦¸50 ·L¤½§J/¤½¤çªº¾¯¶q¤U³£¦³°©Àf·î§Îªº²{¶H¡C©ÒÆ[¹î¨ìªº¼vÅT¬°¦³¤@°¦¤j¹«­L¨à¦]§À´Õ°©¯Ê¥¢ ¦Ó§Î¦¨½uª¬§À¤Ú¡A¦³¤@°¦¨ß¤l­L¨à¦]¨â°¦«e¸}ªº²Ä¤@«ü¨S¦³´x°©»P³k°©¦Ó³y¦¨¤j©æ«ü¯Ê¥¢¡A¥t ¦³¨ß¤l­L¨à«h¬O¥X²{²Ä¥|©M²Ä¤­ÀV´Õ¤¤¤ß¿Ä¦Xªº²{¶H¡C¤j¹«»P¨ß¤lªº­L¨à³£¦³§e¾¯¶q¬ÛÃö©Êªº Åé­«´î»´²{¶H¡C¦b¨C¤T¤Ñ§ë¤©¤@¦¸5·L¤½§J/¤½¤ç¤Î§ó°ªªº¾¯¶q¤U¡AMircera¦b¥ÀÃ~¤¤ªºÃÄ®Ä¾Ç§@ ¥Î·|§ó¥[ÂX¤j¡C ¹ïÃh¥¥¥À¹«¨C¶g§ë¤©¤@¦¸³Ì°ª¹F50·L¤½§J/¤½¤ç/¾¯¤§¾¯¶qªºMircera¡A¨Ã¤£·|¹ïÃh¥¥°Ñ¼Æ¡B¦ÛµM ¥Í²£©Î¥J¹«Æ[¹îµ²ªG³y¦¨¤£¨}ªº¼vÅT¡CF1¥N¥J¹«¦b­÷¨Å¤Î­èÂ_¥¤´Á¶¡¦³¦º¤`²v¤É°ª¤Î¥Íªø³t²v ©úÅã­°§Cªº²{¶H¡C¤£¹L¡A¦b¤Ï®g¤ÏÀ³¡B¨­Åé©Mª¾¯àµo®i©Î¥Í´Þ¯à¤O¤è­±¡A¦U¾¯¶q²ÕªºF1¥N¥J¹« ¤¤¬Ò¥¼µo²{¥ô¦ó©úÅãªº¼vÅT¡C ¥Ø«e¨ÃµL¥ô¦ó¾A·í¥B±±¨î¨}¦nªº¥¥°ü¬ã¨s¡C¥u¦³¦b¼ç¦b®Ä¯q¶W¶V­L¨à¥i¯à­±Á{¤§­·ÀIªº±¡ªp ¤U¡A¤~¥i©óÃh¥¥´Á¶¡¨Ï¥ÎMircera¡C,Unknown ¨S¦³¸ê®Æ,EPOETIN ALFA: Compatible ¥é³æ¸ê°T¡G ¥Ø«e¨Ã¤£½Tª¾Mircera¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C¤@¶µ¤j¹«ªº¬ã¨sÅã¥Ü¡AMircera·|¤Àªc¶i¤J ¥À¨Å¡C¥Ñ©ó³\¦hÃÄª«³£·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¦]¦¹¡A¹ï±Â¨Å°ü¤k§ë¤©Mircera®ÉÀ³ÂÔ·V¡C,IV;SC;,,,,,Intravenous: Inject into the venous port of the hemodialysis tubing. SC: Inject into the outer aspect of the upper arms¡A abdomen (except for 2 inches around the navel)¡A or front aspect of the middle thighs. Do not inject into an area that has scars or stretch marks or is tender¡A red¡A bruised¡A or hard. Rotate injection sites with each injection to prevent soreness.
LSIM,Simethicone,(­­¸z­G¤¤¤ß)Simethicone 20mg/mL suspension,ALIM,Relief of flatulence & abdominal discomfort due to excess GI gas.,Intestinal perforation or obstruction.,Mild diarrhea¡A nausea & vomiting¡A regurgitation.,25¢J¥H¤UÁ×¥ú,Adult & children > 3 years : 2mL TID - QID¡A or when needed; Children < 3 years should consult with doctor.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ILIP20,MCT + Omega-3-triglyceride + Soya Oil,Lipoplus inj 20% 250mL,NUTR,Supply of lipids¡A including essential omega-6 fatty acids and omega-3 fatty acids¡A as part of a parenteral nutrition regimen for adults¡A when oral or enteral nutrition is impossible¡A insufficient or contra-indicated.,Severe hyperlipidemia¡A severe blood coagulation disorders¡A intrahepatic cholestasis¡A severe liver failure¡A severe renal failure without access to hemofiltration or dialysis¡A acute phase of MI or stroke¡A acute thromboembolic disease¡A lipid embolism. Hypersensitivity to egg¡A fish¡A or soya-bean protein. General contraindications to infusion therapy include unstable hemodynamic status with compromised vital functions (conditions of collapse & shock)¡A unstable metabolic conditions (eg. severe post-traumatic conditions¡A uncompensated diabetes mellitus¡A severe sepsis¡A acidosis)¡A acute pulmonary edema¡A hyperhydration¡A decompensated cardiac insufficiency¡A hypotonic dehydration¡A hypokalemia.,Dyspnea¡A allergic reaction¡A hyperglycemia¡A nausea¡A vomiting,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Dosage Adult: 0.7-1.5g lipids/kg body weight/day¡A maximum: 2g lipids/kg body weight/day. For home TPN apply > 6 months or short bowel syndrome: <1g lipids/kg body weight/day. Children and adolescents: 2-3g lipids/kg body weight/day. Preterm neonatal infants¡A term newborn infants¡A infants and toddlers: 2-3g lipids/kg body weight/day. Maximum infusion rate Adults: Up to 0.15 g lipids/kg body weight/hr. Children and adolescents: Up to 0.15 g lipids/kg body weight/hr. Preterm neonatal infants¡A term newborn infants¡A infants and toddlers: Up to 0.15 g lipids/kg body weight/hr.,µL»Ý½Õ¾ã¾¯¶q,­Y¦¨¦~¤Hªº¦å¼ß¤T»Ä¥Ìªoà­¿@«×¶W¹L4.6 mmol/L (400 mg/dl )¡A«ØÄ³­°§C¿éª`³t²v ­Y¦¨¦~¤Hªº¦å¼ß¤T»Ä¥Ìªoà­¿@«×¶W¹L11.4 mmol/L (1000 mg/dl )¡A«ØÄ³°±¤î¿éª` ÄY­«¨x¥\¯à¤£¥þªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,¿éª`³t²v: 0.25 - 0.5 mL/kg/hr,1. ¥»¯×ªÕ¨Å¾¯¥i¸g¥Ñ¶gÃäÀR¯ß©Î¤¤¥¡ÀR¯ß¾ÉºÞ¿éª`¡A­Y¨Ï¥Î§t¹LÂo¾¹¤§¿éª`®M¡A¥²¶·¿ï¾Ü¾A¦X¯×ªÕ¨Å¾¯ªÌ¡C 2. ¯×ªÕ¨Å¾¯À³¥HºC³t¿éª`¬°­ì«h¡A¤×¨ä¿éª`¶}©lªº¤Q¤­¤ÀÄÁ¡A¨C¤p®É¨C¤½¤çÅé­«¤£¶W¹L0.375mL¡C 3. ³Ì¤j¿éª`³t«×¨C¤p®É¨C¤½¤çÅé­«0.75mL¡C
OEST,Estradiol Valerate,Estrade 2mg,HM,Relief of menopausal symptoms including patients with ovariectomy,Sever hepatic dysfunction¡A thrombophlebitis¡A thromboembolic disorders¡A hormone-dependent tumors¡A undiagnosed vag bleeding¡A pregnancy.,Breast tenderness¡A nausea¡A weight change¡A edema¡A headache¡A dizziness¡A abdominal pain.,25¢J¥H¤U,Initial dose as 2 mg once daily for 20-21 days and stop for at least 1 week¡A followed by decrease dose to 1mg.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª±wªÌ¶·ÂÔ·V§ë»P,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OFAM,Famciclovir,Famvir 250mg,QANB,Herpes zoster infections,Known hypersensitivity to famciclovir.,Headache¡A nausea. Gastrointestinal: Diarrhea (1.8% to 9% )¡A Flatulence (0.6% to 4.8% )¡A Nausea (2.2% to 12.5% )¡A Vomiting (1.2% to 4.8% ) Neurologic: Headache (9.7% to 39.3% ) Reproductive: Dysmenorrhea (0.9% to 7.6% ),30¢J¥H¤U°®Àê³B,Adult: Herpes zoster (shingles): 250 mg orally TID for 7 days. Primary genital Herpes: 250 mg orally TID for 5 days. Recurrent genital Herpes: 125 mg orally BID for 5 days.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IKA+X1,Triamcinolone Acetonide,Kenacort-A + 1% Xylocaine,HM,,,,,,,,,,,,,,,,,,,
IKA+X2,Triamcinolone Acetonide,Kenacort-A + 2% Xylocaine,HM,,,,,,,,,,,,,,,,,,,
IKCL1,Potassium Chloride,KCl inj (­­²K¥[¥Î) 15%¡A10mL,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia¡A pain or phlebitis at injection site.,Á×¥ú,As TPN material. NOTE: Never give injectable potassium chloride undiluted. Standard daily potassium requirement: IV: 1 to 2 mEq/kg/day; adjust daily dose and selection of potassium additive (eg¡A chloride or acetate) based on serum potassium and clinical considerations; usual maximum: 10 mEq/hour (ASPEN 2019; Siparsky 2020).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVA;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°°ª¿@«×¹[Â÷¤l·»²G¡A¶·µ}ÄÀ«á¨Ï¥Î¡A­­ÃÄ¾¯¬ì¥Î©ó»s¾¯½Õ°t¡C 2. KCl»s¾¯¿@«× >= 0.1 mEq/mL®É¤£¥i±q©PÃäµ¹ÃÄ¡C½Ð½T»{¯f¤H¦³¤¤¥¡ÀR¯ß¾ÉºÞ(Central venous catheter¡A CVC)¡A¨Ã¦b³B¤èºàµù©ú¥Ñ¤¤¥¡ÀR¯ß¾ÉºÞµ¹ÃÄ¡C
ILED,Triamcinolone Hexacetonide,Lederspan(Aristospan) 20mg/mL,HM,,Arthritis¡A severe dermatitis.,,,Adult: 2 ~ 40 mg IA,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ILEUP,Leuprolide,Leuplin Depot inj 3.75mg,RACA,,¾AÀ³¯g: Palliative treatment of advanced prostatic cancer. Treatment of endometriosis (experience has been limited to women ¡Ù18 years treated for 6 months). Treatment of uterine leiomyoma. Treatment of central precocious puberty. Palliative treatment of premenopausal breast cancer. °Æ§@¥Î: Hot flushes¡A anorexia¡A nausea. ¸T§Ò: Women who are or may become pregnant while receiving the drug.,,«Ç·Å,1 vial monthly as a single SC inj. Central precocious puberty A dose of 30 mcg/kg¡A may be increased up to 90 mcg/kg.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,
ILEUV,Folinic Acid,BW-Folin inj 1000mg/100mL,ZADT,,¾AÀ³¯g: Megaloblastic anemia due to folic acid deficiency¡A Intoxication & side-effects of folic acid antagonists¡A associated with high-dose methotrexate. °Æ§@¥Î:Occasionally Allergic reactions. Pyrexia may occur after inj ¸T§Ò: Untreated vit B12 deficiency. Never given alone or in conjunction with inadequate amounts of hydroxocobalamin.,,2-8 C,For large dose of methotrexate: IV 75 mg within 12hrs¡A followed by IM 12mg/6hrs for 4 doses. For less severe overdosage: IM 6-12mg/6hrs for 4 doses. For megaloblastic anemia: 1-15mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,°t¥î¸T§Ò: 1. Droperidol»P¥»ÃÄ²V¦X¦b¤@°_©Î¦@¥ÎY-site·|¥X²{¨I¾ý¡A¤£¥i¦@¥Î¡C 2. Foscarnet»P¥»ÃÄ²V¦X¦b¤@°_·|¥X²{²V¿B¶À¦â·»²G¡A¤£¥i¦@¥Î¡C
OBER,Fenoterol,Berotec (Fenoterol) 2.5mg,ERSP,,¾AÀ³¯g:¹w¨¾¤ÎªvÀø¤ä®ðºÞµjÅË(A028501100),,RT,Oral: Adult: 2.5-5 mg tid. Child: Up to 1 yr: 1.25 mg bid-tid. 1-6 yrs: 1.25 mg-2.5 mg tid. 6-14 yrs: 2.5 mg tid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OBIOC,Tricalcium phosphate + Cholecalciferol,Bio-Cal chewable,NUTR,,¾AÀ³¯g:Osteoporosis¡A Ca deficiency. ¸T§Ò: Hypercalcemia.,,«Ç·Å,2-4 tab daily.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OBIOF,Lactobacillus Acidophilus,Biofermin,ALIM,,Digestant¡A antidiarrhea.,,,Adult: 8 tab tid¡A pc. Child 5-15 yrs: 4 tab tid. Under 5 yrs: reduced doses.,,,,,,,,,,,,,,
LSUL,Sulfamethoxazole + Trimethoprim,Sulfacotrim 40/8mg/mL¡A 60mL suspension,QANB,Acute exacerbations of chronic bronchitis¡A UTI & acute otitis media due to susceptible organisms; treatment & prophylaxis of P. carinii pneumonia; travelers?diarrhea due to susceptible strains of enterotoxigenic E. coli.,Hypersensitivity; megaloblastic anemia.,GI disturbances¡A allergic skin reactions (discontinue)¡A folic acid deficiency; mild & transient hematological abnormalities; rarely¡A megaloblastic anemia¡A purpura¡A agranulocytosis.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Adults: trimethoprim/sulfamethoxazole 160/800-240/1200 mg (20-30 mL) BID for 7 days or 80/400 mg (10 mL) BID for 14 days. Children 6 weeks to 5 months: 20/100 mg (2.5 mL) BID; 6 months to 5 years: 40/200 mg (5 mL) BID; 6 years to 12 years: 80/400 mg (10 mL) BID.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IHYC,Topotecan,Hycamtin inj 4mg,RACA,Metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Small cell lung cancer sensitive disease after failure of 1st-line chemotherapy.,Severe hypersensitivity to topotecan or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Severe renal impairment (CrCl <20 mL/minute); pregnancy; breastfeeding; severe bone marrow depression,Neutropenia¡A leucopenia¡A thrombocytopenia¡A anemia¡A sepsis. GI disturbances¡A fatigue¡A fever¡A pain¡A asthenia¡A alopecia¡A rash¡A coughing¡A dyspnea¡A headache Dermatologic: Alopecia (IV¡A 49% ; oral¡A 10% to 20% )¡A Rash (IV¡A 16% ) Gastrointestinal: Abdominal pain (5% to 22% )¡A Constipation (5% to 29% )¡A Diarrhea (IV¡A 6% to 32% ; oral¡A 14% to 22% )¡A Nausea (IV¡A 8% to 64% ; oral¡A 27% to 33% )¡A Stomatitis (6% to 18% )¡A Vomiting (IV¡A 10% to 45% ; oral¡A 19% to 21% ) Hematologic: Anemia (IV¡A 89% to 94% ; oral¡A 94% to 98% )¡A Leukopenia (IV¡A 91% to 97% ; oral¡A 86% to 90% )¡A Neutropenia (IV¡A 89% to 97% ; oral¡A 83% to 91% )¡A Thrombocytopenia (IV¡A 69% to 74% ; oral¡A 81% ) Neurologic: Asthenia (IV¡A 25% ; oral¡A 3% to 7% )¡A Headache (IV¡A 18% )¡A Pain (23% ) Respiratory: Cough (15% )¡A Dyspnea (6% to 22% ) Other: Fatigue (IV¡A 29% ; oral¡A 11% to 19% )¡A Fever (28%¡A intravenous ; 5% to 7%¡A oral ),30¢J¥H¤U,Baseline neutrophil count should be ?1¡A500/mm3 (1.5 x 10^9/L)¡A platelets should be ?100¡A000/mm3 (100 x 10^9/L) and hemoglobin ?9 g/dL prior to treatment; for re-treatment¡A neutrophil count should be >1¡A000/mm3 (1 x 10^9/L); platelets >100¡A000/mm3 and hemoglobin ?9 g/dL. [Ovarian Cancer and Small Cell Lung Cancer] 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days¡A starting on day 1 of a 21-day course. In the absence of tumor progression¡A a minimum of 4 courses is recommended because tumor response may be delayed. The median time to response in 3 ovarian clinical trials was 9-12 weeks¡A and median time to response in 4 small cell lung cancer trials was 5-7 weeks.  [Cervical Cancer] 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1¡A 2¡A and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. Topotecan 4 mg ¯»¥½¶·¥H4 mL D/Wªw»s¡Aªw»s«á¤§·»²G¿@«× 1mg/mL¡Cªw»s«á·»²G»Ý¥H¾A·íÅé¿nN/S©ÎD5W¶i¤@¨Bµ}ÄÀ¡A³Ì²×¿@«× 25 - 50 mcg/mL¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡Aª`·N¬O§_¥X²{¶¡½è©ÊªÍ¯f¯gª¬ («y¹Â¡Bµo¿N¡B©I§l§xÃø©Î¯Ê®ñ)¡C
ENOV4,NovoPen 4,NovoPen 4,ZOTH,,,,,,,,,,,,,,,,,,,
OINV,Paliperidone,Invega 3mg extended release,CNEU,Treatment of schizophrenia.,Hypersensitivity to risperidone. Congenital long QT syndrome¡A cardiac arrhythmias. Pre-existing severe GI narrowing. Lactation.,Cardiac disturbances¡A arrhythmia¡A GI disturbances¡A upper abdominal pain¡A extrapyramidal disorder¡A weight increase. Rarely edema¡A hypersensitivity reactions¡A dystonia¡A hypotension¡A venous thromboembolism. Cardiovascular: Tachycardia (16% geriatric ) Endocrine metabolic: Hyperprolactinemia (geriatric¡A 45% to 49% )¡A Weight gain (4% to 9% ) Gastrointestinal: Constipation (4% to 5% )¡A Indigestion (5% to 6% ) Neurologic: Akathisia (3% to 10% )¡A Extrapyramidal disease (2% to 20% )¡A Somnolence (6% to 12% ) Respiratory: Nasopharyngitis (2% to 5% ),25¢J¥H¤U,Schizophrenia: Adults: 3-12mg QD. When the dose >6 mg/day¡A increased by 3 mg/day at intervals of more than 5 days. maximum: 12mg/day. 12-17 years old: initial dose: 3mg QD. The dose should be increased by 3 mg/day at intervals of more than 5 days. maximum dose:<51kg:6mg/day; >=51kg:12mg/day Schizoaffective Disorder: 6mg QD¡A increase by 3 mg/day at intervals of more than 4 days. maximum: 12mg/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
OPROV,Modafinil,Provigil 200mg,CNEU,,,,,,,,,,,,,,,,,,,
OAVE4,Moxifloxacin,Avelox 400mg (¬F©²´£¨Ñ),QANB,,¾AÀ³¯g:Treatment of adults ? 18 years with upper & lower respiratory tract infections such as acute sinusitis¡A acute exacerbation of chronic bronchitis¡A community acquired pneumonia; skin & soft tissue infections; complicated intra-abdominal infection °Æ§@¥Î:GI disturbances (eg nausea¡A vomiting¡A dyspepsia¡A abdominal pain); headache¡A dizziness; taste perversion; musculoskeletal effects (eg back pain¡A arthralgia); CVS effects (eg tachycardia¡A hypertension); hematological changes; CNS disturbances eg (insomnia¡A convulsion); skin reactions (eg rash¡A pruritus); visual disturbances. ¸T§Ò:Hypersensitivity. Children¡A growing adolescent. Pregnancy¡A lactation,,«Ç·Å,1 tab/bot (400 mg) once daily. Duration: Acute exacerbation of chronic bronchitis 5 days. Community acquired pneumonia 10 days (IV 7-14 days). Acute sinusitis 7 days. Skin & soft tissue infection 7-21 days. Complicated intra-abdominal infection 5-14 days,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OALU,Aluminum Hydroxide,Aluminum 324mg,ALIM,As an antacid. Phosphate-binding agent (but not TFDA indication).,Hypophosphatemia.,Constipation.,¸m©ó25¢J¥H¤UÁ×¥ú¨¾¼éªº®e¾¹¤¤,Adult 1-2 tablets 3-6 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OCEPO,Captopril,Ceporin 25mg,CAVS,Hypertension¡A chronic heart failure.,Pregnancy,Dysgeusia¡A skin rash¡A cough,30¢J¥H¤U¡AÂÔ¨¾Àã®ð,HTN initial 25mg TIDAC slow titrate up Maximum 450mg/day (Take one hour before meals ) CHF: initial dose of 6.25 or 12.5 mg TID in patients with normal or low blood pressure; maintence dose: -50mg TIDAC,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PO;,,,,,
ODIG,Digoxin,Digoxin 0.25mg,CAVS,Heart failure¡A atrial fibrillation &/or flutter & supraventricular tachycardia.,Intermittent complete heart block or 2nd-degree AV block¡A especially if there is a history of Stokes-Adams attacks; arrhythmias caused by cardiac glycoside intoxication; supraventricular arrhythmias associated with an accessory AV pathway¡A as in the Wolff-Parkinson-White syndrome¡A unless the electrophysiological characteristics of the accessory pathway & any possible deleterious effect of digoxin on these characteristics has been evaluated. If an accessory pathway is known or suspected to be present & there is no history of previous supraventricular arrhythmias. Hypertrophic obstructive cardiomyopathy unless with concomitant atrial fibrillation & heart failure. Hypersensitivity to other digitalis glycosides.,Arrhythmias; anorexia¡A nausea¡A vomiting; lower abdominal pain¡A abnormal fatigue or weakness; abnormal bradycardia; visual disturbances; diarrhea; depression & psychosis¡A drowsiness¡A headache¡A malaise. Gynecomastia in prolonged use.,25¢J¥H¤U,Adults and children over 10 years: Oral: Rapid digitalization: A total of 0.75-1.5 mg. if necessary¡A eg.¡A elderly or high sensitivity patients to clinical response¡A drug levels¡A and toxicity¡A that should be administered in several portions at 6-hour intervals with roughly half the total dose given as the first dose. Slow digitalization: 0.25-0.75 mg QD for 7 days. Maintenance: 0.125-0.25 mg QD. 0.0625mg or lower dose daily might be used on patients who have side effects. Infants and children under 10 years: Oral: Digitalization: This dose should be administered in several portions¡A with roughly half the total given as the first dose. Additional fractions of this planned total dose may be given at 4 to 8-hour intervals. <1.5kg¡A <1 month infant: 0.025mg/kg/24hour 1.5-2.5kg¡A <1 month infants: 0.03mg/kg/24hour 1 month ~ 2 years old children: 0.045mg/kg/24hour 2 ~ 5 years old children: 0.035mg/kg/24hour 5 ~ 10 years old children: 0.025mg/kg/24hour Maintenance: <1 month infants: daily dose = loading dose*20% 1 month ~ 10 years children: daily dose = loading dose*25%,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ] ©|µL digoxin ¼vÅT¤HÃþ¥Í¨|¤Oªº¸ê®Æ¡C¹ï©ó digoxin ¬O§_¨ã­P·î©Ê¡A¥çµL¬ÛÃö¸ê®Æ¡C ¥¥°ü¤£¸T¥Î digoxin¡A¦ý¥¥°ü©Ò»Ý¾¯¶q¸ûÃø¹w´ú¡C¦³¨Ç¤HÃh¥¥®É»Ý­n¼W¥[ digoxin ªº¾¯¶q¡C¦p¦P¨ä¥LÃÄª«¡A¥¥°ü¨Ï¥Îdigoxin À³¥ý¿Å¶qªvÀø¹ï¥¥°ü¤§¯q³B¬O§_¤j©ó¹ï­L¨à¥i¯à³y¦¨ªº­·ÀI¡C§Y¨Ï²£«e¤j¶q¼ÉÅS©ó¤ò¦a¶À(digitalis)ªº°t¤è¡A·í¥ÀÅéªº digoxin ¦å²M¿@«×¤´¦b¥¿±`½d³ò®É¡A¥Ø«e¥¼Æ[¹î¨ì­L¨à©Î·s¥Í¨à¥X²{¥ô¦ó©úÅãªº¤£¨}¤ÏÀ³¡CÁöµM®Ú¾Ú±ÀÂ_¡Adigoxin ¹ï¤l®c¦Ù¼hªºª½±µ§@¥Î¥i¯à¾É­P¬Û¹ï¦­²£»P¸û§Cªº¥X¥ÍÅé­«¡A¤£¹LµLªk±Æ°£¦¹Ãþµ²ªG¬O¬J¦³¤ßÅ¦¯e¯f©Ò¾É­Pªº¥i¯à©Ê¡C¹L¥h´¿¦¨¥\¦b¥ÀÅé§ë¤© digoxin ªvÀø­L¨à¤§¤ß·i¥[³t¤ÎÆ{¦å©Ê¤ß°IºÜ¡C ´¿¦³³q³ø¹L­L¨àªº¤£¨}¤ÏÀ³¦b¥ÀÅé¦³¤ò¦a¶À¤¤¬rªº±¡ªp¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] Digoxin ·|¤Àªc¦b¨Å¥Ä¤¤¡A¦ý¤Àªc¶q·¥¤Ö¡A¨Ï¥Î digoxin ´Á¶¡¤£¥²°±¤îÁý¥¤¡C,AC;AC15;PC;PO;WM;,,,,,
IALI1,Pemetrexed,Alimta inj 100mg,RACA,In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.,Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.,Common: Itching (1-24%)¡A Rash (16-25%)¡A Constipation (1-51%)¡A Diarrhea (5-37%)¡A Loss of appetite (19-27%)¡A Nausea (12-82%)¡A Pharyngitis¡A Stomatitis¡A Vomiting (6-57%)¡A Anemia¡A All Grades (15-33%)¡A Neutropenia¡A All Grades (6-56%)¡A Thrombocytopenia¡A All Grades (1-23%)¡A Cough (21-24%)¡A Dyspnea (21-39%)¡A Fatigue (18-71%)¡A Fever (1-20%) Serious: Peeling of skin¡A Radiation recall reaction due to cytotoxic therapy¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Gastrointestinal obstruction¡A Grade 3 and 4 (<1%)¡A Anemia¡A Grades 3 and 4 (3-6%)¡A Febrile neutropenia (Up to 5% (all Grades); 1-5% (Grade 3 or 4))¡A Neutropenia¡A Grades 3 and 4 (3-23%)¡A Thrombocytopenia¡A Grades 3 and 4 (2-5%)¡A Sensory neuropathy (1%)¡A Renal failure (Up to 5%)¡A Acute lung injury¡A Interstitial pneumonia¡A Pulmonary embolism (<1%),25¢J¥H¤U,500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,Hold Breast Feeding ¼È°±­÷¨Å,PEMETREXED: Hold Breastfeeding Contraindicated (if Combined with Cisplatin),IVD;,,,,,
IALI5,Pemetrexed,ALIMTA inj 500mg,RACA,In combination with cisplatin for the treatment of malignant pleural mesothelioma. Monotherapy for the 2nd-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer. In combination with cisplatin therapy for the 1st-line treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.,Severe hypersensitivity to pemetrexed or any component of the formulation. Canadian labeling: Additional contraindications (not in the US labeling): Concomitant yellow fever vaccine.,Common: Itching (1-24%)¡A Rash (16-25%)¡A Constipation (1-51%)¡A Diarrhea (5-37%)¡A Loss of appetite (19-27%)¡A Nausea (12-82%)¡A Pharyngitis¡A Stomatitis¡A Vomiting (6-57%)¡A Anemia¡A All Grades (15-33%)¡A Neutropenia¡A All Grades (6-56%)¡A Thrombocytopenia¡A All Grades (1-23%)¡A Cough (21-24%)¡A Dyspnea (21-39%)¡A Fatigue (18-71%)¡A Fever (1-20%) Serious: Peeling of skin¡A Radiation recall reaction due to cytotoxic therapy¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Gastrointestinal obstruction¡A Grade 3 and 4 (<1%)¡A Anemia¡A Grades 3 and 4 (3-6%)¡A Febrile neutropenia (Up to 5% (all Grades); 1-5% (Grade 3 or 4))¡A Neutropenia¡A Grades 3 and 4 (3-23%)¡A Thrombocytopenia¡A Grades 3 and 4 (2-5%)¡A Sensory neuropathy (1%)¡A Renal failure (Up to 5%)¡A Acute lung injury¡A Interstitial pneumonia¡A Pulmonary embolism (<1%),25¢J¥H¤U,500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Hold Breast Feeding ¼È°±­÷¨Å,PEMETREXED: Hold Breastfeeding Contraindicated (if Combined with Cisplatin),,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ¥»ÃÄ«~¤£¥i»P§t¦³¶tÂ÷¤lªº·»²G²V¦X¡C 3. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C 4. «ØÄ³ºÊ´úhomocysteine¦å¤¤¿@«×¡C
ONTG6,Nitroglycerin,Nitrostat (NTG) 0.6mg,CAVS,Treatment & prophylaxis of angina pectoris.,Severe anemia; raised intracranial pressure¡A early MI¡A patients taking sildenafil.,Headache¡A vertigo¡A weakness¡A palpitation & postural hypotension. Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea¡A vomiting¡A weakness¡A diaphoresis¡A pallor & collapse). Flushing¡A drug rash & exfoliative dermatitis. Cardiovascular: Hypotension Dermatologic: Erythroderma¡A Flushing¡A Rash Neurologic: Headache (63% )¡A Lightheadedness (6% ),20-25¢JÁ×§K¼éÀã,Angina pectoris¡A acute: 0.6 mg sublingually or buccally at 1st sign of acute attack¡A may be repeated every 5 minutes for 3 doses. If no relief after taking 3 doses within 15 minutes¡A seek medical attention promptly. Angina pectoris¡A prophylaxis: 0.6 mg sublingually or buccally 5-10 minutes prior to the activity which may precipitate an attack.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SL;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¦Þ¤U¿õ¡A¥iª½±µ¸m©ó¦Þ¤U¨Ï¥Î¡C
OWELX,Bupropion,Wellbutrin XL 150mg,CNEU,Treatment of depressive illnesses.,Seizure disorder¡A undergoing abrupt discontinuation of alcohol or sedatives¡A current or previous diagnosis of bulimia or anorexia nervosa. Concomitant with other MAOIs.,Common: Tachycardia (11%)¡A Weight gain (2-3%)¡A Weight loss (14-19%)¡A Abdominal pain (2-9%)¡A Constipation (5-10%)¡A Nausea (13-18%)¡A Xerostomia (17-26%)¡A Confusion (8%)¡A Dizziness (6-11%)¡A Headache (25-34%)¡A Insomnia (11-20%)¡A Agitation (2-9%)¡A Nasopharyngitis (13%)¡A Pharyngitis (3-11%)¡A Upper respiratory infection (9%) Serious: Complete atrioventricular block¡A Hypertension (2-6.1%)¡A Myocardial infarction¡A Colitis¡A Pancreatitis¡A Hepatitis¡A Jaundice¡A Liver damage¡A Liver function tests outside reference range¡A Anaphylaxis¡A Delayed hypersensitivity disorder¡A Rhabdomyolysis¡A Seizure (0.1-0.4%)¡A Angle-closure glaucoma¡A Delusional disorder¡A Depression¡A Worsening¡A Hallucinations¡A Hostile behavior (6%)¡A Hypomania¡A Mania¡A Precipitation of episode¡A Paranoid ideation¡A Psychotic disorder¡A Activation¡A Suicidal behavior¡A Suicidal thoughts¡A Pulmonary embolism¡A Angioedema,25¢J¥H¤U¡A°®Àê³±²D³B,Adults¡A > 18 years old: Initial dose: 150mg QD. maximum: 300 mg QD. There must be a 24 hour interval between doses. Children and adolescents¡A <18 years old: Safety and effectiveness have not been established. Elderly: More sensitive to bupropion. It may be necessary to reduce the frequency and/or dose of the drug.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ±wªÌ«ØÄ³³Ì°ª¾¯¶q100 mg/day OR 150 mg every other day ­««×¨x¥\¯à¤£¥þ±wªÌ«ØÄ³³Ì°ª¾¯¶q100 mg/day OR 150 mg every other day,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A»Ý¾ãÁû§]ªA¤Å©CÄZ¡B­é¥b©Î¿i¯»¡C
OLAC4,Lacidipine,LaciPIL 4mg,CAVS,,¾AÀ³¯g: Treatment of hypertension either alone or in combination with other antihypertensive agents. °Æ§@¥Î: Headache¡A flushing¡A oedema¡A dizziness¡A palpitation. Infrequently¡A asthenia¡A skin rash¡A gastric upset¡A nausea¡A polyuria¡A chest pain¡A gingival hyperplasia¡A aggravation of underlying angina. ¸T§Ò: Hypersensitivity to any component of the Lacipil.,,«Ç·Å,Initially 2 mg once dialy; dosage may be increased after 3-4 weeks to 4 mg daily¡A then if necessary to 6 mg daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OLAMS,Terbinafine,Lamisil 250mg (ÀøÅðµÎ),QANB,Tinea corporis¡A tinea cruris¡A tinea pedis & onychomycosis caused by dermatophyte & skin infections caused by Candida albicans.,Hypersensitivity to any of the ingredients of Lamisil.,GI symptoms¡A skin reactions. Gastrointestinal: Diarrhea (oral granules¡A 3% ; oral tablets¡A 5.6% ) Neurologic: Headache (oral granules¡A 7% ; oral tablet¡A 12.9% ),30¢J¥H¤U,Adults: 250 mg orally once daily. Children > 2 years: < 20 kg: 62.5 mg once daily; 20-40 kg: 125 mg once daily; > 40 kg: 250 mg once daily. Treatment duration varies from 2 to 12 weeks.,»Ý½Õ¾ã¾¯¶q,¸T§Ò¨Ï¥Î©óºC©Ê©Î«æ©Ê¨x¯e¯f±wªÌ,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OLAS,Furosemide,Lasix 40mg,CAVS,Cardiac¡A renal & hepatic edema; edema due to burns; mild to moderate hypertension,Acute renal failure with anuria¡A hepatic coma¡A hypokalemia¡A hyponatremia¡A hypovolemia with or without hypotension. Impaired renal or hepatic function.,Minor GI upset; Ca¡A K & Na depletion¡A nephrocalcinosis in premature infants; aggravation of metabolic alkalosis; diabetes. Rarely¡A anaphylactic shock¡A allergic reactions¡A bone marrow depression; acute pancreatitis¡A auditory disorders. Endocrine metabolic: Hyperuricemia (40%)¡A Hypomagnesemia Gastrointestinal: Loss of appetite Renal: Spasm of bladder,Á×¥ú,Cardiac¡A renal and hepatic edema; edema due to burns; mild to moderate hypertension: Adult: Initially 20-80 mg daily; maintenance 20-40 mg daily. Children: 2 mg/kg daily. Maximum: 40 mg daily. [Micromidex 2021/07/20] Maximum adult daily oral dose: 600mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,[¥é³æ] Furosemide ·|³q¹L­L½L»Ù¾À¡A¦]¦¹¡A°£«D¦³±j¨î©ÊªºÂå¾Ç²z¥Ñ¡A §_«h¤£¥i©óÃh¥¥´Á¶¡¨Ï¥Î Lasix¡C ­Y©óÃh¥¥´Á¶¡¨Ï¥ÎLasix¡A«h¶·ºÊ´ú­L¨àªºµo¨|±¡§Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Furosemide ·|²¾¦æ¶i¤J¨Å¥Ä¤¤¡A¨Ã§í¨î¨Å¥Ä¤Àªc¡A¦]¦¹¡A¤£¥i©óÁý­÷¥À¨Å´Á¶¡¨Ï¥Î Lasix¡C,AC;AC15;PO;,,,,,
OMEL5,Minocycline,Melicin 50mg,QANB,,¾AÀ³¯g: Respiratory tract¡A GUT¡A soft tissue¡A ENT¡A ophthalmologic infection¡A periodontitis. °Æ§@¥Î: GI disorders. Maculopapular & erythematous rashes¡A photosensitivity¡A tooth discoloration¡A hypersensitivity reactions. Neurologic: Dizziness (9% )¡A Vertigo ¸T§Ò: Hypersensitivity to tetracyclines. Last half of pregnancy¡A infants¡A children ? 8 years.,,«Ç·Å,Acne vulgaris 100 mg daily as a single dose or in divided dose. Non gonococcal urethritis 200 mg daily as a single or in divided dose for 10-14 days. Gonorrhea Adult male 200 mg initially followed by 100 mg 12 hrly for min of 4 days. Adult female Same dosage as male for 10-14 days. Systemic infection 100 mg 12 hrly. Prophylaxis of asymptomatic meningococcal carriers 100 mg bid for 5 days. Children >8 years 50 mg 12 hrly.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OMIR,Mirtazapine,pms-Mirtazapine 30mg,CNEU,,¾AÀ³¯g: Depression. °Æ§@¥Î: Increase in appetite and wt¡A oedema; drowsiness or sedation; dizziness¡A headache¡A increased liver enzyme levels; jaundice. Orthostatic hypotension¡A rash¡A nightmares¡A agitation¡A mania¡A hallucinations¡A paraesthesia¡A convulsions¡A tremor¡A myoclonus¡A akathisia¡A restless legs syndrome¡A arthralgia¡A myalgia¡A reversible agranulocytosis¡A leucopenia¡A granulocytopenia¡A hyponatraemia. Endocrine metabolic: Increased appetite (17% )¡A Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )¡A Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) Gastrointestinal: Constipation (13% )¡A Xerostomia (25% ) Hepatic: ALT/SGPT level raised (2% ) Neurologic: Asthenia (8% )¡A Dizziness (7% )¡A Somnolence (54% ) Psychiatric: Disturbance in thinking (3% ),,«Ç·Å,PO Initial: 15 mg/day; may increase gradually based on response. Usual range: 15-45 mg/day as 1-2 divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OBOK,Acetylsalicylic Acid,Bokey 100mg,HEMT,Reducing the risk of mortality in patients with a suspected acute MI or a history of MI; secondary prevention of stroke; reducing the risk of transient ischaemic attacks (TIA) & stroke in patients with TIA; reducing the risk of morbidity & death in patients with stable & unstable angina pectoris; prevention of thromboembolism after vascular surgery or interventions; prophylaxis of deep vein thrombosis & lung embolism after longer-term immobilisation; reducing the risk of first MI in patients with CV risk factors.,Active peptic ulcers; haemorrhagic diathesis; a history of asthma induced by acetylsalicylic acid or other NSAIDs; combination with methotrexate at doses of ? 15 mg/week; last trimester of pregnancy.,Frequency not defined: Cardiac arrhythmia¡A hypotension¡A tachycardia¡A Dehydration¡A hyperglycemia¡A hyperkalemia¡A hypoglycemia (children)¡A increased thirst¡A metabolic acidosis¡A Abdominal pain¡A dyspepsia¡A gastrointestinal perforation¡A gastrointestinal ulcer¡A heartburn¡A nausea¡A vomiting¡A Postpartum hemorrhage¡A post-term pregnancy¡A prolonged labor¡A proteinuria¡A stillborn infant¡A Disorder of hemostatic components of blood¡A disseminated intravascular coagulation¡A hemorrhage¡A prolonged bleeding time¡A prolonged prothrombin time¡A thrombocytopenia¡A Hepatitis¡A increased liver enzymes¡A Agitation¡A brain edema¡A coma¡A confusion¡A dizziness¡A headache¡A hypothermia¡A lethargy¡A seizure¡A Increased blood urea nitrogen¡A increased serum creatinine¡A interstitial nephritis¡A renal failure syndrome¡A renal insufficiency¡A renal papillary necrosis¡A Hyperventilation¡A laryngeal edema¡A pulmonary edema¡A respiratory alkalosis¡A tachypnea¡A Fever¡A low birth weight. Postmarketing: Urticaria¡A Hyperuricemia (doses ?325 mg/day)¡A Gastrointestinal hemorrhage¡A pancreatitis¡A Anaphylaxis¡A angioedema¡A Drug reaction with eosinophilia and systemic symptoms¡A Intracranial hemorrhage¡A Reye's syndrome¡A Rhabdomyolysis¡A Macular degeneration (age-related)¡A Hearing loss¡A tinnitus¡A Asthma¡A bronchospasm.,25¢J¥H¤U,Take 100-200 mg every day or 300 mg every other day: Reduce the mortality of patients who may have acute myocardial infarction¡A Prevent deep vein thrombosis and pulmonary embolism caused by long-term immobility¡A Reduce the risk of first myocardial infarction in patients with cardiovascular risk factors¡A such as diabetes¡A hyperlipidemia¡A hypertension¡A obesity¡A smoking¡A and the elderly. Take 100-300 mg every day: Reduce the recurrence rate and mortality of patients with myocardial infarction¡A Prevent secondary-stroke¡A Reduce the recurrence of transient ischemic attack and stroke in patients with transient ischemic attack¡A Reduce the incidence and mortality of patients with stable and unstable angina¡A Prevent thromboembolism caused by vascular surgery or invasive treatment¡A such as percutaneous coronary angioplasty¡A coronary artery separation¡A flow transplantation¡A carotid endarterectomy¡A arteriovenous catheter.,»Ý½Õ¾ã¾¯¶q,Avoid use in severe liver disease.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,1.Compatible (Low Dose) 40~150mg/day 2.PREGNANCY RECOMMENDATION: Human Data Suggest Risk in 1st and 3rd Trimesters (Full Dose),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»½¦Ån¡A¥i©î½¦Ån«áªA¥Î¡C¦ý¤£¥i±N½¦Ån¤ºªº¸z·»·L²É¬ã¿i©ÎÀ£¸H¡C
OBON,Meclizine,Bonamine 25mg,CNEU,,Management of nausea¡A vomiting¡A and dizziness associated with motion sickness.,,,Antivertigo: 25-100 mg/day. Motion sickness: 25-50mg 1 hr before travel.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OBONE,Clodronate,Bonefos 400mg,META,Treatment of osteolysis due to malignancy and malignant hypercalcemia.,Coadministration with other bisphosphonates.,Mild GI irritation¡A asymptomatic hypocalcemia¡A elevations of aminotransferases. Rarely¡A respiratory disorders¡A renal impairment.,15-25¢J,1600 mg daily¡A maximum 3200mg daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PO;,,,,,
OBUS,Hyoscin-Butylbromide,Buscopan 10mg,ALIM,,Gastric and duodenal ulcer¡A intestinal colic¡A cholelithic colic¡A spasmodic dysmenorrhea¡A visceral spasms.,,,Oral: 10-20 mg tid-qid. IM¡A IV¡A SC: 10-20 mg qd¡A repeated as needed.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OCACO3,Calcium Carbonate,Ca. Carbonate 500mg,NUTR,,¾AÀ³¯g: Relief of the symptoms of gastric hyperacidity. °Æ§@¥Î: Mild GI disturbances. ¸T§Ò: Hypercalcaemia due to myeloma¡A bone metastases or other malignant bone disease¡A sarcoidosis; primary hyperparathyroidism¡A vitamin D overdosage; severe renal failure.,,«Ç·Å,1-2 tab before meals & at bedtime. Max: 8 tab/day.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,,,,,
OCAP,Calcium Acetate,Caphos 667mg,NUTR,,¾AÀ³¯g: Control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. °Æ§@¥Î: Hypercalemia¡A nausea¡A constipation¡A allergy reaction ¸T§Ò: Hypercalemia,,«Ç·Å,Initial dose for the adult dialysis pt's is 2 tablets with each meal. The dosage may be increased gradually to bring serum phosphate value below 6 mg/ml¡A as long as hypercalcemia does not develop. Most pt's require 3-4 tablets with each meal.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OROX,Roxatidine Acetate,Roxane 75mg,ALIM,,Duodenal ulcers¡A benign gastric ulcers. Prophylasix of recurrent gastric & duodenal ulcers.,,,Adult 1 cap in the morning and at night or 2 cap at night.,,,,,,,,,,,,,,
ORYT,Propafenone,Rytmonorm 150mg,CAVS,,¾AÀ³¯g: Ventricular & supraventricular tachyarrhythmias¡A Wolff-Parkinson-White syndrome. °Æ§@¥Î: May induce arrhythmia eg. bradycardia¡A induction disorder¡A tachycardia. Rarely ventricular fibrillation. May increase severity of heart failure. Hypotension. GI disturbances. Paresthesia¡A visual disturbances¡A dizziness. Rarely fatigue¡A headache¡A psychotic disorders. Blood disorders. Rarely¡A skin allergy¡A bronchospasm. Cardiovascular: Chest pain (1.8% )¡A Edema (5% to 13% )¡A Palpitations (3.4% ) Gastrointestinal: Constipation (8% to 14% )¡A Nausea (9% to 17% )¡A Taste sense altered (6% to 22% )¡A Vomiting (0% to 6% ) Neurologic: Dizziness (21% to 23% ) Psychiatric: Anxiety (10% to 13% ) Respiratory: Dyspnea (13% to 17% )¡A Upper respiratory infection (8% to 12% ) Other: Fatigue (11% to 13% ) ¸T§Ò: Manifest heart failure; cardiogenic shock (except for shock induced by arrhythmia); severe bradycardia within 3 months after MI; pre-existing high degree SA¡A AV & intraventricular disorders of impulse conduction; sick sinus syndrome; manifest disorders of electrolyte balance; severe obstructive pulmonary disease; marked hypotension¡A myasthenia gravis.,,«Ç·Å,Adult 70 kg Initial & maintenance dose: 450-600 mg daily. May be increased to 900 mg daily.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¨ü·lªº¯f±wÀ³½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OMUB,Ambroxol,Mubroxol 30mg,ERSP,,¾AÀ³¯g: Expectorant. °Æ§@¥Î: Mild GI effects¡A allergic reactions.,,«Ç·Å,Adult & children > 10 years 1 tab tid. (Adult Dosage:most studies have used of 60 to 180 milligrams/day in 2 or 3 divided doses) Children 5-10 years 1/2 tab tid. In long-term therapy the dose may be reduced to bid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OCAT4,Otilonium,Catilon 40mg,ALIM,Relief of abdominal pain due to irritable bowel syndrome.,Glaucoma,Mild nausea¡A vomiting¡A upper abdominal pain¡A dizziness & headache.,25¢J¥H¤U,Oral¡A 40 mg BID-TID. Adult: Up to 120 mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¨ÃµLÃh¥¥°ü¤k¨Ï¥Îotilonium bromideªºÁ{§É¬ã¨s¡C°Êª«¸ÕÅç¨Ã¥¼«ü©ú¹ï¥Í¨|¬r©Ê¦³ª½±µ©Î¶¡±µªº¤£¨}¼vÅT¡C¹w¨¾°_¨£¡AÃh¥¥´Á¶¡³Ì¦nÁ×§K¨Ï¥Îotilonium bromide¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¨ÃµL­÷¨Å¤¤¤k©Ê¨Ï¥Îotilonium bromideªºÁ{§É¸ê®Æ¡C ¦p¦P©Ò¦³ÃÄª«¡A¥u¦³µ´¹ï¥²­n¨Ã¦³±K¤ÁÂåÀøºÊ·þªº±¡ªp¤U¡A¤~À³«ØÄ³Ãh¥¥¤k©Ê»P­÷¨Å¤¤¥À¿Ë¨Ï¥Îotilonium bromide¡C,,,,,,
OJAN,Sitagliptin,Januvia 100mg,META,,¾AÀ³¯g: Type 2 DM. °Æ§@¥Î: Upper respiratory tract infection¡A nasopharyngitis & headache. Hypoglycemia. Endocrine metabolic: Hypoglycemia (0.6% to 12.2% ) Neurologic: Headache (1.1% to 5.9% ) Respiratory: Nasopharyngitis (5.2% to 6.3% )¡A Upper respiratory infection (4.5% to 6.3% ) ¸T§Ò: Type 1 DM¡A diabetic ketoacidosis.,,«Ç·Å,usually dose :100 mg once daily with or without food Dosage in renal impairment: CrCl < 50 ml/min 50mg qd CrCl < 30 ml/min 25mg qd,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OVAL,Valaciclovir,Valtrex 500mg,QANB,Treatment of herpes zoster & herpes labialis. Treatment & prevention of recurrent herpes simplex infections of the skin & mucous membranes including initial & recurrent genital herpes. Prophylaxis of cytomegalovirus (CMV) infection & disease¡A following renal transplantation.,Hypersensitivity to valacyclovir or acyclovir.,Headache¡A rash¡A GI disturbances. Uncommonly¡A reversible neurological reactions such as dizziness¡A confusion¡A hallucinations¡A decreased consciousness (rare) in patients with renal impairment or on high dose therapy. Rarely¡A renal insufficiency¡A microangiopathic hemolytic anemia & thrombocytopenia in severely immunocompromised patients with high doses & prolonged periods but these have also been observed in patients not on valacyclovir having the same underlying conditions.,30¢J¥H¤U,(¥é³æ) Adult: Herpes zoster (shingles): 1000 mg orally 3 times daily for 7 days. Herpes simplex virus infection: 500 mg orally 2 times daily for 5-10 days. Herpes simplex virus¡A prevention: 500 mg/day divided Q12-24H; 500 mg twice daily for immunocompromised patients. (¼ö¯f) Pediatric: Oral herpes (> or = 12 years) 2 g twice daily for 1 day. Varicella zoster virus (Chickenpox) (2-18 years): 60 mg/kg/day¡A divided Q8H for 5 days,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,Breastfeeding 1) Thomson Lactation Rating: Infant risk is minimal.,AC;AC15;PC;PO;WM;,,,,,
OLEUK,Chlorambucil,Leukeran 2mg,RACA,Management of chronic lymphocytic leukemia (CLL)¡A Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL).,Hypersensitivity to chlorambucil or any component of the formulation; hypersensitivity to other alkylating agents (may have cross-hypersensitivity); prior (demonstrated) resistance to chlorambucil. Canadian labeling: Additional contraindications (not in US labeling): Use within 4 weeks of a full course of radiation or chemotherapy.,Bone marrow suppression; GI disturbances. Occasionally: severe interstitial pulmonary fibrosis; hepatotoxicity & jaundice. Fever¡A skin hypersensitivity¡A peripheral neuropathy¡A interstitial pneumonia & sterile cystitis. Seizures.,2-8¢XC,Take daily on an empty stomach (at least 1 hour before meals or 3 hours after meals). May be used in the management of Hodgkin's disease and non- Hodgkin's lymphomas in children. The dosage regimens are similar to those used in adults.  [Hodgkin's disease] 0.2 mg/kg/day for 4-8 weeks as a single agent in the palliative treatment of advanced disease[Non-Hodgkin's lymphoma] 0.1-0.2 mg/kg/day as a single agent for 4-8 weeks initially; maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment.  [Chronic lymphocytic leukaemia] 0.15 mg/kg/day initially until the total leukocyte count has fallen to 10¡A000/mL. Treatment may be resumed 4 weeks after the end of the first course and continued at a dosage of 0.1 mg/kg/day. [Waldenstrom's macroglobulinaema] Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.,»Ý½Õ¾ã¾¯¶q,¦³ÅãµÛ¨x¥\¯à»ÙÃªªº¯f¤H¡AÀ³¦Ò¼{´î¤Ö¾¯¶q,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OPROGY,Estradiol Valerate + Norgestrel,Progyluton 21's/box,HM,,¾AÀ³¯g:¤ë¸g°±¤î«áªº§ó¦~´Á¯g­Ô¸s Pre- & postmenopausal symptoms¡A primary & secondary amenorrhea; menstrual irregularities; deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases °Æ§@¥Î:Rarely¡A breast tension¡A gastric upsets¡A nausea¡A headache¡A influence on body weight & libido¡A unscheduled bleeding. ¸T§Ò:Pregnancy; severe liver dysfunction; jaundice or severe pruritus during a previous pregnancy; previous or existing liver tumours; existing or suspected hormone-dependent tumours of uterus or mammae. Severe diabetes with vascular changes¡A previous or existing thromboembolic processes; endometriosis; disturbances of lipometabolism¡A a history of herpes gestationis¡A otosclerosis with deterioration during previous pregnancies¡A Dubin-Johnson syndrome¡A Rotor syndrome¡A sickle-cell anemia,,«Ç·Å,1 tab daily for 21 days beginning on the 5th day of the cycle¡A pause for 7 days,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IDOR3,Midazolam,Dormicum inj 15mg/3mL,ZANE,,,,,,,,,,,,,,,,,,,
EPRO3,Tacrolimus,Protopic 0.03% oint 5gm,TDER,,¾AÀ³¯g: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. °Æ§@¥Î: Burning sensation¡A pruritus¡A flu-like symptoms & headache. Dermatologic: Alopecia (systemic formulations: up to 28.9% topical: 1% )¡A Persistent erythema of skin (topical: 7% to 28% )¡A Persistent erythema of skin (20% to 58% )¡A Pruritus (systemic formulations: 15% to 36% ; topical: 19% to 46% ) Gastrointestinal: Constipation (systemic formulations: 23% to 35% ; topical: between 0.2% and 1% )¡A Diarrhea (systemic formulations: 37% to 72% ; topical: 3% to 5% )¡A Nausea (systemic formulations: 32% to 46% ; topical: 1% to 3% )¡A Vomiting (systemic formulations: 14% to 29% ; topical: 1% to 6% ) Hematologic: Anemia (systemic formulations: 5% to 65.4% ; topical: between 0.2% and less than 1% )¡A Leukocytosis (8% to 32% )¡A Thrombocytopenia (14% to 24% ) Neurologic: Headache (systemic formulations: 37% to 64% ; topical: 5% to 20% )¡A Insomnia (systemic formulations: 32% to 64% ; topical: 1% to 4% )¡A Paresthesia (systemic formulations: 17% to 40% ; topical: 2% to 3% )¡A Tremor (15% to 56% ) ¸T§Ò: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15 ~ 30 ¢XC,Adult & children 2-15 years Apply thinly & rub in bid¡A continue for 1 week after signs & symptoms clear.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EPROT,Tacrolimus,Protopic 0.1% oint 5gm,TDER,,¾AÀ³¯g: Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis. °Æ§@¥Î: Burning sensation¡A pruritus¡A flu-like symptoms & headache. Dermatologic: Alopecia (systemic formulations: up to 28.9% topical: 1% )¡A Persistent erythema of skin (topical: 7% to 28% )¡A Persistent erythema of skin (20% to 58% )¡A Pruritus (systemic formulations: 15% to 36% ; topical: 19% to 46% ) Gastrointestinal: Constipation (systemic formulations: 23% to 35% ; topical: between 0.2% and 1% )¡A Diarrhea (systemic formulations: 37% to 72% ; topical: 3% to 5% )¡A Nausea (systemic formulations: 32% to 46% ; topical: 1% to 3% )¡A Vomiting (systemic formulations: 14% to 29% ; topical: 1% to 6% ) Hematologic: Anemia (systemic formulations: 5% to 65.4% ; topical: between 0.2% and less than 1% )¡A Leukocytosis (8% to 32% )¡A Thrombocytopenia (14% to 24% ) Neurologic: Headache (systemic formulations: 37% to 64% ; topical: 5% to 20% )¡A Insomnia (systemic formulations: 32% to 64% ; topical: 1% to 4% )¡A Paresthesia (systemic formulations: 17% to 40% ; topical: 2% to 3% )¡A Tremor (15% to 56% ) ¸T§Ò: Patients with a history of hypersensitivity to tacrolimus or any other component of Protopic.,,15-30¢J,Adult & children 2-15 years Apply thinly & rub in bid¡A continue for 1 week after signs & symptoms clear.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
EDEV,Acyclovir,Devirus 4.5gm ophthalmic ointment,TOPH,Herpes simplex virus infection of the eyes including initial & recurrent genital herpes & herpes labialis.,Patients known to be hypersensitive to acyclovir or propylene glycol.,Transient burning or stinging. Mild drying & flaking. Erythema & itching. Common: Contact dermatitis (topical cream¡A 2%)¡A Diarrhea (2.4-3.2%)¡A Nausea (2.7-4.8%)¡A Vomiting¡A Headache (2.2%)¡A Follicular conjunctivitis (Ophthalmic ointment¡A 2-10%)¡A Pain in eye¡A or stinging (Ophthalmic ointment¡A 2-10%)¡A Malaise (11.5%) Serious: Thrombotic thrombocytopenic purpura¡A Hemolytic Uremia Syndrome¡A Superficial punctate keratitis (Ophthalmic ointment¡A 2-10%)¡A Renal failure,25¢J¥H¤U,Apply 1 cm ribbon of the ointment should be placed inside the lower conjunctival sac five times a day at approximately four hourly intervals. Treatment should continue for at least three days after ending.",µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,OD;OL;OU;,,,,,
EALC8,Alcohol,95% Alcohol 4000mL,TDER,,,,,,,,,,,,,,,,,,,
ENACL,Sodium Chloride,Sodium Chloride eye drop 3%¡A 5mL,TOPH,To reduce swelling of the cornea.,Hypersensitivity to any component of the formulation.,Ocular irritation,2-8¢J,Corneal edema: Instill 1 to 2 drops in affected eye(s) every 3 to 4 hours. [Micromedex 2021/08/02] 2% solution Instill 1 to 2 drops in affected eye(s) every 3 to 4 hours. [UpToDate 2021/08/02] Infants¡A Children¡A and Adolescents: Ophthalmic solution (5%): Instill 1 to 2 drops into affected eye(s) every 3 to 4 hours as needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
ICLI,Clindamycin,Clindamycin inj 300mg/2mL,QANB,,¾AÀ³¯g: Infections caused by susceptible strains of strep¡A staph¡A pneumococci¡A anaerobic bacteria. °Æ§@¥Î: Abdominal pain¡A nausea¡A vomiting¡A diarrhea¡A urticaria¡A maculopapular reactions¡A jaundice¡A blood disorders. ¸T§Ò: Hypersensitivity¡A meningitis.,,«Ç·Å,Adult 600-1200 mg IM daily in 2-4 doses. Severe infections: 1200-2700 mg daily in 2-4 doses. Children > 1 month 15-25 mg/kg/day in 3-4 doses. Severe infections: 25-40 mg/kg/day in 3-4 doses.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ÀR¯ßµ¹ÃÄ«e¡y¥²»Ý¡z­nµ}ÄÀ¡C 2. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡Aª`·N¬O§_µo¥Í¸¡Âm¡C
OANT,Cyproheptadine,Antisemin 4mg,HIMM,,¾AÀ³¯g: Allergic rhinitis¡A vasomotor rhinitis¡A urticaria¡A allergic skin & blood disorders. Pruritus due to chicken pox. °Æ§@¥Î: Sedation; drowsiness; dry mouth¡A nose & throat; Increase thickness of bronchial secretion¡A dizziness¡A upper abdominal discomfort. ¸T§Ò: Acute asthmatic attack. Premature infants,,«Ç·Å,Allergy: Adult: 4mg tid (max. 32mg/day). Child: 2-6yrs: 2mg tid (max. 12mg/day). Child: 6-14yrs: 4mg tid (max: 16mg/day). Stimulation of appetite: Adult: 2-4mg tid-qid. Child: 2-6yrs: Max. of 8mg/day. Migraine: Initially 4mg¡A not to exceed 8mg within 4-6hrs.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OSPA6,Alverine,SpasMOL 60mg,ALIM,,¾AÀ³¯g: Dysmenorrhoea; GI tract spasm. °Æ§@¥Î: Nausea¡A headache; pruritus¡A rash; dizziness; allergic reactions. ¸T§Ò: Paralytic ileus. Pregnancy¡A lactation¡A intestinal obstruction.,,«Ç·Å,60-120 mg 1-3 times/day.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IUVAN,Vancomycin,U-Vanco inj 500mg,QANB,,¾AÀ³¯g: Serious staphylococcal or other gm+ve infections. Brain abscess¡A staphylococcal meningitis¡A peritonitis associated with continuous ambulatory peritoneal dialysis & septicaemia. Treatment & prophylaxis of endocarditis¡A prophylaxis of surgical infection & in intensive care¡A management of immunocompromised patients. Treatment of antibiotic-associated colitis. °Æ§@¥Î: 'Red-neck' or 'red-man' syndrome characterised by erythema¡A flushing¡A rash over the face & upper torso¡A hypotension¡A shock-like symptoms. Hypersensitivity reactions¡A eg rashes¡A fever¡A chills¡A anaphylactoid reactions. Reversible neutropenia¡A eosinophilia & thrombocytopenia. Nephrotoxicity¡A ototoxicity¡A tinnitus¡A hearing loss. Thrombophlebitis. Tissue necrosis. ¸T§Ò: Known hypersensitivity.,,«Ç·Å,Adult 500 mg 6 hrly or 1 g 12 hrly by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses 8 hrly for patients undergoing GI or GU procedures. Children 10 mg/kg body weight 6 hrly. Neonates initial 15 mg/kg followed by 10 mg/kg 12 hrly in 1st weeks of life & 8 hrly up to 1 month of age.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C 2. ª`·N¿éª`¹L§Ö®Éªº¤£¨}¤ÏÀ³¡G§C¦åÀ£¡B©I§l§xÃø¡BëC³Â¯l¡C 3. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C
OZIE,Dicloxacillin,Ziefmycin 250mg,QANB,Respiratory tract¡A skin & soft tissue infections caused by penicillinase-producing Staph.,Hypersensitivity to penicillins.,Allergic reactions; angioedema; bronchospasm.,25¢J¥H¤UÁ×¥úÀx¦s,Adults and children > 40 kg: 125-250 mg orally Q6H 1-2 hours before meals. Children < 40 kg: 12.5-25 mg/kg/day divided Q6H 1-2 hours before meals. [Micromedex 20210920] Methicillin-susceptible Staphylococcus aureus: 500 mg orally 4 times daily. [Sanford Guide to Antimicrobial Therapy 2021] Usual Dose: 125-500mg Q6H before meals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;PO;,,,,,
OCEN,Calcium Citrate,Cenca 950mg,NUTR,,¾AÀ³¯g: Ca supplement¡A renal osteodystrophy.,,«Ç·Å,Adult & children > 4 years 2-5 tabs daily.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OCAT2,Diclofenac,Cataflam 25mg,CNEU,Relief of pain & inflammation in RA¡A osteoarthritis¡A ankylosing spondylitis¡A migraine attacks¡A low back pain¡A painful syndromes of the vertebral column¡A non-articular rheumatism¡A painful post-traumatic & post-op inflammation.,Peptic ulcer; known hypersensitivity to diclofenac or other NSAIDs; patients in whom attacks of asthma¡A urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs.,Epigastric pain¡A nausea¡A vomiting¡A diarrhea¡A abdominal cramps¡A dyspepsia¡A flatulence¡A anorexia¡A headache¡A dizziness¡A vertigo¡A rashes or skin eruptions¡A elevation of serum aminotransferase. Rarely¡A GI bleeding¡A fatigue¡A urticaria¡A gastric or intestinal ulcer¡A drowsiness¡A edema¡A hepatitis with or without jaundice. Dermatologic: Application site reaction (gel: all reactions¡A 7%; dermatitis¡A 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )¡A Keratitis (up to 28% )¡A Lacrimation and lacrimal drainage - finding (up to 30% )¡A Raised intraocular pressure (up to 15% ),30¢J¥H¤U¨¾¼é»PÁ×¥úÀx¦s,>14 years old: 75-100mg/day in 2-3 divided doses. Children: Recommend drops or suppositories for treatment. Elders: Treat with caution.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling; however¡A may require dosage adjustment due to extensive hepatic metabolism.,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;,,,,,
OCHA5,Varenicline,Champix 0.5mg,ZADT,Aid to smoking cessation treatment.,,Nausea¡A sleep disturbance¡A constipation¡A flatulence¡A vomiting. Diarrhea¡A gingivitis¡A chest pain¡A flu-like illness¡A edema¡A thirst¡A abnormal liver function test¡A increased weight¡A arthralgia¡A back pain¡A muscle cramp¡A musculoskeletal pain¡A myalgia¡A attention disturbance¡A dizziness¡A sensory disturbance¡A anxiety¡A depression¡A emotional disorder¡A irritability¡A restlessness¡A polyuria¡A menstrual disorder¡A epistaxis¡A respiratory disorders¡A hyperhidrosis¡A hot flush¡A HTN. Gastrointestinal: Constipation (5% to 8% )¡A Flatulence (6% to 9% )¡A Nausea (16% to 40% )¡A Vomiting (1% to 5% ) Neurologic: Dream disorder (9% to 13% )¡A Headache (15% to 19% )¡A Insomnia (18% to 19% ),25¢J,"Days 1-3: 0.5 mg once daily.Days 4-7: 0.5 mg twice daily.Days 8 and later (maintenance): 1 mg twice daily. Continue maintenance dose for at least 11 weeks to 1 year (for a total of at least 12 weeks of treatment).Approaches to selecting a tobacco quit date: May either choose a fixed quit date (ie¡A start varenicline¡A then quit on day 8) or a flexible quit date (ie¡A start varenicline¡A then quit between days 8-35). Alternatively¡A consider a gradual quit date (ie¡A start varenicline and reduce smoking 50% by week 4¡A reduce an additional 50% by week 8¡A and continue reducing with a goal of complete abstinence by week 12) followed by a maintenance dose for 12 weeks (for a total of at least 24 weeks of treatment).",µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCRAS,Potassium Citrate Monohydrate + Citric Acid,Crashtone Granules 5gm,SGU,,¾AÀ³¯g: Prevention of uric acid nephrolithiasis; prevention of Ca renal stones in patients with hypocitraturia; avoidance of the complication of Ca stone formation in uric lithiasis. °Æ§@¥Î: Abdominal pain; dyspepsia; gastroenteritis; hyperkinesia; nervousness. ¸T§Ò: Hyperkalemia¡A peptic ulcer¡A abnormal renal function¡A anuria.,,«Ç·Å,5 gm Qd-qid.,,,,¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSCA,Acetaminophen,Scanol 500mg,CNEU,,Analgesic and antipyretic actions¡A no anti-inflammatory properties.,,RT,Adult:500 mg q4h as needed¡A (max. 4 g/day). For long term therapy¡A not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed¡A (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period. Syrup: 3 months-1 yr.:2.5-5 ml qid. 1-6 yrs.:5-10 ml qid. 6-10 yrs.:20 ml qid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OSCAN,Hydrochlorothiazide + Amiloride,Scanduretic,CAVS,,I: Hypertension¡A CHF¡A hepatic cirrhosis with ascites. CI: Hyperkalemia¡A other concomitant antikaliuretic therapy or K supplementation¡A renal insufficiency.,,,1-2 tab/day¡A pc¡A up to 4 tab/day.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OPLAV,Clopidogrel,Plavix 75mg,HEMT,,¾AÀ³¯g: Prevention of atherothrombotic events in patients suffering from MI¡A ischemic stroke or established peripheral arterial disease; in patients suffering from non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) in combination with aspirin. ST segment elevation acute MI in combination with aspirin in patients eligible for thrombolytic therapy. °Æ§@¥Î: GI bleeding¡A purpura¡A bruising¡A haematoma¡A epistaxis¡A haematuria¡A ocular haemorrhage¡A intracranial bleeding¡A abdominal pain¡A dyspepsia¡A gastritis & diarrhoea¡A rash¡A pruritus. Cardiovascular: Chest pain¡A Hypertension (4.3% ) Dermatologic: Pruritus (3.3% )¡A Purpuric disorder (5.3% )¡A Rash (4.2% ) Endocrine metabolic: Hypercholesterolemia Gastrointestinal: Abdominal pain¡A Constipation¡A Diarrhea¡A Gastritis¡A Indigestion Hematologic: Epistaxis (2.9% )¡A Purpura (5.3% ) Musculoskeletal: Arthralgia (6.3% )¡A Backache (5.8% ) Neurologic: Headache (7.6% ) ¸T§Ò: Severe liver impairment. Peptic ulcer & intracranial haemorrhage. Lactation.,,«Ç·Å,Adult & elderly 75 mg once daily. Patients with non-ST segment elevation acute coronary syndrome Initially 300 mg as single loading dose & then continued at 75 mg once daily (with 75-325 mg aspirin daily). Recommended dose of aspirin should not be >100 mg. ST segment elevation acute MI Initially 75 mg daily as single loading dose in combination with aspirin & with or without thrombolytics.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EDUA,Budesonide,Duasma MDI 200mcg/puff,ERSP,,I: Chronic control of bronchial asthma. ADR: Mild irritation of the throat¡A coughing¡A reversible hoarseness of voice¡A bad taste¡A dryness of the throat. Candidiasis of the mouth & throat. Paradoxical bronchoconstriction. CI: Moderate to severe bronchiectasis.,,RT,Adult & Children > 12 yr: initially 400 ~ 1600 mcg daily divided into 2 ~ 4 administrations. Maintenance: 200 ~ 400 mcg bid¡A up to 1600 mcg/day Children 6 ~ 12 yr initially 200 ~ 400 mcg daily in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OSEL,Naproxen,Seladin 250mg,CNEU,,RA¡A osteoarthritis¡A ankylosing spondylitis¡A acute gout¡A musculoskeletal disorders.,,,1 cap bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OSENN,Sennosides,Sennapur 12.5mg,ALIM,,Relief of functional constipation¡A chronic geriatric¡A antepartum¡A postpartum¡A drug induced¡A pediatric & concurrent with heart disease or anorectal surgery.,,,Adult: 2-4 tab¡A at bedtime. Childn: 1-2 tab at bedtime,,,,,,,,,,,,,,
OSER,Oxazolam,Serenal 10mg,CNEU,,¾AÀ³¯g: Anxiety-tension-depression-sleep disorders in neurosis; somatic symptoms & anxiety-tension-depression in psychosomatic diseases¡A Pre-anaesth. °Æ§@¥Î: Drowsiness¡A dizziness; headache; insomnia; anorexia¡A impaired tongue movement¡A dry mouth; fatigue; rarely¡A impatience; skin eruption; tachycardia (pre-anesth medication); drug dependence (massive dose). ¸T§Ò: Acute narrow-angle glaucoma; myasthenia gravis.,,«Ç·Å,Anxiety-tension-depression-sleep disorders in neurosis; somatic symptoms & anxiety-tension-depression in psychosomatic diseases Adult 10-20 mg tid. Pre-anaesth medication 1-2 mg/kg body weight before operation. Dosage varies according to age & intensity of symptoms.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
EDERC,Clobetasol,Dermovate cream 5gm,TDER,,¾AÀ³¯g: Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids. °Æ§@¥Î: Features of hypercorticism¡A local atrophic changes¡A pigmentation changes & hypertrichosis. Exacerbation of symptoms may occur. ¸T§Ò: Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus; primary cutaneous viral infection; bacterial¡A fungal infected skin lesions; perianal & genital pruritus; dermatoses in infant < 1 year including dermatitis & napkin eruptions. ¬O¤@ºØ±j®ÄªºÃþ©T¾JÃÄ»I¡A±j®ÄÃþ©T¾J¬O¸û¤£¾A¦X¡u¥Î¦b¨zªù¤Î¥Í´Þ¾¹¡v¡A¬O¦]¬°¦¹³¡¦ìªí¥Ö¼h«ÜÁ¡¡A­Y¦³µoª¢²{¶H¥i±Ä¥Î®z®Ä©Î¤¤®ÄÃþ©T¾J¡A¥H§K§l¦¬±j®ÄÃÄ«~¡A²£¥Í¤£¨}°Æ§@¥Î,,«Ç·Å,Apply sparingly to the affected area once or bid.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IFAS,Fulvestrant,Faslodex inj 250mg/5mL,RACA,Breast cancer¡A metastatic¡A breast cancer¡A advanced or metastatic (second-line endocrine-based combination therapy),a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema,>10%: Central nervous system: Fatigue (8% to 29%)¡A headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%)¡A diarrhea (19%)¡A constipation (5% to 16%)¡A stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis¡A upper respiratory infection¡A urinary tract infection¡A influenza¡A bronchitis¡A rhinitis¡A conjunctivitis¡A pneumonia¡A sinusitis¡A cystitis¡A oral herpes¡A respiratory tract infection) Local: Pain at injection site (12%; including neuralgia¡A peripheral neuropathy¡A sciatica) 1% to 10%: Dermatologic: Alopecia (6%)¡A skin rash (6%)¡A xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%)¡A anorexia (6%)¡A vomiting (6%)¡A dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%)¡A leukopenia (5%; grade 3: 1%; grade 4: 1%)¡A neutropenia (4%; grade 3: 1%)¡A febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%)¡A arthralgia (8%)¡A back pain (8%)¡A limb pain (7%)¡A musculoskeletal pain (6%)¡A weakness (5% to 6%) Ophthalmic: Blurred vision (2%)¡A dry eye syndrome (2%)¡A increased lacrimation (1%) Respiratory: Cough (5%)¡A dyspnea (4%)¡A epistaxis (2%),2-8¢JÁ×¥ú,500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections¡A one in each buttock¡A on Days 1¡A 15¡A 29¡A and once monthly thereafter.,»Ý½Õ¾ã¾¯¶q,­««×¨x¥\¯à¤£¥þªÌ¬°¸T§Ò¡C,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;,,,,,§ë»PFaslodexÀ³¥H¨â¦¸³sÄòªº5²@¤É¦bÁv³¡¦Ù¦×³B½wºCª`®g(1-2¤ÀÄÁª`®g)¡A¤@Ãä¤@¦¸¡C
OLAF,Ferric Hydroxide,La Ferrum Chewable 100mg,NUTR,,¾AÀ³¯g: Fe-deficiency anaemia. °Æ§@¥Î: GI irritation¡A epigastric pain¡A stomach cramping¡A constipation¡A nausea¡A vomiting¡A diarrhoea¡A dark stools¡A heart burn¡A discoloured urine¡A teeth staining. IM: pain at inj site¡A abdominal pain at lower quadrant and local inflammation with inguinal lymphadenopathy. IV: Joint and muscle pain¡A bronchospasm¡A hypotension¡A tachycardia¡A flushing¡A sweating¡A dizziness. ¸T§Ò: Hypersensitivity or intolerance to iron and overloading of iron in the body. Anaemia not caused by iron deficiency. Disturbances in iron utilisation¡A thalassemia. Patients receiving repeated blood transfusion. Parenteral: Iron overload¡A Ostler-Rendu-Weber syndrome¡A chronic polyarthritis¡A bronchial asthma¡A inflammation or infection of kidney or liver¡A uncontrolled hyperparathyroidism¡A decompensated liver cirrhosis. Pregnancy (1st trimester).,,«Ç·Å,1 tab qd-tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ONAV3,Vinorelbine,NAVELBINE 30mg,RACA,Non-small cell lung cancer. Metastatic breast cancer.,Disease significantly affecting absorption; previous significant surgical resection of stomach or small bowel. Severe hepatic impairment; pregnancy & lactation; patients requiring long-term O2 therapy. Coadministration with meningocococal conjugate vaccine or other live virus vaccines¡A phenytoin & itraconazole. Pretreatment granulocyte counts <1000/mm3,Neutropenia¡A anemia¡A thrombocytopenia; nausea & vomiting¡A diarrhea¡A anorexia¡A stomatitis¡A esophagitis; loss of tendon reflexes¡A neuromotor disorders¡A neuroconstipation (rarely progressing to paralytic ileus); alopecia; fatigue¡A fever¡A arthralgia including jaw pain¡A myalgia¡A pain including pain at tumor site. Vial Ischemic cardiac disease (rare)¡A abnormal liver function tests¡A dyspnea¡A bronchospasm¡A generalized cutaneous reactions (rare).,2-8¢J,As a single agent¡A first three administrations: 60 mg/m2 once weekly. Beyond the third administration¡A it is recommended to increase the dose to 80mg/m2 once weekly except in those patients for whom the neutrophil count dropped once < 500/mm3 or 500-1000/mm3 during the first three administrations at 60mg/m2.,»Ý½Õ¾ã¾¯¶q,»´«×¨x¥\¯à¤£¥þ±wªÌ(Áx¬õ¯À<1.5­¿¡A¥BALAT ©Î/©M ASAT ¬°1.5¦Ü2.5­¿ULN):¨C©P¥iµ¹¤©60mg/m^2 ¼Ð·Ç¾¯¶q ¤¤«×¨x¥\¯à¤£¥þ±wªÌ(Áx¬õ¯À¬°1.5 ~ 3 ­¿¡A¥BµL½×ALAT ©M ASAT ¼Æ­È¬°¦ó):¨C©PÀ³µ¹50mg/m^2¼Ð·Ç¾¯¶q ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦Ån»Ý¥H¤ô¾ãÁû§]ªA¡C
IZOM,Zoledronic Acid,Zometa infusion 4mg,META,,¾AÀ³¯g: Prevention of skeletal related events (pathological fractures¡A spinal compression¡A radiation or surgery to bone¡A or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone. Treatment of hypercalcemia of malignancy (HCM). °Æ§@¥Î: Very common: Hypophosphatemia. Common: Anemia¡A headache¡A conjunctivitis¡A nausea¡A vomiting¡A anorexia¡A bone pain¡A myalgia¡A arthralgia¡A renal impairment¡A fever¡A flu-like syndrome¡A blood creatinine & blood urea increase¡A hypocalcemia. Cardiovascular: Peripheral edema (Paget's Disease¡A 3%; osteoporosis¡A 4.6% to 5.5%; bone metastasis¡A 21% ) Endocrine metabolic: Weight decreased (bone metastasis¡A 16% ) Gastrointestinal: Abdominal pain (osteoporosis (female)¡A 0.9% to 4.6%; osteoporosis (male)¡A 7.9%; Paget's disease¡A 2%; hypercalcemia of malignancy¡A 16%; bone metastasis¡A 14% )¡A Constipation (Paget's disease¡A 6%; hypercalcemia of malignancy¡A 27%; bone metastasis¡A 31% )¡A Diarrhea (osteoporosis¡A 5.2% to 6%; Paget's disease¡A 6%; hypercalcemia of malignancy¡A 17%; bone metastasis¡A 24% )¡A Loss of appetite (osteoporosis¡A 1% to 2%; Paget's disease¡A 2%; hypercalcemia of malignancy¡A 9%; bone metastasis¡A 22% )¡A Nausea (osteoporosis¡A 4.5% to 8.5%; Paget's disease¡A 9%; hypercalcemia of malignancy¡A 29%; bone metastasis¡A 46% )¡A Vomiting (Paget's disease¡A 2%; osteoporosis¡A 3.4% to 4.6%; hypercalcemia of malignancy¡A 14%; bone metastasis¡A 32% ) Musculoskeletal: Arthralgia (osteoporosis (female)¡A 17.9% to 23.8%; osteoporosis (male)¡A 11.1%; hypercalcemia of malignancy¡A 5% to less than 10%; Paget's disease¡A 9%; bone metastasis¡A 21% )¡A Backache (Paget's disease¡A 4%; bone metastasis¡A 15% ) Neurologic: Asthenia (osteoporosis¡A 3.2 to 5.3%; Paget's disease¡A 2%; bone metastasis¡A 24% )¡A Dizziness (osteoporosis¡A 2% to 7.6%; Paget's disease¡A 9%; bone metastasis¡A 18% )¡A Headache (osteoporosis (female)¡A 3.9% to 12.4%; osteoporosis (male)¡A 15%; Paget's disease¡A 11%; hypercalcemia of malignancy¡A 5% to less than 10%; bone metastasis¡A 19% )¡A Insomnia (hypercalcemia of malignancy¡A 15%; bone metastasis¡A 16% )¡A Paresthesia (Paget's disease¡A 2%; bone metastasis¡A 15% .) Renal: Nephrotoxicity (bone metastasis¡A 11% to 17% ) Other: Fatigue (osteoporosis (female)¡A 2.1% to 5.4%; osteoporosis (male)¡A 17.6%; Paget's disease¡A 8%; bone metastasis¡A 39% )¡A Fever (osteoporosis (female)¡A 7% to 18%; osteoporosis (male)¡A 15.7%; Paget's disease¡A 3% to 11%; hypercalcemia of malignancy¡A 44%; bone metastasis¡A 32% ) ¸T§Ò: Known hypersensitivity to zoledronic acid or other bisphosphonates.,,«Ç·Å,Prevention of skeletal related events in patients with advanced malignancies involving bone 4 mg reconstituted & further diluted¡A given as a single 15-min IV infusion every 3-4 weeks. Treatment of HCM 4 mg reconstituted & further diluted¡A given as a single 15-min IV infusion. Retreatment may be given with 8 mg IV for patients with relapse or those refractory to initial treatment. Allow at least 1 week before retreatment.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However¡A as zoledronic acid binds to bone long-term¡A it is recommended that it should not be administered to a nursing woman.,,,,,,1. patients should be adequately hydrated prior to administration 2. If previously refrigerated¡A allow solution to reach room temperature before administration 3. administer as a single-dose IV infusion in a vented line separate from other drugs; infuse over no less than 15 minutes¡A over a constant infusion rate 4. Do not allow solution to come in contact with calcium-containing solutions or other divalent cation-containing infusion solutions (eg¡A lactated Ringer)
OTRE,Pentoxifylline,Trenfylline 400mg,CAVS,,¾AÀ³¯g: Peripheral circulatory disorders¡A chronic occlusive arterial disease. °Æ§@¥Î: Cardiac arrhythmias¡A headache¡A nausea¡A GI effects¡A dizziness¡A flushing. ¸T§Ò: Cerebral or retinal hemorrhage¡A intolerance to xanthine derivatives.,,«Ç·Å,1 tab bid or tid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Pentoxifylline and its metabolites are excreted into human breast milk. Because of the potential for tumorigenicity demonstrated in rat studies of pentoxifylline¡A it is recommended to discontinue nursing or discontinue the drug¡A taking into consideration the importance of the drug to the mother.,,,,,,
ICLI15,Amino Acid + Dextrose + Electrolytes,Clinimix N17G35E inj 1500mL,NUTR,Parenteral nutrition when oral or enteral alimentation is impossible¡A insufficient or contraindicated.,Renal failure in the absence of haemodialysis¡A haemofiltration or haemo-diafiltration. Severe liver disease. Amino acid metabolism disorder. Metabolic acidosis¡A hyperlactataemia. Adrenal insufficiency. Hyperosmolar coma.,Hypertonic solutions may cause venous irritation if infused into a peripheral vein. Hyperglycaemia¡A glycosuria & hyperosmolar syndrome may occur.,«Ç·Å¤Å§N­á,Adult: 1-2 g amino acids/kg/day¡A 25-40 kcal/kg/day. Maximum daily dose: 30 mL/kg body weight. Maximum infusion rate: 1.4mL/kg body weight/hr. Children: 2-3g amino acids/kg/day.,µL»Ý½Õ¾ã¾¯¶q,­ì¨Ó¤w¦³¨xÅ¦¯e¯f©Î¨x¥\¯à¤£¥þªº¯f±w¡A°£¨Ò¦æªº¨x¥\¯à´ú¸Õ¤§¥~¡A¥çÀ³±±¨î¥i¯à¥X²{ªº°ª®ò¦å¯gª¬,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¥»ÃÄ«~­­ÃÄ¾¯¬ì½Õ¾¯TPN¨Ï¥Î
HE5003,Dianeal 1500cc 2.5% (PD4Âù³U),Dianeal 1500mL 2.5% (PD4Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
OEFE3,Venlafaxine,Efexor XR 37.5mg,CNEU,,¾AÀ³¯g: Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder. °Æ§@¥Î: Dizziness¡A sedation¡A dry mouth¡A insomnia¡A nervousness¡A tremor¡A somnolence¡A anorexia¡A constipation¡A nausea¡A vomiting¡A abnormal ejaculation/orgasm (males)¡A erectile dysfunction¡A urinary hesitancy¡A sweating¡A asthenia¡A hypertension¡A hot flushes¡A ecchymosis¡A mucous membrane bleeding¡A thrombocytopenia¡A hypercholesterolaemia¡A yawning¡A fatigue¡A nausea¡A appetite & weight loss¡A decreased libido¡A sweating¡A anorexia¡A visual disturbances. ¸T§Ò:Concomitant or within 14 days of MAOIs. Efexor XR must be discontinued for at least 7 days before starting treatment with MAOI. Severe renal or hepatic impairment. Pregnancy & lactation. Children < 18 years.,,«Ç·Å,75 mg once daily. After 2 weeks¡A the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ILUC2,Ranibizumab,Lucentis inj 0.23mL,TOPH,,¾AÀ³¯g: Treatment of neovascular (wet) age-related macular degeneration (AMD). °Æ§@¥Î: Nasopharyngitis¡A influenza; anemia; anxiety; headache¡A stroke; intraocular inflammation¡A vitritis¡A vitreous detachment¡A retinal hemorrhage¡A visual disturbance¡A eye pain¡A vitreous floaters¡A conjunctival hemorrhage¡A eye irritation¡A foreign body sensation in eyes¡A lacrimation increased¡A blepharitis¡A dry eye¡A ocular hyperemia¡A eye pruritus; retinal degeneration¡A retinal disorder¡A retinal detachment¡A retinal tear¡A detachment of retinal pigment epithelium¡A retinal pigment epithelium tear¡A visual acuity reduced¡A vitreous hemorrhage¡A vitreous disorder¡A uveitis¡A iritis¡A iridacyclitis¡A cataract¡A calaract subcapsular¡A posterior capsule opacification¡A punctuate keratitis¡A corneal abrasion¡A anterior chamber flare¡A vision blurred¡A inj site hemorrhage¡A eye hemorrhage¡A conjunctivitis¡A conjunctivitis allergic¡A eye discharge¡A photopsia¡A photophobia¡A ocular discomfort¡A eyelid edema¡A eyelid pain¡A conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased. Common Ophthalmic: Cataract ( eovascular(wet) age-related macular degeneration 11% to 17%;macular edema following retinal vein occlusion¡A2%) ¡A conjunctival hemorrhage (neovascular (wet) age- related macular degeneration 64% to 74%; macular edema following retinal vein occlusion¡A 48%) ¡A Eye irritation (neovascular (wet) age- related macular degeneration 13% to 15% ; macular edema following retinal vein occlusion¡A7%) ¡A Foreign body sensation¡A in the eyes (neovascular (wet) age- related macular degeneration 13% to 16%; macular edema following retinal vein occlusion¡A 7% to 16%) ¡AInflammatory disorder of the eye (neovascular (wet) age- related macular degeneration 13% to 18% )¡A Pain in eye (neovascular (wet) age- related macular degeneration 26 % to 35% ; macular edema following retinal vein occlusion¡A 17% )¡A Raised intraocular pressure (neovascular (wet) age- related macular degeneration 17% to 24% ; macular edema following retinal vein occlusion¡A7% ) ¡AVisual disturbance (neovascular (wet) age- related macular degeneration 13% to 18% ; macular edema following retinal vein occlusion¡A5% )¡A Vitreous detachment (neovascular (wet) age- related macular degeneration 15% to 21% ; macular edema following retinal vein occlusion¡A4% ) ¡A Vitreous floaters (neovascular (wet) age- related macular degeneration19 % to 27% ; macular edema following retinal vein occlusion¡A 7 %) ¸T§Ò: Active or suspected ocular or periocular infections¡A active intraocular inflammation.,,2-8¢J,0.5 mg (0.05 mL) by intravitreous inj¡A initiated with a loading phase of 1 inj/mth for 3 consecutive months followed by a maintenance phase in which patients should be monitored for visual acuity on a monthly basis. Interval between 2 doses should not be < 1 month.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVI;,,,,,¶È¨Ñ¬Á¼þÅé¤ºª`®g¡A­­¥ÑÂå®v¨Ï¥Î
OCAS,Bicalutamide,Casodex 50mg,RACA,Treatment of advanced prostate cancer in combination with LHRH analogue therapy or surgical castration.castration.,Females. Pregnancy and lactation. Hypersensitivity to bicalutamide or any component of the formulation; use in women. Patients with localized prostate cancer undergoing watchful waiting; children,Hot flushes¡A pruritus¡A diarrhea¡A nausea¡A vomiting¡A asthenia¡A dry skin¡A breast tenderness¡A gynecomastia¡A hot flushes¡A raised liver transaminases¡A jaundice¡A fatigue. Cardiovascular: Peripheral edema (13% ) Dermatologic: Hot sweats (53% ) Gastrointestinal: Abdominal pain (11% )¡A Constipation (22% )¡A Diarrhea (12% )¡A Nausea (15% ) Immunologic: Infectious disease (18% ) Musculoskeletal: Backache (25% )¡A Pain in pelvis (21% ) Neurologic: Asthenia (22% ) Renal: Hematuria (12% )¡A Nocturia (12% ) Respiratory: Dyspnea (13% ) Other: Pain (35% ),¤Å¶W¹L30¢J¥H¤W,50 mg once daily in conjunction with a gonadotropin-releasing hormone analog (luteinizing hormone-releasing hormone).,µL»Ý½Õ¾ã¾¯¶q,¤¤­««×¨x¥\¯à¤£¥þÀ³ª`·N,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OCLOM,Clomiphene,Clomiphene 50mg,HM,Induction of ovulation in patients with persistent ovulatory dysfunction as the cause of infertility.,Hepatic impairment¡A endometrial carcinoma or ovarian cysts¡A polycystic ovary¡A pregnancy.,Ovarian enlargement (reversible)¡A vasomotor flushes resembling menopausal symptoms¡A abdominal or pelvic discomfort or pain¡A nausea¡A vomiting¡A blurring of vision. Cardiovascular: Syncope Dermatologic: Acne¡A Dermatitis (less than 1% )¡A Dry hair (less than 1% )¡A Erythema¡A Erythema multiforme¡A Erythema nodosum¡A Flushing¡A Vasomotor (10.4% )¡A Hypertrichosis¡A Loss of hair (less than 1% )¡A Pruritus¡A Rash (less than 1% )¡A Urticaria Endocrine metabolic: Disorder of thyroid gland¡A Weight gain (less than 1% )¡A Weight loss (less than 1% ) Gastrointestinal: Abdominal discomfort (5.5% )¡A Abdominal pain¡A Acute (less than 1% )¡A Constipation (less than 1% )¡A Diarrhea (less than 1% )¡A Gastrointestinal tract finding (2.2% )¡A Increased appetite (less than 1% ) Hepatic: Increased liver enzymes Musculoskeletal: Arthralgia¡A Backache¡A Myalgia Neurologic: Asthenia¡A Dizziness (less than 1% )¡A Headache (1.3% )¡A Insomnia (less than 1% )¡A Lightheadedness (less than 1% )¡A Migraine¡A Paresthesia¡A Unsteady when walking¡A Vertigo (less than 1% ) Ophthalmic: Eye / vision finding (1.5% )¡A Functional visual loss¡A Temporary¡A Pain in eye¡A Photopsia Otic: Tinnitus Psychiatric: Anxiety¡A Depression (less than 1% )¡A Fatigue (less than 1% )¡A Feeling nervous (less than 1% )¡A Irritability¡A Mood disorder Renal: Polyuria (less than 1% ) Reproductive: Cyst of ovary¡A Endometriosis¡A Hyperstimulation of ovaries¡A Pain of breast (2.1% )¡A Urogenital finding¡A Vaginal dryness (less than 1% ) Other: Fever,25¢J¥H¤UÁ×¥ú,First treatment regimen: 50mg daily for 5 days¡A starting from the 5th day of the menstrual cycle. Second treatment regimen: 100mg daily for 5 days¡A starting from the 5th day of the next menstrual cycle if the first regimen failed. Third treatment regimen: same as second regimen.,µL»Ý½Õ¾ã¾¯¶q,¨x·l¶Ë©ÎªÌ¦³¨x¯e¯fªº±wªÌ¤£«ØÄ³¨Ï¥Î(¥i¯à¨Ï±o¨x·l®`±¡§Î´c¤Æ),µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCON,Bisoprolol,CONCOR 5mg,CAVS,1.25 mg & 2.5 mg tab Stable chronic moderate to severe heart failure. 5 mg & 10 mg tab Management of hypertension¡A angina pectoris & stable¡A chronic moderate to severe heart failure (NYHA class III¡A IV).,Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy¡A cardiogenic shock¡A AV block of grades II & III (without pacemaker)¡A sick sinus syndrome¡A SA block¡A bradycardia with < 60 beats/min; severe bronchial asthma or severe COPD¡A hypotension (systolic BP < 100 mmHg)¡A advanced stages of peripheral arterial circulatory disturbance & Raynaud's syndrome¡A untreated pheochromocytoma¡A metabolic acidosis.,Feeling of coldness or numbness in the extremities¡A nausea¡A vomiting¡A diarrhea¡A constipation. Tiredness¡A exhaustion¡A dizziness¡A headache (occur at the beginning of the therapy & usually disappear within 1-2 weeks). Gastrointestinal: Diarrhea (2.6% to 3.5% ) Neurologic: Headache (8.8% to 10.9% ) Respiratory: Rhinitis (2.9% to 4% )¡A Upper respiratory infection (4.8% to 5% .) Other: Fatigue (6.6% to 8.2%),30¢J¥H¤U,Hypertension¡A angina: Initially 5mg QD¡A may up to 10mg QD if needed. Maximum: 20mg QD. Stable mild to server chronic heart failure: Patient must be treated at an optimal dose with an ACE inhibitor¡A a diuretic¡A & optionally cardiac glycosides¡A prior to the administration of bisoprolol. Titrate gradually as follows: Week 1: 1.25 mg QD. Week 2: 2.5 mg QD. Week 3: 3.75 mg QD. Week 4-7: 5 mg QD. Week 8-11: 7.5 mg QD. Week 12 and beyond: 10 mg QD as maintenance therapy. Maximum: 10 mg daily.,µL»Ý½Õ¾ã¾¯¶q,«ØÄ³ªì©l¾¯¶q: 2.5 mg ORALLY once daily ³Ì°ª¾¯¶q:10 mg ORALLY once daily,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] Ãh¥¥´Á¶¡¡A±dªÖ¥²¶·¸g¹LÂå®v¤p¤ßµû¦ô¨ä§Q¯q»P­·ÀI«á¤~¯à¨Ï¥Î¡C¤@¯ë»¡¨Ó¡A£]-ªýÂ_¾¯·|­°§C­L½Lªº¦å¬y¶q¡A¦]¦¹¦³¥i¯à·|¼vÅT­L¨àªºµo¨|¡C¦b³oºØ±¡ªp¤U¡AÀ³ºÊ´ú­L½L¤Î¤l®cªº¦å¬y¶q»P­L¨àªº¥Íªøµo¨|ª¬ªp¡A­Y¹ïÃh¥¥¤Î­L¨à³y¦¨¤£¨}¼vÅT¡A«hÀ³¦Ò¼{§ï¥Î¨ä¥Lªº´À¥N©ÊªvÀø¡C ·s¥ÍÀ¦¨à¦b¥X¥Í«áÀ³¤©¥HÄY±KºÊ´ú¡C³q±`¦å¿}­°§C¤Î¯ß·i´î½wªº¯gª¬¦³¥i¯à¦b¥X¥Í«áªº 3 ¤Ñ¤º¥X²{¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e©|µL¦³Ãö bisoprolol fumarate ¤Àªc©ó¥À¨Å¤ÎÀ¦¨àÄá¨ú bisoprolol fumarate ªº¦w¥þ©Ê¼Æ¾Ú¡C ¦]¦¹¡A±dªÖ¤£«ØÄ³©ó±Â¨Å´Á¶¡ªA¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
ODEP2,Valproate Sodium,Depakine 200mg,CNEU,Treatment of generalized or partial epilepsy; mania.,Acute or chronic hepatitis¡A personal or family history of severe hepatitis¡A hepatic porphyria. Combination with mefloquine.,GI disturbances¡A ataxia¡A tremor¡A increased appetite & weight gain¡A edema¡A thrombocytopenia¡A inhibition of platelet aggregation; impaired hepatic function¡A rashes¡A sedation. Rarely¡A pancreatitis (discontinue). Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )¡A Rash (6% ) Endocrine metabolic: Increased appetite (6% )¡A Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )¡A Constipation (5% )¡A Diarrhea (12% to 23% )¡A Indigestion (8% to 13% )¡A Loss of appetite (4% to 12% )¡A Nausea (22% to 48% )¡A Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )¡A Backache (8% ) Neurologic: Amnesia (4% to 7% )¡A Ataxia (8% )¡A Dizziness (12% to 25% )¡A Headache (5% to 31% )¡A Insomnia (9% to 15% )¡A Somnolence (17% to 30% )¡A Tremor (9% to 57% ) Ophthalmic: Amblyopia¡A Blurred vision¡A Diplopia (16% )¡A Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )¡A Disturbance in thinking (6% )¡A Feeling nervous (7% to 11% )¡A Mood swings (6% ) Respiratory: Bronchitis (5% )¡A Dyspnea (5% )¡A Pharyngitis (8% )¡A Respiratory tract infection (12% to 20% )¡A Rhinitis (5% ) Other: Fever (2% )¡A Influenza (12% ),§C©ó25¢J,Giving with food to decrease gastrointestinal irritation. Children 6 years and below: syrup or oral liquid is recommended for administration. DEPAKINE 500mg Chrono Tablet is only recommended for adult and children > 17 kg. Average daily dose (per 24 hours): Adult and adolescents: 20-30 mg/kg/day in 2 or 3 divided doses. Children: 30 mg/kg/day in 2 or 3 divided doses. (< 1 year old: in 2 divided doses),»Ý½Õ¾ã¾¯¶q,Severe impairment: Use is contraindicated.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,[¥é³æ]Ãh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÄ¼Æ{¯g¡C °£«DÅöíwªvÀø¨S¦³¦X¾Aªº´À¥NÃÄª«¡A§_«hÃh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÅöíw¡C °£«D¯à½T¹ê°õ¦æÁ×¥¥­pµe¡A§_«h¨ã¥Í¨|¯à¤Oªº°ü¤k¸T¥Î valproate¡C ¨Ï¥Î¥»«~¥i¯à·|¾É­P­«¤jªº¥ý¤Ñ©Ê·î§Î¡A¯S§O¬O¯«¸gºÞ·î§Î¡]¦p¡G¯á¬Wµõ¡A spina bifida¡^¡A ¥B¥i¯à·|¾É­P­L¨à´¼°Ó¤U­°¡A¬G¥»«~À³¶È­­¥Î©óµLªk¥H¨ä¥LÃÄª«±±¨î¯gª¬¡A ©Î¦³¨ä¥¦­ì¦]µLªk¨Ï¥Î¨ä¥LÃÄª«ªvÀø¤§¥¥°ü¡C ¦Ò¶q¨Ï¥Î¥»«~¥i¯à·|¦³¨Ï«Äµ£´¼°Ó­°§C¡Bµo¥Í¯«¸gºÞ¯Ê³´¤Î¨ä¥LÄY­«¥ý¤Ñ©Ê·î§Î¤§­·ÀI¡A ¥B¸Óµ¥­·ÀI¥i¯àµo¥Í©óÃh¥¥¦­´Á¡A¬G°£«D¥²­n¨Ï¥Î¡A§_«h¤£À³¨Ï¥Î©ó¨ã¥Í¨|¯à¤O©Î¦³Ãh¥¥¥i¯à¤§°ü¤k¡C Á×¥¥­pµe¡G Valproate¦³°ª«×ªº­P·î©Ê¡A¥B­L¨à¦b¤l®c¤¤ÃnÅS©óvalproate¦³¾É­P¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº°ª «×­·ÀI¡C ¥»«~¸T¥Î©ó¥H¤U±¡ªp¡G ªvÀøÅöíw ¡E ¦bÃh¥¥ª¬ºA¤U¡A°£«D¨S¦³¾A¦Xªº´À¥NÀøªk ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe ªvÀøÄ¼Æ{¯g ¡E ¦bÃh¥¥ª¬ºA¤U ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe Á×¥¥­pµe±ø¥ó¡G ³B¤èÂå®vÀ³½T«O ¡E ¨Ì¯f¤H­Ó§Oª¬ªp¶i¦æµû¦ô¨Ã»P¤§°Q½×¡C³o¬O¬°¤F«OÃÒ¯f¤H¯à½T¹ê°t¦X¨Ã¤F¸ÑªvÀø¿ï¾Ü¤Î¨ä­·ÀI¡A ¥H¤Î¬°¤F­°§C­·ÀI¦Ó±Ä¨úªº±¹¬I¡C ¡E ©Ò¦³¤k©Ê¯f¤H³£À³°w¹ïÃh¥¥ªº¥i¯à©Ê¶i¦æµû¦ô¡C ¡E ¯f¤HÀ³¤F¸Ñ¨Ã»{ª¾¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº­·ÀI¡A¥]¬A­L¨à¦b¤l®c¤¤ÃnÅS©óvalproateªº­·ÀIµ{«×¡C ¡E ¯f¤HÀ³¤F¸Ñ¡AªvÀø«e¤ÎªvÀø´Á¶¡(¥²­n®É)¥²¶·¶i¦æÃh¥¥ÀË´ú¡C ¡E À³§i¶D¯f¤H¥²¶·Á×¥¥¡A¥B¯f¤H¦b¾ã­ÓvalproateªvÀø´Á¶¡¥²¶·¤£¶¡Â_¦a±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I ¡E ¯f¤HÀ³¤F¸Ñ¡AÅý¦³Åöíw©ÎÄ¼Æ{¯gªvÀø¸gÅçªº±M¬ìÂå®v©w´Á(¦Ü¤Ö¨C¦~¤@¦¸)µû¦ôªvÀøµ²ªG¦³¨ä¥²­n©Ê¡C ¡E ¤k©Ê¯f¤HÀ³¤F¸Ñ¡A·í¨ä­pµeÃh¥¥®É¡AÀ³ºÉ§Ö¿Ô¸ßÂå®v¡A¥H½T«O¯à¤Î®É°Q½×¨Ã¦bÃh¥¥«e¤Î°±¤îÁ×¥¥«e§ó´«ªvÀøÃÄª«¡C ¡E ¯f¤HÀ³¤F¸Ñ¡A·íµo²{Ãh¥¥®ÉÀ³ºò«æ³qª¾Âå®v¡C ¡E ¯f¤H¤w¦¬¨ì¯f¤H¥ÎÃÄ«ü«n¡C ¡E ¤k©Ê¯f¤H¤w½T»{¤F¸Ñ¡A¨Ï¥Îvalproate¤§¬ÛÃö­·ÀI©MÀ³ª`·N¨Æ¶µ (¦~«×­·ÀI½T»{ªí)¡C ³o¨Ç±ø¥ó¥ç¾A¥Î©ó¥Ø«eµL©Ê¦æ¬°ªº°ü¤k¡A°£«D³B¤èÂå®v¥R¤À¤§²z¥Ñ»{¬°¨äµLÃh¥¥­·ÀI¡C ÃÄ®v©Î¨ä¥LÂåÀø±M·~¤H­ûÀ³½T«O ¡E ¨C¦¸½Õ°tvalproate®É³£¦³¥æ¥I¯f¤H¥d¡AÅý¯f¤H¤F¸Ñ¨ä¤º®e¡C ¡E §iª¾¯f¤H·í­pµeÃh¥¥©ÎºÃ¦üÃh¥¥®É¡Avalproate¤£À³¾Õ¦Û°±ÃÄ¡AÀ³¥ß¨è³sµ¸±M¬ìÂå®v¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]valproate ¤Àªc¨ì¨Å¥Ä¤¤ªº¶q«Ü§C¡A¿@«×¤j¬ù¬O¥ÀÅé¦å²M¿@«×ªº 1%¦Ü 10%¤§¶¡¡C ®Ú¾Ú¤åÄm©MÁ{§É¸gÅç¡A­Y­n­÷¨Å¡A»Ý¦Ò¼{¥»«~ÃÄª«¦w¥þ©Ê¡A¯S§O¬O¦å²G¬ÛÃöªº¯e¯f¡C µM¦Ó¡AÃh¥¥´Á¶¡¼ÉÅS©ó sodium valproate ªº¥®¨à¡A¥i¯à­°§C»y¨¥¯à¤O¡A«ØÄ³ªvÀø®É¤£­n±Â¨Å¡C,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã¿õ§]ªA¡A¤£¥i«r¸H¡C°|¤º³Æ¦³¦P¦¨¥÷ÃÄ¤ôDepakin solution¥i¨ÑµLªk§]ªA¯f±w¨Ï¥Î¡C
ODOG2,Sulpiride,DOGMATYL 200mg,CNEU,,¾AÀ³¯g: §Ü¼ìºÅ¤Î±¡ºü¦w©w¾¯(A026976100) Treatment of psychotic disorders. Management of gastric & duodenal ulcers. °Æ§@¥Î: Neuroleptic malignant syndrome. Extrapyramidal symptoms¡A parkinsonism & endocrine side effects. Perspiration¡A nausea¡A dry mouth¡A lowered BP¡A agitated state¡A difficulty in falling asleep¡A sexual stimulation¡A dysopia¡A profuse salivation¡A increase in wt & allergy. ¸T§Ò: Pheochromocytoma. Infants.,,«Ç·Å,Gastric & duodenal ulcers¡G -Adult 150 mg daily in 3 divided doses. Schizophrenia ¡G -300-600 mg daily in divided doses. -May increase to 1200 mg daily. Depression or depressive state¡G -150-300 mg daily in divided doses. -May increase to 600 mg daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OGOU,Benzbromarone,Goutil 50mg,CNEU,Hyperuricemia.,Severe renal disease¡A nephrolithiasis; pregnancy & lactation,Rarely¡A diarrhoea¡A mild GI disturbances,¾B¥ú«O¦s(25¢J¥H¤U),50mg QD to BID.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T§Ò¡GÃh¥¥¤Î¥i¯àÃh¥¥ªº°ü¤k¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥¼¦³¬ÛÃö¸ê®Æ¡C,AC;AC15;PC;PO;WM;,,,,,
EFUBO,Polycresolfonate,Fubodyl vag supp 90mg,SGU,,¾AÀ³¯g: Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis¡A cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration. °Æ§@¥Î: Occasionally¡A mild local discomfort at beginning of treatment which disappears on discontinuation. ¸T§Ò: Concomitant use of other topical agents in treating the affected areas.,,2-8«×C,1 to be inserted on alternate days. ªc¨Å: ¥¼¦³¸ê®Æ,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OPHY,Aminophylline,Phyllocontin 225mg,ERSP,Treatment & prophylaxis of bronchospasm associated with asthma¡A emphysema & chronic bronchitis. Treatment of cardiac asthma & left ventricular or congestive cardiac failure.,Phyllocontin should not be given concomitantly with ephedrine in children.,Common: Diarrhea¡A Nausea¡A Vomiting¡A Dizziness¡A Headache¡A Insomnia¡A Tremor¡A Irritability¡A Restlessness¡A Diuresis Serious: Atrial fibrillation¡A Bradyarrhythmia¡A Too quick administration¡A Cardiac arrest¡A Tachyarrhythmia¡A Erythroderma¡A Necrotizing enterocolitis in fetus OR newborn¡A Hypersensitivity reaction¡A Intracranial hemorrhage¡A Seizure,25¢J¥H¤U,Elderly: 1 TAB BID in the initial week¡A then adjust the dose depends on clinical response. Adult & adolescent: 1 TAB BID in the initial week¡A then 2 TAB BID. Age >3 years Child: Maintenance dose: 12mg/kg BID. The dosage may up to 125mg. If the patient has not taken xanthine preparations before¡A it is recommended that treat with half of maintenance dose during the first week. Some patient with chronic asthma may require 13-20mg/kg BID.,»Ý½Õ¾ã¾¯¶q,Initial: 0.25 mg/kg/hour; maximum dose: 507 mg/day unless serum concentrations indicate need for larger dose. Use with caution and monitor serum theophylline concentrations frequently.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,Theophylline: Compatible,Compatible ­÷¨Å®É¥i¨Ï¥Î,Theophylline: Compatible,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¾ã²É§]ªA¡A¤£¥i©CÄZ©Î¿i¸H¡C°|¤º¥t¦³Theophylline¦¨¥÷ÃÄ¤ôCentertheo 60mL (5.34mg/mL) liquid¤Î«ùÄò©ÊÃÄ®Ä½¦ÅnXanthium 200mg¡C
OPRO5,Medroxyprogesterone,Provera 5mg,HM,Primary & secondary amenorrhea¡A Dysfunctional bleeding¡A Endometriosis.,Thrombophlebitis¡A thromboembolic disorders¡A cerebral apoplexy; liver dysfunction or disease; known or suspected malignancy of breast or genital organs; undiagnosed vag bleeding; pregnancy¡A missed abortion.,Nausea; fatigue¡A depression; acne¡A hirsutism; breast tenderness¡A galactorrhea¡A amenorrhea & anovulation; decreased glucose tolerance; thromboembolic phenomena; anaphylaxis; corticoid-like activity (high doses). Endocrine metabolic: Weight change finding (>5% ) Gastrointestinal: Abdominal pain ( >5% ) Neurologic: Asthenia ( >5% )¡A Dizziness ( >5% )¡A Headache ( >5% ) Psychiatric: Feeling nervous ( >5% ) Reproductive: Amenorrhea (>5% )¡A Break-through bleeding¡A Disorder of menstruation ( >5% )¡A Scanty vaginal bleeding,20-25¢J,Secondary menopause: 5-10mg daily for 5-10 days. Abnormal bleeding in the uterus due to hormonal imbalance: 5-10mg daily for 5-10 days from day 16 or day 21 of menstrual cycle.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OUCA,Calcium Carbonate,U-Cal 500mg,NUTR,,¾AÀ³¯g: Relief of the symptoms of gastric hyperacidity. °Æ§@¥Î: Mild GI disturbances. ¸T§Ò: Hypercalcaemia due to myeloma¡A bone metastases or other malignant bone disease¡A sarcoidosis; primary hyperparathyroidism¡A vitamin D overdosage; severe renal failure.,,«Ç·Å,1-2 tab before meals & at bedtime. Max: 6 tab/day.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,,,,,
OZES,Lisinopril,Zestril 10mg,CAVS,,¾AÀ³¯g: Hypertension¡A CHF¡A AMI¡A Renal complications of diabetes mellitus. °Æ§@¥Î: Dizziness¡A headache¡A diarrhoea¡A fatigue¡A cough¡A nausea¡A rash¡A orthostatic effects¡A asthenia. Rarely¡A angioedema¡A MI¡A CVA possibly secondary to excessive hypotension in high risk patients¡A palpitations¡A tachycardia¡A abdominal pain and indigestion¡A dry mouth¡A hepatitis¡A jaundice¡A vomiting¡A mood alterations¡A mental confusion¡A vertigo¡A urticaria¡A diaphoresis¡A uraemia¡A oliguria/anuria¡A renal dysfunction¡A acute renal failure¡A impotence¡A a symptom complex which may include fever¡A vasculitis¡A myalgia¡A arthralgia/arthritis¡A positive ANA¡A elevated ESR¡A eosinophilia & leukocytosis. Rash¡A photosensitivity or other dermatological manifestations. Increases (usually reversible) in blood urea¡A serum creatinine¡A liver enzymes & serum bilirubin. Small decreases in hemoglobin & hematocrit. Hyperkalemia¡A hyponatremia¡A leucopenia¡A thrombocytopenia¡A bone marrow depression¡A manifest as anaemia¡A paraesthesia¡A pancreatitis. Rarely¡A haemolytic anaemia. ¸T§Ò: Angioedema associated with ACE inhibitors & in patients with hereditary or idiopathic angioedema.,,«Ç·Å,Hypertension Usual maintenance dose: 20 mg once daily. Starting dose: 10 mg once daily. Lower starting dose required in renal impairment¡A renovascular hypertension¡A vol or salt depletion when diuretics cannot be discontinued. Max: 80 mg/day. CHF 5-20 mg once daily. Starting dose: 2.5 mg. AMI 1st dose of 5 mg followed by 5 mg after 24 hr¡A 10 mg after 48 hr & then 10 mg once daily thereafter. Renal complications of diabetes mellitus 10-20 mg once daily.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ITAX8,Docetaxel,TAXOTERE inj 80mg/4mL,RACA,Breast cancer¡A non-small cell lung cancer¡A prostate cancer¡A gastric adenocarcinoma¡A head & neck cancer.,Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1¡A500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding,Hematologic reactions especially neutropenia¡A fever¡A hypersensitivity reactions¡A fluid retention¡A GI disturbances¡A cutaneous reactions¡A neurologic symptoms¡A asthenia¡A alopecia. Cardiovascular: Edema (47% to 64.1% )¡A Vasodilatation (27% ) Dermatologic: Alopecia (56.3% to 97.8% )¡A Disorder of nail (11.4% to 18.5% )¡A Disorder of skin AND/OR subcutaneous tissue¡A Nail changes (8.1% to 30.6% )¡A Pruritus¡A Rash Gastrointestinal: Diarrhea (32.8% to 42.6% )¡A Nausea (38.8% to 80.5% )¡A Stomatitis (41.7% to 69.4% )¡A Vomiting (22.3% to 44.5% ) Hematologic: Anemia (89.1% to 93.6% )¡A Leukopenia (95.6% to 98.6% )¡A Neutropenia (71.4% to 99.5% ) Neurologic: Asthenia (61.8% to 80.8% )¡A Neuropathy Reproductive: Amenorrhea (61.7% ) Other: Fever of unknown origin (31.2% to 46.5% ),25¢J¥H¤UÁ×¥ú,[Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL¡Emin; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles¡A followed by radiation therapy.,»Ý½Õ¾ã¾¯¶q,¨Ï¥Î³æ¤@ÃÄª«100 mg / m 2¤§ÃÄª«°Ê¤O¾Ç¸ê®Æ¡AALT©M/©ÎAST¤j©ó¥¿±`½d³ò¤W­­1.5­¿©MÆP©ÊÁC»Ä¤j©ó2.5­¿¡A«ØÄ³¾¯¶q¬°75 mg / m2¡C¦å²MÁx¬õ¯À°ª©ó¥¿±`­È¡A©M/©ÎALT©MAST>¥¿±`­È3.5­¿¥BÆP©ÊÁC»Ä>¥¿±`­È 6­¿±wªÌ¡A¨S¦³´î¶q«ØÄ³¡A°£«D¯S®í±¡ªp¡A§_«h¤£À³¨Ï¥Î¡C¨Ö¥ÎCisplatin©M5-FUªvÀø­GÀù±wªÌ Á{§É¬ã¨s±Æ°£ALT©M/©ÎAST>1.5­¿¥¿±`­È»PÆP©ÊÁC»Ä>2.5¥¿±`­È¡AÁx¬õ¯À>¥¿±`­Èªº±wªÌ¡F¹ï©ó³o¨Ç±wªÌ¡A¨S¦³´î¶q«ØÄ³¡A°£«D¯S®í±¡ªp¡A§_«h¤£À³¨Ï¥Î¡C¥t¤@¤è­±¡A©|µL¨x·l¶Ë±wªÌ¨Ï¥Î¤§¬ã¨s³ø§i¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tPVC¶ì½¦§÷½è¡Cµ¹ÃÄ®ÉÀ³¨Ï¥Î polyethylene §÷½èªº¿é²G®M¡C 3. °t»s¦nªº¿éª`·»²G¿@«×Á×§K¶W¹L 0.74 mg/mL¡A°t¸m¦n6¤p®É¤º¥HÀR¯ß¿éª`¤è¦¡¨Ï¥Î (¥]§t¿éª`®É¶¡)¡A¦b§C©ó25¢J¥H¤Uµ¹¤©¯f±w¡C¨Ï¥Î«eÀ³¦A¦¸¥ØµøÀË¬d¡A­Y¦³¨I¾ýª«©Îµ²´¹À³¤©¥H¥á±ó¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C 5. ºÊ´úCBC¡B¨x¥\¯à¡C
EDOB,Sod Borate + Glycerin + Liq Phenol,Dobell's soln,TENT,,Antiseptic for oral hygiene.,,,Appropriate as much as necessary.,,,,,,,,,,,,,,
EDUL,Bisacodyl,Dulcolax ®ê¾¯ 10mg,ALIM,,¾AÀ³¯g: Constipation. Preparation of diagnostic procedures¡A in pre- & post-op treatment & in conditions which require defecation to be facilitated. °Æ§@¥Î: Rarely¡A abdominal cramps¡A abdominal pain & diarrhea. Allergic reactions. ¸T§Ò: Ileus¡A intestinal obstruction¡A acute surgical abdominal conditions including appendicitis¡A acute inflammatory bowel diseases & severe dehydration. Rare hereditary conditions of galactose intolerance eg. galactosemia or fructose intolerance. Lactation.,,«Ç·Å,Constipation Adult & children > 10 years 5-10 mg at bedtime or 1 supp. Children 4-10 years 5 mg at bedtime or 0.5 supp¡A < 4 years Pediatric supp recommended. Preparation of diagnostic procedures & preoperatively Adult 10-20 mg the night before the exam¡A followed by 1 supp in the morning of the exam. Children >= 4 years 5 mg in the evening & 1 pediatric supp on the following morning.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EDUO,Salicylic Acid + Lactic Acid,Duofilm 15mL,TDER,,¸T§Ò¡GHypersensitivity to salicylic acid or any component of the formulation. Impaired circulation (eg¡A diabetes¡A peripheral vascular disease); moles¡A birthmarks; warts with hair growth or on face. ¾AÀ³¯g: Removal of warts. °Æ§@¥Î: Local irritation.,,«Ç·Å,Soak lesion in hot water for 5 mins & dry thoroughly. Rub surface with pumice stone or emery board & apply to affected area 2-4 drops once daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EDUR,Petrolatum + Lanolin + Mineral Oil,Duratears ointment 3.5gm,TOPH,Temporary relief of ocular irritation due to eye dryness.,Hypersensitivity to any ingredients of the ointment.,Transient blurring in vision¡A allergic reaction.,25¢J¥H¤U,Apply a small amount of cream (approximately 1 cm) to the pouch whitch formed by pull the lower eyelid away from the eye when needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
EELD,Hydroquinone,Eldopague Forte 4% cream,TDER,,I: Chloasma¡Amelasma¡Afreckles¡Asenile lentigines¡A& other unwanted areas of melanin hyperpigmentation. AR: Hypersensitivity.,,,Apply to the affected area bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EESP,Desoximetasone,Esperson oint 0.25%¡A 5gm,TDER,,I: Eczema¡A neurodermatitis¡A dermatitis¡A psoriasis¡A 1st degree burns¡A sunburn. AR: Folliculitis¡A acne¡A changes in skin pigmentation¡A telangiectasis¡A striae distensae¡A skin atrophy. CI: Skin changes due to chickenpox¡A syphilis¡A TB¡A vaccinations¡A rosacea or perioral dermatitis. Treatment of extensive areas in pregnant & lactating mothers.,,,Initially apply bid-tid¡A then once daily.,,,,,,,,,,,,,,
EESTT,Estradiol 17B,Estraderm MX 50,HM,,I: Signs & symptoms of natural or surgically induced estrogen deficiency due to menopause. AR: Skin irritation at application site¡A estrogen-treatment related reactions¡A eg. breast discomfort¡A migraine. Isolated cases; generalised pruritus & exanthema¡A thromboembolic disorders¡A anaphylactoid reactions¡A jaundice. CI: Breast or endometrial carcinoma; endometrosis¡A vag bleeding of unknown origin; severe liver damage; a history of¡A or active¡A thrombophlebitis¡A thrombosis or thromboembolic disorders; pregnancy & lactation.,,,Continuous therapy: Apply every 3-4 days. Cyclic administration: 3 wk treatment followed by 1 wk without treatment. In patients with intactuterus¡A supplement without progestogen.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
EETH,Enflurane,Ethrane 250mL,ZANE,,¾AÀ³¯g: Induction and maintenance of general anesth. °Æ§@¥Î: Convulsions; liver damage; shivering; nausea; vomiting; involuntary muscle movements; hiccup; coughing; bronchospasm; laryngospasm; hypotension; cardiac arrhythmias; resp depression; mild hypothermia; malignant hyperthermia; uterine relaxation (high concentrations); resp depression; hypotension; asthma. ¸T§Ò: Known or suspected susceptibility to malignant hyperthermia. Porphyria.,,«Ç·Å,Inhalation Induction: 0.4% v/v in air¡A O2 or nitrous oxide-oxygen mixtures¡A increase in steps of 0.5% v/v every few breaths. Max: 4.5%. Maintenance: 0.5-3% v/v. Not to exceed 3% v/v during spontaneous resp.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EEURL,Crotamiton,Eurax lotion 10%,TDER,,I: Symptomatic treatment of pruritus¡A scabies¡A pediculosis capitis. AR: Local skin irritation. CI: Do not apply on nipples when breastfeeding.,,,Apply bid-tid; occlusive dressings not to be used.,,,,,,,,,,,,,,
EEXO,Naftifine,Exoderil cream 15gm,TDER,,I: Tinea corporis¡ATinea inguinalis¡ATinea manuum¡ATinea pedum¡AOnychomycoses¡A Candida infections of the skin¡A Pityriasis versicolor¡Ainflammatory dermatomycoses¡] with and without pruritus¡^. AR: Dryness¡A reddening & burning.,,RT,Apply once daily to the affected skin area and its vicinity after thorough cleaning and drying. To prevent recurrent infection continue treatment for at least 2 weeks after clinical healing.,,,,¥i¯à¦w¥þ,,,,,,,,,,
ILIP1,Soybean Oil,Lipovenos 10% 100mL(¤p¨àTPN¥Î),NUTR,,¾AÀ³¯g:¬°¥®¨à¯×½èÀç¾i¸Éµ¹²G(B020726255),,RT,Adult¡A neonate¡A infant & childn 1-2 g fat/kg body wt/day. Max infusion rate: 26 drrops/min.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OGLI8,Gliclazide,Glicalin 80mg,META,,¾AÀ³¯g: Type 2 DM °Æ§@¥Î: GI disturbances. Skin allergy (rare). ¸T§Ò: Diabetes complicated by ketosis¡A acidosis¡A surgery¡A infection¡A severe trauma¡A severe diarrhea or nausea & vomiting; pregnancy. Severe renal or hepatic impairment.,,«Ç·Å,PO Initial: 40-80 mg/day¡A increase slowly if needed. Doses >160 mg/day may be given in 2 divided doses.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IAVA,Bevacizumab,Avastin inj 100mg/4mL,RACA,In combination with irinotecan/5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin as 1st-line treatment of metastatic carcinoma of the colon or rectum,Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanised antibodies; untreated CNS metastases.,Common: Hypertension¡A All Grades (19-42%)¡A Hyperglycemia (26-31%)¡A Hypomagnesemia (24-27%)¡A Weight decreased (11-21%)¡A Abdominal pain (12-61%)¡A Constipation (13-40%)¡A Diarrhea (19-39%)¡A Indigestion (17-24%)¡A Loss of appetite (34-43%)¡A Nausea (58-72%)¡A Stomatitis (15-33%)¡A Taste sense altered (14-21%)¡A Vomiting (33-52%)¡A Hemorrhage¡A All Grades¡A Neutropenia¡A All Grades (Cervical cancer¡A 12%; ovarian cancer¡A 30.7%)¡A Thrombocytopenia¡A All Grades (Colorectal carcinoma¡A 5%; ovarian cancer¡A 58%)¡A Infectious disease (Cervical¡A ovarian¡A and non-small cell lung cancer¡A 10-13.6%; glioblastoma¡A 55%)¡A Arthralgia (28-45%)¡A Headache (22-49%)¡A Proteinuria¡A All Grades (5-20%)¡A Bleeding from nose (10-55%)¡A Dyspnea (25-30%)¡A Upper respiratory infection (40-47%)¡A Fatigue (33-82%) Serious: Hypertension¡A Grades 3 to 5 (5-18%)¡A Impaired wound healing (5-15%)¡A Injection site extravasation¡A Necrotizing fasciitis¡A Wound dehiscence¡A Bleeding esophageal varices¡A Bleeding gastroesophageal varices¡A Gastrointestinal fistula (Up to 4.1%)¡A Gastrointestinal hemorrhage (19-24%)¡A Gastrointestinal perforation (0.3-3%)¡A Tracheoesophageal fistula¡A Arterial thromboembolism (5%)¡A Deep venous thrombosis (6-9%)¡A Febrile neutropenia¡A Grades 3 to 5 (5-6.2%)¡A Hemorrhage¡A Grade 3 or greater (0.4-7%)¡A Leukopenia¡A Grade 3 or 4 (37-51%)¡A Lymphocytopenia¡A Grade 3 or 4 (6%)¡A Microangiopathic hemolytic anemia¡A Neutropenia¡A Grades 3 to 5 (Cervical cancer¡A 7.8%; colorectal and lung cancer¡A 21-27%)¡A Thrombocytopenia¡A Grade 3 or 4 (21-40.1%)¡A Thrombotic microangiopathy¡A Fistula of bile duct¡A Anaphylaxis¡A Hypersensitivity reaction¡A Intracranial hemorrhage (1.2-5%)¡A Posterior reversible encephalopathy syndrome (<0.5%)¡A Bladder fistula¡A Fistula from renal pelvis¡A Nephrotic syndrome (<1%)¡A Proteinuria¡A Grades 3 to 5 (3-10%)¡A Serum creatinine above reference range (13-16%)¡A Non-menstrual vaginal bleeding (4%)¡A Vaginal fistula finding¡A Bronchopleural fistula¡A Perforation of nasal septum¡A Pulmonary hemorrhage (4-31%)¡A Pulmonary hypertension,2-8¢JÁ×¥ú,Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. Continue treatment until disease progression or unacceptable toxicity.  [Metastatic Colorectal Cancer (mCRC)]- 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination withfluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Avastin-containing regimen.- 10 mg/kg every 2 weeks or 15 mg/kg every 2 weeks for Avastin-naive patients as second-line therapy.  [Metastatic Breast Cancer (mBC)] 10 mg/kg every 2 weeks  [Glioblastoma] 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks  [Non-Squamous Non-Small Cell Lung Cancer (NSCLC)] 15 mg/kg every 3 weeks  [Ovarian (epithelial)¡A fallopian tube¡A or primary peritoneal cancer] - Stage III/IV disease following initial surgical resection: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for up to 6 cycles¡A followed by bevacizumab 15 mg/kg every 3 weeks (monotherapy)¡A for a total of up to 22 cycles (=15 months) or until disease progression (whichever occurs earlier)- Platinum-sensitive recurrent: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6-10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity- Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks (in combination with paclitaxel¡A doxorubicin [liposomal]¡A or topotecan)  [Cervical cancer] 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BEVACIZUMAB: Limited Human Data¡XProbably Compatible (Intravitreal) Potential Toxicity (Intravenous),IVD;,,¡iN/S¡j¥i¿ï ¡C,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. µ}ÄÀ«á¿éª`·»²GÀ³Â\©ñ©ó2-8«×CÀx¦s¡A¶W¹L8¤p®É¥¼¨Ï¥ÎÀ³¥á±ó¡C 3. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü30-60¤ÀÄÁ¡C 4. ºÊ´ú³J¥Õ§¿¡C 5. ¨C2-3¶gºÊ´ú¦åÀ£ÅÜ¤Æ¡C
IPITR,Vasopressin,Pitressin inj 20 Units/1mL,HM,Esophageal varices bleeding. Diabetes insipidus.,Anaphylaxis or hypersensitivity to the drug or its components,Tremor; sweating; vertigo; circumoral pallor; `pounding' in the head; abdominal cramps; urticaria; vomiting; bronchial constriction; MI¡A cardiac arrest; water intoxication.,25¢J¥H¤U¤Å§N­á,Abdominal swelling caused by surgery: IV or IM 5 units (0.25mL)¡A up to 10 units (0.5mL)¡A repeated every 3-4 hour if needed. Abdominal radiography: IM 10 units (0.5mL) for two times¡A two hours and an half hour before radiography. Diabetes insipidus: IM or SC 5-10 units (0.25-0.5mL) or IV 0.1 units¡A repeated every 4-12 hours if needed. Bleeding from esophageal varices: Diluted 20 units of Pitressin into 100-200mL of 5% D5NS¡A infusion for 10-20 minutes¡A repeated every 1-2 hour¡A if needed¡A up to 4 doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IN;IVD;SC;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¿éª`³t²v < 0.4 U/min,
OICO,Itraconazole,Icomein 100mg,QANB,Vulvovag candidiasis¡A Dermatomycosis¡A Plantar tinea pedis & palmar tinea manus¡A Pityriasis versicolor¡A Oral candidiasis¡A Fungal keratitis¡A Onychomycosis¡A Aspergillosis¡A Candidosis¡A Non-meningeal cryptococcosis¡A Cryptococcal meningitis ¡A Histoplasmosis¡A Blastomycosis¡A Lymphocutaneous & cutaneous sporotrichosis¡A Paracoccidioidomycosis¡A Chromomycosis.,Pregnancy & lactation.,Dyspepsia¡A nausea¡A abdominal pain & constipation. Less frequently¡A headache¡A reversible increases in hepatic enzymes¡A menstrual disorders¡A dizziness¡A allergic reactions (e.g. pruritus¡A rash¡A urticaria¡A angio-edema).,15-30¢J°®Àê³B,(¥é³æ) Adult: 100-200 mg 1-2 times daily after meals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OFEM,Letrozole,Femara 2.5mg,RACA,Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status¡A who have previously been treated with antioestrogens. 1st-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Extended adjuvant treatment of hormone receptor +ve & LN metastasis +ve breast cancer patient who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor +ve invasive early breast cancer.,Hypersensitivity to letrozole or any component of the formulation; pregnancy. Use in patients <18 years of age; premenopausal endocrine status; breastfeeding.,Headache¡A nausea¡A peripheral edema¡A fatigue¡A hot flushes. Cardiovascular: Edema (7.2% to 18.4% ) Dermatologic: Hot sweats (5% to 49.7% )¡A Sweating (up to 24.2% ) Gastrointestinal: Constipation (1.5% to 11.3% )¡A Diarrhea (5% to 8% )¡A Loss of appetite (3% to 5% )¡A Nausea (8.6% to 17% )¡A Vomiting (2.7% to 7% ) Musculoskeletal: Arthralgia (8% to 22% )¡A Arthritis (6.7% to 21.1%)¡A Backache (5% to 18% )¡A Bone pain (22% )¡A Myalgia (6.4% to 6.7% ) Neurologic: Asthenia (4% to 33.6% )¡A Dizziness (2.4% to 14.2% .)¡A Headache (3.5% to 20.1% )¡A Insomnia (5.8% to 7% .)¡A Somnolence (2% to 3% .) Respiratory: Dyspnea (5.5% to 18% ) Other: Fatigue (6% to 13% ),30¢J¥H¤U°®Àê³B,2.5 mg orally once a day¡A without regard to meals for a planned duration of 5 years; discontinue at relapse¡A disease progression or unacceptable toxicity. In patients with advanced disease¡A treatment with Femara should continue until tumor progression is evident.,µL»Ý½Õ¾ã¾¯¶q,Child-Pugh C±K¤ÁºÊ±±,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OHAL2,Haloperidol,Apo-Haloperidol 2mg,CNEU,,¾AÀ³¯g: Acute & chronic psychotic disorders including schizophrenia & manic states¡A Tourette's syndrome. Severe behavioral problems & hyperactivity in children. Nausea & vomiting associated with antineoplastic therapy & surgery. °Æ§@¥Î: Occasionally¡A depression¡A anxiety¡A agitation¡A confusion¡A vertigo¡A exacerbation of psychotic symptoms & seizures. Hyperprolactinaemia¡A gynaecomastia¡A menstrual irregularities¡A impotence. Rarely¡A tachycardia¡A orthostatic hypotension. ¸T§Ò: Endogenous depression without agitation¡A comatose conditions¡A severe CNS depression. Pregnancy¡A children.,,«Ç·Å,Initially 1-2 mg bid-tid & gradually increase up to 4-6 mg tid if required. Severely disturbed patients Up to 100 mg/day. Maintenance: 1-2 mg tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OIMOV,Zopiclone,Imovane 7.5mg,CNEU,Insomnia.,Myasthenia gravis. Respiratory failure¡A severe sleep apnea syndrome. Severe hepatic insufficiency.,Bitter-taste; dizziness¡A headache¡A residual somnolence; GI disturbances; allergic reactions; psychiatric & paradoxical reactions; rebound insomnia & withdrawal phenomena. Gastrointestinal: Disorder of taste (8% to 34% )¡A Vomiting (3% ) Neurologic: Dizziness (1% to 7% )¡A Headache (13% to 21% )¡A Migraine (1% or greater ) Respiratory: Respiratory tract infection (5% to 10% ),25¢J¥H¤U,Adult 7.5mg(1 TAB) at bedtime. Elderly Initially 1/2 TAB at bedtime & if necessary increase to 1 TAB. In hepatic or renal function or non-decompensated respiratory insufficiency 1/2 TAB at bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
LKID,Prednisolone,Kidsolone solution 1mg/mL¡A 60mL,HM,Allergic and inflammatory disorders¡A Rheumatoid arthritis¡A Multiple sclerosis.,Hypersensitivity; live vaccines; herpes simplex keratitis¡A systemic infections.,Cushing's syndrome and growth retardation in childn; osteoporosis¡A fractures. Peptic ulceration; glaucoma¡A cataracts; hyperglycaemia¡A pancreatitis; increased appetite¡A obesity.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Adult: 5-60mL daily. Child: 0.14-2mg/kg/day devided into 3-4 times.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LUCE,Cefadroxil,Ucefa susp 25mg/mL¡A 60mL,QANB,,¾AÀ³¯g: Infection of the GUT¡A respiratory tract¡A skin & soft tissue by susceptible organisms. °Æ§@¥Î: Nausea¡A vomiting¡A diarrhea¡A abdominal discomfort; Allergic reactions¡A eosinophilia¡A angioedema¡A anaphylaxis¡A neutropenia¡A superinfection¡A pseudomembranous colitis¡A genital pruritus. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Children 30 mg/kg body wt¡A divided twice daily up to a maximum of 2 g/day,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ORELA,Carisoprodol + Acetaminophen,RelaX 175/350mg,CNEU,,¾AÀ³¯g: Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders e.g. stiff shoulder¡A sprains¡A strains¡A lumbago¡A arthralgia & myalgia. °Æ§@¥Î: Drowsiness¡A dizziness¡A vertigo¡A ataxia¡A idiosyncratic reactions¡A hypersensitivity reactions¡A hypotension¡A tachycardia¡A cardiac arrhythmias¡A GI disturbances. Neurologic: Dizziness (7% to 8% )¡A Headache (3% to 5% )¡A Somnolence (13% to 17% ) ¸T§Ò: Acute intermittent porphyria¡A lactation.,,«Ç·Å,Adult : 1 ~ 2 Tablets qid.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³´î§C¨C¤é¾¯¶q ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ORIS,Risperidone,Risperdal 2mg,CNEU,,¾AÀ³¯g: Treatment of schizophrenia¡A including 1st episode psychoses¡A acute schizophrenic exacerbations¡A chronic schizophrenia¡A & other psychotic conditions. Alleviates affective symptoms (eg. depression¡A guilt feelings¡A anxiety) associated with schizophrenia. Long-term therapy for the prevention of relapse in chronic schizophrenia. Treatment of behavioral disturbances in patients with dementia. As adjunctive therapy to mood stabilizers or monotherapy in the treatment of manic episodes associated with bipolar disorder. Treatment of conduct & other disruptive behavioral disorders in children¡A adolescents & adults with subaverage intellectual functioning or mental retardation. °Æ§@¥Î: Common: insomnia¡A agitation¡A anxiety¡A headache. Less common: somnolence¡A fatigue¡A dizziness¡A impaired concentration¡A constipation¡A dyspepsia¡A nausea/vomiting¡A abdominal pain¡A blurred vision¡A priapism¡A erectile dysfunction¡A ejaculatory dysfunction¡A urinary incontinence¡A rhinitis¡A rash & other allergic reactions. Occasionally¡A orthostatic hypotension¡A reflex tachycardia or hypertension. Cardiovascular: Peripheral edema (adults¡A up to 3%; children¡A less than 5% .)¡A Tachycardia (oral¡A adults¡A up to 5%; children¡A up to 7% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% ) Dermatologic: Rash (oral¡A adults¡A 2% to 4%; children¡A up to 11% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% ) Endocrine metabolic: Hyperprolactinemia (oral¡A adults¡A less than 1%; children¡A 49% to 87% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Weight gain (oral¡A adults¡A up to 18%; children¡A up to 14%; intramuscular¡A schizophrenia¡A 4% to 5%; bipolar I disorder¡A 5% to 7% ) Gastrointestinal: Abdominal pain (oral¡A adults¡A 2% to 4%; children¡A 15% to 18% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Constipation (oral¡A adults¡A 5% to 9%; children¡A 21% ; intramuscular¡A schizophrenia¡A 5% to 7% )¡A Diarrhea (oral¡A adults¡A up to 6%; children¡A 7% to 8% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Excessive salivation (oral¡A adults¡A 1% to 4%; children¡A up to 22% ; intramuscular¡A schizophrenia¡A 1% to 4% )¡A Increased appetite (oral¡A children¡A 4 to 49% ; intramuscular¡A bipolar I disorder¡A 4% )¡A Indigestion (oral¡A adults¡A 4% to 10%; children¡A 5% to 16% ; intramuscular¡A schizophrenia¡A 6% )¡A Nausea (oral¡A adults¡A 4% to 9%; children¡A 8% to 16% ; intramuscular¡A schizophrenia¡A 3% to 4% )¡A Vomiting (oral¡A children¡A 10% to 12% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Xerostomia (oral¡A adults¡A up to 4%; children¡A up to 13% ; intramuscular¡A schizophrenia¡A 0% to 7%) Musculoskeletal: Pain¡A in Extremity (intramuscular¡A schizophrenia¡A 2% to 6% ) Neurologic: Akathisia (oral¡A adults¡A 5% to 9%; children¡A up to 10% ; intramuscular¡A schizophrenic adults¡A 4% to 11% )¡A Dizziness (oral¡A adults¡A 4% to 11%; children¡A 7% to 16% ; intramuscular¡A schizophrenia¡A 7% to 11%; bipolar I disorder¡A 3% )¡A Extrapyramidal disease (adults¡A 7% to 31% )¡A Headache (intramuscular¡A 15% to 21% )¡A Insomnia (oral¡A adults¡A less than 1%; children¡A less than 5% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Parkinsonism (oral¡A adults¡A 0.6% to 20%; children¡A 2% to 16% ; intramuscular¡A schizophrenia¡A 8% to 15%; bipolar I disorder¡A 15% )¡A Somnolence (oral¡A adults¡A 5% to 14%; children¡A 12% to 67% ; intramuscular¡A schizophrenia¡A 5% to 6%; bipolar I disorder¡A 7% )¡A Tremor (oral¡A adults¡A up to 5% to 6%; children¡A 10% to 12% ; intramuscular¡A schizophrenia¡A 0% to 3%; bipolar I disorder¡A 24% ),,«Ç·Å,Adult May be given once or bid. Initially 2 mg/day. Usual dose: 2-6 mg/day. Elderly or patient with renal or liver disease Initially 0.5 mg bid¡A increasing to 1-2 mg bid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
YSTR,Polydimethylsiloxanes¡A siloxanes,Strataderm gel 10gm,TDER,,,,,,,,,,,,,,,,,,,
YPOLY,Polysiloxane,Polyxal silicone gel 15gm,TDER,,,,Àx¦s¦b³±²DÀê³B,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;SKIN;TOPI;,,,,,
OMTX,Methotrexate,Methotrexate 2.5mg,RACA,Acute lymphoblastic leukemia¡A Cutaneous T-cell lymphoma (mycosis fungoides¡A advanced)¡A Gestational trophoblastic neoplasia¡A Meningeal leukemia¡A prophylaxis and treatment¡A Osteosarcoma¡A Psoriasis¡A Rheumatoid arthritis.,Hypersensitivity to methotrexate¡A including a history of severe hypersensitivity reactions (eg¡A anaphylaxis). Lactation. Severe renal impairment (CrCl < 10 mL/min) Alcoholism¡A alcoholic liver disease¡A or chronic liver disease. Overt or laboratory evidence of immunodeficiency syndromes. Preexisting blood dyscrasias¡A such as bone marrow hypoplasia¡A leukopenia¡A thrombocytopenia¡A or significant anemia. Pregnancy.,Common: Alopecia (0.5-10%)¡A Burning sensation¡A Photosensitivity (3-10%)¡A Rash (0.2%)¡A Abdominal pain¡A Diarrhea¡A Indigestion¡A Nausea¡A Stomatitis (Up to 10%)¡A Vomiting¡A Thrombocytopenia (Up to 10%)¡A Increased liver function test (14-15%)¡A Headache (1.2%)¡A Bronchitis¡A Nasopharyngitis Serious: Thromboembolic disorder¡A Erythema multiforme¡A Skin cancer¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hemorrhagic enteritis of intestine¡A Perforation of intestine¡A Agranulocytosis¡A Aplastic anemia¡A Leukopenia (Up to 3%)¡A Pancytopenia (Up to 3%)¡A Cirrhosis of liver (0.1%)¡A Hepatic fibrosis (7%)¡A Hepatitis¡A Acute¡A Hepatotoxicity¡A Anaphylaxis¡A Malignant lymphoma¡A Opportunistic infection¡A Encephalopathy¡A Leukoencephalopathy¡A Neurotoxicity¡A Seizure¡A Renal failure¡A Interstitial pneumonia¡A Pulmonary toxicity¡A Infectious disease,Á×¥úÀx¦s©ó25¢J¥H¤U,[Choriocarcinoma and similar trophoblastic diseases] 15-30 mg orally or IM daily for a 5-day course. Repeat 3-5 times as required with rest periods of 1 or more weeks interposed between courses¡A until any manifesting toxic symptoms subside. [Leukemia] Induction: 3.3 mg/m2 in combination with prednisone 60 mg/m2 daily for 4-6 weeks. Maintenance therapy: orally or IM 2 times weekly intotal weekly doses of 30 mg/m2 or 2.5 mg/kg intravenously every 14 days. If and when relapse occurs¡A repeat the initial induction regimen. [Lymphomas] 10-25 mg/day orally for 4-8 days. Treatment in all stages usually consists of several courses interposed with 7-10 day rest periods. Lymphosarcomas in Stage III may respond to combined drug therapy with 0.625-2.5 mg/kg daily. [Psoriasis] 10-25 mg orally¡A IM or IV once weekly or 2.5 mg orally at 12-hour intervals for 3 doses every 1 week until adequate response is achieved. 30 mg/week should not ordinarily be exceeded.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] Methotrexate¨ã¦³¼ç¦b¤§«æ©Ê¨xª¢¤ÎºC©Ê¡]ÅÖºûÅÜ©Ê¤Îµw¤Æ¡^¤§¨xÅ¦¬r©Ê¡AºC©Ê¬r©Ê¥i¯à¾É­P¦º¤`¡A³q±`¦bªø´Á¨Ï¥Î«á¡]³q±`¦b¨â¦~©Î§ó¤[¡^©ÎÁ`¾¯¶q¦Ü¤Ö¹F1.5g«á¥i¯àµo¥ÍºC©Ê¬r©Ê¡C¬ã¨s«ü¥X¡A°®Å~ªº¯f¤H¨x¬r©Ê»PÁ`²Ö¿n¾¯¶q¦³Ãö¡A¥B·|¦]¬°°sºë¤¤¬r¡BªÎ­D¡B¿}§¿¯f¡B¦~¬ö¸ûªø¦Ó¼W¥[¨ä¬r©Ê¡C,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,[¥é³æ] Ãh¥¥°ü¤kªA¥Îmethotrexate·|¤Þ°_­L¨à¦º¤`¡B­F­L¬r©Ê¡B¬y²£©Î­P·î§Î§@¥Î¡C¹ï±w¦³°®Å~©ÎÃþ­·Àã©ÊÃö¸`ª¢¤§Ãh¥¥¯f¤H¡A¥»ÃÄ¤´ÄÝ¸T§Ò¡C °£«D½T©w¨S¦³Ãh¥¥¡A§_«h¥»ÃÄ¤£±o¨Ï¥Î©ó¨ã¥Í¨|¯à¤O°ü¤k¡A¦pªG¦b¥ÎÃÄ´Á¶¡¨ü¥¥®ÉÀ³¥R¤ÀÀË°Q¨ä¹ï­L¨à¥i¯à²£¥Í¤§ÄY­«¦M®`¡C°t°¸¤§¥ô¦ó¤@¤è¦p¦b±µ¨üMethotrexate´Á¶¡À³Á×§K¨ü¥¥¡C °t°¸¤§¥ô¦ó¤@¤è¤¤Â_MethotrexateªvÀø»P¥i¨ü¥¥¤§²z·Qªº®É¶¡¶¡¹j©|¥¼½T©w¡C¬ã¨s³ø§i«ØÄ³ªº®É¶¡¶¡¹j¬°¤T­Ó¤ë¦Ü¤@¦~¡C ¥¿¦b¨Ï¥Îmethotrexateªº¯f¤H¡AµL½×¨k¤k¡A¬ÒÀ³»P¯f¤H°Q½×¼vÅT¥Í¨|¯à¤Oªº­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] Methotrexate´¿¦b¤H¨Å¤¤ÀË´ú¥X¨Ó¡A¦]¦¹methotrexate¸T¤î©ó­÷¨Å´Á¨Ï¥Î¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
ONAHCO3,Sodium Bicarbonate,NaHCO3 300mg,ALIM,Relief of dyspepsia¡A Urinary alkalinization¡A Antacid.,Metabolic or respiratory alkalosis¡A hypocalcaemia¡A hypochlorhydria. Avoid overtreatment.,Metabolic alkalosis; shortness of breath & muscle weakness; muscle hypertonicity¡A twitching & tetany; Na overloading & hyperosmolality. Stomach cramps & flatulence. Tissue necrosis at inj site.,25¢J¥H¤UÁ×¥ú,Metabolic acidosis¡A Chronic initial¡A 600 mg 3 times daily; increase to 4.8g/day (16 tablets). Severe Metabolic acidosis: used IV Sodium Bicarbonate. Urinary alkalinization: 3g every 2 hours¡A until urine pH>7 .maintain dose 5-10g/day (¥é³æ),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ONIM,Nimodipine,Nimotop F.C 30mg,CAVS,Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasms following subarachnoid haemorrhage.,Patients with severely impaired liver function (eg¡A cirrhosis of the liver). In view of its indication area¡A Nimotop tablet is not used during pregnancy or lactation.,Hypotension¡A GI disturbances.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Subarachnoid hemorrhage¡A From ruptured intracranial berry aneurysms: treatment or prophylaxis: 60mg Q4H for 7 days (1 hour before or 2 hours after meals)¡A after IV infusion Nimotop for 5-14 days.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¯f±w(especially liver cirrhosis)¡A«ØÄ³30 mg ORALLY every 4 hours ©Î¦Ò¼{°±¤îªvÀø,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OORF5,Warfarin,ORFARIN 5mg,HEMT,,¾AÀ³¯g: Treatment & prophylaxis of thromboembolic disorders. °Æ§@¥Î: Alopecia¡A skin rashes of various kinds¡A hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ) ¸T§Ò: Severe hepatic or renal disease¡A actual or potential haemorrhagic conditions¡A severe hypertension¡A endocarditis¡A ulceration of the GI & urinary tract¡A visceral carcinoma¡A endocarditis¡A neurosurgery¡A recent surgery on the eye¡A brain or spinal cord. Pregnancy.,,«Ç·Å,Initially¡A 10-15 mg daily¡A adjusted with relation to the result of control tests. Maintenance dosage adjusted according to INR.,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,WHO:Compatible with breast-feeding.,,,,,,
ILOS,Omeprazole,Losec 40mg inf,ALIM,,¾AÀ³¯g: Duodenal & gastric ulcer¡A reflux esophagitis¡A Zollinger-Ellison syndrome. °Æ§@¥Î: Headache¡A diarrhea¡A constipation¡A abdominal pain¡A nausea/vomiting¡A flatulence. Rarely fatigue¡A rash &/or pruritus¡A dizziness¡A paresthesia¡A somnolence¡A insomnia¡A increased liver enzymes.,,«Ç·Å,Duodenal & gastric ulcer¡A reflux esophagitis 40 mg IV once daily. Zollinger-Ellison syndrome Dose should be adjusted individually. Higher doses &/or several doses daily may be required.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ILUM,Phenobarbital,Lumian inj,CNEU,,Insomnia¡A anxiety¡A excitement¡A epilepsy¡A tetanus¡A preanesthetic medication¡A cardiac and gastric neurosis.,,,Adult:For anticonvulsant: Oral: 50-100 mg bid-tid. IM¡A slow IV: 100-300 mg may be repeated in 6hrs as needed. For hypnotic: 100-200 mg qN. For sedative: 15-30 mg bid-tid. Child:Oral: 3-6 mg/kg in divided doses. IM¡A IV: 3-5 mg/kg q3-4h as needed.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IMART,Maltose,Maltose-10 inj 10% 500mL,NUTR,,¾AÀ³¯g:ÁÞÃþ¸Éµ¹²G,,«Ç·Å,Adult: 500-1000 ml at rate of 500 ml/120 mins.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IMEA,Measles Vaccine,³Â¯l¦Û¶O¬Ì­],HIMM,,Active immunization against measles.,,,SC¡A children over 1 yr¡A 1 vial (0.5 ml after reconstitution).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IMEAA,Measles Vaccine,Rimevax inj( MEASLES )(½Ã¥Í¸p),HIMM,,Active immunization against measles.,,,SC¡A children over 1 yr¡A 1 vial (0.5 ml after reconstitution).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IMETY,Mecobalamin,Methycobal inj 500mcg/1mL,CNEU,Megaloblastic anemia due to vit B12 deficiency & peripheral neuropathies.,Hypersensitivity to any component of the formulation.,Infrequently: Anorexia¡A nausea¡A diarrhea¡A pain & induration at IM inj site. Rarely: Skin rash¡A headache¡A sweating or hot sensation. Dermatologic: Injection site pain Musculoskeletal: Arthralgia (12% ) Neurologic: Dizziness (12% )¡A Headache (12% ) Respiratory: Nasopharyngitis (12% ),«Ç·Å,Peripheral neuropathies: 500 mcg IM/IV 3 times/week.Megaloblastic anemia due to vit B12 deficiency: 500 mcg IM/IV 3 times/week for 2 months¡A then 500 mcg every 1-3 months as maintenance therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVP;IVPUSH;,,,,,1.IM is the preferred route of administration. IV administration is not recommended because the drug is excreted more rapidly and almost all of the cyanocobalamin is lost in the urine. 2.The medicine is light sensitive¡A so protection from light is recommended.
IMF1000,Mix Fungus,MF 1000,ZOTH,,,,,,,,,,,,,,,,,,,
IMGSO4,Magnesium Sulfate,Magnesium Sulfate inj 10%¡A 20mL,NUTR,Hypomagnesemia; emergency treatment of life-threatening arrhythmias; prevention of recurrent seizures in eclampsia or pre-eclampsia.,Patients with heart block¡A myocardial damage or severe renal impairment.,Hypermagnesaemia characterized by loss of tendon reflexes & respiratory depression¡A flushing¡A thirst¡A hypotension¡A drowsiness¡A nausea¡A vomiting¡A confusion¡A muscle weakness¡A cardiac arrhythmias¡A coma & cardiac arrest.,25¢J¥H¤U,As TPN material only. Each mL contains: 0.1g magnesium sulfate salt=0.81mEq of elemental magnesium=0.405 mmol of elemental magnesium. [Uptodate 20210731] Standard daily magnesium requirement: IV: Elemental magnesium 8 to 20 mEq (4 to 10 mmol) daily as component of parenteral nutrition; adjust daily dose based on serum magnesium and clinical considerations (ASPEN 2019).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IMIA,Salmon Calcitonin,Miacalcic inj 50 IU/1mL,META,Hypercalcemia¡A Paget's disease of bone¡A postmenopausal osteoporosis.,Hypersensitivity to Miacalcic.,Inj Nausea¡A vomiting¡A dizziness¡A flushing accompanied by heat¡A arthralgia¡A polyuria¡A chills¡A hypersensitivity reactions. Dermatologic: Flushing¡A Face or hands (approximately 2% to 5% )¡A Injection site reaction (about 10% ) Gastrointestinal: Nausea (approximately 10% ) Respiratory: Rhinitis (12% )¡A Sinusitis (2.3% ),2-8¢JÁ×§K§N­á,IM¡A SC¡A IVD¡A Paget's disease 100 IU IM or SC once daily or every alternate day. Emergency treatment of hypercalcemic crisis 5-10 IU/kg daily by IV infusion over at least 6 hours or by slow IV inj in 2-4 divided doses. Chronic hypercalcemic states 5-10 IU/kg IM or SC daily as a single dose or in 2 divided doses. If the volume to be injected is >2 mL¡A use IM administration.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;SC;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,°ª¦å¶t¦M¶H®É¥i¯à±Ä¥ÎÀR¯ß¿éª`¡A¾¯¶q 5-10 U/Kg/day ¥[¤J500 mL N/S¡A§@6¤p®É¥H¤WÀR¯ß¿éª`¡A©Î±N¤é¾¯¶q§¡¤À¦¨2-4¦¸ºC³tÀR¯ßª`®g¡C,1. ª`®g¶q >2 mL«ØÄ³±Ä¦Ù¦×ª`®g¡A¨Ã©ó¤£¦P³¡¦ì¬I¥´¡C¡C 2. °ª¦å¶t¦M¶H®É¥i¯à±Ä¥ÎÀR¯ß¿éª`¡A¾¯¶q 5-10 U/Kg/day ¥[¤J500 mL N/S¡A§@6¤p®É¥H¤WÀR¯ß¿éª`¡A©Î±N¤é¾¯¶q§¡¤À¦¨2-4¦¸ºC³tÀR¯ßª`®g¡C
IMIN,Minocycline,Minocin 100mg,QANB,,Resp. tract¡A GUT¡Asoft tissue¡A ENT¡A ophthalmologic infection¡Aperiodonitis.,,,Acne vulgaris : 100 mg qd or 50mg bid. Non-gonococcal urethritis: 200 mg qd or 100mg bid for 10-14 days. Gonorrhea : Adult male 200 mg initially followed by 100 mg 12 hrly for min of 4 days. Adult female Same dosage as male for 10-14 days. Systemic infection: 100 mg q12h. Prophylaxis of asymptomatic meningococcal carriers:100 mg bid for 5 days.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IMIO,Carbachol,Miostat inj 0.01% 1.5mL,TOPH,Intraocular use for miosis during surgery.,Hypersensitivity to carbachol or any component of the formulation. Use with caution in patients with asthma¡A peptic ulcer disease or gastrointestinal spasm¡A acute heart failure¡A hyperthyroidism¡A Parkinson's disease¡A and urinary tract obstruction.,Ophthalmic: Blurred vision¡A corneal edema¡A corneal opacity¡A epithelial keratopathy (bullous)¡A eye pain¡A increased intraocular pressure¡A iritis (postoperative)¡A ocular hyperemia¡A ophthalmic inflammation¡A retinal detachment¡A visual impairment.,Äá¤ó15-30«×«Ç·Å,Ophthalmic surgery¡A miosis: Intraocular: 0.5 mL instilled into the anterior chamber before or after securing sutures.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,[¥é³æ] ¥¥°üÃþ§OC.¥»«~©|¥¼¦³¹ï¥¥°ü§@¾A·í¤Î±±¨î¶q¦Ñ¤§¬ã¨s³ø§i¡C ¥u¦³¦bÅv¿Å¯q³B¤j©ó¹ï­L¨à¤§¦MÀI©Ê®É¤~±o¥H¨Ï¥Î¥»«~¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥»«~¬O§_·|¥Ñ¨Å¯×¤Àªc¥¼ª¾¡C±Â¨Å°ü¨Ï¥Î¥»«~À³¤©¥HÄµ§i¡C,LI;TOPI;,,,,,Intraocular route 1) It is recommended that no more than 0.5 milliliter of a 0.01% carbachol solution be instilled into the anterior chamber of the eye to obtain miosis before or after securing sutures.
OLACS,Etodolac,Lacoxa SR 400mg,CNEU,,¾AÀ³¯g: RA & osteoarthritis. °Æ§@¥Î: GI discomfort¡A hypersensitivity reactions¡A bronchospasm¡A headache¡A dizziness¡A nervousness¡A depression¡A drowsiness¡A insomnia¡A vertigo¡A hearing disturbances¡A photosensitivity¡A haematuria. Cardiovascular: Edema (1% to 10% ) Gastrointestinal: Abdominal pain (3% to 9% )¡A Diarrhea (3% to 9% )¡A Flatulence (3% to 9% )¡A Indigestion (10% )¡A Nausea (3% to 9% ) Hepatic: Increased liver function test (up to 15% ) Neurologic: Dizziness (3% to 9% )¡A Headache (3% to 4% ) Other: Malaise (3% to 9% ) ¸T§Ò: Patients in whom aspirin & other NSAIDs precipitate attacks of asthma¡A angioedema¡A urticaria or rhinitis; active peptic ulceration.,,«Ç·Å,Initially 600-1200 mg daily in divided doses adjusted according to response to a max of 1200mg daily,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IKAB1,Glucose + Amino Acid + lipid,Kabiven ¤¤¤ßÀR¯ß¿éª`1540mL,NUTR,,,,,,,,,,,,,,,,,,,
EVIG,Moxifloxacin,Vigamox 0.5%¡A 5mL ophthalmic solution,TOPH,The treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-positive microorganisms (Corynebacterium species¡A Micrococcus luteus¡A Staphylococcus aureus¡A Staphylococcus epidermidis¡A Staphylococcus haemolyticus¡A Staphylococcus hominis¡A Staphylococcus warneri¡A Streptococcus pneumoniae¡A Streptococcus viridans group)¡A Aerobic Gram-negative microorganisms (Acinetobacter lwoffii¡A Haemophilus influenzae¡A Haemophilus parainfluenzae)¡A Other microorganisms (Chlamydia trachomatis).,History of hypersensitivity to moxifloxacin¡A to other quinolones¡A or to any of the components in this medication.,Conjunctivitis¡A decreased visual acuity¡A dry eye¡A keratitis¡A ocular discomfort¡A ocular hyperemia¡A ocular pain¡A ocular pruritus¡A subconjunctival hemorrhage¡A and tearing.(1-6%) Fever¡A increased cough¡A infection¡A otitis media¡A pharyngitis¡A rash¡A and rhinitis.(1-4%),30¢XC¥H¤U,instill 1 drop in the affected eye TID for 7 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,[¥é³æ]Ãh¥¥ªº¤j¹«¦b¾¹©x§Î¦¨´Á¡A¤fªAmoxifloxacin³Ì°ª¹F500 mg/kg/dayªº¾¯¶q¡]¬ù¬°¤HÃþ²´³¡¨C¤é³Ì°ª«ØÄ³Á`¶q¤§21700­¿¡^¨Ã¤£¨ã­P·î­L©Ê¡FµM¦Ó«oµo²{·|³y¦¨­L¨àÅé­«´î»´¤Î­L¨à°©Àfµo®i²¤¬°©µ¿ð¡CÃh¥¥ªºCynomogusµU¤fªAmoxifloxacin°ª¹F100 mg/kg/dayªº¾¯¶q¡]¬ù¬°¤HÃþ²´³¡¨C¤é³Ì°ª«ØÄ³Á`¶q¤§4300­¿¡^¨Ã¥¼µo²{­P·î­LªºÃÒ¾Ú¡F¦b100 mg/kg/dayªº¾¯¶q¤U¡A­L¨à¸û¤pªºµo¥Í²v¼W°ª¡C ¥Ñ©ó¥Î©óÃh¥¥°ü¤k¨ÃµL¾A·íªº¹ï·Ó¬ã¨s¡A¥u¦³¦b¼ç¦b®Ä¯q°ª©ó¹ï­L¨àªº¼ç¦b¶Ë®`®É¡A¤è¥i±NVigamoxÂI²´²G¥Î©óÃh¥¥°ü¤k¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]ÁöµM¥i¥H°²³]moxifloxacin·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡A¦ý¬O¨ÃµLªk¦b¤HÃþ¨Å¥Ä¤¤°»´ú¥Xmoxifloxacin¡C VigamoxÂI²´²G¥Î©ó­÷¨Å°ü¤kÀ³ÂÔ·V¨Ï¥Î¡C,OD;OL;OU;,,,,,1. ¤£¥i§@¬°ª`®g¾¯¨Ï¥Î¡C 2. ¤£¥i©óµ²½¤¤Uª`®gVigamox¡A¤]¤£¥iª½±µª`¤J²´·ú«e©Ð¡C
IFUC,Hyoscin-Butylbromide,Fucon inj 20mg/1mL,ALIM,Spasm & hyperkinesia of the GIT¡A spasm & dyskinesia of the biliary tract¡A urinary tract & female genital tracts.,Myasthenia gravis¡A toxic megacolon¡A narrow angle glaucoma¡A tachycardia¡A prostatic enlargement with urinary retention¡A pyloric stenosis & paralytic ileus.,Dry mouth¡A dyshidrosis¡A visual accommodation disturbances¡A tachycardia¡A dizziness¡A constipation¡A urinary retention¡A hypotension¡A allergic reactions¡A inj site pain.,25¢J¥H¤U,Adult 20 mg 3-5 times daily IM/IV/SC.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;SC;,,¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö>1¤ÀÄÁ (¨àµ£¡G¦Ü¤Ö2-3¤ÀÄÁ),Intravenous routes¡A at a slow injection rate of 1 mL/min. No dilution of the solution is necessary prior to administration.,
OGLI5,Metformin,Glibudon 500mg,META,,¾AÀ³¯g: Type 2 diabetes mellitus. °Æ§@¥Î: GI disturbances; skin rash or dermatitis (rare). Endocrine metabolic: Cobalamin deficiency (up to 9.9% ) Gastrointestinal: Diarrhea (53.2% (immediate-release) ; 9.6% to 12.5% (extended-release) )¡A Flatulence (12.1% )¡A Indigestion (7.1% )¡A Malabsorption syndrome (up to 9.9% )¡A Nausea (up to 25.5% (immediate-release); ; 6.7% (extended-release) )¡A Vomiting (up to 25.5% ) ¸T§Ò: Patients with ketoacidosis¡A severe infections¡A stress¡A trauma. Severe renal impairment. Heart failure¡A dehydration¡A acute or chronic alcoholism¡A predisposition to lactic acidosis.,,«Ç·Å,1 tab tid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OWIL,Dicyclomine + Alumium Hydroxide + Magnesium Oxide,Wilcon-U,ALIM,,¾AÀ³¯g: Acute & chronic gastritis¡A indigestion¡A hyperacidity & symptomatic relief of pain due to peptic or duodenal ulceration. °Æ§@¥Î: Constipation¡A transient bradycardia (followed by tachycardia)¡A reduced bronchial secretions¡A urinary urgency & retention¡A dilatation of the pupils with loss of accommodation¡A photophobia¡A dry mouth¡A flushing & dryness of skin. ¸T§Ò: Angle-closure glaucoma¡A myasthenia gravis¡A paralytic ileus¡A pyloric stenosis¡A prostatic enlargement.,,«Ç·Å,Adult 1-2 tab tid & at bedtime.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EMIK,Carteolol,Mikelan LA 2%¡A 2.5mL ophthalmic solution,TOPH,Glaucoma & ocular hypertension.,Unsatisfactorily controlled cardiac insufficiency; risk of bronchial asthma & bronchospasm; sinus bradycardia; AV block (II & III); cardiogenic shock; right ventricular insufficiency due to pulmonary hypertension & CHF.,Cardiovascular: Angina Neurologic: Asthenia (7% .)¡A Dizziness (4% to 15% .)¡A Headache (4% to 17% .)¡A Insomnia (2% to 12%.) Ophthalmic: Blurred vision¡A Burning sensation in eye (25% )¡A Conjunctival edema (25% )¡A Conjunctival hyperemia (25% )¡A Epiphora (25% )¡A Eye irritation (25% ),25¢J¥H¤U,Instill 1 drop QD into the conjunctival sac.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
OKBT,Kaolin + (BiO)2CO3 + Al. Tannate,KBT,ALIM,,¾AÀ³¯g: Diarrhea. ¸T§Ò: Intestinal obstruction.,,«Ç·Å,Adult 1-2 tab 4 hrly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OLEX3,Bromazepam,Lexotan 3mg,CNEU,Functional disturbances of the CV & respiratory systems¡A GIT & GUT. Emotional disturbances & reactions to chronic organic diseases. Psychosomatic disorders & adjuvant to psychotherapy in psychoneurosis.,Early pregnancy¡A lactation. Myasthenia gravis.,Fatigue¡A drowsiness; rarely¡A muscle weakness (high doses). May impair ability to drive or operate machinery.,30¢J¥H¤U,Outpatient 1.5-3 mg TID. Severe case¡A esp in hospital 6-12 mg BID or TID.,µL»Ý½Õ¾ã¾¯¶q,»´·L©Î¤¤«×¨x¥\¯à¤£¥þ±wªÌ«ØÄ³±q³Ì§C¾¯¶q¶}©l¨Ï¥Î ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OLON,Etodolac,Lonine 200mg,CNEU,Osteoarthritis. Pain. Rheumatoid arthritis.,Asthma¡A urticaria¡A or allergic-type reaction following aspirin or other NSAID administration; severe¡A even fatal anaphylactic-like reactions have been reported. hypersensitivity to etodolac. CABG surgery within 14 days¡A treatment of perioperative pain.,Common Cardiovascular: Edema (1% to 10% ) Gastrointestinal: Abdominal pain (3% to 9% )¡A Diarrhea (3% to 9% )¡A Flatulence (3% to 9% )¡A Indigestion (10% )¡A Nausea (3% to 9% ) Hepatic: Increased liver function test (up to 15% ) Neurologic: Dizziness (3% to 9% )¡A Headache (3% to 4% ) Other: Malaise (3% to 9% ) Serious Cardiovascular: Congestive heart failure (less than 1% )¡A Hypertension (less than 1% )¡A Myocardial infarction (less than 1% )¡A Thrombotic tendency observations Dermatologic: Erythroderma¡A Stevens-Johnson syndrome (less than 1% )¡A Toxic epidermal necrolysis (less than 1% ) Gastrointestinal: Gastrointestinal hemorrhage¡A Gastrointestinal perforation¡A Gastrointestinal ulcer¡A Inflammatory disorder of digestive tract Hematologic: Thrombocytopenia (less than 1% ) Hepatic: Hepatic necrosis¡A Hepatitis (less than 1% )¡A Liver failure (less than 1% ) Immunologic: Anaphylactoid reaction (less than 1% ) Neurologic: Cerebrovascular accident Renal: Acute renal failure (less than 1% )¡A Papillary necrosis (less than 1% ) Respiratory: Bronchospasm,25¢J¥H¤U,Pain: 200 to 400 mg orally every 6 to 8 hours; maximum 1200 mg/day. Rheumatoid arthritis or osteoarthritis: 300 mg orally BID to TID; or 500mg BID,µL»Ý½Õ¾ã¾¯¶q,In patients with compensated hepatic cirrhosis¡A the dose of etodolac does not need to be adjusted. However¡A the dose may need to be decreased in patients with severe hepatic failure.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ]¥Î©ó¥¥°ü:¥Ñ°Êª«¹êÅçÅã¥Ü¡A¦b2~10mg/kgªº¨C¤é¾¯¶q¤U¡A¦¹ÃÄ¹ï¤j¹«©Î®a§K§¡µL­P­L©Ê©Î­F­L¬r©Ê. ¦b3~15mg/kgªº¨C¤é¾¯¶q¤U¡A¹ï©ó¶¯¹«¤Î¶¯¹«ªº¥Í¨|¤O©M¥þ­±ªº¥Í´Þªí²{¡A¥H¤Î³o¨Ç»Û¹«©Ò²£¤Uªº«á¥N¡A³£¥u¦³«Ü¤pªº¼vÅT. ¾Ú¹êÅçÃÒ©ú¡A­YÃh¥¥°Êª«¨Ï¥Î§í¨î«e¦C¸¢¯À¥Íª«¦X¦¨ªºÃÄª«¡A¥i¯à·|¾É­PÃø²£©Î©µ¿ð¥Í²£. ¥Ñ°w¹ï¨C¤ÑªA¥ÎLONINE 3~15 mg/kgªº¤j¹«©ó²£«e²£«áªº±¡ªp©Ò¶i¦æªº¬ã¨s¡Aµo²{¦b¨C¤ÑªA¥Î15mg/kgªº¤@²Õ¸Ì¡Aµo¥ÍÃø²£©Î¥¥´Á©µªøªº¥À¹«¼Æ¥Ø¡A¥H¤Î¨C¤@²£ªº¦º­L¼Æ¥Ø¡A³£¤ñ¥­±`¦h. ¦Ü©ó¥¥°ü¡A¥Ø«e¥¼¦³¨¬°÷¥B±±¨îÄYÂÔªº¬ã¨sµ²ªG¥i´`. ¦]¦¹¡A¹ï©ó¥¥°ü¡A¤]¥u¦³¦b¸g¹L¿Å¶q«á½T©w±wªÌ¥i¯àÀò±oªº§Q¯q­«©ó­L¨à¥i¯à¾D¨üªº¦M®`®É¡A¤~¥i¥H¨Ï¥ÎLONINE¡A¦³¤@³¡¥÷«e¦C¸¢¯À¥Íª«¦X¦¨§í¨î¾¯¾ÚÃÒ¹ê·|§«Ãª°Ê¯ß¾ÉºÞªº³¬¦X; ©Ò¥H¡A¦bÃh¥¥¥½´Á¤T­Ó¤ë¸Ì¨Ã¤£±ÀÂË¨Ï¥ÎLONINE. [20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Î©ó±Â¨Å°ü:±Â¨Å´Á¶¡¨Ï¥ÎLONINE¤§¦w¥þ©Ê©|¥¼«Ø¥ß.­PÀù©Ê¡A­P¬ðÅÜ©Ê¥H¤Î¹ï¥Í¨|¤Oªº·l®`: ¬°¤Fµû¦ôLONINEªº­PÀù©Ê¡A·|¶i¦æ¤@¶µªø¹F2¦~ªº¤j¹«¹êÅç¡A¥H¤Î¥t¤@¶µ¡H´Á18­Ó¤ëªº¤p¹«¹êÅç; µ²ªG¨Ã¨S¦³µo²{¥ô¦ó­PÀù©Ê. LONINE¥ç¸gAmes¤ó­P¬ðÅÜ©Ê´úÅçÃÒ©úµL­PÅÜ©Ê.,AC;AC15;PC;PO;WM;,,,,,
OMEP,Procaterol,Meptin - Mini 25mcg,ERSP,Bronchial asthma¡A chronic bronchitis & pulmonary emphysema.,Hypersensitivity to any component of the formulation.,Infrequent palpitations & tremors.,30¢J¥H¤UÁ×¥ú¨¾¼éÀx¦s,Adult: 50 mcg HS or 50 mcg BID (in the morning and bedtime). Age >6 years: 25 mcg HS or 25 mcg BID (in the morning and bedtime). The dose may decrease or increase depends on patient¡¦s age and symptoms.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[Lexidrug] Safety has not been established in pregnancy; the manufacturer recommends that procaterol be used in pregnant patients only if the potential benefits outweigh the risk.,Unknown ¨S¦³¸ê®Æ,[Lexidrug] It is not known if procaterol is present in breast milk; the manufacturer recommends discontinuing breastfeeding prior to therapy.,AC;AC15;PC;PO;WM;,,,,,
ONEOT,Acitretin,Neotigason 10mg,TDER,Severe forms of psoriasis & disorders of keratinization.,Hepatic or renal impairment. Elevated blood lipid levels. Pregnancy¡A lactation. Women of childbearing potential.,Common: Alopecia (50-75%)¡A Cheilitis (greater than 75%)¡A Disorder of nail (25-50%)¡A Peeling of skin (50-75%)¡A Pruritus (25-50%)¡A Xeroderma (25-50%)¡A Hypertriglyceridemia¡A Lipids outside reference range¡A Xerostomia (10-25%)¡A Arthralgia (10-25%)¡A Hyperesthesia (10-25%)¡A Paresthesia (10-25%)¡A Dry eye syndrome (23%)¡A Xerophthalmia (10-25%)¡A Bleeding from nose (10-25%)¡A Nasal mucosa dry¡A Rhinitis (25-50%) Serious: Myocardial infarction¡A Hepatotoxicity¡A Increased liver aminotransferase level¡A Pseudotumor cerebri¡A Ototoxicity - deafness (< 1%)¡A Depression (1-10%)¡A Capillary leak syndrome,25¢J¥H¤U,Psoriasis Adult Initial daily dosage¡A 25mg or 30 mg for 2-4 weeks. Maintenance: 25-50mg for 6-8 weeks. Maximum: 75mg/day. Keratinization disorders the lowest dose treatment is required. Less than 20 mg/day¡A but not more than 50 mg/day. Child: Safety and efficacy for pediatric patients have not been established. use with caution¡A 0.5 mg/kg. Maximum: 35mg/day.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ¡BÀ£¸H©Î¥´¶}½¦Ån¡C¥»ÃÄ¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C
ONUX,Piracetam,Nuxitam 1200mg,CNEU,,¾AÀ³¯g: Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin. °Æ§@¥Î: Hyperkinesia¡A wt gain¡A nervousness¡A somnolence¡A depression¡A asthenia. ¸T§Ò: Cerebral hemorrhage; severe renal impairment.,,«Ç·Å,Cerebrovascular insufficiency & age-related cognitive impairment Loading dose: 4.8 g daily during initial weeks of treatment. Maintenance: 1.2-2.4 g daily. Cortical myoclonus Initially 7.2 g daily¡A increasing by 4.8 g/day every 3-4 days to a max of 24 g/day in divided doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,,,,,,
OCHL5,Chlordiazepoxide,Chlordiazepoxide 5mg,CNEU,Neurosis¡A anxiety & tension¡A depression especially agitated depression.,Acute narrow-angle glaucoma; myasthenia gravis¡A shock; severe psychoses.,Drowsiness¡A ataxia¡A confusion; skin eruptions¡A edema; menstrual irregularities; nausea & constipation; extrapyramidal symptoms & decreased libido; blood dyscrasias; jaundice & hepatic dysfunction. Skin rashes; nausea; headache; decreased tolerance to alcohol.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adult 10mg (2 tablets) BID-TID¡A may be increased to 60mg-90mg (12-18 tablets) daily in 3-4 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OCYT,Misoprostol,Cytotec 200mcg,ALIM,Healing of duodenal & gastric ulcer & NSAID-induced peptic ulcer; Prophylaxis of NSAID-induced peptic ulcer.,Pregnancy¡A women planning a pregnancy¡A premenopausal women¡A lactation. Known allergy to prostaglandins.,GI disturbances including diarrhea¡A abdominal pain with or without dyspepsia¡A flatulence¡A nausea & vomiting¡A menorrhagia¡A vag bleeding & intermenstrual bleeding¡A rashes¡A dizziness. Gastrointestinal: Abdominal pain (7% to 20% )¡A Diarrhea (13% to 40% ),30¢J¥H¤UÁ×§K¨ü¼é,Duodenal ulcer & Gastric ulcer: 800 mcg/day in 2-4 divided doses for 4-8 weeks.Prophylaxis of NSAID-induced ulcer: 200 mcg BID¡A TID or QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,Misoprostol: Contraindicated (Oral) Human Data Suggest Low Risk (Term Cervical Ripening) [¥é³æ] Misoprostol·|¤Þ°_¤l®c¦¬ÁY¡A¨Ã»P¬y²£¡B¦­²£¡B­L¨à¦º¤`©M­L¨à·î«¬¦³Ãö¡C ³ø§iÅã¥Ü¬Û¸û©óµo¥Í²v¬°2%ªº¹ï·Ó²Õ¡A¦b§³®W²Ä¤@´Á(first trimester)´Á¶¡±µÄ²misoprostolµo¥Í·î«¬ªº­·ÀI¼W¥[¬ù3­¿¡C ¯S§O¬O¡A¤wµo²{²£«e±µÄ²misoprostol»PMoebius¯g­Ô¸s(¥ý¤Ñ©ÊÃC­±¯«¸g³Â·ô¦]¦Ó¾É­P¯Ê¥FÁy³¡ªí±¡¡B§l§m©M§]Ã`¥H¤Î²´²y¹B°Ê»ÙÃª¡A¨Ö¦³©Î¥¼¦³ªÏÅé¯Ê³´)¡F¦Ï½¤±a¯g­Ô¸s(ªÏÅé·î«¬/ºIªÏ¡A¯S§O¬O¤ºÂ½¨¬¡BµL¤â·î«¬¡B¯Ê³k¡BÃEµõ)©M¤¤¼Ï¯«¸g¨t²Î²§±`(¸£©MÆ`²§±`¡A¦pµL¸£·î«¬¡B¤ô¸£¯g¡B¤p¸£µo¨|¤£¥þ¡B¯«¸gºÞ¯Ê³´)¦³Ãö¡C´¿Æ[¹î¨ì¨ä¥L¯Ê³´¡A¦pÃö¸`ÅËÁY¡C¦]¦¹¡G - À³§iª¾¤k©Ê­P·î­Lªº­·ÀI¡C - ¦pªG¯f¤H§Æ±æ¦b¤l®c¤º¼ÉÅSmisoprostol«áÄ~ÄòÃh¥¥¡A¥²¶·¶i¦æ¥J²Ó ªº¶W­µªi±½´yºÊ´úÃh¥¥¡A¨Ã¯S§Oª`·N¥|ªÏ©MÀY³¡¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Misoprostol¦b¥ÀÅé¤º¨³³t¥NÁÂ¬°misoprostol acid¡A«áªÌ¦³¥Íª«¬¡©Ê¥B³Q¤Àªc¦Ü¥À¨Å¤¤¡C ­÷¨Åªº¥À¿Ë¤£¸Ó¨Ï¥Îmisoprostol¡A¦]¬°misoprostolacidªº¤Àªc¥i¯à¹ï­÷¨ÅªºÀ¦¨à³y¦¨¸¡Âmµ¥¤£¨}¼vÅT¡C,AC;PO;SL;VAG;,,,,,
ODAM,Bethanechol Chloride,Dampurine 25mg,SGU,Treatment of acute post-op & postpartum non-obstructive urinary retention & neurogenic atony of the urinary bladder with retention.,Intestinal or urinary obstruction¡A hyperthyroidism¡A peptic ulcer disease¡A epilepsy¡A obstructive pulmonary disease¡A bradycardia¡A vasomotor instability¡A AV conduction defects¡A hypotension¡A parkinsonism.,Nausea¡A vomiting¡A sweating¡A intestinal colic.,25¢J¥H¤U,Urinary retention¡A neurogenic bladder: To determine minimal effective dose: 5 to 10 mg; repeat the same dose hourly until effective response or a maximum of 50 mg is reached; usual dose: 10 to 50 mg 3 to 4 times daily. Cholinergic effects at higher oral dosages may be cumulative.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;PO;,,,,,
ODEF,Cimetidine,Defense 300mg,ALIM,,¾AÀ³¯g: Treatment of duodenal & gastric ulcer¡A GERD¡A persistent dyspepsia & pathological hypersecretory states eg Zollinger-Ellison syndrome. °Æ§@¥Î: Altered bowel habits¡A diarrhoea¡A headache¡A tiredness¡A dizziness¡A somnolence¡A rash¡A reversible impotence¡A gynaecomastia¡A reversible confusional states¡A reversible hepatic damage. ¸T§Ò: Exclude gastric malignancy before treatment.,,«Ç·Å,Tab 300mg tid & at bedtime for 4-6 weeks. The dosage may be increased to 600mg qid if necessary. Max: 2400mg/day,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ¯f±w·|«ØÄ³ 50% reduction in the dose,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ODET4,Tolterodine,DETRUSITOL SR 4mg prolonged-release,SGU,Treatment of overactive bladder with symptoms of urinary urgency¡A frequency¡Aor urge incontinence.,Urinary retention¡A uncontrolled narrow angle glaucoma¡A myasthenia gravis¡A severe ulcerative colitis¡A toxic megacolon.,Dry mouth¡A dyspepsia¡A dry eyes¡A fatigue¡A constipation¡A abdominal pain¡A dizziness¡A headache¡A somnolence¡A flatulence¡A vomiting¡A paresthesia¡A nervousness¡A dry skin. Gastrointestinal: Constipation (6% to 7% )¡A Xerostomia (15% to 30% ) Neurologic: Headache [7% (immediate release); 6% (extended release)],25¢J¥H¤U,Adults: Immediate release tablet: 2 mg BID; the dose may be lowered to 1 mg BID based on individual response and tolerability. Extended release capsule: 4 mg QD; dose may be lowered to 2 mg QD based on individual response and tolerability.,»Ý½Õ¾ã¾¯¶q,»´«×©Î¤¤«×¨x¥\¯à¤£¥þ±wªÌ(Child-Pugh Class A or B):«ØÄ³¾¯¶q¬O¨C¦¸2²@§J¡B¤@¤Ñ¤@¦¸ ÄY­«¨x¥\¯à¤£¥þ±wªÌ(Child-Pugh C):¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄòÄÀ©ñ½¦Ån¡A»Ý¾ãÁû§]ªA¡A¤Å©î¶}½¦Ån¡B«r¸H¡BÀ£¸H¡B­é¥b©Î¿i¯»¡C¼t°Ó¥¼¯à´£¨Ñ¯}Ãa¾¯«¬«áªº¦³®Ä©Ê¤Î¦w©w©Ê¡C
ODOLC,Pipemidic Acid,Dolcol 250mg,QANB,UTI¡A Bacillary dysentery¡A enteritis¡A otitis media and sinusitis,Hypersensitivity to any component of the formulation.,GI symptoms. CNS¡A skin reactions. Muscular weakness¡A myalgia. CI: Hypersensitivity¡A children¡A pregnancy and lactation. infants < 3 months.,«Ç·Å25¢J¦s©ñ,Adult: 500-2000 mg/day¡A divided Q6-8H. For adults with pyelonephritis¡A pyelitis¡A cystitis¡A urethritis¡A and prostatitis: 2-8 tablets (500-2000mg) daily¡A divided into 3-4 doses. For adults with otitis media¡A sinusitis¡A enteritis¡A and bacterial dysentery: 6-8 tablets (1500-2000mg)¡A divided into 3-4 doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;PO;,,,,,
OCAR,Activated Charcoal,Carbomix 61.5gm,ZADT,Emergency treatment of acute oral poisoning or drug overdose. Also binding of bacteriotoxins & other diarrhea-inducing substances in the gastrointestinal tract.,Corrosive substance intoxication.,Common: Black feces¡A Diarrhea¡A Vomiting¡A Pulmonary aspiration Serious: Hypotension (rare)¡A Electrolyte imbalance (rare)¡A Gastrointestinal obstruction,«Ç·ÅÃÄ¡AÁ×§KÀã®ð,Acute poisoning -Adult 50-100 g in susp immediately followed by 20 g Q4-6H for a few days. -Children 1 g/kg body weight. Diarrhea -Adult 1 sachet/time several times daily. -Children 1 sachet in several divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PO;,,,,,
OCAT,Clonidine,CataPRES 75mcg,CAVS,All grades of hypertension except when due to pheochromocytoma.,Sick-sinus syndrome. 2nd or 3rd degree AV block.,Initially¡A dry mouth & fatigue; orthostatic complaints especially with IV. Dermatologic: Contact dermatitis (5% to 47% )¡A Erythema (26% )¡A Pruritus Gastrointestinal: Xerostomia (25% ) Neurologic: Dizziness (2% )¡A Headache (5% )¡A Sedated (3% )¡A Somnolence (12% ) Other: Fatigue (6% ),25¢J¥H¤U,HTN: Mild to moderate HTN: initial 0.075mg -0.15mg BID¡A may up to 0.3mg/day severe HTN: initial 0.3mg TID (0.9mg/day),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCEF5,Cefixime,Cefspan 50mg,QANB,,Otitis media¡A pharyngitis¡A bronchitis and UTI.,,,Adult & child over 30 kg: 50-100 mg q12h¡A up to 200 mg q12h. Child: 1.5-3 mg/kg q12h¡A up to 6 mg/kg q12h.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OCEL,Pergolide,Celance 0.05mg,CNEU,,,,,,,,,,,,,,,,,,,
OCEP,Diphenidol,Cephadol 25mg,CNEU,,Peripheral (labyrinthine) vertigo¡A Meniere's disease¡A middle and inner ear surgery (labyrinthitis)¡A nausea¡A vomiting.,,,Adult: 25-50mg qid (max. 300mg/day). Child over 6 months or over 12kg: 0.9mg/kg¡A may be repeated in 1hr with subsequent doses of q4h as needed¡A (max. 5.5mg/kg/day).,,,,,,,,,,,,,,
OCIPR,Ciprofloxacin,Ciproxin tab 250mg,QANB,,¾AÀ³¯g: ²Óµß©Ê·P¬V UTI .Respiratory tract¡A bone & joint & biliary tract infection.GI (infectious diarrhea). Gonorrhea. °Æ§@¥Î:Nausea¡A diarrhoea¡A vomiting¡A dyspepsia¡A abdominal pain¡A flatulence¡A anorexia¡A dizziness¡A headache¡A tiredness¡A agitation¡A trembling. Very rarely¡A insomnia¡A peripheral paralgesia¡A sweating¡A unsteady gait¡A convulsions¡A increase in intracranial pressure¡A anxiety states¡A nightmares¡A confusion¡A depression¡A hallucinations¡A impaired taste & smell¡A visual disturbances¡A tinnitus¡A transitory impairment of hearing¡A especially at high frequencies¡A skin reactions. ¸T§Ò:Hypersensitivity to ciprofloxacin or other quinolones. Children¡A adolescents¡A pregnancy & lactation.,,«Ç·Å,UTI Uncomplicated:250mg bid. UTI Complicated: 500mg bid. Resp tract¡A bone&joint¡Askin&biliary tract infection Moderate infection:500mg bid. Severe infection:750mg bid. GI (infectious diarrhea): 500mg bid for 5 days. Gonorrhea 250mg as a single dose.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OCLAR,Loratadine + Pseudoephedrine,Clarinase 5/120mg,HIMM,,¾AÀ³¯g: Relief of symptoms associated with allergic rhinitis & common cold including nasal congestion¡A sneezing¡A rhinorrhea¡A pruritus & lacrimation. °Æ§@¥Î: Insomnia¡A dry mouth. ¸T§Ò: Patients receiving MAOI therapy or within 14 days of discontinuing such treatment. Narrow-angle glaucoma¡A urinary retention¡A severe hypertension¡A severe coronary artery disease¡A hyperthyroidism.,,«Ç·Å,1 tab bid.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OCLO,Clomiphene,Clomid 50mg,HM,,,,,,,,,,,,,,,,,,,
OCLO2,Clomipramine,Clopran 25mg,CNEU,,¾AÀ³¯g: Depression °Æ§@¥Î: Thirst¡A reduced appetite¡A hypotension¡A frequent pulse¡A difficulty with micturition¡A intraocular pressure¡A blurred vision¡A constipation. ¸T§Ò: Recent MI¡A hypersensitive to tricyclic antidepressants¡A glaucoma.,,«Ç·Å,50-100 mg daily in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IFOR7,Teriparatide,Forteo 750mcg/3mL¡A 28dose,META,Treatment of postmenopausal women with osteoporosis who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.,Paget's disease of bone¡A unexplained elevations of alkaline phosphatase¡A prior history of radiation therapy involving the skeleton¡A bone metastases or a history of skeletal malignancies¡A metabolic bone diseases (other than osteoporosis)¡A pre-existing hypercalcemia¡A children or adolescents with open epiphyses.,GI disturbances¡A asthenia¡A hypotension¡A arthralgia¡A leg cramps¡A dizziness¡A depression¡A insomnia¡A vertigo¡A rhinitis¡A cough¡A pharyngitis¡A dyspnea¡A rash¡A increased sweating¡A hypercalcemia. Cardiovascular: Hypotension¡A Syncope Dermatologic: Rash¡A Sweating symptom Endocrine metabolic: Hyperuricemia Gastrointestinal: Constipation¡A Diarrhea¡A Indigestion¡A Nausea¡A Vomiting Musculoskeletal: Arthralgia (10.1% )¡A Spasm (1% to 10% ) Neurologic: Asthenia¡A Dizziness Respiratory: Increasing frequency of cough¡A Pharyngitis¡A Rhinitis,2-8¢JÁ×¥úÁ×§K§N­á,SC¡A 20 mcg once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,SC;,,,,,2020/10/30:¸ß°Ý¼t°Ó«á§iª¾25«×C¥H¤U¥i«O24¤p®É¦w©w.
IABI1,Cisplatin,Abiplatin inj 10mg/20mL,RACA,,¾AÀ³¯g: Metastatic testicular tumors¡A Metastatic ovarian tumors¡A Advanced bladder cancer. °Æ§@¥Î: Nausea & vomiting¡A renal toxicity¡A bone-marrow depression¡A ototoxicity¡A serum electrolyte disturbances¡A peripheral neuropathy¡A retinal toxicity¡A anaphylactic reactions¡A cardiac abnormalities. ¸T§Ò: Hearing or renal impairment¡A myelosuppression¡A dehydration.,,«Ç·Å,IV infusion over 6-8 hrs¡A As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin¡A 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin¡A 50 mg/mL once every 3 wks.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gcisplatinªº¾¹¨ã¤£¥i§t¦³¾T¡C 3. µ}ÄÀ«áªº¿éª`·»²GÀ³Á×¥ú«O¦s¡C 4. µ¹ÃÄ«e«áÀ³µ¹¤©¯f¤H¾A·í¤ô¤À¸É¥R¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C 6. ©w´Á¯«¸g¾Ç¡BÅ¥¤OÀË´ú¡C
OCHE,Sulfamethoxazole + Trimethoprim,Chemix (Baktar) 400/80mg,QANB,Acute infective exacerbation of chronic obstructive pulmonary disease¡A pneumocystis pneumonia¡A shigellosis¡A traveler's diarrhea¡A urinary tract infectious¡A acute otitis.,Liver parenchymal damage¡A blood dyscrasias; severe renal insufficiency. Pregnancy¡A lactation. Porphyria.,GI disturbances; allergic skin reactions; hallucinations¡A depression¡A apathy¡A nervousness. Arthralgia¡A myalgia. Neurologic reactions.,25¢J¥H¤UÁ×¥ú,Trimethoprim-sulfamethoxazole (TMP-SMX)Adult and children > 12 years: 80/400-240/1200 mg (1-3 tablets) twice daily. Children (6-12 years): 80/400 mg (1 tablet) twice daily. Children (6 months-5 years): 40/200 mg (0.5 tablet) twice daily. Children (6 weeks-5 months): 20/100 mg (0.25 tablet) twice daily. Pediatric dose is calculated based on TPM 6 mg/kg/day and SMX 30 mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
ICLA,Cefotaxime,Claforan iInj 500mg,QANB,,,,,,,,,,,,,,,,,,,
OPRO2,Estradiol Valerate,Progynova 2mg 21's/pk,HM,,¾AÀ³¯g: Climacteric complaints after cessation of monthly bleeding¡A or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases. °Æ§@¥Î: Breast tension¡A gastric upsets¡A nausea¡A headache¡A increase in body wt¡A uterine bleeding. ¸T§Ò: Pregnancy; severe disturbance of liver function; jaundice or persistent itching during a previous pregnancy; Dubin-Johnson syndrome¡A Rotor syndrome; previous or existing liver tumours; existing or previous thromboembolic processes; sickle-cell anaemia; existing or suspected hormone-dependent tumours of the uterus or mammae; endometriosis; severe diabetes with vascular changes; congenital disturbances of lipometabolism; otosclerosis with deterioration during pregnancy.,,«Ç·Å,1 tab. daily.Pause for at least 1 week after each 21-day regimen. Dose may be reduced to 1 tab every other day.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
EFLUC,Fluorometholone,Flucason oph soln 0.02%¡A 5mL,TOPH,,¾AÀ³¯g: Acute & chronic iritis¡A iridocyclitis¡A scleritis¡A episcleritis¡A conjunctivitis¡A keratitis¡A resistant ocular allergy & inflammation following surgery °Æ§@¥Î: Glaucoma with optic nerve damage¡A visual acuity or field defects¡A raised intraocular pressure¡A secondary infection (persistent corneal ulceration¡A possibly fungal invasion)¡A perforation of globe¡A posterior subcapsular cataract formation ¸T§Ò: Acute superficial herpes simplex keratitis¡A fungal diseases of ocular structure; vaccinia¡A varicella & other viral diseases of the cornea & conjunctiva¡A eye TB,,«Ç·Å,Instill 1-2 drops bid-qid,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EHUM,Humapen Luxura,Humapen Luxura,ZOTH,,,,,,,,,,,,,,,,,,,
INEX,Esomeprazole,Nexium °w¾¯ 40mg,ALIM,,¾AÀ³¯g:As an alternative to oral therapy when oral intake is not appropriate for GERD in patients with esophagitis &/or severe symptoms of reflux & for healing of gastric ulcers associated with NSAID therapy. °Æ§@¥Î:Headache¡A abdominal pain¡A diarrhea¡A flatulence¡A nausea/vomiting¡A constipation. Uncommonly¡A dermatitis¡A pruritus¡A urticaria¡A dizziness¡A dry mouth¡A blurred vision. Rarely hypersensitivity reactions¡A elevation of liver enzymes¡A Steven-Johnson syndrome¡A erythema multiforme¡A myalgia. Dermatologic: Injection site reaction (1.7%) Gastrointestinal: Abdominal pain (5.8%%)¡A Constipation (2.5%)¡A Diarrhea (3.9%)¡A Flatulence (10.3%)¡A Indigestion (6.4%)¡A Nausea (6.4%)¡A Xerostomia (3.9%) Neurologic: Dizziness (2.5%)¡A Headache (10.9%) ¸T§Ò:Hypersensitivity to benzimidadazoles.,,,20-40 mg IV once daily over > 3 min or infusion over 10-30 min. Reflux esophagitis 40 mg once daily. Symptomatic treatment for reflux disease 20 mg once daily.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¨}¤§¯f±w¨ä¨Ï¥Î³Ì°ª¶q¤£À³¶W¹L20 mg,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IV;IVD;IVP;,IV:5 mL N/S,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,ª`®g³t²v > 3 min (40mg),IV infusion¡A pediatrics: Give as IV infusion over 10 to 30 minutes. 80 mg loading dose¡A adults: Give IV infusion over 30 minutes.,½Õ°t§¹¦¨¤§·»²Gªº­°¸Ñ¹ï©ópH¦³°ª«×¨Ì¿à©Ê¡A¦]¦¹¥»«~¥u¯à¥H0.9%´â¤Æ¶u·»²G½Õ°t«á¥Î©óÀR¯ßª`®g¡C½Õ°t§¹¦¨¤§·»²G¤£À³¦b¦P¤@ÀR¯ß¿é²GºÞ¤¤¡A»P¨ä¥LÃÄ«~²V¦X©Î¦P®Éµ¹ÃÄ¡C ½Õ°t§¹¦¨¤§·»²GÀ³»P¨ä¥LÃÄ«~¤À¶}µ¹ÃÄ¡C
OFIN,Loratadine + Pseudoephedrine,Finska-LP SR 10/240mg,HIMM,,¾AÀ³¯g:Relief of symptoms associated with allergic rhinitis & common cold. °Æ§@¥Î:Insomnia¡A dry mouth¡A headache¡A drowsiness. ¸T§Ò:Patients receiving MAOI therapy or within 14 days of discontinuing such treatment. Narrow-angle glaucoma¡A urinary retention¡A severe hypertension¡A severe coronary artery disease¡A hyperthyroidism.,,«Ç·Å,Adult & children > 12 years 1 tab qd.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ISYN,Pneumococcal Vaccine Polyvalent,Synflorix (10»ùªÍª¢¬Ì­]) 0.5mL/dose,HIMM,,¾AÀ³¯g:active immunization of infants and children from 6 weeks up to 2 years of age against Streptococcus pneumoniae serotypes 1¡A 4¡A 5¡A 6B¡A 7F¡A 9V¡A 14¡A 18C¡A 19F and 23F and invasive disease caused by these serotypes (including sepsis¡A meningitis¡A bacteraemic pneumonia¡A pleural empyema and bacteraemia). °Æ§@¥Î: Very common (¡Ù 1/10) drowsiness¡A appetite loss¡A pain¡A redness¡A swelling at the injection site¡A fever (¡Ù 38¢XC rectally)¡Airritability -------------------------------------------------------------------------------------------------------------- Common (¡Ù 1/100 to < 1/10) injection site induration¡A fever (> 39¢XC rectally) -------------------------------------------------------------------------------------------------------------- Uncommon (¡Ù 1/1¡A000 to < 1/100) diarrhoea¡A vomiting¡A injection site haematoma¡A haemorrhage and nodule¡A fever (> 40¢XC rectally)*¡A crying abnormal¡A apnoea in very premature infants (? 28 weeks of gestation) -------------------------------------------------------------------------------------------------------------- Rare (¡Ù 1/10¡A000 to < 1/1¡A000) febrile and non-febrile convulsions¡A rash¡A urticaria¡A allergic reactions (such as allergic dermatitis¡A atopic dermatitis¡A eczema),,2-8¢J,Infants from 6 weeks to 6 months of age: The primary vaccination schedule consists of three doses of 0.5 mL with an interval of at least 1 month between doses A booster dose is recommended at least 6 months after the last priming dose and preferably between 12 and 18 months of age. ----------------------------------------------------------------------------------------- Infants aged 7-11 months: The vaccination schedule consists of two doses of 0.5 mL with an interval of at least 1 month between doses. A third dose is recommended in the second year of life with an interval of at least 2 months between doses. ------------------------------------------------------------------------------------------ Children aged 12-23 months: The vaccination schedule consists of two doses of 0.5 mL with an interval of at least 2 months between doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OPLE,Felodipine,Plendil 5mg,CAVS,Hypertension¡A angina pectoris.,Pregnancy¡A uncompensated heart failure¡A acute MI¡A unstable angina pectoris.,Flushing¡A headache¡A palpitations¡A dizziness¡A fatigue¡A peripheral oedema. Cardiovascular: Peripheral edema (2% to 17.4% ) Dermatologic: Flushing (3.9% to 6.9% ) Gastrointestinal: Indigestion (0.5% to 3.9% ) Neurologic: Headache (10.6% to 14.7% ) Respiratory: Upper respiratory infection (0.7% to 3.9% ),30¢J¥H¤U,HTN: Initially 5 mg QD. Maintenance: 5-10 mg QD. Angina pectoris :5 mg QD¡A may increase to 10 mg QD. Elderly: Initially 2.5 mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OSINM,Carbidopa + Levodopa,Sinemet 25/100mg,CNEU,Symptomatic treatment of Parkinsonism.,Narrow-angle glaucoma. Undiagnosed skin lesions or history of melanoma. Hypersensitivity to any component of this product.,Dyskinesia including choreiform¡A dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% ),30¢J¥H¤U¡AÁ×¥ú¡A¨¾¼é,Initial¡A 1 tablet TID. Maximum : 8 tablets/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,Levodopa: Human Data Suggest Low Risk Carbidopa: Limited Human Data¡XAnimal Data Suggest Risk [¥é³æ] ÁöµMSINEMET¥Î©ó¤HÃþ¥¥°ü¤§§@¥Î¥¼ª¾¡AµMlevodopacarbidopa-levodopaªº½Æ¤è»s¾¯§¡·|¤Þ°_¨ß¤l¤ºÅ¦¤Î°©Àfªº·î§Î¡C¦]¦¹¡A¹ï¥i¯àÃh¥¥¤§°ü¤k¡A¶·¦Ò¼{¸U¤@¦bªA¥ÎSINEMET´Á¶¡Ãh¥¥¡A«h­n¿Å¶q¥»«~©Ò±a¨Óªº¦n³B¬O§_¶W¹L¨ä©Ò¥i¯à±a¨Óªº¦MÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Levodopa: Limited Human Data¡XProbably Compatible Carbidopa: No Human Data¡XProbably Compatible [¥é³æ] ¥Ø«e¨Ã¤£ª¾¹DCarbidopa©Îlevodopa¬O§_·|±Æ¦Ü¤H¨Å¤¤¡C´¿³ø¾É¦b¤@­Ó¬ã¨s¤¤¡A¦³¤@¦ì±w¬fª÷´Ë¤ó¯g¤§­÷¨Å°ü¤k¡Alevodopa±Æ¤J¨ä¨Å¥Ä¤¤¡C¦]¬°«Ü¦hÃÄª«§¡·|±Æ¤J¤H¨Å¡A¥B¦]¬°¥»«~¥i¯à·|¹ïÀ¦¥®¨à³y¦¨ÄY­«¶Ë®`¡A¦]¦¹¹ï©ó­÷¨Å°ü¤k¶·¦Ò¼{¥»«~¹ï¥À¿Ëªº­«­n©Ê¨Ó¨M©w¬O§_°±¤î±Â¨Å©Î°±¤îªA¥ÎSINEMET¡C,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¿õ¾¯¤Wªº¨è²ª¡A¬O«K©ó­é¥b§]Ã`¡A¦Ó«D¥Î©ó¤À¦¨¬Ûµ¥ªº¾¯¶q¡C¿õ¾¯¸g­é¥b«á¡AÀ³ªA¥Î§¹¾ã¾¯¶q¡C
OSON,Nicametate,Songora 50mg,CAVS,Peripheral vascular circulation disorders & cerebral insufficiency.,Arterial bleeding.,GI disturbances¡A anorexia¡A palpitations¡A cutaneous flushing¡A heat sensation¡A tiredness¡A rarely dizziness¡A vertigo¡A headache. Rashes¡A dry skin¡A pruritus¡A hyperpigmentation. Amblyopia¡A jaundice¡A decreased glucose tolerance¡A hyperglycaemia¡A hyperuricaemia.,«Ç·ÅÃÄ«~¡AÁ×¥ú«O¦s,50-100 mg TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,
OTRIL,Oxcarbazepine,Trileptal 300mg,CNEU,Monotherapy & adjunctive treatment of partial seizures in adult. Adjunctive treatment of partial seizure in children <1 month.,Hypersensitivity.,Frequent: Fatigue¡A dizziness¡A headache¡A somnolence¡A nausea¡A vomiting¡A diplopia. Common: Asthenia¡A agitation¡A amnesia¡A apathy¡A ataxia¡A impaired concentration¡A confusion¡A depression¡A emotional lability¡A nystagmus¡A tremor¡A constipation¡A diarrhea¡A abdominal pain¡A asymptomatic hyponatremia¡A acne¡A alopecia¡A rash¡A vertigo¡A vision disorders. Uncommon: Leucopenia¡A increase in liver enzyme¡A urticaria. Very rare: Angioedema¡A multi-organ hypersensitivity disorders¡A arrhythmia¡A thrombocytopenia¡A hepatitis¡A symptomatic hyponatremia¡A Stevens-Johnson syndrome¡A SLE.,30¢J¥H¤U,Adult 600-2400 mg/day in 2 divided doses. Children Initially 8-10 mg/kg/day in 2 divided doses. Dosage may be increased according to response in steps of up to 10 mg/kg daily at weekly intervals. maximum: 46 mg/kg daily in divided doses.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OTAR,Erlotinib,Tarceva 150mg,RACA,Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least 1 prior chemotherapy regimen.,Hypersensitivity to any component of the formulation.,Rash¡A diarrhea¡A anorexia¡A fatigue¡A dyspnea¡A cough¡A nausea¡A vomiting¡A stomatitis¡A pruritus¡A dry skin¡A conjunctivitis¡A keratoconjunctivitis sicca¡A abdominal pain. Rarely¡A elevated liver enzymes¡A GI bleeding (in association with concomitant administration of warfarin or NSAIDs). Cardiovascular: Edema (37% ) Dermatologic: Alopecia (14% )¡A Pruritus (7.4% to 13% )¡A Rash¡A Any grade (49.2% to 75% ) Endocrine metabolic: Weight decreased (3.9% to 39% ) Gastrointestinal: Abdominal pain (11% to 46% )¡A Diarrhea¡A Any grade (20.3% to 54% )¡A Flatulence (13% )¡A Indigestion (17% )¡A Inflammatory disease of mucous membrane (17% to 22% )¡A Loss of appetite (9.2% to 52% )¡A Nausea (33% to 60% )¡A Vomiting (23% to 42% ) Hepatic: Hyperbilirubinemia¡A Increased liver enzymes Immunologic: Infectious disease (39% ) Musculoskeletal: Bone pain (25% )¡A Myalgia (21% ) Neurologic: Headache (15% ) Ophthalmic: Conjunctivitis (12% )¡A Keratoconjunctivitis sicca (12% ) Psychiatric: Anxiety (13% )¡A Depression (19% ) Respiratory: Cough (16% to 33% )¡A Dyspnea (24% to 41% ) Other: Fatigue (9% to 73% )¡A Fever (36% ),½ÐÀx¦s©ó30¢Jªº·Å«×¤U,[Non¡Vsmall cell lung cancer (NSCLC) (as first-line therapy¡A maintenance treatment¡A or for progressive disease)] 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.,»Ý½Õ¾ã¾¯¶q,Total bilirubin >3 times ULN: Use extreme caution. The following adjustments have also been studied: A reduced starting dose (75 mg once daily) has been recommended in patients with hepatic dysfunction (AST ?3 times ULN or direct bilirubin 1 to 7 mg/dL)¡A with individualized dosage escalation if tolerated; another study determined that pharmacokinetic and safety profiles were similar between patients with normal hepatic function and moderate hepatic impairment.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
EART2,Carteolol,Arteoptic 2% oph sol 5mL,TOPH,,¾AÀ³¯g: Glaucoma & ocular hypertension. °Æ§@¥Î¡GLocal irritation¡A visual disturbances¡A foreign body sensation¡A orbital fat¡A conjunctivitis¡A blepharitis¡A photophobia. Bradycardia. Headache¡A discomfort¡A fatigue¡A dizziness. Asthma¡A syncope¡A myasthenia gravis. ¸T§Ò: Unsatisfactorily controlled cardiac insufficiency; risk of bronchial asthma & bronchospasm; sinus bradycardia; AV block (II & III); cardiogenic shock; right ventricular insufficiency due to pulmonary hypertension & CHF.,,«Ç·Å,1 gtt qd-bid.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OULT,Tramadol + Acetaminophen,Ultracet 37.5/325mg,CNEU,Management of moderate to severe pain,Acute intoxication with alcohol¡A hypnotics¡A narcotics¡A centrally acting analgesics¡A opioids or psychotropic drugs.,Nausea¡A dizziness¡A somnolence¡A asthenia¡A fatigue¡A hot flushes¡A headache¡A tremor¡A GI disturbances¡A anorexia¡A anxiety¡A confusion¡A euphoria¡A insomnia¡A nervousness¡A pruritus¡A rash¡A increased sweating.,¶J©ó25¢XC¥H¤U,Adult & children > 16 years 1-2 TAB every 4-6 hr. Maximum: 8 TAB /day.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ¯f¤H¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OGEM,Gemfibrozil,Gemnpid 300mg,CAVS,,¾AÀ³¯g: Dyslipidemia type IIa¡A IIb¡A III¡A IV & V. Reduces risk of CHD. °Æ§@¥Î: GI upset¡A rash¡A pruritus¡A headache¡A dizziness¡A hematopoietic disorders. Gastrointestinal: Abdominal pain (9.8% )¡A Acute appendicitis (1.2% )¡A Indigestion (19.6% .) ¸T§Ò: Gallbladder disease¡A hepatic¡A renal dysfunction including primary cirrhosis.,,«Ç·Å,1200 mg daily in 2 divided doses.(Should be taken on an empty stomach ),,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OHARD,Tamsulosin,Harnalidge D 0.2mg,SGU,,¾AÀ³¯g: Urinary dysfunction caused by benign prostatic hyperplasia. °Æ§@¥Î: Dizziness¡A GI discomfort¡A allergy¡A impaired hepatic function¡A nasal congestion¡A peripheral edema¡A asthenia. Immunologic: Infectious disease (9% to 10.8% ) Musculoskeletal: Backache (7% to 8.3% ) Neurologic: Asthenia (7.8% to 8.5% )¡A Dizziness (14.9% to 17.1% )¡A Headache (19.3% to 21.1% )¡A Insomnia (1.4% to 2.4% )¡A Somnolence (3% to 4.3% ) Reproductive: Abnormal ejaculation (8.4% to 18.1% ) Respiratory: Rhinitis (13.1% to 17.9% ),,«Ç·Å,0.2mg once daily. May increase dose to 0.4mg once daily. (Micromedex 2.0¡A«D½Ã¥Í¸p¥é³æ«ØÄ³¾¯¶q) Benign prostatic hyperplasia: initial¡A 0.4 mg ORALLY once daily; if no response after 2 to 4 weeks¡A may increase dose to 0.8 mg ORALLY once daily,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSERO,Paroxetine,Seroxat 20mg,CNEU,For adults: Treatment of symptoms and prevention of recurrence of major depressive disorder. Treatment of symptoms of obsessive-compulsive disorder. Treatment of symptoms and prevention of recurrence of panic disorder. Treatment of social anxiety disorder (social phobia). Treatment of symptoms and prevention of recurrence of generalized anxiety disorder. Treatment of posttraumatic stress disorder (PTSD).,Hypersensitivity to paroxetine or any component of the product. Concomitant use with an MAOI¡A including linezolid or IV methylene blue¡A or use of paroxetine hydrochloride within 14 days of discontinuing an MAOI used to treat psychiatric disorders¡A or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing paroxetine hydrochloride; increased risk of serotonin syndrome. Concomitant use with drugs that prolong the QT interval and are also metabolized by CYP450 2D6 (such as thioridazine or pimozide).,[Common] Palpitations (2-3% )¡A Vasodilatation (1-5% )¡A Diaphoresis (5-14% )¡A Constipation (2-16% )¡A Diarrhea (6-18% )¡A Loss of appetite (1-12% )¡A Nausea (4-26% )¡A Xerostomia (1-18% )¡A Asthenia (12-22% )¡A Dizziness (6-14% )¡A Headache (17-27% )¡A Insomnia (7-24% )¡A Somnolence (3-24%)¡A Tremor (4-11% )¡A Blurred vision (Up to 5% )¡A Abnormal ejaculation (13-28% )¡A Erectile dysfunction (2-10% )¡A Orgasm disorder (2-10% )¡A Reduced libido (0-15%)¡A Yawning (2-4% ) [Serious] Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hyponatremia (<0.1% ; elderly¡A 12% )¡A Hemorrhage¡A Acute hepatitis¡A Seizure (0.1% )¡A Depression¡A Exacerbation (1-5% )¡A Mania (0.1-1% )¡A Suicidal thoughts¡A Suicide¡A Serotonin syndrome¡A Withdrawal symptom (11-66% ),¤£¶W¹L30¢XC,Adults: May increase/reduce dosage by 10mg per week if needed. Elderly: Max: 40mg/day. -Major Depression: 20mg once daily. Max: 50mg/day. -Obsessive-Compulsive Disorder (OCD): 20-40mg once daily. Max: 60mg/day. -Panic disorder: 10-40mg once daily. Max: 50mg/day. -Social Anxiety Disorder (Social Phobia): 20mg once daily. Max: 50mg/day. -Generalized Anxiety Disorder: 20mg once daily. Max: 50mg/day. -Post-Traumatic Stress Disorder (PTSD): 20mg once daily. Max: 50mg/day.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ÄY­«¨xÅ¦·l®`¤§¯f¤H¡A«ØÄ³¾¯¶q¬°¨C¤é20²@§J¡C­Y¶·¼W¶q¡AÀ³«]­­©ó¾¯¶q½d³ò¤ºªº§C­­¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,[¥é³æ] °Êª«¬ã¨s¨Ã¥¼Åã¥Ü¦³¥ô¦óªº­P·î©Ê©Î¿ï¾Ü©Êªº­L¨à¬r©Ê¡C °w¹ï¦bÃh¥¥«e¤T­Ó¤ë¥À¿Ë¨Ï¥Î§Ü¼~Æ{¾¯«á¨äÃh¥¥¤§µ²ªG¤§¬y¦æ¾Ç³ø§i«ü¥X¡A·|¼W¥[¥ý¤Ñ©Ê·î§Îªº­·ÀI¡A ¯S§O¬O¤ß¦åºÞ¤è­±(¨Ò¦p¤ß«Ç»P¤ß©Ð¹j½¤¯Ê³´)¡A»Pparoxetineªº¨Ï¥Î¦³Ãö¡C ¼Æ¾Ú«ü¥X¥À¿Ë¨Ï¥Îparoxetine³y¦¨À¦¨à¤ß¦åºÞ¯Ê³´ªº­·ÀI¬ù¬O1/50¡A¤@¯ë±Ú¸sÀ¦¨à¬O1/100¡C ¹ï©óÃh¥¥©Î¬O­pµeÃh¥¥ªº°ü¤k¡AÂå®v¥²¶·¦Ò¼{´À¥NªvÀøªº¿ï¾Ü¤è®×¡A¥u¯à¦b¼ç¦b§Q¯q¤j©ó¼ç¦b­·ÀI®É¤~¯à¨Ï¥Î¡C ¦³¨Ç³ø§i¬OÃö©ó¥¥°ü¨Ï¥Îparoxetine©Î¨ä¥LSSRIs¦Ó¦³¦­²£±¡§Î¡A¦ý©|¥¼«Ø¥ß¨ä¦]ªGÃö«Y¡C ¦]¦¹¡A¤£À³©óÃh¥¥´Á¶¡¨Ï¥Î¡A°£«D¨ä¼ç¦b®Ä¯q¶W¶V¨ä¥i¯àªº¦MÀI©Ê¡C Æ[¹î©Ê¬ã¨s¼Æ¾Ú«ü¥X©ó¥Í²£«e¤@­Ó¤ë¼ÉÅS©óSSRI¤ÎSNRIÃþÃÄ«~·|¼W¥[²£«á¥X¦å­·ÀI(¤p©ó2­¿)¡C ´¿¦³³ø§i«ü¥XÀ¦¨à·|¦]¬°¦ÜÃh¥¥ªº²Ä¤T´Á¤´¨Ï¥ÎSEROXAT©Î¬O¨ä¥LSSRIs¦Ó²£¥Í¨Öµo¯g¡A ¥BÃÄª«ªvÀøªº¦]ªGÃö«Y¤´¥¼«Ø¥ß¡A¬G¥À¿Ë«ùÄò¨Ï¥Î¨ìÃh¥¥«á´Á«h¥²¶·Æ[¹îÀ¦¨à±¡§Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¦³¤Ö¶qªºparoxetine·|¤Àªc¨ì¨Å¥Ä¡C¦b¤wµoªíªº¬ã¨s¤¤¡A¥À¨ÅÁý¾iªºÀ¦¨à¡A ¦å¿@«×¬O°»´ú¤£¨ìªº(<2 ng/mL)©Î«D±`§C(<4 ng/mL)¡C¦b³o¨ÇÀ¦¨à¨ÃµLÃÄª«§@¥Îªº¼xª¬¡C µM¦Ó¤´¤£«ØÄ³¦b­÷¨Å´Á¶¡¨Ï¥ÎSEROXAT¡C°£«DÃÒ©ú¦b¥À¿Ë¤§´Á«Ý§Q¯q¶W¹LÀ¦¨àªº¼ç¦b­·ÀI¡C,AC;AC15;PC;PO;WM;,,,,,
OSIB,Flunarizine,Sibelium (Flunarizine) 5mg,CAVS,,¾AÀ³¯g:¥Dªväú¤ß¡B¯t·w¡B·w°Ê¯f¡B¥½±é¦åºÞ´`Àô»ÙÃªµ¥(A028955100)(B022622100) CI: History of depressive illness¡A history of extrapyramidal syndrome or Parkinsonism.,,RT,1 cap bid¡A 2 cap qn.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OSLOF,Dried FeSO4 + Folic Acid,Slow-Fe Folic160mg/400mcg,NUTR,,During the second and third trimesters of pregnancy for prophylaxis of iron and folic acid deficiency. Prevent the occurrence of megaloblastic anaemia due to folate deficiency.,,,1~2 tab daily.,,,,,,,,,,,,,,
OSLOK,Potassium Chloride,Slow-K 600mg/8mEq,NUTR,,¾AÀ³¯g: Hypokalemia. °Æ§@¥Î: GI upsets. ¸T§Ò: Hyperkalemia; marked renal failure; concomitant treatment with K-sparing diuretics & patients in whom there is cause for arrest or delay in tab passage through the GI.,,«Ç·Å,Prophylaxis: 2-3 tab daily. Treatment: 5-6 tab¡A up to 12 tab daily.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OSMA,Captopril,Smarten 25mg,CAVS,,,,,,,,,,,,,,,,,,,
OSOR,Isosorbide Dinitrate,Sorbitrate 10mg,CAVS,,Angina pectoris.,,,Oral: 2.5-10 mg tid-qid¡A ac.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OSPAE,Sulfacarbamide + Phenazopyridine,SPASMO-Euvernil 500/50,QANB,,¾AÀ³¯g: Treatment of UTI eg cystitis¡A prostatitis¡A urethritis. °Æ§@¥Î: GI disturbances¡A hypersensitivity reactions¡A blood disorders¡A hypoglycaemia¡A hypothyroidism¡A neurological reactions¡A kernicterus in premature neonates¡A abnormal coloration of body tissues or fluids. ¸T§Ò: Impaired renal function or severe hepatitis¡A blood disorders. Hypersensitivity.,,«Ç·Å,Adult & school children 2 tab tid. Pre-school children 1 tab tid. Max: 10 tab daily. Initial infection 2 tab tid for 10 days.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OSTE,Trifluoperazine,Stelazine 5mg,CNEU,,Symptomatic treatment of psychotic disorders¡A short-term management of nonpsychotic anxiety.,,,Adult: Initially 0.5-1 tab bid. Maintenance: 3-4 tab/day. Max: 6 tab/day.,,,,,,,,,,,,,,
OSUL,Sulindac,Sulindec 200mg,CNEU,,¾AÀ³¯g: Osteoarthritis¡A RA¡A ankylosing spondylitis¡A acute painfull shoulder¡A acute gouty arthritis. °Æ§@¥Î:GI disturbances¡A headache¡A dizziness. GI ulceration & bleeding. Depression¡A drowsiness¡A tinnitus¡A confusion¡A lightheadedness¡A insomnia¡A psychiatric disturbances¡A syncope¡A convulsions¡A coma¡A peripheral neuropathy¡A blurred vision & other ocular effects. Edema¡A weight gain¡A hypertension¡A hematuria¡A skin rashes¡A stomatitis¡A alopecia. Hypersensitivity reactions. Blood disorders. Hepatitis¡A jaundice or renal failure. ¸T§Ò:Peptic ulcer. History of GI lesion. Sensitivity to aspirin.,,«Ç·Å,Antirheumatic: 150-200 mg bid with meals¡A (max. 400 mg/day). Acute gout: 200 mg bid.,µL»Ý½Õ¾ã¾¯¶q,monitor patient closely and reduce dosage if necessary,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IVIN1,Vincristine,Vincristine inj 1mg/1mL,RACA,Acute leukemia & for Hodgkin's disease & non-Hodgkin's malignant lymphomas¡A rhabdomyosarcoma¡A neuroblastoma. Wilms' tumor¡A reticulum cell sarcoma¡A lymphosarcoma.,Demyelinating form of Charcot-Marie-Tooth syndrome; avoid use in patients receiving radiation therapy through ports that include the liver.,Neurotoxicity¡A hypertension & hypotension¡A ataxia¡A foot drop¡A depression¡A agitation¡A insomnia¡A hallucinations¡A episodes of altered consciousness¡A anemia¡A thrombocytopenia¡A constipation¡A paralytic ileus¡A hyperuricemia¡A bladder atony¡A alopecia¡A hypersecretion of ADH¡A fever & headache¡A abnormal Valsalva response¡A impotence. Rarely¡A allergic-type reactions such as anaphylaxis.,2-8¢JÁ×¥ú,(Micromedex) [Acute leukemia] 1.4-2 mg/m2/week IVD. [AIDS-related Kaposi's sarcoma] 0.03-1.4 mg/m2/week. Maximum: 2 mg/m2. Dosing and frequency may vary by protocol and/or treatment phase.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à²§±`©ÎÁx¬õ¯À°ª©ó3mg/mlªÌ¾¯¶qÀ³´î¥b,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest high risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,
OSTU,Cinnarizine,Stugeron 25mg,CAVS,,¾AÀ³¯g¡Gäú¤ß¡B¯t·w¡B°g¸ô»ÙÃª¡B·w°Ê¯f¡B¥½±é¦åºÞ´`Àô»ÙÃª¡C °Æ§@¥Î¡GExtrapyramidal symptoms sometimes associated with severe depression. Drowsiness¡A headache¡A GI upsets¡A unsteadiness¡A headache; rarely skin and hypersensitivity reactions¡A dry mouth¡A blurred vision¡A urinary difficulty or retention¡A constipation and increased gastric reflux¡A fatigue. Hypolipidaemic effect. ¸T§Ò¡GProven hypersensitivity to the drug. Parkinson's disease. Childn and neonates.,,«Ç·Å,PO Peripheral vascular diseases 75 mg 2-3 times/day. Motion sickness 30 mg 2 hr before travel and 15 mg 8 hrly during travel if needed. Cerebrovascular disorders 75 mg 1-3 times/day. Vertigo and vestibular disorders 30 mg 3 times/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OAVO,Dutasteride,Avodart 0.5mg,SGU,,¾AÀ³¯g:Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms¡A reduce the risk of acute urinary retention & reduce the need for BPH-related surgery. °Æ§@¥Î:Impotence¡A decreased libido¡A ejaculation disorder¡A gynecomastia. Endocrine & metabolic: Impotence (1% to 5%)¡A libido decreased (?3%)¡A ejaculation disorders (?1%)¡A gynecomastia (including breast tenderness¡A breast enlargement; ?1%) ¸T§Ò:Use in women & children.,,«Ç·Å,Benign prostatic hyperplasia: 0.5 mg ORALLY once a day,,,,¤£¥i¨Ï¥Î,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OTRAM,Tramadol,Tramtor 50mg,CNEU,,¾AÀ³¯g: Moderate to severe acute or chronic pain. °Æ§@¥Î: Nausea¡A vomiting¡A constipation¡A drowsiness & confusion. Difficulty in micturition & biliary spasm. Dry mouth¡A sweating¡A facial flushing¡A vertigo¡A bradycardia¡A palpitations¡A orthostatic hypotension¡A hypothermia¡A restlessness¡A changes of mood¡A hallucinations¡A miosis. Raised intracranial pressure. Muscle rigidity in high doses. Dermatologic: Flushing (1% to 15.8% )¡A Pruritus (3% to 11.9% ) Gastrointestinal: Constipation (10% to 29.7% )¡A Nausea (13% to 26.2% )¡A Vomiting (3% to 9.4% )¡A Xerostomia (1% to 9.8% ) Neurologic: Dizziness (7% to 28.2% )¡A Headache (3% to 15.8% )¡A Insomnia (1% to 10.9% )¡A Somnolence (4% to 20.3% ) ¸T§Ò: Acute alcoholism¡A head injuries & conditions in which intraocular pressure is raised. Attack of bronchial asthma or in heart failure secondary to lung disease.,,«Ç·Å,safety and efficacy <16 y/o have not been established Usual dose: 50-100mg q 4-6 h¡A max 400mg/day Dosage in renal impairment: Clcr< 30 ml/min¡A increase dosing interval to 12 h ; max. 200 mg/day dose for patients with cirrhosis: 50 mg q 12 h Thomson: Infant risk cannot be ruled out,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OSIN1,Montelukast,SINGULAIR 10mg,ERSP,SINGULAIR is indicated in adult & pediatric patients 6 months of age & older for the prophylaxis & chronic treatment of asthma¡A including the prevention of day- & nighttime symptoms¡A the treatment of aspirin-sensitive asthmatic patients¡A & the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adults & pediatric patients 2 years of age & older for the relief of day- & nighttime symptoms of seasonal allergic rhinitis.,Hypersensitivity to any component of Singulair.,Abdominal pain¡A headache¡A thirst¡A diarrhea¡A hyperkinesia¡A asthma¡A eczematous dermatitis¡A rash. Neurologic: Headache (Adult and adolescent; 18.4%; pediatric¡A 2% and greater ),30¢J¥H¤U¡AÁ×§K¼éÀã»P¥ú½u·Ó®g,Should be taken once daily. For asthma¡A the dose should be taken in the evening. For seasonal allergic rhinitis¡A the time of administration may be individualized. Patients with both asthma & seasonal allergic rhinitis should take only 1 TAB daily in the evening. Asthma and/or seasonal allergic rhinitis- Age > or = 15 years: 10 mg QD. Age 6-14 years: One 5 mg chewable TAB QD. Age 2-5 years: One 4 mg chewable TAB QD or one packet of 4 mg oral granules QD. Age 6 months-2 years with asthma: One packet of 4 mg oral granules QD.,»Ý½Õ¾ã¾¯¶q,Mild-to-moderate impairment: No dosage adjustment necessary. Severe impairment: No dosage adjustment provided in manufacturer¡¦s labeling; has not been studied.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OZAN,Lercanidipine,Zanidip 10mg,CAVS,Treatment of essential hypertension.,Known sensitivity to dihydropyridines. Pregnancy & lactation.,Flushing¡A peripheral edema¡A palpitation¡A headache¡A dizziness.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,HTN: initial 10mg QD¡A May increase to 20 mg.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¤§¯f±w¸T¤î¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨S¦³ lercanidipine ¥Î©óÃh¥¥¤k©Êªº¬ÛÃö¸ê®Æ¡C µLÃÒ¾ÚÅã¥Ü¹ï°Êª«¦³­P·î­L§@¥Î¡C ¦ý¹L¥h´¿¦³¨ä¥L dihydropyridine Ãþ¤Æ¦Xª«¤¤Æ[¹î¨ì­P·î­L§@¥Î¡A ¬G lercanidipine ¤£À³¥Î©óÃh¥¥´Á¶¡¥H¤Î¥¼¹ê¬IÁ×¥¥ªº¨ã¥Í¨|¯à¤O¤k©Ê¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¤£²M·¡ lercanidipine ¥NÁÂª«¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡C ¦]µLªk±Æ°£¹ï·s¥Í¨à/À¦¨à³y¦¨ªº­·ÀI¡A­÷Áý¥À¨Å´Á¶¡¤£¥i¨Ï¥Î lercanidipine¡C,AC;PO;,,,,,¹L¥h¦b¨Ï¥Î lercanidipine ®É¡A´¿¦b¸¡½¤³zªR¯f¤H¨­¤W¥X²{²V¿Bªº¸¡½¤³zªR¬y¥X²G¡C¦¹²V¿B²{¶H»F¦]©ó¸¡½¤³zªR¬y¥X²G¤¤¸û°ªªº¤T»Ä¥Ìªoà­¿@«×¡CÁöµM¾÷¨î¤£©ú¡A¦ý¦¹²V¿B²{¶H©¹©¹¦b°±¥Îlercanidipne «á¨³³t®ø¥¢¡C³o¬O¤@­ÓÀ³¿ë»{ªº­«­n¬Û¦ñ²{¶H¡A¦]¬°¦³¥i¯à±N²V¿Bªº¸¡½¤³zªR¬y¥X²G»~»{¬°·P¬V©Ê¸¡½¤ª¢¡A¶i¦Ó³y¦¨¤£¥²­nªº¦í°|¤Î¸gÅç©Ê§Ü¥Í¯À¬I¥Î¡C
ELIDP,Lidocaine,Lidopat patch 5% (3¤ù/¥]),ZANE,Relief of post-herpetic neuralgia.,Known history of sensitivity to local anesth of the amide type. Avoid in cardiac disease patients: 2nd & 3rd degree AV block (without pacemaker)¡A severe SA block (without pacemaker)¡A current administration of Class I antiarrhythmic agents (quinidine¡A flecainide¡A disopyramide¡A procainamide) to patients previously on amiodarone therapy¡A hypotension due to arrhythmia¡A bradycardia¡A ventricular arrhythmia.,Severe hepatic disease. Avoid application to broken or inflamed skin or contact with eyes.,30¢J¥H¤U,Apply to intact skin once daily up to 12 hours within a 24-hours period. Maximum: 3 patches/24 hours. When needed¡A the patches may be cut into smaller sizes with scissors prior to removal of the release liner.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,lactation: µL¸ê®Æ;¦ýlidocain ·|¶i¤J¨Å¥Ä,EXT;,,,,,
OLIC,Ticlopidine,Licodin 100mg,HEMT,To reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors or who have had a completed thrombotic stroke¡A & are intolerant or allergic to or who have failed aspirin therapy. As adjunctive therapy with aspirin to reduce incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation.,Hemorrhagic diathesis¡A GI ulcers¡A severe liver dysfunction¡A leukopenia.,GI disturbances; skin rashes. Blood dyscrasias; vertigo; jaundice.,«Ç·Å,200-500mg daily devided into 2-3 times.,»Ý½Õ¾ã¾¯¶q,Use with caution. Use is contraindicated in severe hepatic impairment.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IGW5A,Glucose,°tÃÄ¥ÎGlucose inj 5% 500mL,NUTR,,,,,°tÃÄ¥Î¤lÂå¥O,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,©óÀR¯ßª`®g®ÉÀ³ºÉ¥i¯à´îºC³t²v¡A¥H§K¤Þ°_ª`®g³¡¦ì¯kµh©ÎÀR¯ßª¢,,1.°ª±i²G©óÀR¯ßª`®g®ÉÀ³ºÉ¥i¯à´îºC³t²v¡A¥H§K¤Þ°_ª`®g³¡¦ì¯kµh©ÎÀR¯ßª¢¡C 2.¨C¤ä20mL§t¦³10g Dextrose¡C
OVGR,Sildenafil,Viagra 50mg (4 tablets/box),SGU,,¾AÀ³¯g: Treatment of erectile dysfunction. °Æ§@¥Î: Headache¡A flushing¡A dizziness¡A dyspepsia¡A nasal congestion¡A altered vision. ¸T§Ò: Patients who use nitric oxide donors or nitrates. Viagra should not be used in men for whom sexual activity is inadvisable (patients with severe CV disorders eg unstable angina or severe cardiac failure). Severe hepatic impairment¡A hypotension (< 90/50 mm Hg) or hypertension (> 170/100 mm Hg)¡A recent history of stroke or MI¡A known hereditary degenerative retinal disorders such as retinitis pigmentosa. Not indicated for women.,,«Ç·Å,Adult 50-100 mg once daily¡A taken approximately 25-60 min before sexual activity. Max: 100 mg once daily. Hepatic impairment (eg. cirrhosis¡A 80%)¡A severe renal impairment (creatinine clearance < 30 mL/min¡A 100%)¡A and concomitant of potent cytochrome P450 3A4 inhibitors; Starting dose of 25 mg should be considered¡A may increase to 50-100 mg based on efficacy & toleration. Max dosing frequency is once per day. Pulmonary hypertension:(°ª¤s¯g) 20mg tid or ¥»°| 50mg qd as needed,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OWIN1,Chlorpromazine,Winsumin 12.5mg,CNEU,,¾AÀ³¯g: Nausea¡A vomiting¡A spasm¡A severe insomnia¡A nightmares¡A frequent micturition¡A nocturnal enuresis¡A pain¡A visceral neurosis¡A premed for anaesth¡A artificial hibernation¡A nausea & vomiting in pregnancy¡A eclampsia¡A psychoneurosis. °Æ§@¥Î: Drowsiness; hypotension; dry mouth; blurred vision; constipation; palpitations. ¸T§Ò: Comatose patients & those with bone marrow depression¡A blood dyscrasias; Parkinsonism; severe cardiac insufficiency; renal or liver damage; marked cerebral atherosclerosis.,,«Ç·Å,Adult: Oral: Antiemetic: 10-25 mg q4-6h. Antipsychotic: 25-50 mg tid¡A (max. 1 g/day). Deep IM: 10-50 mg¡A repeated 3-4 times in 24 hrs if necessary. Child over 6 months. Oral: 0.5 mg/kg qid. IM: 0.5 mg/kg q6-8h as needed.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OXEN,Orlistat,Xenical 120mg (42 capsules/box),META,Obesity management.,Chronic malabsorption syndrome¡A cholestasis.,Common Gastrointestinal: Abdominal discomfort¡A Abdominal pain (Up to 41.1% )¡A Defecation urgency (For up to 1 year¡A 22.1% to 38.9% ; for up to 2 years¡A 2.8% )¡A Discharge from anus¡A Oily (2.3% to 11.9% )¡A Flatulence (For up to 1 year¡A 23.9% to 43.9%; for up to 2 years¡A 2.1% )¡A Increased frequency of defecation (2.6% to 10.8% )¡A Soiling¡A Oily (For up to 1 year¡A 26.6% to 37.2% ; for up to 2 years¡A 4.4% )¡A Steatorrhea (For up to 1 year¡A 20%; for up to 2 years¡A 5.5% ) Musculoskeletal: Backache (13.9% )¡A Pain in lower limb (10.8% ) Neurologic: Headache (30.6% ) Respiratory: Upper respiratory infection (26.1% to 38.1% ) Other: Influenza (39.7% ) Serious Hepatic: Liver failure Renal: Nephrolithiasis¡A oxalate¡A Oxalate nephropathy¡A with renal failure,25¢XC ¥H¤U,120 mg 3 times daily with each main meal containing fat (during or up to 1 hour after the meal).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ] ©ó°Êª«¥Í´Þ¹êÅç¤¤¨Ã¥¼µo²{orlistat¦³­F­L¬r©Ê©Î­P·î­L®ÄÀ³¡C ¦bµL°Êª«¤§­P·î­L®ÄÀ³¤U¡A©ó¤HÃþ¤¤¥ç¤£¹w´Á¦³­P·î­Lªº¤ÏÀ³¡C µM¦Ó¡A¦b¯Ê¤ÖÁ{§É¼Æ¾Ú¤U¡A¨Ã¤£«ØÄ³Ãh¥¥®ÉªA¥ÎXenical¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ©|µL¹ï orlistat ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤ªº¬ã¨s¡C­÷¨Å®É¤£À³ªA¥ÎXenical¡C,PC;PO;WM;,,,,,
ECH10,Chloral hydrate,Chloral hydrate 10%,CNEU,,¾AÀ³¯g: Insomnia¡ASedation °Æ§@¥Î: Gastric irritation¡A abdominal distention and flatulence¡A vertigo¡A ataxia¡A staggering gait¡A rashes¡A malaise¡A lightheadedness¡A headache¡A ketonuria¡A excitement¡A nightmares¡A delirium (especially in elderly)¡A eosinophilia¡A reduction in white blood cell count; dependence on prolonged use. ¸T§Ò: Hepatic or renal impairment¡A cardiac disease¡A hypersensitivity¡A porphyria¡A oesophagitis¡A gastritis. Pregnancy and lactation.,,,Chloral hydrate 10% = 100 mg/mL Dosing: Adult Sedation¡A anxiety: Oral: 250 mg 3 times/day Hypnotic: Oral: 500-1000 mg at bedtime or 30 minutes prior to procedure¡A not to exceed 2 g/24 hours Discontinuation: Withdraw gradually over 2 weeks if patient has been maintained on high doses for prolonged period of time. Do not stop drug abruptly; sudden withdrawal may result in delirium. Dosing: Pediatric Sedation¡A anxiety: Oral¡A rectal: 5-15 mg/kg/dose every 8 hours¡A maximum: 500 mg/dose Prior to EEG: Oral¡A rectal: 20-25 mg/kg/dose¡A 30-60 minutes prior to EEG; may repeat in 30 minutes to maximum of 100 mg/kg or 2 g total Hypnotic: Oral¡A rectal: 20-40 mg/kg/dose up to a maximum of 50 mg/kg/24 hours or 1 g/dose or 2 g/24 hours Conscious sedation: Oral: 50-75 mg/kg/dose 30-60 minutes prior to procedure; may repeat 30 minutes after initial dose if needed¡A to a total maximum dose of 120 mg/kg or 1 g total Discontinuation: Withdraw gradually over 2 weeks if patient has been maintained on high doses for prolonged period of time. Do not stop drug abruptly; sudden withdrawal may result in delirium.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EATR2,Atropine,Atropine 0.25%¡A 10mL,TOPH,,¾AÀ³¯g: Topical mydriatic & cycloplegic; uveitis. °Æ§@¥Î: Stinging¡A increased intraocular pressure¡A conjunctivitis. May precipitate glaucoma. ¸T§Ò: Closed- & narrow-angle glaucoma.,,2-8 ¢XC,1 gtt hs: for treatment of myopia. (0.1 %¡A 0.25 % and 0.5%) 1 gtt qid: for use in uveitis. (1.0 %),,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IGLY5,Glycerin + Fructose + NaCl,Glyceol 10% 500mL,CAVS,,¾AÀ³¯g: Treatment of increased intracranial pressure & intracranial edema¡A improvement of impaired consciousness & neurologic deficits in cerebral infarct¡A intracerebral & subarachnoid hemorrhages¡A head injury¡A brain tumor¡A cerebromeningitis. Post-op therapy following brain surgery; reduction of brain vol at time of brain surgery. °Æ§@¥Î: Lactic acidosis; hemoglobinuria; headache¡A thirst¡A nausea; hypernatremia. ¸T§Ò: Hereditary fructose intolerance.,,«Ç·Å,Adult 200-500 mL once or bid IV drip in 2-3 hr/500 mL.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IGON,Follitropin Alpha,Gonal-F 75 IU inj,HM,Anovulation including polycystic ovarian disease (PCOD) in women who have not responded to clomiphene citrate therapy. Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART).,Pregnancy & lactation¡A ovarian enlargement or cyst not due to polycystic ovarian disease¡A gynaecological haemorrhages of unknown aetiology¡A ovarian¡A uterine or mammary carcinoma¡A case of tumours of the hypothalamus & pituitary gland¡A hypersensitivity to follitropin £\¡A FSH or to any of the excipients. When an effective response cannot be obtained¡A such as primary ovarian failure¡A malformation of sexual organs incompatible with pregnancy¡A fibroid tumours of the uterus incompatible with pregnancy.,Local reactions at the inj site. Fever¡A arthralgia¡A pain in the lower abdominal region¡A nausea¡A vomiting¡A weight gain.,25¢J¥H¤UÁ×¥ú,Women with anovulation (including PCOD) 75-150 IU daily & increased by 37.5 or 75 IU at 7 or 14 day intervals. Maximum daily dose: 225 IU. When an optimal response is obtained a single injection of up to 5¡A000 IU¡A up to 10¡A000 IU hCG should be given 24-48 hr after the last Gonal-F injection. The patient is recommended to have coitus on the day of¡A & the day after hCG administration. Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other ART 150-225 IU of Gonal-F daily¡A commencing on day 2 or 3 of the cycle. When an optimal response is obtained a single injection of up to 5¡A000 IU¡A up to 10¡A000 IU hCG should be given 24-48 hour after the last Gonal-F injection. Dose adjustment should not exceed 450 IU daily. A single inj of up to 10¡A000 IU hCG is administered 24-48 hour after the last Gonal-f inj to induce final follicular maturation. Women with anovulation resulting from severe LH and FSH deficiency usually is starting as dose of GONAL-f 75-150 IU together with 75 IU of lutropin alfa¡A dose increased should be after 7-14 day intervals and preferablt by 37.5-75 IU. When an optimal response is obtained a single injection of up to 5¡A000 IU¡A up to 10¡A000 IU hCG should be given 24-48 hr after the last Gonal-F injection. Men with hypogonadotrophic hypogonadism should be given at a dose of 150 IU three times a week¡A together with hCG¡A for minimum of 4 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Micromedex: Fetal harm has been demonstrated. (MDX) [¥é³æ] Ãh¥¥´Á¶¡¤£¾A¥Î¡C¦³­­ªº¬ÛÃöÃh¥¥®×¨Ò¼Æ¾ÚÅã¥Ü(¤Ö©ó300­ÓÃh¥¥®×¨Ò )¡Afollitropin alfa ¨S¦³·î­L©Î­L¨à/·s¥Í¨à¬r©Ê¡C°Êª«¸ÕÅç¨Ã¥¼µo²{­P·î­L§@¥Î¡A¦ýÁ{§É¼Æ¾Ú¤´¤£¨¬¥H±Æ°£Ãh¥¥´Á¶¡¼ÉÅS©óGONAL-f ¦Ó³y¦¨­P·î­L§@¥Îªº¥i¯à©Ê¡C,Unknown ¨S¦³¸ê®Æ,Micromedex: Infant risk cannot be ruled out. [¥é³æ] GONAL-f ¤£¾A¦X±Â¨Å´Á¶¡¨Ï¥Î¡C¦b±Â¨Å´Á¶¡ prolactin ªº¤Àªc·|¹ï¨ë¿E±Æ§Z²£¥Í¤£¨}¹w«á¡C,SC;,,,,,
IGON1,Follitropin(r-hFSH),Gonal-F 150IU,HM,,,,,,,,,,,,,,,,,,,
IGS25,Dextrose + Sodium Chloride,2.5 % Dextrose in 0.45% NaCl 500mL,MSIV,Replacement & maintenance of fluid & electrolytes.,,,µL¯S§O«ü¥Ü,Individualized dosage. Each Dextrose 2.5% and Sodium chloride 0.45% solution mL contains: Dextrose 25mg¡A Sodium chloride 4.5mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,
IGS33,Dextrose + Sodium Chloride,5% Dextrose in 0.33% NaCl 500mL,MSIV,¬°¸²µå¿}»P­¹ÆQ¤ôª`®g²G¤Æ(A022666277),,,³±²DÁ×¥ú,Individualized dosage. Each Dextrose 5% and Sodium chloride 0.33% solution mL contains: Dextrose 50mg¡A Sodium chloride 3.3mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,
IGW10,Dextrose,10% Dextrose inj 500mL,MSIV,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,«Ç·ÅÁ×¥ú,Individualise dosage. Adult 20-500 mL¡A maximun infusion rate: 0.5g/kg/hr.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVPUSH;,,,,,
IGW20,Dextrose,20% Vitagen inj (Glucose) 20mL,NUTR,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,Á×¥ú,Only for Postpartum Nursing Care Center using. [UpToDate 20270731] Hypoglycemia: IV: 10 to 25 g (50 to 125 mL of 20% solution); repeat as needed in severe cases. Oral: 15 to 20 g as a single dose; repeat in 15 minutes if self-monitoring of blood glucose (SMBG) shows continued hypoglycemia. Once the SMBG returns to normal¡A a meal or snack should be consumed to prevent recurrence of hypoglycemia (ADA 2020).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,,,,,,
IGW250,Dextrose,Glucose inj 5% 250mL,MSIV,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,µL¯S§O«ü¥Ü,Individualized dosage. Adult 500-1000 mL each time IV drip.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
EEXT,Nystatin+Neomycin+Gramicidin+Triamcinolone,Extracomb cream 12gm,TDER,,Allergic and inflammatary skin disorders. Candida and yeast infection of the skin.,,,Apply bid ~ tid.,,,,,,,,,,,,,,
EFEM,Butoconazole,Femstat VS 100mg,SGU,,¾AÀ³¯g:Åðµß¤Þ°_¤§³±¹Dª¢(A032378500) AR: Vulvar itching¡A burning & swelling¡A vag burning; headache¡A rash. CI: Hypersensitivity. 1st trimester of pregnancy.,,RT,Non-pregnant patients 1 vag supp at bedtime for 3 days. Pregnant patients (2nd & 3rd trimesters only) 1 vag supp at bedtime for 6 days.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EFEN,Fentanyl,Fentanyl patch 25mcg/hr,CNEU,Intractable cancer pain,Hypersensitivity.,Nausea¡A vomiting; bradycardia¡A oedema¡A CNS depression¡A confusion¡A dizziness¡Adrowsiness¡A headache¡A sedation¡A transient hypotension¡A peripheral vasodilation; increased intracranial pressure. High IV dose may cause chest wall rigidity. Transdermal: Rash¡A erythema and itching.,25¢J¥H¤U,Adults: Initial dose:12 mcg/hr or 25mcg/hr. Maintenance dose: Increase and decrease by 12 mcg/hr or 25 mcg/hr to lowest appropriate dose. Renew every 72 hours. Children¡A 2-16 years old: Fentanyl transdermal patch can only be used on children have drug tolerance to opioids. Before use fentanyl transdermal patch¡A the child must be receiving opioids potency are equal to 30 mg oral morphine. The dose of fentanyl transdermal patch can be calculated from the 24-hour morphine dose with the same analgesic effect.(The conversion ratio of oral morphine to fentanyl transdermal patch is about 150:1) If fentanyl transdermal patches have to be discontinued¡A they should be replaced with other opioids (start with a low dose and slowly increase the dose).,»Ý½Õ¾ã¾¯¶q,[Micromedex 20210714] Hepatic impairment (mild to moderate): Initiate with 50% of the usual dosage. Hepatic impairment (severe): Avoid use.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,[¥é³æ] ¥¼¦³¥R¤ÀÃö©óÃh¥¥°ü¤k¨Ï¥Î§h©Z¥§¬ï¥Ö¶K¤ù¾¯ªº¸ê®Æ¡C¦b°Êª«¸ÕÅç¤¤´¿Åã¥Ü¨ã¦³¬Y¨Ç¥Í´Þ¬r©Ê¡CÁa¨Ï§@¬°ÀR¯ß³Â¾K¾¯ªº fentanyl ´¿³Qµo²{¦b¤HÃþ¦­´ÁÃh¥¥®É·|¬ï¹L­L½L¡A¦ý¹ï©ó¤HÃþªº¼ç¦b¦MÀI©Ê¤´ÄÝ¥¼ª¾¡C¥À¿Ë¦bÃh¥¥´Á¶¡ªø´Á¨Ï¥Î§h©Z¥§¬ï¥Ö¶K¤ù¾¯ªº·s¥ÍÀ¦¨à´¿³Q³ø¾É¦³·s¥Í¨à§ÙÂ_¯gª¬¡C Ãh¥¥´Á¶¡¤£¯à¨Ï¥Î§h©Z¥§¬ï¥Ö¶K¤ù¾¯¡A°£«D½T¹ê¦³¥²­n¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¤£«ØÄ³¦b¤À®Y´Á¶¡¨Ï¥Î§h©Z¥§¬ï¥Ö¶K¤ù¾¯¡A¦]¬°§h©Z¥§¬ï¥Ö¶K¤ù¾¯¤£À³¥Î©ó±±¨î«æ©Ê©Î³N«á¯kµh¡C¦¹¥~¡A¥Ñ©ó fentanyl ·|¬ï¹L­L½L¡A¦b¤À®Y®É¨Ï¥Î§h©Z¥§¬ï¥Ö¶K¤ù¾¯¥i¯à·|¾É­P·s¥Í¨àªº©I§l§í¨î¡C Fentanyl ·|±Æªn¨ì¤HÅé¨Å¥Ä¤º¥B¥i¯à·|¹ï·s¥Í¨à³y¦¨ÂíÀR/©I§l§í¨î¡C¦]¦¹¡A­÷¨Å°ü¤k¤£«ØÄ³¨Ï¥Î§h©Z¥§¬ï¥Ö¶K¤ù¾¯¡C,EXT;,,,,,
EFLA,Silver Sulfadiazine,Flamazine cream 1% 50gm,TDER,,I: Treatment of skin graft donor sites¡A wounds¡A burns¡A infected leg ulcers and pressure sores. CI: Pregnancy at term¡A premature infants.,,,Apply topically once daily,,,,¥i¯à¦w¥þ,,,,,,,,,,
EFLE,Sod Chloride,Atomic enema 20mL,ALIM,Constipation.,GI obstruction¡A abdominal pain¡A nausea¡A vomiting. Children <3 years.,Diarrhea¡A rectal irritation¡A abdominal discomfort.,25¢J¥H¤U,Adult & children >6 years Insert 1-2 ball and retain for 15 mins. 3-6 years 0.5 adult dose.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,RECT;,,,,,
EFLI,Fluticasone,Flixotide Accuhaler 50mcg/dose,ERSP,,,,,,,,,,,,,,,,,,,
EFLIA,Fluticasone,Flixotide Accuhaler 250mcg/dos,ERSP,,I: Prophylaxis of asthma. AR: Mouth & throat candidiasis¡A hoarseness¡A paradoxical bronchospasm¡A cutaneous hypersensitivity reactions.,,RT,Adult& childn> 16 yr Mild asthma:100-250£gg¡A Moderate asthma:250-500£gg Severe asthma:500-1000£gg. To be inhaled bid. Childn > 4 yr :50-200£gg bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EFLII,Fluticasone,Flixotide 50 Inhaler 50mcg/dose,ERSP,,I: Prophylaxis of asthma. AR: Mouth & throat candidiasis¡A hoarseness¡A paradoxical bronchospasm¡A cutaneous hypersensitivity reactions.,,,Adult& childn> 16 yr Mild asthma:100-250£gg¡A Moderate asthma:250-500£gg Severe asthma:500-1000£gg. To be inhaled bid. Childn > 4 yr :50-200£gg bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EFML,Fluorometholone,Flumetholon oph drop 0.1%¡A 5mL(­­¦Û¶O),TOPH,,¾AÀ³¯g: Ocular inflammation. °Æ§@¥Î: Glaucoma with optic nerve damage¡A visual acuity or field defects¡A raised intraocular pressure¡A secondary infection (persistent corneal ulceration¡A possibly fungal invasion)¡A perforation of globe¡A posterior subcapsular cataract formation. ¸T§Ò: Hypersensitivity to fluorometholone or any component of the formulation; viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis¡A vaccinia¡A and varicella); mycobacterial or fungal infections of the eye; untreated eye infections which may be masked/enhanced by a steroid.,,«Ç·Å,Instill 1-2 drop 2-4 times daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EFOR,Isoflurane,Forane 100mL,ZANE,,¾AÀ³¯g: Inhalation anesth for induction & maintenance of general anesth. °Æ§@¥Î: Dose-dependent respiratory depression¡A hypotension¡A arrhythmias; transient rise in CSF pressure; jaundice; malignant hyperthermia. Hepatic injury. Post-op shivering¡A GI upset¡A ileus. ¸T§Ò: Genetic susceptibility to malignant hyperthermia.,,«Ç·Å,Induction: 1.5-3%¡A maintenance: 1-2.5%.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EFUT,Futraful,Futraful zupo 200mg,RACA,,,,,,,,,,,,,,,,,,,
OFAX,Venlafaxine,Faxine 37.5mg,CNEU,Treatment of depression¡A including melancholia.,Coadministration with MAOIs.,Dizziness¡A sedation¡A dry mouth¡A insomnia¡A nervousness¡A tremor¡A somnolence¡A anorexia¡A constipation¡A nausea¡A vomiting¡A abnormal ejaculation/orgasm (males)¡A erectile dysfunction¡A urinary hesitancy¡A sweating¡A asthenia¡A hypertension¡A hot flushes¡A ecchymosis¡A mucus membrane bleeding¡A thrombocytopenia¡A hypercholesterolemia¡A yawning¡A fatigue¡A nausea¡A appetite & wt loss¡A decreased libido¡A sweating¡A anorexia¡A visual disturbances Cardiovascular: Hypertension (3% to 13%) Dermatologic: Sweating symptom (6.7% to 25% ) Endocrine metabolic: Weight loss (3% to 47% ) Gastrointestinal: Constipation (8% to 15% )¡A Loss of appetite (8% to 22% )¡A Nausea (21% to 58% )¡A Xerostomia (12% to 22% ) Neurologic: Asthenia (8% to 19% )¡A Dizziness (11% to 23.9% )¡A Dream disorder (3% to 7% )¡A Headache (25% to 38% )¡A Insomnia (14% to 24% )¡A Somnolence (14% to 26% )¡A Tremor (1.1% to 10.2% ) Ophthalmic: Blurred vision (4% to 6% ) Psychiatric: Feeling nervous (4% to 21.3% ) Reproductive: Abnormal ejaculation (2.2% to 19% )¡A Impotence (2.1% to 6% )¡A Orgasm disorder (2% to 5% ),Àx¦s©ó°®Àêªº25¢J¥H¤U,Adult Initially 75 mg/day in 2-3 divided doses¡A can be increased in increments of up to 75 mg/day at intervals of ¡Ö¡â 4 days. Dose can be titrated up to 225 mg/day in moderate depression & 375 mg/day for severe depression,»Ý½Õ¾ã¾¯¶q,»´«×©Î¤¤«×¨x¥\¯à¤£¥þ¯f±w«ØÄ³­°§C usual dosage by 50% or more,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,[¥é³æ] ­P·î§@¥Î---Ãh¥¥ C ¯Å¥ÎÃÄ ¦pªG¯f¤H¦bÃÄª«ªvÀø´Á¶¡¡A¤wÃh¥¥©Î­pµeÃh¥¥¡AÀ³¸Ó©Z¥Õ§i¶DÂå®v¡CÆ[¹î©Ê¬ã¨s¼Æ¾Ú«ü¥X©ó¥Í²£«e¤@­Ó¤ë¼ÉÅS©ó SSRI ¤Î SNRI ÃþÃÄ«~·|¼W¥[²£«á¥X¦åªº­·ÀI(¤p©ó 2 ­¿)¡C¥H mg/kg ¬°°ò·Ç®É¡A¦b¾¯¶q°ª¹F 11 ­¿(¤j¹«)©Î 12 ­¿(¨ß¤l)ªº¤HÃþ³Ì¤j¨C¤é«ØÄ³¾¯¶q¤U¡A ©Î¥H mg/m2 ¬°°ò·Ç®Éªº 2.5 ­¿(¤j¹«)©Î 4 ­¿(¨ß¤l)ªº¤HÃþ¨C¤é¾¯¶q¤U¡Avenlafaxine ¥Î©ó¤j¹«©Î¨ß¤l³£¤£·|²£¥Í·î«¬«á¥N¡C¦ý¬O¡A¦b¤j¹«¤¤¡A·í¦bÃh¥¥´Á¶¡¶}©lµ¹ÃÄ¨Ã«ùÄò¦ÜÂ_¥¤®É¡D¦b­÷¨Åªº«e¤­¤Ñ¤¤¡A·|¥X²{¥®¹«Åé­«´î»´¡A¦º²£¥®¹«¼W¥[¥B¥®¹«¦º¤`¼W¥[ªº²{¶H¡C¥Ø«e¨Ã¤£¤F¸Ñ³y¦¨³o¨Ç¦º¤`ªº­ì¦]¬°¦ó¡C·í¾¯¶q¬° 10 ­¿(mg/kg)©Î 2.5 ­¿(mg/m2)ªº³Ì¤j¤HÃþ¨C¤é¾¯¶q¤U¡A«K·|µo¥Í³o¨Ç§@¥Î¡C¤£·|³y¦¨¥®¹«¦º¤`ªº¾¯¶q¬° 1.4 ­¿(¥H mg/kg ³æ¦ì¬°·Ç)©Î 0.25 ­¿(¥H mg/m2³æ¦ì¬°·Ç)ªº¤HÃþ¾¯¶q¡C ¥Ø«e¹ïÃh¥¥°ü¤k¨S¦³¾A·í¥B±±¨î¨}¦nªº¬ã¨s¡C¦]¬°°Êª«¥Í´Þ¤O¬ã¨sµLªkºë½T¹w´ú¤HÃþ¤ÏÀ³¡A¦]¦¹¥u¦³¦b©ú½T»Ý­n¤U¡A¦¹ÃÄ¤~¥i¨Ï¥Î©óÃh¥¥´Á¶¡¡C ¥Í²£»P¤À®Y¡GVenlafaxine hydrochloride ¹ï¤HÃþ¥Í²£»P¤À®Yªº¼vÅT©|«Ý¤F¸Ñ¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¯f¤H­Y¥H¥À¨ÅÁý­¹À¦¨à®ÉÀ³§iª¾Âå®v¡A¥Ø«e¤£ª¾ venlafaxine©Î¨ä¥NÁÂª«¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡A¦]¬°³\¦hÃÄª«³£·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡A©Ò¥H·í­÷¨Å®É¡AªA¥Î venlafaxineÀ³¯S§Oª`·N¡C ¥Ø«e¤£ª¾venlafaxine©Î¨ä¥NÁÂª«¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡C¦]¬°³\¦hÃÄª«³£·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡A ©Ò¥H·í­÷¨Å¥À¿ËªA¥Î venlafaxine hydrochloride ®ÉÀ³¯S§Oª`·N¡C,PO;WM;,,,,,
OMIY,Clostridium Butyricum Miyairi 588,Miyarisan BM 1gm,ALIM,Intestinal disorders (prepare the bowel movement)¡A loose stools¡A constipation¡A abdominal bloating.,Hypersensitivity to any component of the formulation.,Flatulence,25¢J¥H¤UÁ×¥ú°®Àê³B,Adult & children >12 years: PO¡A 1 Pack¡A TID-QID. 6-12 years: PO¡A 0.5 Pack¡A TID-QID. 3-6 years: PO¡A 0.25 Pack¡A TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,»PAminophylline¡BIsoniazid²V¦X®É·|¨Ï¥»ÃÄ«~ÅÜ¦â¡AÁ×§K¦P®ÉªA¥Î¡C(¥é³æ)
ICOL,Colistin Methanesulfonate,Colimycin inj 2MU,QANB,GI infections; Bowel sterilisation.,Hypersensitivity. Anuria; porphyria; myasthenia gravis. Pregnancy and lactation.,Superinfection; renal damage; visual disturbances; GI disturbances¡A dizziness¡A nausea¡A vomiting; confusion¡A peripheral neuropathy; respiratory insufficiency and muscle weakness.,«Ç·Å25¢J,Colimycin 2MU: colistin base 66.8 mg/2mL/vial. All doses are expressed as colistin base activity (CBA). Adults: IV 2.5-5 mg/kg/day divided Q12H (slowly inject for over 3-5 minutes or infuse over 1-2 hours at a rate of 5-6 mg/hours) or IM 2.5-5 mg/kg/day divided Q6-12H. (¼ö¯f) Adult: For severe systemic infection: give loading dose (4x body weight in kg using lower of ideal or actual weight)¡A then begin daily maintenance dosing 12 hours later. Inhalation therapy: 50-75 mg CBA in 3-4 mL saline via vibrating mesh nebulizer 2-3 times/day. Meningitis (intraventricular or intrathecal dose): 10 mg/day x several weeks; intrathecal dose often combined with IV dosing. Pediatric dose: systemic Infection: 2.5-5 mg/kg/day in 2-4 divided doses (based on ideal body weight). Cystic fibrosis: 3-8 mg/kg/day in 3 divided doses (based on ideal body weight).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;IM;IVD;,"IM: 2 mL D/W¡A N/S; IV: 2mL D/W¡A N/S¡A D5W",¡iL/R¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ,¶}©lªº1~2¤p®É¡A¥H5-6mg/hr½wºCºwª`,1. ¿éª`²G»Ý·sÂA°t»s¡A«Ç·Å¤U¥u¯àÂ\©ñ24¤p®É 2. µÇ¥\¯à¤£¥þ¯f±w»Ý´îºCª`®g³t²v¡C
EZOVO,Acyclovir,Zovirax ²´¥ÎÃÄ»I 3%¡A 4.5gm,TOPH,,¾AÀ³¯g: Herpes simplex virus infection of the eyes including initial & recurrent genital herpes & herpes labialis. °Æ§@¥Î: Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction¡A Topical Preparation (5% )¡A Contact dermatitis¡A Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )¡A Nausea (2.4% to 4.8% )¡A Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ) ¸T§Ò: Patients known to be hypersensitive to acyclovir or propylene glycol.,,«Ç·Å,Adult & children Apply 5 times daily at approximately 4 hr interval for 5-10 days.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OSONI,Zaleplon,Sonimax 10mg,CNEU,,¾AÀ³¯g:Insomnia °Æ§@¥Î:Headache¡A light headedness¡A asthenia¡A dizziness¡A nausea¡A somnolence¡A rash¡A myalgia¡A back pain¡A chest pain¡A taste perversion¡A fever¡A migraine¡A constipation¡A dry mouth¡A dyspepsia¡A arthralgia¡A anxiety¡A depression¡A difficulty concentrating¡A amnesia¡A confusion¡A hallucinations. Transient impairment of memory and psychomotor function. Decreased inhibition¡A behavioural changes (e.g. bizarre behaviour¡A depersonalisation)¡A complex sleep related behaviour (e.g. sleep driving). Neurologic: Dizziness (7% to 9% )¡A Headache (30% to 42% ) ¸T§Ò:ÄY­«¨x¥\¯à¤£¥þ¡AºÎ¯v°±¤î©I§l¯g­Ô¸s¡A­«¯g¦ÙµL¤O¡AÄY­«©I§l¥\¯à¤£¥þ¡A ¨àµ£(¤Q¤K·³¥H¤U),,«Ç·Å,PO 10 mg/day at bedtime. Max: 20 mg/day ¦¨¦~¤H:10mg ¦Ñ¦~¤H:5mg ¨x¥\¯à¤£¥þ:»´¦Ü¤¤«×¨x¥\¯à¤£¥þ¤§¯f¤H¨Ï¥Î5mg,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
HE5000,,Dianeal 1500mL 1.5% (PD2Âù³U),NUTR,,,,,,,,,,,,,,,,,,,
HE5001,,Dianeal 1500mL 1.5% (PD4Âù³U),NUTR,,,,,,,,,,,,,,,,,,,
HE5002,,Dianeal 1500mL 2.5% (PD2Âù³U),NUTR,,,,,,,,,,,,,,,,,,,
EFEN5,Fentanyl,DUROGESIC 50mcg/hr,CNEU,,¾AÀ³¯g: Management of chronic pain & intractable pain requiring opioid analgesia. °Æ§@¥Î: Hypoventilation¡A nausea¡A vomiting¡A constipation¡A somnolence¡A confusion¡A hallucination¡A euphoria¡A pruritus & urinary retention. ¸T§Ò: Patients with known hypersensitivity to fentanyl or to the adhesives present in the system.,,«Ç·Å,Opioid-naive patients: 25 mcg/hr as initial dose. Opioid-tolerant patients: Convert from oral or parenteral opioids to Durogesic according to suggested equianalgesic potency conversion. May be worn continuously for 72 hr.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EDEX,Dexamethasone,Dexaltin(¤f¤º»I)0.1% 5gm,TENT,,¾AÀ³¯g: Intractable stomatitis or glossitis associated with erosion or ulceration. °Æ§@¥Î: Fungal or bacterial infection of the oral cavity; hypersensitivity; hypofunction of pituitary-adrenocortical system (prolonged use). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin¡A Finding of skin healing¡A Impaired Endocrine metabolic: Cushing's syndrome¡A Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )¡A Raised intraocular pressure (25% ) Psychiatric: Depression¡A Euphoria Respiratory: Pulmonary tuberculosis ¸T§Ò: Patients with tuberculotic¡A viral or other purulent infections of the oral cavity.,,«Ç·Å,Apply adequate amount to the affected area once to several times daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EELOO,Mometasone,Elomet oint 0.1%¡A 5gm,TDER,,¾AÀ³¯g: Inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses. °Æ§@¥Î: Very rarely¡A paresthesia¡A pruritus¡A burning¡A tingling/stinging¡A signs of skin atrophy. Dermatologic: Atrophic condition of skin¡A Topical¡A Pruritus¡A Topical Gastrointestinal: Abdominal pain (2%-3%¡A oral inhalation)¡A Indigestion (3%-5%¡A oral inhalation)¡A Nausea (1%-3%¡A oral inhalation) Musculoskeletal: Backache (3%-6%¡A oral inhalation)¡A Musculoskeletal pain (4%-8%¡A oral inhalation)¡A Myalgia unspecified (2%-3%¡A oral inhalation) Neurologic: Headache (4%¡A intranasal; 17%-22%¡A oral inhalation) Reproductive: Dysmenorrhea (4%-9%¡A oral inhalation) Respiratory: Allergic rhinitis (11%-15%¡A oral inhalation)¡A Candidiasis¡A oral (4%-6%¡A oral inhalation)¡A Epistaxis¡A Intranasal (5%)¡A Pharyngitis (8%-13%¡A oral inhalation)¡A Upper respiratory infection (8%-15%¡A oral inhalation) Other: Burning sensation¡A Topical¡A Fatigue (13%¡A oral inhalation)¡A Viral disease¡A Intranasal (3%),,«Ç·Å,Children >= 2 years Apply once daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EFLIE,Fluticasone,Flixotide 50mcg evohaler 120dose,ERSP,Prophylactic management in mild¡A moderate & severe asthma for adult & childn.,Patients with a history of hypersensitivity to any of the components of Flixotide.,Mouth & throat candidiasis¡A hoarseness¡A paradoxical bronchospasm. Cutaneous hypersensitivity reactions. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ),30¢J¥H¤U,Adult & children >16 years:100-1000 mcg BID. Mild asthma 100-250 mcg BID. Moderate asthma 250-500 mcg BID. Severe asthma 500-1000 mcg BID. Children >4 years: 50-200 mcg BID. Children 1-4 years: 500-100 mcg BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
ETOP,Fluocinonide,Topsym lotion 0.05%¡A 10gm,TDER,Eczema; dermatitis; psoriasis; vitiligo; alopecia; pustulosis; prurigo.,Vaccinia & varicella.,Burning¡A itching¡A irritation¡A dryness; perioral dermatitis; allergic contact dermatitis; skin atrophy. Dermatologic: Dry skin¡A Pruritus¡A Sensation of burning of skin Neurologic: Headache¡A with 0.1% cream (4%) Other: Irritation symptom,25¢J¥H¤U,Apply QD-TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,EXT;,,,,,
IHUMA,Insulin lispro 50% + Insulin protamine 50%,Humalog Mix 50 100IU/mL 3mL,META,,¾AÀ³¯g:type 1¡A type 2 DM °Æ§@¥Î:Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj ¸T§Ò:Hypoglycaemia.,,2-8 ¢J,Should be taken with food. (Administer w/in 15 mins before or immediately after meals.) Subcutaneous Diabetes mellitus Adult: Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Administer 15 min before or immediately after a meal. Renal impairment: Decreased dose may be necessary. Hepatic impairment: Decreased dose may be necessary.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IGW50,Dextrose,50% GW inj (Vitagen) 20mL,NUTR,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,25¢J¥H¤U,[UpToDate 20270731] Hypoglycemia: IV: 10 to 25 g (20 to 50 mL of 50% solution); repeat as needed in severe cases. Oral: 15 to 20 g as a single dose; repeat in 15 minutes if self-monitoring of blood glucose (SMBG) shows continued hypoglycemia. Once the SMBG returns to normal¡A a meal or snack should be consumed to prevent recurrence of hypoglycemia (ADA 2020). Glucose tolerance test (Glutol): Oral: One-step (ADA 2020): 75 g as single dose to a fasting patient; assess plasma glucose 2 hours after dose in nonpregnant adults or 1 and 2 hours after dose in pregnant women.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;LI;PO;,,,©óÀR¯ßª`®g®ÉÀ³ºÉ¥i¯à´îºC³t²v¡A¥H§K¤Þ°_ª`®g³¡¦ì¯kµh©ÎÀR¯ßª¢,,1.°ª±i²G©óÀR¯ßª`®g®ÉÀ³ºÉ¥i¯à´îºC³t²v¡A¥H§K¤Þ°_ª`®g³¡¦ì¯kµh©ÎÀR¯ßª¢¡C 2.¨C¤ä20mL§t¦³10g Dextrose¡C
IHAE,Gelatine Polypeptides,Haemaccel inj 500mL,HEMT,,Hypovolemic shock¡A loss of blood or plasma¡A exsiccosis¡A wt. Loss during & after surgery.,,,Adult: 500-1500 ml (Max: 2000 ml).,,,,,,,,,,,,,,
IASP,Lysine Acetylsalicylate,Aspegic inj 0.5gm,CNEU,,¾AÀ³¯g:¸Ñ¼ö£¿Âíµh£¿­·Àã©Ê¯kµh(B0215282B9),,RT,Slow IV or deep IM: Adult: 1-4 vials/day. Child: 10-25 mg/kg/day (claculated as aspirin) in 2 divided doses.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IHAL,Haloperidol,Haloperidol(Binison)50mg/mL,CNEU,,Antidyskinetic (in Gilles de la Tourette's disease)¡A antipsychotic.,,,Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially¡A adjusted as needed. Child: 3-12 yrs¡A 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OAMIY,Amino Acids + Histidine,Amiyu granules 2.5mg,NUTR,,¾AÀ³¯g: ºC©ÊµÇ¤£¥þ®ÉÓi°ò»Ä¤§¸Éµ¹¾¯(A025449114) °Æ§@¥Î: Rash¡A general urticaria¡A itching¡A GI upsets. Rare temporary increase of GOT¡A GPT¡A palpitation¡A acidosis. ¸T§Ò: Patients with possibility of hepatic coma,,RT,Adult: one pack three times a day¡Aafter meals.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OAMO5,Amoxicillin,AMOXICILLIN 500mg,QANB,,¾AÀ³¯g: G(+) & G(-) infections °Æ§@¥Î: Nausea¡A vomiting¡A diarrhea¡A glossitis¡A stomatitis¡A black hairy tongue; skin rashes¡A urticaria¡A exfoliative dermatitis¡A erythema multiforme; anemia¡A thrombocytopenia¡A eosinophilia¡A leukopenia¡A agranulocytosis. ¸T§Ò: Hypersensitivity to penicillins.,,«Ç·Å,Adult : 250-500 mg q8h¡A(max. 4.5 g/day) Child under 20 kg: 20-40 mg/kg/day in 3 divided doses. Acute uncomplicated gonorrhea: Adult: 3 g once. Child over 2 yrs: 50mg/kg with 25 mg/kg probenecid once.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OAMP5,Ampicillin,Ampicillin 500mg(Pentrexyl),QANB,,Active against G(-) organism¡A generally less active against G(+) organism¡A except enterococci.,,,Adult & child over 20kg: Oral: 250-500 mg q6h¡A (max. 6 g/day). IM¡A slow IV or IV infusion: 250-500 mg q6h. For bacterial meningitis or septicemia: 1-2 g q3-4h¡A(max.16 g/day or 300 mg/kg/day). Child under 20 kg: Oral: 12.5-25 mg/kg q6h¡A (max. 200 mg/kg/day). IM¡A slow IV or IV infusion: 6.25-25 mg/kg q6h. For bacterial meningitis or septicemia: 16.7-41.7 mg/kg q4h¡A(max. 400 mg/kg/day ).,,,,¥i¯à¦w¥þ,,,,,,,,,,
OAND,Cyproterone,Androcur 50mg,RACA,Antiandrogen with progestogenic activity,Hypersensitivity to cyproterone or any component of the formulation; liver disease or hepatic dysfunction; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumors (if not due to metastases from prostate cancer); presence or history of meningioma; wasting diseases (except inoperable prostate cancer); severe chronic depression; existing thromboembolic processes,Decreased libido¡A erectile dysfunction¡A inhibition of ovulation¡A reversible inhibition of spermatogenesis¡A weight increase/decrease¡A mood depression¡A restlessness¡A breast tenderness¡A gynecomastia¡A fatigue¡A hot flushes¡A sweating.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Dosage in females [For severe signs of androgenisation]100 mg are to be taken with some liquid after a meal from the 5th to the14th day of the cycle (i.e. for ten days). Every 28 days (the usual duration of a menstrual cycle)¡A the above dosage regimen is to be followed. Seven inactive tablets are taken once daily after 21 days¡A during which time a withdrawal bleeding occurs. Exactly 4 weeks after the first course of treatment was started¡A i.e. on the same day of the week¡A the next cyclical course of combined treatment is started¡A regardless of whether bleeding has stopped or not. Following clinical improvement¡A the daily dose of Androcur 50 mg during the 10 days of the combined treatment with a combined oral contraceptive can be reduced to one or half a tablet of Androcur 50 mg. Dosage in males [Reduction of drive in sexual deviations] 50 mg twice daily initially; may be increased to 100 mg 2-3 time daily. Quite often 25 mg twice daily (50 mg daily) is sufficient. When establishing the maintenance dose or when discontinuing the preparation¡A dosage should not be reduced abruptly¡A but gradually. [Antiandrogen treatment in inoperable carcinoma of the prostate] 100 mg 2-3 times daily (= 200-300 mg/day)- To reduce the initial increase of male sex hormones in treatment with GnRH agonists: 100 mg twice daily alone for 5-7 days¡A followed by 100 mg twice daily for 3-4 weeks together with a GnRH agonist in the dosage recommended by the manufacturer.- To treat hot flushes in patients under treatment with GnRH analogues or who have had orchidectomy: 50-150 mg daily; may be increased to 300 mg/day as needed.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à²§±`ªÌ¬°¸T§Ò,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°§Ü¶¯©Ê¿E¯À»s¾¯¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©ó¤p«Ä¤ÎÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OAPR5,Hydralazine,Apresoline 50mg,CAVS,Hypertension.,Idiopathic SLE and related diseases. Severe tachycardia and heart failure with high cardiac output. Myocardial insufficiency due to mechanical obstruction. Right ventricular heart failure due to pulmonary HTN. Dissecting aortic aneurysm.,Tachycardia¡A palpitation¡A anginal symptoms¡A flushing¡A headache¡A dizziness¡A nasal congestion¡A GI disturbances.,¸m©ó³±²D³B15-30¢J¥BÁ×§K¼éÀã,HTN Adult: 10-50 mg QID slowly titrate up (Maximum dose 300 mg/day). Child: 0.75 mg/kg/day in 4 divided doses¡A up to 7.5 mg/kg/day. (Maximum dose 300mg/day).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,No reports linking the use of hydralazine with congenital defects have been located. However¡A fetal toxicity has been associated with use of the drug in the 3rd trimester.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EGARO,Gentamicin Sulfate + Betamethasone,Garasone eye oint,TOPH,,I: Ocular inflammation when concurrent use of an antibiotic is necessary. AR: Increased intraocular pressure¡A glaucoma¡A infrequent optic nerve damage¡A cataract¡A acute anterior uveitis¡A perforation of the globe. CI: Epithelial herpes simplex keratitis¡A dendritic keratitis¡A viral disease of the cornea & conjunctiva¡A mycobacterial or fungal infectoin¡A trachoma.,,,Apply tid-qid.,,,,,,,,,,,,,,
IMIV,Mivacurium,Mivacron,CNEU,,¾AÀ³¯g: Adjunct to general anesth¡A Endotracheal intubation¡A Maintenance of neuromuscular block. °Æ§@¥Î: Cutaneous flushing¡A mild hypotension¡A moderate wheezing; tachycardia¡A bradycardia¡A phlebitis; bronchospasm¡A hypoxaemia; rash¡A inj site reaction; dizziness; prolonged drug effect; muscle spasms. ¸T§Ò: Patients known or suspected to be homozygous for the atypical plasma cholinesterase gene.,,«Ç·Å,IV Adjunct to general anesth Initial: 70-250 mcg/kg via inj. Maintenance: 100 mcg/kg at 15-min intervals. Patients w/ asthma/CV disease: ¡Ø150 mcg/kg. Endotracheal intubation Initial: 150 mcg/kg¡A then 100 mcg/kg 30 sec later. Maintenance of neuromuscular block Infuse 8-10 mcg/kg/min¡A adjusted every 3 mins¡A if needed¡A up to a usual rate of 6-7 mcg/kg/min.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IAMIX1,Amino Acid + Glucose,Aminomix 1500mL,NUTR,,Complete parenteral nutrition & electrolyte & fluid subsitution in catabolic situation. In the post-aggressive phase.,,,20-30 ml/kg/day (approx 1400-2100 ml/day for 70 kg body weight).Max¡G 40ml/kg/day.Infusion¡G1000ml/pack.,,,,,,,,,,,,,,
IMMRA,Measles + Mumps + Rubella,Pluserix inj ( MMR )(½Ã¥Í¸p),HIMM,,Measles¡A mumps and rubella immunisation in adults and children over 15 months.,,,SC¡A child 15 months and over¡A 1 vial (0.5 ml after reconstitution).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IMORI,Amino Acids,Moriamin-SN inj 200mL,NUTR,,¾AÀ³¯g:¬°¦¨¤H®ò°ò»Ä¸É¥R²G(A024029263),,RT,Peripheral infusion: Adult: 200-400 ml slow infusion. Central venous infusion: Adult: 400-800 ml daily,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IMORP,Morphine,Morphine inj 10mg/1mL,CNEU,Relief of moderate to severe pain. Pre-op anesth.,Respiratory depression¡A head injury¡A obstructive airways disease¡A paralytic ileus¡A GI obstruction¡A delayed gastric emptying¡A acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,Nausea¡A vomiting¡A constipation¡A drowsiness¡A palpitations¡A headache¡A disorientation¡A vertigo¡A mood changes¡A decreased libido¡A ureteric spasm¡A urinary retention¡A rash¡A sweating¡A facial flushing¡A miosis.,«Ç·ÅÁ×¥ú,SC/IV Opiate agonist naive patients Initially 2-5 mg every 3-4 hours. Higher dose may be used for patients used before. 0.8-10 mg/hr by continuous infusion. Patient with assisted ventilation (for 70 kg body weight) 0.7-10 mg IV per 1-2 hour or 5-35 mg/hr as continuous infusion. Epidural: 1-5 mg as single dose. Continuous infusion: Initially 1-5 mg at rate of 0.1-1 mg/hr. Subarachnoid injection: Opiate agonist naive patients 0.1-0.3 mg each time to provide 24 hours relief. Not recommended to repeat dose. Pain relief of surgical anesthesia: adjust dose according to age & symptoms.,µL»Ý½Õ¾ã¾¯¶q,Start with lower initial doses and titrate slowly OR increase dosing interval by 1.5 to 2 times that of a normal dose,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;IVD;IVP;IVPUSH;SC;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö4-5¤ÀÄÁ,°_©l¾¯¶q: ¨C3-4¤p®É2.0-5mg¡A«ùÄò¿éª`: 0.8-10mg/hr¡F¥Î©I§l¾¹ªº¯f±w(¥H70kg­p)°_©l¾¯¶q:¨C1-2¤p®É0.7-10mg¡A«ùÄò¿éª`:5-35mg/hr,1. IVµ¹ÃÄ¿@«×0.5-3mg/mL¡A½wºCª`®g4-5¤ÀÄÁ¡C
IMORPBAD,Morphine,Morphine inj 10mg/1mL´Ý¾l¾PÀì,CNEU,Relief of visceral pain¡A preanesthetic medication¡A sedation and hypnosis when pain is present¡A dyspneic seizures of acute left ventricular failure and pulmonary edema.,,,,Adult: PO: Initial¡A 10-30 mg q4h. IM or SC:5-20 mg (usually 10 mg) q4h as needed. IV (only rarely): 2.5-10 mg diluted in 4-5 ml of water for injection¡A administered slowly over 4-5 mins. Child: SC:0.1-0.2 mg/kg¡A not to exceed 15 mg/dose.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,,,,
INAA,Sodium Acetate Anhydrous,Sodium acetate inj 20mL (4mEq/mL),NUTR,Electrolyte imbalance or severe Na depletion.,Hypernatremia. Fluid retention.,Serious Endocrine metabolic: Hypervolemia¡A Metabolic alkalosis Other: Aluminum poisoning¡A Hypernatremia,25¢J¥H¤U,As TPN material. Each mL contains: Sodium Acetate anhydrous 328.16mg = 4mEq Sodium Acetate. Parenteral nutrition; maintenance sodium requirement: Note: A combination of salt forms may be necessary to fulfill sodium requirement. Neonatal: 2 - 5 mEq/kg/day of sodium as an additive to parenteral nutrition solution. Infants and Children < or = 50 kg: IV: 2 - 5 mEq/kg/day of sodium as an additive to parenteral nutrition solution. Children > 50 kg and Adolescents: IV: 1 - 2 mEq/kg/day of sodium as an additive to parenteral nutrition solution. [Uptodate 20210731] Sodium maintenance electrolyte requirement (combination of chloride and acetate¡A where applicable): IV: 1 to 2 mEq/kg/24 hours; customize amounts based on individual patient needs (Mirtallo 2004). General maximum sodium acetate: 100 to 150 mEq/24 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVA;,,,,,1. ¨CmL§tSodium Acetate Anhydrous 328.16 mg¡A¬Û·í©ó 4 mEq/mL¡A¨Ï¥Î«e¶·µ}ÄÀ¡C 2. ²K¥[©óÀR¯ß¿éª`²G¡A¿@«×>154 mEq/L¶·¸g¥Ñ¤¤¥¡ÀR¯ßµ¹¤©¡C³Ì¤j¿éª`³t²v 1 mEq/kg/hour 3. ¥»ÃÄ«~¬°ÃÄ¾¯¬ì°t¸mTPN»s¾¯±M¥Î¡C
INAN,Nitroprusside,Sodium Nitroprusside 50mg,CAVS,,¾AÀ³¯g:¦M«æ©Ê°ª¦åÀ£(B021879248),,RT,Only be used as IV infusion Adult: 0.5 mcg/kg/min¡A adjusted slowly in increments of 0.5 mcg according to response¡A usual dose is 3 mcg/kg/min¡A up to 10mcg/kg/min. Child: 1.4 mcg/kg/min.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
INAR,Naloxone,Narcan inj 0.4mg/1mL,ZADT,,¾AÀ³¯g:³Â¾KÃÄ«~¸Ñ¬r¾¯(B021318209),,RT,IV ¡A IM or SC.The IV dose may be repeated at 2-3 mins intervals as needed. Opioid overdose: Adult: 0.4-2 mg. Child: 0.01 mg/kg. Postoperative opioid depression: 0.1-0.2 mg every 2-3 min Opioid-induced respiratory depression : 0.01 mg/kg.,,,,¥i¯à¦w¥þ,,,,,,,,,,
INEO,Phenylephedrine,Neo-synesin 1mg,CAVS,,¾AÀ³¯g:¬°¦åºÞ¦¬ÁY¾¯ ¸T§Ò: Pregnancy.,,«Ç·Å,SC & IM: Adult 2-5 mg. Max: 10 mg. IV: Adult 0.2 mg. Dose range: 0.1-0.5 mg. IV infusion: 0.5-1 mg/100ml blood.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OCAL9,Calcium Citrate,Callate 950mg,NUTR,,¾AÀ³¯g: Ca supplement¡A renal osteodystrophy.,,«Ç·Å,Adult & children > 4 years 2-5 tabs daily.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IAVA0,Bevacizumab,Avastin inj 100mg/4mL (Sample),RACA,In combination with irinotecan/5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin as 1st-line treatment of metastatic carcinoma of the colon or rectum,Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanised antibodies; untreated CNS metastases.,Common: Hypertension¡A All Grades (19-42%)¡A Hyperglycemia (26-31%)¡A Hypomagnesemia (24-27%)¡A Weight decreased (11-21%)¡A Abdominal pain (12-61%)¡A Constipation (13-40%)¡A Diarrhea (19-39%)¡A Indigestion (17-24%)¡A Loss of appetite (34-43%)¡A Nausea (58-72%)¡A Stomatitis (15-33%)¡A Taste sense altered (14-21%)¡A Vomiting (33-52%)¡A Hemorrhage¡A All Grades¡A Neutropenia¡A All Grades (Cervical cancer¡A 12%; ovarian cancer¡A 30.7%)¡A Thrombocytopenia¡A All Grades (Colorectal carcinoma¡A 5%; ovarian cancer¡A 58%)¡A Infectious disease (Cervical¡A ovarian¡A and non-small cell lung cancer¡A 10-13.6%; glioblastoma¡A 55%)¡A Arthralgia (28-45%)¡A Headache (22-49%)¡A Proteinuria¡A All Grades (5-20%)¡A Bleeding from nose (10-55%)¡A Dyspnea (25-30%)¡A Upper respiratory infection (40-47%)¡A Fatigue (33-82%) Serious: Hypertension¡A Grades 3 to 5 (5-18%)¡A Impaired wound healing (5-15%)¡A Injection site extravasation¡A Necrotizing fasciitis¡A Wound dehiscence¡A Bleeding esophageal varices¡A Bleeding gastroesophageal varices¡A Gastrointestinal fistula (Up to 4.1%)¡A Gastrointestinal hemorrhage (19-24%)¡A Gastrointestinal perforation (0.3-3%)¡A Tracheoesophageal fistula¡A Arterial thromboembolism (5%)¡A Deep venous thrombosis (6-9%)¡A Febrile neutropenia¡A Grades 3 to 5 (5-6.2%)¡A Hemorrhage¡A Grade 3 or greater (0.4-7%)¡A Leukopenia¡A Grade 3 or 4 (37-51%)¡A Lymphocytopenia¡A Grade 3 or 4 (6%)¡A Microangiopathic hemolytic anemia¡A Neutropenia¡A Grades 3 to 5 (Cervical cancer¡A 7.8%; colorectal and lung cancer¡A 21-27%)¡A Thrombocytopenia¡A Grade 3 or 4 (21-40.1%)¡A Thrombotic microangiopathy¡A Fistula of bile duct¡A Anaphylaxis¡A Hypersensitivity reaction¡A Intracranial hemorrhage (1.2-5%)¡A Posterior reversible encephalopathy syndrome (<0.5%)¡A Bladder fistula¡A Fistula from renal pelvis¡A Nephrotic syndrome (<1%)¡A Proteinuria¡A Grades 3 to 5 (3-10%)¡A Serum creatinine above reference range (13-16%)¡A Non-menstrual vaginal bleeding (4%)¡A Vaginal fistula finding¡A Bronchopleural fistula¡A Perforation of nasal septum¡A Pulmonary hemorrhage (4-31%)¡A Pulmonary hypertension,2-8¢JÁ×¥ú,Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. Continue treatment until disease progression or unacceptable toxicity.  [Metastatic Colorectal Cancer (mCRC)]- 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination withfluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Avastin-containing regimen.- 10 mg/kg every 2 weeks or 15 mg/kg every 2 weeks for Avastin-naive patients as second-line therapy.  [Metastatic Breast Cancer (mBC)] 10 mg/kg every 2 weeks  [Glioblastoma] 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks  [Non-Squamous Non-Small Cell Lung Cancer (NSCLC)] 15 mg/kg every 3 weeks  [Ovarian (epithelial)¡A fallopian tube¡A or primary peritoneal cancer] - Stage III/IV disease following initial surgical resection: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for up to 6 cycles¡A followed by bevacizumab 15 mg/kg every 3 weeks (monotherapy)¡A for a total of up to 22 cycles (=15 months) or until disease progression (whichever occurs earlier)- Platinum-sensitive recurrent: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6-10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity- Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks (in combination with paclitaxel¡A doxorubicin [liposomal]¡A or topotecan)  [Cervical cancer] 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BEVACIZUMAB: Limited Human Data¡XProbably Compatible (Intravitreal) Potential Toxicity (Intravenous),IVD;,,¡iN/S¡j¥i¿ï ¡C,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. µ}ÄÀ«á¿éª`·»²GÀ³Â\©ñ©ó2-8«×CÀx¦s¡A¶W¹L8¤p®É¥¼¨Ï¥ÎÀ³¥á±ó¡C 3. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü30-60¤ÀÄÁ¡C 4. ºÊ´ú³J¥Õ§¿¡C 5. ¨C2-3¶gºÊ´ú¦åÀ£ÅÜ¤Æ¡C
OSINE,Doxepin,Sinequan 25mg,CNEU,,¾AÀ³¯g:Anxiety or depression. °Æ§@¥Î:Dry mouth¡A blurred vision¡A constipation¡A drowsiness¡A confusion¡A paresthesias¡A extrapyramidal effects¡A seizures¡A hypotension¡A tachycardia; skin rash. ¸T§Ò:Glaucoma; urinary retention.,,«Ç·Å,Mild to moderate: 75 mg daily. Optimum dose: 75-150 mg/day. Severe: Higher doses with subsequent gradual increase to 300 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IPRO125,Hydroxyprogesterone caproate,Progeston Depot-S 125mg/1mL inj,HM,,¸T§Ò: Undiagnosed vaginal bleeding¡A breast cancer¡A pregnancy¡A lactation. Thrombophlebitis¡A thromboembolic disorders¡A cerebral apoplexy or a history of these conditions. Markedly impaired liver function. °Æ§@¥Î: GI disturbances¡A increased appetite¡A wt gain or loss¡A oedema¡A acne¡A allergic skin rashes¡A urticaria¡A mental depression¡A discomfort in breast; cough¡A dyspnoea¡A circulatory disturbances. Pain at site of inj. ¾AÀ³¯g: Recurrent miscarriage¡A Amenorrhoea¡A Abnormal uterine bleeding¡A Palliative treatment of advanced¡A inoperable endometrial carcinoma,,«Ç·Å,Adult: IM Recurrent miscarriage 65-125 mg/wk during the 1st half of pregnancy. To reduce the risk of preterm birth: Pregnant females > OR = 16 years: I.M.: 250 mg once weekly. Treatment may begin between 16 weeks 0 days and 20 weeks 6 days of gestation. Continue weekly administration until 37 weeks gestation or until delivery¡A whichever comes first. Amenorrhoea or abnormal uterine bleeding 375 mg as a single dose; may repeat at 4-wkly intervals if needed. After 4 days of desquamation¡A or if there is no bleeding w/in 21 days after administration of the drug¡A may initiate cyclic therapy that includes an oestrogen.,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
LPS45,Sodium Phosphate,Phospho-Soda 45mL,ALIM,,¾AÀ³¯g: Relief of occasional constipation. For use as part of a bowel cleansing regimen in preparing the patient for surgery or for preparing the colon for X-ray or endoscopic exam. °Æ§@¥Î: Nausea¡A vomiting¡A bloating. ¸T§Ò: Congenital megacolon¡A intestinal obstruction or CHF. Children < 5 years.,,«Ç·Å,Prep for diagnostic procedures & pre-op 45 mL the evening before & repeat on the morning of the procedure. Constipation Adult & children >= 12 years Dilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 45 mL/24 hr. Children 10-11 yearsDilute 15 mL in 240 mL liqd & drink at least 240 mL. Max: 15 mL/24 hr. 5-9 years Dilute 7.5 mL in 240 mL liqd & drink at least 240 mL. Max: 7.5 mL/24 hr. Take 120 ml cool water with 45 ml of the Fleet phospho-soda to drink¡A and follow up more than 240 ml of cool water. Twice a day.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
LSHO,Cyproheptadine,Showmin 0.4mg/mL¡A 60mL,HIMM,,¾AÀ³¯g: Symptomatic relief of allergic conditions¡A eg urticaria¡A angioedema¡A rhinitis¡A conjunctivitis¡A pruritic skin disorders. Vascular headaches¡A migraine. °Æ§@¥Î: Increased appetite & weight gain. CNS depression¡A drowsiness¡A lassitude¡A dizziness¡A incoordination¡A sedation. Headache¡A psychomotor impairment¡A dry mouth¡A thickened respiratory tract secretions¡A blurred vision¡A urinary difficulty & retention¡A constipation¡A increased gastric reflux. Rashes¡A hypersensitivity reactions. Convulsion¡A sweating¡A myalgia¡A paresthesia¡A extrapyramidal effects¡A tremor¡A sleep disturbances¡A depression¡A tinnitus¡A hypotension¡A hair loss. ¸T§Ò: Pregnancy & lactation. Neonates. Debilitated patients¡A elderly.,,«Ç·Å,Allergic conditions & pruritus Adult Initial: 4 mg tid. Maintenance: 12-16 mg/day in 3 or 4 divided doses. Max: 32 mg/day. Children 7-14 years 4 mg bid-tid (max: 16 mg/day)¡A 2-6 years 2 mg bid-tid (max: 12 mg/day). Vascular headache & migraine 4-8 mg 4-6 hrly.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EACU,Adapalene,Acure gel 0.1% 15gm,TDER,,¾AÀ³¯g: Treatment of acne vulgaris. °Æ§@¥Î: Skin irritation such as redness & sensation of heat. Dermatologic: Dry skin (36.1% or less )¡A Erythema (0.2% to 21.8% )¡A Scaly skin (25.3% or less),,«Ç·Å,Apply once daily at bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
EALC2,Alcohol,75% Alcohol 20mL/bottle,TDER,Antiseptics and disinfectants.,Hypersensitivity to any component of the formulation.,Mild local discomfort.,25¢J¥H¤UÀx¦s,Use appropriate amount for disinfection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,EXT;,,,,,
EAND,Testosterone,Androgel 50mg,HM,Testosterone replacement therapy in male hypogonadal disorders.,Prostatic or mammary carcinoma.,Acne¡A alopecia¡A application site reaction¡A asthenia¡A depression¡A emotional lability¡A gynecomastia¡A headache¡A hypertension¡A abnormal lab tests (e.g. elevated hemoglobin or hematocrit¡A hyperlipidemia¡A elevated triglycerides¡A hypokalemia¡A decreased HDL¡A elevated glucose¡A elevated creatinine¡A or elevated total bilirubin)¡A libido decreased¡A nervousness¡A breast pain¡A prostate disorder¡A testis disorder. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation¡A Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ),¥é³æµL«ü¥Ü,Adult and elders: 5 g (50mg testosterone) of gel once daily¡A best in the morning¡A Maximum dose 10g /day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;,,,,,
EBRIS,Terbutaline,Bricanyl solution 5mg/2mL,ERSP,Relief of bronchospasm in bronchial asthma¡A chronic bronchitis¡A emphysema & other bronchopulmonary conditions when bronchoconstriction is a complicating factor.,Hypersensitivity to any of the ingredients of Bricanyl.,Tremor¡A tonic cramp & palpitations. Tachycardia¡A arrhythmia. Urticaria & exanthema may occur.,30¢J¥H¤UÀx¦s,Single dose 5mg QID. If a single dose is not used up¡A it can be stored in the storage tank of the nebulizer within 24 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;INHL;,,,,,
IPCA3,PCA-3 inj 300mL (¦Û¶O),PCA-3 inj 300mL (¦Û¶O),CNEU,,,,,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Fentanyl PREGNANCY RECOMMENDATION: Human Data Suggest Risk Ropivacaine PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Fentanyl BREASTFEEDING RECOMMENDATION: Compatible Ropivacaine BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IVD;,,,,,¦¨¥÷¡GFentanyl 0.5mg/10mL+ Ropica 400mg/40mL¡A in N/S 250 mL
ECIL,Ciprofloxacin,Ciloxan 0.3%¡A 5mL ophthalmic solution,TOPH,Corneal ulcer ¡AConjunctivitis.,Hypersensitivity to quinolones.,Local burning or discomfort¡A itching¡A lid edema¡A tearing¡A white crystalline precipitates which will resolve.,30¢J¥H¤UÀx¦s,Corneal ulcer: Instill 2 drops into affected eye every 15 minutes for the first 6 hours¡A then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On day 2¡A instill 2 drops into the affected eye hourly. On days 3-14¡A instill 2 drops into affected eye every 4 hours. Treatment may continue after day 14 if re-epithelialization has not occurred. Bacterial conjunctivitis: Instill 1 to 2 drops into the conjunctival sac every 2 hours while awake for 2 days and 1 to 2 drops every 4 hours while awake for the next 5 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,Ciprofloxacin: Contraindicated (Use only if no other alternatives) [¥é³æ] °w¹ïCILOXANÂI²´²G¥Î©óÃh¥¥¤k©Ê¡A¥Ø«eµL¸ê®Æ©Î¶È¦³¦³­­ªº¸ê®Æ¡CCiprofloxacinªº°Êª«¬ã¨s¥¼Åã¥Ü¥Í´Þ¬r©Ê¤è­±ªºª½±µ¦³®`§@¥Î¡C ¬°¤F¦w¥þ°_¨£¡AÃh¥¥´Á¶¡«ØÄ³Á×§K¨Ï¥ÎCILOXANÂI²´²G¡C °w¹ï§½³¡²´·úµ¹¤©CILOXAN¹ï©ó¥Í¨|ªº¼vÅT¡A¥Ø«e©|µL¬ÛÃö¼Æ¾Ú¡C°Êª«¤fªA¸ÕÅç¨Ã¥¼«ü¥X¹ï¥Í´Þ¯à¤O¦³ª½±µ¦³®`ªº¼vÅT¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Ciprofloxacin: Contraindicated (Use only if no other alternatives) [¥é³æ] ¥¼ª¾§½³¡²´¥Îciprofloxacin¬O§_·|Âà²¾¦Ü¨Å¥Ä¡C¨t²Î©Êµ¹¤©Ciprofloxacin¥i©ó¤HÃþ¨Å¥Ä¤¤´ú±o¡C¾A·íªº²´·ú§½³¡¨Ï¥Î¥»ÃÄ¡A¤£¤Ó¥i¯à¦b¨Å¥Ä¤º°»´ú¨ìCiprofloxacin¡A¥ç¤£·|¹ïÀ¦¨à³y¦¨Á{§É¤Wªº¼vÅT¡AµM¦Ó¤´µM¤£¯à±Æ°£¹ï­÷¨Å«Ä¤lªº­·ÀI¡A¥²¶·¦Ò¶qÀ¦¨à­÷¨Åªº§Q¯q»P¥À¿Ë±µ¨üªvÀøªº§Q¯q¡A¨Ó¨M©w°±¤î­÷¨Å©Î°±¥Î©Î¸Tµ´±µ¨üCILOXANÂI²´²GªvÀø¡C,OD;OL;OU;,,,,,
ECOMB,Brimonidine + Timolol,Combigan 5mL ophthalmic solution,TOPH,Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.,Bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; in patients receiving MAOIs therapy.,Conjunctival hyperemia¡A ocular burning & stinging.,25¢J¥H¤UÀx¦s,Instill 1 drop in the affected eye(s) Q12H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,Brimonidine ophthalmic: Limited Human Data¡XProbably Compatible Timolol ophthalmic: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] ¥Ø«e¦bCOMBIGANR¨Ï¥Î©óÃh¥¥°ü¤k¤è­±©|µL¨¬°÷ªº¸ê®Æ¡C°£«D¦³©úÅãªº¥²­n©Ê¡A§_«h¤£À³©óÃh¥¥´Á¶¡¨Ï¥ÎCOMBIGANR. Brimonidine tartrate©óÃh¥¥´Á¶¡¨Ï¥Î¡A¥Ø«e©|µL¨¬°÷ªºÁ{§É¸ê®Æ¡C¦b°Êª«¸ÕÅç¤¤¡Abrimonidine tartrate¨Ã¥¼¤Þ°_¥ô¦ó­P·î­L§@¥Î¡CBrinonidine tartrate¸gÃÒ¹ê¡A¥i¤Þµo¨ß¤l¤§¬y²£¡A¤]·|¨Ï¤j¹«¥X¥Í«á¤§¥Íªø¨ü¨ì§í¨î¡A ¨âªÌªº¥þ¨­¼ÉÅS¶q¬ù¤À§O¬°¤H Åé±µ¨üªvÀø©ÒÀò±oªº¼ÉÅS¶q37­¿¤Î134­¿¡C Timolol¬y¦æ¯f¾Ç¬ã¨sÅã¥Ü¡A©ó¤fªA§ë»P¤éªýÂ_¾¯«á¡A¥¼¥X²{­P·î­Lªº²{¶H¡A¦ý¥i¯à¦³¤l®c¤º­L¨à¥Íªø¿ðº¢ªº­·ÀI¡C ¦¹¥~¡A·í¤éªýÂ_¾¯«ùÄò§ë»P¦Ü¤À®Y®É¡A¦b­L¨à¤Î·s¥Í¨à¨­¤W¡A·|¥X²{BªýÂ_¾¯ªº¼x¥ü¤Î¯gª¬(¨Ò¦p¡A¤ß°Ê¹L½w¡A§C¦åÀ£¡A©I§lµ~­¢¤Î§C¦å¿})¡C­YCOMBIGANR «ùÄò§ë»P¦Ü¤À®Y®É¡A ·s¥Í¨à©ó¥X¥Í­º¤é»ÝÄY±KºÊ±±¡C°w¹ï¤p¹«¡B¤j¹«¤Î¨ß¤l ©Ò¶i¦æ¤§­P·î­L©Ê¬ã¨sÅã¥Ü¡A¨Ï¥Î¤ñ¤HÅéCOMBIGANR ¨C¤é¾¯¶q°ª 4200 ­¿¤§¤fªA¾¯¶q¡A¨Ã¥¼¥X²{­L¨à·î§Îªº²{¶H¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Brimonidine ophthalmic: Limited Human Data¡XProbably Compatible Timolol ophthalmic: Limited Human Data¡XProbably Compatible [¥é³æ] Timolol¥i±q¥À¨Å¤¤¤Àªc¥XÅé¥~¡C¥Ø«e©|¤£²M·¡brimonidine¬O§_·|¦Û¥À¨Å¤¤¤Àªc¡A¦ý¤wª¾¥i±q¤j¹«ªº¨Å¥Ä¤¤¤Àªc¥XÅé¥~¡A¦]¦¹¡A±Â¨Å°ü¤k¤£À³¨Ï¥ÎCOMBIGANR¡C,OD;OL;OU;,,,,,
ECUS5,Timolol,CUSIMOLOL 0.5%¡A 5mL,TOPH,,¾AÀ³¯g: Reduction of increased intraocular pressure in conditions such as ocular hypertension¡A chronic open-angle glaucoma (including aphakic patients) & certain instances of secondary glaucoma. °Æ§@¥Î: Conjunctivitis¡A blepharitis¡A keratitis. Rarely hypersensitivity¡A urticaria¡A local or general eruptions. Mild bradycardia¡A hypotension¡A bronchospasm¡A congestive cardiac insufficiency & masking of hypoglycemic symptoms of IDDM patients. Cardiovascular: Angina¡A Bradyarrhythmia (9%)¡A Heart failure¡A Hypotension Dermatologic: Pruritus¡A Rash¡A Urticaria Gastrointestinal: Abdominal pain¡A Diarrhea¡A Indigestion¡A Nausea¡A Vomiting Musculoskeletal: Cramp Neurologic: Confusion (13%)¡A Dizziness (2%-10%)¡A Headache (2%-12%) Ophthalmic: Blurred vision¡A Burning sensation in eye (15%-20%)¡A Cataract¡A Conjunctival hyperemia¡A Corneal anesthesia (15%-20%)¡A Dry eyes (15%-20%)¡A Reduced visual acuity¡A Ophthalmic Psychiatric: Depression (12%)¡A Hallucinations (11%)¡A Psychotic disorder (3%) Respiratory: Cough¡A Dyspnea Other: Fatigue (3%-11%)¡A Infectious disease,,«Ç·Å,1 drop of 0.25 % soln in affected eye bid. If responseis not satisfactory¡A use 1 drop of 0.5 % soln in the affected eye bid.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
EDDA,Desmopressin,Minirin 0.01%¡A 2.5mL Nasal Spray,HM,,¾AÀ³¯g: Central diabetes insipidus¡A Renal concentrating capacity test. °Æ§@¥Î: Headache¡A abdominal pain¡A nausea¡A hyponatraemia¡A dizziness¡A peripheral edema¡A daytime polyuria¡A stomach pain¡A dry mouth¡A weight gain. Rarely¡A emotional disturbances in children¡A allergic skin reactions. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea¡A Will respond to dosage decrease Neurologic: Fatigue (10% )¡A Headache (22.5% ) ¸T§Ò: Habitual or psychogenic polydipsia¡A history of known or suspected cardiac insufficiency & other conditions requiring diuretic treatment¡A moderate to severe renal insufficiency¡A syndrome of inappropriate ADH secretion¡A known hyponatraemia.,,25¢XC ¥H¤U,Central diabetes insipidus: Adult 10-20 mcg 1-2 times daily. children 5-10 mcg 1-2 times daily. Renal concentrating capacity test Nasal spray Adult 40 mcg¡A Children >1 years 20 mcg¡A Infant <1 years 10 mcg.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IN;,,,,,
EDERO,Clobetasol,Dermovate ointment 0.05% 5gm,TDER,,¾AÀ³¯g: Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids. °Æ§@¥Î: Features of hypercorticism¡A local atrophic changes¡A pigmentation changes & hypertrichosis. Exacerbation of symptoms may occur. ¸T§Ò: Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus; primary cutaneous viral infection; bacterial¡A fungal infected skin lesions; perianal & genital pruritus; dermatoses in infant < 1 year including dermatitis & napkin eruptions. ¬O¤@ºØ±j®ÄªºÃþ©T¾JÃÄ»I¡A±j®ÄÃþ©T¾J¬O¸û¤£¾A¦X¡u¥Î¦b¨zªù¤Î¥Í´Þ¾¹¡v¡A¬O¦]¬°¦¹³¡¦ìªí¥Ö¼h«ÜÁ¡¡A­Y¦³µoª¢²{¶H¥i±Ä¥Î®z®Ä©Î¤¤®ÄÃþ©T¾J¡A¥H§K§l¦¬±j®ÄÃÄ«~¡A²£¥Í¤£¨}°Æ§@¥Î,,«Ç·Å,Apply sparingly to the affected area once or bid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EEML,Lidocaine + Prilocaine,Emla cream 5%¡A 5gm,TDER,Topical anesth of the skin in connection with insertion of IV catheters¡A blood sampling & superficial surgical procedures.,Hypersensitivity to local anaesthetics of the amide type or to any other component of Emla.,Rarely¡A mild local reactions eg edema¡A itching¡A erythema; corneal irritation¡A methemoglobinemia (rare).,30¢J¥H¤U,Apply a thick layer to intact skin and cover with an occlusive dressing. Dermal analgesia can be expected to increase for up to 3 hours under occlusive dressing and persist for 1 to 2 hours after removal of the cream. adult¡A minor dermal procedures (eg¡A IV cannulation or venipuncture): Apply 2.5 g (1/2 of the 5 g tube) over 20 to 25 cm2 of skin surface area) for at least 1 hour pediatrics Minor dermal procedures (eg¡A IV access¡A venipuncture¡A IM injection); anesthetic <5 kg: Apply < or = 1 g per 10 cm2 area; cover with an occlusive dressing for the usual duration of application of 60 minutes prior to the procedure. maximum total dose (for all sites combined): 1 g; maximum application area: 10 cm2; maximum application time: 1 hour. 5 kg to 10 kg: Apply 1 to 2 g per 10 cm2 area; cover with an occlusive dressing for at least 60 minutes. Max total dose (for all sites combined): 2 g; maximum application area: 20 cm2; maximum application time: 4 hours. >10 kg to 20 kg: Apply 1 to 2 g per 10 cm2 area; cover with an occlusive dressing for at least 60 minutes. maximum total dose (for all sites combined): 10 g; maximum application area: 100 cm2; maximum application time: 4 hours. >20 kg: Apply 1 to 2 g per 10 cm2 area; cover with an occlusive dressing for at least 60 minutes. maximum total dose (for all sites combined): 20 g; maximum application area: 200 cm2; maximum application time: 4 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
IPCA1,PCA-1 inj 100mL (¦Û¶O),PCA-1 inj 100mL (¦Û¶O),CNEU,,,,,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,,,,¦¨¥÷¡GMorphine 100mg/10mL in N/S 89 mL
IPCA2,PCA-2 inj 125mL (¦Û¶O),PCA-2 inj 125mL (¦Û¶O),CNEU,,,,,,,,,,,,,,,,,,,¦¨¥÷¡GFentanyl 0.25mg/5mL+Chirocaine**0.5%¡A 20mL¡A in N/S 100 mL
EONMD,Neostigmine Methylsulfate,ONSD 0.01% 10mL,TOPH,Relief of fatigue of ocular muscle.,Hypersensitivity to any component of the formulation.,Transient stinging,30¢J¥H¤U,Instill 2 drops TID .The dosage may be increased or decreased moderately.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,Neostigmine: Limited Human Data¡XNo Relevant Animal Data,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Neostigmine: Limited Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
ETEI,Etofenamate,Teiria gel 5%¡A 40gm,CNEU,,¾AÀ³¯g: Relief of pain & inflammation associated with musculoskeletal¡A joint & soft tissue disorders e.g. stiff shoulder¡A sprains¡A strains¡A lumbago¡A arthralgia & myalgia. °Æ§@¥Î: Rarely¡A allergic skin reactions.,,«Ç·Å,Apply tid-qid to the affected area.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EZNO,Zinc Oxide,Zin ointment 20%¡A 1oz (28.4gm),TDER,,¾AÀ³¯g:Eczema¡A scalp dermatoses.,,«Ç·Å,Apply several times as need.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OGLI3,Gliclazide,Gliclax SR 30mg,META,,¾AÀ³¯g: ²Ä¤G«¬¿}§¿¯f(B023503100) Type 2 DM. °Æ§@¥Î: Hypoglycaemia¡A nausea¡A dyspepsia¡A diarrhoea¡A constipation. ¸T§Ò: Type 1 diabetes¡A diabetic keto-acidosis or diabetic pre-coma¡A severe renal or hepatic insufficiency¡A co-administration with miconazole¡A pregnancy¡A lactation. Avoid coadministration with phenylbutazone or danazol.,,«Ç·Å,1-4 tab taken once daily at breakfast. Max : 120 mg daily.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OREQ,Ropinirole,ReQuip PD 2mg PR,CNEU,,¾AÀ³¯g:Treatment of idiopathic Parkinson's disease. °Æ§@¥Î:Hallucinations¡A confusion¡A somnolence¡A syncope¡A dizziness (including vertigo)¡A dyskinesia¡A nausea¡A abdominal pain¡A vomiting¡A dyspepsia¡A constipation¡A peripheral edema (including leg edema)¡A nervousness¡A fatigue¡A postural hypotension¡A hypotension.,,«Ç·Å,Adult Parkinson's disease: The starting dose is 2mg taken once daily for 1-2 weeks¡A followed by increases of 2mg/day at 1 week or longer intervals as appropriate¡A depending on therapeutic response and tolerability¡A up to a maximally recommended dose of 24mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
EEXEP,Rivastigmine,Exelon Patch 5,CNEU,Mild to moderate Alzheimer's disease.,Hypersensitivity to rivastigmine¡A other carbamate derivatives or any other components of the product.,More frequent: diarrhea; weight loss; Iindigestion; loss of strength ; nausea; vomiting; loss of appetite; abdominal pain; confusion; constipation; depression; dizziness; fatigue ; headache; insomnia Less frequent: high blood pressure; fainting; general feeling of discomfort or illness; increased sweating; runny nose. Rare: aggression; seizures; trembling and shaking of hands and fingers; trouble in urinating,30¢J¥H¤U,Mild-to-moderate Alzheimer¡¦s dementia: Initial¡A 4.6 mg/24 hours patch (Exelon patch 5) topically once daily; after a minimum of 4 weeks and good tolerability¡A may titrate dose to 9.5 mg/24 hours patch (Exelon patch 10) topically once daily. Conversion from oral therapy: If oral daily dose <6 mg¡A switch to 4.6 mg/24 hours patch. Apply patch on the next day following last oral dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ©|µL¦bÃh¥¥°ü¤k¶i¦æªº§¹¾ã¨}¦n¹ï·Ó¸ÕÅç¡C©óÃh¥¥¤j¹«¤Î¨ß¤l¶i¦æªº¤fªA¥Í´Þ¸ÕÅç¡AÅã¥ÜµL­P·î­L©Ê¡C©ó¤j¹«¸ÕÅçµo²{­L¨àªºÅé­«µy·L¤U­°¡A¤@¯ë¦b¦¹¾¯¶q¤U·|¦³¤@¨Ç¥ÀÅé¬r©Ê¡C ¦bÃh¥¥°Êª«¤¤¡Arivastigmine ¤Î/©Î ¨ä¥NÁÂª«·|³q¹L­L½L¡C©|¥¼©úÁA¬O§_·|µo¥Í¦b¤HÃþ¡C °Êª«¥Í´Þ©Ê¸ÕÅç¨Ã¤£¯à§¹¥þ¥Î¨Ó¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹Ãh¥¥´Á¶¡¥u¦³¦b¼ç¦bªº®Ä¯q¤j©ó¹ï­L¨àªº¦M®`ªº±¡ªp¤U¤è¥i¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¤£²M·¡Exelon ·|¤£·|³Q¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C©ó¤j¹«¤fªA§ë¤©rivastigmine«á¡Arivastigmine»P¨ä¥NÁÂª«·|¤Àªc¦Ü¨Å¥Ä·í¤¤¡A¦b¨Å¥Ä¤¤ªºrivastigmine¤Î¨ä¥NÁÂª«ªº¿@«×¬ù¬°¥ÀÅé¦å¼ß¿@«×ªº¤G­¿¡C ¦]¬°³\¦hÃÄª«·|¤Àªc¨ì¤HÃþªº¨Å¥Ä¤¤¡A¥B¦]¬°Exelon Patch¹ï§l¨ÅªºÀ¦¨à¥i¯à³y¦¨ÄY­«¤£¨}¤ÏÀ³¡A¬GÀ³¦Ò¶qÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡A¨M©w¬O§_°±¤î­÷¨Å©Î°±¥ÎÃÄª«¡C,EXT;,,,,,
IPUL,Metoclopramide,Pulin inj 10mg/2mL,ALIM,Prophylaxis of nausea and vomiting¡A Gastroesophageal reflux disease¡A Gastroparesis due to diabetes mellitus.,Preexisting pheochromocytoma or other catecholamine-releasing paragangliomas; increased risk of hypertensive crisis. Sensitivity or intolerance to metoclopramide products.,Common Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )¡A Taste sense altered (Nasal route¡A 15% )¡A Vomiting (1.4% to 2.1% ) Neurologic: Asthenia¡A Headache (4.2% to 5.2% )¡A Somnolence (Oral¡A 2.1% to 2.8% ; IV¡A 70% ) Serious Neurologic: Neuroleptic malignant syndrome¡A Tardive dyskinesia,25¢J¥H¤U,Adult: 1AMP(10mg) BID-QD IM¡A IVPUSH or IVD. Pediatric: QD IM¡A IVPUSH or IVD. Child>6 years-old: 0.2mg/kg or 1/2-2/3AMP(5-6.6mg) or 1-1.3mL. Age 3-6 years: 0.2-0.25mg/kg or 1/3-1/2AMP(3.3-5mg) or 0.7-1.0mL. Age1-3 years: 0.25mg/kg or 1/4-1/3AMP(2.5-3.3mg) or 0.5-0.7mL. Age 6-12 months: 0.3mg/kg or 1/4AMP(2.5mg) or 0.5mL. Newborn: QD 0.25mL(0.4mg/kg)¡A Age < 6 months: 0.3-0.4mL(0.4-0.35mg/kg) IM.,µL»Ý½Õ¾ã¾¯¶q,(UpToDate 20221219)There are no dosage adjustments provided in the manufacturer's labeling; however¡A metoclopramide has been used safely in patients with advanced liver disease with normal renal function.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ]Ãh¥¥¥ÎÃÄ¤À¯ÅB: °Êª«¹êÅçÃÒ¹ê¹ï­L¨àµL®`¦ý¯Ê¥F¨¬°÷ªº¥¥°ü¹êÅç; ©Î°Êª«¹êÅç¦³°Æ§@¥Î³ø§i¡A¦ý¥¥°ü¹êÅçµLªkÃÒ©ú¹ïÃh¥¥ªì´Á¤Î«á´Á¤§­L¨à¦³®`¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]µL¬ÛÃö»¡©ú¡C,IM;IVD;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,over 1 to 2 minutes,The following Administration of Recommended is according to UpToDate(20221206): Adult¡A higher doses (>10 mg) are to be diluted in 50 mL of compatible solution (preferably N/S) and at least 15 minutes.,1. The following Administration of Recommended is according to UpToDate(20221206): lower doses (< or =10 mg) of metoclopramide can be given IV push undiluted over 1 to 2 minutes. 2. ¿ðµo©Ê¹B°Ê»ÙÃª(Tarddive dyskinesia)µo¥Íªº­·ÀI»PÁ`²Ö¿n¾¯¶q¦³¥¿¬ÛÃö©Ê¡A¤ÀªR«á¦³20%¯f±w¨Ï¥Î¶W¹L12¶g¡A¬G¤£«ØÄ³ªø´Á(>12¶g)¨Ï¥Î¡A°£«D¸g¹Lµû¦ô¨äªvÀø®Ä¯q°ª©óTarddive dyskinesia¤§­·ÀI¡C 3. ¥X²{À@Åé¥~°Æ§@¥Î¯gª¬®É½Ð°±¤îµ¹ÃÄ¡A¤×¨ä¬O¤p¨à±Ú¸s¤ñ¦¨¤H§ó®e©öµo¥Í¡C
EEXE,Sulconazole Nitrate,Exelderm solution 10mL,TDER,Tinea pedis¡A tinea cruris¡A tinea corporis¡A candidiasis¡A tinea versicolor.,Hypersensitivity to any component of the formulation.,Local itch¡A stinging¡A burning sensation¡A contact dermatitis¡A inflammation.,25¢J¥H¤U¡AÁ×¥ú±K³¬®e¾¹Àx¦s,Apply BID-TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Sulconazole (Exelderm): No Human Data¡XPotential Toxicity,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Sulconazole (Exelderm): No Human Data¡XProbably Compatible,EXT;SKIN;TOPI;,,,,,
ESERT,Salmeterol + Fluticasone,Seretide 250 Accuhaler,ERSP,,I: Regular treatment of reversible obstructive airways disease¡A including asthma in childn and adults. ADR : (salmeterol) tremor¡A subjective palpitations¡A headache. Cardiac arrhythmias may occur in susceptible patients. (fluticasone) hoarseness¡A candidiasis of the mouth and throat. CI : Hypersensitivity to any component of this product.,,< 30 ¢J,Adult & Childn > 12 yr : 1 inhalation twice daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OUTA,Quetiapine,Utapine 200mg,CNEU,Bipolar I disorder¡A Acute manic episode of Bipolar disorder¡A Schizophrenia.,Hypersensitivity to quetiapine.,Common Cardiovascular: Increased diastolic arterial pressure (Pediatric¡A 40.6% )¡A Increased systolic arterial pressure (Pediatric¡A 15.2% )¡A Orthostatic hypotension (Up to 7% )¡A Tachycardia (Up to 6% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )¡A Serum triglycerides raised (8% to 28% )¡A Weight gain (3% to 28% ) Gastrointestinal: Abdominal pain (3% to 7% )¡A Constipation (2% to 11% )¡A Increased appetite (2% to 12% )¡A Indigestion (2% to 7% )¡A Nausea (Pediatric¡A 6% to 10% )¡A Vomiting (Pediatric¡A 7% to 8% )¡A Xerostomia (Adult¡A 9% to 44%; pediatric¡A 4% to 10% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (Up to 10% )¡A Dizziness (8% to 19% )¡A Extrapyramidal disease (1.1% to 12.9% )¡A Headache (17% to 21% )¡A Insomnia (8% to 12% )¡A Lethargy (1% to 5% )¡A Somnolence (18% to 57% )¡A Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )¡A Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )¡A Pain (7% ) Serious Cardiovascular: Prolonged QT interval (0.1% to less than 1% )¡A Sudden cardiac death¡A Syncope (0.3% to 2% ) Endocrine metabolic: Diabetic ketoacidosis Gastrointestinal: Bowel obstruction¡A Pancreatitis Hematologic: Agranulocytosis¡A Leukopenia¡A Neutropenia (0.3% to 1.5% ) Immunologic: Anaphylaxis Neurologic: Seizure (0.05% to 0.5% )¡A Tardive dyskinesia Psychiatric: Suicidal thoughts Reproductive: Priapism Other: Neuroleptic malignant syndrome,¤Å¶W¹L25¢J,Schizophrenia: Initial: 50mg/day on Day1¡A 100mg/day on Day 2¡A 200mg/day on Day 3 and 300mg/day on Day 4. Increase further to a target dose of 300 to 450 mg/day and adjust dose based on response and tolerability. Usual dosage range: 150 to 750 mg/day. Bipolar I disorder: Initial: 100mg /day on day 1¡A 200mg/day on day 2¡A 300mg/day on day 3¡A 400mg/day on day 4. Increase further to a target dose of 200 to 800 mg/day and adjust dose based on response and tolerability. Usual effective dose is 400 to 800 mg/day.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³°_©l¾¯¶q¬° 25 mg/day¡A increase dose daily in increments of 25 to 50 mg/day to an effective dose based on response and tolerability,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ¸`¿ý]¥Ø«e¹ï©óQuetiapine¨Ï¥Î©ó¥¥°ü¡AÁÙ¨S¦³¾A·í¥B±±¨î¨}¦nªº¬ã¨s¡C¦b¦³­­ªº¥Xª©¤åÄm¤¤¡A¨S¦³­«¤j·î§Î»PÃh¥¥´Á¶¡¼ÉÅS©óquetiazine¦³Ãö¡C «D­P·î§@¥Î¡G¦b§³®W²Ä¤T´Á¼ÉÅS©ó§Üºë¯«¯fÃÄª«(¥]¬AQuetiapine)¡A·s¥Í¨à¥X¥Í«á¦³µo¥ÍÀ@Åé¥~®|©M/©Î§ÙÂ_¯gª¬ªº­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Quetiapine·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡A¦]¦¹«ØÄ³°ü¤k¦bªA¥ÎQuetiapine´Á¶¡¤£­nÁý¥À¥¤¡C¦b¥Xª©ªº¯f¨Ò³ø§i¤¤¡AQuetiapine¦b¨Å¥Ä¤¤ªº¿@«×±qÀË´ú¤£¨ìªºµ{«×¨ì170£gg/L¡C¦ô­pªºÀ¦¨à¾¯¶q¬O¸gÅé­«®Õ¥¿ªº¥À¿Ë¾¯¶qªº0.09%¦Ü0.43%¡C®Ú¾Ú¦³­­ªº¥À¿Ë/À¦¨à°t¹ï¼Æ(N=8)¡Aºâ¥XÀ¦¨à¨C¤é¾¯¶q±q¤p©ó0.01mg/kg(¥À¿ËÄ~¶q°ª¹F¨C¤Ñ400mg)¦Ü0.01mg/kg(¥À¿ËÄ~¶q°ª¹F¨C¤Ñ400mg)¡C,AC;AC15;PC;PO;WM;,,,,,
IACT,Human Plasminogen Activator,Actilyse inj 50mg,HEMT,Thrombolytic treatment in acute myocardial infarction¡A acute massive pulmonary embolism with haemodynamic instability & acute ischaemic stroke,Patients with known hypersensitivity to the active substance alteplase¡A gentamicin (a trace residue from the manufacturing process) or to any of the excipients listed in Description. Contraindications in acute myocardial infarction¡A acute massive pulmonary embolism and acute ischaemic stroke: high risk of haemorrhage such as: significant bleeding disorder at present or within the past 6 months; known haemorrhagic diathesis; patients receiving effective oral anticoagulant treatment¡A e.g. warfarin sodium (INR > 1.3); manifest or recent severe or dangerous bleeding; known history of or suspected intracranial haemorrhage; suspected subarachnoid haemorrhage or condition after subarachnoid haemorrhage from aneurysm; any history of central nervous system damage (i.e. neoplasm¡A aneurysm¡A intracranial or spinal surgery); recent (less than 10 days) traumatic external heart massage¡A obstetrical delivery¡A recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture); severe uncontrolled arterial hypertension; bacterial endocarditis¡A pericarditis; acute pancreatitis; documented ulcerative gastrointestinal disease during the last 3 months¡A oesophageal varices¡A arterial-aneurysm¡A arterial/venous malformations; neoplasm with increased bleeding risk; severe liver disease¡A including hepatic failure¡A cirrhosis¡A portal hypertension (oesophageal varices) and active hepatitis; major surgery or significant trauma in past 3 months. Additional contraindications in acute myocardial infarction: any known history of haemorrhagic stroke or stroke of unknown origin; known history of ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months except current acute ischaemic stroke within 4.5 hours. Additional contraindications in acute massive pulmonary embolism: any known history of haemorrhagic stroke or stroke of unknown origin; known history of ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months except current acute ischaemic stroke within 4.5 hours. Additional contraindications in acute ischaemic stroke: symptoms of ischaemic attack beginning more than 4.5 hours prior to infusion start or symptoms for which the onset time is unknown and could potentially be more than 4.5 hours ago (see Pharmacology: Pharmacodynamics under Actions); minor neurological deficit or symptoms rapidly improving before start of infusion; severe stroke as assessed clinically (e.g. NIHSS>25) and/or by appropriate imaging techniques; seizure at onset of stroke; evidence of intracranial haemorrhage (ICH) on the CT-scan; symptoms suggestive of subarachnoid haemorrhage¡A even if CT-scan is normal; administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory; patients with any history of prior stroke and concomitant diabetes; prior stroke within the last 3 months; platelet count of below 100¡A000/mm3; systolic blood pressure > 185 mm Hg or diastolic BP > 110 mm Hg¡A or aggressive management (intravenous pharmacotherapy) necessary to reduce BP to these limits; blood glucose < 50 mg/dl or > 400 mg/dl (< 2.8mM or > 22.2mM).,Serious Cardiovascular: Cardiac dysrhythmia¡A Cardiac tamponade¡A Laceration - injury¡A Myocardial rupture¡A Pericardial effusion¡A Pericarditis Gastrointestinal: Gastrointestinal hemorrhage (5% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis¡A Hypersensitivity reaction Neurologic: Cerebral herniation¡A Cerebrovascular accident (1.6% )¡A Intracranial hemorrhage (0.4 to 1.3% )¡A Ischemic stroke¡A Seizure Respiratory: Pleural effusion¡A Pulmonary edema Other: Angioedema¡A Orolingual,30¢J¥H¤U,Myocardial infarction: a)90 mins (accelerated) dose regimen and patients with body weight > 65 kg¡A started within 6 hr after symptom onset: 15 mg as an IV bolus¡A 50 mg as an infusion over the 1st 30 mins¡A followed by an infusion of 35 mg over 60 mins until the max dose of 100 mg. Patients with body weight < 65 kg: 15 mg as an IV bolus & 0.75 mg/kg over 30 mins (max 50 mg)¡A followed by an infusion of 0.5 mg/kg over 60 mins (max 35 mg). MI: b)3 hr dose regimen for patients in whom treatment can be started between 6 & 12 hr after symptom onset: 10 mg as an IV bolus¡A then 50 mg as an IV infusion over 1st hr¡A followed by infusions of 40 mg over 120 mins¡A until the max dose of 100 mg . Patient < 65 kg Max total dose: 1.5 mg/kg. Pulmonary embolism 10 mg as an IV bolus over 1-2 mins¡A followed by 90 mg as an IV infusion over 2 hr¡A until the max dose of 100 mg. Patients with body weight < 65 kg.Max total dose: 1.5 mg/kg . Acute ischemic stroke: Activase: IV: Within 3 hours of the onset of symptom onset (labeled use) or within 3 to 4.5 hours of symptom onset: Note: Perform non-contrast-enhanced CT or MRI prior to administration. Aspirin initiation is generally delayed ?24 hours after administration of alteplase; use of antiplatelet agents (eg¡A aspirin) or therapeutic-dose anticoagulants (eg¡A heparin) within 24 hours of alteplase administration is not recommended.Recommended total dose: 0.9 mg/kg (maximum total dose: 90 mg)Load with 0.09 mg/kg (10% of 0.9 mg/kg dose) as an IV bolus¡A followed by 0.81 mg/kg (90% of 0.9 mg/kg dose) as a continuous infusion over 60 minutes.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,¨Ï¥Î©Òªþµ}ÄÀ·»²G (50mL)½Õ°t¦nªºActilyse 1 mg/mL,¡iN/S¡j¥i¿ï ¡C,X,Acute ischaemic stroke: 0.9 mg/kg via infusion over 60 min. MI: 15 mg as bolus¡A then 50 mg (0.75 mg/kg in patients <65 kg) via infusion over 30 min¡A followed by 35 mg (0.5 mg/kg in patients <65 kg) via infusion over 1 hr. Max total: 100mg.,1. ¨Ï¥Î©Òªþµ}ÄÀ·»²G (50mL)½Õ°t¦nªºActilyse 1 mg/mL¡A¥i¥ÎN/S¶i¤@¨Bµ}ÄÀ¡A³Ì§C¿@«× 0.2 mg/mL¡C¤£¥i¨Ï¥Î¨ä¥L¿éª`²Gµ}ÄÀ¡A¤]¤£¥i»P¨ä¥LÃÄª«²V¦X¡C 2. ª`®g³t²v¨Ì·ÓÂåÅñ«ü¥Ü¡A¤£¦P¾AÀ³¯g¦³¤£¦Pªºµ¹ÃÄ®Éµ{ªí¡C
IBCGI8,BCG Immunotherapeutic,BCG 81mg Immucyst,RACA,,¾AÀ³¯g: Treatment & prophylaxis of primary or recurrent carcinoma in-situ (CIS) of the urinary bladder & prophylaxis following transurethral resection of primary or recurrent stage Ta &/or T1 papillary tumours¡A regardless of antecedent intravesical treatment. °Æ§@¥Î:Hematuria¡A urinary frequency¡A dysuria¡A bacterial UTI. Local irritative symptoms¡A fever¡A prostatitis¡A ureteral obstruction¡A systemic BCG infection. ¸T§Ò: Patients on immunosuppressive therapy or with compromised immune systems. Patients who had a transurethral resection or traumatic bladder catheterization in the previous weeks. Active TB¡A evidence of systemic BCG reaction¡A fever¡A UTI.,,2-8¢J,81 mg intravesically once weekly for 6-8 weeks (induction therapy). Therapy is resumed after 6 weeks rest with a weekly installation for its 1-3 weeks. Repeat every 6 months until 36 months.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IHER,Trastuzumab,Herceptin inj 440mg,RACA,Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery¡A chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).,Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin,Abdominal pain¡A accidental injury¡A asthenia¡A back pain¡A chest pain¡A chills¡A fever¡A flu syndrome¡A headache¡A infection¡A neck pain¡A vasodilation¡A GI disturbances¡A peripheral edema¡A edema¡A arthralgia¡A myalgia¡A anxiety¡A depression¡A dizziness¡A insomnia¡A paresthesia¡A somnolence¡A asthma¡A cough increased¡A dyspnea¡A epistaxis¡A lung disorders¡A pleural effusion¡A pharyngitis¡A rhinitis¡A sinusitis¡A pruritus¡A rash. Cardiovascular: Edema (8% monotherapy )¡A Peripheral edema (5% to 10% )¡A Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% )¡A Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy )¡A Loss of appetite (14% monotherapy )¡A Nausea (6% to 33% )¡A Vomiting (3.5% to 23% ) Hematologic: Anemia (4% )¡A Febrile neutropenia (23% adjuvant therapy )¡A Leukopenia (3% )¡A Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% )¡A Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% )¡A Dizziness (4% to 13% )¡A Headache (6% to 26% )¡A Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% )¡A Dyspnea (3% to 22% )¡A Pharyngitis (12% monotherapy )¡A Rhinitis (2% to 14% ) Other: Fever (6% to 36% ),2-8¢J,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion¡A then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks¡A or initial dose of 8 mg/kg over 90 minutes IV infusion¡A then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion¡A followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü³Ìµu30 ¤ÀÄÁ¡C 3. ¿éª`®Éª`·N¯f¤H¬O§_¥X²{©I§l§xÃø¡B©PÃä¤ô¸~¡B§C¦åÀ£©Î¨ä¥L«æ©Ê¹L±Ó¤ÏÀ³¯gª¬¡C 4. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
IINT2,Eptifibatide,Integrilin inj 20mg/10mL,HEMT,,¾AÀ³¯g: Unstable angina¡A Angioplasty °Æ§@¥Î: Bleeding¡A hypotension; localised Inj site reaction; thrombocytopaenia; back pain; anaphylaxis; GI¡A intracranial or pulmonary haemorrhage. Cardiovascular: Hypotension Hematologic: Bleeding¡A Minor (3 -12%) ¸T§Ò: Active bleeding¡A increased risk of haemorrhage including hemorrhagic disorders¡A cerebrovascular disorders¡A history of stroke¡A uncontrolled hypertension¡A severe trauma¡A severe renal impairment¡A recent major surgery. Lactation.,,2-8 ¢XC,IV Unstable angina 180 mcg/kg followed by 2 mcg/kg/min for up to 72 hr. If percutaneous coronary procedure is performed during therapy¡A continue infusion for 18-24 hr after procedure¡A up to a max total of 96 hr. Angioplasty Initial: 180 mcg/kg immediately pre-op¡A followed by 2 mcg/kg/min. A 2nd dose of 180 mcg/kg should be given 10 mins later. Continue infusion until discharge or up to 18-24 hr. Min treatment duration: 12 hr.,,,,¥i¯à¦w¥þ,,,Hold Breast Feeding ¼È°±­÷¨Å,,,,,,,
IMV,Multivitamin,Multivita inj 2mL,NUTR,,¾AÀ³¯g:Multivit deficiency.,,2-8¢J,2-5 mL as a single dose IV. Per mL Vit A 2¡A000 iu¡A vit B1 10 mg¡A vit B2 2 mg¡A vit B6 3 mg¡A nicotinamide 20 mg¡A pantothenol 5 mg¡A vit C 100 mg¡A vit D 200 iu¡A vit E 1 mg,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ITRA5,Atosiban,Tractocile inj 5mL (7.5mg/mL) infusion,SGU,Delay imminent preterm birth in pregnant women with regular uterine contractions of at least 30 seconds duration at a rate of >=4 per 30 mins; cervical dilation of 1-3 cm (0-3 for nulliparas) & effacement of >=50%¡A age >=18 years; gestational age of 24-33 weeks¡A normal fetal heart rate.,Gestation ages <24 weeks or >33 weeks premature rupture of the membranes > 30 weeks of gestation¡A intrauterine growth retardation & abnormal fetal heart rate¡A antepartum uterine hemorrhage requiring immediate delivery¡A eclampsia & severe pre-eclampsia requiring delivery¡A intrauterine fetal death¡A suspected intrauterine infection¡A placenta praevia¡A abruptio placenta¡A abnormal or high-risk pregnancy.,Very common (>10%): nausea. Common (1-10%): headache¡A dizziness¡A hot flushes¡A vomiting¡A tachycardia¡A hypotension¡A inj site reactions¡A hyperglycemia. Uncommon (0.1%-1%): fever¡A insomnia¡A pruritus¡A rash. Rare (<0.1%): incidental cases of uterine haemorrhage/uterine atony and one case of allergic reaction were reported.,2-8¢J,Premature labour: Adult: Initially¡A 6.75 mg bolus (as 7.5 mg/mL solution) over 1 minute¡A immediately followed by continuous infusion (as 0.75 mg/mL solution) of 0.3 mg/min for 3 hr¡A then 0.1 mg/min for up to 45 hr. Total duration: < or = 48 hr. the maximum dose: 330.75 mg. Stage 1: 0.9mL IV bolus¡A over 1 minute¡A total 6.75mg. Stage 2: IV infusion over 3 hours¡A 24mL/hour¡A 18mg/hour. Stage 3: IV infusion¡A 8mL/hour¡A 6mg/hour. Reconstitution: for infusion: Withdraw 10 mL from a 100-mL bag of NaCl 0.9%¡A glucose 5% or Ringer¡¦s lactate solution and replace with 10 mL of atosiban concentrate (using 2 vials of 37.5 mg/5 mL solution) to produce a final concentration of 0.75 mg/mL.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,ªì©l¾¯¶q¡G6.75mg/0.9mL ±Àª`1¤ÀÄÁ,ºû«ù¾¯¶q:100~300 mcg/min,1.¤£¥i»P¨ä¥LÃÄª«²V¦X 2.ºû«ù¾¯¶q:100~300 mcg/min 3.°_©l¾¯¶q:7.5mg/mL¡A±Àª`®É¶¡¦Ü¤Ö1¤ÀÄÁ
LIDO1,Ibuprofen,Idofen 20mg/mL¡A 120mL suspension,CNEU,Relief of pain¡A inflammation & fever.,Peptic ulceration; patients in whom attacks of asthma¡A angioedema¡A urticaria or rhinitis are precipitated by aspirin & other NSAIDs.,GI effects including ulceration; rashes; bronchospasm. Rarely¡A thrombocytopenia.,25¢J¥H¤UÁ×§K¶§¥úª½®g,Children: Antipyretic: For children aged 6 months to 12 years old¡A if the body temperature is lower than 102.5 ¢XF (about 39.2 ¢X C)¡A the recommended dose is 0.25 mL/kg; if the body temperature is 102.5 ¢X F (about 39.2 ¢X C) or higher¡A the recommended dose is 0.5 mL/kg. The duration is generally maintained for 6 to 8 hours. maximum dose: 2 mL/kg/day. Analgesic: For children from 6 months to 12 years of age to relieve mild to moderate pain¡A the recommended dose is 0.5 mL/kg Q6H-Q8H. maximum daily dose: 2 mL/kg/day Juvenile arthritis: 1.5-2 mL/kg/day in 3-4 divided doses. Children with mild symptoms 1 mL/kg/day. Adults: Antipyretic:20mL Q4-6H. Primary menstrual pain:20mL Q4H Rheumatoid arthritis and osteoarthritis¡A chronic diseases including sudden symptoms :60 mL-160 mL per day (15 mL QID; 20 mL-40 mL¡A TID-QID),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IGLY1,Glycerin + Fructose + Sodium chloride,GLYCETOSE inj 10%¡A 500mL,CAVS,Treatment of increased intracranial pressure & intracranial edema¡A improvement of impaired consciousness & neurologic deficits in cerebral infarct¡A intracerebral & subarachnoid hemorrhages¡A head injury¡A brain tumor¡A cerebromeningitis. Post-op therapy following brain surgery; reduction of brain vol at time of brain surgery.,Hereditary fructose intolerance.,Lactic acidosis; hemoglobinuria; headache¡A thirst¡A nausea; hypernatremia.,µL¯S§O«ü¥Ü,Adult usual dosage: 200-500 mL QD-BID IV infusion (rate: 500 mL over 2-3 hours). Duration of treatment usually is about 1-2 weeks¡A the dosage may be adjusted according to age and symptoms. Reduction of the brain volume during brain surgery: IV bolus of 500 mL over 30 minutes.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,Glycerin: Limited Human Data¡XProbably Compatible Fructose: no data,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Glycerin: No Human Data¡XProbably Compatible Fructose: no data,IVD;,,,,¥H500mL/2~3 hours ³t²vºwª`,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IART3,Sodium Hyaluronate,Arti Aid I-A inj 3mL,CNEU,,¾AÀ³¯g: Treatment of pain in osteoarthritis in knee in patients who have failed simple analgesics (e.g. acetaminophen) & nonpharmacologic treatment. °Æ§@¥Î: Transient swelling¡A pain¡A heat & redness may occur sporadically at the injection site. ¸T§Ò: 1. Hypersensitivity to the product components. 2. Infections or skin diseases at injection site.,,2-8¢J,Inject 1 syringe once weekly for 5 weeks.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IDIF,Fluconazole,Diflucan °w¾¯ 100mg/50mL,QANB,Candidemia¡A disseminated candidiasis & invasive candidiasis¡A Oropharyngeal candidiasis¡A Esophageal candidiasis¡A Vag candidiasis¡A Cryptococcal meningitis¡A Dermal infection (tinea corporis¡A cruris & dermal candidal infection)¡A tinea pedis¡A Prevention of fungal infection in patients with AIDS.,Patients with known hypersensitivity to fluconazole or to related azole compounds.,Common: Nausea (2.3-7%)¡A Vomiting (1.7%)¡A Headache (1.9-13%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Agranulocytosis¡A Anaphylaxis¡A Seizure,30¢J¥H¤U,Adult: Cryptococcal meningitis and cryptococcosis: 400 mg on day 1¡A then 200-400 mg once daily for 6-8 weeks; cryptococcal meningitis prophylaxis in patients with AIDS: 100 mg once daily. Candidiasis: 400 mg on day 1¡A followed by 200-400 mg once daily. Oropharyngeal candidiasis: 50-100 mg once daily. Vaginal candidiasis: 150 mg as a single dose. Children (> 1 year): 1-2 mg/kg/day for superficial fungal infection; 3-6 mg/kg/day for systemic fungal infection. *****NEONATE ANTIBIOTICS DOSE***** Fluconazole: Invasive Candidiasis Duration of therapy for candidemia: 2 weeks after documented clearance of Candida from the bloodstream and resolution of symptoms (without metastatic complications) Prophylaxis: 3 mg/kg/dose¡A twice weekly¡A duration up to 6 weeks Treatment: loading dose 25 mg/kg GA <= 29 week Postnatal 0-14 days: maintenance dose 12mg/kg Q48H GA <= 29 week Postnatal >=15days : maintenance dose 12mg/kg Q24H GA 30-44 week Postnatal 0-7 days: maintenance dose 12mg/kg Q48H GA 30-44 week Postnatal >=8 days: maintenance dose 12mg/kg Q24H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,PREGNANCY RECOMMENDATION: Human Data Suggest Risk (¤j©ó400 mg/day),Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,¥H10mL/¤ÀÄÁ³t²v½wºCºwª` (¨C¤p²~¦Ü¤Öºwª`¶W¹L30¤ÀÄÁ)¡Aµ¹ÃÄ³t²v < 200 mg/hr,1. ª`·N¬O§_µo¥Í¥Ö½§¯l¡B¸¡µh¯gª¬¡C 2. ºÊ´ú¨xµÇ¥\¯à»P¤ß¹q¹ÏÅÜ¤Æ¡C
IEPO1,Recombinant Human Erythropoietin,EPO inj 1 IU (¬~µÇªù¶E¥Ó³ø¥Î),HEMT,Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy,Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.,Increased BP¡A thrombotic or vascular events. Flu-like symptoms¡A bone pain & chills after inj. Seizures. Skin reactions¡A palpebral edema. Rarely¡A erythroblastopenia.,2-8¢JÁ×¥úÁ×§K§N­á,Chronic renal failure Adult patients Correction phase: 50 IU/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 IU/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 IU/kg. Pediatric patients Correction phase: 50 IU/kg 3 times/week IV. When necessary¡A dose adjustments should be made in increments of 25 IU/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally¡A children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 IU/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 IU/kg for an additional 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ¥»ÃÄ«~¬°¹w¥ý¥R¶ñªº°wµ©¡A­­³æ¦¸¨Ï¥Î¡Aµ¹ÃÄ«e¶·¥ýÀË¬d½T©w·»²GµLÂø½è©ÎÅÜ¦â¡C 2. ¥Ö¤Uª`®g¨C¦¸Åé¿n¤£¥i¶W¹L1 mL¡C¦p»Ýª`®g¸û¤j¶q¡AÀ³©ó¤£¦P³¡¦ìµ¹ÃÄ¡C 3. ÀR¯ßª`®g®É¶¡¦Ü¤Ö¶·¶W¹L 1-5 ¤ÀÄÁ¡C¦å²G³zªR¯f¤H¦b³zªR´Á¶¡¡A¥i¸g¥Ñ³zªR½u¤º¤@­Ó¾A·íªºÀR¯ß¤J¤f¶i¦æ¤j¶qª`®g¡C 4. ¥»ÃÄ«~¡u¤£¥i¥H¡vÀR¯ßÂIºw¿éª`©Î»P¨ä¥LÃÄª«²V¥Î¡C
IFOR,Ceftazidime,Fortum 1gm,QANB,,¾AÀ³¯g: Severe infections of resp tract¡A ENT¡A urinary tract¡A GI¡A biliary & abdominal. Skin & soft tissue infections¡A bone & joint infections. Infections associated with haemo- & peritoneal dialysis & with continuous ambulatory peritoneal dialysis (CAPD). °Æ§@¥Î: Phlebitis or thrombophlebitis at IV inj site¡A pain &/or inflammation after IM inj. Hypersensitivity reactions¡A maculopapular or urticarial rash¡A fever¡A pruritus. GI disturbances¡A candidiasis¡A vaginitis¡A headache¡A dizziness¡A parasthesia¡A bad taste. Transient hematological changes. Cardiovascular: Phlebitis (less than 2%) Dermatologic: Injection site pain Gastrointestinal: Diarrhea (less than 2%) Immunologic: Immune hypersensitivity reaction¡A Rash (2%) ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult Dose range: 1-6 g/day in 2-3 divided doses by IV/IM inj. Majority of infections: 1 g 8 hrly or 2 g 12 hrly. UTI 500-1¡A000 mg 12 hrly. Severe infections¡A especially immunocompromised patients¡A including those with neutropenia 2 g 8 or 12 hrly or 3 g 12 hrly. As a prophylactic agent in prostatic surgery 1 g at the induction of anaesth. A 2nd dose at the time of catheter removal. Fibrocystic adults with normal renal function who have pseudomonal lung infections 100-150mg/kg/day in 3 divided doses. Infant & children >2 month 30-100 mg/kg/day in 2-3 divided doses. Immunocompromised¡A fibrocystic or children w/ meningitis Up to 150 mg/kg/day (max 6 g/day) in 3 divided doses. Neonate & children up to 2 month 25-60 mg/kg/day given in 2 divided doses.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ª`®g«e¸ß°Ý¯f±w¬O§_¦³£]-ñQÓiÃþ§Ü¥Í¯À¹L±Ó¥v¡C 2. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡BPT­È¡Aª`·N¬O§_µo¥Í§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C
ISTE,Ustekinumab,Stelara inj 45mg/0.5mL,TDER,Psoriasis (Ps) (1) Treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. (2) Pediatric Psoriasis: Treatment of moderate to severe plaque psoriasis in pediatric and adolescent patients (6 years and older) who are inadequately controlled on or intolerant to phototherapy or other systemic therapies. Psoriatic Arthritis (PsA) (1) Treatment of active psoriatic arthritis in patients (6 years and older) who have had an inadequate response to disease-modifying antirheumatic drug (DMARD) therapy. It can be used alone or in combination with methotrexate (MTX). (2) Treatment of active psoriatic arthritis in adult patients (18 years and older) who have had an inadequate response to DMARD therapy¡A to inhibit the progression of structural damage associated with the disease. Crohn¡¦s Disease: treatment of moderate to severe active Crohn's Disease in adults who (1) have failed or are intolerant to treatment with immunomodulators or corticosteroids¡A and have received treatment with anti-TNF£\ agents without failure. (2) have failed or are intolerant to treatment with immunomodulators or corticosteroids¡A and have not previously received anti-TNF£\ agents. (3) have failed or are intolerant to one or more anti-TNF£\ agents. Ulcerative Colitis: treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to¡A lost response to¡A or were intolerant to conventional therapy (e.g¡A corticosteroids¡A 6-mercaptopurine¡A azathioprine)¡A or a biologic agent (e.g.¡A a TNF-alpha antagonist or vedolizumab).,Clinically significant hypersensitivity to ustekinumab or to any component of the product. Clinically significant active infections (e.g.¡A active tuberculosis).,Common: Erythema at injection site (1-5%)¡A Pruritus (1-4%)¡A Abdominal pain (7%)¡A Diarrhea (2-4%)¡A Nausea (3%)¡A Vomiting (4%)¡A Headache (5-10%)¡A Urinary tract infectious disease (4%)¡A Mycosis (Crohn disease¡A 5%)¡A Bronchitis (5%)¡A Nasopharyngitis (7-24%)¡A Sinusitis (3-4%)¡A Upper respiratory infection (4-5%)¡A Fatigue (3-4%)¡A Fever (5%)¡A Infectious disease (Psoriasis¡A 27-72.3%) Serious: Skin cancer¡A Non-melanoma (Up to 1.5%)¡A Diverticulitis (Less than 1%)¡A Anaphylaxis (Crohn disease¡A 0.1%)¡A Hypersensitivity reaction (Crohn disease¡A 0.08%)¡A Posterior reversible encephalopathy syndrome¡A Herpes zoster ophthalmicus (Less than 1%)¡A Cryptogenic organizing pneumonia¡A Interstitial pneumonia¡A Pulmonary eosinophilia¡A Angioedema¡A Cancer (Up to 1.7%)¡A Infectious disease¡A Serious (Up to 2.8%),2-8¢XCÀx¦s¥B»ÝÁ×¥ú¡A¤Á¤Å§N­á»P®¶·n,[Plaque psoriasis] Adults: (<=100 kg) 45 mg SC initially and 4 weeks later¡A followed by 45 mg every 12 weeks. (>100 kg) 90 mg SC initially and 4 weeks later¡A followed by 90 mg every 12 weeks. Pediatric Psoriasis (6 years and older): (<60 kg) 0.75 mg/kg SC at Weeks 0 and 4¡A then every 12 weeks. (60-100 kg) 45 mg SC at Weeks 0 and 4¡A then every 12 weeks. (>100 kg) 90 mg SC at Weeks 0 and 4¡A then every 12 weeks. Consider discontinuation if no therapeutic benefit after 28 weeks of treatment. [Psoriatic Arthritis] Adults: 45 m SC initially¡A followed by 45 mg 4 weeks later¡A then 45 mg every 12 weeks. For patients with co-existent moderate to severe plaque psoriasis weighing >100 kg: 90 mg SC initially¡A followed by 90 mg 4 weeks later¡A then 90 mg every 12 weeks. Pediatrics (6-17 years): (<60 kg) 0.75 mg/kg SC at Weeks 0 and 4¡A followed by the same dose every 12 weeks. (60-100 kg) 45 mg SC at Weeks 0 and 4¡A followed by the same dose every 12 weeks. (>100 kg with co-existent moderate to severe plaque psoriasis) 90 mg SC at Weeks 0 and 4¡A followed by the same dose every 12 weeks. [Crohn¡¦s Disease and Ulcerative Colitis] (>=55 kg) Induction¡A 260 mg IV over at least 1 hour as a single dose; maintenance¡A followed 8 weeks later with 90 mg subQ every 8 weeks¡A followed by 90 mg every 12 weeks. (>55-85 kg) Induction¡A 390 mg IV over at least 1 hour as a single dose; maintenance¡A followed 8 weeks later with 90 mg subQ every 8 weeks¡A followed by 90 mg every 12 weeks. (>85 kg) Induction¡A 520 mg IV over at least 1 hour as a single dose; maintenance¡A followed 8 weeks later with 90 mg subQ every 8 weeks¡A followed by 90 mg every 12 weeks. For patients losing response on 12-week dosing¡A dose escalation to every 8 weeks may be considered and found beneficial. Based on clinical judgment¡A patients may subsequently be treated with 90 mg every 8 weeks or 12 weeks. Discontinue therapy if evidence of loss of clinical benefit at 16 weeks following dose escalation or 16 weeks following initiation at the every 8 week dosing. Immunosuppressants and/or corticosteroids may be continued during treatment. Tapering or discontinuation of corticosteroids may be considered in patients who have responded to treatment per standard practice. Resuming therapy with subcutaneous administration every 8 weeks after a treatment interruption is safe and effective.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¹ï¥¥°ü¨Ï¥ÎSTELARA¤è­±ªº¦³­­¸ê®Æ¡A©|¤£¨¬¥H½T»{¬O§_¦s¦³ÃÄª«¬ÛÃö­·ÀI¡C¦b°Êª«¥Í´Þµo¨|¬r©Ê¬ã¨s¤¤¡A¹ïÃh¥¥µU¤l§ë¤©¼ÉÅS¶q¸û¤HÃþ©ó³Ì°ª«ØÄ³¥Ö¤Uª`®g¾¯¶q(MRHD)¤U©Ò¹F¨ì¤§¼ÉÅS¶q°ª¥X100­¿ªºustekinumab¤§«á¡A¨Ã¥¼µo²{¥ô¦ó¤£¨}µo¨|¼vÅT¡C ¦bÆ[¹î©Ê¬ã¨s¡B¤wµoªíªº¯f¨Ò³ø§i¤Î¤W¥««áªººÊµø¸ê®Æ¤¤¡A¹ï¥¥°ü¨Ï¥ÎSTELARAR¤è­±ªº¸ê®Æ¦³­­¡A©|¤£¨¬¥H½T»{¬O§_¦s¦³ÃÄª«¬ÛÃö­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e¨ÃµL¥ô¦óÃö©óustekinumab¬O§_·|¥X²{©ó¤HÃþ¨Å¥Ä¡B¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT¡B©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅT¤è­±ªº¸ê®Æ¡C¥ÀÅéªºIgG¤wª¾·|¥X²{©ó¤HÃþªº¨Å¥Ä¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡AÁý­÷¥À¨Å¤§À¦¨àªº¥þ¨­¼ÉÅS¶q¹w´ÁÀ³¸Ó«Ü§C¡A¦]¬°ustekinumab¬O¤j¤À¤l¡A¨Ã¥B¦b­G¸z¹D¤¤·|­°¸Ñ¡CµM¦Ó¡A¦pªGustekinumab·|Âà²¾¶i¤J¤HÃþªº¨Å¥Ä¡A¥Ø«e¨Ã¤£½Tª¾­G¸z¹D¤¤ªº§½³¡¼ÉÅS·|³y¦¨¦óºØ¼vÅT¡C À³±NÁý­÷¥À¨Å¹ïµo¨|»P°·±dªº¦n³B©M¥À¿Ë¹ïSTELARAªºÁ{§É»Ý¨D¡A¥H¤ÎSTELARA©Î¥À¿Ëªº°òÂ¦¯e¯f¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C,SC;,,,,,1.«ØÄ³¨C¦¸ª`®g³£À³¬I¥´©ó©M¤W¦¸¤£¦P³¡¦ì¡A¤£¥iª`¤J¥Ö½§¦³Ä²µh¡B·ï¶Ë¡B¬õ´³©Îµw¤Æ²{¶Hªº°Ï°ì¡C 2.»Ý§NÂÃ¶J¦s©ó2-8¢XC¡C¤Å§N­á¡C¤Å®¶·n¡C­Y¶J¦s©ó°ª¹F30¢XC¡A³Ìªø¹F³æ¦¸30¤Ñ¡C¤@¥¹¤w³Q¶J¦s©ó«Ç·Å¤U¡A¤Å±N¨ä©ñ¦^¦B½c¶J¦s¡A¦pªG¨S¦³¦b30¤Ñ¤º¨Ï¥Î½Ð¥á±ó¡C
IGLYB,Glycerin + Fructose + NaCl,Glybrain inj 10%¡A 500mL,CAVS,,¾AÀ³¯g: Treatment of increased intracranial pressure & intracranial edema¡A improvement of impaired consciousness & neurologic deficits in cerebral infarct¡A intracerebral & subarachnoid hemorrhages¡A head injury¡A brain tumor¡A cerebromeningitis. Post-op therapy following brain surgery; reduction of brain vol at time of brain surgery. °Æ§@¥Î: Lactic acidosis; hemoglobinuria; headache¡A thirst¡A nausea; hypernatremia. ¸T§Ò: Hereditary fructose intolerance.,,«Ç·Å,Adult 200-500 mL once or bid IV drip in 2-3 hr/500 mL.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IGW5,Dextrose,Glucose inj 5% 500mL,MSIV,Treatment of carbohydrate and fluid depletion.,Hypersensitivity to any component of the formulation.,Hyperglycemia,«Ç·Å,Individualized dosage. Adult 500-1000 mL each time IV drip.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IRR;IVD;PO;,,,,,
IHBIG0,Hepatitis B Immune Globulin,HyperHep B 0.5mL/dose(¦Û¶OB¨x§K¬Ì²y³J¥Õ),HIMM,Prophylaxis of hepatitis B.,Severe platelet deficiency or other coagulation disorders.,Occasionally temporary tenderness at inj site¡A skin reactions & elevations of temperature.,2-8¢JÁ×§K§N­á,IM¡A acute exposure to blood containing HBsAg 0.06 mL/kg within 24 hours. Prophylaxis of infants born to HBsAg & HBeAg postive mothers 0.5 mL to be given within 12 hours of birth. Sexual exposure to an HBsAg postive person 0.06 mL/kg as a single dose within 14 days of sexual contact. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ]¥¥°ü¨Ï¥Î«á¬O§_·|¶Ë®`­L¨à¡B©Î¼vÅT¥Í´Þ¯à¤O¤]¤£¤Ó²M·¡¡A°ß¦³©ú½T»Ý­n®É¤~¥i§ë»P¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
OGEN,Ursodeoxycholic Acid,Genurso 100mg,ALIM,Dissolution of cholesterol-rich gallstones¡A Primary biliary cirrhosis¡A Prevention of gallstones in patients undergoing rapid wt loss.,Calcified and pigment gallstones¡A radio opaque gallstones. Nonfunctioning gall bladders; chronic liver and peptic ulcer disease. Inflammatory disease of colon and small intestine. Pregnancy.,Diarrhoea¡A pruritus¡A nausea¡A vomiting¡A gallstone calcification.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adult 13-15mg/kg devided into four times a day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OGUT,Midodrine,Gutron 2.5mg,CAVS,,I: Orthostatic circulatory regulation disturbances & dysregulation¡A constitutional & symptoms hypotension¡A constitutional Management of side effects produced by hypertensive. CI: Raised BP¡A severe organic heart diseases¡A acute nephritis¡A thyrotoxicosis¡A pheochromocytoma.,,,Adult & adolescent Tab 1/2 tab. To be taken once or bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OLIG,Lithium Carbonate,Ligilin 300mg,CNEU,Bipolar disorder¡A prevention of manic-depressive disorder.,Cardiovascular disease¡A significant; high risk of lithium toxicity; if treatment is required¡A monitoring in a hospital setting is necessary. Concomitant use of diuretics; if treatment is required¡A monitoring in a hospital setting is necessary. Debilitation¡A severe; high risk of lithium toxicity; if treatment is required¡A monitoring in a hospital setting is necessary. Dehydration¡A severe; high risk of lithium toxicity; if treatment is required¡A monitoring in a hospital setting is necessary. Renal disease¡A significant; high risk of lithium toxicity; if treatment is required¡A monitoring in a hospital setting is necessary. Sodium depletion; high risk of lithium toxicity; if treatment is required¡A monitoring in a hospital setting is necessary.,Common: Acne¡A Hyperparathyroidism (2.7-23.2%)¡A Hypothyroidism¡A Weight increased¡A Gastritis¡A Nausea¡A Xerostomia¡A Leukocytosis¡A Dizziness (23%)¡A Hyperreflexia¡A Deep tendon¡A Nephrotoxicity¡A Fatigue (26%)¡A Increased thirst (28%) Serious: Bradyarrhythmia (Severe)¡A Brugada syndrome¡A Sinus node dysfunction¡A Transient reduction in peripheral circulation as a whole¡A Erythema multiforme¡A Diabetes insipidus¡A Hyponatremia¡A Angioedema¡A Ataxia¡A Coma¡A Neuroleptic malignant syndrome¡A Pseudotumor cerebri¡A Increased intracranial pressure and papilledema¡A Seizure¡A Epileptiform¡A Blurred vision (9%)¡A Tinnitus¡A Giddiness¡A Nephrotic syndrome¡A Polyuria (38%)¡A Renal interstitial fibrosis¡A Renal tubular acidosis¡A Tubulointerstitial nephritis¡A Serotonin syndrome,Á×¥úÁ×¼ö¡AÀx¦s©ó25¢J¥H¤U,Acute mania: 900-1800mg/day in 3 divided doses. Adjust blood lithium concentration to about 1.0-1.5mEq/L. Check the blood lithium concentration twice a week until the effective blood concentration is reached and the clinical symptoms are stable. Long-term treatment: 900-1200mg in 3-4 divided doses to adjust the blood lithium concentration to 0.6-1.2mEq/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,[¥é³æ] ¦³¼Æ¾ÚÅã¥Ü¾Y¹ï­L¨à¦³¤£¨}¤ÏÀ³¡A¦b¥¥°ü¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡A¤×¨ä¬OÃh¥¥«e¤T­Ó¤ë¡A Á×§K¨Ï¥Î¥»¾¯¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¾Y¯à±Æ¤J¨Å¥Ä¤¤¡A±Â¨ÅªÌ«ØÄ³¤£­n¨Ï¥Î©ÎÅv©y§Q¹ú¨Ï¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
OLIS0,Metergoline,Liserdol 4mg(¦Û¶O),HM,,Amenorrhoea¡A galactorrhea¡A female infertility¡A lactational disorder¡A puerperal breast engorgement¡A Parkinson's disease¡A premenstrual mammary syndrojme¡A male infertility due to hyperprolactinemia spermacrasia¡A acromegalia.,,RT,1 tab once-tid¡A increased gradually at meals.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
OMAD2,Levodopa + Benserazide,Madopar 200/50mg,CNEU,Parkinsonism.,Severely decompensated endocrine¡A renal¡A hepatic function & cardiac disorders. Psychoses & severe psychoneuroses. Patients <25 years. Pregnancy. Combination with MAOIs (except selegiline¡A rasagiline¡A moclobemide).,Anorexia¡A GI upsets (rare); cardiac arrhythmias & orthostatic hypotension. Abnormal involuntary movements. Mild¡A transient leucopenia & thrombocytopenia (rare). Psychotic disturbances. Urine discoloration.,30¢J¥H¤U,Should be taken on an empty stomach¡A and avoid high protein diets.Initially 1/2 tablet TID-QID. Optimal daily dosage: 300-800 mg levodopa and 75-200 mg benserazide¡A divided into 3 or more doses. Average maintenance dose: 1 tablet (levodopa 100 mg/benserazide 25 mg) 3-6 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Levodopa - human suggest low risk Benserazide- [18] no data,Unknown ¨S¦³¸ê®Æ,Levodopa - probably compatible Benserazide-[8] no data,AC;PC;PO;,,,,,
OMOR3,Morphine,MORPHINE SR 30mg,CNEU,,¾AÀ³¯g: Relief of mild to moderate pain especially associated with cancer¡A MI & surgery. Anxiety & sleeplessness associated with severe pain. Symptomatic treatment of diarrhoea. Relief of dyspnoea of left ventricular failure & pulmonary edema. Suppression of cough. Pre-op to anaesth. General anaesth in specialized procedures. °Æ§@¥Î: Respiratory depression¡A apnoea¡A circulatory depression¡A respiratory arrest¡A shock¡A cardiac arrest. Constipation¡A lightheadedness¡A dizziness¡A sedation¡A nausea¡A vomiting¡A sweating¡A dysphoria & euphoria. ¸T§Ò: Acute or severe bronchial asthma; respiratory depression; biliary colic; GI obstruction¡A concurrent MAOI therapy.,,«Ç·Å,1 tab 12 hrly.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ICOS,Dactinomycin,Cosmegen inj 0.5mg,RACA,,¾AÀ³¯g:Treatment of cancers in children & testicular cancer. Wilms' tumor¡A rhabdomyosarcoma¡A palliative treatment of other types of cancer. °Æ§@¥Î:Malaise¡A fatigue¡A lethargy¡A fever¡A myalgia¡A proctitis¡A hypocalcemia¡A growth retardation¡A infection. Pneumonitis. Cheilitis¡A dysphagia¡A esophagitis¡A ulcerative stomatitis¡A pharyngitis. Anorexia¡A nausea¡A vomiting¡A abdominal pain¡A diarrhea¡A gastrointestinal ulceration. Liver toxicity including liver function test abnormalities¡A ascites¡A hepatomegaly¡A hepatitis¡A hepatic failure with reports of death¡A hepatic veno-occlusive disease which may be associated with intravascular clotting disorder & multi-organ failure. Anemia¡A agranulocytosis¡A leukopenia¡A neutropenia¡A febrile neutropenia¡A thrombocytopenia. Baldness¡A skin eruptions¡A acne¡A flare-up of erythema or darkening pigmentation of skin. ¸T§Ò:Chicken pox or herpes zoster infections. Pregnancy¡A lactation.,,«Ç·Å,Adult 0.5 mg IV daily for max. 5 days. Children 15 mcg/kg IV for 5 days or total dosage of 2¡A500 mcg/m2 IV for 7 days. Adult & children 2nd cycle can only start 3 weeks later.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,1. ÃÄ«~µ}ÄÀ¦¨¿@«×10mcg/mL©Î¥H¤W®É¡A ¦b¬Á¼þ©ÎPVC¿éª`®e¾¹¤º¡A «Ç·Å¤U¥i¦w©w10¤p®É.
OPER7,Dipyridamole,Persantin 75mg,HEMT,,Coronary insufficiency; Inhibition of platelet aggregation.,,,Adult: Coronary insufficiency : 150-225mg daily in divided doses. Inhibition of platelet aggregation : 300- 450mg daily in divided doses. Childn in general¡A 5-10mg/kg body weight.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OPRE6,Conjugated Estrogen,Premarin 0.625mg,HM,,¾AÀ³¯g:¤k©Ê¶Pº¸»X¯Ê¥F(B018977100),,RT,Osteoporosis: 1.25 mg/day cyclically. Moderate to severe vasomotor symptoms associated with the menopause: 1.25 mg/day if the patient is menstruating¡A begin administration on day 5 of bleeding.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OQUIN,Quinidine Gluconate,Quinaglute 324mg,CAVS,,Premature atrial & ventricular comtrctions¡A paroxysmal Superventricular tachycardia¡A atrial flutter¡A paroxysmal ventricular fibrillation. Maintenace of conversion of atrial fibrillation.,,,324-648 mg q6-12h¡A (max. 4 g/day).,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OQUIS,Quinidine,Quinidine sulfate 200mg,CAVS,,I: Premature atrial & ventricular comtrctions¡A paroxysmal Superventricular tachycardia¡A atrial flutter¡A paroxysmal ventricular fibrillation. Maintenace of conversion of atrial fibrillation. ADR: Headache¡A dizziness¡A visual disturbance¡A nausea¡A abdominal pain¡A skin itch. CI: Complete heart block.,,RT,Premature atrial & ventricular comtrctions: 1 ~ 1/2 tab tid ~ qid Sudden ventricular tachycaedia: 2 ~ 3 tab 2 ~ 3 hrly until tachycardia is terminated. Atrial fibrillation: individualised dosage.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OREM,Mirtazapine,RemeRon 30mg Sol Tab,CNEU,,¾AÀ³¯g: Major depressive disorder °Æ§@¥Î: Common ¡½Endocrine metabolic: Increased appetite (17% )¡A Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )¡A Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) ¡½Gastrointestinal: Constipation (13% )¡A Xerostomia (25% ) ¡½Hepatic: ALT (SGPT) level raised (2% ) ¡½Neurologic: Asthenia (8% )¡A Dizziness (7% )¡A Somnolence (54% ) ¡½Psychiatric: Disturbance in thinking (2%)¡A Dream disorder (3%) Serious ¡½Hematologic: Agranulocytosis¡A Neutropenia ¡½Neurologic: Grand mal seizure (less than 0.1% )¡A Status epilepticus ¡½Psychiatric: Depression¡A exacerbation¡A Mania (0.2%)¡A Suicidal thoughts¡A Suicide (rare) ¸T§Ò: hypersensitivity to mirtazapine,,«Ç·Å,15 mg/day ORALLY at bedtime; may increase in dose every 1-2 weeks to a max dose of 45 mg/day,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OSEC4,Acebutolol,Sectral 400mg,CAVS,,¾AÀ³¯g: Hypertension¡A ventricular arrhythmia¡A angina pectoris. °Æ§@¥Î: Bradycardia¡A GI effects¡A cold extremities¡A lethargy. Rarely¡A central effects¡A dry eyes¡A rashes¡A bronchospasm¡A hypersensitivity¡A pneumonitis¡A myalgia¡A arthralgia. Neurologic: Dizziness (6% )¡A Headache (6% ) Other: Fatigue (11% ) ¸T§Ò: Cardiogenic shock¡A bronchial asthma¡A obstructive lung disorders¡A uncontrolled heart failure¡A 2nd or 3rd degree intranodal AV block¡A severe bradycardia.,,«Ç·Å,Initially¡A 400mg daily as single or 2 divided doses. Dosage may be increased to 800mg daily or 400mg bid.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OSULF,Sulfinpyrazone,Sulfin 100mg,CNEU,,I: Chronic gouty arthritis and intermittent gouty arthritis. AR: Nausea¡A vomiting¡A stomach pain¡A anemia¡A dermatitis¡A dizziness¡A flushing¡A geadache¡A hepatic necrosis¡A increased bleeding time ( decreased platelet aggregation )¡A leukopenia¡A nephrotic symdrome¡A polyuria¡A rash¡A uric acid stones. CI: Active peptic ulcers¡A hypersensitivity to sulfinpyrazone¡A phenylbutazone¡A or other pyrazoles¡A GI inflammation¡A blood dyscrasias.,,,D: Adult 100-200 mg twice daily; maximum daily dose: 800 mg.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OVESI,Solifenacin,Vesicare 5mg,SGU,Treatment of overactive bladder with symptoms of urge urinary incontinence¡A urinary frequency & urgency.,Urinary retention¡A gastric retention¡A uncontrolled narrow angle glaucoma.,Dry mouth¡A GI disturbances including constipation¡A blurred vision¡A dry eyes¡A urinary retention¡A lower limb edema¡A fatigue¡A cough. <Common> Gastrointestinal: Constipation (5.4% to 13.4% )¡A Xerostomia (10.9% to 27.6% ) <Serious> Cardiovascular: Prolonged QT interval Gastrointestinal: Bowel obstruction¡A Fecal impaction¡A Obstruction of colon Immunologic: Anaphylaxis Neurologic: Confusion¡A Headache¡A Somnolence Psychiatric: Hallucinations Other: Angioedema,30¢J¥H¤U,5-10 mg once a day.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þªÌÀ³ÂÔ·Vµ¹ÃÄ¡A¨C¤é¤£¥i¦h©ó 5 mg,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¥»ÃÄ»Ý¾ãÁû¥H¤ô§]ªA¡C
EBOS,Epinephrine,Bosmin soln 500mL,CAVS,,¾AÀ³¯g:Vasoconstriction¡A circulatory dystonia¡A esporthostatic¡A constitutional & symptoms hypotension. °Æ§@¥Î:Whole body reactions such as pulmonary edema¡A severe hypokalemia (inhalation). Palpitation¡A BP fluctuation¡A face flushing¡A pallor¡A headache¡A tremor¡A sweating¡A paranoid. GI disturbances¡A rashes¡A resp disturbances. ¸T§Ò:Patients receiving halothane or halogen-containing inhalation anesth¡A butyrophenone or phenothiazine antipsychotics¡A £\-blockers¡A isoproterenol¡A sympathetic stimulants (except in emergency). Closed-angle glaucoma.,,«Ç·Å,As hemostatic agent in surgery Apply as original concentration or 5 times more concentrated soln with cotton or gauze to the skin. Add 2-5 drops when use as local anesth. ENT Apply as original concentration or 5 times more concentrated soln as ear/nose drops. Asthma¡A whooping cough Add 2-3 mL to 100 mL salt water as daily dose. Inhale 2-3 times/day. Coughing spasmUse 1-3 drops.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OEPI,Scopolam + Dicyclomine + Chlordiazepoxide,Epilon,ALIM,,¾AÀ³¯g: Antacid plus antispasmodic & sedative. °Æ§@¥Î: Constipation¡A intestinal impaction; phosphate depletion; diarrhea¡A dehydration; sedation; accommodation disturbances; urinary incontinence; jaundice; dry mouth. ¸T§Ò: Appendicitis; hypophosphatemia; closed-angle glaucoma; prostatic enlargement; paralytic ileus or pyloric stenosis.,,«Ç·Å,Adult 1-2 tab tid-qid. Each Tablet contains: Butylscopolamine Bromide 2mg + Dicyclomine HCl 2mg + Chlordiazepoxide 5mg + Magnesium Aluminum Hydroxide co-dried Gel 350mg + Magnesium Oxide 40mg + Chlorophyll Sodium Copper 3mg,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IDIAG,Indocyanine Green,Diagnogreen inj 25mg,ZOTH,Assessment of hepatic function¡A cardiac output.,Hypersensitivity to any component of the formulation.,Urticaria¡A pruritus¡A headache¡A discolouration of faeces¡A diaphoresis. Potentially Fatal: Anaphylaxis.,25¢J¥H¤UÁ×¥ú,Adults Liver Function Test¡A for determination of Plasma Elimination Rate and Blood Retention Rate: 0.5 mg/kg of body weight as indocyanine green is diluted to a concentration of 5 mg/mL with water for injection and is injected IV gradually into the cubitus vein within 30 sec with careful observation of the symptoms. Liver Function Test¡A the measurement of hepatic blood flow: After 25mg as indocyanine green is dissolved in as small amount of water for injections as possible¡A the solution is diluted to a concentration of 2.5-5mg/ml with 0.9% sodium chloride and an amount of this solution equivalent to 3mg as indocyanine green is injected intravenously. Then¡A intravenous drip infusion is performed at a constant speed until blood collection for about 50 minutes at a rate of 0.27 ~ 0.49mg/minute is completed. Circulatory function test: Depending on the purpose¡A a solution of indocyanine green is injected at various vascular sites until it reaches the peripheral veins from inside the heart. Usually¡A the injection is via the forearm vein. The amount each time per adult is 5 ~ 10mg of indocyanine green (about 1 ~ 2mL). Doses for children are decreased in accordance with the body weight.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVP;IVPUSH;,¨Ï¥Î¼t°Ó´£¨Ñ¤§10mLª`®g¥Î¤ôµ}ÄÀ,,Max: 2 mg/kg/dose.,,
OEM125,Aprepitant,EMEND 125mg,CNEU,Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of highly & moderately emetogenic cancer chemotherapy.,Concurrent administration with pimozide¡A terfenadine¡A astemizole¡A or cisapride.,Hiccups¡A asthenia/fatigue¡A ALT increased¡A constipation¡A headache¡A anorexia. Central nervous system: Fatigue (?18%) Gastrointestinal: Nausea (6% to 13%)¡A constipation (9% to 10%) Neuromuscular & skeletal: Weakness (?18%) Miscellaneous: Hiccups (11%),30¢J¥H¤U,Given as part of a 3-day regimen that includes a corticosteroid and a 5-HT3 antagonist. Recommended dose: 125 mg orally 1 hour prior to chemotherapy (day 1) and 80 mg once daily in the morning on day 2 and day 3.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OLOR,Loratadine + Pseudoephedrine,Lorapseudo SR 10/240mg,HIMM,Relief of symptoms associated with allergic rhinitis & common cold.,Patients receiving MAOI therapy or within 14 days of discontinuing such treatment. Narrow-angle glaucoma¡A urinary retention¡A severe hypertension¡A severe coronary artery disease¡A hyperthyroidism.,Insomnia¡A dry mouth¡A headache¡A drowsiness.,25¢J¥H¤U¡A³±²D°®Àê³B,Adult & children > or = 12 years 1 TAB QD.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling; use with caution.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human (and animal) data suggest risk,Loratadine-Limited Human Data¡XAnimal Data Suggest Low Risk Pseudoephedrine Human Data Suggest Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Loratadine- Limited Human Data¡XProbably Compatible Pseudoephedrine -Limited Human Data¡XProbably Compatible,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½wÄÀ¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
IPRIM,Gadoxetate,Primovist inj 2.5mmol/10mL,SCAN,MRI of liver,Specific contraindications have not been determined. Precautions: diabetes; elderly patients¡A renal insufficiency¡A asthma¡A allergy¡A previous contrast media reaction¡A or other hypersensitivity disorders.,Common Gastrointestinal: Nausea (1.1%) Neurologic: Headache (1.1%) Serious Cardiovascular: Bundle branch block (less than 0.1%)¡A Shock. Immunologic: Anaphylactoid reaction. Renal: Injury of kidney¡A Acute¡A Nephrogenic systemic fibrosis.,30¢J¥H¤U,Adults: 0.1 mL / kg body weight. [Micromedex 2021/08/05] Usual dose: 0.1 mL/kg (0.025 millimoles/kg) given undiluted as a single IV bolus injection at a flow rate of approximately 2 mL/sec,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;,,,,,1. ¤@¯ë¦¨¤H¨Ï¥Î¾¯¶q¡G0.1 mL/kg 2. ¥»ÃÄ«~¤£À³»P¨ä¥LÃÄ«~²V¦X¨Ï¥Î¡C 3. ¥»¹w¶ñ°wµ©­­³æ¦¸¨Ï¥Î¡A¥¼¥Î§¹ªºÅã¼v¾¯¤@«ß¥á±ó¡C 4. ¥»«~¬°¥i°¨¤W¨Ï¥Î¤£»Ýµ}ÄÀªºÀR¯ßª`®g¤ô·»²G¡A¥H¤j¬ù 2 mL/¬íªº³t«×¬I¥´¡C¥»«~¨Ï¥Î«á¡AÀR¯ß¯dº¢°wÀ³¥Î¥Í²z­¹ÆQ¤ô¨R¬~¡C
OVIR3,Tenofovir,Viread 300mg,QANB,Treatment of HIV-1 infection in combination with other antiretrovirals. Chronic hepatitis B.,Lactation. Not for treatment for chronic hepatitis B virus infection. Do not co-administer with fixed dose combinations containing tenofovir.,Asthenia¡A pain¡A headache¡A abdominal pain¡A back pain¡A chest pain¡A fever; diarrhea¡A nausea¡A vomiting¡A anorexia¡A dyspepsia¡A flatulence¡A pneumonia; depression¡A insomnia¡A peripheral neuropathy¡A dizziness; rash¡A sweating¡A myalgia; wt loss; allergic reaction; increased amylase¡A pancreatitis; increased liver enzymes¡A hepatitis; renal & urinary disorders.,30¢J¥H¤U,Adults and children > 12 years (> 35 kg): 300 mg orally once daily. (¼ö¯f) Pediatric: age 2 to < 12 years: 8 mg/kg (maximum: 300 mg) Q24H. Weight based tablet recommendations: 17 to <22 kg: 150 mg Q24H; 22 to <28 kg: 200 mg Q24H; 28 to <35 kg: 250 mg Q24H; > or = 35 kg: 300 mg Q24H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,
OGEN5,Fluvoxamine,Genbou 50mg,CNEU,,¾AÀ³¯g: Treatment of symptoms of depressive illness. Obsessive compulsive disorder in children & adolescents. °Æ§@¥Î: Nausea¡A vomiting¡A asthenia¡A headache¡A malaise¡A palpitations/tachycardia¡A abdominal pain¡A anorexia¡A constipation¡A diarrhoea¡A dry mouth¡A dyspepsia¡A agitation¡A anxiety¡A dizziness¡A insomnia¡A nervousness¡A somnolence¡A tremor¡A sweating¡A (postural) hypotension¡A arthralgia¡A myalgia¡A ataxia¡A confusion¡A extrapyramidal symptoms¡A hallucinations¡A abnormal (delayed) ejaculation¡A cutaneous hypersensitivity reactions (including rash¡A pruritus¡A angioedema)¡A liver dysfunction¡A convulsions¡A mania¡A galactorrhoea¡A photosensitivity¡A weight gain/loss¡A serotonin syndrome¡A neuroleptic malignant syndrome-like events¡A hyponatremia & SIADH¡A withdrawal reactions¡A haemorrhage¡A paresthesia¡A anorgasmy & taste perversion. Dermatologic: Sweating (immediate-release¡A 7%; extended-release (social anxiety disorder)¡A 6%; extended-release (obsessive-compulsive disorder)¡A 7% ) Gastrointestinal: Diarrhea (immediate-release¡A 11%; extended-release (social anxiety disorder)¡A 14%; extended-release (obsessive-compulsive disorder)¡A 18% )¡A Indigestion (immediate-release¡A 10%; extended-release (social anxiety disorder)¡A 10%; extended-release (obsessive-compulsive disorder)¡A 8% )¡A Loss of appetite (immediate-release¡A 6%; extended-release (social anxiety disorder)¡A 14%; extended-release (obsessive-compulsive disorder)¡A 13% )¡A Nausea (immediate-release¡A 40%; extended-release (social anxiety disorder)¡A 39%; extended-release (obsessive-compulsive disorder)¡A 34% )¡A Xerostomia (immediate-release¡A 14%; extended-release (social anxiety disorder)¡A 11%; extended-release (obsessive-compulsive disorder)¡A 10% ) Neurologic: Asthenia (immediate-release¡A 14%; extended-release (social anxiety disorder)¡A 24%; extended-release (obsessive-compulsive disorder)¡A 26% )¡A Dizziness (immediate-release¡A 11%; extended-release (social anxiety disorder)¡A 15%; extended-release (obsessive-compulsive disorder)¡A 12% )¡A Insomnia (immediate-release¡A 21%; extended-release (social anxiety disorder)¡A 32%; extended-release (obsessive-compulsive disorder)¡A 35% )¡A Somnolence (immediate-release¡A 22%; extended-release (social anxiety disorder)¡A 26%; extended-release (obsessive-compulsive disorder)¡A 27% )¡A Tremor (immediate-release¡A 5%; extended-release (social anxiety disorder)¡A 8%; extended-release (obsessive-compulsive disorder)¡A 6% ) Psychiatric: Agitation (immediate-release¡A 2%; extended-release (social anxiety disorder)¡A 3%; extended-release (obsessive-compulsive disorder)¡A 2% )¡A Anxiety (immediate-release¡A 5%; extended-release (social anxiety disorder)¡A 8%; extended-release (obsessive-compulsive disorder)¡A 6% )¡A Feeling nervous (immediate-release¡A 12%; extended-release (social anxiety disorder)¡A 10% ) Reproductive: Abnormal ejaculation (immediate-release¡A 8%; extended-release (social anxiety disorder)¡A 11%; extended-release (obsessive-compulsive disorder)¡A 10% )¡A Orgasm incapacity (immediate-release¡A 2%; extended-release¡A 5% ),,«Ç·Å,May be taken with or without food 100-200 mg daily. Max: 300 mg daily. The minimum recommended starting dose is 100 mg/day and can be given as a single dose; preferably in the evening.It is advisable that a total daily dose over 150 mg be given in 2 or 3 divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OEM80,Aprepitant,Emend 80mg,CNEU,,¾AÀ³¯g:Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of highly & moderately emetogenic cancer chemotherapy. °Æ§@¥Î:Hiccups¡A asthenia/fatigue¡A ALT increased¡A constipation¡A headache¡A anorexia. Central nervous system: Fatigue (?18%) Gastrointestinal: Nausea (6% to 13%)¡A constipation (9% to 10%) Neuromuscular & skeletal: Weakness (?18%) Miscellaneous: Hiccups (11%) ¸T§Ò:Concurrent administration with pimozide¡A terfenadine¡A astemizole¡A or cisapride.,,«Ç·Å,Given as part of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist. Recommended dose: 125 mg orally 1 hr prior to chemotherapy (day 1) & 80 mg once daily in the morning on days 2 & 3.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IHAV0,Inactivated Hepatitis A Virus Vaccine,Havrix 720 (¤p¨àA¨x¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Active immunisation against infections caused by hepatitis A virus.,Hypersensitivity.,Inj site soreness¡A mild redness & swelling¡A headache¡A malaise¡A vomiting¡A fever¡A nausea & loss of appetite.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5mL¡A 12 months-15 years primary immunization. A booster dose after 6-36 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡Aµ´¹ï»Ý­n®É¤~µ¹¤©¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡Aµ´¹ï»Ý­n®É¤~µ¹¤©¡C,IM;,,,,,
IOMN5,Iohexol + Tromethamine,Omnipaque 350mg I/mL¡A 50mL,SCAN,¯áÅè³y¼v¡A ¦åºÞ³y¼v¡A ¹q¸£Â_¼h±½´y¼W±j³y¼v¾¯¡A ªc§¿¹D³y¼v Intrathecal: Myelography; contrast enhancement for computerized tomography Intravascular: Angiocardiography¡A aortography¡A digital subtraction angiography¡A peripheral arteriography¡A excretory urography; contrast enhancement for computed tomographic imaging Oral/body cavity: Arthrography¡A GI tract examination¡A hysterosalpingography¡A pancreatography¡A cholangiopancreatography¡A herniography¡A cystourethrography; enhanced computed tomography of the abdomen,Hypersensitivity to iohexol or any component of the formulation.,¥þ¨­·Å¼ö·P¡A ¼È®É©Êª÷ÄÝ¨ý¹D¡A ¸¡³¡¤£¾A¡A äú¤ß¡A ¹Ã¦R¡A ¹L±Ó©Ê¤ÏÀ³ Cardiovascular: Asystole¡A arrhythmia¡A bradycardia¡A cardiopulmonary collapse¡A edema¡A heart failure¡A hypertension (in patients with phenochromocytoma after intra-arterial injection)¡A hypotension¡A syncope¡A transient ischemic attacks¡A vasovagal attacks¡A venous thrombosis¡A ventricular fibrillation¡A ventricular tachycardia Central nervous system: Anxiety¡A confusion¡A dizziness¡A headache¡A loss of consciousness¡A seizure¡A vertigo Dermatologic: Pruritus¡A rash¡A urticaria Endocrine & metabolic: Thyrotoxicosis exacerbation Gastrointestinal: Cramping¡A diarrhea¡A nausea¡A salivary gland swelling¡A vomiting Local: Burning sensation¡A pain at injection site¡A thrombophlebitis Neuromuscular & skeletal: Parasthesia¡A polyarthropathy¡A tremor Ocular: Vision abnormalities Renal: Contrast-associated nephropathy¡A creatinine increased¡A renal dysfunction Respiratory: Bronchospasm¡A cough¡A dyspnea¡A pulmonary edema¡A rhinitis¡A sneezing Miscellaneous: Anaphylactoid reaction¡A diaphoresis¡A hypersensitivity reactions,µL¯S§O«ü¥ÜÀx¦s·Å«×¦ý¥i©ó¨Ï¥Î«e¥[¼ö¦ÜÅé·Åªº37¢J,Dosing is based numerous variables including: type of examination¡A route of administration¡A patient age/weight and product. Consult specific product information for detailed dosing. Intrathecal route: Myelogram a) Lumbosacral:The usual recommended dose for use in lumbar myelography is 10 to 17 milliliters of iohexol 180 milligrams iodine/milliliter (mgI/mL) or 7 to 12.5 milliliters of iohexol 240 mgI/mL administered by lumbar injection. b) Thoracic:The usual recommended dose for thoracic myelography is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter (mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL administered by lumbar or cervical injection. c) Cervical:For cervial myelography given by lumbar injections¡A the following doses have been used: 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. If iohexol is administered by C1-2 injection¡A the recommended dose is 7 to 10 mL of iohexol 180 mgI/mL¡A 6 to 12.5 mL of iohexol 240 mgI/mL¡A or 4 to 10 mL of iohexol 300 mgI/mL. d) Spinal cord:The usual dose for total columnar myelography (lumbar injection) is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. Intravascular route: CT of head The recommended dose for HEAD IMAGING is 70 to 150 milliliters of iohexol 300 milligram iodine/milliliter (mgI/mL) or 80 mL of iohexol 350 mgI/mL by injection or 120 to 250 mL of iohexol 240 mgI/mL by infusion. For BODY IMAGING the dose is 50 to 200 mL of iohexol 300 mgI/mL or 60 to 100 mL of iohexol 350 mgI/mL by injection. Angiocardiography a) DOSAGE SUMMARY:Iohexol 350 milligrams iodine/milliliter is recommended for use in ANGIOCARDIOGRAPHY. b) VENTRICULOGRAPHY:The usual adult volume is a single injection of 40 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 30 mL to 60 mL). This may be repeated as necessary. When combined with selective coronary arteriography the total administered dose should not exceed 250 milliliters (87.5 grams iodine). c) SELECTIVE CORONARY ARTERIOGRAPHY:The usual adult dose for right or left coronary arteriography is 5 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 3 mL to 14 mL) per injection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IA;IRR;IT;IV;IVP;IVPUSH;PO;R;RECT;,,,,,1.ÅéµÄ¨Ï¥Î³~®|¥H¤ôµ}ÄÀ¡A ¦¨¤H¨àµ£¤Î³¡¦ì¤£¦P¨Ì1:1~1:50¤£µ¥¤ñ¨Òµ}ÄÀ 2.µÇ¥\¯à¥¿±`¯f±wÀ³¥ß§Y°±¥ÎMeformin 48¤p®É¡A«ÝµÇ¥\¯à«ì´_«á¦A±Ò¥Î;¦pµÇ¥\¯à¤£¨Î¯f±w¡A½Ðµû¦ô¯f±w±¡ªp¡A´£«e48¤p®É°±¥ÎMeformin.
IOMN1,Iohexol + Tromethamine,Omnipaque 350mg I/mL¡A 100mL,SCAN,¯áÅè³y¼v¡A ¦åºÞ³y¼v¡A ¹q¸£Â_¼h±½´y¼W±j³y¼v¾¯¡A ªc§¿¹D³y¼v Intrathecal: Myelography; contrast enhancement for computerized tomography Intravascular: Angiocardiography¡A aortography¡A digital subtraction angiography¡A peripheral arteriography¡A excretory urography; contrast enhancement for computed tomographic imaging Oral/body cavity: Arthrography¡A GI tract examination¡A hysterosalpingography¡A pancreatography¡A cholangiopancreatography¡A herniography¡A cystourethrography; enhanced computed tomography of the abdomen,Hypersensitivity to iohexol or any component of the formulation.,¥þ¨­·Å¼ö·P¡A ¼È®É©Êª÷ÄÝ¨ý¹D¡A ¸¡³¡¤£¾A¡A äú¤ß¡A ¹Ã¦R¡A ¹L±Ó©Ê¤ÏÀ³ Cardiovascular: Asystole¡A arrhythmia¡A bradycardia¡A cardiopulmonary collapse¡A edema¡A heart failure¡A hypertension (in patients with phenochromocytoma after intra-arterial injection)¡A hypotension¡A syncope¡A transient ischemic attacks¡A vasovagal attacks¡A venous thrombosis¡A ventricular fibrillation¡A ventricular tachycardia Central nervous system: Anxiety¡A confusion¡A dizziness¡A headache¡A loss of consciousness¡A seizure¡A vertigo Dermatologic: Pruritus¡A rash¡A urticaria Endocrine & metabolic: Thyrotoxicosis exacerbation Gastrointestinal: Cramping¡A diarrhea¡A nausea¡A salivary gland swelling¡A vomiting Local: Burning sensation¡A pain at injection site¡A thrombophlebitis Neuromuscular & skeletal: Parasthesia¡A polyarthropathy¡A tremor Ocular: Vision abnormalities Renal: Contrast-associated nephropathy¡A creatinine increased¡A renal dysfunction Respiratory: Bronchospasm¡A cough¡A dyspnea¡A pulmonary edema¡A rhinitis¡A sneezing Miscellaneous: Anaphylactoid reaction¡A diaphoresis¡A hypersensitivity reactions,µL¯S§O«ü¥ÜÀx¦s·Å«×¦ý¥i©ó¨Ï¥Î«e¥[¼ö¦ÜÅé·Åªº37¢J,Dosing is based numerous variables including: type of examination¡A route of administration¡A patient age/weight and product. Consult specific product information for detailed dosing. Intrathecal route: Myelogram a) Lumbosacral:The usual recommended dose for use in lumbar myelography is 10 to 17 milliliters of iohexol 180 milligrams iodine/milliliter (mgI/mL) or 7 to 12.5 milliliters of iohexol 240 mgI/mL administered by lumbar injection. b) Thoracic:The usual recommended dose for thoracic myelography is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter (mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL administered by lumbar or cervical injection. c) Cervical:For cervial myelography given by lumbar injections¡A the following doses have been used: 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. If iohexol is administered by C1-2 injection¡A the recommended dose is 7 to 10 mL of iohexol 180 mgI/mL¡A 6 to 12.5 mL of iohexol 240 mgI/mL¡A or 4 to 10 mL of iohexol 300 mgI/mL. d) Spinal cord:The usual dose for total columnar myelography (lumbar injection) is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. Intravascular route: CT of head The recommended dose for HEAD IMAGING is 70 to 150 milliliters of iohexol 300 milligram iodine/milliliter (mgI/mL) or 80 mL of iohexol 350 mgI/mL by injection or 120 to 250 mL of iohexol 240 mgI/mL by infusion. For BODY IMAGING the dose is 50 to 200 mL of iohexol 300 mgI/mL or 60 to 100 mL of iohexol 350 mgI/mL by injection. Angiocardiography a) DOSAGE SUMMARY:Iohexol 350 milligrams iodine/milliliter is recommended for use in ANGIOCARDIOGRAPHY. b) VENTRICULOGRAPHY:The usual adult volume is a single injection of 40 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 30 mL to 60 mL). This may be repeated as necessary. When combined with selective coronary arteriography the total administered dose should not exceed 250 milliliters (87.5 grams iodine). c) SELECTIVE CORONARY ARTERIOGRAPHY:The usual adult dose for right or left coronary arteriography is 5 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 3 mL to 14 mL) per injection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IA;IV;IVP;IVPUSH;PO;R;RECT;,,,,,1.ÅéµÄ¨Ï¥Î³~®|¥H¤ôµ}ÄÀ¡A ¦¨¤H¨àµ£¤Î³¡¦ì¤£¦P¨Ì1:1~1:50¤£µ¥¤ñ¨Òµ}ÄÀ 2.µÇ¥\¯à¥¿±`¯f±wÀ³¥ß§Y°±¥ÎMeformin 48¤p®É¡A«ÝµÇ¥\¯à«ì´_«á¦A±Ò¥Î;¦pµÇ¥\¯à¤£¨Î¯f±w¡A½Ðµû¦ô¯f±w±¡ªp¡A´£«e48¤p®É°±¥ÎMeformin.
OEPB,Ethambutol,Epbutol (EMB) 400mg,QANB,TB.,Diabetes¡A alcohol poisoning. Patients who are unable to appreciate & report visual side effects or changes in vision (e.g. young children¡A unconscious patients); optic neuritis.,Decreased visual acuity¡A leukopenia¡A neutropenia¡A thrombocytopenia¡A hypersensitivity¡A anaphylactoid reactions¡A headache¡A mental confusion¡A disorientation & possible hallucinations¡A dizziness¡A hypoaesthesia¡A paraesthesia¡A peripheral neuropathy¡A pulmonary infiltrates with or without eosinophilia¡A GI disturbances¡A dermatitis¡A rash¡A pruritus¡A Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A gout¡A hyperuricemia¡A joint pain¡A fever¡A malaise.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,15-25 mg/kg orally once daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OFEL,Piroxicam,Feldene 10mg,CNEU,,An analgesic¡A anti-inflammatory agent¡A gout attacks.,,,Antirheumatic: 20 mg/day in single or divided doses (range 10-30 mg/day). Acute gout: 40 mg/day for 5-7 days.,,,,,,,,,,,,,,
IERB2,Cetuximab,Erbitux inj 100mg/20mL,RACA,Colorectal cancer¡A metastatic: Treatment of KRAS wild-type (without mutation)¡A epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer as determined by approved tests (in combination with FOLFIRI [irinotecan¡A fluorouracil¡A and leucovorin] as first-line treatment¡A in combination with irinotecan [in patients refractory to irinotecan-based chemotherapy]¡A or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan). Limitation of use: Cetuximab is not indicated for the treatment of RAS-mutant colorectal cancer or when results of the RAS mutation tests are unknown. Head and neck cancer¡A squamous cell: Treatment of squamous cell cancer of the head and neck (as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease).,Known severe hypersensitivity reactions to cetuximab.,Mild or moderate infusion-related reactions eg fever¡A chills¡A dizziness or dyspnea; mild to moderate mucositis¡A increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea¡A nausea¡A vomiting; dehydration¡A hypocalcemia¡A anorexia; fatigue.,2-8¢XC,Weekly dosing: Initial loading dose: 400 mg/m2 infused over 120 minutes. Maintenance dose: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity. Complete cetuximab dose 1 hour prior to chemotherapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V no relevant animal data,[¥é³æ] ªí¥Ö¥Íªø¦]¤l¨üÅé©M­L¨àªºµo¨|¦³Ãö¡C¦b¦³­­ªº°Êª«¬ã¨sÆ[¹îµo²{cetuximab ¤Î¨ä¥L§K¬Ì²y³J¥ÕG(IgG)§ÜÅé¯à°÷³q¹L­L½Lªº»Ù¾À¡C°Êª«¹êÅç¼Æ¾ÚÅã¥Ü¥Ø«eµL­P·î­L±¡§Î¡AµM¦Ó¡AÀHµÛ¾¯¶q¼W¥[¡A¬y²£µo¥Íªº¾÷²v¬Û¹ï¼W¥[¡C¥Ø«eÁÙ¨S¦³¨¬°÷ªº¥¥°ü¨Ï¥Î¼Æ¾Ú¡C ±j¯P«ØÄ³¡A¥u¦³·í¥i¯àªº®Ä¯q¶W¹L¹ï­L¨àªº¥i¯à¦MÀI©Ê®É¡A¤~¥i¥Hµ¹¤©¥¥°ü©Î¨S¦³¾A·íÁ×¥¥±¹¬Iªº°ü¤k¨Ï¥Î Erbitux¡C ¥Ø«e©|µL cetuximab ¹ï¤HÃþ¥Í¨|¤O¼vÅTªº¸ê®Æ¡C¥¿¦¡ªº°Êª«¸ÕÅç¤¤¡A¥¼´¿¹ï¶¯©Ê¤Î»Û©Ê°Êª«ªº¥Í¨|¤O°µ¹Lµû¦ô¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¦bErbituxR ªvÀø´Á¶¡©M³Ì«á¤@¾¯ªvÀø«áªº¤G­Ó¤ë¤ºªº°ü¤k¡A¤£­n­÷Áý¥À¨Å¡A¦]¬°©|¥¼ª¾ ErbituxR¬O§_·|±q¥À¨Å±Æ¥X¡C,IVD;,,,,Administer through a low protein-binding 0.22 micrometer in-line filter. Administer via infusion pump or syringe pump at a rate not to exceed 10 mg/minute. Do not administer as IV push or bolus. Do not shake or dilute.,1. ¿éª`¥»ÃÄ«~¤@©w­n³æ¿W¨Ï¥Î¤@±øºÞ½u¡A¿éª`µ²§ô®É¤@©w­n¥ÎµLµßªº¥Í²z­¹ÆQ¤ô¨R¬~ºÞ½u¡C
IFEB,Ferric-Hydroxide-Sucrose Complex,Fe-Back inj 2%¡A 5mL,NUTR,Rapid correction of Fe-deficiency anemia.,Evidence of iron overload. Severe hepatic or renal impairment. Potentially Fatal: Anaphylaxis.,Anaphylactoid reactions.,25¢J¡A¤£¥i§NÂÃ,Iron sucrose contains 20 mg elemental iron/mL slow IV or IV infusion only. Iron-deficiency anaemia < 5 kg: IVD 1.25mL¡A may repeat treatment if clinically indicated. 5-10 kg: IVD 2.5 mL¡A may repeat treatment if clinically indicated. Adult: 10 mL¡A may repeat treatment if clinically indicated. Slow IV injection rate: 1 mL/min. IV infusion rate: 2.5-5 mL via infusion over at least 15 min. 10 mL via infusion over at least 30 min.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;,,¡iN/S¡j¥i¿ï ¡C,½wºCª`®g¡A¨C¤ÀÄÁ1mL (20mg ¤¸¯ÀÅK) ³t²v¡A¨C²~5 mL ±Àª`®É¶¡¦Ü¤Ö 5 ¤ÀÄÁ¡C,«ØÄ³ 5 mL Fe-Back µ}ÄÀ¦¨100 mL¡A¥H¤j¬ù15¤ÀÄÁ®É¶¡ºwª`¡A­Y¾¯¶q > 120mg ºwª`»Ý 2 ¤p®É¡C (Fe-Back ¨C mL §t¦³ 400 mg Ferric-Hydroxide-Sucrose Complex¡A¬Û·í©ó20mg iron),1.¥»ÃÄ«~»Ý½wºCÀR¯ßª`®g¡A«ØÄ³³t²v¡G1 mL/¤ÀÄÁ¡A³æ¦¸ª`®g¤£­n¶W¹L10 mL¡C 2.ªì¦¸¨Ï¥Î«eÀ³¥ý¥Î´ú¸Õ¾¯¶q1 mL¡AÆ[¹î30¤ÀÄÁ¡A½T©wµL¥ô¦ó¤£¨}¤ÏÀ³¡A¡H¦pÀY¡H¡BÁy¤ô¸~¡B©I§l§xÃø 3.ÀR¯ßºwª`«ØÄ³¨Ï¥Î0.9%¥Í²z­¹ÆQ¤ôµ}ÄÀ¡C5 mL Fe-Back inj 2%µ}ÄÀ¦¨100 mL¡A¥H¤j¬ù15¤ÀÄÁ®É¶¡ºwª`¡C 4.¡H¯f¤H¤§«e´¿¨Ï¥Î§tÅK¦¨¤À°w¾¯ÃÄ«~µo¥Í¹L±Ó¤ÏÀ³¡A©Î±w¦³§K¬Ì©Îµoª¢(¡H¦p¡H­··Ã©ÊÃö¸`ª¢)¬ÛÃö¯e¯f¡A©Î¦³®ð³Ý¡BÀã¯l¡B¹L±Ó¯f¥v¡AÀ³¥D°Ê§iª¾Âå®v¡C
IFOR10,Paclitaxel,FORMOXOL inj 60mg/10mL,RACA,After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma.,Hypersensitivity to paclitaxel¡A polyoxyl 35/polyoxyethylated castor oil (Cremophor EL)¡A or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1¡A500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1¡A000/mm3.,Bone marrow suppression¡A peripheral neuropathy¡A GI disturbances¡A alopecia¡A hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% )¡A Inflammatory disease of mucous membrane (5% to 45% )¡A Nausea and vomiting¡A Any grade (9% to 88% ) Hematologic: Anemia¡A Any grade (47% to 96% )¡A Leukopenia (90% )¡A Neutropenia¡A Any grade (78% to 100% )¡A Thrombocytopenia¡A Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction¡A Any grade (2% to 45% ) Musculoskeletal: Arthralgia¡A Myalgia Neurologic: Peripheral neuropathy¡A Any grade (42% to 79% ),25¢J¥H¤UÁ×¥ú,Premedication with dexamethasone 20 mg orally at 12 and 6 hours prior to paclitaxel¡A promethazine 25 or 50 mg or diphenhydromine 50 mg IV 30-60 minutes prior to paclitaxel¡A and cimetidine 300 mg¡A ranitidine 50 mg or famotidine 20 mg IV 30-60 minutes prior to paclitaxel is recommended.Baseline neutrophil count should be ?1¡A500 cells/mm3 (1.5 x 10^9 cells/L)¡A platelets should be ?100¡A000 cells/mm3 (100 x 10^9 cells/L) prior to treatment. [Ovarian Caner¡A advanced]- Previously untreated: 175 mg/m2 infused over 3 hours every 3 weeks in combination with cisplatin 75 mg/m2 or 135 mg/m2 over 24 hours administered every 3 weeks in combination with cisplatin 75 mg/m2.- Previously treated: 135 or 175 mg/m2 infused over 3 hours every 3 weeks.  [Breast Cancer]- Adjuvant treatment: 175 mg/m2 infused over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).- Breast cancer¡A metastatic or relapsed: 175 mg/m2 infused over 3 hours every 3 weeks. [Non-small cell lung cancer (NSCLC)] 135 mg/m2 infused over 24 hours every 3 weeks in combination with cisplatin 75 mg/m2. [Kaposi sarcoma¡A AIDS related] 135 mg/m2 over 3 hours every 3 weeks or 100 mg/m2 over 3 hours every 2 weeks (due to dose-related toxicity¡A the 100 mg/m2 dose should be used for patients with a lower performance status).,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌµo¥Í¤£¨}¤ÏÀ³¾÷²v·|¼W¥[¡A½Ð°Ñ¦Ò¥é³æ¹ï·Óªí½Õ¾ã¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tDEHPªºPVC¶ì½¦§÷½è¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.3 - 1.2 mg/mL¡A«Ç·Å¤U¦w©w©Êºû«ù 27¤p®É¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C¿éª`¶}©lªº²Ä¤@­Ó¤p®ÉÀ³ºÊ´úVital Sign¡C 5. ´¿¨Ï¥Î Paclitaxelµo¥Í¤ßÅ¦¶Ç¾É²§±`ªº¯f¤H¡A¤§«á¨Ï¥ÎPaclitaxel´Á¶¡À³¶i¦æ³sÄò¤ß¹q¹ÏºÊ´ú¡C 6. ºÊ´úCBC¡C 7.§t¦³ãÉ³Âªo¦¨¤À¡A®e©ö³y¦¨¯f±w¹L±Ó¤ÏÀ³¡A¬I¥´®ÉÀ³¥Ñ§C³t²v¶}©l½Õ¾ã¡A¨Ãª`·N¯f¤H¤ÏÀ³¡C
IFORM,Paclitaxel,Formoxol inj 30mg/5mL,RACA,After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma.,Hypersensitivity to paclitaxel¡A polyoxyl 35/polyoxyethylated castor oil (Cremophor EL)¡A or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1¡A500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1¡A000/mm3.,Bone marrow suppression¡A peripheral neuropathy¡A GI disturbances¡A alopecia¡A hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% )¡A Inflammatory disease of mucous membrane (5% to 45% )¡A Nausea and vomiting¡A Any grade (9% to 88% ) Hematologic: Anemia¡A Any grade (47% to 96% )¡A Leukopenia (90% )¡A Neutropenia¡A Any grade (78% to 100% )¡A Thrombocytopenia¡A Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction¡A Any grade (2% to 45% ) Musculoskeletal: Arthralgia¡A Myalgia Neurologic: Peripheral neuropathy¡A Any grade (42% to 79% ),25¢J¥H¤UÁ×¥ú,Premedication with dexamethasone 20 mg orally at 12 and 6 hours prior to paclitaxel¡A promethazine 25 or 50 mg or diphenhydromine 50 mg IV 30-60 minutes prior to paclitaxel¡A and cimetidine 300 mg¡A ranitidine 50 mg or famotidine 20 mg IV 30-60 minutes prior to paclitaxel is recommended.Baseline neutrophil count should be ?1¡A500 cells/mm3 (1.5 x 10^9 cells/L)¡A platelets should be ?100¡A000 cells/mm3 (100 x 10^9 cells/L) prior to treatment. [Ovarian Caner¡A advanced]- Previously untreated: 175 mg/m2 infused over 3 hours every 3 weeks in combination with cisplatin 75 mg/m2 or 135 mg/m2 over 24 hours administered every 3 weeks in combination with cisplatin 75 mg/m2.- Previously treated: 135 or 175 mg/m2 infused over 3 hours every 3 weeks.  [Breast Cancer]- Adjuvant treatment: 175 mg/m2 infused over 3 hours every 3 weeks for 4 cycles (administer sequentially following an anthracycline-containing regimen).- Breast cancer¡A metastatic or relapsed: 175 mg/m2 infused over 3 hours every 3 weeks. [Non-small cell lung cancer (NSCLC)] 135 mg/m2 infused over 24 hours every 3 weeks in combination with cisplatin 75 mg/m2. [Kaposi sarcoma¡A AIDS related] 135 mg/m2 over 3 hours every 3 weeks or 100 mg/m2 over 3 hours every 2 weeks (due to dose-related toxicity¡A the 100 mg/m2 dose should be used for patients with a lower performance status).,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌµo¥Í¤£¨}¤ÏÀ³¾÷²v·|¼W¥[¡A½Ð°Ñ¦Ò¥é³æ¹ï·Óªí½Õ¾ã¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tDEHPªºPVC¶ì½¦§÷½è¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.3 - 1.2 mg/mL¡A«Ç·Å¤U¦w©w©Êºû«ù 27¤p®É¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C¿éª`¶}©lªº²Ä¤@­Ó¤p®ÉÀ³ºÊ´úVital Sign¡C 5. ´¿¨Ï¥Î Paclitaxelµo¥Í¤ßÅ¦¶Ç¾É²§±`ªº¯f¤H¡A¤§«á¨Ï¥ÎPaclitaxel´Á¶¡À³¶i¦æ³sÄò¤ß¹q¹ÏºÊ´ú¡C 6. ºÊ´úCBC¡C §t¦³ãÉ³Âªo¦¨¤À¡A®e©ö³y¦¨¯f±w¹L±Ó¤ÏÀ³¡A¬I¥´®ÉÀ³¥Ñ§C³t²v¶}©l½Õ¾ã¡A¨Ãª`·N¯f¤H¤ÏÀ³¡C
ISUB,Ampicillin + Sulbactam,SUBAcillin inj 1.5gm,QANB,Infections due to susceptible strains of Streptococcus¡A S. aureus¡A Enterococcus¡A Escherichia coli¡A Klebsiella spp.¡A Serratia¡A H. influenza¡A gm-ve bacteria¡A Citrobacter & anerobic bacterias (Bacteroides¡A Fusobacterium & Clostridium difficile)¡A Branhamella catarrhalis.,Hypersensitivity to penicillins.,Common: Injection site pain (IV¡A 3%; IM¡A 16%)¡A Rash¡A Urticaria¡A Diarrhea (3%) Serious: Clostridium difficile colitis¡A Clostridium difficile diarrhea¡A Hepatotoxicity¡A Erythema multiforme¡A Erythroderma¡A Toxic epidermal necrolysis¡A Agranulocytosis¡A Thrombocytopenia¡A Anaphylaxis,25¢J¥H¤U,Subacillin may be administered by either IV or IM routes (following dilution). Adults: usual dose 1.5-3 g every 6-12 hours for 5-14 days (maximum: ampicillin/sulbactam 12 g/day; sulbactam 4 g/day). Surgical prophylaxis: 1.5-3 g at induction of anesthesia¡A may repeat the dose once every 6-8 hours¡A total duration should be ?24 hours. Gonorrhea¡A uncomplicated: 1.5 g IV/IM as single dose in combination with oral probenecid 1 g. For children and younger¡A 150 mg/kg/day IV/IM in 3-4 divided doses; neonates < 1 week¡A 75 mg/kg/day in 2 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,AMPICILLIN PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk SULBACTAM PREGNANCY RECOMMENDATION: Compatible,Compatible ­÷¨Å®É¥i¨Ï¥Î,Subactam·|¤Àªc¦Ü¨Å¥Ä AMPICILLIN BREASTFEEDING RECOMMENDATION: Compatible SULBACTAM BREASTFEEDING RECOMMENDATION: Compatible,IM;IVD;IVP;IVPUSH;,,,,,1.deep IM ¯kµh®É¥i¥Î0.5%·Àµßlidocaine hydrochloride anhydrous°t»s 2. ¥»«~¦b§t¦³¸²µå¿}©Î¨ä¥LÁÞÃþ·»²G¤¤¸û¤£Ã­©w¡A¤]¤£¥i»P¦å«~¡B³J¥Õ½è¤ô¸Ñª«¡BÓi°òÁÞÃþ²V¦X¡C 3. ª`®g¾¯À³©ó°t¸m«á1¤p®É¤º¨Ï¥Î¡C
IASI,Aminophylline,Asiphylline inj 250mg/10mL,ERSP,Relaxation of bronchial smooth muscle & stimulation of myocardium.,Hypersensitivity to xanthines.,Common: Diarrhea¡A Nausea¡A Vomiting¡A Dizziness¡A Headache¡A Insomnia¡A Tremor¡A Irritability¡A Restlessness¡A Diuresis Serious: Atrial fibrillation¡A Bradyarrhythmia¡A Too quick administration¡A Cardiac arrest¡A Tachyarrhythmia¡A Erythroderma¡A Necrotizing enterocolitis in fetus OR newborn¡A Hypersensitivity reaction¡A Intracranial hemorrhage¡A Seizure,15-30¢JÁ×¥úÁ×§K§N­á,Bronchodilator- Adult: 250-500mg Q6H via IV. Child: 5mg/kg or 150mg/m2 Q6H via IV. Acute symptoms- Adult: Loading dose: 6mg/kg for over 20 min via IV infusion. Maintenance dose: Elderly or patient with cor pulmonale: 0.6mg/kg/hr for 12 hr via IV infusion¡A then 0.3mg/kg/hr. Healthy people who don't smoke: 0.7mg/kg/hr for 12 hr via IV infusion¡A then 0.5mg/kg/hr. CHF orlLiver failure: 0.5mg/ kg/hr for 12 hr via IV infusion¡A then 0.1-0.2mg/kg/hr. Child: Loading dose: Age < 6 months: Individually determined by the physician. Age 6 months -16 years: 6mg/kg for over 20 min via IV infusion. Maintenance dose: Age < 6 months: Individually determined by the physician. Age 6 months - 9 years: 1.2mg/kg/hr for 12 hr via IV infusion¡A then 1mg/kg/hr. Age 9- 16 years: 1mg/kg/hr for 12 hr via IV infusion¡A then 0.8mg/kg/hr. Cardiac stimulants- Adult: 500mg via slowly IV.,»Ý½Õ¾ã¾¯¶q,Initial: 0.25 mg/kg/hour; maximum dose: 507 mg/day unless serum concentrations indicate need for larger dose. Use with caution and monitor serum theophylline concentrations frequently.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,See Theophylline. [¥é³æ] Theophylline·|³q¹L­L½L»Ù¾À¾É­P¦b·s¥Í¨à¦å²M¡H¤§¿@«×¹L°ª¦Ó¨ã¼ç¦b¤§¦MÀI©Ê¡A¥¥°ü¨Ï¥Î¥»ÃÄÀ³ºÊµøTheophyllineªº¬r©Ê¼x­Ô¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,See Theophylline. [¥é³æ] Theophylline·|±Æªn©ó¨Å¥Ä¤¤¡A¬G­÷¨Å¤§°ü¤k¨Ï¥Î¥»ÃÄ®É¹ïÀ¦¨à·|¤Þ°_¨ë¿E©Ê¨ä¥L°Æ§@¥Î¡C,INHL;IVD;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,1.¿éª`®É¶¡À³¦b20¤ÀÄÁ¥H¤W¡C 2.¥HÀR¯ßª`®g§ëÃÄ®É¥u¯à¨Ï¥Î25mg/mL¤§ª`®g²G¡A¨Ã¥B¶·¥HÀR¯ßª`®g²Gµ}ÄÀ¡C 3.À³¥H¨C¤ÀÄÁ25mgªº³t«×½wºCª`®g¡A³Ì¦n¨Æ¥ýµ}ÄÀ¡C 4.Rate of IV infusion should not exceed 7.5 mg/kg over 30 minutes. For IV intermittent therapy¡A dilute the dose in 50 mL of fluid and infuse over 30 minutes. [Micromedex 20211207] 5.Usual Infusion Concentrations: Adult: IV infusion: 250mg in 250mL (concentration: 1mg/mL) of D5W or NS. [Uptodate(Lexicomp) 20211207] 6.Usual Infusion Concentrations: Pediatric: IV infusion: 1mg/mL. [Uptodate(Lexicomp) 20211207],1.³æ¿Wµ¹ÃÄ¡A¤£±o¥[¤J¨ä¥LÃÄª«¦@¦P¿éª`¡C 2.In healthy elderly adults (older than 60 years of age): The initial theophylline dose should not exceed 400 mg/day. [Micromedex 20211207]
OOTS,Aripiprazole,Otsuka Abilify 10mg,CNEU,,¾AÀ³¯g: Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years. °Æ§@¥Î: Headache¡A asthenia¡A accidental injury¡A peripheral edema¡A hypertension¡A GI disturbances¡A myalgia¡A agitation¡A anxiety¡A insomnia¡A lightheadedness¡A somnolence¡A akathisia¡A extrapyramidal syndrome¡A tremor¡A increased salivation¡A rhinitis¡A pharyngitis¡A coughing¡A blurred vision. Endocrine metabolic: Weight increased (2% to 30% ) Gastrointestinal: Constipation (5% to 11% )¡A Nausea (8% to 15% )¡A Vomiting (3% to 11% ) Neurologic: Akathisia (2% to 25% )¡A Dizziness (4% to 10% )¡A Extrapyramidal disease (2% to 27.3% )¡A Headache (12% to 27% )¡A Insomnia (8% to 18% )¡A Sedated (1% to 8% )¡A Somnolence (5% to 26.3% )¡A Tremor (2% to 11.8% ) Ophthalmic: Blurred vision (3% to 8% ) Psychiatric: Anxiety (4% to 17% )¡A Restlessness (2% to 12% ) Other: Fatigue (2% to 11% ) ¸T§Ò: Known hypersensitivity to aripiprazole.,,«Ç·Å,Schizophrenia Acute treatment: Adult Initially 10 mg or 15 mg once daily. Dose may be increased at intervals of not < 2 weeks. Effective dose range: 10-30 mg/day. Adolescent 13-17 years Initially 2 mg/day¡A titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Bipolar disorder Acute treatment: Adult Initially 15 mg once daily¡A may be increased to 30 mg/day. Children 10-17 years Initially 2 mg/day¡A titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Adjunctive treatment of major depressive disorder Acute treatment: Adult Initially 2-5 mg/day. Dose range: 2-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week. Irritability associated with autistic disorder Children 6-17 years Initially 2 mg/day. Dose range: 5-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IHER0,Trastuzumab,Herceptin inj 440mg (Sample),RACA,Treatment of metastatic breast cancer who have tumours that overexpress Human Epidermal Growth Factor Receptor 2 protein (HER2). As single agent or in combination with paclitaxel or docetaxel. Treatment of HER2 +ve early breast cancer patients (EBC) following surgery¡A chemotherapy (neoadjuvant or adjuvant)& radiotherapy (if applicable).,Patients with known hypersensitivity to trastuzumab or to any other component of Herceptin,Abdominal pain¡A accidental injury¡A asthenia¡A back pain¡A chest pain¡A chills¡A fever¡A flu syndrome¡A headache¡A infection¡A neck pain¡A vasodilation¡A GI disturbances¡A peripheral edema¡A edema¡A arthralgia¡A myalgia¡A anxiety¡A depression¡A dizziness¡A insomnia¡A paresthesia¡A somnolence¡A asthma¡A cough increased¡A dyspnea¡A epistaxis¡A lung disorders¡A pleural effusion¡A pharyngitis¡A rhinitis¡A sinusitis¡A pruritus¡A rash. Cardiovascular: Edema (8% monotherapy )¡A Peripheral edema (5% to 10% )¡A Tachycardia (5% monotherapy ) Dermatologic: Rash (4% to 18% ) Gastrointestinal: Abdominal pain (2% to 22% )¡A Diarrhea (7% to 25% monotherapy; 1.6% grade 3/5 adjuvant therapy )¡A Loss of appetite (14% monotherapy )¡A Nausea (6% to 33% )¡A Vomiting (3.5% to 23% ) Hematologic: Anemia (4% )¡A Febrile neutropenia (23% adjuvant therapy )¡A Leukopenia (3% )¡A Neutropenia (32% grade 3/4; 2% grade 4/5 ) Immunologic: Infectious disease (20% monotherapy; 22% grade 2/5 adjuvant therapy ) Musculoskeletal: Backache (5% to 22% )¡A Myalgia (4% to 10% ) Neurologic: Asthenia (4.5% to 42% )¡A Dizziness (4% to 13% )¡A Headache (6% to 26% )¡A Insomnia (14% monotherapy; 3.7% grade 2/5 adjuvant therapy ) Respiratory: Cough (2% to 26% )¡A Dyspnea (3% to 22% )¡A Pharyngitis (12% monotherapy )¡A Rhinitis (2% to 14% ) Other: Fever (6% to 36% ),2-8¢JÁ×¥úÁ×§K§N­á,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion¡A then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks¡A or initial dose of 8 mg/kg over 90 minutes IV infusion¡A then 6 mg/kg over 30?90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion¡A followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü³Ìµu30 ¤ÀÄÁ¡C 3. ¿éª`®Éª`·N¯f¤H¬O§_¥X²{©I§l§xÃø¡B©PÃä¤ô¸~¡B§C¦åÀ£©Î¨ä¥L«æ©Ê¹L±Ó¤ÏÀ³¯gª¬¡C 4. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
ICAG2,Calcium gluconate,Ca. gluconate 10% 200mL,NUTR,,¾AÀ³¯g:Ca deficiency. °Æ§@¥Î: Cardiovascular (with rapid I.V. injection): Arrhythmia¡A bradycardia¡A cardiac arrest¡A hypotension¡A syncope¡A vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection) ¸T§Ò¡GVentricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),,«Ç·Å,Calcium: 96.1mg/mL¡A equal to 0.465 meq/mL (200 mL/Bot) Calcium Gluconate: IV infusion not to exceed 0.5 mL/min. Adult: 0.5-2 g as required. Child: 0.5 g/kg/day in divided doses.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,¥»«~¬°200 mL¥]¸Ë¡A¶È¨ÑTPN½Õ°t¨Ï¥Î¡A¸T¤îª½±µ¨Ï¥Î©óÀR¯ßª`®g¡C
EPROS,Dinoprostone,Prostin E2 Vaginal Tablet 3mg,SGU,Induction & augmentation of labor near term.,Hypersensitivity to Prostin E2 (dinoprostone)¡A prostaglandins¡A or any other component of the product. Do not use in patients in whom oxytocic drugs are generally contraindicated such as: - multiple gestation - grand multiparity (6 or more previous term pregnancies) - engagement of the head has not taken place - previous uterine surgery (e.g.¡A cesarean section¡A hysterotomy) - cephalopelvic disproportion - fetal heart rate pattern suggests incipient fetal compromise - obstetric conditions where either maternal or fetal benefit/risk ratio favors surgical intervention - unexplained vaginal discharge and/or abnormal uterine bleeding during current pregnancy - nonvertex presentation,Common: Diarrhea (Vaginal insert¡A <1%; vaginal suppository¡A approximately 40%)¡A Nausea (Vaginal insert¡A <1%; vaginal suppository¡A 33%)¡A Vomiting (Vaginal insert¡A <1%; vaginal suppository¡A approximately 66%)¡A Headache (Vaginal suppository¡A approximately 10%)¡A Fever (vaginal insert¡A <1%)¡A Shivering (Vaginal suppository¡A approximately 10%) Serious: Decreased diastolic arterial pressure (Vaginal suppository¡A 10%)¡A Myocardial infarction¡A Disseminated intravascular coagulation¡A Hypersensitivity reaction¡A Hypertonic uterine dysfunction (Vaginal insert¡A 2-4.7%)¡A Infection of amniotic cavity¡A Intrauterine sepsis of fetus¡A Non-allergic anaphylaxis¡A Premature rupture of membranes¡A Rupture of uterus¡A Vaginospasmm¡A Fetal distress (Vaginal insert¡A 2.9-3.8%),2-8¢XC¦B½c,Initially¡A insert 1 vaginal tablet high into posterior fornix. Second tablet may be inserted after 6-8 hr if labor is not established. the maximum dose: 6 mg in 24 hr.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Contraindicated,PREGNANCY RECOMMENDATION: First 28 Weeks of Pregnancy¡XContraindicated Unless for Termination/Evacuation of Pregnancy Compatible¡XNear or at Term [¥é³æ] ´¶¬¥µÎ©w-¯q¤G«¬¨Ï¥Î©ó¹w²£´Á¤Î±µªñ¹w²£´ÁÃh¥¥°ü¤k¡C¦b¦Ñ¹«»P¨ß¤lªº°Êª«¹êÅç¤¤¡A «e¦C¸¢¯ÀE2ªº¥Í¦¨¼W¥[·|³y¦¨°©Àf²§±`¡C¥Ø«e¤w¦³ÃÒ¾ÚÅã¥Ü¦b¦Ñ¹«»P¨ß¤l¤¤´¶¬¥µÎ©w-¯q¤G«¬ ¨ã¦³­F­L¬r©Ê¡Aµ¹¤©¥ô¤@¾¯¶q³£·|³y¦¨¤l®c±i¤O«ùÄò¤W¤É¡A¦Ó¹ï­F­L©Î­L¨à³y¦¨«Â¯Ù¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¨Å¥Ä¤¤¶È§t¦³·L¶q«e¦C¸¢¯À¡A¦Ó¥B¦b¥Í¤U¦­²£¨à°ü¤k¤Î ¨¬¤ë¥Í²£¤§°ü¤k©Ò¤Àªc¨Å¥Ä¤¤´ú±o§t¶q¨Ã¨S¦³ÅãµÛ®t²§¡C,VAG;,,,,,¥~·½©Ê«e¦C¸¢¯ÀªvÀø¥i¯à·|¥[±j¶Ê²£¯Àªº§@¥Î¡C¤£«ØÄ³¦P®É¨Ö¥Î¨ä¥Lªº¶Ê²£»s¾¯¡C¤@¯ë«ØÄ³¦b¨Ï¥ÎProstin E2«á¦Ü¤Ö¶¡¹j¤»¤p®É¦A¨Ï¥Î¶Ê²£¯À¡C
ILAS,Furosemide,Lasix °w¾¯ 20mg/2mL,CAVS,Cardiac¡A renal & hepatic edema; edema due to burns; mild to moderate hypertension¡A Acute pulmonary edema¡A Forced diuresis.,Acute renal failure with anuria¡A hepatic coma¡A hypokalemia¡A hyponatremia¡A hypovolemia with or without hypotension. Impaired renal or hepatic function.,Minor GI upset; Ca¡A K & Na depletion¡A nephrocalcinosis in premature infants; aggravation of metabolic alkalosis; diabetes. Rarely¡A anaphylactic shock¡A allergic reactions¡A bone marrow depression; acute pancreatitis¡A auditory disorders. Endocrine metabolic: Hyperuricemia (40%)¡A Hypomagnesemia Gastrointestinal: Loss of appetite Renal: Spasm of bladder,30¢J¥H¤UÁ×¥ú,Adult and children >15 years: Initially 20-40 mg IM or IV¡A may increase stepwise by 20 mg at 2-hour interval. Acute pulmonary edema: Initially 40 mg IV¡A then 20-40 mg after 20 minutes. Forced diuresis: 20-40 mg given in addition to infusion of electrolyte solution. Infant and children <15 years: 1 mg/kg body weight IM or IV up to daily maximum of 20 mg. Intravenous administration should be given slowly¡A not exceeding an injection rate of 4 mg/minute. In patients with severe impairment of renal function (serum creatinine > 5 mg/dl)¡A the infusion rate should not exceed 2.5 mg/minute. Intramuscular administration must be restricted to exceptional cases where neither oral nor intravenous administration is feasible. Intramuscular injection is not suitable for the treatment of acute conditions such as pulmonary oedema.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,[¥é³æ] Furosemide ·|³q¹L­L½L»Ù¾À¡A¦]¦¹¡A°£«D¦³±j¨î©ÊªºÂå¾Ç²z¥Ñ¡A §_«h¤£¥i©óÃh¥¥´Á¶¡¨Ï¥Î Lasix¡C ­Y©óÃh¥¥´Á¶¡¨Ï¥ÎLasix¡A«h¶·ºÊ´ú­L¨àªºµo¨|±¡§Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Furosemide ·|²¾¦æ¶i¤J¨Å¥Ä¤¤¡A¨Ã§í¨î¨Å¥Ä¤Àªc¡A¦]¦¹¡A¤£¥i©óÁý­÷¥À¨Å´Á¶¡¨Ï¥Î Lasix¡C,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö 5¤ÀÄÁ,ºwª`³t²v <4mg/min¡Aµ}ÄÀ«ápH­È¶·ºû«ù¦b®zÆP (7-10¤§¶¡),1.pH>5.5®ÉIVD < 4mg/min 2.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î 3.Á×¥ú¨Ï¥Î¡A·»²GÅÜ¦â§Y¤£¥i¨Ï¥Î
ILIP21,Soybean Oil,Lipofundin (¤p¨àTPN¥Î100mL¡A 20%),NUTR,In parenteral nutrition for energy & essential fatty acids.,Disturbances in fat metabolism; ketoacidosis¡A hypoxia¡A thromboembolism & acute shock states.,Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea¡A cyanosis¡A allergic reactions¡A hyperlipaemia¡A hypercoagulability¡A nausea¡A vomiting¡A headache¡A flushing¡A hyperthermia¡A sweating¡A chills¡A sleepiness¡A chest and back pain. Delayed Reactions: Hepatomegaly¡A jaundice due to central lobular cholestasis¡A splenomegaly¡A thrombocytopenia¡A leucopenia¡A transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system¡A the so-called "IV Fat Pigment"¡A has also been reported. The cause and the significance of this phenomenon are unknown.,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Dosage Adult: 0.7-1.5g lipids/kg body weight/day¡A maximum: 2g lipids/kg body weight/day. For home TPN apply>6 months or Short Bowel Syndrome: < 1g lipids/kg body weight/day. Children and adolescents: 2-3g lipids/kg body weight/day. Preterm neonatal infants¡A term newborn infants¡A infants and toddlers: <3g lipids/kg body weight/day. (Maximum: 4g lipids/kg body weight/day). Maximum infusion rate Adults: Up to 0.15 g lipids/kg body weight/hr. Children and adolescents: Up to 0.13 g lipids/kg body weight/hr. Preterm neonatal infants¡A term newborn infants¡A infants and toddlers: Up to 0.17 g lipids/kg body weight/hr.,µL»Ý½Õ¾ã¾¯¶q,­Y¦¨¦~¤Hªº¦å¼ß¤T»Ä¥Ìªoà­¿@«×¶W¹L3 mmol/L ¡A«ØÄ³­°§C¿éª`³t²v©Î°±¤î¿éª` ­Y¨àµ£ªº¦å¼ß¤T»Ä¥Ìªoà­¿@«×¶W¹L1.7 mmol/L ¡A«ØÄ³­°§C¿éª`³t²v©Î°±¤î¿éª`,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,¿éª`ªº³Ìªì15¤ÀÄÁ¤£©y¶W¹L¨C¤p®É¨C¤½¤çÅé­«0.05 ¡V 0.1 g ¯×ªÕ¶q¡A¬Û·í©ó0.25 ¡V 0.5 ml/kg/hr¡C ³Ì¤j¿éª`³t²v ¡G¨C¤p®É¨C¤½¤çÅé­«¤£¤j©ó 0.15 g ¯×ªÕ¶q¡A¬Û·í©ó0.75 mL/kg/hr ³Ì¤jºwª`³t²v ¡G¨C¤ÀÄÁ¨C¤½¤çÅé­«¤£¶W¹L0.25ºw¡C( 0.25 gtt/kg/min ) ¥HÅé­«70¤½¤çªº¯f±w¬°¨Ò¡A³Ì¤j¿éª`³t²v¬°¨C¤p®É50 ml©Î¨C¤ÀÄÁ18ºw¡C ¨C¤é¾¯¶qªº«ØÄ³¿éª`³t²v¤£¥i¤Ö©ó16¤p®É¡A¸û¦nªº¿éª`®É¶¡¬°³sÄò¿éª`24¤p®É¡C,¯×ªÕ¨Å¾¯À³¥HºC³t¿éª`¬°­ì«h¡C Àç¾i¤£¶q±wªÌ¤Î¨àµ£À³½Õ­°¿éª`³t²v¡C
IMEN,FSH 75 IU + LH 75 IU,Menopur 75/75 IU,HM,Infertility in male & female.,Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus¡A ovaries & breasts.,Ovarian hyperstimulation¡A ascites¡A hydrothorax¡A oliguria¡A hypotension¡A thromboembolism¡A hypersensitivity reactions¡A fever¡A nausea & vomiting¡A inj site reactions¡A unintentional multiple pregnancies.,30¢J¥H¤UÁ×¥úÁ×§K§N­á,PCOD: treatment should be started within the first 7 days of the menstrual cycle. The recommended initial dose is 75-150 IU daily¡A which should be maintained for at least 7 days. The recommended dose increment is 37.5 IU per adjustment¡A and should not exceed 75 IU. Maximum daily dose < 225 IU. When an optimal response is obtained¡A a single injection of 5000 - 10000 IU hCG should be given 1 day after the last Menopur injection .Women undergoing controlled ovarian hyperstimulation for multiple follicular development for assisted reproductive technologies (ART): Menopur therapy should start approximately 2 weeks after the start of agonist treatment. The recommended initial dose of Menopur is 150-225 IU daily for at least the first 5 days of treatment. Adjustment depending on clinical response¡A should not exceed more than 150 IU per adjustment. The maximum daily dose < 450 IU daily and in most cases dosing beyond 20 days is not recommended.Male infertility: 75-150IU Menopur combinded with hCG¡A 2-3 times/week¡A for 90 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T¥Î©óÃh¥¥°ü¤k¡C¥Ø«e¨Ï¥Î©óÃh¥¥°ü¤kªº¼Æ¾Ú¤´¦³­­¡C¥Ø«e©|¥¼°õ¦æ¦bÃh¥¥´Á¶¡¤§°Êª«¹êÅçµû¦ô¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T¥Î©ó±Â¨Å°ü¤k¡C,SC;,¨Ï¥Î¼t°Ó´£¨Ñ¤§1mL·»¾¯·»¸Ñ¤§,,,,
IMETE,Methylergometrine,Methergin inj 0.2mg/1mL,SGU,Active management of the 3rd stage of labour¡A Uterine atony/hemorrhage¡A Subinvolution¡A lochiometra¡A puerperal bleeding.,Pregnancy; 1st & 2nd stage of labour & before crowning of the head; severe hypertension¡A hypertensive toxemia; occlusive vascular disease; sepsis.,Abdominal pain¡A hypertension¡A headache¡A skin eruptions¡A dizziness¡A nausea¡A vomiting¡A convulsions¡A sweating¡A chest pain¡A hypotension¡A bradycardia¡A tachycardia¡A palpitations¡A peripheral vasospastic reaction. Very rarely¡A hallucinations¡A anaphylactic reactions¡A MI.,2-8¢JÁ×¥ú¡A Á×§K§N­á,Effective management of the third stage of labor: 0.5-1 mL (0.1-0.2 mg) intravenously slowly when the baby is delivered to the front shoulder or at least immediately after the baby is born. Usually¡A the first strong contraction after MetherginR is given¡A the placenta needs to be expelled by applying pressure at the base of the hand. The recommended dose for production under general anesthesia is 1 mL(0.2 mg). Treatment of uterine relaxation/bleeding: 1 mL (0.2 mg) intramuscularly or 0.5-1 mL (0.1-0.2 mg) intravenously slowly. If necessary¡A repeat every 2 to 4 hours¡A up to 5 times in 24 hours. Intramuscularly: 1 mL¡A 0.2 mg¡A after delivery of the anterior shoulder¡A after delivery of the placenta¡A or during the puerperium. May be repeated as required¡A at intervals of 2-4 hours. Intravenously: 1 mL¡A 0.2 mg¡A administered slowly over a period of no less than 60 seconds.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,METHYLERGONOVINE MALEATE: Contraindicated,Compatible ­÷¨Å®É¥i¨Ï¥Î,METHYLERGONOVINE MALEATE: Compatible,IM;IVPUSH;,,¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡ > 60¬í,,Administer slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. ½Ð¸m©óÄá¤ó 2-8 «×¦B½c§NÂÃ¡A Á×¥ú¡A Á×§K§N­á
OANS,Metformin,Ansures ER 500mg,META,,¾AÀ³¯g:Type 2 diabetes mellitus °Æ§@¥Î:Diarrhea¡A nausea¡A vomiting Endocrine metabolic: Cobalamin deficiency (up to 9.9% ) Gastrointestinal: Diarrhea (53.2% (immediate-release) ; 9.6% to 12.5% (extended-release) )¡A Flatulence (12.1% )¡A Indigestion (7.1% )¡A Malabsorption syndrome (up to 9.9% )¡A Nausea (up to 25.5% (immediate-release); ; 6.7% (extended-release) )¡A Vomiting (up to 25.5% ) Neurologic: Asthenia (9.2% )¡A Headache (5.7% ) ¸T§Ò:Renal/hepatic diseases¡A renal impairment¡A CHF¡A acute/chronic metabolic toxicity including ketoacidosis. Discontinue before administration of parenteral iodinated contrast media for radiological diagnosis & before surgery.,,«Ç·Å,Adult Initially 500 mg during dinner. May increase by 500 mg after 1 week. Max: 2000 mg in 1-2 divided doses,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OCLIN,Clindamycin,Clincin 150mg,QANB,,¾AÀ³¯g: ²Óµß©Ê·P¬V(A032065100) Treatment of infections caused by susceptible strains of Strep¡A staphylococcus¡A pneumococci & anaerobic bacteria. °Æ§@¥Î: Diarrhea occasionally with acute colitis¡A abdominal pain¡A GI upsets; skin reactions¡A jaundice¡A hematopoietic changes. ¸T§Ò: Hypersensitivity to clindamycin or lincomycin. History of GI diseases¡A severe renal or liver impairment.,,«Ç·Å,Adult: 150-300 mg 6 hrly. Severe infection: 300-400 mg 6 hrly. Children: 8-16 mg/kg/day in 3-4 equal doses. Severe infection: 16-20 mg/kg/day in 3-4 equal doses.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ITT5,Electrolytes + Water,¥x¤j No.5 400mL,MSIV,Supplement of water¡A electrolytes & nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30¢J¥H¤U,Central vein or peripheral vein infusion¡A as needed. Taita No.1: Na 25mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 20mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 38g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.2: Na 40mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 26mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 33g/L¡A 500mL/Bot¡A 287mOsm/L. Taita No.3: Na 75mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 61mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 20g/L¡A 500mL/Bot¡A 285mOsm/L. Taita No.4: Na 110mEq/L¡A K 20mEq/L¡A Mg 0mEq/L¡A Cl 102mEq/L¡A Acetate 16mEq/L¡A Phosphate 12mM/L¡A Glucose 8g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.5: Na 36mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 17mEq/L¡A Acetate 28mEq/L¡A Phosphate 12mM/L¡A Glucose 100g/L¡A 400mL/Bot¡A 669mOsm/L.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¯SÂI¤Î¾AÀ³¯g Taita No.1: Na¡BCl ¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì§C¡F¤p¨à¥Îºû«ù²G¡B¹q¸Ñ½è¡B¤ô¥÷¡B¾i¥÷¸É¥R Taita No.2: ¦¨¤À»PTaita No.1¬Û¦ü¦ýNa¡BCl¸û¦h;¼ö¶q¤ÎK§t¶q¸û§C¡A¥i§@¬°¤p¨à©Î¦¨¤H¥Îºû«ù²G Taita No.3: NaCl§t¶q¦ü0.45 %N/S¡A¥i¥Î©óµ¥±i©Ê²æ¤ô¡B¿}§¿¯f©Ê»Ä¤¤¬r Taita No.4: Na¡BK¡BCl¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì°ª¡A¥i¥Î©ó§C±i©Ê²æ¤ô¡B§CÁC¦å¯g Taita No.5: ¥x¤j¹q¸Ñ½è¿é²G¨t¦C¤¤¡A§tAcetate¤Î¼ö¶q³Ì°ª¡A¥i¥Î©ó°ª¼ö¶q¹q¸Ñ½è¸É¥R²G¡B§CÁC¦å¯g
OMETR,Metronidazole,Metrozole 250mg,QANB,Vaginitis caused by Trichomonas. Amebiasis & metronidazole-susceptible anaerobic infection.,Blood dyscrasias. Active CNS disease.,GI disturbances; peripheral neuropathy; drowsiness; leukopenia; rarely¡A skin reactions¡A darkening of urine¡A anaphylaxis¡A encephalopathy. Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,(¥é³æ) Adults: Anaerobic infections: 7.5 mg/kg Q6H for 7 days (maximum 1 g/dose; 4 g/day).Helicobacter pylori: 500 mg orally Q8H in combination with bismuth and other antibiotics for 1-2 weeks. Amebiasis: 500-700 mg orally Q8H for 5-7 days. Trichomoniasis: 2 g orally as a single dose¡A 1 g Q12H for 1 day or 250 mg Q8H for 7 days. Dracunculiasis: 250 mg Q8H for 10 days. Children: Anaerobic infections:7.5 mg/kg Q6H or 10 mg/kg Q8H. Amebiasis: 11.6-16.7 mg/kg Q8H for 10 days. Trichomoniasis: 5 mg/kg Q8H for 7 days. Dracunculiasis: 8.3 mg/kg (max 250 mg/dose) Q8H for 10 days.,»Ý½Õ¾ã¾¯¶q,Dosage adjustments are not required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment receiving IV metronidazole or the immediate-release tablet or capsule¡A reduce the dose by 50%. In patients treated with the 375-mg oral capsule for trichomoniasis¡A increase the dosage interval from every 12 hours to every 24 hours.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest low risk,[¥é³æ] ¸T§Ò: Ãh¥¥¤T­Ó¤ë¤º¤§°ü¤k¡C¦]¹ïÅj¾¦°Êª«¦³­PÀù©Ê¡A¦]¦¹¥¥°ü¶·¦bÅãµÛ»Ý­n¤U¤è¥i¨Ï¥Î¡C,Hold Breast Feeding ¼È°±­÷¨Å,Metronidazole: Hold Breastfeeding (Oral/IV Single Dose) Limited Human Data¡XPotential Toxicity (Oral/IV Divided Dose) Compatible (Topical/Intravaginal) [¥é³æ] ¦b¹«Ãþ¹êÅç¤¤µo¥Í¸~½F²{¶H¡A¦]¦¹±Â¨Å°ü¨Ï¥Î¥»ÃÄ®É¡AÀ³¨M©w¤£Ä~Äò±Â¨Å¡A§_«hÀ³°±¤î§ë»P¡C,AC;AC15;PC;PO;WM;,,,,,
ITYG,Tigecycline,Tygacil inj 50mg,QANB,Treatment of complicated skin & skin structure infections¡A complicated intra-abdominal infections & community-acquired pneumonia caused by susceptible microorganisms sensitive to tigecycline.,Hypersensitivity.,Abdominal pain¡A abscess¡A asthenia¡A back pain¡A fever¡A headache¡A infection¡A pain; HTN¡A hypotension¡A phlebitis; constipation¡A diarrhea¡A dyspepsia¡A nausea¡A vomiting; anemia¡A leukocytosis¡A thrombocythemia; increased alkaline phosphatase/amylase/BUN/lactic dehydrogenase/SGOT/SGPT¡A bilirubinemia¡A abnormal healing¡A hyperglycemia¡A hypokalemia¡A hypoproteinemia¡A peripheral edema; dizziness¡A insomnia; increased cough¡A dyspnea¡A pulmonary physical finding; pruritus¡A rash¡A sweating; inj site reactions.,20-25¢J,Adult: a single loading dose of 100 mg IV initially¡A then 50 mg IV Q12H over 30-60 minutes for 5-14 days.,»Ý½Õ¾ã¾¯¶q,Child-Pugh A and B: No adjustment necessary;Child-Pugh C:Initial dose¡A 100 mg IV once¡A followed by 25 mg IV every 12 hours,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,1.IVD: 5.3 mL N/S©ÎD5W©ÎL/R¡A½Õ°t¦¨ÃÄ²G¿@«×10mg/mL¡A¥u»Ý¨ú¥X5mL.,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,µ¹ÃÄ¿@«×¡Ø 1mg/mL¡A«ØÄ³¥H >30 ~ 60¤ÀÄÁ½wºCºwª`,1. µ}ÄÀ©ó¤p²~¤ºªº·»²G«Ç·Å³Ì¦hÂ\©ñ6¤p®É¡Aµ}ÄÀ¦nªº¿éª`·»²G«Ç·Å¤U³Ì¦hÂ\©ñ24¤p®É (¥]§t­ì¥ý¦b¤p²~¤ºªº6¤p®É)¡C¦]¦¹¡A­Y¨Ï¥Î¤è¦¡¬°25mg Q12H¡A«ØÄ³±N¤p²~¤º³Ñ¾lªºÃÄ²G¸m©ó¦B½c§NÂÃ (³Ì¦h48¤p®É)¡A¤U¦¸µ¹ÃÄ«e¦A¥[©ó¿éª`·»²G¡C 2. ÃÄ²G­YÅÜ¦â«h¤£¥i¨Ï¥Î¡C(½Õ°t¦nªºÃÄ²GÀ³§e¶À¦â©Î¾í¦â) 3. Tygacilµ¹ÃÄ®É¥²¶·¨Ï¥Î±M¥Îªº¿éª`ºÞ¸ô¡A©Î¨Ï¥ÎY«¬¿éª`ºÞ¸ô¡A¥H«K»P¨ä¥L¿éª`ÃÄ²G°Ï§O¡C 4. ºÊ´úÅé·Å¡BCBC»P·P¬V¯gª¬ÅÜ¤Æ¡C 5. ºÊ´ú¨x¥\¯à¡C
IMAN1,D-Mannitol,Maniton inj 20% 100mL,CAVS,,¾AÀ³¯g: Treatment of cerebral oedema; to increase urine flow in acute renal failure; reduce raised intracranial pressure; short-term management of glaucoma; promote excretion of toxic substances by forced diuresis. °Æ§@¥Î: Fluid & electrolyte imbalance¡A nausea & vomiting¡A thirst¡A headache¡A chills¡A fever¡A allergic reactions. ¸T§Ò: Pulmonary oedema¡A intracranial bleeding (except during craniotomy)¡A heart failure & renal failure (unless a test dose has produced a diuretic response).,,,Adult 1-2 g/kg as a 20% soln given by rapid IV infusion.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,,¿éª`³t²v: 0.5 - 1 g/kg/30~60min «ØÄ³¨Ï¥Î0.22 micron fillter¹LÂo,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î 2.IVD:«ØÄ³¨Ï¥Î0.22 micron fillter¹LÂo
IPEGA,Peginterferon alfa-2a,Pegasys 180mcg/0.5mL,QANB,,¾AÀ³¯g:Treatment of both HBeAg-positive & HBeAg-negative chronic hepatitis B in non-cirrhotic & cirrhotic patients with compensated liver disease & evidence of viral replication & liver inflammation. Treatment of chronic hepatitis C¡A alone or in combination with ribavirin¡A in non-cirrhotic patients & cirrhotic patients with compensated liver disease. °Æ§@¥Î:Fatigue¡A rigors¡A pyrexia¡A inj site reaction¡A pain¡A asthenia¡A GI disorders¡A anorexia¡A weight loss¡A myalgia¡A arthralgia¡A back pain¡A headache¡A insomnia¡A dizziness¡A concentration impairment¡A depression¡A irritability¡A anxiety¡A dyspnea¡A cough¡A alopecia¡A pruritus¡A dry skin. Dermatologic: Alopecia (18% to 28% )¡A Dermatitis (8% to 16% )¡A Dry skin (4% to 10% )¡A Injection site inflammation (10% to 31% )¡A Injection site reaction (22% to 23% )¡A Pruritus (12% to 19% )¡A Rash (5% to 8% ) Endocrine metabolic: Weight decreased (4% to 16% ) Gastrointestinal: Abdominal pain (8% to 26% )¡A Diarrhea (11% to 31% )¡A Loss of appetite (16% to 24% )¡A Nausea and vomiting (5% to 25% ) Hematologic: Lymphocyte count abnormal (3% to 14% )¡A Thrombocytopenia (5% to 8% ) Musculoskeletal: Arthralgia (22% to 28% )¡A Myalgia (26% to 51% ) Neurologic: Dizziness (13% to 23% )¡A Headache (27% to 54% )¡A Insomnia (19% to 30% )¡A Reduced concentration (8% to 10% ) Psychiatric: Anxiety (19% to 33% )¡A Feeling nervous (19% to 33% )¡A Irritability (19% to 33% ) Respiratory: Cough (4% to 10% )¡A Dyspnea (4% to 13% ) Other: Fatigue (24% to 67% )¡A Fever (24% to 54% )¡A Influenza-like illness¡A Rigor (25% to 47% ) ¸T§Ò:Autoimmune hepatitis¡A decompensated cirrhosis¡A use in neonates & infants ? 3 years. Pegasys/ribavirin combination therapy must not be used during pregnancy,,2-8¢J,HBeAg-positive & HBeAg-negative chronic hepatitis B 180 mcg SC once weekly for 48 weeks Chronic hepatitis C 180 mcg SC once weekly for 48 weeks in monotherapy & individualised based on the patient's viral genotype in combination therapy.,»Ý½Õ¾ã¾¯¶q,¿©±wC«¬¨xª¢ªº¯f¤H·í¥X²{ALT«ùÄò¤W¤É¥B°ª©ó°ò·Ç­È®É¡AÀ³±N¾¯¶q­°§C¨ì±q135·L¤½§J¶}©l¡F¦Ó·í§Y¨Ï­°§C¾¯¶q¡AALT¿@«×¤´µM«ùÄò¼W¥[¡A©Î¬O¦ñÀH¥X²{Áx¬õ¯À¼W¥[©Î¨xÅ¦¥NÀv¾÷¯à´c¤ÆªºÃÒ¾Ú®É¡AÀ³°±¤î¶i¦æªvÀø¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
IROC,Ceftriaxone,Rocephin inj 500mg,QANB,,¾AÀ³¯g:Infections caused by pathogens sensitive to Rocephin¡A eg sepsis; meningitis; infection in patients with impaired defence mechanisms; UTI; infection of respiratory tract¡A abdominal¡A bone¡A joint¡A soft tissue¡A skin¡A GUT¡A ENT; genital infection including gonorrhea. °Æ§@¥Î:GI upsets¡A hematological changes¡A skin reactions¡A coagulation disorders¡A phlebitis (IV administration). Rarely¡A agranulocytosis¡A renal precipitations. ¸T§Ò:Known hypersensitivity to cephalosporins. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing soln or products.,,«Ç·Å,Adult & children >12 years 1-2 g IV infusion once daily. Severe infection: 2-4 g once daily. Infant & children 20-80 mg/kg/day; neonate 20-50 mg/kg/day.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ¥»ÃÄ«~¤Å»P§t¶t©Î¨ä¥L§Ü¥Í¯À·»²G²V¦X¡C 2. ª`®g«e¸ß°Ý¯f±w¬O§_¦³£]-ñQÓiÃþ§Ü¥Í¯À¹L±Ó¥v¡C 3. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡A§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 4. RocheÃÄ¼t´£¨Ñ¥»ÃÄ¶ÈIV©ÎIVDµ¹ÃÄ¡C
IMV13,Multivitamin,Lyo-Povigent inj 4mL (13ºØ¦¨¥÷),NUTR,Nutritional supplementary for urgent situations induced by surgery¡A severe burns¡A fracture and trauma¡A severe infection¡A and coma.,Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis,Cardiovascular: Angioedema¡A edema Central nervous system: Agitation¡A anxiety¡A dizziness¡A headache Dermatologic: Erythema¡A pruritus¡A rash¡A urticaria Ocular: Diplopia Respiratory: Dyspnea¡A wheezing Miscellaneous: Allergic reactions¡A anaphylaxis¡A hypervitaminosis,2-8¢JÁ×¥ú,As TPN material. For TPN Adult: 4 mL/day. For TPN Pediatric: see [³B¤è¶°ªþ¿ý¤Q¤­ ¦­²£¨àÀR¯ßÀç¾i¤¤ºû¥Í¯À»P·L¶q¤¸¯À«ØÄ³¾¯¶qªí] Each Vial contains: (PART ¢¹) Thiamine Hydrochloride 3.9mg¡A Riboflavin-5'-phosphate Sodium 4.6mg¡A Pyridoxine Hydrochloride 4.9mg¡A Cyanocobalamin 0.005mg¡A Niacinamide 40mg¡A Folic acid 0.4mg¡A Ascorbic acid 100mg¡A D-Panthenol 14mg¡A Biotin 0.06mg¡A Each Ampoule contains: (PART ¢º) Vitamin A palmitate 3300IU¡A Cholecalciferol 0.005mg(200IU)¡A dl-£\-Tocopheryl Acetate 10mg¡A Phytonadione 2mg,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,Refer to individual vitamin monographs for requirements while breast-feeding,IVA;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¥»¾¯PART¢¹¡BPART¢º²V¦X·»¸Ñ«á¡A¥[¤J°ª¼ö¶q¿éª`²G«áµ}ÄÀ¨Ï¥Î,1.¯×·»©Êºû¥Í¯Àªºº¯³zÀ£«Ü°ª¡A¥é³æ«ØÄ³¡u¥»¾¯Á×§K³æ¿W§ë»P¡A¤Î¥½±éÀR¯ß¤º§ë»P¡v¡C¼t°Ó«ØÄ³¡G¦pªG»Ý¶gÃä¬I¥´ (º¯³zÀ£ < 300 mOsm/L)¡A¨C¾¯4mL½Ð¨Ï¥Î500-1000 mL¥H¤Wªº·»¾¯µ}ÄÀ¡C·»¾¯¥i¿ï¥ÎN/S©ÎD5W¡C 2. ¥é³æ«ØÄ³¡u¥»¾¯PART¢¹¡APART¢º²V¦X·»¸Ñ«á¡AÀ³¨³³t¥[¤J°ª¼ö¶q¿é²G¤¤µ}ÄÀ«á¤~¯à¨Ï¥Î¡A³q±`À³¦b12¤p®É¤º¨Ï¥Î§¹¡C¬°¨¾¤îºû¥L©R³Q¥ú¤À¸Ñ¡A¦]¦¹¦b¶J¦s¡A·»¸Ñ¨Ï¥Î®É¡A§¡À³Á×¥ú¡C¡v¼t°Ó«ØÄ³¡G ²V¦X«á¥¼¨Ï¥Î§¹²¦¡A§NÂÃ3¤Ñ¡C
EPER2,Minocycline,Periofeel Dental oint 2%,TENT,,,,,,,,,,,,,,,,,,,
IZYV,Linezolid,Zyvox inj 600mg/300mL,QANB,Vancomycin-resistant Enterococcus faecium infections¡A including cases with concurrent bacteremia ¡A Nosocomial pneumonia caused by Staphylococcus aureus ¡AComplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains)¡A Streptococcus pyogenes¡A or Streptococcus agalactiae,Patients who have known hypersensitivity to linezolid or any of the other components of Zyvox.,Diarrhea (incidence across studies: 2.8-11%)¡A headache (incidence across studies: 0.5-11.3%) and nausea (incidence across studies: 3.4-9.6%).,25¢J¥H¤UÁ×¥ú,Adult and children > 12 years: 600 mg PO/IV Q12H; uncomplicated skin/skin structure infections: 400-600 mg PO Q12H. Children (0-11 years): 10 mg/kg PO/IV Q8H; uncomplicated skin/skin structure infection: (5-11 years) 10 mg/kg PO Q12H¡A (< 5 years) 10 mg/kg PO Q8H. Administer IV infusion over 30-120 minutes. *****NEONATE ANTIBIOTICS DOSE***** Linezolid: Oral¡A IV. Bacteremia¡A community/ hospital-acquired pneumonia¡A skin infections. Vancomycin-resistant Enterococcus faecium (VREF) infection GA <34 week Postnatal 0-7 days¡A dose: 10mg/kg Q12H GA <34 week Postnatal >=8 days¡A dose: 10mg/kg Q8H GA 33-44 week Postnatal 0-28 days¡A dose: 10mg/kg Q8H,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Linezolid©M¥NÁÂª«·|¤Àªc¦Ü±Â¨Å¤j¹«ªº¨Å¥Ä,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¿éª`®É¶¡«ØÄ³¥H30¦Ü120¤ÀÄÁ,1. ÀR¯ß§ë»PZyvox Inj. ®É¡A¿éª`®É¶¡À³¬°30¦Ü120¤ÀÄÁ¡C¤£±o¨Ï¥Î¦¹ÀR¯ß¿éª`³U§@¤@¨t¦CªºÁpµ²¡C²K¥[ª«¤£±oª`¤J¦¹¿éª`²G¤¤¡C·í¨Ï¥ÎZYVOXÀR¯ßª`®g¾¯¥²¶·¦P®É¨Ö¥Î¨ä¥LÃÄª«®É¡AÀ³¸Ó®Ú¾Ú¨C¤@­ÓÃÄ«~ªº«ØÄ³¾¯¶q©M§ë»P³~®|¤À¶}§ë»P¡C 2. Zyvox Inj.À³Á×¥úÀx¦s©ó25¢XC¥H¤U¡C²~¤fÀ³ºò³¬¥HÁ×§K¼éÀã¡C¿éª`³U¦b¨Ï¥Î«e¡A«ØÄ³À³«O¦s¦b¾Tºä¥~¥]¸Ë¤º¡C¿éª`³UÀ³¹w¨¾µ²¦B¡CÃÄª«¦b§ë»P¤§«eÀ³¥Î²´·úÀË¬d¬O§_¦³·L²É¦s¦b¡C 3. ª`·N°Æ§@¥Î¡G¨Å»Ä©Ê»Ä¤¤¬r¡B¦å²M¯À¯g­Ô¸s(¨Ö¥Î¦å²M¯ÀÃþ»s¾¯©Î¹TÓi»Ä­¹«~)¡B¶gÃä¯«¸g¯fÅÜ¤Îµø¯«¸g¯fÅÜ¡BµjÅË¡C
IACL,Zoledronic Acid,Aclasta inj 5mg/100mL,META,Treatment and prevention of postmenopausal osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment and prevention of glucocorticoid-induced osteoporosis. Treatment of Paget¡¦s disease of bone in men and women.,Hypocalcemia. Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. Hypersensitivity to any component of Aclasta.,Common: Peripheral edema (Paget disease¡A 3%; osteoporosis¡A 4.6-5.5%; osteopenia¡A 3.9-5.6%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 21%)¡A Weight decreased (bone metastasis¡A 16%)¡A Abdominal pain (osteoporosis (female)¡A 0.9-4.6%; osteoporosis (male)¡A 7.9%; osteoporosis (male and female)¡A 7.5%; osteopenia¡A 6.6-8.6%; Paget disease¡A 2%; hypercalcemia of malignancy¡A 16%; bone metastasis¡A 14%)¡A Constipation (Paget disease¡A 6%; hypercalcemia of malignancy¡A 27%)¡A Diarrhea (osteoporosis¡A 5.2-6%; osteopenia¡A 6.6-8.1%; Paget disease¡A 6%; hypercalcemia of malignancy¡A 17%; bone metastasis¡A 24%)¡A Loss of appetite (osteoporosis¡A 1-2%; osteopenia¡A 0.6-2%; Paget disease¡A 2%; hypercalcemia of malignancy¡A 9%; bone metastasis¡A 22%)¡A Nausea (osteoporosis (female)¡A 4.5-8.5%; osteoporosis (male and female)¡A 9.6%; osteopenia¡A 11.6-17.7%; Paget disease¡A 9%; hypercalcemia of malignancy¡A 29%; bone metastasis¡A 46%)¡A Vomiting (Paget disease¡A 2%; osteoporosis¡A 3.4-4.6%; osteopenia¡A 5-7.6%; hypercalcemia of malignancy¡A 14%; bone metastasis¡A 32%)¡A Arthralgia (Osteoporosis (female)¡A 17.9-23.8%¡A (acute phase¡A 3-7%); osteoporosis (male¡A acute phase)¡A 11.1%; osteopenia¡A 18.8-27.3%¡A (acute phase¡A 6.1%); hypercalcemia of malignancy¡A 5-<10%; Paget disease¡A 9%; bone metastasis¡A 21%)¡A Backache (Osteoporosis (male and female)¡A 4.3%; osteoporosis (male¡A acute phase)¡A 3.3%; osteopenia¡A 16.6-18.2%¡A (acute phase¡A 1.7%); Paget disease¡A 4%; bone metastasis¡A 15%)¡A Pain in limb (Osteoporosis (female)¡A 5.9-11.3%; osteoporosis (male and female)¡A 3.1%; osteopenia¡A 11.1-16%¡A (acute phase¡A 3.9%); bone metastasis¡A 14%)¡A Asthenia (osteoporosis¡A 3.2 to 5.3%; osteopenia¡A 2.8-6.1%; Paget disease¡A 2%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 24%)¡A Dizziness (osteoporosis¡A 2-7.6%; osteopenia¡A 6.1-7.6%; Paget disease¡A 9%; bone metastasis¡A 18%)¡A Headache (osteoporosis (female)¡A 3.9-12.4%¡A (acute phase¡A 7%); osteoporosis (male)¡A 15%¡A (acute phase¡A 9.8%); osteopenia¡A 14.6-20.4%¡A (acute phase¡A 13.3%); Paget disease¡A 11%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 19%)¡A Insomnia (hypercalcemia of malignancy¡A 15%; bone metastasis¡A 16%)¡A Paresthesia (Paget disease¡A 2%; bone metastasis¡A 15% .)¡A Nephrotoxicity (bone metastasis¡A 11-17%)¡A Fatigue (osteoporosis (female)¡A 2.1-5.4%; osteoporosis (male)¡A 17.6%¡A (acute phase¡A 12.4%); osteopenia¡A 9.9-14.6%¡A (acute phase¡A 8.3%); Paget disease¡A 8%; bone metastasis¡A 39%)¡A Fever (osteoporosis (female¡A acute phase)¡A 7-18%; osteoporosis (male¡A acute phase)¡A 15.7%; osteopenia¡A 21-21.7% (acute phase¡A 19.3%); Paget disease¡A 3-11%; hypercalcemia of malignancy (acute phase)¡A 44%; bone metastasis¡A 32%) Serious: Atrial fibrillation (osteoporosis (female)¡A 1.3-2.8%; osteoporosis (male)¡A 3.3%; osteoporosis (male and female)¡A 0.7%)¡A Cardiac dysrhythmia¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hypocalcemia (Osteoporosis¡A up to 0.2%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 1.3%; Paget disease¡A 3-21%)¡A Bone pain (Osteoporosis (female)¡A 3.2-5.8%; osteoporosis (male and female)¡A 3.1%; osteopenia¡A 3.3-5.1%; Paget disease¡A 9%; hypercalcemia of malignancy¡A 12%; bone metastasis¡A 55%)¡A Myalgia (Osteoporosis (female)¡A 4.9-11.7%¡A (acute phase¡A 9%); osteoporosis (male)¡A 19.6%¡A (acute phase¡A 17.1%); osteopenia¡A 19.2-22.7%; Paget disease¡A 7%; bone metastasis¡A 23%)¡A Necrosis of bone¡A acute¡A Osteonecrosis of jaw¡A Tetany¡A Cerebrovascular accident (osteoporosis¡A 2.3%)¡A Numbness¡A Seizure¡A Nephrotoxic acute renal failure¡A Serum creatinine above reference range (osteoporosis¡A 1.2-2.1%; bone metastasis¡A 1%; hypercalcemia of malignancy¡A 2%)¡A Dyspnea (Paget disease¡A 5%; osteoporosis (male)¡A 6.5%; hypercalcemia of malignancy¡A 22%; bone metastasis¡A 27%),15-30¢J,IVD¡A 5 mg once every year.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,,,¿éª`®É¶¡ > 15 ¤ÀÄÁ(¿éª`§¹À³¥H10mL N/S¨RºÞ¸ô),1.ª`®g²G¤£¥i±µÄ²§t¦³¶tÂ÷¤l©Î¨ä¥L¤G»ùÂ÷¤lªº·»²G (¨Ò¦p¡Glactated Ringer)¡A¥²¶·¥H³æ¿Wªº¿éª`ºÞ¸ôµ¹ÃÄ¡C 2.­YÃÄ«~¤w§NÂÃ¡A¿éª`«e¥ýÅýª`®g·»²G¦^´_¨ì«Ç·Å¡C¶}²~«áªº·»²G¦bÄá¤ó2-8«×¤U¥i«O¦s24¤p®É¡C 3.¯f¤H±µ¨üAclasta¿éª`«e¡A¥²¶·«O«ù¤ô¤À¥R¨¬ªºª¬ºA(adequately hydrated)¡C
IBAY,Hepatitis B Immune Globulin,BayHep B 0.5mL,HIMM,,¾AÀ³¯g:Post-exposure prophylaxis of hepatitis. Acute exposure to blood containing HBsAg¡A perinatal exposure of infants born to HBsAg +ve mothers¡A sexual exposure to an HBsAg +ve person¡A household exposure to persons with acute HBV infection. °Æ§@¥Î: Local pain & tenderness at the inj site¡A urticaria & angioedema¡A anaphylactic reactions.,,2-8,By IM inj only. Acute exposure to blood containing HBsAg 0.06 mL/kg body weight within 24 hr. Prophylaxis of infants born to HBsAg & HBeAg +ve mothers 0.5 mL to be given within 12 hr of birth. Sexual exposure to an HBsAg +ve person 0.06 mL/kg as a single dose within 14 days of sexual contact. Give together with 1st dose of 1 mL IM of vaccine. Household exposure to persons with acute HBV infection Infants < 12 months 0.5 mL.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ICAR,Carboplatin,Carboplatin inj 150mg/15mL,RACA,,¾AÀ³¯g: Treatment of advanced ovarian carcinoma in combination with other chemotherapeutic agents. Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy¡A including patients who have previously been treated with cisplatin. Metastatic small cell carcinoma of the lung. °Æ§@¥Î: Myelosuppression especially thrombocytopenia¡A leukopenia; nausea & vomiting¡A abdominal pain¡A diarrhea¡A constipation; nephrotoxicity; neurotoxicity including paresthesia & decreased deep tendon reflexes; transient visual disturbances¡A ototoxicity manifesting as tinnitus; abnormal liver function tests; hypersensitivity reactions. ¸T§Ò: Severe bone marrow suppression or significant bleeding; severe pre-existing renal impairment (creatinine clearance <=20 mL/min).,,«Ç·Å,Advanced ovarian carcinoma Initial treatment: 300 mg/m2 IV on day 1 at 4-week intervals for 6 cycles. Secondary treatment: 360 mg/m2 IV on day 1 at 4-week intervals. Metastatic small cell carcinoma of the lung 400 mg/m2 IV over 15-60 mins at 4-week intervals.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gcisplatinªº¾¹¨ã¤£¥i§t¦³¾T¡C 3. µ}ÄÀ«áªº¿éª`·»²G­Y¶W¹L8¤p®É¥¼¥Î§¹¡AÀ³¥á±ó¤£¥Î¡C 4. ºÊ´úCBC¡C
ICAV,Alprostadil,Caverject 20mcg inj,SGU,Erectile dysfunction of neurogenic etiology¡A Erectile dysfunction of vasculogenic¡A psychogenic or mixed etiology¡A Diagnosis of erectile dysfunction.,Predisposition to priapism eg sickle cell anemia or trait¡A multiple myeloma or leukaemia. Anatomical deformation of the penis eg angulation¡A cavernosal fibrosis or Peyronie's disease. Patients with penile implants¡A men for whom sexual activity is inadvisable or contraindicated.,Common: Bradyarrhythmia (Neonates¡A 7%)¡A Hypotension (Adult¡A up to 3% ; pediatric¡A 4%)¡A Tachycardia (Neonates¡A 3%)¡A Flushing (Neonates¡A 10%)¡A Urethral discomfort (Adult¡A 12-13%)¡A Pain in penis (Adult¡A 29-37%)¡A Pain in testicle (Adult¡A 1-5%)¡A Fever (Neonates¡A 14%) Serious: Cardiac arrest (Neonates¡A 1%)¡A Gastrointestinal obstruction (Neonates¡A 6.8%)¡A Disseminated intravascular coagulation (Neonates¡A 1%)¡A Infantile cortical hyperostosis¡A Seizure (Neonates¡A 4%)¡A Fibrosis of penis (Intracavernous¡A 3-7.8%)¡A Priapism (Adult¡A less than 1%)¡A Prolonged erection of penis (Adult¡A 0.3-4%)¡A Apnea (Neonates¡A 10-12%),2-8¢XC,Erectile dysfunction of neurogenic etiology Starting dose: 1.25 mcg¡A 2nd dose: 2.5 mcg¡A 3rd dose: 5 mcg. Erectile dysfunction of vasculogenic¡A psychogenic or mixed etiology Starting dose: 2.5 mcg¡A 2nd dose: 5-7.5 mcg¡A 3rd dose: 5-10 mcg. The lowest effective dose to maintain an erection by direct intracavernosal inj is used. Maintenance therapy: once daily & not >3 times weekly. Diagnosis of erectile dysfunction A single dose that induces a firm erection is used.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,LI;,¨Ï¥Î¼t°Ó´£¨Ñ¤§ª`®g¥Î¤ôµ}ÄÀ,,,,
ETEA,Dextran 70 + Hydromellose,Tears Naturale 15mL,TOPH,Temporary relief of ocular irritation due to eye dryness.,Wearing of soft contact lenses.,Occasionally ocular redness¡A swelling¡A burning sensation¡A pain¡A stinging.,30¢J¥H¤U,Instill 1-2 drops TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
IHEP50,Heparin,Heparin for flushing 50IU/mL¡A100mL,HEMT,,¾AÀ³¯g:Flush in central line only. °Æ§@¥Î:Hemorrhage¡A allergic reactions ¸T§Ò:Patients predisposed to active bleeding including thrombocytopenia¡A peptic ulcer disease¡A cerebrovascular disorders¡A haemorrhagic blood disorders¡A bacterial endocarditis¡A severe hypertension¡A oesophageal varices. Hypersensitivity to heparin.,,20-25¢J,Flush in central line only.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,¤£¥i¥Î©ó¦Ù¦×ª`®g¡C
IHEP250,Heparin,Heparin inj 250IU/mL¡A250mL(for H/D),HEMT,,,,,,,,,,,,,,IVD;,,,,,
EALC1,Alcohol,75% Alcohol 10mL/bot,TDER,,,,,,,,,,,,,,,,,,,
IPERG,FSH 150IU + LH 75IU,Pergoveris 150 IU/75 IU,HM,,¾AÀ³¯g: Infertility in male & female. °Æ§@¥Î: Ovarian hyperstimulation¡A ascites¡A hydrothorax¡A oliguria¡A hypotension¡A thromboembolism¡A hypersensitivity reactions¡A fever¡A nausea & vomiting¡A inj site reactions¡A unintentional multiple pregnancies. ¸T§Ò: Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus¡A ovaries & breasts.,,,By IM or SC inj. Female Initially 75-150 iu of FSH (1-2 vials) daily & gradually adjusted if necessary until an adequate response is achieved. To induce ovulation¡A 5000-10¡A000 iu HCG should be administered by IM inj after the last dose of HMG. A 2nd HCG administration of 5000 iu may be given 7 days afterwards to improve luteal function. Male 1 vial of Pergoveris administered 3 times/week¡A along with 3000 iu of HCG/week. This dosage should be maintained for 10-12 wks¡A or until there is evidence of improvement in spermatogenesis.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G·»¸Ñ,,,,
IOCI,Oxacillin,Ocillina inj 500mg,QANB,Staphylococcal infections resistant to benzylpenicillin,Hypersensitivity to penicillins,Fever; rash; diarrhoea¡A nausea¡A vomiting; agranulocytosis¡A eosinophilia¡A leukopenia¡A neutropenia¡A thrombocytopenia; AST increased¡A hepatotoxicity; acute interstitial nephritis¡A haematuria; serum sickness-like reactions. Potentially Fatal: Anaphylaxis.,30¢J¥H¤UÁ×¥ú,(¥é³æ+¼ö¯f) Adults and children > 40 kg: 0.25-2 g IV/IM Q4-6H over 10 minutes. Children < 40 kg: 50-200 mg Q4-6H. *****NEONATE ANTIBIOTICS DOSE***** Oxacillin: General infection Body weight <1kg Age<=7 day 25 mg/kg Q12H  Age 8-14 day 25 mg/kg Q12H  Age 15-28 day 25 mg/kg Q8H Body weight 1-2kg Age<=7 day 25 mg/kg Q12H   Age 8-14 day 25 mg/kg Q8H   Age 15-28 day 25 mg/kg Q8H Body weight >2kg Age<=7 day 25 mg/kg Q8H  Age 8-14 day 25 mg/kg Q6H  Age 15-28 day 25 mg/kg Q6H Meningitis Body weight <1kg ge<=7 day 0mg/kg Q12H  Age 8-14 day 0mg/kg Q12H  Age 15-28 day 0 mg/kg Q8H Body weight 1-2kg ge<=7day 0mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age <=7day 50 mg/kg Q8H  Age 8-14 day 50 mg/kg Q6H  Age 15-28 day 50mg/kg Q6H,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,IM: 2.7 mL D/W IV: 5mL D/W¡A N/S,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C,±Àª`³t²v < 100 mg/¤ÀÄÁ¡A«ØÄ³±Àª`> 10¤ÀÄÁ,µ¹ÃÄ¿@«×0.5~40 mg/mL¡A«ØÄ³¿éª`> 30¤ÀÄÁ,ª`®g«eÀË¬d¯f±w¬O§_¦³Penicillin¹L±Ó¥v 1.ª`®g³t²v¤Ó§Ö¥i¯à³y¦¨µjÅË©ÊÅöíw¡C 2.¦Ñ¦~¤HÀ³´îºCµ¹ÃÄ³t²v¡AÁ×§Kµo¥Í¦å®ê©ÊÀR¯ßª¢¡C 3.ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡B¨xµÇ¥\¯à¡C 4.¯S®í±Ú¸s: ¦~ªøªÌ¡B¨x¡BµÇ¥\¯à¨ü·lªÌ¤£»Ý½Õ¾ã¾¯¶q¡C 5. ¿@«×0.5~2 mg/mL ªºÃÄª«¦w©w©Ê¡G¦b6¤p®É·|´î¤Ö10%¥H¤Uªº¬¡©Ê¡C
OCON3,Methylphenidate,CONCERTA 36mg,CNEU,For treatment of attention deficit hyperactivity disorder.,Patients with marked anxiety¡A tension & agitation¡A glaucoma¡A Tourette's syndrome¡A & patients on MAOI therapy.,Headache¡A stomach ache¡A loss of appetite¡A insomnia¡A aggravation reaction¡A asthenia¡A hypertension¡A nausea &/or vomiting¡A dyspepsia¡A weight loss¡A twitching (tics)¡A dizziness¡A emotional lability¡A somnolence¡A anxiety¡A depression¡A nervousness¡A hostility¡A rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )¡A Loss of appetite (5% )¡A Nausea (12% )¡A Vomiting (10% ) Neurologic: Headache¡A Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )¡A Nasopharyngitis (5% ),25¢J¥H¤UÁ×§K¼éÀã,Attention deficit disorder : (Child over 6 yrs and adult) Concerta: 36mg(1 TAB) QD. (maximum for Child: 54 mg/day; maximum for adult : 72 mg/day ),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°ªø®Ä¿õ¡A½Ð¾ã²É§]ªA¡A¤£¥i¼·¥b©Î¿i¯»¡C
IOMNI,Gadodiamide + Caldiamide,OmniSCAN inj 0.5 mmol/mL¡A 20mL,SCAN,¸£¯áÅèºÏ®¶Åã¼v¤Î¥þ¨­ºÏ®¶Åã¼v Magnetic resonance imaging¡A Brain¡A spine and associated tissues; Intrathoracic (noncardiac)¡A abdominal¡A pelvic¡A and retroperitoneal regions.,Kidney disease¡A chronic and severe (GFR less than 30 mL/min/1.73 m(2)); high risk for fatal or debilitating nephrogenic systemic fibrosis. Kidney injury¡A acute; high risk for fatal or debilitating nephrogenic systemic fibrosis. Hypersensitivity to gadodiamide or any component of the formulation.,Common: Nausea (General¡A 3% or less ; cardiac¡A 23%)¡A Dizziness (3% or less)¡A Headache (3% or less)¡A Discomfort due to sensations of heat or cold¡A Injection site pain (common)¡A Changes in taste and smell¡A Vomiting¡A Somnolence¡A Paresthesia¡A Vision blurred¡A Diarrhea¡A Restlessness¡A Dyspnea¡A Chest pain¡A Palpitations¡A Tremors¡A Arthralgia. Serious: Deep thrombophlebitis (1% or less)¡A Heart failure (1% or less)¡A Myocardial infarction (1% or less)¡A Syncope (1% or less)¡A Nephrogenic systemic fibrosis¡A Serum iron level outside reference range¡A Anaphylaxis (1% or less)¡A Hypersensitivity reaction (1% or less)¡A Exacerbation of multiple sclerosis (1% or less)¡A Acute renal failure (1% or less)¡A Angioedema (<1%)¡A Systemic sclerosis,30¢J¥H¤UÁ×¥ú,Magnetic resonance imaging¡A Brain¡A spine and associated tissues; Intrathoracic (noncardiac)¡A abdominal¡A pelvic¡A and retroperitoneal regions: CNS imaging¡A 0.2 mL/kg (0.1 mmol/kg) as an IV bolus injection. kidney imaging¡A 0.1 mL/kg (0.05 mmol/kg) IV. intrathoracic (noncardiac)¡A intra-abdominal¡A pelvic cavities imaging¡A 0.2 mL/kg (0.1 mmol/kg) IV.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,GADODIAMIDE PREGNANCY RECOMMENDATION: Limited Human Data¡XAnimal Data Suggest Moderate Risk CaldiamideµL¸ê®Æ,Human Data Suggest Potential Toxicity,GADODIAMIDE BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible CaldiamideµL¸ê®Æ,IV;IVP;IVPUSH;,,,,,
OTS1,Tegafur + Gimeracil + Oteracil K,TS-1 20mg,RACA,Post-op adjuvant chemotherapy for locally advanced [stage II (excluding T1)¡A IIIA or IIIB) gastric cancer. Treatment for advanced Inoperable or recurrent gastric cancer.,Severe bone marrow depression¡A renal & hepatic disorder. Treatment with other fluoropyrimidine-group anticancer drugs (including combination therapies) & flucytosine. Pregnancy & lactation.,Leukopenia¡A decreased Hb¡A thrombocytopenia¡A decreased neutrophil count; increased AST/ALT¡A bilirubin & creatinine; glycosuria¡A stomatitis¡A anorexia¡A nausea¡A vomiting¡A diarrhea¡A abdominal pain¡A constipation¡A rash¡A pigmentation¡A lacrimation¡A taste abnormality¡A dizziness¡A decreased weight¡A pyrexia¡A nasopharyngitis & fatigue.,«Ç·Å25¢J«O¦s,In general¡A for adults¡A the initial dose is determined based on body surface area (BSA). BSA < 1.25 m2: 40 mg/dose (80 mg/day); BSA 1.25 to < 1.5 m2: 50 mg/dose (100 mg/day); BSA >= 1.5 m2: 60 mg/dose (120 mg/day). Administer TS-1 capsule orally twice daily¡A after breakfast and dinner¡A for 28 consecutive days (4 weeks)¡A followed by a 14-day (2 weeks) rest for a 6-week course. For colorectal cancer¡A TS-1 administered orally twice daily on days 1 through 14 of a 28-day cycle in combination with irinotecan 125 mg/m2 IVD once every 14 days on day 1 and 15. TS-1 must NOT be taken with other fluoropyrimidine-group anti-cancer drug.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à»ÙÃª¯×±wªÌÀ³Äµ·V§ë»P ÄY­«¨x¥\¯à»ÙÃª±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OHAL5,Haloperidol,Binin-U 5mg,CNEU,,¾AÀ³¯g: Acute & chronic psychotic disorders including schizophrenia & manic states¡A Tourette's syndrome. Severe behavioral problems & hyperactivity in children. Nausea & vomiting associated with antineoplastic therapy & surgery. °Æ§@¥Î: Occasionally¡A depression¡A anxiety¡A agitation¡A confusion¡A vertigo¡A exacerbation of psychotic symptoms & seizures. Hyperprolactinaemia¡A gynaecomastia¡A menstrual irregularities¡A impotence. Rarely¡A tachycardia¡A orthostatic hypotension. ¸T§Ò: Endogenous depression without agitation¡A comatose conditions¡A severe CNS depression. Pregnancy¡A children.,,«Ç·Å,Initially 1-2 mg bid-tid & gradually increase up to 4-6 mg tid if required. Severely disturbed patients Up to 100 mg/day. Maintenance: 1-2 mg tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ISOBI,Sodium Bicarbonate,NaHCO3 (Rolikan) inj 7% 20mL,NUTR,Antacid. Treatment of metabolic acidosis & certain drug intoxications.,Metabolic or respiratory alkalosis¡A hypocalcemia¡A hypochlorhydria.,Excessive administration may cause hypokalaemia & metabolic alkalosis.,25¢J¥H¤UÁ×§K§N­á,Each mL contains: 70 mg¡A this package contains: 16.67 mEq/20mL. Cardiac arrest¡A Due To Hyperkalemia: IV: 50 mEq over 5 minutes. [Uptodate 20210731] Cardiac arrest (ACLS 2010): IV: Initial: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases Metabolic acidosis: IV: Dosage should be based on the following formula if blood gases and pH measurements are available: HCO3-(mEq) = 0.5 x weight (kg) x [24 - serum HCO3-(mEq/L)] or HCO3-(mEq) = 0.5 x weight (kg) x [desired increase in serum HCO3-(mEq/L)] Administer 1/2 dose initially¡A then remaining 1/2 dose over the next 24 hours; monitor pH¡A serum HCO3-¡A and clinical status. If acid-base status is not available: 2 to 5 mEq/kg IV infusion over 4 to 8 hours; subsequent doses should be based on patient's acid-base status.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IH;IRR;IVD;IVP;IVPUSH;LI;SC;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,Administer slowly (maximum rate in infants: 10 mEq/minute),IV infusion¡A dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over 2 hours (maximum rate of administration: 1 mEq/kg/hour) ¥¼µ}ÄÀ¥ç¥i¨Ï¥Î¡A¤£¥i»P§t¶t»s¾¯²V¦X¨Ï¥Î,1. 16.7 mEq / 20 mL / Amp 2. For I.V. administration to infants¡A use the 0.5 mEq/mL solution or dilute the 1 mEq/mL solution 1:1 with sterile water 3. Direct I.V. infusion in emergencies: administer slowly (maximum rate in infants: 10 mEq/minute) 4. IV infusion¡A dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over 2 hours (maximum rate of administration: 1 mEq/kg/hour) 5. Avoid extravasation¡A tissue necrosis can occur due to the hypertonicity of NaHCO3
ITAP,Piperacillin + Tazobactam,Tapimycin inj 2.25gm,QANB,Lower respiratory tract infections¡A complicated & uncomplicated UTI¡A intra-abdominal infections¡A skin & skin structure infections¡A bacterial septicaemia¡A polymicrobic infections¡A bacterial infections in neutropenic adults in combination with an aminoglycoside.,Hypersensitivity to penicillins¡A cephalosporins or £]-lactamase inhibitors.,Diarrhea¡A constipation¡A nausea¡A headache¡A insomnia¡A rash¡A erythema¡A pruritus¡A vomiting¡A allergic reactions¡A urticaria & superinfection. Dermatologic: Pruritus (3.1% to 3.2% )¡A Rash (1.3% to 4.2% ) Gastrointestinal: Constipation (1.1% to 8.4% )¡A Diarrhea (4.4% to 20% )¡A Nausea (1.8% to 6.9% )¡A Oral candidiasis (1.8% 3.9% )¡A Vomiting (2.6% to 3.7% ) Neurologic: Headache (1.4% to 7.7% )¡A Insomnia (4.5% to 6.6% ) Psychiatric: Agitation (2.1% to 7.1% ) Other: Fever (2.4% to 4.8% )¡A Pain (1.7% to 3.2% ),25¢J¥H¤U,Usual dose range: 4.5 g every 6-8 hr. Renal insufficiency¡A creatinine clearance > 40 mL/min 3.375 g every 6 hr¡A 20-40 mL/min 2.25 g every 6 hr¡A < 20 mL/min 2.25 g every 8 hr. Hemodialysis patients 2.25 g every 12 hr¡A Maximum dose: 2.25 g every 8 hr with additional 0.75 g following each dialysis period on hemodialysis days. Neutropenia 4.5 g every 6 hr in combination with an aminoglycoside. Hospital-acquired pneumonia : creatinine clearance > 40 mL/min 4.5 g every 6 hr¡A 20-40 mL/min 3.375 g every 6 hr¡A < 20 mL/min 2.25 g every 6 hr. Hemodialysis patients 2.25 g every 8 hr¡A Maximum dose: 2.25 g every 8 hr with additional 0.75 g following each dialysis period on hemodialysis days. *****NEONATE ANTIBIOTICS DOSE***** Piperacillin 2G+ Tazobactam 0.25G (Tapimycin): Dose base on piperacillin component Body weight <1kg ge<=7day 100mg/kg Q12H  Age 8-14 day 100mg/kg Q12H  Age 15-28 day 100mg/kg Q8H Body weight 1-2kg ge<=7day 100mg/kg Q12H  Age 8-14 day 100 mg/kg Q8H  Age 15-28 day 100mg/kg Q8H Body weight >2kg Age<=7day 100 mg/kg Q8H  Age 8-14 day 80 mg/kg Q6H  Age 15-28 day 80 mg/kg Q6H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,PIPERACILLIN PREGNANCY RECOMMENDATION: Compatible TAZOBACTAM PREGNANCY RECOMMENDATION: Limited Human Data¡XAnimal Data Suggest Low Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,PIPERACILLIN BREASTFEEDING RECOMMENDATION: Compatible TAZOBACTAM BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible,IVD;,10 mL D/W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥H > 30¤ÀÄÁ³t²v½wºCºwª`¡C(µ¹¥»ÃÄ¿é²G®É¡A»Ý¼È°±­ì¦³¤§¿é²Gµ¹ÃÄ¡C),1. ª`®g«eÀË¬d¯f±w¬O§_¦³PCN¹L±Ó¥v¡C 2. ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡B¦å¹[¡B¨xµÇ¥\¯à¡C
ITAR,Teicoplanin,Targocid inj 200mg,QANB,Infective endocarditis¡A osteomyelitis¡A pneumonia¡A sepsis¡A soft tissue infections¡A enteritis¡A and pseudomembranous colitis caused by Staphylococcus aureus infection. Teicoplanin is suitable for severe infections caused by Gram-positive bacteria¡A including those that cannot be treated with antibiotics such as penicillin and cephalosporins. Teicoplanin is suitable for severe Staphylococcus aureus infections that cannot be treated with penicillin and cephalosporins¡A or in cases of treatment failure¡A or when resistance to other antibiotics has developed. Teicoplanin is effective for infections of the skin and soft tissue¡A urinary tract¡A lower respiratory tract¡A joints and bones¡A sepsis¡A endocarditis¡A and peritonitis caused by continuous ambulatory peritoneal dialysis.,Hypersensitivity to teicoplanin or any component of the product.,Common: Local pain¡A Nausea¡A Dizziness¡A Headache¡A Eosinophilia¡A Leukopenia¡A Erythema¡A Pruritus¡A Rash (1-<10%)¡A Fever (1-<10%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Thrombocytopenia (0.1-<1%)¡A Anaphylaxis (0.1-<1%)¡A Hypersensitivity reaction¡A Toxic deafness (0.1-<1%)¡A Renal failure,25¢J¥H¤U,Adult: 6 mg/kg Q12H x 3 IV/IM doses (target trough: >15 £gg/mL)¡A then 6 mg/kg IV/IM once daily (target trough: >15 £gg/mL). Bone and joint infection: 12 mg/kg IV Q12H x 3-5 doses (target trough: >20 £gg/mL)¡A then 12 mg/kg IV/IM Q24H (target trough: >20 £gg/mL). Endocarditis: 12 mg/kg IV Q12H x 3-5 doses (target trough: 30-40 £gg/mL)¡A then 12 mg/kg IV/IM Q24H (target trough: >30 £gg/mL); a total treatment duration 21 days is recommended. Pediatric: Age 0 to <=2 months: 16mg/kg IVD x 1 dose on Day 1¡A then 8mg/kg IVD q24h since Day 2 Age 2 months to 16 years: 10mg/kg IV q12h x 3 doses¡A then 6-10mg/kg IV/IM q24h NOTE: Target trough should measured by FPIA (Fluorescence Polarization Immunoassay). After loading dose¡A trough should be measured at day 3-5; during maintenance dose¡A trough should be measured weekly. *****NEONATE ANTIBIOTICS DOSE***** Teicoplanin (Targocid): loading dose 16 mg/kg/dose¡A followed by 8 mg/kg/dose QD,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IM;IMP;IVD;IVP;IVPUSH;,IM¡A IV: 3mL D/W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ,«ØÄ³¥H30¤ÀÄÁ½wºCºwª`,1. ¤Å¥Î¤O·n®Ì¡A­Y¥X²{ªwªj¥iÀR¸m15¤ÀÄÁ¡C 2. µ}ÄÀ«áÀ³©ó24¤p®É¤º¨Ï¥Î¡CºÊ´úÅé·Å¡BCBC¡Aªø´Á¨Ï¥Î»Ýª`·NÅ¥¤OÅÜ¤Æ¡C 3.¥»«~»PaminoglycosideÃþ§Ü¥Í¯À¤£¬Û®e¡A¤£¥i²V¦X©Î¦P®Éª`®g ¡C 4.¹ïVancomycine¹L±ÓªÌÀ³¤p¤ß¨Ï¥Î¡A¥i¯àµo¥Í¥æ¤e¹L±Ó¡C
IURO,Urokinase,UROKINASE 60¡A000IU (ºñ¤Q¦r),HEMT,Acute coronary embolism¡A clearance of occluded catheters & shunts¡A acute pulmonary embolism¡A peripheral arterial or venous thromboembolism.,Intracranial hemorrhage¡A hemoptysis¡A difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.,Bleeding tendency. Fever¡A chills¡A headache & malaise may occur. Rarely¡A shock¡A sweating¡A disturbed pulse & dyspnea; rash¡A urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria. Hematologic: Decreased hematocrit level (37%),«Ç·Å,Cerebral thrombosis (within 5 days after onset of symptoms & without hemorrhage) 60¡A000 iu once daily for 7 days. Peripheral arterial/venous occlusion 60¡A000 to 240¡A000 iu on first day of treatment followed by tapered doses for about 7 days. Acute coronary embolism 26¡A000-52¡A000 iu daily for 7 days. Deep vein thrombosis or acute pulmonary embolism IV loading 250¡A000 iu/hr¡A then 1¡A000 iu/kg/hr (or 60¡A000 -100¡A000 iu/hr) for 72 hr.,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IV;IVD;,,,,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr
IYUT,Ritodrine,Yutopar°w¾¯ 50mg/5mL,SGU,,¾AÀ³¯g: Prevention of preterm labour¡A Acute fetal distress¡A Prevention of preterm labour after operation. °Æ§@¥Î: Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor¡A nausea¡A vomiting¡A headache or erythema¡A nervousness¡A restlessness¡A jitteriness¡A emotional upset¡A anxiety or malaise. Infrequently cardiac symptoms¡A eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment. ¸T§Ò: Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,,«Ç·Å,Prevention of preterm labour IV infusion Initially 0.05 mg/min¡A to be gradually increased by 0.05 mg/min every 10-15 mins. IM inj 10 mg 4-6 hrly. Continue treatment for 12-48 hr after ceased contraction. Oral maintenance Initiate oral therapy 30-60 mins before termination of parenteral therapy. Tab 1-2 tab 2-6 hrly. Max: 120 mg daily. Usually 80-120 mg equally divided over the day. Acute fetal distress Follow initial IV treatment for preterm labour. Prevention of preterm labour after operation Follow treatment for preterm labour.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ¿éª`²G«ØÄ³¨Ï¥ÎD5W¡C­Y¨Ï¥ÎN/Sµ}ÄÀ¡A±N¼W¥[µo¥ÍªÍ¤ô¸~¤§¥i¯à©Ê¡C(½Ã¥Í¸p¤½¤å¡GFDAÃÄ¦r²Ä1001409159¸¹)
LCENZ,Sertraline,CenZoft solution 60mL¡A20mg/mL,CNEU,,¾AÀ³¯g: Depression¡A obsessive-compulsive disorder (OCD)¡A panic disorder¡A post traumatic stress disorder (PTSD)¡A social phobia¡A premenstrual dysphoric disorder (PMDD). °Æ§@¥Î: Nausea¡A diarrhoea/loose stools¡A anorexia¡A dyspepsia; male sexual dysfunction (ejaculatory delay); tremor; dry mouth; increased sweating. Sertraline has been associated with PALPITATIONS¡A CHEST PAIN¡A HYPERTENSION¡A HYPOTENSION¡A EDEMA¡A SYNCOPE¡A and TACHYCARDIA ¸T§Ò: Patients with known hypersensitivity to sertraline. Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).,,«Ç·Å,Depression; Obsessive-compulsive disorder Initial: 2.5mL once daily¡A may increase slowly. Max: 10 mL/day. Panic disorder; Post-traumatic stress disorder; Social anxiety disorder Initial: 1.25 mL/day¡A increased to 2.5 mL/day after 1 wk. May increase slowly. Max: 10 mL/day. Premenstrual dysphoric disorder Initial: 2.5 mL/day throughout the menstrual cycle or only during luteal phase. May increase by 2.5 mL/cycle. Max: 7.5 mL/day for continuous dosing or 5 mL/day for luteal phase-only dosing.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IPKE5,Streptococus Pyogenes,Picibanil inj 5KE,RACA,Cancers of the digestive organs¡A head & neck¡A thyroid¡A lung.,History of anaphylactic reactions to benzylpenicillin. History of previous shock reactions to the drug.,Nausea¡A vomiting¡A anorexia; pyrexia¡A generalized fatigability¡A headache¡A arthralgia; pain¡A swelling at site of inj. Rarely¡A hypersensitivity reactions¡A shock¡A anemia.,10¢J¥H¤UÁ×§K§N­á,For intravenous injection¡A starting at 0.2-1 KE 2-3 times weekly; may increase to 1-3 KE 2-3 times weekly as maintenance therapy. For local injection¡A 5-10 KE dissolved in 2 mL normal saline as a single dose administered locally once daily or once a few days. For administration into the serous cavity¡A a single dose of 5-10 KE in 2 mL normal saline 2-3 times weekly. For intramuscular or subcutaneous injection¡A starting at 0.2-0.5 KE in 2 mL normal saline once daily or once every other day. May consider increasing dose gradually after 3-5 doses. Maintenance dose: 1-5 KE 1-3 times weeekly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IPLE;,ÀR¯ßª`®g:¥H2mL¥Í²z­¹ÆQ¤ô©Î5%¸²µå¿}²G·»¸Ñ¡A°µÀR¯ß¤ºª`®g¡A©Î»P¿é¤J²G¡B¸É²Gµ¥ ²V¦X¦Ó°µÀR¯ßÂIºw¡C §½³¡©Î¼ß½¤µÄ¤º¨Ï¥Î: ¥H2mL­¹ÆQ¤ô·»¸Ñ.,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,1. ¥»¾¯§t­f¥Ò°ò«CÅð¯À¡A¹ï«CÅð¯À¹L±Ó¯f±w¤£©y¨Ï¥Î¡C 2. ¥H2mL¥Í²z­¹ÆQ¤ô·»¸Ñ¡A²V¦X¿é²G¤¤
IVOR,Diclofenac,VOREN inj 75mg/3mL,CNEU,Rheumatism¡A acute musculoskeletal disorders¡A post-traumatic & post-op inflammation & swelling.,Patients sensitive to aspirin or other NSAIDs.,GI disturbances. Peptic ulceration. GI bleeding. Headache¡A dizziness¡A nervousness¡A skin rash¡A pruritus¡A tinnitus¡A edema¡A depression¡A drowsiness¡A insomnia¡A & blurred vision. Hypersensitivity. Impairment of liver & kidney function. Agranulocytosis & thrombopenia. Dermatologic: Application site reaction (gel: all reactions¡A 7%; dermatitis¡A 4% to 11% ) Hematologic: Blood coagulation disorder (1% to 10% ) Ophthalmic: Burning sensation in eye (15% )¡A Keratitis (up to 28% )¡A Lacrimation and lacrimal drainage - finding (up to 30% )¡A Raised intraocular pressure (up to 15% ),25¢J¥H¤U,Adults: 75 mg(1 ampoule) IM once a day. Slow injection deep into the lateral buttock muscles.,µL»Ý½Õ¾ã¾¯¶q,Moderate to severe impairment: Use is not recommended (has not been studied).,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,¥é³æÄµ»y¡G ¡]1¡^¤ß¦åºÞ¨Æ¥ó¡G¥i¯à´c¤Æ°ª¦åÀ£¡A¥i¯àµo¥ÍÅé²Gº¢¯d©Î¤ô¸~¡]2¡^­G¸z¹D§@¥Î¡G­G¸z¼ìºÅ¡B¥X¦å¤Î¬ï¤Õ¤§¦MÀI©Ê¡]3¡^¨xÅ¦§@¥Î¡G¨x«ü¼Æ¤É°ª ¡]4¡^µÇÅ¦§@¥Î¡Gªø´Á§ë»P¥i¯à³y¦¨µÇÅ¦·l¶Ë ¡]5¡^¥Ö½§¤ÏÀ³¡G¥i¯àµo¥ÍÄY­«¦Ó­P¦º©Êªº¤£¨}¤ÏÀ³¡A¦p¡GSJS¡BTENS¡]6¡^¦å²G§@¥Î ¡Gª`·N³h¦å¡B¦å¤pªO­p¼Æ
EALL,Antazoline + Tetrahydrozoline,Allergopos Eye Drops 10mL,TOPH,,¾AÀ³¯g:Irritant conjunctivitis¡A allergic inflammatory conditions of the conjunctiva¡A particularly hay fever conjunctivitis & vernal conjunctivitis. °Æ§@¥Î: Mild burning sensation; Blurred vision ¸T§Ò: Narrow-angle glaucoma.,,«Ç·Å,instill 1 drop 3 to 4 times daily into the eye.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ICAL2,Calcitriol,Caltsue inj 4mcg/2mL,META,,¾AÀ³¯g¡G Management of hypocalcemia in patients undergoing chronic renal dialysis. °Æ§@¥Î¡G Weakness¡A headache¡A somnolence; nausea¡A vomiting¡A dry mouth¡A constipation; muscle pain¡A bone pain & metallic taste. ¸T§Ò¡G Hypercalcemia or evidence of vit D toxicity.,,«Ç·Å,Initially 1 mcg (0.02 mcg/kg) to 2 mcg 3 times weekly¡A approximately every other day. Dose may be increased by 0.5-1 mcg at 2- to 4-week intervals.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
IPRO6,Denosumab,Prolia inj 60mg,META,Treatment of postmenopausal women w/ osteoporosis at high risk for fracture; bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer; bone loss in men receiving androgen deprivation therapy for prostate cancer.,Hypocalcemia. Pregnancy & lactation. Severe renal impairment. Hypersensitivity to any component of the product; facial swelling and urticaria have been reported.,Common: Hypercholesterolemia (Osteoporosis¡A 7.2%)¡A Constipation (Hypercalcemia of malignancy¡A 21% ; Glucocorticoid-induced osteoporosis¡A 2.8% ; giant cell tumor of bone¡A 10% or greater)¡A Diarrhea (10% or greater)¡A Nausea (10% or greater)¡A Toothache (10% or greater)¡A Vomiting (10% or greater)¡A Anemia (Hypercalcemia of malignancy¡A multiple myeloma¡A 21-22% ; osteoporosis¡A 3.3%)¡A Arthralgia (6.7-14.3%)¡A Backache (4.6-34.7%)¡A Musculoskeletal pain (6-10% or greater)¡A Pain in limb (9.9-11.7%)¡A Asthenia (Osteoporosis¡A postmenopausal¡A 2.3%; multiple myeloma¡A bone metastases¡A breast cancer-related¡A 13-20%)¡A Headache (3.6-24%)¡A Cystitis (5.9%)¡A Cough (10% or greater)¡A Nasopharyngitis (6.7-10% or greater)¡A Upper respiratory infection (4.9-15%)¡A Fatigue (11-25%) Serious: Endocarditis (0.08%)¡A Cellulitis¡A Dermatitis¡A Erysipelas¡A Rash (2.5-5.1%)¡A Hypercalcemia¡A Hypocalcemia (1.7-18%)¡A Hypophosphatemia (Bone metastases¡A 32%; hypercalcemia of malignancy¡A 76%; bone metastases¡A giant cell tumor of bone¡A multiple myeloma (severe)¡A 9.5-21%)¡A Pancreatitis (0.2-0.8%)¡A Anaphylaxis¡A Hypersensitivity reaction¡A Infectious disease¡A Serious (3.9-6%)¡A Fracture of femur¡A Atypical (0.9%)¡A Osteonecrosis of jaw (Up to 6.6%)¡A Polymyalgia rheumatica¡A Worsening (2.0%)¡A Dyspnea (21-27%)¡A Pneumonia¡A Cancer (1.9-4.8%)¡A Substance withdrawal¡A Rebound effect (3-6%),2-8¢JÁ×¥úÁ×§K§N­á,SC¡A 60 mg every 6 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¦³¥Í¨|¯à¤O¤§°ü¤k©óªvÀø´Á¶¡¦Ü³Ì«á¤@¾¯ÃÄª««á¤­­Ó¤ë¤º¡AÀ³±Ä¦³®ÄªºÁ×¥¥±¹¬I.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,1. ª`®g«e©ó¦B½c¨ú¥X¡A¥i©ó«Ç·ÅÂ\©ñ15-30¤ÀÄÁ¦^·Å¡A¥»ÃÄ«~¤£¥i¥[¼ö¡C 2. ¥Ö¤Uª`®g³¡¦ì¡G¤WÁu¡B¤WÁv©Î¸¡³¡¡C
OPROZ,Fluoxetine,Prozac 20mg,CNEU,,¾AÀ³¯g: Treatment of depression¡A obsessive-compulsive disorder & bulimia nervosa. °Æ§@¥Î: Hypersensitivity reactions including rash¡A anxiety¡A nervousness¡A insomnia¡A anorexia¡A weight loss¡A asthenia¡A GI disturbances¡A somnolence¡A tremor¡A pharyngitis¡A sweating¡A impotence¡A abnormal ejaculation¡A mania or hypomania. Dermatologic: Diaphoresis¡A Rash (7% ) Gastrointestinal: Loss of appetite (3.5% to 15% )¡A Nausea (20% to 30% .)¡A Xerostomia Neurologic: Asthenia (9% to 21% )¡A Dizziness (2% to 11% )¡A Insomnia (9% to 26% )¡A Somnolence (13% )¡A Tremor (12% ) Psychiatric: Anxiety (3% to 9% )¡A Feeling nervous (3% to 14% ) Respiratory: Pharyngitis (6% to 10% )¡A Rhinitis (16% to 23% ) ¸T§Ò: Should not be used within a min of 14 days of discontinuation of MAOI. At least 5 weeks should elapse between discontinuation of fluoxetine & initiation of MAOI therapy. Concomitant use with thioridazine.,,«Ç·Å,Adult Depression Initially 20 mg/day in the morning¡A increase after several weeks if required to 20 mg morning & noon. Max: 80 mg/day. Maintenance: 20 mg/day. Obsessive-compulsive disorder 20-60 mg/day. Max: 80 mg/day. Bulimia 60 mg/day. Children Lower starting dose should be considered. Doses > 60 mg/day have not been systematically evaluated in children 7-18 years.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OROA,Isotretinoin,Roaccutane 10mg,TDER,Severe forms of acne resistant to therapy¡A especially cystic acne & acne conglobata.,Pregnancy & lactation. Hepatic or renal insufficiency. Hypervitaminosis A. Patients with excessively elevated blood lipid values. Supplementary treatment with tetracycline.,Dry mucosa; dermatitis facialis¡A pruritus¡A sweating. Occasionally¡A reversible alopecia¡A muscle & joint pain. Rarely¡A inflammatory bowel disease; hyperuricaemia; benign intracranial hypertension¡A visual disturbances & photosensitivity reactions. Hematuria/proteinuria¡A hirsutism¡A pancreatitis¡A lymphadenopathy. Rarely¡A depression. Dermatologic: Alopecia (6.4% )¡A Cheilitis (91.3% to 95.5% )¡A Dry skin (87.1% )¡A Pruritus (22.8% )¡A Retinoid dermatitis (68% ) Gastrointestinal: Xerostomia Musculoskeletal: Arthralgia¡A Backache Ophthalmic: Conjunctivitis Respiratory: Epistaxis,30¢J¥H¤U,Acne (severe recalcitrant nodular): Initially¡A 0.5 mg/kg/day in 2 divided doses ¡A if Severe acnes then slowly adjust dose to 2mg/kg/day,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªº±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦ÅnÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ¡BÀ£¸H©Î¥´¶}½¦Ån¡C¥»ÃÄ¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C
OROWA,Pipoxolan,Rowapraxin 10mg,ALIM,,¾AÀ³¯g: Antispasmodic in the management of spasm & colic in the GI¡A biliary & renal-urogenital tracts. Treatment of vascular headache. ¸T§Ò: Narrow-angle glaucoma¡A patients susceptible to intestinal or urinary outlet obstruction. Pregnancy.,,«Ç·Å,Adult Vascular headache 10 mg tid. Other indications 10-30 mg tid. Children > 6 years 10-30 mg once-bid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSAB,Vigabatrin,Sabril 500mg,CNEU,Treatment of epilepsy which is not satisfactorily controlled by other antiepileptic drugs.,pregnancy & lactation.,Aggression & psychosis. Drowsiness¡A fatigue¡A dizziness¡A nervousness¡A irritability¡A depression¡A headache. Less commonly¡A confusion¡A memory disturbance¡A diplopia. Wt gain¡A minor GI side effects. Dermatologic: Rash (4% to 11% ) Endocrine metabolic: Weight increased (6% to 14% ) Gastrointestinal: Constipation (5% to 14% )¡A Diarrhea (7% to 16% )¡A Nausea (2% to 10% )¡A Vomiting (6% to 20% ) Immunologic: Viral disease (19% to 20% ) Musculoskeletal: Arthralgia (5% to 10% )¡A Muscle twitch (1% to 9% ) Neurologic: Confusion (4% to 14% )¡A Coordination problem (7% to 16% )¡A Dizziness (15% to 26% )¡A Headache (18% to 33% )¡A Insomnia (7% to 12% )¡A Memory impairment (7% to 16% )¡A Sedated (adults¡A 4%; children¡A 17% to 19% )¡A Somnolence (17% to 45% )¡A Tremor (7% to 16% ) Ophthalmic: Blurred vision (6% to 16% )¡A Diplopia (6% to 16% )¡A Nystagmus (7% to 19% ) Otic: Infection of ear (7% to 14% )¡A Otitis media (10% to 44% ) Psychiatric: Depression (6% to 14% )¡A Irritability (7% to 23% ) Renal: Urinary tract infectious disease (4% to 6% ) Reproductive: Dysmenorrhea (5% to 9% )¡A Erectile dysfunction (5% ) Respiratory: Bronchitis (adults¡A 5%; children¡A 30% )¡A Cough (2% to 14% )¡A Nasopharyngitis (9% to 14% )¡A Pain in throat (7% to 14% )¡A Pneumonia (11% to 13% )¡A Upper respiratory infection (adults¡A 7% to 9%; children 46% to 51% ) Other: Fatigue (16% to 40% )¡A Fever (adults¡A 4% to 7%; children¡A 19% to 29% )¡A Influenza (3% to 7% ),Á×¥ú¦s©ñ©ó30¢J¥H¤U,Sabril 500mg film-coated tablet is not suitable for children under the age of 6 years¡A because of the risk of choking. Adult usual dose: 2000-3000 mg/day. Treatment should be initiated at 1000 mg/day (divided to 1-2 doses). Total daily dose may be increased in 500 mg increments at weekly intervals¡A depending on response. Maximum: 3000 mg/day. Children: recommended starting dose 40 mg/kg/day (divided to 1-2 doses)¡A maintenance dose in relation to bodyweight: > 50 kg¡A 2000-3000 mg/day¡A 30-50 kg¡A 1500-3000 mg/day¡A 15-30 kg¡A 1000-1500 mg/day¡A 10-15 kg¡A 500-1000 mg/day. Adjustment of dose or frequency of administration must be considered in elderly and patients with creatinine clearance less than 60 mL/min.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ©|¥¼¦³°w¹ïÃh¥¥°ü¤k¨Ï¥Îvigabatrin©Ò³]­pªº¾A·í¥B±±¨î¨}¦nªºÁ{§É¬ã¨s¡C¥u¦³¦bµ´¹ï¥²­n®É¡A¤~¯à©óÃh¥¥´Á¶¡¨Ï¥Îvigabatrin¡C ¥À¿Ë¨Ï¥Î§ÜÅöíwÃÄª«ªvÀø®É¡A¤p«Äµo¥Í¥ý¤Ñ²§±`ªº­·ÀI¼W¥[2¦Ü3­¿¡C³Ì±`¨£ªº³ø§i¬°®BÃEµõ¡B¤ß¦åºÞ©M¯«¸gºÞ¯Ê³´¡C §ÜÅöíwÃÄª«¤§¦h­«Àøªk¬Û¸û©ó³æ¤@Àøªk¡A¥i¯à»P¥ý¤Ñ·î§Î¦³§ó°ªªº¬ÛÃö©Ê¡C ¦pªG¯f¤HÃh¥¥¡AÀ³­«·sµû¦ôªvÀø¡C¬ðµM¤¤Â_­ì¥»¦³®Äªº§ÜÅöíwÀøªk¡A¥i¯à·|¾É­P¥À¿Ëªº¯f±¡ªº´c¤Æ¦Ó¾É­P­F­Lªº¶Ë®`¡C ­L¨à®É´Á¦]¥À¿ËªA¥Î¥»ÃÄ«~¦Ó´¿¼ÉÅS©óvigabatrin¤§¥®¨à¡A¨äµo¥Íµø³¥»ÙÃªªº¥i¯à©Ê¡A¥Ø«eµL¬ÛÃö¸ê®Æ¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Vigabatrin·|¸g¥Ñ¥À¨Å¤Àªc¡CVigabatrinªvÀø´Á¶¡¤£«ØÄ³Áý­¹¥À¨Å¡C,,,,,,
OSAL,Sulfasalazine,Salazopyrin EN 0.5gm,CNEU,,¾AÀ³¯g: Inflammatory bowel disease including Crohn's disease¡A ulcerative colitis¡A Active RA¡A ankylosing spondylitis. °Æ§@¥Î: Nausea¡A anorexia¡A raised temp; erythema & pruritus; headache. Rarely¡A hematological¡A GI¡A CNS¡A renal¡A dermatological reactions. Dermatologic: Pruritus (3% to 4% )¡A Rash (3% to 13% ) Gastrointestinal: Abdominal pain (8% )¡A Indigestion (13% to 33% )¡A Loss of appetite (33% )¡A Nausea (19% to 33% )¡A Stomatitis (4% )¡A Vomiting (8% to 33% ) Neurologic: Dizziness (4% )¡A Headache (9% to 33% ) Renal: Discolored urine Reproductive: Oligozoospermia¡A Reversible (33% ) Other: Fever (3% to 5% ) ¸T§Ò: Hypersensitivity to sulfonamides & salicylates. Acute intermittent porphyria. Infant < 2 years.,,«Ç·Å,Inflammatory bowel disease including Crohn's disease¡A ulcerative colitis Adult Mild to moderate attacks: 2 tab tid or qid. Severe attacks: 2-4 tab tid or qid. Children 40-60 mg/kg body weight/day in 3-6 doses. Maintenance: Adult 2 tab bid or tid. Children 20-30 mg/kg body weight/day in 3-6 divided doses. Active RA¡A ankylosing spondylitis 2 tab bid or tid.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OSEB,Telbivudine,Sebivo 600mg,QANB,,¾AÀ³¯g: Treatment of chronic hepatitis B with evidence of viral replication & active liver inflammation. °Æ§@¥Î: Headache¡A dizziness¡A diarrhea¡A nausea¡A rash¡A fatigue. Increased serum amylase¡A serum lipase¡A serum alanine aminotransferase¡A serum creatinine phosphokinase. Musculoskeletal: Finding of creatine kinase level (11% )¡A Finding of creatine kinase level¡A grade 3/4 (13%) Neurologic: Headache (10% ) Respiratory: Cough (6% to 16%) Other: Fatigue (13% to 18%)¡A Influenza (18% to 21%) ¸T§Ò: Hypersensitivity to telbivudine or to any of the excipients of Sebivo.,,,Adult 600 mg once daily. Renal impairment: CrCl 30-49 mL/min 600 mg once every 48 hr. CrCl <30 mL/min (not requiring dialysis) 600 mg once every 72 hr. End stage renal disease 600 mg every 96 hr.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IPED5,DTaP5-IPV-HIB,Pediacel (¤­¦X¤@¬Ì­]¡A ¦Û¶O) 0.5mL/dose,HIMM,,¾AÀ³¯g:Active immunization of children from 2 months of age to 7 years against diphtheria¡A tetanus¡A pertussis¡A poliomyelitis & invasive Haemophilus influenzae type b disease. °Æ§@¥Î:Redness¡A tenderness & swelling at inj site; fever¡A crying¡A drowsiness; decreased feeding¡A vomiting¡A irritability. ¸T§Ò:Hypersensitivity to neomycin¡A streptomycin or polymyxin B. Postpone vaccination in acute febrile illness. Children > 7 yr¡A adults.,,2-8¢J,1 dose = 0.5 mL. Primary immunization with the following schedule is recommended: One 0.5-mL dose administered IM at 2¡A 4¡A 6 and 18 months. Where more rapid protection is preferred¡A the first 3 doses may be administered at intervals of 4 weeks,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,1. ª`®g«eÀ³¥R¤À·n¤Ã¡C 2. À³¥H¦Ù¦×ª`®g¤è¦¡§ë¤©¡A³Ì¦nª`®g©ó¤j»L¤¤¬qªº«e¥~°¼ (ªÑ¥~°¼¦Ù) ©Î¤âÁuªº¤T¨¤¦Ù¡C¶W¹L¤@·³ªº«Äµ£¡A³Ì¦n¬Oª`®g¦b¤T¨¤¦Ù¡C
IPET,Meperidine,Pethidine HCl inj 50mg/1mL,CNEU,Analgesia.,Concurrent use with MAOIs or within 2 weeks of the therapy.,Respiratory depression. Lightheadednes¡A dizziness¡A sedation¡A nausea¡A vomiting¡A perspiration. CNS disturbances¡A muscle spasm¡A visual disturbances. Dry mouth¡A constipation¡A biliary spasm. Urinary retention. Pain at inj site,Á×¥úÀx¦s©ó«Ç·Å,Adult 50-100 mg SC/IM¡A may be repeated every 3-4 hours. Children 1.1-1.76 mg/kg SC/IM¡A may be repeated every 3-4 hours.(Do not exceed adult dose) Pre-op sedation induction Adult 50-100 mg SC/IM 30-90 min before the beginning of anesthesia. Children 1-2.2 mg/kg SC/IM 30-90 min before the beginning of anesthesia.(Do not exceed adult dose). Obstetric analgesia 50-100 mg SC/IM. May repeat at 1-3 hours interval.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¯f±w«ØÄ³­°§C°_©l¾¯¶q,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,½wºC±Àª`,¥H¾A·í¿éª`²Gµ}ÄÀ¦¨1 mg/mL¡Aµ¹ÃÄ³t²v¨Ì¯f¤H¤ÏÀ³¶i¦æ½Õ¾ã;¤£¯à³sÄò¶W¹L48¤p®É¡A©Î¬O²Ö¿n¾¯¶q¤£¯à¶W¹L 600mg/24¤p®É,1. IM: ª`®g©ó¤jªº¦Ù¦×¡C 2. µ¹ÃÄ®É³Ì¦nÅý¯f¤H½ö¤U¡C 3. ¹ï©óµÇ¥\¯à¥¿±`ªº¯f¤H¡APethidine ³sÄò¨Ï¥Î¤£¯à¶W¹L48 ¤p®É¡A©Î¬O²Ö¿n¾¯¶q¤£¯à¶W¹L600 mg/24 ¤p®É¡C
IPROM,Alprostadil,Promostan inj 20mcg,CAVS,Improvement of symptoms caused by peripheral arterial occlusive diseases. Maintenance of blood flow after vascular reconstructive surgery.,Patients with severe heart failure or pulmonary edema. Patients with bleeding disorders (such as intracranial bleeding¡A hemorrhagic eye diseases¡A gastrointestinal bleeding¡A hemoptysis¡A etc.¡A as it may increase the risk of bleeding). Pregnant women or women who may be pregnant (please refer to medication guidelines for pregnant women¡A postpartum women¡A breastfeeding women¡A etc.). Patients who have experienced allergic reactions to this medication.,Common: Bradyarrhythmia (Neonates¡A 7%)¡A Hypotension (Adult¡A up to 3% ; pediatric¡A 4%)¡A Tachycardia (Neonates¡A 3%)¡A Flushing (Neonates¡A 10%)¡A Urethral discomfort (Adult¡A 12-13%)¡A Pain in penis (Adult¡A 29-37%)¡A Pain in testicle (Adult¡A 1-5%)¡A Fever (Neonates¡A 14%) Serious: Cardiac arrest (Neonates¡A 1%)¡A Gastrointestinal obstruction (Neonates¡A 6.8%)¡A Disseminated intravascular coagulation (Neonates¡A 1%)¡A Infantile cortical hyperostosis¡A Seizure (Neonates¡A 4%)¡A Fibrosis of penis (Intracavernous¡A 3-7.8%)¡A Priapism (Adult¡A less than 1%)¡A Prolonged erection of penis (Adult¡A 0.3-4%)¡A Apnea (Neonates¡A 10-12%),Á×¥ú¡B«Ç·Å«O¦s,Peripheral artery occlusive disease (POAD) adult: IVD¡A 2-3 vial (40-60 mcg) in NS 500 mL IVD > 2 hr. ( infusion rate: 5-10 ng/kg/min) once or twice daily (maximum: 0.6 mcg/kg/hr),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥¥°ü¤Î¥i¯à¤wÃh¥¥ªº°ü¤k¸T¤îµ¹ÃÄ¡C,Unknown ¨S¦³¸ê®Æ,,IVD;LI;,IV:5 mL N/S,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,IVD: 5-10ng/kg/min,1.Max:20 mcg/mL 2.µ¹ÃÄ³t²vÅé­«¨C¤½¤ç2¤p®É¤º¤£¶W¹L1.2mcg.
IRIN4,Betamethasone,Rinderon inj 4mg/1mL,HM,Shock¡A hypersensitivity disorders¡A bronchial asthma¡A severe infection,Peptic ulcer¡A osteoporosis¡A psychoses or severe psychoneuroses¡A active or quiescent TB; acute infection; live vaccines,Fluid & salt retention¡A edema¡A hypertension; amenorrhea¡A hyperhidrosis; mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; visual disturbances; local atrophy; increased appetite; growth retardation.,25¢J¥H¤UÁ×¥ú,IV and IM: 4-12 mg (1-3 mL). IVD: 4-20 mg (1-5 mL). INS: 0.4-1 mL for large joint¡A 0.2-0.5 mL for middle joint¡A 0.1-0.2 mL for smaller joint. Intra soft tissue: 0.4-6 mg (0.1-1.5 mL). Subconjectival or retrobulbar injection: 0.4-2 mg (0.1-0.5mL). SPI: 1-4 mg(0.25-1 mL).,µL»Ý½Õ¾ã¾¯¶q,¨xµw¤Æ¡A¯×ªÕ¨xªº±wªÌÀ³ÂÔ·V§ë»P,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¥¥°ü©Î¥i¯àÃh¥¥°ü¤H¤§§ëÃÄ¶È­­©ó¦bªvÀø¤W§PÂ_¨ä¦³¯q©Ê³Ó¹L¦MÀI©Ê®É¨Ï¥Î¡C(©ó·s¥Í¨à´¿¦³ ¤Þ°_µÇ¤W¸¢¥Ö½è¤£¥þ¤§¯f¨Ò¡C¦¹¥~¡A¥ç¦³¦åÀ£¤W¤É¡B¤ß¦ÙªÎ¤jªº³ø§i¡C°Êª«¹êÅç(¤p¹«¡B¤j¹«) ¦³­P·î­L§@¥Î¤§³ø§i) ),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¦Ò¼{ªvÀø©M¥À¨ÅÀç¾iªº¯q³B¡A§ë»P´Á¶¡¡AÀ³¦Ò¼{Ä~Äò©Î°±¤î­÷¨Å¡C¥»ÃÄ¯à²¾¦æ¦Ü¥À¨Å¤¤¡C,IM;INS;IS;IVD;IVP;IVPUSH;LI;SPI;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,Slow intravenous injection over half to one minute.,1-5mL (4-20mg) daily diluted in Normal Saline or Dextrose Water.,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î 2.1-3 mL IV or IM slowly 3-4 hourly
ISUS,Testosterone,Sustanon inj (Testosterone250mg/1mL),HM,Testosterone replacement therapy in male hypogonadal disorders. Osteoporosis due to androgen deficiency.,Known or suspected prostatic or mammary carcinoma.,Priapism¡A signs of excessive sexual stimulation¡A oligospermia¡A decreased ejaculatory vol; fluid & salt retention. In prepubertal boys¡A precocious sexual development¡A increased frequency of erections¡A phallic enlargement¡A premature epiphyseal closure. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation¡A Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ),8-30¢J¡A¤£»Ý§NÂÃ©Î§N­á,1 mL every 3 weeks. Deep IM only.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,Use is contraindicated during pregnancy.(UpToDate)2021/0125,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Testosterone is present in breast milk. Some products are specifically contraindicated while breastfeeding. (UpToDate)2021/0125,IM;,,,,,
OSER2,Quetiapine,Seroquel 25mg,CNEU,Schizophrenia¡A manic episodes associated with bipolar disorder.,Hypersensitivity to quetiapine or any component of the product. Anaphylactic reactions have been reported.,Dry mouth¡A somnolence¡A dizziness ¡A & dyspepsia. Heart rate increased¡A hypotension¡A weight increased¡A tremor¡A akathisia¡A increased appetite¡A blurred vision¡A postural dizziness¡A pyrexia¡A dysarthria¡A dystonia¡A drooling¡A syncope¡A tardive dyskinesia¡A dysphagia¡A leukopenia & rash. Anaphylactic reaction¡A peripheral edema¡A rhinitis¡A eosinophilia¡A hypersensitivity¡A elevations in £^- GT levels & restless legs syndrome have also been reported. Cardiovascular: Hypertension (1% to 2% (adults); 15.2 to 40.6% (children and adolescents) )¡A Orthostatic hypotension (4% to 7% (adults); less than 1% (children and adolescents) )¡A Tachycardia (0.5% to 7% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )¡A Serum triglycerides raised (8% to 22% )¡A Weight gain (3% to 23% ) Gastrointestinal: Abdominal pain (4% to 7% )¡A Constipation (2% to 11% )¡A Increased appetite (2% to 12% )¡A Indigestion (2% to 7% )¡A Vomiting (1% to 11% )¡A Xerostomia (4.1% to 44% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (2% to 10% )¡A Dizziness (9% to 18% )¡A Extrapyramidal disease (3% to 12.9% )¡A Headache (7.4% to 21% )¡A Insomnia (8% to 12% )¡A Lethargy (1% to 5% )¡A Somnolence (16% to 57% )¡A Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )¡A Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )¡A Pain (1% to 7% ),25¢J¥H¤U,Adults: Schizophrenia: initial dose:50 mg (Day 1)¡A 100 mg (Day 2)¡A 200 mg (Day 3)¡A 300 mg (Day 4)¡A then titrate to 300-450/day. Adjust dose within the range of 150-750 mg/day depending on clinical response & tolerability of the patient. Manic episodes associated with bipolar disorder: As monotherapy of as adjunct therapy to mood stabilizers¡A initial dose: 100 mg (Day 1)¡A 200 mg (Day 2)¡A 300 mg (Day 3)¡A 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of no > 200 mg/day. Adjust dose within the range of 200-800 mg/day depending on clinical response & tolerability of the patient. Usual effective dose range: 400-800 mg/day. Elders: Initial dose:25mg¡A increase by 25-50mg daily to the effective dose. Children: Not approved for use under 18 years of age.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³°_©l¾¯¶q¬° 25 mg/day¡A increase dose daily in increments of 25 to 50 mg/day to an effective dose based on response and tolerability,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OSIN4,Montelukast,Singulair 4mg,ERSP,SINGULAIR is indicated in adult & pediatric patients 6 months of age & older for the prophylaxis & chronic treatment of asthma¡A including the prevention of day- & nighttime symptoms¡A the treatment of aspirin-sensitive asthmatic patients¡A & the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adults & pediatric patients 2 years of age & older for the relief of day- & nighttime symptoms of seasonal allergic rhinitis.,Hypersensitivity to any component of Singulair.,Abdominal pain¡A headache¡A thirst¡A diarrhea¡A hyperkinesia¡A asthma¡A eczematous dermatitis¡A rash. Neurologic: Headache (Adult and adolescent; 18.4%; pediatric¡A 2% and greater ),30¢J¥H¤U¡AÁ×§K¼éÀã»P¥ú½u·Ó®g,Should be taken once daily. For asthma¡A the dose should be taken in the evening. For seasonal allergic rhinitis¡A the time of administration may be individualized. Patients with both asthma & seasonal allergic rhinitis should take only 1 TAB daily in the evening. Asthma and/or seasonal allergic rhinitis- Age > or = 15 years: 10 mg QD. Age 6-14 years: One 5 mg chewable TAB QD. Age 2-5 years: One 4 mg chewable TAB QD or one packet of 4 mg oral granules QD. Age 6 months-2 years with asthma: One packet of 4 mg oral granules QD.,»Ý½Õ¾ã¾¯¶q,Mild-to-moderate impairment: No dosage adjustment necessary. Severe impairment: No dosage adjustment provided in manufacturer¡¦s labeling; has not been studied.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OSTI,Zolpidem,Stilnox 10mg,CNEU,Insomnia.,Children < 15 years; pregnancy & lactation.,Occasional dizziness¡A drowsiness¡A nausea & headache. Gastrointestinal: Diarrhea (1% to 3% )¡A Nausea (1% to 7% ) Immunologic: Allergy (4% ) Neurologic: Dizziness (1% to 23.5% )¡A Drugged state (3% )¡A Headache (1% to 19% )¡A Somnolence (2% to 15% ) Ophthalmic: Visual disturbance (3% ),30¢J¥H¤U,Oral Short-term management of insomnia Adult: Initial dose: woman : 5mg; man: 5 or 10mg immediately before bedtime; maximum: 10 mg/day. Elderly: 5mg before bedtime. Hepatic impairment: 5 mg before bedtime. In good tolerance or insufficient clinical response may be 10 mg. Severe: contraindicated.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³±q¨C¤é5mg¶}©lªvÀø,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;VAG;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OTAMI,Oseltamivir,Tamiflu 75mg (¬F©²´£¨Ñ),QANB,Prophylaxis & treatment of influenza in adult & children.,Hypersensitivity.,Common: Nausea (8-10%)¡A Vomiting (Adult and adolescent¡A 2-8%; pediatric¡A 8-16%)¡A Headache (Influenza treatment¡A 2%; influenza prophylaxis¡A 17%) Serious: Cardiac dysrhythmia¡A Erythema multiforme (Rare)¡A Facial swelling¡A Stevens-Johnson syndrome (Rare)¡A Toxic epidermal necrolysis (Rare)¡A Gastrointestinal hemorrhage¡A Hemorrhagic colitis¡A Hepatitis¡A Anaphylaxis (Rare)¡A Seizure¡A Abnormal behavior¡A Delirium,25¢J¥H¤U,(¥é³æ) Influenza: Treatment (for patients > 1 year): - Adult: Usual Dose for uncomplicated influenza of <48 hrs duration: 75 mg PO BID x 5 days; complicated influenza in immunocompromised patients even if ill over 48 hrs: 75 mg PO BID x 10 or more days. - Children > 40 kg: 75 mg BID x 5 days - Children > 23-40 kg: 60 mg BID x 5 days - Children > 15-23 kg: 45 mg BID x 5 days - Children < or = 15 kg: 30 mg BID x 5 days - Infant 0-12 months: 3 mg/kg BID x 5 days Prophylaxis (for patients > 1 year): - Adults: 75 mg orally once daily for 10 days to 6 weeks. - Children > 40 kg: 75 mg QD x 10 days - Children > 23-40 kg: 60 mg QD x 10 days - Children > 15-23 kg: 45 mg QD x 10 days - Children < or = 15 kg: 30 mg QD x 10 days - Infants 3-11 months: 3 mg/kg once daily (¼ö¯f),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OTEGCR,Carbamazepine,Tegretol CR 200mg,CNEU,Epilepsy¡A trigeminal neuralgia¡A bipolar disorder¡A diabetes insipidus centralis¡A glossopharyngeal neuralgia.,AV block. History of bone marrow depression or acute intermittent porphyria.,Frequent: dizziness¡A ataxia¡A mild allergic skin reactions¡A mild leucopenia. Occasionally: diplopia¡A liver enzyme elevations¡A vomiting¡A thrombocytopenia¡A hyponatremia¡A accommodation disorders. Rare: exfoliative dermatitis¡A Stevens-Johnson syndrome¡A jaundice¡A hepatitis¡A delayed multi-organ hypersensitivity disorders¡A SLE-like syndrome. Isolated cases: neuritis¡A hallucinations¡A agitation¡A depression¡A Lyell's syndrome¡A blood dyscrasias¡A anaphylactic reaction¡A AV-block¡A congestive heart failure¡A thromboembolism¡A osteomalacia¡A renal dysfunction¡A interstitial nephritis¡A sexual disturbances.,30¢J¥H¤U¨Ã¨¾¼é,Adult -Initially 100-200 mg QD or BID¡A may be gradually increased to 400mg BID or TID. Daily dosage may be 1600-2000 mg . Children (4 years or less)Initially 20-60 mg/kg body weight/day.Children (over 4 years) )Initially 100 mg/kg body weight/day¡Athen weekly increased to 100mg . Maintenance dose of children: 10-20 mg/kg body weight/day in divided doses. Continuous treatment of bipolar disorder: 400-1600mg/day¡Ausually 400-600mg in 2-3 times a day. Treatment of trigeminal neuralgia:Initially 200-400mg/day and then slowly increase until the pain disappears. (Usually 3 to 4 times a day¡A 200mg each time) Nephrogenic diabetes insipidus:adults 2 to 3 times a day¡A 200mg each time.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ] ¥»¨­±w¦³Åöíwªº°ü¤k¡A¨ä­L¨àµo¨|²§±`¬Æ¦Ü·î­Lªº¾÷²v¤]¸û°ª¡CÁöµMµLªk¥Ñ¥Hcarbamazepine¬°³æ¤@ÃÄª«ªvÀø¾¯¤§±±¨î²Õ¹êÅç¤¤Àò±o¦¹¶µµ²½×¡A¦ý¤w¦³¦]¨Ï¥Î Tegretol ¦Ó¾É­P­L¨à¯«¸gµo®i»ÙÃª(neurodevelopment disorders)¤Î·î­L¡]¥]¬A¯á¬Wµõ¥H¤Î¨ä¥L¥ý¤Ñ©Ê·î§Î¡A¦pÆ`ÃC¯Ê³´¡B¤ß¦åºÞ·î«¬¡B§¿¹D¤Uµõ»P¦hºØ¨­Åé¨t²Î²§±`µ¥)ªº¯f¨Ò³ø§i¡C®Ú¾Ú¥_¬üÃh¥¥µn¿ý®wªº¼Æ¾ÚÅã¥Ü¡AÃh¥¥«e¤T­Ó¤ë¤º´¿±µ¨ü¹Lcarbamazepine³æ¤@ÃÄª«ªvÀøªº¥À¿Ë¡A¨ä­L¨à¥X¥Í«á12¶g¤º³Q¶EÂ_¥XÄY­«¥ý¤Ñ©Ê·î«¬(©w¸q¬°¶·¶i¦æ¤â³N¡BÃÄª«©Î¾ã§ÎªvÀø)ªº¾÷²v¬ù¬°3.0% (95% CI¤¶©ó2.1¦Ü4.2%)¡A¦Ó¥¼ªA¥Î¥ô¦ó§ÜÅöíwÃÄª«¤§Ãh¥¥°ü¤kªº·î­L¾÷²v«h¬°1.1% (95% CI¤¶©ó0.35¦Ü2.5%) (¬Û¹ï­·ÀI¬°2.7¡A95% CI¤¶©ó1.1¦Ü7.0%)¡C¦ÓÃö©óÃh¥¥®É¼ÉÅS©ócarbamazepineªº«Äµ£¯«¸gµo®i»ÙÃª¤§­·ÀI¡A¥Ø«e¬ÛÃö¬ã¨sµ²ªG¬O¤£¤@­Pªº¡A¦ý­·ÀIµLªk±Æ°£¡C Á{§ÉÀ³¯S§Oª`·N¤U¦C¨Æ¶µ¡G ¿©±wÅöíwªºÃh¥¥°ü¤kÀ³¸Ó¶i¦æ¯S§O·ÓÅU¡C ­Y¦b¨Ï¥Î Tegretol ªvÀø´Á¶¡Ãh¥¥©Î­pµeÃh¥¥¡A©Î¦bÃh¥¥´Á¶¡¨Ï¥Î Tegretol ªvÀø¡A«h»Ý¥ý¿Å¶q¨ä§Q¹ú¡A¤×¨ä¦b³Ìªì¤T­Ó¤ë¡C ¨|ÄÖ´Áªº°ü¤k¨Ï¥Î Tegretol À³¾¨¥i¯à¨Ï¥Î³æ¤@ÃÄª«Àøªk¡A¦]¬°¨Ö¥Î¨ä¥Lªº§ÜÅöíw¾¯¨ä²£¤U¥ý¤Ñ©Ê²§±`­L¨àªº¾÷²v¸û¥u±µ¨ü³æ¤@ÃÄª«ªvÀø¥¥°üªº¾÷²v¬°¤j¡C±µ¨ücarbamazepine¦h­«ÃÄª«ªvÀø«á­L¨à¥X²{·î«¬ªº­·ÀI¡AÀH¨Ï¥Îªº¯S©wÃÄª«¦Ó¦³¤£¦P¡A§tvalproate¤§¦h­«ÃÄª«ªvÀøªº­·ÀI¥i¯à·|¸û°ª¡C À³¨Ï¥Î³Ì¤Ö¦³®Ä¾¯¶q¡A¨Ã¥B«ØÄ³­nºÊ´ú¦å¤¤¿@«×¡CÅöíw¯fªp¨ü¨ì±±¨î«á¡A§YÀ³±NÃÄª«ªº¦å¼ß¿@«×ºû«ù¦bªvÀø½d³ò4¨ì12·L§J/mLªº¤U­­¡A¼Æ¾ÚÅã¥Ücarbamazepine²£¥Í·î«¬ªº­·ÀI¥i¯à·|¨ü¾¯¶q©Ò¼vÅT¡A§Y¨C¤é¾¯¶q< 400mg²£¥Í·î­Lªº¾÷²v·|§C©ó¸û°ª¾¯¶q¤§carbamazepine¡C ¯f¤H»Ý³Q§iª¾¦³·|´£°ª²£¥Í·î­Lªº¥i¯à©Ê¡A¥B­n°µ²£«eÀË¬d¡C Ãh¥¥´Á¶¡¤£À³°±¤î§ÜÅöíwÃÄªºªvÀø¡A¦]¬°¯e¯fªº´c¤Æ·|¦M®`¨ì¥ÀÅé¤Î­L¨à¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] carbamazepine ¦å¤¤¿@«×ªº 25¡ã60¢H ·|¶i¤J¨Å¥Ä¡C¦]¦¹»Ýµû¦ô¿Ë¦Û±Â¨Åªº¦n³B¬O§_»·¶W¹L¨ä¹ïÀ¦¨à¥i¯à±a¨Óªº°Æ§@¥Î¡CªA¥Î Tegretol ªº¥À¿Ë¥u¦³¨äÀ¦¨à±µ¨üÄY±KªººÊ´ú¤U¤~¥i±Â¨Å¡A¥H¹w¨¾¥i¯àªº°Æ§@¥Î¡]¦p¡GÄY­«¶ÝºÎ¡B¥Ö½§¹L±Ó¤ÏÀ³¡^¡C ´¿¦³²£«e¤Î/©Î±Â¨Å´Á¶¡±µÄ²¨ìcarbamazepineªº·s¥Í¨à¥X²{Áx¥ÄÆ{º¢©Ê¨xª¢ªº®×¨Ò¡A¬GÀ³¥J²ÓÆ[¹î¥Ñ±µ¨ücabamazepineªvÀø¤§¥À¿Ë±Â¨ÅªºÀ¦¨à¬O§_¥X²{¨xÁx¤£¨}¤ÏÀ³¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°ªø®Ä¿õ¡A»Ý¾ãÁû§]ªA¤Å©CÄZ¡B­é¥b©Î¿i¯»¡C
OTEN5,Atenolol,Tenormin 50mg,CAVS,,¾AÀ³¯g: Antihypertension¡A anti angina. °Æ§@¥Î: Cold extremities¡A fatigue¡A GI disturbances¡A bradycardia. Occasionally¡A headache¡A mood changes¡A dizziness & deterioration of heart failure. Rarely¡A sleep disturbances¡A alopecia¡A thrombocytopenia¡A purpura¡A psoriasiform skin reactions¡A exacerbation of psoriasis¡A visual disturbances¡A psychoses¡A hallucinations¡A heart block¡A postural hypotension which may be associated with syncope. Intermittent claudication. Raynaud's phenomenon. Bronchospasm. Rashes & dry eyes¡A paraesthesia. Cardiovascular: Bradyarrhythmia (3% to 18% )¡A Cold extremities (12% )¡A Hypotension (4% to 25% ) Neurologic: Dizziness (13% ) Psychiatric: Depression (up to 12% ) Other: Fatigue (up to 26% ) ¸T§Ò: Presence of 2nd or 3rd degree heart block; cardiogenic shock. Bradycardia¡A hypotension¡A metabolic acidosis¡A severe peripheral circulatory disturbances¡A sick sinus syndrome¡A untreated phaeochromocytoma¡A uncontrolled heart failure.,,«Ç·Å,50-100 mg daily.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
INOC,Vecuronium,Norcuron 10mg,CNEU,,¾AÀ³¯g: Facilitate endotracheal intubation; Muscle relaxant in general anesth °Æ§@¥Î: Muscle weakness¡A paralysis¡A muscle atrophy (after long term use)¡A hypersensitivity reactions e.g urticaria and erythema. ¸T§Ò: Hypersensitivity to vecuronium or bromide.,,«Ç·Å,IV Facilitate endotracheal intubation; Muscle relaxant in general anesth Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg¡A adjust according to response. Alternatively¡A as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IENB,Etanercept,Enbrel 25mg inj,HIMM,,¾AÀ³¯g:Treatment of active RA in adults when the response to disease-modifying antirheumatic drugs¡A including methotrexate has been inadequate. Treatment of severe¡A active & progressive RA in adults not previously treated with methotrexate. Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to¡A or who are intolerant of¡A methotrexate. Treatment of active & progressive psoriatic arthritis in adults when the response to DMARD therapy has been inadequate. Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to¡A or have a contraindication to¡A or are intolerant to other systemic therapy including cyclosporine¡A methotrexate or PUVA.Treatment of active polyarticular juvenile idiopathic arthritis in adolescents & childn ?4 yr w/ inadequate response or intolerant to methotrexate. Treatment of chronic severe plaque psoriasis in adolescents & childn ?8 yr inadequately controlled by or intolerant to other systemic therapies or phototherapies. °Æ§@¥Î:Inj site reactions¡A infections¡A allergic reactions¡A autoantibody formation¡A pruritus¡A fever. Rarely¡A serious infections including sepsis¡A CNS demyelinating disorders¡A worsening of CHF¡A pancytopenia (& very rarely aplastic anaemia). ¸T§Ò:Sepsis or risk of sepsis; active infections including chronic or localized infections.,,2-8¢J,SC Adult (18-64 years) RA 25 mg twice weekly or 50 mg once weekly. Psoriatic arthritis & ankylosing spondylitis 25 mg twice weekly or 50 mg once weekly. Plaque psoriasis Initially 25 mg twice weekly or 50 mg twice weekly for up to 12 weeks¡A then reduce to 25 mg twice weekly. Treatment should continue until remission is achieved¡A for up to 24 weeks; discontinue if no response after 12 weeks. Children >= 4 years Juvenile idiopathic arthritis 0.4 mg/kg (max: 25 mg/dose) twice weekly at 3-4 day intervals. Children >= 8 years Pediatric plaque psoriasis 0.8 mg/kg (max: 50 mg/dose) weekly for up to 24 weeks,,,,¥i¯à¦w¥þ,,,Human Data Suggest Potential Toxicity,animal data suggest low risk.,,,,,,¡½(prefilled syringe and autoinjector) allow 15 to 30 minutes for syringe to reach room temperature before injecting; do not remove needle cover while allowing the syringe to come to room temperature ¡½do not shake vial or syringe ¡½visually inspect solution prior to administration; do not use if solution is cloudy¡A or if particulate matter is present ¡½inject into thigh¡A abdomen¡A or upper arm; rotate sites on subsequent doses; avoid tender¡A bruised¡A red or hard areas of the skin
OPR150,Dabigatran,Pradaxa 150mg,HEMT,reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation,Pathological bleeding,Gastrointestinal: Dyspepsia (11%; includes abdominal discomfort/pain¡A epigastric discomfort) GI hemorrhage (<6%)¡A gastritis-like symptom Hematologic: Bleeding (8% to 33%; major: <6%) Anemia (1% to 4%) hematoma (1% to 2%) hemoglobin decreased (1% to 2%) hemorrhage (postprocedural or wound: 1% to 2%) Hepatic: ALT increased (>3 x ULN: 2% to 3%) Renal: Hematuria (1%) Miscellaneous: Wound secretion (5%)¡A postprocedural discharge (1%),30¢J¥H¤U¡AÁ×§KÀã®ð,Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation: adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily¡A with or without food. For prophylaxis of venous thrombosis of hip replacement surgery¡A starting 75mg within 1-4 hours after the operation¡A then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days¡A then 150mg twice a day for 6 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling; consistent changes in exposure or pharmacodynamics were not observed in a study of patients with moderate impairment.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©Î¥´¶}½¦Ån¡C­Y¯}Ãa¾¯«¬·|³y¦¨¥ÍÅé¥i¥Î²v¼W¥[1.4­¿¦Ó¼W¥[¥X¦å­·ÀI¡C
OTOP,Alginic Acid+Colloidal Al(OH)3+MgHCO3,Topaal chewable Tab,ALIM,,¾AÀ³¯g: Reflux esophagitis¡A hiatal hernia¡A heartburn¡A peptic ulcer¡A gastric hyperacidity. °Æ§@¥Î: Diarrhea¡A constipation.,,«Ç·Å,2 tab bid-tid.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OTOPA,Topiramate,Topamax 25mg,CNEU,,¾AÀ³¯g: Adjunctive therapy in adults & children >= 2 years with partial seizures¡A seizures associated with the Lennox-Gastaut Syndrome¡A as well as with tonic-clonic seizures. Monotherapy in patients with partial onset seizure. Migraine prophylaxis. °Æ§@¥Î: Ataxia¡A impaired conc¡A confusion¡A dizziness¡A fatigue¡A paresthesia¡A somnolence¡A abnormal thinking. Less commonly¡A agitation¡A amnesia¡A anorexia¡A aphasia¡A depression¡A diplopia¡A emotional lability¡A nausea¡A nystagmus¡A speech disorder¡A taste perversion¡A abnormal vision & weight decrease. Nephrolithiasis (rare). Gastrointestinal: Diarrhea (5% to 11% )¡A Loss of appetite (4% to 24% )¡A Nausea (6% to 14% )¡A Taste sense altered (3% to 15% )¡A Weight decreased (6% to 21% ) Neurologic: Confusion (3% to 14% )¡A Disorder of language (6% to 10% )¡A Dizziness (8% to 32% )¡A Feeling nervous (7% to 14% )¡A Headache¡A Impaired psychomotor performance (3% to 21% )¡A Memory impairment (5% to 14% )¡A Paresthesia (2% to 51% )¡A Reduced concentration span (4% to 14% )¡A Somnolence (9% to 29% )¡A Speech and language disorder Ophthalmic: Abnormal vision (2% to 13% )¡A Diplopia (1% to 10% )¡A Nystagmus (10% to 11% ) Other: Fatigue (14% to 30% ) ¸T§Ò: Pregnancy.,,«Ç·Å,Adjunctive therapy Adult 200-600 mg/day in 2 doses. Children >= 2 years 6-9 mg/kg/day in 2 doses. Max: 1000mg/day. Monotherapy Adult Initial target dose 100mg/day in 2 doses. Children >= 2 years 3-6 mg/kg/day in 2 doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OUTR,Progesterone,Utrogestan 100mg,HM,,¾AÀ³¯g¡GPre-menstrual syndrome¡A dysmenorrhea¡A endometriosis¡A habitual abortion¡A infertility due to luteal insufficiency¡A secondary amenorrhea¡A uterine bleeding¡A threatened abortion. °Æ§@¥Î¡GDrowsiness¡A slight spotting before menstruation or a clear shortening of the cycle.,,«Ç·Å,Revention: 200-400 mg q8h on the 1st day¡A then 100-200 mg q8h afterward till 36th week of pregnancy. Supplement: 100-200 mg hs x 10-14 days (may give an extra 100 mg in the morning if needed) starting from the 12th day of the menstrual cycle.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OVEN2,Estradiol + Medroxyprogesterone,Venina 1/2.5mg (28 tablets/pack),HM,Hormone replacement therapy (HRT) for estrogen deficiency symptoms & prophylaxis of osteoporosis in women with an intact uterus.,Pregnancy & lactation. Known¡A suspected or past history of breast cancer or estrogen-dependent tumour¡A undiagnosed vag bleeding¡A confirmed active venous thromboembolism (VTE) within the last 2 years. History of recurrent VTE or known thrombophilic disease in patients not on anticoagulant¡A acute or chronic liver diseases or a history of liver disease.,Breast tenderness & enlargement¡A uterine bleeding¡A increase in size of uterine fibroids¡A headache¡A GI discomfort¡A weight changes¡A edema¡A mood changes including anxiety & depressive mood¡A changes in libido.,25¢J¥H¤U,1 tablet (MPA 2.5mg) daily¡A Rule out the possibility of endometrial abnormalities may up to 5mg.,µL»Ý½Õ¾ã¾¯¶q,«æºC©Ê¨x¯f±wªÌ©Î´¿±w¨x¯f¡A¥B¨ä¨x¥\¯à¥¼«ì´_¥¿±`ªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OXANT,Theophylline,Xanthium 200mg,ERSP,Treatment & prevention of bronchospasm in asthma & COPD.,Allergy to theophylline¡A aminophylline or other xanthines.,GI discomfort (nausea¡A vomiting). CNS disturbances (palpitation¡A arrhythmia).,25¢J¥H¤U,QD (in the morning or evening) or Q12H. Age 6-9 years: 20mg/kg/day¡A maximum dose: 400mg/day. Age 9-12 years: 18mg/kg/day¡A maximum dose: 400-600mg/day. Age 12-16 years: 16mg/kg/day¡A maximum dose: 600-800mg/day. Age >17 years: 10mg/kg/day¡A maximum dose: 600-1000mg/day. Elderly: 6-8mg/kg/day¡A maximum dose: 400-600mg/day. Patient with obesity should adjust by standard weight.,»Ý½Õ¾ã¾¯¶q,Oral: There are no specific dosage adjustments provided in manufacturer's labeling. Dose reduction and frequent monitoring of serum theophylline concentration are required; risk of severe and potentially fatal toxicity may occur. Maximum dose: 400 mg/day,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»½¦Ån¡A¥i©î½¦Ån«áªA¥Î¡C¦ý¤£¥i±N½¦Ån¤ºªº¸z·»·L²É¬ã¿i©ÎÀ£¸H¡C°|¤º¥t¦³Theophylline¦¨¥÷ÃÄ¤ôCentertheo 60mL (5.34mg/mL) liquid¡C
OXEL,Capecitabine,Xeloda 500mg,RACA,,¾AÀ³¯g:Colon cancer¡A Adjuvant therapy¡A Duke's Stage C¡A when treatment with a fluoropyrimidine alone is preferred. Metastatic breast cancer¡A metastatic colorectal cancer¡A 1-line therapy when treatment with a fluoropyrimidine alone is preferred. °Æ§@¥Î: GI disturbances; hand-foot syndrome¡A alopecia¡A pruritus¡A rash; fatigue¡A pyrexia¡A lethargy¡A asthenia; dizziness¡A taste disturbance; anorexia; conjunctivitis; neutropenia. Dermatologic: Dermatitis (27% to 37% ) Gastrointestinal: Abdominal pain¡A Constipation¡A Loss of appetite¡A Nausea¡A Stomatitis¡A Vomiting Other: Fatigue ¸T§Ò:Known hypersensitivity to capecitabine¡A fluorouracil¡A or any component of the formulation; severe renal impairment (CrCl <30 mL/minute). Canadian labeling: Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg¡A brivudine).,,«Ç·Å,Breast cancer¡A metastatic: Oral: 1¡A250 mg/m2 twice daily for 2 weeks¡A every 21 days (as either monotherapy or in combination with docetaxel). Colorectal cancer¡A metastatic: Oral: 1¡A250 mg/m2 twice daily for 2 weeks¡A every 21 days. Breast cancer¡A adjuvant therapy (off-label; in HER2-negative patients with residual disease after neoadjuvant therapy and surgery): Oral: 1¡A250 mg/m2 twice daily on days 1 to 14 of a 21-day treatment cycle for 6 to 8 cycles.,,µL¨¬°÷¦w¥þ©Ê»PÀø®Ä¬ÛÃö¸ê®Æ´£¨Ñ¡C,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OYAZ,Drospirenone + Ethinylestradiol,YAZ ®®«º¿õ (28 tablets/box),HM,Treatment of moderate acne vulgaris in women at least 14 years of age¡A who have no known contraindications to OC therapy¡A & have achieved menarche,Yaz is contraindicated in women known to have or have had the following conditions: 1. Impaired kidney function. 2. Adrenal insufficiency. 3. Women at high risk for arterial or venous thrombotic diseases¡A such as: - Women aged 35 and above who smoke. - Current or past history of deep vein thrombosis or pulmonary embolism. - History of cerebrovascular disease. - Coronary artery disease. - Thrombotic valvular or rhythm diseases of the heart (e.g.¡A valvular disease or atrial fibrillation associated with subacute bacterial endocarditis). - Congenital or acquired hypercoagulopathies. - Uncontrolled hypertension. - Diabetes with vascular complications. - Headache with focal neurological symptoms¡A or women aged 35 and above with migraine headaches with or without aura. 4. Undiagnosed abnormal uterine bleeding. 5. Past or present breast cancer or other estrogen- or progestin-sensitive cancer. 6. Liver tumors (benign or malignant) or liver disease. 7. Pregnancy¡A as there is no reason to use combined oral contraceptives during pregnancy. 8. Concomitant use with hepatitis C medications containing ombitasvir¡A paritaprevir/ritonavir with or without dasabuvir¡A which may lead to elevated ALT levels.,Upper respiratory infection¡A headache¡A breast pain¡A vag moniliasis¡A leukorrhea¡A diarrhea¡A nausea¡A vomiting¡A vaginitis¡A abdominal pain¡A flu syndrome¡A dysmenorrhea¡A moniliasis¡A allergic reaction¡A UTI¡A accidental injury¡A cystitis¡A tooth disorder¡A sore throat¡A infection¡A fever¡A surgery¡A sinusitis¡A back pain¡A emotional lability¡A migraine¡A suspicious Papanicolaou smear¡A dyspepsia¡A rhinitis¡A acne¡A gastroenteritis¡A bronchitis¡A pharyngitis¡A skin disorder¡A intermenstrual bleeding¡A decreased libido¡A weight gain¡A pain¡A depression¡A increased cough¡A dizziness¡A menstrual disorder¡A pain in extremity¡A pelvic pain & asthenia,30¢J¥H¤U,Start on day 1 of menstrual cycle¡A take one light pink tablet QD for 24 consecutive days followed by one white inert tablet QD for 4 days. If YAZ is first taken later than the first day of the menstrual cycle¡A other contraceptive methods must be used until after the first 7 consecutive days of product administration.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¯e¯f¤HªÌ¸T¤î¨Ï¥ÎYAZ¡C¬Û¸û©ó¨x¥\¯à¥¿±`ªº¤k©Ê¡A¤¤«×¨x¥\¯à¥¢½Õ¤k©ÊªºDRSP¥­§¡¼ÉÅS¶q¬ù°ª¥X3­¿¡C¥Ø«e©|µL°w¹ïÄY­«¨xÅ¦¨ü·lªº¤k©Ê¡A©Ò¶i¦æ¤§YAZ¬ã¨s¡C,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ] °ü¤k©óÃh¥¥ªì´Á»~¥Î½Æ¦X«¬¤fªAÁ×¥¥ÃÄ¦Ó²£¤U¤Ñ¥Í·î§ÎÀ¦¨àªº­·ÀI·¥§C©Î¤£·|¼W¥[¸Ó­·ÀI¡C¬y¦æ¯f¾Ç¬ã¨s¤Î²Î¦X¤ÀªRµ²ªG¨Ã¥¼Åã¥Ü¦bÃh¥¥«e©ÎÃh¥¥ªì´Á¼ÉÅS©ó§C¾¯¶q½Æ¦X«¬¤fªAÁ×¥¥ÃÄ«á¡A·|¼W¥[¥Í´Þ¾¹©x©Î«D¥Í´Þ¾¹©x¤Ñ¥Í·î§Î(¥]¬A¤ßÅ¦µo¨|¤£¥þ¤ÎªÏÅéÁY¤p¯Ê³´)¤§­·ÀI¡C ¨Ï¥Î¤fªAÁ×¥¥ÃÄ»¤µo°±ÃÄ©Ê¥X¦å¡]withdrawal bleeding¡^¤£À³¸Ó§@¬°Ãh¥¥ÀËÅç¨Ï¥Î¡C¤£±o©óÃh¥¥´Á¶¡¨Ï¥Î½Æ¦X«¬¤fªAÁ×¥¥ÃÄªvÀø¥ý¥ü©Ê¬y²£©Î²ßºD©Ê¬y²£¡C ¥¼±Â¨Å¤§°ü¤k³Ì¦­¥i©ó²£«á4¶g«á¶}©l¨Ï¥Î½Æ¦X«¬¤fªAÁ×¥¥ÃÄ¡C ¶·¦Ò¶q©ó²£¿È´Á¤º(¥Í²£«á¤»©P¤º)­«·s¶}©l¨Ï¥Î¦¹ÃÄ«~¤§°ü¤k¦³¸û°ªµo¥ÍÀR¯ß¦å®ê¤§­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ­Y¥i¯à¡A­n©¾§i­÷¨Åªº¥À¿Ë¡A¦b¤p«Ä©|¥¼§¹¥þÂ_¥¤«e¡A¶·¨Ï¥Î¨ä¥LªºÁ×¥¥¤è¦¡¡C§t¦³»Û¿E¯Àªº½Æ¦X«¬¤fªAÁ×¥¥ÃÄ¦b­÷¨Åªº¥À¿Ë·|­°§Cªc¨Å¶q¡C¤@¥¹¥À¨ÅÁý­¹¤w¸g¥R¤À«Ø¥ß¡A³o¼Ëªºª¬ªp¤ñ¸û¤£¥i¯àµo¥Í¡AµM¦Ó¹ï©ó¤@¨Ç¤k©Ê¡A³o¼Ëªº±¡§Î·|µo¥Í¦b¥ô¦ó®É­Ô¡C¤Ö¶q¤fªAÁ×¥¥ÃÄªº©T¾J¤Î/©Î¥NÁÂª«·|¥X²{¦b¥À¨Å¤¤¡C ²£«á¤k©Ê¤fªA3 mg DRSP/0.03 mg EE¿õ¾¯«á¡A24 ¤p®É¤º·|¦³¬ù0.02%ªºdrospirenone¾¯¶q¤Àªc¨ì¥À¨Å¤¤¡A¦¹ºØ±¡ªp·|¾É­PÀ¦¨à¨C¤é±µ¨üªº³Ì¤j¾¯¶q¬ù 0.003²@§Jªº drospirenone¡C,AC;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OZOL,Sertraline,Zoloft 50mg,CNEU,Depression¡A obsessive-compulsive disorder (OCD)¡A panic disorder¡A post traumatic stress disorder (PTSD)¡A social phobia¡A premenstrual dysphoric disorder (PMDD).,Patients with known hypersensitivity to sertraline. Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).,Nausea¡A diarrhoea/loose stools¡A anorexia¡A dyspepsia; male sexual dysfunction (ejaculatory delay); tremor; dry mouth; increased sweating. Sertraline has been associated with PALPITATIONS¡A CHEST PAIN¡A HYPERTENSION¡A HYPOTENSION¡A EDEMA¡A SYNCOPE¡A and TACHYCARDIA,30¢J¥H¤U,50-200 mg daily. Dosage may be increased in 50 mg increments to maximum 200 mg over a period of weeks.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³: Lower or less frequent doses should be used,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LAMO,Amoxicillin,Amoxicillin syr 25mg/mL,QANB,,¾AÀ³¯g: Gm+ve & gm-ve infections. °Æ§@¥Î: Nausea¡A vomiting¡A diarrhea¡A glossitis¡A stomatitis¡A black hairy tongue; skin rashes¡A urticaria¡A exfoliative dermatitis¡A erythema multiforme; anemia¡A thrombocytopenia¡A eosinophilia¡A leukopenia¡A agranulocytosis. ¸T§Ò: Hypersensitivity to penicillins.,,«Ç·Å,Adult 250 mg 8 hrly. Children >= 20 kg Adult dose¡A < 20 kg 20 mg/kg/day 8 hrly. Severe infections or penicillin non-sensitive bacterial infections: Adult 500 mg 8 hrly. Children >= 20 kg Adult dose¡A < 20 kg 40 mg/kg/day 8 hrly. Gonorrhea Adult 3 g as a single dose.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OGLUF,Mitiglinide,GluFAST 10mg,META,,¾AÀ³¯g¡GTo improve the postprandial plasma glucose transition in patient with type 2 DM who do not sufficiently respond to dietary treatment & exercise therapy alone¡A use of £\-glucosidase inhibitors¡A use of thiazolidinediones in addition to diet & physical exercise. °Æ§@¥Î¡GHypoglycemic symptoms¡A weight increase¡A edema¡A abdominal distension¡A constipation. ¸T§Ò¡GSevere ketosis¡A diabetic coma or pre-coma¡A or type 1 DM. Severe infections¡A before or after operation¡A or with serious trauma. Pregnancy.,,«Ç·Å,Adult 10 mg tid. Should be taken with food (Take immediately before meals.).,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ISCA3,Mepivacaine,Scandonest 3%(for Dental) 1.8mL,ZANE,Dental infiltration and dental nerve block.,Complete heart block. Porphyria. Do not inject through infected skin when using for epidural anaesthesia.,Restlessness¡A excitement¡A nervousness¡A paraesthesias; dizziness¡A tinnitus¡A blurred vision; nausea¡A vomiting; muscle twitching¡A tremors¡A convulsions; numbness of the tongue and perioral region; lightheadedness¡A drowsiness¡A respiratory failure¡A coma¡A hypotension.,«Ç·Å,3~6 years:maximum 1.8mL 6~14 years:usual dose:1.35mL; maximum 2.7mL,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,LI;,,,,,
OIND4,Propranolol,Inderal 40mg,CAVS,,¾AÀ³¯g: Adult HTN¡A Angina¡A migraine & essential tremor¡A Arrhythmias¡A anxiety tachycardia¡A thyrotoxicosis¡A Pheochromocytoma. °Æ§@¥Î: Cold extremities¡A GI & sleep disturbances¡A fatigue¡A lassitude. Deterioration in heart failure¡A mood changes. Isolated cases of paresthesia. Rarely bradycardia¡A dizziness¡A postural hypotension which may be associated with syncope¡A heart block¡A alopecia¡A thrombocytopenia¡A purpura¡A psoriasiform skin reactions¡A exacerbation of psoriasis¡A visual disturbances¡A CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication¡A Raynaud's phenomenon¡A bronchospasm¡A increased antinuclear antibodies. Dermatologic: Dermatitis¡A Pruritus¡A Urticaria Neurologic: Dizziness (4% to 7% ) Other: Fatigue (5% to 7% ) ¸T§Ò: History of bronchial asthma or bronchospasm¡A bradycardia¡A cardiogenic shock¡A hypotension¡A metabolic acidosis¡A after prolonged fasting¡A severe peripheral arterial circulatory disturbances¡A 2nd or 3rd degree heart block¡A sick sinus syndrome¡A untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma¡A uncontrolled heart failure¡A Prinzmetal's angina.,,«Ç·Å,Angina: PO¡A initially¡A 10-20mg tid-qid; maintenance¡A 160-240mg/day. Arrhythmia: Adult: PO¡A 10-30mg tid-qid ac. IV¡A 0.5-3mg; a second dose may be given 2 min later if necessary; additional doses may be given at intervals of no less than 4hr. Child: PO¡A initially¡A 1.5-2mg/kg/day¡A titrate up to a max. 16mg/kg/day in 4 doses. Essential tremor: PO¡A initially¡A 40mg bid; maintenance¡A 120-320mg/day in 3 doses. Hypertension: PO. Adult: Initially¡A 40mg bid; maintenance¡A 160-480mg/day. Child: Initially¡A 1mg/kg/day in 2 doses; maintenance¡A 1-5mg/kg/day in 2-4 doses. Migraine: PO¡A initially¡A 80mg/day in divided doses; maintenance¡A160-240 mg/day. Pheochromocytoma: PO¡A 60mg/day in divided doses for 3 days before surgery; 30 mg/day in divideddoses with an adrenergic blocker as an adjunct to prolonged treatment of intolerable pheochromocytoma. Post-MI: PO¡A 180-240mg/day in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
EENT3,Tyrothricin,ENT oint 3.5gm,TENT,,¾AÀ³¯g: Acute & chronic forms of rhinitis & treatment of bacterial infection of the nasal mucosa. °Æ§@¥Î: Rarely¡A hypersensitivity reactions. ¸T§Ò: Acute & congestive glaucoma. Children <= 2 years.,,«Ç·Å,Apply to the nasal mucosa several times daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSALA,Pilocarpine,Salagen 5mg,CNEU,Treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head & neck. Treatment of symptoms of dry mouth in patients with Sjogren's syndrome.,Uncontrolled asthma¡A acute iritis & angle closure glaucoma.,Sweating¡A nausea¡A diarrhea¡A chills¡A flushing¡A urinary frequency¡A dizziness¡A asthenia¡A headache¡A dyspepsia¡A lacrimation¡A edema¡A abdominal pain¡A amblyopia¡A vomiting¡A pharyngitis¡A hypertension.,15-30¢J,Head & neck cancer - Radiation-induced xerostomia: Initially 5 mg TID. Usual dosage range: 15-30 mg daily (do not exceed 10 mg/dose). Sjogren's syndrome - Xerostomia: 5 mg QID.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ¯f±w (Child-Pugh score of 7 to 9): 5 mg ORALLY twice daily¡A regardless of indication¡Afollowed by dose adjustment for therapeutic effect and tolerability ­««×¨x¥\¯à¤£¥þ¯f±w (Child-Pugh score of 10 to 15): ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Infant risk cannot be ruled out: Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when Pilocarpine is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Pilocarpine during breast-feeding.,AC;AC15;PC;PO;WM;,,,,,
OARH,Leflunomide,Arheuma 20²@§J,HIMM,,¾AÀ³¯g:Treatment of RA & psoriatic arthritis in adult. °Æ§@¥Î:Increase in BP; GI disturbances¡A anorexia¡A oral mucosal disorders¡A weight loss; headache¡A dizziness¡A asthenia¡A paraesthesia; tenosynovitis; alopecia¡A eczema¡A dry skin¡A rash¡A pruritus; hypersensitivity reactions¡A leucopenia. ¸T§Ò:Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A multiforme epithelium. Hepatic dysfunction¡A severe immunodeficiency such as AIDS¡A bone-marrow dysplasia¡A severe infections¡A moderate to severe renal dysfunction¡A severe hypoproteinaemia. Pregnancy¡A lactation.,,«Ç·Å,Adult Initially 100 mg once daily for 3 days then maintenance¡A 10-20 mg once daily.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OPOT2,Strontium Ranelate,Protos 2gm 28pk/box,META,,¾AÀ³¯g: Treatment of postmenopausal osteoporosis to reduce the risk of vertebral & hip fractures. °Æ§@¥Î: Nausea¡A diarrhea¡A loose stools¡A headache¡A dermatitis¡A eczema¡A VTE¡A memory loss¡A seizures. ¸T§Ò: Hypersensitivity to strontium ranelate or to any of the excipients of Protos.,,«Ç·Å,The recommended dose is 2 g daily ¨C¤é¤@¥]¥R¤À¥[¤ôÅÍ©Õ«áªA¥Î¡A given preferably at night and at least 2 hours after food.(MICROMEDEX) Strontium ranelate should not be given with food¡A milk or antacids (2hours apart); Because of possible complex formation¡A strontium ranelate should not be given with oral tetracyclines or quinolones. ¾÷Âà: Strontium ranelate is claimed to stimulate bone formation as well as reduce bone resorption.,,,,ºÉ¶qÁ×§K,,,Human Data Suggest Potential Toxicity,,,,,,,
OLIN,Clindamycin,Lindacin 150mg,QANB,Treatment of infections caused by susceptible strains of Strep¡A staphylococcus¡A pneumococci and anaerobic bacteria.,Hypersensitivity to clindamycin or lincomycin. History of GI diseases¡A severe renal or liver impairment.,GI disturbances¡A hypersensitivity reactions¡A pruritus.,15-30¢J¡AÁ×¥ú³B¤Îºò±K®e¾¹¤¤,Adults: 150-450 mg orally Q6H; severe disease: 600 mg orally Q6-8H. Children > 1 month of age: 8-25 mg/kg/day¡A divided Q6-8H. (¼ö¯f) Adults: 150-450 mg orally Q6-8H (maximum: 1.8 gm/day). Pediatric dose for age > 28 days: Oral: 30-40 mg/kg/day¡A divided Q6-8H.,»Ý½Õ¾ã¾¯¶q,dose reductions are recommended in active liver disease,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,Clindamycin: Compatible¡XAvoid 1st Trimester if Possible [¥é³æ] ¥Î©ó¥¥°üªº¦w¥þ©Ê©|¥¼½T¥ß¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¾Ú³ø¾Éclindamycin ¥X²{¦b¨Å¥Ä¤ºªº¿@«×½d³ò¬O0.7~3.8pg/mL¡C,AC;AC15;PC;PO;WM;,,,,,
OTOF,Imipramine,Tofranil 25mg,CNEU,Depressive states of varying etiology & symptomatology¡A panic attacks¡A chronic painful conditions¡A pavor nocturnus¡A nocturnal enuresis.,Acute stage of MI. Mania.,Anticholinergic effects are frequent. Rarely¡A liver disorders¡A CV effects.,«Ç·ÅÃÄ¡AÁ×¥úÁ×¼ö,Adults: Outpatient initial dose: 75mg/day. The dose can be increased to 150mg/day. maximum: 200mg/day. Maintenance dose: 50-150mg/day. Inpatient initial dose: 100mg/day in divided doses. If necessary¡A the dose can be gradually increased to 200mg/day. If there is no improvement after two weeks¡A increase to 250-300mg/day. Teenager and elderly: 30-40mg/day. maximum: 100mg/day. Children with enuresis: > 6 years old: 25mg 1 hour before bed. If there is no improvement after a week:<12 years old: 50mg¡A >12 years old:75mg. maximum:2.5mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LULE,Cephalexin,Ulexin 25mg/mL¡A 60mL suspension,QANB,Susceptible infections¡A Prophylaxis against recurrent UTI.,Hypersensitivity to cephalosporins.,Common: Diarrhea Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile colitis¡A Direct Coombs test positive¡A Prothrombin time increased¡A Allergic reaction¡A Anaphylaxis¡A Seizure¡A Renal failure¡A Tubulointerstitial nephritis¡A Angioedema,«Ç·ÅÃÄ«~¡A¥[¤J§N¶}¤ô¦Ü60cc·»¸Ñ«á2-8¢J§NÂÃÀx¦s¡A¨Ã©ó¤@¬P´Á¤º¨Ï¥Î§¹²¦,Adults: 0.25-1 g Q6H or 500 mg Q12H (maximum: 4 g/day). Children: 25-100 mg/kg/day divided Q6H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ODIL9,Diltiazem,Diltelan 90mg,CAVS,,¾AÀ³¯g: ¥Dªv°ª¦åÀ£¡B¤ßµ±µh(B021113100) Hypertension. °Æ§@¥Î: Bradycardia¡A 1st degree AV block¡A ankle edema¡A nausea¡A headache¡A skin rashes¡A finger swelling. Cardiovascular: Bradyarrhythmia (1.7% to 3.6% )¡A Peripheral edema (4.6% to 8% ) Neurologic: Dizziness (3.5% to 6.4% )¡A Headache (4.6% ) Respiratory: Cough (2% ) Other: Fatigue (4.8% ) CI: Pregnancy¡A lactation; sick sinus syndrome¡A AV block II or III¡A severe bradycardia.,,«Ç·Å,Intial: 30 mg qid ac. Maintenance: 180-360 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
LCYP,Cyproheptadine,Cypromin solution 0.4mg/mL¡A 60mL,HIMM,Symptomatic relief of allergic conditions¡A eg urticaria¡A angioedema¡A rhinitis¡A conjunctivitis¡A pruritic skin disorders. Vascular headaches¡A migraine.,Pregnancy & lactation. Neonates. Debilitated patients¡A elderly.,Increased appetite & weight gain. CNS depression¡A drowsiness¡A lassitude¡A dizziness¡A incoordination¡A sedation. Headache¡A psychomotor impairment¡A dry mouth¡A thickened respiratory tract secretions¡A blurred vision¡A urinary difficulty & retention¡A constipation¡A increased gastric reflux. Rashes¡A hypersensitivity reactions. Convulsion¡A sweating¡A myalgia¡A paresthesia¡A extrapyramidal effects¡A tremor¡A sleep disturbances¡A depression¡A tinnitus¡A hypotension¡A hair loss.,±K«ÊÀx¦s25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Allergic conditions & pruritus Adult Initial: 10~50mL/day. Maintenance: 30-40 mL/day in 3 divided doses. Maximum: 80 mL/day. Children: 7-14 years 10 mL BID-TID (Maximum: 40 mL/day)¡A 2-6 years 5 mL every 8 - 12 hours. (Maximum: 30 mL/day). Vascular headache & migraine 4-8 mg Q4-6H.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment provided in manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OURA,Trospium,Uracare 10mg,SGU,Antispasmodics of smooth muscle. Overactive bladder.,Urinary retention; gastric retention¡A toxic megacolon; uncontrolled narrow-angle glaucoma¡A hypersensitivity; myasthenia gravis; tachyarrhythmia; severe renal or hepatic impairment.,Dry mouth¡A dry eyes¡A blurred vision¡A flatulence¡A constipation¡A abdominal pain¡A nausea¡A vomiting¡A dyspepsia¡A urinary retention¡A tachycardia.,25¢J¥H¤U,Bladder hyperactive disorder: 1-2 tablets BID before meals; Smooth muscle spasm & pain: 1-2 tablets TID before meals.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;PO;,,,,,
IFLU10,Fluorescein,Fluorescite 10% 5mL,ZOTH,Diagnostic fluorescein angiography or angioscopy of the fundus & iris vasculature.,Not for intrathecal administration. Care must be taken to avoid extravasation during injection. History of allergy or bronchial asthma. Pregnancy¡A especially in the 1st trimester. Lactation.,Nausea¡A headache¡A GI distress¡A syncope¡A vomiting¡A hypotension¡A hypersensitivity. Reported cardiac arrest¡A basilar artery ischemia¡A severe shock¡A convulsions & thrombophlebitis at inj site. Extravasation may cause severe pain & pain at inj site. Occasionally¡A urticaria¡A itch¡A bronchial spasm.,25¢J¥H¤UÁ×§K§N­á,Use in adults¡A including the elderly: Inject 5 mL of Fluorescein 10% solution for injection rapidly into the antecubital vein after taking precautions to avoid extravasation. In cases when highly sensitive imaging systems¡A e.g.¡A scanning laser ophthalmoscope are used¡A the dose of this product should be reduced to 2 mL of Fluorescein 10% solution for injection. Use in paediatric patients: For children¡A the dose should be calculated on the basis of 35 mg for each 10 pounds of body weight (7.7 mg/kg body weight).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,FLUORESCEIN SODIUM PREGNANCY RECOMMENDATION: Limited Human Data¡XAnimal Data Suggest Low Risk,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,FLUORESCEIN SODIUM BREASTFEEDING RECOMMENDATION: Limited Human Data¡XPotential Toxicity (IV) Limited Human Data¡XProbably Compatible (Topical),IVP;IVPUSH;,,,Adult: 500 mg (as a 10% soln) over 5-10 sec into the antecubital vein. (1 mL/second),,1. Prior to injection¡A an intradermal test dose of 0.05 mL may be used if an allergy is suspected. Evaluate 30-60 minutes following intradermal injection. A negative skin test does not exclude the potential for a reaction to occur. 2.IV: Inject into the antecubital vein at a rate of ~1 mL/second using a 23-gauge butterfly needle attached to a small syringe. Prior to turning off room light¡A ensure extravasation has not occurred.
OMOBI,Meloxicam,Mobicam 15mg,CNEU,Painful osteoarthritis¡A rheumatoid arthritis¡A ankylosing spondylitis.,Hypersensitivity to NSAIDs or aspirin. Active peptic ulceration¡A severe hepatic insufficiency¡A non-dialysed severe renal insufficiency. Children < 15 years. Pregnancy & lactation.,Dyspepsia¡A nausea¡A vomiting¡A abdominal pain¡A constipation¡A flatulence¡A diarrhoea¡A anaemia¡A pruritus¡A rash¡A lightheadedness¡A headache¡A oedema. Cardiovascular: Edema (0.6% to 4.5% ) Gastrointestinal: Abdominal pain (1.9% to 4.7% )¡A Constipation (0.8% to 2.6% )¡A Diarrhea (1.9% to 7.8% )¡A Flatulence (3.2% )¡A Indigestion (3.8% to 9.5% )¡A Nausea (2.4% to 7.2% )¡A Vomiting Neurologic: Dizziness (1.1% to 3.8% )¡A Headache (2.4% to 8.3% ) Respiratory: Upper respiratory infection (up to 8.3% ) Other: Fever,25¢J¥H¤U,Adults: maximum:15mg/day Osteoarthritis: 7.5mg/day¡A the dose can be increased to 15mg/day if needed Rheumatoid arthritis: 15mg/day¡A can be reduced to 7.5mg/day based on clinical response. Ankylosing Spondylitis (AS):15mg/day Patients who are more likely to have adverse reactions: Should start from 7.5mg/day Severe renal failure: Don't exceed 7.5mg/day Children: Data has not been established.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OBIN2,Haloperidol,Binin-U 2mg,CNEU,,¾AÀ³¯g: Acute & chronic psychotic disorders including schizophrenia & manic states¡A Tourette's syndrome. Severe behavioral problems & hyperactivity in children. Nausea & vomiting associated with antineoplastic therapy & surgery. °Æ§@¥Î: Occasionally¡A depression¡A anxiety¡A agitation¡A confusion¡A vertigo¡A exacerbation of psychotic symptoms & seizures. Hyperprolactinaemia¡A gynaecomastia¡A menstrual irregularities¡A impotence. Rarely¡A tachycardia¡A orthostatic hypotension. ¸T§Ò: Endogenous depression without agitation¡A comatose conditions¡A severe CNS depression. Pregnancy¡A children.,,«Ç·Å,Initially 1-2 mg bid-tid & gradually increase up to 4-6 mg tid if required. Severely disturbed patients Up to 100 mg/day. Maintenance: 1-2 mg tid-qid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
INOV1,Eptacog alfa,Novo Seven RT 1mg,HEMT,Treatment of bleeding episodes & prevention of excessive bleeding in those undergoing surgery or invasive procedure in patients with congenital hemophilia with inhibitors¡A acquired hemophilia¡A Factor VII (FVII) deficiency¡A Glanzmann's thrombathenia.,Hypersensitivity to mouse¡A hamsters or bovine protein.,Rarely rash¡A itching¡A fever¡A nausea¡A headache¡A general discomfort¡A perspiration or changes in BP.,25¢J¥H¤UÁ×¥ú¤Å§N­á,1.Hemophilia with inhibitors or acquired hemophilia or severe bleeding: 90 mcg/kg 2-3 hourly as single IV bolus. May increase dosing frequency to 4¡A 6¡A 8 or 12 hourly. One single injection of 270 £gg/kg body can be given to hemophilia patients with mild to moderate bleeding episodes. 2.FVII deficiency: 15-30 mcg/kg 4-6 hourly by IV bolus. 3.Glanzmann's thrombasthenia: 90 mcg/kg body weight (80-120 mcg/kg body weight ) 2 hourly (1.5-2.5 hr) at least 3 doses.4.off-labeled use:Post-partum haemorrhage (PPH) unresponsive to standard therapy: 90 mcg/kg assingle IV bolus (over 2-5 min). At 20 min if no response¡A check and optimise: temperature; acidemia; serum calcium; platelets¡A fibrinogen. May consider administer a second dose of 90 mcg/kg. Australian and New Zealand Journal of Obstetrics and Gynaecology 2008; 48: 12¡V16,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling; use with caution.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;,¨Ï¥Î²£«~©Òªþ·»²Gµ}ÄÀ,,½wºC¦a¶i¦æÀR¯ßª`®g¡Aª`®g®É¶¡2-5¤ÀÄÁ¬°©y,½wºC¦a¶i¦æÀR¯ßª`®g¡Aª`®g®É¶¡2-5¤ÀÄÁ¬°©y,1.­­¥Î±M¥Îª`®g·»¾¯¡A ¤£¥i»P¨ä¥L¿éª`²G²V¦X 2.½wºC¦a¶i¦æÀR¯ßª`®g¡Aª`®g®É¶¡2-5¤ÀÄÁ¬°©y¡A¤£¥i¥HÂIºw¤è¦¡µ¹ÃÄ¡C
LGASC,Simethicone,Gascon drop 20mg/mL,ALIM,,¾AÀ³¯g: Elimination of foamy mucus for gastric endoscopy °Æ§@¥Î: Very rarely¡A soft stool & GI discomfort,,«Ç·Å,Should be taken with food (Take after meals & at bedtime.). 2-10 mL 10-40 mins prior to test by oral.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OBIP2,Biperiden,Bipiden 2mg,CNEU,,¾AÀ³¯g: Parkinsonism. °Æ§@¥Î: GI disturbances; dry mouth; visual disorders; drowsiness¡A dizziness; fatigue; urinary retention. ¸T§Ò: Narrow-angle glaucoma; mechanical stenoses of the GIT¡A megacolon.,,«Ç·Å,1 tab tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EH2O2,Hydrogen Peroxide,H2O2 solution 3%,TDER,Wound cleansing,Inj or instillation of hydrogen peroxide into closed body cavities.,Irritating burns on the skin and mucous membranes (strong solutions); reversible hypertrophy of the papillae of the tongue with continued use as mouthwash; gas embolism¡A rupture of the colon¡A proctitis¡A ulcerative colitis and gangrene of the intestines have occurred following colonic lavage with hydrogen peroxide solution.,30¢J¥H¤U,Mouth/throat Acute stomatitis As 1.5% solution: Use as mouthwash or gargle. Otic Earwax removal As 6% solution: Dilute and use as directed. Topical Wound cleansing As 6% solution or 1-1.5% cream: Use as directed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
EGENT,Gentamicin,Gentamicin eye drops 5mL,TOPH,Blepharitis¡A conjunctivitis¡A keratitis¡A iridocyclitis¡A meibomianitis & dacryocystitis.,Hypersensitivity.,Rarely¡A transient stinging.,25¢J¥H¤U,Instill 2 drops to the affected eye(s) TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,OD;OL;OU;TOPI;,,,,,
ECALA,Calamine + Diphenhydramine + ZnO,Calamaum lotion 120mL,TDER,,¾AÀ³¯g: Symptomatic relief of skin irritation & itch associated with urticaria¡A insect bites¡A nappy rash & other minor skin problems. ¸T§Ò: Avoid use on broken or eczematous skin. May affect ability to drive or operate machinery.,,«Ç·Å,Apply 3-4 times daily on the affected area.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OSYN2,Piracetam,Syntam granules 2400mg,CNEU,,¾AÀ³¯g: Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin. °Æ§@¥Î: Hyperkinesia¡A wt gain¡A nervousness¡A somnolence¡A depression¡A asthenia. ¸T§Ò: Cerebral hemorrhage; severe renal impairment.,,«Ç·Å,Cerebrovascular insufficiency & age-related cognitive impairment Loading dose: 4.8 g daily during initial weeks of treatment. Maintenance: 1.2-2.4 g daily. Cortical myoclonus Initially 7.2 g daily¡A increasing by 4.8 g/day every 3-4 days to a max of 24 g/day in divided doses.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSAN1,Ciclosporin,Sandimmun Neoral 100mg,HIMM,Immunosuppression in organ transplant¡A psoriasis¡A severe atopic dermatitis¡A rheumatoid arthritis¡A nephrotic syndrome¡A prevention of graft rejection in bone marrow transplantation.,Hypersensitivity; malignant neoplasms; uncontrolled hypertension; psoriasis; lactation.,Hypertension; hepatoxicity; tremor; paraesthesia¡A hypertrichosis¡A facial oedema¡A acne; gingival hypertrophy; hyperkalaemia¡A fluid retention; increased susceptibility to infections; GI symptoms. Potentially Fatal: Nephrotoxicity; convulsions.,¤ÅÀx¦s©ó30¢J¥H¤W,Transplant rejection initial 10-15 mg/kg before transplant¡A then divided twice daily into 2 equal doses for 1 to 2 weeks¡A titrate subsequent doses to achieve predefined blood concentrations. Plaque psoriasis initial 2.5 mg/kg/day in divided doses twice daily. Maximum 5 mg/kg/day. Rheumatoid arthritis initial 3 mg/kg/day in divided doses twice daily. Maximum 5 mg/kg/day. Atopic dermatitis 2.5-5 mg/kg/day in divided doses twice daily. Nephrotic syndrome adult 5 mg/kg/day¡A children 6 mg/kg/day.,»Ý½Õ¾ã¾¯¶q,Monitor blood concentrations; may require dose reduction.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ³n½¦Ån¡AÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©ÎÀ£¸H¡C¥»ÃÄ¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C
OYUB,Sodium Fluoride,Yubon 0.25mg¡A 100's/bot,TENT,,¾AÀ³¯g:¹w¨¾³E¤ú °Æ§@¥Î:»´·L¨ë¿E¤ÏÀ³(¬õ¯l) ¸T§Ò:¹ïNaF¹L±Ó,,«Ç·Å,2¶g~2·³: 0.25 mg/day 2~3·³: 0.5 mg/day 4~5·³: 0.75 mg/day 6·³¥H¤W: 1 mg/day Ãh¥¥´Á: 1 mg/day,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IGLUB,Ca Gluconate+ Glucoheptonate+ Lactobionate+ Saccha,Glucal Black inj 4.5mEq/5mL,NUTR,,¾AÀ³¯g:Ca deficiency,,«Ç·Å,2-5 mL IM or IV at 2 mL/min¡A 5-20 mL daily or every other day.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ÀR¯ßª`®g®É¡A¥i¥Î5%©Î20%¸²µå¿}ª`®g²Gµ}ÄÀ¡A¥B¶·¨C¤ÀÄÁ2 mL ¤§½wºC³t«×ª`®g¡C 2. ¥»¾¯»P¤A¾J(Alcohol)²V¦X®É·|¦³¨I¾ýªR¥X¡A¬Gª`®gµ©¦p¥Î°sºë®ø¬r®É¡A¶·«Ý¨ä§¹¥þ°®Àê©l¥i¨Ï¥Î¡C 3. ¤p¨à»PÀ¦¨à¶·§@ÀR¯ßª`®g¡A°£«D§Þ³N¤W¦³§xÃø¡C 4. ´¿¸g¨Ï¥Î©Î¥¿¦b¨Ï¥Î¬v¦a¶À©Î¨äÃþ¦ü»s¾¯ªÌ¡A¦]¶tÂ÷¤l¥i¼W±j¨ä§@¥Î¡A©Ò¥H¨Ï¥Î¥»¾¯®É¡A°È½Ð¸U¤À¤p¤ß¡C
IUBI,Articaine,Ubistesin 4%(for Dental) 1.7mL,ZANE,Dental infiltration and dental nerve block,¹ï³ÂÃÄ¦¨¤À¹L±Ó¡B¤ßÅ¦¦³ÄY­«ªº¶Ç¾É¨t²Î»ÙÃª¡B«æ©Ê¤ß°IºÜ¡BÄY­«§C¦åÀ£,Tinnitus¡A dizziness¡A nausea¡A vomiting¡A restlessness. Central nervous system: Headache (4%)¡A paresthesia (1%) Gastrointestinal: Gingivitis (1%) Miscellaneous: Pain (body as a whole 13%)¡A facial edema (1%),«Ç·Å,For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection. Injection rate: <= 0.5 mL/15 seconds. Children 20-30 kg: 0.25-1 mL; maximum: 1.5 mL each time and 2.5 mL/24 hours. Children 30-45 kg: 0.5-2 mL; maximum: 2 mL each time and 5 mL/24 hours. Adult: 0.5-1.7 mL each time¡A total maximum: 500mg¡A equivalent to 12.5 mL (7mg/kg).,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,LA;LI;,,,,,
IZIA,Lidocaine + Epinephrine,Ziacaine 2%(for Dental) 1.8mL,ZANE,Dental infiltration and dental nerve block.,Thyrotoxicosis¡A hypertension¡A severe heart disease (particularly when tachycardia is present)¡A diabetes; hypovolaemia¡A shock¡A heart block; when inflammation or sepsis is present in the region of the proposed inj. Soln containing epinephrine should not be used for local anesth inj in digits & appendages.,Nervousness¡A dizziness¡A blurred vision¡A tremor¡A drowsiness¡A tinnitus¡A numbness¡A disorientation¡A nausea & vomiting.,«Ç·Å,4~6 years:usual dose:0.9ml; maximum.1.8ml 6~14 years:usual dose:1.35ml; maximum.2.7ml >15 years:usual dose:1.8ml; maximum.3.6ml,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,LA;LI;,,,,,
OCOT,Dextromethorphan+Lysozyme+K Cresolsulfonate,Cotazym 20/20/90mg,ERSP,,¾AÀ³¯g: Antitussive¡A expectorant. °Æ§@¥Î: Rarely¡A dizziness; GI disturbances; drowsiness. ¸T§Ò: MAOI therapy.,,«Ç·Å,Drug leaflet: Adult 1 cap tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IOMN2,Iohexol + Tromethamine,Omnipaque 350mg I/mL¡A 200mL,SCAN,¯áÅè³y¼v¡A ¦åºÞ³y¼v¡A ¹q¸£Â_¼h±½´y¼W±j³y¼v¾¯¡A ªc§¿¹D³y¼v Intrathecal: Myelography; contrast enhancement for computerized tomography Intravascular: Angiocardiography¡A aortography¡A digital subtraction angiography¡A peripheral arteriography¡A excretory urography; contrast enhancement for computed tomographic imaging Oral/body cavity: Arthrography¡A GI tract examination¡A hysterosalpingography¡A pancreatography¡A cholangiopancreatography¡A herniography¡A cystourethrography; enhanced computed tomography of the abdomen,Hypersensitivity to iohexol or any component of the formulation.,¥þ¨­·Å¼ö·P¡A ¼È®É©Êª÷ÄÝ¨ý¹D¡A ¸¡³¡¤£¾A¡A äú¤ß¡A ¹Ã¦R¡A ¹L±Ó©Ê¤ÏÀ³ Cardiovascular: Asystole¡A arrhythmia¡A bradycardia¡A cardiopulmonary collapse¡A edema¡A heart failure¡A hypertension (in patients with phenochromocytoma after intra-arterial injection)¡A hypotension¡A syncope¡A transient ischemic attacks¡A vasovagal attacks¡A venous thrombosis¡A ventricular fibrillation¡A ventricular tachycardia Central nervous system: Anxiety¡A confusion¡A dizziness¡A headache¡A loss of consciousness¡A seizure¡A vertigo Dermatologic: Pruritus¡A rash¡A urticaria Endocrine & metabolic: Thyrotoxicosis exacerbation Gastrointestinal: Cramping¡A diarrhea¡A nausea¡A salivary gland swelling¡A vomiting Local: Burning sensation¡A pain at injection site¡A thrombophlebitis Neuromuscular & skeletal: Parasthesia¡A polyarthropathy¡A tremor Ocular: Vision abnormalities Renal: Contrast-associated nephropathy¡A creatinine increased¡A renal dysfunction Respiratory: Bronchospasm¡A cough¡A dyspnea¡A pulmonary edema¡A rhinitis¡A sneezing Miscellaneous: Anaphylactoid reaction¡A diaphoresis¡A hypersensitivity reactions,µL¯S§O«ü¥ÜÀx¦s·Å«×¦ý¥i©ó¨Ï¥Î«e¥[¼ö¦ÜÅé·Åªº37¢J,Dosing is based numerous variables including: type of examination¡A route of administration¡A patient age/weight and product. Consult specific product information for detailed dosing. Intrathecal route: Myelogram a) Lumbosacral:The usual recommended dose for use in lumbar myelography is 10 to 17 milliliters of iohexol 180 milligrams iodine/milliliter (mgI/mL) or 7 to 12.5 milliliters of iohexol 240 mgI/mL administered by lumbar injection. b) Thoracic:The usual recommended dose for thoracic myelography is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter (mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL administered by lumbar or cervical injection. c) Cervical:For cervial myelography given by lumbar injections¡A the following doses have been used: 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. If iohexol is administered by C1-2 injection¡A the recommended dose is 7 to 10 mL of iohexol 180 mgI/mL¡A 6 to 12.5 mL of iohexol 240 mgI/mL¡A or 4 to 10 mL of iohexol 300 mgI/mL. d) Spinal cord:The usual dose for total columnar myelography (lumbar injection) is 6 to 12.5 milliliters of iohexol 240 milligrams iodine/milliliter(mgI/mL) or 6 to 10 mL of iohexol 300 mgI/mL. Intravascular route: CT of head The recommended dose for HEAD IMAGING is 70 to 150 milliliters of iohexol 300 milligram iodine/milliliter (mgI/mL) or 80 mL of iohexol 350 mgI/mL by injection or 120 to 250 mL of iohexol 240 mgI/mL by infusion. For BODY IMAGING the dose is 50 to 200 mL of iohexol 300 mgI/mL or 60 to 100 mL of iohexol 350 mgI/mL by injection. Angiocardiography a) DOSAGE SUMMARY:Iohexol 350 milligrams iodine/milliliter is recommended for use in ANGIOCARDIOGRAPHY. b) VENTRICULOGRAPHY:The usual adult volume is a single injection of 40 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 30 mL to 60 mL). This may be repeated as necessary. When combined with selective coronary arteriography the total administered dose should not exceed 250 milliliters (87.5 grams iodine). c) SELECTIVE CORONARY ARTERIOGRAPHY:The usual adult dose for right or left coronary arteriography is 5 milliliters (mL) of iohexol 350 milligrams iodine/mL (range 3 mL to 14 mL) per injection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IA;IV;IVP;IVPUSH;R;RECT;,,,,,1.ÅéµÄ¨Ï¥Î³~®|¥H¤ôµ}ÄÀ¡A ¦¨¤H¨àµ£¤Î³¡¦ì¤£¦P¨Ì1:1~1:50¤£µ¥¤ñ¨Òµ}ÄÀ 2.µÇ¥\¯à¥¿±`¯f±wÀ³¥ß§Y°±¥ÎMeformin 48¤p®É¡A«ÝµÇ¥\¯à«ì´_«á¦A±Ò¥Î;¦pµÇ¥\¯à¤£¨Î¯f±w¡A½Ðµû¦ô¯f±w±¡ªp¡A´£«e48¤p®É°±¥ÎMeformin.
IMV5,Multivitamin,Multivita inj 5mL,NUTR,,¾AÀ³¯g:Multivit deficiency.,,2-8¢J,2-5 mL as a single dose IV. Per mL Vit A 2¡A000 iu¡A vit B1 10 mg¡A vit B2 2 mg¡A vit B6 3 mg¡A nicotinamide 20 mg¡A pantothenol 5 mg¡A vit C 100 mg¡A vit D 200 iu¡A vit E 1 mg,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IAVE,Moxifloxacin,Avelox °w¾¯ 400mg/250mL,QANB,Treatment of adults >= 18 years with upper & lower respiratory tract infections such as acute sinusitis¡A acute exacerbation of chronic bronchitis¡A community acquired pneumonia; skin & soft tissue infections; complicated intra-abdominal infection.,Hypersensitivity. Children¡A growing adolescent. Pregnancy¡A lactation.,GI disturbances (eg nausea¡A vomiting¡A dyspepsia¡A abdominal pain); headache¡A dizziness; taste perversion; musculoskeletal effects (eg back pain¡A arthralgia); CVS effects (eg tachycardia¡A hypertension); hematological changes; CNS disturbances eg (insomnia¡A convulsion); skin reactions (eg rash¡A pruritus); visual disturbances.,«Ç·Å15¢J -25¢J,Adult: 400 IV over 60 minutes Q24H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD10W¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¥H¶W¹L60¤ÀÄÁ½wºCºwª`¡C¤£«ØÄ³¨Ï¥Î¦bpediatric patients,1. ºÊ´úÅé·Å¡BCBC¡Aª`·N¬O§_¦³Åöíw¡B¤ß«ß¤£¾ã¼xª¬¡C 2. ¥»«~¥iª½±µ¿éª`©Î³z¹LT-tube»P¨ä¥L¬Û®eªº¿éª`²G¤@¦P¿éª`¡C 3. ¨Ì2016¦~²Ä2¦¸ADR·|Ä³¨MÄ³: ¦]QuinolonesÃþÃÄª«±`¨£¤Þ°_ÀR¯ßª¢¡A«ØÄ³¿éª`®É¶¡À³¶W¹L60¤ÀÄÁ¡C
ICEF7,Cefuroxime,Cefuroxime inj 750mg,QANB,,¾AÀ³¯g: Infections due to Staphylococci¡A Streptococci¡A Pneumococci¡A Meningococci & other susceptible bacteria. °Æ§@¥Î: Allergic reactions¡A GI intolerance¡A superinfection¡A eosinophilia. Rarely¡A transient hematological abnormalities; pseudomembranous colitis¡A phlebitis. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult 750 mg tid IM or IV. Severe infections: 1.5 g tid IV. Children 30-100 mg/kg/day in 3 or 4 divided doses. Neonate 30-100 mg/kg/day in 2 or 3 divided doses.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BPT­È¡C
ICIP,Ciprofloxacin,Ciproxin °w¾¯ 100mg/50mL,QANB,,¾AÀ³¯g: Complicated UTI¡A bone & joint¡A complicated intra-abdominal & lower respiratory tract infection. °Æ§@¥Î: Nausea¡A diarrhea¡A vomiting¡A dyspepsia¡A abdominal pain¡A flatulence¡A anorexia¡A dizziness¡A headache¡A tiredness¡A agitation¡A trembling. Very rarely¡A insomnia¡A peripheral paralgesia¡A sweating¡A unsteady gait¡A convulsions¡A increase in intracranial pressure¡A anxiety states¡A nightmares¡A confusion¡A depression¡A hallucinations¡A impaired taste & smell¡A visual disturbances¡A tinnitus¡A transitory impairment of hearing¡A especially at high frequencies¡A skin reactions. ¸T§Ò: Hypersensitivity to ciprofloxacin or other quinolones. Children¡A adolescents¡A pregnancy & lactation.,,«Ç·Å,Complicated UTI¡A bone & joint¡A complicated intra-abdominal & lower respiratory tract infection 400 mg 12 hrly. Particularly severe¡A life threatening infections: septicemia¡A peritonitis¡A bone & joint infections¡A recurrent infections in cystic fibrosis 400 mg 8 hrly.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. »ÝÁ×¥úÀx¦s¡A¥ú·Ó¤U(¥¼¶}²~)ÃÄ®Ä¥u¯àºû«ù3¤Ñ¡C 2. ºÊ´úÅé·Å¡BCBC¡Aªø´Á¨Ï¥ÎÀ³ºÊ´ú¨xµÇ¥\¯à¡C
IFUR,Cefuroxime,Furoxime inj 750mg,QANB,,¾AÀ³¯g: Infections due to Staphylococci¡A Streptococci¡A Pneumococci¡A Meningococci & other susceptible bacteria. °Æ§@¥Î: Allergic reactions¡A GI intolerance¡A superinfection¡A eosinophilia. Rarely¡A transient hematological abnormalities; pseudomembranous colitis¡A phlebitis. ¸T§Ò: Hypersensitivity to cephalosporins.,,«Ç·Å,Adult 750 mg tid IM or IV. Severe infections: 1.5 g tid IV. Children(above 3months of age) 50-100 mg/kg/day in 3 or 4 divided doses. Neonate 30-100 mg/kg/day in 2 or 3 divided doses.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,AAP: Maternal medication usually compatible with breastfeeding. Micromedex: Infant risk is minimal. Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.,,,,,,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BPT­È¡C 2. IM µ¹ÃÄ¡G1.5 gm/vial °®¯»¥H6 mL D/W·»¸Ñ IV bolus¡G1.5 gm/vial °®¯»¥H¦Ü¤Ö15 mL¬Û®eµ}ÄÀ²G·»¸Ñ¡A±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ IV infusion¡G1.5 gm/vial °®¯»µ}ÄÀ¦¨50-100 mL¡Aºwª`15 ~ 60¤ÀÄÁ
EEAR,Ofloxacin,Earflo otic solution 3mg/mL,TENT,,¾AÀ³¯g: Otitis media¡A otitis externa caused by ofloxacin-susceptible pathogen: Staph¡A Strep¡A Proteus sp¡A Pseudomonas aeruginosa¡A & haemophilus influenzae. °Æ§@¥Î: Infrequently¡A earache¡A superinfection. Dermatologic: Pruritus¡A Rash Gastrointestinal: Diarrhea¡A Nausea (up to 3.5% )¡A Vomiting Neurologic: Dizziness (up to 8% )¡A Headache (up to 8% )¡A Insomnia (up to 13% ) Ophthalmic: Burning sensation in eye¡A Pain in eye ¸T§Ò: Hypersensitivity to quinolones; pregnancy and lactation; prolongation of the QT interval; uncorrected hypokalaemia.,,«Ç·Å,Otic/Aural Otic infections Adult: Apply 10 drops of 0.3% solution in the affected ear once daily for 7 days. Lie with the affected ear upwards for 5 min to facilitate penetration into the ear canal. Child: 6 mth-13 yr: 5 drops of 0.3% solution in the affected ear once daily for 7 days. >13 yr: 10 drops of 0.3% solution in the affected ear once daily for 7 days. Lie with the affected ear upwards for 5 min to facilitate penetration into the ear canal.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OFOL,Folinate,Folina 15mg,ZADT,Antidote for folic acid antagonists overdosage. In folinic acid rescue to reduce toxicity of methotrexate. To potentiate cytotoxic effects of fluorouracil in advanced colorectal cancer. Treatment of folate-deficient megaloblastic anaemia.,Untreated vit B12 deficiency. Never give alone or in conjunction with inadequate amounts of hydroxocobalamin; pernicious anaemia & other megaloblastic anaemia where vit B12 is deficient.,Occasional hypersensitivity reactions; rarely pyrexia after inj. GI complaints at high doses. Haematological remissions with simultaneous progression of neurological disturbances.,25¢J¥H¤U,Methotrexate-rescue (high-dose): 15 mg (~10 mg/m2) orally; start 8-24 hours after beginning methotrexate infusion; continue every 6 hours for 10 doses¡A until methotrexate level is <0.05 micromolar. Monitor levels of serum creatinine and methotrexate¡A as well as urine alkalinization. Folate Deficiency: adults: 10-20 mg orally once daily. Children < 12 years: 0.25 mg/kg.day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OBIOT,Biodiastase + Lipase + Newlase,Biotase,ALIM,,¾AÀ³¯g:Indigestion °Æ§@¥Î: Hypersensitivity reactions.,,«Ç·Å,Adult 2-3 tab tid¡A children 6-12 years 1/2 adult dose¡A 3-6 years 1/4 adult dose.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OTED,Fe (III) Hydroxide Polymaltose Complex,Tedalin 100mg Chewable,NUTR,Fe-deficiency anaemia.,Hypersensitivity or intolerance to iron and overloading of iron in the body. Anaemia not caused by iron deficiency. Disturbances in iron utilisation¡A thalassemia. Patients receiving repeated blood transfusion. Pregnancy (1st trimester).,GI irritation¡A epigastric pain¡A stomach cramping¡A constipation¡A nausea¡A vomiting¡A diarrhoea¡A dark stools¡A heart burn¡A discoloured urine¡A teeth staining.,25¢J¥H¤Uºò±K®e¾¹«O¦s,PO dose: 100mg QD-BID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]µL¬ÛÃö°O¸ü,Unknown ¨S¦³¸ê®Æ,[¥é³æ]µL¬ÛÃö°O¸ü,AC;AC15;PC;PO;WM;,,,,,
EPOL0,Tar + Cade Oil + Coal Tar Soln,Polytar Liquid 1% 150mL (­­¦Û¶O),TDER,,¾AÀ³¯g: Seborrhea¡A psoriasis. Dandruff & itching scalp. °Æ§@¥Î: Skin irritation¡A rash¡A mild photosensitivity.,,«Ç·Å,Use as scalp cleanser once or twice weekly.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OTRAJ,Linagliptin,Trajenta 5mg,META,Management of type 2 diabetes mellitus (noninsulin dependent¡A NIDDM) as an adjunct to diet and exercise as monotherapy or in combination with other antidiabetic agents.,Hypersensitivity to linagliptin or any component of the formulation.,>10%: Endocrine & metabolic: Hypoglycemia (combined with metformin/sulfonylurea [15%]¡A metformin [<1%]¡A pioglitazone [<1%]; monotherapy [<1%]) Central nervous system: Headache (6%) Endocrine & metabolic: Hyperuricemia (3%)¡A lipids increased (3%)¡A triglycerides increased (2%)¡A weight gain (2%) Neuromuscular & skeletal: Arthralgia (6%)¡A back pain (6%) Respiratory: Nasopharyngitis (6%)¡A cough (2%) <1% (Limited to important or life-threatening): Angioedema¡A hypersensitivity¡A pancreatitis,30¢J¥H¤U,5 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ICET,Cefmetazole,CetaZONE inj 1gm,QANB,,¾AÀ³¯g:Treatment and prophylaxis of anaerobic and mixed bacterial infections¡A gonorrhoea. °Æ§@¥Î:Hypersensitivity reactions; nephrotoxicity; neutropenia; thrombocytopenia; agranulocytosis; bleeding complications related to hypoprothrombinaemia or platelet dysfunction; GI effects; CNS toxicity; superinfection; pain at Inj site (IM); thrombophloebitis (IV infusion); hepatitis; cholestatic jaundice. Potentially Fatal: Pseudomembranous colitis. ¸T§Ò:Hypersensitivity to cephalosporins.,,,(MICREMEDEX) Intravenous route a) Cefmetazole is generally dosed intravenously as 2 grams every 6 to 12 hours for 5 to 14 days¡A with severe or life-threatening infections requiring 8 grams/day. The drug can also be given as a single 2-gram dose 30 to 90 minutes before procedures as surgical prophylaxis to reduce the incidence of postoperative infections. An alternative regimen in this setting would be 1 gram intravenously 30 to 90 minutes before surgery or after clamping the umbilical cord in cesarean section¡A with 1 gram again 8 and 16 hours later. If surgery lasts longer than 4 hours¡A the preoperative dose should be repeated. b) Clinical trials have used daily intravenous doses of cefmetazole that ranged from 1 to 8 grams divided every 6 to 12 hours for urinary tract infections¡A respiratory tract infections¡A skin and soft tissue infections¡A abdominal infections¡A pelvic inflammatory disease¡A and surgical prophylaxis. c) Intravenous cefmetazole was given to patients who were undergoing appendectomies by infiltrating the layers of the abdominal wall. Peri-incisional infiltration was effective in preventing wound infections.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IV;IVD;IVP;IVPUSH;,IV: 10mL D/W¡A N/S¡A D5W,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,½wºCª`®g,«ØÄ³¥H30 ~ 90¤ÀÄÁ½wºCºwª`,1.¥é³æ¨ÃµL´£¤Î¥i¥HIM¡C
EVIT,Vitamin A,Vita A eye oint,TOPH,,¾AÀ³¯g: Superficial diffuse keratitis¡A exfoliative epithelial keratitis¡A viral keratitis¡A vesicular keratitis & other types of keratitis. °Æ§@¥Î: Hypersensitivity reactions.,,«Ç·Å,Apply once to several times daily.,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IAPR,Hydralazine,Aprelazine inj 20mg/1mL,CAVS,,¾AÀ³¯g: Treatment of hypertensive emergencies¡A including those associated with pre-eclampsia & toxaemia of pregnancy. °Æ§@¥Î:Tachycardia¡A palpitation¡A flushing¡A hypotension¡A anginal symptoms¡A headache¡A arthralgia¡A joint swelling¡A myalgia¡A GI disturbances. Rarely¡A SLE-like syndrome after long-term therapy with doses > 100 mg daily (or less in women & in slow acetylators). ¸T§Ò: Idiopathic SLE & related disorders¡A severe tachycardia¡A high output heart failure¡A myocardial insufficiency due to mechanical obstruction¡A cor pulmonale¡A dissecting aortic aneurysm.,,«Ç·Å,Adult Initially 5-10 mg by IM or slow IV inj; if necessary¡A dosage may be repeated after 20-30 mins. Or by continuous IV infusion at an initial dose of 200-300 mcg/min. Maintenance dose: 50-150 mcg/min.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ÀR¯ßª`®gÀ³½wºC¡AÁ×§K¥­§¡°Ê¯ßÀ£¬ðµM¤U­°¡C 2. Apresoline¤£¥i»P¸²µå¿}ª`®g²G²V¦X¡A¦]¥D¦¨¤À·|¨³³t¤À¸Ñ¡C
IDOPM,Dopamine,DOPmin inj 200mg/5mL,CAVS,,¾AÀ³¯g: Correction of poor perfusion¡A low cardiac output¡A impending renal failure & shock associated with MI¡A trauma¡A endotoxic septicemia¡A open heart surgery¡A heart failure. °Æ§@¥Î: Most frequently: ectopic beats¡A nausea¡A vomiting¡A tachycardia¡A anginal pain¡A palpitations¡A dyspnoea¡A headache¡A hypotension & vasoconstriction. Other infrequent side effects include aberrant conduction¡A bradycardia¡A piloerection¡A widened QRS complex¡A azotaemia & hypertension. ¸T§Ò: Phaeochromocytoma; uncorrected hypovolaemia; uncorrected tachyarrhythmia or ventricular fibrillation.,,«Ç·Å,Initial flow rate 2-4 mcg/kg body weight/min by IV infusion into medium to large veins. May be increased by 5-10 mcg/kg/min increment up to 20-50 mcg/kg/min if needed.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1.¤Å¥[¤JÆP©ÊÃÄ«~
IIVIG,Human Immunoglobulin,Human Immunoglobulin 2.5gm/50mL,HIMM,,¾AÀ³¯g:¬°¤HÃþ§K¬Ì²y³J¥Õ»s¾¯(K000215248)(K000215299)(K000672248),,2-8,IV infusion (not exceeding 20 drops/min). Immunoglobulin deficiency: Adult: 0.1-0.15 g/kg; child: 0.15 g/kg; Infant: 0.2 g/kg¡A (max. 0.4 g/kg); repeated every 3-4 wks. Serious bacterial infections including sepsis: As above¡A repeated every 1-2 days if needed. Idiopathic thrombocytopenic purpura & Kawasaki disease: 0.4 g/kg/day for 5 consecutive days.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IKA,Triamcinolone,Kenacort-A inj 10mg/mL,HM,,Inflammatory dermatoses.,,,Intra-articular: 2.5-15 mg. Intradermal or intralesional: less than 1 mg/site. IM: 40-80 mg.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IKCL4,Potassium Chloride,20mEq KCl in 5% D/W 500mL,NUTR,,¾AÀ³¯g: Hypokalaemia. °Æ§@¥Î: Hyperkalemia¡A pain or phlebitis at injection site. ¸T§Ò: Hyperkalemia.,,2-8«×C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr¡A with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
ILUP,Leuprolide,Leuprolide (Lupron) 5mg/mL¡A 2.8mL,RACA,,¾AÀ³¯g: Palliative treatment of advanced prostatic cancer. °Æ§@¥Î: Hot flushes¡A anorexia¡A nausea. ¸T§Ò: Women who are or may become pregnant while receiving the drug.,,2-8¢J,1 mg SC as a single dose.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,
INAL,Naloxone,Naloxone inj 0.4mg/1mL,ZADT,Complete or partial reversal of narcotic depression including respiratory depression¡A induced by opioids including natural & synthetic narcotics & narcotic-antagonist analgesics. Diagnosis of suspected acute opioid overdosage,Hypersensitivity to any component of the formulation.,Hypertension¡A hypotension¡A ventricular tachycardia¡A pulmonary oedema¡A tremulousness¡A nausea/vomiting¡A sweating.,«Ç·Å,(Micromedex) Overdose of opiate¡A known or suspected: (Injection solution) 0.4-2 mg IV¡A repeat every 2-3 minutes as needed; if no response after 10 mg¡A reconsider diagnosis of opioid toxicity; may administer IM or SC if IV route is unavailable.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,IV push: Administer over 30 seconds as undiluted preparation or administer as diluted preparation slow IV push by diluting 0.4 mg (1 mL) ampul with 9 mL of normal saline for a total volume of 10 mL to achieve a concentration of 0.04 mg/mL.,2 mg naloxone¥H500mL N/S¡AD5Wµ}ÄÀ¬°0.004 mg/mL¡A¨Ì¯f¤HÁ{§É¤ÏÀ³½Õ¾ãµ¹ÃÄ³t²v,1. IV infusion¡G2 mg naloxone¥H500 mL N/S ©Î 5% Dextrose solutionµ}ÄÀ¬°0.004 mg/mL¡A¨Ì¯f¤HÁ{§É¤ÏÀ³½Õ¾ãµ¹ÃÄ³t²v¡C
IPROE,Isoproterenol,Proternol inj 0.2mg/1mL(Isoproterenol),CAVS,,¾AÀ³¯g:¤ß«ß¤£¾ã(B012225209) CI: Tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; angina pectoris.,,RT,IM or SC: 0.2 mg. IV: 0.01-0.06 mg. IV infusion: 1-2 mg in 500 ml of 5% dextose¡A at a rate of 0.5-5 mcg/min or adjusted as needed.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OSEV,Amlodipine + Olmesartan,Sevikar 5/20mg(¤p¾¯¶q),CAVS,Treatment of HTN. Not indicated for the initial therapy.,Pregnancy.,Edema¡A dizziness¡A flushing¡A palpitation¡A somnolence.,25¢J¥H¤U,HTN initial: 1 tablet QD¡A after 2 weeks may titrate up to 2 tablet QD (maximum 10/40mg),»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ¨Ï¥Î®ÉÀ³ÂÔ·V¤p¤ß¡A¥i¦Ò¼{±q³Ì§C¥i¨ú±o¤§Amlodipine¾¯¶q (2.5mg) ¶}©lªvÀø,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,Amlodipine: Human Data Suggest Low Risk Olmesartan: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] Ãh¥¥¤À¯ÅD¡AÄµ»y¡G­L¨à¬r©Ê¡A­Yµo²{Ãh¥¥¡AÀ³¥ß§Y°±¥ÎSevikarR¡AªA¥Îª½±µ§@¥Î©óµÇ¯À¡Ð¦åºÞ¦¬ÁY¯À¨t²ÎªºÃÄª«¡A¥i¯à¶Ë®`µo¨|¤¤­L¨à¬Æ¦Ü ³y¦¨¦º¤`¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Amlodipine: Compatible Olmesartan: No Human Data¡XProbably Compatible [¥é³æ] ¥Ø«e¨Ã¤£½T©wSevikarRªºamlodipine©Îolmesartanmedoxomil¦¨¥÷¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¦ý¤wª¾ªc¨Å¤j¹«ªº¨Å¥Ä¤¤·|¥X²{§C¿@«×olmesartan¡C¥Ñ©ó¦¹ÃÄª«¥i¯à ¾É­P±µ¨ü­÷¨ÅªºÀ¦¨à²£¥Í¤£¨}¤ÏÀ³¡AÀ³¦Ò¼{ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡A¨M©w¬O§_°±¤î­÷¨Å©Î°±¥ÎÃÄª«¡C,AC;AC15;PC;PO;WM;,,,,,
ITEST,Testosterone,Testosterone inj 250mg/1mL,HM,,¾AÀ³¯g:¨k©Ê§ó¦~´Á»ÙÃª ¤k©Ê°±¸g«áÀù¯g¤§ªvÀø(A000138209)(A003006209),,RT,IM inj. only¡A Female: 250mg IM every 2 wks; cystic mastopathy: 100mg between the 15th and 18th days of the cycle. Male: 250mg IM every 2-3 wks; maintenance¡A 250mg IM every 3-6wks. Climacteric: 50-100mg q2-3 wks¡A repeated cures of 4-8 wks's at 4 wk's intervals are recommended.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
EFLAR,Fluorometholone,Flarex 0.1%¡A 5mL,TOPH,,¾AÀ³¯g: Treatment of steroid-responsive inflammation of the palpebral & bulbar conjunctiva¡A cornea & anterior segment of the eye. °Æ§@¥Î: Glaucoma with optic nerve damage¡A visual acuity & field defects¡A cataract formation¡A secondary ocular infection following suppression of host response & perforation of the globe may occur. ¸T§Ò: Acute superficial herpes simplex keratitis¡A varicella & most viral diseases of the cornea & conjunctiva; TB; fungal diseases; acute purulent infections.,,«Ç·Å,Initially 2 drops 2 hrly for 1st 1-2 days¡A then 1-2 drops qid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EFUC,Fusidic Acid,Fucidin cream 2%¡A 5gm,TDER,,¾AÀ³¯g: Skin infections caused by Staph¡A Strep & other organisms sensitive to fusidic acid. °Æ§@¥Î: Hypersensitivity (rare).,,«Ç·Å,Apply bid-tid.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;,,,,,
EGIN,Carbomer,Ginpol eye gel 10gm,TOPH,,¾AÀ³¯g: Substitute for lacrimal fluid in deficiency of tear production or dry eye. °Æ§@¥Î: Transient blurring in vision. ¸T§Ò: Hypersensitivity to cetrimide.,,«Ç·Å,Instill 1 drop into conjunctival sac 3-5 times daily or more frequently during the day & before retiring at night.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,OD;OL;OU;,,,,,
EICH,Doxepin,Ichderm cream 50mg/gm¡A 15gm,TDER,Temporary relief of moderate itch associated with eczematous dermatitis.,Hypersensitivity to any component of the formulation.,Local skin irritation¡A drowsiness. Gastrointestinal: Constipation (oral¡A 4% )¡A Nausea (topical¡A less than 1%; oral¡A 2% )¡A Xerostomia (topical¡A 1%; oral¡A 15% ) Neurologic: Dizziness (topical¡A 1% to 10% )¡A Somnolence (topical¡A 22%; oral¡A 6% to 9% ) Renal: Urinary retention Respiratory: Upper respiratory infection (oral¡A 2% to 4%),25¢J¥H¤U,Apply QID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,EXT;,,,,,
EJOY,Aluminum Hydroxychloride,Joyla liquid 30mL,TDER,,¾AÀ³¯g: Hyperhidrosis.,,«Ç·Å,Apply to skin when necessary.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OAPR1,Hydralazine,Apresoline 10mg,CAVS,,¾AÀ³¯g: Hypertension¡A¬°©PÃä¦åºÞÂX±i¾¯(A030879100) °Æ§@¥Î:Tachycardia¡A palpitation¡A anginal symptoms¡A flushing¡A headache¡A dizziness¡A nasal congestion¡A GI disturbances. ¸T§Ò:Idiopathic SLE & related diseases. Severe tachycardia & heart failure with high cardiac output. Myocardial insufficiency due to mechanical obstruction. Right ventricular heart failure due to pulmonary HTN. Dissecting aortic aneurysm.,,«Ç·Å,Adult: 10-50 mg qid (max. dose 200-300 mg/day). Child: 0.75 mg/kg/day in 4 divided doses¡A up to 7.5 mg/kg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OLOP,Loperamide,Loperam 2mg (Loperamide),ALIM,Acute & chronic diarrhea,Diarrhea associated with organisms which penetrate the mucosa; pseudomembranous colitis or diarrhea associated with broad spectrum antibiotics.,Flatulence¡A constipation¡A nausea¡A abdominal pain¡A dry mouth; giddiness.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Oral Adult: Initially¡A 4 mg followed by 2 mg after each loose stool. Maximum dose: 16 mg daily. Child: Initially¡A 2 mg followed by 2 mg after each loose stool. Maximum dose: 8-12 mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ISTR,Streptomycin,Streptomycin inj 1gm,QANB,,¾AÀ³¯g: Tuberculosis. Bacterial endocarditis. Plague¡A tularemia & brucellosis. Mycetoma & Whipple's disease. °Æ§@¥Î: Vestibular & auditory damage¡A nephrotoxicity¡A paraesthesia of face¡A rash¡A fever¡A urticaria¡A angioneurotic edema¡A eosinophilia. ¸T§Ò: Hypersensitivity.,,«Ç·Å,TB Adult 15-20 mg/kg body weight/day. Max: 1 g/day. Adult > 40 years & < 50 kg Max: 500-750 mg/day. May be given as part of intermittent regimen 2 or 3 times weekly. Children 15-20 mg/kg/day. Max: 1 g/day. Non-tuberculous infections Adult 1-2 g/day in divided doses. Children Up to 40 mg/kg daily in divided doses. Max: 1 g/day. Course of treatment (except TB) should be limited to 7-14 days.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C
ITRA2,Atracurium Besylate,Tracrium inj 25mg /2.5mL,CNEU,,¾AÀ³¯g: Highly selective¡A nondepolarizing muscle relaxant. As an adjunct to general anaesth to enable tracheal intubation¡A to relax skeletal muscles during surgery or controlled ventilation & to facilitate control of mechanical ventilation in ICU patient. °Æ§@¥Î: Skin flushing¡A mild transient hypotension¡A bronchospasm. Rarely¡A anaphylactoid reactions. Dermatologic: Flushing (5%) ¸T§Ò: Hypersensitivity to atracurium¡A cisatracurium or benzenesulfonic acid.,,2-8¢J,Adult & children > 1 month 0.3-0.6 mg/kg. Endotracheal intubation 0.5 to 0.6 mg/kg IV. Supplementary dosage: 0.1-0.2 mg/kg. Maintenance: 0.3-0.6 mg/kg/hr by IV infusion. ICU patient initial dose: 0.3-0.6 mg/kg¡A maintenance rate: 0.65-0.78 mg/kg/hr.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
IVAG,Neostigmine Methylsulfate,Vagostin inj 0.5mg/1mL,CNEU,Paralytic ileus¡A myasthenia gravis¡A vascular spasm¡A ocular myasthenia gravis.,Mechanical GI or urinary tract obstruction¡A peritonitis.,Increased salivation & sweating¡A nausea & vomiting¡A abdominal cramps¡A diarrhea¡A allergic reactions¡A miosis¡A increased bronchial secretions¡A bradycardia¡A bronchospasm¡A weakness¡A muscle cramps¡A fasciculation¡A hypotension.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adult: 0.5 mg IM QD¡A may adjust dosage to 1.5mg QD or 0.5mg several times a day¡A according to patient's age and symptom. Paralytic ileus: 0.5 mg Q4-5H. Ophthalmology: 0.25-1 mg SC.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;SC;,,,,,
IVENA,Diphenhydramine,Venan inj 30mg/1mL,HIMM,,¾AÀ³¯g: Urticaria¡A dermatologic disease¡A pruritus¡A acute rhinitis & hay fever. °Æ§@¥Î: Drowsiness¡A dizziness¡A antimuscarinic effects. CV & CNS effects. Muscular weakness. Allergic reaction. Blood disorders. ¸T§Ò: Acute asthmatic attack. Premature infants.,,«Ç·Å,1 mL tid. Adult: 10-50mg¡A (max. 400 mg/day). Child: 5 mg/kg/day or 150 mg/Kg/day¡A (max. 300mg/day).,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.,,,,,,102.02.25 ½Ã¥Í¸p¤½§i (¤@)1. ¡uÀ¦¥®¨à(premature infants¤Îneonate)¤£«ØÄ³¨Ï¥Î¡v 2. ¡u¦Ñ¤H©y¥H³Ì§C¦³®Ä°_©l¾¯¶q¶}©lªvÀø¡v 3.¡uµÇ¥\¯à¤£¥þªÌÀ³©µªøµ¹ÃÄ¶¡¹j¡F»´«×(GFR>50 mL/min)¡G¶¡¹j6¤p®É¡F¤¤«×(GFR 10-50 mL/min)¡G¶¡¹j6-12¤p®É¡F­««×(GFR<10 mL/min)¡G¶¡¹j12-18¤p®É¡v¡C (¤G) ¥i¨ÑÀR¯ßª`®g¾¯«¬¤§ÃÄ«~¡A¨C¦¸diphenhydramine¤§¾¯¶q¥H10-50mg¬°©y¡A¥B¨äª`®g³t²v¤£©y¶W¹L25mg/min¡C
YAMO,¬ü¥Ò²Õ for Amocoat,¬ü¥Ò²Õ for Amocoat,ZOTH,,,,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,TOPI;,,,,,
IPNS1,Sodium Chloride,PREFILLED 0.9% Saline 10mL,NUTR,,,,,,,,,,,,,,,,,,,
IPROG,Progesterone,Progesterone inj 25mg/1mL,HM,Amenorrhoea; Dysfunctional uterine bleeding¡ARecurrent miscarriage w/ progesterone deficiency¡A,Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding¡A incomplete abortion¡A hormone-dependent carcinoma¡A as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease.,GI disturbances¡A appetite/wt change¡A fluid retention¡A oedema¡A acne¡A skin rash¡A urticaria¡A depression¡A headache¡A fever¡A fatigue¡A breast changes¡A hirsutism¡A changes in libido¡A altered menstrual cycles or irregular menstrual bleeding (rare). Gastrointestinal: Abdominal pain (oral¡A 10% to 20%; vaginal gel¡A 5% to 12%; vaginal insert¡A 12% )¡A Constipation (vaginal gel¡A 27%; vaginal insert¡A 2% to 3% )¡A Nausea (oral¡A 8%; vaginal gel¡A 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral¡A 7% to 12% ) Musculoskeletal: Cramp (vaginal gel¡A 15% to 26% ) Neurologic: Dizziness (oral¡A 15% to 24%; vaginal gel¡A 5% )¡A Headache (oral¡A 10% to 31%; vaginal gel¡A 13% to 19%¡A vaginal insert¡A 3% to 4% )¡A Sleep disorder (vaginal gel¡A 18% )¡A Somnolence (vaginal gel¡A 27% ) Psychiatric: Depression (oral¡A 19%; vaginal gel¡A 11% to 19% )¡A Feeling nervous (vaginal gel¡A 16% )¡A Mood swings (oral¡A 6%; vaginal gel¡A 22% to 23% ) Reproductive: Breast tenderness (oral¡A 16% to 27% )¡A Large breast (vaginal gel¡A 40% )¡A Pain¡A Post-oocyte retrieval (vaginal insert¡A 25% to 28% )¡A Pain of breast (oral¡A 6% to 16%; vaginal gel¡A 13% )¡A Perineal pain (vaginal gel¡A 17% ) Other: Fatigue (oral¡A 8% to 9%; vaginal gel¡A 21% to 22%; vaginal insert¡A 2% to 3% ),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Pain and bleeding of habitual abortion: 10-25mg daily¡A then 10mg twice a week IM.Uterine bleeding in middle age and menopause: 5-10mg daily IM.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,It may also be used to prevent spontaneous preterm birth in women with a singleton pregnancy who have a cervix <20 mm before or at 24 weeks' gestation. Use is not recommended as an intervention for women with multiple gestations (ACOG 2012). (UpToDate)2021/0125,Unknown ¨S¦³¸ê®Æ,Breastfeeding recommendations vary by manufacturer; the decision to breastfeed during therapy should consider the risk of infant exposure¡A the benefits of breastfeeding to the infant¡A and the benefits of treatment to the mother. (UpToDate)2021/0125,IM;,,,,,
OBLA,Flavoxate,Bladderon 200mg,SGU,,Symptoms relief of prostatitis¡A urinary frequency.,,,100-200 mg tid-qid¡A may be reduced when symptoms improve.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OCAR2,Activated Charcoal,Carbomix 2gm/pk,ZADT,,¾AÀ³¯g: ¬°¬¡©ÊºÒ¡A¸Ñ¬r¤§¥Î(B0215491CC) Emergency treatment of acute oral poisoning or drug overdose. Also binding of bacteriotoxins & other diarrhea-inducing substances in the GIT. °Æ§@¥Î: Diarrhea or constipation (occasionally). ¸T§Ò: Corrosive substance intoxication.,,,Acute poisoning -Adult 50-100 g in susp immediately followed by 20 g 4-6 hrly for a few days. -Children 1 g/kg body wt. Diarrhea -Adult 1 sachet/time several times daily. -Children 1 sachet in several divided doses.,,,,,,,,,,,,,,
OCOMB,Vitamin B Complex,Combeplex S.C. Tab,NUTR,,I: Prevention & treatment of vit. B deficiency.,,RT,Oral: 1 tab tid.,,,,¦w¥þ,,,,,,,,,,
ODAI,Gliclazide,Dail 80mg,META,,¾AÀ³¯g:¬°­°¦å¿}ÃÄ¡A©y¶º«e15¤ÀÄÁªA¥Î(A034350100),,RT,Initial 40-80mg/day then 320mg/day qd or 160 mg bid¡A use before meal.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
ODEP5,Valproate Sodium,DEPAKINE 500mg,CNEU,Treatment of generalized or partial epilepsy; mania.,Acute or chronic hepatitis¡A personal or family history of severe hepatitis¡A hepatic porphyria. Combination with mefloquine.,GI disturbances¡A ataxia¡A tremor¡A increased appetite and weight gain¡A edema¡A thrombocytopenia¡A inhibition of platelet aggregation; impaired hepatic function¡A rashes¡A sedation. Rarely¡A pancreatitis (discontinue). Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )¡A Rash (6% ) Endocrine metabolic: Increased appetite (6% )¡A Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )¡A Constipation (5% )¡A Diarrhea (12% to 23% )¡A Indigestion (8% to 13% )¡A Loss of appetite (4% to 12% )¡A Nausea (22% to 48% )¡A Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )¡A Backache (8% ) Neurologic: Amnesia (4% to 7% )¡A Ataxia (8% )¡A Dizziness (12% to 25% )¡A Headache (5% to 31% )¡A Insomnia (9% to 15% )¡A Somnolence (17% to 30% )¡A Tremor (9% to 57% ) Ophthalmic: Amblyopia¡A Blurred vision¡A Diplopia (16% )¡A Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )¡A Disturbance in thinking (6% )¡A Feeling nervous (7% to 11% )¡A Mood swings (6% ) Respiratory: Bronchitis (5% )¡A Dyspnea (5% )¡A Pharyngitis (8% )¡A Respiratory tract infection (12% to 20% )¡A Rhinitis (5% ) Other: Fever (2% )¡A Influenza (12% ),§C©ó25¢J,Epilepsy: Adult and children > 17 kg: Initially 10-15 mg/kg/day ¡Athen increase to the appropriate dose: 20-30 mg/kg/day in 1-2 divided doses. When epilepsy is not controlled or side effects are suspected¡A the blood concentration of valproic acid can be used for clinical follow-up. The effective therapeutic concentration is usually between 40-100 mg/L (280 to 700 £gmol/L). Mania: Initially 600 mg daily increasing by 200 mg/day every 3 days to reach desired clinical effect. Usual dose range: 1000-2000 mg/day (20-30 mg/kg/day) Dose may be further increased to maximum 2500 mg/day if necessary.,»Ý½Õ¾ã¾¯¶q,Severe impairment: Use is contraindicated.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,[¥é³æ]Ãh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÄ¼Æ{¯g¡C °£«DÅöíwªvÀø¨S¦³¦X¾Aªº´À¥NÃÄª«¡A§_«hÃh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÅöíw¡C °£«D¯à½T¹ê°õ¦æÁ×¥¥­pµe¡A§_«h¨ã¥Í¨|¯à¤Oªº°ü¤k¸T¥Î valproate¡C ¨Ï¥Î¥»«~¥i¯à·|¾É­P­«¤jªº¥ý¤Ñ©Ê·î§Î¡A¯S§O¬O¯«¸gºÞ·î§Î¡]¦p¡G¯á¬Wµõ¡A spina bifida¡^¡A ¥B¥i¯à·|¾É­P­L¨à´¼°Ó¤U­°¡A¬G¥»«~À³¶È­­¥Î©óµLªk¥H¨ä¥LÃÄª«±±¨î¯gª¬¡A ©Î¦³¨ä¥¦­ì¦]µLªk¨Ï¥Î¨ä¥LÃÄª«ªvÀø¤§¥¥°ü¡C ¦Ò¶q¨Ï¥Î¥»«~¥i¯à·|¦³¨Ï«Äµ£´¼°Ó­°§C¡Bµo¥Í¯«¸gºÞ¯Ê³´¤Î¨ä¥LÄY­«¥ý¤Ñ©Ê·î§Î¤§­·ÀI¡A ¥B¸Óµ¥­·ÀI¥i¯àµo¥Í©óÃh¥¥¦­´Á¡A¬G°£«D¥²­n¨Ï¥Î¡A§_«h¤£À³¨Ï¥Î©ó¨ã¥Í¨|¯à¤O©Î¦³Ãh¥¥¥i¯à¤§°ü¤k¡C Á×¥¥­pµe¡G Valproate¦³°ª«×ªº­P·î©Ê¡A¥B­L¨à¦b¤l®c¤¤ÃnÅS©óvalproate¦³¾É­P¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº°ª «×­·ÀI¡C ¥»«~¸T¥Î©ó¥H¤U±¡ªp¡G ªvÀøÅöíw ¡E ¦bÃh¥¥ª¬ºA¤U¡A°£«D¨S¦³¾A¦Xªº´À¥NÀøªk ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe ªvÀøÄ¼Æ{¯g ¡E ¦bÃh¥¥ª¬ºA¤U ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe Á×¥¥­pµe±ø¥ó¡G ³B¤èÂå®vÀ³½T«O ¡E ¨Ì¯f¤H­Ó§Oª¬ªp¶i¦æµû¦ô¨Ã»P¤§°Q½×¡C³o¬O¬°¤F«OÃÒ¯f¤H¯à½T¹ê°t¦X¨Ã¤F¸ÑªvÀø¿ï¾Ü¤Î¨ä­·ÀI¡A ¥H¤Î¬°¤F­°§C­·ÀI¦Ó±Ä¨úªº±¹¬I¡C ¡E ©Ò¦³¤k©Ê¯f¤H³£À³°w¹ïÃh¥¥ªº¥i¯à©Ê¶i¦æµû¦ô¡C ¡E ¯f¤HÀ³¤F¸Ñ¨Ã»{ª¾¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº­·ÀI¡A¥]¬A­L¨à¦b¤l®c¤¤ÃnÅS©óvalproateªº­·ÀIµ{«×¡C ¡E ¯f¤HÀ³¤F¸Ñ¡AªvÀø«e¤ÎªvÀø´Á¶¡(¥²­n®É)¥²¶·¶i¦æÃh¥¥ÀË´ú¡C ¡E À³§i¶D¯f¤H¥²¶·Á×¥¥¡A¥B¯f¤H¦b¾ã­ÓvalproateªvÀø´Á¶¡¥²¶·¤£¶¡Â_¦a±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I ¡E ¯f¤HÀ³¤F¸Ñ¡AÅý¦³Åöíw©ÎÄ¼Æ{¯gªvÀø¸gÅçªº±M¬ìÂå®v©w´Á(¦Ü¤Ö¨C¦~¤@¦¸)µû¦ôªvÀøµ²ªG¦³¨ä¥²­n©Ê¡C ¡E ¤k©Ê¯f¤HÀ³¤F¸Ñ¡A·í¨ä­pµeÃh¥¥®É¡AÀ³ºÉ§Ö¿Ô¸ßÂå®v¡A¥H½T«O¯à¤Î®É°Q½×¨Ã¦bÃh¥¥«e¤Î°±¤îÁ×¥¥«e§ó´«ªvÀøÃÄª«¡C ¡E ¯f¤HÀ³¤F¸Ñ¡A·íµo²{Ãh¥¥®ÉÀ³ºò«æ³qª¾Âå®v¡C ¡E ¯f¤H¤w¦¬¨ì¯f¤H¥ÎÃÄ«ü«n¡C ¡E ¤k©Ê¯f¤H¤w½T»{¤F¸Ñ¡A¨Ï¥Îvalproate¤§¬ÛÃö­·ÀI©MÀ³ª`·N¨Æ¶µ (¦~«×­·ÀI½T»{ªí)¡C ³o¨Ç±ø¥ó¥ç¾A¥Î©ó¥Ø«eµL©Ê¦æ¬°ªº°ü¤k¡A°£«D³B¤èÂå®v¥R¤À¤§²z¥Ñ»{¬°¨äµLÃh¥¥­·ÀI¡C ÃÄ®v©Î¨ä¥LÂåÀø±M·~¤H­ûÀ³½T«O ¡E ¨C¦¸½Õ°tvalproate®É³£¦³¥æ¥I¯f¤H¥d¡AÅý¯f¤H¤F¸Ñ¨ä¤º®e¡C ¡E §iª¾¯f¤H·í­pµeÃh¥¥©ÎºÃ¦üÃh¥¥®É¡Avalproate¤£À³¾Õ¦Û°±ÃÄ¡AÀ³¥ß¨è³sµ¸±M¬ìÂå®v¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]valproate ¤Àªc¨ì¨Å¥Ä¤¤ªº¶q«Ü§C¡A¿@«×¤j¬ù¬O¥ÀÅé¦å²M¿@«×ªº 1%¦Ü 10%¤§¶¡¡C ®Ú¾Ú¤åÄm©MÁ{§É¸gÅç¡A­Y­n­÷¨Å¡A»Ý¦Ò¼{¥»«~ÃÄª«¦w¥þ©Ê¡A¯S§O¬O¦å²G¬ÛÃöªº¯e¯f¡C µM¦Ó¡AÃh¥¥´Á¶¡¼ÉÅS©ó sodium valproate ªº¥®¨à¡A¥i¯à­°§C»y¨¥¯à¤O¡A«ØÄ³ªvÀø®É¤£­n±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õÀ³¾ã¿õ§]ªA¡A¤£¥i«r¸H¡C°|¤º³Æ¦³¦P¦¨¥÷ÃÄ¤ôDepakin solution¥i¨ÑµLªk§]ªA¯f±w¨Ï¥Î¡C
ODIZ5,Diazepam,Diazepam 5mg(VALIUM 5mg),CNEU,,Anxiety¡A acute alcohol withdrawal¡A anticonvulsant.,,,Adult: Antianxiety: 2-10 mg bid-qid. Sedative-hypnotic (acute alcohol withdrawal): 10 mg tid-qid during the first 24 hrs¡A then 5 mg tid-qid as needed. Anticonvulsant and skeletal muscle relaxant: 2-10 mg bid-qid. Child 6 months of age and over: 0.04-0.2 mg/kg tid-qid.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OELT,Levothyroxine,Eltroxin 50mcg,META,Hypothyroidism.,Hypersensitivity to the active substance or to any of the excipients. Thyrotoxicosis. Acute myocardial infarction¡A Acute myocarditis¡A Acute pancarditis.,Following excessive dosage: Anginal pain¡A cardiac arrhythmias¡A palpitation & cramps in skeletal muscle¡A tachycardia¡A diarrhoea¡A vomiting¡A tremors¡A restlessness¡A excitability¡A insomnia¡A headache¡A flushing¡A sweating¡A excessive weight loss & muscular weakness,¤Å¶W¹L«Ç·Å25¢J,Adult Initially 50-100 mcg daily¡A adjusted 4-6 weekly by 50 mcg until normal metabolism is maintained. This may require doses of 100-200 mcg daily. Adult >50 years <50 mcg/day¡A with cardiac disease 25 mcg/day or 50 mcg on alternate days¡A may be increased by 25 mcg at intervals of 4 week. Congenital hypothyroidism Infant Initially 25 mcg¡A increase by 25 mcg 2-4 weekly until mild toxic symptoms appear. Juvenile myxoedema Children >1 year 2.5-5 mcg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¤w¦³³\¦hªº¥¥°ü¤Î¥¿­È¥Í¨|¦~ÄÖªº°ü¤kªA¥Î¹LELTROXIN¡F¨ì¥Ø«e¬°¤î¡A¦bÃh¥¥¥Í²£¹Lµ{¤¤¨Ã¥¼µo²{¥ô¦ó©ú½T§Î¦¡ªº¤zÂZ¡CµM¦Ó¡A¥À¿Ë¥Òª¬¸¢¾÷¯à§C¸¨©Î¤®¶i¡A¥i¯à¹ï­L¨à¥X¥Í©Î°·±d¦³¤£§Qªº¼vÅT¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¤Àªc¨ì¨Å¥Äªº¥Òª¬¸¢¯À(levothyroxine)¿@«×«Ü§C¡A¦ý¨¬¥H¤zÂZ·s¥Í¨à¥Òª¬¸¢¾÷¯à¤£¨¬¯gªº¿zÀË¡C,AC;PO;,,,,,
OFLUN,Flunarizine,Flunazon 5mg,CAVS,,¾AÀ³¯g: Migraine prophylaxis; Prophylaxis of peripheral and cerebrovascular disorders; Prophylaxis of vertigo and vestibular disorders. °Æ§@¥Î: Drowsiness. Rarely wt gain¡A headache¡A depression¡A gastric pain¡A dry mouth¡A insomnia¡A extrapyramidal reactions¡A galactorrhoea. ¸T§Ò: Pregnancy¡A lactation¡A GI or urinary tract obstruction¡A acute porphyrias.,,«Ç·Å,5-10 mg/day at bedtime.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IANEG,Metronidazole,Anegyn inj 500mg/100mL,QANB,,¾AÀ³¯g: Infections with anaerobic causative agents. Infections of the GIT¡A after colon surgery¡A in peritonitis¡A purulent diseases of the pelvic cavity¡A infections of the female genital tract as well as puerperal fever. °Æ§@¥Î: GI disturbances¡A somnolence¡A vertigo¡A headache¡A ataxia¡A darkening of urine¡A itch¡A cutaneous eruption¡A peripheral neuropathy. Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction ¸T§Ò: Hypersensitivity. Blood dyscrasias.,,«Ç·Å,Anaerobic infections: Max. 1 g/dose¡A 4 g/day. Oral: 7.5 mg/kg q6h for 7 days or longer. IV infusion only (over 1 hr): 15 mg/kg as a loading dose¡A then 7.5 mg/kg q6h for 7 days or longer. Amebiasis: oral: Adult: 500-750 mg tid for 10 days. Child: 11.6-16.7 mg/kg tid for 10 days. Trichomoniasis: oral: Adult: 2 g as a single dose; 1 g bid for 1 day; or 250mg tid for 7 days. Child: 5 mg/kg tid for 7 days. Giardiasis: Adult: 2 g qd x 3 days or 250-500 mg tid x 5-7 days. Child: 5 mg/kg tid x 5 days.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡Aª`·N¤ß´¼»P¯«¸g¥\¯àÅÜ¤Æ¡C 2. Àøµ{«ØÄ³¤£¶W¹L10¤Ñ¡C
EDUAC,Clindamycin + Benzoyl Peroxide,Duac gel 6gm,TDER,,¾AÀ³¯g: Topical treatment of inflammatory acne vulgaris. °Æ§@¥Î: Stinging¡A burning or redness¡A peeling. Dermatologic: Dry skin (12% ) ¸T§Ò: Patients suffering or with history of regional enteritis¡A ulcerative colitis or antibiotic-associated colitis.,,2-8¢J,Apply once daily in the evening to the affected areas.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ENAS,Mometasone,Nasonex 50mcg/dose¡A 140dose nasal spray,TENT,Treatment of seasonal or perennial rhinitis & associated symptoms in adults¡A adolescents & children > 3 years. Treatment of mild to severe nasal polyps & associated symptoms in adults > 18 years.,Hypersensitivity to any ingredients of Nasonex,Headache¡A epistaxis¡A pharyngitis¡A nasal burning¡A nasal irritation & nasal ulceration.,25¢J¥H¤UÁ×¶}¼ö·½,Allergic rhinitis¡A Seasonal and perennial adult¡A 2 sprays/nostril (50 mcg/spray) once daily (total daily dose¡A 200 mcg) maximum 4 sprays/nostril (50 mcg/spray) once daily (total daily dose¡A 400 mcg) 2 to 11 Years: Usual dosage: 1 spray (50 mcg/spray) in each nostril once daily (total daily dose¡A 100 mcg Polyp of the nasal cavity and/or nasal sinus Age >18 Years : 2 sprays/nostril (50 mcg/spray) twice daily (total daily dose¡A 400 mcg); some patients may respond to 2 sprays/nostril once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IN;,,,,,
ESIN,Sulfamethoxazole,Sinomin oph soln 4%¡A 15mL,TOPH,,¾AÀ³¯g: Trachoma or inclusion conjunctivitis. °Æ§@¥Î: Conjunctival or corneal scarring may occur.,,«Ç·Å,1-2 drop once-tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ITAX1,Docetaxel,Taxotere inj 1mg(²Õ®M¥Î),RACA,,,,,,,,,,,,,,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tPVC¶ì½¦§÷½è¡Cµ¹ÃÄ®ÉÀ³¨Ï¥Î polyethylene §÷½èªº¿é²G®M¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.3 - 0.74 mg/mL¡A«Ç·Å¦w©w©Êºû«ù 4 ¤p®É¡C¨Ï¥Î«eÀ³¦A¦¸¥ØµøÀË¬d¬O§_¦³µ²´¹ªR¥X¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C 5. ºÊ´úCBC¡B¨x¥\¯à¡C
IPH1,Epirubicin,Pharmorubicin inj 1mg(²Õ®M¥Î),RACA,,,,,,,,,,,,,,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C
IFORM1,Paclitaxel,Formoxol Inj 1mg(²Õ®M¥Î),RACA,,,,,,,,,,,,,,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tDEHPªºPVC¶ì½¦§÷½è¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.3 - 1.2 mg/mL¡A«Ç·Å¤U¦w©w©Êºû«ù 27¤p®É¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C¿éª`¶}©lªº²Ä¤@­Ó¤p®ÉÀ³ºÊ´úVital Sign¡C 5. ´¿¨Ï¥Î Paclitaxelµo¥Í¤ßÅ¦¶Ç¾É²§±`ªº¯f¤H¡A¤§«á¨Ï¥ÎPaclitaxel´Á¶¡À³¶i¦æ³sÄò¤ß¹q¹ÏºÊ´ú¡C 6. ºÊ´úCBC¡C
IBCO,Vitamin B Complex,B-complex°w¾¯1mL (Combeplex),NUTR,,¾AÀ³¯g: Vit B-complex deficiency. °Æ§@¥Î:Nausea¡A vomiting¡A abdominal cramps¡A pruritus¡A flushing¡A sensation of heat¡A faintness¡A pounding in the head,,«Ç·Å,1 mL as a single dose. Max dose: 1-2 mL daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IV;IVD;SC;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,
IBLE5,Bleomycin,Bleocin inj 5mg,RACA,,¾AÀ³¯g:Carcinoma of the skin¡A head & neck¡A lung¡A oesophagus¡A uterine cervix & thyroid¡A malignant lymphomas¡A glioma. °Æ§@¥Î:Severe interstitial pneumonia & pulmonary fibrosis¡A hypersensitivity¡A fever¡A haemorrhage¡A scleroderma-like changes in skin¡A anorexia¡A diarrhea¡A GI upsets; renal¡A urinary & neuropsychic disturbances¡A hypertrophy of venous wall¡A narrowing of venous lumen & induration around administration site. Phlebalgia with IV administration. Dermatologic: Alopecia (1-10%)¡A Skin reaction - finding¡A Erythema¡A rash¡A striae¡A vesiculation¡A hyperpigmentation¡A skin tenderness (50%) Endocrine metabolic: Shivering Gastrointestinal: Nausea and vomiting¡A Stomatitis Psychiatric: Confusion Other: Fever ¸T§Ò:Severe pulmonary¡A renal or cardiac dysfunction. Hypersensitivity to bleomycin or any component of the formulation.,,,15-30 mg IM or IV 2 times/wk. May be given once a day for consecutive days or once a weeks.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¡C,,,1. ¤Å¨Ï¥ÎD5W©Î¨ä¥L§t¦³dextroseªºµ}ÄÀ²G¡C 2. IM¡BSQµ¹ÃÄ¡G15 mg·»©ó1 mL¨ì 5 mLªºNS©Îª`®g¥Î¤ô¡C 3. IV µ¹ÃÄ¡G15 mg·»©ó 5 mLªºNS¡A½wºCÀR¯ßª`®g¶W¹L10¤ÀÄÁ¡C 4. Intrapleuralµ¹ÃÄ¡G·»©ó50 ¨ì100 mL ªºNS ¡A¸g¥Ñthoracostomy tube§ëÃÄ¡C 5. ºÊ´ú¶µ¥Ø¡GPulmonary function tests (total lung volume¡A forced vital capacity¡A carbon monoxide diffusion)¡A renal function¡A liver function¡A chest x-ray¡A temperature initially; check body weight at regular intervals
IDIA,Diazepam,Diazepam(Dianlin) °w¾¯ 10mg/2mL,CNEU,,¾AÀ³¯g: Insomnia¡A anxiety¡A muscle spasm¡A status epilepticus. °Æ§@¥Î: Drowsiness & lightheadedness; confusion & ataxia; amnesia; dependence; paradoxical increase in aggression; muscle weakness; headache¡A vertigo¡A hypotension¡A salivation changes¡A GI disturbances¡A visual disturbances¡A dysarthria¡A tremor¡A changes in libido¡A incontinence¡A urinary retention; thrombophlebitis. Cardiovascular: Hypotension Dermatologic: Rash (3%¡A rectal gel ) Gastrointestinal: Diarrhea (4%¡A rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia¡A Incoordination (3%¡A rectal gel )¡A Somnolence Psychiatric: Euphoria (3%¡A rectal gel ) Respiratory: Respiratory depression Other: Fatigue ¸T§Ò: Respiratory depression; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment.,,«Ç·Å,Adult Acute anxiety 2-5 mg IV¡A repeated if necessary after 4 hr. The dosage may be increased to 5-10 mg in severe anxiety. Management of agitation associated with acute alcohol withdrawal Initially 10 mg IV¡A repeated if necessary after>= 4 hr. Pre-op sedation 10 mg IV 1-2 hr before surgery. Facilitation of labour 10-20 mg IM (or IV in extreme excitation) when cervix dilation is 2-5 cm. Painful musculoskeletal conditions & spasticity Initially 5-10 mg IV¡A repeated after 3-4 hr if necessary. Tetanus Up to 20 mg every 2-8 hr parenterally. Status epilepticus Initially 10-20 mg IV¡A in the following hr: 20 mg IM or by IV drip infusion,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;IV;IVD;,,,,,1. IM: inject deeply into muscle mass. 2. IV: inject slowly; do not administer faster than 5 mg/min. Do not use small veins for injection; if direct injection is not feasible¡A may inject through infusion tubing as close as possible to the vein insertion. 3. Do not mix or dilute with other solutions or drugs in syringe or infusion flask.
IFEN,Fentanyl,Fentanyl inj 0.5mg/10mL,CNEU,,¾AÀ³¯g: Premed prior to surgery¡A Adjunct to general anesth induction¡A Adjunct to regional anesth¡A Post-operatively . °Æ§@¥Î: Respiratory depression¡A apnoea¡A muscle rigidity & bradycardia. ¸T§Ò: Children <2 years¡A bronchial asthma¡A respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,,25¢J¥H¤UÁ×¥ú,Premed 50-100 mcg IM 30-60 mins prior to surgery. Adjunct to general anesth induction 50-100 mcg IV & repeated at 2-3 mins intervals until the desired effect is achieved. Adjunct to regional anesth 50-100 mcg IM or slow IV inj. Post-operatively 50-100 mcg IM repeated in 1-2 hr as needed. Induction & maintenance of anaesth Children 2-12 years 20-30 mcg/10 kg body wt.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IHAV7,Inactivated Hepatitis A Virus Vaccine,Havrix 720 (¤p¨àA¨x¬Ì­]) 0.5mL/dose,HIMM,Active immunisation against infections caused by hepatitis A virus.,Hypersensitivity.,Inj site soreness¡A mild redness & swelling¡A headache¡A malaise¡A vomiting¡A fever¡A nausea & loss of appetite.,2-8¢J,Children & adolescents 1-18 years Primary immunisation: A single IM dose. A booster dose at any time between 6 & 12 months after the single dose is recommended in order to ensure long-term protection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡Aµ´¹ï»Ý­n®É¤~µ¹¤©¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡Aµ´¹ï»Ý­n®É¤~µ¹¤©¡C,IM;,,,,,1. ¦Ù¦×ª`®g©ó¦¨¤H©Î«Äµ£ªº¤T¨¤¦Ù³¡¦ì¡AÀ¦¨à«hÀ³ª`®g©ó¤j»L«e°¼³¡¦ì¡C
IINT7,Eptifibatide,Integrilin inj 75mg/100mL,HEMT,,¾AÀ³¯g: Unstable angina¡A Angioplasty °Æ§@¥Î: Bleeding¡A hypotension; localised Inj site reaction; thrombocytopaenia; back pain; anaphylaxis; GI¡A intracranial or pulmonary haemorrhage. Cardiovascular: Hypotension Hematologic: Bleeding¡A Minor (3 -12%) ¸T§Ò: Active bleeding¡A increased risk of haemorrhage including hemorrhagic disorders¡A cerebrovascular disorders¡A history of stroke¡A uncontrolled hypertension¡A severe trauma¡A severe renal impairment¡A recent major surgery. Lactation.,,2-8 ¢XC,IV Unstable angina 180 mcg/kg followed by 2 mcg/kg/min for up to 72 hr. If percutaneous coronary procedure is performed during therapy¡A continue infusion for 18-24 hr after procedure¡A up to a max total of 96 hr. Angioplasty Initial: 180 mcg/kg immediately pre-op¡A followed by 2 mcg/kg/min. A 2nd dose of 180 mcg/kg should be given 10 mins later. Continue infusion until discharge or up to 18-24 hr. Min treatment duration: 12 hr.,,,,¥i¯à¦w¥þ,,,Hold Breast Feeding ¼È°±­÷¨Å,,,,,,,
IIRI,Irinotecan,Irino IV infusion 100mg/5mL,RACA,Refractory colorectal malignancies ¡A 1st line treatment of metastatic colorectal cancer,Known hypersensitivity to irinotecan or any component of the formulation. Coadministraton with azole antifungals (ketoconazole¡A fluconazole¡A itraconazole); patients with hereditary fructose intolerance,Neutropenia¡A anemia¡A thrombocytopenia; acute diarrhoea¡A sweating¡A hypersalivation¡A abdominal cramps¡A lachrymation¡A miosis¡A weakness; nausea¡A vomiting¡A alopecia and skin reactions; cardiovascular toxicity. Potentially Fatal: Fatal sepsis due to myelosuppression; severe¡A chronic diarrhoea,25¢J¥H¤UÁ×¥ú,Monotherapy (for previously treated patient): [Colorectal cancer¡A metastatic] 350 mg/m2 as a single agent infused over 90 minutes once every 3 weeks. [Gastric cancer¡A metastatic or locally advanced] 150 mg/m2 as a single agent infused over 30-90 minutes on days 1 and 15 of a 4-week treatment cycle. Combination therapy (for treatment naive patients):180 mg/m2 over 90 minutes on days 1¡A 15¡A and 29 in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin).,»Ý½Õ¾ã¾¯¶q,Bilirubin >ULN to ?2 mg/dL: Consider reducing initial dose by one dose level Bilirubin >2 mg/dL: Use is not recommended,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.12 - 2.8 mg/mL¡A«Ç·Å¦w©w©Êºû«ù 12 ¤p®É¡C 3. ºÊ´úCBC¡B¨x¥\¯à¡C 4. ª`·N¯f¤H¥i¯à¥X²{¸¡ÂmªºÃÄª«°Æ§@¥Î¡A¤×¨ä¬O65·³¥H¤Wªº¦Ñ¦~¤H¡C ­Y¯f¤Hª`®gIrinotecan«áµo¥Í©µ¿ð©Ê¸¡Âm¡AÀ³ºÉ§ÖÁpµ¸Âå®v¡Aµ¹¤©¾A·íªvÀø¡C
IFLU1,5-Fluorouracil,Fluorouracil inj 1000mg/20mL,RACA,,¾AÀ³¯g: Palliative management of carcinoma of the colon¡A rectum¡A breast¡A stomach & pancreas. °Æ§@¥Î: Stomatitis¡A esophagopharyngitis¡A diarrhea¡A anorexia¡A nausea¡A vomiting¡A enteritis¡A cramps¡A abdominal pain & ulceration¡A glossitis¡A pharyngitis¡A leukopenia¡A alopecia¡A dermatitis¡A ocular irritation¡A central neurotoxicity (acute cerebellar syndrome)¡A myocardial ischemia & angina. ¸T§Ò: Patients in a poor nutritional state; with depressed bone marrow function or potentially serious infections.,,«Ç·Å,IV inj Initial dosage 12 mg/kg once daily (to a max of 800 mg daily) for 4 days. If no toxicity is observed¡A this may be followed by 6 mg/kg on the 6th¡A 8th¡A 10th & 12th days¡A unless toxicity occurs. Poor risk patients or those in a poor nutritional state 6 mg/kg/day (to a max of 400 mg daily) for 3 days. If no toxicity is observed¡A 3 mg/kg is given on the 5th¡A 7th & 9th days¡A unless toxicity occurs. Maintenance therapy Repeat the dosage of the 1st course every 30 days after the last day of the previous course of treatment. Alternatively¡A administer a maintenance dose of 10-15 mg/kg/week (to a max of 1 g/week) as a single dose. IV infusion 15 mg/kg/day (to a max of 1 g daily) being infused in 500 mL of 5% dextrose or 0.9% NaCl over 4 hours & repeated on successive days until toxicity occurs or a total of 12-15 g has been given. Continuous infusion may also be used. The course may be repeated after 4-6 weeks.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¦å¿}ÅÜ¤Æ (DM¯f¤H)¡C
IKYT1,Granisetron,Kytron inj 1mg/1mL,CNEU,,¾AÀ³¯g: Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation. °Æ§@¥Î: Headache¡A constipation. Gastrointestinal: Constipation (5.4% ) ¸T§Ò: Hypersensitivity to granisetron or related substances.,,,Prevention & treatment of nausea & vomiting due to cytostatic therapy & radiation Adult 3 mg either in 15 mL infusion fluid as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid & administered over 5 mins. Max dose over 24 hr: 9 mg. Children 10-40 mcg/kg body weight (up to 3 mg) diluted in 10-30 mL infusion fluid & administered over 5 mins. Max dose: 1 additional dose of 40 mcg/kg (up to 3 mg) within 24 hr if necessary. Max: 9 mg/day. For prevention¡A administration should be completed prior to the start of cytostatic therapy and anesth induction.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö 30¬í,,
OPOLU,Propylthiouracil,Polupi 50mg (PTU),META,Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy; treatment of hyperthyroidism in patients intolerant of methimazole and not candidates for surgical/radiotherapy,Hypersensitivity to propylthiouracil or any component of the formulation,Cardiovascular: Periarteritis¡A vasculitis (ANCA-positive¡A cutaneous¡A leukocytoclastic) Central nervous system: Drowsiness¡A drug fever¡A fever¡A headache¡A neuritis¡A vertigo Dermatologic: Alopecia¡A erythema nodosum¡A exfoliative dermatitis¡A pruritus¡A skin pigmentation¡A skin rash¡A skin ulcers¡A urticaria Endocrine & metabolic: Goiter¡A weight gain Gastrointestinal: Constipation¡A loss of taste¡A nausea¡A sialoadenopathy¡A splenomegaly¡A stomach pain¡A taste perversion¡A vomiting Hematologic: Agranulocytosis¡A aplastic anemia¡A bleeding¡A granulopenia¡A hypoprothrombinemia¡A leukopenia¡A thrombocytopenia Hepatic: Acute liver failure¡A cholestatic jaundice¡A hepatitis Neuromuscular & skeletal: Arthralgia¡A myalgia¡A paresthesia Renal: Acute renal failure¡A glomerulonephritis¡A nephritis Respiratory: Alveolar hemorrhage¡A interstitial pneumonitis Miscellaneous: Lymphadenopathy¡A SLE-like syndrome,25¢J¥H¤UÁ×¥ú,Adult initial 300 mg/day in 3-4 divided doses (severe condition 400-600 mg/day)¡A maintenance dose 50-100 mg/day. Children 10-14 years 200-300 mg/day¡A 5-9 years 100- 200 mg/day in 2-4 divided doses¡A maintenance dose 50-100 mg/day in 1-2 divided doses. Pregnancy initial 150-300 mg/day in 3-4 divided doses¡A maintenance dose 50-100 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCTC1,Levonorgestrel+Ethinyl Estradiol 0.15/0.03mg,®a­p1¸¹¤fªAÁ×¥¥ÃÄ(28's),HM,,¾AÀ³¯g: Oral Contraceptives °Æ§@¥Î: Breast tenderness¡A pain¡A secretion; headache; migraine; changes in libido; depressive moods; contact lens intolerance; nausea; vomiting; changes in vaginal secretion; various skin disorders; fluid retention; change in body weight; hypersensitivity reaction. Rarely¡A benign or malignant liver tumors which may lead to life-threatening intra-abdominal hemorrhage have been observed. ¸T§Ò: Venous or arterial thromboembolic events including MI & CVA. Prodromi of thrombosis (transient ischemic attack¡A angina pectoris)¡A diabetes mellitus with vascular involvement. Severe or multiple risk factors for venous or arterial thrombosis. Severe hepatic disease¡A benign or malignant liver tumours. Malignant conditions of the genital organs or breasts¡A if sex steroid-influenced. Undiagnosed vag bleeding. Pregnancy.,,«Ç·Å,1 tab daily for 28 consecutive days. Levonorgestrel 0.15mg + Ethinyl estradiol 0.03mg x 21 Áû¡B¤£§tÃÄ x 7¿õ (¨Ì¥]¸Ë¶¶§Ç¨C¤éªA¥Î1Áû),,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EBAAG,Boric Acid + Alcohol Glycerin,BAAG soln 20mL,TENT,,¾AÀ³¯g: Chronic otitis media¡A mastoidectomy.,,«Ç·Å,Apply topically as directed.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EPRE1,Conjugated Estrogen,Premarin Vaginal Cream 14gm,SGU,Atrophic vaginitis. Post-menopausal atrophic urethritis.,Known or suspected breast cancer¡A estrogen-dependent neoplasia¡A active thromboembolic disease¡A undiagnosed abnormal genital bleeding. Pregnancy.,Rarely nausea¡A vomiting. Breakthrough bleeding¡A spotting¡A change in menstrual flow¡A amenorrhea. Breast tenderness¡A enlargement¡A secretion. GI effects¡A cholestatic jaundice. Chloasma or melasma. Steepening of the corneal curvature; intolerance to contact lenses. Headache¡A migraine¡A dizziness; chorea. Wt changes; edema; changes in libido. Cardiovascular: Edema¡A Vasodilatation (vaginal cream¡A 21 days on/7 off regimen¡A 3.5%; 2 times/wk regimen¡A 5% ) Dermatologic: Chloasma¡A Hirsutism¡A Injection site reaction¡A Pruritus (5% ) Endocrine metabolic: Weight change finding Gastrointestinal: Abdominal pain (vaginal cream¡A 21 days on/7 off regimen¡A 7.7%; 2 times/wk regimen¡A 6.4% )¡A Bloating symptom¡A Diarrhea (vaginal cream¡A 21 days on/7 off regimen¡A 2.8%; 2 times/wk regimen¡A 7.1% )¡A Flatulence (7% )¡A Nausea (oral¡A 9% ; vaginal cream¡A 21 days on/7 off regimen¡A 3.5%; 2 times/wk regimen¡A 2.1% )¡A Stomach cramps¡A Vomiting Musculoskeletal: Backache (vaginal cream¡A 21 days on/7 off regimen¡A 4.9%; 2 times/wk regimen¡A 9.3% )¡A Leg cramp Neurologic: Asthenia (vaginal cream¡A 21 days on/7 off regimen¡A 5.6%; 2 times/wk regimen¡A 1.4% )¡A Headache (vaginal cream¡A 21 days on/7 off regimen¡A 11.2%; 2 times/wk regimen¡A 17.9% )¡A Migraine Psychiatric: Depression¡A Disturbance in mood Reproductive: Disorder of menstruation¡A Pain of breast (oral¡A 12% ; vaginal cream¡A 21 days on/7 off regimen¡A 5.6%; 2 times/wk regimen¡A 2.9% )¡A Swelling of breast¡A Vaginitis (vaginal cream¡A 21 days on/7 off regimen¡A 5.6%; 2 times/wk regimen¡A 5% )¡A Withdrawal bleeding Respiratory: Increasing frequency of cough (vaginal cream¡A 21 days on/7 off regimen¡A 0%; 2 times/wk regimen¡A 5% )¡A Pharyngitis (vaginal cream¡A 21 days on/7 off regimen¡A 2.1%; 2 times/wk regimen¡A 5% ) Other: Accidental injury (vaginal cream¡A 21 days on/7 off regimen¡A 2.8%; 2 times/wk regimen¡A 6.4% )¡A Disorder of skin appendage (vaginal cream¡A 21 days on/7 off regimen¡A 8.4%; 2 times/wk regimen¡A 11.4% )¡A Infectious disease (vaginal cream¡A 21 days on/7 off regimen¡A 4.9%; 2 times/wk regimen¡A 11.4% )¡A Pain (vaginal cream¡A 21 days on/7 off regimen¡A 7%; 2 times/wk regimen¡A 2.9% ),20 -25¢J,Intravaginally or topically¡A 0.5-2 g daily depending on severity of condition. the maximum dose: 4 g/day. Cyclic administration (3 weeks on and 1 week off) should be used.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;VAG;,,,,,
EBUT,Butorphanol,Butaro Nasal Spray 10mg/mL,CNEU,Management of pain when the use of an opioid analgesic is appropriate.,Hypersensitivity to Butorphanol¡A benzenthonium chloride¡A or any component of the formulation.,Common: Nausea/vomiting¡A Dizziness (19-54%)¡A Insomnia (11%)¡A Sedated (30-40%)¡A Somnolence (43-88%)¡A Nasal congestion¡A Long-term use of intranasal product (13%) Serious: Respiratory depression,25¢J¥H¤UÀx¦s,Initially 1 mg (1 spray in 1 nostril); if adequate pain relief is not achieved within 60-90 mins¡A an additional 1 mg dose may be given; may repeat initial dose sequence in 3-4 hr as required after the 2nd dose of the sequence. Alternatively¡A an initial dose of 2 mg (1 spray in each nostril) may be used in patients who will be able to remain recumbent in the event drowsiness or dizziness occurs; additional 2 mg doses should not be given for 3-4 hr.,»Ý½Õ¾ã¾¯¶q,Nasal spray: Initial: One spray (1 mg per spray) in 1 nostril; a second dose may be given after 90 to 120 minutes if needed. Repeated dosing must be based on initial response rather than fixed intervals¡A but generally should be at least 6 hours apart.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ] ¦b¦Ñ¹«¤Î¨ß¤lªº¾¹©x¥Í¦¨´Á¥Í´Þ¹êÅçÅã¥Ü¡Abutorphanol¨ÃµL­P·î­Lªº¥i¯à©Ê¡CµM¦Ó¡A¹ïÃh¥¥¤j¹«¬I¤©¥Ö¤Uª`®g1mg/kg(5.9 mg/m2) butorphanol·|³y¦¨¸û°ªªº¦º²£²v¡C¸g¤fµ¹»P30mg/kg(360 mg/m2)¤Î60mg/kg(720 mg/m2)ªºbutorphanol·|¨Ï±o¨ß¤l¦³¸û°ªªºµÛ§É«á·l¶Ë²v¡C ¥Ø«e¹ï©óbutorphanol tartrate ¨Ï¥Î©óÃh¥¥37©P«eªº°ü¤k¨ÃµL©ú½Tªº¬ã¨s¡C ¦]¦¹°ß¦³·í¥ÎÃÄ¦n³B¦h©ó·s¥Í¨à¥i¯àµo¥Í¤§¼ç¦b­·ÀI¤§®É¤~¥i¬I¤©¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¨Ï¥Îbutorphanol tartrate«á¦b¥À¨Å¤¤¥iÀË´ú¥Xbutorphanol¡C·s¥Í¨à©Ò±µ¨üªº¶q¦bÁ{§É¤W¨Ã¤£ÅãµÛ (±À´ú¬°4£gg/L milk¡A¨ä¥À¿Ë±µ¨ü¦Ù¦×ª`®g2mg¡A¤@¤é¥|¦¸)¡C ÁöµM¨S¦³Ãö©ó­÷¨Å¥À¿Ë¨Ï¥Îbutorphanol NSªºÁ{§É³ø§i¡A¦ý¬O¥i¹w´úªº¬O¡AbutorphanolÀ³·|¥Hªñ¥G¬Û¦Pªº¶q±Æ¦Ü¥À¨Å¤¤¡C,IN;,,,,,
OURI,Silodosin,Urief 4mg,SGU,,¾AÀ³¯g:Treatment of signs and symptoms of benign prostatic hyperplasia (BPH). °Æ§@¥Î:Drowsiness¡A postural hypotension¡A syncope¡A asthenia¡A depression¡A headache¡A dry mouth¡A GI disturbances¡A edema¡A blurred vision¡A rhinitis¡A erectile disorders¡A tachycardia¡A palpitation¡A hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy. ¸T§Ò:Severe hepatic impairment; severe renal insufficiency.,,«Ç·Å,Oral: 4 mg bid after meal.,»Ý½Õ¾ã¾¯¶q,Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary. Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied).,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
YEUR,Silicone Gel,Eurogel Plus 20gm,TDER,,,,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;SKIN;TOPI;,,,,,
EBIA5,Povidone-iodine,Povidone-iodine soln 500mL,TDER,,¾AÀ³¯g: Post-op infections¡A bacterial or fungal skin infections. surgical scrub Antiseptic cleanser for pre-op scrubbing & washing by surgeons & theatre staff¡A & pre-op preparation of patients' skin. °Æ§@¥Î: Local irritation (discontinue).,,«Ç·Å,Aqueous soln As directed. Surgical disinfection Use 5 mL undiluted & allow to work for 5 mins¡A rinse off & repeat. Pre-op antiseptic skin cleanser Use undiluted.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OTRAD,Labetalol,Trandate 200mg,CAVS,Mild to severe hypertension¡A hypertension in pregnancy¡A angina pectoris with coexisting hypertension.,2nd or 3rd degree heart block¡A cardiogenic shock¡A severe and prolonged hypotension or severe bradycardia. Hypertensive episodes after acute MI when peripheral vasoconstriction suggests low cardiac output.,Pronounced postural hypotension¡A nasal congestion. Rarely hypersensitivity¡A rash¡A pruritus¡A angioedema and dyspnea; raised liver function tests¡A jaundice¡A hepatitis and hepatitis necrosis; bradycardia¡A heart block. Cardiovascular: Orthostatic hypotension (1%¡A oral ; 58%¡A IV ) Dermatologic: Has tingling sensation (7% .) Gastrointestinal: Nausea (14% ) Neurologic: Dizziness (9% to 20% ) Respiratory: Nasal congestion (3% ) Other: Fatigue (11% ),30¢J¥H¤U,Hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently in every 2-14 days. Maximum: 800 mg/day in 2 divided doses. Patients with severe hypertension may require 2400 mg/day¡A in 3-4 divided doses. Gestational hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently in 1-week interval. Total daily dose may be divided to 3 doses for patient with severe hypertension. Maximum: 2400mg/day.,»Ý½Õ¾ã¾¯¶q,Average required dose is 50% of usual dosing,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IADE,Adenosine,Adenocor inj 6mg/2mL,CAVS,Treatment of paroxysmal supraventricular tachycardias. Diagnostic in narrow & broad-complex tachycardias,2nd or 3rd degree AV block (except in patients with a functioning artificial pacemaker). Sick sinus syndrome (except in patients with a functioning artificial pacemaker). Asthma.,Common: Chest discomfort (40%)¡A Flushing (18-44%)¡A Abdominal discomfort (13%)¡A Pain of head and neck region (15%)¡A Dizziness (1-12%)¡A Headache (2-18%)¡A Dyspnea (12-28%) Serious: Cardiac arrest¡A Cardiac dysrhythmia (1%)¡A Complete atrioventricular block (less than 1%)¡A Heart failure¡A Ventricular arrhythmia (less than 1%)¡A Ventricular tachycardia¡A Bronchospasm¡A In asthmatics,¤£­n§NÂÃ,Paroxysmal supraventricular tachycardia: IV (rapid¡A over 1 to 2 seconds¡A via peripheral line): Initial: 6 mg; if not effective within 1 to 2 minutes¡A 12 mg may be given; may repeat 12 mg bolus if needed (maximum single dose: 12 mg). Follow each dose with 20 mL N/S flush.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVP;IVPUSH;,,,§Ö³tÀR¯ßª`®g (over 1 to 2 seconds)¡C,,1.¥»ÃÄ«~¹ï¦~ªøªÌ¸û¨ã·P¨ü©Ê¡C
IANE,Flumazenil,Anexate inj 0.5mg/5mL,ZADT,Reversal of centrally sedative effects of benzodiazepines,Patients with known hypersensitivity to flumazenil.,During anaesth¡A flushing & GI upsets occur rarely. After rapid inj¡A anxiety¡A palpitation¡A fear (occasionally).,30¢J¥H¤U,Initial dose: 0.2 mg over 15 seconds. Repeat doses: If the desired level of consciousness is not obtained¡A 0.1 mg may be repeated at 1-minute intervals. Maximum total cumulative dose: 1 mg (usual total dose: 0.3-0.6 mg). Loss of Consciousness in intensive care units: 0.3 mg initially; repeat doses at 1-minute intervals¡A if the desired level of consciousness is not obtained. Maximum total cumulative dose: 2 mg.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³¤p¤ß½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,IV over 15~30 seconds,0.1-0.4 mg/hr IV infusion,
EACR,Ethacridine,Acrinol soln 450mL,TDER,,,,,,,,,,,,,,,,,,,
IENC,Acetylcysteine,Encore inj 300mg/3mL,ZADT,Acute & chronic affections of the respiratory tract with abundant mucous secretions in bronchitis¡A emphysema & bronchiectasis¡A prophylaxis & treatment of bronchopulmonary complications with mucostasis¡A bronchial catarrh¡A acetaminophen overdose.,Hypersensitivity to any component of the formulation.,Common: Pruritus (1-3%)¡A Rash (4-5%)¡A Urticaria¡A Diarrhea¡A Nausea (2-7%)¡A Vomiting (9-12%) Serious: Decreased cardiac function¡A Electrocardiogram abnormal¡A Hypervolemia¡A Hypersensitivity reaction (Adult¡A 8-18%; pediatric¡A 10%)¡A Non-allergic anaphylaxis (0.1-0.2%)¡A Status epilepticus¡A Bronchospasm¡A Respiratory distress,«Ç·ÅÁ×¥ú«O¦s,Adult: 300 mg deep IM 1-2 times daily; children: give half of the adult dose. Acetaminophen overdose: 21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg. Loading dose: 150 mg/kg infused over 15 minutes. Second dose: 50 mg/kg infused over 4 hours. Third dose: 100 mg/kg infused over 16 hours. For inhalation (nebulization)¡A 1 ampoule 1-2 times daily for 5-10 days. For intratracheal instillation¡A 1 ampoule 1-2 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;IM;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C,,«ØÄ³¥H>60¤ÀÄÁ½wºCºwª`,1. IV¥Î©óAcetaminophen¹L¶qªº¦¨¤H¾¯¶q¡G loading dose¡A 150 mg/kg in 200 mL of compatible solution IV over 60 minutes¡A then 50 mg/kg in 500 mL of solution IV over 4 hours¡A followed by 100 mg/kg in 1000 mL of solution IV over 16 hours.
IEND,Cyclophosphamide,Endoxan Asta inj 200mg,RACA,Treatment of acute lymphoblastic leukemia (ALL)¡A acute myelocytic leukemia (AML)¡A breast cancer¡A chronic lymphocytic leukemia (CLL)¡A chronic myeloid leukemia (CML)¡A Hodgkin lymphoma¡A mycosis fungoides¡A multiple myeloma¡A neuroblastoma¡A non-Hodgkin lymphomas (including Burkitt lymphoma)¡A ovarian adenocarcinoma¡A retinoblastoma¡A and nephrotic syndrome.,Hypersensitivity to cyclophosphamide or its metabolites¡A urinary outflow obstructions¡A severe myelosuppression¡A severe renal or hepatic impairment¡A active infection (especially varicella zoster)¡A severe immunosuppression.,GI upsets; alopecia; reticulo-endothelial system depression; hematuria; reversible amenorrhea & azoospermia; myocardial damage with very high doses; pigmentation¡A macrocytosis¡A water retention; induction of hyperglycemia or hypoglycemia; risk of secondary malignancies.,25¢J¥H¤U,The dosage must be adapted to each patient individually.Unless otherwise prescribed the following dosages are recommended: - for continuous treatment in adults and children: 3-6 mg/kg body weight daily (= 120-240 mg/m2 body surface) - for intermittent treatment: 10-15 mg/kg body weight (= 400-600 mg/m2 body surface) at intervals of 2-5 days - for high-dose intermittent treatment¡A e.g. 20-40 mg/kg body weight (= 800-1600 mg/m2 body surface) and higher doses (e.g. for conditioning prior to bone-marrow transplantation) at intervals of 21-28 days.,»Ý½Õ¾ã¾¯¶q,¦å²MÁx¬õ¯À­È¬°3.1-5mg/100mlªÌ¡A­°§C25%ªº¾¯¶q,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡C 3. ©w´Á§¿²GÀË´ú¡Aª`·N¦å§¿¡C
IGLYC,Glycopyrrolate,Glycopyrodyn inj 0.2mg/1mL,ALIM,Preoperatively to inhibit salivation & excessive secretions of the respiratory tract; reversal of neuromuscular blockade; control of upper airway secretions; adjunct in treatment of peptic ulcer.,In management of peptic ulcer¡A may be C/I in glaucoma; obstructive uropathy; achalasia; pyloroduodenal stenosis; paralytic ileus; intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Inj Newborn infant <1 mth.,Dry mouth; urinary hesitancy & retention; blurred vision. Increased ocular tension; tachycardia; palpitations; decreased sweating¡A loss of taste¡A headache¡A nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; severe allergic reaction¡A drug idiosyncrasies; urticaria; mental confusion.,25¢J¥H¤UÁ×¥ú,Preoperative Adult & children 1 month-12 years 0.002 mg/pound body weight (0.01 mL) IM 30-60 mins before procedure or to be administered with preanesthetic narcotic & sedative. children 1 month-2 years may incresed 0.004 mg/pound body weight (0.02 mL).Intraoperative Adult 0.1 mg (0.5 mL) IV. May repeat at intervals of 2-3 mins. Children 0.002 mg/pound body weight (0.01 mL) IV. Maximum: 0.1 mg (0.5 mL)/dose. May repeat at intervals of 2-3 mins. Reversal of neuromuscular blockade Adult & children 0.2 mg (1 mL) IV for each 1 mg of neostigmine or 5 mg of pyridostigmine.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,1. ¨Ï¥Î«eÀ³¥ýÀË¬d¯f¤H¬O§_¦³¥ô¦ó¤ß·i¹L³tªº²{¶H¡A¦]¬°¨Ï¥Î¥»ÃÄ«~«á¦³¥i¯à¼W¥[¤ß¸õ³t²v¡C
IHALD,Haloperidol,Haldol inj 5mg/1mL,CNEU,Acute psychosis ¡ANausea and vomiting¡A Restlessness and confusion,Severe toxic CNS depression; preexisting coma; Parkinson's disease; lactation,Tardive dyskinesia; extrapyramidal reactions. Anxiety¡A drowsiness¡A depression¡A anorexia¡A transient tachycardia¡A postural hypotension¡A leukopenia; anticholinergic side effects.,15-30¢JÁ×¥ú,Adults: Acute psychosis¡A acute excitement: 5mg IM. Can be repeated every hour until the symptoms are effectively controlled.maximum:20mg/day. Vomiting caused by the central nervous system: 5mg IM Prevent vomiting after surgery: 2.5-5mg IM at the end of the operation. Elders: Start with half of the adult dose¡A and adjust according to the needs of the result.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;,,,,,
ILIPD,Doxorubicin,Lipo-Dox inj 20mg (¦Û¶O¥Î),RACA,Treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 (< 200 CD4 lymphocytes/mm3) & diseases in mucosa¡A skin & internal organs. Treatment of metastasis carcinoma of the ovary in patients with disease that is recurrent to both 1st-line platinum- & paclitaxel-based chemotherapy regimens. As monotherapy for patients with metastatic breast cancer¡A where there is an increased cardiac risk.,Severe hypersensitivity (including anaphylaxis) to doxorubicin liposomal¡A conventional doxorubicin¡A or any component of the formulation. Breast-feeding. AIDS-KS patients effectively treat with local or systemic £\-interferon,Infusion-associated acute reactions¡A stomatitis¡A Palmar-plantar erythrodysesthesia¡A cardiac toxicity. Nausea¡A leukopenia¡A neutropenia¡A anemia & thrombocytopenia. Asthenia¡A alopecia¡A fever¡A diarrhea. Resp infections¡A laboratory abnormalities.,2-8¢JÁ×§K§N­á,[Breast cancer/Ovarian cancer] 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.[Multiple myeloma] 30 mg/m2 on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 mg/m2 on days 1¡A 4¡A 8¡A and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart. [AIDS-related Kaposi sarcoma (AIDS-KS)] 20 mg/m2 once every 2-3 weeks for 2-3 months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response. Avoid intervals shorter than 10 days.,»Ý½Õ¾ã¾¯¶q,Bilirubin 1.2-3 mg/dL: Initial dose: Reduce dose to 75% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes¡A may increase to full dose with cycle 2 Bilirubin >3 mg/dL: Initial dose: Reduce dose to 50% of normal dose; if tolerated and no change in bilirubin/hepatic enzymes¡A may increase dose to 75% of normal dose for cycle 2; if cycle 2 dose tolerated¡A may increase to full dose for subsequent cycles.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iD5W¡j¥é³æ«ØÄ³¡C,,µ¹ÃÄ¾¯¶q¦b90mg¥H¤U¡G¥H250 ml¤§5%¸²µå¿}·»²G(Dextrose 5% in Water)µ}ÄÀ µ¹ÃÄ¾¯¶q¦b90mg(§t)¥H¤W¡G¥H500 ml¤§5%¸²µå¿}·»²Gµ}ÄÀ¡C °_©l¾¯¶qªº¿éª`³t²vÀ³¤£¶W¹L1 mg/min¡C­YµL¿éª`¤£¨}¤ÏÀ³¡A³Ñ¾lÃÄª«¥i¥H60¤ÀÄÁ¿éª`§¹²¦¡C,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C
IDOB2,Dobutamine,Gendobu inj 250mg/20mL,CAVS,Short-term treatment of cardiac decompensation due to depressed contractility resulting from heart disease or cardiac surgery.,Obstructive cardiomyopathy.,Tachycardia¡A nausea¡A non-specific chest pain & palpitation. Cardiovascular: Angina (1% to 3% )¡A Hypertension (7.5% )¡A Tachyarrhythmia (approximately 10% ) Neurologic: Headache (1% to 3% ),25¢J¥H¤U,Must be diluted before infusion. Recommended dosage: usually 2.5-10 mcg/kg/minute as IV infusion. Infusion rate > 20 mcg/kg/minute for hemodynamic improvement. In rare cases¡A doses up to 40 mcg/kg/minute have been administered.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,2.5-10 mcg/kg/min as IV infusion,1.¤Å¥[¤JÆP©ÊÃÄ«~ 2.¶}«Ê«á½Ð©ó24¤p®É¤º¥Î§¹ 3.ÀR¯ß¿éª`³¡¦ì¤§¤ÏÀ³¡Ð°¸¦Óµo¥ÍÀR¯ßª¢ªº³ø§i¡A¤£¤p¤ßªº¿éª`º¯º|¤Þµo§½³¡µoª¢ªºÅÜ¤Æ¡C´¿¦³¥Ö½§Ãa¦º­Ó®×³ø§i¡]¯}Ãa¥Ö½§²ÕÂ´¡^¡C
OEVO,Cevimeline,Evoxac 30mg,CNEU,Treatment of symptoms of dry mouth in patients with Sjogren's Syndrome.,Uncontrolled asthma¡A when miosis is undesirable eg. in acute iritis & in narrow-angle glaucoma.,Excessive sweating¡A nausea¡A rhinitis¡A diarrhea¡A excessive salivation¡A urinary frequency¡A asthenia¡A flushing¡A palpitation¡A dyspepsia¡A abdominal pain¡A UTI¡A cough¡A vomiting. (Common) Dermatologic: Sweating symptom Gastrointestinal: Diarrhea¡A Excessive salivation¡A Indigestion¡A Nausea¡A Vomiting Renal: Urinary tract infectious disease Respiratory: Bronchitis¡A Cough¡A Rhinitis¡A Sinusitis¡A Upper respiratory infection (Serious) Cardiovascular: Chest pain (1-3%)¡A Edema (1-3%)¡A Palpitations (1-3%) Ophthalmic: Eye / vision finding (1-3%),25¢J¥H¤U,Sjogren's syndrome - Xerostomia: 30 mg PO TID.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌ«ùÄòºû«ùÃÄª«¦å¤¤°ª¿@«×¡A¦Ó¥i¯à´£°ª°Æ§@¥Îªºµo¥Í²v,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,[¥é³æ] ¹ï Sprague-Dawley¥À¹«±q¥æ°t«e14¤Ñ¶}©l§ë»P¨Ã¸g¹L7¤Ñ§³®W´Á¡A§ë»P³Ì°ª¾¯¶q45mg/kg/day cevimeline(¦¹¾¯¶q¬Û·í©ó¥HÅéªí­±¿n®Õ¥¿«á¡AÅé­«60¤½¤çªº¦¨¤H³Ì°ª¾¯¶qªº5­¿)¡A¨ä¥­§¡µÛ§É¼Æ¥Ø´î¤Ö¡C³oºØ¼vÅT¥i¯à¬O¥Ñ©óÃÄª«¹ï¥ÀÅéªº¬r©Ê©Ò³y¦¨¡C ¦ý¥Ø«e©|¥¼°w¹ïÃh¥¥°ü¤k¶i¦æÁ{§É¸ÕÅç¡A©Ò¥H¨ä¦w¥þ©Ê¥¼ª¾¡C ¹ïÃh¥¥´Á¶¡¬O§_¥i¥H¨Ï¥Î¡AÀ³¿Å¶q¨äªvÀø®Ä¯q¤j©ó¹ï­L¨à¤§¦MÀI®É¡A¤~¥i¨Ï¥Îcevimeline¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«eÁÙ©|¥¼ª¾¦¹ÃÄª«¬O§_·|¤Àªc¨ì¤H¨Å¥Ä¤¤¡C¦ý¦]¬°³\¦hÃÄª«³£¥i¯à¤Àªc¦Ü¤H¨Å¤¤¡A ©Ò¥Hcevimeline¥i¯à·|¹ï­÷¨Å¤¤ªºÀ¦¨à¤ÞµoÄY­«ªº°Æ§@¥Î¡A¦]¦¹¥²¶·¥ý¦Ò¶q¦¹ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¦A¨M©w¬O§_­n°±¤î±Â¨Å©Î°±ÃÄ¡C,AC;AC15;PO;,,,,,
ONYS,Nystatin,Nystatin 50¸UU,QANB,,¾AÀ³¯g: Monilial infection of oral cavity¡A intestinal moniliasis. °Æ§@¥Î: Diarrhoea¡A GI distress¡A nausea and vomiting. vaginal pessaries/cream: May damage latex contraceptives (e.g. diaphragms¡A condoms)¡A additional contraceptive measures should be taken. ¸T§Ò: History of hypersensitivity to nystatin.,,«Ç·Å,Adult: PO Intestinal or oropharyngeal candidiasis 500¡A000 or 1¡A000¡A000 u 3-4 times/day. Oral candidiasis As pastilles or oral susp: 100¡A000 u 4 times/day. Continue for 48 hr after lesions have healed. Prophylaxis of intestinal candidiasis 1¡A000¡A000 u/day in divided doses.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OVBC,Vitamin B complex,Vitamin B complex,NUTR,Prevention & treatment of vit B deficiency.,Hypersensitivity to any component of the formulation; pre-existing hypervitaminosis,GI complaints at high doses.,«Ç·Å,Adult 2-3 capsules daily. the maxinum dose: 3 capsules/day. Each capsule contains: Thiamine HCl 5mg¡A Riboflavin 2mg¡A Nicotinamide 10.1mg¡A Pyridoxine HCl 0.25mg¡A Cyanocobalamine 1 mcg¡A Calcium Pantothenate 2.75mg¡A Folic Acid 0.1 mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ICER1,HPV type16/18 L1 protein,Cervarix(gsk) inj 0.5mL(­­±M®×­û¤u¥Î),HIMM,,¾AÀ³¯g: Prevention of cervical cancer in females 10-25 years¡A by protecting against incident & persistent infections¡A cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN)¡A CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by HPV Types 16 & 18. °Æ§@¥Î:Headache¡A GI disturbances¡A itch¡A rash¡A myalgia¡A arthralgia¡A inj site reactions¡A fatigue¡A fever. ¸T§Ò: Subjects with known hypersensitivity to any component of Cervarix.,,2-8¢J,3 separated doses given at baseline¡A 1¡A and 6 months by intramuscular injection,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. ¨Ï¥Î«eÀ³¥ý¥R¤À·n¤Ã¡C 2. À³¥H¦Ù¦×ª`®gªº¤è¦¡¬I¥´©ó¤WÁu¤T¨¤¦Ù³¡¦ì¡C
LAMO6,Amoxicillin,Amolin 25mg/mL¡A 60mL suspension,QANB,Infection of staphylococcus¡A streptococcus¡A pneumococcus¡A meningococcus¡A or other susceptibility bacteria.,Hypersensitivity to penicillins. Infectious mononucleosis.,Allergic reactions¡A GI disturbances¡A pseudomembranous colitis¡A hemolytic anemia¡A leukopenia.,25¢J¥H¤U,Adult: 250 mg 3-4 times daily; children: 20-40 mg/kg in divided doses 3-4 times daily. Before administration¡A add water 60 mL into the bottle and shake until all the powder is thoroughly mixed.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LCAS,Castor Oil,Castor oil,ALIM,,¾AÀ³¯g: As laxative. °Æ§@¥Î: Severe purgation¡A nausea & vomiting¡A abdominal cramps¡A flatus¡A rebound constipation¡A irritation of colon¡A dehydration¡A electrolyte imbalance. ¸T§Ò: Dehydration¡A constipation¡A abdominal pain¡A nausea & vomiting¡A appendicitis¡A GI bleeding¡A ulceration¡A purgation¡A intestinal obstruction¡A pregnancy¡A menstruation.,,«Ç·Å,Adult 15-60 mL as single dose 16 hr before procedure. Children 2-12 years 5-15 mL¡A < 2 years 1-5 mL.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
LMYC,Nystatin,Mycostatin 10¸U³æ¦ì/mL suspension,QANB,Treatment of susceptible cutaneous¡A mucocutaneous¡A and oral cavity fungal infections normally caused by the Candida species,Hypersensitivity to nystatin or any component of the formulation,Diarrhea¡A nausea¡A stomach pain¡A vomiting,25¢J¥H¤U,Oral candidiasis: (Suspension) Premature infants: 100¡A000 units 4 times/day; paint suspension into recesses of the mouth Infants: 200¡A000 units 4 times/day or 100¡A000 units to each side of mouth 4 times/day; paint suspension into recesses of the mouth Children: 400¡A000-600¡A000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing Adult: Suspension (swish and swallow): 400¡A000-600¡A000 units 4 times/day; swish in the mouth and retain for as long as possible (several minutes) before swallowing,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;TOPI;WM;,,,,,
EALV,Ciclesonide,Alvesco Inhaler 160mcg/puff¡A 60 puffs,ERSP,Persistent asthma in patients aged four and above.,Hypersensitivity to ciclesonide or any component of the product. Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive intervention.,Common: Arthralgia (oral inhalation¡A 0.9-3.5%)¡A Backache (oral inhalation¡A 0.6-3.1%)¡A Headache (intranasal¡A up to 3.1% ; oral inhalation¡A 4.9-11%)¡A Otalgia (intranasal¡A 2.2%)¡A Bleeding from nose (intranasal¡A 2.9-11.4%)¡A Nasal congestion (oral inhalation¡A 1.8-5.5%)¡A Nasopharyngitis (intranasal¡A 3.7%; oral inhalation¡A 7-10.5%)¡A Pain in throat (oral inhalation¡A 2.4-4.7%)¡A Sinusitis (oral inhalation¡A 3.1-5.5%)¡A Upper respiratory infection (intranasal¡A at least 2% ; oral inhalation¡A 4.1-8.7%)¡A Pain¡A In extremity (oral inhalation¡A 0.3-3.1%) Serious: Adrenal insufficiency¡A Type 2 diabetes mellitus¡A Hypersensitivity reaction (rare)¡A Cataract¡A Glaucoma¡A Raised intraocular pressure¡A Asthma¡A acute (6%)¡A Bronchospasm,«Ç·Å,Initial¡A 80 mcg oral inhalation twice daily; higher doses may provide additional control in patients who do no respond adequately after 4 weeks of treatment; MAX¡A 320 mcg twice daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
EOEKC,Estriol,OEKOLP creme 25gm,SGU,,¾AÀ³¯g: Vag or cervical inflammation¡A atrophic vaginitis. °Æ§@¥Î: Local irritation or itch¡A breast tenderness¡A fluid retention.,,«Ç·Å,Apply 0.5 g daily.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EPULR,Budesonide,Pulmicort respules 1mg/2mL,ERSP,Patients with bronchial asthma not well controlled by bronchodilators &/or antiallergic agents.,Hypersensitivity to budesonide or any other ingredients.,Common: Hypertension (Oral¡A 12%)¡A Peripheral edema (Oral¡A 17%)¡A Acne (Oral¡A 2.4-11%)¡A Dermatitis (Oral¡A 6%)¡A Hirsutism (Oral¡A 5%)¡A Weight gain (Inhalation¡A 1-3% ; oral¡A 7%)¡A Diarrhea (Inhalation¡A 2-4% ; oral¡A 10%)¡A Indigestion (Oral¡A 6-7%)¡A Nausea (Inhalation¡A 1.8% ; oral¡A 5.1-11%; rectal¡A 2%)¡A Leukocytosis (Oral¡A up to 6%)¡A Arthralgia (Oral¡A 2-6%)¡A Spasm (Oral¡A 12%)¡A Headache (Inhalation¡A >3% ; oral¡A 10-21%)¡A Bleeding from nose (Inhalation¡A 2-4% ; intranasal¡A 8%)¡A Dyspnea (Oral¡A 6%)¡A Nasal stinging/burning (Intranasal¡A up to 1%)¡A Respiratory tract infection (Inhalation¡A 3-38% ; oral¡A 8-11%)¡A Sinusitis (Inhalation¡A 3% or greater ; oral¡A 8%)¡A Edema of face (Oral¡A 8%)¡A Fatigue (Inhalation¡A 1-<3% ; oral¡A 3.1-5%) Serious: Syncope (Inhalation¡A 1-3%)¡A Cushing's syndrome (Oral¡A 5-15% ; inhalation¡A rare)¡A Hyperglycemia¡A Hypocortisolism secondary to another disorder (Inhalation¡A rare ; oral¡A 4.3% ; rectal¡A 4%)¡A Type 2 diabetes mellitus¡A Anaphylaxis¡A Hypersensitivity reaction¡A Fracture of bone (Inhalation¡A 1-3%)¡A Osteoporosis¡A Cataract¡A Glaucoma¡A Pneumonia¡A Angioedema,30¢J¥H¤U,The required dose can be administered at one time under 1mg¡A otherwise¡A divided in 2 times daily when the required dose above 1mg. Adult: Initial dose: 1-2 mg daily. Maintenance dose: 0.5-4mg daily. May increase the dosage with the very severe patient. Child > 6 months: Loading dose: 0.25-0.5mg daily. May up to 1mg daily if required. Maintenance dose: 0.25-2mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,PREGNANCY RECOMMENDATION: Compatible (Inhaled/Nasal) No Human Data¡XAnimal Data Suggest Risk (Oral),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;INHL;,,,,,
ESPEO,Bacitracin + Neomycin + Ploymyxin B,Spersin ointment 10gm,TDER,Infections caused by neomycin &/or bacitracin-susceptible organisms.,Hypersensitivity to any component of the formulation.,Allergic reactions like reddening & dryness of skin¡A skin rashes & pruritus.,25¢J¥H¤U,Apply BID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥¼¦³¬ÛÃö°O¸ü Bacitracin - Compatible (Topical) Neomycin - Human Data Suggest Low Risk Ploymyxin B - Unknown,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼¦³¬ÛÃö°O¸ü Bacitracin - Compatible (Topical) Neomycin - No Human Data¡XProbably Compatible Ploymyxin B - Unknown,EXT;SKIN;TOPI;,,,,,
ESUT,Metronidazole,Sutrol gel-vaginal 7.5mg/gm¡A 25gm,SGU,Treatment of vag infections such as Hemophilus vaginitis¡A Gardnerealla vaginitis¡A nonspecific vaginitis¡A Corynebacterium vaginitis or anaerobic vaginosis.,Hypersensitivity to parabens or other nitroimidazole.,Vag discomfort¡A vag candidiasis¡A vag irritation¡A pelvic discomfort. GI disturbances¡A nausea¡A vomiting¡A unpleasant smell¡A diarrhea¡A loss of appetite¡A flatulence¡A dry mouth. Headache¡A dizziness¡A depression. Itch or rash. Skin irritation. Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction,«Ç·Å,Apply 5 g QD-BID for 5 days. Apply before bedtime if to be used once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ] ¤fªA Metronidazole µL·î­LÅã¥Ü¡C³±¹D¥Î¾®½¦µL¬ã¨s³ø§i¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,Metronidazole: Hold Breastfeeding (Oral/IV Single Dose) Limited Human Data¡XPotential Toxicity (Oral/IV Divided Dose) Compatible (Topical/Intravaginal) [¥é³æ] ¨Ï¥Î¥»ÃÄª«®ÉÀ³¨M©w¤£Ä~Äò±Â¨Å©Î°±¤î¥ÎÃÄ¡C,VAG;,,,,,
ETOB,Tobramycin + Dexamethasone,Tobradex 5mL ophthalmic suspension,TOPH,Steroid-responsive inflammatory ocular conditions.,Epithelial herpes simplex keratitis (dendritic keratitis)¡A vaccinia¡A varicella & many other viral diseases of the cornea & conjunctiva. Mycobacterial eye infection. Fungal diseases of ocular structures. After uncomplicated removal of a corneal foreign body.,Localized ocular toxicity & hypersensitivity including lid itching & swelling & conjunctival erythema. Secondary infection.,30¢J¥H¤U¤Å§N­á,One to two drops instilled into the conjunctival sac every 4 to 6 hours. During the initial 24 to 48 hours¡A the dosage may be increased to 1 to 2 drops every 2 hours. Shake well before use.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,TOBRAMYCIN OPHTHALMIC:No Human Data¡XProbably Compatible DEXAMETHASONE: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,TOBRAMYCIN OPHTHALMIC:No Human Data¡XProbably Compatible DEXAMETHASONE: No Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
EVENI,Salbutamol,Ventolin inhaler 0.1mg/dose,ERSP,Relief of acute bronchospasm¡A Prevention of allergen or exercise-induced bronchospasm.,Threatened abortion. Inhaled prep not appropriate for managing premature labour.,Fine tremor of skeletal muscle¡A feelings of tension¡A peripheral vasodilation¡A a compensatory small increase in heart rate¡A headaches¡A transient muscle cramps¡A hypersensitivity reactions¡A potentially serious hypokalaemia¡A hyperactivity in children¡A tachycardia¡A cardiac arrhythmias. Mouth & throat irritations (inhalers).,Á×¥úÁ×µ²Á÷¥B30¢J¥H¤U,Relief of acute bronchospasm- Adult: 100-200 mcg. Children: 100 mcg¡A may be increased to 200 mcg if required. Prevention of allergen or exercise-induced bronchospasm- Adult: 200 mcg before contact challenge or exercise. Children 100 mcg before contact challenge or exercise¡A may be increased to 200 mcg if required. Chronic therapy- Adult: 200 mcg QID. Children: 200 mcg QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
IPKM,Amantadine,PK-Merz infusion 200mg/500mL,CNEU,,I: intensive & initial treatment of severe & life-threatening cases of Parkinsonism. CI: states of agitation & confusion¡A predelirious or delirious conditions & history of psychosis.,,«Ç·Å,1-2 * 500 ml daily may be increased to 3 *500 ml daily.(55 drops/min),,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
EXYLJ,Lidocaine,Xylocaine ¾®½¦ 30gm¡A 2%,ZANE,Surface anaesth.,Known hypersensitivity to local anesth of the amide type.,Rarely¡A anaphylactic shock. Post-op sore throat following endotracheal tube lubrication. Acute systemic toxicity.,25¢J¥H¤U¡A¤£¥i§N­á,Urethral anesthesia Men 20 mL is instilled slowly until the patient has a feeling of tension or until almost half the tube (10 mL) has been emptied. Apply a penile clamp for several mins¡A then instill the rest of the jelly. Women 5-10 mL in small portions to fill the whole urethra. Endoscopy 10-20 mL. Lubrication for endotracheal intubation 2 mL applied to the surface of the tube just prior to insertion. Children < 12 years Maximum: 6 mg/kg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
ECOMS,Benzydamine,Comfflam spray 1.5mg/mL¡A 30mL/Bot,CNEU,,¾AÀ³¯g:Relief of painful conditions of the mouth & throat including tonsillitis¡A sore throat¡A radiation mucositis¡A aphthous ulcers¡A post orosurgical & periodontal procedures. °Æ§@¥Î:Oral numbness; dryness or thirst¡A tingling¡A warm feeling in mouth¡A altered sense of taste. ¸T§Ò:Hepatic or renal impairment. Pregnancy¡A children < 6 years. In bacterial infection¡A appropriate antibacterial therapy should be used in addition to product.,,«Ç·Å,Adult & children > 12 years 4-8 sprays onto the affected area¡A children 6-12 years 4 sprays onto the affected area. May be repeated every 1.5-3 hrly. Duration should not exceed 7 days.,,,,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IHUM4,Adalimumab,Humira 40mg inj,HIMM,,¾AÀ³¯g:Monotherapy or in combination with methotrexate or other DMARDs for reducing of the signs & symptoms & to inhibit the progression of structural damage in adult patients with moderately to severely active RA. Monotherapy or in combination with other DMARDs for reducing the signs & symptoms of active arthritis in patients with psoriatic arthritis. Reduction of signs & symptoms in patients with active ankylosing spondylitis. Reduction of signs & symptoms & inducing & maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy or if they have also lost response to or are intolerant to infliximab. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy & when other systemic therapies are medically less appropriate. Reduction of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 13-17 years. °Æ§@¥Î:Resp tract infections¡A leucopenia¡A anemia¡A increased lipids¡A headache¡A abdominal pain¡A nausea & vomiting¡A elevated liver enzymes¡A rash¡A musculoskeletal pain¡A inj site reaction. ¸T§Ò:Known hypersensitivity to adalimumab or any of the excipients of Humira.,,2-8¢J,Adult RA¡A psoriatic arthritis¡A ankylosing spondylitis¡A polyarticular juvenile idiopathic arthritis Single dose of 40 mg SC every other week. If not taking concomitantly with methotrexate¡A increasing the dosing frequency to 40 mg weekly may derive additional benefit. Crohn's disease 160 mg initially at day 1 (as four 40-mg inj in 1 day or as two 40-mg inj/day for 2 consecutive days)¡A followed by 80 mg 2 weeks later (day 15). Another 2 weeks later (day 29) begin a maintenance dose of 40 mg every other week. Patients who experience decrease in their response may benefit from an increase in dose intensity to 40 mg every week. Plaque psoriasis Initially 80 mg¡A followed by 40 mg given every other week starting 1 week after the initial dose.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
EKIN1,Atropine,Kintropine 0.125% 10mL,TOPH,,¾AÀ³¯g: As a mydriatic & cycloplegic in various eye disorders. °Æ§@¥Î: May cause whole body reactions if used on long-term. Sensitivity to light¡A visual disturbances. ¸T§Ò: Closed- & narrow-angle glaucoma.,,«Ç·Å,Cycloplegic refraction 1 drop once-bid. Uveitis 1 drop once-tid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EKIN2,Atropine,KINTROPINE 0.25% 10mL,TOPH,,¾AÀ³¯g: As a mydriatic & cycloplegic in various eye disorders. °Æ§@¥Î: May cause whole body reactions if used on long-term. Sensitivity to light¡A visual disturbances. ¸T§Ò: Closed- & narrow-angle glaucoma.,,«Ç·Å,Cycloplegic refraction 1 drop once-bid. Uveitis 1 drop once-tid.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IPANT,Vit B1+ B2 + B6 + C + Nicotinamide + Pantothenyl,Pantogen inj 500mL,META,Prevention & treatment of vit B & vit C deficiency.,Use of hypertonic glucose soln in patients with anuria; intracranial or intraspinal hemorrhage; delirium tremens with dehydration,Nausea¡A vomiting¡A abdominal cramps¡A pruritus¡A flushing¡A sensation of heat¡A faintness¡A pounding in the head.,µL¯S§O«ü¥Ü,Individualised dosage. Slow IV only¡A injection rate: 2 mL/min.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
IPERD,Nicardipine,Perdipine inj 10mg/10mL,CAVS,Cerebral blood flow disturbances ¡AEssential hypertension¡A Short-term therapy of hypertension or of unusual hypertension during surgery,Incomplete hemostasis following intracranial hemorrhage; acute cerebral apoplexy¡A elevated intracranial pressure¡A Hypersensitivity to nicardipine or any component of the formulation; advanced aortic stenosis,Infrequently¡A anorexia¡A nausea¡A vomiting; flushing; palpitation; headache. Rarely¡A granulocytopenia; dry mouth¡A constipation¡A diarrhea; peripheral edema; rash. Cardiovascular: Hypotension (5.6% )¡A Peripheral edema (5.9% )¡A Tachyarrhythmia (3.5% ) Gastrointestinal: Nausea (1.9% to 4.9% )¡A Vomiting (0.6% to 4.9%) Neurologic: Headache (6.2% to 14.6% ),30¢J¥H¤UÁ×¥ú,adult¡A HTN: initial 3-5mg/hr ¡A titrate up 0.5-1 mg/hr every 15 minutes maximum 15mg/hr HTN emergency: Initial: 5 mg/hr; may increase by 2.5 mg/hr every 5 to 15 minutes maximum of 15 mg/hour. [Micromedex 20211013] Intracerebral hemorrhage / Subarachnoid hemorrhage blood pressure management (off-label use): 5 mg/hr; may increase by 2.5 mg/hr every 5 to 15 minutes (for gradual titration) up to a maximum of 15 mg/hr.,µL»Ý½Õ¾ã¾¯¶q,Consider lower initial doses and titrate infusion gradually,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,ÀR¯ß¿éª`®É¡Aµ}ÄÀ¦¨0.1-0.2 mg/mL¿@«×¡A¦¨¤H°_©l¾¯¶q:3-5 mg/hour¡A«ùÄò¿éª`15¤ÀÄÁ¡A¦ý¤£¥i¶W¹L15 mg/hour;¤p¨à°_©l¾¯¶q:0.5-5 mcg/kg/min¡A«ØÄ³ºû«ù¾¯¶q¬°1-4mcg/kg/min¡C,¨Ì103¦~8¤ë7¤é½ÃºÖ³¡µo§G©ó¤£¨}¤ÏÀ³¤¤¤ß¦w¥þ©Êµû¦ôµ²ªG¡C 1.IV infusion ¦¨¤H°_©l¾¯¶q:3-5 mg/h¡A«ùÄò¿éª`15¤ÀÄÁ¡A¦ý¤£¥i¶W¹L15 mg/hour 2.IV infusion ¦Ñ¤H¡B¥¥°ü¤Î¨xµÇ¥\¯à¤£¨}ªÌ°_©l¾¯¶q:1-5 mg/hour¡A¤£¥i¶W¹L15 mg/hour 3.IV infusion ¤p¨à°_©l¾¯¶q:0.5-5 mcg/kg/min¡A«ØÄ³ºû«ù¾¯¶q¬°1-4mcg/kg/min 4.¥»ÃÄ¹J¥ú·|ºCºCªºÅÜ¤Æ¡C
IPROL,Propofol,Propofol 1% 20mL,ZANE,,¾AÀ³¯g:Short-acting IV anesth for induction & maintenance of general anesth. Conscious sedation for surgical & diagnostic procedures. Sedation of ventilated patients receiving intensive care. °Æ§@¥Î:Hypotension¡A transient apnea¡A epileptiform movements¡A mild degree of local pain¡A post-op fever & discoloration of urine¡A anaphylaxis¡A edema¡A bronchospasm¡A erythema. Dermatologic: Injection site pain (up to 28.5% ) Gastrointestinal: Nausea and vomiting (2% to 2.5% ) Musculoskeletal: Involuntary movement¡A Muscle (17%) ¸T§Ò:Pregnancy¡A lactation & obstetrics (except abortion). General anesth in children <1 month & for sedation of children <16 years in ICU.,,«Ç·Å,General anesth Adult <55 years Induction: 2-2.5 mg/kg IV. Maintenance by continuous IV infusion: 4-12 mg/kg/hr. Maintenance by repeat bolus inj: increments of 25-50 mg may be given according to clinical need. Children >=3 years Induction: 2.5 mg/kg IV. Maintenance: 9-15 mg/kg/hr. Sedation of ventilated patients receiving intensive care Adult Continuous infusion recommended; infusion rate should be determined by the desired depth of sedation. Rates at 0.3-4 mg/kg/hr should achieve satisfactory sedation Conscious sedation for surgical & diagnostic procedures Adult Induction: 0.5-1 mg/kg over 1-5 mins. Maintenance: 1.5-4.5 mg/kg/hr. In addition to the infusion¡A bolus administration of 10-20 mg may be used for rapid increase in the depth of sedation.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1.¨Ï¥Î¿@«×¤Å§C©ó2 mg/mL¡C(³Ì¤jµ}ÄÀ¤ñ¨Ò 1:4)) 2.¿éª`®É¤£¥i¨Ï¥Î§t·L¥Íª«¹LÂo¾¹¤§¿é²G®M¡C¿éª`¥»«~«ØÄ³¨Ï¥Î¬y³tºw©w©ÎÅé¿n³]©wÀ°®ú±±¨î¬y³t¡C 3.¥»«~¤£§t¨¾»G¾¯¡A¶}²~«áÀ³¥ß§Y©â¨ú¦ÜµLµß°wµ©©Î¿é²G®M¡A³Ñ¾lªº´Ý¶qÀ³¥á±ó¤£¥Î¡C 4.¿éª`¥¼¸gµ}ÄÀªºPropofol 1% 20mL®É¡A¨Ï¥Î¦P¤@¨t²Î¿éª`®É¶¡¤£©y¶W¹L12¤p®É¡C¨Ï¥Î12¤p®É«á¡A¿éª`ºÞ¸ô»P³Ñ¾lªºÃÄª«À³¥á±ó¡B§ó´«¡C 5.¿éª`µ}ÄÀ¹LªºPropofol 1% 20mL®É¡AÀ³©ó§ëÃÄ«e¥HµLµß¾Þ§@¥ß§Y½Õ°t¡A¥B°È¥²©ó6¤p®É¤º¨Ï¥Î¡C
OCEPH,Cephalexin,Cephalexin 250mg,QANB,Infections caused by Staph¡A Strep¡A pneumococci & other susceptible bacteria.,Hypersensitivity to cephalosporins.,Common: Diarrhea Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile colitis¡A Direct Coombs test positive¡A Prothrombin time increased¡A Allergic reaction¡A Anaphylaxis¡A Seizure¡A Renal failure¡A Tubulointerstitial nephritis¡A Angioedema,15-30¢Jºò±K®e¾¹,(¥é³æ) Adults: 250 mg Q6H. Children: 25-50 mg/kg/day. (Uptodate+Ulexin¥é³æ) Adults: 0.25-1 g Q6H or 500 mg Q12H (maximum: 4 g/day). Children: 25-100 mg/kg/day divided Q6H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OFOL5,Folic Acid,Folacin FC 5mg(¦Û¶O),NUTR,Pernicious anemia¡A pregnancy¡A megaloblastic anemia¡A aplastic anemia.,Hypersensitivity to any component of the formulation.,GI complaints at high doses.,25¢J¥H¤Uºò±K®e¾¹,1 TAB contains 5 mg folic acid. Adult: Initially 1 TAB TID for 14 days. Maintenance: 1 TAB daily for 1-7 days. Children 6-12 years: Initially 2 TAB/day. Maintenance: As half of initial dose. Children 1-5 years: Initially 1 TAB /day. Maintenance: As half of initial dose. Children <1 years: 0.5 mg/kg body weight/day. Maintenance: As half of initial dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LCET,Cetirizine,Cetirizine 1mg/mL¡A 60mL oral solution,HIMM,Symptomatic treatment of seasonal rhinitis & conjunctivitis¡A perennial allergic rhinitis as well as pruritus & urticaria of allergic origin.,Lactation.,Headache¡A dizziness¡A drowsiness¡A agitation¡A dry mouth¡A GI discomfort¡A skin reactions & angioedema.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Adult & children >6 years : 10 mg once daily¡A taking with dinner and liquids. Children 3-6 years: initial dose: 5 mg once daily¡A taking with dinner¡A or 2.5mg every 12 hours.Patient with renal function impairment should reduce dosage to half.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IPNS3,Sodium Chloride,Prefilled 0.9% Saline 3mL,NUTR,,,,,,,,,,,,,,,,,,,
LCH10,Chloral hydrate,Chloral hydrate 10%¡A 10mL,CNEU,,¾AÀ³¯g: Insomnia¡ASedation °Æ§@¥Î: Gastric irritation¡A abdominal distention and flatulence¡A vertigo¡A ataxia¡A staggering gait¡A rashes¡A malaise¡A lightheadedness¡A headache¡A ketonuria¡A excitement¡A nightmares¡A delirium (especially in elderly)¡A eosinophilia¡A reduction in white blood cell count; dependence on prolonged use. ¸T§Ò: Hepatic or renal impairment¡A cardiac disease¡A hypersensitivity¡A porphyria¡A oesophagitis¡A gastritis. Pregnancy and lactation.,,2-8 ¢J,Chloral hydrate 10%= 100 mg/mL --Dosing: Adult Sedation¡A anxiety: Oral: 250 mg 3 times daily Hypnotic: Oral: 500-1000 mg 15-30 minutes before bedtime or 30 minutes prior to procedure¡A not to exceed 2000 mg per 24 hours --Dosing: Pediatric Hypnotic: Oral: 50 mg/kg/day in 1 or more divided doses; maximum single dose: 1000 mg Sedation or anxiety: Oral: 25 mg/kg/day in 1 or more divided doses; maximum single dose: 500 mg Procedural sedation: Oral: 25-50 mg/kg/dose¡A 30 minutes prior to procedure; may repeat in 30 minutes using half the dose,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EJAL,Benzyl benzoate,Jaline Lotion 25%¡A 150mL,TDER,Treatment of scabies¡A head lice.,Hypersensitivity to any component of the formulation.,Skin irritation¡A burning sensation.,25¢J¥H¤U,Scabies Apply over the whole body; repeat without bathing on the following day & wash off 24 hr later. A repeat application may be required in some cases,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
INESP,Darbepoetin alfa,NESP inj 20mcg(¬~µÇ¥Î),HEMT,Anemia: Treatment of anemia due to concurrent myelosuppressive chemotherapy in patients with cancer (nonmyeloid malignancies) receiving chemotherapy (palliative intent) for a planned minimum of 2 additional months of chemotherapy; treatment of anemia due to chronic kidney disease (including patients on dialysis and not on dialysis),Hypersensitivity to darbepoetin or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (due to darbepoetin or other erythropoietin protein drugs),Hypertension (31%)¡A peripheral edema (17%)¡A edema (6% to 13%)¡A Abdominal pain (10% to 13%)¡A Dyspnea (17%)¡A cough (12%),2-8¢JÁ×¥ú¤Å§N­á¤Å·n,Initial dose as 0.45mcg/kg IV or SC every week for treatment of chronic renal failure patient with anemia¡A keeping Hb between 10-12g/dL. For patient with chemotherapy¡A 2.25mcg/kg SC as initial dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,¥é³æ¸ê°T¡GÃh¥¥¤À¯ÅC ©|¥¼¦³¨¬°÷¥B±±¨î¨}¦nªºÃh¥¥°ü¤kªºDarbepoetin alfa¸ÕÅç¡C °Êª«ªº¥Í´Þ¤Îµo¨|¬r©Ê¸ÕÅç¤¤¡ADarbepoetin alfa¼W¥[µÛ§É«áªº¬y²£¡C °ß¦³ªvÀøªº¯q³B¨¬¥HÀ±¸É¹ï¹ï­L¨à³y¦¨¼ç¦b¶Ë®`ªº­·ÀI¡A¤~¨Ï¥ÎDarbepoetin alfa©óÃh¥¥¯f¤H¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,¥é³æ¸ê°T¡G©|¤£²M·¡Darbepoetin alfa¬O§_·|¤Àªc¨ì¤HÅéªº¨Å¥Ä¤¤¡A ¦]¬°³\¦hÃÄ·|¤Àªc¨ì¤HÅéªº¨Å¥Ä¤¤¡AÃö©ó±Â¨Å°ü¤kDarbepoetin alfa§ë»PÀ³ÂÔ·V¡C,IV;SC;,,,,,
ODOB,Mebeverine,Dobecon 100mg,ALIM,Diarrhea¡A abdominal pain & flatulence due to irritable colon¡A diverticulitis,1. Hypersensitivity to mebeverine 2.Severe hepatic impairment 3.Cystic fibrosis,Skin rash¡A hives¡A dizziness¡A headache,25¢J¥H¤U,Adult: The usual oral adult dose of mebeverine hydrochloride for irritable bowel syndrome is one 100 mg tablet 3 times daily taken with fluids 20 minutes before a meal. The dosage of mebeverine may be reduced gradually after a few weeks of treatment¡A if the desired effect has been achieved.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PO;,,,,,
OPLEY,Cilostazol,Pleya 100mg,HEMT,,¾AÀ³¯g: Reduction of symptoms of intermittent claudication¡A as indicated by an increased walking distance. °Æ§@¥Î: Abdominal pain¡A back pain¡A headache¡A infection¡A palpitation¡A tachycardia¡A GI effects¡A peripheral edema¡A myalgia¡A dizziness¡A vertigo¡A cough¡A pharyngitis¡A rhinitis. Cardiovascular: Palpitations (5% to 10% )¡A Peripheral edema (7% to 9% )¡A Tachyarrhythmia (4% ) Gastrointestinal: Abdominal pain (4% to 5% )¡A Diarrhea (12% to 19% )¡A Feces contents abnormal (12% to 15% )¡A Indigestion (6% ) Hematologic: Decreased platelet aggregation Musculoskeletal: Backache (6% to 7% )¡A Myalgia (2% to 3% ) Neurologic: Dizziness (9% to 10% )¡A Headache (27% to 34% ) Respiratory: Increasing frequency of cough (3% to 4% )¡A Pharyngitis (7% to 12% )¡A Rhinitis (7% to 12% ) Other: Infectious disease (10% to 14% ) ¸T§Ò: Patients with CHF of any severity.,,«Ç·Å,100 mg BID,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ESPIR,Tiotropium,Spiriva Respimat 2.5mcg/puff,ERSP,Maintenance treatment of patients with COPD (including chronic bronchitis & emphysema).,Patients with a history of hypersensitivity to atropine or its derivatives eg¡A ipratropium or oxitropium¡A or to any component of Spiriva.,GI disturbances¡A cough & local irritation¡A dysuria¡A urinary retention (in men)¡A tachycardia¡A allergic reactions. Gastrointestinal: Constipation (4% )¡A Xerostomia (12% to 16% ) Respiratory: Pharyngitis (7% to 9% )¡A Sinusitis (3% to 11% )¡A Upper respiratory infection (41% to 43% ),30¢J¥H¤U¤Å§N­á,Adult:Inhale 2 puffs once daily at the same time of day. Age 6-17 years with asthma: 2 puffs once daily at the same time of day. Age <6 years: Limited data available.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;INHL;,,,,,
IOLI3,Amino Acid + Dextrose + Electrolytes + Lipid,Oliclinomel N4-550E Emulsion 1500mL,NUTR,Parenteral nutrition when oral or enteral alimentation is impossible¡A insufficient or contraindicated.,Renal failure in the absence of haemodialysis¡A haemofiltration or haemo-diafiltration. Severe liver disease. Amino acid metabolism disorder. Metabolic acidosis¡A hyperlactataemia. Adrenal insufficiency. Hyperosmolar coma.,Hypertonic solutions may cause venous irritation if infused into a peripheral vein. Hyperglycaemia¡A glycosuria & hyperosmolar syndrome may occur.,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Adult: 1-2 g amino acids/kg/day¡A 25-40 kcal/kg/day. Maximum daily dose: 40mL/kg body weight. Maximum infusion rate: 3mL of the emulsion for infusion/kg/hr. 12-18 years: 1-2g amino acids/kg/day¡A 30-75kcal/kg/day. Maximum daily dose: 100mL/kg body weight. Maximum infusion rate: 5.5mL of the emulsion for infusion/kg/hr. 2-11 years: 1-2g amino acids/kg/day (maximum: 3g amino acids/kg/day)¡A 60-90kcal/kg/day. Maximum daily dose: 100mL/kg body weight. Maximum infusion rate: 6.5mL of the emulsion for infusion/kg/hr.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌÀ³ÂÔ·V¨Ï¥Î¡A¦]¬°¦³µo¥Í°ª®ò¦å¯g¬ÛÃö¯«¸g¾Ç¯e¯f©Î´c¤Æªº­·ÀI,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,1.¦¹¿éª`¨Å²G³Ì¤j¿éª`³t²v¤Å¶W¹L3²@¤É/¤½¤ç/¤p®É¡C 2.­Y¦³¥ô¦ó¯gª¬©Î¸ñ¶HÅã¥Ü¹L±Ó¤ÏÀ³(¦p¡Gµo¿N¡BÅ¸§Ý¡B¥Ö¯l©Î©I§l§xÃø)¡AÀ³¥ß§Y°±¤î¿éª`¡C 3.¥»¿éª`¨Å²Gµ´¹ï¤£¥i©ó¿é¦å®É¨Ï¥Î¬Û¦Pªº¿éª`¾ÉºÞ¸Ë¸m¡A¦]¬°¥i¯à¾É­P°²©Ê¾®¦å¸ñ¶H¡C 4.¥»²£«~»Ý¦b¤T³U²GÅé¥R¤À²V¦X«á¤è¥i¨Ï¥Î¡A­­³æ¦¸¨Ï¥Î¡C
ITRAN,Tranexamic Acid,Transamin inj 250mg/5mL,HEMT,Hemorrhage¡A abnormal bleeding¡A genital & renal bleeding¡A bleeding due to prostatectomy.,Hypersensitivity to any component of the formulation.,GI disturbances. Gastrointestinal: Abdominal pain (oral¡A 19.8% ) Hematologic: Anemia (oral¡A 5.6% ) Musculoskeletal: Arthralgia (oral¡A 6.9% )¡A Backache (oral¡A 20.7% )¡A Cramp (oral¡A 6.5% )¡A Musculoskeletal pain (oral¡A 11.2% ) Neurologic: Headache (oral¡A 50.4% )¡A Migraine (oral¡A 6% ) Respiratory: Nasal sinus problem (oral¡A 25.4% ) Other: Fatigue (oral¡A 5.2% ),25¢J«O¦s,Adult: 250-500mg divide 1-2 times¡A IV/IM.During or after surgery: 500-1000 mg IV or 500-2500 mg by IV infusion.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment is necessary.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. Clinical Management: There are limited data on nursing an infant while on tranexamic acid. Data have shown that only minimal amounts of the drug are excreted in breast milk. Breast milk concentrations were reported to be approximately 1% of peak serum levels 1 hour following the last dose of a 2-day treatment regimen. Tranexamic acid should only be used in a nursing mother only if clearly needed and use caution when tranexamic acid is administered to a nursing mother.,IM;INS;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,1000 mg ±Àª`®É¶¡¦Ü¤Ö 10 mins (³t²v < 2 mL/min),1000 mg ±Àª`®É¶¡¦Ü¤Ö 10 mins ¿éª`³t²v < 2500mg/24hr,1. ÀR¯ß¤ºª`®g®ÉÀ³½wºC¶i¦æ¡A«æ³tµ¹ÃÄ®É¡A¥i¯à·|¥X²{äú¤ß¡B¯Ý³¡¤£¾A¡B¤ß±ª¤®¶i©Î¦åÀ£¤U­°¡C 2.¤£¥i»P¦å«~©Î§tpenicillinªºÃÄª«²V¦X
IPAM2,Pralidoxime,Pampara inj 500mg/20mL,ZADT,Treatment of muscle weakness and/or respiratory depression secondary to poisoning due to organophosphate anticholinesterase pesticides and chemicals (eg¡A nerve agents); control of overdose of anticholinesterase medications used to treat myasthenia gravis (ambenonium¡A neostigmine¡A pyridostigmine),According to the manufacturer¡A relative contraindications include hypersensitivity to pralidoxime or any component of the formulation and other situations where the risk of administration clearly outweighs possible benefit.,Cardiovascular: Cardiac arrest¡A hypertension¡A tachycardia Central nervous system: Dizziness¡A drowsiness¡A headache¡A paralysis¡A seizure Dermatologic: Skin rash Gastrointestinal: Nausea Hepatic: Increased serum ALT (transient)¡A increased serum AST (transient) Local: Pain at injection site (IM) Neuromuscular & skeletal: Fasciculations¡A increased creatine phosphokinase¡A laryngospasm¡A muscle rigidity¡A weakness Ophthalmic: Accommodation disturbance¡A blurred vision¡A diplopia Renal: Renal insufficiency Respiratory: Apnea¡A hyperventilation,µL¯S§O«ü¥Ü,(¥é³æ) Loading dose 1 g IV; may repeat bolus of 1 g after 30 minutes if symptoms have not been relieved.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,Hold Breast Feeding ¼È°±­÷¨Å,,IVD;,,¡iN/S¡j¥i¿ï ¡C,slow injection,¥H10~20 mg/mL ºwª` 15~30 min¡AMax: 200 mg/min,Intravenous 1.dilute to a final concentration of 10 to 20 mg/mL in NS; infuse over 15 to 30 minutes 2.maximum infusion rate is 200 mg/min
OSEN,Sennosides,Sennoside 12mg,ALIM,,¾AÀ³¯g: Treatment of constipation & for bowel evacuation before investigational procedures or surgery. °Æ§@¥Î: Mild abdominal discomfort¡A eg colic or cramps. Prolonged use or overdosage can result in diarrhoea with excessive loss of water & electrolytes¡A particularly K; possibility of developing an atonic non-functioning colon. May colour urine yellow-brown at acid pH¡A & red at alkaline pH. Reversible melanosis coli has been reported following chronic use. ¸T§Ò: Patients with intestinal obstruction or with undiagnosed abdominal symptoms.,,«Ç·Å,Constipation Adult 12-50 mg. Bowel evacuation up to 158 mg.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EDIP,Betamethasone + Gentamicin,Diprogenta cream 5gm,TDER,,¾AÀ³¯g: Dermatoses complicated by infection in psoriasis¡A neurodermatitis¡A lichen planus¡A eczema¡A intertrigo¡A dyshidrosis¡A seborrhoeic¡A contact¡A atopic¡A exfoliative¡A solar¡A stasis dermatitis; anogenital & senile pruritus. °Æ§@¥Î: Burning¡A itching¡A irritation¡A dryness¡A folliculitis¡A hypertrichosis¡A perioral dermatitis¡A allergic contact dermatitis¡A acneiform eruption¡A hypopigmentation¡A maceration of the skin¡A skin atrophy¡A secondary infection¡A striae & miliaria. ¸T§Ò: Hypersensitivity to any of the component of Diprogenta.,,«Ç·Å,Cover affected area completely bid.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IMAR4,Bupivacaine,Marcaine Spinal 0.5% 4mL inj (³Â¾K¬ì¥Î),ZANE,Spinal anaesth for surgery.,Diseases of the cerebrospinal system; septicaemia; pernicious anemia with cord symptoms; cardiac decompensation; massive pleural effusions & markedly increased intra-abdominal pressure; pyogenic infection of skin.,Drowsiness¡A unconsciousness¡A respiratory arrest; hypotension¡A myocardial depression¡A bradycardia¡A possibly cardiac arrest; numbness of the tongue¡A light-headedness¡A dizziness¡A tremor followed by convulsions may rarely occur.,2-25¢JÁ×§K§N­á,Marcaine Spinal 0.5% contains bupivacaine 5mg/mL¡A 4mL/ampoule. Intrapinal injection. Spinal injections should only be made after the subarachnoid space has been clearly identified by lumbar puncture. No drug should be injected until clear cerebrospinal fluid (CSF) is seen to escape from the spinal needle or it is detected by aspiration. The dose required for the most effective blocking (patient in the supine horizontal position): For lower limbs¡A urinary tract and perineum surgery: 10-15 mg inject into L3/4/5. For hip and lower abdomen surgery: 15-20 mg and inject into L2/3/4.,µL»Ý½Õ¾ã¾¯¶q,±ß´Á¨x¯f±wªÌÀ³¤p¤ß¨Ï¥Î¡A¥H´î§Cµo¥Í¦MÀI°Æ§@¥Îªº­·ÀI,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IT;,,,,,§½³¡³Â¾K¾¯¡A­­¥ÑÂå®v¨Ï¥Î¡C
LPOL,Multivitamin,Poly Baby Multivitamin Drops 50mL,NUTR,,°Æ§@¥Î: Allergic reactions¡A dizziness¡A hypervitaminosis ¾AÀ³¯g: Vitamin and mineral supplement for infants.,,«Ç·Å,Infant(Age <3yr): 1mL¡AQD. Infant(Age <3 month): 0.6mL¡AQD.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ITPN1A,TPN-1 Solution,TPN-1A Solution (1000mL/bag),NUTR,,,,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
IALBU,Albumin,Albumin 25% 50mL (Albuminar-25),HEMT,,¾AÀ³¯g (FDA-Labeled Indications ): ¡½Acute respiratory distress syndrome ¡½Ascites; Adjunct ¡½Burn - Hypovolemia ¡½Cardiopulmonary bypass operation ¡½Cellulitis¡A Extensive ¡½Hemodialysis; Adjunct ¡½Hypoalbuminemia ¡½Hypovolemic shock ¡½Liver failure (Acute) ¡½Mediastinitis ¡½Neonatal hyperbilirubinemia ¡½Nephropathy¡A acute; Adjunct ¡½Ovarian hyperstimulation syndrome ¡½Pancreatitis ¡½Peritonitis ¡½Transfusion of red blood cells °Æ§@¥ÎSerious: Immunologic: Immune hypersensitivity reaction (rare) ¸T§Ò: ¡½hypersensitivity to albumin ¡½patients at risk for acute circulatory overload (cardiac failure¡A pulmonary edema¡A severe anemia),,«Ç·Å,Adult Dosing ¡½Acute respiratory distress syndrome: 25 g (100 mL of 25% solution) IV over 30 minutes¡A repeated at 8 hours for 3 days if necessary ¡½Ascites; Adjunct: 6 to 8 g of 25% albumin for every 1000 mL of ascitic fluid removed ¡½Burn - Hypovolemia: after the first 24 hours¡A dose albumin 5% or 25% IV to achieve plasma albumin level of approximately 2.5g/100mL or a total plasma protein concentration of 5.2g/100mL; an initial dose of 25 g of albumin (500 mL of 5% solution) is recommended ¡½Cardiopulmonary bypass operation: (AlbuRx(R) 25¡A Plasbumin(R)-5%¡A Plasbumin(R)-25%) adjust albumin and crystalloid pump prime to achieve a hematocrit of 20% and a plasma albumin concentration of 2.5 g/100 mL ¡½Hemodialysis; Adjunct: (25% solution) 25 g (100 mL) IV ¡½Hypoalbuminemia: initial¡A 25 g (100 mL of 25% solution) IV¡A usual daily dose 50 to 75 g (200 to 300 mL of 25% solution ) IV¡A additional doses may be given as clinically indicated; MAX 2 g/kg/day ¡½Hypovolemic shock: initial¡A 12.5 to 25 g IV (250 to 500 mL of 5% solution¡A 50 to 100 mL of 25% solution)¡A may repeat in 15 to 30 minutes; further doses based on clinical response¡A blood pressure¡A and anemia assessment ¡½Liver failure (Acute): 10 to 20 g infusion in combination with octreotide 200 micrograms subcutaneous three times daily and midrodrine titrated to 12.5 mg by mouth three times daily for 20 days ¡½Nephropathy¡A acute; Adjunct: initial¡A 25 g (100 mL of 25% solution) IV daily for 7 to 10 days with loop diuretics ¡½Ovarian hyperstimulation syndrome: 50 to 100 g IV over 4 hours¡A repeat at 4 to 12 hour intervals as needed or 10 to 50 g as a single infusion ¡½Transfusion of red blood cells: 25 g (100 mL of 25% albumin) per liter of erythrocytes¡A added to washed red cell suspension immediately prior to transfusion [1][6] Pediatric Dosing ¡½Acute respiratory distress syndrome: (Kedbumin(TM)) 12 to 16 years¡A 25 g (100 mL of 25% solution) IV over 30 minutes¡A repeated at 8 hours for 3 days if necessary ¡½Burn - Hypovolemia: (Kedbumin(TM)) 12 to 16 years¡A dose should be determined by measurement of plasma oncotic pressure or protein content¡A or by direct observation of vital signs. Patients should be adequately hydrated while receiving Kedbumin(TM) ¡½Cardiopulmonary bypass operation: (Kedbumin(TM)) 12 to 16 years¡A estimate dose from difference between desired and actual total serum protein concentration¡A multiplied by the estimated plasma volume (40 mL/kg) times 2 ¡½Hemodialysis; Adjunct: (Kedbumin(TM)) 12 to 16 years¡A 25 g (100 mL) IV ¡½Hypoalbuminemia: (Kedbumin(TM)) 12 to 16 years¡A 50 to 75 g (200 to 300 mL of 25% solution) IV ¡½Hypovolemic shock: neonate¡A infants¡A and young children¡A 0.5 to 1 g/kg (10 to 20 mL/kg of 5% solution) IV; further doses based on clinical response¡A blood pressure¡A and anemia assessment ¡½Hypovolemic shock: (Buminate(TM) 5%) older children¡A initial¡A 12.5 to 25 g (250 to 500 mL) IV¡A may repeat at 30 minute intervals; further doses should be individualized ¡½Neonatal hyperbilirubinemia: 1 g/kg of 25% albumin 1 hour prior to or during exchange transfusion ¡½Ovarian hyperstimulation syndrome: 50 to 100 g IV over 4 hours¡A repeat at 4 to 12 hour intervals as needed or 10 to 50 g as a single infusion,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î
EELO,Mometasone,Elomet cream 0.1%¡A 5gm,TDER,Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid),Hypersensitivity to mometasone furoate¡A other corticosteroids¡A or any component of the formulation; untreated fungal¡A bacterial¡A and viral (ie¡A herpes simplex¡A chicken pox¡A and vaccinia) infections involving the skin.,Bacterial skin infection¡A burning¡A furunculosis¡A pruritus¡A skin atrophy¡A tingling/stinging,25¢J¥H¤U,Topical: Apply sparingly¡A do not use occlusive dressings. Therapy should be discontinued when control is achieved; consider reassessment of diagnosis if no improvement is seen within 2 weeks. Cream¡A ointment: Apply a thin film to affected area once daily,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
EACR5,Acrinol,Acrinol solution 500mL,TDER,Topical agents and dressings for local wound care.,Hypersensitivity¡A pregnancy.,Hypersensitivity¡A prolonged use delays wound healing,Àx¦s©ó25 ¢J¥H¤U,Pre-op antiseptic skin cleanser Use undiluted.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
LHALD,Haloperidol,Haldomin 2mg/mL¡A 15mL oral solution,CNEU,,¾AÀ³¯g: Mania¡A psychotic disorders¡A nausea¡A vomiting¡A combative & explosive type of behaviour problems¡A chorea. °Æ§@¥Î: Hypotension¡A tardive dyskinesia¡A extrapyramidal reactions. Blurred vision¡A blood disorders¡A GI disturbances. CV disorders¡A photosensitivity. CNS disorders. ¸T§Ò: Coma¡A severe CNS depression¡A parkinsonism.,,«Ç·Å,May be taken with or without food (May be taken w/ meals to minimise GI irritation.). Antipsychotic: Oral: Adult:0.5-5 mg bid-tid initially¡A adjusted as needed. Child: 3-12 yrs¡A 0.05-0.15 mg/kg/day in 2-3 divided doses. Mental retardation with hyperactivity: 10-15 mg/day in divided doses up to 60 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LBM1,Opium Tincture + Glycyrrhiza + Antimony K tartrate,Brown mixture 120mL,ERSP,Expectorant & antitussive.,Hypersensitivity to any component of the formulation. Severe respiratory depression. Severe liver impairment. Acute alcoholic intoxication.,Constipation¡A Nausea¡A Vomiting¡A Dizziness¡A Lightheadedness¡A Sedated¡A Hypotension¡A Tachycardia¡A Seizure¡A Apnea¡A Respiratory depression¡A Drug withdrawal.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Adult: 5 mL TID-QID. Can titrate dose up or down if needed.,µL»Ý½Õ¾ã¾¯¶q,Severe impairment: No dosage adjustment provided in manufacturer¡¦s labeling; has not been studied.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,OPIUM: Human Data Suggest Risk in 3rd Trimester Glycyrrhiza + Antimony K tartrateµL¸ê®Æ,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥¤Î­÷¨Å¤£«ØÄ³¨Ï¥Î OPIUM: No Human Data¡XProbably Compatible Glycyrrhiza + Antimony K tartrateµL¸ê®Æ,AC;AC15;PC;PO;WM;,,,,,
OGLUS,Glucosamine Sulphate,Glustrong 250mg,CNEU,,Vertebral artrosis¡A coxofemoral¡A scapulo-humeral¡A gonarthrosis¡A periarthritis¡A lumbosciatalgies¡A arthrosis of any etiology.,,RT,4-6 cap daily for 30-60 days.,,,,¨S¦³¸ê®Æ,,,,,,,,,,
IMID,Midazolam,Midatin inj 5mg/1mL,ZANE,,¾AÀ³¯g: Sedation with amnesia; sedation in intensive care; premed¡A induction of anaesth. °Æ§@¥Î: Rarely cardio-resp adverse events¡A nausea¡A vomiting¡A headache¡A hiccoughs¡A laryngospasm¡A dyspnoea¡A hallucination¡A oversedation drowsiness¡A ataxia¡A paradoxical reactions¡A amnesic episodes. ¸T§Ò: Premature infants. Myasthenia gravis.,,«Ç·Å,Premed before an operation 20-30 mins before induction of anaesth¡A alone or in combination with anticholinergics. Adult 0.07-0.1 mg/kg IM. Children 0.15-0.2 mg/kg body weight by IM. Sedation in interventions under local anaesth 2.5-5 mg IV 5-10 mins before start of operation. Elderly > 60 years 1-3.5 mg IV slowly. Induction agent in inhalation anesth or sleep-inducing component in combined anesth 10-15 mg IV in combination with analgesics. Maintenance of anesth Further small doses should be injected IV or by continuous infusion. Sedation in ICU Dosage should be individualised & titrated to the desired state of sedation. Loading dose: 0.03-0.3 mg/kg. Maintenance dose: 0.03-0.2 mg/kg/hr.,,,,ºÉ¶qÁ×§K,,,,,,,,,,
OMELE,Mexiletine,Meletin 100mg,CAVS,Ventricular arrhythmia.,Gastrointestinal: Heartburn¡A Nausea¡A Vomiting Neurologic: Coordination problem (approximately 10% )¡A Dizziness¡A Lightheadedness¡A Tremor (13.2% ) Ophthalmic: Blurred vision¡A Visual disturbance Psychiatric: Feeling nervous (5% to 11.3% ),Indigestion; hiccups; unpleasant taste¡A nausea¡A vomiting; joint pains; drowsiness¡A dizziness; confusion; disarticulated speech; blurred vision; nystagmus; tremor; paresthesia¡A ataxia; convulsions; hypotension¡A sinus bradycardia¡A atrial fibrillation¡A palpitations.,15-30¢Jºò±K®e¾¹,Initially¡A 400 mg as loading dose. Maintenance dose should be started 2-6 hours after initial dose. Usual daily dosage: 400-800 mg in 2-3 divided doses; maximum: 1200 mg/day.,»Ý½Õ¾ã¾¯¶q,±w¦³µL¥NÀv©Ê¨xµw¤Æ¤§¯f±w¡AÀ³¨Ì¯f±w­Ó§Oª¬ªp½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¥»ÃÄÀ³¨Ö¥Î¨¬¶q²GÅé¥B¾ã²É§]ªA¡C
ONEU1,Gabapentin,Neurontin 100mg,CNEU,Adjunctive therapy for the treatment of partial seizures with and without secondary generalization in adults and pediatric patients 3 years and older and postherpetic neuralgia in patients 18 years and older.,Hypersensitivity to gabapentin or any component of the product.,Common: Peripheral edema (1.7-8.3%)¡A Nausea (Greater than 1%)¡A Vomiting (3.3%)¡A Viral disease (10.9%)¡A Ataxia (Adult¡A 3%; adult and adolescent¡A 13%)¡A Nystagmus (Adult and adolescent¡A 8%)¡A Fatigue (3-11%)¡A Fever (Pediatric¡A 10%) Serious: Stevens-Johnson syndrome¡A Hypoglycemia¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Dizziness (Adults¡A 28%; adults and adolescents¡A 17%; pediatrics¡A 3%)¡A Somnolence (Adults¡A 21%; adults and adolescents¡A 19%; pediatrics¡A 8%)¡A Disorder of form of thought (Pediatric¡A 1.7%)¡A Disturbance in thinking (2-3%)¡A Hostile behavior (Pediatric¡A 5.2%)¡A Hyperactive behavior (Pediatric¡A 4.7%)¡A Mood swings (Pediatric¡A 6%)¡A Suicidal thoughts¡A Respiratory depression¡A Angioedema,«Ç·Å15¢XC¦Ü30¢XC,Epilepsy: Adults and pediatric patients 12 years and older: 900-1800 mg/day divided equally into three doses. The Initial dose is 300 mg TID. Dosages can then be titrated up as needed to a maximum of 1800 mg/day in three divided doses. Doses up to 2400 mg/day have shown good tolerability in some patients. Doses should not exceed 12 hour intervals to prevent breakthrough seizures. Pediatric patients aged 3-12 years: Initial dose range 0-15 mg/kg/day given TID. Aged >=5 years: 25-35 mg/kg/day divided into three doses. Aged 3 to <5 years: 40 mg/kg/day divided into three doses. Maximum dose: 50 mg/kg/day. Doses should not exceed 12 hour intervals. Therapeutic drug monitoring of gabapentin plasma concentrations is not required. Gabapentin may be used in combination with other antiepileptic drugs without concern for alteration of gabapentin concentrations or concentrations of concomitant antiepileptic drugs. Neuropathic Pain in Adults: Initial dose 900 mg/day divided TID. Maximum dose 1800 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ] Gabapentin¥i¬ï³z¤HÃþªº­L½L¡C´¿¦³³ø§i¨Ï¥Îgabapentin¦³¥ý¤Ñ©Ê·î§Î»P¤£¨}¤§Ãh¥¥µ²ªG¡AµM¦Ó¥Ø«e¹ï¥¥°ü¤´µL¨¬°÷§¹¾ã¥B±±¨î¨}¦nªº¬ã¨s¡A¨Ã¥B¹ï©óÃh¥¥´Á¶¡¨Ï¥Îgabapentin¬O§_»P¥ý¤Ñ©Ê·î§Î©Î¨ä¥Lµo¨|¤£¨}µ²ªGªº­·ÀI¼W¥[¦]ªGÃö«Y¤´µL©ú½Tµ²½×¡C±µ¨ü§ÜÅöíwÃÄ«~ªvÀøªº¥À¿Ë¡A¨ä¤l¤k¦³¥X¥Í¯Ê³´ªº­·ÀI¼W¥[¤F2-3­¿¡C °Êª«¬ã¨s¤wÅã¥Ü¨ã¥Í´Þ¬r©Ê¡C¹ï¤HÃþªº¼ç¦b­·ÀI¥¼ª¾¡C·í¹ï¥À¿Ëªº¼ç¦b®Ä¯q©úÅã¤j©ó¹ï­L¨àªº¼ç¦b­·ÀI®É¤~¯à©óÃh¥¥´Á¶¡¨Ï¥Îgabapentin¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Gabapentin·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡C¥Ñ©ó¥¦¹ï¦Y¥À¥¤¤§À¦¨àªº¼vÅT¤£©ú¡A¬G¶·ÂÔ·V¥Î©ó±Â¨Åªº¥À¿Ë¡C±Â¨Åªº¥À¿Ë¥u¦³¦bªvÀø®Ä¯q©ú½TÀu©ó¦MÀI©Ê®É¡A¤~¥i¨Ï¥Îgabapentin¡C,AC;AC15;PC;PO;WM;,,,,,
OPAR,Selegiline,Parkryl 5mg,CNEU,,¾AÀ³¯g: Parkinson's disease. °Æ§@¥Î: Psychokinesia¡A insomnia¡A hallucination¡A GI disturbances. Gastrointestinal: Abdominal pain (4% )¡A Nausea (10 to 11% )¡A Oral irritation Neurologic: Dizziness (11% )¡A Headache (7% )¡A Insomnia (7% ) Psychiatric: Hallucinations (4% ) ¸T§Ò: Active ulceration. Pregnancy and lactation.,,«Ç·Å,Parkinson's disease¡A in combination with levodopa/carbidopa; Adjunct: 5 mg ORALLY twice a day (with breakfast and lunch); MAX 10 mg/day Parkinson's disease¡A in combination with levodopa/carbidopa; Adjunct: (Zelapar(TM) orally disintegrating TAB) initial¡A 1.25 mg dissolved ORALLY on the tongue once daily (before breakfast) for at least 6 weeks Parkinson's disease¡A in combination with levodopa/carbidopa; Adjunct: (Zelapar(TM) orally disintegrating TAB) maintenance¡A may increase dose up to 2.5 mg dissolved ORALLY on the tongue once daily (before breakfast)¡A MAX 2.5 mg/day,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OLIVA,Pitavastatin,Livalo 2mg,CAVS,,¸T§Ò: Hypersensitivity to pitavastatin or any component of the formulation; active liver disease including unexplained persistent elevations of hepatic transaminases; concurrent use with cyclosporine; pregnancy; breast-feeding °Æ§@¥Î: 2% to 10%: Gastrointestinal: Constipation (2% to 4%)¡A diarrhea (2% to 3%) Neuromuscular & skeletal: Back pain (1% to 4%)¡A myalgia (2% to 3%)¡A pain in extremities (1% to 2%) <2% (Limited to important or life-threatening): Alkaline phosphatase increased¡A amnesia (reversible)¡A arthralgia¡A bilirubin increased¡A blood glucose increased¡A cognitive impairment (reversible)¡A confusion (reversible)¡A CPK increased¡A glycosylated hemoglobin (Hb A1c) increased¡A headache¡A hyperglycemia¡A influenza¡A memory disturbance (reversible)¡A memory impairment (reversible)¡A nasopharyngitis¡A pruritus¡A rash¡A transaminases increased¡A urticaria ¾AÀ³¯g:Primary hyperlipidemia and mixed dyslipidemia for Adult and 10 years older chindren.,,«Ç·Å,Dosing: Adult:Primary hyperlipidemia and mixed dyslipidemia: Oral: Initial: 2 mg once daily; may be increased to maximum 4 mg once daily 10 years older chindren: Oral: Initial: 1 mg once daily; may be increased to maximum 2 mg once daily Note: Doses should be individualized according to the baseline LDL-cholesterol levels¡A the recommended goal of therapy¡A and patient response; adjustments should be made at intervals of 4 weeks. Dosage adjustment with concomitant medications: Erythromycin: Pitavastatin dose should not exceed 1 mg once daily Rifampin: Pitavastatin dose should not exceed 2 mg once daily Dosing: Geriatric Refer to adult dosing. Safety and efficacy not established in pediatric patients,»Ý½Õ¾ã¾¯¶q,1 mg once daily; may be increased to maximum 2 mg once daily,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of pitavastatin during human lactation or measuring the amount¡A if any¡A of the drug excreted into milk have been located. Because of the potential for adverse events in nursing infants¡A pitavastatin use is contraindicated during lactation,,,,,,
INS1,Sodium Chloride,Sodium chloride 0.9% inj 1000mL,MSIV,¬°­¹ÆQ¤ô¨R¬~²G(A001085209),,,«Ç·Å,Individualized dosage.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IRR;IVD;,,,,,
IMYC,Micafungin,Mycamine inj 50mg,QANB,Candidemia¡A acute disseminated candidiasis¡A and Candida peritonitis and abscesses¡A Esophageal candidiasis¡A Prophylaxis of Candida infection in hematopoietic stem cell transplantation,Hypersensitivity to micafungin¡A other echinocandins¡A or any component of the formulation,>10%: Cardiovascular: Tachycardia (3% to 26%)¡A localized phlebitis (with peripheral administration; 5% to 19%) Central nervous system: Headache (2% to 44%)¡A insomnia (4% to 37%)¡A anxiety (?23%)¡A dizziness (13%) Dermatologic: Pruritus (pediatric patients ages 3 days through 16 years: ?33%; adults 6%)¡A skin rash (2% to 30%)¡A urticaria (pediatric patients ages 3 days through 16 years: ?19%; adults <5%) Endocrine & metabolic: Hypokalemia (14% to 18%)¡A hypomagnesemia (6% to 13%) Gastrointestinal: Diarrhea (7% to 77%)¡A nausea (7% to 71%)¡A vomiting (7% to 66%)¡A abdominal pain (2% to 35%)¡A abdominal distension (pediatric patients ages 3 days through 16 years: 2% to 19%)¡A mucositis (14%)¡A constipation (11%) Genitourinary: Decreased urine output (pediatric patients ages 3 days through 16 years: ?23%)¡A hematuria (pediatric patients ages 3 days through 16 years: ?23%) Hematologic & oncologic: Neutropenia (5% to 75%)¡A thrombocytopenia (4% to 75%)¡A anemia (pediatric patients ages 3 days through 16 years: 13% to 51%; adults 3% to 10%)¡A febrile neutropenia (?16%) Hepatic: Increased serum ALT (pediatric patients ages 3 days through 16 years: ?16%; adults 5%)¡A abnormal hepatic function tests (pediatric patients ages 3 days through 16 years: <15%; adults 4%)¡A hyperbilirubinemia (pediatric patients ages 3 days through 16 years: <15%; adults <1%) Renal: Renal failure (pediatric patients ages 3 days through 16 years: <15%) Miscellaneous: Fever (pediatric patients ages 3 days through 16 years: 9% to 61%; adults 7% to 20%)¡A infusion related reaction (pediatric patients ages 3 days through 16 years: ?16%; adults <5%),15-30¢JÁ×¥ú,Adult: Candida esophagitis: 150 mg IV Q24H; candidemia: 100 mg IV Q24H; prophylaxis¡A post transplant: 50 mg IV Q24H. Children > 4 months: Esophageal candidiasis: (weight< 30 kg) 3 mg/kg Q24H or (weight > 30 kg) 2.5 mg/kg Q24H (maximum 150 mg); candidiasis: 2 mg/kg Q24H (maximum 100 mg); prophylaxis in HSCT recipients: 1 mg/kg Q24H (maximum 50 mg).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,IVD: 5mL N/S¡A D5W(»Ý´î¤Öªwªj§Î¦¨),¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,µ¹ÃÄ¿@«×0.5~1.5mg/mL¡A«ØÄ³ºwª`1¤p®É¥H¤W,¥»«~°t»s«áÀ³Á×¥ú¡A¨Ã¥iÀx¦s¦b­ì¤p²~¤º¡A«Ç·Å25¢J(77¢K)¤U³Ì¦h«O¦s24¤p®É¡C
ITTA1,Tetanus Toxoid Alum Precipitate,Tetanus Toxoid 0.5mL/dose¡A 1mL/vial,HIMM,,¾AÀ³¯g: Active immunization of tetanus. °Æ§@¥Î: Drowsiness¡A malaise¡A hypersensitivity. ¸T§Ò¡GHypersensitivity to tetanus toxoid or any component of the formulation,,2-8¢J,IM¡A 0.5 mL/dose. Primary immunization: I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose Routine booster dose: Recommended every 10 years Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated¡A the immunization status of the patient¡A proper use of tetanus toxoid and/or tetanus immune globulin (TIG)¡A wound cleaning¡A and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,IM;,,,,,
IHALA,Eribulin,Halaven inj 1mg/2mL,RACA,Treatment of Breast cancer¡A metastatic.,Hypersensitivity to eribulin mesylate¡A halichondrin B¡A or its chemical derivatives.,>10%: Central nervous system: Fatigue (54%)¡A fever (21%)¡A headache (19%) Dermatologic: Alopecia (45%) Gastrointestinal: Nausea (35%)¡A constipation (25%)¡A weight loss (21%)¡A anorexia (20%)¡A diarrhea (18%)¡A stomatitis (5% to 18%)¡A vomiting (18%) Hematologic: Neutropenia (82%; grades 3: 28%; grade 4: 29%; nadir: 13 days; recovery: 8 days)¡A anemia (58%; grades 3/4: 2%) Hepatic: ALT increased (18%) Neuromuscular & skeletal: Weakness (54%)¡A peripheral neuropathy (35%; grades 3/4: ?8%)¡A arthralgia/myalgia (22%)¡A back pain (16%)¡A bone pain (12%)¡A limb pain (11%) Respiratory: Dyspnea (16%)¡A cough (14%) 1% to 10%: Cardiovascular: Peripheral edema Central nervous system: Depression¡A dizziness¡A insomnia Dermatologic: Rash Endocrine & metabolic: Hypokalemia Gastrointestinal: Mucosal inflammation (9%)¡A abdominal pain¡A dyspepsia¡A taste alteration¡A xerostomia Genitourinary: Urinary tract infection (10%) Hematologic: Neutropenic fever (5%)¡A thrombocytopenia (grades 3/4: 1%) Neuromuscular & skeletal: Muscle spasm Ocular: Lacrimation increased Respiratory: Upper respiratory infection <1% (Limited to important or life-threatening): Pancreatitis¡A pharyngolaryngeal pain¡A sepsis,25¢J¥H¤U,1.4 mg/m2 on days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.,»Ý½Õ¾ã¾¯¶q,Mild hepatic impairment (Child-Pugh class A): Reduce initial dose to 1.1 mg/m2. Moderate hepatic impairment (Child-Pugh class B): Reduce initial dose to 0.7 mg/m2.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,¼t°Ó Ãh¥¥¤À¯Å«Ø¥ß: D,IVD;,,¡iN/S¡j¥é³æ«ØÄ³¡C,,¥iµ¹¤©¥¼µ}ÄÀ©Î¥H100 mL 0.9% ´â¤Æ¶u·»²Gµ}ÄÀ«áªºª`®g²G¡C ÀR¯ßª`®gµ¹ÃÄ®É¶¡¬°2¦Ü5¤ÀÄÁ¡C,¤£¥i¥H¸²µå¿}·»²Gµ}ÄÀ©Î§t¸²µå¿}·»²G¤§ÀR¯ßª`®gºÞ½uµ¹ÃÄ¡C
OCEFA,Cefadroxil,Cefadroxil 500mg ½çºÖ±o­×,QANB,Susceptible infections.,Hypersensitivity to cephalosporins.,Nausea¡A vomiting¡A diarrhoea¡A abdominal discomfort; skin rash¡A angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida. Potentially Fatal: Anaphylactic reaction; pseudomembranous colitis.,25¢J¥H¤UÁ×¥ú,(¥é³æ) Adults: 1-2 g orally in 1-2 divided doses daily. (Uptodate) Children and adolescents: 15-30 mg/kg/dose every 12 hours (maximum daily dose: 2 g/day),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OPKM,Amantadine,PK-Merz 100mg,CNEU,,¾AÀ³¯g: Parkinsonism of various origin¡A senile Parkinsonism¡A residual symptoms & discomfort after stereotactic operations. °Æ§@¥Î: Occasional dry mouth; dizziness. Paranoid exogenous psychoses associated with visual hallucinations¡A visual disturbances; motor or mental restlessness¡A urinary retention in the case of prostatic hypertrophy¡A signs of cardiac insufficiency¡A cardiac dysrhythmia associated with tachycardia¡A nausea¡A sleep disturbances¡A orthostatic dysregulation; very rarely¡A myoclonus & symptoms of peripheral neuropathy; livedo reticularis (marble skin) & lower-leg & ankle oedema are common occurrences; very rarely¡A increased photosensitivity; very rarely haematological side effects¡A such as leukopenia & thrombocytopenia; very rarely¡A anaphylactic reactions after infusion therapy. Cardiovascular: Orthostatic hypotension (1% to 5% )¡A Peripheral edema (1% to 5% ) Gastrointestinal: Constipation (1% to 5% )¡A Diarrhea (1% to 5% )¡A Loss of appetite (1% to 5% )¡A Nausea (5% to 10% )¡A Xerostomia (1% to 5% ) Neurologic: Ataxia (1% to 5% )¡A Confusion (1% to 5% )¡A Dizziness (5% to 10% )¡A Headache (1% to 5% )¡A Insomnia (5% to 10% )¡A Somnolence (1% to 5% ) Psychiatric: Agitation (1% to 5% )¡A Anxiety (1% to 5% )¡A Depression (1% to 5% )¡A Dream disorder (1% to 5% )¡A Feeling nervous (1% to 5% )¡A Hallucinations (1% to 5% )¡A Irritability (1% to 5% ) Other: Fatigue (1% to 5% ) ¸T§Ò: Severe CHF (NYHA class IV)¡A cardiomyopathies & myocarditis¡A 2nd or 3rd degree AV block¡A existing bradycardia under 55 beats/min¡A known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis ¡A history of serious ventricular arrhythmias including torsade de pointes¡A simultaneous treatment with budipine or other drugs that prolong the QT interval¡A reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.,,«Ç·Å,100 mg/day for the first 4-7 days¡A followed by a once-weekly increase in daily dose of 100 mg until the maintenance dose is reached. Usual effective dose: 200-600 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OWELL,Bupropion,Wellbutrin SR 150mg (±Æ¸Ë),CNEU,,¾AÀ³¯g: Treatment of depressive illnesses. °Æ§@¥Î: Very common: Insomnia¡A headache¡A dry mouth¡A GI disturbances eg nausea & vomiting. Common: Hypersensitivity reactions eg urticaria¡A anorexia¡A agitation¡A anxiety¡A tremor¡A dizziness¡A taste disorders¡A visual disturbances¡A tinnitus¡A hypertension¡A flushing¡A abdominal pain¡A constipation¡A rash¡A pruritus¡A sweating¡A fever¡A chest pain¡A asthenia. Cardiovascular: Hypertension (2.5% to 4.3% )¡A Tachyarrhythmia (10.8% ) Dermatologic: Pruritus (2% to 4% )¡A Rash (3% to 5% )¡A Urticaria (1% to 2% ) Gastrointestinal: Constipation (5% to 26% )¡A Nausea (9% to 24% ) Musculoskeletal: Arthralgia (1% to 5% )¡A Myalgia (2% to 6% ) Neurologic: Confusion (8.4% )¡A Dizziness (6% to 22.3% )¡A Headache (approximately 25% )¡A Insomnia (11% to 40% )¡A Tremor (2% to 21.1% ) Otic: Tinnitus (3% ) Psychiatric: Agitation (2% to 31.9% )¡A Anxiety (3.1% to 8% )¡A Hostile behavior (6% ) Reproductive: Disorder of menstruation (5% ) Respiratory: Pharyngitis (3% to 11% ) Other: Xerostomia (10% to 27.6% ) ¸T§Ò: Seizure disorder¡A undergoing abrupt discontinuation of alcohol or sedatives¡A current or previous diagnosis of bulimia or anorexia nervosa. Concomitant with other MAOIs.,,«Ç·Å,Adult & adolescents > 18 years Initially 150 mg as a single daily dose. Max: 300 mg/day in 2 divided doses at least 8 hr apart.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IKCL6,Potassium Chloride,§NÂÃ20mEq KCl in¡iD5W 250mL¡j,NUTR,,,,2-8¢J,Adult: Initial loading dose: 40~60 mEq¡A with ECG monitoring then based on serum potassium levels¡A Serum K>2.5 mEq/L: concentration < 30 mEq/L¡A with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia¡A treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
ICEFT,Ceftazidime,Cetazine inj 1gm,QANB,Severe infections of resp tract¡A ENT¡A urinary tract¡A GI¡A biliary & abdominal. Skin & soft tissue infections¡A bone & joint infections. Infections associated with haemo- & peritoneal dialysis & with continuous ambulatory peritoneal dialysis (CAPD).,Hypersensitivity to cephalosporins.,Phlebitis or thrombophlebitis at IV inj site¡A pain &/or inflammation after IM inj. Hypersensitivity reactions¡A maculopapular or urticarial rash¡A fever¡A pruritus. GI disturbances¡A candidiasis¡A vaginitis¡A headache¡A dizziness¡A parasthesia¡A bad taste. Transient hematological changes. Cardiovascular: Phlebitis (less than 2%) Dermatologic: Injection site pain Gastrointestinal: Diarrhea (less than 2%) Immunologic: Immune hypersensitivity reaction¡A Rash (2%),25¢J¥H¤UÁ×¥ú,Adults: 0.5-2 g IV/IM Q8-12H; cystic fibrosis: 100-150 mg/kg/day (divided Q8H). Children aged 2 months to 1 years: 25-50 mg/kg Q8-12H *****NEONATE ANTIBIOTICS DOSE***** Ceftazidime (Fortum): general infection Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50mg/kg Q12H  Age 15-28 day 50 mg/kg Q8H Body weight 1-2kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H Meningitis: use smaller doses and longer intervals for neonates <2 kg Age<=7days 100-150 mg/kg/day divided Q12-Q8H 8-28 days 150 mg/kg/day divided Q8H Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight 1-2kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IMP;IVD;IVI;IVP;IVPUSH;SCI;SUBCI;,"IM: 3.5 mL D/W; IV: 10mL D/W¡A N/S¡A D5W",¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ,µ¹ÃÄ¿@«×20mg/mL¡A¥H20 ~ 30¤ÀÄÁ½wºCºwª`,1. ª`®g«e¸ß°Ý¯f±w¬O§_¦³£]-ñQÓiÃþ§Ü¥Í¯À¹L±Ó¥v¡C 2. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡BPT­È¡Aª`·N¬O§_µo¥Í§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 3. 2020/11/26¸ß°Ý¼t°Ó: 2-8«×C«O¦s¡A¥D¦¨¥÷¦w©w©Ê¬°4¤Ñ¡C
EPRE2,Prednisolone,Pred Mild 0.12% 5mL oph susp,TOPH,,¾AÀ³¯g: Steroid responsive inflammation of the palpebral & bulbar conjunctiva¡A cornea & anterior segment of the globe. °Æ§@¥Î: Increased intraocular pressure with optic nerve damage¡A visual field defects. Posterior subcapsular cataract formation (heavy or protracted use)¡A secondary ocular infection from fungi or viruses liberated from ocular tissues & perforation of the globe when there is thinning of the cornea or sclera. Systemic side effects may occur with extensive use of steroids. ¸T§Ò: Acute untreated purulent ocular infections¡A acute superficial herpes simplex (dendritic keratitis)¡A vaccinia¡A varicella & most other viral diseases of the cornea & conjunctiva¡A ocular TB & fungal diseases of the eye.,,«Ç·Å,1-2 drop bid-qid; during the initial 24-48 hr the dosage may be increased to 2 drop hrly.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
EETH7,Alcohol,75% Ethanol 200mL,TDER,,,,25¢J¥H¤U,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,EXT;,,,,,
OXELJ,Tofacitinib,Xeljanz 5mg,HIMM,Rheumatoid arthritis (Moderate to Severe)¡A Psoriatic arthritis¡A Ankylosing spondylitis¡A Ulcerative colitis (Moderate to Severe),Hypersensitivity to tofacitinib or any component of the formulation,Common: Increased HDL level (10-12%)¡A Low density lipoprotein cholesterol above reference range (15-19%)¡A Headache (3.4-9%)¡A Urinary tract infectious disease (2%)¡A Nasopharyngitis (2.8-14%)¡A Upper respiratory infection (3.8-6%) Serious: Cardiovascular morbidity¡A Major adverse cardiac events (MACE)¡A Death¡A Cardiovascular¡A Myocardial infarction¡A Skin cancer¡A Non-melanoma¡A Gastrointestinal perforation¡A Anemia (2-4%)¡A Arterial thrombosis¡A Decreased lymphocyte count (0.04%)¡A Deep venous thrombosis¡A Neutropenia (0.07%)¡A Hepatotoxicity¡A Infectious disease (20-22%)¡A Malignant lymphoma¡A Opportunistic infection¡A Post-transplant lymphoproliferative disorder¡A Epstein Barr virus associated (2.3%)¡A Tuberculosis¡A Cerebrovascular accident¡A Lung cancer¡A Pulmonary embolism¡A Cancer,30¢J¥H¤U,Rheumatoid arthritis¡A psoriatic arthritis¡A ankylosing spondylitis: 5 mg orally twice daily. Ulcerative colitis induction dose 10 mg orally twice daily (8-16 weeks)¡A maintenance dose 5 mg orally twice daily.,»Ý½Õ¾ã¾¯¶q,Moderate impairment: Reduce dose to 5 mg (immediate release) once daily. Severe impairment: Use is not recommended (has not been studied in patients with severe hepatic impairment or in patients with hepatitis B or hepatitis C viruses).,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,PREGNANCY RECOMMENDATION: Contraindicated if Combined with Methotrexate,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Contraindicated if Combined with Methotrexate,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°§K¬Ì§í¨î¾¯¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OPRAD,Dabigatran,Pradaxa 110mg,HEMT,Prevention of venous thromboembolic events in patients who have undergone elective total hip or knee replacement surgery; stroke & systemic embolism in patients w/ atrial fibrillation in whom anti-coagulation is appropriate.,Severe renal impairment (CrCl <30 mL/min)¡A haemorrhagic manifestations¡A bleeding diathesis or patients w/ spontaneous or pharmacological impairment of haemostasis¡A lesions at risk of clinically significant bleeding¡A concomitant treatment w/ strong p-glycoprotein (p-gp) inhibitors eg ketoconazole.,Anemia¡A GI haemorrhage¡A haematoma¡A hematuria¡A wound haemorrhage; wound secretion¡A postprocedural haematoma¡A postprocedural haemorrhage¡A post-op anemia¡A traumatic haematoma¡A postprocedural discharge; ALT ¡Ù3 x ULN¡A decreased haemoglobin. Epistaxis¡A urogenital haemorrhage; abdominal pain¡A diarrhoea¡A dyspepsia¡A nausea.,30¢J¥H¤U¡AÁ×§KÀã®ð,Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation:adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily¡A with or without food. For prophylaxis of venous thrombosis of hip replacement surgery¡A starting 75mg within 1-4 hours after the operation¡A then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days¡A then 150mg twice a day for 6 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling; consistent changes in exposure or pharmacodynamics were not observed in a study of patients with moderate impairment.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©Î¥´¶}½¦Ån¡C­Y¯}Ãa¾¯«¬·|³y¦¨¥ÍÅé¥i¥Î²v¼W¥[1.4­¿¦Ó¼W¥[¥X¦å­·ÀI¡C
IHEPA1,Heparin,Hepac inj 1KIU/0.2mL (¥Ó³ø­p»ù),HEMT,,Hypersensitivity to any component of the formulation.,,25¢J¥H¤U,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IRR;IVD;,,,,,
IABI5,Cisplatin,Abiplatin inj 50mg/100mL,RACA,,¾AÀ³¯g: Metastatic testicular tumors¡A Metastatic ovarian tumors¡A Advanced bladder cancer. °Æ§@¥Î: Nausea & vomiting¡A renal toxicity¡A bone-marrow depression¡A ototoxicity¡A serum electrolyte disturbances¡A peripheral neuropathy¡A retinal toxicity¡A anaphylactic reactions¡A cardiac abnormalities. ¸T§Ò: Hearing or renal impairment¡A myelosuppression¡A dehydration.,,«Ç·Å,IV infusion over 6-8 hrs¡A As a single agent: 50-100 mg/ml once every 4 wks. Metastatic testicular tumors: combined with vinblastine & bleomycin¡A 20/mL/day for 5 days every 3 wks for 3 courses. Metastatic ovarian tumors: combined with doxorubicin¡A 50 mg/mL once every 3 wks.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gcisplatinªº¾¹¨ã¤£¥i§t¦³¾T¡C 3. µ}ÄÀ«áªº¿éª`·»²GÀ³Á×¥ú«O¦s¡C 4. µ¹ÃÄ«e«áÀ³µ¹¤©¯f¤H¾A·í¤ô¤À¸É¥R¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C 6. ©w´Á¯«¸g¾Ç¡BÅ¥¤OÀË´ú¡C
ECLOO,Clobetasol,Clobetasol ointment 0.05% 7gm,TDER,,¾AÀ³¯g: Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids. °Æ§@¥Î: Features of hypercorticism¡A local atrophic changes¡A pigmentation changes & hypertrichosis. Exacerbation of symptoms may occur. ¸T§Ò: Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus; primary cutaneous viral infection; bacterial¡A fungal infected skin lesions; perianal & genital pruritus; dermatoses in infant < 1 year including dermatitis & napkin eruptions. ¬O¤@ºØ±j®ÄªºÃþ©T¾JÃÄ»I¡A±j®ÄÃþ©T¾J¬O¸û¤£¾A¦X¡u¥Î¦b¨zªù¤Î¥Í´Þ¾¹¡v¡A¬O¦]¬°¦¹³¡¦ìªí¥Ö¼h«ÜÁ¡¡A­Y¦³µoª¢²{¶H¥i±Ä¥Î®z®Ä©Î¤¤®ÄÃþ©T¾J¡A¥H§K§l¦¬±j®ÄÃÄ«~¡A²£¥Í¤£¨}°Æ§@¥Î,,«Ç·Å,Apply sparingly to the affected area once or bid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;SKIN;TOPI;,,,,,
OCOMT,Entacapone,Comtan 200mg,CNEU,Pregnancy & lactation. Liver impairment. Pheochromocytoma. Concomitant use w/ non-selective MAO-A & MAO-B inhibitors. Concomitant use w/ a selective MAO-A plus a selective MAO-B inhibitor. History of neuroleptic malignant syndrome (NMS) &/or non-traumatic rhabdomyolysis.,Management of Parkinson's disease as an adjunct to levodopa therapy.,Dyskinesia; GI symptoms; urine discoloration; fatigue¡A insomnia¡A paranoia¡A confusion¡A hallucinations; dizziness¡A postural hypotension¡A vertigo¡A headache; leg cramps¡A hyperkinesia¡A tremor¡A increased sweating; slight decrease in Hb¡A erythrocyte count¡A & hematocrit. Rarely¡A increases in liver enzymes.,30¢J¥H¤U,Entacapone is used in combination with either levodopa/carbidopa or levodopa/benserazide. Other antiparkinsonian drugs may be used simultaneously. Give 200 mg orally with each dose of levodopa/dopa-decarboxylase inhibitor¡A up to a maximum of 10 times daily (maximum daily dose: 2000 mg); reductions in daily levodopa dose or extension of levodopa dosing intervals may be necessary to optimize patient's response. If entacapone treatment is discontinued¡A it is necessary to adjust the dosage of other antiparkinsonian treatments¡A especially levodopa¡A to achieve a sufficient level of control of the parkinsonian symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EDIF,Benzydamine,Difflam forte 3mg/mL¡A 15mL,CNEU,Relief of painful conditions of the mouth & throat including tonsillitis¡A sore throat¡A radiation mucositis¡A aphthous ulcers¡A post orosurgical & periodontal procedures.,Hepatic or renal impairment. children < 6 years. In bacterial infection¡A appropriate antibacterial therapy should be used in addition to product.,Oral numbness; dryness or thirst¡A tingling¡A warm feeling in mouth¡A altered sense of taste.,25¢J¥H¤U,Adult & children > 12 years: 2-4 sprays onto the affected area. Children 6-12 years: 2 sprays onto the affected area. May be repeated every 1.5-3 hourly. Duration should not exceed 7 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãþ§OB2¡C°Êª«¬ã¨s¸ê®ÆÅã¥Ü¥¼¦³¨¬°÷ªºÃÒ¾Ú·|¼W¥[¨ä¹ï­L¨àªº¶Ë®`¡C ¥¥°ü¨Ï¥Îbenzydamine hydrochlorideªº¦w¥þ©Ê©|¥¼«Ø¥ß¡A¥¥°ü¨Ï¥Î¥»«~«e¶·µû¦ô¨ä®Ä¯q©Ê¬O§_³Ó¹L¨ä¼ç¦bªº¦MÀI©Ê¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¥¼¦³¸ê®Æ¡C,ORO;,,,,,
IMTX,Methotrexate,Methotrexate 500mg/20mL inj,RACA,,¾AÀ³¯g:Oncology uses: Acute lymphoblastic leukemia (ALL) maintenance treatment¡A ALL meningeal leukemia (preservative-free only; prophylaxis and treatment); treatment of trophoblastic neoplasms (gestational choriocarcinoma¡A chorioadenoma destruens and hydatidiform mole)¡A breast cancer¡A head and neck cancer (epidermoid)¡A cutaneous T-Cell lymphoma (advanced mycosis fungoides)¡A lung cancer (squamous cell and small cell)¡A advanced non-Hodgkin lymphomas (NHL)¡A osteosarcoma (preservative-free only). Nononcology uses: Treatment of psoriasis (severe¡A recalcitrant¡A disabling) that is unresponsive to other therapies; severe¡A active rheumatoid arthritis (RA) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs); active polyarticular-course juvenile idiopathic arthritis (pJIA) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs). Off-Label: Abortion (medical management); Acute graft-versus-host disease (prophylaxis); Acute promyelocytic leukemia (APL) maintenance (adults); Bladder cancer; CNS lymphoma; Crohn disease (maintenance of remission); Dermatomyositis/polymyositis; Ectopic pregnancy; Multiple sclerosis; Nonleukemic meningeal cancer; Soft tissue sarcoma (desmoid tumors¡A aggressive fibromatosis)¡A advanced; Systemic lupus erythematosus¡A moderate-to-severe; Takayasu arteritis¡A refractory or relapsing disease; Uveitis (adults) °Æ§@¥Î:Ulcerative stomatitis¡A leukopenia¡A nausea & abdominal distress. malaise¡A fatigue¡A chills & fever¡A dizziness & decreased resistance to infection. Erythematous rashes¡A pruritus¡A urticaria¡A photosensitivity¡A depigmentation¡A alopecia¡A ecchymosis¡A telangiectasia¡A acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes¡A precipitating diabetes¡A osteoporosis¡A conjunctivitis¡A abnormal tissue cell changes¡A anaphylaxis. ¸T§Ò:Known hypersensitivity to methotrexate or any component of the formulation; breast-feeding. Additional contraindications for patients with psoriasis¡A rheumatoid arthritis or polyarticular-course juvenile idiopathic arthritis: Pregnancy¡A alcoholism¡A alcoholic liver disease or other chronic liver disease¡A immunodeficiency syndromes (overt or laboratory evidence); preexisting blood dyscrasias (eg¡A bone marrow hypoplasia¡A leukopenia¡A thrombocytopenia¡A significant anemia).,,RT,Choriocarcinoma: Oral or IM¡A 15-30 mg/day for a 5 day course. Acute leukemia: Induction¡A oral or IV¡A 3.3 mg/m2/day with prednisolone; maintenance¡A oral or IM¡A 30 mg/mL twice a week¡A or IV¡A 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal¡A 0.2-0.5 mg/kg or 12 mg/mL (max. 15mg) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma (stage I & II): Oral¡A 10-25 mg/day for 4-8 days. Psoriasis: Oral¡A IM or IV¡A 10-25 mg/week. Rheumatoid arthritis: Oral¡A 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral¡A 2.5-10 mg/day for weeks or months; IM¡A 50mg/week.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OTAM7,Oseltamivir,Tamiflu 75mg (¦Û¶O),QANB,Prophylaxis & treatment of influenza in adult & children.,Hypersensitivity.,Common: Nausea (8-10%)¡A Vomiting (Adult and adolescent¡A 2-8%; pediatric¡A 8-16%)¡A Headache (Influenza treatment¡A 2%; influenza prophylaxis¡A 17%) Serious: Cardiac dysrhythmia¡A Erythema multiforme (Rare)¡A Facial swelling¡A Stevens-Johnson syndrome (Rare)¡A Toxic epidermal necrolysis (Rare)¡A Gastrointestinal hemorrhage¡A Hemorrhagic colitis¡A Hepatitis¡A Anaphylaxis (Rare)¡A Seizure¡A Abnormal behavior¡A Delirium,25¢J¥H¤U,(¥é³æ) Influenza: Treatment (for patients > 1 year): - Adult: Usual Dose for uncomplicated influenza of <48 hrs duration: 75 mg PO BID x 5 days; complicated influenza in immunocompromised patients even if ill over 48 hrs: 75 mg PO BID x 10 or more days. - Children > 40 kg: 75 mg BID x 5 days - Children > 23-40 kg: 60 mg BID x 5 days - Children > 15-23 kg: 45 mg BID x 5 days - Children < or = 15 kg: 30 mg BID x 5 days - Infant 0-12 months: 3 mg/kg BID x 5 days Prophylaxis (for patients > 1 year): - Adults: 75 mg orally once daily for 10 days to 6 weeks. - Children > 40 kg: 75 mg QD x 10 days - Children > 23-40 kg: 60 mg QD x 10 days - Children > 15-23 kg: 45 mg QD x 10 days - Children < or = 15 kg: 30 mg QD x 10 days - Infants 3-11 months: 3 mg/kg once daily (¼ö¯f),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IOXA5,Oxacillin,Oxacillin Sod. inj 500mg,QANB,,¾AÀ³¯g:Staphylococcal infections resistant to benzylpenicillin °Æ§@¥Î:Fever; rash; diarrhoea¡A nausea¡A vomiting; agranulocytosis¡A eosinophilia¡A leukopenia¡A neutropenia¡A thrombocytopenia; AST increased¡A hepatotoxicity; acute interstitial nephritis¡A haematuria; serum sickness-like reactions. Potentially Fatal: Anaphylaxis. ¸T§Ò:Hypersensitivity to penicillins,,«Ç·Å,Infections due to staphylococci resistant to benzylpenicillin Adult: 0.5-1 g IM¡A slow IV over 10 minutes or by IV infusion every 4-6 hr. Doses may be increased in severe infections. Child: <40 kg: 50-100 mg/kg/day in divided doses. Elderly: Dosage adjustment recommended. Renal impairment: Dosage adjustment recommended,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1. ª`®g«eÀË¬d¯f±w¬O§_¦³PCN¹L±Ó¥v¡C 2. ¦Ñ¦~¤HÀ³´îºCµ¹ÃÄ³t²v¡AÁ×§Kµo¥Í¦å®ê©ÊÀR¯ßª¢ 3. ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡B¨xµÇ¥\¯à¡C
IPG2,Polysaccharides of Astragalus membranaceus,PG2 inj 500mg,RACA,As a complementary and palliative medicine for managing cancer-related fatigue.,1.Hypersensitivity to Astragalus. 2.Precautionary use in individuals with autoimmune disease 3.Discontinue prior to elective surgery to reduce risk of bleeding,Itching (2.38%)¡A skin rash (9.21%)¡A dizziness (2.38%)¡A Fever(7.24%)¡A feeling cold(5.26%)¡A chills(2.63%),25¢J¥H¤U°®Àê³BÁ×¥ú,Adults: 500 mg infused intravenously for 2.5-3.5 hours 2-4 times/week for a total of 2-4 weeks. Reconstitute each vial of 500 mg of PG2 with 10 mL normal saline. Shake thoroughly until dissolved completely. Mix the dissolved solution with normal saline (490mL) for IV infusion.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,¥ý©â10 mL N/S·»¸Ñ°®¯»¡A¨Ãª`®g¦^­ì500 mLÂIºw²~,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥ý©â10 mL N/S·»¸Ñ°®¯»¡A¨Ãª`®g¦^­ì500 mLÂIºw²~ «ØÄ³¥H2.5-3.5¤p®É½wºCºwª`¡A»Ý¨Ï¥Î0.22 micron fillter¹LÂo,1.»Ý¨Ï¥Î»Ý¨Ï¥Î0.22 micron fillter¹LÂo¡C 2.¥ý©â10 mL N/S·»¸Ñ°®¯»¡A¨Ãª`®g¦^­ì500 mLÂIºw²~¡C 3.¨C¶g2-4¦¸¨Ï¥Î¡A¨Ï¥Î2-4¶g¡C 4.­Y»Ý¹w¨¾¿éª`¤ÏÀ³¡A¥i©µªøºwª`®É¶¡¡C¸g¸ß°Ý¼t°Ó(20220518)¥»ÃÄªw»s«á¤§¦w©w©Ê¥i¹F24¤p®É¡A¦ý¦¹¦w©w©Ê¸ê®Æ¤£¥]§t°t»s®Éªº·L¥Íª«ÅÜ¦]¡C
IOLA5,Oxaliplatin,Olatin I.V. inj 50mg/10mL,RACA,,¾AÀ³¯g:Adjuvant treatment of stage III colon cancer after complete resection of primary tumor and advanced colorectal cancer (in combination with infusional fluorouracil and leucovorin). °Æ§@¥Î:Nausea¡A vomiting¡A diarrhea; anemia¡A leucopenia¡A granulocytopenia¡A thrombocytopenia; peripheral neuropathies; fever¡A rash¡A anorexia. Gastrointestinal: Abdominal pain (monotherapy¡A 31%; combination therapy¡A up to 39% )¡A Constipation (combination therapy¡A up to 32% )¡A Diarrhea (monotherapy¡A 46%; combination therapy¡A up to 76% )¡A Loss of appetite (monotherapy¡A 20%; combination therapy¡A up to 35% )¡A Nausea (monotherapy¡A 64%; combination therapy¡A up to 83% )¡A Stomatitis (monotherapy¡A 14%; combination therapy¡A up to 42% )¡A Vomiting (monotherapy¡A 4%; combination therapy¡A up to 64% ) Hematologic: Anemia (monotherapy¡A 64%; combination therapy¡A up to 81% )¡A Neutropenia¡A All grades (monotherapy¡A 7%; combination therapy¡A up to 81% ) Musculoskeletal: Backache Respiratory: Cough (monotherapy¡A 11%; combination therapy¡A up to 35% ) Other: Fatigue (monotherapy¡A 61%; combination therapy¡A up to 70% )¡A Fever (monotherapy¡A 25%; combination therapy¡A up to 29% ) ¸T§Ò:Hypersensitivity to oxaliplatin¡A other platinum-containing compounds¡A or any component of the formulation. Pregnancy¡A breast-feeding; severe renal impairment (CrCl <30 mL/minute),,«Ç·Å,Ovarian cancer: 130 mg/m2 every 3 weeks as single agent or in combination chemotherapy. Adult Adjuvant therapy 85 mg/m2 IV every 2 wk for 6 mth (12 cycles). Metastatic colorectal cancer 85 mg/m2 IV every 2 wk. Gastric cancer: usual dose is 65-85 mg/m2 IV infusion over 2 hours. Colon cancer or metastatic colorectal cancer¡A adjuvant¡A stage III or metastatic colorectal cancer: 85 mg/m2 every 2 wk in combination with infusional 5-fluorouracil/leucovorin. Colorectal cancer¡A advanced: 130 mg/m2 every 3 wk in combination with capecitabine.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gªº¾¹¨ã¤£¥i§t¦³¾T¡C¥»ÃÄ«~¤£¥i¨Ï¥Î§t¦³´âªºµ}ÄÀ·»²G (¨Ò¦p¡GN/S)¡Aµ¹ÃÄ®ÉÁ×§K©MÆP©ÊÃÄª«(¨Ò¦p¡G5-FU)¨Ï¥Î¬Û¦PºÞ¸ô¡C 3. µ}ÄÀ«áªº¿éª`·»²G¦b«Ç·Å¤U¦w©w©Êºû«ù6¤p®É¡C 4. ºÊ´úCBC¡BµÇ¥\¯à¡Aª`·N¯f¤H¬O§_¦³©I§l¤è­±ªº²§±`¯gª¬¡C 5. ©w´Á¯«¸g¾ÇÀË´ú¡C
LMEG4,Megestrol,Megatus 40mg/mL¡A 120mL suspension,HM,Treatment of anorexia¡A cachexia¡A or unexplained significant weight loss in patients with AIDS or cancer. Palliative treatment of breast and endometrial carcinoma.,1.Hypersensitivity to megestrol or any component of the formulation. 2.Known or suspected pregnancy.,Abdominal pain¡A chest pain¡A infections. Cardiomyopathy¡A palpitations. Constipation¡A dry mouth¡A liver enlargement¡A increased salivation¡A oral candida infections. Leukopenia¡A increased LDH¡A edema. CNS disturbances. Dysnea¡A cough¡A pharyngitis¡A lung disease. Hair loss¡A papule¡A pruritus & other skin disorders¡A poor vision¡A proteinuria¡A incontinence¡A UTI¡A gynecomastia. Cardiovascular: Hypertension (?8%)¡A cardiomyopathy (1% to 3%)¡A chest pain (1% to 3%)¡A edema (1% to 3%)¡A palpitation (1% to 3%)¡A peripheral edema (1% to 3%)¡A heart failure Central nervous system: Headache (?10%)¡A insomnia (?6%)¡A fever (1% to 6%)¡A pain (?6%¡A similar to placebo)¡A abnormal thinking (1% to 3%)¡A confusion (1% to 3%)¡A depression (1% to 3%)¡A hypoesthesia (1% to 3%)¡A seizure (1% to 3%)¡A mood changes¡A malaise¡A lethargy Dermatologic: Rash (2% to 12%)¡A alopecia (1% to 3%)¡A pruritus (1% to 3%)¡A vesiculobullous rash (1% to 3%) Endocrine & metabolic: Hyperglycemia (?6%)¡A gynecomastia (1% to 3%)¡A adrenal insufficiency¡A amenorrhea¡A breakthrough bleeding¡A cervical erosion and secretions (changes)¡A breast tenderness increased¡A Cushing's syndrome¡A diabetes¡A glucose intolerance¡A HPA axis suppression¡A hot flashes¡A hypercalcemia¡A menstrual flow changes¡A spotting¡A vaginal bleeding pattern changes Gastrointestinal: Diarrhea (6% to 15%¡A similar to placebo)¡A flatulence (?10%)¡A vomiting (?6%)¡A nausea (?5%)¡A dyspepsia (?4%)¡A abdominal pain (1% to 3%)¡A constipation (1% to 3%)¡A salivation increased (1% to 3%)¡A xerostomia (1% to 3%)¡A weight gain (not attributed to edema or fluid retention) Genitourinary: Impotence (4% to 14%)¡A decreased libido (?5%)¡A urinary incontinence (1% to 3%)¡A urinary tract infection (1% to 3%)¡A urinary frequency (?2%) Hematologic: Anemia (?5%)¡A leukopenia (1% to 3%) Hepatic: Hepatomegaly (1% to 3%)¡A LDH increased (1% to 3%)¡A cholestatic jaundice¡A hepatotoxicity Neuromuscular & skeletal: Weakness (2% to 6%)¡A neuropathy (1% to 3%)¡A paresthesia (1% to 3%)¡A carpal tunnel syndrome Ocular: Amblyopia (1% to 3%) Renal: Albuminuria (1% to 3%) Respiratory: Dyspnea (1% to 3%)¡A cough (1% to 3%)¡A pharyngitis (1% to 3%)¡A pneumonia (?2%)¡A hyperpnea Miscellaneous: Diaphoresis (1% to 3%)¡A herpes infection (1% to 3%)¡A infection (1% to 3%)¡A moniliasis (1% to 3%)¡A tumor flare Postmarketing and/or case reports: Thromboembolic phenomena (including deep vein thrombosis¡A pulmonary embolism¡A thrombophlebitis),25¢J¥H¤U³±²D³B,400-800mg(10-20mL)/day,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Use is contraindicated for the treatment of anorexia or cachexia in pregnant females with HIV infection. Megestrol may cause fetal harm if administered during pregnancy.(UpToDate)2021/0125,Unknown ¨S¦³¸ê®Æ,Due to the potential for adverse reaction in the breastfed newborn¡A the manufacturer recommends discontinuing breastfeeding while receiving megestrol for the treatment of cancer. Due to the potential for HIV transmission¡A breastfeeding is not recommended when treating females for anorexia or cachexia associated with HIV infection. (UpToDate)2021/0125,AC;AC15;PC;PO;WM;,,,,,
ICEF1,Cefazolin,Cefa inj 1gm,QANB,Susceptible infections¡A Surgical prophylaxis.,Hypersensitivity.,Superinfection; nausea¡A vomiting¡A abdominal pain¡A anorexia¡A diarrhoea; rash¡A leukopenia¡A thrombocytopaenia¡A haemorrhage¡A elevated transaminases.,Á×¥ú,"(¥é³æ) Usually¡A adult: 1 g/day; children: 25-50 mg/kg/day in 2 divided doses. For intravenous administration¡A inject directly over 3-5 minutes or infuse as an intermittent infusion over 30-60 minutes.(¼ö¯f) Adult 1-1.5 g IV/IM Q8H; 2 g IV Q8H for serious infection (maximum: 12 g/day). Pediatric 50-150 mg/kg/day (divided Q6-8H) (maximum: 6 g/day).(Uptodate) Surgical prophylaxis: 2 g for patients <120 kg or 3 g for patients > or =120 kg; administer within 60 minutes of surgical incision. " *****NEONATE ANTIBIOTICS DOSE***** Cefazolin: general infection Body weight <1kg ge<=7day 5 mg/kg Q12H  Age 8-14 day 5 mg/kg Q8H  Age 15-28 day 5 mg/kg Q8H Body weight 1-2kg ge<=7day 5 mg/kg Q12H  Age 8-14 day 25 mg/kg Q8H  Age 15-28 day 25 mg/kg Q8H Body weight >2kg Age<=7 day 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,IM;INS;IRR;IRRI;IS;IVD;IVP;IVPUSH;,IM: 3.5 mL D/W; 4.5 mL N/S; 4.5mL D5W IV: 10mL D/W¡A N/S¡A D5W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö 5¤ÀÄÁ,µ¹ÃÄ¿@«×10-20 mg/mL¡A¥H30~60¤ÀÄÁ¿éª`¡C,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡BPT­È¡C 2. ª`·N¬O§_µo¥Í§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 3. (IM) 1gm/vial °®¯»¥[¤J3.5 mL D/W ªw»s¡C 4. (IV bolus) 1gm/vial °®¯»¥[¤J5 mL D/W ªw»s¡A¦A¥[¤J5 mLµ}ÄÀ²G¡A½wºC±Àª`¦Ü¤Ö3 ~ 5¤ÀÄÁ¡C ¤p¨àµ¹ÃÄ«ØÄ³¡G IV push¡A 50-100 mg/mL over 3-5 minutes. In fluid-restricted patients¡A 138mg/mL has been administered. Intermittent infusion¡A 5-20 mg/mL over 10-60 minutes.
OMET1,Methylphenidate,apo-Methylphenidate 10mg,CNEU,Attention-deficit hyperactivity disorder; narcolepsy.,Anxiety & tension states¡A agitation¡A tics¡A tics in siblings¡A family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias¡A severe angina pectoris.,Frequent: nervousness¡A insomnia¡A decreased appetite. Occasional: headache¡A drowsiness¡A dizziness¡A dry mouth¡A tachycardia¡A palpitations¡A arrhythmias¡A changes in BP & heart rate; GI disturbances¡A skin reactions¡A fever¡A arthralgia. Rare: blurred vision¡A moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )¡A Loss of appetite (5% )¡A Nausea (12% )¡A Vomiting (10% ) Neurologic: Headache¡A Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )¡A Nasopharyngitis (5%),15-30¢J¡AÁ×§K¼ö¤Î¼éÀã,"Children >= 6 years: Initially 5 mg QD or BID with gradual increments of 5-10 mg weekly. maximum: 60 mg/day.Adult: 10 to 60 mg/day divided 2 to 3 times¡A preferably 30 to 45 minutes before meals. If the patient is unable to fall asleep due to taking the medicine late¡A the last dose should be taken before 6 pm. If no improvement in symptoms is seen after an appropriate dose adjustment for more than one month¡A the drug should be discontinued.",µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OCUR,Amoxicillin + Clavulanic Acid,Curam 1000mg,QANB,Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis.,History of hypersensitivity to £]-lactams. History of penicillin-associated jaundice/hepatic dysfunction.,Common: Diaper rash (3.5-6%)¡A Rash (1.1-3%)¡A Urticaria¡A Diarrhea (2.9-14.5%)¡A Loose stool (1.6-9%)¡A Nausea (up to 3%)¡A Vomiting (up to 2.2%)¡A Mycosis (3.3%)¡A Vaginitis (1%)¡A Candidiasis (1.4%) Serious: Drug reaction with eosinophilia and systemic symptoms¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Cholestasis¡A Hepatitis¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Angioedema¡A Serum sickness due to drug,25¢J¥H¤U,Adults and children > 12 years: Curam 1000 mg orally twice daily. Swallow whole tablets or in half. Curam 1000 mg is not recommended for children younger than 12 years.,µL»Ý½Õ¾ã¾¯¶q,[Micromedex 20200729] Hepatic impairment: Use with caution and monitor hepatic function with prolonged therapy,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,AMOXICILLIN: Human Data Suggest Low Risk CLAVULANATE¡A POTASSIUM: Compatible. [¥é³æ]§Q¥Î¤p¦Ñ¹«¤Î¤j¥Õ¹«©Ò¶i¦æªº°Êª«¸ÕÅç¤¤¡A¦b¸g¤f¤Îª`®gªº¤è¦¡§ë¤©amoxycillin + clavulanic acid «áÅã¥Ü¦¹ÃÄ¨Ã¤£·|¦³·î­Lªº±¡§Îµo¥Í. ¤@°w¹ï¥¥°ü¦­²£©M­F­L½¤¦­¼ô¯}µõ(premature rupture of the foetal membrane¡ApPROM)¶i¦æ¤§³æª¼¸ÕÅç«ü¥X¡A Amoxycillin+clavulanic acid¤§¹w¨¾Àøªk¥i¯à»P·s¥Í¨àÃa¦º©Ê¸zª¢ªº¦MÀI©Ê¼W¥[¦³Ãö¡C ¦p¦P©Ò¦³¨ä¥LÃÄ«~¤@¼Ë¡A­Y«DÂå®v»{¬°¦³¥²­n¡A¦bÃh¥¥´Á¶¡À³Á×§K¨Ï¥Î¡A ¤×¨ä¬O¦bÃh¥¥ªº«e¤T­Ó¤ë¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,AMOXICILLIN: Compatible CLAVULANATE¡A POTASSIUM: No Human Data - Probably Compatible. [¥é³æ]¦b±Â¨Åªº´Á¶¡¤´¥i¨Ï¥Îamoxycillin+clavulanic acid¡A¥»ÃÄ¥Î©ó¥ÀÅé®É¡A ¹ï©óÀ¦¨à¨Ã¤£·|¦³©Ò¶Ë®`¡A°ß¤@ªº¨Ò¥~¬O·í·L¶qªºÃÄª«ÀHµÛ¥À¨Å¶i¤JÀ¦¨àÅé¡H®É¡A ¥i¯à·|¦³³y¦¨¹L±Óªº¦MÀI¡C,PO;WM;,,,,,1. ¿õ¾¯»Ý¾ãÁû§]ªA¡A¤£¥i©CÄZ¡C¦p¦³»Ý­n¥i±N¿õ¾¯¤À¶}¦¨¨â¥b¥H§Q§]ªA¡A¦ý¤£¥i©CÄZ¡C 2. ¬°¤F±N¦¹ÃÄª«¹ï¸z­G©Ò³y¦¨ªº¤£¾A­°¦Ü³Ì§C¡AÀ³©ó¥ÎÀ\¶}©l®ÉªA¥Î¡C¦¹ÃÄ¦b¥ÎÀ\¶}©l®ÉªA¥Î¥i±o¨ì³Ì¨Î§l¦¬®ÄªG¡C
EBIS,Bisacodyl,Bisacodyl suppository 10mg,ALIM,Constipation. Preparation of diagnostic procedures¡A in pre- & post-examination & in conditions which require defecation to be facilitated.,Ileus¡A intestinal obstruction¡A acute surgical abdominal conditions including appendicitis¡A acute inflammatory bowel diseases & severe dehydration. Rare hereditary conditions of galactose intolerance eg. galactosemia or fructose intolerance. Lactation.,Rarely¡A abdominal cramps¡A abdominal pain & diarrhea. Allergic reactions.,25¢J¥H¤UÀx¦s,Dosing: Adult & children > 10 years Relief of constipation: Rectal: Suppository: 5-10 mg as single dose Children: Rectal (suppository) 4-10 years: 5mg <4 years: 5 mg as a single dose,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ] ©|µL¥»ÃÄ¥Î©óÃh¥¥°ü¤kªº¾A·í¤Î±±¨î¨}¦n¤§¬ã¨s¡Cªø´Á¥ÎÃÄ¸gÅçÅã¥ÜÃh¥¥´Á¶¡¡A¨Ï¥Î ¥»ÃÄµL¤£¨}¤ÏÀ³©Î¶Ë®`©Ê¡CµM¦Ó¡A¦p¦P©Ò¦³ªºÃÄª«¡AÃh¥¥´Á¶¡¡A°£«D¦³ÂåÅñ¡A§_«h¥¥°ü ¤£¥i¨Ï¥ÎBisacodyl¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Á{§É¸ê®ÆÅã¥Ü¡Abisacodylªº¬¡©Ê¦¨¤ÀBHPM(bis-(p-hydroxyphenyl)-pyridyl-2-methane)©Î¨ä¿}îÇ»Ä ¤Æ¦Xª«(glucuronides)³£¤£·|¤Àªc¶i¤J°·±d±Â¨Å°ü¤kªº¨Å¥Ä¤¤¡C,RECT;,,,,,
INUT1,Amino Acid + Dextrose + Electrolytes,Nutriflex peri 40/80 1000mL,NUTR,Parenteral nutrition when oral or enteral alimentation is impossible¡A insufficient or contraindicated.,Renal failure in the absence of haemodialysis¡A haemofiltration or haemo-diafiltration. Severe liver disease. Amino acid metabolism disorder. Metabolic acidosis¡A hyperlactataemia. Adrenal insufficiency. Hyperosmolar coma.,Hypertonic solutions may cause venous irritation if infused into a peripheral vein. Hyperglycaemia¡A glycosuria & hyperosmolar syndrome may occur.,15-25¢J¡A²V¦X«á¥ß§Y¿éª`¨Ã©ó24~48¤p®É¤º¿éª`§¹²¦,Adults Maximum daily dose: 40 ml /kg body weight/day¡A =1.6 g amino acids/kg body weight/day = 3.2 g glucose/kg body weight/day. Maximum infusion rate: 2.5 ml /kg body weight/hour¡A = 0.100 g amino acids/kg body weight /hour¡A=0.20 g glucose/kg body weight/hour. 2-17 years of age: Maximum daily dose: 50 ml/kg body weight/day¡A = 2.0 g amino acids/kg body weight/day =4.0 g glucose/kg body weight/day. 2 to 12 years of age: Maximum infusion rate: 2.5 ml /kg body weight/hour¡A =0.10 g amino acids/kg body weight/hour=0.20 g glucose/kg body weight/hour. 13 to 17 years of age Maximum infusion rate: 2.25 ml/kg body weight/hour¡A =0.09 g amino acids/kg body weight/hour=0.18 g glucose/body weight/hour. Nutrifex peri is contraindicated in newborn infants¡A infants and toddlers < 2 years of age.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¥»ÃÄ«~­­ÃÄ¾¯¬ì½Õ¾¯TPN¨Ï¥Î
OPREP,Cisapride,Prepulsid 5mg,ALIM,,Gastroparesis¡A gastro-oesophageal reflux disorders.,,,Adult: 5-10 mg bid-qid ¡A Child & infant: 0.2 mg/kg tid-qid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
INSW,Sodium Chloride,Normal Saline irrigation 500mL(¨R¬~¥Î),MSIV,,¾AÀ³¯g:¬°¥Í²z­¹ÆQ¤ô¨R¬~²G,,«Ç·Å,Individualised dosage.,,,,¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
ITRAS,Tranexamic Acid,Transamin S °w¾¯ 10% 10mL,HEMT,,¾AÀ³¯g: Hemorrhage¡A abnormal bleeding¡A genital & renal bleeding¡A bleeding due to prostatectomy. °Æ§@¥Î: GI disturbances. Gastrointestinal: Abdominal pain (oral¡A 19.8% ) Hematologic: Anemia (oral¡A 5.6% ) Musculoskeletal: Arthralgia (oral¡A 6.9% )¡A Backache (oral¡A 20.7% )¡A Cramp (oral¡A 6.5% )¡A Musculoskeletal pain (oral¡A 11.2% ) Neurologic: Headache (oral¡A 50.4% )¡A Migraine (oral¡A 6% ) Respiratory: Nasal sinus problem (oral¡A 25.4% ) Other: Fatigue (oral¡A 5.2% ),,«Ç·Å,Adult Cap/Tab 750-2000 mg/day tid-qid. Amp 250-500 mg/day in 1-2 divided doses IV/IM. During or after surgery: 500-1000 mg IV or 500-2500 mg by IV infusion.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. Clinical Management: There are limited data on nursing an infant while on tranexamic acid. Data have shown that only minimal amounts of the drug are excreted in breast milk. Breast milk concentrations were reported to be approximately 1% of peak serum levels 1 hour following the last dose of a 2-day treatment regimen. Tranexamic acid should only be used in a nursing mother only if clearly needed and use caution when tranexamic acid is administered to a nursing mother.,,,,,,1. ÀR¯ß¤ºª`®g®ÉÀ³½wºC¶i¦æ¡A«æ³tµ¹ÃÄ®É¡A¥i¯à·|¥X²{äú¤ß¡B¯Ý³¡¤£¾A¡B¤ß±ª¤®¶i©Î¦åÀ£¤U­°¡C
IDEPP,Medroxyprogesterone,Depo-provera inj 150mg,HM,,I : Contraception.,,,150mg every 3 mth,,,,,,,,,,,,,,
OHAR4,Tamsulosin,Harnalidge OCAS 0.4mg prolonged release,SGU,Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Hypersensitivity to tamsulosin or any component of the formulation,Cardiovascular: Orthostatic hypotension (6% to 19%) Central nervous system: Headache (19% to 21%)¡A dizziness (15% to 17%) Genitourinary: Abnormal ejaculation (8% to 18%) Respiratory: Rhinitis (13% to 18%) Miscellaneous: Infection (9% to 11%),30¢J¥H¤U,Benign prostatic hyperplasia: Oral¡A Initial and maintenance: 0.4 mg once daily¡A may increase to 0.8 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] »´«×¦Ü¤¤«×¨x¥\¯à¤£¥þªº±wªÌµL¶·½Õ¾ã¾¯¶q¡CÄY­«¨x¥\¯à¤£¥þªº±wªÌ¸T¥Î¡C,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä½¤¦ç¿õÀ³¾ã²É§]ªA¡A¤£¥i©CÄZ©Î¿i¸H¡C
IOXO,Oxytocin,Oxocin inj 10 IU/1mL,SGU,,¾AÀ³¯g:Induction of labor for medical reasons; stimulation or reinforcement of labor in hypotonic uterine inertia; during caesarean section¡A following delivery of the child; adjunctive therapy in the management of incomplete¡A inevitable¡A or missed abortion; prevention & treatment of postpartum uterine atony & haemorrhage. °Æ§@¥Î:Uterine spasm¡A uterine overstimulation (usually with excessive doses); water intoxication associated with maternal & neonatal hyponatraemia; nausea¡A vomiting¡A arrhythmias; rashes & anaphylactoid reactions. Rapid IV bolus inj may result in an acute short-lasting drop in BP. ¸T§Ò:Significant cephalopelvic disproportion or unfavorable presentation of the fetus¡A placenta praevia or vasa praevia¡A cord presentation or prolapse¡A mechanical obstruction to delivery¡A fetal distress or hypertonic uterine contractions; multiple pregnancy or high parity¡A polyhydramnios¡A or the presence of a uterine scar from previous caesarean section. Avoid prolonged administration in patients with oxytocin-resistant uterine inertia¡A severe pre-eclampsia or severe CV disorders.,,«Ç·Å,Dosing: Adult Note: IV administration requires the use of an infusion pump. --Induction or enhancement of labor 1 iu oxytocin/100 mL by IV drip infusion --Prevention & treatment of post-partum haemorrhage; incomplete¡A inevitable or missed abortion 5-10 iu IM. Postpartum hemorrhage: 10 to 40 units of oxytocin added to running IV infusion (maximum 40 units to 1000 mL IV solution),,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,WHO: Compatible with breastfeeding. (micromedex) Pregnancy Category: C (micromedex),,,,,,
IPAR2,Electrolytes + Dextrose,Paren-Aid N0.2 inj 400mL,NUTR,Fluid¡A electrolytes & calories supplement¡A especially for those who are poor-oral absorption or malnutrition,Hyperkalemia¡A hyperphosphatemia¡A hypermagnesemia¡A hypocalcemia¡A hepatic coma¡Asevere renal insufficiency¡A disturbances in amino acid metabolism¡A peripheral parenteral administration.,Hyperglycemia. At high dose or rapid administration: pulmonary & peripheral edema¡A acidosis.,30¢J¥H¤U,As TPN material.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,CVC;,,,,,1. °ª±i¿éª`²G¡A­­¥Ñ¤¤¥¡ÀR¯ß¾ÉºÞµ¹ÃÄ¡C 2. ¥»«~±M¨ÑÃÄ¾¯¬ì½Õ°tTPN»s¾¯¨Ï¥Î¡C
ISHI1,Triamcinolone acetonide,Shincort inj 10mg/mL¡A 5mL,HM,,¸T§Ò: Acute psychoses¡A serious fungal or viral infection¡A untreated acute or chronic infection including TB. °Æ§@¥Î: Transient local discomfort¡A depigmentation & local atrophy¡A abscess formation; skeletal muscle wasting & weakness¡A impaired blood glucose control. Water & electrolyte imbalance¡A Cushing's syndrome. ¾AÀ³¯g: RA; synovitis; allergic rhinitis¡A asthma & dermatitis; pemphigus; allergic & inflammatory ophth diseases.,,«Ç·Å,IA/ID 2.5-5 mg for smaller joints; 5-15 mg for larger joints.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IGLU5,Dextrose,(TPN½Õ°t¨Ï¥Î) Glucose inj 50%¡A 500mL,NUTR,Treatment of hypoglycemia,Hypersensitivity to corn or corn products; hypertonic solutions in patients with intracranial or intraspinal hemorrhage¡A diabetic coma¡A or delirium tremens¡A especially if dehydrated; severe dehydration; glucose-galactose malabsorption syndrome,Cardiovascular: Edema¡A localized phlebitis¡A phlebitis¡A venous thrombosis Central nervous system: Confusion¡A loss of consciousness Endocrine & metabolic: Acidosis¡A dehydration¡A glycosuria¡A hyperglycemia¡A hyperosmolar syndrome¡A hypervolemia¡A hypokalemia¡A hypomagnesemia¡A hypophosphatemia¡A hypovolemia¡A ketonuria¡A polydipsia Gastrointestinal: nausea Local: Local pain¡A local tissue necrosis Renal: Polyuria Respiratory: Pulmonary edema¡A tachypnea Miscellaneous: Fever,30¢J¥H¤UÁ×¥ú,As TPN material.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,50 % Glucose Solution¡A°ª±i¸²µå¿}²G¡A­­ÃÄ¾¯¬ì½Õ°tTPN¨Ï¥Î
IKEP,Levetiracetam,Keppra inj 500mg/5mL,CNEU,Focal (partial) onset: Adjunctive therapy in the treatment of focal (partial) onset seizures in adults and children >=4 years of age and >20 kg with epilepsy. Generalized onset: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years and older with juvenile myoclonic epilepsy. Primary generalized tonic-clonic seizures: Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and 16 years and older with idiopathic generalized epilepsy.,Hypersensitivity to levetiracetam.,Common Gastrointestinal: Loss of appetite (3% to 8% )¡A Vomiting (15% ) Immunologic: Infectious disease (13% ) Musculoskeletal: Decreased bone mineral density (70% )¡A Neck pain (2% to 8% ) Neurologic: Asthenia (15% )¡A Dizziness (5% to 9% )¡A Headache (14% to 19% ) Psychiatric: Abnormal behavior (7% to 37.6% )¡A Irritability (6% to 12% ) Respiratory: Cough (2% to 9% )¡A Nasopharyngitis (7% to 15% ) Other: Fatigue (10% to 11% ) Serious Dermatologic: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis due to drug Hematologic: Decreased erythrocyte production¡A Decreased white blood cell count (2.4% to 3.2% )¡A Eosinophil count raised (8.6% )¡A Neutropenia ( 2.4% )¡A Pancytopenia¡A Thrombocytopenia Hepatic: Liver failure Immunologic: Anaphylaxis Neurologic: Somnolence (8% to 45% ) Psychiatric: Suicidal intent (0.5% )¡A Suicide Other: Angioedema,Äá¤ó30«×C¥H¤U,Monotherapy: Adults¡A 16 Years and Older: Initial¡A 250 mg twice daily IV/orally; titration¡A may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults¡A 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily¡A increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ]¦b¤@¤j¶q¤W¥««á¸ê®Æ¤¤¡A±µ¨ü levetiracetam ³æ¤@ªvÀøªº¥¥°ü¡]¶W¹L 1800 ¨Ò¡A¨ä¤¤¶W¹L 1500 ¨Òµo¥Í¦bÃh¥¥ªº«e¤T­Ó¤ë´Á¶¡¡^¥D­n¥ý¤Ñ©Ê·î§Îªº­·ÀI¨Ã¥¼¼W¥[¡C Ãö©ó¦b¤l®c¤º±µ¨ü levetiracetam ³æ¤@ªvÀøªº¨àµ£¯«¸gµo¨|¡A¥Ø«e¶È¦³¦³­­ªºÃÒ¾Ú¡C¦ý¥Ø«e¬y¦æ¯f¾Ç¬ã¨s¡]¬ù 100 ¦W¨àµ£¡^¨Ã¥¼¦³¯«¸gµo¨|»ÙÃª©Î©µ¿ðªº­·ÀI¼W¥[¡C Levetiracetam ¦pªG¦b¸g¥J²Óµû¦ô«á»{¬°¥¦¬OÁ{§É¤W©Ò»Ý­n®É¡A¤~¥i¥H¦bÃh¥¥´Á¶¡¨Ï¥Î¡C ¦b³oºØ±¡ªp¤U¡A«ØÄ³¨Ï¥Î³Ì§C¦³®Ä¾¯¶q¡CÃh¥¥´Á¶¡ªº¥Í²zÅÜ¤Æ¤]¥i¯à·|¼vÅT levetiracetam ªº¿@«×¡C ´¿¦³¦bÃh¥¥´Á¶¡¥X²{¦å¼ß¤¤ levetiracetam ¿@«×­°§C²{¶Hªº³ø§i¡C³oºØ¿@«×­°§Cªº²{¶H¦b²Ä¤T¥¥´Á·|§ó¬°ÅãµÛ(­°§Cµ{«×³Ì°ª¥i¹FÃh¥¥«e¤§°òÂ¦¿@«×ªº 60%)¡C ½Ð°È¥²¬°±µ¨üªvÀøªºÃh¥¥°ü¤k¶i¦æ¾A·íªºÁ{§É³B¸m¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Levetiracetam ·|±Æªn¦Ü¤HÃþ¨Å¥Ä¤¤¡A¬G¤£«ØÄ³±Â¨Å¡C ¦ý¦pªG¦b±Â¨Å´Á¶¡»Ý­nªA¥Îlevetiracetam¡A¶·µû¦ôªvÀø®Ä¯q¤Î­·ÀI»P±Â¨Åªº­«­n©Ê¡C,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥²»Ýµ}ÄÀ¨ì¦Ü¤Ö100 mLªº¬Û®eµ}ÄÀ²G«á¡A«ØÄ³¥H15¤ÀÄÁ½wºCºwª`¡C,1. Keppra Inj 500mg/5mL¶ÈÀR¯ß¿éª`¨Ï¥Î¡A«ØÄ³¾¯¶q¥²»Ýµ}ÄÀ¨ì¦Ü¤Ö100 mLªº¬Û®eµ}ÄÀ²G¤¤¡A¥H15¤ÀÄÁªºÀR¯ß¿éª`®É¶¡µ¹ÃÄ¡C 2.¥»ÃÄ¬°³æ¦¸¨Ï¥Î¡A¥¼¥Î§¹ªº·»²G¤£À³«O¯d¡C¸gµ}ÄÀ«á±q·L¥Íª«¾ÇªºÆ[ÂIÀ³¥ß§Y¨Ï¥Î¡A­YµLªk¥ß§Y¨Ï¥Î³q±`2-8¢XC¤£¶W¹L24¤p®É¡A°£«Dµ}ÄÀ¨BÆJ¥HµLµßÀô¹Ò¤U¶i¦æ¡C¸gµ}ÄÀ«áªº¤Æ¾ÇÃ­©w»P¤U¦Cµ}ÄÀ²G(D5W¡AN/S¡AL/R)¦b«Ç·Å15-25¢XC¤UPVC³U¤¤¹F24¤p®É¡C
EILO1,Erythromycin,Erythromycin 0.5%¡A 3.5gm ophthalmic ointment,TOPH,Treatment of bacterial infections of the eye involving the conjunctiva &/or cornea caused by susceptible organisms.,Hypersensitivity to any component of the formulation.,Rarely¡A hypersensitivity reactions¡A ocular irritation or redness.,µL¯S§O«ü¥Ü,Instill 1 cm ribbon of the ointment into affected eye(s) up to 6 times daily¡A depending on the severity of the infection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;OD;OL;OU;SKIN;,,,,,
OSMO4,Nicotine,Smokquit Mint Lozenges 4mg¤f§t¿õ,ZADT,,,,,(Uptodate) Lozenge: Do not use more than 1 lozenge at a time. 4 mg for patients who smoke their first cigarette within 30 minutes of waking; 2 mg for others. The 12-week dosing schedule: Weeks 1-6: 1 lozenge every 1-2 hours (max: 5 lozenges Q6H; 20 lozenges/day); to increase chances of quitting¡A use at least 9 lozenges/day during the first 6 weeks. Weeks 7-9: 1 lozenge every 2-4 hours (max: 5 lozenges Q6H; 20 lozenges/day). Weeks 10-12: 1 lozenge Q4-8H (max: 5 lozenges Q6H; 20 lozenges/day).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,
OCER,Cefaclor,Cero 250mg,QANB,Otitis media¡A lower and upper respiratory tract infection¡A UTI¡A skin infection.,Hypersensitivity.,Hypersensitivity reactions. GI symptoms.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adults: 250-500 mg orally every 8-12 hours. Children: 20-40 mg/kg/day in 2-3 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OEFE7,Venlafaxine,Effexor XR 75mg,CNEU,Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder.,Concomitant or within 14 days of MAOIs. Efexor XR must be discontinued for at least 7 days before starting treatment with MAOI. Severe renal or hepatic impairment. Pregnancy & lactation. Children < 18 years.,Dizziness¡A sedation¡A dry mouth¡A insomnia¡A nervousness¡A tremor¡A somnolence¡A anorexia¡A constipation¡A nausea¡A vomiting¡A abnormal ejaculation/orgasm (males)¡A erectile dysfunction¡A urinary hesitancy¡A sweating¡A asthenia¡A hypertension¡A hot flushes¡A ecchymosis¡A mucous membrane bleeding¡A thrombocytopenia¡A hypercholesterolaemia¡A yawning¡A fatigue¡A nausea¡A appetite & weight loss¡A decreased libido¡A sweating¡A anorexia¡A visual disturbances. Cardiovascular: Hypertension (3% to 13%) Dermatologic: Sweating symptom (6.7% to 25% ) Endocrine metabolic: Weight loss (3% to 47% ) Gastrointestinal: Constipation (8% to 15% )¡A Loss of appetite (8% to 22% )¡A Nausea (21% to 58% )¡A Xerostomia (12% to 22% ) Neurologic: Asthenia (8% to 19% )¡A Dizziness (11% to 23.9% )¡A Dream disorder (3% to 7% )¡A Headache (25% to 38% )¡A Insomnia (14% to 24% )¡A Somnolence (14% to 26% )¡A Tremor (1.1% to 10.2% ) Ophthalmic: Blurred vision (4% to 6% ) Psychiatric: Feeling nervous (4% to 21.3% ) Reproductive: Abnormal ejaculation (2.2% to 19% )¡A Impotence (2.1% to 6% )¡A Orgasm disorder (2% to 5% ),20-25¢Jªº«Ç·Å¤U,Should be taken with food (XR cap: Swallow whole¡A do not chew/crush.). Dosage: 75 mg once daily. After 2 weeks¡A the dose may be increased to 150 mg once daily & further to 225 mg once daily if needed.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x»ÙÃª¯f±w¡AÀ³¥H´î¥b¥Î¶q¶}©lªvÀø ¦]­Ó§O¨xµw¤Æ±wªÌ¤§®t²§©Ê¤j¡A¥i¯à»Ý­n­Ó§O½Õ¾ã¥Î¶q,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,[¥é³æ] ­P·î§@¥Î¢wÃh¥¥¤ÀÃþ C¡G¥Hmg/m2¬°°ò·Ç®É¡A¨Ï¥Î¶q°ª¹F¤HÃþ³Ì¤j¨C¤é«ØÄ³¾¯¶q2.5­¿Äé­¹¤j¹«©Î4­¿§ë¤©¨ß¤l¡AÅã¥Üvenlafaxine¤£·|¹ï­F­L²£¥Í·î­L¡CµM¦Ó¡A¦bÃh¥¥¤j¹«¦Ü¥®¹«Â_¥¤´Á¶¡§ë¤©ÃÄ«~¡A§ë¤©¾¯¶q¬O¤HÃþ³Ì¤j±ÀÂË¥Î¶qªº2.5­¿¡Aµo²{¥®¹«Åé­«´î»´¡B¦º­L¼W¥[¡B­÷¨Å«e¤­¤Ñ¥®¹«¦º¤`¼W¥[¡A¦º¦]¥¼ª¾¡C¹ï¥®¹«¦º¤`²v¨S¦³¼vÅTªº¾¯¶q¬°¤HÃþ¾¯¶qªº0.25­¿¡C¦b¨Ï¥ÎO-desmethylvenlafaxine (ODV¡A¬°venlafaxine¦b¤HÅé¤º¥D­nªº¥NÁÂª«) ¶i¦æªº¤j¹«©M¨ß¤l¥Í´Þµo¨|¸ÕÅç¤¤¡A©ó13 (¤j¹«) ©M0.3 (¨ß¤l) ªº¼ÉÅS¬É­­ (exposure margin) ¤U¨Ã¥¼Æ[¹î¨ì­P·î©ÊªºÃÒ¾Ú¡C ¹ïÃh¥¥°ü¤k¦Ó¨¥¡A¥Ø«e©|µL¨¬°÷¥B±±¨î¨}¦nªº¸ÕÅç¡C°ß¦³·í¼ç¦b®Ä¯q³Ó¹L¥i¯à¹ï­L¨à³y¦¨ªº¼ç¦b­·ÀI®É¡A¤~¯à¦bÃh¥¥´Á¶¡¨Ï¥ÎEffexor XR¡C¦]¬°°Êª«ªº¥Í¨|¬ã¨s¤£¤@©w¯à¹w´ú¤HÃþªº¤ÏÀ³¡A°ß¦³½T©w»Ý­n¡A¤~¥i¨Ï¥Î©óÃh¥¥´Á¶¡¡C «D­P·î§@¥Î¡G¦bÃh¥¥8-9­Ó¤ë(late in the third trimester)¼ÉÅS¦bEffexor XR¡B¨ä¥LSNRIs (serotonin¤Înorepinephrine¦^¦¬§í¨î¾¯)©ÎSSRIs (¿ï¾Ü©Êserotonin¦^¦¬§í¨î¾¯) ªº·s¥Í¨à¡A¤w²£¥Í¨Öµo¯g¡A©Ò¥H»Ý­n©µªø¦í°|¡B·Ç³Æ©I§l¤ä«ù¤ÎºÞÄéÁý­¹¡C³o¨Ç¨Öµo¯g¥i¯à¦b¤À®Y«á¥ß§Y¥X²{¡CÁ{§É³ø§i«ü¥X¡A³o®É´Á¥i¯à·|¥X²{¥]¬A©I§l¤£¶¶¡BµoÖæ¡B²¿®§¡BµjÅËµo§@¡BÅé·Å¤£Ã­¡BÁý­¹§xÃø¡B¹Ã¦R¡B§C¦å¿}¡B¦Ù±i¤O¹L§C¡B¦Ù±i¤O¤®¶i¡B¹L«×¤Ï®g¡BÅ¸§Ý¡B±ª°Ê¡B©ö«ã¤Î­ú¾x¤£°±¡C³o¨Ç¼xª¬²Å¦XSSRIs©MSNRIsªºª½±µ¬r©Ê¡A¤]¥i¯à¬O°±ÃÄªº§ÙÂ_¯gª¬¡C¥²¶·ª`·Nªº¬O¡A¦b¬Y¨Ç®×¨Ò¤¤¡A³o¨ÇÁ{§Éª¬ªp¥ç²Å¦X¦å²M¯À¯g­Ô¸s¡C·í¥HEffexor XRªvÀøÃh¥¥7-9­Ó¤ë(third trimester)ªº°ü¤k®É¡AÂå®v¥²¶·¤p¤ßªºµû¦ôªvÀøªº­·ÀI»P§Q¯q¡C Æ[¹î©Ê¬ã¨s¼Æ¾Ú«ü¥X©ó¥Í²£«e¤@­Ó¤ë¼ÉÅS©óSSRIs ¤ÎSNRIs ÃþÃÄ«~·|¼W¥[²£«á¥X¦å­·ÀI(¤p©ó2­¿)¡C ¤À®Y¡GVenlafaxine¹ï©ó¤HÃþ¥Í²£ªº¼vÅT¥Ø«e¥¼ª¾¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«eÃÒ©úvenlafaxine»PODV¥NÁÂª«·|¤Àªc¦Ü¨Å¥Ä¡C¦]Effexor XR¥i¯à¹ï­÷¨Å¤¤ªºÀ¦¨à¦³ÄY­«°Æ§@¥Îªº¼ç¦b©Ê¡A¬G»Ý°w¹ï¥À¿Ë¥ÎÃÄªº­«­n©Êµû¦ô¡A¦Ó¨M©w»Ý­n°±¤î­÷¨Å©Î°±ÃÄ¡C,PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä½¦ÅnÀ³¾ã²É§]ªA¡A ¤Å«rÄZ©ÎÀ£¸H¡C­Y¦³ºÞÄé»Ý¨D¥i©î¶}½¦Ån«á¨Ï¥Î¡A¦ý¤£¥i±N½¦Ån¤º·L²ÉÀ£¸H©Î¿i¯»¡C
ONEOV,TTFD,Neo-Vibon 50mg,NUTR,,,,,,,,,,,,,,,,,,,
EETO,Etofenamate,Eto gel 10%¡A 40gm,CNEU,Relief of pain & inflammation associated with musculoskeletal¡A joint & soft tissue disorders e.g. stiff shoulder¡A sprains¡A strains¡A lumbago¡A arthralgia & myalgia.,Hypersensitivity to any component of the formulation.,Rarely¡A allergic skin reactions.,30¢J¥H¤U,Apply BID-TID to the affected area.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|µL¸ê°T¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|µL¸ê°T¡C,EXT;,,,,,
ODOS,Cabergoline,Dostinex 0.5mg,HM,Treatment of hyperprolactinemic disorders¡A either idiopathic or caused by pituitary adenomas.,Known hypersensitivity to cabergoline¡A ergot derivatives¡A or any component of the formulation; uncontrolled hypertension; history of cardiac valvular disorders; history of pulmonary¡A pericardial¡A or retroperitoneal fibrotic disorders.,Headache (26%)¡A dizziness (15% to 17%)¡A Nausea (27% to 29%)¡A Orthostatic hypotension (4%)¡A hypotension (1%)¡A dependent edema (1%)¡A edema (peripheral 1%)¡A palpitation (1%)¡A syncope (1%)¡A Fatigue (5% to 7%)¡A vertigo (1% to 4%)¡A depression (3%)¡A somnolence (2% to 5%)¡A nervousness (1% to 2%)¡A anxiety (1%)¡A insomnia (1%)¡A concentration impaired (1%)¡A malaise (1%)¡A Acne (1%)¡A pruritus (1%)¡A Hot flashes (1% to 3%)¡A breast pain (1% to 2%)¡A dysmenorrhea (1%)¡A Constipation (7% to 10%)¡A abdominal pain (5%)¡A dyspepsia (2% to 5%)¡A vomiting (2% to 4%)¡A xerostomia (2%)¡A diarrhea (2%)¡A flatulence (2%)¡A anorexia (1%)¡A throat irritation (1%)¡A toothache (1%)¡A Weakness (6% to 9%)¡A pain (2%)¡A paresthesia (1% to 2%)¡A arthralgia (1%)¡A Abnormal vision (1%)¡A periorbital edema (1%)¡A Rhinitis (1%)¡A Flu-like syndrome (1%) <1% (Limited to important or life-threatening): Aggression¡A alopecia¡A cardiac fibrosis¡A duodenal ulcer (in PD patients)¡A gastric ulcer (in PD patients)¡A pleural effusion¡A psychosis¡A pulmonary fibrosis¡A valvular regurgitation¡A valvulopathy.,25¢J¥H¤U,Inhibition of physiological lactation soon after parturition 1 mg as a single dose during the 1st postpartum day. Suppression of established lactation: 0.25 mg Q12H for 2 days. Hyperprolactinemic disorders: Initially 0.5 mg/week in 1 or 2 doses which should be increased gradually by adding 0.5 mg/week at monthly intervals. Therapeutic range: 0.25-2 mg/week.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª(Child-Pugh scores of 10 or higher)À³´î§C¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,PO;WM;,,,,,
IVAN,Vancomycin,Vancomycin inj 500mg,QANB,,¾AÀ³¯g: Treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci. For penicillin-allergic patients. Staphylococcal endocarditis. Infections due to staphylococci eg septicemia¡A bone infections¡A lower resp tract infections¡A skin & skin structure infections. Diphtheroid endocarditis. Oral treatment for antibiotic-associated pseudomembranous colitis. °Æ§@¥Î: Anaphylactoid reactions following rapid infusion. Nephrotoxicity¡A ototoxicity¡A reversible neutropenia¡A pseudomembranous colitis; chemical peritonitis following intraperitoneal administration. ¸T§Ò:Hypersensitivity.,,«Ç·Å,Adult 500 mg 6 hrly or 1 g 12 hrly by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses 8 hrly for patients undergoing GI or GU procedures. Children 10 mg/kg body weight 6 hrly. Neonates initial 15 mg/kg followed by 10 mg/kg 12 hrly in 1st weeks of life & 8 hrly up to 1 month of age.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C 2. ª`·N¿éª`¹L§Ö®Éªº¤£¨}¤ÏÀ³¡G§C¦åÀ£¡B©I§l§xÃø¡BëC³Â¯l¡C 3. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C
OCOF5,Warfarin,COFARIN 5mg,HEMT,Treatment & prophylaxis of thromboembolic disorders.,Severe hepatic or renal disease¡A actual or potential haemorrhagic conditions¡A severe hypertension¡A endocarditis¡A ulceration of the GI & urinary tract¡A visceral carcinoma¡A endocarditis¡A neurosurgery¡A recent surgery on the eye¡A brain or spinal cord. Pregnancy.,Alopecia¡A skin rashes of various kinds¡A hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ),15-30¢JÁ×¥ú,Initial dose as 2-5mg once daily¡A depends on patient's PT/INR. Maintenance dose would be 2-10mg¡A adjusted by patient's PT/INR. Duration of the treatment should be kept until the risks have been excluded.,»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling. However¡A the response to oral anticoagulants may be markedly enhanced in obstructive jaundice¡A hepatitis¡A and cirrhosis. INR should be closely monitored.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,,Compatible ­÷¨Å®É¥i¨Ï¥Î,WHO:Compatible with breast-feed,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ»Pfeeding nutrition¦³¥æ¤¬§@¥Î¦Ó¼vÅT§l¦¬¡A¥i¿i¯»¦ý»Ý»Pnutrition¶¡¹j1¤p®É¡A¨Ã±K¤ÁºÊ´úINR­È¡C
EDUR1,Fentanyl,Durogesic D-trans Patch 12mcg/h,CNEU,Management of chronic & intractable pain requiring opioid analgesia.,Hypersensitivity.,Hypoventilation. Nausea¡A vomiting¡A constipation; hypotension¡A somnolence¡A confusion¡A hallucinations¡A euphoria¡A pruritus¡A urinary retention; rash¡A erythema¡A itching.,30¢J¥H¤U,Adults: Initial dose:12 mcg/hr or 25mcg/hr. Maintenance dose: Increase and drcrease by 12 mcg/hr or 25 mcg/hr to lowest appropriate dose. Renew every 72 hours. Children¡A 2-16 years old: Fentanyl transdermal patch can only be used on children have drug tolerance to opioids. Before use fentanyl transdermal patch¡A the child must be receiving opioids potency are equal to 30 mg oral morphine. The dose of fentanyl transdermal patch can be calculated from the 24-hour morphine dose with the same analgesic effect.(The conversion ratio of oral morphine to fentanyl transdermal patch is about 150:1) If fentanyl transdermal patches have to be discontinued¡A they should be replaced with other opioids (start with a low dose and slowly increase the dose).,»Ý½Õ¾ã¾¯¶q,[Micromedex 20210714] Hepatic impairment (mild to moderate): Initiate with 50% of the usual dosage. Hepatic impairment (severe): Avoid use.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,[¥é³æ] ¥¼¦³¥R¤ÀÃö©óÃh¥¥°ü¤k¨Ï¥ÎDUROGESICRªº¸ê®Æ¡C¦b°Êª«¸ÕÅç¤¤´¿Åã¥Ü¨ã¦³¬Y¨Ç¥Í´Þ¬r©Ê¡CÁa¨Ï§@¬°ÀR¯ß³Â¾K¾¯ªºfentanyl´¿³Qµo²{¦b¤HÃþÃh¥¥´Á¶¡·|¬ï¹L­L½L¡A¦ý¹ï©ó¤HÃþªº¼ç¦b¦MÀI©Ê¤´ÄÝ¥¼ª¾¡C¥À¿Ë¦bÃh¥¥´Á¶¡ªø´Á¨Ï¥ÎDUROGESICRªº·s¥ÍÀ¦¨à´¿³Q³ø¾É¦³·s¥Í¨à§ÙÂ_¯gª¬¡C Ãh¥¥´Á¶¡¤£¯à¨Ï¥ÎDUROGESICR¡A°£«D½T¹ê¦³¥²­n¡C ¤£«ØÄ³¦b¤À®Y´Á¶¡¨Ï¥ÎDUROGESICR¡A¦]¬°DUROGESICR¤£À³¥Î©ó±±¨î«æ©Ê©Î³N«á¯kµh¡C¦¹¥~¡A¥Ñ©ófentanyl·|¬ï¹L­L½L¡A¦b¤À®Y®É¨Ï¥ÎDUROGESICR¥i¯à·|¾É­P·s¥Í¨àªº©I§l§í¨î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¹ï±Â¨Å°ü¤k¤£«ØÄ³¨Ï¥ÎDUROGESICR¡CFentanyl·|±Æªn¨ì¤HÅé¨Å¥Ä¤º¥B¥i¯à·|¹ï³QÁý¨Åªº·s¥Í¨à³y¦¨ÂíÀR/©I§l§í¨î¡C,EXT;,,,,,
OAMIZ,Hydrochlorothiazide + Amiloride,AmiZide 50/5mg,CAVS,Hypertension¡A edema of cardiac origin & hepatic cirrhosis with ascites & edema.,Hyperkalemia¡A other concomitant antikaliuretic therapy or K supplementation¡A renal insufficiency.,Headache¡A weakness¡A nausea¡A anorexia¡A rash & dizziness; orthostatic effects. Dermatologic: Rash (3% to 8% ) Gastrointestinal: Nausea Neurologic: Asthenia (3% to 8% )¡A Dizziness (3% to 8% )¡A Headache (3% to 8% ),25¢J¥H¤U,Initially¡A 1-2 tablets daily. Maximum: 4 tablets/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,Hydrochlorothiazide: ¤ñ·Ó Chlorothiazide - Compatible Amiloride: Limited Human Data¡XAnimal Data Suggest Low Risk ¥¥°ü¤£¥i¨Ï¥Î¡A¦]¬°Thiazide·|³q¹L­L½L(¥é³æ),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Hydrochlorothiazide: ¤ñ·Ó Chlorothiazide - Compatible Amiloride: No Human Data¡XProbably Compatible Thiazide·|¤Àªc©ó¨Å¥Ä¡AÀ³°±¤î­÷¨Å(¥é³æ),AC;AC15;PC;PO;WM;,,,,,
IUROK,Urokinase,UROKINASE 60¡A000IU (ÃÄ¤§¶m),HEMT,Acute coronary embolism¡A clearance of occluded catheters & shunts¡A acute pulmonary embolism¡A peripheral arterial or venous thromboembolism.,Intracranial hemorrhage¡A hemoptysis¡A difficulty in hemostatic management; undergone intracranial or spinal surgery or with such injury (in the last 2 months); aneurysm; serious disturbance of consciousness.,Bleeding tendency. Fever¡A chills¡A headache & malaise may occur. Rarely¡A shock¡A sweating¡A disturbed pulse & dyspnea; rash¡A urticaria;nausea; vomiting & anorexia; abnormal liver function test; hematuria. Hematologic: Decreased hematocrit level (37%),15-30¢J,60000-240000 IU on the first day¡A then decrease the dose day by day for about 7 days.,µL»Ý½Õ¾ã¾¯¶q,¦³ÄY­«¨xµÇ»ÙÃª¯f¤H»ÝÂÔ·V¨Ï¥Î¡C,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IA;IPL;IRR;IVD;,10 mL N/S¡AD5W,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,µ}ÄÀ¨ìÁ`Åé¿n¬°195 mL¡A°_©l¾¯¶q:90 mL/hr ¿éª`¶W¹L 10 minutes¡Aºû«ù¾¯¶q:15 mL/hr «ùÄò12¤p®É,1. Total dose diluted to the recommended final volume of 195 mL 2. (loading dose) 90 mL/hr over 10 minutes (continuous infusion) 15 mL/hr for a period of 12 hr
OJOH,Bisacodyl,Johnlax 5mg,ALIM,Treatment of constipation; colonic evacuation prior to procedures or examination.,Hypersensitivity to bisacodyl or any component of the formulation; abdominal pain or obstruction¡A nausea¡A or vomiting,Abdominal cramps (mild)¡A electrolyte disturbance (metabolic acidosis or alkalosis¡A hypocalcemia)¡A nausea¡A rectal irritation (burning)¡A vertigo¡A vomiting,25¢J¥H¤UÁ×¥ú¡Aºò±K®e¾¹,Dosing: Adult & children >10 years Relief of constipation: Oral: 5-10 mg as single dose Dosing: Pediatric Relief of constipation: Oral: Children 4-10 years: 5 mg as single dose Oral: Children <4 years: recommend Rectal suppository,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ] ªø´Á¥ÎÃÄ¸gÅçÅã¥ÜÃh¥¥´Á¶¡¡A¨Ï¥Î¥»ÃÄµL¤£¨}¤ÏÀ³©Î¶Ë®`©Ê¡C µM¦Ó»P©Ò¦³ªºÃÄª«¬Û¦P¡AÃh¥¥´Á¶¡¡A°£«D¦³ÂåÅñ¡A§_«h¥¥°ü¤£¥i¨Ï¥Î Bisacodyl¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ©|¥¼½T©w Bisacodyl ¬O§_¶i¤J¨Å¥Ä¤¤¡A¦]¦¹¨Ï¥Î Bisacodyl ªvÀø®É¤£«ØÄ³±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»¿}¦ç¿õ¡C¶·¾ã²É§]ªA¡A¤Å«rÄZ©ÎÀ£¸H¡C
ISUX,Succinylcholine,Suxamethonium inj 100mg/2mL,CNEU,,¾AÀ³¯g: Production of skeletal muscle relaxation in anaesth; for procedures eg endotracheal intubation¡A endoscopic exam¡A orthopaedic manipulations¡A short surgical procedures & electroconvulsive therapy. °Æ§@¥Î: Post-op muscle pain or fasciculation¡A rhabdomyolisis¡A myoglobinuria¡A myoglobinaemia¡A elevated creatine phosphokinase¡A hypertonia¡A bradycardia¡A tachycardia¡A arrhythmia¡A cardiac arrest¡A HTN¡A hypotension¡A tachyphylaxis¡A ventricular fibrillation¡A resp or GI disorders¡A malignant hyperthermia¡A porphyria¡A hyperkalaemia¡A excessive salivation¡A increased intraocular & intracranial pressure¡A renal failure¡A precipitation or exacerbation of myasthenia gravis¡A hypersensitivity reactions. ¸T§Ò: Familial history of malignant hyperthermia¡A disorders of pseudocholinesterase¡A myopathy¡A Duchenne's muscular dystrophy¡A severe hyperkalaemia¡A acute narrow-angle glaucoma¡A penetrating eye injuries. Major burns or multiple trauma¡A renal impairment w/ hyperkalaemia¡A extensive muscle degeneration¡A severe chronic sepsis.,,2-8¢XC,Individualised dosage. Adult Short procedures 0.6 mg/kg (range: 0.3-1.1 mg/kg) IV over 10-30 sec. Prolonged surgical procedures 2.5-4.3 mg/min by IV infusion. Childn 1-2 mg/kg IV. IM Adult & childn 2.5 mg/kg¡A max total dose: 150 mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,for Intubation: Adult dose - 0.6 mg/kg (range: 0.3 to 1.1 mg/kg),IVD: (continuous infusion) a solution diluted to 1 mg/mL in D5W or N/S may be administered at a rate of 0.5 to 10 mg/min depending on patient specific factors.,1. ¦¨¤H²`«×¦Ù¦×ÃP¦¢IM: 15mg-100 mg. 2. IVD: (continuous infusion) a solution diluted to 1 mg/mL in D5W or N/S may be administered at a rate of 0.5 to 10 mg/min depending on patient specific factors.
OSAM,Tolvaptan,Samsca 15mg,CAVS,Clinically significant hypervolemic & euvolemic hyponatremia including patients w/ heart failure & syndrome of inappropriate antidiuretic hormone (SIADH).,Urgent need to raise serum Na acutely; inability to sense or appropriately respond to thirst; hypovolemic hyponatremia; strong CYP3A inhibitors (eg clarithromycin¡A ketoconazole¡A itraconazole¡A ritonavir¡A indinavir¡A nelfinavir¡A saquinavir¡A nefazodone & telithromycin); anuric patients.,Thirst¡A dry mouth¡A pollakiuria or polyuria¡A asthenia¡A constipation¡A hyperglycemia¡A pyrexia & anorexia.,Àx¦s©ó25¢J,Adult: Initial¡A 15 mg QD; may increase to 30 mg QD¡A after at least 24 hours¡A to maximum of 60 mg QD; do not administer for more than 30 days. Patient should be hospitalized for initiation or reinitiation of tolvaptan therapy to evaluate therapeutic response and avoid too rapid correction of hyponatremia. Serum sodium levels should be monitored for prevention of too rapid correction of hyponatremia. (Correction of hyponatremia < 10-12 mEq/L in 24 hours¡A and < 18 mEq/L in 48 hours),µL»Ý½Õ¾ã¾¯¶q,¦]Á{§É¸ê®Æ¦³­­¡A¨Ï¥Î©ó­««×¨x¥\¯à¤£¥þ(Child-Pugh classes C)ªº¯f¤H¥²¶·¯S§O¤p¤ß¡C Tolvaptan Á×§K¨Ï¥Î©ó¦³¨x¯e¯f(underlying liver disease)ªº¯f¤H¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
EMAD,Asiaticoside + Asiatic Acid + Madecassic Acid,Madecassol onit 10gm,TDER,,Burns¡A wound of surgical operation¡A skin transplantaion¡A ulcerated skin¡A bed sore.,,,Apply 1-3 times daily.,,,,,,,,,,,,,,
IXYL11,Lidocaine,Xylocaine 1% inj 1mL,ZANE,,,,,,,,,,,,,,,,,,,
OEMB,Ethambutol,EMB(Myambutol) 400mg,QANB,,¾AÀ³¯g: Combination therapy of pulmonary TB. °Æ§@¥Î: Decreased visual acuity¡A leukopenia¡A neutropenia¡A thrombocytopenia¡A hypersensitivity¡A anaphylactoid reactions¡A headache¡A mental confusion¡A disorientation & possible hallucinations¡A dizziness¡A hypoaesthesia¡A paraesthesia¡A peripheral neuropathy¡A pulmonary infiltrates with or without eosinophilia¡A GI disturbances¡A dermatitis¡A rash¡A pruritus¡A Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A gout¡A hyperuricemia¡A joint pain¡A fever¡A malaise. ¸T§Ò: ¤wª¾¹ï¤AÓi¤B¾J(ethambutol)©Î¹ï¥ô¦ó¨ä¥L¦¨¤À¹L±ÓªÌ¤£±o¨Ï¥Î¥»¾¯¡C ©sªí¦h¸T¤î¨Ï¥Î©óµLªk¥¿½Tµû¦ôµøÄ±ªº°Æ§@¥Î»PÅÜ¤Æªº¯f¤H¡]¨Ò¦p¥®µ£¡B¥¢¥h·NÃÑªº¯f¤H¡^¡C ¹ï¤wª¾±w¦³µø¯«¸gª¢¤§±wªÌ¤£±o¨Ï¥Î¥»¾¯¡A°£«D¸gÁ{§É¬ã°Q«á¨M©w¥i¥H¨Ï¥Î¡C ¹ï²§µÒÆPñQ¯â(Isoniazid)ªº¨Ï¥Î©|µLµ´¹ï¸T§Ò¤§³ø§i¡C,,«Ç·Å,Initial treatment (patients never on anti-TB therapy) 15 mg/kg as a single dose 24 hrly. Retreatment (patients previously on anti-TB therapy) 25 mg/kg as a single dose 24 hrly. Concurrently administer at least 1 other anti-TB drug to which the organisms have been demonstrated to be susceptible. After 60 days¡A decrease dose to 15 mg/kg body weight as a single dose 24 hrly. Intermittent therapy 15 or 25 mg/kg/day for 2 months¡A then 50 mg/kg twice weekly.,,,,¥i¯à¦w¥þ,,,,,,,,,,
LRIS,Risperidone,Risperdal solution 1mg/mL¡A 30mL,CNEU,Treatment of schizophrenia¡A including 1st episode psychoses¡A acute schizophrenic exacerbations¡A chronic schizophrenia¡A & other psychotic conditions. Alleviates affective symptoms (eg. depression¡A guilt feelings¡A anxiety) associated with schizophrenia. Long-term therapy for the prevention of relapse in chronic schizophrenia. Treatment of behavioral disturbances in patients with dementia. As adjunctive therapy to mood stabilizers or monotherapy in the treatment of manic episodes associated with bipolar disorder. Treatment of conduct & other disruptive behavioral disorders in children¡A adolescents & adults with subaverage intellectual functioning or mental retardation.,Hypersensitivity.,Common: insomnia¡A agitation¡A anxiety¡A headache. Less common: somnolence¡A fatigue¡A dizziness¡A impaired concentration¡A constipation¡A dyspepsia¡A nausea/vomiting¡A abdominal pain¡A blurred vision¡A priapism¡A erectile dysfunction¡A ejaculatory dysfunction¡A urinary incontinence¡A rhinitis¡A rash & other allergic reactions. Occasionally¡A orthostatic hypotension¡A reflex tachycardia or hypertension.,15-30¢JÁ×§K§N­á,Schizophrenia: Adults: Initial dose: 2 mg/day in a single dose or 2 divided doses. The dose can be increased to 4 mg the next day. Adjust according to individual when necessary. The general dosage is 4-6 mg/day. Dosage over 10 mg/day may cause extrapyramidal symptoms. maximum: 16mg/day Children(13-17 years old) :0.5mg QD. The dose is increased by 0.5 mg/day or 1 mg/day adjust to the recommended dose of 3 mg/day when necessary. (The adjustment interval cannot be less than 24 hours). maximum:6mg/day. Data for children under 13 years of age with schizophrenia are not esTABlished. Elderly (65 years old and above): Initial dose:0.5mg BID¡A increased by 0.5mg each dose adjust to 1-2 mg BID. Manic episodes of bipolar disorder: Adults:2mg or 3mg QD¡A increased by no more than 1 mg/day. Effective at 1mg-6mg/day. Children(10-17 years old):0.5mg QD¡A increased by 0.5 mg or 1mg/day adjust to 2.5mg/day.(The adjustment interval cannot be less than 24 hours). Effective at 0.5mg-6mg/day.If the patient has persistent sleepiness¡A adjust the frequency from QD to half of the original dose twice a day. Data for children under 10 years of age with bipolar manic episode are not established. Agitation¡A aggressive behavior¡A or psychotic symptoms in patients with Alzheimer's disease: 0.25mg BID¡A increased by 0.25mg each doses adjust to 0.5mg BID or 1mg BID. (The adjustment interval cannot be less than 2 days.) After determining the sTABle dose¡A dose frequency can be changed to QD. Behavioral Disorders and Other Disruptive Behavior Disorders(5-18 years old): >=50 kg:0.5mg/day. When necessary¡A it can be increased by 0.5 mg/day adjust to 1mg QD¡A or 1.5mg QD.(The adjustment interval cannot be less than 2 days.) <50kg:0.25mg/day.When necessary¡A dose can be increased by 0.25 mg/day adjust to 0.5mg QD¡A or 0.75mg QD.(The adjustment interval cannot be less than 2 days.) Data for children under 5 years of age are not esTABlished. Agitated symptoms in children and adolescents with autism(5-17 years old): Dose frequency:1-2times/day. <20kg:0.25mg/day(day1-3)¡A 0.5mg/day(day4-14)¡A dose can be increased by 0.25 mg/day adjust to 0.5-1.5mg/day.(The adjustment interval cannot be less than 2 weeks.) >=20kg:0.5mg/day(day1-3)¡A 1mg/day(day4-14)¡A dose can be increased by 0.5 mg/day adjust to 1-2.5mg/day.(The adjustment interval cannot be less than 2 weeks.) If the patient has persistent sleepiness¡A adjust the frequency from QD to HS¡A or half of the original dose twice a day. Data for children under 5 years of age are not established.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ±wªÌ(Child Pugh 10 to 15): Initial¡A 0.5 mg orally twice daily; increase dose in increments of no more than 0.5 mg twice a day¡A with increases to dosages above 1.5 mg twice a day occurring at intervals of at least 1 week,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ESHO,Chloramphenicol,Showen 0.25% eye drops¡A 5mL,TOPH,,¾AÀ³¯g:Superficial bacterial eye infections °Æ§@¥Î: Transient stinging.,,«Ç·Å,Apply 1 drop every 2 hr & reduce frequency as infection is controlled; continue for 48 hr after healing.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IPER0,Pertuzumab,Perjeta inj 420mg/14mL (sample),RACA,PERJETA? (pertuzumab) is approved for use in combination with Herceptin? (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.,PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.,The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are: Diarrhea Hair loss Low levels of white blood cells with or without a fever Nausea Feeling tired Rash Damage to the nerves (numbness¡A tingling¡A pain in hands/feet),2-8¢JÁ×¥ú,Initial dose of 840 mg infused over 60 minutes followed by a maintenance dose of 420 mg infused over 30-60 minutes every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,¶È¥i¨Ï¥Î0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C¤£¥i¨Ï¥Î¸²µå¿}(5%)·»²G¡C
IPERJ,Pertuzumab,Perjeta inj 420mg/14mL,RACA,PERJETA (pertuzumab) is approved for use in combination with Herceptin (trastuzumab) and docetaxel (chemotherapy) in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.,Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.,The most common side effects of PERJETA when given with Herceptin and docetaxel (chemotherapy) for treatment of breast cancer that has spread to other parts of the body (metastatic) are: Diarrhea Hair loss Low levels of white blood cells with or without a fever Nausea Feeling tired Rash Damage to the nerves (numbness¡A tingling¡A pain in hands/feet),2-8¢XCÁ×¥ú,Initial dose of 840 mg infused over 60 minutes followed by a maintenance dose of 420 mg infused over 30-60 minutes every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,Loading dose 840 mg as an intravenous infusion over 60 minutes¡A followed by 420 mg as an intravenous infusion over 30 to 60 minutes every 3 weeks.,¶È¥i¨Ï¥Î0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C¤£¥i¨Ï¥Î¸²µå¿}(5%)·»²G¡C
IKAD0,Trastuzumab Emtansine,Kadcyla inj 100mg (sample),RACA,Metastatic breast cancer¡A HER2 overexpression¡A monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common: Constipation (17-27%)¡A Nausea (40-42%)¡A Hemorrhage¡A All Grades (29-32%)¡A Thrombocytopenia¡A All Grades (29-31%)¡A Increased liver enzymes¡A All Grades (29-32%)¡A Musculoskeletal pain (30-36%)¡A Headache (28%)¡A Fatigue (36%) Serious: Heart failure¡A Left ventricular cardiac dysfunction (1.8-3%)¡A Injection site extravasation¡A Anemia¡A Grade 3 or 4 (1.1-4.1%)¡A Hemorrhage¡A Grade 3 or 4 (0.4-1.8%)¡A Thrombocytopenia¡A Grade 3 or 4 (6-15%)¡A Hepatotoxicity¡A Increased liver enzymes¡A Grade 3 or 4 (1.5-8%)¡A Injury of liver¡A Liver regeneration (0.3-0.4%)¡A Non-allergic anaphylaxis¡A Dyspnea (8-12%)¡A Interstitial lung disease¡A Pneumonitis (1.1-1.2%),2-8¢J,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever¡A chills¡A or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,µL»Ý½Õ¾ã¾¯¶q,Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution. Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded¡A a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü³Ìµu30 ¤ÀÄÁ¡C½Ð¨Ï¥Î0.2-0.22·L¦Ì¡B¤£§lªþ³J¥Õ½èªººÞ½u¤º polyethersulfone (PES)¹LÂo¾¹¡C 3. ·»²G°t¸m«áÀ³¥ß§Y¨Ï¥Î¡A§NÂÃ©ó2-8¢J³Ì¦hÀx¦s24¤p®É¡C 4. ¿éª`®Éª`·N¯f¤H¬O§_¥X²{©I§l§xÃø¡B©PÃä¤ô¸~¡B§C¦åÀ£©Î¨ä¥L«æ©Ê¹L±Ó¤ÏÀ³¯gª¬¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
INS45/20,Sodium Chloride,0.45% NaCl inj 20mL (­­RT¨Ï¥Î),MSIV,,,,,Only for respiratory treatment of in-patient.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IH;,,,,,
IERB0,Cetuximab,Erbitux inj 100mg/20mL (sample),RACA,Colorectal cancer¡A metastatic: Treatment of KRAS wild-type (without mutation)¡A epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer as determined by approved tests (in combination with FOLFIRI [irinotecan¡A fluorouracil¡A and leucovorin] as first-line treatment¡A in combination with irinotecan [in patients refractory to irinotecan-based chemotherapy]¡A or as a single agent in patients who have failed irinotecan- and oxaliplatin-based chemotherapy or who are intolerant to irinotecan). Limitation of use: Cetuximab is not indicated for the treatment of RAS-mutant colorectal cancer or when results of the RAS mutation tests are unknown. Head and neck cancer¡A squamous cell: Treatment of squamous cell cancer of the head and neck (as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease).,Known severe hypersensitivity reactions to cetuximab.,Mild or moderate infusion-related reactions eg fever¡A chills¡A dizziness or dyspnea; mild to moderate mucositis¡A increase in liver enzyme levels; skin reactions mainly as acne-like rash; headache; conjunctivitis; diarrhea¡A nausea¡A vomiting; dehydration¡A hypocalcemia¡A anorexia; fatigue.,2-8¢XC,Weekly dosing: Initial loading dose: 400 mg/m2 infused over 120 minutes. Maintenance dose: 250 mg/m2 infused over 60 minutes once weekly until disease progression or unacceptable toxicity. Complete cetuximab dose 1 hour prior to chemotherapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V no relevant animal data,[¥é³æ] ªí¥Ö¥Íªø¦]¤l¨üÅé©M­L¨àªºµo¨|¦³Ãö¡C¦b¦³­­ªº°Êª«¬ã¨sÆ[¹îµo²{cetuximab ¤Î¨ä¥L§K¬Ì²y³J¥ÕG(IgG)§ÜÅé¯à°÷³q¹L­L½Lªº»Ù¾À¡C°Êª«¹êÅç¼Æ¾ÚÅã¥Ü¥Ø«eµL­P·î­L±¡§Î¡AµM¦Ó¡AÀHµÛ¾¯¶q¼W¥[¡A¬y²£µo¥Íªº¾÷²v¬Û¹ï¼W¥[¡C¥Ø«eÁÙ¨S¦³¨¬°÷ªº¥¥°ü¨Ï¥Î¼Æ¾Ú¡C ±j¯P«ØÄ³¡A¥u¦³·í¥i¯àªº®Ä¯q¶W¹L¹ï­L¨àªº¥i¯à¦MÀI©Ê®É¡A¤~¥i¥Hµ¹¤©¥¥°ü©Î¨S¦³¾A·íÁ×¥¥±¹¬Iªº°ü¤k¨Ï¥Î Erbitux¡C ¥Ø«e©|µL cetuximab ¹ï¤HÃþ¥Í¨|¤O¼vÅTªº¸ê®Æ¡C¥¿¦¡ªº°Êª«¸ÕÅç¤¤¡A¥¼´¿¹ï¶¯©Ê¤Î»Û©Ê°Êª«ªº¥Í¨|¤O°µ¹Lµû¦ô¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¦bErbituxR ªvÀø´Á¶¡©M³Ì«á¤@¾¯ªvÀø«áªº¤G­Ó¤ë¤ºªº°ü¤k¡A¤£­n­÷Áý¥À¨Å¡A¦]¬°©|¥¼ª¾ ErbituxR¬O§_·|±q¥À¨Å±Æ¥X¡C,IVD;,,,,,1. ¿éª`¥»ÃÄ«~¤@©w­n³æ¿W¨Ï¥Î¤@±øºÞ½u¡A¿éª`µ²§ô®É¤@©w­n¥ÎµLµßªº¥Í²z­¹ÆQ¤ô¨R¬~ºÞ½u¡C
ODIA,Diazepam,Diazepam 2mg,CNEU,,¾AÀ³¯g: ¡½Anxiety ¡½Sedation¡A Premedication before surgery¡A endoscopic procedures and cardioversion ¡½Seizure¡A Refractory¡A increased frequency ¡½Seizure; Adjunct ¡½Skeletal muscle spasm; Adjunct ¡½Skeletal muscle spasm - Tetanus ¡½Status epilepticus °Æ§@¥Î: Common ¡½Cardiovascular: Hypotension ¡½Dermatologic: Rash (3%¡A rectal gel ) ¡½Gastrointestinal: Diarrhea (4%¡A rectal gel ) ¡½Musculoskeletal: Muscle weakness ¡½Neurologic: Ataxia¡A Incoordination (3%¡A rectal gel )¡A Somnolence ¡½Psychiatric: Euphoria (3%¡A rectal gel ) ¡½Respiratory: Respiratory depression ¡½Other: Fatigue Serious ¡½Hematologic: Neutropenia ¸T§Ò: Contraindications ¡½hepatic insufficiency¡A severe ¡½hypersensitivity to diazepam ¡½myasthenia gravis ¡½narrow-angle glaucoma¡A acute ¡½pediatric patients less than 6 months of age ¡½respiratory insufficiency¡A severe ¡½sleep apnea syndrome,,«Ç·Å,,,,,ºÉ¶qÁ×§K,,,Human Data Suggest Potential Toxicity,AAP: Drugs for which the effect on nursing infants is unknown but may be of concern. ¡½WHO: Compatible with breastfeeding. Monitor infant for side effects. ¡½Micromedex: Infant risk has been demonstrated.,,,,,,
IESM,Rocuronium Bromide,Esmeron inj 50mg/5mL,CNEU,,¸T§Ò: Hypersensitivity. °Æ§@¥Î: Anaphylactic & anaphylactoid reactions¡A anaphylactic & anaphylactoid shock; flaccid paralysis; tachycardia; hypotension¡A circulatory collapse & shock¡A flushing; bronchospasm; angioneurotic edema¡A urticaria¡A rash¡A erythematous rash; muscular weakness¡A steroid myopathy; face oedema¡A injection site pain & reaction; airway complication of anaesth¡A delayed recovery from anaesth. ¾AÀ³¯g: Adjunct to general anaesth to facilitate tracheal intubation¡A during routine & rapid sequence induction¡A & to provide skeletal muscle relaxation during surgery. Adjunct in ICU to facilitate intubation & mechanical ventilation.,,2-8¢J,Tracheal intubation Intubating dose: 0.6 mg/kg body wt. Maintenance: 0.15 mg/kg body wt. Infusion rate: 0.3-0.6 mg/kg/hr. Rapid sequence induction 1 mg/kg body wt. Caesarean section 0.6 mg/kg body wt. Mechanical ventilation 0.6 mg/kg body wt followed by a continuous infusion as soon as twitch height recovers to 10% or upon reappearance of 1-2 twitches to train of 4 stimulation.,»Ý½Õ¾ã¾¯¶q,¨Ï¥Î 0.6 mg.kg-1 ¤§ rocuronium bromide¬°§Ö³t³Â¾K»¤¾É¤§´¡ºÞ¾¯¶q®É¡A¦¹Ãþ¯f¤H¤§Á{§É§@¥Î®É¶¡¹w´Á¥i¯à·|©µªø¡CµL½×¨Ï¥Î¦óºØ³Â¾K§Þ³N¡A³oÃþ¯f¤H¤§±ÀÂËºû«ù¾¯¶q¬°0.075-0.1 mg.kg-1¤§rocuronium bromide¡A¦Ó±ÀÂË¿éª`²v¬°0.3~0.4 mg.kg-1.h-1,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,IV bolus as an adjunct to facilitate tracheal intubation.,0.3~0.4mg/kg/h (¿@«×¡G0.5 mg/mL ©Î 2 mg/mL ),1.Esmeron¥HÀR¯ß§ëÃÄ±Ä¤@¦¸ª`¤J©Î³sÄò¿éª`¤è¦¡
OCOMP,Prednisolone,Compesolon 5mg,HM,RA¡A lupus erythematosus¡A periarthritis nodosum¡A allergic & inflammatory skin disorders.,Peptic ulcer¡A osteoporosis¡A psychoses or severe neuropsychosis; active or doubtfully quiescent TB; acute infection; live vaccines.,Fluid & salt retention¡A edema¡A hypertension; amenorrhea¡A hyperhidrosis¡A mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; local atrophy; increased appetite; growth retardation.,25¢J¥H¤U,Asthma: 30-60mg daily in one week¡A from then decrease dosage to maintain as 10-30mg daily. Arthritis: 20mg daily¡A or 30mg daily in severe patient.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IAAA,A. Acutus antivenin,§Ü¦Ê¨B³D¬r¦å²M,HIMM,,¾AÀ³¯g:Therapy for the bite of D. acutus snake. °Æ§@¥Î:allergic phenomena including anaphylaxis¡A hypotension¡A serum sickness. ¸T§Ò: Hypersensitivity to antivenin.,,2-8¢J,1000 or more units per dose. Adult 1 dose. (SC: 0.5 dose near bite; 0.5 dose IV or IM),,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. µ}ÄÀªk¡G¨úµ}ÄÀ·»²G10 mLª`¤J­á´¹»s¾¯¤¤¡AÁ×§K¥Î¤O®¶·n¡AÀ³©ó2¤p®É¤º¥Î§¹¡C 2. ©y¾¨¦­ª`®g¡A³Q«r¶Ë«á4¤p®É¤ºª`®g³Ì¦³®Ä¡C 3. ª`®g³¡¦ì¡G«r¶Ë®É¶¡¤G¤p®É¤º¡A¥i±N¤@¥b¾¯¶qª`®g¦b«r¶Ë³¡¦ì©P³ò¥Ö¤U¡A¥t¤@¥b«hIV©ÎIM¡C 4. ª`®g³t²v¡GIV: ²Ä1 mLª`®g®É¶¡¬°5¤ÀÄÁ¥H¤W¡A¤§«á¨C¤ÀÄÁ¤£¥i¶W¹L1 mL¡CIVD: ¤@¾¯§Ü³D¬r¦å²Mµ}ÄÀ©ó300mL N/S¡C 5. ª`®g¾¯¶q¡G¦¨¤H¬°¤@¾¯¶q¡A10·³¥H¤U¨àµ£¥[­¿¡C¦p¯gª¬Ä~Äò´c¤Æ¡A¹j30¤ÀÄÁ¦Ü¤@¤p®É«á¥i¦A¥´¤@¾¯¡C 6. ³D¬r¦å²M¬°°¨ªº¦å²M»s¾¯¡A¥i¯à¦³¹L±Ó¤ÏÀ³¡A¥i¥ý°µ¥Ö½§¸ÕÅç¨Ã·Ç³Æ1:1000 Epinephrine³Æ¥Î¡C
EULT1,Indacaterol + Glycopyrronium,Ultibro Breezhaler 110/50mcg,ERSP,Once-daily maintenance bronchodilator treatment to relieve symptoms & reduce exacerbations in patients with COPD.,hypersensitivity to glycopyrrolate¡A indacaterol maleate¡A or any excipients of the product,Cardiovascular: Chest pain (1% to less than 10% ) Endocrine metabolic: High glucose level in blood (4.1% ) Gastrointestinal: Indigestion (1% to less than 10% ) Neurologic: Dizziness (1% to less than 10% )¡A Headache (1% to less than 10% ) Respiratory: Cough (1% to less than 10% )¡A Nasopharyngitis (1% to less than 10% )¡A Pain in throat (1% to less than 10% .)¡A Rhinitis (1% to less than 10% )¡A Sinusitis (1% to less than 10% )¡A Throat irritation¡A Upper respiratory infection (10% or more ) Other: Fever (1% to less than 10% ),30¢J¥H¤U,Adult Dosing Chronic obstructive pulmonary disease: 1 capsule via INHALATION once a day using Ultibro Breezhaler inhaler. Safety and efficacy not established in children<18years.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,INDACATEROL Respiratory (Bronchodilator) PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk GlycopyrroniumµL¸ê®Æ BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,Unknown ¨S¦³¸ê®Æ,Micromedex Lactation Rating: Infant risk cannot be ruled out. It is not known if indacaterol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering indacaterol to nursing women. The use of beta2-receptor agonists are not considered a contraindication to breast-feeding INDACATEROL BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible GlycopyrroniumµL¸ê®Æ,IH;,,,,,1. ¨C­ÓUltibro Breezhaler ¥]¸Ë§t¦³: ¤@­ÓUltibro Breezhaler §l¤J¾¹ / ¾Tºä¤ù¡A¤º§t¦³¨ÑUltibro Breezhaler §l¤J¾¹¨Ï¥Îªº½¦Ån 2. ¤£¥i§]ªAUltibro Breezhaler ½¦Ån: Ultibro Breezhaler §l¤J¾¹¬O¤@ºØ¾¹§÷¡A¨Ñ±z¦b§l¤JUltibro Breezhaler ½¦Ån¤¤ªºÃÄ«~®É¨Ï¥Î¡C 3. ¥u¥i¨Ï¥Î¥]¸Ë¤¤ªºUltibro Breezhaler §l¤J¾¹¡C 4. Ultibro Breezhaler ½¦Ån¤£¥i¨Ï¥Î¨ä¥L§l¤J¾¹¡A¨ä¥L½¦ÅnÃÄ«~¤]¤£¥i¨Ï¥ÎUltibro Breezhaler §l¤J¾¹¡C
IAMP5,Ampicillin,Ampicillin inj 0.5gm,QANB,,Active against G(-) organism¡A generally less active against G(+) organism¡A except enterococci.,,,Adult & child over 20kg: Oral: 250-500 mg q6h¡A (max. 6 g/day). IM¡A slow IV or IV infusion: 250-500 mg q6h. For bacterial meningitis or septicemia: 1-2 g q3-4h¡A(max.16 g/day or 300 mg/kg/day). Child under 20 kg: Oral: 12.5-25 mg/kg q6h¡A (max. 200 mg/kg/day). IM¡A slow IV or IV infusion: 6.25-25 mg/kg q6h. For bacterial meningitis or septicemia: 16.7-41.7 mg/kg q4h¡A(max. 400 mg/kg/day ).,,,,¥i¯à¦w¥þ,,,,,,,,,,
OFLA,Metronidazole,Flagyl 250mg,QANB,,¾AÀ³¯g:Vaginitis caused by Trichomonas. Amebiasis & metronidazole-susceptible anaerobic infection. °Æ§@¥Î:GI disturbances; peripheral neuropathy; drowsiness; leukopenia; rarely¡A skin reactions¡A darkening of urine¡A anaphylaxis¡A encephalopathy. Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction ¸T§Ò:Blood dyscrasias. Active CNS disease.,,«Ç·Å,Anaerobic infections: Max. 1 g/dose¡A 4 g/day. Oral: 7.5 mg/kg q6h for 7 days or longer. IV infusion only (over 1 hr): 15 mg/kg as a loading dose¡A then 7.5 mg/kg q6h for 7 days or longer. Amebiasis: oral: Adult: 500-750 mg tid for 10 days. Child: 11.6-16.7 mg/kg tid for 10 days. Trichomoniasis: oral: Adult: 2 g as a single dose; 1 g bid for 1 day; or 250mg tid for 7 days. Child: 5 mg/kg tid for 7 days. Giardiasis: Adult: 2 g qd x 3 days or 250-500 mg tid x 5-7 days. Child: 5 mg/kg tid x 5 days.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OACAL,Calcium Carbonate,A-Cal 500mg,NUTR,,¾AÀ³¯g: Relief of the symptoms of gastric hyperacidity. °Æ§@¥Î: Mild GI disturbances. ¸T§Ò: Hypercalcaemia due to myeloma¡A bone metastases or other malignant bone disease¡A sarcoidosis; primary hyperparathyroidism¡A vitamin D overdosage; severe renal failure.,,«Ç·Å,1-2 tab before meals & at bedtime. Max: 8 tab/day.,,,,¨S¦³¸ê®Æ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,,,,,,
ICIS,Cisplatin,Cisplatin 50mg/50mL,RACA,Bladder cancer¡A advanced. Ovarian cancer¡A metastatic. Testicular cancer¡A metastatic.,History of allergic reactions to cisplatin¡A other platinum-containing compounds¡A or any component of the formulation; preexisting renal impairment; myelosuppressed patients; hearing impairment.,Nausea & vomiting¡A renal toxicity¡A bone-marrow depression¡A ototoxicity¡A serum electrolyte disturbances¡A peripheral neuropathy¡A retinal toxicity¡A anaphylactic reactions¡A cardiac abnormalities.,15-25¢JÁ×¥ú¤Å§NÂÃ,50-100 mg/m2 every 3-4 weeks or 15-20 mg/m2 for 5 days every 3-4 weeks.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gcisplatinªº¾¹¨ã¤£¥i§t¦³¾T¡C 3. µ}ÄÀ«áªº¿éª`·»²GÀ³Á×¥ú«O¦s¡C 4. µ¹ÃÄ«e«áÀ³µ¹¤©¯f¤H¾A·í¤ô¤À¸É¥R¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C 6. ©w´Á¯«¸g¾Ç¡BÅ¥¤OÀË´ú¡C
HCVDA13,Glecaprevir + Pibrentasvir (1~6type/12¶g),HCVDAA0013(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1-6«¬/12¶g,QANB,,,,,,,,,,,,,,,,,,,
OSUB,Buprenorphine + Naloxone,Suboxone 8/2mg,CNEU,Treatment of opioid dependence.,Hypersensitivity to buprenorphine¡A naloxone¡A or any component of the formulation,Central nervous system: Headache (36%)¡A withdrawal syndrome (25%; placebo 37%)¡A pain (22%) Dermatologic: Diaphoresis (14%) Gastrointestinal: Glossodynia (film)¡A oral hypoesthesia (film)¡A oral mucosa erythema (film),30¢J¥H¤U,Adults and teenagers over 15 years old: Day 1 induction dose: Initial: Buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg sublingual; may increase the dose with buprenorphine 2 to 4 mg/naloxone 0.5 to 1 mg¡A based on control of acute withdrawal symptoms. Adjust and maintain dose: Titrate the dose with buprenorphine 2 to 8 mg based on patient's clinical and psychological status(Max:buprenorphine 24mg/day). Heroin or short-acting opioid dependency: Start treatment when withdrawal symptoms occur¡A but 6 hours after patient takes the last opiods. For patients taking methadone: Patients taking methadone > 30mg/day should start the treatment from Buprenorphine 2 mg/naloxone 0.5 mg and mind the half-life of methadone. Start treatment when withdrawal symptoms occur¡A but 24 hours after patient takes the last dose of methadone. Buprenorphine may increase withdrawal symptoms of methadone.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à·l¶Ëªº¯f±wªº¾¯¶qÀ³½Õ¾ã¡A¥BÀ³Æ[¹î¯f±w¬O§_¦³¬ðµoªº¾~¤ùÃþ§ÙÂ_ªº¯gª¬ Moderate impairment: Use with caution during maintenance treatment (due to reduced clearance of naloxone and potential for reduced buprenorphine efficacy¡A use may not be appropriate). Suboxone use is not recommended during induction therapy. Severe impairment: Use is not recommended,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,Buprenorphine PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible Naloxone PREGNANCY RECOMMENDATION: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Buprenorphine BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible Naloxone BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,SL;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¦Þ¤U¿õ¡A¥iª½±µ¸m©ó¯f±w¦Þ¤U¡C
OCON2,Methylphenidate,Concerta ER 27mg,CNEU,For treatment of attention deficit hyperactivity disorder.,Patients with marked anxiety¡A tension & agitation¡A glaucoma¡A Tourette's syndrome¡A & patients on MAOI therapy.,Headache¡A stomach ache¡A loss of appetite¡A insomnia¡A aggravation reaction¡A asthenia¡A hypertension¡A nausea &/or vomiting¡A dyspepsia¡A weight loss¡A twitching (tics)¡A dizziness¡A emotional lability¡A somnolence¡A anxiety¡A depression¡A nervousness¡A hostility¡A rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% )¡A Loss of appetite (5% )¡A Nausea (12% )¡A Vomiting (10% ) Neurologic: Headache¡A Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% )¡A Nasopharyngitis (5% ),25¢J¥H¤UÁ×§K¼éÀã,Attention deficit disorder : (Child over 6 years and adult) Concerta: 27mg(1 TAB) QD. ( maximum for Child: 54 mg/day; maximum for adult : 72 mg/day ),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°ªø®Ä¿õ¡A½Ð¾ã²É§]ªA¡A¤£¥i¼·¥b©Î¿i¯»¡C
OGEMD,Gemfibrozil,Gemd 300mg,CAVS,,¾AÀ³¯g: Dyslipidemia type IIa¡A IIb¡A III¡A IV & V. Reduces risk of CHD. °Æ§@¥Î: GI upset¡A rash¡A pruritus¡A headache¡A dizziness¡A hematopoietic disorders. Gastrointestinal: Abdominal pain (9.8% )¡A Acute appendicitis (1.2% )¡A Indigestion (19.6% .) ¸T§Ò: Gallbladder disease¡A hepatic¡A renal dysfunction including primary cirrhosis.,,«Ç·Å,1200 mg daily in 2 divided doses.(Should be taken on an empty stomach ),,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
EBETA,Betamethasone + Gentamicin,Sinbeta derm cream 10gm,TDER,Dermatoses complicated by infection in psoriasis¡A neurodermatitis¡A lichen planus¡A eczema¡A intertrigo¡A dyshidrosis¡A seborrhoeic¡A contact¡A atopic¡A exfoliative¡A solar¡A stasis dermatitis; anogenital & senile pruritus.,Hypersensitivity to any of the component.,Burning¡A itching¡A irritation¡A dryness¡A folliculitis¡A hypertrichosis¡A perioral dermatitis¡A allergic contact dermatitis¡A acneiform eruption¡A hypopigmentation¡A maceration of the skin¡A skin atrophy¡A secondary infection¡A striae & miliaria.,25¢J¥H¤UÀx¦s,Cover affected area completely BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,Betamethasone - Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk Gentamicin - Gentamicin,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Betamethasone - No Human Data¡XProbably Compatible Gentamicin - Compatible,EXT;,,,,,
ODIA2,Diazepam,·í¥ß¥­Diapin 2mg,CNEU,Management of anxiety disorders¡A ethanol withdrawal symptoms; skeletal muscle relaxant; treatment of convulsive disorders; preoperative or preprocedural sedation and amnesia,Hypersensitivity to diazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; acute narrow-angle glaucoma; not for use in infants <6 months of age (oral),Hypotension¡A localized phlebitis¡A vasodilatation¡A Amnesia¡A ataxia¡A confusion¡A depression¡A drowsiness¡A dysarthria¡A fatigue¡A headache¡A slurred speech¡A vertigo¡A Skin rash¡A Change in libido¡A Altered salivation (dry mouth or hypersalivation)¡A constipation¡A diarrhea¡A nausea¡A Urinary incontinence¡A urinary retention¡A Jaundice¡A Pain at injection site¡A Tremor¡A weakness¡A Blurred vision¡A diplopia¡A Apnea¡A asthma¡A bradypnea¡A Paradoxical reaction (eg¡A aggressiveness¡A agitation¡A anxiety¡A delusions¡A hallucinations¡A inappropriate behavior¡A increased muscle spasms¡A insomnia¡A irritability¡A psychoses¡A rage¡A restlessness¡A sleep disturbances¡A stimulation),30¢J°®ÀêÁ×¥ú,Adults: Anxiety¡A Insomnia: 5-30mg HS¡A or in 2-4 divided doses. Acute alcohol withdrawal: Initial dose:10mg¡A then TID-QID as needed. Spasm: 2-10mg TID-QID Skeletal muscle relaxation: 2-10mg TID-QID. Elderly and frail patients: 2-2.5mg QD-BID¡A titrate the dose as needed and tolerability. Children: Not recommended for children under 6 years old. Children 6 years and older:1-2.5mg¡A or 0.04mg-0.2mg/kg¡A or 1.17¡ã6mg per square meter of body surface area TID-QID¡A titrate the dose as needed and tolerability.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] ¥»ÃÄ·|³q¹L­L½L»Ù¾À¡CÃh¥¥´Á«e¤T­Ó¤ë¨Ï¥Î¥»ÃÄ·|¼W¥[¥ý¤Ñ©Ê·î§Îªº¦MÀI¡A¬GÀ³´N¨ä¨Ï¥Î¤§¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡A³Ì¦nÁ×§K¨Ï¥Î¡C FDA Pregnancy Category¡]Ãh¥¥¥ÎÃÄ¯Å¼Æ¡^¡GD Ãh¥¥¹ï¨Ï¥Î¥»ÃÄ·|²£¥Í¨Ì¿à©Ê¡A¹ï·s¥Í¨à¥ç·|²£¥Í§ÙÂ_¯gª¬¡C ¥¥°ü¤À®Y«e¼Æ¬P´Á¨Ï¥Î¥»ÃÄ·í¦w¯v¾¯¡A¥i¯à¾É­P·s¥Í¨à¤§¤¤¼Ï¯«¸g¨t²Î§í¨î¡C ¥¥°ü©ó¤À®Y®É©Î¤À®Y«e¨Ï¥Î¥»ÃÄ¡A¥i¯à¤Þ°_·s¥Í¨àªº¦¢½wµL¤O¡]Flaccidity¡^¡C °ü¤k©ó¥Í²£«e 15 ¤p®É¤§¤º§ë¥Î¥»ÃÄ 30mg ¥H¤W¡A¯S§O¬O¦Ù¦×©ÎÀR¯ßª`®g¡A¥i¯à³y¦¨·s¥Í¨à²¿®§¡B¦Ù±i¤O¹L§C¡BÅé·Å¹L§C¡B­¹¼¤¤£®¶¡A¤Î¹ï´H§N¨ë¿E¤§¥NÁÂ¤ÏÀ³¨ü·l¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥¼¦³¬ÛÃö¸ê®Æ¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OFOS,Alendronate,Fosamax 10mg,META,,Treatment of osteoporosis in postmenopausal women.,,,10 mg once daily.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
IGEN,Gentamicin,Garamycin 80mg/2mL,QANB,,THIS IS A TESTING,,,,,,,,,,,,,,,,,
SK1001,,§³®W²Ó¯¾Âù®ÄÁ÷,TDER,,,,,,,,,,,,,,,,,,,
ESTI,Erythromycin,Stiemycin solution 2% 25mL,TDER,,I: Topical treatment of acne vulgais¡A in particular¡A inflamed forms with papules & pustules. CI: Hypersensitivity.,,,Apply bid. Continue for ¡Ù6-12weeks.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OSIN,Montelukast,Singulair Chewable 5mg,ERSP,SINGULAIR is indicated in adult & pediatric patients 6 months of age & older for the prophylaxis & chronic treatment of asthma¡A including the prevention of day- & nighttime symptoms¡A the treatment of aspirin-sensitive asthmatic patients¡A & the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adults & pediatric patients 2 years of age & older for the relief of day- & nighttime symptoms of seasonal allergic rhinitis.,Hypersensitivity to any component of Singulair.,Abdominal pain¡A headache¡A thirst¡A diarrhea¡A hyperkinesia¡A asthma¡A eczematous dermatitis¡A rash. Neurologic: Headache (Adult and adolescent; 18.4%; pediatric¡A 2% and greater ),30¢J¥H¤U¡AÁ×§K´ÂÀã»P¥ú½u·Ó®g,Should be taken once daily. For asthma¡A the dose should be taken in the evening. For seasonal allergic rhinitis¡A the time of administration may be individualized. Patients with both asthma & seasonal allergic rhinitis should take only 1 TAB daily in the evening. Asthma and/or seasonal allergic rhinitis- Age > or = 15 years: 10 mg QD. Age 6-14 years: One 5 mg chewable TAB QD. Age 2-5 years: One 4 mg chewable TAB QD or one packet of 4 mg oral granules QD. Age 6 months-2 years with asthma: One packet of 4 mg oral granules QD.,»Ý½Õ¾ã¾¯¶q,Mild-to-moderate impairment: No dosage adjustment necessary. Severe impairment: No dosage adjustment provided in manufacturer¡¦s labeling; has not been studied.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°©CÄZ¿õ¡A«r¸H«á§]ªA§Y¥i¡C
OMERC,Desogestrel + Ethinylestradiol,Mercilon (21 tablets/box),HM,Oral Contraceptives,Thrombophlebitis¡A thromboembolic disorders¡A CV disease or past history of these conditions; severe hypertension; severe liver disorder¡A cholestatic jaundice¡A Rotor syndrome¡A Dubin-Johnson syndrome; known or suspected estrogen-dependent tumours; endometrial hyperplasia; undiagnosed vag bleeding; porphyria; hyperlipoproteinemia; history during pregnancy of severe pruritus or herpes gestationis. Pregnancy.,GI upsets¡A cholestatic jaundice; thrombosis¡A BP elevation; chloasma¡A erythema¡A nodosum¡A rash; headache¡A migraine¡A mood changes; breast tenderness¡A pain¡A enlargement¡A secretion; fluid retention¡A reduced glucose tolerance¡A change in body wt; intermenstrual bleeding¡A post-medication amenorrhea¡A changes in cervical secretion¡A increase in size of uterine fibromyomata¡A aggravation of endometriosis¡A vag infection.,30¢J¥H¤U¤Å§N­á¡AÁ×§K¥ú½u»PÀã®ð,1 tablet daily for 21 days¡A starting on the 1st day of the cycle¡A then 7 tablet-free days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Desogestrel [18] Ethinylestradiol Ethinylestradil [18] by book . micromedex : Teratogenicity/Effects in Pregnancy Rating Fetal risk cannot be ruled out.,Unknown ¨S¦³¸ê®Æ,Desogestrel [8] ¡EEvidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding lEthinylestradiol Ethinylestradil [8] Evidence and/or expert consensus has demonstrated harmful infant effects when used during breastfeeding up to date: Lactation Enters breast milk/not recommended,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¬ÛÃö­·ÀI¡A¤×¨äÁ×§K¼ÉÅS©óÃh¥¥©Î·Ç³ÆÃh¥¥°ü¤k¡C
OTIN,Oxatomide,Tinset 30mg,HIMM,,Hay fever¡A chronic urticaria¡A pruritus¡A adjuvant in allergic asthma¡A prevention of food allergies¡A food and drug induced exanthema¡A allergic rhumitis.,,,Adult: Allergic asthma: 2 tab bid¡A Other indications: 1 tab. bid. Child: 0.5mg/kg bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
OCALW,Calcium Citrate,Calwell chewable 950mg,NUTR,,¾AÀ³¯g: Ca supplement¡A renal osteodystrophy. °Æ§@¥Î: -Mild hypercalcemia (calcium: >10.5 mg/dL) may be asymptomatic or manifest itself as constipation¡A anorexia¡A nausea¡A and vomiting. -More severe hypercalcemia (calcium: >12 mg/dL) is associated with confusion¡A delirium¡A stupor¡A and coma -Central nervous system: Headache -Endocrine & metabolic: Hypophosphatemia¡A hypercalcemia -Gastrointestinal: Nausea¡A anorexia¡A vomiting¡A abdominal pain¡A constipation -Miscellaneous: Thirst ¸T§Ò: Hypersensitivity to any component of the formulation,,«Ç·Å,Adult & children > 4 years 2-5 tabs daily.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,(UpToDate) 1 g calcium citrate = elemental calcium 211 mg = calcium 10.5 mEq = calcium 5.25 mmol
ICOL1,Colistin Methanesulfonate,Colomycin inj 1MU,QANB,,¾AÀ³¯g: GI infections; Bowel sterilisation. °Æ§@¥Î: Superinfection; renal damage; visual disturbances; GI disturbances¡A dizziness¡A nausea¡A vomiting; confusion¡A peripheral neuropathy; respiratory insufficiency and muscle weakness. ¸T§Ò: Hypersensitivity. Anuria; porphyria; myasthenia gravis. Pregnancy and lactation.,,«Ç·Å,IV/IM GI infections; Bowel sterilisation As colistimethate Na: 6 million units/day in 3 divided doses. Max: 6 million units/24 hr. (¨C¤p²~100¸U³æ¦ì=80mg Colistimethate sodium=33.4mg colistin base activity ) Normal renal function: 2.5-5mg/kg/day divided in 2-4 doses Mild renal impairment: 2.8-3.8mg/kg/day divided in 2 doses Moderate renal impairment: 2.5mg/kg/day divided in 1-2 doses,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ¿éª`²G»Ý·sÂA°t»s¡A«Ç·Å¤U¥u¯àÂ\©ñ24¤p®É 2. µÇ¥\¯à¤£¥þ¯f±w»Ý´îºCª`®g³t²v¡C
EATR3,Atropine,0.3% ANTOL¡A 5mL,TOPH,,¾AÀ³¯g: Topical mydriatic & cycloplegic; uveitis. °Æ§@¥Î: Stinging¡A increased intraocular pressure¡A conjunctivitis. May precipitate glaucoma. ¸T§Ò: Closed- & narrow-angle glaucoma.,,«Ç·Å,1 gtt hs: for treatment of myopia. (0.1 %¡A 0.25 % and 0.5%) 1 gtt qid: for use in uveitis. (1.0 %),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
ETET,Tetracycline,Tetracycline oph oint 1%¡A 5gm,TOPH,,¸T§Ò: Hypersensitivity to doxycycline or other tetracyclines. °Æ§@¥Î: Local irritation ¾AÀ³¯g: Local treatment of ophth infections due to gm+ve & gm-ve bacteria eg acute & chronic conjunctivitis¡A blepharoadenitis¡A acute keratitis & trachoma.,,«Ç·Å,For eye infections: Adults and children¡XUse every two to four hours¡A depending on severity of infection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AD;AL;AS;AU;EXT;OD;OL;OU;SKIN;TOPI;,,,,,
OCHAL,Calcium polystyrene sulfonate,Chalian powder 5g/pk,ZADT,,¾AÀ³¯g: Treatment of hyperkalemia °Æ§@¥Î: Endocrine & metabolic: Hypercalcemia¡A hypokalemia¡A hypomagnesemia Gastrointestinal: Anorexia¡A concretions (bezoars; oral administration)¡A constipation¡A diarrhea¡A fecal impaction (rectal administration)¡A gastric irritation¡A GI necrosis/ulceration¡A ischemic colitis¡A nausea¡A obstruction (rare)¡A rectal hemorrhage¡A vomiting Respiratory: Acute bronchitis¡A bronchopneumonia ¸T§Ò: Hypersensitivity to polystyrene sulfonate resins or any component of the formulation; potassium <5 mmol/L (5 mEq/L); conditions associated with hypercalcemia (eg¡A metastatic carcinoma¡A hyperparathyroidism); obstructive bowel disease; oral administration in neonates; use in neonates with reduced gut motility (postoperative¡A drug induced),,«Ç·Å,Dosing: Adult Hyperkalemia: Initiate treatment if potassium level >6 mmol/L (6 mEq/L); discontinue when potassium < 5 mmol/L (5 mEq/L). Oral: 15 g 3-4 times/day Rectal: 30 g once daily,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,(104.01.15)ÃÄ«~¼t°Ó«ØÄ³¤é·¥¶q 30 g.,,,,,,
OACT6,Acetylcysteine,Actein 600mg µoªw¿õ,ERSP,,¾AÀ³¯g: Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis¡A emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms. °Æ§@¥Î: Bronchospasm¡A GI upsets¡A stomatitis; rhinorrhea¡A fever¡A hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )¡A Rash (4% to 5% )¡A Urticaria Gastrointestinal: Diarrhea¡A Nausea (2% to 7% )¡A Vomiting (9% to 12% ) ¸T§Ò: Effervescent tab Phenylketonuria.,,«Ç·Å,Effervescent tab Adult & children > 6 years 1 effervescent tab qd ~ bid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OARI,Donepezil,Aricept 5mg,CNEU,Mild to moderate Alzheimer's disease.,,,,1 TAB daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OCRA,Levofloxacin,Cravit F.C. 100mg,QANB,,Resp tract¡A ENT¡A GUT infection. Intracterine infections¡A cervicitis¡A uterine adnesxitis¡A folliculitis. GIT infections¡A lymphangitis¡A mild to moderate skin & skin tissue infections.,,,Adult 100mg bid-tid. Severe case: 200mg bid.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
HE5005,Dianeal 1500cc 4.25% (PD 4Âù³U),Dianeal 1500mL 4.25% (PD 4Âù³U),NUTR,,,,,DIANEAL low calcium peritoneal dialysis solutions are intended for intraperitoneal administration only. The mode of therapy¡A frequency of treatment¡A formulation¡A exchange volume¡A duration of dwell¡A and length of dialysis should be selected by the physician responsible for and supervising the treatment of the individual patient. Continuous Ambulatory Peritoneal Dialysis (CAPD): Patients on CAPD typically perform 4 cycles per day (24 hours) Automated Peritoneal Dialysis (APD): Patients on APD typically perform 4-5 cycles at night and up to 2 cycles during the day. The fill volume depends on body size¡A usually from 2.0 - 2.5 liters per 1.73m2,,,,,,,,,,,,,,
ECIV,Heparinoid,Cividoid gel 20gm,TDER,Treatment of superficial thrombophlebitis & relief of superficial bruising & haematoma.,Hypersensitivity to this medicine. Not for oral or ophthalmic use.,Hypersensitivity reaction.,25¢J¥H¤UÀx¦s,superficial thrombophlebitis & hematoma Use 2-3 times a day¡A till symptom resolved,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¨àµ£¡A¥¥°ü¡A¥i¯àÃh¥¥°ü¤k¤Î­÷¨Å°ü¡A¨Ï¥Î«e½Ð¥ý¿Ô¸ßÂå®vÃÄ®vÃÄ¾¯¥Í.,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¨àµ£¡A¥¥°ü¡A¥i¯àÃh¥¥°ü¤k¤Î­÷¨Å°ü¡A¨Ï¥Î«e½Ð¥ý¿Ô¸ßÂå®vÃÄ®vÃÄ¾¯¥Í.,EXT;SKIN;TOPI;,,,,,
IPRI,Metoclopramide hydrochloride,Primperan °w¾¯ 10mg/2mL,ALIM,Prevention of nausea & vomiting¡A GERD & diabetic gastroparesis.,GI hemorrhage¡A mechanical obstruction or digestive perforation; Pheochromocytoma; previous history of tardive dyskinesia with neuroleptics. Epilepsy,Syndrome malin. Occasionally GI disturbances¡A headache¡A lightheadedness¡A drowsiness. Rarely¡A endocrinal disorders eg. amenorrhea¡A hyperprolactinemia¡A gynecomastia in males¡A breast enlargement in women; extrapyrimidal symptoms¡A hypotension¡A tachycardia¡A arrhythmia Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )¡A Vomiting (1.4% to 2.1% ) Neurologic: Asthenia (10% )¡A Headache (4.2% to 5.2% .)¡A Somnolence (oral¡A 2.1% to 10%; IV¡A 70%) Other: Fatigue (2.1% to 2.8% ),30¢J¥H¤U¡A¸m©ó­ì¥]¸Ë¤ºÁ×¥ú¶J¦s,Actute condition: Adult 10mg¡A may repeat if necessary; Children > 14 years: 10mg; 6-14 years: 2.5-5mg; Children 1-6 years: 0.1mg/kg/dose; Children < 1 year: 0.1mg/kg/dose with maximum 2 times per day. Recommended dosage: 0.1mg/kg/dose¡A maximum 3 times per day. Maximum dosage: 0.2mg/kg/dose. Daily maximum dosage: < 0.5mg/kg.,»Ý½Õ¾ã¾¯¶q,¤¤«×©Î­««×¨x¥\¯à¤£¥þ(Child-Pugh B or C)¯f±w ¥Î¨ÓªvÀøGERD¡A«ØÄ³³Ì°ªÁ`¾¯¶q30 mg/day ¥Î¨ÓªvÀødiabetic gastroparesis¡A«ØÄ³³Ì°ªÁ`¾¯¶q20 mg/day,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C¡iD10W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,Primperan inj.½Ð slowly push (¦Ü¤Ö3 ¤ÀÄÁ)¡A¶W¹L 1 amp ½Ð IV drip¡C,¤ÆÀø«eÀR¯ßª`®g¡G10 mg / 50 mL ½wºC¿éª`¶W¹L 15 ¤ÀÄÁ¡C,1. ¤ÆÀø«eÀR¯ßª`®g¡G10 mg / 50 mL ½wºC¿éª`¶W¹L 15 ¤ÀÄÁ¡C 2. Primperan 10 mg IV ½Ð slowly push (¦Ü¤Ö3 ¤ÀÄÁ)¡A¶W¹L 1 amp ½Ð IV drip¡C(2008/03/11 ÃÄª«¤£¨}¤ÏÀ³¤p²Õ)
EZIN,Zinc Oxide,Zin ointment 20%¡A 28.4gm,TDER,Eczema¡A scalp dermatoses.,Hypersensitivity to any component of the formulation.,Drying or tightening of skin.,25¢J¥H¤U,Apply several times as need.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
IVIT,Calcium chloride¡A Glucose,Vitacal inj 5.44mEq / 20mL,NUTR,,¾AÀ³¯g: Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg¡A tetany¡A seizures¡A arrhythmias); emergent treatment of severe hypermagnesemia. °Æ§@¥Î: Cardiovascular (following rapid IV injection): Bradycardia¡A cardiac arrest¡A cardiac arrhythmia¡A hypotension¡A syncope¡A vasodilatation Central nervous system: Feeling abnormal (sense of oppression; with rapid IV injection)¡A tingling sensation (with rapid IV injection) Endocrine & metabolic: Hot flash (with rapid IV injection)¡A hypercalcemia Gastrointestinal: Dysgeusia (chalky taste)¡A gastrointestinal irritation¡A increased serum amylase Local: Local tissue necrosis (following extravasation) Renal: Nephrolithiasis Postmarketing and/or case reports (Limited to important or life-threatening): Cutaneous calcification ¸T§Ò: Known or suspected digoxin toxicity; not recommended as routine treatment in cardiac arrest (includes asystole¡A ventricular fibrillation¡A pulseless ventricular tachycardia¡A or pulseless electrical activity),,«Ç·Å,Vitacal inj (Calcium chloride 400mg + Glucose.H2O 2gm / 20mL) Adult Dosing --Hypocalcemia: 200 mg to 1 g calcium chloride (55 to 273 mg elemental calcium) IV every 1 to 3 days. --Cardiac arrest or cardiotoxicity in the presence of hyperkalemia¡A hypocalcemia¡A or hypermagnesemia: IV: 500-1000 mg over 2-5 minutes; may repeat as necessary. --Beta-blocker overdose¡A refractory to glucagon and high-dose vasopressors (off-label use): IV: 20 mg/kg over 5-10 minutes followed by an infusion of 20 mg/kg/hour titrated to adequate hemodynamic response. --Calcium channel blocker overdose (off-label use): IV: Initial: 1000-2000 mg over 5 minutes; may repeat every 10-20 minutes with 3-4 additional doses or 1000 mg every 2-3 minutes until clinical effect is achieved; if favorable response obtained¡A consider IV infusion. IV infusion: 20-40 mg/kg/hour.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1. 1 g calcium chloride = elemental calcium 273 mg = calcium 13.6 mEq = calcium 6.8 mmol 2. For IV administration only and administration via central or deep vein is preferred. 3. stop the infusion if the patient complains of pain or discomfort. 4. Monitor ECG if calcium is infused faster than 2.5 mEq/minute 5. Do not infuse calcium chloride in the same IV line as phosphate-containing solutions. 6. Avoid rapid administration (do not exceed 100mg/minute).
IPAN5,Pantoprazole,Pantoprazole inj 40mg,ALIM,,¾AÀ³¯g: - Reflux oesophagitis - Gastric and duodenal ulcer - Zollinger ¡V Ellison Syndrome and other pathological hypersecretory conditions. °Æ§@¥Î:Headache¡A Diarrhea¡A Nausea¡A Abdominal pain¡A Vomiting¡A Flatulence¡A Dizziness¡A Arthralgia ¸T§Ò:Hypersensitivity (eg¡A anaphylaxis¡A anaphylactic shock¡A angioedema¡A bronchospasm¡A acute interstitial nephritis¡A urticaria) to pantoprazole¡A other substituted benzimidazole proton pump inhibitors¡A or any component of the formulation,,,Dosing: Adult Erosive esophagitis associated with GERD: IV: 40 mg once daily for 7 to 10 days. Hypersecretory disorders (including Zollinger-Ellison):IV: 80 mg every 12 hours; adjust dose based on acid output measurements; 160 to 240 mg daily in divided doses has been used for a limited period (up to 7 days). Prevention of rebleeding in peptic ulcer bleed (off-label use): IV:Continuous infusion: Loading dose of 80 mg¡A followed by 8 mg/hour infusion for 72 hours. Dosing: Pediatric IV: Dosage not established,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þªº¯f¤H¨C¤é¾¯¶q¶·­°¦ÜPantoprazole 20mg¡A¨Ã¥B¦bªvÀø´Á¶¡¡A©w´ÁºÊ´ú¨x»Ã¯À ­Y¨x»Ã¯À«ü¼Æ¤É°ª¡AÀ³°±¤î¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¡C,±Àª`®É¶¡> 2-15¤ÀÄÁ,¥»«~¿éª`®É¶¡À³¶W¹L2-15¤ÀÄÁ,¥»ÃÄ»Ý¥ý¥H10mL N/S·»¸Ñ¡A°t»s«á¤§·»²G¥iª½±µª`®g§ë¤©©Î¥H100mL«ØÄ³¿éª`²G²V¦Xºwª`¡C
IK2P,K2HPO4+KH2PO4,Potassium Phosphate inj 20mL,NUTR,For TPN preparation¡A Severe hypophosphataemia.,Severe renal impairment¡A hyperkalaemia¡A hypocalcaemia¡A infected phosphate renal calculi.,Hyperphosphataemia esp in renal failure which may lead to hypocalcaemia and ectopic calcification esp in hypercalcaemic patients. Hypotension and organ damage due to tissue calcification which may cause acute renal failure. Hyperphosphataemia¡A hypocalcaemia¡A tissue calcification; nausea¡A vomiting¡A diarrhoea¡A abdominal pain¡A flatulence; bradycardia; hyperkalaemia; weakness; dyspnoea.,25¢J¥H¤U,As TPN material only. Each mL contains: Potassium 4.4 mEq and phosphorus 3 mmol = potassium 170 mg and elemental phosphorus 93 mg. Dose and rate of administration are dependent on individual patient needs.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,¡iN/S¡j¥i¿ï ¡C,,For adult patients with severe symptomatic hypophosphatemia (ie¡A <1.5 mg/dL)¡A may administer at rates up to 15 mmol phosphate/hour (this rate will deliver potassium at 22.5 mEq/hour). Potassium infusion rates >10 mEq/hour should be administered via central line (minimizes burning and phlebitis). ECG monitoring is recommended for potassium infusions >10 mEq/hour in adults or >0.5 mEq/kg/hour in children. In patients with renal dysfunction and/or less severe hypophosphatemia¡A slower administration rates (eg¡A over 4 to 6 hours) or oral repletion is recommended.,1. ¥»«~¬°°ª¿@«×¹[Â÷¤l·»²G¡A¶·µ}ÄÀ«á¨Ï¥Î¡A­­ÃÄ¾¯¬ì¥Î©ó»s¾¯½Õ°t¡C 2. ¨C mL§tphosphate : 3 mmole¡A potassium : 4.4 mEq
ONEW2,Multivitamins + Minerals + Fe,New Prenatal 200's/bot,NUTR,,¾AÀ³¯g: Nutritional supplement for vits & minerals during pregnancy & lactation.,,«Ç·Å,1 tab daily or as directed by the physician.,,,,¦w¥þ,,,,,,,,,,
EISO2,Pilocarpine,Isopto carpine 2% 15mL,TOPH,Control of intraocular pressure.,Acute iritis¡A anterior uveitis¡A acute inflammatory disease of the anterior segment.,Burning¡A itching & smarting of the eyes¡A blurred vision¡A conjunctival vascular congestion¡A myopia¡A lens changes (chronic use)¡A vitreous haemorrhage¡A pupillary block¡A headache. Dermatologic: Flushing¡A Oral formulation (8-13%)¡A Sweating symptom¡A Oral formulation (29-68%) Endocrine metabolic: Shivering¡A Oral formulation (3-15%) Gastrointestinal: Nausea¡A Oral formulation (6-15%) Neurologic: Dizziness¡A Oral formulation (5-12%) Ophthalmic: Blurred vision¡A Ophthalmic formulation¡A Burning sensation in eye¡A Ophthalmic formulation¡A Itching of eye¡A Ophthalmic formulation¡A Scotopic sensitivity¡A Difficulty¡A with ophthalmic formulation Renal: Increased frequency of urination¡A Oral formulation (9-12%) Respiratory: Rhinitis¡A Oral formulation (5-14%),8-30¢J,Instill 2 drops TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
EAZA,Timolol + Brinzolamide,Azarga 0.5/1%¡A 5mL ophthalmic suspension,TOPH,Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,Hypersensitivity to brinzolamide¡A timolol¡A other beta-blockers¡A sulfonamides¡A or any component of the formulation; current or history of bronchial asthma; severe chronic obstructive pulmonary disease (COPD); severe allergic rhinitis and bronchial hyper-reactivity; sinus bradycardia¡A second-/third degree atrioventricular (AV) block¡A overt cardiac failure¡A cardiogenic shock; hyperchloremic acidosis; severe renal impairment,Taste perversion (2%)¡A Blurred vision (6%)¡A eye irritation (4%)¡A eye pain (3%)¡A foreign body sensation in eyes (1%),30¢J¥H¤UÀx¦s,Instill 1 drop BID into the conjunctival sac. Age <18 years: Not recommend use.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,TIMOLOL: Human Data Suggest Risk in 2nd and 3rd Trimesters BRINZOLAMIDE OPHTHALMIC: No Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,TIMOLOL: Limited Human Data¡XProbably Compatible BRINZOLAMIDE OPHTHALMIC: No Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
IVISI,Iodixanol,Visipaque inj 320mg I/mL¡A 100mL,SCAN,Intra-arterial: Digital subtraction angiography¡A angiocardiography¡A peripheral arteriography¡A visceral arteriography¡A cerebral arteriography Intravenous: Contrast enhanced computed tomography imaging¡A excretory urography¡A and peripheral venography,Hypersensitivity to iodixanol or any component of the formulation; not intended for intrathecal use In pediatric population: Prolonged fasting or laxative administration prior to iodixanol administration Refer to product labeling for procedure-specific contraindications.,Common: Discomfort¡A Pain (2%)¡A Temperature-associated finding¡A Feels warm (29%) Serious: Cardiac arrest¡A Cardiac dysrhythmia (Up to 0.5%)¡A Decompensated cardiac failure (Up to 0.5%)¡A Hypertensive crisis¡A Hypotension (Up to 0.5%)¡A Myocardial infarction (Up to 0.5%)¡A Myocardial ischemia¡A Shock¡A Generalized exanthematous pustulosis¡A acute¡A Injection site extravasation¡A Stevens Johnson syndrome AND toxic epidermal necrolysis overlap¡A Thyroid dysfunction¡A Thyroid storm¡A Sickle cell anemia with crisis¡A Thromboembolic disorder¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Acute renal failure (Up to 0.5%)¡A Acute renal failure¡A Contrast-induced,30¢J¥H¤UÁ×¥ú,the Remencomended dose: Indication or investigation; Concentration; Volume per injection: Intra-arterial use: Selective Cerebral Aortgraphy; 320mg I/mL( Both strengths are documented¡A but 270mg I/mL is recommened in most case); 5-10mL. Aortography; 320mg I/mL; 40-60mL. Peropheral; 320mg I/mL; 30-60mL. Cardioangiography: Adults Left ventricle and aortic root; 320mg I/mL; 30-60mL. Adults Selevtive coronary arteriography; 320mg I/mL; 4-8mL. Children; 320mg I/mL; depending on age¡A weight¡A and pathology. Remencomended maximum total dose is 10mL/Kg. Intravenous use: Urography¡A Adults; 320mg I/mL; 40-80mL(higher doses can be used in some cases). Urography¡A Children <7kg; 320mg I/mL; 2-4mL/kg. Urography¡A Children >7kg; 320mg I/mL; 2-3mL/kg.(depending on age¡A weight¡A and pathology. Remencomended maximum total dose is 50mL.) Venography: CT-enhancement; 270mg I/mL; 50-150mL/leg. Adults CT of the head; 320mg I/mL; 50-150mL. Adults CT of the body; 320mg I/mL; 75-150mL. Children CT of the head and body; 320mg I/mL; 2-3mL/kg¡A the maximum dose is 50mL¡A but 150mL can be used in some cases. Intrathecal use: Lumbar and thoracic myelography (lumbar injection); 320mg I/mL; 10mL.(to minimize possible adverse reactions a total dose of 3.2g iodine should not be exceeded.) Cervical myelography (cervical or lumbar injection); 320mg I/mL; 10mL.(to minimize possible adverse reactions a total dose of 3.2g iodine should not be exceeded.),µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¤£¥þ¤Î/©ÎµÇ¥\¯à¤£¥þ¯f¤H¡A¥i¨Ï¥Î¤@¯ë©Î«ØÄ³¾¯¶q¡C¹ï­««×¨x¡BµÇ¥\¯à¤£¥þ¯f¤H¡A¶·µ¹¤©¯S®íªº·ÓÅU¡A¦]¥L­Ì¥i¯à¹ï±Æ°£§t¸KÅã¼v¾¯¦³ÅãµÛ©µ¿ð®ÄÀ³¡C¦å²G³zªR¯f¤H¥i¯à©ó©ñ®g¬ìÀË¬d¬yµ{¤¤¨Ï¥ÎÅã¼v¾¯¡A¦ý¤£»Ý­n°t¦X¦å²G³zªR½Õ¾ãÅã¼v¾¯ª`®gªº®É¶¡¡C¦]¬°¨Ã¨S¦³ÃÒ¾ÚÅã¥Ü¦å²G³zªR¯à«OÅ@µÇ¥\¯à¤£¥þªº¯f¤H¡A¨Ï¨ä§K©óÅã¼v¾¯¤Þµo¤§µÇ¯fÅÜ¡C,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IA;IT;ITH;IV;IVP;IVPUSH;,,,,,
IGRA,Granisetron,Grantron inj 3mg/3mL,CNEU,Prevention or treatment of nausea & vomiting induced by cytostatic therapy & radiation.,Hypersensitivity to granisetron or related substances.,Common: Asthenia (oral¡A 14-18%)¡A Headache (8.6-21%)¡A Somnolence (up to 10%)¡A Fever (3-56%)¡A Hypertension¡A Hypotension¡A Dermatitis¡A Flushing¡A Rash¡A Constipation¡A Diarrhea¡A Disorder of taste¡A Indigestion¡A Xerostomia¡A Increased liver enzymes¡A Central nervous system stimulation¡A Dizziness¡A Extrapyramidal sign¡A Insomnia¡A Agitation¡A Anxiety¡A Oliguria¡A Copious sputum¡A Cough¡A Pain. Serious: Prolonged QT interval¡A Bradyarrhythmia¡A Cardiac dysrhythmia¡A Electrocardiogram abnormal¡A Hypersensitivity reaction.,25¢J¥H¤UÁ×¥ú,Prophylaxis or treatment of chemotherapy-induced nausea and vomiting: Prophylactic dose given before chemotherapy. Adult: 1-3 mg (10-40 mcg/kg) either as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid and administered over >5 minutes. Maximum dose over 24 hours: 9 mg. Children: 10-40 mcg/kg body weight (up to 3 mg) diluted in 10-30 mL infusion fluid and administered over >5 minutes. One additional dose may be given within 24 hr if necessary. (Repeat infusions should be separated with each by at least 10-minute intervals.) Prevention & treatment of radiation-induced nausea and vomiting: Prophylactic dose given before radiation. Adult: 1-3 mg (10-40 mcg/kg) either as IV bolus over not less than 30 seconds or diluted in 20-50 mL infusion fluid and administered over >5 minutes. Maximum: 9 mg/24 hours. Postoperative nausea and vomiting: Adult: 1 mg (10 mcg/kg) either as IV bolus over not less than 30 seconds. Maximum: 3 mg/24 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5W¡j¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö¶W¹L30¬í,µ}ÄÀ©ó20-50mL¿éª`²G¡A¿éª`®É¶¡>5¤ÀÄÁ,
IGS5,Dextrose + Sodium Chloride,5% Dextrose in 0.9% NaCl 500mL,MSIV,Replacement & maintenance of fluid & electrolytes.,,,30¢J¥H¤U,Individualized dosage. Each Dextrose 5% and Sodium chloride 0.9% solution mL contains: Dextrose 50mg¡A Sodium chloride 9mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,
INS45,Sodium Chloride,0.45% Saline inj 500mL,MSIV,¬°0.45 % ­¹ÆQ¤ôª`®g²G(A036014277),,,«Ç·Å,IV infusion as needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
IHMGS,FSH75IU + LH75IU,Pergonal 75 IU,HM,,Stimulation of follicular maturation in anovulatory¡A infertile women & spermatogenesis in infertile males.,,,Individual-dependent.,,,,,,,,,,,,,,
OCONS,Bisacodyl + DSS + Sennoside,Conslife 2/20/10mg,ALIM,,¾AÀ³¯g: Constipation. °Æ§@¥Î: Diarrhea¡A abdominal pain¡A discomfor or cramping¡A allergy¡A electrolye imbalance. ¸T§Ò: Ileus¡A intestinal obstruction¡A acute abdominal conditions including appendicitis¡A acute inflammatory bowel diseases & severe abdominal pain associated with nausea & vomiting. Severe dehydration.,,«Ç·Å,Oral: Adult: 2-3 tablets once daily¡A taking before sleeping. Child over 6 y/o: 2 tablets once daily¡A taking before sleeping.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
LBAR,Barium sulfate,Baritop-120 300mL,SCAN,,¾AÀ³¯g: ¡½Computerized axial tomography ¡½Endoscopy of esophagus ¡½Gastrointestinal investigation ¡½Radiography of intestine °Æ§@¥Î: ¡½Cardiovascular: Cardiorespiratory arrest¡A Edema ¡½Gastrointestinal: Impaction of intestine¡A Small bowel obstruction ¡½Immunologic: Immune hypersensitivity reaction (rare) ¸T§Ò: ¡½colon obstruction¡A known or suspected ¡½distal small bowel obstruction¡A suspected ¡½duodenal or jejunal obstruction¡A complete¡A in newborns ¡½gastrointestinal tract leakage¡A possibility of (eg¡A necrotizing enterocolitis¡A unexplained pneumoperitoneum¡A gasless abdomen¡A other bowel perforation¡A esophageal perforation¡A or postoperative anastomosis)¡A in infants and young children ¡½gastrointestinal tract perforation¡A known or suspected ¡½hypersensitivity to barium sulfate or any product component ¡½latex allergy or hypersensitivity; balloon retention enema tips contain latex ¡½obstructing lesions of the small intestine ¡½procedures requiring small volumes of contrast media in very small preterm infants or young babies ¡½pyloric stenosis ¡½rectal biopsy¡A recent ¡½rectum inflammation or neoplastic lesions ¡½swallowing disorders in infants ¡½tracheoesophageal fistula¡A suspected,,«Ç·Å,Computerized axial tomography:Total bowel opacification: 300 milliliters (mL) orally the evening prior to examination¡A 300 mL orally the 2 hours prior to exam¡A and 300 mL orally 15 minutes prior to exam.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,micromedex (Pregnancy Category):Fetal risk is minimal. (TH) micromedex (Breastfeeding):Breastfeeding a) Micromedex Lactation Rating: Infant risk is minimal. 1) The weight of an adequate body of evidence and/or expert consensus suggests this drug poses minimal risk to the infant when used during breastfeeding. b) Clinical Management 1) Nursing mothers may use barium sulfate products,PO;,,,,,
IHUM0,Adalimumab,Humira 40mg inj (sample),HIMM,,¾AÀ³¯g:Monotherapy or in combination with methotrexate or other DMARDs for reducing of the signs & symptoms & to inhibit the progression of structural damage in adult patients with moderately to severely active RA. Monotherapy or in combination with other DMARDs for reducing the signs & symptoms of active arthritis in patients with psoriatic arthritis. Reduction of signs & symptoms in patients with active ankylosing spondylitis. Reduction of signs & symptoms & inducing & maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy or if they have also lost response to or are intolerant to infliximab. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy & when other systemic therapies are medically less appropriate. Reduction of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 13-17 years. °Æ§@¥Î:Resp tract infections¡A leucopenia¡A anemia¡A increased lipids¡A headache¡A abdominal pain¡A nausea & vomiting¡A elevated liver enzymes¡A rash¡A musculoskeletal pain¡A inj site reaction. ¸T§Ò:Known hypersensitivity to adalimumab or any of the excipients of Humira.,,2-8¢J,Adult RA¡A psoriatic arthritis¡A ankylosing spondylitis¡A polyarticular juvenile idiopathic arthritis Single dose of 40 mg SC every other week. If not taking concomitantly with methotrexate¡A increasing the dosing frequency to 40 mg weekly may derive additional benefit. Crohn's disease 160 mg initially at day 1 (as four 40-mg inj in 1 day or as two 40-mg inj/day for 2 consecutive days)¡A followed by 80 mg 2 weeks later (day 15). Another 2 weeks later (day 29) begin a maintenance dose of 40 mg every other week. Patients who experience decrease in their response may benefit from an increase in dose intensity to 40 mg every week. Plaque psoriasis Initially 80 mg¡A followed by 40 mg given every other week starting 1 week after the initial dose.,,,,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,SC;,,,,,
IBOL,Zoledronic Acid,Bolenic IV infusion 4mg,META,Prevention of skeletal related events (pathological fractures¡A spinal compression¡A radiation or surgery to bone¡A or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone. Treatment of hypercalcemia of malignancy (HCM).,Known hypersensitivity to zoledronic acid or other bisphosphonates.,Common: Peripheral edema (Paget disease¡A 3%; osteoporosis¡A 4.6-5.5%; osteopenia¡A 3.9-5.6%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 21%)¡A Weight decreased (bone metastasis¡A 16%)¡A Abdominal pain (osteoporosis (female)¡A 0.9-4.6%; osteoporosis (male)¡A 7.9%; osteoporosis (male and female)¡A 7.5%; osteopenia¡A 6.6-8.6%; Paget disease¡A 2%; hypercalcemia of malignancy¡A 16%; bone metastasis¡A 14%)¡A Constipation (Paget disease¡A 6%; hypercalcemia of malignancy¡A 27%)¡A Diarrhea (osteoporosis¡A 5.2-6%; osteopenia¡A 6.6-8.1%; Paget disease¡A 6%; hypercalcemia of malignancy¡A 17%; bone metastasis¡A 24%)¡A Loss of appetite (osteoporosis¡A 1-2%; osteopenia¡A 0.6-2%; Paget disease¡A 2%; hypercalcemia of malignancy¡A 9%; bone metastasis¡A 22%)¡A Nausea (osteoporosis (female)¡A 4.5-8.5%; osteoporosis (male and female)¡A 9.6%; osteopenia¡A 11.6-17.7%; Paget disease¡A 9%; hypercalcemia of malignancy¡A 29%; bone metastasis¡A 46%)¡A Vomiting (Paget disease¡A 2%; osteoporosis¡A 3.4-4.6%; osteopenia¡A 5-7.6%; hypercalcemia of malignancy¡A 14%; bone metastasis¡A 32%)¡A Arthralgia (Osteoporosis (female)¡A 17.9-23.8%¡A (acute phase¡A 3-7%); osteoporosis (male¡A acute phase)¡A 11.1%; osteopenia¡A 18.8-27.3%¡A (acute phase¡A 6.1%); hypercalcemia of malignancy¡A 5-<10%; Paget disease¡A 9%; bone metastasis¡A 21%)¡A Backache (Osteoporosis (male and female)¡A 4.3%; osteoporosis (male¡A acute phase)¡A 3.3%; osteopenia¡A 16.6-18.2%¡A (acute phase¡A 1.7%); Paget disease¡A 4%; bone metastasis¡A 15%)¡A Pain in limb (Osteoporosis (female)¡A 5.9-11.3%; osteoporosis (male and female)¡A 3.1%; osteopenia¡A 11.1-16%¡A (acute phase¡A 3.9%); bone metastasis¡A 14%)¡A Asthenia (osteoporosis¡A 3.2 to 5.3%; osteopenia¡A 2.8-6.1%; Paget disease¡A 2%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 24%)¡A Dizziness (osteoporosis¡A 2-7.6%; osteopenia¡A 6.1-7.6%; Paget disease¡A 9%; bone metastasis¡A 18%)¡A Headache (osteoporosis (female)¡A 3.9-12.4%¡A (acute phase¡A 7%); osteoporosis (male)¡A 15%¡A (acute phase¡A 9.8%); osteopenia¡A 14.6-20.4%¡A (acute phase¡A 13.3%); Paget disease¡A 11%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 19%)¡A Insomnia (hypercalcemia of malignancy¡A 15%; bone metastasis¡A 16%)¡A Paresthesia (Paget disease¡A 2%; bone metastasis¡A 15% .)¡A Nephrotoxicity (bone metastasis¡A 11-17%)¡A Fatigue (osteoporosis (female)¡A 2.1-5.4%; osteoporosis (male)¡A 17.6%¡A (acute phase¡A 12.4%); osteopenia¡A 9.9-14.6%¡A (acute phase¡A 8.3%); Paget disease¡A 8%; bone metastasis¡A 39%)¡A Fever (osteoporosis (female¡A acute phase)¡A 7-18%; osteoporosis (male¡A acute phase)¡A 15.7%; osteopenia¡A 21-21.7% (acute phase¡A 19.3%); Paget disease¡A 3-11%; hypercalcemia of malignancy (acute phase)¡A 44%; bone metastasis¡A 32%) Serious: Atrial fibrillation (osteoporosis (female)¡A 1.3-2.8%; osteoporosis (male)¡A 3.3%; osteoporosis (male and female)¡A 0.7%)¡A Cardiac dysrhythmia¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hypocalcemia (Osteoporosis¡A up to 0.2%; hypercalcemia of malignancy¡A 5-<10%; bone metastasis¡A 1.3%; Paget disease¡A 3-21%)¡A Bone pain (Osteoporosis (female)¡A 3.2-5.8%; osteoporosis (male and female)¡A 3.1%; osteopenia¡A 3.3-5.1%; Paget disease¡A 9%; hypercalcemia of malignancy¡A 12%; bone metastasis¡A 55%)¡A Myalgia (Osteoporosis (female)¡A 4.9-11.7%¡A (acute phase¡A 9%); osteoporosis (male)¡A 19.6%¡A (acute phase¡A 17.1%); osteopenia¡A 19.2-22.7%; Paget disease¡A 7%; bone metastasis¡A 23%)¡A Necrosis of bone¡A acute¡A Osteonecrosis of jaw¡A Tetany¡A Cerebrovascular accident (osteoporosis¡A 2.3%)¡A Numbness¡A Seizure¡A Nephrotoxic acute renal failure¡A Serum creatinine above reference range (osteoporosis¡A 1.2-2.1%; bone metastasis¡A 1%; hypercalcemia of malignancy¡A 2%)¡A Dyspnea (Paget disease¡A 5%; osteoporosis (male)¡A 6.5%; hypercalcemia of malignancy¡A 22%; bone metastasis¡A 27%),30¢J¥H¤U,IVD¡A 4 mg once every 3-4 weeks.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management It is not known whether zoledronic acid is excreted into human breast milk and the potential for adverse effects in the nursing infant from exposure to the drug are unknown. However¡A as zoledronic acid binds to bone long-term¡A it is recommended that it should not be administered to a nursing woman.,IVD;,5mLª`®g¥Î¤ôµ}ÄÀ,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¥[¤J100mL¬Û®e¿éª`²G¤¤¿éª`¡AIVD > 15 mins¡A¤£¥i¨Ï¥Î§t¶t©Î¨â»ù¶§Â÷¤lªº·»²G,1. patients should be adequately hydrated prior to administration 2. If previously refrigerated¡A allow solution to reach room temperature before administration 3. administer as a single-dose IV infusion in a vented line separate from other drugs; infuse over no less than 15 minutes¡A over a constant infusion rate 4. Do not allow solution to come in contact with calcium-containing solutions or other divalent cation-containing infusion solutions (eg¡A lactated Ringer)
EDIV,Estradiol,Divigel 0.1% gel,HM,,¾AÀ³¯g:¤k©Ê¥Ñ©ó¦ÛµM°±¸g©Î¤â³N¤Þ°_¤§¤k©Ê²üº¸»X¯Ê¥F¯gª¬ªº²üº¸»X´À¥NÀøªk§ó¦~´Áªº¼ö¼é¬õ©Î¥Í²z¤£¾A¡BµLªk¤Àªc¤k©Ê²üº¸»X¦Ó¤Þ°_ªº¦UºØ¤£¾A¡CTreatment of the climacteric syndrome associated with natural or artificial menopause (estro-genic deficiency¡A e.g. hot flushes¡A night sweatings¡A urogenital atrophy and prevention of postmenopausal (type 1) osteoporosis. °Æ§@¥Î: ÀYµh¡A¨Å©Ðº¦µh¡A¤ô¸~¡AÅé­«¼W¥[¡Aäú¤ß¡A¹Ã¦R¡A¤£³W«h¤§³±¹D¥X¦å©ÎÂIª¬¥X¦å©Î¥Ö½§¨ë¿E©Êµ¥¡CCommon side effects that may occur with Divigel? include headache; breast pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps¡A bloating; nausea and vomiting; hair loss; fluid retention and vaginal yeast infection. Serious but less common side effects include heart attack¡A stroke¡A blood clots¡A dementia¡A breast cancer¡A cancer of the uterus¡A ovarian cancer¡A high blood pressure¡A high blood sugar¡A gallbladder disease¡A liver problems¡A and enlargement of benign uterus tumors (¡§fibroids¡¨). ¸T§Ò: ¤£©ú­ì¦]³±¹D¥X¦å¡C¹L¥h¨â¦~¤º±w¦³ÀR¯ß¦å®ê(¨Ò¦p:²`³¡ÀR¯ß¦å®ê©ÎªÍ®ê¶ë)¡C¤S´_µo©ÊÀR¯ß¦å®ê¯f¥v©Î¦³¦å®ê¯e¯f¦Ó©|¥¼±µ¨ü§Ü¾®¦åÃÄª«ªvÀøªÌ¡CÄY­«¨x¯e¯f±wªÌ¡C¤wª¾©ÎÃhºÃ¤§´c©Ê¸~½F¡A¥i¯à¨üÃþ©T¾J¼vÅTªÌ¡A¯S§O¬O¨ÅÀù©Î¤l®c¤º½¤Àù¡C¹ï¸Ó¦¨¤À¹L±Óunusual vaginal bleeding¡A currently have or have had certain cancers¡A including cancer of the breast or uterus¡A had a stroke or heart attack; currently have or have had blood clots¡A currently have or have had liver problems¡A have been diagnosed with a bleeding disorder¡A are allergic to Divigel?or any of its ingredients¡A or think you may be pregnant.,,,Divigel can be used for continuous or cyclical treatment. The dose can be adjusted individually from 0.5g-1.5g per day¡A corresponding to 0.5-1.5mg estradiol per day. The usual starting dose is 1.0mg estradiol daily and can be readjusted after 2 to 3 cycles. The Divigel gel is applied once daily¡A on the skin of the lower trunk or the right or left thighs¡A on alternate days. The application surface should be 1-2times the size of the hand. Divigel should not be applied on the breasts¡A on the face or irritated skin. After application the gel should be allowed to dry for a few minutes and the application site should not be washed within one hour.Hands should be washed after application.,,,,¤£¥i¨Ï¥Î,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
LCUR,Amoxicillin + Clavulanic Acid,Curam Äa¯B²G 312.5mg/5mL¡A 60mL,QANB,Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI¡A pelvic¡A head & neck¡A cardiac¡A renal¡A joint replacement & biliary tract.,Hypersensitivity to penicillins¡A possible cross sensitivity with other £]-lactam antibiotics.,Common: Diaper rash (3.5-6%)¡A Rash (1.1-3%)¡A Urticaria¡A Diarrhea (2.9-14.5%)¡A Loose stool (1.6-9%)¡A Nausea (up to 3%)¡A Vomiting (up to 2.2%)¡A Mycosis (3.3%)¡A Vaginitis (1%)¡A Candidiasis (1.4%) Serious: Drug reaction with eosinophilia and systemic symptoms¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Cholestasis¡A Hepatitis¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Angioedema¡A Serum sickness due to drug,«Ç·Å,(Amoxicillin 250 mg and clavulanate 62.5 mg per 5mL) For children aged 2-12: 30-60 mg/kg/day (calculated based on anhydrous amoxicillin)¡A divided into 3 doses. For children under 2 years old: 30-40 mg/kg/day (calculated based on anhydrous amoxicillin)¡A divided into 3 doses. It is recommended to take Curam before meals. Shake the bottle before each use of the oral suspension.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,AMOXICILLIN: Human Data Suggest Low Risk CLAVULANATE¡A POTASSIUM: Compatible [¥é³æ] ¥u¦³·íÂå¥Í§P©w»{¬°¼ç¦b¯q³B¤j©ó¼ç¦b­·ÀI®É¡A¤~¥i©óÃh¥¥´Á¶¡¯S§O¤p¤ß¨Ï¥ÎCuram¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,AMOXICILLIN: Compatible CLAVULANATE¡A POTASSIUM: No Human Data¡XProbably Compatible [¥é³æ] CuramR·|±Æ¥X¨ì¨Å¥Ä¤¤¡A©Ò¥HÁý­¹¥À¨ÅªºÀ¦¨à¥i¯à¦]¦¹¦Ó²£¥Í¸¡Âm¥H¤Î»Ã¥Àµß¦bÂH½¤¼W¥Í¡A²£¥Í³oºØµ²ªG®É¥i¯à»Ý­n°±¤î±Â¥H¥À¨Å¡CÁý­¹¥À¨Å®É¤]¥²¶·±N¥i¯à²£¥Íªº¹L±Ó¤ÏÀ³¦Ò¼{¶i¥h¡C,AC;AC15;PC;PO;WM;,,,,,
IALO,Palonosetron,Aloxi inj 0.25mg/5mL,CNEU,Chemotherapy-induced nausea and vomiting,Hypersensitivity to palonosetron or any component of the formulation,1% to 10%: Cardiovascular: Prolonged Q-T interval on ECG (PONV 1% to 5%; chemotherapy-associated <1%)¡A bradycardia (chemotherapy-associated 1%)¡A sinus bradycardia (PONV: 1%)¡A tachycardia (may be nonsustained; 1%)¡A hypotension (<=1%) Central nervous system: Headache (chemotherapy-associated: Adults 9%; infants¡A children¡A and adolescents <1%)¡A anxiety (chemotherapy-associated: 1%)¡A dizziness (infants¡A children¡A adolescents¡A and adults ?1%) Dermatologic: Pruritus (PONV: 1%) Endocrine & metabolic: Hyperkalemia (chemotherapy-associated: 1%) Gastrointestinal: Constipation (chemotherapy-associated: 5%)¡A diarrhea (<=1%)¡A flatulence (<=1%) Genitourinary: Urinary retention (<=1%) Hepatic: Increased serum ALT (<=1%; may be transient)¡A increased serum AST (<=1%; may be transient) Neuromuscular & skeletal: Weakness (chemotherapy-associated: 1%),25¢J¥H¤U¡AÁ×§K§N­á,Chemotherapy-induced nausea and vomiting¡A associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,¦¨¤H:¤Æ¾ÇªvÀø«e30¤ÀÄÁµ¹ÃÄ¡A¥HÀR¯ßª`®g»Ý¶W¹L30¬í¡C,1­Ó¤ë-17·³¤p«Ä¤p«Ä:¦b¶}©l¤ÆÀø«e30¤ÀÄÁµ¹ÃÄ¡AÀR¯ßª`®g»Ý¶W¹L15¤ÀÄÁ¡C,1.§ë»P¥»ÃÄ«e»P«á§¡»Ý¥H¥Í²z­¹ÆQ¤ô¨R¬~¿éª`ºÞ½u¡A¤£À³»P¨ä¥LÃÄª«²V¦X 2.¥é³æ«ØÄ³µ¹ÃÄ¤è¦¡:¦¨¤H:¤Æ¾ÇªvÀø«e30¤ÀÄÁµ¹ÃÄ¡A¥HÀR¯ßª`®g»Ý¶W¹L30¬í¡F1­Ó¤ë-17·³¤p«Ä:¦b¶}©l¤ÆÀø«e30¤ÀÄÁµ¹ÃÄ¡AÀR¯ßª`®g»Ý¶W¹L15¤ÀÄÁ¡C
ICETR,Cetrorelix,Cetrotide inj 0.25mg,HM,Prevention of premature ovulation in patients undergoing controlled ovarian stimulation¡A followed by oocyte pick-up & assisted reproduction techniques.,Hypersensitivity to extrinsic peptide hormones or mannitol. Postmenopausal women¡A moderate & severe renal or hepatic impairment. Pregnancy¡A lactation.,Reactions at inj site¡A nausea¡A headache¡A ovarian hyperstimulation syndrome.,2-8¢JÁ×¥ú,SC inj Cetrotide 0.25 mg Administration in the morning 1 vial once daily commencing on day 5 or 6 of ovarian stimulation (approximately 96-120 hr after initiation of ovarian stimulation). Administration in the evening 1 vial once daily on day 5 of ovarian stimulation (approximately 96-108 hr) after initiation of ovarian stimulation. To be given w/ urinary or recombinant gonadotrophins & continued throughout gonadotrophin treatment until the evening prior to the day of ovulation induction.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌµL¬ÛÃö¬ã¨s¡AÀ³ÂÔ·V¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,H;SC;,¨Ï¥Î¼t°Ó´£¨Ñ¤§ª`®g¥Î¤ôµ}ÄÀ¡A¥H·Å©M±ÛÂà¤è¦¡¨Ó·»¸Ñ¡AÁ×§K¼@¯P·n®Ì²£¥Í®ðªw,,,,
LALG,Alginate+Calcium Carbonate+NaHCO3,Alginos oral susp 210mL,ALIM,,¾AÀ³¯g: Symptomatic relief of gastric distress¡A heartburn¡A hyperacidity & indigestion. °Æ§@¥Î: Flatulence. ¸T§Ò©ÎÄµ»y: Each 10 ml of Alginos contains Na 141 mg¡A so Na ingestion should be calculted for patients with renal or CV diseases & requiring limited Na diet.,,«Ç·Å,Adult (>12yr): 10-20 ml tid-qid. child(2-12yr): 5-10 ml tid-qid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,Each 10 ml of Alginos contains Na 141 mg¡A so Na ingestion should be calculted for patients with renal or CV diseases & requiring limited Na diet.
OEXF,Amlodipine + Valsartan,Exforge 5/80mg,CAVS,Hypertension,¡½Severe hepatic impairment¡A biliary cirrhosis or cholestasis. Severe renal impairment (GFR <30 mL/min/1.73 m2) & dialysis patients. Pregnancy. ¡½hypersensitivity to amlodipine¡A valsartan¡A or any other component ¡½concomitant aliskiren use in diabetic patients,Common: Peripheral edema (5.4%)¡A Dizziness (2.1%)¡A Nasopharyngitis (4.3%)¡A Upper respiratory infection (2.9%) Serious: Hypotension (0.4%),30¢J¥H¤UÁ×¥ú,HTN initial: 1tablet QD slowly titiate up to 2 tablet QD (maximum 10mg/160mg),»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ¤ÎÁx¹Dªý¶ë±wªÌ¨Ï¥Î®ÉÀ³ÂÔ·V¤p¤ß¡A¥i¦Ò¼{±q³Ì§C¥i¨ú±o¤§Amlodipine¾¯¶q¶}©lªvÀø,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 2nd and 3 rd trimesters,Amlodipine: Human Data Suggest Low Risk Valsartan: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] Ãh¥¥´Á¶¡¤£±o¨Ï¥Î¥ô¦óª½±µ§@¥Î©óRAAS ªºÃÄª«¡A¦pExforge¡C¦åºÞ¦¬ÁY¯ÀªýÂ_¾¯¹ï­L¨àªº­·ÀIµLªk³Q±Æ°£¡A¦bÃh¥¥²Ä¤G¶¥¬q©M²Ä¤T¶¥¬q¨Ï¥Î¦åºÞ¦¬ÁY¯ÀÂà¤ÆžJ§í¨î¾¯·|³y¦¨µo¨|¤¤­L¨à¶Ë®`©M¦º¤`¡A°£¦¹¤§¥~¡A¦^·¹©Ê¼Æ¾ÚÅã¥Ü¦bÃh¥¥²Ä¤@¶¥¬q¨Ï¥Î¦åºÞ¦¬ÁY¯ÀÂà¤ÆžJ§í¨î¾¯¹ï­L¨àªº¤Ñ¥Í¯Ê³´¨ã¼ç¦b­·ÀI¡A¦³¸ê®Æµo²{Ãh¥¥°ü¤k¦b¤£¸g·NªA¥Îvalsartan«á¥X²{¬y²£¡B¦Ï¤ô¹L¤Ö¡B·s¥Í¨àµÇ¥\¯à¤£¥þ¡C ¨ÃµLÃh¥¥°ü¤k¨Ï¥ÎamlodipineªºÁ{§É¸ê®Æ¡A¦b°Êª«¸ÕÅç¤¤Åã¥Üµ¹¤©¤HÅé«ØÄ³¾¯¶q8­¿ªº¶q«á©l²£¥Í¥Í´Þ¬r©Ê¡A¹ï¤HÅéªº¼ç¦b­·ÀI¬O¥¼ª¾ªº¡C ­Y¦bÀøµ{¤¤µo²{Ãh¥¥®É¡AÀ³¾¨¦­°±¤î¨Ï¥ÎExforge¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Amlodipine: Compatible Valsartan: No Human Data¡XProbably Compatible [¥é³æ] ¥Ø«e©|¥¼ª¾valsartan¬O§_·|¤Àªc©ó¤HÃþªº¨Å¥Ä¤¤¡C¾Ú³q³ø¡Aamlodipine·|¤Àªc©ó¤HÃþªº¨Å¥Ä¤¤¡CÀ¦¨à±µ¨üªº¥ÀÅé¾¯¶q¤ñ¨Ò¦ô­p¬°3 - 7%ªº¥|¤À¦ì¶Z¡A³Ì°ª¬°15%¡CAmlodipine¹ïÀ¦¨àªº¼vÅT©|¥¼ª¾¡CValsartan·|¤Àªc¦Ü¤j¹«ªº¨Å¥Ä¤¤¡A¦]¬°­÷¨ÅÀ¦¨à¦³¼ç¦b¤£¨}¤ÏÀ³¡AÀ³¦Ò¶qÃÄª«¹ï¥À¿Ëªº­«­n©Ê¨Ó¨M©w¬O§_°±¤î­÷¨Å©Î°±¥ÎÃÄª«¡C,AC;AC15;PC;PO;WM;,,,,,
OTYK,Lapatinib ditosylate,Tykerb 250mg,RACA,In combination w/ capecitabine for the treatment of patients w/ advanced/metastatic breast cancer whose tumours overexpress HER2 & who have received prior therapy including anthracycline¡A taxane & trastuzumab. In combination w/ letrozole for the treatment of post-menopausal women w/ hormone receptor positive metastatic breast cancer that overexpress HER2 receptor for whom hormonal therapy is indicated.,Hypersensitivity to lapatinib ditosylate or to any of the excipients of Tykerb,Anorexia¡A diarrhea¡A nausea¡A vomiting¡A rash¡A fatigue¡A dyspepsia¡A dry skin¡A stomatitis¡A constipation¡A abdominal pain¡A palmar-plantar erythrodysesthesia¡A mucosal inflammation¡A pain in extremity¡A back pain¡A insomnia¡A epistaxis¡A alopecia; decreased LVEF¡A nail disorders¡A headache.,¶J¦s·Å«×¤Á¤Å¶W¹L 30¢XC,Monitor left ventricular ejection fraction (baseline and periodic) before and during therapy. TYKERB should be taken at least one hour before or one hour after a meal. [Advanced/metastatic breast cancer] 1250 mg (5 tablets) once daily on Days 1-21 continuously in combination with capecitabine 2¡A000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle. [Hormone receptor (+)¡A HER2 (+) metastatic breast cancer] 1500 mg (6 tablets) once daily continuously in combination with letrozole 2.5 mg once daily.,»Ý½Õ¾ã¾¯¶q,severe hepatic impairment (Child-Pugh class C): consider dose reduction to 750 mg ORALLY once daily (human epidermal receptor-2 (HER2) positive metastatic breast cancer) or 1000 mg ORALLY once daily (hormone receptor positive¡A HER2 positive breast cancer),µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
IEP50,Epirubicin,EPICIN 50mg/25mL,RACA,Leukemia¡A lymphoma¡A breast cancer¡A sarcomas¡A small-cell lung carcinoma¡A ovarian cancer¡A gastric cancer. Liver cancer¡A head & neck cancer¡A pancreatic cancer.,Myelosuppression. Cardiac impairment. Previous full cumulative doses of anthracyclines. Pregnancy. Lactation.,Myelosuppression¡A cardiotoxicity¡A alopecia¡A mucositis¡A GI disturbances¡A hyperpyrexia.,2-8¢JÁ×¥ú,(¥é³æ) Epirubicin should be administered intravenously or intravesicularly. Do not administer epirubicin orally¡A intramuscularly or subcutaneously. A lifetime maximum cumulative dose >1000 mg/m2 should be avoided. Usual dose: 75-90 mg/m2 intravenously once every 3 weeks. Intravesicular: 50 mg once weekly for 8 weeks; dose range: 30-80 mg.,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IRR;IVD;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C 3.Epirubicinªº²Ö¿n¾¯¶q»P¤ßÅ¦¬r©Ê¬ÛÃö¡A±N²Ö¿n¾¯¶q­­¨î¦b1000mg/m2¥H¤U¥i¥H­°§C¬ÛÃö­·ÀI.
IIND,Indomethacin,Indocin IV 1mg,CNEU,,¾AÀ³¯g: Patent ductus arteriosus in premature infants when after 48 hrs usual medication management. ¸T§Ò: neonates are bleeding or with proven or suspected infection that is untreated¡A,,«Ç·Å,A course of therapy is defined as three IV doses given at 12-24 hr intervals¡A with careful attention to urinary output. AGE at 1st DOSE: Less than 48 hrs: 0.2 mg/kg (1st)¡A 0.1mg/kg (2nd)¡A 0.1 mg/kg (3rd) 2-7 days: 0.2 mg/kg (1st)¡A 0.2mg/kg (2nd)¡A 0.2 mg/kg (3rd) over 7 days: 0.2 mg/kg (1st)¡A 0.25mg/kg (2nd)¡A 0.25 mg/kg (3rd) If the ductus arteriosus closes or reduced in size after an interval of 48 hr¡A no further doses are necessary. RE-OPEN: A second course of 1-3 doses may be given¡A each separated 12-24 hrs interval UNRESPONSIVE: surgery may be necessary if unresponsive after 2 courses.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OBIO,Biodiastase + Vitamin B complex,Biogen,ALIM,,¾AÀ³¯g:ªvÀø®ø¤Æ¤£¨}©Î®ø¤Æ»ÙÃª(A021755100),,«Ç·Å,Adult: 2-3 tab tid Child: reduced doses,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OBAL,NaAl(OH)2CO3,Baluna 350mg,ALIM,,Acute & chronic gastritis¡A gastric & duodenal ulcer.,,,1-2 tab tid-qid¡A chewed before swallowing.,,,,,,,,,,,,,,
IH1N13,Inactivated H1N1 Influenza Virus,H1N1·s«¬¬y·P(1-3·³) 0.25mL/dose,HIMM,,,,,,,,,,,,,,,,,,,
EDEC,Salicylic Acid + Lactic Acid,Decorn solution 10mL¡A 16.7%,TDER,Removal of warts.,Hypersensitivity to salicylic acid or any component of the formulation. Impaired circulation (eg¡A diabetes¡A peripheral vascular disease); moles¡A birthmarks; warts with hair growth or on face.,Local irritation.,25¢J¥H¤U,Soak lesion in hot water for 5 mins & dry thoroughly. Rub surface with pumice stone or emery board & apply to affected area 2-4 drops once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;SKIN;TOPI;,,,,,¤j½d³ò¤Îªø´Á¨Ï¥Î·|³y¦¨¤ô·¨»Ä®ÄÀ³ (¦Õ»ï¡B·w¯t¡Bäú¤ß¡B¹Ã¦Rµ¥) ¸T§Ò¡G¿}§¿¯f±wªÌ¤Î¦³¦å´`»ÙÃª¤§¯f¤H¤£©y¨Ï¥Î¡C¥ç¤£¯à¨Ï¥Î©óªvÀø¶Âµi¡B­L°O©Î¥Í¤ò¤§¬Ð¡C
OZYV,Linezolid,Zyvox 600mg,QANB,Vancomycin-resistant Enterococcus faecium infections¡A including cases with concurrent bacteremia ¡A Nosocomial pneumonia caused by Staphylococcus aureus ¡AComplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains)¡A Streptococcus pyogenes¡A or Streptococcus agalactiae,Patients who have known hypersensitivity to linezolid or any of the other components of Zyvox.,Diarrhea (incidence across studies: 2.8-11%)¡A headache (incidence across studies: 0.5-11.3%) and nausea (incidence across studies: 3.4-9.6%).,25¢J¥H¤UÁ×¥ú,Adult and children > 12 years: 600 mg po/IV Q12H; uncomplicated skin/skin structure infections: 400-600 mg po Q12H. Children (0-11 years): 10 mg/kg po/IV Q8H; uncomplicated skin/skin structure infection: (5-11 years) 10 mg/kg po Q12H¡A (< 5 years) 10 mg/kg po Q8H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EALP,Brimonidine,Alphagan-P 0.15%¡A 5mL ophthalmic solution,TOPH,Lowering of ocular pressure in patients with open-angle glaucoma or ocular hypertension.,Patients on MAOI therapy.,Oral dryness¡A ocular hyperemia¡A burning & stinging¡A headache¡A blurring¡A foreign body sensation¡A fatigue/drowsiness¡A conjunctival follicles¡A ocular allergic reactions¡A & ocular pruritus.,25¢J¥H¤UÀx¦s,Instill 1 drop in the affected eye(s) 3 times daily¡A about 8 hours apart.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
OMAG,Magnesium Oxide,Magnesium Oxide 250mg,ALIM,Treatment of various GI problems associated with hyperacidity; as a laxative.,Hypersensitivity to any component of the formulation.,Diarrhea¡A abdominal cramps¡A nausea¡A hypermagnesemia¡A renal stones,25¢J¥H¤U°®Àê³B©Ò,Adult & children >12 years: Antacids 1 TAB TID-QID. Laxative 1-2 TAB QD-TID. 6-12 years: one half dose of Adult.3-6 years: one quarter dose of Adult.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥¼»¡©ú [Micromedex]D¯Å,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥¼»¡©ú [Micromedex] AAP: Maternal medication usually compatible with breastfeeding. WHO: Compatible with breastfeeding. Micromedex: Infant risk is minimal.,AC;AC15;P;P1;P2;P3;P4;PC;PO;WM;,,,,,
OKCIT,Potassium Citrate Monohydrate + Citric Acid,K-citrate granules 5gm,SGU,Prevention of uric acid nephrolithiasis; prevention of Ca renal stones in patients with hypocitraturia; avoidance of the complication of Ca stone formation in uric lithiasis.,Hyperkalemia¡A peptic ulcer¡A abnormal renal function¡A anuria.,Abdominal pain; dyspepsia; gastroenteritis; hyperkinesia; nervousness.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,5 gm dissolved in water QD-QID; adjust dose to urinary pH. (Target urinary pH: 6.5-7.4),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,POTASSIUM CITRATE PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible,Unknown ¨S¦³¸ê®Æ,POTASSIUM CITRATE BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,PC;PO;,,,,,
EESA,Escin + Heparinoid + Diethylamine Salicylate,Esarin gel 20gm,TDER,,¾AÀ³¯g:chronic venous insufficiency and relief of pain. °Æ§@¥Î:Rash¡A pruritus ¸T§Ò:hypersensitivity to these drug,,«Ç·Å,Apply gently or massage once daily or more.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
ORIT2,Methylphenidate,Ritalin LA 20mg,CNEU,Attention-deficit hyperactivity disorder; narcolepsy.,Anxiety & tension states¡A agitation¡A tics¡A tics in siblings¡A family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias¡A severe angina pectoris.,Common: Tachycardia (4.8-7%)¡A Diaphoresis (Adult¡A 5.1%)¡A Weight decreased (2.4-12%)¡A Abdominal pain (Pediatric¡A 4-15%)¡A Decrease in appetite (2-35%)¡A Loss of appetite (Adult¡A 1.7% ; pediatric¡A 3.1-9% or greater )¡A Nausea (2.4-12.8%)¡A Vomiting (1.7-9%)¡A Xerostomia (3-14%)¡A Dizziness (Adult¡A 6.7%; pediatric¡A 1.9-3% .)¡A Headache (Adult¡A 22.2% ; pediatric¡A 2.4-19%)¡A Insomnia (2.8-41%)¡A Anxiety (Adult¡A 8.2%)¡A Depression (Adult¡A 1.7-3.9%)¡A Irritability (5.8-10%) Serious: Myocardial infarction¡A Peripheral vascular disease¡A Raynaud's phenomenon¡A Sudden cardiac death¡A Decreased body growth¡A Gastrointestinal obstruction¡A With preexisting severe gastrointestinal narrowing and use of controlled-release formulations¡A Abnormal liver function¡A Cerebral artery occlusion¡A Cerebral hemorrhage¡A Cerebrovascular accident¡A Gilles de la Tourette's syndrome¡A Worsening¡A Lowered convulsive threshold¡A Seizure¡A Tic (Pediatric¡A 1-9%)¡A Angle-closure glaucoma¡A Blurred vision (1.7-2% or greater )¡A Raised intraocular pressure¡A Aggressive behavior (1.7-2.4%)¡A Mania¡A Psychotic disorder¡A Priapism¡A Drug abuse¡A Substance dependence,30¢J¥H¤U«O«ù²~»\ºò³¬,Children >= 6 years (immediate-release Tablets) Initially 10mg. Dose adjustment can be based on the observed tolerance and therapeutic effect with gradual increments of 10 mg weekly. maximum: 40 mg/day. Adult: 20 mg QD initially.maximum: 60 mg/day.Ritalin LA sustained action capsules can be adjusted by increasing the dosage by 10 mg weekly. Immediate-release Tablets convert to extended-release Tablets: 5mg methylphenidate BID (immediate-release TABlets) is equivalent to 10mg methylphenidate(extended release Tablets) QD.10mg methylphenidate BID (immediate-release Tablets) is equivalent to 20mg methylphenidate(extended release Tablets) QD. 15mg methylphenidate BID (immediate-release TABlets) is equivalent to 30mg methylphenidate(extended release Tablets) QD. 20mg methylphenidate BID (immediate-release Tablets) is equivalent to 40mg methylphenidate(extended release Tablets) QD.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,[¥é³æ] Methylphenidate ¥Î©óÃh¥¥°ü¤kªº¬ÛÃö¸gÅç¤£¨¬¡C °£«D¹w´Á¹ï­L¨à¤§§Q¦h©ó¹ú¡A§_«h¥¥°ü¤£À³¨Ï¥Î Ritalin LA¡CMethylphenidate ¹ï¨ß¤l¨ã¼ç¦b­P·î­L©Ê¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¦³®×¨Ò³ø§iÅã¥Ü methylphenidate ·|¤À¥¬©ó¨Å¥Ä¤¤¡A¥B¦b¨Å¥Ä¤¤ªº¿@«×¬ù¬°¦å¼ß¤¤ªº 2.5­¿¡C À³¦Ò¶q­÷¨Å¹ï«Äµ£ªº¯q³B¤ÎªvÀø¹ï°ü¤kªº¯q³B¡A¥H¨M©w¬O§_°±¤î­÷¨Å©Î°±¤î Ritalin ªºªvÀø¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä½¦Ån¡A½Ð¾ã²É§]ªA¡A¤£¥i¼·¥b©Î¿i¯»¡C
IKCL,Potassium Chloride,10mEq KCl in 0.9%NaCl 500mL,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia¡A pain or phlebitis at injection site.,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Adult: Initial loading dose: 40~60 mEq¡A with ECG monitoring then based on serum potassium levels¡A Serum K>2.5 mEq/L: concentration < 30 mEq/L¡A with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia¡A treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
EAMO,Amorolfine,Amocoat Nail Lacquer 5mL,TDER,Fungal nail infections.,Hypersensitvity.,Skin irritation with erythema and pruritus; slight transient burning sensation (rare); hypersensitivity reactions.,25¢J¥H¤UÀx¦s,Fungal nail infections Adult: Topical As 5% nail lacquer: Apply 1-2 times/week. Usual treatment duration: 6 months for fingernails and 9-12 months for toenails.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
OWIN5,Chlorpromazine,Winsumin 50mg (­Ó®×Á{±Ä),CNEU,Management of psychotic disorders (control of mania¡A treatment of schizophrenia); control of nausea and vomiting; relief of restlessness and apprehension before surgery; acute intermittent porphyria; adjunct in the treatment of tetanus; intractable hiccups; combativeness and/or explosive hyperexcitable behavior in children 1-12 years of age and in short-term treatment of hyperactive children.,Hypersensitivity to chlorpromazine or any component of the formulation (cross-reactivity between phenothiazines may occur). Comatose state. Concomitant use with large doses of CNS depressants (eg¡A barbiturates¡A alcohol¡A narcotics),Common: Orthostatic hypotension¡A Tachycardia¡A Ineffective thermoregulation¡A Heatstroke or Hypothermia¡A Constipation¡A Nausea¡A Xerostomia¡A Akathisia¡A Dizziness¡A Parkinsonism¡A Somnolence¡A Tardive dyskinesia Serious: Prolonged QT interval¡A Erythroderma¡A Obstipation¡A Paralytic ileus¡A Agranulocytosis¡A Aplastic anemia¡A Leukopenia¡A Jaundice¡A Non-allergic anaphylaxis¡A Systemic lupus erythematosus¡A Dystonia¡A Neuroleptic malignant syndrome¡A Seizure¡A Priapism,«Ç·Å,Dosing: Adult --Schizophrenia/psychoses: Oral: Range: 30-800 mg/day in 1-4 divided doses¡A initiate at lower doses and titrate as needed; usual dose: 200~600 mg/day; some patients may require 1-2 g/day --Intractable hiccups: Oral: 25-50 mg 3-4 times/day --Nausea and vomiting: Oral: 10-25 mg every 4-6 hours Dosing: Pediatric (Children >=6 months) --Schizophrenia/psychoses: Oral: 0.5-1 mg/kg/dose every 4-6 hours; older children may require 200 mg/day or higher. --Nausea and vomiting: Oral: 0.5-1 mg/kg/dose every 4-6 hours as needed,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Lactation Enters breast milk/not recommended (up to date),,,,,,
EFLUS,Flumethasone + Salicylic Acid,Flusalic ointment 15gm,TDER,Seborrheic eczema¡A contact eczema¡A atopic dermatitis¡A localized neurodermatitis¡A psoriasis vulgaris¡A lichen planus¡A hyperkeratosis of the palms & soles.,Tuberculous¡A syphilitic & fresh viral skin affections¡A vaccination reactions. Perioral dermatitis¡A acne vulgaris.,Mild transient burning sensation¡A itching; in isolated cases¡A mild skin atrophy; changes in skin pigmentation¡A telangiectasia¡A purpura¡A steroid acne particularly after prolonged application.,1 5¢J- 30¢J,Apply the ointment to the affected areas in a thin film once or twice daily and gently rubbed-in. An occlusive dressing may also be used.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Flumethasone - Unknown Salicylic Acid - Unknown,Unknown ¨S¦³¸ê®Æ,Flumethasone - Unknown Salicylic Acid - Unknown,EXT;SKIN;TOPI;,,,,,
OSME,Dioctahedral Smectite,Smecta 3gm/pack,ALIM,Treatment of acute & chronic diarrhea.,Hypersensitivity to Dioctahedral Smectite.,Rarely¡A constipation.,30¢J¥H¤U,Adult 3 sachet/day. Children > 2 years 2-3 sachet/day¡A To be administered in 2-3 divided doses. In acute diarrhea¡A the daily dose can be doubled at the beginning of treatment. Each sachet can be mixed with 50 mL of water or semi-liquid. Administer preferably after meals in oesophagitis¡A or in between meals in other indications.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨S¦³Ãh¥¥°ü©Î¸ê®Æ¦³­­. °Êª«¹êÅçªº¸ê®Æ¤£¨¬¥H§P©w¬O§_¦³¥Í´Þ¬r©Ê. Ãh¥¥´Á¶¡¤£«ØÄ³¨Ï¥Î,Unknown ¨S¦³¸ê®Æ,[¥é³æ]­÷¨Å´Á¶¡¨Ï¥Îªº¸ê®Æ¦³­­.­÷¨Å´Á¶¡¤£«ØÄ³¨Ï¥Î,AC;AC15;PC;PO;WM;,,,,,
EFOX,Fluorometholone,Foxone 0.02% oph susp 5mL,TOPH,,¾AÀ³¯g: Acute & chronic iritis¡A iridocyclitis¡A scleritis¡A episcleritis¡A conjunctivitis¡A keratitis¡A resistant ocular allergy & inflammation following surgery °Æ§@¥Î: Glaucoma with optic nerve damage¡A visual acuity or field defects¡A raised intraocular pressure¡A secondary infection (persistent corneal ulceration¡A possibly fungal invasion)¡A perforation of globe¡A posterior subcapsular cataract formation ¸T§Ò: Acute superficial herpes simplex keratitis¡A fungal diseases of ocular structure; vaccinia¡A varicella & other viral diseases of the cornea & conjunctiva¡A eye TB,,«Ç·Å,Instill 1-2 drops bid-qid,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ISCA2,Epinephrine + Mepivacaine,Scandonest 2%(for Dental) 1.8mL,ZANE,Amide-type anesthetic used for local infiltration anesthesia; injection near nerve trunks to produce nerve block,Hypersensitivity to local anesthetics of the amide type or any component of the formulation,Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of local anesthetic. Cardiovascular: Myocardial effects include a decrease in contraction force as well as a decrease in electrical excitability and myocardial conduction rate resulting in bradycardia and reduction in cardiac output Central nervous system: High blood levels result in anxiety¡A restlessness¡A disorientation¡A confusion¡A dizziness¡A and seizure. This is followed by depression of CNS resulting in somnolence¡A unconsciousness and possible respiratory arrest. In some cases¡A symptoms of CNS stimulation may be absent and the primary CNS effects are somnolence and unconsciousness. Gastrointestinal: Nausea and vomiting may occur,«Ç·Å,Dental anesthesia¡A single site in upper or lower jaw: Infiltration: 54 mg (1.8 mL) as a 3% solution Infiltration and nerve block of entire oral cavity: 270 mg (9 mL) as a 3% solution; up to a maximum of 6.6 mg/kg of body weight but not to exceed 300 mg per appointment. Manufacturer's maximum recommended dose is not more than 400 mg to normal healthy adults. The effective anesthetic dose varies with procedure¡A intensity of anesthesia needed¡A duration of anesthesia required¡A and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,(Up to date) Pregnancy Risk Factor:C Lactation:Excretion in breast milk unknown/use caution,,,,,,Pharmacodynamics/Kinetics Onset of action: Upper jaw: 30-120 seconds; Lower jaw: 1-4 minutes Duration: Upper jaw: 20 minutes; Lower jaw: 40 minutes Half-life elimination¡A serum: 1.9 hours
ILEU1,Leuprorelin Acetate,LEUPLIN 3M inj 11.25mg (¤T­Ó¤ë),RACA,,¾AÀ³¯g: Prostate Cancer¡A Endometriosis¡A Menorrhagia and anemia cause by uterine fibroids who intends to carry out surgical resection¡A Premenopausal breast cancer as postoperative supplementary treatment. °Æ§@¥Î: Increased LDH¡A Hot flashes¡A feeling of warmth¡A anorexia¡A nausea¡A Headache¡A facial hot flushes¡A dizziness¡A diaphoresis¡A decreased libido¡A erectile dysfunction¡A gyecomastia¡A testicular atrophy or discomfort in the perineal region¡A Pains¡A such as arthralgia¡A and bone pain. ¸T§Ò: CONTRAINDICATIONS Leuplin Depot 3M is contraindicated in the following patients. 1) Patients with a history of hypersensitivity to any of the ingredients of this drug or synthetic LH-RH or LH-RH derivatives For Endometriosis and Uterine Leiomyomata (Fibroids) 2) Pregnant women or women having possibilities of being pregnant¡A or nursing mothers. 3) Patients with abnormal genital bleeding of indeterminable nature [There is a possibility of malignant disease.] For Premenopausal breast cancer as postoperative supplementary treatment 4) Pregnant women or women having possibilities of being pregnant¡A or nursing mothers.,,,Usually¡A for adults¡A 11.25 mg subcutaneously once every 12 weeks.  [Prostate Cancer] Monitor serum testosterone concentration periodically¡A at least once per 3 months¡A within 6 months treatment is required. [Endometriosis] therapy duration: 6 months. [Uterine Leiomyomata (Fibroids)] one Leuplin Depot 3M injection. The symptoms associated with uterine leiomyomata will recur following discontinuation of therapy. If additional treatment with Leuplin Depot 3M is contemplated¡A bone density should be assessed prior to initiation of therapy to ensure that values are within normal limits. [Central Precocious Puberty] Children with a body weight ? 20 kg: 1 ml (11.25 mg leuprorelin acetate) every 3 months as a single subcutaneous injection; children with a body weight < 20 kg: 0.5 ml (5.625 mg leuprorelin acetate) once every 3 months as a single subcutaneous injection. The bone age should be monitored during treatment at 6-12 month intervals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,SC;,¥H¼t°Ó©Ò²KªþªºÄa¿B¥Î·»¸Ñ²Gµ}ÄÀ,,,,
OCIA5,Tadalafil,Cialis 5mg (28 tablets/box),SGU,1.Treatment of erectile dysfunction. 2.Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),1.Concomitant use of nitrates (any form) either regularly or intermittently. 2.Hypersensitivity to tadalafil; Stevens-Johnson syndrome and exfoliative dermatitis have been reported,headache¡A dyspepsia¡A back pain¡A myalgia¡A nasopharyngitis¡A cough¡A or flushing Common ¡½Dermatologic: Flushing (1% to 13% ) ¡½Gastrointestinal: Indigestion (1% to 13% )¡A Nausea (up to 11% ) ¡½Musculoskeletal: Backache (2.4% to 12% )¡A Myalgia (1% to 14% ) ¡½Neurologic: Headache (3% to 42% ) ¡½Respiratory: Nasopharyngitis (2% to 13% )¡A Respiratory tract infection (3% to 13% ) Serious ¡½Cardiovascular: Angina (less than 2% )¡A Chest pain (less than 2% )¡A Heart failure¡A Myocardial infarction (less than 2% )¡A Tachycardia (less than 2% ) ¡½Dermatologic: Stevens-Johnson syndrome ¡½Neurologic: Cerebral hemorrhage¡A Cerebrovascular accident¡A Seizure ¡½Ophthalmic: Non-arteritic ischemic optic neuropathy¡A Retinal artery occlusion¡A Thrombosis of retinal vein ¡½Otic: Decreased hearing¡A Sudden onset (less than 2% )¡A Sudden hearing loss (less than 2% ),30¢J¥H¤U,Erectile Dysfunction: The recommended starting dose of CIALIS for once daily use is 2.5 mg¡A taken at approximately the same time every day¡A without regard to timing of sexual activity. The CIALIS dose for once daily use may be increased to 5 mg¡A based on individual efficacy and tolerability. Benign Prostatic Hyperplasia: The recommended dose of CIALIS for once daily use is 5 mg¡A taken at approximately the same time every day. The recommended dose of CIALIS for once daily use is 5 mg¡A taken at approximately the same time every day for up to 26 weeks.,»Ý½Õ¾ã¾¯¶q,»´«×©Î¤¤«×¨x¥\¯à¤£¥þ±wªÌ (Child-Pugh A or B) (erectile dysfunction): as-needed use¡A MAX dose is 10 mg ORALLY once daily »´«×©Î¤¤«×¨x¥\¯à¤£¥þ±wªÌ(Child-Pugh A or B) (pulmonary hypertension): start dosing at 20 mg orally once daily ­««×¨x¥\¯à¤£¥þªÌ(Child-Pugh class C):Á×§K¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,Micromedex: Infant risk cannot be ruled out. (1)Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. (2)Clinical Management:Tadalafil is not indicated for use in women and there are no reports describing the use of tadalafil during human lactation availableThe effects on the nursing infant from exposure to the drug in milk are unknown. Tadalafil is secreted into the milk of lactating rats at approximately 2.4 times the concentration found in plasma. No information is available on the secretion of tadalafil into human breast milk.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¥»ÃÄ»Ý¾ãÁûªA¥Î¡C
OTHR,Sennosides,Through (Sennosides) 12mg,ALIM,Treatment of constipation & for bowel evacuation before investigational procedures or surgery.,Patients with intestinal obstruction or with undiagnosed abdominal symptoms.,Mild abdominal discomfort¡A eg colic or cramps. Prolonged use or overdosage can result in diarrhoea with excessive loss of water & electrolytes¡A particularly K; possibility of developing an atonic non-functioning colon. May colour urine yellow-brown at acid pH¡A & red at alkaline pH. Reversible melanosis coli has been reported following chronic use.,25¢J¥H¤U¡AÁ×§K¶§¥úª½®g,Adult & children >12 years: PO 1-2 TAB HS. 6-12 years: one half dose of Adult. 3-6 years: one quarter dose of Adult.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;PO;,,,,,
IHEPA,Heparin,HEPAC inj 25KIU/5mL,HEMT,Unstable angina; Venous thromboembolism; Peripheral arterial embolism¡A Prevention of re-occlusion of the coronary arteries following thrombolytic therapy ¡A Venous thromboembolism ¡AProphylaxis of post-op venous thromboembolism¡A Prevention of mural thrombosis,Patients predisposed to active bleeding including thrombocytopenia¡A peptic ulcer disease¡A cerebrovascular disorders¡A haemorrhagic blood disorders¡A bacterial endocarditis¡A severe hypertension¡A oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage¡A abdominal or thoracic bleeding into closed space¡A severe traumatic bleed¡A hepatic¡A renal¡A splenic or arterial injury¡A severe haemostatic defect¡A arterial thrombosis with heparin-associated thrombocytopenia. IM admin.,Slight fever¡A headache¡A chills¡A nausea¡A vomiting¡A constipation¡A epistaxis¡A bruising¡A slight haematuria¡A skin necrosis (SC inj)¡A osteoporosis¡A alopecia. Hypersensitivity reactions include urticaria¡A conjunctivitis¡A rhinitis¡A asthma¡A angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding Dermatologic: Erythema¡A Injection site ulcer¡A After deep subcutaneous injection Hematologic: Hematoma¡A Heparin-induced thrombocytopenia (up to 30% ) Neurologic: Pain (Mild) Other: Irritation symptom¡A Local,25¢J¥H¤U,IV: 10000 IU as first dose¡A followed by 5000-10000 IU every 4-6 hours. IV infusion: 20000-40000 IU/day¡A adding in 1000mL solvent. Deep SC: 10000 IU every 8 hours or 15000-20000 IU every 12 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IA;IRR;IV;IVD;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iH/S¡j¥i¿ï ¡C,,¿éª`³t²v 10~20 u/mL/min,1.¥¼µ}ÄÀ¥ç¥i¨Ï¥Î 2.¼t°Ó«ØÄ³¨Ï¥Îµ}ÄÀ¥ç¬°N/S
ISIM,Golimumab,Simponi inj 50mg/0.5mL,HIMM,In combination w/ methotrexate for the treatment of moderate to severe active RA. Alone or in combination w/ methotrexate for active psoriatic arthritis (PsA). Treatment of active ankylosing spondylitis (AS).,Canadian labeling: Hypersensitivity to golimumab¡A latex¡A or any other component of formulation or packaging; patients with severe infections (eg¡A sepsis¡A tuberculosis¡A opportunistic infections); moderate or severe heart failure (NYHA class III/IV),Serious infections¡A malignancies¡A autoimmune disorders & autoantibodies¡A inj site reactions¡A new onset & exacerbations of psoriasis¡A immunogenicity¡A upper resp tract infection¡A nasopharyngitis¡A sepsis¡A increased ALT & AST; HTN¡A bronchitis¡A dizziness¡A sinusitis¡A flu¡A pharyngitis¡A rhinitis¡A pyrexia¡A oral herpes¡A paraesthesia.,2-8¢JÁ×¥úÁ×§K§N­á,SC¡A rheumatoid arthritis¡A psoriatic arthritis and ankylosing spondylitis 50 mg once a month. Moderate to severe active ulcerative colitis( body weight<80 kg) 200 mg at week 0¡A then 100 mg at week 2¡A followed by 50-100 mg every 4 weeks.( body weight > or = 80kg) 200 mg at week 0¡A then 100 mg at week 2¡A followed by 100 mg every 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,PREGNANCY RECOMMENDATION: Contraindicated if combined with methotrexate.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Contraindicated if combined with methotrexate.,SC;,,,,,¦w¥þª`®g¶·ª¾»P¨BÆJ: ¥²¶·¥ÑÂåÀø±M·~¤H­û¬I¥´¡C 1. ¨Ï¥Î«e¡A±q¦B½c¨ú¥X¹w¥R°wµ©©Î¹w¥RSmartJect¦Û°Êª`®g¾¹¡A¦Û¥]¸Ë²°¤¤¨ú¥X¡A¦b«Ç·Å¤U©ñ¸m¦Ü¤Ö30¤ÀÄÁ¡C¤Å¥H¥ô¦ó¨ä¥¦¤è¦¡¥[¼ö¡C¦bµ¥­Ô¦^·Å®É¤£¥i²¾°£°wÀY®M©Îª`®g¾¹Å@®M¡C§Y±Nª`®g«e¤~²¾°£¡C 2. Á`¦@·|Å¥¨ì¨â¦¸¡u³ØÜÖ¡vÁn¡A¤§«á°wÀY·|¦Û°ÊÁY¦^¡C¦b°wÀY©Ô¦^¤§«e¡A¤Á¤Å±N¦Û°Êª`®g¾¹¦Û¥Ö½§ªí­±©Ô¶}¡C¦b²Ä¤@­Ó¡u³ØÜÖ¡vÁn¤§«á¡A³q±`¥u­n¸g¹L3¦Ü6¬í´N·|Å¥¨ì²Ä¤G­Ó¡u³ØÜÖ¡vÁn¡A¦ý¤]¥i¯à·|»Ý­nªø¹F15¬í¡C 3. ª`®g§¹¦¨«á¡A¨Ì·Ó¼o±óÂåÀø¦y¾Uª«³B²z­ì«h¥á±ó°w¨ã¡C
OEDA,Azilsartan medoxomil,Edarbi 40mg,CAVS,Treatment of hypertension; may be used alone or in combination with other antihypertensives.,Hypersensitivity to azilsartan medoxomil or any component of the formulation; concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR <60 mL/minute/1.73 m2).,Hypotension¡A orthostatic hypotension¡A Dizziness¡A fatigue¡A Diarrhea¡A nausea¡A Decreased hemoglobin¡A decreased hematocrit¡A decreased red blood cells¡A leukopenia (rare)¡A thrombocytopenia (rare)¡A Muscle spasm¡A weakness¡A Increased serum creatinine¡A Cough,30¢J¥H¤U¡AÁ×§K¥ú·Ó¤Î¼éÀã,HTN Initial: 20-40 mg QD; titrate up to maximum 80 mg QD,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] Ãh¥¥´Á¶¡¤£À³¶}©l¨Ï¥Î¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯¡C­pµeÃh¥¥¤§°ü¤kÀ³§ï¥Î¨ä¥LÃh¥¥¦w¥þ©Ê¤w½T¥ß¤§­°¦åÀ£ÃÄ¡C½T©wÃh¥¥«áÀ³¥ß§Y°±¥Î¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯¡A¨Ãµø»Ý­n¶}©l¨Ï¥Î¨ä¥LÃÄª«¡C ²Ä¤@¥¥´Á¸T¤î¨Ï¥Î¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯¡C²Ä¤G»P²Ä¤T¥¥´Á°ü¤k¸T¤î¨Ï¥Î¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯¡C ¥Ø«e©|µLÃh¥¥°ü¤k¨Ï¥Îazilsartan medoxomilªº¸ê®Æ¡C°Êª«¸ÕÅçÅã¥Ü¥Í´Þ¬r©Ê¡C ©|µL¨M©w©Êªº¬y¦æ¯f¾ÇÃÒ¾Ú¡AÃÒ¹ê©ó²Ä¤@¥¥´Á¨Ï¥Î¦åºÞ¦¬ÁY¯ÀÂà¤ÆžJ§í¨î¾¯¡A·|¤Þ°_­P·î­L­·ÀI¡F¦ý¬O¡AµLªk±Æ°£­·ÀI²¤·L¼W¥[ªº¥i¯à¡CÃö©ó¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯ªº­·ÀI¡A¾¨ºÞ¨S¦³¹ï·Ó¬ã¨sªº¬y¦æ¯f¾Ç¸ê®Æ¡A¦ý¦¹ÃþÃÄª«¥i¯à¨ã¦³¬Û¦üªº­·ÀI¡C­pµeÃh¥¥¤§°ü¤kÀ³§ï¥Î¨ä¥LÃh¥¥¦w¥þ©Ê¤w½T¥ß¤§­°¦åÀ£ÃÄ¡C½T©wÃh¥¥«áÀ³¥ß§Y°±¥Î¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯¡A¨Ãµø»Ý­n¶}©l¨Ï¥Î¨ä¥LÃÄª«¡C ©ó²Ä¤G»P²Ä¤T¥¥´Á¨Ï¥Î¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯¡A¤wª¾·|»¤µo­L¨à¬r©Ê¡]µÇ¥\¯à­°§C¡B¦Ï¤ô¹L¤Ö¡BÆ`°©°©¤Æ¿ð½w¡^»P·s¥Í¨à¬r©Ê¡]µÇ°IºÜ¡B§C¦åÀ£¡B°ª¦å¹[¡^¡C­Y²Ä¤G¥¥´Á°_´¿¼ÉÅS©ó¦åºÞ¦¬ÁY¯À II ¨üÅé«ú§Ü¾¯¡A«ØÄ³¥H¶W­µªiÀË¬dµÇ¥\¯à»PÆ`°©µo¨|¡C´¿±µ¨ü¦åºÞ¦¬ÁY¯ÀII¨üÅé«ú§Ü¾¯ªº°ü¤k¡A©Ò²£¤UªºÀ¦¨à¡AÀ³±K¤Áª`·N§C¦åÀ£ªºµo¥Í¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ñ©ó¯Ê¥F­÷¨Å´Á¶¡¨Ï¥Îazilsartan medoxomilªº¸ê°T¡A¬G­÷¨Å®É¤£«ØÄ³¨Ï¥Î©ö±o¥­¿õ¡A«ØÄ³§ï¥Î¨ä¥L¦w¥þ©Ê¸û½T¥ßªºÃÄª«¡A¤×¨ä¬O¬°·s¥Í¨à©Î¦­²£¨à­÷¨Å´Á¶¡¡C,AC;AC15;PC;PO;WM;,,,,,
OKES,Amino Acids + Ketoanalogues,Ketosteril,NUTR,Chronic renal insufficiency amino acid supplement,hypersentivity¡Ahypercalcinemia,hypercalcinemia,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Take 4-8 tablets three times a day during meals. Swallow whole. This dosage applies to adults (70kg/BW). Health insurance regulations: eGFR <or = 15mL/min /1.73 m2 and have not received dialysis treatment¡A use up to six pills a day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥Ñ©ó¥»«~±a¦³¯ä¨ý¡A­Y¨Ï¥Î¿i¯»¤À¥]¾÷·|¦¾¬VÃø¥H²M¼ä¡C¼t°Ó¥çµL¬ÛÃö¸ê®Æ¡C¦]¦¹«ØÄ³¤£­n±NÃÄ¿õ¿i¯»¨Ï¥Î¡C
IXGE,Denosumab,Xgeva inj 120mg,META,Bone metastases from solid tumors: Prevention of skeletal-related events (eg¡A fracture¡A spinal cord compression¡A bone pain requiring surgery/radiation therapy) in patients with bone metastases from solid tumors. Giant cell tumor of bone: Treatment of giant cell tumor of bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity. Hypercalcemia of malignancy: Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.,Hypersensitivity. Severe¡A symptomatic hypocalcaemia.,>10%: Cardiovascular: Hypertension (11%) Central nervous system: Fatigue (Xgeva: <45%)¡A headache (Xgeva: 13% to 24%)¡A peripheral edema (5%; Xgeva: 24%) Dermatologic: Dermatitis (4% to 11%)¡A eczema (4% to 11%)¡A skin rash (3% to 11%) Endocrine & metabolic: Hypophosphatemia (Xgeva: 32%)¡A hypocalcemia (2%; Xgeva: 3% to 18%) Gastrointestinal: Nausea (Xgeva: 31%)¡A decreased appetite (Xgeva: 24%)¡A vomiting (Xgeva: 24%)¡A constipation (Xgeva: 21%)¡A diarrhea (Xgeva: 20%) Hematologic & oncologic: Anemia (Xgeva: 21%) Infection: Influenza (11%) Neuromuscular & skeletal: Weakness (Xgeva: ?45%)¡A arthralgia (7% to 14%)¡A limb pain (10% to 12%)¡A back pain (8% to 12%) Respiratory: Dyspnea (Xgeva: 21% to 27%)¡A cough (Xgeva: 15%),2-8¢JÁ×¥úÁ×§K§N­á,SC¡A bone metastasis associated with solid tumors 120 mg every 4 weeks. Giant cell tumor of bone¡A hypercalcemia of malignancy 120 mg every 4 weeks¡A with additional 120 mg doses on days 8 and 15 of first month of therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,¥Ö¤Uª`®g³¡¦ì¡G¤WÁu¡B¤WÁv©Î¸¡³¡¡C
OXAR,Rivaroxaban,XARELTO 15mg,HEMT,Xarelto 10 mg Prevention of Venous Thrombosis(VTE) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15 mg & 20 mg Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation w/ ¡Ù1 risk factors eg CHF¡A HTN¡A age ¡Ù75 yr¡A DM¡A prior stroke or transient ischaemic attack. Treatment of Deep Venous Thrombosis (DVT) & PE¡A & prevention of recurrent DVT & PE following an acute DVT in adults.,Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation.,Anemia¡A dizziness¡A headache¡A syncope¡A eye haemorrhage¡A tachycardia¡A hypotension¡A haematoma¡A epistaxis¡A GI disorders¡A pruritus¡A pain in extremity¡A urogenital tract haemorrhage¡A fever¡A peripheral oedema¡A decreased general strength & energy¡A increased transaminases¡A postprocedural haemorrhage.,Àx¦s·Å«×¤£¥i¶W¹L30¢J,Prevention of stroke and systemic embolism for patients with non-valvular atrial fibrillation: 15-20mg QD.(Clcr > 50 mL/min). Deep vein thrombosis(DVT)¡A pulmonary embolism(PE) treatment and prophylaxis: 15mg BID on day 1-21¡A followed by 20mg QD from day 22. Prophylaxis of VTE high risk patient: 10mg QD.,»Ý½Õ¾ã¾¯¶q,Moderate to severe impairment (Child-Pugh class B or C) and any hepatic disease associated with coagulopathy: Avoid use.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]µL¥¥°ü¨Ï¥Îªº¦w¥þ©Ê»P¦³®Ä©Ê¸ê®Æ¡A°Êª«¹êÅç¤¤Åã²{¥Í´Þ©Ê¬r©Ê¡A¥B¥»ÃÄ¥i¥H³q¹L­L½L¡A Ãh¥¥°ü¤k¸T¤î¨Ï¥Î. ¨ã¥Í¨|¯à¤O°ü¤kÀ³±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I.,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]µL±Â¨Å°ü¨Ï¥Îªº¦w¥þ©Ê»P¦³®Ä©Ê¸ê®Æ¡A°Êª«¹êÅç¤¤Åã²{¥»ÃÄ¥i¥H¤Àªc­P¨Å¥Ä¤¤¡A ¦]¦¹¶È¯à¦b°±¤î­÷¨Å«á¨Ï¥Î.,PC;PO;WM;,,,,,
INEOP,Ibuprofen,Neoprofen 20mg/2mL,CNEU,,¾AÀ³¯g: Treatment of Patent Ductus Arteriosus (PDA) in premature neonates. °Æ§@¥Î: Injection: Ibuprofen lysine (NeoProfen?): >10%: Cardiovascular: Intraventricular hemorrhage (29%; grade 3/4: 15%) Dermatologic: Skin irritation (16%) Endocrine & metabolic: Hypocalcemia (12%)¡A hypoglycemia (12%) Gastrointestinal: GI disorders¡A non NEC (22%) Hematologic: Anemia (32%) Respiratory: Apnea (28%)¡A respiratory infection (19%) Miscellaneous: Sepsis (43%) 1% to 10%: Cardiovascular: Edema (4%) Endocrine & metabolic: Adrenal insufficiency (7%)¡A hypernatremia (7%) Genitourinary: Urinary tract infection (9%) Renal: Urea increased (7%)¡A renal impairment (6%)¡A creatinine increased (3%)¡A urine output decreased (3%; small decrease reported on days 2-6 with compensatory increase in output on day 9)¡A renal failure (1%) Respiratory: Respiratory failure (10%)¡A atelectasis (4%) ¸T§Ò: Hypersensitivity to ibuprofen; history of asthma¡A urticaria¡A or allergic-type reaction to aspirin or other NSAIDs; aspirin triad (eg¡A bronchial asthma¡A aspirin intolerance¡A rhinitis); perioperative pain in the setting of coronary artery bypass graft (CABG) surgery,,«Ç·Å,PDA: Each course of therapy consists of 3 doses administered at 24-hour intervals. First dose is 10 mg/kg; second and third doses are 5 mg/kg each¡A If anuria or oliguria (urine output <0.6 mL/kg per hour) withhold the dose until renal function has returned to normal. If ductus arteriosus fails to close or reopens¡A a second course of ibuprofen¡A may be needed,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,NeoProfen (ibuprofen lysine): For I.V. administration only; administration via umbilical arterial line has not been evaluated. Infuse over 15 minutes through port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed¡A interrupt TPN for 15 minutes prior to and after ibuprofen administration¡A keeping line open with dextrose or saline.
OZCO,Benzonatate,Zcough 100mg,ERSP,Symptomatic relief of nonproductive cough,Hypersensitivity to benzonatate¡A related compounds (such as tetracaine)¡A or any component of the formulation¡A age < 14yr.,Sedation¡A headache¡A dizziness¡A itch¡A skin eruption¡A nasal congestion¡A constipation¡A GI upset¡A chills¡A chest tightness¡A allergy.,25¢J¤UÀx¦s,Adult 1-2 cap TID Maximum dose is 600 mg/day,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦Ån¡A¥é³æ«ØÄ³À³¾ã²É§]ªA¡A¤Á¤Å«rÄZ©ÎÀ£¸H¡C
OARH1,Leflunomide,Arheuma 10mg,HIMM,Treatment of rheumatoid arthritis (RA) and psoriatic arthritis in adults.,Contraindicated in patients with hypersensitivity to Leflunomide and its active metabolite A771726 (Teriflunomide)¡A especially those with a history of Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A and erythema multiforme. Patients with hepatic impairment. Patients with severe immune system deficiency¡A such as AIDS. Patients with significant bone marrow dysfunction or hematological abnormalities not due to rheumatoid arthritis or psoriatic arthritis. Patients with severe infections. Patients with moderate to severe renal impairment. Patients with severe hypoproteinemia¡A such as nephrotic syndrome. Pregnancy. Lactation. Male patients should use effective contraception during treatment¡A as the drug may cause male-mediated fetal toxicity. Not recommended for use in patients under 18 years of age.,Common: Alopecia (9-17%)¡A Rash (10-12%)¡A Diarrhea (17-27%)¡A Ulcer of mouth (3-5%)¡A Dizziness (4-7%)¡A Headache (7-13%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Agranulocytosis¡A Pancytopenia¡A Thrombocytopenia¡A ALT/SGPT level raised (1.5-4.4%)¡A Hepatic necrosis¡A Injury of liver¡A Liver failure¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Infectious disease¡A Opportunistic infection¡A Tuberculosis¡A Peripheral neuropathy¡A Interstitial lung disease¡A Pneumocystis pneumonia¡A Respiratory tract infection (10% or greater),25¢J¥H¤UÁ×§K¥ú½uª½±µ·Ó®g,Adult loading dose 100 mg once daily for 3 days. Maintenance dose rheumatoid arthritis 10-20 mg once daily¡A psoriatic arthritis 20 mg once daily.,»Ý½Õ¾ã¾¯¶q,Not recommended for use in patients with preexisting liver disease or those with baseline ALT >2 times ULN; monitor liver function closely. Use is contraindicated in severe hepatic impairment.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°§K¬Ì§í¨î¾¯¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C 1. ³Ü¨¬°÷¶qªº¥Õ¶}¤ô±NArheuma¿õ¾ãÁû§]ªA¡A­¹ª«¤£·|¼vÅTLeflunomide§l¦¬¡C
IDIPH,Diphenhydramine,Diphenhydramine inj 30mg/1mL,HIMM,Urticaria¡A dermatologic disease¡A pruritus¡A acute rhinitis & hay fever.,Acute asthmatic attack. Premature infants.,Drowsiness¡A dizziness¡A antimuscarinic effects. CV & CNS effects. Muscular weakness. Allergic reaction. Blood disorders.,15-30¢JÁ×¥ú,Adult: 30mg QD¡A Child: half dose of adult. Do not recommended for use to premature infants and neonate. Patient with renal function impairment should prolong interval. Depend on eGFR.IV 10~50mg each time¡A injection rate does not exceed 25mg/min.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Diphenhydramine is excreted into breast milk; drowsiness has been reported in a breast-feeding infant. Premature infants and newborns have a higher risk of intolerance to antihistamines. Breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.,IM;IVD;IVP;IVPUSH;SC;,,¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¦¨¤H: 10-50mg(max. 400 mg/day);¤p«Ä: 5 mg/kg/day(max. 300mg/day),102.02.25 ½Ã¥Í¸p¤½§i 1. ¡uÀ¦¥®¨à(premature infants¤Îneonate)¤£«ØÄ³¨Ï¥Î¡v 2. ¡u¦Ñ¤H©y¥H³Ì§C¦³®Ä°_©l¾¯¶q¶}©lªvÀø¡v 3.¡uµÇ¥\¯à¤£¥þªÌÀ³©µªøµ¹ÃÄ¶¡¹j¡F»´«×(GFR>50 mL/min)¡G¶¡¹j6¤p®É¡F¤¤«×(GFR 10-50 mL/min)¡G¶¡¹j6-12¤p®É¡F­««×(GFR<10 mL/min)¡G¶¡¹j12-18¤p®É¡v¡C
OZON1,Zonisamide,Zonegran 100mg,CNEU,Adjunctive treatment of partial seizures.,Hypersensitivity to zonisamide¡A sulfonamides¡A or any component of the formulation.,Frequencies noted in patients receiving other anticonvulsants: >10%: Central nervous system: Somnolence (17%)¡A dizziness (13%) Gastrointestinal: Anorexia (13%) 1% to 10%: Central nervous system: Headache (10%)¡A agitation/irritability (9%)¡A fatigue (8%)¡A tiredness (7%)¡A ataxia (6%)¡A confusion (6%)¡A concentration decreased (6%)¡A memory impairment (6%)¡A depression (6%)¡A insomnia (6%)¡A speech disorders (5%)¡A mental slowing (4%)¡A anxiety (3%)¡A nervousness (2%)¡A schizophrenic/schizophreniform behavior (2%)¡A difficulty in verbal expression (2%)¡A status epilepticus (1%)¡A seizure (1%)¡A hyperesthesia (1%)¡A incoordination (1%) Dermatologic: Rash (3%)¡A bruising (2%)¡A pruritus (1%) Gastrointestinal: Nausea (9%)¡A abdominal pain (6%)¡A diarrhea (5%)¡A dyspepsia (3%)¡A weight loss (3%)¡A constipation (2%)¡A taste perversion (2%)¡A xerostomia (2%)¡A vomiting (1%) Neuromuscular & skeletal: Paresthesia (4%)¡A abnormal gait (1%)¡A tremor (1%)¡A weakness (1%) Ocular: Diplopia (6%)¡A nystagmus (4%)¡A amblyopia (1%) Otic: Tinnitus (1%) Renal: Kidney stones (4%¡A children 3% to 8%) Respiratory: Rhinitis (2%)¡A pharyngitis (1%)¡A increased cough (1%) Miscellaneous: Flu-like syndrome (4%) accidental injury (1%) <1% (Limited to important or life threatening): Agranulocytosis¡A allergic reaction¡A alopecia¡A amenorrhea¡A aplastic anemia¡A apnea¡A arthritis¡A atrial fibrillation¡A bladder calculus¡A bradycardia¡A cerebrovascular accident¡A cholangitis¡A cholecystitis¡A cholestatic jaundice¡A colitis¡A deafness¡A duodenitis¡A encephalopathy¡A fecal incontinence¡A gingivitis¡A GI ulcer¡A glaucoma¡A heart failure¡A hematuria¡A hemoptysis¡A hirsutism¡A hyper-/hypotension¡A hyperthermia¡A hypoglycemia¡A hyponatremia¡A immunodeficiency¡A impotence¡A iritis¡A leukopenia¡A lupus erythematosus¡A lymphadenopathy¡A mastitis¡A menorrhagia¡A metabolic acidosis¡A neuropathy¡A oculogyric crisis¡A oligohidrosis (children)¡A pancreatitis¡A photophobia¡A pulmonary embolus¡A rectal hemorrhage¡A Stevens-Johnson syndrome¡A stroke¡A suicidal behavior/ideation¡A syncope¡A thrombocytopenia¡A thrombophlebitis¡A toxic epidermal necrolysis¡A urinary incontinence¡A ventricular extrasystoles,30¢J¥H¤U,Partial seizure¡A Monotherapy: Adult¡A initially 100 mg daily¡A daily dose may be increased in 100mg increments every 2 weeks up to 300 mg or more. Maximum: 500 mg/day. Partial seizure¡A Adjunct: Adult¡A initially 100 mg daily¡A daily dose may be increased every 1-2 weeks up to 200-400 mg daily (in 1-3 divided doses). Maximum: 500 mg/day.,µL»Ý½Õ¾ã¾¯¶q,»´«×©Î¤¤«×¨x¥\¯à¤£¥þ±wªÌªvÀø®ÉÀ³ÂÔ·V¡A¥i¯à»Ý­n´îºC½Õ°ªzonisamide¾¯¶qªº³t«× ­««×¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest high risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Zonisamide °±ÃÄ¤@­Ó¤ë«á¡A¤è¥iÄ~Äò¶}©l±Â¨Å¡C (ÃÄ«~¥é³æ),,,,,,
EBET,Betamethasone + Neomycin,Betason-N ²´ÃÄ»I3gm,TOPH,Inflammatory dermatoses responsive to topical corticosteroid therapy¡A where secondary bacterial infection is present or suspected or likely to occur. Management of insect bites¡A prickly heat¡A anal & genital intertrigo & otitis externa.,Rosacea; acne vulgaris; perioral dermatitis; perianal & genital pruritus. Primary cutaneous viral infection; treatment of primarily infected skin lesions caused by infection w/ fungi or bacteria; primary or secondary infections due to yeast; dermatoses in childn <1 yr. Otitis externa when tympanum is perforated. Secondary infections due to Pseudomonas or Proteus spp.,Local atrophic skin changes; hypercorticism; hypersensitivity.,25¢J¥H¤UÀx¦s,Apply 1-3 times a day on affected part.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,BETAMETHASONE: Compatible NEOMYCIN: Human Data Suggest Low Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BETAMETHASONE: No Human Data¡XProbably Compatible NEOMYCIN: No Human Data¡XProbably Compatible,AD;AL;AS;AU;EXT;NA;OD;OL;OU;SKIN;TOPI;,,,,,
OSOO,Amoxicillin + Clavulanic Acid,Soonmelt 625mg,QANB,,¾AÀ³¯g:Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis. °Æ§@¥Î:Diarrhea¡A nausea¡A vomiting¡A mucocutaneous candidiasis. Dermatologic: Diaper rash (3.5% )¡A Rash (1.1% to 3% ) Gastrointestinal: Diarrhea (2.9% to 14.5% )¡A Loose stool (1.6% )¡A Nausea (2.1% to 3% )¡A Vomiting (1% to 2.2% ) Reproductive: Mycosis (3.3% )¡A Vaginitis (1% ) Other: Candidiasis (1.4% ) ¸T§Ò:History of hypersensitivity to £]-lactams. History of penicillin-associated jaundice/hepatic dysfunction.,,«Ç·Å,Adult & child over 40 kg: 250-500 mg q8h. Child under 40 kg: 20-40 mg/kg/day in 3 divided doses.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,WHO: Compatible with breastfeeding Micromedex: Infant,,,,,,
ICAC,Calcitriol,Cacare inj 2mcg/1mL,META,Management of hypocalcemia in patients undergoing chronic renal dialysis.,Hypercalcemia or evidence of vit D toxicity.,Weakness¡A headache¡A somnolence; nausea¡A vomiting¡A dry mouth¡A constipation; muscle pain¡A bone pain & metallic taste.,25¢J¥H¤UÁ×¥ú,Initially 0.5 mcg (0.01 mcg/kg) administered 3 times a week¡A approximately every other day. Dose may be increased by 0.25 ~ 0.5 mcg at 2 ~ 4 week intervals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ] ¨Ì¤åÄm°O¸ü¡A¦b¤fªAµ¹¤©¨ß¤l4©M15­¿¤HÃþ«ØÄ³¾¯¶q¤§ calcitriol ªº³ø§i¤¤¡AÅã¥Ü¦³­P·î©Ê¡C ¤T­L¤¤Á`¦@ 15­Ó­L¨à¦b¦¹¾¯¶q¤U¡AÅã¥Ü¦³¥~Æ[¤Î°©Àf·î«¬ªº²{¶H¡C¦ý¬O¡A¦b¨ä¥L23­L¤¤(156­Ó­L¨à)¡A»P¹ï·Ó ²Õ¬Û¤ñ¡A¨Ã¥¼Åã¥Ü¥XÅãµÛªº·î«¬²{¶H¡C¤j¹«ªº­P·î©Ê¬ã¨s¨Ã¥¼Åã¥Ü¦³­P·î©ÊªºÃÒ¾Ú¡C¥Ø«e¨Ã¨S¦³¹ïÃh¥¥°ü¤k¶i¦æ¾A·í¤Î±±¨î¨}¦nªº¬ã¨s¡C °£«D¦bÁ{§É·N¸q­«©ó¹ï­L¨àªº¼ç¦b¦MÀI©Ê¡A§_«h Cacare ¤£À³¨Ï¥Î©óÃh¥¥´Á¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¥Ø«e¤£ª¾¦¹ÃÄ¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡C¦]¬°³\¦hÃÄª«³£·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡C¥Bcalcitriol ¹ï¨ü¨ÅÀ¦¨à¨ã¦³ÄY­«¤£¨}¤ÏÀ³ªº¼ç¦b¯à¤O¡A©Ò¥HÀ³¦b°±¤î­÷¨Å¤Î°±¤î¥ÎÃÄ¶¡§@¤@§à¾Ü¡A¨Ã¦Ò¼{ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡C,IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,May be administered as a bolus dose IV through the catheter at the end of hemodialysis.,,May be administered as a bolus dose IV through the catheter at the end of hemodialysis.
EPROV,Methacholine,Provocholine Inhalation 100mg,ZOTH,Diagnosis of bronchial airway hyperactivity,Hypersensitivity to methacholine¡A other parasympathomimetic agents¡A or any component of the formulation; concomitant use of beta-blockers; repeat administration (other than day of challenge test with increasing doses),Central nervous system: Headache¡A lightheadedness Dermatologic: Itching Gastrointestinal: Throat irritation,¥¼¶}«Ê15-30¢J,Age >5 years old and Adult: Use 0.03¡A 0.0625¡A 0.125¡A 0.25¡A 0.5¡A 1¡A 2¡A 4¡A 8¡A 16 mg/mL solution for inhalation only. Stop dosing if the FEV1 has fallen by 20% from the mean baseline¡A the FEV1 is 1.5 L¡A or the highest dose has been administered (whichever comes first).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Methacholine chloride¨Ã¨S¦³¶i¦æ¥ô¦ó°Êª«Ác´Þ¸ÕÅç¡A¤´¥¼ª¾§ë»Pmethacholine chloride¦ÜÃh¥¥¯f±w¬O§_·|³y¦¨­F­L¶Ë®`©Î¼vÅT¥Í´Þ¯à¤O¡A¥u¦³¦b©úÅã»Ý­n®É¤~¥iµ¹¤©Ãh¥¥°ü¤kmethacholine chloride¡C ¹ïÃh¥¥¥i¯àªº¤k©Ê¯f±w¡AProvocholineR (methacholine chloride§l¤J¥Î¯»¥½)§l¤J©Ê´ú¸Õ¥u¯à¦b¸g´Á¶}©l«á10¤Ñ¤º©ÎÅç¥¥µ²ªG¬°³±©Ê¤§«á2¶g¤º¶i¦æ¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¤£À³µ¹¤©­÷¨Å¤¤ªº¥À¿ËProvocholineR (methacholine chloride§l¤J¥Î¯»¥½)§l¤J©Ê´ú¸Õ¡A¦]¬°¤£ª¾methacholine chloride¬O§_·|¤Àªc¦Ü¨Å¥Ä¤¤¡C,IH;,0.9%´â¤Æ¶uª`®g²G(¥Í²z­¹ÆQ¤ô)©Î§t¦³0.4%×ôªº0.9%´â¤Æ¶uª`®g¾¯(§t¦³0.4%×ô¤§¥Í²z­¹ÆQ¤ô)©Î§t¦³0.9%­f¥Ò¾Jªº0.9%´â¤Æ¶uª`®g¾¯(§t¦³0.9%­f¥Ò¾Jªº¥Í²z­¹ÆQ¤ô),,,,¥HµLµß§Þ³N°t»sªºProvocholineR·»²G«O¦s¦b¦B½c¤º(2-8¢J)¥i«O¦s2¬P´Á¡C§N­á«O¦s¤£·|¯}Ãaµ}ÄÀ²GªºÃ­©w©Ê¡C ¦]¬°·»²Gªº·Å«×·|¼vÅT¼QÃú¾¹ªº¼Q¥X¶q¡A¦]¦¹¨Ï¥Î«e(¬ù30¤ÀÄÁ¥H«e)À³¥ý±N·»²G±q¦B½c¨ú¥X¡A¨Ï·»²G·Å«×¦^´_¦Ü»P«Ç·Å¬Û¦P¡C
OLINI,Niacin + Lovastatin,Linicor F.C.T. 500/20mg,CAVS,Primary hypercholesterolemia/mixed dyslipidemia: Treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) in combination with a standard cholesterol-lowering diet.,Hypersensitivity to lovastatin¡A niacin¡A or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; active peptic ulcer disease; arterial bleeding; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg¡A clarithromycin¡A erythromycin¡A itraconazole¡A ketoconazole¡A nefazodone¡A posaconazole¡A voriconazole¡A protease inhibitors including boceprevir and telaprevir¡A telithromycin¡A and cobicistat-containing products),>10%: Cardiovascular: Flushing (53% to 83%) Infection: Infection (20%) 1% to 10%: Central nervous system: Headache (9%)¡A pain (8%) Dermatologic: Pruritus (7%)¡A skin rash (5%) Endocrine & metabolic: Hyperglycemia (4%)¡A hypophosphatemia Gastrointestinal: Nausea (7%)¡A diarrhea (6%)¡A abdominal pain (4%)¡A dyspepsia (3%)¡A vomiting (3%) Hematologic & oncologic: Increased prothrombin time (2%) Respiratory: Flu-like symptoms (6%),25¢J¥H¤U,Hyperlipidemia adult¡A initial 1tab HS (niacin/lovastatin 500mg/20mg) slowly titrate up. maximum 2 tab /day (niacin/lovastatin 1000 mg/40mg),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated ¡V 1st trimester,Niacin - Compatible Lovastatin - Contraindicated 1st Trimester [¥é³æ] ½wÄÀ¾¯«¬niacin/lovastatin½Æ¤è¿õ¾¯¥u¯à¨Ï¥Î¦b·¥«×¤£¥i¯àÃh­L±¡ªp¥B¤w³Q§iª¾¨ä¨Ï¥Î­·ÀI¤§°ü¤k¨­¤W¡C ½wÄÀ¾¯«¬niacin/lovastatin½Æ¤è¿õ¾¯¹ï©ó¥¥°üªº¦w¥þ©Ê©|¥¼«Ø¥ß¥B¦bÃh¥¥´Á¶¡±µ¨üªvÀø¨Ã¥¼¥X²{ÅãµÛ¦n³B¡C ¤@¥¹Ãh¥¥½T©w®ÉÀ³¥ß§Y¤¤¤î¦¹ÃÄª«ªvÀø¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Niacin - Compatible Lovastatin - Contraindicated [¥é³æ] ¥Ø«e¥¼´¿¦³½wÄÀ¾¯«¬niacin/lovastatin½Æ¤è¿õ¾¯¹ï©ó­÷¨Å¤¤°ü¤kªº¬ã¨s¡C ¦]¬°niacin©Mlovastatinªº¾¯¶q¯à³y¦¨¦å¯×§ïÅÜ¡A¹ï©ó­÷¨Å¤¤ªº­L¨à¦³¼ç¦bªºÄY­«¤£¨}¤ÏÀ³¡A ¦]¦¹·í¥À¿Ë¥¿¦b­÷¨Å®É¤£À³¸ÓªA¥Î½wÄÀ¾¯«¬niacin/lovastatin½Æ¤è¿õ¾¯¡C,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Lovastatin¥[½wÄÀ¾¯«¬Niacin¡A»Ý¾ãÁû§]ªA¤Å©CÄZ¡B­é¥b©Î¿i¯»¡CµLªk§]ªA¯f±w¥i§ï¥Î°|¤º¦P¦¨¥÷¤@¯ë¾¯«¬ÃÄª«¡C
OVES,Ranitidine,VesYCA 150mg,ALIM,,¾AÀ³¯g: Duodenal ulcer¡A benign gastrac ulcer¡A peptic ulcer¡A reflux esophagitis¡A Zollinger-Ellison Syndrome. °Æ§@¥Î: ¡½Gastrointestinal: Abdominal pain¡A Constipation¡A Diarrhea ¡½Neurologic: Headache ¸T§Ò: ¡½hypersensitivity to ranitidine or any of its ingredients,,«Ç·Å,Adult Dosing ¡½Duodenal ulcer disease: 150 mg ORALLY twice daily OR 300 mg once daily after the evening meal or at bedtime¡A Maintenance: 150 mg ORALLY once daily at bedtime ¡½Erosive esophagitis: initial¡A 150 mg ORALLY 4 times daily¡A maintenance¡A 150 mg ORALLY twice daily ¡½Gastric hypersecretion: (oral) 150 mg ORALLY twice daily ¡½Gastric ulcer: 150 mg ORALLY twice daily¡A Maintenance: 150 mg ORALLY once daily at bedtime ¡½Gastroesophageal reflux disease: 150 mg ORALLY twice daily ¡½Indigestion¡A Non-ulcer: (treatment) 75 to 150 mg ORALLY once or twice daily¡A MAX 300 mg/day ¡½Stress ulcer; Prophylaxis: 150 mg NG or ORALLY twice daily ¡½Zollinger-Ellison syndrome: (oral) 150 mg ORALLY twice daily Pediatric Dosing ¡½Duodenal ulcer disease: (1 month to 16 yr) 2 to 4 mg/kg ORALLY twice daily¡A MAX 300 mg/day ¡½Erosive esophagitis: (1 month to 16 years) initial¡A 5 to 10 mg/kg/day ORALLY in 2 divided doses ¡½Gastric ulcer: (1 month to 16 years) 2 to 4 mg/kg ORALLY twice daily¡A MAX 300 mg/day ¡½Gastroesophageal reflux disease: (1 month to 16 yr) 5 to 10 mg/kg/day ORALLY in 2 divided doses ¡½Indigestion¡A Non-ulcer: (treatment) 12 yr of age and older¡A 75 to 150 mg ORALLY once or twice daily¡A MAX 300 mg/day,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ODEXI,Dexlansoprazole,Dexilant delay-release 60mg,ALIM,Treatment of erosive esophagitis (EE) in patients aged 12 and above for up to 8 weeks. Maintenance of healed erosive esophagitis in patients aged 12 and above who have already healed from EE; in adults for up to 6 months¡A and in patients aged 12-17 for up to 16 weeks. Symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD) in patients aged 12 and above for a duration of 4 weeks.,Known hypersensitivity (eg¡A anaphylaxis¡A anaphylactic shock¡A angioedema¡A bronchospasm¡A acute tubulointerstitial nephritis¡A urticaria) to dexlansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine.,Common: Abdominal pain (3.5-5%)¡A Diarrhea (4.7-5.1%)¡A Flatulence (1.4-2.6%)¡A Nausea (2.8-3.3%)¡A Vomiting (1.4-2.2%)¡A Nasopharyngitis (Pediatrics¡A >5%)¡A Pain¡A Oropharyngeal (Pediatrics¡A >5%)¡A Upper respiratory infection (1.7-2.9%) Serious: Cutaneous lupus erythematosus¡A acute generalized exanthematous pustulosis¡A Stevens-Johnson syndrome (SJS)¡A Toxic epidermal necrolysis (TEN)¡A Cobalamin deficiency (Rare)¡A Hypomagnesemia¡A Clostridium difficile diarrhea¡A Fundic gland polyposis of stomach¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms (DRESS)¡A Hypersensitivity reaction (<2%)¡A Systemic lupus erythematosus¡A Fracture of bone (<2%)¡A acute tubulointerstitial nephritis,30¢J¥H¤U,Erosive esophagitis¡A Healing of all grades Age > 12 years-old¡A 60 mg orally once daily for up to 8 weeks. Erosive esophagitis¡A Maintenance of healing - Heartburn 30 mg orally once daily for up to 6 months. Gastroesophageal reflux disease¡A nonerosive 30 mg orally once daily for 4 weeks.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ¡]Child-Pugh¤À¯ÅB¡^ªº±wªÌ¡A¨C¤Ñ³Ì°ª¾¯¶q¬°30 mgªvÀø8¶g¡C ­««×¨x¥\¯à¤£¥þ¡]Child-Pugh¤À¯ÅC¡^ªº±wªÌ¤£«ØÄ³¨Ï¥Î¥»«~,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¨Ã¥¼¦³°w¹ï¥¥°ü¶i¦ædexlansoprazole¸ÕÅç¥H½T»{ÃÄª«¬ÛÃöªº­·ÀI¡Cdexlansoprazole¬OlansoprazoleªºR¦¡Ãè¹³²§ºcª«¡A¦bÃh¥¥´Á¶¡¨Ï¥Îlansoprazoleªº¤wµoªíÆ[¹î©Ê¸ÕÅç¤¤¡A¨Ã¥¼Åã¥Ü¤£¨}Ãh¥¥¬ÛÃöµ²ªG»Plansoprazole¤§¶¡¨ã¦³ÃöÁp©Ê¡C ¦b°Êª«¥Í´Þ¸ÕÅç¤¤¡A©ó¤j¹«¾¹©x§Î¦¨´Á¦Ü­÷¨Å´Á¶¡¤fªAµ¹¤©¤HÅédexlansoprazole³Ì°ª«ØÄ³¾¯¶qªº1.8­¿¡A·|³y¦¨¤l¥Nªº¥X¥Í«á²Ä21¤ÑªÑ°©­«¶q¡BªÑ°©ªø«×¡BÀYÁvªø»P¥ÍªøªO«p«×(¶È¤½¹«)¤U­°¡C³o¨Ç²{¶H»PÅé­«¼W´T´î¤Ö¦³ÃöÁp¡CÀ³¦VÃh¥¥°ü¤k§iª¾¦¹¶µ¹ï­L¨àªº¼ç¦b­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] µLªk±oª¾dexlansoprazole¬O§_·|¥X²{©ó¥À¨Å¤¤¤Î¹ï©ó¥À¨Å­÷¨ÅÀ¦¨à©Î¹ï¨Å¥Ä¤Àªcªº¼vÅT¡C¤£¹L¡A¥i¦b¤j¹«¨Å¥Ä¤¤µo²{lansoprazole¤Î¨ä¥NÁÂª«¡C¬GÀ³¦Ò¼{¥À¨Å­÷¨|¹ïÀ¦¨àµo¨|©M°·±dªº¯q³B¡B­÷¨Å°ü¤k¹ï±o³ß­G³qªºÁ{§É»Ý¨D¡F¥H¤ÎªA¥Î±o³ß­G³q¹ï©ó¥À¨Å­÷¨|ªºÀ¦¨à¥i¯à¦s¦bªº¤£¨}¤ÏÀ³©Î¥ÀÅé¥»¨­ªº°·±d±¡ªp¨Ó¨M©w¬O§_¨Ï¥Î±o³ß­G³q¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½wÄÀ½¦Ån¡A»Ý¾ãÁû§]ªA¡A¤Å«r¸H¡BÀ£¸H¡B­é¥b©Î¿i¯»¡C¼t°Ó´£¨Ñ¤§«ØÄ³:¹ï©ó¤£·|§]½¦Ån¤§±wªÌ¡A¥i¥´¶}½wÄÀ½¦Ån¡A¨Ã±NÃÄ²ÉÅx¦b¤@´ö°ÍÄ«ªGÂæ(ªGªd)¤W¡A¥ß¨è§]ªA¡A¤£¥i©CÄZÃÄ¯»Áû²É¡C¹ï©óºÞÄéªº¯f¤H¡A¥i¥´¶}½wÄÀ½¦Ån¡A¨Ã±NÃÄ¯»Áû²É¥[¤J20 mL§N¶}¤ô¤¤¡A»´·n¨Ã¤Ï©â¦Ü°wµ©¡A¥´¤J»ó­GºÞ¤¤¡C(¤£­n¨ÏÃÄ²É·»¸Ñ)
OSANC,Dipyridamole,Sancin F.C. 50mg,HEMT,Coronary insufficiency¡A Inhibition of platelet aggregation.,Hypersensitivity to dipyridamole or any other product component.,Worsening of angina¡A flushing¡A dizziness¡A palpitations. Lightheadedness¡A headache¡A asthenia¡A hypersensitivity reactions. GI disturbances. Cardiovascular: Electrocardiogram abnormal (15.9%)¡A Hypotension¡A IV (4.6%) Gastrointestinal: Abdominal discomfort¡A Oral (6.1%)¡A Nausea¡A IV (4.6%) Neurologic: Dizziness (12%)¡A Headache¡A IV (12.2%)¡A Headache¡A Oral (2.3%),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,25mg TID on empty stomach.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OASA8,Mesalazine,Asacol 800mg,ALIM,,¾AÀ³¯g:Treatment of moderately active ulcerative colitis °Æ§@¥Î: >10%: Central nervous system: Headache (2% to 35%)¡A pain (?14%) Gastrointestinal: Abdominal pain (1% to 18%)¡A eructation (16%)¡A nausea (3% to 13%) Respiratory: Pharyngitis (11%) ¸T§Ò: U.S. labeling: Hypersensitivity to mesalamine¡A aminosalicylates¡A salicylates¡A or any component of the formulation (including suppository vehicle of vegetable fatty acid esters) Canadian labeling: Hypersensitivity to mesalamine¡A salicylates¡A or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer¡A urinary tract obstruction¡A use in children <2 years of age (Asacol¡A Asacol 800¡A Mesasal¡A Pentasa¡A Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol¡A Asacol 800); renal parenchymal disease (Pentasa),,«Ç·Å,800 mg to 3.2 g in divided doses daily; for severe active disease may increase to 4.8 g daily,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ILEU3,Leuprorelin Acetate,Leuplin Depot 1M inj 3.75mg,RACA,Palliative treatment of prostate cancer¡A treatment of endometriosis¡A treatment of pediatric patients with central precocious puberty¡A anemia (uterine leiomyoma or preoperatively with iron therapy)¡A premenopausal breast cancer.,Hypersensitivity to leuprolide¡A gonadotropin releasing hormone (GnRH)¡A GnRH agonists or any of the excipients in the formulations. Pregnancy. Undiagnosed and abnormal uterine bleeding.,Common: Edema (Adults¡A 8.2-20.8%)¡A Acne (Endometriosis 10%)¡A Flushing (Central precocious puberty¡A 5% ; prostate cancer¡A 52-73.3%)¡A Hyperhidrosis (Central precocious puberty¡A 4%)¡A Injection site disorder (Central precocious puberty¡A 9-78% ; prostate cancer¡A 8.2-37.5%)¡A Injection site pain (Central precocious puberty¡A 19-31% ; prostate cancer¡A 19.2%)¡A Rash (Central precocious puberty¡A 3-7% ; prostate cancer¡A 6%)¡A Serum triglycerides above reference range (Endometriosis¡A 12-32%)¡A Testosterone level above reference range¡A Transient¡A Weight increased (Central precocious puberty¡A 7%)¡A Abdominal pain (Central precocious puberty¡A 9-18%)¡A Constipation (Central precocious puberty¡A 6% ; prostate cancer¡A 9.9%)¡A Nausea (Central precocious puberty¡A 8%)¡A Nausea and vomiting (Central precocious puberty¡A 13% ; endometriosis¡A 13-29%; uterine fibroids¡A 4.8-5%)¡A Vomiting (Central precocious puberty¡A 6%)¡A Anemia (Prostate cancer¡A 2.3-6.6%)¡A Arthralgia (Prostate cancer¡A 9.3%)¡A Arthropathy (Prostate cancer¡A 4.2-16.3%)¡A Backache (Central precocious puberty¡A 7%)¡A Decreased bone mineral density¡A Fracture of bone (Central precocious puberty¡A 4%)¡A Myalgia (Prostate cancer¡A 7.9%)¡A Pain in limb (Central precocious puberty¡A 9%)¡A Sprain of ligament (Central precocious puberty¡A 7%)¡A Asthenia (Prostate cancer¡A 12.2% ; uterine fibroids¡A 8-18%)¡A Dizziness (Endometriosis¡A 11% ; uterine fibroids¡A 1.8%)¡A Headache (Central precocious puberty¡A 2-33% ; endometriosis¡A 32% ; prostate cancer¡A 4.2%)¡A Insomnia (Central precocious puberty¡A 4%)¡A Lethargy¡A Mental disorder (Central precocious puberty¡A 22%)¡A Mood swings (Central precocious puberty¡A 2-5%)¡A Dysuria¡A Atrophy of testis (Prostate cancer¡A 4.4-20.2%)¡A Breast tenderness (4%)¡A Vaginitis (Endometriosis¡A 8-28%; uterine fibroids¡A 11-11.4%)¡A Bronchospasm (Central precocious puberty¡A 6%)¡A Cough (Central precocious puberty¡A 13% prostate cancer¡A 6.6%)¡A Nasopharyngitis (Central precocious puberty¡A 22%)¡A Productive cough (Central precocious puberty¡A 6%)¡A Chest pain (Central precocious puberty¡A 4%)¡A Fever (Central precocious puberty¡A 13-17%)¡A Malaise and fatigue (Prostate cancer¡A 6-17.5%)¡A Pain (Central precocious puberty¡A 3% ; endometriosis¡A 19-29% ; prostate cancer¡A 4.2-32.7% ; uterine fibroids¡A 8-6.1%) Serious: Heart failure (Adults¡A <5%)¡A Myocardial infarction¡A Prolonged QT interval¡A Injury of liver¡A Fracture of vertebral column¡A Pseudotumor cerebri¡A Seizure (Prostate cancer¡A <0.5%)¡A Depression (Up to 5%)¡A Suicidal thoughts¡A Pulmonary embolism,25¢J¥H¤U,[Endometriosis] 3.75 mg subcutaneously once every 4 weeks¡A with the first injection given on days 1-5 of menstruation. Treatment duration is recommended for 6 months. [Uterine fibroids causing excessive menstrual bleeding and anemia¡A scheduled for surgical removal] Recommended treatment duration is up to 3 months. 1.88-3.75mg subcutaneously every 4 weeks¡A with the first injection given on days 1-5 of menstruation. [Prostate cancer and Premenopausal breast cancer] 3.75 mg subcutaneously once every 4 weeks. [Central precocious puberty] For body weight < 20 kg: 1.88-3.75 mg; for body weight >= 20 kg: 3.75-7.5 subcutaneously once every 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,Leuprolide: Contraindicated,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Leuprolide: Contraindicated,SC;,¥H¼t°Ó©Ò²KªþªºÄa¿B¥Î·»¸Ñ²Gµ}ÄÀ,,,,§ë»P Leuplin ®M²Õ®É¡AÀ³±N©Ò¦³®e¶qªºÄa¿B¥Îª`®g·»²G¥H±À¶i¾¹À£¤J¯»¾¯³¡¤À¡A·í¥R¤ÀÄa¿B«á¤~¥iª`®g¡C¨Ï¥Î¥»«~¶·«O«ùª`®g°wÀY´Â¤W¡A¤p¤ß¥H§K²£¥Í®ðªw¡A¦]¨Ï¥Î Leuplin ®M²ÕµLªk½Õ¾ã¾¯¶q¡A©Ò¥HÀ³¨Ï¥Î¦b»Ý­n¤@¦¸¨Ï¥Î§¹¥þ³¡¾¯¶qªº¯f¤H¨­¤W¡C
OCOR5,Ivabradine,Coralan 5mg,CAVS,For adult patients with stable¡A symptomatic chronic heart failure to reduce the risk of hospitalization for worsening heart failure. It should only be used in patients with an ejection fraction of 35% or less who are in sinus rhythm¡A have a resting heart rate of at least 70 beats per minute¡A and are receiving the maximally tolerated beta-blocker dose (or have a contraindication to beta-blocker use),Acute decompensated heart failure; blood pressure <90/50 mm Hg; sick sinus syndrome¡A sinoatrial block¡A or third-degree AV block (unless a functioning demand pacemaker is present); resting heart rate <60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence (heart rate maintained exclusively by the pacemaker); concomitant use with strong CYP3A4 inhibitors.,Cardiovascular: Bradycardia (6% to 10%)¡A hypertension (9%)¡A atrial fibrillation (5% to 8%)¡A heart block¡A sinoatrial arrest Central nervous system: Phosphene (3%) <1% (Limited to important or life-threatening): Angioedema¡A diplopia¡A erythema¡A hypotension¡A pruritus¡A skin rash¡A syncope¡A urticaria¡A vertigo¡A visual impairment.,30¢J¥H¤U,Initial¡A 5 mg orally twice daily with food; after 2 weeks¡A adjust based on heart rate; for resting rate greater than 60 beats per minute (bpm)¡A increase dose by 2.5 mg twice daily; for 50 to 60 bpm¡A continue current dose; for less than 50 bpm or for signs or symptoms of bradycardia¡A decrease dose by 2.5 mg twice daily; Maximum dose: 7.5 mg twice daily.,µL»Ý½Õ¾ã¾¯¶q,¸T¤î¨Ï¥Î©ó­««×¨x¥\¯à¤£¥þ¤§¯f¤H,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ¸T§Ò: Ãh¥¥°ü¤k¡B±Â¨Å°ü¤k¡B¥H¤Î¥¼¨Ï¥Î¾A·íÁ×¥¥±¹¬I¤§¨|ÄÖ°ü¤k¡C ¨|ÄÖ°ü¤k©óªvÀø´Á¶¡À³¨Ï¥Î¾A·íªºÁ×¥¥±¹¬I¡CÃö©óIvabradine¥Î©óÃh¥¥°ü¤kªº¸ê®Æ©|¤£»ô¥þ¡C°Êª«¬ã¨sÅã¥Ü¦³Ác´Þ¬r©Ê¡A­F­L¬r©Ê¤Î­P·î­L§@¥Î¡C¹ï¤HÃþ¥i¯àªº­·ÀI¤´¥¼ª¾¡C¦]¦¹Ivabradine¦bÃh¥¥´Á¶¡¸T¤î¨Ï¥Î¡C ¹ï¤j¹«ªº¬ã¨sÅã¥Ü¹ï¶¯©Ê»P»Û©Êªº¥Í¨|¤OµL¼vÅT¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¸T§Ò: Ãh¥¥°ü¤k¡B±Â¨Å°ü¤k¡B¥H¤Î¥¼¨Ï¥Î¾A·íÁ×¥¥±¹¬I¤§¨|ÄÖ°ü¤k¡C°Êª«¬ã¨s«ü¥XIvabradine·|¤Àªc¨ì¨Å¥Ä¤¤¡C¦]¦¹Ivabradine¸T¥Î©ó±Â¨Å°ü¤k¡C ¥²¶·¥HIvabradineªvÀøªº°ü¤k¤£¥i­÷Áý¥À¨Å¡AÀ³¿ï¾Ü¥H¨ä¥L¤è¦¡¼¾¾i¨ä¤l¤k¡C,PO;WM;,,,,,
OGALM,Vildagliptin + Metformin,GalVUS Met 50/850mg,META,Type 2 diabetes mellitus,A) alcohol intoxication¡A acute¡A or alcoholism B) diabetic ketoacidosis or diabetic pre-coma C) hepatic impairment D) hypersensitivity to vildagliptin¡A metformin hydrochloride¡A or any components of the product E) hypoxic conditions¡A acute or chronic (eg¡A cardiac or respiratory failure¡A recent myocardial infarction¡A shock) F) lactation G) renal failure or renal impairment (CrCl less than 60 mL/min) H) renal function-altering acute conditions (eg¡A dehydration¡A severe infection¡A shock¡A intravascular administration of iodinated contrast agents),Endocrine metabolic: Hypoglycemia (1% to less than 10% ) Gastrointestinal: Nausea (1% to less than 10% ) Neurologic: Dizziness (1% to less than 10% )¡A Headache (1% to less than 10% )¡A Tremor (1% to less than 10% ),30¢JÀx¦s,1 TAB BID¡A not to exceed vildagliptin 100 mg/day or metformin 3000mg/day.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;WM;,,,,,
OAKI2,Biperiden,Akinfree 2mg,CNEU,Parkinsonism.,Narrow-angle glaucoma; mechanical stenoses of the GIT¡A megacolon.,GI disturbances; dry mouth; visual disorders; drowsiness¡A dizziness; fatigue; urinary retention.,25¢J¥H¤UÀx¦s,2mg TID-QID. Maximum: 16 mg/day (MicroMedex).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IONC5,BCG Immunotherapeutic,OncoTICE 2-8¡Ñ10^8 CFU (±M®×¶i¤f),RACA,Bladder cancer¡A Stage Ta and/or T1 papillary tumors following transurethral resection.,1. immunocompromised status including HIV infection (percutaneous and intravesical) 2. urinary tract infection or hematuria (intravesical) 3.acute febrile illness (intravesical) 4. 7 to 14 days following biopsy¡A transurethral resection¡A or traumatic catheterization; increased risk for systemic BCG infection (intravesical) 5. active tuberculosis (intravesical) 6. hypersensitivity to BCG products,Hematuria¡A urinary frequency¡A dysuria¡A bacterial UTI. Local irritative symptoms¡A fever¡A prostatitis¡A ureteral obstruction¡A systemic BCG infection.,2-8¢JÁ×¥ú,TICE BCG: One dose instilled into the bladder (retain for 2 hours) once weekly for 6 weeks (may repeat cycle 1 time) followed by approximately once monthly for at least 6-12 months. Have patient avoid fluid intake for 4 hours prior to treatment and empty bladder prior to instillation. Slowly instill via catheter into the bladder by gravity flow; do not force by depressing plunger. Retain suspension for up to 2 hours¡A repositioning the patient every 15 minutes from left side to right side¡A and supine to prone. After 2 hours¡A have patient void in a seated position. Have patient increase fluid intake to flush bladder; dispose of all urine voided for 6 hours after instillation with an equal volume of household bleach (this should be done for the first 6 hours after therapy). After administration¡A patients should drink plenty of water in order to flush the bladder.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IRR;,¥H1mL N/S°t»s¡A»´»´·n¤Ã,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥H1mL NS°t»s¡A»´»´·n¤Ã¡A¨ú¥X«á¥HNSµ}ÄÀ¦Ü50mL,ONCOTICE (CONTAINING 2-8¡Ñ10^8 CFU TICE BCG) ¬°»H¯ÖÄé¬~¥Î·»²G¡C
IKCL5A,KCl + D5W,¥Ó³ø¥Î¥N½X KCl 10mEq in D5W 250mL,NUTR,,,,,,,,,,,,,,,,,,,
IKCL6A,KCl + D5W,¥Ó³ø¥Î¥N½X KCl 20mEq in D5W 250mL,NUTR,,,,,­p»ù¥Î¤lÂå¥O,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,IVD;,,,,,
IKCL7A,KCl + D5S,¥Ó³ø¥Î¥N½X KCl 20mEq in D5NS 500mL,NUTR,,,,,,,,,,,,,,,,,,,
EPERI,Minocycline,Periocline periodontal oint 10mg/0.5g/syringe,TENT,Adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. May be used as part of a periodontal maintenance program which includes good oral hygiene¡A scaling¡A and root planing.,Known hypersensitivity to minocycline¡A tetracyclines¡A or any component of the formulation; children <8 years of age,>10%: Gastrointestinal: Tooth disorder (12%) 1% to 10%: Central nervous system: Headache (9%)¡A pain (4%) Gastrointestinal: Dental caries (10%)¡A dental pain (10%)¡A gingivitis (9%)¡A mouth ulceration (5%)¡A dyspepsia (4%)¡A mucous membrane disorder (3%) Respiratory: Pharyngitis (4%) Miscellaneous: Infection (8%)¡A flu-like syndrome (5%) Postmarketing and/or case reports: Anaphylaxis¡A angioneurotic edema¡A erythema multiforme (oral minocycline)¡A pruritus¡A rash¡A Stevens-Johnson syndrome (oral minocylcine)¡A swelling of face¡A urticaria,2-8«× §NÂÃ¤ÎÁ×¥ú,Once a week. Adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. May be used as part of a periodontal maintenance program which includes good oral hygiene¡A scaling¡A and root planing.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Up to date: Pregnancy Risk Factor: D Lactation: Enters breast milk/not recommended,,,,,,
OPRI,Dapoxetine,Priligy 30mg (3 tablets/box),SGU,Treatment of premature ejaculation (PE) in men,Hypersensitivity. Significant pathological cardiac conditions eg heart failure (NYHA class II-IV)¡A conduction abnormalities (2nd- or 3rd-degree AV block or sick sinus syndrome) not treated w/ a permanent pacemaker¡A ischemic heart disease¡A valvular disease. Concomitant w/ MAOIs¡A thioridazine¡A selective serotonin re-uptake inhibitors (SSRIs)¡A serotonin-norepinephrine re-uptake inhibitors (SNRIs)¡A TCAs or other medicinal/herbal products w/ serotonergic effects (including recreational drugs)¡A CYP3A4 inhibitors. Moderate & severe hepatic impairment (Child-Pugh class B & C). Childn <18 yr.,Dizziness¡A headache¡A nausea¡A insomnia¡A anxiety¡A agitation¡A restlessness¡A decreased libido¡A abnormal dreams¡A somnolence¡A attention disturbance¡A tremor¡A paraesthesia¡A blurred vision¡A tinnitus¡A flushing¡A sinus congestion¡A yawning¡A GI disturbances¡A hyperhidrosis¡A erectile dysfunction¡A fatigue¡A irritability¡A increased BP,25¢J¥H¤U,30 mg 1-3 hours prior to sexual activity. The recommended dose: 30mg/day.,µL»Ý½Õ¾ã¾¯¶q,¤¤«×¥H¤Î­««×¨x¥\¯à¤£¥þ¯f¤H(Child-Pugh B & C)¸T¤î¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©Î­é¥b¡C¼t°Ó¥çµL¬ÛÃöªº¦w©w©Ê¤ÎÀø®Ä¼Æ¾Ú¡C
OPRO6,Calcium Acetate,Procal 667mg (¾L»Ä¶t),NUTR,Control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption.,Hypercalemia,Hypercalemia¡A nausea¡A constipation¡A allergy reaction,25¢J¥H¤U,Initial dose for the adult dialysis patient is 2 TAB with each meal. The dosage may be increased gradually to bring serum phosphate value below 6 mg/dL¡A as long as hypercalcemia does not develop. Most patient require 3-4 TAB with each meal. 1 TAB contains: 667 mg calcium acetate = 169 mg elemental calcium.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC15;PO;WM;,,,,,Calcium acetate 667 mg = elemental calcium 169 mg = calcium 8.45 mEq = calcium 4.23 mmol
IMEP2,Meropenem,(¬ü¥­)Mepem inj 0.25gm,QANB,Bacterial meningitis: Treatment of bacterial meningitis in pediatric patients 3 months and older caused by Streptococcus pneumoniae¡A Haemophilus influenzae¡A and Neisseria meningitidis Complicated skin and skin structure infections: Treatment of complicated skin and skin structure infections in adults and pediatric patients 3 months and older caused by Staphylococcus aureus (methicillin-susceptible isolates only)¡A Streptococcus pyogenes¡A S. agalactiae¡A viridans group streptococci¡A Enterococcus faecalis (vancomycin-susceptible isolates only)¡A Pseudomonas aeruginosa¡A Escherichia coli¡A Proteus mirabilis¡A Bacteroides fragilis¡A and Peptostreptococcus species Intra-abdominal infections: Treatment of complicated appendicitis and peritonitis in adult and pediatric patients caused by viridans group streptococci¡A E. coli¡A Klebsiella pneumoniae¡A P. aeruginosa¡A B. fragilis¡A B. thetaiotaomicron¡A and Peptostreptococcus species Canadian labeling: Additional indications (not in U.S. labeling): Treatment of lower respiratory tract infections (community-acquired and nosocomial pneumonias)¡A uncomplicated skin and skin structure infections¡A complicated urinary tract infections¡A gynecologic infections (excluding chlamydia)¡A and septicemia; treatment of bacterial meningitis in adults caused by S. pneumoniae¡A H. influenzae¡A and N. meningitidis (use in adult meningitis based on pediatric data),Hypersensitivity to meropenem¡A other drugs in the same class¡A or any component of the formulation; patients who have experienced anaphylactic reactions to beta-lactams,Shock¡A serious renal disorders including acute renal failure¡A serious colitis accompanied with bloody stool¡A pseudomembranous colitis¡A interstitial pneumonia & PIE syndrome. CNS convulsion e.g. seizures¡A consciousness disorders. Lyell syndrome¡A Steven-Johnson syndrome¡A pancytopenia¡A agranulocytosis¡A leucopenia¡A hepatic disorders¡A jaundice¡A rash¡A urticaria¡A feeling of warmth¡A erythema¡A pruritus¡A fever & redness. Granulocytopenia¡A eosinophilia¡A thrombocytopenia or thrombocytosis & lymphocytosis increased GOT/GPT/LDH/A1-P/LAP/£^-GTP/bilirubin/urinary urobilinogen¡A decreased cholinesterase¡A increased urinary £]2-microglobulin/BUN/creatinine¡A abdominal pain¡A diarrhea¡A nausea¡A vomiting & anorexia¡A stomatitis¡A candidiasis¡A vit K deficiency symptoms¡A vit B complex deficiency symptoms¡A headache¡A malaise. Dermatologic: Injection site inflammation (2.4% ) Gastrointestinal: Constipation (1.4% to 7% )¡A Diarrhea (3.5% to 7% )¡A Nausea and vomiting (3.6% adults; 0.8% children ) Neurologic: Headache (2.3% to 7.8% ),25¢J¥H¤U,Adults: 0.5-2 g in 2-3 divided doses IV infused over 30 minutes. Children: 30-120 mg/kg in 2-3 divided doses IV infused over 30 minutes (max. 2 g/day). *****NEONATE ANTIBIOTICS DOSE***** Meropenem: general infection Body weight <1kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20mg/kg Q12H  Age 15-28 day 20 mg/kg Q8H Body weight 1-2kg ge<=7day 20mg/kg Q12H  Age 8-14 day 20 mg/kg Q8H  Age 15-28 day 20 mg/kg Q8H Body weight >2kg Age<=7day 20 mg/kg Q8H  Age 8-14 day 30 mg/kg Q8H  Age 15-28 day 30mg/kg Q8H meningitis Body weight <1kg ge<=7day 40mg/kg Q12H  Age 8-14 day 40mg/kg Q12H  Age 15-28 day 40 mg/kg Q8H Body weight 1-2kg ge<=7day 40mg/kg Q12H  Age 8-14 day 40 mg/kg Q8H  Age 15-28 day 40 mg/kg Q8H Body weight >2kg Age <=7ayd 40 mg/kg Q8H  Age 8-14 d ay 40 mg/kg Q8H  Age 15-28 day 40mg/kg Q8H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,IVD: 5mL N/S,¡iN/S¡j¥i¿ï ¡C,,³q±`0.25g-2g¥Î100mL¥H¤Wªº¥Í²z­¹ÆQ¤ô·»¸Ñ«á¨Ï¥Î¡A§Y2.5-20mg/mL©Î§ó¤p¿@«×¡A«ØÄ³¥H>30¤ÀÄÁ½wºCºwª`¡C,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡Aª`·N¬O§_¦³¦Ù¦×¾_Å¸©ÎÅöíwµo§@¼xª¬¡C 2. µ¹ÃÄ«á²Ä3 ~ 5¤ÑÀ³¯S§OÆ[¹î¥Ö¯lµ¥¤£¨}¤ÏÀ³¡C 3. ·»¸Ñ«áÀ³¥ß§Y¨Ï¥Î¡C¥Hµ¥±i­¹ÆQ¤ô·»¸Ñ«á¡A«Ç·Å25¢J¥i«O¦s6¤p®É¡A5¢J¥i«O¦s24¤p®É¡C¸Ô²Ó¦w©w©Ê¼Æ¾Ú½Ð°Ñ¨£ÃÄª«¥é³æ¡C
IATM,Tr.mucrosquamatus antivenin+Tr.gramineus antivenin,§ÜÀt´ßªá¤Î¨ª§Àì|³D¬r¦å²M,HIMM,,¾AÀ³¯g:Therapy for the bite of Tr. mucrosquamatus and Tr. stejneteri snakes. °Æ§@¥Î:allergic phenomena including anaphylaxis¡A hypotension¡A serum sickness. ¸T§Ò: Hypersensitivity to antivenin.,,2-8¢J,Adult 1 dose.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. µ}ÄÀªk¡G¨úµ}ÄÀ·»²G10 mLª`¤J­á´¹»s¾¯¤¤¡AÁ×§K¥Î¤O®¶·n¡AÀ³©ó2¤p®É¤º¥Î§¹¡C 2. ©y¾¨¦­ª`®g¡A³Q«r¶Ë«á4¤p®É¤ºª`®g³Ì¦³®Ä¡C 3. ª`®g³¡¦ì¡G«r¶Ë®É¶¡¤G¤p®É¤º¡A¥i±N¤@¥b¾¯¶qª`®g¦b«r¶Ë³¡¦ì©P³ò¥Ö¤U¡A¥t¤@¥b«hIV©ÎIM¡C 4. ª`®g³t²v¡GIV: ²Ä1 mL¼Æ¤ÀÄÁª`§¹¡A¥H«á¨C1 mL¤£§Ö©ó¤@¤ÀÄÁ (30-60¤ÀÄÁ¤º¥´§¹)¡CIVD: ¤@¾¯§Ü³D¬r¦å²Mµ}ÄÀ©ó300mL N/S¡C 5. ª`®g¾¯¶q¡G¦¨¤H¬°¤@¾¯¶q¡A10·³¥H¤U¨àµ£¥[­¿¡C¦p¯gª¬Ä~Äò´c¤Æ¹j30¤ÀÄÁ¦Ü¤@¤p®É«á¥i¦A¥´¤@¾¯¡C 6. ³D¬r¦å²M¬°°¨ªº¦å²M»s¾¯¡A¬°¨¾¹L±Ó¤ÏÀ³¡A¥i¥ý°µ¥Ö½§¸ÕÅç¨Ã·Ç³Æ1:1000 Epinephrine³Æ¥Î¡C
OALA,Nifedipine,Alat 10mg,CAVS,Hypertension¡A chronic stable angina pectoris,CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,Initially mild & transient vasodilatation¡A hypotension¡A rarely GI¡A skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established¡A discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia¡A gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )¡A Palpitations (up to 7% )¡A Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )¡A Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough¡A Dyspnea,25¢J¥H¤UÁ×¥ú¥B°®Àê³BÀx¦s,HTN¡A angina 10-20mg TID¡A maximum 180mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°·L²É½¦Ån¡A¥i©î½¦Ån«áªA¥Î¡C¦ý¤£¥i±N½¦Ån¤ºªº·L²É¬ã¿i©ÎÀ£¸H¡CºÞÄé®É«ØÄ³¤À¦¸¨Ï¥Î¡Aª`·NªgÂH¤Î°ô¶ëºÞ¸ô¡C
OLICA,Methimazole,§Q¥Ò Lica 5mg,META,Hyperthyroidism.,Pregnancy¡A lactation.,Skin rash¡A urticaria¡A nausea¡A vomiting¡A epigastric distress¡A hair loss¡A myalgia¡A edema¡A jaundice¡A sialadenopathy¡A lymphadenopathy & much less frequency of inhibition of myelopoiesis.,25¢J¥H¤U,Mild hyperthyroidism 15mg daily¡A moderate hyperthyroidism 30-40 mg daily¡A severe hyperthyroidism 60 mg daily¡A > 60 mg should be taken in 3 divided doses.Maintenance dose 5-15 mg in3 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IJET,Ocriplasmin,Jetrea inj 0.5mg/0.2mL,TOPH,,¾AÀ³¯g:Vitreomacular adhesion: Treatment of symptomatic vitreomacular adhesion (VMA) °Æ§@¥Î: >10%: Ocular: Blurred vision (5% to 20%)¡A conjunctival hemorrhage (5% to 20%)¡A eye pain (5% to 20%)¡A macular hole (5% to 20%)¡A photopsia (5% to 20%)¡A retinal edema (5% to 20%)¡A visual acuity decreased (5% to 20%)¡A visual impairment (5% to 20%)¡A vitreous floaters (5% to 20%) 1% to 10%: Ocular: Intraocular inflammation (7%)¡A anterior chamber cell (2% to 5%)¡A cataract (2% to 5%)¡A conjunctival hyperemia (2% to 5%)¡A dry eyes (2% to 5%)¡A intraocular pressure increased (2% to 5%)¡A iritis (2% to 5%)¡A macular edema (2% to 5%)¡A metamorphopsia (2% to 5%)¡A ocular discomfort (2% to 5%)¡A photophobia (2% to 5%)¡A retinal degeneration (2% to 5%)¡A vitreous detachment (2% to 5%)¡A dyschromatopsia (2%)¡A a-wave and b-wave amplitude decreased (1%) <1% (Limited to important or life-threatening): Lens subluxation (high dose; 0.175 mg)¡A retinal detachment ¸T§Ò:Hypersensitivity to ocriplasmin or any component of the formulation; active or suspected ocular or periocular infections.,,store in -20¢XC,Adult: Vitreomacular adhesion: Intravitreal: 0.125 mg once (as a single dose to the affected eye) Dosing: Renal Impairment There are no dosage adjustments provided in the manufacturer's labeling. However¡A dosage adjustment unlikely due to low systemic absorption.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVI;,,,,,
IKCL8,Potassium Chloride,20mEq KCl in N/S 100mL,NUTR,,¾AÀ³¯g: Hypokalaemia. °Æ§@¥Î: Hyperkalemia¡A pain or phlebitis at injection site. ¸T§Ò: Hyperkalemia.,,2-8«×C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr¡A with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
IMET4,Methylprednisolone,Methylprednisolone inj 40mg,HM,Primarily as an anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of dermatologic¡A endocrine¡A GI¡A hematologic¡A allergic¡A inflammatory¡A neoplastic¡A neurologic¡A ophthalmic¡A renal¡A respiratory¡A and autoimmune origin. Prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation.,Hypersensitivity to methylprednisolone or any component of the formulation; systemic fungal infection; administration of live virus vaccines; methylprednisolone formulations containing benzyl alcohol preservative are contraindicated in premature infants; IM administration in idiopathic thrombocytopenic purpura; intrathecal administration,Common Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin¡A Impaired wound healing Endocrine metabolic: Body fluid retention¡A Decreased body growth¡A Hypernatremia¡A Hypokalemia Gastrointestinal: Disorder of gastrointestinal tract¡A Peptic ulcer disease Hepatic: Liver function tests abnormal (Mild) Immunologic: At risk for infection Musculoskeletal: Muscle weakness Psychiatric: Depression¡A Euphoria Serious Cardiovascular: Cardiac dysrhythmia¡A Congestive heart failure Endocrine metabolic: Adrenal insufficiency¡A Cushing's syndrome¡A Hyperglycemia Hepatic: Hepatotoxicity Musculoskeletal: Osteoporosis Neurologic: Cerebrovascular accident¡A Infarction of spinal cord¡A Nerve injury¡A Paraplegia¡A Raised intracranial pressure¡A Seizure¡A Tetraplegia Ophthalmic: Cataract¡A Cortical blindness¡A Glaucoma Renal: Acute scleroderma renal crisis Respiratory: Pulmonary tuberculosis,25¢J¥H¤U,--Anti-inflammatory or immunosuppressive: IM (sodium succinate): 10 to 80 mg/day once daily IV (sodium succinate): 10 to 40 mg over a period of several minutes and repeated IV or IM at intervals depending on clinical response; when high dosages are needed¡A give 30 mg/kg over a period >=30 minutes and may be repeated every 4 to 6 hours for 48 hours. --Dermatomyositis/polymyositis: IV (sodium succinate): 1 g/day for 3 to 5 days for severe muscle weakness¡A followed by conversion to oral prednisone. --Asthma exacerbations¡A including status asthmaticus (emergency medical care or hospital doses): IV: 40 to 80 mg/day in 1 to 2 divided doses until peak expiratory flow is 70% of predicted or personal best --Acute spinal cord injury: 30 mg/kg IV bolus followed by a continuous infusion of 5.4 mg/kg/hr for 24 hours if treatment is started within 3 hours of the injury or 48 hours if treatment is started between 3 and 8 hours after the injury.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,UpToDate­÷¨Å«ØÄ³:Corticosteroids are excreted in human milk. The manufacturer notes that when used systemically¡A maternal use of corticosteroids have the potential to cause adverse events in a nursing infant (eg¡A growth suppression¡A interfere with endogenous corticosteroid production) and therefore recommends a decision be made whether to discontinue nursing or to discontinue the drug¡A taking into account the importance of treatment to the mother. If there is concern about exposure to the infant¡A some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breast-feeding in order to decrease potential exposure to the nursing infant (based on a study using prednisolone).,IM;IVD;IVP;IVPUSH;,µLµßª`®g¥Î¤ô2mL. ¨Ì¼t°Ó´£¨Ñ¦w©w©Ê¸ê°T¥ç¥i¥Î1mLªº5% glucose¤Î0.9% Sodium Chloride.,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,ª`®g®É¶¡60¬í¦Ü¼Æ¤ÀÄÁ¥H¤W.,30mg/kg¡AÀR¯ßª`®g10-20¤ÀÄÁ.48¤p®É¤º¥i4-6¤p®É­«½Æ¤@¦¸.,1.reconstitute with the accompanying diluent or bacteriostatic water for injection with benzyl alcohol only and use with 48 hours of mixing. 2.IVD:methylPREDNISolone solutions in D5W should be infused within 8 hours of mixing due to stability concerns. adult: high-dose therapy (30 mg/kg)¡A administer IV over at least 30 minutes. adult: (bolus) reconstituted solution may be given via direct IV injection over several minutes without further dilution.
IMV9,Multivitamin,Lyo-Povigen inj 5mL (9ºØ¦¨¥÷),NUTR,,¾AÀ³¯g: Nutritional supplementary for urgent situations induced by surgery¡A severe burns¡A fracture and trauma¡A severe infection¡A and coma. °Æ§@¥Î¡G Cardiovascular: Angioedema¡A edema Central nervous system: Agitation¡A anxiety¡A dizziness¡A headache Dermatologic: Erythema¡A pruritus¡A rash¡A urticaria Ocular: Diplopia Respiratory: Dyspnea¡A wheezing Miscellaneous: Allergic reactions¡A anaphylaxis¡A hypervitaminosis ¸T§Ò¡GHypersensitivity to any component of the formulation; pre-existing hypervitaminosis,,2-8¢J,Adult: I.V. (not for direct infusion¡A solution must be diluted prior to administration): 1-5 mL/day added to TPN or > 500 mL of appropriate solution Each 5 mL reconstituted solution contains:Vitamin A 10¡A000 I.U.¡A Vitamin D2 (Ergocalciferol) 1¡A000 I.U.¡A dl-£\-Tocopheryl Acetate(Vit. E) 5 I.U.¡A Ascorbic Acid (Vit.C) 500mg¡A Thiamine Hydrochloride (Vit.B1) 50mg¡A Riboflavin 10mg¡A Niacinamide 100mg¡A Pyridoxine Hydrochloride (Vit.B6) 15mg¡A d-Panthenol 25mg,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Refer to individual vitamin monographs for requirements while breast-feeding,,,,,,1.¥»¾¯¤ô·»©Êºû¥L©R¸s¸g­áµ²°®Àê¡A§Î¦¨¦h¤Õ©ö·»ªº¦w©w©Êµ²´¹¡C¥t¤@¦wÞÀ¤º«h¬°¯×·»©Êºû¥L©RªºµLµß¤ô·»²G¡A«Y§@­áµ²°®Àê¦¨¤À¤§·»ÄÀ¥Î¡C¨Ï¥Î®É¡A¥ý±N·»ÄÀ²G¾É¤J­áµ²°®Àê²~¤º¡A¤ÏÂÐ»´·n¤£¨Ï¥Í®ðªw¡A§@¦¨§¡¤@·»²G¡C·»¸Ñ«á¤§pH­È¬°2.5-4 2.¥Ñ©ó¥»¾¯§t¦³Thiamine¦¨¤À¡A±Ó·P¯f±w¦³¹L±Ó©Êªº³ø§i¡C 3.¥»¾¯¤£±o¥H¥¼µ}ÄÀ¤è¦¡§ë»P¡A¥i¯à²£¥Í¯t·w¡A©ü­Ë²{¶H¡C
IPRE1,Pneumococcal Vaccine Polyvalent,Prevenar (¬F©²´£¨Ñ¡A13»ùªÍª¢) 0.5mL/dose,HIMM,Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1¡A 3¡A 4¡A 5¡A 6A¡A 6B¡A 7F¡A 9V¡A 14¡A 18C¡A 19A¡A 19F and 23F in infants and children from 2 month-5 years.,Hypersensitivity.,Decreased appetite¡A irritability¡A drowsiness/increased sleep¡A restless sleep/decreased sleep¡A fever¡A inj site erythema¡A induration/swelling or pain/tenderness¡A rash.,2-8¢JÁ×§K§N­á,IM¡A 0.5mL¡A children 2-6 months 3 doses primary immunization at intervals of 1 month (the 1st dose can be given at 6 weeks of age)¡A a booster dose at 12-15 months. 7-11 months 2 doses primary immunization at intervals of 1 month ¡A a booster dose at 12 months. 12-23 months 2 doses at intervals of 2 months. > or = 2 years a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,VACCINE¡A PNEUMOCOCCAL POLYVALENT: Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,VACCINE¡A PNEUMOCOCCAL POLYVALENT: No Human Data¡XProbably Compatible,IM;,,,,,1. À³¥H¦Ù¦×ª`®g¤è¦¡§ë¤©¡A³Ì¦nª`®g¦bÀ¦¨à¤j»L«e¥~°¼ªºªÑ¥~°¼¦Ù¡A©Î¬O¥®µ£¤WÁuªº¤T¨¤¦Ù¡C
OFLUP,Fludiazepam,FluPINE 0.25mg,CNEU,Anxiety¡A insomnia & muscle spasm.,Acute narrow angle glaucoma¡A serious myasthenia,Dependence¡A irritability¡A excitation¡A confusion¡A dizziness¡A dull headache¡A tremor¡A ataxia¡A visual disturbances¡A dizziness on standing up¡A delirium¡A amnesia¡A insomnia¡A vivid dreams¡A dyslalia¡A increased AST/ALT¡A dry mouth¡A anorexia¡A GI discomfort¡A rash¡A pruritus¡A fatigue¡A malaise¡A muscle weakness¡A decreased libido¡A dysuria¡A yawning¡A closed pharynx sensation¡A numbness of tongue & hands¡A diaphoresis¡A slight fever¡A enlarged axillary glands¡A urinary incontinence¡A premenstrual tension¡A alopecia.,25¢J¥H¤Uºò±K®e¾¹,Adult 0.25 mg TID¡A adjusted according to age & symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
ITAXO,Docetaxel,Taxotere inj 20mg/1mL,RACA,Breast cancer¡A non-small cell lung cancer¡A prostate cancer¡A gastric adenocarcinoma¡A head & neck cancer.,Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1¡A500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding,Hematologic reactions especially neutropenia¡A fever¡A hypersensitivity reactions¡A fluid retention¡A GI disturbances¡A cutaneous reactions¡A neurologic symptoms¡A asthenia¡A alopecia. Cardiovascular: Edema (47% to 64.1% )¡A Vasodilatation (27% ) Dermatologic: Alopecia (56.3% to 97.8% )¡A Disorder of nail (11.4% to 18.5% )¡A Disorder of skin AND/OR subcutaneous tissue¡A Nail changes (8.1% to 30.6% )¡A Pruritus¡A Rash Gastrointestinal: Diarrhea (32.8% to 42.6% )¡A Nausea (38.8% to 80.5% )¡A Stomatitis (41.7% to 69.4% )¡A Vomiting (22.3% to 44.5% ) Hematologic: Anemia (89.1% to 93.6% )¡A Leukopenia (95.6% to 98.6% )¡A Neutropenia (71.4% to 99.5% ) Neurologic: Asthenia (61.8% to 80.8% )¡A Neuropathy Reproductive: Amenorrhea (61.7% ) Other: Fever of unknown origin (31.2% to 46.5% ),25¢J¥H¤UÁ×¥ú,[Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL¡Emin; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles¡A followed by radiation therapy.,»Ý½Õ¾ã¾¯¶q,¨Ï¥Î³æ¤@ÃÄª«100 mg / m 2¤§ÃÄª«°Ê¤O¾Ç¸ê®Æ¡AALT©M/©ÎAST¤j©ó¥¿±`½d³ò¤W­­1.5­¿©MÆP©ÊÁC»Ä¤j©ó2.5­¿¡A«ØÄ³¾¯¶q¬°75 mg / m2¡C¦å²MÁx¬õ¯À°ª©ó¥¿±`­È¡A©M/©ÎALT©MAST>¥¿±`­È3.5­¿¥BÆP©ÊÁC»Ä>¥¿±`­È 6­¿±wªÌ¡A¨S¦³´î¶q«ØÄ³¡A°£«D¯S®í±¡ªp¡A§_«h¤£À³¨Ï¥Î¡C¨Ö¥ÎCisplatin©M5-FUªvÀø­GÀù±wªÌ Á{§É¬ã¨s±Æ°£ALT©M/©ÎAST>1.5­¿¥¿±`­È»PÆP©ÊÁC»Ä>2.5¥¿±`­È¡AÁx¬õ¯À>¥¿±`­Èªº±wªÌ¡F¹ï©ó³o¨Ç±wªÌ¡A¨S¦³´î¶q«ØÄ³¡A°£«D¯S®í±¡ªp¡A§_«h¤£À³¨Ï¥Î¡C¥t¤@¤è­±¡A©|µL¨x·l¶Ë±wªÌ¨Ï¥Î¤§¬ã¨s³ø§i¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tPVC¶ì½¦§÷½è¡Cµ¹ÃÄ®ÉÀ³¨Ï¥Î polyethylene §÷½èªº¿é²G®M¡C 3. °t»s¦nªº¿éª`·»²G¿@«×Á×§K¶W¹L 0.74 mg/mL¡A°t¸m¦n6¤p®É¤º¥HÀR¯ß¿éª`¤è¦¡¨Ï¥Î (¥]§t¿éª`®É¶¡)¡A¦b§C©ó25¢J¥H¤Uµ¹¤©¯f±w¡C¨Ï¥Î«eÀ³¦A¦¸¥ØµøÀË¬d¡A­Y¦³¨I¾ýª«©Îµ²´¹À³¤©¥H¥á±ó¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C 5. ºÊ´úCBC¡B¨x¥\¯à¡C
IROP,Ropivacaine,Ropica inj 200mg/20mL,ZANE,Acute pain management: For acute pain management administered as an epidural continuous infusion¡A intermittent bolus (eg¡A postoperative or labor)¡A or local infiltration. Surgical anesthesia: For the production of local or regional anesthesia for surgery administered as an epidural block¡A including cesarean section¡A major nerve block¡A or local infiltration.,Hypersensitivity to ropivacaine¡A amide-type local anesthetics (eg¡A bupivacaine¡A mepivacaine¡A lidocaine)¡A or any component of the formulation,>10%: Cardiovascular: Hypotension (32% to 69%)¡A bradycardia (6% to 20%); Gastrointestinal: Nausea (13% to 25%)¡A vomiting (7% to 12%); Neuromuscular & skeletal: Back pain (4% to 16%) 1% to 10%: Cardiovascular: Chest pain (1% to 5%)¡A hypertension (1% to 5%)¡A tachycardia (1% to 5%); Central nervous system: Headache (5% to 8%)¡A pain (4% to 8%)¡A paresthesia (2% to 6%)¡A dizziness (3%)¡A chills (<=3%)¡A rigors (<=3%)¡A hypoesthesia (2%)¡A anxiety (1%); Dermatologic: Pruritus (1% to 5%); Endocrine & metabolic: Hypokalemia (1% to 5%); Genitourinary: Oliguria (1% to 5%)¡A urinary retention (1% to 5%)¡A urinary tract infection (1% to 5%)¡A disorder of breast milk secretion (1%)¡A poor progression of labor (1%); Hematologic & oncologic: Anemia (6%); Neuromuscular & skeletal: Muscle cramps (1% to 5%); Respiratory: Dyspnea (1% to 5%)¡A rhinitis (1%); Miscellaneous: Fever (2% to 9%)¡A postoperative complication (3% to 7%) <1%¡A postmarketing¡A and/or case reports: Accidental injury¡A agitation¡A amnesia¡A angioedema¡A asthenia¡A atrial fibrillation¡A auditory disturbance¡A blepharoptosis¡A bronchospasm¡A cardiac arrhythmia¡A coma¡A confusion¡A cough¡A deep vein thrombosis¡A drowsiness¡A dyskinesia¡A ECG abnormality¡A emotional lability¡A extrasystoles¡A fecal incontinence¡A hallucination¡A Horner's syndrome¡A hypersensitivity reaction¡A hypokinesia¡A hypomagnesemia¡A hypothermia¡A hypotonia¡A insomnia¡A jaundice¡A malaise¡A myalgia¡A myocardial infarction¡A nervousness¡A neuropathy¡A nightmares¡A orthostatic hypotension¡A pain at injection site¡A paresis¡A phlebitis¡A pulmonary embolism¡A seizure¡A skin rash¡A ST segment changes on ECG¡A stupor¡A syncope¡A tenesmus¡A tinnitus¡A tremor¡A urinary incontinence¡A urination disorder¡A urticaria¡A uterine atony¡A vertigo¡A visual disturbance,25¢J¥H¤UÁ×§K§N­á,Ropivacaine should only be used by¡A or under the supervision¡A of clinicians experienced in regional anaesthesia. Adults and children > 12 years of age: Lumbar epidural administration: Surgery: 15-20 mL of 10% solution (150-200 mg). Cesarean section: 15-20 mL of 7.5% solution (113-150 mg). Thoracic epidural administration: To establish block for post-operative pain relief: 5-15 mL of 7.5% solution (38-113 mg). Field block (minor nerve blocks and infiltration): 1-30 mL of 7.5% solution (7.5-225 mg). For acute pain management: Lumbar epidural administration: Bolus 10-20 mL of 2% solution (20-40 mg). Intermittent injections (top-up): 10-15 mL of 2% solution (20-30 mg)¡A minimum interval 30 minutes. Continuous infusion (labour pain): 6-10 mL/hour of 2% solution (12-20 mg/hour). Postoperative pain management: 6-14 mL/hour of 2% solution (12-28 mg/hour). Thoracic epidural administration: Continuous infusion (postoperative pain management): 6-14 mL/hour of 2% solution (12-28 mg/hour). Field block (minor nerve blocks and infiltration): 1-100 mL of 2% solution (2-200 mg). Post knee arthroscopy pain: Intra-articular¡A 20 mL of 7.5% solution (150 mg).,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¯f±wÀ³¤p¤ß¨Ï¥Î¡A»Ý­«½Æµ¹ÃÄªÌ¦]±Æ°£¸ûºC¡A¥i¯à»Ý­n­°§C¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,INS;IS;LA;SPI;,,¡iN/S¡j¥i¿ï ¡C,,,¥~¬ì³Â¾K¡Gµw½¤¥~ªýÂ_³Â¾K¥H¶i¦æ¥~¬ì¤â³N¡A¥]¬A­å¸¡²£¤Î°Ï°ìªýÂ_¡C «æ©Ê¯kµh³B²z¡G«ùÄò©Êµw½¤¥~¿éª`©Î¶¡·²©Ê¤§¤@¦¸ª`®gµ¹ÃÄ¡A¦p¡G¤â³N«á©Î²£«á¯kµh¡F°Ï°ìªýÂ_¤ÎÃö¸`¤ºª`®g¡C 1¦Ü12·³¨àµ£¤§«æ©Ê¯kµh³B²z¡A­­³æ¤@ª`®g¡G§À³¡¯á´Õµw½¤¥~(Caudal)ªýÂ_¡A¶gÃä¯«¸gªýÂ_¡A¥H¸Ñ°£¤â³N´Á¶¡©Î¤â³N«á¯kµh¡C ¥»«~¶È¨Ñ¦³³Â¾K¸gÅçªºÁ{§ÉÂå¥Í©Î¦b¨ä«ü¾É¤U¨Ï¥Î¡C
OOLM,Olmesartan medoxomil,Olmetec 40mg,CAVS,Hypertension: Treatment of hypertension with or without concurrent use of other antihypertensive agents,Concomitant use with aliskiren in patients with diabetes mellitus Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2),1% to 10%: Central nervous system: Dizziness¡A headache Endocrine & metabolic: Hyperglycemia¡A hypertriglyceridemia Gastrointestinal: Diarrhea Neuromuscular & skeletal: Back pain¡A CPK increased Renal: Hematuria Respiratory: Bronchitis¡A pharyngitis¡A rhinitis¡A sinusitis Miscellaneous: Flu-like syndrome,25¢J¥H¤U,HTN: initial 20mg QD¡A after 2weeks may titrate up to 40mg QD.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] Ãh¥¥°ü¤kªA¥ÎOlmetecR·|¹ï­L¨à³y¦¨¶Ë®`¡C¦bÃh¥¥²Ä2©M²Ä3´Á®É¡A¨Ï¥ÎµÇ¯À-¦åºÞª@À£¯À¨t²ÎªºÃÄª«¨Ï­L¨àµÇ¥\¯à­°§C¤Î¼W¥[­L¨à©M·s¥Í¨à¿©¯f²v»P¦º¤`¡C ¦h¼Æ¬y¦æ¯f¾Ç¬ã¨sÅã¥Ü¡A¦bÃh¥¥²Ä¤@´Á¨Ï¥ÎµÇ¯À-¦åºÞª@À£¯À¨t²ÎÃÄª«ªvÀø°ª¦åÀ£©Ò²£¥Íªº­L¨à²§±`©M¨Ï¥Î¨ä¥LºØÃþªº§Ü°ª¦åÀ£ÃÄª«¨ÃµL¤À§O¡C ¤@¥¹¯f¤H½T©wÃh¥¥¡A»Ý¥ß§YÅý¯f¤H°±¥ÎOlmetecR¡CÃh¥¥´Á¶¡À³¦Ò¼{´À¥N§Ü°ª¦åÀ£ªvÀø¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] µL¬ÛÃö¸ê°TÅã¥Ü¬O§_¤HÃþ¨Å¥Ä¤¤¦s¦bolmesartan¡B¼vÅT­÷¨Å­L¨à©Î¼vÅT¨Å¥Ä²£¥Í¡A¦ýªc¨Å¤j¹«·|¤Àªc§C¿@«×olmesartan¨ì¨Å¥Ä¤¤¡C¦]¬°¨ä¹ï­÷¨Å­L¨à¥i¯à²£¥Íªº°Æ§@¥Î¡AÀ³µû¦ôÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡A¥H¨M©w­n°±¤î­÷¨Å©Î°±¤î¥ÎÃÄ¡C,AC;AC15;PC;PO;WM;,,,,,
ODALP,Flurazepam,Dalpam 30mg,CNEU,,¾AÀ³¯g:Short-term treatment of insomnia °Æ§@¥Î: Cardiovascular: Chest pain¡A flushing¡A hypotension¡A palpitation Central nervous system: Apprehension¡A ataxia¡A confusion¡A depression¡A dizziness¡A drowsiness¡A euphoria¡A faintness¡A falling¡A hallucinations¡A hangover effect¡A headache¡A irritability¡A lightheadedness¡A memory impairment¡A nervousness¡A paradoxical reactions¡A restlessness¡A slurred speech¡A staggering¡A talkativeness Dermatologic: Pruritus¡A rash Gastrointestinal: Appetite increased/decreased¡A bitter taste¡A constipation¡A diarrhea¡A GI pain¡A heartburn¡A nausea¡A salivation increased/excessive¡A upset stomach¡A vomiting¡A weight gain/loss¡A xerostomia Hematologic: Granulocytopenia¡A leukopenia Hepatic: Alkaline phosphatase increased¡A ALT increased¡A AST increased¡A cholestatic jaundice¡A total bilirubin increased Neuromuscular & skeletal: Body/joint pain¡A dysarthria¡A reflex slowing¡A weakness Ocular: Blurred vision¡A burning eyes¡A difficulty focusing Respiratory: Apnea¡A dyspnea Miscellaneous: Diaphoresis¡A drug dependence ¸T§Ò:Hypersensitivity to flurazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma; pregnancy,,«Ç·Å,Dosing: Adult Insomnia (short-term treatment): Oral: 15-30 mg at bedtime Dosing: Geriatric Oral: 15 mg at bedtime. Avoid use if possible.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ICAN,Caspofungin,Cancidas inj 50mg,QANB,,¾AÀ³¯g: Empirical therapy for presumed fungal infections in febrile¡A neutropenic patients. Treatment of invasive candidiasis¡A including candidemia¡A esophageal candidiasis & invasive aspergillosis in patients refractory to or intolerant of other therapies. °Æ§@¥Î: Fever¡A headache¡A chills; nausea¡A diarrhea¡A vomiting; elevated liver enzyme levels; anemia; tachycardia; catheter site pain¡A flushing¡A hypotension; phlebitis/thrombophlebitis¡A infusion-site pruritus; arthralgia; dyspnea; rash¡A pruritus¡A sweating¡A erythema. ¸T§Ò: Hypersensitivity.,,2-8 C,Dosing: Adult Aspergillosis (invasive): I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily. Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression and until lesions have resolved. Salvage treatment with 70 mg once daily (unlabeled dosing) has been reported. Candidemia: I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; generally continue for at least 14 days after the last positive culture or longer if neutropenia warrants. Higher doses (150 mg once daily infused over ~2 hours) compared to the standard adult dosing regimen (50 mg once daily) have not demonstrated additional benefit or toxicity in patients with invasive candidiasis. Esophageal candidiasis: I.V.: 50 mg once daily; continue for 7-14 days after symptom resolution. Note: The majority of patients studied for this indication also had oropharyngeal involvement. Empiric therapy: I.V.: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily; continue until resolution of neutropenia; if fungal infection confirmed¡A continue for a minimum of 14 days (continue for at least 7 days after resolution of both neutropenia and clinical symptoms); if clinical response inadequate¡A may increase up to 70 mg once daily if tolerated¡A but increased efficacy not demonstrated. Dosage adjustment with concomitant use of an enzyme inducer: Patients receiving rifampin: 70 mg caspofungin once daily Patients receiving carbamazepine¡A dexamethasone¡A efavirenz¡A nevirapine¡A or phenytoin (and possibly other enzyme inducers): May require an increased dose of caspofungin 70 mg once daily.,»Ý½Õ¾ã¾¯¶q,»´«×¨x¥\¯à¤£¥þ¦¨¤H±wªÌ(Child-Pughµ¥¯Å¡G5¦Ü6)¤£¶·­n½Õ¾ã¾¯¶q¡C¹ï©ó¤¤«×¨x¥\¯à¤£¥þ¦¨¤H±wªÌ(Child-Pughµ¥¯Å¡G7¦Ü9)¡A®Ú¾ÚÃÄª«°Ê¤O¾Çµ²ªG«ØÄ³±N¨C¤ÑªºCANCIDAS¾¯¶q§ï¬°35²@§J¡C¤£¹L¡A¨Ì¨Ï¥Î«ØÄ³¡A¤´À³©ó²Ä1¤Ñ§ë¤©70²@§Jªº°_©l¾¯¶q¡C©|µLÄY­«¨x¥\¯à¤£¥þ¦¨¤H±wªÌ(Child-Pughµ¥¯Å¡G9¥H¤W)©M¥ô¦óµ{«×¨x¥\¯à¤£¥þ¨àµ£±wªÌªºÁ{§É¨Ï¥Î¸gÅç¡C Mild (Child-Pugh score 5 to 6): No dose adjustment is necessary Moderate (Child-Pugh score 7 to 9): 70 mg IV loading dose on day 1 when a loading dose is recommended (otherwise give 35 mg IV)¡A followed by 35 mg IV once daily,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,10.5mL 0.9%¥Í²z­¹ÆQ¤ô¡AµLµßª`®g¥Î¤ôµ}ÄÀ¦¨5.2mg/mL,¡iH/S¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,
ETIS,Thrombin+calcium chloride+aprotinin+protein clotta,Tisseel solution for sealant 2mL/set,HEMT,,¾AÀ³¯g:Adjunct to hemostasis in cardiopulmonary bypass surgery (including fully heparinized patients) and splenic injury (due to blunt or penetrating trauma to the abdomen) when the control of bleeding by conventional surgical techniques is ineffective or impractical; adjunctive sealant for closure of colostomies. °Æ§@¥Î: May be related to aprotinin contained in some products. Frequency may vary by product. 1% to 10%: Cardiovascular: Bradycardia (?10%) Central nervous system: Fever (6%) Dermatologic: Pruritus (?1%) Gastrointestinal: Abdominal distension (4%) Hematologic & oncologic: Hematoma (Facial rhytidectomy: 1% to 4%)¡A hemorrhage (internal¡A postprocedural; 2%)¡A increased serum fibrinogen (2%) Immunologic: Antibody development (1% to 2%) Local: Skin graft failure (3%) Respiratory: Pulmonary embolism (<1% to 3%) ¸T§Ò:Hypersensitivity to aprotinin; direct intravascular injection; severe or brisk arterial bleeding,,-18¢J¥H¤U§N­á,Dosing: Adult Adjunct to hemostasis: Apply topically in an even Tisseel: Package size to be used is determined by the size of the surface to be covered. Apply in thick layer to completely cover the application area. Maximum area to be sealed: 8 cm2 Required package size of Tisseel: 2 mL Maximum area to be sealed: 16 cm2 Required package size of Tisseel: 4 mL Maximum area to be sealed: 40 cm2 Required package size of Tisseel: 10 mL,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Upper table Pregnancy Risk Factor: C (up to date),,,,,,
IFAM,Famotidine,Famodine inj 20mg/2mL,ALIM,,¾AÀ³¯g: Upper GI hemorrhage¡A Zollinger-Ellison syndrome. °Æ§@¥Î: Infrequently¡A rash; constipation¡A diarrhea; dry mouth¡A nausea. Rarely¡A leukopenia¡A thrombocytopenia; tinnitus¡A increased pulse & BP; reversible mental confusion. Gastrointestinal: Constipation (1.2% )¡A Diarrhea (1.7% ),,,Upper GI hemorrhage¡A Zollinger-Ellison syndrome Adult 20 mg dissolved in 20 mL physiological saline or glucose soln by slow IV. Premed Adult 20 mg dissolved in 1-1.5 mL distilled water for inj IM or dissolved in 20 mL physiological saline or glucose soln by slow IV¡A 1 hr before anesthetization.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,ÃÄ«~¥é³æ: ­÷¨Å¤ÎÃh¥¥¤£«ØÄ³¨Ï¥Î¡C,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,¶·¥H5-10 mL¾A·í·»²Gµ}ÄÀ«á¡A±Àª`®É¶¡¦Ü¤Ö 2 mins,¥[¤J¾A·íµ}ÄÀ²G100mL «á¡A¥H15 ~ 30¤ÀÄÁ½wºCºwª`,I.V. push: Inject over at least 2 minutes. (¥[¤J¾A·íµ}ÄÀ²G5-10mL) Solution for infusion: Administer over 15-30 minutes. (¥[¤J¾A·íµ}ÄÀ²G100mL)
EMYC6,Triamcinolone + Neomycin + Gramicidin + Nystatin,Mycomb ¨Å»I 16gm,TDER,,¾AÀ³¯g: Treatment of inflammatory skin lesions where bacterial or candidal infections are suspected. °Æ§@¥Î: Skin atrophy; ototoxicity; nephrotoxicity. ¸T§Ò: Tuberculous & most viral lesions of skin¡A especially herpes simplex¡A vaccinia¡A varicella.,,«Ç·Å,apply bid or tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;,,,,,
OVALD,Agomelatine,Valdoxan 25mg,CNEU,Treatment for adult patients with major depression and generalized anxiety disorder.,Concomitant use of potent CYP1A2 inhibitors. Hepatic impairment (ie¡A cirrhosis or active liver disease) or transaminase levels greater than 3 times ULN. Hypersensitivity to agomelatine or any component of the product..,Common: Hyperhidrosis (0.1% to <1%)¡A Abdominal pain (1% to <10%)¡A Constipation (1% to <10%)¡A Diarrhea (1% to <10%)¡A Nausea (1% to <10%)¡A Vomiting (1% to <10%)¡A Backache (1% to <10%)¡A Dizziness (1% to <10%)¡A Headache (>=10%)¡A Insomnia (1% to <10%)¡A Migraine (0.1% to <1%)¡A Somnolence (1% to <10%)¡A Anxiety (1% to <10%)¡A Fatigue (1% to <10%) Serious: Hepatitis (0.01% to <0.1%)¡A Jaundice (0.01% to <0.1%)¡A Liver failure (0.01% to <0.1%)¡A Hallucinations (0.01% to <0.1%),30¢J¥H¤U,Generally¡A take 25mg orally before bedtime. Treatment should last at least 6 months to ensure symptom resolution. Dose adjustment: If no improvement¡A increase the dose to 50mg at bedtime. 1) For depression: After 2 weeks of initial treatment. 2) For generalized anxiety disorder: After 4 weeks of initial treatment.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌ¦p:cirrhosis¡A active liver disease¡A or transaminases exceeding 3 times ULN)¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,It is not known whether agomelatine is excreted into human milk. Agomelatine and/or its metabolites were excreted in the milk of lactating rats. There were no adverse effects on offspring following oral administration of agomelatine to rats from prior to mating until weaning¡A with systemic exposures (plasma AUC) of 100-fold human exposure at the maximal recommended clinical dose.The effects of agomelatine on the nursing infant have not been established. If treatment with agomelatine is considered necessary¡A breastfeeding should be discontinued.,AC;AC15;PC;PO;WM;,,,,,
ECIN,Dexamethasone + Neomycin,Cindecason oph oint 3.5gm,TOPH,,¾AÀ³¯g: Non-infectious forms of conjunctivitis¡A keratitis & blepharitis¡A especially of allergic origin¡A inflammation of the anterior uvea¡A scleritis¡A episcleritis & orbital myositis. Sympathetic ophthalmia. °Æ§@¥Î:Glaucoma¡A cataract¡A transient blurred vision. Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin¡A Finding of skin healing¡A Impaired Endocrine metabolic: Cushing's syndrome¡A Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )¡A Raised intraocular pressure (25% ) Psychiatric: Depression¡A Euphoria Respiratory: Pulmonary tuberculosis ¸T§Ò: Herpes cornea superficialis; injuries & ulcerous processes of the cornea; ocular TB; ophth mycosis; ulcerous lesions of the cornea; narrow- & open-angle glaucoma.,,«Ç·Å,Once to several times daily.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IANG,Isosorbide Dinitrate,Angidil inj 0.1% 10mL,CAVS,Treatment of angina.,Severe hypotension¡A hypovolaemia¡A marked anaemia¡A heart failure due to obstruction¡A raised intracranial pressure due to head trauma or cerebral haemorrhage.,Flushing¡A dizziness¡A tachycardia¡A throbbing headache.,25¢J¥H¤U,Diluted in saline or dextrose solution to 100 mcg/mL before use. Usual adult dosage: 2-7 mg/hour by IV infusion; some patients may require up to 10 mg/hour.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IA;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¤@¯ëµ}ÄÀ¿@«×¡G100 mcg/mL¡A¤@¯ë¿éª`³t²v2-7 mg/hr¡A³Ì¤j¿éª`³t²v10 mg/hr¡Aµ¹ÃÄºÞ¸ô»Pµ}ÄÀ·»²GÀ³¨Ï¥Î¡u«DPVC¤§§÷½è¡v¡C,1. ¤@¯ëµ}ÄÀ¿@«×¡G50 mL Angidil 0.1 % ¥H¾A·í·»²Gµ}ÄÀ¦Ü500 mL¡A¨CmL§t¦³100 mcg isosorbide dinitrate¡C 2. µ}ÄÀ®ÉÀ³¨Ï¥Î¬Á¼þ©Î«DPVC¤§µw¶ì½¦§÷½è®e¾¹ªºµ}ÄÀ·»²G¡C 3. ª`®g®É«ØÄ³¨Ï¥Î»E¤A²m(PE)§÷½èªº¿éª`®M©Îµw¶ì½¦§÷½èªº°wµ©À°®ú¡C 4. §ëÃÄ´Á¶¡À³ÄY±KºÊ´ú¯ß·i»P¦åÀ£¡C
IDEP4,Valproate Sodium,Depakine °w¾¯ 400mg,CNEU,Absence seizure¡A Simple and complex. Complex partial epileptic seizure. Manic bipolar I disorder.Migraine; Prophylaxis.Seizure¡A Multiple seizure types.,Hypersensitivity to any component of the formulation.,Cardiovascular: Peripheral edema (3% to 8% ) Dermatologic: Alopecia (6% to 24% )¡A Rash (6% ) Endocrine metabolic: Increased appetite (6% )¡A Weight increased (4% to 9% ) Gastrointestinal: Abdominal pain (9% to 23% )¡A Constipation (5% )¡A Diarrhea (12% to 23% )¡A Indigestion (8% to 13% )¡A Loss of appetite (4% to 12% )¡A Nausea (22% to 48% )¡A Vomiting (11% to 27% ) Hematologic: Ecchymosis (4% to 5% ) Musculoskeletal: Asthenia (10% to 27% )¡A Backache (8% ) Neurologic: Amnesia (4% to 7% )¡A Ataxia (8% )¡A Dizziness (12% to 25% )¡A Headache (5% to 31% )¡A Insomnia (9% to 15% )¡A Somnolence (17% to 30% )¡A Tremor (9% to 57% ) Ophthalmic: Amblyopia¡A Blurred vision¡A Diplopia (16% )¡A Nystagmus (1% to 8% ) Otic: Tinnitus (1% to 7% ) Psychiatric: Depression (4% to 5% )¡A Disturbance in thinking (6% )¡A Feeling nervous (7% to 11% )¡A Mood swings (6% ) Respiratory: Bronchitis (5% )¡A Dyspnea (5% )¡A Pharyngitis (8% )¡A Respiratory tract infection (12% to 20% )¡A Rhinitis (5% ) Other: Fever (2% )¡A Influenza (12% ),30¢J¥H¤U,Seizures unable to use oral form valproic acid: Total daily IV dose should be equivalent to the total daily oral valproate dose (expressed as valproic acid) and divided every 6 hours. Administer each dose as a 60-minute infusion (rate 20 mg/minute). Start intravenous administration 4 to 6 hours after the last oral administration. The original oral dose (usually an average dose of 20 to 30 mg/kg/day) can be administered by drip for 24 hours. To achieve therapeutic levels of valproic acid quickly: initially give 15 mg/kg by a slow intravenous injection (> 5 minutes)¡A followed by 1 mg/kg/hour intravenous continuous infusion¡A and adjust the dose according to target serum level and clinical symptoms.,µL»Ý½Õ¾ã¾¯¶q,Valproic acid should not be administered to patients with hepatic disease or significant hepatic insufficiency,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest low risk,[¥é³æ]Ãh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÄ¼Æ{¯g¡C °£«DÅöíwªvÀø¨S¦³¦X¾Aªº´À¥NÃÄª«¡A§_«hÃh¥¥´Á¶¡¸T¤î¨Ï¥Î valproate ªvÀøÅöíw¡C °£«D¯à½T¹ê°õ¦æÁ×¥¥­pµe¡A§_«h¨ã¥Í¨|¯à¤Oªº°ü¤k¸T¥Î valproate¡C ¨Ï¥Î¥»«~¥i¯à·|¾É­P­«¤jªº¥ý¤Ñ©Ê·î§Î¡A¯S§O¬O¯«¸gºÞ·î§Î¡]¦p¡G¯á¬Wµõ¡A spina bifida¡^¡A ¥B¥i¯à·|¾É­P­L¨à´¼°Ó¤U­°¡A¬G¥»«~À³¶È­­¥Î©óµLªk¥H¨ä¥LÃÄª«±±¨î¯gª¬¡A ©Î¦³¨ä¥¦­ì¦]µLªk¨Ï¥Î¨ä¥LÃÄª«ªvÀø¤§¥¥°ü¡C ¦Ò¶q¨Ï¥Î¥»«~¥i¯à·|¦³¨Ï«Äµ£´¼°Ó­°§C¡Bµo¥Í¯«¸gºÞ¯Ê³´¤Î¨ä¥LÄY­«¥ý¤Ñ©Ê·î§Î¤§­·ÀI¡A ¥B¸Óµ¥­·ÀI¥i¯àµo¥Í©óÃh¥¥¦­´Á¡A¬G°£«D¥²­n¨Ï¥Î¡A§_«h¤£À³¨Ï¥Î©ó¨ã¥Í¨|¯à¤O©Î¦³Ãh¥¥¥i¯à¤§°ü¤k¡C Á×¥¥­pµe¡G Valproate¦³°ª«×ªº­P·î©Ê¡A¥B­L¨à¦b¤l®c¤¤ÃnÅS©óvalproate¦³¾É­P¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº°ª «×­·ÀI¡C ¥»«~¸T¥Î©ó¥H¤U±¡ªp¡G ªvÀøÅöíw ¡E ¦bÃh¥¥ª¬ºA¤U¡A°£«D¨S¦³¾A¦Xªº´À¥NÀøªk ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe ªvÀøÄ¼Æ{¯g ¡E ¦bÃh¥¥ª¬ºA¤U ¡E ¨ã¦³¥Í¨|¯à¤Oªº°ü¤k¡A°£«D¯à½T¹ê¼i¦æÁ×¥¥­pµe Á×¥¥­pµe±ø¥ó¡G ³B¤èÂå®vÀ³½T«O ¡E ¨Ì¯f¤H­Ó§Oª¬ªp¶i¦æµû¦ô¨Ã»P¤§°Q½×¡C³o¬O¬°¤F«OÃÒ¯f¤H¯à½T¹ê°t¦X¨Ã¤F¸ÑªvÀø¿ï¾Ü¤Î¨ä­·ÀI¡A ¥H¤Î¬°¤F­°§C­·ÀI¦Ó±Ä¨úªº±¹¬I¡C ¡E ©Ò¦³¤k©Ê¯f¤H³£À³°w¹ïÃh¥¥ªº¥i¯à©Ê¶i¦æµû¦ô¡C ¡E ¯f¤HÀ³¤F¸Ñ¨Ã»{ª¾¥ý¤Ñ©Ê·î§Î©M¯«¸gµo¨|¯Ê³´ªº­·ÀI¡A¥]¬A­L¨à¦b¤l®c¤¤ÃnÅS©óvalproateªº­·ÀIµ{«×¡C ¡E ¯f¤HÀ³¤F¸Ñ¡AªvÀø«e¤ÎªvÀø´Á¶¡(¥²­n®É)¥²¶·¶i¦æÃh¥¥ÀË´ú¡C ¡E À³§i¶D¯f¤H¥²¶·Á×¥¥¡A¥B¯f¤H¦b¾ã­ÓvalproateªvÀø´Á¶¡¥²¶·¤£¶¡Â_¦a±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I ¡E ¯f¤HÀ³¤F¸Ñ¡AÅý¦³Åöíw©ÎÄ¼Æ{¯gªvÀø¸gÅçªº±M¬ìÂå®v©w´Á(¦Ü¤Ö¨C¦~¤@¦¸)µû¦ôªvÀøµ²ªG¦³¨ä¥²­n©Ê¡C ¡E ¤k©Ê¯f¤HÀ³¤F¸Ñ¡A·í¨ä­pµeÃh¥¥®É¡AÀ³ºÉ§Ö¿Ô¸ßÂå®v¡A¥H½T«O¯à¤Î®É°Q½×¨Ã¦bÃh¥¥«e¤Î°±¤îÁ×¥¥«e§ó´«ªvÀøÃÄª«¡C ¡E ¯f¤HÀ³¤F¸Ñ¡A·íµo²{Ãh¥¥®ÉÀ³ºò«æ³qª¾Âå®v¡C ¡E ¯f¤H¤w¦¬¨ì¯f¤H¥ÎÃÄ«ü«n¡C ¡E ¤k©Ê¯f¤H¤w½T»{¤F¸Ñ¡A¨Ï¥Îvalproate¤§¬ÛÃö­·ÀI©MÀ³ª`·N¨Æ¶µ (¦~«×­·ÀI½T»{ªí)¡C ³o¨Ç±ø¥ó¥ç¾A¥Î©ó¥Ø«eµL©Ê¦æ¬°ªº°ü¤k¡A°£«D³B¤èÂå®v¥R¤À¤§²z¥Ñ»{¬°¨äµLÃh¥¥­·ÀI¡C ÃÄ®v©Î¨ä¥LÂåÀø±M·~¤H­ûÀ³½T«O ¡E ¨C¦¸½Õ°tvalproate®É³£¦³¥æ¥I¯f¤H¥d¡AÅý¯f¤H¤F¸Ñ¨ä¤º®e¡C ¡E §iª¾¯f¤H·í­pµeÃh¥¥©ÎºÃ¦üÃh¥¥®É¡Avalproate¤£À³¾Õ¦Û°±ÃÄ¡AÀ³¥ß¨è³sµ¸±M¬ìÂå®v¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]valproate ¤Àªc¨ì¨Å¥Ä¤¤ªº¶q«Ü§C¡A¿@«×¤j¬ù¬O¥ÀÅé¦å²M¿@«×ªº 1%¦Ü 10%¤§¶¡¡C ®Ú¾Ú¤åÄm©MÁ{§É¸gÅç¡A­Y­n­÷¨Å¡A»Ý¦Ò¼{¥»«~ÃÄª«¦w¥þ©Ê¡A¯S§O¬O¦å²G¬ÛÃöªº¯e¯f¡C µM¦Ó¡AÃh¥¥´Á¶¡¼ÉÅS©ó sodium valproate ªº¥®¨à¡A¥i¯à­°§C»y¨¥¯à¤O¡A«ØÄ³ªvÀø®É¤£­n±Â¨Å¡C,IVD;,±N4²@¤Éª`®g¥Î¤ôª`¤J¤p²~¤¤¡AÃÄ¯»·»¸Ñ«á¦A¨ú¥X©Ò»Ý¾¯¶q¥[¤JÂIºw¤¤¡C,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,ª`®g³t²v < 20mg/min;¥ý15mg/kg slow IV >5mins¡A ¦A1mg/kg/hr,¨Ï¥Î«eÀ³¥ý½Õ¾¯¡A±N4²@¤Éª`®g¥Î¤ôª`¤J¤p²~¤¤¡AÃÄ¯»·»¸Ñ«á¦A¨ú¥X©Ò»Ý¾¯¶q¥[¤JÂIºw¤¤¡C
IKCL5,Potassium Chloride,10mEq KCl in 5% Glucose 250mL,NUTR,,¾AÀ³¯g: Hypokalaemia. °Æ§@¥Î: Hyperkalemia¡A pain or phlebitis at injection site. ¸T§Ò: Hyperkalemia.,,2-8«×C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr¡A with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
IFYT,Etoposide,Fytosid inj 100mg/5mL,RACA,Small cell carcinoma of lung¡A In combination with other approved chemotherapeutic agents as first line¡A Testicular cancer¡A In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical¡A chemotherapeutic¡A and radiotherapeutic therapy,Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment,Alopecia¡A Shivering¡A Diarrhea¡A Inflammatory disease of mucous membrane¡A Loss of appetite¡A Nausea¡A Vomiting¡A Asthenia¡A Fever¡A Malaise,25¢J¥H¤UÁ×¥ú,[Testicular cancer (combination chemotherapy)] Usual dose ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1¡A 3 and 5. [Small cell lung cancer (combination chemotherapy)] Usual dose ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,µ¹ÃÄ¿@«× 0.2-0.4mg/ml (Max 0.4mg/ml) ; «ØÄ³¥H30 ~ 60¤ÀÄÁ½wºCºwª`,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.2 - 0.4 mg/mL¡A¨Ï¥Î«eÀ³¦A¦¸¥ØµøÀË¬d¬O§_¦³Áû²É¨I¾ý©ÎÅÜ¦â¡C 3. ¿éª`¹L§Ö¥i¯àµo¥Í§C¦åÀ£¡C 4. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
OALGI,Alginic Acid+Colloidal Al(OH)3+MgHCO3,Algitab chewable,ALIM,Reflux esophagitis¡A hiatal hernia¡A heartburn¡A peptic ulcer¡A gastric hyperacidity.,Hypersensitivity to any component of the formulation.,Diarrhea¡A constipation.,¸m©ó25¢J³±²D³B©Ò¡AÁ×§K¶§¥úª½®g,usual dose: 2 TAB TID. (Each tablet contains Sodium 0.4mEq),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;P1;P2;P3;P4;PC;PO;WM;,,,,,
ICAL,Calcitriol,Calcijex inj 2mcg/1mL,META,,¾AÀ³¯g¡G Management of hypocalcemia in patients undergoing chronic renal dialysis. °Æ§@¥Î¡G Weakness¡A headache¡A somnolence; nausea¡A vomiting¡A dry mouth¡A constipation; muscle pain¡A bone pain & metallic taste. ¸T§Ò¡G Hypercalcemia or evidence of vit D toxicity.,,«Ç·Å,Initially 0.5 mcg (0.01 mcg/kg) administered 3 times wkly¡A approx every other day. Dose may be increased by 0.25 ~ 0.5 mcg at 2 ~ 4 wk intervals.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
I5FU,5-Fluorouracil,5-FU inj 1000mg/20mL,RACA,,¾AÀ³¯g: Palliative management of carcinoma of the colon¡A rectum¡A breast¡A stomach & pancreas. °Æ§@¥Î: Stomatitis¡A esophagopharyngitis¡A diarrhea¡A anorexia¡A nausea¡A vomiting¡A enteritis¡A cramps¡A abdominal pain & ulceration¡A glossitis¡A pharyngitis¡A leukopenia¡A alopecia¡A dermatitis¡A ocular irritation¡A central neurotoxicity (acute cerebellar syndrome)¡A myocardial ischemia & angina. ¸T§Ò: Patients in a poor nutritional state; with depressed bone marrow function or potentially serious infections.,,RT,IV inj Initial dosage 12 mg/kg once daily (to a max of 800 mg daily) for 4 days. If no toxicity is observed¡A this may be followed by 6 mg/kg on the 6th¡A 8th¡A 10th & 12th days¡A unless toxicity occurs. Poor risk patients or those in a poor nutritional state 6 mg/kg/day (to a max of 400 mg daily) for 3 days. If no toxicity is observed¡A 3 mg/kg is given on the 5th¡A 7th & 9th days¡A unless toxicity occurs. Maintenance therapy Repeat the dosage of the 1st course every 30 days after the last day of the previous course of treatment. Alternatively¡A administer a maintenance dose of 10-15 mg/kg/week (to a max of 1 g/week) as a single dose. IV infusion 15 mg/kg/day (to a max of 1 g daily) being infused in 500 mL of 5% dextrose or 0.9% NaCl over 4 hours & repeated on successive days until toxicity occurs or a total of 12-15 g has been given. Continuous infusion may also be used. The course may be repeated after 4-6 weeks.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¦å¿}ÅÜ¤Æ (DM¯f¤H)¡C
ICAG,Calcium gluconate,Calglon inj 10% 10mL,NUTR,Ca deficiency.,Ventricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),Cardiovascular (with rapid I.V. injection): Arrhythmia¡A bradycardia¡A cardiac arrest¡A hypotension¡A syncope¡A vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection),30¢J¥H¤U,Each mL contains: 100 mg calcium gluconate= 9.3 mg (0.465 mEq) of elemental calcium. Adult: The usual dose is 10 mL of Calcium Gluconate 10 % each time a day or every other day. Childen patients: 2~5 mL of Calcium Gluconate 10 % each time. [UpToDate 20210731] Cardiac arrest or cardiotoxicity in the presence of hyperkalemia¡A hypocalcemia¡A or hypermagnesemia: IV: 1.5 to 3 g over 2 to 5 minutes (Vanden Hoek 2010). Hypocalcemia: IV: Mild (ionized calcium: 4 to 5 mg/dL [1 to 1.2 mmol/L]): 1 to 2 g over 2 hours; asymptomatic patients may be given oral calcium (Ariyan 2004; French 2012). Moderate to severe (without seizure or tetany; ionized calcium: <4 mg/dL [<1 mmol/L]): 4 g over 4 hours (French 2012). Severe symptomatic (eg¡A seizure¡A tetany): 1 to 2 g over 10 minutes; repeat every 60 minutes until symptoms resolve (French 2012).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;PO;,,¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,Slow IV < 1.8mEq/min (< 2 mL/min)¡A±Àª`®É¶¡¦Ü¤Ö 3-5 ¤ÀÄÁ ; ¦bcardiac arrest ±¡ªp¤U over 10-20 seconds,µ}ÄÀ¦Ü50 mg/mL«á¡A¥H120-240 mg/kg (0.6-1.2mEq calcium/kg) ¿éª` > 1 hour,1. ¶t§t¶q0.46 mEq/mL 2. I.V.: infuse slow IVP over 3-5 minutes or at a maximum rate of 50-100 mg calcium gluconate/minute; in situations of cardiac arrest¡A calcium gluconate may be administered over 10-20 seconds. 3. I.V. infusion: Dilute to 50 mg/mL and infuse at 120-240 mg/kg (0.6-1.2mEq calcium/kg) over 1 hour 4.¤£¥i I.M. ©ÎSubQ µ¹ÃÄ¡AIVª`®g¤£¥i¥~º¯¡A¥H§Kµo¥ÍÄY­«²ÕÂ´Ãa¦º©Î²æ®h¡C 5.­YÃÄ²G¤º¥X²{µ²´¹¨I¾ý¡A«ØÄ³¥i¥H¬IÀ£»s«~®e¾¹¡AÀËµø»s«~¬O§_º|²G¡A¥X²{º|²G®É¡A¤£À³¨Ï¥Î¡C­YµLº|²G²{¶H¡A¥i¯à¦]·Å«×ÅÜ¤Æ©Î¬O¦]¹B°e¹Lµ{¤¤¡A²~¤º²£¥Íªº®ðªw¡Aºc¦¨´¹®Ö¡A¶i¦ÓªR¥Xµ²´¹¨I¾ý¡C¦¹®É¥i¸m©ó65¢J¤ô¯D¤º¶i¦æ·Å¼ö¡A¨Ïµ²´¹·»¸Ñ¡AÃÄ²G¼á²M«á¡A¤è¥i¦w¤ß¨Ï¥Î¡C(20211126¼t°Ó«ØÄ³)
ICAR1,Carboplatin,Carboplatin inj 150mg/15mL,RACA,,¾AÀ³¯g: Treatment of advanced ovarian carcinoma in combination with other chemotherapeutic agents. Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy¡A including patients who have previously been treated with cisplatin. Metastatic small cell carcinoma of the lung. °Æ§@¥Î: Myelosuppression especially thrombocytopenia¡A leukopenia; nausea & vomiting¡A abdominal pain¡A diarrhea¡A constipation; nephrotoxicity; neurotoxicity including paresthesia & decreased deep tendon reflexes; transient visual disturbances¡A ototoxicity manifesting as tinnitus; abnormal liver function tests; hypersensitivity reactions. ¸T§Ò: Severe bone marrow suppression or significant bleeding; severe pre-existing renal impairment (creatinine clearance <=20 mL/min).,,«Ç·Å,Advanced ovarian carcinoma Initial treatment: 300 mg/m2 IV on day 1 at 4-week intervals for 6 cycles. Secondary treatment: 360 mg/m2 IV on day 1 at 4-week intervals. Metastatic small cell carcinoma of the lung 400 mg/m2 IV over 15-60 mins at 4-week intervals.,,,,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,«Ç·Å¡A°t»s«á¦w©w©Ê«Ç·Å8¤p®É
ECOL2,Mesalazine,Colasa enema 2gm/100mL,ALIM,Treatment of active mild to moderate distal ulcerative colitis¡A proctosigmoiditis¡A or proctitis,Hypersensitivity to mesalazine or any component in the preparation. History of hypersensitivity to salicylate preparations. Severe liver impairment. Severe renal impairment (GFR less than 30 ml/minute/1.73m2).,Nausea¡A diarrhea¡A abdominal pain¡A headache,25¢J¥H¤UÀx¦s,Adults: 2gm-4gm once at night. Children: Dose is not determined.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]ÄY­«¨x·l¶Ë¸T¥Î¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,upper table (According to up to date of Pregnancy Risk Factor),RECT;,,,,,
OBUSR,Buspirone,Busron 10mg,CNEU,Anxiety.,Epilepsy¡A severe hepatic or renal impairment¡A pregnancy & lactation. Breast feeding.,Dizziness¡A nausea¡A headache¡A nervousness¡A lightheadedness¡A excitement; rarely tachycardia¡A palpitations¡A chest pain¡A drowsiness¡A tinnitus. Gastrointestinal: Nausea (3%) Neurologic: Asthenia (2%)¡A Confusion (2%)¡A Dizziness (9%)¡A Excitement (2%)¡A Headache (3%)¡A Numbness (2%) Ophthalmic: Blurred vision (2%) Psychiatric: Feeling angry (2%)¡A Feeling nervous (4%)¡A Hostile behavior (2%),«Ç·Å¤UÀx¦s¡AÁ×§K¼ÉÅS©ó°ª©ó40¢J¤§¤U¡CÁ×§K¶§¥úª½®g,Initial dose:15mg/day(5mg TID). If needed¡A increased by 5mg/day every 2~3 days. General dose:20-30mg/day in divided doses. maximum dose: 60mg/day.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,Limited Human Data¡XAnimal Data Suggest Low Risk,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IRL,NaCl + KCl + Calcium Chloride + Lactose,Ringer Lactate 500mL,MSIV,¬°¹q¸Ñ½è¸É¥R²G(A002801277),,,«Ç·Å,Each time 500-1000 mL or 20-30 mL/kg IV infusion. [UpToDate 20210731] Irrigation: Dose dependent on area to be irrigated and the procedure. Septic shock or sepsis-induced hypoperfusion¡A fluid resuscitation (off-label use): IV: Minimum of 30 mL/kg to be given within the first 1 hour of identification of sepsis for initial resuscitation; following initial resuscitation¡A additional fluid administration guided by frequent reassessment of hemodynamic status.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
ITT1,Electrolytes + Water,¥x¤j No.1 500mL,MSIV,Supplement of water¡B electrolytes ¡B nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30¢J¥H¤U,Central vein or peripheral vein infusion¡A as needed. Taita No.1: Na 25mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 20mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 38g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.2: Na 40mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 26mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 33g/L¡A 500mL/Bot¡A 287mOsm/L. Taita No.3: Na 75mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 61mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 20g/L¡A 500mL/Bot¡A 285mOsm/L. Taita No.4: Na 110mEq/L¡A K 20mEq/L¡A Mg 0mEq/L¡A Cl 102mEq/L¡A Acetate 16mEq/L¡A Phosphate 12mM/L¡A Glucose 8g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.5: Na 36mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 17mEq/L¡A Acetate 28mEq/L¡A Phosphate 12mM/L¡A Glucose 100g/L¡A 400mL/Bot¡A 669mOsm/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¯SÂI¤Î¾AÀ³¯g Taita No.1: Na¡BCl ¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì§C¡F¤p¨à¥Îºû«ù²G¡B¹q¸Ñ½è¡B¤ô¥÷¡B¾i¥÷¸É¥R Taita No.2: ¦¨¤À»PTaita No.1¬Û¦ü¦ýNa¡BCl¸û¦h;¼ö¶q¤ÎK§t¶q¸û§C¡A¥i§@¬°¤p¨à©Î¦¨¤H¥Îºû«ù²G Taita No.3: NaCl§t¶q¦ü0.45 %N/S¡A¥i¥Î©óµ¥±i©Ê²æ¤ô¡B¿}§¿¯f©Ê»Ä¤¤¬r Taita No.4: Na¡BK¡BCl¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì°ª¡A¥i¥Î©ó§C±i©Ê²æ¤ô¡B§CÁC¦å¯g Taita No.5: ¥x¤j¹q¸Ñ½è¿é²G¨t¦C¤¤¡A§tAcetate¤Î¼ö¶q³Ì°ª¡A¥i¥Î©ó°ª¼ö¶q¹q¸Ñ½è¸É¥R²G¡B§CÁC¦å¯g
OPYR,Pyridoxine,Pyridoxine (B6) 50mg,NUTR,Prevention & treatment of vit B6 deficiency.,Hypersensitivity.,Severe peripheral neuropathies (long-term administration of large doses).,«Ç·Å¥BÁ×¥ú«O¦s,50-100 mg/day. [Micromedex 20210731] Adverse reaction to drug - Vitamin B6 deficiency: (deficiency due to isoniazid) 100 mg/day IV or IM for 3 weeks¡A followed by 30 mg/day ORAL maintenance dose. [UpToDate 20210731] Nausea and vomiting of pregnancy (off-label use): Oral: 10 to 25 mg 3 to 4 times a day. May be given alone or in combination with doxylamine. Adjust dose based on severity of symptoms (ACOG 189 2018).,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OEND,Cyclophosphamide,Endoxan 50mg,RACA,Treatment of acute lymphoblastic leukemia (ALL)¡A acute myelocytic leukemia (AML)¡A breast cancer¡A chronic lymphocytic leukemia (CLL)¡A chronic myeloid leukemia (CML)¡A Hodgkin lymphoma¡A mycosis fungoides¡A multiple myeloma¡A neuroblastoma¡A non-Hodgkin lymphomas (including Burkitt lymphoma)¡A ovarian adenocarcinoma¡A retinoblastoma¡A and nephrotic syndrome.,Hypersensitivity to cyclophosphamide or its metabolites¡A urinary outflow obstructions¡A severe myelosuppression¡A severe renal or hepatic impairment¡A active infection (especially varicella zoster)¡A severe immunosuppression.,Nausea¡A vomiting; bone marrow depression¡A leukopenia; alopecia; mucosal ulceration; pigmentation; interstitial pulmonary fibrosis; fluid retention,25¢J¥H¤U,For continuous therapy 1-4 tablets (50-200 mg) daily; if necessary¡A more tablets may be taken. The dose recommendations given mainly apply to the treatment with cyclophosphamide as a monotherapy. In combination with other cytostatics of similar toxicity¡A a dose reduction or extension of the therapy-free intervals may be necessary.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ±wªÌ¶·­°§C¾¯¶q¡A¦å²MÁx¬õ¯À­È 3.1 - 5 mg/100mlªÌ¡A­°§C25%ªº¾¯¶q,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
IPEDE,Ibuprofen,Pedea inj 10mg/2mL (±M®×¶i¤f),CNEU,Treatment of Patent Ductus Arteriosus (PDA) in premature neonates (>34 weeks' gestational age),for Pedea: untreated infection¡A bleeding¡A thrombocytopenia; coagulation defects¡A necrotizing enterocolitis¡A renal impairment¡A congenital heart disease if patency of the ductus arteriosus is necessary for pulmonary or systemic blood flow (e.g.¡A pulmonary atresia¡A severe tetralogy of Fallot¡A severe coarctation of the aorta).,For Pedea sepsis¡A anemia¡A bleeding¡A apnea¡A adverse GI effects¡A renal impairment¡A respiratory tract infection¡A dermatologic effects¡A hypoglycemia¡A hypocalcemia¡A respiratory failure. Cardiovascular: Hypotension (intravenous¡A up to 10% ) Dermatologic: Rash (oral¡A 3% to 9% ) Endocrine metabolic: Hypernatremia (intravenous¡A up to 10% )¡A Hypoalbuminemia (intravenous¡A 3% to 10% )¡A Hypoproteinemia (intravenous¡A up to 13% )¡A Serum lactate dehydrogenase level elevated (intravenous¡A 3% to 10% ) Gastrointestinal: Flatulence (injection¡A 7% to 16% )¡A Heartburn (oral¡A 3% to 9% )¡A Nausea (oral¡A 3% to 9%; intravenous¡A 53% to 57% )¡A Vomiting (oral¡A 1% to 3%; intravenous¡A 15% to 22% ) Hematologic: Thrombocytosis (intravenous¡A 3% to 10% ) Immunologic: Bacteremia (injection¡A 13% ) Neurologic: Dizziness (oral¡A 3% to 9%; intravenous 4% to 6% )¡A Headache (oral¡A 1% to 3%; intravenous¡A 9% to 11% ) Renal: Serum blood urea nitrogen raised (intravenous¡A up to 10% )¡A Urinary retention (intravenous¡A 3% to 5% ) Respiratory: Bacterial pneumonia (intravenous¡A 3% to 10% ),¥é³æµL¯S§O«ü¥Ü,Micromedex: Patent ductus arteriosus (PDA): 10 mg/kg/dose IV followed by 5 mg/kg at 24 and 48 hours after treatment initiation.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 1st and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¿éª`®É¶¡¦Ü¤Ö 15¤ÀÄÁ,Pedea should be administered as a short infusion over 15 minutes¡A preferably undiluted. To facilitate the administration an infusion pump may be used.
OBIO3,Calcium + Cholecalciferol,Bio-Cal plus 450mg/330IU,NUTR,Osteoporosis¡A Ca deficiency.,Hypercalcemia.,itch¡A rash¡A Nausea¡A vomiting¡A diarrhea¡A constipation,25¢J¥H¤U,2-3 TAB daily. 1 TAB contains: Tribasic calcium phosphate equivalent to calcium 450 mg¡A and Cholecalciferol 330 IU.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,1. ¥»«~¤@Áû¿õ¾¯§t¶qTribasic calcium phosphate 1203mg + Cholecalciferol 330IU 2. Tribasic calcium phosphate 1203mg= Calcium 450mg
OFOSP,Alendronate + Colecalciferol,Fosamax Plus 70mg/5600IU,META,,¾AÀ³¯g:Treatment of osteoporosis in postmenopausal women to increase bone mass & reduce incidence of fractures¡A including those of the hip & spine (vertebral compression fractures). Treatment of osteoporosis in men to increase bone mass. °Æ§@¥Î: Nausea¡A vomiting¡A black &/or bloody stool¡A oesophagitis¡A oesophageal ulcer¡A oesophageal erosions. ¸T§Ò: Hypersensitivity. Abnormalities of the oesophagus eg stricture or achalasia. Inability to stand or sit upright for at least 30 min. Hypocalcaemia.,,«Ç·Å,1 tab once weekly.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,ªAÃÄ«á¡A¤W¥b¨­»Ýª½¥ß30¤ÀÄÁ¥H¤W¡C
ICERE,Cerebrolysin concentrate,Cerebrolysin 215.2mg/mL¡A 10mL,NUTR,Amino acid supplement for disturbances of protein digestion & malabsorption due to disorders¡A heavy protein loss due to wounds¡A burns¡A fractures¡A purulency or operation..,Severe renal impairment,Hypersensitivity reactions.,µL¯S§O«ü¥Ü,Initial IV/IM 2 mL/day¡A then extended interval to 2mL in 2-3 days. High dose: 5-40 mL/day slow IV or IV infusion. A treatment cycles needs 10-15 AMP¡A may take a series of cycles.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IM;IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,1.«ØÄ³¥H60 ~ 120¤ÀÄÁ½wºCºwª` 2.10ml - 50ml Cerebrolysin diluted to at least 100ml total volume with Saline¡A Ringer solution or 5% glucose solution. Infuse within 15 minutes. [202004¬d¸ß¼t°Ó°ê¥~©xºôhttps://www.cerebrolysin.com/en/cerebrolysin/administration.html],
IFOLI,Folinate,Folina °w¾¯100mg/10mL,ZADT,Megaloblastic anemia due to folic acid deficiency¡A Intoxication & side-effects of folic acid antagonists¡A associated with high-dose methotrexate.,Hypersensitivity. Pernicious or other anaemia due to vit B12 deficiency.,Dermatologic: Rash¡A pruritus¡A erythema¡A urticaria Hematologic: Thrombocytosis Respiratory: Wheezing Miscellaneous: Allergic reactions¡A anaphylactoid reactions,2-8¢JÁ×¥úÁ×§K§N­á,Methotrexate-rescue (high-dose): 15 mg (~10 mg/m2) IV; start 24 hours after beginning methotrexate (12-15 mg/m2) infused > 4 hours; continue every 6 hours for 10 doses¡A until methotrexate level is <0.05 micromolar. Monitor levels of serum creatinine and methotrexate once daily. Methotrexate overdose (inadvertent) (begin as soon as possible after overdose): Oral¡A IM¡A IV: 10 mg/m2 Q6H until the methotrexate level is <0.01 micromolar. If serum creatinine is increased >50% above baseline 24 hours after methotrexate administration¡A if 24 hours methotrexate level is >5 micromolar¡A or if 48 hours methotrexate level is >0.9 micromolar¡A increase leucovorin dose to 100 mg/m2 IV Q3H until the methotrexate level is <0.01 micromolar. Megaloblastic anemia¡A folate-deficient: 1 mg IM/IV QD. Colorectal cancer¡A advanced: 200 mg/m2/day for 5 days every 4 weeks in combination with fluorouracil.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,< 160mg/min,IV infusion over 15 minutes to 2 hours.,1. Due to calcium content¡A do not administer IV solutions at a rate >160 mg/minute. 2. Should be administered IM¡A IV push¡A or IV infusion (15 minutes to 2 hours). 3. Droperidol»P¥»ÃÄ²V¦X¦b¤@°_©Î¦@¥ÎY-site·|¥X²{¨I¾ý¡A¤£¥i¦@¥Î¡C
IMARS,Bupivacaine,Marcaine Spinal 0.5% Heavy inj 4mL,ZANE,Spinal anaesth for surgery.,Acute active disease of the CNS¡A such as meningitis¡A tumours¡A poliomyelitis & cranial haemorrhage¡A active TB or metastatic lesions in the vertebral column. Septicaemia. Pernicious anaemia with subacute combined degeneration of the spinal cord. Pyrogenic infection of the skin at or adjacent to the site of puncture. Cardiogenic or hypovolaemic shock. Coagulation disorders or ongoing anticoagulant treatment.,Hypotension¡A bradycardia¡A post-spinal headache. Rarely¡A high or total spinal blockade resulting in CV & respiratory depression¡A neurological complications.,2-25¢JÁ×§K§N­á,Marcaine Spinal 0.5% Heavy contains bupivacaine 5mg/mL¡A 4mL/ampoule (with glucose monohydrate to adjust a specific gravity of 1.026 at 20¢XC). Intrapinal injection. Spinal injections should only be made after the subarachnoid space has been clearly identified by lumbar puncture. No drug should be injected until clear cerebrospinal fluid (CSF) is seen to escape from the spinal needle or it is detected by aspiration. The dose required for the most effective blocking: For lower limbs¡A urinary tract and perineum surgery (patient in the sitting position): 7.5-15 mg inject into L3/4/5. For lower abdomen surgery (patient in the supine horizontal position): 15-20 mg and inject into L2/3/4.,µL»Ý½Õ¾ã¾¯¶q,±ß´Á¨x¯f±wªÌÀ³¤p¤ß¨Ï¥Î¡A¥H´î§Cµo¥Í¦MÀI°Æ§@¥Îªº­·ÀI,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,Bupivacaine [18],Unknown ¨S¦³¸ê®Æ,Bupivacaine [8],IT;,,,,,§½³¡³Â¾K¾¯¡A­­¥ÑÂå®v¨Ï¥Î¡C
ODOF,Mephenoxalone,Doflex 200mg,CNEU,Muscle spasms.,Porphyria; pregnancy and lactation,Drowsiness; GI disturbances¡A paraesthesia¡A weakness; headache¡A dizziness¡A ataxia¡A paradoxical excitement; visual disturbances; arrhythmias¡A hypotension; hypersensitivity reactions; blood dyscrasias.,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adult: 200-400 mg TID. Maximum: 2000mg daily.Children 6-15 years: 100mg TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
ECLOB,Clobetasol propionate,Clobex Shampoo 60mL¡A 0.05%,TDER,Treatment of moderate to severe forms of scalp psoriasis in patient ¡Ù18 yr.,Hypersensitivity to clobetasol or any ingredient in the preparation (gel¡A cream¡A ointment),Burning/stinging¡A pruritus¡A edema¡A folliculitis¡A acne¡A dry skin¡A irritant dermatitis¡A alopecia¡A urticaria¡A skin atrophy & telangiectasia.,30¢J¥H¤UÀx¦s,Scalp psoriasis (Moderate to Severe) (Shampoo) Apply topically onto dry scalp once daily in a thin film to affected areas only; leave in place 15 minutes before lathering and rinsing; maximum 50 mL/week for 2 consecutive weeks,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
IKAD1,Trastuzumab Emtansine,Kadcyla inj 100mg,RACA,Metastatic breast cancer¡A HER2 overexpression¡A monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common: Constipation (17-27%)¡A Nausea (40-42%)¡A Hemorrhage¡A All Grades (29-32%)¡A Thrombocytopenia¡A All Grades (29-31%)¡A Increased liver enzymes¡A All Grades (29-32%)¡A Musculoskeletal pain (30-36%)¡A Headache (28%)¡A Fatigue (36%) Serious: Heart failure¡A Left ventricular cardiac dysfunction (1.8-3%)¡A Injection site extravasation¡A Anemia¡A Grade 3 or 4 (1.1-4.1%)¡A Hemorrhage¡A Grade 3 or 4 (0.4-1.8%)¡A Thrombocytopenia¡A Grade 3 or 4 (6-15%)¡A Hepatotoxicity¡A Increased liver enzymes¡A Grade 3 or 4 (1.5-8%)¡A Injury of liver¡A Liver regeneration (0.3-0.4%)¡A Non-allergic anaphylaxis¡A Dyspnea (8-12%)¡A Interstitial lung disease¡A Pneumonitis (1.1-1.2%),2-8¢J,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever¡A chills¡A or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,µL»Ý½Õ¾ã¾¯¶q,Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution. Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded¡A a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü³Ìµu30 ¤ÀÄÁ¡C½Ð¨Ï¥Î0.2-0.22·L¦Ì¡B¤£§lªþ³J¥Õ½èªººÞ½u¤º polyethersulfone (PES)¹LÂo¾¹¡C 3. ·»²G°t¸m«áÀ³¥ß§Y¨Ï¥Î¡A§NÂÃ©ó2-8¢J³Ì¦hÀx¦s24¤p®É¡C 4. ¿éª`®Éª`·N¯f¤H¬O§_¥X²{©I§l§xÃø¡B©PÃä¤ô¸~¡B§C¦åÀ£©Î¨ä¥L«æ©Ê¹L±Ó¤ÏÀ³¯gª¬¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
OFER,Ferrous Gluconate + Vit B1 + Vit C,Ferrous gluco-B 300/10/30,NUTR,Treatment & prevention of iron deficiency anemia¡A vit B1 & C deficiency.,Hypersensitivity to any component of the formulation.,Nausea & GI irritation¡A tachycardia(5%),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,1 TAB contains¡GFerrous gluconte 300mg¡A Vitamin B1 10mg¡A Vitamin C 30mg. PO dose: 1 TAB TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,
OCOF1,Warfarin,Cofarin 1mg,HEMT,Treatment & prophylaxis of thromboembolic disorders.,Severe hepatic or renal disease¡A actual or potential haemorrhagic conditions¡A severe hypertension¡A endocarditis¡A ulceration of the GI & urinary tract¡A visceral carcinoma¡A endocarditis¡A neurosurgery¡A recent surgery on the eye¡A brain or spinal cord. Pregnancy.,Alopecia¡A skin rashes of various kinds¡A hemorrhagic skin necrosis. Cardiovascular: Cholesterol embolus syndrome Dermatologic: Tissue necrosis Hematologic: Hemorrhage Immunologic: Hypersensitivity reaction (infrequent ) Ophthalmic: Intraocular hemorrhage (5% to 11% ),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Initial dose as 2-5mg once daily¡A depends on patient's PT/INR. Maintenance dose would be 2-10mg¡A adjusted by patient's PT/INR. Duration of the treatment should be kept until the risks have been excluded.,»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling. However¡A the response to oral anticoagulants may be markedly enhanced in obstructive jaundice¡A hepatitis¡A and cirrhosis. INR should be closely monitored.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,,Compatible ­÷¨Å®É¥i¨Ï¥Î,WHO:Compatible with breast-feeding.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ»Pfeeding nutrition¦³¥æ¤¬§@¥Î¦Ó¼vÅT§l¦¬¡A¥i¿i¯»¦ý»Ý»Pnutrition¶¡¹j1¤p®É¡A¨Ã±K¤ÁºÊ´úINR­È¡C
IBFL,Amino Acid + Dextrose + Electrolytes + Vitamin B1,Bfluid inj 1000mL,NUTR,Provision of electrolytes¡A glucose & amino acids in inadequate oral intake before & after surgery.,Hepatic coma or risk of hepatic coma; severe renal disorder or azotemia; CHF; severe acidosis; abnormal electrolyte metabolism¡A hyperpotassemia¡A hyperphosphatemia¡A hypermagnesemia¡A hypercalcemia; reduced urine output; abnormal amino acid metabolism,Rash¡A chest discomfort¡A palpitation¡A cerebral¡A pulmonary & peripheral edema¡A hyperpotassemia¡A acidosis¡A water intoxication¡A vascular pain¡A phlebitis¡A chills¡A fever¡A feeling of warmth¡A headache.,25¢J¥H¤UÁ×¥ú,Adult Usual dose: 500 mL infused via peripheral vein. Maximum dose: 2500 mL/day. Infusion rate: 500 mL/120 min¡A slowed in elderly & critically ill patients. The dosage should be adjusted according to the patient¡¦s condition¡A body weight¡A and age.,»Ý½Õ¾ã¾¯¶q,¨x»ÙÃªªº±wªÌ½ÐÂÔ·V¨Ï¥Î ¦³¨x©Ê©ü°g¤§¸·ªº±wªÌ¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,IVD: 150mL/60min¡A¨C¤é³Ì¤j§ë»P¾¯¶q 2500mL,1. ¨C¤é³Ì¤j§ë»P¾¯¶q 2500mL 2. ¨Ï¥Î«e¡A¥ÎÂù¤âÀ£¤W«Ç©Î¤U«Ç¥H¥´³q¨â«Ç¶¡ªº³sµ²³B¡A¨Ï¤G«Ç·»²G§¹¥þ²V¦X¡C 3.¦¨¤H¼Ð·Ç¿éª`³t«×¬°60¤ÀÄÁ¤ºª`®g150mL(¼t°Ó«ØÄ³)¡C¦Ñ¤H¤Î­«¯g±wªÌÀ³´î½w¿éª`³t«×¡C 4.¼t°Ó«ØÄ³¥i¦b¥~¥[K¶q ©PÃäÀR¯ß:¥i¦A¥~¥[20mEq; ¤¤¥¡ÀR¯ß¥i¦A¥~¥[60mEq¡C 5.­Y¦³¥X²{µ²´¹½Ð»P¼t°Ó§ó´«¡C
ODOR4,Dexamethasone,Dorison 4mg,HM,Conditions where the anti-inflammatory and immunosuppressive effects of the corticosteroids are desirable¡A especially for intensive treatment during shorter periods.,Systemic fungal infection¡A hypersensitivity. Administration of live virus vaccine¡A unstable or infected joint¡A diagnosed sepsis.,Common: Hypertension (Diabetic macular edema¡A 13%)¡A Cushing's syndrome¡A Decreased body growth¡A Abnormal vision (1-9%)¡A Cataract (Diabetic macular edema¡A 68%; retinal vein occlusion and uveitis¡A 5-54%)¡A Conjunctival edema (5%)¡A Conjunctivitis (6%)¡A Corneal edema (Postoperative ocular inflammation and pain¡A 1% ; postoperative inflammation¡A 5-15%)¡A Discomfort¡A Eye (10%)¡A Disorder of anterior chamber of eye¡A Inflammation (10%)¡A Dry eye syndrome (5%)¡A Iridocyclitis¡A Iritis (5-15%)¡A Raised intraocular pressure (Retinal vein occlusion and uveitis¡A 24-25% ; postoperative inflammation and pain¡A 5-15% ; ocular itching¡A 3% i)¡A Vitreous floaters (1-5%)¡A Depression¡A Euphoria¡A Pulmonary tuberculosis Serious: Cardiomyopathy¡A Rupture of ventricle due to acute myocardial infarction¡A Hyperglycemia¡A Hypokalemia¡A Pancreatitis¡A Infectious disease¡A Osteoporosis¡A Conjunctival hemorrhage (Diabetic macular edema¡A 23%; retinal vein occlusion and uveitis¡A 22%)¡A Glaucoma (Diabetic macular edema¡A 1.2%)¡A Keratitis (2%)¡A Posterior subcapsular cataract¡A Retinal tear (2%)¡A Retinal vascular disorder (3%)¡A Uveitis (2%),«Ç·Å15-30¢JÁ×¥ú¡Aºò±K®e¾¹Àx¦s,Adult: Usually 4-20 mg/day given QD or in 2-4 divided doses; High dose: 0.4-0.8 mg/kg/day (usually <= 40 mg/day). Pediatric: 0.02-0.6 mg/kg/day given QD or in 2-4 divided doses; MAX 16 mg/day. Cerebral edema: Loading dose: 1-2 mg/kg/dose as a single dose; maintenance: 1-2 mg/kg/day in divided doses Q4-6H; MAX 16 mg/day. Chemotherapy-induced nausea and vomiting¡A prevention: (Reduce dose by 50% if administered concomitantly with aprepitant) Highly/severely emetogenic chemotherapy: 6 mg/m2/dose Q6H. Moderately emetogenic chemotherapy: BSA <= 0.6 m2: 2mg Q12H; BSA > 0.6 m2: 4mg Q12H. COVID-19 treatment: 0.15-0.3 mg/kg/dose QD for up to 10 days; MAX 6 mg/dose.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ] ¥¼¦³¬ÛÃö±Ô­z¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥¼¦³¬ÛÃö±Ô­z¡C,AC;AC15;PC;PO;WM;,,,,,1.¹ï­G¸z¼ìºÅ±wªÌ¡AÀ³ª`·N¬O§_¥X²{¥X¦å©Î¼ìºÅ´c¤Æµ¥ª¬ªp¡C 2.µÇÅ¦¯e±w¤Î°ª¦åÀ£±wªÌÀ³ª`·N¯B¸~¡B¦åÀ£¤W¤Éµ¥°Æ§@¥Î¡C 3.¿}§¿¯f±wªÌ¨Ï¥Î®É¥i¯à¼vÅT¦å¿}±±¨î¡AÀ³±K¤ÁºÊ´ú¦å¿}ÅÜ¤Æ¡C
OVEP,Etoposide,Vepesid 50mg,RACA,,¾AÀ³¯g:Small cell carcinoma of lung¡A In combination with other approved chemotherapeutic agents as first line¡A Testicular cancer¡A In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical¡A chemotherapeutic¡A and radiotherapeutic therapy °Æ§@¥Î:Alopecia¡A Shivering¡A Diarrhea¡A Inflammatory disease of mucous membrane¡A Loss of appetite¡A Nausea¡A Vomiting¡A Asthenia¡A Fever¡A Malaise ¸T§Ò:Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment,,«Ç·Å,Non-Hodgkin lymphoma (in combination with other agents)¡A nonsmall cell lung cancer (alone or in combination)¡A small cell lung cancer (first-line in combination; second-line alone or in combination)¡A testicular cancer (in combination; oral therapy for refractory disease): Oral: 100-200 mg/m2/day for 5 days; administer daily doses >200 mg in 2 divided doses.,»Ý½Õ¾ã¾¯¶q,UpToDate Floyd 2006: Bilirubin 1.5 to 3 mg/dL or AST >3 times ULN: Administer 50% of dose King 2001; Koren¡A 1992: Bilirubin 1.5 to 3 mg/dL or AST >180 units/L: Administer 50% of dose Bilirubin 1.5 to 3 mg/dL or AST >3 times ULN: Administer 50% of dose,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,
IDRO,Droperidol,Dropel inj 2.5mg/1mL,CNEU,Management of nausea & vomiting following surgical or diagnostic procedures.,Pre-existing CNS depression or coma¡A parkinsonism; known or suspected QT prolongation¡A including congenital long QT syndrome. Hypokalemia or hypomagnesiemia. Bradycardia.,Common: Hypotension¡A Tachycardia¡A Somnolence¡A Postoperative¡A Anxiety¡A Dysphoric mood¡A Hyperactive behavior¡A Restlessness Serious: Cardiac arrest¡A Prolonged QT interval¡A Torsades de pointes¡A Ventricular tachycardia¡A Anaphylaxis¡A Neuroleptic malignant syndrome (very rare),30¢J¥H¤UÁ×§K§N­á,Nausea and vomiting¡A Associated with surgical or diagnostic procedures; Prophylaxis: Adult: 2.5 mg IM/IV¡A followed by additional doses of 1.25 mg if potential benefit outweighs potential risk. Children 2-12 years old: maximum initial dose: 0.1 mg/kg IM/IV¡A additional doses should be administered with caution and if pot.ential benefit outweighs potential risk. Psychosis: 2.5-15 mg IV. Maximum single dose: 10 mg IV. Second dose may be given at 4-6 hr interval IM/IV.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,,,IV push administration should be slow.,,½wºCª`®g¡A¦¨¤H³Ì¤jªì©l¾¯¶q2.5mg;¤p«Ä(2-12·³)³Ì¤jªì©l¾¯¶q0.1mg/kg
IKCL7,Potassium Chloride,20mEq KCl in D5NS 500mL,NUTR,,¾AÀ³¯g: Hypokalaemia. °Æ§@¥Î: Hyperkalemia¡A pain or phlebitis at injection site. ¸T§Ò: Hyperkalemia.,,2-8«×C,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr¡A with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day.,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
OLYR,Pregabalin,Lyrica 75mg,CNEU,Diabetic peripheral neuropathy - neuropathic pain¡A fibromyalgia¡A neuropathic pain - spinal cord injury¡A partial seizure ¡V adjunct¡A postherpetic neuralgia.,Hypersensitivity to pregabalin or any other component of the product.,(Common) Cardiovascular: Peripheral edema (5% to 12% ) Endocrine metabolic: Increased appetite (5% )¡A Weight gain (3.3% to 12% ) Gastrointestinal: Constipation (4% to 8.2% )¡A Xerostomia (2.3% to 11% ) Neurologic: Asthenia (5% to 10% )¡A Ataxia (3% to 15% )¡A Dizziness (9.1% to 42.7% )¡A Headache (5.6% to 9.3% )¡A Incoordination (2% to 10.1% )¡A Somnolence (10.2% to 35.7% )¡A Tremor (1% to 11.2% ) Ophthalmic: Blurred vision (3.4% to 10.1% )¡A Diplopia (2% to 9% ) Psychiatric: Disturbance in thinking (2% to 8% )¡A Euphoria (2% to 6% ) Respiratory: Nasopharyngitis (8.2% ) Other: Fatigue (7% to 11% ) (Serious) Hepatic: Jaundice Immunologic: Hypersensitivity reaction Musculoskeletal: Increased creatine kinase level (1.5% to 2.7% ) Psychiatric: Suicidal thoughts Other: Angioedema,25¢J¥H¤U,Diabetic peripheral neuropathy - neuropathic pain: initial¡A 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (maximum 300 mg/day). Fibromyalgia: initial¡A 75 mg twice a day (150 mg/day)¡A may increase to 150 mg twice a day (300 mg/day) within 1 week and to 225 mg twice a day (maximum 450 mg/day). Neuropathic pain - spinal cord injury: initial¡A 75 mg two times a day; may increase to 150 mg two times a day within 1 week; may further increase to 300 mg two times a day for insufficient pain relief after 2 to 3 weeks of treatment. Partial seizure - adjunct: initial¡A no greater than 75 mg two times a day or 50 mg three times a day (150 mg/day) and increased to a maximum dose of 600 mg/day in divided doses (either two or three times a day) based on response and tolerability. Postherpetic neuralgia: initial¡A 75 mg two times a day or 50 mg three times a day; maintenance¡A 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day)¡A in patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and are tolerating pregabalin¡A may increase dosage up to 300 mg two times a day¡A or 200 mg three times a day (600 mg/day). Safety and efficacy have not been established in pediatric patients.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,AC;AC15;PC;PO;WM;,,,,,
EONB,Indacaterol,Onbrez Breezhaler 150mcg,ERSP,,¾AÀ³¯g: Manitenance treatment of airflow obstruction in patients wih chronic obstructive pulmonary disease. °Æ§@¥Î: (Common) Headache (5.1%)¡A cough (6.5% to 24% )¡A nasopharyngitis (5.3% ) (Serious) Hypersensitivity reaction¡A paradoxical bronchospasm (Overdose) palpitation¡A headace¡A fatigue¡A hypokalemia¡A hyperglycemia ¸T§Ò: Hypersensitivity to indacaterol or any of other components of Onbrez Breezhaler,,«Ç·Å,Adults: inhalation of the content of one 150 mcg capsule once a day¡A using the Onbrez Breezhaler inhaler. Safety and effectiveness not established in pediatric patients. (< 18 years),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out. It is not known if indacaterol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering indacaterol to nursing women. The use of beta2-receptor agonists are not considered a contraindication to breast-feeding,IH;,,,,,1. ¨C­ÓOnbrez Breezhaler ¥]¸Ë§t¦³: ¤@­ÓOnbrez Breezhaler §l¤J¾¹ / ¾Tºä¤ù¡A¤º§t¦³¨ÑOnbrez Breezhaler §l¤J¾¹¨Ï¥Îªº½¦Ån 2. ¤£¥i§]ªAOnbrez Breezhaler ½¦Ån: Onbrez Breezhaler §l¤J¾¹¬O¤@ºØ¾¹§÷¡A¨Ñ±z¦b§l¤JOnbrez Breezhaler ½¦Ån¤¤ªºÃÄ«~®É¨Ï¥Î¡C 3. ¥u¥i¨Ï¥Î¥]¸Ë¤¤ªºOnbrez Breezhaler §l¤J¾¹¡C 4. Onbrez Breezhaler ½¦Ån¤£¥i¨Ï¥Î¨ä¥L§l¤J¾¹¡A¨ä¥L½¦ÅnÃÄ«~¤]¤£¥i¨Ï¥ÎOnbrez Breezhaler §l¤J¾¹¡C
IFUR1,Cefuroxime,FuroXime inj 1.5gm,QANB,Infections due to Staphylococci¡A Streptococci¡A Pneumococci¡A Meningococci & other susceptible bacteria.,Hypersensitivity to cephalosporins.,Allergic reactions¡A GI intolerance¡A superinfection¡A eosinophilia. Rarely¡A transient hematological abnormalities; pseudomembranous colitis¡A phlebitis.,Á×¥ú«O¦s,Adults: 0.75-1.5 g IV/IM Q6-12H (dose ranges from 1.5-6 g/day); surgical prophylaxis: 1.5 g at induction of anesthesia and 1.5 g IM 6-8 hours after; gonorrhea: a single IM dose of 1.5 g (administer two doses of 750 mg at seperate area). Children: 30-100 mg/kg/day divided Q6-8H. Newborn: 30-100 mg/kg/day divided Q8-12H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,AAP: Maternal medication usually compatible with breastfeeding. Micromedex: Infant risk is minimal. Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.,IM;IV;IVD;IVP;IVPUSH;,IV:15 mL D/W,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ,µ¹ÃÄ¿@«×1~30mg/mL¡A ºwª`®É¶¡ > 15~ 60¤ÀÄÁ,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BPT­È¡C 2.IM¥Îªk:¥[¤J3mLª`®g¥Î¤ô©ó750mg Cefuroxime¡A1.5gmÀ³µ¹¤©2¤ä750mg¤£¦P³¡¦ì¦Ù¦×ª`®g¡A¦p¨â°¼Áv³¡¡C 3.°t»s«á©ó25¢XC¥H¤U¥i«O¦s5¤p®É¡A§NÂÃ¥i«O¦s48¤p®É¡C
IHYA,Sodium Hyaluronate,Hyalubrix Intra-articular inj,CNEU,Treatment of pain in osteoarthritis in knee in patients who have failed simple analgesics (e.g. acetaminophen) & nonpharmacologic treatment.,1. Hypersensitivity to the product components. 2. Infections or skin diseases at injection site.,Transient swelling¡A pain¡A heat & redness may occur sporadically at the injection site.,25¢J¥H¤U,Inject in the affected joint at weekly intervals for 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,[8] unknow- by book,INS;IS;,,,,,
OCER4,Pentoxifylline,Ceretal S.C. 400mg,CAVS,Peripheral circulatory disorders¡A chronic occlusive arterial disease.,Cerebral or retinal hemorrhage¡A intolerance to xanthine derivatives.,Cardiac arrhythmias¡A headache¡A nausea¡A GI effects¡A dizziness¡A flushing.,«Ç·Å¤U¡A¨¾Àã»PÁ×¥úÀx¦s,1 TAB TID with meal.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Pentoxifylline is excreted into human milk. Five healthy women who had been breastfeeding for at least 6 weeks were given a single 400-mg sustained-release tablet of pentoxifylline after a 4-hour fast. The mean milk:plasma ratio of unmetabolized pentoxifylline at 4 hours was 0.87. Mean milk:plasma ratios for the three major metabolites at 4 hours were 0.76¡A 0.54¡A and 1.13. Mean milk concentration of pentoxifylline at 2 hours (73.9 ng/mL) was approximately twice as much as that occurring at 4 hours (35.7 ng/mL) (3). Pentoxifylline and its metabolites are stable in breast milk for 3 weeks when stored at ?15¢XC. The effects of this exposure on a nursing infant are unknown.,PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©Ê¿}¦ç¿õ¡AÀ³¾ã²É§]ªA¡A¤Á¤Å«rÄZ©ÎÀ£¸H¡C
OTOP5,Topiramate,Topamax film-coated 50mg,CNEU,,¾AÀ³¯g: Adjunctive therapy in adults & children >= 2 years with partial seizures¡A seizures associated with the Lennox-Gastaut Syndrome¡A as well as with tonic-clonic seizures. Monotherapy in patients with partial onset seizure. Migraine prophylaxis. °Æ§@¥Î: Ataxia¡A impaired conc¡A confusion¡A dizziness¡A fatigue¡A paresthesia¡A somnolence¡A abnormal thinking. Less commonly¡A agitation¡A amnesia¡A anorexia¡A aphasia¡A depression¡A diplopia¡A emotional lability¡A nausea¡A nystagmus¡A speech disorder¡A taste perversion¡A abnormal vision & weight decrease. Nephrolithiasis (rare). Gastrointestinal: Diarrhea (5% to 11% )¡A Loss of appetite (4% to 24% )¡A Nausea (6% to 14% )¡A Taste sense altered (3% to 15% )¡A Weight decreased (6% to 21% ) Neurologic: Confusion (3% to 14% )¡A Disorder of language (6% to 10% )¡A Dizziness (8% to 32% )¡A Feeling nervous (7% to 14% )¡A Headache¡A Impaired psychomotor performance (3% to 21% )¡A Memory impairment (5% to 14% )¡A Paresthesia (2% to 51% )¡A Reduced concentration span (4% to 14% )¡A Somnolence (9% to 29% )¡A Speech and language disorder Ophthalmic: Abnormal vision (2% to 13% )¡A Diplopia (1% to 10% )¡A Nystagmus (10% to 11% ) Other: Fatigue (14% to 30% ) ¸T§Ò: Pregnancy.,,«Ç·Å,Adjunctive therapy Adult 200-600 mg/day in 2 doses. Children >= 2 years 6-9 mg/kg/day in 2 doses. Max: 1000mg/day. Monotherapy Adult Initial target dose 100mg/day in 2 doses. Children >= 2 years 3-6 mg/kg/day in 2 doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex: Infant risk cannot be ruled out.,,,,,,May be taken with or without food: Swallow whole¡A do not chew/crush.
IVFEN,Voriconazole,Vfend inj 200mg,QANB,Treatment of invasive aspergillosis¡A candidemia in non-neutropenic patients¡A fluconazole-resistant serious invasive Candida infections (including C. krusei)¡A esophageal candidiasis¡A serious fungal infections caused by Scedosporium spp & Fusarium spp in patients w/ progressive¡A possibly life-threatening infections.,Co-administration w/ terfenadine¡A astemizole¡A cisapride¡A pimozide¡A quinidine¡A sirolimus¡A rifampicin¡A carbamazepine¡A long-acting barbiturates (eg phenobarb)¡A ritonavir¡A ergot alkaloids (eg ergotamine & dihydroergotamine)¡A St. John's wort,Headache¡A visual disturbances¡A nausea¡A vomiting¡A diarrhea¡A abdominal pain¡A rash¡A fever¡A peripheral edema.,25¢J¥H¤U,(¥é³æ+¼ö¯f) Loading dose is recommended. Adult and children (12-14 years and weighing > or = 50 kg¡A or 15-17 years): 6 mg/kg IV Q12H x 2 doses (loading)¡A then 3-4 mg/kg IV Q12H. Children (2-12 years¡A or 12-14 years and weighing < 50 kg): 9 mg/kg IV Q12H x 2 doses¡A then 4-8 mg/kg IV Q12H.,»Ý½Õ¾ã¾¯¶q,Child-Pugh Class A and B: «ØÄ³¤´¥Î¼Ð·Çªº­t²ü¾¯¶q(6 mg/kg IV every 12 hours for 2 doses)¡A¦ýºû«ù¾¯¶q»Ý´î¥b(2 mg/kg IV every 12 hours),»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,IVD: 19 mLª`®g¥Î¤ô¡A°t»s¦¨20 mLªº³z©ú·»²G,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,µ¹ÃÄ¿@«×0.5~5mg/mL¡Aµ¹ÃÄ³t²v³Ì°ª 3mg/kg/hr,
IENB5,Etanercept,Enbrel 50mg prefilled pen,HIMM,In combination w/ methotrexate in the treatment of moderate to severe active RA in adults when response to disease-modifying antirheumatic drugs (DMARDs) has been inadequate. As monotherapy in case of intolerance to methotrexate or when continued treatment w/ methotrexate is inappropriate. Treatment of severe¡A active & progressive RA in adults not previously treated w/ methotrexate. As monotherapy or in combination w/ methotrexate to reduce progression rate of joint damage & improve physical function. Treatment of active & progressive psoriatic arthritis in adults when the response to previous DMARDs has been inadequate. Treatment of adults w/ severe active ankylosing spondylitis not responsive to conventional therapy. Treatment of adults w/ moderate to severe plaque psoriasis who failed to respond to¡A contraindicated to or intolerant of other systemic therapy including cyclosporine¡A methotrexate or PUVA. Treatment of chronic severe plaque psoriasis in childn & adolescents ¡Ù8 yr inadequately controlled by or intolerant to other systemic therapies or phototherapies. Treatment of active polyarticular juvenile idiopathic arthritis in childn ¡Ù4 yr w/ inadequate response or intolerant to methotrexate.,Sepsis,>10%: Headache (17% to 19%)¡A Skin rash (3% to 13%)¡A Abdominal pain (5%; children 19%)¡A diarrhea (3% to 16%)¡A vomiting (3%; children 13%)¡A Infection (50% to 81%; children 62%)¡A Injection site reaction (14% to 43%; bleeding¡A bruising¡A erythema¡A itching¡A pain¡A or swelling)¡A Upper respiratory tract infection (38% to 65%)¡A respiratory tract infection (21% to 54%)¡A rhinitis (12%)¡A Antibody development (positive antidouble-stranded DNA antibodies 15% by RIA¡A 3% by Crithidia luciliae assay)¡A positive ANA titer (11%),2-8¢JÁ×¥úÁ×§K§N­á,SC¡A ankylosing spondylitis¡A psoriatic arthritis¡A rheumatoid arthritis¡A plaque psoriasis 50 mg once weekly or 25 mg twice weekly. Alternatively¡A plaque psoriasis 50 mg twice weekly for 12 weeks¡A then 50 mg once weekly or 25 mg twice weekly for 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,¦b¤j¹«¤Î¨ß¤lªºµo¨|¬r©Ê¹êÅç¤¤¡A¨Ã¥¼µo²{etanercept¶Ë®`¤j¹«­L¨à©Î·s¥Í¨àªºÃÒ¾Ú¡C¥Ø«e¤w¦b¨â¶µÆ[¹î©Ê¥@¥N¬ã¨s¤¤±´°Qetanercept¹ïÃh¥¥µ²ªGªº¼vÅT¡C¦b¨ä¤¤¤@¶µÆ[¹î©Ê¬ã¨s¤¤µo²{¡A¬Û¸û©ó¦bÃh¥¥´Á¶¡¨S¦³¼ÉÅS©óetanercept ©Î¨ä¥L TNF §Ü«ú¾¯ªºÃh¥¥°ü¤k(n=164)¡AÃh¥¥«e¤T­Ó¤ë¤¤¼ÉÅS©óetanercept ªºÃh¥¥°ü¤k(n=370) µo¥Í­«¤j¥ý¤Ñ¯Ê³´ªº¤ñ²v¸û°ª(½Õ¾ã³Óºâ¤ñ2.4¡A95% CI: 1.0-5.5)¡C­«¤j¥ý¤Ñ¯Ê³´ªºÃþ«¬©M¤@¯ë±Ú¸s³Ì±`³ø§iªºÃþ«¬¤@­P¡A¥B¨S¦³²§±`ªº¯S©w¼Ò¦¡¡C¦ÛµM¬y²£¡B­L¦º¸¡¤¤©Î»´·L·î§Îªº¤ñ²v¨S¦³Æ[¹î¨ìÅÜ¤Æ¡C¥t¤@¶µÆ[¹î©Ê¦h°êµn¿ý¸ÕÅç¤ñ¸û¦bÃh¥¥ªº«e90 ¤Ñ¤¤¼ÉÅS©óetanercept¤§°ü¤k(n=425) »P¼ÉÅS©ó«D¥Íª«»s¾¯ÃÄª«¤§°ü¤k(n=3497) ªº¤£¨}Ãh¥¥µ²ªG­·ÀI¡A¨Ã¥¼Æ[¹î¨ì­«¤j¥ý¤Ñ¯Ê³´­·ÀI¤W¤É±¡§Î(²Ê³Óºâ¤ñ[OR]= 1.22¡A 95% CI: 0.79-1.90¡F¦b®Õ¥¿°ê§O¡B¥À¿Ë¯e¯f¡B­L¦¸¡B¥À¿Ë¦~ÄÖ©MÃh¥¥¦­´Á§lµÒ¦]¤l«á¤§½Õ¾ã³Óºâ¤ñ= 0.96¡A 95% CI: 0.58-1.60)¡C¦¹¸ÕÅç¤]Åã¥Ü¦bÃh¥¥´Á¶¡¼ÉÅS©óetanerceptªº°ü¤kµo¥Í»´·L¥ý¤Ñ¯Ê³´¡B¦­²£¡B­L¦º¸¡¤¤©Î·s¥Í¨à¦b¥X¥Í«á²Ä¤@¦~¤ºµo¥Í·P¬V¤§­·ÀI¨Ã¥¼¼W¥[¡CÃh¥¥´Á¶¡¨Ï¥Î®¦³ÕÀ³¶È­­©ó¦³©ú½T»Ý¨D®É¡C Etanercept ·|³q¹L­L½L¡AÃh¥¥´Á¶¡±µ¨ü®¦³ÕªvÀøªº°ü¤k¡A²£¤UªºÀ¦¨à¦å²M¤¤´¿´ú¨ìetanercept¡C¦¹³¡¤ÀªºÁ{§É¼vÅT¥¼ª¾¡A¦ý¥i¯à´£°ªÀ¦¨à¨ü¨ì·P¬Vªº­·ÀI¡C¤@¯ë¨Ó»¡¡A¥À¿Ë§ë»P³Ì«á¤@¾¯®¦³Õ«á¥¼º¡16¶g«e¡A«ØÄ³¤£­n¬°À¦¨à±µºØ¬¡¬Ì­](live vaccines)¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,¦³¥Ö¤Uµ¹¤©etanercept«á¡Aetanercept¤Àªc©ó¤HÃþ¨Å¥Äªº³ø§i¡C­÷¨Åªº¤j¥Õ¹«¥Ö¤Uµ¹¤©®¦³Õ®É¡A®¦³Õ·|¤Àªc¨ì¨Å¥Ä¡A¥B¥®¹«ªº¦å¼ß¯à°»´ú¨ì®¦³Õªº¿@«×¡C¥Ñ©ó§K¬Ì²y³J¥Õ(±`¨£©ó³\¦hÂåÃÄ«~) ·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡A¦]¦¹±ý¨Ï¥Î®¦³Õ©ó­÷¨Å´Á¶¡ªº°ü¤k®É¡A¦b¿Å¶q­÷¨Åªº¦n³B»P­÷¨Å°ü¤kªvÀøªº¯q³B®É¡AÀ³¦Ò¶q¬O§_°±¤î­÷¨Å©Î°±ÃÄ¡C,SC;,,,,,¦^·Å: ¨Ï¥Î«e«O¯d¥Õ¦â°w»\¡Aµ¥­Ô15-30¤ÀÄÁ¥ª¥k¡AÅý®¦³Õ¤¤ªº·»²G¹F¨ì«Ç·Å¡C«Ý·»²G¹F¨ì«Ç·Å«á¨Ïª`®g®Éªº·PÄ±¸û¬°µÎªA¦Aª`®g¡C¤Á¤Å¥H¥ô¦ó¨ä¥¦¤è¦¡¥[¼ö¡C ÀË¬dÃÄª«: ³z¹L³z©úÀËµøµ¡¤fÀËµøª`®g¾¯©Îª`®gµ§¤¤ªº·»²G¡Cª`®g¾¯©Îª`®gµ§¤¤ªº·»²G¥²¶·¬°¼á²M¡BµL¦â¦Ü²H¶À¦â©Î²H´Ä¦âªº·»²G¡A¨Ã¥B¨S¦³¥ô¦ó¦×²´¥i¨£ªº·L²É¡A¤~¥i¥Î©óª`®g¡C ª`®g³¡¦ì: «ØÄ³ªºª`®g³¡¦ì¬°¤j»L«e­±ªº¤¤¬q¡C¤]¥i¥H¿ï¾Üª`®g¦b¸¡³¡°Ï°ì¡A¦ý½Ð½T©w±z©Ò¿ï¾Üªº¦ì¸m¶ZÂ÷¨{ÂÀ¦Ü¤Ö5¤½¤À¥H¤W¡C¦pªG¦³¨ä¥L¤H¬°±zª`®g¡A¥ç¥i¿ï¾Üª`®g¦b¤WÁu¥~°¼¡C §Ñ°O§ëÃÄ: ¦pªG§Ñ°O§ëÃÄ¡AÀ³¦b·Q°_®É¥ß§Y§ëÃÄ¡A°£«D¤U¤@¦¸¹w©wªº§ëÃÄ®É¶¡¬O¦b¹j¤Ñ¡F¦b³oºØ±¡ªp¤U¡AÀ³¸Ó¸õ¹L¿ù¹Lªº¾¯¶q¡AµM«á¦b¥­±`ªº®É¶¡Ä~Äò§ëÃÄ¡C¦pªGª½¨ì¤U¤@¦¸§ëÃÄ®É¶¡¤~°O±o¡A½Ð¤£­n¬I¥ÎÂù­¿¾¯¶q¡C
OSAL5,Sulfasalazine,Salazine 500mg,CNEU,Inflammatory bowel disease including Crohn's disease¡A ulcerative colitis¡A Active RA¡A ankylosing spondylitis.,Hypersensitivity to sulfonamides & salicylates. Acute intermittent porphyria. Infant < 2 years.,Nausea¡A anorexia¡A raised temp; erythema & pruritus; headache. Rarely¡A hematological¡A GI¡A CNS¡A renal¡A dermatological reactions. Dermatologic: Pruritus (3% to 4% )¡A Rash (3% to 13% ) Gastrointestinal: Abdominal pain (8% )¡A Indigestion (13% to 33% )¡A Loss of appetite (33% )¡A Nausea (19% to 33% )¡A Stomatitis (4% )¡A Vomiting (8% to 33% ) Neurologic: Dizziness (4% )¡A Headache (9% to 33% ) Renal: Discolored urine Reproductive: Oligozoospermia¡A Reversible (33% ) Other: Fever (3% to 5% ),15-30¢J±K»\®e¾¹,Inflammatory bowel disease including Crohn's disease¡A ulcerative colitis: Adult moderate attacks: 2 tables TID-QID. Severe attacks: 2-4 TABTID-QID. Children: 40-60 mg/kg/day in 3-6 doses. Maintenance: Adult 2 tablets BID-TID. Children 20-30 mg/kg/day in 3-6 divided doses. RA : 2 tablets BID. Child (Juvenile chronic arthritis)¡A no enough information.,µL»Ý½Õ¾ã¾¯¶q,µÇ¤Î¨x¥\¯à¤£¥þªÌÀ³¤p¤ß¨Ï¥Î¡A¥BÀ³©w´ÁÀË¬d§¿²G¤Î¨x¥\¯à,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»¿õ¡AÀ³¾ã²É§]ªA¡A¤£¥i«r¸H©Î©CÄZ¡C
IDEC,Triptorelin,Decapeptyl inj 0.1mg/1mL,RACA,Advanced prostate cancer: Palliative treatment of advanced prostate cancer Assisted reproductive technologies: Decapeptyl: Adjunctive therapy in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART),Hypersensitivity to triptorelin or any component of the formulation¡A other GnRH agonists or GnRH; pregnancy Canadian labeling: Additional contraindications (not in U.S. labeling): Breast-feeding women,>10%: Endocrine & metabolic: Hot flash¡A increased serum glucose¡A increased testosterone (peak: days 2-4; decline to low levels by weeks 3-4) Hematologic & oncologic: Decreased hemoglobin¡A decreased red blood cells Hepatic: Increased serum alkaline phosphatase¡A increased serum ALT¡A increased serum AST Neuromuscular & skeletal: Musculoskeletal pain Renal: Increased blood urea nitrogen,2-8¢JÁ×¥úÁ×§K§N­á,0.5 mg SC once daily for 7-10 days¡A followed by 0.1 mg SC once daily as maintenance therapy,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,SC;,,,,,
EFOX2,Fluorometholone,Foxone 0.02% 10mL ophthalmic suspension,TOPH,Acute & chronic iritis¡A iridocyclitis¡A scleritis¡A episcleritis¡A conjunctivitis¡A keratitis¡A resistant ocular allergy & inflammation following surgery,Acute superficial herpes simplex keratitis¡A fungal diseases of ocular structure; vaccinia¡A varicella & other viral diseases of the cornea & conjunctiva¡A eye TB,Glaucoma with optic nerve damage¡A visual acuity or field defects¡A raised intraocular pressure¡A secondary infection (persistent corneal ulceration¡A possibly fungal invasion)¡A perforation of globe¡A posterior subcapsular cataract formation,25¢J¥H¤U,Instill 1 drop into conjunctival sac 2 to 4 times daily; may instill 1 drop every 4 hours during initial 24 to 48 hours. Shake well before use.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AD;AL;AS;AU;OD;OL;OU;,,,,,
IMTX5,Methotrexate,MTX inj 500mg/5mL,RACA,,¾AÀ³¯g: Gestational choriocarcinoma¡A acute lymphocytic leukemia¡A meningeal leukemia¡A chorioadenoma destruens¡A hydatidiform mole¡A epidermoid cancers of the head & neck¡A lung cancer¡A bladder cancer & lymphosarcoma. °Æ§@¥Î: Ulcerative stomatitis¡A leukopenia¡A nausea & abdominal distress. malaise¡A fatigue¡A chills & fever¡A dizziness & decreased resistance to infection. Erythematous rashes¡A pruritus¡A urticaria¡A photosensitivity¡A depigmentation¡A alopecia¡A ecchymosis¡A telangiectasia¡A acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes¡A precipitating diabetes¡A osteoporosis¡A conjunctivitis¡A abnormal tissue cell changes¡A anaphylaxis. ¸T§Ò: Pregnant psoriatic patients. Psoriatic patients with severe renal or hepatic disorders¡A preexisting blood dyscrasias.,,«Ç·Å,Choriocarcinoma: Oral or IM¡A 15-30 mg/day for a 5 day course. Acute leukemia: Induction¡A oral or IV¡A 3.3 mg/m2/day with prednisolone; maintenance¡A oral or IM¡A 30 mg/mL twice a week¡A or IV¡A 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal¡A 0.2-0.5 mg/kg or 12 mg/mL (max. 15mg) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma (stage I & II): Oral¡A 10-25 mg/day for 4-8 days. Psoriasis: Oral¡A IM or IV¡A 10-25 mg/week. Rheumatoid arthritis: Oral¡A 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral¡A 2.5-10 mg/day for weeks or months; IM¡A 50mg/week.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C 3. Methotrexate¥HÀR¯ß¤è¦¡µ¹ÃÄ»Ý½wºC±Àª`¡A¤]¥i¥Hµu®É¶¡ÀR¯ß¿éª`©ÎÀR¯ß«ùÄò¿éª`µ¹ÃÄ¡C¨ÌªvÀø²Õ¦X»PÂåÅñ¨M©w¡C
ISIV4,Triamcinolone,SIVKORT Suspension 400mg/10mL,HM,,¾AÀ³¯g: Intra-articular Inflammatory joint disease °Æ§@¥Î: Common ¡½Cardiovascular: Hypertension ¡½Dermatologic: Atrophic condition of skin¡A Finding of skin healing¡A Impaired ¡½Endocrine metabolic: Cushing's syndrome¡A Decreased body growth ¡½Gastrointestinal: Disorder of gastrointestinal tract¡A Loss of appetite ¡½Musculoskeletal: Osteoporosis ¡½Psychiatric: Depression¡A Euphoria Serious ¡½Endocrine metabolic: Hyperglycemia¡A Primary adrenocortical insufficiency ¡½Ophthalmic: Cataract¡A Glaucoma ¡½Respiratory: Pulmonary tuberculosis ¸T§Ò: ¡½hypersensitivity to triamcinolone ¡½systemic fungal infections,,«Ç·Å,,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
EBIO,Sulfur Precipitated,Biofur acne lotion 5% 30mL,TDER,,¾AÀ³¯g: Acne vulgaris. °Æ§@¥Î: Skin dryness; less frequently¡A skin irritation ¸T§Ò: hypersensitivity ª`·N¨Æ¶µ: Topical: Avoid contact with the eyes; for external use only,,«Ç·Å,Apply a thin film of Biofur twice daily to affected area.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OSTV,Regorafenib,Stivarga 40mg (28#/Bot),RACA,Colorectal cancer: Treatment of patients with metastatic colorectal cancer (mCRC) who have previously received the following therapies¡A including fluoropyrimidine-¡A oxaliplatin-¡A irinotecan-based chemotherapy¡A and anti-vascular endothelial growth factor (anti-VEGF) therapy; If KRAS is a wild type¡A the patient needs to have received anti-epidermal growth factor receptor (anti-EGFR) therapy. Gastrointestinal stromal tumors: Treatment of locally advanced¡A unresectable or metastatic gastrointestinal stromal tumors in patients who have previously received imatinib mesylate and sunitinib malate. Hepatocellular carcinoma: Treatment of hepatocellular carcinoma (HCC) patients who have received sorafenib treatment.,Hypersensitivity to regorafenib¡A any component of the formulation¡A or sorafenib.,Hypertension¡A Fatigue¡A dysphonia¡A pain¡A fever¡A headache¡A Palmar-plantar erythrodysesthesia¡A rash¡A alopecia¡A Hypocalcemia¡A hypophosphatemia¡A hyponatremia¡A hypokalemia¡A hypothyroidism¡A Appetite decreased¡A lipase increased¡A diarrhea¡A mucositis¡A weight loss¡A amylase increased¡A nausea¡A vomiting¡A Anemia¡A lymphopenia¡A thrombocytopenia¡A INR increased¡A hemorrhage¡A neutropenia¡A AST increased¡A ALT increased¡A hyperbilirubinemia¡A Stiffness¡A Proteinuria¡A Infection.,30¢J¥H¤U,160 mg (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.Take Stivarga at the same time each day. Swallow tablet whole with a low-fat breakfast that contains less than 30% fat. Examples of a low-fat breakfast include 2 slices of white toast with 1 tablespoon of low-fat margarine and 1 tablespoon of jelly¡A and 8 ounces of skim milk (319 calories and 8.2 g fat); or 1 cup of cereal¡A 8 ounces of skim milk¡A 1 slice of toast with jam¡A apple juice¡A and 1 cup of coffee or tea (520 calories and 2 g fat).,»Ý½Õ¾ã¾¯¶q,Preexisting severe impairment (total bilirubin >3 times ULN): Use is not recommended,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,(UPp to date) Pregnancy Risk Factor: D ¥é³æ: Ãh¥¥¤À¯ÅD; ±Â¨Å:¸T¥Î,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OBECA,Entecavir,Becavir 0.5mg,QANB,,¾AÀ³¯g:Treatment of chronic HBV infection in adults with evidence of active viral replication & either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. °Æ§@¥Î:Diarrhea¡A dyspepsia¡A nausea¡A vomiting. Fatigue. Headache¡A dizziness¡A somnolence. Insomnia. Gastrointestinal: Nausea (all grades¡A 3% or greater; grade 2 to 4¡A less than 1% ) Neurologic: Dizziness (all grades¡A 3% or greater; grade 2 to 4¡A less than 1% )¡A Headache (all grades¡A 3% or greater; grade 2 to 4¡A 2% to 4% ) Other: Fatigue (all grades¡A 3% or greater; grade 2 to 4¡A 1% to 3% ) ¸T§Ò:Patients who previously demonstrated hypersensitivity to entecavir.,,,Active type B viral hepatitis¡A chronic: (nucleoside-treatment-naive patients) 0.5 mg ORALLY once daily Active type B viral hepatitis¡A chronic: (history of hepatitis B viremia while receiving lamivudine or known lamivudine resistant mutations) 1 mg ORALLY once daily,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,HIV: [U.S. Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection. Determine HIV status prior to initiating treatment with entecavir. Not recommended for HIV/HBV coinfected patients unless also receiving highly active antiretroviral therapy (HAART).,,,,,,
OZYD,Aripiprazole,Zydus Aripiprazole 10mg,CNEU,,¾AÀ³¯g: Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years. °Æ§@¥Î: Headache¡A asthenia¡A accidental injury¡A peripheral edema¡A hypertension¡A GI disturbances¡A myalgia¡A agitation¡A anxiety¡A insomnia¡A lightheadedness¡A somnolence¡A akathisia¡A extrapyramidal syndrome¡A tremor¡A increased salivation¡A rhinitis¡A pharyngitis¡A coughing¡A blurred vision. Endocrine metabolic: Weight increased (2% to 30% ) Gastrointestinal: Constipation (5% to 11% )¡A Nausea (8% to 15% )¡A Vomiting (3% to 11% ) Neurologic: Akathisia (2% to 25% )¡A Dizziness (4% to 10% )¡A Extrapyramidal disease (2% to 27.3% )¡A Headache (12% to 27% )¡A Insomnia (8% to 18% )¡A Sedated (1% to 8% )¡A Somnolence (5% to 26.3% )¡A Tremor (2% to 11.8% ) Ophthalmic: Blurred vision (3% to 8% ) Psychiatric: Anxiety (4% to 17% )¡A Restlessness (2% to 12% ) Other: Fatigue (2% to 11% ) ¸T§Ò: Known hypersensitivity to aripiprazole.,,«Ç·Å,Schizophrenia Acute treatment: Adult Initially 10 mg or 15 mg once daily. Dose may be increased at intervals of not < 2 weeks. Effective dose range: 10-30 mg/day. Adolescent 13-17 years Initially 2 mg/day¡A titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Bipolar disorder Acute treatment: Adult Initially 15 mg once daily¡A may be increased to 30 mg/day. Children 10-17 years Initially 2 mg/day¡A titrated to 5 mg/day after 2 days & to the target dose of 10 mg/day after 2 additional days. Subsequent dose increases should be administered in 5-mg/day increment. Max: 30 mg/day. Adjunctive treatment of major depressive disorder Acute treatment: Adult Initially 2-5 mg/day. Dose range: 2-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week. Irritability associated with autistic disorder Children 6-17 years Initially 2 mg/day. Dose range: 5-15 mg/day. Gradually adjust dose up to 5 mg/day at intervals of not < 1 week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OCOV7,Alendronate,Covaxin 70mg,META,,¾AÀ³¯g: ¡E Treatment of osteoporosis in postmenopausal women ¡E Treatment to increase bone mass in men with osteoporosis °Æ§@¥ÎCommon: Common ¡½Gastrointestinal: Abdominal pain (2.1% to 6.6% )¡A Constipation (0.3% to 3.1% )¡A Diarrhea (0.6% to 3.1% )¡A Flatulence (2.6% to 4.1% )¡A Indigestion (1.7% to 3.6% )¡A Vomiting (pediatric patients¡A 29.4% ) ¡½Neurologic: Headache (2.6% ) ¡½Other: Fever (24% )¡A Influenza-like symptoms Serious ¡½Gastrointestinal: Duodenal ulcer disease¡A Esophageal erosions¡A Esophageal perforation¡A Esophageal stricture¡A Esophagitis (1.5% )¡A Gastric ulcer (up to 13.2% )¡A Ulcerative pharyngitis¡A acute¡A Ulcer of esophagus (1.5% ) ¡½Immunologic: Hypersensitivity reaction ¡½Musculoskeletal: Arthralgia¡A Aseptic necrosis of bone of jaw (0.017% to 0.03% )¡A Bone pain¡A Myalgia ¸T§Ò: ¡E Abnormalities of the esophagus which delay emptying such as stricture or achalasia ¡E Inability to stand/sit upright for at least 30 minutes ¡E Increased risk of aspiration ¡E Hypocalcemia ¡E Hypersensitivity to any component of this product,,«Ç·Å,1 tab once weekly.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OSER1,Paroxetine,Seroxat CR 12.5mg,CNEU,¡½Generalized anxiety disorder ¡½Major depressive disorder ¡½Obsessive-compulsive disorder ¡½Panic disorder ¡½Posttraumatic stress disorder ¡½Premenstrual dysphoric disorder ¡½Social phobia,¡½coadministration with an MAOI¡A including linezolid or IV methylene blue¡A or use of paroxetine hydrochloride within 14 days of discontinuing an MAOI used to treat psychiatric disorders¡A or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing paroxetine hydrochloride; increased risk of serotonin syndrome ¡½concomitant use with pimozide ¡½concomitant use with thioridazine ¡½hypersensitivity to paroxetine or any component of the product,Common ¡½Cardiovascular: Palpitations (up to 3% )¡A Vasodilatation (2% to 4% ) ¡½Dermatologic: Diaphoresis (5% to 14% ) ¡½Gastrointestinal: Constipation (up to 16% )¡A Diarrhea (up to 18% )¡A Loss of appetite (up to 9% )¡A Nausea (up to 26% )¡A Xerostomia (9% to 18% ) ¡½Neurologic: Asthenia (up to 22% )¡A Dizziness (6% to 14% )¡A Headache (17% to 27% )¡A Insomnia (up to 24% )¡A Somnolence (up to 24%)¡A Tremor (4% to 11% ) ¡½Ophthalmic: Blurred vision (up to 5% ) ¡½Reproductive: Abnormal ejaculation (13% to 28% )¡A Impotence (2% to 9% )¡A Orgasm disorder (females; 2% to 9% )¡A Reduced libido (males: 6% to 15%; females: 0% to 9%) ¡½Respiratory: Yawning (4% ) Serious ¡½Dermatologic: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis ¡½Hepatic: Acute hepatitis (rare) ¡½Neurologic: Seizure (0.1% ) ¡½Psychiatric: Depression¡A exacerbation¡A Suicidal thoughts (rare)¡A Suicide (rare) ¡½Other: Serotonin syndrome,Àx¦s·Å«×¤£¶W¹L25¢J,Major depressive disorder: controlled-release¡A 25 mg/day orally in the morning; may increase dosage by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 62.5 mg/day Panic disorder: controlled-release¡A 12.5 mg/day orally in the morning; may increase dosage by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 75 mg/day Premenstrual dysphoric disorder: controlled-release¡A 12.5 mg/day orally in the morning; may increase to 25 mg/day at interval of at least 1 week; may be administered daily throughout the menstrual cycle or limited to daily administration during the luteal phase of the menstrual cycle Social phobia: controlled-release¡A 12.5 mg/day orally in the morning; may be increased by 12.5-mg/day increments at intervals of at least 1 week to a maximum dose of 37.5 mg/day,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ±wªÌ«ØÄ³±N¾¯¶q­­¨î¦b³Ì§C½d³ò,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A»Ý¾ãÁû§]ªA¡A¤Å«r¸H¡BÀ£¸H¡B­é¥b©Î¿i¯»¡C
IAET,Polidocanol,Aethoxysklerol 2% 2mL/amp (±M®×¶i¤f),CAVS,,¾AÀ³¯g: Treatment of small¡A uncomplicated varicose veins of the lower extremities °Æ§@¥Î: >10%: Local: Hematoma (42%)¡A irritation (41%)¡A discoloration (38%)¡A pain (24%)¡A pruritus (19%)¡A warmth (16%) 1% to 10%: Local: Neovascularization (8%)¡A injection site thrombosis (6%) ¸T§Ò: Hypersensitivity to polidocanol or any component of the formulation; acute thromboembolic diseases,,,Adult Varicose veins of lower extremity: initial¡A 0.5-1ml; depending on the outcome and the length of of the segment to be treated¡A several injections with up to 2ml per injection may be administered in subsequent treatment sessions. Max. 2mg/kg/day. Pediatric Safety and efficacy have not been established.,,,,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,For intravenous use only. Avoid extravasation. After injection¡A apply compression in the form of a stocking or bandage (maintain for 2-3 days [spider veins] and 5-7 days [reticular veins]). After applying compression¡A patient should walk for 15-20 minutes and be observed for anaphylactic or allergic reaction.
IHLF,Heparin,Hepac Lock Flush 1000 Unit/10mL,HEMT,Solution is intended for maintenance of patency of intravenous injection devices only. (central line use),Hypersensitivity to the drug¡A Bleeding disorders¡A Severe thrombocytopenia¡A Patients who can't undergo regular blood coagulation tests,Hemorrhage¡A allergic reactions,20-25¢J,Adult dosing: Port-A flush only. Hepac Lock Flush Solution is intended for maintenance of patency of intravenous injection devices only and is not to be used for anticoagulant therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IRR;IRRI;,,,,,¤£¥i¥Î©ó¦Ù¦×ª`®g¡C
IDOPA,Dopamine,Dopamin inj 200mg/5mL,CAVS,Correction of poor perfusion¡A low cardiac output¡A impending renal failure & shock associated with MI¡A trauma¡A endotoxic septicemia¡A open heart surgery¡A heart failure.,Phaeochromocytoma; uncorrected hypovolaemia; uncorrected tachyarrhythmia or ventricular fibrillation.,Most frequently: ectopic beats¡A nausea¡A vomiting¡A tachycardia¡A anginal pain¡A palpitations¡A dyspnoea¡A headache¡A hypotension & vasoconstriction. Other infrequent side effects include aberrant conduction¡A bradycardia¡A piloerection¡A widened QRS complex¡A azotaemia & hypertension.,15-30¢JÁ×¥úÁ×§K§N­á,Must be diluted before infusion. Adult usual dosage: Initially¡A 1-5 mcg/kg/minute¡A increased gradually by 1-4 mcg/kg/minute in every 10-15 minutes according to patient's cardiac and urine output¡A blood pressure. Chronic refractory congestive heart failure: Initially¡A 0.5-2 mcg/kg/minute and increased gradually until the desired response is obtained. Severely ill patients: Initially¡A 5 mcg/kg/min¡A increased gradually by 5-10 mcg/kg/minute until the desired response is obtained. Maximum: 20-50 mcg/kg/minute.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Initiate at a rate of 2~5 mcg/kg/min increment up to 20-50 mcg/kg/min if needed,1.¤Å¥[¤JÆP©ÊÃÄ«~ 2.ª`®g®ÉÀ³¿ï¸û¤jÀR¯ß¡A³Ì¦n¬O¨y«eºÛ¡A¥H¨¾¤î¥~·¸¦Ó¤Þ°_²ÕÂ´Ãa¦º©MÀôÂ¶²ÕÂ´»G¦×¥Í¦¨.¦p¦³¥²­n»Ý¥Ñ¤â©Î¨¬½ïÀR¯ßµ¹ÃÄ®É¡Aª`®g³¡¦ì¤´À³¾¨³t§ïÅÜ¨ì¸û¤jªºÀR¯ß. ¦p¦³¾¯¶q¥~·¸µo¥Í®É¡A¥ß¨è¥H§t5-10mg Phentolamine Mesylate¤§0.9%Sodium Chlorideª`®g²G10-15mL®û¼í±w³¡¥H¨¾¤î»G¦×¥Í«°©MÃa¦º.
ORAK,Rasagiline,Rakinson 1mg,CNEU,Parkinson's disease,Concomitant use with MAOIs (including other selective MAO-B inhibitors)¡A meperidine¡A methadone¡A propoxyphene¡A or tramadol due to the risk of serotonin syndrome; allow at least 14 days between rasagiline discontinuation and initiation of these agents. Concomitant use with cyclobenzaprine or St. John's wort. Concomitant use with dextromethorphan due to the risk of psychotic episodes or bizarre behavior.,Common: Orthostatic hypotension (3-44%)¡A Peripheral edema (7%)¡A Rash (3-6%)¡A Weight decreasing (2-9%)¡A Constipation (4-9%)¡A Indigestion (4-7%)¡A Nausea (6-12%)¡A Vomiting (4-7%)¡A Xerostomia (2-6%)¡A Arthralgia (5-11%)¡A Ataxia (3-6%)¡A Dizziness (7%)¡A Dyskinesia (18%)¡A Headache (6-14%)¡A Depression (5%)¡A Falling injury (5-12%)¡A Influenza-like illness (5%) Serious: Hypertension (4%)¡A Compulsive behavior¡A Serotonin syndrome,25¢J¥H¤U¡A¤ð»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Monotherapy: 1 mg once daily Adjunctive therapy with levodopa: Initial: 0.5 mg once daily; may increase to 1 mg once daily based on response and tolerability,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ¯f±w(Child-Pugh score 5 or 6) «ØÄ³ 0.5 mg orally once daily ¨x¥\¯à¤£¥þ¯f±w(Child-Pugh score 7 to 15)¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,1) Micromedex Lactation Rating: Milk effects are possible. a) Evidence suggests this drug may alter milk production or composition. If an alternative to this drug is not prescribed¡A monitor the infant for adverse effects and/or adequate milk intake. 2) Clinical Management a) Rasagiline inhibits prolactin secretion in rats¡A and may inhibit milk secretion in females. Data regarding use in lactating women are not available. Caution should be exercised when rasagiline is administered to a lactating woman.,AC;AC15;PC;PO;WM;,,,,,
EATR1,Atropine,Antol 0.125%¡A 5mL,TOPH,Topical mydriatic & cycloplegic; uveitis.,Closed- & narrow-angle glaucoma.,Stinging¡A increased intraocular pressure¡A conjunctivitis. May precipitate glaucoma.,25¢J¥H¤UÀx¦s,Ciliary muscle paralyzation: Instill 1 drop 1 to 2 times per day at conjunctiva. Age < 1 year: 0.125% or depending on the doctor¡¦s instruction. Age 1-5 years: 0.25% or depending on the doctor¡¦s instruction. Age > or = 5 years with blue iris: 0.25% or depending on the doctor¡¦s instruction. Age > or = 5 years with dark iris: 0.5% or 1% or depending on the doctor¡¦s instruction. Uveitis: Apply 1 drop in the conjunctival sac 1 to 3 times daily(0.125%-1%) For pupil dilation after operation: Instill 1 drop 1 to 3 times per day (or depending on the doctor¡¦s instruction) at conjunctiva. (0.5% or 1%),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
ISIV1,Triamcinolone,Sivkort Suspension 10mg/1mL,HM,,¾AÀ³¯g: Intra-articular Inflammatory joint disease °Æ§@¥Î: HPA axis supression¡A intracranial hypertension¡A Cushing's syndrome¡A growth retardation in children; osteoporosis¡A fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas¡A broken skin or under occlusive dressing. ¸T§Ò: Untreated systemic fungal¡A bacterial¡A viral or parasitic infection¡A hypersensitivity. Neonates (Parenteral),,«Ç·Å,Intra-articular Inflammatory joint disease As acetonide: Smaller joints: 2.5-5 mg (up to 10 mg)¡A larger joints: 5-15 mg (up to 40 mg). Max: 20-80 mg/treatment. As hexacetonide: Initial: 2-20 mg/day.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IS;,,,,,
INS5,Sodium Chloride,0.9% NaCl inj 500mL(µw²~),MSIV,¬°¥Í²z­¹ÆQ¤ôª`®g²G(A001085277),,,«Ç·Å,IV infusion as needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IRR;IRRI;IV;IVD;,,,,,
ITT4,Electrolytes + Water,¥x¤j No.4 500mL,MSIV,Supplement of water¡A electrolytes & nutrition,Hypersensitivity to any component of the formulation.,Electrolyte imbalance,30¢J¥H¤U,Central vein or peripheral vein infusion¡A as needed. Taita No.1: Na 25mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 20mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 38g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.2: Na 40mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 26mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 33g/L¡A 500mL/Bot¡A 287mOsm/L. Taita No.3: Na 75mEq/L¡A K 12mEq/L¡A Mg 0mEq/L¡A Cl 61mEq/L¡A Acetate 20mEq/L¡A Phosphate 6mM/L¡A Glucose 20g/L¡A 500mL/Bot¡A 285mOsm/L. Taita No.4: Na 110mEq/L¡A K 20mEq/L¡A Mg 0mEq/L¡A Cl 102mEq/L¡A Acetate 16mEq/L¡A Phosphate 12mM/L¡A Glucose 8g/L¡A 500mL/Bot¡A 300mOsm/L. Taita No.5: Na 36mEq/L¡A K 18mEq/L¡A Mg 3mEq/L¡A Cl 17mEq/L¡A Acetate 28mEq/L¡A Phosphate 12mM/L¡A Glucose 100g/L¡A 400mL/Bot¡A 669mOsm/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,¯SÂI¤Î¾AÀ³¯g Taita No.1: Na¡BCl ¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì§C¡F¤p¨à¥Îºû«ù²G¡B¹q¸Ñ½è¡B¤ô¥÷¡B¾i¥÷¸É¥R Taita No.2: ¦¨¤À»PTaita No.1¬Û¦ü¦ýNa¡BCl¸û¦h;¼ö¶q¤ÎK§t¶q¸û§C¡A¥i§@¬°¤p¨à©Î¦¨¤H¥Îºû«ù²G Taita No.3: NaCl§t¶q¦ü0.45 %N/S¡A¥i¥Î©óµ¥±i©Ê²æ¤ô¡B¿}§¿¯f©Ê»Ä¤¤¬r Taita No.4: Na¡BK¡BCl¬O¦U¥x¤j¹q¸Ñ½è¿é²G¤¤§t¶q³Ì°ª¡A¥i¥Î©ó§C±i©Ê²æ¤ô¡B§CÁC¦å¯g Taita No.5: ¥x¤j¹q¸Ñ½è¿é²G¨t¦C¤¤¡A§tAcetate¤Î¼ö¶q³Ì°ª¡A¥i¥Î©ó°ª¼ö¶q¹q¸Ñ½è¸É¥R²G¡B§CÁC¦å¯g
OANP,Ritodrine,Anpo 10mg,SGU,Prevention of preterm labour¡A Acute fetal distress¡A Prevention of preterm labour after operation Follow treatment for preterm labour.,Antepartum haemorrhage due to any cause but particularly placenta previa & abruptio placentae. Eclampsia & severe pre-eclampsia. Intra-uterine foetal death. Chorioamnionitis. Maternal cardiac disorder. Hyperthyroidism. Uncontrolled hypertension. Any other condition which can endanger cardiac function. Parenteral: Asthmatics (due to sulfite component).,Pulmonary oedema (several cases reported with fatal results). Maternal & foetal heart rate can increase. Frequently: Tremor¡A nausea¡A vomiting¡A headache or erythema¡A nervousness¡A restlessness¡A jitteriness¡A emotional upset¡A anxiety or malaise. Infrequently cardiac symptoms¡A eg chest pain or tightness with or without ECG abnormalities & cardiac arrhythmias. Hepatic impairment.,25¢J¥H¤U°®ÀêÁ×¥ú,Uncomplicated premature labour Adult: Start oral therapy 30 minutes before termination of IV infusion at 10 mg every 2 hours for 24 hours. Subsequently¡A 10-20 mg every 4-6 hours according to patient's response. the maximum oral dose: 120 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
IESC,Hyoscin-Butylbromide,Escopan inj 20mg/1mL,ALIM,,¾AÀ³¯g: Spasm & hyperkinesia of the GIT¡A spasm & dyskinesia of the biliary tract¡A urinary tract & female genital tracts. °Æ§@¥Î: Dry mouth¡A dyshidrosis¡A visual accommodation disturbances¡A tachycardia¡A dizziness¡A constipation¡A urinary retention¡A hypotension¡A allergic reactions¡A inj site pain. ¸T§Ò: Myasthenia gravis¡A toxic megacolon¡A narrow angle glaucoma¡A tachycardia¡A prostatic enlargement with urinary retention¡A pyloric stenosis & paralytic ileus.,,,Adult 20 mg 1-5 times daily IM/IV/SC.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IV;IVD;IVP;SC;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö>1¤ÀÄÁ,,
IEP10,Epirubicin,Epicin 10mg/5mL,RACA,Leukemia¡A lymphoma¡A breast cancer¡A sarcomas¡A small-cell lung carcinoma¡A ovarian cancer¡A gastric cancer. Liver cancer¡A head & neck cancer¡A pancreatic cancer.,Myelosuppression. Cardiac impairment. Previous full cumulative doses of anthracyclines. Pregnancy. Lactation.,Myelosuppression¡A cardiotoxicity¡A alopecia¡A mucositis¡A GI disturbances¡A hyperpyrexia.,2-8¢JÁ×¥ú,(¥é³æ) Epirubicin should be administered intravenously or intravesicularly. Do not administer epirubicin orally¡A intramuscularly or subcutaneously. A lifetime maximum cumulative dose >1000 mg/m2 should be avoided. Usual dose: 75-90 mg/m2 intravenously once every 3 weeks. Intravesicular: 50 mg once weekly for 8 weeks; dose range: 30-80 mg.,»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IRR;IVD;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C 3.Epirubicinªº²Ö¿n¾¯¶q»P¤ßÅ¦¬r©Ê¬ÛÃö¡A±N²Ö¿n¾¯¶q­­¨î¦b1000mg/m2¥H¤U¥i¥H­°§C¬ÛÃö­·ÀI.
OCAR90,Diltiazem,Cardizem Retard 90mg,CAVS,,¾AÀ³¯g: ¥Dªv°ª¦åÀ£¡B¤ßµ±µh(B021113100) Hypertension. °Æ§@¥Î: Bradycardia¡A 1st degree AV block¡A ankle edema¡A nausea¡A headache¡A skin rashes¡A finger swelling. Cardiovascular: Bradyarrhythmia (1.7% to 3.6% )¡A Peripheral edema (4.6% to 8% ) Neurologic: Dizziness (3.5% to 6.4% )¡A Headache (4.6% ) Respiratory: Cough (2% ) Other: Fatigue (4.8% ) CI: Pregnancy¡A lactation; sick sinus syndrome¡A AV block II or III¡A severe bradycardia.,,«Ç·Å,Intial: 30 mg qid ac. Maintenance: 180-360 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OCAF,Ergotamine tartrate + Caffeine,Cafergot 1/100mg,CNEU,,¾AÀ³¯g: Acute attacks of migraine & related types of vascular headache. °Æ§@¥Î: Nausea and vomiting. Paraesthesia¡A pain and weakness in the extremities or peripheral vasoconstriction may occur in susceptible patients or following prolonged treatment. If ergotamine-containing drugs are used excessively over years¡A they may induce fibrotic changes¡A in particular of the pleura and the retroperitoneum. ¸T§Ò: Impaired peripheral circulation¡A obliterative vascular disease¡A CHD; severe hypertension; renal or hepatic insufficiency¡A sepsis; pregnancy¡A lactation.,,«Ç·Å,2 tab at 1st attack.if no relief ¡A1 tab after 1/2hr. Subsequent attack initially: 3 Tab Max: 6 tab/daily and 10 tab/weekly,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
OKLU,Gliclazide,Kludone MR 60mg,META,Management of type 2 diabetes mellitus (noninsulin dependent¡A NIDDM),Hypersensitivity to gliclazide¡A other sulfonylureas or sulfonamides¡A or any component of the formulation; unstable and/or type 1 diabetes mellitus (insulin dependent¡A IDDM); diabetic ketoacidosis; diabetic pre-coma and coma; severe renal or hepatic impairment; stress conditions (eg¡A serious infection¡A trauma¡A surgery); concurrent use with miconazole (systemic or oromucosal gel); pregnancy; breast-feeding,Hypoglycemia¡A Hypertension¡A angina¡A peripheral edema¡A Headache¡A dizziness¡A depression¡A insomnia¡A Skin disorder¡A dermatitis¡A rash¡A pruritus¡A¡A hyperlipidemia¡A lipid metabolism disorder¡A Diarrhea¡A constipation¡A gastroenteritis¡A abdominal pain¡A gastritis¡A nausea¡A Urinary tract infection¡A Back pain¡A arthralgia¡A weakness¡A arthrosis¡A myalgia¡A arthritis¡A neuralgia¡A tendonitis¡A Conjunctivitis¡A Otitis media¡A Bronchitis¡A rhinitis¡A pharyngitis¡A upper respiratory infection¡A cough¡A pneumonia¡A sinusitis¡A Viral infection,25¢J¥H¤U³±²D°®Àê³B,0.5-2 TAB once daily at breakfast. (30-120 mg/day),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,upper table (according to up to date) Pregnancy Implications: Use during pregnancy is contraindicated. Lactation: Excretion in breast milk unknown/contraindicated. Breast-Feeding Considerations: Potential for neonatal hypoglycemia in a nursing infant contraindicates use.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
EVIRL,Acyclovir,Virless cream 5%¡A 5gm,TDER,Herpes simplex virus infection of the skin including initial & recurrent genital herpes & herpes labialis.,Patients known to be hypersensitive to acyclovir or propylene glycol.,Transient burning or stinging. Mild drying & flaking. Erythema & itching. Dermatologic: Application site reaction¡A Topical Preparation (5% )¡A Contact dermatitis¡A Topical Preparation (2% ) Gastrointestinal: Diarrhea (2.4% to 3.2% )¡A Nausea (2.4% to 4.8% )¡A Vomiting Neurologic: Headache (2.2% ) Other: Malaise (11.5% ),25¢J¥H¤UÁ×¥úÀx¦s,Herpes simplex: Initial therapy: Apply ointment topically every 3 hours (6 times per day) for 7 days in sufficient quantities to adequately cover lesion,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;,,,,,
OBAR1,Entecavir,1mg BARACLUDE,QANB,Treatment of chronic active type B viral hepatitis or reactivation of hepatitis B viral hepatitis in adults and children over 2 years of age.,Hypersensitivity to entecavir or any component of the formulation.,Common: Nausea (Adult¡A <1%; Pediatric¡A >1%)¡A Dizziness (<1%)¡A Headache (2-4%)¡A Fatigue (1-3%) Serious: Lactic acidosis¡A Hepatomegaly (Severe)¡A With steatosis¡A Recurrent hepatitis,30¢J¥H¤UÁ×¥ú,Administer on an empty stomach (2 hours before or after a meal). Adults and adolescents > 16 years: nucleoside-treatment naive¡A compensated liver disease: 0.5 mg once daily; decompensated liver disease: 1 mg once daily. Children and adolescents 2 to <16 years: 10 to 11 kg: 0.15 mg oral solution once daily >11 to 14 kg: 0.2 mg oral solution once daily >14 to 17 kg: 0.25 mg oral solution once daily >17 to 20 kg: 0.3 mg oral solution once daily >20 to 23 kg: 0.35 mg oral solution once daily >23 to 26 kg: 0.4 mg oral solution once daily >26 to 30 kg: 0.45 mg oral solution once daily >30 kg: 0.5 mg oral solution or tablet once daily,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]¦b¥¥°ü¤¤¨ÃµL¾A·í¥B¨ã¦³¨}¦n¹ï·ÓªºBARACLUDE¬ã¨s¡C¦]¬°°Êª«¥Í´Þ¬ã¨s¥¼¥²¯à¹w´ú¤HÅéªº¤ÏÀ³¡A©Ò¥H¥u¦³¦b¼ç¦b®Ä¯q°ª©ó¹ï­L¨àªº¼ç¦b­·ÀI®É¡A¤è¯à©óÃh¥¥´Á¶¡¨Ï¥ÎBARACLUDE (entecavir)¡C ¦b°Êª«¥Í´Þ¬ã¨s¤¤¡Aentecavir ¹F¨ìÁ{§É·N¸q¼ÉÅS®É¡A¨Ã¥¼Æ[¹î¨ì¤£¨}µo¨|¼vÅT¡C¥þ¨­¼ÉÅS¶q (AUC) ¬ù¬°¤HÃþ³Ì¤j«ØÄ³¾¯¶q (MRHD) ¨C¤é1 mgªº 25 ­¿ (¤j¹«) »P 200­¿ (¨ß¤l) ®É¡A¨Ã¥¼Æ[¹î¨ìµo¨|¬r©Ê¡C¦b­L¨à¾¹©x§Î¦¨´Á¶¡ (§³®W²Ä 6 ¦Ü 15 ¤Ñ [¤j¹«] »P§³®W²Ä 6 ¦Ü 18 ¤Ñ [¨ß¤l])¡A¹ïÃh¥¥ªº¤j¹« (¨C¤é¨C¤½¤çÅé­« 2¡B20 ¤Î 200 ²@§J) »P¨ß¤l (¨C¤é¨C¤½¤çÅé­« 1¡B4 ¤Î 16 ²@§J) ¤fªA¬I¥Î entecavir¡C¦b¤j¹«¤¤¡A·í¥ÀÅé¥þ¨­¼ÉÅS (AUC) ¬° MRHD ªº 3100 ­¿®É¡AÆ[¹î¨ì­F­L¡Ð­L¨à¬r©Ê¡A¥]¬AµÛ§É«á¬y²£¡B­F­L¦A§l¦¬¡B§À¤Ú»P¯á´Õ·î§Î¡B°©ÀfÅÜ¤Æ¡A¥]¬A¦¨°©¤£¥þ (¯á´Õ¡B¯Ý°©¸`»P«ü°©)¡B¦h¾lªº¸y´Õ»P¦Ø°©¡B­L¨àÅé­«¸û»´¡C¦b¸Ó¾¯¶q¿@«×¤]Æ[¹î¨ì¥ÀÅé¬r©Ê¡C¦b¨ß¤l¤¤¡A·í¥ÀÅé¥þ¨­¼ÉÅS (AUC) ¬° MRHDªº 883 ­¿®É¡AÆ[¹î¨ì­F­L¡Ð­L¨à¬r©Ê¡A¥]¬AµÛ§É«á¬y²£¡B­F­L¦A§l¦¬¤Î°©ÀfÅÜ¤Æ¡A¥]¬A¦¨°©¤£¥þ (¦Þ°©)¡B²Ä 13 ¦Ø°©ªºµo¥Í²v¼W¥[¡C·íÃh¥¥°Êª«¤fªA¬I¥Îªº entecavir¬ù¬° 28 ­¿ (¤j¹«) »P 212 ­¿ (¨ß¤l) ¤§ MRHD ¤HÅé¼ÉÅS¶q (AUC) ®É¡A¨ÃµL­F­L¡Ð­L¨à¬r©Êªº²{¶H¡C¦b²£«e¤Î²£«áµo¨|¸ÕÅç¤¤¡A±q§³®W²Ä 6 ¤Ñ¦Ü­÷¨Å´Á/²£«á 20 ¤Ñ¡A¹ïÃh¥¥¤j¹«¤fªA¬I¥Î entecavir¡A¾¯¶q¬°¨C¤é¨C¤½¤çÅé­« 0.3¡B3 ¤Î 30 ²@§J¡C¦bµû¦ôªº³Ì°ª¾¯¶q¤U¡A¼ÉÅS¶q (AUC) °ª©ó MRHD 94 ­¿¡A¨Ã¥¼¹ï«á¥N²£¥Í¤£¨}¼vÅT¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Breastfeeding Recommendation: Contraindicated (HIV) ; No Human Data¡XProbably Compatible (Hepatitis B) [¥é³æ]¥Ø«e©|¤£²M·¡ BARACLUDE ¬O§_·|±Æ¤J¤HÃþ¨Å¥Ä¡B¼vÅT¥À¨Å¤Àªc¡A©Î¹ï­÷¨ÅÀ¦¨à³y¦¨¼vÅT¡C ¦b¤j¹«­÷¨Å´Á¬I¥Î®É¡Aentecavir ·|¥X²{¦b¨Å¥Ä¤¤ (½Ð¨£¸ê®Æ)¡C¦b¦Ò¶q­÷Áý¥À¨Å¹ïµo¨|©M°·±d®Ä¯q®É¡AÀ³¤@¨Ö¦Ò¶q²£°ü¹ï BARACLUDE ªºÁ{§É»Ý¨D¡A¥H¤Î BARACLUDE©Î²£°üªº¨­Åéª¬ªp¹ïÁý­÷¥À¨ÅÀ¦¨àªº©Ò¦³¥i¯à¤£¨}¤ÏÀ³¡C¦b¤j¹«­÷¨Å²Ä7¤Ñ¤fªA³æ¾¯ entecavir 10 mg/kg «á¡Aentecavir ·|¤Àªc¦Ü¤j¹«ªº¨Å¥Ä ¤¤¡C¨Å¥Ä¤¤ªº entecavir ¬ù¬°¥ÀÅé¦å¼ß¤¤ªº 25% (®Ú¾Ú AUC)¡C,AC;AC15;PO;,,,,,
EHYD,Hydrocortisone,Hydrocortisone cream 1%¡A 10gm,TDER,Relief of inflammation of corticosteroid-responsive dermatoses (low and medium potency topical corticosteroid); adjunctive treatment of ulcerative colitis; mild-to-moderate atopic dermatitis; inflamed hemorrhoids¡A postirradiation (factitial) proctitis¡A and other inflammatory conditions of anorectum and pruritus ani,Hypersensitivity to any component of the formulation.,Acneiform eruptions¡A burning¡A dryness¡A folliculitis¡A hypertrichosis¡A hypopigmentation¡A irritation¡A itching¡A maceration of skin¡A miliaria¡A perioral dermatitis¡A secondary infection¡A skin atrophy¡A striae,25¢J¥H¤U,Apply thin film to affected area 2-4 times/day,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
IMEP,Meropenem,Mepem inj 0.5gm,QANB,,¾AÀ³¯g: Septicemia¡A phlegmon¡A lymphadenitis¡A tonsillar abscess¡A osteomyelitis¡A arthritis¡A periproctic abscess¡A traumatic wound infection¡A burn wound infection¡A operative wound infection¡A chronic bronchitis¡A bronchiectasis (with infection)¡A secondary infection in chronic respiratory disease¡A pneumonia¡A lung abscess & pyothorax¡A pyelonephritis¡A complicated cystitis¡A cholecystitis¡A cholangitis¡A & liver abscess¡A peritonitis¡A uterine adnexitis¡A intrauterine infection¡A inflammation of pelvic dead space¡A & parametritis¡A purulent meningitis¡A panophthalmitis¡A otitis media & sinusitis¡A gnathitis & phlegmon around the jaw. °Æ§@¥Î: Shock¡A serious renal disorders including acute renal failure¡A serious colitis accompanied with bloody stool¡A pseudomembranous colitis¡A interstitial pneumonia & PIE syndrome. CNS convulsion e.g. seizures¡A consciousness disorders. Lyell syndrome¡A Steven-Johnson syndrome¡A pancytopenia¡A agranulocytosis¡A leucopenia¡A hepatic disorders¡A jaundice¡A rash¡A urticaria¡A feeling of warmth¡A erythema¡A pruritus¡A fever & redness. Granulocytopenia¡A eosinophilia¡A thrombocytopenia or thrombocytosis & lymphocytosis increased GOT/GPT/LDH/A1-P/LAP/£^-GTP/bilirubin/urinary urobilinogen¡A decreased cholinesterase¡A increased urinary £]2-microglobulin/BUN/creatinine¡A abdominal pain¡A diarrhea¡A nausea¡A vomiting & anorexia¡A stomatitis¡A candidiasis¡A vit K deficiency symptoms¡A vit B complex deficiency symptoms¡A headache¡A malaise. Dermatologic: Injection site inflammation (2.4% ) Gastrointestinal: Constipation (1.4% to 7% )¡A Diarrhea (3.5% to 7% )¡A Nausea and vomiting (3.6% adults; 0.8% children ) Neurologic: Headache (2.3% to 7.8% ) ¸T§Ò: Hypersensitivity; coadministration with Na valproate.,,«Ç·Å,Adult 0.5-1 g IV infusion over > 30 min daily in 2-3 divided doses. Max: 2 g/day. Children 30-60 mg/kg IV infusion over > 30 min daily in 3 divided doses. May increase to 120 mg/kg but not exceeding the adult max daily dose of 2 g. Renal impairment: (Adults) Clcr 26-50 mL/minute: Administer recommended dose based on indication every 12 hours Clcr 10-25 mL/minute: Administer one-half recommended dose based on indication every 12 hours Clcr <10 mL/minute: Administer one-half recommended dose based on indication every 24 hours Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Meropenem and its metabolite are readily dialyzable: 500 mg every 24 hours.,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡Aª`·N¬O§_¦³¦Ù¦×¾_Å¸©ÎÅöíwµo§@¼xª¬¡C 2. µ¹ÃÄ«á²Ä3 ~ 5¤ÑÀ³¯S§OÆ[¹î¥Ö¯lµ¥¤£¨}¤ÏÀ³¡C 3. Meropenem 0.5 gm/vial °®¯»¨Ï¥Î100 mL¾A·í¿éª`²Gµ}ÄÀ¡AÀR¯ßÂIºw¿éª` > 30¤ÀÄÁµ¹ÃÄ¡C
ITPN2,TPN Solution,TPN-2 Solution,NUTR,,¾AÀ³¯g:¬°20%ÀR¯ßÀç¾i¿éª`²G(TPN0502297),,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
OPIL,Cyproheptadine,Pilian 4mg,HIMM,Allergic rhinitis¡A vasomotor rhinitis¡A urticaria¡A allergic skin & blood disorders. Pruritus due to chicken pox.,Acute asthmatic attack. Premature infants,Sedation; drowsiness; dry mouth¡A nose & throat; Increase thickness of bronchial secretion¡A dizziness¡A upper abdominal discomfort.,25¢J¥H¤UÁ×¥ú,Adult: 1 TAB TID-QID. Children: 7-14years 1/2 TAB¡A 2-6 years 1/4 TAB TID-QID.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment provided in manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EKAR,Tazarotene,Karac cream 0.1%¡A 30gm,TDER,,¾AÀ³¯g: Stable plaque psoriasis¡A acne vulgaris. °Æ§@¥Î: Pruritus¡A burning/stinging¡A erythema¡A worsening of psoriasis¡A irritation¡A pain¡A rash¡A desquamation¡A irritation¡A contact dermatitis. ¸T§Ò: Pregnancy.,,«Ç·Å,Apply once daily at night.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
OSMO2,Nicotine,Smokquit Mint Lozenges 2mg¤f§t¿õ,ZADT,,,,,(Uptodate) Lozenge: Do not use more than 1 lozenge at a time. 4 mg for patients who smoke their first cigarette within 30 minutes of waking; 2 mg for others. The 12-week dosing schedule: Weeks 1-6: 1 lozenge every 1-2 hours (max: 5 lozenges Q6H; 20 lozenges/day); to increase chances of quitting¡A use at least 9 lozenges/day during the first 6 weeks. Weeks 7-9: 1 lozenge every 2-4 hours (max: 5 lozenges Q6H; 20 lozenges/day). Weeks 10-12: 1 lozenge Q4-8H (max: 5 lozenges Q6H; 20 lozenges/day).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,
IPROP,Propofol,Propofol-Lipuro 1% 20mL,ZANE,Induction of anesthesia in patients >=3 years of age; maintenance of anesthesia in patients >2 months of age; in adults¡A for monitored anesthesia care sedation during procedures; in adults¡A for sedation in intubated¡A mechanically-ventilated ICU patients.,Pregnancy¡A lactation & obstetrics (except abortion). General anesth in children <1 month & for sedation of children <16 years in ICU.,>10%:Cardiovascular: Hypotension (children 17%; adults 3% to 26%); Central nervous system: Movement (children 17%; adults 3% to 10%); Local: Injection site burning¡A stinging¡A or pain (children 10%; adults 18%); Respiratory: Apnea lasting 30-60 seconds (children 10%; adults 24%)¡A apnea lasting >60 seconds (children 5%; adults 12%) 1% to 10%: Cardiovascular: Hypertension (children 8%)¡A arrhythmia (1% to 3%)¡A bradycardia (1% to 3%)¡A cardiac output decreased (1% to 3%; concurrent opioid use increases incidence)¡A tachycardia (1% to 3%); Dermatologic: Pruritus (1% to 3%)¡A rash (children 5%; adults 1% to 3%); Endocrine & metabolic: Hypertriglyceridemia (3% to 10%); Respiratory: Respiratory acidosis during weaning (3% to 10%) <1% (Limited to important or life-threatening): Agitation¡A amblyopia¡A anaphylaxis¡A anaphylactoid reaction¡A anticholinergic syndrome¡A asystole¡A atrial arrhythmia¡A bigeminy¡A cardiac arrest¡A chills¡A cough¡A dizziness¡A delirium¡A discoloration (green [urine¡A hair¡A or nailbeds])¡A extremity pain¡A fever¡A flushing¡A hemorrhage¡A hypersalivation¡A hypertonia¡A hypomagnesemia¡A hypoxia¡A infusion site reactions (including pain¡A swelling¡A blisters and/or tissue necrosis following accidental extravasation); laryngospasm¡A leukocytosis¡A lung function decreased¡A myalgia¡A myoclonia (rarely including convulsions and opisthotonos)¡A nausea¡A pancreatitis¡A paresthesia¡A phlebitis¡A postoperative unconsciousness with or without increase in muscle tone¡A premature atrial contractions¡A premature ventricular contractions¡A pulmonary edema¡A propofol-related infusion syndrome¡A rhabdomyolysis¡A somnolence¡A syncope¡A thrombosis¡A urine cloudy¡A vision abnormality¡A wheezing,25¢J¥H¤UÁ×§K§N­á,Given intravenously. Induction of general anesthesia: 20-40 mg every 10 seconds titrated against the patient's response. Adult < 55 years: 1.5-2.5 mg/kg IV. Patients > 55 years and of ASA (American society of anesthesiologists) grade III/IV may reduce dosage to 1 mg/kg and apply slower rate (20mg every 10 seconds). Children 1 month-3 years: 2.5-4 mg/kg. Children > 8 years: 2.5 mg/kg. Maintenance of general anesthesia: Adult: Continuous IV infusion: 4-12 mg/kg/hour. Adult: Repeat IV bolus: increments of 25-50 mg may be given according to clinical need. Children: 9-15 mg/kg/hour. Sedation of mechanically ventilated patients receiving intensive care: Continuous infusion: infusion rate should be determined by the desired depth of sedation. Rates at 0.3-4 mg/kg/hour should achieve satisfactory sedation. Do not use in sedation of ventilated ICU patients who is under 16 years. Procedural sedation for adults: Induction: 0.5-1 mg/kg over 1-5 minutes. Maintenance: 1.5-4.5 mg/kg/hour. In addition to the infusion¡A bolus administration of 10-20 mg may be used for rapid increase in the depth of sedation.Do not use in sedation for surgical & diagnostic procedures patients who is under 16 years.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥þ³Â¥Îªk IVD:50~100mcg/kg/min¡A¿éª`®É¶¡¤£©y¶W¹L12¤p®É¡A¨Ï¥Î¿@«×¤Å§C©ó2mg/mL¡C(³Ì¤jµ}ÄÀ¤ñ¨Ò 1:4),1.¨Ï¥Î¿@«×¤Å§C©ó2 mg/mL¡C(³Ì¤jµ}ÄÀ¤ñ¨Ò 1:4) 2.¿éª`®É¤£¥i¨Ï¥Î§t·L¥Íª«¹LÂo¾¹¤§¿é²G®M¡C¿éª`¥»«~«ØÄ³¨Ï¥Î¬y³tºw©w©ÎÅé¿n³]©wÀ°®ú±±¨î¬y³t¡C 3.¥»«~¤£§t¨¾»G¾¯¡A¶}²~«áÀ³¥ß§Y©â¨ú¦ÜµLµß°wµ©©Î¿é²G®M¡A³Ñ¾lªº´Ý¶qÀ³¥á±ó¤£¥Î¡C 4.¿éª`¥¼¸gµ}ÄÀªºPropofol 1% 20mL®É¡A¨Ï¥Î¦P¤@¨t²Î¿éª`®É¶¡¤£©y¶W¹L12¤p®É¡C¨Ï¥Î12¤p®É«á¡A¿éª`ºÞ¸ô»P³Ñ¾lªºÃÄª«À³¥á±ó¡B§ó´«¡C 5.¿éª`µ}ÄÀ¹LªºPropofol 1% 20mL®É¡AÀ³©ó§ëÃÄ«e¥HµLµß¾Þ§@¥ß§Y½Õ°t¡A¥B°È¥²©ó6¤p®É¤º¨Ï¥Î¡C 6.¥i¥HÂÇ¥Ñ¿ï¾Ü«eÁu¤Î¨y«eºÛ³B¸û¤jÀR¯ß¦åºÞ¶i¦æª`®g¨Ó´î§C¯kµh¡C
OMUCR,Iodopropylidene Glycerol,Mucora 30mg,ERSP,,Reduce the viscosity of sputum and expectorant.,,RT,Adult: 30-60 mg¡A tid-qid¡A Child: 30-60 mg/10kg¡A tid-qid.,,,,¤£¥i¨Ï¥Î,,,,,,,,,,
IMEA1,Measles Vaccine,³Â¯l¬Ì­](§K¶O),HIMM,,,,,,,,,,,,,,,,,,,
IXYL2,Lidocaine,Xylocaine 2% inj 20mL§½³Â,ZANE,For the production of local or regional anesth by infiltration¡A IV regional anesth¡A minor & major nerve blocks¡A epidural block & subarachnoid block.,Epidural or spinal anesth in patients with uncorrected hypotension or with coagulation disorders or receiving anti-coagulation treatment; inflammation &/or sepsis in the region of proposed inj or in the presence of septicemia; general contraindications related to epidural anesth should also be taken into account.,CNS reactions¡A either excitatory or depressant. CV reactions¡A mainly depressant. Maternal hypotension. Rarely allergic reactions.,25¢J¥H¤UÁ×§K§N­á,Maximum recommended single dose of lidocaine is 3 mg/kg (plain solution) or 7 mg/kg (solution with adrenaline). Adult¡A 70 kg: Retrobulbar or peribulbar: 4 mL of 2% solution (80 mg). Sciatic nerve block: 15-20 mL of 2% solution (300-400 mg). Epidural anesthesia¡A Lumbar: 15-25 mL of 2% solution (300-500 mg). Epidural anesthesia¡A Thoracic: 15-20 mL of 2% solution (300-400 mg).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IRR;LA;LI;,,,,,
OMUCA,Oxethazaine+Aluminum hydroxide+Magnesium oxide,Mucaine,ALIM,Symptomatic relief of gastric pain & heartburn due to gastric hyperacidity.,Hypophosphatemia; severe renal impairment; symptoms of appendicitis.,Hypersensitivity reactions¡A dermatitis¡A urticaria¡A pruritus¡A glossitis¡A angioedema & collapse. In large doses¡A dizziness¡A faintness or drowsiness. Diarrhea¡A constipation.,±K³¬¸m©ó§N·t³B,2-4 TAB QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC15;PO;,,,,,
IPAR,Carboplatin,Paraplatin inj 150mg/15mL,RACA,Ovarian cancer¡A advanced: Initial treatment of advanced ovarian cancer in combination with other established chemotherapy agents; palliative treatment of recurrent ovarian cancer after prior chemotherapy¡A including cisplatin-based treatment.,History of severe allergic reaction to carboplatin¡A cisplatin¡A other platinum-containing formulations¡A mannitol¡A or any component of the formulation; should not be used in patients with severe bone marrow depression or significant bleeding.,Myelosuppression especially thrombocytopenia¡A leukopenia; nausea & vomiting¡A abdominal pain¡A diarrhea¡A constipation; nephrotoxicity; neurotoxicity including paresthesia & decreased deep tendon reflexes; transient visual disturbances¡A ototoxicity manifesting as tinnitus; abnormal liver function tests; hypersensitivity reactions.,15-25¢JÁ×¥ú,CALVERT FORMULA FOR CARBOPLATIN DOSING: Total Dose (mg) = (target AUC mg/mL¡Emin)) x (GFR mL/min + 25)Target AUC of 4-6 mg/mL¡Emin using single-agent carboplatin appears to provide the most appropriate dose range in previously treated patients.  [Recurrent Ovarian Carcinoma] 360 mg/m2 as a single agent on day 1 every 4 weeks. Treatment course should not be repeated until the neutrophil count is > 2¡A000 and the platelet count is > 100¡A000.  [Advanced Ovarian Cancer¡A previously untreated] 300 mg/m2 in combination with cyclophosphamide 600 mg/m2 on day 1 every 4 weeks for 6 cycles. Treatment course should not be repeated until the neutrophil count is > 2¡A000 and the platelet count is > 100¡A000.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,PARAPLATIN ³q±`¿éª`15 ¤ÀÄÁ¥H¤W,1. «Ç·Å¡A°t»s«á¦w©w©Ê«Ç·Å8¤p®É 2. ¤£¥i¨Ï¥Î§t¾T°wÀY©Î¥i¯à»PÃÄ«~±µÄ²³¡¦ì§t¾TªºÀR¯ßµ¹ÃÄ¾¹²Õ¡C
ILAN,Insulin glargine,Lantus inj 100U/mL 3mL pre-filled Pen,META,,¾AÀ³¯g:Treatment of type 1 diabetes mellitus (insulin dependent¡A IDDM) and type 2 diabetes mellitus (noninsulin dependent¡A NIDDM) to improve glycemic control. °Æ§@¥Î:Primarily symptoms of hypoglycemia ¸T§Ò:Hypersensitivity to insulin glargine or to any of the excipients.,,2-8 C,---Diabetes mellitus¡A type 2: SubQ: Initial basal insulin dose: 10 units (or 0.2 units/kg) once daily ---Conversion to insulin glargine from other insulin therapies: Converting from once-daily NPH insulin: May be substituted on an equivalent unit-per-unit basis Converting from twice-daily NPH insulin: Initial dose: Use 80% of the total daily dose of NPH (eg¡A 20% reduction); administer once daily; adjust dosage according to patient response,,,,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,SC;,,,,,
OOXB,Oxybutynin,Oxbu 5mg extended-release,SGU,Relief of symptoms associated w/ voiding in patients w/ uninhibited neurogenic & reflex neurogenic bladder.,Myasthenia gravis¡A glaucoma; GI obstruction¡A paralytic ileus¡A intestinal atony¡A megacolon¡A severe colitis; acute haemorrhage.,Dry mouth¡A blurred vision¡A tachycardia¡A dizziness¡A impotence; allergic reactions.,25¢J¥H¤U,Initially¡A 5 mg once daily increased by 5 mg every week if necessary to the maximum 30 mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½wÄÀ¿õ¾ã²É§]ªA¡A¤£¥i©CÄZ©Î¿i¸H¡C
ORAD,Potassium Gluconate,Radi-K (2.54 mEq K+/tab),NUTR,,¾AÀ³¯g: Hypokalemia. °Æ§@¥Î: GI upsets. ¸T§Ò: Hyperkalemia; marked renal failure; concomitant treatment with K-sparing diuretics & patients in whom there is cause for arrest or delay in tab passage through the GI.,,«Ç·Å,Prophylaxis: 3-9 tab daily. 1 g potassium gluconate = elemental potassium 167 mg = potassium 4.3 mEq = potassium 4.3 mmol,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OLIP20,Atorvastatin,Lipitor 20mg,CAVS,Hyperlipidemia.,Active liver disease or persistent elevations of serum transaminases > 3 times the upper limit of normal. Pregnancy & lactation.,Common: Diarrhea (up to 14.1%)¡A Arthralgia (up to 11.7%)¡A Myalgia (up to 8.4%)¡A Urinary tract infectious disease (up to 8%)¡A Nasopharyngitis (8.3%)¡A Pain¡A In extremity (up to 9.3%) Serious: Dermatomyositis¡A Diabetes mellitus¡A Increased liver enzymes (0.2-2.3%)¡A Liver failure¡A Autoimmune disease¡A Systemic lupus erythematosus¡A Autoimmune necrotizing myopathy¡A Statin-associated (Rare)¡A Disorder of muscle¡A Rhabdomyolysis¡A Rupture of tendon¡A Hemorrhagic cerebral infarction (2.3%),30¢J¥H¤U,Adults: Initial 10 mg once daily at any time of the day¡A with or without food; dosage range: 10-80 mg/day. Children aged 10-17 years: 10-20 mg/day.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨Ï¥Î¥»«~¥i¯à¤Þ°_¯f¤H¨xÂà®òžJªº«ùÄò¤É°ª¡A«ØÄ³©Ò¦³¯f¤H©ó°_©lªvÀø«e±µ¨ü¨x¥\¯àÀË´ú¡A¨Ã§iª¾¯f¤H©óªvÀø®ÉÀ³ª`·N¬O§_¥X²{¨x·l¶Ë¤§¯gª¬¡A¥]¬A¯h³Ò¡B­¹¼¤´î°h¡B¥k¤W¸¡¤£¾A¡B§¿¦â²`©Î¶À¯nµ¥¡C«ØÄ³©ó¥ÎÃÄ«e¡B¥X²{¨x·l¶Ë¤§Á{§É¯gª¬®É¡]¦p¯h³Ò¡B­¹¼¤´î°h¡BÅé­«´î»´¡B¥k¤W¸¡¤£¾A¡B²`¦â§¿©Î¶À¯nµ¥¡^¡B´£°ª¾¯¶q¡B§ó´«ÃÄ«~«~¶µ¡A©ÎÁ{§ÉÂå®v»{¬°»Ý­n®ÉºÊ´ú¨x¥\¯à¡C,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,¥H¤W­÷¨Å¤ÎÃh¥¥¤À¯Å°Ñ¦Ò¨Ó·½¬°ÃÄ«~¥é³æ¡C,AC;AC15;PC;PO;WM;,,,,,
OSYN3,Flurazepam,Syndoman 30mg,CNEU,Short-term treatment of insomnia,Hypersensitivity to flurazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma; pregnancy,Cardiovascular: Chest pain¡A flushing¡A hypotension¡A palpitation Central nervous system: Apprehension¡A ataxia¡A confusion¡A depression¡A dizziness¡A drowsiness¡A euphoria¡A faintness¡A falling¡A hallucinations¡A hangover effect¡A headache¡A irritability¡A lightheadedness¡A memory impairment¡A nervousness¡A paradoxical reactions¡A restlessness¡A slurred speech¡A staggering¡A talkativeness Dermatologic: Pruritus¡A rash Gastrointestinal: Appetite increased/decreased¡A bitter taste¡A constipation¡A diarrhea¡A GI pain¡A heartburn¡A nausea¡A salivation increased/excessive¡A upset stomach¡A vomiting¡A weight gain/loss¡A xerostomia Hematologic: Granulocytopenia¡A leukopenia Hepatic: Alkaline phosphatase increased¡A ALT increased¡A AST increased¡A cholestatic jaundice¡A total bilirubin increased Neuromuscular & skeletal: Body/joint pain¡A dysarthria¡A reflex slowing¡A weakness Ocular: Blurred vision¡A burning eyes¡A difficulty focusing Respiratory: Apnea¡A dyspnea Miscellaneous: Diaphoresis¡A drug dependence,25¢J¥H¤U°®Àê¥BÁ×¥úªº³B©Ò,Adults: General dose: 30mg HS. Dosage range: 15-60mg. The elderly and the frail: Initial dose: 15mg¡A increase according to the individual response.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Potential toxicity if combined with other CNS depressants,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
ITPN2A,TPN-2 Solution,TPN-2A Solution (1500mL/bag),NUTR,,,,,,»Ý½Õ¾ã¾¯¶q,Use with caution in patients with hepatic impairment; dosage adjustments may be necessary. Some products are contraindicated in patients in hepatic coma.,»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IV;IVD;,,,,,
IVIC,Liraglutide,Victoza inj 6mg/mL¡A 3mL,META,Type 2 diabetes mellitus. Disorder of cardiovascular system; Prophylaxis - Type 2 diabetes mellitus.,Hypersensitivity to liraglutide or any component of the product. Personal or family history of medullary thyroid carcinoma. Personal of family history of multiple endocrine neoplasia syndrome type 2. Pregnancy¡A in patients treated for obesity.,Common: Hypoglycemia (Adult¡A monotherapy¡A 7.1-12.6%; adult¡A combination therapy¡A 3.6-28.2% ; pediatric¡A 15.2 to 21.2%)¡A Constipation (Type 2 diabetes¡A 5-9.9%; weight management¡A 4.8-19.4%)¡A Decrease in appetite (9-10%)¡A Diarrhea (10-22.4%)¡A Indigestion (4-9.6%)¡A Nausea (Type 2 diabetes¡A 18-28.4%; weight management¡A 39.3-42.4%)¡A Vomiting (Type 2 diabetes¡A 6-15.7%; weight management¡A 34.4% (pediatric))¡A Headache (9.1-13.6%)¡A Upper respiratory infection (6-9.5%) Serious: Breast cancer (0.6%)¡A C-cell hyperplasia of thyroid¡A Medullary thyroid carcinoma¡A Papillary thyroid carcinoma (0.2%)¡A Cholecystitis (0.8%)¡A Cholelithiasis (1.15 to 2.2%)¡A Colorectal cancer (0.2%)¡A Pancreatic cancer¡A Pancreatitis (0.3-0.8%)¡A Anaphylaxis¡A Suicidal¡A completed (Pediatric¡A 0.8%)¡A Suicidal thoughts (0.3%)¡A Acute renal failure¡A Angioedema¡A Breast cancer (0.7%)¡A Pancreatic cancer,2-8C,initial: 0.6 mg SC every day for 1 week. maintenance: 1.2 mg SC once daily; may increase to 1.8 mg/day if needed; MAX: 1.8 mg/day. If more than 3 days elapse between doses¡A reinitiate at 0.6 mg/day subQ,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
OBRI,Ticagrelor,Brilinta 90mg,HEMT,Prevention of atherothrombotic events in patients w/ acute coronary syndromes (ACS) [unstable angina¡A non-ST elevation MI (NSTEMI) or ST elevation MI (STEMI)] including patients managed medically & managed w/ percutaneous coronary intervention (PCI) or CABG co-administered w/ acetylsalicylic acid (ASA).,Active pathological bleeding¡A history of intracranial haemorrhage¡A moderate to severe hepatic impairment¡A co-administration w/ strong CYP3A4 inhibitors.,Dyspnoea¡A epistaxis¡A GI haemorrhage¡A subcutaneous or dermal bleeding¡A bruising¡A procedural site haemorrhage.,30¢J¥H¤U«O«ù°®Àê,Acute coronary heart disease: loading dose as 180mg and followed by 90mg BID for 12 months. Patient with MI history combined with high risk of arterial thrombosis¡A needed an extended treatment: 60mg BID.,»Ý½Õ¾ã¾¯¶q,Moderate impairment: There are no dosage adjustments provided in the manufacturer¡¦s labeling (has not been studied); however¡A undergoes hepatic metabolism; use caution. Severe impairment: Avoid use.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;PC;PO;,,,,,
OSERM,Nicergoline,Sermion 5mg,CAVS,,¾AÀ³¯g: Acute or chronic vascular or metabolic cerebral insufficiency (cerebral arteriosclerosis¡A cerebral thrombosis and embolism¡A transient cerebral ischaemia). Acute or chronic peripheral vascular insufficiency (obliterative vascular diseases of the limbs¡A Raynaud's syndrome¡A other syndromes due to altered peripheral flow). Headache. As an adjuvant to the therapy of arterial hypertension and parenterally¡A of hypertensive crises. °Æ§@¥Î: Rare cases of mild side effects have been reported¡A which in general may be related to the vasoactive action of Sermion. These are hypotension and vertigo after parenteral administration¡A slight gastric disturbances¡A feeling of heat and flushing¡A drowsiness and insomnia. ¸T§Ò: Hypersensitivity to nicergoline.,,«Ç·Å,Oral: 5-10 mg 3 times daily at regular intervals for prolonged periods. In order to improve absorption¡A the drug should be taken between meals. 60 mg a day in two administrations orally at regular intervals,,,,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,,,,,,
OFEB,Febuxostat,Feburic 80mg,CNEU,Chronic hyperuricaemia where urate deposition had occurred including history or presence of tophus &/or gouty arthritis.,Hypersensitivity. Concomitant use of azathioprine or mercaptopurine.,Common: Rash (0.5-1.6%)¡A Diarrhea (>1%)¡A Nausea (1.1-1.3%)¡A Arthralgia (0.7-1.1%) Serious: Myocardial infarction¡A Drug reaction with eosinophilia and systemic symptoms¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Abnormal liver function (4.6-6.6%)¡A ALT/SGPT level raised (3%)¡A Aspartate aminotransferase serum level above reference range (2%)¡A Gout¡A acute¡A Myositis¡A Rhabdomyolysis¡A Cerebrovascular accident,30¢J¥H¤U,Gout: Initial dose: 40mg QD. If the serum uric acid concentration is not lower than 6mg/dL after taking the medicine for 2 weeks¡A change to 80mg QD. Tumor lysis syndrome: Two days before the start of cytotoxic drug treatment¡A 80 mg QD for 7 days. According to the clinical response during chemotherapy¡A it can be extended to 9 days.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¥»«~¨Ï¥Î¦b¥¥°üªº¸ê®Æ¼Æ¾Ú¦³­­¡CÃh¥¥´Á¶¡¥u¦³·í¼ç¦b®Ä¯q¶W¹L¹ï­L¨àªº¼ç¦b­·ÀI®É¤è¥i¨Ï¥ÎFeburic¡C ¦b²£«e©M²£«áµo¨|¬ã¨s¤¤¡A¹ïÃh¥¥»Û¤j¹«±qÃh¥¥²Ä7¤Ñª½¨ì­÷¨Å´Á²Ä20¤Ñµ¹¤©febuxostat ¤fªA¾¯¶q¡A¦b¾¯¶q¬ù¬°MRHDªº11­¿®É(¥HAUC­pºâ¡A¥ÀÅéªº¤fªA¾¯¶q¬°12 mg/kg/day)¡A¹ï¤À®Y©Î¥®¥Jªº¥Íªøµo¨|¨S¦³¼vÅT¡CµM¦Ó¡A¦b¾¯¶q¬ù¬°MRHDªº40­¿®É(¥HAUC­pºâ¡A¥ÀÅé¤fªA¾¯¶q¬°48 mg/kg/day)¡AÆ[¹î¨ì¦³¥ÀÅéªº¬r©Ê¡A·s¥Í¹«¦º¤`²v¼W¥[©M¥®¹«Åé­«ªº¼W¥[·|´î¤Ö¡C ¤fªAµ¹¤©Ãh¥¥ªº¤j¹««á¡Afebuxostat ³q¹L­L½L«Ì»Ù¡A¨Ã¦b­L¨à²ÕÂ´¤¤³QÀË´ú¨ì¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¨S¦³Ãö©ó febuxostat¦s¦b©ó¤HÃþ¨Å¥Ä¡B¹ï¨Å¨àªº¼vÅT¡A©Î¼vÅT¨Å¥Ä»s³yªº¼Æ¾Ú¡CFebuxostat·|¦s¦b©ó¤j¹«ªº¨Å¥Ä¤¤¡C ­÷Áý¥À¨Å¹ïµo¨|©M°·±dªº¯q³B¡AÀ³¸Ó»P¥À¿Ë¹ï FeburicªºÁ{§É»Ý¨D¡A¥H¤ÎFeburic©Î¥À¿Ëªº¼ç¦bª¬ªp¹ï¨Å¨àªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¤@°_¦Ò¼{¡C,AC;AC15;PC;PO;WM;,,,,,
EDEH,Calamine + Diphenhydramine,Dehist lotion 100mL,TDER,,¾AÀ³¯g: Symptomatic relief of skin irritation & itch associated with urticaria¡A insect bites¡A nappy rash & other minor skin problems. ¸T§Ò: Avoid use on broken or eczematous skin. May affect ability to drive or operate machinery.,,«Ç·Å,Apply 3-4 times daily on the affected area.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IHAL0,Eribulin,Halaven inj 1mg/2mL (sample),RACA,Treatment of Breast cancer¡A metastatic.,Hypersensitivity to eribulin mesylate¡A halichondrin B¡A or its chemical derivatives.,>10%: Central nervous system: Fatigue (54%)¡A fever (21%)¡A headache (19%) Dermatologic: Alopecia (45%) Gastrointestinal: Nausea (35%)¡A constipation (25%)¡A weight loss (21%)¡A anorexia (20%)¡A diarrhea (18%)¡A stomatitis (5% to 18%)¡A vomiting (18%) Hematologic: Neutropenia (82%; grades 3: 28%; grade 4: 29%; nadir: 13 days; recovery: 8 days)¡A anemia (58%; grades 3/4: 2%) Hepatic: ALT increased (18%) Neuromuscular & skeletal: Weakness (54%)¡A peripheral neuropathy (35%; grades 3/4: ?8%)¡A arthralgia/myalgia (22%)¡A back pain (16%)¡A bone pain (12%)¡A limb pain (11%) Respiratory: Dyspnea (16%)¡A cough (14%) 1% to 10%: Cardiovascular: Peripheral edema Central nervous system: Depression¡A dizziness¡A insomnia Dermatologic: Rash Endocrine & metabolic: Hypokalemia Gastrointestinal: Mucosal inflammation (9%)¡A abdominal pain¡A dyspepsia¡A taste alteration¡A xerostomia Genitourinary: Urinary tract infection (10%) Hematologic: Neutropenic fever (5%)¡A thrombocytopenia (grades 3/4: 1%) Neuromuscular & skeletal: Muscle spasm Ocular: Lacrimation increased Respiratory: Upper respiratory infection <1% (Limited to important or life-threatening): Pancreatitis¡A pharyngolaryngeal pain¡A sepsis,25¢J¥H¤U,1.4 mg/m2 on days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,¤£¥i¥H¸²µå¿}·»²Gµ}ÄÀ©Î§t¸²µå¿}·»²G¤§ÀR¯ßª`®gºÞ½uµ¹ÃÄ¡C
OUTRO,Progesterone,Utrogestan 100mg,HM,Oral: Prevention of endometrial hyperplasia in nonhysterectomized¡A postmenopausal women who are receiving conjugated estrogen tablets; secondary amenorrhea.,Hypersensitivity to progesterone or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT¡A PE); active or history of arterial thromboembolic disease (eg¡A stroke¡A MI); history of or known or suspected carcinoma of the breast or genital organs; hepatic dysfunction or disease; missed abortion or ectopic pregnancy; diagnostic test for pregnancy; capsules are also contraindicated for use during pregnancy,Central nervous system: Headache (16% to 31%)¡A dizziness (15% to 24%)¡A depression (19%) Endocrine & metabolic: Breast tenderness (27%)¡A breast pain (6% to 16%) Gastrointestinal: Abdominal pain (10% to 20%)¡A abdominal bloating (8% to 12%) Genitourinary: Urinary problems (11%) Neuromuscular & skeletal: Joint pain (20%)¡A musculoskeletal pain (12%) Miscellaneous: Viral infection (12%),30¢J¥H¤U,Oral: 200-300mg devided into 1-2 tims. Vaginal: 100mg two times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;VAG;WM;,,,,,[¿i¯»/ºÞÄéµù°O]³n½¦Ån¤£¥i­é¥b©Î¿i¯»¡CµLªk§]ªA¯f±w¥i¥H·Å¤ô·»¸Ñ«áªA¥Î¡C
IVAQ,Inactivated Hepatitis A Virus Vaccine,Vaqta(¤p¨àA¨x¬Ì­]) 0.5mL/dose,HIMM,Vaccination against infection caused by hepatitis A virus.,Hypersensitivity to any component of the vaccine.,Pain¡A tenderness & swelling at inj site. Warmth¡A erythema¡A ecchymosis¡A abdominal pain¡A diarrhoea¡A vomiting¡A headache¡A pharyngitis.,2-8¢JÁ×§K§N­á,IM¡A 0.5mL¡A 12 months-18 years primary immunization. A booster dose after 6-18 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,1. ¦Ù¦×ª`®g©ó¦¨¤H©Î«Äµ£ªº¤T¨¤¦Ù³¡¦ì¡AÀ¦¨à«hÀ³ª`®g©ó¤j»L«e¥~°¼³¡¦ì¡C
OLEN,Brotizolam,Lendormin 0.25mg,CNEU,Insomnia,Hypersensitivity to Brotizolam,Dizziness¡A headache¡A tiredness,25¢J¥H¤U,Adults: Oral: 0.25 mg at bedtime. Elderly: 0.125 mg - 0.25 mg. Treatment should be started with the lowest recommended dose. The recommended dose of 0.25 mg should not be exceeded because of the increased risk of unacceptable CNS-adverse effects.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
IEYL,Aflibercept,Eylea aflibercept 2mg/0.05mL,TOPH,Treatment of neovascular (wet) age-related macular degeneration (AMD).,1.Ocular or periocular infection 2.Active intraocular inflammation 3.Hypersensitivity,Common: Blurred vision (1-7%)¡A Cataract (Adult¡A up to 19%; pediatric¡A 1%)¡A Conjunctival hemorrhage (Adult¡A 1-31%; pediatric¡A 5-9%)¡A Corneal erosion (1-7%)¡A Foreign body sensation¡A In eyes (Up to 4%)¡A Pain in eye (4-13%)¡A Retinal hemorrhage (1-4%)¡A Visual discomfort¡A Vitreous floaters (1-8%) Serious: Myocardial infarction¡A Arterial thrombosis (0.4-6.4%)¡A Hypersensitivity reaction (Less than 1%)¡A Cerebrovascular accident¡A Endophthalmitis (Less than 1%)¡A Raised intraocular pressure (1-9%)¡A Retinal detachment (Up to 6%)¡A Retinal pigment epithelial detachment (1-5%)¡A Retinal venous tortuosity¡A Vitreous detachment (1-8%),2-8¢JÁ×¥úÁ×§K§N­á,Wet type (Neovascular) of age-related macular degeneration (wAMD): 2 mg every 4 weeks for the first 3 injections then every 8 weeks thereafter. Macular edema following central retinal vein occlusion (CRVO): 2 mg every 4 weeks via IVIA. Diabetic macular edema: 2 mg every 4 weeks for the first 5 injections¡A followed by 2 mg every 8 weeks. Macular edema induced visual impairment following branch retinal vein occlusion (BRVO): 2 mg every 4 weeks for the first 6 injections¡A followed by 2 mg every 8 weeks. Choroidal neovascularization(CNV) following pathological myopia: 2 mg single dose via IVIA. May repeat 1 to 3 times a year with the 1 month- interval according to the doctor's judgment on vision and/or anatomy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVI;,,,,,¶È¨Ñ²´¬ì¬Á¼þÅé¤ºª`®g¥Î¡CEYLEA ¥²¶·¥Ñ¦X®æÂå®vª`®g¡C
EXYL,Zinc Oxide+ Lidocaine+ Alu. Acetate+Hydrocortisone,Xylmol oint 15gm,ALIM,,¾AÀ³¯g: Hemorrhoids¡A anal rhagades & inflammatory conditions¡A perianal abscess¡A proctoptosis.,,«Ç·Å,Apply tid-qid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;RECT;,,,,,
OFLUC,Acetylcysteine,Flucil 100mg/PK,ERSP,,¾AÀ³¯g: Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis¡A emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms. °Æ§@¥Î: Bronchospasm¡A GI upsets¡A stomatitis; rhinorrhea¡A fever¡A hemoptysis; rarely anaphylactic reactions. Dermatologic: Pruritus (1% to 4.3% )¡A Rash (4% to 5% )¡A Urticaria Gastrointestinal: Diarrhea¡A Nausea (2% to 7% )¡A Vomiting (9% to 12% ) ¸T§Ò: Effervescent tab Phenylketonuria.,,«Ç·Å,Adult and 12 years older Children: 200 mg tid. 6Y-12Y Children:100 mg tid. 3Y-6Y Children: 50mg tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ODUO,Dutasteride + Tamsulosin,Duodart 0.5/0.4mg,SGU,Benign prostatic hyperplasia: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate,Hypersensitivity (clinically significant) to dutasteride¡A tamsulosin¡A other 5-alpha-reductase inhibitors (eg¡A finasteride)¡A or any component of the formulation; children; women of childbearing potential; pregnancy,1% to 10%: Central nervous system: Dizziness (2%) Endocrine & metabolic: Decreased libido (5% to 6%)¡A breast changes (3% to 5%¡A including enlargement¡A swelling¡A pain¡A tenderness¡A gynecomastia¡A nipple pain¡A nipple swelling) Genitourinary: Ejaculatory disorder (10% to 11%)¡A impotence (8% to 10%) <1% (Limited to important or life-threatening): Prostate cancer (high-grade),25¢JªºÀô¹Ò¤¤,The recommended dose of Duodart is 1 capsule daily (0.5 mg / 0.4 mg). Duodart must always be taken with a glass of water¡A up to 30 minutes after a meal. It must never be taken on an empty stomach. Ideally¡A it should be taken at the same time of the day (this means with the same meal). The capsules should be swallowed whole and not chewed or opened¡A as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.,µL»Ý½Õ¾ã¾¯¶q,Dutasteride¥¼¬ã¨s¹L¨x¥\¯à¨ü·lªºÃÄª«°Ê¤O¾Ç¼vÅT Tamsulosin¦b¤¤«×¨x¥\¯à¨ü·l±wªÌ¤WµL¶·½Õ¾ã¾¯¶q¡AÄY­«¨x¥\¯à¨ü·l±wªÌ¥¼°µ¬ã¨s,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,TAMSULOSIN PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk BREASTFEEDING RECOMMENDATION: No Human Data¡XPotential Toxicity,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),Up-to date: Breast-Feeding Considerations:It is not known if dutasteride or tamsulosin are excreted in human milk. Use is contraindicated in women of childbearing potential. TAMSULOSIN BREASTFEEDING RECOMMENDATION: No Human Data¡XPotential Toxicity,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ¡BÀ£¸H©Î¥´¶}½¦Ån¡C¥»ÃÄ¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C
OAFI,Everolimus,Afinitor 5mg,RACA,Treatment of postmenopausal women w/ advanced hormone receptor positive & HER-2 negative breast cancer in combination w/ exemestane after failure of treatment w/ letrozole or anastrozole. Progressive neuroendocrine tumors of pancreatic origin (PNET) w/ unresectable¡A locally advanced or metastatic disease. Advanced renal cell carcinoma (RCC) after failure of treatment w/ sunitinib or sorafenib.,Hypersensitivity to everolimus or other rapamycin derivatives.,Stomatitis¡A infections¡A rash¡A fatigue¡A diarrhea¡A decreased appetite¡A hyperglycemia¡A dyspnea¡A pneumonitis¡A hypercholesterolemia¡A increased AST & ALT¡A anemia¡A leukopenia¡A thrombocytopenia¡A lymphopenia¡A hypertriglyceridemia¡A decreased K.,15-30¢JÁ×¥ú¤ÎÁ×§K¼éÀã,[Advanced Breast cancer¡A hormone receptor-positive¡A HER2-negative; Advanced Neuroendocrine tumors (GI¡A lung¡A or pancreatic origin); Advanced Renal cell cancer (RCC)] 10 mg orally once daily¡A continue treatment until disease progression or unacceptable toxicity,»Ý½Õ¾ã¾¯¶q,- »´«×¨x¥\¯à¤£¥þ(Child-Pugh A)- «ØÄ³¾¯¶q¬°¨C¤é7.5 ²@§J¡F­YµLªk§Ô¨ü¡A¾¯¶q¥i½Õ­°¦Ü5 ²@§J¡C - ¤¤«×¨x¥\¯à¤£¨}(Child-Pugh B)- «ØÄ³¾¯¶q¬°¨C¤é5 ²@§J¡F­YµLªk§Ô¨ü¡A¾¯¶q¥i½Õ­°¦Ü2.5 ²@§J¡C - ­««×¨x¥\¯à¤£¨}(Child-Pugh C)- ­Y´Á±æªº¯q³B¶W¥X­·ÀI¡A¥iµ¹¤©¨C¤é2.5 ²@§J¡A¦ý¤£¥i¶W¹L¦¹¾¯¶q¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest moderate risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¤£¥i©CÄZ©Î«r¸H¿õ¾¯¡C¹ïµLªk§]ªA¿õ¾¯ªº¯f¤H¡AÀ³±N¥»ÃÄ¥H»´»´ÅÍ©Õªº¤è¦¡§¹¥þ·»´²( ¬ù7 ¤ÀÄÁ) ©ó¤@ªM¤ô( ¬ù30 ²@¤É) ¤¤¡A¨Ã¥ß§Y³Ü¤U¡C¦A©óªM¤¤­Ë¤Jµ¥¶qªº¤ô¬~º°¡AµM«á±N¬~º°²G¥þ³¡³Ü±¼¡A¥H½T«OªA¤U§¹¾ã¾¯¶q¡C
OVEM,Tenofovir alafenamide,Vemlidy 25mg,QANB,Chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.,Hypersensitivity to tenofovir alafenamide or any component of the formulation.,Headache¡A abdominal pain¡A fatigue¡A cough¡A nausea¡A back pain.,30¢J¥H¤U,Adutl: 25 mg orally once daily.,»Ý½Õ¾ã¾¯¶q,Decompensated cirrhosis (Child-Pugh class B or C): Use is not recommended.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,
EDHEP,Acyclovir,Deherp cream 5%¡A 5gm,TDER,Herpes simplex virus infection of the skin.,Hypersensitivity to acyclovir or any other component of the product. Hypersensitivity to any component of this product with the topical ointment.,Common: Contact dermatitis (topical cream¡A 2%)¡A Diarrhea (2.4-3.2%)¡A Nausea (2.7-4.8%)¡A Vomiting¡A Headache (2.2%)¡A Follicular conjunctivitis (Ophthalmic ointment¡A 2-10%)¡A Pain in eye¡A or stinging (Ophthalmic ointment¡A 2-10%)¡A Malaise (11.5%) Serious: Thrombotic thrombocytopenic purpura¡A Hemolytic Uremia Syndrome¡A Superficial punctate keratitis (Ophthalmic ointment¡A 2-10%)¡A Renal failure,25¢J¥H¤U°®Àê³B,Apply topically every 4 hours¡A 5 times per day for 5 days in sufficient quantities to adequately cover the lesion. Maybe prolong to 10 days if necessary.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]µL¥R¤À¸ê®Æ«ü¥X¨Ï¥Î¥»«~¹ï¥¥°ü¤Î­L¨à¤§¼vÅT¡A¥H¤Î¨Ï¥Î¥»«~«á¨Å¥Ä¤¤Acyclovir¤§¿@«×¡C ¦]¦¹¥¥°ü¤Î±Â¨Å°ü¤k©y¼f·Vµû¦ô§Q¹ú«á¦A¨Ï¥Î¥»«~¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]µL¥R¤À¸ê®Æ«ü¥X¨Ï¥Î¥»«~¹ï¥¥°ü¤Î­L¨à¤§¼vÅT¡A¥H¤Î¨Ï¥Î¥»«~«á¨Å¥Ä¤¤Acyclovir¤§¿@«×¡C ¦]¦¹¥¥°ü¤Î±Â¨Å°ü¤k©y¼f·Vµû¦ô§Q¹ú«á¦A¨Ï¥Î¥»«~¡C,EXT;,,,,,
IGLY3,Glycerin + Fructose + Sodium chloride,Glycetose inj 10%¡A 300mL,CAVS,Treatment of increased intracranial pressure and intracranial edema¡A improvement of impaired consciousness and neurologic deficits in cerebral infarct¡A intracerebral and subarachnoid hemorrhages¡A head injury¡A brain tumor¡A cerebromeningitis. Post operation therapy following brain surgery; reduction of brain volume at time of brain surgery.,Hypersensitivity to any component in the preparation.,Lactic acidosis; hemoglobinuria; headache¡A thirst¡A nausea; hypernatremia.,µL¯S§O«ü¥Ü,Adult usual dosage: 200-500 mL QD-BID IV infusion (rate: 500 mL over 2-3 hours). Duration of treatment usually is about 1-2 weeks¡A the dosage may be adjusted according to age and symptoms. Reduction of the brain volume during brain surgery: IV bolus of 500 mL over 30 minutes.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,Glycerin: Limited Human Data - Probably Compatible [¥é³æ]¨S¦³¬ÛÃö»¡©ú,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Glycerin: No Human Data - Probably Compatible [¥é³æ]¨S¦³¬ÛÃö»¡©ú,IVD;,,,,¥é³æ«ØÄ³500mL¥H2~3¤p®Éºwª`¡A­Y¬°ÁY¤p¸£®e¶q¬°¥ØªºªÌ500mL¥H30¤ÀÄÁºwª`,¼t°Ó«ØÄ³¥»ÃÄ¶}«Ê«á¶È¨Ñ·í¦¸¨Ï¥Î¡A¤£¥i«O¦s¡C
ICOMDBA1,SARS-CoV-2 Spike glycoprotein [mRNA],BA1Âù»ùModerna(Covid19) 0.5mL/dose(2.5mL/vial),HIMM,Moderna COVID-19 Vaccine¡A for active immunization to prevent COVID-19 in individuals 18 years of age and older.,Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g.¡A anaphylaxis) to any component of the Moderna COVID-19 Vaccine.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,-50¢J¦Ü-15¢J¥i«O¦s9­Ó¤ë¡C2-8¢JÁ×§K¥ú·Ó¡A¥i«O¦s30¤Ñ¡CÂ÷§NÂÃ©ó8-25¢J¥u¥i«O¦s24¤p®É,IM¡A 0.5 mL¡A > or = 18 years¡A As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine¡A bivalent Original/Omicron BA.1 which contains elasomeran and an additional mRNA molecule.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤j¶qªºÆ[¹î©Ê¸ê®ÆÅã¥Ü¡A¥¥°ü¦b²Ä¤G»P²Ä¤T¥¥´Á±µºØSpikevax­ì¯f¬r®è¬Ì­]¨Ã¥¼¼W¥[¤£¨}Ãh¥¥µ²ªG¡C ÁöµM¦b²Ä¤@¥¥´Á±µºØªºÃh¥¥µ²ªG¸ê®Æ¦³­­¡A¦ý¬O¨Ã¥¼µo²{¬y²£­·ÀI¦³¤W¤Éªº²{¶H¡C °Êª«¸ÕÅç¨Ã¥¼Åã¥ÜSpikevax­ì¯f¬r®è¬Ì­]·|¹ïÃh¥¥¡B­F­L¡þ­L¨àµo¨|¡B¤À®Y©Î²£«áµo¨|·|³y¦¨ª½±µ©Î¶¡±µ¦³®`ªº¼vÅT¡C Ãh¥¥´Á¶¡¥i¥H±µºØSpikevax­ì¯f¬r®è¬Ì­]¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ñ©ó­÷¨Å°ü¤k±µºØSpikevax­ì¯f¬r®è¬Ì­]«á¤§¥þ¨­©Ê¼ÉÅS¥i³Q©¿²¤¡A¹w´Á¹ï©óÁý­÷¥À¨Å¤§·s¥Í¨à/À¦¨à¤£¨ã¼vÅT¡C Æ[¹î©Ê¸ê®ÆÅã¥Ü­÷¨Å°ü¤k±µºØ¬Ì­]«á¡A¨Ã¥¼¥X²{¹ïÁý­÷¥À¨Å¤§·s¥Í¨à/À¦¨à¦³®`ªº¼vÅT¡C ­÷¨Å´Á¶¡¥i¥H±µºØSpikevax­ì¯f¬r®è¬Ì­]¡C,IM;,,,,,1. ¥»ÃÄ¬°¦h¾¯¶qÃÄ²~¡C¨C²~¥i©â¨ú5¾¯¡A¨C¾¯0.5mL¡C 2. ¥¼¶}«ÊÃÄ²~¡A§NÂÃ©ó2-8¢J¤U¥i«O¦s30¤Ñ¡A«Ç·Å«O¦s©ó8-25¢J¤U¥i«O¦s24¤p®É¡C¤w©â²GÃÄ²~¡A§NÂÃ©Î«Ç·Å¤U¥i«O¦s19¤p®É¡A19¤p®É«á¶·¥á±ó¡C 3. ¸Ñ­á«á¡A½Ð¤Å­«·s§N­á¡C¨Ï¥Î«e½Ð¥ý±NÃÄ²~¸Ñ­á¡A¸Ñ­á¤è¦¡¡G©ñ¸m§NÂÃ«Ç(2-8¢J)2¤p®É30¤ÀÄÁ¡A¨Ã©ó¬I¥´«e½Ð±NÃÄ²~©ñ¸m«Ç·Å(15-25¢J)15¤ÀÄÁ¡C©ÎªÌ©ñ¸m«Ç·Å(15¦Ü25¢J)1¤p®É¡C 4. ¥»¬Ì­]À³¥H¦Ù¦×ª`®g¤è¦¡¬I¥´¡A²z·Qª`®g³¡¦ì¬°¤WÁu¤T¨¤¦Ù¡C½Ð¤Å¥H¦åºÞ¤ºª`®g¡B¥Ö¤Uª`®g©Î¥Ö¤ºª`®g¤è¦¡¬I¥´¥»¬Ì­]¡C
HE1806,,#8 ¦å²G³zªR²G-3.8L A²G,NUTR,,,,Á×¥ú¡B«Ç·Å¶J¦s¡A½Ð¤Å§N­á¡C,"«HªF"¦å²G³zªR²G8¸¹¨Ï¥Î®É°t¦X"«HªF"µÇÅ¦³zªR²G300¸¹(¤A)¡BR.O.¤ô¨Ï¥Î¡C³zªR®É½Ð¿í·Ó¤H¤uµÇÅ¦¾÷¾Þ§@»¡©ú¡B¾Þ§@¤èªk¶i¦æ³zªR¡C³zªR²G¬°: acid concentrate:bicarbonate concentrate:R.O. water = 1 1¡A83 34,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,
ESAT,Atropine sulfate monohydrate,Santone 0.01% 7mL ophthalmic solution,TOPH,Mydriasis¡A cycloplegia.,Patients with glaucoma or a tendency for narrow-angle glaucoma. Hypersensitivity to the medication or any component of the formulation.,Common: Palpitations¡A Flushing¡A Abdominal pain¡A Constipation¡A Nausea¡A Swollen abdomen¡A Vomiting¡A Xerostomia¡A Confusion¡A Dizziness¡A Headache¡A Blurred vision¡A Finding of lacrimation¡A Decreased¡A Pain in eye¡A Photophobia¡A Superficial keratitis¡A Delay when starting to pass urine¡A Difficulty passing urine¡A Urinary retention¡A Erectile dysfunction¡A Lack of libido Serious: Asystole¡A Cardiac dysrhythmia¡A Cardiac syncope¡A Electrocardiogram abnormal¡A Hypotension¡A Myocardial infarction¡A Tachycardia¡A Ventricular fibrillation¡A Ventricular tachycardia¡A Anhidrosis¡A Anaphylaxis¡A Hypersensitivity reaction¡A Laryngeal spasm¡A Coma¡A Acute angle-closure glaucoma¡A Respiratory depression¡A Hyperpyrexia,25¢J ¥H¤UÁ×¥ú,Instill 1 to 2 drops into affected eye(s) 1 to 4 times daily. Adjust based on symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ] Atropine Sulfate ©|¥¼¦³°Êª«¥Í´Þ¬ã¨s¡A¥Ø«e©|¥¼²M·¡§½³¡ Atropine Sulfate¬O§_·|¹ï­L¨à ³y¦¨¶Ë®`©Î¼vÅT¥Í´Þ¯à¤O¡C¶È·í²M·¡»Ý­n®É¡A¥»ÃÄ¥iÀ³¥Î©ó¥¥°ü¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
IRHO1,Rho D Immune Globulin,Rho (D) Immune Globulin [HyperRHO] ±M®×¶i¤f,HIMM,Antepartum and postpartum RhD prophylaxis for the prevention of hemolytic disease of the newborn; RhD prophylaxis following spontaneous or induced abortion¡A ruptured tubal pregnancy¡A amniocentesis or abdominal trauma.,Known anaphylaxis or severe hypersensitivity reaction to human immune globulin products. Patients with a history of autoimmune hemolytic anemia¡A pre-existing hemolysis¡A or who are at high risk for hemolysis. IgA deficiency with antibodies against IgA. Infants for the suppression of Rh isoimmunization.,Common: Injection site pain (0.5%)¡A Nausea (0.7%)¡A Extravascular hemolysis (Mild) (21%)¡A Hemoglobin below reference range¡A Dizziness (0.5%)¡A Headache (0.5-14.3%)¡A Malaise (0.5%) Serious: Intravascular hemolysis¡A Anaphylaxis (rare)¡A Renal failure¡A acute,§NÂÃ2-8¢J¡B¤£¥i§N­á,Routine antepartum prophylaxis: IM 300 mcg; give at 26-28 weeks gestation; if given early in pregnancy (before 26-28 weeks gestation)¡A repeat dose at 12-week intervals to maintain adequate protection. Postpartum prophylaxis: if newborn is Rh-positive: IM 300 mcg; administer as soon as possible and within 72 hours after delivery. Abortion¡A miscarriage¡A or termination of ectopic pregnancy (13 weeks gestation or greater): IM 300 mcg; administer within 72 hours. Amniocentesis or chorionic villus sampling: IM 300 mcg; administer within 72 hours of procedure; if dose given between 13 and 18 weeks gestation¡A repeat dose at 26-28 weeks. Abdominal trauma or manipulation: IM 300 mcg; administer within 72 hours after complication/procedure; if dose given between 13 and 18 weeks gestation¡A repeat dose at 26 to 28 weeks and within 72 hours of delivery. Threatened abortion with continuation of pregnancy: IM 300 mcg.,µL»Ý½Õ¾ã¾¯¶q,[Lexidrug] There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,[Lexidrug] Available evidence suggests that Rho(D) immune globulin administration during pregnancy does not harm the fetus or affect future pregnancies. [Package Insert] Animal reproduction studies have not been conducted with Rho(D) Immune Globulin (Human) ¡X HyperRHO S/D Full Dose. It is also not known whether it can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.,Unknown ¨S¦³¸ê®Æ,[Lexidrug] The purified immune globulin in these products is obtained from human donors; the Rho(D) antibodies are endogenous to human plasma. Adverse events in the breastfeeding infant have not been observed when administered to patients for the suppression of RhD isoimmunization. According to the manufacturer¡A the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure¡A the benefits of breastfeeding to the infant¡A and benefits of treatment to the mother.,IM;,,,,,1. ¶È­­¦Ù¦×ª`®g¡F½Ð¤ÅÀR¯ßª`®g¡C½Ðª`®g©ó¤WÁu¤T¨¤¦Ù¦Ù¦×©Î¤W¤j»L«e¥~°¼¡C¤@¯ë¦Ó¨¥¡AÀ³Á×§KÁv³¡°Ï°ì¥H§K·l¶Ë§¤°©¯«¸g¡C­Y¥²¶·¨Ï¥ÎÁv³¡°Ï°ì¡A½Ð¶È¦b¤W¥~¶H­­ª`®g¡C­Y»Ý­n¤j¾¯¶q(>5²@¤É)¡A«ØÄ³¤À¦¸©ó¤£¦P³¡¦ìª`®g¡C 2. ·s¥Í¨à¤£±o¨Ï¥Î¡C 3. ºÊ´ú¦åÀ£¡F¥i¯à¾É­P°ª¦åÀ£/§C¦åÀ£¡Cª`·N¥i¯àµo¥Í¹L±Ó©Ê¥ð§Jªº¥i¯à©Ê¡C¹ï©ó±w¦³ITP¡B³h¦å¡BµÇ¥\¯à¤£¥þ¡B­Iµh¡BÅ¸§Ý¡B´H¾Ô¡B§¿²GÅÜ¦â©Î¦å§¿ªº¯f¤H¡AºÊ´ú¦åºÞ¤º·»¦å(IVH)ªº¼x¶H©M¯gª¬¡FÆ[¹îµ¹ÃÄ«á8¤p®É¤ºªº°Æ§@¥Î¡C
IOPD,Nivolumab,Opdivo inj 100mg/10mL,RACA,Unresectable or Metastatic Melanoma. Adjuvant Treatment of Melanoma. Metastatic Non-Small Cell Lung Cancer. Advanced Renal Cell Carcinoma. Classical Hodgkin Lymphoma. Squamous Cell Carcinoma of the Head and Neck. Urothelial Carcinoma. Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient. Hepatocellular Carcinoma.,Specific contraindications have not been determined.,Common Hypertension (36% )¡A Hand-foot syndrome due to cytotoxic therapy (40% )¡A Pruritus (10% to 53% )¡A Rash (16% to 53% )¡A Hyperglycemia (6% to 19% )¡A Abdominal pain (10% to 34% )¡A Constipation (10% or greater )¡A Decrease in appetite (14% to 35% )¡A Nausea (16% to 34% )¡A Stomatitis (Up to 37% )¡A Vomiting (12% to 31% )¡A Arthralgia (10% to 23% )¡A Backache (Renal cell carcinoma¡A 21% )¡A Musculoskeletal pain (17% to 42% )¡A Headache (11% to 23% )¡A Neuropathy (Up to 12% )¡A Cough (10% to 37% )¡A Dyspnea (2% or greater )¡A Upper respiratory infection (9% to 44% )¡A Fatigue (12% or 62% ). Serious Myocarditis¡A Pericarditis¡A Shock¡A Vasculitis¡A Erythroderma¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Adrenal insufficiency (0.6% to 18% )¡A Diabetic ketoacidosis (0.1% )¡A Hyperthyroidism (2.7% to 12% )¡A Hypophysitis (0.6% to 9% )¡A Hypopituitarism¡A Hypothyroidism (4.5% to 34% )¡A Thyroiditis (0.6% )¡A Type 1 diabetes mellitus (0.9% )¡A Colitis (1.9% to 26% )¡A Diarrhea (17% to 64% )¡A Duodenitis¡A Esophageal fistula¡A Fatal (0.5% )¡A Gastritis¡A Gastrointestinal hemorrhage¡A Fatal (0.5% )¡A Pancreatitis¡A Perforation of colon (Less than 10% )¡A Aplastic anemia¡A Autoimmune hemolytic anemia¡A Hemoptysis¡A Massive¡A Idiopathic thrombocytopenic purpura¡A Thrombocytopenia¡A Hepatitis (1.8% to 21% )¡A Hepatotoxicity (44% )¡A Veno-occlusive disease of the liver¡A Graft versus host disease¡A Histiocytic necrotizing lymphadenitis¡A Sarcoidosis¡A Transplanted organ rejection¡A Arthritis¡A Eaton-Lambert syndrome¡A Myasthenia gravis¡A Myositis¡A Polymyalgia rheumatica¡A Polymyositis¡A Rhabdomyolysis¡A Demyelination of spinal cord¡A Encephalitis¡A Guillain-Barre syndrome¡A Meningitis¡A Myelitis¡A Iritis¡A Myasthenia gravis¡A ocular¡A Unexplained visual loss¡A Uveitis (0.8% )¡A Vogt-Koyanagi-Harada disease¡A Nephritis¡A Renal impairment¡A Urinary tract infectious disease (Urothelial carcinoma¡A 17% )¡A Interstitial lung disease (16% )¡A Pleural effusion (2% or greater )¡A Pneumonia (2% or greater )¡A Pneumonitis (1.3% to 10% )¡A Pulmonary embolism (Non-small cell lung cancer¡A recurrent¡A 4.2% )¡A Respiratory failure (2% or greater )¡A Respiratory tract infection (2% or greater ) Other: Cytomegalovirus infection¡A Disorder characterized by fever¡A Steroid-requiring¡A Sepsis (2% or greater ),2-8¢J¤Å§N­á,Monotherapy: [Melanoma¡A unresectable or metastatic; Non-small cell lung cancer¡A metastatic¡A progressive; Renal cell carcinoma¡A advanced; Hodgkin lymphoma¡A classical; Head and neck cancer¡A squamous cell; Urothelial carcinoma¡A locally advanced or metastatic; Gastric cancer or gastroesophageal junction cancer¡A advanced or metastatic; Hepatocellular carcinoma; Colorectal cancer¡A metastatic¡A microsatellite instability-high or mismatch repair deficient] 3 mg/kg infused over 30 minutes once every 2 weeks until disease progression or unacceptable toxicity. [Esophageal carcinoma¡A squamous cell¡A unresectable advanced¡A recurrent¡A or metastatic] 240 mg infused over 30 minutes once every 2 weeks until disease recurrence or unacceptable toxicity. [Melanoma¡A adjuvant treatment] 3 mg/kg infused over 30 minutes once every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year. Combination therapy: [Melanoma¡A unresectable or metastatic] 1 mg/kg once every 3 weeks in combination with ipilimumab 3 mg/kg over 90 minutes for a maximum of 4 combination doses or until unacceptable toxicity (whichever occurs earlier)¡A followed by nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity. [Non-small cell lung cancer¡A metastatic¡A PD-L1-expressing] 3 mg/kg once every 2 weeks in combination with ipilimumab 1 mg/kg once every 6 weeks until disease progression¡A unacceptable toxicity or for up to 2 years in patients without disease progression. [Non-small cell lung cancer¡A metastatic or recurrent] 360 mg once every 3 weeks in combination with ipilimumab 1 mg/kg every 6 weeks and histology-based platinum-doublet chemotherapy every 3 weeks until disease progression¡A unacceptable toxicity or for up to 2 years in patients without disease progression. [Renal cell carcinoma¡A advanced¡A first-line treatment; intermediate or poor risk] 3 mg/kg once every 3 weeks in combination with ipilimumab 1 mg/kg over 30 minutes for 4 combination doses¡A followed by 3 mg/kg once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. [Colorectal cancer¡A metastatic¡A microsatellite instability-high or mismatch repair deficient] 3 mg/kg once every 3 weeks in combination with ipilimumab 1 mg/kg over 30 minutes for 4 combination doses¡A followed by 3 mg/kg once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ]®Ú¾Ú¨ä§@¥Î¾÷Âà©M°Êª«¸ÕÅç¸ê®Æ¡A·í¹ï¥¥°ü§ë¤© OPDIVO¡A¥i¯à·|¹ï­L¨à³y¦¨¶Ë®`¡C¦b°Êª«¥Í´Þ¬ã¨s¤¤¡A¹ï°¨¨ÓµU±q¾¹©x§Î¦¨¶}©l¨ì¥Í²£´Á¶¡§ë¤© nivolumab¡A¾É­P¬y²£©M¦­²£­L¨à¦º¤`±¡§Î¼W¥[¡C ¤wª¾¤HÃþ IgG4 ·|³q¹L­L½L»Ù¾À¡Anivolumab ¥ç¬°¤@ºØ§K¬Ì²y³J¥Õ G4 (IgG4)¡F¦]¦¹¡Anivolumab ¥i¯à·|±q¥ÀÅé¶Ç»¼¨ìµo¨|¤¤ªº­L¨à¡C OPDIVO ¹ï²Ä¤G¤Î²Ä¤T¥¥´Áªº¼vÅT¥i¯à¸û¤j¡C¥Ø«e©|µL¥i»¡©ú¦¹ÃÄª«¬ÛÃö­·ÀIªº¤HÃþ¬ã¨s¸ê®Æ¡CÀ³§iª¾¥¥°ü¥»«~¹ï­L¨àªº¼ç¦b­·ÀI¡C ¥Ø«e¤£²M·¡¹ï¾A¥Î±Ú¸s¤§­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº­I´º­·ÀI¡F¤£¹L¡A¦b¬ü°ê¤@¯ë±Ú¸s¤¤¡AÁ{§É¤W½T»{Ãh¥¥ªº­I´º­·ÀI¤À§O¬O­«¤j¥ý¤Ñ¯Ê³´¬° 2%-4%¡A¥H¤Î¬y²£¬° 15%-20%¡C PD-1/ PD-L1 ³~®|ªº¤@¶µ®Ö¤ß§@¥Î¬°³z¹Lºû«ù¥ÀÅé¹ï­L¨àªº§K¬Ì­@¨ü©Ê¨Ó«ùÄò¥¥´Á¡C¤w¦bÃh¥¥¹«¼Ò«¬ÃÒ©ú¡AªýÂ_ PD-L1 «H¸¹·|¯}Ãa¹ï­L¨àªº­@¨ü©Ê¨Ã¾É­P¬y²£ªº¼W¥[¡C ±q¾¹©x§Î¦¨¶}©l¨ì¥Í²£´Á¶¡¡A¹ïµU¤l¨C¶g§ë¤©¨â¦¸ nivolumab (¨äÃnÃÄ¶q¤ñ±µ¨ü nivolumab 3 mg/kg Á{§É¾¯¶q©ÒÆ[¹î¨ì¤§ÃnÃÄ¶q°ª¥X 9 ¦Ü 42 ­¿[®Ú¾Ú¦å¤¤¿@«×®É¶¡¦±½u¤U­±¿n¡AAUC])¡A¥Hµû¦ô nivolumab ¹ï²£«e©M²£«áµo¨|ªº¼vÅT¡C §ë¤© nivolumab ·|¾É­P«D¾¯¶q¬ÛÃöªº¦ÛµM¬y²£©M·s¥Í¨à¦º¤`¼W¥[¡C®Ú¾Ú¨ä§@¥Î¾÷Âà¡A­L¨à¼ÉÅS©ó nivolumab ¥i¯à·|¨Ï§K¬Ì½Õ¸`©Ê²§±`©Î¥¿±`§K¬Ì¤ÏÀ³§ïÅÜªº­·ÀI¼W¥[¡A¦b PD-1 °ò¦]­ç°£¤p¹«¤¤´¿µo¥Í§K¬Ì½Õ¸`©Ê²§±`¡C ±µ¨ünivolumab ªvÀøªº°¨¨ÓµU¦s¬¡¤l¥N¤¤ (32 °¦¤¤¦³ 18 °¦¬Û¸û©ó¥¼µ¹ÃÄ²Õ 16 °¦¦³ 11 °¦)¡A²£«á 6 ­Ó¤ë´Á¶¡¨Ã¥¼¥X²{©úÅã·î§Î¥B¥¼¹ï¯«¸g¦æ¬°¡B§K¬Ì¾Ç©MÁ{§É¯f²z¾Ç°Ñ¼Æ³y¦¨¼vÅT¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ø«e¤£²M·¡ OPDIVO ¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡C ¥Ñ©ó³\¦hÃÄª«(¥]¬A§ÜÅé)·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡A ¥B¦]¬°OPDIVO ¹ï±µ¨ü­÷¨ÅªºÀ¦¨à¥i¯à³y¦¨ÄY­«¤£¨}¤ÏÀ³¡A «ØÄ³¥¥°ü¦b±µ¨ü OPDIVO ªvÀø´Á¶¡°±¤î­÷¨Å¡C,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,©â¨ú©Ò»ÝªºOPDIVO®e¿n¡A»s³Æ¦¨³Ì²×¿@«×¬°1mg/mL¦Ü10mg/mLªº¿éª`²G¡C ¹ï©óÅé­«¡Ù30 kg ªº¯f¤Hµ¹¤© 240 mg ©Î 360 mg ©T©w¾¯¶q(flat-dose)ªºÁ`Åé¿n¤£±o¶W¹L150mL ¦ÓÅé­«<30 kg ªº¯f¤Hµ¹¤©¤§Á`Åé¿n¤£±o¶W¹L100mL¡C »´»´Â½Âà²V¦Xµ}ÄÀ²G¡C ½Ð¤Å®¶·n¿é²G³U¡C,1.±q»s³Æ¶}©l¡A¸m©ó«Ç·Å¤Uªº®É¶¡¤£±o¶W¹L8¤p®É¡C¥]¬AIV¿é²G³U¤º¿éª`²G©ñ¸m©ó«Ç·Å¤U2.³z¹L§tµLµß¡BµL¼ö­ì¡B§C³J¥Õµ²¦X²v¹LÂo¾¹(¤Õ®|¤j¤p¬°0.2·L¦Ì¦Ü1.2·L¦Ì)ªºÀR¯ß¾ÉºÞ³sÄò¿éª`30¤ÀÄÁ 3.½Ð¤Å¥H¬Û¦PªºÀR¯ß¾ÉºÞ¦P®É¿éª`¨ä¥LÃÄª«¡C¿éª`µ²§ô«áÀ³¨R¬~ÀR¯ß¾ÉºÞ 4.¨Ö¥Îipilimumab®É¡A¦P¤@¤Ñ¥ýµ¹¤©OPDIVO«á¦Aµ¹¤©ipilimumab¡C·í¨Ö¥Îipilimumab©M¤Æ¾ÇªvÀø®É¡A¦P¤@¤ÑÀ³¥ýµ¹¤©OPDIVO±µµÛµ¹¤©ipilimumab¡A³Ì«á¦Aµ¹¤©¤Æ¾ÇªvÀø 5.À³¨Ï¥Î­Ó§Oªº¿é²G³U©M¹LÂo¾¹
IAJO,Fremanezumab,Ajovy inj 225mg/1.5mL,CNEU,For the preventive treatment of migraine in adults.,Patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.,Common Dermatologic: Injection site disorder (43% to 45% ) Serious Immunologic: Anaphylaxis¡A Hypersensitivity reaction Other: Angioedema,Á×¥ú§NÂÃÀx¦s©ó2-8¢XC,225 mg monthly¡A or 675 mg every 3 months (quarterly).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«e¯Ê¥F»PÃh¥¥¤k©Ê¨Ï¥ÎAJOVY¦³Ãöªºµo¨|­·ÀI¼Æ¾Ú¡CAJOVY¥b°I´Á¸ûªø¡C¦]¦¹¡AÃh¥¥©Î­pµeÃh¥¥ªº¤k©Ê¨Ï¥ÎAJOVY®ÉÀ³±N¦¹­·ÀI¯Ç¤J¦Ò¶q¡C¦b¤j¹«¤Î¨ß¤l¾¹©x§Î¦¨´Á¶¡©Î¤j¹«Ãh¥¥¤Î­÷¨Å´Á¶¡¡A§ë¤©¾É­P¦å¼ß¿@«×°ª©óÁ{§É¹w´Á¿@«×¾¯¶qªºfremanezumab¡A¥¼¹ïµo¨|³y¦¨¤£¨}¤ÏÀ³¡C¦b¬ü°ê¤@¯ë±Ú¸s¤¤¡A®Ú¾ÚÁ{§É©ÒÆ[¹î¨ìªºÃh¥¥±¡§Î¡A­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº¹w¦ô­I´º­·ÀI¤À§O¬°2 - 4%©M15 - 20%¡C°¾ÀYµh¤k©Ê²£¤U­«¤j¥ý¤Ñ¯Ê³´(2.2 - 2.9%)»P¬y²£(17%)ªº¹w¦ô¤ñ¨Ò»PµL°¾ÀYµh¤k©Ê¬Ûªñ¡C µoªíªº¼Æ¾Ú«ü¥X°¾ÀYµh¤k©Ê©óÃh¥¥´Á¶¡µo¥Í¤lß«e¯gªº­·ÀI¥i¯à¸û°ª¡C ¦b¤½¹«»P¥À¹«¥æ°t«e¤Î¥æ°t´Á¶¡¡A¥H¥Ö¤Uª`®g¤è¦¡§ë¤©¨C¶g¤@¦¸¤§fremanezumab (0¡B50¡B100©Î 200 mg/kg)¡A¨Ã¹ï­F­L¾¹©x§Î¦¨´Á¶¡¤§Ãh¥¥¥À¹««ùÄòµ¹ÃÄ¡A¥¼Æ[¹î¨ì­F­L­L¨à¤£¨}¤ÏÀ³¡C³Ì°ª¸ÕÅç¾¯¶qªº¦å¼ßÃÄ«~¼ÉÅS¶q(¥HAUCªí¥Ü)¬ù¬°¤HÅé±µ¨ü675 mg¾¯¶qªº2­¿¡C¦b­F­L¾¹©x§Î¦¨´Á¶¡¤§Ãh¥¥¨ß¤l¤¤¡A¥H¥Ö¤Uª`®g¤è¦¡§ë¤©¨C¶g¤@¦¸¤§fremanezumab (0¡B10¡B50©Î100 mg/kg) ¡A¥¼Æ[¹î¨ì¹ï­F­L­L¨àµo¨|³y¦¨¤£¨}¼vÅT¡C³Ì°ª¸ÕÅç¾¯¶qªº¦å¼ßÃÄ«~¼ÉÅS¶q(¥HAUCªí¥Ü)¬ù¬°¤HÅé(675 mg)ªº3­¿¡C¦b¥À¹«Ãh¥¥¤Î­÷¨Å´Á¶¡¡A¥H¥Ö¤Uª`®g¤è¦¡§ë¤©¨C¶g¤@¦¸¤§fremanezumab (0¡B50¡B100©Î 200 mg/kg)¡A¥¼Æ[¹î¨ì¹ï­L¨à²£«e»P²£«áµo¨|³y¦¨¤£¨}¼vÅT¡C³Ì°ªÀË´ú¾¯¶qªº¦å¼ßÃÄ«~¼ÉÅS¶q(¥HAUCªí¥Ü)¬ù¬°¤HÅé(675 mg)ªº2­¿¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨ÃµL¼Æ¾ÚÅã¥Ü¤HÅé¥À¨Å¤¤¬O§_¥X²{fremanezumab¡B¬O§_¼vÅT­÷¨Å¤¤¥®¨à©Î¬O§_¼vÅT¥À¨Å¥Í²£¡CÀ³¿Å¶q­÷¨Å¹ï©óµo¨|©M°·±dªº§Q¯q¡A©M¥À¿Ë¹ï©óAJOVYªºÁ{§É»Ý¨D¡A¥H¤ÎAJOVY©Î¼ç¦b¥ÀÅé¯fªp¹ï©ó­÷¨ÅÀ¦¨àªº¥ô¦ó¥i¯à¤£¨}§@¥Î¡C,SC;,,,,,1. ¥»ÃÄ¶È¨Ñ¥Ö¤Uª`®g¡A»ÝÁ×¥ú§NÂÃÀx¦s©ó2-8¢XC¡C­Y¸m©ó«Ç·Å³Ì°ª25¢XC¤U¶W¹L24¤p®É¡A½Ð¤Å¨Ï¥Î¡C 2. ¨Ï¥Î«e¡A±q¦B½c¤¤¨ú¥X¥»ÃÄ¡A¸m©ó«Ç·Å¤U30¤ÀÄÁ¡A¨ÃÁ×§K¥ú½uª½±µ·Ó®g¡C­Y¤w¸m©ó«Ç·Å¤U¶W¹L24¤p®É¡A½Ð¤Å¨Ï¥Î¡C 3. ¥Ö¤Uª`®g©óµLÄ²µh¡B·ï¦å¡Bµo¬õ©Îµwµ²ªº¸¡³¡¡B¤j»L©Î¤WÁu³¡¦ì¡C¦h¦¸ª`®g¥i¦b¬Û¦P¨­Åé³¡¦ì¶i¦æª`®g¡A¦ý¤£¥i¨Ï¥Î»P«e¦¸ª`®g¬Û¦Pªº¦ì¸m¡C 4. §ó´«¾¯¶q®É¡A©ó¤U¦¸¹w©w§ëÃÄ¤é§ë¤©²Ä¤@¾¯·sªºÀøµ{¾¯¶q¡C­Yº|¥´¤@¾¯¡AÀ³¾¨§Ö§ëÃÄ¡A¤§«á¡A¥H³Ì«á¤@¦¸§ëÃÄ¤é¨Ó±Æ©w«áÄòªº§ëÃÄ®É¶¡¡C
IORG,Ganirelix,Orgalutran inj 0.25mg/0.5mL,HM,For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.,Known hypersensitivity to Ganirelix Acetate or to any of its components. Known hypersensitivity to GnRH or any other GnRH analog. Known or suspected pregnancy.,Common Neurologic: Headache (3% ) Reproductive: Abdominal pain¡A Gynecological (4.8% )¡A Vaginal bleeding (1.8% ) Serious Immunologic: Hypersensitivity reaction Reproductive: Ovarian hyperstimulation syndrome (2.4% ) Other: Undelivered in utero fetal death (3.7% ),¤Å§N­á¡C½ÐÁ×¥ú«O¦s¦bÄá¤ó2-30¢J¡C,250 mcg once daily during the mid-to-late phase after initiating follicle-stimulating hormone on day 2 or 3 of cycle. Treatment should be continued daily until the day of chorionic gonadotropin administration.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¹ï©ó¨Ï¥Î©ó¥¥°ü¡A¥Ø«e¨ÃµLÁ{§É¸ê®Æ¡C °Êª«¤¤¡A¦bµÛ§É®É¼ÉÅSganirelix·|¾É­P¨üºë§Z¦A§l¦¬¡C ³o¨Ç¸ê®Æ¹ï©ó¤HÃþªºÃöÁp©Ê«h©|¥¼±oª¾¡C ¦bÃh¥¥»P­÷¨Å®É¨Ï¥ÎOrgalutran¬O¸T§Òªº¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¤£²M·¡ganirelix¬O§_·|¤Àªc¦Ü¨Å¥Ä¤¤¡C ¦bÃh¥¥»P­÷¨Å®É¨Ï¥ÎOrgalutran¬O¸T§Òªº¡C,SC;,,,,,1. ¥»ÃÄÀ³¸Ó¸g¥Ñ¥Ö¤Uª`®gµ¹ÃÄ¡A³Ì¦n¬O¦b¤j»L¡C¨C¦¸ª`®gÀ³¸Ó¨ú¤£¦Pªº³¡¦ì¡A¥H¹w¨¾¥Ö¤U¯×ªÕµäÁY¡C 2. ¥»ÃÄ¤Å§N­á¡C½ÐÁ×¥ú«O¦s¦bÄá¤ó2-30¢J¡C 3. ¦b¹w¥R¶ñ°wµ©¤¤¥i¯à·|¬Ý¨ì®ðªw¬O¥i¹w´Áªº¡AµL¶·¥h°£®ðªw¡C
LAZI,Azithromycin,Azithrom 40mg/mL¡A 15mL suspension,QANB,Lower respiratory tract infections (including bronchitis and pneumonia) skin and soft tissue infections¡A otitis media¡A upper respiratory tract infections¡A and sexually transmitted infections caused by Gram-positive¡A negative and anaerobic bacteria.,Cholestatic jaundice with prior azithromycin therapy. Hepatic dysfunction with prior azithromycin therapy. Hypersensitivity to azithromycin or to any product component¡A erythromycin¡A or any macrolide or ketolide antibiotic.,Common: Injection site disorder (3.1-6.5%)¡A Abdominal pain (adult¡A 1.9-14%; pediatric¡A 2-4%)¡A Diarrhea (Adult¡A 4.3-12%; pediatric¡A 7-10%)¡A Flatulence (5%)¡A Nausea (Adult¡A 3-14%; pediatric¡A 4%)¡A Vomiting (Adult¡A up to 13%; pediatric¡A 11-14%)¡A Increased liver enzymes (<1-6%)¡A Headache (up to 5%)¡A Abnormal vision (5%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Congenital hypertrophic pyloric stenosis¡A Hepatic necrosis¡A Hepatitis (<1%)¡A Liver failure¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Eaton-Lambert syndrome¡A Myasthenia gravis¡A Exacerbation of¡A Myasthenic crisis¡A Corneal erosion (<1%),«Ç·Å25¢J¥H¤U«O¦s¡Cªw»s«á«Ç·Å«O¦s10¤Ñ¡C,Adults and children weighing > or = 45 kg: 500 mg orally once daily with or without food for 3 days. Sexually transmitted diseases caused by Chlamydia trachomatis: 1 g as single oral dose. Children 10 mg/kg once daily for 3 days.,µL»Ý½Õ¾ã¾¯¶q,¨Ö¦³»´(A¯Å)¦Ü¤¤«×(B¯Å)¨x¥\¯à·l®`ªº±wªÌ¡AµL¶·½Õ¾ã,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ] ¬ã¨s¤H­û´¿¥H¾¯¶q³vº¥»¼¼W¡B³Ì²×¹F¨ì¥ÀÅé¬r©Ê¾¯¶qªº¤è¦¡¶i¦æ°Êª«¥Í´Þ¬ã¨s¡C¦b³o¨Ç¬ã¨s¤¤¡A¯f·|µo²{¥ô¦óÅã¥ÜAzithromycin·|¹ï­L¨à³y¦¨¦MÀIªºÃÒ¾Ú¡C°Êª«¤§¥Í´Þ¬r©Ê¸ÕÅçÅã¥ÜAzithromycin·|¬ï¹L­L½L¡A¦ý¥¼µo²{­P·î­L©Ê¡C¤£¹L¡A¥Ø«e©|µL¾A·í¥B±±¨î¨}¦nªº¥¥°ü¬ã¨s¡C¥Ñ©ó°Êª«¥Í´Þ¬ã¨sªºµ²ªG¨Ã¤£¤@©w¯à¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹¡A¥u¦³¦bµ´¹ï¥²­nªº±¡ªp¤U¤~¥i©óÃh¥¥´Á¶¡¨Ï¥ÎAzithromycin¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]³ø§i«ü¥X¡A Azithromycin·|ªc¤J¨Å¥Ä¡A¦ý¥Ø«e©|¥¼°w¹ï±Â¨Å°ü¤k¶i¦æ¨}¦nªº¹ï·Ó¸ÕÅç¡A¬ã¨s§ë¤©Azithromycinªº¤HÃþ¨Å¥Ä¤ÀªcÃÄª«°Ê¤O¾Ç¡C¦]¦¹¡A°£«DÂå®v§PÂ_¥ÎÃÄ®Ä¯q¤j©ó¹ïÀ¦¨àªº¼ç¦b­·ÀI¡A§_«h±Â¨Å°ü¤k¤£±o¨Ï¥ÎAzithromycin¡C,AC;PC;PO;WM;,,,,,1. ½Ð¥ý±NÃÄ¯»·n´²¡A ¥[¤J§N¶}¤ô9mL²V¦X§¡¤Ã«á¨Ï¥Î¡C 2. ªw»s«á¥i«Ç·Å«O¦s10¤Ñ¡C
OCAN,Canagliflozin,Canaglu 100mg,META,Type 2 diabetes.,History of serious hypersensitivity to canagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2); end-stage renal disease or patients on dialysis.,>10%: Increased serum potassium (>5.4 mEq/mL [eGFR 30 to 50]: 27%; >5.4 mEq/mL [eGFR 45 to 60]: 9%; ?6.5 mEq/mL [eGFR 30 to 50]: 2%)¡A Genitourinary fungal infection (females: 11% to 12%; males: 4%; patients who developed infections were more likely to experience recurrence)¡A Renal insufficiency (?30% decrease in eGFR from baseline: 1% to 23%; eGFR decline was more common in patients with moderate renal impairment) 1% to 10%: Falling (2%)¡A fatigue (2%)¡A Hypoglycemia (4%)¡A hypovolemia (2% to 3%)¡A increased thirst (2% to 3%)¡A Abdominal pain (2%)¡A constipation (2%)¡A nausea (2%)¡A Urinary tract infection (6%)¡A increased urine output (5%)¡A vulvovaginal pruritus (2% to 3%)¡A Increased hemoglobin (3% to 4%)¡A Hypersensitivity reaction (4%)¡A Asthenia (?1%) Frequency not defined: Hypermagnesemia¡A increased serum cholesterol (non-HDL)¡A increased serum phosphate¡A Bone fracture¡A decreased bone mineral density¡A Increased serum creatinine <1%¡A postmarketing¡A and/or case reports: Acute renal failure¡A anaphylaxis¡A angioedema¡A increased LDL cholesterol¡A ketoacidosis¡A necrotizing fasciitis (perineum)¡A pancreatitis¡A phimosis¡A pyelonephritis¡A skin photosensitivity¡A urinary tract infection with sepsis,25¢J¥H¤U,100 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IANO,D-Mannitol,Anol inj 200mg/mL¡A100mL/bag,CAVS,Treatment of cerebral oedema; to increase urine flow in acute renal failure; reduce raised intracranial pressure; short-term management of glaucoma; promote excretion of toxic substances by forced diuresis.,Children under 12 years old¡A Pulmonary oedema¡A intracranial bleeding (except during craniotomy)¡A heart failure & renal failure (unless a test dose has produced a diuretic response).,Fluid & electrolyte imbalance¡A nausea & vomiting¡A thirst¡A headache¡A chills¡A fever¡A allergic reactions.,20-30«×C,Osmotic reduction of intracranial pressure: 0.5 to 2 gm/kg of a 15-25% solution IV infusion over 30-60 minutes. Diuresis: 50-100 gm of a 5-25% solution IV infusion to keep urine output 30-50 mL/hours. (Children dosage: 2 gm/kg or 60mg/m2) Determination of glomerular filtration rate: 20 gm (100 mL of 20% solution) in 180 mL saline diluted to 7.2% solution¡A IV infusion rate: 20 mL/minutes.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iN/S¡j¥é³æ«ØÄ³¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,,º¯³z­°À£§@¥Î:IVD¡A 0.5~2g/kg (as a 15~25% solution)¡A 30~60min §Q§¿§@¥Î:IVD¡A Adult: 50~100g¡A Children: 2g/kg¡A or 60mg/m2 body surface area (as a 5~25% solution)¡A ºû«ù§¿²G¬y¶q30~50mL/hour.,1.¥V©u©Î§NÂÃ®É¡A¥i¯à²£¥Íµ²´¹¡A¥i±N¨ä«O·Å©óÄá¤ó40-50«×¡A«Ý·»¸Ñ«á§N«o¦ÜÅé·Å¨Ï¥Î¡C 2.½Ð¨Ï¥Îªþ¦³¹LÂo¸Ë¸m¤§¿é²G®M¡A¾É¤J°wÀ³¥H««ª½¤è¦¡´¡¤J¾ó¥Ö¶ë¡A´¡¤J«á¤Å§áÂà¡A¥H§K²£¥Í¸H¤ù¡C 3.¨Ï¥Î«eÀ³¦AÀËµø¡A½T©wµL²§ª«¤è¥i¨Ï¥Î¡C
IBOT,Botulinum Toxin type A,Botox 100 Unit/Vial,CNEU,For the treatment of strabismus & blepharospasm associated with dystonia¡A including benign essential blepharospasm or VII nerve disorders in patients >= 12 years. Treatment of spasmodic torticollis (cervical dystonia) in adults. Treatment of dynamic equinus foot deformity due to spasticity in pediatric cerebral palsy patients >= 2 years. Treatment of primary hyperhidrosis of the axilla. Treatment of glabellar lines associated with corrugator &/or procerus muscle activity. Management of focal spasticity¡A including treatment of upper limb spasticity associated with stroke in adults.,Myasthenia gravis or Eaton Lambert syndrome¡A infection at inj site.,Localized pain¡A tenderness &/or bruising¡A local weakness¡A ptosis¡A vertical deviation¡A irritation/tearing. Rarely¡A skin rash (including erythema multiforme¡A urticaria & psoriasiform eruption)¡A pruritus¡A allergic reactions¡A dysphagia¡A pneumonia. Dermatologic: Injection site reaction (cervical dystonia¡A 5% to 22%; glabellar lines¡A 3% ) Gastrointestinal: Xerostomia (cervical dystonia¡A 13% to 39% ) Musculoskeletal: Muscle weakness (cervical dystonia¡A 11% to 56% ) Neurologic: Difficulty speaking (cervical dystonia¡A 6% to 28% )¡A Headache (9% to 11% ) Ophthalmic: Disorder of eye (cervical dystonia¡A 6% to 17% ) Respiratory: Nasopharyngitis (glabellar lines¡A 10% ),2-8¢J©Î-5~-20¢J,Strabismus: Intramuscular. Vertical muscles and for horizontal strabismus of < 20 prism diopters: 1.25-2.5 units in any one muscle. Horizontal strabismus of 20-50 prism diopters: 2.5-5 units in any one muscle. Persistent VI nerve palsy of >= 1 month: 1.25-2.5 units in the medial rectus muscle. Maximum: 25 units as single injection for any one muscle. Blepharospasm: Intramuscular. Initially 1.25-2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and into the lateral pretarsal orbicularis oculi of the lower lid. Maximum cumulative dose: 200 units in 2-month period. VII nerve disorders: Patients with hemifacial spasm or VII nerve disorder should be treated as for unilateral blepharospasm. Maximum cumulative dose: 200 units in 2-month period. Spastic torticollis (Cervical dystonia): Intramuscular. Individualised dosing. Maximum cumulative dose:<= 360 units in 2-month period and administer no more frequently than every 2 months. Spasticity (due to juvenile cerebral palsy) in patients 2 years of age and older: Intramuscular. 4 units/kg into each of 2 sites in the medial and lateral heads of the gastrocnemius muscle of the affected lower limb(s). Maximum total dose in 30-day period: 200 units. Primary axillary hyperhidrosis: 50 unit intradermally to each axilla evenly distributed in multiple sites about 1-2 cm apart. Administer no more frequently than every 2 months. Reduction of glabellar lines: Intramuscular. Inject 4 units into each of 5 sites¡A two in each corrugator muscle and one in the procerus muscle for a total dose of 20 units. Reduction of lateral canthus lines (Crow's feet): Intramuscular. Inject 2-6 units into 3 injection sites per side (6 total injection points) in the lateral orbicularis oculi muscle. Reduction of forehead lines: Intramuscular. Inject 2 to 6 units into each of four sites in the frontalis muscle every 1 to 2 cm along either side of forehead crease and 2 to 3 cm above eyebrows for total dose of 8-24 units. Stroke-related upper limb spasticity: Intramuscular. Inject into selected muscles (typically the flexor muscles of the elbow¡A wrist & fingers)¡A start with lowest dose¡A maximum: 50 units/site. Maximum dose per treatment session: 360 units. May be repeated when the effects have lessened¡A but generally no sooner than 12 weeks after the previous injection. Lower limb spasticity: Intramuscular. Total dose of 300 to 400 units IM divided among 5 muscles (gastrocnemius¡A soleus¡A posterior tibial¡A flexor pollicis longus and flexor digitorum longus). May be repeated when the effects have lessened¡A but generally no sooner than 12 weeks after the previous injection. Chronic migraine: Intramuscular. Total dose of 155 units as 5 units into each of 31 sites divided across 7 specific head/neck muscle areas. Usual retreatment every 12 weeks. Bladder dysfunction: Intradetrusor. Detrusor overactivity associated with neurologic condition: Total dose of 100 units/treatment initially¡A may increase to the maximum: 200 units/treatment¡A if necessary. Overactive bladder: Total dose of 100 units administered as twenty 10 units injections into the detrusor muscle; injections should be spaced approximately 1 cm apart. Median time to retreatment is approximately 24 weeks¡A but should be no sooner than 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;SC;,¥[¤J0.9% N/S 10mLµ}ÄÀ«á.¨C0.1 mL§t¦³1 Unit,,,,
EZAL5,Sertaconazole,ZALAIN ³±¹D¿õ 500mg,SGU,Vulvovag candidiasis.,Hypersensitivity to any component of the formulation.,Slight local & transient erythematous reaction.,30¢J¥H¤U,Insert 1 vaginal tablet at bedtime. Administer second dose 1-2 weeks later if symptoms not reside.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,VAG;,,,,,
ECLO5,Clotrimazole,Clomazole vaginal tablet 500mg,SGU,Vulvovaginal candidiasis,Hypersensitivity.,Erythema¡A stinging¡A irritation; hypersensitivity reactions.,Àx¦s©ó³±²D15-30¢J³B,1 vaginal tablet every three days at bedtime. [Micromrdex 2021/06/15] 500 mg vaginal suppository intravaginally once weekly or 200 mg vaginal tablet intravaginally twice weekly for at least 6 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,VAG;,,,,,
ECLF,Hydroquinone + Tretinoin + Fluocinolone acetonide,Cleanfleck cream 5gm,TDER,For short-term treatment of moderate to severe melasma of the face.,Hypersensitivity to fluocinolone acetonide¡A hydroquinone¡A tretinoin¡A or any components of the product.,Common Dermatologic: Burning sensation (18% )¡A Dry skin (14% )¡A Erythema (41% )¡A Peeling of skin (38% )¡A Pruritus (11% ),2-8¢J§NÂÃ«O¦s¡A¶}«Ê«á½Ð«O«ù±K«Ê¡C,Each gram contains Fluocinolone acetonide 0.1mg(0.01%) + Hydroquinone 40mg(4%) + Tretinoin 0.5mg(0.05%). For short-term treatment of moderate to severe melasma of the face¡A apply a thin film of the cream topically to affected areas once nightly at least 30 minutes prior to bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,Hydroquinone of Pregnancy Recommendation: Limited Human Data - Probably Compatible. Tretinoin(Topical) of Pregnancy Recommendation: Human Data Suggest Low Risk. Fluocinolone(Topical) of Pregnancy Recommendation: Limited Human Data¡XAnimal Data Suggest Risk. [¥é³æ]¥»ÃÄ©óÃh¥¥´Á¶¡¨Ï¥Îªº¦w¥þ©Ê¤Î¦³®Ä©Ê©|¥¼½T¥ß¡AÃh¥¥´Á¶¡°£«DµL¨ä¥L´À¥NÃÄ«~¡A¥BÁ{§É®Ä¯q¤j©ó­·ÀI®É¤è¥i¦Ò¼{¨Ï¥Î¡F ¦Ó¨|ÄÖ°ü¤k¨Ï¥Î´Á¶¡À³±Ä¦æ¥²­nªºÁ×¥¥±¹¬I¡C¦]¨Ì¾Ú°Êª«¬ã¨sÅã¥Ü§tretinoidsÃþ¤fªA¾¯«¬ÃÄ«~¥Î©óÃh¥¥°ü¤k¥i¯à¾É­P­L¦Ó¨ã¦³¥ý¤Ñ©Ê²§±`¤§­·ÀI¡AÁö¨Ì¥Ø«eÁ{§É¤åÄm¸ê®Æ¡A­Y¨Ì·Ó¥é³æ«ØÄ³¥Îªk¥Î¶q¡A¥~¥Î¾¯«¬retinoidsÃþÃÄ«~¡A¦]¸g¥Ö§l¦¬¶q·L¤p¡A¨Ã¥¼¦³©ú½TÃÒ¾ÚÅã¥Ü¹ï©ó­L¨à°·±d¦³®`¡A¦ý¤´À³¸g¹L¼f·Vµû¦ô«á¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Hydroquinone of Breastfeeding Recommendation: No Human Data - Probably Compatible. Tretinoin(Topical) of Breastfeeding Recommendation: No Human Data - Probably Compatible. Fluocinolone(Topical) of Breastfeeding Recommendation: No Human Data¡XPotential Toxicity. [¥é³æ]¥þ¨­©Ê¨Ï¥Î¥Ö½èÃþ©T¾J®É¡A¥X²{©ó¤HÃþ¨Å¥Ä¡A¦ý¥¼ª¾§½³¡¶îÀ¿¥»°t¤è®É¡A¬O§_¥i¯à¦]¥þ¨­©Ê§l¦¬¡A¦Ó©ó¤HÃþ¨Å¥Ä¤¤²£¥Í¥i°»´ú¶qªºFluocinolone acetonide¡BHydroquinone©ÎTretinoin¡F ¥Ñ©ó³\¦hÃÄª«·|¤Àªc©ó¤HÃþ¨Å¥Ä¡A¦]¦¹¥»°t¤è§ë¤©­÷¨Å°ü®ÉÀ³¼f·V¡FÀ³¤p¤ßÁ×§K³Q­÷¨ÅªºÀ¦¨à±µÄ²¨ì¥»°t¤è¡C,EXT;SKIN;,,,,,
OSEV3,Amlodipine + Olmesartan,SEVIKAR 5/40mg,CAVS,Management of hypertension¡A not recommended for initial therapy.,Combined use of Sevikar and drugs containing aliskiren in patients with diabetes or renal insufficiency (GFR<60ml/min/1.73 m2). Known hypersensitivity to Sevikar or any of its components.,Peripheral edema (dose related: 18-26%)¡A anaphylaxis¡A hypotension¡A nocturia¡A orthostatic hypotension¡A palpitations¡A pruritus¡A skin rash¡A urinary frequency.,25¢XC¥H¤U,Initial: 5/20 mg q24h. After 2 weeks of treatment¡A the dose can be increased to 10/40 mg q24h as needed (Max: 10/40mg). If blood pressure control is still not ideal¡A alternative treatments can be considered¡A such as increasing the dose of one or both components.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¥Ø«e¨ÃµL¸ÕÅç¬ã¨sSevikar¹ï¨x¥\¯à¤£¥þ¯f¤Hªº¼vÅT¡A¦ý¤w¦³¸ê®ÆÅã¥Üamlodipine©Molmesartan medoxomil¦b¨x¥\¯à¤£¥þ¯f¤H¤¤¿@«×·|¤¤«×¼W¥[¡C­««×¨x¥\¯à¤£¥þ¯f¤Hªºamlodipine«ØÄ³°_©l¾¯¶q¬°2.5mg¡ASevikar µL¦¹¾¯¶q¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,Amlodipine: Human Data Suggest Low Risk Olmesartan: Human Data Suggest Risk in 2nd and 3rd Trimesters [¥é³æ] ¹ïÃh¥¥¤k©Ê§ë¤©Sevikar¥i¯à·|¹ï­L¨à³y¦¨¶Ë®`¡C¦bÃh¥¥²Ä2©M²Ä3´Á®É¡A ¨Ï¥ÎµÇ¯À-¦åºÞª@À£¯À¨t²ÎªºÃÄª«·|¨Ï­L¨àµÇ¥\¯à­°§C¤Î¼W¥[­L¨à©M·s¥Í¨à¿©¯f²v»P¦º¤`¡C ÃÄª«³y¦¨ªº¦Ï¤ô¹L¤Ö«h»P­L¨àªÍ³¡µo¨|¤£¨}¤Î­L¨à¥|ªÏÅËÁY¦³Ãö¡C¼ç¦bªº·s¥Í¨à°Æ§@¥Î¥]¬AÆ`°©µo¨|¤£¥þ¡BµL§¿¯g¡B§C¦åÀ£¡BµÇÅ¦°IºÜ¤Î¦º¤`¡C ¤@¥¹¯f¤H½T©wÃh¥¥¡A»Ý¥ß§YÅý¯f¤H°±¥ÎSevikar¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Amlodipine: Compatible Olmesartan: No Human Data¡XProbably Compatible [¥é³æ] ¦³ÃöSevikar¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡B¹ï­÷¨ÅÀ¦¨à¼vÅT©Î¹ï¨Å¥Ä¤Àªc¼vÅTªº¸ê®Æ¦³­­¡C Amlodipine·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡COlmesartan·|¤Àªc¦Ü¤j¹«¨Å¥Ä¡C ¥Ñ©óÃÄª«¹ï±Â¨ÅÀ¦¨à¨ã¦³¼ç¦b¤£¨}§@¥Î¡AÀ³§iª¾±Â¨Å¤k©Ê±µ¨üSevikarªvÀø´Á¶¡¤£«ØÄ³­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
IVAB,Faricimab,Vabysmo intravitreal inj 6mg/0.05mL,TOPH,For intravitreal injection. Neovascular (wet) age-related macular degeneration (nAMD)¡A diabetic macular edema (DME),Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash¡A itching¡A urticaria¡A erythema¡A or severe intraocular inflammation).,Common: Conjunctival hemorrhage (7-8%) Serious: Arterial thromboembolism (1-5%)¡A Raised intraocular pressure (3-4%)¡A Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3%),Á×¥ú§NÂÃ(2-8¢XC)Àx¦s¡B¤£¥i§N­á¡C,Neovascular age-related macular degeneration (nAMD): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Maximum interval: Every 16 weeks (4 months)¡A but can be adjusted to every 12 weeks (3 months) or every 8 weeks (2 months). Limited safety data for intervals shorter than 8 weeks. Diabetic macular edema (DME): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Dosing intervals: Gradual extension of injection intervals¡A up to every 16 weeks (4 months). No clinical trial data available for intervals shorter than 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¤£´¿¬ã¨sVabysmo ¥Î©ó¨x¥\¯à¤£¥þ¯f¤Hªº¦w¥þ©Ê»PÀø®Ä¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL Vabysmo ¥Î©óÃh¥¥¤k©Êªº¸ê®Æ¡C ¥Ø«e¨Ã¤£ª¾¹Dµ¹¤©Ãh¥¥¤k©Ê®É¡A Vabysmo ¬O§_·|³q¹L­L½L©Î¶Ë®`­L¨à¡C®Ú¾Ú VEGF »P Ang-2§í¨î¾¯ªº§@¥Î¾÷Âà¡A ¦s¦b¹ï¤k©Ê¥Í´Þ¯à¤O¥H¤Î­F­L­L¨àµo¨|ªº¼ç¦b­·ÀI¡CÁöµM²´³¡µ¹ÃÄ«á¥þ¨­¼ÉÅS«D±`§C¡A ¦ý°£«D¹ï¯f¤Hªº¼ç¦b®Ä¯q¶W¹L¹ï­L¨àªº¼ç¦b­·ÀI¡A§_«h¤£À³©óÃh¥¥´Á¶¡¨Ï¥ÎVabysmo¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¥¼ª¾ Vabysmo ¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤º¡C¥Ø«e©|¥¼¶i¦æ¸ÕÅçµû¦ô Vabysmo ¹ï©ó¨Å¥Ä»s³yªº¼vÅT©Î¨ä¬O§_·|¶i¤J¨Å¥Ä¸Ì¡C ¥Ñ©ó³\¦hÃÄª«·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡A¦s¦b§l¦¬¦Ó¶Ë®`À¦¨à¥Íªø»Pµo¨|ªº¼ç¦b¥i¯à¡A ¦]¦¹ Vabysmo µ¹¤©­÷¨Å¤¤¤k©Ê®ÉÀ³¯S§O¤p¤ß¡CÀ³¦P®É¦Ò¼{­÷¨Å¹ï©óµo¨|©M°·±dªº¯q³B¡A ¥H¤Î¥À¿Ë¹ï©ó Vabysmo ªºÁ{§É»Ý­n»P Vabysmo ¹ï©ó±µ¨ü­÷¨Å«Äµ£ªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¡C,IVI;,,,,,1. ¶È¨Ñ¬Á¼þÅé¤ºª`®g¨Ï¥Î¡CVabysmo ¥²¶·¥Ñ¨ã³Æ¬Á¼þÅé¤ºª`®g¸gÅçªº¦X®æÂå®vµ¹¤©¡C¨C¤p²~¶ÈÀ³¨Ï¥Î©óªvÀø³æ²´¡C
OMTCB,Mecobalamin,METHYCOBAL 500mcg,CNEU,Peripheral neuropathies¡A megaloblastic anaemia caused by vit B12 deficiency.,Hypersensitivity to mecobalamin¡A cobalt¡A vitamin B12¡A or any component of the product.,Common: Asthenia (4-16%)¡A Headache (4-20%)¡A Paresthesia (4%)¡A Stomach discomfort¡A Loss of appetite¡A Nausea¡A Diarrhea¡A Rash. Serious: Congestive heart failure¡A Pulmonary edema¡A Thrombosis¡A Anaphylaxis¡A Optic atrophy.,¹ï¥ú¤£¦w©w¡A»ÝÁ×¥ú«O¦s,Adult: 500mcg TID PO. May adjust dosage according to patient's age and synptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,VITAMIN B12 (cyanocobalamin): Compatible,Compatible ­÷¨Å®É¥i¨Ï¥Î,VITAMIN B12 (cyanocobalamin): Compatible,AC;AC15;PC;PO;WM;,,,,,
EPOLI,Policresulen,Polinin 90mg vaginal suppository,SGU,Local treatment of cervical & vag inflammatory & concomitant discharge. Vaginitis & cervicitis¡A cervical erosion; trichomoniasis & moniliasis. To stop bleeding after biopsy & removal of cervical polyps. Decubital ulcers caused by pessaries. After electrocoagulation to activate regeneration.,Concomitant use of other topical agents in treating the affected areas.,Occasionally¡A mild local discomfort at beginning of treatment which disappears on discontinuation.,25¢J¥H¤U,1 vaginal suppository at bedtime every 2 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,¥é³æ:¬ã¨s¦Ü¥Ø«e©|µLªk»¡©úÃh¥¥°ü¤kµ¹ÃÄªº¦MÀI©Ê¡A©|¥B¤£ª¾¬O§_¥D¦¨¤À·|±Æ°£©ó±Â¨Å°üªº¨Å¥Ä¤º¡C,VAG;,,,,,
EFRO,Metronidazole,®ê¾¯Frotin 250mg,SGU,Vaginitis due to trichomonas vaginalis.,Blood dyscrasias. Active CNS disease.,GI upset¡A urticaria¡A angioedema. Rarely¡A drowsiness¡A skin reactions¡A darkening of urine¡A anaphylaxis¡A neuropathy¡A encephalopathy. Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction,³±²DÁ×¥ú¤§³B,1 suppository at bedtime for 10-21 days¡A after treatment 1-2 weeks or at menstrual cycle ending < 3 months must have trichomonas test.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,METRONIDAZOLE PREGNANCY RECOMMENDATION: Human Data Suggest Low Risk,Hold Breast Feeding ¼È°±­÷¨Å,METRONIDAZOLE BREASTFEEDING RECOMMENDATION: Hold Breastfeeding (Single Dose) Limited Human Data¡XPotential Toxicity (Divided Dose),VAG;,,,,,
ILEV3,Insulin Detemir,Levemir FlexPen 100 Unit/mL¡A 3mL,META,Treatment of diabetes mellitus.,Hypersensitivity to insulin detemir or to any of the excipients of Levemir.,Hypoglycemia¡A inj site reactions. Rarely¡A lipodystrophy¡A allergic reactions.,2-8¢JÁ×¥úÁ×§K§N­á,SC¡A initial 0.1 - 0.2 unit/kg once daily in the evening or 10 units once or twice daily. The dose adjusted to achieve glycemic targets.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,SC;,,,,,
INOVX,Insulin Aspart,NovoRapid FlexPen 100U/mL 3mL,META,Treatment of patients with diabetes mellitus.,Hypoglycaemia.,Hypoglycaemia¡A edema¡A refraction anomalies¡A hypersensitivity reactions¡A lipodystrophy.,2-8¢J,IVA¡A IVD¡A SC¡A according to the individual needs of the patient¡A the insulin requirements of adults and children are usually 0.5 to 1.0 unit/kg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVA;IVD;SC;,,¡iN/S¡j¥i¿ï ¡C,,¨Ï¥ÎÀR¯ßª`®g®É¡A¨Ï¥Î polypropylene ¿éª`³U¡A¨Ã¥B¥H 0.9% sodium chloride ©Î§t¦³ 40 mmol/l potassium chloride ¤§ 5%©Î 10% dextrose ¬°¿éª`·»²G°t»s¿@«×0.05 U/ml ¨ì 1.0 U/ml ªº NovoRapidR100 U/ml ¤§¿éª`¨t²Î¡A¦b«Ç·Å¤U¥iºû«ù¦w©w¹F 24 ¤p®É¡C ÁöµMÀHµÛ®É¶¡¯à«O«ùÃ­©w¡A¦ý¦³¤Ö¶qªº¯Ø®q¯À¦b¤@¶}©l·|³Q¿éª`³U©Ò§l¦¬¡C ¦b¿éª`¹Lµ{¤¤¡A¦å¿}ªººÊ±±¬O¥²»Ýªº¡C,
EATREU,Atropine,Atropine Eye Drops 0.01%¡A 0.5mL/¤ä,TOPH,Mydriasis¡A cycloplegia.,Hypersensitivity to any component of the product. Primary glaucoma or predisposition to narrow anterior chamber angle glaucoma.,Common Ophthalmic: Blurred vision¡A Finding of lacrimation¡A Decreased¡A Pain in eye¡A Photophobia¡A Superficial keratitis Serious Immunologic: Anaphylaxis¡A Hypersensitivity reaction¡A Ophthalmic: acute angle-closure glaucoma,25¢J¥H¤UÀx¦s,1-4 times a day¡A each time used 1-2 drops.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]©|¥¼¦³°Êª«¥Í´Þ¬ã¨s¡A¥Ø«e©|¥¼²M·¡§½¤£Atropine¬O§_·|¹ï­L¨à³y¦¨¶Ë®`©Î¼vÅT¥Í´Þ¯à¤O. ¶È·í²M·¡»Ý­n®É¡A¥»«~¥i¥H¥Î©ó¥¥°ü.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]µL¬ÛÃö»¡©ú,OD;OL;OU;,,,,,
IBNT1,SARS-CoV-2 Spike glycoprotein [mRNA],Pfizer-BioNTech (5-11·³) 0.2mL/dose (1.3mL/vial),HIMM,The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age,Hypersensitivity to the active substance or to any of the excipients.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,¹B¿éª¬ºA¦Ó©w¸Ô¾\¥é³æ,IM¡A 0.2 mL¡A 5-11 years old¡A 2-dose series separated by at least 3 weeks,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]±qÃh¥¥¤¤´Á©M±ß´Á±µºØBNT162b2¬Ì­]¤§¥¥°üªº¤j¶qÆ[¹î¸ê®ÆÅã¥Ü¡A¤£¨}Ãh¥¥µ²ªG¨Ã¥¼¼W¥[¡C ÁöµM¥Ø«e¦bÃh¥¥«e¤T­Ó¤ë±µºØ¬Ì­]¤§«áªºÃh¥¥µ²ªG¤§¬ÛÃö¸ê®Æ¦³­­¡A¦ý¨Ã¥¼µo²{¬y²£­·ÀI¼W¥[¡C °Êª«¸ÕÅç¨Ã¥¼Åã¥ÜBNT162b2¬Ì­]·|¹ïÃh¥¥¡B­F­L¡þ­L¨àµo¨|¡B¤À®Y©Î²£«áµo¨|³y¦¨ª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C ±µºØ¬Ì­]¹ï©ó¥¥°ü©M­L¨àªº¼ç¦b¯q³B°ª©ó¼ç¦b­·ÀI®É¡A¥i¦Ò¼{¦bÃh¥¥´Á¶¡±µºØ¥»«~¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¹w´Á¹ï­÷¨Åªº·s¥Í¨à¡þÀ¦¨à¨S¦³¼vÅT¡A¦]¬°Áý­÷¥À¨Å¤§°ü¤kªºBNT162b2¬Ì­]¥þ¨­¼ÉÅS¶q·L¥G¨ä·L¡C ±q±µºØ¬Ì­]«áÁý­÷¥À¨Å¤§°ü¤kªºÆ[¹î¸ê®ÆÅã¥Ü¡A­÷¨Åªº·s¥Í¨à¡þÀ¦¨à¨ÃµL¤£¨}¤ÏÀ³ªº­·ÀI¡C Áý­÷¥À¨Åªº°ü¤k¥i±µºØBNT162b2¬Ì­]¡C,IM;,,,,,1.¨C²~(1.3 mL)¤À´²²G¡A¸g¥H 1.3 mL ªº 0.9%´â¤Æ¶uª`®g²G¶i¦æµ}ÄÀ«á¡A§t¦³ 10 ¾¯¨C¾¯ 0.2mLªºª`®g²G 2.¥¼¶}«ÊªºÃÄ²~¥i¦b8-30¢XCªº·Å«×¤U«O¦s12¤p®É¡A¥B­º¦¸¬ï¨ëÃÄ²~¡A¦b2-30¢XC¤U¥i«O¦s12¤p®É¡C³Ì¦h¦@«O¦s24¤p®É¡C 3.¥¼¶}«ÊªºÃÄ²~¦b¦b2-8¢XC¥i«O«ù¦w©w¹F10¶g¡C
EXAM,Calcipotriol + Betamethasone,Xamiol gel 30gm,TDER,Plaque psoriasis:,Hypersensitivity to calcipotriene¡A betamethasone¡A or any component of the formulation; viral (herpes simplex¡A varicella¡A vaccinia)¡A fungal or bacterial infection of the skin; parasitic infections; tuberculosis of the skin; syphilitic skin infections; ophthalmic use; calcium metabolism disorders; perioral dermatitis; atrophic skin; striae atrophicae; fragility of skin veins; ichthyosis; acne vulgaris; acne rosacea; rosacea; ulcers; wounds; perianal and genital pruritus; psoriasis (guttate¡A erythrodermic¡A exfoliative); severe hepatic disorders; severe renal insufficiency,1% to 10%: Dermatologic: Pruritus (4% to 7%)¡A psoriasis (2% to 3%)¡A erythema (1% to 2%)¡A skin atrophy (<2%)¡A burning sensation of skin (1%)¡A ecchymoses (1%)¡A exfoliative dermatitis (1%)¡A hand dermatosis (1%)¡A skin depigmentation (1%)¡A skin irritation (1%)¡A folliculitis (<1%) <1% (Limited to important or life-threatening): Acneiform eruption¡A acne vulgaris¡A application-site pruritus¡A contact dermatitis¡A dermatitis¡A exacerbation of psoriasis¡A eye irritation¡A facial edema¡A HPA-axis suppression¡A hypercalcemia¡A hypercalciuria¡A hyperpigmentation¡A hypopigmentation¡A otitis externa¡A papular rash¡A psoriasis flare¡A psoriasis (rebound)¡A pustular psoriasis¡A pustular rash¡A skin pain¡A skin rash¡A telangiectasia¡A xeroderma,30¢J¥H¤UÀx¦s,Apply to the affected area once daily. Recommended treatment period: 4 weeks. After this period¡A repeated treatment can be initiated under medical supervision. Max daily dose: 15 g. Maximum weekly dose: 100 g. Maximum treated area: 30% of body surface.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Ãh¥¥¤À¯Å: C (UpToDate),EXT;,,,,,
ICOVMVC,SARS-CoV-2 Spike glycoprotein,COVID-19 Vaccine Medigen 0.5mL/dose(10 dose/vial),HIMM,Medigen COVID-19 Vaccine is indicated for active immunization of individuals 20 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).,History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,Á×¥ú¡A2-8¢XC¡A¤£¥i§N­á,Age > or = 20 years old: IM: 0.5 mL per dose for 2 doses administered 28 days apart.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]°ªºÝ·s«aªÍª¢¬Ì­]¥Î©óÃh¥¥¤k©ÊªºÁ{§É¸gÅç¦³­­¡C ¦b¤j¹«¥Í´Þ»Pµo¨|¬r©Ê¸ÕÅç¤¤¡A¹ï¸ÕÅç¥À¹«µ¹¤©§t¶q¬°5©Î25 £gg SARS-CoV2­«²Õ´Æ³J¥Õ»²¥H750 £gg CpG 1080¤Î375 £gg²B®ñ¤Æ¾T¦õ¾¯¤§0.5²@¤É¬Ì­]¾¯¶q¡Fµ¹¤©¤§®É¶¡ÂI¬°¡G¥æ°t«e²@¤É¬Ì­]¾¯¶q¡Fµ¹¤©¤§®É¶¡ÂI¬°¡G¥æ°t«e3¶g¡B¥æ°t«e1¶g¡BÃh¥¥²Ä6¤Ñ¡BÃh¥¥²Ä18¤Ñ¤Î­÷¨Å²Ä7¤Ñ¦U±µ¨ü¤@¾¯ ¡C µ²ªGÅã¥Ü¡A¦U¾¯¶q²Õ¬Ò¥¼Æ[¹î¨ì¥À¹«¥Í¨|¯à¤O¡B­F­Lµo©Î¥J¨ü¼vÅT¡C ©óÃh¥¥´Á¶¡¡A°ß¦³¬I¥´°ªºÝ·s«aªÍª¢¬Ì­]¹ï¥À¿Ë©M­L¨àªº¼ç¦b¯q³B°ª©ó¥ô¦ó¼ç¦b­·ÀI®É¡A¤~À³¦Ò¼{¬I¥´¥»¬Ì­]¡C ¥i¯àÃh¥¥©Î¦³­pµe¤§¤k©Ê¡A¬ÒÀ³µû¦ô±µºØ§Q¯q»P­·ÀI¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨Ã¤£²M·¡°ªºÝ·s«aªÍª¢¬Ì­]©Ò»¤µoªº§ÜÅé¬O§_·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡C ®Ú¾Ú¤j¹«¥Í´Þ»Pµo¨|¬r©Ê¸ÕÅçªº¦å²M¾Ç¼ÆÅã¥Ü¡A§ÜSARS-CoV 2­«²Õ´Æ³J¥Õ¤§IgG§ÜÅé¥i¯à·|¸g¥Ñ¨Å¥ÄÂà²¾¨ì¥J¹«¨­¤W¡C ¥Ø«e¨ÃµL±µºØ°ªºÝ·s«aªÍª¢¬Ì­]¹ï­÷¨ÅÀ¦¨à¼vÅTªº¬ã¨s¡A¦ý²z½×¤WµL¥Íª«¬¡©Êªº¬Ì­]¤£·|·P¬V¥À¿Ë©ÎÀ¦¨à¡A©Ò¥H±Â¨Å¥iµû¦ô±µºØ¤§§Q¯q»P­·ÀI«á±µºØ°ªºÝ·s«aªÍª¢¬Ì­]¡C,IM;,,,,,¥H¦Ù¦×ª`®gªº¤è¦¡±N 0.5 mL°ªºÝ·s«aªÍª¢¬Ì­]ª`®g¦Ü¤âÁu¡A¦@¨â¾¯¡A¶¡¹j 28¤Ñ¡C ¨Ï¥Î«e½Ð·n®Ì§¡¤Ã¡A¶È­­¥H¦Ù¦×ª`®g¤è¦¡¬I¥Î¡A³Ì¦nª`®g©ó¤WÁuªº¤T¨¤¦Ù (Deltoid)¡C ¤£¥i¦b¦åºÞ¤º¡B¥Ö¤Uª`®g¬Ì­]¡C °ªºÝ·s«aªÍª¢¬Ì­]ªº¥~Æ[¬°µL¦â¼á©ú²G¡A¸g·n¤Ã²V¿B¥ÕÄa¯B¡C¦pªG¹w¥R¶ñ¦¡°w¾¯¤ºªºÄa¯B²GÅÜ¦â©Î¦³Áû²É¡A½Ð¥á±ó¡C
EVYZ,Latanoprostene bunod,Vyzulta 0.024%¡A 5mL ophthalmic solution,TOPH,The reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.,Hypersensitivity to any component of the formulation.,Common Ophthalmic: Conjunctival hyperemia (6%) Serious Ophthalmic: Bacterial keratitis¡A Cystoid macular edema¡A Macular retinal edema.,2-8¢XC«O¦s,1 drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¤´¥¼°w¹ï¤HÃþ©ó¥¥´Á¶¡¨Ï¥Î VYZULTAªº¬ÛÃöÃÄª«­·ÀIµû¦ô¸ê®Æ¡C Latanoprostene bunod´¿¤Þ°_¨ß°¦¬y²£¡B¤p²£©M­L¨à·l¶Ë¡C¹ï¥¥¨ß¸gÀR¯ß¡]IV¡^¬I¤©¤j©óÁ{§É0.28­¿¤§latanoprostene bunod«á¡Aµo²{¦¹ª«½è¤Þ°_¬y²£©M·î­L¡C ¦Û­L¨ß©Ò¨£µ²ºc²§±`¥]¬A¥D°Ê¯ß¤}¤j¦åºÞ²§±`¡B¶ê³»Æ`¡B¯Ý°©»P¯á°©²§±`¡BªÏÅé¹L«×¦ù®i¤ÎÂà°Ê²§±`¡B¸¡³¡¹ªµÈ¤Î¤ô¸~¡C¥H¨C¤Ñ150 mcg/kgªº¾¯¶q¡]Á{§É¾¯¶qªº87­¿¡^¸gÀR¯ß¨Ï¥Î©ó¤j¹««á¡Aµo²{latanoprostene bunod¹ï©ó¤j¹«¤£¨ã­P·î­L©Ê¡C ¥Ø«e©ó¥¥´Á¶¡¨Ï¥Î¦¹ÃÄ«~»P¦h¼Æ·s¥Í¨à¯Ê³´¤Î¬y²£ªº­·ÀI¤´¥¼ª¾¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¹ï©ó VYZULTAÀH¤HÃþ¨Å¥Äªc¥X¡B¹ï©ó±Â¨ÅÀ¦¨à©Î¹ï¨Å¥Ä¤Àªcª¬ªpªº¼vÅTªº¬ÛÃö¸ê®Æ¡C ¨Ï¥Î«eÀ³°w¹ï¾ãÅé¦Ò¶q­÷¨Å¹ïÀ¦¨àµo¨|©M°·±dªº¯q³B¡B¥À¿Ë¹ï©óVYZULTAªºÁ{§É»Ý¨D¡A¥H¤ÎVYZULTA¹ï©ó±Â¨ÅÀ¦¨àªº¥i¯à¤£¨}®ÄÀ³¡C,OD;OL;OU;,,,,,1. ¥¼¶}±ÒªºÃÄ²~À³©ñ¤J2-8¢XCÀô¹Ò«O¦s¡CÃÄ²~¶}«Ê«á¡A¥i¦b§C©ó25¢XCªºÀô¹Ò¤U«O¦s8¶g¡C¹B°eÃÄ²~®É¡A¥i±NÃÄ²~«O¦s¦b40¢XC¥H¤UªºÀô¹Ò¡A¥B«O¦s®É¶¡¤£±o¶W¹L14¤Ñ¡C
ICOVBNT,SARS-CoV-2 Spike glycoprotein [mRNA],COVID-19 Vaccine BioNTech 0.3mL/dose (0.45mL/vial),HIMM,BioNTech COVID-19 Vaccine¡A for active immunization to prevent COVID-19 in individuals 12 years of age and older.,Hypersensitivity to the active substance or to any of the excipients.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,¹B¿éª¬ºA¦Ó©w¸Ô¾\¥é³æ,IM¡A 0.3 mL¡A > or = 18 years 2 doses administered 3 weeks apart. (Taiwan CDC suggests 2 doses administered 4 weeks apart.),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥¥°ü±µºØBNT162b2¬Ì­]ªº¹ê»Ú®×¨Ò¦³­­¡C °Êª«¸ÕÅç¨Ã¥¼Åã¥ÜBNT162b2¬Ì­]·|¹ïÃh¥¥¡B­F­L/­L¨àµo¨|¡B¤À®Y©Î²£«áµo¨|³y¦¨ª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C À³¶È¦b¹ï©ó¥¥°ü©M­L¨àªº¼ç¦b¯q³B°ª©ó¥ô¦ó¼ç¦b­·ÀI®É¡A¤~¦Ò¼{¦bÃh¥¥´Á¶¡±µºØ¥»«~¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|¤£²M·¡BNT162b2¬Ì­]¬O§_·|¤Àªc¦Ü¥À¨Å¤¤¡A¤]¯Ê¥F¸ê°T»¡©ú±µºØBNT162b2¬Ì­]¹ï­÷¨ÅÀ¦¨à¬O§_¦³¼vÅT¡C ­÷¨Å´Á¶¡¤§¤k©Ê¡AÀ³©ó±µºØBNT162b2¬Ì­]«eµû¦ô¼ç¦b¯q³B¬O§_°ª©ó¼ç¦b­·ÀI¡C,IM;,,,,,¶·±Ä¥Î21¸¹©ÎºÞ®|§ó¤pªº°wÀY©MµLµß§Þ³N¡A¦b­ì©lÃÄ²~¤¤ª`¤J1.8 mLªº0.9%´â¤Æ¶uª`®g²G¶i¦æµ}ÄÀ¡Cµ}ÄÀ«á¡AÃÄ²~§t2.25 mL²G¾¯¡A¥i©â¨ú6¾¯0.3 mL¤§¬Ì­]¡C¨C¾¯¥²¶·§t¦³0.3 mL¬Ì­]¡C¦pªGÃÄ²~¤¤³Ñ¾l¶q¤£°÷©â¨ú0.3 mLªº§¹¾ã¾¯¶q¡AÀ³¥á±ó¡C¥ô¦ó¥¼©óµ}ÄÀ«á6¤p®É¤º¨Ï¥Î§¹²¦ªº¬Ì­]¬ÒÀ³¥á±ó¡C ¸Ñ­á«áªºÃÄ²~:¥i©ó2-8 ¢XC«O¦s1­Ó¤ë¡C¥¼¶}«ÊªºÃÄ²~¨Ï¥Î«e¦b³Ì°ª30 ¢XCªº·Å«×¤U³Ì¦h¥i«O¦s2¤p®É¡C¸Ñ­á«áªº¬Ì­]¤£¥i¦A¦¸§N­á¡C¨Ï¥Î0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ«á¡A¦b2-30 oC¤U¡A¨ä¦w©w©Ê(¥]¬A¹B¿é´Á¶¡)¥iºû«ù6¤p®É¡C
OLENV,Lenvatinib,Lenvima 4mg,RACA,1. Differentiated thyroid cancer (DTC): Used for adults with progressive¡A locally advanced¡A or metastatic DTC¡A unresponsive to radioactive iodine treatment. 2. Renal cell carcinoma (RCC): Used as a first-line treatment in combination with pembrolizumab for advanced RCC patients. Also used in combination with everolimus for advanced RCC patients who have received prior anti-angiogenic therapy. 3. Hepatocellular carcinoma (HCC): Suitable for advanced HCC patients who are ineligible for surgical resection or local therapies. 4. Endometrial carcinoma (EC): Used in combination with pembrolizumab for advanced EC patients who have had disease progression after systemic therapy and are not candidates for curative surgery or radiotherapy.,Hypersensitivity to Lenvima or any component of the formulation.,Common: Hypertension (42-73%)¡A Peripheral edema (14-42%)¡A Hand-foot syndrome due to cytotoxic therapy (23-32%)¡A Impaired wound healing¡A Rash (14-37%)¡A Hypothyroidism (21-67%)¡A Abdominal pain (31-37%)¡A Constipation (16-29%)¡A Decrease in appetite (34-54%)¡A Nausea (20-49%)¡A Stomatitis (35-44%)¡A Vomiting (16-48%)¡A Weight decreased (30-51%)¡A Hemorrhage (23-35%)¡A Arthralgia¡A Disorder of the musculoskeletal system (53%)¡A Myalgia¡A Headache (10-38%)¡A Proteinuria (26-34%)¡A Urinary tract infectious disease (11-31%)¡A Cough (24-37%)¡A Difficulty talking (18-31%)¡A Dysphonia (22-30%)¡A Dyspnea (35%)¡A Fatigue (44-73%) Serious: Myocardial dysfunction (7-10%)¡A Myocardial infarction¡A Prolonged QT interval (2-11%)¡A Right ventricular dysfunction¡A Diarrhea (39-81%)¡A Gastrointestinal obstruction¡A Malignant¡A Lower gastrointestinal hemorrhage¡A Perforation of the intestine¡A Anemia (Renal cell carcinoma¡A 6%)¡A Arterial thrombosis (2-5%)¡A Myelodysplastic syndrome¡A Thrombocytopenia (Renal cell carcinoma¡A 5%)¡A Hepatic encephalopathy (Hepatocellular carcinoma¡A 8%)¡A Hepatitis¡A Hepatorenal syndrome¡A Hepatotoxicity (25%)¡A Liver failure¡A Osteonecrosis of the jaw (0.4%)¡A Posterior reversible encephalopathy syndrome (0.3%)¡A Acute injury of the kidney¡A Nephritis¡A Renal failure (Renal cell carcinoma¡A 18%)¡A Renal impairment (7-18%)¡A Pneumonia¡A Pneumonitis¡A Pulmonary embolism¡A Cardiorespiratory arrest¡A Dehydration (9-10%)¡A Multiple organ failure¡A Sepsis,25¢J¥H¤U,Endometrial cancer¡A Carcinoma¡A advanced disease¡A that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H)¡A in combination with pembrolizumab in patients with disease progression following prior systemic therapy in any setting who are not candidates for curative surgery or radiation: 20mg QD PO + pembrolizumab 200mg IV over 30 minutes Q3W. Liver carcinoma¡A Unresectable¡A first-line therapy: (<60kg) 8mg QD PO¡A (>=60kg) 12mg QD PO. Renal cell carcinoma¡A Advanced¡A in combination with everolimus¡A after 1 prior anti-angiogenic therapy: 18mg QD PO + everolimus 5mg QD PO. Renal cell carcinoma¡A Advanced¡A in combination with pembrolizumab¡A first-line treatment: 20mg QD PO + pembrolizumab 200 mg IV over 30 minutes Q3W up to 2 years; following 2 years of combination therapy¡A may give lenvatinib as a single agent until disease progression or unacceptable toxicity. Thyroid cancer¡A Differentiated¡A locally recurrent or metastatic¡A progressive¡A refractory to radioactive iodine: 24mg QD PO,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ­««×¨x¥\¯à¤£¥þ(Child-Pugh C)¤§DTC¡BRCC ©Î¤l®c¤º½¤Àù¯f¤H¤§«ØÄ³¾¯¶q¬°¡G ¤À¤Æ«¬¥Òª¬¸¢Àù¡G14mg QD PO¡FµÇ²Ó­MÀù¡G10mg QD PO¡F¤l®c¤º½¤Àù¡G10mg QD PO¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ]¨Ì¾Ú§@¥Î¾÷Âà¤Î°Êª«¥Í´Þ¸ÕÅç¼Æ¾Ú¡AÃh¥¥°ü¤k¨Ï¥Î·|¹ï­L¨à³y¦¨¶Ë®`¡C °Êª«¥Í´Þ¸ÕÅç¤¤¡A©ó¤j¹«¤Î¨ß¤l¾¹©xµo®i®É´Á¤fªAµ¹¤© Lenvatinib¡A ¨ä¾¯¶q§C©ó¤HÅé«ØÄ³¾¯¶q®É¡A·|¾É­P­F­L¬r©Ê¡B­L¨à¬r©Ê©M­P·î­L©Ê¡C ¹ï©óÃÄª«¬ÛÃöªº­·ÀI¡A¥Ø«eµL¤HÅé¸ÕÅç¼Æ¾Ú¡CÀ³§iª¾Ãh¥¥°ü¤k¡A¨ä¹ï­L¨à¤§¼ç¦b­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ©|¥¼ª¾¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡AµM¦Ó¡Alenvatinib ¤Î¨ä¥NÁÂª«·|¤Àªc¦Ü¤j¹«¨Å¥Ä¤¤¥B ¨ä¿@«×°ª©ó¥ÀÅé¦å¼ß¤ºªº¿@«×¡C¦]¦¹ÃÄ¥i¯à¹ï­÷Áý¤§À¦¨à³y¦¨ÄY­«¤£¨}¤ÏÀ³¡A ¶·§iª¾°ü¤k¨Ï¥Î¥i¯à¹ï­÷Áý¤§À¦¨à³y¦¨ÄY­«¤£¨}¤ÏÀ³¡A ¶·§iª¾°ü¤kªvÀø´Á¶¡¤ÎªA¥Î³Ì«á¤@­Ó¾¯¶q«á¦Ü¤Ö1©P»Ý°±¤î­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³ºÞÄé»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ³B²z¡A¨Ãª`·N¬ÛÃö­·ÀI¡C LenvimaR½¦Ån¥i¾ã²É§]ªA¡A©Î±N½¦Ån¥ý·»¸Ñ©ó¤pªM²GÅé«áªA¥Î¡C±N½¦Ån©ñ¤J¤@¤j´ö°Íªº¤ô©ÎÄ«ªG¥Ä¤¤(½¦Ån¤£»Ý¥´¶}©ÎÀ£¸H)¡A¥H·»¸Ñ©ó²GÅé¡C±N½¦ÅnÀR¸m©ó¤ô©ÎÄ«ªG¥Ä¤¤¦Ü¤Ö10 ¤ÀÄÁ¡A¦AÅÍ©Õ¦Ü¤Ö3¤ÀÄÁ¡C¶¼¥Î²V¦X²G«á¡A¦A¥[¤J¤@¤j´ö°Íªº¤ô©ÎÄ«ªG¥Ä©ó¬Á¼þªM¤¤¡AÅÍ¤Ã«á¦A¶¼¥Î§¹¤ô©ÎÄ«ªG¥Ä¡C
ICLIN9,Amino Acid + Dextrose + Electrolytes,Clinimix N9G15E inj 1500mL,NUTR,For parenteral nutrition when the intestines cannot absorb nutrients or malabsorption occurs¡A and enteral nutrition is deemed unsuitable.,Hypersensitivity to one or more amino acids¡A dextrose¡A or any component of the formulation. Inborn errors of amino acid metabolism (eg¡A maple syrup urine disease¡A isovaleric acidemia). Severe hyperglycemia. Metabolic acidosis; hyperlactatemia. Hypernatremia; hyperkalemia; hypercalcemia; hyperphosphatemia; hypermagnesemia. Neonates (<28 days of age) receiving concomitant ceftriaxone. Simultaneous administration of ceftriaxone through the same infusion line in patients >28 days of age.,Phlebitis¡A thrombosis¡A erythema¡A fluid and electrolyte disturbance¡A azotemia.,Àx¦s·Å«×30¢J¡A¥H¨¾¥ú·Ó¡A½Ð¤Å§N­á¡C,Osmotic Pressure: 845 mOsm/L. Maximum infusion rate: 3 mL/kg/hour. Maximum daily dose: 40 mL/kg. Dose based on metabolic needs¡A energy expenditure¡A and clinical condition. Adults: Required dosage ranges from 0.16-0.35 g of nitrogen/kg/day (approximately 1-2 g of amino acids/kg/day). Children: Required dosage ranges from 0.35-0.45 g of nitrogen/kg/day (approximately 2-3 g of amino acids/kg/day). Caloric needs range from 25-40 kcal/kg/day¡A depending on nutritional status and metabolic rate.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ñ©ó¯Ê¥F¬ÛÃöÁ{§É¬ã¨s¡ACLINIMIX¦b¥Í´Þ¡B§³®W©M­÷¨Å¤è­±ªº¦w¥þ©Ê©|¥¼Àò±oÃÒ¹ê¡C¹ïÃh¥¥©Î­÷¨Å°ü¤k§ë¤©¥»²£«~®É¡A³B¤è¶}¥ßªÌ¥²¶·¦Ò¶q¥ÎÃÄ­·ÀI»P§Q¯q¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ñ©ó¯Ê¥F¬ÛÃöÁ{§É¬ã¨s¡ACLINIMIX¦b¥Í´Þ¡B§³®W©M­÷¨Å¤è­±ªº¦w¥þ©Ê©|¥¼Àò±oÃÒ¹ê¡C¹ïÃh¥¥©Î­÷¨Å°ü¤k§ë¤©¥»²£«~®É¡A³B¤è¶}¥ßªÌ¥²¶·¦Ò¶q¥ÎÃÄ­·ÀI»P§Q¯q¡C,IVD;,,,,Maximum infusion rate: 3 mL/kg/hour. Maximum daily dose: 40 mL/kg.,1. ÃÄ§½½Õ¾¯¡A«D¤@¯ë¥æ¥IÃÄ«~¡C 2. µ¹ÃÄ«e¥²¶·¥ýÀ½À£©Î±²°_µÄ«Ç§Ë¯}¤À¹j±ø¡A§¡¤Ã²V©MÃÄ«~·»²G¡C 3. ¥»«~§t¶t¡A¸T¤î¨Ö¥Îceftriaxone¡A¥H§Kµo¥Í¨I¾ý¡C 4. ³Ì¤j¿éª`³t²v¬° 3mL/kg/hour¡C¨C¤é³Ì¤j¾¯¶q¬° 40mL/kg¡C 5. ¤À¹j±ø¯}Ãa«á¡A¤Æ¾Ç¤Îª«²zªº¨Ï¥ÎÃ­©w©ÊÃÒ©ú²V¦X²G¥i¦b 2-8¢XC¤U«O¦s7¤Ñ¡A¤§«á¦b25¢XC¤U«O¦s48¤p®É¡C 6. ¥Î©ó¥¼º¡ 2 ·³ªº¨àµ£®É½ÐÁ×§K¥ú·Ó¡Aª½¨ìµ¹ÃÄ§¹¦¨¬°¤î¡C
ONIF,Nifedipine,Nifedipine S.R.F.C. 30mg,CAVS,Hypertension¡A chronic stable angina pectoris,CV shock; pregnancy & lactation. Unstable angina & after recent MI (immediate release).,Initially mild & transient vasodilatation¡A hypotension¡A rarely GI¡A skin & other reactions. Very rarely: transient visual change; chest discomfort (if relation established¡A discontinue therapy). Extremely rare: on prolonged use gingival hyperplasia¡A gynaecomastia (both regressing on discontinuation); hepatobiliary disorders. Cardiovascular: Hypotension (up to 5% )¡A Palpitations (up to 7% )¡A Peripheral edema (7% to 29% ) Dermatologic: Flushing (4% to 25%) Gastrointestinal: Nausea (up to 10% ) Neurologic: Dizziness (4% to 10% )¡A Headache (19% to 23%) Psychiatric: Feeling nervous Respiratory: Cough¡A Dyspnea,30¢J¥H¤U,angina: 30mg QD. HTN: 30mg QD up to 120mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;AM;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©Ê½¤¦ç¿õ¾ã²É§]ªA¡A¤£¥i©CÄZ©Î¿i¸H¡C
HCVDA14,Glecaprevir + Pibrentasvir (1¡A3type/16¶g),HCVDAA0014(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1©Î3«¬/16¶g,QANB,,,,,,,,,,,,,,,,,,,
IHER60,Trastuzumab,HERCEPTIN inj 600mg/5mL (sample),RACA,Breast cancer¡A adjuvant treatment¡A breast cancer¡A metastatic¡A gastric cancer¡A metastatic.,Hypersensitivity to trastuzumab¡A Chinese hamster ovary (CHO) cell proteins¡A or any component of the formulation.,>10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%)¡A chills (5% to 32%)¡A headache (10% to 26%)¡A insomnia (14%)¡A dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%)¡A diarrhea (7% to 25%)¡A vomiting (4% to 23%)¡A abdominal pain (2% to 22%)¡A anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%)¡A back pain (5% to 22%) Respiratory: Cough (5% to 26%)¡A dyspnea (3% to 22%)¡A rhinitis (2% to 14%)¡A pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%¡A chills and fever most common; severe: 1%)¡A fever (6% to 36%),2-8¢JÁ×¥úÁ×§K§N­á,600 mg (600 mg trastuzumab and 10¡A000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,SC;,,,,,1.¥»«~¶È¯à¥H¥Ö¤Uª`®gµ¹¤©¡Cª`®g®É¶¡À³¬°2-5¤ÀÄÁ¡C 2.¤£½×±wªÌÅé­«¦h¹è¡A¥»«~¤§«ØÄ³©T©w¾¯¶q¬°600mg¡A¨C3¶gµ¹ÃÄ£¸¦¸¡C 3.ª`®g³¡¦ìÀ³¦b¥ª¥k¤j»L¤§¶¡½ü´À¡A·sªºª`®g³¡¦ì»PÂÂªºª`®g³¡¦ìÀ³¬Û¶Z¦Ü¤Ö2.5¤½¤À¡A¥B¤£±o¦b¥Ö½§µo¬õ¡B·ï«C¡BÄ²µh©Îµw¶ô³Bª`®g¡C 4.²Ä¤@¦¸¥Ö¤Uª`®g«á6¤p®É¥H¤Î«áÄòªº¥Ö¤Uª`®g«á2¤p®É¡AÀ³Æ[¹î±wªÌ¬O§_¥X²{ª`®g¬ÛÃö¤ÏÀ³¡C
OFRIS,Clobazam,Frisium 10mg,CNEU,Anxiety or Adjunct in epilepsy.,History of hypersensitivity to clobazam or any component of the product. Myasthenia gravis. Severe respiratory insufficiency. Sleep apnoea syndrome. Severe hepatic impairment. Lactation.,Common Gastrointestinal: Constipation (2% to 10% )¡A Drooling (Up to 14% ) Neurologic: Ataxia (2% to 10% )¡A Dysarthria (2% to 5% )¡A Insomnia (2% to 7% )¡A Lethargy (5% to 15% )¡A Sedated (2% to 9% )¡A Somnolence (16% to 25% ) Psychiatric: Aggressive behavior (3% to 14% ) Renal: Urinary tract infectious disease (2% to 5% ) Respiratory: Cough (3% to 7% ) Other: Fever (10% to 17% .) Serious Dermatologic: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Immunologic: Hypersensitivity reaction Respiratory: Respiratory depression,25¢J¥H¤U,Anxiety: Adult: 20-30 mg daily in divided doses or as a single dose preferably at bedtime. Duration of treatment: Not exceeding 4 weeks and the patient must be re-assessed after. Use the lowest possible dose for the shortest possible time. Child > or = 3 years: Recommended dose is half of the adult dose. Elderly: 10-15 mg daily. Observe carefully during gradual dose increments. Adjunct in epilepsy: Adult: Initially¡A 5-15 mg daily. Max: 80 mg daily. usual Maintenance dose: 20mg/day. [Micromedex 20210922]Pediatric Dosing Lennox-Gastaut syndrome - Seizure; Adjunct 2 years or older and 30 kg or less: Initial¡A 5 mg orally daily; may titrate to 10 mg daily (2 divided doses) on day 7 and to 20 mg daily (2 divided doses) on day 14. 2 years or older and greater than 30 kg: Initial¡A 10 mg orally daily (2 divided doses); may titrate to 20 mg daily (2 divided doses) on day 7 and to 40 mg daily (2 divided doses) on day 14.,»Ý½Õ¾ã¾¯¶q,[Micromedex 20210920] Hepatic impairment (Child-Pugh score 5 to 9): Initial¡A 5 mg/day orally for all patients. Titrate no faster than weekly to half usual dose¡A according to weight. For 30 kg or less¡A may increase to 10 mg orally on day 14; for greater than 30 kg¡A may increase to 10 mg/day on day 7 and to 20 mg/day on day 14. If tolerated and necessary¡A additional titration to MAX dose¡A 20 mg/day (30 kg or less) or 40 mg/day (greater than 30 kg) may be started on day 21,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Limited Human Date - Potential Toxicity. [¥é³æ]°Êª«¸ÕÅçÃÒ¹ê¨ã¦³¥Í´Þ¬r©Ê¡C¦b¤W¥««á¦w¥þ¸ê®Æ¤¤¡A¥¥°üªA¥Îclobazam¤§¸ê®Æ¦³­­¡A¨ä¤¤¦³Ãö­L¨à©Î·s¥Í¨à¯e¯f¤§®×¨Ò¤]³Q³ø¾É¹L¡C Clobazam¥i¬ï³z­L½L¡C¦bÃh¥¥©Î¨ã¦³Ãh¥¥¼ç¤O¦ý¥¼Á×¥¥ªº¤k©Ê¡A¤£«ØÄ³¨Ï¥Îclobazam¡CÃh¥¥´Á¶¡³Ì¦nÁ×§K¨Ï¥Îclobazam¡C¥u¦³¦b¹ï­L¨à¤§¼ç¦b§Q¯q¤j©ó­·ÀI®É¡AÃh¥¥°ü¤k¤~¥i¨Ï¥Îclobazam¡C ¨ã¦³Ãh¥¥¼ç¤Oªº°ü¤k¥²¶·³Q§iª¾©óÃh¥¥´Á¶¡¨Ï¥Îclobazamªº­·ÀI»P§Q¯q¡C¦pªG°ü¤k­pµeÃh¥¥©Î¤w¸gÃh¥¥¡AÀ³¤p¤ßµû¦ô¨ä­·ÀI»P§Q¯q¡A¥H¤Î¬O§_À³¸Ó°±¤îªA¥ÎFrisium¡C µû¦ô«á¡A¦pªG¤´­nÄ~ÄòªA¥ÎFrisium¡AÀ³¥H³Ì§C¦³®Ä¾¯¶qªA¥Î¡C¬Y¨Ç¯f¨ÒÅã¥Ü¡A¦bÃh¥¥¤¤´Á¤Î/©ÎÃh¥¥«á´ÁªA¥Îbenzodiazepines·|³y¦¨­L¨à¹B°Ê´î¤Ö©M­L¨à¤ß²vÅÜ²§¡C Ãh¥¥«á´Á©Î¤À®Y´Á¶¡ªA¥Îclobazam¥i¯à·|¾É­P·s¥Í¨à¥X²{©I§l§í¨î²{¶H¡]¥]¬A©I§lµ~­¢¤Î©I§l¼È°±¡^¡A¤]¦³¥i¯à¥X²{¨ä¥L¤£¾A¡A¨Ò¦p¡AÂíÀR¼x¥ü¡BÅé·Å¹L§C¡B¦Ù¦×±i¤O°¾§C¡B©ÎÁý­¹§xÃø¡]¥i¯à¾É­PÅé­«¼W¥[¤£¨Î¡^¡]³o¨Ç¯gª¬¤Î¼x¥ü²ÎºÙ¬°¡§À¦¨àÂÚ¶\¯g­Ô¸s¡¨(floppy infant syndrome)¡^¡C ¦¹¥~¡A­Y¥ÀÅéªø´ÁªA¥Îbenzodiazepines¦ÜÃh¥¥«á´Á¡A«hÀ¦¨à¥X¥Í«á¥i¯à¥X²{¥Í²z©Ê¨Ì¿à¡A¥B¦³§ÙÂ_¯gª¬ªº­·ÀI¡C«ØÄ³·s¥Í¨à¦b¥X¥Í«áµ¹¤©¾A·íºÊ´ú¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]±Â¨Å°ü¤k¤£¥i¨Ï¥ÎFrisium¡C,,,,,,
ECOL4,Mesalazine,Colasa enema 4gm/100mL,ALIM,Ulcerative colitis¡A mild to moderate proctitis and proctosigmoiditis.,Hypersensitivity to mesalazine or any component in the preparation. History of hypersensitivity to salicylate preparations. Severe liver impairment. Severe renal impairment (GFR less than 30 ml/minute/1.73m2).,Nausea¡A diarrhea¡A abdominal pain¡A headache.,25¢J¥H¤U°®ÀêÁ×¥ú,Adults: 2gm-4gm once at night. Children: Dose is not determined.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ÄY­«¨x·l¶Ë¸T¥Î¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,MESALAMINE: Compatible [¥é³æ] Mesalazine¥Î©óÃh¥¥°ü¤k¤§Á{§É¬ã¨s«D±`¦³­­¡C¦³­­ªº¬ã¨s¤¤¨Ã¥¼µo²{mesalazine ¹ïÃh¥¥°ü¤k©Î°·±d­L¨à/·s¥Í¨à³y¦¨¶Ë®`¡C ¨´¤µ¬°¤îÁÙ¥¼¦³¨ä¥L¬ÛÃöªº¬y¦æ¯f¾Ç¼Æ¾Ú¡CMesalazine°Êª«¤fªA¸ÕÅç¡A ¹ïÃh¥¥¡B­F­L/­L¨àªºµo®i¨ÃµLª½±µ©Î¶¡±µ¶Ë®`¡A¯S§O¬O²£«áµo®i¡C Ãh¥¥´Á¶¡¡AmesalazineÀ³¶È­­©óÂå®v§PÂ_ªvÀø»Ý­n©Ê¤j©ó¥i¯àµo¥Í¤§­·ÀI¡A¥BÀ³ÂÔ·V¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,MESALAMINE: Limited Human Data¡XPotential Toxicity [¥é³æ] ¨´¤µ¬°¤î­÷¨Å¤§¬ÛÃö¬ã¨s¦³­­¡CÀ¦¥®¨àµLªk±Æ°£¤§¹L±Ó¤ÏÀ³¡A¦p¡G¸¡Âm¡C ¦]¦¹¡A­÷¨Å´Á¶¡¨Ï¥Î mesalazine À³§PÂ_ªvÀø»Ý­n©Ê¤j©ó¥i¯àµo¥Í¤§­·ÀI¡C °²¦p¯f¤H¦bªvÀø´Á¶¡¥X²{À¦¥®¨à¸¡Âm¯gª¬À³¥ß§Y°±¤î­÷¨Å¡C,RECT;,,,,,
IPRA,Alirocumab,Praluent solution for injection 75mg,CAVS,Hyperlipidemia¡A primary: Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease¡A who require additional lowering of LDL-C. Prevent cardiovascular events,Hypersensitivity.,Common: Injection site disorder (3.8-16.6%)¡A Nasopharyngitis (6-11.3%)¡A Influenza (5.7%) Serious: Hypersensitivity reaction (8.6%)¡A Angioedema,2-8¢JÁ×¥úÁ×§K§N­á,75 mg SC once every 2 weeks or 300 mg SC monthly. Maximum dose: 150 mg SC every 2 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,No reports describing the use of alirocumab in human pregnancy have been located. Animal data suggest low risk¡A but the absence of human pregnancy data prevents a better assessment of the embryo¡Vfetal risk. Based on studies in monkeys¡A exposure of the fetus late in pregnancy should be expected (see below). In addition¡A the drug is given to patients under treatment with statins. Statins are classified as contraindicated in pregnancy because interruption of cholesterol-lowering therapy during pregnancy should have no effect on the long-term treatment of hyperlipidemia and because of the human data reported with lovastatin (see Lovastatin). Consequently¡A alirocumab should also be classified contraindicated.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,1.¥¼§NÂÃ¥B25«×C¥H¤U³Ì¦h¤£¥i¶W¹L30¤Ñ.
OPLK,Finasteride,Proleak 5mg,SGU,,¾AÀ³¯g: Treatment & control of benign prostatic hyperplasia (BPH) to cause regression of enlarged prostate¡A improve urine flow & improve the symptoms of BPH. °Æ§@¥Î: Common Reproductive: Abnormal ejaculation (1.2% to 7.2% )¡A Breast tenderness (0.4% to 0.7% )¡A Reduced libido (1.8% to 10% ) Serious Endocrine metabolic: Neoplasm of male breast Reproductive: Prostate cancer¡A high-grade (1.8% ) Other: Neoplasm of male breast ¸T§Ò:Hypersensitivity to any component of the product. Pregnancy¡A or women who may be pregnant or plan to become pregnant.,,«Ç·Å,PO 5mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,[¥é³æ]Ãh¥¥©Î¥i¯àÃh¥¥¤§°ü¤k¸T¥ÎFinasteride.¥»ÃþÃÄª«Ãh¥¥°ü¤kªA¥Î¡A¥i¯à¤Þ°_¨k©Ê­L¨à¥~¥Í´Þ¾¹²§±`. Ãh¥¥©Î¥i¯àÃh¥¥¤§°ü¤k¤£¥i±µÄ²¤wÀ£¸H©Î¯}·l¤§Finasteride¿õ¾¯¡A¥i¯à¸g¥Ö½§§l¦¬¦Ó¹ï¨k©Ê­L¦Ó³y¦¨¦MÀI. [Micromedex] Pregnancy Category : X (FDA) 2020/06/01,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Finasteride¤£¾A¥Î©ó°ü¤k¡A¥Ø«e©|¥¼½Tª¾¬O§_·|±Æ¤J¤H¨Å¥Ä¤¤. [Micromedex] Breast Feeding: Infant risk cannot be ruled out. 2020/06/01,AC;PC;PO;WM;,,,,,
OVERZ0,Abemaciclib,Verzenio 150mg (sample) (28 tablets/box),RACA,Breast cancer¡A Advanced or metastatic¡A hormone receptor-positive disease¡A HER2-negative¡A in combination with an aromatase inhibitor for initial endocrine therapy in postmenopausal women and men. Breast cancer¡A Advanced or metastatic¡A hormone receptor-positive disease¡A HER2-negative¡A in combination with fulvestrant for progression following endocrine therapy. Breast cancer¡A Advanced or metastatic¡A hormone receptor-positive disease¡A HER2-negative¡A monotherapy for progression following endocrine therapy and prior chemotherapy in the metastatic setting. Breast cancer¡A Early¡A hormone receptor-positive¡A HER2-negative¡A node-positive¡A high-risk¡A in combination with adjuvant endocrine therapy.,Allergic to the active ingredients or excipients in Verzenio.,Common: Abdominal pain (29-39%)¡A Decrease in appetite (12-45%)¡A Diarrhea¡A All Grades (81-90%)¡A Nausea (39-64%)¡A Vomiting (26-35%)¡A Anemia¡A All Grades (25-29%)¡A Leukopenia¡A All Grades (17-28%)¡A Neutropenia¡A All Grades (37-46%)¡A Infectious disease (31-51%)¡A Headache (20%)¡A Fatigue (40-65%) Serious: Diarrhea¡A Grade 3 (8-20%)¡A Febrile neutropenia (Less than 1%)¡A Neutropenia¡A Grade 3 or higher (19-32%)¡A Neutropenic sepsis¡A Venous thromboembolism (2-5%)¡A ALT/SGPT level raised (Grade 3 or higher¡A 2-6%)¡A Aspartate aminotransferase serum level above reference range (Grade 3 or higher¡A 2-3%)¡A Cerebral infarction¡A Interstitial lung disease¡A Pneumonitis,Àx¦s©ó30¢XC¥H¤U,In combination with fulvestrant¡A tamoxifen¡A or an aromatase inhibitor¡A the recommended dose is 150 mg taken orally twice daily. As monotherapy¡A the recommended dose is 200 mg taken orally twice daily. Dose Modifications for Adverse Reactions: In combination with fulvestrant¡A tamoxifen¡A or an aromatase inhibitor: Recommended starting dose: 150 mg twice daily -> First dose reduction: 100 mg twice daily -> Second dose reduction: 50 mg twice daily -> Third dose reduction: not applicable. As monotherapy: Recommended starting dose: 200 mg twice daily -> First dose reduction: 150 mg twice daily -> Second dose reduction: 100 mg twice daily -> Third dose reduction: 50 mg twice daily.,»Ý½Õ¾ã¾¯¶q,­Y¯f¤H¬°­««×¨x¥\¯à¤£¥þ(Child Pugh-C)¡AÀ³±NVERZENIO¥ÎÃÄÀW²v´î¤Ö¬°¨C¤é¤@¦¸¡C CTCAE Grade for ALT and AST: 1. Grade 1 (>ULN-3.0 x ULN) Grade 2 (>3.0-5.0 x ULN)¡A WITHOUT increase in total bilirubin above 2 x ULN: No dose modification is required. 2. Persistent or Recurrent Grade 2¡A or Grade 3 (>5.020.0 x ULN)¡A WITHOUT increase in total bilirubin above 2 x ULN: Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose. 3. Elevation in AST and/or ALT >3 x ULN WITH total bilirubin >2 x ULN¡A in the absence of cholestasis: Discontinue. 4. Grade 4 (>20.0 x ULN): Discontinue.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]®Ú¾Ú°Êª«¸ÕÅçªºµo²{¤ÎÃÄª«§@¥Î¾÷Âà¡A­Yµ¹¤©Ãh¥¥°ü¤kVERZENIO¡A¥i¯à·|³y¦¨­L¨à¶Ë®`¡C¥Ø«e¨ÃµL¤HÃþªºÃÄª«­·ÀI¸ê®Æ¡CÀ³§iª¾Ãh¥¥°ü¤k¦¹ÃÄª«¥i¯à¹ï­L¨à³y¦¨¤§¼ç¦b¦M®`¡C¦b°Êª«¥Í´Þ¸ÕÅç¤¤¡A¦b¾¹©x§Î¦¨´Á¶¡§ë¤©abemaciclib¡Aabemaciclibªº¥ÀÅéÃnÅS¶q»P³Ì¤j«ØÄ³¤HÅé¾¯¶q¤UªºAUC¤§¤HÃþÁ{§ÉÃnÅS¶q¬Ûªñ®É¡A¨ã¦³­P·î­L©Ê¤]·|¾É­P­L¨àÅé­«´î»´¡CÀ³§iª¾Ãh¥¥°ü¤k¦¹ÃÄª«¥i¯à¹ï­L¨à³y¦¨¤§¼ç¦b¦M®`¡C ¦³Ãö¯S©w±Ú¸sµo¥Í­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº­I´º­·ÀI©|¤£²M·¡¡CµM¦Ó¦b¬ü°ê¤@¯ë±Ú¸sªºÁ{§É½T»{Ãh¥¥¤¤¡Aµo¥Í­«¤j¥ý¤Ñ¯Ê³´ªº­I´º­·ÀI¬°2¦Ü4%¡A¬y²£ªº­I´º­·ÀI¬°15¦Ü20%¡C ¦b¤@¶µ­F­L¡Ð­L¨àµo¨|¸ÕÅç¤¤¡A©ó¾¹©x§Î¦¨´Á¶¡µ¹¤©Ãh¥¥¤j¹«³Ì°ª¹F15 mg/kg/dayªºabemaciclib¤fªA¾¯¶q¡C¾¯¶q?4 mg/kg/day·|¾É­P­L¨àÅé­«­°§C¡A¤Î¤ß¦åºÞ©M°©Àf·î§Î»PÅÜ²§¨Æ¥óªºµo¥Í²v´£°ª¡C³o¨Çµo²{¥]¬A¯Ê¥FµL¦W°Ê¯ß©M¥D°Ê¯ß¤}¡BÂê°©¤U°Ê¯ß¿ù¦ì¡B¯Ý°©¥¼°©¤Æ¡B¯Ý´Õ´ÕÅéªº¤G¤À°©¤Æ¡A¤ÎÂú¦Ø©Îµ²¸`ª¬¦Ø°©¡C¨Ï¥Î4 mg/kg/dayªº¤j¹«¨ä¥ÀÅé¥þ¨­ÃnÅS¶q¤j¬ù»P«ØÄ³¾¯¶qªº¤HÅéÃnÅS¶q(AUC)¬Û·í¡C §iª¾¨ã¦³¥Í¨|¯à¤Oªº¤k©Ê¡A¦bVERZENIOªvÀø´Á¶¡¤Î±µ¨ü³Ì«á¤@¾¯ªvÀø«á3¶gÀ³±Ä¥Î¦³®ÄªºÁ×¥¥±¹¬I¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨S¦³abemaciclib¬O§_¶i¤J¤HÅé¨Å¥Ä¡A¹ï±Â¨ÅÀ¦¨à©Î¹ï¨Å¥Ä¤Àªc¼vÅTªº¸ê®Æ¡C¥Ñ©óVERZENIO¥i¯à¨Ï±Â¨ÅÀ¦¨àµo¥ÍÄY­«¤£¨}¤ÏÀ³¡AÀ³§iª¾­÷¨Å°ü¤k©óVERZENIOªvÀø´Á¶¡¤Î±µ¨ü³Ì«á¤@¾¯ªvÀø«á3¶g¤º¤£¥i­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¯f¤HÀ³§]ªA¾ãÁû¿õ¾¯¡A¤£¥i±N¿õ¾¯©CÄZ¡BÀ£¸H©Î¤Á¥b«á§]ªA¡C¦pªG¿õ¾¯¯}µõ¡Bµõ¶}©Î¤£§¹¾ã¡A½Ð¯f¤H¤£­nªA¥Î¡C
ESPOT,Tiotropium + Olodaterol,¾A­¿¼ÖSpiolto Respimat 2.5/2.5mcg/puff,ERSP,a long term maintenance treatment of patients with Chronic Obstructive Pulmonary Disease¡A including chronic bronchitis and emphysema.,Hypersensitivity to the active substances or to any of the excipients. History of hypersensitivity to atropine or its derivatives¡A e.g. ipratropium or oxitropium.,Common Musculoskeletal: Backache (3.6% ) Respiratory: Nasopharyngitis (12.4% ) Serious Cardiovascular: Disorder of cardiovascular system (3% or less )¡A Electrocardiogram abnormal Immunologic: Hypersensitivity reaction (3% or less ) Ophthalmic: Angle-closure glaucoma¡A Worsening (3% or less ) Renal: Urinary retention¡A Worsening (3% or less ) Respiratory: Bronchospasm (3% or less )¡A Pneumonia,30¢XC¥H¤U¤Å§N­á,Adults: The recommended dose is 5 mcg tiotropium and 5 mcg olodaterol (2 puffs) QD¡A at the same time of the day. SPIOLTOR RESPIMAT should not be used more frequently than once daily. Age < 18 years: Usually will not use.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,Tiotropium: PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk Olodaterol: PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk [¥é³æ] Tiotropium: Ãö©ó tiotropium ©ó¥¥°üªº¨Ï¥Î¸gÅç¡A¥Ø«e¬ÛÃö¸ê®Æ¤Q¤À¦³­­¡CÁ{§É«e¬ã¨s¨Ã¥¼Åã¥Ütiotropium ¦bÁ{§É¬ÛÃöªº¾¯¶q¤U¡A¥i¯à¨ã¦³¥Í´Þ¬r©Ê¦Ó³y¦¨ª½±µ©Î¶¡±µªº¶Ë®`¡C Olodaterol: ¥Ø«e©|µL olodaterol ¦b¥¥°ü¤¤¨Ï¥Îªº¬ÛÃöÁ{§É¸ê®Æ¡COlodaterol ªºÁ{§É«e¸ê®ÆÅã¥Ü¡A¦b¸ûªvÀø¾¯¶q°ª¥X¦h­¿ªº¾¯¶q¤U¡A·|¥X²{ s-µÇ¤W¸¢¯À¨üÅé«P®Ä¾¯ªº¨å«¬§@¥Î¡C §@¬°¨¾½d±¹¬I¡A«ØÄ³Ãh¥¥´Á¶¡À³Á×§K¨Ï¥Î SPIOLTOR RESPIMATR¡C¦p¦P¨ä¥L s2-µÇ¤W¸¢¯À¨üÅé«P®Ä¾¯¡ASPIOLTOR RESPIMATR©Ò§t¦¨¤À olodaterol ¹ï¤l®c¥­·Æ¦Ù¨ã¦³ÃP¦¢§@¥Î¡A¦]¦¹¥i¯à¹ï¤À®Y¹Lµ{¨ã§í¨î§@¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Tiotropium: BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible Olodaterol: BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible [¥é³æ] ¥Ø«e©|µL tiotropium ¤Î/©Î olodaterol ¦b±Â¨Å°ü¤k¨Ï¥Îªº¬ÛÃöÁ{§É¸ê®Æ¡C Tiotropium ©M olodaterol ªº°Êª«¹êÅçµo²{¡A¦bªc¨Å¤j¹«ªº¨Å¥Ä¤¤¥i°»´ú¨ì¥»ÃÄª«¤Î/©Î¨ä¥NÁÂ²£ª«¡A¦ý¤£²M·¡ tiotropium ¤Î/©Î olodaterol ¬O§_¥i¤Àªc¦Ü¤H¨Å¡C ¦b¨M©w¬O§_Ä~Äò/°±¤î­÷¨Å©ÎÄ~Äò/°±¤î SPIOLTOR RESPIMATRªvÀø®É¡AÀ³¦Ò¶q­÷¨Å¹ïÀ¦¨àªº¯q³B»P SPIOLTO RESPIMAT ªvÀø¹ï°ü¤kªº¯q³B¡C,IH;,,,,,
ENNG,Testosterone,Natesto nasal gel 4.5%¡A 11gm,HM,Testosterone replacement therapy in adult males,Natesto is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precaution. Natesto is contraindicated in women who are or who may become pregnant¡A or who are breastfeeding. Natesto may cause fetal harm when administered to a pregnant woman. Natesto may cause serious adverse reactions in nursing infants. Exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization. If a pregnant woman is exposed to Natesto¡A she should be apprised of the potential hazard to the fetus.,Common Dermatologic: Acne (Up to 8% )¡A Application site reaction (2% to 16.1% )¡A Scab of skin¡A Nasal (3.8% to 5.8% ) Endocrine metabolic: Gynecomastia (1% to 3% ) Gastrointestinal: Oral irritation (9.2% ) Neurologic: Headache (1% to 6% ) Reproductive: Large prostate (11.7% )¡A Raised prostate specific antigen (1% to 11.1% ) Respiratory: Bleeding from nose (3.8% to 6.5% )¡A Bronchitis (3.8% to 4.3% )¡A Discomfort¡A Nasal (3.8% to 5.9% )¡A Nasal discharge (3.8% to 7.8% )¡A Nasopharyngitis (3.8% to 8.7% )¡A Sense of smell altered (5.8% )¡A Sinusitis (3.8% )¡A Upper respiratory infection (3.8% to 4.3% ) Serious Cardiovascular: Death¡A Cardiovascular¡A Edema¡A Myocardial infarction Hematologic: Deep venous thrombosis¡A Venous thromboembolism Hepatic: Cholestatic jaundice syndrome¡A Liver carcinoma¡A Neoplasm of liver¡A Peliosis hepatis Neurologic: Cerebrovascular accident Reproductive: Benign prostatic hyperplasia (Up to 2% )¡A Prostate cancer (Up to 1.2% ) Respiratory: Pulmonary embolism,«O¦s©ó«Ç·Å¤U(25¢XC),Recommended Dose and Dosage Adjustment The recommended starting dose of NATESTO (testosterone) is 11.0 mg of testosterone (1 actuation per nostril) administered intranasally twice daily for a total daily dose of 22.0 mg. To ensure proper dosing¡A serum total testosterone concentrations should be measured after initiation of therapy to ensure that the desired concentrations (300 to 1050 nanogram/dL) are achieved. The NATESTO dose can be adjusted at least 30 days after starting treatment based on the serum total testosterone concentrations from a single blood draw¡A taken 20 minutes to 2 hours after morning administration of NATESTO. If the total testosterone measurement is less than 300 nanogram/dL¡A the daily testosterone dose may be increased from 22.0 mg (twice daily administration) to 33.0 mg (thrice daily administration)¡A as instructed by a physician. Serum total testosterone concentrations should be checked periodically. The following rules should be applied: 1. For patients on 22.0 mg (twice daily administration): If the measured serum total testosterone concentration from the single morning blood draw is less than 300 nanogram/dL¡A the NATESTO? Product Monograph Page 15 of 39 daily dose of NATESTO may be increased from 22.0 mg (twice daily administration) to 33.0 mg (thrice daily administration); 2. For patients on 33.0 mg (thrice daily administration): If the measured serum total testosterone concentration from the single morning blood draw is consistently less than 300 nanogram/dL¡A or if a desired clinical response is not achieved¡A NATESTO should be discontinued and an alternative treatment should be considered. If a post-dose morning total testosterone concentration consistently exceeds 1050 nanogram/dL¡A NATESTO should be discontinued.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¥Ñ©ó¯Ê¥F¬ÛÃöµû¦ô¥B¥i¯à¦³¶¯©Ê¤Æ§@¥Î¡ANATESTO ¨ÃµL¨Ï¥Î©ó¤k©Êªº¾AÀ³¯g¡C NATESTO ¸T¥Î©óÃh¥¥´Á¶¡¡A©Î¥i¯à¨ü¥¥ªº¤k©Ê¡C¸A©Tà¬¨ã¦³­P·î­L©Ê¡A¥i¯à¹ï­L¨à³y¦¨¦M®`¡C ¦pªG¦¹ÃÄ¦bÃh¥¥´Á¶¡¨Ï¥Î¡A©ÎªÌ±wªÌ¦b¨Ï¥Î¦¹ÃÄ´Á¶¡¨ü¥¥¡A±wªÌÀ³ª¾±x¥i¯à¹ï­L¨à³y¦¨ªº¦M®`¡C ¤k©Ê­L¨à­Y¼ÉÅS©ó¶¯©Ê¯À¤¤¡A¥i¯à¾É­Pµ{«×¤£¤@ªº¶¯©Ê¤Æ¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ÁöµM¥Ø«e¤£²M·¡¦³¦h¤Ö¸A©Tà¬·|¶i¤J¤HÃþ¨Å¥Ä¡A ¦ý¥Ñ©ó¥i¯à¦b³Ü¥À¨ÅªºÀ¦¨à¨­¤W¤Þ°_ÄY­«¤£¨}¤ÏÀ³¡A¦]¦¹ NATESTO ¸T¤î¥Î©ó­÷¨Å¤¤¤k©Ê¡C,IN;,,,,,¨C«ö¤@¦¸µ¹ÃÄÀ°®ú¥i°e¥X5.5mgªº¸A©Tà¬¡A¦]¦¹¥ª¥k»ó¤Õ¦Uµ¹ÃÄ¤@¦¸¥i°e¥X11mg¡C
OSERM1,Nicergoline,Sermion 10mg,CAVS,Cerebral circulation disorders.,Hypersensitivity to nicergoline¡A or Ergotamine. Myocardial infarction. Acute bleeding. Postural hypotension. Severe bradycardia,Rare cases of mild side effects have been reported¡A which in general may be related to the vasoactive action of Sermion. These are hypotension and vertigo after parenteral administration¡A slight gastric disturbances¡A feeling of heat and flushing¡A drowsiness and insomnia.,25¢J¥H¤U,5-10 mg three times daily. Take Sermion between meals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Nicergoline¤£·|³y¦¨Ãh¥¥¦Ñ¹«©M¨ß¤lªº¥Í´Þ¬r©Ê¡C¦bÃh¥¥°ü¤kªº¬ã¨s©|¥¼¶i¦æ¡C ´N¥Ø«e®Ö­ãªº¾AÀ³¯g¦Ó¨¥¡A¤£¤Ó¥i¯à·|¨Ï¥Înicergoline©óÃh¥¥°ü¤k©M­÷¨Å°ü¤k¡C ¦bÃh¥¥´Á¶¡¡AnicergolineÀ³¶È¯à¦b¹ï¯f¤Hªº¼ç¦b¯q³B¤j©ó¹ï­L¨àªº¼ç¦b­·ÀI®É¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«eÁÙ¤£ª¾¹Dnicergoline¬O§_·|¤Àªc¦b¤HÃþ¥À¨Å¤¤¡C ¦]¦¹¡A¤£«ØÄ³­÷¨Å´Á¶¡¨Ï¥Înicergoline¡C,AC;AC15;PC;PO;,,,,,
IALF1,Alfentanil,Alfentanil inj 1mg/2mL,CNEU,An analgesic supplement and an anaesthetic induction agent.,Hypersensitivity to alfentanil or any component of the formulation. known intolerance to alfentanil or opioids.,Common: Hypertension (18%)¡A Tachycardia (12%)¡A Nausea (28%)¡A Vomiting (18%)¡A Involuntary movement¡A Skeletal muscle (3-9%) Serious: Asystole¡A Bradyarrhythmia¡A Cardiac dysrhythmia¡A Hypotension (10%)¡A Anaphylaxis (Less than 1%)¡A Muscle rigidity (17%)¡A Raised intracranial pressure¡A Seizure¡A Apnea (3-9%)¡A Laryngeal spasm (0.3-1%)¡A Respiratory depression (1-3%)¡A Serotonin syndrome,30¢J¥H¤U,Anesthetic Induction: An intravenous bolus dose of > or =120 micrograms/kg (17mL/70kg). For short procedures or out patient¡A an initial dose 7-15 micrograms/kg at induction¡A with intermittent boluses up to 15 micrograms/kg (7-15 micrograms/kg) at 10-15 minute intervals are most useful. If the dose is less than 7 micrograms/kg and IV injection slowly¡A most patients can still maintain normal respiratory function. the recommended additional dose is 3.5 micrograms/kg. For procedures of longer duration¡A a higher dose may be given at induction and further increments titrated to effect. For procedures of longer duration¡A a higher dose may be given at induction and further increments titrated to effect. Duration of the procedure: 10-30 minutes; Alfentanil IV bolus dose: 20-40 Micrograms/kg; 3-6mL/70kg; Duration of the procedure: 30-60 minutes; Alfentanil IV bolus dose: 40-80 Micrograms/kg; 6-12mL/70kg; Duration of the procedure: >60 minutes; Alfentanil IV bolus dose: 80-150 Micrograms/kg; 12-20mL/70kg; When surgery is more prolonged or more traumatic¡A analgesia should be maintained by: either increments of up to 15 micrograms/kg (2mL/70kg) Alfentanil when required (to avoid post-operative respiratory depression¡A no Alfentanil should be administered during the last 10 minutes of surgery); Or an Alfentanil infusion at a rate of 0.5 to 1 microgram/kg/minutes (0.14mL/70kg/minutes) until 5 to 10 minutes before the completion of surgery. Continuous infusion is preferable for cases greater than 60 minutes duration. Alfentanil should not be given in the last 10 minutes prior to completion of surgery.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ]ÁöµM¦b°Êª«¹êÅç¨Ã¨S¦³µo²{·î§Î©Î«æ©Ê­L¬r®ÄÀ³¡A¦ý¥Ø«e¤´µM¨S¦³¨¬°÷ªº¼Æ¾Ú¥i¥Î¥Hµû¦ô¹ï¤HÃþªº¥ô¦ó¦³®`§@¥Î¡A¦]¦¹¥¥°ü©óµ¹ÃÄ«eÀ³°µ¼f·Vªº§Q¹úµû¦ô¡C ¦b¤À®Y(¥]¬A­å¸¡¥Í²£)ªº¹Lµ{¤£«ØÄ³ÀR¯ßª`®g¥»«~¡A¦]¬°Alfentanil injection·|¬ï¹L­L½L¡A¥B­L¨àªº©I§l¤¤¼Ï¹ï¾~¤ùÃþÃÄª«¸û±Ó·P¡C ¦p©ó¤À®Y®É¨Ï¥ÎAlfentanil injection¡AÀ³³Æ§´»²§U©I§l³]³Æ¨Ñ¥ÀÀ¦»Ý­n®É¨Ï¥Î¡C ¾~¤ùÃþÃÄª«ªº«ú§Ü¾¯À³¨Æ¥ý¬°­L¨à³Æ§´¡C¾~¤ùÃþÃÄª««ú§Ü¾¯ªº¥b°I´Á¥i¯à¤ñAlfentanilªº¥b°I´Áµu¡A¦]¦¹¦h¾¯§ë»P¾~¤ùÃþÃÄª««ú§Ü¾¯¥i¯à¬O¥²­nªº¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]Alfentanil injection·|¤Àªc¨ì¨Å¥Ä¤¤¡A¦]¦¹¡A¦bAlfentanil injectionµ¹ÃÄ«áªº24¤p®É¤º¤£­n±Â¨Å©ÎÁý­÷À½¥Xªº¥À¨Å¡C,IVD;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,Administered over 3 minutes.,¤¤ªø®É¶¡ªº¤â³N¡GÃÄª«ªºªì¦¸¾¯¶q»P¤â³N¹w´Á®É¶¡ªº°t¦X¦p¤U¡G ¤â³N®É¶¡(¤ÀÄÁ) Alfentanil (micrograms/kg) ÀR¯ßª`®g¤@¦¸µ¹ÃÄ¾¯¶q (mL/70kg) 10-30 20~40 3-6 30-60 40~80 6-12 > 60 80~150 12-20,¼t°Ó´£¨Ñªº¦w©w©Ê¸ÕÅç: 1¤äµ}ÄÀ©ó500mLªºª`®g¥Î¥Í²z­¹ÆQ¤ô©Î5%¸²µå¿}¤ô¤¤¥i«O«ù24¤p®É¦w©w¡C [Micromedex 20220526] Recommended concentration was diluted to 25 to 80 mcg/mL. [Micromedex 20220526] Induction dosage: 8 to 20 mcg/kg IV administered over 3 minutes.
IALF1BAD,Alfentanil,Alfentanil inj 1mg/2mL ´Ý¾l¾P·´,CNEU,,,,,,,,,,,,,,,,,,,
ITRUL,Dulaglutide,Trulicity inj 1.5mg/0.5mL,META,Type 2 diabetes mellitus.,Hypersensitivity to dulaglutide or any of its components. Multiple endocrine neoplasia syndrome type 2 or personal or family history of medullary thyroid carcinoma.,Common Gastrointestinal: Abdominal pain (6.5% to 9.4% )¡A Decrease in appetite (4.9% to 8.6% )¡A Diarrhea (7% to 12.6% )¡A Nausea (12.4% to 21.1% )¡A Vomiting (5.6% to 12.7% ) Serious Cardiovascular: Atrioventricular block¡A First degree (1.7% to 2.3% ) Endocrine metabolic: C-cell hyperplasia of thyroid¡A Hypoglycemia (0.3% to 77% )¡A Thyroid cancer Gastrointestinal: Cholecystitis¡A Cholelithiasis¡A Pancreatitis Immunologic: Anaphylaxis¡A Hypersensitivity reaction¡A Systemic (0.5% ) Ophthalmic: Retinopathy due to diabetes mellitus (1.9% ) Renal: Acute renal failure¡A Chronic renal failure¡A Exacerbation Other: Angioedema,Àx¦s©ó2-8¢XC¡A¤£¥i§N­á,This product is a single dose of 1.5mg¡A and the dose cannot be adjusted. Initial¡A 0.75 mg once weekly; may increase to 1.5 mg once weekly for additional glycemic control; The maximum dose: 1.5 mg once weekly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]Ãh¥¥°ü¤k¨Ï¥Î©ö¶g¿}Rªº¼Æ¾Ú¦³­­¡A¤£¨¬¥H½T©w­«¤j¥X¥Í¯Ê³´©M¬y²£ªº­·ÀI»PÃÄª«¬ÛÃö¡CÀ³¯d·NÃö©óÃh¥¥´Á¶¡¿}§¿¯f±±¨î¤£¨Î¦bÁ{§É¦Ò¶q¤Wªº­·ÀI¡C¨Ì¾Ú°Êª«¥Í´Þ¸ÕÅç¡A¦bÃh¥¥´Á¶¡¼ÉÅS©ódulaglutide¥i¯à¹ï­L¨à¦³­·ÀI¡C¥u¦³·í¼ç¦b¯q³B°ª¹L¹ï­L¨àªº¼ç¦b­·ÀI®É¡A¤~¥i¦bÃh¥¥´Á¶¡¨Ï¥Î©ö¶g¿}R¡C ©óÃh¥¥¤j¹«ªº¾¹©x¥Í¦¨´Áµ¹¤©dulaglutide¡A·í¥þ¨­¼ÉÅS¶q¬°¤HÃþ³Ì¤j«ØÄ³¾¯¶q¡]Maximum recommended human dose¡A MRHD¡A¨C¶g1.5mg¡^14­¿¥H¤W®É¡A´¿µo¥Í¦­´Á­F­L¦º¤`¡B­L¨à¥Íªø¿ð½w©M­L¨à²§±`¡C©óÃh¥¥¨ß¤lªº¾¹©x¥Í¦¨´Áµ¹¤©dulaglutide¡A¦b13­¿¤HÃþ³Ì¤j«ØÄ³¾¯¶q¡]MRHD¡^¤U¡A´¿µo¥Í­«¤j­L¨à²§±`¡Cµo¥Í¦b°Êª«ªº¤£¨}­F­L/­L¨à§@¥Î»PdulaglutideÃÄ²z§@¥Î³y¦¨¥ÀÅéÅé­«´î»´¥H¤ÎÄá­¹´î¤Ö¬ÛÃö¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨Ã¤£²M·¡dulaglutide¬O§_¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡A¥çµL©ö¶g¿}R¬O§_·|¹ï­÷¨ÅÀ¦¨à©Î¨Å¥Ä²£¶q³y¦¨¼vÅTªº¬ÛÃö¸ê°T¡CÁÙ¤£½T©wdulaglutide¬O§_¤Àªc¨ì±µ¨üªvÀøªº­÷¨Å¤¤°Êª«ªº¨Å¥Ä¤¤¡C­÷¨Å¹ïµo¨|©M°·±dªº¯q³B¡AÀ³»P¥À¿Ë¹ï©ö¶g¿}RªºÁ{§É»Ý­n¥H¤Î¦]©ö¶g¿}R©Î¥ÀÅé¥»¨­ª¬ªp¹ï­÷¨ÅÀ¦¨à¥i¯à³y¦¨ªº¥ô¦ó¤£¨}¼vÅT¤@°_°µ¿Å¶q¡C,SC;,,,,,1.¥»ÃÄ¶È¨Ñ¥Ö¤Uª`®g¡C 2.»Ý©ó2-8¢XC§NÂÃ«O¦s¡A¤£¥i§N­á¡C­Y¸m©ó«Ç·Å¤£¶W¹L30¢XC¥u¯à«O¦s14¤Ñ¡C 3.­Y»Ý½Õ¾ãµ¹ÃÄ®É¶¡®É¡A»Ýª`·N¨â¦¸ª`®g¤§¶¡À³¶¡¹j¦Ü¤Ö3¤Ñ(¶W¹L72¤p®É)¡C 4.¿ù¹L­ì©wµ¹ÃÄ®É¶¡¥B¶ZÂ÷¤U¤@¦¸¹w©wµ¹ÃÄ®É¶¡¦Ü¤Ö3¤é(72¤p®É)¡A«hÀ³¾¨§Ö¨Ï¥Î¡C­Y¶ZÂ÷¤U¦¸¹w©wµ¹ÃÄ®É¶¡¥¼º¡3¤é¡A«hÀ³¸õ¹L¿ù¹Lªº¾¯¶q¡A©ó­ì¥»¹w©wªº¤é´Áµ¹¤©¤U¤@¦¸¾¯¶q¡C¤W­z¨âºØ±¡ªp¤U¡A¯f¤H§¡¥i«ì´_­ì¥»¨C¶g¤@¦¸ªºµ¹ÃÄ®Éµ{¡C
ISLIP1,MCT + Fish oil + Olive oil + Soybean oil,SMOFlipid (¤p¨àTPN¥Î100mL¡A 20%),NUTR,Use as part of parenteral nutrition for parients who cannot take sudiffient oral or enteral nutrition.,- Individuals who are high sensitivity to the main ingredients or excipients of this product¡A such as egg¡A soy¡A or peanut protein. - Severe hyperlipidemia. - Severe liver dysfunction. - Severe coagulation abnormalities. - Severe renal dysfunction and have not undergone blood filtration or dialysis treatment. - Acute shock. - Contraindications for infusion therapy: acute pulmonary edema¡A excessive body fluid volume¡A and decompensated heart failure. - Unstable conditions (e.g.¡A severe post-traumatic state¡A uncompensated diabetes¡A acute myocardial infarction¡A stroke¡A embolism¡A metabolic acidosis¡A severe sepsis¡A and hypovolemic dehydration).,Common: Hyperglycemia (2-5%)¡A Nausea (Adult¡A 2%; pediatric¡A 18%)¡A Vomiting (7-9%)¡A Anemia (Adult¡A 2%; pediatric¡A 18%) Serious: Aluminum poisoning¡A Hypertriglyceridemia¡A Hypervolemia (<1%)¡A Refeeding syndrome¡A Thrombophlebitis (<1%)¡A Cholestasis of parenteral nutrition (2.4-4%)¡A Parenteral nutrition associated liver disease¡A Hypersensitivity reaction¡A Fat overload syndrome¡A Infectious disease¡A Sepsis (2%),¤£±o¶W¹L25¢XC¡C¤£¥i§N­á¡C,Adults: 1-2 gm of fat/kg/day (5-10 mL/kg/day). Infusion rate: 0.125-0.15 gm of fat/kg/hour (0.63-0.75 mL/kg/hour) Newborns and infants: 0.5-1 gm of fat/kg/day; Maximum 3 gm of fat/kg/day (15 mL/kg/day). Increase dose at a rate of 0.5-1 gm of fat/kg/day. Infusion rate: <= 0.125 gm of fat/kg/hour. Children: <= 2 gm of fat/kg/day (10 mL/kg/day). Infusion rate: <= 0.15 gm of fat/kg/hour.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥¥°ü©Î­÷¨Å°ü¤k¨Ï¥ÎSMOFlipidªº¸ê®Æ¡A¥çµL°Êª«ªº¥Í´Þ¬r©Ê¬ã¨s¸ê®Æ¡C Ãh¥¥©M­÷¨Å´Á¶¡ÀR¯ßÀç¾i¿éª`¥i¯à¦³¨ä¥²­n¡A¥u¦³¸g¹L¥J²Ó¦Ò¶q«á¡A ¤~¥iµ¹¤©¥¥°ü©M­÷¨Å°ü¤kSMOFlipid¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥¥°ü©Î­÷¨Å°ü¤k¨Ï¥ÎSMOFlipidªº¸ê®Æ¡A¥çµL°Êª«ªº¥Í´Þ¬r©Ê¬ã¨s¸ê®Æ¡C Ãh¥¥©M­÷¨Å´Á¶¡ÀR¯ßÀç¾i¿éª`¥i¯à¦³¨ä¥²­n¡A¥u¦³¸g¹L¥J²Ó¦Ò¶q«á¡A ¤~¥iµ¹¤©¥¥°ü©M­÷¨Å°ü¤kSMOFlipid¡C,IVD;,,,,Adults infusion rate: 0.125-0.15 gm of fat/kg/hour (0.63-0.75 mL/kg/hour) Newborns/infants infusion rate: <= 0.125 gm of fat/kg/hour (0.63 mL/kg/hour) Children infusion rate: <= 0.15 gm of fat/kg/hour (0.75 mL/kg/hour),1. ¥i¥Ñ©PÃä©Î¤¤¤ßÀR¯ß¿éª`µ¹ÃÄ¡C 2. ·í¥Î©ó·s¥Í¨à©M 2 ·³¥H¤U¨àµ£®É¡A·»²G©M¿é²G³UÀ³Á×¥úª½¦Üµ¹ÃÄ§¹¦¨¡C 3. ¨Ï¥Î«e¶·½T»{¨Å¾¯¨S¦³¼h¬Û¤ÀÂ÷©Î¨I¾ýª«¡A§e§¡½èª¬ºA¤~¥i¨Ï¥Î¡C 4. µo¥Í°Æ§@¥Î©Î¿éª`´Á¶¡¤T»Ä¥Ìªoà­¿@«×¤W¤É¶W¹L 3 mmol/L¡AÀ³°±¤î¿éª`©Îµø»Ý­n­°§C¾¯¶qÄ~Äò¿éª`¡C
ICTX,Ceftriaxone,Ceftriaxone Kabi inj 1gm,QANB,Infections caused by pathogens sensitive to Rocephin¡A eg sepsis; meningitis; infection in patients with impaired defence mechanisms; UTI; infection of respiratory tract¡A abdominal¡A bone¡A joint¡A soft tissue¡A skin¡A GUT¡A ENT; genital infection including gonorrhea.,Known hypersensitivity to cephalosporins. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing soln or products.,GI upsets¡A hematological changes¡A skin reactions¡A coagulation disorders¡A phlebitis (IV administration). Rarely¡A agranulocytosis¡A renal precipitations.,25¢J¥H¤UÁ×¥ú,Adults and adolescents (> 12 years) > or = 50 kg: 1-2 g Q24H (maximum 4 g); surgical prophylaxis: a single dose of 1-2 g administered 0.5-1.5 hours before surgery; uncomplicated gonococcal infections: a single IM dose of 250 mg. Children (15 days-12 years): 20-80 mg/kg Q24H (100 mg/kg/day for meningitis) (maximum 2 g/day). Newborn (0-14 days): 20-50 mg/kg Q24H. *****NEONATE ANTIBIOTICS DOSE***** Ceftriaxone (Rocephin): Sepsis: Use cefotaxime in place of ceftriaxone if hyperbilirubinemia or receiving calcium-containing intravenous solutions Body weight <1kg ge<=7day 50mg/kg QD  Age 8-14 ayd 50mg/kg QD  Age 15-28 day 50 mg/kg QD Body weight 1-2kg ge<=7day 50mg/kg QD  Age 8-14 day 50 mg/kg QD  Age 15-28 day 50 mg/kg QD Body weight >2kg Age<=7day 50 mg/kg QD  Age 8-14 day 50 mg/kg QD  Age 15-28 day 75mg/kg QD Ceftriaxone:meningitis: In neonates¡A IDSA guidelines suggest cefotaxime as the preferred nonpseudomonal third-generation cephalosporin; no ceftriaxone dosing is provided in the guidelines.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,IM: 3.5mL 1% Lidocaine / Water for injection; IV: 10mL Water for injection. IM­Y¥H3.5mL Water for injectionµ}ÄÀ«áµ¹ÃÄ¡A¶·IM Lidocaine§½³Â§¹¦¨«á¦Aµ¹¤©Ceftriaxone.,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö2 ~ 4¤ÀÄÁ,¥H> 30¤ÀÄÁ½wºCºwª`,1. ¥»ÃÄ«~¤Å»P§t¶t©Î¨ä¥L§Ü¥Í¯À·»²G²V¦X¡C 2. ª`®g«e¸ß°Ý¯f±w¬O§_¦³£]-ñQÓiÃþ§Ü¥Í¯À¹L±Ó¥v¡C 3. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡A§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 4.¦Ù¦×ª`®g®É¡A±NCeftriaxone Kabi 1 g°®¯»ª`®g¾¯·»©ó3.5 mL 1%ÆQ»Ä§Q¦h¥d¦](Lidocaine hydrochloride)·»²G«áª`¤J²`³¡Áv¦Ù¡C¨C¤@¨­°¼ª`®gceftriaxone¤£±o¶W¹L1 g¡C¦Ù¦×ª`®g¨C¤é³Ì¤j¾¯¶q¤£±o¶W¹L2 g¡C 5.¦Ù¦×ª`®gCeftriaxone Kabi 1.0§J¤£¾A¥Î©óµÜ©i¯f¡]²ÄII©MIII´Á¡^¡C
ITOU,Insulin glargine,Toujeo inj 300 Unit/mL¡A 1.5mL Pen,META,Treatment of diabetes mellitus in adults.,Hypersensitivity,Hypoglycaemia,2-8¢JÁ×¥úÁ×§K§N­á,SC¡A once daily preferably at the same time each day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,SC;,,,,,
INOVM,Insulin Aspart 30 + NPH 70,NovoMix 30 FlexPen 100U/mL 3mL,META,Treatment of patients with diabetes mellitus.,Hypoglycaemia.,Hypoglycemia (Type 1 diabetes mellitus¡A 69% to 75%; type 2 diabetes mellitus¡A 47% to 58% ) Gastrointestinal: Abdominal pain (Type 2 diabetes mellitus¡A 5% )¡A Diarrhea (7% to 8% )¡A Indigestion (Type 1 diabetes mellitus¡A 9% )¡A Backache (Type 1 diabetes mellitus¡A 7% )¡A Musculoskeletal pain (Type 1 diabetes mellitus¡A 5% )¡A Headache (Type 1 diabetes mellitus¡A 17% to 35%; type 2 diabetes mellitus¡A 9% to 13% )¡A Neuropathy (Type 2 diabetes mellitus¡A 8% )¡A Pharyngitis (6% to 7% )¡A Rhinitis (5% )¡A Upper respiratory infection (5% to 17% )¡A Influenza-like symptoms (Type 1 diabetes mellitus¡A 13% )¡A Hypoglycemia (Severe) (Type 1 diabetes mellitus¡A 16%; type 2 diabetes mellitus¡A 4% )¡A Hypokalemia¡A Hypersensitivity reaction.,Á×¥úÁ×§K§N­á¡A¶}«Ê«e2-8¢J¡A±Ò¥Î«á¥i©ñ30¢J¥H¤U¨Ã¥i¥H¨Ï¥Î¥|¬P´Á,SC¡A according to the individual needs of the patient.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]Ãh¥¥´Á¨Ï¥Î NovoMixR30 ªºÁ{§É¸gÅç¦³­­¡C¹ï©óÃh¥¥°ü¤k¡A©|¥¼¦³ NovoMixR30 ¤§¬ã¨s¡C µM¦Ó¡A¦Û¨â²ÕÀH¾÷¹ï·ÓÁ{§É¸ÕÅçªº¸ê®ÆÅã¥Ü¡A¬Û¸û©ó¥i·»©Ê¤HÃþ¯Ø®q¯À¡A insulin aspart ¹ï©óÃh¥¥©Î­L¨à/·s¥Í¨à¤§°·±d¨Ã¥¼¥X²{¤£¨}¤ÏÀ³ ¤@¯ë¨Ó»¡¡A¹ï©ó¤wÃh¥¥©Î­p¹ºÃh¥¥ªº¿}§¿¯f°ü¤k«ØÄ³©ó¾ã­ÓÃh¥¥´Á¥þµ{±Ä¥Î±K¶°¦å¿}±±¨î©MºÊµø¡C ¯Ø®q¯À»Ý¨D¶q³q±`¦bÃh¥¥ªº²Ä 1 ¦Ü 3 ­Ó¤ë·|¤U­°¡AÀH«á¦b²Ä4 ¦Ü 9 ­Ó¤ë«h³vº¥¼W¥[¡A ²£«á³q±`·|§Y¨è¦^¨ìÃh¥¥«eªº»Ý¨D¶q¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]±Â¨Å´Á¨Ï¥Î NovoMixR30 ¨ÃµL­­¨î¡A±Â¨Å´Á¶¡¥À¿Ë±µ¨ü¯Ø®q¯ÀªvÀø¹ïÀ¦¨à¨S¦³¦MÀI©Ê¡A ¦ý NovoMixR30 ªº¾¯¶q¥i¯à»Ý­n½Õ¾ã¡C,SC;,,,,,¦b­«·s®¶·n²V¦X«á¡AÃÄ«~­Y¤£¬O§e²{§¡¤Ãªº¥Õ¦â¶³Ãúª¬²GÅé«h¤£¥i¨Ï¥Î¡C
INOVM5,Insulin Aspart 50 + NPH 50,50 NOVOMIX FlexPen 100 Unit/mL¡A 3mL,META,Treatment of patients with diabetes mellitus.,Hypoglycaemia.,Hypoglycemia (Type 1 diabetes mellitus¡A 69% to 75%; type 2 diabetes mellitus¡A 47% to 58% ) Gastrointestinal: Abdominal pain (Type 2 diabetes mellitus¡A 5% )¡A Diarrhea (7% to 8% )¡A Indigestion (Type 1 diabetes mellitus¡A 9% )¡A Backache (Type 1 diabetes mellitus¡A 7% )¡A Musculoskeletal pain (Type 1 diabetes mellitus¡A 5% )¡A Headache (Type 1 diabetes mellitus¡A 17% to 35%; type 2 diabetes mellitus¡A 9% to 13% )¡A Neuropathy (Type 2 diabetes mellitus¡A 8% )¡A Pharyngitis (6% to 7% )¡A Rhinitis (5% )¡A Upper respiratory infection (5% to 17% )¡A Influenza-like symptoms (Type 1 diabetes mellitus¡A 13% )¡A Hypoglycemia (Severe) (Type 1 diabetes mellitus¡A 16%; type 2 diabetes mellitus¡A 4% )¡A Hypokalemia¡A Hypersensitivity reaction.,Á×¥úÁ×§K§N­á¡A¶}«Ê«e2-8¢J¡A±Ò¥Î«á¥i©ñ30¢J¥H¤U¨Ã¥i¥H¨Ï¥Î¥|¬P´Á,SC¡A according to the individual needs of the patient.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]NovoMixR50 ¦bÃh¥¥´Á¨Ï¥ÎªºÁ{§É¬ã¨s¬Û·í¦³­­¡C ¦b°Êª«¥Í´Þ¬ã¨s¡AÅã¥Ü¥X insulin aspart ©M human insulin ¹ï©ó­F­L¬r©Ê¤Î­P·î©Ê¨ÃµL¥ô¦ó®t²§¡C ¤@¯ë¨Ó»¡¡A¹ï©ó¤wÃh¥¥©Î­p¹ºÃh¥¥ªº¿}§¿¯f°ü¤k«ØÄ³©ó¾ã­ÓÃh¥¥´Á¥þµ{±Ä¥Î±K¶°¦å¿}±±¨î©MºÊµø¡C ¯Ø®q¯À»Ý¨D¶q³q±`¦bÃh¥¥ªº²Ä 1 ¦Ü 3 ­Ó¤ë·|¤U­°¡AÀH«á¦b²Ä4 ¦Ü 9 ­Ó¤ë«h³vº¥¼W¥[¡A ²£«á§Y¨è¦^¨ìÃh¥¥«eªº»Ý¨D¶q¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]±Â¨Å´Á¨Ï¥Î NovoMixR50 ¨ÃµL­­¨î¡A ±Â¨Å´Á¶¡¥À¿Ë±µ¨ü¯Ø®q¯ÀªvÀø¹ïÀ¦¨à¨S¦³¦MÀI©Ê¡A ¦ý NovoMixR50 ªº¾¯¶q¥i¯à»Ý­n½Õ¾ã¡C,SC;,,,,,¦b­«·s®¶·n²V¦X«á¡AÃÄ«~­Y¤£¬O§e²{§¡¤Ãªº¥Õ¦â¶³Ãúª¬²GÅé«h¤£¥i¨Ï¥Î¡C
OBET5,Mirabegron,Betmiga 50mg prolonged-release,SGU,Neurogenic detrusor overactivity. Overactive bladder¡A Monotherapy or in combination with solifenacin¡A with symptoms of urge urinary incontinence¡A urgency¡A and urinary frequency.,Hypersensitivity to mirabegron or any components of the product.,Common Cardiovascular: Hypertension (7% to 11.3% )¡A Tachycardia (1.2% to 2.2% ) Gastrointestinal: Constipation (1.2% to 4.7% )¡A Xerostomia (2.8% to 9.3% ) Neurologic: Headache (1.6% to 4.1% ) Renal: Urinary tract infectious disease (Adult¡A 2.9% to 8.4% ; pediatric¡A 24.4% ) Respiratory: Nasopharyngitis (3.5% to 5.8% ) Serious Neurologic: Cerebrovascular accident (0.4% ) Renal: Urinary retention Other: Cancer (0.1% to 1.3% ),30¢J¥H¤UÀx¦s,25-50 mg once daily. May be taken with or without food. Swallow whole¡A do not chew¡A divide or crush.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤«×¨x¥\¯à¤£¥þªº¯f¤H(Child-Pugh Class B):¨C¤é¾¯¶q¤£¥i¶W¹L25 mg ¤@¤Ñ¤@¦¸¡C¥½´ÁµÇ¯fªº¯f¤H¡A©Î­««×¨x¥\¯à¤£¥þªº¯f¤H(Child-Pugh Class C)¡A¤£«ØÄ³Betmiga¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¹ï©ó¥¥°ü¨Ï¥ÎBetmiga¡A©|µL¾A·í¥B±±¨î¨}¦nªº¬ã¨s¡C Ãh¥¥´Á¶¡¶È¦b¯f¤Hªº¼ç¦b®Ä¯q³Ó¹L¹ï¯f¤H©M­L¨àªº¦MÀI©Ê®É¡A¤~¥i¨Ï¥ÎBetmiga¡C ¹ªÀy¦bBetmigaªvÀø´Á¶¡Ãh¥¥ªº°ü¤kÁpÃ´Âå®v¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¹ï©óBetmiga¬O§_¥X²{©ó¤HÃþ¨Å¥Ä¤¤¡B¹ï©ó¥H¥À¨ÅÁý¾i¤§¥®¨àªº¼vÅT¡B©Î¬O¹ï©ó¨Å¥Ä¥Í¦¨ªº¼vÅT¡A¥Ø«e©|µL¸ê°T¡C ­÷¨Å¤¤¤j¹«¤fªA³æ¾¯10 mg/kgªº14C¼Ð°Oªºmirabegron«á¡A¥i¥H¦b¤j¹«¨Å¥Ä¤Î¥®¹«ªº­G¤¤µo²{mirabegron¬ÛÃöª«½è¡C À³¦P®É¦Ò¶q¨ì­÷¨Å¹ïµo¨|¤Î°·±dªº¯q³B¡B¥ÀÅé¹ï©óBetmigaªºÁ{§É»Ý¨D¤ÎBetmiga©Î¥ÀÅé¯fªp¹ï¥À¨ÅÁý¾i¤§¥®¨àªº¥i¯à¤£¨}¼vÅT¡C,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡AªA¥Î®ÉÀ³¥H¤ô¾ã²É§]ªA¡A¤£¥iÄZ¸H¡B¤Á³Î©ÎÀ£¸H¡C
OBEL1,Lorcaserin,Belviq 10mg F.C. Tab 60's/box,META,,,,,,,,,,,,,,,,,,,
ELOC2,Amorolfine,Loceryl nail 5% 2.5mL Lacquer,TDER,Topical treatment of onychomycosis caused by dermatophytes¡A yeasts and moulds.,Patients who have shown hypersensitivity to any ingredient of Loceryl.,In exceptional cases¡A a slight¡A transient periungual burning sensation was observed after the application of the nail lacquer.,<30«×C¡AÁ×¶}¼ö·½,Fungal nail infections Adult: Topical As 5% nail lacquer: Apply 1-2 times/week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ±NÃh¥¥¥À¨ß¼ÉÅS©óÅé¤º°ª¾¯¶qamorolfine·|³y¦¨­F­L¦A§l¦¬(­F­L¬r©Ê)»´·L¼W¥[¡C¥Ñ©ó¨Ï¥ÎLoceryl³k(«ü)¥Òªo¾¯¤§«á¡AamorolfineªºÅé¤º§t¶q·¥§C¡A¦]¦¹¹ï©ó¤HÃþ­L¨àªº­·ÀIÀ³¥i©¿²¤¡C µM¦Ó¥Ñ©ó¯Ê¥FªvÀøÃh¥¥©M­÷¨Å¥À¿Ë¤§Á{§É¸gÅç¡A¦]¦¹¥»ªo¾¯À³Á×§K¥Î©ó¥¥´Á©M­÷¨Å´Á´Á¶¡¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ±NÃh¥¥¥À¨ß¼ÉÅS©óÅé¤º°ª¾¯¶qamorolfine·|³y¦¨­F­L¦A§l¦¬(­F­L¬r©Ê)»´·L¼W¥[¡C¥Ñ©ó¨Ï¥ÎLoceryl³k(«ü)¥Òªo¾¯¤§«á¡AamorolfineªºÅé¤º§t¶q·¥§C¡A¦]¦¹¹ï©ó¤HÃþ­L¨àªº­·ÀIÀ³¥i©¿²¤¡C µM¦Ó¥Ñ©ó¯Ê¥FªvÀøÃh¥¥©M­÷¨Å¥À¿Ë¤§Á{§É¸gÅç¡A¦]¦¹¥»ªo¾¯À³Á×§K¥Î©ó¥¥´Á©M­÷¨Å´Á´Á¶¡¡C,EXT;,,,,,
IAMII1,Amino Acids,Aminosteril infant 10% 100mL,NUTR,For partial parenteral nutrition in premature infants¡A babies and small children. Together with corresponding amounts of electrolytes¡A carbohydrates and fat emulsions as energy donors¡A the solution may serve for total parenteral nutrition.,Disturbances in amino acid metabolism¡A acidosis¡A hyperhydration¡A hypokalemia.,Fluid¡A electrolyte¡A amino acid imbalance.,25¢J¥H¤UÁ×¥ú,Maximum Daily Dosage: 1st year of living: 1.5-2.5 g amino acids/kg body weight; 2nd year of living: 1.5 g amino acids/kg body weight; 3rd-5th year of living: 1.5 g amino acids/kg body weight.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] µÇ¥\¯à¤£¨}©Î¨x¥\¯à¤£¨}¯f¤H¶·µ¹­Ó§O¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,Maximum Infusion Rate: Up to 0.1 g amino acids/kg body weight/hr = 1 mL/kg body weight/hr.,·í¥Î©ó·s¥Í¨à©M2 ·³¥H¤U¨àµ£®É¡A·»²G©M¿é²G³UÀ³Á×¥úª½¦Üµ¹ÃÄ§¹¦¨¡C ¿éª`³t«×¤Ó§Ö¡A¥i¯à¸g¥ÑµÇÅ¦¬y¥¢¡A¦Ó³y¦¨®ò°ò»Ä¤£¥­¿Å¡C
OSQL4,Nicotine,SMOKQUIT 4mg (24 tablets/box),ZADT,Smoking Cessation Aid.,Hypersensitivity to nicotine or any component of the product.,Common Dermatologic: Skin irritation¡A Patch Respiratory: Nasal irritation¡A Nasal spray¡A Oral irritation¡A Airway¡A inhaler Other: Nicotine withdrawal¡A Dizziness¡A headache¡A insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare)¡A Hypertension (rare)¡A Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare),«Ç·Å25¢J¥H¤U,Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours¡A use at least 9 lozenges/day. Weeks 7 to 9: 1 lozenge every 2 to 4 hours. Weeks 10 to 12: 1 lozenge every 4 to 8 hours. The recommended maximum dose: 15 lozenges/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,Contraindicated (with any use of tobacco) [¥é³æ] «ØÄ³¥¥°ü¤Î±Â¨Å°ü¤£¥i¨Ï¥Î§t¦³¥§¥j¤B¦¨¤À¡A¦p¤f§t¿õ¡B¶K¤ù©Î¤f­»¿}¨Ó§ÙµÒ¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] «ØÄ³¥¥°ü¤Î±Â¨Å°ü¤£¥i¨Ï¥Î§t¦³¥§¥j¤B¦¨¤À¡A¦p¤f§t¿õ¡B¶K¤ù©Î¤f­»¿}¨Ó§ÙµÒ¡C,SL;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¤f§t¿õ¡A¤£¥i©CÄZ©Î§]ªA¡CªAÃÄ«á±N¤f§t¿õ§t¦b¤fµÄ¨â°¼²¾°Ê¡A«ùÄò20-30¤ÀÄÁª½¨ì§¹¥þ·»¸Ñ¡C
OENTR,Sacubitril + Valsartan,Entresto 100mg,CAVS,Heart failure¡A chronic. Symptomatic congestive heart failure¡A In Patients with Systemic Left Ventricular Dysfunction¡A,Angioedema to prior ACE inhibitor or angiotensin II receptor blocker therapy. Concomitant aliskiren use in diabetic patients. Concomitant use of ACE inhibitors; do not administer within 36 hours of each other. Hypersensitivity to sacubitril¡A valsartan¡A or any component of the product.,Common: Hypotension (18%)¡A Hyperkalemia (12-16%)¡A Dizziness (6%) Serious: Renal failure (5%)¡A Angioedema (0.5%),30¢J¥H¤U¡Aª`·N¨¾¼é,CHF adult¡A initial 100mg BID¡A maintain dose: 200mg BID after 2-4 weeks. ( if Entresto switch from ACEI¡A it must be separated at least 36 hr),»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à(Child-Pugh B)¤£¥þ±wªÌ¤§«ØÄ³°_©l¾¯¶q¬°¨C¤é2¦¸50mg ¨Ì±wªÌ­@¨ü±¡ªp¡A¨C2¦Ü4©P¥[­¿Entrestoªº¾¯¶q¡A¹F¨ì¨C¤é2¦¸200mgªº¥Ø¼Ðºû«ù¾¯¶q ­««×¨x¥\¯à¤£¥þ±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ENTRESTOR ¥Î©óÃh¥¥¤k©Ê·|¹ï­L¨à³y¦¨¶Ë®`¡C¦b§³®W²Ä¤G¡B¤T´Á¨Ï¥Î§@¥Î©óµÇ¯À - ¦åºÞ¦¬ÁY¯À¨t²ÎªºÃÄª«¡A·|­°§C­L¨àµÇ¥\¯à¨Ã¼W¥[­L¨à¤Î·s¥Í¨à¯e¯f©M¦º¤`²v¡C ¦pªGÃh¥¥¡A½Ð§ï¥Î¨ä¥LÃÄª«¡A¨Ã°±¥Î ENTRESTOR¡C µM¦Ó¡A¦pªG°£¤F§@¥Î©óµÇ¯À - ¦åºÞ¦¬ÁY¯À¨t²ÎªºÃÄª«¡A¨S¦³¨ä¥L¾A·í´À¥NÃÄª«¡A©Î·í¥»ÃÄ¥i±Ïªv¥À¿Ë©Ê©R®É¡A½Ð§iª¾Ãh¥¥¤k©Ê¥»ÃÄª«¹ï­L¨àªº¼ç¦b­·ÀI¡C Sacubitril: No data Valsartan: Human Data Suggest Risk in 2nd and 3rd Trimesters,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ©|µL¸ê®ÆÅã¥Ü sacubitril/valsartan ¬O§_·|±Æ¤J¤HÃþªº¨Å¥Ä¡B¹ï±µ¨ü­÷¨ÅÀ¦¨àªº¼vÅT¡A©Î¹ï¥À¨Å¤Àªcªº§@¥Î¡C ¦ýsacubitril/valsartan ·|±Æ¤J¤j¹«ªº¨Å¥Ä¤¤¡C ¥Ñ©ó±µ¨ü­÷¨ÅÀ¦¨à¼ÉÅS©ó sacubitril/valsartan ¥i¯àµo¥ÍÄY­«¤£¨}¤ÏÀ³¡A¤£«ØÄ³¦b­÷¨Å´Á¶¡±µ¨ü ENTRESTOR ªvÀø¡C Sacubitril: No data Valsartan: No Human Data¡XProbably Compatible,AC;AC15;PC;PO;WM;,,,,,
OACTN6,Acetylcysteine,Actein effervescent 600mg,ERSP,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
OIBI,Isosorbide 5-Mononitrate,Ibimo C.R.F.C. 60 mg,CAVS,Prevention of angina pectoris.,Allergic to isosorbide mononitrate¡A isosorbide dinitrate¡A other nitrates or nitrites. Low blood pressure (<90mmHg)¡A circulatorycollapse¡A Shock¡A or with failing heart¡A unless could keep blood pressure. Angina caused by hypertrophic cardiomyopathy may be aggravated. Increased intracranial pressure. Pericarditis.,Common Dizziness (Extended-release¡A 8% to 11%)¡A Headache (Extended-release¡A 38% to 57%)¡A Orthostatic Hypotension Serious Cardiovascular: Atrial fibrillation (5% or less)¡A Bradyarrhythmia (5% or less )¡A Bundle branch block (5% or less)¡A Chest pain (Immediate-release¡A up to 2% )¡A Heart failure (5% or less )¡A Hemorrhage¡A Ventricular tachycardia (5% or less)¡A Angina pectoris (5% or less)¡A,Á×¥ú»P¨¾¼ö¡A25¢J¥H¤U,60 mg in the morning¡A may be increased to 120 mg once daily. Reduce to 0.5 TAB when headache occurs.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¥Ñ©óIsosorbide 5-Mononitrate¯Ê¤Ö³o¤è­±ªºÁ{§É¸gÅç¡A¦]¦¹¸ÓÃÄ¤£À³µ¹¤©Ãh¥¥¤Î±Â¨Å´Á±wªÌªA¥Î¡A ­Y¥²­n®É¡AÀ³¿Ô¸ßÂå®v¡AÅv©y§Q¹ú¨Ï¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ñ©óIsosorbide 5-Mononitrate¯Ê¤Ö³o¤è­±ªºÁ{§É¸gÅç¡A¦]¦¹¸ÓÃÄ¤£À³µ¹¤©Ãh¥¥¤Î±Â¨Å´Á±wªÌªA¥Î¡A ­Y¥²­n®É¡AÀ³¿Ô¸ßÂå®v¡AÅv©y§Q¹ú¨Ï¥Î¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä½¤¦ç¿õ¡A¥i¾ã²É©Î­é¥b§]ªA¡A¦ý¤£¥i«rÄZ¡BÀ£¸H©Î¿i¯»¡C¿i¯»ºÞÄé»Ý¨D°|¤º³Æ¦³¦P¦¨¥÷Coxine 20mg¡C
OFLU6,Acetylcysteine,Fluimucil granules 600mg/3gm,ERSP,A mucolytic agent that reduces the viscosity of respiratory mucous secretions and serves as an antidote for intentional or occasional ACETAMINOPHEN poisoning.,Hypersensitivity to acetylcysteine or to any other component in its formula.,Common: Pruritus (1-3%)¡A Rash (4-5%)¡A Urticaria¡A Diarrhea¡A Nausea (2-7%)¡A Vomiting (9-12%) Serious: Decreased cardiac function¡A Electrocardiogram abnormal¡A Hypervolemia¡A Hypersensitivity reaction (Adult¡A 8-18%; pediatric¡A 10%)¡A Non-allergic anaphylaxis (0.1-0.2%)¡A Status epilepticus¡A Bronchospasm¡A Respiratory distress,30¢J¥H¤U,Aged six and above: Take 1 packet of Fluimucil orally¡A 1-2 times/day (preferably in the evening). Place the granules from one packet into a glass container¡A dissolve them with a small amount of water¡A mix well¡A and if needed¡A use a spoon. This will result in a palatable solution that can be consumed directly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EANO,Umeclidinium + Vilanterol trifenatate,Anoro Ellipta 55/22mcg inhalation powder,ERSP,Maintenance treatment for airway obstruction symptoms in patients with chronic obstructive pulmonary disease (COPD).,Severe hypersensitivity to milk proteins. Hypersensitivity to umeclidinium¡A vilanterol¡A or any component of the product. Asthma treatment¡A without use of an inhaled corticosteroid.,Common: Chest pain (1%)¡A Constipation (1%)¡A Diarrhea (2%)¡A Neck pain (1%)¡A Pain in limb (2%)¡A Spasm (1%)¡A Lower respiratory tract infection (1%)¡A Pharyngitis (2%)¡A Sinusitis (1% or greater) Serious: Atrial fibrillation (<1%)¡A Cardiovascular system problem¡A Death (Due to cardiovascular events)¡A Electrocardiogram abnormal¡A Increased heart rate¡A Myocardial infarction (<1%)¡A Prolonged QT interval¡A Hypersensitivity reaction¡A Paradoxical bronchospasm,Á×¥ú°®Àê30¢XC¥H¤U,Once-daily inhalation only. Administered orally through inhalation. Take at the same time every day. Do not use more than once in 24 hours.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¦b¤¤«×¨x¥\¯à¤£¥þ(Child-Pugh µû¤À¬° 7-9 ¤À)ªº¯f¤H¤¤¡ACmax»P AUC ¬Ò¥¼¥X²{¬ÛÃö ªº¤É°ª²{¶H¡A³J¥Õµ²¦X²v¤]¨S¦³®t²§¡C¥Ø«e©|¥¼°w¹ïÄY­«¨x¥\¯à¤£¥þªº¯f¤H¶i¦æ¬ÛÃö¬ã¨s¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¨S¦³¤HÅé¸ÕÅçµû¦ôANORO ELLIPTA¡B umeclidinium ©Î vilanterol ¹ï¤À®Y»P¥Í²£ªº¼vÅT¡C ¦]¬°£]§@¥Î¾¯¦³¥i¯à¤zÂZ¤l®c¦¬ÁY¡A°ß¦³®Ä¯q©úÅã¤j©ó­·ÀIªº¯f¤H¤~¥i©ó¤À®Y´Á¶¡¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥ô¦óÃö©ó umeclidinium ©Î vilanterol ¬O§_·|¥X²{©ó¤HÃþªº¨Å¥Ä¤¤¡B¹ïÁý­÷¥À¨Å¤§ À¦¨àªº¼vÅT©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅTµ¥¤è­±ªº¸ê°T¡C§ë¤© umeclidinium ªº±Â¨Å¤j¹«¡A©ó ¨ä¤l¥N¦å¼ß¥i°»´ú¨ì umeclidinium¡A±À´ú umeclidinium ·|¥X²{©ó¥ÀÅé¨Å¥Ä¤¤¡CÀ³±NÁý­÷¥À¨Å¹ï À¦¨àµo¨|»P°·±dªº®Ä¯q»P¥À¿ËªºÁ{§É»Ý¨D¡A¥H¤Î umeclidinium¡Bvilanterol ©Î¥À¿Ëªº°òÂ¦¯e¯f ¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C,IH;,,,,,
LFUL,Sodium Phosphate,Fulisay oral solution 45mL (°·¶E±M¥Î),ALIM,Relief of occasional constipation. For use as part of a bowel cleansing regimen in preparing the patient for surgery or for preparing the colon for X-ray or endoscopic exam.,CHF¡A renal failure¡A rectal bleeding¡A no bowel movement with in 5 hour¡A dehydration. Childn <5 yr.,Nausea¡A vomiting¡A bloating.,«Ç·Å,Per 15 mL Monobasic Na phosphate 7.2 g¡A dibasic Na phosphate 2.7 g. (Equivalent to 111.2mg sodium per mL) Laxative: Adult & children > 12 years 15-45 mL; 10-11 years 15 mL¡A 5-9 years 7.5 mL. Intestine cleansing: Adult & children > 12 years 30-45 mL use two times¡A taking interval 10-12 hours.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;PC;PO;,,,,,
IGAR9A,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,¤E»ù¤l®cÀVÀù¬Ì­](°ü¥®¹Å¦~µØ±M®×),HIMM,,,,,,,,,,,,,,,,,,,
IETOM2,Etomidate,Etomidate inj 20mg/10mL (±M®×¶i¤f),ZANE,Induction of general anesthesia¡A Maintenance of general anesthesia; Adjunct,Hypersensitivity to etomidate products,Injection site pain ¡A Nausea¡A Vomiting,25¢J¥H¤UÁ×¥úÁ×§K§N­á,Adult Dosing ¡½Induction of general anesthesia: induction¡A usual dose 0.3 mg/kg IV (range 0.2 to 0.6 mg/kg) over 30 to 60 sec ¡½Maintenance of general anesthesia; Adjunct: maintenance¡A 0.01 to 0.02 mg/kg/min IV infusion; dosage must be individualized ¡½Procedural sedation: 0.1 to 0.2 mg/kg IV over 30 to 60 seconds¡A followed by 0.05 mg/kg every 3 to 5 minutes as needed for sedation ¡½Rapid sequence intubation¡A Induction: 0.15 to 0.3 mg/kg IV Pediatric Dosing ¡½not recommended in children under 10 y of age ¡½Induction of general anesthesia: (children 10 y and older) induction¡A usual dose 0.3 mg/kg IV (range 0.2 to 0.6 mg/kg) over 30 to 60 sec ¡½Rapid sequence intubation¡A Induction: 0.2 to 0.3 mg/kg IV,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVPUSH;,,,±Àª`®É¶¡>30¬í Administer IV push over 30 to 60 seconds.,,1. Etomidate-Lipuro¥¼§@¬Û®e©Ê´ú¸Õ«e¡A¤£±o»P¨ä¥L¿éª`²G²V¦X¡C¦¹¥~¡A°£«D¤w½T»{¬Û®e©Ê¡A§_«hEtomidate-Lipuro¤£±o¦P®É»P¨ä¥Lª`®g²G¥H¦P¤@¿éª`ºÞµ¹¤©¡F»Ý­n¦X¨Öµ¹¤©¤§ÃÄª«¦p¤îµh¾¯¡A¥H¦P¤@¿éª`ºÞ©Î­Ó§OÀR¯ß´¡ºÞ±µÄòµ¹ÃÄ¡C 2. Etomidate-Lipuro¤£§t§Üµß¨¾»G¾¯¡C¦]¬°¯×ªÕ¨Å¾¯·|«P¶i·L¥Íª«¥Íªø¡A¦wÞÀ¶}²~«áÀ³©óµLµßª¬ºA¤U¥ß§Y¥Hª`®g¾¹©â¥X¨Ã¿éª`¡C³Ñ¾l³¡¥÷À³¥á±ó¡C 3. §ë¤©Etomidate-Lipuro«eÀ³¾A«×«eÅXµ¹ÃÄ¥HÁ×§K¦Ù°}µjªºµo¥Í¡C«ØÄ³©ó§ëÃÄ«e1¤p®ÉIMµ¹¤©©Î10¤ÀÄÁ«eIVµ¹¤©BZDÃþÃÄª«¡C
LAMO5,Amoxicillin,Amolin 50mg/mL¡A 60mL suspension,QANB,Infection of staphylococcus¡A streptococcus¡A pneumococcus¡A meningococcus¡A or other susceptibility bacteria.,Hypersensitivity to penicillins.,Common Dermatologic: Rash (greater than 1% ) Gastrointestinal: Diarrhea (overall¡A greater than 1%; Helicobacter pylori therapy¡A 7% to 8% )¡A Nausea (greater than 1% )¡A Vomiting (greater than 1% ) Neurologic: Headache (Helicobacter pylori therapy¡A 6% to 7%; extended-release tablets¡A 1% ) Reproductive: Vulvovaginitis¡A Mycotic (extended-release¡A 2% ) Serious Cardiovascular: Shock Dermatologic: Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile diarrhea Immunologic: Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction Other: Angioedema,25¢J¥H¤U¡Aªw»s«á2-8¢J§NÂÃ¥i«O¦s7¤Ñ¡C,Adult: 250 mg 3-4 times daily; children: 20-40 mg/kg in divided doses 3-4 times daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ]¥Î©ó¥¥°ü¡A¥»ÃÄ¹ï§³®W¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¥¼¦³¬ÛÃö»¡©ú¡C,AC;AC15;PC;PO;WM;,,,,,1. ªw»s¤èªk:¥ý¥[¤J§N¶}¤ô¤j¬ù¦Ü¨è«×50mL«á·n¤Ã¡A¦A¥[¤ôµ}ÄÀ¦¨60mL¡C 2. ¥»ÃÄ¸gªw»s«á»Ý§NÂÃ2-8¢J¡A¶È«O¦s7¤Ñ¡C¨C¦¸¨Ï¥Î«eÀ³¥ý·n¤Ã¡C
IENH0,Trastuzumab Deruxtecan,Enhertu inj 100mg (sample),RACA,Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.,There are no contraindications listed in the manufacturer's labeling.,Nausea¡A fatigue¡A vomiting¡A alopecia¡A constipation¡A decreased appetite¡A anemia¡A neutropenia¡A diarrhea¡A leukopenia¡A cough¡A and thrombocytopenia. Interstitial lung disease (ILD)¡A pneumonitis¡A and left ventricular dysfunction.,2-8¢J§NÂÃ,5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨Ï¥Î©ó¤¤«×¨x¥\¯à¤£¥þ¯f¤H®ÉÀ³¥J²ÓºÊ´ú¡C©|µL­««× (Á`Áx¬õ¯À> 3¦Ü10­¿ULN¤Î¥ô¦óAST¼Æ­È) ¨x¥\¯à¤£¥þ¯f¤Hªº¸ê®Æ¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¬I¥Î©óÃh¥¥¤k©Ê¥i¯à¾É­P­L¨à¶Ë®`¡C¥Ø«e¨ÃµL¨Ï¥Î©óÃh¥¥¤k©Êªº¸ê®Æ¡C ¤£«ØÄ³¬I¥Î©óÃh¥¥¤k©Ê¡AÀ³¦b¯f¤HÃh¥¥«e§iª¾¯f¤HÃÄª«¹ï©ó­L¨àªº¼ç¦b­·ÀI¡C ­Y¤k©Ê©óªvÀø´Á¶¡©Î³Ì«á¤@¾¯«á7­Ó¤ë¤ºÃh¥¥¡A¥²¶·¥ß§YÁpµ¸Âå®v¡A«ØÄ³¶i¦æ±K¤ÁºÊ´ú¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¥¼ª¾ENHERTUR¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡A¥ç¥¼ª¾¹ï­÷¨ÅÀ¦¨à¥i¯à³y¦¨ªº¼vÅT¡C ¦]¬°­÷¨ÅÀ¦¨à¦³µo¥ÍÄY­«¤£¨}¤ÏÀ³ªº¼ç¦b¥i¯à¡A¤k©ÊÀ³©óªì¦¸¬I¥Î«e°±¤î­÷¨Å¡C ¤k©Ê¥i©óµ²§ôªvÀø7­Ó¤ë«á¶}©l­÷¨Å¡C,IVD;,Sterile Water for Injection 5 mL per 100 mg vial,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Reconstitute each 100 mg vial with 5 mL of Sterile Water for Injection (final 20 mg/mL). Dilute in 100 mL of 5% Dextrose Injection. FIRST infusion over 90 minutes; subsequent infusions over 30 minutes if prior infusions were well tolerated. Cover the infusion bag to protect from light. Administer with an infusion set made of polyolefin or polybutadiene and a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter.,­Y¥X²{¿éª`¬ÛÃö¯gª¬¡AÀ³­°§C¿éª`³t²v©Î¤¤Â_¿éª`¡C­Yµo¥ÍÄY­«¿éª`¤ÏÀ³¡AÀ³¥Ã¤[°±¥Î¡C
IACTMV10,Tocilizumab,Actemra Infusion 200mg/10mL/Vial ±M®×(­­Covid-19),HIMM,Rheumatoid Arthritis (RA); Polyarticular Juvenile Idiopathic Arthritis (pJIA); Systemic Juvenile Idiopathic Arthritis (sJIA).,Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.,Common Cardiovascular: Hypertension (Adult¡A 4% to 6% ) Dermatologic: Injection site reaction ( Rheumatoid arthritis¡A 2.4% to 10.1% ; polyarticular juvenile idiopathic arthritis¡A 28.8% ; systemic juvenile idiopathic arthritis¡A 41.2% )¡A Rash (Rheumatoid arthritis¡A 2% to 4% ) Gastrointestinal: Diarrhea (Pediatric¡A greater than 5% )¡A Upper abdominal pain (Adult¡A 2% to 3% ) Hepatic: ALT/SGPT level raised (Rheumatoid arthritis¡A 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis¡A 4% to 13% )¡A Aspartate aminotransferase serum level raised (Rheumatoid arthritis¡A 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis¡A less than 1% to 5% ) Neurologic: Dizziness (Adult¡A 2% to 3% )¡A Headache (Adults¡A 5% to 7%; pediatric¡A greater than 5% ) Respiratory: Nasopharyngitis (Rheumatoid arthritis¡A 4% to 7%; systemic juvenile idiopathic arthritis¡A 5% or higher ) Other: Infusion reaction (Rheumatoid arthritis¡A 7% to 8%; polyarticular juvenile idiopathic arthritis¡A 16% to 20.2% ) Serious Gastrointestinal: Gastrointestinal perforation¡A Pancreatitis Hematologic: Decreased platelet count (1% to 4% )¡A Neutropenia (Rheumatoid arthritis¡A 1.8% to 3.7% ; polyarticular or systemic juvenile idiopathic arthritis¡A 7% to 15.4% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis¡A Hypersensitivity reaction (Up to 0.9% )¡A Opportunistic infection¡A Tuberculosis Respiratory: Upper respiratory infection (Rheumatoid arthritis¡A 6% to 8%; systemic juvenile idiopathic arthritis¡A 5% or higher ) Other: Cancer¡A Severe infectious disease,2-8¢J,TFDA·s«¬«aª¬¯f¬r¡]SARS-CoV-2¡^·P¬VÁ{§É³B¸m¼È¦æ«ü¤Þ²Ä¤Q¤@ª©: »Pdexamethasone¦X¨Ö¥Î©óÄY­«ªÍª¢¥H¤W(¥¼¨Ï¥Î§l®ñªvÀø¤USpO2=<94%¡B»Ý¨Ï¥Î§l®ñªvÀø¡B°ª¬y¶q®ñ®ð©Î«D«IÅ§©Ê©I§l¾¹¡B¨Ï¥Î¾÷±ñ¦¡©I§l¾¹©ÎECMO)¤§¯f±w¡F©Î»Pdexamethasone + remdesivir ¦X¨Ö¥Î©ó¥¼¨Ï¥Î§l®ñªvÀø¤USpO2=<94%¡B»Ý¨Ï¥Î§l®ñªvÀø¡B°ª¬y¶q®ñ®ð©Î«D«IÅ§©Ê©I§l¾¹¤§¯f±w¡C¯f±w¦í°|3¤Ñ¤º¡A¥B¤J¦íICU 24¤p®É¤º©Î¥¼¤J¦íICU¦ýµoª¢«ü¼Æ¤W¤É(CRP>=7.5 mg/dL) ¡C¾¯¶q¡G8mg/kg¡A³æ¦¸ÀR¯ßª`®g¡A¦Ü¦h800mg [Micromedex 20210623] COVID-19 (Severe) - Pneumonia 8 mg/kg (actual body weight) as single IV dose¡A Maximum dose 800 mg; give in combination with dexamethasone 6 mg IV or orally daily for up to 10 days or another corticosteroid at an equivalent dose (guideline dosage),µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¥Ø«e©|¥¼«Ø¥ß¨x¥\¯à¤£¥þªÌ¨Ï¥Îªº¦w¥þ©Ê¤ÎÀø®Ä³ø§i.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«eÃö©ó¥Î©ó¥¥°üªº¦³­­¸ê®Æ©|¤£¨¬¥H½T¬O§_¦³·|¤Þµo­«¤j¥X¥Í¯Ê³´¤Î¬y²£ªºÃÄª«¬ÛÃö­·ÀI¡H ³æ®è§ÜÅé¦ptocilizumab¦b²Ä3¥¥´Á·|³z¹L¥D°Ê¹B¿é³q¹L­L½L¡A¨Ã¥i¯à·|¼vÅT¥X¥Í«e¼ÉÅS©óÃÄª«¤§À¦¨àªº§K¬Ì¤ÏÀ³¡C ¦b°Êª«¥Í´Þ¬ã¨s¤¤¡A©ó°¨¨ÓµU¦b¾¹©x¥Í¦¨¹Lµ{¤¤ÀR¯ßª`®g§ë¤©tocilizumab¡A·|¾É­P¬y²£/­F­L-­L¨àªº¦º¤`¡A¨ä¾¯¶q¬Û·í©ó¤HÃþ³Ì°ª«ØÄ³¾¯¶qªº1.25­¿¡]§t¡^¥H¤W¡C °Êª«¸ÕÅç¤åÄm«ü¥X¡AIL-6¶Ç°T§@¥Î¨ü¨ì§í¨î¥i¯à·|¤zÂZ¤l®cÀVªº¦¨¼ô»PÂX±i¡A¥H¤Î¤l®c¥­·Æ¦Ùªº¦¬ÁY¬¡©Ê¡A¥i¯à¦³¨Ï­L¨à¨ü¨ì¼vÅTªº­·ÀI¡C ¥Ø«e¨Ã¤£½Tª¾¥»«~¤§¾A¥Î±Ú¸sµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº¦ô­p­I´º­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©ótocilizumab¬O§_·|¥X©ó¤HÃþ¨Å¥Ä¡B¥»ÃÄ¹ï­÷¥À¨Å¤§À¦¨àªº¼vÅT¡B©Î¥»ÃÄ¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅTµ¥¤è­±ªº¸ê®Æ¡C ¥ÀÅéªº§K¬Ì²y³JG(lgG)·|¥X²{©ó¤HÃþªº¨Å¥Ä¤¤¡C¦pªGtocilizumab·|Âà²¾¶i¤J¤HÃþªº¨Å¥Ä¡A¥Ø«e¤´¤£½Tª¾tocilizumab¦bÀ¦¨à­G¸z¹D¤¤ªº§½³¡¼ÉÅS¤Î¥i¯à¦³­­ªº¥þ¨­¼É·|³y¦¨¦óºØ¼vÅT¡C ¥Ñ©ó¯Ê¥F±Â¨Å´Á¶¡ªºÁ{§É¸ê®Æ¡A¥Ø«e¨ÃµLªk½T©w¦b±Â¨Å¶¡¨Ï¥Î Actemra¹ïÀ¦¨à©Ò±a¨Óªº­·ÀI¡F ¦]¦¹¡AÀ³±NÁý­÷¥À¨Å¹ïµo¨|»P°·±dªº¦n³B©M¥À¿Ë¹ï ActemraªºÁ{§É»Ý¨D¡A¥H¤Î©Î¥À¿Ëªº°òÂ¦¯e¯f¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C,IVD;,,¡iH/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,30¤½¤ç¥H¤U¯f±w:¥H50mL 0.9%©Î0.45%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C 30¤½¤ç¥H¤W¯f±w:¥H100mL 0.9%©Î0.45%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C µ}ÄÀ®É½Ð»´»´­Ë¸m¨ÏÃÄ¾¯²V¦X¡AÁ×§K²£¥Íªwªj¡C¿éª`®É¶¡À³¶W¹L60¤ÀÄÁ,¥»ÃÄ¥H0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ«á¸m©ó2-8¢XC©Î«Ç·Å¥i«O¦s24¤p®É¡C¥H0.45%´â¤Æ¶uª`®g²Gµ}ÄÀ«á¸m©ó2-8¢XC¥i«O¦s24¤p®É©Î«Ç·Å¥i«O¦s4¤p®É¡CÀx¦s®ÉÀ³Á×¥ú¡C
OINH3,Isoniazid,ISONIAZID 300mg (¬F©²´£¨Ñ),QANB,Treatment of susceptible active tuberculosis (eg¡A Mycobacterium tuberculosis) infections.,¡EAcute liver disease. ¡EHistory of severe adverse reactions to isoniazid such as drug fever¡A chills¡A or arthritis. ¡EHistory of isoniazid associated hepatic injury or drug induced liver injury. ¡ESevere hypersensitivity to isoniazid.,Common ¡EHepatic: Increased liver enzymes (10% to 20% ) ¡ENeurologic: Neuropathy¡A Neurotoxicity Serious ¡EDermatologic: Rash ¡EHematologic: Agranulocytosis¡A Anemia¡A Thrombocytopenia ¡EHepatic: Hepatitis (Severe)¡A Hepatotoxicity¡A Injury of liver ¡EImmunologic: Systemic lupus erythematosus ¡EMusculoskeletal: Rhabdomyolysis ¡ENeurologic: Seizure,,(UpToDate) DOT = directly observed therapy. Adult: Once-daily therapy: 5 mg/kg/dose (usual dose: 300 mg) once daily; Three-times-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered 3 times weekly; Twice-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered twice weekly; Once-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered once weekly.Pediatrc: Once daily therapy: children < 15 years¡A weighing < or = 40 kg: 10-15 mg/kg/dose once daily (maximum 300 mg/dose); children < 15 years weighing > 40 kg or children > or = 15 years: 5 mg/kg/dose once daily; typical dose: 300 mg/dose.,»Ý½Õ¾ã¾¯¶q,Advanced disease or AST greater than 3 times ULN and not due to TB: Isoniazid-based regimens are preferred if possible; expert consultation and dosage adjustments may be necessary. If isoniazid cannot be used¡A consider treatment regimens with fewer potentially hepatotoxic drugs.,µL»Ý½Õ¾ã¾¯¶q,,Compatible ¡V maternal benefit >> embryo-fetal risk,PREGNANCY RECOMMENDATION: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;,,,,,
OMORC,Sulfamethoxazole + Trimethoprim,Morcasin (Baktar) 400/80mg,QANB,Infection.,History of sulfonamide- or trimethoprim-induced immune thrombocytopenia. Hypersensitivity to sulfonamides or trimethoprim. Infants younger than 2 months of age. Marked hepatic damage. Megaloblastic anemia due to folate deficiency.,Common Dermatologic: Rash¡A Urticaria Gastrointestinal: Loss of appetite¡A Nausea¡A Vomiting Serious Cardiovascular: Cardiogenic shock¡A Prolonged QT interval¡A Torsades de pointes¡A Ventricular tachycardia Dermatologic: Drug reaction with eosinophilia and systemic symptoms¡A Erythema multiforme¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Sweet's syndrome¡A Toxic epidermal necrolysis Endocrine metabolic: Hyponatremia Gastrointestinal: Clostridioides difficile infection¡A Associated diarrhea Hematologic: Agranulocytosis¡A Aplastic anemia¡A Disorder of hematopoietic structure¡A Neutropenia¡A Thrombocytopenia Hepatic: Hepatic necrosis¡A Fulminant Immunologic: Anaphylaxis Musculoskeletal: Rhabdomyolysis,15-30¢J,Trimethoprim-sulfamethoxazole (TMP-SMX) Adult: 160/800 mg (2 tablets) orally 3 times daily. Children (6-12 years): 80/400 mg (1 tablet) orally 3 times daily. Reduce dose for children < 6 years of age.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment (marked hepatic damage): Use is contraindicated.[Micromedex20210514],»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,Trimethoprim: Human and Animal Data Suggest Risk Sulfamethoxazole (Sulfonamides): Human Data Suggest Risk in 3rd Trimester [¥é³æ] ¸T§Ò: ¥¥°ü,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Trimethoprim: Compatible Sulfamethoxazole (Sulfonamides): Limited Human Data¡XPotential Toxicity [¥é³æ] ¥Ø«e©|µL¸ê°T¡C,AC;AC15;PC;PO;WM;,,,,,
EATL,Hydroxypropylmethylcellulose,Artelac eye drops 10mL,TOPH,Temporarily relieves burning and irritation caused by dry eyes.,Hypersensitivity to Artelac eye drops or any component of the formulation.,Occasional eye redness¡A swelling¡A burning¡A and stinging sensation.,Á×§K¶§¥úª½®g,Instill 1 to 2 drops into affected eye(s) 3 to 4 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Micromedex Pregnancy Rating: Fetal risk cannot be ruled out. 1) Available evidence is inconclusive or inadequate for determining fetal risk when used in pregnant women.,Unknown ¨S¦³¸ê®Æ,Micromedex Lactation Rating: Infant risk cannot be ruled out. 1) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,OD;OL;OU;,,,,,¦³®Ä¦¨¤À¤Î§t¶q: ¨C²@¤É§tHydroxypropylmethylcellulose (HPMC 2906) 3.2 mg
OHARV,Ledipasvir + Sofosbuvir,Harvoni 90/400mg,QANB,Treatment of chronic HCV genotype 1 infection in adults.,If ledipasvir/sofosbuvir is administered with ribavirin¡A the contraindications to ribavirin also apply. Hypersensitivity to any component of the formulation.,>10%: Central nervous system: Headache (11% to 29%)¡A fatigue (10% to 18%) Neuromuscular & skeletal: Weakness (18% to 31%) 1% to 10%: Central nervous system: Irritability (8%)¡A insomnia (3% to 6%)¡A dizziness (5%)¡A depression (<5%; including in subjects with preexisting history of psychiatric illness) Gastrointestinal: Nausea (6% to 9%)¡A increased serum lipase (>3 x ULN: ?9%)¡A diarrhea (3% to 7%) Hepatic: Hyperbilirubinemia (>1.5 x ULN: ?3%) Neuromuscular & skeletal: Myalgia (9%)¡A increased creatine phosphokinase (1%) Respiratory: Cough (5%)¡A dyspnea (3%) <1% (Limited to important or life-threatening): Skin rash (with blisters or angioedema-like swelling),30¢J¥H¤U,One tablet once daily with concomitant ribavirin for 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Sofosbuvir: No Human Data¡XAnimal Data Suggest Low Risk (Contraindicated if combined with Ribavirin) Ledipasvir: UNKNOW,Unknown ¨S¦³¸ê®Æ,Sofosbuvir: No Human Data¡XProbable Compatible (Potential toxicity if combined with Ribavirin) Ledipasvir: UNKNOW,AC;AC15;PC;PO;WM;,,,,,
OSOV,Sofosbuvir,Sovaldi FC 400mg,QANB,Chronic hepatitis C: Treatment of genotype 1¡A 2¡A 3¡A or 4 chronic hepatitis C (CHC) as a component of a combination antiviral treatment regimen.,Hypersensivity¡A Pregnancy.,Fatigue¡A headache¡A nausea¡A insomnia & anemia. Pruritus¡A asthenia¡A rash¡A decreased appetite¡A chills¡A influenza-like illness¡A pyrexia¡A diarrhea¡A neutropenia¡A myalgia¡A irritability.,30¢J¥H¤U«Ç·ÅÀô¹Ò,(¥é³æ) 400 mg oraly once daily in combination with ribavirin or pegylated interferon + ribavirin. (Uptodate) Chronic hepatitis C (CHC) infection: Adults: Genotype 3¡A peginterferon + ribavirin treatment¡Vexperienced patients with compensated cirrhosis (Child-Pugh class A): 400 mg once daily with concomitant elbasvir/grazoprevir for 12 weeks. All genotypes¡A patients with prior glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir treatment failure¡A + or - cirrhosis (Child-Pugh class A): 400 mg once daily in combination with ribavirin and glecaprevir/pibrentasvir for 16 weeks. Children > or =3 years and Adolescents: weight < 17 kg: 150 mg once daily; 17-35 kg: 200 mg once daily; > or = 35 kg: 400 mg once daily. Treatment duration: Genotype 2: 12 weeks. Genotype 3: 24 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,No Human Data¡XAnimal Data Suggest Low Risk (Contraindicated if combined with Ribavirin),,,,,,
OCLON,Clonazepam,Clonopam 0.5mg,CNEU,Seizure¡A Lennox syndrome.,Hypersensitivity to Clonazepam. Severe hypopnea.,Common Neurologic: Ataxia (5% to 30% )¡A Coordination problem (6% )¡A Dizziness (8% )¡A Somnolence (37% to 50% ) Psychiatric: Problem behavior (25% ) Respiratory: Upper respiratory infection (8% ) Other: Fatigue (7% ) Serious Psychiatric: Depression (7% )¡A Suicidal thoughts Respiratory: Respiratory depression,25¢J¥H¤U,The daily dose has to be slowly increased to a suitable maintenance dose for each patient to avoid the adverse effects of initial treatment. The daily dose can be given in a single dose at night if the target dose is reached. The maximum dose should be given at night if the daily dose must be divided several times. For adults: The maintenance dose is 2-4mg/day. The maximum dose is 20 mg/day. For infants and children under 10 years old (or weighing less than 30 Kg): The initial dose is 0.01- 0.03 mg/Kg/day. The maintenance dose is 0.05-0.1mg/Kg/day. For children over 10 years old (or weighing more than 30 Kg): The initial dose is 1-2 mg/day. The maintenance dose is 1.5-3mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ]±qÁ{§É«eªº¬ã¨s¤¤¡A¨Ã¤£¯à±Æ°£Clonazepam¦³¥ý¤Ñ·î§Îªº¥i¯à©Ê.±q¬y¦æ¯f¾Çµû¦ô¡AÃÒ¹ê§ÜµjÅËÃÄ¬°­P·î­L­ì¡AµM¦Ó¡A±qµoªíªº¬y¯f¾Ç³ø§i¤¤¡A«ÜÃø¥h¨M©w­þ¤@­ÓÃÄ©ÎÃÄª«¨Ö¥Î³y¦¨·s¥Í¨àªº¯Ê³´.¨ä¥L¦]¯À¦p¿ò¶Ç¦]¤l©ÎÅöíwª¬ªp¥»¨­¥i¯à¤ñ¾É­P¥ý¤Ñ¯Ê³´ªºÃÄª«§ó­«­nªº¥i¯à©Ê¦s¦b. ¦b³oºØª¬ªp¤U¡Aµ¹¤©¥¥°ü¦¹ÃÄ¡A¥u¦³·í¥i¯àªº®Ä¯q³Ó¹L¹ï­L¨àªº¦MÀI©Ê®É.¦bÃh¥¥´Á¡A¥u¦³·í¤@©w­n¨Ï¥ÎClonazepam®É¡A¤~µ¹¤©. ¦bÃh¥¥ªº³Ì«á¤T­Ó¤ë©Î¤À®Y®Éµ¹¤©°ª¾¯¶qClonazepam¥i¯à³y¦¨¥¼¥X¥Í¨àªº¤ß¸õ¤£³W«h¡A ©M·s¥Í¨àªºÅé·Å¹L§C¡A¦Ù±i¤O¹L§C¡A»´«×©I§l§í¨î©Mpoor feeding. À³¨c°OÃh¥¥¥»¨­©M¬ðµM°±ÃÄ¥i¯à¥[­«Åöíw¯f±¡.,Compatible ­÷¨Å®É¥i¨Ï¥Î,Breastfeeding recommendation: Compatible but Potential toxicity if combined with other CNS depressants. [¥é³æ] ÁöµM¤wµo²{Clonazepamªº¬¡©Ê¦¨¤À¥u¦³¤Ö³¡¤À·|¶i¤J¥À¨Å¤¤¡A¶i¦æ¦¹ÃÄªvÀøªº¥À¿Ë¤£À³±Â¨Å¡A ¦p¤@©w­n¨Ï¥ÎClonazepam®É¡AÀ³°±¤î±Â¨Å.,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
IALF,Alfentanil,Alfentanil inj 1mg/2mL (HAMELN),CNEU,Analgesia & anaesthetic induction in both short & long surgical procedures.,Resp insufficiency. Special Precautions: CV disorders; impaired liver function.,Resp depression¡A apnoea¡A muscular rigidity¡A bradycardia¡A hypotension¡A dizziness¡A nausea¡A CNS disturbances.,25¢J¥H¤U,Individualised dosage. ¡½Administration of analgesic; Adjunct - Surgical procedure: surgery duration 30 min or less; 8-20 mcg/kg IV¡A then continuous IV infusion of 0.5-1 mcg/kg/min; total dose 8-40 mcg/kg ¡½Administration of analgesic; Adjunct - Surgical procedure: surgery duration 30-60 min; 20-50 mcg/kg IV¡A then maintenance IV injections of 5-15 mcg/kg every 5-20 min; total dose up to 75 mcg/kg ¡½Administration of analgesic; Adjunct - Surgical procedure: surgery duration longer than 45 min; 50-75 mcg/kg IV¡A then continuous IV infusion of 0.5-3 mcg/kg/min ¡½Anesthesia: individualized according to type and duration of surgical procedure/anesthesia ¡½Anesthesia: when used as primary anesthetic agent; 130-245 mcg/kg induction dose followed by continuous IV infusion of 0.5-1.5 mcg/kg/min,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªº¯f±wÀ³ÂÔ·V¨Ï¥Î¨Ã¦Ò¼{­°§C¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,Administer doses slowly over at least 3 minutes.,Continuous IV infusion 0.5-1.5 mcg/kg/min. (Alfentanil was diluted to a concentration of 25 to 80 mcg/mL in clinical studies.),Duration¡A general anesthesia: Discontinue use at least 10 to 15 minutes prior to the end of surgery
ICOV,Folinate,Covorin inj 50mg/5mL,ZADT,Folate antagonist overdose (e.g.¡A methotrexate) antidote.,Pernicious or other megaloblastic anemias due to vitamin B12 deficiency,Common: Diarrhea¡A Nausea¡A Stomatitis¡A Vomiting¡A Fatigue Serious: Allergic reaction.,2-8¢J¤Å§N­á¡AÁ×§K¥ú½u·Ó®g¡C,IV up to 75 mg may be given in the first 12 hours¡A followed by IM doses of 12 mg q6h for 4 doses. Administer as IV injection¡A IM injection¡A or IV infusion. Efficacy in counteracting toxicity may be reduced with delays in therapy for folic acid antagonist overdose; administer as promptly as possible. [Colon cancer¡A Adjuvant stage II/III (in combination with 5-fluorouracil and oxaliplatin)] Oxaliplatin 85 mg/m(2) IV on weeks 1¡A3¡A5 for three 8-week cycles with an IV bolus of fluorouracil 500 mg/m(2) and leucovorin 500 mg/m(2) IV weekly for 6 weeks of an 8-week cycle for 3 cycles. [Colorectal cancer¡A Advanced¡A in combination with 5-fluorouracil (palliative treatment)] Leucovorin 200 mg/m(2) slow IV injection over a minimum of 3 minutes¡A followed by 5-fluorouracil 370 mg/m(2) IV daily for 5 days; may repeat in 4-week (28 day) intervals for 2 courses and then 4- to 5-week (28 to 35 day) intervals if recovery from toxic effects of the prior course. [Leucovorin rescue¡A to diminish the toxicity and counteract the effects of impaired MTX elimination and of inadvertent overdose] 15-10 mg/m(2) IM/IV/orally q6h initiated within 24 hours of MTX; if leucovorin doses are >25 mg or if there is gastrointestinal toxicity¡A nausea¡A or vomiting give parenterally; continue until serum MTX level is <10(-8) Molar. If 24-hour serum creatinine has increased 50% above baseline¡A or if 24-hour MTX level is >5 x 10(-6) Molar¡A or if 48-hour MTX level is >9 x 10(-7) Molar¡A increase dose to 150 mg (100 mg/m(2)) IV q3h until serum MTX <10(-8) Molar. Concomitant hydration therapy¡A hydration 3 L/day and urinary alkalinization with sodium bicarbonate dosage adjusted to maintain urine pH of 7 or greater. [Megaloblastic anemia due to folate deficiency¡A When oral therapy is not feasible] Up to 1 mg IV daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,Leucovorin (folinic acid): Compatible [¥é³æ] ©|µLfolinate calciumªº°Êª«¥Í´Þ¬ã¨s¡Afolinate calcium¬O§_¹ïÃh¥¥°ü¤k¦³­P©R¶Ë®`©Î¼vÅT¥Í´Þ¯à¤O©|¤£±o¦Óª¾¡A¦]¦¹¡A¥u¦³·íÃh¥¥°ü¤k©ú½T¥²­nªA¥Î¸­»Ä®É¡A¤~¥iªA¥Î¡C ±N¤À®Yªº¥¥°ü©óÃh¥¥´Áµ²§ô«e¡A¤£À³¶}©l¨Ï¥Îfolinate calciumªvÀø¡C¦pªG¦bªAÃÄ¹Lµ{¤¤Ãh¥¥¡AÀ³¥R¤À§iª¾¦¹ÃÄ¹ï­L¨à¥i¯àµo¥ÍªºÄY­«¦MÀI¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,Leucovorin (folinic acid): Compatible [¥é³æ] ¦¹ÃÄ¬O§_¤Àªc©ó¥À¨Å¤¤©|µLªk½T©w¡A¥Ñ©ó³\¦hÃÄ«~¤Àªc©ó¥À¨Å¤¤¡A·íÁý¥À¨Åªº¥À¿Ë¨Ï¥Îfolinate calcium®É¡AÀ³¯S§O¤p¤ß¡C,IM;IVD;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,<160 mg/min,IV infusion over 15 minutes to 2 hours.,1. IV maximum rate: 160 mg/min. [Micromedex] 2. Administer as IM¡A IV push¡A or IV infusion. 3. Do not mix with 5-fluorouracil in the same infusion.
IMIT2,Mitomycin C,Mitonco inj 10mg (±M®×¶i¤f)°·«O110.01.01-112.09.30,RACA,Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.,Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders¡A or other increased bleeding tendency,Leukopenia¡A thrombocytopenia¡A anorexia¡A nausea/vomiting¡A malaise¡A weight loss¡A bleeding tendency & anemia. Haemolytic-uremic syndrome¡A microangiopathic hemolytic anemia¡A nephropathy¡A bone marrow depression¡A interstitial pneumonia¡A liver & biliary tract disorders.,Äá¤ó30«×C¥H¤U,(Micromedex) Carcinoma of bladder: 20-40 mg intravesically every week in 20-100 mL of normal saline or in 20-40 mL water. For gastric cancer and pancreatic cancer¡A 20 mg/m2/dose IV every 6-8 weeks in combination with other agents.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest high risk,,Hold Breast Feeding ¼È°±­÷¨Å,,IRR;IVD;,IVD:¥H25mLµLµßª`®g¥Î¤ô·»¸Ñ,¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡BµÇ¥\¯à¡C
ITTA6,Tetanus toxoid,Tetanus vaccine 0.5mL/dose/amp(±M®×¶i¤f),HIMM,Active immunization of tetanus.,Febrile illness or acute infection; defer vaccination. History of systemic allergic or neurologic reactions to previous injection of the vaccine; only passive immunization should be given using Tetanus Immune Globulin (Human) (TIG). Hypersensitivity to any component of the vaccine¡A including thimerosal.,Common Dermatologic: Localized adverse reaction to administration of drug Gastrointestinal: Nausea Musculoskeletal: Arthralgia Other: Fever¡A Malaise Serious Immunologic: Anaphylaxis (rare)¡A Arthus type urticaria Neurologic: Encephalopathy¡A Guillain-Barre syndrome¡A Seizure Ophthalmic: Third cranial nerve weakness,2-8¢J,IM¡A 0.5 mL¡A 2 doses primary immunization at an interval of 4 weeks¡A a booster dose after 6-12 months. Routine booster dose can be given every 5-10 years.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥i¬I¥´¡C [Micromedex]¤£¯à±Æ°£­L¨à¤ÎÀ¦¨àªº­·ÀI¡C,Unknown ¨S¦³¸ê®Æ,[Micromedex]¤£¯à±Æ°£­L¨à¤ÎÀ¦¨àªº­·ÀI¡C,IM;,,,,,
ILFT,Cefoxitin,Lofatin inj 2gm,QANB,Infections caused by staphylococcus¡A streptococcus¡A pneumococcus¡A meningococcus¡A and other susceptible bacteria.,Hypersensitivity to cefoxitin and cephalosporins.,1% to 10%: Gastrointestinal: Diarrhea <1%: Anaphylaxis¡A angioedema¡A bone marrow depression¡A dyspnea¡A eosinophilia¡A exacerbation of myasthenia gravis¡A exfoliative dermatitis¡A fever¡A hemolytic anemia¡A hypotension¡A increased blood urea nitrogen¡A increased serum creatinine¡A increased serum transaminases¡A interstitial nephritis¡A jaundice¡A leukopenia¡A nausea¡A nephrotoxicity (increased; with aminoglycosides)¡A phlebitis¡A prolonged prothrombin time¡A pruritus¡A pseudomembranous colitis¡A skin rash¡A thrombocytopenia¡A thrombophlebitis¡A toxic epidermal necrolysis¡A urticaria¡A vomiting,25¢XC¥H¤UÁ×¥ú,[¥é³æ] 2-4g/day¡A divided into 2-4 doses [UpToDate] Usual adult dosage range: IV 1-2 g every 6-8 hours; pediatric (ages >=3 months) general dosing: IV 80-160 mg/kg/day divided every 4-8 hours; maximum: 12 g/day,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] ¹ï¥¥°ü¤§¦w¥þ©Ê©|¥¼½T¥ß¡A¶·°ò©ó¦³¯q©Ê¤§§PÂ_¦A¨Ï¥Î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVPUSH;,[¥é³æ] ¥[»]ÃH¤ô¡B¥Í²z­¹ÆQ¤ô¦æÀR¯ß©ÎÂIºwª`®g¡C [Micromedex] For IV bolus¡A reconstitute 2-g vial with 10 or 20 mL sterile water for injection. For IV infusion¡A reconstitute 2-g vial with 10 or 20 mL sterile water for injection¡A bacteriostatic water for injection¡A NS¡A or D5W.,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,[Micromedex] IV bolus >3-5 minutes. May give 1-g doses over 2 minutes¡A and 2-g doses over 5 minutes.,[Micromedex] Reconstituted vials may be further diluted in 50-100 mL of NS¡A D5W¡A or D10W Injection [UpToDate] intermittent infusion over 10-60 minutes,[¥é³æ] 1. ÀR¯ß¤º¤j¶q§ë»P·|¤Þ°_¦åºÞµh¡B¦å®êÀR¯ßª¢¡A¹w¨¾¤èªk¶·ª`·Nª`®g²G¤§½Õ»s¡Aª`®g³¡¦ì¤Îª`®g¤èªk¡A´îºCª`®g³t«×¡C 2. °®¯»·»¸Ñ«á¶·¾¨³t¨Ï¥Î¡Aµ}ÄÀ©ó¿éª`²G«á­YÀx¦s©ó25¢XC¥H¤U¥i«O¦s24¤p®É¡A¦b2-8¢XC¥i«O¦s5¤Ñ¥H¤º¨Ï¥Î¡C
LOSTA,Oseltamivir,Oseltamivir (¬F©²´£¨Ñ) 6mg/mL 60mL oral suspension,QANB,Treatment of influenza in adults and children (including full-term newborns). Prevention of influenza in adults and children aged 1 and above.,Known allergies to oseltamivir phosphate or any of its components.,Common: Nausea (8-10%)¡A Vomiting (Adult and adolescent¡A 2-8%; pediatric¡A 8-16%)¡A Headache (Influenza treatment¡A 2%; influenza prophylaxis¡A 17%) Serious: Cardiac dysrhythmia¡A Erythema multiforme (Rare)¡A Facial swelling¡A Stevens-Johnson syndrome (Rare)¡A Toxic epidermal necrolysis (Rare)¡A Gastrointestinal hemorrhage¡A Hemorrhagic colitis¡A Hepatitis¡A Anaphylaxis (Rare)¡A Seizure¡A Abnormal behavior¡A Delirium,25¢XC¥H¤U¡C½Õ°t«á¡G§NÂÃ(2-8¢J)17¤Ñ©Î«Ç·Å(<25¢J)10¤Ñ,Treatment of influenza: must begin treatment within the first or second day of experiencing influenza symptoms. - Adults and adolescents (>=13years): 75mg PO BID for 5 days. - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO BID for 5 days. >15-23kg: 45mg (7.5mL) PO BID for 5 days. >23-40kg: 60mg (10mL) PO BID for 5 days. >40kg: 75mg (12.5mL) PO BID for 5 days. - Children under 1 year: 3mg/kg PO BID for 5 days (not for infants with a gestational age of <36 weeks). Prophylaxis of influenza: must begin prophylaxis within 2 days of exposure to the source. - Adults and adolescents: 75mg PO QD for 10 or more days (safety and efficacy confirmed for 6 weeks). - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO QD for 10 days. >15-23kg: 45mg (7.5mL) PO QD for 10 days. >23-40kg: 60mg (10mL) PO QD for 10 days. > 40kg: 75mg (12.5mL) PO QD for 10 days.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¹ï©ó»´«×¦Ü¤¤«×ªº¨x¥\¯à¤£¥þ¯f¤H¦b¬y¦æ©Ê·P«_ªºªvÀø¤Î¹w¨¾¤W¡A¥ç¨S¦³½Õ¾ã¾¯¶qªº¥²­n¡C¹ï©ó­««×¨x¥\¯à¤£¥þ¯f¤H¤§¦w¥þ©Ê¤Î¨äÃÄ°Ê¾Ç¤è­±¡A©|¥¼¶i¦æ¹L¬ÛÃö¬ã¨s¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ] ±q¤W¥««á³ø§i¤ÎÆ[¹î©Ê¬ã¨s¤¤¨ú±oªº¸ê®Æ©M°Êª«¬ã¨sµ²ªGÅã¥Ü¹ïÃh¥¥¡B­F­L/­L¨à©Î ¥X¥Í«áªºµo¨|¨ÃµLª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C¦b¦Ò¶q¤wª¾ªº¦w¥þ©Ê¤Î®Ä¯q¸ê®Æ¡B¬y¦æ¤¤¤§ ¬y¦æ©Ê·P«_¯f¬r®èªº­P¯f©Ê¡B¤ÎÃh¥¥°ü¤k¥»¨­ª¬ªp«á¡AÃh¥¥°ü¤k¥i¯à¥i¨Ï¥Î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¦b±Â¨Å¤j¹«¤¤µo²{¡AOseltamivir ¤Î¨ä¬¡©Ê¥NÁÂª«·|³Q¤Àªc¦Ü¨Å¥Ä¤¤¡C±Â¨Å¥À¿ËªA¥ÎOseltamivir ¹ï§l§m¥À¨Å¤§¥®¨àªº¼vÅT¤ÎOseltamivir ±Æªn©ó¨Å¥Ä¤¤ªº¸ê°T«D±`¦³­­¡C¦³­­ªº¸ê®ÆÅã¥Ü¡A Oseltamivir¤Î¨ä¬¡©Ê¥NÁÂª«¥i¦b¨Å¥Ä¤¤³Q°»´ú¥X¨Ó¡A¦ý¨ä¿@«×§C©Ò¥H¹ï©óÀ¦¨à¦Ó¨¥§C©óªvÀø¾¯¶q¡C °ò©ó¤W­z¸ê°T¡B¥¿¦b¬y¦æ¤¤¤§¬y¦æ©Ê·P«_¯f¬r®è¤§­P¯f©Ê¤Î±Â¨Å°ü¤kªº¼ç¦bª¬ªp¡A¨Ã½T»{ ¹ï±Â¨Å¥À¿Ëªº¯q³B¤j©ó¥i¯à¹ï­÷¨|¤¤À¦¨àªº¦MÀI¤§«á¡A¥i¯à¥i¥Hµ¹¤©±Â¨Å°ü¤k¡C,AC;AC15;PC;PO;WM;,,,,,1. °t»s¤è¦¡¡G©ç¥´Åø¤l¥HÃP´²¯»¥½¡C±N55²@¤É½Õ§N¤ô¥[¤J²~¤¤¡A»\ºò²~»\«á·n¤Ã¦Ü¥Õ¦â§¡¤ÃÄa²G¡C 2. ½Õ°t«á¥i§NÂÃ(2-8¢J)«O¦s17¤Ñ©Î«Ç·Å(<25¢J)«O¦s10¤Ñ¡C 3. ¥i¥H©M©Î¤£©M­¹ª«¤@°_ªA¥Î¡C©M­¹ª«¤@°_ªA¥Î¥i¯à¥i¼W¥[¹ïÃÄª«ªº­@¨ü©Ê¡C
ONUM,Carbidopa + Levodopa,Numient 48.75/195mg extended-release,CNEU,Parkinson's disease¡A post-encephalitic Parkinsonian syndrome¡A symptomatic Parkinsonian syndrome (due to carbon monoxide or manganese toxicity).,Hypersensitivity to Numient or any component of the formulation. Narrow-angle glaucoma. Pheochromocytoma. Concurrent use with non-selective monoamine oxidase (MAO) inhibitors. These inhibitors must be discontinued at least two weeks before starting treatment. History of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis.,Common: Vitamin B6 deficiency¡A Nausea (Enteral¡A 30%; oral¡A 5.5-5.7%)¡A Confusion (2.3-3.7%)¡A Dizziness (2.3-2.9%)¡A Headache (1.9-2%)¡A Peripheral neuropathy (Enteral¡A 8.7-30.4%) Serious: Myocardial infarction¡A Melanoma¡A Dyskinesia (Enteral¡A 14% ; oral¡A 12.2-28.4%)¡A Depression (Enteral¡A 11%; oral¡A 1.3-2.2%)¡A Hallucinations (Enteral; 5%; oral¡A 3.2-3.9%)¡A Suicidal thoughts¡A Neuroleptic malignant syndrome,25¢XC¥H¤U¡AÁ×¥úÁ×·Ã,Dose recommendations should be followed at initiation of treatment and adapted according to clinical response. Initial dose and titration in levodopa-naive patients: In the first 3 days¡A the initial dose is one capsule containing levodopa 95 mg and carbidopa 23.75 mg TID. Starting from the 4th day¡A the dose can be increased to one capsule containing levodopa 145 mg and carbidopa 36.25 mg TID. For patients who have not received levodopa treatment¡A limited experience exists with daily levodopa doses exceeding 1¡A170 mg. Numient is recommended to be taken orally 3 to 5 times per day. Maximum dose: 4 hard capsules 195 mg/48.75 mg TID. Each capsule's dosage can be taken individually or in combination with other capsules as needed. There is limited research on co-administration with other levodopa-containing medications.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] Numient ¬ÛÃö¬ã¨s©|¥¼°w¹ï¨Ï¥Î©ó¨x¥\¯à¤£¥þ±wªÌ¶i¦æ±´¨s¡C«ØÄ³ÂÔ·V§ë¤©­««×¨x¥\¯à¤£¥þ±wªÌ¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,CARBIDOPA: Limited Human Data¡XAnimal Data Suggest Risk LEVODOPA: Human Data Suggest Low Risk [¥é³æ] Levodopa/carbidopa ¨Ï¥Î©ó¥¥°üªº¼Æ¾Ú±q¯Ê©Î¦³­­¡C°Êª«¬ã¨sÅã¥Ü¥Í´Þ¬r©Ê¡C °£«DNumient¹ï¥À¿Ë¯q³B³Ó¹L­L¨à¥i¯à©Ó¨üªº­·ÀI¡A§_«hNumient¤£«ØÄ³¨Ï¥Î©óÃh¥¥´Á¶¡¤Î¨ã¦³¥Í¨|¼ç¤O¥B¥¼Á×¥¥ªº¤k©Ê¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,CARBIDOPA: No Human Data¡XProbably Compatible LEVODOPA: Limited Human Data¡XProbably Compatible [¥é³æ] Carbidopa ¥i¤Àªc¦Ü¤j¹«¨Å¥Ä¤¤¡A¦ý¬O¥Ø«e©|¥¼±oª¾carbidopa ©Î¨ä¥NÁÂ²£ª«¬O§_·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤¡C¤@¶µ°w¹ï¤@¦ì±w¦³©¬ª÷´Ë¤ó¯gªº­÷¨Å¥À¿Ë¶i¦æªº¬ã¨sÅã¥Ü¡Alevodopa ¥i¤Àªc¦Ü¤HÃþ¥À¨Å¤¤¡CÃö©ó levodopa/carbidopa ©Î¨ä¥NÁÂ²£ª«¹ï©ó·s¥Í¨à/À¦¨àªº¼vÅT¡A¥Ø«e¯Ê¤Ö¨¬°÷¸ê®Æ¡C Numient ªvÀø´Á¶¡À³°±¤î­÷Áý¥À¨Å¡C,AC;AC15;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O] ¥»ÃÄ¬°½wÄÀ½¦Ån¡A½Ð¾ã²É§]ªA¡A¤£¥i­é¥b©Î¿i¯»¡C 1. °w¹ï§]Ã`½¦Ån¦³§xÃøªº±wªÌ¡A¥i¥H¤p¤ß¥´¶}½¦Ån¡A±N§¹¾ã¤º®eª«¼»¦b¤Ö¶q(¨Ò¦p2¯ù°Í)³n©Ê­¹ª«¤W¡A¨Ò¦pÄ«ªGÂæ¡BÀu®æ©Î¥¬¤B¡AÃÄ«~/­¹ª«²V¦Xª«À³¥ß§Y¥þ³¡§]Ã`§¹²¦¡A¤£¸g©CÄZ¡A²V©M«áÀ³¥ß¨èªA¥Î¡C 2. °ª¯×°ª¼ö¶q¶¼­¹·|¨Ï§l¦¬©µ½w¨â¤p®É¡CªA¥Î®É¤£À³¦P®ÉÄá¨ú°ª³J¥Õ½è¶¼­¹¡A¦]¨ä¥i¯à­°§C levodopa §l¦¬¦Ó«d®zÁ{§É¤ÏÀ³¡C 3. ÃÄ«~¤£À³¸g¹L¥[¼ö©Î¥[¤J¼ö­¹ªA¥Î¡C 4. §t¦³²¸»Ä¨ÈÅKªºÃÄ«~À³»P levodopa/carbidopa ¤À¶}ªA¥Î¡A¨Ã¥BºÉ¥i¯à©ÔªøªAÃÄªº¶¡¹j®É¶¡¡C
EDEXO,Dexamethasone,Dexa orabase 0.1%¡A 5gm,TENT,Intractable stomatitis or glossitis associated with erosion or ulceration.,Patients with tuberculotic¡A viral or other purulent infections of the oral cavity.,Fungal or bacterial infection of the oral cavity; hypersensitivity; hypofunction of pituitary-adrenocortical system (prolonged use). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin¡A Finding of skin healing¡A Impaired Endocrine metabolic: Cushing's syndrome¡A Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )¡A Raised intraocular pressure (25% ) Psychiatric: Depression¡A Euphoria Respiratory: Pulmonary tuberculosis,1 5¢J-30¢J,Apply adequate amount to the affected area once to several times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,TOPI;,,,,,
OBRIN1,Vortioxetine,BrinteLLIX 10mg (Lundbeck),CNEU,Treatment of major depressive disorder (MDD).,Hypersensitivity to vortioxetine or any component of the formulation. Use of monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders (concurrently or within 21 days of discontinuing vortioxetine or within 14 days of discontinuing the MAOI). Initiation of vortioxetine in a patient receiving IV methylene blue.,Common: Constipation (3-6%)¡A Nausea (21-32%)¡A Vomiting (3-6%) Serious: Hyponatremia¡A Hemorrhage¡A Hypersensitivity reaction¡A Sexual dysfunction (Women¡A 22-34%; men¡A 16-29%)¡A Serotonin syndrome,30¢XC¥H¤U,Adult <65 years old: Initial 10mg QD PO. The dose can be increased up to 20mg or decreased to 5mg based on individual response. >=65 years and older: Initial 5mg QD PO. Caution is advised when using doses exceeding 10mg daily. Treatment should continue for at least 6 months after symptom relief to consolidate the antidepressant effect. Vortioxetine is administered orally and can be taken with or without food.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥¥°ü¨Ï¥Îvortioxetine¶È¦³¦³­­Á{§É¸ê®Æ¡C°Êª«¬ã¨s¤wÅã¥Ü¥Í´Þ¬r©Ê¡C ­Y¦bÃh¥¥«á´Á¨Ï¥Î¦å²M¯À§@¥ÎÃÄª«®É¡A·s¥Í¨à¥i¯à·|¥X²{¥H¤U¯gª¬¡G©I§lµ~­¢¡BµoÖæ¡B©I§l¤¤¤î¡BµjÅË¡BÅé·Å¤£Ã­¡BÁý­¹§xÃø¡B¹Ã¦R¡B¦å¿}¹L§C¡B°ª±i¤O¡B§C±i¤O¡B¤Ï®g¤®¶i¡BÅ¸§Ý¡B¾_Å¸¡B©ö«ã¡B©üºÎ¡B­ú¾x¤£°±¡B¶ÝºÎ¡B©MÃø¥H¤JºÎ¡C³o¨Ç¯gª¬¥i¯à¬O¦]§ÙÂ_¤ÏÀ³©Î¬O¹L¦h¦å²M¯À§@¥Î©Ò¤Þ°_¡C©ó¤j¦h¼Æªº®×¨Ò¤¤¡A¤W­z¯gª¬·|¦b¥Í²£«á¥ß§Y©Î«Ü§Ö¦a(<24¤p®É)¥X²{¡C ¬y¦æ¯f¾Çªº¸ê®ÆÅã¥Ü¥X¦bÃh¥¥´Á¶¡¨Ï¥ÎSSRI¡A¤×¨ä¬O¦b«á´Á¡A¥i¯à·|¼W¥[·s¥Í¨à«ùÄò©ÊªÍ°Ê¯ß°ª¦åÀ£¯g(Persistent pulmonary hypertension in the new born¡A PPHN)ªº­·ÀI¡CÁöµM¨S¦³¬ã¨s³ø§i«ü¥XvortioxetineªvÀø»PPPHNªºÃöÁp©Ê¡A·í¦Ò¶q¬ÛÃöªº§@¥Î¾÷Âà(¼W¥[¦å²M¯À¿@«×)®É¡AµLªk±Æ°£¦¹¶µªº¼ç¦b­·ÀI¡C VortioxetineÀ³¦b¼ç¦b§Q¯q°ª©ó­L¨à¼ç¦b­·ÀI®É¡A¤è¥i©óÃh¥¥´Á¶¡¨Ï¥Î¡CÆ[¹î©Ê¼Æ¾Ú¤wÃÒ©ú¡AÃh¥¥°ü¤k¦b¥Í²£«eªº¤@­Ó¤ë¤º¼ÉÅS©óSSRI©ÎSNRI«á¡A²£«á¥X¦åªº­·ÀI¼W¥[(¤p©ó2­¿)¡CÁöµM©|¥¼¬ã¨s½Õ¬dªvÀø©M²£«á¥X¦å¤§¶¡ªºÃöÁp¡A¦ý¦Ò¼{¨ì¬ÛÃöªº§@¥Î¾÷Âà¡A¨ä¤´¦s¦b¼ç¦b­·ÀI¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] °Êª«¸ÕÅçÅã¥Ü¡A¤Î¨ä¥NÁÂ²£ª«·|±Æªn¦Ü¨Å¥Ä¤¤¡C ¦]¦¹¹w´Ávortioxetine·|³Q±Æªn¦Ü¥À¨Å¤¤¡C¤£¯à±Æ°£¹ï©óÁý­¹¥À¨Å¥®¨àªº­·ÀI¡C ¶·¦Ò¶q¥®¨àÁý­¹¥À¨Å»P¹ï¤k©Ê¯f¤H¤§ÂåÀø®Ä¯q¡A¨M©w¬O§_¤¤Â_Áý­¹¥À¨Å©Î°±¥Î¢A§ÙÂ_vortioxetineªvÀø¡C,AC;AC15;PC;PO;WM;,,,,,
IPLE1,Peginterferon beta-1a,Plegridy inj 63mcg (¾ï¦â),HIMM,Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.,Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.,Common Dermatologic: Erythema at injection site (subQ¡A 25% to 62% )¡A Injection site pain (11% to 15% )¡A Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )¡A Headache (36% to 44% ) Other: Fever (45% )¡A Influenza-like illness (47% )¡A Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )¡A Decreased platelet count (Less than 1% )¡A Decreased white blood cell count (7% )¡A Neutropenia (Less than 1% )¡A Pancytopenia (Rare )¡A Thrombocytopenia Hepatic: Autoimmune hepatitis¡A Hepatitis¡A Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema,2-8¢XCÁ×¥úÁ×§K§N­á,The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)¡A increasing to 94 micrograms at dose 2 (on day 14)¡A reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¨Ì¾Ú»´«×¡B¤¤«×¡B­««×µÇ¥\¯à¤£¥þ¥H¤Î¥½´ÁµÇ¯f±wªÌªºÁ{§É¸ê®Æ¡AµÇ¥\¯à¤£¥þ±wªÌ¤£¶·½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¨Ó¦Ûµn¿ý¬ã¨s©M¤W¥««á¸gÅçªº¤j¶q¼Æ¾Ú(¶W¹L1000­Ó§³®Wµ²ªG)Åã¥Ü¡A¦b¨ü¥¥«e©Î§³®W²Ä¤@¥¥´Á¼ÉÅS©óinterferon beta¡Aµo¥Í­«¤j¥ý¤Ñ©Ê²§±`ªº­·ÀI¨Ã¥¼¼W¥[¡C µM¦Ó¡A¥Ñ©ó¦b¦¬¶°¦¹¼Æ¾Ú®Éinterferon beta©|ÄÝÃh¥¥´Á¶¡¤§¨Ï¥Î¸T§Ò¡A¦bÀË´ú¥X/©Î½T»{Ãh¥¥«á¥i¯à·|¤¤Â_ªvÀø¡A¦]¦¹µLªk½T©w¦b§³®W²Ä¤@¥¥´Áªº¼ÉÅS®É¶¡¡C¦Ó¼ÉÅS©ó§³®W²Ä¤G¥¥´Á©M²Ä¤T¥¥´Áªº¸gÅç«D±`¦³­­¡C ®Ú¾Ú°Êª«¸ÕÅç¸ê®Æ¡A¦Ûµo©Ê¬y²£ªº­·ÀI¥i¯à·|¼W¥[¡C µM¦Ó¨Ì¾Ú¥Ø«e¥iÀò±oªº¸ê®Æ¡A©|µLªk¥R¤Àµû¦ô¼ÉÅS©óinterferon betaªº¥¥°ü¨ä¦Ûµo©Ê¬y²£ªº­·ÀI¡A¦ý¥Ø«e¸Ó¸ê®Æ¨Ã¥¼Åã¥Ü¦³¼W¥[ªº­·ÀI¡C ¦p¦³Á{§É»Ý­n¡A¥i¥H¦bÃh¥¥´Á¶¡¦Ò¼{¨Ï¥ÎPlegridy¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,PEGINTERFERON BETA-1a: No Human Data - Compatible [¥é³æ]¥Ø«e¤£ª¾ peginterferon beta-1a ¬O§_·|¤Àªc©ó¨Å¥Ä¤¤¡C Ãö©óinterferon beta-1a¤À¥¬¨ì¥À¨Å¤¤ªº¸ê®Æ¦³­­¡A¦Ò¶qinterferon betaªº¤Æ¾Ç/¥Í²z¾Ç¯S©Ê¡A¥À¨Å¤¤¤Àªcªºinterferon beta-1aªº¶qÀ³«Ü¤Ö¡C À³¦Ò¶q¹ï¥®¨àªº¼ç¦b­·ÀI©M¹ï¥À¿ËªºªvÀø®Ä¯q¡A¨M©w¬O§_°±¤îÁý­÷¥À¨Å©Î°±¤î¥ÎÃÄ¡C,SC;,,,,,1.¨Ï¥Î«e½Ð¸Ô¾\Plegridy¹w¥R¶ñµ§«¬ª`®g²Gª`®g«ü¤Þ¡C 2.¶J¦s¦b­ì¥]¸Ë¤¤¥HÁ×§K¥ú·Ó¡C¶J¦s¦b¦B½c (§NÂÃ)¡A2-8¢XC¡C½Ð¤Å§N­á¡C¦Û¦B½c¨ú¥X«á¥i©ó«Ç·Å(³Ì°ª25¢XC)«O¦s³Ì¦h30¤Ñ¡C­Y»Ý­n¡A¥i¤£¥u¤@¦¸¦Û¦B½c¨ú¥X¦A©ñ¦^§NÂÃ¡C¦ý¸m©ó¦B½c¥~ªºÁ`©M®É¶¡¤£¶W¹L30¤Ñ¡C 3.¨C¦¸ª`®g®É¡A½Ð¾¨¶q¦b¦P¤@¤Ñªº¦P¤@®É¶¡¨Ï¥ÎPlegridy¡C 4.½ÐÅÜ´«±z¥Ö¤Uª`®gªº³¡¦ì¡C½Ð¤Å¦b¬Û¦Pªºª`®g³¡¦ì³sÄòª`®g¡C 5.½Ð³W«ßªº¥ÎÃÄ¡C­Y±z§Ñ°O¥ÎÃÄ¡A½Ð¦b³Ìµu®É¶¡¤º¸Éª`®g¡A¤§«á«h·Ó±`ª`®g¡CµM¦Ó¡A¦b7¤Ñ´Á¶¡¤º½Ð¤Åª`®g¦h©ó1¾¯¡C¤£¥i¦P®Éª`®g2¾¯¨ÓÀ±¸É§Ñ°Oª`®gªº¾¯¶q¡C
IPLE2,Peginterferon beta-1a,Plegridy inj 94mcg (ÂÅ¦â),HIMM,Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.,Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.,Common Dermatologic: Erythema at injection site (subQ¡A 25% to 62% )¡A Injection site pain (11% to 15% )¡A Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )¡A Headache (36% to 44% ) Other: Fever (45% )¡A Influenza-like illness (47% )¡A Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )¡A Decreased platelet count (Less than 1% )¡A Decreased white blood cell count (7% )¡A Neutropenia (Less than 1% )¡A Pancytopenia (Rare )¡A Thrombocytopenia Hepatic: Autoimmune hepatitis¡A Hepatitis¡A Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema,2-8¢XC Á×¥úÁ×§K§N­á,The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)¡A increasing to 94 micrograms at dose 2 (on day 14)¡A reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¨Ì¾Ú»´«×¡B¤¤«×¡B­««×µÇ¥\¯à¤£¥þ¥H¤Î¥½´ÁµÇ¯f±wªÌªºÁ{§É¸ê®Æ¡AµÇ¥\¯à¤£¥þ±wªÌ¤£¶·½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¨Ó¦Ûµn¿ý¬ã¨s©M¤W¥««á¸gÅçªº¤j¶q¼Æ¾Ú(¶W¹L1000­Ó§³®Wµ²ªG)Åã¥Ü¡A¦b¨ü¥¥«e©Î§³®W²Ä¤@¥¥´Á¼ÉÅS©óinterferon beta¡Aµo¥Í­«¤j¥ý¤Ñ©Ê²§±`ªº­·ÀI¨Ã¥¼¼W¥[¡C µM¦Ó¡A¥Ñ©ó¦b¦¬¶°¦¹¼Æ¾Ú®Éinterferon beta©|ÄÝÃh¥¥´Á¶¡¤§¨Ï¥Î¸T§Ò¡A¦bÀË´ú¥X/©Î½T»{Ãh¥¥«á¥i¯à·|¤¤Â_ªvÀø¡A¦]¦¹µLªk½T©w¦b§³®W²Ä¤@¥¥´Áªº¼ÉÅS®É¶¡¡C¦Ó¼ÉÅS©ó§³®W²Ä¤G¥¥´Á©M²Ä¤T¥¥´Áªº¸gÅç«D±`¦³­­¡C ®Ú¾Ú°Êª«¸ÕÅç¸ê®Æ¡A¦Ûµo©Ê¬y²£ªº­·ÀI¥i¯à·|¼W¥[¡C µM¦Ó¨Ì¾Ú¥Ø«e¥iÀò±oªº¸ê®Æ¡A©|µLªk¥R¤Àµû¦ô¼ÉÅS©óinterferon betaªº¥¥°ü¨ä¦Ûµo©Ê¬y²£ªº­·ÀI¡A¦ý¥Ø«e¸Ó¸ê®Æ¨Ã¥¼Åã¥Ü¦³¼W¥[ªº­·ÀI¡C ¦p¦³Á{§É»Ý­n¡A¥i¥H¦bÃh¥¥´Á¶¡¦Ò¼{¨Ï¥ÎPlegridy¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,PEGINTERFERON BETA-1a: No Human Data - Compatible [¥é³æ]¥Ø«e¤£ª¾ peginterferon beta-1a ¬O§_·|¤Àªc©ó¨Å¥Ä¤¤¡C Ãö©óinterferon beta-1a¤À¥¬¨ì¥À¨Å¤¤ªº¸ê®Æ¦³­­¡A¦Ò¶qinterferon betaªº¤Æ¾Ç/¥Í²z¾Ç¯S©Ê¡A¥À¨Å¤¤¤Àªcªºinterferon beta-1aªº¶qÀ³«Ü¤Ö¡C À³¦Ò¶q¹ï¥®¨àªº¼ç¦b­·ÀI©M¹ï¥À¿ËªºªvÀø®Ä¯q¡A¨M©w¬O§_°±¤îÁý­÷¥À¨Å©Î°±¤î¥ÎÃÄ¡C,SC;,,,,,1.¨Ï¥Î«e½Ð¸Ô¾\Plegridy¹w¥R¶ñµ§«¬ª`®g²Gª`®g«ü¤Þ¡C 2.¶J¦s¦b­ì¥]¸Ë¤¤¥HÁ×§K¥ú·Ó¡C¶J¦s¦b¦B½c (§NÂÃ)¡A2-8¢XC¡C½Ð¤Å§N­á¡C¦Û¦B½c¨ú¥X«á¥i©ó«Ç·Å(³Ì°ª25¢XC)«O¦s³Ì¦h30¤Ñ¡C­Y»Ý­n¡A¥i¤£¥u¤@¦¸¦Û¦B½c¨ú¥X¦A©ñ¦^§NÂÃ¡C¦ý¸m©ó¦B½c¥~ªºÁ`©M®É¶¡¤£¶W¹L30¤Ñ¡C 3.¨C¦¸ª`®g®É¡A½Ð¾¨¶q¦b¦P¤@¤Ñªº¦P¤@®É¶¡¨Ï¥ÎPlegridy¡C 4.½ÐÅÜ´«±z¥Ö¤Uª`®gªº³¡¦ì¡C½Ð¤Å¦b¬Û¦Pªºª`®g³¡¦ì³sÄòª`®g¡C 5.½Ð³W«ßªº¥ÎÃÄ¡C­Y±z§Ñ°O¥ÎÃÄ¡A½Ð¦b³Ìµu®É¶¡¤º¸Éª`®g¡A¤§«á«h·Ó±`ª`®g¡CµM¦Ó¡A¦b7¤Ñ´Á¶¡¤º½Ð¤Åª`®g¦h©ó1¾¯¡C¤£¥i¦P®Éª`®g2¾¯¨ÓÀ±¸É§Ñ°Oª`®gªº¾¯¶q¡C
IPLE3,Peginterferon beta-1a,PLEGRIDY inj 125mcg,HIMM,Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis.,Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients. Patients with current severe depression and/or suicidal ideation.,Common Dermatologic: Erythema at injection site (subQ¡A 25% to 62% )¡A Injection site pain (11% to 15% )¡A Injection site pruritus (13% ) Musculoskeletal: Arthralgia (11% ) Neurologic: Asthenia (13% )¡A Headache (36% to 44% ) Other: Fever (45% )¡A Influenza-like illness (47% )¡A Shivering (17% to 36% ) Serious Cardiovascular: Congestive heart failure Dermatologic: Injection site necrosis Hematologic: Decreased lymphocyte count (Less than 1% )¡A Decreased platelet count (Less than 1% )¡A Decreased white blood cell count (7% )¡A Neutropenia (Less than 1% )¡A Pancytopenia (Rare )¡A Thrombocytopenia Hepatic: Autoimmune hepatitis¡A Hepatitis¡A Liver failure Immunologic: Autoimmune disease (Less than 1% ) Neurologic: Seizure (Less than 1% ) Psychiatric: Suicidal thoughts Other: Angioedema,2-8¢XCÁ×¥úÁ×§K§N­á,The recommended dose of Plegridy is 125 micrograms injected SC every 2 weeks (14 days). Treatment initiation: It is generally recommended that patients start SC treatment with 63 micrograms at dose 1 (on day 0)¡A increasing to 94 micrograms at dose 2 (on day 14)¡A reaching the full dose of 125 micrograms by dose 3 (on day 28) and continuing with the full dose (125 micrograms) every 2 weeks (14 days) thereafter.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¨Ì¾Ú»´«×¡B¤¤«×¡B­««×µÇ¥\¯à¤£¥þ¥H¤Î¥½´ÁµÇ¯f±wªÌªºÁ{§É¸ê®Æ¡AµÇ¥\¯à¤£¥þ±wªÌ¤£¶·½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¨Ó¦Ûµn¿ý¬ã¨s©M¤W¥««á¸gÅçªº¤j¶q¼Æ¾Ú(¶W¹L1000­Ó§³®Wµ²ªG)Åã¥Ü¡A¦b¨ü¥¥«e©Î§³®W²Ä¤@¥¥´Á¼ÉÅS©óinterferon beta¡Aµo¥Í­«¤j¥ý¤Ñ©Ê²§±`ªº­·ÀI¨Ã¥¼¼W¥[¡C µM¦Ó¡A¥Ñ©ó¦b¦¬¶°¦¹¼Æ¾Ú®Éinterferon beta©|ÄÝÃh¥¥´Á¶¡¤§¨Ï¥Î¸T§Ò¡A¦bÀË´ú¥X/©Î½T»{Ãh¥¥«á¥i¯à·|¤¤Â_ªvÀø¡A¦]¦¹µLªk½T©w¦b§³®W²Ä¤@¥¥´Áªº¼ÉÅS®É¶¡¡C¦Ó¼ÉÅS©ó§³®W²Ä¤G¥¥´Á©M²Ä¤T¥¥´Áªº¸gÅç«D±`¦³­­¡C ®Ú¾Ú°Êª«¸ÕÅç¸ê®Æ¡A¦Ûµo©Ê¬y²£ªº­·ÀI¥i¯à·|¼W¥[¡C µM¦Ó¨Ì¾Ú¥Ø«e¥iÀò±oªº¸ê®Æ¡A©|µLªk¥R¤Àµû¦ô¼ÉÅS©óinterferon betaªº¥¥°ü¨ä¦Ûµo©Ê¬y²£ªº­·ÀI¡A¦ý¥Ø«e¸Ó¸ê®Æ¨Ã¥¼Åã¥Ü¦³¼W¥[ªº­·ÀI¡C ¦p¦³Á{§É»Ý­n¡A¥i¥H¦bÃh¥¥´Á¶¡¦Ò¼{¨Ï¥ÎPlegridy¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,PEGINTERFERON BETA-1a: No Human Data - Compatible [¥é³æ]¥Ø«e¤£ª¾ peginterferon beta-1a ¬O§_·|¤Àªc©ó¨Å¥Ä¤¤¡C Ãö©óinterferon beta-1a¤À¥¬¨ì¥À¨Å¤¤ªº¸ê®Æ¦³­­¡A¦Ò¶qinterferon betaªº¤Æ¾Ç/¥Í²z¾Ç¯S©Ê¡A¥À¨Å¤¤¤Àªcªºinterferon beta-1aªº¶qÀ³«Ü¤Ö¡C À³¦Ò¶q¹ï¥®¨àªº¼ç¦b­·ÀI©M¹ï¥À¿ËªºªvÀø®Ä¯q¡A¨M©w¬O§_°±¤îÁý­÷¥À¨Å©Î°±¤î¥ÎÃÄ¡C,SC;,,,,,1.¨Ï¥Î«e½Ð¸Ô¾\Plegridy¹w¥R¶ñµ§«¬ª`®g²Gª`®g«ü¤Þ¡C 2.¶J¦s¦b­ì¥]¸Ë¤¤¥HÁ×§K¥ú·Ó¡C¶J¦s¦b¦B½c (§NÂÃ)¡A2-8¢XC¡C½Ð¤Å§N­á¡C¦Û¦B½c¨ú¥X«á¥i©ó«Ç·Å(³Ì°ª25¢XC)«O¦s³Ì¦h30¤Ñ¡C­Y»Ý­n¡A¥i¤£¥u¤@¦¸¦Û¦B½c¨ú¥X¦A©ñ¦^§NÂÃ¡C¦ý¸m©ó¦B½c¥~ªºÁ`©M®É¶¡¤£¶W¹L30¤Ñ¡C 3.¨C¦¸ª`®g®É¡A½Ð¾¨¶q¦b¦P¤@¤Ñªº¦P¤@®É¶¡¨Ï¥ÎPlegridy¡C 4.½ÐÅÜ´«±z¥Ö¤Uª`®gªº³¡¦ì¡C½Ð¤Å¦b¬Û¦Pªºª`®g³¡¦ì³sÄòª`®g¡C 5.½Ð³W«ßªº¥ÎÃÄ¡C­Y±z§Ñ°O¥ÎÃÄ¡A½Ð¦b³Ìµu®É¶¡¤º¸Éª`®g¡A¤§«á«h·Ó±`ª`®g¡CµM¦Ó¡A¦b7¤Ñ´Á¶¡¤º½Ð¤Åª`®g¦h©ó1¾¯¡C¤£¥i¦P®Éª`®g2¾¯¨ÓÀ±¸É§Ñ°Oª`®gªº¾¯¶q¡C
IGLU1,Glucose,(¤ÆÀø½Õ°t¥Î) Glucose inj 5%¡A 1000mL,MSIV,Provision of calories and/or fluid replacement.,Hypersensitivity to corn or corn products; hypertonic solutions in patients with intracranial or intraspinal hemorrhage¡A diabetic coma¡A or delirium tremens¡A especially if dehydrated; severe dehydration; glucose-galactose malabsorption syndrome.,Cardiovascular: Edema¡A localized phlebitis¡A phlebitis¡A venous thrombosis Central nervous system: Confusion¡A loss of consciousness Endocrine & metabolic: Acidosis¡A dehydration¡A glycosuria¡A hyperglycemia¡A hyperosmolar syndrome¡A hypervolemia¡A hypokalemia¡A hypomagnesemia¡A hypophosphatemia¡A hypovolemia¡A ketonuria¡A polydipsia Local: Local pain¡A local tissue necrosis Renal: Polyuria Respiratory: Pulmonary edema¡A tachypnea Miscellaneous: Fever,30¢J¥H¤UÁ×¥ú,¤ÆÀø½Õ°t¥Î,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
IALVO,Teriparatide,Alvosteo inj 20mcg/80microliters¡A 2.4mL,META,Postmenopausal osteoporosis¡A High risk of fracture or have failed or are intolerant to other osteoporosis therapy. Osteoporosis¡A Primary or hypogonadal in men; at high risk for fracture or have failed or are intolerant to other osteoporosis therapy. Osteoporosis due to systemic glucocorticoid therapy (daily dose equivalent to ?5 mg prednisone)¡A High risk of osteoporosis-induced fractures¡A including individuals with a history of osteoporotic fractures¡A multiple fracture risk factors¡A or have failed or are intolerant to other osteoporosis treatments.,Patients with known allergies to teriparatide or any of its excipients¡A including angioedema and anaphylaxis.,Common Gastrointestinal: Nausea (8.5% to 14% ) Musculoskeletal: Arthralgia (10.1% ) Other: Pain (21.3% ) Serious Cardiovascular: Angina pectoris (2.5% )¡A Orthostatic hypotension (5% )¡A Syncope (2.6% ) Dermatologic: Calcinosis cutis Endocrine metabolic: Hypercalcemia (Transient¡A 6% to 11%; verified on consecutive measurements¡A 1% to 3% ) Immunologic: Anaphylaxis¡A Hypersensitivity reaction Musculoskeletal: Osteosarcoma Other: Angioedema,2-8¢XC¦B½cÁ×¥ú§NÂÃ¡A¤£¥i§N­á,20 mcg subcutaneous injection once daily in the thigh or abdomen. Patients are advised to supplement calcium and vitamin D if their daily intake is insufficient.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ©|¥¼¥H¨x¥\¯à¤£¥þªº¯f¤H¶i¦æ¬ÛÃö¬ã¨s¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ©|µL¼Æ¾Ú¥i¥Î©óµû¦ôÃh¥¥°ü¤k±µ¨üteriparatideªvÀø«áµo¥Í»PÃÄª«¬ÛÃöªº­«¤j¥ý¤Ñ¯Ê³´¡B¬y²£©Î³y¦¨¥ÀÅé©Î­L¨à¤£¨}µ²ªG¤§­·ÀI¡C ½T»{Ãh¥¥«á¡AÀ³¦Ò¼{°±¥ÎAlvosteo¡C °Êª«¬ã¨s¤¤¡A¥Ö¤U§ë»P¬Û·í©ó¤HÅé¨C¤é«ØÄ³¾¯¶q¡e20·L§J(mcg)¡f60­¿¥H¤Wªºteriparatide(®Ú¾ÚÅéªí­±¿n¡Amcg/m2)¡A­L¹«°©Àf²§±`ªºµo¥Í²v·|¼W¥[¡F¥Ö¤U§ë»P¬Û·í©ó¤HÅé¾¯¶qªº120­¿¥H¤W¡A¥®¹«·|¦³¥Íªø¿ð½w¤Î¬¡°Ê¤O­°§Cªº±¡ªp¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ©|¤£²M·¡teriparatide¬O§_·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡B¼vÅT¤HÃþªc¨Å¶q©Î¹ï¥H¥À¨Å­÷ÁýÀ¦¨à¦³¼vÅT¡C ­÷¨Å´Áªº°ü¤kÀ³Á×§K¨Ï¥ÎAlvosteo¡C,SC;,,,,,1. ¤£¥i±Nª`®gµ§¥d¦¡ºÞ¤§¤º§tÃÄ²GÂà²¾¦Üª`®g°wµ©¡C 2. ªì¦¸ªvÀøÀ³¦b¯f¤H¥i¥H§¤©Î½ö¤UªºÀô¹Ò§ë»P¡A¥H¨¾µo¥Í«º¶Õ©Ê§C¦åÀ£¯gª¬¡C
ICOSE,Secukinumab,Cosentyx 150mg prefilled pen,HIMM,Ankylosing spondylitis Plaque psoriasis (Moderate to Severe)¡A In patients who are candidates for systemic therapy or phototherapy Psoriatic arthritis,Hypersensitivity to secukinumab or any component of the product.,[Common] Diarrhea (2.6% to 4.1% )¡A Nasopharyngitis (Ankylosing spondylitis¡A 2% or more ; plaque psoriasis¡A 11.4% to 12.3% ; psoriatic arthritis¡A 2% or more )¡A Upper respiratory infection (Ankylosing spondylitis¡A 2% or more ; plaque psoriasis¡A 2.5% to 3.2% ; psoriatic arthritis¡A 2% or more ) [Serious] Crohn's disease (Ankylosing spondylitis¡A 0.87% )¡A Crohn's disease¡A Exacerbation (Plaque psoriasis¡A 0.09% )¡A Inflammatory bowel disease¡A Ulcerative colitis (Ankylosing spondylitis¡A 0.5%; plaque psoriasis¡A 0.06% )¡A Ulcerative colitis¡A Exacerbation (Plaque psoriasis¡A 0.06% )¡A Anaphylaxis¡A Infectious disease (Ankylosing spondylitis¡A 31% ; plaque psoriasis (up to 12 weeks)¡A 28.7%; plaque psoriasis (up to 52 weeks)¡A 47.5% ; psoriatic arthritis¡A 29% ),2-8¢JÁ×¥ú¤Å§N­á,SC¡A plaque psoriasis 300 mg weeks 0¡A 1¡A 2¡A 3¡A and 4¡A followed by every 4 weeks.( some patients may only need 150 mg) Psoriatic arthritis¡A ankylosing spondylitis¡A Non-radiographic axial spondyloarthritis¡A 150 mg weeks 0¡A 1¡A 2¡A 3¡A and 4¡A followed by 300 mg every 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,¡½The removable cap contains natural rubber latex and should not be handled by latex-sensitive individuals. ¡½Allow Sensoready(R) pen to reach room temperature (15 to 30 minutes) before injecting; administer within 1 hour after removing from refrigerator. ¡½Administer each injection at a different anatomic location (eg¡A upper arms¡A thighs¡A or any quadrant of abdomen) than the previous injection; avoid areas where skin is tender¡A bruised¡A erythematous¡A indurated¡A or affected by psoriasis.
IBNT6M,SARS-CoV-2 Spike glycoprotein [mRNA],Pfizer-BioNTech (6M-4·³) 0.2mL/dose (0.4mL/vial),HIMM,The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 months to 4 Years of Age,Hypersensitivity to the active substance or to any of the excipients.,Common Dermatologic: Erythema at injection site¡A Injection site pain¡A Swelling at injection site. Musculoskeletal: Arthralgia¡A Myalgia. Neurologic: Headache. Other: Fatigue¡A Fever¡A Shivering. Serious Gastrointestinal: Appendicitis. Immunologic: Anaphylaxis¡A Hypersensitivity reaction.,¹B¿éª¬ºA¦Ó©w¸Ô¾\¥é³æ,6 months to 4 years: Primary series¡A 0.2 mL IM for 2 doses¡A administered 3 weeks apart¡A followed by a third dose (0.2 mL) administered at least 8 weeks after the second dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤£¾A¥Î©ó5·³¥H¤Wªº­Ó¤H¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¤£¾A¥Î©ó5·³¥H¤Wªº­Ó¤H¡C,IM;,,,,,1.¨C²~(0.4 mL)¤À´²²G¡A¸g¥H2.2mLªº0.9%´â¤Æ¶uª`®g²G¶i¦æµ}ÄÀ«á¡A§t¦³10¾¯¨C¾¯0.2mLªºª`®g²G¡C 2.¥¼¶}«ÊªºÃÄ²~¥i¦b8-30¢XCªº·Å«×¤U«O¦s12¤p®É¡A¥B­º¦¸¬ï¨ëÃÄ²~¤§«á¥i«O¦s12¤p®É¡A³Ì¦h¦@«O¦s 24¤p®É¡C 3.¥¼¶}«ÊªºÃÄ²~¦b¦b2-8¢XC¥i«O«ù¦w©w¹F10¶g¡C
IVEK,Remdesivir,Veklury inj 100mg (¤½¶O/­á´¹),QANB,Hospitalized patients of COVID-19,History of clinically significant hypersensitivity to remdesivir or any component of the product.,Common: Gastrointestinal: Nausea (3% to 7% ) Serious: Cardiovascular: Cardiac arrest Hepatic: ALT/SGPT level raised (2% to 7% )¡A Aspartate aminotransferase serum level raised (3% to 6% )¡A Hepatotoxicity Immunologic: Anaphylaxis¡A Hypersensitivity reaction (Less than 2% ) Other: Infusion reaction,30¢J¥H¤U,Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement. Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 10 days. (12 years or older and at least 40 kg) Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement (12 years or older and at least 40 kg) Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 10 days Children <12 years: 3.5 kg to <40 kg: IV: Loading dose: 5 mg/kg/dose on day 1¡A followed by 2.5 mg/kg/dose once daily,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¥Ø«e¥¼¦³¨x¥\¯à¤£¥þªºÃÄª«°Ê¤O¾Ç¡C¶}©l¨Ï¥Î«e»P±µ¨üªvÀø´Á¶¡À³ÀËÅç¨xÅ¦¥\¯à¡C [Micromedex] Consider discontinuation if ALT levels increase to greater than 10x ULN. Discontinue if ALT elevation is accompanied by signs or symptoms of liver inflammation.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥u¦³¦b¼ç¦b®Ä¯q¶W¶V¼ç¦b­·ÀIªº±¡ªp¤U¡A¤~¥i¹ï¥¥°ü©Î¥i¯àÃh¥¥ªº°ü¤k§ë¤©remdesivir¡C ¦b¥HÃh¥¥¤§¤j¹«©M¨ß¤l©Ò¶i¦æªº­F­L - ­L¨àµo¨|¼vÅT¬ã¨s¤¤¡AIV §ë¤©¾¯¶q°ª¹F20²@§J / ¤½¤çªºremdesivir¡i¨ä¥D­n´`Àô¥NÁÂª«¡]®ÖäÃþ¦üª«¡^ªº¥þ¨­¼ÉÅS¶q¡]AUC¡^¬Û·í©ó®Ö­ã¾¯¶q©Ò¹F¨ì¤§¼ÉÅS¶qªº4­¿¡^¡j¨Ã¥¼¹ï­F­L-­L¨àªºµo¨|³y¦¨¥ô¦ó¼vÅT¡C ¦b¤@¶µ¥H¥À¤j¹«©Ò¶i¦æªº¥Í¨|¤O»P¦­´Á­F­Lµo¨|¼vÅT¬ã¨s¤¤¡A©óÀR¯ß§ë¤©remdesivir 10²@§J/¤½¤ç¡i¨ä¥D­n´`Àô¥NÁÂª«¡]®ÖäÃþ¦üª«¡^ªº¥þ¨­¼ÉÅS¶q¡]AUC¡^¬Û·í©ó®Ö­ã¾¯¶q©Ò¹F¨ì¤§¼ÉÅS¶qªº1.3­¿¡j¤§«á¡A´¿Æ[¹î¨ì¶ÀÅé¡B­F­LµÛ§É¤Î¦s¬¡­F­L´î¤Öªº²{¶H¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]À³Åv¿ÅªvÀøªº®Ä¯q»PÁý­÷¥À¨Åªº®Ä¯q¡AµM«á¨M©wÄ~Äò©Î°±¤î­÷¨Å¡C ¦b°Êª«¬ã¨s¡]¤j¹«¡^¤¤¡A´¿¦b§ë¤©remdesivir¤§¥À¹«©Ò­÷¨Åªº¥J¹«Åé¤ºÀË¥Xremdesivir¤Î¨ä¥NÁÂª«¡A³o¥i¯à¬Oremdesivir¥X²{©ó¥À¨Å¤¤©Ò­P¡C,IVD;,19mLª`®g¥Î¤ô,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¹ï¦¨¤H»PÅé­«¤j©ó 40¤½¤çªº¨àµ£¡A²Ä1¤Ñªº§ëÃÄ(Remdesivir 200mg)À³¨Ï¥Î2¤ä¤p²~¡A¨ÃÀ³±N¨C¤ä¤p²~¤¤ªº20mL·»²G(¦@40mL)¥[¤J¥Í²z­¹ÆQ¤ô¤¤¡A¨ÏÁ`Åé¿n¹F¨ì100mL©Î250mL¡C¥H30-120¤ÀÄÁªº®É¶¡ÀR¯ß¿éª`¡C ¦Ü©ó²Ä2¤Ñ°_ªº§ëÃÄ(Remdesivir 100mg)¡A«hÀ³±N1¤ä¤p²~¤¤ªº20mL·»²G¥[¤J¥Í²z­¹ÆQ¤ô¤¤¡A¨ÏÁ`Åé¿n¹F¨ì100mL©Î250mL¡C¥H30-120¤ÀÄÁªº®É¶¡ÀR¯ß¿éª`¡C,1.±N19mLª`®g¥Î¤ô¥[¤J¤p²~¤¤¡A¥ß§Y¦A«×®¶·n30¬í¡CÀR¸m2-3¤ÀÄÁ¤§«á¡AÀ³½T»{¤p²~¤¤ªº·»²G¬O§_¼á²M(¿@«×¡G5mg/mL)¡C¦pªG¤p²~¤¤ªº¤º®eª«¥¼§¹¥þ·»¸Ñ¡AÀ³­«½Æ®¶·n¤p²~¡A¨Ï¤º®eª«¼á²M¡C 2.¿éª`§¹¦¨¤§«á¡A½Ð¥Î¦Ü¤Ö30²@¤Éªº0.9%¥Í²z­¹ÆQ¤ô¨R¬~¡C 3.¥Hª`®g¥Î¤ô½Õ»s¤§«á¡Aµ}ÄÀªºremdesivir·»²G¦b20-25¢Jªº·Å«×¤UÀ³©ó4¤p®É¤º¶i¦æ»s³Æ¡A¦b2-8¢Jªº·Å«×¤UÀ³©ó24¤p®É¤º¶i¦æ»s³Æ¡C 4.»s³Æ¦nªºµ}ÄÀ·»²G¦b«Ç·Å(20-25¢XC)¤U¥iºû«ù¦w©w4¤p®É¡A¦b2-8¢XCªº¦B½c¤¤¥iºû«ù24¤p®É¡C
IGLYP8,Terlipressin,Glypressin inj 0.1mg/mL¡A 8.5mL,HM,Bleeding oesophageal varices¡A and hepatorenal syndrome (HRS) Type 1,Pregnancy. Hypersensitivity to terlipressin or to any of the excipients. In patients with septic shock with a low cardiac output terlipressin should not be used. Contraindicated in patients with current or recent (within the last 3 months) ischaemic cardiovascular disease.,(1-10%) Paleness¡A hypertension¡A abdominal pain¡A nausea¡A and diarrhea. Hyponatremia¡A ischemia¡A bradycardia¡A respiratory failure¡A and Torsade de pointes.,2-8¢J§NÂÃÁ×¥ú,[Bleeding oesophageal varices] Initial: 2 ampoules IV Q4H¡A maintained until bleeding has been controlled but up to a maximum of 48 hours. Body weight <50kg : 1 ampoule IV Q4H; maintenance dosage (if necessary)¡A 1 ampoule IV Q4H for a maximum of 3 days. Duration of treatment must not exceed 5 days. [Type 1 hepatorenal syndrome] 3-4 ampoules IV Q24H¡A divided as 3 or 4 administrations. In the absence of any reduction of the serum creatinine after 3 days of treatment¡A cessation of treatment is advised. In the other cases¡A treatment is to be pursued until the obtaining either of a serum creatinine < 130 £gmol/litre or of a drop of at least 30 % in the serum creatinine with respect to the value measured at the time of diagnosis of hepatorenal syndrome. The standard average duration of treatment is 10 days.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥´Á¶¡terlipressin ªvÀø¬O¸T§Ò¡C¥Ø«e¤w¸gÅã¥Ü¡A©óÃh¥¥ªì´Á¡Aterlipressin ·|³y¦¨¤l®c¦¬ÁY©M¼W¥[¤l®c¤ºÀ£¡A¥H¤Î­°§C¤l®c¦å¬y¡CTerlipressin ¥i¯à¹ïÃh¥¥¤Î­L¨à¦³®`¡C °Êª«¸ÕÅçµ²ªGÅã¥Ü¨ß¤l±µ¨üterlipressin ªvÀø«á¡A¥X²{¦Ûµo©Ê¬y²£©M·î§Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Ãö©ó terlipressin ¶i¤J¨ì¤H¨Å¥Äªº±¡ªp¡A¥Ø«e¨Ã¨S¦³¨¬°÷ªº¸ê®Æ¡C­÷¨Åªº°ü¤k¤£¯à¨Ï¥Îterlipressin¡C,IVPUSH;,,¡iD5W¡j¥i¿ï ¡C,IV bolus slowly >2 minutes. Flush the line after administration.,Total dose: 2 to 12 mg/day. A dose of teripressin in 5% dextrose 50mL¡A administered via IV pump. (³Æµù¡G¦¹¥Îªk«D¥é³æ®Ö­ã¡A¬°¼Ú¬wÂåÃÄºÞ²z§½¹ïµo¥Xªº«ØÄ³¡A¥Î©ó²Ä¤@«¬¨xµÇ¯g­Ô¸s¡ATFDA¤´¦bµû¦ô¤¤¡A ¦¹ÃÄ¥é³æ¤£«ØÄ³¥[¤J¨ä¥L·»²G¡A¦]¦¹¥Ø«e¥¼³]©wIVD³~®|¡C),1. °²¨ÏªvÀø«ùÄò¼Æ¤Ñ¡A¥²¶·ºÊ´ú§¿¶q¤Î¦å²G¹q¸Ñ½è¡C¬°¤FÁ×§Kª`®g³¡¦ì§½³¡Ãa¦º¡A¤@©w­nÀR¯ßª`®g¡C 2. [UpToDate] ¥Ñ©PÃä©Î¤¤¥¡ÀR¯ß½wºCµ¹ÃÄ¡]»Ý¶W¹L2¤ÀÄÁ¡^¡Aµ¹ÃÄ«á½Ð¨R¬~ºÞ¸ô¡C 3. ¤£¥i¶W¹L«ØÄ³¾¯¶q (1.7 mg terlipressin /4 ¤p®É)¡A¦]¬°ÄY­«¤£¨}§@¥Î­·ÀI»P¾¯¶q¬ÛÃö¡CªvÀø´Á¶¡µo¥Í¤ß²v¹L½w¥i¨Ï¥Î atropine ªvÀø¡C
ILATO,Ketorolac,Laston inj 30mg/1mL,CNEU,Short-term (<=5 days) use for relieving moderate to severe acute pain in patients unable to take orally¡A typically post-surgery,1. Allergic history to this medication. 2. History of allergy due to Aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). 3. Prohibited within 14 days after Coronary Artery Bypass Graft (CABG) surgery.,Common: Edema (1-10%)¡A Hypertension (1-10%)¡A Injection site pain (injection¡A 1-10%)¡A Pruritus (1-10%)¡A Rash (1-10%)¡A Sweating (1-10%)¡A Abdominal pain (1-10%)¡A Constipation¡A Diarrhea¡A Flatulence (1-10%)¡A Heartburn (1-10%)¡A Indigestion (1-10%)¡A Nausea (greater than 10%)¡A Stomatitis (1-10%)¡A Vomiting (1-10%)¡A Anemia (1-10%)¡A Purpuric disorder (1-10%)¡A Dizziness (1-10%)¡A Headache (greater than 10%)¡A Somnolence (1-10%)¡A Burning sensation in eye (20-40%)¡A Corneal edema (1-10%)¡A Eye infection (1-10%)¡A Eye irritation (1-10%)¡A Iritis (1-10%)¡A Pain in eye (1-10%)¡A Superficial keratitis (1-10%)¡A Nasal irritation (15%)¡A Pain of nose (13%) Serious: Myocardial infarction¡A Thrombotic tendency observations¡A Erythroderma¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Gastrointestinal hemorrhage (1-10%)¡A Gastrointestinal perforation¡A Gastrointestinal ulcer (1-10%)¡A Melena (<1%)¡A Blood coagulation disorder with prolonged bleeding time (1-10%)¡A Hematoma¡A Hemorrhage¡A Postoperative hemorrhage¡A Hepatitis (<1%)¡A Hepatotoxicity¡A Increased liver function test (1-10%)¡A Jaundice (<1%)¡A Non-allergic anaphylaxis¡A Cerebrovascular accident¡A Corneal thinning¡A Perforation of cornea¡A Hearing loss (<1%)¡A Injury of kidney¡A Nephrotic syndrome¡A Renal failure (<1%)¡A Tubulointerstitial nephritis (<1%)¡A Bronchospasm¡A Dyspnea (<1%)¡A Pulmonary edema (<1%),25¢J¥H¤U¡BÁ×¥ú¶J¦s(¤ºªþ¶Â¦âÁ×¥ú³U),Not recommended for children. Single Dose Therapy: (1) Intramuscular Injection: <65 years: 60mg/dose; >=65 years¡A renal insufficiency¡A body weight <50kg: 30mg/dose. (2) Intravenous Injection: <65 years: 30mg/dose; >=65 years¡A renal insufficiency¡A body weight <50kg: 15mg/dose. Repeat Dosing Regimen (Intravenous or Intramuscular Injection): <65 years: 30mg q6h (maximum 120mg/day); >=65 years¡A renal insufficiency¡A body weight <50kg: 15mg q6h (maximum 60mg/day),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 1st and 3 rd trimesters,[¥é³æ] ¥»ÃÄ¦]·|¼vÅT­L¨à¤§´`Àô¡B§í¨î¤l®c¦¬ÁY¥H¤Î·|§í¨î·s¥Í¨à¤§Prostaglandin¡A ¬G§Ò¥Î©ó¥¥°ü¡BÁ{¬Ö¤Î±Â¨Å°ü¤k¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;IVD;IVPUSH;,,¡iN/S¡j¥i¿ï ¡C,administer over 15 seconds,15mg or 30mg in 0.9% NaCl 50mL IVD infused over 30 minutes,1. ÀR¯ßª`®g (bolus) ®É¶¡¤£±o§C©ó15¬í¡A¦Ù¦×ª`®gÀ³±Ä½wºC¤Î²`³¡§ë»P¡C 2. ¸T¥Î©ó´ÕºÞ¤º»Pµw½¤¥~µ¹ÃÄ¡C
LPSE,Triprolidine + Pseudoephedrine,Pseu solution 60mL (0.25+6mg/mL),HIMM,Temporary relief of symptoms (runny nose¡A nasal congestion¡A sneezing¡A itchy nose or throat¡A itchy/watery eyes¡A nasal passages swelling) associated with common cold¡A hay fever (allergic rhinitis)¡A or other upper respiratory allergies.,Hypersensitivity to Pseu solution¡A pseudoephedrine¡A triprolidine or any component of the formulation.,Tachycardia¡A dizziness¡A drowsiness¡A excitement (transient)¡A fatigue¡A headache¡A insomnia¡A nervousness¡A diaphoresis¡A weight gain¡A abdominal pain¡A diarrhea¡A increased appetite¡A nausea¡A xerostomia¡A dysuria¡A arthralgia¡A weakness¡A pharyngitis¡A thickening of bronchial secretions.,25¢J ¥H¤UÁ×¥ú,Ingredient content: Triprolidine 0.25 mg/mL + Pseudoephedrine 6 mg/mL Adults and Children ?12 years: 10 mL every 4-8 hours as needed; MAX 4 doses (40 mL) per 24 hours. Children 6 to <12 years: 5 mL every 4-8 hours as needed; MAX 4 doses (20 mL) per 24 hours. Children 2-5 years: 2.5 mL/dose. Children 6 months - under 2 years: 1.25 mL/dose.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¥Ø«e©|µL¸ê°T¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Triprolidine: Compatible Pseudoephedrine: Human Data Suggest Risk [¥é³æ] Ãh¥¥´Á¤§¦w¥þ©Ê©|¤£©ú½T¡A¦]¦¹Ãh¥¥°ü¤k°£«D¥²­n¡AÁ×§K¨Ï¥Î¥»«~¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Triprolidine: Limited Human Data¡XProbably Compatible Pseudoephedrine: Limited Human Data¡XProbably Compatible [¥é³æ] ±Â¨Å¤§°ü¤k«h¶·¦Ò¼{°±¥Î¥»«~©Î°±¤î±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,¥»«~¬°¤fªA²G¾¯¡A¶È¨Ñ¤fªA¨Ï¥Î¡C
IHUM5,Adalimumab,Humira inj 40mg/0.4mL,HIMM,Monotherapy or in combination with methotrexate or other DMARDs for reducing of the signs & symptoms & to inhibit the progression of structural damage in adult patients with moderately to severely active RA. Monotherapy or in combination with other DMARDs for reducing the signs & symptoms of active arthritis in patients with psoriatic arthritis. Reduction of signs & symptoms in patients with active ankylosing spondylitis. Reduction of signs & symptoms & inducing & maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy or if they have also lost response to or are intolerant to infliximab. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy & when other systemic therapies are medically less appropriate. Reduction of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients 13-17 years.,Known hypersensitivity to adalimumab or any of the excipients of Humira.,Common: Injection site disorder (5-20%)¡A Injection site pain (Pediatric¡A 6-19%)¡A Rash (12%)¡A Headache (12%)¡A Sinusitis (11%)¡A Upper respiratory infection (17%) Serious: Atrial fibrillation (Less than 5%)¡A Cardiac arrest (Less than 5%)¡A Cardiac dysrhythmia (Less than 5%)¡A Chest pain (Less than 5%)¡A Congestive heart failure¡A Hypertensive encephalopathy (Less than 5%)¡A Myocardial infarction (Less than 5%)¡A Palpitations (Less than 5%)¡A Pericardial effusion (Less than 5%)¡A Pericarditis (Less than 5%)¡A Syncope (Less than 5%)¡A Erythema multiforme¡A Stevens-Johnson syndrome¡A Gastrointestinal hemorrhage (Less than 5%)¡A Agranulocytosis (Less than 5%)¡A Erythrocytosis (Less than 5%)¡A Leukopenia (Infrequent)¡A Pancytopenia (Rare)¡A Thrombocytopenia (Infrequent)¡A Thrombosis¡A Leg (Less than 5%)¡A Hepatic failure¡A acute¡A Hepatic necrosis (Less than 5%)¡A Reactivation of hepatitis B viral hepatitis¡A Hepatosplenic T-cell lymphoma¡A Herpes zoster¡A Hypersensitivity reaction (Pediatric¡A 5-6%)¡A Malignant lymphoma¡A Bone necrosis (Less than 5%)¡A Demyelinating disease of central nervous system (Rare)¡A Peripheral demyelinating neuropathy (Rare)¡A Subdural hematoma (Less than 5%)¡A Bronchospasm (Less than 5%)¡A Dyspnea (Less than 5%)¡A Pleural effusion (Less than 5%)¡A Tuberculosis¡A Infectious disease (Pediatric¡A 45-78%)¡A Invasive fungal infection,2-8¢JÁ×¥úÁ×§K§N­á,SC¡A Adult Rheumatoid arthritis¡A psoriatic arthritis¡A ankylosing spondylitis¡A polyarticular juvenile idiopathic arthritis 40 mg every other week. If not taking concomitantly with methotrexate¡A increasing the dosing frequency to 40 mg weekly may derive additional benefit. Crohn's disease¡A ulcerative colitis 160 mg initially at day 1 (as four 40-mg in 1 day or as two 40-mg/day for 2 consecutive days)¡A followed by 80 mg 2 weeks later (day 15). Another 2 weeks later (day 29) begin a maintenance dose of 40 mg every other week. Patients who experience decrease in their response may benefit from an increase in dose intensity to 40 mg every week. Plaque psoriasis Initially 80 mg¡A followed by 40 mg given every other week starting 1 week after the initial dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
IEV71,Inactivated Enterovirus 71 virus particles,EnVAX-A71 inj 0.5mL/dose (°ê¥ú),HIMM,Primary immunization for infants and toddlers aged 2 months to less than 6 years to prevent diseases caused by enterovirus type 71 infection.,Use in individuals with a history of severe allergic reactions to this vaccine or any of its components¡A including formaldehyde.,Pain (21.57%)¡A tenderness (17.59%)¡A redness (13.42%)¡A swelling (7.36%)¡A bruising (3.88%)¡A fever (?38¢XC) (10.34%)¡A nausea/vomiting (6.56%)¡A diarrhea (6.86%)¡A decreased appetite (12.52%)¡A fatigue (10.74%).,2-8¢JÁ×¥ú§NÂÃ¡AÁ×§K§N­á¡C,Infants aged 2 months to <6 years: administered via intramuscular injection in the arm or outer thigh. Each dose is 0.5 mL¡A given in two doses with a 28-day interval. Shake well and visually inspect for abnormalities before use. Need for additional booster doses not established.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¤£¾A¥Î¡C¥»¬Ì­]¬I¥´±Ú¸s¬°2­Ó¤ë¥H¤W¦Ü¥¼º¡6·³¤§À¦¥®¨à¡C ¥Ø«e©|µL¥»¬Ì­]¨Ï¥Î©óÃh¥¥°ü¤k¤§¬ÛÃö¸ê®Æ¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¤£¾A¥Î¡C¥»¬Ì­]¬I¥´±Ú¸s¬°2­Ó¤ë¥H¤W¦Ü¥¼º¡6·³¤§À¦¥®¨à¡C ¥Ø«e©|µL¥»¬Ì­]¨Ï¥Î©ó±Â¨Å´Á¶¡°ü¤k¤§¬ÛÃö¸ê®Æ¡C,IM;,,,,,1. ¥H¦Ù¦×ª`®gµ¹ÃÄ¡A¤£¥i¥H¦åºÞ¤º©Î¥Ö¤U¤è¦¡¬I¥´¡C 2. ¥»¬Ì­]ÀR¸m®É¥~Æ[¬°µL¦â²GÅé¡A¨Ï¥Î«eÀ³¥ý±N¬Ì­]¦^·Å¦Ü«Ç·Å¡A¨Ï¥Î«eÀ³·n¤Ã¬°²V¿B¥Õ¦âÄa¯B²G¡A¨Ã¥ØµøÆ[¹î½T»{¨S¦³²§±`¡C 3. ¥Ø«e©|¥¼¬ã¨s¥»¬Ì­]»P¨ä¥L¬Ì­]¨Ö¥Î®É¬O§_¼vÅT§K¬Ì¤ÏÀ³¡C²Ä¤T´ÁÁ{§É¸ÕÅç¤¤¡A³W©w¬I¥´¨C¾¯¥»¬Ì­]¤§«e14¤Ñ¸T¤î¬I¥´¨ä¥L¬¡©Ê´î¬r©Î¤£¬¡¤Æ¬Ì­]¡C¥Ø«eµL¸ê®Æ»¡©ú¬I¥´¥»¬Ì­]«á28¤Ñ¤º¬I¥´¨ä¥L¬Ì­]¹ï©ó§K¬Ì¤ÏÀ³ªº¼vÅT¡C
IMENO,Minocycline,Menocik inj 100mg,QANB,Infections caused by Gram-positive and Gram-negative bacteria¡A Rickettsia¡A Chlamydia¡A and giant filterable viruses.,Hypersensitivity to any tetracycline or any component of the product.,Common: Dizziness (9%)¡A Headache (23%)¡A Fatigue (9%) Serious: Acidosis¡A Hyperphosphatemia¡A Clostridioides difficile infection¡A Enamel hypoplasia¡A Tooth discolored¡A Autoimmune hepatitis¡A Hepatic failure¡A acute¡A Hepatitis¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Systemic lupus erythematosus¡A Systemic lupus erythematosus-related syndrome¡A Arrest of bone development AND/OR growth¡A Lightheadedness¡A Pseudotumor cerebri¡A Pseudotumor cerebri¡A Azotemia¡A Serum blood urea nitrogen raised¡A Serum sickness caused by drug,«Ç·Å(25¢XC¥H¤U)³±²D³BÁ×¥ú,Adult: 200 mg orally/IVD over 1 hour followed by 100 mg orally/IVD q12h infused over 1 hour (only use IV therapy if oral therapy is not adequate or not tolerated; switch to oral therapy as soon as possible). MAX IV daily dose: 400 mg. Children (Older than 8 years): 4 mg/kg orally/IV initially¡A then 2 mg/kg orally/IV q12h. MAX: 200 mg in 24 hours.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¹ï©óªvÀø°ª¦MÀI¸s¯f¤H(§³®W©Î¤wª¾µÇ¥\¯à©Î¨x¥\¯à¤£¥þ)¦bªvÀø«e©MªvÀø´Á¶¡§¡»Ý§@¨x¥\¯à©MµÇ¥\¯àÀË¬d¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated ¡V 2nd and 3 rd trimesters,See Tetracycline. Tetracycline: Contraindicated¡X2nd and 3rd Trimesters [¥é³æ] ¸g°Êª«¹êÅçµ²ªGÅã¥Ü¥|Àô¯ÀÃþ¯à³q¹L­L½L¦b­L¨à¦U²ÕÂ´¤º§¡¸gµo²{¡A¯à¹ï¦¨ªø¤¤¤§­L¨à¨ã¦³¬r©Ê(³q±`»P­L¨à°©Àfµo¨|©µ½w¦³Ãö)¡C¹ï§³®W°Êª«¦­´Á¦æ¥|Àô¯À¾¯ªvÀø¤Þ­P¹ï­L¤§¬r©Ê¥ç¦³¹ê¨Ò¡C §³®W´Á¶¡¨Ï¥ÎMinocycline¤§¦w¥þ©Ê©|¥¼½T©w¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,See Tetracycline. Tetracycline: Compatible [¥é³æ] ­÷¨Å°ü¤H¤§¨Å¥Ä¤º±o¦³¥|Àô±ÚÃþ¤§¦s¦b¡C©Ò¦³¥|Àô±Ú¾¯§¡¦b¤Æ°©²ÕÂ´¤º§Î¦¨Ã­©w¤§¶t½Æ¦XÅé¡C¹ï¦­²£¨à¨C¹j¤»¤p®Éµ¹¤©25²@§J/¤½¤ç¥|Àô¯À¤fªA¾¯´¿µo²{µÌ°©¥Íªø²v´î§C¤§²{¶H¡A¦¹ºØ²{¶H¬°¥i°f©Ê¡A·íµ¹ÃÄ¤¤¤î«á§Y¥i«ì´_¡C,IPLE;IVD;,IV: Reconstitute with 5 mL sterile water for 100 mg injection.,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Infuse over 60 minutes; avoid rapid administration. Reconstitute with 5 mL sterile water for injection and further dilute immediately in 100 to 1000 mL of NS¡A dextrose injection¡A or dextrose and sodium chloride injection.,½Ð¤Å¥Î¥ô¦ó§t¶t·»²Gµ}ÄÀ¡A¦]¬°¦³¨I¾ý­·ÀI¡A¦b¤¤©Ê©MÆP©Ê·»²G¤¤§ó®e©öµo¥Í¡C °t»s¦¨·»²G«á¥i¦b«Ç·Å«O¦s24¤p®É¡A¤£¼vÅT¨ä¤O»ù¡A¦ýµ}ÄÀ«á»Ý¥ß¨è¨Ï¥Î¡C ©µªøÀR¯ßª`®gªºÀøµ{¥i¯à·|¾É­P¦å®ê©ÊÀR¯ßª¢¡C
IMET5,Methylprednisolone,Mepron inj 40mg,HM,Adrenal insufficiency¡A acute shock¡A asthma¡A collagen diseases (systemic autoimmune diseases)¡A allergic reactions¡A and generalized infections.,Systemic fungal infections. Hypersensitivity to methylprednisolone sodium succinate or any constituent of the product. Administration of live virus vaccines; methylprednisolone formulations containing benzyl alcohol preservative are contraindicated in premature infants; IM administration in idiopathic thrombocytopenic purpura; intrathecal administration.,Common: Hypertension¡A Atrophic condition of skin¡A Impaired wound healing¡A Body fluid retention¡A Decreased body growth¡A Hypernatremia¡A Hypokalemia¡A Disorder of gastrointestinal tract¡A Peptic ulcer disease¡A Liver function tests outside reference range (Mild)¡A At risk for infection¡A Muscle weakness¡A Depression¡A Euphoria. Serious: Cardiac dysrhythmia¡A Congestive heart failure¡A Adrenal insufficiency¡A Cushing's syndrome¡A Hyperglycemia¡A Hepatotoxicity¡A Osteoporosis¡A Cerebrovascular accident¡A Infarction of spinal cord¡A Nerve injury¡A Paraplegia¡A Raised intracranial pressure¡A Seizure¡A Tetraplegia¡A Cataract¡A Cortical blindness¡A Glaucoma¡A Acute scleroderma renal crisis¡A Pulmonary tuberculosis.,25¢J¥H¤U,For large dose¡A IV 30mg/kg for 10-20 minutes¡A could repeat every 4-6 hours in 48 hours. In other indications¡A 10-40mg for the first dose¡A adjusted by patient's condition from second dose. For multiple sclerosis¡A 160mg daily for one week¡A then 80mg every two days for one month.,µL»Ý½Õ¾ã¾¯¶q,pulsed IV methylprednisolone(³q±`¾¯¶q¬°¨C¤é1gm )¥i¯à·|¾É­PÃÄª«©Ê¨x·l¶Ë¦p«æ©Ê¨xª¢,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¦]¬°¨Ï¥ÎÃþ©T¾J©M¤HÃþ¥Í´Þ¤§¦³Ãö¬ã¨s©|¤£¨¬¡A¦]¦¹¦¹ÃþÃÄ«~¨Ï¥Î©ó¥¥°ü¡B­÷¨Å¤§¥À¿Ë¤Î¥Í¨|¦~ÄÖ¤§°ü¤k®É¡A »Ý¿Å¶qÃÄ®Ä©M¹ï¥¥°ü¡B­F­L©M­L¨àªº¦MÀI©Ê¨âªÌ¶¡ªº§Q®`±o¥¢¡C ¦bÃh¥¥´Á¶¡´¿¨Ï¥Î¤j¶qµÇ¤W¸¢¥Ö½èÃþ©T¾J¥À¿Ë©Ò¥Íªº·s¥Í¨à¡AÀ³¸Ó¤p¤ßÆ[¹î¬O§_¦³µÇ¤W¸¢¾÷¯à¤£¥þ²{¶Hµo¥Í¡C [Micromedex] Fetal risk cannot be ruled out.,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¦]¬°¨Ï¥ÎÃþ©T¾J©M¤HÃþ¥Í´Þ¤§¦³Ãö¬ã¨s©|¤£¨¬¡A ¦]¦¹¦¹ÃþÃÄ«~¨Ï¥Î©ó¥¥°ü¡B­÷¨Å¤§¥À¿Ë¤Î¥Í¨|¦~ÄÖ¤§°ü¤k®É¡A »Ý¿Å¶qÃÄ®Ä©M¹ï¥¥°ü¡B­F­L©M­L¨àªº¦MÀI©Ê¨âªÌ¶¡ªº§Q®`±o¥¢¡C [Micromedex] Infant risk cannot be ruled out.,IM;IVD;IVPUSH;,40mg²K¥[1-2mLª`®g¥Î¤ô½Õ°tª`®g²G,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,administer slowly over 1 minute,Reconstitute 40mg with 1-2mL water for injection. Dilute with 5% dextrose¡A 0.9% sodium chloride or 5% dextrose and 0.9% sodium chloride injection. [UpToDate] Infused >15-60 minutes. For doses >250 mg¡A infused >30-60 minutes. [Micromedex] Adult: high-dose therapy (30 mg/kg) infused >30 minutes; Pediatric: high doses (15-30 mg/kg or 500-1000 mg/dose) can be diluted to a concentration of 2.5-20 mg/mL in D5W¡A NS and infused over 30-120 minutes.,¤w½Õ°t¦nªº·»²GÀ³§NÂÃ¨ÃÀ³©ó48 ¤p®É¤º¥Î§¹¡C
INSO5,Sodium Chloride,0.9% NaCl 500mL bag(Otsuka),MSIV,Water or electrolyte replenishment.,Hypernatremic and fluid retention syndromes. Immediately following surgery.,Common Cardiovascular: Phlebitis Dermatologic: Injection site extravasation¡A Injection site reaction Endocrine metabolic: Hypervolemia Serious Cardiovascular: Congestive heart failure Endocrine metabolic: Hypernatremia¡A Overhydration Hematologic: Disseminated intravascular coagulation Respiratory: Respiratory distress,30¢J¥H¤U,Individualised dosage. Sodium chloride 0.9% injection contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¨S¦³¸ê®Æ,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¨S¦³¸ê®Æ,IA;IRR;IVD;,,,,To correct acute (<48 hours) or chronic (>48 hours or duration unknown). In general¡A a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia¡A overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours (maximum rate: 8 mEq/L in any 24-hour period).,0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.
INSO250,Sodium Chloride,0.9% NaCl 250mL bag(Otsuka),MSIV,Water or electrolyte replenishment.,Hypernatremic and fluid retention syndromes. Immediately following surgery.,Common Cardiovascular: Phlebitis Dermatologic: Injection site extravasation¡A Injection site reaction Endocrine metabolic: Hypervolemia Serious Cardiovascular: Congestive heart failure Endocrine metabolic: Hypernatremia¡A Overhydration Hematologic: Disseminated intravascular coagulation Respiratory: Respiratory distress,30¢J¥H¤U,Individualised dosage. Sodium chloride 0.9% injection contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¨S¦³¸ê®Æ,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¨S¦³¸ê®Æ,IA;IRR;IVD;,,,,To correct acute (<48 hours) or chronic (>48 hours or duration unknown). In general¡A a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia¡A overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours (maximum rate: 8 mEq/L in any 24-hour period).,0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.
OWEC,Bethanechol Chloride,Wecoli 25mg,SGU,Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention. Treatment of neurogenic atony of the urinary bladder with retention.,Hypersensitivity to bethanechol or any component of the formulation; hyperthyroidism¡A peptic ulcer disease¡A epilepsy¡A asthma¡A pronounced bradycardia or hypotension¡A vasomotor instability¡A coronary artery disease¡A or parkinsonism; mechanical obstruction of the GI or GU tract or when the strength or integrity of the GI or bladder wall is in question; when increased muscular activity of the GI tract or urinary bladder might prove harmful (eg¡A following urinary bladder surgery¡A GI resection and anastomosis¡A possible GI obstruction); bladder neck obstruction¡A spastic GI disturbances¡A acute inflammatory lesions of the GI tract¡A peritonitis¡A marked vagotonia.,Abdominal cramps¡A colic¡A nausea¡A vomiting¡A bloating¡A diarrhea¡A borborygmi¡A salivation¡A frequent urination¡A headache¡A flushing¡A sweating¡A asthma¡A lacrimation¡A miosis¡A hypotension¡A tachycardia¡A malaise¡A and seizure.,25¢J¥H¤U,Adult: Usual dose: 10 to 50 mg 3 to 4 times daily before meals. Minimum effective dose: Initial: 5 to 10 mg; repeat the same dose hourly until effective response or a maximum of 50 mg is reached. Children and adolescents (Limited data): 0.3 to 0.6 mg/kg/day in 3 to 4 divided doses; maximum dose: 10 mg/dose for children.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,[¥é³æ] Bethanechol¬O§_¹ï©ó°Êª«¥Í´Þ¨t²Î¤§¼vÅT©|¥¼¬ã¨s¡C ¨ä¹ïÃh¥¥°ü¤k¨Ï¥Î¥»ÃÄ¤§«á¬O§_¹ï­L¨à³y¦¨¶Ë®`¡A©Î¬O§_·|¼vÅT¥ÎÃÄ¯f¤Hªº¥Í¨|¯à¤O¨Ã¥¼ª¾¡C ¦]¦¹¡ABethanechol À³¸Ó¥u¥Î©ó¦³­¢¤Á»Ý­nªºÃh¥¥°ü¤k¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«eÁÙ¤£ª¾¹D¥»ÃÄ¬O§_·|±Æ©ó¥À¨Å¡C ¦ý¬O¦]¬°¦³¦hºØÃÄ·|±Æ©ó¥À¨Å¡A¥BBethanechol ¹ï©ó±Â¨Å¤§À¦¨à¥i¯à·|²£¥ÍÄY­«°Æ§@¥Î¡F ¦]¦¹¦b¦Ò¼{ÃÄ¹ï¥À¿Ëªº­«­n©Ê¤§«á¡A¦A¦æ¨M©w¬O­n°±¤î­÷¨Å¡A©Î¬O°±¤î¥ÎÃÄ¡C,AC;PO;,,,,,
ETRE,Fluticasone furoate + Umeclidinium + Vilanterol,Trelegy Ellipta 92/55/22 mcg Inhalation Powder,ERSP,Chronic obstructive pulmonary disease,Hypersensitivity to fluticasone¡A umeclidinium¡A vilanterol¡A or any component of the formulation; severe hypersensitivity to milk proteins,1% to 10%: Headache (4%)¡A voice disorder (>=1%)¡A Diarrhea (2%)¡A dysgeusia (2%)¡A constipation (>=1%)¡A oral candidiasis (>=1%)¡A gastroenteritis (1%)¡A Urinary tract infection (>=1%)¡A Influenza (>=1%)¡A Back pain (4%)¡A arthralgia (>=1%)¡A Pneumonia (8%)¡A bronchitis (>=1%)¡A pharyngitis (>=1%)¡A rhinitis (>=1%)¡A sinusitis (>=1%)¡A upper respiratory tract infection (>=1%)¡A cough (1%)¡A oropharyngeal pain (1%) Frequency not defined:Paradoxical bronchospasm <1%¡A postmarketing¡A and/or case reports: Anaphylaxis,Á×¥ú°®Àê30¢J¥H¤U,Oral inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,FLUTICASONE: Compatible Umeclidinium: Unknown Vilanterol: Unknown [¥é³æ] ¥u¦³¦A¼ç¦b®Ä¯q¶W¶Vbeta§@¥Î¾¯¤zÂZ¤l®c¦¬ÁY§@¥Î¤è­±¤§¥i¯à­·ÀIªº±¡ªp¤U¡A ¤~¥i©óÃh¥¥«á´Á»P¤À®Y´Á¶¡¨Ï¥Î,Unknown ¨S¦³¸ê®Æ,FLUTICASONE: No Human Data¡XProbably Compatible Umeclidinium: Unknown Vilanterol: Unknown [¥é³æ](¸`¿ý) ¥Ø«eµL¤HÃþ¸ê®Æ¡A°Êª«¹êÅç¸ê®ÆUmeclidinium·|¶i¤J¨Å¥Ä.,INHL;,,,,,
IWAT500,Water for injection,Water for injection 500mL,NUTR,,,,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,It is for use only as a sterile solvent or diluent vehicle for drugs or solutions suitable for parenteral administration.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,INHL;IRR;IVD;,,,,,
OJADU,Empagliflozin + Metformin,(½Æ¤è) Jardiance Duo 12.5/850mg,META,Disorder of cardiovascular system; Prophylaxis - Heart failure - Type 2 diabetes mellitus. Disorder of cardiovascular system; Prophylaxis - Type 2 diabetes mellitus. Type 2 diabetes mellitus.,Severe renal impairment (estimated GFR less than 30 mL/min/1.73 m(2))¡A ESRD¡A or dialysis. Acute or chronic metabolic acidosis¡A including diabetic ketoacidosis. History of serious hypersensitivity to empagliflozin¡A metformin hydrochloride¡A or any component of the product.,Common: Diarrhea (>5%)¡A Flatulence (>5%)¡A Indigestion (>5%)¡A Nausea¡A Headache (>5%)¡A Urinary tract infectious disease (6.9-9.4%)¡A Female genital infection¡A Mycotic Serious: Hypotension¡A Hypovolemia¡A Diabetic ketoacidosis¡A Hypoglycemia (1.4-15.6%)¡A Lactic acidosis¡A Vitamin B12 level below reference range¡A Acute renal failure¡A Pyelonephritis¡A Sepsis due to urinary tract infection¡A Necrotizing fasciitis¡A Perineum,30¢XC ¥H¤U,Type 2 diabetes mellitus (Immediate-release) MAX: empagliflozin 25 mg/metformin 2000 mg per day. Currently taking metformin: Choose strength that will provide empagliflozin 5 mg PO BID plus similar total daily metformin dose; gradually adjust dose as needed. Currently taking empagliflozin: Choose strength that will provide metformin 500 mg PO BID plus similar total daily empagliflozin dose; gradually adjust dose as needed. Currently taking both components as separate tablets: Choose strength that provides the same daily dose of both components when administered PO BID ; gradually adjust dose as needed. Iodinated contrast imaging procedure in patients with history of liver disease¡A alcoholism¡A or heart failure¡A or patients receiving intraarterial administration of iodinated contrast: Discontinue use at time of or before procedure; evaluate eGFR 48 hours after imaging procedure; restart if renal function stable. Surgery: Withhold treatment for at least 3 days¡A if possible¡A prior to major surgery or procedures associated with prolonged fasting. Resume when the patient is clinically stable and has resumed oral intake.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¥Ñ©ó´¿¦³¤@¨Ç¨x¥\¯à¤£¥þ¯f¤H¦bmetforminªvÀø®É¥X²{¨Å»Ä¤¤¬r¡A¦]¦¹¤£«ØÄ³®¦¬ü¿}¥Î©ó¨x¥\¯à¤£¥þ¯f¤H¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,Empagliflozin: No Human Data¡XAnimal Data Suggest Low Risk Metformin: Human Data Suggest Low Risk [¥é³æ] ¥Ñ©ó±qempagliflozinªº°Êª«¸ê®ÆÅã¥Ü¦³¤£¨}µÇÅ¦¼vÅT¡A¦]¦¹¤£«ØÄ³¦bÃh¥¥²Ä¤G¥¥´Á©M²Ä¤T¥¥´Á®É¨Ï¥Î®¦¬ü¿}¡C ¦b°Êª«¸ÕÅç¤¤¡A¦b¬Û·í©ó¤HÃþ²Ä¤G¥¥´Á±ß´Á©M²Ä¤T¥¥´Áªº¤j¹«µÇÅ¦µo¨|´Á¶¡¬I¥Îempagliflozin®É¡Aempagliflozin·|¾É­P¤j¹«¦³¤£¨}µÇÅ¦ÅÜ¤Æ¡C¬ù¬°³Ì¤jÁ{§É¾¯¶q13­¿ªº¾¯¶q¤Þµo¥i´_­ìªºµÇª»©MµÇ¤pºÞÂX±i¡C·ímetformin¬I¥Î©óÃh¥¥ªº¤j¹«©M¨ß¤l¡A¥¼Æ[¹î¨ì¹ïµo¨|¦³¤£¨}¼vÅT¡C ¦bÃh¥¥°ü¤k¨Ï¥Î®¦¬ü¿}©Îempagliflozinªº²{¦³¸ê®Æ·¥¤Ö¡A¦]¦¹µLªk¾Ú¥H§P©wÃÄª«»P­«¤j¥ý¤Ñ¯Ê³´©M¬y²£­·ÀI¤§¶¡¬O§_¨ã¦³¬ÛÃö©Ê¡C¦bÃh¥¥´Á¶¡¨Ï¥Îmetforminªº¤wµoªí¤§¸ÕÅç¤¤¡A¥¼³ø§imetformin»P­«¤j¥ý¤Ñ¯Ê³´©M¬y²£­·ÀI¤§¶¡¨ã¦³©ú½Tªº¬ÛÃö©Ê¡CÃh¥¥´Á¶¡¿}§¿¯f±±¨î¤£¨Î¥i¯à¹ï¥ÀÅé©M­L¨à³y¦¨­·ÀI¡C ½Ð»P°±¸g«eªº°ü¤k°Q½×·N¥~Ãh¥¥ªº¥i¯à©Ê¡A¦]¬°metforminªvÀø¥i¯à³y¦¨¬Y¨ÇµL±Æ§Zªº°ü¤k¶}©l±Æ§Z¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Empagliflozin: No Human Data¡XPotential Toxicity Metformin: Compatible [¥é³æ] ¥Ø«e¶È¦³­­ªº¸ê®Æ¥i»¡©ú¡AÃö©óempagliflozin©Îmetformin¬O§_·|¶i¤J¤H¨Å¥H¤Î¨ä¹ï­÷¨ÅÀ¦¨à©Î¨Å¥Ä¥Í¦¨¦³¦ó¼vÅT¡C ¦³·¥¤Ö¼Æ¤wµoªíªº¸ÕÅç³ø§i«ü¥X¡Ametformin·|¥X²{¦b¤H¨Å¤¤¡CEmpagliflozin·|¶i¤Jªc¨Å¤j¹«ªº¨Å¥Ä¤¤¡C¥Ñ©ó¤HÃþµÇÅ¦ªº¦¨¼ôµo¥Í¦Û¥ÀÅé¤º¦Ü¥i¯à±µÄ²¨Å¥Äªº2·³«e¶¥¬q¡A¬G¦¹ÃÄ¥i¯à¹ïµo¨|¤¤ªº¤HÃþµÇÅ¦±a¨Ó­·ÀI¡C ¦]¬°®¦¬ü¿}¥i¯à¹ï­÷¨ÅÀ¦¨à³y¦¨ÄY­«ªº¤£¨}¤ÏÀ³¡A¥]§tempagliflozin¥i¯à¼vÅT­L¨à¥X¥Í«áªºµÇÅ¦µo¨|¡AÀ³§iª¾¯f¤H¡A¤£«ØÄ³¦b­÷¨Å´Á¶¡¨Ï¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
OCRET,Ezetimibe + Rosuvastatin,CreTROL 10/20mg,CAVS,Primary Hypercholesterolemia.,Hypersensitivity to rosuvastatin¡A ezetimibe¡A or any component of the product. Active liver disease¡A including unexplained persistent elevation of transaminases. Muscular dystrophy. Concurrent use of cyclosporine. Current pregnancy or breastfeeding¡A as well as women of childbearing potential not using proper contraceptive measures. Rare genetic disorders such as lactose intolerance¡A Lapp lactase deficiency¡A or glucose-galactose malabsorption.,Common: Abdominal pain (Rosuvastatin¡A 2.4%)¡A Constipation (Rosuvastatin¡A 2.4-12.7%)¡A Diarrhea (Ezetimibe¡A 2.5-4.1%)¡A Nausea (Rosuvastatin¡A 3.4%)¡A ALT/SGPT level raised¡A Greater than 3x ULN (Rosuvastatin¡A 2.2%)¡A Arthralgia (Rosuvastatin¡A 10.1%; ezetimibe¡A 2.6 to 3%)¡A Backache (Ezetimibe¡A 2.4%)¡A Creatine kinase level above reference range (Rosuvastatin¡A 2.6%)¡A Myalgia (Rosuvastatin¡A 2.8-12.7%; ezetimibe¡A 3.2%)¡A Pain in limb (Ezetimibe¡A 2.1-2.7%)¡A Asthenia (Rosuvastatin¡A 2.7-12.7%)¡A Dizziness (Rosuvastatin¡A 4%)¡A Headache (Rosuvastatin¡A 5.5-6.4%)¡A Nasopharyngitis (Ezetimibe¡A 3.7%)¡A Sinusitis (Ezetimibe¡A 2.8%)¡A Upper respiratory infection (Ezetimibe¡A 2.9-4.3%)¡A Fatigue (Ezetimibe¡A 2-2.4%)¡A Influenza (Ezetimibe¡A 2-2.2%) Serious: High hemoglobin A1c level¡A Impaired fasting glucose¡A Increased liver enzymes¡A Liver failure¡A Autoimmune necrotizing myopathy¡A Disorder of muscle¡A Rhabdomyolysis¡A Acute renal failure¡A Hematuria¡A Proteinuria,30¢J¥H¤UÁ×¥úÀx¦s,Dosing: 10/10 mg to 10/20 mg once daily¡A at any time of the day¡A with or without food. Maximum: ezetimibe 10 mg/rosuvastatin 20 mg once daily. Start with a cholesterol-lowering diet before and during treatment. Individualize dosage based on LDL-C levels¡A treatment goals¡A and response. Analyze lipid concentrations at least every 4 weeks and adjust the dose accordingly. (1) Avoid use with Cyclosporine¡A Atazanavir/Ritonavir¡A Lopinavir/Ritonavir¡A or Simeprevir. For certain antivirals¡A limit the dosage to 10/10 mg once daily. (2) When using with bile acid-binding resins¡A administer this medication 2 hours before or 4 hours after the resin.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ­YªvÀø´Á¶¡Á{§É¼x¶H¥X²{ÄY­«¨x¥\¯à¤£¥þ©M/©Î°ªÁx¬õ¯À¦å¯g©Î¶À¯n¡AÀ³¥ß¨è°±ÃÄ¡C­Y¥¼µo²{¨ä¥L­ì¦]¡A«h¤£À³«ì´_ªvÀø¡C¹ï©óÂàÓižJ¤É°ªªº¯f¤H¡AÀ³«ùÄòºÊ´úª½¨ì¤£¨}¯gª¬§ïµ½¬°¤î¡C­Y¦å²MÂàÓižJ¿@«×¶W¹LULNªº3­¿¡AÀ³½Õ­°¾¯¶q©Î°±ÃÄ¡C,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,EZETIMIBE: Limited Human Data¡XAnimal Data Suggest Moderate Risk ROSUVASTATIN: Contraindicated 1st Trimester,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,EZETIMIBE: Contraindicated ROSUVASTATIN: Contraindicated,AC;AC15;PC;PO;WM;,,,,,
OJIN4,Tolvaptan,Jinarc 45mg,CAVS,Indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) and eGFR greater than 25mL/min/1.73m2 with signs of rapid disease progression¡A to slow the growth of cysts and decline in kidney function associated with autosomal dominant polycystic kidney disease.,Hypersensitivity to tolvaptan or any component of the product or benzazepine or benzazepine derivatives. Presence of liver enzyme elevation and/or liver damage signs or symptoms that meet the criteria for permanent discontinuation of tolvaptan before starting treatment. Anuria. Volume depletion. Hypernatremia. Unable to sense or respond to thirst. Pregnancy. Breastfeeding.,Common: Hypernatremia (0.7-25.6%)¡A Diarrhea (13.3%)¡A Increased thirst (12-63.7%)¡A Nausea (8-21%)¡A Xerostomia (7-23%)¡A ALT/SGPT level raised¡A Serum bilirubin above reference range¡A Asthenia (9%)¡A Dizziness (4.8-11.3%)¡A Increased frequency of urination (69.5%)¡A Polyuria (4-24%)¡A Fatigue (13.6%) Serious: Hypovolemia¡A Gastrointestinal hemorrhage¡A In cirrhotic patients (10%)¡A Hepatic failure¡A acute¡A Injury of liver¡A Osmotic demyelination syndrome,25¢J¥H¤U,Take twice daily. Dosage options: 45mg + 15mg¡A 60mg + 30mg¡A or 90mg + 30mg (split dose regimen). First dose 30 minutes before breakfast. Second dose can be taken with or without food. Initial: total dose 60mg (45mg on waking¡A 15mg after 8 hours). If tolerated¡A increase to 90mg daily (60mg + 30mg)¡A then up to the target dose of 120mg daily (90mg + 30mg). At each dosage adjustment¡A allow at least one week interval.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¦b§C¶u¦å¯g¬ã¨s¤¤¡Aµo²{¤¤«×©Î­««×ªº¨x¥\¯à¤£¥þ·|­°§C tolvaptan ªº²M°£²v¨Ã¼W¥[¨ä¤À§GÅé¿n¡C ADPKD ¯f¤H©|¥¼¬ã¨s³oºØÅÜ¤Æªº¼vÅT¡C¦b¥Î©óªvÀø­««×¨x¥\¯à¤£¥þ¯f¤H®É¡AÀ³ÂÔ·Vµû¦ôªvÀø®Ä¯q¤Î­·ÀI¡A¥B¥²¶·ÂÔ·V±±¨î¯f¤Hªº±¡ªp¡A¥H¤Î©w´ÁºÊ´ú¨xÅ¦»Ã¯À¡C¦b¶}©lªvÀø¤§«e¡A¥X²{²Å¦X¥Ã¤[°±¥Î tolvaptan ³W©w¤§¨xÅ¦»Ã¯À¤É°ª¤Î/©Î¨xÅ¦·l¶Ë¼x­Ô©Î¯gª¬ªº¯f¤H«h¸T¥Î Jinarc¡C,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest low risk,PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk [¥é³æ] ¥Ø«e¦b¥¥°üªA¥Î tolvaptan ¤è­±©|µL¸ê®Æ©Î¸ê®Æ¦³­­¡C°Êª«¸ÕÅçÅã¥Ü¥»ÃÄ«~¨ã¦³¥Í´Þ¬r ©Ê¡CJinarc ¤£«ØÄ³¥Î©ó¥¼±Ä¨úÁ×¥¥±¹¬Iªº¨|ÄÖ°ü¤k¡CÃh¥¥®É¤£±oªA¥Î Jinarc¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BREASTFEEDING RECOMMENDATION: No Human Data¡XPotential Toxicity [¥é³æ] ¥Ø«e©|¤£²M·¡ tolvaptan ¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¤¤¡A¦ý¬O®Ú¾Ú¤j¹«¸ÕÅçÅã¥Ü tolvaptan ·|¤Àªc¨ì¨Å¥Ä¤¤¡C¤£¯à±Æ°£·s¥Í¨à/À¦¨àªº­·ÀI¡C­÷¨Å´Á¶¡¸T¥Î Jinarc¡C,AC;PO;,,,,,
IGEN8,Gentamicin,Gentamycin inj 80mg/2mL,QANB,Susceptible infections¡A Surgical prophylaxis.,History of hypersensitivity to aminoglycoside; pregnancy; perforated ear drum.,Dizziness or vertigo; acute renal failure¡A interstitial nephritis¡A acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea¡A vomiting; convulsions¡A mental depression¡A hallucinations. Atrophy or rat necrosis at inj sites.,µL¯S§O«ü¥Ü,(¥é³æ) Adult: 1 mg/kg IM Q8H or 1 mg/kg IV Q8H; dose range 3-5 mg/kg QOD. Pediatric: Infants < 7 days: 3 mg/kg IM Q12H; infants > or = 7 days: 2 mg/kg IM Q8H; children 1-1.7 mg/kg IM Q8H. For IV administration¡A 1-2 mg/kg Q8H. (¼ö¯f) Adult: Multiple Daily Dose: 2 mg/kg load¡A then 1.7-2 mg/kg Q8H. Target peak 4¡V10 £gg/mL¡A trough 1¡V2 £gg/mL; Once Daily Dose: 5.1 mg/kg Q24H (7 mg/kg Q24H if critically ill). Target trough <1 £gg/mL. Pediatric age > 28 days: 5-7 mg/kg/day Q24H or 2.5 mg/kg Q8H *****NEONATE ANTIBIOTICS DOSE***** Gentamicin: Draw peak 30 min after completion infusion; draw trough just before the next dose (©ó²Ä4­Ódoseµ¹ÃÄ«e) PMA <=29 week Postnatal 0 to 7 days dose : 5mg/kg Q48H PMA <=29 week Postnatal 8 to 28 days dose : 4mg/kg Q36H PMA <=29 week Postnatal >=29 days dose : 4mg/kg Q24H PMA 30 ¡V 34 week Postnatal 0 to 7 days dose : 4.5mg/kg Q36H PMA 30 ¡V 34 week Postnatal >= 8 days dose : 4mg/kg Q24H PMA 35 - 44 week Postnatal all dose : 4mg/kg Q24H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IH;IM;IMP;IRR;IVD;IVI;SCI;SUBCI;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,,µ¹ÃÄ¿@«×< 1 mg/mL (IV infuse over 30 minutes to 2 hours)¡C NeoFax«ØÄ³¡GInfuse over a period of 30 to 120 minutes using a concentration of 2 mg/mL or 10 mg/mL.,1. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡B¦å¶t¡B¦å¹[¡B¦å¶u¡B¦åÁâ¡BÅ¥Ä±¥\¯à¡C 2. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C
HE1816,,¦å²G³zªR¿@ÁY²G A-198,NUTR,,,,,¨CL§t¦³¡GSodium Chloride 210.7gm¡A Calcium Chloride 2H2O 6.43gm¡A Potassium Chloride 5.22gm¡A Magnesium Chloride 6H2O 3.56gm¡A Acetic Acid Glacial 6.31gm¡A Dextrose Monohydrate 38.5gm,,,,,,,,,,,,,,
HE1817,Sodium Bicarbonate,­«ºÒ»Ä¶u³zªR¥Î¯»¾¯,NUTR,,,,,,,,,,,,,,,,,,,
IFLUC,Fluconazole,Fluconazole (Flucon) inj 200mg/100mL,QANB,Treatment of mycotic infections. (Antifungal agent),Patients with known hypersensitivity to fluconazole¡A any excipients¡A or other azole antifungal compounds. Concomitant administration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400mg per day or higher. Patients receiving concomitant medications that are known to prolong the QT interval and are metabolized through the enzyme CYP3A4¡A such as cisapride¡A astemizole¡A erythromycin¡A pimozide¡A and quinidine.,Common: Nausea (2.3-7%)¡A Vomiting (1.7%)¡A Headache (1.9-13%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Agranulocytosis¡A Anaphylaxis¡A Seizure,30¢J¥H¤U,Adult: Cryptococcal meningitis and other systemic cryptococcal infections: 400 mg on the first day¡A followed by 200-400 mg daily thereafter. Duration: usually 6-8 weeks. Following completion of initial therapy¡A give at least 100 mg once daily to prevent relapse of cryptococcal meningitis in AIDS patients. Candidemia¡A disseminated candidiasis¡A and other invasive candidal infections: 400 mg on the first day¡A followed by 200-400 mg daily. Oropharyngeal candidiasis: 50 mg once daily for 7-14 days. In immunocompromised patients¡A the treatment duration may be extended. For denture-related atrophic oral candidiasis¡A the usual dose is 50 mg once daily for 14 days¡A with concurrent use of a local disinfectant at the denture site. Other mucosal candidal infections (excluding vaginal candidiasis)¡A such as esophagitis¡A noninvasive bronchopulmonary infections¡A candiduria¡A and cutaneous/mucocutaneous candidiasis: 50-100 mg once daily for 14-30 days. Vaginal candidiasis: a single 150 mg dose. Prophylaxis for cancer patients at risk of fungal infection due to cytotoxic chemotherapy or radiation therapy: 50 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] Fluconazole À³·V¥Î©ó¨x¥\¯à¤£¥þªº¯f¤H¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,FLUCONAZOLE: Human Data Suggest Risk (?400 mg/day) [¥é³æ] Ãh¥¥®ÉÀ³Á×§K¨Ï¥Î¥»«~¡A°£«D¯f¤H±w¦³ÄY­«©Î¥i¯à¦M¤Î¥Í©RªºÅðµß·P¬V¥B¹w´Á¨ä¯q³B¤j©ó¹ï­L¨à¥i¯àªº­·ÀI®É¡A¤è¥i¨Ï¥Î¡C ´¿¦³¥À¿Ë¦b²Ä¤@¥¥´Á±µ¨ü³æ¾¯©Î­«½Æ¾¯¶q¤§fluconazole 150mg«á¡Aµo¥Í¦ÛµM¬y²£©MÀ¦¨à¥ý¤Ñ²§±`ªº³ø§i¡C ¦³³ø§i«ü¥X¨Ï¥Î°ª¾¯¶q(400mg/day-800mg/day)fluconazole¤T­Ó¤ë©Î¤T­Ó¤ë¥H¤W¥HªvÀø coccidioidomycosis·P¬Vªº¤k©Ê¡A²£¤U¦h­«©Ê¥ý¤Ñ²§±`ªºÀ¦¨à¡CFluconazoleªº¨Ï¥Î»P³o¨Ç¨Æ¥ó¤§¶¡ªºÃö«Y¥¼©ú¡C¶È¦b°Êª«¹êÅç¡AªA¥Î°ª¾¯¶q¦Ó²£¥Í¥ÀÅé¬r©Ê®É·|¥X²{­L¨àªº°Æ§@¥Î¤§³ø§i¡C¦b5mg/kg©Î10mg/kgªº¾¯¶q¤U¹ï­L¨à¨S¦³¼vÅT¡A¦b25mg/kg©M50mg/kg©M§ó°ªªº¾¯¶q¤UÆ[¹î¨ì·|¼W¥[­L¨àªºµ²ºc¤WÅÜ²§(¦h¾lªº¦Ø°©¡BµÇª»¿±µÈ)¤Î¦¨°©§@¥Î©µ¿ð¡C¦b80mg/kg(¬ù¬°¤HÃþ«ØÄ³¾¯¶qªº20-60­¿)¨ì320mg/kgªº¾¯¶q½d³ò¤º¡A·|¼W¥[¤j¹«ªº­F­L­P¦º²v¤Î­L¨à·î§Î¡]¥]¬Aªi®ö«¬ªº¦Ø°©¡B®BÃEµõ©M¤£¥¿±`ªºÆ`­±¦¨°©¡^¡C³o¨Ç¼vÅT»P¤j¹«¹êÅç¸Ì§í¨î»Û¿E¯À¦X¦¨§@¥Î¤@­P¡A¥B¥i¯à¬O¥Ø«e¤wª¾ªº¦bÃh¥¥´Á¡B¾¹©x§Î¦¨´Á¤Î¤À®Y®É»Û¿E¯À¸û§Cªºµ²ªG¡C ¯f¨Ò³ø§i«ü¥X¡A¦b¤j³¡¥÷©Î¾ã­Ó²Ä¤@¥¥´Á´Á¶¡¨Ï¥Î°ª¾¯¶q(400-800²@§J/¤é)fluconazole¤§¥À¿Ë©Ò¥Í¤UªºÀ¦¨à¤¤¡A¦³¤@ºØ¯S®í¦Ó¨u¨£ªº¥X¥Í¯Ê³´±¡§Î¡F³o¨ÇÀ¦¨à©Ò§e²{ªº¯S¼x¥]¬A¡GÀY«¬¼eµu¡BÃC­±²§±`¡BÆ`³»µo¨|²§±`¡BÃEµõ¡BªÑ°©Ås¦±¡B¦Ø°©¤Îªø°©ÅÜÁ¡¡BÃö¸`Ås¦±¡B¥H¤Î¥ý¤Ñ©Ê¤ßÅ¦¯f¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] Fluconazole´¿¦b¥À¨Å¤¤µo²{¨ä¿@«×»P¦å¼ß¤¤¬Û·í¡C¥À¨Åªº±Æ°£¥b°I´Á»P¦å¼ßªº±Æ°£¥b°I´Á¬Ûªñ(30¤p®É)¡C®Ú¾Ú¥­§¡¦y®p¥À¨Å¿@«×¦ôºâ¥XÀ¦¨à¨C¤é±q¥À¨Å¤¤Äá¨ú¤§fluconazoleªº¾¯¶q¬°0.39mg/kg/day(°²³]¥­§¡¥À¨ÅÄá¨ú¶q¬°150mL/kg/day)¡A¬ù¬°ÂH½¤©À¯]µß¯f¤§«ØÄ³·s¥Í¨à(<2¶g¤j)¾¯¶qªº40%¡A©Î«ØÄ³À¦¨à¾¯¶qªº13%¡C ¬I¥Î³æ¦¸¾¯¶q150mg fluconazole«á¥i¯à¥i¥HÄ~Äò­÷Áý¥À¨Å¡C±µ¨ü­«½Æ¾¯¶q©Î°ª¾¯¶qfluconazole«á¡A«h¤£«ØÄ³­÷Áý¥À¨Å¡C­÷Áý¥À¨Å¦bµo¨|©M°·±d¤Wªº¯q³B¡AÀ³»P¥À¿Ë¹ïfluconazoleªºÁ{§É»Ý¨D¡A¥H¤Îfluconazole¹ï­÷¨Å¤¤À¦¨à¥i¯à³y¦¨¼ç¦bªº¤£¨}§@¥Î©Î¥ÀÅé­ì¦³¯e¯fªºª¬ªp§@ºî¦X¦Ò¶q¡C,IVD;,,,,Infusion rate <=10 mg/minute (5 mL/minute),1. ª`·N¬O§_µo¥Í¥Ö½§¯l¡B¸¡µh¯gª¬¡C 2. ºÊ´ú¨xµÇ¥\¯à»P¤ß¹q¹ÏÅÜ¤Æ¡C 3. ½Ð¨Ï¥Îªþ¦³¹LÂo¸Ë¸m¤§¿é²G®M¡A¾É¤J°wÀ³««ª½´¡¤J¾ó¥Ö¶ë¡A´¡¤J«á½Ð¤Å§áÂà¡C 4. ¨C200²@§J(100²@¤É²~¸Ë) ¦U§t15mmolªº¶uÂ÷¤l©M´âÂ÷¤l¡C
OSYNG,Piracetam,Syntam granules 1200mg/¥],CNEU,Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin.,Cerebral hemorrhage; severe renal impairment.,Hyperkinesia¡A wt gain¡A nervousness¡A somnolence¡A depression¡A asthenia.,25¢J¥H¤U°®Àê³B,Cerebrovascular insufficiency & age-related cognitive impairment Loading dose: 4.8 g daily during initial weeks of treatment. Maintenance: 1.2-2.4 g daily. maximum: 4.8g/day. Cortical myoclonus Initially 7.2 g daily¡A increasing by 4.8 g/day every 3-4 days to a maximum of 24 g/day in divided 2-3 doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅçÅã¥Ü¨Ã¤£·|¹ïÃh¥¥ªÌ¡A¥Íªø¤¤ªº­F­L¡A¤Î¥X¥Í«áªº­L¨à³y¦¨ª½±µ©Î¶¡±µªº¶Ë®`. ¦ý¨´¤µ¨ÃµL¥¥°ü¨Ï¥Îpiracetam ªºÁ{§É¸ê®Æ¡A piracetam·|³q¹L­L½L?·s¥Í¨àÅé¤ºªºÃÄ«~¿@«×¬ù¬°¥ÀÅéªº70 -90%. ¦]¦¹°£«D¥²­n¡AÃh¥¥´Á¶¡¤£À³¨Ï¥Îpiracetam,Unknown ¨S¦³¸ê®Æ,[¥é³æ]piracetam·|º¯¤J¨Å¥Ä¡A¦]¦¹±Â¨Å´Á¶¡À³Á×§K¨Ï¥Î¥»ÃÄ¡A ©Î¬O¦b¨Ï¥Îpiracetam ªvÀø´Á¶¡À³°±¤î±Â¨Å.,AC;AC15;PC;PO;WM;,,,,,
IHAV14,Inactivated Hepatitis A Virus Vaccine,HAVRIX 1440¡A 1mL/dose (±M®×¶i¤f¦¨¤HA¨x¬Ì­]),HIMM,HAVRIX is indicated for active immunisation against hepatitis A virus (HAV) infection in susceptible subjects at risk of exposure to HAV.,History of immediate or severe allergic or hypersensitivity reactions (eg¡A anaphylaxis) after previous administration of any hepatitis A-containing vaccine or any of its components¡A including neomycin.,Common: Erythema at injection site (20-24%)¡A Injection site induration¡A Injection site pain (21-56%)¡A Swelling (9-10%)¡A Loss of appetite (1-26%)¡A Nausea (1-10%)¡A Headache (Up to 14%)¡A Somnolence (22-35%)¡A Irritability (27-44%)¡A Fatigue (1-10%)¡A Fever (Up to 10%)¡A Malaise (1-10%) Serious: Thrombocytopenia¡A Anaphylaxis¡A Non-allergic anaphylaxis¡A Seizure (0.13%)¡A Angioedema¡A Transfusion reaction due to serum protein reaction,§NÂÃ2-8¢XC¡A¤£¥i§N­á,Adults (16 years and older): 1 mL (1440 ELISA units) IM x 1 dose; booster dose 6-12 months later.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,[¥é³æ] Adequate human data on use during pregnancy and adequate animal reproduction studies are not available. Although there is no convincing evidence of risk to the foetus from immunisation of pregnant women using inactivated virus vaccines¡A HAVRIX should be used during pregnancy only when clearly needed.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Adequate human data on use during lactation and adequate animal reproduction studies are not available. HAVRIX should therefore be used with caution in breast feeding women.,IM;,,,,,1. ¶È¨Ñ¦Ù¦×ª`®g¡C ¤T¨¤¦Ù¬°­º¿ïª`®g³¡¦ì¡C¨Ï¥Î«e½Ð·n¤Ã¡F¦pªGÄa¯B²GÅÜ¦â©Î·n®Ì«á¤£§¡¤Ã¡A«h¥á±ó¡C¤£¥iµ}ÄÀ¡C 2. ¹w¶ñ¥Rª`®g°wµ©»P¬¡¶ë¥i¯à§t¦³¤ÑµM¨Å½¦¾ó½¦¡A¥i¯à·|¤Þ°_¹L±Ó¤ÏÀ³¡C 3. ºÊ´ú¯f¤Hª`®g¬Ì­]«áªº¤ÏÀ³¡A¥i¯à¥X²{·w³Ö©Î¦ñÀHµu¼Èªº¯«¸g¬ÛÃö¯gª¬¡A¦pµøÄ±»ÙÃª¡B·PÄ±²§±`©M±jª½°}ÅË©ÊªÏÅé¹B°Êµ¥¡C 4. ¤£¥i»P¨ä¥L¬Ì­]²V©M¡C
IGAR0,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,Gardasil 9 (HPV¬Ì­]¡A¬F©²´£¨Ñ) inj 0.5mL/dose,HIMM,For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer¡A genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix¡A vulva¡A vagina and anus caused by HPV types 6¡A 11¡A 16¡A 18¡A 31¡A 33¡A 45¡A 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.,Hypersensitivity¡Ahypersensitivity to yeast.,Injection site reactions¡A fever¡A nausea¡A dizziness.,2-8¢JÁ×¥ú,IM¡A 0.5mL¡A in the deltoid region of the upper arm or in the higher anterolateral area of the thigh¡A 9-45 years 3 doses at 0¡A 2¡A and 6 months. 9-14 years can also take 2 doses at 0 and 6-12 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[³X³æ]²{¦³ªº¤HÃþ¸ÕÅç¸ê®Æ¨Ã¥¼Åã¥Ü¦bÃh¥¥´Á¶¡¬I¥´GARDASIL 9·|¨Ïµo¥Í­«¤j¥X¥Í¯Ê³´»P ¬y²£ªº­·ÀI¦]¨Ï¥Î¬Ì­]¦Ó¤É°ª¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]²{¦³ªº¸ê®Æ¨Ã¤£¨¬¥Hµû¦ôGARDASIL 9¹ïÁý­÷¥À¨Å¤§À¦¨à©Î¹ï¨Å¥Ä¥Í¦¨/¤Àªc§@¥Îªº¼vÅT¡C À³±NÁý­÷¥À¨Å¹ïµo¨|¤Î°·±dªº®Ä¯q©M¥À¿Ë¹ïGARDASIL 9ªºÁ{§É»Ý¨D¡A¥H¤ÎGARDASIL 9©Î¥À¿Ë ªº°òÂ¦ª¬ºA¹ïÁý­÷¥À¨Å¤§¥®¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C ´N¹w¨¾©Ê¬Ì­]¦Ó¨¥¡A¥À¿Ëªº°òÂ¦ª¬ºA«Y«ü¹ï¸Ó¬Ì­]©Ò­n¹w¨¾¤§¯e¯fªº©ö·P©Ê¡C,IM;,,,,,1. ¨Ï¥Î«e½Ð¥R¤À·n¤Ã¡A¨Ï¬Ì­]«O«ùÄa¯B²Gªºª¬ºA¡C 2. Gardasil 9 À³¥H¦Ù¦×ª`®gªº¤è¦¡¬I¥´©ó¤WÁuªº¤T¨¤¦Ù°Ï°ì¡A©Î¬O¤j»L«e¥~°¼°Ï°ì¸û°ªªº³¡¦ì¡C
IVIR,Acyclovir,Virless inj 250mg,QANB,Infections caused by herpes zoster virus and herpes simplex virus¡A prevention of herpes simplex infection in immunocompromised patients caused by bone marrow transplantation and leukemia¡A and neonatal herpes simplex infection.,Hypersensitivity to acyclovir or valacyclovir or any component of the formulation.,Common: Injection site inflammation (Approximately 9%)¡A Nausea¡A Vomiting¡A Serum blood urea nitrogen raised¡A Transient¡A Serum creatinine above reference range¡A Transient Serious: Injection site extravasation¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Thrombotic thrombocytopenic purpura¡A Neurotoxicity¡A Hemolytic uremic syndrome¡A Renal failure,25¢J¥H¤U,Adult: 5 mg/kg IVD Q8H. Immunocompromised patients: 10 mg/kg IVD Q8H. Children aged 3 months-12 years: 250 mg/m2 Q8H; MAX 20 mg/kg Q8H. Immunocompromised children: 500 mg/m2 Q8H. Usually 10-20 mg/kg IVD Q8H for 10 days. Herpes Simplex Encephalitis: 3 months-12 years: 20 mg/kg IVD Q8H for 10 days. 5 months-12 years: 10-15 mg/kg IVD Q8H for 14-21 days. 12 years or older: 10 mg/kg IVD Q8H for 10 days or 14-21 days. Genital Herpes Simplex¡A Severe: 12 years or older: 5-10 mg/kg IVD Q8H for 2-7 days¡A followed by oral therapy to complete at least 10 days of total treatment. Neonatal herpes simplex virus (HSV) infections¡A known or suspected: 10 mg/kg/dose IVD Q8H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] ¨Ï¥Î¥»ÃÄ®ÉÀ³¤p¤ßÅv¿ÅªvÀø§Q¯q»P¼ç¦b¦MÀI©Ê¡C¥u¦³¦b¼ç¦bªº¯q³B¤j©ó¥i¯àªº¥¼ª¾­·ÀI®É¤~¨Ï¥ÎAcyclovir¡C¤W¥««áªºAcyclovirÃh¥¥µn¿ý¬ã¨s¤w°O¿ý°ü¤k±µÄ²¦UºØAcyclovir°t¤èªºÃh¥¥µ²ªG¡C¸Óµn¿ýµo²{»P¤@¯ë¤H¤f¬Û¤ñ¡A¥¼Åã¥Ü¦³¼W¥[·î§Î²£ªº¼Æ¶q¡A¦Ó·î§Î²£»P¸ÓÃÄ¤]¨S¦³¯S®í©Ê©Î¤@­P©ÊªºÃö«Y¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¥¿¦b­÷¨Å¤¤ªº°ü¤k­Y­nªA¥ÎAcyclovirÀ³·¥¬°¤p¤ß¡C¨C¤Ñ¤fªAAcyclovir 200 mg 5¦¸¡A¥i¦b¨Å¥Ä¤¤ÀËÅç¥XAcyclovir¿@«×¬°¬Û¹ï¦å¤¤¿@«×ªº0.6~4.1­¿¡C³oºØ¿@«×¥i¯à·|¨Ï¥¿¦b¶¼¥Î¥À¥¤ªºÀ¦¨à¡AÄá¤J°ª¹F0.3 mg/kg/¤ÑªºAcyclovir¾¯¶q¡C,IVD;,IVD: 10mL D/W¡A N/S,¡iH/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,> 60¤ÀÄÁ¥H¤W®É¶¡½wºCºwª`¡C¥[¤J¾A·í¿éª`²Gµ}ÄÀ¡A¿@«×¤£¥i¶W¹L 5 mg/mL¡C,1.¥»«~¤£§t§Üµß¾¯¡A°t»s©Îµ}ÄÀ«áªº·»²GÀ³¥ß§Y¨Ï¥Î¡A¤£¥i§NÂÃ¡C 2.¥»«~À³¥H½wºCÀR¯ß¿éª`1¤p®Éµ¹ÃÄ¦Ó«D IV bolus¡A¨Ãµ¹¤©¥R¨¬¤ô¤À¸É¥R¡AÁ×§K¦å§¿¯À»P¦ÙÓi»ÄÓþ§Ö³t¼W¥[¡C 3.µ}ÄÀ¤èªk¡G¨C¤p²~ 250 mg °®¯»¥[¤J 10 mL ª`®g¥Î¤ô©Î0.9%ª`®g¥Î¥Í²z­¹ÆQ¤ô·»¸Ñ¡C¨ú¥XÂåÅñ©Ò»Ý¾¯¶q¡A¥[¤J¾A·í¿éª`²Gµ}ÄÀ¡A³Ì²×¿@«×¤£¥i¶W¹L 5 mg/mL¡C 4.¨Ì·Ó«ü¥Ü°t»s«áªºÀR¯ß¿éª`²G pH­È¬ù¬° 11¡A¤£¥i§NÂÃ¡AÀ³Àx¦s©ó 25¢J¥H¤U¡C«Ç·Å¤U(15-25¢J)¥i«O«ù12¤p®ÉªºÃ­©w©Ê¡C 5.¦p¦b¿éª`«e©Î¿éª`¤¤µo²{·»²G¤¤¥X²{²V¿B©Îµ²´¹®É¡AÀ³¥ß§Y¥á±ó¡C 6.¸û°ª¿@«×(¦p 10 mg/mL)®e©ö²£¥ÍÀR¯ßª¢¡Bª`®g³¡¦ìµoª¢¡C¦pªGµo¥Í¥~º¯¡A«h±Ä¥Î°®¼ö©M©ï°ªªvÀø¡AÁ×§K¤¤©MpH ­È¡AªuµÛ¥~º¯³¡¦ì©M¤ô¸~²ÕÂ´ª`®g hyaluronidase¡A°Ê¯ß¤º¥~º¯À³¦Ò¼{µ¹¤©¥þ¨­¨x¯À©M¬Pª¬¯«¸g¸`ªýÂ_³NªvÀø¡C 7.ºÊ´ú¯f¤HÅé·Å¡BCBC¡BµÇ¥\¯à¡B·P¬V¯g¯gª¬¡C
ESPD,Urea,Sinpharderm cream 40%¡A 10gm (¥h¨¤½è),TDER,Exfoliation,Hypersensitivity to any component of the formulation.,Local transient pain¡A burning sensation¡A itching.,30¢J¥H¤U,Apply topically to affected area(s) 1-2 times daily. To soften extremely rough or dry cracked skin¡A calluses¡A and nail tissues (including ingrown nails) and relieve skin dryness: (1) Apply an appropriate amount of the cream to the affected area and cover it with gauze for protection. (2) Apply the medicine evenly to the treatment area until the cream is completely absorbed. If necessary¡A cover with a bandage or gauze and fix it with tape. For the nail area¡A it is recommended to use finger cots (plastic gloves can be used to cut suitable finger cots) for protection. (3) Wash off excess cream with soap and water¡A and avoid contact with eyes.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[Briggs Drugs in Pregnancy and Lactation 12th] No Human Data¡XNo Relevant Animal Data,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
OLEV7,Levofloxacin,Levofloxacin 750mg (¬F©²´£¨Ñ),QANB,Treatment of the following infections in adults caused by susceptible pathogens to Levofloxacin: Acute sinusitis¡A Acute exacerbation of chronic bronchitis¡A Community-acquired pneumonia¡A Complicated urinary tract infections (including pyelonephritis)¡A Chronic bacterial prostatitis¡A Skin and soft tissue infections.,Allergic to Levofloxacin¡A other quinolones¡A or any excipients. Patients with epilepsy. History of tendon disorders related to prior use of fluoroquinolones. Pregnant or breastfeeding women.,Common: Diarrhea (Ophthalmic¡A 1-2% ; oral/intravenous¡A 5%)¡A Nausea (Ophthalmic¡A 1-2% ; oral/intravenous¡A 7%)¡A Dizziness (3%)¡A Headache (6-10%)¡A Insomnia (4%) Serious: Aortic aneurysm¡A/dissection¡A Cardiac arrest (0.1-1%)¡A Prolonged QT interval¡A Torsades de pointes¡A Ventricular tachycardia (0.1-1%)¡A Erythema multiforme¡A Stevens-Johnson syndrome¡A Hypoglycemia (0.1-1%)¡A Aplastic anemia¡A Pancytopenia¡A Thrombocytopenic purpura¡A Hepatitis¡A Liver failure¡A Hypersensitivity reaction (0.1-1%)¡A Non-allergic anaphylaxis¡A Myasthenia gravis¡A Exacerbation¡A Rupture of tendon¡A Tendinitis (0.1-1%)¡A Disorientated¡A Disturbance of attention¡A Guillain-Barre syndrome¡A Memory impairment¡A Peripheral neuropathy¡A Pseudotumor cerebri¡A Raised intracranial pressure¡A Seizure (0.1-1%)¡A Retinal detachment¡A Delirium¡A Depression (0.1-1%)¡A Hallucinations (0.1-1%)¡A Paranoid disorder¡A Psychotic disorder¡A Suicidal¡A Acute renal failure (0.1-1%)¡A Tubulointerstitial nephritis,25¢XC¥H¤U¡A±K³¬Á×¥ú,,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible,AC;PO;,,,,,
ORPT,Rifapentine,Priftin 150mg (¬F©²´£¨Ñ),QANB,Inactive tuberculosis¡A With isoniazid in patients with high risk of progression to active disease Tuberculosis¡A,Hypersensitivity to rifamycins. concomitant use with rilpivirine.,Common Dermatologic: Rash (2.5% to 4.2% ) Gastrointestinal: Clostridium difficile diarrhea Hematologic: Anemia (1.6% to 11.4% ) Hepatic: ALT/SGPT level raised (2.2% to 5% )¡A AST/SGOT level raised (2.2% to 4.2% ) Immunologic: Lymphocytopenia (3.2% to 10.5% ) Musculoskeletal: Arthralgia (0.9% to 3.6% ) Neurologic: Headache (0.9% to 3% ) Ophthalmic: Conjunctivitis (0.3% to 2.2% ) Respiratory: Hemoptysis (1.9% to 7.5% ) Other: Abnormal color¡A Red/orange body fluid Serious Hematologic: Neutropenia (6.1% to 8.5% ) Hepatic: Hepatotoxicity Immunologic: Hypersensitivity reaction (Adult¡A 4%; pediatric¡A 1.3% ),30¢J¥H¤U,Adult: in combination with isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; Maximum: 900 mg) 25.1-32 kg once a week¡A Rifapentine 600 mg each time; 32.1-50 kg once a week¡A Rifapentine 750 mg each time; >50 kg once a week¡A Rifapentine 900 mg each time (maximum Dose: 900 mg) for 12 weeks. Children: in combination with isoniazid 15 mg/kg (rounded up to the nearest 50 or 100 mg; Maximum: 900 mg); 10-14 kg once a week¡A Rifapentine 300 mg each time; 14.1-25 kg once a week¡A Rifapentine 450 mg each time; 25.1-32 kg once a week¡A Rifapentine 600 mg each time; 32.1-50 kg once a week¡A Rifapentine 750 mg each time; >50 kg once a week¡A Rifapentine 900 mg each time (maximum dose: 900 mg) for 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Micromedex: Milk effects are possible.,AC;AC15;PC;PO;WM;,,,,,
LRIV,Rivastigmine,Rivast 2mg/mL¡A 120mL solution,CNEU,Alzheimer's disease - Dementia (Mild to Moderate). Dementia (Mild to Moderate) - Parkinson's disease,Hypersensitivity to rivastigmine¡A carbamate derivatives¡A or other components of the product.,Common Endocrine metabolic: Weight loss (26%¡A female; 18%¡A male ) Gastrointestinal: Abdominal pain (13% )¡A Diarrhea (7% to 19% )¡A Indigestion (9% )¡A Loss of appetite (6% to 17% )¡A Nausea (29% to 47% )¡A Vomiting (13% to 31% ) Neurologic: Asthenia (4% to 6% )¡A Dizziness (6% to 21% )¡A Headache (4% to 17% )¡A Tremor (4% to 23% ) Serious Cardiovascular: Atrial fibrillation (1% or more )¡A Atrioventricular block (0.1% to 1% )¡A Myocardial infarction (1% or more )¡A Peripheral ischemia (0.1% to 1% )¡A Sick sinus syndrome (0.1% to 1% ) Endocrine metabolic: Hypokalemia (1% or more )¡A Hyponatremia (0.1% to 1% ) Gastrointestinal: Gastrointestinal hemorrhage (0.1% to 1% )¡A Hematemesis (0.1% to 1% )¡A Melena (0.1% to 1% )¡A Pancreatitis (0.1% to 1% )¡A Rectal hemorrhage (0.1% to 1% )¡A Rupture of esophagus Hepatic: Gamma-glutamyl transferase raised (0.1% to 1% )¡A Hepatitis¡A Liver function tests abnormal (0.1% to 1% ) Neurologic: Cerebrovascular accident¡A Intracranial hemorrhage (0.1% to 1% )¡A Seizure (1% or more )¡A Transient ischemic attack (1% or more ) Ophthalmic: Glaucoma (0.1% to 1% ) Psychiatric: Suicidal behavior Renal: Acute renal failure (0.1% to 1% ) Respiratory: Bronchospasm (0.1% to 1% ),25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Initial¡A 1.5 mg orally twice daily for 2 weeks. Titration¡A if well tolerated¡A increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks; Maximum 12 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¦b°Êª«¬ã¨s¤W¡ARivastigmine ¤£·|¾É­P·î­L(teratogenic)¡A µM¦Ó Rivastigmine ¦bÃh¥¥°ü¤k¨­¤Wªº¦w¥þ©Ê©|¥¼«Ø¥ß¡A ¦]¦¹¡A¹ï©óÃh¥¥°ü¤k¥u¦³¦bªvÀø§Q¯q¤j©ó¹ï­L¨à¦MÀI©Ê¤U¤~¯àµ¹ÃÄ¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Rivastigmine ·|¤£·|³Q¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡A¨Ã¤£²M·¡¡A¦]¦¹¯f±wªA¥Î Rivastigmine ®É¤£¥i¥H­÷¨Å¡C,PC;WM;,,,,,
OLID,Lithium Carbonate,Lidin 300mg,CNEU,Treatment of mania¡A and prevention of bipolar disorder,Significant renal or cardiovascular disease¡A concomitant use of diuretics¡A severe debilitation¡A severe dehydration¡A or sodium depletion.,Bloating¡A vomiting¡A lethargy¡A muscle weakness¡A slight tremors¡A dizziness¡A tinnitus¡A and polyuria.,Á×¥úÁ×¼ö¡AÀx¦s©ó30¢J¥H¤U,Acute mania: 900-1800mg/day in 3 divided doses. Adjust blood lithium concentration to 1.0-1.5mEq/L. Check the blood lithium concentration twice a week until the effective blood concentration is reached and the clinical symptoms are stable. Long-term treatment: 900-1200mg in 3-4 divided doses to adjust the blood lithium concentration to 0.6-1.2mEq/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,[¥é³æ] ¦³¼Æ¾ÚÅã¥Ü¾Y¹ï­L¨à¦³¤£¨}¤ÏÀ³¡A¦b¥¥°ü¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡A¤×¨ä¬OÃh¥¥«e¤T­Ó¤ë¡A Á×§K¨Ï¥Î¥»¾¯¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¾Y¯à±Æ¤J¨Å¥Ä¤¤¡A±Â¨ÅªÌ«ØÄ³¤£­n¨Ï¥Î©ÎÅv©y§Q¹ú¨Ï¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
ILAR,NaCl + KCl + Calcium Chloride + Lactose,Lactated Ringer's inj 500mL,MSIV,For electrolyte replacement. As a plasma substitute for burns¡A surgeries¡A and blood loss.,Hypersensitivity to sodium lactate or any component of the formulation; concomitant use with ceftriaxone in neonates (?28 days).,Serious: Hyperkalemia¡A Hypervolemia¡A Hyponatremia¡A Hypersensitivity reaction¡A Hyponatremic encephalopathy¡A Osmotic demyelination syndrome,«Ç·Å20-25¢XC,Adults: IV: Volume¡A rate and duration are to be individualized and dependent upon the indication for use¡A patient age¡A weight¡A concomitant treatment and clinical condition as well as laboratory determinations. Pediatric: Septic shock: IV: 10 or 20 mL/kg; reassess often and repeat as needed. Monitoring Parameters: Serum sodium¡A potassium¡A chloride¡A calcium¡A bicarbonate concentrations¡A acid-base balance¡A and osmolarity; I & O¡A weight. Monitor infusion site.,µL»Ý½Õ¾ã¾¯¶q,[Lexicomp 20240318] Extreme caution or avoidance in severe hepatic insufficiency due to impaired lactate metabolism.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,1.¨CmL¤¤§t¦³ ´â¤Æ¶t(CaCl2¡P 2H2O) 0.2mg¡A ´â¤Æ¹[(KCI) 0.3mg¡A ´â¤Æ¶u(NaCl) 6mg¡A ¨Å»Ä¶u(C3H5NaO3) 3.1mg¡C½á§Î¾¯: Sodium Hydroxide¡A Water for Injection¡C 2. ¥»«~§t¶t¡A¤£¥i»Pceftriaxone¦P®É¸g¥Ñ¦P¤@¿éª`ºÞ¸ôµ¹ÃÄ¡AÁ×§K§Î¦¨¶tÆQ¨I¾ý¡C 3.¤£¥i³z¹L¦P¤@µ¹ÃÄ¸Ë¸m»PÂfÂc»ÄÆQ§Ü¾®¦å/«O¦sªº¦å«~(citrate anticoagulated/preserved blood)¦P®Éµ¹ÃÄ¡F ¥»«~¤¤ªº¶t¥i¯à·|¾É­P¶tÆQ¨I¾ý¡C 4. ªvÀø´Á¶¡«ØÄ³ºÊ´ú¶u¡B¹[©M´â¿@«×¡B²GÅéª¬ºA¡B¦å²M¨Å»Ä¤ô¥­¡B»ÄÆP¥­¿Å¡B¯«¸g¨t²Î¨Öµo¯gªº¯gª¬¡C
OTAR1,Erlotinib,Tarceva 150mg,RACA,Indicated for first-line and maintenance treatment in patients with locally invasive or metastatic non-small cell lung cancer (NSCLC) with EGFR-TK mutations. Also applicable as second-line therapy for patients with lung adenocarcinoma who have previously undergone chemotherapy but still experience local deterioration or metastasis.,Hypersensitivity to any component of the formulation.,Common: Edema (37%)¡A Alopecia (14%)¡A Pruritus (13-16%)¡A Rash¡A Any grade (60-85%)¡A Weight decreased (39%)¡A Abdominal pain (11-46%)¡A Diarrhea¡A Any grade (20-62%)¡A Flatulence (13%)¡A Indigestion (17%)¡A Inflammatory disease of mucous membrane (17-22%)¡A Loss of appetite (52%)¡A Nausea (33-60%)¡A Vomiting (23-42%)¡A Hyperbilirubinemia¡A Increased liver enzymes¡A Infectious disease (24-39%)¡A Bone pain (25%)¡A Myalgia (21%)¡A Headache (15%)¡A Conjunctivitis (12-18%)¡A Keratoconjunctivitis sicca (12%)¡A Anxiety (13%)¡A Depression (19%)¡A Cough (16-48%)¡A Dyspnea¡A Any grade (41-45%)¡A Fatigue (52%)¡A Fever (36%) Serious: Cardiac dysrhythmia (Grade 3 or higher)¡A Myocardial infarction¡A Syncope (Grade 3 or higher)¡A Rash (Grade 3 or 4) (5-14%)¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Bowel obstruction (Grade 3 or higher)¡A Diarrhea (Grade 3 or 4) ( 2-5%)¡A Gastrointestinal hemorrhage¡A Gastrointestinal perforation¡A Pancreatitis (Grade 3 or higher)¡A Deep venous thrombosis (3.9%)¡A Microangiopathic hemolytic anemia¡A With thrombocytopenia (up to 1.4%)¡A Hepatorenal syndrome¡A Liver failure¡A Cerebrovascular accident (2.5%)¡A Corneal ulcer¡A Perforation of cornea¡A Acute renal failure¡A Dyspnea (Grade 3 or 4) (8-17%)¡A Interstitial lung disease,½ÐÀx¦s©ó30¢Jªº·Å«×¤U,[Non¡Vsmall cell lung cancer (NSCLC) (as first-line therapy¡A maintenance treatment¡A or for progressive disease)] 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¦b¨Ï¥ÎTarceva´Á¶¡À³±K¤ÁºÊ´ú¨x¨ü·l(Á`Áx¬õ¯À>ULN¡A©ÎChild-Pugh A¡BB¤ÎC)¤§¯f¤H¡C¥HTarcevaªvÀøÁ`Áx¬õ¯À>3 x ULNªº¯f¤H®ÉÀ³¯S§O¤p¤ß¡C [Micromedex] Hepatic impairment or biliary obstruction (preexisting)¡A a 2-fold increase of total bilirubin or a 3-fold increase of transaminases above baseline impairment: Interrupt erlotinib until resolved to baseline or Grade 1 or less in severity and restart erlotinib with a daily dose reduction by 50 mg. Discontinue use if significant improvement or resolution does not occur within 3 weeks. Hepatic impairment (direct bilirubin > 17 micromol/L or AST 3x ULN or greater): Consider reducing initial dose by 50% and increase as tolerated.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,[¥é³æ] ¦bªvÀø´Á¶¡¡A¥H¤ÎªvÀø§¹¦¨«áªº¦Ü¤Ö2¶g¤º¡A³£À³±Ä¨ú¾A·íªºÁ×¥¥¤èªk¡C¥Ø«e¨ÃµL¥ô¦ó¾A·í¥B±±¨î¨}¦nªº°w¹ï¨Ï¥ÎTarceva¤§¥¥°ü©Ò¶i¦æªº¬ã¨s¡C°Êª«¬ã¨sÅã¥Ü¥X¬Y¨Ç¥Í´Þ¬r©Ê¡A¹ï¤HÃþªº¼ç¦b­·ÀI¥¼ª¾¡C¹ï¨ã¥Í¨|¯à¤Oªº°ü¤k¡AÀ³§iª¾¨ä¦b¨Ï¥ÎTarcevaªvÀø´Á¶¡­nÁ×§KÃh¥¥¡C¥u¦³¦b¥À¿Ëªº¼ç¦b®Ä¯q¶W¶V­L¨à©Ò­±Á{¤§­·ÀIªº±¡ªp¤U¡A¤~¥iÅý¥¥°üÄ~Äò±µ¨üªvÀø¡C¦pªG­n¦bÃh¥¥´Á¶¡¨Ï¥ÎTarceva¡AÀ³§iª¾¯f¤H­L¨à©Ò¥i¯à­±Á{ªº¦MÀI©Î¬y²£ªº¼ç¦b­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e¥¼ª¾erlotinib¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C©|¥¼¶i¦æ¥ô¦ó¬ã¨s¨Óµû¦ôTarceva ¹ï¨Å¥Ä¤Àªc©Î¨ä¦b¨Å¥Ä¤¤ªº¼vÅT¡C¥Ñ©ó¹ï­÷¨ÅÀ¦¨à¥i¯à³y¦¨ªº¶Ë®`©|¤£²M·¡¡A©Ò¥HÀ³§iª¾¥À¿Ë¦b±µ¨üTarcevaªvÀø®É³Ì«á¤@¾¯«á¦Ü¤Ö2¶g¤£±o±Â¨Å¡C,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OSET,Granisetron,Setron 2mg,CNEU,Prevention or treatment of chemotherapy or radiation therapy associated nausea and vomiting.,Hypersensitivity to granisetron or any of its components.,Common: Asthenia (oral¡A 14-18%)¡A Headache (8.6-21%)¡A Somnolence (up to 10%)¡A Fever (3-56%)¡A Hypertension¡A Hypotension¡A Dermatitis¡A Flushing¡A Rash¡A Constipation¡A Diarrhea¡A Disorder of taste¡A Indigestion¡A Xerostomia¡A Increased liver enzymes¡A Central nervous system stimulation¡A Dizziness¡A Extrapyramidal sign¡A Insomnia¡A Agitation¡A Anxiety¡A Oliguria¡A Copious sputum¡A Cough¡A Pain. Serious: Prolonged QT interval¡A Bradyarrhythmia¡A Cardiac dysrhythmia¡A Electrocardiogram abnormal¡A Hypersensitivity reaction.,½Ð¤ÅÀx¦s©ó¶W¹L25¢JªºÀô¹Ò,Prophylaxis of Chemotherapy-induced nausea and vomiting: 2 mg QD¡A taking 1 hour before chemotherapy at the first time. Prophylaxis of Radiation therapy-induced nausea and vomiting: 2 mg QD¡A taking 1 hour before radiation therapy at the first time. Not up to a week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ø«e©|µLÃh¥¥°ü¤kªº¸ÕÅç¡A¬G©|¥¼ª¾granisetron HCl¬O§_·|³Q¤Àªc©ó¤HÅé¨Å¥Ä¤¤¡C¥u¦³·í¹ï¥À¿Ë¤§¼ç¦b¯q³B¤j©ó¹ï­L¨à¤Î¨ü¨ÅÀ¦¨à¤§¼ç¦b¦MÀIªº«e´£¤U¡A¤~¥i©óÃh¥¥¤Î­÷¨Å´Á¶¡¨Ï¥Îgranisetron HCl (¨£Á{§É«e¦w¥þ©Ê¸ê®Æ) ¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|µLÃh¥¥°ü¤kªº¸ÕÅç¡A¬G©|¥¼ª¾granisetron HCl¬O§_·|³Q¤Àªc©ó¤HÅé¨Å¥Ä¤¤¡C¥u¦³·í¹ï¥À¿Ë¤§¼ç¦b¯q³B¤j©ó¹ï­L¨à¤Î¨ü¨ÅÀ¦¨à¤§¼ç¦b¦MÀIªº«e´£¤U¡A¤~¥i©óÃh¥¥¤Î­÷¨Å´Á¶¡¨Ï¥Îgranisetron HCl (¨£Á{§É«e¦w¥þ©Ê¸ê®Æ) ¡C,AC;AC15;PC;PO;WM;,,,,,
IOZE4,Semaglutide,Ozempic inj 4mg/3mL,META,Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.,Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.,Common: Hypoglycemia (Monotherapy¡A 1.6-3.8%; combination therapy¡A 6-30%)¡A Abdominal pain (Diabetes¡A 5.7-11%; weight management¡A 15-20%)¡A Constipation (Diabetes¡A 3.1-6%; weight management¡A 6-24%)¡A Diarrhea (Diabetes¡A 8.5-10%; weight management¡A 22-30%)¡A Nausea (Diabetes¡A 11-20.3%; weight management¡A 42-44%)¡A Vomiting (Diabetes¡A 5-9.2% ; weight management¡A 24-36%)¡A Headache (14-17%) Serious: Increased heart rate¡A Medullary thyroid carcinoma¡A Cholecystitis (0.6-0.8%)¡A Cholelithiasis (0.4-3.8%)¡A Pancreatitis¡A Anaphylaxis¡A Hypersensitivity reaction¡A Retinopathy due to diabetes mellitus¡A Anxiety¡A Depression¡A Suicidal thoughts¡A Angioedema,Á×¥ú¤Å§N­á¡Cªì¦¸¨Ï¥Î«e¡G½Ð¦s©ñ©ó2-8¢XC; ªì¦¸¨Ï¥Î«á½Ð¦s©ñ©ó30¢XC¥H¤U©Î 2-8¢XC ¦@¤»¶g,SC¡A 0.25 mg once weekly for 4 weeks¡A then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¤£¥þªº¯f¤H¤£»Ý½Õ¾ã¾¯¶q¡ASemaglutide ¥Î©ó­««×¨x¥\¯à¤£¥þ¯f¤Hªº¸gÅç¦³­­¡C¥H semaglutide ªvÀø³o¨Ç¯f¤H®É¡AÀ³¯S§OÂÔ·V¡C,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¦b°Êª«¸ÕÅç¤¤Åã¥Ü¨ã¥Í´Þ¬r©Ê¡CÃh¥¥¤k©Ê¨Ï¥Î semaglutide ªº¸ê®Æ¦³­­¡A¦]¦¹Ãh¥¥´Á¶¡¤£¥i¨Ï¥Î semaglutide¡C ¦pªG¯f¤H·Q­nÃh¥¥©Î¤wÃh¥¥¡AÀ³°±¥Î semaglutide¡C¥Ñ©ó semaglutide ªº¥b°I´Á¸ûªø¡A­pµeÃh¥¥«e¦Ü¤Ö¨â­Ó¤ëÀ³°±¥Î semaglutide¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¤j¹«ªºªc¨Å¹êÅçÅã¥Ü¡Asemaglutide ·|¤Àªc¦Ü¨Å¥Ä¤¤¡C¥Ñ©óµLªk±Æ°£­÷¨ÅÀ¦¥®¨àªº­·ÀI¡A­÷¨Å´Á¶¡¤£À³¨Ï¥Î semaglutide¡C,SC;,,,,,1.¨Ï¥Î·sªºª`®gµ§²Ä¤@¦¸ª`®g«e¡A½Ð¥ýÀË¬d¬O§_¤w±ÆªÅ¡C 2.¦s©ñ©ó30¢XC¥H¤U¥i«O¦s6¶g.¤£¥i§N­á. 3.¥²­n®É¥i§ïÅÜ¨C¶gª`®gªº¤é´Á¡A¦ý¨â¦¸ª`®g¤§¶¡À³¦Ü¤Ö¬Û¹j 3 ¤Ñ (¶W¹L 72 ¤p®É)¡C¿ï©w·sªºª`®g¤é¤§«á¡AÀ³«ùÄò¨C¶gª`®g¤@¦¸¡C 4.¦pªG¿ù¹L¤@¾¯ÃÄª«¡AÀ³¦b 5 ¤Ñ¤º¾¨§Ö¬I¥´¡C¦pªG¶W¹L 5 ¤Ñ«hÀ³¸õ¹L¡A¨Ì­ì­q®Éµ{Ä~Äòª`®g¤U¤@¾¯¡C¹J¨ì³oÃþ±¡ªp¡A¯f¤H¤§«á¥i«ì´_¨C¶g¤@¦¸ªº¥ÎÃÄ®Éµ{¡C
ISAX,Liraglutide,Saxenda inj 18mg/3mL,META,Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: **Adult** patients with an initial BMI of (1) 30 kg/m2 or higher (obese)¡A or (2) 27 kg/m2 or higher (overweight) and having at least one weight-related comorbid condition (such as hypertension¡A type 2 diabetes mellitus¡A or dyslipidemia). **Pediatric** patients aged 12 years or older with body weight over 60 kg¡A and an initial BMI equivalent to 30 kg/m2 for adults (obese) based on international standards.,Hypersensitivity to liraglutide or any component of the product. Personal or family history of medullary thyroid carcinoma. Personal of family history of multiple endocrine neoplasia syndrome type 2. Pregnancy.,[Common] Hypoglycemia (Adult¡A monotherapy¡A 7.1-12.6%; adult¡A combination therapy¡A 3.6-28.2%; pediatric¡A 15.2 to 21.2%)¡A Constipation (Type 2 diabetes¡A 5-9.9%; weight management¡A 4.8-19.4%)¡A Decrease in appetite (9-10%)¡A Diarrhea (10-22.4%)¡A Indigestion (4-9.6%)¡A Nausea (Type 2 diabetes¡A 18-28.4%; weight management¡A 39.3-42.4%)¡A Vomiting (Type 2 Diabetes¡A 6-15.7%; weight management¡A 34.4% (pediatric))¡A Headache (9.1-13.6%)¡A Upper respiratory infection (6-9.5%) [Serious] Breast cancer (0.6%)¡A C-cell hyperplasia of thyroid¡A Medullary thyroid carcinoma¡A Papillary thyroid carcinoma (0.2%)¡A Cholecystitis (0.8% )¡A Cholelithiasis (1.15-2.2%)¡A Colorectal cancer (0.2%)¡A Pancreatic cancer¡A Pancreatitis (0.3-0.8%)¡A Anaphylaxis¡A Suicidal¡A completed (Pediatric¡A 0.8%)¡A Suicidal thoughts (0.3%)¡A Acute renal failure¡A Angioedema,2-8¢XC§NÂÃ¡A½Ð¤Å§N­á,[Adults and Children >= 12 years old] Obesity¡A or overweight in the presence of at least one weight-related comorbidity: Initial¡A 0.6 mg subQ once daily for 1 week; increase weekly in increments of 0.6 mg/day until maintenance dosage of 3 mg once daily is reached.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤£«ØÄ³¥Î©ó­««×¨x¥\¯à¤£¥þ¯f¤H¡F¥Î©ó»´«×©Î¤¤«×¨x¥\¯à¤£¥þ¯f¤HÀ³ÂÔ·V,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ]Ãh¥¥¤k©Ê¨Ï¥Î liraglutide ªº¸ê®Æ¦³­­¡A°Êª«¸ÕÅç¤wÃÒ¹ê¨ã¥Í´Þ¬r©Ê¡A¦ý¹ï¤HÅéªº¼ç¦b­·ÀI¥¼ª¾¡CÃh¥¥´Á¶¡¤£À³¨Ï¥Î liraglutide¡A¦pªG¯f¤H·Q­nÃh¥¥©Î¤wÃh¥¥¡AÀ³°±¤î liraglutide ªvÀø¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¤£²M·¡ liraglutide ¬O§_·|¤Àªc¨ì¥À¨Å¡C°Êª«¸ÕÅçÅã¥Ü¡Aliraglutide ©Mµ²ºc¬Ûªñªº¥NÁÂª«Âà²¾¨ì¨Å¥Ä¤¤ªº¾÷·|«Ü§C¡A¦b«DÁ{§É¸ÕÅç¤¤¡Aµo²{¥¼Â_¥¤ªº·s¥Í¤j¹«¦³ªvÀø¬ÛÃöªº¥Íªø´î½w°ÝÃD¡C¥Ñ©ó¯Ê¥F¸ê®Æ¡A­÷¨Å´Á¶¡¤£À³¨Ï¥Îµ½ÅÖ¹F¡C,SC;,,,,,1. ¥¼¨Ï¥Î«e©ó2¡V8¢XC§NÂÃ«O¦s¡A½Ð¤Å§N­á¡Cªì¦¸¨Ï¥Î«á¦s©ñ©ó30¢XC¥H¤U©Î2¡V8¢XC§NÂÃ¡A¥i«O¦s1­Ó¤ë¡C 2. ­­¥Ö¤Uª`®g¨Ï¥Î¡A¤£±oÀR¯ßª`®g©Î¦Ù¦×ª`®g¡CÀ³ª`®g¦b¸¡³¡¡B¤j»L©Î¤WÁu¡C
OMIRA,Pramipexole,MiraPex 0.375mg prolonged-release,CNEU,Treatment of signs & symptoms of Parkinson's disease.,Hypersensitivity. Lactation.,Abnormal behaviors (eg¡A binge eating¡A compulsive shopping¡A hypersexuality¡A pathological gambling)¡A abnormal dreams¡A amnesia¡A cardiac failure¡A confusion¡A constipation¡A delusion¡A dizziness¡A dyskinesia¡A dyspnoea¡A fatigue¡A hallucinations¡A headache¡A hiccups¡A hyperkinesia¡A hyperphagia¡A hypotension¡A inappropriate antidiuretic hormone secretion¡A insomnia¡A libido disorders¡A nausea¡A paranoia¡A peripheral oedema; pneumonia; pruritus¡A rash; restlessness¡A somnolence¡A sudden onset of sleep¡A syncope¡A visual impairment including diplopia¡A blurred vision¡A reduced visual acuity; vomiting¡A decreased appetite¡A increased/decreased wt.,30¢J¥H¤U¡AÁ×§K¼ÉÅS©ó°ªÀã®ð,Parkinson's disease: start from 0.375 mg given once per day. Based on efficacy and tolerability¡A dosages may be increased gradually¡A not more frequently than every 5 to 7 days¡A first to 0.75 mg per day and then by 0.75 mg increments up to a maximum recommended dose of 4.5 mg per day. When discontinuing therapy¡A taper the dose gradually over a period of one week. In patients with moderate renal impairment (creatinine clearance 30-50 mL/min)¡A start from 0.375 mg given every other day. Dose adjustment should occur no more frequently than at weekly intervals. Maximum: 2.25 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
OBEF,Baclofen,Befon 5 mg,CNEU,Treatment for muscle spasms caused by spinal cord and brain disorders or injuries.,Hypersensitivity to baclofen or any component of the formulation. Pregnant¡A potentially pregnant¡A and breastfeeding women.,Common: Hypotension (0-9%)¡A Constipation (intrathecal bolus¡A 0.2%; intrathecal titration¡A 1.5%; intrathecal maintenance¡A 5.1% ; oral¡A 2-6%)¡A Nausea (Intrathecal bolus¡A 1.4%¡A intrathecal titration¡A 3.3%¡A intrathecal maintenance¡A 7.3% ; oral¡A 4-12%)¡A Vomiting (intrathecal bolus¡A 6.2%; intrathecal titration¡A 8.5%; intrathecal maintenance¡A 4%)¡A Poor muscle tone (intrathecal bolus¡A 2.4-5.4%; intrathecal titration¡A 13.5-14.4%; intrathecal maintenance¡A 25.3-34.7%)¡A Asthenia (0.7-15%)¡A Dizziness (Intrathecal bolus¡A 1.7-2.4%; intrathecal titration¡A 1.9-2.6%; intrathecal maintenance¡A 7.9-8% ; oral¡A 5-15%)¡A Headache (intrathecal bolus¡A 1.6-6.6%; intrathecal titration¡A 2.5-7.8%; intrathecal maintenance¡A 5.1-10.7% ; oral¡A 4-8%)¡A Somnolence (Intrathecal bolus¡A 5.7-7.6%; intrathecal titration¡A 5.9-10.5%; intrathecal maintenance¡A 18.7-20.9% ; oral¡A 10-63%)¡A Urinary complication (2-6%)¡A Fatigue (2-4%)¡A Shivering (0.5-1.3%) Serious: Gastrointestinal hemorrhage¡A Aseptic meningitis¡A with intrathecal administration¡A Coma (0.5-1.5%)¡A Seizure (Intrathecal bolus¡A 0.5-0.9%; intrathecal titration¡A 1.3-3.3%; intrathecal maintenance¡A 4.7-10%)¡A Pneumonia (0.2-2%)¡A Substance withdrawal,«Ç·Å25¢XC¥H¤U,Adult: Initial 5mg 1-3 times daily; may increase by 5 mg/dose every 3 days based on response and tolerability; maximum: 80 mg/day in divided doses. (Limited data available in children <12 years) Children 2-7 years: (1) 5-10 mg/day divided Q8H and may titrate dose by 5 mg increments Q3D. (2) 2.5mg TID; titrate dose by 5mg increments at weekly intervals to patient response; usual dose: 20-40 mg/day. Maximum: 60 mg/day. Children ?8 years: 5mg 3 times daily; titrate dose to patient response every 3-7 days to usual dose of 30-40 mg/day; some patients ?12 years may require every-6-hour dosing. Maximum daily dose: 80 mg/day.,µL»Ý½Õ¾ã¾¯¶q,[Lexidrug] There are no dosage adjustments provided in the manufacturer¡¦s labeling.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,[¥é³æ] §³°ü¡B¦³§³®W¥i¯à©Ê°ü¤H¤Î±Â¨Å¤¤°ü¤H½Ð¤ÅªA¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] §³°ü¡B¦³§³®W¥i¯à©Ê°ü¤H¤Î±Â¨Å¤¤°ü¤H½Ð¤ÅªA¥Î¡C,PC;PO;,,,,,
IOGI,Trastuzumab,Ogivri inj 440 mg (°·«O),RACA,Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin¡A cyclophosphamide¡A and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil¡A for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.,Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.,Common Dermatologic: Rash (Adjuvant breast cancer¡A 4%; metastatic breast cancer¡A 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )¡A Nausea (Adjuvant breast cancer¡A 6%; metastatic breast cancer¡A 33% to 76% )¡A Stomatitis (24% )¡A Vomiting (Adjuvant breast cancer¡A 3.5%; metastatic breast cancer¡A 23% to 53% ) Hematologic: Anemia¡A All Grades (4% to 36% )¡A Neutropenia¡A All Grades (Breast cancer¡A 6.4%; gastric cancer¡A 78% )¡A Thrombocytopenia¡A All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer¡A 6.2% to 10%; metastatic breast cancer¡A 26% to 44% )¡A Insomnia (Adjuvant breast cancer¡A 4.3%; metastatic breast cancer¡A 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer¡A 5%; metastatic breast cancer¡A 26% to 43% ) Other: Fatigue (29.5% to 35% )¡A Fever (Adjuvant breast cancer¡A 6%; metastatic breast cancer¡A 36% to 56%; gastric cancer¡A 18% )¡A Shivering (Adjuvant breast cancer¡A 5%; metastatic breast cancer¡A 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )¡A Heart failure (Adjuvant breast cancer¡A 0.4% to 3.2%; metastatic breast cancer¡A 7% to 28% )¡A Left ventricular cardiac dysfunction (5% to 18.5% )¡A Myocardial ischemia¡A Grade 3 or 4 Hematologic: Febrile neutropenia (23% )¡A Neutropenia¡A Grade 3 or 4 (32% to 34% )¡A Thrombocytopenia¡A Grade 3 or 4 (5% )¡A Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer¡A 2.4% to 11.8%; metastatic breast cancer¡A 22% to 42% )¡A Interstitial pneumonia¡A acute (0.2% to 0.7% )¡A Pulmonary hypertension (0.2% )¡A Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )¡A Tumor lysis syndrome,2-8¢J,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion¡A then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks¡A or initial dose of 8 mg/kg over 90 minutes IV infusion¡A then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion¡A followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ]¹ï¥¥°ü§ë¤©trastuzumab·|¹ï­L¨à³y¦¨¶Ë®`¡C®Ú¾Ú¤W¥««áªº¯f¨Ò³ø§i¡A¦bÃh¥¥´Á¶¡¨Ï¥Îtrastuzumab·|´£°ª©ó²Ä¤G¤Î²Ä¤T¥¥´Á¥X²{¦Ï¤ô¹L¤Ö²{¶Hªº­·ÀI¡C¦pªG°ü¤k¦bÃh¥¥´Á¶¡¨Ï¥Î¤Ftrastuzumab¡A©Î©ó¨Ï¥Îtrastuzumab´Á¶¡Ãh¥¥¡AÀ³±N­L¨à¥i¯à¨ü¨ìªº¦M®`§iª¾¸Ó¦W°ü¤k¡C¤W¥«¤§«á¡A¦bÃh¥¥´Á¶¡±µ¨ü³æ¤@trastuzumab©Î»P¤Æ¾ÇÀøªk¨Ö¥ÎªvÀøªº°ü¤k¤¤´¿¦³¥X²{¦Ï¤ô¹L¤Ö²{¶Hªº³ø§i¡C¨ä¤¤¦³¥b¼Æªº°ü¤k¦b°±¥Îtrastuzumab¤§«á§Y¥X²{¦Ï¤ô«ü¼Æ¤W¤Éªº²{¶H¡C¦³¤@­Ó¯f¨Ò¦b¦Ï¤ô«ü¼Æ§ïµ½¤§«á¤S­«·s¶}©l¨Ï¥Îtrastuzumab¡Aµ²ªG¦A«×¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡C¤W¥«¤§«á¡A¦b±µ¨ütrastuzumabªº¥¥°ü¤¤´¿¦³³ø¾É­L¨à¦Ï¤ô¹L¤Ö¯g¦ñÀHµÇÅ¦¦¨?¤Î/©Î¥\¯à¨ü·lªº®×¨Ò¡A¨ä¤¤¦³³y¦¨­L¨àªÍ³¡¾¹©xµo¨|¤£¥þ¦Ó¾É­P¦º¤`ªº³ø¾É¡C¹ï©ó¦bÃh¥¥´Á¶¡¨Ï¥ÎOgivriªº°ü¤k¡AÀ³ºÊµø¬O§_¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡C¦pªG¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡A§YÀ³¶i¦æ¾A¦X¨ä§³®W¶g¼Æ¥B²Å¦XªÀ·|·ÓÅ@¼Ð·Çªº­L¨àÀË¬d¡C´¿¸g¦b§ë¤©¨ä¥L¤Æ¾ÇªvÀø¾¯¤§«á¥X²{¦Ï¤ô¹L¤Öªº²{¶H®É¥HÀR¯ß¿éª`(IV)ªº¤è¦¡ÃB¥~¸É¥R¤ô¥÷¡Aµ²ªG»á¦³§U¯q¡A¦ý¥Ø«e¨Ã¤£½Tª¾¨Ï¥ÎtrastuzumabªvÀø®É¥HÀR¯ß¿éª`¤§¤è¦¡ÃB¥~¸É¥R¤ô¥÷ªº®ÄªG¡C¦b¥H°ª¹F¤HÃþ¨C¶g«ØÄ³¾¯¶q(2²@§J/¤½¤çÅé­«)¤§25­¿ªºtrastuzumab©Ò¶i¦æªº­¹ÃÉµU¥Í´Þ¬ã¨s¤¤¡A¨Ã¥¼µo²{¥ô¦óÅã¥Ü­L¨à¨ü¨ì¶Ë®`ªºÃÒ¾Ú¡C¤£¹L¡A³\¦h­F­L²ÕÂ´³£¦³¬Û·í©úÅãªºHER2³J¥Õ¹L«×ªí²{ªº²{¶H¡A¥]¬A¤ßÅ¦»P¯«¸g²ÕÂ´¡F¦b¯Ê¥FHER2ªº¬ðÅÜ¤p¹«¤¤¡A­F­L¬Ò©óÃh¥¥ªì´Á§Y¦º¤`¡C°w¹ïµU¤l©Ò¶i¦æªº¬ã¨sµo²{¡A¦b­L¨àµo¨|¶¥¬qªºªì´Á(Ãh¥¥²Ä20-50¤Ñ)¤Î«á´Á(Ãh¥¥²Ä120-150¤Ñ)¡Atrastuzumab·|³q¹L­L½LÂà²¾¦Ü­L¨àÅé¤º¡C¥Ñ©ó°Êª«¥Í´Þ¬ã¨sªºµ²ªG¨Ã¤£¡H©w¯à¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹¡A¥u¦³¦b¥À¿Ëªº¼ç¦b®Ä¯q¶W¶V­L¨à¥i¯à­±Á{¤§­·ÀIªº±¡ªp¤U¡A¤~¥i©óÃh¥¥´Á¶¡¨Ï¥ÎOgivri¡C ¨|ÄÖ´Á°ü¤k©óOgivriªvÀø´Á¶¡¤ÎªvÀøµ²§ô«á7­Ó¤ë¤ºÀ³³Q«ØÄ³±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I¡C ­Y¥¥°ü±µ¨üOgivriªvÀø¡A©Î¬O¯f±w¦b±µ¨üOgivriªvÀø´Á¶¡©Î³Ì«á¤@¾¯Ogivri«á7­Ó¤ë¤ºÃh¥¥¡A³Ì¦n¥Ñ¸ó¬ì§O¹Î¶¤¶i¦æÄY±KºÊ´ú¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ø«e¨Ã¤£½Tª¾trastuzumab¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¦ý¤HÃþªºIgG·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡A¨Å¥Ä§ÜÅé¨Ã¤£·|¤j¶q¶i¤J·s¥Í¨à¤ÎÀ¦¨àªºÅé¤º´`Àô¡C¹ï±Â¨Å­¹ÃÉµU§ë¤©¬Û·í©ó¤HÃþ¨C¶g«ØÄ³¾¯¶q(2²@§J/¤½¤çÅé­«)¤§12.5­¿ªºtrastuzumab¤§«áµo²{¡Atrastuzumab·|¥X²{©ó¨Å¥Ä¤¤¡C¦å²M¤¤ÀË¥Xtrastuzumabªº¥®µU¦b¥X¥Í«á¦Ü3­Ó¤ë¤j´Á¶¡¨Ã¥¼µo¥Í¥ô¦ó¥Í?©Îµo¨|¤è­±ªº¤£¨}¼vÅT¡F¤£¹L¡A°Êª«¨Å¥Ä¤¤ªºtrastuzumab§t¶q¨Ã¤£¯àºë½T¦a¤Ï¬M¤HÃþ¨Å¥Ä¤¤ªº§t¶q¡C ¥Ñ©ó³\¦hÃÄª«³£·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¥BÁý­÷¥À¨ÅªºÀ¦¨à¥i¯à·|¦]±µÄ²Ogivri¦Óµo¥ÍÄY­«ªº¤£¨}¤ÏÀ³¡A¦]¦¹¡AÀ³¦Ò¼{Ogivriªº±Æ°£¥b°I´Á¤Î¦¹ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡AµM«á¨M©w¬O§_­n°±¤îÁý­÷¥À¨Å©Î¬O°±¥Î¦¹ÃÄ¡C,IVD;,¥]¸Ë¤¤ªºµ}ÄÀ²G(20 ²@¤É§t1.1%­f¥Ò¾Jªº¨îµßª`®g¥Î¤ô)¡C,,,©â¨ú¯f±wÃÄª«¶q«á¥[¨ì¸Ë¦³0.9%´â¤Æ¶u250 ²@¤Éªºª`®g³U¤¤µ}ÄÀ¡A°_©l¾¯¶q«ØÄ³ÀR¯ß¿éª`90 ¤ÀÄÁ¡Cºû«ù¾¯¶q®É­Y¯f¤H¹ï¥ý«e¾¯¶qªº­@¨ü¤O¨Î¡A¥i¿éª`30 ¤ÀÄÁ§Y¥i¡C,1.°t»sªº»¡©ú: ¨Ï¥ÎµLµß°wµ©¡AºCºCª`¤J20 ²@¤É¨îµßª`®g¥Î¤ô©ó§t­á´¹Ogivri ªº¤p²~¡Aª½±µª`®g¦Ü­á´¹¶ô¡C¦A·Å©M¦aÂà°Ê¤p²~À°§U½Õ°t¡A¤£­n·n®Ì¡C 2.¨Ï¥Î¥]¸Ë¤¤©Ò´£¨Ñªº¨îµßª`®g¥Î¤ô²V¦X«áªº°t»s«á·»²G¡A§NÂÃ¦b2-8¢J¥i¥Hºû«ù28 ¤Ñªº¦w©w¡C¦pªG¨Ï¥Î·Àµß¤ô°t»s«h¶Èºû«ù24 ¤p®É¦w©w¡A¤§«á¥²¶·¥á±ó¡C 3.°t»s©ó¸Ë¦³0.9%´â¤Æ¶u·»²Gªºª`®g¥Î³U¤¤¡A¦b2-8¢J¤U¨äª«¤Æ©Ê½è¥iºû«ùÃ­©w24 ¤p®É¡C 4.¸T¤î¨Ï¥Î5%ªºdextrose ·»²G¡A¦]¬°·|¤Þ°_³J¥Õ½è¾®¶°¡C
IPROA2,Protamine sulphate,Protamine sulphate inj 50mg/5mL (±M®×¶i¤f),ZADT,Treatment of overdosage or haemorrhage during heparin or Low Molecular Weight Heparin (LMWH) therapy. To counteract the anticoagulant effects of heparin or LMWH before emergency surgery. To reverse the anticoagulant effects of heparin in cardiopulmonary bypass procedures.,Hypersensitivity to the active substance or to any of the excipients.,Common: Flushing¡A Nausea¡A Vomiting¡A Dyspnea Serious: Bradyarrhythmia¡A Hypotension¡A Anaphylaxis¡A Non-allergic anaphylaxis¡A Circulatory collapse¡A capillary leak¡A noncardiogenic pulmonary edema,«Ç·ÅÁ×¥ú,Administered as a slow intravenous injection over 10 minutes or as a slow intravenous infusion. Bolus dose not to exceed 5 mL. Dose ideally guided by blood coagulation studies¡A such as APTT¡A ACT¡A anti-Xa¡A and protamine neutralization test. Coagulation tests performed 5-15 minutes after administration. Additional doses may be required due to rapid clearance from the blood. - For heparin neutralization: 1 mL of Protamine sulphate neutralizes approximately 1400 IU of heparin. - For LMWH neutralization: consult manufacturer guidelines; 1 mL per 1000 anti Xa IU is recommended. Repeat administrations may be necessary¡A especially for subcutaneously administered LMWH. - In cardiopulmonary bypass procedures: 0.1-0.2 mL for each 100 units of heparin given. Doses should be guided by blood coagulation studies.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] No information is available with regard to the use of protamine sulphate in patients with renal or hepatic insufficiency.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,PREGNANCY RECOMMENDATION: Compatible¡XMaternal Benefit and Embryo¡VFetal Risk [¥é³æ] There are no or limited amount of data from the use of protamine sulphate in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Protamine sulphate is not recommended during pregnancy and in woman of childbearing potential not using contraception¡A unless the clinical condition of the woman strongly requires treatment with protamine sulphate.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] It is unknown whether protamine sulphate is excreted in human milk. A risk to the infants cannot be excluded. Breast-feeding should be discontinued during treatment with protamine sulphate.,IVD;,,¡iN/S¡j¥é³æ«ØÄ³¡C,slow IV push over 10 minutes,IV infused over 10 minutes,1. ¸gÀR¯ßª`®g«á¡A¹ï¨x¯Àªº¤¤©M§@¥Î¦b5-15¤ÀÄÁ¤ºµo¥Í¡C 2. µ¹ÃÄ¹L§Ö¥i¯à¤Þ°_§C¦åÀ£¡]µu¼È©ÎÄY­«¡^©Î¤ß·i¹LºC¡A¼W¥[¹L±Ó¤ÏÀ³ªº­·ÀI¡C 3.1 mL§t¦³²¸»Ä³½ºë³J¥Õ 1400 §Ü¨x¯À°ê»Ú³æ¦ì anti-heparin IU (10mg )
IEYL0,Aflibercept,Eylea aflibercept 2mg/0.05mL (Sample),TOPH,Treatment of neovascular (wet) age-related macular degeneration (AMD).,Active intraocular inflammation. Hypersensitivity to aflibercept or any component of the product¡A including severe anaphylactic/anaphylactoid reactions¡A severe intraocular inflammation¡A or other hypersensitivity reactions. Ocular or periocular infections.,Common: Blurred vision (1-7%)¡A Cataract (Adult¡A up to 19%; pediatric¡A 1%)¡A Conjunctival hemorrhage (Adult¡A 1-31%; pediatric¡A 5-9%)¡A Corneal erosion (1-7%)¡A Foreign body sensation¡A In eyes (Up to 4%)¡A Pain in eye (4-13%)¡A Retinal hemorrhage (1-4%)¡A Visual discomfort¡A Vitreous floaters (1-8%) Serious: Myocardial infarction¡A Arterial thrombosis (0.4-6.4%)¡A Hypersensitivity reaction (Less than 1%)¡A Cerebrovascular accident¡A Endophthalmitis (Less than 1%)¡A Raised intraocular pressure (1-9%)¡A Retinal detachment (Up to 6%)¡A Retinal pigment epithelial detachment (1-5%)¡A Retinal venous tortuosity¡A Vitreous detachment (1-8%),2-8¢JÁ×¥úÁ×§K§N­á,Wet type (Neovascular) of age-related macular degeneration (wAMD): 2 mg every 4 weeks for the first 3 injections then every 8 weeks thereafter. Macular edema following central retinal vein occlusion (CRVO): 2 mg every 4 weeks via IVIA. Diabetic macular edema: 2 mg every 4 weeks for the first 5 injections¡A followed by 2 mg every 8 weeks. Macular edema induced visual impairment following branch retinal vein occlusion (BRVO): 2 mg every 4 weeks for the first 6 injections¡A followed by 2 mg every 8 weeks. Choroidal neovascularization(CNV) following pathological myopia: 2 mg single dose via IVIA. May repeat 1 to 3 times a year with the 1 month- interval according to the doctor's judgment on vision and/or anatomy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVI;,,,,,¶È¨Ñ²´¬ì¬Á¼þÅé¤ºª`®g¥Î¡CEYLEA ¥²¶·¥Ñ¦X®æÂå®vª`®g¡C
IENTH,Vedolizumab,Entyvio inj 108mg/0.68mL ¥Ö¤Uª`®g,HIMM,Treatment of moderate to severe active ulcerative colitis and moderate to severe active Crohn's disease in adults. In patients who have responded inadequately¡A lost response¡A or are intolerant to treatment with tumor necrosis factor (TNF) blockers or immunomodulatory therapy; or in those who have shown inadequate response¡A intolerance¡A or demonstrated dependence on corticosteroid therapy.,Known severe or hypersensitive reaction to Entyvio or its excipients¡A such as difficulty breathing¡A bronchospasm¡A urticaria¡A flushing¡A rash¡A and increased heart rate.,Common: Nausea (9%)¡A Arthralgia (12%)¡A Headache (12%)¡A Nasopharyngitis (13%)¡A Upper respiratory infection (7%)¡A Fatigue (6%)¡A Fever (9%) Serious: Aminotransferase abnormal¡A Increased (Up to 2%)¡A Hepatitis¡A Serum bilirubin above reference range¡A Anaphylaxis (0.07%)¡A Hypersensitivity reaction¡A Progressive multifocal leukoencephalopathy¡A Tuberculosis¡A Cancer (0.4%)¡A Infectious disease¡A Infusion reaction (4%)¡A Sepsis (0.03%),2-8¢XC§NÂÃ,After at least 2 intravenous infusions¡A for maintenance therapy with subQ Entyvio¡A the recommended dosing regimen is 108 mg SC every 2 weeks. The first subQ dose should replace the next scheduled intravenous dose¡A followed by subsequent subQ injections every 2 weeks. If subQ Entyvio treatment is interrupted or a dose is missed¡A instruct patients to administer the next dose as soon as possible¡A followed by subsequent injections every 2 weeks. In clinical trials¡A interruptions up to 46 weeks showed no increased adverse events or notable increase in injection site reactions upon reinitiating treatment.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ±µ¨ü¦w¼ì±yªº¯f¤H¡A´¿µo¥ÍÂàÓižJ¤Î/©ÎÁx¬õ¯À¤É°ª¡Cµo¥Í¶À¯n©Î¨ä¥LÅãµÛ¨xÅ¦·l¶ËÃÒ¾Úªº¯f¤H¡AÀ³°±¥Î¦w¼ì±y¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¨Ì¾Ú²{¦³ªºÃÄª«¦w¥þºÊµø¸ê®Æ¡B¶i¦æ¤¤ªºÃh¥¥µn¿ý¸ê®Æ¡B¤wµoªíªº¥¥°ü­Ó®×³ø§i¤Î¥@¥N¬ã¨s¸ê®Æ¡A¨Ã¥¼µo²{»P¦w¼ì±y¦³Ãöªº­«¤j¥ý¤Ñ©Ê¯Ê³´¡B¬y²£¡A©Î¥ÀÅé©Î­L¨àªº¤£¨}µ²ªG¡CÃh¥¥´Á¶¡ªºµoª¢©Ê¸z¹D¯e¯f¡A¹ï¥À¿Ë©M­L¨à³£¦³­·ÀI¡C ©|¥¼¶i¦æ¦w¼ì±y¥Î©óÃh¥¥¤k©Êªº¸ÕÅç¡C ¦w¼ì±y¤§¥ô¦óÃh¥¥¤£¨}§@¥Î¡A¦bÃh¥¥²Ä¤G©M²Ä¤T¥¥´Á®É¥i¯à¸ûÄY­«¡C³æ®è§ÜÅé·|ÀH¥¥´Á¶i®i¦Ó¥H½u©Ê¤è¦¡³q¹L­L½L¡A¦b²Ä¤T¥¥´Áªº¶Ç°e¶q³Ì¤j¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¤@¥÷Á{§É­÷¨Å¬ã¨sªº¸ê®ÆÅã¥Üvedolizumab·|¶i¤J¤HÃþªº¨Å¥Ä¡C¥­§¡­pºâÀ¦¨à¨C¤évedolizumab¤fªA¾¯¶q¬°0.02 ²@§J/¤½¤ç/¤Ñ¡C¨ü­÷¨ÅÀ¦¨àªº¥þ¨­©Ê¼ÉÅS¶q¥i¹w´Á¬°§C¡A¦]¬°³æ®è§ÜÅé·|¦b­G¸z¹D¤j¶q­°¸Ñ¡C µL¸ÕÅç¸ê®ÆÅã¥Ü¦w¼ì±y¹ï¨ü­÷¨ÅÀ¦¨à©Î¨Å¥Ä¤Àªc¶qªº¼vÅT¡C Ãö©óvedolizumab¹ï¨ü­÷¨ÅÀ¦¨à©Î¨Å¥Ä¤Àªcªº¼vÅT¡A©|µL¸ê®Æ¡C¦Ò¼{­÷¨Å¹ï©óµo¨|©M°·±dªº®Ä¯q®É¡AÀ³¿Å¶q¥À¿Ë¹ï¦w¼ì±yªºÁ{§É»Ý¨D¡A¤Î¨Ó¦Û¦w¼ì±y©Î¥ÀÅé°òÂ¦¯e¯f¹ï¨ü­÷¨ÅÀ¦¨àªº¼ç¦b¤£¨}¤ÏÀ³¡C,SC;,,,,,1. §NÂÃÀx¦s(2¢XC - 8¢XC)¡AÁ×§K¥ú·Ó¡C½Ð¤Å§N­á¡C¦Û¦B½c¨ú¥X«á¥i©ó25¢XCÁ×¥úÀô¹Ò«O¦s³Ì¦h7¤Ñ©Î30¢XC¤U³Ì¦h24¤p®É¡C 2. ª`®g«eÀ³¾\Åª¨Ã¿í·Ó "14 ¯f¤H¨Ï¥Î¶·ª¾" ¤§¨Ï¥Î»¡©ú https://mcp.fda.gov.tw/im_detail_1/%E8%A1%9B%E9%83%A8%E8%8F%8C%E7%96%AB%E8%BC%B8%E5%AD%97%E7%AC%AC001186%E8%99%9F
IENH,Trastuzumab Deruxtecan,Enhertu inj 100mg,RACA,Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.,There are no contraindications listed in the manufacturer's labeling.,Nausea¡A fatigue¡A vomiting¡A alopecia¡A constipation¡A decreased appetite¡A anemia¡A neutropenia¡A diarrhea¡A leukopenia¡A cough¡A and thrombocytopenia. Interstitial lung disease (ILD)¡A pneumonitis¡A and left ventricular dysfunction.,2-8¢J§NÂÃ,5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨Ï¥Î©ó¤¤«×¨x¥\¯à¤£¥þ¯f¤H®ÉÀ³¥J²ÓºÊ´ú¡C©|µL­««× (Á`Áx¬õ¯À> 3¦Ü10­¿ULN¤Î¥ô¦óAST¼Æ­È) ¨x¥\¯à¤£¥þ¯f¤Hªº¸ê®Æ¡C,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¬I¥Î©óÃh¥¥¤k©Ê¥i¯à¾É­P­L¨à¶Ë®`¡C¥Ø«e¨ÃµL¨Ï¥Î©óÃh¥¥¤k©Êªº¸ê®Æ¡C ¤£«ØÄ³¬I¥Î©óÃh¥¥¤k©Ê¡AÀ³¦b¯f¤HÃh¥¥«e§iª¾¯f¤HÃÄª«¹ï©ó­L¨àªº¼ç¦b­·ÀI¡C ­Y¤k©Ê©óªvÀø´Á¶¡©Î³Ì«á¤@¾¯«á7­Ó¤ë¤ºÃh¥¥¡A¥²¶·¥ß§YÁpµ¸Âå®v¡A«ØÄ³¶i¦æ±K¤ÁºÊ´ú¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¥¼ª¾ENHERTUR¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡A¥ç¥¼ª¾¹ï­÷¨ÅÀ¦¨à¥i¯à³y¦¨ªº¼vÅT¡C ¦]¬°­÷¨ÅÀ¦¨à¦³µo¥ÍÄY­«¤£¨}¤ÏÀ³ªº¼ç¦b¥i¯à¡A¤k©ÊÀ³©óªì¦¸¬I¥Î«e°±¤î­÷¨Å¡C ¤k©Ê¥i©óµ²§ôªvÀø7­Ó¤ë«á¶}©l­÷¨Å¡C,IVD;,Sterile Water for Injection 5 mL per 100 mg vial,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Reconstitute each 100 mg vial with 5 mL of Sterile Water for Injection (final 20 mg/mL). Dilute in 100 mL of 5% Dextrose Injection. FIRST infusion over 90 minutes; subsequent infusions over 30 minutes if prior infusions were well tolerated. Cover the infusion bag to protect from light. Administer with an infusion set made of polyolefin or polybutadiene and a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter.,­Y¥X²{¿éª`¬ÛÃö¯gª¬¡AÀ³­°§C¿éª`³t²v©Î¤¤Â_¿éª`¡C­Yµo¥ÍÄY­«¿éª`¤ÏÀ³¡AÀ³¥Ã¤[°±¥Î¡C
IAGG,Tirofiban,Aggrastat inj 12.5mg/50mL,HEMT,Unstable angina/non-ST-elevation myocardial infarction: To decrease the rate of thrombotic cardiovascular events (combined end point of death¡A MI¡A or refractory ischemia/repeat cardiac procedure) in patients with non-ST-elevation acute coronary syndrome (unstable angina/non-ST-elevation myocardial infarction.,Severe hypersensitivity reaction (ie¡A anaphylactic reaction) to tirofiban or any component of the formulation; history of thrombocytopenia following prior exposure to tirofiban; active internal bleeding or a history of bleeding diathesis¡A major surgical procedure¡A or severe physical trauma within the previous month.,>10%: Minor hemorrhage 1% to 10%:Coronary artery dissection¡A bradycardia¡A edema¡A vasodepressor syncope¡A dizziness¡A headache¡A diaphoresis¡A nausea¡A pelvic pain¡A major hemorrhage¡A leg pain¡A fever.,15-30¢XC,Non-ST elevation acute coronary syndromes: (combined with heparin) loading infusion rate as 0.4 mcg/kg/min for 30 minutes¡A followed by 0.1 mcg/kg/min as maintenance infusion rate for at least 48 hours¡A up to 108 hours. Percutaneous coronary intervention: (combined with heparin) initial bolus 25 mcg/kg for at least 3 minutes¡A followed by 0.15 mcg/kg/min as maintenance infusion rate for 12-24 hours¡A do not more than 48 hours.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk,Hold Breast Feeding ¼È°±­÷¨Å,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,Maintenance infusion: 0.1-0.15 mcg/kg/minute according to indication.,1.¨Ï¥Î«e¶·µ}ÄÀ¤£¥i¨Ï¥Î­ì²G¡Aµ}ÄÀ¤èªk:¨ú250mLª`®g¥ÎN/S©ÎD5W©â±¼50mL¥á±ó¡C¥[¤J50mLÃÄ²Gµ}ÄÀ©ó200mL·»²G¡A¨Ï³Ì²×¿@«×¬°50 mcg/mL¡C 2.¨ÌÅé­«½Õ¾ã¾A¦X¾¯¶q§ë»PÃÄ«~¡C 3.¥»ÃÄ¤£¥i»Pdiazepam ¨Ï¥Î¦P¡X¤äÀR¯ß¿éª`ºÞ¡C 4.Á×¥úÀx¦s
EKING,Sulfamethoxazole,Kingmin 4%¡A 10mL opthalmic solution,TOPH,Trachoma or inclusion conjunctivitis.,Hypersensitivity to sulfonamides or sulfa drugs.,Conjunctival or corneal scarring may occur. Hypersensitivity reaction.,«Ç·ÅÁ×¥ú«O¦s,Instill a few drops at a time¡A 3 to 4 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Drugs in pregnancy and lactation(11th): SULFONAMIDES Anti-infective: Human Data Suggest Risk in 3rd Trimester [¥é³æ]µL¬ÛÃö¬ö¸ü,Unknown ¨S¦³¸ê®Æ,Drugs in pregnancy and lactation(11th): SULFONAMIDES Anti-infective: Limited Human Data¡XPotential Toxicity [¥é³æ]µL¬ÛÃö¬ö¸ü,OD;OL;OU;,,,,,
LSOO,Amoxicillin + Clavulanic Acid,Soonmelt ¿}¼ß 31.25mg/mL¡A 100mL,QANB,Treatment of infections due to Staph¡A Strep¡A pneumococcus¡A meningococcus & other susceptible organisms such as infections of the upper & lower respiratory tract¡A GUT¡A skin & soft tissue¡A bone & joint. Dental infections¡A septic abortion¡A puerperal sepsis¡A intra-abdominal sepsis. Vial Also indicated for prophylaxis against infection which may be associated with major surgical procedures such as GI¡A pelvic¡A head & neck¡A cardiac¡A renal¡A joint replacement & biliary tract.,History of allergy to amoxicillin¡A other penicillins¡A or clavulanic acid. History of allergy to other £]-lactam antibiotics¡A such as cephalosporins. History of jaundice or impaired liver function due to previous use of this medication or penicillin.,Common: Diaper rash (3.5-6%)¡A Rash (1.1-3%)¡A Urticaria¡A Diarrhea (2.9-14.5%)¡A Loose stool (1.6-9%)¡A Nausea (up to 3%)¡A Vomiting (up to 2.2%)¡A Mycosis (3.3%)¡A Vaginitis (1%)¡A Candidiasis (1.4%) Serious: Drug reaction with eosinophilia and systemic symptoms¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Cholestasis¡A Hepatitis¡A Hepatotoxicity¡A Anaphylaxis¡A Hypersensitivity reaction¡A Angioedema¡A Serum sickness caused by drug,°®Àê¡B³±²D³B¡A«Ç·Å<25¢J,(Each mL contain: Amoxicillin 25mg + Clavulanic Acid 6.25mg) Immediate-release formulations: Infants¡A Children¡A and Adolescents: 4:1 formulation: Oral 20-40 mg amoxicillin/kg/day divided into q8h. Maximum 1500 mg/day. Children aged 7-12 years: 10-20 mL TID. Children aged 2-7 years: 5-10 mL TID. Children aged 9 months to 2 years: 2.5-5 mL TID. Children aged 0-9 months: No oral dosage form suitable for this age group available. Do not exceed 14 days without reevaluation.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¥»ÃÄªvÀø´Á¶¡¥i¯à§ïÅÜ¨x¥\¯à«ü¼Æ¡AÁöµM¦¹ºØÅÜ¤Æ¤§Á{§É·N¸q©|¥¼½T©w¡A¦ýÄY­«¨x¥\¯à¤£¥þ¯f±w¨Ï¥Î¥»ÃÄ®É©y¤p¤ß¡C¨x¥\¯à¨ü·l¯f¤H©yÂÔ·V¥ÎÃÄ¾¯¶q¡A¨Ã©ó©T©w®É¶¡ºÊ´ú¨x¥\¯à§@¥Î¡C´¿¦³¨Ï¥Îamoxicillin/clavulanic acid¤Þ°_¤Ö¼Æ³ø¾É¹LÄY­«©ÊÁx¥ÄÆ{º¢©Ê¶À¯n¡A¦ý³£¬O¥i«ì´_ªº¡C«Ü¥i¯à¦b°±¤îªvÀø6¬P´Á«á¡A¯g­Ô©M¼x¥ü¤~ÅÜªº¤£©úÅã¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,Amoxicillin: Human Data Suggest Low Risk Clavulanate potassium: Compatible [¥é³æ] ¤fªA©Mª`®gµ¹»Pamoxicillin/clavulanic acid¶i¦æ°Êª«¬ã¨sÅã¥Ü¡A¨ÃµL­P·î­F®ÄÀ³¡C¥»ÃÄ¥Î©ó¥¥°ü¤§¯f¨Ò¦³­­¡A°ß°£«DÂå®vÂ_©w¦³¨ä¥²­n¡A§_«h¥»ÃÄ¤£±ÀÂË¥Î©ó¥¥°ü¡C ¦p¦P©Ò¦³ÃÄª«¤@¯ë¡A¥»ÃÄ¥²¶·¾¨¥i¯àÁ×§K©ó¥¥´Á¨Ï¥Î¡A¤×¨äÃh¥¥ÀY¤T­Ó¤ë¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Amoxicillin: Compatible Clavulanate potassium: No Human Data¡XProbably Compatible [¥é³æ] ¥»ÃÄ¦b±Â¨Å´Á¶¡¨Ï¥Î¡A°£«D¦]¨Å¥Ä¤¤ÀË´ú¨ì·L¶q«CÅð¯À·|³y¦¨¹L±Ó¦MÀI©Ê¡A§_«h¤£­P¦³¤£§Q©ó¤p«Äªº®ÄªG¡C,AC;AC15;PC;PO;WM;,,,,,1.¥ÎÀ\«e©Î«á¨Ï¥Î¡A¤fªA§l¦¬¨}¦n¡C»PÀ\¨ÖªA¥i´î»´¸z­G¤£¾A¡B¼W¥[§l¦¬¡C 2.½Õ»s¤è¦¡¡G¥ý®¶·nÃP´²¯»¥½¡A¥[«Ç·Å§N¤ô¦Ü²~¤W°O¸¹³B100mL«á¹ý©³®¶·n¡A«ØÄ³¤ô¥ý¥[¦Ü¥b¶q(¬ù50mL)®¶·n§¡¤Ã¡A©ñ¸m5¤ÀÄÁ¡A½T«OÃÄ¯»§¹¥þ¤Ã´²«á¦A¥[¤ô¦Ü²~¤W°O¸¹³B(Á`¶q100mL)¡C½Õ»s«áÀx¦s©ó¦B½c¡A¥i«O¦s¤C¤é¡C¨C¦¸¨ú¥Î«e§¡»Ý¹ý©³·n¤Ã¡C
IETP,Ertapenem,Ertapenem inj 1gm,QANB,Treat moderate to severe infections caused by microorganisms susceptible to Ertapenem. Empiric therapy in the following infections before the causative pathogens have been identified: ¡E Complicated intra-abdominal infections¡A ¡E Complicated skin and skin structure infections ¡E Community-acquired pneumonia ¡E Complicated urinary tract infections¡A including pyelonephritis ¡E Acute pelvic infections¡A including postpartum endometritis¡A septic abortion¡A and gynecological infections after surgery.,Anaphylactic reaction to beta-lactam antibiotics. Hypersensitivity to ertapenem sodium or to any other component of the product or other drugs in the carbapenem class. Hypersensitivity to amide-type local anesthetics due to lidocaine hydrochloride used as a diluent with IM route only.,[Common] Injection site pain (5.5%)¡A Abdominal pain (3.6-4.7%)¡A Constipation (2.3-4%)¡A Diarrhea (6.5-11.7%)¡A Nausea (Adult¡A 6.4-8.5%; pediatric¡A >0.5%)¡A Vomiting (2.1-10.2%)¡A Headache (4.4-6.8%)¡A Vaginitis (1.4-3.3%)¡A Infusion reaction (5.4-7.1%) [Serious] Cardiac arrest (>0.1%)¡A Heart failure (>0.1%)¡A Necrosis (>0.1%)¡A Clostridioides difficile infection (>0.1%)¡A Congenital pyloric stenosis (>0.1%)¡A Gastrointestinal hemorrhage (>0.1%)¡A Large intestine anastomotic leak (>0.5%)¡A Anaphylaxis¡A Hypersensitivity reaction¡A Cerebrovascular accident (>0.5%)¡A Seizure (>0.1-0.5%)¡A Subdural hemorrhage (>0.1%)¡A Renal impairment (>0.1%)¡A Atelectasis (3.4%)¡A Hemoptysis (>0.1%)¡A Hypoxemia (>0.1%)¡A Pleural effusion (>0.1%)¡A Respiratory distress (>0.1%)¡A Sepsis (>0.1%)¡A Septic shock (>0.1%),­á´¹°®¯»¤§Àx¦s¤£¥i¶W¹L 25¢XC,Patients aged 13 years and older: 1 gm IV/IM q24h Children aged 3 months to 12 years: 15 mg/kg IV/IM¡A divided q12h (max 1 gm/day). [Sanford Guide 2023] Pediatric (age > 28 days): 30 mg/kg/day¡A divided q12h (max 1 gm/day).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«e©|µL¦³ÃöÃh¥¥°ü¤k¤§¾A·í¤Î³]­p¨}¦nªº¹ï·Ó¸ÕÅç¡C ¶È¦³¦b¹ï¥ÀÅé¤Î­L¨àªº¼ç¦b¯q³B¤j©ó¦MÀI©Ê®É¡A¤~¥i¦bÃh¥¥´Á¶¡¨Ï¥ÎErtapenem for Injection¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«eErtapenem·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C ·í±Â¨Å°ü¤k±µ¨üErtapenem for InjectionªvÀø®É¡A¥²¶·ÂÔ·V¤p¤ß¡C,IM;IVD;,IVD: Reconstitute 1gm vial with 10mL water for injection or Normal Saline 10mL. Shake well. Deep IM: Reconstitute 1 gm vial with 3.2 mL of lidocaine HCl 1% or 2% injection (without epinephrine). Shake well. Use within 1 hour of preparation.,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,After reconstitution¡A further dilute dose with Normal Saline; for adolescents and adults (age >= 13 years)¡A transfer dose to 50 mL Normal Saline; for children (3 months to 12 years)¡A dilute dose to a final concentration<=20 mg/mL. Infuse over 30 minutes; complete infusion within 6 hours of reconstitution.,1. ¤£¥i¥H±NErtapenem for Injection»P¨ä¥LÃÄ«~²V¦X©Î¦P®É¿éª`¡C 2. ¤£¥i¥H¨Ï¥Î§t¦³¸²µå¿}(£\-D-GLUCOSE)ªºµ}ÄÀ²G¡C 3. ª`®g°®¯»¸g·»¸Ñ¨Ã¥ß§Y¥H0.9%´â¤Æ¶uª`®g²G50mLµ}ÄÀ«á¡A¥i©ñ¦b«Ç·Å(25¢XC)©ó6¤p®É¤º¨Ï¥Î¡A¤]¥i§NÂÃ(5¢XC)¦Ü¦h24¤p®É¡A¦Û§NÂÃ¨ú¥X«á¶·©ó4¤p®É¤º¨Ï¥Î¡C¤£¥i§N­á¡C
OXEN8,Orlistat,Xenical 120mg (84 capsules/box),META,Management of obesity¡A including weight loss and weight maintenance¡A in conjunction with a reduced-calorie diet; also indicated to reduce the risk for weight regain after prior weight loss. For adults: Suitable for the treatment of obesity in conjunction with a low-calorie diet¡A including patients with obesity-related risk factors. For adolescents: Orlistat treatment is only considered when other treatment approaches¡A including balanced diet suitable for the patient's age and a behavior-correcting exercise plan¡A have failed for a period of six months or more.,Pregnancy. Chronic malabsorption syndrome. Cholestasis. Known hypersensitivity to orlistat or any other component of the product.,Common Gastrointestinal: Abdominal discomfort¡A Abdominal pain (Up to 41.1% )¡A Defecation urgency (For up to 1 year¡A 22.1% to 38.9% ; for up to 2 years¡A 2.8% )¡A Discharge from anus¡A Oily (2.3% to 11.9% )¡A Flatulence (For up to 1 year¡A 23.9% to 43.9%; for up to 2 years¡A 2.1% )¡A Increased frequency of defecation (2.6% to 10.8% )¡A Soiling¡A Oily (For up to 1 year¡A 26.6% to 37.2% ; for up to 2 years¡A 4.4% )¡A Steatorrhea (For up to 1 year¡A 20%; for up to 2 years¡A 5.5% ) Musculoskeletal: Backache (13.9% )¡A Pain in lower limb (10.8% ) Neurologic: Headache (30.6% ) Respiratory: Upper respiratory infection (26.1% to 38.1% ) Other: Influenza (39.7% ) Serious Hepatic: Liver failure Renal: Nephrolithiasis¡A Oxalate¡A Oxalate nephropathy¡A with renal failure,25¢XC ¥H¤U,Adults: Take 120 mg orally 3 times a day with each main meal containing fat (during or up to 1 hour after the meal). Skip if the meal is fat-free or skipped. Maintain a balanced¡A low-calorie diet with around 30% of daily calories from fat¡A distributed evenly among the 3 main meals. Adolescents (12 years or older): 120 mg orally 3 times a day with each main meal containing fat (during or up to 1 hour after the meal). Consume a nutritionally balanced diet with approximately 30% of calories from fat. Due to a lack of long-term treatment experience¡A the duration of treatment for adolescents should be limited to 1 year. Advise patients to take a daily multivitamin supplement providing fat-soluble vitamins and beta-carotene. The supplement should be taken at least 2 hours before or after orlistat.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¹ï©ó¨x¥\¯à¤Î/©ÎµÇ¥\¯à¨ü·l¯f±wªºÁ{§É¬ã¨s©|¥¼¶i¦æ¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ] ©ó°Êª«¥Í´Þ¹êÅç¤¤¨Ã¥¼µo²{orlistat¦³­F­L¬r©Ê©Î­P·î­L®ÄÀ³¡C¦bµL°Êª«¤§­P·î­L®ÄÀ³¤U¡A©ó¤HÃþ¤¤¥ç¤£¹w´Á¦³­P·î­Lªº¤ÏÀ³¡CµM¦Ó¡A¦b¯Ê¤ÖÁ{§É¼Æ¾Ú¤U¡A¨Ã¤£«ØÄ³Ãh¥¥®ÉªA¥ÎXenicalR¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ©|µL¹ïorlistat¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤ªº¬ã¨s¡C­÷¨Å®É¤£À³ªA¥ÎXenicalR¡C,PC;PO;WM;,,,,,
EEYB,Omidenepag isopropyl,Eybelis 0.002% 2.5mL ophthalmic solution,TOPH,Treatment for open-angle glaucoma¡A ocular hypertension - raised intraocular pressure.,Patients without a natural lens or those who have undergone intraocular lens (IOL) implantation. Concomitant use with tafluprost. Hypersensitivity to the active ingredient or any excipients.,Common: Headache (2%)¡A Application site pain (3%)¡A Blurred vision (4%)¡A Conjunctival hyperemia (9%)¡A Dry eyes (3%)¡A Eye irritation (1%)¡A Hyperemia of eye (2%)¡A Pain in eye (2%)¡A Photophobia (5%)¡A Superficial punctate keratitis (2%)¡A Visual impairment (1%) Serious: Application site pigmentation changes¡A Iris/periorbital tissue/eyelash¡A Eyelash formation¡A Changes¡A Macular retinal edema¡A Uveitis,Á×¥ú«O¦s¡A¥¼¶}«Ê»Ý§NÂÃ(2-8¢XC)¡A¶}«Ê«á¥i30¢XC¥H¤U«O¦s¤@­Ó¤ë,For ophthalmic use only. Administer 1 drop in affected eye(s) once daily in the evening. Do not exceed one drop per affected eye per day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµLÃö©óÃh¥¥¤k©Ê¨Ï¥Îomidenepag isopropylªº¾A·í¸ê®Æ¡C¤@¶µ¨ß¤l¹êÅç¤w¸gµo²{¥Í´Þ¬r©Ê¡C¦]¦¹¡A¶È¦³¦b§PÂ_«á¡A¹w´ÁªvÀø¯q³B¤j©óªvÀø¬ÛÃö¥i¯à­·ÀI®É¡A¤~¯à±NEYBELIS¥Î©óÃh¥¥©Î¥i¯àÃh¥¥ªº¤k©Ê¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¥¼ª¾omidenepag isopropyl©Î¨ä¥NÁÂª«¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡C¤@¶µ¤j¹«¹êÅçÃÒ¹ê¡A¦b³æ¦¸¥Ö¤Uª`®gµ¹ÃÄ«á¡A¦b¤j¹«¥À¨Å¤¤¨Ã¥¼°»´ú¨ìomidenepag isopropyl¡C­÷¨Å¤¤¤k©Ê¨Ï¥ÎEYBELIS®É¡AÀ³±NªvÀø»P­÷¨Åªº¯q³B¯Ç¤J¦Ò¶q¡Aµû¦ô¬O§_­÷¨Å¡C,OD;OL;OU;,,,,,1. µ¹ÃÄ«e»´»´·n®Ì²~¤l¡C 2. Á×§K²´·ú±µÄ²²~¦y¡A¥H¨¾¤îÃÄª«¦Ã¬V¡C 3. µ¹ÃÄ«e¨ú¤UÁô§Î²´Ãè¡Aµ¥«Ý 15 ¤ÀÄÁ«á¦A­«·sÀ¹¤W¡C 4. ¬I¥Î¦hºØ²´¥Î²£«~¤§¶¡¦Ü¤Ö¶¡¹j 5 ¤ÀÄÁ¡C
ISAB,Metronidazole,SABS inj 500mg/100mL,QANB,Treatment for severe infections caused by anaerobic bacteria sensitive to Metronidazole and infections caused by Bacteroides fragilis resistant to Clindamycin¡A Chloramphenicol¡A and Penicillin.,[Micromedex] Hypersensitivity to metronidazole or any other component of the product or to other nitroimidazole agents. Alcohol¡A or products containing propylene glycol¡A use during and for at least 3 days after metronidazole use. Concomitant use with or within the last 2 weeks of disulfiram. Cockayne syndrome. [Package insert] Patients with blood disorders (may experience leukopenia). Patients with brain or spinal cord disorders (may exhibit central nervous system symptoms). Women in the first three months of pregnancy.,Common: Abdominal discomfort (4-7%)¡A Abnormal taste in mouth (2-9%)¡A Diarrhea (1-4%)¡A Nausea (1.6-10%)¡A Jarisch Herxheimer reaction¡A Dizziness (2-4%)¡A Headache (Vaginal gel and topical¡A 2.2-5%; extended-release tablets¡A 18%)¡A Candida infection of genital region¡A Vaginal discharge (12%)¡A Vaginal irritation (9%)¡A Vaginitis (15%) Serious: Prolonged QT interval¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Leukopenia¡A Hepatic failure¡A acute¡A Hepatotoxicity¡A Aseptic meningitis¡A Encephalopathy¡A Peripheral neuropathy¡A Seizure¡A Disorder of optic nerve¡A Ototoxicity¡A Hemolytic uremic syndrome,³±²D(15~30¢J)Á×¥ú³B¡AÁ×§K§N­á¡C,Adult: (data from Micromedex) Infection caused by anaerobic bacteria¡A anaerobic abscess¡A bacterial meningitis: Loading dose¡A 15 mg/kg IV over 1 hour; maintenance dose¡A 7.5 mg/kg IV infused over 1 hour q6h¡A starting 6 hours after loading dose; duration 7-10 days or longer as clinically indicated; MAX 4 g/day. Postoperative infection; Prophylaxis: 500 mg IV 1 hour prior-surgery; total treatment duration should not exceed 24 hours OR 15 mg/kg IV over 30-60 minutes¡A complete 1 hour before surgery; follow with 7.5 mg/kg IV over 30-60 minutes at 6 and 12 hours after initial dose; limit treatment-day of surgery and discontinue within 12 hours following completion of surgery. Postoperative infection; Prophylaxis - Procedure on female genital system: 500 mg IV single dose plus single dose of either gentamicin 1.5 mg/kg IV or a quinolone (ciprofloxacin¡A levofloxacin¡A moxifloxacin) 400 mg IV Clostridium difficile diarrhea¡A including Pseudomembranous Colitis: Fulminant disease¡A 500 mg IV q8h plus vancomycin 500 mg orally/NG tube QID; if complete ileus¡A consider adding vancomycin retention enema (500 mg in 100 mL normal saline) rectally q6h. Necrotizing fasciitis (Mixed infection): 500 mg IV q6h PLUS cefotaxime 2 g IV q6h; administer until further debridement is no longer necessary¡A the patient has clinically improved¡A and has been afebrile for 48-72 hours. Pediatric (Infants¡A Children¡A and Adolescents): (package insert: not established; below data from Lexidrug) IV 22.5-40 mg/kg/day in divided doses q6h to q8h; MAX 4 g/day. Surgical prophylaxis (Children and Adolescents): IV 15 mg/kg as a single dose 30-60 minutes prior to procedure; MAX 500 mg/dose.,»Ý½Õ¾ã¾¯¶q,[Lexidrug] Child-Pugh A¡A B: No dosage adjustment necessary. Child-Pugh C: If usual recommended frequency is q12h: No adjustment necessary. If usual recommended frequency is q6h to q8h: Reduce frequency to q12h.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,[¥é³æ] ¸T§Ò¡GÃh¥¥¤T­Ó¤ë¤º¤§°ü¤k¡C¦]¹ïÅj¾¦°Êª«¦³­PÀù©Ê¡A¦]¦¹¥¥°ü¶·¦bÅãµÛ»Ý­n¤U¤è¥i¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Metronidazole: Hold Breastfeeding (Oral/IV Single Dose) Limited Human Data¡XPotential Toxicity (Oral/IV Divided Dose) Compatible (Topical/Intravaginal) [¥é³æ] ¦b¹«Ãþ¹êÅç¤¤µo¥Í¸~½F²{¶H¡A¦]¦¹±Â¨Å°ü¨Ï¥Î¥»¾¯®É¡AÀ³¨M©w¤£Ä~Äò±Â¨Å¡A§_«hÀ³°±¤î§ë»P¡C,IVD;,,,Slow intravenous infusion only.,Slow IV over 1 hour. Do not mix with other solutions or drugs.,1. ¥»«~»Ý¸m©ó«Ç·Å(15-30¢J)Á×¥ú³±²D°®Àê³B¡C 2. ¥»«~¤£±o»P¾T»s«~(¦p:°w¡B®MºÞµ¥)±µÄ²¡C 3. ¥»«~À³½wºCÀR¯ß¿éª`1¤p®É¡A¤£»Ýµ}ÄÀ¡A¸T¤î»P¨ä¥L·»²G¦P®É¨Ï¥Î¡C 4. ºÊ´úÅé·Å¡BCBC¡B¦å²y¤À¤Æ­p¼Æ¡Aª`·N¤ß´¼»P¯«¸g¥\¯àÅÜ¤Æ¡C 5. Àøµ{«ØÄ³¤£¶W¹L10¤Ñ¡C
OLOW,Lorazepam,Lowen 0.5mg,CNEU,Anxiety state.,Hypersensitivity to benzodiazepines or any component of the product¡A polyethylene glycol¡A propylene glycol. Acute narrow-angle glaucoma. Respiratory insufficiency¡A severe; in the absence of resuscitative equipment. Sleep apnea syndrome.,Common: Neurologic: Asthenia (4.2%)¡A Dizziness (6.9%)¡A Sedated (15.9%)¡A Unsteadiness present (3.4%)¡A Depression Serious: Acidosis (<1%)¡A Delirium,30¢J¥H¤UÁ×¥ú¥BÁ×¼ö,Anxiety: 1-4 mg/day divided into 2-3 doses. Insomnia: 2-4 mg once a day¡A before bedtime. Prior to surgery: 2-4 mg on the night before or 1-2 hours before surgery. Elderly or debilitated patients: 1-2 mg/day in divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible^1 ^1 Potential toxicity if combined with other CNS depressants.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
EDUAH,Budesonide,Duasma HFA Inhaler 200mcg/puff¡A 200 puffs,ERSP,Bronchial asthma,Hypersensitivity to budesonide or any component of the formulation. Moderate to severe bronchial dilation.,Common: Hypertension (Oral¡A 12%)¡A Peripheral edema (Oral¡A 17%)¡A Acne (Oral¡A 2.4-11%)¡A Dermatitis (Oral¡A 6%)¡A Hirsutism (Oral¡A 5%)¡A Weight gain (Inhalation¡A 1-3% ; oral¡A 7%)¡A Diarrhea (Inhalation¡A 2-4% ; oral¡A 10%)¡A Indigestion (Oral¡A 6-7%)¡A Nausea (Inhalation¡A 1.8% ; oral¡A 5.1-11%; rectal¡A 2%)¡A Leukocytosis (Oral¡A up to 6%)¡A Arthralgia (Oral¡A 2-6%)¡A Spasm (Oral¡A 12%)¡A Headache (Inhalation¡A >3% ; oral¡A 10-21%)¡A Bleeding from nose (Inhalation¡A 2-4% ; intranasal¡A 8%)¡A Dyspnea (Oral¡A 6%)¡A Nasal stinging/burning (Intranasal¡A up to 1%)¡A Respiratory tract infection (Inhalation¡A 3-38% ; oral¡A 8-11%)¡A Sinusitis (Inhalation¡A 3% or greater ; oral¡A 8%)¡A Edema of face (Oral¡A 8%)¡A Fatigue (Inhalation¡A 1-<3% ; oral¡A 3.1-5%) Serious: Syncope (Inhalation¡A 1-3%)¡A Cushing's syndrome (Oral¡A 5-15% ; inhalation¡A rare)¡A Hyperglycemia¡A Hypocortisolism secondary to another disorder (Inhalation¡A rare ; oral¡A 4.3% ; rectal¡A 4%)¡A Type 2 diabetes mellitus¡A Anaphylaxis¡A Hypersensitivity reaction¡A Fracture of bone (Inhalation¡A 1-3%)¡A Osteoporosis¡A Cataract¡A Glaucoma¡A Pneumonia¡A Angioedema,30¢J¥H¤U,For adults and children aged 12 and above: Initial dose: 400-1600 mcg/day¡A divided into 2-4 doses. Maintenance dose: 200-400 mcg/day¡A divided into 2 doses. For children aged 6-12: Initial dose: 200-400 mcg/day¡A divided into 2 doses. Maintenance dose: Individualized-the minimum dose needed-keep patients symptom-free. For stable asthma¡A twice daily usage is usually sufficient. Patients using inhaled bronchodilators should use the bronchodilator a few minutes before using Budesonide to enhance drug penetration into the bronchial branches and reduce local side effects¡A such as cough. When the dose exceeds 800mcg¡A the use of a spacer is recommended¡A as it can reduce systemic absorption and improve drug deposition in the lungs.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,BUDESONIDE: Compatible (Inhaled/Nasal) No Human Data¡XAnimal Data Suggest Risk (Oral) [¥é³æ] Budesonide¹ï©óÃh¥¥°Êª«ªº­L¨à·|³y¦¨µo¨|¤£¥¿±`¡A¹ï©ó¤HÃþ©|¤£ª¾¡A¦ý¬O¦bÃh¥¥´Á¶¡À³Á×§K¨Ï¥Î¡A°£«D¦³­¢¤Á»Ý­nªº²z¥Ñ¡A¦b°Êª«¹êÅç¤¤µo²{Budesonide·|³q¹L­L½L¡C­Y¥À¿Ë¨Ï¥ÎÃþ©T¾J¦³¬Û·íªº¾¯¶q®É¡AÀ³Æ[¹î¨ä·s¥ÍÀ¦¨à¬O§_¦³¥Ö½è¯À§C¤Uªº±¡ªp¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BUDESONIDE: Limited Human Data¡XProbably Compatible [¥é³æ] ¿}¥Ö½èÃþ©T¾J¤Àªc©ó¨Å¥Ä¤¤¡AÁöµMBudesonide¨S¦³³o¼Ëªº¸ê®Æ¡A¦ýBudesonideuÀ³»P¨äÃþ¦ü¡A¤]·|¤Àªc©ó¨Å¥Ä¡A­÷¨Å°ü¨Ï¥ÎBudesonide®ÉÀ³¸Ó¤p¤ß¦aµû¦ô¨ä¦MÀI©Ê¤Î¯q³B¡C,IH;,,,,,
HE1814,,¦å²G³zªR¿@ÁY²G A-168,NUTR,,,,±K«Ê¦s©ñ©ó40¢XC¥H¤U¡A¤£¥i§N­á,¨CL§t¦³¡GSodium Chloride 210.7gm¡A Calcium Chloride 2H2O 7.72gm¡A Potassium Chloride 5.22gm¡A Magnesium Chloride 6H2O 3.56gm¡A Acetic Acid Glacial 6.31gm¡A Dextrose Monohydrate 77gm,,,,,,,,,,,,,,
HE1815,,¦å²G³zªR¿@ÁY²G A-188,NUTR,,,,,¨CL§t¦³¡GSodium Chloride 210.7gm¡A Calcium Chloride 2H2O 9gm¡A Potassium Chloride 5.22gm¡A Magnesium Chloride 6H2O 3.56gm¡A Acetic Acid Glacial 6.31gm¡A Dextrose Monohydrate 77gm,,,,,,,,,,,,,,
OMIRA1,Pramipexole,1mg MIRAPEX,CNEU,Treatment of signs & symptoms of Parkinson's disease.,Hypersensitivity. Lactation.,Abnormal behaviors (eg¡A binge eating¡A compulsive shopping¡A hypersexuality¡A pathological gambling)¡A abnormal dreams¡A amnesia¡A cardiac failure¡A confusion¡A constipation¡A delusion¡A dizziness¡A dyskinesia¡A dyspnoea¡A fatigue¡A hallucinations¡A headache¡A hiccups¡A hyperkinesia¡A hyperphagia¡A hypotension¡A inappropriate antidiuretic hormone secretion¡A insomnia¡A libido disorders¡A nausea¡A paranoia¡A peripheral oedema; pneumonia; pruritus¡A rash; restlessness¡A somnolence¡A sudden onset of sleep¡A syncope¡A visual impairment including diplopia¡A blurred vision¡A reduced visual acuity; vomiting¡A decreased appetite¡A increased/decreased wt.,30¢J¥H¤U,Parkinson's disease: start from 0.125 mg TID for one week¡A increased to 0.25 mg TID in the second week¡A and increased to 0.5 mg TID in the third week. Dose may be further increased by 0.75 mg weekly. Maximum: 4.5 mg/day. When discontinuing therapy¡A taper off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg. Thereafter¡A the dose may be reduced by 0.375 mg per day. In patients with creatinine clearance 20-50 mL/min¡A start from 0.125 mg BID. Maximum: 2.25 mg/day. In patients with creatinine clearance <20 mL/min¡A start from 0.125 mg QD. Maximum: 1.5 mg/day. Restless legs syndrome: 0.125 mg once daily initially¡A taken 2 to 3 hours prior to bedtime; may increase by doubling dose every 4 to 7 days if needed; maximum: 0.75 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OPAD,Mebeverine,Padalin 100mg,ALIM,Gastrointestinal tract spasm¡A enteritis¡A gastritis¡A irritable bowel syndrome.,Hypersensitivity to mebeverine. Paralytic ileus. Severe hepatic impairment.,Dizziness¡A drowsiness¡A headache¡A constipation¡A nausea¡A loss of appetite¡A allergies¡A hypersensitivity (e.g. urticaria¡A erythematous rash¡A angioedema).,«Ç·Å25¢J¥H¤U,Adult: 200 mg bid¡A before meals.,µL»Ý½Õ¾ã¾¯¶q,[Micromedex] Use with caution in patients with marked renal insufficiency or marked hepatic impairment.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[Micromedex] Do not administer mebeverine during pregnancy.,Unknown ¨S¦³¸ê®Æ,[Micromedex] Do not administer mebeverine to women who are breastfeeding.,AC;PC;PO;,,,,,
IGW5O,Dextrose,5% Dextrose inj 500mL "OTSUKA",MSIV,Supplement of water and nutrition for surgery and other diseases.,Hypersensitivity to any component of the formulation.,Hyperglycemia¡A edema¡A electrolytes imbalance.,30¢J¥H¤U,Individualized dosage. Usually¡A adult: 500-1000mL as an intravenous infusion¡A and then increase or decrease appropriately according to symptoms. Dextrose monohydrate 50 mg/mL,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,
IEND5,Cyclophosphamide,Endoxan inj 500mg,RACA,Treatment for lymphatic leukemia¡A disseminated tumors¡A chronic lymphatic leukemia¡A lymphosarcoma¡A various reticuloendotheliosis¡A and to prevent tumor relapse.,Allergic to cyclophosphamide. Severe bone marrow dysfunction¡A especially in patients previously treated with cytotoxic agents or radiation therapy. Cystitis. Urethral blockage. Active infections. Pregnancy and lactation.,Common: Alopecia¡A Disorder of skin pigmentation¡A Injury of nail¡A Rash¡A Abdominal discomfort¡A Diarrhea¡A Loss of appetite¡A Nausea and vomiting¡A Leukopenia¡A Neutropenia¡A Amenorrhea Serious: Cardiac tamponade¡A Cardiotoxicity¡A Congestive heart failure¡A Pericardial effusion¡A Erythema multiforme¡A Malignant tumor of dermis¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Acute myeloid leukemia¡A Chronic myeloid leukemia¡A Malignant tumor of lymphoid hemopoietic and related tissue¡A Myelodysplastic syndrome¡A Angiosarcoma of liver¡A Anaphylaxis¡A Acquired contracture of bladder neck¡A Bladder cancer¡A Fibrosis of urinary bladder¡A Hemorrhagic cystitis¡A Metastatic malignant neoplasm to renal pelvis¡A Pyelitis¡A Renal hematuria¡A Azoospermia¡A Oligozoospermia¡A Interstitial pneumonia¡A Pulmonary fibrosis¡A Infectious disease,¤£±o°ª©ó25¢J,Maintenance therapy: IV 3-6mg/kg/day (equivalent to 120-240mg/m2 of BSA). Intermittent therapy: 10-15mg/kg (equivalent to 400-600mg/m2 of BSA)¡A followed by intervals of 2-5 days. High-dose intermittent therapy: 20-40mg/kg (equivalent to 800-1600mg/m2 of BSA) or higher doses¡A especially in the case of bone marrow transplantation¡A with intervals of 21-28 days.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¦å²MÁx¬õ¯À­È¬° 3.1-5mg/100mLªÌ¡A­°§C 25%ªº¾¯¶q,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,,,IVD;,0.9% sodium chloride 25mL,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,
OASZ,Azathioprine,Asazipam 50mg,HIMM,Adjuvant therapy for preventing rejection in kidney transplant surgery¡A systemic lupus erythematosus¡A severe rheumatoid arthritis¡A acute and chronic leukemia.,Hypersensitivity to azathioprine or 6-mercaptopurine (6-MP). Pregnant or potentially pregnant patients. Patients with rheumatoid arthritis previously treated with alkylating agents.,Common: Nausea and vomiting (12%) Serious: Pericarditis¡A Skin cancer¡A Pancreatitis¡A Hypersensitivity¡A Acute myeloid leukemia¡A Hematologic toxicity¡A Leukopenia (Renal transplant¡A more than 50%; rheumatoid arthritis¡A 28%)¡A Leukopenia (Severe)¡A <2500 cells/mm[3] (renal transplant¡A 16%; rheumatoid arthritis¡A 5.3%)¡A Macrocytic anemia¡A Myelodysplastic syndrome¡A Myelosuppression (5%)¡A Pancytopenia¡A Thrombocytopenia¡A Hepatotoxicity (<1%)¡A Lymphoma involves liver¡A Veno-occlusive disease of the liver¡A Hypersensitivity reaction¡A Malignant lymphoma (0.5%)¡A T-cell lymphoma¡A Hepatosplenic¡A Progressive multifocal leukoencephalopathy¡A Adenocarcinoma of lung¡A Infectious disease (renal transplant¡A 20%; rheumatoid arthritis¡A <1%)¡A Neoplastic disease (0.5-11.9%),25¢J¥H¤U,Organ transplantation: Adults and children - up to 5 mg/kg/day; maintenance: 1-4 mg/kg/ay. Other conditions:Adults and children - 1-3 mg/kg/day. If the patient continues to take the medication for 3 months without any improvement in symptoms¡A discontinuation may be considered.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¤£¨}¯f¤H§ë¤©Azathioprine´Á¶¡À³ª`·N¡A¨Ã¥BÀ³©w´Á§¹¦¨¦å²y­p¼Æ¤Î¨x¥\¯àªº¸ÕÅç¡C¹ï©óAzathioprine¥NÁÂ¥i¯à¨ü·lªº¯f¤H¾¯¶qÀ³¦A­°§C¨ì«ØÄ³¾¯¶qªº¸û§CÂI¡C¦p¨xÅ¦©Î¦å²G¬r©Ê²£¥Í¡A¾¯¶qÀ³¸Ó¦A­°§C¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ] Ãh¥¥´Á¶¡­n¨Ï¥ÎAzathioprine»Ý¥J²Óµû¦ô¦MÀI©Ê»P¬Û¹ï¤§¯q³B¡C ¥¥°ü¨Ï¥ÎAzathioprine«á¡A©ó­L¨à¦å²G¤Î¦Ï¤ô¤¤µo²{§C¿@«×ªºAzathioprine¤Î¨ä¥NÁÂª«¡C ¤w¦³³ø§i¥À¿ËÃh¥¥®É´ÁªA¥ÎAzathioprine¡A³¡¥÷·s¥Í¨à¥X²{¥Õ¦å²y´î¤Ö¡A¤Î¡þ©Î¦å¤pªO´î¤Ö¯g¡C ¦]¦¹Ãh¥¥´Á¶¡»ÝÃB¥~¤p¤ßºÊ´ú¦å²G¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] 6-Mercaptopurine¤w¸g³Q½T»{¥X²{¦b±µ¨üAzathioprineªvÀø¥À¿Ë¤§ªì¨Å¤Î¨Å¥Ä¤¤¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°§K¬Ì§í¨î¾¯¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
ICAR2,Carboplatin,Carboplatin inj 150mg/15mL,RACA,Ovarian Cancer. First-line treatment for Advanced Ovarian Cancer¡A use as the initial treatment for advanced ovarian cancer¡A in combination with other approved chemotherapeutic agents. Secondary Treatment for Advanced Ovarian Cancer¡A for patients with recurrent ovarian cancer after chemotherapy as a palliative treatment¡A including those previously treated with cisplatin.,Patients with a history of severe allergic reactions to carboplatin or other platinum-containing compounds. Patients with existing severe renal dysfunction¡A unless¡A in the judgment of the physician and the patient¡A the potential benefits of treatment are deemed to outweigh the risks. Patients suffering from severe bone marrow suppression. Patients with hemorrhagic tumors.,Common: Alopecia (2-50%)¡A Hypocalcemia (29-31%)¡A Hypokalemia (20-28%)¡A Hypomagnesemia (29-43%)¡A Hyponatremia (29-47%)¡A Abdominal pain (17%)¡A Diarrhea (6%)¡A Nausea (75-80%)¡A Vomiting (65-81%)¡A Anemia (21-90%)¡A Leukopenia (26-71%)¡A Neutropenia (16-67%)¡A Thrombocytopenia (35-62%)¡A Alkaline phosphatase above reference range (24-37%)¡A Aspartate aminotransferase serum level above reference range (15-19%)¡A Blood urea outside reference range (14-22%)¡A Serum creatinine above reference range (6-10%)¡A Pain (23%) Serious: Myelosuppression¡A Hypersensitivity reaction (2%)¡A Unexplained visual loss¡A Visual disturbance (1%),30¢J¥H¤UÁ×¥úÀx¦s,Monotherapy: 360mg/m2 IVD on day 1¡A repeated every 4 weeks. Wait until neutrophil count is >2¡A000 and platelet count is >100¡A000 before repeating. Combination with cyclophosphamide: For advanced ovarian cancer¡A Carboplatin - 300mg/m2 on day 1¡A repeated every 4 weeks for 6 cycles. Cyclophosphamide - 600mg/m2 on day 1¡A repeated every 4 weeks for 6 cycles. Repeat only if neutrophil count is >2¡A000 and platelet count is >100¡A000.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated ¡V 1st trimester,[¥é³æ] ¥¥°ü¨Ï¥Îcarboplatinª`®g²G·|¾É­P­L¨à¶Ë®`¡C¦b¤j¹«ªº¾¹©x¦¨§Î´Á¶¡µ¹¤©carboplatin ¤]ÃÒ¹ê·|¤Þ°_­F­L¬r©Ê»P­P·î©Ê¡C¥Ø«e©|µL¥H¥¥°ü¬°¹ï¶Hªº¾A·í¥B¨}¦nªº¹ï·Ó¬ã¨s¡C ±wªÌ­Y­n¦bÃh¥¥´Á¶¡¨Ï¥Îcarboplatin¡A©Î¦b¨Ï¥Îcarboplatin´Á¶¡Ãh¥¥¡A«hÀ³§iª¾¹ï­L ¨àªº¼ç¦b¦MÀI©Ê¡CÀ³ÄU§i¥i¯àÃh¥¥ªº°ü¤kÁ×¥¥¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ¥Ø«eÁÙ¤£²M·¡¦¹ÃÄ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡C¦]¬°³\¦hÃÄ«~·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡A¤S ¦]carboplatin ¥i¯à·|¨Ï¦Y¥À¨ÅªºÀ¦¨à²£¥ÍÄY­«¤£¨}¤ÏÀ³¡A¬GÀ³¦Ò¼{¥»ÃÄ¹ï¥À¿Ëªº­«­n ©Ê¡A¨M©w°±¤î±Â¨Å©Î°±ÃÄ¡C,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,Administer IV over 15 minutes or longer,1. ¾T·|»Pcarboplatin¤ÏÀ³¦Ó§Î¦¨¨H¾ý¡A¨Ã¨Ï¤O»ù³à¥¢¡C¦]¦¹¡A»s³Æ©Îµ¹¤©carboplatin®É¡A¤£¥i¥H¨Ï¥Î§t¾T°wÀY¡A©Î¥i¯à»PÃÄ«~±µÄ²³¡¦ì§t¾TªºÀR¯ßµ¹ÃÄ¾¹²Õ¡C 2. Carboplatin¥u¯à¥HºC³tÀR¯ß¿éª`¤è¦¡¡A¤£À³¥Ñ§Ö³tÀR¯ßª`®g¤è¦¡µ¹¤©¡C 3. ³q±`¿éª`15¤ÀÄÁ¥H¤W¡A¤£»Ý­nªvÀø«e©ÎªvÀø«áµ¹¤j¶q²GÅé¡A¤]¤£»Ý­n±j­¢§Q§¿¡C 4. ¥i¥H¥Î D5W ©Î N/S ¶i¤@¨Bµ}ÄÀ(³Ì§C¿@«× 0.5 mg/mL)¡F µ}ÄÀ«á8¤p®É¤º¨Ï¥Î¡C
OIBR10,Palbociclib,Ibrance 100mg (Sample),RACA,Breast cancer¡A advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive¡A human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer¡A advanced (with disease progression following endocrine therapy): Treatment of HR-positive¡A HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).,Common Dermatologic: Alopecia (18% to 33% )¡A Rash (17% to 18% ) Gastrointestinal: Constipation (20% )¡A Decrease in appetite (15% to 16% )¡A Diarrhea (24% to 26% )¡A Nausea (34% to 35% )¡A Stomatitis (28% to 30% )¡A Vomiting (16% to 19% ) Hematologic: Anemia¡A All Grades (24% to 30% )¡A Leukopenia¡A All Grades (39% to 53% )¡A Neutropenia¡A All Grades (80% to 83% )¡A Thrombocytopenia¡A All Grades (16% to 23% ) Immunologic: Infectious disease (47% to 60% ) Neurologic: Asthenia (8% to 13% )¡A Headache (26% )¡A Peripheral neuropathy (13% ) Respiratory: Bleeding from nose (6.7% to 9.2% )¡A Upper respiratory infection (31% ) Other: Asthenia (7.5% to 17% )¡A Fatigue (37% to 41% )¡A Fever (12% to 13% ) Serious Hematologic: Anemia¡A Grade 3 or 4 (Up to 5% )¡A Febrile neutropenia (0.9% to 2.5%)¡A Leukopenia¡A Grade 3 or 4 (Grade 3¡A 24% to 30%; Grade 4¡A up to 1% )¡A Neutropenia¡A Grade 3 or 4 (Grade 3¡A 55% to 56%; Grade 4¡A 10% to 11% )¡A Thrombocytopenia¡A Grade 3 or 4 (Up to 2% ),30 ¢J¥H¤U,The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE¡A the recommended dose of fulvestrant is 500 mg administered on Days 1¡A 15¡A 29¡A and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. Recommended Dose Modification for Adverse Reactions: (Dose Level; Dose) Recommended starting dose: 125 mg/day; First dose reduction: 100 mg/day; Second dose reduction: 75 mg/day. Dose Modification and Management ¡V Hematologic Toxicities: Monitor complete blood counts prior to the start of IBRANCE therapy and at the beginning of each cycle¡A as well as on Day 15 of the first 2 cycles¡A and as clinically indicated. For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles¡A monitor complete blood counts for subsequent cycles every 3 months¡A prior to the beginning of a cycle and as clinically indicated. (CTCAE Grade) Grade 1 or 2: No dose adjustment is required. Grade 3: Day 1 of cycle: Withhold IBRANCE¡A repeat complete blood count monitoring within 1 week. When recovered to Grade 2¡A start the next cycle at the same dose. Day 15 of first 2 cycles: If Grade 3 on Day 15¡A continue IBRANCE at current dose to complete cycle and repeat complete blood count on Day 22. If Grade 4 on Day 22¡A see Grade 4 dose modification guidelines below. Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles. Grade 3 neutropeniab with fever more than 38.5 oC and/or infection: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose. Grade 4: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¹ï­««×¨x¥\¯à¤£¥þ(Child-Pugh¤À¯ÅC)ªº¯f¤H¡AIbrance¹ï©ó3/1 Àøµ{¯f¤Hªº«ØÄ³¾¯¶q¬°¨C¤é¤@¦¸75 ²@§J¡C [Micromedex 20210905]Hepatic impairment (severe¡A Child-Pugh C): 75 mg orally once daily for 21 consecutive days followed by 7 days off treatment of a 28-day cycle.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¥Ø«e¨ÃµL©Î¶È¦³¦³­­ªº¥¥°ü¨Ï¥Îpalbociclib ªº¸ê®Æ¡C °Êª«¬ã¨sÅã¥Ü¥»«~¨ã¦³¥Í´Þ¬r©Ê¡C Ibrance¨Ã¤£«ØÄ³©óÃh¥¥´Á¶¡¨Ï¥Î¡A¤]¤£«ØÄ³¥Î©ó¨ã¥Í¨|¯à¤O¦ý¥¼±Ä¨úÁ×¥¥±¹¬Iªº°ü¤k¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ]¥Ø«e©|¥¼¶i¦æ¹L¥ô¦óµû¦ôpalbociclib ¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅT¡B¬O§_¥X²{©ó¨Å¥Ä¤¤¡B©Î¨ä¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅTªº¤HÅé¬ã¨s©Î°Êª«¬ã¨s¡C ¥Ø«e¨Ã¤£½Tª¾palbociclib ¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C ±µ¨üpalbociclib ªvÀøªº¯f¤H¤£¥iÁý­÷¥À¨Å¡C,WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¥é³æ«ØÄ³À³¾ãÁû§]ªA¡A¤Å©CÄZ¡B«r¸H©Î¥´¶}½¦Ån¡C
OMEPR,Methylprednisolone,Methylprednisolone 4mg,HM,RA¡A acute & subacute bursitis¡A exfoliative dermatitis¡A allergic rhinitis¡A bronchial asthma¡A contact dermatitis & allergic conjunctivitis.,Systemic fungal infection; immunization. Lactation,Fluid & electrolyte disturbances; muscle weakness¡A aseptic osteonecrosis¡A osteoporosis; peptic ulcer with perforation¡A hemorrhage¡A abdominal distention¡A impaired wound healing; increased intraocular pressure; Cushingoid state¡A growth suppression¡A menstrual irregularities¡A posterior subcapsular cataracts.,25¢J¥H¤UÁ×¥úÀx¦s,4-48mg/day,µL»Ý½Õ¾ã¾¯¶q,¨xµw¤Æ¡A¯×ªÕ¨x±wªÌÀ³ÂÔ·V§ë»P,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,PREDNISOLONE: Human Data Suggest Risk Methylprednisolone is classified as a nonfluorinated corticosteroid. When systemic corticosteroids are needed in pregnancy for rheumatic disorders¡A nonfluorinated corticosteroids are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,Unknown ¨S¦³¸ê®Æ,PREDNISOLONE: Compatible Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses; however¡A monitoring of the breastfeeding infant is recommended (WHO 2002). Methylprednisolone is classified as a nonfluorinated corticosteroid; when systemic corticosteroids are needed in a lactating woman for rheumatic disorders¡A low doses of nonfluorinated corticosteroids are preferred (ACR [Sammaritano 2020]).( UpToDate) 2021/0125,AC;AC15;PC;PO;WM;,,,,,
EFLUT,Fluticasone,Fluticosone cream 0.05%¡A 5gm,TDER,Relief of the inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses such as: eczema including atopic¡A infantile & discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses including lichen simplex; lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus; an adjunct to systemic steroid therapy in generalised erythroderma; insect bite reactions; prickly heat.,Rosacea¡A acne vulgaris¡A perioral dermatitis; primary cutaneous viral infections (eg. Herpes simplex¡A chickenpox; perianal & genital pruritus¡A dermatoses in infant < 3 month including dermatitis & napkin eruptions. Primarily infected skin lesions caused by infection with fungi or bacteria.,Local burning¡A pruritus¡A local atrophic skin changes. Secondary infection¡A exacerbation of the signs & symptoms of the dermatoses¡A hypercorticism. Neurologic: Headache (8% to 9% ) Respiratory: Epistaxis (4% to 20% ),25¢J¥H¤U,Inflammatory dermatoses Adult¡A children¡A infants >=3 months Apply thinly to the affected skin areas once or BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,Respiratory (Corticosteroid) - Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
IHMCP,Fibrinogen human,Haemocomplettan P inj 1gm/vial,HEMT,Bleeding disorder. 1) Congenital hypo-¡A dys-¡A or afibrinogenemia. 2) Acquired hypofibrinogenemia caused by the following symptoms: a. Severe liver parenchymal injury leading to synthesis disorder. b. Excessive consumption due to disseminated intravascular coagulation (DIC) and hyperfibrinolysis response.,Contraindicated in individuals allergic to the active ingredient or any excipients. Avoid in cases of thrombosis or myocardial infarction¡A unless in extremely severe and life-threatening bleeding situations.,Common: Nausea (>5%)¡A Vomiting (>5%)¡A Thrombocytosis (>5%)¡A Headache (>1%)¡A Fever (>1%) Serious: Myocardial infarction¡A Arterial thrombosis¡A Deep venous thrombosis¡A Thromboembolic disorder¡A Anaphylaxis¡A Hypersensitivity reaction¡A Pulmonary embolism,2-8¢J¡A¤Å§N­á¡A¤p²~À³©ñ¸m©ó¥~²°¤ºÁ×¥ú,Dosage for replacement therapy and duration should be based on disease severity¡A bleeding location and extent¡A and the patient's clinical condition. To calculate the patient's dosage¡A measure functional fibrinogen levels. Individual dosing and frequency should be determined based on routine measurements of plasma fibrinogen concentration¡A and continuous monitoring of the patient's clinical condition and use of other replacement therapies. Normal plasma fibrinogen: 1.5-4.5g/L. Critical plasma fibrinogen: 0.5-1.0g/L or below may result in bleeding. (1) For patients with congenital hypo-¡A dys-¡A or afibrinogenemia and known bleeding tendencies for prophylaxis: - Preventive treatment is recommended to raise fibrinogen levels to 1 g/L to ensure safe hemostasis and maintain fibrinogen levels >0.5g/L until complete wound healing. - For surgical or bleeding event treatment: Fibrinogen dosage (mg/kg) = [(Target concentration in g/L) - (Measured concentration in g/L)] / 0.017 (g/L per mg/kg). - Appropriate subsequent dosages should be based on the patient's clinical condition and laboratory reports. - Half-life of fibrinogen is 3-4 days. Repeated administration is usually unnecessary in the absence of consumption. (2) For bleeding treatment: Adults: 1-2g (or 30 mg/kg) as needed¡A followed by additional transfusions. Severe bleeding: 4-8g may be required. Children: 20-30mg/kg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ©|¥¼¬I¦æ Haemocomplettan ¤§°Êª«¥Í´Þ¬ã¨s¡C¥Ñ©ó¬O¤HÃþ¨Ó·½¤§¬¡©Ê¦¨¤À¡A¨ä»P±wªÌ¦Û¨­ ³J¥Õ½èªº¤À¸Ñ¥NÁÂ¬O¬Û¦Pªº¡C³o¨Ç¤HÅé¦å²Gªº¥Í²z²Õ¦¨¹ï©ó¥Í´Þ©Î¬O­L¨à¥¼¹w´Á³y¦¨°Æ§@¥Î¡C ¥Ø«e©|¥¼«Ø¥ß¤HÅé¦å¼ßÅÖºû³J¥Õ­ì²£«~¨Ï¥Î©ó¤HÅéÃh¥¥´Á¶¡ªº¦w¥þ©Ê¹ï·ÓÁ{§É¸ÕÅç¡C ÅÖºû³J¥Õ­ì²£«~ªvÀø²£¬ì¨Öµo¯g¤§Á{§É¸gÅç¡AÅã¥Ü¹ï©óÃh¥¥´Á¶¡©Î­L¨à©Î·s¥Í¨àªº°·±dµL¤£¨}¼vÅT¬O¥i¹w´Áªº¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Haemocomplettan ¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤´¥¼ª¾¡C¥Ø«e©|¥¼«Ø¥ß¤HÅé¦å¼ßÅÖºû³J¥Õ­ì ²£«~©ó­÷¨Å´Á¶¡¨Ï¥Î¤§¦w¥þ©ÊªºÁ{§É¹ï·Ó¸ÕÅç¡C¹ï±Â¨Å«Äµ£ªº­·ÀI¬OµLªk±Æ°£ªº¡C À³¦Ò¶q­÷¨Å¹ï©ó«Äµ£ªº§Q¯q¥H¤ÎªvÀø¹ï©ó¤k©Êªº§Q¯q¡A¥H¨M©w¬O§_¤¤Â_­÷¨Å©Î¬O¤¤Â_/Á×§K ¥HHaemocomplettan ªvÀø¡C,IVD;IVPUSH;,¨C²~ Haemocomplettan 1g/vial¥H50mLª`®g¥Î¤ô°t»s¡C(20mg/mL),,µ¹ÃÄ³t²v¤£¶W¹L5mL/minute¡Cµ¹ÃÄ«eÀ³¦^·Å¡C,µ¹ÃÄ³t²v¤£¶W¹L5mL/minute¡Cµ¹ÃÄ«eÀ³¦^·Å¡C,1. Haemocomplettan 1g/vial¥H50mLª`®g¥Î¤ô°t»s¡A°t¸m«á±o20²@§J/²@¤Éªº¤HÅéÅÖºû³J¥Õ­ì 2. °t»s«á·»²GÀ³©óµ¹ÃÄ«e¦^·Å¦Ü«Ç·Å©ÎÅé·Å¡AµM«á¥H±wªÌ³ÌµÎ¾Aªº³t«×½wºCª`®g©Î¿éª`¡Cª`®g©Î¿é³t«×¬ù¤£¶W¹L5mL/minute¡C 3. À³±N°t²G¬ï¨ë¾¹´¡¤J²£«~²~¶ë¤W¡A±N°wµ©±µ¨ì²°¤ºÀHªþªº¹LÂo¾¹¡A¦A¥H°wµ©¥Ñ°t²G¬ï¨ë¾¹©â¨ú·»²G¡C
OAAS,Aminophylline,Antiasth 225mg slow release,ERSP,Asthma and bronchospasm.,Hypersensitivity to theophylline¡A ethylenediamine¡A or to any product component.,Common: Diarrhea¡A Nausea¡A Vomiting¡A Dizziness¡A Headache¡A Insomnia¡A Tremor¡A Irritability¡A Restlessness¡A Diuresis Serious: Atrial fibrillation¡A Bradyarrhythmia¡A Too quick administration¡A Cardiac arrest¡A Tachyarrhythmia¡A Erythroderma¡A Necrotizing enterocolitis in fetus OR newborn¡A Hypersensitivity reaction¡A Intracranial hemorrhage¡A Seizure,«Ç·Å25¢J¥H¤UÁ×¥ú°®Àê³B,Adults: 1-2 tablet BID. For nocturnal bronchospasm prevention¡A 1 tablet before bedtime. Children: 12-20mg/kg/day. Children >8 years: 0.5 to 1 tablet/dose. Chronic asthma: 25-42mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,[Lexidrug] Oral (extended release tablets): There are no dosage adjustments provided in the manufacturer's labeling; use caution (accumulation may occur). Consider reduced doses and more frequent monitoring of serum theophylline concentration.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,Theophylline: Compatible,Compatible ­÷¨Å®É¥i¨Ï¥Î,Theophylline: Compatible,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¾ã²É§]ªA¡A¤£¥i©CÄZ©Î¿i¸H¡C°|¤º¥t¦³Theophylline¦¨¥÷ÃÄ¤ôCentertheo 60mL (5.34mg/mL) liquid¤Î«ùÄò©ÊÃÄ®Ä½¦ÅnXanthium 200mg¡C
ISLIP,MCT + Fish oil + Olive oil + Soybean oil,SMOFlipid inj 20% 250mL,NUTR,Use as part of parenteral nutrition for parients who cannot take sudiffient oral or enteral nutrition.,- Individuals who are high sensitivity to the main ingredients or excipients of this product¡A such as egg¡A soy¡A or peanut protein. - Severe hyperlipidemia. - Severe liver dysfunction. - Severe coagulation abnormalities. - Severe renal dysfunction and have not undergone blood filtration or dialysis treatment. - Acute shock. - Contraindications for infusion therapy: acute pulmonary edema¡A excessive body fluid volume¡A and decompensated heart failure. - Unstable conditions (e.g.¡A severe post-traumatic state¡A uncompensated diabetes¡A acute myocardial infarction¡A stroke¡A embolism¡A metabolic acidosis¡A severe sepsis¡A and hypovolemic dehydration).,Common: Hyperglycemia (2-5%)¡A Nausea (Adult¡A 2%; pediatric¡A 18%)¡A Vomiting (7-9%)¡A Anemia (Adult¡A 2%; pediatric¡A 18%) Serious: Aluminum poisoning¡A Hypertriglyceridemia¡A Hypervolemia (<1%)¡A Refeeding syndrome¡A Thrombophlebitis (<1%)¡A Cholestasis of parenteral nutrition (2.4-4%)¡A Parenteral nutrition associated liver disease¡A Hypersensitivity reaction¡A Fat overload syndrome¡A Infectious disease¡A Sepsis (2%),¤£±o¶W¹L25¢XC¡C¤£¥i§N­á¡C,Adults: 1-2 gm of fat/kg/day (5-10 mL/kg/day). Infusion rate: 0.125-0.15 gm of fat/kg/hour (0.63-0.75 mL/kg/hour) Newborns and infants: 0.5-1 gm of fat/kg/day; Maximum 3 gm of fat/kg/day (15 mL/kg/day). Increase dose at a rate of 0.5-1 gm of fat/kg/day. Infusion rate: <= 0.125 gm of fat/kg/hour. Children: <= 2 gm of fat/kg/day (10 mL/kg/day). Infusion rate: <= 0.15 gm of fat/kg/hour.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥¥°ü©Î­÷¨Å°ü¤k¨Ï¥ÎSMOFlipidªº¸ê®Æ¡A¥çµL°Êª«ªº¥Í´Þ¬r©Ê¬ã¨s¸ê®Æ¡C Ãh¥¥©M­÷¨Å´Á¶¡ÀR¯ßÀç¾i¿éª`¥i¯à¦³¨ä¥²­n¡A¥u¦³¸g¹L¥J²Ó¦Ò¶q«á¡A ¤~¥iµ¹¤©¥¥°ü©M­÷¨Å°ü¤kSMOFlipid¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥¥°ü©Î­÷¨Å°ü¤k¨Ï¥ÎSMOFlipidªº¸ê®Æ¡A¥çµL°Êª«ªº¥Í´Þ¬r©Ê¬ã¨s¸ê®Æ¡C Ãh¥¥©M­÷¨Å´Á¶¡ÀR¯ßÀç¾i¿éª`¥i¯à¦³¨ä¥²­n¡A¥u¦³¸g¹L¥J²Ó¦Ò¶q«á¡A ¤~¥iµ¹¤©¥¥°ü©M­÷¨Å°ü¤kSMOFlipid¡C,IVD;,,,,Adults infusion rate: 0.125-0.15 gm of fat/kg/hour (0.63-0.75 mL/kg/hour) Newborns/infants infusion rate: <= 0.125 gm of fat/kg/hour (0.63 mL/kg/hour) Children infusion rate: <= 0.15 gm of fat/kg/hour (0.75 mL/kg/hour),1. ¥i¥Ñ©PÃä©Î¤¤¤ßÀR¯ß¿éª`µ¹ÃÄ¡C 2. ·í¥Î©ó·s¥Í¨à©M 2 ·³¥H¤U¨àµ£®É¡A·»²G©M¿é²G³UÀ³Á×¥úª½¦Üµ¹ÃÄ§¹¦¨¡C 3. ¨Ï¥Î«e¶·½T»{¨Å¾¯¨S¦³¼h¬Û¤ÀÂ÷©Î¨I¾ýª«¡A§e§¡½èª¬ºA¤~¥i¨Ï¥Î¡C 4. µo¥Í°Æ§@¥Î©Î¿éª`´Á¶¡¤T»Ä¥Ìªoà­¿@«×¤W¤É¶W¹L 3 mmol/L¡AÀ³°±¤î¿éª`©Îµø»Ý­n­°§C¾¯¶qÄ~Äò¿éª`¡C
OKIS,Ribociclib,Kisqali 200mg,RACA,Treatment of hormone receptor (HR)-positive¡A human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy.,Known hypersensitivity to Ribociclib succinate.,>10%: Cardiovascular: Peripheral edema (12%) Central nervous system: Fatigue (37%)¡A headache (22%)¡A insomnia (12%) Dermatologic: Alopecia (33%)¡A skin rash (17%)¡A pruritus (14%) Endocrine & metabolic: Decreased serum potassium (11%) Gastrointestinal: Nausea (52%)¡A diarrhea (35%)¡A vomiting (29%)¡A constipation (25%)¡A decreased appetite (19%)¡A stomatitis (12%)¡A abdominal pain (11%) Genitourinary: Urinary tract infection (11%) Hematologic & oncologic: Neutropenia (75%; grade 3: 50%; grade 4: 10%)¡A leukopenia (33%; grade 3: 20%; grade 4: 1%)¡A decreased platelet count (29%; grade 3: 1%)¡A anemia (18%; grade 4: <1%)¡A abnormal phosphorus levels (decreased; 13%; grade 3: 5%; grade 4: 1%)¡A lymphocytopenia (11%; grade 3: 6%; grade 4: 1%) Hepatic: Increased serum ALT (<46%)¡A increased serum AST (<44%)¡A increased serum bilirubin (18%) Neuromuscular & skeletal: Back pain (20%) Renal: Increased serum creatinine (20%) Respiratory: Dyspnea (12%) Miscellaneous: Fever (13%),30¢J¥H¤U,600 mg orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food. Coadminister KISQALI with letrozole 2.5 mg taken once daily throughout the 28-day cycle. Patients should take their dose of KISQALI and letrozole at approximately the same time each day¡A preferably in themorning.  Recommended Dose Modification for Adverse Reactions: - Starting dose: 600 mg/day (three 200 mg tablets) - 1st dose reduction: 400 mg/day (two 200 mg tablets) - 2nd dose reduction: 200 mg/day (one 200 mg tablet) If further dose reduction below 200 mg/day is required¡A discontinue the treatment.,»Ý½Õ¾ã¾¯¶q,Moderate or severe impairment (Child-Pugh class B or C): Reduce initial dose to 400 mg/day.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¥é³æ«ØÄ³À³¾ãÁû§]ªA¡A¤Å«rÄZ©ÎÀ£¸H¡C
ICOMDBA5,SARS-CoV-2 Spike glycoprotein [mRNA],BA4/5¦¸¥@¥NModerna(Covid19) 0.5mL/dose(2.5mL/vial),HIMM,Moderna COVID-19 Vaccine¡A for active immunization to prevent COVID-19 in individuals 18 years of age and older.,History of a severe allergic reaction (e.g.¡A anaphylaxis) to any component of the Moderna COVID-19 Vaccine.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,-50¢J¦Ü-15¢J¥i«O¦s9­Ó¤ë¡C2-8¢JÁ×§K¥ú·Ó¡A¥i«O¦s30¤Ñ¡CÂ÷§NÂÃ©ó8-25¢J¥u¥i«O¦s24¤p®É,IM¡A 0.5 mL¡A > or = 12 years¡A As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine¡A bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. IM¡A 0.25 mL¡A 6-11 years¡A As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine¡A bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤j¶qªºÆ[¹î©Ê¸ê®ÆÅã¥Ü¡A¥¥°ü¦b²Ä¤G»P²Ä¤T¥¥´Á±µºØ Spikevax ­ì¯f¬r®è¬Ì­]¨Ã¥¼¼W¥[¤£¨}Ãh¥¥µ²ªG¡C ÁöµM¦b²Ä¤@¥¥´Á±µºØªºÃh¥¥µ²ªG¸ê®Æ¦³­­¡A¦ý¬O¨Ã¥¼µo²{¬y²£­·ÀI¦³¤W¤Éªº²{¶H¡C °Êª«¸ÕÅç¨Ã¥¼Åã¥ÜSpikevax ­ì¯f¬r®è¬Ì­]·|¹ïÃh¥¥¡B­F­L¡þ­L¨àµo¨|¡B¤À®Y©Î²£«áµo¨|·|³y¦¨ª½±µ©Î¶¡±µ¦³®`ªº¼vÅT¡C Ãh¥¥´Á¶¡¥i¥H±µºØSpikevax ­ì¯f¬r®è¬Ì­]¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ñ©ó­÷¨Å°ü¤k±µºØSpikevax­ì¯f¬r®è¬Ì­]«á¤§¥þ¨­©Ê¼ÉÅS¥i³Q©¿²¤¡A¹w´Á¹ï©óÁý­÷¥À¨Å¤§·s¥Í¨à/À¦¨à¤£¨ã¼vÅT¡C Æ[¹î©Ê¸ê®ÆÅã¥Ü­÷¨Å°ü¤k±µºØ¬Ì­]«á¡A¨Ã¥¼¥X²{¹ïÁý­÷¥À¨Å¤§·s¥Í¨à/À¦¨à¦³®`ªº¼vÅT¡C ­÷¨Å´Á¶¡¥i¥H±µºØSpikevax­ì¯f¬r®è¬Ì­]¡C,IM;,,,,,1. ¥»ÃÄ¬°¦h¾¯¶qÃÄ²~¡C¨C²~¥i©â¨ú5¾¯¡A¨C¾¯0.5mL¡C 2. ¥¼¶}«ÊÃÄ²~¡A§NÂÃ©ó2-8¢J¤U¥i«O¦s30¤Ñ¡A«Ç·Å«O¦s©ó8-25¢J¤U¥i«O¦s24¤p®É¡C¤w©â²GÃÄ²~¡A§NÂÃ©Î«Ç·Å¤U¥i«O¦s19¤p®É¡A19¤p®É«á¶·¥á±ó¡C 3. ¸Ñ­á«á¡A½Ð¤Å­«·s§N­á¡C¨Ï¥Î«e½Ð¥ý±NÃÄ²~¸Ñ­á¡A¸Ñ­á¤è¦¡¡G©ñ¸m§NÂÃ«Ç(2-8¢J)2¤p®É30¤ÀÄÁ¡A¨Ã©ó¬I¥´«e½Ð±NÃÄ²~©ñ¸m«Ç·Å(15-25¢J)15¤ÀÄÁ¡C©ÎªÌ©ñ¸m«Ç·Å(15¦Ü25¢J)1¤p®É¡C 4. ¥»¬Ì­]À³¥H¦Ù¦×ª`®g¤è¦¡¬I¥´¡A²z·Qª`®g³¡¦ì¬°¤WÁu¤T¨¤¦Ù¡C½Ð¤Å¥H¦åºÞ¤ºª`®g¡B¥Ö¤Uª`®g©Î¥Ö¤ºª`®g¤è¦¡¬I¥´¥»¬Ì­]¡C
EPMT,Permethrin,Permethrin cream 5%¡A 30gm (±M®×¶i¤f),TDER,Permethrin 5% w/w Cream is indicated for the treatment of scabies.,Hypersensitivity to any pyrethroid or pyrethrin¡A or to any component of the formulation.,Localized burning¡A localized numbness¡A tingling of skin¡A pruritus¡A erythema¡A skin rash (scalp)¡A stinging of the skin¡A localized edema.,25¢J¥H¤U,Scabies: Topical: Cream 5%: Thoroughly massage cream (30 g for average adult) from head to soles of feet; leave on for 8 to 14 hours before removing (shower or bath); for infants and the elderly¡A also apply on the hairline¡A neck¡A scalp¡A temple¡A and forehead; may repeat if living mites are observed 14 days after first treatment; one application is generally curative.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
IGS5N,Dextrose + Sodium Chloride,5% Dextrose in 0.9% NaCl inj 500mL "N.K.",MSIV,Glucose and saline injection to replenish water¡A electrolytes¡A and nutrition.,Hypersensitivity to any component of the formulation.,Hyperglycemia¡A edema¡A electrolyte imbalance.,30¢J¥H¤U,Individualized dosage. Usually¡A adult: 500-1000mL as an intravenous infusion¡A and then increase or decrease appropriately according to symptoms. Dextrose monohydrate 50 mg/mL + Sodium chloride 9 mg/mL,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,
ENS5C,Sodium Chloride,Sodium chloride 0.9% Irrigation 500mL,MSIV,Wash skin¡A wound surface¡A mucous membrane¡A wet cloth¡A gargle¡A wash bronchial mucosa¡A promote phlegm discharge¡A wash medical equipment.,,,«Ç·Å,For irrigation only. Not for injection. As sterile irrigation of tissues or wounds¡A and for washing¡A rinsing medical device.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;GAR;IH;IN;INHL;IRR;SHA;SKIN;TOPI;,,,,,
OFUCO,Acetaminophen,Fucole Paran 500mg,CNEU,,¾AÀ³¯g: Relief of painful disorders such as headache¡A dysmenorrhea¡A conditions involving musculoskeletal pain¡A myalgias & neuralgias. After dental work¡A tooth extractions & in teething. As an analgesic & antipyretic in conditions accompanied by discomfort & fever¡A such as common cold & viral infections. °Æ§@¥Î: Acetaminophen has rarely been found to produce any side effects. It is usually well tolerated by aspirin-sensitive patients. Severe recurrent pain or high continued fever may indicate a serious conditions. Under these circumstances consult a physician. ¸T§Ò:When used for self-medication¡A do not use with other drug products containing acetaminophen or if allergic to acetaminophen or any of the inactive ingredients.,,«Ç·Å,Adult:500 mg q4h as needed¡A (max. 4 g/day). For long term therapy¡A not exceeding 2.6 g/day. Child: 10-15 mg/kg q4h as needed¡A (max. 65 mg/kg/day) not more than 5 doses in each 24 hrs period.,»Ý½Õ¾ã¾¯¶q,In patients with hepatic impairment/cirrhosis and active alcohol use¡A most experts recommend avoiding use as much as possible¡A and if used¡A limiting therapy to short-term use only at doses =<2 g/day.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;P1;P2;P3;P4;PC;PO;,,,,,
OAVE,Moxifloxacin,Avelox 400mg,QANB,Acute infective exacerbation of the chronic obstructive pulmonary disease. Bacterial conjunctivitis. Bacterial sinusitis¡A acute. Community-acquired pneumonia. Infection of skin and/or subcutaneous tissue¡A Complicated. Infection of skin and/or subcutaneous tissue¡A Uncomplicated. Infectious disease of the abdomen¡A Complicated. Treatment and Prophylaxis of Plague.,Hypersensitivity to moxifloxacin¡A other quinolone antibiotics¡A or any component of the formulation. pregnancy and lactation women.,Common Endocrine metabolic: Hypokalemia (1% ) Gastrointestinal: Abdominal pain (2% )¡A Constipation (2% )¡A Diarrhea (6% )¡A Nausea (7% )¡A Vomiting (2% ) Hepatic: ALT/SGPT level abnormal (1% ) Neurologic: Dizziness (3% )¡A Headache (4% ) Ophthalmic: Dry eyes (Ophthalmic¡A 1% to 6% )¡A Keratitis (Ophthalmic¡A 1% to 6% )¡A Pain in eye (Ophthalmic¡A 1% to 6% )¡A Reduced visual acuity (Ophthalmic¡A 1% to 6% ) Serious Cardiovascular: Aortic aneurysm¡A Or dissection¡A Prolonged QT interval (Oral/IV¡A 0.1% to less than 1% )¡A Torsades de pointes Dermatologic: Rash (Oral/IV¡A 0.1% to less than 1% )¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Endocrine metabolic: Hyperglycemia (Oral/IV¡A 0.1% to less than 1% )¡A Hypoglycemia Gastrointestinal: Clostridium difficile diarrhea Hematologic: Agranulocytosis¡A Aplastic anemia¡A Hemolytic anemia¡A Pancytopenia¡A Thrombocytopenia (Oral/IV¡A 0.1% to less than 1% ) Hepatic: Hepatic necrosis¡A Hepatitis¡A Liver failure Immunologic: Hypersensitivity reaction¡A Non-allergic anaphylaxis Musculoskeletal: Myasthenia gravis¡A Exacerbation¡A Rupture of tendon¡A Tendinitis Neurologic: Disorientated¡A Disturbance of attention¡A Guillain-Barre syndrome¡A Memory impairment¡A Peripheral neuropathy¡A Pseudotumor cerebri¡A Raised intracranial pressure¡A Seizure Ophthalmic: Retinal detachment Psychiatric: Agitation¡A Feeling nervous (0.1% to less than 1% )¡A Paranoid disorder¡A Suicidal Renal: Renal failure (0.1% to less than 1% ) Respiratory: Extrinsic allergic alveolitis Other: Serum sickness due to drug,¤£¥i¶W¹L30¢J¡A°®Àê³B,Community-acquired pneumonia¡A Adult: 400 mg once daily for 10 days. Acute bacterial exacerbation of chronic bronchitis¡A Adult: 400 mg once daily for 5-10 days. Acute bacterial sinusitis¡A Adult: 400 mg once daily for 7 days. Pelvic inflammatory disease¡A Adult: In combination with another antibacterial in mild to moderate cases: 400 mg once daily for 14 days. Complicated skin and skin structure infections¡A Adult: 400 mg once daily for 7-21 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ]Ãh¥¥°ü¤k¨Ï¥Î¥»ÃÄªº¦w¥þ©Ê¸ê®Æ©|¥¼³Q«Ø¥ß¡A¥i°f©ÊÃö¸`·l¶Ëµo¥Í©ó±µ¨üfluoroquinolonesªvÀøªº¤p«Ä¡AµM¦Ó¦¹²{¶H¨Ã¥¼³Q³ø¾Éµo¥Í©ó´¿¸g¼ÉÅS©ómoxifloxacinªº­L¨à¡A°Êª«¹êÅç¤wÅã¥Ü¨ã¦³¥Í´Þ¬r©Ê¡A¹ï¤HÅé¼ç¦bªº­·ÀI¥Ø«e¥¼ª¾¡C ¦]¦¹¡A¥»ÃÄ©óÃh¥¥´Áªº¨Ï¥Î¬O¸T¤îªº¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¦p¦P¨ä¥Lfluoroquinolones¡A¥»ÃÄ¤wª¾·|¾É­P¥®¦~°Êª«­t­«Ãö¸`³n°©ªº·l¶Ë¡AÁ{§É«e¸ê®ÆÅã¥Ü¤Ö¶qªºmoxifloxacin·|¤Àªc¨ì¤HÅé¨Å¥Ä¤¤¡A¥Ø«e©|µLªc¨Å©Î­÷¨Å°ü¤kªº¸ê®Æ¡A ¦]¦¹¨Ï¥Îmoxifloxacin©ó­÷¨Å°ü¤k¬O¸T¤îªº¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³»P¤ô¾ãÁû§]ªA¡C
IKCL5S,Potassium Chloride,20mEq KCl in¡iD5W 500mL¡j,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia¡A pain or phlebitis at injection site.,,Adult: Initial loading dose: 40~60 mEq¡A with ECG monitoring then based on serum potassium levels¡A Serum K>2.5 mEq/L: concentration < 30 mEq/L¡A with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia¡A treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
OMOL,Molnupiravir,Molnupiravir 200mg (¤½¶O),QANB,An Emergency Use Authorization (EUA) for the emergency use of Molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults who are at high-risk for progression to severe COVID-19.,NOT for use in patients who are less than 18 years of age. NOT for initiation of treatment in patients requiring hospitalization due to COVID-19. NOT for use for longer than 5 consecutive days. NOT for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19. Not recommended for use during pregnancy.,Common Gastrointestinal: Diarrhea (2% to 3% )¡A Nausea (2% ) Neurologic: Dizziness (1% )¡A Headache (1% ),¦b30¢J¥H¤U«O¦s,800 mg (four 200-mg capsules) orally every 12 hours for 5 days with or without food; administer as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤£«ØÄ³©óÃh¥¥´Á¶¡¨Ï¥Îmolnupiravir¡A¦ý­Y³B¤èÂå®v½T»{®Ä¯q¶W¶V­·ÀI¡A¨M©w¹ï¥¥°ü¨Ï¥Îmolnupiravir®É¡A¥²¶·¦V¸Ó¥¥°ü¸Ô²Ó§iª¾¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravirªº­·ÀI¡C³B¤èÂå®vÀ³©óÃh¥¥±wªÌ¨Ï¥Îmolnupiravir´Á¶¡³z¹L¹q¸Ü¡G02-66316000©Î¹q¤l¶l¥ó: dpoc_taiwan@merck.com³q³ø¨äÃnÃÄ±¡§Î¡A¨Ã«ØÄ³±wªÌ¨Ì¤W­zÁpÃ´ºÞ¹D±NÃh¥¥µ²ªG³q³øµ¹¬ü°ÓÀq¨FªFÃÄ¼tªÑ¥÷¦³­­¤½¥q¥xÆW¤À¤½¥q¡C ®Ú¾Ú°Êª«¸ÕÅçªº¸ê®Æ¡A¹ï¥¥°ü§ë¤©molnupiravir¥i¯à·|¹ï­L¨à³y¦¨¶Ë®`¡C¥Ø«e¨ÃµL¥ô¦ó¹ï¥¥°ü¨Ï¥Îmolnupiravirªº¤HÃþ¸ê®Æ¥i¾Ú¥Hµû¦ôµo¥Í­«¤j¥X¥Í¯Ê³´¡B¬y²£©Î¥ÀÅé©Î­L¨à¤£¨}µ²ªGªº­·ÀI¡F¦]¦¹¡A¨Ã¤£«ØÄ³¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravir¡C¤@¶µ°Êª«¥Í´Þ¬ã¨sÅã¥Ü¡A¹ïÃh¥¥¤j¹«©ó¾¹©xµo¥Í´Á¶¡¤fªA§ë¤©molnupiravir¤§«á¡A¦b¬Û·í©ó¤HÃþ¦b«ØÄ³¤HÃþ¾¯¶q(RHD)¤U©Ò¹F¨ì¤§¤HÃþNHC (N4-hydroxycytidine)¼ÉÅS¶qªº8­¿¼ÉÅS¶q¤U·|¾É­P­F­L­L¨à¦º¤`©M·î§Î¡A¦b¤HÃþ¦bRHD¾¯¶q¤U©Ò¹F¨ì¤§¤HÃþNHC¼ÉÅS¶qªº?3­¿¼ÉÅS¶q¤U·|¾É­P­L¨à¥Íªø´îºC¡C¹ïÃh¥¥¨ß¤l©ó©ó¾¹©xµo¥Í´Á¶¡¤fªA§ë¤©molnupiravir¤§«á¡A¦b¬Û·í©ó¤HÃþ¦bRHD¾¯¶q¤U©Ò¹F¨ì¤§¤HÃþNHC¼ÉÅS¶qªº18­¿¼ÉÅS¶q¤U·|¾É­P­L¨àÅé­«´î»´¡C¦Ò¼{­n¹ï¥¥°ü¨Ï¥Îmolnupiravir®É¡A³B¤èÂå®v¥²¶·¦V¸Ó¥¥°ü»¡©ú¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravirªº¤wª¾©M¼ç¦b®Ä¯q¡A¥H¤Î¼ç¦bªº­·ÀI¡C¥u¦³¦bÂåÀø·ÓÅ@¤H­û½T©w¹ï­Ó§O¥¥°üªº®Ä¯q¶W¶V­·ÀI¤§«á¡A¤~¥i³B¤èmolnupiravirµ¹¸Ó­Ó§O¯f¤H¡C¦pªG¨M©w­n¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravir¡A³B¤èÂå®v¥²¶·µù°O¤w¦V¸Ó­Ó§O¥¥°ü»¡©ú¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravirªº¤wª¾©M¼ç¦b®Ä¯q¡A¥H¤Î¼ç¦bªº­·ÀI¡C¦bÃh¥¥´Á¶¡¡A¥¼¸gªvÀøªºCOVID-19¤]·|¬°¥ÀÅé©M­L¨à±a¨Ó­·ÀI¡C ¥Ø«e¨Ã¤£½Tª¾¥»«~¤§¾A¥Î±Ú¸sµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº¦ô­p­I´º­·ÀI¡C©Ò¦³ªºÃh¥¥³£¦³µo¥Í¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­I´º­·ÀI¡C´N¬ü°êªº¤@¯ë¤H¤f¦Ó¨¥¡A¦b¸g¹LÁ{§É½T»{ªºÃh¥¥¤H¤f¤¤¡Aµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº­I´º­·ÀI¤À§O¬°2¦Ü4%»P15¦Ü20%¡C Molnupiravir¤£«ØÄ³¥Î©óÃh¥¥°ü¤k,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©ómolnupiravir©Î¨ä¥NÁÂª«¬O§_·|¥X²{©ó¤HÃþªº¨Å¥Ä¤è­±ªº¸ê®Æ¡C´¿¦b§ë¤©molnupiravir¤§±Â¨Å¤j¹«©Ò­÷¨Å¤§¥J¹«ªº¦å¼ß¤¤ÀË¥XNHC¡C¥Ø«e¨Ã¤£½Tª¾molnupiravir¬O§_·|¹ïÁý­÷¥À¨ÅªºÀ¦¨à³y¦¨¼vÅT¡A©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î³y¦¨¼vÅT¡C ¥Ñ©óÀ¦¨à¥i¯à·|¹ïmolnupiravir²£¥Í¤£¨}¤ÏÀ³¡A¦]¦¹¡A¦b¨Ï¥ÎmolnupiravirªvÀø´Á¶¡©M¨Ï¥Î³Ì«á¤@¾¯ÃÄª««á4¤Ñ¤º¤£«ØÄ³Áý­÷¥À¨Å¡C¦bªvÀø´Á¶¡©M¨Ï¥Î³Ì«á¤@¾¯molnupiravir«á4¤Ñ¤º¡A­÷¨Å¯f¤H¥i¯à­n¦Ò¼{¤¤Â_Áý­÷¥À¨Å¡A¤]¥i¯à­n¦Ò¼{±N¨Å¥Ä§l¥X¨Ã¥á±ó¡C ¦b¥X¥Í«e«áµo¨|¬ã¨s¤¤¡A¹ï±Â¨Å¤j¹«§ë¤©?250²@§J/¤½¤ç/¤é¤§¾¯¶qªºmolnupiravir¤§«á¡A´¿¦b­÷¨Å¥J¹«ªº¦å¼ß¤¤ÀË¥XNHC¡C ®Ú¾Ú°Êª«¬ã¨sªºµ²ªG¡A¹ï¥¥°ü§ë¤©molnupiravir¥i¯à·|¹ï­L¨à³y¦¨¶Ë®`¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã²É§]ªA¡C¤£±o¥´¶}½¦Ån¡CµLªk§]ªA±wªÌ(¨ÌÁ{§É¸ÕÅç)µ¹ÃÄ¤èªk:±N¥|Áû½¦Ån«á¦Ü©ó½Õ»sªM©Îª`®g¾¹¤¤¡A¥[¤ô40mLÅÍ©Õ3¤ÀÄÁ¥B§¡¤Ã²V¦X¡A°t»s§¹½ÐºÉ§ÖªA¥Î©ÎºÞÄé¡A¥i¦bªA¥Î«á¦Aµ¹¤©240mL¥H¤U¤ô¤À½T«O©Ò¦³ÃÄª«§]Ã`§¹¦¨¡C
OKUZ,Sodium polystyrene sulfonate,Kuzem powder 15g/pack,ZADT,Hyperkalemia.,Patients with hypokalemia or those who are hypersensitive.,Gastric irritation¡A anorexia¡A nausea¡A vomiting¡A constipation¡A occasional diarrhea; hypokalemia¡A hypocalcemia¡A Na retention.,25¢J¥H¤U°®Àê³B,(¥é³æ+Uptodate) Adult: Oral: 15 g 1-4 times daily. Rectal: 30-50 g Q6H. Children: Oral: Initail: 1 g/kg/day in divided doses (maximum: 15 g/dose); Maintenance: 0.5 g/kg/day in divided doses. Rectal: 1 g/kg/day. Neonate: Rectal: 0.5-1 g/kg/day. NOTE: Do not mix in orange juice or in any fruit juice known to contain potassium. Shake the suspension well prior to administration. For rectal doses¡A administer cleansing enema first¡A then sodium polystyrene sulfonate as a warm emulsion (body temperature). Retain the enema in the colon for at least 30-60 minutes and for 9 hours¡A if possible (neonates: 30 minutes). Once retention time is complete¡A irrigate the colon with a nonsodium-containing solution to remove resin.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,ÃÄ«~¥é³æ:¤£«ØÄ³¨Ï¥ÎÃh¥¥¤Î­÷¨Å´Á¡C,AC;AC15;PC;PO;R;RECT;WM;,,,,,
EMET3,Metronidazole,Metrogel 0.75%¡A 30gm,TDER,,¾AÀ³¯g: Topical treatment of inflammatory papules¡A pustules & erythema of rosacea. °Æ§@¥Î: Transient redness¡A mild dryness¡A burning & skin irritation. Watery (tearing) eyes if applied too near the eyes Gastrointestinal: Abdominal discomfort (7%)¡A Loss of appetite¡A Metallic taste¡A Nausea and vomiting (4%) Immunologic: Jarisch Herxheimer reaction Neurologic: Dizziness (1% to 4% )¡A Headache (tablets¡A 15% to 18%; vaginal gel¡A 5% )¡A Peripheral neuropathy Reproductive: Candida infection of genital region¡A Symptomatic cervicitis/vaginitis (10%)¡A Vaginal discharge (12%) Other: Drug interaction with alcohol¡A Disulfiram-like reaction ¸T§Ò: Hypersensitivity to metronidazole.,,«Ç·Å,Apply and rub a thin film of Metrogel topical gel twice daily¡A morning and evening¡A to the entire affected areas after washing. Significant therapeutic results should be noticed within 3 weeks. Clinical studies have demonstrated continuing improvement through 9 weeks of therapy. Areas to be treated should be cleansed before application of Metrogel. Patients may use cosmetics after application of Metrogel.,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,EXT;,,,,,
ITRO,Sacituzumab govitecan,Trodelvy inj 180mg,RACA,Treatment of locally advanced or metastatic triple-negative breast cancer in adult patients who have previously received two or more systemic therapies (at least one for metastatic disease) and are ineligible for surgical removal.,Severe hypersensitivity reaction to sacituzumab govitecan.,Common: Alopecia (38-49%)¡A Rash (12-32%)¡A Abdominal pain (20-31%)¡A Constipation (34-37%)¡A Decrease in appetite (21-41%)¡A Diarrhea¡A All Grades (59-72%)¡A Inflammatory disease of mucous membrane (14%)¡A Nausea¡A All Grades (57-69%)¡A Vomiting¡A All Grades (23-49%)¡A Neutropenia¡A All Grades (64%)¡A Fatigue (51-68%) Serious: Diarrhea¡A Grade 3 or 4 (9-12%)¡A Nausea¡A Grade 3 or 4 (1-6%)¡A Perforation of intestine (0.09%)¡A Vomiting¡A Grade 3 or 4 (1-6%)¡A Anemia¡A Grade 3 or 4 (9-21%)¡A Febrile neutropenia (6-7%)¡A Neutropenia¡A Grade 3 or 4 (43-58%)¡A Anaphylaxis (0.2%)¡A Hypersensitivity reaction (35%)¡A Suicide¡A Pneumonia (4%)¡A Respiratory failure¡A Respiratory tract infection (26%),Á×¥ú§NÂÃÀx¦s(2-8¢XC)¡A½Ð¤Å§N­á,Recommended dose: 10 mg/kg¡A not exceeding 10 mg/kg. Administer via intravenous infusion on Days 1 and 8 of a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Only use intravenous infusion; no bolus or push administration. Initial infusion: Over 3 hours with 30-minute post-infusion observation. Subsequent infusions: May be infused over 1 to 2 hours or longer if tolerated¡A with 30-minute post-infusion observation.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] »´«×¨x¥\¯à¤£¥þµL»Ý½Õ¾ã°_©l¾¯¶q¡C¤¤«×(Á`Áx¬õ¯À >1.5-3.0­¿ ULN)©Î­««×(Á`Áx¬õ¯À> 3.0­¿¥¿±`­È¤W­­ [ULN]¡^¨x¥\¯à¤£¥þ¯f¤H¤¤ªº¦w¥þ©Ê©|¥¼½T¥ß¡C ©|¥¼¦bAST©ÎALT>3­¿ULNµL¨xÂà²¾ªº¯f¤H¡A©ÎAST©ÎALT>5­¿ULN¦³¨xÂà²¾ªº¯f¤H¤¤¶i¦æ´ú¸Õ¡CµLªk¹ï³o¨Ç¯f¤Hªº°_©l¾¯¶q´£¥X«ØÄ³¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ®Ú¾Ú¨ä§@¥Î¾÷Âà¡A·í¹ï¥¥°ü§ëÃÄ®É¥i¯à¾É­P­P·î­L©Ê¤Î/©Î­F­L-­L¨à­P¦º©Ê¡C ¥Ø«e©|µL¥i¥ÎªºÃh¥¥°ü¤k¼Æ¾Ú¡A¦]¦¹µLªkÀòª¾ÃÄª«¬ÛÃö­·ÀI¡C §iª¾¥¥°ü©M¨ã¥Í¨|¯à¤O¤k©Ê¡A¥»«~¹ï­L¨àªº¼ç¦b­·ÀI¡C °w¹ï¾AÀ³¯g±Ú¸s¡A­«¤j¥ý¤Ñ¯Ê³´»P¬y²£ªº­I´º­·ÀI¦ô­p­È¥Ø«e¤£©ú¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¦³Ãösacituzumab govitecan©ÎSN-38¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡B¹ï±µ¨ü¥À¨Å­÷ÁýªºÀ¦¨à¤§¼vÅT¡A ©Î¹ï¨Å¥Ä¥Í¦¨¤§¼vÅT¡A¥Ø«e©|µL¬ÛÃö¸ê°T¡C Å²©ó±µ¨ü¥À¨Å­÷ÁýªºÀ¦¨à¥i¯à·|¦]¥»«~µo¥ÍÄY­«¤£¨}¤ÏÀ³¡A «ØÄ³­÷¨Å´Á°ü¤k¦bTRODELVYªvÀø´Á¶¡¤Î³Ì«á¤@¦¸µ¹ÃÄ«á1­Ó¤ë¤º¤£­n­÷¨Å¡C,IVD;,20mL 0.9% NaCl (Final concentration: 10 mg/mL),¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Dilute with 0.9% NaCl solution to a final concentration of 1.1 to 3.4 mg/mL. Infuse over 3 hours for the initial dose. Subsequent infusions may be infused over 1 to 2 hours or longer if tolerated.,1. ¶È¨ÑÀR¯ßºwª`(IVD)µ¹ÃÄ¡A¥i¨Ï¥Î¿éª`À°®ú¡C¿é²G³UÀ³Á×¥úª½¨ìµ¹ÃÄ§¹¦¨¡A¿é²G¹Lµ{¤¤µL»Ý¾B»\¿é²GºÞ½u©Î¨Ï¥ÎÁ×¥úºÞ½u¡C¥i¨Ï¥Î¿éª`À°®ú¡C 2. µ}ÄÀ«á·»²G¿@«×½d³ò¬°1.1 mg/mL¦Ü3.4 mg/mL (¹ï©óÅé­«<=170kg ¯f¤H¡AÁ`·»²G¶q¤£À³¶W¹L 500mL) 3. §t¥»«~·»²Gªº¿é²G³U©ó2-8¢XC§NÂÃ¨ÃÁ×¥ú«O¦s³Ìªø¦Ü24¤p®É¡C§NÂÃ«O¦s«á¡Aµ}ÄÀ·»²G©ó³Ì°ª¦Ü25¢XCªº«Ç·Å¤UÀ³¦b8¤p®É¤º(§t¿éª`©Ò»Ýªº®É¶¡)§ë¤©¡C 4. ­º¦¸¿éª`¡G¿éª`¶i¦æ®É¶¡¶W¹L3¤p®É¡C«áÄò¿éª`¡G¦pªG¹ï¥ý«eªº¿éª`¨ã¦³­@¨ü©Ê¡A«h¿éª`®É¶¡¥i¦b1¦Ü2¤p®É¥H¤W¡C¦b¿éª`´Á¶¡©M¿éª`«á¦Ü¤Ö30¤ÀÄÁÆ[¹î¯f¤H¬O§_¥X²{¿éª`¬ÛÃö¤ÏÀ³ªº¼x¥ü©Î¯gª¬¡C
ICLAR2,Gadoterate meglumine,Clariscan inj 0.5 mmol/mL¡A 20mL/Bot,SCAN,MRI contrast agent,Have a history of allergies to gadoteric acid or gadoterate meglumine patient. Contraindications for MRI¡A such as the patient with rhythm regulators and those with vascular clamps.,1% to 10%:Central nervous system: Headache (<=1%)Gastrointestinal: Nausea (<=1) <1%¡A postmarketing¡A and/or case reports: Altered sense of smell¡A anaphylactoid reaction¡A anaphylaxis¡A angioedema¡A anxiety¡A bradycardia¡A bronchospasm¡A burning sensation¡A cardiac arrest¡A cardiac arrhythmia¡A circulatory shock¡A coma¡A conjunctivitis¡A convulsions¡A cyanosis¡A diarrhea¡A dizziness¡A drowsiness¡A dysgeusia¡A eyelid edema¡A fatigue¡A feeling hot¡A fever¡A hyperhidrosis¡A hypersensitivity reaction¡A hypertension¡A hypotension¡A increased lacrimation¡A increased serum creatinine¡A inflammation at injection site¡A injection site pruritus¡A injection site reaction (including cold¡A warmth)¡A laryngeal discomfort¡A laryngospasm¡A limb pain¡A malaise¡A muscle spasm¡A myasthenia¡A ocular hyperemia¡A pain¡A pain at injection site¡A palpitations¡A paresthesia¡A pharyngeal edema¡A phlebitis (superficial)¡A presyncope¡A pruritus¡A respiratory arrest¡A sensation of cold¡A sialorrhea¡A skin rash¡A swelling at injection site¡A syncope¡A tachycardia¡A tremor¡A urticaria¡A vomiting¡A weakness,30¢J¥H¤U,MRI of brain and spine: Adults: The recommended dose is 0.1 mmol/kg(0.2 mL/kg). In patients with brain tumours¡A an additional dose of 0.2 mmol/kg(0.4 mL/kg)¡A may improve tumor characterisation and facilitate therapeutic decision making. Children (0-18 years): The recommended and maximum dose of Clariscan is 0.1 mmol/kg. Do not use more than one dose during a scan. Careful consideration in neonates up to 4 weeks and infants up to 1 year of age. Lack of information on repeated administration¡A Clariscan injections should not be repeated before 7 days. Whole body MRI (including lesions of the liver¡A kidneys¡A pancreas¡A pelvis¡A lungs¡A heart¡A breast¡A and musculoskeletal system): Adults and children over 6 months: The recommended dose is 0.1 mmol/kg(0.2 mL/kg). Angiography: Adults only: The recommended dose¡A IV injection is 0.1 mmol/kg(0.2 mL/kg).,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¥¿³B¨x²¾´Ó´Á¶¡ªº¯f¤H¡AÀ³¥ýÂÔ·Vµû¦ô¡A¦pªG¥²¶·¨Ï¥Î¡A¨C¤½¤çÅé­«ªºª`®g¾¯¶q¤£¥i¶W¹L 0.1 mmol/kg¡C¨C¦¸±½´y¤§ª`®g¤£¥i¶W¹L¤@¦¸¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¨Ï¥Îgadoteric acid©ó¥¥°üªº¦w¥þ©Ê¨ÃµL¸ê®Æ¡C°Êª«¸ÕÅçµLª½±µ©Î¶¡±µÃÒ¾ÚÅã¥Ü¦³¥Í´Þ¬r©Ê¡C GBCAs¬ï¹L¤H­L½L¨Ã¾É­P­L¨à¼ÉÅS©Mgadolinium´Ý¯d¡A¦ýÃö©óGBCAs»P¤£§Q­L¨àµ²ªG¤§¶¡ÃöÁp©Ê¤HÃþ¼Æ¾Ú¤´¦³­­©M¤£½T©w¡C °£«DÁ{§É±¡ªp¥²¶·¨Ï¥ÎGadoteric acid§_«h¤£À³¨Ï¥Î©óÃh¥¥°ü¤k¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|¥¼¦³gadoteric acid¬O§_·|±q­÷¨Å´Á¥À¿Ë¨Å¥Ä±Æ¥Xªº¤HÃþ¬ã¨s¡C GBCAs¥Î©ó­÷¨Å¥À¿Ë¦³­­ªº®×¨Ò³ø§iÅã¥Ü0.01¢H¦Ü0.04¢H¥ÀÅégadolinium¾¯¶q·|¦b±Æ¥X¦Ü¤HÃþ¥À¨Å¤¤¡C ¥Ñ©ó³\¦hÃÄª«³£¸g¨Å¥Ä±Æ¥X¡A©Ò¥H·ígadoteric acid¥Î©ó­÷¨Å¤k©Ê®ÉÀ³ÂÔ·V¡C §tgadoliniumÅã¼v¾¯·|¦³·¥¤Ö¶q¥Ñ¨Å¥Ä±Æ¥X¡A©óÁ{§É¾¯¶q¡A¦]¬°¨Å¥Ä¤¤§t¶q·¥¤Ö¥B¸z­G§l¦¬¤£¨Î¡C Âå®v¤Î­÷¨Åªº°ü¤kÀ³¨M©wª`®g«á¬O§_Ä~Äò­÷¨Å©Î°±¤î24¤p®É¡C,IV;IVP;IVPUSH;,,,Administer as an IV bolus injection. Infuse at a rate of approximately 2 mL/second. To ensure complete injection of contrast agent¡A flush line after administration.,,µ¹ÃÄ«á¡AÀ³¦Ü¤ÖÆ[¹î¥b¤p®É¡A¦]¬°Á{§É¸gÅçÅã¥Ü¤j³¡¤À¤£¨}¤ÏÀ³µo¥Í¦b³o¬q®É¶¡¤º¡C
OARIE,Donepezil,Aricept 10mg orodispersible,CNEU,Treatment of mild to moderate dementia of the Alzheimer's type.,Patients with a known hypersensitivity to donepezil HCl¡A piperidine derivatives or to any excipients used in Aricept. Use in children: Aricept is not recommended for use in children.,Nausea¡A diarrhea¡A insomnia¡A vomiting¡A muscle cramp¡A fatigue & anorexia. Syncopal episodes have been reported. Cardiovascular: Hypertension (3% )¡A Syncope (2% ) Endocrine metabolic: Weight decreased (3% to 5% ) Gastrointestinal: Diarrhea (5% to 15% )¡A Loss of appetite (2% to 8% )¡A Nausea (3% to 19% )¡A Vomiting (3% to 9% ) Hematologic: Contusion (2% )¡A Ecchymosis (4% to 5% ) Musculoskeletal: Cramp (3% to 8% )¡A Increased creatine kinase level (3% ) Neurologic: Asthenia (1% to 2% )¡A Dizziness (2% to 8% )¡A Headache (3% to 4% )¡A Insomnia (2% to 14% )¡A Somnolence (1% to 2% ) Psychiatric: Depression (2% to 3% )¡A Dream disorder (3% ) Renal: Urinary incontinence (1% to 3% ) Other: Fatigue (1% to 8% ),30¢J¥H¤U,Initial¡A 5 mg orally once daily at bedtime; if suboptimal clinical response¡A may titrate to 10 mg orally once daily at 4 to 6 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¦bÃh¥¥°ü¤k¡A©|µL¥R¨¬©Î±±¨î¨}¦n¤§¬ã¨s¡C Ãh¥¥°ü¤k¶È¯à¦bªvÀø®Ä¯q°ª©ó¹ï­L¨à¤§¦MÀI©Ê®É¤~¥i¥HªA¥Î¥»ÃÄ¡C Ãh¥¥¤j¹«©M¨ß¤l¦b­L¨à¾¹©x¥Í¦¨´Á¶¡¤fªAµ¹¤©donepezil¡A ¦b¾¯¶q¤À§O°ª¹F¨C¤é16 mg/kg¤Î¨C¤é10 mg/kg®É¤£·|¾É­P·î­L¡C ¤j¹«¦b§³®W±ß´Á©M¾ã­Óªc¨Å´Á¦ÜÂ_¥¤´Á¤fªAµ¹¤©donepezil (¨C¤é1¡B3¡B10 mg/kg)¡A ¦b³Ì°ª¾¯¶q²Õ¾É­P¦º²£¼W¥[¡A¨Ã¥B­°§C²£«á 4 ¤Ñ¤§«á¥N¦s¬¡²v¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Donepezil¬O§_·|³Q¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤©|¥¼ª¾±x¡A±Â¨Å°ü¤kªA¥ÎAricept®ÉÀ³¤p¤ß¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¤f±Y¿õ¡A¥i·»¤ô±Y´²«áºÞÄé¡C
ILID1,Lidocaine,Lidocaine inj 20mg/mL¡A 1mL§½³Â,ZANE,Local injectable for anesthesia.,Hypersensitivity to lidocaine or any component of the formulation. History of hypersensitivity to local anesthetics of the amide type. Severe degrees of SA¡A AV¡A or intraventricular heart block.,Common Dermatologic: Erythema¡A Skin irritation Gastrointestinal: Hoarse¡A Loss of voice¡A Pain in throat Serious Hematologic: Methemoglobinemia Immunologic: Allergic reaction¡A Anaphylaxis,25¢J¥H¤U,Adult Caudal anesthetic: Obstetrical analgesia¡A Usual dosage: 200 - 300 mg. Surgical anesthesia¡A Usual dosage: 225 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic lumbar epidural block Usual dosage (analgesia): 250 - 300 mg. Usual dosage (anesthesia): 200 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic intravenous regional block¡A Usual dosage: 50 - 300 mg Local anesthesia¡A by infiltration¡A Usual dosage: 5 - 300 mg Peripheral block anesthesia¡A Brachial¡A intercostal¡A paravertebral¡A or pudendal Brachial Nerve Block¡A Usual dosage: 225 - 300 mg. Intercostal Nerve Block¡A Usual dosage: 30 mg. Paravertebral Nerve Block¡A Usual dosage: 30 - 50 mg. Pudendal Nerve Block¡A Usual dosage: 100 mg. Paracervical block anesthesia¡A Usual dosage (Obstetrical analgesia): 100 mg on each side injected slowly¡A with a 5-minute period between sides. Peripheral block anesthesia¡A Dental¡A Usual dosage: 20 - 100 mg. Retrobulbar infiltration of local anesthetic¡A the Recommended dose is 120 - 200 mg. Cervical sympathetic block (Obstetrical )¡A Usual dosage: 50 mg Lumbar sympathetic block¡A Usual dosage: 50 - 100 mg Maximum single dose: 4.5 mg/kg or 300 mg total dose but Local anesthetic intravenous regional block¡A Maximum individual dose: 4 mg/kg. Maximum dose of Dental: 6.6mg/kg or 300 mg total dose each visit.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ]¥¼¦³¬ÛÃö±Ô­z¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]±Â¨Å´Á°ü¤k¦w¥þ©Ê©|¥¼½T©w¡C,IRR;LA;LI;,,,,,¥»ÃÄ¤£¥i¥Î©óÀR¯ßµ¹ÃÄ¡C
EECO,Prednisolone,Econopred Plus 1%¡A 5mL ophthalmic suspension,TOPH,Steroid-responsive inflammatory conditions of the palpebral & bulbar conjunctiva¡A cornea & anterior segment of the globe.,Viral diseases of the cornea & conjunctiva including epithelial herpes simplex keratitis¡A vaccinia & varicella; mycobacterial eye infection¡A fungal diseases of ocular structures & acute untreated purulent ocular infections¡A Hypersensitivity to prednisolone¡A any component of the formulation.,IOP elevation w/ possible development of glaucoma & infrequent optic nerve damage¡A posterior subcapsular cataract formation & delayed wound healing. Acute anterior uveitis¡A visual field defects¡A globe perforation¡A secondary ocular infection.,30¢J¥H¤U,Instill 2 drops in the affected eye(s) 2 to 4 times daily. Use with antibiotics if bacterial infection. Do not discontinue therapy hastily. If signs and symptoms fail to improve after 2 days¡A re-evaluate. Do not discontinue therapy prematurely; withdraw therapy with gradual tapering of dose in chronic conditions. Shake well before using.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,Monitor IOP in any patient receiving treatment for >=10 days.
OTELO,Terazosin,Telowsin 2mg,CAVS,Hypertension¡A benign prostatic hyperplasia (BPH).,Hypersensitivity to terazosin or any component of the formulation,Dizziness¡A nasal congestion¡A drowsiness¡A nausea¡A peripheral edema¡A asthenia¡A postural hypotension.,25¢J¥H¤U,Benign prostatic hyperplasia: initially 1 mg at bedtime¡A increase dose in a stepwise fasion to 2 mg¡A 5 mg¡A or 10 mg once daily to achieve desired improvement. If no response after 4-6 weeks of 10 mg once daily¡A may increase to a maximum dose of 20 mg once daily. Hypertension: initially 1 mg at bedtime¡A then titrate gradually¡A as needed¡A based on response and tolerability up to 20 mg/day in 1 or 2 divided doses. Usual dosage: 1-5 mg QD.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;P;P1;P2;P3;P4;PC;PO;,,,,,
LBAR3,Barium sulfate,Baritop LV 300gm,SCAN,Computed tomography. Endoscopy of esophagus. Gastrointestinal investigation. Radiography of intestine.,Known or suspected colon obstruction. Suspected distal small bowel obstruction. Complete duodenal or jejunal obstruction¡A in newborns. Possibility of gastrointestinal tract leakage (eg¡A necrotizing enterocolitis¡A unexplained pneumoperitoneum¡A gasless abdomen¡A other bowel perforation¡A esophageal perforation¡A or postoperative anastomosis)¡A in infants and young children. Gastrointestinal tract obstruction. Known or suspected gastrointestinal tract perforation. High risk of aspiration (eg¡A prior aspiration¡A tracheoesophageal fistula¡A or obtundation). High risk of gastrointestinal (GI) tract perforation (eg¡A recent GI perforation¡A acute GI hemorrhage or ischemia¡A toxic megacolon¡A severe ileus¡A post GI surgery or biopsy¡A acute GI injury or burn¡A or recent radiotherapy to the pelvis). Hypersensitivity to barium sulfate or any product component. Latex allergy or hypersensitivity; balloon retention enema tips contain latex. Obstructing lesions of the small intestine. Procedures requiring small volumes of contrast media in very small preterm infants or young babies. Pyloric stenosis. Recent rectal biopsy. Rectum inflammation or neoplastic lesions. Swallowing disorders in infants. Suspected tracheoesophageal fistula.,Serious: Cardiorespiratory arrest¡A Edema¡A Impaction of intestine¡A Small bowel obstruction¡A Hypersensitivity reaction (rare),Á×§Kº|®ð¥B¦s©ñ¦b«Ç·Å°®Àê³B,Refer to individual product labeling for dosage and administration information.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,micromedex (Pregnancy Category):Fetal risk is minimal. (TH) micromedex (Breastfeeding):Breastfeeding a) Micromedex Lactation Rating: Infant risk is minimal,PO;,,,,,
IDUPI2,Dupilumab,Dupixent inj 200mg/1.14mL,TDER,Atopic Dermatitis: For moderate to severe atopic dermatitis in adults and children (6 months and older) with inadequate response to topical prescription treatments or unsuitable for such therapy. Can be used with or without topical corticosteroid therapy. Asthma: As add-on maintenance therapy for asthma patients (6 years and older) with eosinophilic phenotype or corticosteroid-dependent asthma¡A who are inadequately controlled on medium to high-dose inhaled corticosteroids (ICS) and a second controller (e.g.¡A LABA¡A LTRA¡A LAMA¡A or methylxanthines)¡A or on high-dose ICS alone. Chronic Rhinosinusitis with Nasal Polyps: As add-on maintenance therapy for adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who remain uncontrolled despite nasal corticosteroid therapy.,Known hypersensitivity to dupilumab or any of its excipients.,Common: Injection site disorder (Adult¡A 6-18%; adult and pediatric¡A 38%)¡A Oral herpes simplex infection (3-4%)¡A Pain in throat¡A and mouth (2%)¡A Herpes simplex¡A Excluding oral and ophthalmic herpes simplex (1-2%)¡A Blepharitis (Up to 5%)¡A Conjunctivitis (Asthma¡A 1.5% ; atopic dermatitis¡A 9-20% ; chronic rhinosinusitis with nasal polyposis¡A 2%; prurigo nodularis¡A 4% ; eosinophilic esophagitis¡A 4%)¡A Dry eyes (Up to 2%)¡A Itching of eye (1-2%)¡A Keratitis (Atopic dermatitis¡A up to 4%) Serious: Arterial thromboembolism (0-0.9%)¡A Vasculitis¡A Eosinophil count above reference range (1-2%)¡A Hypersensitivity reaction (<1%)¡A Arthralgia (2-3%)¡A Pulmonary eosinophilia¡A Angioedema¡A Helminth infection,¸m©ñ¦b­ì¦³¯È²°¨ÃÀx¦s©ó¦B½c2¢X-8¢XC Á×§K¥ú·Ó,Atopic dermatitis - Adults: 600mg subQ once¡A then 300mg every 2 weeks. Children (6 months - 5 years): 5 - < 15 kg: 200mg every 4 weeks (Q4W) 15 - < 30 kg: 300mg every 4 weeks (Q4W) Children (6-17 years): 15 - < 30 kg: 600mg (300mg x 2) initially¡A then 300mg every 4 weeks (Q4W) 30 - < 60 kg: 400mg (200mg x 2) initially¡A then 200mg every 2 weeks (Q2W) > 60 kg: 600mg (300mg x 2) initially¡A then 300mg every 2 weeks (Q2W) Asthma - Adults and children (>12 years): Initial 400mg (200mg x 2)¡A then 200mg every 2 weeks (Q2W). Patients with steroid-dependent asthma¡A moderate to severe atopic dermatitis¡A or chronic rhinosinusitis with nasal polyps: Initial 600mg (300mg x 2)¡A then 300mg every 2 weeks (Q2W). Children (6-11 years) - 15 to < 30 kg: 100mg every 2 weeks (Q2W) or 300mg every 4 weeks (Q4W). > 30 kg: 200mg every 2 weeks (Q2W). Chronic rhinosinusitis with nasal polyps - Adults: 300mg every 2 weeks (Q2W).,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à©ÎµÇ¥\¯à¤£¥þ¹ïdupilumabÃÄ°Ê¾Çªº¼vÅT©|µL¥¿¦¡¬ã¨s¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ®ð³Ý±±¨î®t©Î¤¤«×±±¨îªº°ü¤k¡A¦³ÃÒ¾ÚÅã¥Ü·|¼W¥[¥ÀÅé¤lÅö«e¯g¤Î·s¥Í¨à¦­²£¡B §C¥X¥ÍÅé­«©M­L¨à¤p©ó§³®W¦~ÄÖªº­·ÀI¡CÀ³ÄY±KºÊ´úÃh¥¥°ü¤kªº®ð³Ý±±¨îª¬ªp¡A ¥B¥²­n®ÉÀ³½Õ¾ãªvÀø¥Hºû«ù³Ì¾A±±¨î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Dupilumab¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¡B¹ï§l§m¥À¨Å¤§À¦¨àªº¼vÅT¡A©Î¹ï¥À¨Å¥Í¦¨ªº¼vÅT¡A ¥Ø«e©|µL¬ÛÃö¸ê®Æ¡C¤wª¾¥ÀÅé§K¬Ì²y³J¥ÕG (IgG)·|¶i¤J¤HÅé¨Å¥Ä¡C§l§m¥À¨Å¤§À¦¨à¡A ¨ä­G¸z¹D§½³¡¼ÉÅS©M¥þ¨­©Ê¦³­­¼ÉÅS©ódupilumab©Ò³y¦¨ªº¼vÅT¡A¥Ø«e¤£±o¦Óª¾¡C ·í¦Ò¶q­÷¨Å¹ïÀ¦¨àµo¨|¤Î°·±dªº¯q³B®É¡AÀ³¦P®É¦Ò¼{¥À¿Ë¤§Á{§É»Ý¨D¥H¤Î¼ç¦b¯fªp¹ï§l§m¥À¨Åªº¥®¨à¥i¯à³y¦¨ªº¥ô¦ó¤£¨}¼vÅT¡C,SC;,,,,,
EQCSP,Lidocaine,Quicaine spray 10%¡A 50mL,ZANE,Local anesthesia.,Allergic history to local anesthetics of the amide class or other ingredients in the spray solution.,Local irritation¡A allergic reactions¡A acute systemic toxicity.,25¢J¥H¤U,For mucosal surface anesthesia¡A effect lasts 10-15 minutes. Anesthesia occurs within 1-5 minutes¡A depending on the area of use. Each press of the plunger releases 10mg of Lidocaine. No need to dry the sprayed area before use. - ENT procedures: 3 sprays for maxillary sinus puncture or minor surgery. - Pleural fluid drainage: 3 sprays. - Labor and delivery: Up to 20 sprays (200mg Lidocaine) at most. - Respiratory or digestive procedures: Up to 20 sprays (200mg Lidocaine)¡A with a maximum of 400mg Lidocaine for prolonged procedures. Total dosage should not exceed 400mg when combined with other Lidocaine products. - Dental procedures: 1-5 mucosal sprays. Special Patients: Elderly¡A children above 12 years¡A acutely ill¡A or septic patients should receive appropriate doses based on their age¡A weight¡A and condition.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] °²©w¤w¦³¬Û·í¦h¤§¥¥°ü¤Î¨|ÄÖ°ü¤k¤w¨Ï¥Î¹LLidocaine ¬O«Ü¦X²zªº¡C ¨´¤µ©|µL¹ï¥Í´Þ¹Lµ{·|²£¥Í©ú½TªýÃªªº³ø§i¡A¨Ò¦p·î§Îªºµo¥Í²v¨ÃµL¼W¥[¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¦p¦P¨ä¥L§½³¡³Â¾K¾¯¡ALidocaine ¥i¯à¤J¥À¿Ë¤§¨Å¥Ä¡A¦ý¦b³o»ò¤pªº¾¯¶q¤U¡A ³q±`¨ÃµL¹ï·s¥Í¨à³y¦¨¼vÅTªº¦MÀI©Ê¡C,EXT;LA;SKIN;TOPI;,,,,,
LEXD,Procaterol,Exdila liquid 5mcg/mL¡A 60mL,ERSP,Obstructive airway disorders in conditions such as bronchial asthma¡A chronic bronchitis¡A and emphysema.,Hypersensitivity to Exdila liquid or any component of the formulation.,Significant: May exacerbate hyperthyroidism or diabetes mellitus; increased blood pressure¡A acute asthma episodes (during prolonged use for bronchial asthma); palpitations¡A exacerbated heart disease; shock¡A anaphylactoid reactions; decreased serum K levels. Common: Tinnitus. Nausea¡A vomiting¡A dry mouth¡A gastric discomfort. Generalised malaise or fatigue. Muscle spasticity. Headache or dull headache¡A tremors¡A dizziness¡A numbness of limbs¡A drowsiness. Insomnia. Nasal congestion¡A tracheopharyngeal abnormal feeling. Rash¡A pruritus¡A cold sweat. Facial flushing. Serious: Cardiac arrhythmias or arrest (continuous excessive doses). [source:MIMS],25¢J¥H¤UÁ×§K¶§¥úª½®g¡A¤£¶·§NÂÃ,For adults: 10 mL (Procaterol 504mcg) at bedtime or 10 mL twice daily (morning and at bedtime). For children aged 6 years and older: 5 mL (Procaterol 254mcg) at bedtime or 5 mL twice daily (morning and at bedtime). For children aged less than 6 years: 0.25 mL/kg (Procaterol 1.25mcg) 1-3 times/day (morning¡A evening¡A and at bedtime). Standard doses for a single administration in children under 6 years old are as follows: Under 1 year: 2-3 mL (Procaterol 10-15mcg). 1-3 years: 3-4 mL (Procaterol 15-20mcg). 3-6 years: 4-5 mL (Procaterol 20-25mcg).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥¥°ü©y·V­«§ë»P¥»¾¯¡C,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OLIX,Edoxaban,Lixiana F.C. 30mg,HEMT,Deep vein thrombosis and pulmonary embolism: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. Nonvalvular atrial fibrillation: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF),Active pathological bleeding¡A hypersenstive.,>10%: Hematologic and oncologic: Hemorrhage (22%) 1% to 10%: Dermatologic: Dermal hemorrhage (6%)¡A skin rash (4%) Gastrointestinal: Gastrointestinal hemorrhage (4%)¡A lower GI bleeding (3%) Genitourinary: Vaginal hemorrhage (9%)¡A gross hematuria¡A urethral bleeding Hematologic and oncologic: Major hemorrhage¡A nonlife-threatening (7% to 9%; noncritical organ: 1%; critical organ: <1%)¡A major hemorrhage (1%)¡A oral hemorrhage (3%)¡A anemia (2%)¡A decreased hemoglobin (1%)¡A puncture site bleeding (1%) Hepatic: Abnormal hepatic function tests (5% to 8%) Respiratory: Epistaxis (5%)¡A pharyngeal bleeding,30¢J¥H¤U,Prevent stroke and systemic embolism: oral 60mg once daily.  Treatment of DVT and PE: oral 60mg once daily after at least 5 days of parenteral anticoagulant therapy.,»Ý½Õ¾ã¾¯¶q,Moderate to severe impairment (Child-Pugh class B and C): Use is not recommended.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
EPULT,Budesonide,Pulmicort Turbuhaler 200mcg/dose,ERSP,Patients with bronchial asthma not well controlled by bronchodilators &/or antiallergic agents.,Hypersensitivity to budesonide or any other ingredients.,Common: Hypertension (Oral¡A 12%)¡A Peripheral edema (Oral¡A 17%)¡A Acne (Oral¡A 2.4-11%)¡A Dermatitis (Oral¡A 6%)¡A Hirsutism (Oral¡A 5%)¡A Weight gain (Inhalation¡A 1-3% ; oral¡A 7%)¡A Diarrhea (Inhalation¡A 2-4% ; oral¡A 10%)¡A Indigestion (Oral¡A 6-7%)¡A Nausea (Inhalation¡A 1.8% ; oral¡A 5.1-11%; rectal¡A 2%)¡A Leukocytosis (Oral¡A up to 6%)¡A Arthralgia (Oral¡A 2-6%)¡A Spasm (Oral¡A 12%)¡A Headache (Inhalation¡A >3% ; oral¡A 10-21%)¡A Bleeding from nose (Inhalation¡A 2-4% ; intranasal¡A 8%)¡A Dyspnea (Oral¡A 6%)¡A Nasal stinging/burning (Intranasal¡A up to 1%)¡A Respiratory tract infection (Inhalation¡A 3-38% ; oral¡A 8-11%)¡A Sinusitis (Inhalation¡A 3% or greater ; oral¡A 8%)¡A Edema of face (Oral¡A 8%)¡A Fatigue (Inhalation¡A 1-<3% ; oral¡A 3.1-5%) Serious: Syncope (Inhalation¡A 1-3%)¡A Cushing's syndrome (Oral¡A 5-15% ; inhalation¡A rare)¡A Hyperglycemia¡A Hypocortisolism secondary to another disorder (Inhalation¡A rare ; oral¡A 4.3% ; rectal¡A 4%)¡A Type 2 diabetes mellitus¡A Anaphylaxis¡A Hypersensitivity reaction¡A Fracture of bone (Inhalation¡A 1-3%)¡A Osteoporosis¡A Cataract¡A Glaucoma¡A Pneumonia¡A Angioedema,30¢J¥H¤U,Adult: 200-800mcg daily in divided doses 2-4 times. May increase the dosage to 1600mcg with the severe patient. The required dose can be administered at one time under 400mcg. Age >6 years: 200-800mcg daily in divided doses 2-4 times. The required dose can be administered at one time under 400mcg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,PREGNANCY RECOMMENDATION: Compatible (Inhaled/Nasal) No Human Data¡XAnimal Data Suggest Risk (Oral),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
RIUCB,Bimekizumab/Adalimumab/Placebo,¸ÕPS0008(Bimekizumab 160mg/Adalimumab 40mg/Placebo,HIMM,,,,,,,,,,,,,,,,,,,
IEPIP3,Epinephrine,Epipen Auto-Injector 0.3mg (±M®×¶i¤f),ZADT,Used for emergency treatment of insect bites¡A food¡A drugs¡A and other allergens¡A as well as primary or exercise-induced severe allergic reactions (anaphylaxis).,There are no absolute contraindications to the use of injectable epinephrine in a life-threatening situation.,Common: Palpitations¡A Pale complexion¡A Sweating¡A Nausea and vomiting¡A Asthenia¡A Dizziness¡A Headache¡A Tremor¡A Anxiety¡A Apprehension¡A Restlessness¡A Difficulty breathing Serious: Cardiac dysrhythmia¡A Hypertension¡A acute¡A Ventricular fibrillation¡A Injection site extravasation¡A Cerebral hemorrhage¡A Renal impairment¡A Pulmonary edema¡A Injection site infection,15-30¢JÁ×¥ú(25¢J³Ì¨Î)¡A½Ð¤Å§NÂÃ,Epinephrine auto-injector 0.3 mg for patients weighing > 30 kg. Usual dose: 0.3 mg; pediatric dose: 0.01 mg/kg. IM into the anterolateral aspect of the thigh¡A through clothing if necessary; may repeat every 5-15 minutes or sooner if patient does not adequately respond to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,[¥é³æ] Ãh¥¥´Á¶¡ªº¥þ¨­©Ê¹L±Ó¤ÏÀ³(anaphylaxis)ªvÀø»P¤@¯ë¤HªºªvÀø¬Û¦ü¡C µÇ¤W¸¢¯À¬OªvÀø¥þ¨­©Ê¹L±Ó¤ÏÀ³(anaphylaxis)ªº­º¿ïÃÄª«¡F ¥¦À³¸Ó¥H¬Û¦Pªº¤è¦¡¥Î©óÃh¥¥©M«DÃh¥¥±wªÌ¡C ¦b¬I¥´µÇ¤W¸¢¯À«á¡A±wªÌÀ³¥ß§Y´M¨DÂåÀø¤ÎÂå°|ªºÂåÀø·ÓÅ@¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e©|¥¼¦³µÇ¤W¸¢¯À¤Àªc¦Ü¥À¨Å¡B¹ï¥H¥À¨Å­÷¨|ªºÀ¦¨àªº¼vÅT©Î¹ï¥À¨Å¤Àªc¼vÅTªº¸ê®Æ¡C µÇ¤W¸¢¯À¬O¥Î©óªvÀø¹L±Ó©Ê¤ÏÀ³(anaphylaxis)ªº²Ä¤@½u¿ï¾ÜÃÄª«¡A ¦]¦¹«ØÄ³À³¸Ó¥H¬Û¦Pªº¤è¦¡ªvÀø­÷¨|¤¤©Î«D­÷¨Å¤¤ªº¯f¤H¡C,IM;,,,,,1. ¥²­n®É¥i¥H¹jµÛ¦çª«¬I¥´ 2. ¦p»Ý­n²Ä¤G¦¸¾¯¶q®É¤£­nª`®g¦b¦P¤@³¡¦ì 3. ¤£¥i¬I¥´©óÁv³¡¡A¤â¡A¸}¡A«üÀY
ODIL2,Diltiazem,DilTELAN 120mg,CAVS,Hypertension¡A chronic stable angina¡A vasospastic angina,Pregnancy¡A Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); hypotension (systolic <90 mm Hg); acute MI and pulmonary congestion,>10%: Cardiovascular: Peripheral edema (5% to 15%) 1% to 10%: Cardiovascular: Lower extremity edema (5% to 8%)¡A bradycardia (3% to 4%)¡A first-degree atrioventricular block (3% to 4%)¡A hypotension (3% to 4%)¡A edema (2% to 3%)¡A vasodilation (2% to 3%)¡A extrasystoles (2%)¡A palpitations (1% to 2%)¡A angina pectoris (<2%)¡A bundle branch block (<2%)¡A cardiac failure (<2%)¡A complete atrioventricular block (<2%)¡A ECG abnormality (<2%)¡A second degree atrioventricular block (<2%)¡A syncope (<2%)¡A tachycardia (<2%)¡A ventricular premature contractions (<2%)¡A cardiac arrhythmia (1%) Central nervous system: Dizziness (2% to 10%)¡A headache (2% to 8%)¡A pain (6%)¡A fatigue (5%)¡A nervousness (2%)¡A abnormal dreams (<2%)¡A abnormal gait (<2%)¡A amnesia (<2%)¡A depression (<2%)¡A drowsiness (<2%)¡A hallucination (<2%)¡A insomnia (<2%)¡A paresthesia (<2%)¡A personality changes (<2%) Dermatologic: Skin rash (1% to 2%)¡A pruritus (<2%)¡A skin photosensitivity (<2%) Endocrine & metabolic: Gout (1% to 2%)¡A albuminuria (<2%)¡A gynecomastia (<2%)¡A hyperglycemia (<2%)¡A hyperuricemia (<2%)¡A increased lactate dehydrogenase (<2%)¡A increased thirst (<2%)¡A weight gain (<2%) Gastrointestinal: Dyspepsia (1% to 6%)¡A abdominal enlargement (2%)¡A nausea (2%)¡A diarrhea (1% to 2%)¡A anorexia (<2%)¡A constipation (<2%)¡A dysgeusia (<2%)¡A vomiting (<2%)¡A xerostomia (<2%) Genitourinary: Impotence (2%)¡A crystalluria (<2%)¡A nocturia (<2%)¡A sexual difficulty (<2%) Hematologic & oncologic: Petechia (<2%) Hepatic: Increased serum alanine aminotransferase (<2%)¡A increased serum alkaline phosphatase (<2%)¡A increased serum aspartate transaminase (<2%) Hypersensitivity: Hypersensitivity reaction (<2%) Infection: Infection (1% to 6%) Local: Burning sensation at injection site (?4%)¡A itching at injection site (?4%) Neuromuscular & skeletal: Asthenia (1% to 4%)¡A myalgia (2%)¡A increased creatine phosphokinase in blood specimen (<2%)¡A muscle cramps (<2%)¡A neck stiffness (<2%)¡A osteoarthritis (<2%)¡A tremor (<2%) Ophthalmic: Conjunctivitis (2%)¡A amblyopia (<2%)¡A eye irritation (<2%) Otic: Tinnitus (<2%) Renal: Polyuria (<2%) Respiratory: Pharyngitis (6%)¡A dyspnea (1% to 6%)¡A bronchitis (1% to 4%)¡A flu-like symptoms (2%)¡A cough (1% to 2%)¡A paranasal sinus congestion (1% to 2%)¡A epistaxis (<2%)¡A rhinitis (<2%) <1%: Atrial flutter¡A chest pain¡A sinus node dysfunction¡A urticaria¡A ventricular fibrillation¡A ventricular tachycardia Frequency not defined: Hepatic: Hepatic injury¡A increased serum bilirubin Postmarketing: Acute generalized exanthematous pustulosis¡A alopecia¡A angioedema¡A asystole¡A cutaneous lupus erythematosus (Crowson 1995; Srivastava 2003)¡A erythema multiforme¡A exfoliative dermatitis¡A extrapyramidal reaction¡A gingival hyperplasia¡A hemolytic anemia¡A hypersensitivity angiitis¡A leukopenia¡A myopathy¡A prolonged bleeding time¡A purpuric disease¡A retinopathy¡A Stevens-Johnson syndrome¡A thrombocytopenia¡A toxic epidermal necrolysis,25¢J¥H¤UÁ×¥úÀx¦s,HTN: adult initial 90mg QD¡A maximum dose: 360mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest low risk,[¥é³æ] ¸T§Ò: ¥¥°ü¤Î¥i¯àÃh¥¥¤§°ü¤k¡C «ØÄ³Ãh¥¥°ü¤k¤Î­÷¨Å´Á°ü¤k¶È¦bµ´¹ï¥²­nªº±¡ªp¤U¡A¤~ªA¥Î§tDBPªºÃÄ«~¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] «ØÄ³Ãh¥¥°ü¤k¤Î­÷¨Å´Á°ü¤k¶È¦bµ´¹ï¥²­nªº±¡ªp¤U¡A¤~ªA¥Î§tDBPªºÃÄ«~¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©Ê½¦ÅnÀ³¾ã²É§]ªA¡A ¤Å«rÄZ©ÎÀ£¸H¡C­Y¦³¿i¯»ºÞÄé»Ý¨D¥i§ï¥Î°|¤º¦P¦¨¤ÀHerbesser 30mg¡C
ODIG2,Digoxin,Digosin 0.25mg (±M®×¶i¤f),CAVS,,¾AÀ³¯g: Heart failure¡A atrial fibrillation &/or flutter & supraventricular tachycardia. °Æ§@¥Î: Arrhythmias; anorexia¡A nausea¡A vomiting; lower abdominal pain¡A abnormal fatigue or weakness; abnormal bradycardia; visual disturbances; diarrhea; depression & psychosis¡A drowsiness¡A headache¡A malaise. Gynecomastia in prolonged use. ¸T§Ò:Intermittent complete heart block or 2nd-degree AV block¡A especially if there is a history of Stokes-Adams attacks; arrhythmias caused by cardiac glycoside intoxication; supraventricular arrhythmias associated with an accessory AV pathway¡A as in the Wolff-Parkinson-White syndrome¡A unless the electrophysiological characteristics of the accessory pathway & any possible deleterious effect of digoxin on these characteristics has been evaluated. If an accessory pathway is known or suspected to be present & there is no history of previous supraventricular arrhythmias. Hypertrophic obstructive cardiomyopathy unless with concomitant atrial fibrillation & heart failure. Hypersensitivity to other digitalis glycosides.,,«Ç·Å,Adult and child over 10 yrs: Oral: Rapid digitalization: A total of 1-1.5 mg divided into 2 or more doses given q6-8h. Slow digitalization: 0.125-0.5 mg qd for 7 days. Maintenance: 0.125-0.5 mg qd. Infant and child under 10 yrs: Oral: Digitalization: The following amounts divided into 2 or more doses given q6-8h. 2-10 yrs: 0.04-0.06 mg/kg. 1 month-2 yrs: 0.06-0.08 mg/kg. Under 1 month: 0.04-0.06 mg/kg. Maintenance: 1/5-1/3 of the total digitalizing dose¡A qd.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ODCA,Thiamine¡A Riboflavin¡A Pyridoxine¡A Cyanocobalamin,DailyCare Actibest (Vitamin B1¡A B2¡A B6¡A B12),NUTR,Treatment and Prophylaxis of Thiamine¡A Riboflavin¡A Pyridoxine¡A and Cyanocobalamin deficiency.,Hypersensitivity to any component of the product.,Common Neurologic: Asthenia (4% to 16% )¡A Headache (4% to 20% )¡A Paresthesia (4% )¡A Decreased folic acid. Neurologic: Paresthesia¡A Somnolence. Dermatologic: Contact dermatitis. Serious Cardiovascular: Congestive heart failure¡A Pulmonary edema¡A Thrombosis. Immunologic: Anaphylaxis¡A Non-allergic anaphylaxis. Ophthalmic: Optic atrophy.,25¢J¥H¤U,Adult 1-3 tablets daily. Each tablet contains: Thiamine disulfide 50mg¡A Riboflavin 5mg¡A Pyridoxine HCl 5mg¡A and Cyanocobalamine 10 mcg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¨S¦³°O¸ü,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¨S¦³°O¸ü,AC;AC15;PC;PO;WM;,,,,,
IOGIS0,Trastuzumab,Ogivri inj 440 mg (®¦·O±M®×) (Sample),RACA,Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin¡A cyclophosphamide¡A and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil¡A for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.,Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.,Common Dermatologic: Rash (Adjuvant breast cancer¡A 4%; metastatic breast cancer¡A 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )¡A Nausea (Adjuvant breast cancer¡A 6%; metastatic breast cancer¡A 33% to 76% )¡A Stomatitis (24% )¡A Vomiting (Adjuvant breast cancer¡A 3.5%; metastatic breast cancer¡A 23% to 53% ) Hematologic: Anemia¡A All Grades (4% to 36% )¡A Neutropenia¡A All Grades (Breast cancer¡A 6.4%; gastric cancer¡A 78% )¡A Thrombocytopenia¡A All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer¡A 6.2% to 10%; metastatic breast cancer¡A 26% to 44% )¡A Insomnia (Adjuvant breast cancer¡A 4.3%; metastatic breast cancer¡A 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer¡A 5%; metastatic breast cancer¡A 26% to 43% ) Other: Fatigue (29.5% to 35% )¡A Fever (Adjuvant breast cancer¡A 6%; metastatic breast cancer¡A 36% to 56%; gastric cancer¡A 18% )¡A Shivering (Adjuvant breast cancer¡A 5%; metastatic breast cancer¡A 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )¡A Heart failure (Adjuvant breast cancer¡A 0.4% to 3.2%; metastatic breast cancer¡A 7% to 28% )¡A Left ventricular cardiac dysfunction (5% to 18.5% )¡A Myocardial ischemia¡A Grade 3 or 4 Hematologic: Febrile neutropenia (23% )¡A Neutropenia¡A Grade 3 or 4 (32% to 34% )¡A Thrombocytopenia¡A Grade 3 or 4 (5% )¡A Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer¡A 2.4% to 11.8%; metastatic breast cancer¡A 22% to 42% )¡A Interstitial pneumonia¡A acute (0.2% to 0.7% )¡A Pulmonary hypertension (0.2% )¡A Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )¡A Tumor lysis syndrome,2-8¢J,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion¡A then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks¡A or initial dose of 8 mg/kg over 90 minutes IV infusion¡A then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion¡A followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ]¹ï¥¥°ü§ë¤©trastuzumab·|¹ï­L¨à³y¦¨¶Ë®`¡C®Ú¾Ú¤W¥««áªº¯f¨Ò³ø§i¡A¦bÃh¥¥´Á¶¡¨Ï¥Îtrastuzumab·|´£°ª©ó²Ä¤G¤Î²Ä¤T¥¥´Á¥X²{¦Ï¤ô¹L¤Ö²{¶Hªº­·ÀI¡C¦pªG°ü¤k¦bÃh¥¥´Á¶¡¨Ï¥Î¤Ftrastuzumab¡A©Î©ó¨Ï¥Îtrastuzumab´Á¶¡Ãh¥¥¡AÀ³±N­L¨à¥i¯à¨ü¨ìªº¦M®`§iª¾¸Ó¦W°ü¤k¡C¤W¥«¤§«á¡A¦bÃh¥¥´Á¶¡±µ¨ü³æ¤@trastuzumab©Î»P¤Æ¾ÇÀøªk¨Ö¥ÎªvÀøªº°ü¤k¤¤´¿¦³¥X²{¦Ï¤ô¹L¤Ö²{¶Hªº³ø§i¡C¨ä¤¤¦³¥b¼Æªº°ü¤k¦b°±¥Îtrastuzumab¤§«á§Y¥X²{¦Ï¤ô«ü¼Æ¤W¤Éªº²{¶H¡C¦³¤@­Ó¯f¨Ò¦b¦Ï¤ô«ü¼Æ§ïµ½¤§«á¤S­«·s¶}©l¨Ï¥Îtrastuzumab¡Aµ²ªG¦A«×¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡C¤W¥«¤§«á¡A¦b±µ¨ütrastuzumabªº¥¥°ü¤¤´¿¦³³ø¾É­L¨à¦Ï¤ô¹L¤Ö¯g¦ñÀHµÇÅ¦¦¨?¤Î/©Î¥\¯à¨ü·lªº®×¨Ò¡A¨ä¤¤¦³³y¦¨­L¨àªÍ³¡¾¹©xµo¨|¤£¥þ¦Ó¾É­P¦º¤`ªº³ø¾É¡C¹ï©ó¦bÃh¥¥´Á¶¡¨Ï¥ÎOgivriªº°ü¤k¡AÀ³ºÊµø¬O§_¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡C¦pªG¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡A§YÀ³¶i¦æ¾A¦X¨ä§³®W¶g¼Æ¥B²Å¦XªÀ·|·ÓÅ@¼Ð·Çªº­L¨àÀË¬d¡C´¿¸g¦b§ë¤©¨ä¥L¤Æ¾ÇªvÀø¾¯¤§«á¥X²{¦Ï¤ô¹L¤Öªº²{¶H®É¥HÀR¯ß¿éª`(IV)ªº¤è¦¡ÃB¥~¸É¥R¤ô¥÷¡Aµ²ªG»á¦³§U¯q¡A¦ý¥Ø«e¨Ã¤£½Tª¾¨Ï¥ÎtrastuzumabªvÀø®É¥HÀR¯ß¿éª`¤§¤è¦¡ÃB¥~¸É¥R¤ô¥÷ªº®ÄªG¡C¦b¥H°ª¹F¤HÃþ¨C¶g«ØÄ³¾¯¶q(2²@§J/¤½¤çÅé­«)¤§25­¿ªºtrastuzumab©Ò¶i¦æªº­¹ÃÉµU¥Í´Þ¬ã¨s¤¤¡A¨Ã¥¼µo²{¥ô¦óÅã¥Ü­L¨à¨ü¨ì¶Ë®`ªºÃÒ¾Ú¡C¤£¹L¡A³\¦h­F­L²ÕÂ´³£¦³¬Û·í©úÅãªºHER2³J¥Õ¹L«×ªí²{ªº²{¶H¡A¥]¬A¤ßÅ¦»P¯«¸g²ÕÂ´¡F¦b¯Ê¥FHER2ªº¬ðÅÜ¤p¹«¤¤¡A­F­L¬Ò©óÃh¥¥ªì´Á§Y¦º¤`¡C°w¹ïµU¤l©Ò¶i¦æªº¬ã¨sµo²{¡A¦b­L¨àµo¨|¶¥¬qªºªì´Á(Ãh¥¥²Ä20-50¤Ñ)¤Î«á´Á(Ãh¥¥²Ä120-150¤Ñ)¡Atrastuzumab·|³q¹L­L½LÂà²¾¦Ü­L¨àÅé¤º¡C¥Ñ©ó°Êª«¥Í´Þ¬ã¨sªºµ²ªG¨Ã¤£¡H©w¯à¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹¡A¥u¦³¦b¥À¿Ëªº¼ç¦b®Ä¯q¶W¶V­L¨à¥i¯à­±Á{¤§­·ÀIªº±¡ªp¤U¡A¤~¥i©óÃh¥¥´Á¶¡¨Ï¥ÎOgivri¡C ¨|ÄÖ´Á°ü¤k©óOgivriªvÀø´Á¶¡¤ÎªvÀøµ²§ô«á7­Ó¤ë¤ºÀ³³Q«ØÄ³±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I¡C ­Y¥¥°ü±µ¨üOgivriªvÀø¡A©Î¬O¯f±w¦b±µ¨üOgivriªvÀø´Á¶¡©Î³Ì«á¤@¾¯Ogivri«á7­Ó¤ë¤ºÃh¥¥¡A³Ì¦n¥Ñ¸ó¬ì§O¹Î¶¤¶i¦æÄY±KºÊ´ú¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ø«e¨Ã¤£½Tª¾trastuzumab¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¦ý¤HÃþªºIgG·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡A¨Å¥Ä§ÜÅé¨Ã¤£·|¤j¶q¶i¤J·s¥Í¨à¤ÎÀ¦¨àªºÅé¤º´`Àô¡C¹ï±Â¨Å­¹ÃÉµU§ë¤©¬Û·í©ó¤HÃþ¨C¶g«ØÄ³¾¯¶q(2²@§J/¤½¤çÅé­«)¤§12.5­¿ªºtrastuzumab¤§«áµo²{¡Atrastuzumab·|¥X²{©ó¨Å¥Ä¤¤¡C¦å²M¤¤ÀË¥Xtrastuzumabªº¥®µU¦b¥X¥Í«á¦Ü3­Ó¤ë¤j´Á¶¡¨Ã¥¼µo¥Í¥ô¦ó¥Í?©Îµo¨|¤è­±ªº¤£¨}¼vÅT¡F¤£¹L¡A°Êª«¨Å¥Ä¤¤ªºtrastuzumab§t¶q¨Ã¤£¯àºë½T¦a¤Ï¬M¤HÃþ¨Å¥Ä¤¤ªº§t¶q¡C ¥Ñ©ó³\¦hÃÄª«³£·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¥BÁý­÷¥À¨ÅªºÀ¦¨à¥i¯à·|¦]±µÄ²Ogivri¦Óµo¥ÍÄY­«ªº¤£¨}¤ÏÀ³¡A¦]¦¹¡AÀ³¦Ò¼{Ogivriªº±Æ°£¥b°I´Á¤Î¦¹ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡AµM«á¨M©w¬O§_­n°±¤îÁý­÷¥À¨Å©Î¬O°±¥Î¦¹ÃÄ¡C,IVD;,¥]¸Ë¤¤ªºµ}ÄÀ²G(20 ²@¤É§t1.1%­f¥Ò¾Jªº¨îµßª`®g¥Î¤ô)¡C,,,©â¨ú¯f±wÃÄª«¶q«á¥[¨ì¸Ë¦³0.9%´â¤Æ¶u250 ²@¤Éªºª`®g³U¤¤µ}ÄÀ¡A°_©l¾¯¶q«ØÄ³ÀR¯ß¿éª`90 ¤ÀÄÁ¡Cºû«ù¾¯¶q®É­Y¯f¤H¹ï¥ý«e¾¯¶qªº­@¨ü¤O¨Î¡A¥i¿éª`30 ¤ÀÄÁ§Y¥i¡C,1.°t»sªº»¡©ú: ¨Ï¥ÎµLµß°wµ©¡AºCºCª`¤J20 ²@¤É¨îµßª`®g¥Î¤ô©ó§t­á´¹Ogivri ªº¤p²~¡Aª½±µª`®g¦Ü­á´¹¶ô¡C¦A·Å©M¦aÂà°Ê¤p²~À°§U½Õ°t¡A¤£­n·n®Ì¡C 2.¨Ï¥Î¥]¸Ë¤¤©Ò´£¨Ñªº¨îµßª`®g¥Î¤ô²V¦X«áªº°t»s«á·»²G¡A§NÂÃ¦b2-8¢J¥i¥Hºû«ù28 ¤Ñªº¦w©w¡C¦pªG¨Ï¥Î·Àµß¤ô°t»s«h¶Èºû«ù24 ¤p®É¦w©w¡A¤§«á¥²¶·¥á±ó¡C 3.°t»s©ó¸Ë¦³0.9%´â¤Æ¶u·»²Gªºª`®g¥Î³U¤¤¡A¦b2-8¢J¤U¨äª«¤Æ©Ê½è¥iºû«ùÃ­©w24 ¤p®É¡C 4.¸T¤î¨Ï¥Î5%ªºdextrose ·»²G¡A¦]¬°·|¤Þ°_³J¥Õ½è¾®¶°¡C
ONUB,Darolutamide,Nubeqa F.C. 300mg,RACA,Treating patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Used in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer (mCSPC¡A also known as mHSPC).,Hypersensitivity to darolutamide or any component of the formulation. Women and children.,Common: Rash (3%)¡A Pain in limb (6%)¡A Fatigue (16%) >10%: Decreased neutrophils (20%; grades 3/4: 4%)¡A Increased serum aspartate aminotransferase (23%)¡A increased serum bilirubin (16%)¡A Asthenia (16%)¡A fatigue (16%) 1-10%: Heart failure (2%)¡A ischemic heart disease (4%)¡A Skin rash (4%)¡A Limb pain (6%) Frequency not defined: Hypertension¡A Diarrhea¡A nausea¡A Hematuria¡A urinary retention¡A Pneumonia,30¢XC¥H¤U°®Àê³B,Prostate cancer¡A Nonmetastatic¡A castration resistant: 600mg (two 300mg tablets) PO BID with food until disease progression or unacceptable toxicity. Adverse reactions (Grade 3 or greater toxicity or intolerable events): Withhold dosing or reduce to 300mg BID until symptoms improve; then resume at a dose of 600mg BID; dosage reduction below 300mg BID is not recommended Hormone sensitive prostate cancer¡A Metastatic¡A in combination with docetaxel: 600mg (two 300mg tablets) PO BID with food in combination with docetaxel 75mg/m(2) IV on day 1 and every 21 days for 6 cycles (start within 6 weeks of darolutamide)e; continue until disease progression or unacceptable toxicity even if a cycle of docetaxel is delayed¡A interrupted¡A or discontinued. Give a gonadotropin-releasing hormone (GnRH) analog concurrently in patients without a bilateral orchiectomy.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] Mild: No dose reduction is needed. Moderate¡A Child-Pugh Class B: Reduce dosage to 300 mg BID. Severe¡A Child-Pugh Class C: No specific recommendations are available.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] NUBEQA¤£¥i¥Î©ó¤k©Ê¡CNUBEQA¤£¥i¥Î©ó¥¿¦b©Î¬O¥i¯àÃh¥¥ªº¤k©Ê¡C ¦pªG¯f¤H»P¥i¯à·|Ãh¦³«Ä¤lªº¤k©Ê¶i¦æ©Ê¦æ¬°¡A«h¦bªvÀø´Á¶¡¥H¤Î³Ì«á¤@¦¸NUBEQAªvÀø«á1¶g¤º¶·±Ä¨ú±j¦Ó¦³®ÄªºÁ×¥¥±¹¬I¥H¨¾¤îÃh¥¥¡C ¦pªG¯f¤H»P¥¥°ü¶i¦æ©Ê¦æ¬°¡A«h¦bªvÀø´Á¶¡¥H¤Î³Ì«á¤@¦¸ªA¥ÎNUBEQA«á1¶g¤º¶·­n¨Ï¥Î«OÀI®M¡C¥²¶·Á×§K³q¹Lºë²GÂà²¾µ¹¥¥°ü¦Ó¨Ï­L¨à¼ÉÅS©ó¶¯©Ê¯À¨üÅé§í¨î¾¯¡A¦]¬°³o¥i¯à·|¼vÅT­L¨àªºµo¨|¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] NUBEQA¤£¥i¥Î©ó¤k©Ê¡CNUBEQA¤£¥i¥Î©ó¥¿¦b©Î¬O¥i¯à­÷¨Åªº¤k©Ê¡C,PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡AÃÄ¿õ»Ý¾ãÁû§]ªA¡A¤£¥i¯}Ãa­ì¾¯«¬¡C
OEQU,Safinamide,Equfina 50mg,CNEU,Parkinson disease: Adjunctive treatment to carbidopa/levodopa in patients with Parkinson disease experiencing "off" episodes.,Hypersensitivity to safinamide or any component of the formulation. Severe hepatic impairment (Child-Pugh class C) Concomitant use of methylphenidate¡A amphetamine¡A and their derivatives¡A or dextromethorphan. Concomitant use with or within 2 weeks of other monoamine oxidase inhibitors or other drugs that are potent inhibitors of monoamine oxidase (including linezolid)¡A opioids (eg¡A meperidine¡A methadone¡A propoxyphene¡A tramadol)¡A serotonin-norepinephrine reuptake inhibitors¡A tricyclic¡A tetracyclic¡A or triazolopyridine antidepressants¡A cyclobenzaprine¡A St John's wort. Albinism¡A retinal degeneration¡A uveitis¡A inherited retinopathy or any active retinopathy (including severe progressive diabetic retinopathy).,Common: Nausea (3-6%)¡A Dyskinesia (17-21%)¡A Insomnia (1-4%)¡A Falls (4-6%) Serious: Hypertension (5-7%)¡A Hallucinations¡A Impulse control disorder¡A Serotonin syndrome >10%: Dyskinesia (17-21%) 1-10%: Cardiovascular: Hypertension (including exacerbation of hypertension: 5-7%)¡A orthostatic hypotension (2%)¡A Dyspepsia (2%)¡A nausea (6%)¡A Increased serum alanine aminotransferase (5-7%)¡A increased serum aspartate aminotransferase (6-7%)¡A Anxiety (2%)¡A falling (6%)¡A insomnia (4%)¡A Cough (2%) Frequency not defined: Nervous system: Impulse control disorder¡A sudden onset of sleep Postmarketing: Hypersensitivity reaction¡A Headache,30¢J¥H¤U¡C¾Tºä¶}«Ê«áÀ³Á×ÀãÀx¦s¡C,Parkinson disease: Oral 50 mg once daily (in combination with carbidopa/levodopa); after 2 weeks may increase to 100 mg once daily (in combination with carbidopa/levodopa) based on response and tolerability. Discontinuation of therapy: Decrease dose to 50 mg for one week before discontinuing therapy.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ­««×¨x¥\¯à¤£¥þ¯f¤H¸T¥Î¡C»´«×¨x¥\¯à¤£¥þ¯f¤HµL»Ý½Õ¾ã¾¯¶q¡C«ØÄ³¤¤«×¨x¥\¯à¤£¥þ¯f¤H¨Ï¥Î¨C¤é¤@¦¸ 50 mg¡C¦p±q¤¤«×¨x¥\¯à¤£¥þ´c¤Æ¦Ü­««×¨x¥\¯à¤£¥þÀ³°±¥Îsafinamide¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,SELEGILINE: Limited Human Data¡XAnimal Data Suggest Low Risk [¥é³æ] ¥¥°ü¨Ï¥Î safinamide ªº¸ê®Æ©|µL©Î¦³­­¡C°Êª«¸ÕÅçÅã¥Ü¦³¥Í´Þ¬r©Ê¡C ¤£«ØÄ³¦bÃh¥¥´Á¶¡¥H¤Î¦³¥Í¨|¯à¤O«o¥¼Á×¥¥ªº¤k©Ê¨Ï¥Î safinamide¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,SELEGILINE: Limited Human Data¡XPotential Toxicity [¥é³æ] ¥Ø«e¤wª¾°Êª«ªºÃÄ®Ä¾Ç/¬r²z¾Ç¸ê®ÆÅã¥Ü¡Asafinamide ·|¤Àªc¨ì¨Å¥Ä¤¤¡C ¤£¯à±Æ°£¥H¥À¨ÅÁý¾i¤§«Ä¤lªº­·ÀI¡C­÷¨Å´Á¶¡¤£À³¨Ï¥Î safinamide¡C,AC;AC15;PC;PO;WM;,,,,,
OCEX,Cefixime,CEXime 100mg,QANB,Streptococcus VSS S. pneumoniae¡A N. gonorrhoeae¡A Branhamella catarrhalis¡A E. coli¡A Klebsiella VSS Serratia VSS Proteus VSS H. Influenzae¡A the following infection caused by Cefixime susceptibility: bronchitis¡A bronchiectasis (infection)¡A secondary infection of chronic respiratory diseases¡A pneumonia¡A pyelonephritis¡A cystitis¡A bacterial urethritis¡A otitis media¡A sinusitis.,Hypersensitivity to cefixime¡A any component of the formulation¡A or other cephalosporins or penicillins,>10%: Gastrointestinal: Diarrhea (16%) 2% to 10%: Gastrointestinal: Abdominal pain¡A nausea¡A dyspepsia¡A flatulence¡A loose stools <2%: Acute renal failure¡A anaphylactoid reaction¡A anaphylaxis¡A angioedema¡A candidiasis¡A dizziness¡A drug fever¡A eosinophilia¡A erythema multiforme¡A facial edema¡A fever¡A headache¡A hepatitis¡A hyperbilirubinemia¡A increased blood urea nitrogen¡A increased serum creatinine¡A increased serum transaminases¡A jaundice¡A leukopenia¡A neutropenia¡A prolonged prothrombin time¡A pruritus¡A pseudomembranous colitis¡A seizure¡A serum sickness-like reaction¡A skin rash¡A Stevens-Johnson syndrome¡A thrombocytopenia¡A toxic epidermal necrolysis¡A urticaria¡A vaginitis¡A vomitingy.,25¢J¥H¤U,Adults and children > 30 kg: 50-100 mg orally twice daily; 200 mg twice daily for serious infection. [Sanford Guide to Antimicrobial Therapy 2021] Pediatric dose: Age > 28days: 8 mg/kg/day¡A divided Q12-24H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OPZA5,Pyrazinamide,Piramide 500mg,QANB,,¾AÀ³¯g: Treatment of pulmonary & extrapulmonary TB. °Æ§@¥Î: Hepatotoxicity¡A jaundice¡A hyperuricemia leading to attacks of gout¡A anorexia¡A nausea¡A vomiting¡A arthralgia¡A malaise¡A fever¡A sideroblastic anemia¡A difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea¡A Vomiting Musculoskeletal: Arthralgia (40%) ¸T§Ò: Liver damage.,,,20-35 mg/kg daily in 3-4 divided doses. (max. 3 g/day).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IOZU,Dexamethasone,Ozurdex (intravitreal implant) 0.7mg,TOPH,Diabetic macular edema (pseudophakic or phakic patients scheduled for cataract surgery) or macular edema (following BRVO or CRVO),Hypersensitivity to dexamethasone or any component of the formulation or product; glaucoma with cup to disc ratios of >0.8; active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva¡A including active epithelial herpes simplex keratitis (dendritic keratitis)¡A vaccinia¡A varicella¡A mycobacterial infections¡A and fungal diseases; use in patients with a posterior lens capsule that is torn or ruptured,Common: Hypertension (Diabetic macular edema¡A 13%)¡A Cushing's syndrome¡A Decreased body growth¡A Abnormal vision (1-9%)¡A Cataract (Diabetic macular edema¡A 68%; retinal vein occlusion and uveitis¡A 5-54%)¡A Conjunctival edema (5%)¡A Conjunctivitis (6%)¡A Corneal edema (Postoperative ocular inflammation and pain¡A 1% ; postoperative inflammation¡A 5-15%)¡A Discomfort¡A Eye (10%)¡A Disorder of anterior chamber of eye¡A Inflammation (10%)¡A Dry eye syndrome (5%)¡A Iridocyclitis¡A Iritis (5-15%)¡A Raised intraocular pressure (Retinal vein occlusion and uveitis¡A 24-25% ; postoperative inflammation and pain¡A 5-15% ; ocular itching¡A 3% i)¡A Vitreous floaters (1-5%)¡A Depression¡A Euphoria¡A Pulmonary tuberculosis Serious: Cardiomyopathy¡A Rupture of ventricle due to acute myocardial infarction¡A Hyperglycemia¡A Hypokalemia¡A Pancreatitis¡A Infectious disease¡A Osteoporosis¡A Conjunctival hemorrhage (Diabetic macular edema¡A 23%; retinal vein occlusion and uveitis¡A 22%)¡A Glaucoma (Diabetic macular edema¡A 1.2%)¡A Keratitis (2%)¡A Posterior subcapsular cataract¡A Retinal tear (2%)¡A Retinal vascular disorder (3%)¡A Uveitis (2%),25¢J¥H¤U,Ocular implant: Intravitreal injection: 0.7 mg implant injected in affected eye.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,DEXAMETHASONE IMPLANT OPHTHALMIC Corticosteroid PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,DEXAMETHASONE IMPLANT OPHTHALMIC Corticosteroid BREASTFEEDING RECOMMENATION: No Human Data¡XProbably Compatible,IVI;,,,,,1.¤£«ØÄ³Âù²´¦P®É±µ¨üª`®g.
OLEEV,Imatinib,Leevk 100mg,RACA,Adult & pediatrics with newly diagnosed chronic myeloid leukemia (CML)¡A CML in blast crisis¡A accelerated phase or chronic phase after failure of interferon-£\ therapy. Adult with newly diagnosed Philadelphia chromosome +ve acute lymphoblastic leukemia (Ph+ALL) integrated with chemotherapy; with relapsed or refractory Ph+ALL as montherapy; myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; systemic mastocytosis (SM) without D816V c-Kit mutation or with c-Kit mutation status unknown; hypereosinophilic syndrome (HES) &/or chronic eosinophilic leukemia (CEL); unresectable &/or metastatic¡A malignant GI stromal tumors (GIST); unresectable¡A recurrent &/or dermatofibrosarcoma protuberans (DFSP).,Hypersensitivity to imatinib or any component of the formulation,GI disturbances¡A anorexia¡A gastro-esophageal reflux¡A mouth ulceration¡A myalgia¡A muscle cramps¡A joint swelling¡A headache¡A dizziness¡A taste disturbance¡A paraesthesia¡A insomnia¡A conjunctivitis¡A increased lacrimation¡A blurred vision¡A epistaxis¡A dyspnea¡A weight gain¡A periorbital edema¡A dermatitis¡A rash¡A face & eyelid edema¡A pruritus¡A erythema¡A dry skin¡A alopecia¡A night sweats¡A fluid retention & edema¡A fatigue; pyrexia¡A weakness¡A rigors; neutropenia & febrile neutropenia¡A thrombocytopenia¡A anemia. Cardiovascular: Edema (1.1% to 86.1% ) Dermatologic: Night sweats (13% to 17% )¡A Rash (up to 49.8% ) Endocrine metabolic: Weight gain (up to 32% ) Gastrointestinal: Diarrhea (3% to 58.2% )¡A Nausea (3% to 73% )¡A Vomiting (2% to 58% ) Musculoskeletal: Arthralgia (12.3% to 40% )¡A Cramp (up to 62% )¡A Musculoskeletal pain (up to 49% )¡A Myalgia (9% to 32.2% ) Neurologic: Asthenia (15% to 21% )¡A Dizziness (12% to 16% )¡A Headache (up to 36% )¡A Insomnia (10% to 14% ) Respiratory: Cough (14% to 27% )¡A Nasopharyngitis (10% to 30.5% )¡A Pain¡A Pharyngolaryngeal (18.1% )¡A Pharyngitis (10% to 15% ) Other: Fatigue (25% to 48% )¡A Fever (16.7% to 41% )¡A Influenza (0.8% to 13.8% )¡A Rigor (10% to 12% ),30¢J¥H¤U¡A¨¾¼é,[Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)]- Chronic phase: 400 mg once daily¡A may be increased to 600 mg daily- Accelerated phase or blast crisis: 600 mg once daily¡A may be increased to 800 mg daily (400 mg twice daily) [Ph+ acute lymphoblastic leukemia (ALL)] 600 mg once daily [Myelodysplastic/myeloproliferative disease (MDS/MPD)] 400 mg once daily [Aggressive systemic mastocytosis (ASM) associated with eosinophilia] Initiate at 100 mg once daily; if assessments demonstrate insufficient response¡A increase from 100-400 mg/day in the absence of adverse reactions. [ASM without D816V c-Kit mutation or c-Kit mutation status unknown] 400 mg once daily [Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)] 400 mg once daily [HES/CEL with FIP1L1-PDGFR£\ fusion kinase] Initiate at 100 mg once daily; if assessments demonstrate insufficient response¡A increase from 100-400 mg/day in the absence of adverse reactions. [Gastrointestinal stromal tumors (GIST)]- Adjuvant treatment following complete resection: 400 mg once daily; recommended treatment duration: 3 years- Unresectable and/or metastatic malignant: 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily)¡A if tolerated¡A for disease progression. [Dermatofibrosarcoma protuberans (DFSP)] 400-800 mg/day (400 mg once or twice daily),»Ý½Õ¾ã¾¯¶q,Severe impairment: Reduce dose by 25%.,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
OBEL,Lorcaserin,Belviq 10mg 60's/box,META,,¾AÀ³¯g:Weight management: Chronic weight management¡A as an adjunct to a reduced-calorie diet and increased physical activity¡A in adults with either an initial body mass index (BMI) of ?30 kg/m2 or an initial BMI of ?27 kg/m2 and at least one weight-related comorbid condition (eg¡A hypertension¡A dyslipidemia¡A type 2 diabetes). °Æ§@¥Î: >10%: Central nervous system: Headache (15% to 17%) Endocrine & metabolic: Hypoglycemia (diabetic patients 29%; symptomatic 7%; severe: 2%) Hematologic: Abnormal lymphocytes (below lower limit of normal after >=1 year¡A 12%) Neuromuscular & skeletal: Back pain (6% to 12%) Respiratory: Upper respiratory tract infection (14%)¡A nasopharyngitis (11% to 13%) ¸T§Ò:Hypersensitivity to lorcaserin or any component of the formulation; pregnancy.,,«Ç·Å,Dosing: Adult Weight management: Oral: Note: Evaluate response by week 12; if patient has not lost ?5% of baseline body weight¡A discontinue therapy. Immediate release: 10 mg twice daily (maximum: 20 mg/day).,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IEVU,Tixagevimab + Cilgavimab,Evusheld inj 150mg/150mg/3mL/dose (¬F©²´£¨Ñ),QANB,COVID-19¡A Pre-exposure in patients not currently infected with SARS-CoV-2 and have not had a known recent exposure and who have moderate to severe immune compromise/may not mount an adequate response to vaccination or are unable to receive a COVID-19 vaccination; Prophylaxis,Severe hypersensitivity reactions¡A including anaphylaxis¡A to tixagevimab¡A cilgavimab¡A or any component of the formulation.,Common: Headache (6%)¡A Cough (3%)¡A Fatigue (4%) Serious: Cardiac dysrhythmia¡A Cardiomegaly¡A Cardiomyopathy¡A Cardiorespiratory arrest¡A Coronary arteriosclerosis¡A Heart failure (0.2%)¡A Myocardial infarction (0.2-0.4%)¡A Myocardial ischemia¡A Sudden cardiac death (0.2%)¡A Anaphylaxis¡A Hypersensitivity reaction,Á×¥ú§NÂÃ(2-8¢XC),,µL»Ý½Õ¾ã¾¯¶q,[Micromedex] The effect of hepatic impairment on the pharmacokinetics of tixagevimab and cilgavimab is unknown,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[Micromedex] Fetal risk cannot be ruled out. [Lexidrug] ©|¥¼¶i¦æ«DÁ{§É¥Í´Þ¬r©Ê¬ã¨s¡CTixagevimab ©M cilgavimab ³£¥i¥H¬ï¹L­L½L¡C¼ÉÅS¶q¨ú¨M©ó IgG ¨È«¬¡B¥ÀÅé¦å²M¿@«×¡B­L½L§¹¾ã©Ê¡B·s¥Í¨à¥X¥ÍÅé­«©M§³®W¶g¼Æ¡A³q±`ÀHµÛÃh¥¥ªº¶i®i¦Ó¼W¥[¡C¹w­p¦b¾¹©x§Î¦¨´Á¶¡±µÄ²¶q³Ì§C¡A§³®W±ß´Á±µÄ²¶q³Ì°ª¡C,Unknown ¨S¦³¸ê®Æ,[Micromedex] Infant risk cannot be ruled out. [Lexidrug] ¥Ø«e©|¤£²M·¡¥À¨Å¤¤¬O§_¦³tixagevimab ©M cilgavimab ¡CªvÀø´Á¶¡¥À¨Å­÷¨|ªº¨M©wÀ³¦Ò¼{À¦¨à¼ÉÅSªº­·ÀI¡B¥À¨Å­÷¨|¹ïÀ¦¨àªº¯q³B¥H¤ÎªvÀø¹ï¥À¿Ëªº¯q³B¡C¤£«ØÄ³­÷¨Å´Á±wªÌ½Õ¾ã¾¯¶q¡C,IM;,,,,,1. ÃÄª«¤p²~(vial)¬ï¨ë«á¶·©ó4¤p®É¤º§¹¦¨µ¹ÃÄ¡C 2. ¦b¤£¦Pªºª`®g³¡¦ì³sÄò¶i¦æ¨â¦¸¦Ù¦×ª`®g¡A«ØÄ³ª`®g©óÁv¦Ù¡C
OAPR,Irbesartan,Aprovel 300mg,CAVS,,¾AÀ³¯g: Diabetic nephropathy: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Hypertension: Treatment of hypertension alone or in combination with other antihypertensives °Æ§@¥Î: >10%: Endocrine & metabolic: Hyperkalemia (diabetic nephropathy: 19%; rarely seen in hypertension) 1% to 10%: Cardiovascular: Orthostatic hypotension (diabetic nephropathy: 5%: hypertension: <1%) Central nervous system: Dizziness (diabetic nephropathy: 10%)¡A fatigue (4%) Gastrointestinal: Diarrhea (3%)¡A dyspepsia (2%) Respiratory: Upper respiratory tract infection (9%) <1%¡A postmarketing¡A and/or case reports: Abdominal distention¡A anemia (case report; Simonetti 2007)¡A angina pectoris¡A angioedema¡A arthritis¡A auditory disturbance¡A bronchitis¡A bursitis¡A cardiac arrhythmia¡A cardiac failure¡A cerebrovascular accident¡A chills¡A conjunctivitis¡A constipation¡A decreased libido¡A depression¡A dermatitis¡A drowsiness¡A dyspnea¡A ecchymoses¡A epistaxis¡A erythema¡A facial edema¡A fever¡A flatulence¡A flushing¡A gastroenteritis¡A gout¡A hepatitis¡A hypertension¡A hypertensive crisis¡A hypotension¡A increased liver enzymes¡A increased serum transaminases¡A jaundice¡A muscle cramps¡A myalgia¡A myasthenia¡A myocardial infarction¡A nasal congestion¡A noncardiac chest pain¡A numbness¡A otalgia¡A otic infection¡A paresthesia¡A prostatic disease¡A pruritus¡A pulmonary congestion¡A renal failure¡A renal insufficiency¡A sexual disorder¡A sleep disorder¡A thrombocytopenia¡A transient ischemic attacks¡A tremor¡A upper extremity edema¡A urination disorder¡A urticaria¡A visual disturbance¡A wheezing ¸T§Ò:Hypersensitivity to irbesartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus.,,«Ç·Å,Initial dose 150 mg once daily; titrate as needed based on patient response up to 300 mg once daily¡A maximum dose: 300 mg/day. Elderly >75 yr & haemodialysis patients Consider initiating with 75 mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ICOVMDN,SARS-CoV-2 Spike glycoprotein [mRNA],COVID-19 Vaccine Moderna 0.5mL/dose (5mL/vial),HIMM,Moderna COVID-19 Vaccine¡A for active immunization to prevent COVID-19 in individuals 18 years of age and older.,Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g.¡A anaphylaxis) to any component of the Moderna COVID-19 Vaccine.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,2~8¢J¥i©ñ¤@­Ó¤ë,IM¡A 0.5 mL¡A > or = 18 years 2 doses administered 28 days apart.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,©Ò¦³§³®W³£¦³µo¥Í¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²§½ªº­·ÀI¡C¦b¬ü˜Çªº¤@¯ë¤H¸s¤¤¡A¦b¸g¹LÁ{§É½T»{ªº§³®W¤¤¡A­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¤À¡H¬°2%¦Ü4%©M15%¦Ü20%¡C ¦³Ãö¥¥°ü±µºØModerna COVID-19 ¬Ì­]ªº¥i¥Î¼Æ¾Ú©|¤£¨¬¥H´¦¥Ü§³®W´Á¶¡±µºØ¬Ì­]ªº¬ÛÃö­·ÀI¡C ¦b¤@¶µµo¨|¬r©Ê¬ã¨s¤¤¡A¦b»Û©Ê¤j¹«¥æ°t«e28¤Ñ©M14¤Ñ¡B¥H¤Î§³®W²Ä1¤Ñ©M²Ä13¤Ñ³o¥|ºØ±¡úG¤U¡A¤À¡H¸g¦Ù¦×±µºØ0.2 mL¬Ì­]»s¾¯¡A¨ä¤¤©Ò§tªº¸g®Öä­×¹¢ªºmRNA(100 mcg) ©M¨ä¥¦¦¨¤À»P¤H¥Î³æ¦¸¾¯¶qªºModerna COVID-19 ¬Ì­]ªº§t¶q¬Û¦P¡C ¦b¸Ó¬ã¨s¤¤¥¼³ø§i¼vÅT»Û©Ê¥Í¨|¯à¤O¡B­L¨àµo¨|©Î²£«áµo¨|ªº»P¬Ì­]¬ÛÃöªº¤£¨}¤ÏÀ³¡C,Unknown ¨S¦³¸ê®Æ,©|µL¼Æ¾Ú¥i¥Î©óµû¦ôModerna COVID-19¬Ì­]¹ï¥À¨ÅÁý¾iÀ¦¨à©Î¨Å¥Ä²£¥Í/¤Àªcªº¼vÅT¡C,IM;,,,,,1.§NÀx±ø¥ó: -25¦Ü-15¢XC§N­á«O¦s¡A¤£±o§C©ó-40¢XC¥B¤£±o¨Ï¥Î°®¦B§N¹B§NÀx.­YÂà¸m¨ì2~8¢XC§NÂÃ³]³Æ«O¦s¥²¶·©ó30¤Ñ¤º¨Ï¥Î§¹²¦. 2.¦h¾¯¶qÃÄ²~§tµL¨¾»G¾¯ªº§N­á²VÄa²G¡A¦b±µºØ«e¥²¶·¸Ñ­á.¦b2-8¢XCªº§NÂÃ±ø¥ó¤U¸Ñ­á2¤p®É30¤ÀÄÁ.¸Ñ­á«á¦b±µºØ«eÅýÃÄ²~¦b«Ç·Å¤UÀR¸m15¤ÀÄÁ. ©ÎªÌ¦b15-25¢XCªº«Ç·Å¤U¸Ñ­á1¤p®É. ¸Ñ­á«á¡A½Ð¤Å­«·s§N­á. ¸Ñ­á«á©M¦b¨C¦¸©âÃÄ¤§«e¡A»´»´±Û°ÊÃÄ²~.¤Á¤Å·n®Ì.¤Á¤Åµ}ÄÀ¬Ì­]. 3.¦b²Ä¤@¾¯³Q©â¥X«á¡AÃÄ²~À³«O¦s¦b2-25¢XC¤§¶¡.¦b¬Ì­]ÃÄ²~¼ÐÅÒ¤W°O¿ý­º¦¸¨Ï¥Îªº¤é´Á©M®É¶¡.6 ¤p®É«á¥á±óÃÄ²~.¤Á¤Å­«·s§N­á.
HCVDA17,Sofosbuvir + Velpatasvir + Voxilaprevir (1-6/12¶g),HCVDAA0017(C¨x¥þ¤fªA·sÃÄ°·«O­pµe)1-6«¬(S/V/V)12¶g,QANB,,,,,,,,,,,,,,,,,,,
EROY,Clindamycin,Royalsense acne gel 1% 20gm,TDER,Acne vulgaris.,Allergic to Clindamycin or Lincomycin. Patients with a history of regional enteritis¡A ulcerative colitis¡A or antibiotic-associated colitis.,Skin rash¡A itching¡A redness¡A swelling dryness¡A scaliness¡A peeling of skin.,25¢XC¥H¤U,Apply twice daily to affected area.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[Briggs Drugs in Pregnancy and Lactation] Compatible¡XAvoid 1st Trimester if Possible [¥é³æ]¥Ø«eµL¥i«H¿à¤§Á{§É¸ÕÅç¥iÃÒ©ú¥¥°ü¨Ï¥Î¤§¦w¥þ©Ê¡A¬G°£«D¥²­n¡A¥¥°ü½Ð¤Å¨Ï¥Î¥»¾¯¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
IOGIS,Trastuzumab,Ogivri inj 440 mg (µ´¹ï¦Û¶O),RACA,Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature breast cancer: 1.as part of a treatment regimen consisting of doxorubicin¡A cyclophosphamide¡A and either paclitaxel or docetaxel. 2.as part of a treatment regimen with docetaxel and carboplatin. 3.as a single agent following multi-modality anthracycline based therapy. In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer. As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. In combination with cisplatin and capecitabine or 5-fluorouracil¡A for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.,Patients with known hypersensitivity to trastuzumab or to any other component of Ogivri.,Common Dermatologic: Rash (Adjuvant breast cancer¡A 4%; metastatic breast cancer¡A 18% to 38% ) Endocrine metabolic: Weight decreased (23% ) Gastrointestinal: Diarrhea (7% to 51% )¡A Nausea (Adjuvant breast cancer¡A 6%; metastatic breast cancer¡A 33% to 76% )¡A Stomatitis (24% )¡A Vomiting (Adjuvant breast cancer¡A 3.5%; metastatic breast cancer¡A 23% to 53% ) Hematologic: Anemia¡A All Grades (4% to 36% )¡A Neutropenia¡A All Grades (Breast cancer¡A 6.4%; gastric cancer¡A 78% )¡A Thrombocytopenia¡A All Grades (16% ) Immunologic: Infectious disease (20% to 47% ) Neurologic: Headache (Adjuvant breast cancer¡A 6.2% to 10%; metastatic breast cancer¡A 26% to 44% )¡A Insomnia (Adjuvant breast cancer¡A 4.3%; metastatic breast cancer¡A 14% to 29% ) Respiratory: Cough (Adjuvant breast cancer¡A 5%; metastatic breast cancer¡A 26% to 43% ) Other: Fatigue (29.5% to 35% )¡A Fever (Adjuvant breast cancer¡A 6%; metastatic breast cancer¡A 36% to 56%; gastric cancer¡A 18% )¡A Shivering (Adjuvant breast cancer¡A 5%; metastatic breast cancer¡A 32% to 41% ) Serious Cardiovascular: Cardiac dysrhythmia (3% )¡A Heart failure (Adjuvant breast cancer¡A 0.4% to 3.2%; metastatic breast cancer¡A 7% to 28% )¡A Left ventricular cardiac dysfunction (5% to 18.5% )¡A Myocardial ischemia¡A Grade 3 or 4 Hematologic: Febrile neutropenia (23% )¡A Neutropenia¡A Grade 3 or 4 (32% to 34% )¡A Thrombocytopenia¡A Grade 3 or 4 (5% )¡A Thrombosis (2.1% to 3.7% ) Immunologic: Hypersensitivity reaction (0.6% to 8% ) Renal: Renal failure Respiratory: Dyspnea (Adjuvant breast cancer¡A 2.4% to 11.8%; metastatic breast cancer¡A 22% to 42% )¡A Interstitial pneumonia¡A acute (0.2% to 0.7% )¡A Pulmonary hypertension (0.2% )¡A Pulmonary toxicity (14.3% ) Other: Infusion reaction (21% to 40% )¡A Tumor lysis syndrome,2-8¢J,[Adjuvant Treatment of HER2-Overexpressing Breast Cancer] Administer at either: initial dose of 4 mg/kg over 90 minute IV infusion¡A then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks¡A or initial dose of 8 mg/kg over 90 minutes IV infusion¡A then 6 mg/kg over 30 - 90 minutes IV infusion every 3 weeks for 52 weeks. [Metastatic HER2-Overexpressing Breast Cancer] Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions. [Metastatic HER2-overexpressing Gastric Cancer] Initial dose of 8 mg/kg over 90 minutes IV infusion¡A followed by 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ]¹ï¥¥°ü§ë¤©trastuzumab·|¹ï­L¨à³y¦¨¶Ë®`¡C®Ú¾Ú¤W¥««áªº¯f¨Ò³ø§i¡A¦bÃh¥¥´Á¶¡¨Ï¥Îtrastuzumab·|´£°ª©ó²Ä¤G¤Î²Ä¤T¥¥´Á¥X²{¦Ï¤ô¹L¤Ö²{¶Hªº­·ÀI¡C¦pªG°ü¤k¦bÃh¥¥´Á¶¡¨Ï¥Î¤Ftrastuzumab¡A©Î©ó¨Ï¥Îtrastuzumab´Á¶¡Ãh¥¥¡AÀ³±N­L¨à¥i¯à¨ü¨ìªº¦M®`§iª¾¸Ó¦W°ü¤k¡C¤W¥«¤§«á¡A¦bÃh¥¥´Á¶¡±µ¨ü³æ¤@trastuzumab©Î»P¤Æ¾ÇÀøªk¨Ö¥ÎªvÀøªº°ü¤k¤¤´¿¦³¥X²{¦Ï¤ô¹L¤Ö²{¶Hªº³ø§i¡C¨ä¤¤¦³¥b¼Æªº°ü¤k¦b°±¥Îtrastuzumab¤§«á§Y¥X²{¦Ï¤ô«ü¼Æ¤W¤Éªº²{¶H¡C¦³¤@­Ó¯f¨Ò¦b¦Ï¤ô«ü¼Æ§ïµ½¤§«á¤S­«·s¶}©l¨Ï¥Îtrastuzumab¡Aµ²ªG¦A«×¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡C¤W¥«¤§«á¡A¦b±µ¨ütrastuzumabªº¥¥°ü¤¤´¿¦³³ø¾É­L¨à¦Ï¤ô¹L¤Ö¯g¦ñÀHµÇÅ¦¦¨?¤Î/©Î¥\¯à¨ü·lªº®×¨Ò¡A¨ä¤¤¦³³y¦¨­L¨àªÍ³¡¾¹©xµo¨|¤£¥þ¦Ó¾É­P¦º¤`ªº³ø¾É¡C¹ï©ó¦bÃh¥¥´Á¶¡¨Ï¥ÎOgivriªº°ü¤k¡AÀ³ºÊµø¬O§_¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡C¦pªG¥X²{¦Ï¤ô¹L¤Öªº²{¶H¡A§YÀ³¶i¦æ¾A¦X¨ä§³®W¶g¼Æ¥B²Å¦XªÀ·|·ÓÅ@¼Ð·Çªº­L¨àÀË¬d¡C´¿¸g¦b§ë¤©¨ä¥L¤Æ¾ÇªvÀø¾¯¤§«á¥X²{¦Ï¤ô¹L¤Öªº²{¶H®É¥HÀR¯ß¿éª`(IV)ªº¤è¦¡ÃB¥~¸É¥R¤ô¥÷¡Aµ²ªG»á¦³§U¯q¡A¦ý¥Ø«e¨Ã¤£½Tª¾¨Ï¥ÎtrastuzumabªvÀø®É¥HÀR¯ß¿éª`¤§¤è¦¡ÃB¥~¸É¥R¤ô¥÷ªº®ÄªG¡C¦b¥H°ª¹F¤HÃþ¨C¶g«ØÄ³¾¯¶q(2²@§J/¤½¤çÅé­«)¤§25­¿ªºtrastuzumab©Ò¶i¦æªº­¹ÃÉµU¥Í´Þ¬ã¨s¤¤¡A¨Ã¥¼µo²{¥ô¦óÅã¥Ü­L¨à¨ü¨ì¶Ë®`ªºÃÒ¾Ú¡C¤£¹L¡A³\¦h­F­L²ÕÂ´³£¦³¬Û·í©úÅãªºHER2³J¥Õ¹L«×ªí²{ªº²{¶H¡A¥]¬A¤ßÅ¦»P¯«¸g²ÕÂ´¡F¦b¯Ê¥FHER2ªº¬ðÅÜ¤p¹«¤¤¡A­F­L¬Ò©óÃh¥¥ªì´Á§Y¦º¤`¡C°w¹ïµU¤l©Ò¶i¦æªº¬ã¨sµo²{¡A¦b­L¨àµo¨|¶¥¬qªºªì´Á(Ãh¥¥²Ä20-50¤Ñ)¤Î«á´Á(Ãh¥¥²Ä120-150¤Ñ)¡Atrastuzumab·|³q¹L­L½LÂà²¾¦Ü­L¨àÅé¤º¡C¥Ñ©ó°Êª«¥Í´Þ¬ã¨sªºµ²ªG¨Ã¤£¡H©w¯à¹w´ú¤HÃþªº¤ÏÀ³¡A¦]¦¹¡A¥u¦³¦b¥À¿Ëªº¼ç¦b®Ä¯q¶W¶V­L¨à¥i¯à­±Á{¤§­·ÀIªº±¡ªp¤U¡A¤~¥i©óÃh¥¥´Á¶¡¨Ï¥ÎOgivri¡C ¨|ÄÖ´Á°ü¤k©óOgivriªvÀø´Á¶¡¤ÎªvÀøµ²§ô«á7­Ó¤ë¤ºÀ³³Q«ØÄ³±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I¡C ­Y¥¥°ü±µ¨üOgivriªvÀø¡A©Î¬O¯f±w¦b±µ¨üOgivriªvÀø´Á¶¡©Î³Ì«á¤@¾¯Ogivri«á7­Ó¤ë¤ºÃh¥¥¡A³Ì¦n¥Ñ¸ó¬ì§O¹Î¶¤¶i¦æÄY±KºÊ´ú¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ø«e¨Ã¤£½Tª¾trastuzumab¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¦ý¤HÃþªºIgG·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡A¨Å¥Ä§ÜÅé¨Ã¤£·|¤j¶q¶i¤J·s¥Í¨à¤ÎÀ¦¨àªºÅé¤º´`Àô¡C¹ï±Â¨Å­¹ÃÉµU§ë¤©¬Û·í©ó¤HÃþ¨C¶g«ØÄ³¾¯¶q(2²@§J/¤½¤çÅé­«)¤§12.5­¿ªºtrastuzumab¤§«áµo²{¡Atrastuzumab·|¥X²{©ó¨Å¥Ä¤¤¡C¦å²M¤¤ÀË¥Xtrastuzumabªº¥®µU¦b¥X¥Í«á¦Ü3­Ó¤ë¤j´Á¶¡¨Ã¥¼µo¥Í¥ô¦ó¥Í?©Îµo¨|¤è­±ªº¤£¨}¼vÅT¡F¤£¹L¡A°Êª«¨Å¥Ä¤¤ªºtrastuzumab§t¶q¨Ã¤£¯àºë½T¦a¤Ï¬M¤HÃþ¨Å¥Ä¤¤ªº§t¶q¡C ¥Ñ©ó³\¦hÃÄª«³£·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡A¥BÁý­÷¥À¨ÅªºÀ¦¨à¥i¯à·|¦]±µÄ²Ogivri¦Óµo¥ÍÄY­«ªº¤£¨}¤ÏÀ³¡A¦]¦¹¡AÀ³¦Ò¼{Ogivriªº±Æ°£¥b°I´Á¤Î¦¹ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡AµM«á¨M©w¬O§_­n°±¤îÁý­÷¥À¨Å©Î¬O°±¥Î¦¹ÃÄ¡C,IVD;,¥]¸Ë¤¤ªºµ}ÄÀ²G(20 ²@¤É§t1.1%­f¥Ò¾Jªº¨îµßª`®g¥Î¤ô)¡C,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,©â¨ú¯f±wÃÄª«¶q«á¥[¨ì¸Ë¦³0.9%´â¤Æ¶u250 ²@¤Éªºª`®g³U¤¤µ}ÄÀ¡A°_©l¾¯¶q«ØÄ³ÀR¯ß¿éª`90 ¤ÀÄÁ¡Cºû«ù¾¯¶q®É­Y¯f¤H¹ï¥ý«e¾¯¶qªº­@¨ü¤O¨Î¡A¥i¿éª`30 ¤ÀÄÁ§Y¥i¡C,1.°t»sªº»¡©ú: ¨Ï¥ÎµLµß°wµ©¡AºCºCª`¤J20 ²@¤É¨îµßª`®g¥Î¤ô©ó§t­á´¹Ogivri ªº¤p²~¡Aª½±µª`®g¦Ü­á´¹¶ô¡C¦A·Å©M¦aÂà°Ê¤p²~À°§U½Õ°t¡A¤£­n·n®Ì¡C 2.¨Ï¥Î¥]¸Ë¤¤©Ò´£¨Ñªº¨îµßª`®g¥Î¤ô²V¦X«áªº°t»s«á·»²G¡A§NÂÃ¦b2-8¢J¥i¥Hºû«ù28 ¤Ñªº¦w©w¡C¦pªG¨Ï¥Î·Àµß¤ô°t»s«h¶Èºû«ù24 ¤p®É¦w©w¡A¤§«á¥²¶·¥á±ó¡C 3.°t»s©ó¸Ë¦³0.9%´â¤Æ¶u·»²Gªºª`®g¥Î³U¤¤¡A¦b2-8¢J¤U¨äª«¤Æ©Ê½è¥iºû«ùÃ­©w24 ¤p®É¡C 4.¸T¤î¨Ï¥Î5%ªºdextrose ·»²G¡A¦]¬°·|¤Þ°_³J¥Õ½è¾®¶°¡C
IENV,Inactivated Enterovirus 71 whole virus,Envacgen inj 0.5mL/dose,HIMM,Primary immunization for infants and toddlers aged 2 months to less than 6 years to prevent diseases caused by enterovirus type 71 infection.,Previous severe allergic reaction to this vaccine. Known allergy to any vaccine component. Severe allergy to formaldehyde.,Reduced appetite¡A drowsiness¡A diarrhea¡A vomiting¡A nausea¡A injection site pain¡A fever¡A injection site swelling¡A injection site redness¡A injection site bruising¡A injection site lump¡A restlessness¡A limited limb mobility¡A rash¡A erythema¡A ecchymosis¡A urticaria¡A and allergy.,Á×¥ú§NÂÃÀx¦s(2-8¢J),For infants aged 2 months to under 6 years: One 0.5 mL muscle injection in the upper arm or thigh¡A two doses with a 56-day gap. For infants under 2 at first dose¡A consider a booster after one year.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] µL¬ÛÃö¬ã¨s¸ê®Æ¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¤£¾A¥Î¡C¥»¬Ì­]¬I¥´±Ú¸s¬°2­Ó¤ë¥H¤W¦Ü¥¼º¡6·³¤§À¦¥®¨à¡C ¥Ø«e©|µL¥»¬Ì­]¨Ï¥Î©óÃh¥¥°ü¤k¤§¬ÛÃö¸ê®Æ¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¤£¾A¥Î¡C¥»¬Ì­]¬I¥´±Ú¸s¬°2­Ó¤ë¥H¤W¦Ü¥¼º¡6·³¤§À¦¥®¨à¡C ¥Ø«e©|µL¥»¬Ì­]¨Ï¥Î©ó±Â¨Å´Á¶¡°ü¤k¤§¬ÛÃö¸ê®Æ¡C,IM;,,,,,1. ¬I¥´¦¹¬Ì­]«e«á14¤Ñ¸T¤î¬I¥´¨ä¥L¬¡©Ê´î¬r¬Ì­]¡C 2. µL¬Û®e©Ê¬ã¨s¡A¥»«~¤£±o»P¨ä¥LÃÄª«²V¦X¨Ï¥Î¡C 3. ¬Ì­]¥~Æ[¬°µL¦â¼á©ú²G¡A¨Ï¥Î«e½Ð»´»´¤W¤U­ËÂà²V¦X§¡¤Ã¬°²V¿B¥Õ¦âÄa¯B²G¡C 4. ¶È¨Ñ¦Ù¦×ª`®g¡A¤Å¥H¦åºÞ¤º¡B¥Ö¤U©Î¥Ö¤ºª`®g¤è¦¡¬I¥´¬Ì­]¡C
LOSTAS,Oseltamivir,Oseltamivir Phosphate 6mg/mL¡A 60mL oral suspension,QANB,Treatment of influenza in adults and children (including full-term newborns). Prevention of influenza in adults and children aged 1 and above.,Known allergies to oseltamivir phosphate or any of its components.,Common: Nausea (8-10%)¡A Vomiting (Adult and adolescent¡A 2-8%; pediatric¡A 8-16%)¡A Headache (Influenza treatment¡A 2%; influenza prophylaxis¡A 17%) Serious: Cardiac dysrhythmia¡A Erythema multiforme (Rare)¡A Facial swelling¡A Stevens-Johnson syndrome (Rare)¡A Toxic epidermal necrolysis (Rare)¡A Gastrointestinal hemorrhage¡A Hemorrhagic colitis¡A Hepatitis¡A Anaphylaxis (Rare)¡A Seizure¡A Abnormal behavior¡A Delirium,25¢XC¥H¤U¡C½Õ°t«á¡G§NÂÃ(2-8¢J)17¤Ñ©Î«Ç·Å(<25¢J)10¤Ñ,Treatment of influenza: must begin treatment within the first or second day of experiencing influenza symptoms. - Adults and adolescents (>=13years): 75mg PO BID for 5 days. - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO BID for 5 days. >15-23kg: 45mg (7.5mL) PO BID for 5 days. >23-40kg: 60mg (10mL) PO BID for 5 days. >40kg: 75mg (12.5mL) PO BID for 5 days. - Children under 1 year: 3mg/kg PO BID for 5 days (not for infants with a gestational age of <36 weeks). Prophylaxis of influenza: must begin prophylaxis within 2 days of exposure to the source. - Adults and adolescents: 75mg PO QD for 10 or more days (safety and efficacy confirmed for 6 weeks). - Children (dosages based on body weight): <=15kg: 30mg (5mL) PO QD for 10 days. >15-23kg: 45mg (7.5mL) PO QD for 10 days. >23-40kg: 60mg (10mL) PO QD for 10 days. > 40kg: 75mg (12.5mL) PO QD for 10 days.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¹ï©ó»´«×¦Ü¤¤«×ªº¨x¥\¯à¤£¥þ¯f¤H¦b¬y¦æ©Ê·P«_ªºªvÀø¤Î¹w¨¾¤W¡A¥ç¨S¦³½Õ¾ã¾¯¶qªº¥²­n¡C¹ï©ó­««×¨x¥\¯à¤£¥þ¯f¤H¤§¦w¥þ©Ê¤Î¨äÃÄ°Ê¾Ç¤è­±¡A©|¥¼¶i¦æ¹L¬ÛÃö¬ã¨s¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ] ±q¤W¥««á³ø§i¤ÎÆ[¹î©Ê¬ã¨s¤¤¨ú±oªº¸ê®Æ©M°Êª«¬ã¨sµ²ªGÅã¥Ü¹ïÃh¥¥¡B­F­L/­L¨à©Î ¥X¥Í«áªºµo¨|¨ÃµLª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C¦b¦Ò¶q¤wª¾ªº¦w¥þ©Ê¤Î®Ä¯q¸ê®Æ¡B¬y¦æ¤¤¤§ ¬y¦æ©Ê·P«_¯f¬r®èªº­P¯f©Ê¡B¤ÎÃh¥¥°ü¤k¥»¨­ª¬ªp«á¡AÃh¥¥°ü¤k¥i¯à¥i¨Ï¥Î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¦b±Â¨Å¤j¹«¤¤µo²{¡AOseltamivir ¤Î¨ä¬¡©Ê¥NÁÂª«·|³Q¤Àªc¦Ü¨Å¥Ä¤¤¡C±Â¨Å¥À¿ËªA¥ÎOseltamivir ¹ï§l§m¥À¨Å¤§¥®¨àªº¼vÅT¤ÎOseltamivir ±Æªn©ó¨Å¥Ä¤¤ªº¸ê°T«D±`¦³­­¡C¦³­­ªº¸ê®ÆÅã¥Ü¡A Oseltamivir¤Î¨ä¬¡©Ê¥NÁÂª«¥i¦b¨Å¥Ä¤¤³Q°»´ú¥X¨Ó¡A¦ý¨ä¿@«×§C©Ò¥H¹ï©óÀ¦¨à¦Ó¨¥§C©óªvÀø¾¯¶q¡C °ò©ó¤W­z¸ê°T¡B¥¿¦b¬y¦æ¤¤¤§¬y¦æ©Ê·P«_¯f¬r®è¤§­P¯f©Ê¤Î±Â¨Å°ü¤kªº¼ç¦bª¬ªp¡A¨Ã½T»{ ¹ï±Â¨Å¥À¿Ëªº¯q³B¤j©ó¥i¯à¹ï­÷¨|¤¤À¦¨àªº¦MÀI¤§«á¡A¥i¯à¥i¥Hµ¹¤©±Â¨Å°ü¤k¡C,AC;AC15;PC;PO;WM;,,,,,1. °t»s¤è¦¡¡G©ç¥´Åø¤l¥HÃP´²¯»¥½¡C±N55²@¤É½Õ§N¤ô¥[¤J²~¤¤¡A»\ºò²~»\«á·n¤Ã¦Ü¥Õ¦â§¡¤ÃÄa²G¡C 2. ½Õ°t«á¥i§NÂÃ(2-8¢J)«O¦s17¤Ñ©Î«Ç·Å(<25¢J)«O¦s10¤Ñ¡C 3. ¥i¥H©M©Î¤£©M­¹ª«¤@°_ªA¥Î¡C©M­¹ª«¤@°_ªA¥Î¥i¯à¥i¼W¥[¹ïÃÄª«ªº­@¨ü©Ê¡C
OMAI,Methylcobalamin,Maiyitong 500mcg,CNEU,Peripheral neuropathies¡A megaloblastic anaemia caused by vit B12 deficiency.,Hypersensitivity to any component of the formulation.,Anorexia¡A nausea¡A vomiting and diarrhoea. Parenteral: Rash¡A headache¡A hot sensation.,¹ï¥ú¤£¦w©w¡A»Ý¾B¥ú«O¦s,Adult: 500 mcg TID . May adjust dosage according to patient's age and synptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OIBR,Palbociclib,IBRANCE 125mg,RACA,Breast cancer¡A advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive¡A human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer¡A advanced (with disease progression following endocrine therapy): Treatment of HR-positive¡A HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).,Common Dermatologic: Alopecia (18% to 33% )¡A Rash (17% to 18% ) Gastrointestinal: Constipation (20% )¡A Decrease in appetite (15% to 16% )¡A Diarrhea (24% to 26% )¡A Nausea (34% to 35% )¡A Stomatitis (28% to 30% )¡A Vomiting (16% to 19% ) Hematologic: Anemia¡A All Grades (24% to 30% )¡A Leukopenia¡A All Grades (39% to 53% )¡A Neutropenia¡A All Grades (80% to 83% )¡A Thrombocytopenia¡A All Grades (16% to 23% ) Immunologic: Infectious disease (47% to 60% ) Neurologic: Asthenia (8% to 13% )¡A Headache (26% )¡A Peripheral neuropathy (13% ) Respiratory: Bleeding from nose (6.7% to 9.2% )¡A Upper respiratory infection (31% ) Other: Asthenia (7.5% to 17% )¡A Fatigue (37% to 41% )¡A Fever (12% to 13% ) Serious Hematologic: Anemia¡A Grade 3 or 4 (Up to 5% )¡A Febrile neutropenia (0.9% to 2.5%)¡A Leukopenia¡A Grade 3 or 4 (Grade 3¡A 24% to 30%; Grade 4¡A up to 1% )¡A Neutropenia¡A Grade 3 or 4 (Grade 3¡A 55% to 56%; Grade 4¡A 10% to 11% )¡A Thrombocytopenia¡A Grade 3 or 4 (Up to 2% ),30 ¢J¥H¤U¡C,The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE¡A the recommended dose of fulvestrant is 500 mg administered on Days 1¡A 15¡A 29¡A and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¹ï­««×¨x¥\¯à¤£¥þ(Child-Pugh ¤À¯ÅC) ªº¯f¤H¡AIbrance¹ï©ó3/1 Àøµ{¯f¤Hªº«ØÄ³¾¯¶q¬°¨C¤é¤@¦¸75 ²@§J [Micromedex 20210905]Hepatic impairment (severe¡A Child-Pugh C): 75 mg orally once daily for 21 consecutive days followed by 7 days off treatment of a 28-day cycle,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¥Ø«e¨ÃµL©Î¶È¦³¦³­­ªº¥¥°ü¨Ï¥Îpalbociclib ªº¸ê®Æ¡C °Êª«¬ã¨sÅã¥Ü¥»«~¨ã¦³¥Í´Þ¬r©Ê¡C Ibrance¨Ã¤£«ØÄ³©óÃh¥¥´Á¶¡¨Ï¥Î¡A¤]¤£«ØÄ³¥Î©ó¨ã¥Í¨|¯à¤O¦ý¥¼±Ä¨úÁ×¥¥±¹¬Iªº°ü¤k¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ]¥Ø«e©|¥¼¶i¦æ¹L¥ô¦óµû¦ôpalbociclib ¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅT¡B¬O§_¥X²{©ó¨Å¥Ä¤¤¡B©Î¨ä¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅTªº¤HÅé¬ã¨s©Î°Êª«¬ã¨s¡C ¥Ø«e¨Ã¤£½Tª¾palbociclib ¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C ±µ¨üpalbociclib ªvÀøªº¯f¤H¤£¥iÁý­÷¥À¨Å¡C,PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¥é³æ«ØÄ³À³¾ãÁû§]ªA¡A¤Å©CÄZ¡B«r¸H©Î¥´¶}½¦Ån¡C
OSQL2,Nicotine,Smokquit 2mg (24 tablets/box),ZADT,Smoking Cessation Aid,Hypersensitivity to nicotine or any component of the product.,Common Dermatologic: Skin irritation¡A Patch Respiratory: Nasal irritation¡A Nasal spray¡A Oral irritation¡A Airway¡A inhaler Other: Nicotine withdrawal¡A Dizziness¡A headache¡A insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare)¡A Hypertension (rare)¡A Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare),«Ç·Å25¢J¥H¤U,Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule: Weeks 1 to 6: 1 lozenge every 1 to 2 hours¡A use at least 9 lozenges/day. Weeks 7 to 9: 1 lozenge every 2 to 4 hours. Weeks 10 to 12: 1 lozenge every 4 to 8 hours. The recommended maximum dose: 15 lozenges/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,Contraindicated (with any use of tobacco) [¥é³æ] «ØÄ³¥¥°ü¤Î±Â¨Å°ü¤£¥i¨Ï¥Î§t¦³¥§¥j¤B¦¨¤À¡A¦p¤f§t¿õ¡B¶K¤ù©Î¤f­»¿}¨Ó§ÙµÒ¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] «ØÄ³¥¥°ü¤Î±Â¨Å°ü¤£¥i¨Ï¥Î§t¦³¥§¥j¤B¦¨¤À¡A¦p¤f§t¿õ¡B¶K¤ù©Î¤f­»¿}¨Ó§ÙµÒ¡C,SL;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¤f§t¿õ¡A¤£¥i©CÄZ©Î§]ªA¡CªAÃÄ«á±N¤f§t¿õ§t¦b¤fµÄ¨â°¼²¾°Ê¡A«ùÄò20-30¤ÀÄÁª½¨ì§¹¥þ·»¸Ñ¡C
ECRO,Cromolyn,Cromo oph drops 2%¡A 10mL,TOPH,,¾AÀ³¯g:Treatment of vernal keratoconjunctivitis¡A vernal conjunctivitis¡A and vernal keratitis °Æ§@¥Î: Ocular: Conjunctival injection¡A dryness around the eye¡A edema¡A eye irritation¡A immediate hypersensitivity reactions¡A itchy eyes¡A puffy eyes¡A styes¡A rash¡A watery eyes ¸T§Ò:Hypersensitivity to cromolyn or any component of the formulation,,«Ç·Å,Conjunctivitis and keratitis: Ophthalmic: 1-2 drops in each eye 4-6 times/day,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OMIN6,Desmopressin,Minirin Melt 60mcg,HM,Central Diabetes Insipidus¡A Primary Nocturnal Enuresis¡A Renal Concentrating Capacity Test¡A Symptomatic treatment of nocturia in adults associated with nocturnal polyuria ie¡A nocturnal urine production exceeding bladder capacity. Hemophilia A and von Willebrand's Disease,Habitual and psychogenic polydipsia¡A syndrome of inappropriate ADH secretion (SIADH)¡A known hyponatremia¡A known or suspected cardiac decompensation and other conditions that require diuretics¡A moderate and severe renal impairment.,Nausea¡A abdominal pain¡A headache¡A nasal congestion/rhinitis¡A nose bleeds. Nasal spray May cause bronchospasm due to the presence of benzalkonium Cl. Dermatologic: Flushing Gastrointestinal: Nausea¡A Will respond to dosage decrease Neurologic: Fatigue (10% )¡A Headache (22.5% ),25¢J¥H¤UÁ×¥ú,Central diabetes insipidus: Initial dose as 60mcg three times per day¡A followed by 60-120mcg three times per day as maintain dose.(Total daily dose:120mcg-720mcg.) Primary nocturia: 120mcg at bedtime¡A up to 240mcg if needed. Nocturia: 60mcg at bedtime¡A up to 120mcg after one week & subsequently 240mcg weekly dose escalations.To be administered sublingually.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°­á´¹¤f·»¿õ¡C¥i·»¤ô±Y¸Ñ«áºÞÄé¡C
IBRID,Sugammadex,Bridion inj 200mg/2mL,ZADT,Reversal of rocuronium or vecuronium: Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery,Hypersensitivity to sugammadex or any component of the formulation,>10%: Cardiovascular: Hypotension (5% to 13%) Central nervous system: Headache (10%) Gastrointestinal: Nausea (26%)¡A vomiting (11% to 15%) Local: Pain at injection site (48% to 52%) 1% to 10%: Cardiovascular: Hypertension (9%)¡A prolonged QT interval on ECG (6%)¡A bradycardia (5%)¡A tachycardia (2% to 5%) Central nervous system: Anesthesia complication (1% to 9%)¡A chills (7%)¡A incisional pain (4% to 6%)¡A dizziness (3% to 6%)¡A insomnia (5%)¡A hypoesthesia (3%)¡A anxiety (1% to 3%)¡A restlessness (1% to 2%)¡A depression (2%) Dermatologic: Pruritus (3%)¡A erythema (2%) Endocrine & metabolic: Hypocalcemia (2%) Gastrointestinal: Abdominal pain (4% to 6%)¡A flatulence (3%)¡A xerostomia (2%) Hematologic & oncologic: Wound hemorrhage (2%)¡A decreased red blood cells (1% to 2%) Neuromuscular & skeletal: Limb pain (6%)¡A musculoskeletal pain (2%)¡A myalgia (2%)¡A increased creatine phosphokinase (1% to 2%)¡A neuromuscular blockade (<=2%; reoccurrence) Respiratory: Cough (3% to 8%) Miscellaneous: Fever (5% to 9%)¡A procedural complications (8%)¡A hysterectomy (2%) <1%¡A postmarketing¡A and/or case reports: Anaphylactic shock¡A anaphylactoid reaction¡A anaphylaxis¡A atrial fibrillation¡A atrioventricular block¡A bronchospasm¡A dyspnea¡A extrasystoles¡A hypersensitivity reaction¡A laryngospasm¡A pulmonary edema¡A ST segment changes on ECG¡A supraventricular extrasystole¡A supraventricular tachycardia¡A urticaria¡A ventricular fibrillation¡A ventricular tachycardia¡A wheezing,30¢JÁ×¥úÁ×§K§N­á,Routine reversal of rocuronium- or vecuronium-induced blockade: IV: Deep block (at least 1 to 2 post-tetanic counts but prior to appearance of T2): 4 mg/kg as a single dose Moderate block (after appearance of T2): 2 mg/kg as a single dose Readministration of rocuronium or vecuronium: Following sugammadex use for routine reversal¡A waiting times for readministration of rocuronium or vecuronium vary greatly (5 minutes to 24 hours) depending on agent¡A dose¡A and renal function; if immediate neuromuscular blockade is needed¡A a nonsteroidal neuromuscular-blocking agent may be required. Immediate reversal of rocuronium-induced blockade: IV: 16 mg/kg as a single dose administered soon (~3 minutes) after administration of a single dose of rocuronium 1.2 mg/kg. Note: This dose of sugammadex has not been evaluated following administration of vecuronium.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x·l¶Ë©Î¾®¦å¥\¯à¦ñ¦³¨x¥\¯à·l¶Ë±wªÌÀ³¤p¤ßÂÔ·V¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,IV push over 10 seconds,¤£¥i»P¨ä¥LÃÄ«~²V¦Xª`¤J¡A±N¥»ÃÄ¦b10¬í¤ºª`¤J²{¦sÀR¯ßª`®gºÞ½u¤¤,IV: Administer as rapid IV push over 10 seconds; if administered in same IV line as other products¡A flush with saline before and after administration of sugammadex. The pH is between 7 and 8 and osmolality is between 300 and 500 mOsm/kg. ¤wÃÒ©ú­º¦¸¶}±Ò¤Îµ}ÄÀ«á¦b5-25¢J¤Uªº¤Æ¾Ç¤Îª«²zÃ­©w©Ê¥i¹F48¤p®É¡C±q·L¥Íª«Æ[ÂI¨Ó¬Ý¡Aµ}ÄÀ«áªº²£«~À³¥ß§Y¨Ï¥Î¡C¦pªG¥¼¥ß§Y¨Ï¥Îªº¸Ü¡A°£«D¦b¦³±±¨î³q­·ªºµLµßª¬ªp¤U¶i¦æµ}ÄÀ¡A¨Ï¥Î«e¤§Àx¦s®É¶¡»P±ø¥ó¬°¨Ï¥ÎªÌªº³d¥ô¡A¦Ó¥B³q±`¦b5-8¢J¤U¤£À³¶W¹L24¤p®É¡C 2·³¤Î¥H¤W¨àµ£©M«C¤Ö¦~¡A¥i¨Ï¥Î0.9%NaCl±NBridionµ}ÄÀ¦Ü10 mg/mL¡A¥H´£°ªµ¹ÃÄªº¥¿½T©Ê¡C
OREV,Sildenafil,Revatio 20mg,CAVS,Pulmonary arterial hypertension (PAH),Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg¡A nitroglycerin¡A isosorbide dinitrate); concomitant use of riociguat (a guanylate cyclase stimulator).,>10%: Flushing (10% to 19%)¡A Headache (16% to 46%)¡A Dyspepsia (3% to 17%; dose-related)¡A Visual disturbance (2% to 11%; including vision color changes¡A blurred vision¡A and photophobia; dose-related)¡A Epistaxis (9% to 13%) 2% to 10%: Insomnia (7%)¡A dizziness (2% to 4%)¡A paresthesia (3%)¡A Erythema (6%)¡A skin rash (1% to 3%)¡A Diarrhea (3% to 9%)¡A gastritis (?3%)¡A nausea (2% to 3%)¡A Urinary tract infection (3%)¡A Increased liver enzymes (2% to 10%)¡A Myalgia (2% to 7%)¡A back pain (3% to 4%)¡A Nasal congestion (4% to 9%)¡A exacerbation of dyspnea (7%)¡A nasal congestion (4%)¡A rhinitis (4%)¡A sinusitis (3%)¡A Fever (6%),Àx¦s©ó25¢XC,Pulmonary arterial hypertension 20 mg TID; give doses approximately 4 to 6 hours apart. (maximum: 60mg/day),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OLONS,Trifluridine + Tipiracil,Lonsurf 20mg,RACA,Metastatic colorectal cancer in adults,There are no contraindications listed in the manufacturer's labeling.,>10%: Fatigue (52%)¡A Nausea (37% to 48%)¡A decreased appetite (34% to 39%)¡A diarrhea (23% to 32%)¡A vomiting (25% to 28%)¡A abdominal pain (21%)¡A Anemia (63% to 77%; grades 3/4: 18% to 19%)¡A neutropenia (66% to 67%; grades 3/4: 38%;)¡A thrombocytopenia (34% to 42%; grades 3/4: 5% to 6%)¡A febrile neutropenia (grades 3/4: 3%)¡A Infection (23% to 27%)¡A Asthenia (?52%)¡A Fever (19%) 1% to 10%: Pulmonary embolism (2% to 3%)¡A Alopecia (7%)¡A Stomatitis (8%; grades 3/4: <1%)¡A dysgeusia (7%) <1%: postmarketing¡A and/or case reports: Interstitial pulmonary disease,25¢J¥H¤U,35 mg/m2 (based on the trifluridine component) twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle (maximum per dose: trifluridine 80 mg); continue until disease progression or unacceptable toxicity. The manufacturer recommends rounding each dose to the nearest 5 mg increment.,»Ý½Õ¾ã¾¯¶q,Moderate impairment (total bilirubin >1.5 to 3 times ULN and any AST) or severe impairment (total bilirubin >3 times ULN and any AST): Do not initiate therapy.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Micromedex: Fetal risk cannot be ruled out.,Unknown ¨S¦³¸ê®Æ,Micromedex: Infant risk cannot be ruled out.,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
IENT,Vedolizumab,ENTYVIO inj 300mg (infusion),HIMM,Crohn disease or ulcerative colitis,Hypersensitivity reaction¡A severe or serious¡A to vedolizumab or any of its excipients.,Common: Nausea (9%)¡A Arthralgia (12%)¡A Headache (12%)¡A Nasopharyngitis (13%)¡A Upper respiratory infection (7%)¡A Fatigue (6%)¡A Fever (9%) Serious: Aminotransferase abnormal¡A Increased (Up to 2%)¡A Hepatitis¡A Serum bilirubin above reference range¡A Anaphylaxis (0.07%)¡A Hypersensitivity reaction¡A Progressive multifocal leukoencephalopathy¡A Tuberculosis¡A Cancer (0.4%)¡A Infectious disease¡A Infusion reaction (4%)¡A Sepsis (0.03%),2-8¢JÁ×¥ú,IVD¡A ulcerative colitis¡A Crohn's disease 300 mg at week 0¡A 2 and 6¡A followed by every 8 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ­·ÀIºK­n ¨Ì¾Ú²{¦³ªºÃÄª«¦w¥þºÊµø¸ê®Æ¡B¶i¦æ¤¤ªºÃh¥¥µn¿ý¸ê®Æ¡B¤wµoªíªº¥¥°ü­Ó®×³ø§i¤Î¥@¥N¬ã¨s¸ê®Æ¡A¨Ã¥¼µo²{»P¦w¼ì±y¦³Ãöªº­«¤j¥ý¤Ñ©Ê¯Ê³´¡B¬y²£¡A©Î¥ÀÅé©Î­L¨àªº¤£¨}µ²ªG¡CÃh¥¥´Á¶¡ªºµoª¢©Ê¸z¹D¯e¯f¡A¹ï¥À¿Ë©M­L¨à³£¦³­·ÀI(°Ñ¨£Á{§É¦Ò¶q)¡C©|¥¼¶i¦æ¦w¼ì±y¥Î©óÃh¥¥¤k©Êªº¸ÕÅç¡C°Êª«¥Í´Þ¸ÕÅç¤¤¡A¨ß¤l©MµU¤lÀR¯ßª`®g°ª©ó¤HÅé«ØÄ³¾¯¶q20­¿ªºvedolizumab¡A¨Ã¥¼Æ[¹î¨ì­F­L¶Ë®`(°Ñ¨£¸ÕÅç¸ê®Æ)¡C¯S©w±Ú¸sµo¥Í­«¤j¥ý¤Ñ©Ê¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¡A¥Ø«e©|¤£²M·¡¡C©Ò¦³Ãh¥¥³£¦³¥ý¤Ñ¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­I´º­·ÀI¡C¦b¬ü°ê¤@¯ë±Ú¸s¡AÁ{§É¤W½T»{Ãh¥¥«á¡Aµo¥Í­«¤j¥ý¤Ñ©Ê¯Ê³´©M¬y²£ªº¹w¦ô­I´º­·ÀI¡A¤À§O¬°2¦Ü4%¤Î15¦Ü20%¡C Á{§É¦Ò¶q ¦w¼ì±y¤§¥ô¦óÃh¥¥¤£¨}§@¥Î¡A¦bÃh¥¥²Ä¤G©M²Ä¤T¥¥´Á®É¥i¯à¸ûÄY­«¡C³æ®è§ÜÅé·|ÀH¥¥´Á¶i®i¦Ó¥H½u©Ê¤è¦¡³q¹L­L½L¡A¦b²Ä¤T¥¥´Áªº¶Ç°e¶q³Ì¤j¡C ¯e¯f¬ÛÃöªº¥ÀÅé©M­F­L/­L¨à­·ÀI ¤wµoªíªº¸ê®ÆÅã¥Ü¡A¿©±wµoª¢©Ê¸z¹D¯e¯f(IBD)ªº¤k©Ê¡AÃh¥¥µ²ªG¤£¨}ªº­·ÀI»P¯e¯f¬¡°Ê«×¼W¥[¦³Ãö¡CÃh¥¥ªº¤£¨}µ²ªG¥]¬A¦­²£(Ãh¥¥¶g¼Æ¥¼º¡37¶g)¡BÀ¦¨à¥X¥ÍÅé­«°¾§C(§C©ó2500¤½§J)¤Î¥X¥ÍÅé­«¤£¨¬¡C ­L¨à/·s¥Í¨à¤£¨}¤ÏÀ³ Ãh¥¥´Á¶¡¨Ï¥Î¦w¼ì±y¡A¥i¯à·|¼vÅT¦b¤l®c¤º¨ü¼ÉÅSªº·s¥Í¨à¤ÎÀ¦¨à¤§§K¬Ì¤ÏÀ³¡CÀ¦¨à¦b¤l®c¤º¼ÉÅS©ó§C¿@«×¦w¼ì±y¤§Á{§É¼vÅT¡A¥Ø«e©|¤£²M·¡¡C¨ü¼ÉÅSªºÀ¦¨à¬I¥´¬¡¬r©Î´î¬r¬Ì­]¤§¦w¥þ©Ê¡A¥Ø«e¤]©|¤£²M·¡¡C ¸ÕÅç¸ê®Æ °Êª«¸ê®Æ ¹ïÃh¥¥¨ß¤lªº¥Í´Þ¸ÕÅç¤¤¡A¦b§³®W²Ä7¤ÑÀR¯ßª`®g³æ¾¯³Ì°ª100²@§J/¤½¤ç¾¯¶qªºvedolizumab(¬ù¬°¤HÅé«ØÄ³¾¯¶qªº20­¿)¡A¨ÃµLÃÒ¾ÚÅã¥Ü¾É­P¥Í¨|¯à¤O¨ü·l©Î­L¨à¶Ë®`¡C¤@¶µµU¤lªº²£«e¤Î²£«áµo¨|¸ÕÅç¤¤¡AÀR¯ßª`®g³Ì°ª100²@§J/¤½¤ç¾¯¶qvedolizumab(¬ù¬°¤HÅé«ØÄ³¾¯¶qªº20­¿)¡A¨ÃµLÃÒ¾ÚÅã¥Ü¹ï²£«e¤Î²£«áµo¨|²£¥Í¥ô¦ó¤£¨}§@¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ²{¦³ªº¤wµoªí¤åÄmÅã¥Üvedolizumab·|¶i¤J¤HÃþªº¨Å¥Ä¡CVedolizumab§½³¡­G¸z¹D¼ÉÅS¤Î¥i¹w´Áªº¥þ¨­©Ê§C¼ÉÅS¹ï¨ü­÷¨ÅÀ¦¨à¤§¼vÅT¡A¥Ø«e©|¤£²M·¡¡C¦b¤@¶µ¶È±Â¨Å¨Óµû¦ô¦b±µ¨üvedolizumabªvÀø¼ìºÅ©Êµ²¸zª¢©Î§J¶©¤ó¯g±Â¨Å°ü¤k¨Å¥Ävedolizumab¿@«×¸ÕÅç¤¤¡A¦b¤HÃþ¨Å¥Ä¸Ìvedolizumab¿@«×¬ù¬°¥ÀÅé¦å¤¤¿@«×(¨ú¦Û¹L¥hvedolizumab¸ÕÅç¼Æ¾Ú)ªº0.4%¦Ü2.2%¡C±À¦ôÀ¦¨à¥­§¡¨C¤évedolizumabÄá¨ú¶q¬°0.02 mg/kg/day¡A¬Û·í©ó¥ÀÅé¨C¤éÄá¨ú¶qªº21%(¸gÅé­«½Õ¾ã)¡C¦Ò¼{­÷¨Å¹ï©óµo¨|©M°·±dªº®Ä¯q®É¡AÀ³¿Å¶q¥À¿Ë¹ï¦w¼ì±yªºÁ{§É»Ý¨D¡A¤Î¨Ó¦Û¦w¼ì±y©Î¥ÀÅé°òÂ¦¯e¯f¹ï¨ü­÷¨ÅÀ¦¨àªº¼ç¦b¤£¨}¤ÏÀ³¡C,IVD;,4.8mLª`®g¥ÎµLµß¤ô,¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥HÀR¯ß¿éª`30¤ÀÄÁ¤è¦¡µ¹¤©¡A ½Ð¤Å¥HÀR¯ßª`®g©Î±Àª`¤è¦¡µ¹ÃÄ¡C¿éª`§¹¦¨«á¨Ï¥Î30mLªºN/S©ÎL/R¨R¬~¡C¿éª`·»²G°t»s§¹¦¨¨Ãµ}ÄÀ«á¡A½Ð¾¨§Ö¨Ï¥Î¡C µ}ÄÀ»¡©ú: ±N5mL(300 mg)°t»s§¹¦¨ªº·»²G¡A¥[¤J250²@¤ÉªºµLµßN/S©ÎL/R¡A¨Ã»´»´®Ì°Ê¿éª`³U. ½Ð¤Å±N¨ä¥LÃÄ«~¥[¤J·Ç³Æ¦nªº¿éª`·»²G©ÎÀR¯ß¿éª`ºÞ½u²Õ.,À³¨Ï¥ÎµLµß§Þ³N¦b20-25¢J¤U°t»s: 1.¨Ï¥Î21¦Ü25 gauge°wÀY¡A¥H4.8mLª`®g¥ÎµLµß¤ô°t»s¡C 2.°wÀY´¡¤J¨Ã¾É¤Þª`®g¥ÎµLµß¤ôªuÃÄ²~¬Á¼þ¾À¬y¤U¡A¥H§K²£¥Íªwªj¡C 3.»´®Ì°Ê¦Ü¤Ö15¬í¡A¤Å¥Î¤O·n®Ì©Î­ËÂà¡C 4.«Ç·Å¤UÀR¸m³Ì¦h20¤ÀÄÁ¡A¥H«K°t»s¨Ãµ¥©Ò¦³ªwªj®ø¥¢¡A¦p¥¼§¹¥þ·»¸Ñ¡A¥i¦A©ñ¸m10¤ÀÄÁ.¥¼¦b30¤ÀÄÁ¤º·»¸Ñ¡A¤Å¨Ï¥Î¦¹ÃÄ¡C 5.·»²GÀ³¬°²Mº«©Î¥b³z©ú¡AµL¦â¦Ü²L´Ä¶À¦â¡A¤£§tÁû²É.­Y·»²GÃC¦â²§±`©Î§tÁû²É¡A¤Å¨Ï¥Î¡C 6.»´­ËÂàÃÄ²~¤T¦¸¡A¦A©â¨ú°t»s¦nªº·»²G5mL¡AÃÄ²~¤º³Ñ¾lªº·»²G½Ð¥á±ó¡C Àx¦s:°t»s«áÀ³¥ß§Y¨Ï¥Î¡A¦p§NÂÃ¥i«O¦s8¤p®É¡Cµ}ÄÀ©óN/S«á20-25¢J¥i«O¦s12¤p®É¡A2-8¢J§NÂÃ¥i24¤p®É¡Cµ}ÄÀ©óL/R«áÀ³¥ß§Y¨Ï¥Î¡A2-8¢J§NÂÃ¥i6¤p®É¡C
IFOR25,Paclitaxel,FORMOXOL inj 150mg/25mL,RACA,,¾AÀ³¯g: After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma. °Æ§@¥Î: Bone marrow suppression¡A peripheral neuropathy¡A GI disturbances¡A alopecia¡A hypersensitivity. Dermatologic: Alopecia (55% to 96% ) Gastrointestinal: Diarrhea (16% to 90% )¡A Inflammatory disease of mucous membrane (5% to 45% )¡A Nausea and vomiting¡A Any grade (9% to 88% ) Hematologic: Anemia¡A Any grade (47% to 96% )¡A Leukopenia (90% )¡A Neutropenia¡A Any grade (78% to 100% )¡A Thrombocytopenia¡A Any grade (4% to 68% ) Immunologic: Immune hypersensitivity reaction¡A Any grade (2% to 45% ) Musculoskeletal: Arthralgia¡A Myalgia Neurologic: Peripheral neuropathy¡A Any grade (42% to 79% ) ¸T§Ò: Hypersensitivity to paclitaxel¡A polyoxyl 35/polyoxyethylated castor oil (Cremophor EL)¡A or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts <1¡A500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts <1¡A000/mm3.,,«Ç·Å,135-175 mg/m2 IV over 3 hr every 3 weeks. Patients must be premedicated dexamethasone¡A diphenhydramine & cimetidine prior to administration.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªÌµo¥Í¤£¨}¤ÏÀ³¾÷²v·|¼W¥[¡A½Ð°Ñ¦Ò¥é³æ¹ï·Óªí½Õ¾ã¡C,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. µ}ÄÀ·»²G»P¾¹¨ãÀ³¨Ï¥Î¬Á¼þ¡B»E¤þ²m(polypropylene)¡B»E²m(polyolefin)§÷½è¡A¤£¥i¨Ï¥Î§tDEHPªºPVC¶ì½¦§÷½è¡C 3. °t»s¦nªº¿éª`·»²G¿@«×¦b 0.3 - 1.2 mg/mL¡A«Ç·Å¤U¦w©w©Êºû«ù 27¤p®É¡C 4. ª`®g«eÀ³¥ýµ¹¤©¹w¨¾¹L±ÓªºÃÄª«¡C¿éª`¶}©lªº²Ä¤@­Ó¤p®ÉÀ³ºÊ´úVital Sign¡C 5. ´¿¨Ï¥Î Paclitaxelµo¥Í¤ßÅ¦¶Ç¾É²§±`ªº¯f¤H¡A¤§«á¨Ï¥ÎPaclitaxel´Á¶¡À³¶i¦æ³sÄò¤ß¹q¹ÏºÊ´ú¡C 6. ºÊ´úCBC¡C 7.§t¦³ãÉ³Âªo¦¨¤À¡A®e©ö³y¦¨¯f±w¹L±Ó¤ÏÀ³¡A¬I¥´®ÉÀ³¥Ñ§C³t²v¶}©l½Õ¾ã¡A¨Ãª`·N¯f¤H¤ÏÀ³¡C
OSYN1,Piracetam,Syntam F.C. 1200mg(ªY©Z),CNEU,Cognitive disorders. Cortical myoclonus¡A adjunctive.,Patients who are allergic to Piracetam¡A or allergic to any of the compositions in Syntam¡A or allergic to pyrrolidone derivatives. Patients with intracerebral hemorrhage or End Stage Renal Disease.,Hyperkinesis¡A Weight gain¡A Neuroticism¡A Lethargy¡A Depression¡A Powerless¡A Dizziness¡A Abdominal pain¡A upper abdominal pain¡A diarrhea¡A nausea¡A vomiting¡A acute allergic reaction¡A peace of mind¡A imbalance¡A worsening epilepsy¡A headache¡A insomnia¡A drowsiness¡A emotional agitation¡A anxiety¡A disorders¡A hallucinations¡A Angioedema¡A dermatitis¡A itching¡A urticaria.,25¢J¥H¤U°®Àê³B,Cognitive disorders: 1.2 to 4.8 g daily in 2 to 4 divided doses Cortical myoclonus¡A adjunctive: Initial: 7.2 g daily administered in 2 to 3 divided doses; may increase total daily dose by 4.8 g every 3 to 4 days if needed (maximum daily dose: 24 g),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅçÅã¥Ü Piracetam ¨Ã¤£·|¹ïÃh¥¥ªÌ¡B¥Íªø¤¤ªº­F­L¡A¤Î¥X¥Í«áªº­L¨à³y¦¨ª½±µ©Î¶¡±µªº¶Ë®`¡C ¦ý¨´¤µ¨ÃµL¥¥°ü¨Ï¥ÎPiracetamªºÁ{§É¸ê®Æ¡CPiracetam ·|³q¹L­L½L¡C ·s¥Í¨àÅé¤ºªºÃÄ«~¿@«×¬ù¬°¥ÀÅéªº70-90%¦]¦¹°£«D¥²­n¡AÃh¥¥´Á¶¡¤£À³¨Ï¥ÎPiracetam¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Piracetam ·|º¯¤J¨Å¥Ä¡A¦]¦¹±Â¨Å´Á¶¡À³Á×§K¨Ï¥Î¥»ÃÄ¡A©Î¬O¦b¨Ï¥ÎPiracetam ªvÀø´Á¶¡À³°±¤î±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
IXOL,Omalizumab,Xolair inj 150mg/1.2mL,ERSP,--Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. --Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.,Hypersensitivity reaction to omalizumab or any component of the formulation,>10%: Central nervous system: Headache (6% to 12%) 1% to 10%: Cardiovascular: Peripheral edema (>2%) Central nervous system: Anxiety (>2%)¡A migraine (>2%) Dermatologic: Alopecia (>2%) Gastrointestinal: Toothache (>2%) Genitourinary: Urinary tract infection (>2%) Infection: Fungal infection (>2%) Local: Injection site reaction (3%) Neuromuscular & skeletal: Arthralgia (3%)¡A limb pain (>2%)¡A musculoskeletal pain (>2%)¡A myalgia (>2%) Respiratory: Nasopharyngitis (9%)¡A sinusitis (5%)¡A upper respiratory tract infection (3%)¡A asthma (>2%)¡A oropharyngeal pain (>2%)¡A sinus headache (>2%)¡A cough (2%)¡A viral upper respiratory tract infection (<2%) Miscellaneous: Fever (>2%) All indications: <1% (Limited to important or life-threatening): Alopecia¡A anaphylaxis¡A antibody development¡A arthritis¡A chest tightness¡A Churg-Strauss syndrome¡A lymphadenopathy¡A malignant neoplasm¡A pulmonary hypertension¡A syncope¡A thrombocytopenia¡A transient ischemic attacks,2-8¢JÁ×¥úÁ×§K§N­á,Allergic asthma: The appropriate dose and frequency of Xolair is determined by baseline IgE (IU/ml)¡A measured before the start of treatment¡A and body weight (kg). Prior to administration of the initial dose¡A patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements¡A 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration. Chronic spontaneous urticaria(CSU): Usual dose: 150 or 300 mg every 4 weeks. Dosing for this indication is not dependent on serum IgE (free or total) level or body weight.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,SC;,¨Ï¥Î©Òªþµ}ÄÀ·»²G,,,,1.¥»ÃÄ¶È¨Ñ³æ¦¸¨Ï¥Îªº¤p²~¡A°t»s«áÃÄ«~©ó2¢J¦Ü8¢J¥i©ñ¸m8 ¤p®É¡A©ó30¢J¤U¬°4 ¤p®É¡C 2.¥H°t³Æ¦³¤j¤º®|18 ¸¹°wÀY¡A¦Û¦wÞÀ¤¤©â1.4 ²@¤Éª`®g¥Î¤ô¡A¨Ãª`¤Jomalizumab ¤p²~¤¤¡C 3. ±N¤p²~«O«ùª½¥ß¡A¤£°±¦a±ÛÂàª½¥ß¤p²~¡]¤£¥i¤W¤U·n°Ê¡^¡A­á´¹°®¯»§¹¥þ·»¸Ñ¥i¯àªá¶O¶W¹L20 ¤ÀÄÁ¡C°t»s«áÃÄ«~¬°¼á²M©Î¨Ç³\¤£³z©ú·P¡C­Y¦³²§ª«§Y¤£¥i¨Ï¥Î¡C 4. ¥H 25 ¸¹°wÀY¶i¦æ¥Ö¤Uª`®g¡C±Æ°£®ðÅé¡B¤j®ðªw¤Î¦h¾lªº·»²G¡A¦¹ª`®g¤p²~§t1.2 ²@¤É¡]150 ²@§J¡^ªº³ß·ç¼Ö¡C¦]·»²G¸ûÖß¸Y¡Aª`®g»Ý5-10 ¬í¡C 5. ©ó¤âÁu©Î¤j»Lªº¤T¨¤¦Ù°Ï°ì¶i¦æ¥Ö¤Uª`®g¡AÁ×¶}ëC³Â¯l¯f¨_³B¡C
OACT40,Acetylcysteine,Actein 100mg/2.5gm,ERSP,Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis¡A emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms.,Phenylketonuria.,Common: Pruritus (1-3%)¡A Rash (4-5%)¡A Urticaria¡A Diarrhea¡A Nausea (2-7%)¡A Vomiting (9-12%) Serious: Decreased cardiac function¡A Electrocardiogram abnormal¡A Hypervolemia¡A Hypersensitivity reaction (Adult¡A 8-18%; pediatric¡A 10%)¡A Non-allergic anaphylaxis (0.1-0.2%)¡A Status epilepticus¡A Bronchospasm¡A Respiratory distress,25¢J¥H¤U°®Àê³B©Ò,Adult and 12 years older Children: 200 mg TID. 6-12 years old Children:100 mg TID. 3-6 years old Children: 50mg TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]¥¼¦³«ØÄ³,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼¦³«ØÄ³,AC;AC15;P1;P2;PC;PO;WM;,,,,,
ORIBA,Ribavirin,Ribarin 200mg (¼¯µÎ¨x²M),QANB,In combination with interferon £\ for the treatment of chronic hepatitis C in adult patients who are £\-interferon-naive or who have relapsed following £\-interferon therapy.,History of severe pre-existing cardiac disease; haemoglobinopathies; severe¡A debilitating medical conditions; severe hepatic dysfunction or decompensated liver cirrhosis; autoimmune hepatitis or a history of autoimmune disease; pre-existing thyroid disease. Pregnancy & lactation.,Haemolysis¡A anaemia¡A neutropenia¡A dry mouth¡A hyperhidrosis¡A asthenia¡A chest pain¡A fatigue¡A fever¡A headache¡A flu-like symptoms¡A malaise¡A rigors¡A weight loss¡A dizziness¡A paresthesia¡A GI disturbances¡A arthralgia¡A myalgia¡A CNS effects¡A viral infection¡A cough¡A dyspnoea¡A pharyngitis¡A rhinitis¡A alopecia¡A pruritus¡A rash¡A dry skin¡A parageusia¡A blurred vision. Dermatologic: Pruritus¡A Rash Gastrointestinal: Indigestion¡A Loss of appetite¡A Nausea Hematologic: Neutropenia (8% to 40% ) Neurologic: Headache Other: Fatigue,25¢J¥H¤U,Adult >= 18 years 1000-1200 mg daily in 2 divided doses¡A in combination with interferon £\ soln for inj administered SC at a dose of 3MIU 3 times/wk. The recommended dose of ribavirin is based on body weight (consistent with food): 1000 mg per day for patients weighing < 75 kg and 1200 mg for weight >= 75 kg¡A and should be divided into twice daily doses.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ISUP,Ondansetron,Supren inj 8mg/4mL,CNEU,Prevention or treatment of nausea and vomiting caused by surgery¡A chemotherapy or radiation therapy.,Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine,Common Gastrointestinal: Constipation (11% )¡A Diarrhea (adults¡A 16%; pediatrics¡A 2%)¡A Xerostomia (5% ) Hepatic: Increased liver enzymes (17% ) Neurologic: Headache (17% ) Other: Fever (2% to 8% ) Serious Cardiovascular: Atrial fibrillation¡A Electrocardiogram abnormal¡A Prolonged QT interval¡A Torsades de pointes Neurologic: Oculogyric crisis Other: Serotonin syndrome,,,,,,,,,,,IM;IVD;IVPUSH;,,,,,
ITRAM,Tramadol,Tramtor inj 100mg/2mL,CNEU,Relief of moderate to moderately-severe pain,Hypersensitivity to tramadol¡A opioids¡A or any component of the formulation,Common: Flushing (7.7-15.8%)¡A Pruritus (3-11.9%)¡A Constipation (10-46%)¡A Nausea (13-40%)¡A Vomiting (3-17%)¡A Xerostomia (1-10%)¡A Dizziness (7-33%)¡A Headache (3-32%)¡A Insomnia (1-10.9%)¡A Somnolence (4-25%) Serious: Myocardial infarction (0.5-1%)¡A Hypoglycemia¡A Pancreatitis (0.5-1%)¡A Allergic reaction¡A Anaphylaxis¡A Seizure (<1%)¡A Difficulty breathing¡A Dyspnea (<5%)¡A Respiratory depression¡A Serotonin syndrome (<1%),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Adults and teenagers over 12 years old: 50-100 mg(1-2 amp) every 4-6 hours.IM/IV/SC¡A maximum dose: 400 mg/day. If after 30-60 minutes of administration of a single dose of Tramadol hydrochloride 50 mg¡A pain relief cannot be achieved¡A a second single dose of 50 mg can be given. The dosage is higher than normal use¡A and the demand usually does not exceed 24 hours. Children¡A >1 year old: 1-2 mg/kg¡A maximum dose:8mg/kg/day¡A and don't exced 400mg/day. Elders¡A >75 years old: Extend the dosing interval,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à»ÙÃª¦³Cirrhosisªº¯f±w«ØÄ³¾¯¶q 50 mg every 12 hours ÄY­«¨x¥\¯à»ÙÃª¯f±w¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;IVD;IVP;IVPUSH;SC;,,¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö2 ~ 3¤ÀÄÁ,infusion concentration 0.5-4 mg/mL.,
EDEX2,Dexamethasone,Dexaltin(¤f¤º»I) 0.1%¡A 2gm,TENT,,¾AÀ³¯g: Intractable stomatitis or glossitis associated with erosion or ulceration. °Æ§@¥Î: Fungal or bacterial infection of the oral cavity; hypersensitivity; hypofunction of pituitary-adrenocortical system (prolonged use). Cardiovascular: Hypertension Dermatologic: Atrophic condition of skin¡A Finding of skin healing¡A Impaired Endocrine metabolic: Cushing's syndrome¡A Decreased body growth Gastrointestinal: Disorder of gastrointestinal tract Immunologic: At risk for infection Musculoskeletal: Osteoporosis Ophthalmic: Cataract (4% )¡A Raised intraocular pressure (25% ) Psychiatric: Depression¡A Euphoria Respiratory: Pulmonary tuberculosis ¸T§Ò: Patients with tuberculotic¡A viral or other purulent infections of the oral cavity.,,«Ç·Å,Apply adequate amount to the affected area once to several times daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ODIBO,Acarbose,Dibose 100mg,META,Diabetes mellitus¡A type 2: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (noninsulin dependent¡A NIDDM).,Hypersensitivity to acarbose or any component of the formulation; diabetic ketoacidosis; cirrhosis; inflammatory bowel disease¡A colonic ulceration¡A partial intestinal obstruction¡A patients predisposed to intestinal obstruction; chronic intestinal diseases associated with marked disorders of digestion or absorption; conditions that may deteriorate as a result of increased gas formation in the intestine.,Common: Abdominal pain (19%)¡A Diarrhea (31%)¡A Flatulence (74%) Others: Erythema multiforme¡A Hypersensitivity reaction¡A Bowel obstruction¡A Microscopic colitis¡A Pneumatosis cystoides intestinalis¡A Anemia¡A Thrombocytopenia¡A Fulminant hepatitis¡A Hepatotoxicity¡A Increased liver enzymes,25¢J¥H¤UÁ×§K¼éÀã¤Î¶§¥ú·Ó®g,50-100 mg TID¡A maximum 200 mg TID.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]Ãh¥¥¤£¥i¨Ï¥Î,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PO;WM;,,,,,
OVERZ,Abemaciclib,Verzenio 150mg,RACA,Breast cancer¡A Advanced or metastatic¡A hormone receptor-positive disease¡A HER2-negative¡A in combination with an aromatase inhibitor for initial endocrine therapy in postmenopausal women and men. Breast cancer¡A Advanced or metastatic¡A hormone receptor-positive disease¡A HER2-negative¡A in combination with fulvestrant for progression following endocrine therapy. Breast cancer¡A Advanced or metastatic¡A hormone receptor-positive disease¡A HER2-negative¡A monotherapy for progression following endocrine therapy and prior chemotherapy in the metastatic setting. Breast cancer¡A Early¡A hormone receptor-positive¡A HER2-negative¡A node-positive¡A high-risk¡A in combination with adjuvant endocrine therapy.,Allergic to the active ingredients or excipients in Verzenio.,Common: Abdominal pain (29-39%)¡A Decrease in appetite (12-45%)¡A Diarrhea¡A All Grades (81-90%)¡A Nausea (39-64%)¡A Vomiting (26-35%)¡A Anemia¡A All Grades (25-29%)¡A Leukopenia¡A All Grades (17-28%)¡A Neutropenia¡A All Grades (37-46%)¡A Infectious disease (31-51%)¡A Headache (20%)¡A Fatigue (40-65%) Serious: Diarrhea¡A Grade 3 (8-20%)¡A Febrile neutropenia (Less than 1%)¡A Neutropenia¡A Grade 3 or higher (19-32%)¡A Neutropenic sepsis¡A Venous thromboembolism (2-5%)¡A ALT/SGPT level raised (Grade 3 or higher¡A 2-6%)¡A Aspartate aminotransferase serum level above reference range (Grade 3 or higher¡A 2-3%)¡A Cerebral infarction¡A Interstitial lung disease¡A Pneumonitis,Àx¦s©ó30¢XC¥H¤U,In combination with fulvestrant¡A tamoxifen¡A or an aromatase inhibitor¡A the recommended dose is 150 mg taken orally twice daily. As monotherapy¡A the recommended dose is 200 mg taken orally twice daily. Dose Modifications for Adverse Reactions: In combination with fulvestrant¡A tamoxifen¡A or an aromatase inhibitor: Recommended starting dose: 150 mg twice daily -> First dose reduction: 100 mg twice daily -> Second dose reduction: 50 mg twice daily -> Third dose reduction: not applicable. As monotherapy: Recommended starting dose: 200 mg twice daily -> First dose reduction: 150 mg twice daily -> Second dose reduction: 100 mg twice daily -> Third dose reduction: 50 mg twice daily.,»Ý½Õ¾ã¾¯¶q,­Y¯f¤H¬°­««×¨x¥\¯à¤£¥þ(Child Pugh-C)¡AÀ³±NVERZENIO¥ÎÃÄÀW²v´î¤Ö¬°¨C¤é¤@¦¸¡C CTCAE Grade for ALT and AST: 1. Grade 1 (>ULN-3.0 x ULN) Grade 2 (>3.0-5.0 x ULN)¡A WITHOUT increase in total bilirubin above 2 x ULN: No dose modification is required. 2. Persistent or Recurrent Grade 2¡A or Grade 3 (>5.020.0 x ULN)¡A WITHOUT increase in total bilirubin above 2 x ULN: Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose. 3. Elevation in AST and/or ALT >3 x ULN WITH total bilirubin >2 x ULN¡A in the absence of cholestasis: Discontinue. 4. Grade 4 (>20.0 x ULN): Discontinue.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]®Ú¾Ú°Êª«¸ÕÅçªºµo²{¤ÎÃÄª«§@¥Î¾÷Âà¡A­Yµ¹¤©Ãh¥¥°ü¤kVERZENIO¡A¥i¯à·|³y¦¨­L¨à¶Ë®`¡C¥Ø«e¨ÃµL¤HÃþªºÃÄª«­·ÀI¸ê®Æ¡CÀ³§iª¾Ãh¥¥°ü¤k¦¹ÃÄª«¥i¯à¹ï­L¨à³y¦¨¤§¼ç¦b¦M®`¡C¦b°Êª«¥Í´Þ¸ÕÅç¤¤¡A¦b¾¹©x§Î¦¨´Á¶¡§ë¤©abemaciclib¡Aabemaciclibªº¥ÀÅéÃnÅS¶q»P³Ì¤j«ØÄ³¤HÅé¾¯¶q¤UªºAUC¤§¤HÃþÁ{§ÉÃnÅS¶q¬Ûªñ®É¡A¨ã¦³­P·î­L©Ê¤]·|¾É­P­L¨àÅé­«´î»´¡CÀ³§iª¾Ãh¥¥°ü¤k¦¹ÃÄª«¥i¯à¹ï­L¨à³y¦¨¤§¼ç¦b¦M®`¡C ¦³Ãö¯S©w±Ú¸sµo¥Í­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº­I´º­·ÀI©|¤£²M·¡¡CµM¦Ó¦b¬ü°ê¤@¯ë±Ú¸sªºÁ{§É½T»{Ãh¥¥¤¤¡Aµo¥Í­«¤j¥ý¤Ñ¯Ê³´ªº­I´º­·ÀI¬°2¦Ü4%¡A¬y²£ªº­I´º­·ÀI¬°15¦Ü20%¡C ¦b¤@¶µ­F­L¡Ð­L¨àµo¨|¸ÕÅç¤¤¡A©ó¾¹©x§Î¦¨´Á¶¡µ¹¤©Ãh¥¥¤j¹«³Ì°ª¹F15 mg/kg/dayªºabemaciclib¤fªA¾¯¶q¡C¾¯¶q?4 mg/kg/day·|¾É­P­L¨àÅé­«­°§C¡A¤Î¤ß¦åºÞ©M°©Àf·î§Î»PÅÜ²§¨Æ¥óªºµo¥Í²v´£°ª¡C³o¨Çµo²{¥]¬A¯Ê¥FµL¦W°Ê¯ß©M¥D°Ê¯ß¤}¡BÂê°©¤U°Ê¯ß¿ù¦ì¡B¯Ý°©¥¼°©¤Æ¡B¯Ý´Õ´ÕÅéªº¤G¤À°©¤Æ¡A¤ÎÂú¦Ø©Îµ²¸`ª¬¦Ø°©¡C¨Ï¥Î4 mg/kg/dayªº¤j¹«¨ä¥ÀÅé¥þ¨­ÃnÅS¶q¤j¬ù»P«ØÄ³¾¯¶qªº¤HÅéÃnÅS¶q(AUC)¬Û·í¡C §iª¾¨ã¦³¥Í¨|¯à¤Oªº¤k©Ê¡A¦bVERZENIOªvÀø´Á¶¡¤Î±µ¨ü³Ì«á¤@¾¯ªvÀø«á3¶gÀ³±Ä¥Î¦³®ÄªºÁ×¥¥±¹¬I¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨S¦³abemaciclib¬O§_¶i¤J¤HÅé¨Å¥Ä¡A¹ï±Â¨ÅÀ¦¨à©Î¹ï¨Å¥Ä¤Àªc¼vÅTªº¸ê®Æ¡C¥Ñ©óVERZENIO¥i¯à¨Ï±Â¨ÅÀ¦¨àµo¥ÍÄY­«¤£¨}¤ÏÀ³¡AÀ³§iª¾­÷¨Å°ü¤k©óVERZENIOªvÀø´Á¶¡¤Î±µ¨ü³Ì«á¤@¾¯ªvÀø«á3¶g¤º¤£¥i­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¯f¤HÀ³§]ªA¾ãÁû¿õ¾¯¡A¤£¥i±N¿õ¾¯©CÄZ¡BÀ£¸H©Î¤Á¥b«á§]ªA¡C¦pªG¿õ¾¯¯}µõ¡Bµõ¶}©Î¤£§¹¾ã¡A½Ð¯f¤H¤£­nªA¥Î¡C
ICEFS,Ceftriaxone,Ceft-S inj 1gm,QANB,Infections caused by staphylococcus¡A streptococcus¡A pneumococcus¡A meningococcus¡A and other susceptible bacteria.,Concurrent administration of calcium-containing IV solutions¡A including continuous calcium-containing infusions such as parenteral nutrition¡A in neonates aged 28 days or less due to risk of fatal salt precipitation in lungs and kidneys. Hyperbilirubinemic neonates¡A due to increased risk of bilirubin encephalopathy (kernicterus)¡A especially in premature neonates. Hypersensitivity to cephalosporins. Pregnant women¡A especially during the first three months¡A should avoid using unless absolutely necessary.,Common: Injection site induration¡A Warmth¡A tightness¡A or induration (5-17%)¡A Diarrhea (2.7-5.6%)¡A Eosinophil count above reference range (6%)¡A Thrombocytosis (5.1%) Serious: Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile colitis¡A Hemolytic anemia (<1%)¡A Neutropenia¡A Hypersensitivity reaction (2.7-3.3%)¡A Kernicterus of newborn¡A Renal failure¡A Injury of lung,25¢J¥H¤U¡C½Õ°t«á«Ç·Å¥i«O¦s6¤p®É¡C,For adults: 1-2g once daily. Severe infections: maximum 4g/day¡A divided into two doses. For neonates (up to 2 weeks old): 20-50mg/kg/day¡A maximum 50mg/kg. For infants and children (3 weeks-12 years old): 20-80mg/kg/day¡A administered once daily. (Sanford Guide) Adult - Usual: 1-2g IV q24h. Purulent meningitis: 2g IV q12h. Gonococcal urethritis: single dose of 500mg IM (if <150kg)¡A 1g IM (if >=150kg). Meningococcal PEP (age >=15): single dose of 250 mg IM Pediatric - Age >28 Days: 50-100mg/kg q24h; Meningitis 50mg/kg q12h. Meningococcal PEP (age <15): 125mg IM x 1 dose,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Compatible,[¥é³æ] ÁöµM¹êÅç±oª¾¥»«~¤£·|²£¥Í¬ðÅÜ©Î·î«¬§@¥Î¡A¦ý¬°¤F¦w¥þ°_¨£¡AÃh¥¥°ü¤k(¤×¨ä«e3­Ó¤ë) °£«D¯f±¡µ´¹ï»Ý­n¡A§_«h½Ð¤Å§ë¤©¥»ÃÄ¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVPUSH;,IV: 1 g/vial in 10 mL sterile water for injection¡A 0.9% sodium chloride¡A 5% or 10% dextrose¡A 0.45% sodium chloride 2% dextrose; IM: 1 g/vial in 3.5 mL 1% lidocaine IM­Y¥H3.5mL Water for injectionµ}ÄÀ«áµ¹ÃÄ¡A¶·IM Lidocaine§½³Â§¹¦¨«á¦Aµ¹¤©Ceftriaxone.,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD2.5HS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,½wºC±Àª`¦Ü¤Ö2¦Ü4¤ÀÄÁ,Infuse over 5-15 minutes; 2 g in 40 mL,1. ¥»ÃÄ«~¤Å»P§t¶t©Î¨ä¥L§Ü¥Í¯À·»²G²V¦X¡C½Õ°t«á«Ç·Å¥i«O¦s6¤p®É¡C 2. ª`®g«e¸ß°Ý¯f±w¬O§_¦³£]-ñQÓiÃþ§Ü¥Í¯À¹L±Ó¥v¡C 3. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡A§Ü¥Í¯À¤Þ°_ªº¸¡Âm¡C 4. ÀR¯ßºwª`µ¹ÃÄ¡Aµ¹ÃÄ®É¶¡30-60¤ÀÄÁ(¿@«×: 10-40 mg/mL or lower) [Micromedex] 5. ¦Ù¦×ª`®g®É¡A±NCeft-S 1g°®¯»ª`®g¾¯·»©ó3.5 mL 1%ÆQ»Ä§Q¦h¥d¦](Lidocaine hydrochloride)·»²G«áª`¤J²`³¡Áv¦Ù¡A¨CÃäª`®g¾¯¶q¤£¥i¶W¹L1g¡A¦Ù¦×ª`®g¨C¤é³Ì¤j¾¯¶q¤£±o¶W¹L2 g¡CLidocaine·»²G¤£À³¸ÓÀR¯ßµ¹ÃÄ¡C
OEPR,Escitalopram,Epram 10mg,CNEU,Treatment of depression and prevention of recurrence¡A treatment of panic disorder¡A social anxiety disorder¡A general anxiety disorder and obsessive-compulsive disorder.,Concomitant treatment with non-selective¡A irreversible MAOIs.,Appetite decreased¡A libido decreased¡A anorgasmia (female)¡A insomnia¡A somnolence¡A dizziness¡A sinusitis¡A yawning¡A nausea¡A diarrhoea¡A constipation¡A sweating increased¡A ejaculation disorder¡A impotence¡A fatigue¡A pyrexia. Rarely¡A hyponatraemia¡A seizures¡A ecchymoses. Cardiovascular: Hypertension (1% or greater )¡A Palpitations (1% or greater ) Dermatologic: Diaphoresis (4% to 5% )¡A Rash (1% or greater ) Endocrine metabolic: Weight increased (1% or greater ) Gastrointestinal: Constipation (3% to 6% )¡A Diarrhea (6% to 14% )¡A Gastroenteritis (1% or greater )¡A Heartburn (1% or greater )¡A Indigestion (2% to 6% )¡A Nausea (15% to 18% )¡A Xerostomia (4% to 9% ) Musculoskeletal: Arthralgia (1% or greater )¡A Myalgia (1% or greater ) Neurologic: Dizziness (4% to 7% )¡A Headache (24% )¡A Insomnia (7% to 14% )¡A Lightheadedness (1% or greater )¡A Somnolence (4% to 9% ) Reproductive: Disorder of ejaculation (9% to 14%)¡A Impotence (3% )¡A Orgasm incapacity (females¡A 2% to 6% )¡A Reduced libido (males¡A 6%; females¡A 3%) Other: Fatigue (2% to 6% ),Á×¥ú¨Ã©ó25¢J¥H¤UÀx¦s,Adults: 10 mg once a day; may be increased to maximum dose 20 mg once a day. Elderly¡A >65 years old: 5 mg once a day; maximum dose: 10mg/day Children¡A <18 years old: Contraindicated. There have been reports of suicidal behaviors or thoughts in children after taking medicine.,»Ý½Õ¾ã¾¯¶q,max: 10mg/day.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ] ¥¥°ü¼ÉÅS©óEscitalopram¶È¦³¦³­­Á{§É¸ê®Æ¡C°Êª«¸ÕÅçÅã¥Ü¥X¥Í´Þ¬r©Ê¡AEscitalopram¤£À³¨Ï¥Î¦b¥¥°ü¡A°£«D¤w¸g¹L­·ÀI¯q³B¤§ÂÔ·Vµû¦ô«á¤´µMÄ±±o¥²¶·§ë¤©¡C ¦pªGÃh¥¥°ü¤k¦bÃh¥¥«á´Á¡A¯S§O¬O¦b²Ä¤T´Á¡A¤´¦b¨Ï¥Î escitalopram¡A«KÀ³·íÆ[¹î·s¥Í¨àªºª¬ªp¡C­Y¨Ï¥Îescitalopramª½¨ì¤À®Y¤£¤[«e¡A¦b·s¥Í¨à¥i¯à¦³§ÙÂ_¤ÏÀ³¡C¥À¿Ë¦bÃh¥¥«á´Á¨Ï¥ÎSSRI/SNRI®É¡A·s¥Í¨à¥i¯à·|¥X²{¥H¤Uªº¯gª¬¡G©I§lµ~­¢¡BµoÖæ¡B©I§l¤¤¤î¡BµjÅË¡BÅé·Å¥¢½Õ¡B Áý­¹¤£©ö¡B¹Ã¦R¡B¦å¿}¹L§C¡B¦åÀ£¹L°ª¡B¦åÀ£¹L§C¡B¤Ï®g¹L±j¡BÅ¸§Ý¡B±ª°Ê¡B¤£¦w¡B©üºÎ¡B­ú¾x¤£°±¡B¶ÝºÎ©MÃø¥H¤JºÎ¡C³o¨Ç¯gª¬¥i¯à¬O¦]¬°§ÙÂ_¤ÏÀ³©Î¬O¹L¦hªº¦å²M¯À§@¥Î¡C¦b¤j¦h¼Æªº®×¨Ò¤¤¡A¨Öµo¯g¬O¦b¥Í²£«á¥ß§Y¥X²{©Î«Ü§Ö¦a¡]¡Õ24¤p®É¡^¥X²{¡C¬y¦æ¯f¾Çªº¸ê®ÆÅã¥Ü¥X¦bÃh¥¥®É´Á¨Ï¥ÎSSRI¡A¤×¨ä¬O¦b«á´Á¡A¥i¯à·|¼W¥[·s¥Í¨à«ùÄò©ÊªÍ°Ê¯ß°ª¦åÀ£¯g(Persistent pulmonary hypertension in the newborn¡A PPHN)ªº­·ÀI¡A©ÒÆ[¹î¨ìªº­·ÀI¬ù¨C1000¦ì¥¥°ü¦³5­Ó®×¨Ò¡C¦Ó¤@¯ë±Ú¸s¨C1000¦ì¥¥°ü¥X²{1¨ì2­Ó®×¨Ò¡CÆ[¹î©Ê¼Æ¾ÚÅã¥Ü¡A¦b¥X¥Í«eªº¤@­Ó¤ë¤º¼ÉÅS©óSSRI©ÎSNRI«á¡A²£«á¥X¦åªº­·ÀI¼W¥[¡]¤p©ó2­¿¡^¡C Æ[¹î©Ê¬ã¨s¼Æ¾Ú«ü¥X©ó¥Í²£«e¤@­Ó¤ë¼ÉÅS©ó SSRI ¤Î SNRI ÃþÃÄ«~·|¼W¥[²£«á¥X¦å­·ÀI(¤p©ó 2 ­¿)¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Escitalopram³Q¹w´Á·|±Æªn¦Ü¨Å¥Ä¤¤¡A¦]¦¹©óªvÀø´Á¶¡¤£«ØÄ³­÷¨Å¡C,AC;PC;PO;WM;,,,,,
ETON,Etofenamate,Tonin gel 10%¡A 40gm,CNEU,Muscular rheumatism¡A periarthritis of the shoulder¡A lower back pain¡A sciatica¡A tenosynovitis¡A bursitis.,Hypersensitivity to Tonin gel or any component of the formulation.,Skin itching¡A irritation¡A reddness¡A allergic dermatitis¡A urticaria.,25¢J¥H¤U,Apply a suitable amount of the gel to the affected area 2-3 times daily. Repeat the application 2-3 times by applying a suitable amount of gel until it dries. Complete one application when the gel is naturally dry and cool.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;TOPI;,,,,,
RIBISSM,Spesolimab/Placebo,¸ÕBI-655130-1368-0016 (150mg Spesolimab/Placebo),HIMM,,,,,,,,,,,,,,,,,,,
IPROD125,Hydroxyprogesterone caproate,Progeston Depot inj 125mg/1mL(´¶Ä_­L),HM,Amenorrhoea¡A Abnormal uterine bleeding¡A Recurrent miscarriage¡A Threatened abortion,Severe hepatic impairment;History of Pruritic Urticarial Papules and Plaques of Pregnancy,Common: Injection site disorder (4.5%)¡A Injection site pain (34.8%)¡A Injection site pruritus (5.8%)¡A Pruritus (7.7%)¡A Swelling at injection site (17.1%)¡A Urticaria (12.3%)¡A Diarrhea (2.3%)¡A Nausea (5.8%) Serious: Thromboembolic disorder,25¢J¥H¤UÁ×¥ú,IM 65-125mg per week.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¤§¨x»ÙÃª¤Î¨x¯e±wªÌ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥i¥Î©ó¥¥°ü¡A¦Ó¹ï¤l®c¤º¤§­L¨àµL¤£¨}¼vÅT,Unknown ¨S¦³¸ê®Æ,¥Îªk¥Î¶q¨Ì¾Ú¥é³æ¡A Up to date,IM;,,,,,
IVAX3,Purified Split Inactivated Influenza Virus,§K¶O¬y·P(3~12·³) 0.5mL/dose,HIMM,,,,,,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,
IVAX5,Purified Split Inactivated Influenza Virus,§K¶O¥®¨à¬y·P(6M~3Y) 0.25mL/dose,HIMM,,¾AÀ³¯g: Active immunisation against influenza. °Æ§@¥Î: Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome. ¸T§Ò: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 ¢XC,Adult & Children >= 36 mth IM Chidren <= 8 yr who have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,
IFLU4,Purified Split Inactivated Influenza Virus,GSK 4»ù¦Û¶O¬y·P(Fluarix Tetra)0.5mL/dose,HIMM,Active immunisation against influenza.,History of severe allergic reactions (e.g.¡A anaphylaxis) to any component of the vaccine.,Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome.,2-8¢XC.½Ð¤Å§N­á,IM¡A 0.5 mL¡A > or = 6 months (< 9 years who have not been vaccinated previously¡A the second dose can be given after 4 weeks.),µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]µû¦ô­·ÀI©M¯q³B«á¡AÃh¥¥¤Î­÷¨Å°ü¤k±o¬I¥´¥»¬Ì­]¡C¥Ø«e©|¥¼©óÁ{§É¸ÕÅç¤¤µû¦ô¹ï¥¥°ü¬I¥´Fluarix Tetraªº¦w¥þ©Ê¡C ®Ú¾Ú¨t²Î©Ê¤åÄmºî­zÀò±o¤§¥h¬¡¤Æ©u¸`©Ê¬y·P¬Ì­]ªº¦w¥þ©Ê¸ê®Æ¥H¤Î¥i¥Îªº¤W¥««á¨Ï¥Î¸gÅç¡A©ó§³®W´Á¶¡±µºØ¥h¬¡¤Æ©u¸`©Ê¬y·P¬Ì­]¡A¨Ã¥¼Åã¥Ü±N¼W¥[¥¥´Á¤£¨}¤ÏÀ³ªº­·ÀI¡C ¥HFluarix Tetra©Ò¶i¦æªº°Êª«¬ã¨s¡A¨Ã¥¼µo²{¥ô¦óª½±µ©Î¶¡±µ¹ï¥Í´Þ»Pµo¨|¬r©Ê¤è­±ªº¦³®`¼vÅT(°Ñ¨£«DÁ{§É¬ÛÃö¸ê°T)¡C ¥Ø«e©|¥¼µû¦ôÁý­÷¥À¨Åªº°ü¤k¬I¥´Fluarix Tetraªº¦w¥þ©Ê¡C¥Ø«e¤]¤£½Tª¾Fluarix Tetra¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] µû¦ô­·ÀI©M¯q³B«á¡AÃh¥¥¤Î­÷¨Å°ü¤k±o¬I¥´¥»¬Ì­]¡C ¥Ø«e©|¥¼µû¦ôÁý­÷¥À¨Åªº°ü¤k¬I¥´Fluarix Tetraªº¦w¥þ©Ê¡C ¥Ø«e¤]¤£½Tª¾Fluarix Tetra¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C,IM;,,,,,½Ð«O¦s©ó¦B½c¤¤(2¢XC¦Ü8¢XC)¡C¤Á¤Å§N­á¡C¬I¥´«eÀ³¥ý¥R¤À®¶·n°wµ© Fluarix Tetra¬O¤@­Ó¥h¬¡¤Æ¬y·P¯f¬r¬Ì­]¡A§t¦³¥ÑÂû³J­F­L¤¤©ÒÁc´Þ»s³y¦Ó¨Óªº§Ü­ì¡A§t¦³¤U¦C¬y·P¯f¬r®è§Ü­ì¡GA/Victoria/2570 /2019 (H1N1)pdm09 - like strain (A/Victoria/2570 /2019¡A IVR-215);A/Cambodia/e0826360/2020 (H3N2) - like strain (A/Tasmania/503/2020¡A IVR-221);B/Washington/02/2019 - like strain (B/Washington/02/2019¡A wild type);B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013¡A wild type).
ITET,DTaP-IPV,Tetraxim (¥|¦X¤@¡A ¬F©²´£¨Ñ) 0.5mL/dose,HIMM,TETRAXIM is indicated to help protect your child against diphtheria¡A tetanus¡A pertussis and poliomyelitis in children from 2 months of age as a primary vaccination and as a booster dose during the second year of life and in children from 5 to 11 years or 11 to 13 years of age¡A according to national official recommendations.,Hypersensitivity. Acute illness eg febrile illness¡A encephalopathy of unknown origin w/in 7 days of previous pertussis vaccination. Pregnancy & lactation.,Adolescents and Adults- Injection site pain¡A erythema and swelling¡A tiredness¡A headache¡A bodyache¡A chills¡A nausea¡A fever¡A arthralgia or joint swelling (1/10) Diarrhoea¡A vomiting (<1/10 and >1/100) Children 5 to 6 years old - Injection site pain and swelling; fatigue (1/10) Injection site erythema and pruritus; fever >38¢XC (<1/10 and >1/100) Diarrhoea¡A vomiting (<1/100 and >1/1¡A000),2-8¢JÁ×§K§N­á,IM¡A 0.5 mL¡A 5-13 years.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[³X³æ]µL¸ê®Æ¡C,Unknown ¨S¦³¸ê®Æ,[³X³æ]µL¸ê®Æ¡C,IM;,,,,,
OMOR1,Morphine,Morphine 15mg,CNEU,Relief of moderate to severe pain. Pre-op anesth.,Respiratory depression¡A head injury¡A obstructive airways disease¡A paralytic ileus¡A GI obstruction¡A delayed gastric emptying¡A acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,Nausea¡A vomiting¡A constipation¡A drowsiness¡A palpitations¡A headache¡A disorientation¡A vertigo¡A mood changes¡A decreased libido¡A ureteric spasm¡A urinary retention¡A rash¡A sweating¡A facial flushing¡A miosis. Cardiovascular: Peripheral edema (5% to 10% ) Dermatologic: Pruritus (up to 80% )¡A Rash (5% to 10% )¡A Sweating (5% to 10% ) Gastrointestinal: Abdominal pain (5% to 10% )¡A Constipation (> 10% )¡A Diarrhea (5% to 10% )¡A Loss of appetite (5% to 10% )¡A Nausea and vomiting (7% to 70% )¡A Xerostomia (5% to 10% ) Hepatic: Liver function tests abnormal (< 5% ) Musculoskeletal: Backache (5% to 10% ) Neurologic: Asthenia (5% to 10% )¡A Dizziness (6% )¡A Headache (>10% )¡A Insomnia (5% to 10% )¡A Lightheadedness¡A Paresthesia (5% to 10% )¡A Somnolence (> 10% ) Ophthalmic: Amblyopia (< 5% )¡A Miosis Psychiatric: Anxiety (6% )¡A Depression (5% to 10% ) Renal: Urinary retention (oral: < 5% ; epidural/intrathecal: 15% to 70% ) Other: Fever (5% to 10% )¡A Hiccoughs (< 5% ),25¢J¥H¤Uºò±KÁ×¥ú®e¾¹,5-30 mg every 4 hours.,µL»Ý½Õ¾ã¾¯¶q,Start with lower initial doses and titrate slowly OR increase dosing interval by 1.5 to 2 times that of a normal dose,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
EKEL,Ketorolac,Kelac 0.5%¡A 5mL ophthalmic solution,TOPH,Temporary relief of ocular itching due to seasonal allergic conjunctivitis. Treatment of post-operational inflammation in patients who have undergone cataract extraction.,Patients who have previously demonstrated hypersensitivity to any of the ingredients of Kelac ophthalmic solution.,Common Ophthalmic: Burning sensation in eye (20% to 40% )¡A Corneal edema (1% to 10% )¡A Eye infection (1% to 10% )¡A Eye irritation (1% to 10% )¡A Iritis (1% to 10% )¡A Pain in eye (1% to 10% )¡A Superficial keratitis (1% to 10% ) Serious Ophthalmic: Corneal thinning¡A Perforation of cornea,Àx¦s©óÄá¤ó25«×¥H¤U,Relief of ocular itching due to seasonal allergic conjunctivitis: Instill 1 drop QID. Treatment of inflammation in patients who have undergone cataract extraction: Instill 1 drop QID (above 24 hrs post-operation)¡A and use constantly until 2 weeks after surgery.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,[¥é³æ]­P·î­L®ÄÀ³¡G¹ï¨ß¨Ï¥Î3.5mg/kg¨C¤é¤fªA¾¯¶q¤Î¤j¹«¨Ï¥Î10mg/kg©ó¾¹©xµo¥Í¨ä¶¡¶i¦æ¥Í´Þ¬ã¨s¡A¬ã¨sµ²ªG¨Ã¥¼³y¦¨­L¨à·î§Î¡AKetorolac tromethamine¤fªA¾¯¶q1.5mg/kg¡A¤D¤HÃþ¤fªA¾¯¶q¤§¥b¡A©ó¤j¹«§³®W17¤é«á§ëÃÄ¤ÞµoÃø²£¤Î¦º¤`²v¼W°ª¡F¨ÃµL¥Î©ó¥¥°ü¤§¥R¤À¥B¸g¹L¹ý©³¹ï·Ó¬ã¨s¡A¬G°ß¦³©ó¼ç¦b®Ä¯q¶W¹L¹ï­F­L¤§¼ç¦b­·ÀI®É¤è¥i¥Î©ó¥¥°ü¡C«D­P·î­L®ÄÀ³¡G¥Ñ©ó¤wª¾«e¦C¸¢¯À§í¨î©ÊÃÄª«¹ï­L¨à¤ß¦åºÞªº¼vÅT(°Ê¯ß¾ÉºÞ³¬¦X)¡A¦]¦¹©óÃh¥¥¥½´Á¶i¾¯¨Ï¥Î¥»«~¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥»«~§ë»P±Â¨Å°ü®ÉÀ³¼f·V¡C,OD;OL;OU;,,,,,1.«OºÞ®É­Y®e¾¹«eºÝ©M»\¤l¥X²{µ²´¹¡A½Ð¥H°®²b¯½¥¬À¿«ø«á¨Ï¥Î¡C 2.¶}²~ª`·N¨Æ¶µ:²£«~¨Ï¥Î«e¡A¥ý¥H¶¶®É°w¤è¦¡¦V¤U±Ûºò¤@°é«á¦A°f®É°wÂà¶}ÃÄ²~¨Ï¥Î¡A¥H§QÃÄ²Gºw¥X¡C
EFOS,Beclomethasone + Formoterol,Foster 100/6mcg/dose,ERSP,Regular treatment of asthma for patients not adequately controlled w/ inhaled corticosteroid & inhaled short-acting £]2-agonists; patients adequately controlled on both inhaled corticosteroids & long-acting £]2-agonists.,Hypersensitivity.,Pharyngitis¡A headache¡A dysphonia. Common Cardiovascular: Chest pain (1.9% to 3.2% )¡A Palpitations Gastrointestinal: Diarrhea (4.9% )¡A Nausea (4.9% )¡A Xerostomia (1.3% to 3.3% ) Neurologic: Dizziness (0.9% to 2.4% )¡A Headache (Less than 5% ; oral inhalation¡A 8% to 25% )¡A Insomnia (1.5% to 2.4% )¡A Tremor (1.9% to 8.6% ) Serious Cardiovascular: Cardiac dysrhythmia Respiratory: Death¡A Asthma-related¡A Exacerbation of asthma (Severe) Endocrine metabolic: Hypocortisolism secondary to another disorder¡A Type 2 diabetes mellitus Immunologic: Hypersensitivity reaction¡A Immunosuppression Ophthalmic: Cataract¡A Glaucoma Respiratory: Bronchospasm,¨Ï¥Î«e2-8 ¢J,Asthma: Adult >=18 year old¡A Maintenance therapy: 1 or 2 inhalations BID. the maximum daily dose: 4 inhalations; Maintenance and reliever therapy: Patients take their daily maintenance dose of Foster and in addition take Foster as needed in response to asthma symptoms. Patients should be advised to always have Foster available for rescue use. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes¡A an additional inhalation should be taken. The maximum daily dose is 8 inhalations. COPD: Adult >=18 year old: 2 inhalations BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,BECLOMETHASONE PREGNANCY RECOMMENDATION: Compatible FORMOTEROL PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BECLOMETHASONE BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible FORMOTEROL BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IH;,,,,,µoÃÄ«e¡G½ÐÀx¦s©ó¦B½c¡]2-8¢XC¡^¡]³Ìªø¥i¦s©ñ 18 ­Ó¤ë¡^¡C µoÃÄ«á¡G½Ð¤ÅÀx¦s©ó 25¢XC ¥H¤WÀô¹Ò¡]³Ìªø¥i¦s©ñ 3 ­Ó¤ë¡^¡C
OINS,Eplerenone,Inspra F.C. 50mg,CAVS,Congestive Heart Failure Post-Myocardial Infarction. NYHA Class 2 of Heart Failure.,For All Patients with hypersensitivity to eplerenone¡A hyperkalemia or clinically significant hyperkalemia¡A serum potassium >5.0 mEq/L at initiation¡A creatinine clearance < or =30 mL/min¡A severe hepatic insufficiency (Child-Pugh class C)¡A concomitant administration of strong CYP3A4 inhibitors¡A or concomitant administration of angiotensin-converting enzyme inhibitors(ACEI) or angiotensin receptor blockers(ARB). For the treatment of hypertension in patients with type 2 diabetes with microalbuminuria¡A serum creatinine >2.0 mg/dL in males or >1.8 mg/dL in females¡A creatinine clearance <50 mL/min¡A or concomitant administration of potassium supplements or potassium-sparing diuretics.,ommon Endocrine metabolic: Hyperkalemia (3.4% ) Renal: Serum creatinine raised (2.4% ) Serious Cardiovascular: Angina pectoris¡A Myocardial infarction,«Ç·Å,Heart failure - Myocardial infarction with complication: initial¡A 25 mg once daily; titration preferably within 4 weeks to 50 mg once daily. Hypertension: initial¡A 50 mg once daily; allow 4 weeks to achieve optimum antihypertensive effect; may increase to maximum 50 mg twice daily for inadequate response. New York Heart Association class II (chronic) heart failure: initial¡A 25 mg once daily¡A followed by an increase to 50 mg once daily after 4 weeks if potassium level no more than 5 mmol/L.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Eplerenone¥¼´¿¦b¥¥°ü°µ¹L¬ã¨s¡C°Êª«¸ÕÅç¥¼Åã¥Ü¹ïÃh¥¥¡B­F­L­L¨àµo¨|¡B¤À®Y»P¥X¥Í«áµo¨|¦³ª½±µ©Î¶¡±µªº¤£¨}¼vÅT¡C³B¤èeplerenoneµ¹¥¥°üÀ³ÂÔ·V¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ²{¦bÁÙ¤£ª¾¹D¥»ÃÄ¤fªA«á¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡CµM¦ÓÁ{§É«eªº¸ê®ÆÅã¥Ü eplerenone¤Î/©Î¥NÁÂ²£ª«¦s¦b©ó¤j¹«ªº¨Å¥Ä¤¤¡A¦Ó¸g¥Ñ³oºØ³~®|¼ÉÅSªº¥®¹«µo¨|¥¿±`¡C¦]¬°³\¦hÃÄª«·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡A¤S¦]¹ï¦Y¥À¥¤ªºÀ¦¨à³y¦¨¤£¨}¤ÏÀ³ªº¥i¯à©Ê¤£©ú¡A¬G¶·Åv¿ÅÃÄª«¹ï¥À¿Ëªº­«­n©Ê¨Ó¨M©w°±¤î±Â¨Å©Î°±ÃÄ¡C,AC;AC15;PC;PO;WM;,,,,,
ICIP2,Ciprofloxacin,Ciproxin °w¾¯ 200mg/100mL,QANB,Complicated UTI¡A bone & joint¡A complicated intra-abdominal & lower respiratory tract infection.,Hypersensitivity to ciprofloxacin or other quinolones. Children¡A adolescents¡A pregnancy & lactation.,Nausea¡A diarrhea¡A vomiting¡A dyspepsia¡A abdominal pain¡A flatulence¡A anorexia¡A dizziness¡A headache¡A tiredness¡A agitation¡A trembling. Very rarely¡A insomnia¡A peripheral paralgesia¡A sweating¡A unsteady gait¡A convulsions¡A increase in intracranial pressure¡A anxiety states¡A nightmares¡A confusion¡A depression¡A hallucinations¡A impaired taste & smell¡A visual disturbances¡A tinnitus¡A transitory impairment of hearing¡A especially at high frequencies¡A skin reactions.,25¢J¥H¤UÁ×¥ú¤Å§NÂÃ,Ciproxin should be infused intravenously over 60 minutes. Adults: usual dose: 100-400 mg IV Q12H; severe/complicated infections: 400 mg IV Q8H. Chiledren (aged 1-17 years): 6-10 mg/kg IV Q8-12H (maximum 400 mg/dose).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,¡iD10W¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,¥H > 60¤ÀÄÁ½wºCºwª`,1. »ÝÁ×¥úÀx¦s¡A¥ú·Ó¤U(¥¼¶}²~)ÃÄ®Ä¥u¯àºû«ù3¤Ñ¡C 2. ºÊ´úÅé·Å¡BCBC¡Aªø´Á¨Ï¥ÎÀ³ºÊ´ú¨xµÇ¥\¯à¡C
ITREM,Guselkumab,Tremfya inj 100mg/1mL,HIMM,Plaque psoriasis. Psoriatic arthritis,History of serious hypersensitivity reaction to guselkumab or to any of the excipients.,Common Respiratory: Bronchitis (1.6% )¡A Upper respiratory infection (14.3% ) Serious Immunologic: Anaphylaxis¡A Hypersensitivity reaction Respiratory: Tuberculosis Other: Infectious disease (23% ),2-8¢JÁ×¥úÁ×§K§N­á,SC¡A plaque psoriasis¡A palmoplantar pustulosis¡A psoriasis arthritis 100 mg at week 0 and week 4¡A followed by 100 mg every 8 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¥ô¦ó¥¥°ü¨Ï¥ÎTREMFYARªº¸ê®Æ¥i¾Ú¥H½T»{TREMFYAR¬O§_¦s¦³¤£¨}µo¨|¼vÅT¤è­±ªºÃÄª«¬ÛÃö­·ÀI¡C ¤HÃþIgG§ÜÅé¤wª¾·|³q¹L­L½L»Ù¾À¡F¦]¦¹¡ATREMFYAR¦³¥i¯à·|±q¥ÀÅé´²¼½¦Üµo¨|¤¤ªº­L¨àÅé¤º¡C¦b¤@¶µ¦X¨Ö­F­L­L¨àµo¨|»P©P²£´Á«e«áµo¨|ªº¬ã¨s¤¤¡A©ó¾¹©xµo¥Í´Á¦Ü¥Í²£´Á¶¡¥Ö¤Uª`®g¾¯¶q³Ì°ª¹F¤HÃþ³Ì°ª«ØÄ³¾¯¶q(MRHD)¤§30­¿ªºguselkumab¤§«á¡A¨Ã¥¼µo²{¥Í¤Uªº¥JµU¥X²{¥ô¦ó¤£¨}µo¨|¤§¼vÅT¡C ¦b6¦Ü30­¿MRHDªº¾¯¶q¤U¡A´¿Æ[¹î¨ì·s¥Í¥JµU¦º¤`ªº®×¨Ò¡C¥Ø«e¨Ã¤£½Tª¾³o¨Ç«DÁ{§Éµo²{ªºÁ{§É·N¸q¡C©Ò¦³ªºÃh¥¥³£¨ã¦³¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­I´º­·ÀI¡C¥Ø«e¨Ã¤£½Tª¾¥»«~ªº¾A¥Î±Ú¸sµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº¦ô­p­I´º­·ÀI¡C´N¬ü°êªº¤@¯ë¤H¤f¦Ó¨¥¡A¦b¸g¹LÁ{§É½T»{ªºÃh¥¥¤H¤f¤¤¡A­«¤j¥X¥Í¯Ê³´»P¬y²£ªº¦ô­p­I´º­·ÀI¤À§O¬°2%¦Ü4%»P15%¦Ü20%¡C °Êª«¸ÕÅç¸ê®Æ¦b¤@¶µ¦X¨Ö­F­L­L¨àµo¨|»P©P²£´Á«e«áµo¨|ªº¬ã¨s¤¤¡A´¿¹ïÃh¥¥ªº­¹ÃÉµU©ó¾¹©xµo¥Í´Á¶}©l¦Ü¥Í²£´Á¶¡¨C¶g¥Ö¤Uª`®g¾¯¶q³Ì°ª¹F50²@ §J/¤½¤ç(30­¿MRHD¡A¥H²@§J/¤½¤ç¬°¤ñ¸û°òÂ¦)ªºguselkumab¡C¦³1°¦¹ï·Ó²ÕµU¤l¡B3°¦§ë¤©10²@§J/¤½¤ç/¶g(6­¿MRHD¡A¥H²@§J/¤½¤ç ¬°¤ñ¸û°òÂ¦)¤§guselkumabªºµU¤l¤Î3°¦§ë¤©50²@§J/¤½¤ç/¶g(30­¿ MRHD¡A¥H²@§J/¤½¤ç¬°¤ñ¸û°òÂ¦)¤§guselkumabªºµU¤l©Ò¥Í¤Uªº¤l¥N¥X²{·s¥Í¥JµU¦º¤`ªº±¡ªp¡C ¥Ø«e¨Ã¤£½Tª¾³o¨Çµo²{ªºÁ{§É·N¸q¡C ¦b¥JµU¥X¥Í«á¦Ü6­Ó¤ë¤j´Á¶¡¡A¦b©x¯àµo¨|©Î§K¬Ì¥\¯àµo¨|¤è­±¬Ò¥¼ µo²{¥ô¦ó»Pguselkumab¬ÛÃöªº¼vÅT¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©óguselkumab¬O§_·|¥X²{©ó¤HÃþ¨Å¥Ä¡B¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT¡B©Î¹ï¨Å¥Ä¥Í¦¨¼vÅT¤è­±ªº¸ê®Æ¡C ¦bªc¨Å­¹ÃÉµUªº¨Å¥Ä¤¤¨Ã¥¼ÀË¥Xguselkumab¡C¥ÀÅéIgG¤wª¾·|¥X²{©ó¤HÃþªº¨Å¥Ä¤¤¡C À³¤@¨Ö¦Ò¼{Áý­÷¥À¨Å¹ïµo¨|»P°·±dªº¦n³B©M¥À¿Ë¹ïTREMFYARªºÁ{§É»Ý¨D¡A¥H¤ÎÁý­÷¥À¨Å¤§À¦¨à¥i¯à¦]TREMFYAR©Î¼ç¦b¤§¥ÀÅé¯e¯f¦Ó¨ü¨ìªº¥ô¦ó¤£¨}¼vÅT¡C,SC;,,,,,ª`®g¤§«e¡AÀ³¥ý±NTREMFYAR¹w¥R¶ñ¦¡°wµ©©Î¹w¥R¶ñ¦¡ª`®gµ§¦Û¦B½c¨ú¥X¡AÅýTREMFYAR ¨Ñ¥Ö¤Uª`®g¨Ï¥Î¡Aµ´¹ï¤£¥iª`¤J¦Ù¦×©Î¦åºÞ¡C ª`®g¤§«á¡A°wÀY·|ÁY¶i¦¹¸Ë¸mªºµ©¨­¤¤¨ÃÂê¦í¡C ¹F¨ì«Ç·Å(µ¥­Ô30¤ÀÄÁ)¡A¦¹®ÉÁÙ¤£­n²¾°£°wÀY®M¡C ¦b§ëÃÄ¤§«e¡AÀ³¥ØµøÀË¬dTREMFYAR¬O§_¦³·L²É²§ª«©ÎÅÜ¦âªº²{¶H¡C TREMFYAR¬°¼á²M¡BµL¦â¦Ü²H¶À¦âªº·»²G¡A·»²G¤¤¥i¯à§t¦³·L¤pªº¥b³z©úÁû²É¡C ¦pªG·»²G¤¤§t¦³¤j«¬Áû²É¡A©Î¦³ÅÜ¦â©Î²V¿Bªº²{¶H¡A¤Á¤Å¨Ï¥Î¡C
IKEY1,Pembrolizumab,KEYTRUDA inj 100mg/4mL,RACA,KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and¡A if BRAF V600 mutation positive¡A a BRAF inhibitor.,Hypersensitivity to pembrolizumab or any component of the formulation.,>10%: Cardiovascular: Facial edema (10%) Central nervous system: Fatigue (43%) Dermatologic: Pruritus (28%)¡A skin rash (24%; immune-mediated: 1%) Endocrine & metabolic: Hyperglycemia (49%)¡A hypoalbuminemia (37%)¡A hyponatremia (37%)¡A hypertriglyceridemia (33%)¡A decreased serum bicarbonate (22%)¡A hypocalcemia (21%) Gastrointestinal: Constipation (22%)¡A nausea (22%)¡A decreased appetite (20%)¡A diarrhea (20%)¡A abdominal pain (13%)¡A vomiting (13%) Hematologic & oncologic: Anemia (44%; grades 3/4: 10%)¡A lymphocytopenia (40%; grades 3/4: 9%) Hepatic: Increased serum alkaline phosphatase (26%)¡A increased serum AST (24%)¡A increased serum ALT (21%) Neuromuscular & skeletal: Arthralgia (14%) Respiratory: Dyspnea (?20%)¡A cough (18%) Miscellaneous: Fever (14%) 1% to 10%: Central nervous system: Confusion (>2%)¡A peripheral neuropathy (2%) Endocrine & metabolic: Hypothyroidism (immune-mediated; 9%)¡A hyperthyroidism (immune-mediated; 3%) Gastrointestinal: Colitis (immune-mediated; 2%) Immunologic: Antibody development (2%) Neuromuscular & skeletal: Weakness (10%)¡A arthritis (immune-mediated; 2%) Respiratory: Pneumonitis (3%)¡A pleural effusion (>2%)¡A pneumonia (>2%)¡A respiratory failure (>2%),2-8¢XCÁ×¥úÁ×§K§N­á,[Melanoma] 2 mg/kg infused over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity. [Non-Small Cell Lung Cancer (NSCLC)] 200 mg for untreated patients or 2 mg/kg as a single agent for previously treated patients infused over 30 minutes once every 3 weeks until disease progression¡A unacceptable toxicity¡A or up to 24 months. [Classical Hodgkin Lymphoma (cHL)¡A Head and Neck Squamous Cell Cancer (HNSCC)¡A Urothelial Carcinoma] 200 mg infused over 30 minutes once every 3 weeks until disease progression¡A unacceptable toxicity¡A or up to 24 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Contraindicated,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,IV infusion over 30 minutes.,»s³Æ: 1. ©â¨ú»Ý­nªºÃÄ¶q¡Aª`¤J0.9%´â¤Æ¶uª`®g²G©Î5%¸²µå¿}ª`®g²GªºÀR¯ß¿éª`³U¤¤¡C(»´Âàªº¤è¦¡²V¤Ã·»²G)¡C 2. ·»²Gªº³Ì²×¿@«×À³¬°1²@§J/²@¤É¦Ü10²@§J/²@¤É¤§¶¡¡C 6. µ}ÄÀ«á¥i¦s©ñ«Ç·Å¡A¦ý¤£¥i¶W¹L6¤p®É¡C(¥]¬A©ó«Ç·Å¤U¡Aªw»s«á¤§ÃÄ²~ªº¦s©ñ®É¶¡¡BIV³U¤¤¤§¿éª`·»²Gªº¦s©ñ®É¶¡¡B¥H¤Î¿éª`©Ò»Ý­nªº®É¶¡)
IENT0,Vedolizumab,ENTYVIO inj 300mg (Sample) (infusion),HIMM,Crohn disease or ulcerative colitis,Hypersensitivity reaction¡A severe or serious¡A to vedolizumab or any of its excipients.,Common: Nausea (9%)¡A Arthralgia (12%)¡A Headache (12%)¡A Nasopharyngitis (13%)¡A Upper respiratory infection (7%)¡A Fatigue (6%)¡A Fever (9%) Serious: Aminotransferase abnormal¡A Increased (Up to 2%)¡A Hepatitis¡A Serum bilirubin above reference range¡A Anaphylaxis (0.07%)¡A Hypersensitivity reaction¡A Progressive multifocal leukoencephalopathy¡A Tuberculosis¡A Cancer (0.4%)¡A Infectious disease¡A Infusion reaction (4%)¡A Sepsis (0.03%),2-8¢JÁ×¥ú,IVD¡A ulcerative colitis¡A Crohn's disease 300 mg at week 0¡A 2 and 6¡A followed by every 8 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ­·ÀIºK­n ¨Ì¾Ú²{¦³ªºÃÄª«¦w¥þºÊµø¸ê®Æ¡B¶i¦æ¤¤ªºÃh¥¥µn¿ý¸ê®Æ¡B¤wµoªíªº¥¥°ü­Ó®×³ø§i¤Î¥@¥N¬ã¨s¸ê®Æ¡A¨Ã¥¼µo²{»P¦w¼ì±y¦³Ãöªº­«¤j¥ý¤Ñ©Ê¯Ê³´¡B¬y²£¡A©Î¥ÀÅé©Î­L¨àªº¤£¨}µ²ªG¡CÃh¥¥´Á¶¡ªºµoª¢©Ê¸z¹D¯e¯f¡A¹ï¥À¿Ë©M­L¨à³£¦³­·ÀI(°Ñ¨£Á{§É¦Ò¶q)¡C©|¥¼¶i¦æ¦w¼ì±y¥Î©óÃh¥¥¤k©Êªº¸ÕÅç¡C°Êª«¥Í´Þ¸ÕÅç¤¤¡A¨ß¤l©MµU¤lÀR¯ßª`®g°ª©ó¤HÅé«ØÄ³¾¯¶q20­¿ªºvedolizumab¡A¨Ã¥¼Æ[¹î¨ì­F­L¶Ë®`(°Ñ¨£¸ÕÅç¸ê®Æ)¡C¯S©w±Ú¸sµo¥Í­«¤j¥ý¤Ñ©Ê¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¡A¥Ø«e©|¤£²M·¡¡C©Ò¦³Ãh¥¥³£¦³¥ý¤Ñ¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­I´º­·ÀI¡C¦b¬ü°ê¤@¯ë±Ú¸s¡AÁ{§É¤W½T»{Ãh¥¥«á¡Aµo¥Í­«¤j¥ý¤Ñ©Ê¯Ê³´©M¬y²£ªº¹w¦ô­I´º­·ÀI¡A¤À§O¬°2¦Ü4%¤Î15¦Ü20%¡C Á{§É¦Ò¶q ¦w¼ì±y¤§¥ô¦óÃh¥¥¤£¨}§@¥Î¡A¦bÃh¥¥²Ä¤G©M²Ä¤T¥¥´Á®É¥i¯à¸ûÄY­«¡C³æ®è§ÜÅé·|ÀH¥¥´Á¶i®i¦Ó¥H½u©Ê¤è¦¡³q¹L­L½L¡A¦b²Ä¤T¥¥´Áªº¶Ç°e¶q³Ì¤j¡C ¯e¯f¬ÛÃöªº¥ÀÅé©M­F­L/­L¨à­·ÀI ¤wµoªíªº¸ê®ÆÅã¥Ü¡A¿©±wµoª¢©Ê¸z¹D¯e¯f(IBD)ªº¤k©Ê¡AÃh¥¥µ²ªG¤£¨}ªº­·ÀI»P¯e¯f¬¡°Ê«×¼W¥[¦³Ãö¡CÃh¥¥ªº¤£¨}µ²ªG¥]¬A¦­²£(Ãh¥¥¶g¼Æ¥¼º¡37¶g)¡BÀ¦¨à¥X¥ÍÅé­«°¾§C(§C©ó2500¤½§J)¤Î¥X¥ÍÅé­«¤£¨¬¡C ­L¨à/·s¥Í¨à¤£¨}¤ÏÀ³ Ãh¥¥´Á¶¡¨Ï¥Î¦w¼ì±y¡A¥i¯à·|¼vÅT¦b¤l®c¤º¨ü¼ÉÅSªº·s¥Í¨à¤ÎÀ¦¨à¤§§K¬Ì¤ÏÀ³¡CÀ¦¨à¦b¤l®c¤º¼ÉÅS©ó§C¿@«×¦w¼ì±y¤§Á{§É¼vÅT¡A¥Ø«e©|¤£²M·¡¡C¨ü¼ÉÅSªºÀ¦¨à¬I¥´¬¡¬r©Î´î¬r¬Ì­]¤§¦w¥þ©Ê¡A¥Ø«e¤]©|¤£²M·¡¡C ¸ÕÅç¸ê®Æ °Êª«¸ê®Æ ¹ïÃh¥¥¨ß¤lªº¥Í´Þ¸ÕÅç¤¤¡A¦b§³®W²Ä7¤ÑÀR¯ßª`®g³æ¾¯³Ì°ª100²@§J/¤½¤ç¾¯¶qªºvedolizumab(¬ù¬°¤HÅé«ØÄ³¾¯¶qªº20­¿)¡A¨ÃµLÃÒ¾ÚÅã¥Ü¾É­P¥Í¨|¯à¤O¨ü·l©Î­L¨à¶Ë®`¡C¤@¶µµU¤lªº²£«e¤Î²£«áµo¨|¸ÕÅç¤¤¡AÀR¯ßª`®g³Ì°ª100²@§J/¤½¤ç¾¯¶qvedolizumab(¬ù¬°¤HÅé«ØÄ³¾¯¶qªº20­¿)¡A¨ÃµLÃÒ¾ÚÅã¥Ü¹ï²£«e¤Î²£«áµo¨|²£¥Í¥ô¦ó¤£¨}§@¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ²{¦³ªº¤wµoªí¤åÄmÅã¥Üvedolizumab·|¶i¤J¤HÃþªº¨Å¥Ä¡CVedolizumab§½³¡­G¸z¹D¼ÉÅS¤Î¥i¹w´Áªº¥þ¨­©Ê§C¼ÉÅS¹ï¨ü­÷¨ÅÀ¦¨à¤§¼vÅT¡A¥Ø«e©|¤£²M·¡¡C¦b¤@¶µ¶È±Â¨Å¨Óµû¦ô¦b±µ¨üvedolizumabªvÀø¼ìºÅ©Êµ²¸zª¢©Î§J¶©¤ó¯g±Â¨Å°ü¤k¨Å¥Ävedolizumab¿@«×¸ÕÅç¤¤¡A¦b¤HÃþ¨Å¥Ä¸Ìvedolizumab¿@«×¬ù¬°¥ÀÅé¦å¤¤¿@«×(¨ú¦Û¹L¥hvedolizumab¸ÕÅç¼Æ¾Ú)ªº0.4%¦Ü2.2%¡C±À¦ôÀ¦¨à¥­§¡¨C¤évedolizumabÄá¨ú¶q¬°0.02 mg/kg/day¡A¬Û·í©ó¥ÀÅé¨C¤éÄá¨ú¶qªº21%(¸gÅé­«½Õ¾ã)¡C¦Ò¼{­÷¨Å¹ï©óµo¨|©M°·±dªº®Ä¯q®É¡AÀ³¿Å¶q¥À¿Ë¹ï¦w¼ì±yªºÁ{§É»Ý¨D¡A¤Î¨Ó¦Û¦w¼ì±y©Î¥ÀÅé°òÂ¦¯e¯f¹ï¨ü­÷¨ÅÀ¦¨àªº¼ç¦b¤£¨}¤ÏÀ³¡C,IVD;,4.8mLª`®g¥ÎµLµß¤ô,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥HÀR¯ß¿éª`30¤ÀÄÁ¤è¦¡µ¹¤©¡A ½Ð¤Å¥HÀR¯ßª`®g©Î±Àª`¤è¦¡µ¹ÃÄ¡C¿éª`§¹¦¨«á¨Ï¥Î30mLªºN/S©ÎL/R¨R¬~¡C¿éª`·»²G°t»s§¹¦¨¨Ãµ}ÄÀ«á¡A½Ð¾¨§Ö¨Ï¥Î¡C µ}ÄÀ»¡©ú: ±N5mL(300 mg)°t»s§¹¦¨ªº·»²G¡A¥[¤J250²@¤ÉªºµLµßN/S©ÎL/R¡A¨Ã»´»´®Ì°Ê¿éª`³U. ½Ð¤Å±N¨ä¥LÃÄ«~¥[¤J·Ç³Æ¦nªº¿éª`·»²G©ÎÀR¯ß¿éª`ºÞ½u²Õ. ¿éª`·»²G°t»s§¹¦¨¨Ãµ}ÄÀ«á¡A½ÐºÉ§Ö¨Ï¥Î.,À³¨Ï¥ÎµLµß§Þ³N¦b20-25¢J¤U°t»s: 1.¨Ï¥Î21¦Ü25 gauge°wÀY¡A¥H4.8mLª`®g¥ÎµLµß¤ô°t»s¡C 2.°wÀY´¡¤J¨Ã¾É¤Þª`®g¥ÎµLµß¤ôªuÃÄ²~¬Á¼þ¾À¬y¤U¡A¥H§K²£¥Íªwªj¡C 3.»´®Ì°Ê¦Ü¤Ö15¬í¡A¤Å¥Î¤O·n®Ì©Î­ËÂà¡C 4.«Ç·Å¤UÀR¸m³Ì¦h20¤ÀÄÁ¡A¥H«K°t»s¨Ãµ¥©Ò¦³ªwªj®ø¥¢¡A¦p¥¼§¹¥þ·»¸Ñ¡A¥i¦A©ñ¸m10¤ÀÄÁ.¥¼¦b30¤ÀÄÁ¤º·»¸Ñ¡A¤Å¨Ï¥Î¦¹ÃÄ¡C 5.·»²GÀ³¬°²Mº«©Î¥b³z©ú¡AµL¦â¦Ü²L´Ä¶À¦â¡A¤£§tÁû²É.­Y·»²GÃC¦â²§±`©Î§tÁû²É¡A¤Å¨Ï¥Î¡C 6.»´­ËÂàÃÄ²~¤T¦¸¡A¦A©â¨ú°t»s¦nªº·»²G5mL¡AÃÄ²~¤º³Ñ¾lªº·»²G½Ð¥á±ó¡C Àx¦s:°t»s«áÀ³¥ß§Y¨Ï¥Î¡A¦p§NÂÃ¥i«O¦s8¤p®É¡Cµ}ÄÀ©óN/S«á20-25¢J¥i«O¦s12¤p®É¡A2-8¢J§NÂÃ¥i24¤p®É¡Cµ}ÄÀ©óL/R«áÀ³¥ß§Y¨Ï¥Î¡A2-8¢J§NÂÃ¥i6¤p®É¡C
EFLO,Ofloxacin,Ofloxin otic solution 0.3%¡A 5mL,TENT,Chronic suppurative otitis media¡A acute otitis media with or without tympanostomy tube¡A otitis externa.,Patients with a history of hypersensitivity to ofloxacin.,superinfection¡A earache¡A Vestibular nerve disorder¡A Hearing Impairments¡A ear itching¡A headache¡A redness of the ear canal¡A Redness of the external ear canal,Àx¦s©óÄá¤ó25«×C¥H¤U,Otitis media¡A chronic suppurative (with perforated tympanic membranes): Otic: Instill 6-10 drops into affected ear(s) twice daily for 14 days,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives) [¥é³æ]¥¼¦³¬ÛÃö«ØÄ³,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼¦³¬ÛÃö«ØÄ³,AD;AL;AS;AU;,,,,,1.«OºÞ®É­Y®e¾¹«eºÝ©M»\¤l¥X²{µ²´¹¡A½Ð¥H°®²b¯½¥¬À¿«ø«á¨Ï¥Î¡C 2.¶}²~ª`·N¨Æ¶µ:²£«~¨Ï¥Î«e¡A¥ý¥H¶¶®É°w¤è¦¡¦V¤U±Ûºò¤@°é«á¦A°f®É°wÂà¶}ÃÄ²~¨Ï¥Î¡A¥H§QÃÄ²Gºw¥X¡C
OREX,Brexpiprazole,Rexulti 1mg,CNEU,Schizophrenia.,Hypersensitivity to brexpiprazole or any component of the product.,Common Endocrine metabolic: Hyperglycemia (9% to 10% )¡A Serum triglycerides raised (Short-term use¡A 5% to 13%; long-term use¡A 13% to 17% )¡A Weight increased (Short-term use¡A 2% to 11%; long-term use¡A 20% to 30% ) Neurologic: Akathisia ( 4% to 14% )¡A Extrapyramidal movements¡A Excluding akathisia (5% to 6% )¡A Headache (4% to 9% ) Serious Cardiovascular: Cerebrovascular accident¡A Orthostatic hypotension ( 0.1% to 0.4% )¡A Syncope (0.1% )¡A Transient ischemic attack Endocrine metabolic: Diabetic ketoacidosis Hematologic: Agranulocytosis Neurologic: Seizure Psychiatric: At risk for suicide Other: Neuroleptic malignant syndrome,30¢XC¥H¤U,Initial¡A 1 mg orally once daily on days 1 through 4; titrate to 2 mg orally once daily on days 5 through 7¡A then to target dosage of 4 mg orally once daily beginning on day 8¡A based on response and tolerability; Maximum 4 mg orally once daily; periodically reassess dosage and need for treatment.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment¡A moderate to severe (Child-Pugh score 7 or greater): MAX 2 mg once daily (major depressive disorder) or MAX 3 mg once daily (schizophrenia) [Micromedex 20210330],»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] REXULTI ¥Ø«e©|µL°w¹ïÃh¥¥¤k©Ê¶i¦æ¤§¾A·í¥B±±¨î¨}¦nªº¸ÕÅç¡A¬GµLªk´£¨ÑÃÄª«¬ÛÃö­·ÀIªº¸ê°T¡C ¤£¹L¡A¦bÃh¥¥²Ä¤T´ÁÃnÅS©ó§Üºë¯«¯fÃÄª«(¥]¬A REXULTI)ªº·s¥Í¨à¦³À@Åé¥~®|¯gª¬©M / ©Î¸TÂ_¯gª¬ªº­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥Ø«e©|µLµû¦ô brexpiprazole ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡B ¹ïÁý¥¤À¦¨à¦³¦ó¼vÅT¡A©Î¹ï¨Å¥Ä¤§²£¥Í¦³¦ó¼vÅTªºªc¨Å¬ã¨s¡C®Ú¾Ú¬ã¨s¡Abrexpiprazole ·|¤Àªc¦Ü¤j¹«¨Å¥Ä¤¤¡C°£¦Ò¶q­÷¨Å¹ïµo¨|¤Î°·±dªº¯q³B¥~¡A¥çÀ³¦P®É¦Ò¶q¥À¿Ë¹ï REXULTI ªºÁ{§É»Ý¨D¡A¥H¤Î REXULTI ©Î¨Ó¦Û¥ÀÅéª¬ªp¥i¯à¹ïÁý¥¤À¦¨àªº¥ô¦ó¤£¨}§@¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
IMUT,Nalbuphine,Mutonpain inj 10mg/1mL,CNEU,The management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine can also be used as a supplement to balanced anesthesia¡A for preoperative and postoperative analgesia¡A and for obstetrical analgesia during labor and delivery.,Hypersensitivity to nalbuphine to any of the other ingredients in Mutonpain.,Common Dermatologic: Diaphoresis (up to 9% ) Gastrointestinal: Nausea and vomiting (6% )¡A Xerostomia (4% ) Neurologic: Dizziness (up to 5% )¡A Headache (3% )¡A Sedated (36% )¡A Vertigo (up to 5% ) Serious Cardiovascular: Hypotension Endocrine metabolic: Adrenal insufficiency Immunologic: Hypersensitivity reaction (1% or less ) Neurologic: Loss of consciousness¡A Seizure Respiratory: Pulmonary edema¡A Respiratory depression (1% or less ) Other: Drug dependence¡A Opioid withdrawal,25¢J¥H¤UÁ×¥ú,The usual recommended adult dose is 10 mg for a 70 kg individual administered subcutaneously¡A intramuscularly¡A or intravenously; this dose may be repeated every 3 to 6 hours as necessary. Dosage should be adjusted according to the severity of the pain¡A the physical status of the patient¡A and other medications which the patient may be receiving. In nontolerant individuals¡A the recommended the single maximum dose is 20 mg¡A and the maximum total daily dose is 160 mg. The use of Mutonpain as a supplement to balanced anesthesia requires larger doses than those recommended for analgesia. Induction doses of nalbuphine hydrochloride range from 0.3 mg/kg to 3 mg/kg intravenously to be administered over a 10 to 15 minute period with maintenance doses of 0.25 to 0.5 mg/kg in single intravenous administrations as required. The use of Mutonpain may be followed by respiratory depression which can be reversed with the opioid antagonist naloxone hydrochloride.,»Ý½Õ¾ã¾¯¶q,¥»ÃÄ¸g¥Ñ¨xÅ¦¥NÁÂ¡A¨x¥\¯à»ÙÃª±wªÌ½Ð¤p¤ß¨Ã´î¶q¨Ï¥Î[¥é³æ],»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 3 rd trimester,[¥é³æ]Ãh¥¥¨Ï¥Î¤ÀÃþ:B¡A ¹ï¤j¦Ñ¹«¤Î¨ß¤lªº¥Í´Þ¬ã¨sÅã¥Ü¡A¥H°ª©ó¨C¤é³Ì¤j«ØÄ³¾¯¶qªº¤Q¥|¨ì¤T¤Q¤@­¿ªº¾¯¶q§ë¤©¡A¨S¦³·l®`¥Í¨|¤§±¡§Î©Î¹ï­L¨à³y¦¨·l¶Ë. µM¦Ó¦]©|¥¼¦³°w¹ïÃh¥¥°ü¤k¶i¦æ¤§§¹¾ã¬ã¨s¡A°ò©ó°Êª«¥Í´Þ¬ã¨s¥¼¯àµ´¹ï¾A¥Î©ó¤HÅé¤ÏÀ³¡A©Ò¥HÃh¥¥°ü¤k¥u¦³¦b½T¹ê¥²­n®É¤~¥i¥Hµ¹ÃÄ. ¥Î©ó¥Í²£¤Î¤À®Yªº¹Lµ{: Nalbuphine ³z¹L­L½LªºÂà²¾¤ñ²v¬Û·í°ª¥B¨³³t¡A¥ÀÅé»P­L¨àªº¤ñ²v§ïÅÜ¥i±q1¡G0.37 ¦Ü1¡G1.6¡C´¿¦³³ø§iÅã¥Ü¡A ¦b¥ÀÅéÃh¥¥´Á¶¡§ë¤©nalbuphine¦Ó¼vÅT­L¨à¤Î·s¥Í¨à¤§°Æ§@¥Î¦@¥]¬A¤F¡G­L¨à¤ß¸õ´î½w¡B©I§l§í¨î¡B·s¥Í¨à²¿®§¡BµoÖæ¤Î¦Ù¦×±i¤O§C®z¡C¬Y¨Ç­Ó®×Åã¥Ü¡A§³®W´Á¶¡¦b¥ÀÅé§ënaloxone¥iÁB¥¿³o¨Ç°Æ§@¥Î¡C ¥t¥~¡AÄY­«»P©µªø­L¨à¤ß¸õ´î½w¤]´¿¸g¦³³ø§i¡C´¿µo¥Í¦]­L¨à¤ß¸õ´î½w¦Ó¾É­P­L¨à¥Ã¤[©Êªº¯«¸g¶Ë®`¡C¥t¦³³ø§iÅã¥Ü¡A¨Ï¥Înalbuphine®É¡A­L¨à¥X²{Äuª¬¸`²v¡]sinusoidal¡^¤§¤ß¸õ¡A¦bÃh¥¥´Á¶¡©Î¥Í²£¤À®Y°ü¤k¨Ï¥Înalbuphine hydrochloride/¶·¯S§O¤p¤ß¡A ¹ï·s¥Í¨à§ó¶·ÄY¥[Æ[¹î¬O§_¥X²{©I§l§í¨î¡B²¿®§¡B¤ß¸õ´î½w»P¤ß²v¤£¾ã¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¦³­­ªº¸ê®ÆÅã¥Ü¥»ÃÄ¥u¦³¤Ö¶q¸g¥Ñ¨Å¥Ä±Æ¥X(¤Ö©ó§ë¤©¾¯¶qªº¦Ê¤À¤§¤@)¡A¦bÁ{§É¤WµLÅãµÛ·N¸q. ¥»ÃÄ§ë¤©­÷¨Å°ü¤k»Ý¤p¤ß.,IM;IVD;IVPUSH;SC;,,¡iD10W¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,ÀR¯ßª`®g®É¶¡»Ý¶W¹L10-15¤ÀÄÁ(­°§C¾¯¶q©Î©µªøª`®g®É¶¡¥i´î¤Ö°Æ§@¥Î),¥é³æ¨ÃµLµ}ÄÀ¿@«×©Îª`®g³t²v«ØÄ³¡A2021/04/13¼t°Ó¦^ÂÐ¡G¦]¥»ÃÄ¥i¤£¸gµ}ÄÀª½±µ¨Ï¥Î¡A¬GµL°t»s¿@«×»P¿éª`³t²v«ØÄ³¡A½Ð¯d·N¯f±wÁ{§É¤ÏÀ³¡A¥B­°§C¬y³t©Î¿@«×¥i´î¤Ö°Æ§@¥Î¡C,¥é³æµL«ØÄ³ªºµ}ÄÀ²G¡A2021/04/13¼t°Ó¦^ÂÐ¥i¨Ì°Ñ¦Ò®Ñ Handbook on Injectable Drugs¡A¦bD5W¡A D10W¡A Normal Saline¡A Ringer's solution¥|ºØµ}ÄÀ·»²G¤¤¥i¬Û®e¥B¦w©w48¤p®É.
LWIL,Simethicone,Wilcon 20mg/mL¡A 60mL suspension,ALIM,Relief of pressure¡A bloating¡A fullness¡A and discomfort of gastrointestinal gas.,Hypersensitivity to simethicone or any component of the formulation,Loose stools,25¢J¥H¤UÁ×¥ú«O¦s,Adult and Children > 3 years old: 2 mL TID-QID. Children < 3 years old: depended on doctor.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¥¼¦³¬ÛÃö»¡©ú,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼¦³¬ÛÃö»¡©ú,AC;AC15;PC;PO;WM;,,,,,
IEVE,Romosozumab,Evenity inj 105mg/1.17mL,META,The treatment of osteoporosis in postmenopausal women at high risk for fracture¡A defined as a history of osteoporotic fracture¡A or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.,Hypocalcemia. Known hypersensitivity to Evenity.,Common Musculoskeletal: Arthralgia (8.1% to 13.1% ) Neurologic: Headache (5.2% to 6.6% ) Serious Cardiovascular: Myocardial infarction (0.3% to 0.8% ) Endocrine metabolic: Hypocalcemia (0.04% ) Immunologic: Hypersensitivity reaction (6.5% ) Musculoskeletal: Femur shaft fracture (0.02% )¡A Osteonecrosis of jaw (0.02% ) Neurologic: Cerebrovascular accident (0.2% to 0.6% ),2-8¢JÁ×¥ú¡A¤Å§N­á,Two separate syringes (and two separate subcutaneous injections) are needed to administer the total dose of 210 mg of Evenity. Inject two 105 mg/1.17 mL prefilled syringes¡A one after the other. Should be administered by a healthcare provider. Administer 210 mg subcutaneously once every month for 12 doses in the abdomen¡A thigh¡A or upper arm. Adequately supplement calcium and vitamin D during treatment.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] EVENITY¨Ã¥¼®Ö­ã¥Î©ó¦³¥Í¨|¯à¤Oªº¤k©Ê¡C ¦b°Êª«¥Í´Þ¸ÕÅç¤¤¡A¦b¾¹©x§Î¦¨´Á¨C¶gµ¹¤©Ãh¥¥¤j¹«romosozumab ¶W¹L32­¿ªºÁ{§É¼ÉÅS¾¯¶q¡A·|¾É­P¤l¥N°©Àf²§±`¡C ¦b¥æ°t«e¨ì­÷¨Åµ²§ô´Á¶¡µ¹¤©¤j¹«romosozumab 1.5¦Ü56­¿ªº¤HÅé¹w´Á¼ÉÅS¾¯¶q¡A·|¾É­P¤l¥NªºªÑ°©°©½è±K«×¤Î/©Î°©¤º¥Ö½è©P³ò¤p´T©Î·L´T´î¤Ö¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] EVENITY ¨Ã¥¼®Ö­ã¥Î©ó¨ã¥Í¨|¯à¤Oªº¤k©Ê¡C ¦b°Êª«¸ÕÅç¤¤¡AÃh¥¥¤j¹«¦Û¦P©~«e 6 ¶g¨ì¥æ°t©M­÷¨Å´Á¶¡¡A¨C¶g±µ¨ü romosozumab 10¡B60 ©Î 300 ²@§J/¤½¤çªº¾¯¶q (®Ú¾Ú AUC ¤ñ¸ûµ²ªG¡A¬Û·í©ó¨C¤ë¥Ö¤Uª`®g 210 ²@§J¤§Á{§É¼ÉÅS¶qªº 1.5¡B19 ©Î 56 ­¿)¡A²£«á²Ä 21 ¤Ñ¡A¤l¥Nªº romosozumab ¦å²M¿@«×§e²{¾¯¶q¨Ì¿àÃö«Y¡A¤¶©ó¥ÀÅé¼ÉÅS¶q 0.01 ­¿¦Ü 2.4 ­¿¤§¶¡¡A¨Ì§³®W´Á©M/©Î­÷¨Å´Áªº¼ÉÅS¶q¦Ó²§¡C,SC;,,,,,«ØÄ³¾¯¶q¬°¥Ö¤Uª`®g 210 ²@§J©ó¸¡³¡¡B¤j»L©Î¤WÁu¡C¨C­Ó¤ë¬I¥´¤@¦¸¡CªvÀø´Á¶¡¬°¨C­Ó¤ë¬I¥´¤@¦¸¦@­p12­Ó¤ë¡C¦pªGº|¥´¤@¦¸Evenity¡AÀ³­«·s¦w±Æªù¶E®É¶¡¾¨§Ö¬I¥´¡C¤§«á¦A±q³Ì«á¤@¦¸ª`®gªº¤é´Áºâ°_¡A±Æ©w¨C­Ó¤ëEvenityªº¬I¥´®É¶¡¡C
OCHOP,Cholestyramine,Choles powder 4gm/Pack,CAVS,Hypercholesterolemia. Pruritus of skin with partial biliary obstruction. Diarrhea due to bile acid malabsorption.,Complete biliary obstruction. Hypersensitivity to cholestyramine or any of its components.,Common Gastrointestinal: Abdominal discomfort¡A Constipation¡A Flatulence¡A Nausea and vomiting.,³±²D³B«O¦s(¤Å¶W¹L30¢J),Choles powder: 444mg/gm¡A 9gm/Pack¡A Each pack contains 4gm Cholestyramine Resin. Hypercholesterolemia: Adult: Initial¡A 4gm(1 pack) BID; increase gradually over 1-2 weeks intervals; maintenance: 8gm(2 packs) BID; maximum: 24gm(6 packs)/day; Recommend dose interval is BID¡A but daily dose could be in 1-6 divided doses a day. Pruritus of skin with partial biliary obstruction: Adult: 4-8g(1-2 packs)/day. Child: (body weight * Adult dose )/70¡A Recommend once daily¡A increase gradually 5-7days intervals based on response and tolerability. Diarrhea due to bile acid malabsorption: Adult: Initial 4g(1 pack) TID¡A increase gradually based on response and tolerability. Child: 2-8g(0.5-2 packs)/day in 3 divided doses. If diarrhea is progressing for 3 days¡A should consider changing Colestyramine therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ñ©óCholestyramine Resin¬°«D¥þ¨­©Êªº§l¦¬¡AÃh¥¥´Á¶¡¨Ì«ØÄ³¾¯¶q¨Ï¥Î¡A¤£·|¶Ë®`­L¨à¡C¹ï¥¥°ü¨Ã¨S¦³¨¬°÷¤Î±±¨î¨}¦nªº¬ã¨s¡A¤wª¾¨ä¤zÂZ¯×·»©Êºû¥Í¯Àªº§l¦¬¥i¯à¦³®`¡A§Y¨Ï¥¿¦b¸É¥R³o¨Çºû¥Í¯À¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥²¶·Äµ§i¨Ï¥ÎCholestyramine Resinªº±Â¨Å°ü¡A¦p¡§¥¥°ü¡¨Äæ©Ò­z¡A¥ÀÅé¥i¯à¯Ê¥F§¹¥þªººû¥Í¯À§l¦¬¦Ó¼vÅT­÷¨ÅªºÀ¦¨à¡C,AC;PC;PO;,,,,,¨C¥]ÃÄ¯»¥H120-180mL²GÅé·»¸Ñ«áªA¥Î¡C
OERY1,Erythromycin,Erymycin 250mg,QANB,Staphylococcus¡A Streptococcus¡A Pneumococcus¡A Meningococcus¡A and other infections caused by susceptible bacteria.,Concomitant therapy with astemizole¡A cisapride¡A pimozide¡A or terfenadine. Hypersensitivity to erythromycin products. Pregnancy; risk of maternal hepatotoxicity.,Common: Diarrhea¡A Loss of appetite¡A Nausea¡A Stomach cramps¡A Vomiting Serious: Prolonged QT interval¡A Torsades de pointes¡A Ventricular arrhythmia¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis due to drug¡A Clostridium difficile colitis¡A Pancreatitis¡A Cholestatic hepatitis¡A Hepatitis¡A Anaphylaxis¡A Seizure¡A Ototoxicity¡A Tubulointerstitial nephritis,³±²D(15~30¢J)°®Àê³B,Adults: Antibacterial/Antiprotozoal: 250mg Q6H or 500mg Q12H. Maximum dose: 8g. Streptococcal Prevention for those with rheumatic heart disease or rheumatic fever: 250mg Q12H. Gonorrhea: 500mg Q6H for 7 days. Legionnaires' Disease: 250-1000mg Q6H. Syphilis: Early stage - 500mg Q6H for 15 days; Late stage - 500mg Q6H for 30 days. Children: Antibacterial: 7.5mg-25mg/kg Q6H¡A or 15mg-50mg/kg Q12H. Antiprotozoal: 7.5mg-12.5mg/kg Q6H for 10-14 days.,µL»Ý½Õ¾ã¾¯¶q,[Micromedex] hepatic impairment: drug may accumulate in patients with severe liver disease; no specific dosing recommendations available,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,PREGNANCY RECOMMENDATION: Compatible (Excludes estolate salt) ¦¹ÃÄ¦¨¤À: Erythromycin estolate [¥é³æ] ¥Ñ©ó¥»ÃÄ·|³q¹L­L½L»Ù¾À(¦ý¦b­L¨à¦å¼ß¿@«×¤£°ª)¡A¦Ó¥B¥ç·|±Æªn©ó¨Å¥Ä¤¤¡A¦]¦¹¡A ¥¥°ü¤Î­÷¨Å¥À¿ËÀ³´N¨ä¨Ï¥Î¤W¤§¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¥Ñ©ó¥»ÃÄ·|³q¹L­L½L»Ù¾À(¦ý¦b­L¨à¦å¼ß¿@«×¤£°ª)¡A¦Ó¥B¥ç·|±Æªn©ó¨Å¥Ä¤¤¡A¦]¦¹¡A ¥¥°ü¤Î­÷¨Å¥À¿ËÀ³´N¨ä¨Ï¥Î¤W¤§¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡C,AC;AC15;PC;PO;WM;,,,,,
OBRVA,Brivaracetam,Briviact 100mg,CNEU,Adjunct in partial seizures for 4 years older.,Hypersensitivity to brivaracetam or any excipient in the product,Common: Nausea and vomiting (5%)¡A Dizziness (12%)¡A Sedated¡A Somnolence¡A Fatigue (9%) Serious: Hypersensitivity reaction¡A Cerebellar ataxia¡A Impairment of balance¡A Psychiatric sign or symptom (13%)¡A Suicidal behavior¡A Suicidal thoughts¡A Bronchospasm¡A Angioedema,Àx¦s©ó25¢XC¤U,Adult (Age > 16): Initially¡A 50 mg BID (100mg/day). Maintenance and maximum dose: 25-100mg BID (50-200mg/day). Child > or = 4 years¡A > 50 kg: Initially¡A 25-50 mg BID (50-100mg/day). Maintenance and maximum dose: 25-100mg BID (50-200mg/day). Child > or = 4 years¡A 20-50 kg: Initially¡A 0.5-1 mg/kg BID (1-2mg/kg/day). Maintenance and maximum dose: 0.5-2 mg/kg BID (1-4mg/kg/day). Child > or = 4 years¡A 11-20 kg: Initially¡A 0.5-1.25 mg/kg BID (1-2.5mg/kg/day). Maintenance and maximum dose: 0.5-2.5 mg/kg BID (1-5mg/kg/day).,»Ý½Õ¾ã¾¯¶q,[¥é³æ¡G°w¹ï©Ò¦³¶¥¬qªº¨x¥\¯à¤£¥þ] ¦¨¦~»PÅé­«50¤½¤ç©Î¥H¤W¤§¨àµ£:°_©l¾¯¶q¬°25 mg¡A¨C¤é2¦¸(¨C¤é50 mg)¡A³Ì¤j¾¯¶q¬°75 mg¡A¨C¤é2¦¸(¨C¤é150 mg)¡CÅé­«11-50¤½¤ç¤§¨àµ£:°_©l¾¯¶q¬°0.5 mg/kg¡A¨C¤é2¦¸(¨C¤é1 mg/kg)¡CÅé­«20-50¤½¤ç¤§¨àµ£:³Ì¤j¾¯¶q¬°1.5 mg/kg¡A¨C¤é2¦¸(¨C¤é3 mg/kg)¡FÅé­«11-20¤½¤ç¤§¨àµ£³Ì¤j¾¯¶q¬°2 mg/kg¡A¨C¤é2¦¸(¨C¤é4 mg/kg)¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ±q¥_¬ü§ÜÅöíwÃÄª« (NAAED) §³®Wµn¿ý¸ê®Æ®w¡B«eÂ¤©Ê¹ï¦C¬ã¨s¡B¯f¨Ò³ø§i©M¨t¦C®×¨Ò©Ò±oªº¥i¥Î¼Æ¾Ú©|¤£¨¬¥H¹ïÃh¥¥¤¤¨Ï¥ÎBRIVIACT¬O§_·|¦³­«¤j¥Í´Þ¯Ê³´¡B¬y²£©Î¨ä¥L¥¥²£°ü»P­L¨à¤§¤£¨}µ²ªGªº­·ÀI¤U©w½×¡C°Êª«¸ÕÅç¤¤¡A¥ÀÅé¦å¼ßÃnÃÄ¶q°ª©óÁ{§ÉÃnÃÄ¶q®É¡A¥i¨£brivaracetam¨ãµo¨|¬r©ÊªºÃÒ¾Ú(¨ß¤l¤¤­F­L­L¨à¦º¤`²v¼W¥[¤Î­L¨àÅé­«¤U­°¡F¤j¹«¤l¥N¥Íªø½wºC¡B©Ê¦¨¼ô©µ¿ð¤Îªø´Á¯«¸g¦æ¬°ÅÜ¤Æ),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¤½¶}¤åÄm«ü¥Xbrivaracetam·|¥X²{©ó¤HÃþ¨Å¥Ä¤¤¡A¦ýbrivaracetam¹ï­÷¨ÅÀ¦¨à©Î¨Å¥Ä²£ª«²£¥Í¤§¼vÅT©|¥¼¦³¬ÛÃö¸ê®Æ¡CÀ³¦P®É¦Ò¼{­÷¨Åªºµo¨|©M°·±d®Ä¯q¥H¤Î¥À¿Ë¹ïBRIVIACTªºÁ{§É»Ý¨D»PBRIVIACT©Î¬J¦³¥ÀÅé¯f¯g¹ï­÷¨ÅÀ¦¨àªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ¤£«ØÄ³¿i¯»:¦]ÃÄª«¿i¯»«á¦³­W¨ý(¼t°Ó¦^ÂÐ2022.02.15)
IBCO2,Thiamine+Riboflavin+Nicotinamide+Pyridoxine,B-complex °w¾¯1mL,NUTR,Vit B-complex deficiency.,Hypersensitivity to any component of the formulation,Nausea¡A vomiting¡A abdominal cramps¡A pruritus¡A flushing¡A sensation of heat¡A faintness¡A pounding in the head,25¢J¥H¤U,Adult: IV/IM 1 mL once or few times a week. Each mL contains: Thiamine HCl 60mg¡A Riboflavin-5 Phosphate Sodium 3mg¡A Nicotinamide 30mg¡A Pyridoxine HCl 3mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,Thiamin:Compatible Riboflavin:Compatible Niacinamide:Compatible Pyridoxine:Compatible,Compatible ­÷¨Å®É¥i¨Ï¥Î,Thiamin:Compatible Riboflavin:Compatible Niacinamide:Compatible Pyridoxine:Compatible,IM;IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,¤åÄm¤£«ØÄ³IVPµ¹ÃÄ,Thiamine IV route: Dilute with 100 mL of N/S or D5W¡A and infuse over 30 minutes. (Micromedex),Thiamine: the risk of hypersensitivity reactions is increased with repeated IV or IM administration.(Micromedex)
OZUL,Pitavastatin,Zulitor 4mg,CAVS,Primary hypercholesterolemia and mixed dyslipidemia,Active liver disease¡A Breastfeeding¡A Concomitant use of cyclosporine¡A Hypersensitivity to pitavastatin or any other component of the product¡A Pregnancy¡A Unexplained persistent elevations of serum transaminase levels.,Common Gastrointestinal: Constipation (1.5% to 3.6% )¡A Diarrhea (1.5% to 2.6% ) Musculoskeletal: Backache (1.4% to 3.9% )¡A Myalgia (1.9% to 3.1% )¡A Pain in limb (0.6% to 2.3% ) Serious Endocrine metabolic: Disorder of glucose regulation Hepatic: ALT/SGPT level raised (0.5% )¡A AST/SGOT level raised¡A Increased liver enzymes¡A Liver failure Musculoskeletal: Disorder of muscle¡A Statin-associated¡A Increased creatine kinase level (1.9% )¡A Rhabdomyolysis,25¢J¥H¤U,Adult: 1-4 mg orally once daily. Dose adjustments should be made at intervals of 4 weeks.,»Ý½Õ¾ã¾¯¶q,¦³¨x¥\¯à»ÙÃªªº¦¨¤H¥H1mg/day¶}©l¡A³Ì¤j¤£¶W¹L2mg/day.¨x¥\¯à»ÙÃªªº¨àµ£1mg/dayµ¹ÃÄ.[¥é³æ] Active liver disease (including unexplained persistent elevations of hepatic transaminases): Use is contraindicated [Micromedex 2020/06/08],»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,[¥é³æ¸`¿ý] °w¹ïÃh¥¥¤j¹«¶i¦æ²£«e/²£«á(perinatal/postnatal)¸ÕÅç¡A......µ²ªG©Ò¦³¾¯¶q§¡¨ã¥ÀÅé¬r©Ê¡A...... ­°§C¤F¦U¾¯¶q²Õªº·s¥Í¨à¦s¬¡²v¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ]¥Ø«e¥¼ª¾Pitavastatin¬O§_·|±Æ¦Ü¤HÅé¥À¨Å¤¤¡A ¦ý¤wÃÒ¹ê¨ä¥L¦PÃþ«¬ÃÄª«¤§¨ä¤¤¤@ºØ·|¦³·L¶q±Æ¦Ü¥À¨Å¡C¤j¹«¹êÅçÃÒ¹êPitavastatin·|±Æ¦Ü¨Å¥Ä¤¤¡C ¥Ñ©ó¦PÃþ«¬ÃÄª«¤§¨ä¤¤¤@ºØ·|±Æ¦Ü¥À¨Å¡A¥BHMG-CoAÁÙ­ì§í¨î¾¯¦³¥i¯à³y¦¨­÷¨ÅÀ¦¨àªºÄY­«¤£¨}¤ÏÀ³¡A ¦]¦¹À³§iª¾»Ý­n¥HPitavastatinªvÀøªº°ü¤k¤£¥i¶i¦æ­÷¨Å©ÎÀ³°±¥ÎPitavastatin,AC;AC15;PC;PO;WM;,,,,,
ORYB,Semaglutide,Rybelsus 7mg,META,Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.,Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.,[Common] Hypoglycemia (Monotherapy¡A 1.6-3.8%; combination therapy¡A 6-30% )¡A Abdominal pain (Diabetes¡A 5.7-11% ; weight management¡A 15-20% )¡A Constipation (Diabetes¡A 3.1-6% ; weight management¡A 6-24% )¡A Diarrhea (Diabetes¡A 8.5-10% ; weight management¡A 22-30% )¡A Nausea (Diabetes¡A 11-20.3% ; weight management¡A 42-44% )¡A Vomiting (Diabetes¡A 5-9.2% ; weight management¡A 24-36% )¡A Headache (14-17% ) [Serious] Increased heart rate¡A Medullary thyroid carcinoma¡A Cholecystitis (0.6-0.8% )¡A Cholelithiasis (0.4-3.8% )¡A Pancreatitis¡A Anaphylaxis¡A Hypersensitivity reaction¡A Retinopathy due to diabetes mellitus¡A Angioedema,30¢XC¥H¤U°®ÀêÁ×¥ú³B,3 mg orally QD for 30 days¡A then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þªº¯f¤H¤£»Ý½Õ¾ã¾¯¶q¡Csemaglutide ¥Î©ó­««×¨x¥\¯à¤£¥þ¯f¤Hªº¸gÅç¦³­­¡AªvÀø®ÉÀ³¯S§OÂÔ·V¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] °Êª«¸ÕÅç¤wÃÒ¹ê¨ã¥Í´Þ¬r©Ê¡AÃh¥¥¤k©Ê¨Ï¥Î semaglutide ªº¸ê®Æ¦³­­¡A ¦]¦¹Ãh¥¥´Á¶¡¤£¥i¨Ï¥Î semaglutide¡C¦pªG¯f¤H·Q­nÃh¥¥©Î¤wÃh¥¥¡AÀ³°±¥Î semaglutide¡C ¥Ñ©ó semaglutide ªº¥b°I´Á¸ûªø¡A­pµeÃh¥¥«e¦Ü¤Ö¨â­Ó¤ëÀ³°±¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ­÷¨Å¤j¹«·|±N semaglutide¡Bsalcaprozate sodium ¤Î/©Î¨ä¥NÁÂª«³z¹L¨Å¥Ä±Æ¥X¡C ¥Ñ©óµLªk±Æ°£­÷¨ÅÀ¦¥®¨àªº­·ÀI¡A­÷¨Å´Á¶¡¤£À³¨Ï¥Î¡C,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O] ¥é³æ«ØÄ³¾ãÁû§]ªA¡C¿õ¾¯¤£À³­é¶}¡BÀ£¸H©Î©CÄZ¡A¦]¬°©|¤£²M·¡¬O§_·|¼vÅT semaglutide ªº§l¦¬¡C
ITRI1,Triamcinolone,Triamcinolone 10mg/1mL,HM,Intra-articular Inflammatory joint disease,Untreated systemic fungal¡A bacterial¡A viral or parasitic infection¡A hypersensitivity. Neonates (Parenteral),HPA axis supression¡A intracranial hypertension¡A Cushing's syndrome¡A growth retardation in children; osteoporosis¡A fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas¡A broken skin or under occlusive dressing.,25¢J¥H¤UÁ×¥ú,Adult: INS 2.5-40mg or IM 40-60mg per time¡A could inject 2-3 times if symptoms reappear. Children > 6 years: IM 30-200mcg daily to weekly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,ID;IM;INS;IVI;LI;SKIN;,,,,,
IREM,Remdesivir,Remdesivir Inj. 150mg,QANB,,,,,[UpToDate]Coronavirus disease 2019: IV: Limited data available; dosing used in clinical trials: 200 mg as a single dose on day 1¡A followed by 100 mg once daily for a total duration of 5 to 10 days. [Micromedex]COVID-19: 1) Dosage: 200 mg IV once on day 1¡A then 100 mg IV daily. 2) Duration of therapy: Until respiratory symptoms improve,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,
OHYXQ,Hydroxychloroquine,Hydroquine 200mg,QANP,,¾AÀ³¯g:Lupus erythematosus¡A Malaria¡A Malaria(Prophylaxis)¡A Rheumatoid arthritis. °Æ§@¥Î: 1% to 10%: Retinopathy (4%; serum concentration dependent; early changes reversible [may progress despite discontinuation if advanced]) Frequency not defined: Acute generalized exanthematous pustulosis¡A alopecia¡A bullous rash¡A dyschromia (skin and mucosal)¡A erythema multiforme¡A exacerbation of psoriasis¡A exfoliative dermatitis¡A hair discoloration¡A pruritus¡A skin photosensitivity¡A skin rash¡A Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A urticaria¡A Exacerbation of porphyria¡A severe hypoglycemia¡A weight loss¡A Abdominal pain¡A decreased appetite¡A diarrhea¡A nausea¡A vomiting¡A Agranulocytosis¡A anemia¡A aplastic anemia¡A bone marrow failure¡A hemolysis (in patients with glucose-6-phosphate deficiency)¡A leukopenia¡A thrombocytopenia¡AAbnormal hepatic function tests¡A acute hepatic failure¡A Angioedema¡A Drug reaction with eosinophilia and systemic symptoms¡A Ataxia¡A dizziness¡A emotional lability¡A fatigue¡A headache¡A irritability¡A nervousness¡A nightmares¡A psychosis¡A seizure¡A sensorineural hearing loss¡A suicidal tendencies¡A vertigo¡A Myopathy (including palsy or neuromyopathy¡A leading to progressive weakness and atrophy of proximal muscle groups; may be associated with mild sensory changes and loss of deep tendon reflexes)¡A Corneal changes (corneal edema¡A corneal opacity¡A corneal sensitivity¡A corneal deposits¡A visual disturbance¡A blurred vision¡A photophobia)¡A decreased visual acuity¡A macular degeneration¡A maculopathy¡A nystagmus disorder¡A retinal pigment changes¡A retinitis pigmentosa¡A scotoma¡A vision color changes¡A visual field defect¡A Deafness¡A tinnitus¡A Bronchospasm Postmarketing: Cardiomyopathy¡A prolonged QT interval on ECG¡A torsades de pointes¡A ventricular arrhythmia¡A Hypoglycemia¡A Epithelial keratopathy. ¸T§Ò: Known hypersensitivity to hydroxychloroquine¡A 4-aminoquinoline derivatives¡A or any component of the formulation. Retinopathy,,«Ç·Å25«×C¥H¤U,Systemic lupus erythematosus: Oral: 200 to 400 mg daily. Due to the risk of retinal toxicity¡A most patients should not receive a daily dose >6.5 mg/kg/day using ideal body weight or 400 mg. Discoid lupus erythematosus and subacute cutaneous lupus erythematosus: For use if response to local therapy is inadequate or impractical due to widespread skin lesions.Oral: 200 to 400 mg daily. Due to the risk of retinal toxicity¡A most patients should not receive a daily dose >6.5 mg/kg/day using actual body weight or 400 mg¡A whichever is lower. Malaria: Initial¡A 800 mg orally for 1 dose followed by 400 mg at 6~8¡A 24¡A and 48 hours after the initial dose (total dose: 2g). Another way of weight-based dosage: 12.9 mg/kg (MAX¡A 800 mg) orally for 1 dose¡A followed by 6.5 mg/kg (MAX¡A 400 mg) orally at 6¡A 24¡A and 48 hours after the first dose. [Micromedex] Malaria; Prophylaxis: 400 mg orally once weekly on the same day each week beginning 2 weeks prior to travel to malarious area¡A continue on same day each week while in area and for 4 weeks after leaving area. Another way of weight-based dosage: 6.5 mg/kg (MAX 400 mg) orally once weekly on the same day each week beginning 2 weeks prior to travel to malarious area¡A continue on same day each week while in area and for 4 weeks after leaving area.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling; use with caution.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ] ¥»ÃÄ·|³q¹L­L½L¡AÃh¥¥®É¨Ï¥Îªº¸ê®Æ¦³­­¡A ¦ý¦bªvÀø¾¯¶q¤U¨Ï¥Î4-aminoquinolones·|³y¦¨¤¤¼Ï¯«¸gªº·l¶Ë¡A¥]¬A¦Õ¬r©Ê¡Aµøºô½¤¥X¦å¡A ¤£¥¿±`ªºµøºô½¤¦â¯À¨I¿n. ¦]¦¹Ãh¥¥®É¤£À³¨Ï¥Î,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ±Â¨Å´Á¶¡¦p±ý¨Ï¥Î¥»ÃÄÀ³¥J²Ó¦Ò¼{¡A¦]¬°¦³¤Ö¶q¥»ÃÄ·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡A ¦ÓÀ¦¨à¹ï4-aminoquinolonesªº¬r©Ê¬Û·í±Ó·P.,PC;PO;WM;,,,,,
ICISA2,Cisatracurium,Cisatracurium inj 10mg/5mL (±M®×),CNEU,,¾AÀ³¯g:Muscle relaxation during surgical procedures eg cardiac surgery¡A other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU¡A to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation. °Æ§@¥Î:Bradycardia¡A hypotension. Rarely cutaneous flushing¡A bronchospasm¡A rash. ¸T§Ò:Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol),,2-8¢XC,IV bolus Tracheal intubation Adult Initially 0.15 mg/kg over 5-10 sec. Maintenance: 0.03 mg/kg. Childn 1 mth-12 yr Same as adult dose. Maintenance: 0.02 mg/kg. IV infusion Adult & childn 1 mth-12 yr Maintenance of neuromuscular block 3 mcg/kg/min to restore 89-99% T1 suppression then 1-2 mcg/kg/min to maintain block in this range.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,¥H¤WÃh¥¥¤À¯Å¬°: UpToDate¸ê®Æ¡C,IVD;IVP;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,IVP¿éª`®É¶¡»Ý5-10sec (®ðºÞ¤º´¡ºÞ),IVDµ¹ÃÄ³t²v¬°0.03-0.6 mg/kg/hr (µ¹ÃÄ¿@«× 0.1-2 mg/mL) Maintenance infusion in ICU¡A 3 mcg/kg/min IV infusion (range of 0.5 to 10.2 mcg/kg/min due to interpatient variability).,1.¶È¨ÑÀR¯ßµ¹ÃÄ¡C 2.µ¹ÃÄ¿@«× 0.1-2 mg/mL¡C 3.¥»«~»Ý§NÂÃÁ×¥ú¶J¦s 4.¤£¥i»PÆP©Ê·»²G²V¦X 5.­­¨Ï¥Î¤H¤u©I§l¾¹ªvÀø¯f±w¨Ï¥Î
INPH,Insulin NPH,Insulin Insulatard HM 100U/mL 10mL,META,,¾AÀ³¯g: Treatment of type 1 diabetes mellitus (insulin dependent¡A IDDM) and type 2 diabetes mellitus (noninsulin dependent¡A NIDDM) to improve glycemic control. °Æ§@¥Î: Primarily symptoms of hypoglycemia. Pallor¡A palpitation¡A tachycardia¡A Fatigue¡A headache¡A hypothermia¡A loss of consciousness¡A mental confusion¡A Redness¡A urticaria¡A Hypoglycemia¡A hypokalemia¡A Hunger¡A nausea¡A numbness of mouth¡A Atrophy or hypertrophy of SubQ fat tissue; edema¡A itching¡A pain or warmth at injection site; stinging¡A Muscle weakness¡A paresthesia¡A tremor¡A Transient presbyopia or blurred vision¡A Anaphylaxis¡A diaphoresis¡A local and/or systemic hypersensitivity reactions. ¸T§Ò: Hypersensitivity to insulin NPH or any component of the formulation,,2 ~ 8 ¢XC,According to individual requirements.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,SC;,,,,,
IELO,Corifollitropin alfa,Elonva inj 150mcg/0.5mL,HM,Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.,Hypersensitivity to the active substance or to any of the excipients. Tumors of the ovary¡A breast¡A uterus¡A pituitary or hypothalamus. Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. Primary ovarian failure. Ovarian cysts or enlarged ovaries. Fibroid Tumors of the uterus incompatible with pregnancy. Malformations of the reproductive organs incompatible with pregnancy. Pregnancy (see Use in Pregnancy & Lactation). Risk factors of OHSS: A history of Ovarian Hyperstimulation Syndrome (OHSS); A previous COS cycle that resulted in more than 30 follicles > or = 11 mm measured by ultrasound examination; A basal antral follicle count > 20; Polycystic ovarian syndrome (PCOS).,Common Gastrointestinal: Nausea (2.3% ) Musculoskeletal: Discomfort¡A In pelvis (6% )¡A Pain in pelvis (2.9% ) Neurologic: Headache (4% ) Reproductive: Breast tenderness (1.3% ) Other: Fatigue (1.5% ) Serious Reproductive: Ovarian hyperstimulation syndrome (4.3% )¡A Torsion of ovary (0.1% to less than 1% ),2-8¢J¡A¤Å§N­á,In the treatment of women of reproductive age¡A the dose of Elonva is based on weight and age. A single 100-microgram dose is recommended in women who weigh less than or equal to 60 kilograms and who are 36 years of age or younger. A single 150-microgram dose is recommended in women: who weigh more than 60 kilograms¡A regardless of age; who weigh 50 kilograms or more and who are older than 36 years of age. Women older than 36 years of age who weighed less than 50 kilograms were not studied. The recommended doses of Elonva have only been established in a treatment cycle with a GnRH antagonist that was administered from stimulation day 5 or day 6 onwards. Stimulation day 1: Elonva should be administered as a single subcutaneous injection¡A preferably in the abdominal wall¡A during the early follicular phase of the menstrual cycle. Stimulation day 5 or 6: Treatment with a Gonadotropin Releasing Hormone (GnRH) antagonist should be started on stimulation day 5 or day 6 depending on the ovarian response¡A i.e. the number and size of growing follicles. The concurrent determination of serum estradiol levels may also be useful. The GnRH antagonist is used to prevent premature Luteinizing Hormone (LH) surges. Stimulation day 8: Seven days after the injection with Elonva on stimulation day 1¡A COS treatment may be continued with daily injections of (recombinant) Follicle Stimulating Hormone ((rec)FSH) until the criterion for triggering final oocyte maturation (3 follicles > or = 17 mm) has been reached. The daily dose of (rec)FSH may depend on the ovarian response¡A which should be monitored by regular ultrasonographic assessments from stimulation day 5 or 6 onwards. In normal responders a daily dose of 150 IU (rec)FSH is advised. Administration of (rec)FSH on the day of human Chorionic Gonadotropin (hCG) administration can be omitted¡A depending on the ovarian response. In general¡A adequate follicular development is achieved on average by the ninth day of treatment (range 6 to 18 days). As soon as three follicles > or = 17 mm are observed¡A a single injection of 5¡A000 up to 10¡A000 IU urinary hCG is administered the same day or the day thereafter to induce final oocyte maturation. In case of an excessive ovarian response¡A see the recommendations given in Precautions in order to reduce the risk for developing ovarian hyperstimulation syndrome (OHSS).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Elonva¤£¥i¨Ï¥Î©óÃh¥¥°ü¤k¡C ­Y¦bÃh¥¥´Á¶¡¤£¤p¤ß±µÄ²¨ìElonva®É¡A²{¦³ªºÁ{§É¸ê®Æ¨Ã¤£¨¬¥H±Æ°£µo¥ÍÃh¥¥¤£¨}µ²ªGªº¥i¯à©Ê¡C ¦b°Êª«¬ã¨s¤¤´¿Æ[¹î¨ì¥X²{¥Í´Þ¨t²Î¬r©Êªº²{¶H,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¦bÁý­÷¥À¨Å´Á¶¡¤£¾A¦X¨Ï¥ÎElonva¡C,SC;,,,,,½Ð¶J¦s©ó¦B½c¤¤(2¢XC-8¢XC)¡C¬°¤è«K¨Ï¥Î°_¨£¡A¯f¤H¥i±N¥»«~¦s©ñ25¢XC©Î(§t)¥H¤Uªº·Å«×¡A¦ý¤£¥i¶W¹L1­Ó¤ë¡C ¤Á¤Å§N­á¡C
OACZ,Der pte extract + Der far extract,Acarizax 12 SQ-HDM (30 tablets/box),HIMM,House dust mite-induced allergic rhinitis for 12-65 years old patients.,Hypersensitivity to any of the excipients. Patients with FEV1 <70% of predicted value (after adequate pharmacological treatment) at initiation of treatment. Patients who have experienced a severe asthma exacerbation within the last 3 months. In patients with asthma and experiencing an acute respiratory tract infection¡A initiation of ACARIZAX treatment should be postponed until the infection has resolved. Patients with active or poorly controlled autoimmune diseases¡A immune defects¡A immunodeficiencies¡A immunosuppression or malignant neoplastic diseases with current disease relevance. Patients with acute severe oral inflammation or oral wounds.,Common Gastrointestinal: Itching¡A in the mouth (63.1% )¡A Lip swelling (18% )¡A Tongue swelling (15.8% )¡A Uvulitis (19.8% ) Otic: Itching of ear (51.7% ) Respiratory: Throat irritation (67% ) Serious Gastrointestinal: Eosinophilic esophagitis (0.07% ) Immunologic: Allergic reaction Respiratory: Airway constriction¡A Asthma,¤£¶W¹L30 ¢XC,Usual dosage: 1 tablet (12 SQ-HDM) daily. Without swallowing for at least 1 minute¡A and with no food or beverage for 5 minutes. If the treatment is interrupted for more than 7 days it is recommended to contact a physician before resuming the treatment. Active ingredient: Der pte extract (Dermatophagoides pteronyssinus)¡A Der far extract (Dermatophagoides farinae),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|¥¼¦³Ãh¥¥°ü¤k¨Ï¥Îªü§J¥ß¦Þ¤U¿õªºÁ{§É¸ê®Æ¡C °Êª«¹êÅç¤¤¡A¨Ï¥Îªü§J¥ß¦Þ¤U¿õ©|¥¼µo²{¦³¼W¥[­L¨à¦M®`ªº­·ÀI¡C Ãh¥¥´Á¶¡¤£À³¨Ï¥Îªü§J¥ß¦Þ¤U¿õ¡C­Y¦bªü§J¥ß¦Þ¤U¿õªvÀø´Á¶¡Ãh¥¥¡A¥i¸g¥Ñµû¦ô¯f¤H¨­Åéª¬ªp(¥]§tªÍ¥\¯à) ¥H¤Î¯f¤H¥ý«e¨Ï¥Îªü§J¥ß¦Þ¤U¿õªº¤ÏÀ³±¡ªp¡A¦Ó¨M©wÄ~Äò¥ÎÃÄ¡C «ØÄ³¦³®ð³Ý¯f¥vªº¯f¤H¡AÀ³©óÃh¥¥´Á¶¡±K¤ÁºÊ´ú¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|¥¼¦³¦bªü§J¥ß¦Þ¤U¿õªvÀø´Á¶¡±Â¨ÅªºÁ{§É¸ê®Æ¡C ¹w´Á±Â¨ÅÀ¦¨à¥i¤£¨üªü§J¥ß¦Þ¤U¿õªº¼vÅT¡C,SL;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¦Þ¤U¿õ¡A¥Ø«e¬ÛÃöÁ{§É¬ã¨s¬Ò¥H¦Þ¤Uµ¹ÃÄ¡A¥¼¸g¥Ñ¦Þ¤Uµ¹ÃÄªºÀø®Ä»P¦w¥þ©ÊµLªkÃÒ¹ê¡C¥é³æ«ØÄ³¥Îªk:¥´¶}ªü§J¥ß¦Þ¤U¿õªº¥]¸Ëªw´ß¡AÀ³¥ß§Y¥Î°®Àêªº¤â«ü±N¤fªA¿õ©ñ¤J¦Þ¤U¥O¨ä·»¸Ñ¡CÀ³Á×§K¦b¤j¬ù1¤ÀÄÁ¤º§]ªA¡C±µ¤U¨Ó5¤ÀÄÁ¤º¤£¥i¥H¦YªF¦è©Î³Ü¶¼®Æ¡C
OATM25,Atomoxetine,apo-ATOMOXETINE 25mg,CNEU,Attention deficit hyperactivity disorder.,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma¡A current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg¡A 15 to 20 mm Hg) or heart rate (eg¡A 20 beats per minute),Common: Increased heart rate (Adult¡A 10.2-22.4%; pediatric¡A 12.2-23.4%)¡A Weight decreased (Adult¡A 2%; pediatric¡A 3%)¡A Abdominal pain (Adult¡A 7%; pediatric¡A 18%)¡A Constipation (Adult¡A 8%; pediatric¡A 1-2%)¡A Decrease in appetite (Adult¡A 16%; pediatric¡A 16%)¡A Nausea (Adult¡A 26%; pediatric¡A 10%)¡A Vomiting (Adult¡A 4%; pediatric¡A 11%)¡A Xerostomia (Adult¡A 20%)¡A Dizziness (Adult¡A 8%; pediatric¡A 5%)¡A Headache (Pediatric¡A 19%)¡A Insomnia (Adult¡A 15%; pediatric¡A at least 2%)¡A Somnolence (Adult¡A 8%; pediatric¡A 11%)¡A Delay when starting to pass urine (Adult¡A 6%)¡A Dysmenorrhea (Adult¡A 3%)¡A Erectile dysfunction (Adult¡A 8%)¡A Fatigue (Adult¡A 10%; pediatric¡A 8%) Serious: Increased diastolic arterial pressure (Adult¡A 4.8-12.6%; pediatric¡A 9.3-21.5%)¡A Increased systolic arterial pressure (Adult¡A 4.2-12.4%; pediatric¡A 4.9-12.5%)¡A Myocardial infarction¡A Sudden cardiac death¡A Tachycardia (Adult¡A 1.5%; pediatric¡A 0.3%)¡A Injury of liver (Severe)¡A Liver failure¡A Cerebrovascular accident¡A Aggressive behavior¡A Hostile behavior¡A Mania¡A Psychotic disorder¡A Suicidal thoughts (Pediatric¡A 0.4%)¡A Priapism,Àx¦s©ó25¢J¥H¤U,6 years or older¡A up to 70 kg: Acute treatment: Initial¡A approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily¡A as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day¡A whichever is less 6 years or older¡A greater than 70 kg: Acute treatment: Initial¡A 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks;Maximum 100 mg daily,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤«×ªº¨x¥\¯à¤£¥þ¯f±w(Child-Pugh Class B)¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 50¢H¡C ±w¦³ÄY­«¨x¥\¯à¤£¥þ(Child-Pugh Class C)ªº¯f±w¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 25¢H¡C,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ¦bÃh¥¥¨ß¤lªº¾¹©x§Î¦¨´Á¶¡¡AÁý­¹¾¯¶q³Ì°ª¦Ü 100 mg/ kg/ day ªºAtomoxetine¡C¦b¤T½g¬ã¨s¤¤ªº¤@½g¡AÆ[¹î¨ì¬¡­L¼Æ´î¤Ö¡A¦­´Á¦A§l¦¬¼W¥[¡C¤£¥¿±`ÀV°Ê¯ß°_·½¤Î¯Ê¤ÖÂê°©¤U°Ê¯ßªºµo¥Í²vµy·L¼W¥[¡C³o¨Çµ²ªGµo²{©ó·|¤Þ°_»´·L¥ÀÅé¬r©Êªº¾¯¶q¡C ³o¨Çµ²ªGªºµL§@¥Î¾¯¶q¡]no-effect dose¡^¬° 30 mg/ kg/ day¡C¥Hmg/ m2­p¡A100 mg/ kg ªº¾¯¶q¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 23 ­¿¡A¨ß¤l¦å¤¤ªº Atomoxetine¿@«×¡]AUC¡^¦ô­p¬°±µ¨ü³Ì°ª¤HÅé¾¯¶qªº¤HÅé¤ºªº 3.3 ­¿¡]§Ö³t¥NÁÂªÌ¡^©Î 0.4 ­¿¡]½wºC¥NÁÂªÌ¡^¡C ±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î 10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨¤Î­÷¨Å´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J¤£¶W¹L¤j¬ù 50 mg/ kg/ day ªº atomoxetine¡]¥H mg/ m2­pºâ¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 6 ­¿¡^¡C ¦b¤G½g¬ã¨sªº¨ä¤¤¤@½g¡Aµo²{¤p¹«Åé­«¤Î¦s¬¡¼Æ´î¤Ö¡C¦b 25 mg/ kg¡]«D 13 mg/ kg¡^¡A¤]µo²{¨ì¤p¹«ªº¦s¬¡´î¤Öªº²{¶H¡C ¤@½g±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J Atomoxetine ªº¬ã¨s¤¤¡A40mg/ kg/ day¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 5 ­¿¡^¡Aµo²{¨ì­L¹«Åé­«´î¤Ö¡]¶È¥À¹«¡^¤Î´Õ°©¤}¡]vertebral arch¡^¤£§¹¥þ¦¨°©ªºµo¥Í²v¼W¥[ªº²{¶H¡A¦¹²{¶H¨Ã¨S¦³¦b 20 mg/ kg/ day ¾¯¶q²Õ¤¤µo²{¡C ¦b¾¹©x§Î¦¨´Á¶¡¡A¥H 150 mg/ kg/ day ªº¾¯¶q¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº17 ­¿¡^Áý­¹Ãh¥¥¥À¹«¡A­L¨à¨Ã¥¼¥X²{¥ô¦óªº°Æ§@¥Î¡C ¥Ø«e©|µLÃö©óÃh¥¥°ü¤k¤§¥R¤À¤Î§¹¾ãªº¹ï·Ó©Ê¬ã¨s¡C Ãh¥¥´Á¶¡¤£¥iªA¥Î Atomoxetine¡A°£«D®Ä¯q¶W¹L­L¨à¥i¯à²£¥Íªº­·ÀI©Ê¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Atomoxetine ¤Î/ ©Î¨ä¥NÁÂª«·|¤Àªc¦Ü¦Ñ¹«ªº¨Å¥Ä¤¤¡C Atomoxetine ¬O§_·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤«h¥¼ª¾¡C ­÷¨Å¤¤ªº°ü¤k­YªA¥Î Atomoxetine ®É¡AÀ³¥[¥Hª`·N¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½Ð¾ãÁû½¦Ån§]ªA¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¥»ÃÄ¯»¥½¨ã¦³²´³¡¨ë¿E©Ê¡C
IINVZ,Ertapenem,InVanZ inj 1gm,QANB,Treatment of moderate to severe infections caused by susceptible strains of microorganisms as well as initial empiric therapy prior to identification of causative organisms in complicated intra-abdominal infections; complicated skin & skin structure infections¡A including diabetic foot infections w/o osteomyelitis; community acquired pneumonia; complicated UTI including pyelonephritis; acute pelvic infections¡A including postpartum endomyometritis¡A septic abortion & post surgical gynecologic infections. Prophylaxis of surgical site infection following elective colorectal surgery in adults.,Anaphylactic reaction to beta-lactam antibiotics. Hypersensitivity to amide-type local anesthetics due to lidocaine hydrochloride used as a diluent with IM route only. Hypersensitivity to ertapenem sodium or to any other component of the product or other drugs in the carbapenem class.,Common Gastrointestinal: Abdominal pain (Adult¡A 3.6% to 4.3%; Pediatric¡A 4.7% )¡A Constipation (Adult¡A 3.3% to 4%; pediatric¡A 2.3% )¡A Diarrhea (Adult¡A 9.2% to 10.3%; Pediatric¡A 11.7% )¡A Nausea ( Adult¡A 6.4% to 8.5%; pediatric¡A 1.6% )¡A Vomiting (Adult¡A 3.7% to 4%; Pediatric¡A 10.2%) Hematologic: Neutrophil count abnormal (5.8% ) Neurologic: Headache (5.6% to 6.8% ) Reproductive: Vaginitis (1.4% ) Serious Neurologic: Seizure (0.5% ) Dermatologic: Stevens-Johnson Syndrome¡A Toxic Epidermal Necrolysis,¤£¥i¶W¹L25¢XC,Adult & children > or = 13 years: 1 g QD IM or IVD. 3 months-12 years: 15 mg/kg QD¡A maximum 1 g/day. IM or IVD. [The Sanford Guide to Antimicrobial Therapy 2021] Pediatric dose: Age>28 days: 30mg/kg/day¡A divided Q12H¡A the maximum dose: 1g/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ] ¥Ø«e©|µL¦³ÃöÃh¥¥°ü¤k¤§¾A·í¤Î³]­p¨}¦nªº¹ï·Ó¸ÕÅç¡C ¶È¦³¦b¹ï¥ÀÅé¤Î­L¨àªº¼ç¦b¯q³B¤j©ó¦MÀI©Ê®É¡A¤~¥i¦bÃh¥¥´Á¶¡¨Ï¥ÎINVANZ¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«eErtapenem·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C ·í±Â¨Å°ü¤k±µ¨üINVANZªvÀø®É¡A¥²¶·ÂÔ·V¤p¤ß¡C,IM;IVD;,10mLªºª`®g¥Î¤ô©Î0.9%´â¤Æ¶uª`®g²G,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,ÀR¯ß¿éª`®É¶¡>30¤ÀÄÁ¡C ¦~ÄÖ>13·³: ¥[¤J10mLªºª`®g¥Î¤ô©Î0.9%´â¤Æ¶uª`®g¡A¥R¤À·n°Ê¨ÏÃÄ«~·»¸Ñ¨Ã¥ß¨è±N·»²G²¾¨ì50mLªº0.9%´â¤Æ¶uª`®g²G¤¤¡A¸gµ}ÄÀªºÃÄ«~¥²¶·¦b6¤p®É¤º§¹¦¨¿éª`¡C 3­Ó¤ë¦Ü12·³: ¥[¤J10mLªºª`®g¥Î¤ô©Î0.9%´â¤Æ¶uª`®g¡A¥R¤À·n°Ê¨ÏÃÄ«~·»¸Ñ¨Ã¥ß¨è©â¨úÅé¿n¬Û·í©ó15mg/¤½¤çÅé­«ªº·»²G(¤£¶W¹L1gm/¤Ñ)¡A¥H0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ¦¨¿@«×¬°20mg/mL©Î§óµ}¡A¸gµ}ÄÀªºÃÄ«~¥²¶·¦b6¤p®É¤º§¹¦¨¿éª`¡C [Micromedex 20211005] IV infusion should be administered over 30 minutes and completed within 6 hours of reconstitution.,°®¯»¸g·»¸Ñ¨Ã¥H0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ«á¥i«Ç·Å(25¢XC)6¤p®É¤º¨Ï¥Î¡A¤]¥i§NÂÃ(5¢XC)¦Ü¦h24¤p®É¡A¦Û§NÂÃ¨ú¥X«á¶·©ó4¤p®É¤º¨Ï¥Î¡C ¤£¥i¥H¨Ï¥Î§t¦³¸²µå¿}ªºµ}ÄÀ²G¡C ¦Ù¦×ª`®gªº·Ç³Æ¨BÆJ: ¦~ÄÖ>13·³:¥[¤J3.2mLªº1%©Î2%¤§lidocaine HClª`®g²G(¤£§tepinephrine)¡C¥R¤À·n°Ê·»¸Ñ¦¨·»²G¡A¥H²`³¡¦Ù¦×ª`®gªº¤è¦¡±NÃÄ«~ª`¤J¨ì¤j¦Ù¦×³¡¦ì(¨Ò¦pÁv³¡¦Ù¦×©Î¤j»L°¼Ãä¦Ù¦×)¡C·»²G¶·¦b1¤p®É¤º¨Ï¥Î¥B¤£¥iÀR¯ß§ë. ­Y¥Î©ó3­Ó¤ë¦Ü12·³:¬I¥´Åé¿nÀ³¬°15mg/¤½¤çÅé­«(¤£¶W¹L1gm/¤Ñ)ªº·»²G.
ONER,Neratinib,Nerlynx 40 mg (180 tablets/bot),RACA,Breast cancer¡A Extended adjuvant¡A early stage¡A HER2-positive¡A following adjuvant trastuzumab based therapy.,None.,Common Dermatologic: Rash (18% ) Endocrine metabolic: Weight decreased (5% to 20% ) Gastrointestinal: Abdominal pain (36% )¡A Constipation (31% )¡A Decrease in appetite (12% to 35% )¡A Diarrhea (78% to 98% )¡A Indigestion (10% )¡A Nausea (43% to 53% )¡A Stomatitis (14% )¡A Vomiting (26% to 46% ) Hepatic: ALT/SGPT level raised (9% )¡A Aspartate aminotransferase serum level raised (7% ) Musculoskeletal: Spasm (11% ) Neurologic: Dizziness (14% ) Other: Fatigue (27% to 45% ) Serious Renal: Renal impairment (7% ),Àx¦s©ó«Ç·Å30¢XC¥H¤U,Adjuvant treatment of HER2-positive early carcinoma of breast: As extended adjuvant treatment in patients who completed adjuvant trastuzumab-based therapy: 240 mg once daily¡A given continuously until disease recurrence or for up to 1 year. Antidiarrheal prophylaxis is recommended during the first 56 days of therapy; initiate with the 1st neratinib dose. Dose reduction¡A dosing interruption¡A or discontinuation may be required according to individual safety or tolerability. HER2-positive advanced carcinoma of breast¡A HER2-positive metastatic carcinoma of breast: In patients who have received > or = 2 prior anti-HER2 based regimens in the metastatic setting: 240 mg once daily on days 1-21 of a 21-day cycle; given with capecitabine on days 1-14 of a 21-day cycle¡A until disease progression or unacceptable toxicity. Antidiarrheal prophylaxis is recommended during the first 56 days of therapy; initiate with the 1st neratinib dose. Dose reduction¡A dosing interruption¡A or discontinuation may be required according to individual safety or tolerability. Nerlynx Dose Modifications for Adverse Reactions (Dose Level and Nerlynx Dose): Recommended starting dose: 240 mg daily; First dose reduction: 200 mg daily; Second dose reduction: 160 mg daily; Third dose reduction: 120 mg daily.,»Ý½Õ¾ã¾¯¶q,­««×¨x¥\¯à¤£¥þ(Child Pugh C¯Å)ªº¯f¤H¶·­°§CNERLYNXªº°_©l¾¯¶q¦Ü80 mg¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]®Ú¾Ú°Êª«¸ÕÅçªºµo²{¤Î¨ä§@¥Î¾÷Âà¡ANERLYNX§ë¤©Ãh¥¥¤k©Ê®É¥i¯à¹ï­L¨à³y¦¨¶Ë®`¡C ¥Ø«e¨ÃµLNERLYNX¥Î©óÃh¥¥¤k©Êªº¸ê®Æ¥i±oª¾ÃÄª«¬ÛÃö­·ÀI¡C ¦b°Êª«¥Í´Þ¸ÕÅç¤¤¡A¦b¾¹©xµo¥Í´Á¶¡(organogenesis)¹ïÃh¥¥¨ß¤l§ë¤©neratinib¡A¦b°Êª«¥ÀÅéÃnÃÄ¶q(¦±½u¤U­±¿n)¬ù¬°±µ¨ü«ØÄ³¾¯¶q¤§¯f¤Hªº0.2­¿¤§¤U¡Aneratinib¾É­P¨ß¤lµo¥Í¬y²£¡B­F­L-­L¨à¦º¤`»P­L¨à²§±`¡C À³§iª¾Ãh¥¥¤k©Ê¦³ÃöNERLYNX¹ï©ó­L¨àªº¼ç¦b­·ÀI¡C °w¹ï¾AÀ³¯g±Ú¸s¡A¨ä­«¤j¥ý¤Ñ¯Ê³´»P¬y²£ªº­I´º­·ÀI¥Ø«e¤£©ú¡CµM¦Ó¡A¦b¬ü°êªº¤@¯ë±Ú¸s¤¤¡AÁ{§É»{ª¾Ãh¥¥ªº­«¤j¥ý¤Ñ¯Ê³´­I´º­·ÀI¬°2%¦Ü4%¡A¦Ó¬y²£«h¬°15%¦Ü20%¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Ãö©óneratinib©Î¨ä¥NÁÂª«¥X²{¦b¤HÃþ¨Å¥Ä¤¤¡A©Î¨ä¹ï­÷¨Å¤¤À¦¨à©Î¨Å¥Ä²£¥Íªº¼vÅT¡A¥Ø«e¨ÃµL¬ÛÃö¸ê®Æ¡C ¥Ñ©ó­÷¨Å¤¤À¦¨à¥i¯à¦]NERLYNX¦Óµo¥ÍÄY­«¤£¨}¤ÏÀ³¡AÀ³«ü¥Ü­÷¨Å¤k©Ê¦bªA¥ÎNERLYNX´Á¶¡¥H¤Î³Ì«á¤@¾¯ÃÄª««á¦Ü¤Ö1­Ó¤ë¤º¤£±o­÷¨Å¡C,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¥é³æ«ØÄ³À³¾ã¿õ§]ªA¡A¤£¥i«r¸H©Î¼·¥b¡C
EACG,Test Strips,Accu-Chek Guide 50 strips(Ã¹¤ó´¼¯è),ZOTH,For use with the Accu-Chek Guide Meter¡A Accu-Chek Guide Link Meter¡A and Accu-Chek Guide Me Meter to measure the blood glucose.,,,4-30¢J¡AÀã«×10-90%¡F½Ð¤Å§N­á¡BÁ×§K¼ÉÅS©ó°ª·Å¼éÀã³B,For use with the Accu-Chek Guide Meter¡A Accu-Chek Guide Link Meter¡A and Accu-Chek Guide Me Meter to measure the blood glucose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,¼t°Ó«ØÄ³¤Å±N¥»²£«~¸m©ó¦B½c©Î¨¾¼é½c¡A¦]©ö²£¥ÍÀã«×ÀWÁcÅÜ¤Æ¡C
EEFU,Metronidazole,Efucon gel 0.75%¡A 15gm,TDER,Topical treatment of inflammatory papules¡A pustules & erythema of rosacea.,Hypersensitivity to metronidazole.,xeroderma¡A Erythema¡A burning sensation of skin,25¢J¥H¤U,Rosacea: 0.75%: Apply and rub a thin film twice daily¡A morning and evening¡A to entire affected areas after washing.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ]¥¥°ü°£«D¥²­n¡A¥BÀ³¤p¤ß¨Ï¥Î.,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Hold Breastfeeding (Single Dose) Limited Human Data¡XPotential Toxicity (Divided Dose) [¥é³æ]µL¬ÛÃö¬ö¸ü.,EXT;,,,,,
IKET2,Ketamine,Ketamine-hameln inj 500mg/10mL(±M®×¶i¤f),ZANE,Anaesthetic agent in adults and children: - for induction and maintenance of general anaesthesia¡A if applicable in com- bination with sleep medication (hypnotic agents)¡A - supplementary to other anaesthetics in local anaesthesia¡A - for anaesthesia and pain treatment (analgesia) in emergency medicine¡A - for treatment of frequent and persistent attacks of dyspnoea (treatment- resistant status asthmaticus)¡A - for treatment of pain during mechanical ventilation (intubation).,- Patients with hypersensitivity to ketamine or any of the excipients - Elevation of blood pressure or intracranial pressure forms a serious risk - Poorly controlled or untreated high blood pressure (arterial hypertension¡A systolic/diastolic resting blood pressure above 180/100 mmHg) - High blood pressure caused by pregnancy¡A with protein excretion in the urine (preeclampsia) and seizures (eclampsia) - Untreated or poorly treated overactive thyroid (hyperthyroidism) - Situations which require relaxed uterus myometrium e.g. threatening uterus rupture¡A prolapsed umbilical cord - When used as sole anaesthetic agent in patients with manifest ischaemic cardiac disorders,Common: Hypertension¡A Increased cardiac index¡A Tachycardia¡A Emergence from anesthesia¡A Psychiatric sign or symptom (12-50%) Serious: Bradyarrhythmia¡A Cardiac dysrhythmia¡A Hypotension¡A Anaphylaxis¡A Apnea¡A Laryngeal spasm¡A Pulmonary edema¡A Respiratory depression,Á×¥úÀx¦s©ó25¢XC ¥H¤U¡C¤£¥i§N­á¡C,For induction of general anaesthesia: 1-2 mg/kg IV or 4-8 mg/kg IM. To maintain general anaesthesia¡A half of the initial dose is injected as needed¡A generally every 10-15 minutes. Continuous infusion: 1-6 mg/kg/hr. The dose should be reduced in cases of multiple injuries (polytrauma) or with patients in poor general condition. To supplement local anaesthetic agents¡A 0.25-0.5 mg/kg PRN. For analgesia during mechanical ventilation (intubated intensive-care patients)¡A usually 0.5 mg/kg as bolus¡A with subsequent continuous infusion of 0.4-1 (up to 3) mg/kg/hr with simultaneous administration of a benzodiazepine. Treatment should not extend beyond 4 to 6 weeks. For anaesthesia in emergency medicine¡A 0.5-1 mg/kg IM or 0.25-0.5 mg/kg IV. For the treatment of frequent and persistent dyspnoea (treatment-resistant status asthmaticus)¡A 1-2 (up to 5) mg/kg IV.,»Ý½Õ¾ã¾¯¶q,A prolonged duration of action may occur in patients with cirrhosis or other types of liver impairment. Dose reductions should be considered in these patients.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] Animal reproduction studies are insufficient¡A but available data do not indicate any adverse effects on pregnancy¡A embryo-foetal development¡A parturition or postnatal development. The potential risk for humans is unknown. Use of ketamine should be restricted during pregnancy and only administered after consideration if the potential benefits for the mother outweighs the possible hazard for the child. Ketamine crosses the placental barrier. If doses higher than 2 mg IV per kg body weight are applied¡A respiratory depression in the new-born must be expected.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Ketamine is excreted into breast milk¡A but an effect on the child seems unlikely when using therapeutic doses.,IM;IVD;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,Administer slowly IV over 60 seconds [Micromedex],dilute in N/S or D5W to a final concentration of 1 or 2 mg/mL [Micromedex] Continuous infusion: 1-6 mg/kg/hr; 0.4-3 mg/kg/hr with simultaneous administration of a benzodiazepine. [¥é³æ],1. Storage: [Opened vials] 28 days at 20-25¢XC after the first opening; [Prepared infusion solutions] Use immediately. If not¡A normally not be longer than 24 hours at 2-8¢XC. 2. ¤£¥i»Pbarbiturates¡A benzodiazepines (e.g. diazepam)¡A 4-hydroxybutyric acid (sodium salt)¡A theophylline¡A furosemide sodium or sodium hydrogen carbonate ²V©M¡A·|²£¥Í¨I¾ý¡C
ELAD,Estradiol,Ladiol Gel 0.6mg/gm¡A 30gm,HM,Natural or surgical menopause¡A estrogen deficiencies; vasomotor disorders associated with menopause; tropic disorders caused by disturbances in ovarian secretions as in vag atrophy¡A kraurosis vulvae¡A female hypogonadism¡A castration in women¡A primary ovarian deficiency.,Malignant tumors of the breast or uterus. Pituitary tumors.,Cardiovascular: Edema (transdermal system¡A 0.5% to 13% ) Dermatologic: Application site irritation (transdermal spray¡A 1.3% ; transdermal system¡A 5.7% to 56.7% )¡A Chloasma¡A Hirsutism¡A Persistent erythema of skin (transdermal patch¡A 17% )¡A Pruritus (topical emulsion¡A 4% ; topical gel¡A 4.8% ) Endocrine metabolic: Weight change finding Gastrointestinal: Bloating symptom¡A Nausea¡A Vomiting Neurologic: Migraine Psychiatric: Depression (transdermal system¡A 1% to 8% )¡A Disturbance in mood Reproductive: Breast tenderness (topical gel¡A 2.5% to 8.8% ; transdermal spray¡A 5% to 7% ; transdermal system¡A 6.5% to 17.0% )¡A Disorder of menstruation¡A Leukorrhea¡A Swelling of breast¡A Vaginal discomfort (vaginal cream¡A 5% ; vaginal ring¡A 5% )¡A Withdrawal bleeding,30¢J¥H¤U,Apply 2.5gm daily (preferably on the abdomen) from day 1 to day 24 every month.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;,,,,,Á×§K¶î©Ù©ó¨Å©Ð¡B³±¹D©Î¤ò¾v³B¡C Äµ »y:«ØÄ³¶î©óªÓ³¡¡B¤âÁu©Î¸¡³¡¡A¨Ã¤Å¥Î©ó¨àµ£
IPHES,Pertuzumab + Trastuzumab,Phesgo inj 600/600mg/10mL,RACA,Breast cancer¡A Adjuvant¡A HER2-positive¡A early stage¡A at high risk of recurrence¡A in combination with chemotherapyView additional information. Breast cancer¡A Neoadjuvant¡A HER2-positive¡A locally advanced¡A inflammatory¡A or early stage (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen in combination with chemotherapyView additional information. Metastatic breast cancer¡A HER2-positive¡A in combination with docetaxel¡A in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease,Hypersensitivity to pertuzumab¡A trastuzumab¡A or hyaluronidase¡A or any component of the formulation.,Common Dermatologic: Alopecia (77% )¡A Injection site disorder (15% )¡A Radiation injury (19% )¡A Rash (16% ) Gastrointestinal: Constipation (22% )¡A Decrease in appetite (17% )¡A Diarrhea (60% )¡A Inflammatory disease of mucous membrane (15% )¡A Nausea (60% )¡A Stomatitis (25% )¡A Taste sense altered (17% )¡A Vomiting (20% ) Hematologic: Anemia¡A All Grades (36% )¡A Neutropenia¡A All Grades (22% ) Musculoskeletal: Arthralgia (24% ) Neurologic: Asthenia (31% )¡A Headache (17% )¡A Insomnia (17% )¡A Sensory neuropathy (16% ) Other: Fatigue (29% ) Serious Cardiovascular: Cardiomyopathy¡A Heart failure (0.8% )¡A Left ventricular cardiac dysfunction Hematologic: Febrile neutropenia¡A Grade 3 or 4 (7% )¡A Neutropenia¡A Grade 3 or 4 (14% ) Immunologic: Anaphylaxis¡A Hypersensitivity reaction (1.2% ) Respiratory: Pulmonary toxicity Other: Infusion reaction (21% ),¸Ë©ó­ì²°¤¤¡AÁ×¥úÀx¦s©ó2-8¢XC¦B½c¤¤¡C¤£¥i§N­á¡C¤£¥i·n®Ì¡C,Initial dosage¡A Pertuzumab 1200mg/Trastuzumab 600mg/Hyaluronidase-zzxf 30000units¡A 15mL¡A SC over approximately 8 minutes. Maintenance dosage: Pertuzumab 600mg/Trastuzumab 600mg/Hyaluronidase-zzxf 20000units¡A 10mL¡A SC over approximately 5 minutes every 3 weeks for 3 to 6 cycles as part of a treatment regimen.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,PREGNANCY RECOMMENDATION: Trastuzumab: No Human Data¡XAnimal Data Suggest Moderate Risk Pertuzumab: Contraindicated [¥é³æ]¬°Ãh¥¥¤k©Ê¬I¥´Phesgo¥i¯à¾É­P­L¨à·l¶Ë¡C ¦b¤W¥««á³ø§i¤¤¡A©óÃh¥¥´Á¶¡¥HÀR¯ß¿éª`Herceptin (trastuzumab)´¿¤Þ°_¦Ï¤ô¹L¤Ö¥H¤Îªí²{¬°ªÍÅ¦µo¨|¤£¥þ¡B°©Àf²§±`©M·s¥Í¨à¦º¤`ªº¦Ï¤ô¹L¤Ö¯g­Ô¸s¡C ¦b¤@¶µ°Êª«¥Í´Þ¸ÕÅç¤¤¡AÃh¥¥­¹ÃÉônµU¦b¾¹©x¥Í¦¨¶¥¬q±µ¨üÁ{§É¬ÛÃöÃnÃÄ¶q°ª©ó2.5¦Ü20­¿¤HÅé±µ¨ü«ØÄ³¾¯¶q¤§ÃnÃÄ¶qªºpertuzumab®É¡A·|¾É­P¦Ï¤ô¹L¤Ö¡B­L¨àµÇÅ¦µo¨|¿ð½w¡B©M­F­L-­L¨à¦º¤`¡C À³§iª¾¯f¤H¹ï©ó­L¨àªº¥i¯à­·ÀI¡C­Y¦bÃh¥¥´Á¶¡©Î¨ü¥¥«e7­Ó¤ë¤º¨Ï¥ÎPhesgo¡AÀ³¶i¦æÁ{§É¤Wªº¦Ò¶q»Pµû¦ô¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,BREASTFEEDING RECOMMENDATION: Trastuzumab: No Human Data¡XPotential Toxicity Pertuzumab: Contraindicated [¥é³æ]¥Ø«e¥¼¦³pertuzumab¡Btrastuzumab©Î¬Á§¿»Ä¶i¤J¤HÅé¨Å¥Ä¡B¹ï©ó­÷¨ÅÀ¦¨à©Î¨Å¥Ä¥Í¦¨¼vÅT¤§¸ê®Æ¡C ¤wµoªí¸ê®ÆÅã¥Ü¡A¤HÅéIgG¦s¦b©ó¤HÅé¨Å¥Ä¤º¡A¦ý¥¼¤j¶q¶i¤J·s¥Í¨à©MÀ¦¨à´`Àô¡C Trastuzumab¦s¦b©ó­÷¨Å­¹ÃÉônµUªº¨Å¥Ä¤º¡A¦ý¥¼¥X²{¬ÛÃö·s¥Í¨à¬r©Ê¡C À³¦Ò¶q­÷¨Å¹ï©óµo¨|©M°·±dªº§Q¯q¡A¥H¤Î¥À¿Ë¹ï©óPhesgoªvÀøªºÁ{§É»Ý¨D¡A©MPhesgo©Î¼ç¦b¥ÀÅé±¡ªp¹ï©ó­÷¨ÅÀ¦¨àªº¥ô¦ó¼ç¦b¤£¨}§@¥Î¡C ¦¹¶µ¦Ò¶q¤]À³±Npertuzumabªº±Æ°£¥b°I´Á¤Îtrastuzumab²M°£´Á¬°7­Ó¤ë¯Ç¤J¦Ò¶q¡C,SC;,,,,,1. ¶È¥i¥H¥Ö¤U¬I¥´©ó¤j»L¡C½Ð¤Å¬I¥´¨ìÀR¯ß¡C¥H¬ù5¤ÀÄÁ¥Ö¤U¬I¥´¡Aª`®g³¡¦ì¶ÈÀ³¦b¥ª¥k°¼¤j»L¤§¶¡½ü´«¡C 2. ·»²G¤w±q¤p²~©â¨ú¨ì°wµ©¤¤¡A½Ð±NÂà²¾°wÀY´«¦¨°wÀY»\¡CÀx¦s©ó¦B½c(2-8¢XC)³Ì¦h24¤p®É¤Î«Ç·Å(20-25¢XC)³Ì¦h4¤p®É¡C 3. ½Ð¤Å»PPerjeta(pertuzumab)¡BHerceptin(trastuzumab)¡BKadcyla(trastuzumab emtansine)¤¬¬Û´À´«¡C
IPRE2,Pneumococcal Vaccine Polyvalent,Prevenar (¤½¶O65·³¥H¤W¡A13»ùªÍª¢) 0.5mL/dose,HIMM,For infants and children aged 2 months to 17 years¡A as well as adolescents¡A this vaccine is indicated for active immunization to prevent invasive diseases caused by Streptococcus pneumoniae serotypes 1¡A 3¡A 4¡A 5¡A 6A¡A 6B¡A 7F¡A 9V¡A 14¡A 18C¡A 19A¡A 19F¡A and 23F. Pneumococcal 13-valent conjugate vaccine can also be used to prevent otitis media caused by serotypes 4¡A 6B¡A 9V¡A 14¡A 18C¡A 19F¡A and 23F in infants and toddlers under 2 years of age. Additionally¡A this vaccine is indicated for active immunization in adults and the elderly aged 18 and above to prevent invasive diseases and pneumonia caused by Streptococcus pneumoniae serotypes 1¡A 3¡A 4¡A 5¡A 6A¡A 6B¡A 7F¡A 9V¡A 14¡A 18C¡A 19A¡A 19F¡A and 23F.,Severe allergic reactions (eg¡A anaphylaxis)¡A to any component of the vaccine or diphtheria toxoid,Common: Erythema at injection site (Adults¡A 4.9-30.5% ; pediatrics¡A 24.3-70%)¡A Injection site pain (Adults¡A 51-96.7%)¡A Swelling at injection site (Adults¡A 6.8-39.4%; pediatrics¡A 19.6-44.5%)¡A Tenderness (pediatrics¡A 47.3-89%)¡A Decrease in appetite (Adults¡A 5.3-55.6%; pediatrics¡A 16.3-51%)¡A Arthralgia¡A New onset (Adults¡A 7.4-41.7%)¡A Difficulty moving arm (Adults¡A 10.5-75.2%)¡A Myalgia¡A New onset (Adults¡A 18.4-82%)¡A Decreased sleep (pediatrics¡A 5.7-46.5%)¡A Headache (Adults¡A 23.7-81.4%)¡A Hypersomnia (pediatrics¡A 18.8-71.5%)¡A Irritability (pediatrics¡A 25.2-85.6%)¡A Fatigue (Adults¡A 34-80.5%) Serious: Gastroenteritis (pediatrics¡A 0.9%)¡A Seizure (pediatrics¡A <1%)¡A Bronchiolitis (pediatrics¡A 0.9%)¡A Pneumonia (pediatrics¡A 0.9%)¡A Sudden infant death syndrome (0.063%),2-8¢JÁ×§K§N­á,Infants (2 to 6 months): Administer 3 doses of PCV13¡A 0.5 mL each¡A with at least a 1-month interval. First dose can be given as early as 6 weeks after birth¡A and a fourth dose is recommended at 12-15 months. Preterm Infants (<37 weeks gestation): Administer 3 doses of PCV13¡A 0.5 mL each¡A with at least a 1-month interval¡A starting at 2 months of age. The first dose can be given as early as 6 weeks. Consider a fourth dose between 11-15 months. Infants and Toddlers (7 months to 5 years) not previously vaccinated: (1) Infants (7-11 months): Administer 2 doses of PCV13¡A 0.5 mL each¡A with at least a 1-month interval. Recommend a third dose at 1 year of age. (2) Toddlers (12-23 months): Administer 2 doses¡A 0.5 mL each¡A with at least a 2-month interval. (3) Children (2-5 years): Administer a single dose of 0.5 mL. Children and Adolescents (6-17 years): Administer a single dose of 0.5 mL. Adults and Elderly (18 years and above): Administer a single dose of 0.5 mL. The need for subsequent doses of PCV13 is not established. If suitable for 23-valent pneumococcal polysaccharide vaccine¡A administer PCV13 first¡A followed by 23-valent vaccine at least 8 weeks later.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] ¥Ø«e¨ÃµL¥ô¦ó¹ï¥¥°ü¨Ï¥ÎªÍª¢Ãì²yµß¤Q¤T»ùµ²¦X«¬¬Ì­]ªº¸ê®Æ¥i¨Ñ°Ñ¦Ò¡A¦]¦¹¡A Ãh¥¥´Á¶¡À³Á×§K¨Ï¥Î¨K¨àªÍª¢Ãì²yµß¤Q¤T»ùµ²¦X«¬¬Ì­]¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«e¨Ã¤£½Tª¾ªÍª¢Ãì²yµß¤Q¤T»ùµ²¦X«¬¬Ì­]¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C,IM;,,,,,1.¥»¬Ì­]À³¥H¦Ù¦×ª`®g¤è¦¡§ë¤©¡C³Ì¦nª`®g¦bÀ¦¨à¤§¤j»L«e¥~°¼ªºªÑ¥~°¼¦Ù(vastus lateralis muscle)¡A©Î¬O¥®µ£¤Î¦¨¤H¤§¤WÁuªº¤T¨¤¦Ù¡C
ILIG2,Lidocaine,Lignocaine inj 2% 100mg/5mL,ZANE,,¾AÀ³¯g: Emergency treatment of ventricular arrhythmia. °Æ§@¥Î: Conduction block¡A shock. Rarely malignant hyperthermia. Confusion¡A dizziness¡A drowsiness¡A nervousness¡A euphoria¡A vomiting¡A numbness. ¸T§Ò: Complete AV block. Sensitivity to local anesthetics of the amide type or to any other component of the product.,,25¢J¥H¤U,Intravenous administration. Usually dose: 50~100 mg (1~2 mg/kg¡A 2.5~5 mL of 2% injection) for adults is given by intravenous injection slowly in 1~2 minutes. If no effect is observed after the first injection¡A the same dose may be repeated after 5 minutes. May repeat at 10-20 minutes intervals. The maximum dose within one hour is 300 mg (2% injection: 15 mL). Intravenous injection of this medicine generally is recovery within 10-20 minutes.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment: Administer maintenance infusion at lower rate with close monitoring,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¥¥°ü¡B²£°ü¡B±Â¨Å°üªºµ¹ÃÄ¹ï¥¥°ü©Î¥i¯à¤wÃh¥¥ªº°ü¤k¡A ­­©ó§PÂ_¨äªvÀø¤Wªº¦³¯q©Ê¶W¶V¦MÀI©Ê®É¤~¥iµ¹ÃÄ¡]¦³ÃöÃh¥¥¤¤µ¹ÃÄªº¦w¥þ©Ê©|¥¼½T¥ß¡^¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¥°ü¡B²£°ü¡B±Â¨Å°üªºµ¹ÃÄ¹ï¥¥°ü©Î¥i¯à¤wÃh¥¥ªº°ü¤k¡A ­­©ó§PÂ_¨äªvÀø¤Wªº¦³¯q©Ê¶W¶V¦MÀI©Ê®É¤~¥iµ¹ÃÄ¡]¦³ÃöÃh¥¥¤¤µ¹ÃÄªº¦w¥þ©Ê©|¥¼½T¥ß¡^¡C,IVPUSH;,,,³q±`¦¨¤H¤@¦¸ 50~100 mg¡]1~2 mg/kg¡A2%ª`®g²G 2.5~5 mL¡^¥H 1~2 ¤ÀÄÁªº®É¶¡¡A½wºC¦aÀR¯ßª`®g¡C®ÄªG¤£¹ü®É¡A¦b 5 ¤ÀÄÁ«áµ¹¤©¬Û¦Pªº¾¯¶q¡A¥t¥~¡A´Á«Ý®ÄªG±o¥H«ùÄò®É¡A¥H¶¡¹j 10~20 ¤ÀÄÁªº®É¶¡°l¥[µ¹»P¬Û¦Pªº¾¯¶q¤]µL§«¡A¦ý¤@¤p®É¤º³Ì°ªªº°ò·Çµ¹ÃÄ¶q¬O 300 mg¡]2%ª`®g²G¡G15 mL¡^¡C,,½Õ°t®É¡G¦]¥»¾¯¤¤ªº Lidocaine ¬OÆQ»ÄÆQ¡A±N¥»ÃÄ»PºÒ»Ä²B¶uµ¥ÆP©Êª`®g²G²V¦X®É·|¨Ï Lidocaine ªR¥X¡A¦]¦¹½Ð¤Å±N¨ä²V¦X¨Ï¥Î¡C
OABI,Aripiprazole,Abilify 5mg,CNEU,Schizophrenia in adults & adolescents 13-17 years. Monotherapy or adjunctive therapy to either lithium or valproate for the acute manic & mixed episodes associated with Bipolar I disorder in adults & pediatrics 10-17 years. Adjunctive treatment of major depressive disorders. Irritability associated with autistic disorder in pediatric patients 6-17 years.,Known hypersensitivity to aripiprazole.,Common: Weight increased¡A 7% or greater (2.2-26.3%)¡A Constipation (5-11%)¡A Decrease in appetite (7%)¡A Excessive salivation ( 4%)¡A Increased appetite (3-7%)¡A Nausea (8-15%)¡A Vomiting (3-11%)¡A Akathisia (2-25%)¡A Dizziness (4-10%)¡A Extrapyramidal disease (2-27.3%)¡A Headache (10-27%)¡A Insomnia (8-18%)¡A Lethargy (5%)¡A Sedated (3-21%)¡A Somnolence (6-26.3%)¡A Tremor (2-11.8%)¡A Blurred vision (3-8%)¡A Anxiety (4-17%)¡A Restlessness (2-12%)¡A Nasopharyngitis (3-9%)¡A Fatigue (2-17%) Serious: Cardiorespiratory arrest (0.1-1%)¡A Cardiorespiratory failure (Up to 0.1%)¡A Myocardial infarction (Up to 0.1%)¡A Myocardial ischemia (Up to 0.1%)¡A Orthostatic hypotension (0.2-1%)¡A Prolonged QT interval (Up to 0.1%)¡A Diabetic ketoacidosis¡A Hyperglycemia (0.8-8%)¡A Dysphagia¡A Pancreatitis¡A Agranulocytosis¡A Leukopenia¡A Neutropenia (5.7%)¡A Rhabdomyolysis (Up to 0.1%)¡A Seizure (Up to 0.1%)¡A Tardive dyskinesia (Pediatric¡A 1.7%)¡A At increased risk for suicide¡A Compulsive gambling¡A Suicidal behavior¡A Angioedema¡A Increased body temperature¡A Neuroleptic malignant syndrome,15-30¢J,Schizophrenia: Adults: 10mg or 15mg QD. Effective range: 10-30 mg/day. Do not increase the dose until the course of treatment is up to 2 weeks. Teenagers¡A 13-17 years old: The initial daily dose is 2 mg¡A and it will be adjusted to 5 mg after 2 days¡A and then adjusted to the target dose of 10 mg after another 2 days. Bipolar disorder manic episodes and mixed episodes: Adults: 15mg QD. The initial dose for adjuvant therapy of lithium or valproate is 10-15 mg/day. Can be increased to 30 mg/day based on clinical response. Children¡A 10-17 years old: The initial daily dose is 2 mg¡A and adjusted to 5 mg after 2 days¡A and then adjusted to the target dose of 10 mg after another 2 days. If necessary after the adjustment¡A the dose should be increased by 5 mg each time. Adjuvant treatment of major depression: Adults: Inintial dose:2-5mg/day¡A titrate the dose to 10 mg/day or 15 mg/day in a manner not exceeding 5 mg/day each time. The adjustment interval should be more than 1 week. Tourette syndrome¡A 6~18 years old: <50kg: The initial dose is 2 mg per day¡A and the target dose of 5 mg/day will be reached after two days. In patients whose tics are not well controlled¡A the dose can be increased to 10 mg/day. The dosage should be adjusted step by step not to exceed 5 mg/day each time¡A and the interval should not be less than 1 week. >50kg: The initial dose is 2 mg/day for 2 days¡A then the dose is increased to 5 mg/day for 5 days¡A and the target dose is 10 mg/day on the 8th day. In patients whose tics are not well controlled¡A the dose can be increased to 20 mg/day. The dose should be adjusted step by step not to exceed 5 mg/day each time¡A and the interval should not be less than 1 week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OMIRA15,Pramipexole,1.5mg MIRAPEX prolonged-release,CNEU,,¾AÀ³¯g:Treatment of signs & symptoms of Parkinson's disease. °Æ§@¥Î:Abnormal behaviors (eg¡A binge eating¡A compulsive shopping¡A hypersexuality¡A pathological gambling)¡A abnormal dreams¡A amnesia¡A cardiac failure¡A confusion¡A constipation¡A delusion¡A dizziness¡A dyskinesia¡A dyspnoea¡A fatigue¡A hallucinations¡A headache¡A hiccups¡A hyperkinesia¡A hyperphagia¡A hypotension¡A inappropriate antidiuretic hormone secretion¡A insomnia¡A libido disorders¡A nausea¡A paranoia¡A peripheral oedema; pneumonia; pruritus¡A rash; restlessness¡A somnolence¡A sudden onset of sleep¡A syncope¡A visual impairment including diplopia¡A blurred vision¡A reduced visual acuity; vomiting¡A decreased appetite¡A increased/decreased wt. ¸T§Ò:Hypersensitivity. Lactation.,,,,,,,,,,,,AC;PO;WM;,,,,,
ILID,Lidocaine,Lidocaine inj 20mg/mL¡A 20mL§½³Â,ZANE,Local injectable for anesthesia.,Hypersensitivity to lidocaine or any component of the formulation. History of hypersensitivity to local anesthetics of the amide type. Severe degrees of SA¡A AV¡A or intraventricular heart block.,Common Dermatologic: Erythema¡A Skin irritation Gastrointestinal: Hoarse¡A Loss of voice¡A Pain in throat Serious Hematologic: Methemoglobinemia Immunologic: Allergic reaction¡A Anaphylaxis,25¢J¥H¤U,Adult Caudal anesthetic: Obstetrical analgesia¡A Usual dosage: 200 - 300 mg. Surgical anesthesia¡A Usual dosage: 225 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic lumbar epidural block Usual dosage (analgesia): 250 - 300 mg. Usual dosage (anesthesia): 200 - 300 mg. Should not be administered at intervals of less than 90 minutes. Local anesthetic intravenous regional block¡A Usual dosage: 50 - 300 mg Local anesthesia¡A by infiltration¡A Usual dosage: 5 - 300 mg Peripheral block anesthesia¡A Brachial¡A intercostal¡A paravertebral¡A or pudendal Brachial Nerve Block¡A Usual dosage: 225 - 300 mg. Intercostal Nerve Block¡A Usual dosage: 30 mg. Paravertebral Nerve Block¡A Usual dosage: 30 - 50 mg. Pudendal Nerve Block¡A Usual dosage: 100 mg. Paracervical block anesthesia¡A Usual dosage (Obstetrical analgesia): 100 mg on each side injected slowly¡A with a 5-minute period between sides. Peripheral block anesthesia¡A Dental¡A Usual dosage: 20 - 100 mg. Retrobulbar infiltration of local anesthetic¡A the Recommended dose is 120 - 200 mg. Cervical sympathetic block (Obstetrical )¡A Usual dosage: 50 mg Lumbar sympathetic block¡A Usual dosage: 50 - 100 mg Maximum single dose: 4.5 mg/kg or 300 mg total dose but Local anesthetic intravenous regional block¡A Maximum individual dose: 4 mg/kg. Maximum dose of Dental: 6.6mg/kg or 300 mg total dose each visit.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ]¥¼¦³¬ÛÃö±Ô­z¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]±Â¨Å´Á°ü¤k¦w¥þ©Ê©|¥¼½T©w¡C,IRR;LA;LI;,,,,,¥»ÃÄ¤£¥i¥Î©óÀR¯ßµ¹ÃÄ¡C
ITRU,Rituximab,Truxima inj 500mg/50mL,RACA,The treatment of adult patients with Non-Hodgkin¡¦s Lymphoma (NHL): Relapsed or refractory¡A low-grade or follicular¡A CD20-positive B-cell NHL as a single agent; OR Previously untreated follicular¡A CD20-positive¡A B-cell NHL in combination with first-line chemotherapy and¡A in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy¡A as single-agent maintenance therapy; OR Non-progressing (including stable disease)¡A low-grade¡A CD20-positive¡A B-cell NHL as a single agent after first-line cyclophosphamide¡A vincristine¡A and prednisone (CVP) chemotherapy. Chronic lymphoid leukemia: In combination for first-line treatment; OR in combination with fludarabine and cyclophosphamide; OR maintenance¡A following rituximab-containing chemotherapy. Granulomatosis with polyangiitis or Microscopic polyangiitis: In combination with glucocorticoids,Hypersensitivity to rituximab and any excipients or proteins in this product.,Common Dermatologic: Pruritus (10% to 14% ) Gastrointestinal: Nausea (23% ) Hematologic: Anemia¡A All Grades (8% to 35% )¡A Lymphocytopenia¡A All Grades (48% ) Neurologic: Asthenia (26% )¡A Headache (19% ) Other: Fever (53% )¡A Shivering (33% ) Serious Cardiovascular: Cardiogenic shock¡A Hypotension (10% )¡A Myocardial infarction¡A Ventricular fibrillation Dermatologic: Lichen simplex chronicus¡A Pemphigus paraneoplastica¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Gastrointestinal perforation Hematologic: Anemia¡A Grade 3 or 4 (3% )¡A Leukopenia¡A Grade 3 or 4 (4% )¡A Lymphocytopenia¡A Grade 3 or 4 (40% )¡A Neutropenia¡A Grade 3 or 4 (4% to 6% )¡A Pancytopenia¡A Grade 3 or 4¡A Thrombocytopenia¡A Grade 3 or 4 (2%) Hepatic: Reactivation of hepatitis B viral hepatitis Neurologic: Progressive multifocal leukoencephalopathy Renal: Nephrotoxicity Respiratory: Bronchospasm (8% )¡A Pulmonary toxicity (18% ) Other: Angioedema (11% )¡A Infectious disease (19% to 37% )¡A Infusion reaction (Equal to or greater than 25% )¡A Tumor lysis syndrome,§NÂÃ2-8¢XC«O¦s¡C¤Á¤Å§N­á¡C,Recommended Dose for Non-Hodgkin¡¦s Lymphoma (NHL): The recommended dose is 375 mg/m2. Relapsed or Refractory¡A Low-Grade or Follicular¡A CD20-Positive¡A B-Cell NHL: Administer once weekly for 4 or 8 doses. Retreatment for Relapsed or Refractory¡A Low-Grade or Follicular¡A CD20Positive¡A B-Cell NHL: Administer once weekly for 4 doses. Previously Untreated¡A Follicular¡A CD20-Positive¡A B-Cell NHL: Administer on Day 1 of each cycle of chemotherapy¡A for up to 8 doses. In patients with complete or partial response¡A initiate TRUXIMA maintenance eight weeks following completion of a rituximab product in combination with chemotherapy. Administer TRUXIMA as a single-agent every 8 weeks for 12 doses. Non-progressing¡A Low-Grade¡A CD20-Positive¡A B-Cell NHL¡A after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy¡A administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. First Infusion: Initiate infusion at a rate of 50 mg/hour. In the absence of infusion toxicity¡A increase infusion rate by 50 mg/hr increments every 30 minutes¡A to a maximum of 400 mg/hour. Subsequent Infusions: Standard Infusion: Initiate infusion at a rate of 100 mg/hour. In the absence of infusion toxicity¡A increase rate by 100 mg/hour increments at 30-minute intervals¡A to a maximum of 400 mg/hour. Chronic lymphocytic leukemia: 375 mg/m2 on the day prior to fludarabine/cyclophosphamide in cycle 1¡A then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis or microscopic polyangiitis:Induction therapy: 375 mg/m2 once weekly for 4 doses or 1 g once every 2 weeks for 2 doses; for either dosing regimen¡A administer in combination with a systemic glucocorticoid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ] ¤wª¾§K¬Ì²y³J¥ÕIgG·|¬ï¹L­L½L«Ì»Ù¡C ¥Ø«e¨Ã¥¼´¿¦b­ì¶}µo¼tÃÄ«~¤§Á{§É¸ÕÅç¤¤¬ã¨s¹L¥ÀÅé±µÄ²¹Lrituximab¤§¤HÃþ·s¥Í¨àÅé¤ºªºB²Ó­M¿@«×¡C¥Ø«e©|µL¨¬°÷ ¥B±±¨î¨}¦nªº¥¥°ü¬ã¨s¸ê®Æ¡A¤£¹L¡A¦bÃh¥¥´Á¶¡±µÄ²¹Lrituximab¤§¥À¿Ë©Ò¥Í¤UªºÀ¦¨à¤¤¡A´¿¦³¤@¨Çµo¥Í¼È®É©ÊB²Ó­M ¯ÓºÜ¤Î²O¤Ú²y´î¤Ö¯gªº³ø§i¡C¦]¦¹¤£¥i¹ï¥¥°ü§ë¤©TRUXIMA¡A°£«D¥i¯àªº®Ä¯q¶W¹L¼ç¦bªº­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Rituximab¬O§_¤Àªc©ó¥À¨Å¤¤©|¥¼±oª¾¡CµM¦Ó¡A¬JµM¥ÀÅéªº§K¬Ì²y³J¥ÕIgG·|¶i¤J¥À¨Å¤¤¡A¤£À³µ¹¤©±Â¨Å°ü¤kTRUXIMAR¡C,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,¤£¥i¥HÀR¯ß±Àª`,¥HµLµß¾Þ§@¤è¦¡¨ú¥X©Ò»ÝÃÄ¶q¡Aª`¤J0.9% NaCl©ÎDextrose 5%¤§¿éª`²G¤¤¡Aµ}ÄÀ«á¿@«×»Ý¬°Rituximab 1-4mg/mL¡C»´»´­ËÂà¿éª`³U²V¦X·»²G¡AÁ×§K²£¥Íªwªj¡Cµ¹¤©ª`®gÃÄ«~¤§«e¡AÀ³¥ØµøÀË¬d¬O§_¦³Áû²Éª«½è¤ÎÅÜ¦â¡C,1.¤w½Õ°t¤§Truxima¿éª`²Gªºª«²z¤Î¤Æ¾ÇÃ­©w©Ê¥i¦b2 ¢XC - 8 ¢XC¤Uºû«ù24¤p®É¡AÀH«á¦b«Ç·Å¤U¡]¤£¶W¹L30 ¢XC¡^ºû«ù12¤p®É¡C 2.¥¼½Õ°t¤§TruximaÀ³§NÂÃ2-8¢XC«O¦s.¤Á¤Å§N­á. 3.ªvÀø´Á¶¡¤Î¤§«á 12 ­Ó¤ë¤º¡A¨|ÄÖ°ü¤kÀ³¨Ï¥Î¦³®ÄªºÁ×¥¥¤èªk¡C
IGS3O,Dextrose + Sodium Chloride,5% Dextrose in 0.3% NaCl inj 500mL "OTSUKA",MSIV,Supply of water¡A electrolytes and nutrients for surgery and other diseases.,Hypersensitivity to any component of the formulation.,Hyperglycemia¡A edema¡A electrolyte imbalance.,30¢J¥H¤U,Individualized dosage. Usually¡A adult: 500-1000mL as an intravenous infusion¡A and then increase or decrease appropriately according to symptoms. Dextrose monohydrate 50 mg/mL + Sodium chloride 3 mg/mL,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IVD;,,,,,
ITAK,Lansoprazole,Takepron °w¾¯ 30mg,ALIM,As an alternative to oral therapy when oral intake is not appropriate for GERD in patients with esophagitis &/or severe symptoms of reflux & for healing of gastric ulcers associated with NSAID therapy.,Hypersensitivity to Lansoprazole.,Headache¡A abdominal pain¡A diarrhea¡A flatulence¡A nausea/vomiting¡A constipation. Abnormal hepatic function tests¡A hyperbilirubinemia¡A increased serum alkaline phosphatase¡A increased serum ALT¡A increased serum AST.,25¢J¥H¤U,30 mg IV once or twice daily infusion over 30 minutes.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¨}¤§¯f±w»Ý¤p¤ß¨Ï¥Î¡C,µL»Ý½Õ¾ã¾¯¶q,,Human data suggest low risk,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Intravenous infusion over 30 minutes.,µ¹ÃÄ³~®|¡G¶È¥iÀR¯ß¿éª`¤è¦¡§ë¤©¡C °t»sÃÄ«~: 1. ¥[¤J5 mL 0.9%´â¤Æ¶uª`®g²G©Î5%¸²µå¿}ª`®g²G¦ÜÃÄ²~¤º¡A¨Ã»´»´²V¦X¦Ü¯»¥½·»¸Ñ¡C 2. ¥H50 mLªº0.9%´â¤Æ¶uª`®g²G©Î5%¸²µå¿}ª`®g²Gµ}ÄÀ°t»s²G¡C 3. ²V¦X²G°t»s§¹¦¨«á¤£¥i¦s©ñ¡AÀ³¥ß§Y¨Ï¥Î¡C
OMOR1BAD,Morphine,Morphine 15mg ´Ý¾l¾PÀì,CNEU,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
IELI,Leuprorelin Acetate,Eligard inj 22.5mg extended-release,RACA,For the palliative treatment of advanced prostate cancer.,Patients with hypersensitivity to GnRH¡A GnRH agonist analogs¡A or any of the components of ELIGARD. Women and pediatric patients.,Common Cardiovascular: Edema (Adults¡A 8.2% to 20.8% ) Dermatologic: Acne (Endometriosis 10% )¡A Flushing (Central precocious puberty¡A 5% ; prostate cancer¡A 52% to 73.3% )¡A Injection site disorder (Central precocious puberty¡A 9% ; prostate cancer¡A 8.2% to 37.5% )¡A Injection site pain (Central precocious puberty¡A 19% to 31% ; prostate cancer¡A 19.2% )¡A Rash (Central precocious puberty¡A 3% ; prostate cancer¡A 6% ) Endocrine metabolic: Increased testosterone level¡A Transient¡A Serum triglycerides raised (Endometriosis¡A 12% to 32% )¡A Weight increased (Central precocious puberty¡A 7% ) Gastrointestinal: Abdominal pain (Central precocious puberty¡A 9% )¡A Constipation (Central precocious puberty¡A 6% ; prostate cancer¡A 9.9% )¡A Nausea (Central precocious puberty¡A 8% )¡A Nausea and vomiting (Endometriosis¡A 13% to 29%; uterine fibroids¡A 4.8% to 5% )¡A Vomiting (Central precocious puberty¡A 6% ) Hematologic: Anemia (Prostate cancer¡A 2.3% to 6.6% ) Musculoskeletal: Arthralgia (Prostate cancer¡A 9.3% )¡A Arthropathy (Prostate cancer¡A 4.2% to 16.3% )¡A Decreased bone mineral density¡A Myalgia (Prostate cancer¡A 7.9% ) Neurologic: Asthenia (Prostate cancer¡A 12.2% ; uterine fibroids¡A 8% to 18% )¡A Dizziness (Endometriosis¡A 11% ; uterine fibroids¡A 1.8% )¡A Headache (Central precocious puberty¡A 2% to 16% ; endometriosis¡A 32% ; prostate cancer¡A 4.2% )¡A Insomnia¡A Lethargy Psychiatric: Mood swings (Central precocious puberty¡A 2% to 5% ) Renal: Dysuria (6% ) Reproductive: Atrophy of testis (Prostate cancer¡A 4.4% to 20.2% )¡A Vaginitis (Endometriosis¡A 8% to 28%; uterine fibroids¡A 11% to 11.4% ) Respiratory: Bronchospasm (Central precocious puberty¡A 6% )¡A Cough (Central precocious puberty¡A 13% prostate cancer¡A 6.6% )¡A Nasopharyngitis (Central precocious puberty¡A 22% )¡A Productive cough (Central precocious puberty¡A 6% ) Other: Fever (Central precocious puberty¡A 17% )¡A Malaise and fatigue (Prostate cancer¡A 6% to 17.5% )¡A Pain (Central precocious puberty¡A 3% ; endometriosis¡A 19% to 29% ; prostate cancer¡A 4.2% to 32.7% ; uterine fibroids¡A 8% to 6.1% ) Serious Cardiovascular: Heart failure (Adults¡A less than 5% )¡A Myocardial infarction¡A Prolonged QT interval Hepatic: Injury of liver Musculoskeletal: Fracture of vertebral column Neurologic: Fracture of vertebral column¡A Pseudotumor cerebri¡A Seizure (Prostate cancer¡A less than 0.5% ) Psychiatric: Depression (Up to 5% )¡A Suicidal thoughts Respiratory: Pulmonary embolism,2-8¢XC¡A«Ç·Å(<25¢XC)¥i4¶g,Eligard 22.5mg is administered subcutaneously every 3 months. The injection provides continuous release of leuprolide acetate over the treatment period.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,LEUPROLIDE: Contraindicated [¥é³æ] ¥»ÃÄ¸T¥Î©ó°ü¤k,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,LEUPROLIDE: Contraindicated [¥é³æ] ¥»ÃÄ¸T¥Î©ó°ü¤k,SC;,,,,,1. ½Ð¨Ì·Ó¥é³æ¹Ï¥Ü¨Ì¨BÆJ°t»sÃÄ«~¡A¤@¥¹°t»s¦nÀ³¥ß§Y¨Ï¥Î¡A¦]¬°·»²GªºÂH«×·|ÀH®É¶¡¼W¥[¡C 2. ¥¼©î«ÊÃÄ«~Â÷¶}¦B½c¦s©ñ©ó25¢J¥H¤U¡A¥i«O¦s4¶g¡C
IKEY,Pembrolizumab,Keytruda inj 50mg/vial,RACA,,¾AÀ³¯g:KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and¡A if BRAF V600 mutation positive¡A a BRAF inhibitor. °Æ§@¥Î:>10%: Cardiovascular: Facial edema (10%) Central nervous system: Fatigue (43%) Dermatologic: Pruritus (28%)¡A skin rash (24%; immune-mediated: 1%) Endocrine & metabolic: Hyperglycemia (49%)¡A hypoalbuminemia (37%)¡A hyponatremia (37%)¡A hypertriglyceridemia (33%)¡A decreased serum bicarbonate (22%)¡A hypocalcemia (21%) Gastrointestinal: Constipation (22%)¡A nausea (22%)¡A decreased appetite (20%)¡A diarrhea (20%)¡A abdominal pain (13%)¡A vomiting (13%) Hematologic & oncologic: Anemia (44%; grades 3/4: 10%)¡A lymphocytopenia (40%; grades 3/4: 9%) Hepatic: Increased serum alkaline phosphatase (26%)¡A increased serum AST (24%)¡A increased serum ALT (21%) Neuromuscular & skeletal: Arthralgia (14%) Respiratory: Dyspnea (?20%)¡A cough (18%) Miscellaneous: Fever (14%) 1% to 10%: Central nervous system: Confusion (>2%)¡A peripheral neuropathy (2%) Endocrine & metabolic: Hypothyroidism (immune-mediated; 9%)¡A hyperthyroidism (immune-mediated; 3%) Gastrointestinal: Colitis (immune-mediated; 2%) Immunologic: Antibody development (2%) Neuromuscular & skeletal: Weakness (10%)¡A arthritis (immune-mediated; 2%) Respiratory: Pneumonitis (3%)¡A pleural effusion (>2%)¡A pneumonia (>2%)¡A respiratory failure (>2%) ¸T§Ò:Hypersensitivity to pembrolizumab or any component of the formulation.,,2-8¢XC,The recommended dose of KEYTRUDA is 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. [OFF-LABLE USE IN TAIWAN] Colorectal cancer¡A Unresectable or metastatic¡A progressed following treatment with a fluoropyrimidine¡A oxaliplatin¡A and irinotecan - Microsatellite instability-high¡A Or mismatch repair deficient : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Head and neck cancer¡A Recurrent or metastatic¡A squamous cell¡A with disease progression on or after platinum-based chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Hodgkin's disease¡A Classical¡A refractory or relapsed after 3 or more prior lines of therapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Metastatic urothelial carcinoma¡A Or locally advanced¡A in patients not eligible for cisplatin-containing chemotherapy¡A or with progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Microsatellite instability-high¡A Or mismatch repair deficient - Solid tumor¡A Unresectable or metastatic¡A progressed following prior treatment and who have no satisfactory alternative treatment options : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Non-small cell lung cancer¡A Metastatic¡A high PD-L1 expression¡A first-line treatment¡A with no EGFR or ALK tumor aberrations : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Non-small cell lung cancer¡A Metastatic¡A PD-L1 expression¡A with disease progression on or after platinum-based chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab : 200 mg IV infusion over 30 minutes every 3 weeks; continue treatment for up to 24 months or until disease progression or unacceptable toxicity Nonsquamous non-small cell lung cancer¡A Metastatic¡A first-line treatment in combination with pemetrexed and carboplatin : 200 mg IV infusion over 30 minutes every 3 weeks¡A for up to 24 months or until disease progression or unacceptable toxicity. Give prior to pemetrexed 500 mg/m(2) IV and carboplatin AUC 5 mg/mL/min IV on day 1 of each 21-day cycle for 4 cycles¡A followed by pembrolizumab monotherapy with or without pemetrexed maintenance.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,,,,»s³Æ: 1. ªuµÛÃÄ²~¤º¾À¥[¤J2.3²@¤ÉµLµßª`®g¥Î¤ô(USP)¡A¤£­nª½±µ¥[¦b§N­á°®ÀêÃÄ¯»¤W(©Ò§Î¦¨ªº¿@«×¬°25²@§J/²@¤É)¡C 2. »´ÂàÃÄ²~¤Å¾_·n¡CÀR¸m5¤ÀÄÁ¡A«Ý®ðªw®ø¥¢¡C 3. ªw»s«á¬°µL¦â¦Ü²H¶À¦â·»²G¡A­YÆ[¹î¨ì¨ä¥L²§ª«¡A«hÀ³¥á±ó¤£¥Î¡C 4. ©â¨ú»Ý­nªºÃÄ¶q¡Aª`¤J0.9%´â¤Æ¶uª`®g²G©Î5%¸²µå¿}ª`®g²GªºÀR¯ß¿éª`³U¤¤¡C(»´Âàªº¤è¦¡²V¤Ã·»²G)¡C 5. ·»²Gªº³Ì²×¿@«×À³¬°1²@§J/²@¤É¦Ü10²@§J/²@¤É¤§¶¡¡C 6. µ}ÄÀ«á¥i¦s©ñ«Ç·Å¡A¦ý¤£¥i¶W¹L6¤p®É¡C(¥]¬A©ó«Ç·Å¤U¡Aªw»s«á¤§ÃÄ²~ªº¦s©ñ®É¶¡¡BIV³U¤¤¤§¿éª`·»²Gªº¦s©ñ®É¶¡¡B¥H¤Î¿éª`©Ò»Ý­nªº®É¶¡)
EMYC20,Triamcinolone + Neomycin + Gramicidin + Nystatin,Mycomb ¨Å»I 20gm,TDER,Treatment of inflammatory skin lesions where bacterial or candidal infections are suspected.,Tuberculous & most viral lesions of skin¡A especially herpes simplex¡A vaccinia¡A varicella.,Skin atrophy; ototoxicity; nephrotoxicity.,25¢J¥H¤U,apply BID or TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Triamcinolone - Human and Animal Data Suggest Risk (Oral/Parenteral/Topical) Neomycin - Human Data Suggest Low Risk Gramicidin - Unknown Nystatin - Compatible,Unknown ¨S¦³¸ê®Æ,Triamcinolone - No Human Data¡XProbably Compatible Neomycin - No Human Data¡XProbably Compatible Gramicidin - Unknown Nystatin - Compatible,EXT;,,,,,
OPAX,Nirmatrelvir + Ritonavir,Paxlovid 300/100mg¡A 10 doses (¤½¶O),QANB,An Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing¡A and who are at high risk for progression to severe COVID-19¡A including hospitalization or death.,History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.,Common Gastrointestinal: Diarrhea (3%)¡A Taste sense altered (6%) Serious Hepatic: Hepatitis¡A Including increased transaminase levels.,Àx¦s©ó25¢J¥H¤U¡C,Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together orally twice daily for 5 days.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤£«ØÄ³­««×¨x¥\¯à¤£¥þ¯f¤H¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|µL§³®W´Á¶¡¨ÏPF-07321332ªº¤HÅé¸ê®Æ¥i¥Î©óµû¦ô¥D­n¥X¥Í¯Ê³´¡B¬y²£©Î¥ÀÅé©Î­L¨à¤£¨}ªºÃÄª«¬ÛÃö­·ÀI¡C¤wµoªíªºÃö©ó¥¥°ü¨Ï¥ÎritonavirªºÆ[¹î©Ê¬ã¨s¥¼µo²{­«¤j¥X¥Í¯Ê³´ªº­·ÀI¼W¥[¡C¤wµoªíªºritonavir¬ã¨s¤£¨¬¥H½T©wÃÄª«¬ÛÃöªº¬y²£­·ÀI¡C§³®W´Á¶¡¦p¤£¤©ªvÀø¡ACOVID-19·|¹ï¥ÀÀ¦ºc¦¨­·ÀI¡C ¦bPF-07321332ªº°Êª«­F­L-­L¨àµo¨|¬ã¨s¤¤¡A§³®W¥À¨ß¤fªAµ¹¤©PF-07321332¡A¦b¥þ¨­¼ÉÅS¶q(AUC)¬ùPAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº10­¿®É¡AÆ[¹î¨ì­L¨àÅé­«´î»´¡C¦bPF-07321332ªº°Êª«¥Í´Þ¬ã¨s¤¤¡A¦b¥þ¨­¼ÉÅS¶q(AUC)¬°PAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº3­¿©Î3­¿¥H¤W®É¡A¥¼Æ[¹î¨ì¨ä¥L¤£¨}µo¨|µ²ªG¡C ¦britonavirªº°Êª«¥Í´Þ¬ã¨s¤¤¡A§³®W¤j¹«©M¥À¨ß¤fªAµ¹¤©ritonavir¡A¾¯¶q¡]¨Ì¾ÚÅéªí­±¿nÂà´«¡^©Î¥þ¨­¼ÉÅS¶q(AUC)¬°Á{§É¾¯¶q©ÎPAXLOVIDªº®Ö­ã¤HÅé¾¯¶q¼ÉÅS¶qªº3­¿©Î3­¿¥H¤W®É¡A¥¼Æ[¹î¨ì¤£¨}µo¨|µ²ªGªºÃÒ¾Ú¡C ¦b¾A¥Î¤H¸s¤¤¡A¥D­n¥X¥Í¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¤£©ú¡C©Ò¦³§³®W§¡­±Á{¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­·ÀI¡C¦b¬ü°ê¤@¯ë¤H¸s¤¤¡AÁ{§É½T»{ªº§³®W¤¤¥D­n¥X¥Í¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¤À§O¬°2-4%©M15-20%¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Ãö©óPF-07321332¬O§_¥i¤Àªc¦Ü¤H©Î°Êª«¨Å¥Ä¡B¹ï¥À¨ÅÁý¾iÀ¦¨àªº¼vÅT©Î¹ï¨Å¥Ä¤Àªcªº¼vÅT¡A¥Ø«e©|µL¥i¨ú±oªº¸ê®Æ¡C¦bµ¹¤©PF-07321332ªº¤j¹«ªº­÷¨Å«á¥N¤¤Æ[¹î¨ìÅé­«¼È®É©Ê¤U­°¡C¦³­­ªº¤wµoªí¸ê®ÆÅã¥Ü¡Aritonavir¥X²{©ó¨Å¥Ä¤¤¡C©|µLÃö©óritonavir¹ï¥À¨ÅÁý¾iÀ¦¨à²£¥Íªº¼vÅT©ÎÃÄª«¹ïªc¨Å¶q²£¥Íªº¼vÅTªº¸ê®Æ¡CÀ³¦Ò¼{¥À¨ÅÁý¾iªºµo¨|©M°·±d¯q³B¡A¥H¤Î¥À¿Ë¹ïPAXLOVIDªºÁ{§É»Ý¨D¥H¤ÎPAXLOVID©Î¥ÀÅé°òÂ¦ª¬ªp¹ï¥À¨ÅÁý¾iÀ¦¨àªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¡C·P¬VCOVID?19ªº­÷¨Å´Á¤k©ÊÀ³¿í´`Á{§É«ü¤Þªº³W©w¡A¥HÁ×§K¨ÏÀ¦¨à¼ÉÅS©óCOVID?19¡C ¦b²£«e©M²£«áµo¨|¬ã¨s¤¤¡Aµ¹¤©§³®W¤j¹«PF-07321332ªº¥þ¨­¼ÉÅS¶q(AUC24)¬ù¬°PAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº8­¿®É¡A¦b¤l¥NÆ[¹î¨ìÅé­«¤U­°¡]³Ì°ª¹F8%¡^¡C¦b¥ÀÅé¥þ¨­¼ÉÅS¶q(AUC24)¬ù¬°PAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº5­¿®É¡A¥¼Æ[¹î¨ì¤l¥NªºÅé­«ÅÜ¤Æ¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã²É§]ªA¡C¤£±o©CÄZ¡B¯}Ãa©ÎÀ£¸H¿õ¾¯¡C
INS3YF,Sodium Chloride,3% NaCl inj 500mL(YF),NUTR,Supplementation of sodium and chloride ions (to increase the concentration of sodium and chloride ions in the serum)¡A Addisonian crisis¡A diabetic coma.,Hypersensitivity to sodium chloride or any component of the formulation; hypertonic uterus¡A hypernatremia¡A fluid retention,Common: Disorder of fluid AND/OR electrolyte¡A Hypercalciuria¡A Hypernatremia¡A Hypokalemia¡A Phlebitis¡A Injection site disorder¡A Injection site extravasation¡A Hypervolemia Serious: Congestive heart failure¡A Hypernatremia¡A Overhydration¡A Disseminated intravascular coagulation¡A Respiratory distress,25¢J¥H¤U,[Lexicomp 20230720] Initially¡A 100 mL infused slowly over a 1-hour period. Before additional amounts are administered¡A serum electrolyte concentrations¡A including chloride and bicarbonate¡A should be determined to assess the need for additional sodium chloride. IV infusion of 3 or 5% sodium chloride injection should not exceed 100 mL/hour. Maximum 400 mL in 24 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IH;IVD;LI;,,,,[Lexicomp] Infusion rate: Administer the solution slowly; maximum 100 mL/hour. Maximum 400 mL in 24 hours.,1. ¥»ÃÄ«~¬°°ª±i¿éª`²G¡A¶·¯S§Oª`·Nµ¹ÃÄ³t²v¡C
IFADI,Famotidine,Fadin Lyo inj 20mg,ALIM,,¾AÀ³¯g: Gastroesophageal reflux disease¡A Heartburn¡A Peptic ulcer disease °Æ§@¥Î: >10%: Central nervous system: Agitation (infants: <=14%; adults: <1%) 1% to 10%: Central nervous system: Headache (5%)¡A dizziness (1%) Gastrointestinal: Diarrhea (2%)¡A constipation (1%)¡A necrotizing enterocolitis Frequency not defined: Local: Irritation at injection site (IV) <1%¡A postmarketing¡A and/or case reports: Abdominal distress¡A acne vulgaris¡A agranulocytosis¡A alopecia¡A anaphylaxis¡A angioedema¡A anorexia¡A anxiety¡A arthralgia¡A asthenia¡A atrioventricular block¡A bronchospasm¡A cardiac arrhythmia¡A cholestatic jaundice¡A confusion¡A conjunctival injection¡A decreased libido¡A depression¡A drowsiness¡A facial edema¡A fatigue¡A fever¡A flushing¡A hallucination¡A hepatitis¡A hypersensitivity reaction¡A impotence¡A increased liver enzymes¡A insomnia¡A interstitial pneumonitis¡A leukopenia¡A muscle cramps¡A musculoskeletal pain¡A nausea¡A palpitations¡A pancytopenia¡A paresthesia¡A periorbital edema¡A prolonged Q-T interval on ECG¡A pruritus¡A psychiatric disturbance¡A rhabdomyolysis¡A seizure¡A skin rash¡A Stevens-Johnson syndrome¡A taste disorder¡A thrombocytopenia¡A tinnitus¡A toxic epidermal necrolysis¡A urticaria¡A vomiting¡A xeroderma¡A xerostomia Gastrointestinal: Constipation (1.2% )¡A Diarrhea (1.7% ) ¸T§Ò¯g: Serious hypersensitivity (eg¡A anaphylaxis) to famotidine¡A other H2 antagonists¡A or any component of the formulation,,25«×C¥H¤U«Ç·Å,20 mg twice daily,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] ¹ï©óÃh¥¥¤¤§ë»P¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡A¦]¦¹¥¥°ü©Î¥i¯àÃh¥¥ªº°ü¤k¡A³Ì¦n¤£­n§ë»P.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥»ÃÄ·|²¾¦æ¦Ü¥À¨Å¤¤¡A¦]¦¹­Y§ë»P±Â¨Å¤¤¤§°ü¤k¡AÀ³ª`·N¤£­n±Â¨Å.,IVD;IVP;IVPUSH;,IV: 20mL N/S¡A D5W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,±Àª`®É¶¡¦Ü¤Ö 2 mins,[Micromedex]Solution for infusion: Administer over 15-30 minutes. Dilute 2 mL of famotidine 10 mg/mL solution with 100 mL of D5W or other compatible solution.,¨C¤ä20mg¥H20mL¥Í²z­¹ÆQ¤ô©Î¸²µå¿}¤ô·»¸Ñ«á¥ß§Y¨Ï¥Î¡C ¥iÀR¯ß½wºCª`®g©Î¥[¤JÀR¯ß¿é²GÂIºwµ¹¤©¡C
IKAD6,Trastuzumab Emtansine,KADCYLA inj 160mg,RACA,Metastatic breast cancer¡A HER2 overexpression¡A monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common: Constipation (17-27%)¡A Nausea (40-42%)¡A Hemorrhage¡A All Grades (29-32%)¡A Thrombocytopenia¡A All Grades (29-31%)¡A Increased liver enzymes¡A All Grades (29-32%)¡A Musculoskeletal pain (30-36%)¡A Headache (28%)¡A Fatigue (36%) Serious: Heart failure¡A Left ventricular cardiac dysfunction (1.8-3%)¡A Injection site extravasation¡A Anemia¡A Grade 3 or 4 (1.1-4.1%)¡A Hemorrhage¡A Grade 3 or 4 (0.4-1.8%)¡A Thrombocytopenia¡A Grade 3 or 4 (6-15%)¡A Hepatotoxicity¡A Increased liver enzymes¡A Grade 3 or 4 (1.5-8%)¡A Injury of liver¡A Liver regeneration (0.3-0.4%)¡A Non-allergic anaphylaxis¡A Dyspnea (8-12%)¡A Interstitial lung disease¡A Pneumonitis (1.1-1.2%),2-8¢J,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever¡A chills¡A or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,µL»Ý½Õ¾ã¾¯¶q,Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution. Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded¡A a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü³Ìµu30 ¤ÀÄÁ¡C½Ð¨Ï¥Î0.2-0.22·L¦Ì¡B¤£§lªþ³J¥Õ½èªººÞ½u¤º polyethersulfone (PES)¹LÂo¾¹¡C 3. ·»²G°t¸m«áÀ³¥ß§Y¨Ï¥Î¡A§NÂÃ©ó2-8¢J³Ì¦hÀx¦s24¤p®É¡C 4. ¿éª`®Éª`·N¯f¤H¬O§_¥X²{©I§l§xÃø¡B©PÃä¤ô¸~¡B§C¦åÀ£©Î¨ä¥L«æ©Ê¹L±Ó¤ÏÀ³¯gª¬¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
ISYNA1,Palivizumab,Synagis inj 50mg/0.5mL,HIMM,Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease¡A including infants with bronchopulmonary dysplasia¡A a history of premature birth (<=35 weeks gestational age)¡A & children with hemodynamically significant congenital heart disease.,Hypersensitivity to palivizumab or humanized monoclonal antibodies.,Upper respiratory infections¡A otitis media¡A rhinitis¡A rash¡A pain¡A hernia¡A increased SGOT¡A pharyngitis.,2-8¢J,IM¡A 15 mg/kg/month.,µL»Ý½Õ¾ã¾¯¶q,Infants and Children <24 months: There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V no relevant animal data,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
IMTX2,Methotrexate,Methotrexate inj 50mg/2mL,RACA,Trophoblastic tumors¡A leukemia¡A lymphoma¡A osteogenic & bronchogenic carcinoma¡A breast¡A head & neck cancer¡A mycosis fungoides.,Pregnancy & lactation. Psoriatic patient in a poor state of nutrition¡A serious renal or liver disorders¡A bone marrow hyperplasia¡A leukopenia¡A thrombocytopenia or anemia.,Hepatotoxicity¡A GI¡A dermatological¡A liver & GUT toxicity.,25¢J¥H¤UÁ×¥ú,[Choriocarcinoma and similar trophoblastic diseases] 15-30 mg orally or intramuscularly daily for a 5-day course repeated for 3-5 times as required with rest periods of 1 or more weeks interposed between courses until any manifesting toxic symptoms subside. [Breast cancer] 40 mg/m2 IV on days 1 and 8 in combination with cyclophosphamide and fluorouracil. [Leukemia] Induction: 3.3 mg/m2 in combination with prednisolone 60 mg/m2 daily for 4-6 weeks. Maintenance therapy: administer 2 times weekly orally or IM in total weekly doses of 30 mg/m2 or 2.5 mg/kg IV every 14 days. If and when relapse occurs¡A repeat initial induction regimen. [Meningeal Leukemia] 0.2-0.5 mg/kg intrathecally at intervals of 2-5 days until the cell count of the cerebrospinal fluid returns to normal. At this point one additional dose is advisable. Alternative: 12 mg/m2 intrathecally once weekly for 2 weeks¡A then once monthly. [Lymphomas] 0.625-2.5 mg/kg daily. Treatment in all stages usually consists of several courses interposed with 7-10 day rest periods. 0.625-2.5 mg/kg daily.[Mycosis fungoides] 50 mg IM once weekly or 25 mg IM twice weekly.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;IVD;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
IACET,Propacetamol,Acetamol inj 1gm,CNEU,Relief of pain¡A fever.,Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or severe active liver disease.,Hypertension¡A hypotension¡A peripheral edema¡A tachycardia¡A agitation (children)¡A anxiety¡A fatigue¡A headache (more common in adults)¡A insomnia (more common in adults)¡A trismus¡A pruritus (children)¡A skin rash¡A hypervolemia¡A hypoalbuminemia¡A hypokalemia¡A hypomagnesemia¡A hypophosphatemia¡A abdominal pain¡A diarrhea¡A headache (more common in adults)¡A insomnia (more common in adults)¡A nausea (more common in adults)¡A vomiting (more common in adults)¡A oliguria¡A anemia¡A increased serum transaminases¡A infusion site reaction(pain)¡A limb pain¡A muscle spasm¡A periorbital edema¡A abnormal breath sounds¡A atelectasis (children)¡A dyspnea¡A hypoxia¡A pleural effusion¡A pulmonary edema¡A stridor¡A wheezing¡A fever.,25¢J¥H¤U,Pain and fever Adult: 1-2 g every 4 hr¡A up to 4 times daily. May be given via IV inj. Maximum dose: 8 g daily. Child: 20-30 mg/kg¡A given over 15 min¡A up to 4 times daily. Maximum dose: 120 mg/kg/day.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à»ÙÃª±wªÌ¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,Acetaminophen: Short-Term Use Suggests Low Risk; Long-Term Use Suggests Risk [¥é³æ] ¬Û¹ï¸T§Ò¯g: Ãh¥¥ªì´Á3­Ó¤ë¤£«ØÄ³¨Ï¥Î¥»²£«~¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,Acetaminophen: Compatible [¥é³æ] ¥Ø«e©|µL¸ê®Æ¡C,IVD;IVPUSH;,½Ð¨Ï¥Î¼t°Ó©Òªþ¤§±M¥Îµ}ÄÀ²G(5mL)¡C,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,IVPUSH: ¦¨¤HÀR¯ßª`®g¥H20mL N/Sµ}ÄÀ¡A¨Ïº¯³zÀ£¬ù¬°400 mOsm/L¡C¥i¨â¤ÀÄÁ¤ºª½±µª`®g¡C(½wºC±Àª`Á×§Kª`®g®É¯kµh),IVD: ¦¨¤H«ØÄ³±NÃÄª«¥[¤J125mL N/S«á15¤ÀÄÁ¤º¿éª`§¹²¦¡C¥|·³¥H¤W(©ÎÅé­«17kg¥H¤W)«Äµ£«ØÄ³¥ý¥[¤JD5W©ÎN/S¡A¦A¥H¨C¤½¤çÅé­«¨C¦¸ª`®g1-2mL¡A©ó¥­§¡¬°®É15¤ÀÄÁªº®É¶¡ÀR¯ß¿éª`¡C(¿éª`§¹À³¥H10mL N/S¨RºÞ¸ô),1.¼t°Ó«ØÄ³Á×§KIVPUSH¤è¦¡µ¹ÃÄÁ×§Kª`®g³¡¦ì¯kµh¡C(20211123¿Ô¸ßÃÄ¼t) 2.¥»ÃÄ¶·¨Ï¥Î¼t°Ó´£¨Ñ¤§µ}ÄÀ²G·»¸Ñ¡C 3.¥»«~¶}²~«áÀ³¤@¦¸¨Ï¥Î§¹²¦¡A¤£±o¤À¦¸ª`®g¡C 4.¥»«~½Õ°t«á¶·©ó30¤ÀÄÁ¤º¨Ï¥Î¡A¤£¥i»P¨ä¥LÃÄª«²V¦X¨Ï¥Î¡C 5.¯f¤H¥i¥H¤fªA®ÉÀ³ºÉ§Ö§ï¥Î¤fªAAcetaminophen¡C 6.¹ïAcetaminophen¹L±ÓªÌ¸T¥Î¡C 7.¯S®í±Ú¸s¡G¨x¡BµÇ¥\¯à¨ü·lªÌ»Ý½Õ¾ã¾¯¶q¡C
OGLUB1,Acarbose,Glucobay 100mg,META,,¾AÀ³¯g: Additional therapy in association w/ diet in patients w/ DM. °Æ§@¥Î: Flatulence. Diarrhoea¡A GI & abdominal pain. ¸T§Ò: Hypersensitivity; chronic intestinal disorders associated w/ distinct disturbances of digestion & absorption¡A conditions which may deteriorate as a result of increased intestinal gas formation. Severe renal impairment.,,«Ç·Å,Adult: Initially 50 mg tids¡A up to 100 mg tids.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IPRM,Metoclopramide hydrochloride,Promeran inj 9.08mg/2mL,ALIM,,¾AÀ³¯g:Prevention of nausea & vomiting¡A GERD & diabetic gastroparesis. °Æ§@¥Î:Syndrome malin. Occasionally GI disturbances¡A headache¡A lightheadedness¡A drowsiness. Rarely¡A endocrinal disorders eg. amenorrhea¡A hyperprolactinemia¡A gynecomastia in males¡A breast enlargement in women; extrapyrimidal symptoms¡A hypotension¡A tachycardia¡A arrhythmia Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )¡A Vomiting (1.4% to 2.1% ) Neurologic: Asthenia (10% )¡A Headache (4.2% to 5.2% .)¡A Somnolence (oral¡A 2.1% to 10%; IV¡A 70%) Other: Fatigue (2.1% to 2.8% ) ¸T§Ò:GI hemorrhage¡A mechanical obstruction or digestive perforation; Pheochromocytoma; previous history of tardive dyskinesia with neuroleptics. Epilepsy,,«Ç·Å,Adult Usual dose: IM or IV 7.68mg/2mL. 1~2 times/day. Children 1/2 adult dose,,,,¥i¯à¦w¥þ,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,1. ¤ÆÀø«eÀR¯ßª`®g¡G10 mg / 50 mL ½wºC¿éª`¶W¹L 15 ¤ÀÄÁ¡C 2. Primperan 10 mg IV ½Ð slowly push (¬ù 1~2 ¤ÀÄÁ)¡A¶W¹L 1 amp ½Ð IV drip¡C(2008/03/11 ÃÄª«¤£¨}¤ÏÀ³¤p²Õ)
IPAT,Patent blue V,Patent blue V inj 50mg/2mL,ZOTH,Identification of lymph vessels and arterial territories.,Hypersensitivity.,Hypotension¡A nausea¡A laryngeal edema¡A pruritus.,¥é³æµL¯S§O«ü¥Ü,Location of lymphatic vessels: approximately 1mL of Patent Blue V is injected into the subcutaneous tissue. Marking lymph vessels and the sentinel node: 1 to 2 mL subcutaneously around the tumour or areola. Location of arterial territories: Intra-arterial injection of Patent Blue V results in a colouring of the tissues vascularised by the vesseis. Marking arterial regions: not more than 10 mL intra-arterially. To control the correct position of the catheter destined ti intra-arterial chimiotherapy¡A 50mL of a solution comprised of: 80mL of an isotonic sodium in water solution¡A 40mL of a 2.5% Patent Blue V solution and 20mL of a 1% xylocaine solution are perfused.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,,,Unknown ¨S¦³¸ê®Æ,,IA;LI;SC;,,,,,1. °Ê¯ßª`®gPatent Blue V¯à±N¦³¦åºÞªº²ÕÂ´¬V¦â¡A¤@¦¸Äéª`¥H¤U²V¦X·»²Gªº50mL·»²G¡A·»²G¥]§t: *80mLµ¥±i¶u¤ô·»²G¡C *40mL 2.5%Patent Blue V·»²G¡C *20mL 1%Xylocaine·»²G¡C 2. Patent blue V ¥i¯à²£¥Í¹L±Ó°Æ§@¥Î¡Aª`®g«e»Ý¤F¸Ñ¯f±w¹L¥h¦³µL¹L±Ó©Î¤£¨}¤ÏÀ³°O¿ý¡A¥²­n®É¥i¨Æ¥ý§ë¤©Corticosteroid »P Antihistamine¡C
ETEA1,Dextran 70 + Hydromellose,Tears Naturale 15mL,TOPH,Temporarily relieves burning and irritation due to dry eyes.,People with prior allergies to this medication's components.,Occasionally ocular redness¡A swelling¡A burning sensation¡A pain¡A stinging.,30¢XC ¥H¤U,Instill 1-2 drops TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
IVANS,Vancomycin,Vancomycin inj 1gm,QANB,Treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci. For penicillin-allergic patients. Staphylococcal endocarditis. Infections due to staphylococci eg septicemia¡A bone infections¡A lower resp tract infections¡A skin & skin structure infections. Diphtheroid endocarditis. Oral treatment for antibiotic-associated pseudomembranous colitis.,Hypersensitivity.,Anaphylactoid reactions following rapid infusion. Nephrotoxicity¡A ototoxicity¡A reversible neutropenia¡A pseudomembranous colitis; chemical peritonitis following intraperitoneal administration.,25¢J¥H¤U,Adult 500 mg Q6H or 1 g Q12H by intermittent infusion. Duration: At least 3 weeks in staphylococcal endocarditis. Prophylaxis of endocarditis in high-risk penicillin-allergic patients undergoing dental or other procedures 1 g by IV infusion as a single dose before the procedure together with gentamicin IV. Repeat doses Q8H for patients undergoing GI or GU procedures. Children 10 mg/kg body weight Q6H. Neonates initial 15 mg/kg followed by 10 mg/kg Q12H in 1st weeks of life & Q8H up to 1 month of age. *****NEONATE ANTIBIOTICS DOSE***** Vancomycin: Dilute to a final concentration <=5 mg/mL; IV infusion over 90 minutes Draw trough level within 30 mins before the fourth dose. peak level 60 mins after end of infusion Sepsis PMA <=29 week Postnatal 0-14 days¡A dose: 10mg/kg Q18H PMA <=29 week Postnatal >=15 days¡A dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days¡A dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days¡A dose: 10mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days¡A dose 10mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days¡A dose 10mg/kg Q8H PMA >=45 week: 10mg/kg Q6H Meningitis PMA<=29 week Postnatal 0-14 days dose: 15mg/kg Q18H PMA <=29 week Postnatal >=15 days¡A dose: : 15mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days¡A dose: 15mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days¡A dose: 15mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days¡A dose: 15mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days¡A dose: 15mg/kg Q8H PMA >=45 week: 15mg/kg Q6H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[¥é³æ] ©|¥¼¦³°Êª«¥Í´Þ¬ã¨s¡A¥¼ª¾¬O§_·|¼vÅT¥Í¨|¤O.¦³®×¨Ò¦bÂÀ±a¦å¤¤µo²{¥»ÃÄ¡A ¦³¤@À¦¨à¡A¨ä¥À¿Ë©óÃh¥¥²Ä¤T´Á¨Ï¥Î¥»ÃÄ¡A¦³¶Ç¾É©Ê¥¢Áo¡A¦ý«D¥Ñ¥»ÃÄ©Ò­P¡A¦b¦¹¬ã¨s¤¤¡A¦]¯f¤H¼Æ¥Ø¦³­­¡A ¥B¥u¦bÃh¥¥´Á²Ä¤G´Á»P²Ä¤T´Á§ë»P¥»ÃÄ¡A°µ¦¹ÃÄ¬O§_·|¾É­P­L¨à¶Ë®`¡A¥Ø«e¤´¥¼±oª¾. °£«D½T¹ê¦³¥²­n®É¡A¤~µ¹¥¥°ü§ë»P¦¹ÃÄ,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Vancomycin·|±Æªn¨ì¥À¨Å¤¤.¬G±Â¨Å°ü¨Ï¥Î®ÉÀ³ª`·N. ¥Ñ©ó¦³°Æ§@¥Îµo¥Íªº¥i¯à¡A¶··r°uÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡A¨M©w¬O§_°±¤î±Â¨Å©Î°±ÃÄ.,IMP;INS;IRR;IS;IVD;IVI;SCI;SUBCI;,IVD: 20 mL D/W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C,,µ¹ÃÄ¿@«× 2.5~5mg/mL¡A¿éª`³t²v< 10 mg/min¡A¨àµ£¦Ü¤Ö¥H¶W¹L60¤ÀÄÁ¥H¤W®É¶¡½wºCºwª`¡C,1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C 2. ª`·N¿éª`¹L§Ö®Éªº¤£¨}¤ÏÀ³¡G§C¦åÀ£¡B©I§l§xÃø¡BëC³Â¯l¡C 3. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C 4. µ¹ÃÄ¿@«×: 2.5~5mg/mL¡A§Q¥Î¿éª`²Gµ¹ÃÄ¡A¿@«×¤£¥i¶W¹L 5mg/mL¡C 5. ½Õ°t¤Î©âÃÄ®É«ØÄ³¨Ï¥ÎG21¸¹°wÀY(¥~®|0.8mm)¡A¨Ã¥B©ó¾ó½¦¶ë¤¤¥¡¦ì¸m°wÀY90«×¦V¤U¬ï¨ë¡AÁ×§K²£¥Í¾ó½¦¶ë¸H®h¡C 6. ¥[¤J10 mL·Àµßª`®g¥Î¤ô©ó500 mgµLµßvancomycin°®¯»¤§¤p²~¤º¡C¥H¦¹ªk½Õ±o50 mg/ mLªº·»²G¡A¶·¶i¤@¨Bµ}ÄÀ¡C·»²G½Õ°t¤§«á»Ý§NÂÃ¡A¥i©ó¦B½c¤¤«O¦s14¤Ñ¦Ó¤£·|©úÅã­°§C¤O»ù¡C
OVOS,Sofosbuvir + Velpatasvir + Voxilaprevir,Vosevi 400/100/100mg,QANB,Treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: (1) genotype 1¡A 2¡A 3¡A 4¡A 5¡A or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. (2) genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.,Concomitant use with rifampin. Hypersetitivity to Sofosbuvir/Velpatasvir/Voxilaprevir or any ingredients of this product.,Common Gastrointestinal: Diarrhea (13% to 14% )¡A Nausea Neurologic: Headache (21% to 23% ) Other: Fatigue (17% to 19% ) Serious Cardiovascular: Bradyarrhythmia¡A Cardiac arrest Hepatic: Decreased liver function¡A Liver failure¡A Reactivation of hepatitis B viral hepatitis,30¢J¥H¤U,One tablet contains sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg. 1 tablet once daily with meal for 12 weeks.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤£«ØÄ³¨Ï¥Î©ó¤¤©Î­««×¨x¥\¯à¤£¥þ¡]Child-Pugh B ¯Å©ÎC ¯Å¡^ªº¯f¤H¡A¦]¬°voxilaprevir ©ó³o¨Ç¯f¤Hªº¼ÉÅS¶q·|¤É°ª¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,SOFOSBUVIR: No Human Data¡XAnimal Data Suggest Low Risk (Contraindicated if Combined with Ribavirin) Velpatasvir: Unknown Voxilaprevir: Unknown [¥é³æ] Ãö©óVOSEVI¬O§_¹ïÃh¥¥³y¦¨­·ÀI¡A¥Ø«e©|µL¥R¨¬ªº¤HÃþ¸ê®Æ¥i¨Ñ§PÂ_¡C¦b°Êª«¥Í´Þ¬ã¨s¤¤¡AVOSEVI­Ó§O¦¨¤À¡]sofosbuvir¡Bvelpatasvir ©Îvoxilaprevir¡^ªº¼ÉÅS¶q°ª©ó¤HÃþ«ØÄ³¾¯¶q¡]RHD¡^¤§¼ÉÅS¶q¡A¨Ã¥¼Æ[¹î¨ì¤£¨}µo¨|ªºÃÒ¾Ú¡C¦b¾¹©xµo¥Í´Á¶¡¡Avelpatasvirªº¥þ¨­©Ê¼ÉÅS¶q¡]AUC¡^¬ù¹F¤HÃþ«ØÄ³¾¯¶q¡]RHD¡^¤§¼ÉÅS¶qªº23¡]¤p¹«¡^¡B4¡]¤j¹«¡^¤Î0.5¡]¨ß¤l¡^­¿¡Avoxilaprevirªº¥þ¨­©Ê¼ÉÅS¶q¡]AUC¡^¬ù¹F¤HÃþ«ØÄ³¾¯¶q¡]RHD¡^¤§¼ÉÅS¶qªº141¡]¤j¹«¡^¤Î4¡]¨ß¤l¡^­¿¡Asofosbuvir¥D­n´`Àô¥NÁÂª«¡]GS331007¡^ªº¼ÉÅS¶q¬ù¹F¤HÃþ«ØÄ³¾¯¶q¡]RHD¡^¤§¼ÉÅS¶qªº6¡]¤j¹«¡^¤Î16¡]¨ß¤l¡^­¿¡C¦b¤j¹«ªº¥X¥Í«e/«áµo¨|¬ã¨s¤¤¡AVOSEVI­Ó§O¦¨¤À¦b¥ÀÅé¤ºªº¥þ¨­©Ê¼ÉÅS¶q¡]AUC¡^¬ù¹F¤HÃþ«ØÄ³¾¯¶q¡]RHD¡^¤§¼ÉÅS¶qªº7¡]sofosbuvir¥NÁÂª«GS-331007¡^¡B3¡]velpatasvir¡^¤Î238¡]voxilaprevir¡^­¿¡C ¹ï©ó¯S©w±Ú¸s¤§­«¤j¥ý¤Ñ¯Ê³´¤Î¬y²£ªº­I´º­·ÀI©|¤£²M·¡¡C¦b¬ü°ê¤@¯ë±Ú¸s¡BÁ{§É½T»{ªºÃh¥¥¤¤¡A­«¤j¥ý¤Ñ¯Ê³´¤Î¬y²£ªº­I´º­·ÀI¦ô­p¤À§O¬°2-4%¤Î15-20%¡C,Unknown ¨S¦³¸ê®Æ,SOFOSBUVIR: No Human Data¡XProbable Compatible (Potential Toxicity if Combined with Ribavirin) Velpatasvir: Unknown Voxilaprevir: Unknown [¥é³æ] ¥Ø«e©|¤£ª¾¹DVOSEVI­Ó§O¦¨¤À¤Î¨ä¥NÁÂª«¬O§_·|¶i¤J¤HÃþ¨Å¥Ä¤¤¡B¬O§_·|¼vÅT¤HÃþ¨Å¥Ä¤Àªc©Î¹ï³Q­÷¨ÅªºÀ¦¨à³y¦¨¼vÅT¡C¹ï­÷¨Å¤¤ªº¤j¹«§ë¤©VOSEVI ­Ó§O¦¨¤À«á¡A¥i¦b¨Å¥Ä¤¤´ú±oGS331007¡]sofosbuvir ªº¥D­n´`Àô¥NÁÂª«¡^¤Îvelpatasvir¡A³Q­÷¨Å¥J¹«ªº¦å²G¤¤¥i´ú±ovoxilaprevir¡A³o¥i¯à¬O¦]¬°¨Å¥Ä¤¤¦³voxilaprevir¡C¦b³Q­÷¨Åªº¥J¹«¤¤¨Ã¥¼Æ[¹î¨ì¥ô¦óÃÄ«~ªºÅãµÛ§@¥Î¡C ­÷¨Å¹ïÀ¦¨àµo¨|¤Î°·±dªº¯q³B¡B¥À¿Ë¹ïVOSEVIªº»Ý¨D¥H¤ÎVOSEVI©Î¥À¿Ëª¬ªp¹ï­÷¨Å¤¤À¦¨à¼ç¦bªº¤£¨}¼vÅT¡A³£À³¤@¨Ö¦Ò¼{¡C,PO;WM;,,,,,
EAZL,Azelaic Acid,Azel cream 30gm,TDER,Acne vulgaris.,Hypersensitivity to propylene glycol. Hypersensitivity to azelaic acid or any component of the formulation.,Common: Burning sensation¡A Pruritus (Rosacea¡A 11% ; acne vulgaris¡A 1-5% )¡A Stinging of skin¡A Tingling of skin Serious: Skin irritation¡A Hypersensitivity reaction,30¢J¥H¤U,Apply to affected skin areas twice daily¡A in the morning and evening¡A unless otherwise instructed by a physician. If skin irritation occurs¡A reduce the frequency to once daily until the irritation subsides¡A otherwise¡A treatment should be temporarily discontinued. Continuous use is recommended for approximately 4 weeks to several months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[Micromedex] Fetal risk cannot be ruled out - available evidence is inconclusive or inadequate for determining fetal risk when used in pregnant women.,Unknown ¨S¦³¸ê®Æ,[Micromedex] Infant risk cannot be ruled out - Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.,EXT;SKIN;TOPI;,,,,,
ICOXBB15,SARS-CoV-2 Spike glycoprotein [mRNA],COVID-19 XBB.1.5 0.5mL/dose (2.5mL/vial),HIMM,For active immunization in children aged 6 months and above¡A adolescents¡A and adults to prevent COVID-19 (severe acute respiratory syndrome coronavirus 2 disease).,Known history of severe allergic reactions (eg¡A anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine¡A acetic acid¡A sodium acetate¡A sucrose¡A sphingomyelin¡A cholesterol¡A distearoylphosphatidylcholine¡A and polyethylene glycol [ie¡A PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine.,Common: Erythema at injection site (Adult¡A 2.4-9%; adolescent¡A 13.5-19.5%; pediatric¡A 3.5-18.7%)¡A Injection site pain (Adult¡A 73.9-89.9%; adolescent¡A 92.4-93.1%; pediatric¡A 37.4-94.8%)¡A Swelling at injection site (Adult¡A 4.5-12.7%; adolescent¡A 16.2-20.5%; pediatric¡A 2.8-17%)¡A Nausea and vomiting (Adult¡A 5.2-21.4%; adolescent¡A 11.3-23.9%; pediatric¡A 6.8-24%)¡A Axillary lymphadenopathy¡A Tenderness (Adult¡A 6.1-16.2%; adolescent¡A 21-23.3%; pediatric¡A 15.5-18%)¡A Arthralgia (Adult¡A 16.4-45.6%; adolescent¡A 15-28.9%; pediatric¡A 6.2-16.1%)¡A Myalgia (Adults¡A 19.7-61.7%; adolescents¡A 26.9-46.6%; pediatrics¡A 9.9-28.2%)¡A Headache (Adult¡A 24.5-63%; adolescent¡A 43.4-70.2%; pediatric¡A 11.5-54.3%)¡A Fatigue (Adult¡A 33.3-67.8%; adolescent¡A 47.9-67.8%; pediatric¡A 40.1-64.5%)¡A Fever (Adult¡A 0.3-17.4%; adolescent¡A 2.5-12.2%; pediatric¡A 3.3-23.9%)¡A Shivering (Adult¡A 5.3-48.7%; adolescent¡A 18.4-43%; pediatric¡A 6.4-30.3%) Serious: Myocarditis¡A Pericarditis¡A Facial swelling¡A Anaphylaxis¡A Hypersensitivity reaction (1.5-4.3%),¥¼¶}«Ê: -50¦Ü-15¢XC§N­á«O¦s9­Ó¤ë¡C¸Ñ­á«á(¤Å¦A§N­á): 2-8¢XC¤U§NÂÃ30¤Ñ¡CÂ÷¶}§NÂÃ«á: 24¤p®É¡C,For children aged 6 months to 4 years: (1) No prior COVID-19 vaccination and no known SARS-CoV-2 infection history: Two doses¡A 0.25 mL (25 micrograms) each¡A at least 28 days apart. (2) Previously received one dose of any Spikevax vaccine: Single 0.25 mL (25 micrograms) dose¡A at least 28 days after the previous dose. (3) Previously received two doses of Spikevax or had a SARS-CoV-2 infection: Single 0.25 mL (25 micrograms) dose¡A at least 3 months after the previous dose. For children aged 5 to 11 years: Single 0.25 mL (25 micrograms) dose¡A with a minimum 3-month interval if previously vaccinated. For adolescents aged 12 and adults: Single 0.5 mL (50 micrograms) dose¡A with a minimum 3-month interval if previously vaccinated.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|µL¦bÃh¥¥´Á¶¡¨Ï¥Î¬ÛÃö¸ê®Æ¡CSpikevax XBB.1.5¨Ï¥Î©óÃh¥¥°ü¤kªº¨Ì¾Ú¥D­n¨Ó¦Û ±µºØSpikevax ­ì¯f¬r®è¬Ì­]ªº¸gÅç¡C°Êª«¸ÕÅç¨Ã¥¼Åã¥Ü Spikevax ­ì¯f¬r®è¬Ì­]¹ïÃh¥¥¡B­F­L/­L¨àµo¨|¡B¤À®Y©Î²£«áµo¨|·|³y¦¨ª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C ¤j¶qªºÁ{§ÉÆ[¹î©Ê¸ê®ÆÅã¥Ü¡A¥¥°ü¦b²Ä¤G¥¥´Á©M²Ä¤T¥¥´Á±µºØSpikevax ­ì¯f¬r®è¬Ì­]¨Ã¥¼¼W¥[¤£¨}Ãh¥¥µ²ªG¡C ÁöµM¦b²Ä¤@¥¥´Á±µºØªºÃh¥¥µ²ªG¸ê®Æ¦³­­¡A¦ý¥¼µo²{¬y²£­·ÀI¼W¥[¦³¤W¤Éªº²{¶H¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|µL­÷¨Å´Á¨Ï¥Î¬ÛÃö¸ê®Æ¡CSpikevax XBB.1.5¨Ï¥Î©ó­÷¨Å´Á°ü¤kªº¨Ì¾Ú¥D­n¨Ó¦Û±µºØ Spikevax ­ì¯f¬r®è¬Ì­]ªº¸gÅç¡C¥Ñ©ó­÷¨Å°ü¤k±µºØSpikevax­ì¯f¬r®è¬Ì­]«á¤§¥þ¨­©Ê¼ÉÅS¥i³Q©¿²¤¡A ¹w´Á¹ï©óÁý­÷¥À¨Å¤§·s¥Í¨à/À¦¨à¤£¨ã¼vÅT¡CÆ[¹î©Ê¸ê®ÆÅã¥Ü­÷¨Å°ü¤k±µºØ¬Ì­]«á¡A ¨Ã¥¼¥X²{¹ïÁý­÷¥À¨Å¤§·s¥Í¨à/À¦¨à¦³®`ªº¼vÅT¡C,IM;,,,,,1. ¥»¬Ì­]¨Ï¥ÎÀ³¨Ì¾Ú½Ã¥Í¥DºÞ¾÷Ãö COVID-19 ¬Ì­]±µºØ«ØÄ³¬I¥´¡C 2. §N­á«O¦s(-50¦Ü-15¢XC)¡A¨Ï¥Î«e¶·¸Ñ­á(¸m©ó«Ç·Å15-25¢XC: 1¤p®É¡F§NÂÃ2-8¢XC: 2.5¤p®É)¡C¸Ñ­á«á½Ð¤Å­«·s§N­á¡C 3. ¶È¨Ñ¦Ù¦×ª`®gµ¹ÃÄ¡C¸Ñ­á«á¤Î¨C¦¸©âÃÄ«e½Ð»´®ÌÃÄ²~¡C¤£¥i®¶·n¡Bµ}ÄÀ©Î²V¦X¨ä¥L¬Ì­]¡C 4. ²Ä¤@¾¯©â¥X«á¦b2-25¢XC¥i¦s©ñ19¤p®É¡F2-8¢XC¤U¥i30¤Ñ¡C
OAMOX,Amoxicillin,AMOXICILLIN 500mg,QANB,G(+) & G(-) infections. Ear¡A nose¡A and throat infection. Helicobacter pylori gastrointestinal tract infection. Infection of skin and/or subcutaneous tissue. Infectious disease of genitourinary system. Lower respiratory tract infection. Pharyngitis - Tonsillitis. Sinusitis.,Serious hypersensitivity reactions¡A such as anaphylaxis and Stevens-Johnson syndrome¡A to amoxicillin or other beta-lactam antibiotics (eg¡A penicillins¡A cephalosporins),Common: Rash (greater than 1%)¡A Diarrhea (overall¡A greater than 1%; Helicobacter pylori therapy¡A 7-8%)¡A Nausea (greater than 1%)¡A Vomiting (greater than 1%)¡A Headache (Helicobacter pylori therapy¡A 6-7%; extended-release tablets¡A 1%)¡A Vulvovaginitis¡A Mycotic (extended-release¡A 2%) Serious: Shock¡A Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Clostridium difficile diarrhea¡A Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Angioedema,«Ç·ÅÁ×¥ú,Infection of upper respiratory tract¡A genitourinary tract and skin/soft tissue: Adult: 250-500 mg orally once every 8 hours; children: 20-40 mg/kg/day in divided doses every 8 hours. Lower respiratory tract infection: Adult: 500 mg every 8 hours; children: 40 mg/kg/day in divided doses every 8 hours. Children > 20 kg should be dosed according to the adult recommendations. Gonorrhea¡A acute uncomplicated genitourinary tract infections caused by N. gonorrhoeae in males and females: Adult: 3 g as single oral dose. All patients with gonorrhea should be evaluated for syphilis. The following Pediatric dose recommendation is from Sanford Guide to Antimicrobial Therapy.(2022/11/08): Age>28 days: 25-100mg/kg/day divided Q8-12H.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest risk in 1st and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ODEPY,Acetaminophen,Depyretin 500mg,CNEU,Relief of painful disorders such as headache¡A dysmenorrhea¡A conditions involving musculoskeletal pain¡A myalgias & neuralgias. After dental work¡A tooth extractions & in teething. As an analgesic & antipyretic in conditions accompanied by discomfort & fever¡A such as common cold & viral infections.,When used for self-medication¡A do not use with other drug products containing acetaminophen or if allergic to acetaminophen or any of the inactive ingredients.,Common: Pruritus (5% or greater)¡A Constipation (5% or greater)¡A Nausea (adult¡A 34%; pediatric¡A 5% or greater)¡A Vomiting (adult¡A 15%; pediatric¡A 5% or greater)¡A Headache (1-10%)¡A Insomnia (1-7%)¡A Agitation (5% or greater)¡A Atelectasis (5% or greater) Serious: Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Liver failure¡A Pneumonitis,25¢J¥H¤U°®ÀêÁ×¥ú,>12 years old: 500-1000mg(1-2 Tablet) Q4-6H. Use the minimum recommended dose for the first time¡A and then increase or decrease the dose based on symptoms. No more than 4 times in 24 hours. 6-12 years old: 1/2 of adult dose. 3-6 years old: 1/4 of adult dose.,»Ý½Õ¾ã¾¯¶q,In patients with hepatic impairment/cirrhosis and active alcohol use¡A most experts recommend avoiding use as much as possible¡A and if used¡A limiting therapy to short-term use only at doses =<2 g/day.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ERINA,Betamethasone + Fradiomycin,Rinderon-A eye soln¡A 5mL,TOPH,,¾AÀ³¯g: Inflammatory conditions of the eye when secondary bacteria infection is present. °Æ§@¥Î: Allergic reactions¡A superinfection¡A delayed wound healing¡A raised intraocular pressure¡A thinning of cornea (possible perforation). ¸T§Ò: Viral¡A fungal or TB conditions; glaucoma¡A herpetic keratitis.,,2-8 C,1-2 drops¡A 3-5 times daily.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OBNGP,·íÂk¡A¶ÀÍÁ¡A¬õ¯Ï¡A¤ÑªÇ¶À¡A¤H°Ñ¡A®ã­J¡A¶À³s¡A¥Ì¯ó,BNG-1 powder 3gm/pack,HEMT,In combination with Aspirin to assist in improving activities of daily living for adult patients from 20 to under 65 years of age who have an ischemic stroke.,Pregnancy. Lactation. Patients under 20 years of age or above 65 years of age.,Constipation¡A diarrhea¡A upper abdominal pain¡A pyrexia¡A liver function test abnormal¡A allergic rhinitis¡A nasopharyngitis¡A upper respiratory tract infection¡A back pain¡A dizziness¡A headache¡A anxiety¡A haematuria¡A nocturia¡A cough.,25¢J¥H¤U,1 sachet TID for 4 weeks. Take with warm water¡A and take on an empty stomach (1 hour before meals or 2 hours after meals). BNG-1 and aspirin should be taken at least one hour apart.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ²Ä¤T´ÁÁ{§É¸ÕÅç±Æ°£¦³¤wª¾Á{§É­«¤j¯e¯f±wªÌ(¨Ò¦p:¨xµÇ©Ê¯e¯f)¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥»«~¹ï©óÃh¥¥°ü¤k¡B­÷¨Å°ü¤k¡A¦w¥þ©Ê¤Î¦³®ÄÃÒ¾Ú©|¥¼½T¥ß¡AÀ³Á×§K¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥»«~¹ï©óÃh¥¥°ü¤k¡B­÷¨Å°ü¤k¡A¦w¥þ©Ê¤Î¦³®ÄÃÒ¾Ú©|¥¼½T¥ß¡AÀ³Á×§K¨Ï¥Î¡C,AC;PO;,,,,,
IMMR,Measles + Mumps + Rubella,Priorix inj (MMR) 0.5mL/dose (¦Û¶O³Â¯lµ¥¤TºØ¬Ì­]),HIMM,Immunization against measles¡A mumps & rubella in individuals ¡Ù 12 months¡A non-pregnant adolescents¡A adult female & postpartum women. Children ¡Ø12 months¡A should be revaccinated after reaching 15 months.,Pregnancy. Any febrile infection or febrile respiratory illness. Active untreated TB¡A blood dyscrasias¡A leukemia¡A lymphomas of any type¡A malignant neoplasms affecting the bone marrow or lymphatic system. Patients receiving immunosuppressive therapy. Primary & acquired immunodeficiency states¡A or family history of immunodeficiency. Hypersensitivity to neomycin or eggs.,Burning¡A stinging at inj site. Headache¡A fever¡A sore throat¡A GI upset¡A rash¡A arthralgia &/or arthritis¡A parotitis¡A nerve deafness¡A optic neuritis. Lymphadenopathy¡A afebrile convulsions¡A ataxia¡A Guillain-Barre syndrome¡A thrombocytopenia purpura¡A dizziness¡A paraesthesias.,2-8¢JÁ×¥ú,SC¡A 0.5mL¡A children 6-12 months primary immunization¡A the second dose at 15 months of age¡A the third dose at 4-6 years or 11-12 years. Age > or = 12 months primary immunization¡A the second dose at 4-6 years or 11-12 years.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]Ãh¥¥°ü¤k¤£±o¨Ï¥ÎPriorix.µM¦Ó¡AÃh¥¥°ü¤k¦b¬I¥´³Â¯l¡A¸|¸¢ª¢¡A¼w°ê³Â¯l¬Ì­]«á¡A¨ÖµLµo¥ÍÄY­«¶Ë®`ªº¬ö¿ý. ¾¨ºÞ­ì²z¤Wªº­·ÀIµLªk³Q±Æ°£¡A¦ý¦³¶W¹L3500¤£ª¾¤wÃh¥¥°ü¤k¡A¦b±µºØ¥]§t¼w°ê³Â¯l¬Ì­]«á¡A¨Ã¨S¦³¥X²{¦³¥ý¤Ñ ©Ê¼w°ê³Â¯l¯g­Ô¸sªº®×¨Ò. ¦]¦¹¡A¹ï©ó¤£ª¾¤wÃh¥¥ªº°ü¤k¦b«D¨è·N±µºØ¥]§t³Â¯l¡A¸|¸¢ª¢¡A©Î¼w°ê³Â¯l¬Ì­]«á¡A¤£»Ý¦]¦¹²×¤îÃh¥¥. ¨|ÄÖ°ü¤kÀ³Á×§K©ó±µºØ«á¥|¶g¤ºÃh¥¥¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¦³Ãö±Â¨Å°ü¤k¨Ï¥Î±¡ªpªº¸ê®Æ«Ü¤Ö¡A·íÅv¿Å«á¡A¨ä§Q¯q°ª©ó­·ÀI«h¥i±µºØ¬Ì­].,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G¡A¨Ï¥Î¹w¶ñ¥R°wµ©°t»s¥»¬Ì­]ªº¨BÆJ½Ð¸Ô¾\¥é³æ¹Ï¸Ñ¡C,,,,1. ª`®gMMR®É¡A¤£¥i¦P®Éµ¹¤©§K¬Ì²y³J¥Õ¡C¦Ù¦×ª`®g§K¬Ì²y³J¥Õ«áÀ³¶¡¹j3­Ó¤ë¦Aª`®gPriorix¡A¿é¦å©ÎÀR¯ßª`®g¦å²G»s¾¯«áÀ³¶¡¹j6­Ó¤ë¦Aª`®gPriorix¡A±µ¨ü°ª¾¯¶qÀR¯ß§K¬Ì²y³J¥ÕÀ³¶¡¹j11­Ó¤ë¦Aª`®gPriorix¡C 2. ¥Ö¤Uª`®g³Ì¦nªºª`®g¦ì¸m¬O¤WÁuªº¥~°¼¡C 3. °t»s«áÀ³¥ß§Y¨Ï¥Î¡A­Y°t»s«á¸m©ó2-8«×C¥i«O¦s8¤p®É¡C
ISONA,Perfluorobutane microbubbles,Sonazoid inj 8 microliter/mL¡A 2mL,SCAN,Contrast-enhanced ultrasonography of focal liver lesions and focal breast lesions.,Hypersensitivity to Perfluorobutane microbubbles.,Headache¡A diarrhea¡A nausea¡A vomiting¡A abdominal pain¡A fever.,25¢J¥H¤U¡A¤Å§NÂÃ,Sonazoid contain perfluorobutane (PFB) microbubbles: 8 microliter per mL¡A powder and solvent for dispersion for injection. Adult: subsequent dosage adjustments should be made based on body weight. IV push only. 40kg:0.6mL; 50kg:0.75mL; 60kg:0.9mL; 70kg:1.05mL; 80kg: 1.2mL; 90kg:1.35mL; 100kg:1.5mL,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVP;IVPUSH;,ÃÄ«~±M¥Îµ}ÄÀ²G,,IV bolus for contrast-enhanced ultrasonography.,,1.¨Ï¥Îª`®g°w¤Õ®|¦Ü¤Ö¬°22G¡C 2.ÀR¸m®ÉÄa¯B²G·|¤ÀÂ÷¡A©Ò¥H¦b§ë»P¤§«e¡A½Ð¥ß§Y·n®Ì¥»«~¡A¥H½T«O¤º®eª«ªº§¡¤@©Ê¡C 3.¦b§ëÃÄ«áÀ³¥ß§Y¥H¤Ö¶qªºµ¥±i´â¤Æ¶u·»²G(ISCS) ¨R¬~ª`®g³~®|¡C 4.¶È¨Ñ³æ¦¸¨Ï¥Î¡C 5.Äa²GÀ³¦b°t»s«á¤§2¤p®É¤º¨Ï¥Î
OBIN,Alendronate,Binosto effervescent 70mg,META,Treatment of osteoporosis in postmenopausal women. Treatment to increase bone mass in men with osteoporosis.,Esophageal abnormalities (eg¡A stricture or achalasia) that delay esophageal emptying. Hypersensitivity to alendronate or any component of the product. Hypocalcemia; resolve prior to beginning therapy. Inability to stand or sit upright for 30 minutes. Patients at increased risk of aspiration should not receive oral solution or effervescent tablets.,Common: Abdominal pain (2.1-6.6%)¡A Constipation (0.3-3.1%)¡A Diarrhea (0.6-3.1%)¡A Flatulence (2.6-4.1%)¡A Indigestion (1.7-3.6%)¡A Vomiting (pediatric patients¡A 29.4%)¡A Headache (2.6%)¡A Fever (24%)¡A Influenza-like illness Serious: Heart failure¡A Esophageal erosions¡A Esophageal perforation¡A Esophageal stricture¡A Esophagitis (1.5%)¡A Gastric ulcer (up to 13.2%)¡A Ulcerative pharyngitis¡A acute¡A Ulcer of duodenum¡A Ulcer of esophagus (1.5%)¡A Hypersensitivity reaction¡A Arthralgia¡A Bone pain¡A Myalgia¡A Osteonecrosis caused by drug¡A External auditory canal¡A Osteonecrosis of jaw (0.017-0.03%),20-25¢JÁ×§K¨ü¼é,1 tablet once weekly.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°µoªw¿õ¡A¥H120mL±`·Å¥Õ¶}¤ô°t»s¦¨·»²G¡A µoªw°±¤î«á¡A¦AÅÍ©Õ10¬íÄÁ«á¶¼ºÉ¡C¦ý¥»ÃÄ¶¼¥Î«á»Ý«O«ù¤W¥b¨­ª½¥ß¦Ü¤Ö30¤ÀÄÁ¡C
OJAR2,Empagliflozin,Jardiance 25mg,META,Diabetes mellitus¡A type 2,History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2)¡A end-stage renal disease (ESRD)¡A or dialysis,>10%: Endocrine & metabolic: Hypoglycemia (combination therapy with insulin: 28%¡A severe hypoglycemia: <=1%; combination therapy with metformin and a sulfonylurea: 12% to 16%; combination therapy with metformin: 1% to 2%) Genitourinary: Urinary tract infection (9%; females: 18%; males: 4%)¡A increased urine output (includes polyuria¡A pollakiuria¡A nocturia: 3%) 1% to 10%: Endocrine & metabolic: Increased LDL cholesterol (5% to 7%)¡A dyslipidemia (4%)¡A increased thirst (including polydipsia: 2%) Gastrointestinal: Nausea (2%) Hematologic & oncologic: Increased hematocrit (3% to 4%) Infection: Genitourinary fungal infection (4%; females: 5% to 6% [includes bacterial vaginosis¡A cervicitis¡A vulvitis¡A vulvovaginal candidiasis¡A vulvovaginal infection¡A vulvovaginitis]; males: 2% to 3% [includes balanitis¡A balanoposthitis¡A genitourinary fungal infection¡A penile infection¡A scrotal abscess]),30¢J¥H¤U,Initial 10 mg once daily¡A may increase to 25 mg once daily as tolerated.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,AC;AC15;P1;P2;P3;P4;PC;PO;,,,,,
OMIRT,Mirtazapine,MirTapine 30mg orally disintegrating,CNEU,Major depressive disorder: Treatment of major depressive disorder (MDD),Hypersensitivity to mirtazapine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either mirtazapine or the MAO inhibitor); initiation of mirtazapine in a patient receiving linezolid or intravenous methylene blue.,Increase in appetite and wt¡A oedema; drowsiness or sedation; dizziness¡A headache¡A increased liver enzyme levels; jaundice. Orthostatic hypotension¡A rash¡A nightmares¡A agitation¡A mania¡A hallucinations¡A paraesthesia¡A convulsions¡A tremor¡A myoclonus¡A akathisia¡A restless legs syndrome¡A arthralgia¡A myalgia¡A reversible agranulocytosis¡A leucopenia¡A granulocytopenia¡A hyponatraemia. Endocrine metabolic: Increased appetite (17% )¡A Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )¡A Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) Gastrointestinal: Constipation (13% )¡A Xerostomia (25% ) Hepatic: ALT/SGPT level raised (2% ) Neurologic: Asthenia (8% )¡A Dizziness (7% )¡A Somnolence (54% ) Psychiatric: Disturbance in thinking (3% ),25¢J¥H¤U³±·t°®Àê³B,Major depressive disorder (MDD): Oral: Initial: 15 mg nightly¡A may titrate dose up no more frequently than every 1 to 2 weeks to a maximum of 45 mg/day; dosage range: 15 to 45 mg daily.,µL»Ý½Õ¾ã¾¯¶q,¤fªA³æ¾¯15²@§Jmirtazapine«á¡A¬Û¸û©ó¨x¥\¯à¥¿±`ªº¨ü¸ÕªÌ¡A»´·L¦Ü¤¤«×¨xÅ¦¨ü·lªº±wªÌ¡A¨ämirtazapine ªº²M°£²v¬ù­°§C35%¡CMirtazapineªº¥­§¡¦å¤¤¿@«×¬ù¼W¥[55%¡C,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¤f·»¿õ¡A¥i·»¤ô±Y´²«áªA¥Î¡C
IMID5,Midazolam,Midazolam-hameln inj 5mg/1mL,CNEU,Sedation for awareness¡A emergency ICU sedation¡A preoperative medication¡A anesthesia induction¡A and maintenance.,Hypersensitivity to benzodiazepine¡A midazolam or any excipient in the formulation.,Common: Excessive somnolence (1.6%)¡A Headache (1.3-1.5%)¡A Somnolence (1.2%)¡A Hiccoughs (3.6%) Serious: Cardiac arrest¡A Usually in combinations with CNS depressant drug¡A Involuntary movement¡A Sedated¡A Agitation (Up to 4%)¡A Apnea (Adult¡A 15.4%; pediatric¡A 2.8%)¡A Desaturation of blood¡A Pediatric patients (4.6%)¡A Respiratory arrest¡A Usually in combinations with CNS depressant drug¡A Respiratory depression¡A Respiratory obstruction (5%),30¢J¥H¤UÁ×¥ú¡A¤£±o§N­á¡C,[Sedation] (< 60 years) 2.5 mg IV over at least 2 minutes¡A administer 5-10 minutes prior to procedure. Allow 2 additional minutes to evaluate full effect after each 1 mg increment. Dose range: 3.5-7.5mg. A total dose >5 mg is usually not necessary. (>= 60 years) 1 mg IV over at least 2 minutes¡A administer 5-10 minutes prior to procedure. Allow 2 additional minutes to evaluate full effect after each 0.5-1 mg increment. A total dose > 3.5 mg is usually not necessary. (Non-neonatal) 0.1-0.15 mg/kg IM as a single dose. May use up to 0.5 mg/kg for more anxious patients. Total dose <= 10 mg. (6 months to 5 years) 0.05-0.1 mg/kg IV over 2-3 minutes. Total dose 0.6 mg/kg (maximum 6 mg). (6 to 12 years) 0.025-0.05 mg/kg IV over 2-3 minutes. Total dose 0.4 mg/kg (maximum 10 mg). (12 years to 16 years) as adult dosing. [Preoperative sedation] IM 20-60 minutes before anesthesia induction. (American Society of Anesthesia Physical Status I & II¡A < 60 years) 0.07-1 mg/kg (approximately 5 mg) IM up to 1 hour before surgery. (>= 60 years) 0.025-0.05 mg/kg IM (normally 2-3 mg). (1 to 15 years) 0.08-0.2 mg/kg IM. Rectal administration in children: Total dose 0.3-0.5 mg/kg¡A administered 20-30 minutes before anesthesia induction. The injection solution for rectal administration is injected using a plastic pusher fixed to the syringe end. If the delivered volume is too small¡A water can be added to bring the total volume to 10 mL. [Induction of general anesthesia] Each dose not exceeding 5 mg¡A injection time is 20-30 seconds¡A with a 2-minute interval between doses. Midazolam is not recommended for anesthesia induction in children. (< 60 years¡A premedicated) 0.15-0.2 mg/kg IV over 20-30 seconds¡A with a 2-minute interval. (< 60 years¡A non-premedicated) 0.3-0.35 mg/kg IV over 20-30 seconds¡A with a 2-minute interval. If complete induction is needed¡A approximately 25% of the original starting dose may be required. For patients with resistance¡A a total dose of up to 0.6 mg/kg may be needed. (>= 60 years) 0.3 mg/kg. Particularly frail individuals 0.15-0.25 mg/kg. Maintenance Dose: (Adults) Intermittent IV injection of small doses¡A 0.03-0.1 mg/kg¡A or continuous IV infusion of midazolam 0.03-0.1 mg/kg/hour¡A in combination with analgesics to maintain the desired level of anesthesia. (Children receiving ketamine anesthesia (analgesia)): 0.15-0.20 mg/kg IM. [ICU Sedation] (Adults) Loading dose: intermittent injection 1-2.5 mg/dose IV over 20-30 seconds¡A with a 2-minute interval. Total dose usually not exceeding 15 mg. When midazolam is used with potent analgesics¡A analgesic should be administered first. Maintenance dose: 0.03-0.2 mg/kg/hour; may be reduced to 25% of the usual dose if needed. (Children) Loading dose 0.05-0.2 mg/kg IV at least every 2-3 minutes¡A followed by continuous IV infusion of 0.06-0.12 mg/kg/hour (1-2 mcg/kg/minute). (< 32 weeks of gestation newborns) Continuous IV infusion at 0.03 mg/kg/hour (0.5 mcg/kg/minute). (> 32 weeks of gestation newborns) Continuous IV infusion at 0.06 mg/kg/hour (1 mcg/kg/minute). Loading dose should not be administered by IV injection in newborns.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¨ü·l·|­°§CÀR¯ßª`®gmidazolamªº²M°£²v¡A¶i¦Ó¼Wªø³Ì²×¥b°I´Á¡A¦]¦¹¡AÁ{§É®ÄªG¥i¯à·|¼W±j©Î©µªø¡C¥i¯à­°§Cmiadazolam¾¯¶q¡A¨Ã¾A·íºÊ±±¥Í©R¸ñ¶H¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ] ¥Ø«e¥¼¦³¨¬°÷ªº¼Æ¾Ú¥Hµû¦ô¥Î©óÃh¥¥¤§¦w¥þ©Ê¡C°£«D¨S¦³§ó¦w¥þªº¥N´À¤èªk¡A§_«hÃh¥¥´Á¶¡À³Á×§K¨Ïbenzodiazepines¡C ¦bÃh¥¥ªº³Ì«á¤T­Ó¤ëµ¹¤©midazolam©Î¤À®Y´Á¶¡µ¹¤©°ª¾¯¶q¡A¦³³ø§i«ü¥X­L¨àªº¤ß¸õ¤£³W«h¡B·s¥Í¨à¥X²{¦Ù±i¤O¹L®z¡B§l§m¤O¤£¨¬¡BÅé·Å¹L§C©M¤¤«×©I§l§í¨îµ¥§@¥Î¡C¦AªÌ¡A¥ÀÅé­Y©óÃh¥¥«á´Á¶¥¬qªø´Á±µ¨übenzodiazepines¡AÀ¦¨à¥i¯à·|µo®i¥X¥Í²z¨Ì¿à©Ê¡A¥B¦b²£«á´Á¶¡¤]¥i¯àµo®i¥X§ÙÂ_¯gª¬ªº¦MÀI©Ê¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,Midazolam: Compatible (Potential Toxicity If Combined With Other CNS Depressants.) [¥é³æ] Midazolam·|¤Ö¶q¤Àªc©ó¨Å¥Ä¤¤¡A©Ò¥H«ØÄ³±Â¨Å¥À¿ËÀ³¦bªA¥Îmidazolam 24¤p®É¤º°±¤î±Â¨Å¡C,IM;IVD;IVPUSH;RECT;,,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,slow IV push at least 2 minutes,15mg in 100 to 1000mL intraveneous solution,
OPAXS1,Nirmatrelvir + Ritonavir,Paxlovid 300/100mg¡A 10 doses ¦Û¶O,QANB,An Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing¡A and who are at high risk for progression to severe COVID-19¡A including hospitalization or death.,History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.,Common: Diarrhea (3%)¡A Taste sense altered (5%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hepatitis¡A Including increased transaminase levels¡A Anaphylaxis¡A Hypersensitivity reaction,25¢J¥H¤U,Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together orally twice daily for 5 days.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¤£«ØÄ³­««×¨x¥\¯à¤£¥þ¯f¤H¨Ï¥Î¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[Lexidrug 20240326] Nirmatrelvir©Mritonavir¬Ò¥i¬ï¹L­L½L¡C¥À¿Ë¦bÃh¥¥´Á¶¡¨Ï¥Îritonavir-boosted nirmatrelvir «áªºµ²ªG¸ê®Æ¦³­­¡C ¤@¯ë¨Ó»¡¡AÃh¥¥´Á¶¡·P¬V COVID-19 ªºªvÀø»P«DÃh¥¥±wªÌ¬Û¦P¡CµM¦Ó¡A¥Ñ©ó¤j¦h¼Æ§³®W±wªÌªvÀøÃÄª«ªº¼Æ¾Ú¦³­­¡A¦]¦¹À³±NªvÀø¿ï¾Ü§@¬°¦@¦P¨Mµ¦¹Lµ{ªº¤@³¡¤À¶i¦æµû¦ô¡]NIH 2023¡^¡C Ãh¥¥¬OÄY­« COVID-19 ªº¦MÀI¦]¤l¡C«ØÄ³¨Ï¥Îritonavir-boosted nirmatrelvir¡A¨Ã¥B¥i¥H¦b¥¼¦í°|¥B COVID-19 ÀË´ú§e¶§©Ê©Î°ª«×ÃhºÃ§e¶§©Êªº¥¥°ü¤¤¶}©l¨Ï¥Î¡C¦b³B¤è«eµû¦ô¼ç¦bªºÃÄª«¥æ¤¬§@¥Î¡]ACOG 2023¡FNIH 2023¡^¡C,Unknown ¨S¦³¸ê®Æ,[Lexidrug 20240326] Ritonavir¦s¦b©ó¥À¨Å¤¤¡F nirmatrelvir ªº±Æªn©|¤£²M·¡¡C ­÷¨Å´Á±wªÌ¨Ï¥Îritonavir-boosted nirmatrelvir«áªºµ²ªG¼Æ¾Ú¦³­­¡C ©|¥¼µo²{¥À¨Å¬O COVID-19 ·P¬Vªº¨Ó·½¡A¥¥²£°ü·P¬V¤]¤£¬O¥À¨Å­÷¨|ªº¸T§Ò¯g¡C ¦b COVID-19 ªvÀø´Á¶¡¥À¨Å­÷¨|ªº¨M©wÀ³§@¬°¦@¦P¨Mµ¦¹Lµ{ªº¤@³¡¤À¶i¦æµû¦ô¡C¦pªG»Ý­nritonavir-boosted nirmatrelvir¨ÓªvÀø COVID-19¡A«h¥i¥HÄ~Äò­÷¨Å¡CµM¦Ó¡A·P¬VCOVID-19ªº­÷¨Å±wªÌ¥i³z¹L©I§l¹D­¸ªj¶Ç¼½¯f¬r¡AÀ³±Ä¨ú¤@¤Á¹w¨¾±¹¬IÁ×§K±N¯f¬r¶Ç¼½µ¹À¦¨à¡]¨Ò¦p«O«ù¤â³¡½Ã¥Í¡BÀ¹¤f¸n¡^¡F©ÎªÌ¡A¥i¥H¥Ñ¥¼½T¶E©ÎºÃ¦ü COVID-19 ªº¤HÀ½¥X¥À¨Å¨ÃÁýµ¹À¦¨à¡]ACOG 2023¡FNIH 2023¡^¡C,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã²É§]ªA¡C¤£±o©CÄZ¡B¯}Ãa©ÎÀ£¸H¿õ¾¯¡C
OIBR1,Palbociclib,Ibrance 100mg,RACA,Breast cancer¡A advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive¡A human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer¡A advanced (with disease progression following endocrine therapy): Treatment of HR-positive¡A HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).,Common Dermatologic: Alopecia (18% to 33% )¡A Rash (17% to 18% ) Gastrointestinal: Constipation (20% )¡A Decrease in appetite (15% to 16% )¡A Diarrhea (24% to 26% )¡A Nausea (34% to 35% )¡A Stomatitis (28% to 30% )¡A Vomiting (16% to 19% ) Hematologic: Anemia¡A All Grades (24% to 30% )¡A Leukopenia¡A All Grades (39% to 53% )¡A Neutropenia¡A All Grades (80% to 83% )¡A Thrombocytopenia¡A All Grades (16% to 23% ) Immunologic: Infectious disease (47% to 60% ) Neurologic: Asthenia (8% to 13% )¡A Headache (26% )¡A Peripheral neuropathy (13% ) Respiratory: Bleeding from nose (6.7% to 9.2% )¡A Upper respiratory infection (31% ) Other: Asthenia (7.5% to 17% )¡A Fatigue (37% to 41% )¡A Fever (12% to 13% ) Serious Hematologic: Anemia¡A Grade 3 or 4 (Up to 5% )¡A Febrile neutropenia (0.9% to 2.5%)¡A Leukopenia¡A Grade 3 or 4 (Grade 3¡A 24% to 30%; Grade 4¡A up to 1% )¡A Neutropenia¡A Grade 3 or 4 (Grade 3¡A 55% to 56%; Grade 4¡A 10% to 11% )¡A Thrombocytopenia¡A Grade 3 or 4 (Up to 2% ),30 ¢J¥H¤U,The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE¡A the recommended dose of fulvestrant is 500 mg administered on Days 1¡A 15¡A 29¡A and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. Recommended Dose Modification for Adverse Reactions: (Dose Level; Dose) Recommended starting dose: 125 mg/day; First dose reduction: 100 mg/day; Second dose reduction: 75 mg/day. Dose Modification and Management ¡V Hematologic Toxicities: Monitor complete blood counts prior to the start of IBRANCE therapy and at the beginning of each cycle¡A as well as on Day 15 of the first 2 cycles¡A and as clinically indicated. For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles¡A monitor complete blood counts for subsequent cycles every 3 months¡A prior to the beginning of a cycle and as clinically indicated. (CTCAE Grade) Grade 1 or 2: No dose adjustment is required. Grade 3: Day 1 of cycle: Withhold IBRANCE¡A repeat complete blood count monitoring within 1 week. When recovered to Grade 2¡A start the next cycle at the same dose. Day 15 of first 2 cycles: If Grade 3 on Day 15¡A continue IBRANCE at current dose to complete cycle and repeat complete blood count on Day 22. If Grade 4 on Day 22¡A see Grade 4 dose modification guidelines below. Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles. Grade 3 neutropeniab with fever more than 38.5 oC and/or infection: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose. Grade 4: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¹ï­««×¨x¥\¯à¤£¥þ(Child-Pugh¤À¯ÅC)ªº¯f¤H¡AIbrance¹ï©ó3/1 Àøµ{¯f¤Hªº«ØÄ³¾¯¶q¬°¨C¤é¤@¦¸75 ²@§J¡C [Micromedex 20210905]Hepatic impairment (severe¡A Child-Pugh C): 75 mg orally once daily for 21 consecutive days followed by 7 days off treatment of a 28-day cycle.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¥Ø«e¨ÃµL©Î¶È¦³¦³­­ªº¥¥°ü¨Ï¥Îpalbociclib ªº¸ê®Æ¡C °Êª«¬ã¨sÅã¥Ü¥»«~¨ã¦³¥Í´Þ¬r©Ê¡C Ibrance¨Ã¤£«ØÄ³©óÃh¥¥´Á¶¡¨Ï¥Î¡A¤]¤£«ØÄ³¥Î©ó¨ã¥Í¨|¯à¤O¦ý¥¼±Ä¨úÁ×¥¥±¹¬Iªº°ü¤k¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ]¥Ø«e©|¥¼¶i¦æ¹L¥ô¦óµû¦ôpalbociclib ¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅT¡B¬O§_¥X²{©ó¨Å¥Ä¤¤¡B©Î¨ä¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅTªº¤HÅé¬ã¨s©Î°Êª«¬ã¨s¡C ¥Ø«e¨Ã¤£½Tª¾palbociclib ¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C ±µ¨üpalbociclib ªvÀøªº¯f¤H¤£¥iÁý­÷¥À¨Å¡C,WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¥é³æ«ØÄ³À³¾ãÁû§]ªA¡A¤Å©CÄZ¡B«r¸H©Î¥´¶}½¦Ån¡C
OALP,Alprazolam,Alprazolam 0.5mg,CNEU,,¾AÀ³¯g: Anxiety states¡A Anxiety with symptoms of depression. °Æ§@¥Î: Drowsiness. Less commonly lightheadedness¡A blurred vision¡A coordination disorders; GI effects; autonomic effects; dependence¡A withdrawal syndrome. Rarely¡A paradoxical agitation¡A confusion. ¸T§Ò: Hypersensitivity to alprazolam or any component of the formulation¡A Acute narrow angle glaucoma.,,«Ç·Å,Anxiety states Adult 0.25-0.5 mg tid. Elderly or debilitated patient 0.25 mg bid-tid. Anxiety with symptoms of depression Adult 0.5-4 mg daily in divided doses. Elderly or presence of debilitating diseases 0.5-0.75 mg daily in divided doses.,»Ý½Õ¾ã¾¯¶q,Advanced liver disease: Immediate release tablet: 0.25 mg 2 to 3 times daily.,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OVEP5,Etoposide,Vepesid 50mg (±M®×¶i¤f),RACA,Small cell carcinoma of lung¡A In combination with other approved chemotherapeutic agents as first line¡A Testicular cancer¡A In combination with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical¡A chemotherapeutic¡A and radiotherapeutic therapy,Hypersensitivity to etoposide or any component of the formulation. Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment,Alopecia¡A Shivering¡A Diarrhea¡A Inflammatory disease of mucous membrane¡A Loss of appetite¡A Nausea¡A Vomiting¡A Asthenia¡A Fever¡A Malaise,10-25¢J,(µLTFDA¥é³æ) (US FDA¥é³æ) [Testicular cancer] dose ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1¡A 3¡A and 5 in combination with other approved chemotherapeutic agents. [Small cell lung cancer] dose ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.,»Ý½Õ¾ã¾¯¶q,UpToDate Floyd 2006: Bilirubin 1.5 to 3 mg/dL or AST >3 times ULN: Administer 50% of dose King 2001; Koren¡A 1992: Bilirubin 1.5 to 3 mg/dL or AST >180 units/L: Administer 50% of dose Bilirubin 1.5 to 3 mg/dL or AST >3 times ULN: Administer 50% of dose,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OUROD,Phenazopyridine,Urodine 100mg,SGU,Symptomatic relief of pain¡A burning¡A urgency¡A frequency¡A and other discomforts that arise from irritation of the lower urinary tract mucosa.,Hypersensitivity to phenazopyridine products. Renal insufficiency. Pyelonephritis in Pregnancy. Severe hepatitis.,Common Neurologic: Headache Serious Hematologic: Hemolytic anemia Hepatic: Hepatotoxicity Immunologic: Anaphylactoid reaction Renal: Nephrotoxicity,«Ç·Å,Adult: 100-200mg TID. [Micromedex 20210913] Dysuria¡A Symptomatic relief: 200 mg ORALLY 3 times a day after meals; use should not exceed 2 days when used concomitantly with an antibiotic.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,¥é³æµL¬ÛÃö»¡©ú,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,BREASTFEEDING SUMMARY - No reports describing the use of phenazopyridine during human lactation have been located. The molecular weight suggests that the drug will be excreted into breast milk. Because phenazopyridine can cause methemoglobinemia¡A sulfhemoglobinemia¡A and hemolytic anemia¡A it should not be used during breastfeeding¡A especially with an infant under 1 month of age or with G-6-PD deficiency. ¥é³æµL¬ÛÃö»¡©ú,PC;PO;WM;,,,,,
IDOX,Doxorubicin,Doxor lyo inj 10mg (­á´¹),RACA,Acute and chronic leukocytosis¡A sarcoma¡A lymphoma¡A fibrosarcoma¡A neuroblastoma¡A breast cancer¡A lung cancer.,Allergic reaction to the main ingredient or other excipients. Allergic reaction to other anthracyclines or anthracenediones. Intravenous injection use: Previous persistent bone marrow suppression caused by other antineoplastic drugs or radiation therapy. Severe hepatic dysfunction. Severe myocardial dysfunction. Recent myocardial infarction. Severe arrhythmias. Previous treatment with the maximum cumulative dose of doxorubicin¡A daunorubicin¡A epirubicin¡A idarubicin¡A and/or other anthracyclines and anthracenediones. Intravesical use: Urethral infection. Bladder inflammation. Hematuria.,Common: Alopecia (92%)¡A Nausea (>10%)¡A Vomiting (34-37%) Serious: Cardiomyopathy¡A Congestive heart failure¡A Left ventricular failure¡A acute¡A Myocardial infarction¡A Myocarditis¡A Pericarditis¡A Tachyarrhythmia¡A Injection site extravasation¡A Radiation recall reaction due to cytotoxic therapy¡A Tissue necrosis¡A Pancreatitis¡A Acute myeloid leukemia¡A Leukopenia¡A Grade 3 or 4 (3.7%)¡A Myelodysplastic syndrome¡A Myelosuppression¡A Neutropenia¡A Thrombocytopenia¡A Grade 3 or 4 (0.1%)¡A Hepatitis¡A Veno-occlusive disease of the liver¡A Anaphylaxis¡A Septic shock (2%)¡A Radiation pneumonitis¡A Tumor lysis syndrome,25'C¥H¤U«Ç·Å«O¦s¡AÁ×¥ú¡C,Administer by intravenous injection or¡A for local tumor treatment¡A slow infusion through the local artery or instillation into the bladder via catheter. Dissolve using provided solvent. Do not administer orally¡A or via intramuscular or intrathecal injection. [Intravenous Injection] The cumulative dose of intravenous doxorubicin should not exceed 550 mg/m2. Monotherapy: (Adults) 60-75 mg/m2 IVD every 21 days. (Elderly or immunocompromised) 60 mg/m2 IVD every 21 days. (Pediatric) 30 mg/m2 IVD¡A administered daily for three consecutive days¡A repeated every 4 weeks. Combination Therapy: (With bone marrow suppressants) 25-50 mg/m2 IVD every 3-4 weeks. (Without bone marrow suppressants) 60-75 mg/m2 IVD every 3-4 weeks. [Intravesical Administration] Instill 30-50 mg into the bladder let it stay for 1-2 hours every 1 week to 1 month. Recommended concentration: 1 mg/mL. Rotate body during instillation for optimal contact. Instruct patients not to drink liquids 12 hours before to avoid dilution. Prompt voiding after instillation.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ­««×¨x¥\¯à¤£¥þ±wªÌ¡A¤£±o¨Ï¥Îdoxorubicin¡CSerum bilirubin of 1.2-3 mg/dL: Reduce dose by 50%. Serum bilirubin >3 mg/dL: Reduce dose by 75% [Micromedex] Severe hepatic impairment (Child-Pugh C or serum bilirubin >5 mg/dL): Contraindicated for use.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,[¥é³æ] Åé¤º©MÅé¥~¬ã¨s¤wÃÒ¹ê¡Adoxorubicin¥i¯à¨ã­F­L¬r©Ê¡C»Û©Ê¤j¹«¦b¥æ°t¡BÃh¥¥©M±Â¨Å«e ¤Î´Á¶¡¨Ï¥Î®É¡Adoxorubicin¹ï©ó¥ÀÅé©M­F­L§¡¨ã¦³¬r©Ê¡CÃh¥¥´Á¶¡¨Ï¥Î·|¾É­P­F­L¨ü·l¡C ¥²¶·§iª¾Ãh¥¥´Á¶¡¨Ï¥Îdoxorubicin©ÎªvÀø´Á¶¡Ãh¥¥ªº±wªÌ¡A¹ï©ó­F­Lªº¥i¯à­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] Doxorubicin·|±Æ¤J¨Å¥Ä¡C¤k©Ê±µ¨üdoxorubicinªvÀø´Á¶¡¡A¤£À³±Â¨Å¡C,IA;IRR;IVD;,Dissolve using provided solvent 5mL (ampoule) - Water for injection,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¨xµÇ¥\¯à¡B§¿»Ä»P¦å¤¤¹q¸Ñ½è¿@«×¡C 3. ¥»«~µ}ÄÀ«á¡A¦b«Ç·ÅÁ×¥ú¤U¥i«O¦s 24 ¤p®É¡A¦ý¦b 4¢XC~10¢XC ®É¥i«O¦s 48 ¤p®É¡C
OCONI,Benidipine,Coniel 4mg,CAVS,Hypertension,Cardiogenic shock (possibly worsening symptoms). Pregnant women and women who may become pregnant.,tachycardia¡A flushing¡A headaches¡A Liver dysfunction¡A jaundice¡A AST (GOT)¡A ALT (GPT)¡A £^-GTP increase¡A Kidney BUN rises¡A Creatinine rises¡A Leukopenia¡A Eosinophilia¡A Thrombocytopenia¡A feeling fever¡A hypotensive¡A Chest pressure¡A Bradycardia¡A palpitations¡A dizziness¡A the dark feeling when standing¡A Drowsiness¡A numbness¡A Constipation¡A Abdominal discomfort¡A Vomiting¡A Chest tightness¡A Thirsty¡A diarrhea¡A Vomit¡A gingival hyperplasia¡A Rash¡A Itching¡A Photosensitivity¡A tinnitus¡A Redness of the skin of the fingers¡A Feeling of heat¡A Shoulder pain¡A cough¡A Frequent urination¡A Burnout¡A Increased plasma potassium¡A Gynecomastia¡A Conjunctival hyperemia¡A Blurred vision¡A sweat,25¢J¥H¤U,HTN: adult 2-4mg QD after breakfast. Severe HTN: 4-8mg QD.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤£«ØÄ³¨Ï¥Î©ó¨x¥\¯à¤£¥þ±wªÌ,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T§Ò: ¥¥°ü©M¥i¯àÃh¥¥ªº°ü¤k¡C¥¥°ü©M¥i¯àÃh¥¥ªº°ü¤kÀ³¸ÓÁ×§KªA¥Î¥»«~¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] À³Á×§Kµ¹ÃÄ©ó±Â¨Å°ü¡A¦pªG¤£±o¤w¥²¶·µ¹ÃÄ®É¡AÀ³¸Ó°±¤îÁý¥¤¡C,PC;PO;,,,,,
OMON,Fosfomycin,Monurol 3gm/pack,QANB,,¾AÀ³¯g: Uncomplicated urinary tract infections: Treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis. °Æ§@¥Î: Central nervous system: Headache (4% to 10%)¡A pain (2%)¡A dizziness (1% to 2%) Dermatologic: Rash (1%) Endocrine and metabolic: Dysmenorrhea (3%) Gastrointestinal: Diarrhea (9% to 10%)¡A nausea (4% to 5%)¡A abdominal pain (2%)¡A dyspepsia (1% to 2%) Genitourinary: Vaginitis (6% to 8%) Neuromuscular & skeletal: Back pain (3%)¡A weakness (1% to 2%) Respiratory: Rhinitis (5%)¡A pharyngitis (3%) ¸T§Ò: Hypersensitivity to fosfomycin or any component of the formulation,,,Acute lower uncomplicated UTI 1 sachet. Prophylaxis prior to transurethral surgery & diagnostic procedures 2 sachets¡A the 1st taken 3 hrs before surgery¡A the 2nd 24 hr after surgery.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OFUN,Terbinafine,Fungitech 250mg,QANB,Onychomycosis¡A Tinea capitis¡A derma fungal infection which is severe¡A extensive¡A and partly treated in vain.,Allergy toTerbinafine.,Common Dermatologic: Rash (oral granules¡A 2% ; oral tablets¡A 5.6% ) Gastrointestinal: Diarrhea (oral granules¡A 3% ; oral tablets¡A 5.6% )¡A Disorder of taste (oral tablets¡A 2.8% )¡A Indigestion (oral tablets¡A 4.3% )¡A Nausea (oral granules¡A 2% ; oral tablets¡A 2.6% )¡A Vomiting (oral granules¡A 5% ) Hepatic: Increased liver enzymes (oral tablets¡A 3.3% ) Neurologic: Headache (oral granules¡A 7% ; oral tablet¡A 12.9% ) Respiratory: Cough (oral granules¡A 6% )¡A Nasopharyngitis (oral granules¡A 10% )¡A Upper respiratory infection (oral granules¡A 5% ) Other: Fever (oral granules¡A 7% ) Serious Dermatologic: Cutaneous lupus erythematosus¡A Erythema multiforme¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Hematologic: Neutropenic disorder (Severe)¡A Thrombotic microangiopathy Hepatic: Liver failure Immunologic: Drug reaction with eosinophilia and systemic symptoms¡A Systemic lupus erythematosus Otic: Hearing loss,25¢J¥H¤U,Adult: 250mg once a day. Children above 3 years old: weight<20kg: 62.5mg once a day¡A weight 20-40kg: 125mg once a day¡A weight>40kg: 250mg once a day. Treatment duration Cutaneous infection: Feet tinea(between the toes¡A pachyderm) 2-6weeks. Ringworm of the body tinea cruris 2-4weeks. Cutaneous candida infection 2-4weeks. Infections of scalp hair: Tinea capitis 4weeks. Tinea capitis occurs mostly in children. Onychomycosis most patients need a 6-12weeks period of treatment. In Fingernail onychomycosis¡A most patients need 6 weeks. In toenail onychomycosis¡A most patients need 12 weeks.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]Ã­©w¥BºC©Ê¨x¥\¯à²§±`ªº¯f¤H¡AÀ³¨Ï¥Î«ØÄ³¾¯¶qªº¤@¥b¡C¨ÃÀ³¦b¥ÎÃÄ«e«á°lÂÜ¨ä¨x¥\¯à¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]­L¨à¬r©Ê»P±Âºë²vªº°Êª«¹êÅç¡AÅã¥ÜµL¦¹¤£¨}§@¥Î¡C Ãh¥¥ªÌ¨Ï¥ÎÅð¯S§JµÎªº¸gÅç«Ü¤Ö¡A«ØÄ³Ãh¥¥°ü¤k¤£­n¨Ï¥Î¡A°£«D¨Ï¥ÎÅð¯S§JµÎ¥i¯àªº¦n³B¤j©ó¥i¯àªº¦MÀI©Ê¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Terbinafine¥i¯à¥X²{¦b¨Å¥Ä¤¤¡A¤fªA¨Ï¥ÎÅð¯S§JµÎªÌ¤£¥i±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
ENICI,Nicotine,Nicorette 10mg inhaler (18 cartridges/box),ZADT,Smoking cessation aid.,Hypersensitivity to nicotine or any component of the formulation. Recent cerebrovascular accident¡A acute Myocardial infarction¡A unstable or worsening angina pectoris¡A severe cardiac arrhythmias.,Common Dermatologic: Skin irritation¡A Patch Respiratory: Nasal irritation¡A Nasal spray¡A Oral irritation¡A Airway¡A inhaler Other: Nicotine withdrawal¡A Dizziness¡A headache¡A insomnia Serious Cardiovascular: Cardiac dysrhythmia (rare)¡A Hypertension (rare)¡A Tachyarrhythmia (rare) Immunologic: Hypersensitivity reaction (rare),25¢J¥H¤U,Initial treatment: 6 to 16 cartridges/day (at least 6 cartridges/day for the first 3 to 6 weeks) for up to 12 weeks; maximum: 16 cartridges/day. Note: Best effect achieved with frequent continuous puffing (20 minutes). Use beyond 6 months is not recommended (has not been studied). If patient is unable to stop smoking by the fourth week of therapy¡A consider discontinuation. Discontinuation of therapy: After initial treatment¡A gradually reduce daily dose over 6 to 12 weeks. Some patients may not require gradual reduction of dosage and may stop treatment abruptly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]¥¥°ü©M­÷¨Åªº©âµÒªÌÀ³¦b¿Ô¸ß¹LÂå®vªº«ØÄ³«á¤~¥i¨Ï¥Î§l¤J¾¯¡C ©âµÒ·|ÄY­«¶Ë®`¨ì¥®¨à¡A¥§¥j¤B·|¶Ç»¼µ¹­L¨à¡A¼vÅT¨ä©I§l¹B°Ê©M´`Àô¡C ¹ï©I§l©M´`Àôªº¼vÅT¨ú¨M©ó¾¯¶q¤j¤p¡C ¦]¦¹¡A¥¥°üÀ³¸ÓÁ`¬O³Q§iª¾ÃÄ¦b¤£¨Ï¥Î¥§¥j¤B´À¥NªvÀø¤U§¹¥þ§ÙµÒ¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥§¥j¤B·|¤Ö¶qº¯¤J¥À¨Å¦Ó¹ïÀ¦¨à³y¦¨¼vÅT¡A§Y¨Ï¬OªvÀø¾¯¶q¤]·|³y¦¨¼vÅT¡C ¦]¦¹À³Á×§K¦b­÷¨Å´Á¶¡¨Ï¥Î¥§¥j¤B§l¤J¾¯¡A¨ÃÀ³¦b§¹¦¨­÷¨Å«á¨Ï¥Î¡C,INHL;,,,,,
OZYT,Abiraterone,Zytiga 250mg,RACA,Prostate cancer: Treatment of metastatic¡A castration-resistant prostate cancer (in combination with prednisone).,Hypersensitivity. Pregnancy.,Common: Contusion (13.3%)¡A Flushing (15-22.3%)¡A Hypercholesterolemia (Greater than 20%)¡A Hyperglycemia (56.6%)¡A Hypertriglyceridemia (62.5%)¡A Hypophosphatemia (23.8%)¡A Diarrhea (17.6-21.6%)¡A Vomiting (10% or higher)¡A Anemia (Greater than 20%)¡A Lymphocytopenia¡A All Grades (38.2%)¡A Alkaline phosphatase above reference range (Greater than 20%)¡A Joint swelling (29.5-30.3%)¡A Urinary tract infectious disease (7-11.5%)¡A Cough (6.5-17.3%)¡A Dyspnea (11.8%)¡A Fatigue (39.1%) Serious: Cardiac dysrhythmia (7.2%)¡A Cardiorespiratory arrest (0.5%)¡A Chest discomfort¡A Chest pain¡A Edema (25.1-26.7%)¡A Heart failure (2.3-2.6%)¡A Hypertension (8.5-37%)¡A Myocardial infarction¡A Sudden cardiac death¡A Torsades de pointes¡A Adrenal insufficiency (0.5%)¡A Hypoglycemia¡A Hypokalemia (17.2-28.3%)¡A Lymphocytopenia¡A Grade 3 or 4 (8.7%)¡A ALT/SGPT level raised (11.1-41.9%)¡A Aspartate aminotransferase serum level above reference range (16-37.3%)¡A Hepatotoxicity¡A Serum bilirubin above reference range (6.6%),30¢J¥H¤U,[Metastatic castration-resistant prostate cancer] 1000 mg orally once daily with prednisone 5 mg orally twice daily.[Metastatic castration-sensitive prostate cancer] 1000 mg orally once daily with prednisone 5 mg orally once daily.Patients receiving ZYTIGA should also receive a gonadotropin-releasinghormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ZYTIGA must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ¡]Child-Pugh Class B¡^ªº±wªÌ¡AÀ³±NZYTIGAR ªº«ØÄ³¾¯¶q­°§C¦Ü250 ²@§J¨C¤é¤@¦¸¡C ­««×¨x¥\¯à¤£¥þ¡]Child-Pugh Class C¡^ªº±wªÌ¡A½Ð¤£­n¨Ï¥ÎZYTIGAR¡C,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ] ¹ï©ó¤k©Ê¨Ï¥Îªº¦w¥þ©Ê»PÀø®Ä©|¥¼«Ø¥ß¡C®Ú¾Ú¨ä§@¥Î¾÷¨î»P°Êª«¸ÕÅçªºµo²{¡A¹ï©ó¥¥°ü¨Ï¥ÎZytiga·|³y¦¨­L¨à¶Ë®`¡A¨Ã¥i¯à¾É­P¬y²£¡C¥Ø«e¨ÃµL¥¥°ü¨Ï¥Îªº¤HÅé¸ÕÅç¸ê®Æ¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ¹ï©ó¤k©Ê¨Ï¥Îªº¦w¥þ©Ê»PÀø®Ä©|¥¼«Ø¥ß¡C¥Ø«e¨ÃµLÃö©óabiraterone acetate¬O§_·|¥X²{©ó¤HÃþªº¨Å¥Ä¤¤¡B¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT¡B©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅTµ¥¤è­±ªº¸ê®Æ¡C,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C¥é³æ«ØÄ³À³¾ã¿õ§]ªA¡A¤£¥i«r¸H©Î¼·¥b¡C ¥»ÃÄ»ÝªÅ¸¡ªA¥Î¡AªA¥Î«e2¤p®É©M«á1¤p®É¤£­n¶i­¹¡C
EPEDO,Minocycline,Periocure 10mg/0.5gm/syringe dental ointment,TENT,Periodontitis.,Should not be used in any patient who has a known sensitivity to minocycline or tetracyclines.,Headache¡A gum discomfort¡A pain¡A soreness¡A or toothache,25¢XC¥H¤U,once a week¡A Injection into the periodontal pockets. Periocure is indicated as an adjunct to scaling and root planing procedures for the reduction of pocket depth in patients with adult periodontitis. Periocure may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human data suggest risk in 2nd and 3 rd trimesters,See Tetracycline. Tetracycline: Contraindicated¡X2nd and 3rd Trimesters [¥é³æ] ¤@¯ë¨Ï¥Î¤W¨ãÀø®Ä¡A°ß©ó¥¥°ü¡B²£°ü¡B±Â¨Å°üµ¥¨Ï¥Î¨ä¦MÀI©Ê¥i¯à¬Û¹ï´£¤É (¥¥°ü¡B¥i¯àÃh¥¥ªº°ü¤k¨ä¥ÎÃÄ¦w¥þ©Ê¤´¥¼½T©w),Compatible ­÷¨Å®É¥i¨Ï¥Î,See Tetracycline. Tetracycline: Compatible [¥é³æ] ¤@¯ë¨Ï¥Î¤W¨ãÀø®Ä¡A°ß©ó¥¥°ü¡B²£°ü¡B±Â¨Å°üµ¥¨Ï¥Î¨ä¦MÀI©Ê¥i¯à¬Û¹ï´£¤É (¥¥°ü¡B¥i¯àÃh¥¥ªº°ü¤k¨ä¥ÎÃÄ¦w¥þ©Ê¤´¥¼½T©w),LI;,,,,,
OSUN,Asunaprevir,Sunvepra 100mg,QANB,Chronic hepatitis C: Treatment of chronic hepatitis C (CHC) in adult patients with hepatitis C virus (HCV) genotypes 1 or 4 and compensated liver disease¡A including cirrhosis. Must be administered as part of combination therapy with other anti-HCV agents.,Hypersensitivity to asunaprevir or any component of the formulation; moderate or severe hepatic impairment (Child-Pugh class B or C¡A score 7 or greater) and with decompensated hepatic disease; concurrent use with daclatasvir¡A peginterferon alfa¡A and ribavirin in women who are pregnant or may become pregnant and men whose female partners are pregnant¡A may be pregnant¡A or plan to become pregnant; concurrent use with drugs dependent on the cytochrome P450 2D6 (CYP2D6) for clearance and for which elevated plasma concentrations are associated with serious ventricular arrhythmias and sudden death; concurrent use with moderate or strong inducers and inhibitors of CYP3A or with strong inhibitors of organic anion transporting polypeptide (OATP) 1B1 or 2B1. The following drugs are included in the manufacturer labeling as being contraindicated: atazanavir¡A bosentan¡A carbamazepine¡A clarithromycin¡A cobicistat or cobicistat-containing regimens¡A cyclosporine¡A darunavir/ritonavir¡A dexamethasone¡A diltiazem¡A efavirenz¡A erythromycin¡A etravirine¡A flecainide¡A fluconazole¡A fosamprenavir¡A gemfibrozil¡A indinavir¡A itraconazole¡A ketoconazole¡A lopinavir/ritonavir¡A modafinil¡A nafcillin¡A nelfinavir¡A nevirapine¡A oxcarbazepine¡A phenobarbital¡A phenytoin¡A posaconazole¡A propafenone¡A rifabutin¡A rifampin¡A rifapentine¡A ritonavir¡A saquinavir¡A St. John¡¦s wort¡A telithromycin¡A thioridazine¡A verapamil¡A voriconazole,>10%: Central nervous system: Fatigue (12% to 39%)¡A headache (6% to 28%)¡A insomnia (4% to 21%)¡A irritability (16%) Dermatologic: Pruritus (6% to 25%)¡A skin rash (5% to 18%)¡A alopecia (3% to 16%) Gastrointestinal: Nausea (4% to 15%) Hematologic & oncologic: Anemia (19%)¡A neutropenia Hepatic: Increased serum AST (2% to 13%)¡A increased serum ALT (4% to 12%) Neuromuscular & skeletal: Weakness (23%) Respiratory: Flu-like symptoms (22%) 1% to 10%: Cardiovascular: Atrial fibrillation¡A hypertension¡A syncope Central nervous system: Amnesia¡A anxiety¡A depression¡A disturbance in attention¡A dizziness¡A emotional lability¡A malaise¡A pain¡A sleep disorder¡A vertigo Dermatologic: Dermatitis¡A eczema¡A erythema¡A exfoliative dermatitis¡A maculopapular rash¡A psoriasis¡A seborrheic dermatitis¡A xeroderma Endocrine & metabolic: Weight loss Gastrointestinal: Abdominal pain¡A constipation¡A decreased appetite¡A diarrhea¡A dyspepsia¡A dysphagia¡A hemorrhoids¡A stomatitis¡A vomiting Hematologic & oncologic: Eosinophilia¡A leukopenia¡A lymphocytopenia¡A thrombocytopenia Hepatic: Increased serum bilirubin (1% to 10%)¡A hyperbilirubinemia Infection: Influenza Neuromuscular & skeletal: Arthralgia¡A back pain¡A musculoskeletal chest pain¡A myalgia Ophthalmic: Xerophthalmia Respiratory: Cough¡A dyspnea¡A dyspnea on exertion¡A nasopharyngitis¡A oropharyngeal pain Miscellaneous: Fever <1% (Limited to important or life-threatening): Erythema multiforme,30¢J¥H¤U,For hepatitis C in adults¡A Genotype 1b (treatment-naive or treatment-experienced¡A ¡Ó compensated cirrhosis): 100 mg orally twice daily for 24 weeks in combination with daclatasvir; Genotype 1 or 4 (treatment-naive or treatment-experienced¡A ¡Ó compensated cirrhosis): 100 mg orally twice daily for 24 weeks in combination with daclatasvir¡A peginterferon alfa¡A and ribavirin.,»Ý½Õ¾ã¾¯¶q,¸T¥Î©ó¤¤«×©Î­««×¨x¥\¯à¤£¥þªº±wªÌ (Child-Pugh B©Î C)¤Î¥¢¥NÀv©Ê¨x¯f±wªÌ,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,Ãh¥¥¤Î­÷¨Å«ØÄ³¸ê®Æ¨Ó·½¬°ÃÄ«~¥é³æ¡C,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦ÅnÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©ÎÀ£¸H¡AµLªk§]ªA±wªÌ¥i¥H·Å¤ô·»¸Ñ«áªA¥Î¡C
OANT6,Pyridostigmine,Antilon 60mg,CNEU,Myasthenia gravis.,Hypersensitivity to anticholinesterase agents. Mechanical intestinal obstruction. Urinary obstruction.,Common Dermatologic: Diaphoresis Gastrointestinal: Diarrhea¡A Excessive salivation¡A Increased peristalsis¡A Stomach cramps Musculoskeletal: Cramp¡A Muscle fasciculation Neurologic: Asthenia Ophthalmic: Miosis Respiratory: Excessive bronchial secretion,25¢J¥H¤U,Myasthenia gravis: each time 60-180 mg¡A BID-QID. [Micromedex 20211004] Myasthenia gravis: 600 mg (ten 60-mg tablets) orally daily¡A spaced throughout the day to provide maximum relief when maximum strength is needed; dosage and frequency must be individualized; mild cases may respond to 60 to 360 mg (one to six 60-mg tablets) daily¡A while severe cases may require up to 1500 mg (twenty five 60-mg tablets) daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]µL¬ÛÃö»¡©ú,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]µL¬ÛÃö»¡©ú,AC;AC15;PC;PO;WM;,,,,,
IXYA,Lidocaine + Epinephrine,Xylestesin-A (for Dental) 1.7mL,ZANE,Local anaesthesia (infiltration and nerve-block anaesthesia) in dentistry. Xylestesin-A is indicated in adults¡A children and adolescents.,- hypersensitivity to the lidocaine¡A adrenaline¡A sodium sulphite¡A Sodium chloride¡A Hydrochloric acid. - severe¡A uncontrolled or untreated excitation and conduction disorders of the heart (e.g. grade II and III AV block¡A pronounced bradycardia) - acutely decompensated heart failure¡A - severe hypotension - Heart diseases such as: „h unstable angina pectoris¡A „h recent myocardial infarction¡A „h refractory arrhythmia and paroxysmal tachycardia or high-frequency¡A continuous arrhythmia¡A „h untreated or uncontrolled severe hypertension¡A „h untreated or uncontrolled congestive heart failure¡A ƒ{ Concomitant treatment with monoamine oxidase (MAO) inhibitors or tricyclic antidepressants. ƒ{ Xylestesin-A is not allowed to be used in acra of extremities. - severe bronchial asthma.,Infections and infestations: Oral herpes Immune system disorders: anaphylactic reaction¡A anaphylactic shock¡A type I hypersensitivity Psychiatric disorders: confusional state Nervous system disorders: dizziness¡A headache¡A somnolence¡A facial palsy¡A paresis¡A syncope¡A dysarthria Eye disorders: accommodation disorder¡A blindness¡A diplopia¡A eye swelling¡A vision blurred¡A eyelid ptosis¡A mydriasis¡A ophthalmoplegia Cardiac disorders: palpitations Vascular disorders: haematoma¡A pallor Respiratory¡A thoracic and mediastinal disorder: bronchospasm¡A laryngeal oedema¡A respiratory failure¡A throat tightness¡A wheezing¡A dyspnoea¡A cough Gastrointestinal disorders: hypoaesthesia oral¡A toothache¡A nausea¡A tongue oedema¡A vomiting Skin and subcutaneous tissue disorders: haemorrhage subcutaneous¡A dermatitis bullous¡A dermatitis contact¡A hypoaesthesia facial¡A pruritus¡A rash¡A swelling face General disorders and administration site conditions: medicine ineffective¡A pain¡A injection site swelling¡A injection site haematoma Investigations:allergy test positive¡A heart rate increased¡A heart rate irregular Injury¡A poisoning and procedural complications:Uncommon,«Ç·Å,Dosage requirements should be determined on an individual basis. For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection. Children > 15 years and adult: dosages of 1-4 mL are usually effective. Lidocaine maximum dosage: 500mg (7 mg/kg). Epinephrine maximum dosage: 0.25mg (equivalent to 20 mL). Children 20-30 kg: 0.25-1 mL. Children 30-45 kg: 0.5-2 mL. Lidocaine maximum dosage of children: 5 mg/kg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,LIDOCAINE: Compatible EPINEPHRINE: Human Data Suggest Risk,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,LIDOCAINE: Limited Human Data¡XProbably Compatible EPINEPHRINE: No Human Data¡XPotential Toxicity,LA;LI;,,,,,
EBSS1,Balanced salt solution,BSS sterile irrigation solusion 500mL/Bag,TOPH,For use as an extraocular and intraocular irrigating solution during ocular or other surgical procedures.,Hypersensitivity to any component of the formulation.,When the corneal endothelium is abnormal¡A irrigation or any other trauma may result in bullous keratopathy.,«Ç·Å,For irrigation during operations of the eyes¡A ears¡A nose and throat.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AD;AL;AS;AU;EXT;G;GAR;IN;IRR;IRRI;OD;OL;ORO;OU;SKIN;TOPI;,,,,,
IIXE,Ixabepilone,Ixempra inj 15mg (2mg/mL),RACA,Breast cancer (metastatic or locally advanced),History of severe (grade 3 or 4) hypersensitivity to polyoxyethylated castor oil (Cremophor EL) or its derivatives; neutrophil count <1¡A500/mm3 or platelet count <100¡A000/mm3; combination therapy with ixabepilone and capecitabine in patients with AST or ALT >2.5 times ULN or bilirubin >1 times ULN,>10%: Peripheral neuropathy (63%; grades 3/4: 14%; grade 3/4 median onset: Cycle 4)¡A peripheral sensory neuropathy (62%; grades 3/4: 14%)¡A headache (11%)¡A Alopecia (48%)¡A Nausea (42%)¡A vomiting (29%)¡A mucositis (?29%)¡A stomatitis (?29%)¡A diarrhea (22%)¡A anorexia (19%)¡A constipation (16%)¡A abdominal pain (13%)¡A Leukopenia (grade 3: 36%; grade 4: 13%)¡A neutropenia (grade 3: 31%; grade 4: 23%)¡A Weakness (56%)¡A arthralgia (?49%)¡A myalgia (?49%)¡A musculoskeletal pain (20%) 1% to 10%: Edema (9%)¡A chest pain (5%)¡A Peripheral motor neuropathy (10%; grade 3: 1%)¡A pain (8%)¡A dizziness (7%)¡A insomnia (5%)¡A Nail disease (9%)¡A skin rash (9%)¡A palmar-plantar erythrodysesthesia (8%)¡A pruritus (6%)¡A desquamation (2%)¡A hyperpigmentation (2%)¡A Hot flash (6%)¡A weight loss (6%)¡A dehydration (2%)¡A Dysgeusia (6%)¡A gastroesophageal reflux (6%)¡A Anemia (grade 3: 6%; grade 4: 2%)¡A febrile neutropenia (3%; grade 3: 3%)¡A thrombocytopenia (grade 3: 5%; grade 4: 2%)¡A Hypersensitivity (5%; grade 3: 1%)¡A Infection (5%)¡A Increased lacrimation (4%)¡A Dyspnea (9%)¡A upper respiratory tract infection (6%)¡A cough (2%)¡A Fever (8%) <1%¡A postmarketing¡A and/or case reports: Acute hepatic failure¡A acute pulmonary edema¡A angina pectoris¡A atrial flutter¡A autonomic neuropathy¡A blood coagulation disorder¡A cardiomyopathy¡A cerebral hemorrhage¡A colitis¡A delayed gastric emptying¡A dysphagia¡A embolism¡A enterocolitis¡A erythema multiforme¡A gastrointestinal hemorrhage¡A hemorrhage¡A hypokalemia¡A hyponatremia¡A hypotension¡A hypovolemia¡A hypovolemic shock¡A hypoxia¡A increased gamma-glutamyl transferase¡A increased serum alkaline phosphatase¡A increased serum transaminases¡A interstitial pneumonitis¡A intestinal obstruction¡A jaundice¡A left ventricular dysfunction¡A metabolic acidosis¡A myocardial infarction¡A nephrolithiasis¡A neutropenic infection¡A orthostatic hypotension¡A pneumonia¡A pneumonitis¡A radiation recall phenomenon¡A renal failure¡A respiratory failure¡A sepsis¡A septic shock¡A supraventricular cardiac arrhythmia¡A syncope¡A thrombosis¡A trismus¡A urinary tract infection¡A vasculitis¡A voice disorder,2-8¢XCÁ×¥ú,40 mg/m2 infused intravenously over 3 hours once every 3 weeks. Doses for patients with body surface area (BSA) greater > 2.2 m2 should be calculated based on 2.2 m2.,»Ý½Õ¾ã¾¯¶q,Monotherapy (initial cycle; adjust doses for subsequent cycles based on toxicity): AST and ALT 2.5 times ULN and bilirubin 1 times ULN: No dosage adjustment necessary AST and ALT >2.5 to 10 times ULN and bilirubin >1 to 1.5 times ULN: Reduce dose to 32 mg/m2 AST and ALT 10 times ULN and bilirubin >1.5 to ?3 times ULN: Reduce dose to 20 to 30 mg/m2 (initiate treatment at 20 mg/m2¡A may escalate up to a maximum of 30 mg/m2 in subsequent cycles if tolerated) AST or ALT >10 times ULN or bilirubin >3 times ULN: Use is not recommended Combination therapy with capecitabine: AST and ALT 2.5 times ULN and bilirubin 1 times ULN: No dosage adjustment necessary AST or ALT >2.5 times ULN or bilirubin >1 times ULN: Use is contraindicated,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest moderate risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,¨Ï¥Î¥]¸Ë¤ºªþ8mLµ}ÄÀ²G·»¸Ñ°®¯»¡Aµ}ÄÀ²G±q¦B½c¨ú¥X¶·ÀR¸m30¤ÀÄÁ¡A¦^¨ì«Ç·Å«á¨Ï¥Î¡C,¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1.¨Ï¥Î0.9% Normal saline§@¬°ÂIºw²G®É¡A¥²¶·­É¥Ñ¥[¤J2mEqªººÒ»Ä²B¶uª`®g²G±NpH­È½Õ¾ã¦¨6.0-9.0¤§¶¡. 2.¥»ÃÄ«~»Ý¸Ë©ó¤£§tDEHPªº¥]¸Ë¤¤. 3.¬°®e³\©â¨ú·l¥¢¡A¥»«~¥]¸Ë¤º§t16mg Ixabepilone¡A¥[¤J8mLµ}ÄÀ²G«á¡A°t»s¦¨¿@«×2mg/mL. 4.°t»s¥»ÃÄ®É¡A±N8mLµ}ÄÀ²G©â¨ú¨Ãª`¤JÃÄ²~¤¤¡A¤w»´»´±ÛÂà¤ÎÂ½ÂàÃÄ²~ªº¤è¦¡ª½¨ì§¹¥þ·»¸Ñ.
OTRAZB,Trazodone,,CNEU,Depression.,Serious hepatic impairment. Hypersensitivity to trazodone hydrochloride.,Common Gastrointestinal: Constipation (7% to 8% )¡A Diarrhea (up to 9% )¡A Nausea (21% )¡A Vomiting (at least 1% )¡A Xerostomia (14% to 33.8% ) Musculoskeletal: Backache (5% ) Neurologic: Confusion (up to 5.7% )¡A Dizziness (25% )¡A Headache (9.9% to 33% )¡A Insomnia (6.4% to 9.9% )¡A Somnolence (23.9% to 46% ) Ophthalmic: Blurred vision (5% to 14.7% ) Psychiatric: Dream disorder (up to 5.1% )¡A Feeling nervous (6.4% to 14.8% ) Other: Fatigue (5.7% to 15% ) Serious Cardiovascular: Cardiac dysrhythmia¡A Hypotension (3.8% to 7% )¡A Prolonged QT interval¡A Torsades de pointes Immunologic: Hypersensitivity reaction (less than 1% ) Neurologic: Seizure¡A Serotonin syndrome Psychiatric: Suicidal thoughts (rare)¡A Suicide Reproductive: Priapism,25¢J¥H¤UÀx¦s¡C,Initial dose: 150 mg/day. Dose may be gradually increased by 50mg/day at adjustment interval of 3-4 days. maximum dose(in divided doses): Out-patient 400 mg/day¡A in-patient 600 mg/day.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]ÄY­«¨x¥\¯à»ÙÃª¤§¯f¤H¬°¸T§Ò¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ñ©ó¯Ê¥F¸gÅç¡A¥»«~¤£±ÀÂË¨Ï¥Î¦bÃh¥¥°ü¤k¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ñ©ó¯Ê¥F¸gÅç¡A¥»«~¤£±ÀÂË¨Ï¥Î¦b­÷¨Å¤¤°ü¤k¡C,PC;PO;WM;,,,,,
IHU50,Insulin Lispro 50% + Insulin Protamine 50%,Humalog Mix 50 kwikpen 100U/mL¡A 3mL,META,,¾AÀ³¯g:type 1¡A type 2 DM °Æ§@¥Î:Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj ¸T§Ò:Hypoglycaemia.,,2-8 ¢J,Should be taken with food. (Administer w/in 15 mins before or immediately after meals.) Subcutaneous Diabetes mellitus Adult: Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Administer 15 min before or immediately after a meal. Renal impairment: Decreased dose may be necessary. Hepatic impairment: Decreased dose may be necessary.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,SC;,,,,,
ORHY,Propafenone,Rhynorm 150mg («ß¿Õ),CAVS,Ventricular & supraventricular tachyarrhythmias¡A Wolff-Parkinson-White syndrome.,Manifest heart failure; cardiogenic shock (except for shock induced by arrhythmia); severe bradycardia within 3 months after MI; pre-existing high degree SA¡A AV & intraventricular disorders of impulse conduction; sick sinus syndrome; manifest disorders of electrolyte balance; severe obstructive pulmonary disease; marked hypotension¡A myasthenia gravis.,May induce arrhythmia eg. bradycardia¡A induction disorder¡A tachycardia. Rarely ventricular fibrillation. May increase severity of heart failure. Hypotension. GI disturbances. Paresthesia¡A visual disturbances¡A dizziness. Rarely fatigue¡A headache¡A psychotic disorders. Blood disorders. Rarely¡A skin allergy¡A bronchospasm. Cardiovascular: Chest pain (1.8% )¡A Edema (5% to 13% )¡A Palpitations (3.4% ) Gastrointestinal: Constipation (8% to 14% )¡A Nausea (9% to 17% )¡A Taste sense altered (6% to 22% )¡A Vomiting (0% to 6% ) Neurologic: Dizziness (21% to 23% ) Psychiatric: Anxiety (10% to 13% ) Respiratory: Dyspnea (13% to 17% )¡A Upper respiratory infection (8% to 12% ) Other: Fatigue (11% to 13% ),25¢J¥H¤U,Adult (70 kg): Initial and maintenance dose: 450-600 mg/day in 2-3 divided doses. May increase to 900 mg/day. Dosage may be adjusted in patients with lower body weight. Children: 10-20mg/kg/day in 3-4 divided doses.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¨ü·lªº¯f±wÀ³½Õ¾ã¾¯¶q,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
INIMB,Cisatracurium,Nimbex inj 10mg/5mL,CNEU,Muscle relaxation during surgical procedures eg cardiac surgery¡A other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU¡A to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation.,Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol),Bradycardia¡A hypotension. Rarely cutaneous flushing¡A bronchospasm¡A rash.,2-8¢JÁ×¥úÁ×§K§N­á,IV bolus Tracheal intubation: Adult: Initially 0.15 mg/kg over 5-10 seconds. Maintenance: 0.03 mg/kg. Children 1 month-12 years same as adult dose. Maintenance: 0.02 mg/kg. IV infusion for maintenance of neuromuscular blockade: Adult & children 1 month-12 years: 3 mcg/kg/min initially and 1-2 mcg/kg/min thereafter to maintain 89-99% neuromuscular blockade.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,[7] contrainication ¥H¤WÃh¥¥¤À¯Å¬°: UpToDate¸ê®Æ¡C,IVD;IVP;IVPUSH;,,¡iD2.5HS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1.¶È¨ÑÀR¯ßµ¹ÃÄ¡C 2.µ¹ÃÄ¿@«× 0.1-2.0 mg/mL¡C 3.¥»«~»Ý§NÂÃÁ×¥ú¶J¦s 4.¤£¥i»PÆP©Ê·»²G²V¦X 5.¥H¤pÀR¯ß°µ¬°ª`®g³B®É¡AÀ³¨Ï¥Î¾A·íªºÀR¯ß¿éª`²G(¦p0.9%´â¤Æ¶uÀR¯ßª`®g²G)±NNimbexª`®g¾¯¬~¤JÀR¯ß¤º.
INALD,Dinalbuphine,Naldebain ER inj 150mg/2mL,CNEU,ain management: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Surgical anesthesia supplement: Supplement to balanced anesthesia¡A for preoperative and postoperative analgesia¡A and for obstetrical analgesia during labor and delivery.,Hypersensitivity to nalbuphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; GI obstruction¡A including paralytic ileus (known or suspected). Documentation of allergenic cross-reactivity for opioids is limited. However¡A because of similarities in chemical structure and/or pharmacologic actions¡A the possibility of cross-sensitivity cannot be ruled out with certainty.,>10%: Central nervous system: Sedation (36%) 1% to 10%: Central nervous system: Dizziness (5%)¡A headache (3%) Dermatologic: Cold and clammy skin (9%) Gastrointestinal: Nausea and vomiting (6%)¡A xerostomia (4%),25¢J¥H¤UÁ×¥ú,IM: Single dose 150mg,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ¤p¤ß¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,Monitor relief of pain¡A resp and mental status¡A BP.,IM;,,,,,¥»«~¶È¨Ñ¦Ù¦×ª`®g¨Ï¥Î¡C 1. ¨Ï¥Î«e¦^´_¦Ü«Ç·Å¡C 2. ¨Ï¥Î«e¥ý¥H°sºë´Ö²M¼ä¬Á¼þ¤p²~¤§²~»\¡C 3. ©â¥X2 mLÃÄ«~·»²G¡C 4. ¦b²M¼ä¥Ö½§¤§«á¡A±NÃÄ«~¬I¥´¦bÁv¤j¦Ùªº¥~°¼¤W³¡1/4³B¡CÃÄ«~·»²G¬Oªoª¬¥BÂH¸Yªº¡A¬G«ØÄ³½wºC ¦aª`®g¡C 5. »´À£ª`®g³¡¦ì¨¾¤îÃÄ«~·»²Gº|¥X¡C 6. ½Ð¤Å«ö¼¯ª`®g³¡¦ì¡C
IEMG,Galcanezumab,Emgality inj 120 mg/1mL,CNEU,Episodic cluster headacheView additional information. Migraine; Prophylaxis,Serious hypersensitivity to galcanezumab-gnlm or to any of the components of the product.,Common Immunologic: Injection site reaction (18% ) Serious Immunologic: Anaphylaxis¡A Hypersensitivity reaction Other: Angioedema,2-8¢JÁ×¥úÁ×§K§N­á,Migraine; Prophylaxis Usual dosage: 240 mg (2 consecutive 120-mg doses) once as a loading dose¡A followed by 120 mg once monthly. Missed dose: If a dose is missed¡A administer as soon as possible. Thereafter¡A schedule monthly from the date of the last dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ] Ãö©óÃh¥¥¤k©Ê¨Ï¥Î EMGALITY ªºµo¨|­·ÀIµL¨¬°÷ªº¼Æ¾Ú¡C©ó¾¹©x§Î¦¨´Á¶¡µ¹¤©¤j¹«©M¨ß¤l galcanezumab¡A ©Î¦b¤j¹«ªº¾ã­Ó§³®W´Á©M­÷¨Å´Áµ¹¤©°ª©óÁ{§É¹w´Áªº¦å¼ß¼ÉÅS¶q¡A¨Ã¤£·|¹ïµo¨|²£¥Í¤£¨}¼vÅT¡C ¬ü°ê¤@¯ë±Ú¸s¤¤¡A¦ô­p¦bÁ{§É¤W»{©w¤§Ãh¥¥¹Lµ{¤¤µo¥Í­«¤j¥ý¤Ñ¯Ê³´¤Î¬y²£ªº­I´º­·ÀI¤À§O¬° 2-4%¤Î 15-20%¡C °¾ÀYµh°ü¤k¤À®Y¤¤ªº­«¤j¥X¥Í¯Ê³´(2.2¢H-2.9¢H)©M¬y²£(17¢H)ªº¦ô­pµo¥Í²v»PµL°¾ÀYµh°ü¤kªº³q³ø²v¬Û¦ü¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨S¦³Ãö©ó galcanezumab ¶i¤J¤HÃþ¨Å¥Ä¡B¹ï©ó­÷¨ÅÀ¦¨à©Î¹ï©ó¨Å¥Ä¤Àªc¤§¼vÅTªº¸ê®Æ¡C ¦b¦Ò¶q­÷¨Å¹ï©óµo¨|»P°·±d¤§¯q³B®É¡A¤]À³ÅU¤Î¥À¿Ë¹ï©ó EMGALITY ªºÁ{§É»Ý¨D¡A ¥H¤Î EMGALITY ©Î¼ç¦bªº¥ÀÅéª¬ªp¹ï©ó­÷¨ÅÀ¦¨à¥i¯à³y¦¨¤§¤£¨}¼vÅT¡C,SC;,,,,,1.¸m©ó­ì¥~²°¤¤§NÂÃ¦s©ñ©ó 2¢XC ¨ì 8¢XC ¤§¶¡¡A¥H§K¨ü¥ú½u·Ó®g¦Ü¨Ï¥Î¬°¤î¡C 2.¤£¥i§N­á¡A¤£¥i·n®Ì¡CÀx¦s©ó¦B½c¥~¡B·Å«×³Ì°ª 30¢XC¥H¤U³Ì¦h 7 ¤Ñ¡C 3.­Y¤wÀx¦s¦b¦B½c¥~¡A½Ð¤Å±NEMGALITY ©ñ¦^¦B½c¤¤¡C­Y¶W¹L³o¨ÇÀx¦s±ø¥ó¡A¥²¶·¥á±ó ¡C 4.¨Ï¥Î«áÀ³±N EMGALITY ³æ¾¯¹w¥R¶ñª`®gµ§¥á±ó©ó¨¾¬ï¨ë«O¦s²°¤¤¡C
LKEP,Levetiracetam,Keppra solution 100mg/mL¡A 300mL,CNEU,Monotherapy for focal seizures (with or without secondary generalized seizures) in patients above 16 years of age. Adjunctive therapy for (1) focal seizures (with or without secondary generalized seizures) in children aged 4 years and above¡A (2) in adolescents and adults aged 12 years and above for myoclonic seizures and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy.,Hypersensitivity to levetiracetam.,Common: Loss of appetite (3-8%)¡A Vomiting (15%)¡A Infectious disease (13%)¡A Decreased bone mineral density (70%)¡A Neck pain (2-8%)¡A Asthenia (15%)¡A Dizziness (5-9%)¡A Headache (14-19%)¡A Abnormal behavior (7-37.6%)¡A Irritability (6-12%)¡A Cough (2-9%)¡A Nasopharyngitis (7-15%)¡A Fatigue (10-11%) Serious: Stevens-Johnson syndrome (SJS)¡A Toxic epidermal necrolysis (TEN)¡A Decreased erythrocyte production¡A Decreased white blood cell count (2.4-3.2%)¡A Eosinophil count above reference range (8.6%)¡A Neutropenia ( 2.4%)¡A Pancytopenia¡A Thrombocytopenia¡A Liver failure¡A Anaphylaxis¡A Somnolence (8-45%)¡A Suicidal intent (0.5%)¡A Suicide¡A Angioedema,30¢J¥H¤U,Monotherapy: Adults¡A 16 Years and Older: Initial¡A 250 mg twice daily IV/orally; titration¡A may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults¡A 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily¡A increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ]¦b¤@¤j¶q¤W¥««á¸ê®Æ¤¤¡A±µ¨ü levetiracetam ³æ¤@ªvÀøªº¥¥°ü¡]¶W¹L 1800 ¨Ò¡A¨ä¤¤¶W¹L 1500 ¨Òµo¥Í¦bÃh¥¥ªº«e¤T­Ó¤ë´Á¶¡¡^¥D­n¥ý¤Ñ©Ê·î§Îªº­·ÀI¨Ã¥¼¼W¥[¡C Ãö©ó¦b¤l®c¤º±µ¨ü levetiracetam ³æ¤@ªvÀøªº¨àµ£¯«¸gµo¨|¡A¥Ø«e¶È¦³¦³­­ªºÃÒ¾Ú¡C¦ý¥Ø«e¬y¦æ¯f¾Ç¬ã¨s¡]¬ù 100 ¦W¨àµ£¡^¨Ã¥¼¦³¯«¸gµo¨|»ÙÃª©Î©µ¿ðªº­·ÀI¼W¥[¡C Levetiracetam ¦pªG¦b¸g¥J²Óµû¦ô«á»{¬°¥¦¬OÁ{§É¤W©Ò»Ý­n®É¡A¤~¥i¥H¦bÃh¥¥´Á¶¡¨Ï¥Î¡C ¦b³oºØ±¡ªp¤U¡A«ØÄ³¨Ï¥Î³Ì§C¦³®Ä¾¯¶q¡CÃh¥¥´Á¶¡ªº¥Í²zÅÜ¤Æ¤]¥i¯à·|¼vÅT levetiracetam ªº¿@«×¡C ´¿¦³¦bÃh¥¥´Á¶¡¥X²{¦å¼ß¤¤ levetiracetam ¿@«×­°§C²{¶Hªº³ø§i¡C³oºØ¿@«×­°§Cªº²{¶H¦b²Ä¤T¥¥´Á·|§ó¬°ÅãµÛ(­°§Cµ{«×³Ì°ª¥i¹FÃh¥¥«e¤§°òÂ¦¿@«×ªº 60%)¡C ½Ð°È¥²¬°±µ¨üªvÀøªºÃh¥¥°ü¤k¶i¦æ¾A·íªºÁ{§É³B¸m¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Levetiracetam ·|±Æªn¦Ü¤HÃþ¨Å¥Ä¤¤¡A¬G¤£«ØÄ³±Â¨Å¡C ¦ý¦pªG¦b±Â¨Å´Á¶¡»Ý­nªA¥Îlevetiracetam¡A¶·µû¦ôªvÀø®Ä¯q¤Î­·ÀI»P±Â¨Åªº­«­n©Ê¡C,AC;AC15;PC;PO;WM;,,,,,
EULTA,Sevoflurane,Ultane Inhalation Liquid 250mL,ZANE,,¾AÀ³¯g: Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery. °Æ§@¥Î: >10%: Cardiovascular: Hypotension (4% to 11%; dose-dependent) Central nervous system: Agitation (7% to 15%) Gastrointestinal: Nausea (25%)¡A vomiting (18%) Respiratory: Cough (5% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2% to 6%)¡A bradycardia (5%)¡A hypertension (2%) Central nervous system: Drowsiness (9%)¡A shivering (6%)¡A dizziness (4%)¡A headache (1%)¡A hypothermia (1%)¡A myoclonus (1%)¡A delirium (emergence) Gastrointestinal: Sialorrhea (2% to 4%) Respiratory: Airway obstruction (8%)¡A laryngospasm (2% to 8%)¡A breath-holding (2% to 5%)¡A apnea (2%) Miscellaneous: Fever (1%) ¸T§Ò:Hypersensitivity to sevoflurane¡A other halogenated anesthetics¡A or any component of the formulation; known or suspected susceptibility to malignant hyperthermia.,,15-30¢XC,Individualized dosage. Adult Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (25 years) Sevoflurane in oxygen: 2.6%¡A Sevoflurane in 65% N20/35% oxygen: 1.4% (40 years) Sevoflurane in oxygen: 2.1%¡A Sevoflurane in 65% N20/35% oxygen: 1.1% (60 years) Sevoflurane in oxygen: 1.7%¡A Sevoflurane in 65% N20/35% oxygen: 0.9% (80 years) Sevoflurane in oxygen: 1.4%¡A Sevoflurane in 65% N20/35% oxygen: 0.7% Pediatric Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide; the concentration at which amnesia and loss of awareness occur is 0.6%. MAC values for surgical levels of anesthesia: (0 to 1 month old full-term neonates) Sevoflurane in oxygen: 3.3% (1 to <6 months) Sevoflurane in oxygen: 3% (6 months to <1 year) Sevoflurane in oxygen: 2.8%¡A Sevoflurane in 65% N20/35% oxygen: 2% (1 to <3 years) Sevoflurane in oxygen: 2.8%¡A Sevoflurane in 60% N20/40% oxygen: 2% (3-12 years) Sevoflurane in oxygen: 2.5%,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
IRAP,Alfentanil,Rapifen inj 1mg/2mL,CNEU,an analgesic supplement and an anaesthetic induction agent.,Hypersensitivity to alfentanil or any component of the formulation. known intolerance to alfentanil or opioids.,Common Cardiovascular: Hypertension (18% )¡A Tachycardia (12% ) Gastrointestinal: Nausea (28% )¡A Vomiting (18% ) Musculoskeletal: Involuntary movement¡A Skeletal muscle (3% to 9% ) Serious Cardiovascular: Asystole¡A Bradyarrhythmia¡A Cardiac dysrhythmia¡A Hypotension (10% ) Immunologic: Anaphylaxis (Less than 1% ) Musculoskeletal: Muscle rigidity (17% ) Neurologic: Raised intracranial pressure¡A Seizure Respiratory: Apnea (3% to 9% )¡A Laryngeal spasm (0.3% to 1% )¡A Respiratory depression (1% to 3% ) Other: Serotonin syndrome,15-30¢J,Use as an Induction Agent: An intravenous bolus dose of > or =120 micrograms/kg (17mL/70kg) RAPIFEN will induce hypnosis and analgesia while maintaining good cardiovascular stability in patients with adequate muscle relaxation. For short procedures¡A an initial dose 7-15 micrograms/kg at induction¡A with intermittent boluses up to 15 micrograms/kg (7-15 micrograms/kg) at 10-15 minute intervals are most useful. If the dose is less than 7micrograms/kg and IV injection slowly¡A most patients can still maintain normal respiratory function. the recommended additional dose is 3.5micrograms/kg. For procedures of longer duration¡A a higher dose may be given at induction and further increments titrated to effect. Duration of the procedure(min):10-30; Rapifen IV bolus dose: 20-40 Micrograms/kg ; 3-6mL/70kg; Duration of the procedure(min):30-60; Rapifen IV bolus dose: 40-80 Micrograms/kg ; 6-12mL/70kg; Duration of the procedure(min):>60; Rapifen IV bolus dose: 80-150 Micrograms/kg ; 12-20mL/70kg; When surgery is more prolonged or more traumatic¡A analgesia should be maintained by: ¡E either increments of up to 15 micrograms/kg (2mL/70kg) RAPIFEN when required (to avoid post-operative respiratory depression¡A no RAPIFEN should be administered during the last 10 minutes of surgery); ¡E or a RAPIFEN infusion at a rate of 0.5 to 1 microgram/kg/min (0.14mL/70kg/min) until 5 to 10 minutes before the completion of surgery. Continuous infusion is preferable for cases greater than 60 minutes duration. Rapifen should not be given in the last 10 minutes prior to completion of surgery.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ]ÁöµM¦b°Êª«¹êÅç¨Ã¨S¦³µo²{·î§Î©Î«æ©Ê­L¬r®ÄÀ³¡A¦ý¥Ø«e¤´µM¨S¦³¨¬°÷ªº¼Æ¾Ú¥i¥Î¥Hµû¦ô¹ï¤HÃþªº¥ô¦ó¦³®`§@¥Î¡C¦]¦¹¥¥°ü©óµ¹ÃÄ«eÀ³°µ¼f·Vªº§Q¹úµû¦ô¡C ¦b¤À®Y(¥]¬A­å¸¡¥Í²£)ªº¹Lµ{¤£«ØÄ³ÀR¯ßª`®g¥»«~¡A¦]¬°Rapifen·|¬ï¹L­L½L¡A¥i¯à·|§í¨î·s¥Í¨àªº¦ÛµM©I§l¡C ¦p©ó¤À®Y®É¨Ï¥ÎRapifen¡AÀ³³Æ§´»²§U©I§l³]³Æ¨Ñ¥ÀÀ¦»Ý­n®É¨Ï¥Î¡A¾~¤ùÃþÃÄª«ªº«ú§Ü¾¯À³¨Æ¥ý¬°­L¨à³Æ§´¡C ¾~¤ùÃþÃÄª««ú§Ü¾¯ªº¥b°I´Á¥i¯à¤ñAlfentanilªº¥b°I´Áµu¡A¦]¦¹¦h¾¯¶q§ë»P¾~¤ùÃþÃÄª««ú§Ü¾¯¥i¯à¬O¥²­nªº¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]Rapifen·|¤Àªc¨ì¨Å¥Ä¤¤¡C¦]¦¹¡A¦bRapifenµ¹ÃÄ«áªº24¤p®É¤º¤£­n±Â¨Å©ÎÁý­÷À½¥Xªº¥À¨Å¡C,IVD;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,Administer doses slowly over at least 3 minutes.,Alfentanil was diluted to a concentration of 25 to 80 mcg/mL in clinical studies. _____________________________________________________________________________ ¤â³N®É¶¡(¤ÀÄÁ) RapifenÀR¯ßª`®g¤@¦¸µ¹ÃÄ¾¯¶q(mcg/Kg) mL/70Kg 10-30 20~40 3-6 30-60 40~80 6-12 > 60 80~150 12-20,Duration¡A general anesthesia: Discontinue use at least 10 to 15 minutes prior to the end of surgery Rapifen¤£¥i©M¨ä¥LÃÄ«~²V¦X.¥i¥H²V¦X´â¤Æ¶u©Î¸²µå¿}ÀR¯ß¿éª`·»²G¡A»Ý¦b24¤p®É¤º¨Ï¥Î§¹²¦.
ISHG,Varicella Zoster Virus glycoprotein E,Shingrix inj 0.5mL/dose,HIMM,Prevention of herpes zoster (HZ) in adults aged 50 years and older or in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.,History of severe allergic reaction (e.g.¡A anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.,Pain (78%)¡A redness (38%)¡A swelling (26%)¡A myalgia (45%)¡A fatigue (45%)¡A headache (38%)¡A shivering (27%)¡A fever (21%)¡A and gastrointestinal symptoms (17%),2-8¢J Á×¥ú,IM only. Two doses (0.5 mL/dose) in total. A first dose at Month 0 followed by a second dose administered 2-6 months later. For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: A first dose at Month 0 followed by a second dose administered 1-2 months later.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥ô¦óÃh¥¥°ü¤k¨Ï¥ÎShingrix¤è­±ªº¸ê®Æ¡C°Êª«¬ã¨sµ²ªG¨Ã¥¼Åã¥ÜShingrix¹ïÃh¥¥¡B­F­L/­L¨àµo¨|¡B¤À®Y¡B©Î²£«áµo¨|¤è­±¨ã¦³ª½±µ©Î¶¡±µªº¦³®`§@¥Î¡C¤wª¾Ãh¥¥ªº°ü¤kÀ³Á×§K±µºØShingrix¬Ì­]¡CThe data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women.,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|¥¼¬ã¨s¥À¿Ë¦b¬I¥´Shingrix«á¡A¹ï±µ¨ü¥À¨Å­÷¨|¤§À¦¨àªº¼vÅT¡CIt is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion.,IM;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G,,¤£¥i,¤£¥i,ªw»s¤§«á¡A¬Ì­]À³¥ß§Y¨Ï¥Î¡F¦pªGµLªk¥ß§Y¨Ï¥Î¡AÀ³±N¬Ì­]¦s©ñ©ó¦B½c¤¤(2¢XC¦Ü8¢XC)¡C¦pªG¥¼¦b6¤p®É¤º¨Ï¥Î¡AÀ³¤©¥H¥á±ó¡C
IFUL0,Pegfilgrastim,Fulphila inj 6mg/0.6mL (sample),HEMT,To decrease the incidence of infection¡A as manifested by febrile neutropenia¡A in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.,Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.,Common: Bone pain (31%)¡A Pain in limb (9%) Serious: Aortitis¡A Capillary leak syndrome¡A Acute myeloid leukemia¡A Leukocytosis (<1% )¡A Myelodysplastic syndrome¡A Rupture of spleen¡A Sickle cell anemia with crisis¡A Thrombocytopenia¡A Anaphylaxis¡A Glomerulonephritis¡A Acute respiratory distress syndrome,©ó²°¤ºÁ×¥ú§NÂÃ2-8¢J,Patients with cancer receiving myelosuppressive chemotherapy: 6 mg subQ once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¥Ø«e©|µL¸ê°T¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ÁöµM¦bÃh¥¥°ü¤k¤¤¨Ï¥Îpegfilgrastimªº²{¦³¼Æ¾Ú¤£¨¬¥H½T©w¬O§_¦s¦b»P¥D­n¥ý¤Ñ©Ê²§±`¡A ¬y²£©Î¤£§Q©ó¥ÀÅé©Î­L¨à¬ÛÃöªºÃÄª«­·ÀI¡A¦ý¦³¤w¤½¥¬ªº¬ã¨sÅã¥ÜÃh¥¥°ü¤k±µÄ²filgrastimÃÄ«~ªº¼Æ¾Ú¡A ³o¨Ç¬ã¨s©|¥¼½T©wÃh¥¥´Á¶¡¨Ï¥ÎfilgrastimÃÄ«~»P¥D­n¥ý¤Ñ©Ê²§±`¡A¬y²£©Î¤£§Q©ó¥ÀÅé©Î­L¨à¤§ÃöÁp¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¨S¦³Ãö©ópegfilgrastim¦s¦b©ó¤H¨Å¤¤¡B¹ï­÷¨Å¨àµ£ªº¼vÅT©Î¹ï²£¨Å¶qªº¼vÅT¤§¼Æ¾Ú¡C ¨ä¥LfilgrastimÃÄ«~«Ü¤Ö³Q¤Àªc©ó¨Å¥Ä¤¤¤Î·s¥Í¨à¤£·|¤fªA§l¦¬filgrastimÃÄ«~¡C ©ó¦Ò¶q­÷¨Åªºµo¨|©M°·±d¯q³B®É¡A¥À¿Ë¹ïpegfilgrastimªºÁ{§É»Ý¨D¡Bpegfilgrastim©Î¼ç¦bªº¥ÀÅéª¬ªp¹ï­÷¨Å¨àµ£ªº¼ç¦b¤£§Q¼vÅTÀ³¤@¨Ö¦C¤J¦Ò¶q¡C,SC;,,,,,1. Á×§K®¶·n¡C¸m©ó«Ç·Å(¤£¶W¹L30¢J)¶W¹L48¤p®É«á»Ý¥á±ó¡CÁ×§K§N­á¡C 2. µ¹ÃÄ«eÀ³¥ØµøÀË¬dÁû²Éª«½è¤ÎÅÜ¦â¡C·íµo²{Áû²Éª«½è©ÎÅÜ¦â®É¡A½Ð¤Å¨Ï¥Î¡C 3. ³æ¦¸¨Ï¥Îªº¹w¥R¶ñ°wµ©ªº°wÀY»\§t¦³°®Àêªº¤ÑµM¾ó¥Ö(­l¥Í¦Û¨Å½¦)¡F¹ï¨Å½¦¹L±Óªº¤H¤£¥i¨Ï¥Î¥»²£«~¡C
ENS1C,Sodium Chloride,Sodium chloride 0.9% Irrigation 1000mL,MSIV,Wash skin¡A wound surface¡A mucous membrane¡A wet cloth¡A gargle¡A wash bronchial mucosa¡A promote phlegm discharge¡A wash medical equipment.,,,«Ç·Å,For irrigation only. Not for injection. As sterile irrigation of tissues or wounds¡A and for washing¡A rinsing medical device.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;GAR;IH;IN;INHL;IRR;SHA;SKIN;TOPI;,,,,,
HCVDA16,Sofosbuvir + Velpatasvir +/- Ribavirin (1-6/12¶g),HCVDAA0016(C¨x¥þ¤fªA·sÃÄ°·«O­pµe)1-6«¬(E+R)12¶g,QANB,,,,,,,,,,,,,,,,,,,
HCVDA15,Sofosbuvir + Velpatasvir (1-6/12¶g),HCVDAA0015(C¨x¥þ¤fªA·sÃÄ°·«O­pµe)1-6«¬Epclusa12¶g,QANB,,,,,,,,,,,,,,,,,,,
OVIAS,Glucosamine Sulphate,Viartril-S powder 1.5gm (¦Û¶O),CNEU,All forms of degenerative osteoarticular disease. Primary & secondary osteoarthrosis such as: cervical arthrosis¡A coxofemoral arthrosis¡A gonarthrosis¡A dorsal arthrosis¡A lumbosacral arthrosis¡A scapulohumeral arthrosis¡A periarthritis¡A lumbago¡A fractures¡A osteoarticular dystrophies¡A chronic & subacute arthritis.,Hypersensitivity to glucosamine and shellfish.,Headache¡A fatigue¡A drowsiness¡A flushing.,25¢J¥H¤U°®Àê¦a¤è¥BÁ×§K¶§¥úª½®g©Î°ª·Å,Sachet: 0.5 sachet once daily for 3 months. Repeat at an interval of 2 months.,µL»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þªÌ¡AÀ³¦bÂåÅ@ºÊ·þ¤Uµ¹»P,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OMEZ,Clozapine,MezaPin 100mg,CNEU,Schizophrenia¡A treatment resistant: Treatment of severely ill patients with schizophrenia who fail to respond adequately to antipsychotic treatment. Suicidal behavior in schizophrenia or schizoaffective disorder: To reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior¡A based on history and recent clinical state.,Serious hypersensitivity to clozapine or any component of the formulation (eg¡A photosensitivity¡A vasculitis¡A erythema multiforme¡A or Stevens-Johnson syndrome [SJS]),Initially drowsiness¡A hypersalivation¡A granulocytopenia & agranulocytosis¡A palpitation¡A fatigue. Dry mouth¡A blurred vision¡A orthostatic hypotension¡A disturbance in temp regulation. Tachycardia¡A ECG changes. Rarely: delirium¡A extrapyramidal reactions. Cardiovascular: Hypotension¡A Tachyarrhythmia (25%) Dermatologic: Rash (2%)¡A Sweating symptom (6%) Endocrine metabolic: Excessive salivation (31% )¡A Weight gain (4%) Gastrointestinal: Constipation (14% )¡A Excessive salivation (31% )¡A Nausea (5% )¡A Xerostomia (6% ) Musculoskeletal: Motor function behavior finding (4%)¡A Muscle rigidity (3%) Neurologic: Akathisia (3%)¡A Confusion (3%)¡A Dizziness (19%)¡A Headache (7%)¡A Insomnia (2%)¡A Somnolence (39%)¡A Tremor (6%)¡A Vertigo (19%) Ophthalmic: Visual disturbance (5%) Psychiatric: Agitation (4%)¡A Dyssomnia¡A Nightmares (4%)¡A Restlessness (4%) Other: Fatigue (2%)¡A Fever (5%) Tachycardia¡A ECG changes. Rarely: delirium¡A extrapyramidal reactions.,25¢J¥H¤UÁ×¥ú,Schizophrenia: Oral: Initial: 12.5 mg once or twice daily; increase¡A as tolerated¡A in increments of 25 to 50 mg daily to a target dose of 300 to 450 mg daily (administered in divided doses) by the end of 2 weeks; may further titrate in increments not exceeding 100 mg and no more frequently than once or twice weekly. Maximum total daily dose: 900 mg. Suicidal behavior in schizophrenia or schizoaffective disorder: Oral: Initial: 12.5 mg once or twice daily; increased¡A as tolerated¡A in increments of 25 to 50 mg daily to a target dose of 300 to 450 mg daily (administered in divided doses) by the end of 2 weeks; may further titrate in increments not exceeding 100 mg and no more frequently than once or twice weekly. Mean dose is ~300 mg daily; maximum total daily dose: 900 mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OBRO,Bromelain + L-Cysteine,Broen-C 20000IU/20mg,CNEU,Relief of postoperative and post-traumatic swelling¡A sinusitis¡A breast engorgement¡A respiratory conditions with difficult mucus expectoration¡A difficulty in coughing up mucus after tracheal anesthesia¡A hemorrhoids.,Digestive tract ulcers¡A severe liver or kidney impairment¡A blood coagulation disorders¡A allergy to pineapple.,Stomach ache¡A diarrhea¡A erythema¡A pruritus¡A palpitations(rare)¡A bronchial asthma (rare).,25¢J¥H¤U³±²D³B,3-6 tablets/day in divided doses Q6-8H.,»Ý½Õ¾ã¾¯¶q,­««×¨x¥\¯à¤£¥þªÌ©Î¾®¦å¾÷¯à²§±`ªÌ¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Bromelain [18] L-Cysteine [18],Unknown ¨S¦³¸ê®Æ,Bromelain [8] L-Cysteine [8],AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»¿õ¡A½Ð¾ã²É§]ªA¡A¤Á¤Å«rÄZ©ÎÀ£¸H¡C ¹ï»ñ±ù¹L±ÓªÌ¸T¥Î
OZOP7,Zopiclone,Zolon 7.5mg,CNEU,Insomnia.,Hypersensitivity to Zopiclone¡A myasthenia gravis¡A respiratory failure¡A severe sleep apnea¡A severe hepatic insufficiency¡A patients who have experienced complex sleep behaviors (such as sleepwalking¡A dream driving¡A or engaging in other activities while not fully awake) after using similar drugs.,Bitter taste¡A drowsiness¡A dry mouth¡A dizziness¡A headache¡A nausea¡A vomiting¡A fatigue¡A agitation¡A and nightmares. Aggressive behavior¡A agitation¡A depression¡A confusion¡A falling¡A memory impairment¡A muscle spasm¡A dyspepsia¡A anaphylaxis¡A angioedema¡A delirium¡A delusion¡A disturbance in attention¡A drug dependence¡A myasthenia¡A outbursts of anger¡A rebound insomnia¡A restlessness¡A withdrawal syndrome¡A complex sleep related disorder (including sleep driving¡A sleep talking¡A somnambulism)¡A respiratory depression.,25¢J¥H¤U,Adult: 7.5 mg orally¡A administered 30-60 minutes before bedtime. Elderly¡A mild-to-moderate hepatic impairment¡A renal impairment¡A respiratory impairment: Initial: 3.75 mg orally once daily at bedtime. Duration should be as short as possible¡A including the period of dose reduction¡A and should not exceed 4 weeks. Transient insomnia: 2-5 days; short-term insomnia: 2-3 weeks.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¨ü·lªº±wªÌ±ÀÂË°_©l¾¯¶q¬°3.75mg(1/2¿õ)¡AÀH«á¾¯¶q¥i¥H¼W¥[¨ì7.5mg(1¿õ)¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[Micromedex] Fetal harm has been demonstrated. Prescribe an alternative¡A if possible. [¥é³æ] ¥Ø«e©|µL¨¬°÷ªº¸ê®Æ¥iµû¦ô¤HÃþ¦bÃh¥¥¤Î±Â¨Å´Á¶¡¨Ï¥ÎZopiclone¤§¦w¥þ©Ê¡C Ãh¥¥´Á¤£±ÀÂË¨Ï¥Î¥»ÃÄ¡C­YÃh¥¥«á´Á¤T­Ó¤ë©Î¤À®Y®ÉªA¥ÎZopiclone¡A¹ï­L¨à¥i¯à·|¦³¦pÅé·Å¹L§C¡A¦Ù±i¤O¹L§C(Hypotonia)¤Î©I§l§í¨î¡C Àøµ{·Uµu·U¦n¥B¤£À³¶W¹L¥|¶g(¥]¬A³vº¥­°§C¾¯¶qªº´Á¶¡¦b¤º)¡C ­Y¥ÀÅé¦bÃh¥¥«á´Áªø´Á¨Ï¥Î¡A«hÀ¦¨à¦³¥i¯à¥X²{¥Í²z¤Wªº¨Ì¿à©Ê¡A²£«á¤]¦³¥X²{§ÙÂ_¯gª¬ªº­·ÀI¡C ¨|ÄÖ´Á°ü¤k­Yµ¹»PZopiclone¡A¥²¶·§iª¾±wªÌ·í¨äµo²{©ÎÃhºÃ¤w¸gÃh¥¥®É¡AÀ³»PÂå®vÁpÃ´¨Ã°±¥Î¸ÓÃÄª«¡C,Unknown ¨S¦³¸ê®Æ,[Micromedex] Infant risk cannot be ruled out. Advise women to avoid breastfeeding during zopiclone therapy. [¥é³æ] ¥Ø«e©|µL¨¬°÷ªº¸ê®Æ¥iµû¦ô¤HÃþ¦bÃh¥¥¤Î±Â¨Å´Á¶¡¨Ï¥ÎZopiclone¤§¦w¥þ©Ê¡C ÁöµM¥À¨Å¤¤Zopiclone ªº¿@«×«D±`§C¡A ±Â¨Å¥À¿Ë¤´¤£À³ªA¥ÎZopiclone¡C,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OVIE,Ombitasvir + Paritaprevir + Ritonavir,Viekirax FC 12.5/75/50mg,QANB,,¾AÀ³¯g:Treatment of chronic hepatitis C in patients with genotypes 1 and 4 in combination with other drugs. °Æ§@¥Î: Central nervous system: Fatigue (7%)¡A insomnia (5%) Dermatologic: Allergic skin reaction (5%)¡A pruritus (5%) Gastrointestinal: Nausea (9%) Hematologic & oncologic: Anemia¡A decreased hemoglobin Hepatic: Increased serum ALT Neuromuscular & skeletal: Weakness (25%) Miscellaneous: Tachyphylaxis <1%¡A postmarketing¡A and/or case reports: Hepatic failure (in patients with underlying cirrhosis; FDA Safety Alert¡A October 22¡A 2015)¡A hypersensitivity reaction (including angioedema)¡A liver decompensation (in patients with underlying cirrhosis; FDA Safety Alert¡A October 22¡A 2015)¡A reactivation of HBV ¸T§Ò: Hypersensitivity to ritonavir (eg¡A toxic epidermal necrolysis¡A Stevens-Johnson syndrome) or any component of the formulation; moderate to severe hepatic impairment (Child-Pugh class B or C); concurrent use of drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events; concurrent use of moderate or strong inducers of CYP3A. Concurrent use of drugs that are contraindicated include¡A but are not necessarily limited to: Alfuzosin¡A colchicine (not in Canadian labeling)¡A carbamazepine¡A cisapride¡A dronedarone¡A ergot derivatives (ergonovine¡A ergotamine¡A dihydroergotamine¡A methylergonovine)¡A ethinyl estradiol-containing products¡A efavirenz¡A lovastatin¡A lurasidone¡A midazolam (oral)¡A phenobarbital¡A phenytoin¡A pimozide¡A ranolazine¡A rifampin¡A sildenafil (when used for the treatment of pulmonary arterial hypertension [eg¡A Revatio])¡A simvastatin¡A St John's wort¡A triazolam. Note: Contraindications to ribavirin also apply; see ribavirin prescribing information.,,,Chronic hepatitis C: Oral: Note: Ombitasvir¡A paritaprevir¡A and ritonavir are a fixed-dose combination tablet. The recommended oral dose of Viekirax is two 12.5 mg / 75 mg / 50 mg tablets once daily with food. Viekirax should be used in combination with other medicinal products for the treatment of HCV. =genotype 1: Viekirax (ombitasvir 25mg/paritaprevir 150mg/ritonavir 100mg) should be taken once daily and Exviera 250mg should be taken twice daily¡A with or without ribavirin taken twice daily. =genotype 4: Viekirax (ombitasvir 25mg/paritaprevir 150mg/ritonavir 100mg) once daily¡A taken with ribavirin dosed twice daily. =Patient population Treatment* Duration =============================================================================== Genotype 1b¡A without cirrhosis or with compensated cirrhosis Viekirax + dasabuvir 12 weeks Genotype 1a¡A without cirrhosis Viekirax + dasabuvir + ribavirin* 12 weeks Genotype 1a¡A with compensated cirrhosis Viekirax + dasabuvir + ribavirin* 24 weeks Genotype 4¡A without cirrhosis or with compensated cirrhosis Viekirax + ribavirin 12 weeks --------------------------------------------------------------------------------------------------------------------------------------- *Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Pregnancy Risk Factor: ¸T¥Î (ÃÄ«~¥é³æ),,,,,,
EFUS,Betamethasone,FUSone eye drops 0.1%¡A 0.5mL,TOPH,Inflammatory conditions of the eyes.,Hypersensitivity.,Increased intraocular pressure.,25¢J¥H¤U,instill 1-2 drops 3 to 4 times daily into the eye.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
IOPT,Ioversol,Optiray 350 inj 74% 100mL,ZOTH,Arteriography¡A venography¡A head & body CT¡A excretory urography.,Patients with known or suspected hypersensitivity or in clinically significant cases of hepatic & renal impairment.,Hypotension¡A nausea¡A vomiting¡A headache¡A laryngeal edema¡A urticaria¡A pruritus¡A extravasation.,30¢J¥H¤UÁ×¥úÁ×§K§N­á,Intra-arterial Procedures in Adults: Cerebral Arteriography. Peripheral Arteriography: Diagnostic area; Dose; Maximum Cumulative Dose aorta-iliac runoff; 60 mL (range 20 to 90 mL); 250 mL. common iliac¡A femoral; 40 mL (range 10 to 50 mL); 250 mL. subclavian¡A brachial; 20 mL (range 15 to 30 mL); 250 mL. Coronary Arteriography and Left Ventriculography: Diagnostic area; Dose; Maximum Cumulative Dose left coronary; 8 mL (range 2 to 10 mL); 250 mL. right coronary; 6 mL (range 1 to 10 mL); 250 mL. left ventricle; 40 mL (range 30 to 50 mL); 250 mL. Intravenous Procedures in Adults: Computed Tomography. Head Imaging: Infusion 50 to 150 mL. Body Imaging: Bolus Injection 25 to 75 mL¡A Infusion 50 to 150 mL. Venography: The recommended dose is 50 to 100 mL per extremity; with a maximum cumulative dose of 250 mL. Intravenous Urography: Usual Dose:50 to 75 mL¡A High Dose Urography: 1.4 mL/kg¡A Maximum Dose: 140 mL. Intravenous Digital Subtraction Angiography (IV-DSA): The recommended dose range per injection is 30 to 50 mL; may repeat as necessary with a maximum cumulative dose of 250mL. Injection rates will vary depending on the site of catheter placement and vessel size. Central catheter injections are usually made at a rate of between 10 and 30 mL/second. Peripheral injections are usually made at a rate of between 12 and 20 mL/second.,»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling. Use caution in patients with combined hepatic and renal disease.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,¥é³æ«ØÄ³:¨Ï¥ÎÃÄ«~«á°±¤î­÷¨Å48¤p®É¡C,IA;IV;IVD;IVP;IVPUSH;,,,Usual rates of administration are 10 to 30 mL/second for central catheter injections and 12 to 20 mL/second for peripheral injections.,May be utilized as IV bolus¡A IV infusion¡A or combination of both; scanning intervals will vary based upon indication and target organ. Use lowest dose necessary for optimal visualization and individualize dosage.,1. For intravascular use only; not for intrathecal use. 2. Do not mix with other medications¡A solutions¡A or total parenteral nutrition. 3. Avoid extravasation during injection¡A especially in patients with severe arterial or venous disease. 4. Adequately hydrate patients before and after administration.
OACAM,Acamprosate,Acamprosate 333mg Delayed-Release(±M®×¶i¤f),ZADT,Alcoholism¡A maintenance of abstinence,Hypersensitivity to acamprosate calcium or any of its components¡A Severe renal impairment (CrCl of 30 mL/min or less).,>10% Gastrointestinal: Diarrhea (10% to 17%) 1% to 10%: Cardiovascular: Chest pain¡A hypertension¡A palpitations¡A peripheral edema¡A syncope¡A vasodilation Central nervous system: Insomnia (6% to 9%)¡A anxiety (5% to 8%)¡A depression (4% to 8%)¡A dizziness (3% to 4%)¡A pain (2% to 4%)¡A paresthesia (2% to 3%)¡A abnormality in thinking¡A amnesia¡A attempted suicide¡A chills¡A drowsiness¡A headache Dermatologic: Pruritus (3% to 4%)¡A diaphoresis (2% to 3%)¡A skin rash Endocrine & metabolic: Decreased libido¡A weight gain Gastrointestinal: Anorexia (2% to 5%)¡A nausea (3% to 4%)¡A flatulence (1% to 4%)¡A xerostomia (1% to 3%)¡A abdominal pain¡A constipation¡A dysgeusia¡A dyspepsia¡A increased appetite¡A vomiting Genitourinary: Impotence Infection: Infection Neuromuscular & skeletal: Weakness (5% to 7%)¡A arthralgia¡A back pain¡A myalgia¡A tremor Ophthalmic: Visual disturbance Respiratory: Bronchitis¡A dyspnea¡A flu-like symptoms¡A increased cough¡A pharyngitis¡A rhinitis <1%¡A postmarketing¡A and/or case reports: Abnormal hepatic function tests¡A agitation¡A alopecia¡A anemia¡A angina pectoris¡A asthma¡A brain disease¡A colitis¡A confusion¡A deafness¡A diabetes mellitus¡A duodenal ulcer¡A eosinophilia¡A epistaxis¡A exfoliative dermatitis¡A fever¡A gastrointestinal hemorrhage¡A gout¡A hallucination¡A hemorrhage¡A hepatic cirrhosis¡A hepatitis¡A hostility¡A hyperbilirubinemia¡A hyperesthesia¡A hyperglycemia¡A hypersensitivity reaction¡A hyperuricemia¡A hyponatremia¡A hypotension¡A hypothyroidism¡A increased serum creatinine¡A increased serum transaminases¡A leukopenia¡A lymphadenopathy¡A lymphocytosis¡A myocardial infarction¡A nephrolithiasis¡A neuralgia¡A ophthalmic inflammation¡A orthostatic hypotension¡A pancreatitis¡A pneumonia¡A psychoneurosis¡A psychosis¡A pulmonary embolism¡A rectal hemorrhage¡A renal failure¡A seizure¡A skin photosensitivity¡A suicidal ideation¡A tachycardia¡A thrombocytopenia¡A urticaria¡A withdrawal syndrome,15-30¢J¡A25¢J¬°¨Î,Alcoholism¡A maintenance of abstinence: 666 mg orally 3 times daily.,µL»Ý½Õ¾ã¾¯¶q,Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary. Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in manufacturer's labeling.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest high risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Micromedex: Infant risk cannot be ruled out.,AC;AC15;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½wÄÀ¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
ONAL,Naltrexone,Naltrexone 50mg (±M®×¶i¤f),ZADT,Alcohol use disorder,Hypersensitivity to naltrexone or any component of the formulation; current physiological opioid dependence or current use of opioid analgesics (including partial opioid agonists); acute opioid withdrawal; failure to pass naloxone challenge or positive urine screen for opioids,>10%: Syncope (=<13%)¡A Headache (25%)¡A insomnia (=<14%)¡A sleep disorder (=<14%)¡A dizziness (=<13%)¡A anxiety (12%)¡A Nausea (33%)¡A vomiting (14%)¡A anorexia (=<14%)¡A change in appetite (=<14%)¡A decreased appetite (=<14%)¡A diarrhea (13%)¡A abdominal pain (11%)¡A Increased serum transaminases (20%)¡A increased serum aspartate aminotransferase (2% to 14%)¡A Increased creatine phosphokinase in blood specimen (11% to 39%)¡A asthenia (23%)¡A arthralgia (=<12%)¡A arthritis (=<12%)¡A joint stiffness (=<12%)¡A Pharyngitis (11%) 1% to 10%: Depression (8% to 10%)¡A drowsiness (=<4%)¡A sedated state (=<4%)¡A suicidal ideation (=<1%)¡A suicidal tendencies (=<1%)¡A Skin rash (6%)¡A Xerostomia (5%)¡A Muscle cramps (8%)¡A back pain (=<6%)¡A back stiffness (=<6%),«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,(Micromedex) Alcohol dependence¡A Maintenance of abstinence: 50 mg orally once daily for <= 12 weeks. Opioid dependence: 25 mg orally on day 1; if no withdrawal signs occur¡A may increase to 50 mg orally once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;AM;PC;PO;WM;,,,,,
OKCB,Dibismuth trioxide,KCB 120mg,ALIM,gastric and duodenal ulceration.,Hypersensitivity¡A moderate-severe renal insufficiency.,Gray stools. Nausea¡A vomiting.,25¢J¥H¤U,usual dose: Adult: 2 TAB BID before meal¡A or 1 TAB QID before meal for 4 weeks¡A may be extended to 8 weeks if needed.,µL»Ý½Õ¾ã¾¯¶q,µL¬ÛÃö«ØÄ³¸ê®Æ,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,Human Data Suggest Potential Toxicity,,AC;PO;,,,,,
IVAB0,Faricimab,Vabysmo intravitreal inj 6mg/0.05mL(Sample),TOPH,For intravitreal injection. Neovascular (wet) age-related macular degeneration (nAMD)¡A diabetic macular edema (DME),Ocular or periocular infection. Active intraocular inflammation. Known hypersensitivity to faricimab or any of its excipients (allergic reactions may manifest as rash¡A itching¡A urticaria¡A erythema¡A or severe intraocular inflammation).,Common: Conjunctival hemorrhage (7-8%) Serious: Arterial thromboembolism (1-5%)¡A Raised intraocular pressure (3-4%)¡A Retinal pigment epithelial detachment with tear of retinal pigment epithelium (3%),Á×¥ú§NÂÃ(2-8¢XC)Àx¦s¡B¤£¥i§N­á¡C,Neovascular age-related macular degeneration (nAMD): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Maximum interval: Every 16 weeks (4 months)¡A but can be adjusted to every 12 weeks (3 months) or every 8 weeks (2 months). Limited safety data for intervals shorter than 8 weeks. Diabetic macular edema (DME): 6mg (0.05mL) via intravitreal injection. Initial dosing: Once every 4 weeks (monthly) for the first 4 doses. Dosing intervals: Gradual extension of injection intervals¡A up to every 16 weeks (4 months). No clinical trial data available for intervals shorter than 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¤£´¿¬ã¨sVabysmo ¥Î©ó¨x¥\¯à¤£¥þ¯f¤Hªº¦w¥þ©Ê»PÀø®Ä¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL Vabysmo ¥Î©óÃh¥¥¤k©Êªº¸ê®Æ¡C ¥Ø«e¨Ã¤£ª¾¹Dµ¹¤©Ãh¥¥¤k©Ê®É¡A Vabysmo ¬O§_·|³q¹L­L½L©Î¶Ë®`­L¨à¡C®Ú¾Ú VEGF »P Ang-2§í¨î¾¯ªº§@¥Î¾÷Âà¡A ¦s¦b¹ï¤k©Ê¥Í´Þ¯à¤O¥H¤Î­F­L­L¨àµo¨|ªº¼ç¦b­·ÀI¡CÁöµM²´³¡µ¹ÃÄ«á¥þ¨­¼ÉÅS«D±`§C¡A ¦ý°£«D¹ï¯f¤Hªº¼ç¦b®Ä¯q¶W¹L¹ï­L¨àªº¼ç¦b­·ÀI¡A§_«h¤£À³©óÃh¥¥´Á¶¡¨Ï¥ÎVabysmo¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¥¼ª¾ Vabysmo ¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤º¡C¥Ø«e©|¥¼¶i¦æ¸ÕÅçµû¦ô Vabysmo ¹ï©ó¨Å¥Ä»s³yªº¼vÅT©Î¨ä¬O§_·|¶i¤J¨Å¥Ä¸Ì¡C ¥Ñ©ó³\¦hÃÄª«·|¤Àªc¦Ü¤HÅé¨Å¥Ä¤¤¡A¦s¦b§l¦¬¦Ó¶Ë®`À¦¨à¥Íªø»Pµo¨|ªº¼ç¦b¥i¯à¡A ¦]¦¹ Vabysmo µ¹¤©­÷¨Å¤¤¤k©Ê®ÉÀ³¯S§O¤p¤ß¡CÀ³¦P®É¦Ò¼{­÷¨Å¹ï©óµo¨|©M°·±dªº¯q³B¡A ¥H¤Î¥À¿Ë¹ï©ó Vabysmo ªºÁ{§É»Ý­n»P Vabysmo ¹ï©ó±µ¨ü­÷¨Å«Äµ£ªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¡C,IVI;,,,,,1. ¶È¨Ñ¬Á¼þÅé¤ºª`®g¨Ï¥Î¡CVabysmo ¥²¶·¥Ñ¨ã³Æ¬Á¼þÅé¤ºª`®g¸gÅçªº¦X®æÂå®vµ¹¤©¡C¨C¤p²~¶ÈÀ³¨Ï¥Î©óªvÀø³æ²´¡C
OJIN1,Tolvaptan,Jinarc 15mg,CAVS,Indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) and eGFR greater than 25mL/min/1.73m2 with signs of rapid disease progression¡A to slow the growth of cysts and decline in kidney function associated with autosomal dominant polycystic kidney disease.,Hypersensitivity to tolvaptan or any component of the product or benzazepine or benzazepine derivatives. Presence of liver enzyme elevation and/or liver damage signs or symptoms that meet the criteria for permanent discontinuation of tolvaptan before starting treatment. Anuria. Volume depletion. Hypernatremia. Unable to sense or respond to thirst. Pregnancy. Breastfeeding.,Common: Hypernatremia (0.7-25.6%)¡A Diarrhea (13.3%)¡A Increased thirst (12-63.7%)¡A Nausea (8-21%)¡A Xerostomia (7-23%)¡A ALT/SGPT level raised¡A Serum bilirubin above reference range¡A Asthenia (9%)¡A Dizziness (4.8-11.3%)¡A Increased frequency of urination (69.5%)¡A Polyuria (4-24%)¡A Fatigue (13.6%) Serious: Hypovolemia¡A Gastrointestinal hemorrhage¡A In cirrhotic patients (10%)¡A Hepatic failure¡A acute¡A Injury of liver¡A Osmotic demyelination syndrome,25¢J¥H¤U,Take twice daily. Dosage options: 45mg + 15mg¡A 60mg + 30mg¡A or 90mg + 30mg (split dose regimen). First dose 30 minutes before breakfast. Second dose can be taken with or without food. Initial: total dose 60mg (45mg on waking¡A 15mg after 8 hours). If tolerated¡A increase to 90mg daily (60mg + 30mg)¡A then up to the target dose of 120mg daily (90mg + 30mg). At each dosage adjustment¡A allow at least one week interval.,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¦b§C¶u¦å¯g¬ã¨s¤¤¡Aµo²{¤¤«×©Î­««×ªº¨x¥\¯à¤£¥þ·|­°§C tolvaptan ªº²M°£²v¨Ã¼W¥[¨ä¤À§GÅé¿n¡C ADPKD ¯f¤H©|¥¼¬ã¨s³oºØÅÜ¤Æªº¼vÅT¡C¦b¥Î©óªvÀø­««×¨x¥\¯à¤£¥þ¯f¤H®É¡AÀ³ÂÔ·Vµû¦ôªvÀø®Ä¯q¤Î­·ÀI¡A¥B¥²¶·ÂÔ·V±±¨î¯f¤Hªº±¡ªp¡A¥H¤Î©w´ÁºÊ´ú¨xÅ¦»Ã¯À¡C¦b¶}©lªvÀø¤§«e¡A¥X²{²Å¦X¥Ã¤[°±¥Î tolvaptan ³W©w¤§¨xÅ¦»Ã¯À¤É°ª¤Î/©Î¨xÅ¦·l¶Ë¼x­Ô©Î¯gª¬ªº¯f¤H«h¸T¥Î Jinarc¡C,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest low risk,PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk [¥é³æ] ¥Ø«e¦b¥¥°üªA¥Î tolvaptan ¤è­±©|µL¸ê®Æ©Î¸ê®Æ¦³­­¡C°Êª«¸ÕÅçÅã¥Ü¥»ÃÄ«~¨ã¦³¥Í´Þ¬r ©Ê¡CJinarc ¤£«ØÄ³¥Î©ó¥¼±Ä¨úÁ×¥¥±¹¬Iªº¨|ÄÖ°ü¤k¡CÃh¥¥®É¤£±oªA¥Î Jinarc¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BREASTFEEDING RECOMMENDATION: No Human Data¡XPotential Toxicity [¥é³æ] ¥Ø«e©|¤£²M·¡ tolvaptan ¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¤¤¡A¦ý¬O®Ú¾Ú¤j¹«¸ÕÅçÅã¥Ü tolvaptan ·|¤Àªc¨ì¨Å¥Ä¤¤¡C¤£¯à±Æ°£·s¥Í¨à/À¦¨àªº­·ÀI¡C­÷¨Å´Á¶¡¸T¥Î Jinarc¡C,AC;PO;,,,,,
ICLI3,Clindamycin,Clincin inj 300mg/2mL,QANB,Serious infections caused by clindamycin-susceptible strains of streptococci¡A pneumococci and staphylococci eg¡A resp tract infections eg¡A peritonitis and intra-abdominal abscess; female pelvis and genital tract infections eg¡A non-gonococcal tubo-ovarian abcess¡A pelvic cellulitis and post-op vag cuff infection; skin and soft tissue infections.,Hypersensitivity to clindamycin or lincomycin. History of GI diseases¡A severe renal or liver impairment.,Common Dermatologic: Dry skin¡A Morbilliform eruption Gastrointestinal: Diarrhea (vaginal cream¡A less than 1%)¡A Nausea Reproductive: Candida vaginitis (vaginal cream¡A 14% ; vaginal suppository¡A 1.5%)¡A Vaginal pain (vaginal suppository¡A 1.9%) Serious Dermatologic: Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile colitis¡A Clostridium difficile colitis¡A Hemorrhagic diarrhea Hematologic: Agranulocytosis Hepatic: Increased liver function test¡A Jaundice Immunologic: Drug reaction with eosinophilia and systemic symptoms,«Ç·Å,Adults: 600-1200 mg/day IV Q6-12H; severe infection: 1.2-2.7 g/day IV Q6-12H; life-threatening: 4.8 g/day. Children > 1 month of age: 15-25 mg/kg/day (350 mg/m2/day) IV Q6-8H; severe condition: 25-40 mg/kg/day (450 mg/m2/day) IV Q6-8H. Do not exceed 600 mg in a single deep IM injection. Dilute to a concentration < 12 mg/mL for IV administration and do not exceed 1200 mg/hour. (¼ö¯f) Adult: IV/IM: 1.2-2.7 g/day divided Q8H (maximum 4.8 g/day). To avoid neuromuscular blockade¡A do not exceed infusion rate of 30 mg/minute. Final concentration < 18 mg/mL. Administering > 1200 mg in a 1-hr infusion not recommended. Pediatric dose for age > 28 days: IV: 20-40 mg/kg/day¡A divided Q6-8H. *****NEONATE ANTIBIOTICS DOSE***** Clindamycin: general infection dose 5 mg/kg/dose; infusion > 30-60min Body weight <1kg Age <=7day 5mg/kg Q12H Age 8-14 day 5 mg/kg Q12H Age 15-28 day 5 mg/kg Q8H Body weight 1-2kg Age<=7day 5 mg/kg Q12H Age 8-14 day 5 mg/kg Q8H Age 15-28 day 5 mg/kg Q8H Body weight >2kg Age<=7day 5 mg/kg Q8H Age 8-14 day 5 mg/kg Q6H Age 15-28 day 5 mg/kg Q6H,»Ý½Õ¾ã¾¯¶q,dose reductions are recommended in active liver disease,µL»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Enters breast milk/not recommended (AAP rates ¡§compatible¡¨; AAP 2001 update pending) Breast-Feeding Considerations:Small amounts of clindamycin transfer to human milk. The manufacturer does not recommend the use of clindamycin during breast-feeding. Nondose-related effects could include modification of bowel flora. One case of bloody stools in an infant occurred after a mother received clindamycin while breast-feeding; however¡A a casual relationship was not confirmed.,IM;IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C,,,
IRAPBAD,Alfentanil,Rapifen inj 1mg/2mL ´Ý¾l¾P·´,CNEU,,,,,,,,,,,,,,IV;IVPUSH;,,,,,
IINV2,Paliperidone,INVEGA inj 150mg (=234mg),CNEU,Acute & maintenance treatment of schizophrenia in adults.,Hypersensitivity to paliperidone or risperidone.,Cerebrovascular events including stroke. Neuroleptic malignant syndrome¡A QT prolongation¡A tardive dyskinesia¡A hyperglycemia & DM¡A wt gain¡A hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia¡A neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures¡A dysphagia¡A suicide¡A priapism¡A TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions¡A somnolence/sedation¡A dizziness¡A akathisia & extrapyramidal disorder.,30¢XC¥H¤U,Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen¡A adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,Micromedex Pregnancy Rating: Fetal risk cannot be ruled out. Although no structural malformations attributable to risperidone have been reported¡A the number of exposures is too low to fully assess the embryo¡Vfetal risk. In addition¡A there is a risk of extrapyramidal and/or withdrawal symptoms in the newborn if the drug is used in the 3rd trimester. Nevertheless¡A risperidone is indicated for severe debilitating mental disease and the benefits to the mother appear to outweigh the potential embryo¡Vfetal risks. Folic acid 4 mg/day has been recommended for women taking atypical antipsychotics because they may have a higher risk of neural tube defects due to inadequate folate intake and obesity,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex Lactation Rating: Infant risk cannot be ruled out.,IM;,,,,,1.¥é³æ¹ï©ó¤£¦Pª`®g³¡¦ì¤Î¯f±wÅé­««ØÄ³¨Ï¥Î¤£¦Pªº°wÀY¡A½Ð°Ñ·Ó. 2.½Ð¶J¦s©ó30¢XC¥H¤U¡C¤Á¤Å»P¥ô¦ó¨ä¥¦²£«~©Îµ}ÄÀ¾¯²V¦X¨Ï¥Î¡C
HCVDA01,Daklinza + Sunvepra (1b/24¶g),HCVDAA0001(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1b/24¶g,QANB,,,,,,,,,,,,,,,,,,,
HCVDA03,Viekirax + Exviera + Ribavirin (1a/12¶g),HCVDAA0003(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1a/12¶g,QANB,,,,,,,,,,,,,,,,,,,
HCVDA02,Viekirax + Exviera (1b/12¶g),HCVDAA0002(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1b/12¶g,QANB,,,,,,,,,,,,,,,,,,,
ELYC,Permethrin,Lyclear Cream 5%¡A 30gm (±M®×¶i¤f),TDER,,¾AÀ³¯g: Head lice (lotion/cream rinse): Treatment of head lice (Pediculus humanus capitis) and its nits (eggs). Scabies (cream): Treatment of scabies (Sarcoptes scabiei) infestation °Æ§@¥Î: Central nervous system: Local discomfort (scalp)¡A localized burning¡A localized numbness¡A tingling of skin Dermatologic: Pruritus¡A erythema¡A skin rash (scalp)¡A stinging of the skin Local: Localized edema ¸T§Ò: Hypersensitivity to any pyrethroid or pyrethrin¡A or to any component of the formulation. OTC labeling (cream rinse/lotion): When used for self-medication¡A do not use on infants <2 months of age; near the eyes; inside the nose¡A ear¡A mouth¡A or vagina. Consult health care provider for use on eyebrows or eyelashes.,,«Ç·Å,-To treat scabies Adults and adolescents over 12 years of age. Apply up to 30 g of cream (corresponding to one tube of 30 g) Children aged from 6 - 12 years. Apply up to 15 g of cream (corresponding to 1/2 tube of 30 g) Children aged from 2 months - 5 years. Apply up to 7.5 g of cream (corresponding to 1/4 tube of 30 g) -To treat crab lice Adults over 18 years of age: Apply up to 30 g of cream (corresponding to one tube of 30 g).,,,,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
EOES8,Estradiol,Oestrogel gel 0.75mg/pump¡A 64pump/bottle,HM,Hormone replacement therapy: Treatment of symptoms related to menopause (hot flushes¡A excessive sweating¡A urinary symptoms¡A dryness of the vagina¡A etc).,Ongoing thromboembolic diseases (inflammation of a vein with formation of a blood clot¡A obliteration of a pulmonary vessel¡A myocardial infarction¡A cerebrovascular accident related to a blood clot). Certain diseases of the liver and malignant tumours of the breast or uterus. Endometriosis Undiagnosed vaginal bleeding. Hypersensitivity to any of the components of Oestrogel. Oestrogel has no indication during pregnancy.,Common Cardiovascular: Edema (Transdermal system¡A 0.5% to 13% ) Dermatologic: Application site irritation (transdermal system¡A 5.7% to 56.7% )¡A Chloasma¡A Hirsutism¡A Loss of scalp hair¡A Persistent erythema of skin (Transdermal system¡A less than or equal to 3.2% ) Endocrine metabolic: Weight increased (Transdermal system¡A up to 8.5% ) Gastrointestinal: Abdominal pain (Topical gel¡A 7.7%)¡A Bloating symptom Neurologic: Headache (Topical gel¡A 9.5%) Reproductive: Breast tenderness (Topical gel¡A 2.5% to 8.8%)¡A Disorder of menstruation¡A Pain of breast (Topical gel¡A 10.7%)¡A Swelling of breast¡A Withdrawal bleeding Respiratory: Upper respiratory infection (Topical gel¡A 1.6% to 5.9% ) Other: Pain (Transdermal system¡A 0% to 11% ) Serious Cardiovascular: Heart disease¡A Myocardial infarction Endocrine metabolic: Body fluid retention¡A Hypercalcemia Gastrointestinal: Disorder of gallbladder Hematologic: Deep venous thrombosis¡A Venous thromboembolism Neurologic: Cerebrovascular accident¡A Dementia Ophthalmic: Thrombosis of retinal vein Reproductive: Breast cancer¡A Endometrial cancer¡A Ovarian cancer Respiratory: Pulmonary embolism Other: Angioedema,30¢J¥H¤U,Each pump contain 1.25gm Gel = 0.75mg Estradiol. Apply 1.25mg Estradiol (2 pumps)/day 3 weeks on¡A 1 week off¡A and with oral progesterone on days 8 to 21. Topically use to clean¡A dry¡A unbroken skin on the arm; apply in a thin layer from wrist to shoulder; allow gel to dry for up to 3 minutes before dressing. If necessary¡A Apply 1.25mg Estradiol (2 pumps)/day on days 1 to 24¡A And with oral progesterone on days 8 to 21.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¤wª¾Ãh¥¥©ÎÃhºÃ¤wÃh¥¥ªÌ¥²¶·¥ß§Y°±¤î¨Ï¥Î¦¹ÃÄ¡A°Ê±¡¯ÀªvÀø¤§¾AÀ³¯g¤£¥]§t¬y²£¤Î§í¨îªc¨Å¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¤wª¾Ãh¥¥©ÎÃhºÃ¤wÃh¥¥ªÌ¥²¶·¥ß§Y°±¤î¨Ï¥Î¦¹ÃÄ¡A°Ê±¡¯ÀªvÀø¤§¾AÀ³¯g¤£¥]§t¬y²£¤Î§í¨îªc¨Å¡C,EXT;SKIN;TOPI;,,,,,1. ¤Å¶î©Ù©ó¨Å©Ð¡B³±³¡©Î³±¹DÂH½¤¡C 2. ¾¨¥i¯à¦a¶î¶}©ó«eÁu¡B¤âÁu¡B¨âªÓ©ÎªÌ§¹¾ã¤j­±¿nªº¥Ö½§¤W¡C­Y¼Å¥Î¤T¤ÀÄÁ«á¤´ÂHµÛ¡Aªí¥Ü¶î¼Å­±¿n¤Ó¤p¡A¤U¦¸¨Ï¥Î®ÉÀ³¶î¸û¤j­±¿n¡C 3. °ü¤k¦Û¤v¶î©Ù¡C¦­©Î±ß¨N¯D«á¡A¨C¤Ñ¦P¤@®É¶¡¼Å¥Î¡C
OISO4,Verapamil,Isoptin 40mg,CAVS,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
ETRP,Brillant Green,Tripledye 500mL,TDER,,,,,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
IORE,Oxaliplatin,Orectalip inj 50mg/10mL,RACA,Adjuvant treatment of stage III colon cancer after complete resection of primary tumor and advanced colorectal cancer (in combination with infusional fluorouracil and leucovorin).,Hypersensitivity to oxaliplatin¡A other platinum-containing compounds¡A or any component of the formulation. Pregnancy¡A breast-feeding; severe renal impairment (CrCl <30 mL/minute),Nausea¡A vomiting¡A diarrhea; anemia¡A leucopenia¡A granulocytopenia¡A thrombocytopenia; peripheral neuropathies; fever¡A rash¡A anorexia. Gastrointestinal: Abdominal pain (monotherapy¡A 31%; combination therapy¡A up to 39% )¡A Constipation (combination therapy¡A up to 32% )¡A Diarrhea (monotherapy¡A 46%; combination therapy¡A up to 76% )¡A Loss of appetite (monotherapy¡A 20%; combination therapy¡A up to 35% )¡A Nausea (monotherapy¡A 64%; combination therapy¡A up to 83% )¡A Stomatitis (monotherapy¡A 14%; combination therapy¡A up to 42% )¡A Vomiting (monotherapy¡A 4%; combination therapy¡A up to 64% ) Hematologic: Anemia (monotherapy¡A 64%; combination therapy¡A up to 81% )¡A Neutropenia¡A All grades (monotherapy¡A 7%; combination therapy¡A up to 81% ) Musculoskeletal: Backache Respiratory: Cough (monotherapy¡A 11%; combination therapy¡A up to 35% ) Other: Fatigue (monotherapy¡A 61%; combination therapy¡A up to 70% )¡A Fever (monotherapy¡A 25%; combination therapy¡A up to 29% ),30¢J¥H¤U,[Adjuvant therapy] 85 mg/m2 administered intravenously every 2 weeks for up to 12 cycles. [Colorectal cancer (advanced)] 85 mg/m2 on day 1 every 2 weeks until disease progression or unacceptable toxicity. [Gastric cancer] 130 mg/m2 every 3 weeks (either 130 mg/m2 on day 1 or 65 mg/m2 on day 1 and day 8). Administer oxaliplatin before fluoropyrimidine (ie.¡A 5-fluorouracil) when coadministration.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,ÃÄ«~¥é³æ:Ãh¥¥¤Î±Â¨ÅªÌ¸T¥Î¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,Micromedex: Infant risk cannot be ruled out. No reports describing the use of oxaliplatin during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. It is not known if oxaliplatin affects the quantity and composition of breast milk. Breastfeeding is not recommended while taking oxaliplatin due to the potential risk to the nursing infant. The manufacturer recommends making a decision to discontinue nursing or delay use of oxaliplatin in breastfeeding women.,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,,1. IV: Dilute in 250 to 500 mL D5W (do not use NS) to a final concentration > 0.2 mg/mL. Administer as IV infusion over 2-6 hours. 2. Flush infusion line with D5W prior to administration of any concomitant medication.,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ½Õ°t»Pª`®gªº¾¹¨ã¤£¥i§t¦³¾T¡C¥»ÃÄ«~¤£¥i¨Ï¥Î§t¦³´âªºµ}ÄÀ·»²G (¨Ò¦p¡GN/S)¡Aµ¹ÃÄ®ÉÁ×§K©MÆP©ÊÃÄª«(¨Ò¦p¡G5-FU)¨Ï¥Î¬Û¦PºÞ¸ô¡C 3. µ}ÄÀ«áªº¿éª`·»²G¦b«Ç·Å¤U¦w©w©Êºû«ù24¤p®É¡C 4. ºÊ´úCBC¡BµÇ¥\¯à¡Aª`·N¯f¤H¬O§_¦³©I§l¤è­±ªº²§±`¯gª¬¡C 5. ©w´Á¯«¸g¾ÇÀË´ú¡C
OKLAR,Clarithromycin,Klarith 500mg,QANB,,¾AÀ³¯g: Upper & lower respiratory tract. Eradication of H. pylori when used with omeprazole. °Æ§@¥Î: Central nervous system: Headache¡A insomnia¡A skin rash¡A dysgeusia¡A vomiting¡A diarrhea¡A nausea¡A abdominal pain¡A dyspepsia¡A prolonged prothrombin time¡A abnormal hepatic function tests¡A anaphylactoid reaction¡A candidiasis¡A increased blood urea nitrogen. ¸T§Ò: Hypersensitivity to clarithromycin¡A erythromycin¡A any of the macrolide antibiotics¡A or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin; concomitant use with cisapride¡A pimozide¡A ergot alkaloids (eg¡A ergotamine¡A dihydroergotamine)¡A or HMG-CoA reductase inhibitors extensively metabolized by CYP3A4 (eg¡A lovastatin¡A simvastatin); concomitant use with colchicine in patients with renal or hepatic impairment.,,«Ç·Å,Oral Susceptible infections¡A Respiratory tract infections¡A Skin and soft tissue infections. Adult: 250 mg bid¡A increased to 500 mg bid for severe infections¡A if necessary¡A for 7-14 days. Child: 7.5 mg/kg bid for 5-10 days. Eradication of H. pylori associated with peptic ulcer disease Adult: 500 mg bid¡A in combination w/ another antibacterial and either a PPI or H2-receptor antagonist for 7-14 days.,»Ý½Õ¾ã¾¯¶q,No dosage adjustment necessary if renal function is normal; however¡A in patients with hepatic impairment and concomitant severe renal impairment¡A a dosage reduction or prolonged dosing intervals may be appropriate.,»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IOKM,Palonosetron,OKmilon inj 0.25mg/5mL,CNEU,Prevention of chemotherapy-induced nausea and vomiting. Prevention of postoperative nausea and vomiting.,Hypersensitivity to palonosetron or any component of the formulation,Common Cardiovascular: Bradyarrhythmia (1% to 4% ); Gastrointestinal: Constipation (up to 5% ); Neurologic: Headache (up to 9% ) Serious Cardiovascular: Prolonged QT interval; Immunologic: Anaphylaxis¡A Hypersensitivity reaction; Neurologic: Seizure; Other: Serotonin syndrome,30¢J¥H¤U¡CÁ×§K§N­á¤Î¥ú·Ó¡C,Chemotherapy-induced nausea and vomiting¡A associated with emetogenic chemotherapy; Prophylaxis: Adult: 0.25 mg IV over 30 seconds approximately 30 minutes prior to starting chemotherapy. Children and Adolescents (1 month to 17 years old): 20 mcg/kg IV over 15 minutes approximately 30 minutes prior to starting chemotherapy; maximum dose: 1.5 mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¦bÃh¥¥°ü¤k¨­¤WPalonosetron¨Ã¨S¦³¶i¦æ¾A·í¤Î¨}¦n±±¨îªº¬ã¨s¡C¦b¤j¥Õ¹«¤Î¨ß¤lªº¾¹©x§Î¦¨´Á¥H¤fªA§ë»Ppalonosetronªº°Êª«¥Í´Þ¸ÕÅç¡A¾¯¶q°ª¹F¤HÃþ«ØÄ³ÀR¯ß±Â¤©ªº1894­¿¤Î3789­¿¡AÆ[¹î¨ì¹ï­F­L-­L¨àµo¨|µL¼vÅT¡C ¦]¬°°Êª«¥Í´Þ¸ÕÅçµLªk§¹¥þ¥Î¥H¹w´ú¤HÃþªº¤ÏÀ³¡A©Ò¥H¡A¦bÃh¥¥´Á¶¡¡APalonosetron¥u¦³½T»{¶·­n®É¤~¥i¨Ï¥Î¡C ¦b°Êª«¹êÅç¡A¦bÃh¥¥¤j¥Õ¹«ªº¾¹©x§Î¦¨´Á¥H¤fªA§ë»Ppalonosetron°ª¹F60 mg/kg/day (¬ù¬°®Ú¾ÚÅéªí­±¿n©Ò­pºâ¤§¤HÃþ«ØÄ³ÀR¯ß§ë»P¾¯¶qªº1894­¿)©Î¦bÃh¥¥¨ß¤lªº¾¹©x§Î¦¨´Á¥H¤fªA§ë»Ppalonosetron°ª¹F60 mg/kg/day (¬ù¬°®Ú¾ÚÅéªí­±¿n©Ò­pºâ¤§¤HÃþ«ØÄ³ÀR¯ß§ë»P¾¯¶qªº3789­¿)¡AÆ[¹î¨ì¹ï­F­L-­L¨àµo¨|µL¼vÅT¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¤´¥¼ª¾Palonosetron¬O§_·|¦s¦b¨Å¥Ä¤¤¡C¥Ñ©ó³\¦hÃÄª«·|¤Àªc©ó¨Å¥Ä¤¤¡A¥i¯à¹ï¨ü¨ÅªºÀ¦¨à²£¥ÍÄY­«¤£¨}ªº¤ÏÀ³¡A¥H¤Îpalonosetron¦b¤j¥Õ¹«­PÀù©Ê¸ÕÅçÅã¥Ü¥i¯à¾É­P²£¥Í¸~½F¡C ¦]¦¹¡A·í¦Ò¼{¨ìÃÄª«¹ï¥À¿Ëªº­«­n©Ê®É¡A¶·¨M©w°±¤î­÷¨Å©Î°±¤îªAÃÄ¡C,IVD;IVPUSH;,,¡iN/S¡j¥i¿ï ¡C,¦¨¤H¡GÀR¯ßª`®g¶W¹L30¬í,¨àµ£»P«C¤Ö¦~(1 ­Ó¤ë¤j¦Ü 17 ·³)¡G³æ¤@¾¯¶q20mcg/kg(³Ì¤j¾¯¶q¤£¥i¶W¹L1500 mcg)¡AÀR¯ß¿éª`®É¶¡¶·¶W¹L15¤ÀÄÁ¡C,1.¥»«~¶È¨ÑÀR¯ßª`®g¥Î¡A¤£À³»P¨ä¥LÃÄª«²V¦X¡C§ë»P¥»«~«e«á§¡¶·¥Î¥Í²z­¹ÆQ¤ô¨R¬~¿éª`ºÞ½u¡C 2.¼t°Ó´£¨Ñ¤ä¦w©w©Ê¸ê®Æ: ¥»«~3AMP(15mL)µ}ÄÀ©ó250mL 0.9% Sodium Chloride¤Î 2AMP(10mL)µ}ÄÀ©ó90mL 0.9% Sodium Chloride¬Ò¦³4¤p®Éªº¦w©w©Ê¡C
OTET3,Tetracycline,Tetracycline 250mg,QANB,Gram-positive bacterial infections¡A bacterial infections¡A infections caused by Leptospira species¡A and infections caused by giant filtrating viruses.,Hypersensitivity to tetracycline products Last half of pregnancy/infancy/childhood up to 8 years of age.,Common: Tooth discolored Serious: Phototoxicity¡A Acidosis¡A Azotemia¡A Serum blood urea nitrogen raised¡A Bulging fontanelle¡A Pseudotumor cerebri¡A Raised intracranial pressure,³±²D(15-30¢J)°®ÀêÁ×¥ú¥B¨àµ£¤£©ö¨ú±o³B,[Adult] Usual dose: 250-500mg q6h po¡A or 500-1000mg q12h po. Maximum 4g/day. Acne: Initial 500-2000mg/day in divided doses. Once the condition improves (typically after 3 weeks)¡A maintenance dose 125-500mg/day. Intermittent or alternate-day therapy can also alleviate symptoms. Gonorrhea: 500mg q6h po for 5 days Syphilis: 500mg q6h po for 15 days (early syphilis)¡A or 30 days (late syphilis) [Pediatric] Age >8 years: 6.5-12.5mg/kg q6h po¡A or 12.5-25mg q12h po,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¦³¨xµÇ¥\¯à¤£¥þµ¥ÂåÀø°ÝÃD¦s¦b®É¡A¥»ÃÄ¨Ï¥ÎÀ³¤p¤ß¦Ò¼{¡C,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 2nd and 3 rd trimesters,[¥é³æ] ¥»ÃÄ¯à³q¹L­L½L¡A¾É­P­L¨à¤ú¾¦¥Ã¤[©ÊªºÅÜ¦â¡A¾¦¹V½èµo¨|¤£¥þ¤Î§í¨î°©Àfªº¥Íªø¡A ¬G¦bÃh¥¥«á¥b´Á¶¡¤£¯à¨Ï¥Î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] ¥»ÃÄ¯à¤Àªc©ó¨Å¥Ä¤¤¡AÁöµM¥i¯à·|»P¨Å²G¤¤ªº¶tÂ÷¤l§Î¦¨¤£¯à§l¦¬ªº¿ù¦Xª«¡A¦ý¦]·| ¾É­PÀ¦¨à¤ú¾¦¥Ã¤[©ÊÅÜ¦â¡A¾¦¹V½èµo¨|¤£¥þ¤Î§í¨î°©Àf¥Íªøµ¥¡A¬GÀ³´N¨ä¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡C,AC;AC15;PC;PO;WM;,,,,,
EHIR,Heparinoid,Hirudoid cream 0.3%¡A 40gm,TDER,,¾AÀ³¯g: Treatment of superficial thrombophlebitis & relief of superficial bruising & haematoma. °Æ§@¥Î:Rash¡A pruritus ¸T§Ò:Hypersensitivity to Heparinoid.,,«Ç·Å,Apply gently or massage 2-3 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
EALC752,Alcohol,75% Alcohol 200mL/bottle,TDER,,,,25¢J¥H¤UÀx¦s,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,EXT;,,,,,
ETAF,Tafluprost,Taflotan oph soln 0.0015%¡A 2.5mL,TOPH,,¾AÀ³¯g:Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension °Æ§@¥Î: >10%: Ocular: Conjunctival hyperemia (4% to 20%) 1% to 10%: Central nervous system: Headache (6%) Genitourinary: Urinary tract infection (2%) Ocular: Stinging/irritation (7%)¡A conjunctivitis (5%)¡A cataract (3%)¡A dry eye (3%)¡A ocular pain (3%)¡A eyelash darkening (2%)¡A eyelash growth (2%)¡A vision blurred (2%) Respiratory: Common cold (4%)¡A cough (3%) Postmarketing and/or case reports (Limited to important or life-threatening): Dyspnea¡A exacerbation of asthma; macular edema (reported with prostaglandin analog use) ¸T§Ò:Hypersensitivity to Tafluprost.,,«Ç·Å,Glaucoma: Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IDUR,Carbetocin,Duratocin inj 100mcg/1mL,SGU,Prevention of uterine atony and postpartum hemorrhage following elective cesarean section under anesthesia (epidural or spinal),Hypersensitivity to carbetocin¡A oxytocin¡A or any component of the formulation; administration prior to delivery of infant for any reason (including elective or medical induction of labor); vascular disease; use in children,>10%: Cardiovascular: Flushing¡A hypotension Central nervous system: Headache Dermatologic: Pruritus Gastrointestinal: Abdominal pain¡A nausea¡A vomiting Neuromuscular & skeletal: Tremor Miscellaneous: Feeling of warmth,30¢J¥H¤UÁ×¥úÁ×§K§N­á,Caesarean section under epidural or spinal anaesthesia: Withdraw 1 ml of DuratocinR containing 100 micrograms carbetocin and administer only by intravenous injection¡A under adequate medical supervision in a hospital. Vaginal delivery: Withdraw 1 ml of DuratocinR containing 100 micrograms carbetocin and administer by intravenous injection or intramuscular injection¡A under adequate medical supervision in a hospital.,µL»Ý½Õ¾ã¾¯¶q,¨xÅ¦¯e¯f©ÎµÇÅ¦¯e¯f¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,UpToDate Lactation:Enters breast milk/use caution,IVP;IVPUSH;,,,Slow IV < 100mcg/1min,,1.¤£¥i»P¨ä¥LÃÄª«²V¦X 2.¹ïCarbetocin©Îoxytocin¹L±ÓªÌ¸T¥Î
ICONVXBB,SARS-CoV-2 Spike glycoprotein,COVID-19 XBB.1.5 Novavax 0.5mL/dose (2.5mL/vial),HIMM,For active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 12 years of age and older.,History of severe allergic reaction to any component of the vaccine or those who experienced a severe allergic reaction after a previous dose of this vaccine.,Common: Erythema at injection site (0.7-7.5%)¡A Injection site pain¡A Swelling at injection site (0.8-8%)¡A Tenderness¡A Injection site¡A Nausea¡A Vomiting¡A Arthralgia (6.2-23.4%)¡A Myalgia (12.6-50.7%)¡A Headache (15.3-56.9%)¡A Fatigue¡A Fever (0.4-16.9%)¡A Malaise Serious: Congestive heart failure (0.004%)¡A Heart failure¡A Myocarditis (0.06%)¡A Pericarditis¡A Acute cholecystitis (0.02%)¡A Deep venous thrombosis (0.007%)¡A Portal vein thrombosis (0.004%)¡A Thrombosis (0.007%)¡A Thrombosis of mesenteric artery (0.004%)¡A Anaphylaxis¡A Hypersensitivity reaction (0.1%)¡A Pulmonary embolism (0.02%)¡A Angioedema,2-8¢XC Á×¥ú,Patients aged 12 years or older: - Not Previously Vaccinated with Any COVID-19 Vaccine: 0.5 mL IM for 2 doses administered 3 weeks apart. - Previously Vaccinated with Any COVID-19 Vaccine: 0.5 mL IM as a single dose at least 3 months after receipt of a previous dose of COVID-19 vaccine.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¹ïÃh¥¥¤k©Ê±µºØ Nuvaxovid ªº¸gÅç¦³­­¡C °Êª«¸ÕÅç¨Ã¥¼Åã¥Ü¹ïÃh¥¥¡B­F­L/­L¨àµo¨|¡B¤À®Y©Î¥X¥Í«áµo¨|¦³ª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C ¶È©ó¹ï¥ÀÅé©M­L¨àªº¼ç¦b¯q³B»·°ª©ó¼ç¦b­·ÀI®É¡A¤~À³¦Ò¼{ÅýÃh¥¥¤k©Ê±µºØNuvaxovid XBB.1.5¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e©|¤£ª¾ Nuvaxovid XBB.1.5 ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡C ¥Ñ©ó­÷¨Å¤k©Êªº Nuvaxovid XBB.1.5 ¥þ¨­©Ê¼ÉÅS¶q¥i©¿²¤¤£­p¡A¹w´Á¹ï­÷¨Å·s¥Í¨à/À¦¨àµL¼vÅT¡C,IM;,,,,,1. Nuvaxovid XBB.1.5 ¶È¨Ñ¦Ù¦×ª`®g¨Ï¥Î¡A²z·Qª`®g³¡¦ì¬°¤WÁu¤T¨¤¦Ù¡C 2. ½Ð¤Å¥H¦åºÞ¤ºª`®g¡B¥Ö¤Uª`®g©Î¥Ö¤ºª`®g¤è¦¡¬I¥´¡C 3. ¤£±o»P¥ô¦ó¨ä¥L¬Ì­]©ÎÃÄ«~²V¦X©ó¦P¤@ª`®g¾¹¤º¬I¥´¡C 4. ­º¦¸°w¨ë«á¡A¥i¦s©ñ¦b 2¢XC¦Ü8¢XCÀô¹Ò¤U³Ì¦h12¤p®É¤º©Î©ó«Ç·Å¤U¡]³Ì°ª 25¢XC¡^¦s©ñ³Ì¦h6¤p®É¤º¨Ï¥Î¬Ì­]¡C 5. ¦b¨C¦¸©â¨ú¾¯¶q¤§«e©M¤§¶¡¡A½Ð»´»´±ÛÂà¦h¾¯¶qÃÄ²~¡C½Ð¤Å·n®ÌÃÄ²~¡C¨C­Ó¦h¾¯¶qÃÄ²~§¡§tµL¦â¦Ü²H¶À¦â¡A³z©ú¦Ü·L¨Å¥Õ¦âªº¤À´²¾¯¡C
ILEV2,Norepinephrine,Norepinephrine inj 4mg/4mL,CAVS,Restoration of BP in acute hypotensive states. Adjunct in the treatment of cardiac arrest & profound hypotension.,Patients who are hypotensive from blood vol deficits except as emergency measure until blood vol therapy can be completed. Cyclopropane & halothane anesth¡A mesenteric or peripheral vascular thrombosis.,Occasionally¡A bradycardia; anxiety¡A transient headache. Plasma vol depletion (prolonged administration). Respiratory difficulty¡A ischemic injury.,30¢J¥H¤UÁ×¥ú,Must be diluted in dextrose containing solutions prior to infusion. Add 4 mL/AMP to 1000 mL of 5% dextrose solution to final concentration of 4 mcg/mL Norepinephrine. IV infusion¡A Adult: 8-12 mcg/minute initially¡A adjust the rate of flow to establish and maintain a low normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation to vital organs. The average maintenance dose ranges from 2-4 mcg/minute. High dosage: Individual variation occurs in the dose required to attain and maintain an adequate blood pressure. Occasionally much larger or even enormous daily doses (as high as 68 mg) may be necessary if the patient remains hypotensive¡A but occult blood volume depletion should always be suspected and corrected when present. Central venous pressure monitoring is usually helpful in detecting and treating this situation.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD10W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C,,ºwª`³t²v¬° 2-4 mcg/min¡C IV infusion: 4 mg in 250 mL (concentration: 16 mcg/mL) or 8 mg in 250 mL (concentration: 32 mcg/mL).,1.Norepinephrine¨Ï¥Î«eÀ³µ}ÄÀ©ó§t¸²µå¿}ªºª`®g²G¡C 2.¥»«~¾¨¥i¯àª`®g©ó¤jÀR¯ß¡A¯S§O¬O¨y«eÀR¯ß¡A¦]¬°ªø®É¶¡ªº¦åºÞ¦¬ÁY¦Ó³y¦¨¤W¼h¥Ö½§Ãa¦ºªº¦MÀI¡A¨Ï¥Î¥»¤è¦¡·¥¤Ö¦³¤§¡C¤]¦³±M®a«ØÄ³¥ÑªÑÀR¯ßª`®g¡CÀ³Á×§K¨Ï¥Î¾ÉºÞ tie-in §Þ³N(catheter tie-in technique)¡A¦]¬°ºÞ¤l©P³ò¦å¬yªýÃª·|³y¦¨¦å¦æ°±º¢¡A¨Ã¼W¥[ÃÄª«ªº§½³¡¿@«×¡C³q±`¤UªÏ²£¥Í³¬¶ë©Ê¦åºÞ¯e¯fªº¥i¯à©Ê¸û¤WªÏ¤j¡C¦]¦¹¦~¦Ñ±wªÌ©Î´¿±wÃþ¦ü¯e¯f¤§±wªÌ¡A­nÁ×§K»L³¡ÀR¯ßµ¹ÃÄ¡A½ïÀR¯ßµ¹ÃÄ´¿¦³¤UªÏ¥½ºÝ²£¥ÍÃa¯jªº³ø§i¡C
OELI,Apixaban,ELIQUIS 5mg,HEMT,Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)¡A w/ >=1 risk factors [eg¡A prior stroke or transient ischaemic attack¡A age >=75 yr¡A HTN¡A DM¡A symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.,Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg¡A current or recent GI ulceration¡A presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury¡A brain/spinal/ophth surgery¡A intracranial haemorrhage; known or suspected oesophageal varices¡A arteriovenous malformations¡A vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg¡A unfractionated heparin (UFH)¡A low molecular wt heparins¡A heparin derivatives¡A oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter.,Common: Contusion (1.4-2.2%)¡A Bleeding gums (<0.1-1.4%)¡A Hematoma (DVT¡A 1.3-1.5%)¡A Menorrhagia (1.4%)¡A Bleeding from nose (DVT and pulmonary embolism¡A 1.5-3.6%; DVT prophylaxis¡A 0.1-<1%)¡A Hemoptysis (<0.1-1.2%) Serious: Gastrointestinal hemorrhage (Atrial fibrillation¡A 0.83%/year; DVT prophylaxis¡A 0.1-<1%; DVT and pulmonary embolism¡A 0.1-<1%)¡A Hematochezia (0.1-<1%)¡A Rectal hemorrhage (<0.1-1%)¡A Upper gastrointestinal bleeding¡A Hemorrhage (Atrial fibrillation¡A 2.08%/year ; DVT prophylaxis¡A 2.88-4.83%)¡A Hemorrhage (0.1-1.4%)¡A Hemorrhage¡A Major (0.1-2.13%)¡A Hemorrhage¡A Operative (DVT prophylaxis¡A 0.1-<1%)¡A Alkaline phosphatase above reference range (DVT prophylaxis¡A 0.1-<1%)¡A Liver function tests outside reference range (DVT prophylaxis¡A 0.1-<1%)¡A Serum bilirubin above reference range (DVT prophylaxis¡A 0.1-<1%)¡A Hypersensitivity reaction (atrial fibrillation¡A <1%)¡A Hemorrhage of muscle (<0.1-<1%)¡A Extradural intracranial hematoma¡A Intracranial hemorrhage (0.33-0.34% per year)¡A Non-traumatic spinal subdural hematoma¡A Traumatic spinal subdural hematoma¡A Conjunctival hemorrhage (0.1-<1%)¡A Retinal hemorrhage (0.1-<1%)¡A Hematuria (DVT¡A 1.4-2.1% ; DVT prophylaxis¡A 0.1-<1%),30¢J¥H¤U,Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years¡A body weight =<60 kg¡A or serum creatinine >=1.5 mg/dL¡A then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT,»Ý½Õ¾ã¾¯¶q,UpToDate:Severe impairment (Child-Pugh class C): Use is not recommended.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,APIXABAN: No Human Data¡XPotential Risk [¥é³æ] Ãö©ó¥¥°ü¨Ï¥ÎELIQUISªº¥i¥Î¸ê®Æ¦³­­¡A¤£¨¬¥HÅã¥Ü»PÃÄª«¬Ûªº­«¤j¥ý¤Ñ¯Ê³´¡B¬y²£©Î¤£¨}µo¨|µ²ªG­·ÀI¡C¨Ï¥Î¥»«~ªvÀø¥i¯à·|¼W¥[Ãh¥¥»P¥Í²£´Á¶¡ªº¥X¦å­·ÀI¡C¦b°Êª«Ác´Þ¸ÕÅç¤¤¡A©ó¾¹©x§Î¦¨´Á¶¡¤À¡Hµ¹¤©¤j¹«¡]¤fªA¡^¡B¨ß¤l¡]ÀR¯ßª`®g¡^¤Î¤p¹«¡]¤fªA¡^¬Û·í©ó¤HÃþ¥¼µ²¦XapixabanÃnÃÄ¶q¤À¡H¬°4¡B1¤Î19­¿¾¯¶q[¥H¦å¤¤¿@«×¦±½u¤U­±¿n(AUC)¬°°òÂ¦¡A©M5²@§J¨C¤é¨â¦¸ªº¤HÃþ³Ì°ª«ØÄ³¾¯¶q(MRHD)¶i¦æ¤ñ¸û]¡A¥¼Æ[¹î¨ìapixaban¨ã¦³¹ïµo¨|ªº¤£¨}¼vÅT¡C Ãh¥¥·|¼W¥[¦å®ê®ê¶ëªº­·ÀI¡A¹ï©ó¨ã¦³¼ç¦b¦å®ê®ê¶ë©Ê¯e¯f©M¯S©w°ª­·ÀI§³®Wª¬úGªº°ü¤k¨Ó»¡¡A¦å®ê®ê¶ëªº­·ÀI§ó°ª¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡A¥ý«e¨ã¦³ÀR¯ß¦å®ê§Î¦¨¯f¥vªº¤k©Ê¦bÃh¥¥´Á¶¡¦³«Ü°ªªº´_µo­·ÀI¡C ¨Ï¥Î¥]¬AELIQUISªº§Ü¾®¦å¾¯¡A¥i¯à·|¼W¥[­L¨à©M·s¥Í¨à¥X¦åªº­·ÀI¡C ©Ò¦³±µ¨ü§Ü¾®¦å¾¯ªvÀøªº¯f¤H¡]¥]¬A¥¥°ü¡^¡A³£¦³¥X¦åªº­·ÀI¡C ±µ¨ü´ÕºÞ³Â¾Kªº¤k©Ê¤¤¡A¦b¤À®Y©Î¥Í²£´Á¶¡¨Ï¥ÎELIQUIS¥i¯à·|¾É­Pµw¯á½¤¥~©Î¯áÅè¦å¸~¡C¥i¦Ò¼{©ó¥Í²£´Á¶¡¨Ï¥Î§óµu®Äªº§Ü¾®¦å¾¯¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,APIXABAN: No Human Data¡XPotential Toxicity [¥é³æ] ¥Ø«e¨S¦³Ãö©ó¤HÃþ¨Å¥Ä¤¤apixaban©Î¨ä¥NÁÂ²£ª«ªº¦s¦b¡A¹ï¥À¨Å­÷«Ä¤l©Î¹ïªc¨Å¶q¼vÀ\ªº¸ê®ÆApixaban©M/©Î¨ä¥NÁÂ²£ª«¦s¦b©ó¤j¹«¨Å¥Ä¤¤¡C¥Ñ©ó©|¤£²M·¡¤HÃþ¬O§_·|³z¹L¨Å¥Ä±µÄ²ÃÄª«¡A¦]¦¹±µ¨üELIQUISªvÀø´Á¶¡¤£«ØÄ³¥À¨ÅÁý­÷¡C,AC;AC15;PC;PO;,,,,,
ITES1,Testosterone cypionate,Testosterone cypionate inj 200mg/1mL,HM,,¾AÀ³¯g: Testosterone replacement therapy in male hypogonadal disorders. Osteoporosis due to androgen deficiency. °Æ§@¥Î: Priapism¡A signs of excessive sexual stimulation¡A oligospermia¡A decreased ejaculatory vol; fluid & salt retention. In prepubertal boys¡A precocious sexual development¡A increased frequency of erections¡A phallic enlargement¡A premature epiphyseal closure. Dermatologic: Acne (up to 8% ) Endocrine metabolic: Gynecomastia (up to 3% ) Gastrointestinal: Oral irritation¡A Buccal system (9.2% ) Neurologic: Headache (up to 4% ) Reproductive: Large prostate (11.7% ) ¸T§Ò: Known or suspected prostatic or mammary carcinoma.,,«Ç·Å,IM 200 to 400 mg every 3 to 4 weeks,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,IM;,,,,,¥»ÃÄ«~­­¥Î©ó¦Ù¦×ª`®g¡C
OXIG,Dapagliflozin + Metformin,Xigduo XR 10mg/1000mg Extended-Release,META,Type 2 Diabetes Mellitus,Acute or chronic metabolic acidosis (e.g. diabetic ketoacidosis¡A lactic acidosis)¡A diabetic pre-coma¡A acute alcohol intoxication or alcoholism¡A acute or chronic disease that may cause hypoxia (e.g. cardiac or respiratory failure¡A recent MI¡A shock)¡A conditions which may alter renal function (e.g. severe infection¡A dehydration). Hepatic and moderate to severe renal impairment (CrCl <60 mL/min).,Hypoglycaemia¡A bone fracture¡A genital mycotic infections¡A hypotension¡A ketoacidosis¡A increased LDL-C¡A acute renal impairment¡A urinary infections (e.g. urosepsis¡A pyelonephritis)¡A vitamin B12 deficiency. Rarely¡A hypersensitivity reactions (e.g. angioedema¡A urticaria). Gastrointestinal disorders: Nausea¡A vomiting¡A diarrhoea¡A abdominal pain. Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Headache¡A taste disturbance¡A dizziness. Renal and urinary disorders: UTI¡A increased urination. Reproductive system and breast disorders: Vaginal moniliasis¡A vulvovaginitis¡A balanitis. Respiratory¡A thoracic and mediastinal disorders: Nasopharyngitis¡A cough. Skin and subcutaneous tissue disorders: Rash.,30¢J¥H¤U,1 TAB once daily¡A maximum: dapagliflozin 10 mg and metformin 2000 mg daily.,»Ý½Õ¾ã¾¯¶q,Contraindicated.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,DAPAGLIFLOZIN: No Human Data¡XAnimal Data Suggest Low Risk METFORMIN: Human Data Suggest Low Risk,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,DAPAGLIFLOZIN: No Human Data¡XPotential Toxicity METFORMIN: Compatible,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A»Ý¾ãÁû§]ªA¤Å©CÄZ¡B­é¥b©Î¿i¯»¡CµLªk§]ªA¯f±w¥i§ï¥Î°|¤º¦P¦¨¥÷¤@¯ë¾¯«¬ÃÄª«¡C
ICOVAZ,SARS-CoV-2 Spike glycoprotein [ChAdOx1-S],COVID-19 Vaccine AstraZeneca 0.5mL/dose (5mL/vial),HIMM,AstraZeneca COVID-19 Vaccine is indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).,History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5 mL¡A > or = 18 years 2 doses administered 4 to 12 weeks apart. (Taiwan CDC suggests 2 doses administered 8 to 12 weeks apart.),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥»¬Ì­]¥Î©óÃh¥¥¤k©Êªº¸gÅç¦³­­.°Êª«¥Í´Þ¬r©Ê¸ÕÅç©|¥¼§¹¦¨.®Ú¾Úªì¨B¸ÕÅçµ²ªG¡A¥¼Æ[¹î¨ì¹ï­L¨àµo¨|ªº¼vÅT. °£«D¥i¯à®Ä¯q°ª©ó¹ï¥À¿Ë©M­L¨àªº¼ç¦b­·ÀI¡A§_«hÃh¥¥´Á¶¡¤£À³¬I¥´¥»¬Ì­]. ¥¿¦b­÷¨Å¡A¥i¯àÃh¥¥©Î¦³­pµeÃh¥¥¤§¤k©Ê¡A¬ÒÀ³µû¦ô±µºØ¤§§Q¯q»P­·ÀI.,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨Ã¤£²M·¡¥»¬Ì­]¬O§_·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤.,IM;,,,,,1.¶È¥Î©ó¦Ù¦×ª`®g¡A³Ì¦n¦b¤WÁuªº¤T¨¤¦Ù(Deltoid)¡C 2.¤£¥i»P¨ä¥L¬Ì­]©ÎÃÄ«~¦b¦P¤@ª`®g¾¹¤¤²V¦X¨Ï¥Î¡C 3.¥¼¶}«ÊÃÄª«»Ý¸m©ó¦B½c2-8¢J§NÂÃ¡A¤£¥i§N­á¡F¶}«Ê«á¥i¥H¤£¶W¹L30¢Jªº±¡ªp¤U«O¦s6¤p®É¡A½Ð¤Å¦A©ñ¦^¦B½c§NÂÃ¡C 4.¥»¬Ì­]¤£±o»P¨ä¥L¬Ì­]¦P®É±µºØ¡A¨ÃÀ³»P¨ä¥L¤£¬¡¤Æ¬Ì­]¶¡¹j¦Ü¤Ö14¤Ñ¡A»P¨ä¥L¬¡©Ê´î¬r¬Ì­]¶¡¹j¦Ü¤Ö28¤Ñ
IZOF,Ondansetron,Zofran inj 8mg/4mL(­­³Â¾K²Õ®M),CNEU,Prevention or treatment of nausea and vomiting caused by surgery¡A chemotherapy or radiation therapy.,Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine,Common Gastrointestinal: Constipation (11% )¡A Diarrhea (adults¡A 16%; pediatrics¡A 2%)¡A Xerostomia (5% ) Hepatic: Increased liver enzymes (17% ) Neurologic: Headache (17% ) Other: Fever (2% to 8% ) Serious Cardiovascular: Atrial fibrillation¡A Electrocardiogram abnormal¡A Prolonged QT interval¡A Torsades de pointes Neurologic: Oculogyric crisis Other: Serotonin syndrome,Àx¦s©ó30¢J¥H¤U¡AÁ×¥ú,Prevention of nausea and vomiting caused by surgery: single dose of 4 mg IM or slowly IV (more than 30 seconds). Treatment of nausea and vomiting caused by surgery: A single dose of 4 mg is recommended for most patients¡A administered IM or slowly IV. increased to 8 mg if necessary. Children from 1 month to 17 years: A clinical trial in children under 2-years-old has not been conducted. slow IV injection (more than 30 seconds) before¡A during or after induction of anesthesia¡A 0.1 mg/kg¡A and up to 4 mg. Nausea and vomiting due to chemotherapy or radiation therapy: Adult: The recommended dose is 8 mg IV or IM before treatment. After 24 hours¡A oral medication is recommended to prevent delayed or prolonged vomiting. For highly emetogenic chemotherapy (high dose cisplatin): a single 8 mg dose by slow IV or IM immediately before chemotherapy. 8-16 mg can only be administered by IV infusion after dilution with 50 to 100 ml of normal saline or other compatible infusion solutions¡A and the infusion time should be more than 15 minutes. A single dose should not exceed 16 mg¡A cause QT interval prolongation is dose-dependent. Slow IV injection (more than 30 seconds) or IM 8 mg before chemotherapy¡A and next two doses of 8 mg every 2 to 4 hours or continuous infusion (1 mg/hour) for a maximum of 24 hours. Children over 6 months and adolescents: dosage according to body surface area (BSA) or body weight. Dosage according to body surface area (BSA): administered as a single intravenous injection of 5 mg/m2 immediately before chemotherapy. It should be administered by intravenous infusion for a period of not less than 15 minutes. Oral ondansetron can begin after 12 hours and can last up to 5 days. The intravenous dose should not exceed 8 mg. Dosage according to body weight: administered as a single dose of 0.15 mg/kg given before chemotherapy by intravenous infusion for a period of not less than 15 minutes¡A and the intravenous dose should not exceed 8 mg. Two additional doses can be repeat 4 and 8 hours after the first dose. Oral ondansetron can begin after 12 hours and can last up to 5 days. <= 10 kg: on day 1¡A up to 3 doses of 0.15 mg/kg every 4 hours. > 10 kg: on day 1¡A up to 3 doses of 0.15 mg/kg every 4 hours.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤«×©Î­««×¨x¥\¯à¤£¥þªÌªºondansetron²M°£²vÅãµÛ­°§C¡A¦å²M¥b°I´ÁÅãµÛ©µªø¡C ¥Î©ó³oÃþ¯f¤H®É¡AÀR¯ßª`®g©Î¤fªAªº¨C¤éÁ`¾¯¶q¤£¥i¶W¹L8²@§J¡C,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Human (and animal) data suggest risk,[¥é³æ]¨ô¥±Äõ¥Î©ó¥¥°üªº¦w¥þ©Ê¥Ø«e©|¥¼Àò±oÃÒ¹ê¡C¦b¤j¹«©M¨ß¤lªº¥Í´Þ¸ÕÅç¤¤¡A©ó¾¹©x¥Í¦¨´Á¶¡¤À§Oµ¹¤©¨Ì¾ÚÅéªí­±¿n¬ù¬Û·í6©M24­¿©ó¤HÅé³Ì¤j«ØÄ³¤fªA¾¯¶q¨C¤Ñ24²@§Jªºondansetron®É¡A¥¼Æ[¹î¨ì¶Ë®`­L¨àªºÃÒ¾Ú¡C µM¦Ó¡A¥Ñ©ó¤£¤@©w¯à¦Û°Êª«¸ÕÅç¹w´ú¤HÅé¤ÏÀ³¡A¤£«ØÄ³©óÃh¥¥´Á¶¡¨Ï¥Îondansetron ¡C¦³ÃöÃh¥¥´Á¶¡¨Ï¥Îondansetronªº¦w¥þ©Ê¸ê®Æ¦³­­¡A¥B¨ú¦ÛÃÄª«¬y¦æ¯f¾Ç¸ÕÅçªºµo²{¨Ã¤£¤@­P¡C ¤W¥««á³ø§i¤¤´y­z¤FÃh¥¥´Á¶¡¨Ï¥ÎZofranªº¥ý¤Ñ·î§Î¯f¨Ò¡F µM¦Ó¡A³o¨Ç³ø§i¨Ã¤£¨¬¥H«Ø¥ß¦]ªGÃö«Y¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¤£²M·¡Zofran¬O§_·|¶i¤J¤HÅé¨Å¥Ä¡C ¥Ø«e¨ÃµLÃö©óZofran¼vÅT­÷¨ÅÀ¦¨à©ÎZofran¼vÅT¨Å¥Ä¥Í¦¨ªº¸ê®Æ¡C µM¦Ó¡A¤wª¾ondansetron·|¶i¤J­÷¨Å°Êª«(¤j¹«)ªº¨Å¥Ä¡C ¦]¦¹¡A«ØÄ³±µ¨üondansetronªº¥À¿Ë¤£À³­÷¨|À¦¨à¡C,IM;IVD;IVPUSH;,,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iIKCL2¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iIKCL5S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,IV bolus over no less than 30 seconds¡A preferably over 2 to 5 minutes.,Dilute 8mg (or 16 mg) dose in 50 mL (or 100mL) of compatible solutions and infuse dose over 15 minutes.,¬°«O«ù¨}¦nªº»s¾¯ª¬ºA¡A ÀR¯ß¿éª`²GÀ³©ó¿éª`«e¤~½Õ°t¡A ¨Ã«O«ù¦b¾A·íªºµLµß±ø¥ó¤U¡CµL¨¾»G¾¯ªºondansetron©M¤U¦CÀR¯ß¿éª`²G²V¦X«á¡A©ñ¸m©ó«Ç·Å(25¢J¥H¤U)ªº¿Ã¥ú¿O¤U©Î§NÂÃ¡A¥iºû«ù¦w©w¹F7¤Ñ¡GSodium Chloride IV Infusion BP 0.9%w/v; Glucose IV Infusion BP 5%w/v; Mannitol IV Infusion BP 10%w/v; Ringer IV Infusion; Potassium Chloride 0.3%w/v and Sodium Chloride 0.9%w/v IV Infusion BP; Potassium Chloride 0.3%w/v and Glucose5%w/v IV Infusion BP¡C
EDIFF,Adapalene,Differin gel 0.1%¡A 15gm,TDER,Treatment of acne vulgaris.,Hypersensitivity to adapalene or any component of the formulation.,Common: Erythema (0.2-21.8%)¡A Scaly skin (<25.3%)¡A Xeroderma (<36.1%)¡A Exfoliation of skin (<=44%)¡A Burning sensation of skin (<=29%)¡A Stinging of the skin (<=29%)¡A Skin abnormalities (1-6%; discomfort)¡A Desquamation (2%)¡A Pruritus (<=2%)¡A Skin irritation (1-2%)¡A Sunburn (1-2%) Serious: Angioedema¡A Hypersensitivity reaction <1%: Postmarketing: Acne flare¡A angioedema (gel)¡A application site pain (gel)¡A conjunctivitis¡A contact dermatitis¡A dermatitis¡A eczema¡A eyelid edema¡A facial edema (gel)¡A skin discoloration¡A skin rash (cream/gel)¡A swelling of lips (gel),25¢J¥H¤U,Acne vulgaris Apply once daily in the evening before bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ø«e©|µL¦³ÃöAdapalene¹ï©ó¥¥°üªº¼vÅT¸ê°T¡A¦]¦¹¤£¾A©ó°ü¤kÃh¥¥®É¨Ï¥Î.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¹ï¥»«~¬O§_³Q¤Àªc©ó°Êª«©Î¤HÃþ¨Å¥Ä¤¤¤]©|¥¼ª¾¡C ¥Ñ©ó¦hºØÃÄª«¬Ò¥i¯à¤Àªc©ó¨Å¥Ä¤¤¡A¦]¦¹±Â¨Å´Á°ü¤k¨Ï¥Î®ÉÀ³ÂÔ·V¡C ¦¹²£«~¤£À³¨Ï¥Î©ó¯Ý³¡¡C,EXT;,,,,,
IHYA1,Hyaluronidase,Hyalase inj 1500IU (±M®×¶i¤f),ZADT,Hyaluronidase can be used to enhance permeation of subcutaneous or intramuscular injections¡A local anaesthetics and subcutaneous infusions and to promote resorption of excess fluids and blood in the tissues.,Hypersensitivity¡A malignancy. Direct application to the cornea¡A reduction of swelling of bites or stings. Inj into or around infected area. IV admin; unexplained premature labour.,Cardiovascular: Edema Local: Injection site reaction <1% (Limited to important or life-threatening): anaphylactic-like reactions (retrobulbar block or IV injections)¡A anaphylaxis¡A hypersensitivity reaction,¤p©ó25¢XC,[°ê¥~¥é³æ](https://gp2u.com.au/static/pdf/H/HYALASE-PI.pdf) Hypodermoclysis: 1500 units dissolved in sterile distilled water 1 mL. Approximately 200mL of fluid can be administered in 20 minutes. In general¡A 1500 units of Hyalase are sufficient for 500-1000 mL of most fluids; 3000 units may be required for whole blood.Obstetric anesthesia: the anesthetic mixture is prepared as follows: Hyalase 1500 units; Adrenaline hydrochloride 0.5 mL of 1000 dilution; Procaine hydrochloride 1% 30 mL. The needle is passed horizontally to the ischial spine¡A and 5mL of the solution is deposited here to anesthetize the pudendal nerve as it enters Alcock's canal. Next¡A 5mL of the mixture is infiltrated in the superior portion of the labia minora to anesthetize the perineal branches of the ilioinguinal nerve. The same procedure is carried out on both sides of the perineum.Prevention of postpartum hemorrhage: 1500 units in ergometrine solution 1 mL (0.5 mg) IM into the thigh at the moment of the crowning or delivery of the fetal head. Correct timing is most important.Local anesthesia in ophthalmology: 25 units of Hyalase to each mL of anesthetic solution.Local anesthesia in fracture reduction: 1500 units mixed with 1% procaine 20 mL for Colles fracture or 40 mL for Pott's fracture. Separate into 2 injections: most of the solution injected into the fracture hematoma and 2-3 mL infiltrated around the ulnar styloid process. Manipulate the fracture after needle removal.Radiography: Pyelography: 750 units added to 5 mL of 35% diodone solution and made up to 15 mL with sterile distilled water. 15 mL subcutaneously in the scapular region and followed by another 15 mL at another site. Massage the injection area to aid dispersion.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,UpToDate: Pregnancy Risk Factor C,IM;SC;,,,,,
ONOT,Naltrexone,Notholic 50mg,ZADT,For the blockade of the effects of exogenously administered opioids. Hotholic has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.,Concomitant use of opioid analgesics. Hypersensitivity to naltrexone hydrochloride or any component of the product. Cross-sensitivity with naloxone or phenanthrene-containing opioids is unknown. Opioid dependency¡A including maintenance with opiate agonists (eg¡A methadone) or partial agonists (eg¡A buprenorphine). Acute opioid withdrawal. Failure to pass a naloxone challenge test or positive opioid urine screen. Acute hepatitis or liver failure.,Common Gastrointestinal: Abdominal cramps¡A Abdominal pain¡A Nausea (10% or greater ) Musculoskeletal: Arthralgia¡A Myalgia Neurologic: Difficulty sleeping (opioid addiction¡A greater than 10% )¡A Headache (alcoholism¡A 7%; opioid addiction¡A greater than 10% )¡A Lack of energy (opioid addiction¡A greater than 10% ) Psychiatric: Anxiety (opioid addiction¡A greater than 10%; alcoholism¡A 2% )¡A Feeling nervous (opioid addiction¡A greater than 10%; alcoholism¡A 4% ) Serious Hepatic: Hepatitis¡A Hepatotoxicity Psychiatric: Suicidal (alcoholism¡A up to 1% ) Other: Opioid withdrawal,25¢J¥H¤U«O¦s,Opioid use disorder¡A adult: Initial: 25 mg once daily. If no withdrawal signs occur¡A administer 50 mg once daily thereafter. Alternative maintenance dosing schedules (have to used carfully): 50 mg orally on weekdays and 100 mg on Saturday; OR 100 mg orally every other day; OR 150 mg orally every third day. [Micromedex 2022.02.13] Alcohol dependence¡A Maintenance of abstinence: 50 mg orally once daily for <= 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¤fªANaltrexone (100 mg/kg/day [600 mg/m2/day];¥HÅéªí­±¿n´«ºâ«á¬°«ØÄ³¾¯¶qªº16­¿¡^¤Þ°_¤j¹«°²¥¥ÅãµÛ¼W¦h¡A»Û¹«¨ü¥¥²v¤U­°¡A¦ý³o¼Ëªº¾¯¶q¨Ã¥¼¼vÅT¶¯©Êªº¥Í¨|¤O¡C³o¨ÇÆ[¹î»P¤HÃþ¥Í¨|¤Oªº¬ÛÃö©Ê©|¤£²M·¡¡C ­P·î­L©Ê: ¬ã¨sÅã¥Ü¦b¤j¹«µ¹¤©¤j©ó30 mg/kg/day (180 mg/m2/day¡F¥HÅéªí­±¿n´«ºâ«á¬°«ØÄ³¾¯¶qªº5­¿)¡A¨ß¤l¤j©ó60mg/kg/day (720 mg/m2/day¡F¥HÅéªí­±¿n´«ºâ«á¬°«ØÄ³¾¯¶qªº18­¿)ªº¤fªA¾¯¶q®É·|¼W¥[­L¨à¦­´Á¬y¥¢¡C·íµ¹¤©¤j¹«©M¨ß¤lNaltrexone¤fªA¾¯¶q°ª¹F200 mg/kg/day (¥HÅéªí­±¿n´«ºâ«á¤À§O¬°«ØÄ³¾¯¶qªº32©M65­¿) ®É¡A¨Ã¨S¦³¨¬°÷ªºÃÒ¾ÚÃÒ¹ê¦b¥D­n¾¹©x¥Í¦¨ªº´Á¶¡·|¦³­P·î­L©Ê¡C¤j¹«¨Ã¤£·|¥Í¦¨¨¬°÷¼Æ¶qªº¤HÅé¥D­n¥NÁÂª«6-£]-naltrexol¡A¦]¦¹©|¤£²M·¡¦¹¥NÁÂª«¹ï¤j¹«ªº¼ç¦b¥Í´Þ¬r©Ê¡C ©|µL°w¹ï¥¥°üªº¾A·í¥B±±¨î¨}¦nªº¬ã¨s¡A¶È¦b¼ç¦b®Ä¯q¶W¹L¹ï©ó­L¨àªº­·ÀI®É¤è¥i¥Î©ó¥¥°ü¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]Naltrexone Hydrochloride¬O§_¤Àªc©ó¤H¨Å¥¼ª¾¡A¦ý¦]¦hºØÃÄª«§¡·|¤Àªc©ó¤H¨Å¡A¬G¥»«~§ë¤©­÷¨Å°ü¤k¥²¶·¤p¤ß¡C,AC;AC15;PC;PO;WM;,,,,,1.¨Ï¥Î¥»«~«e7-10¤Ñ¡A¥²¶·¥ý°±¤îªA¥ÎÃþ¾~¤ùÃÄ«~¡C 2.ÃÄ¿õ¥i­é¥b¤À¬°¬Ûµ¥ªº¾¯¶q¡A­é¥b«á¿õ¾¯¦p¥¼¨Ï¥Î§¹²¦¡AÀ³©ó25¢J¥H¤UÀô¹Ò§´µ½Àx¦s¡A¦s©ñ¶W¹L7¤Ñ¤§©î«Ê«á­é¥b¿õ¾¯½Ð¤ÅÄ~Äò¨Ï¥Î¡C
IPNE1,Pneumococcal Vaccine Polyvalent,Pneumovax 23 (23»ùªÍª¢¡A¥x¥_¥«) 0.5mL/dose,HIMM,Immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine,Hypersensitivity. Revaccination of adults with Pneumovax 23 is contraindicated except for those at highest risk of pneumococcal infections. Patients with Hodgkin's disease immunised < 7 to 10 days prior to or during immunosuppressive therapy & patients with Hodgkin's disease who have received extensive chemotherapy &/or nodal irradiation.,Local inj-site soreness¡A warmth¡A erythema & swelling. Fever¡A headache¡A malaise¡A rash¡A urticaria¡A arthritis¡A arthralgia.,2-8¢J,IM or SC¡A 0.5mL¡A > or = 2 years a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¥Ø«e¤£ª¾Ãh¥¥°ü¤k±µºØ«á¬O§_·|³y¦¨­L¨àªº¶Ë®`©Î¼vÅT¨ä¥Í¨|¤O¡A ¥u¦³¦b©ú½Tª¾¹D¥²¬I¥´ªº±¡ªp¤U¡A¥¥°ü¤~¯à¬I¥´¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¤£ª¾¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¦]¦¹±µºØ¤§±Â¨Å°ü¤k»Ýª`·N¡C,IM;,,,,,
RIAB066,Risankizumab,¸ÕABBV-066-M15-997 (Risankizumab 75mg),HIMM,,,,,,,,,,,,,,SC;,,,,,
RENP888,NP-000888/Placebo,¸ÕNP-000888-100535 (270mcg/g or Placebo),TDER,,,,,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,EXT;,,,,,
ILIPF,Soyean oil + MCT+ Egg Yolk Phospholipids+ Glycerol,LIPOFUNDIN 10% 500mL,NUTR,,¾AÀ³¯g: In parenteral nutrition for energy & essential fatty acids. °Æ§@¥Î: Adverse reactions directly related to fat emulsions in general are of 2 types: Immediate (Acute) Reactions: Dyspnea¡A cyanosis¡A allergic reactions¡A hyperlipaemia¡A hypercoagulability¡A nausea¡A vomiting¡A headache¡A flushing¡A hyperthermia¡A sweating¡A chills¡A sleepiness¡A chest and back pain. Delayed Reactions: Hepatomegaly¡A jaundice due to central lobular cholestasis¡A splenomegaly¡A thrombocytopenia¡A leucopenia¡A transient increases in liver function tests and overloading syndrome. The deposition of a brown pigmentation in the reticuloendothelial system¡A the so-called "IV Fat Pigment"¡A has also been reported. The cause and the significance of this phenomenon are unknown. ¸T§Ò: Disturbances in fat metabolism; ketoacidosis¡A hypoxia¡A thromboembolism & acute shock states.,,§C©ó25¢XC ¡A¤£±o§N­á,The normal dose is 0.7-1.5 g/kg/day. The maximum dose is 2.0 g/kg/day. It should not be exceeded even patients' energy requirements are high or fat utilization is increased (eg¡A tumor patients). For long-term in-home intravenous nutrition therapy (> 6 months) and patients with short bowel syndrome¡A the intravenous fat supply should not exceed 1.0 g/kg/day. ¡V Pediatric patients A gradual increase in fat intake of 0.5-1.0 g/kg/day may be beneficial for plasma triglyceride levels and preventing hyperlipidemia. Premature newborns¡A term newborns¡A infants and toddlers It is recommended that the amount of fat does not exceed 3.0 (maximum 4.0) g/kg/day. For preterm neonates¡A full-term neonates¡A infants and young children¡A the maximum daily fat mass should be infused continuously for more than 24 hours. Children and youth It is recommended that the amount of fat does not exceed 2.0-3.0 g/kg/day.,µL»Ý½Õ¾ã¾¯¶q,­Y¦b¯×ªÕ¨Å¾¯µ¹ÃÄ´Á¶¡¡A¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¶W¹L4.6 mmol/l¡A«ØÄ³­°§C¿éª`³t²v¡C ­Y¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¶W¹L11.4 mmol/l¡A¥²¶·¤¤¤î¿éª`¡C ­YÀ¦¨à¦å¼ß¤T»Ä¥Ìªo¯×ªº¿@«×¶W¹L2.8 mmol/l¡AÀ³¦Ò¼{­°§C¾¯¶q¡C ­Y¦~ÄÖ¸û¤jªº¨àµ£¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¶W¹L4.5 mmol/l¡AÀ³¦Ò¼{­°§C¾¯¶q¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,[¥é³æ] ¥H¤Hµ¹ÃÄ¾¯¶q¶i¦æªº°Êª«¹êÅç¨S¦³´£¨Ñ¥ô¦óÃÒ¾ÚÃÒ©ú·|¼vÅT¥Í¨|©MÁc´Þ¥\¯à¡C ¨S¦³±Mªù´ú¸Õ­P·î©Ê¡A¦]¬°¥»ÃÄ«~ªº¦¨¤À¬O¤ÑµMª«½è¥H¤Î/©Î¥Í²z¥NÁÂªº¤¤¶¡²£ª«¡A ¤@¯ë»{¬°¤£¨ã­P·î©Ê¡C,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,1.¿éª`³t²v: ¿éª`À³·í¦bºÉ¥i¯à§Cªº¿éª`³t²v¤U¶i¦æ¡C¿éª`³Ì¶}©l15¤ÀÄÁªº¿éª`³t²vÀ³·í¶È¬°©Ò¥Î³Ì¤j¿éª`³t²vªº¤@¥b¡C 2.³Ì¤j¿éª`³t²v: ¦¨¤H¯f¤H: ¨C¤p®É¨C¤½¤çÅé­«¤£¤j©ó0.15 g¯×ªÕ(1.5mL/kg/hr)¡C ¦­²£·s¥Í¨à¡B¨¬¤ë·s¥Í¨à¡BÀ¦¨à¤Î¥®¨à: ¨C¤p®É¨C¤½¤çÅé­«¤£¤j©ó0.17 g¯×ªÕ(1.7mL/kg/hr)¡C ¨àµ£¤Î«C¤Ö¦~: ¨C¤p®É¨C¤½¤çÅé­«¤£¤j©ó0.13 g¯×ªÕ(1.3mL/kg/hr)¡C,1. ­Y¯×ªÕ¨Å¾¯»PÓi°ò»Ä¤ÎºÒ¤ô¤Æ¦Xª«¦P®É¿éª`®É¡AY«¬©Î°¼¬y±µ¦X¾¹À³¾¨¥i¯à¾aªñ¯f¤HºÝ¡C 2. ¶}«Ê«á¡AÃÄ«~À³¥ß§Y¨Ï¥Î¡C 3. ¥»«~¤£±o¥Î§@¹q¸Ñ½è¿@ÁY²G©Î¨ä¥LÃÄ«~ªº·»²G¸üÅé¡A©ÎªÌ¦b¥¼¸gÅçÃÒªº±¡ªp¤U»P¨ä¥¦ª`®g¾¯²V¦X¡A¦]¬°¦p¦¹´N¤£¯à½T«O¨Å¾¯ªº¦w©w©Ê¡C 4. ­Y¦b¯×ªÕ¨Å¾¯µ¹ÃÄ´Á¶¡¡A¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¶W¹L4.6 mmol/l¡A«ØÄ³­°§C¿éª`³t²v¡C­Y¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¶W¹L11.4 mmol/l¡A¥²¶·¤¤¤î¿éª`¡C­YÀ¦¨à¦å¼ß¤T»Ä¥Ìªo¯×ªº¿@«×¶W¹L2.8 mmol/l¡AÀ³¦Ò¼{­°§C¾¯¶q¡C­Y¦~ÄÖ¸û¤jªº¨àµ£¦å¼ß¤T»Ä¥Ìªo¯×¿@«×¶W¹L4.5 mmol/l¡AÀ³¦Ò¼{­°§C¾¯¶q¡C
ECLOB1,Clobetasol propionate,Clobex Shampoo 125mL¡A 0.05%,TDER,Topical treatment of moderate scalp psoriasis in adults.,Hypersensitivity to clobetasol propionate¡A other corticosteroids¡A or any of the ingredients in this preparation. Avoid using in areas of the skin with bacterial¡A mycobacterial¡A viral¡A fungal¡A parasitic infections¡A or ulcerative lesions. Avoid using on the eyes or eyelids (as there is a risk of glaucoma and cataracts).,Burning/stinging¡A pruritus¡A edema¡A folliculitis¡A acne¡A dry skin¡A irritant dermatitis¡A alopecia¡A urticaria¡A skin atrophy & telangiectasia.,30¢J¥H¤U¡C¨Ï¥Î«e¤Î¨Ï¥Î«á½Ð«O«ù²~»\ºò³¬¡C,Scalp psoriasis (Moderate to Severe) (Shampoo) Apply topically onto dry scalp once daily in a thin film to affected areas only; leave in place 15 minutes before lathering and rinsing; maximum 50 mL/week for 2 consecutive weeks,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ¹êÅç°Êª«·í±µ¨ü¥H¬Û¹ï¸û§C¾¯¶q¿@«×¥þ¨­©Ê§ë¤©¥Ö½èÃþ©T¾J®É¡A Åã¥Ü¥Ö½èÃþ©T¾J¨ã¦³­P·î­L§@¥Î¡A­Y¤z¥Ö½èÃþ©T¾J©ó¸g¥Ö¬I¥Î©ó¹êÅç°Êª«¤]Åã¥Ü¨ã¦³­P·î­L§@¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥þ¨­©Ê§ë¤©¥Ö½èÃþ©T¾J·|¥X²{©ó¤HÃþ¨Å¥Ä¡A¥i¯à§í¨îÀ¦¨àªº¦¨ªø¡A¤zÂZÀ¦¨à¤º¥Í©Ê¥Ö½èÃþ©T¾Jªº»s³y¡A©Î³y¦¨¨ä¥¦¤£¨}ªº¼vÅT¡C ¥Ø«e¥¼ª¾§½³¡§ë¤©¥Ö½èÃþ©T¾J¡A¬O§_¥i¯à¾É­P¦³¨¬¶qªº¥þ¨­©Ê§l¦¬¡A¦]¦Ó¦b¤HÃþ¨Å¥Ä¤º²£¥Í¥iÀË´ú¼Æ¶q¡F ¥Ñ©ó¦h¶µÃÄª«³£¥i¯à¤Àªc©ó¤HÃþ¨Å¥Ä¡A¦]¦¹­÷¨Å°ü¨Ï¥Î®ÉÀ³¼f·V¡C,EXT;SKIN;TOPI;,,,,,
LSLI,Sodium Phosphate,SlipFeel 45mL Oral Laxative (°·¶E±M¥Î),ALIM,Relieve occasional constipation¡A and bowel irrigation before surgery¡A X-ray¡A or endoscopic examination.,Congestive heart failure¡A kidney disease¡A or children aged below 5 years.,Electrolyte imbalance¡A acute phosphate nephropathy¡A rash¡A and itching.,25¢XC¥H¤U,[Laxative] Do not exceed the recommended dose within 24 hours. - Adults and children >= 12: Add 15 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 240 mL. Maximum daily dose: 45 mL. - Children aged 10 to 11: Add 15 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 240 mL. Maximum daily dose: 15 mL - Children aged 5 to 9: Add 7.5 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 240 mL. Maximum daily dose: 7.5 mL - Children under 5 years old: Not to be used. [Bowel preparation before medical procedures] Use 30 mL or 45 mL of the medicine twice for bowel preparation¡A with a 10-12 hour interval between doses. - Adults and children >= 12: Add 30-45 mL to cold drinks/water 240 mL and drink it. Drink cold drinks/water at least 720 mL. - Children aged 5 to 11: Ask doctor. - Children under 5 years old: Not to be used.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Ãh¥¥¡B±Â¨Å¡B­­¶u¶¼­¹©Î¦³¥ô¦óÂåÀøª¬ªpªÌ¡A½Ð¸ß°Ý¹LÂå®v«á¦A¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Ãh¥¥¡B±Â¨Å¡B­­¶u¶¼­¹©Î¦³¥ô¦óÂåÀøª¬ªpªÌ¡A½Ð¸ß°Ý¹LÂå®v«á¦A¨Ï¥Î¡C,AC;AC15;PC;PO;,,,,,1. ¥»²£«~¤£§t¥ô¦ó¿}¥÷¡A¨CmL¤¤§t¶u111.3mg¡C 2. ªA¥Î«á¬ù30¤ÀÄÁ¦Ü6¤p®É·|±Æ«K¡C
IFIR,Degarelix,FIRMAGON inj 120mg/3mL,RACA,Advanced hormone-dependent prostate cancer in adult male patients.,Known hypersensitivity to degarelix or any component of the formulation; pregnant.,Hot flush¡A inj site reactions. Anemia; increased wt; insomnia; dizziness¡A headache¡A diarrhea¡A nausea; increased liver transaminases; hyperhidrosis (including night sweats)¡A rash¡A musculoskeletal pain & discomfort; gynecomastia¡A testicular atrophy¡A erectile dysfunction; chills¡A pyrexia¡A fatigue¡A flu-like illness.,30¢J¥H¤UÁ×§K§N­á,Loading dose: 240 mg administered as two 120 mg (3 mL) injections; Maintenance dose: 80 mg administered as one 4 mL injection every 28 days (beginning 28 days after initial loading dose),µL»Ý½Õ¾ã¾¯¶q,Severe hepatic impairment (Child Pugh class C): use with caution,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥¤ÀÃþµ¥¯ÅX¡C Degarelix ¸T¥Î©óÃh¥¥©Î¥i¯àÃh¥¥ªº°ü¤k¡C§ë»P degarelix ©óÃh¥¥°ü¤k·|¹ï­L¨à²£¥Í¶Ë®`¡C¥HÅéªí­±¿n(mg/m2)¬°°òÂ¦¡A§ë»P degarelix Á{§É¤Wªì©l¾¯¶q(240mg)ªº0.02%·|¾É­P¾¹©x§Î¦¨´Áªº¨ß¤l­F­L©M­L¨à¦º¤`¤Î¬y²£¡C¥HÅéªí­±¿n(mg/m2)¬°°òÂ¦¡A¹ï¾¹©x§Î¦¨´ÁªºÃh¥¥¶¯©Ê¤j¹«§ë»P degarelix Á{§É¤Wªì©l¾¯¶qªº 0.036%¡A·|¾É­P­F­LµÛ§É«á¬y²£¼W¥[©M­°§C¬¡­L¼Æ¡C °²¦p³o­ÓÃÄ«~¥Î©óÃh¥¥´Á¶¡©Î°²¦p¯f±w¦b¥ÎÃÄ´Á¶¡Ãh¥¥¡A»Ý­n¥ý§iª¾¯f±wÃÄª«¹ï­L¨àªº¼ç¦b¼vÅT¡C,Unknown ¨S¦³¸ê®Æ,,SC;,,,X,X,¡E THE VIALS SHOULD NOT BE SHAKEN 1. Remove the cover from the vial adapter pack 2. Prepare the pre-filled syringe by attaching the plunger rod.
OMONT4,Montelukast,Monteka 4mg,ERSP,Prevention and long-term treatment of asthma in adults and children¡A including prevention of daytime and nighttime asthma symptoms¡A and prevention of exercise-induced bronchoconstriction. Prevention and long-term treatment of daytime and nighttime allergic rhinitis in adults and children who have previously received other anti-allergic medications but have had poor efficacy or cannot tolerate them.,Hypersensitivity to any component of the product.,Common: Abdominal pain (>=2%)¡A Diarrhea (Pediatric¡A >=2%)¡A Headache (Adult and adolescent¡A 18.4%; pediatric¡A >=2%)¡A Otitis (Pediatric¡A >=2%)¡A Otitis media (Pediatric¡A >=2%)¡A Cough (>=1%)¡A Nasal discharge (Pediatric¡A >=2%)¡A Pharyngitis (Pediatric¡A >=2%)¡A Sinusitis (>=1%)¡A Upper respiratory infection (>=1%)¡A Fever (Adult and adolescent¡A 1.5%; pediatric¡A >=2%)¡A Influenza (Adult and adolescent¡A 4.2%; pediatric¡A >=2%) Serious: Eosinophilic granulomatosis with polyangiitis¡A Disorientated¡A Disturbance of attention¡A Insomnia (0.7-6% )¡A Memory impairment¡A Stuttering¡A Tic¡A Tremor¡A Aggressive behavior¡A Agitation¡A Anxiety (0.14% )¡A Depression (0.15% )¡A Dream disorder¡A Hallucinations¡A Irritability (0.27% )¡A Nightmares (0.12% )¡A Obsessive-compulsive disorder¡A Restlessness (0.11% )¡A Sleep walking disorder¡A Suicidal behavior¡A Suicidal thoughts,30¢J¥H¤U¡AÁ×§K¼éÀã¤Î¥ú½u·Ó®g,For children aged 2-5 with asthma and/or allergic rhinitis: - Asthma: 4mg once daily at bedtime; - Seasonal or perennial allergic rhinitis: 4mg once daily in any time of the day; - Patients with both asthma and allergic rhinitis: 4mg once daily at bedtime.,µL»Ý½Õ¾ã¾¯¶q,[Micromedex] Mild to moderate: Dosage adjustment is not recommended. Severe¡A or with hepatitis: No specific recommendations are available; has not been evaluated.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]Montelukast ©|¥¼©ó¥¥°ü¸ÕÅç¡CÃh¥¥´Á¤¤¡A¥u¦³¦b½T©w»Ý­n¤§¤U¤~¥i¨Ï¥Î Montelukast¡C ¦b¥þ²y¤W¥««á¨Ï¥Î¸gÅç¤¤¡AÃh¥¥´Á¶¡´¿¨Ï¥Î Montelukast ªº°ü¤k¨ä¤p«Ä¦³¥ý¤Ñ©ÊªÏÅé¯Ê³´ ªº®×¨Ò«D±`¨u¨£¡C¦Ó³o¨Ç°ü¤k¤j¦h¼Æ¦bÃh¥¥´Á¶¡¡A¦P®É¤]ªA¥Î¨ä¥L®ð³ÝªvÀøÃÄª«¡C³o¨Ç¨Æ ¥ó»P Montelukast ¤§¶¡ªº¦]ªGÃö«Y©|¥¼«Ø¥ß¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¥¼ª¾ Montelukast ¬O§_·|¤Àªc¤J¤H¨Å¤¤¡C¥Ñ©ó³\¦hÃÄª«·|¤Àªc¤J¤H¨Å¤¤¡A¦]¦¹·í­÷ ¨Å¥À¿ËªA¥Î Montelukast ®É¶·¯S§Oª`·N¡C,AC;AC15;PC;PO;WM;,,,,,1.¥»«~¦]§t¦³¨Å¿}¡]lactose¡^½á§Î¾¯¡A¦]¦¹±w¦³¨u¨£¿ò¶Ç©Ê¯e¯f¦p¥b¨Å¿}¤£­@¯g¡]galactose intolerance¡^¡BLapp ¨Å¿}»Ã¯À¯Ê¥F¯g¡]Lapp lactase deficiency¡^©Î¸²µå¿}-¥b¨Å¿}§l¦¬¤£¨}¡]glucose-galactose malabsorption¡^¤§¯f±w¤£À³¨Ï¥Î¥»«~¡C
ETAFS,Tafluprost,Taflotan-S 0.0015% 0.3mL ²´ÃÄ¤ô(30¤ä/²°),TOPH,Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension,Hypersensitivity to Tafluprost. Used with omidenepag isopropyl.,>10%: Ocular: Conjunctival hyperemia (4% to 20%) 1% to 10%: Central nervous system: Headache (6%) Genitourinary: Urinary tract infection (2%) Ocular: Stinging/irritation (7%)¡A conjunctivitis (5%)¡A cataract (3%)¡A dry eye (3%)¡A ocular pain (3%)¡A eyelash darkening (2%)¡A eyelash growth (2%)¡A vision blurred (2%) Respiratory: Common cold (4%)¡A cough (3%) Postmarketing and/or case reports (Limited to important or life-threatening): Dyspnea¡A exacerbation of asthma; macular edema (reported with prostaglandin analog use),Á×¥ú2-8¢J,Instill 1 drop in the affected eye(s) once daily in the evening.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
IBETA,Betamethasone,Betamethasone inj 4mg/1mL,HM,,¾AÀ³¯g:hypersensitivity disorders¡A bronchial asthma¡A severe infection. °Æ§@¥Î:Fluid & salt retention¡A edema¡A hypertension; amenorrhea¡A hyperhidrosis; mental disturbances; acute pancreatitis; aseptic osteonecrosis; muscle weakness; Cushingoid state; raised intraocular pressure; visual disturbances; local atrophy; increased appetite; growth retardation. ¸T§Ò:Hypersensitivity to any component of the formulation¡A peptic ulcer¡A osteoporosis¡A psychoses or severe psychoneuroses¡A active or quiescent TB; acute infection; live vaccines,,«Ç·Å,IV or IM: 4-12mg¡A qd-bid. Rheumatoid and osteoarthritis: Intra-articular: 0.4 mg to 4 mg for one dose. Dose is based upon the joint size:,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;IS;IVD;IVP;LI;,,¡iD5W¡j¥é³æ«ØÄ³¡C¡iN/S¡j¥é³æ«ØÄ³¡C,Slow intravenous injection over half to one minute.,1-5mL (4-20mg) daily diluted in Normal Saline or Dextrose Water.,1.ÂIºwÀR¯ßª`®g¡A¥H¥Í²z­¹ÆQ¤ô©Îµ}¸²µå¿}²Gµ}ÄÀª`®g¡C 2.Ãö¸`µÄ¤ºª`®g0.4¡ã4mg ¬°«×¡A¦ý¥HÃö¸`¤§¤j¤p«×¶q¤§¡C 3.¥»²£«~§t¦³¨¾»G¾¯¦¨¤À¡A¤£À³¥H´ÕºÞ¤º(intracanal)©Îµw¯á½¤¥~(epidural)ª`®gµ¹ÃÄ¡C
LFUM,Furosemide,Fumide solution 10mg/mL¡A 120mL,CAVS,Edema: Management of edema associated with heart failure and hepatic or renal disease; acute pulmonary edema. Hypertension: Management of hypertension. Note: Not recommended for the initial treatment of hypertension.,Hypersensitivity to furosemide or any component of the formulation. hepatic cirrhosis; renal failure accompanied by hepatic coma and precoma; renal failure due to poisoning with nephrotoxic or hepatotoxic substances.,Cardiovascular: Necrotizing angiitis¡A orthostatic hypotension¡A thrombophlebitis¡A vasculitis Central nervous system: Dizziness¡A headache¡A paresthesia¡A restlessness¡A vertigo Dermatologic: Acute generalized exanthematous pustulosis¡A bullous pemphigoid¡A erythema multiforme¡A exfoliative dermatitis¡A pruritus¡A skin photosensitivity¡A skin rash¡A Stevens-Johnson syndrome¡A toxic epidermal necrolysis¡A urticaria Endocrine & metabolic: Glycosuria¡A hyperglycemia¡A hyperuricemia¡A increased serum cholesterol¡A increased serum triglycerides Gastrointestinal: Abdominal cramps¡A anorexia¡A constipation¡A diarrhea¡A gastric irritation¡A mouth irritation¡A nausea¡A pancreatitis¡A vomiting Genitourinary: Bladder spasm Hematologic & oncologic: Agranulocytosis¡A anemia¡A aplastic anemia¡A eosinophilia¡A hemolytic anemia¡A leukopenia¡A purpura¡A thrombocytopenia Hepatic: Hepatic encephalopathy¡A intrahepatic cholestatic jaundice¡A liver enzymes increased Hypersensitivity: Anaphylaxis¡A anaphylactoid reaction¡A anaphylactic shock Immunologic: DRESS syndrome Local: Pain at injection site (following IM injection) Neuromuscular & skeletal: Muscle spasm¡A weakness Ophthalmic: Blurred vision¡A xanthopsia Otic: Deafness¡A tinnitus Renal: Interstitial nephritis (allergic)¡A renal disease Miscellaneous: Fever,25¢J¥H¤U,Adult oral dosage: Edema: Initial¡A 20 to 80 mg/dose; if response is not adequate¡A may repeat the same dose or increase dose in increments of 20 to 40 mg/dose; may titrate up to 600 mg/day with severe edematous states; usual maintenance dose interval is once or twice daily. Hypertension: 40 mg twice daily; usual maintenance dose: 40-80 mg/day¡A divided in 1-2 doses. [Micromidex 2021/07/20] Pediatric oral dosage: Edema: Initial¡A 2 mg/kg orally as a single dose; may increase by 1 to 2 mg/kg no sooner than 6 to 8 hours following previous dose; titrate to minimum effective level; maximum: 6 mg/kg/dose. Hypertension: (1 year or older) Initial¡A 0.5 to 2 mg/kg once to twice daily; maximum: 6 mg/kg/dose.,»Ý½Õ¾ã¾¯¶q,Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis. Monitor effects¡A particularly with high doses.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,UpToDate: Pregnancy Risk Factor: C (above table),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;PC;PO;,,,,,
OVIS2,Dienogest,Visanne 2mg,HM,Management of pelvic pain associated with endometriosis.,Hypersensitivity to dienogest or any component of the formulation; undiagnosed abnormal vaginal bleeding; active venous thromboembolic disorder; history of or current arterial and cardiovascular disease (eg¡A MI¡A ischemic heart disease¡A cerebrovascular accident); diabetes mellitus with vascular involvement; history of or current severe hepatic disease where liver function tests remain abnormal; history of or current hepatic neoplasia (benign or malignant); known or suspected sex-hormone-dependent malignancy; ocular lesions due to ophthalmic vascular disease¡A such as partial or complete vision loss or defect in visual fields; current or history of migraine with focal aura; breast-feeding; known or suspected pregnancy.,1% to 10%: Central nervous system: Headache (7%)¡A depression (3%)¡A disturbed sleep (2%)¡A irritability (1%)¡A migraine (1%)¡A nervousness (1%) Dermatologic: Acne vulgaris (2%)¡A alopecia (1%) Endocrine & metabolic: Breast changes (discomfort: 5%)¡A weight gain (4%)¡A ovarian cyst (3%)¡A decreased libido (2%) Gastrointestinal: Nausea (4%)¡A abdominal pain (2%) Genitourinary: Vaginal hemorrhage (1%) Neuromuscular & skeletal: Weakness (2%) <1%¡A postmarketing¡A and/or case reports: Abdominal distress¡A anemia¡A anxiety¡A back pain¡A breast induration¡A constipation¡A decreased glucose tolerance¡A dermatitis¡A diarrhea¡A disturbance in attention¡A dysautonomia¡A edema¡A feeling of heaviness (extremities)¡A fibrocystic breast disease¡A flatulence¡A genital discharge¡A GI inflammation¡A hot flash¡A increased appetite¡A limb pain¡A lump in breast¡A mood changes¡A muscle spasm¡A onychoclasis¡A ostealgia¡A palpitations¡A pelvic pain¡A pruritus¡A skin pigmentation¡A skin photosensitivity¡A tinnitus¡A urinary tract infection¡A vulvovaginal candidiasis¡A vomiting¡A vulvar dryness¡A xeroderma¡A xerophthalmia.,25¢J¥H¤U,1 tablet once daily.,µL»Ý½Õ¾ã¾¯¶q,¥¿¦b©Î´¿¸g¿©±w­««×¨xÅ¦¯e¯fªº±w¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,Use is contraindicated during pregnancy. Based on limited data¡A inadvertent exposure in pregnancy has not shown adverse effects to the fetus.(UpToDate)2021/01/25,Unknown ¨S¦³¸ê®Æ,It is not known if dienogest is present in breast milk. Use is contraindicated in breastfeeding women. The risk of thromboembolism may be increased immediately postpartum.(UpToDate)2021/01/25,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¶Pº¸»X¥ÎÃÄ¡A¤Å©ñ¤J¿i¯»¾÷¤À¥]¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡C Oral: Administer preferably at the same time each day with liquid and without regard to meals. Tablets should be taken continuously regardless of any vaginal bleeding. If vomiting and/or diarrhea occur within 3 to 4 hours of administration¡A repeat dose.
OBMZ,Bromazepam,Bromazin 3mg,CNEU,Anxiety neurosis,Narrow angle glaucoma¡A myasthenia gravis¡A hypersensitivity to bromazepam¡A sleep apnea syndrome¡A severe respiratory insufficiency¡A severe hepatic insufficiency.,Somnolence¡A dizziness¡A headache¡A ataxia¡A nausea¡A constipation¡A fatigue¡A respiratory depression.,25¢J¥H¤U,Adult: Usual dose 1.5 to 3mg TID; for severe cases¡A 6 to 12mg BID to TID.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment¡A mild to moderate: initiate therapy at a very low dose. Hepatic impairment¡A severe: contraindicated.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] §³®W¤¤¨Ï¥Î¨ä¥LBenzodiazepine ¨t¤Æ¦Xª«¤§±wªÌ´¿¦³¤Þ°_·î§Î¨à¤Î»ÙÃª¨à¤§¯f¨Ò³ø§i¡A¬G¥¥°ü¤Î¥i¯àÃh¥¥°ü¤k°È½Ð·r°u¨äªvÀø¤W¤§¦³¯q©Ê©Î¦MÀI©Ê¦Ó·V­«§ëÃÄ¡C ¨ä¥LBenzodiazepine¨t¤Æ¦Xª«(Diazepam¡A Nitrazepam) ´¿¦³¾É­P·s¥Í¨à­÷¨Å§xÃø¡A¦Ù¦×ºò±i´î§C¡A¶Ý¯v¤Î¶À¯n¤§¼W±jµ¥¯gª¬¤§³ø§i¨Ò¡A¬G§³®W«á´Á¤§°ü¤H°È¶··r°u¨äªvÀø¤W¤§§Q®`Ãö«Y¦Ó·V­«§ëÃÄ¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¦]¨Ï¥Î¨ä¥LBenzodiazepine ¨t¤Æ¦Xª«(Diazepam) ¥i¯à¾É­P¥À¨Å¤¤¤§²¾¦æ¦Ó¤Þ°_·s¥Í¨à¤§¶Ý¯v¡BÅé­«´î»´¡B¶À¯n¤§¼W±j¡A¬G±Â¨Å°ü§Æ¤Å¨Ï¥Î¡A­Y¤£±o¤£¨Ï¥Î®É¡A½ÐÁ×§K±Â¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
OGLY,Glycopyrrolate,Glycopyrodyn 1mg,ALIM,,¾AÀ³¯g: --For use as adjunctive therapy in the treatment of peptic ulcer. --Used preoperatively to inhibit salivation and excessive secretions of the respiratory tract¡A reduce volume and acidity of gastric secretions¡A and blockade of cardiac vagal inhibitory reflexes during induction of anesthesia and intubation; used intraoperatively to counteract surgically¡A drug-induced¡A or vagal mediated bradyarrhythmias; reversal of the muscarinic effects of cholinergic agents¡A such as neostigmine and pyridostigmine¡A during reversal of neuromuscular blockade. °Æ§@¥Î: --Cardiovascular: Arrhythmias¡A cardiac arrest¡A flushing¡A heart block¡A hyper-/hypotension¡A malignant hyperthermia¡A pallor¡A palpitation¡A QTc-interval prolongation¡A tachycardia --Central nervous system: Aggressiveness¡A agitation¡A confusion¡A crying (abnormal)¡A dizziness¡A drowsiness¡A excitement¡A headache¡A insomnia¡A irritability¡A mood changes¡A pain ¡A restlessness ¡A nervousness¡A seizure --Dermatologic: Dry skin¡A pruritus¡A rash¡A urticaria --Endocrine & metabolic: Dehydration¡A lactation suppression --Gastrointestinal: Abdominal distention¡A abdominal pain¡A constipation¡A flatulence¡A retching¡A bloated feeling¡A intestinal obstruction¡A loss of taste¡A nausea¡A pseudo-obstructio¡A vomiting¡A xerostomia --Genitourinary: Impotence¡A urinary hesitancy¡A urinary retention¡A urinary tract infection --Local: Injection site reactions (edema¡A erythema¡A pain) --Neuromuscular & skeletal: Weakness --Ocular: Blurred vision¡A cycloplegia¡A mydriasis¡A nystagmus¡A ocular tension increased¡A photophobia¡A sensitivity to light increased --Respiratory: Bronchial secretion (thickening)¡A nasal congestion¡A nasal dryness¡A pneumonia¡A respiratory depression¡A sinusitis¡A upper respiratory tract infection --Miscellaneous: Anaphylactoid reactions¡A diaphoresis decreased¡A hypersensitivity reactions ¸T§Ò:Hypersensitivity to glycopyrrolate or any component of the formulation; medical conditions that preclude use of anticholinergic medication; severe ulcerative colitis¡A toxic megacolon complicating ulcerative colitis¡A paralytic ileus¡A obstructive disease of GI tract (eg¡A pyloric stenosis)¡A intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; narrow-angle glaucoma; acute hemorrhage; tachycardia; obstructive uropathy; myasthenia gravis,,«Ç·Å,One or two tablets three times a day.Maintenance dose: 1 mg orally twice daily to a maximum of 8 mg per day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
IFLUV1,Purified Split Inactivated Influenza Virus,§K¶O¦¨¤H4»ù¬y·P 0.5mL/dose,HIMM,Active immunisation against influenza.,Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome.,2 ~ 8 ¢XC,IM¡A 0.5 mL¡A > or = 6 months (< 9 years who have not been vaccinated previously¡A the second dose can be given after 4 weeks.),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,
IFLUV3,Purified Split Inactivated Influenza Virus,§K¶O¤p¨à4»ù¬y·P(>3·³) 0.5mL/dose,HIMM,Active immunisation against influenza.,Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome.,2 ~ 8 ¢XC,Adult & Children >= 36 months 0.5mL IM Chidren(>= 3years¡A < 9 years who have not been vaccinated previously¡A the second dose can be given at an interval of at least 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,
LPUS,Propranolol,Pushingon oral solution 2mg/mL¡A 60mL(±M®×»s³y),CAVS,¥»«~µLÃÄ«~³\¥iÃÒ¡A¨Ì¾Ú¡u¨àµ£§xÃø¨ú±o¤§Á{§É¥²­nÃÄ«~¤ÎÂå§÷½Õ«×¤¤¤ß¡v­pµe¡A­¹ÃÄ¸p¦P·N±M®×»s³y¡C Infantile hemangioma. Acute myocardial infarction¡A Reduction of cardiovascular mortality after myocardial infarction. Angina pectoris¡A chronic. Cardiac dysrhythmia. Essential tremor. Hypertension. Idiopathic hypertrophic subaortic stenosis. Migraine; Prophylaxis. Pheochromocytoma; Adjunct.,Hypersensitivity to propranolol hydrochloride or any component of the product. Pheochromocytoma. Blood pressure <50/30 mmHg¡A Heart rate <80 beats/min History of bronchial asthma or bronchospasm. Cardiogenic shock¡A Decompensated heart failure¡A Second or third degree heart block (if no pacemaker is present)¡A Sick sinus syndrome (if no pacemaker is present)¡A Sinus bradycardia (if no pacemaker is present). Premature infants with corrected age <5 weeks. Infants weighing <2 kg.,Common: Diarrhea¡A Vomiting¡A Dizziness (Hypertension¡A 4-7%)¡A Sleep disorder¡A Fatigue (5-7%) Serious: Bradyarrhythmia¡A Cardiogenic shock¡A Congestive heart failure¡A Heart block¡A Heart failure¡A Hypotension¡A Prolonged PR interval¡A Shortened QT interval¡A Erythroderma¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hypoglycemia¡A Anaphylaxis¡A Cerebrovascular accident¡A Bronchospasm¡A Withdrawal symptom,«Ç·ÅÁ×¥ú,[Micromedex] Infantile hemangioma: (FDA dosage) Initial: 0.6 mg/kg orally twice daily given at least 9 hours apart beginning at 5 weeks to 5 months of age; after 1 week¡A increase to 1.1 mg/kg twice daily for 2 weeks then begin the maintenance dose. Maintenance: 1.7 mg/kg orally twice daily for 6 months; adjust periodically per weight increases. (Guideline dosage) 2 to 3 mg/kg/day orally unless there are comorbidities (eg¡A PHACE syndrome [disease characterized by congenital anomalies]) or adverse effects that necessitates lower doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;PC;PO;WM;,,,,,
IROCU,Rocuronium Bromide,Rocuronium Kabi 50mg/5mL,CNEU,Adjunct to general anaesth to facilitate tracheal intubation¡A during routine & rapid sequence induction¡A & to provide skeletal muscle relaxation during surgery. Adjunct in ICU to facilitate intubation & mechanical ventilation.,Hypersensitivity.,Anaphylactic & anaphylactoid reactions¡A anaphylactic & anaphylactoid shock; flaccid paralysis; tachycardia; hypotension¡A circulatory collapse & shock¡A flushing; bronchospasm; angioneurotic edema¡A urticaria¡A rash¡A erythematous rash; muscular weakness¡A steroid myopathy; face oedema¡A injection site pain & reaction; airway complication of anaesth¡A delayed recovery from anaesth.,2-8¢J,Tracheal intubation: IV bolus 0.6 mg/kg. Rapid sequence induction: 1 mg/kg. Maintenance: 0.15 mg/kg. Continuous infusion: 0.3-0.4 mg/kg/hour. Elderly patients with liver/biliary disorders or renal failure: maintenance dose 0.075-0.1 mg/kg and the infusion rate 0.3-0.4 mg/kg/hour. Intensive care unit paralysis: Initial bolus of 0.6 mg/kg. When the neuromuscular blockage begins to recover to maintain the contracture response to 10% of the control contracture height or the TOF1-2 message response appears¡A the infusion mode is started. The recommended infusion rate for adults within the first hour of administration is 0.3-0.6 mg/kg/hr. During the next 6-12 hours¡A the dose should be reduced according to the patient's condition.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,IV bolus as an adjunct to facilitate tracheal intubation.,0.3~0.4mg/kg/h (¿@«×¡G0.5 mg/mL ©Î 2 mg/mL ),1.Rocuronium bromide ¥HÀR¯ß§ëÃÄ±Ä¤@¦¸ª`¤J©Î³sÄò¿éª`¤è¦¡
LKGLU,Potassium Gluconate,K-Glu oral solution 20mEq/15mL,NUTR,Hypokalemia.,Those who are allergic to Potassium Gluconate or other ingredients of this medicine. Patients with severe kidney disease. Patients with adrenal disease (Addison's disease). Patients taking potassium-sparing diuretics.,Nausea¡A stomach cramps¡A vomiting,Àx¦s©ó 25¢J¥H¤U¡C,3 - 4 times a day¡A each time 15mL ¡A can be mixed with water or juice¡A and taken after meals. 1 g potassium gluconate = elemental potassium 167 mg = potassium 4.3 mEq = potassium 4.3 mmol,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,See Potassium Chloride. [¥é³æ] ¥»ÃÄ¤£«ØÄ³¨Ï¥Î©ó¥¥°ü¤Î±Â¨Å°ü¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,See Potassium Chloride. [¥é³æ] ¥»ÃÄ¤£«ØÄ³¨Ï¥Î©ó¥¥°ü¤Î±Â¨Å°ü¡C,AC;AC15;PC;PO;WM;,,,,,
OEPC,Sofosbuvir + Velpatasvir,Epclusa 400/100mg,QANB,Treatment of adult chronic hepatitis C virus (HCV) genotype 1¡A 2¡A 3¡A 4¡A 5 or 6 infections.,Hypersensitivity to sofosbuvir¡A velpatasvir¡A or any component of the formulation. If sofosbuvir/velpatasvir is administered with ribavirin¡A the contraindications to ribavirin also apply. See ribavirin manufacturer's labeling information.,>10%: Central nervous system: Headache (22%)¡A fatigue (15%) 1% to 10%: Central nervous system: Irritability (?5%)¡A insomnia (5%)¡A depression (1%) Dermatologic: Skin rash (2%) Gastrointestinal: Nausea (9%)¡A increased serum lipase (>3X ULN: 3% to 6%) Neuromuscular & skeletal: Weakness (5%)¡A increased creatine phosphokinase (?10X ULN: 1% to 2%) Frequency not defined: Infection: Reactivation of HBV <1%: postmarketing¡A and/or case reports: Angioedema,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,One tablet contains sofosbuvir 400 mg/velpatasvir 100 mg. One tablet once daily for 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,¹ï»´«×¡B¤¤«×©Î­««×¨x¥\¯à¤£¥þ¡]CPT A¡BB©ÎC¯Å¡^ªº±wªÌ¡A¨Ã¤£¶·½Õ¾ãEpclusaªº¾¯¶q¡C´¿°w¹ï¨Ö¦³CPT B¯Å¨xµw¤Æªº±wªÌµû¦ô¹LEpclusaªº¦w¥þ©Ê»PÀø®Ä¡A¦ý©|¥¼¹ï¨Ö¦³CPT C¯Å¨xµw¤Æªº±wªÌ¶i¦æ¹L³o¤è­±ªºµû¦ô,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Sofosbuvir: No Human Data¡XAnimal Data Suggest Low Risk (Contraindicated if combined with Ribavirin) Velpatasvir: UNKNOW,Unknown ¨S¦³¸ê®Æ,Sofosbuvir: No Human Data¡XProbable Compatible (Potential toxicity if combined with Ribavirin) Velpatasvir: UNKNOW,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥Ñ©ó¥»«~±a¦³­W¨ý¡A¦]¦¹«ØÄ³¤£­n±N½¤¦ç¿õÄZ¸H©Î¬ã¸H¨Ï¥Î¡C
INSO100,Sodium Chloride,0.9% NaCl 100mL bag(Otsuka),MSIV,Water or electrolyte replenishment.,Hypernatremic and fluid retention syndromes. Immediately following surgery.,Common Cardiovascular: Phlebitis Dermatologic: Injection site extravasation¡A Injection site reaction Endocrine metabolic: Hypervolemia Serious Cardiovascular: Congestive heart failure Endocrine metabolic: Hypernatremia¡A Overhydration Hematologic: Disseminated intravascular coagulation Respiratory: Respiratory distress,30¢J¥H¤U,Individualised dosage. Sodium chloride 0.9% injection contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¨S¦³¸ê®Æ,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¨S¦³¸ê®Æ,IA;IRR;IVD;,,,,To correct acute (<48 hours) or chronic (>48 hours or duration unknown). In general¡A a serum sodium concentration increase of 4 to 6 mEq/L within a 24-hour period is sufficient to improve most symptoms of hyponatremia. In chronic severe hyponatremia¡A overcorrection risks iatrogenic osmotic demyelination syndrome. Goal of initial therapy is to increase serum sodium concentration by 4 to 6 mEq/L within the first 24 hours (maximum rate: 8 mEq/L in any 24-hour period).,0.9% Sodium chloride solution contains 154 mEq/L sodium and 154 mEq/L chloride. Calculated osmolarity is 308 mOsmol/L.
IACTMV,Tocilizumab,Actemra Infusion 80mg/4mL/Vial ±M®×(­­Covid-19),HIMM,Rheumatoid Arthritis (RA); Polyarticular Juvenile Idiopathic Arthritis (pJIA); Systemic Juvenile Idiopathic Arthritis (sJIA).,Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.,Common Cardiovascular: Hypertension (Adult¡A 4% to 6% ) Dermatologic: Injection site reaction ( Rheumatoid arthritis¡A 2.4% to 10.1% ; polyarticular juvenile idiopathic arthritis¡A 28.8% ; systemic juvenile idiopathic arthritis¡A 41.2% )¡A Rash (Rheumatoid arthritis¡A 2% to 4% ) Gastrointestinal: Diarrhea (Pediatric¡A greater than 5% )¡A Upper abdominal pain (Adult¡A 2% to 3% ) Hepatic: ALT/SGPT level raised (Rheumatoid arthritis¡A 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis¡A 4% to 13% )¡A Aspartate aminotransferase serum level raised (Rheumatoid arthritis¡A 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis¡A less than 1% to 5% ) Neurologic: Dizziness (Adult¡A 2% to 3% )¡A Headache (Adults¡A 5% to 7%; pediatric¡A greater than 5% ) Respiratory: Nasopharyngitis (Rheumatoid arthritis¡A 4% to 7%; systemic juvenile idiopathic arthritis¡A 5% or higher ) Other: Infusion reaction (Rheumatoid arthritis¡A 7% to 8%; polyarticular juvenile idiopathic arthritis¡A 16% to 20.2% ) Serious Gastrointestinal: Gastrointestinal perforation¡A Pancreatitis Hematologic: Decreased platelet count (1% to 4% )¡A Neutropenia (Rheumatoid arthritis¡A 1.8% to 3.7% ; polyarticular or systemic juvenile idiopathic arthritis¡A 7% to 15.4% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis¡A Hypersensitivity reaction (Up to 0.9% )¡A Opportunistic infection¡A Tuberculosis Respiratory: Upper respiratory infection (Rheumatoid arthritis¡A 6% to 8%; systemic juvenile idiopathic arthritis¡A 5% or higher ) Other: Cancer¡A Severe infectious disease,2-8¢J¡A½Ð¤Å§N­á,TFDA·s«¬«aª¬¯f¬r¡]SARS-CoV-2¡^·P¬VÁ{§É³B¸m¼È¦æ«ü¤Þ²Ä¤Q¤@ª©: »Pdexamethasone¦X¨Ö¥Î©óÄY­«ªÍª¢¥H¤W(¥¼¨Ï¥Î§l®ñªvÀø¤USpO2=<94%¡B»Ý¨Ï¥Î§l®ñªvÀø¡B°ª¬y¶q®ñ®ð©Î«D«IÅ§©Ê©I§l¾¹¡B¨Ï¥Î¾÷±ñ¦¡©I§l¾¹©ÎECMO)¤§¯f±w¡F©Î»Pdexamethasone + remdesivir ¦X¨Ö¥Î©ó¥¼¨Ï¥Î§l®ñªvÀø¤USpO2=<94%¡B»Ý¨Ï¥Î§l®ñªvÀø¡B°ª¬y¶q®ñ®ð©Î«D«IÅ§©Ê©I§l¾¹¤§¯f±w¡C¯f±w¦í°|3¤Ñ¤º¡A¥B¤J¦íICU 24¤p®É¤º©Î¥¼¤J¦íICU¦ýµoª¢«ü¼Æ¤W¤É(CRP>=7.5 mg/dL) ¡C¾¯¶q¡G8mg/kg¡A³æ¦¸ÀR¯ßª`®g¡A¦Ü¦h800mg [Micromedex 20210623] COVID-19 (Severe) - Pneumonia 8 mg/kg (actual body weight) as single IV dose¡A Maximum dose 800 mg; give in combination with dexamethasone 6 mg IV or orally daily for up to 10 days or another corticosteroid at an equivalent dose (guideline dosage),µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¥Ø«e©|¥¼«Ø¥ß¨x¥\¯à¤£¥þªÌ¨Ï¥Îªº¦w¥þ©Ê¤ÎÀø®Ä³ø§i.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«eÃö©ó¥Î©ó¥¥°üªº¦³­­¸ê®Æ©|¤£¨¬¥H½T¬O§_¦³·|¤Þµo­«¤j¥X¥Í¯Ê³´¤Î¬y²£ªºÃÄª«¬ÛÃö­·ÀI¡H ³æ®è§ÜÅé¦ptocilizumab¦b²Ä3¥¥´Á·|³z¹L¥D°Ê¹B¿é³q¹L­L½L¡A¨Ã¥i¯à·|¼vÅT¥X¥Í«e¼ÉÅS©óÃÄª«¤§À¦¨àªº§K¬Ì¤ÏÀ³¡C ¦b°Êª«¥Í´Þ¬ã¨s¤¤¡A©ó°¨¨ÓµU¦b¾¹©x¥Í¦¨¹Lµ{¤¤ÀR¯ßª`®g§ë¤©tocilizumab¡A·|¾É­P¬y²£/­F­L-­L¨àªº¦º¤`¡A¨ä¾¯¶q¬Û·í©ó¤HÃþ³Ì°ª«ØÄ³¾¯¶qªº1.25­¿¡]§t¡^¥H¤W¡C °Êª«¸ÕÅç¤åÄm«ü¥X¡AIL-6¶Ç°T§@¥Î¨ü¨ì§í¨î¥i¯à·|¤zÂZ¤l®cÀVªº¦¨¼ô»PÂX±i¡A¥H¤Î¤l®c¥­·Æ¦Ùªº¦¬ÁY¬¡©Ê¡A¥i¯à¦³¨Ï­L¨à¨ü¨ì¼vÅTªº­·ÀI¡C¥Ø«e¨Ã¤£½Tª¾¥»«~¤§¾A¥Î±Ú¸sµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº¦ô­p­I´º­·ÀI¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©ótocilizumab¬O§_·|¥X©ó¤HÃþ¨Å¥Ä¡B¥»ÃÄ¹ï­÷¥À¨Å¤§À¦¨àªº¼vÅT¡B©Î¥»ÃÄ¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅTµ¥¤è­±ªº¸ê®Æ¡C ¥ÀÅéªº§K¬Ì²y³JG(lgG)·|¥X²{©ó¤HÃþªº¨Å¥Ä¤¤¡C¦pªGtocilizumab·|Âà²¾¶i¤J¤HÃþªº¨Å¥Ä¡A¥Ø«e¤´¤£½Tª¾tocilizumab¦bÀ¦¨à­G¸z¹D¤¤ªº§½³¡¼ÉÅS¤Î¥i¯à¦³­­ªº¥þ¨­¼É·|³y¦¨¦óºØ¼vÅT¡C ¥Ñ©ó¯Ê¥F±Â¨Å´Á¶¡ªºÁ{§É¸ê®Æ¡A¥Ø«e¨ÃµLªk½T©w¦b±Â¨Å¶¡¨Ï¥Î Actemra¹ïÀ¦¨à©Ò±a¨Óªº­·ÀI¡F ¦]¦¹¡AÀ³±NÁý­÷¥À¨Å¹ïµo¨|»P°·±dªº¦n³B©M¥À¿Ë¹ï ActemraªºÁ{§É»Ý¨D¡A¥H¤Î©Î¥À¿Ëªº°òÂ¦¯e¯f¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C,IVD;,,¡iH/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,30¤½¤ç¥H¤U¯f±w:¥H50mL 0.9%©Î0.45%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C 30¤½¤ç¥H¤W¯f±w:¥H100mL 0.9%©Î0.45%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C µ}ÄÀ®É½Ð»´»´­Ë¸m¨ÏÃÄ¾¯²V¦X¡AÁ×§K²£¥Íªwªj¡C¿éª`®É¶¡À³¶W¹L60¤ÀÄÁ,¥»ÃÄ¥H0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ«á¸m©ó2-8¢XC©Î«Ç·Å¥i«O¦s24¤p®É¡C¥H0.45%´â¤Æ¶uª`®g²Gµ}ÄÀ«á¸m©ó2-8¢XC¥i«O¦s24¤p®É©Î«Ç·Å¥i«O¦s4¤p®É¡CÀx¦s®ÉÀ³Á×¥ú¡C
OBENT,Dicyclomine,Bentyl 10mg,ALIM,Diseases associated with smooth muscle spasm (diseases of gastrointestinal spasm¡A gallbladder¡A bile duct spasm¡A and ureteral spasm).,Age less than 6 months. Benign prostatic hyperplasia¡A urinary retention¡A pyloric stenosis. Use with caution in glaucoma patients.,Common Gastrointestinal: Nausea (14% )¡A Xerostomia (33% ) Neurologic: Asthenia (7% )¡A Dizziness (40% )¡A Feeling nervous (6% )¡A Somnolence (9% ) Ophthalmic: Blurred vision (27% ) Serious Cardiovascular: Syncope Dermatologic: Diminished sweating Gastrointestinal: Paralytic ileus¡A Perforation of intestine¡A Primary chronic pseudo-obstruction of colon¡A Toxic dilatation of intestine¡A Toxic megacolon Immunologic: Anaphylaxis Musculoskeletal: Poor muscle tone Neurologic: Coma¡A Seizure Psychiatric: Psychotic disorder Respiratory: Apnea¡A Dyspnea¡A Respiratory arrest¡A Respiratory depression Other: Angioedema,30¢J¥H¤U,Adult: 10-20mg TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ] FDA Pregnancy category(Ãh¥¥¥ÎÃÄ¯Å¼Æ):B¡C [Micromedex 20240115] Fetal risk cannot be ruled out. (MDX),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥¼¦³¬ÛÃö°O¸ü¡C [Micromedex 20240115] Infant risk has been demonstrated.,AC;AC15;PC;PO;WM;,,,,,
EMENL,Calamine + Zinc oxide,Menphencala lotion 100mL,TDER,Symptomatic relief of skin irritation & nappy rash.,Hypersensitivity to any component of the formulation,Local irritation,25¢J¥H¤U,Skin protectant: Topical: Apply to affected area as often as needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]µL«ØÄ³,Unknown ¨S¦³¸ê®Æ,[¥é³æ]µL«ØÄ³,EXT;,,,,,
ISTE9,Ustekinumab,STELARA inj 90mg/1mL,TDER,Treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Treatment of adult patients with active psoriatic arthritis. Can be used alone or in combination with methotrexate (MTX). Treatment of adult patients with moderately to severely active Crohn¡¦s disease. Treatment of adult patients with moderately to severely active ulcerative colitis.,patients with clinically significant hypersensitivity to ustekinumab or to any of the excipients. Clinically important¡A active infection .,Common Dermatologic: Erythema at injection site (1% to 5% )¡A Pruritus (1% to 4% ) Gastrointestinal: Abdominal pain (7% )¡A Diarrhea (2% to 4% )¡A Nausea (3% )¡A Vomiting (4% ) Neurologic: Headache (5% to 10% ) Renal: Urinary tract infectious disease (4% ) Reproductive: Mycosis (Crohn disease¡A 5% ) Respiratory: Bronchitis (5% )¡A Nasopharyngitis (7% to 24% )¡A Sinusitis (3% to 4% )¡A Upper respiratory infection (4% to 5% ) Other: Fatigue (3% to 4% )¡A Fever (5% )¡A Infectious disease (Psoriasis¡A 27% to 72.3% ) Serious Dermatologic: Skin cancer¡A Non-melanoma (Up to 1.5% ) Gastrointestinal: Diverticulitis (Less than 1% ) Immunologic: Anaphylaxis (Crohn disease¡A 0.1% )¡A Hypersensitivity reaction (Crohn disease¡A 0.08% ) Neurologic: Posterior reversible encephalopathy syndrome Ophthalmic: Herpes zoster with ophthalmic complication (Less than 1% ) Respiratory: Cryptogenic organizing pneumonia¡A Interstitial pneumonia¡A Pulmonary eosinophilia Other: Angioedema¡A Cancer (Up to 1.7% )¡A Infectious disease¡A Serious (Up to 2.8% ),2-8¢XCÀx¦s¥B»ÝÁ×¥ú¡A¤Á¤Å§N­á»P®¶·n,Plaque psoriasis (Moderate to Severe) (100 kg or less) 45 mg SC initially and 4 weeks later¡A followed by 45 mg every 12 weeks (Greater than 100 kg) 90 mg SC initially and 4 weeks later¡A followed by 90 mg every 12 weeks Psoriatic arthritis 45 mg SC initially and 4 weeks later¡A followed by 45 mg SC every 12 weeks Coexistent moderate to severe plaque psoriasis and weight greater than 100 kg¡A 90 mg SC initially and 4 weeks later¡A followed by 90 mg SC every 12 weeks Crohn's disease & Ulcerative colitis (Moderate to Severe) (55 kg or less) Induction¡A 260 mg (two 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance¡A 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 55 kg to 85 kg) Induction¡A 390 mg (three 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance¡A 90 mg SC every 8 weeks beginning 8 weeks after induction dose (Greater than 85 kg) Induction¡A 520 mg (four 130 mg/26 mL vials) IV over at least 1 hour as a single dose; maintenance¡A 90 mg SC every 8 weeks beginning 8 weeks after induction dose,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©óustekinumab¬O§_·|¥X²{©ó¤H ¨Å¥Ä¡B¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT¡B©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅT¤è­±ªº¸ê®Æ¡C Ustekinumab·|¥X²{©ó§ë¤©ustekinumab¤§ªc¨Å¥ÀµUªº¨Å¥Ä¤¤¡C¥Ñ©ó¦bªc¨Å¥Í²z¾Ç¤è­±¦³¨ãª«ºØ¯S²§©Êªº®t²§¡A¦]¦¹¡A°Êª«¸ÕÅçªº¸ê®Æ¥i¯àµLªk¥i¾a¦a¹w´ú¤HÃþ¨Å¥Ä¤¤ªºÃÄª«§t¶q¡C¥ÀÅéªºIgG¤wª¾·|¥X²{©ó¤HÃþªº¨Å¥Ä¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡AÁý­÷¥À¨Å¤§À¦¨àªº¥þ¨­¼ÉÅS¶q¹w´ÁÀ³¸Ó«Ü§C¡A¦]¬°ustekinumab¬O¤j¤À¤l¡A¨Ã¥B¦b­G¸z¹D¤¤·|­°¸Ñ¡CµM¦Ó¡A¦pªGustekinumab·|Âà²¾¶i¤J¤HÃþªº¨Å¥Ä¡A¥Ø«e¨Ã¤£½Tª¾­G¸z¹D¤¤ªº§½³¡¼ÉÅS·|³y¦¨¦óºØ¼vÅT¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]À³±NÁý­÷¥À¨Å¹ïµo¨|»P°·±dªº¦n³B©M¥À¿Ë¹ïSTELARARªºÁ{§É»Ý¨D¡A¥H¤ÎSTELARAR©Î¥À¿Ëªº°òÂ¦¯e¯f¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C,SC;,,,,,1.«ØÄ³¨C¦¸ª`®g³£À³¬I¥´©ó©M¤W¦¸¤£¦P³¡¦ì¡A¤£¥iª`¤J¥Ö½§¦³Ä²µh¡B·ï¶Ë¡B¬õ´³©Îµw¤Æ²{¶Hªº°Ï°ì¡C 2.»Ý§NÂÃ¶J¦s©ó2-8¢XC¡C¤Å§N­á¡C¤Å®¶·n¡C­Y¶J¦s©ó°ª¹F30¢XC¡A³Ìªø¹F³æ¦¸30¤Ñ¡C¤@¥¹¤w³Q¶J¦s©ó«Ç·Å¤U¡A¤Å±N¨ä©ñ¦^¦B½c¶J¦s¡A¦pªG¨S¦³¦b30¤Ñ¤º¨Ï¥Î½Ð¥á±ó¡C
IMIT3,Mitomycin C,Mitonco inj 10mg,RACA,Relief of gastric cancer¡A bladder cancer (Intravesical therapy)¡A lung cancer¡A sarcoma¡A leukemia¡A and other symptoms.,History of hypersensitivity or idiosyncratic reaction to mitomycin.,Common Gastrointestinal: Abdominal pain (Pyelocalyceal instillation¡A 28% )¡A Inflammatory disease of mucous membrane (20% to 40% )¡A Loss of appetite¡A Nausea (Pyelocalyceal instillation¡A 25% )¡A Nausea and vomiting (100% )¡A Vomiting (Pyelocalyceal instillation¡A 20% ) Ophthalmic: Blebitis¡A Cataract¡A Disorder of cornea¡A Endophthalmitis¡A Hyphema¡A Hypotony of eye¡A Leaking filtering bleb¡A Retinal hemorrhage¡A Thrombosis of retinal vein Renal: Dysuria (Pyelocalyceal instillation¡A 23% )¡A Flank pain (Pyelocalyceal instillation¡A 41% )¡A Hematuria (Pyelocalyceal instillation¡A 34% )¡A Renal impairment (Pyelocalyceal instillation¡A 25% )¡A Urinary tract infectious disease (Pyelocalyceal instillation¡A 34% ) Other: Fatigue (Pyelocalyceal instillation¡A 27% )¡A Fever (Pyelocalyceal instillation¡A 13% ) Serious Dermatologic: Cellulitis Hematologic: Disseminated intravascular coagulation¡A Myelosuppression (64.4% )¡A Neutropenia¡A Grade 3 (1.4% )¡A Thrombocytopenia¡A Grade 3 (4.2% ) Renal: Hemolytic uremic syndrome¡A Occlusion of ureter (Pyelocalyceal instillation¡A 58% ),©ó25¢J¥H¤U³±²D³B¡C,Bladder cancer (Intravesical therapy) for prevention of relapse: once a day or every other day¡A inject Mitomycin C 4-10mg into the bladder. For treatment: once a day¡A inject Mitomycin-C 10-40 mg into the bladder. The dosage could be increased or decreased according to age and symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest high risk,[¥é³æ]Mitomycin-C ¤£±ÀÂË¨Ï¥Î©óÃh¥¥©Î¥i¯àÃh¥¥ªº°ü¤k¡C°Êª«(¤p¹«)¹êÅçÅã¥Ü¦¹ÃÄ·|³y¦¨·î§Î­L¡A¦p­L¨à¥Íªø§í¨î¡BÃEµõ¡B§À³¡µo¨|¤£¥þ¡B¾g°©µo¨|¤£¥þ¡B¯Ê³kµ¥¡C,Hold Breast Feeding ¼È°±­÷¨Å,[¥é³æ]²£«á±Â¨Å°ü¤k®ÉÀ³°±¤î±Â¨Å¡A¦]¦³Ãöªº¦w¥þ©Ê©|«Ý½T¥ß¡C,IA;IP;IPLE;IRR;IVD;,¨C2mg (¤O»ù)Mitomycin C¥Î5mL Normal Saline¥[¥H·»¸Ñ¡C,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,(1) ÀR¯ßª`®g¥i¯à·|¤Þ°_¦åºÞµh¡BÀR¯ßª¢¡B¦å®êµ¥¡A¦]¦¹¹ïª`®g³¡¦ì¡Aª`®g¤èªkµ¥¶·¤Q¤Àª`·N¡Aª`®g³t«×À³½wºC¡C (2) ÀR¯ßª`®g¦ÓÃÄ²Gº|¥X¦åºÞ¥~®É¡A¥i¯à·|¤Þ°_ª`®g³¡¦ì¤§µwµ²¡BÃa¦ºµ¥¡A¦]¦¹À³¤p¤ßª`®g¡A¨ÏÃÄ²G¤£º|¥X¦åºÞ¥~¡C (3) ¦]°Ê¯ßª`®g¥i¯à¾É­P°Ê¯ß©P³ò¥Ö½§²§±`¡A¦p¯kµh¡Bµo¬õ¡B¬õ´³¡B¤ôªw¡BÁSÄê¡B¼ìºÅµ¥¥Ö½§¯e¯f¡A¬Æ¦Ü¤Þ°_¥Ö½§¡B¦Ù¦×Ãa¦º¡C¦p¥X²{³oºØ¯gª¬®É¡AÀ³¥ß§Y¤¤¤î§ë»P¡A°µ¾A·í³B¸m¡C,1. ¥»«~¶}«Ê¡B½Õ¾¯«áÀx¦s©ó­ì¥]¸Ë25¢J¥H¤UÀô¹Ò¡A¥i¦s©ñ24 ¤p®É¡C 2. Mitomycin CªºÃÄ®Ä¥i¯à¦]·»¸Ñ²GªºpH ­È¤Ó§C¦Ó´î®z¡AÃÄ²G»s¦¨«á¾¨§Ö¨Ï¥Î¡AÁ×§K»P§CpH­Èªºª`®g²G²V¦X¡C 3. ª`®g²G¤§½Õ»sªk: ¨C2mg (¤O»ù)Mitomycin C¥Î5mL Normal Saline¥[¥H·»¸Ñ¡C
ORIF5,Rifampicin,Rifampicin 300mg (¥ß¦ÆÅð¯À),QANB,TB & meningococcal carriers.,Jaundice. Hypersensitivity to rifampicin.,Skin reactions; GI discomfort; hepatitis; thrombopenia; flu-syndrome; reddish discoloration of urine¡A sputum & tears; stains soft contact lenses.,25¢J¥H¤U°®ÀêÁ×¥ú,Neisseria meningitidis carrier: Adult: 600 mg QD for 4 days. >=5 years old: 10-20 mg/kg QD for 4 days. Tuberculosis: Adult: 600 mg QD. >=5 years old: 10-20 mg/kg QD for 4 days. Elders & weak patient: 10 mg/kg QD. Maximum: 600 mg/day. May use 1.8g/day in some types of infections.,µL»Ý½Õ¾ã¾¯¶q,Significantly prolonged half-life has been reported in patients with liver disease; no specific dosing recommendations available. (Micromedex 20210301),»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Compatible,[¥é³æ]°Êª«¹êÅç¤¤¦³¶Ê·î§@¥Î¤§³ø§i¡A¹ï©ó¥¥°ü¤Î¥i¯àÃh¥¥¤§°ü¤k¤£­n§ë»P.,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¹ï©ó±Â¨Å°ü¤k¤§§ë»P¡AÀ³Åv¿Å¨äªvÀø¤W¤§¦³¯q©Ê¤Î¦MÀI©Ê«á·V­«§ë»P.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½¦Ån¤ºÃÄ¯»©ö¦¾¬V¿i¯»¤À¥]¾÷¡A½Ð¦Û¦æ¿i¯»¡C
INS1C,Sodium Chloride,0.9% NaCl inj 1000mL (CHI SHENG),MSIV,Supply of water¡A and electrolytes for surgery and other diseases.,Hypersensitivity to any component of the formulation.,Electrolyte imbalance¡A edema¡A hypervolemia.,25¢J¥H¤U,Individualized dosage. Subcutaneous injection of 500-1000mL¡A intravenous injection of 300-500mL¡A or drip infusion¡A to be determined by the physician according to the patient's needs.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IRR;IVD;,,,,,
ELOC5,Amorolfine,Loceryl nail 5% 3mL,TDER,,¾AÀ³¯g: Topical treatment of onychomycosis caused by dermatophytes¡A yeasts and moulds. °Æ§@¥Î:In exceptional cases¡A a slight¡A transient periungual burning sensation was observed after the application of the nail lacquer. ¸T§Ò: Patients who have shown hypersensitivity to any ingredient of Loceryl.,,«Ç·Å,Apply Loceryl Nail Lacquer to the affected nails at a dosage of 1 to 2 applications weekly.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ±NÃh¥¥¥À¨ß¼ÉÅS©óÅé¤º°ª¾¯¶qamorolfine·|³y¦¨­F­L¦A§l¦¬(­F­L¬r©Ê)»´·L¼W¥[¡C¥Ñ©ó¨Ï¥ÎLoceryl³k(«ü)¥Òªo¾¯¤§«á¡AamorolfineªºÅé¤º§t¶q·¥§C¡A¦]¦¹¹ï©ó¤HÃþ­L¨àªº­·ÀIÀ³¥i©¿²¤¡C µM¦Ó¥Ñ©ó¯Ê¥FªvÀøÃh¥¥©M­÷¨Å¥À¿Ë¤§Á{§É¸gÅç¡A¦]¦¹¥»ªo¾¯À³Á×§K¥Î©ó¥¥´Á©M­÷¨Å´Á´Á¶¡¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ±NÃh¥¥¥À¨ß¼ÉÅS©óÅé¤º°ª¾¯¶qamorolfine·|³y¦¨­F­L¦A§l¦¬(­F­L¬r©Ê)»´·L¼W¥[¡C¥Ñ©ó¨Ï¥ÎLoceryl³k(«ü)¥Òªo¾¯¤§«á¡AamorolfineªºÅé¤º§t¶q·¥§C¡A¦]¦¹¹ï©ó¤HÃþ­L¨àªº­·ÀIÀ³¥i©¿²¤¡C µM¦Ó¥Ñ©ó¯Ê¥FªvÀøÃh¥¥©M­÷¨Å¥À¿Ë¤§Á{§É¸gÅç¡A¦]¦¹¥»ªo¾¯À³Á×§K¥Î©ó¥¥´Á©M­÷¨Å´Á´Á¶¡¡C,EXT;,,,,,
OOFE,Nintedanib,Ofev 150mg,RACA,Idiopathic pulmonary fibrosis (IPF)¡A progressive pulmonary fibrosis¡A systemic sclerosis-associated interstitial lung disease.,Hypersensitivity to nintedanib¡A peanut or soya. Pregnancy & lactation.,Diarrhoea¡A nausea¡A abdominal pain; increased hepatic enzyme. Decreased wt & appetite; epistaxis; vomiting; increased alanine aminotransferase (ALT)¡A aspartate aminotransferase (AST) & £^-glutamyl transferase (GGT).,25¢J¥H¤U¡AÁ×§K¼ÉÅS©ó°ª«×¼éÀã»P¹L¼öªº³õ©Ò,150 mg orally every 12 hours (maximum: 300 mg/day)Administer with food. Swallow capsules whole with liquid; do not chew or crush.,»Ý½Õ¾ã¾¯¶q,Mild impairment (Child-Pugh class A): 100 mg every 12 hours. If a patient does not tolerate 100 mg every 12 hours¡A consider treatment interruption or discontinue treatment to manage adverse reactions. Moderate to severe impairment (Child-Pugh class B or C): Use is not recommended (exposure is increased in moderate impairment; has not been studied in severe impairment).,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦ÅnÀ³¾ã²É§]ªA¡A¤Á¤Å«rÄZ©ÎÀ£¸H¡C¥t¥»ÃÄ¨ý¹D·¥­W¡A¥BµL«rÄZ©ÎÀ£¸H³n½¦Ånªº¬ÛÃöÃÄ°Ê¾Ç¸ê®Æ¡C
OENZI,Amantadine,Enzil 100mg,CNEU,,¾AÀ³¯g: Parkinsonism of various origin¡A senile Parkinsonism¡A residual symptoms & discomfort after stereotactic operations. °Æ§@¥Î: Occasional dry mouth; dizziness. Paranoid exogenous psychoses associated with visual hallucinations¡A visual disturbances; motor or mental restlessness¡A urinary retention in the case of prostatic hypertrophy¡A signs of cardiac insufficiency¡A cardiac dysrhythmia associated with tachycardia¡A nausea¡A sleep disturbances¡A orthostatic dysregulation; very rarely¡A myoclonus & symptoms of peripheral neuropathy; livedo reticularis (marble skin) & lower-leg & ankle oedema are common occurrences; very rarely¡A increased photosensitivity; very rarely haematological side effects¡A such as leukopenia & thrombocytopenia; very rarely¡A anaphylactic reactions after infusion therapy. Cardiovascular: Orthostatic hypotension (1% to 5% )¡A Peripheral edema (1% to 5% ) Gastrointestinal: Constipation (1% to 5% )¡A Diarrhea (1% to 5% )¡A Loss of appetite (1% to 5% )¡A Nausea (5% to 10% )¡A Xerostomia (1% to 5% ) Neurologic: Ataxia (1% to 5% )¡A Confusion (1% to 5% )¡A Dizziness (5% to 10% )¡A Headache (1% to 5% )¡A Insomnia (5% to 10% )¡A Somnolence (1% to 5% ) Psychiatric: Agitation (1% to 5% )¡A Anxiety (1% to 5% )¡A Depression (1% to 5% )¡A Dream disorder (1% to 5% )¡A Feeling nervous (1% to 5% )¡A Hallucinations (1% to 5% )¡A Irritability (1% to 5% ) Other: Fatigue (1% to 5% ) ¸T§Ò: Severe CHF (NYHA class IV)¡A cardiomyopathies & myocarditis¡A 2nd or 3rd degree AV block¡A existing bradycardia under 55 beats/min¡A known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis ¡A history of serious ventricular arrhythmias including torsade de pointes¡A simultaneous treatment with budipine or other drugs that prolong the QT interval¡A reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.,,«Ç·Å,Adult:100 mg/day for the first 5-7 days¡A followed by a once-weekly increase in daily dose of 100 mg until the maintenance dose is reached. Usual effective dose: 200-600 mg/day. child(1-9yr): 4-8mg/kg/day¡A maxium daily dose:150mg.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IFRA5,Dalteparin,Fragmin inj 5000 IU/0.2mL single dose syringe,HEMT,Treatment of acute deep venous thrombosis. Deep venous thrombosis¡A In medical patients with severely restricted mobility due to acute illness; Prophylaxis. Postoperative deep vein thrombosis; Prophylaxis - Total replacement of hip. Venous thromboembolism¡A Symptomatic.,Active major bleeding. History of heparin-induced thrombocytopenia with or without thrombosis. Hypersensitivity to dalteparin sodium¡A heparin¡A or pork products. In patients undergoing epidural or neuraxial anesthesia do not administer dalteparin for unstable angina¡A non-Q-wave myocardial infarction¡A or prolonged VTE prophylaxis.,Common Dermatologic: Contusion (12% )¡A Hematoma¡A Injection site (7% to 35%)¡A Injection site bruising (30% )¡A Injection site pain (4.5% to 12% ) Respiratory: Bleeding from nose (10% ) Other: Irritation symptom¡A Local Serious Hematologic: Extradural intracranial hematoma¡A Hematoma¡A Spinal¡A Hemorrhage¡A Major (Up to 13.6%)¡A Hemorrhagic cerebral infarction (8% )¡A Intracranial hemorrhage¡A Subdural hemorrhage¡A Intrauterine¡A Thrombocytopenia (Adult¡A non-cancer indications¡A less than 1%; patients with cancer¡A 10.9% to 13.6% ; pediatric¡A 21% ) Hepatic: Increased liver function test (up to 4.3%) Immunologic: Anaphylactoid reaction (rare) Neurologic: Paralysis,25¢J¥H¤U,Prophylaxis of venous thromboembolism during surgical procedures: Usually: 2500 IU given 2 hours before the procedure followed by 2500 IU once daily for 5-7 days or until the patient is fully ambulant. High-risk patients: 2500 IU given 2 hours before and 8-12 hours after the procedure¡A and followed by 5000 IU daily for 5-10 days. Or 5000 IU single dose in the evening before the procedure¡A and followed by 5000 IU every evening 5-10 days. Orthopedic surgery (for example¡A hip replacement surgery): up to 5 weeks. 5000 IU given in the evening before surgery followed by 5000 IU each subsequent evening. Or 2500 IU given 2 hours before and 8-12 hours after the procedure¡A and followed by 5000 IU daily. Or 2500 IU 4-8 hours after the procedure¡A and followed by 5000 IU daily. Venous thromboembolism Initial¡A 200 IU/kg every 24 hours for the first 30 days¡A followed by 150 IU/kg(= or <56kg: 7500 IU; 57-68kg:10000 IU; 69-82kg: 12500 IU; 83-98kg: 15000 IU; > or =99kg: 18000 IU) every 24 hours during months 2 to 6; Maximum daily dose¡A 18000 IU/day. Deep venous thrombosis¡A In medical patients with severely restricted mobility due to acute illness; Prophylaxis 5000 IU once daily for 12 to 14 days.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]­Y¦bÃh¥¥´Á¶¡¨Ï¥Îdalteparin¡A¹ï­L¨à³y¦¨¶Ë®`ªº¥i¯à©Ê·¥¤p¡G µM¦Ó¦]¬°¤£¯à§¹¥þ±Æ°£¶Ë®`¥i¯à©Ê¡A©Ò¥HÃh¥¥´Á¶¡¤£¸Ó¨Ï¥Îdalteparin¡A¥u¦³¦bÅãµÛ»Ý­n®É¤è¥i¨Ï¥Î¡C ¦b¤j¶qªº¥¥°ü¨Ï¥Î¸ê®Æ¤¤(¶W¹L1000­Ó¥H¤WªºÃnÃÄ«áµ²ªG)¡A¨Ã¥¼µo²{¥ô¦ó­P·î©Ê©Î­L¨à/·s¥Í¨à¬r©Ê¡C ¦pªGÁ{§Éª¬ªp»Ý­n¡Adalteparin sodium¥ç¥i©óÃh¥¥´Á¶¡¨Ï¥Î¡C¥Ø«e¤w¦³¶W¹L2¡A000­Ó©óÃh¥¥´Á¶¡§ë¤©dalteparinªº¤wµoªí¯f¨Ò(¬ã¨s¡B¨t¦C¯f¨Ò¬ã¨s»P­Ó¨Ò³ø§i)¡C ³ø§i«ü¥X¡A©MUFH¬Û¤ñ¸û¡A¤£¶È¥X¦å¶É¦V¸û§C¡Aµo¥Í°©½è²¨ÃP©Ê°©§éªº­·ÀI¤]¦³­°§Cªº²{¶H¡C¦b³Ì¤j«¬ªº«eÂ¤©Ê¬ã¨s¡u©ó§³®W´Á¶¡¤¶¤JªvÀøªº¦å®ê¹w¨¾®ÄªG(EThIG)¬ã¨s¡v¤¤¡A¤@¦@¦¬¿ý¤F810¦ì¥¥°ü¡A¨Ã±´°Q¨C¤Ñ§ë¤©¤¶©ó50¦Ü150 IU/¤½¤çÅé­«(­Ó§O¯f¨Ò³Ì°ª¹F200 IU/¤½¤çÅé­«)¤§dalteparinªº¥¥°ü¯S¦³­·ÀI¤À¼hÅé¨t(§C«×¡B°ª«×¡B·¥°ª«×ªºVTE ­·ÀI)¡C ¤£¹L¡A¦b¹ï¥¥°ü¨Ï¥Î§C¤À¤l¶q¨x¯À¤è­±¡A¥Ø«e¥u¦³¬Û·í¦³­­ªºÀH¾÷¹ï·Ó¬ã¨s¡C°Êª«¸ÕÅç¨Ã¥¼µo²{dalteparin¨ã¦³¥ô¦ó­P·î©Ê©Î­L¨à¬r©Ê¡C±µ¨ü°ª¾¯¶q§Ü¾®¦å¾¯ªvÀø¤§°ü¤k¦b¤À®Y®Éµ´¹ï¤£¥i¨Ï¥Îµw¸£½¤¥~³Â¾K¡C ¦bªvÀø¥X¦å­·ÀI¸û°ªªº¯f¤H(¦p©P²£´Á°ü¤k)®É¡A«ØÄ³À³ÂÔ·V¡CÃh¥¥°ü¤k¦b§³®W²Ä¤T´Á©Ò´ú±o¤§dalteparin§ÜXa¦]¤l¥b°I´Á¬°4¦Ü5¤p®É¡C ´¿¦³¹ï¸Ë¸m¤H¤u¤ßÅ¦Ã¤½¤¤§¥¥°ü¨Ï¥Î§¹¾ã§Ü¾®¦å¾¯¶q¤§§C¤À¤l¶q¨x¯À¦ýªvÀø¥¢±Ñªº³ø§i¡C¥Ø«e©|¥¼¥R¤À¬ã¨s¹Ldalteparin¥Î©ó¸Ë¸m¤H¤u¤ßÅ¦Ã¤½¤¤§¥¥°üªºµ²ªG¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]Ãö©ódalteparin¬O§_·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤ªº¸ê®Æ¦³­­¡C ¤@¶µ¬ã¨s¦b15¦W±µ¨üdalteparin¬°¹w¨¾©ÊªvÀø¤§±Â¨Å°ü¨Å¥Ä¤¤°»´ú¨ì¤Ö¶qªº§ÜXa¦]¤l¬¡©Ê¡A¬Û·í©ó¨Å¥Ä/¦å¼ß¤ñ­È<0.025¦Ü0.224¡C §C¤À¤l¶q¨x¯Àªº¤fªA§l¦¬·¥§C¡A¦]¦¹³oºØ¤Ö¶qªº§Ü¾®¦å¬¡©Ê¹ï¦Y¥À¥¤À¦¨àªºÁ{§É·N¸q¤£©ú(¦pªGªº¸Ü)¡C,SC;,,,,,¥»ª`®g²G¥i»P¸Ë©ó¬Á¼þ©Î¶ì½¦®e¾¹¤¤ªº¥Í²z­¹ÆQ¤ô·»²G(0.9% NaCl)©Îµ¥±i¸²µå¿}·»²G(5%) ²V¦X¡C
OMCL,Phenprobamate,Mocolax 400mg,CNEU,Relief of muscle tension such as muscle spasm and muscle stiffness.,Hypersensitivity to any components of the product.,Drowsiness¡A dizziness¡A headache¡A loss of strength¡A fatigue¡A nausea¡A vomiting¡A loss of appetite¡A diarrhea¡A constipation¡A stomachache.,25¢J¥H¤UÀx¦s,400mg BID-TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Ãh¥¥¤¤¤§ªA¥Î¤Î¦]ÁÙ¨S½T©w¹ï©ó¨Å¨à¡B¤p¨à¤§¦w¥þ©Ê¡A©Ò¥H¹ï©ó¥¥°ü©Î¦³¥i¯àÃh¥¥¤§°ü¤H¡A¤Î¨Å¨à¡B¤p¨à¶È¦b³Q§PÂ_©óªvÀø¤W¤§¦³¯q©Ê¤ñ¦MÀI©ÊÁÙ¤j®É¤~ªA¥Î¡C¤S§Æ±æ±Â¨Å¤¤°ü¤H¤£­nªA¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Ãh¥¥¤¤¤§ªA¥Î¤Î¦]ÁÙ¨S½T©w¹ï©ó¨Å¨à¡B¤p¨à¤§¦w¥þ©Ê¡A©Ò¥H¹ï©ó¥¥°ü©Î¦³¥i¯àÃh¥¥¤§°ü¤H¡A¤Î¨Å¨à¡B¤p¨à¶È¦b³Q§PÂ_©óªvÀø¤W¤§¦³¯q©Ê¤ñ¦MÀI©ÊÁÙ¤j®É¤~ªA¥Î¡C¤S§Æ±æ±Â¨Å¤¤°ü¤H¤£­nªA¥Î¡C,AC;AC15;PC;PO;WM;,,,,,
OBRIN,Vortioxetine,BrinteLLIX 10mg(±Ó¯S«ä),CNEU,Major depressive disorder.,Hypersensitivity (eg¡A angioedema) to vortioxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 21 days of discontinuing vortioxetine or within 14 days of discontinuing the MAO inhibitor); initiation of vortioxetine in a patient receiving linezolid or intravenous methylene blue.,>10%: Central nervous system: Female sexual disorder (1% to 2%; Arizona Sexual Experiences Scale: 22% to 34%)¡A male sexual disorder (3% to 5%; Arizona Sexual Experiences Scale: 16% to 29%). Gastrointestinal: Nausea (21% to 32%) 1% to 10%: Central nervous system: Dizziness (8% to 9%)¡A abnormal dreams (2% to 3%). Dermatologic: Pruritus (2% to 3%). Gastrointestinal: Diarrhea (7% to 10%)¡A xerostomia (7% to 8%)¡A constipation (5% to 6%)¡A vomiting (3% to 6%)¡A flatulence (2% to 3%). Frequency not defined: Cardiovascular: Flushing. Central nervous system: Suicidal ideation¡A suicidal tendencies¡A vertigo. Gastrointestinal: Dysgeusia¡A dyspepsia <1%¡A postmarketing¡A and/or case reports: Acute pancreatitis¡A anaphylaxis¡A angle-closure glaucoma¡A hypersensitivity reaction¡A hypomania¡A hyponatremia¡A mania¡A seizure¡A serotonin syndrome¡A skin rash¡A urticaria¡A weight gain¡A withdrawal syndrome,30¢J¥H¤UÀx¦s,Adults: Initial: 10 mg once daily; dosage range:5-20mg/day Elderly¡A > or = 65 years old: 5mg QD¡A dose of more than 10mg should be treated with caution. Children and teenagers (< 18 years old): No data,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥¥°ü¨Ï¥Îvortioxetine¶È¦³¦³­­Á{§É¸ê®Æ¡C°Êª«¬ã¨s¤wÅã¥Ü¥Í´Þ¬r©Ê¡C­Y¦bÃh¥¥«á´Á¨Ï¥Î¦å²M¯À§@¥ÎÃÄª«®É¡A·s¥Í¨à¥i¯à·|¥X²{¥H¤U¯gª¬¡G©I§lµ~­¢¡BµoÖæ¡B©I§l¤¤¤î¡BµjÅË¡BÅé·Å¤£Ã­¡BÁý­¹§xÃø¡B¹Ã¦R¡B¦å¿}¹L§C¡B°ª±i¤O¡B§C±i¤O¡B¤Ï®g¤®¶i¡BÅ¸§Ý¡B¾_Å¸¡B©ö«ã¡B©üºÎ¡B­ú¾x¤£°±¡B¶ÝºÎ¡B©MÃø¥H¤JºÎ¡C³o¨Ç¯gª¬¥i¯à¬O¦]§ÙÂ_¤ÏÀ³©Î¬O¹L¦h¦å²M¯À§@¥Î©Ò¤Þ°_¡C©ó¤j¦h¼Æªº®×¨Ò¤¤¡A¤W­z¯gª¬·|¦b¥Í²£«á¥ß§Y©Î«Ü§Ö¦a(<24¤p®É)¥X²{¡C¬y¦æ¯f¾Çªº¸ê®ÆÅã¥Ü¥X¦bÃh¥¥´Á¶¡¨Ï¥ÎSSRI¡A¤×¨ä¬O¦b«á´Á¡A¥i¯à·|¼W¥[·s¥Í¨à«ùÄò©ÊªÍ°Ê¯ß°ª¦åÀ£¯g(Persistent pulmonary hypertension in the new born¡A PPHN)ªº­·ÀI¡CÁöµM¨S¦³¬ã¨s³ø§i«ü¥XvortioxetineªvÀø»PPPHNªºÃöÁp©Ê¡A·í¦Ò¶q¬ÛÃöªº§@¥Î¾÷Âà(¼W¥[¦å²M¯À¿@«×)®É¡AµLªk±Æ°£¦¹¶µªº¼ç¦b­·ÀI¡CBrintellixÀ³¦b¼ç¦b§Q¯q°ª©ó­L¨à¼ç¦b­·ÀI®É¡A¤è¥i©óÃh¥¥´Á¶¡¨Ï¥Î¡CÆ[¹î©Ê¼Æ¾Ú¤wÃÒ©ú¡AÃh¥¥°ü¤k¦b¥Í²£«eªº¤@­Ó¤ë¤º¼ÉÅS©óSSRI©ÎSNRI«á¡A²£«á¥X¦åªº­·ÀI¼W¥[(¤p©ó2­¿)¡CÁöµM©|¥¼¬ã¨s½Õ¬dvortioxetineªvÀø©M²£«á¥X¦å¤§¶¡ªºÃöÁp¡A¦ý¦Ò¼{¨ì¬ÛÃöªº§@¥Î¾÷Âà¡A¨ä¤´¦s¦b¼ç¦b­·ÀI¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅçÅã¥Ü¡Avortioxetine¤Î¨ä¥NÁÂ²£ª«·|±Æªn¦Ü¨Å¥Ä¤¤¡C¦]¦¹¹w´Ávortioxetine·|³Q±Æªn¦Ü¥À¨Å¤¤¡C¤£¯à±Æ°£¹ï©óÁý­¹¥À¨Å¥®¨àªº­·ÀI¡C¶·¦Ò¶q¥®¨àÁý­¹¥À¨Å»P¹ï¤k©Ê¯f¤H¤§ÂåÀø®Ä¯q¡A¨M©w¬O§_¤¤Â_Áý­¹¥À¨Å©Î°±¥Î/§ÙÂ_BrintellixªvÀø¡C,AC;AC15;PC;PO;WM;,,,,,
ISKY,Risankizumab,Skyrizi 75mg/0.83mL pre-filled syringe,HIMM,Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.,Specific contraindications have not been determined,Common Dermatologic: Injection site reaction (1.5% )¡A Tinea (1.1% ) Immunologic: Antibody development (24%% ) Neurologic: Headache (3.5% ) Respiratory: Upper respiratory infection (13% ) Other: Fatigue (2.5% ) Serious Immunologic: Infectious disease (22.1% )¡A Tuberculosis,2-8¢XCÁ×§K§N­á,SC¡A 150 mg at week 0 and week 4¡A followed by every 12 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ³ß¶}®®R¥Î©óÃh¥¥¤k©Êªº¸ê®Æ¡A¤£¨¬¥H±À¾É±oª¾¥ô¦óÃÄª«¬ÛÃö­·ÀI¡C ¦³¥Í¨|¯à¤O¤k©ÊÀ³¦bªvÀø´Á¶¡¨ìªvÀø«á¦Ü¤Ö 21 ¶g¡A¨Ï¥Î¦³®ÄÁ×¥¥¤èªk¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ©|µL¸ê®ÆÅã¥Ü risankizumab ¬O§_·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¡A¹ï±µ¨ü­÷¨ÅªºÀ¦¨à¦³¦ó¼vÅT¡A©Î¹ï¥À¨Å¤Àªcªº§@¥Î¡CÁöµM¤HÃþ IgG ·|¤Àªc¶i¤J¨Å¥Ä¡A¦ý¤wµoªí¸ê®ÆÅã¥Ü¡A¨Å¥Ä¤¤ªº§ÜÅé¤£·|¤j¶q¶i¤J·s¥Í¨à©MÀ¦¨àªº´`Àô¨t²Î¡CÀ³¦Ò¼{­÷¨Å¹ïÀ¦¥®¨àªº¯q³B¤Î¨Ï¥Îrisankizumab¹ï°ü¤kªº¯q³B¨M©w¬O§_°±¤î¨Ï¥Îrisankizumab¡C,SC;,,,,,Àx¦s¦b 2-8¢XCªº¦B½c¤º¡C¤£¥i§N­á«O¦s¡C ¹w¥R¶ñ¦¡ª`®g¾¹½Ð¦s©ñ©ó¥~²°¥]¸Ë¤¤¡A¥B¶·Á×¥úÀx¦s¡C ½Ð¤Å·n®Ìª`®g¾¹¡C ª`®g«e 15 ¦Ü 30 ¤ÀÄÁ±N¥~²°±q¦B½c¨ú¥X¡A¨Ã©ñ¦b«Ç·Å¤UÁ×¶}ª½®g¶§¥ú³B¡C ½Ð¤Å¥H¨ä¥L¥ô¦ó¤è¦¡¥[¼öÃÄª«¡C½Ð¤Åª`®g¨ì¬Û¦P¦ì¸m¡C ½Ð¤Åª`®g¨ì¯kµh¡B·ï«C¡Bµo¬õ¡Bµw¤Æ¡B¦³½I²ª©Î¦³§³®W¯¾ªº¥Ö½§¤º¡C ½Ð¤Åª`®g¨ì¨ü°®Å~¼vÅTªº³¡¦ì¡C
ROVEM,Tenofovir alafenamide,¸ÕVemlidy 25mg (Á{§É¸ÕÅç),QANB,,,,,Adutl: 25 mg orally once daily.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,PC;PO;WM;,,,,,
EDYM,Azelastine + Fluticasone,Dymista 137/50mcg/dose¡A120dose nasal spray,TENT,Symptomatic treatment of moderate to severe allergic rhinitis & rhinoconjunctivitis in adults and children > or = 6 years-old.,Hypersensitivity to azelastine & fluticasone.,Headache¡A dysgeusia¡A epistaxis.,«Ç·Å30¢XC¥H¤U¡A¤Å§N­á©Î§NÂÃ,1 spray in each nostril BID (morning & evening).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,AZELASTINE of PREGNANCY RECOMMENDATION: No Human Data¡XAnimal Data Suggest Low Risk FLUTICASONE Respiratory of PREGNANCY RECOMMENDATION: Compatible [¥é³æ¸`¿ý]Dymista¤W¥««á¦³­­ªº¥¥°ü¨Ï¥Î¸ê®ÆÅã¥Ü¡A¥¼µo²{¥ô¦ó»PDymista¬ÛÃöªº¬y²£(miscarriage)¡B¥ý¤Ñ©Ê¯Ê³´(birth defects)©Î¨ä¥L¦³®`¥ÀÅé©Î­L¨à¤§­·ÀI¡F¦ÓDymista¤º§t¤§¦U§O¦¨¤À¤w¤W¥«¼Æ¤Q¦~. ÁöµM¦b§³®W´Á¨Ï¥Îfluticasone propionate»óµÄ»s¾¯ªº¬ÛÃö¼Æ¾Ú¸ê®Æ¦³­­¡A¦ýÁ{§É¬ã¨s¼Æ¾Ú¸ê®ÆÅã¥Ü¡A¨Ï¥Î§l¤J©Êfluticasone propionate¨Ã¥¼Åã¥Ü¥X¦³®`¥ÀÅé©Î­L¨àµ²ªGªº­·ÀI¼W¥[. ¥Ø«eDymista°Êª«¥Í´Þ¬ã¨s¤´¤£¥i±o¡AµM¦Ó²{¦b¤w¸g¦³°w¹ïDymistaªº¦U§O³æ¤è¦¨¤À¡Gazelastine hydrochloride©Mfluticasone propionate¶i¦æ¤§¬ã¨s.¦b°Êª«¥Í´Þ¬ã¨s¤¤¡A·í§ë¤©¤fªAazelastine hydrochloride ¬ù10­¿¨C¤éÁ{§É¾¯¶q®É¡A¥¼¦³ÃÒ¾ÚÅã¥Üazelastine hydrochloride·|¹ï°Êª«­L¨à³y¦¨¶Ë®`¡F¦b¾¹©x§Î¦¨´Á¶¡(organogenesis)¡A¥H¤fªA³~®|¦bÃh¥¥ø{¹«¡B¤j¹«©M¨ß¤l§ë¤©azelastine hydrochloride 530­¿¤Î§ó°ª©ó¤HÃþ¨C¤é³Ì°ª«ØÄ³§l¤J¾¯¶q(maximum recommended human daily intranasal dose¡A MRHDID)0.548mg®É¡A·|²£¥Íµo¨|¬r©Ê¡A¥]¬Aµ²ºc²§±`(structural abnormalities)¡B­F­L-­L¨à¦s¬¡²v(embryo-fetal survival)­°§C©M­L¨àÅé­«´î»´±¡§Îµo¥Í¡FµM¦Ó¡A°ò©ó°Êª«¾¯¶qÂà´«¦Ü¤HÃþ¾¯¶qªº­¿¼Æ¬Û·í°ª¡A³o¨Ç°Êª«¶i¦æ¬ã¨sµo²{»P¤HÃþ¥¥°ü¤§¶¡ªºÃöÁp©Ê¨ÌµM¦sºÃ. ¦b°Êª«¥Í´Þ¬ã¨s¤¤¡A¤j¹«¥Ñ»óµÄ§l¤Jfluticasone propionate¨¬¥H²£¥Í¥ÀÅé¬r©Ê¤§¾¯¶q(¥Hmcg/m2¬°­pºâ°ò·Ç¡A¤p©ó¤HÃþ¨C¤é³Ì°ª«ØÄ³§l¤J¾¯¶q®É)¡A·|³y¦¨­L¨àÅé­«´î»´¡A¦ý¨Ã¤£·|»¤µo·î­L(teratogenicity).¥H¥Ö¤U(subcutaneously)³~®|§ë»P¤j¹«¡Bø{¹«©M¨ß¤lfluticasone propionate¨¬¥H²£¥Í¥ÀÅé¬r©Ê¤§¾¯¶q(¥Hmcg/m2¬°­pºâ°ò·Ç¡A¤p©ó¤HÃþ¨C¤é³Ì°ª«ØÄ³§l¤J¾¯¶q200 mcg®É)¡A¥iÆ[¹î¨ì­L¨à·î§Î¡A¦¹¬°¥Ö½èÃþ©T¾J(corticosteroids)¤§¯S©Ê¡B­L¨àÅé­«´î»´©M¡þ©Î°©ÀfÅÜ²§(½Ð°Ñ¾\¼Æ¾Ú¸ê®Æ).¨Ì¾Ú¥Ö½èÃþ©T¾Jªº¨Ï¥Î¸gÅç¡Aø¥¾¦Ãþ°Êª«(rodents)¤ñ¤HÃþ§ó®e©ö¨ü¨ì¥Ö½èÃþ©T¾Jªº·î­L§@¥Î(teratogenic effects)¼vÅT.¯S©w±Ú¸sªº¥D­n¥ý¤Ñ©Ê¯Ê³´©M¬y²£¤§¦ô­p­I´º­·ÀI­È(estimated background risk)¤´¤£²M·¡. Ãh¥¥³£·|¦³¥ý¤Ñ©Ê¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}«áªG¤§­I´º­·ÀI¡A¥H¬ü°ê¤@¯ë¸s²³¨Ó»¡¡A¦bÁ{§É¤W»{¥iªºÃh¥¥±¡ªp¤U¡A¥D­n¥ý¤Ñ©Ê¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI­È¤À§O¬°2-4¢H©M15-20¢H.,Unknown ¨S¦³¸ê®Æ,AZELASTINE of BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible FLUTICASONE Respiratory of BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible [¥é³æ¸`¿ý]¥Ø«eÁÙ¨S¦³Ãö©óazelastine hydrochloride©Îfluticasone propionate¬O§_·|¤Àªc¨ì­÷¨Å°ü¤kªº¨Å¥Ä¹ï­÷¨ÅÀ¦¨à¡B©Î¹ï¨Å¥Ä¥Í¦¨ªº¼vÅT¤§¼Æ¾Ú¸ê®Æ.À³¦b­÷¨Å°ü¤k¨Ï¥Î¥»ÃÄªº´Á¶¡¡AÀ³ºÊ´ú­÷¨ÅÀ¦¨à¹ï¨Å¥Äªº±Æ¥¸²{¶H.Fluticasone propionat·|¤Àªc¨ì¤j¹«¨Å¥Ä¤¤¡A¨ä¥L¥Ö½èÃþ©T¾J¤]´¿¦b¤HÃþ¥À¨Å¥Ä¤¤³QÀË´ú¨ì.µM¦Ó¡A¸g»óµÄ§l¤JªvÀø¾¯¶q«á¡A¦å¼ß¤¤fluticasone propionateªº¿@«×«Ü§C¡A¦]¦¹¤HÃþ¥À¨Å¥Ä¤¤fluticasone propionate¿@«×¤]¬ÛÀ³±o§ó§C.­÷Áý¥À¨Å©Ò±a¨Óªºµo¨|©M°·±d¯q³B¡A»P¥À¿Ë¦bÁ{§É¤W»Ý­n¨Ï¥Î¥»ÃÄ¥H¤Î¥»ÃÄ¹ï­÷¨ÅÀ¦¨à³y¦¨ªº¥ô¦ó¥i¯à¤£§Q¼vÅT¡AÀ³¦P®É¤@¨Ö¦Ò¼{.À³ºÊ´ú¨Ï¥Î¥»ÃÄªvÀøªº­÷¨Å°ü¤k¤§­÷¨ÅÀ¦¨à¹ï¥À¨Å±Æ¥¸ªº²{¶H¡A¦¹²{¶H¥i¯à»Pazelastine hydrochloride³y¦¨¥À¨Åªº­W¨ý¦³Ãö.,IN;,,,,,
OAGT,Acamprosate,Alglutol 333mg delayed-release,ZADT,Alcohol dependence¡A Maintenance of abstinence.,Hypersensitivity to acamprosate calcium or any of its components. Severe renal impairment (CrCl of 30 mL/min or less). Hypercalcemia (avoided long-term using this drug in patients with hypercalcemia).,Common: Pruritus (4%)¡A Diarrhea (10-17%)¡A Flatulence (3%)¡A Nausea (4%)¡A Dizziness (3%)¡A Insomnia (7%)¡A Anxiety (6%)¡A Depression (5%) Serious: Cardiomyopathy¡A Deep thrombophlebitis¡A Heart failure¡A Mesenteric arterial occlusion¡A acute¡A Shock¡A Suicidal intent (1%),Àx¦s©ó25¢Jªº·Å«×¤U¡C,Alcoholism¡A maintenance of abstinence: 666 mg orally 3 times daily.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]­««×¨x¥\¯à¤£¥þ¯f¤H(Child-Pugh¤ó¤ÀÃþªk¤§C¯Å)«h¤£«ØÄ³¨Ï¥Î¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest high risk,[¥é³æ]Ãh¥¥¥ÎÃÄ¤À¯Å¬°C¯Å¡C¥Ø«e©|¥¼°w¹ï¥¥°ü¶i¦æ¾A·í»P±±¨î¨}¦nªº¬ã¨s¡C¶È¦bªA¥Î§Ù°s§´¸z·»¿õªº¼ç¦b¯q³B¤j©ó¹ï­L¨àªº¼ç¦b­·ÀI®É¡A¤~¯à¦bÃh¥¥´Á¶¡¨Ï¥Î§Ù°s§´¸z·»¿õ¡C¨ã¥Í¨|¤O¤§¤k©Ê©ó§Ù°s§´¸z·»¿õªvÀø´Á¶¡¤ÎªA¥Î³Ì«á¤@¾¯¤§«á¤@¶g¤º¡AÀ³Á×§KÃh¥¥¡C ­P·î­L§@¥Î¡G¬ã¨sÅã¥Ü¡A§ë¤©¤j¹«¤j¬ù¬Û·í©ó¤HÅé¾¯¶q¡]¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡^ªºAcamprosate calcium¡A¥H¤Î±N¤j¬ù¬Û·í©ó¤HÅé¾¯¶q3­¿¡]¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡^¤§¾¯¶q§ë¤©¨ß¤l®É¡A·|¥X²{­P·î­L§@¥Î¡C¤j¹«¤fªAAcamprosate calcium¨C¤é¨C¤½¤ç300²@§J¥H¤W®É [¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡A¤j¬ù¬Û·í©ó¤HÅé¨C¤é«ØÄ³³Ì¤j(MRHD)¤fªA¾¯¶q]¡A·|¼W¥[¾¯¶q¬ÛÃöªº·î­L¼Æ¥Ø¡A·î§Î¯gª¬¥]¬AµÇ¤ô¸~¡B­i½¤·î§Î¡Bµøºô½¤µo¨|¤£¨}¤Î­¹¹D«á¤èÂê°©¤U°Ê¯ßÅÜ²§¡C¤fªA¾¯¶q¬°¨C¤é¨C¤½¤ç50²@§J®É¡]¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡A¤j¬ù¬°¤­¤À¤§¤@ªºMRHD¤fªA¾¯¶q¡^¡A¨Ã¥¼Æ[¹î¨ì²§±`²{¶H¡C·í«k®Ú¦a¶À½Å¨ß(Burgundy Tawny rabbits)¤§¤fªA¾¯¶q¬°¨C¤é¨C¤½¤ç400²@§J¥H¤W®É (¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡A¤j¬ù¬°3­¿ªºMRHD¤fªA¾¯¶q)¡A¥iµo²{µÇ¤ô¸~µo¥Í²v¼W¥[¡C¯Ã¦èÄõ¥Õ¨ß(New Zealand white rabbits)¤§¤fªA¾¯¶q³Ì°ª¹F¨C¤é¨C¤½¤ç1000²@§J®É (¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡A¤j¬ù¬°8­¿ªºMRHD¤fªA¾¯¶q)¡A¥¼Æ[¹î¨ì¼vÅTµo¨|ªº±¡§Î¡C°Êª«¹êÅçªºµ²ªGÀ³»P¤wª¾ªº¤A¾J¹ïµo¨|ªº¤£¨}¼vÅT¦³Ãö¡A¦¹Ãþ¼vÅT¥]¬A­L¨à°sºë¯g­Ô¸s¡]Æ`ÃC·î§Î¡B¤l®c¤º©M¥X¥Í«áµo¨|¿ð½w¡Bºë¯«¹B°Ê»P´¼¤Oµo®i¿ð½w¡^¥H¤Î¦b¤HÅéµo¥Í¤§¸û»´·L§Î¦¡ªº¯«¸g»P¦æ¬°»ÙÃª¡C «D­P·î­L§@¥Î¡G¦b¤@¶µ°w¹ïÃh¥¥¥À¹«¶i¦æ¤§¬ã¨s¤¤¡A¦Û¥¥´Á²Ä15¤Ñ°_¡A¦Ü²£«á²Ä28¤Ñ­÷¨Å´Áµ²§ô´Á¶¡¡A¥H¤fªA¤è¦¡§ë¤©Acamprosate calciumµ¹¥À¹«¡A·í¾¯¶q¬°¨C¤é¨C¤½¤ç960²@§J¥H¤W®É¡]¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡A¤j¬ù¬°2­¿ªºMRHD¤fªA¾¯¶q)¡A·|¼W¥[¦º­Lµo¥Í²v¡C·í¾¯¶q¬°¨C¤é¨C¤½¤ç320²@§J®É¡]¥H¨C¥­¤è¤½¤Ø¤§²@§J¼Æ­pºâ¡A¤j¬ù¬°¤G¤À¤§¤@ªºMRHD¤fªA¾¯¶q¡^¡A¥¼Æ[¹î¨ì²§±`¼vÅT¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¦b°Êª«¬ã¨s¤¤¡A¤fªAAcamprosate calcium¤§­÷¨Å¤j¹«ªº¨Å¥Ä·|¤Àªc¥XAcamprosate¡A¨ä¨Å¥Ä»P¦å²G¤¤§t¦³ªºAcamprosate¿@«×¤ñ¨Ò¬°1.3:1¡C¥Ø«e¥¼ª¾¤HÅé¥À¨Å¬O§_·|¤Àªc¥XAcamprosate¡C¤£«ØÄ³©ó§Ù°s§´¸z·»¿õªvÀø´Á¶¡­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¸z·»¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
ESOO,Ivermectin,Soolantra cream 1%¡A 15gm (±M®×¶i¤f),TDER,,¾AÀ³¯g: Rosacea (Soolantra cream): Treatment of inflammatory lesions of rosacea in adult patients. °Æ§@¥Î: 1% to 10%: Central nervous system: Localized burning (<=1%) Dermatologic: Skin irritation (<=1%) <1% (Limited to important or life-threatening): Conjunctivitis¡A eye irritation¡A ocular hyperemia¡A seborrheic dermatitis of scalp¡A xeroderma ¸T§Ò:Hypersensitivity (rare).,,«Ç·Å,Apply to each affected area (eg¡A forehead¡A chin¡A nose¡A each cheek) once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OFLU2,Fluoxetine,Fluronin 20mg,CNEU,,¾AÀ³¯g:Treatment of major depressive disorder (MDD); treatment of binge-eating and vomiting in patients with moderate-to-severe bulimia nervosa; obsessive-compulsive disorder (OCD); premenstrual dysphoric disorder (PMDD); panic disorder with or without agoraphobia; in combination with olanzapine for treatment-resistant or bipolar I depression. °Æ§@¥Î: >10%: Central nervous system: Insomnia (10% to 33%)¡A headache (21%)¡A drowsiness (5% to 17%)¡A anxiety (6% to 15%)¡A nervousness (8% to 14%)¡A yawning (?11%) Endocrine & metabolic: Decreased libido (1% to 11%) Gastrointestinal: Nausea (12% to 29%)¡A diarrhea (8% to 18%)¡A anorexia (4% to 17%)¡A xerostomia (4% to 12%) Neuromuscular & skeletal: Weakness (9% to 21%)¡A tremor (3% to 13%) Respiratory: Pharyngitis (10% to 11%) ¨ä¥L¤p©ó10%°Æ§@¥Îµo¥Í²v¡A¥i°Ñ¦ÒUpToDate http://www.uptodate.com/contents/fluoxetine-drug-information?Source=search_result&search=Fluoxetine&selectedTitle=1%7E150#F172761 ¸T§Ò:Hypersensitivity to fluoxetine or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently¡A within 5 weeks of discontinuing fluoxetine¡A or within 2 weeks of discontinuing the MAO inhibitor); initiation of fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (Note: Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine),,«Ç·Å,Depression¡A obsessive-compulsive disorder: Oral: 20 mg/day in the morning; may increase after several weeks by 20 mg/day increments; maximum: 80 mg/day. Bulimia nervosa: Oral: 60 mg/day; may titrate dose to 60 mg over several days.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ¯S§O¬O¦³cirrhosis±wªÌ«ØÄ³ a lower dose or less frequent dosage schedule,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ICHE,Labetalol,Chenday inj 25mg/5mL,CAVS,,¾AÀ³¯g: Hypertension: Treatment of mild-to-severe hypertension; IV for severe hypertension (eg¡A hypertensive emergencies) °Æ§@¥Î: >10%: Cardiovascular: Orthostatic hypotension (intravenous: <58%) Central nervous system: Dizziness (1% to 20%)¡A fatigue (1% to 11%) Gastrointestinal: Nausea (<19%) 1% to 10%: Cardiovascular: Hypotension¡A edema¡A flushing¡A ventricular arrhythmia (intravenous: 1%) Central nervous system: Paresthesia¡A drowsiness¡A headache¡A vertigo Dermatologic: Tingling of the scalp¡A diaphoresis¡A pruritus¡A skin rash Gastrointestinal: Dyspepsia¡A vomiting¡A dysgeusia Genitourinary: Ejaculatory failure¡A impotence Hepatic: Increased serum transaminases Neuromuscular & skeletal: Weakness Ophthalmic: Visual disturbance Renal: Increased blood urea nitrogen Respiratory: Nasal congestion¡A dyspnea <1% (Limited to important or life-threatening): Anaphylactoid reaction¡A angioedema¡A bradycardia¡A bronchospasm¡A cardiac failure¡A cholestatic jaundice¡A diabetes insipidus¡A heart block¡A hepatic necrosis¡A hepatitis¡A hypersensitivity reaction¡A Peyronie's disease¡A positive ANA titer¡A psoriasiform eruption¡A Raynaud's phenomenon¡A syncope¡A systemic lupus erythematosus¡A toxic myopathy¡A transient alopecia¡A urinary retention¡A urticaria ¸T§Ò:Hypersensitivity to labetalol or any component of the formulation; severe bradycardia; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; bronchial asthma; uncompensated cardiac failure; conditions associated with severe and prolonged hypotension.,,,Severe hypertension including hypertension in pregnancy¡A anesth when a hypotensive technique is indicated¡A hypertensive episodes following acute MI Adult Bolus inj 50 mg IV for at least 1 min. If necessary¡A 50 mg may be repeated at 5-mins intervals until a satisfactory response occurs. Max: 200 mg. IV infusion Dilute 8 amp to 200 mL with NaCl & dextrose inj or 5% dextrose IV infusion. Hypertension of pregnancy Start infusion at 20 mg/hr & doubled every 30 mins until a satisfactory response is obtained or 160 mg/hr is reached. Hypertensive episodes after acute MI Start infusion at 15 mg/hr & gradually increased to a max of 120 mg/hr. Hypertension due to other causes Rate of infusion: 2 mg/min. Dose range: 50-200 mg. Hypotensive anesth Initially 10-20 mg IV.,»Ý½Õ¾ã¾¯¶q,Average required dose is 50% of usual dosing,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,¿éª`³t²v <10 mg/min,Continuous IV infusion: Initial: 0.5 to 2 mg/minute. Some patients may require doses within the range of 2 to 10 mg/minute. Usual Infusion Concentrations: Adult IV infusion: 200 mg in 200 mL (concentration: 1 mg/mL) or 500 mg in 250 mL (concentration: 2 mg/mL) of D5W. Usual Infusion Concentrations: Pediatric IV infusion: 1 mg/mL,do not mix with 5% sodium bicarbonate
IACTM,Tocilizumab,Actemra inj 162mg/0.9mL,HIMM,Moderate to severe active RA in adult patients¡A given alone or in combination w/ methotrexate (MTX) &/or other DMARDs.,Hypersensitivity to tocilizumab.,Upper resp tract infections¡A cellulitis¡A oral herpes simplex¡A herpes zoster; abdominal pain¡A mouth ulceration¡A gastritis; rash¡A pruritus¡A urticaria; headache¡A dizziness; increased hepatic transaminases¡A increased wt; HTN; leucopenia¡A neutropenia; hypercholesterolaemia; peripheral oedema¡A hypersensitivity reaction¡A inj site reaction; cough¡A dyspnoea; conjunctivitis.,2-8¢J¡A½Ð¤Å§N­á,SC¡A rheumatoid arthritis¡A giant cell arteritis: <100 kg 162 mg once every other week¡A increase to 162 mg once a week based on clinical response; > or =100 kg 162 mg once a week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,
ORIFI,Rifampicin + Isoniazid,RifiNAH 300/150mg (¤G¦X¤@),QANB,,¾AÀ³¯g: Treatment of all forms of TB. °Æ§@¥Î:Skin reactions¡A GI intolerance; hepatitis; thrombocytopenia; 'flu syndrome'; red discoloration of urine¡A sputum¡A tears¡A staining contact lenses; polyneuritis. Rarely¡A agranulocytosis¡A hemolytic anemia¡A convulsions; acute renal failure. ¸T§Ò: Hypersensitivity. Jaundice.,,«Ç·Å,Rifinah 300 Patient >= 50 kg 2 cap. Other anti-TB drugs may be given concurrently until the susceptibility of the infecting organism to rifampicin & INH has been confirmed. Should be taken on an empty stomach: Take at least 0.5 hr before or 2 hr after meals.,»Ý½Õ¾ã¾¯¶q,INH: Hepatic impairment (advanced disease or AST greater than 3 times ULN and not due to TB): Isoniazid-based regimens are preferred if possible; expert consultation and dosage adjustments may be necessary. Rifampicin: Dosage reductions of rifampin have been suggested in patients with serum bilirubin levels exceeding 50 mcmol/L. Rifampin 6 to 8 mg/kg biweekly should not be exceeded in patients with severe liver impairment.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,Åé­«¤j©ó50¤½¤ç®É¡G¨C¤é¤@¦¸2Áû Rifinah 300mg
IINV,Paliperidone,Invega inj 100mg (=156mg),CNEU,Acute & maintenance treatment of schizophrenia in adults.,Hypersensitivity to paliperidone or risperidone.,Cerebrovascular events including stroke. Neuroleptic malignant syndrome¡A QT prolongation¡A tardive dyskinesia¡A hyperglycemia & DM¡A wt gain¡A hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia¡A neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures¡A dysphagia¡A suicide¡A priapism¡A TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions¡A somnolence/sedation¡A dizziness¡A akathisia & extrapyramidal disorder.,30¢J¥H¤U,Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen¡A adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;,,,,,
IVAR2,Varicella Virus Vaccine,Varivax (¤ôµk¬Ì­]¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Active immunisation against varicella of healthy infants from 12 months onwards¡A susceptible high-risk patients & their susceptible healthy close contacts.,Pregnancy. Acute febrile illness. Total lymphocyte count < 1200/mm3. Hypersensitivity to neomycin.,Common: Injection site disorder (19.3-32.5%)¡A Rash¡A Varicella-like (0.5-5.5%)¡A Fever (9.5-66.8%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Thrombocytopenic purpura¡A Anaphylaxis¡A Herpes zoster ophthalmicus¡A Encephalitis¡A Febrile seizure (Less than 0.1%),2-8¢JÁ×¥ú,SC¡A 0.5 mL¡A 12 months-12 years 2 doses administered 3 months apart. > or = 13 years 2 doses administered 4-8 weeks apart.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¥Ø«e¥¼ª¾Ãh¥¥°ü¤k±µºØ¬O§_·|¹ï­L¨à³y¦¨¼vÅT¡A ¦]¦¹Ãh¥¥°ü¤k¤£À³±µºØ¡A¥BÀ³Á×§K©ó±µºØ«á¤T­Ó¤ë¤ºÃh¥¥¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¤£½Tª¾¬O§_·|¤Àªc¦Ü¨Å¥Ä¡A¥Ñ©ó¤wª¾¦³¨Ç¯f¬r·|¶i¤J¤HÃþ¨Å¥Ä¡A ¦]¦¹±µºØ¤§­÷¨Å°ü¤k¶·¯S§Oª`·N¡C,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G,,,,1. Varilrix»P§t¦³³Â¯l¦¨¤Àªº¬Ì­]À³¶¡¹j¦Ü¤Ö¤@­Ó¤ë¥H¤W¡C
IDYN,Parecoxib,Dynastat inj 40mg,CNEU,Short-term treatment of post-op pain.,Hypersensitivity to parecoxib or sulfonamides. Active peptic ulceration or GI bleeding¡A inflammatory bowel disease¡A CHF (NYHA II-IV)¡A severe hepatic dysfunction (serum albumin <25 g/L or Child-Pugh score >=10). Patients who have experienced asthma¡A urticaria or allergic-type reactions to aspirin or NSAIDs including selective COX-2 inhibitors. Treatment of post-op pain immediately following CABG surgery. Established ischemic heart disease¡A peripheral arterial disease &/or cerebrovascular disease. Pregnancy (3rd trimester) & lactation.,Nausea. Abdominal pain¡A constipation¡A dyspepsia¡A vomiting; peripheral edema; alveolar osteitis (dry socket); dizziness; insomnia; oliguria; increased sweating¡A pruritis; hypotension.,30¢J¥H¤U,Adults: Initial dose: 40mg IV/IM¡A followed by 20mg Q12H or Q24H. IM: Slowly inject into the deep part of the muscle. The current clinical experience with Dynastat for more than three days is limited. Because the cardiovascular risk of the second type cyclooxygenase-2 (COX-2) specific inhibitor may increase with the increase of the dose¡A try to shorten the treatment period and use the lowest effective dose. Elders: >=65 years old: Generally do not need to adjust the dose. <50kg: The initial dose should be half of the general recommended dose. maximum dose:40mg/day. Children and teenagers: Not recommended.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ(Child-pugh B)¤§¯f±w¡A°_©l¾¯¶q«ØÄ³¬°¤@¯ë¾¯¶qªº1/2¡A¨C¤é³Ì°ª¾¯¶q­°¬°40mg ­««×¨x¥\¯à¤£¥þ(Child-pugh C)¤§¯f±w¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[20201124«DÃþ©T¾J®øª¢ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí] Ãh¥¥20¶g¥H¤W¥¥°ü¨Ï¥ÎNSAIDs¥i¯à·|¾É­P­L¨àµÇ¥\¯à»ÙÃª¨Ã¾É­P¦Ï¤ô¹L¤Ö¡F §³®W30¶g¥H¤W¤§¥¥°ü¥i¯à¾É­P­L¨à°Ê¯ß¾ÉºÞ¹L¦­³¬¦Xªº­·ÀI¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,¥H¤WÃh¥¥¤Î­÷¨Å¤À¯Å¸T§Ò¨Ï¥Î¬°¥é³æ«ØÄ³¡C,IM;IVP;IVPUSH;,IM: 2 mL N/S¡AD5W IV: 2mL N/S¡A D5W,,¦p±ÄÀR¯ßª`®g¡A¥iª½±µ¨³³t¦aª`¤JÀR¯ß. (Intravenous parecoxib has been given as a bolus over at least 15 seconds[Micromedex 20220822]),¥»ÃÄµLIVD¥Îªk¬ÛÃö«ØÄ³¡C,1.­é°£parecoxib 40²@§J¤p²~ªºµµ¦â©ö©Ô»\¡C 2.¥ÎµLµßª`®g°w»P°wµ©©â¨ú2¤½¼¼¾A·íªº·»¾¯¡A±N·»¾¯ª`¤J40²@§J¤p²~¤º¡C 3.»´»´±ÛÂà¤p²~¡A¨Ï¯»¥½·»¸Ñ¡A½Õ°t§¹¦¨«áªºª`®g²GÀ³¬°¼á²M·»²G¡C 4.ª`®g«e¡AÀ³¥ØµøÀË¬dDynastatª`®g²G¬O§_ÅÜ¦â©Î¦³¤£·»ª«½è¡Aª`®g²G¤@¥¹ÅÜ¦â¡B´ý¿B©Î¦³¤£·»ª«½è¡A«h¤£±o¨Ï¥Î 5.½Õ°t§¹¦¨¤§Dynastatª`®g²GÀ³¥ß§Y¡A§_«hÀ³¤©¥H¥á±ó¡C 6.½Õ°t§¹¦¨ªº·»²G¬Oµ¥±i·»²G¡C
OAPA,Mifepristone,Apano 200mg (RU486),HM,,¾AÀ³¯g:Termination of pregnancy (?49 days). °Æ§@¥Î:Uterine bleeding and cramps¡A chills¡A fever¡A malaise¡A dizziness¡A headache¡A diarrhoea¡A nausea¡A vomiting¡A urticaria¡A rash; hypokalaemia¡A GI disturbances¡A decreased appetite¡A drowsiness¡A fatigue¡A dyspnoea¡A anxiety¡A peripheral oedema¡A HTN¡A arthralgia¡A myalgia¡A back pain¡A endometrial thickening¡A cystic dilatation of endometrial glands¡A adrenal insufficiency¡A prolonged QT interval. ¸T§Ò:Termination of pregnancy: Confirmed or suspected ectopic pregnancy¡A undiagnosed adnexal mass¡A chronic adrenal failure¡A porphyria¡A haemorrhagic disorder. Concurrent anticoagulant therapy. Cushing¡¦s syndrome: Women w/ history of vag bleeding¡A endometrial hyperplasia w/ atypia or endometrial carcinoma. Pregnancy. Concomitant use w/ lovastatin¡A simvastatin and CYP3A4 substrates w/ narrow therapeutic range. Concurrent long-term corticosteroid use for serious medical conditions.,,«Ç·Å,Termination of pregnancy Adult: 600 mg as a single dose¡A followed by a prostaglandin (either misoprostol 400 mcg orally or gemeprost 1 mg vaginally) 36-48 hr later. Alternatively¡A 200 mg as a single dose¡A followed by gemeprost 1 mg vaginally 36-48 hr later.,»Ý½Õ¾ã¾¯¶q,Mild-to-moderate impairment: Maximum dose: 600 mg once daily Severe impairment: Use is not recommended,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;,,,,,
ONUS,Hyoscyamine,Nuspas 0.125mg,ALIM,Control gastric secretion¡A visceral spasm & hypermotility in spastic colitis¡A spastic bladder¡A cystitis¡A pylorospasm & associated abdominal cramps,Glaucoma¡A obstructive uropathy¡A GI obstruction¡A paralytic ileus¡A severe ulcerative colitis¡A myasthenia gravis.,Dry mouth¡A urinary hesitancy & retention¡A blur vision¡A tachycardia.,25¢J¥H¤U,Adult & children > 12 years : 1-2 TAB 4 hourly or once when needed . Maximum: 12 TAB/day. Children 2-12 years: 0.5 -1 TAB 4 hourly or once when needed.Maximum: 6 TAB/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V no relevant animal data,MicroMedex: 1) U.S. Food and Drug Administration's Pregnancy Category: Category C (All Trimesters) a) Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus. 2) Australian Drug Evaluation Committee's (ADEC) Category: B2 a) Drugs which have been taken by only a limited number of pregnant women and women of childbearing age¡A without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking¡A but available data show no evidence of an increased occurrence of fetal damage. 3) Crosses Placenta: Unknown 4) Clinical Management a) There has not been sufficient clinical experience to establish the safety of hyoscyamine in general during pregnancy¡A and no published reports of its use in pregnancy have been located. If possible¡A the use of hyoscyamine in pregnancy should be avoided.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) No reports describing the use of hyoscyamine during human lactation are available and the effects on the nursing infant from exposure to the drug in milk are unknown. Hyoscyamine is excreted into breast milk in trace amounts [35]. It is not known if hyoscyamine affects the quantity and composition of breastmilk. Until more data is available¡A use caution when considering the use of hyoscyamine in lactating women.,AC;P;P1;P2;P3;P4;PC;PO;,,,,,
ORIB,Amisulpride,Ribelite 200mg,CNEU,Treatment of psychoses¡A particularly acute or chronic schizophrenic disorders¡A characterized by +ve symptoms (e.g. delirium¡A hallucinations¡A thought disorders) &/or -ve symptoms (eg blunted emotions¡A emotional & social withdrawal)¡A including when the -ve symptoms predominate.,Known or suspected pheochromocytoma carriers. Children < 15 years. Lactation. Known or suspected prolactin-dependent tumour¡A eg prolactin-secreting pituitary adenoma & breast cancer. Severe renal insufficiency. Congenital galactosemia¡A glucose or galactose malabsorption syndrome or lactase deficiency (due to lactose content). In combination with sultopride; dopaminergic agonists except L-dopa (amantadine¡A apomorphine¡A bromocriptine¡A cabergoline¡A entacapone¡A lisuride¡A pergolide¡A piribedil¡A pramipexole¡A quinagolide¡A ropinirole¡A selegiline)¡A except in the case of patients with Parkinson's disease.,Common: Hypotension¡A Injection site pain (6%)¡A Hypokalemia (4%)¡A Prolactin level above reference range (5%)¡A Abdominal distension symptom (2%)¡A Shivering (4%) Serious: Prolonged QT interval,25¢J¥H¤U,<=400 mg daily dose¡A single intake. >400 mg¡A in 2 divided doses. Predominant negative episode 50-300 mg/day as individualized dosage. Optimum dosage: 100 mg/day. Mixed episodes with positive & negative symptoms 400-800 mg/day as individualized dosage to maintain min effective dose. Acute psychotic episodes: Initiate with maximum 400 mg/day IM¡A replaced thereafter with 400-800 mg orally¡A maximum dosage: 1200 mg. Renal insufficiency CrCl 30-60 mL/min: reduce dose to 1/2. CrCl 10-30 mL/min: reduce dose to 1/3.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
EACZ,Benzoyl Peroxide,Aczo gel 50mg/gm¡A 10gm,TDER,Treatment of acne vulgaris.,Hypersensitivity.,Dry skin¡A erythema¡A skin exfoliation and burning sensation¡A pruritus¡A irritation¡A allergic contact dermatitis¡A swelling face,25¢J¥H¤U«O¦s,Acne vulgaris Adult¡A children >= 12 years old¡A initialy 1 time/day. Increased to 2-3 time/day when needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
ICOVNVV,SARS-CoV-2 Spike glycoprotein,COVID-19 Vaccine Novavax 0.5mL/dose (5mL/vial),HIMM,COVID-19 Vaccine is indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).,History of a severe allergic reaction after a previous dose or to a component of the formulation; history of immediate allergic reaction to a previous dose; known allergy to any component of the formulation.,erythema at injection site¡A pain at injection site¡A and swelling at injection site. asthenia¡A fatigue¡A fever¡A headache¡A myalgia¡A and nausea.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5 mL¡A > or = 18 years 2 doses administered > or = 3 weeks apart.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¹ïÃh¥¥¤k©Ê±µºØ Nuvaxovid ªº¸gÅç¦³­­¡C°Êª«¸ÕÅç¨Ã¥¼Åã¥Ü¹ïÃh¥¥¡B­F­L¡þ­L¨àµo¨|¡B¤À®Y©Î¥X¥Í«áµo¨|¦³ª½±µ©Î¶¡±µªº¦³®`¼vÅT¡C ¶È©ó¹ï¥ÀÅé©M­L¨àªº¼ç¦b¯q³B»·°ª©ó¼ç¦b­·ÀI®É¡A¤~À³¦Ò¼{ÅýÃh¥¥¤k©Ê±µºØ Nuvaxovid¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|¥¼ª¾ Nuvaxovid ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¤¤¡C ¹w´Á¹ï­÷¨Å·s¥Í¨à¡þÀ¦¨àµL¼vÅT¡A¦]¬°­÷¨Å¤k©Êªº Nuvaxovid ¥þ¨­©Ê¼ÉÅS¶q«Ü§C¦Ó¥i©¿²¤¡C,IM;,,,,,1.¥¼¶}«ÊÃÄ²~¡A¦b2-8¢XCÁ×¥ú¥i«O¦s6­Ó¤ë¡A25¢XC¤U¥iÃ­©w«O¦s³Ì¦h12 ¤p®É¡C¶}«Ê«áªºÃÄ²~¡A¤wÃÒ¹ê¬Ì­]ªº¤Æ¾Ç©Mª«²z¯S©Ê¦b2-25¢XC¨ã6¤p®Éªº¨Ï¥Î¦w©w©Ê¡C½Ð¤Å§N­á¡C 2.¨C¤@¾¯(0.5 ²@¤É)¤º§t 5 ·L§JSARS-CoV-2´Æ³J¥Õ¥H¤Î¦õ¾¯Matrix-M¡a§t¥ÛÆP¤ì (Quillaja saponaria Molina)¤§µÑ¨úA (42.5·L§J)©MµÑ¨úC (7.5·L§J)¡b¡C
ITRU0,Rituximab,Truxima inj 500mg/50mL (sample),RACA,The treatment of adult patients with Non-Hodgkin¡¦s Lymphoma (NHL): Relapsed or refractory¡A low-grade or follicular¡A CD20-positive B-cell NHL as a single agent; OR Previously untreated follicular¡A CD20-positive¡A B-cell NHL in combination with first-line chemotherapy and¡A in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy¡A as single-agent maintenance therapy; OR Non-progressing (including stable disease)¡A low-grade¡A CD20-positive¡A B-cell NHL as a single agent after first-line cyclophosphamide¡A vincristine¡A and prednisone (CVP) chemotherapy. Chronic lymphoid leukemia: In combination for first-line treatment; OR in combination with fludarabine and cyclophosphamide; OR maintenance¡A following rituximab-containing chemotherapy. Granulomatosis with polyangiitis or Microscopic polyangiitis: In combination with glucocorticoids,Hypersensitivity to rituximab and any excipients or proteins in this product.,Common Dermatologic: Pruritus (10% to 14% ) Gastrointestinal: Nausea (23% ) Hematologic: Anemia¡A All Grades (8% to 35% )¡A Lymphocytopenia¡A All Grades (48% ) Neurologic: Asthenia (26% )¡A Headache (19% ) Other: Fever (53% )¡A Shivering (33% ) Serious Cardiovascular: Cardiogenic shock¡A Hypotension (10% )¡A Myocardial infarction¡A Ventricular fibrillation Dermatologic: Lichen simplex chronicus¡A Pemphigus paraneoplastica¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Gastrointestinal perforation Hematologic: Anemia¡A Grade 3 or 4 (3% )¡A Leukopenia¡A Grade 3 or 4 (4% )¡A Lymphocytopenia¡A Grade 3 or 4 (40% )¡A Neutropenia¡A Grade 3 or 4 (4% to 6% )¡A Pancytopenia¡A Grade 3 or 4¡A Thrombocytopenia¡A Grade 3 or 4 (2%) Hepatic: Reactivation of hepatitis B viral hepatitis Neurologic: Progressive multifocal leukoencephalopathy Renal: Nephrotoxicity Respiratory: Bronchospasm (8% )¡A Pulmonary toxicity (18% ) Other: Angioedema (11% )¡A Infectious disease (19% to 37% )¡A Infusion reaction (Equal to or greater than 25% )¡A Tumor lysis syndrome,§NÂÃ2-8¢XC«O¦s¡C¤Á¤Å§N­á¡C,Recommended Dose for Non-Hodgkin¡¦s Lymphoma (NHL): The recommended dose is 375 mg/m2. Relapsed or Refractory¡A Low-Grade or Follicular¡A CD20-Positive¡A B-Cell NHL: Administer once weekly for 4 or 8 doses. Retreatment for Relapsed or Refractory¡A Low-Grade or Follicular¡A CD20Positive¡A B-Cell NHL: Administer once weekly for 4 doses. Previously Untreated¡A Follicular¡A CD20-Positive¡A B-Cell NHL: Administer on Day 1 of each cycle of chemotherapy¡A for up to 8 doses. In patients with complete or partial response¡A initiate TRUXIMA maintenance eight weeks following completion of a rituximab product in combination with chemotherapy. Administer TRUXIMA as a single-agent every 8 weeks for 12 doses. Non-progressing¡A Low-Grade¡A CD20-Positive¡A B-Cell NHL¡A after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy¡A administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. First Infusion: Initiate infusion at a rate of 50 mg/hour. In the absence of infusion toxicity¡A increase infusion rate by 50 mg/hr increments every 30 minutes¡A to a maximum of 400 mg/hour. Subsequent Infusions: Standard Infusion: Initiate infusion at a rate of 100 mg/hour. In the absence of infusion toxicity¡A increase rate by 100 mg/hour increments at 30-minute intervals¡A to a maximum of 400 mg/hour. Chronic lymphocytic leukemia: 375 mg/m2 on the day prior to fludarabine/cyclophosphamide in cycle 1¡A then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis or microscopic polyangiitis:Induction therapy: 375 mg/m2 once weekly for 4 doses or 1 g once every 2 weeks for 2 doses; for either dosing regimen¡A administer in combination with a systemic glucocorticoid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ] ¤wª¾§K¬Ì²y³J¥ÕIgG·|¬ï¹L­L½L«Ì»Ù¡C ¥Ø«e¨Ã¥¼´¿¦b­ì¶}µo¼tÃÄ«~¤§Á{§É¸ÕÅç¤¤¬ã¨s¹L¥ÀÅé±µÄ²¹Lrituximab¤§¤HÃþ·s¥Í¨àÅé¤ºªºB²Ó­M¿@«×¡C¥Ø«e©|µL¨¬°÷ ¥B±±¨î¨}¦nªº¥¥°ü¬ã¨s¸ê®Æ¡A¤£¹L¡A¦bÃh¥¥´Á¶¡±µÄ²¹Lrituximab¤§¥À¿Ë©Ò¥Í¤UªºÀ¦¨à¤¤¡A´¿¦³¤@¨Çµo¥Í¼È®É©ÊB²Ó­M ¯ÓºÜ¤Î²O¤Ú²y´î¤Ö¯gªº³ø§i¡C¦]¦¹¤£¥i¹ï¥¥°ü§ë¤©TRUXIMA¡A°£«D¥i¯àªº®Ä¯q¶W¹L¼ç¦bªº­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Rituximab¬O§_¤Àªc©ó¥À¨Å¤¤©|¥¼±oª¾¡CµM¦Ó¡A¬JµM¥ÀÅéªº§K¬Ì²y³J¥ÕIgG·|¶i¤J¥À¨Å¤¤¡A¤£À³µ¹¤©±Â¨Å°ü¤kTRUXIMAR¡C,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,¤£¥i¥HÀR¯ß±Àª`,¥HµLµß¾Þ§@¤è¦¡¨ú¥X©Ò»ÝÃÄ¶q¡Aª`¤J0.9% NaCl©ÎDextrose 5%¤§¿éª`²G¤¤¡Aµ}ÄÀ«á¿@«×»Ý¬°Rituximab 1-4mg/mL¡C»´»´­ËÂà¿éª`³U²V¦X·»²G¡AÁ×§K²£¥Íªwªj¡Cµ¹¤©ª`®gÃÄ«~¤§«e¡AÀ³¥ØµøÀË¬d¬O§_¦³Áû²Éª«½è¤ÎÅÜ¦â¡C,1.¤w½Õ°t¤§Truxima¿éª`²Gªºª«²z¤Î¤Æ¾ÇÃ­©w©Ê¥i¦b2 ¢XC - 8 ¢XC¤Uºû«ù24¤p®É¡AÀH«á¦b«Ç·Å¤U¡]¤£¶W¹L30 ¢XC¡^ºû«ù12¤p®É¡C 2.¥¼½Õ°t¤§TruximaÀ³§NÂÃ2-8¢XC«O¦s.¤Á¤Å§N­á. 3.ªvÀø´Á¶¡¤Î¤§«á 12 ­Ó¤ë¤º¡A¨|ÄÖ°ü¤kÀ³¨Ï¥Î¦³®ÄªºÁ×¥¥¤èªk¡C
ERELV2,Fluticasone + Vilanterol,RELVAR Ellipta 184/22mcg(¤j¾¯¶q)inhalation powder,ERSP,For asthma in aged 18 years and over.,Hypersensitivity to fluticasone¡A vilanterol¡A or any component of the formulation. Severe hypersensitivity to milk proteins. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.,Common Gastrointestinal: Difficulty talking (2% )¡A Oropharyngeal candidiasis¡A Pain¡A Oropharyngeal (2% or greater ) Immunologic: Influenza (3% or greater ) Neurologic: Headache (5% to 8% ) Respiratory: Bronchitis (2% or greater )¡A Cough (1% or greater )¡A Nasopharyngitis (9% to 10% )¡A Sinusitis (2% or greater )¡A Upper respiratory infection (2% to 7% ) Serious Cardiovascular: Cardiac dysrhythmia¡A Disorder of cardiovascular system¡A Electrocardiogram abnormal¡A Premature beats (2% or greater )¡A Supraventricular tachycardia Endocrine metabolic: Cushing's syndrome Immunologic: Anaphylaxis Musculoskeletal: Decreased bone mineral density¡A Fracture of bone (2% ) Respiratory: Death¡A Asthma-related¡A Paradoxical bronchospasm¡A Pneumonia (2% or greater ) Other: Angioedema,30¢J¥H¤U,One inhalation of Relvar Ellipta 184/22 micrograms once daily. (maximum dose: 1 inhalation/day). A starting dose of one inhalation of Relvar Ellipta 92/22 micrograms once daily should be considered for adults who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms¡A the dose can be increased to 184/22 micrograms¡A which may provide additional improvement in asthma control.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,PREGNANCY RECOMMENDATION - Fluticasone: Compatible; Vilanterol: No Data [¥é³æ]¦b¹ï¥¥°ü¨Ï¥ÎRELVAR Ellipta¡A Fluticasone¡A Vilanterol¤è­±¡A¥Ø«e¨ÃµL¨¬°÷ªº¸ê®Æ¡C¦b¹ï¥¥°ü¨Ï¥ÎRELVAR Ellipta¤è­±¦³¤@¨ÇÁ{§É¤Wªº¦Ò¶q¡C¦b¤@¶µ°Êª«¥Í´Þ¸ÕÅç¤¤¡A¹ïÃh¥¥ªº¤j¹«©ó¾¹©xµo¥Í´Á¶¡¥H§l¤J¤è¦¡³æ¿W§ë¤©©Î¦X¨Ö§ë¤©Fluticasone¤ÎVilanterol¤§«á¡A¨Ã¥¼¤Þµo¥ô¦ó­L¨àµ²ºc·î§Î¡C¦b³o¶µ¸ÕÅç¤¤©Ò¨Ï¥Î¤§Fluticasone¤ÎVilanterolªº³Ì°ª¾¯¶q¤À§O¬ù¬°200»P25mcg(¦¨¤H)¤§¤HÃþ¨C¤é³Ì°ª«ØÄ³§l¤J¾¯¶q(MRHDID)ªº5­¿»P40­¿¡C(¥H¤U²¤),Unknown ¨S¦³¸ê®Æ,BREASTFEEDING RECOMMENDATION - Fluticasone: No Human Data¡XProbably Compatible; Vilanterol: No Data. [¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©óFluticasone¤ÎVilanterol¬O§_·|½Ñ²{©ó¤HÃþªº¨Å¥Ä¤¤¡B¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅTµ¥¤è­±ªº¸ê°T¡C´¿¦b¤HÃþªº¨Å¥Ä¤¤ÀË¥X§C¿@«×ªº¨ä¥L§l¤J©Ê¥Ö½èÃþ©T¾J¡CÀ¦±NÁý­÷¥À¨Å¹ïµo¨|»P°·±dªº®ÄÀ³©M¥À¿Ë¹ïRELVAR ElliptaÁ{§É»Ý¨D¡A¥H¤ÎFluticasone¤ÎVilanterol©Î¥À¿Ëªº¼ç¦b¯e¯f¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT¤@¨Ö¦Ò¼{¡C,IH;INHL;,,,,,
OZON,Zotepine,Zonin 50mg,CNEU,Schizophrenia.,Patients with coma or circulatory collapse¡A patients on epinephrine¡A hypersensitivity to phenothiazines¡A suspected subcortical lesions (eg encephalitis¡A cerebral tumor & sequelae of brain trauma).Patients receiving central nervous system inhibitors such as Barbiturates or anesthetics (which enhance and prolong the effects of central nervous system inhibitors). Patients with Terfenadine or Astemizole (may have prolonged QT or caused ventricular arrhythmia),Sleepiness¡A weakness¡A malaise¡A insomnia¡A thirst¡A constipation¡A dizziness.,25¢J¥H¤UÀx¦s¡C,Adult 75-150 mg daily in divided doses¡A up to 450 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,(¥é³æ)¦b°Êª«¹êÅç´¿¦³·s¥Í¥J¦º¤`²v¼W¦hªº³ø§i¡A©Ò¥H¹ï¥¥°ü©Î¥i¯àÃh¥¥ªº°ü¤k¡A³Ì¦n¤£­nµ¹ÃÄ,Hold Breast Feeding ¼È°±­÷¨Å,(¥é³æ)±Â¨Å°ü³Ì¦nÁ×§K¨Ï¥Î¥»ÃÄ¡C­Y§PÂ_¥²¶·¨Ï¥Î¥»ÃÄ¡A©óªA¥Î´Á¶¡°È¥²°±¤î­÷¨Å,AC;AC15;PC;PO;WM;,,,,,
IMETE2,Methylergonovine,Methylergonovine inj 0.2mg/1mL,SGU,Prevention and treatment of uterine hemorrhage¡A promotion of uterine contraction¡A postpartum hemorrhage¡A incomplete uterine contraction¡A miscarriage.,Pregnancy¡A before fetal delivery¡A hypersensitivity to methylergonovine products¡A hypertension¡A toxemia¡A preeclampsia,Nausea¡A vomiting¡A abdominal pain¡A diarrhea¡A hypertension¡A frequent or slow pulse¡A headache¡A drowsiness¡A thirst¡A tinnitus¡A excitement¡A chest tightness.,25¢J¥H¤UÁ×¥ú,SubQ or IM injection: 0.5-1mL (0.1-0.2mg) per time; IV injection: 0.25-0.5mL (0.05-0.1mg) administer over 1 minute. (Note: IV administration should only be considered during life-threatening situations.) Postpartum hemorrhage: 0.2 mg IM after delivery of anterior shoulder¡A after delivery of placenta¡A or during puerperium; may repeat Q2-4H as needed.,µL»Ý½Õ¾ã¾¯¶q,Use caution in patients with hepatic impairment.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ] ¸T§Ò,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVPUSH;SC;,,,administer over 1 minute,,1.µo¥Í¤l®c¦¬ÁY§@¥Î®É¶¡¡G¥Ö¤U©Î¦Ù¦×ª`®g«á3-5¤ÀÄÁ¤º¡FÀR¯ßª`®g«á0.5-1¤ÀÄÁ¤º¡C 2.Slowly IV over >60 seconds with careful monitoring of blood pressure. Do not routinely administer IV because of the possibility of inducing sudden hypertension and cerebrovascular accident; only consider IV administration during life-threatening situations.
HE1807,,#9 ¦å²G³zªR²G-3.8L A²G,NUTR,,,,,,,,,,,,,,,,,,,
HE1809,,#11 ¦å²G³zªR²G-3.8L A²G,NUTR,,,,,,,,,,,,,,,,,,,
HE1810,,#13 ¦å²G³zªR²G-3.8L A²G,NUTR,,,,,,,,,,,,,,,,,,,
HE1812,Sodium bicarbonate + Sodium chloride,#300 µÇÅ¦³zªR²G-10L B±í,NUTR,,,,,,,,,,,,,,,,,,,
IFLU2,Fluorouracil,5-FU inj 1000mg/20mL,RACA,Breast cancer¡A Colon and rectal cancer¡A Gastric cancer¡A Pancreatic cancer. Off-Label: Anal carcinoma; Bladder cancer; Cervical cancer; Esophageal cancer¡A advanced; Glaucoma surgery (adjunctive therapy); Head and neck cancer; Hepatobiliary cancers (advanced).,Known hypersensitivity to fluorouracil or any component of the formulation; debilitated patients; poor nutritional state; depressed bone marrow function following radiotherapy or therapy with other antineoplastic agents; potentially serious infections.,Stomatitis¡A esophagopharyngitis¡A diarrhea¡A anorexia¡A nausea¡A vomiting¡A enteritis¡A cramps¡A abdominal pain & ulceration¡A glossitis¡A pharyngitis¡A leukopenia¡A alopecia¡A dermatitis¡A ocular irritation¡A central neurotoxicity (acute cerebellar syndrome)¡A myocardial ischemia & angina.,25¢J¥H¤UÁ×¥ú,(¥é³æ) Usual dose: 12 mg/kg IV daily for 4 days¡A if tolerated then 6 mg/kg IV daily on days 6¡A 8¡A 10¡A 12 (Maximum dose 800 mg/day). For patients with malnutrition or less severe condition¡A 6 mg/kg IV daily for 3 days; if tolerated then 3 mg/kg on days 5¡A 7 and 9 (Maximum dose 400 mg/day). Maintenance therapy: the first course every 30 days if tolerated. For intolerated patients¡A 10-15 mg/kg/week after toxic signs resulting from the initial course of therapy have subsided;Maximum dose 1 g/week. Infuse daily dose over 30-60 minutes or over 24 hours continuously.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,1. ¥»«~¬°¤ÆÀøÃÄª«¡A¿éª`®É»Ýª`·Nª`®g³¡¦ì¡A¨¾¤îÃÄ²G¥~º¯¡C 2. ºÊ´úCBC¡B¦å¿}ÅÜ¤Æ (DM¯f¤H)¡C
LLUG2,Iodine + Potassium Iodide,Lugol's soln 2%¡A 60mL (±M®×¶i¤f),META,(¥»°|®Ö­ã¥Îªk) Enhancing the detection of esophageal squamous dysplasia and early squamous cell carcinoma¡A thyrotoxic crisis/thyroid storm.,Hypersensitivity to iodine or any component of the formulation; active tuberculosis; dermatitis herpetiformis; hypocomplementemic vasculitis; nodular thyroid disease with heart disease,Tingling sensation¡A nausea¡A myxedema¡A weakness.,«Ç·Å,Enhancing the detection of esophageal squamous dysplasia and early squamous cell carcinoma acorrding to the individual needs of the patient. Thyroidectomy preparation in patients with Graves disease: Lugol's 5% solution: 5 to 7 drops (0.25 to 0.35 mL) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery¡A consider concurrent beta-blockade (eg¡A propranolol) in the immediate preoperative period to reduce the risk of thyroid storm. Thyrotoxic crisis/thyroid storm: Lugol's 5% solution: 4 to 8 drops every 6 to 8 hours; initiate therapy at least 1 hour following the initial dose of antithyroid drug therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 2nd and 3 rd trimesters,Potassium Iodine: Human Data Suggest Risk in 2nd and 3rd Trimesters,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Potassium Iodine: Limited Human Data¡XProbably Compatible,PO;,,,,,
INUC,Mepolizumab,Nucala 100mg inj,ERSP,severe refractory eosinophilic asthma,Hypersensitivity to mepolizumab or any component of the formulation,>10%: Central nervous system: Headache (19%) Local: Injection site reaction (8% to 15%) 1% to 10%: Central nervous system: Fatigue (5%) Dermatologic: Eczema (3%)¡A pruritus (3%) Gastrointestinal: Upper abdominal pain (3%) Genitourinary: Urinary tract infection (3%) Hypersensitivity: Hypersensitivity reaction (eosinophilic granulomatosis: 4%)¡A angioedema (eosinophilic granulamatosis: 1%) Immunologic: Immunogenicity (asthma: 6%¡A eosinophilic granulomatosis: <2%; neutralizing: <1%) Infection: Influenza (3%) Neuromuscular & skeletal: Back pain (5%)¡A muscle spasm (3%) Frequency not defined: Hypersensitivity: Delayed hypersensitivity Infection: Herpes zoster,2-8¢JÁ×¥úÁ×§K§N­á,Asthma: Adults and Age >12 years old: 100 mg administered by subcutaneous (SC) injection once every 4 weeks. Age 6-11 years old: 40 mg administered by subcutaneous (SC) injection once every 4 weeks. Eosinophilic granulomatosis with polyangiitis: Adults and Age >12 years old: 300 mg administered by subcutaneous (SC) injection once every 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,1.2 ²@¤ÉªºµLµßª`®g¥Î¤ô,,,,1.«ØÄ³¨Ï¥Î 1.2 ²@¤ÉªºµLµßª`®g¥Î¤ôªw»s¡A³Ì¦n¨Ï¥Î 2 ©Î 3 ²@¤Éªº°wµ©»P 21 ¸¹°wÀY¡C¤Å»P¨ä¥LÃÄª«²V¦X¨Ï¥Î¡C 2.½Ð¥HÂà°éªº¤è¦¡»´»´Âà°Ê¤p²~ª½¨ì¯»¥½·»¸Ñ¬°¤î¡C¤Å¥Î¤O®¶·nªw»sªº·»²G¡A¥i¯à·|¤Þµoªwªj©Î¨I¾ý¡C 3.ªw»s«á¦s©ñ©ó 30¢XC ¥H¤U¡A¤Å§N­á¡A 8 ¤p®É¤º¨Ï¥Î¡A§_«hÀ³¥á±ó¡C
IEPIP,Epinephrine,Epipen Auto-Injector 0.3mg,ZADT,anaphylaxis.,There are no absolute contraindications to the use of injectable epinephrine in a life-threatening situation.,Frequency not defined: Cardiovascular: Angina pectoris¡A cardiac arrhythmia¡A cardiomyopathy (stress)¡A cerebrovascular accident¡A chest pain¡A hypertension¡A increased cardiac work¡A ischemic heart disease¡A limb ischemia¡A localized blanching¡A myocardial infarction¡A palpitations¡A peripheral vasoconstriction¡A supraventricular tachycardia¡A tachyarrhythmia¡A tachycardia¡A vasoconstriction¡A ventricular arrhythmia¡A ventricular ectopy¡A ventricular fibrillation Central nervous system: Anxiety¡A apprehension¡A cerebral hemorrhage¡A disorientation¡A dizziness¡A drowsiness¡A exacerbation of Parkinson disease¡A headache¡A memory impairment¡A panic¡A paresthesia¡A psychomotor agitation¡A restlessness¡A tingling sensation Dermatologic: Diaphoresis¡A gangrene of skin or other tissue (at injection site)¡A pallor¡A piloerection Endocrine & metabolic: Hyperglycemia¡A hypoglycemia¡A hypokalemia¡A insulin resistance¡A lactic acidosis Gastrointestinal: Nausea¡A vomiting Local: Tissue necrosis at injection site Neuromuscular & skeletal: Asthenia¡A tremor Renal: Renal insufficiency Respiratory: Dyspnea¡A pulmonary edema¡A rales,15-30¢JÁ×¥ú¡A25¢J³Ì¨Î,Epinephrine auto-injector 0.3 mg for patients weighing > 30 kg. Usual dose: 0.3 mg; pediatric dose: 0.01 mg/kg. IM into the anterolateral aspect of the thigh¡A through clothing if necessary; may repeat every 5-15 minutes or sooner if patient does not adequately respond to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;,,,,,1. ¥²­n®É¥i¥H¹jµÛ¦çª«¬I¥´ 2. ¦p»Ý­n²Ä¤G¦¸¾¯¶q®É¤£­nª`®g¦b¦P¤@³¡¦ì 3. ¤£¥i¬I¥´©óÁv³¡¡A¤â¡A¸}¡A«üÀY
OINH1,Isoniazid,Isoniazide 100mg,QANB,Treatment of susceptible active tuberculosis (eg¡A Mycobacterium tuberculosis) infections.,¡EAcute liver disease. ¡EHistory of severe adverse reactions to isoniazid such as drug fever¡A chills¡A or arthritis. ¡EHistory of isoniazid associated hepatic injury or drug induced liver injury. ¡ESevere hypersensitivity to isoniazid.,Common ¡EHepatic: Increased liver enzymes (10% to 20% ) ¡ENeurologic: Neuropathy¡A Neurotoxicity Serious ¡EDermatologic: Rash ¡EHematologic: Agranulocytosis¡A Anemia¡A Thrombocytopenia ¡EHepatic: Hepatitis (Severe)¡A Hepatotoxicity¡A Injury of liver ¡EImmunologic: Systemic lupus erythematosus ¡EMusculoskeletal: Rhabdomyolysis ¡ENeurologic: Seizure,25¢J¥H¤U,(¥é³æ) Adult: 50-200 mg/day in 3-5 divided doses after meals. (UpToDate) DOT = directly observed therapy. Adult: Once-daily therapy: 5 mg/kg/dose (usual dose: 300 mg) once daily; Three-times-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered 3 times weekly; Twice-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered twice weekly; Once-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered once weekly.Pediatrc: Once daily therapy: children < 15 years¡A weighing < or = 40 kg: 10-15 mg/kg/dose once daily (maximum 300 mg/dose); children < 15 years weighing > 40 kg or children > or = 15 years: 5 mg/kg/dose once daily; typical dose: 300 mg/dose.,»Ý½Õ¾ã¾¯¶q,Advanced disease or AST greater than 3 times ULN and not due to TB: Isoniazid-based regimens are preferred if possible; expert consultation and dosage adjustments may be necessary. If isoniazid cannot be used¡A consider treatment regimens with fewer potentially hepatotoxic drugs.,µL»Ý½Õ¾ã¾¯¶q,,Compatible ¡V maternal benefit >> embryo-fetal risk,PREGNANCY RECOMMENDATION: Compatible¡XMaternal Benefit >> Embryo¡VFetal Risk,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PC;PO;,,,,,
OTET2,Tetracycline,Tetracycline 250mg,QANB,Chronic bronchitis. Brucellosis¡A chlamydia¡A mycoplasma and rikettsia.,Hypersensitivity to any of the tetracyclines or any component of the formulation.,GI upset. Rarely¡A hypersensitivity reactions¡A hepatotoxicity¡A blood disorders.,½Ð«O¦s©ó°®Àê³±²D³B(15-30¢J),(¥é³æ) Adults: 250-500 mg orally Q6H. (¼ö¯f) Pediatric: age > 8 years: 25-50 mg/kg/day orally¡A divided Q6H,»Ý½Õ¾ã¾¯¶q,Max: 1 g daily.,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated ¡V 2nd and 3 rd trimesters,,Compatible ­÷¨Å®É¥i¨Ï¥Î,UpToDate: Tetracycline is excreted into breast milk .,AC;AC15;PC;PO;WM;,,,,,
ESYMR,Budesonide + Formoterol,(¼QÃú)Symbicort Rapihaler 160/4.5mcg/dose,ERSP,Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting £]2-agonist) is appropriate. Symptomatic treatment of severe COPD & history of repeated exacerbation symptoms despite regular therapy with long-acting bronchodilators.,Hypersensitivity to budesonide¡A formoterol¡A or any component of the formulation.,Palpitation¡A oral candidiasis¡A headache¡A tremor¡A mild throat irritation¡A cough¡A hoarseness.,30¢J¥H¤U¥B§l¼L´Â¤U,Adolescents 12 to 17 years: Symbicort Rapihaler 160/4.5: 2 inhalations once to twice daily. During worsening of asthma the dose may temporarily (1 week maximum.) be increased to a maximum of 4 inhalations twice daily. Adults (18 years and older): Symbicort Rapihaler 160/4.5: 2 inhalations once or twice daily. In some cases up to a maximum of 4 inhalations twice daily may be required as maintenance dose or temporarily during worsening of asthma. Chronic Obstructive Pulmonary Disease (COPD): Adults (18 years and older): Symbicort Rapihaler 160/4.5: 2 inhalations twice daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,BUDESONIDE: Compatible (Inhaled/Nasal) No Human Data¡XAnimal Data Suggest Risk (Oral) FORMOTEROL: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BUDESONIDE: Limited Human Data¡XProbably Compatible FORMOTEROL: No Human Data¡XProbably Compatible,IH;,,,,,
ITEC,Atezolizumab,Tecentriq inj 1200mg/20mL,RACA,Locally advanced or metastatic urothelial carcinoma (UC) after prior chemotherapy¡A or for those considered cisplatin ineligible & whose tumours have a PD-L1 expression ?5%¡A or those not eligible for any platinum-containing chemotherapy regardless of tumor PD-L1 expression level. 1st-line treatment in combination w/ bevacizumab¡A paclitaxel & carboplatin for metastatic non-squamous non-small cell lung cancer (NSCLC) w/ no EGFR or ALK genomic tumor aberrations. Locally advanced or metastatic NSCLC after prior chemotherapy. Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in combination w/ nab-paclitaxel¡A for those whose tumors have PD-L1 expression ?1% & who have not received prior chemotherapy for metastatic disease.,Hypersensitivity.,Common: Hypertension (17-43%)¡A Alopecia (32-48%)¡A Rash (0.6-75%)¡A Constipation (12-36%)¡A Decrease in appetite (15-30%)¡A Diarrhea (11-43%)¡A Nausea (12-50%)¡A Arthralgia (11-26%)¡A Asthenia (25-51%)¡A Neuropathy (33-56%)¡A Urinary tract infectious disease (<10%)¡A Cough (Up to 27%)¡A Dyspnea (Up to 33%)¡A Fatigue (14-61%) Serious: Myocarditis¡A Pericarditis¡A Vasculitis¡A Erythroderma¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Adrenal insufficiency (0.4-1.2%)¡A Hyperthyroidism (0.8-18%)¡A Hypoparathyroidism¡A Hypophysitis (<0.1%)¡A Hypothyroidism (4.9-26%)¡A Thyroiditis (0.2-1.2%)¡A Type 1 diabetes mellitus (0.3%)¡A Abdominal pain (12-25%)¡A Colitis (1%)¡A Duodenitis¡A Gastritis¡A Pancreatitis (<10%)¡A Aplastic anemia¡A Hemolytic anemia (Rare)¡A Hemophagocytic lymphohistiocytosis¡A Histiocytic necrotizing lymphadenitis¡A Immune thrombocytopenia¡A Hepatitis (1.8-6.1%)¡A Veno-occlusive disease of the liver¡A Drug reaction with eosinophilia and systemic symptoms¡A Graft versus host disease¡A Sarcoidosis¡A Systemic inflammatory response syndrome¡A Transplanted organ rejection¡A Arthritis¡A Eaton-Lambert syndrome¡A Myasthenia gravis¡A Myositis¡A Polymyalgia rheumatica¡A Polymyositis¡A Rhabdomyolysis¡A Cerebral infarction¡A Demyelination of spinal cord¡A Encephalitis¡A Guillain-Barre syndrome¡A Meningitis¡A Myelitis¡A Iritis¡A Myasthenia gravis¡A ocular¡A Uveitis (<10%)¡A Visual impairment¡A Vogt-Koyanagi-Harada disease¡A Acute renal failure (2.2%)¡A Nephritis (Up to 1.3%)¡A Chronic obstructive pulmonary disease¡A Pneumonitis (3-13%)¡A Cancer (2.2%)¡A Disorder characterized by fever¡A steroid-requiring¡A Fever (14-49%)¡A Infectious disease¡A Inflammatory disease of mucous membrane¡A Infusion reaction (1.3-11%)¡A Sepsis¡A Sepsis due to Staphylococcus¡A Septic shock,2-8¢JÁ×¥úÁ×§K§N­á,840 mg IV every 2 weeks or 1200 mg IV every 3 weeks¡A or 1680 mg IV every 4 weeks infused over 60 minutes; if the first infusion is tolerated¡A all subsequent infusions may be delivered over 30 minutes.  [Non-squamous NSCLC] In combination with bevacizumab¡A paclitaxel¡A & carboplatin: 1200 mg by IV infusion¡A followed by bevacizumab¡A paclitaxel¡A & then carboplatin every 3 weeks for 4 or 6 cycles during induction phase¡A then¡A followed by maintenance phase without chemotherapy and bevazicumab¡A in which 840 mg IV every 2 weeks or 1200 mg IV every 3 weeks¡A or 1680 mg IV every 4 weeks.  [Triple-negative breast cancer] In combination with nab-paclitaxel: 840 mg by IV infusion¡A followed by 100 mg/m2 nab-paclitaxel. For each 28-day cycle Tecentriq is administered on days 1 & 15¡A & nab-paclitaxel is administered on days 1¡A 8 & 15.  [Small cell lung cancer¡A SCLC] 1200 mg by IV infusion¡A followed by carboplatin AUC 5 mg/mL/min IV on day 1 and etoposide 100 mg/m2 IV on days 1 through 3 of each 21-day cycle for maximum of 4 cycles.  [Liver carcinoma] 1200 mg by IV infusion¡A followed by 15mg/kg bevacizumab every 3 weeks; continue until disease progression or unacceptable toxicity.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ] ®Ú¾Ú¨ä§@¥Î¾÷Âà¡AÃh¥¥¤k©Ê­Y±µ¨üTecentriqªvÀø¥i¯à¾É­P­L¨à¶Ë®`¡C¥Ø«e¨S¦³Ãh¥¥¤k©Ê¨Ï¥ÎTecentriqªº¸ê®Æ¡C °Êª«¸ÕÅç¤wÅã¥Ü¡A§í¨îPD-L1/PD-1³~®|·|¼W¥[µo¨|­L¨àªº§K¬Ì¬ÛÃö±Æ¥¸­·ÀI¡A¦Ó³y¦¨­L¨à¦º¤`¡CÀ³±NÃÄª«¹ï­L¨àªº¼ç¦b­·ÀI§iª¾¨ã¦³¥Í¨|¯à¤Oªº¤k©Ê¯f¤H¡C §iª¾¨ã¦³¥Í¨|¯à¤Oªº¤k©Ê©óTecentriqªvÀø´Á¶¡¥H¤Î³Ì«á¤@¾¯«á¦Ü¤Ö5­Ó¤ë¤º¡AÀ³±Ä¨ú¦³®ÄªºÁ×¥¥±¹¬I¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ] ¥Ø«e¥¼¦³atezolizumab¶i¤J¤HÅé¨Å¥Ä¡B¹ï©ó­÷¨ÅÀ¦¨à©Î¨Å¥Ä¥Í¦¨¼vÅT¤§¸ê®Æ¡C¥Ñ©ó¤HÃþ§K¬Ì²y³J¥ÕG (IgG)·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡AÃÄª«§l¦¬»P¹ïÀ¦¨à¥i¯àªº¶Ë®`¤£©ú¡C ¥Ñ©óTecentriq¥i¯à¹ï­÷¨ÅÀ¦¨à³y¦¨ÄY­«¤£¨}¤ÏÀ³¡AÀ³§iª¾¤k©Ê¦bªvÀø´Á¶¡»P³Ì«á¤@¾¯«á¦Ü¤Ö5­Ó¤ë¤º¤£±o­÷¨Å¡C,IVD;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,µ¹ÃÄ¡G²Ä¤@¦¸¥H60¤ÀÄÁ³z¹L¸Ë©Î¤£¸Ë¦³µLµß¡B«D­P¼ö­ì©Ê(non-pyrogenic)¡B§C³J¥Õµ²¦X©ÊªººÞ½u¤º¸m«¬¹LÂo¾¹(¤Õ®|¤Ø¤o¬°0.2¦Ü0.22·L¦Ì)ÀR¯ßµ¹¤©¡C­Y¯f¤H¥i­@¨ü¥i¥H30¤ÀÄÁ¶i¦æ¿éª`¡C½Ð¤Å¸g¥Ñ¬Û¦PªºÀR¯ßºÞ½u¦P®Éµ¹¤©¨ä¥LÃÄª«¡C¤£±o¥HÀR¯ß±Àª`(push)©Î§Ö³tÄéª`(bolus)¤è¦¡µ¹¤©,1.»s³Æ¿éª`·»²G¡Gª`¤J§t¦³0.9%¬ü°êÃÄ¨å³W®æ¤§´â¤Æ¶uª`®g²Gªº250 mL»E´â¤A²m(PVC)¡B»E¤A²m(PE)©Î»E²mÖL(PO)¿éª`³U¤¤µ}ÄÀ¡C¶È¥i¨Ï¥Î0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ¡C»´»´¤ÏÂà¥H²V¦Xµ}ÄÀ·»²G¡C¤£¥i·n®Ì¡C 2.Àx¦s·»²G¡G©ó«Ç·Å¤U¡A±q»s³Æ®É°_ºâ¤£¶W¹L6¤p®É¡C³o¥]¬A«Ç·Å¤U¿éª`²G¸Ë©ó¿éª`³U ¤¤¡A¥H¤Î¿éª`µ¹ÃÄªº®É¶¡¡A©Î±q»s³Æ®É°_ºâ¡A§NÂÃ©ó2¢XC¦Ü8¢XC¤U¤£¶W¹L24¤p®É¡C
IDYS,Botulinum Toxin type A,Dysport 500 Unit/Vial,CNEU,Symptomatic relief of blepharospasm¡A hemifacial spasm and associated focal dystonias. Reduction of the signs and symptoms of spasmodic torticolis (cervical dystonia). Treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients >=2 yr.,Myasthenia gravis or Eaton Lambert syndrome¡A infection at inj site.,Localized pain¡A tenderness or bruising¡A local weakness¡A ptosis¡A vertical deviation¡A irritation or tearing. Rarely¡A skin rash (including erythema multiforme¡A urticaria and psoriasiform eruption)¡A pruritus¡A allergic reactions¡A dysphagia¡A pneumonia. Dermatologic: Injection site reaction (cervical dystonia¡A 5% to 22%; glabellar lines¡A 3%) Gastrointestinal: Xerostomia (cervical dystonia¡A 13% to 39%) Musculoskeletal: Muscle weakness (cervical dystonia¡A 11% to 56%) Neurologic: Difficulty speaking (cervical dystonia¡A 6% to 28%)¡A Headache (9% to 11%) Ophthalmic: Disorder of eye (cervical dystonia¡A 6% to 17%) Respiratory: Nasopharyngitis (glabellar lines¡A 10%),2-8¢JÁ×§K§N­á,Blepharospasm 1.25 ~ 2.5 units into the medial & lateral orbicularis oculi of the upper lid & into lateral orbicularis oculi of he lower lid. Maximum 100 units every 12 weeks. Hemifacial spasm¡A spasmodic torticolis Individulised dosage. Paediatric cerebral palsy Administer into each of 2 sites in the medial and lateral heads of the affected gastrocnemius muscle. In hemiplegia : total dose of 4 units/kg in the affected limb. In diplegia : total dose of 6 units / kg body wt divided beween the affected lims.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
OMIR3,Mirtazapine,Mirtan 30mg,CNEU,,¾AÀ³¯g: Depression. °Æ§@¥Î: Increase in appetite and wt¡A oedema; drowsiness or sedation; dizziness¡A headache¡A increased liver enzyme levels; jaundice. Orthostatic hypotension¡A rash¡A nightmares¡A agitation¡A mania¡A hallucinations¡A paraesthesia¡A convulsions¡A tremor¡A myoclonus¡A akathisia¡A restless legs syndrome¡A arthralgia¡A myalgia¡A reversible agranulocytosis¡A leucopenia¡A granulocytopenia¡A hyponatraemia. Endocrine metabolic: Increased appetite (17% )¡A Serum triglycerides raised (increases to 500 mg/dL or greater: 6% )¡A Weight gain (body weight increase of 7% or greater: adults 7.5%; pediatrics 49% ) Gastrointestinal: Constipation (13% )¡A Xerostomia (25% ) Hepatic: ALT/SGPT level raised (2% ) Neurologic: Asthenia (8% )¡A Dizziness (7% )¡A Somnolence (54% ) Psychiatric: Disturbance in thinking (3% ),,«Ç·Å,PO Initial: 15 mg/day; may increase gradually based on response. Usual range: 15-45 mg/day as 1-2 divided doses.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IXEN,Iobitridol,Xenetix inj 350mg/mL¡A 100mL,SCAN,Adults and children in a wide range of indications¡A including intravenous (IV) urography¡A head and whole body CT and intra-arterial (IA) or IV digital subtraction angiography (DSA).,Thyrotoxicosis. Hypersensitivity to Iobitridol or any components of the product.,Cardiovascular Effects: Lumbar¡A Abdominal¡A Chest or Generalized Pain (1.7%)¡A Transient Ischemic Attack¡A Ventricular Extrasystoles¡A Tachycardia¡A Hypertension And Hypotension. Dermatologic Effects: Transient Heat Sensations(35%)¡A Injection Site Pain(2%)¡A Various Skin Reactions (1%) Endocrine/metabolic Effects: Hypothermia Gastrointestinal Effects: Taste Disturbances¡A Nausea¡A Vomiting(1% or Less) Hepatic Effects: Hepatotoxicity: Temporary Impairment of Kidney Function. Immunologic Effects: Anaphylaxis¡A Hypersensitivity Reaction Neurologic Effects: Headaches(0.7%)¡A tremor¡A Neurological Complications Including Transient Confusion¡A Somnolence¡A Coma¡A Paresis¡A Convulsions And Facial Weakness Ophthalmic Effects: Visual Disturbances And Lacrimation Renal Effects: Urinary Urgency Respiratory Effects: Rhinitis¡A laryngospasm¡A pulmonary Edema(Intravascular Injection)¡A respiratory Depression(large doses).,¤£¥i°ª©ó30¢XC¡A Á×¥ú¡A,Urography mean dose: 1 mL/kg (minimum/maximum dose:50-100 mL). CT scan: Brain mean dose:1 mL/kg (minimum/maximum dose:40-100 mL); whole body mean dose: 1.8 mL/kg (minimum/maximum dose:90-180 mL). IV digital subtraction angiography mean dose: 2.1 mL/kg (minimum/maximum dose:95-250 mL). Arteriography: Peripheral mean dose: 2.2 mL/kg (minimum/maximum dose:105-205 mL); lower limbs mean dose: 1.8 mL/kg (minimum/maximum dose:80-190 mL); abdominal mean dose: 3.6 mL/kg (minimum/maximum dose:155-330 mL). Angiocardiography: Adult mean dose: 1.9 mL/kg (minimum/maximum dose:65-270 mL); Children mean dose: 4.6 mL/kg (minimum/maximum dose:10-130 mL).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]­F­L¬r©Ê °Êª«¹êÅç¨Ã¥¼Åã­P·î­L§@¥Î¡C¥Ñ©ó¹ï¤£¦P°Êª«ªº¹êÅç¨Ã¥¼Åã¥Ü­P·î­L§@¥Î¡A±À½×¦b¤HÃþ¥ç¦P¡C¦Ü¤µ·|³y¦¨¤HÃþ·î§Îªºª«½è³q±`·|¦b°õ¦æ2ºØ¦X¾A©Ê°Êª«¹êÅçÅã¥Ü­P·î­L§@¥Î¡C ­L¨à¬r©Ê ¦b¶W¹L14¶gµL¤ë¸g±¡§Î§ëÃÄ©ó¥À¿Ë·|¾É­P¼È®É©ÊºÒ¹L¶q¡A¥i¯à¤Þµo­L¨à¥Òª¬¸¢¥\¯à²§±`¡AµM¦Ó¦b¦¹§@¥Î¬°¥i°f¥B¦pªG³æ¿Wª`®g§t¸K³y¼v¾¯¹ïÃh ¥¥¥À¿ËªºÀË¬d¦³¯q¨Ã¸g¹L¤p¤ßµû¦ô«á¡A«h¥i¦b¸g¤W­z¦Ò¶q¤U§ë©ó¥¥°ü¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]§t¸K³y¼v¾¯¶È¤Ö¶q¤Àªc©ó¥À¨Å¤¤¡C³æ¿W¹ï¥À¿Ëµ¹ÃÄ«á¹ïÀ¦¨à¦³»´·Lªº­·ÀI¡A¦]¦¹«ØÄ³ª`®g§t¸K³y¼v¾¯«á°±¤î­÷¨Å24¤p®É¡C,IA;IVD;IVPUSH;,,,,,1.µLªk¹w´úªº¹L±Ó¤ÏÀ³³q±`µo¥Í©ó60¤ÀÄÁ¤º¡A¦ý¥i¯à·|©µ¿ð¦ÜÀË¬d«á7¤Ñ¤º¥X²{¡C 2.¨Ö¥ÎMetformin¯f±w«ØÄ³³y¼v«e48¤p®É°±¤îMetformin¨Ï¥Î¡A¦Ü³y¼v«á48¤p®É©ÎµÇ¥\¯à¦^´_®É¦A¶}©l¨Ï¥ÎMetformin¡C
OEVI6,Raloxifene,Evista 60mg,META,Treatment and prevention of osteoporosis in postmenopausal women.,Active or past history of venous thromboembolism (VTE)¡A including deep vein thrombosis¡A pulmonary embolism¡A and retinal vein thrombosis. Pregnancy or women who may become pregnant.,Common Endocrine metabolic: Hot sweats Musculoskeletal: Leg cramp Serious Hematologic: Deep venous thrombosis¡A Venous thromboembolism (1% ) Neurologic: Cerebrovascular accident Ophthalmic: Thrombosis of retinal vein (rare ) Respiratory: Pulmonary embolism,20-25¢JÀx¦s¡Aµu´Á¹B¿é¥i15-30¢J,60 mg tablet orally once daily.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¨xµÇ¥\¯à¤£¥þÂÔ·V¨Ï¥Î¡C,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ] EVISTA ¸T¥Î©ó¥¥°ü¡A¥B¤£¾A¥Î©ó¨ã¦³¥Í¨|¯à¤Oªº¤k©Ê¡C°ò©ó§@¥Î¾÷Âà¡AEVISTA ¥i¯àªýÂ_»Û¿E¯À¦b§³®W¤¤¦U¶¥¬qªº­«­n¥\¯à¡C EVISTA ¥Î©ó¥¥°üªº¼Æ¾Ú ¦³­­¡A©|¥¼±oª¾»PÃÄª«¬ÛÃöªº¥ý¤Ñ©Ê¯Ê³´©Î¬y²£­·ÀI¡C ¦b¨ß¤l©M¤j¹«ªº¾¹©x§Î¦¨´Á¶¡©Î¦b§³®W©M­÷¨Å´Á¶¡µ¹¤©ÃÄª«¡AEVISTA ²£¥Í¦hºØ¥Í´Þ©Mµo¨|ªº¤£¨}¤ÏÀ³¡A¥]¬A¬y²£¡B­L¨à²§±`¡B©µ¿ð©Î¤¤Â_¤À®Y¾É­P¥ÀÅé©M·s¥Í¨à¦º¤`¡A¨ä©Ò¥Îªº¾¯¶q¬Ò¤p©ó©Î»P¤HÅé³Ì¤j«ØÄ³¨Ï¥Î¾¯¶q¬Û¦ü(¥H¤HÅéªí­±¿n¬°°òÂ¦¶i¦æ¤ñ¸û)¡C,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ]EVISTA ¤£¾A¥Î©ó¨ã¦³¥Í¨|¯à¤Oªº¤k©Ê¡C ¥Ø«e©|¥¼¦³ raloxifene ¦b¤HÃþ¨Å¥Ä¤¤¡B¹ï­÷¨ÅÀ¦¨àªº¼vÅT¡B©Î¹ï¨Å¥Ä¤Àªcªº¼vÅT¤§¬ÛÃö¸ê°T¡C µM¦Ó¡A°ò©ó§@¥Î¾÷Âà¡AEVISTA ¥i¯à·| ªýÂ_»Û¿E¯À¦b­÷¨Å´Á¶¡¨Å¸¢²ÕÂ´¤¤ªº­«­n¥\¯à,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æµL¬ÛÃöµù°O¡A¸ß°Ý¼t°Ó¤£«ØÄ³¯}Ãa¾¯«¬¦]µL¬ÛÃö¸ÕÅç¥i¨Ñ°Ñ¦Ò¡C 1. µLªk¦æ¨«·|¼W¥[ÀR¯ß¦å®ê©Ê®ê¶ë¦MÀI©Ê¡AÀ³¦b¦Ü¤Ö 72 ¤p®É«e©Îªø®É¶¡µLªk¦æ¨«®É(¦p¤â³N«á«ì´_¡Bªø´Áª×§É)°±¥Î¥»ÃÄ¡C¤@ª½¨ì¯f¤H¦æ°Ê¯à¤O§¹¥þ«ì´_«á¤~¥iÄ~Äò¨Ï¥Î¡C 2. À³§iª¾ªA¥Î EVISTA ªº°ü¤k¡Aªø´Á®È¦æ¤§¶¡À³«O«ù©w´Áªº¬¡°Ê¡C
OVOC,Vonoprazan,Vocinti 20mg,ALIM,Erosive esophagitis. Gastric ulcer. Duodenal ulcer. Adjunct to Helicobacter pylori eradication.,Hypersensitivity to any component of the product. Concurrent use with atazanavir or rilpivirine.,Shock¡A anaphylaxis ( frequency unknown ) Pancytopenia¡A agranulocytosis¡A leukopenia¡A and thrombocytopenia ( frequency unknown ) Liver dysfunction: hepatotoxicity¡A jaundice ( frequency unknown ) Toxic epidermolysis: toxic epidermolysis (TEN) ¡A Stevens-Johnson syndrome¡A and erythema multiforme ( frequency unknown ) Severe colitis with bloody stool¡A such as pseudomembranous colitis¡A etc. ( frequency unknown ) The follwing data are based on the trials of vonoprazan ¡A amoxicillin and clarithromycin for gastric or duodenal ulcers. The frequencies are based on the indication for stomach ulcer¡A duodenal ulcer¡A erosive esophagitis. Gastrointestinal: Constipation¡A diarrhea¡A feeling bloated or nauseated (0.1% - < 5%) allergic reaction: rash(0.1% - < 5%) Liver: AST¡A ALT¡A ALP¡A LDH or £^-GTP increased(0.1% - < 5%) Other: Edema or eosinophilia(0.1% - < 5%) The frequencies are based on the indication for eradication of Helicobacter pylori. Gastrointestinal: diarrhea(10.6%)¡A abnormal taste¡A stomatitis¡A abdominal discomfort¡A or abdominal swelling(0.1% - < 5%) allergic reaction: rash(0.1% - < 5%) Liver: AST (GOT)¡A ALL (GPT) increased(0.1% - < 5%),30¢XC¥H¤U¡C,Erosive esophagitis: Vonoprazan 20 mg once daily¡A usually for no more than 4 weeks. Could be up to 8 weeks if needed. For maintenance therapy: 10 mg once daily¡A could be increased to 20 mg once daily if needed. The efficacy and safety data of vonoprazan in the current clinical trials are available for up to one year. Gastric ulcer¡A duodenal ulcer: In general¡A 20 mg once daily. For gastric ulcer treatment of the duration is usually no more than 8 weeks¡A and for duodenal ulcer¡A usually no more than 6 weeks. Helicobacter pylori eradication: In general¡A adults take the following 3 drugs orally twice a day: vonoprazan 20mg/time¡A amoxicillin 750mg/time and clarithromycin 200-400mg/time for 7 days. When the treatment of combination of proton pump inhibitor¡A amoxicillin and clarithromycin is fails¡A the following 3 drugs can be used as an alternative treatment: take 3 drugs orally twice a day: vonoprazan 20mg/time ¡A amoxicillin 750mg/time and metronidazole 250mg/time for 7 days.,»Ý½Õ¾ã¾¯¶q,¤¤«×©M­««×¨x¥\¯à¤£¥þªº¯f¤H¤£«ØÄ³¨Ï¥ÎºÖ¬P©w½¤¦ç¿õ20mg¨C¤Ñ2¦¸¡C©|¥¼¦b¦¹Ãþ¯f¤H±Ú¸sµû¦ôvonoprazan 20mg¨C¤Ñ2¦¸ªº¦w¥þ©Ê¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥u¦³¦b¹w´ÁªºªvÀø®Ä¯q¤j©ó¥i¯àªº­·ÀI±¡§Î¤U¡A¥»ÃÄ¤~¥i¨Ï¥Î©óÃh¥¥°ü¤k©Î¥i¯à¤wÃh¥¥ªº°ü¤k¡C °Êª«¸ÕÅç¤¤¡A·í¤j¹«ªºvonoprazanÃnÅS¶q(AUC)¤j¬ù¹F¨ì³Ì°ªÁ{§É¾¯¶q(40 mg/day)ªº28­¿¥H¤W®É¡A´¿Æ[¹î¨ì¦³­L¹«Åé­«©M­L½L­«¶q´î»´¡B¥~Æ[²§±`(¨zªù¯U¯¶©M§À¤Ú²§±`)¤Î¤ºÅ¦²§±`(½¤«¬¤ß«Ç¤¤»J¯Ê·l©MÂê°©¤U°Ê¯ß²§¦ì)ªº±¡§Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Ä~Äò©Î°±¤î­÷¨ÅÀ³¦Ò¶q¥»ÃÄ¹w´ÁªºªvÀø®Ä¯q©M­÷¨Åªº¦n³B¡C ®Ú¾Ú¤j¹«°Êª«¸ÕÅçªº³ø§i¡Avonoprazan·|¶i¤J¥À¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ¥¼¦³ºÞÄé¿i¯»¬ÛÃöµù°O¡A¸g¸ß°Ý¼t°Ó¤£«ØÄ³ºÞÄé¿i¯»¡A¦]¥¼¦³¬ÛÃö¸ÕÅç¡C(2022/10/11)
OBET2,Mirabegron,Betmiga 25mg prolonged-release,SGU,Treatment of overactive bladder with symptoms of urinary frequency¡A urgency¡A or urge urinary incontinence,Hypersensitivity to mirabegron or any component of the formulation¡A severe uncontrolled hypertension (systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg),>10%: Cardiovascular: Hypertension (9% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2%) Central nervous system: Headache (4%)¡A dizziness (3%) Gastrointestinal: Constipation (2% to 3%)¡A xerostomia (3%)¡A diarrhea (2%) Genitourinary: Urinary tract infection (3% to 6%)¡A cystitis (2%) Neuromuscular & skeletal: Back pain (3%)¡A arthralgia (2%) Respiratory: Nasopharyngitis (4%)¡A sinusitis (3%) Miscellaneous: Flu-like syndrome (3%) <1% (Limited to important or life-threatening): ALT/AST increased¡A atrial fibrillation¡A breast cancer¡A cerebrovascular accident¡A GGT increased¡A glaucoma¡A LDH increased¡A leukocytoclastic vasculitis¡A lung cancer¡A nephrolithiasis¡A osteoarthritis¡A palpitations¡A prostate cancer¡A Stevens-Johnson syndrome¡A urinary retention¡A vaginal infection¡A vulvovaginal pruritus,30¢J¥H¤U,25-50 mg once daily. May be taken with or without food. Swallow whole¡A do not chew/divide/crush.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ¯f±w(Child-pugh B):¨C¤é¾¯¶q¤£¥i¶W¹L 25mg ¤@¤Ñ¤@¦¸ ­««×¨x¥\¯à¤£¥þ¯f±w¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IVIS,Verteporfin,Visudyne inj 15mg/vial,TOPH,Subfoveal choroidal neovascularization: Treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration¡A pathologic myopia¡A or presumed ocular histoplasmosis.,Known hypersensitivity to verteporfin or any component of the formulation; porphyria,>10%: Local: Injection site reactions (including injection site discoloration¡A edema¡A extravasation¡A hemorrhage¡A inflammation¡A pain¡A and rash) Ocular: Blurred vision¡A flashes of light¡A visual acuity decreased¡A visual field defects (including scotoma) 1% to 10%: Cardiovascular: Atrial fibrillation¡A hypertension¡A peripheral vascular disorder¡A varicose veins Central nervous system: Fever¡A hypoesthesia¡A sleep disturbance¡A vertigo Dermatologic: Eczema¡A photosensitivity Gastrointestinal: Constipation¡A gastrointestinal cancers¡A nausea Genitourinary: Prostatic disorder Hematologic: Anemia¡A leukocytosis¡A leukopenia Hepatic: Liver function tests increased Neuromuscular & skeletal: Arthralgia¡A arthrosis¡A back pain (primarily during infusion)¡A myasthenia¡A weakness Ocular: Diplopia¡A lacrimation disorder Treatment site: Blepharitis¡A cataracts¡A conjunctivitis/conjunctival injection¡A dry eyes¡A ocular itching¡A severe vision loss with or without subretinal/retinal or vitreous hemorrhage (decrease in 4 lines or more within 7 days of treatment [1% to 5%]) Otic: Hearing loss Renal: Albuminuria¡A creatinine increased Respiratory: Cough¡A pharyngitis¡A pneumonia Miscellaneous: Flu-like syndrome,25¢J¥H¤U,Adult: 6 mg/m2 by infusion over 10 min¡A followed by activation using a laser tuned to a wavelength of 689 nm 15 min after the start of the infusion. Recommended light dose is 50J/cm2¡A given over 83 sec. Repeat every 3 months for recurrent choroidal neovascular leakage.,µL»Ý½Õ¾ã¾¯¶q,±w¦³¤¤«×©ÎÄY­«¨x¥\¯à·l¶Ë©ÎÁx¹Dªý¶ëªº¯f¤HÀ³¤p¤ß¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,(UptoDate)Verteporfin and its metabolite are excreted in breast milk. Milk concentrations were up to 66% of plasma levels in 1 woman following infusion; the metabolite was still detected 48 hours later. Due to the potential for serious adverse reactions in the nursing infant¡A the manufacturer recommends that nursing be discontinued or treatment be postponed¡A taking into account the importance of treatment to the mother.,IVD;,,¡iD5W¡j¥i¿ï ¡C,,«ØÄ³¥H10¤ÀÄÁ½wºCºwª`. «ØÄ³¨Ï¥Î¤Õ®|¤£¤p©ó1.2£gm¹LÂo¾¹ªº¿éª`ºÞ½u.,1.¤£¥i¥Î¥Í²z­¹ÆQ¤ô¡A·|¨I¾ý¡C 2.¥H7mL"µLµßª`®g¥Î¤ô"¥[¤J¤p²~¤¤¡A¦¹®É¿@«×¬°2mg/mLªº7.5mL·»²G¡A·»²G§e¤£³z©ú·tºñ¦â·»²G¡C 3.¥»«~·»¸Ñµ}ÄÀ«á¶·¥ß§Y¨Ï¥Î¡A­­³æ¦¸¨Ï¥Î¡C(25¢J¤U¡A4­Ó¤p®É¤º¤Æ¾Çª«²z¦w©w) 4.©â¥X©Ò»Ý¾¯¶q¡A¦A¥HD5Wµ}ÄÀ¦¨30mL¿éª`²G¡A¿éª`10¤ÀÄÁ¡C 5.«ØÄ³¨Ï¥ÎÁ{§É¸ÕÅç¨Ï¥Îªº§t¤Õ®|¤£¤p©ó1.2£gm¹LÂo¾¹ªº¿éª`ºÞ½u¡C 6.ª`®g®ÉÀ³¹w¨¾º¯º|¡C­Yµo¥Íº¯º|¡AÀ³¥ß§Y°±¤î¿éª`¡A«OÅ@¸Ó³¡¦ìÁ×§K±j¥úª½®gª½¨ì¸~µÈ¤Î¥Ö½§ÅÜ¦âªº±¡§Î®ø¥¢¡A§N¼Å¥i´î»´¯gª¬¡C 7.­YÃÄ«~°t»s®É¼âÅx¥X¡A¶·¥HÀã¥¬À¿«ø¡CÁ×§K»P²´·ú¤Î¥Ö½§±µÄ²¡C
IXYL1E,Lidocaine + Epinephrine,Xylocaine 1% + E inj 20mL,ZANE,,Local anesthesia.,,RT,Infiltration¡A caudal¡A epidural or peripheral nerve block: As needed¡A up to 50 ml.,,,,°£«DªvÀø¤W»Ý­n,,,,,,,,,,
HE1813,Sodium bicarbonate + Sodium chloride,#300 µÇÅ¦³zªR²G¯»¾¯B¯»,NUTR,,,,Á×¥ú¡B«Ç·Å¶J¦s¡A½Ð¤Å§N­á¡C,¡e¨Ï¥Î¶·ª¾] 1.µÇÅ¦³zªR¯»¤T¡³¡³¸¹(¤A)¥[¯Â¤ô©ÎR.O.¤ô²V¦X«á¤§¿@ÁY²G¡A¥Î©ó³zªR®É¥²»Ý¬°¦P¤@¤Ñ²V¦Xªº¡C¿@ÁY²G»Ý¥H±K³¬®e¾¹¸Ë¦n¡A¥H¾¨¶q´î¤ÖCO¡A¶h¥X·l¥¢¤Î¨H¾ýµo¥Í¡C 2.¦s©ñµÇÅ¦³zªR¯»¤TÆâÆâ¸¹(¤A)¿@ÁY²G¤§®e¾¹À³¬°³Ì¤p®e¿n¬°10¤É¤§¼e¤f®e¾¹¡A¥B¦b9.2¤É³B­n¦³¨è«×¼Ð¥Ü¡A²V¦X®É¥H²Å¦X¦å²G³zªR¤ô½è¼Ð·Ç¤§¯Â¤ô©ÎR.O.¤ô¥[¦Ü¼Ð¥Ü¶q9.2¤É³B(¤ô·Å¦b25¢J~30¢J¶¡)¡A±µµÛ±N1³UµÇÅ¦³zªR¯»¤TÆâÆâ¸¹(¤A)¯»¥½¥[¤J«á®}®}ÅÍ©Õ¦Ü§¹¥þ·»¸Ñ¡A¼á²M¬°¤î¡C¦¹®É¿@ÁY²G¥þ¶q¬°9.5¤É¡C 3.ÅÍ©Õ®É½Ð¤Å¨Ï¥Î¹q¤lÅÍ©Õ¾¹©Î¨ä¥L·|³y¦¨ÃÄ²G·¸¥X©ÎCO¡A¶h¥Xªº¼@¯PÅÍ©Õ¤è¦¡¡C 4.µÇÅ¦³zªR¯»¤TÆâÆâ¸¹(¤A)¿@ÁY²G¨Ï¥Î®É°t¦X¡§«HªF¡¨¦å²G³zªR²GGA¨t¦C¤§A²G¡AR.O.¤ô¨Ï¥Î¡C³zªR®É½Ð¿í·Ó¤H¤uµÇÅ¦¾÷¾Þ§@»¡©ú¡B¾Þ§@¤èªk¶i¦æ³zªR¡A³zªR²G¬°:acid concentrate: bicarbonate concentrate : purified water=1:1.83:34 ¡e¥Îªk¤Î¥Î¶q¡f 1.¥»¯»¾¯(B¥½)¨Ï¥Î®É¡A¶·¥ý¨Ì¨Ï¥Î»¡©ú°t¦¨·»²G-B²G¡A°t¦X¡§«HªF¡¨¦å²G³zªR²GGA¨t¦C¤§A²G¨Ï¥Î¡C 2.A²G:B²G:R.O.¤ô=1:1.83:34,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,,,,,,
OUROS,Sodium Pentosan Polysulfate,Urosan 100mg,SGU,Relieve bladder pain or discomfort caused by interstitial cystitis.,Hypersensitivity to pentosan polysulfate sodium¡A any structurally related compound¡A or excipients.,Common: Alopecia (4%)¡A Rash (3%)¡A Abdominal pain (2%)¡A Diarrhea (4%)¡A Indigestion (Up to 2%)¡A Nausea (4%)¡A Liver enzymes level above reference range (Up to 1.2%)¡A Dizziness (1%)¡A Headache (3%) Serious: Proctitis¡A Rectal hemorrhage (6.3%)¡A Hemorrhage¡A Thrombocytopenia (Up to 1%)¡A Retinal disorder¡A Pigmentary changes,30¢X C ¥H¤U,Usual dosage (16 years or older): 300 mg¡A administered as 100 mg orally three times a day taken either 1 hour before or 2 hours after meals. At least 3 months of therapy should be given before patient reassessment; if no benefit is noted at 3 months¡A an additional 3 months of therapy is warranted¡A provided the patient has exhibited no limiting adverse reactions. The efficacy and safety of continued treatment beyond 6 months in patients with lack of improvement in pain is not known.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] pentosan polysulfate sodium¦b¨xÅ¦©MµÊÅ¦¶i¦æ¥h²¸¤Æ§@¥Î¡C¦ý¬O¨x¥\¯à¤£¥þ©ÎµÊÅ¦²§±`¥i¯à³y¦¨­ì§ÎÃÄª«©Î¬¡©Ê¥NÁÂª«¤§¥ÍÅé¥i¥Î²v¼W¥[ªºµ{«×¥¼ª¾¡A¦]¦¹¤W­z¯f±w¨Ï¥ÎUrosan»Ý¤p¤ß¡C,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¦bÃh¥¥°ü¤k¤è­±©|¥¼¶i¦æ¾A¦X¥B¨}¦n±±¨îªº¸ÕÅç¡C ¦]¬°°Êª«¸ÕÅçµ²ªG¨ÃµLªk¹w´ú¨ì¦b¤HÅéªº¤ÏÀ³¡A¦¹ÃÄ¥u¦³¦b½T¹ê»Ý­n®É¤~¥i¥Î©óÃh¥¥°ü¤k¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¦¹ÃÄ¬O§_·|¤Àªc¦Ü¤H¨Å¤¤¨Ã¥¼ª¾¡C¦]¬°³\¦hÃÄª«·|¤Àªc¦Ü¤H¨Å¤¤¡A ·í­÷¨Å°ü¤kªA¥ÎUrosan®É¡A­n¤p¤ßÂÔ·V¡C,AC;PO;,,,,,
IVIM,Lacosamide,Vimpat °w¾¯ 200mg/20mL,CNEU,1. Monotherapy for localized seizures with or without secondary generalized seizures in patients aged four and above who have experienced either their first or multiple seizures. 2. Adjunctive therapy for the following conditions: (1) Patients aged four and above with complex partial seizures and simple or complex partial seizures with secondary generalization¡A with or without other seizure types. (2) Patients aged four and above with primary generalized tonic-clonic seizures (PGTCS) and idiopathic generalized epilepsy.,Allergic to the main ingredients or any excipients. second-or third-degree AV block.,Common: Nausea (Up to 24%)¡A Dizziness (Oral¡A 16-30% ; IV¡A 20-60%)¡A Headache (11-16%)¡A Diplopia (9-11%) Serious: Atrial fibrillation and flutter¡A First degree atrioventricular block¡A Asymptomatic (0.4%)¡A Prolonged PR interval¡A Drug reaction with eosinophilia and systemic symptoms¡A Suicidal behavior¡A Suicidal thoughts,20-25¢J,Adults (17 years and older): Monotherapy: Initial Dosage: 100 mg twice daily (200 mg per day) Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: 150 mg to 200 mg twice daily (300 mg to 400 mg per day). Adults (17 years and older): Adjunctive Therapy: Initial Dosage: 50 mg twice daily (100 mg per day) Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: 100 mg to 200 mg twice daily (200 mg to 400 mg per day). Adults (17 years and older): Alternate Initial Dosage: 200 mg single loading dose¡A followed 12 hours later by 100 mg twice daily. Pediatric patients weighing 50 kg or more: Initial Dosage: 50 mg twice daily (100 mg per day). Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: Monotherapy: 150 mg to 200 mg twice daily (300 mg to 400 mg per day). Adjunctive Therapy: 100 mg to 200 mg twice daily (200 mg to 400 mg per day). Maximum recommended dose: 400 mg per day.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]°w¹ï»´«×©Î¤¤«×¨x¥\¯à¤£¥þ¯f¤H¡A«ØÄ³´î¤Ö³Ì¤j¾¯¶qªº 25%¡C¨x¥\¯à¤£¥þ¯f¤HÀ³ÂÔ·V¶i¦æ¾¯¶q½Õ¾ã¡CLacosamide ¤£«ØÄ³¥Î©ó­««×¨x¥\¯à¤£¥þªº¯f¤H¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¹ï©ó©Ò¦³ªº§ÜÅöíwÃÄª«¡A¥Î©óªvÀøÃh¥¥°ü¤k«á¡A Åã¥Ü¨ä·s¥Í¨àµo¥Í·î«¬ªº²±¦æ²v¬O¤@¯ë±Ú¸s²±¦æ²v(¬ù¬°3%)ªº 2 ¨ì 3 ­¿¡C ¨Ï¥Î§ÜÅöíwÃÄª«ªvÀøªºÃh¥¥°ü¤k¤¤¡Aµo²{¨ä¤¤±µ¨ü¦h­«ÅöíwÃÄª«ªvÀø«á¡A±N¼W¥[¨ä·s¥Í¨à·î«¬ªº¤ñ¨Ò¡C ¦ý¬O¥Ø«e©|¥¼Âç²MÃÄª«ªvÀø©M/©Î¯e¯f¹ï©ó­P·îµ{«×¤§¼vÅT¦óªÌ¬°¬Æ¡C ¦¹¥~¡A¦³®Äªº§ÜÅöíwªvÀø¤£¥i¤¤Â_¡A¦]¬°¯e¯fªº´c¤Æ±N¤£§Q©ó¥À¿Ë¤Î­L¨à¡C ¨Ï¥Î Lacosamide ¤§¬ÛÃö­·ÀI: ¨S¦³¥¥°ü¨Ï¥Î Lacosamide ªº¨¬°÷¼Æ¾Ú¡C ¦b°Êª«¬ã¨s¤¤¡A¤j¹«©Î¨ß¤l¥¼Åã¥Ü¥ô¦ó­P·î­L§@¥Î ¡A¦ý¦bÆ[¹î¨ì¥ÀÅé¬r©Ê¾¯¶q¤U¡A¹ï©ó¤j¹«©M¨ß¤l¨ã­F­L¬r©Ê¡C ¹ï¤HÃþ¼ç¦bªº­·ÀI¥¼ª¾¡CLacosamide ¤£À³¸Ó¦bÃh¥¥´Á¶¡¨Ï¥Î¡A°£«D©ú½T»Ý­n¡]¦p¹ï¥À¿Ëªº¯q³B©úÅã¤j©ó¹ï­L¨à¼ç¦bªº­·ÀI¡^¡C ¦pªG°ü¤k¨M©wÃh¥¥¡A¨Ï¥Î¥»²£«~À³¥J²Ó­«·sµû¦ô¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Lacosamide ·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤¡A ¦]¦¹À³¦Ò¼{ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡A¨Ó¨M©w¬O§_°±¤î­÷¨Å©Î°±¤î¨Ï¥ÎLacosamide ¡C,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,may infuse over 15 minutes,Lacosamide injection may be administered without further dilution or mixed with NS¡A D5W¡A or LR. Preferably infuse over a period of 30 to 60 minutes; may infuse over 15 minutes if needed.,Preparation: If diluted prior to infusion¡A store at room temperature and administer within 4 hours of dilution.
OCAND8,Candesartan,Candis 8mg,CAVS,,¾AÀ³¯g: Heart failure¡A (NYHA class II to IV¡A ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations. Hypertension. °Æ§@¥Î: Common Cardiovascular: Hypotension (18.8% ) Musculoskeletal: Backache (3% .) Neurologic: Dizziness (less than 5% ) Respiratory: Pharyngitis (2% )¡A Rhinitis (2% )¡A Upper respiratory infection (6% ) ¸T§Ò: Concomitant use with aliskiren in diabetic or renal impairment patients. Hypersensitivity to candesartan. Severe hepatic impairment &/or cholestasis. Lactating women and pregnant women.,,Äá¤ó25«×C¥H¤U,The recommended initial dose and maintenance dose is 8 mg¡A which could be increased to 16 mg. If poor control after four weeks with 16 mg once a day¡A the maximum dose can be increased to 32 mg once a day.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¹ï»´«×¨ì¤¤«×¨x¥\¯à¤£¥þªÌ¡A«ØÄ³¨äªì¾¯¶q¥Ñ2mg¶}©l¡A¤@¤Ñ¤@¦¸¡A¦A¨Ì¨äÁ{§É¤ÏÀ³¨Ó½Õ¾ã¾¯¶q¡C¹ï­««×¨x¥\¯à¤£¥þªÌ¡A¨ÃµLÁ{§É¨Ï¥Î¸gÅç¡C [Micromedex.20201123]Hepatic impairment¡A adult (moderate) in hypertension: Initiate therapy with 8 mg; Hepatic impairment (severe): No specific recommendations are available.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ]¤£«ØÄ³¨Ï¥Î©óªì´Á§³®W¡C¸T¥Î©óÃh¥¥²Ä¤G´Á¤Î²Ä¤T´Á¡C¬y¦æ¯f¾Ç¸ê®Æ©|¥¼¯àÃÒ¹êÃh¥¥ªì´Á¼ÉÅS©óACEI¥i¯à¼W¥[·î­Lªº­·ÀI¡F ¦ýµLªk±Æ°£¦³»´·L´£¤Éªº¥i¯à¡CÁö¥¼¦³angiotensin ¢º±µ¨üÅé«ú§Ü¾¯¦b¬y¦æ¯f¾Çªº¸ê®Æ¡A ¦ý¦]ÄÝ¦PÃþ²£«~¡A¤´¦³¬Û¦Pªº­·ÀI¡C°£«DÄ~Äò¨Ï¥Îangiotensin ¢º±µ¨üÅé«ú§Ü¾¯¬O¥²­nªº¡C §_«h·í¯f¤H¦³­pµe­nÃh¥¥¡A´NÀ³§ï¦¨¨ä¥L¹ï©ó¨Ï¥Î¦bÃh¥¥¯f¤H¨­¤W¦³¦w¥þÀø®Äªº­°¦åÀ£ÃÄ«~¡C ¤@¥¹¶EÂ_Ãh¥¥¡A«hÀ³¥ß§Y°±¤î¨Ï¥Îangiotensin ¢º±µ¨üÅé«ú§Ü¾¯¨Ã¶}©l¨Ï¥Î¨ä¥L¦X¾AªºªvÀø¤è¦¡¡C ¤wª¾­YÃh¥¥²Ä¤G¤Î²Ä¤T´Á¶¡¼ÉÅS¦bangiotensin ¢º±µ¨üÅé«ú§Ü¾¯ªvÀø±N¾É­P·î­L¡C ( µÇ¥\¯à­°§C¡B¦Ï¤ô¹L¤Ö¡BÆ`°©µo¨|¿ðº¢ ) ¤Î­L¨à¬r¦å¯g ( µÇ°IºÜ¡B§C¦åÀ£¡B°ª¦å¹[ ) ·íµo¥Íangiotensin ¢º±µ¨üÅé«ú§Ü¾¯¨Ï¥Î©óÃh¥¥²Ä¤G´Á¡A«ØÄ³¨Ï¥Î¶W­µªi½T»{µÇ¥\¯à¤ÎÆ`³¡¡C ÄY±KÆ[¹î¥À¿Ë¨Ï¥Î¤Fangiotensin ¢º±µ¨üÅé«ú§Ü¾¯ªºÀ¦¨à´Á§C¦åÀ£±¡§Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨Ã¥¼½Tª¾ Candesartan ¬O§_·|¥Ñ¤HÃþ¨Å¥Ä¤¤±Æ¥X¡A ¦ý¤wª¾ Candesartan ·|¥Ñ¤j¥Õ¹«¨Å¥Ä¤¤±Æ¥X¡C ¦]¬°¹ï­÷¨Åªº·s¥Í¨à¨ã¦³¼ç¦bªº¤£¨}¤ÏÀ³¡A ¥²¶·ªA¥Î Candesartan®ÉÀ³°±¤î­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
IVAN1,Vancomycin,Vanlyo inj 1gm,QANB,,¾AÀ³¯g: Caused by Staphylococcal infection: endocarditis¡A osteomyelitis¡A pneumonia¡A sepsis¡A soft tissue infection¡A and enteritis. Pseudomembranous colitis caused by clostridium infection. °Æ§@¥Î: Common Endocrine metabolic: Hypokalemia (13% ) Gastrointestinal: Abdominal pain (15% )¡A Diarrhea (9% )¡A Nausea (17% )¡A Vomiting ( 9% ) Serious Cardiovascular: Cardiac arrest¡A Hypotension Gastrointestinal: Clostridium difficile diarrhea Hematologic: Agranulocytosis¡A Neutropenia¡A Thrombocytopenia Immunologic: Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms Otic: Ototoxicity Renal: Nephrotoxicity (5% ) ¸T§Ò: Allergy to corn or corn products; premixed solution for IV use contains dextrose. Hypersensitivity to vancomycin.,,30¢J¥H¤UÀx¦s,Adult: 2 g/day IV divided every 6 to 12 hours administered over at least 60 minutes. Children: 40 mg/kg/day IV administered over at least 60 minutes. Neonates 2 to 4 weeks: Initial¡A 15 mg/kg IV¡A followed by 10 mg/kg IV every 8 hours; Neonates up to 1 week: Initial¡A 15 mg/kg IV¡A followed by 10 mg/kg IV every 12 hours. *****NEONATE ANTIBIOTICS DOSE***** Vancomycin: Dilute to a final concentration <=5 mg/mL; IV infusion over 90 minutes Draw trough level within 30 mins before the fourth dose. peak level 60 mins after end of infusion Sepsis PMA <=29 week Postnatal 0-14 days¡A dose: 10mg/kg Q18H PMA <=29 week Postnatal >=15 days¡A dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days¡A dose: 10mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days¡A dose: 10mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days¡A dose 10mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days¡A dose 10mg/kg Q8H PMA >=45 week: 10mg/kg Q6H Meningitis PMA<=29 week Postnatal 0-14 days dose: 15mg/kg Q18H PMA <=29 week Postnatal >=15 days¡A dose: : 15mg/kg Q12H PMA 30 to 36 week Postnatal 0-14 days¡A dose: 15mg/kg Q12H PMA 30 to 36 week Postnatal >=15 days¡A dose: 15mg/kg Q8H PMA 37 to 44 week Postnatal 0-7 days¡A dose: 15mg/kg Q12H PMA 37 to 44 week Postnatal>= 8 days¡A dose: 15mg/kg Q8H PMA >=45 week: 15mg/kg Q6H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¥¼¦³¬ÛÃö»¡©ú.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼¦³¬ÛÃö»¡©ú.,IMP;INS;IRR;IVD;IVI;SUBCI;,IVD: 20 mL µLµßª`®g¥Î¤ô,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,µ¹ÃÄ¿@«× 2.5~5mg/mL¡A¿éª`³t²v< 10 mg/min¡A¦Ü¤Ö¥H¶W¹L60¤ÀÄÁ¥H¤W®É¶¡½wºCºwª`¡C¹ï¬Y¨Ç²GÅé»Ý­n­­¨îªº¯f±w¡A¥i¥H±N¿@«×´£°ª¦Ü10mg/mL¡C,[¥é³æ]Vancomycin ¯»¥½1g ²~¸Ë¤º¥[¤J 20ml µLµßª`®g¥Î¤ô¡C»Ý­nµ}ÄÀ¤~¯à¨Ï¥Î¡C°t¦n¤§²G¥i¶J¦s©ó¦B½c¤¤ 96 ¤p®É¡A¥B®Ä¤O¨S¦³©úÅãªº´î°h¡C°t¦n»s¾¯ 1g ¥[¤J 200ml ¥H¤Wªºµ}ÄÀ²Gµ}ÄÀ¡A¨Ì¦¹¾¯¶qµ}ÄÀ¡A¥B¶W¹L 60 ¤ÀÄÁªº¶¡·²©ÊÀR¯ßª`®gµ¹ÃÄ¡C 1. ºÊ´úÅé·Å¡BCBC¡BµÇ¥\¯à¡BÅ¥Ä±¥\¯à¡C 2. ª`·N¿éª`¹L§Ö®Éªº¤£¨}¤ÏÀ³¡G§C¦åÀ£¡B©I§l§xÃø¡BëC³Â¯l¡C 3. «ØÄ³ºÊ´úÃÄª«¦å¤¤¿@«×¡C 4. µ¹ÃÄ¿@«×: 2.5~5mg/mL¡A§Q¥Î¿éª`²Gµ¹ÃÄ¡A¿@«×¤£¥i¶W¹L 5mg/mL¡C
OBISC,Bisacodyl,Bisacodyl E.C. 5mg ¯µ§Jªº¸z·»¿õ,ALIM,,¾AÀ³¯g:Treatment of constipation; colonic evacuation prior to procedures or examination. °Æ§@¥Î:Abdominal cramps (mild)¡A electrolyte disturbance (metabolic acidosis or alkalosis¡A hypocalcemia)¡A nausea¡A rectal irritation (burning)¡A vertigo¡A vomiting ¸T§Ò:Hypersensitivity to bisacodyl or any component of the formulation; abdominal pain or obstruction¡A nausea¡A or vomiting,,Äá¤ó25«×C¥H¤U,Relief of constipation: Adult or 10 years older Children¡A Oral: 5-10 mg at bedtime. 4-10 years old Children¡A Oral: 5 mg at bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]©|µL¥»ÃÄ¥Î©óÃh¥¥°ü¤kªº¾A·í¤Î±±¨î¨}¦n¤§¬ã¨s. ªø´Á¥ÎÃÄ¸gÅçÅã¥ÜÃh¥¥´Á¶¡¡A¨Ï¥Î¥»ÃÄµL¤£¨}¤ÏÀ³©Î¶Ë®`©Ê. µM¦Ó¡A¦p¦P©Ò¦³ªºÃÄª«¡AÃh¥¥´Á¶¡¡A°£«D¦³ÂåÅñ¡A§_«h¥¥°ü¤Î±Â¨ÅªÌ³£¤£¥i¨Ï¥Î.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]©|¥¼½T©wBisacodyl¬O§_¶i¤J¨Å¥Ä¤¤. µM¦Ó¡A¦p¦P©Ò¦³ªºÃÄª«¡AÃh¥¥´Á¶¡¡A°£«D¦³ÂåÅñ¡A§_«h¥¥°ü¤Î±Â¨ÅªÌ³£¤£¥i¨Ï¥Î.,AC;PC;PO;,,,,,
ICAGL,Calcium gluconate,Calcium gluconate inj 10%¡A 10mL,NUTR,,¾AÀ³¯g:Ca deficiency. °Æ§@¥Î: Cardiovascular (with rapid I.V. injection): Arrhythmia¡A bradycardia¡A cardiac arrest¡A hypotension¡A syncope¡A vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection) ¸T§Ò¡GVentricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),,«Ç·Å,Intravenous use. (4.62mEq/10mL) Adult: The usual dose in adults is 5~10 mL per time of Calcium Gluconate 10 %. Childen patients: 2~5 mL per time of Calcium Gluconate 10 %.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1.¥»«~¬°10 mL¥]¸Ë¡A¶È¨ÑTPN½Õ°t¨Ï¥Î¡C 2.adults the intravenous administration rate should not exceed 2 ml (0¡A45 mmol of calcium) per minute.
IGAR1,HPV type 6/11/16/18 L1 protein,Gardasil 0.5mL/dose(­­±M®×­û¤u¥Î),HIMM,,¾AÀ³¯g: Prevention of cervical cancer¡A genital warts & precancerous or dysplastic lesions eg¡A cervical adenocarcinoma in situ¡A cervical intraepithelial neoplasia (CIN) grades 2 & 3¡A vulvar intraepithelial neoplasia (VIN) grades 2 & 3¡A vag intraepithelial neoplasia grades 2 & 3 (VaIN)¡A cervical intraepithelial neoplasia grade 1 in girls & women 9-26 yr. °Æ§@¥Î: Injection site reactions¡A fever¡A nausea¡A dizziness. ¸T§Ò: Hypersensitivity.,,2-8¢J,0.5 mL IM in the deltoid region of the upper arm or in the higher anterolateral area of the thigh¡A according to the following schedule: 1st dose: At elected date; 2nd dose: 2 month after the 1st dose; 3rd dose: 6 month after the 1st dose.,,,,¥i¯à¦w¥þ,,,,,,,,,,
OURI2,Silodosin,Urief 4mg,SGU,,¾AÀ³¯g:Treatment of signs and symptoms of benign prostatic hyperplasia (BPH). °Æ§@¥Î:Drowsiness¡A postural hypotension¡A syncope¡A asthenia¡A depression¡A headache¡A dry mouth¡A GI disturbances¡A edema¡A blurred vision¡A rhinitis¡A erectile disorders¡A tachycardia¡A palpitation¡A hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy. ¸T§Ò:Severe hepatic impairment; severe renal insufficiency.,,«Ç·Å,Oral: 4 mg bid after meal.,µL»Ý½Õ¾ã¾¯¶q,»´«×¤Î¤¤«×¨x¥\¯à»ÙÃªªÌ(Child-Pugh score= 7~9)µL¶·½Õ¾ã¾¯¶q ÄY­«¨x¥\¯à»ÙÃªªÌ(Child-Pugh score¡Ù10)ªºÁ{§É¬ã¨s¥¼°õ¦æ¡A¦]¦¹¥»«~¸T¥Î©óÄY­«¨x¥\¯à»ÙÃªªÌ,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,
EFOX5,Fluorometholone,0.1% FOXONE oph susp 5mL,TOPH,,¾AÀ³¯g: Acute & chronic iritis¡A iridocyclitis¡A scleritis¡A episcleritis¡A conjunctivitis¡A keratitis¡A resistant ocular allergy & inflammation following surgery °Æ§@¥Î: Glaucoma with optic nerve damage¡A visual acuity or field defects¡A raised intraocular pressure¡A secondary infection (persistent corneal ulceration¡A possibly fungal invasion)¡A perforation of globe¡A posterior subcapsular cataract formation ¸T§Ò: Acute superficial herpes simplex keratitis¡A fungal diseases of ocular structure; vaccinia¡A varicella & other viral diseases of the cornea & conjunctiva¡A eye TB,,«Ç·Å,Instill 1-2 drops bid-qid,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
OTRCT,Tramadol + Acetaminophen,Traceton 37.5/325mg,CNEU,Pain¡A acute (Moderate to Severe)¡A Not responsive to non-narcotic analgesics.,Previous hypersensitivity to tramadol¡A acetaminophen¡A any other component of the product¡A or opioids. Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days. Significant respiratory depression. In the event of acute intoxication with alcohol¡A sleep aids¡A narcotics¡A centrally acting analgesics¡A opiates or psychotropic drugs.,Common Dermatologic: Diaphoresis (1% to 4% )¡A Pruritus (1% to 2% ) Gastrointestinal: Constipation (1% to 6% )¡A Diarrhea (1% to 3% )¡A Loss of appetite (1% to 3% )¡A Nausea (1% to 3% )¡A Xerostomia (1% to 2% ) Neurologic: Dizziness (1% to 3% )¡A Insomnia (2% )¡A Somnolence (1% to 6% ) Serious Dermatologic: Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Hepatic: Hepatotoxicity Immunologic: Anaphylaxis Neurologic: Seizure (less than 1% ) Other: Serotonin syndrome,25¢J¥H¤UÀx¦s,Adult and children > 16 years: 1-2 tablets Q4H-Q6H¡A the maximum dose: 8 tablets/day.,»Ý½Õ¾ã¾¯¶q,¤£«ØÄ³¥Î©óÄY­«¨x¥\¯à¤£¥þªº¯f¤H,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,ACETAMINOPHEN: Human Data Suggest Low Risk TRAMADOL: Human Data Suggest Risk [¥é³æ]¤wÃÒ©úTramadol·|¬ï¹L­L½L¡C¥¼¹ïÃh¥¥°ü¤k§@¹L¥R¥÷¥B§¹µ½¹ï·Óªº¬ã¨s¡CÃh¥¥´Á¶¡ªº¨Ï¥Î¦w¥þ©Ê©|¥¼½T©w¡C¦bÃh¥¥´Á¶¡©µªø¨Ï¥Î¥»«~©Î¨ä¥L¾~¤ùÃþÃÄª«¡A¥i¯à¾É­P·s¥Í¨à¾~¤ùÃþÃÄª«§ÙÂ_¯gª¬¡C¯S§O¦bÃh¥¥ªº³Ì«á¤T­Ó¤ë®É·|¼W¥[¦¹­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,ACETAMINOPHEN: Compatible TRAMADOL: Limited Human Data¡XPotential Toxicity [¥é³æ]¦]¥¼´¿¬ã¨s¥»«~¥Î©óÀ¦¨à¤Î·s¥Í¨àªº¦w¥þ©Ê¡A¬G¤£«ØÄ³­÷¨Åªº¥À¿Ë¨Ï¥Î¥»«~¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
EKARY,Pirfenoxone,Kary Uni 0.005%¡A 5mL ophthalmic suspension,TOPH,Incipient senile cataract.,Hypersensitivity to any component of this product.,Blepharitis¡A contact dermatitis¡A itching¡A keratitis superficialis diffusa¡A conjunctival irritation.,1-30¢J,Shake the bottle well¡A and apply 1-2 drops at a time¡A 3-5 times a day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,OD;OL;OU;,,,,,
LSOR,Dextromethorphan+Guaiacol Glycolate+Ipecac extract,®§«y²GSortuss Cough liquid 60mL,ERSP,Cough¡A expectorant,Hypersensitivity to any any excipients.,Common Neurologic: Dizziness (mild)¡A Somnolence (mild)¡A Lethargy Other: Fatigue (mild) Gastrointestinal: Diarrhea¡A Stomach cramps¡A Nausea¡A Vomiting Musculoskeletal: Myalgia¡A Chronic use Serious Renal: Nephrolithiasis¡A Large quantity consumption Cardiovascular: Cardiomyopathy¡A Chronic use,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Adults:10-20 mL Q4H. Pediatric: 6-12 yrs: 6-10 mL Q4H¡A 2-6 yrs: 2-6 mL Q4H.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Dextromethorphan: Compatible. Guaiacol Glycolate: ¨S¦³¸ê®Æ Ipecac Fluid Extract: ¨S¦³¸ê®Æ [¥é³æ] ¨S¦³¬ÛÃö±Ô­z¡C,Unknown ¨S¦³¸ê®Æ,Dextromethorphan: Compatible. Guaiacol Glycolate: ¨S¦³¸ê®Æ Ipecac Fluid Extract: ¨S¦³¸ê®Æ [¥é³æ] ¨S¦³¬ÛÃö±Ô­z¡C,AC;AC15;PC;PO;WM;,,,,,
IMER75,FSH 75 IU + LH 75 IU,Meriofert inj 75/75 IU,HM,Promote ovulation in women who are not ovulating and who have not responded to other treatments.,Hypersensitivity to Meriofert or any component of the formulation; primary ovarian failure as indicated by a high follicle-stimulating hormone level; uncontrolled nongonadal endocrinopathies (eg¡A thyroid¡A adrenal¡A pituitary); pituitary or hypothalamic tumors; sex hormone-dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement not due to polycystic ovary syndrome; pregnancy and lactation. Meriofert is contraindicated when an effective response cannot be achieved¡A for example¡A Primary ovarian failure¡A Malformations of sexual organs incompatible with pregnancy¡A and Fibroid tumors of the uterus incompatible with pregnancy.,Common(1-10%): Ovarian Hyperstimulation Syndrome (symptoms include ovarian cyst formation or enlargement of existing cysts¡A lower stomach pain¡A feeling thirsty and sick¡A and sometimes being sick¡A passing reduced quantities of concentrated urine and weight gain). The following side effects have also been reported: Very Common (likely to affect up to 10%): Headache¡A Swollen or bloated stomach. Common (likely to affect between 1-10%): Abdominal pain or discomfort¡A Pelvic pain¡A Back pain¡A Sensation of heaviness¡A Breast discomfort¡A Dizziness¡A Hot flushes¡A Thirst¡A Feeling sick¡A Tiredness¡A Feeling generally unwell¡A Injection site reactions such as pain and inflammation (frequency higher with IM than SC). Rare (likely to affect up to 0.01-0.1%): Ovarian torsion. Very rare (likely to affect up to 0.001-0.01%): Thromboembolism.,·Å«×¤£¥i¶W¹L25¢JÁ×¥úÀx¦s,Each vial of powder contains highly purified menotrophin (human menopausal gonadotrophin¡A HMG) corresponding to 75 IU human follicle stimulating hormone (FSH) and 75 IU human luteinising hormone (LH) activity. A commonly used regimen starts at 75 to 150 IU of FSH per day and is increased if necessary by 37.5 IU (up to 75 IU)¡A with intervals of 7 or 14 days preferably¡A in order to achieve an adequate but not excessive response. Maximum daily dosages of HMG Meriofert should generally not exceed 225 IU. The treatment should be adjusted to the individual patient's response¡A assessed by measuring the follicle size by ultrasonography and/or oestrogen levels. The daily dose is then maintained until pre-ovulatory conditions are reached. Usually¡A 7 to 14 days of treatment is sufficient to reach this state.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ®Ú¾Ú¤HÅé©Î°Êª«¹êÅçÃÒ¹ê¡A·|¹ï­L¨à¦³¦MÀI©Ê¡C ¦]¦¹¦b§Q¹ú¬Û¸û¤§¤U¡A»PÃh¥¥°ü¤kª`®g¥»ÃÄ«~(HMG)¬O¤Ó¦MÀIªº¡C ¦]¦¹Ãh¥¥°ü¤k¸T¥Î¦¹ÃÄ¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¦Ü©óHMG¬O§_·|º¯³z©ó¥À¨Å¤¤¥H¤Î¹ï§l­¹¥À¨ÅÀ¦¨àªº¼vÅT¡A¬O¥¼ª¾ªº¡C ¦]¦¹¡A±Â¨Å°ü¤k¸T¥Î¦¹ÃÄ¡C,IM;SC;,,,,,1. ²V¦X«áªºMeriofert·»²G¥²¶·¥ß¨è¨Ï¥Î¡C
EGLIC,Povidone Iodine + Iodine,Glycerinum Iodi Compositum 450gm/bottle,TENT,As an antiseptic agent for laryngitis¡A tonsillitis.,Hypersensitivity to iodine or any component of the formulation exists.,Dermatologic: Localized erythema¡A severe dermatological reaction (localized; rare). Hypersensitivity: Local hypersensitivity reaction. Local: Application site pain (persistent or increases)¡A local irritation¡A local swelling.,30¢J¥H¤U¶J¦s,Antiseptic¡A Topical: Apply to the affected area 1 to 3 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¦³¤U¦C±¡§ÎªÌ¡A¨Ï¥Î«e½Ð¥ý¿Ô¸ßÂå®vÃÄ®vÃÄ¾¯¥Í¡G¨àµ£¡B¥¥°ü¡B¥i¯àÃh¥¥°ü¤k¤Î­÷¨Å°ü¤k¡C ¥»ÃÄ¥i¯à¥þ¨­©Ê§l¦¬¡A¤ÏÂÐ¨Ï¥Î¥i¯à·|³y¦¨·s¥Í¨à¥Òª¬¸¢¥\¯à§C¤U¡B¥¥°ü¤Î¨ä­L¨à¤Î­÷¨Å°ü¤k¥Òª¬¸¢¸~¤Î¥Òª¬¸¢¥\¯à§C¤U¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¦³¤U¦C±¡§ÎªÌ¡A¨Ï¥Î«e½Ð¥ý¿Ô¸ßÂå®vÃÄ®vÃÄ¾¯¥Í¡G¨àµ£¡B¥¥°ü¡B¥i¯àÃh¥¥°ü¤k¤Î­÷¨Å°ü¤k¡C ¥»ÃÄ¥i¯à¥þ¨­©Ê§l¦¬¡A¤ÏÂÐ¨Ï¥Î¥i¯à·|³y¦¨·s¥Í¨à¥Òª¬¸¢¥\¯à§C¤U¡B¥¥°ü¤Î¨ä­L¨à¤Î­÷¨Å°ü¤k¥Òª¬¸¢¸~¤Î¥Òª¬¸¢¥\¯à§C¤U¡C,EXT;,,,,,¥»«~¦³®Ä¦¨¤À¤Î§t¶q¡G¨C1000gm§t¦³ Iodine 10gm + Potassium Iodine 20gm
IAMII,Amino Acids,Aminosteril infant 6% 100mL,NUTR,Partial parenteral nutrition in premature infants¡A babies and small children.,Disturbances in amino acid metabolism¡A acidosis¡A hyperhydration¡A hypokalemia. Insufficient renal or hepatic function. Hyponatremia.,Fluid¡A electrolyte imbalance,25¢J¥H¤U,As TPN material. Age of 1 year: 1.5 ¡V 2.5 g amino acids/kg body weight/day. Age of 2-5 years: 1.5 g amino acids/kg body weight/day. Age of 6-14 years: 1.0 g amino acids/kg body weight/day. Maximum infusion rate: 0.1 g amino acids /kg body weight/hr = 1.67 mL/kg body weight/hr.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,IVD: Maximum infusion rate = 1.67 mL/kg/hour (¥é³æ),
IDTAP,Diphtheria + Tetanus + Pertussis,SK-DPT3(¤T¦X¤@¬Ì­]¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,,¾AÀ³¯g:Diphtheria¡A tetanus¡A and pertussis disease prevention °Æ§@¥Î: Central nervous system: Drowsiness¡A irritability¡A lethargy Gastrointestinal: Decreased appetite¡A vomiting Local: Erythema at injection site¡A local pain¡A localized edema¡A tenderness at injection site Miscellaneous: Crying (prolonged or persistent)¡A fever¡A fussiness ¸T§Ò:Hypersensitivity to diphtheria¡A tetanus toxoids¡A pertussis¡A or any component of the formulation; progressive neurologic disorder¡A including infantile spasms¡A uncontrolled epilepsy or progressive epilepsy (postpone until condition stabilized); encephalopathy occurring within 7 days of administration and not attributable to another cause,,§NÂÃ (2-8 C),0.5 mL per dose. Given at 5 to 6 years of age¡A prior to starting school or kindergarten; 0.5 mL IM as a single dose.,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IPV,Inactivated poliovirus vaccine,Imovax Polio(¤p¨à³Â·ô¬Ì­]¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,,¾AÀ³¯g:Poliovirus prevention °Æ§@¥Î: Percentages noted with concomitant administration of DTP or DTaP vaccine and observed within 48 hours of injection. >10%: Central nervous system: Irritability (7% to 65%; most common in infants 2 months of age)¡A tiredness (4% to 61%) Gastrointestinal: Anorexia (1% to 17%) Local: Injection Site: Tenderness (?29%)¡A swelling (?11%) 1% to 10%: Central nervous system: Fever >39¢XC (?4%) Gastrointestinal: Vomiting (1% to 3%) Local: Injection site: Erythema (?3%) Miscellaneous: Persistent crying (?1% reported within 72 hours) ¸T§Ò:Hypersensitivity to any component of the vaccine,,§NÂÃ (2-8 C),Immunization: IM¡A SubQ: Primary immunization: Infants and Children 6 weeks to 47 months: Administer three 0.5 mL doses¡A at 2¡A 4¡A and 6 to 18 months,,,,¨S¦³¸ê®Æ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Ãh¥¥¤Î­÷¨Å¤À¯Å°Ñ¦ÒUpToDate.,,,,,,
ICIM,Certolizumab pegol,Cimzia inj 200mg/1mL,HIMM,Ankylosing spondylitis¡A Active. Crohn's disease¡A Active¡A moderate to severe. Non-radiographic axial spondyloarthritis. Plaque psoriasis¡A Moderate to severe. Psoriatic arthritis¡A Active. Rheumatoid arthritis¡A Active¡A moderate to severe.,Hypersensitivity to certolizumab pegol or any component of the product. Severe infections or Moderate to severe heart failure.,Common ¡EMusculoskeletal: Arthralgia (6%) ¡ERenal: Urinary tract infectious disease (7%) ¡ERespiratory: Upper respiratory infection (19.4% to 21.9%) Serious ¡ECardiovascular: Cardiac dysrhythmia¡A Congestive heart failure¡A Hypertensive heart disease¡A Myocardial infarction¡A Pericardial effusion¡A Pericarditis ¡EDermatologic: Erythema multiforme¡A Erythema nodosum¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Urticaria ¡EGastrointestinal: Bowel obstruction ¡EHematologic: Cytopenia ¡EImmunologic: Hypersensitivity reaction (Rare )¡A Lupus erythematosus (Rare )¡A Malignant lymphoma¡A Opportunistic infection ¡ENeurologic: Demyelinating disease of central nervous system (rare )¡A Seizure ¡EPsychiatric: At risk for suicide ¡ERenal: Nephrotic syndrome¡A Renal failure ¡EOther: Cancer¡A Infectious disease¡A Listeriosis,2-8¢XC§NÂÃ¡A¤£¥i§N­á,SC¡A Ankylosing spondylitis¡A non-radiographic axial spondyloarthritis¡A plaque psoriasis¡A psoriatic arthritis¡A rheumatoid arthritis 400 mg once and then repeat at weeks 2 and 4; maintenance¡A 200 mg every 2 weeks or 400 mg once every 4 weeks. Crohn's disease 400 mg (as 2 injections of 200 mg) once and then repeat at weeks 2 and 4; maintenance ¡A 400 mg once every 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,SC;,,,,,1.¥H¥Ö¤Uª`®g¤è¦¡µ¹ÃÄ¡Cª`®g³¡¦ì¥²¶·½ü´À¡A¥B¤£¥iª`®g©ó¥Ö½§¯Ü®z¡B·ï¦å¡Bµo¬õ©Î»øµwªº³¡¦ì¡C»Ý­nª`®g 400²@§J®É (¥Ö¤Uª`®g 200 ²@§J¨â¾¯)¡AÀ³¤À§Oª`®g©ó¤j»L©Î¸¡³¡ªº¤£¦P³¡¦ì¡C 2. 30 ¤ÀÄÁ«á¥i«ì´_«Ç·Å¡C¤£¥i¨Ï¥Î¨ä¥L¦^·Å¤è¦¡¡C­Y¦³®ðªw¬°¥¿±`²{¶H¡A¦bª`®g«e¤£»Ý²¾°£®ðªw¡C 3.¤£­n·b´|ª`®g³¡¦ì¡C
OEXV,Dasabuvir,Exviera FC 250mg,QANB,,¾AÀ³¯g:With other antivirals for the treatment of chronic hepatitis C genotype 1. °Æ§@¥Î:Insomnia¡A nausea¡A pruritus¡A asthenia¡A fatigue¡A anaemia. Reports of hepatic decompensation and hepatic failure. ¸T§Ò:Severe hepatic impairment. Pregnancy¡A lactation.,,,Treatment of chronic hepatitis C in patients with genotype 1 in combination with other drugs. 250 mg orally twice daily in the morning and evening with food in combination with other HCV drugs.,»Ý½Õ¾ã¾¯¶q,Child-Pugh A and B: No adjustment necessary;Child-Pugh C:Do not use,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
EIZB,Travoprost,Izba 0.003%¡A 2.5mL eye drops,TOPH,Reduction of intraocular pressure in patients with open-angle glaucoma or ocular HTN.,Hypersensitivity to travoprost¡A benzalkonium chloride.,Ocular hyperemia¡A decreased visual acuity¡A eye discomfort¡A itch & pain¡A blepharitis¡A blurred vision¡A conjunctivitis¡A dry eye¡A foreign body sensation¡A iris discoloration¡A keratitis¡A photophobia & tearing. Neurologic: Foreign body sensation (5%-10%) Ophthalmic: Blepharitis¡A Blurred vision¡A Itching of eye (5%-10%)¡A Ocular hyperemia (35%-50%)¡A Pain in eye¡A Reduced visual acuity,30¢J¥H¤U,Instill 1 drop in the affected eye(s) once every evening.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,OD;OL;OU;,,,,,
LLACT,Lactulose,Lactul syrup 666mg/mL¡A 300mL,ALIM,,¾AÀ³¯g: Chronic portal systemic encephalopathy¡A hepatic pre coma¡A hepatic coma °Æ§@¥Î: Flatulence¡A nausea¡A vomiting¡A abdominal pain & diarrhea occasionally with electrolyte imbalance (high doses only). ¸T§Ò: Galactosemia¡A bowel obstruction.,,«Ç·Å,1. Chronic constipation:  Starting dose(for 3 days) aintenance -------------------- ---------------------------------- --------------------- Severe cases 0-45 ml 15-25 ml Moderate cases 5-30 ml 10-15 ml Mild cases 5ml 10 ml 7-14yr 15 ml 10-15 ml 1-6yr 5-10 ml 5-10 ml Infant 1-12mth 5 ml 5 ml All doses to be taken daily preferably as single doses. 2. Precoma & hepatic coma: Starting doses: approx 30-50 ml tid. In acute cases a retention enema is given in a proportion of 300ml Duphalac to 700 ml water. Rectal administration (retention enema): 200 g (300 mL) diluted with 700 mL of water or NS via rectal balloon catheter; retain for 30-60 minutes; may repeat every 4-6 hours; transition to oral treatment prior to discontinuing rectal administration.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Excretion in breast milk unknown/use caution,,,,,,
IMEN6,FSH 600 IU + LH 600 IU,MENOPUR multidose 600 IU,HM,Treatment of infertility in anovulation¡A including polycystic ovarian disease (PCOD)¡A in women unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART)¡A gamete intra-fallopian transfer (GIFT)¡A & intracytoplasmic sperm inj (ICSI).,Hypersensitivity. Women with tumors of pituitary gland or hypothalamus; ovarian¡A uterine or mammary carcinoma; gynaecological haemorrhage of unknown aetiology; ovarian cysts or enlarged ovaries not due to polycystic ovarian disease; primary ovarian failure¡A malformation of sexual organs & fibroid tumors of the uterus incompatible with pregnancy. Pregnancy & lactation.,Abdominal pain & distention¡A nausea¡A enlarged abdomen¡A pain at inj site¡A headache¡A ovarian hyperstimulation syndrome (OHSS) & pelvic pain.,2-8¢JÁ×§K§N­á,Anovulatory infertility (including PCOD):In menstruating patients¡A treatment should be started within the first 7 days of the menstrual cycle. The recommended initial dose is 75-150 IU daily¡A which should be maintained for at least 7 days. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment¡A and should not exceed 75 IU. Maximum daily dose < 225 IU. When an optimal response is obtained¡A a single injection of 5000 - 10000 IU hCG should be given 1 day after the last MENOPUR injection .Women undergoing controlled ovarian hyperstimulation for multiple follicular development for assisted reproductive technologies (ART): MENOPUR therapy should start approximately 2 weeks after the start of agonist treatment. The recommended initial dose of MENOPUR is 150-225 IU daily for at least the first 5 days of treatment. Based on clinical monitoring (including ovarian ultrasound alone or in combination with measurement of oestradiol levels) subsequent dosing should be adjusted according to individual patient response¡A and should not exceed more than 150 IU per adjustment. The maximum daily dose given should not be higher than 450 IU daily and in most cases dosing beyond 20 days is not recommended.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in manufacturer¡¦s labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T¥Î©óÃh¥¥°ü¤k¡C¥Ø«e¨Ï¥Î©óÃh¥¥°ü¤kªº¼Æ¾Ú¤´¦³­­¡C¥Ø«e©|¥¼°õ¦æ¦bÃh¥¥´Á¶¡¤§°Êª«¹êÅçµû¦ô¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¸T¥Î©ó±Â¨Å°ü¤k¡C,IM;SC;,¨Ï¥Î¼t°Ó´£¨Ñ¤§·»¾¯·»¸Ñ,,X,X,Attach the reconstitution needle to the pre-filled syringe. Inject the total contents of the solvent into the vial containing the powder. The powder should dissolve quickly to a clear solution. If not¡A roll the vial gently between the hands until the solution is clear. Vigorous shaking should be avoided.
OPYRZ,Pyrazinamide,Pyrazinamide 500mg,QANB,Treatment of pulmonary & extrapulmonary TB.,Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage,Hepatotoxicity¡A jaundice¡A hyperuricemia leading to attacks of gout¡A anorexia¡A nausea¡A vomiting¡A arthralgia¡A malaise¡A fever¡A sideroblastic anemia¡A difficulty in micturition. Endocrine metabolic: Hyperuricemia Gastrointestinal: Nausea¡A Vomiting Musculoskeletal: Arthralgia (40%),25¢J¥H¤U,(¥é³æ) 1500-2000 mg/day (3-4 tablets) divided into 1-3 doses. (¼ö¯f) Adult: 25 mg/kg po Q24H (maximum: 2.5 g/day). Pediatric: 15-30 mg/kg/day (once daily¡A maximum: 2 g/day) or 50 mg/kg twice weekly (maximum: 2 g/day).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PO;WM;,,,,,
OAMIT,Amitriptyline,Pinsaun 25mg,CNEU,,¾AÀ³¯g: Major depressive disorder °Æ§@¥Î: Frequency not defined. Cardiovascular: Atrioventricular conduction disturbance¡A cardiac arrhythmia¡A cardiomyopathy (rare)¡A cerebrovascular accident¡A ECG changes (nonspecific)¡A edema¡A facial edema¡A heart block¡A hypertension¡A myocardial infarction¡A orthostatic hypotension¡A palpitations¡A syncope¡A tachycardia Central nervous system: Anxiety¡A ataxia¡A cognitive dysfunction¡A coma¡A confusion¡A delusions¡A disorientation¡A dizziness¡A drowsiness¡A drug withdrawal (nausea¡A headache¡A malaise¡A irritability¡A restlessness¡A dream and sleep disturbance¡A mania [rare]¡A and hypomania [rare])¡A dysarthria¡A EEG pattern changes¡A excitement¡A extrapyramidal reaction (including abnormal involuntary movements and tardive dyskinesia)¡A fatigue¡A hallucination¡A headache¡A hyperpyrexia¡A insomnia¡A lack of concentration¡A nightmares¡A numbness¡A paresthesia¡A peripheral neuropathy¡A restlessness¡A sedation¡A seizure¡A tingling of extremities Dermatologic: Allergic skin rash¡A alopecia¡A diaphoresis¡A skin photosensitivity¡A urticaria Endocrine & metabolic: Altered serum glucose¡A decreased libido¡A galactorrhea¡A gynecomastia¡A increased libido¡A SIADH¡A weight gain¡A weight loss Gastrointestinal: Ageusia¡A anorexia¡A constipation¡A diarrhea¡A melanoglossia¡A nausea¡A paralytic ileus¡A parotid gland enlargement¡A stomatitis¡A unpleasant taste¡A vomiting¡A xerostomia Genitourinary: Breast hypertrophy¡A impotence¡A testicular swelling¡A urinary frequency¡A urinary retention¡A urinary tract dilation Hematologic & oncologic: Bone marrow depression (including agranulocytosis¡A leukopenia¡A and thrombocytopenia)¡A eosinophilia¡A purpura Hepatic: Hepatic failure¡A hepatitis (rare; including altered liver function and jaundice) Hypersensitivity: Tongue edema Neuromuscular & skeletal: Lupus-like syndrome¡A tremor¡A weakness Ophthalmic: Accommodation disturbance¡A blurred vision¡A increased intraocular pressure¡A mydriasis Otic: Tinnitus Postmarketing and/or case reports: Angle-closure glaucoma¡A neuroleptic malignant syndrome (rare; Stevens¡A 2008)¡A serotonin syndrome (rare) ¸T§Ò: Hypersensitivity to amitriptyline or any component of the formulation; coadministration with or within 14 days of MAOIs; coadministration with cisapride; acute recovery phase following myocardial infarction,,25«×C¥H¤U±K«Ê«O¦s,Adult 25-50 mg bid-tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,[¥é³æ] ¥¥°ü§ë»P:¤TÀô¨t§ÜÆ{ÃÄª«¡A¸g°Êª«¹êÅç¦³¶Ê·î§Î§@¥Î,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;AM;PC;PO;WM;,,,,,
OSILY,Silymarin,Silygen 70mg(½Æ¤è),ALIM,Chronic liver diseases¡A liver cirrhosis¡A fatty liver.,Hypersensitivity to any ingredients of the capsule.,GI disturbance¡A nausea¡A vomiting¡A flatulence¡A diarrhea¡A diuresis,°®Àê¡A25¢J¥H¤U,1-2 capsules TID orally after meals. Each cap contains: Exsiccated Fructus Cardui Mariae extract 140mg (eq. to 70mg of Silymarin Calculated as Silybin) Thiamine Hydrochloride 4mg Riboflavin 4mg Pyridoxine Hydrochloride 4mg Nicotinamide 12mg Calcium Pantothenate 8mg Cyanocobalamin 1.2mcg,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;AM;PC;PO;WM;,,,,,
OCIZO,Trazodone,Cirzodone 50mg §ö½w§´¿õ,CNEU,,¾AÀ³¯g: Treatment of unipolar major depressive disorder °Æ§@¥Î: >10%: Central nervous system: Drowsiness (24% to 41%)¡A dizziness (20% to 28%)¡A headache (10% to 20%)¡A nervousness (15%)¡A fatigue (6% to 11%) Gastrointestinal: Xerostomia (15% to 34%)¡A nausea and vomiting (10% to 13%) Ophthalmic: Blurred vision (6% to 15%) 1% to 10%: Cardiovascular: Hypotension (4% to 7%)¡A syncope (3% to 5%)¡A palpitations (<2%)¡A sinus bradycardia (<2%)¡A tachycardia (<2%; may include syncope) Central nervous system: Confusion (5%)¡A ataxia (2% to 5%)¡A heavy headedness (3%)¡A malaise (3%)¡A lack of concentration (1% to 3%)¡A disorientation (2%)¡A akathisia (<2%)¡A chest pain (<2%)¡A delusions (<2%)¡A hallucination (<2%)¡A hypomania (<2%)¡A memory impairment (<2%)¡A numbness (<2%)¡A paresthesia (<2%)¡A speech disturbance (<2%) Endocrine & metabolic: Weight loss (6%)¡A weight gain (1% to 5%)¡A change in menstrual flow (<2%)¡A increased libido (<2%) Gastrointestinal: Constipation (7% to 8%)¡A gastrointestinal disease (6%)¡A diarrhea (5%)¡A flatulence (<2%)¡A increased appetite (<2%)¡A sialorrhea (<2%) Genitourinary: Early menses (<2%)¡A hematuria (<2%)¡A impotence (<2%)¡A retrograde ejaculation (<2%)¡A urinary frequency (<2%)¡A urinary hesitancy (<2%) Hematologic & oncologic: Anemia (<2%) Hypersensitivity: Angioedema (3% to 7%)¡A hypersensitivity reaction (<2%) Neuromuscular & skeletal: Myalgia (5% to 6%)¡A tremor (3% to 5%)¡A muscle twitching (<2%) Ophthalmic: Asthenopia (<=3%)¡A eye pruritus (<=3%)¡A eye redness (<=3%) Respiratory: Nasal congestion (<=6%)¡A paranasal sinus congestion (<=6%)¡A dyspnea (<2%) Frequency not defined: Cardiovascular: Hypertension¡A ventricular premature contractions Central nervous system: Suicidal ideation¡A suicidal tendencies <1%¡A postmarketing¡A and/or case reports: Abnormal dreams¡A agitation¡A alopecia¡A anxiety¡A aphasia¡A apnea¡A asthenia¡A atrial fibrillation¡A bradycardia¡A breast engorgement¡A breast hypertrophy¡A cardiac arrhythmia¡A cardiac conduction disturbance¡A cardiac failure¡A cerebrovascular accident¡A chills¡A cholestasis¡A diplopia¡A edema¡A esophageal achalasia¡A extrapyramidal reaction¡A female sexual disorder (clitorism)¡A hemolytic anemia¡A hirsutism¡A hyperbilirubinemia¡A increased amylase¡A insomnia¡A jaundice¡A lactation¡A leukocytosis¡A leukonychia¡A liver enzyme disorder¡A methemoglobinemia¡A myocardial infarction¡A orthostatic hypotension¡A paranoia¡A priapism¡A prolonged QT interval on ECG¡A pruritus¡A psoriasis¡A psychosis¡A SIADH¡A skin rash¡A stupor¡A tardive dyskinesia¡A tonic clonic epilepsy¡A torsades de pointes¡A urinary incontinence¡A urinary retention¡A urticaria¡A vasodilation¡A ventricular ectopy¡A ventricular tachycardia¡A vertigo ¸T§Ò: Hypersensitivity to trazodone or any component of the formulation; use of MAOIs intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either trazodone or the MAOI); initiation of trazodone in a patient receiving linezolid or intravenous methylene blue,,«Ç·ÅÀx¦s,150 mg daily. Dose may be gradually increased. Out-patient Max: 400 mg/day. In-patient 600 mg/day.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] °Êª«¸ÕÅçµo²{30-50­¿¤HÃþ³Ì¤j¾¯¶q·|¼W¥[­L¨à§l¦¬°Æ§@¥Î¡A ¥Î©óÃh¥¥´Á¶¡»Ýµû¦ô¼ç¦b§Q¯q»P­L¨à¼ç¦b¦MÀI.,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IBCGSII,BCG Immunotherapeutic,SII-ONCO-BCG inj 40mg/mL(±M®×¶i¤f),RACA,For treatment of flat Urothelial Cell Carcinoma in Situ of urinary bladder and as adjunctive therapy following. Transurethral resection of primary or relapsing superficial noninvasive papillary tumors that are limited to the bladder mucosa (stage Ta or T1). Intravesical BCG Immunotherapy has been shown to reduce tumor recurrence and prevent progression.,Impaired immune response irrespective of whether this impairment is congenital or caused by disease¡A drugs or other therapy. Positive HIV serology. Pregnancy and lactation; safety of the mode of therapy in pregnant women¡A nursing mothers and children has not been evaluated. Positive tuberculin reaction in conjunction with clinical evidence of existing active tuberculosis. Urinary tract infections : Treatment should be withheld till urine culture is negative and antibiotic therapy is stopped. Trauma to urinary bladder. A patient with fever needs careful evaluation before therapy is instituted. On going treatment with antitubercular agents.,Fever more than 39oC. The fever resolves within 24 ¡V 48 hours with antipyretics and fluids. Systemic BCG infections due to traumatic catheterization¡A perforation of bladder or early BCG instillation after extensive TURBT which may be manifested by pneumonitis¡A hepatitis or cytopenia. Patients with such symptoms should be treated with tuberculostatic drugs as per treatment schedules used. Triple drug therapy with or without cycloserine for some weeks should be used. Granulomatous Prostatitis. Arthritis¡A Arthralgia¡A Haematuria¡A Orchitis¡A Transient urethral obstruction¡A Epididymitis or bladder contraction may occur.,2-8¢J,Treatment should be started 2-3 weeks after performing TURBT(transurethral resection of bladder tumor). The treatment schedule is weekly repeated instillation 120 mg during first 6 weeks¡A followed by 3 consecutive weekly instillations at 3 months¡A at 6 months and thereafter every 6 months upto 36 months. This means that a patient who stays tumor free after the initial resection will receive a total of 27 instillations in a period of three years. The duration and frequency of maintenance treatment should be evaluated on the basis of tumor classification and clinical diagnosis.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Ãh¥¥¦C©ó¸T§Ò¯g¡A¦¹ªvÀø¤è¦¡¹ïÃh¥¥¤k©Ê¡B­÷¨Å°ü¤k¤Î«Äµ£ªº¦w¥þ©Ê©|¥¼³Qµû¦ô¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]­÷¨Å¦C©ó¸T§Ò¯g¡A¦¹ªvÀø¤è¦¡¹ïÃh¥¥¤k©Ê¡B­÷¨Å°ü¤k¤Î«Äµ£ªº¦w¥þ©Ê©|¥¼³Qµû¦ô¡C,IRR;,1mLµLµß¡B¤£§t¨¾»G¾¯ªº¥Í²z­¹ÆQ¤ô,,,,1.À³Á×¥úÀx¦s©ó2¢J-8¢J¡F­«·s½Õ°t«e»P­«·s½Õ°t«áªº¤º®eª«¤£¥i¼ÉÅS©ó¥ú½u¤U¡F­«·s½Õ°t«á¤§ÃÄª«À³¥ß§Y¨Ï¥Î¨Ã¥á±ó¨S¨Ï¥Îªº³¡¤À¡C 2.±wªÌ¶·¦bÄéª`4¤p®É«e¤ÎÄéª`2¤p®É«á¤£±oÄá¨ú¥ô¦ó²GÅé¡F­Y¦³¥ô¦ó¥X¦å©Î³Ð¶Ëªº¸ñ¶H¡A¶·©µ«á¦Ü¤Ö¤@­ÓÂ§«ô¦A¶i¦æªvÀø¡F«ØÄ³Äéª`«á¤@­ÓÂ§«ô¤£­n©Ê¦æ¬°¡A©ÎªÌ¨Ï¥Î«OÀI®M¡C 3.Äéª`«á6¤p®É¤º±Æ¥Xªº§¿²G»Ý¸g¾A·í¦a®ø¬r¡C(¥[¤Jµ¥¶qªºº}¥Õ¤ôÀR¸m15¤ÀÄÁ«á¨R±¼) 4.°t»s: ª`¤J1mLµLµß¡B¤£§t¨¾»G¾¯ªº¥Í²z­¹ÆQ¤ô¦Ü²~¤¤¡AÀR¸m¼Æ¤ÀÄÁ¡CµM«á»´»´±ÛÂàÃÄ²~ª½¨ì²V¦X¦¨§¡¤ÃªºÄa¯B²G¡A¡Aª`·N¤£¥i¼@¯PªºÅÍ°Ê¡C±N°t»s¦nªºÄa¯B²GÂà²¾¦Ü50mL°wµ©¸Ì¡A¦A¥Î1mL¥Í²z­¹ÆQ¤ô¨R¬~ªÅ²~¡A±N²~¾À¤W¤§´Ý¯dÃÄ¾¯¨R¬~¤U¨Ó¡A±N¨R¬~¤U¤§²GÅé¥[¨ì50mL°wµ©¸Ì¡C³Ì«á¦Aª`¤JµLµß¥Í²z­¹ÆQ¤ô©ó°wµ©¤¤¡A¨äÁ`Åé¿n¦Ü¦h50mL¡A¤p¤ß²V¤Ã«á«K¥i¨Ï¥Î¡C 5.µ¹ÃÄ: ±N¾É§¿ºÞ¥HµLµß§Þ³N³q¹L§¿¹D´¡¤J»H¯Ö¡A±ÆªÅ»H¯Öªº§¿²G¡C±N§t¦³ÃÄ«~ªº50mL°wµ©±µ¤W¾É§¿ºÞ¡A§Q¥Î­«¤OºCºCª`¤J¨ì»H¯Ö¡AÀ³ºÉ¶q°±¯dÄa¯B²G¦b»H¯Ö2¤p®É¡F¶}©lÄéª`«áªº15¤ÀÄÁ¤º±wªÌÀ³¥ýºû«ù­Áª×¤§«º¶Õ¡A¤§«á¨C15¤ÀÄÁ§ó´««º¶Õ¦b¨C¤@°¼¡A¥H¨ÏÃÄª«¯à¾A·íªº¤À¥¬¦Ü¾ã­Ó»H¯Ö¡A³Ì«á±wªÌ¶·¥H§¤«º±NÃÄª«±ÆªÅ¡C
IBEX,Meningococcal group B Vaccine,Bexsero 0.5mL/dose (B«¬¸£½¤ª¢Âù²yµß¬Ì­]),HIMM,Vaccine for 2 months older infants¡A children¡A and Adults to prevent meningococcal group B disease (also known as meningitis B) caused by Neisseria meningitidis bacteria.,Hypersensitivity¡A including severe allergic reaction¡A to any component of the vaccine¡A or after a previous dose of Bexsero. (List of excipients: Sodium chloride¡A Histidine¡A Sucrose¡A Water for injections. Kanamycin is used in early manufacturing process and is removed during the later stages of manufacture. If present¡A kanamycin levels in the final vaccine are less than 0.01 micrograms per dose. The safe use of Bexsero in kanamycin-sensitive individuals has not been established.),pain at the injection site (> or =83%)¡A myalgia (> or =48%)¡A erythema (> or =45%)¡A fatigue (> or =35%)¡A headache (> or =33%)¡A induration (> or =28%)¡A nausea (> or =18%)¡A and arthralgia (> or =13%).,2-8¢XC.¤£¥i§N­á,Adult and children > or = 2 years older: 2 doses (0.5 mL) at least 1 month apart. And necessity of booster dose is according to risk of exposure. Children 12-23 months old: 2 doses (0.5 mL) at least 2 month apart. And recommend booster 1 dose after 12-23 months. Infant 6-11 months old: 2 doses (0.5 mL) at least 2 month apart. And recommend booster 1 dose at 24 months old¡A between primary series at least 2 month apart. Infant 2-5 months old: 2 doses (0.5 mL) at least 2 month apart or 3 doses (0.5 mL) at least 1 month apart. And recommend booster 1 dose at 12-15 months old¡A between primary series at least 6 month apart. Children > or = 2 years older and Adult: 2 doses (0.5 mL) at least 1 month apart. Each 0.5-mL dose of Bexsero is formulated to contain 50 micrograms each of recombinant proteins Neisserial adhesin A (NadA)¡A Neisserial Heparin Binding Antigen (NHBA)¡A and factor H binding protein (fHbp)¡A 25 micrograms of Outer Membrane Vesicles (OMV).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¨¬°÷¥¥°ü±µºØ¥»¬Ì­]ªºÁ{§É¸ê®Æ¡C¥Ø«e¨Ã¤£½Tª¾¥¥°üªº¼ç¦b­·ÀI¡C ¤£¹L¡A·í¦³©ú½Tªº¼ÉÅS©ó¸£½¤ª¢Âù²yµß·P¬Vªº­·ÀI®É¡A§Y¤£À³°±¤î±µºØ¬Ì­]¡C ¦b¤@¶µ¹ï¥À¨ß§ë¤©¬ù¬Û·í©ó10­¿¤HÃþ¾¯¶q(¨Ì¾ÚÅé­«)¤§Bexseroªº¸ÕÅç¤¤¡A¨ÃµLÃÒ¾ÚÅã¥Ü¨ã¦³¥ÀÅé©Î­L¨à¬r©Ê¡ABexsero¤]¥¼¹ïÃh¥¥¡B¥ÀÅé¦æ¬°¡B»Û©Ê¥Í¨|¤O©Î¥X¥Í«áµo¨|³y¦¨¼vÅT¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨Ã¨S¦³¬Ì­]¹ï­÷¨Å´Á¶¡¤§°ü¤k¤Î¨ä¥®¨à¤§¦w¥þ©Ê¤è­±ªº¸ê®Æ¡C ¦b¨M©w©ó­÷¨Å´Á¶¡¬I¥´¬Ì­]¤§«e¡AÀ³¥ýµû¦ô®Ä¯q­·ÀI¤ñ²v¡C ¦b±µºØ¬Ì­]ªº¥À¨ß©Î¨ä¥J¨ß­÷¨Å¨ì²Ä29¤Ñ«á¡A¨Ã¥¼µo²{¥ô¦ó¤£¨}¤ÏÀ³¡C ¦b¶}©l­÷¨Å«e±µºØBexsero¬Ì­]ªº¥ÀÅé°Êª«¤¤¨ã¦³§K¬Ì­ì©Ê¡A¦b¤l¥N¤¤¥ç¥iÀË¥X§ÜÅé¡A¦ý¨Å¥Ä¤¤ªº§ÜÅé¿@«×©|¥¼³Q½T©w¡C,IM;,,,,,1.Äa¯B²G¦b¦s©ñ´Á¶¡¥i¯à·|§Î¦¨²Ó·Lªº¦Ç¥Õ¦â¨I¾ýª«¡C¨Ï¥Î«e½Ð¥R¤À®¶·n¨Ï§Î¦¨§¡¤ÃªºÄa¯B²G¡C 2.¬I¥´¦¹¬Ì­]«eÀ³¥ý¥ØµøÀË¬d¬O§_¦³·L²É²§ª«©MÅÜ¦âªº²{¶H¡C¦pªGµo²{¥ô¦ó¥~¨Ó·L²É²§ª«©Îª«²z©Ê½è¤è­±ªºÅÜ¤Æ¡A¤Á¤Å¬I¥´¦¹¬Ì­]¡C
OGLUC,Metformin,GlucoPHAGE 500mg (®w¾|¤Æ),META,Type 2 diabetes mellitus,Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma. Hypersensitivity to metformin. Severe renal impairment (eGFR below 30 mL/min/1.73 m(2)).,Common Endocrine metabolic: Cobalamin deficiency (7% to 17.4% ) Gastrointestinal: Diarrhea (53% (immediate-release) ; 10% to 13% (extended-release) )¡A Flatulence (12% )¡A Indigestion (7% )¡A Malabsorption syndrome (Up to 9.9% )¡A Nausea (7% (extended-release) )¡A Vomiting (Up to 25.5% ) Neurologic: Asthenia (9% )¡A Headache (6% ) Serious Endocrine metabolic: Lactic acidosis Hepatic: Hepatitis,25¢J¥H¤U,According to the individual needs of the patient¡A maximum 3000 mg/day.Contrast media¡A history of liver disease¡A alcoholism¡A or heart failure¡A patient receiving intraarterial administration of iodinated contrast: Discontinue at time of or before procedure; evaluate eGFR 48 hours after imaging procedure; restart if renal function stable.,µL»Ý½Õ¾ã¾¯¶q,Hepatic impairment: Avoid use[Micromedex 20201006],»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,[¥é³æ]Ãh¥¥´Á¶¡¦å¿}¥¼Àò±±¨î¡A©M¥X²{°ª¾÷²vªº¥ý¤Ñ©Ê¦Ù§Î©M¦º­L¬O¦³ÃöÁpªº. ¦³Ãö¥¥°ü¨Ï¥ÎMetforminÁ{§É¸ê®Æ«D±`¦³­­¡A¦ý¸Ó¸ê®Æ¨Ã¥¼Åã¥Ü¦³­L¨à¥ý¤Ñ©Ê²§±`¤è­±ªº°ª¦MÀI©Ê. °Êª«¬ã¨s¥¼Åã¥Ü¹ïÃh¥¥¡A­F­L©Î­L¨àµo¨|¡A¤À®Y©Î¬O²£«á­L¨àªºµo¨|¦³¥ô¦óªº¶Ë®`©Ê.µM¦Ó¡A ·í±wªÌ¥´ºâÃh¥¥¥H¤Î¦bÃh¥¥´Á¶¡¡A¤£©y¨Ï¥ÎMetforminªvÀø¡AÀ³§ï¥Î¯Ø®q¯ÀªvÀø.,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]Metformin·|¤À§G¦Ü¥ÀÅé¨Å¥Ä¡A±qÁý¥À¨Åªº·s¥Í¨à/À¦¨à¨­¤W¥¼Æ[¹î¨ì¦³¥ô¦ó¤£¨}¤ÏÀ³.µM¦Ó¡A ¬ÛÃöªºÁ{§É¸ê®Æ¦³­­.©Ò¥H¯f±w¦b±µ¨üMetforminªvÀø´Á¶¡¡A¤£«ØÄ³¥H¥À¨Å­÷¨|. ¦b¨M©w¬O§_°±¤î­÷¨Å©Î¬O°±¥ÎMetformin¡A³£À³ÅU¼{¨ì¥À¨Å­÷¨|ªº§Q¯q©Ê¡AÃÄª«¹ï¥ÀÅé¼vÅTªº­«­n©Ê¡A ¥H¤ÎÀ¦¨à¥X²{°Æ§@¥Îªº¼ç¦b¦MÀI©Ê.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¶·¾ã²É§]ªA¡A¤£­n©CÄZ¡C(¸g¸ß°Ý¼t°Ó¦]¥»ÃÄ¨ý¹D·¥­W¡A¬G¦³¦¹«ØÄ³¡A¦ý­é¥b¿i¯»¤£¼vÅTÃÄ®Ä¡C)
EHXYL,Betamethasone + Phenylephrine + Lidocaine,High-Xylmol ointment 10gm,ALIM,,¾AÀ³¯g: External hemorrhoids¡A hemorrhoid bleeding¡A hemorrhoid pain¡A anal fissure¡A perianal inflammation¡A anal itching¡A anal eczema¡A anal ulcer,,«Ç·Å,Apply bid-tid.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Phenylephrine (Sympathomimetic): Human Data Suggest Risk. Betamethasone: Compatible - Maternal Benefit >> Embryo - Fetal Risk Lidocaine (Local Anesthetic/Cardiac): Compatible. [¥é³æ]¨S¦³¬ÛÃö¬ö¸ü,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Phenylephrine (Sympathomimetic): No Human Data - Probably Compatible. Betamethasone: No Human Data - Probably Compatible. Lidocaine (Local Anesthetic/Cardiac): Limited Human Data¡XProbably Compatible [¥é³æ]¨S¦³¬ÛÃö¬ö¸ü,RECT;,,,,,
OPAXS,Nirmatrelvir + Ritonavir,Paxlovid (¦Û¶O) 300/100mg¡A 10 doses,QANB,An Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing¡A and who are at high risk for progression to severe COVID-19¡A including hospitalization or death.,History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components. Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions. Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.,Common: Diarrhea (3%)¡A Taste sense altered (5%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hepatitis¡A Including increased transaminase levels¡A Anaphylaxis¡A Hypersensitivity reaction,Àx¦s©ó25¢J¥H¤U¡C,Paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets. The dosage for Paxlovid is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together orally twice daily for 5 days.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤£«ØÄ³­««×¨x¥\¯à¤£¥þ¯f¤H¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|µL§³®W´Á¶¡¨ÏPF-07321332ªº¤HÅé¸ê®Æ¥i¥Î©óµû¦ô¥D­n¥X¥Í¯Ê³´¡B¬y²£©Î¥ÀÅé©Î­L¨à¤£¨}ªºÃÄª«¬ÛÃö­·ÀI¡C¤wµoªíªºÃö©ó¥¥°ü¨Ï¥ÎritonavirªºÆ[¹î©Ê¬ã¨s¥¼µo²{­«¤j¥X¥Í¯Ê³´ªº­·ÀI¼W¥[¡C¤wµoªíªºritonavir¬ã¨s¤£¨¬¥H½T©wÃÄª«¬ÛÃöªº¬y²£­·ÀI¡C§³®W´Á¶¡¦p¤£¤©ªvÀø¡ACOVID-19·|¹ï¥ÀÀ¦ºc¦¨­·ÀI¡C ¦bPF-07321332ªº°Êª«­F­L-­L¨àµo¨|¬ã¨s¤¤¡A§³®W¥À¨ß¤fªAµ¹¤©PF-07321332¡A¦b¥þ¨­¼ÉÅS¶q(AUC)¬ùPAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº10­¿®É¡AÆ[¹î¨ì­L¨àÅé­«´î»´¡C¦bPF-07321332ªº°Êª«¥Í´Þ¬ã¨s¤¤¡A¦b¥þ¨­¼ÉÅS¶q(AUC)¬°PAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº3­¿©Î3­¿¥H¤W®É¡A¥¼Æ[¹î¨ì¨ä¥L¤£¨}µo¨|µ²ªG¡C ¦britonavirªº°Êª«¥Í´Þ¬ã¨s¤¤¡A§³®W¤j¹«©M¥À¨ß¤fªAµ¹¤©ritonavir¡A¾¯¶q¡]¨Ì¾ÚÅéªí­±¿nÂà´«¡^©Î¥þ¨­¼ÉÅS¶q(AUC)¬°Á{§É¾¯¶q©ÎPAXLOVIDªº®Ö­ã¤HÅé¾¯¶q¼ÉÅS¶qªº3­¿©Î3­¿¥H¤W®É¡A¥¼Æ[¹î¨ì¤£¨}µo¨|µ²ªGªºÃÒ¾Ú¡C ¦b¾A¥Î¤H¸s¤¤¡A¥D­n¥X¥Í¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¤£©ú¡C©Ò¦³§³®W§¡­±Á{¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­·ÀI¡C¦b¬ü°ê¤@¯ë¤H¸s¤¤¡AÁ{§É½T»{ªº§³®W¤¤¥D­n¥X¥Í¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¤À§O¬°2-4%©M15-20%¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Ãö©óPF-07321332¬O§_¥i¤Àªc¦Ü¤H©Î°Êª«¨Å¥Ä¡B¹ï¥À¨ÅÁý¾iÀ¦¨àªº¼vÅT©Î¹ï¨Å¥Ä¤Àªcªº¼vÅT¡A¥Ø«e©|µL¥i¨ú±oªº¸ê®Æ¡C¦bµ¹¤©PF-07321332ªº¤j¹«ªº­÷¨Å«á¥N¤¤Æ[¹î¨ìÅé­«¼È®É©Ê¤U­°¡C¦³­­ªº¤wµoªí¸ê®ÆÅã¥Ü¡Aritonavir¥X²{©ó¨Å¥Ä¤¤¡C©|µLÃö©óritonavir¹ï¥À¨ÅÁý¾iÀ¦¨à²£¥Íªº¼vÅT©ÎÃÄª«¹ïªc¨Å¶q²£¥Íªº¼vÅTªº¸ê®Æ¡CÀ³¦Ò¼{¥À¨ÅÁý¾iªºµo¨|©M°·±d¯q³B¡A¥H¤Î¥À¿Ë¹ïPAXLOVIDªºÁ{§É»Ý¨D¥H¤ÎPAXLOVID©Î¥ÀÅé°òÂ¦ª¬ªp¹ï¥À¨ÅÁý¾iÀ¦¨àªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¡C·P¬VCOVID?19ªº­÷¨Å´Á¤k©ÊÀ³¿í´`Á{§É«ü¤Þªº³W©w¡A¥HÁ×§K¨ÏÀ¦¨à¼ÉÅS©óCOVID?19¡C ¦b²£«e©M²£«áµo¨|¬ã¨s¤¤¡Aµ¹¤©§³®W¤j¹«PF-07321332ªº¥þ¨­¼ÉÅS¶q(AUC24)¬ù¬°PAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº8­¿®É¡A¦b¤l¥NÆ[¹î¨ìÅé­«¤U­°¡]³Ì°ª¹F8%¡^¡C¦b¥ÀÅé¥þ¨­¼ÉÅS¶q(AUC24)¬ù¬°PAXLOVIDªº®Ö­ã¤HÅé¾¯¶qÁ{§É¼ÉÅS¶qªº5­¿®É¡A¥¼Æ[¹î¨ì¤l¥NªºÅé­«ÅÜ¤Æ¡C,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã²É§]ªA¡C¤£±o©CÄZ¡B¯}Ãa©ÎÀ£¸H¿õ¾¯¡C
OSPL,Sulpiride,Splotin 50mg,CNEU,Treat psychotic symptoms and peptic ulcer.,Hypersensitivity to sulpiride¡A pheochromocytoma¡A parkinson's disease,Palpitations¡A prolonged QT interval¡A hypertension¡A diaphoresis¡A galactorrhea¡A breast engorgement¡A weight gain¡A xerostomia¡A nausea¡A vomiting¡A constipation¡A anorexia¡A dry mouth¡A leukocytosis¡A venous thromboembolism¡A cholestatic jaundice¡A and hepatotoxicity. Sedation or drowsiness¡A dizziness¡A depression¡A sleep disturbances¡A headache¡A restlessness¡A and impaired concentration. Parkinsonian symptoms¡A acute dystonias¡A akathisia¡A tardive dyskinesia¡A and tardive dystonia. Neuroleptic malignant syndrome¡A seizures¡A blurred vision¡A amenorrhea¡A and pulmonary embolism.,25¢J¥H¤UÁ×¥ú±K«Ê,Schizophrenia: Adults 300-600mg per day orally in divided doses; maximum daily dose 1200mg. Depression and depressive states: Adults 150-300mg per day orally in divided doses; maximum daily dose 600mg. Gastric and duodenal ulcers: Adults 150mg per day orally in 3 divided doses¡A adjusted according to disease severity.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¦³ÃöÃh¥¥¤¤µ¹ÃÄªº¦w¥þ©|¥¼½T¥ß¡A©Ò¥H¦b¥¥°ü©Î¥i¯à¤wÃh¥¥ªº°ü¤k¡A ­­©ó§PÂ_¨äªvÀø¤Wªº¦³¯q©Ê¶W¶V¦MÀI©Ê®É¤~¥iµ¹ÃÄ¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥»¾¯¹ï©ó·s¥Í¨àªº¦w¥þ©Ê©|¥¼½T¥ß¡A©Ò¥H¦b±Â¨Å´Á¶¡ªº°ü¤k¡A ­­©ó§PÂ_¨äªvÀø¤Wªº¦³¯q©Ê¶W¶V¦MÀI®É¤~¥iµ¹ÃÄ¡C,AC;AC15;PC;PO;WM;,,,,,
OVGRO,Sildenafil,Viagra ODT 50mg (4 tablets/box),SGU,Treatment of erectile dysfunction.,Patients who use nitric oxide donors or nitrates. Viagra should not be used in men for whom sexual activity is inadvisable (patients with severe CV disorders eg unstable angina or severe cardiac failure). Severe hepatic impairment¡A hypotension (< 90/50 mm Hg) or hypertension (> 170/100 mm Hg)¡A recent history of stroke or MI¡A known hereditary degenerative retinal disorders such as retinitis pigmentosa. Not indicated for women.,Common: Flushing (9-19%)¡A Indigestion (3-17%)¡A Headache (Erectile dysfunction¡A 16-28% ; pulmonary arterial hypertension¡A 46%)¡A Insomnia (erectile dysfunction¡A less than 2%)¡A Visual disturbance (erectile dysfunction¡A 1-11%)¡A Bleeding from nose (pulmonary arterial hypertension¡A 3-9%)¡A Nasal congestion (erectile dysfunction¡A 4-9%) Serious: Cardiovascular morbidity¡A Myocardial infarction¡A Sickle cell anemia with vasoocclusive crisis¡A Non-arteritic ischemic optic neuropathy¡A Retinal hemorrhage¡A Decreased hearing¡A Sudden onset (erectile dysfunction¡A less than 2%)¡A Sudden hearing loss (erectile dysfunction¡A less than 2%)¡A Priapism¡A Prolonged erection of penis,30¢J¥H¤U,Erectile dysfunction: Sildenafil 25 to 100 mg (50 mg usual dose) orally 1 hour (range 0.5 to 4 hours) prior to sexual activity; the maximum frequency of administration once daily.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¨ü·l¤§±wªÌ(¦p¨xµw¤Æ)±wªÌªº²M°£²v·|¤U­°¡A¦]¦¹À³¦Ò¼{¨Ï¥Î25 mgªº°_©l¾¯¶q¡C°ò©óÃÄ®Ä¤Î­@¨üªº¦Ò¶q¡A¾¯¶q¥i´£°ª¦Ü50 mg©Î100 mg,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] VIAGRA¨Ã¤£¾A¥Î©ó¤k©Ê¡C¥Ø«e©|¥¼¹ïÃh¥¥©Î­÷¨Å°ü¤k¡A¶i¦æ¨¬°÷¥B¥R¤À¹ï·Óªº¸ÕÅç¡C,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),[¥é³æ] ¥Ø«e©|¥¼¹ïÃh¥¥©Î­÷¨Å°ü¤k¡A¶i¦æ¨¬°÷¥B¥R¤À¹ï·Óªº¸ÕÅç¡C,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°¤f·»¿õ¡A¥i¸m©ó¦Þ¤W·»¸Ñ«á¥H¤ô§]ªA©Î¤£¥H¤ôª½±µ§]ªA¡C¥»ÃÄ¤]¤£À³¥Î©óºÞÄé¯f±w¡C
OLEE,Escitalopram,Leeyo F.C. 10mg,CNEU,,¾AÀ³¯g: Treatment of major depressive episodes. °Æ§@¥Î: Appetite decreased¡A libido decreased¡A anorgasmia (female)¡A insomnia¡A somnolence¡A dizziness¡A sinusitis¡A yawning¡A nausea¡A diarrhoea¡A constipation¡A sweating increased¡A ejaculation disorder¡A impotence¡A fatigue¡A pyrexia. Rarely¡A hyponatraemia¡A seizures¡A ecchymoses. Cardiovascular: Hypertension (1% or greater )¡A Palpitations (1% or greater ) Dermatologic: Diaphoresis (4% to 5% )¡A Rash (1% or greater ) Endocrine metabolic: Weight increased (1% or greater ) Gastrointestinal: Constipation (3% to 6% )¡A Diarrhea (6% to 14% )¡A Gastroenteritis (1% or greater )¡A Heartburn (1% or greater )¡A Indigestion (2% to 6% )¡A Nausea (15% to 18% )¡A Xerostomia (4% to 9% ) Musculoskeletal: Arthralgia (1% or greater )¡A Myalgia (1% or greater ) Neurologic: Dizziness (4% to 7% )¡A Headache (24% )¡A Insomnia (7% to 14% )¡A Lightheadedness (1% or greater )¡A Somnolence (4% to 9% ) Reproductive: Disorder of ejaculation (9% to 14%)¡A Impotence (3% )¡A Orgasm incapacity (females¡A 2% to 6% )¡A Reduced libido (males¡A 6%; females¡A 3%) Other: Fatigue (2% to 6% ) ¸T§Ò: Concomitant treatment with non-selective¡A irreversible MAOIs.,,«Ç·Å,Adult:10 mg once daily; may be increased to max 20 mg daily.,»Ý½Õ¾ã¾¯¶q,max: 10mg/day.,»Ý½Õ¾ã¾¯¶q,,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;P1;P2;P3;P4;PC;PO;WM;,,,,,
IABI,Aripiprazole,Abilify Maintena inj 400mg,CNEU,Treating schizophrenia in adults. Monotherapy for maintenance treatment of adult type I bipolar disorder.,Hypersensitivity to aripiprazole or any component of the formulation.,Common: Injection site pain (5-19%)¡A Weight increased¡A 7% or greater (2.2-26.3%)¡A Constipation (5-11%)¡A Decrease in appetite (7%)¡A Excessive salivation ( 4%)¡A Increased appetite (3-7%)¡A Nausea (8-15%)¡A Vomiting (3-11%)¡A Akathisia (2-25%)¡A Dizziness (4-10%)¡A Extrapyramidal disease (2-27.3%)¡A Headache (10-27%)¡A Insomnia (8-18%)¡A Lethargy (5%)¡A Sedated (3-21%)¡A Somnolence (6-26.3%)¡A Tremor (2-11.8%)¡A Blurred vision (3-8%)¡A Anxiety (4-17%)¡A Restlessness (2-12%)¡A Nasopharyngitis (3-9%)¡A Fatigue (2-17%) Serious: Cardiorespiratory arrest (0.1-1%)¡A Cardiorespiratory failure (Up to 0.1%)¡A Myocardial infarction (Up to 0.1%)¡A Myocardial ischemia (Up to 0.1%)¡A Orthostatic hypotension (0.2-1%)¡A Prolonged QT interval (Up to 0.1%)¡A Diabetic ketoacidosis¡A Hyperglycemia (0.8-8%)¡A Dysphagia¡A Pancreatitis¡A Agranulocytosis¡A Leukopenia¡A Neutropenia (5.7%)¡A Rhabdomyolysis (Up to 0.1%)¡A Seizure (Up to 0.1%)¡A Tardive dyskinesia (Pediatric¡A 1.7%)¡A At increased risk for suicide¡A Compulsive gambling¡A Suicidal behavior¡A Angioedema¡A Increased body temperature¡A Neuroleptic malignant syndrome,30¢J¥H¤U¡A¤£­n§N­á¡C,400 mg once monthly (doses should be separated by more than 26 days); Tolerability should be established using oral aripiprazole prior to initiation of parenteral therapy; due to the half-life of oral aripiprazole it may take up to 2 weeks to fully assess tolerability. Continue oral aripiprazole (or other oral antipsychotic) for 14 days during initiation of parenteral therapy.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ·í³B¤è ABILIFY MAINTENA µ¹Ãh¥¥°ü¤k¡A¶·¦Ò¼{¨ì ABILIFY MAINTENA ªº§Q¯q»P­·ÀI¥H¤Î¹ï­L¨à¥i¯àªº­·ÀI¡C §iª¾Ãh¥¥°ü¤k¥»«~¼ç¦b¹ï­L¨àªº­·ÀI¡C¦bÃh¥¥²Ä¤T´Á¼ÉÅS©ó§Üºë¯«¯fÃÄª« ( ¥]¬A ABILIFY MAINTENA) ªº·s¥Í¨à¦³À@Åé¥~®|¯gª¬©M / ©Î¸TÂ_¯gª¬ªº­·ÀI¡CABILIFY MAINTENA ¨Ï¥Î©óÃh¥¥°ü¤k¨ÃµL¨¬°÷ªº¸ê°T¥HÅã¥ÜÃÄ«~¬ÛÃöªº­·ÀI¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Aripiprazole·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡CµM¦Ó¡A¨S¦³¨¬°÷ªº¼Æ¾Úµû¦ôaripiprazole ¦b¤HÃþ¨Å¥Ä¤¤ªº¶q¡A¹ïÁý¥¤À¦¨àªº§@¥Î¤Î¹ï¨Å¥Ä¤Àªcªº¼vÅT¡C À³¦Ò¼{­÷Áý¥À¨Å¹ï¥Íªø¤Î°·±dªºÀu¶Õ¡B¥À¿Ë¹ï ABILIFY MAINTENA ªºÁ{§É»Ý¨D¥H¤Î¨Ó¦Û ABILIFY MAINTENA ©Î¥ÀÅéª¬ªp¹ïÁý¥¤À¦¨à¥i¯àªº¤£¨}¤ÏÀ³¡C,IM;,¨Ï¥Î¹w¥R¶ñÂùµÄª`®gµ©¤º§t¤§ª`®g¥Î¤ô¡A¨Ì¥é³æ«ü¥Ü¶i¦æ²V¦X¡C,,,,1.·»²GÀ³©ó°t¸m«á30¤ÀÄÁ¨Ï¥Î§¹²¦. 2.½Ð¨Ì¥é³æ«ØÄ³°w¹ï¤£¦Pªº¯f±w¿ï¥Î¤£¦Pªº°wÀY. 3.¤£­n·b´|ª`®g³¡¦ì.
ILUMI,Brodalumab,Lumicef 210mg/1.5mL inj,HIMM,Moderate to severe plaque psoriasis¡A pustular psoriasis.,Crohn disease¡A Clinically significant hypersensitivity to brodalumab or any component of the formulation.,Common: Diarrhea (2.2%)¡A Infectious disease (25.4%)¡A Mycosis (1.8-2.4%)¡A Arthralgia (4.7%)¡A Headache (4.3%)¡A Pain in throat (2.1%)¡A Fatigue (2.6%) Serious: Neutropenia¡A Grade 3 or greater (0.5%)¡A Cryptococcal meningitis¡A Suicidal thoughts¡A Suicide,2-8¢JÁ×¥ú¤Å§N­á¤Å·n,SC¡A 210 mg at weeks 0¡A 1¡A and 2¡A followed by 210 mg once every 2 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ](¸`¿ý) ¨S¦³¥¥°ü¨Ï¥Îªº¬ÛÃö­·ÀI³ø§i. ¤wª¾¤HÃþIgG§ÜÅé·|¬ï¹L­L½L«Ì»Ù¡A°Êª«¹êÅç¤¤¥¼µo²{¦³¤£¨}®Ä¯q,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ](¸`¿ý) ¨S¦³±Â¨ÅÀ³¦Ó©Î¨Å¥Ä¤Àªcªº¼vÅT¬ÛÃö¸ê°T. °Êª«¹êÅç¤¤µo²{¨Å¥Ä¤¤ÀË´ú¨ì¥»ÃÄ¡A½Ðµû¦ô¨ü¨ÅÀ¦¨à»P¥ÀÅéª¬ªpªº­·ÀI»P§Q¯q.,SC;,,,,,1.¹w¶ñ¥R°wµ©»ÝÀx¦s©ó2-8«×C¡A¤Å§N­á. 2.½Ð¤Åª`®g©ó¨{ÂÀ©P³ò2¦T¤º. 3.¤Å´|ª`®g³¡¦ì
OROMA,Dextromethorphan+Lysozyme+K Cresolsulfonate,Romicon-A 20/20/90mg,ERSP,Cough suppressant¡A Expectorant.,Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor. Hypersensitivity to Romicon-A or any component of the formulation.,Common Neurologic: Dizziness (mild)¡A Somnolence (mild) Other: Fatigue (mild),25¢J¥H¤UÁ×¥ú,Adult (>15 years- old): one capsule each time¡A three times a day. [Micromedex 2021/07/30] Cough: 12 years or older: 30 mg orally every 6 to 8 hours; the maximum dose: 120 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,TEXTBOOK: Lysozyme+K Cresolsulfonate µL¸ê®Æ [¥é³æ] Ãh¥¥°ü¤k¡AºÃ¦üÃh¥¥°ü¤k¤Î­÷¨Å°ü¤kÀ³Á×§KªA¥Î¥»«~ ªþµù1: °£¥é³æ¸ê°T¥~¡A¨ä¥L¸ê®Æ¬Ò¬°Dextromethorphan³æ¤@¦¨¥÷ªº¸ê®Æ®w¸ê°T. ªþµù2: Pregnancy Category:A - from Micromedex (AUS date).,Compatible ­÷¨Å®É¥i¨Ï¥Î,TEXTBOOK: Lysozyme+K Cresolsulfonate µL¸ê®Æ [¥é³æ] Ãh¥¥°ü¤k¡AºÃ¦üÃh¥¥°ü¤k¤Î­÷¨Å°ü¤kÀ³Á×§KªA¥Î¥»«~,AC;P1;P2;P3;P4;PC;PO;,,,,,
ESOO3,Ivermectin,Soolantra cream 1%¡A 30gm,TDER,Rosacea (Soolantra cream): Treatment of inflammatory lesions of rosacea in adult patients.,Hypersensitivity (rare).,1% to 10%: Central nervous system: Localized burning (<=1%) Dermatologic: Skin irritation (<=1%) <1% (Limited to important or life-threatening): Conjunctivitis¡A eye irritation¡A ocular hyperemia¡A seborrheic dermatitis of scalp¡A xeroderma,25¢J¥H¤U¤Å§N­á,Rosacea Topical Apply to each affected area (eg¡A forehead¡A chin¡A nose¡A each cheek) once daily¡A maximum for 4 month,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Human data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
ODOP,Amantadine,¦h¤Ú©wDopadine100mg,CNEU,Parkinsonism of various origin¡A senile Parkinsonism¡A residual symptoms & discomfort after stereotactic operations.,Severe CHF (NYHA class IV)¡A cardiomyopathies & myocarditis¡A 2nd or 3rd degree AV block¡A existing bradycardia under 55 beats/min¡A known prolonged QT interval (Bazett QTc > 420 ms) or discernible U-waves or congenital QT syndrome in the family anamnesis ¡A history of serious ventricular arrhythmias including torsade de pointes¡A simultaneous treatment with budipine or other drugs that prolong the QT interval¡A reduced levels of potassium or magnesium in the blood. Pregnancy & lactation.,Common: Orthostatic hypotension (1-5% ; 13% (extended-release))¡A Peripheral edema (1-5% ; 16% (extended-release))¡A Constipation (1-5% ; 13% (extended-release))¡A Loss of appetite (1-6%)¡A Nausea (5-10%)¡A Xerostomia (1-5% ; 16% (extended-release))¡A Abnormal gait (3%)¡A Dizziness (5-10% ; 16% (extended-release))¡A Insomnia (5-10%)¡A Agitation (1-5%)¡A Anxiety (1-7%)¡A Depression (1-6% .)¡A Dream disorder (1-5%)¡A Feeling nervous (1-5%)¡A Hallucinations (1-5% .; 21% (extended-release))¡A Urinary tract infectious disease (10%)¡A Falls (13%) Serious: Congestive heart failure (0.1-1%)¡A Leukopenia (<0.1%)¡A Neutropenia (<0.1%)¡A Neuroleptic malignant syndrome¡A Suicidal intent (<0.1% ; 2% (extended-release)),25¢J¥H¤U,Parkinson's disease: Adult: Monotherapy¡A 100 mg orally twice daily; may titrate up to 400 mg/day in divided doses. During a serious related disease or receiving high-dose anti-Parkinson's disease treatment¡A the initial dose of this agent is 100 mg once a day¡A After 1-7 weeks¡A if necessary¡A may titrate up to 100 mg twice a day; and additionally up to 400 mg/day in divided doses. Initiating levodopa and amantadine concurrently¡A hold amantadine at 100 mg once or twice daily while gradually increasing levodopa. Prophylaxis or treatment of Influenza A symptoms: (Due to high resistance rates¡A amantadine is no longer recommended by the CDC for the treatment or prophylaxis of influenza A.) Adult: 100-200mg/day. Children > 10 years old or > 45 kg: 100mg BID. Children > 5 years old: 100mg QD.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ©|¥¼¦³ªø´Á©Ê¬ã¨sµû¦ô¥»¾¯¤§­PÀù©Ê¤Î­P¬ðÅÜ©Ê¡CÃh¥¥®É¸T¤î¨Ï¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¥»¾¯·|¤Àªc©ó¨Å²G¡A±Â¨Å°ü¨Ï¥Î®ÉÀ³ª`·N¡C,AC;AC15;PO;WM;,,,,,
IOZE,Semaglutide,Ozempic inj 2mg/1.5mL,META,Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.,Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.,Common Endocrine metabolic: Hypoglycemia (Monotherapy¡A 1.6% to 3.8%; combination therapy¡A 6% to 30% ) Gastrointestinal: Abdominal pain (5.7% to 11% )¡A Constipation (3.1% to 6% )¡A Diarrhea (8.5% to 10% )¡A Nausea (11% to 20.3% )¡A Vomiting (5% to 9.2% ) Serious Endocrine metabolic: Medullary thyroid carcinoma Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Ophthalmic: Retinopathy due to diabetes mellitus,Á×¥ú¤Å§N­á¡Cªì¦¸¨Ï¥Î«e¡G½Ð¦s©ñ©ó2-8¢XC; ªì¦¸¨Ï¥Î«á½Ð¦s©ñ©ó30¢XC¥H¤U©Î 2-8¢XC ¦@¤»¶g,SC¡A 0.25 mg once weekly for 4 weeks¡A then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¦b°Êª«¸ÕÅç¤¤Åã¥Ü¨ã¥Í´Þ¬r©Ê¡CÃh¥¥¤k©Ê¨Ï¥Î semaglutide ªº¸ê®Æ¦³­­¡A¦]¦¹Ãh¥¥´Á¶¡¤£¥i¨Ï¥Î semaglutide¡C ¦pªG¯f¤H·Q­nÃh¥¥©Î¤wÃh¥¥¡AÀ³°±¥Î semaglutide¡C ¥Ñ©ó semaglutide ªº¥b°I´Á¸ûªø¡A­pµeÃh¥¥«e¦Ü¤Ö¨â­Ó¤ëÀ³°±¥Î semaglutide¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¤j¹«ªºªc¨Å¹êÅçÅã¥Ü¡Asemaglutide ·|¤Àªc¦Ü¨Å¥Ä¤¤¡C ¥Ñ©óµLªk±Æ°£­÷¨ÅÀ¦¥®¨àªº­·ÀI¡A­÷¨Å´Á¶¡¤£À³¨Ï¥Î semaglutide¡C,SC;,,,,,1.¨Ï¥Î·sªºª`®gµ§²Ä¤@¦¸ª`®g«e¡A½Ð¥ýÀË¬d¬O§_¤w±ÆªÅ¡C 2.¦s©ñ©ó30¢XC¥H¤U¥i«O¦s6¶g.¤£¥i§N­á. 3.¥²­n®É¥i§ïÅÜ¨C¶gª`®gªº¤é´Á¡A¦ý¨â¦¸ª`®g¤§¶¡À³¦Ü¤Ö¬Û¹j 3 ¤Ñ (¶W¹L 72 ¤p®É)¡C¿ï©w·sªºª`®g¤é¤§«á¡AÀ³«ùÄò¨C¶gª`®g¤@¦¸¡C 4.¦pªG¿ù¹L¤@¾¯ÃÄª«¡AÀ³¦b 5 ¤Ñ¤º¾¨§Ö¬I¥´¡C¦pªG¶W¹L 5 ¤Ñ«hÀ³¸õ¹L¡A¨Ì­ì­q®Éµ{Ä~Äòª`®g¤U¤@¾¯¡C¹J¨ì³oÃþ±¡ªp¡A¯f¤H¤§«á¥i«ì´_¨C¶g¤@¦¸ªº¥ÎÃÄ®Éµ{¡C
ISEF,Ciprofloxacin,Seforce inj 400mg/200mL,QANB,Acute exacerbation of chronic bronchitis. Bacterial prostatitis¡A chronic. Bacterial sinusitis¡A acute. Febrile neutropenia¡A Empiric therapy. Gonorrhea¡A Uncomplicated. Infection of bone - Infectious disorder of joint. Infection of skin and/or subcutaneous tissue. Infectious diarrheal disease. Infectious disease of the abdomen¡A Complicated. Lower respiratory tract infection. Otitis externa¡A acute. Pyelonephritis. Urinary tract infectious disease.,Concomitant tizanidine administration. Hypersensitivity to ciprofloxacin or any product component¡A or other quinolones.,Common Dermatologic: Rash (Up to 1.8% ) Gastrointestinal: Diarrhea (Multiple indications¡A 1.6% to 4.8% ; Complicated UTI¡A 25% )¡A Nausea (Multiple indications¡A 2.5% to 4%; Complicated UTI 25% )¡A Vomiting (Adult¡A 1% to 2%; pediatric¡A 4.8% ) Neurologic: Headache (Up to 3% ) Psychiatric: Irritability (5% ) Respiratory: Nasal discharge (3% )¡A Nasopharyngitis (5% ) Serious Cardiovascular: Aortic aneurysm¡A Or dissection¡A Cardiorespiratory arrest (Up to 1% )¡A Myocardial infarction (Up to 1% )¡A Prolonged QT interval¡A Syncope (Up to 1% )¡A Torsades de pointes Dermatologic: Photosensitivity¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis (Up to 1% ) Endocrine metabolic: Hypoglycemia (Up to 1% ) Gastrointestinal: Clostridium difficile colitis¡A Clostridium difficile diarrhea (Up to 1% )¡A Gastrointestinal hemorrhage (Up to 1% )¡A Pancreatitis (Up to 1% ) Hematologic: Agranulocytosis (Rare )¡A Aplastic anemia (Rare )¡A Bone marrow depression¡A Hemolytic anemia (Rare )¡A Leukopenia (0.4% )¡A Pancytopenia (0.1% )¡A Thrombocytopenia (Rare ) Hepatic: Hepatic necrosis (Up to 1% )¡A Hepatitis (up to 1% )¡A Hepatotoxicity¡A Liver failure Immunologic: Hypersensitivity reaction (Up to 1% ) Musculoskeletal: Myasthenia gravis¡A Exacerbation¡A Rupture of tendon¡A Tendinitis Neurologic: Disorientated¡A Disturbance of attention¡A Guillain-Barre syndrome¡A Memory impairment¡A Peripheral neuropathy¡A Pseudotumor cerebri¡A Raised intracranial pressure¡A Seizure (Less than 1% ) Ophthalmic: Retinal detachment Psychiatric: Delirium¡A Depression (Up to 1% )¡A Hallucinations¡A Paranoid disorder (Up to 1% )¡A Psychotic disorder (Up to 1% )¡A Suicidal behavior (Rare ) Renal: Acute renal failure (Up to 1% )¡A Hemorrhagic cystitis (Up to 1% )¡A Tubulointerstitial nephritis (Up to 1% ),25¢J¥H¤U¡BÁ×§K§N­á¡BÁ×¥ú,Should be infused intravenously over 60 minutes. Adults: usual dose: 100-400 mg IV Q12H; severe/complicated infections: 400 mg IV Q8H. Chiledren (aged 1-17 years): 6-10 mg/kg IV Q8-12H (maximum 400 mg/dose).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,[¥é³æ]Ciprofloxacin¦bÃh¥¥°ü¤kªº¦w¥þ©Ê©|¥¼«Ø¥ß¡C°Êª«¸ÕÅç¥¼Åã¥Ü¦³¥Í´Þ¬r©Ê¡C®Ú¾Ú°Êª«¸ÕÅçªºµ²ªG¡A¥i¯àµLªk±Æ°£ÃÄª«¥i¯à·|¹ï©|¥¼¦¨¼ô¥Íª«ªºÃö¸`³n°©³y¦¨¶Ë®`¡C¦]¦¹ciprofloxacin¤£«ØÄ³¦bÃh¥¥´Á¶¡¨Ï¥Î¡C°Êª«¹êÅç¦Ü¤µ©|¥¼¦³­P·î­L(·î§Î)ªºÃÒ¾Ú¡C PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Ciprofloxacin·|¤Àªc¨ì¨Å¥Ä¤¤¡A¥Ñ©ó¦³Ãö¸`³n°©¶Ë®`ªº¼ç¦b­·ÀI¡A­÷¨Å°ü¤k¤£¥i¨Ï¥Îciprofloxacin¡C,IVD;,,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,Ciprofloxacin¿éª`²G¥²¶·¸g¥ÑÀR¯ß¿éª`¡A¨Ã¥B¿éª`®É¶¡­n¶W¹L60¤ÀÄÁ¡C½wºCªº±NÃÄ¥´¤J¤jªºÀR¯ß¡A¥i¥H´î¤Ö¯f¤Hªº¤£¾A¤Î­°§CÀR¯ß¨ë¿Eªº¦MÀI©Ê¡C¥i¥Hª½±µµ¹ÃÄ©Î»P¨ä¥¦¬Û®eªº¿éª`·»²G²V¦X«áµ¹ÃÄ¡C,1.¥»ÃÄ¨ã¥ú±Ó·P«×¡AÃÄ«~¶·¦b¨Ï¥Î«e¦A±qÁ×¥ú³U®³¥X¡C¦b¥Õ±Þ¥ú½u¤U¡A§¹¾ãªº®Ä¤O¥u¯à«OÃÒºû«ù3¤Ñ¡C 2.§C·ÅÀx¦sÀô¹Ò¥i¯à·|²£¥Í¨I¾ý¡A¦ý¦b«Ç·Å¤U·|¦A«×·»¸Ñ¡C©Ò¥H¤£¶·±N¦¹¿éª`²G¸m©ó¦B½cÀx¦s¡C 3.¨Ï¥ÎIV set ®É½Ð½T¹ê¿ë»{¥[ÃÄ¤Õ¤Î¿é¥X¤Õ¡A±NIV set ««ª½´¡¤J¦Ü¿é¥X¤Õ¡A¨Ã½T»{§¹¥þ´¡¤J¦Ü©³³¡¡C 4.¨Ì2016¦~²Ä2¦¸ADR·|Ä³¨MÄ³: ¦]QuinolonesÃþÃÄª«±`¨£¤Þ°_ÀR¯ßª¢¡A«ØÄ³¿éª`®É¶¡À³¶W¹L60¤ÀÄÁ¡C
EBUIS,Terbutaline,Butanyl solution 5mg/2mL,ERSP,Treatment and Prophylaxis of Asthma¡A Bronchospasm¡A Reversible¡A associated with bronchitis and emphysema.,Hypersensitivity to sympathomimetic amines or any component of terbutaline sulfate products.,Common Cardiovascular: Palpitations¡A Tachyarrhythmia Neurologic: Headache¡A Seizure¡A Tremor Psychiatric: Feeling nervous Serious Cardiovascular: Cardiac dysrhythmia Respiratory: Paradoxical bronchospasm¡A Pulmonary edema,25¢J¥H¤UÁ×¥úÀx¦s,Single dose 5mg QID. For use in a nebulizer or respirator. If a single dose is not used up¡A it can be stored in the storage tank of the nebulizer within 24 hours.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]·î­L©|¥¼¨£©ó°Êª«¤Î¯f±w¡A¦ý§³®W¤T­Ó¤ë¥H¤ºªº°ü¤k¤´¶·¤p¤ß§ë»P¡CTerbutaline¸g¨Ï¥Î¦h¦~¡A¾A¥Î©ó¥¥°ü¤Î²£°ü¡AµL¤£¨}¼vÅT¤§³ø§i¡A©ö¤£¤zÂZ¥Í´Þ¹Lµ{¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]TerbutalineÁö¬yª`¥À¨Å¡A¦ýÂåÀø¾¯¶q¹ïÀ¦¨àµL¤£¨}¼vÅT¡C ¦b¦­²£ªº·s¥Í¨à¤¤(¨ä¥À¿Ë¦³¨Ï¥Îbeta-2¨ë¿E¾¯¨ÓªvÀø)¡A¦³³ø§i«ü¥X·|¦³µu¼È©Ê§C¦å¿}ªº±¡§Î¡C,IH;,,,,,1.¥»«~«Dª`®g¥Î¡A¥u¾A¥Î©ó©I§l¾¹©Î¼QÃú¾¹¡C 2.±N¥»«~¦s©ó¼QÃú¾¹ªºÀx¦s¼Ñ¥i«O¦s24¤p®É¡C
INTG,Nitroglycerin,NTG inj 0.2mg/mL¡A 250mL (D5W) Premixed,CAVS,,¾AÀ³¯g:Treatment or prevention of angina pectoris Intravenous (IV) administration: Treatment or prevention of angina pectoris; acute decompensated heart failure (especially when associated with acute myocardial infarction); perioperative hypertension (especially during cardiovascular surgery); induction of intraoperative hypotension. °Æ§@¥Î: >10%: Central nervous system: Headache (patch¡A ointment: 50% to 64%; sublingual powder¡A lingual spray: >2%) 1% to 10%: Cardiovascular: Hypotension (<4%)¡A syncope (<4%)¡A peripheral edema (lingual spray: <2%) Central nervous system: Dizziness (>2% to 6%)¡A paresthesia (>2%) Gastrointestinal: Abdominal pain (lingual spray: <2%) Neuromuscular & skeletal: Weakness (all sublingual forms: <2%) Respiratory: Dyspnea (<2%)¡A pharyngitis (lingual spray: <2%)¡A rhinitis (lingual spray: <2%) Frequency not defined: Cardiovascular: Bradycardia¡A exacerbation of angina pectoris¡A flushing¡A orthostatic hypotension Dermatologic: Diaphoresis Gastrointestinal: Vomiting Miscellaneous: Drug tolerance ¸T§Ò: Hypersensitivity to nitroglycerin¡A other nitrates or nitrites¡A or any component of the formulation (includes adhesives for transdermal product); concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (avanafil¡A sildenafil¡A tadalafil¡A or vardenafil); concurrent use with soluble guanylate cyclase (sGC) stimulators (eg¡A riociguat). Additional contraindications for IV product: Hypersensitivity to corn or corn products (solutions containing dextrose); constrictive pericarditis; increased intracranial pressure; pericardial tamponade; restrictive cardiomyopathy; uncorrected hypovolemia.,,«Ç·Å,FOR INTRAVENOUS USE ONLY. NOT FOR DIRECT INTRAVENOUS INJECTION. SHOULD NOT BE MIXED WITH OTHER DRUGS. Initial titration should be in 5 mcg/min increments¡A with increases every 3-5 minutes until some response is noted. If no response is seen at 20 mcg/min¡A increments of 10 and later 20 mcg/min can be used. Once a partial blood pressure response is observed¡A the dose increase should be reduced and the interval between increases should be lengthened.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,,,IV infusion rate: 0.05 - 5 mcg/kg/min¨Ì¾AÀ³¯g¤£¦P¡AÀ³¨Ï¥Î¬Á¼þ©Înon-PVC§÷½è¡C,®e¾¹¤Î¿é²G®M»Ý¿ï¾Ünon-PVC§÷½è¡A¨Ï¥Î¥i±±¨î¬y³t¤§¿é²G¬¦ÀR¯ß¿éª`¡C
IRAPI,Peramivir,Rapiacta 300mg/60mL Drip Infusion,QANB,Treatment of acute¡A influenza A or B in adults,Serious hypersensitivity or anaphylaxis to peramivir or any component of the formulation.,Cardiovascular: Hypertension Central nervous system: Insomnia Endocrine: Increased serum glucose Gastrointestinal: Constipation¡A diarrhea¡A vomiting (children & adolescents) Genitourinary: Proteinuria (children & adolescents) Hematologic and oncologic: Neutropenia Hepatic: Increased serum ALT¡A increased serum AST Neuromuscular & skeletal: Increased creatine phosphokinase Miscellaneous: Fever (children & adolescents) Rare but important or life-threatening: Abnormal behavior¡A anaphylactoid reaction¡A anaphylaxis¡A delirium¡A erythema multiforme¡A exfoliative dermatitis¡A hallucination¡A skin rash¡A Stevens-Johnson syndrome,25¢J¥H¤U,Administer Rapiacta within 2 days of onset of symptoms of influenza. Adult: a single 300-600 mg dose IV infused over 15 minutes. Children > 1 month: a single dose of 10 mg/kg IV infused over 15 minutes (do not exceed 600 mg/dose).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,,X,Administer via IV infusion over 15 to 30 minutes,1. «æ©Ê¬y·P©y©ó¯gª¬µo¥Í«á48¤p®É¤º¨Ï¥Î¥»ÃÄ¡C 2. ¹ï18·³¥H¤W¦¨¤H«æ©Ê¬y·P¯f±w¤§«ØÄ³¾¯¶q¬°³æ¦¸§ë»P300 mg¡A15¤ÀÄÁ¥H¤W³æ¦¸ÂIºwÀR¯ßª`®g¡C 3.¨C³UÃÄ«~½á§Î¾¯¬°´â¤Æ¶u540.0 mg¤Îª`®g¥Î¤ô¡C(¦³¤ßÅ¦¡B´`Àô¾¹©x¥\¯à¤£¨}ªÌ¡BµÇ¥\¯à¤£¥þªÌ»Ýª`·N)
OATOZ,Ezetimibe + Atorvastatin,Atozet 10/20mg,CAVS,Familial hypercholesterolemia. Hyperlipidemia¡A Primary. Mixed hyperlipidemia.,Active liver disease or unexplained persistent elevations in hepatic transaminases. Breastfeeding. Women who are pregnant or may become pregnant. Hypersensitivity to ezetimibe¡A atorvastatin¡A or any component of the product.,Common Gastrointestinal: Diarrhea (2.8% ) Musculoskeletal: Muscle weakness¡A Myalgia (3.6% ) Neurologic: Headache (5.8% ) Respiratory: Upper respiratory infection (3.6% ) Serious Dermatologic: Dermatomyositis¡A Subacute cutaneous lupus erythematosus Hepatic: Hepatitis¡A Increased liver enzymes (0.7% to 3.6% )¡A Jaundice¡A Liver failure Immunologic: Autoimmune disease Musculoskeletal: Autoimmune necrotizing myopathy¡A Statin-associated (Rare )¡A Disorder of muscle (0.2% )¡A Rhabdomyolysis (0.09% ) Respiratory: Bleeding from nose,30¢J¥H¤U,The recommended starting dose of Atozet is ezetimibe/atorvastatin 10/10-10/20 mg once daily. Could be administered at any time of the day with or without food.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]Atozet¸T¥Î©ó±w¦³¬¡°Ê©Ê¨x¯f©Î¨xÅ¦ÂàÓi×Q¥X²{¤£¦W­ì¦]¤ä«ùÄò¤É°ª²{¶Hªº±wªÌ,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,PREGNANCY RECOMMENDATION: EZETIMIBE: Limited Human Data - Animal Data Suggest Moderate Risk ATORVASTATIN: Contraindicated 1st Trimester [¥é³æ]Atozet¸T¥Î©ó¥H¸gÃh¥¥©Î¥i¯àÃh¥¥ªº°ü¤k¡C¦b¥¿±`Ãh¥¥´Á¶¡¡A¦å²MÁx©T¾J»P¤T»Ä¥Ìªo¯×³£·|¤É°ª¡C ¦bÃh¥¥´Á¶¡¡A­°¦å¯×ÃÄª«¨ÃµLªk´£¨Ñ¥ô¦ó®Ä¯q¡A¦]¬°Áx©T¾J»PÁx©T¾J­l¥Íª«¤D¬O¥¿±`­L¨àµo¨|©Ò¥²»Ýªºª«½è¡C °Ê¯ßµ°¼Ëµw¤Æ¬O¤@­Óªø´Áµo®iªº¹Lµ{¡A¦]¦¹¡A¦bÃh¥¥´Á¶¡°±¥Î­°¦å¯×ÃÄª«¹ï­ìµo©Ê°ªÁx©T¾J¦å¯g¤§ªø´ÁªvÀøµ²ªGªº¼vÅTÀ³¸Ó·¥¤p¡C (¥H¤U²¤),Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,BREASTFEEDING RECOMMENDATION: EZETIMIBE: Contraindicated ATORVASTATIN: Contraindicated [¥é³æ]¤j¹«ªº¬ã¨sÅã¥Ü¡AÁý­÷¥À¨Å¤§¥J¹«¤¤ªº¾ãÅéezetimibe¼ÉÅS¶q³Ì°ª¥i¹F¥ÀÅé¦å¼ß¤¤©ÒÆ[¹î¨ì¤§¼ÉÅS¶qªº¤@¥b¡C ¥Ø«e¨Ã¤£½Tª¾ezetimibe¬O§_·|¤Àªc¶i¤J¤HÃþªº¨Å¥Ä¡C ¥Ø«e¨Ã¤£½Tª¾atorvastatin¬O§_·|¤Àªc¶i¤J¤HÃþ¨Å¥Ä¡A¦ý¦PÃþ§Oªº¥t¤@ºØÃÄª«¦³¤Ö¶q·|²¾¦æ¶i¤J¨Å¥Ä¡C ¦bÁý­÷¥À¨Åªº¥J¹«¤¤¡A¦å¼ß¤Î¨xÅ¦ªºatorvastatin¿@«×¤À§O¬Û·í©ó¥À¹«¨Å¥Ä¤¤¤§¿@«×ªº50%»P40%¡C ¥Ñ©ó¥i¯à·|¨ÏÁý­÷¥À¨ÅªºÀ¦¨àµo¥Í¤£¨}¤ÏÀ³¡A¦]¦¹¡A¨Ï¥ÎAtozetªvÀøªº°ü¤k¤£¥iÁý­÷¥À¨Å¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ¸üÀ³±NAtozet¿õ¾¯¾ã²É§]ªA¡C¤£¥i±N¿õ¾¯¬ã¸H¡B·»¸Ñ©Î©CÄZ¨Ï¥Î¡C¸ß°Ý¼t°Ó«á¦^ÂÐµL¯}Ãa¾¯«¬«áªº¦w©w©Ê¤Î¦³®Ä©Ê¸ê®Æ¡A¥B¦³®Ä¦¨¤À·|³Q¯}Ãa¥¢®Ä¨Ã¼vÅT§l¦¬¡C(The active ingredients can break down in the mouth and lose efficacy. This could also impair absorption.) 1. À³´£¿ô¯f±w­Y¦³¤£©ú­ì¦]ªº¦Ù¦×µh¡A Ä²µh©ÎµL¤O¡A ¥B¨Ö¦³µo¿N®É¡A ½Ð¥ß¨è¦^¶E¡C 2. ­Y¨Ö¥ÎHIV§Ü¯f¬rÃÄª«¯f±w¥i¯à·|¥[­«°Æ§@¥Î¡A½ÐÂÔ·V¨Ï¥Î¡C
OMOLS,Molnupiravir,(¦Û¶O) Molnupiravir 200mg (40Áû/²~),QANB,An Emergency Use Authorization (EUA) for the emergency use of Molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults who are at high-risk for progression to severe COVID-19.,NOT for use in patients who are less than 18 years of age. NOT for initiation of treatment in patients requiring hospitalization due to COVID-19. NOT for use for longer than 5 consecutive days. NOT for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19. Not recommended for use during pregnancy.,Common Gastrointestinal: Diarrhea (2% to 3% )¡A Nausea (2% ) Neurologic: Dizziness (1% )¡A Headache (1% ),¦b30¢J¥H¤U«O¦s,800 mg (four 200-mg capsules) orally every 12 hours for 5 days with or without food; administer as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤£«ØÄ³©óÃh¥¥´Á¶¡¨Ï¥Îmolnupiravir¡A¦ý­Y³B¤èÂå®v½T»{®Ä¯q¶W¶V­·ÀI¡A¨M©w¹ï¥¥°ü¨Ï¥Îmolnupiravir®É¡A¥²¶·¦V¸Ó¥¥°ü¸Ô²Ó§iª¾¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravirªº­·ÀI¡C³B¤èÂå®vÀ³©óÃh¥¥±wªÌ¨Ï¥Îmolnupiravir´Á¶¡³z¹L¹q¸Ü¡G02-66316000©Î¹q¤l¶l¥ó: dpoc_taiwan@merck.com³q³ø¨äÃnÃÄ±¡§Î¡A¨Ã«ØÄ³±wªÌ¨Ì¤W­zÁpÃ´ºÞ¹D±NÃh¥¥µ²ªG³q³øµ¹¬ü°ÓÀq¨FªFÃÄ¼tªÑ¥÷¦³­­¤½¥q¥xÆW¤À¤½¥q¡C ®Ú¾Ú°Êª«¸ÕÅçªº¸ê®Æ¡A¹ï¥¥°ü§ë¤©molnupiravir¥i¯à·|¹ï­L¨à³y¦¨¶Ë®`¡C¥Ø«e¨ÃµL¥ô¦ó¹ï¥¥°ü¨Ï¥Îmolnupiravirªº¤HÃþ¸ê®Æ¥i¾Ú¥Hµû¦ôµo¥Í­«¤j¥X¥Í¯Ê³´¡B¬y²£©Î¥ÀÅé©Î­L¨à¤£¨}µ²ªGªº­·ÀI¡F¦]¦¹¡A¨Ã¤£«ØÄ³¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravir¡C¤@¶µ°Êª«¥Í´Þ¬ã¨sÅã¥Ü¡A¹ïÃh¥¥¤j¹«©ó¾¹©xµo¥Í´Á¶¡¤fªA§ë¤©molnupiravir¤§«á¡A¦b¬Û·í©ó¤HÃþ¦b«ØÄ³¤HÃþ¾¯¶q(RHD)¤U©Ò¹F¨ì¤§¤HÃþNHC (N4-hydroxycytidine)¼ÉÅS¶qªº8­¿¼ÉÅS¶q¤U·|¾É­P­F­L­L¨à¦º¤`©M·î§Î¡A¦b¤HÃþ¦bRHD¾¯¶q¤U©Ò¹F¨ì¤§¤HÃþNHC¼ÉÅS¶qªº?3­¿¼ÉÅS¶q¤U·|¾É­P­L¨à¥Íªø´îºC¡C¹ïÃh¥¥¨ß¤l©ó©ó¾¹©xµo¥Í´Á¶¡¤fªA§ë¤©molnupiravir¤§«á¡A¦b¬Û·í©ó¤HÃþ¦bRHD¾¯¶q¤U©Ò¹F¨ì¤§¤HÃþNHC¼ÉÅS¶qªº18­¿¼ÉÅS¶q¤U·|¾É­P­L¨àÅé­«´î»´¡C¦Ò¼{­n¹ï¥¥°ü¨Ï¥Îmolnupiravir®É¡A³B¤èÂå®v¥²¶·¦V¸Ó¥¥°ü»¡©ú¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravirªº¤wª¾©M¼ç¦b®Ä¯q¡A¥H¤Î¼ç¦bªº­·ÀI¡C¥u¦³¦bÂåÀø·ÓÅ@¤H­û½T©w¹ï­Ó§O¥¥°üªº®Ä¯q¶W¶V­·ÀI¤§«á¡A¤~¥i³B¤èmolnupiravirµ¹¸Ó­Ó§O¯f¤H¡C¦pªG¨M©w­n¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravir¡A³B¤èÂå®v¥²¶·µù°O¤w¦V¸Ó­Ó§O¥¥°ü»¡©ú¦bÃh¥¥´Á¶¡¨Ï¥Îmolnupiravirªº¤wª¾©M¼ç¦b®Ä¯q¡A¥H¤Î¼ç¦bªº­·ÀI¡C¦bÃh¥¥´Á¶¡¡A¥¼¸gªvÀøªºCOVID-19¤]·|¬°¥ÀÅé©M­L¨à±a¨Ó­·ÀI¡C ¥Ø«e¨Ã¤£½Tª¾¥»«~¤§¾A¥Î±Ú¸sµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº¦ô­p­I´º­·ÀI¡C©Ò¦³ªºÃh¥¥³£¦³µo¥Í¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­I´º­·ÀI¡C´N¬ü°êªº¤@¯ë¤H¤f¦Ó¨¥¡A¦b¸g¹LÁ{§É½T»{ªºÃh¥¥¤H¤f¤¤¡Aµo¥Í­«¤j¥X¥Í¯Ê³´»P¬y²£ªº­I´º­·ÀI¤À§O¬°2¦Ü4%»P15¦Ü20%¡C Molnupiravir¤£«ØÄ³¥Î©óÃh¥¥°ü¤k,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©ómolnupiravir©Î¨ä¥NÁÂª«¬O§_·|¥X²{©ó¤HÃþªº¨Å¥Ä¤è­±ªº¸ê®Æ¡C´¿¦b§ë¤©molnupiravir¤§±Â¨Å¤j¹«©Ò­÷¨Å¤§¥J¹«ªº¦å¼ß¤¤ÀË¥XNHC¡C¥Ø«e¨Ã¤£½Tª¾molnupiravir¬O§_·|¹ïÁý­÷¥À¨ÅªºÀ¦¨à³y¦¨¼vÅT¡A©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î³y¦¨¼vÅT¡C ¥Ñ©óÀ¦¨à¥i¯à·|¹ïmolnupiravir²£¥Í¤£¨}¤ÏÀ³¡A¦]¦¹¡A¦b¨Ï¥ÎmolnupiravirªvÀø´Á¶¡©M¨Ï¥Î³Ì«á¤@¾¯ÃÄª««á4¤Ñ¤º¤£«ØÄ³Áý­÷¥À¨Å¡C¦bªvÀø´Á¶¡©M¨Ï¥Î³Ì«á¤@¾¯molnupiravir«á4¤Ñ¤º¡A­÷¨Å¯f¤H¥i¯à­n¦Ò¼{¤¤Â_Áý­÷¥À¨Å¡A¤]¥i¯à­n¦Ò¼{±N¨Å¥Ä§l¥X¨Ã¥á±ó¡C ¦b¥X¥Í«e«áµo¨|¬ã¨s¤¤¡A¹ï±Â¨Å¤j¹«§ë¤©?250²@§J/¤½¤ç/¤é¤§¾¯¶qªºmolnupiravir¤§«á¡A´¿¦b­÷¨Å¥J¹«ªº¦å¼ß¤¤ÀË¥XNHC¡C ®Ú¾Ú°Êª«¬ã¨sªºµ²ªG¡A¹ï¥¥°ü§ë¤©molnupiravir¥i¯à·|¹ï­L¨à³y¦¨¶Ë®`¡C,PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã²É§]ªA¡C¤£±o¥´¶}½¦Ån¡CµLªk§]ªA±wªÌ(¨ÌÁ{§É¸ÕÅç)µ¹ÃÄ¤èªk:±N¥|Áû½¦Ån«á¦Ü©ó½Õ»sªM©Îª`®g¾¹¤¤¡A¥[¤ô40mLÅÍ©Õ3¤ÀÄÁ¥B§¡¤Ã²V¦X¡A°t»s§¹½ÐºÉ§ÖªA¥Î©ÎºÞÄé¡A¥i¦bªA¥Î«á¦Aµ¹¤©240mL¥H¤U¤ô¤À½T«O©Ò¦³ÃÄª«§]Ã`§¹¦¨¡C
OOKP,Olanzapine,Okpine F.C. 5mg,CNEU,Treatment of the manifestations of schizophrenia; treatment of acute or mixed mania episodes associated with bipolar I disorder (as monotherapy or in combination with lithium or valproate); maintenance treatment of bipolar I disorder; in combination with fluoxetine for treatment-resistant or bipolar I depression.,Hypersensitivity to olanzapine or any component of the formulation,>10%: Cardiovascular: Orthostatic hypotension (3-20%) Central nervous system: Drowsiness(20-39%)¡A extrapyramidal reaction (10-32%)¡A akathisia (3-27%)¡A parkinsonian-like syndrome (14% to 20%)¡A dizziness (8-11%)¡A headache (adolescents 17%)¡A fatigue (2% to 14%)¡A insomnia (12%) Endocrine & metabolic: Increased serum prolactin (30-47%)¡A weight gain (5-40%) Gastrointestinal: Increased appetite (3-29%)¡A xerostomia (3-22%)¡A dyspepsia (3-11%)¡A constipation (4-11%) Hepatic: Increased serum AST (adolescents 28%)¡A decreased serum bilirubin (adolescents 22%)¡A increased serum ALT (?3 x ULN; adolescents and adults 5% to 12%) Neuromuscular & skeletal: Weakness (8-20%) Miscellaneous: Accidental injury (12%),25¢J¥H¤U¡AÁ×¥ú¤Î¨¾¼éÀã,Adults: Initial dose: Schizophrenia: 10mg QD; manic episodes of bipolar disorder: monotherapy 15mg QD¡A combined therapy 10mg QD; prevent the recurrence of bipolar disorder:10mg QD. The daily dose can be adjusted to 5-20 mg/day according to the patient's clinical condition. The dosing interval should not be less than 24 hours. The elderly¡A >65 years old: consider using a lower initial dose (5 mg/day) Children: Lack of safety and efficacy data. Not recommended for people under 18 years of age.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤¤«×¤£¥þªº¯f±w (¨xµw¤Æ¡BChild-Pugh A©ÎBÃþ¨xª¢ )¡A¨ä°_©l¾¯¶qÀ³¬°5²@§J¡A±ý¼W¥[¾¯¶q®É¶·ÂÔ·V,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OACC6,Acetylcysteine,ACC 600mg µoªw¿õ,ERSP,Acute & chronic respiratory tract infections with abundant mucous secretions. All forms of bronchitis¡A emphysema & bronchopulmonary complications with mucostasis; bronchial catarrh associated with pulmonary tubercular forms.,Effervescent tab Phenylketonuria.,Common: Pruritus (1-3%)¡A Rash (4-5%)¡A Urticaria¡A Diarrhea¡A Nausea (2-7%)¡A Vomiting (9-12%) Serious: Decreased cardiac function¡A Electrocardiogram abnormal¡A Hypervolemia¡A Hypersensitivity reaction (Adult¡A 8-18%; pediatric¡A 10%)¡A Non-allergic anaphylaxis (0.1-0.2%)¡A Status epilepticus¡A Bronchospasm¡A Respiratory distress,25¢J¥H¤U,Effervescent tab Adult & children > 6 years 1 effervescent TAB QD- BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible ¡V maternal benefit >> embryo-fetal risk,ACETYLCYSTEINE PREGNANCY RECOMMENDATION: Compatible¡XMaternal Benefits >> Embryo¡VFetal Risk [¥é³æ]µL¬ÛÃö°O¸ü,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,ACETYLCYSTEINE BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible [¥é³æ]µL¬ÛÃö°O¸ü,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°µoªw¿õ¡AªA¥Î«e±N¦¹µoªw¿õ¸m¬Á¼þ®e¾¹¤¤¡A¥[¤Ö¶q¤ô(60-100mL)·»¸Ñ¡B²V¤Ã«áªA¥Î¡C
RIBI655,Risankizumab/Placebo,¸ÕBI-655066-1311.30 (75mg Risankizumab/Placebo),HIMM,,,,,,,,,,,,,,SC;,,,,,
LCEF,Cefaclor,Cefaclor 25mg/mL¡A 60mL suspension,QANB,2nd generation cephalosporin with in vitro activity against Strep. pyogenes¡A Strep. pneumoniae¡A H. influenzae¡A E. coli¡A Klebsiella sp. and Proteus mirabilis.,Hypersensitivity to cefaclor.,Common Gastrointestinal: Diarrhea (1.4% ) Serious Dermatologic: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile colitis Hematologic: Hemolytic anemia Other: Serum sickness due to drug (0.024% to 0.5% ),15-30¢J¡Aªw»s«á§NÂÃ2-8¢J¥i«O¦s14¤Ñ,Children: 20-40 mg/kg/day in 2-3 divided doses (maximum dose 1 g/day).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]¥¼¦³°O¸ü,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¥¼¦³°O¸ü,AC;AC15;PC;PO;WM;,,,,,
OMAV,Glecaprevir + Pibrentasvir,Maviret 100/40mg,QANB,Treatment of adult chronic hepatitis C virus (HCV) genotype 1¡A 2¡A 3¡A 4¡A 5 or 6 infections.,Hypersensitivity to any component of the formulation.,Headache¡A fatigue¡A Nausea¡A diarrhea,30¢J¥H¤U,Adults and children > or = 12 years: 3 tablets PO once daily with meals (total daily dose: glecaprevir 300 mg¡A pibrentasvir 120 mg) for 8-16 weeks.,»Ý½Õ¾ã¾¯¶q,¤¤«×¨x¥\¯à¤£¥þ¤£«ØÄ³¡A­««×¨x¥\¯à¤£¥þ¸T§Ò¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,PO;WM;,,,,,
EMTS,Mometasone,Metsone cream 0.1%¡A 5gm,TDER,,¾AÀ³¯g:Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid) °Æ§@¥Î: Bacterial skin infection¡A burning¡A furunculosis¡A pruritus¡A skin atrophy¡A tingling/stinging ¸T§Ò:Hypersensitivity to mometasone furoate¡A other corticosteroids¡A or any component of the formulation; untreated fungal¡A bacterial¡A and viral (ie¡A herpes simplex¡A chicken pox¡A and vaccinia) infections involving the skin.,,«Ç·Å,Apply a thin film to affected area once daily,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;,,,,,
OELI2,Apixaban,2.5mg Eliquis ¦ã¥²§J¾®½¤¦ç¿õ,HEMT,Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)¡A w/ >=1 risk factors [eg¡A prior stroke or transient ischaemic attack¡A age >=75 yr¡A HTN¡A DM¡A symptomatic heart failure (NYHA class >=II)]. Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) & pulmonary embolism (PE); prevention of recurrent DVT & PE in adult patients.,Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk. Lesion or condition at significant risk of major bleeding (eg¡A current or recent GI ulceration¡A presence of malignant neoplasms at high risk of bleeding; recent brain/spinal injury¡A brain/spinal/ophth surgery¡A intracranial haemorrhage; known or suspected oesophageal varices¡A arteriovenous malformations¡A vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. Concomitant treatment w/ any other anticoagulant eg¡A unfractionated heparin (UFH)¡A low molecular wt heparins¡A heparin derivatives¡A oral anticoagulants except under the circumstances of switching therapy to or from apixaban or when UFH is given at doses necessary to maintain a patent central venous or arterial catheter.,Common: Contusion (1.4-2.2%)¡A Bleeding gums (<0.1-1.4%)¡A Hematoma (DVT¡A 1.3-1.5%)¡A Menorrhagia (1.4%)¡A Bleeding from nose (DVT and pulmonary embolism¡A 1.5-3.6%; DVT prophylaxis¡A 0.1-<1%)¡A Hemoptysis (<0.1-1.2%) Serious: Gastrointestinal hemorrhage (Atrial fibrillation¡A 0.83%/year; DVT prophylaxis¡A 0.1-<1%; DVT and pulmonary embolism¡A 0.1-<1%)¡A Hematochezia (0.1-<1%)¡A Rectal hemorrhage (<0.1-1%)¡A Upper gastrointestinal bleeding¡A Hemorrhage (Atrial fibrillation¡A 2.08%/year ; DVT prophylaxis¡A 2.88-4.83%)¡A Hemorrhage (0.1-1.4%)¡A Hemorrhage¡A Major (0.1-2.13%)¡A Hemorrhage¡A Operative (DVT prophylaxis¡A 0.1-<1%)¡A Alkaline phosphatase above reference range (DVT prophylaxis¡A 0.1-<1%)¡A Liver function tests outside reference range (DVT prophylaxis¡A 0.1-<1%)¡A Serum bilirubin above reference range (DVT prophylaxis¡A 0.1-<1%)¡A Hypersensitivity reaction (atrial fibrillation¡A <1%)¡A Hemorrhage of muscle (<0.1-<1%)¡A Extradural intracranial hematoma¡A Intracranial hemorrhage (0.33-0.34% per year)¡A Non-traumatic spinal subdural hematoma¡A Traumatic spinal subdural hematoma¡A Conjunctival hemorrhage (0.1-<1%)¡A Retinal hemorrhage (0.1-<1%)¡A Hematuria (DVT¡A 1.4-2.1% ; DVT prophylaxis¡A 0.1-<1%),30¢J¥H¤U,Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 5 mg twice daily unless patient has any 2 of the following: Age >=80 years¡A body weight =<60 kg¡A or serum creatinine >=1.5 mg/dL¡A then reduce dose to 2.5 mg twice daily. Deep venous thrombosis: Oral:Treatment: 10 mg twice daily for 7 days followed by 5 mg twice daily. Reduction in the risk of recurrence: 2.5 mg twice daily after at least 6 months of treatment for DVT,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¸T¥Î©ó¦³¾®¦å²§±`¤ÎÁ{§É¬ÛÃö¥X¦å­·ÀIªº¨x¯f¯f¤H¡C¤£«ØÄ³¥Î©ó­««×¨x¥\¯à¤£¥þªº¯f¤H¡C¹ï©ó»´©Î¤¤«×¨x¥\¯à¤£¥þ(Child Pugh A/B)¯f¤HÀ³ÂÔ·V¨Ï¥Î¡A¤£¶·½Õ¾ã¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,APIXABAN: No Human Data¡XPotential Risk [¥é³æ] Ãö©ó¥¥°ü¨Ï¥ÎELIQUISªº¥i¥Î¸ê®Æ¦³­­¡A¤£¨¬¥HÅã¥Ü»PÃÄª«¬ÛÃöªº­«¤j¥ý¤Ñ¯Ê³´¡B¬y²£©Î¤£¨}µo¨|µ²ªG­·ÀI¡C ¨Ï¥Î¥»«~ªvÀø¥i¯à·|¼W¥[Ãh¥¥»P¥Í²£´Á¶¡ªº¥X¦å­·ÀI¡C¦b°Êª«Ác´Þ¸ÕÅç¤¤¡A©ó¾¹©x§Î¦¨´Á¶¡¤À§Oµ¹¤©¤j¹«¡]¤fªA¡^¡B¨ß¤l¡]ÀR¯ßª`®g¡^¤Î¤p¹«¡]¤fªA¡^¬Û·í©ó¤HÃþ¥¼µ²¦XapixabanÃnÃÄ¶q¤À¡H¬°4¡B1¤Î19­¿¾¯¶q¡A¥¼Æ[¹î¨ìapixaban¨ã¦³¹ïµo¨|ªº¤£¨}¼vÅT¡C ¥Ø«e©|¤£²M·¡«ü©w±Ú¸s­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº¦ô­p­I´º­·ÀI¡C©Ò¦³Ãh¥¥¬Ò¦³¥ý¤Ñ¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªGªº­I´º­·ÀI¡C¦b¬ü°ê¤@¯ë±Ú¸s¤¤¡AÁ{§É¤½»{ªºÃh¥¥­«¤j¥ý¤Ñ¯Ê³´©M¬y²£¦ô­p­I´º­·ÀI¤À¡H¬°2%¦Ü4%©M15%¦Ü20%¡C Á{§É¦Ò¶q »P¯e¯f¬ÛÃöªº¥ÀÅé©M/©Î­F­L/­L¨à­·ÀI Ãh¥¥·|¼W¥[¦å®ê®ê¶ëªº­·ÀI¡A¹ï©ó¨ã¦³¼ç¦b¦å®ê®ê¶ë©Ê¯e¯f©M¯S©w°ª§³®Wªº°ü¤k¨Ó»¡¡A¦å®ê®ê¶ëªº­·ÀI§ó°ª¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡A¥ý«e¨ã¦³¦å®ê§Î¦¨¯f¥vªº¤k©Ê¦bÃh¥¥´Á¶¡¦³«Ü°ªªº´_µo­·ÀI¡C [¥é³æ¸`¿ý]Ãö©ó¥¥°ü¨Ï¥ÎELIQUISªº¥i¥Î¸ê®Æ¦³­­¡A¤£¨¬¥HÅã¥Ü»PÃÄª«¬Ûªº­«¤j¥ý¤Ñ¯Ê³´¡B¬y²£©Î¤£¨}µo¨|µ²ªG­·ÀI¡C¨Ï¥Î¥»«~ªvÀø¥i¯à·|¼W¥[Ãh¥¥»P¥Í²£´Á¶¡ªº¥X¦å­·ÀI¡C¦b°Êª«Ác´Þ¸ÕÅç¤¤¡A©ó¾¹©x§Î¦¨´Á¶¡¤À¡Hµ¹¤©¤j¹«¡]¤fªA¡^¡B¨ß¤l¡]ÀR¯ßª`®g¡^¤Î¤p¹«¡]¤fªA¡^¬Û·í©ó¤HÃþ¥¼µ²¦XapixabanÃnÃÄ¶q¤À¡H¬°4¡B1¤Î19­¿¾¯¶q[¥H¦å¤¤¿@«×¦±½u¤U­±¿n(AUC)¬°°òÂ¦¡A©M5²@§J¨C¤é¨â¦¸ªº¤HÃþ³Ì°ª«ØÄ³¾¯¶q(MRHD)¶i¦æ¤ñ¸û]¡A¥¼Æ[¹î¨ìapixaban¨ã¦³¹ïµo¨|ªº¤£¨}¼vÅT¡C Ãh¥¥·|¼W¥[¦å®ê®ê¶ëªº­·ÀI¡A¹ï©ó¨ã¦³¼ç¦b¦å®ê®ê¶ë©Ê¯e¯f©M¯S©w°ª­·ÀI§³®Wª¬úGªº°ü¤k¨Ó»¡¡A¦å®ê®ê¶ëªº­·ÀI§ó°ª¡C¤wµoªíªº¸ê®ÆÅã¥Ü¡A¥ý«e¨ã¦³ÀR¯ß¦å®ê§Î¦¨¯f¥vªº¤k©Ê¦bÃh¥¥´Á¶¡¦³«Ü°ªªº´_µo­·ÀI¡C ¨Ï¥Î¥]¬AELIQUISªº§Ü¾®¦å¾¯¡A¥i¯à·|¼W¥[­L¨à©M·s¥Í¨à¥X¦åªº­·ÀI¡C ©Ò¦³±µ¨ü§Ü¾®¦å¾¯ªvÀøªº¯f¤H¡]¥]¬A¥¥°ü¡^¡A³£¦³¥X¦åªº­·ÀI¡C ±µ¨ü´ÕºÞ¡H³Â¾Kªº¤k©Ê¤¤¡A¦b¤À®Y©Î¥Í²£´Á¶¡¨Ï¥ÎELIQUIS¥i¯à·|¾É­Pµw¯á½¤¥~©Î¯áÅè¦å¸~¡C¥i¦Ò¼{©ó¥Í²£´Á¶¡¨Ï¥Î§óµu®Äªº§Ü¾®¦å¾¯¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,APIXABAN: No Human Data¡XPotential Toxicity [¥é³æ] ¥Ø«e¨S¦³Ãö©ó¤HÃþ¨Å¥Ä¤¤apixaban©Î¨ä¥NÁÂ²£ª«ªº¦s¦b¡A¹ï¥À¨Å­÷«Ä¤l©Î¹ïªc¨Å¶q¼vÀ\ªº¸ê®ÆApixaban©M/©Î¨ä¥NÁÂ²£ª«¦s¦b©ó¤j¹«¨Å¥Ä¤¤¡C¥Ñ©ó©|¤£²M·¡¤HÃþ¬O§_·|³z¹L¨Å¥Ä±µÄ²ÃÄª«¡A¦]¦¹±µ¨üELIQUISªvÀø´Á¶¡¤£«ØÄ³¥À¨ÅÁý­÷¡C,AC;AC15;PC;PO;,,,,,
IHEP20,Heparin,Hepac Plus for Dialysis 5000 Unit/20mL(250Unit/mL),HEMT,Anticoagulant for extracorporeal circulation device during hemodialysis.,Hypersensitivity to the drug¡A Bleeding disorders¡A Severe thrombocytopenia¡A Patients who can't undergo regular blood coagulation tests¡A Patients with heparin-Induced Thrombocytopenia.,Common Hematologic: Thrombocytopenia (Up to 30% ) Hepatic: Increased liver aminotransferase level Serious Hematologic: Hemorrhage (5% to 10% )¡A Heparin-induced thrombocytopenia (0.6% to 10% )¡A Heparin-induced thrombocytopenia with thrombosis (Less than 1% ) Immunologic: Hypersensitivity reaction Neurologic: Non-traumatic spinal subdural hematoma,30¢J¥H¤U,1000-3000 units before general systemic heparinization¡A followed by 500-1500 units hourly after starting of dialysis¡A or adding on 500-1500 units intermittenly could be considerated.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] §ëÃÄ¤©¥¥°ü¡B²£°ü¡B­÷¨Å°ü¤k: ¥¥°ü©Î¦³Ãh¥¥¥i¯àªº°ü¤H¡A·íªvÀø¤Wªº®Ä¯q»·¤j©ó¦MÀI©Êªºª¬ªp¤U¤~¥i§ëÃÄ¡C ¡£Ãh¥¥¤¤ªº§ëÃÄ¬ÛÃö¦w¥þ©Ê©|¥¼½T¥ß¡C¡¤,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] §ëÃÄ¤©¥¥°ü¡B²£°ü¡B­÷¨Å°ü¤k: ¥¥°ü©Î¦³Ãh¥¥¥i¯àªº°ü¤H¡A·íªvÀø¤Wªº®Ä¯q»·¤j©ó¦MÀI©Êªºª¬ªp¤U¤~¥i§ëÃÄ¡C ¡£Ãh¥¥¤¤ªº§ëÃÄ¬ÛÃö¦w¥þ©Ê©|¥¼½T¥ß¡C¡¤,IRR;,,,,ª`®g°wµ©²£«~¬ÛÃöª`·N¨Æ¶µ: 1)¥~¥]¸Ë¦Ü¨Ï¥Î«e³£¤£­n¶}«Ê 2)°wµ©¦³¥i¯à·|¯}·l¡A¬G»ÝÁ×§K±j¯P½ÄÀ» 3)±q¥~¥]¸Ë¨ú¥X®É¡A¤£­n¥Ñ±À±ì¨ú¥X.½¦¶ëÅÜ§Î¡A±À±ì²æ¸¨ªº¸Ü¡A¥i¯à·|³y¦¨ÃÄ²Gº|¥X 4)ÃÄ²Gº|¥X©Î¬OÃÄ²G¸Ì¦³²V¿B©Î¯B´åª«µ¥²§±`ª¬ªp¬Ò¤£­n¨Ï¥Î 5)°wµ©¯}·lµ¥²§±`ª¬ªpµo¥Í®É¤£­n¨Ï¥Î 6)¨ú¤U°wµ©«eºÝªº¶ë»\«á¡A¤£­n±µÄ²°wµ©«eºÝ³¡¤À 7)ª`¤J«e«á³£¤£­n©Ô±À±ì 8)¶}«Ê«á­­¤@¦¸¨Ï¥Î¡A¨Ï¥Î«áªº´Ý¯d²GÅé»P®e¾¹»Ý¾¨³tºÉ³t¥á±ó 9)°wµ©¤£­n¦A·Àµß¤Î¦A¨Ï¥Î 10)±µ¤Wª`®g°wµ¥®É»Ýª`·N¤£­n¨ë¨ì¡A¨Ã¨c¨c©T©w,¨Ï¥Îª`®gÀ°®ú§ëÃÄ¡AÀ³ª`·N¤U­z´XÂI: 1)°È¥²½T»{¥i¬[³]©óª`®gÀ°®ú¡A¨Ã¥B¨Ì·Óª`®gÀ°®úµ¥ªº¨Ï¥Î»¡©ú®Ñ§ëÃÄ 2)½T¹ê¬[³]©óª`®gÀ°®ú¤ºµ©·Æ°Ê³¡(slider)ªº¹_¤l.­Y¨S¦³¥¿½T¬[³]¡A¥i¯à·|µo¥Í­i§l(¦]¦ÛµM¸¨¤U²£¥Í§Ö³tª`¤J)©Î°f¬y 3)¥»«~¬[³]©ó¦å²GÀ°®ú¤U´å¡A§Ü¾®¦å¾¯ª`¤JºÞ½uªº¦å²G°j¸ô³B.¦]¦å²G°j¸ôªý¶ëµ¥·|µo¥Í·¥ºÝ­tÀ£¡A½¦¶ë¥i¯à·|±q±À±ì²æ¸¨¡A©Î±À±ì¥i¯à·|±qª`®gÀ°®úªº¤ºµ©·Æ°Ê³¡(slider)ªº¹_¤l²æ¸¨¡A³y¦¨¥»«~§Ö³tª`¤J.
IKAD00,Trastuzumab Emtansine,KADCYLA inj 160mg (sample),RACA,Metastatic breast cancer¡A HER2 overexpression¡A monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.,Specific contraindications have not been determined.,Common: Constipation (17-27%)¡A Nausea (40-42%)¡A Hemorrhage¡A All Grades (29-32%)¡A Thrombocytopenia¡A All Grades (29-31%)¡A Increased liver enzymes¡A All Grades (29-32%)¡A Musculoskeletal pain (30-36%)¡A Headache (28%)¡A Fatigue (36%) Serious: Heart failure¡A Left ventricular cardiac dysfunction (1.8-3%)¡A Injection site extravasation¡A Anemia¡A Grade 3 or 4 (1.1-4.1%)¡A Hemorrhage¡A Grade 3 or 4 (0.4-1.8%)¡A Thrombocytopenia¡A Grade 3 or 4 (6-15%)¡A Hepatotoxicity¡A Increased liver enzymes¡A Grade 3 or 4 (1.5-8%)¡A Injury of liver¡A Liver regeneration (0.3-0.4%)¡A Non-allergic anaphylaxis¡A Dyspnea (8-12%)¡A Interstitial lung disease¡A Pneumonitis (1.1-1.2%),2-8¢J,3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever¡A chills¡A or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.,µL»Ý½Õ¾ã¾¯¶q,Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution. Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Lactation studies with trastuzumab emtansine have not been conducted. Small amounts of trastuzumab were excreted in the milk of lactating monkeys following postpartum administration of trastuzumab in doses up to 25 mg/kg (approximately 7 times the recommended human dose). It is unknown whether ado-trastuzumab emtansine is excreted into human milk. Because many drugs are excreted in human milk and risk to the nursing infant cannot be excluded¡A a decision should be made to discontinue treatment or discontinue nursing taking into account the importance of the drug to the mother.,IVD;,,,,,1. ¿éª`·»²G¤£¥i§t¸²µå¿}¡C 2. ²Ä¤@¦¸¨Ï¥Î«ØÄ³¬I¥´90¤ÀÄÁ¡A¤§«áµø¯f¤H­@¨üµ{«×¥iÁYµu¿éª`®É¶¡¦Ü³Ìµu30 ¤ÀÄÁ¡C½Ð¨Ï¥Î0.2-0.22·L¦Ì¡B¤£§lªþ³J¥Õ½èªººÞ½u¤º polyethersulfone (PES)¹LÂo¾¹¡C 3. ·»²G°t¸m«áÀ³¥ß§Y¨Ï¥Î¡A§NÂÃ©ó2-8¢J³Ì¦hÀx¦s24¤p®É¡C 4. ¿éª`®Éª`·N¯f¤H¬O§_¥X²{©I§l§xÃø¡B©PÃä¤ô¸~¡B§C¦åÀ£©Î¨ä¥L«æ©Ê¹L±Ó¤ÏÀ³¯gª¬¡C 5. ºÊ´úCBC¡B¨xµÇ¥\¯à¡C
OCARD4,Propranolol,Cardolol 40mg,CAVS,Adult HTN¡A Angina¡A migraine & essential tremor¡A Arrhythmias¡A anxiety tachycardia¡A thyrotoxicosis¡A Pheochromocytoma.,History of bronchial asthma or bronchospasm¡A bradycardia¡A cardiogenic shock¡A hypotension¡A metabolic acidosis¡A after prolonged fasting¡A severe peripheral arterial circulatory disturbances¡A 2nd or 3rd degree heart block¡A sick sinus syndrome¡A untreated (with an alpha adrenoceptor antagonist) phaeochromocytoma¡A uncontrolled heart failure¡A Prinzmetal's angina.,Cold extremities¡A GI & sleep disturbances¡A fatigue¡A lassitude. Deterioration in heart failure¡A mood changes. Isolated cases of paresthesia. Rarely bradycardia¡A dizziness¡A postural hypotension which may be associated with syncope¡A heart block¡A alopecia¡A thrombocytopenia¡A purpura¡A psoriasiform skin reactions¡A exacerbation of psoriasis¡A visual disturbances¡A CNS symptoms including hallucinations & psychoses; hypoglycaemia in children. Rashes & dry eyes (discontinue drug). Intermittent claudication¡A Raynaud's phenomenon¡A bronchospasm¡A increased antinuclear antibodies. Dermatologic: Dermatitis¡A Pruritus¡A Urticaria Neurologic: Dizziness (4% to 7% ) Other: Fatigue (5% to 7% ),«Ç·Å,Angina: PO¡A initially¡A 10-20mg TID-QID; maintenance¡A 160-240mg/day. Arrhythmia: Adult: PO¡A 10-30mg TID-QID AC. Child: PO¡A initially¡A 1.5-2mg/kg/day¡A titrate up to a maximum. 16mg/kg/day in 4 doses. Essential tremor: PO¡A initially¡A 40mg BID; maintenance¡A 120-320mg/day in 3 doses. Hypertension: PO. Adult: Initially¡A 40mg BID; maintenance¡A 160-480mg/day. Child: Initially¡A 1mg/kg/day in 2 doses; maintenance¡A 1-5mg/kg/day in 2-4 doses. Migraine: PO¡A initially¡A 80mg/day in divided doses; maintenance¡A160-240 mg/day. Pheochromocytoma: PO¡A 60mg/day in divided doses for 3 days before surgery; 30 mg/day in divideddoses with an adrenergic blocker as an adjunct to prolonged treatment of intolerable pheochromocytoma. Post-MI: PO¡A 180-240mg/day in divided doses.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¨}¡A¨Ï¥Î¥»ÃÄ»Ý¸û§C¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
IMMR1,Measles + Mumps + Rubella,MMR II (³Â¯lµ¥¤TºØ¬Ì­]¡A ¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Immunization against measles¡A mumps & rubella in individuals ¡Ù 12 months¡A non-pregnant adolescents¡A adult female & postpartum women. Children ¡Ø12 months¡A should be revaccinated after reaching 15 months.,Pregnancy. Any febrile infection or febrile respiratory illness. Active untreated TB¡A blood dyscrasias¡A leukemia¡A lymphomas of any type¡A malignant neoplasms affecting the bone marrow or lymphatic system. Patients receiving immunosuppressive therapy. Primary & acquired immunodeficiency states¡A or family history of immunodeficiency. Hypersensitivity to neomycin or eggs.,Burning¡A stinging at inj site. Headache¡A fever¡A sore throat¡A GI upset¡A rash¡A arthralgia &/or arthritis¡A parotitis¡A nerve deafness¡A optic neuritis. Lymphadenopathy¡A afebrile convulsions¡A ataxia¡A Guillain-Barre syndrome¡A thrombocytopenia purpura¡A dizziness¡A paraesthesias.,2-8¢JÁ×¥ú,SC¡A 0.5mL¡A children 6-12 months primary immunization¡A the second dose at 15 months of age¡A the third dose at 4-6 years or 11-12 years. Age > or = 12 months primary immunization¡A the second dose at 4-6 years or 11-12 years.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]Ãh¥¥°ü¤k¤£±o¨Ï¥ÎPriorix. µM¦Ó¡AÃh¥¥°ü¤k¦b¬I¥´³Â¯l¡A¸|¸¢ª¢©Î¼w°ê³Â¯l¬Ì­]«á¡A¨ÃµLµo¥ÍÄY­«¶Ë®`ªº°O¿ý. ¾¨ºÞ­ì²z¤Wªº­·ÀIµLªk³Q±Æ°£¡A¦ý¦³¶W¹L3500¤£ª¾¤wÃh¥¥ªº°ü¤k¡A¦b±µºØ¥]§t¼w°ê³Â¯l¬Ì­]«á¡A¨Ã¨S¥X²{¦³¥ý¤Ñ©Ê¼w°ê³Â¯l¯g­Ô¸sªº®×¨Ò. ¦]¦¹¡A¹ï©ó¤£ª¾¤wÃh¥¥ªº°ü¤k¦b«D¨è·N±µºØ¥]§t³Â¯l¡A¸|¸¢ª¢©Î¼w°ê³Â¯l¬Ì­]«á¡A¤£»Ý¦]¦¹¦Ó²×¤îÃh¥¥. ¨|ÄÖ°ü¤kÀ³Á×§K©ó±µºØ«á¥|¶g¤ºÃh¥¥¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Measles- No Human Data-Probably Compatible Mumps- No Human Data-Probably Compatible Rubella- Compatible [¥é³æ]¦³Ãö±Â¨Å°ü¤k¨Ï¥Î±¡ªpªº¸ê®Æ«Ü¤Ö¡A·íÅv¿Å«á¡A¨ä§Q¯q°ª©ó­·ÀI«h¥i±µºØ¬Ì­].,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G,,,,1. ª`®gMMR II®É¡A¤£¥i¦P®Éµ¹¤©§K¬Ì²y³J¥Õ¡C 2. ¥Ö¤Uª`®g³Ì¦nªºª`®g¦ì¸m¬O¤WÁuªº¥~°¼¡C 3.±µ¨ü¤@¯ë¦Ù¦×ª`®g§K¬Ì²y³J¥ÕªvÀø©ÎB«¬¨xª¢§K¬Ì²y³J¥Õ¡A©y¶¡¹j3­Ó¤ë«á¦A±µºØPriorix. 4.¿é¹L¦å©Î±µ¨üÀR¯ßª`®g¦å²G»s«~ªÌ¡A©y¶¡¹j6­Ó¤ë¦A±µºØPriorix. 5.´¿ÀR¯ßª`®g°ª¾¯¶q(¤j©óµ¥©ó1g/kg)§K¬Ì²y³J¥ÕªvÀø®É¡A©y¶¡¹j11­Ó¤ë«á¦A±µ¨üPriorix.
IMMR2,Measles + Mumps + Rubella,M-M-R II 0.5mL/dose (¦Û¶O³Â¯lµ¥¤TºØ¬Ì­]),HIMM,Immunization against measles¡A mumps & rubella in individuals ¡Ù 12 months¡A non-pregnant adolescents¡A adult female & postpartum women. Children ¡Ø12 months¡A should be revaccinated after reaching 15 months.,Pregnancy. Any febrile infection or febrile respiratory illness. Active untreated TB¡A blood dyscrasias¡A leukemia¡A lymphomas of any type¡A malignant neoplasms affecting the bone marrow or lymphatic system. Patients receiving immunosuppressive therapy. Primary & acquired immunodeficiency states¡A or family history of immunodeficiency. Hypersensitivity to neomycin or eggs.,Burning¡A stinging at inj site. Headache¡A fever¡A sore throat¡A GI upset¡A rash¡A arthralgia &/or arthritis¡A parotitis¡A nerve deafness¡A optic neuritis. Lymphadenopathy¡A afebrile convulsions¡A ataxia¡A Guillain-Barre syndrome¡A thrombocytopenia purpura¡A dizziness¡A paraesthesias.,2-8¢J,SC¡A 0.5mL¡A Children 6-12 months primary immunization¡A the second dose at 15 months of age¡A the third dose at 4-6 years or 11-12 years. Age > or = 12 months primary immunization¡A the second dose at 4-6 years or 11-12 years.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]·í¥¥°ü±µºØ M-M-RII®É¡A¬O§_¹ï­L¨à³y¦¨¶Ë®`©Î¼vÅT¥¥°ü¤§¥Í´Þ¯à¤O¡A¥Ø«e©|¥¼ª¾¾å¡C ¦]¦¹¡AÃh¥¥¤k©Ê¤£À³¨Ï¥Î M-M-RII¡C¥t¥~¡A°ü¤k©ó±µºØ¦¹¬Ì­]«á 1 ­Ó¤ë¤ºÀ³Á×§KÃh¥¥¡C ¤@¶µ½Õ¬d 18 ¦~¶¡¡A¶W¹L 1200 ¦ì©óÃh¥¥«e«á 3 ­Ó¤ë¤º±µºØ¼w°ê³Â¯l¬Ì­]°ü¤kªº¬ã¨s¡A¥¼µo²{·s¥Í¨à¦³¥ý¤Ñ©Ê¼w°ê³Â¯l¯g­Ô¸s¤§²§±`¡C ®Ú¾Ú¥Ø«e¤W¥««á³ø§i¤Î¤wµoªí¤§Æ[¹î©Ê¬ã¨s¤¤¥ç©|¥¼µo²{±µºØM-M-R II °ü¤k²£¤Uªº·s¥Í¨à¥X²{¥ý¤Ñ©Ê¼w°ê³Â¯l¯g­Ô¸s¤§²§±`¡C ¦bÃh¥¥ªº«e¤T­Ó¤ë·P¬V¸|¸¢ª¢·|¼W¥[¦ÛµM¬y²£ªº¾÷²v¡CÁöµM¸|¸¢ª¢¬Ì­]¤§¯f¬r³Qµo²{·|·P¬V­L½L¤Î­L¨à¡A¦ý¨S¦³ÃÒ¾ÚÃÒ©ú¨ä·|¾É­P¤HÃþ¥ý¤Ñ©Ê·î§Î¡C ³ø§i«ü¥XÃh¥¥´Á¶¡·P¬V³¥¥ÍºØ³Â¯l·|¼W¥[­L¨à¦MÀI¡C¦ÛµM¬y²£¡B¦º­L¡B¥ý¤Ñ©Ê¯Ê³´¤Î¦­²£ªº¾÷²v³£·|¼W¥[¡C ´î¬rªº³Â¯l¬Ì­]¯f¬r¹ïÃh¥¥¤§¼vÅT¡A©|¥¼¦³¨¬°÷ªº¬ã¨s¡CµM¦Ó¡A³Ì¦n¤p¤ß°²³]³o¨Ç¬Ì­]¯f¬rµß®è¤]·|¹ï­L¨à³y¦¨¤£¨}¼vÅT¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Measles- No Human Data-Probably Compatible Mumps- No Human Data-Probably Compatible Rubella- Compatible [¥é³æ]¦³Ãö±Â¨Å°ü¤k¨Ï¥Î±¡ªpªº¸ê®Æ«Ü¤Ö¡A¨ä§Q¯q°ª©ó­·ÀI«h¥i±µºØ¡C,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G,,,,1. ª`®gMMR II®É¡A¤£¥i¦P®Éµ¹¤©§K¬Ì²y³J¥Õ¡C 2. ¥Ö¤Uª`®g³Ì¦nªºª`®g¦ì¸m¬O¤WÁuªº¥~°¼¡C
IDUPI,Dupilumab,DUPIXENT inj 300mg/2mL,TDER,Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.,Known hypersensitivity to dupilumab or any component of the formulation,Common: Injection site disorder (Adult¡A 6-18%; adult and pediatric¡A 38%)¡A Oral herpes simplex infection (3-4%)¡A Pain in throat¡A and mouth (2%)¡A Herpes simplex¡A Excluding oral and ophthalmic herpes simplex (1-2%)¡A Blepharitis (Up to 5%)¡A Conjunctivitis (Asthma¡A 1.5% ; atopic dermatitis¡A 9-20% ; chronic rhinosinusitis with nasal polyposis¡A 2%; prurigo nodularis¡A 4% ; eosinophilic esophagitis¡A 4%)¡A Dry eyes (Up to 2%)¡A Itching of eye (1-2%)¡A Keratitis (Atopic dermatitis¡A up to 4%) Serious: Arterial thromboembolism (0-0.9%)¡A Vasculitis¡A Eosinophil count above reference range (1-2%)¡A Hypersensitivity reaction (<1%)¡A Arthralgia (2-3%)¡A Pulmonary eosinophilia¡A Angioedema¡A Helminth infection,2-8¢JÁ×¥úÁ×§K§N­á,Atopic dermatitis¡A Moderate to severe Adult¡A initial¡A 600 mg (two 300 mg injections) SC¡A then 300 mg SC every other week Adolescents 12 to 17 Years Old¡A if <60kg 400 mg (two 200 mg injections) SC¡A then 200 mg SC every other week. If>60kg 600 mg (two 300 mg injections) SC¡A then 300 mg SC every other week. Concomitant therapy: Use with or without topical steroids; reserve concomitant use with topical calcineurin inhibitors for problem areas only (eg¡A face¡A neck¡A intertriginous and genital areas Asthma (Moderate to Severe)¡A Adjunct; oral corticosteroid-dependent (12 years or older) Loading¡A 400 mg (two 200 mg injections) SC followed by 200 mg every other week or an initial loading dose of 600 mg (two 300 mg injections) SC followed by 300 mg every other week. For patients with oral corticosteroid-dependent asthma or with comorbid moderate-to-severe atopic dermatitis¡A start with the 600-mg dose followed by 300 mg every other week,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]®Ú¾ÚDupixent¨Ï¥Î©óÃh¥¥°ü¤kªº­Ó®×³ø§i¤Î£¸³s¦ê­Ó®×¤§²{¦³¸ê®Æ¡A¨Ã¥¼µo²{¦³­«¤j¥X¥Í¯Ê³´¡B¬y²£¡A©Î¹ï¥ÀÅé©Î­L¨à³y¦¨¤£¨}¼vÅTªºÃÄª«¬ÛÃö­·ÀI¡C¤wª¾¤HÃþ§K¬Ì²y³J¥ÕG(IgG)·|³q¹L­L½L»Ù¾À¡F¦]¦¹Dupixent¦³¥i¯à·|±q¥ÀÅé¶Ç»¼¦Üµo¨|¤¤ªº­L¨à¡CÃh¥¥´Á®ð³Ý·|¹ï¥ÀÅé©M­L¨à³y¦¨¤£¨}¼vÅT¡C¦b¤@¶µ¶i¶¥«¬¶g²£´Á«e«á¤§¥®­Lµo¨|¬ã¨s¤¤¡AÃh¥¥¥ÀµU¦b­F­L¾¹©x§Î¦¨´Á¦Ü¤À®Y´Á¶¡±µ¨ü§Ü¤¶¥Õ¯À-4£\¨üÅé(IL-4R£\)¤§¦P·½§ÜÅé(homologous antibody)¦Ü¦h¹F10­¿¤HÃþ³Ì¤j«ØÄ³¾¯¶q(MRHD)¤§¥Ö¤Uª`®g¡A¥¼¨£¹ï¥®µUªºµo¨|³y¦¨¤£¨}¼vÅT¡C¯S©w±Ú¸s¤§­«¤j¥X¥Í¯Ê³´¤Î¬y²£ªº¹w¦ô­I´º­·ÀI¨Ã¤£²M·¡¡C©Ò¦³ªºÃh¥¥³£¦³¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªG¤§­I´º­·ÀI¡C¥H¬ü°ê¤@¯ë±Ú¸s¨Ó»¡¡AÁ{§É¤W½T»{¤§Ãh¥¥µo¥Í­«¤j¥X¥Í¯Ê³´¤Î¬y²£ªº¹w¦ô­I´º­·ÀI¤À§O¬°2-4%¤Î15-20%¡C ®ð³Ý±±¨î®t©Î¤¤«×±±¨îªº°ü¤k¡A¦³ÃÒ¾ÚÅã¥Ü·|¼W¥[¥ÀÅé¤lÅö«e¯g¤Î·s¥Í¨à¦­²£¡B§C¥X¥ÍÅé­«©M­L¨à¤p©ó§³®W¦~ÄÖªº­·ÀI¡CÀ³ÄY±KºÊ´úÃh¥¥°ü¤kªº®ð³Ý±±¨îª¬ªp¡A¥B¥²­n®ÉÀ³½Õ¾ãªvÀø¥Hºû«ù³Ì¾A±±¨î¡C ¦b¤@¶µ¶i¶¥«¬¶g²£´Á«e«á¤§¥®­Lµo¨|¬r©Ê¬ã¨s¤¤¡AÃh¥¥­¹ÃÉµU(cynomolgus monkeys)©ó­F­L¾¹©x§Î¦¨ªì´Á¦Ü¤À®Y´Á¶¡¡A¨C¶g¥H¥Ö¤Uª`®g¤è¦¡§ë¤©¦Ü¦h¹F10­¿¤HÃþ³Ì¤j«ØÄ³¾¯¶q(MRHD)(¥Hmg/kg¬°­pºâ°òÂ¦¡A¨ä¾¯¶q¬°100mg/kg/week)ªº§Ü¤¶¥Õ¯À-4£\¨üÅé(IL-4R£\)¤§¦P·½§ÜÅé(homologous antibody)¡A¥JµU±q¥X¥Í°_¦Ü6­Ó¤ë¤j¬Ò¥¼Æ[¹î¨ì¦¹ªvÀø©Ò³y¦¨ªº¤£¨}¼vÅT¡A¥]¬A­F­L-­L¨à¬r©Ê©Î·î§Î¡A¥ç¥¼¨£¦¹ªvÀø¹ï¥JµU©ó«¬ºA¡B¥\¯à©Î§K¬Ì¾Ç¤W¤§µo¨|³y¦¨¤£¨}¼vÅT¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]Dupixent¬O§_·|¤Àªc¦Ü¤HÅé¨Å¥Ä¡B¹ï§l§m¥À¨Å¤§À¦¨àªº¼vÅT¡A©Î¹ï¥À¨Å¥Í¦¨ªº¼vÅT¡A¥Ø«e©|µL¬ÛÃö¸ê®Æ¡C¤wª¾¥ÀÅé§K¬Ì²y³J¥ÕG(IgG)·|¶i¤J¤HÅé¨Å¥Ä¡C§l§m¥À¨Å¤§À¦¨à¡A¨ä­G¸z¹D§½³¡¼ÉÅS©M¥þ¨­©Ê¦³­­¼ÉÅS©ódupilumab©Ò³y¦¨ªº¼vÅT¡A¥Ø«e¤£±o¦Óª¾¡C·í¦Ò¶q­÷¨Å¹ïÀ¦¨àµo¨|¤Î°·±dªº¯q³B®É¡AÀ³¦P®É¦Ò¼{¥À¿Ë¹ïDupixent¤§Á{§É»Ý¨D¡A¥H¤ÎDupixent©Î¥À¿Ëªº¼ç¦b¯fªp¹ï§l§m¥À¨Åªº¥®¨à¥i¯à³y¦¨ªº¥ô¦ó¤£¨}¼vÅT¡C,SC;,,,X,X,1. À³Àx¦s©ó¦B½c2- 8¢J¡A¦b«Ç·Å (³Ì°ª¦Ü25?¢J)¤U¥i«O¦s14¤Ñ¡C¤£¥i¾_·n¡B¥[¼ö¡B§N­áª`®g¾¹¡C 2. ¨Ï¥Î«e©ó¥­­±¤WÀR¸m45¤ÀÄÁ¨Ï¨ä¦ÛµM¦^·Å¦Ü«Ç·Å¡CÁ×§K¤é¥ú·Ó®g¡C 3. ±µ¨üDupixentªvÀøªº¯f¤HÀ³Á×§K±µºØ¬¡©Ê¬Ì­]¡C 4. ­Yº|¥´¤@¦¸¾¯¶q¡AÀ³¦bº|¥´¾¯¶q«áªº¤Ñ¤º¸É¦æª`®g¡A¤§«á«h«ö·Ó­ì¦³®Éµ{µ¹ÃÄ¡C­Yº|¥´ªº¾¯¶q¨S¦³¦b7¤Ñ¤ºª`®g¡A«hÀ³¨Ì·Ó­ì¦³®Éµ{µ¥¨ì¤U¦¸¾¯¶q¦Aµ¹ÃÄ¡C
OCAL5,Calcium Carbonate,Calcium Carbonate 500mg,NUTR,Relief of the symptoms of gastric hyperacidity.,Hypercalcaemia due to myeloma¡A bone metastases or other malignant bone disease¡A sarcoidosis; primary hyperparathyroidism¡A vitamin D overdosage; severe renal failure.,Mild GI disturbances.,25¢J¥H¤U,1 TAB equivalent to 200mg of elemental calcium. >12 years old: 2 TAB TID. 6-12 years old: 1 TAB TID. 3-6 years old: 0.5 TAB TID. [UpToDate 20210731] Adult: Antacid: Generally¡A 1 to 4 tablets as symptoms occur; maximum: 8 g/day as calcium carbonate for up to 2 weeks. Calcium supplementation: 500 mg to 4 g/day as calcium carbonate (equivalent to 200 mg to 1.6 g of elemental calcium) in 1 to 3 divided doses. Pediatric: Antacid: Children 2 to 5 years¡A weighing >10.9 kg: 375 to 400 mg of calcium carbonate as symptoms occur for up to 2 weeks; maximum daily dose: 1500 mg/day of calcium carbonate. Children 6 to 11 years: 750 to 800 mg of calcium carbonate as symptoms occur for up to 2 weeks; maximum daily dose: 3¡A000 mg/day of calcium carbonate. Children > or = 12 years and Adolescents: 500 to 3¡A000 mg of calcium carbonate as symptoms occur for up to 2 weeks; maximum daily dose: 7500 mg/day of calcium carbonate. Calcium dietary supplementation: Children 2 to 4 years: 750 mg of calcium carbonate twice daily. Children > or = 4 years and Adolescents: 750 mg of calcium carbonate 3 times daily.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding.,AC;AC15;PC;PO;WM;,,,,,
ETIS4,Thrombin+calcium chloride+aprotinin+protein clotta,Tisseel solution for sealant 4mL/set,HEMT,Adjunct to hemostasis in cardiopulmonary bypass surgery (including fully heparinized patients) and splenic injury (due to blunt or penetrating trauma to the abdomen) when the control of bleeding by conventional surgical techniques is ineffective or impractical; adjunctive sealant for closure of colostomies.,Hypersensitivity to aprotinin; direct intravascular injection; severe or brisk arterial bleeding,May be related to aprotinin contained in some products. Frequency may vary by product. 1% to 10%: Cardiovascular: Bradycardia (?10%) Central nervous system: Fever (6%) Dermatologic: Pruritus Gastrointestinal: Abdominal distension (4%) Hematologic & oncologic: Hematoma (Facial rhytidectomy: 1% to 4%)¡A hemorrhage (internal¡A postprocedural; 2%)¡A increased serum fibrinogen (2%) Immunologic: Antibody development (1% to 2%) Local: Skin graft failure (3%) Respiratory: Pulmonary embolism (<1% to 3%),-20¢J¥H¤U§N­á,2mL of TISSEEL¡A which means 1mL TISSEEL and 1mL of thrombin solution¡A could cover at least 10cm2¡A depending on surgery type¡A wound size and frequency.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,aprotinin-No Human Data¡XProbably Compatible,Unknown ¨S¦³¸ê®Æ,Pregnancy Risk Factor: C (up to date) aprotinin- No Human Data¡XProbably Compatible,EXT;,,,,,
ETHEW,Thermometer,°ü¤H°òÂ¦·Å«×­p,ZOTH,,,,«Ç·Å,«DÃÄ«~,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;,,,,,
ENEED,Sterile Pen Needle,32G Pen needle ¯Ø®q¯Àµ§«¬°wÀY#320472,ZOTH,,,,µL¯S§O«ü¥Ü,«DÃÄ«~,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,SC;,,,,,
ITIEN,Imipenem + Cilastatin Sodium,Imipenem/Cilastatin Kabi 500/500mg inj,QANB,Intra-abdominal¡A lower respiratory tract¡A gynecological¡A GUT¡A bone & joint¡A skin & soft tissue & mixed infections¡A endocarditis¡A septicemia. Prophylaxis of post-op infections.,Hypersensitivity to amide-type local anaesth¡A severe shock or heart block.,Thrombophlebitis¡A pain¡A induration¡A erythema & tenderness following inj. Rash¡A urticaria¡A pruritus¡A GI disturbances¡A pseudomembranous colitis¡A haematological disturbances¡A increase in liver enzymes¡A taste perversion. Myoclonic activity¡A seizures¡A psychic disturbances¡A confusional states. Dermatologic: Injection site pain Gastrointestinal: Diarrhea (1.8% )¡A Nausea (2% )¡A Vomiting (1.5% ) Hematologic: Thrombophlebitis (3.1% ),25¢J¥H¤UÁ×¥ú,Doses based on imipenem component. Administer 500 mg by IV infusion over 20-30 minutes; 1000 mg over 40-60 minutes. Adults > 70 kg and children > or = 40 kg: 1-2 g/day (250 mg Q6H¡A 500 mg Q8H¡A 1 g Q12H); severe infections: 2-4 g/day (ranges from 500 mg Q6H to 1 g Q6-8H) (maximum: 4 g/day or 50 mg/kg/day). Post-surgical infections prophylaxis in adults: 1 g IV on induction of anesthesia and 1 g 3 hours later. For high-risk surgery¡A 500 mg can be given at 8 and 16 hours after induction. Children (3 months and older) < 40 kg: 15 mg/kg IV Q6H (maximum: 2 g/day).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,No reports describing the use of this antibiotic-enzyme inhibitor combination in the 1st trimester of nonterminated human pregnancies have been located. Four sources consider imipenem¡Vcilastatin to be a safe and effective agent during the perinatal period,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Small amounts of imipenem¡Vcilastatin are excreted into breast milk. These amounts are comparable to other £]-lactam antibiotics. The effects¡A if any¡A on a nursing infant are unknown.,IVD;,N/S¡A D5W,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¾¯¶q¡Ø500 mg®É¡Aºwª`®É¶¡¬ù20 ~ 30¤ÀÄÁ¡A·í¾¯¶q¤j©ó 500 mg ®É¡Aºwª`®É¶¡¬ù40 ~ 60¤ÀÄÁ¡C ¿éª`·»²G«ØÄ³¿@«×¡G5 mg/mL of imipenam¡C,1. ­Y¯f±w¦³äú¤ß·P®ÉÀ³´îºCºwª`³t²v¡C 2. ºÊ´úÅé·Å¡BCBC¡B¨xµÇ¥\¯à¡Aª`·N¬O§_¦³¦Ù¦×¾_Å¸©ÎÅöíwµo§@¼xª¬¡C 3. ·»¸Ñ©Îµ}ÄÀ«á¤§·»²G¶·¥ß§Y¨Ï¥Î¡A¥Ñ·»¸Ñ¶}©l¦Ü§¹¦¨¿éª`®É¶¡¶¡¹j¤£±o¶W¹O 2 ¤p®É¡C 4. ¡§¥d¤ñ¡¨¬Ì¥²¹ç»P¨Å»ÄÆQ(lactate)ÄÝ¤Æ¾Ç°t¥î¸T§Ò¡A©Ò¥H¤£À³¥H§t¨Å»ÄÆQ¤§·»²G¨Óµ}ÄÀ¡C
OPLET1,Cilostazol,Pletaal 100mg,HEMT,Reduction of symptoms of intermittent claudication¡A as indicated by an increased walking distance.,Patients with CHF of any severity.,Abdominal pain¡A back pain¡A headache¡A infection¡A palpitation¡A tachycardia¡A GI effects¡A peripheral edema¡A myalgia¡A dizziness¡A vertigo¡A cough¡A pharyngitis¡A rhinitis. Cardiovascular: Palpitations (5% to 10% )¡A Peripheral edema (7% to 9% )¡A Tachyarrhythmia (4% ) Gastrointestinal: Abdominal pain (4% to 5% )¡A Diarrhea (12% to 19% )¡A Feces contents abnormal (12% to 15% )¡A Indigestion (6% ) Hematologic: Decreased platelet aggregation Musculoskeletal: Backache (6% to 7% )¡A Myalgia (2% to 3% ) Neurologic: Dizziness (9% to 10% )¡A Headache (27% to 34% ) Respiratory: Increasing frequency of cough (3% to 4% )¡A Pharyngitis (7% to 12% )¡A Rhinitis (7% to 12% ) Other: Infectious disease (10% to 14% ),30¢J¥H¤U,Oral 100mg twice daily.,µL»Ý½Õ¾ã¾¯¶q,Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer¡¦s labeling (has not been studied); use with caution.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;PO;,,,,,
OXAR1,Rivaroxaban,Xarelto 10mg,HEMT,,¾AÀ³¯g: Xarelto 10 mg Prevention of Venous Thrombosis(VTE) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15 mg & 20 mg Prevention of stroke & systemic embolism in adult patients w/ non-valvular atrial fibrillation w/ ¡Ù1 risk factors eg CHF¡A HTN¡A age ¡Ù75 yr¡A DM¡A prior stroke or transient ischaemic attack. Treatment of Deep Venous Thrombosis (DVT) & PE¡A & prevention of recurrent DVT & PE following an acute DVT in adults. °Æ§@¥Î: Anemia¡A dizziness¡A headache¡A syncope¡A eye haemorrhage¡A tachycardia¡A hypotension¡A haematoma¡A epistaxis¡A GI disorders¡A pruritus¡A pain in extremity¡A urogenital tract haemorrhage¡A fever¡A peripheral oedema¡A decreased general strength & energy¡A increased transaminases¡A postprocedural haemorrhage. ¸T§Ò:Hypersensitivity. Clinically significant active bleeding. Hepatic disease associated w/ coagulopathy & clinically relevant bleeding risk including cirrhotic Child-Pugh B & C patients. Pregnancy & lactation.,,«Ç·Å,Dosing: Adult Deep vein thrombosis (DVT)¡A pulmonary embolism (PE) treatment: Oral: Initial: 15 mg twice daily with food for 3 weeks followed by 20 mg once daily with food. Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism): Oral: 20 mg once daily with the evening meal. Postoperative DVT thromboprophylaxis: Oral: Note: Initiate therapy after hemostasis has been established¡A 6-10 hours postoperatively. Knee replacement: 10 mg once daily; recommended total duration of therapy: 12-14 days. Hip replacement: 10 mg once daily; total duration of therapy: 35 days.,»Ý½Õ¾ã¾¯¶q,Moderate to severe impairment (Child-Pugh class B or C) and any hepatic disease associated with coagulopathy: Avoid use.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IVAX,Purified Split Inactivated Influenza Virus,¦Û¶O3»ù¬y·P (Vaxigrip)0.5mL/dose,HIMM,,¾AÀ³¯g: Active immunisation against influenza. °Æ§@¥Î: Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome. ¸T§Ò: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 ¢XC,Adult & Children >= 36 mth 0.5ml IM Chidren <= 8 yr who have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,
IVAX1,Purified Split Inactivated Influenza Virus,§K¶O¦¨¤H¬y·P 0.5mL/dose,HIMM,,¾AÀ³¯g: Active immunisation against influenza. °Æ§@¥Î: Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome. ¸T§Ò: Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,,2 ~ 8 ¢XC,Adult & Children >= 36 mth 0.5ml IM Chidren <= 8 yr who have not been vaccinated previously¡A the 2nd dose can be given at an interval of at least 4 wk.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;SC;,,,,,
EMEL1,Hydroquinone,Melquine ointment 4% 10gm,TDER,,¾AÀ³¯g:Skin bleaching: Gradual bleaching of hyperpigmented skin conditions¡A such as chloasma¡A melasma¡A freckles¡A senile lentigines¡A and other unwanted areas of melanin hyperpigmentation. °Æ§@¥Î: Dermatologic: Allergic skin reaction¡A dermatitis¡A erythema¡A inflammation¡A stinging of the skin¡A xeroderma Local: Local irritation ¸T§Ò:Hypersensitivity to hydroquinone or any component of the formulation,,«Ç·Å,Hyperpigmentated skin conditions Adult: Topical apply and rub in a thin layer to affected area bid¡A in the morning and evening.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,EXT;SKIN;TOPI;,,,,,
OFYC,Perampanel,Fycompa 2mg,CNEU,Adjunctive treatment of partial-onset seizures w/ or w/o secondarily generalized seizures in patients >12 yr w/ epilepsy.,Hypersensitivity.,Dizziness¡A somnolence. Decreased/increased appetite; aggression¡A anger¡A anxiety¡A confusional state; ataxia¡A dysarthria¡A balance disorder¡A irritability; diplopia¡A blurred vision; vertigo; nausea; back pain; gait disturbance¡A fatigue; increased wt; fall.,30¢J¥H¤U,For mono/adjuvant treatment of Local epilepsy : Adult & adolescent(A40>12 years) Initially 2 mg daily¡A may be increased by 2-mg increments to a maintenance dose of 4-8 mg daily. Then¡A further increase by 2-mg increments to 12 mg daily. Child (4-11years) (>=30kg):Initially 2 mg daily¡A may be increased by 2-mg increments to a maintenance dose of 4-I418 mg daily. Then¡A further increase by 2-mg increments to 12 mg daily. Child (4-11years) (20-30kg):Initially 1mg daily¡A may be increased by 1-mg increments to a maintenance dose of 4-6mg daily. Then¡A further increase by 1-mg increments to 8mg daily. Child (J404-11years) (<20kg):Initially 1mg daily¡A may be increased by 1-mg increments to a maintenance dose of 2-4mg daily. Then¡A further increase by 0.5-mg increments to 6mg daily. For adjuvant treatment of Primary generalized tonic-clonic seizures : Adult & adolescent(>12 years) Initially 2 mg daily¡A may be increased by 2-mg increments to a maintenance dose of 8mg daily. Then¡A further increase by 2-mg increments to 12 mg daily. Child (7-11years) (>=30kg):Initially 2 mg daily¡A may be increased by 2-mg increments to a maintenance dose of 4-8 mg daily. Then¡A further increase by 2-mg increments to 12 mg daily. Child (7-11years) (20-30kg):Initially 1mg daily¡A may be increased by 1-mg increments to a maintenance dose of 4-6mg daily. Then¡A further increase by 1-mg increments to 8mg daily. Child (7-11years) (<20kg):Initially 1mg daily¡A may be increased by 1-mg increments to a maintenance dose of 2-4mg daily. Then¡A further increase by 0.5-mg increments to 6mg daily.,»Ý½Õ¾ã¾¯¶q,»´«×¨x¥\¯à¤£¥þ¯f±w«ØÄ³°_©l¾¯¶q 2 mg orally once daily at bedtime and may increase dose by 2 mg/day no more frequently than every 2 weeks to MAX¡A 6 mg/day ¤¤«×¨x¥\¯à¤£¥þ¯f±w«ØÄ³°_©l¾¯¶q 2 mg orally once daily at bedtime and may increase dose by 2 mg/day no more frequently than every 2 weeks to MAX¡A 4 mg/day ­««×¨x¥\¯à¤£¥þ¯f±w¤£«ØÄ³¨Ï¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³À³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ©ÎÀ£¸H
IHER6,Trastuzumab,HERCEPTIN inj 600mg/5mL,RACA,Breast cancer¡A adjuvant treatment¡A breast cancer¡A metastatic¡A gastric cancer¡A metastatic.,Hypersensitivity to trastuzumab¡A Chinese hamster ovary (CHO) cell proteins¡A or any component of the formulation.,>10%: Cardiovascular: Decreased left ventricular ejection fraction (4% to 22%) Central nervous system: Pain (47%)¡A chills (5% to 32%)¡A headache (10% to 26%)¡A insomnia (14%)¡A dizziness (4% to 13%) Dermatologic: Skin rash (4% to 18%) Gastrointestinal: Nausea (6% to 33%)¡A diarrhea (7% to 25%)¡A vomiting (4% to 23%)¡A abdominal pain (2% to 22%)¡A anorexia (14%) Infection: Infection (20%) Neuromuscular & skeletal: Weakness (4% to 42%)¡A back pain (5% to 22%) Respiratory: Cough (5% to 26%)¡A dyspnea (3% to 22%)¡A rhinitis (2% to 14%)¡A pharyngitis (12%) Miscellaneous: Infusion related reaction (21% to 40%¡A chills and fever most common; severe: 1%)¡A fever (6% to 36%),2-8¢JÁ×¥úÁ×§K§N­á,600 mg (600 mg trastuzumab and 10¡A000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,SC;,,,,,1.¥»«~¶È¯à¥H¥Ö¤Uª`®gµ¹¤©¡Cª`®g®É¶¡À³¬°2-5¤ÀÄÁ¡C 2.¤£½×±wªÌÅé­«¦h¹è¡A¥»«~¤§«ØÄ³©T©w¾¯¶q¬°600mg¡A¨C3¶gµ¹ÃÄ£¸¦¸¡C 3.ª`®g³¡¦ìÀ³¦b¥ª¥k¤j»L¤§¶¡½ü´À¡A·sªºª`®g³¡¦ì»PÂÂªºª`®g³¡¦ìÀ³¬Û¶Z¦Ü¤Ö2.5¤½¤À¡A¥B¤£±o¦b¥Ö½§µo¬õ¡B·ï«C¡BÄ²µh©Îµw¶ô³Bª`®g¡C 4.²Ä¤@¦¸¥Ö¤Uª`®g«á6¤p®É¥H¤Î«áÄòªº¥Ö¤Uª`®g«á2¤p®É¡AÀ³Æ[¹î±wªÌ¬O§_¥X²{ª`®g¬ÛÃö¤ÏÀ³¡C
OXOFL,Baloxavir marboxil,Xofluza 20mg,QANB,Treatment of acute infections of type A and B influenza viruses for adults and children.,History of hypersensitivity to baloxavir marboxil or any of its ingredients.,Common: Diarrhea (3-5%)¡A Nausea (2%)¡A Vomiting (Pediatric¡A 5% .)¡A Headache (1%)¡A Bronchitis (3%)¡A Sinusitis (2%),25¢XC¥H¤U,Influenza¡A uncomplicated: Administer within 48 hours of influenza symptom onset. Adults (1) 20kg to <80kg: 40mg as a single oral dose; (2) >=80kg: 80mg as a single oral dose. 5 Years or Older (1)<20kg: 2mg/kg as a single oral dose; (2) 20kg to <80kg: 40mg as a single oral dose; (3) >=80kg: 80mg as a single oral dose. Influenza¡A postexposure prophylaxis: Administer within 48 hours of exposure. Adults (1) 20kg to <80kg: 40mg as a single oral dose; (2) >=80kg: 80mg as a single oral dose. 5 Years or Older (1) <20kg: 2mg/kg as a single dose; (2) 20kg to <80kg: 40mg as a single oral dose; (3) >=80kg: 80mg as a single oral dose.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] »´«×(Child-Pugh A)¦Ü¤¤«×(Child-Pugh B)ªº¨x¥\¯à¤£¥þ¯f±wµL»Ý½Õ¾ã¾¯¶q¡C©|µL­««×¨x¥\¯à¤£¥þ¯f±w§ë»P¥»ÃÄ«á¤§ÃÄª«°Ê¤O¾Ç¸ê®Æ¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¹ï©ó¥¥°ü©Î¥i¯àÃh¥¥¤§°ü¤k¡A¦b§PÂ_¨ä©óªvÀø¤Wªº¦³¯q©Ê°ª©ó¦MÀI©Ê®É¤~¥i§ë»P¡C ¥¥´Á§ëÃÄ¤§¬ÛÃö¦w¥þ©Ê©|¥¼½T¥ß¡C°Êª«¹êÅç (¤j¹«¡B¨ß¤l)¤¤¡AÁö»{¬°µL­P·î­L©Ê¡A¦ý¥H°ª¾¯¶q§ë©ó¨ß¤l®É¡A ¦³¬y²£¤ÎÀV³¡ÂØ¥Í¦Ø°©(extra cervical rib)ªº³ø§i¡B©ó¤j¹««h»{¬°¥»ÃÄ·|³q¹L­L½L¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ­÷¨Å°ü½Ð©ó§ëÃÄÀøµ{¤¤Á×§K¥À¨Å­÷Áý¡C ©|¥¼½T¥ß¥»ÃÄ¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¦ý¤j¹«ªº¬ã¨s¤¤¦³¥»ÃÄ¤Àªc¦Ü¨Å¥Äªº³ø§i¡C,AC;AC15;PC;PO;,,,,,
EOPI,Fentanyl,Opiodur Patch 12mcg/h,CNEU,Narcotic analgesics for chronic and intractable pain.,the management of acute pain or patients who require opioid analgesia for a short period of time. the management of post-operative pain. patients with known hypersensitivity to fentanyl or any components of this product.,Common Dermatologic: Diaphoresis (1% to 6% )¡A Pruritus (Adult¡A 1% to 6% ; pediatric¡A 13% )¡A Rash (2% to 6% ) Gastrointestinal: Abdominal pain (1% to 9% )¡A Constipation (9% to 13% )¡A Diarrhea (1% to 13% )¡A Indigestion (1% or greater )¡A Loss of appetite (1% to 5% )¡A Nausea (Adult¡A 39% to 41% ; pediatric¡A 24% )¡A Vomiting (Adult¡A 10.3% to 26% ; pediatric¡A 34% )¡A Xerostomia (1% to 4% ) Hematologic: Anemia (3% ) Neurologic: Asthenia (Adult¡A 2% to 9.7%; pediatric¡A 1% )¡A Confusion (1% or greater )¡A Dizziness (Adult¡A 3% to 10% ; pediatric¡A 2% )¡A Headache (9% to 16%)¡A Insomnia (1% to 10% )¡A Somnolence (Adult¡A 1% to 19% ; pediatric¡A 5% ) Psychiatric: Anxiety (3% to 5.9% )¡A Depression (1% or greater )¡A Hallucinations (1% to 2% ) Renal: Urinary retention (Up to 3% ) Respiratory: Dyspnea (10.4% ) Other: Fatigue (1% to 6% ) Serious Cardiovascular: Bradyarrhythmia¡A Chest pain (1% or greater )¡A Hypotension (2% ) Endocrine metabolic: Adrenal insufficiency Gastrointestinal: Paralytic ileus Neurologic: Coma¡A Seizure Respiratory: Respiratory depression (1% ) Other: Drug dependence¡A Neonatal Abstinence Syndrome¡A Serotonin syndrome,25¢XC¥H¤U,Transdermal system provides continuous systemic delivery of fentanyl for 72 hours. Individualized dosage based on patient's opioid history¡A degree of opioid tolerance¡A current general condition & medical status. Equianalgesic potency conversion Drug Name: IM (mg) => PO (mg) Equianalgesic Dose Morphine: 10 => 60 (acute); 30(chronic) Hydromorphone: 1.5 => 7.5 Methadone: 10 => 20 Oxycodone: 15 => 30 Levorphanol: 2 => 4 Oxymorphone: 1 => 10 (rectal) Meperidine: 75 => --- Codeine: 130 => 200 Buprenorphine: 0.4 => 0.8(Sublingual) Tramadol: 100 => 120 Recommended dose based upon daily oral morphine dose. Oral 24-hour Morphine(mg/day) => Fentanyl Dose(mcg/hr) 30-44(children) => 12 45-134(children) => 25 <135(adult) => 25 135-224 => 50 225-314 => 75 315-404 => 100 405-494 => 125 495-584 => 150 585-674 => 175 675-764 => 200 765-854 => 225 855-944 => 250 945-1034 => 275 1035-1124 => 300,»Ý½Õ¾ã¾¯¶q,[Micromedex 20210714] Hepatic impairment (mild to moderate): Initiate with 50% of the usual dosage. Hepatic impairment (severe): Avoid use.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,[¥é³æ]¥¼¦³¥R¤ÀÃö©óÃh¥¥°ü¤k¨Ï¥Îfentanyl¬ï¥Ö¶K¤ùªº¸ê®Æ¡C¦b°Êª«¸ÕÅç¤¤´¿Åã¥Ü¨ã¦³¬Y¨Ç¥Í´Þ¬r©Ê¡C Áa¨Ï§@¬°ÀR¯ß³Â¾K¾¯ªºfentanyl´¿³Qµo²{¦b¤HÃþ¦­´ÁÃh¥¥®É·|¬ï¹L­L½L¡A¦ý¹ï©ó¤HÃþªº¼ç¦b¦MÀI©Ê¤´ÄÝ¥¼ª¾¡C ¥À¿Ë¦bÃh¥¥´Á¶¡ªø´Á¨Ï¥Îfentanyl¬ï¥Ö¶K¤ùªº·s¥ÍÀ¦¨à´¿³Q³ø¾É¦³·s¥Í¨à§ÙÂ_¯gª¬¡C Ãh¥¥´Á¶¡¤£¯à¨Ï¥Î¥»«~¡A°£«D½T¹ê¦³¥²­n¡C ¤£«ØÄ³¦b¤À®Y´Á¶¡¨Ï¥Î¥»«~¡A¦]¬°¥»«~¤£À³¥Î©ó±±¨î«æ©Ê©Î³N«á¯kµh¡C ¦¹¥~¡A¥Ñ©ófentanyl·|¬ï¹L­L½L¡A¦b¤À®Y®É¨Ï¥Î¥»«~¥i¯à·|¾É­P·s¥Í¨àªº©I§l§í¨î¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] Fentanyl·|±Æªn¨ì¤HÅé¨Å¥Ä¤º¥B¥i¯à·|¹ï³QÁý¨Åªº·s¥Í¨à³y¦¨ÂíÀR/©I§l§í¨î¡C ¦]¦¹¡A¹ï±Â¨Å°ü¤k¤£«ØÄ³¨Ï¥Î¥»«~¡C,EXT;SKIN;,,,,,
IADDV,Cr+Cu+Fe+Zn+Mn+Se+I+F+Mo,Addaven inj 10mL/amp (¦¨¤H¥Î),NUTR,Supplement of trace elements¡A diluted in TPN soln.,- Conditions with total biliary obstruction. - Hypersensitivity to the active substances or to any of the excipients. - Wilson¡¦s disease¡A hemochromatosis. - Children less than 15 kg body weight.,Hypersensitivity reactions of iodide.,30¢XC ¥H¤U,As TPN material ¡A for TPN Adult: 5mL/day Each mL contains: Chromic chloride hexahydrate eq. to Chromium 1.0 mcg Copper chloride dihydrate eq. to Copper 38 mcg Ferric chloride hexahydrate eq. to Ferrum 110 mcg Manganese chloride tetrahydrate eq. to Manganese 5.5 mcg Potassium iodide eq. to Iodine 13 mcg Sodium fluoride eq. to Fluoride 95 mcg Sodium molybdate dehydrate eq. to Molybdenum 1.9 mcg Sodium selenite anhydrous eq. to Selenium 7.9 mcg Zinc chloride eq. to Zinc 500 mcg,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,
ICER0,HPV type16/18 L1 protein,Cervarix (¤HÃþ¨Å¬ð¯f¬r¬Ì­]¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Prevention of cervical cancer in females 10-25 years¡A by protecting against incident & persistent infections¡A cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN)¡A CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by HPV Types 16 & 18.,Subjects with known hypersensitivity to any component of Cervarix.,Headache¡A GI disturbances¡A itch¡A rash¡A myalgia¡A arthralgia¡A inj site reactions¡A fatigue¡A fever.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5mL¡A > or = 15 years 3 doses at 0¡A 1¡A and 6 months. 9-14 years can take 3 doses at 0¡A 1¡A and 6 months or 2 doses at 0 and 6-12 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,[¥é³æ]Á{§É¸ÕÅç¡BÃh¥¥¸ê®Æ®w©M¬y¦æ¯f¾Ç¸ÕÅç¤¤¡A¨ÃµLµo²{±µºØ·|¼W¥[·s¥Í¨à¥]¬A ¥Í¨|¯Ê³´¦b¤ºªº¤£¥¿±`±¡ªp¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¥¼¦³Á{§É¬ã¨sµû¦ô¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT¡A¥u¦³¦b¼ç¦b®Ä¯q¶W¶V ¥i¯à­±Á{¤§­·ÀI®É¤~¥i¨Ï¥Î¡C,IM;,,,,,1. ¨Ï¥Î«eÀ³¥ý¥R¤À·n¤Ã¡C 2. À³¥H¦Ù¦×ª`®gªº¤è¦¡¬I¥´©ó¤WÁu¤T¨¤¦Ù³¡¦ì¡C
OCHEY,Soybean and probiotics fermentation product,Chemo young 4mL/bottle (14bottles/box),RACA,Ameliorating fatique and appetite loss associated with cancer chemotheraphy.,There are no contraindications listed on the label.,constipation¡A diarrhea.,«Ç·Å¤UÁ×¥ú«O¦s,4mL twice daily on an empty stomach¡A after diluting in 100mL of warm water.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,¥é³æ¥¼¦³¬ÛÃö¸ê°T,Unknown ¨S¦³¸ê®Æ,¥é³æ¥¼¦³¬ÛÃö¸ê°T,AC;PO;,,,,,
OAPR2,Hydralazine,Stable 25mg,CAVS,Hypertension.,Hypersensitivity to Hydralazine.,Common Cardiovascular: Angina pectoris¡A Edema¡A Palpitations¡A Tachycardia Gastrointestinal: Diarrhea¡A Loss of appetite¡A Nausea¡A Vomiting Neurologic: Headache Serious Hematologic: Agranulocytosis¡A Leukopenia Hepatic: Hepatotoxicity Immunologic: Lupus pneumonia (Acute)¡A Systemic lupus erythematosus,³±²D°®Àê³B(15-30¢J),Adult: Initial¡A 10 mg orally 4 times daily for 2 to 4 days; increase to 25 mg orally 4 times daily for remainder of week 1; week 2 and subsequent weeks¡A increase to 50mg QID or 100mg BID. Maintenance¡A adjust to lowest effective dose according to individual response. Maximum dose: 300 mg/day. Children: 0.75mg/kg/day in 2 to 4 divided doses; may increase gradually over 3 to 4 weeks¡A maximum dose: 300 mg/day or 7.5 mg/kg/day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 3 rd trimester,[¥é³æ]©|µL¤åÄmÅã¥ÜHydralazine·|¹ï¥¥°ü²£¥Í¥ô¦ó°ÝÃD¡A¦ý¨Ï¥Î®É¤´À³´N¨ä¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡A¦]¨ä¦b°Êª«¸ÕÅç¤W´¿¤Þ°_·î§Î­L¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]µL¬ÛÃö°O¸ü,AC;AC15;PC;PO;WM;,,,,,
IRYZ,Insulin Aspart 30+ Insulin Degludec 70,Ryzodeg FlexTouch 100 Unit/mL 3mL,META,Ryzodeg 70/30 is a mixture of insulin degludec¡A a long-acting human insulin analog¡A and insulin aspart¡A a rapid-acting human insulin analog¡A indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.,During episodes of hypoglycemia. Hypersensitivity to Ryzodeg 70/30 or one of its excipients.,Nasopharyngitis(11.1-24.6%)¡A Headache(9.7%)¡A Upper respiratory tract infection(5.7-9.1%)¡A Influenza(6.9%)¡A Headache(5.6%). Peripheral Edema: sodium retention and edema(1.8-2.2%). Weight Gain. Injection Site Reactions(2.0%)¡A including injection site hematoma¡A pain¡A hemorrhage¡A erythema¡A nodules¡A swelling¡A discoloration¡A pruritus¡A warmth¡A and injection site mass. lipodystrophy(0.1%). Allergic Reactions¡A including anaphylaxis¡A generalized skin reactions¡A angioedema¡A bronchospasm¡A hypotension¡A and shock. Hypersensitivity¡A manifested with swelling of tongue and lips¡A diarrhea¡A nausea¡A tiredness and itching¡A and urticaria(0.5%).,¥¼¨Ï¥ÎÀ³Àx¦s©ó2-8¢J¡A¤Å§N­á.¶}«Ê(¨Ï¥Î¤¤)­Y«O¦s©ó¦B½c©Î«Ç·Å¥H¤U(2-30¢J)¡A¶}«Ê«á¥i«O28¤Ñ.,Starting Dose in Insulin-Naive Patients Type 1 Diabetes Mellitus: The recommended starting dose of Ryzodeg 70/30 in insulin-naive patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as short-or rapid-acting insulin divided between each daily meal. As a general rule¡A 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. Type 2 Diabetes Mellitus: The recommended starting dose of Ryzodeg 70/30 in insulin-naive patients with type 2 diabetes mellitus is 10 units once daily. Starting Dose in Patients with Type 1 or Type 2 Diabetes on a Once or Twice Daily Premix or Self-mix Insulin Alone or as Part of a Regimen of Multiple Daily Injections Adults with Type 1 or Type 2 Diabetes Start Ryzodeg 70/30 at the same unit dose and injection schedule as the premix or self-mix insulin. In patients also using short-or rapid-acting insulin at mealtimes continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30. Pediatric Patients 1 Year of Age and Older with Type 1 or Type 2 Diabetes Start Ryzodeg 70/30 at 80% of the total daily mixed insulin dose in order to minimize the risk of hypoglycemia and administer once daily with the main meal of the day. In patients also using short-or rapid-acting insulin at mealtimes continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30. Starting Dose in Patients with Type 1 or Type 2 Diabetes on a Once or Twice Daily Basal Insulin Alone or as Part of a Regimen of Multiple Daily Injections Adults with Type 1 or Type 2 Diabetes In patients with type 2 diabetes switching from a regimen that includes only a once-or twice-daily basal insulin¡A start Ryzodeg 70/30 at the same unit dose and injection schedule. For patients switching from once-daily basal insulin to once-daily Ryzodeg 70/30¡A monitor blood glucose after starting therapy due to the rapid-acting insulin component. In patients switching from a multiple daily injections regimen that includes a basal and short-or rapid-acting insulin at mealtimes¡A start Ryzodeg 70/30 once daily with the main meal at the same unit dose as the basal insulin. Continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30. Pediatric Patients 1 Year of Age and Older with Type 1 or Type 2 Diabetes Start Ryzodeg 70/30 at 80% of the long-or intermediate-acting insulin component of the daily regimen in order to minimize the risk of hypoglycemia and administer once daily with the main meal of the day. In patients also using short-or rapid-acting insulin at mealtimes continue the short-or rapid-acting insulin at the same dose for meals NOT covered by Ryzodeg 70/30.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,PREGNANCY RECOMMENDATION: Insulin Aspart: No Human Data¡XAnimal Data Suggest Low Risk¡A Insulin Degludec: Limited Human Data¡XProbably Compatible. [¥é³æ]¥Ø«e¨ÃµLRyzodegR©Îinsulin degludec¥Î©óÃh¥¥¤k©Ê¤¤ªº¸ê®Æ»¡©úÃÄª«¬ÛÃöªº­«¤j¥ý¤Ñ¯Ê³´©Î¬y²£­·ÀI¡CInsulin aspart«h¦³ÀH¾÷¤À°t¡B¹ï·Ó¹êÅçÅã¥Ü©óÃh¥¥¤G´Á¨Ï¥Îinsulin aspart»P­«¤j¥ý¤Ñ¯Ê³´©Î¥¥°ü/­L¨à¤£¨}µ²ªGµLÃö¡CÃh¥¥´Á¶¡±±¨î¤£¨}ªº¿}§¿¯f¹ï©ó¥¥°ü¤Î­L¨à¬O¦³­·ÀIªº¡C ¦b°Êª«¥Í´Þ¬r©Ê¸ÕÅç¤¤¡A±NÃh¥¥ªº¤j¹«©óÅ¦¾¹¥Í¦¨´Á¥Ö¤Uª`®ginsulin degludec/insulin aspart¡C¸ÕÅçµ²ªGÅã¥Ü¼ÉÅS¾¯¶q¬°¤HÅé¼ÉÅS¾¯¶q8­¿¾¯¶q¤U(¤HÃþ¼ÉÅS¾¯¶q¥H¤HÃþ¥Ö¤U¾¯¶q1.08 unit/kg/day®É­pºâ) ¡AÆ[¹î¨ì¤ºÅ¦/°©Àf²§±`¡C³o¨Ç¼vÅT»P¦b¤j¹«µ¹¤©¤HÃþ¯Ø®q¯À(NPH)Æ[¹î¨ìªº¼vÅT¬O¤@­Pªº¡C ¦b¤j¹«»P¨ß¤l¥Í´Þ¬r©Ê¸ÕÅç¤¤¡A©óÅ¦¾¹¥Í¦¨´Á¼ÉÅSinsulin degludec¡C¸ÕÅçµ²ªGÅã¥Üinsulin degludecªº¼ÉÅS¾¯¶q¦b¦b¤j¹«»P¨ß¤l¦U¬ù¬°¤HÅé¼ÉÅS¾¯¶qªº5­¿»P10­¿¾¯¶q¤U(¤HÃþ¼ÉÅS¾¯¶q¬Ò¥H¤HÃþ¥Ö¤U¾¯¶q0.75 unit/kg/day®É­pºâ) ¡AÆ[¹î¨ìµÛ§É«e»PµÛ§É«á¬y²£¥H¤Î¤ºÅ¦/ °©Àf²§±`¡CInsulin degludecªº¼vÅT»P¦b¤j¹«µ¹¤©¤HÃþ¯Ø®q¯À(NPH)Æ[¹î¨ìªº¼vÅT¬O¤@­Pªº¡C ¦b°Êª«¥Í´Þ¬r©Ê¸ÕÅç¤¤¡AÃh¥¥ªº¤j¹«¤Î¨ß¤l¦bÅ¦¾¹¥Í¦¨´Á¥Ö¤Uª`®ginsulin aspart¡C¸ÕÅçµ²ªGÅã¥Üinsulin aspartªº¼ÉÅS¾¯¶q¦b¤j¹«»P¨ß¤l¦U¬ù¬°¤HÅé¼ÉÅS¾¯¶q8­¿»P¬Ûµ¥¾¯¶q¤U(¤HÅé¼ÉÅS¾¯¶q¬Ò¥H¤HÃþ¥Ö¤U¾¯¶q1.0 unit/kg/day®É­pºâ) ¡A¨Ã¥¼³y¦¨¤£¨}ªº¼vÅT¡C¦b§ó°ªªº¼ÉÅS¾¯¶q¤UÆ[¹î¨ìµÛ§É«e»PµÛ§É«á¬y²£¥H¤Î¤ºÅ¦/°©Àf²§±`¡A³o¨Ç¼vÅT¥i¯à¬O¨Ó¦Û¥ÀÅé§C¦å¿}¡C³o¨Ç¼vÅT»P¦b¤j¹«µ¹¤©±`³W¤HÃþ¯Ø®q¯À(regular human insulin)Æ[¹î¨ìªº¼vÅT¬O¤@­Pªº¡C ¦b±w¦³§³®W«e¿}§¿¯f¥BHbA1c>7ªº°ü¤k¡AÃh¥¥µo¥Í­«¤j¥ý¤Ñ¯Ê³´ªº¹w¦ô­I´º­·ÀI¬°6~10%¡AHbA1c>10ªº°ü¤k«h´¿³Q³ø§i¦³°ª¹F20~25%ªº­·ÀI¡C¬y²£ªº¹w¦ô­I´º­·ÀI¦b³o­Ó±Ú¸sªº¼Æ¾Ú¥¼ª¾¡C¦b¬ü°ê¤@¯ë±Ú¸s¤¤¡AÁ{§É½T»{ªºÃh¥¥µo¥Í­«¤j¥ý¤Ñ¯Ê³´¤Î¬y²£ªº¹w¦ô­I´º­·ÀI¤À§O¬°2-4%¤Î15-20%¡C (¥H¤U²¤),No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Insulin Aspart: No Human Data¡XProbably Compatible¡A Insulin Degludec: Compatible [¥é³æ]¥Ø«e¨S¦³Ãö©óRyzodegR ©Îinsulin degludec·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡B¹ï³Q­÷¨ÅªºÀ¦¨à¡B©Î¹ï©óªc¨Å¼vÅTªº¸ê®Æ¡C Insulin degludec·|¤Àªc¨ì¤j¹«ªº¨Å¥Ä¤¤¡C¦b¤@­Ó¤p«¬ªº¸ÕÅç¤¤Åã¥Ü¡A¥~·½©Êªº¯Ø®q¯À¡A¥]¬Ainsulin aspart¡A·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡C µM¦Ó¨ÃµL¨¬°÷ªº¸ê®Æ¥H¤F¸Ñinsulin aspart¹ï­÷¨|¥À¨ÅÀ¦¨àªº¼vÅT¡A¥çµL¸ê®Æ¥H¤F¸Ñinsulin aspart¹ïªc¨Åªº¼vÅT¡C ­÷¨|¥À¨ÅªºÀuÂIÀ³»P­÷¨|¥À¨Å¥À¿Ë¹ï©óinsulin»Ý¨D¥H¤ÎRyzodegR¡Binsulin degludec¡Binsulin aspart©Î¥À¿Ë¬J¦³¯e¯f¹ï­÷¨|¥À¨ÅÀ¦¨à¥i¯à²£¥Í¤§°Æ§@¥Î¤@°_¦Ò¶q¡C,SC;,,,,,1. ½Ð¤Å¥HÀR¯ßª`®g¡B¦Ù¦×ª`®g¡A©Î¸Ë©ó¯Ø®q¯À¿éª`À°®ú¤¤§ë¤©Ryzodeg¡C½Ð¤Åµ}ÄÀRyzodeg¡A©Î±N¨ä»P¥ô¦ó¨ä¥L¯Ø®q¯ÀÃÄ«~©Î·»²G²V¦X¡C 2. ­Y§Ñ°Oª`®g¥»ÃÄ¡AÀ³©ó·í¤Ñ¤U¤@¦¸¥¿À\®Éª`®g¡A¨Ã©ó¤§«á«ì´_ªºµ¹ÃÄ®Éµ{¡C¯f¤H¤£À³ª`®gÃB¥~ªº¾¯¶q¥H¸É¨¬§Ñ°Oª`®gªº¾¯¶q¡C 3. ¦P¤@°Ï°ì¤º¨C¦¸³£½ü¬yª`®g©ó¤£¦P³¡¦ì¡A¥H­°§C¯×ªÕ¥NÁÂ»ÙÃª(lipodystrophy)©M§½³¡¥Ö½§Ãþ¾ý¯»¨I¿n¯g(cutaneous amyloidosis)ªº­·ÀI¡C½Ð¤Åª`®g¦Ü¯×ªÕ¥NÁÂ»ÙÃª©Î§½³¡¥Ö½§Ãþ¾ý¯»¨I¿n¯gªº³¡¦ì¡C 4. ¦bÅÜ§ó¯f¤H¯Ø®q¯ÀÀøªk´Á¶¡¡A½Ð¼W¥[¦å¿}ºÊ´úÀW²v¡C
OKAS4,Dimethicone,Kascoal 40mg,ALIM,Relief of pressure¡A bloating¡A fullness¡A and discomfort of gastrointestinal gas.,Hypersensitivity to simethicone or any component of the formulation,Loose stools,25¢J¥H¤U,Adult & children > 3 years: 2 tablets TID to QID or taken when needed; Children < 3 years: should consult with doctor.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IFAS0,Fulvestrant,Faslodex inj 250mg/5mL (sample),RACA,Breast cancer¡A metastatic¡A breast cancer¡A advanced or metastatic (second-line endocrine-based combination therapy),a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema,>10%: Central nervous system: Fatigue (8% to 29%)¡A headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%)¡A diarrhea (19%)¡A constipation (5% to 16%)¡A stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis¡A upper respiratory infection¡A urinary tract infection¡A influenza¡A bronchitis¡A rhinitis¡A conjunctivitis¡A pneumonia¡A sinusitis¡A cystitis¡A oral herpes¡A respiratory tract infection) Local: Pain at injection site (12%; including neuralgia¡A peripheral neuropathy¡A sciatica) 1% to 10%: Dermatologic: Alopecia (6%)¡A skin rash (6%)¡A xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%)¡A anorexia (6%)¡A vomiting (6%)¡A dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%)¡A leukopenia (5%; grade 3: 1%; grade 4: 1%)¡A neutropenia (4%; grade 3: 1%)¡A febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%)¡A arthralgia (8%)¡A back pain (8%)¡A limb pain (7%)¡A musculoskeletal pain (6%)¡A weakness (5% to 6%) Ophthalmic: Blurred vision (2%)¡A dry eye syndrome (2%)¡A increased lacrimation (1%) Respiratory: Cough (5%)¡A dyspnea (4%)¡A epistaxis (2%),2-8¢JÁ×¥ú,500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections¡A one in each buttock¡A on Days 1¡A 15¡A 29¡A and once monthly thereafter.,»Ý½Õ¾ã¾¯¶q,­««×¨x¥\¯à¤£¥þªÌ¬°¸T§Ò¡C,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,IM;,,,,,§ë»PFaslodexÀ³¥H¨â¦¸³sÄòªº5²@¤É¦bÁv³¡¦Ù¦×³B½wºCª`®g(1-2¤ÀÄÁª`®g)¡A¤@Ãä¤@¦¸¡C
EDUR2,Fentanyl,DUROGESIC D-trans Patch 25mcg/h,CNEU,,¾AÀ³¯g: Intractable cancer pain °Æ§@¥Î: Nausea¡A vomiting; bradycardia¡A oedema¡A CNS depression¡A confusion¡A dizziness¡Adrowsiness¡A headache¡A sedation¡A transient hypotension¡A peripheral vasodilation; increased intracranial pressure. High IV dose may cause chest wall rigidity. Transdermal: Rash¡A erythema and itching. ¸T§Ò: Hypersensitivity.,,«Ç·Å,Initial: Apply patch that delivers <=25 mcg/hr of fentanyl in opioid-naive patients. Adjust dose according to response. For patients who have been receiving a strong opioid¡A initial dose should be based on the previous 24-hr opioid requirement. Replace patch 72 hrly and apply new patch to a different site.,»Ý½Õ¾ã¾¯¶q,Mild-to-moderate impairment: Initial: Reduce dose by 50%. Severe impairment: Use not recommended.,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,EXT;,,,,,
IFEN10,Fentanyl,FENTANYL inj 0.5mg/10mL,CNEU,Premed prior to surgery¡A Adjunct to general anesth induction¡A Adjunct to regional anesth¡A Post-operatively .,Children <2 years¡A bronchial asthma¡A respiratory depression & head injury. Patients who received MAOIs within previous 14 days.,Respiratory depression¡A apnoea¡A muscle rigidity & bradycardia.,15-30¢JÁ×¥ú,"As a general anesthesia analgesic aid:Low dose: 2 mcg/kg IV (Minor surgery)Medium dose: 2-20 mcg/kg IV (Complex surgery)High dose: 20-50 mcg/kg IV (Prolonged major surgery. Use with Oxygen¡A Nitrous Oxide to avoid body's stress response)IV injection 25-250 mcg/kg (0.5-5mL) can be given to extend the action time until the completion of the operation.As an anesthetic:When it is important to reduce the stress response during surgery¡A fentanyl can be administered intravenously 50-100 mcg/kg¡A combined with Oxygen and Muscle Relaxants without adding additional anesthetics. This method is often used for heart surgery and other needs to protect the myocardium from hypoxia.Elderly patients: similar to other opioids¡A the dose of the elderly and frail patients should be lowered.Children: The induction and maintenance of anesthesia for children between 2-12 years old¡A the dose should be reduced to 2-3 mcg/kg IV.",µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]§h©Z¥§·|±Æªn¨ì¤HÅé¨Å¥Ä¤¤¡A¦]¦¹§ë»P¥»ÃÄ«áªº24¤p®É¤º¤£«ØÄ³±Â¨Å¡C»Ý¦Ò¶q¦b§h©Z¥§µ¹ÃÄ«á¶i¦æ­÷¨Åªº§Q¹ú¡C,IM;IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦¨¤H > 1-2¤ÀÄÁ¡A¨àµ£ > 2-5¤ÀÄÁ,Usual Infusion Concentrations IV infusion: 10 mcg/mL,
OXTA,Enzalutamide,Xtandi 40mg,RACA,Prostate cancer¡A metastatic: Treatment of metastatic¡A castration-resistant prostate cancer.,Hypersensitivity. Pregnancy.,Asthenia/fatigue; headache; hot flush¡A HTN. Anxiety; memory impairment¡A amnesia¡A attention disturbance¡A restless legs syndrome; gynaecomastia; dry skin¡A pruritus; fractures; falls.,30¢J¥H¤U,160 mg (four 40 mg capsules) administered orally with or without food once daily. Swallow capsules whole. Patients receiving enzalutamide should also receive a gonadotropin-releasing hormone analog concurrently (or have had a bilateral orchiectomy). If a patient experiences a ¡Ù Grade 3 toxicity or an intolerable side effect¡A withhold dosing for one week or until symptoms to ¡Ø Grade 2¡A and then resume the original dose treatment. If necessary¡A the dose can be reduced (120 mg or 80 mg).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦Ån¡A»ÝÀ³¾ã²É§]ªA¡A¤Å©CÄZ¡B·»¸Ñ©Î¥´¶}¡C
IKCL7S,Potassium Chloride,20mEq KCl in¡iD5NS 500mL¡j,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia¡A pain or phlebitis at injection site.,«Ç·Å,Adult: Initial loading dose: 40~60 mEq¡A with ECG monitoring then based on serum potassium levels¡A Serum K>2.5 mEq/L: concentration < 30 mEq/L¡A with speed< 10 mEq/hour (Maximum: 200 mEq/day) Serum K<2 mEq/L with ECG monitoring change or emergency treatment: speed< 2 0mEq/hour (Maximum: 400 mEq/day) Pediatric: maximum 3 mEq/kg or 40 mEq/m2 [Uptodate 20210731] Hypokalemia¡A treatment: Serum potassium 2.5 to 3 mEq/L: Initial: 10 to 20 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hr with continuous ECG monitoring. Serum potassium <2.5 mEq/L (not for emergency treatment of cardiac arrest): Initial: 10 to 40 mEq/hr; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hr with continuous ECG monitoring; some patients may require up to 400 mEq/24 hrs. [Micromedex 20210731] Serum potassium greater than 2.5 mEq/L: Infuse up to 10 mEq/hr IV in a concentration of up to 40 mEq/L or 200 mEq in a 24-hour period. Serum potassium less than 2 mEq/L and ECG changes with or without muscle paralysis: Infuse up to 40 mEq/hr IV or 400 mEq over 24 hours; give carefully under guidance of continuous ECG monitoring and frequent serum potassium level determination.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,,,,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
IKCL8S,Potassium Chloride,1.49% KCl (20mEq) in 0.9%NaCl 100mL,NUTR,Hypokalaemia.,Hyperkalemia.,Hyperkalemia¡A pain or phlebitis at injection site.,«Ç·Å,Only for central vein. Serum K> 2.5 mEq/L: should not usually exceed 10 mEq/hour or 200 mEq for a 24 hour period. Serum K< 2 mEq/L: injection speed can increase to 40 mEq/hour or 400 mEq over a 24 hour period with ECG monitoring.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,CVC;,,,,IV Adult Serum K <2 mEq/L: 20-40 mEq/hr¡A with ECG monitoring. Max: 400 mEq/day. Serum K >2.5 mEq/L: 10-15 mEq/hr; max: 200 mEq/day. Intermittent IV Children 0.5-1 mEq/kg/dose; infuse at 0.3-0.5 mEq/kg/hr; MAX: 1 mEq/kg/hr & 30 mEq/dose; MAX: 3 mEq/kg/day or 40 mEq/m2/day. Central line infusion: maximum rate 40 mEq/hr. peripheral IV infusion: maximum rate 10 mEq/hr.,1.¨Ï¥Î´Á¶¡À³ÄY±KºÊ´ú¯f±w¦å¹[¿@«×»P¤ß¹q¹Ï¡C 2.»PACE§í¨î¾¯¨Ö¥Î¥i¯à¤Þ°_°ª¦å¹[¯g¡C 3.»P«O¹[«¬§Q§¿¾¯¨Ö¥Î¥i¯à¤Þ°_ÄY­«°ª¦å¹[¯g¡B¤ß«ß¤£¾ã»P¤ß¸õ°±¤î¡C 4.¹[Â÷¤l±Æ°£¥\¯à¨ü·l©Î¿éª`¤Ó§Ö®É¡A¥i¯àµo¥Í­P©R©Ê°ª¦å¹[¯g¡C
OOMA,Omega-3- Acid Ethyl Esters 90,Omacor Soft 1000mg,CAVS,Treatment of hypertriglyceridemia.,Hypersensitivity to the active substance¡A to soya or to any of the excipients.,Nausea¡A dyspepsia¡A pruritus¡A skin rash¡A Increased serum ALT or AST,30¢J¥H¤U«Ç·Å¡A¤£¥i§N­á,Adult: 1-2 capsule orally twice daily after meals.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,OMEGA-3 FATTY ACID SUPPLEMENTS PREGNANCY RECOMMENDATION: Compatible BREASTFEEDING RECOMMENDATION: Compatible,Compatible ­÷¨Å®É¥i¨Ï¥Î,¥é³æÃh¥¥¤À¯Å:C,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°³n½¦Ån¡A½Ð¾ã²É§]ªA¡A¤£¥i¤Á¶}¡C
OFAL,Flunitrazepam,Fallep 2mg,CNEU,Insomnia.,Preexisting CNS depression or coma¡A resp depression¡A acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis¡A phobic or obsessional states; may precipitate suicide or aggressive behavior; not to be used alone to treat depression or anxiety associated with depression; glaucoma. Pregnancy¡A lactation. Neonates.,Drowsiness & lightheadedness the next day; confusion & ataxia; dependence.,25¢J¥H¤UÁ×¥ú,Adult 0.5-1 mg at bedtime. Maximum : 2 mg/day. Elderly or debilitated patients Initially 0.5 mg at bedtime. Maximum : 1 mg/day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Uknown ¨S¦³¸ê®Æ,[¥é³æ] FDA Pregency Category(Ãh¥¥¥ÎÃÄ¯Å¼Æ):*D Å²©ó¤U¦C¯gª¬¤§³ø§i¡A©|¥¼½Tª¾¨ä¦w¥þ©Ê¡A¦]¦¹§Æ±æ§³°ü¤Î±Â¨Å°ü¤Å¨Ï¥Î¡C (¤@)¸g¤fªAµ¹ÃÄµ¹Ãh¥¥°Êª«¤§¹êÅç¥H 50 mg/kg ¤§¾¯¶q¡A³Q»{©w¦³­P·î§Î§@¥Î¡C (¤G)¸g¤fªAµ¹Ãh¥¥¤¤¤§¨ä¥L Benzodiazepine ¨t¤Æ¦XÃÄª«¤§±wªÌ¹êÅç³ø§i¤¤¡Aµo²{·î§Î¨àªº¥X¥Í²v¦b§K¬Ì¾Ç¤§½Õ¬d¦³«D±`¦hªº³ø§i¡C (¤T)·s¥Í¨à¤§­÷¨Å§xÃø¡B¦Ù¦×ºò±i§C¤U¡B¶Ý¯v¡B¶À¯n¤§¼W±jµ¥¯gª¬¡A¦b¨ä¥L¤§ Benzodiazepine ¨t¤Æ¦Xª«¤§³ø§i¦³°O¸ü¡C (¥|)¤À®Y«e³sÄò¨Ï¥Î®É¡A¨ä¥Í²£«á¤§·s¥Í¨à¦³¯«¸g¹L±Ó¡AÅ¸§Ý¡A¹L«×ºò±iµ¥¦¹©ó Benzodiazepine ¨t¤Æ¦Xª«¥ç¦³³ø§i¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] Å²©ó¤U¦C¯gª¬¤§³ø§i¡A©|¥¼½Tª¾¨ä¦w¥þ©Ê¡A¦]¦¹§Æ±æ§³°ü¤Î±Â¨Å°ü¤Å¨Ï¥Î¡C Å²©ó­÷¨Å¤¤¤§µ¹ÃÄ¦³¼W±j·s¥Í¨à¶À¯n¤§¥i¯à¡A¦]¦¹§Æ±æ¤Å¨Ï¥Î¡A¦ý¥²¶·¨Ï¥Î®É¡A«hÁ×§K±Â¨Åµ¹·s¥Í¨à¡C 1.°Êª«¹êÅç¤¤¡AÃÒ¹ê·|²¾¦æ©ó¨Å¥Ä¤¤¡C 2.¤HÃþ¥À¨Å²¾¦æ¤¤·|¨Ï­÷¨Å·s¥Í¨à¶Ý¯v¡BÅé­«´î¤Ö¡A¦b¦¹¨ä¥LBenzodiazepine ¤§¤Æ¦XÃÄª«(Diazepam)¥ç¦³³ø§i¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¬°Á×§KºÞ¨îÃÄ«~¦¾¬V¤À¥]¾÷¡AºÞ¨îÃÄ«~¤£¿i¯»¡A½Ð¨Ï¥Î«e¦Û¦æ¬ã¿i¡C
IBOO,Diphtheria + Tetanus + Pertussis,Boostrix 0.5mL/dose (¤T¦X¤@¸É°l¬Ì­]),HIMM,Active booster immunization for the prevention of tetanus diphtheria & pertussis in children¡A adolescents & >= 4 years.,Hypersensitivity. Progressive neurological disorders¡A uncontrolled epilepsy or progressive encephalopathy. Encephalopathy not attributable to identifiable cause. Pregnancy.,Pain¡A swelling¡A erythema at inj site. Tiredness¡A headache¡A fever (> 38¢XC). Axillary lymph node swelling¡A rash¡A body ache or muscle weakness¡A sore or swollen joints. Nausea¡A diarrhea¡A vomiting. Demyelinating CNS diseases¡A peripheral mononeuropathies¡A cranial mononeuropathies & EEG disturbances with encephalopathy (with or without permanent intellectual &/or motor function impairment).,2-8¢J,IM¡A 0.5mL¡A > or = 4 years as a single dose,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]²Ä¤G¡B¤T¥¥´Á¥i¨Ï¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«e©|¥¼µû¦ô¦b±Â¨Å´Á¶¡¨Ï¥Îªº¦w¥þ©Ê¡A¥u¦³·í¼ç¦b®Ä¯q¤j©ó¼ç¦b¦MÀI®É¡A ¤~¥i¦b±Â¨Å´Á¶¡¨Ï¥Î¡C,IM;,,,,,
INOB,Levetiracetam,Nobelin inj 500mg/100mL,CNEU,,¾AÀ³¯g:Monotherapy in partial seizures with or without secondary generalisation in patients with newly diagnosed epilepsy. Adjunct in partial seizures with or without secondary generalisation. Adjunct in juvenile myoclonic epilepsy. Adjunct in idiopathic generalised epilepsy. °Æ§@¥Î: >10%: Cardiovascular: Increased blood pressure (diastolic; infants and children: 17%) Central nervous system: Behavioral problems (includes aggression¡A agitation¡A anger¡A anxiety¡A apathy¡A depersonalization¡A emotional lability¡A irritability¡A neurosis: children and adolescents: 7% to 38%; adults: 7% to 13%)¡A headache (14% to 19%)¡A drowsiness (8% to 15%); immediate release 4¡A000 mg/day¡A no titration: 45%; serious [patients hospitalized]: <1%)¡A psychotic symptoms (infants and children: 17%; adults: 1%)¡A irritability (infants¡A children¡A and adolescents: 6% to 12%)¡A fatigue (10% to 11%) Gastrointestinal: Vomiting (children and adolescents: 15%) Infection: Infection (13%) Neuromuscular & skeletal: Weakness (15%) Respiratory: Nasopharyngitis (7% to 15%) ¸T§Ò: Hypersensitivity to levetiracetam or any component of the formulation.,,«Ç·Å,Monotherapy: Initially 250mg twice daily¡A increasing to 500mg twice daily after 2 weeks¡A then by 250mg twice daily every 2 weeks according to response; max 1.5g twice daily. Add-on therapy: Initially 500mg twice daily. If necessary¡A increase in increments of 500mg twice daily every 2¡X4 weeks; max 1.5g twice daily. IV: For IV use only; infuse over 15 minutes for max 4 days.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,,,¥H15¤ÀÄÁªºÀR¯ß¿éª`®É¶¡µ¹ÃÄ,1. ¶ÈÀR¯ß¿éª`¨Ï¥Î¡A¤£¥iµ}ÄÀ¡A¥H15¤ÀÄÁªºÀR¯ß¿éª`®É¶¡µ¹ÃÄ¡C
ITTA5,Tetanus toxoid,Tetana vaccine 0.5mL/dose¡A 0.5mL/amp (±M®×¶i¤f),HIMM,,¾AÀ³¯g: Active immunization of tetanus. °Æ§@¥Î: Drowsiness¡A malaise¡A hypersensitivity. ¸T§Ò¡GHypersensitivity to tetanus toxoid or any component of the formulation,,2-8¢J,IM¡A 0.5 mL/dose. Primary immunization: I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose Routine booster dose: Recommended every 10 years Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated¡A the immunization status of the patient¡A proper use of tetanus toxoid and/or tetanus immune globulin (TIG)¡A wound cleaning¡A and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules.,IM;,,,,,¥é³æ¨Ï¥Î¤èªk¡G²`¼h¥Ö¤Uª`®g¡A¤@¯ë©ó°ª¦ì¤WÁu¦Ù¦×(¤T¨¤¦Ù)±µ¨üª`®g¡C¥»«~ÄY¸T¦åºÞ¤ºª`®g¡C ¤w¸ß°ÝÃÄ°Ó°ê¥ú¥Íª«¬ì§Þ¡A²`¼h¥Ö¤U¤@µüÂ½Ä¶¦ÛªiÄõ­ì¼t¥é³æªº·í¦a¥Î»y¡A¤WÁu¤T¨¤¦Ù¥u¾A¦X¦Ù¦×ª`®g¡A¥é³æªº¥Îªk·N«ü¡u¦Ù¦×ª`®g¡v¡C
OEFI3,Prasugrel,Efient 3.75mg,HEMT,Percutaneous coronary intervention (PCI) for Acute coronary syndrome (ACS),Hypersensitivity (eg¡A anaphylaxis) to prasugrel or any component of the formulation; active pathological bleeding (eg¡A peptic ulcer¡A intracranial hemorrhage); prior transient ischemic attack or stroke.,1% to 10%: Cardiovascular: Hypertension (8%)¡A hypotension (4%)¡A atrial fibrillation (3%)¡A bradycardia (3%)¡A peripheral edema (3%) Central nervous system: Headache (6%)¡A dizziness (4%)¡A fatigue (4%)¡A noncardiac chest pain (3%) Dermatologic: Skin rash (3%) Endocrine & metabolic: Hypercholesterolemia (?7%)¡A hyperlipidemia (?7%) Gastrointestinal: Nausea (5%)¡A diarrhea (2%)¡A gastrointestinal hemorrhage (2%) Hematologic & oncologic: Leukopenia (3%)¡A anemia (2%)¡A major hemorrhage (2%)¡A minor hemorrhage (2%)¡A major hemmorhage (life-threatening: 1%) Neuromuscular & skeletal: Back pain (5%)¡A limb pain (3%) Respiratory: Epistaxis (6%)¡A dyspnea (5%)¡A cough (4%) Miscellaneous: Fever (3%) <1%¡A postmarketing¡A and/or case reports: Abnormal hepatic function tests¡A anaphylaxis¡A angioedema¡A hematoma¡A hemoptysis¡A hemorrhage (requiring inotropes or transfusion)¡A hypersensitivity reaction¡A intracranial hemorrhage (symptomatic)¡A re-operation due to bleeding¡A thrombocytopenia¡A thrombotic thrombocytopenic purpura,«Ç·Å¤UÀx¦s(25¢J¥H¤U),Loading dose: 20 mg; Maintenance dose: 3.75 mg QD. Not recommended taking Efient on empty stomach except loading dose.,µL»Ý½Õ¾ã¾¯¶q,No dosage adjustment is necessary in patients with mild to moderate hepatic impairment (Child-Pugh Class A and B),µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ¥u¦³¦b¹w´ÁªºªvÀø®Ä¯q°ª©ó¥i¯àªº­·ÀI®É¡A¤~«ØÄ³Ãh¥¥©M¥i¯àÃh¥¥ªº¤k©Ê¨Ï¥Î¡C ©|¥¼«Ø¥ßÃh¥¥¤k©Êªº¦w¥þ©Ê¡A¥B¤wª¾¥»ÃÄ¥NÁÂª«·|¤Àªc¦Ü¤j¹«ªº­L¨à¤¤¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ­÷¨Å¥À¿Ë¦bªA¥Î®ÉÀ³Á×§K±Â¨Å¡C ¤wª¾¥»ÃÄ¥NÁÂª«·|¤Àªc¦Ü¤j¹«ªº¨Å¥Ä¤¤¡C,PC;PO;WM;,,,,,
OIBR0,Palbociclib,IBRANCE 125mg (Sample),RACA,Breast cancer¡A advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive¡A human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer¡A advanced (with disease progression following endocrine therapy): Treatment of HR-positive¡A HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy,Hypersensitivity to palbociclib or any component of the formulation,>10%: Central nervous system: Fatigue (41%)¡A headache (26%)¡A peripheral neuropathy (13%) Dermatologic: Alopecia (18% to 22%)¡A skin rash (17%) Gastrointestinal: Nausea (25% to 34%)¡A stomatitis (25% to 28%)¡A diarrhea (21% to 24%)¡A constipation (20%)¡A vomiting (15% to 19%)¡A decreased appetite (16%) Hematologic & oncologic: Neutropenia (75% to 83%; grade 3: 48% to 55%; grade 4: 6% to 11%)¡A decreased absolute lymphocyte count (81%; grade 3: 17%; grade 4: 1%)¡A anemia (30% to 78%; grade 3: 3% to 5%; grade 4: ?1%)¡A leukopenia (43% to 53%; grade 3: 19% to 30%; grade 4: ?1%)¡A thrombocytopenia (17% to 23%; grade 3: 2%; grade 4: ?1%) Infection: Infection (47% to 55%) Neuromuscular & skeletal: Weakness (8% to 13%) Respiratory: Upper respiratory tract infection (31%)¡A epistaxis (7% to 11%) Miscellaneous: Fever (13%) 1% to 10%: Cardiovascular: Pulmonary embolism (1% to 5%) Dermatologic: Xeroderma (6%) Gastrointestinal: Dysgeusia (7%) Hematologic & oncologic: Febrile neutropenia (1%; grade 3: 1%) Ophthalmic: Blurred vision (6%)¡A increased lacrimation (6%)¡A dry eye syndrome (4%),30 ¢J¥H¤U,125 mg capsule taken orally once daily for 21 days followed by 7 days off treatment to comprise a complete cycle of 28 days.IBRANCE should be taken with food. Administer the recommended dose of an aromatase inhibitor when given with IBRANCE. When given with IBRANCE¡A the recommended dose of fulvestrant is 500 mg administered on Days 1¡A 15¡A 29¡A and once monthly thereafter.Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. For men treated with combination IBRANCE plus aromatase inhibitor therapy¡A consider treatment with an LHRH agonist according to current clinical practice standards. Luteinizing hormone-releasing hormone (LHRH) also called Gonadotropin-Releasing Hormone (GnRH).,»Ý½Õ¾ã¾¯¶q,Severe impairment (Child-Pugh class C): Reduce dose to 75 mg once daily for 21 days¡A followed by 7 days off; repeat every 28 days.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,PO;WM;,,,,,
OSYNT,Carvedilol,Syntrend 25mg,CAVS,,¾AÀ³¯g: Hypertension¡A Heart failure: °Æ§@¥Î: > 10% Cardiovascular: Hypotension (9% to 20%) Central nervous system: Dizziness (2% to 32%)¡A fatigue (4% to 24%) Endocrine & metabolic: Hyperglycemia (5% to 12%) Gastrointestinal: Weight gain (10% to 12%)¡A diarrhea (1% to 12%) Neuromuscular & skeletal: Weakness (7% to 11%) ¸T§Ò:Serious hypersensitivity to carvedilol or any component of the formulation; decompensated cardiac failure requiring intravenous inotropic therapy; bronchial asthma or related bronchospastic conditions; second- or third-degree AV block¡A sick sinus syndrome¡A and severe bradycardia (except in patients with a functioning artificial pacemaker); cardiogenic shock; severe hepatic impairment.,,«Ç·Å,Essential hypertension Initially 12.5mg once daily for 2 days¡Athen 25 mg qd. Max:50 mg daily.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¯f¤H¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Thomson: Infant risk cannot be ruled out,,,,,,
OFAMO,Famotidine,Famotidine 20mg,ALIM,Gastric ulcer¡A duodenal ulcer¡A anastomotic ulcer¡A upper gastrointestinal bleeding (peptic ulcer¡A acute stress ulcer¡A hemorrhagic gastritis)¡A reflux esophagitis¡A Zollinger-Ellison syndrome,Serious hypersensitivity (eg¡A anaphylaxis) to famotidine¡A other H2 antagonists¡A or any component of the formulation,>10%: Central nervous system: Agitation (infants: ?14%; adults: <1%) 1% to 10%: Central nervous system: Headache (5%)¡A dizziness (1%) Gastrointestinal: Diarrhea (2%)¡A constipation (1%)¡A necrotizing enterocolitis (very low birth weight neonates; Guillet 2006) Frequency not defined: Local: <1%¡A postmarketing¡A and/or case reports: Abdominal distress¡A acne vulgaris¡A agranulocytosis¡A alopecia¡A anaphylaxis¡A angioedema¡A anorexia¡A anxiety¡A arthralgia¡A asthenia¡A atrioventricular block¡A bronchospasm¡A cardiac arrhythmia¡A cholestatic jaundice¡A confusion¡A conjunctival injection¡A decreased libido¡A depression¡A drowsiness¡A facial edema¡A fatigue¡A fever¡A flushing¡A hallucination¡A hepatitis¡A hypersensitivity reaction¡A impotence¡A increased liver enzymes¡A insomnia¡A interstitial pneumonitis¡A leukopenia¡A muscle cramps¡A musculoskeletal pain¡A nausea¡A palpitations¡A pancytopenia¡A paresthesia¡A periorbital edema¡A prolonged Q-T interval on ECG¡A pruritus¡A psychiatric disturbance¡A rhabdomyolysis¡A seizure¡A skin rash¡A Stevens-Johnson syndrome¡A taste disorder¡A thrombocytopenia¡A tinnitus¡A toxic epidermal necrolysis¡A urticaria¡A vomiting¡A xeroderma¡A xerostomia,Á×¥ú«Ç·Å30¢J¥H¤UÀx¦s,usual dose: 20mg BID or 40mg HS,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
OBIOP,Antibiotics-resistant Lactic Acid Bacteriae,Biofermin-R 6mg/1gm Powder,ALIM,Treatment of symptoms caused by abnormal enteric microflora during administration of antibiotics or chemotherapeutic agents.,Hypersensitivity to any component of the product.,No side effects listed in package insert.,«Ç·Å«O¦s¡A¶}«Ê«áÁ×§KÀã®ð¡C,Adult: 1gm (1 pack) TID¡A after meals. Increase or decrease dosage according to age and symptoms.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,¥é³æ¥¼¨£¬ÛÃö±Ô­z,Unknown ¨S¦³¸ê®Æ,¥é³æ¥¼¨£¬ÛÃö±Ô­z,AC;AC15;PC;PO;WM;,,,,,1. »PAminophylline©ÎIsoniazid²V¦X®É¡A·|¨Ï¥»ÃÄ«~ÅÜ¦â¡AÀ³Á×§K»P¤W­z¨âºØ¦¨¥÷¤§ÃÄ«~²V¦X¡C 2. ÃÄ«~¬°¥Õ¦â¦Ü·L²H¶À½Å¦â¯»¥½ª¬¡Aµy¨ã²¢¨ý¡C 3. ¥D¦¨¤À­@©Ê¨Å»Äµß (Antibiotics-resistant Lactic Acid Bacteriae)¡AµßºØ¡GStreptococcus faecalis¡C
OATM40,Atomoxetine,40mg APO-ATOMOXETINE,CNEU,Attention deficit hyperactivity disorder.,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma¡A current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg¡A 15 to 20 mm Hg) or heart rate (eg¡A 20 beats per minute),Common: Increased heart rate (Adult¡A 10.2-22.4%; pediatric¡A 12.2-23.4%)¡A Weight decreased (Adult¡A 2%; pediatric¡A 3%)¡A Abdominal pain (Adult¡A 7%; pediatric¡A 18%)¡A Constipation (Adult¡A 8%; pediatric¡A 1-2%)¡A Decrease in appetite (Adult¡A 16%; pediatric¡A 16%)¡A Nausea (Adult¡A 26%; pediatric¡A 10%)¡A Vomiting (Adult¡A 4%; pediatric¡A 11%)¡A Xerostomia (Adult¡A 20%)¡A Dizziness (Adult¡A 8%; pediatric¡A 5%)¡A Headache (Pediatric¡A 19%)¡A Insomnia (Adult¡A 15%; pediatric¡A at least 2%)¡A Somnolence (Adult¡A 8%; pediatric¡A 11%)¡A Delay when starting to pass urine (Adult¡A 6%)¡A Dysmenorrhea (Adult¡A 3%)¡A Erectile dysfunction (Adult¡A 8%)¡A Fatigue (Adult¡A 10%; pediatric¡A 8%) Serious: Increased diastolic arterial pressure (Adult¡A 4.8-12.6%; pediatric¡A 9.3-21.5%)¡A Increased systolic arterial pressure (Adult¡A 4.2-12.4%; pediatric¡A 4.9-12.5%)¡A Myocardial infarction¡A Sudden cardiac death¡A Tachycardia (Adult¡A 1.5%; pediatric¡A 0.3%)¡A Injury of liver (Severe)¡A Liver failure¡A Cerebrovascular accident¡A Aggressive behavior¡A Hostile behavior¡A Mania¡A Psychotic disorder¡A Suicidal thoughts (Pediatric¡A 0.4%)¡A Priapism,Àx¦s©ó25¢J¥H¤U,6 years or older¡A up to 70 kg: Acute treatment: Initial¡A approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily¡A as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day¡A whichever is less 6 years or older¡A greater than 70 kg: Acute treatment: Initial¡A 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks;Maximum 100 mg daily,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤«×ªº¨x¥\¯à¤£¥þ¯f±w(Child-Pugh Class B)¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 50¢H¡C ±w¦³ÄY­«¨x¥\¯à¤£¥þ(Child-Pugh Class C)ªº¯f±w¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 25¢H¡C,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ¦bÃh¥¥¨ß¤lªº¾¹©x§Î¦¨´Á¶¡¡AÁý­¹¾¯¶q³Ì°ª¦Ü 100 mg/ kg/ day ªºAtomoxetine¡C¦b¤T½g¬ã¨s¤¤ªº¤@½g¡AÆ[¹î¨ì¬¡­L¼Æ´î¤Ö¡A¦­´Á¦A§l¦¬¼W¥[¡C¤£¥¿±`ÀV°Ê¯ß°_·½¤Î¯Ê¤ÖÂê°©¤U°Ê¯ßªºµo¥Í²vµy·L¼W¥[¡C³o¨Çµ²ªGµo²{©ó·|¤Þ°_»´·L¥ÀÅé¬r©Êªº¾¯¶q¡C ³o¨Çµ²ªGªºµL§@¥Î¾¯¶q¡]no-effect dose¡^¬° 30 mg/ kg/ day¡C¥Hmg/ m2­p¡A100 mg/ kg ªº¾¯¶q¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 23 ­¿¡A¨ß¤l¦å¤¤ªº Atomoxetine¿@«×¡]AUC¡^¦ô­p¬°±µ¨ü³Ì°ª¤HÅé¾¯¶qªº¤HÅé¤ºªº 3.3 ­¿¡]§Ö³t¥NÁÂªÌ¡^©Î 0.4 ­¿¡]½wºC¥NÁÂªÌ¡^¡C ±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î 10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨¤Î­÷¨Å´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J¤£¶W¹L¤j¬ù 50 mg/ kg/ day ªº atomoxetine¡]¥H mg/ m2­pºâ¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 6 ­¿¡^¡C ¦b¤G½g¬ã¨sªº¨ä¤¤¤@½g¡Aµo²{¤p¹«Åé­«¤Î¦s¬¡¼Æ´î¤Ö¡C¦b 25 mg/ kg¡]«D 13 mg/ kg¡^¡A¤]µo²{¨ì¤p¹«ªº¦s¬¡´î¤Öªº²{¶H¡C ¤@½g±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J Atomoxetine ªº¬ã¨s¤¤¡A40mg/ kg/ day¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 5 ­¿¡^¡Aµo²{¨ì­L¹«Åé­«´î¤Ö¡]¶È¥À¹«¡^¤Î´Õ°©¤}¡]vertebral arch¡^¤£§¹¥þ¦¨°©ªºµo¥Í²v¼W¥[ªº²{¶H¡A¦¹²{¶H¨Ã¨S¦³¦b 20 mg/ kg/ day ¾¯¶q²Õ¤¤µo²{¡C ¦b¾¹©x§Î¦¨´Á¶¡¡A¥H 150 mg/ kg/ day ªº¾¯¶q¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº17 ­¿¡^Áý­¹Ãh¥¥¥À¹«¡A­L¨à¨Ã¥¼¥X²{¥ô¦óªº°Æ§@¥Î¡C ¥Ø«e©|µLÃö©óÃh¥¥°ü¤k¤§¥R¤À¤Î§¹¾ãªº¹ï·Ó©Ê¬ã¨s¡C Ãh¥¥´Á¶¡¤£¥iªA¥Î Atomoxetine¡A°£«D®Ä¯q¶W¹L­L¨à¥i¯à²£¥Íªº­·ÀI©Ê¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Atomoxetine ¤Î/ ©Î¨ä¥NÁÂª«·|¤Àªc¦Ü¦Ñ¹«ªº¨Å¥Ä¤¤¡C Atomoxetine ¬O§_·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤«h¥¼ª¾¡C ­÷¨Å¤¤ªº°ü¤k­YªA¥Î Atomoxetine ®É¡AÀ³¥[¥Hª`·N¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½Ð¾ãÁû½¦Ån§]ªA¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¥»ÃÄ¯»¥½¨ã¦³²´³¡¨ë¿E©Ê¡C
IMEPI,Mepivacaine,Mepivastesin 3%(for Dental) 1.7mL,ZANE,Dental infiltration and dental nerve block.,Complete heart block. Porphyria. Do not inject through infected skin when using for epidural anaesthesia.,Restlessness¡A excitement¡A nervousness¡A paraesthesias; dizziness¡A tinnitus¡A blurred vision; nausea¡A vomiting; muscle twitching¡A tremors¡A convulsions; numbness of the tongue and perioral region; lightheadedness¡A drowsiness¡A respiratory failure¡A coma¡A hypotension.,«Ç·Å,Mepivacaine 30mg/mL. Dosage requirements should be determined on an individual basis. For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection. Adult: dosages of 1-4 mL are usually effective. Children 20-30 kg: 0.25-1 mL. Children 30-45 kg: 0.5-2 mL. Mepivacaine maximum dose: 4 mg/kg (equivalent to 0.133 mL).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,LI;,,,,,
EFOX1,Fluorometholone,0.1% FOXONE 10mL ophthalmic suspension,TOPH,Acute & chronic iritis¡A iridocyclitis¡A scleritis¡A episcleritis¡A conjunctivitis¡A keratitis¡A resistant ocular allergy & inflammation following surgery,Acute superficial herpes simplex keratitis¡A fungal diseases of ocular structure; vaccinia¡A varicella & other viral diseases of the cornea & conjunctiva¡A eye TB,Glaucoma with optic nerve damage¡A visual acuity or field defects¡A raised intraocular pressure¡A secondary infection (persistent corneal ulceration¡A possibly fungal invasion)¡A perforation of globe¡A posterior subcapsular cataract formation,25¢J¥H¤U,Instill 1 to 2 drops into conjunctival sac 2 to 4 times daily; may instill 2 drops every 2 hours or 1 drop every 4 hours during initial 24 to 48 hours. Shake well before use.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AD;AL;AS;AU;OD;OL;OU;,,,,,
EGEN3,Gentamicin,Gentamicin ²´ÃÄ»I 0.3%¡A 5gm,TOPH,Treatment of ocular infections due to susceptible organisms.,Hypersensitivity.,Rarely¡A transient stinging.,30¢J¥H¤U,Apply a small amount of ointment to the affected eye(s) two or three times a day.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest low risk,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AD;AL;AS;AU;EXT;IN;OD;OL;OU;SKIN;TOPI;,,,,,
IVER,Verapamil,U-sodin inj 5mg/2mL (Verapamil),CAVS,Angina pectoris¡A hypertension¡A arrhythmias.,2nd or 3rd degree AV block; hypotension; bradycardia; sick sinus syndrome; cardiogenic shock¡A sino-atrial block; history of heart failure or significantly impaired left ventricular function; atrial flutter or fibrillation complicating Wolff-Parkinson-White syndrome.,Flushing¡A constipation¡A bradycardia¡A hypotension¡A dizziness¡A headache¡A fatigue¡A peripheral oedema¡A allergic reactions (rare)¡A 1st or 2nd degree AV block (after IV administration or high doses). Cardiovascular: Edema (up to 3.7% )¡A Hypotension (1.5% to 3% ) Gastrointestinal: Constipation (7.3% to 13% ) Neurologic: Dizziness (3% to 5.9% )¡A Headache (2.2% to 12.1% ) Respiratory: Pharyngitis (3% )¡A Sinusitis (3% ) Other: Influenza-like symptoms (3.7% ),»ÝÁ×¥úÀx¦s¥HÃ­©wÃÄ®Ä,Acute ventricular rate control (in hemodynamically stable patients¡A due to Atrial fibrillation and flutter): Initial: bolus 5 to 10 mg over > or = 2 min; dose may be repeated after 15 to 30 min¡A may repeat 2-3 times per day. [Micromedex 20211013] Atrial fibrillation and flutter 0.075 to 0.15 mg/kg IV bolus over 2 minutes; may give an additional 10 mg after 30 minutes if no response¡A then 0.005 mg/kg/min infusion.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à»ÙÃª¤§¯f±w«ØÄ³ Use 30% of dose given to patients with normal hepatic function,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,The use of verapamil in any stage of pregnancy appears to be low risk. The drug was not teratogenic in two animal species¡A but did cause death and growth restriction in one species.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö5¤ÀÄÁ,,1.¤£¥i»P§tsodium lactateÃÄª«²V¦X. 2.¤£¥i»PpH­È¤j©ó6ªºÃÄª«²V¦X¡A·|¦³¨I¾ýµo¥Í¡C (Micromedex)
EANE,Adapalene,Anefree gel 0.1% 15gm,TDER,,¾AÀ³¯g: Treatment of acne vulgaris. °Æ§@¥Î: >10%: Dermatologic: Xeroderma (<=45%)¡A exfoliation of skin (<=44%)¡A erythema (<=38%)¡A burning sensation of skin (<=29%)¡A stinging of the skin (<=29%) 1% to 10%: Dermatologic: Skin abnormalities (1% to 6%; discomfort)¡A desquamation (2%)¡A pruritus (<=2%)¡A skin irritation (1% to 2%)¡A sunburn (1% to 2%) ?1%¡A postmarketing¡A and/or case reports: Acne flare¡A angioedema (gel)¡A application site pain (gel)¡A conjunctivitis¡A contact dermatitis¡A dermatitis¡A eczema¡A eyelid edema¡A facial edema (gel)¡A skin discoloration¡A skin rash (cream/gel)¡A swelling of lips (gel) ¸T§Ò: Hypersensitivity to adapalene or any component of the formulation.,,25«×C¥H¤U,Apply once daily in the evening before bedtime.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ø«e¹ï©ó¥¥°üªº¼vÅT¸ê°T¦³­­¡A¦ý¬OAdapalene¦³«Ü§Cªº¥i¯à©Ê·|¸g¥Ñ¥Ö½§§l¦¬¡A ¦]¦¹¡AÃh¥¥¤Î§Y±NÃh¥¥ªº¯f±wÀ³°±¤î¨Ï¥Î¡C¦pªG¦³«D¹w´ÁÃh¥¥ªº±¡§Î¡AªvÀø¥çÀ³°±¤î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¹ï¥»«~¬O§_³Q¤Àªc©ó°Êª«©Î¤HÃþ¨Å¥Ä¤¤¤]©|¥¼ª¾¡C ¥Ñ©ó¦hºØÃÄª«¬Ò¥i¯à¤Àªc©ó¨Å¥Ä¤¤¡A¦]¦¹±Â¨Å´Á°ü¤k¨Ï¥ÎAdapalene¾®½¦®ÉÀ³ÂÔ·V¡C Á×§K²£«~ª½±µ±µÄ²À¦¨à¦¹²£«~¤£À³¨Ï¥Î©ó¯Ý³¡¡C,EXT;,,,,,
OCINO,Ciprofloxacin,Cinolone F.C. 250mg,QANB,UTI .Respiratory tract¡A bone and joint and biliary tract infection.GI (infectious diarrhea). Gonorrhea.,Hypersensitivity to ciprofloxacin or other quinolones. Children¡A adolescents¡A pregnancy and lactation.,Nausea¡A diarrhoea¡A vomiting¡A dyspepsia¡A abdominal pain¡A flatulence¡A anorexia¡A dizziness¡A headache¡A tiredness¡A agitation¡A trembling. Very rarely¡A insomnia¡A peripheral paralgesia¡A sweating¡A unsteady gait¡A convulsions¡A increase in intracranial pressure¡A anxiety states¡A nightmares¡A confusion¡A depression¡A hallucinations¡A impaired taste & smell¡A visual disturbances¡A tinnitus¡A transitory impairment of hearing¡A especially at high frequencies¡A skin reactions.,30¢J¥H¤U¡Aºò±Kªý¥ú®e¾¹¤¤Àx¦s,Take with or without food; do not take with milk¡A yogurt¡A or calcium-fortified juice; but may be taken with meals that contain these products. Adults: 250-750 mg orally Q12H. Children (1-17 years of age): 10-20 mg/kg Q12H (maximum. 750 mg/dose); inhalational anthrax (post-exposure): 15 mg/kg orally Q12H for 60 days (maximum. 500 mg/dose).,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,PREGNANCY RECOMMENDATION: Contraindicated (Use only if no other alternatives),No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;,,,,,
IALC,Alcohol,99.5% Alcohol inj 5mL,RACA,Percutaneous ehtanol injection therapy for hepatocellular carcinoma.,Hypersensitivity to ethyl alcohol or any component of the formulation; seizure disorder and diabetic coma; subarachnoid injection of dehydrated alcohol in patients receiving anticoagulants,Increased serum transaminases¡A fever¡A gastric ulcer¡A throboembolism,25¢J¥H¤U,Anhydrous alcohol injection was performed under the guidance of ultrasound imaging.Tumor number less than or equal to 3 numbers¡A and tumor smaller than 3 cm in diameter: 1-10mL 99.5% Alcohol is injected directly to the liver tumors via percutaneous injection¡A once or twice a week. Maximum: 4-6 times a week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Hold Breast Feeding ¼È°±­÷¨Å,,PI;,,,,,
IFAMO,Famotidine,Famoster inj. 20mg/2mL,ALIM,,,,,,,,,,,,,,IM;IVD;IVP;,,,,,
OMUL,Dronedarone,Multaq 400mg,CAVS,Paroxysmal or persistent atrial fibrillation: To reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF,Hypersensitivity to dronedarone or any component of the formulation; permanent atrial fibrillation (patients in whom normal sinus rhythm will not or cannot be restored); symptomatic heart failure (heart failure with recent [within the last 4 weeks] decompensation requiring hospitalization or NYHA Class III or IV symptoms); liver or lung toxicity related to previous amiodarone use; second-degree or third-degree atrioventricular block or sick sinus syndrome (except when used in conjunction with a functioning artificial pacemaker); bradycardia <50 bpm; concomitant use of strong CYP3A4 inhibitors (eg¡A ketoconazole¡A itraconazole¡A voriconazole¡A cyclosporine¡A telithromycin¡A clarithromycin¡A nefazodone¡A ritonavir); concomitant use of drugs or herbal products known to prolong the QT interval increasing the risk for torsade de pointes (eg¡A phenothiazine antipsychotics¡A tricyclic antidepressants¡A certain oral macrolide antibiotics¡A class I and III antiarrhythmics); QTc (Bazett) interval ?500 msec or PR interval >280 msec; severe hepatic impairment; pregnancy; breastfeeding,Common: Abdominal pain (4%)¡A Diarrhea (9%)¡A Indigestion (2%)¡A Nausea (5%)¡A Vomiting (2%)¡A Asthenia (7%)¡A Serum creatinine above reference range (51%) Serious: Congestive heart failure¡A Prolonged QT interval (28%)¡A Hepatotoxicity¡A Liver failure¡A Acute renal failure¡A Renal failure¡A Interstitial lung disease,30¢XC ¥H¤UÀx¦s,400 mg twice daily with meals,»Ý½Õ¾ã¾¯¶q,Severe impairment: Use is contraindicated.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Human (and animal) data suggest risk,[¥é³æ] ¸T§Ò,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¸T§Ò,WM;,,,,,
IALB20,Albumin,Albumin inj 20% 50mL (TBSF),HEMT,Hypovolemic shock¡A conditions when there is severe hypoalbuminemia¡A as an adjunct in hemodialysis & in cardiopulmonary bypass procedures. In conjunction with exchange transfusion in the treatment of neonatal hyperbilirubinemia.,History of hypersensitivity reaction to albumin preparations or to any component of the product. Patients with severe anemia or cardiac failure with normal or increased intravascular volume. Patients at risk for circulatory overload (eg¡A history of congestive cardiac failure¡A renal insufficiency¡A or stabilized chronic anemia). Patients with chronic kidney disease injected with 20% albumin solution will be rapidly excreted by the kidneys and cannot relieve chronic edema. Not suitable for hypoalbuminemia caused by chronic liver cirrhosis¡A malabsorption¡A intestinal protein loss¡A pancreatic insufficiency and malnutrition.,Frequency not defined: Flushing¡A heart failure¡A hypotension¡A tachycardia¡A Pruritus¡A skin rash¡A urticaria¡A Nausea¡A vomiting¡A Chills¡A rigors¡A Bronchospasm¡A dyspnea¡A pulmonary edema¡A Fever. Postmarketing: Acute myocardial infarction¡A atrial fibrillation¡A Hyperchloremic metabolic acidosis¡A Dysgeusia¡A sialorrhea¡A Anaphylactic shock¡A anaphylaxis (Lozano 2019)¡A hypersensitivity reaction (including severe hypersensitivity reaction)¡A nonimmune anaphylaxis¡A type 1 hypersensitivity reaction¡A Nervous system: Headache¡A Febrile reaction.,30¢XC ¥H¤U¤£¥i§N­á,Hypoproteinaemia in the acutely ill patient The usual daily dose is 50¡V75 g human albumin (250-375 mL of ¡§TBSF¡¨ (20%) Human Albumin Solution). The rate of administration should not exceed 2 mL per minute¡A as more rapid infusion may precipitate circulatory overload and pulmonary edema. The infusion of ¡§TBSF¡¨ (20%) Human Albumin Solution is not justified in hypoproteinaemic states associated with chronic cirrhosis¡A malabsorption¡A protein-losing enteropathies¡A pancreatic insufficiency¡A or undernutrition. Shock The dose should be determined by the patient¡¦s condition and response to treatment. The usual initial dose of 20 g human albumin (100 mL of ¡§TBSF¡¨ (20%) Human Albumin Solution) may be administered as a blood volume expander at a rate of 2 to 4 mL per minute. The rate of infusion may be increased in emergencies and repeated in 15 to 30 minutes if necessary. The total dose should not exceed the level of albumin found in the normal individual i.e. about 2 g per kg body weight in the absence of active bleeding. If concentrated albumin (>4¡V5%) is given¡A it should be accompanied by the intravenous infusion of a crystalloid solution. Failure to supply this additional fluid may lead to dehydration of the tissues. The precise nature and strength of the crystalloid solution will depend on the requirements of the patient for electrolytes and fluid. Burns The usual dose is 20-80 g human albumin (100-400 mL of ¡§TBSF¡¨ (20%) Human Albumin Solution) given daily at the rate of about 1 mL per minute. Beyond 24 hours¡A ¡§TBSF¡¨ (20%) Human Albumin Solution can be used to maintain plasma colloid osmotic pressure. A reasonable goal is the maintenance of a plasma albumin concentration of 25 g/L or a colloid osmotic pressure of 20 mmHg. The continuing need for albumin is occasioned by losses from denuded areas and decreased albumin synthesis.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]©|¥¼¦³¡§°ê¦å»s¾¯¯q±d¡¨(20%)¤H¦å²M¥Õ³J¥Õª`®g¾¯¦b°Êª«¥Í´Þ¬r©Êªº¬ã¨s¡C ¦]¬°¦b°Êª«¼Ò¦¡¤¤·|¹ï¤HÃþ¥Õ³J¥Õ²£¥Í§ÜÅé¦ÓµLªk¶i¦æ¦¹¬ã¨s¡C ¦bÃh¥¥´Á¶¡¨Ï¥Î¡§°ê¦å»s¾¯¯q±d¡¨(20%)¤H¦å²M¥Õ³J¥Õª`®g¾¯¡A©|¥¼«Ø¥ß©ó¹ï·ÓÁ{§É¸ÕÅç¤¤½T¥ß¡A ¦]¦¹¡A¦p¦³©ú½Tªº»Ý­n¤~¥iµ¹¤©¥¥°ü¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]»P¤º¥Í©Ê¦å²M¥Õ³J¥Õ¬Û¦ü¡A ¡§°ê¦å»s¾¯¯q±d¡¨(20%)¤H¦å²M¥Õ³J¥Õª`®g¾¯¥i¯à¤Àªc¦Ü¨Å¥Ä¡C ©|µL¦¹¤è­±ªº¦w¥þ¸ê°T¡C,IVD;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,°ê¦å»s¾¯¯q±d(20%)¤H¦å²M¥Õ³J¥Õª`®g¾¯¥iµ}ÄÀ¦¨µ¥½¦Åéº¯³zÀ£¤§³J¥Õ½è·»²G(4~5%¥Õ³J¥Õ)¡A¨ä¤ñ¨Ò¬°1mL°ê¦å»s¾¯¯q±d(20%)¤H¦å²M¥Õ³J¥Õª`®g¾¯¤ñ4mL´¹Åé·»²G¡A¦A¥H¥­±`ªºÀR¯ßª`®gªkµ¹¤©¡C ¿éª`³t²v¡G «æ©Ê¯f¤Hªº§C³J¥Õ¦å¯g¡G<2mL/¤ÀÄÁ ¥ð§J(·í°µ¦å²GÅé¿nªºÂX±i¾¯)¡G2-4mL/¤ÀÄÁ ¿N¶Ë¡G1mL/¤ÀÄÁ,1.­Y¶·µ}ÄÀ¶·¨Ï¥Î´¹Åé·»²G¡A¦ý¥é³æ¤¤µL«ØÄ³¤§·»²G¡A¼t°Ó¥çµLªk´£¨Ñ¬Û®e©Ê¤å¥ó¡C 2.¤£¥i¥Î¤ô¨Óµ}ÄÀ¡A¦]¬°¨ä§Cº¯³zÀ£·|¾É­P¦åºÞ¤º·»¦å¡C 3.¥»²£«~¤£§t¥ô¦ó§Ü·L¥Íª«¨¾»G¾¯¡A¦]¦¹¡A¦b¶}²~«áÀ³°¨¤W¨Ï¥Î¡C 4.¤Á¤Å¨Ï¥Î´¿¸g³Q§N­á¹Lªº·»²G¡C
ERELV,Fluticasone + Vilanterol,Relvar Ellipta 92/22mcg inhalation powder,ERSP,Asthma¡A and chronic obstructive pulmonary disease of maintenance.,Hypersensitivity to fluticasone¡A vilanterol¡A or any component of the formulation. Severe hypersensitivity to milk proteins. Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.,Common Gastrointestinal: Difficulty talking (2% )¡A Oropharyngeal candidiasis¡A Pain¡A Oropharyngeal (2% or greater ) Immunologic: Influenza (3% or greater ) Neurologic: Headache (5% to 8% ) Respiratory: Bronchitis (2% or greater )¡A Cough (1% or greater )¡A Nasopharyngitis (9% to 10% )¡A Sinusitis (2% or greater )¡A Upper respiratory infection (2% to 7% ) Serious Cardiovascular: Cardiac dysrhythmia¡A Disorder of cardiovascular system¡A Electrocardiogram abnormal¡A Premature beats (2% or greater )¡A Supraventricular tachycardia Endocrine metabolic: Cushing's syndrome Immunologic: Anaphylaxis Musculoskeletal: Decreased bone mineral density¡A Fracture of bone (2% ) Respiratory: Death¡A Asthma-related¡A Paradoxical bronchospasm¡A Pneumonia (2% or greater ) Other: Angioedema,30¢J¥H¤U,One inhalation of Relvar Ellipta 92/22 micrograms once daily. (maximum dose: 1 inhalation/day). A starting dose of one inhalation of Relvar Ellipta 92/22 micrograms once daily should be considered for adults who require a low to mid dose of inhaled corticosteroid in combination with a long-acting beta2-agonist. If patients are inadequately controlled on Relvar Ellipta 92/22 micrograms¡A the dose can be increased to 184/22 micrograms¡A which may provide additional improvement in asthma control.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,PREGNANCY RECOMMENDATION - Fluticasone: Compatible; Vilanterol: No Data [¥é³æ]¦b¹ï¥¥°ü¨Ï¥ÎRELVAR Ellipta¡A Fluticasone¡A Vilanterol¤è­±¡A¥Ø«e¨ÃµL¨¬°÷ªº¸ê®Æ¡C¦b¹ï¥¥°ü¨Ï¥ÎRELVAR Ellipta¤è­±¦³¤@¨ÇÁ{§É¤Wªº¦Ò¶q¡C¦b¤@¶µ°Êª«¥Í´Þ¸ÕÅç¤¤¡A¹ïÃh¥¥ªº¤j¹«©ó¾¹©xµo¥Í´Á¶¡¥H§l¤J¤è¦¡³æ¿W§ë¤©©Î¦X¨Ö§ë¤©Fluticasone¤ÎVilanterol¤§«á¡A¨Ã¥¼¤Þµo¥ô¦ó­L¨àµ²ºc·î§Î¡C¦b³o¶µ¸ÕÅç¤¤©Ò¨Ï¥Î¤§Fluticasone¤ÎVilanterolªº³Ì°ª¾¯¶q¤À§O¬ù¬°200»P25mcg(¦¨¤H)¤§¤HÃþ¨C¤é³Ì°ª«ØÄ³§l¤J¾¯¶q(MRHDID)ªº5­¿»P40­¿¡C(¥H¤U²¤),Unknown ¨S¦³¸ê®Æ,BREASTFEEDING RECOMMENDATION - Fluticasone: No Human Data¡XProbably Compatible; Vilanterol: No Data. [¥é³æ]¥Ø«e¨ÃµL¥ô¦óÃö©óFluticasone¤ÎVilanterol¬O§_·|½Ñ²{©ó¤HÃþªº¨Å¥Ä¤¤¡B¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT©Î¹ï¨Å¥Ä¥Í¦¨§@¥Î¤§¼vÅTµ¥¤è­±ªº¸ê°T¡C´¿¦b¤HÃþªº¨Å¥Ä¤¤ÀË¥X§C¿@«×ªº¨ä¥L§l¤J©Ê¥Ö½èÃþ©T¾J¡CÀ¦±NÁý­÷¥À¨Å¹ïµo¨|»P°·±dªº®ÄÀ³©M¥À¿Ë¹ïRELVAR ElliptaÁ{§É»Ý¨D¡A¥H¤ÎFluticasone¤ÎVilanterol©Î¥À¿Ëªº¼ç¦b¯e¯f¹ïÁý­÷¥À¨Å¤§À¦¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT¤@¨Ö¦Ò¼{¡C,IH;,,,,,
IPEY,Caffeine Citrate,Peyona inj 20mg/1mL (for infusion and oral),CNEU,Treatment of primary apnoea of premature newborns.,Hypersensitivity to the active substance or to any of the excipients.,Cardiovascular: Angina pectoris¡A chest pain¡A flushing¡A palpitations¡A sinus tachycardia¡A supraventricular tachycardia¡A vasodilatation¡A ventricular arrhythmia Central nervous system: Agitation¡A delirium¡A dizziness¡A hallucination¡A headache¡A insomnia¡A irritability¡A psychosis¡A restlessness Dermatologic: Urticaria Gastrointestinal: Esophageal motility disorder (sphincter tone decreased)¡A gastritis Genitourinary: Diuresis Neuromuscular & skeletal: Fasciculations Ophthalmic: Increased intraocular pressure (>180 mg caffeine)¡A miosis,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,Each 1 mL ampoule contains 20 mg caffeine citrate (equivalent to 10 mg caffeine) Apnea of prematurity: Neonates:Loading dose: Minimum dose: 20 mg/kg as caffeine citrate¡A Intravenous infusion over 30 minutes¡A a second loading dose of 10 -20 mg/kg maximum may be given after 24 hours; Maintenance dose: 5 mg/kg/day as caffeine citrate once daily starting 24 hours after the loading dose¡A Intravenous infusion (over 10 minutes) or by oral administration.Oral: May be administered without regard to feedings or meals.,µL»Ý½Õ¾ã¾¯¶q,has not been studied À³®Ú¾ÚCaffeine¦å¤¤¿@«×¨Ó½Õ¾ã¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;IVD;PC;PO;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,X,Infuse loading dose 20 mg/kg as caffeine citrate may be infused over at least 30 minutes; maintenance dose 5 mg/kg/day as caffeine citrate once daily may be infused over at least 10 minutes.,1.Caffeine citrate can be either used without dilution or diluted in sterile solutions for infusion such as glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) or calcium gluconate 100 mg/mL (10%) immediately after withdrawal from the ampoule. 2.Blood samples for monitoring should be taken just before the next dose in the case of therapeutic failure and 2 to 4 hours after the previous dose when suspecting toxicity.
EPROT1,Tacrolimus,Protopic ointment 0.1%¡A10gm,TDER,Atopic dermatitis (Moderate to Severe)¡A Second-line Short-term & intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis for 16 years old and above.,Allergic to Tacrolimus¡A any macrolides¡A or any other component of Protopic.,Infections and parasites: Local skin infections¡A whether or not they have a clear cause¡A include but are not limited to herpetic eczema¡A folliculitis¡A herpes simplex¡A herpes virus infection¡A Kaposi's varicella-like rash¡A Eye herpes infection. Metabolic and nutritional diseases: Alcohol intolerance (face flushing or skin irritation after ingesting alcoholic beverages) Nervous system disease: Sensation abnormalities and dullness (hyperesthesia¡A burning sensation) Skin and subcutaneous tissue diseases: Itching¡A acne¡A vinasse¡A sunburn Systemic diseases and symptoms of the administration site: Administration site burning¡A administration site itching¡A administration site warmth¡A administration site erythema¡A administration site pain¡A administration site irritation¡A administration site paresthesia¡A administration site rash¡A administration site edema,25¢J¥H¤U,Atopic dermatitis (Moderate to Severe)¡A Second-line Adolescents (>16 years) active phase¡A Apply thin layer ointment to affected areas twice daily until signs and symptoms resolve; use minimum amount and rub in gently and completely chronic phase: apply ointment as two times a week to three times a week ¡A re-exame symptoms after 12 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ø«e¯Ê¥FÃh¥¥¤k©Ê¨Ï¥Î tacrolimus ³n»Iªº¾A·í¼Æ¾Ú¡C °Êª«¸ÕÅçÃÒ¹ê¥þ¨­©Ê§ëÃÄ·|³y¦¨¥Í´Þ¬r©Ê¡C ¹ï¤HÃþªº¼ç¦b­·ÀI¤´¥¼ª¾¡C Ãh¥¥´Á¶¡¤£±o¨Ï¥Î Protopic ³n»I¡A°£«D¨ã¦³©ú½T¥²­n©Ê¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¤HÃþ¼Æ¾ÚÃÒ¹ê¥þ¨­©Ê§ëÃÄ«á¡Atacrolimus ·|¤Àªc¦Ü¨Å¥Ä¤º¡C ¾¨ºÞÁ{§É¼Æ¾ÚÅã¥Ü¨Ï¥Î tacrolimus ³n»Iªº¥þ¨­©Ê¼ÉÅS¶q§C¡A ¦ý¤´¤£«ØÄ³©ó±µ¨ü Protopic ³n»IªvÀø´Á¶¡¶i¦æ­÷¨Å¡C,EXT;,,,,,
OQTE,Saxagliptin + Dapagliflozin,Qtern 5/10mg,META,Adults aged 18 years and older with type 2 diabetes mellitus: 1. to improve glycaemic control when metformin and one of the monocomponents of Qtern do not provide adequate glycaemic control. 2. already being treated with the free combination of dapagliflozin and saxagliptin.,history of any serious hypersensitivity reaction to the active substances or to any of the excipients¡A including anaphylaxis or angioedema following exposure to any dipeptidyl peptidase-4 (DPP4) inhibitor.,Common Endocrine metabolic: Hypoglycemia (1% ) Respiratory: Upper respiratory infection (13.6% ) Serious Cardiovascular: Heart failure¡A Hypotension Endocrine metabolic: Diabetic ketoacidosis Gastrointestinal: Pancreatitis (0.2% ) Immunologic: Hypersensitivity reaction Renal: Acute kidney injury¡A nontraumatic¡A Urinary tract infectious disease (5.7% ) Reproductive: Necrotizing fasciitis¡A Perineum,Àx¦s©ó 30¢XC¥H¤U,1 tablet QD. Each tablet contains saxagliptin 5mg and dapagliflozin 10mg.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,PREGNANCY RECOMMENDATION: Dapagliflozin: No Human Data¡XAnimal Data Suggest Low Risk. Saxagliptin: No Human Data¡XAnimal Data Suggest Low Risk. [¥é³æ]¨Ì¾Ú°Êª«¼Æ¾ÚÅã¥Ü¡Adapagliflozin¨ã¦³¹ïµÇÅ¦ªº¤£¨}§@¥Î¡A¤£«ØÄ³¦bÃh¥¥ªº²Ä¤G©M²Ä¤T¥¥´Á¤¤¨Ï¥ÎQtern¡C Qtern©Î¨ä¦¨¤À(saxagliptin©Mdapagliflozin)¥Î©óÃh¥¥¤k©Êªº¼Æ¾Ú¦³­­¡A¤£¨¬¥H§P©w¬O§_¨ã¦³­«¤j¥Í¨|¯Ê³´©Î¬y²£¤§ÃÄ«~¬ÛÃö­·ÀI¡CÃh¥¥´Á¶¡±±¨î¤£¨}ªº¿}§¿¯f¡A¹ï¥À¿Ë©M­L¨à³£¦³¬ÛÃö­·ÀI¡C ¦b°Êª«¸ÕÅç¤¤¡A¦b¹ïÀ³¦Ü¤HÃþÃh¥¥²Ä¤G¥¥´Á«á´Á©M²Ä¤T¥¥´ÁªºµÇÅ¦µo¨|´Á¶¡¡A¤j¹«¼ÉÅS©ódapagliflozin(Qternªº¦¨¤À¤§¤@) ®É¡A©Ò¦³´ú¸Õ¾¯¶q¬Ò´¿Æ[¹î¨ì«D§¹¥þ¥i°fªºµÇª»¤ÎµÇ¤pºÞ¤£¨}ÂX±i¡F³Ì§C¾¯¶qªº¼ÉÅS¶q¬O10mgÁ{§É¾¯¶qªº15­¿¡C µ¹¤©Ãh¥¥¤j¹«©M¨ß¤lSaxagliptin®É¡A¨Ã¥¼Æ[¹î¨ì¤£¨}µo¨|¤ÏÀ³¡C ±w¦³§³®W«e¿}§¿¯f¥BHbA1c >7%ªº¤k©Ê¡A­«¤j¥ý¤Ñ¯Ê³´¤§¦ô­p­I´º­·ÀI¬ù¬°6%¦Ü10%¡F¦Ó HbA1c >10%ªº¤k©Ê¡A«h´¿³q³ø°ª¹F20¦Ü25%ªº­I´º­·ÀI¡C¦³Ãö¯S©w±Ú¸sµo¥Í¬y²£ªº¹w¦ô­I´º­·ÀI©|¤£²M·¡¡C¦b¬ü°ê¤@¯ë±Ú¸s¡AÁ{§É½T»{ªºÃh¥¥¤¤¡Aµo¥Í­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº¹w¦ô­I´º­·ÀI¤ñ¨Ò¤À§O¬°2¦Ü4%©M15¦Ü20%¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BREASTFEEDING RECOMMENDATION: Dapagliflozin: No Human Data¡XPotential Toxicity Saxagliptin: No Human Data¡XProbably Compatible. [¥é³æ]©|µL¸ê®ÆÅã¥ÜQtern©Î¨ä¦¨¤À(saxagliptin ©Mdapagliflozin)¬O§_·|±Æ¤J¤HÃþªº¨Å¥Ä¡B¹ï±µ¨ü­÷¨ÅÀ¦¨àªº¼vÅT¡A©Î¹ï¥À¨Å¤Àªcªº§@¥Î¡CSaxagliptin©Mdapagliflozin·|¤Àªc¦Ü­÷¨Å¤j¹«ªº¨Å¥Ä¤¤ ¡C ¥Ñ©ó¤HÃþµÇÅ¦·|¦b¤l®c¥H¤Î¥X¥Í«á 2 ¦~´Á¶¡¦¨¼ô¡A¦Ó³o¬q´Á¶¡¥i¯à·|³z¹L­÷¨Å¼ÉÅS¡A¦]¦¹¥i¯à·|¹ïµo¨|¤¤¤HÃþµÇÅ¦³y¦¨­·ÀI¡C¦]¬°¹ï©ó­÷¨Å·s¥Í¨à¥i¯à¾É­PÄY­«¤£¨}¤ÏÀ³¡AÀ³§iª¾¤k©Ê¦b­÷¨Å´Á¶¡¤£«ØÄ³¨Ï¥ÎQtern¡C Dapagliflozin¦b¨Å¥Ä/¦å¼ß¤¤¥X²{ªº¤ñ²v¬° 0.49¡AÅã¥Üdapagliflozin©M¨ä¥NÁÂª«·|Âà²¾¶i¤J¨Å¥Ä¡A¨ä¿@«×¬ù¬°¥ÀÅé¦å¼ß¤¤ªº50%¡Cª½±µ¼ÉÅS¨ìdapagliflozinªº¥®¹«Åã¥Ü¦b¦¨¼ô´Á¶¡¨ã¦³µÇÅ¦µo¨|­·ÀI(µÇª»©MµÇ¤pºÞÂX±i)¡C Saxagliptin·|¥H¬Û¹ï©ó¦å¼ßÃÄ«~¿@«×¤§1:1 ¤ñ²v¡A¤Àªc¨ì­÷¨Å¤j¹«ªº¨Å¥Ä¤¤¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¤£¥i­é¥b¿i¯»¡C(¸g¸ß°Ý¼t°Ó¥»ÃÄµL¯S®í±±ÄÀ©Î½wÄÀ¾¯«¬¡A¦ýµL¬ÛÃö¸ÕÅç¦õÃÒ¿i¯»ªºÃÄ°Ê©Î¦w¥þ©Ê¡C2022/01/02)
IGCSF3,Nivestim 300 mcg/0.5mL,Nivestim 300 mcg/0.5mL,HEMT,,,,,,,,,,,,,,,,,,,
HCVDA12,Glecaprevir + Pibrentasvir (1~6type/8¶g),HCVDAA0012(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1-6«¬/8¶g,QANB,,,,,,,,,,,,,,,,,,,
EAZET,Azelastine,Azetin Nasal Spray 140 mcg/dose,TENT,Allergic rhinitis,Hypersensitivity to any ingredients of Azelastine,Disorder of taste (Adults and adolescents¡A 4% to 19.7%; pediatrics¡A 2% to 4% or more )¡A Vomiting (Pediatrics¡A 2% or more )¡A Headache¡A Somnolence¡A Epistaxis (Adults and adolescents¡A 1% to 3.2% ; pediatrics¡A 2% to 5% or more )¡A Nasal irritation (less than 1% to 4% )¡A Pain of nose (Adults and adolescents¡A 1% to 4%; pediatrics¡A less than 1% to 4% or more )¡A Sneezing (Adults and adolescents¡A 1% to 3.1% ; pediatrics¡A 2% to 3% or more )¡A Fatigue (Nasal¡A less than 1% to 2.3% ; ophthalmic¡A 1% to 10% ),25¢J¥H¤UÀx¦s,Seasonal allergic rhinitis: Intranasal One or two sprays in each nostril twice daily,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IN;,,,,,
EALC755,Alcohol,75% Alcohol 500mL/bottle,TDER,,,,25¢J¥H¤U,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,EXT;,,,,,
OLAB,Labetalol,Labtal 200mg,CAVS,Hypertension.,Bronchial asthma. Cardiogenic shock. Overt cardiac failure. Second and third degree heart block. Severe bradycardia. Conditions associated with severe and prolonged hypotension. Hypersensitivity to labetalol or any component of the product.,Common Gastrointestinal: Nausea (Oral¡A 6%) Neurologic: Dizziness (Oral¡A 11%) Other: Fatigue (Oral¡A 5% ) Serious Cardiovascular: Decreased cardiac output¡A Heart failure¡A Hypertension¡A Paradoxical¡A Myocardial ischemia¡A Orthostatic hypotension (Oral¡A 1% ; IV¡A 58% ) Hepatic: Hepatocellular liver damage¡A Jaundice Immunologic: Anaphylaxis Ophthalmic: Intraoperative floppy iris syndrome,25¢J¥H¤U,Hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently every 2-14 days. Usual maintenance: 200mg BID. Maximum: 800 mg/day in 2 divided doses. Patients with severe hypertension may require 2400 mg/day¡A in 3-4 divided doses. Older Adult¡A Initial: 50 mg twice daily and consider lower maintenance doses. Gestational hypertension: Initially 100 mg BID. May increase in increments of 100 mg twice daily intermittently in the 1-week intervals. The total daily dose may be divided into 3 divided doses for patients with severe hypertension. Maximum: 2400mg/day.,»Ý½Õ¾ã¾¯¶q,Average required dose is 50% of usual dosing (Micromedex 20221222),µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,[¥é³æ]FDA Pregnancy Category(Ãh¥¥¥ÎÃÄ¯Å¼Æ):C. Labetalol¦bÃh¥¥¦w¥þ©Ê©|¥¼«Ø¥ß¡A¥²­n®ÉÀ³Åv¿Å§Q¹ú¨Ï¥Î¡CÀ³°O±o Labetalo¥i³q¹L­L½L»Ù¾À¦Ó¥i¯à³y¦¨­L¨à¤Î·s¥Í¨àªº(£\¤Î£]«¬µÇ¤W¸¢±µ¨üÅéªýÂ_¡C¦³·¥¤Ö¼Æªº³ø§i½Í¤Î§³®W«e«á¤Î·s¥Í¨à»ÙÃª(¤ß°Ê®}½w¡B §C¦åÀ£¡B©I§l§í¨î¡B§C¦å¿}¡B§CÅé·Åµ¥)¡C¦³®É¦¹Ãþ¯gª¬¦b¥X¥Í«á¤@¤Ñ©Î¤G¤Ñ¤~µo¥Í¡C¦¹®ÉÀ³µ¹¤©ºò«æªºªvÀø±¹¬I(¨Ò¦p¡AÀR¯ßª`®g²GÅé¤Î¸²µå¿})¡A¦ý¦ñ¦³ÄY­«ªº¤líw¥ý¥ü¡A¤×¥H«ù¤[©ÊªºÀR¯ßª`®gLabetalol¤§«á¡A«h´_­ì®É¶¡·|¸ûºC¡A³o¥i¯à©M¦­²£¨àªº¨x¥NÁÂ¥\¯à¤£§¹¥þ¦³Ãö¡CÁöµM¤]´¿¦³¤l®c¤º¤Î·s¥Í¨à¦º¤`ªº³ø§i¡A¦ý¥i¯à»P¨ä¥LÃÄª«(¦p:¦åºÞµÎ±i¾¯¡B©I§l§í¨î¾¯)¥H¤Î¤líw¥ý¥ü¡B¤l®c¤º¦¨ªø¿ðº¢©M¦­²£µ¥§@¥Î¦³Ãö¡C¥H¤W³o¨ÇÁ{§É¸gÅçÄµ¥Ü¤£¥i¦³¤£¾A·íªºªø´Á°ª¾¯¶q¨Ï¥ÎLabetalol ©µ¿ð¤À®Y¥H¤Î¨Ö¥ÎHydralazine,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]Labetalol¥i±q¨Å¥Ä¤¤±Æ¥X¡A¦ý¥¼¦³¥ô¦ó³ø§i«ü¥X¨ì­÷¨ÅªºÀ¦¨à¦³¤£¨}¤ÏÀ³¡C,PC;PO;WM;,,,,,®ð³Ý©Î©I§l¹D»ÙÃª±wªÌÀ³ÂÔ·V¨Ï¥Î¡C
OATM10,Atomoxetine,apo-Atomoxetine 10mg,CNEU,Attention deficit hyperactivity disorder.,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma¡A current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg¡A 15 to 20 mm Hg) or heart rate (eg¡A 20 beats per minute),Common: Increased heart rate (Adult¡A 10.2-22.4%; pediatric¡A 12.2-23.4%)¡A Weight decreased (Adult¡A 2%; pediatric¡A 3%)¡A Abdominal pain (Adult¡A 7%; pediatric¡A 18%)¡A Constipation (Adult¡A 8%; pediatric¡A 1-2%)¡A Decrease in appetite (Adult¡A 16%; pediatric¡A 16%)¡A Nausea (Adult¡A 26%; pediatric¡A 10%)¡A Vomiting (Adult¡A 4%; pediatric¡A 11%)¡A Xerostomia (Adult¡A 20%)¡A Dizziness (Adult¡A 8%; pediatric¡A 5%)¡A Headache (Pediatric¡A 19%)¡A Insomnia (Adult¡A 15%; pediatric¡A at least 2%)¡A Somnolence (Adult¡A 8%; pediatric¡A 11%)¡A Delay when starting to pass urine (Adult¡A 6%)¡A Dysmenorrhea (Adult¡A 3%)¡A Erectile dysfunction (Adult¡A 8%)¡A Fatigue (Adult¡A 10%; pediatric¡A 8%) Serious: Increased diastolic arterial pressure (Adult¡A 4.8-12.6%; pediatric¡A 9.3-21.5%)¡A Increased systolic arterial pressure (Adult¡A 4.2-12.4%; pediatric¡A 4.9-12.5%)¡A Myocardial infarction¡A Sudden cardiac death¡A Tachycardia (Adult¡A 1.5%; pediatric¡A 0.3%)¡A Injury of liver (Severe)¡A Liver failure¡A Cerebrovascular accident¡A Aggressive behavior¡A Hostile behavior¡A Mania¡A Psychotic disorder¡A Suicidal thoughts (Pediatric¡A 0.4%)¡A Priapism,Àx¦s©ó25¢J¥H¤U,6 years or older¡A up to 70 kg: Acute treatment: Initial¡A approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily¡A as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; Maximum 1.4 mg/kg daily or 100 mg/day¡A whichever is less 6 years or older¡A greater than 70 kg: Acute treatment: Initial¡A 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks;Maximum 100 mg daily,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤«×ªº¨x¥\¯à¤£¥þ¯f±w(Child-Pugh Class B)¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 50¢H¡C ±w¦³ÄY­«¨x¥\¯à¤£¥þ(Child-Pugh Class C)ªº¯f±w¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 25¢H¡C,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ¦bÃh¥¥¨ß¤lªº¾¹©x§Î¦¨´Á¶¡¡AÁý­¹¾¯¶q³Ì°ª¦Ü 100 mg/ kg/ day ªºAtomoxetine¡C¦b¤T½g¬ã¨s¤¤ªº¤@½g¡AÆ[¹î¨ì¬¡­L¼Æ´î¤Ö¡A¦­´Á¦A§l¦¬¼W¥[¡C¤£¥¿±`ÀV°Ê¯ß°_·½¤Î¯Ê¤ÖÂê°©¤U°Ê¯ßªºµo¥Í²vµy·L¼W¥[¡C³o¨Çµ²ªGµo²{©ó·|¤Þ°_»´·L¥ÀÅé¬r©Êªº¾¯¶q¡C ³o¨Çµ²ªGªºµL§@¥Î¾¯¶q¡]no-effect dose¡^¬° 30 mg/ kg/ day¡C¥Hmg/ m2­p¡A100 mg/ kg ªº¾¯¶q¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 23 ­¿¡A¨ß¤l¦å¤¤ªº Atomoxetine¿@«×¡]AUC¡^¦ô­p¬°±µ¨ü³Ì°ª¤HÅé¾¯¶qªº¤HÅé¤ºªº 3.3 ­¿¡]§Ö³t¥NÁÂªÌ¡^©Î 0.4 ­¿¡]½wºC¥NÁÂªÌ¡^¡C ±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î 10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨¤Î­÷¨Å´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J¤£¶W¹L¤j¬ù 50 mg/ kg/ day ªº atomoxetine¡]¥H mg/ m2­pºâ¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 6 ­¿¡^¡C ¦b¤G½g¬ã¨sªº¨ä¤¤¤@½g¡Aµo²{¤p¹«Åé­«¤Î¦s¬¡¼Æ´î¤Ö¡C¦b 25 mg/ kg¡]«D 13 mg/ kg¡^¡A¤]µo²{¨ì¤p¹«ªº¦s¬¡´î¤Öªº²{¶H¡C ¤@½g±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J Atomoxetine ªº¬ã¨s¤¤¡A40mg/ kg/ day¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 5 ­¿¡^¡Aµo²{¨ì­L¹«Åé­«´î¤Ö¡]¶È¥À¹«¡^¤Î´Õ°©¤}¡]vertebral arch¡^¤£§¹¥þ¦¨°©ªºµo¥Í²v¼W¥[ªº²{¶H¡A¦¹²{¶H¨Ã¨S¦³¦b 20 mg/ kg/ day ¾¯¶q²Õ¤¤µo²{¡C ¦b¾¹©x§Î¦¨´Á¶¡¡A¥H 150 mg/ kg/ day ªº¾¯¶q¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº17 ­¿¡^Áý­¹Ãh¥¥¥À¹«¡A­L¨à¨Ã¥¼¥X²{¥ô¦óªº°Æ§@¥Î¡C ¥Ø«e©|µLÃö©óÃh¥¥°ü¤k¤§¥R¤À¤Î§¹¾ãªº¹ï·Ó©Ê¬ã¨s¡C Ãh¥¥´Á¶¡¤£¥iªA¥Î Atomoxetine¡A°£«D®Ä¯q¶W¹L­L¨à¥i¯à²£¥Íªº­·ÀI©Ê¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Atomoxetine ¤Î/ ©Î¨ä¥NÁÂª«·|¤Àªc¦Ü¦Ñ¹«ªº¨Å¥Ä¤¤¡C Atomoxetine ¬O§_·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤«h¥¼ª¾¡C ­÷¨Å¤¤ªº°ü¤k­YªA¥Î Atomoxetine ®É¡AÀ³¥[¥Hª`·N¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½Ð¾ãÁû½¦Ån§]ªA¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¥»ÃÄ¯»¥½¨ã¦³²´³¡¨ë¿E©Ê¡C
IALFBAD,Alfentanil,Alfentanil inj ´Ý¾l¾P·´ (HAMELN),CNEU,,,,,,,,,,,,,,IV;,,¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,,,
ICYR,Ramucirumab,Cyramza inj 100mg/10mL,RACA,Gastric cancer: (1) Ramucirumab combined with paclitaxel is used for the treatment of advanced or metastatic gastric adenocarcinoma (or gastroesophageal junction adenocarcinoma) that is receiving or receiving chemotherapy with fluoropyrimidine and platinum but the disease has deteriorated. (2) Ramucirumab is used as a single drug for the treatment of advanced or metastatic gastric adenocarcinoma (or gastroesophageal junction adenocarcinoma) that is receiving or has received fluoropyrimidine or platinum chemotherapy but the disease has deteriorated and is not suitable for receiving paclitaxel-containing drugs. Non-small cell lung cancer (NSCLC): (1) Ramucirumab and erlotinib are used in the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. (2) Ramucirumab combined with docetaxel is used to treat locally advanced or metastatic non-small cell lung cancer that is receiving or receiving platinum-containing chemotherapy but the disease has deteriorated. Colorectal cancer: Ramucirumab and FOLFIRI (irinotecan¡A folic acid¡A and 5-fluorouracil) are used for the treatment of metastatic colorectal cancer (mCRC) that is receiving or receiving bevacizumab¡A oxaliplatin¡A and fluoropyrimidine treatment but the disease has deteriorated. Hepatocellular carcinoma (HCC): Ramucirumab monotherapy is used for hepatocellular carcinoma patients who have received sorafenib treatment and have alpha-fetoprotein (AFP) ?400 ng/mL.,Hypersensitivity. For NSCLC¡A tumour cavitation or tumour involvement of major vessels.,Neutropenia¡A febrile neutropenia; leukopenia¡A thrombocytopenia; hypoalbuminaemia; HTN; epistaxis; GI haemorrhage events¡A stomatitis; proteinuria; fatigue/asthenia; peripheral oedema; abdominal pain¡A diarrhea; palmar-plantar erythrodysaesthesia syndrome; mucosal inflammation; hypokalaemia; hyponatraemia; headache.,2-8¢JÁ×¥úÁ×§K§N­á,Premedicate prior to infusion with an IV H1 antagonist (eg¡A diphenhydramine); for patients who experienced a grade 1 or 2 infusion reaction with a prior infusion¡A also premedicate with dexamethasone (or equivalent) and acetaminophen. [Gastric Cancer] 8 mg/kg (either as a single agent or in combination with weekly paclitaxel) every 2 weeks administered by intravenous infusion over 60 minutes. If the first infusion is tolerated¡A all subsequent infusions may be administered over 30 minutes. Continue CYRAMZA until disease progression orunacceptable toxicity. When given in combination with paclitaxel¡A administer CYRAMZA prior to administration of paclitaxel. [Non-Small Cell Lung Cancer (NSCLC)] - EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations ¡V CYRAMZA in Combination with Erlotinib: 10 mg/kg infused over 60 minutes every 2 weeks.- Disease Progression On Or After Platinum-based Chemotherapy ¡V CYRAMZA in Combination with Docetaxel: 10 mg/kg infused over 60 minutes on Day 1of a 21-day cycle prior to docetaxel infusion. [Colorectal Cancer] 8 mg/kg infused over 60 minutes every 2 weeks prior to FOLFIRI administration. [Hepatocellular Carcinoma] 8 mg/kg infused over 60 minutes every 2 weeks.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,As a risk to newborns/infants cannot be excluded¡A breast-feeding should be discontinued during treatment with Cyramza and for at least 3 months after the last dose.,IVD;,,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,Do not administer as an IV push or bolus.,Dilute with only 0.9% saline to a final volume of 250 mL. Infuse over 60 minutes through a separate infusion line using an infusion pump; the use of a 0.22 micron protein sparing filter is recommended. Do not administer as an IV push or bolus. Flush the line with NS after infusion is complete.,Do not administer as an IV push or bolus. Do not use dextrose containing solutions. Dilute with only 0.9% saline to a final volume of 250 mL. Infuse over 60 minutes through a separate infusion line using an infusion pump; the use of a 0.22 micron protein sparing filter is recommended.
ESIM,Brinzolamide + Brimonidine tartrate,Simbrinza eye drops 1%/0.2%¡A 5mL,TOPH,Use Reduction of intraocular pressure: Treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.,Hypersensitivity to brinzolamide¡A brimonidine or other sulphonamides. Hyperchloraemic acidosis. Concomitant MAOI therapy¡A antidepressants affecting noradrenergic transmission. Severe renal impairment. children.,Somnolence¡A dizziness¡A dysgeusia¡A eye allergy & pain¡A keratitis¡A ocular discomfort & hyperaemia¡A blurred & abnormal vision¡A conjunctival blanching¡A dry mouth.,25¢J¥H¤U,Adult including elderly: Instill 1 drop in the affected eye BID. Age 2-18 years: Limited data available with child between 2-18 years old. Not recommend use. Age <2 years: Do not use in child under 2 years old.,µL»Ý½Õ¾ã¾¯¶q,use with caution.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,Brinzolamide Ophthalmic: No Human Data¡XProbably Compatible Brimonidine Ophthalmic: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Brinzolamide Ophthalmic: No Human Data¡XProbably Compatible Brimonidine Ophthalmic: Limited Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
IFLUV5,Purified Split Inactivated Influenza Virus,§K¶O¥®¨à4»ù¬y·P(6M~3Y) 0.5mL/dose,HIMM,Active immunisation against influenza.,Known hypersensitivity to egg products. Anaphylactic reaction to a previous dose containing the same antigens.,Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome.,,IM¡A 0.5 mL¡A > or = 6 months (< 9 years who have not been vaccinated previously¡A the second dose can be given after 4 weeks.),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
OGIK,Polyethylene Glycol 3350,GI Klean Powder,ALIM,Bowel prep before colonoscopy¡A colonic surgery¡A radiological exam & other related procedures.,GI obstruction or perforation¡A ileus¡A gastric retention¡A acute intestinal or gastric ulceration¡A toxic colitis or megacolon.,Nausea¡A bloatedness¡A abdominal pain¡A vomiting. Rarely rectal irritation.,25¢J¥H¤U¡A°®ÀêÀx¦s,Adult including elderly & renal insufficiency patient 1 sachet In 1 L water. 250mL to be drunk rapidly every 10-15 mins until all soln has been consumed. Until the rectal effuent is clear or repeat procedure with 4 sachets . Need to be taken within 4-6 hours. Avoid non-fluid food 2 hours before medication.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] µLÃh¥¥®É´Á¨Ï¥Î¤§¬ÛÃö¼Æ¾Ú¡C¹ï¥¥°ü¥ç»Ý¦Ò¼{¬O§_¨Ï¥Î¤§¡A¨Ï¥Î®ÉÀ³¯S§Oª`·N¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«e©|µL¸ê°T¡C,PO;,,,,,
EMIR3,Brimonidine,Mirvaso 3mg/gm gel¡A 30gm,TDER,Symptomatic treatment of facial erythema of rosacea in adult patients.,Hypersensitivity. Patients receiving MAOIs (eg¡A selegeline or moclobemide) & tricyclic (eg¡A imipramine) or tetracyclic (eg¡A maprotiline¡A mianserin or mirtazapin) antidepressants. Do not use in childn or adolescents 2-18 yr or childn <2 yr.,Flushing¡A erythema¡A pruritus¡A skin burning sensation.,25¢J¥H¤U,Rosacea¡A Persistent (nontransient) facial erythema Apply once daily as long as facial erythema is present. Maximum daily recommended dose: 1 g gel¡A divided into 5 pea size amounts on forehead¡A cheeks¡A nose & 2- chin smooth evenly over entire face avoiding lips and eyes.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,ÃÄ«~¥é³æ:­÷¨Å«ØÄ³:¤£À³©ó­÷¨Å´Á¶¡¨Ï¥Î¡C BRIMONIDINE OPHTHALMIC: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,ÃÄ«~¥é³æ:Ãh¥¥«ØÄ³: ¦]¸ê®Æ¦³­­¡A³Ì¦n¤£­n¦bÃh¥¥´Á¶¡¨Ï¥ÎMirvaso¡C BRIMONIDINE OPHTHALMIC: Limited Human Data¡XProbably Compatible,EXT;,,,,,
ICAG1,Calcium gluconate,Calcium gluconate inj 10%¡A 10mL (±M®×¶i¤f),NUTR,,¾AÀ³¯g:Ca deficiency. °Æ§@¥Î: Cardiovascular (with rapid I.V. injection): Arrhythmia¡A bradycardia¡A cardiac arrest¡A hypotension¡A syncope¡A vasodilation Central nervous system: Sense of oppression (with rapid I.V. injection) Endocrine & metabolic: Hypercalcemia Gastrointestinal: Chalky taste Neuromuscular & skeletal: Tingling sensation (with rapid I.V. injection) Miscellaneous: Heat waves (with rapid I.V. injection) ¸T§Ò¡GVentricular fibrillation; hypercalcemia; concomitant use of I.V. calcium gluconate and ceftriaxone in neonates (risk of precipitation of calcium-ceftriaxone),,«Ç·Å,Intravenous use or intramuscular use. (4.66mEq/10mL) 10 ml contain 940 mg calcium gluconate as active ingredient¡A equivalent to 2.10 mmol calcium. Adult: The usual initial dose in adults is 10 ml of Calcium Gluconate 10 % w/v Injection BP¡A corresponding to 2.25 mmol of calcium.If necessary¡A the dose may be repeated¡A depending on the patient¡¦s clinical condition. Subsequent doses should be adjusted according to the actual serum calcium level. Paediatric patients (< 18 years): Age: 3 months 0.4-0.9mL/kg; 6 months 0.3-0.7mL/kg; 1year 0.2-0.5mL/kg; 3 years 0.4-0.7mL/kg; 7.5 years 0.2-0.4mL/kg; 12 years 0.1-0.3mL/kg; >12 years as for adults,,,,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,1.¥»«~¬°10 mL¥]¸Ë¡A¶È¨ÑTPN½Õ°t¨Ï¥Î¡C 2.Paediatric patients (< 18 years):The intravenous administration rate should not exceed 5 ml of a 1:10 dilution per minute of Calcium Gluconate 10% B. Braun in children and adolescents. 3.Intramuscular injections should not be performed in paediatric patients. 4.adults the intravenous administration rate should not exceed 2 ml (0¡A45 mmol of calcium) per minute.
OAZI,Azithromycin,Aziciin 250mg,QANB,Upper & lower respiratory tract infections; skin & soft tissue infections; otitis media; uncomplicated genital infections due to Chlamydia trachomatis & Neisseria gonorrheae.,Cholestatic jaundice with prior azithromycin therapy. Hepatic dysfunction with prior azithromycin therapy. Hypersensitivity to azithromycin or to any product component¡A erythromycin¡A or any macrolide or ketolide antibiotic.,Common: Injection site disorder (3.1-6.5%)¡A Abdominal pain (adult¡A 1.9-14%; pediatric¡A 2-4%)¡A Diarrhea (Adult¡A 4.3-12%; pediatric¡A 7-10%)¡A Flatulence (5%)¡A Nausea (Adult¡A 3-14%; pediatric¡A 4%)¡A Vomiting (Adult¡A up to 13%; pediatric¡A 11-14%)¡A Increased liver enzymes (<1-6%)¡A Headache (up to 5%)¡A Abnormal vision (5%) Serious: Prolonged QT interval¡A Torsades de pointes¡A Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Congenital hypertrophic pyloric stenosis¡A Hepatic necrosis¡A Hepatitis (<1%)¡A Liver failure¡A Drug reaction with eosinophilia and systemic symptoms¡A Hypersensitivity reaction¡A Eaton-Lambert syndrome¡A Myasthenia gravis¡A Exacerbation of¡A Myasthenic crisis¡A Corneal erosion (<1%),,Adults: Sexually transmitted diseases caused by Chlamydia trachomatis or susceptible Neisseria gonorrhoeae the dose is 1g as a single oral dose. Acute infective exacerbation of chronic obstructive pulmonary disease (Mild to Moderate): 500 mg ORALLY once daily for 3 days or 500 mg ORALLY on day 1 followed by 250 mg/day ORALLY on days 2 to day 5. Other infections: 500 mg daily for 3 days. Childn: A single daily dose of 10 mg/kg for 3 days.,µL»Ý½Õ¾ã¾¯¶q,¨Ö¦³»´(A¯Å)¦Ü¤¤«×(B¯Å)¨x¥\¯à·l®`ªº±wªÌ¡AµL¶·½Õ¾ã,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ISTO,Cimetidine,Stogamet inj 200mg/2mL,ALIM,Gastric ulcer. Ulcer of duodenum. Erosive esophagitis.,Hypersensitivity to cimetidine or any component of this product.,Common: Gynecomastia (up to 4%)¡A Serious: Gastric cancer¡A Necrotizing enterocolitis in fetus OR newborn¡A Pancreatitis¡A Psychotic disorder¡A Cardiac arrest¡A Seizure,25¢J¥H¤U,usual dose: IM: 300mg Q6-8H IV: 300mg in 100mL D5W for 15-20 min¡A Q6- 8H. maximum 2.4 g/day children: limitied data¡A usual dose 20-40mg/kg/day IV,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ]¥»¾¯¨Ï¥Î©óÃh¥¥°ü¤k¤§¸gÅç¤´¦³­­¡CÁöµM¬ã¨sÅã¥ÜÃh¥¥¤¤§ë»P¥»¾¯«á¡A¤£·|¦³­P·î­Lªº¦MÀI¡A¦ý¦b¨ä¥L°Êª«©M¤HÃþªº¬ã¨s¤¤µo²{¥»¾¯¥i¥H³q¹L­L½L«Ì»Ù¡A¦]¦¹­Y«DÂå®v¬ã§P¹w´Áªº§Q¯q¤j©ó¥i¯àªº¦MÀI¡AÃh¥¥´Á¶¡³Ì¦nÁ×§K¨Ï¥Î¥»«~¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]Cimetidine ¥i¤Àªc©ó¨Å¥Ä¤¤¡D¯f¤HªAÃÄªº¶¥¬q¤£©y±Â¨Å¡C ¥¥°üÁ{²£¨ü­å¸¡²£³N®É¡A¶i¦æ¥þ¨­³Â¾K¡A¦P®É±Â»P®É¡A¥Ñ©ó¥»ÃÄ¥b°I´Á(2 ¤p®É)¸ûµu¡A¦b¯f¤H´_¤¸¦Ü¥i­÷¨Å®É¡A¥»«~¤Àªc©ó¨Å¥Ä¤¤§t¶q¤w©Ò¦sµL´X¡C,IM;IVD;IVPUSH;,,¡iD10W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,¥H¾A¦Xªº·»²G§â300mg¥»«~µ}ÄÀ¦¨20mL·»²G¡A¥Hªø©ó2¤ÀÄÁªº³t²v½wºCªºÀR¯ßª`®g¡A³oºØµ¹ÃÄ¤è¦¡À³Á×§K¨Ï¥Î¦b±w¦³¤ßÅ¦¦åºÞ¯e¯fªº±wªÌ¡C,¥»«~300mgµ}ÄÀ¦b100mL¾A¦XªºÀR¯ßª`®g·»²G¤¤¡AÀR¯ßÂIºw15-20¤ÀÄÁ¥H¤W¡AÂIºwªº¥­§¡³t²v¦b24¤p®É´Á¶¡¤£¶W¹L75mg/¤p®É¡C,Cimetidine ª`®g²G¥H0.9%´â¤Æ¶uª`®g²G¡A5%©Î10%¥k±ÛÁÞª`®g²G¡A¨Å»Ä¤ÆªL®æ¤ó²Gµ}ÄÀ«á©ó«Ç·Å¤U¥i«O¦s1­Ó¬P´Á¡C
LSCR,Sucralfate,Scrat 1gm/10mL/pack suspension,ALIM,Short-term (?8 weeks) management of duodenal ulcers; maintenance therapy for duodenal ulcers,Hypersensitivity to sucralfate or any component of the formulation,1% to 10%: Gastrointestinal: Constipation (2%) <1%¡A postmarketing¡A and/or case reports: Anaphylaxis¡A back pain¡A bezoar formation¡A bronchospasm¡A diarrhea¡A dizziness¡A drowsiness¡A dyspepsia¡A flatulence¡A headache; hypersensitivity (urticaria¡A angioedema¡A facial swelling¡A laryngospasm¡A respiratory difficulty¡A rhinitis); insomnia¡A nausea¡A pruritus¡A skin rash¡A stomach pain¡A vertigo¡A vomiting¡A xerostomia,«Ç·ÅÃÄ«~¡A¥é³æµL¯S§O«ü¥ÜÀx¦s·Å«×±ø¥ó,usual dose: 1 pack QID on empty stomach,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IIMO,Japanese Encephalitis Vaccine,Imojev inj 0.5mL/dose (¦Û¶O¤é¥»¸£ª¢¬Ì­]),HIMM,Active immunisation against encephalitis due to Japanese encephalitis virus,Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV¡A renal or hepatic diseases in acute¡A exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,Local reactions eg redness¡A swelling¡A tenderness or systemic reactions eg fever¡A chill¡A headache¡A lassitude. Rarely¡A severe adverse reactions manifesting as generalized urticaria or angioedema may occur.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5mL¡A Age > or = 9 months - < 18 years: primary immunization.A booster dose after 12-24 months. Age > or = 18 years: a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅç¨ÃµLª½±µ©Î¶¡±µÃÒ¾ÚÅã¥Ü¹ïÃh¥¥¡B­F­Lµo®i¡B¤À®Y¡B²£«á­L¨à¡Bªc¨Å¨ã¶Ë®`©Ê¡A ¸T¥Î©óÃa¥¥¤Î±Â¨Å°ü¤k¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅç¨ÃµLª½±µ©Î¶¡±µÃÒ¾ÚÅã¥Ü¹ïÃh¥¥¡B­F­Lµo®i¡B¤À®Y¡B²£«á­L¨à¡Bªc¨Å¨ã¶Ë®`©Ê¡A ¸T¥Î©óÃa¥¥¤Î±Â¨Å°ü¤k¡C,SC;,¨Ï¥Î¼t°Ó©Òªþ¤§µ}ÄÀ²G,,,,IMOJEV should not be injected directly into veins.
IJEV0,Japanese Encephalitis Vaccine,Imojev (´î¬r¤é¸£¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Active immunisation against encephalitis due to Japanese encephalitis virus,Avoid use in the following unless absolutely necessary: patients with fever or severe malnutrition; CV¡A renal or hepatic diseases in acute¡A exacerbating or active phases; history of abnormal adverse reactions caused by this vaccine; history of spasmodic symptoms within 1 yr; pregnancy.,Local reactions eg redness¡A swelling¡A tenderness or systemic reactions eg fever¡A chill¡A headache¡A lassitude. Rarely¡A severe adverse reactions manifesting as generalized urticaria or angioedema may occur.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5mL¡A Age > or = 9 months - < 18 years: primary immunization.A booster dose after 12-24 months. Age > or = 18 years: a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅç¨ÃµLª½±µ©Î¶¡±µÃÒ¾ÚÅã¥Ü¹ïÃh¥¥¡B­F­Lµo®i¡B¤À®Y¡B²£«á­L¨à¡Bªc¨Å¨ã¶Ë®`©Ê¡A ¸T¥Î©óÃa¥¥¤Î±Â¨Å°ü¤k¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]°Êª«¸ÕÅç¨ÃµLª½±µ©Î¶¡±µÃÒ¾ÚÅã¥Ü¹ïÃh¥¥¡B­F­Lµo®i¡B¤À®Y¡B²£«á­L¨à¡Bªc¨Å¨ã¶Ë®`©Ê¡A ¸T¥Î©óÃa¥¥¤Î±Â¨Å°ü¤k¡C,SC;,¨Ï¥Î¼t°Ó©Òªþ¤§µ}ÄÀ²G,,,,IMOJEV should not be injected directly into veins.
IHBV,Hepatitis B Vaccine,Engerix-B 1mL/dose (¦Û¶OB¨x¬Ì­]),HIMM,Active immunisation against hepatitis B virus infection.,Severe allergic reaction after a previous dose of any hepatitis B-containing vaccine or to any vaccine component¡A including yeast.,Common: Injection site disorder¡A Diarrhea¡A Nausea¡A Asthenia (>1%)¡A Headache (1-10%)¡A Fatigue (14%)¡A Fever¡A Malaise Serious: Pancytopenia¡A Anaphylaxis,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A > or = 20 years 20 mcg/1mL/dose¡A < or = 19 years 10 mcg/0.5 mL/dose¡A 3 doses at 0¡A 1¡A and 6 months or 4 doses at 0¡A 1¡A 2¡A and 12 months. > or = 20 years rapid immunization 3 doses at 0¡A 7¡A and 21 days with a booster at 12 months. Renal insufficiency > or = 16 years 4 double doses (20 mcg x 2) at 0¡A 1¡A 2¡A and 6 months. 11-15 years 2 doses (20 mcg) at 0 and 6 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] ¥Ø«e¨ÃµL¨¬°÷ªº©ó¤HÃþÃh¥¥´Á¶¡¨Ï¥Î¤§¸ê®Æ¤Î°Êª«¥Í´Þ¬ã¨s¡CµM¦Ó¡A»P¨ä¥¦¥h¬¡©Ê¯f¬r¬Ì­]¤@¼Ë¡A§Ú­Ì¨Ã¤£§Æ±æ­L¨à¨ü¨ì¥ô¦ó¶Ë®`¡C ¦]¦¹¡A¥u¦³¦b©ú½T¥²­n¥B¨ä¼ç¦b®Ä¯q¶W¶V¹ï­L¨àªº¼ç¦b¦MÀI©Ê®É¡A¤~¥i¦bÃh¥¥´Á¶¡¨Ï¥ÎEngerix-B¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¥Ø«e¨ÃµL¨¬°÷ªº©ó¤HÃþ±Â¨Å´Á¶¡¨Ï¥Î¤§¸ê®Æ¤Î°Êª«¥Í´Þ¬ã¨s¡C ©|¥¼½T»{¦³¥ô¦óªº¸T§Ò¡C,IM;,,,,,1. ¥H¦Ù¦×ª`®g©ó¦¨¤H©Î¨àµ£ªº¤âÁu¤T¨¤¦Ù³¡¦ì¡A©Î·s¥Í¨à¡BÀ¦¨à¡B¥®µ£ªº¤j»L«e¥~°¼¡C 2. ¦å¤pªO´î¤Ö¯g©Î¥X¦å©Ê¯e¯f±wªÌ¥i¥H¥Ö¤Uª`®g¤è¦¡§ë»P¡C
IHAV1,Inactivated Hepatitis A Virus Vaccine,HAVRIX 1440¡A 1mL/dose (¦¨¤HA¨x¬Ì­]),HIMM,Active immunisation against infections caused by hepatitis A virus.,Hypersensitivity.,Inj site soreness¡A mild redness & swelling¡A headache¡A malaise¡A vomiting¡A fever¡A nausea & loss of appetite.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5mL¡A > or = 19 years primary immunization. A booster dose after 6-12 months.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡Aµ´¹ï»Ý­n®É¤~µ¹¤©¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e¨ÃµL¤HÃþÃh¥¥´Á¶¡¤Î±Â¨Å´Á¶¡¨Ï¥Î¤§¾A¦X¸ê®Æ¡Aµ´¹ï»Ý­n®É¤~µ¹¤©¡C,IM;,,,,,1. ¦Ù¦×ª`®g©ó¦¨¤H©Î«Äµ£ªº¤T¨¤¦Ù³¡¦ì¡AÀ¦¨à«hÀ³ª`®g©ó¤j»L«e°¼³¡¦ì¡C
OJAR,Empagliflozin,Jardiance FC 10mg,META,,¾AÀ³¯g:Diabetes mellitus¡A type 2 °Æ§@¥Î:>10%: Endocrine & metabolic: Hypoglycemia (combination therapy with insulin: 28%¡A severe hypoglycemia: <=1%; combination therapy with metformin and a sulfonylurea: 12% to 16%; combination therapy with metformin: 1% to 2%) Genitourinary: Urinary tract infection (9%; females: 18%; males: 4%)¡A increased urine output (includes polyuria¡A pollakiuria¡A nocturia: 3%) 1% to 10%: Endocrine & metabolic: Increased LDL cholesterol (5% to 7%)¡A dyslipidemia (4%)¡A increased thirst (including polydipsia: 2%) Gastrointestinal: Nausea (2%) Hematologic & oncologic: Increased hematocrit (3% to 4%) Infection: Genitourinary fungal infection (4%; females: 5% to 6% [includes bacterial vaginosis¡A cervicitis¡A vulvitis¡A vulvovaginal candidiasis¡A vulvovaginal infection¡A vulvovaginitis]; males: 2% to 3% [includes balanitis¡A balanoposthitis¡A genitourinary fungal infection¡A penile infection¡A scrotal abscess]) ¸T§Ò:History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment (eGFR <30 mL/minute/1.73 m2)¡A end-stage renal disease (ESRD)¡A or dialysis,,«Ç·Å,Diabetes mellitus¡A type 2: Oral: Initial: 10 mg once daily; may increase to 25 mg once daily,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,AC;PC;PO;,,,,,
OCAP5,Capecitabine,Calveda 500mg,RACA,Colon cancer¡A Adjuvant therapy¡A Duke's Stage C¡A when treatment with a fluoropyrimidine alone is preferred. Metastatic breast cancer¡A metastatic colorectal cancer¡A 1-line therapy when treatment with a fluoropyrimidine alone is preferred.,Known hypersensitivity to capecitabine¡A fluorouracil¡A or any component of the formulation; severe renal impairment (CrCl <30 mL/minute). Canadian labeling: Additional contraindications (not in the US labeling): Known complete absence of dihydropyrimidine dehydrogenase (DPD) activity; concomitant administration with sorivudine or chemically related analogues (eg¡A brivudine).,GI disturbances; hand-foot syndrome¡A alopecia¡A pruritus¡A rash; fatigue¡A pyrexia¡A lethargy¡A asthenia; dizziness¡A taste disturbance; anorexia; conjunctivitis; neutropenia. Dermatologic: Dermatitis (27% to 37% ) Gastrointestinal: Abdominal pain¡A Constipation¡A Loss of appetite¡A Nausea¡A Stomatitis¡A Vomiting Other: Fatigue,25¢J¥H¤U,Adjuvant treatment is recommended for a total of 6 months (8 cycles) [Metastatic Colorectal Cancer¡A Adjuvant Colorectal Cancer¡A Dukes¡¦ C colon cancer (adjuvant treatment)] 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles for a total of 8 cycles (24 weeks) [Metastatic Breast Cancer] Monotherapy: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles; Combination: 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period¡A combined with docetaxel at 75 mg/m2 as a 1-hour intravenous infusion every 3 weeks.,»Ý½Õ¾ã¾¯¶q,µL¨¬°÷¦w¥þ©Ê»PÀø®Ä¬ÛÃö¸ê®Æ´£¨Ñ¡C ¥é³æ:­««×¨x¥\¯à¨ü·l¸T¥Î¡C,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,No (limited) human data ¡V animal data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°Àù¯g¥ÎÃÄ¡A¤£©y¯}Ãa­ì¾¯«¬¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¡A¨Ãª`·N¬ÛÃö­·ÀI¡C
IBIC,Penicillin G Benzathine,Bicillin L-A inj 2.4 MIU/4mL,QANB,Susceptible infections¡A including mild to moderate upper respiratory strep infections¡A syphilis. Follow-up prophylaxis of rheumatic heart disease¡A acute glomerulonephritis.,Hypersensitivity to penicillins. Avoid intraarterial¡A intravascular¡A or intraneural injection.,Rash¡A serum sickness¡A anaphylaxis¡A blood dyscrasias¡A neuropathy¡A nephropathy¡A inj site reactions.,2-8¢JÁ×§K§N­á,(¥é³æ+Uptodate) Streptococcus¡A group A (pharyngitis): adults and children > 27 kg: 1.2 million units IM as a single dose; children < 27 kg 0.6 million units IM as a single dose. Syphilis: Primary¡A Secondary¡A Early Latent (<1-year duration): 2.4 million units as a single dose. Late Latent¡A Latent with unknown duration¡A Tertiary Syphilis (with normal CSF examination)¡A or Neurosyphilis: 2.4 million units IM once weekly for 3 doses. Yaws¡A bejel¡A and pinta: 1.2 million units IM as a single dose. Rheumatic fever¡A secondary prevention: 1.2 million units every 4 weeks¡A for patients with high risks¡A every 3 weeks. Prevention of glomerulonephritis: 1.2 million units once monthly if needed.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,¤£¥i¨Ï¥ÎIV.,¤£¥i¨Ï¥ÎIV.,1.Bicillin L-A¶È­­²`¼h¦Ù¦×ª`®g¨Ï¥Î¡C 2.½Ð¤Åª`®g¦Ü°Ê¯ß©Î¯«¸g¤º©Î¨ä©P³ò¡A©Î¸g¥ÑÀR¯ß³~®|ª`®g¡A©Î»P¨ä¥LÀR¯ßª`®g²GºU²V¡C 3.½Ð¥H²`¼h¦Ù¦×ª`®g¤è¦¡¡Aª`®g¦ÜÁv³¡ªº¥~¤W°¼(­I°¼Áv¦Ù°Ï)©Î¸¡°¼Áv¦Ù°Ï¡C¦b·s¥Í¨à¡BÀ¦¨à¤Î¦~¥®¨àµ£¤¤¡A¥i¯à¥H¤j»Lªº¤¤¥~°¼¬°­º¿ï¡C
OSINM2,Carbidopa + Levodopa,25/250mg SINEMET,CNEU,,¾AÀ³¯g: Symptomatic treatment of Parkinsonism. °Æ§@¥Î: Dyskinesia including choreiform¡A dystonic & other involuntary movements. Mental changes including paranoid ideation & psychotic episodes; depression with or without development of suicidal tendencies; dementia; & GI disturbances. Gastrointestinal: Nausea (5.5% to 5.7% ) ¸T§Ò: Narrow-angle glaucoma. Undiagnosed skin lesions or history of melanoma. Hypersensitivity to any component of this product.,,«Ç·Å,1 tab tid. Max: 8 tab.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
OAMIO2,Amiodarone,Amiorone 200mg,CAVS,,¾AÀ³¯g: Ventricular arrhythmia¡A Life-threatening; Treatment and Prophylaxis °Æ§@¥Î: Common Cardiovascular: Hypotension (Oral¡A less than 1%; IV¡A 15.6% ) Dermatologic: Photodermatitis (2% to 24% )¡A Photosensitivity (3% to 10% ) Endocrine metabolic: Thyroid dysfunction Gastrointestinal: Constipation (4% to 9% )¡A Loss of appetite (4% to 9% )¡A Nausea (10% to 33% )¡A Vomiting (10% to 33% ) Hepatic: Increased liver enzymes Neurologic: Abnormal gait (4% to 9% )¡A Coordination problem (4% to 9% )¡A Dizziness (4% to 9% )¡A Involuntary movement (4% to 9% )¡A Movement disorder (4% to 9% )¡A Paresthesia (4% to 9% )¡A Peripheral neuropathy Ophthalmic: Corneal deposit¡A Microdeposits¡A Visual disturbance (4% to 9% ) Other: Malaise and fatigue (4% to 9% ) Serious Cardiovascular: Bradyarrhythmia¡A Cardiac dysrhythmia¡A Congestive heart failure¡A High threshold for implanted defibrillator¡A Prolonged QT interval¡A Sinus arrest¡A Torsades de pointes¡A Vasculitis¡A Ventricular arrhythmia Dermatologic: Injection site extravasation¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Endocrine metabolic: Hyperthyroidism (2% )¡A Hypothyroidism (Up to 10% .)¡A Thyroid cancer¡A Thyrotoxicosis Hematologic: Thrombocytopenia Hepatic: Hepatotoxicity Immunologic: Anaphylaxis¡A Hypersensitivity reaction¡A Lupus erythematosus Musculoskeletal: Low back pain¡A acute¡A Rhabdomyolysis Neurologic: Pseudotumor cerebri¡A Raised intracranial pressure Ophthalmic: Blindness AND/OR vision impairment level¡A Optic neuritis¡A Toxic optic neuropathy Renal: Renal impairment Respiratory: Acute respiratory distress syndrome (2% )¡A Pulmonary fibrosis¡A Pulmonary toxicity (Up to 17% ) ¸T§Ò: Cardiogenic shock. Hypersensitivity to amiodarone or to any of its components¡A including iodine. Sick sinus syndrome¡A second- or third-degree atrioventricular block¡A bradycardia leading to syncope without a functioning pacemaker. Severe sinus bradycardia or second or third degree atrioventricular block¡A if no pacemaker is present. Pregnancy¡A lactation.,,Äá¤ó25«×C¥H¤U,initial 200mg tid for 8-10 days maintenance dose: 100-400 mg 5 days a week.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Human (and animal) data suggest risk,[¥é³æ¸`¿ý]°Êª«¹êÅç¥¼Åã¥Ü¦³¥ô¦ó­P·î©Ê...... ¥Ñ©ó­L¨àªº¥Òª¬¸¢¦bÃh¥¥«á²Ä14¶g¤~¶}©l©M¸Kµ²¦X¡A¦]¦¹¦b¦¹¤§«eªA¥Î¥»ÃÄ¨Ã¤£¹w´Á¹ï­L¨àªº¥Òª¬¸¢¦³¥ô¦ó§@¥Î. µM¦Ó¡A¦bÃh¥¥¶W¹L³o´Á¶¡ªA¥ÎAmiodarone¡A·|¨ÏÅé¤º¸K¹L¦h¡A³y¦¨­L¨à¦b¥Íª«©ÎÁ{§É¤W(¥Òª¬¸¢¸~)¤Wªº¥Òª¬¸¢¥\¯à§C¤U. ©Ò¥H¡A¦ÛÃh¥¥²Ä2´Á(²Ä4-6­Ó¤ë)¶}©l¡A¸T¤î¨Ï¥ÎAmiodarone.,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,[¥é³æ]Amiodarone¤Î¨ä¥NÁÂ²£ª«»P¸K¤À¤l¡A¬Ò·|¥H°ª©ó¦b¥ÀÅéªº¦å¼ß¿@«×¦s¦b©ó¨Å¥Ä¤¤. ¥Ñ©ó¨ä¹ï·s¥Í¨à¦³²£¥Í¥Òª¬¸¢§C¤Uªº¦MÀI¡A©Ò¥H¨Ï¥Î¥»«~ªº¥À¿Ë¸T¤î¥H¥À¨Å­÷¨|À¦¨à.,,,,,,
EENO,Enoxolone,Enoxolone Gingival Paste 1%¡A 80gm,TENT,To relieve pain due to disease of the gums and wounds prosthesis.,Hypersensitivity to any component of the formulation.,Hypersensivity.,25¢J¥H¤U,Brushing followed by a massage gums after meal for a few minutes¡A then rinse.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,TOPI;,,,,,
IHIB0,Haemophilus b Conjugate Vaccine,Act-HIB 0.5mL(¶Ý¦å±ìµß¬Ì­]¡A ¬F©²´£¨Ñ),HIMM,,¾AÀ³¯g:Active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib) °Æ§@¥Î: >10%: Central nervous system: Irritability (infants: 67% to 76%; children: 13% to 27%)¡A drowsiness (infants: 49% to 66%; adults: 60%; children: 13% to 36%) Gastrointestinal: Anorexia (infants: 28% to 33%; children: 6% to 13%)¡A diarrhea (booster dose in children: 15%) Local: Pain at injection site (infants: 43% to 57%; children: 21%)¡A erythema at injection site (infants: 19% to 32%; children: <1%)¡A swelling at injection site (infants: 13% to 22%; children: <=4%)¡A tenderness at injection site (<=20%) Miscellaneous: Fever (1% to 35%) 1% to 10%: Gastrointestinal: Vomiting (children: <=5%) Local: Induration (children: <=6%) Frequency not defined: Central nervous system: Guillain-Barre syndrome¡A seizure Dermatologic: Skin rash¡A urticaria Hematologic & oncologic: Thrombocytopenia Local: Injection site: soreness Otic: Otitis media Respiratory: Tracheitis¡A upper respiratory tract infection ¸T§Ò:Hypersensitivity to Haemophilus b polysaccharide¡A tetanus toxoid-containing vaccine (Hiberix and ActHIB only)¡A or any component of the formulation,,2-8¢J,Infants 6 weeks to 6 months: Minimum age for first dose is 6 weeks. -Before 6 months of age: IM: 3 successive 0.5 mL doses at one or two month intervals followed by a booster injection (0.5mL) at 18 months of age. -Between 6 and 12 months¡A two 0.5mL doses at a one month interval followed by a booster injection (0.5mL) at 18 months of age. -From 1 to 5 years:IM: 0.5 mL as a single dose,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,¬Ì­]­á´¹¯»»P±M¥Îµ}ÄÀ²G²V¦X«á¨Ï¥Î¡C
OFRIN,Iron(III) + Cyanocobalamin + Folic acid,Ferrin 150/0.025/1mg,NUTR,,¾AÀ³¯g:Treatment of iron deficiency anemia¡A vit B12 & folic acid deficiency. °Æ§@¥Î:GI irritation¡A constipation¡A nausea. ¸T§Ò:Known hypersensitivity to polysaccharide-iron complex or any component of the formulations; hemochromatosis; hemosiderosis.,,«Ç·Å,1 tab once daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
IFIR8,Degarelix,Firmagon inj 80mg/4mL,RACA,Advanced hormone-dependent prostate cancer in adult male patients.,Known hypersensitivity to degarelix or any component of the formulation; pregnant.,Hot flush¡A inj site reactions. Anemia; increased wt; insomnia; dizziness¡A headache¡A diarrhea¡A nausea; increased liver transaminases; hyperhidrosis (including night sweats)¡A rash¡A musculoskeletal pain & discomfort; gynecomastia¡A testicular atrophy¡A erectile dysfunction; chills¡A pyrexia¡A fatigue¡A flu-like illness.,30¢J¥H¤UÁ×§K§N­á,Loading dose: 240 mg administered as two 120 mg (3 mL) injections; Maintenance dose: 80 mg administered as one 4 mL injection every 28 days (beginning 28 days after initial loading dose),µL»Ý½Õ¾ã¾¯¶q,Severe hepatic impairment (Child Pugh class C): use with caution,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥¤ÀÃþµ¥¯ÅX¡C Degarelix ­Ý¥Î©óÃh¥¥©Î¥i¯àÃh¥¥ªº°ü¤k¡C§ë»P degarelix ©óÃh¥¥°ü¤k·|¹ï­L¨à²£¥Í¶Ë®`¡C¥HÅéªí­±¿n(mg/m2)¬°°òÂ¦¡A§ë»P degarelix Á{§É¤Wªì©l¾¯¶q(240mg)ªº0.02%·|¾É­P¾¹©x§Î¦¨´Áªº¨ß¤l­F­L©M­L¨à¦º¤`¤Î¬y²£¡C¥HÅéªí­±¿n(mg/m2)¬°°òÂ¦¡A¹ï¾¹©x§Î¦¨´ÁªºÃh¥¥¶¯©Ê¤j¹«§ë»P degarelix Á{§É¤Wªì©l¾¯¶qªº 0.036%¡A·|¾É­P­F­LµÛ§É«á¬y²£¼W¥[©M­°§C¬¡­L¼Æ¡C °²¦p³o­ÓÃÄ«~¥Î©óÃh¥¥´Á¶¡©Î°²¦p¯f±w¦b¥ÎÃÄ´Á¶¡Ãh¥¥¡A»Ý­n¥ý§iª¾¯f±wÃÄª«¹ï­L¨àªº¼ç¦b¼vÅT¡C,Unknown ¨S¦³¸ê®Æ,,SC;,,,X,X,¡E THE VIALS SHOULD NOT BE SHAKEN 1. Remove the cover from the vial adapter pack 2. Prepare the pre-filled syringe by attaching the plunger rod.
IHEX,DTaP-IPV-HIB-HBV,Hexaxim (¤»¦X¤@¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,,¾AÀ³¯g:Primary and booster vaccination of infants and toddlers (6 weeks to 24 months) against diphtheria¡A tetanus¡A pertussis¡A hepatitis B¡A poliomyelitis and invasive diseases caused by Haemophilus influenzae type B (Hib). °Æ§@¥Î:Anorexia (decreased appetite)¡A crying¡A somnolence¡A abnormal crying (prolonged crying)¡A vomiting¡A diarrhea¡A injection-site pain¡A erythema and swelling¡A irritability¡A pyrexia (body temperature >38¢XC). ¸T§Ò:Hypersensitivity to diphtheria¡A tetanus¡A acellular pertussis¡A hepatitis B (rDNA)¡A inactivated poliomyelitis and adsorbed Hib conjugate vaccine or to any of the excipients of Hexaxim¡A to trace residuals (glutaraldehyde¡A formaldehyde¡A neomycin¡A streptomycin and polymyxin B)¡A to any pertussis vaccine or after previous administration of Hexaxim or a vaccine containing the same components or constituents.,,2-8¢J,Primary Vaccination: 3 doses of 0.5 mL to be administered at intervals of at least 4 weeks and as per schedules 6¡A 10¡A 14 weeks; 2¡A 3¡A 4 months; 3¡A 4¡A 5 months; 2¡A 4¡A 6 months. Booster vaccination 2nd yr of life at least 6 mth after last priming dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
OVIM,Lacosamide,Vimpat 100mg,CNEU,1. Monotherapy for localized seizures with or without secondary generalized seizures in patients aged four and above who have experienced either their first or multiple seizures. 2. Adjunctive therapy for the following conditions: (1) Patients aged four and above with complex partial seizures and simple or complex partial seizures with secondary generalization¡A with or without other seizure types. (2) Patients aged four and above with primary generalized tonic-clonic seizures (PGTCS) and idiopathic generalized epilepsy.,Allergic to the main ingredients or any excipients. second-or third-degree AV block.,Common: Nausea (Up to 24%)¡A Dizziness (Oral¡A 16-30% ; IV¡A 20-60%)¡A Headache (11-16%)¡A Diplopia (9-11%) Serious: Atrial fibrillation and flutter¡A First degree atrioventricular block¡A Asymptomatic (0.4%)¡A Prolonged PR interval¡A Drug reaction with eosinophilia and systemic symptoms¡A Suicidal behavior¡A Suicidal thoughts,25¢J¥H¤U,Children and adolescents bodyweight >=50 kg and adults: Monotherapy and Adjunctive Therapy: Initial Dosage: 50 mg twice daily. One week later¡A the initial therapeutic dose was increased to 100 mg twice a day. According to response and tolerability¡A the maintenance dose can be increased by 50 mg twice a day (100 mg/day) per week¡A to the maximum recommended daily dose: 200 mg twice a day. Start treatment with a fast-acting dose of Lacosamide:200 mg as a single dose. After 12 hours¡A100 mg twice a day (200 mg/day) as a maintenance dose. Discontinue the drug: recommended to gradually reduce the dose (for example¡A reduce the daily dose by 200 mg/week). For patients with severe cardiac arrhythmia¡A clinical benefit/risk assessment should be performed¡A and Lacosamide should be discontinued if necessary. Switch from a single antiepileptic drug (AED) to Lacosamide monotherapy: The anti-epileptic drugs should not be discontinued until the therapeutic dose of Lacosamide is reached for at least 3 days. It is recommended to gradually stop using anti-epileptic drugs for at least 6 weeks.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]°w¹ï»´«×©Î¤¤«×¨x¥\¯à¤£¥þ¯f¤H¡A«ØÄ³´î¤Ö³Ì¤j¾¯¶qªº 25%¡C¨x¥\¯à¤£¥þ¯f¤HÀ³ÂÔ·V¶i¦æ¾¯¶q½Õ¾ã¡CLacosamide ¤£«ØÄ³¥Î©ó­««×¨x¥\¯à¤£¥þªº¯f¤H¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¹ï©ó©Ò¦³ªº§ÜÅöíwÃÄª«¡A¥Î©óªvÀøÃh¥¥°ü¤k«á¡A Åã¥Ü¨ä·s¥Í¨àµo¥Í·î«¬ªº²±¦æ²v¬O¤@¯ë±Ú¸s²±¦æ²v(¬ù¬°3%)ªº 2 ¨ì 3 ­¿¡C ¨Ï¥Î§ÜÅöíwÃÄª«ªvÀøªºÃh¥¥°ü¤k¤¤¡Aµo²{¨ä¤¤±µ¨ü¦h­«ÅöíwÃÄª«ªvÀø«á¡A±N¼W¥[¨ä·s¥Í¨à·î«¬ªº¤ñ¨Ò¡C ¦ý¬O¥Ø«e©|¥¼Âç²MÃÄª«ªvÀø©M/©Î¯e¯f¹ï©ó­P·îµ{«×¤§¼vÅT¦óªÌ¬°¬Æ¡C ¦¹¥~¡A¦³®Äªº§ÜÅöíwªvÀø¤£¥i¤¤Â_¡A¦]¬°¯e¯fªº´c¤Æ±N¤£§Q©ó¥À¿Ë¤Î­L¨à¡C ¨Ï¥Î Lacosamide ¤§¬ÛÃö­·ÀI: ¨S¦³¥¥°ü¨Ï¥Î Lacosamide ªº¨¬°÷¼Æ¾Ú¡C ¦b°Êª«¬ã¨s¤¤¡A¤j¹«©Î¨ß¤l¥¼Åã¥Ü¥ô¦ó­P·î­L§@¥Î ¡A¦ý¦bÆ[¹î¨ì¥ÀÅé¬r©Ê¾¯¶q¤U¡A¹ï©ó¤j¹«©M¨ß¤l¨ã­F­L¬r©Ê¡C ¹ï¤HÃþ¼ç¦bªº­·ÀI¥¼ª¾¡CLacosamide ¤£À³¸Ó¦bÃh¥¥´Á¶¡¨Ï¥Î¡A°£«D©ú½T»Ý­n¡]¦p¹ï¥À¿Ëªº¯q³B©úÅã¤j©ó¹ï­L¨à¼ç¦bªº­·ÀI¡^¡C ¦pªG°ü¤k¨M©wÃh¥¥¡A¨Ï¥Î¥»²£«~À³¥J²Ó­«·sµû¦ô¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Lacosamide ·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤¡A ¦]¦¹À³¦Ò¼{ÃÄª«¹ï¥À¿Ëªº­«­n©Ê¡A¨Ó¨M©w¬O§_°±¤î­÷¨Å©Î°±¤î¨Ï¥ÎLacosamide ¡C,AC;AC15;PC;PO;WM;,,,,,
OCLOPD,Clopidogrel,Clopidogrel 75mg,HEMT,Prevention of atherothrombotic events in patients suffering from MI¡A ischemic stroke or established peripheral arterial disease; in patients suffering from non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) in combination with aspirin. ST segment elevation acute MI in combination with aspirin in patients eligible for thrombolytic therapy.,Severe liver impairment. Peptic ulcer & intracranial haemorrhage. Lactation.,GI bleeding¡A purpura¡A bruising¡A haematoma¡A epistaxis¡A haematuria¡A ocular haemorrhage¡A intracranial bleeding¡A abdominal pain¡A dyspepsia¡A gastritis & diarrhoea¡A rash¡A pruritus. Cardiovascular: Chest pain¡A Hypertension (4.3% ) Dermatologic: Pruritus (3.3% )¡A Purpuric disorder (5.3% )¡A Rash (4.2% ) Endocrine metabolic: Hypercholesterolemia Gastrointestinal: Abdominal pain¡A Constipation¡A Diarrhea¡A Gastritis¡A Indigestion Hematologic: Epistaxis (2.9% )¡A Purpura (5.3% ) Musculoskeletal: Arthralgia (6.3% )¡A Backache (5.8% ) Neurologic: Headache (7.6% ),25¢J¥H¤U,Adult & elderly recommend 75 mg once daily. Patients with non-ST segment elevation acute coronary syndrome: Initially giving 300 mg as loading dose¡A continued with 75 mg once daily (combined with 75-325 mg aspirin daily). Dose of aspirin should be less than 100 mg. ST segment elevation acute MI: 75 mg daily¡A combined with aspirin.,µL»Ý½Õ¾ã¾¯¶q,1.¨Ï¥Î©ó¥i¯à¦³¥X¦åÅé½èªº¤¤«×¨x¥\¯à¤£¨}±wªÌ¤§¸gÅç¦³­­¡AÀ³¤p¤ß¨Ï¥Î©ó¦¹¯f¤H¸s¡C 2.ÃÄª«°ò¦]¾Ç¡G¨xÅ¦»Ã¯ÀCYP2C19 ¥NÁÂ¥\¯à¤£¨Î¯f¤H·|­°§Cclopidogrel ¤§§Ü¦å¤pªO¤ÏÀ³¡AÁöµM´£°ªclopidogrel ¾¯¶q·|¼W±jCYP2C19 ¥NÁÂ¥\¯à¤£¨Î¯f¤H¤§§Ü¦å¤pªO¤ÏÀ³¡A±©CYP2C19 ¥NÁÂ¥\¯à¤£¨Î¯f¤H¤§¾A·íµ¹ÃÄ¾¯¶q©|¥¼§¹¥þ«Ø¥ß¡C,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ICARN,L-carnitine,L-Carnit inj 1gm/5mL,NUTR,Carnitine deficiency in patients with end-stage renal disease requiring hemodialysis (injection only)¡A primary systemic carnitine deficiency and secondary carnitine deficiency.,Hypersensitivity to levocarnitine or any component of the formulation.,>10%: Cardiovascular: Hypertension (intravenous: 18% to 21%)¡A chest pain (intravenous: 15%) Central nervous system: Headache (intravenous: 37%)¡A dizziness (intravenous: 15% to 18%)¡A paresthesia (intravenous: 12%) Endocrine & metabolic: Hypercalcemia (intravenous: 6% to 15%) Gastrointestinal: Diarrhea (intravenous: 35%)¡A abdominal pain (intravenous: 21%)¡A vomiting (intravenous: 21%)¡A nausea (intravenous: 12%) Hematologic & oncologic: Anemia (intravenous: 5% to 12%) Infection: Infection (intravenous: 24%) Neuromuscular & skeletal: Weakness (intravenous: 9% to 12%) Respiratory: Cough (intravenous: 18%)¡A rhinitis (intravenous: 11%) Miscellaneous: Accidental injury (intravenous: 12%)¡A fever (intravenous: 6% to 12%),30¢J¥H¤UÁ×¥ú,Carnitine deficiency causes Hemodialysis: 2g IV over 2 to 3 min after dialysis. [Micromedex 20210731] Carnitine deficiency¡A Secondary - Inborn error of metabolism ¡E initial¡A 50 mg/kg IV bolus (over 2 to 3 min) or infusion; repeat 50 mg/kg IV daily if clinically indicated; Maximum dose 300 mg/kg. ¡E severe metabolic crisis¡A initial¡A 50 mg/kg IV over 2 to 3 min bolus injection or infusion¡A repeat 50 mg/kg IV in divided dose over 24 hr (every 3 to 4 hr and not less than every 6 hr); repeat 50 mg/kg IV daily if clinically indicated; Maximum dose 300 mg/kg. Carnitine deficiency; Treatment and Prophylaxis - End-stage renal disease - Hemodialysis ¡E initial¡A 10 to 20 mg/kg (dry weight) over 2 to 3 min bolus injection after dialysis; subsequent dose titration determined by trough (predialysis) levocarnitine concentrations.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;IVP;IVPUSH;,,¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,Administer as a bolus dose over 2 to 3 minutes or by infusion.,Intermittent infusion over 15 to 30 minutes. Drug concentrations ranging 0.5-8 mg/mL.,Compatible when mixed with Normal Saline or Lactated Ringer's in concentrations ranging from 0.5 mg/mL to 8 mg/mL
OURI8,Silodosin,Urief F.C. 8mg,SGU,Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).,Severe hepatic impairment; severe renal insufficiency.,Drowsiness¡A postural hypotension¡A syncope¡A asthenia¡A depression¡A headache¡A dry mouth¡A GI disturbances¡A edema¡A blurred vision¡A rhinitis¡A erectile disorders¡A tachycardia¡A palpitation¡A hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy.,½Ð«O¦s©ó±K³¬®e¾¹¡BÁ×¥ú¡B25¢XC¥H¤U,4 mg BID¡A after breakfast and evening meal. Or 8mg QD after meal.,µL»Ý½Õ¾ã¾¯¶q,»´«×¤Î¤¤«×¨x¥\¯à»ÙÃªªÌ(Child-Pugh score= 7~9)µL¶·½Õ¾ã¾¯¶q ÄY­«¨x¥\¯à»ÙÃªªÌ(Child-Pugh score¡Ù10)ªºÁ{§É¬ã¨s¥¼°õ¦æ¡A¦]¦¹¥»«~¸T¥Î©óÄY­«¨x¥\¯à»ÙÃªªÌ,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PC;PO;,,,,,
ILEV,Norepinephrine,Levophed inj 4mg/4mL,CAVS,,¾AÀ³¯g: Restoration of BP in acute hypotensive states. Adjunct in the treatment of cardiac arrest & profound hypotension. °Æ§@¥Î: Occasionally¡A bradycardia; anxiety¡A transient headache. Plasma vol depletion (prolonged administration). Respiratory difficulty¡A ischemic injury. ¸T§Ò: Patients who are hypotensive from blood vol deficits except as emergency measure until blood vol therapy can be completed. Cyclopropane & halothane anesth¡A mesenteric or peripheral vascular thrombosis.,,«Ç·Å,IV infusion¡A Adult: 8-12 mcg/min initially¡A adjusting rate to maintenance a systolic blood pressure = 80-100 mmHg¡A average maintenance dose: 2-4 mcg/min. Child: 2 mcg/m2/min (max. 6 mcg/m2/min).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human (and animal) data suggest risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IVD;,,¡iD5NS¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,¤£¥iIVP¨Ï¥Î¡C,¥é³æ«ØÄ³¡G1 vial (4mg/4 mL) diluted to 1000 mL of 5% dextrose solution (concentration: 4 mcg/mL)¡Aºwª`³t²v¬° 2-4 mcg/min¡C,1.¤£¥i¥Î¥Í²z­¹ÆQ¤ôµ}ÄÀ¡C 2.¥»ÃÄ«~À³ª`®g©ó¤jÀR¯ß¡A¨ÃÀH®ÉÀË¬dª`®g³¡¦ì¦åºÞ¬O§_³qºZ¡AÁ×§KÃÄ«~¥~º¯¨ìªþªñ²ÕÂ´¡C¦]ÃÄª«ªº±j¤O¦åºÞ¦¬ÁY§@¥Î¥i¯à³y¦¨§½³¡²ÕÂ´Ãa¦º¡C
OFOR,Dapagliflozin,Forxiga 10mg,META,Chronic kidney disease¡A (At risk of progression) to reduce the risk of sustained estimated GFR decline¡A end-stage kidney disease¡A cardiovascular death¡A and hospitalization for heart failureView additional information. Disorder of cardiovascular system; Prophylaxis - Type 2 diabetes mellitusView additional information. Heart failure¡A (NYHA class II to IV¡A reduced ejection fraction) to reduce risk of cardiovascular death and hospitalizationView additional information. Type 2 diabetes mellitus.,Dialysis. Serious hypersensitivity reaction (eg¡A anaphylactic reaction or angioedema) to dapagliflozin.,Common Renal: Urinary tract infectious disease (4.3% to 5.7% ) Reproductive: Female genital infection (6.9% to 8.4% ) Respiratory: Nasopharyngitis (6.3% to 6.6% ) Serious Cardiovascular: Hypotension Endocrine metabolic: Diabetic ketoacidosis (0.3% )¡A Hypoglycemia Immunologic: Hypersensitivity reaction (Severe) (0.3% ) Renal: Acute injury of kidney¡A Pyelonephritis¡A Sepsis due to urinary tract infection Reproductive: Fournier's gangrene¡A Genital infection (4.8% to 5.7% ),30¢J¥H¤U,Type 2 diabetes initial 5 mg once daily¡A max 10 mg/day.Heart failure 10 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,¹ï¦³»´«×¡B¤¤«×¡B©Î­««×¨x¥\¯à¤£¥þ¯f¤H¨ÃµL½Õ¾ã¾¯¶q¤§«ØÄ³¡C¦ý¬O¡A¦b¦³­««×¨x¥\¯à¤£¥þ¯f¤H¤¤¡AÀ³­Ó§Oµû¦ô¨Ï¥ÎdapagliflozinªºÀò¯q-­·ÀI¡A¦]¬°©|¥¼¦b¦¹±Ú¸s±Mªù¬ã¨sdapagliflozinªº¦w¥þ©Ê©MÀø®Ä,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¨Ì¾Ú°Êª«¸ê®ÆÅã¥Ü¦³µÇÅ¦¤£¨}¤ÏÀ³¡A¤£«ØÄ³¦bÃh¥¥ªº²Ä¤G©M²Ä¤T¥¥´Á¤¤¨Ï¥ÎForxiga¡C Ãh¥¥¤k©Ê¨Ï¥ÎForxigaªº¸ê®Æ¦³­­¡A¤£¨¬¥H§PÂ_¹ï©ó­«¤j¥ý¤Ñ¯Ê³´©Î¬y²£ªºÃÄª«¬ÛÃö­·ÀI¡CÃh¥¥¤¤¿}§¿¯f±±¨î¤£¨Î¥B¥¼ªvÀø¤ß°IºÜ¹ï©ó¥À¿Ë©M­L¨à¦³¬ÛÃö­·ÀI [¨£Á{§Éµû¦ô¨Æ¶µ]¡C ¦b°Êª«¸ÕÅç¤¤¡A¦b¹ïÀ³¦Ü¤HÃþÃh¥¥²Ä¤G¥¥´Á«á´Á©M²Ä¤T¥¥´ÁªºµÇÅ¦µo¨|´Á¶¡¡A¤j¹«¼ÉÅS©ódapagliflozin®É¡A©Ò¦³´ú¸Õ¾¯¶q¬Ò´¿Æ[¹î¨ì«D§¹¥þ¥i°fªºµÇª»¤ÎµÇ¤pºÞ¤£¨}ÂX±i¡F³Ì§C¾¯¶qªº¼ÉÅS¶q¬O10 mgÁ{§É¾¯¶qªº15­¿ [¨£¸ÕÅç¸ê®Æ]¡C ±w¦³§³®W«e¿}§¿¯f¥BHbA1c >7%ªº¤k©Ê¡A­«¤j¥ý¤Ñ¯Ê³´¤§¦ô­p­I´º­·ÀI¬ù¬°6-10%¡F¦ÓHbA1c >10%ªº¤k©Ê¡A«h´¿³q³ø°ª¹F20¦Ü25%ªº­I´º­·ÀI¡C¦³Ãö¯S©w±Ú¸sµo¥Í¬y²£ªº¹w¦ô­I´º­·ÀI©|¤£²M·¡¡C¦b¬ü°ê¤@¯ë±Ú¸s¡AÁ{§É½T»{ªºÃh¥¥¤¤¡Aµo¥Í­«¤j¥ý¤Ñ¯Ê³´©M¬y²£ªº¹w¦ô­I´º­·ÀI¤ñ¨Ò¤À§O¬°2¦Ü4%©M15¦Ü20%¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Micromedex: Ãh¥¥: C ­÷¨Å:Micromedex: Infant risk cannot be ruled out.,AC;AC15;PC;PO;WM;,,,,,
OMEV4,Pravastatin,Mevalotin 40mg,CAVS,Hyperlipidemia Dysbetalipoproteinemia: Treatment of primary dysbetalipoproteinemia (Fredrickson type III) in patients who do not respond adequately to diet. Heterozygous familial hypercholesterolemia: Adjunct to diet in children >= 8 years and adolescents with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: LDL-C >= 190 mg/dL or LDL >=160 mg/dL with positive family history of premature cardiovascular disease (CVD)¡A or with 2 or more other CVD risk factors. Hypercholesterolemia and mixed dyslipidemia: Adjunct to diet to reduce elevated total cholesterol¡A LDL-C¡A apo B¡A and triglyceride (TG) levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).,Hypersensitivity to pravastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding,1% to 10%: Cardiovascular: Chest pain (4%) Central nervous system: Headache (2% to 6%)¡A fatigue (4%)¡A dizziness (1% to 3%) Dermatologic: Skin rash (4%) Gastrointestinal: Nausea (<7%)¡A vomiting (<7%)¡A diarrhea (6%)¡A heartburn (3%) Genitourinary: Cystitis (interstitial; Huang 2015) Hepatic: Increased serum transaminases (>3x normal on 2 occasions: 1%) Infection: Influenza (2%) Neuromuscular & skeletal: Myalgia (2%) Respiratory: Cough (3%) <1%¡A postmarketing¡A and/or case reports: Alopecia¡A amnesia (reversible)¡A anaphylaxis¡A angioedema¡A cataract¡A change in libido¡A cholestatic jaundice¡A cognitive dysfunction (reversible)¡A confusion (reversible)¡A cranial nerve dysfunction¡A decreased appetite¡A dermatitis¡A dermatomyositis¡A dysgeusia¡A edema¡A erythema multiforme¡A fever¡A flushing¡A fulminant hepatic necrosis¡A gynecomastia¡A hemolytic anemia¡A hepatic cirrhosis¡A hepatic neoplasm¡A hepatitis¡A hypersensitivity reaction¡A increased erythrocyte sedimentation rate¡A insomnia¡A lupus-like syndrome¡A memory impairment (reversible)¡A myasthenia¡A myopathy¡A neuropathy¡A pancreatitis¡A paresthesia¡A peripheral nerve palsy¡A polymyalgia rheumatica¡A positive ANA titer¡A pruritus¡A purpura¡A rhabdomyolysis¡A sexual disorder¡A Stevens-Johnson syndrome¡A tremor¡A urticaria¡A vasculitis¡A vertigo¡A xeroderma,25¢J¥H¤U,Adut: 10-40 mg orally once daily in the evening with or without food.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated ¡V 1st trimester,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,AC;AC15;PC;PO;WM;,,,,,
IZOX,Zoster virus vaccine live,Zostavax 0.65mL/dose,HIMM,Prevention of herpes zoster & herpes zoster-related post-herpetic neuralgia. Reduction of acute & chronic zoster-associated pain. Immunization of adults ¡Ù50 yr.,Hypersensitivity. History of anaphylactoid reaction to neomycin. Acute & chronic leukemias; lymphoma; other conditions affecting bone marrow or lymphatic system; immunosuppression due to HIV/AIDS; cellular immune deficiencies. Active untreated TB. Pregnancy.,Erythema¡A pain¡A swelling¡A pruritus; headache¡A hematoma¡A warmth¡A induration¡A pain in extremity.,2-8¢JÁ×¥ú,SC¡A 0.65 mL¡A 50-79 years a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,[UpToDate2021/0125]ZVL should not be administered to pregnant women; however¡A this scenario is unlikely since it is not indicated for women of childbearing age. [¥é³æ]¥Ø«e¥¼ª¾Ãh¥¥°ü¤k±µºØ¬O§_·|¹ï­L¨à³y¦¨¶Ë®`©Î¼vÅT¥Í´Þ¯à¤O¡A¤wª¾¦ÛµMµo¥Íªº¤ôµk±aª¬¯p¯l¯f ¬r·P¬V¦³®É·|³y¦¨­L¨à¼vÅT¡A¦]¦¹¤£¥i¥Î©ó¥¥°ü¡A¥BÀ³Á×§K©ó±µºØ«á¤T­Ó¤ë¤ºÃh¥¥¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ø«e©|¤£½Tª¾¬O§_·|¤Àªc¦Ü¨Å¥Ä¡A¥Ñ©ó¤wª¾¦³¨Ç¯f¬r·|¶i¤J¤HÃþ¨Å¥Ä¡A ¦]¦¹­÷¨Å°ü¤k±µºØ®ÉÀ³ÂÔ·V¡C,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G,,¤£¥i,¤£¥i,
IHBV2,Hepatitis B Vaccine,H-B-VAX II 1mL/dose(¦Û¶OB¨x¬Ì­] MSD),HIMM,,¾AÀ³¯g:Active immunisation against hepatitis B virus infection °Æ§@¥Î:Redness¡A pain¡A swelling at inj site. Rarely¡A fatigue¡A fever¡A malaise¡A influenza-like symptoms¡A dizziness¡A headache¡A paresthesia¡A nausea¡A vomiting¡A diarrhea¡A abdominal pain¡A abnormal liver function tests¡A arthralgia¡A myalgia¡A rash¡A pruritus¡A urticaria. ¸T§Ò:Hypersensitivity.,,2-8¢J,By IM inj . Pediatric/Adolescent <16 years: 5 mcg/0.5mL/Dose¡A primary immunisation 3 doses at 0¡A 1 & 6 months Adult and >16 years: 10 mcg/1mL/dose¡A primary immunisation 3 doses at 0¡A 1 & 6 months,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IM;,,,,,
OKAS5,Dimethicone,KASCOAL 50mg,ALIM,,¾AÀ³¯g: Relief of pressure¡A bloating¡A fullness¡A and discomfort of gastrointestinal gas. °Æ§@¥Î:Loose stools ¸T§Ò:Hypersensitivity to simethicone or any component of the formulation,,,Adult Gas retention: Oral: Usual dose: 40 to 125 mg 4 times daily as needed after meals and at bedtime; may administer single doses of up to 160 to 500 mg after meals or at bedtime¡A not to exceed a maximum daily dose of 500 mg/day. Infants and Children <2 years or <11 kg: 20 mg 4 times daily after meals and at bedtime¡A as needed (maximum: 240 mg/day) Children >2 years or >11 kg: 40 mg 4 times daily after meals and at bedtime¡A as needed (maximum: 480 mg/day),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;P;P1;P2;P3;P4;PC;PO;,,,,,
ISIMD,Levosimendan,Simdax inj 12.5mg/5mL,CAVS,Short-term treatment of acutely decompensated severe chronic heart failure (ADHF) wherein conventional therapy is not sufficient & in cases where inotropic support is appropriate.,Hypersensitivity. Severe hypotension & tachycardia. Significant mechanical obstructions affecting ventricular filling or outflow or both. Severe renal impairment (CrCl <30 mL/min) & severe hepatic impairment. History of Torsades de Pointes¡A hypotension(SBP<100 mmHg©ÎDBP<60 mmHg).,Headache; ventricular tachycardia; hypotension. Hypokalaemia; insomnia; dizziness; atrial fibrillation¡A tachycardia¡A ventricular extrasystoles¡A cardiac failure¡A myocardial ischaemia¡A extrasystoles; nausea¡A constipation¡A diarrhoea¡A vomiting; decreased Hb.,2-8¢XCÁ×§K§N­á,For the short-term treatment of patients with acute decompensated heart failure when conventional therapies are insufficient and inotropic support is appropriate Adults: IV: Initial: 6 to 12 mcg/kg infused over 10 minutes. Maintenance: 0.05 to 0.1 mcg/kg/minute by continuous infusion for 24hr only.,»Ý½Õ¾ã¾¯¶q,Simdax must be used with caution in patients with mild to moderate hepatic impairment although no dose adjustment appears necessary for these patients. Simdax should not be used in patients with severe hepatic impairment.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C,X,Dilute to 0.025 - 0.05 mg/mL before administration. Initial bolus dose: 6-12 mcg/kg over 10 minutes. Continuous infusion dose: 0.05-0.2 mcg/kg/min.,Lower loading dose of 6 mcg/kg is recommended in patients on concomitant IV vasodilators or inotropes or both at start of infusion. Rate of infusion may be decreased to 0.05 mcg/kg/min or discontinued if response is deemed excessive; may be increased to 0.2 mcg/kg/min if initial dose is tolerated. Duration of infusion: 24 hr. µ}ÄÀ«áªºÃÄ«~¡A¨ä¤Æ¾Ç¤Îª«²z¦w©w©Ê©ó25¢XC¤U¥iºû«ù24¤p®É¡C ¹ï©ó«æ©Ê¥¢¥NÀv©ÊÄY­«ºC©Ê¤ß°IºÜ¯f¤Hªº«ØÄ³¿éª`®É¶¡¬°24¤p®É¡C
IHEXA,DTaP-IPV-HIB-HBV,Hexaxim inj (¤»¦X¤@) 0.5mL/dose,HIMM,Diphtheria¡A tetanus toxoids¡A acellular pertussis¡A inactivated poliovirus¡A Haemophilus influenzae type B¡A hepatitis B conjugate vaccine over 6 weeks old.,History of an anaphylactic reaction after a previous administration of Hexaxim. Hypersensitivity to the active substances¡A to any of the excipients to trace residual (glutaraldehyde¡A formaldehyde¡A neomycin¡A streptomycin and polymyxin B)¡A to any pertussis vaccine¡A or after previous administration of Hexaxim or a vaccine containing the same components or constituents. Vaccination with Hexaxim is contraindicated if the individual has experienced an encephalopathy of unknown aetiology¡A occurring within 7 days following prior vaccination with a pertussis containing vaccine (whole cell or acellular pertussis vaccines). In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria¡A tetanus¡A hepatitis B¡A poliomyelitis and Hib vaccines. Pertussis vaccine should not be administered to individuals with uncontrolled neurologic disorder or uncontrolled epilepsy until treatment for the condition has been established¡A the condition has stabilized and the benefit clearly outweighs the risk.,Hypersensitivity reaction¡A Anaphylactic reaction¡A Anorexia (decreased appetite)¡A Crying¡A somnolence¡A Abnormal crying (prolonged crying)¡A Convulsions with or without fever¡A Hypotonic reactions or hypotonichyporesponsive episodes (HHE)¡A Vomiting¡A Diarrhoea¡A Rash¡A Injection-site pain¡A injection-site erythema¡A injection-site swelling Irritability Pyrexia (body temperature ? 38.0¢XC)¡A Injection-site induration¡A Injection-site nodule Pyrexia (body temperature ? 39.6¢XC)¡A Extensive limb swelling.,2-8¢JÁ×¥úÁ×§K§N­á,Primary Vaccination: 3 doses of 0.5 mL to be administered at intervals of at least 4 weeks and as per schedules 6¡A 10¡A 14 weeks; 2¡A 3¡A 4 months; 3¡A 4¡A 5 months; 2¡A 4¡A 6 months. Booster vaccination second year of life at least 6 months after last priming dose.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Uknown ¨S¦³¸ê®Æ,[³X³æ]µL¸ê®Æ¡C,Unknown ¨S¦³¸ê®Æ,[³X³æ]µL¸ê®Æ¡C,IM;,,,,,
LDUP5,Lactulose,500mL DUPHALAC(667mg/mL) oral solution,ALIM,Chronic portal systemic encephalopathy¡A hepatic pre coma¡A hepatic coma¡A Chronic constipation.,Galactosemia¡A Gastrointestinal perforation¡A Risk of gastrointestinal perforation.,Common Gastrointestinal: Bloating symptom¡A Diarrhea¡A Epigastric pain¡A Flatulence¡A Nausea¡A Vomiting Musculoskeletal: Cramp Serious Endocrine metabolic: Hypernatremia¡A Hypokalemia,25¢J¥H¤U,Chronic constipation: adult: Initial: 10-45 mL; Maintain dose: 10-25 mL. 7-14 years: Initial: 15 mL; Maintain dose: 10-15 mL. 1-6 years: Initial: 5-10 mL; Maintain dose: 5-10 mL. infant: Initial: 5 mL; Maintain dose: 5 mL. Orally once daily in the morning. It takes about 48 hours for a normal bowel movement if there is no response after taking the medicine for two days¡A should consider increasing the dose. Hepatic encephalopathy: adult: Initial dosage: 30-50 mL orally 3 times daily. Maintenance dosage: Adjust every day to achieve 2 to 3 soft formed stools daily. <6years old Children & infant: Initial: 5ml orally 4 times daily for10-12 days. The second and third course of treatment will adjust the dose according to individual conditions. [Micromedex 20210101] Rectal route: Treatment and Prophylaxis of Hepatic encephalopathy: Usual dosage: Mix lactulose 300 mL with 700 mL water or NS and administer rectally via rectal balloon catheter; retain for 30 to 60 minutes. Repeat dosages: Enema may be repeated every 4 to 6 hours for reversal of coma stage; if inadvertently evacuated too promptly¡A repeat immediately. Conversion to oral: When the oral route is viable¡A initiate oral administration before rectal administration is terminated.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]Ãh¥¥´Á¶¡¨Ï¥Î¥»«~¹w´Á¤£·|¹ï­L¨à³y¦¨¼vÅT¡A¦]lactulose¦AÃh¥¥°ü¤k¤§¥þ¨­©Ê¼ÉÅS¶q·¥·L. ¦]¦¹¡AÃh¥¥´Á¶¡¥i¨Ï¥Î¥»«~.¦b²{¦³ªº¼Æ¾Ú¤¤µL·î§Î©Î­L¨à/·s¥Í¨à¬r©Ê. °Êª«¸ÕÅç¤¤µLÅã¥Üª½±µ©Î¶¡±µ¹ïÃh¥¥¡A­F­L/·s¥Í¨àµo®i¡A¤À®Y©Î²£«áµo®i¦³®`.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥»«~¹ï¥À¨ÅÁý¾iªº·s¥Í¨à©ÎÀ¦¨à¹w´ÁµL¥ô¦ó¼vÅT¡A ¦]lactulose¦b±Â¨Å°ü¤k¤§¥þ¨­©Ê¼ÉÅS¶q·¥·L. ¦]¦¹¡A±Â¨Å´Á¶¡¥i¨Ï¥Î¥»«~.,AC;PC;PO;RECT;WM;,,,,,
OPRM,Metoclopramide,Promeran 3.84mg,ALIM,Prophylaxis of nausea and vomiting¡A Gastroesophageal reflux disease¡A Gastroparesis due to diabetes mellitus.,History of tardive dyskinesia. Preexisting pheochromocytoma or other catecholamine-releasing paragangliomas; increased risk of hypertensive crisis. Sensitivity or intolerance to metoclopramide products.,Common Endocrine metabolic: Body fluid retention Gastrointestinal: Nausea (4.2% to 5.6% )¡A Taste sense altered (Nasal route¡A 15% )¡A Vomiting (1.4% to 2.1% ) Neurologic: Asthenia¡A Headache (4.2% to 5.2% )¡A Somnolence (Oral¡A 2.1% to 2.8%) Serious Neurologic: Neuroleptic malignant syndrome¡A Tardive dyskinesia,25¢J¥H¤U,Adult: 1-2 tablets TID before meals. The following does recommend is according to Micromedex (2022/12/06): Adult: Gastroesophageal reflux disease¡A After failure of conventional therapy: Continuous dosing¡A 10 to 15 mg orally 4 times daily given 30 minutes before meals and at bedtime for 4 to 12 weeks depending on endoscopic response; MAX dose¡A 60 mg/day; avoid use for longer than 12 weeks. Gastroparesis due to diabetes mellitus: Earliest symptoms of diabetic gastric stasis¡A 10 mg orally 4 times daily given 30 minutes before each meal and at bedtime for 2 to 8 weeks depending on symptomatic response; MAX dosage 40 mg/day; avoid use for longer than 12 weeks. Pediatric: Chemotherapy-Induced Nausea and Vomiting¡A Adjunct for Breakthrough: 0.1 to 0.2 mg/kg/dose orally every 6 hours; maximum 10 mg/dose. Gastroesophageal Reflux Disease: 0.1 to 0.15 mg/kg orally 4 times a day; maximum 10 mg/dose.,»Ý½Õ¾ã¾¯¶q,[Micromedex 20221206]Hepatic impairment (moderate or severe¡A Child-Pugh B or C) Diabetic Gastroparesis: 5 mg orally 30 minutes before each meal and at bedtime; Maximum: 20 mg/day Gastroesophageal Reflux Disease: 5 mg orally 30 minutes before each meal and at bedtime OR 10 mg 3 times daily; Maximum: 30 mg/day.,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Compatible,[¥é³æ]¦³ÃöÃh¥¥¤¤¤Î±Â¨Å´Á¤¤µ¹ÃÄªº¦w¥þ©Ê©|¥¼½T¥ß¡A©Ò¥H¦b¥¥°ü©Î¥i¯à¤wÃh¥¥ªº°ü¤k¤Î±Â¨Å´Á¤¤°ü¤k¡A­­©ó§PÂ_¨äªvÀø¤Wªº¦³¯q©Ê¶W¶V¦MÀI©Ê®É¡A¤~¥iµ¹ÃÄ¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¦³ÃöÃh¥¥¤¤¤Î±Â¨Å´Á¤¤µ¹ÃÄªº¦w¥þ©Ê©|¥¼½T¥ß¡A©Ò¥H¦b¥¥°ü©Î¥i¯à¤wÃh¥¥ªº°ü¤k¤Î±Â¨Å´Á¤¤°ü¤k¡A­­©ó§PÂ_¨äªvÀø¤Wªº¦³¯q©Ê¶W¶V¦MÀI©Ê®É¡A¤~¥iµ¹ÃÄ¡C,AC;PO;,,,,,1. ¿ðµo©Ê¹B°Ê»ÙÃª(Tarddive dyskinesia)µo¥Íªº­·ÀI»PÁ`²Ö¿n¾¯¶q¦³¥¿¬ÛÃö©Ê¡A¤ÀªR«á¦³20%¯f±w¨Ï¥Î¶W¹L12¶g¡A¬G¤£«ØÄ³ªø´Á(>12¶g)¨Ï¥Î¡A°£«D¸g¹Lµû¦ô¨äªvÀø®Ä¯q°ª©óTarddive dyskinesia¤§­·ÀI¡C 2. ¥X²{À@Åé¥~°Æ§@¥Î¯gª¬®É½Ð°±¤îµ¹ÃÄ¡C 3. ¨u¦³¤º¤Àªc²§±`(Gonadotropin¤ÎProlactin¤Àªc²§±`)ªº°Æ§@¥Î¡A¾É­PµL¤ë¸g¡B«ùÄò©Ê¨Å¥Ä¤Àªc¡B¨k¤l¤k¨Å¯g¡A­Y¦³³o¨Ç¯gª¬½Ð°±¤îµ¹ÃÄ¡C
IEPH4,Ephedrine,Ephedrine inj 40mg/1mL,CAVS,,¾AÀ³¯g:Treatment of anesthesia-induced hypotension Note: The use of ephedrine for the treatment of acute bronchospasm¡A Stokes-Adams syndrome (ie¡A presyncope/syncope) with complete heart block¡A narcolepsy¡A or depression has fallen out of favor given the availability of more effective agents for these conditions. °Æ§@¥Î: Cardiovascular: Angina pectoris¡A cardiac arrhythmia¡A hypertension¡A palpitations¡A tachycardia Central nervous system: Anxiety¡A confusion¡A delirium¡A dizziness¡A hallucination¡A headache¡A insomnia¡A intracranial hemorrhage¡A nervousness¡A precordial pain¡A restlessness¡A tension¡A vertigo Dermatologic: Diaphoresis¡A pallor Gastrointestinal: Anorexia¡A nausea¡A vomiting Genitourinary: Dysuria¡A urinary retention (males with prostatism) Neuromuscular & skeletal: Tremor¡A vesicle sphincter spasm¡A weakness Respiratory: Dyspnea ¸T§Ò:Hypersensitivity to ephedrine or any component of the formulation; angle-closure glaucoma; concurrent use of other sympathomimetic agents,,«Ç·Å,Bronchospasm¡A acute: 12.5 to 25 mg SUBQ/IM administered according to patient response Hypotension induced by anesthesia: IV: 5 to 25 mg/dose slow IV push repeated after 5 to 10 minutes as needed to maintain blood pressure,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,
ILEVET,Levetiracetam,Levetir inj 500mg/5mL,CNEU,,¾AÀ³¯g:Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years with epilepsy. As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults & children > 4 years with epilepsy. Adjunctive therapy in the treatment of myoclonic seizures in adults & adolescents from 12 years with Juvenile Myoclonic Epilepsy. Adjunctive therapy for patients > 16 years with Primary Generalized Tonic¡A Clonic Seizure (PGTCS). °Æ§@¥Î: Most common: Somnolence¡A asthenia. Others: dizziness¡A convulsion¡A headache¡A hyperkinesia. ataxia¡A tremor¡A amnesia¡A agitation¡A aggression¡A anger¡A anxiety¡A confusion¡A depression¡A emotional instability¡A hallucination¡A hostility¡A insomnia¡A irritability¡A or nervousness¡A mental disorder¡A personality disorders¡A thinking abnormal¡A suicide¡A suicide attempt & suicidal ideation¡A GI disturbances¡A anorexia¡A vertigo¡A accidental injury¡A infection¡A cough increased¡A rash¡A alopecia¡A diplopia¡A decreased number of RBC¡A WBC &/or blood platelets. Gastrointestinal: Loss of appetite (partial onset seizures¡A adults¡A 3% ; pediatrics¡A 13% )¡A Vomiting (partial onset seizures¡A pediatrics¡A 15% ) Immunologic: Infectious disease (partial onset seizures¡A adults¡A 13% ) Neurologic: Asthenia (partial onset seizures¡A adults¡A 14.7% ; pediatrics¡A 8.9% )¡A Dizziness (5% to 9% )¡A Headache (partial onset seizures¡A adults¡A 14% )¡A Somnolence (8% to 45% ) Psychiatric: Abnormal behavior¡A Depression (3% to 5% )¡A Feeling nervous (partial onset seizures¡A adults¡A 4% ; pediatrics¡A 10% )¡A Hostile behavior (partial onset seizures¡A adults¡A 2% ; pediatrics¡A 12% )¡A Mood disorder¡A Mood swings (2% to 6% ) Respiratory: Cough (partial onset seizures¡A adults¡A 2% ; pediatrics¡A 11% )¡A Nasopharyngitis (7% to 14% )¡A Pharyngitis (6% to 10% )¡A Rhinitis (partial onset seizures¡A adults¡A 4% ; pediatrics¡A 13% ) Other: Fatigue (primary generalized tonic-clonic seizures¡A 10% )¡A Pain (partial onset seizures¡A adults¡A 7% ; pediatrics¡A 6% ) ¸T§Ò: Patients with hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients of levetir.,,,Focal (partial) onset seizures and generalized onset seizures Initial: 500 mg twice daily; increase every 2 weeks by 500 mg/dose based on response and tolerability to a maximum of 1¡A500 mg twice daily (3000 mg/day),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) Levetiracetam is detected in breastmilk¡A with a mean milk/maternal plasma ratio of approximately 1; adverse effects in the nursing infants were not reported. Based on limited data¡A maternal use of levetiracetam appears to be safe for the nursing infant. However¡A the manufacturer cautions that due to the potential for adverse reactions in nursing infants¡A either nursing or the drug should be discontinued.,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¥²»Ýµ}ÄÀ¨ì¦Ü¤Ö100 mLªº¬Û®eµ}ÄÀ²G«á¡A«ØÄ³¥H15¤ÀÄÁ½wºCºwª`¡C,1. ¶È¨ÑÀR¯ß¿éª`¨Ï¥Î¡A«ØÄ³¾¯¶q¥²»Ýµ}ÄÀ¨ì¦Ü¤Ö100 mLªº¬Û®eµ}ÄÀ²G¤¤¡A¥H15¤ÀÄÁªºÀR¯ß¿éª`®É¶¡µ¹ÃÄ¡C 2.¥»«~µ}ÄÀ«áÀ³¥ß§Y¨Ï¥Î¡A­Y¦bµLµßÀô¹Ò¤U¾Þ§@¡A»P¬Û®eµ}ÄÀ²G¦b«Ç·Å«O¦s¦bPVC³U¤¤¡A¤Æ¾ÇÃ­©w©Ê¥iºû«ù24¤p®É¡C
IBEN,Belimumab,Benlysta inj 400mg,HIMM,Reducing disease activity in adult patients with active autoantibody positive SLE receiving standard therapy.,Hypersensitivity.,Infections. Hypersensitivity reaction; pyrexia¡A infusion-related reaction.,2-8¢JÁ×¥úÁ×§K§N­á,IVD¡A 10 mg/kg over 1 hour every 2 weeks for the first 3 doses and every 4 weeks thereafter.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,Human (and animal) data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,IVD: 4.8mL D/W,¡iH/S¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,X,Benlysta should be infused in 250mL infusion solution over a 1 hour period.,1. The total time from reconstitution of Benlysta to completion of infusion should not exceed 8 hours. 2. Benlysta should not be infused concomitantly in the same IV line with other agents. 3.The 400-mg single-use vial of Benlysta should be reconstituted with 4.8 mL of sterile water for injections to yield a final concentration of belimumab 80 mg/mL. 4.Do not shake. 5.Protect the reconstituted solution from sunlight.
OTRO,Topiramate,Trokendi XR 50mg,CNEU,Migraine prophylaxis. Epilepsy monotherapy or adjuvant therapy.,Recent alcohol use within 6 hours prior to or 6 hours after topiramate use. Metabolic acidosis with concomitant metformin use.,Common Dermatologic: Flushing (Pediatric¡A 5% ) Endocrine metabolic: Serum bicarbonate level abnormal (25% to 67% ) Gastrointestinal: Loss of appetite (10% to 24% )¡A Weight decreased (4% to 21% ) Immunologic: Infectious disease (2% to 8% ) Neurologic: Confusion (3% to 11% )¡A Dizziness (4% to 25% )¡A Impaired cognition (2% to 7% )¡A Impaired psychomotor performance (2% to 13%)¡A Memory impairment (3% to 12% )¡A Paresthesia (1% to 51% )¡A Reduced concentration span (2% to 10% )¡A Somnolence (6% to 29% ) Psychiatric: Feeling nervous (4% to 16% )¡A Mood disorder (4% to 11% ) Other: Fatigue (6% to 16% )¡A Fever (1% to 12% ) Serious Dermatologic: Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Endocrine metabolic: Hyperammonemia (Adolescent¡A 26% )¡A Hypohidrosis¡A Increased body temperature¡A Metabolic acidosis (Adult¡A 14% to 44%; pediatric¡A 9% to 77% ) Hepatic: Liver failure Neurologic: Drug-induced encephalopathy Ophthalmic: Angle-closure glaucoma¡A Glaucoma¡A Myopia¡A Visual field defect (Epilepsy¡A 0.1% to 1% ) Psychiatric: Suicidal thoughts Renal: Nephrolithiasis (Adult¡A 1% to 3% ) Other: Withdrawal symptom,25¢J¥H¤U¡AÁ×§K¨ü¼é¤Î¤é¥ú·Ó®g,Partial seizure or primary generalized tonic-clonic seizure¡A Initial monotherapy: 10 years older: First week¡A 50 mg orally once daily; second week¡A 100 mg once daily; third week¡A 150 mg once daily; fourth week¡A 200 mg once daily; fifth week¡A 300 mg once daily; sixth week and thereafter¡A 400 mg once daily. 6-10 years old: Initial¡A 25 to 50 mg orally once daily; may increase by 25 to 50 mg/day at 1-week intervals to usual maintenance dose of 200 to 400 mg/day. Minimum and maximum maintenance dose: 11kg or less: 150-250 mg/day; 12-22kg: 200-300 mg/day; 23-31kg: 200-350 mg/day; 32-38kg: 250-350 mg/day; up to 38kg: 250-400 mg/day. Partial seizure¡A primary generalized tonic-clonic seizure or Lennox-Gastaut syndrome¡A Adjunct: 6 to 16 years: Initial¡A 25 mg orally (1 to 3 mg/kg/day) once daily at nighttime for 1 week; increase by 1 to 3 mg/kg/day at 1- to 2-week intervals to achieve optimal response; maintenance¡A 5 to 9 mg/kg/day. 17 years or older: Initial¡A 25 to 50 mg orally once daily; may increase by 25 to 50 mg/day at 1-week intervals to usual maintenance dose of 200 to 400 mg/day. Migraine prophylaxis: 12 years or older: Initial¡A 25 mg orally once daily at nighttime for 1 week; titration¡A increase by 25 mg/day in weekly intervals to 100 mg/day¡A longer titration intervals may be used; dosage and titration rate should be based on clinical outcome.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,[¥é³æ] Topiramate ¬I¥Î©ó¥¥°ü®É¥i¹ï­L¨à³y¦¨¶Ë®`¡C·½¦ÛÃh¥¥µn¿ý¸ê®Æ®wªº¸ê®Æ«ü¥X¡A©ó¤l®c¤º´¿±µ¨ütopiramate ¼ÉÅSªºÀ¦¨à¦³¸û°ªªº®Bµõ©M/©ÎÃEµõ¡]¤fµõ¡^¤Î­L¨à¤p©ó§³®W¦~ÄÖµo¥Í­·ÀI¡C ¦b¦h­Ó°Êª«ª«ºØ¤¤¡Atopiramate ´¿¦b¨ã¦³Á{§É·N¸qªº¾¯¶q¤U¥B¥¼¤Þ°_¥ÀÅé¬r©Ê®É®i²{µo¨|¬r©Ê¡A¥]¬A­P·î­L©Ê¡C ¥u¦³·í¼ç¦b®Ä¯q³Ó¹L¼ç¦b­·ÀI®É¡A¤è¥i©óÃh¥¥´Á¶¡¨Ï¥Î¡C­Y©óÃh¥¥´Á¶¡¨Ï¥Î¦¹ÃÄ¡A©Î±wªÌ©óªA¥Î¦¹ÃÄ´Á¶¡¨ü¥¥¡AÀ³§iª¾±wªÌ­L¨à¥i¯à©Ó¨üªº¦MÀI¡C 20231117 ÃÄ«~¦w¥þ¸ê°T­·ÀI·¾³qªí¡G¤wª¾Ãh¥¥´Á¶¡¨Ï¥Î·|¾É­P­L¨àÄY­«¥ý¤Ñ·î§Î¡A¼Ú·ùEMA-PRAC»¡©ú¥i¯à¼W¥[«Äµ£¯«¸gµo¨|»ÙÃªªº­·ÀI¡A¥Ø«e¼Ú·ù«ØÄ³°£«D¨S¦³¨ä¥L¦X¾AªºªvÀø¤è¦¡¡A§_«hÃh¥¥´Á¶¡¤£À³¨Ï¥Îtopiramate¡A¨|ÄÖ°ü¤k¨Ï¥Î®ÉÀ³±Ä¨ú¦³®ÄÁ×¥¥±¹¬I¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] Topiramate ¥i¤Àªc©ó¤H¨Å¤¤¡C­÷¨Å¤¤À¦¨à¼ÉÅS©ó topiramate ¤¤ªº¼vÅT¤´¤£©ú¡C ­÷¨Å¹ïµo¨|©M°·±dªº¯q³B¡AÀ³³s¦P¥À¿Ë¦bÁ{§É¤W¹ï TROKENDI XR ªº»Ý¨D¡A¥H¤Î TROKENDI XR ©Î¼ç¦b¥ÀÅéª¬ªp¹ï­÷¨Å¤¤À¦¨à¥i¯à²£¥Íªº¥ô¦ó¤£¨}¤ÏÀ³¤@¨Ö¦Ò¶q¡C Ãö©ó¦bªc¨Å´Á¶¡±µ¨ü topiramate ªvÀøªº 5 ¦WÅöíw¤k©Ê±wªÌªº¦³­­¸ê®ÆÅã¥Ü¡AÃÄª«¦b¨Å¥Ä¤¤ªº¿@«×«Y»P¦b¥ÀÅé¦å¼ß¤¤ªº¿@«×¬Ûªñ¡C,AC;PC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°½¦Ån½Ð¾ãÁû§]ªA¡A½Ð¤ÅÅx©ó­¹ª«¤W¡B©CÄZ©Î«r¸H¡C¥»ÃÄ¥Ñ¤TºØ¤£¦PÄÀ©ñ®É¶¡ªº±±ÄÀ·L²É²Õ¦¨¡A¦]¦¹ºÞÄéªÌ¥i¥H©î½¦Ån¨Ï¥Î¡A¦ý¤£«ØÄ³©î½¦Ån«á¤À¦¸ªAÃÄ¡C
IFLUCEL,Purified Split Inactivated Influenza Virus,Flucelvax quad (»²¬y«Â¾A¬y·P¬Ì­]) 0.5mL/dose,HIMM,Active immunisation against influenza.,History of severe allergic reactions (e.g.¡A anaphylaxis) to any component of the vaccine.,Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome.,2-8¢XC.½Ð¤Å§N­á,IM¡A 0.5 mL¡A > or = 6 months (< 9 years who have not been vaccinated previously¡A the second dose can be given after 4 weeks.),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]­·ÀIºK­n ©Ò¦³Ãh¥¥§¡¨ã¦³¥X¥Í¯Ê³´¡B¬y²£©Î¨ä¥L¤£¨}µ²ªG¤§­I´º­·ÀI¡C¥Ø«eÃö©ó¥¥°ü±µºØFLUCELVAX QUADªº¼Æ¾Ú¤£¨¬¡A©|µLªk½T¥ß©óÃh¥¥´Á¶¡»P±µºØ¬Ì­]ªº­·ÀI¡C ©|¥¼°w¹ïFLUCELVAX QUAD¶i¦æ°Êª«µo¨|¬r©Ê¬ã¨s¡C¦³¶µFLUCELVAX¡]¤T»ù°t¤è¡^ªºµo¨|¬r©Ê¬ã¨s¡A¬ã¨s¹ï¶H¬°»Û©Ê¨ß¤l¡A©ó¥æ°t«e»PÃh¥¥´Á¶¡¬I¥´¡A¨C¦¸¬I¥´¾¯¶q¬°0.5²@¤É¡]¤HÅé³æ¾¯¶q¬°0.5²@¤É¡^¡C¸Ó¬ã¨sÅã¥ÜFLUCELVAX¡]¤T»ù°t¤è¡^¨Ã¥¼¹ï­L¨à¦³®`¡]½Ð°Ñ¨£8.1¼Æ¾Ú¡^¡C Á{§É¦Ò¶q: »P¯e¯f¦³Ãöªº¥ÀÅé¤Î¡þ©Î­F­L-­L¨à­·ÀI »P«D¥¥°ü¬Û¤ñ¡A¥¥°ü¦]¬y·P¦Ó¿©±w­«¯gªº­·ÀI¸û°ª¡C¿©±w¬y·Pªº¥¥°ü¥X²{¤£¨}§³®Wµ²ªGªº­·ÀI¸û°ª¡A¥]¬A¦­²£©M¤À®Y¡C °Êª«¼Æ¾Ú: ¤@¶µµo¨|¬r©Ê¬ã¨sÅã¥Ü¡A»Û©Ê¨ß¤l¦b¥æ°t«e1¡B3©M5¶g¤ÎÃh¥¥²Ä7©M20¤Ñ³z¹L¦Ù¦×ª`®g¬I¥´FLUCELVAX¡]¤T»ù°t¤è¡^¡C¨C¦¸¬I¥´¾¯¶q¬°0.5²@¤É¡]¤HÅé³æ¾¯¶q¬°0.5²@¤É¡^¡C¸Ó¶µ¬ã¨s¥¼Æ[¹î¨ì»P¬Ì­]¦³Ãöªº­L¨à·î§Î©ÎÅÜ²§¡A¥H¤ÎÂ÷¨Å«eµo¨|ªº¤£¨}¤ÏÀ³¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¥Ø«e¤£²M·¡FLUCELVAX QUAD¬O§_·|¤Àªc©ó¥À¨Å¤¤¡C ©|µL¼Æ¾Ú¥iµû¦ôFLUCELVAX QUAD¹ï©ó­÷¨ÅÀ¦¨à©Î¹ï¥À¨Å²£¶q¡þ¤Àªc¼vÅT¡C À³¾ãÅé¦Ò¶q­÷¨Å¹ï©ó¥®µ£µo¨|©M°·±dªº¯q³B¡B¥À¿Ë±µºØ¬Ì­]¤§Á{§É®Ä¯q¡BFLUCELVAX QUAD©Î¥À¿Ë¨­Åéª¬ªp¹ï¥À¨Å­÷Áý«Äµ£ªº¥ô¦ó¼ç¦b¤£¨}¼vÅT¡C ¹w¨¾©Ê¬Ì­]¥iÁ×§K¥À¿Ë¨­Åéª¬ªp©Î¬O¥À¨Å¤Àªc¨ü¨ì¬y·Pªº¼vÅT¡C,IM;,,,,,2¢XC¦Ü8¢XC.½Ð¤Å§N­á. À³·n®Ì§¡¤Ã«á¦A¬I¥´. ¥|ºØ¬y·P¯f¬r®è¦U§t¦³15·L§J¦å²y¾®¶°¯À¡GA/Washington/19/2020 (an A/Wisconsin/588/2019 (H1N1)pdm09-like virus)¡B A/Tasmania/503/2020 (an A/Cambodia/e0826360/2020 (H3N2)-like virus)¡B B/Darwin/7/2019 (a B/Washington/02/2019-like virus)¡B B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)¡C
IPER4,FSH 450IU + LH 225IU,Pergoveris 450 IU + 225 IU,HM,Infertility in male & female.,Pregnancy & lactation; enlargement of the ovaries or cysts not due to polycystic ovarian syndrome; gynaecological bleeding of unknown origin; tumors in the uterus¡A ovaries & breasts.,Ovarian hyperstimulation¡A ascites¡A hydrothorax¡A oliguria¡A hypotension¡A thromboembolism¡A hypersensitivity reactions¡A fever¡A nausea & vomiting¡A inj site reactions¡A unintentional multiple pregnancies.,2-8¢JÁ×¥úÁ×§K§N­á,FSH 150 IU + LH 75 IU daily¡A adjusted dosage after start treatment 7-14 days¡A each treatment cycle can be extended up to 5 weeks depending on the clinical condition. 5000-10000 IU of hCG or 250 mcg of r-hCG should be given after 24-48 hours of the last dose of Pergoveris.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,SC;,,,,,
OMEZA,Mesalazine,MezaVant XL 1200mg prolonged release,ALIM,Treatment of moderately active ulcerative colitis,U.S. labeling: Hypersensitivity to mesalamine¡A aminosalicylates¡A salicylates¡A or any component of the formulation (including suppository vehicle of vegetable fatty acid esters) Canadian labeling: Hypersensitivity to mesalamine¡A salicylates¡A or any component of the formulation; severe renal impairment (GFR <30 mL/minute/1.73 m2); severe hepatic impairment Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer¡A urinary tract obstruction¡A use in children <2 years of age (Asacol¡A Asacol 800¡A Mesasal¡A Pentasa¡A Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol¡A Asacol 800); renal parenchymal disease (Pentasa),>10%: Central nervous system: Headache (2% to 35%)¡A pain (?14%) Gastrointestinal: Abdominal pain (1% to 18%)¡A eructation (16%)¡A nausea (3% to 13%) Respiratory: Pharyngitis (11%),25¢J¥H¤U,2.4 to 4.8g (2 to 4 tablets) QD,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¨Î±wªÌ¸T§Ò¡A¥¼¦³¯S§O°w¹ï¨x©ÎµÇ¥\¯à¤£¥þ©Ò°µªº¸ÕÅç,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°ªø®Ä¸z·»½¤¦ç¿õ¡AÀ³¾ã²É§]ªA¡A¤£¥i«r¸H©Î©CÄZ¡CµLªk§]ªA±wªÌ¥i¦Ò¼{¨Ï¥Î¦P¦¨¥÷Colasa enema 2gm/100mL¡C
LCLO,Chloral hydrate,Clodrin 100mg/mL¡A 30mL oral solution,CNEU,Sedation¡A mechanically-ventilated patients OR sedation¡A procedural (eg¡A echocardiogram or EEG).,Marked liver or kidney impairment¡A severe heart disease¡A Severe gastritis¡A esophagitis¡A gastric ulcer or duodenal ulcer¡A Purpura¡A Allergic to Chloral hydrate or any component of the formulation¡A Patients with life safety due to risk of respiratory obstruction or disabled Patients with severe obstructive sleep apnea,Central nervous system: Abnormal gait¡A ataxia¡A confusion¡A delirium¡A dizziness¡A drowsiness¡A hallucinations¡A hangover effect¡A malaise¡A nightmares¡A paradoxical excitation¡A somnambulism¡A vertigo Dermatologic: Skin rash (including erythema¡A eczematoid dermatitis¡A urticaria¡A scarlatiniform exanthems) Endocrine & metabolic: Acute porphyria¡A ketonuria Gastrointestinal: Diarrhea¡A flatulence¡A gastric irritation¡A nausea¡A vomiting Hematologic & oncologic: Acute porphyria¡A eosinophilia¡A leukopenia,±K«ÊÀx¦s©ó25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,The sedative drug used before the non-painful procedure for children must be carried out in a medical institution and properly monitored. The dosage of medication must be strictly controlled according to different ages and weights of children. Electroencephalogram (EEG): Infants (1 month to <1 year) and children: 25-50 mg/kg orally. The total maximum dose does not exceed 100mg/kg and infants do not exceed 1g¡A children do not exceed 2g. Sedation before painless examination or treatment (administered 30-60 minutes before process): Infants (1 month to <1 year): 30-50 mg/kg orally. The total maximum dose does not exceed 100 mg/kg and the infant does not exceed 1 g. Children: 50-60mg/kg orally¡A if necessary¡A an additional 10-20mg/kg can be given after 30 minutes. The total maximum dose does not exceed 100 mg/kg and the child dose does not exceed 2 g.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]©úÅã¨x¥\¯à·l®`ªÌ¸T¥Î,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V no relevant animal data,¥é³æ¥¼¦³¬ÛÃö°O¸ü,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,¥é³æ¥¼¦³¬ÛÃö°O¸ü,PO;,,,,,½Ð±K«ÊÀx¦s©ó 25¢J¥H¤U¡A¤ð¶·¦B¦s¨ÃÁ×§K¶§¥úª½®g¡C ¶}«Ê«á¤§«O¦s´Á­­¬° 30 ¤Ñ¡AÀx¦s·Å«×¬° 25¢J¡A¥¼¨Ï¥Î§¹À³¥á±ó¡C
OQUEP,Quetiapine,Quelip XR 200mg,CNEU,Schizophrenia. Schizophrenia¡A Maintenance. Bipolar disorder¡A depressed phase¡A Acute management¡A monotherapy. Bipolar I disorder¡A Acute management¡A in combination with lithium or divalproex. Bipolar I disorder¡A Acute management¡A monotherapy. Bipolar I disorder¡A Maintenance¡A in combination with lithium or divalproex. Major depressive disorder.,Hypersensitivity to quetiapine or any component of the product. Anaphylactic reactions have been reported.,Common Cardiovascular: Increased diastolic arterial pressure (Pediatric¡A 40.6% )¡A Increased systolic arterial pressure (Pediatric¡A 15.2% )¡A Orthostatic hypotension (Up to 7% )¡A Tachycardia (Up to 6% ) Endocrine metabolic: Serum cholesterol raised (7% to 18% )¡A Serum triglycerides raised (8% to 28% )¡A Weight gain (3% to 28% ) Gastrointestinal: Abdominal pain (3% to 7% )¡A Constipation (2% to 11% )¡A Increased appetite (2% to 12% )¡A Indigestion (2% to 7% )¡A Nausea (Pediatric¡A 6% to 10% )¡A Vomiting (Pediatric¡A 7% to 8% )¡A Xerostomia (Adult¡A 9% to 44%; pediatric¡A 4% to 10% ) Hepatic: Increased liver enzymes (1% to 6% ) Musculoskeletal: Backache (3% to 5% ) Neurologic: Asthenia (Up to 10% )¡A Dizziness (8% to 19% )¡A Extrapyramidal disease (1.1% to 12.9% )¡A Headache (17% to 21% )¡A Insomnia (8% to 12% )¡A Lethargy (1% to 5% )¡A Somnolence (18% to 57% )¡A Tremor (2% to 8% ) Psychiatric: Agitation (6% to 20% ) Respiratory: Nasal congestion (3% to 5% )¡A Pharyngitis (4% to 6% ) Other: Fatigue (3% to 14% )¡A Pain (7% ) Serious Cardiovascular: Prolonged QT interval (0.1% to less than 1% )¡A Sudden cardiac death¡A Syncope (0.3% to 2% ) Endocrine metabolic: Diabetic ketoacidosis Gastrointestinal: Bowel obstruction¡A Pancreatitis Hematologic: Agranulocytosis¡A Leukopenia¡A Neutropenia (0.3% to 1.5% ) Immunologic: Anaphylaxis Neurologic: Seizure (0.05% to 0.5% )¡A Tardive dyskinesia Psychiatric: Suicidal thoughts Reproductive: Priapism Other: Neuroleptic malignant syndrome,30¢J¥H¤U,Schizophrenia (Acute): 300 mg orally in the evening on day 1 and titrate to usual maintenance dose between 400 to 800 mg once daily; dose increases may occur at intervals of at least 1 day in increments of up to 300 mg/day; Maximum dose 800 mg/day The safety of doses above 800 mg/day has not been evaluated in clinical trials. Bipolar disorder¡A depressed phase¡A Acute management¡A monotherapy: 50 mg orally once daily on day 1; 100 mg once daily on day 2; 200 mg once daily on day 3; and then 300 mg once daily on day 4¡A with doses given in the evening; usual and Maximum dose is 300 mg/day Bipolar I disorder¡A Acute management¡A in combination with lithium or divalproex: 300 mg orally in the evening on day 1; 600 mg in the evening on day 2; with further dosage adjustment to usual maintenance dose between 400 and 800 mg once daily beginning on day 3¡A depending on patient response and tolerance; Maximum dose 800 mg/day Major depressive disorder¡A Monotherapy: Initial¡A 50 mg orally once daily on days 1 and 2¡A 150 mg once daily on days 3 and 4¡A and 300 mg once daily thereafter¡A with discontinuation of previous antidepressant complete by day 7; may extend titration period to include 3 additional days¡A and reach 300 mg/day by day 8 and reduce to 150 to 200 mg/day for intolerance.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment: Initial dose¡A 50 mg/day; increase in increments of 50 mg/day depending on patient response and tolerance.[Micromedex:2020.06.24],µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,[¥é³æ]¥Ø«e¹ï©ó Quetiapine XR ¨Ï¥Î©ó¥¥°ü¡AÁÙ¨S¦³¾A·í¥B±±¨î¨}¦nªº¬ã¨s¡C ¦b¦³­­ªº¥Xª©¤åÄm¤¤¡A¨S¦³­«¤j·î§Î»PÃh¥¥´Á¶¡¼ÉÅS©ó quetiapine ¦³Ãö¡C ¦b°lÂÜ¤@¨Ç©ó¥¥´Á¨Ï¥Î qutiapine ªº¯f¤H«á¡A¦³¥X²{·s¥Í¨à§ÙÂ_¯g­Ô¸sªº®×¨Ò¡C ¦b°Êª«¸ÕÅçµo¥Í¹L­F­L-­L¨à¬r©Ê¡C ¥u¦³¦bªvÀø®Ä¯q¤j©ó¼ç¦b¦MÀI®É¤è¥i¦bÃh¥¥´Á¶¡¨Ï¥ÎQuetiapine XR¡C Ãö©ó¦bÃh¥¥´Á¶¡¨Ï¥Î quetiapine ªvÀø«äÄ±¥¢½Õ¯g¤Î¨ä¥Lºë¯«¯e¯fªº¥Xª©¸ê®Æ¦³­­¡C ¦b¤@¶µ«eÂ¤©ÊÆ[¹î¬ã¨s¤¤¡A21 ¦W¦bÃh¥¥´Á¶¡¼ÉÅS©ó quetiapine ¤Î¨ä¥Lºë¯«¬¡©ÊÃÄª«ªº°ü¤k¥Í¥XªºÀ¦¨à¨S¦³­«¤j·î§Î¡C ¦b42 ¦W¥ÑÃh¥¥´Á¶¡¨Ï¥Î quetiapine ªº°ü¤k©Ò¥Í¥XªºÀ¦¨à¤¤¡A¨S¦³­«¤j·î§Î³ø§i(¤@¶µ¬ã¨s¦³ 36 ¦W°ü¤k¡A6 ­Ó¯f¨Ò³ø§i)¡C ¥Ñ©óÃh¥¥´Á¶¡¼ÉÅS©ó¥»ÃÄªº¤H¼Æ¦³­­¡A³o¨Ç¤W¥««áªº¸ê®Æ¨Ã¤£¯à¥i¾aªº¦ô­pÀW²v©Î¨S¦³¤£¨}µ²ªG¡C ·íÃh¥¥ªº¤j¹«»P¨ß¤l¦b¾¹©xµo¥Í´Á¼ÉÅS©óquetiapine¡A¦b°ª¹FªvÀø«äÄ±¥¢½Õ¯gªº¤HÃþ³Ì°ª«ØÄ³¾¯¶q 2.4­¿ªº¾¯¶q¤U(MRHD¡A¨Ì mg/m2 ­pºâ¡A¨C¤Ñ 800 mg)¡A­L¨à­«¤j·î§Îªºµo¥Í²v¨Ã¥¼¼W¥[¡FµM¦Ó½T¹ê¦³­F­L/­L¨à¬r©ÊªºÃÒ¾Ú¡C ­L¨à°©Àf°©¤Æ©µ¿ðµo¥Í¦b±µ¨ü¤HÃþ³Ì°ª¾¯¶qªº 0.6 ¦Ü 2.4 ­¿¾¯¶qªº¤j¹«¡A¥H¤Î±µ¨ü¤HÃþ³Ì°ª¾¯¶qªº 1.2 ¦Ü 2.4 ­¿¾¯¶qªº¨ß¤l¡C ¦b¤HÃþ³Ì°ª¾¯¶qªº 2.4 ­¿¾¯¶q¤U¡A¨ß¤l­L¨àªºµÃ/ÛúÅs¦±(»´·L³n²ÕÂ´²§±`)µo¥Í²v¼W¥[¡A³o¨âºØ°Êª«§¡¦³­L¨àÅé­«´î»´ªº²{¶H¡C ¥ÀÅé¬r©Ê(§YÅé­«¼W¥[´î¤Ö¤Î/©Î¦º¤`)µo¥Í¦b±µ¨ü¤HÃþ³Ì°ª¾¯¶qªº 2.4 ­¿¾¯¶qªº¤j¹«¡A¥H¤Î±µ¨ü¤HÃþ³Ì°ª¾¯¶qªº 0.6 ¦Ü 2.4 ­¿¾¯¶q(©Ò¦³ªº¾¯¶q)ªº¨ß¤l¡C ¦b¤@¶µ¤j¹«©P²£´Á/²£«á¥Í´Þ¬ã¨s¤¤¡A¦b±µ¨ü¤HÃþ³Ì°ª¾¯¶qªº 0.01¡B0.12 ¤Î 0.24 ­¿¾¯¶qªvÀøªºÃh¥¥°ü¤k¨Ã¥¼Æ[¹î¨ì»PÃÄª«¦³Ãöªº¼vÅT¡CµM¦Ó¡A¦b¤@¶µªì¨B©P²£´Á/²£«á¥Í´Þ¬ã¨s¤¤¡A¦b¤HÃþ³Ì°ª¾¯¶qªº 3.0­¿ªº¾¯¶q¤U¡A¦³­L¨à©M¥J¹«¦º¤`¼W¥[¡A¥­§¡ºÛ­«´î»´ªº²{¶H¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Quetiapine XR ·|¤Àªc¨ì¤HÃþ¨Å¥Ä¤¤¡C±N Quetiapine XR §ë¤©±Â¨Å°ü®ÉÀ³¤p¤ß¡C ¦b¥Xª©ªº¯f¨Ò³ø§i¤¤¡Aquetiapine ¦b¨Å¥Ä¤¤ªº¿@«×±q¥iÀË´úµ{«×¨ì 170 £gg/L¡C ¦ô­pªºÀ¦¨à¾¯¶q¬O¸gÅé­«®Õ¥¿ªº¥À¿Ë¾¯¶qªº0.09%¦Ü 0.43%¡C ®Ú¾Ú¦³­­ªº¥À¿Ë/À¦¨à°t¹ï¼Æ(N=8)¡Aºâ¥XÀ¦¨à¨C¤é¾¯¶q±q¤p©ó 0.01 mg/kg (¥À¿Ë¾¯¶q°ª¹F¨C¤Ñ 400 mg)¦Ü 0.1 mg/kg (¥À¿Ë¾¯¶q°ª¹F¨C¤Ñ 400 mg)¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]«ùÄò©ÊÃÄ®Ä¿õÀ³¾ã²É§]ªA¡A ¤Å«rÄZ©ÎÀ£¸H¡C°|¤º¥t¦³¦P¦¨¥÷¤@¯ë¾¯«¬Seroquel 25mg¡C
ECLOO2,Clobetasol,Clobetasol ointment 0.05% 25gm,TDER,Psoriasis; recalcitrant eczema; lichen planus; discoid lupus erythematosus & other skin conditions which do not respond satisfactorily to less active steroids.,Hypersensitivity to clobetasol or any ingredient in the preparation. Primary scalp infection. Apply the smallest amount that will cover affected area. For topical use only; avoid contact with eyes and mucous membranes. Do not apply to face¡A scalp¡A axilla¡A groin¡A or intertriginous areas. Do not use if there is atrophy at the treatment site. Minimize contact to nonaffected areas of the body. Wash hands after use.,Common Dermatologic: Asteatotic eczema (2% )¡A Atrophic condition of skin (Up to 4.2% )¡A Burning sensation¡A Discomfort¡A Skin (1.3% )¡A Dry skin (1% to 2% )¡A Pruritus (0.5% to 3% ) Respiratory: Nasopharyngitis (5% )¡A Upper respiratory infection (8% ) Serious Endocrine metabolic: Hypothalamic-pituitary-adrenal axis dysfunction (Adult¡A 15% to 30.8% ; pediatric¡A 42% to 47% ) Neurologic: Intracranial hypertension¡A acute,25¢J¥H¤UÀx¦s,Apply sparingly to the affected area once daily or BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ]§³®W´Á¤£¥i¼sªx¨Ï¥Î¥»ÃÄ.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]µL¬ÛÃö°O¸ü.,EXT;,,,,,
EFOSN,Beclomethasone + Formoterol,(°®¯») Foster Nexthaler 100/6mcg/dose,ERSP,Regular treatment of asthma for patients not adequately controlled w/ inhaled corticosteroids & as needed inhaled short-acting £]2-agonist or on both inhaled corticosteroids & long-acting £]2-agonists.,Hypersensitivity.,Tremor¡A pneumonia (in COPD patients) Common Cardiovascular: Chest pain (1.9% to 3.2% )¡A Palpitations Gastrointestinal: Diarrhea (4.9% )¡A Nausea (4.9% )¡A Xerostomia (1.3% to 3.3% ) Neurologic: Dizziness (0.9% to 2.4% )¡A Headache (Less than 5% ; oral inhalation¡A 8% to 25% )¡A Insomnia (1.5% to 2.4% )¡A Tremor (1.9% to 8.6% ) Serious Cardiovascular: Cardiac dysrhythmia Respiratory: Death¡A Asthma-related¡A Exacerbation of asthma (Severe) Endocrine metabolic: Hypocortisolism secondary to another disorder¡A Type 2 diabetes mellitus Immunologic: Hypersensitivity reaction¡A Immunosuppression Ophthalmic: Cataract¡A Glaucoma Respiratory: Bronchospasm,¥´¶}«OÅ@³U«e30¢J¥H¤U,Asthma: Adult >=18 year old¡A Maintenance therapy: 1 or 2 inhalations BID. the maximum daily dose: 4 inhalations; Maintenance and reliever therapy: Patients take their daily maintenance dose and in addition take Foster Nexthaler as needed in response to asthma symptoms. Patients should be advised to always have Foster Nexthaler available for rescue use. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes¡A an additional inhalation should be taken. The maximum daily dose is 8 inhalations. COPD: Adult >=18 year old: 2 inhalations BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,No (limited) human data ¡V probably compatible,BECLOMETHASONE PREGNANCY RECOMMENDATION: Compatible FORMOTEROL PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,BECLOMETHASONE BREASTFEEDING RECOMMENDATION: Limited Human Data¡XProbably Compatible FORMOTEROL BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IH;INHL;,,,,,
OCOX,Isosorbide 5-Mononitrate,Coxine 20mg,CAVS,Prophylaxis of angina pectoris.,Marked hypotension¡A hypertrophic obstructive cardiomyopathy¡A constrictive pericarditis¡A aortic & mitral stenosis¡A increased intracranial pressure¡A MI with low filling pressure. Avoid sildenafil¡A tadalafil¡A vardenafil.,Transient headache¡A nausea¡A dizziness¡A weakness¡A vomiting¡A tachycardia¡A decreased BP¡A possible formation of methemoglobin¡A rarely allergic skin reactions. Neurologic: Dizziness (8% to 11% )¡A Headache (38% to 57% ),Á×¥ú¨¾¼öÀx¦s,Initial dose: 5-10 mg (1/4-1/2 tablets) BID separate 7 hours apart for day 1 and day 2¡A then increase to 20 mg BID for 2 days. Maintain dose: 20 mg BID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ] ¹ïÃh¥¥¤Î±Â¨Å´Áªº±wªÌ¡G¥Ñ©óIsosorbide-5-mononitrate ¯Ê¤Ö³o¤è­±ªºÁ{§É¸gÅç¡A¦]¦¹¸ÓÃÄ¤£À³µ¹¤©¦¹Ãþ±wªÌªA¥Î¡A­Y¥²­n®É¡AÀ³¿Ô¸ßÂå®v¡AÅv©y§Q¹ú¨Ï¥Î¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¹ïÃh¥¥¤Î±Â¨Å´Áªº±wªÌ¡G¥Ñ©óIsosorbide-5-mononitrate ¯Ê¤Ö³o¤è­±ªºÁ{§É¸gÅç¡A¦]¦¹¸ÓÃÄ¤£À³µ¹¤©¦¹Ãþ±wªÌªA¥Î¡A­Y¥²­n®É¡AÀ³¿Ô¸ßÂå®v¡AÅv©y§Q¹ú¨Ï¥Î¡C,PC;PO;,,,,,
OACH,Carisoprodol + Acetaminophen,Achelex 175/350mg,CNEU,Symptomatic relief of mild to moderate pain of acute musculoskeletal disorders e.g. stiff shoulder¡A sprains¡A strains¡A lumbago¡A arthralgia & myalgia.,Hypersensitivity to any components of the product.,Common Neurologic: Dermatologic: Pruritus (5% or greater ) Gastrointestinal: Constipation (5% or greater )¡A Nausea (adult¡A 34%; pediatric¡A 5% or greater )¡A Vomiting (adult¡A 15%; pediatric¡A 5% or greater ) Neurologic: Headache (1% to 10% )¡A Insomnia (1% to 7% )¡A Dizziness (7% to 8% )¡A Somnolence (13% to 17% ) Psychiatric: Agitation (5% or greater ) Respiratory: Atelectasis (5% or greater ) Serious Neurologic: Seizure Other: Drug abuse¡A Drug dependence¡A Withdrawal symptom Dermatologic: Generalized exanthematous pustulosis¡A acute¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Hepatic: Liver failure Respiratory: Pneumonitis,30¢J¥H¤UÁ×¥ú,Adult : 1-2 tablets QID¡A after meals or before sleeping.,»Ý½Õ¾ã¾¯¶q,[Micromedex20200922] Acetaminophen: Hepatic impairment(severe¡A including active liver disease):contraindicated. [Micromedex20200922] Carisoprodol: Hepatic impairment: consider lower initial doses in severe hepatic impairment; increase gradually as needed and tolerated.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V no relevant animal data,Acetaminophen: Human Data Suggest Low Risk Carisoprodol: Limited Human Data - No Relevant Animal Data [¥é³æ]¥¼¦³¬ÛÃö»¡©ú,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Acetaminophen: Compatible Carisoprodol: Limited Human Data - Probably Compatible [¥é³æ]¥¼¦³¬ÛÃö»¡©ú,AC;AC15;PC;PO;WM;,,,,,
OMOC,Flupentixol + Melitracen,Mocalm 0.5/10mg (¥Ã±dºü),CNEU,Treat mental depressive and anxious symptoms,Hypersensitivity to any components of the product,Restlessness¡A insomnia¡A Suicidal tendency.,25¢J¥H¤U,Adults: 0.5/10mg(1 Tablet) in the morning and afternoon. The dose may be increased to 2 TABlets in the morning dose if need. Elderly: 0.5/10mg(1 Tablet) in the morning. Maintenance dosage: 0.5/10mg(1 Tablet) in the morning. If patients who have severe anxiety and insomnia could consider adding on sedatives.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤£¥i¨Ï¥Î©ó¥¥°ü»P±Â¨Å°ü,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¤£¥i¨Ï¥Î©ó¥¥°ü»P±Â¨Å°ü,AC;AC15;PO;WM;,,,,,
OAKY,Netupitant + Palonosetron,Akynzeo 300/0.5mg,CNEU,Chemotherapy-induced nausea and vomiting¡A Acute and delayed; Prophylaxis.,Specific contraindications have not been determined.,Common Dermatologic: Erythema (3% ) Gastrointestinal: Constipation (3% )¡A Indigestion (4% ) Musculoskeletal: Asthenia (8% ) Neurologic: Headache (9% ) Other: Fatigue (4% to 7% ) Serious Other: Serotonin syndrome,®e³\½d³ò15-30¢J¡A25¢J¬°¨Î,Highly emetogenic chemotherapy (including cisplatin-based regimens): Administer netupitant 300 mg/palonosetron 0.5 mg (1 capsule) orally 1 hour prior to chemotherapy on day 1; coadminister dexamethasone 12 mg orally 30 minutes prior to chemotherapy on day 1¡A and 8 mg QD through day 2 to day 4. Anthracycline and cyclophosphamide-based regimens and other regimens not highly emetogenic: Administer netupitant 300 mg/palonosetron 0.5 mg (1 capsule) orally 1 hour prior to chemotherapy on day 1; coadminister dexamethasone 12 mg orally 30 minutes before chemotherapy on day 1.,»Ý½Õ¾ã¾¯¶q,Hepatic impairment¡A severe (Child-Pugh score greater than 9): Avoid use [Micromedex 20201007],»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Netupitant: ¨S¦³¸ê®Æ Palonosetron: No Human Data - Animal Data Suggest Low Risk [¥é³æ]¤W¥¼°w¹ïÃh¥¥¤k©Ê¶i¦æ¥R¤À¥B¹ï·Ó¨}¦nªºAkynzeo¬ã¨s...²¤...µ¹»P¥À¹«³Ì°ª¦Ü¬Û·í©ó3.7­¿ ¤HÅé«ØÄ³¾¯¶qAUCªºnetupitant¾¯¶q®É¡A¥®¹«¨Ã¥¼Æ[¹î¨ì¤£¨}¤ÏÀ³ªºµo¥Í.¦bpalonosteronªº°Êª«¥Í´Þ ¬ã¨s¤¤¡A©ó­L¨àªº¾¹©x¥Í¦¨¶¥¬q¤À§Oµ¹¤©¤j¹«¤Î¤j¥Õ¨ß¤fªA¬Û·í©ó¹F¤HÅé¤fªA«ØÄ³¾¯¶q921»P 1841­¿ÃÄª«®É¡A¥¼Æ[¹î¨ì¼vÅT­F­L-­L¨àªºµo¨|.AkynzeoÀ³¦b¼ç¦b§Q¯q°ª©ó­L¨à¼ç¦b­·ÀI®É¡A¤è¥i ©óÃh¥¥´Á¶¡¨Ï¥Î.,Unknown ¨S¦³¸ê®Æ,Netupitant: ¨S¦³¸ê®Æ Palonosetron: No Human Data - Probably Compatible [¥é³æ]¥Ø«e©|¥¼ª¾Akynzeo¬O§_·|¶i¤J¤HÅé¨Å¥Ä¤¤.¥Ñ©ó³\¦hÃÄª«·|¶i¤J¤HÅé¨Å¥Ä¤¤¡A¥Bpalonosteron ¦b¤j¹«­PÀù©Ê¬ã¨s¤¤Åã¥Ü¦³¼ç¦b­P¸~½F©Ê¡A¬GÀ³¦Ò¶qÃÄª«¹ï©ó¥À¿Ëªºªº­«­n©Ê¨Ó¨M©w¬O§_°±¤î ­÷¨Å©Î°±ÃÄ.,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½¦Ån¤¤§t¦³¤T¤ù¤pÃÄ¿õ¤Î¤@²É¤p½¦Ån¡A­Y¯f±w¦³»Ý¨D¥i¥H©î¶}«á¨Ì§Ç§]ªA¡C¦ý¤£«ØÄ³¦A±N¤pÃÄ¿õ¤Î¤p½¦Ån©î¶}©Î¿i¯»¡C
OKLA5X,Clarithromycin,Klaricid XL 500mg,QANB,As an antibacterial agents for Clarithromycin-sensitive bacterial infections. Treatment of Lower respiratory tract infections¡A for example acute and chronic bronchitis and pneumonia; Upper respiratory tract infections¡A for example sinusitis and pharyngitis.,Patients with known hypersensitivity to macrolide antibiotic drugs or any of the excipients. Prolonged Release Tablets are contraindicated in patients with creatinine clearance less than 30 mL/min. Concomitant administration of clarithromycin and any of the following drugs: cisapride¡A pimozide¡A astemizole¡A terfenadine¡A or domperidone¡A due to the risk of QT prolongation or ventricular cardiac arrhythmia¡A including torsades de pointe Concomitant administration of clarithromycin and any of the following drugs: ergot alkaloids¡A like ergotamine or dihydroergotamine¡A due to the risk of ergot toxicity. Concomitant administration of clarithromycin and midazolam. Patients with a history of QT prolongation or ventricular cardiac arrhythmia¡A including torsades de pointe. Patients with severe hepatic failure with renal impairment. Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CP3A4¡A (lovastatin or simvastatin)¡A due to the risk of myopathy¡A including rhabdomyolysis. Concomitant administration of clarithromycin (or other strong CYP3A4 inhibitors) and Colchicine. Concomitant administration of clarithromycin with ticagrelor or ranolazine.,Common Gastrointestinal: Abdominal pain (1% to 8% )¡A Diarrhea (2% to 9% )¡A Disorder of taste (8% to 19% )¡A Indigestion (4% )¡A Nausea (3% to 28% )¡A Vomiting (1% to 25% ) Neurologic: Headache (up to 9% ) Serious Cardiovascular: Death¡A Cardiovascular¡A out of hospital¡A Prolonged QT interval (less than 1% ) Dermatologic: Immunoglobulin A vasculitis¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Gastrointestinal: Clostridium difficile diarrhea Hepatic: Hepatitis (greater than or equal to 1% )¡A Liver failure Immunologic: Anaphylaxis¡A Drug reaction with eosinophilia and systemic symptoms Neurologic: Cerebrovascular disease,30¢J¥H¤U¡AÁ×¥úÀx¦s¡C,Adults: The usual recommended dose: 500mg (1 prolonged release tablet) to be taken with food. In more severe infections: can be increased to 1000mg (2 prolonged release tablets) taken as one dose daily. The usual duration of treatment is 7 to 14 days. Children > or = 12 years old: as for adults. Children < 12 years old: Not suitable for children younger than 12 years. An alternative formulation of clarithromycin suitable for children should be used in this patient population¡A like suspension.,»Ý½Õ¾ã¾¯¶q,Clarithromycin ¥D­n¥Ñ¨xÅ¦±Æªn¡C¦]¦¹¹ï¨x¥\¯à¤£¥þ¤§¯f¤HÀ³ÂÔ·V¨Ï¥Î¦¹ºØ§Ü¥Í¯À¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ] Clarithromycin¥Î©óÃh¥¥´Á¶¡ªº¦w¥þ©Ê©|¥¼«Ø¥ß¡C ¦]¦¹¡A­Y¥¼¥J²Ó¿Å¶q§Q¯q»P­·ÀI¡A¥»«~¤£«ØÄ³¨Ï¥Î©óÃh¥¥°ü¤k¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ] Clarithromycin¥Î©ó±Â¨Å´Á¶¡ªº¦w¥þ©Ê©|¥¼«Ø¥ß¡C Clarithromycin·|¤Àªc¨ì¤HÃþ¥À¨Å¤¤¡C,PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A½Ð¾ã²É§]ªA¡A¤£¥i¼·¥b©Î¿i¯»¡C ¥»ÃÄ«ØÄ³ÀHÀ\¨Ï¥Î¡C
OTAI,Nemonoxacin,Taigexyn 250mg,QANB,Treatment of infections¡A sensitive to nemonoxacin in adults.,Allergic to any component of this drug¡A or to other quinolones. Pregnant¡A breastfeeding women¡A or children.,Gastrointestinal Diseases: Nausea (2.5%)¡A Diarrhea (1.3%)¡A Vomiting (1.2%) Blood and Lymphatic System Diseases: Neutropenia (1.9%) Nervous system diseases: Dizziness (1.9%)¡A Headache (1.0%) Other: ALT (SGPT) increased (4.4%)¡A Reduction in white blood cell count (2.1%)¡A AST (SGOT) increased (1.9%)¡A AST (SGOT) increased ( 1.9%),Àx¦s°®Àê³B¡A·Å«×¤£¥i¶W¹L25¢J,Adults: 500mg (2 capsules) once a day on an empty stomach (take at least two hours before or at least two hours after eating) for 7-10 days.,µL»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¥þ¡G¥»ÃÄ«~¥Î©ó¨x¥\¯à¤£¥þ¯f¤HªºÀø®Ä©M¦w¥þ©Ê©|¥¼½T©w¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥»ÃÄ«~¥Î©óÃh¥¥¤k©Êªº¦w¥þ©Ê©|¥¼½T¥ß¡A¤£¯à½T«OÃh¥¥¤k©Êªº¥ÎÃÄ¦w¥þ¡A©Ò¥HÃh¥¥©Î¦³¥i¯àÃh¥¥ªº¤k©Ê¸T¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥»ÃÄ«~¥Î©ó­÷¨Å¤¤°ü¤kªº¦w¥þ©Ê©|¥¼½T¥ß¡A¤£¯à½T«O­÷¨Å¤¤°ü¤kªº¥ÎÃÄ¦w¥þ¡A©Ò¥H­÷¨Å¤¤°ü¤k¸T¥Î¡C ¥u¦³·í¹ï­÷¨Å¤¤°ü¤k¼ç¦b¯q³B¤j©ó¼ç¦b¦MÀI®É¤~¯à±N¥»ÃÄ«~¥Î©ó­÷¨Å¤¤°ü¤k¡A¦ýÀ³¼È°±­÷¨Å¡C,AC;PO;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¥»ÃÄ¥H¤ô¾ã²É§]ªA¡C 1. ¤Å»PÅKÆQ¡B¶t¤ù¡B¨î»Ä¾¯¡B§t©@°Ø¦]¤Î¨Å»s«~ªº­¹ª«¨ÖªA 2. ­«¯g¦ÙµL¤O±wªÌ¤£«ØÄ³¨Ï¥Î
ISONV,Sulphur hexafluoride microbubbles,SonoVue inj 60.7mg,SCAN,Echocardiography. Ultrasonography of liver¡A To characterize focal liver lesions.,Hypersensitivity to sulfur hexafluoride or any component of the formulation.,Common Gastrointestinal: Nausea (0.5% ) Neurologic: Headache (1% ) Serious Cardiovascular: Cardiac arrest¡A Chest pain (0.2% )¡A Shock¡A Syncope¡A Ventricular fibrillation¡A Ventricular tachycardia Immunologic: Anaphylaxis (0.01% )¡A Hypersensitivity reaction (0.01% ) Neurologic: Seizure Respiratory: Respiratory arrest,Àx¦s©ó25¢J,Cardiovascular imaging: 2 mL IV followed by a 5 mL 0.9%NaCl flush; may administer a second 2 mL IV dose followed by a 5 mL 0.9%NaCl flush during the same imaging session to prolong image enhancement. Hepatic ultrasonography: 2.4 mL IV during the procedure; may administer a second 2.4 mL dose during a single examination¡A if needed. Follow injection with an IV flush using 5 mL 0.9%NaCl for injection.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¥Ø«e¨S¦³SonoVue¨Ï¥Î©ó¥¥°üªº¸ê®Æ¨Óµû¦ô»PÃÄ«~¬ÛÃöªº­·ÀI¡C °Êª«¥Í´Þ¸ÕÅçÅã¥Ü©óÃh¥¥¤j¹«©M¨ß¤lªº¾¹©x¥Í¦¨´Á¶¡¡A¨Ì¨äÅéªí­±¿n¡A¤À§Oµ¹¤©¤»¬t¤Æ²¸·Lªw¦Ü¤Ö10©M20­¿ªº¤HÃþ³Ì¤j«ØÄ³¨Ï¥Î¾¯¶q4.8mL¡A¨Ã¨S¦³µo²{¹ï¨e­Ìªºµo¨|²£¥Í¤£¨}¼vÅT¡C ¦b¬ü°êªº¤@¯ë±Ú¸s¡A­«¤j¥X¥Í¯Ê³´(major birth defect)¤Î¬y²£ªº­I´º­·ÀI(backgroung risk)¦ô­p¤À§O¬°2~4%¤Î15~20%¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼µû¦ôSonoVue©ó¤HÅé¨Å¥Ä¤¤ªº¼ÉÅSµ{«×¡B¹ï­÷¨ÅÀ³¦Óªº¼vÅT¡B©Î¹ï¨Å¥Ä¤Àªc¼vÅTªº¼Æ¾Ú¡C À³¦P®É¦Ò¼{­÷¨Å¹ïÀ¦¨àµo¨|¤Î°·±dªº¯q³B¡B¥ô¦ó³Q­÷¨ÅªºÀ¦¨à¥i¯à¦]SonoVue©Î¥À¿Ë­ìµo¯e¯f¦Ó²£¥Íªº°Æ§@¥Î¡C,IVD;IVPUSH;,ÀH³fªþµ¹ªº¥Í²z­¹ÆQ¤ôª`®g²G5mL,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,,1. ¨Ï¥Î¼t°ÓÀH³fªþµ¹ªº¥Í²z­¹ÆQ¤ôª`®g²G»P¬f®Ôª`®g¾¹¡A¨Ì·Ó¥é³æ¶i¦æ°t»s¡C°t»s§¹¦¨«á«Ç·Å«O¦s¡A¶·©ó3¤p®É¤º¨Ï¥Î¡C­Y°t»s§¹¨S¦³¥ß§Y¨Ï¥Î¡AÀ³·n®ÌÃÄª«¼Æ¬í¨Ï·Lªw­«·sÄa¯B¡C 2. ¥»ÃÄ¤£¥i°Ê¯ß¤ºµ¹ÃÄ 3. µ¹ÃÄ«á½Ð±K¤ÁÆ[¹î¯f±w¤ÏÀ³¦Ü¤Ö30¤ÀÄÁ¡A¤j¦h¼ÆÄY­«ªº¤£¨}¤ÏÀ³¦b¥ÎÃÄ«á30¤ÀÄÁ¤ºµo¥Í¡C
IVEKS,Remdesivir,Veklury (¦Û¶O) inj 100mg (­á´¹),QANB,Hospitalized patients of COVID-19,History of clinically significant hypersensitivity to remdesivir or any component of the product.,Common Gastrointestinal: Nausea (3% to 7% ) Serious Cardiovascular: Cardiac arrest Hepatic: ALT/SGPT level raised (2% to 7% )¡A Aspartate aminotransferase serum level raised (3% to 6% )¡A Hepatotoxicity Immunologic: Anaphylaxis¡A Hypersensitivity reaction (Less than 2% ) Other: Infusion reaction,30¢J¥H¤U,Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement. Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 10 days. (12 years or older and at least 40 kg) Patients not requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 5 days; may treat for up to 10 days if patient does not demonstrate clinical improvement (12 years or older and at least 40 kg) Patients requiring invasive mechanical ventilation and/or ECMO: 200 mg IV infusion on day 1¡A then 100 mg IV infusion once daily for a total of 10 days Children <12 years: 3.5 kg to <40 kg: IV: Loading dose: 5 mg/kg/dose on day 1¡A followed by 2.5 mg/kg/dose once daily,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¥Ø«e¥¼¦³¨x¥\¯à¤£¥þªºÃÄª«°Ê¤O¾Ç¡C¶}©l¨Ï¥Î«e»P±µ¨üªvÀø´Á¶¡À³ÀËÅç¨xÅ¦¥\¯à¡C [Micromedex] Consider discontinuation if ALT levels increase to greater than 10x ULN. Discontinue if ALT elevation is accompanied by signs or symptoms of liver inflammation.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥u¦³¦b¼ç¦b®Ä¯q¶W¶V¼ç¦b­·ÀIªº±¡ªp¤U¡A¤~¥i¹ï¥¥°ü©Î¥i¯àÃh¥¥ªº°ü¤k§ë¤©remdesivir¡C ¦b¥HÃh¥¥¤§¤j¹«©M¨ß¤l©Ò¶i¦æªº­F­L - ­L¨àµo¨|¼vÅT¬ã¨s¤¤¡AIV §ë¤©¾¯¶q°ª¹F20²@§J / ¤½¤çªºremdesivir¡i¨ä¥D­n´`Àô¥NÁÂª«¡]®ÖäÃþ¦üª«¡^ªº¥þ¨­¼ÉÅS¶q¡]AUC¡^¬Û·í©ó®Ö­ã¾¯¶q©Ò¹F¨ì¤§¼ÉÅS¶qªº4­¿¡^¡j¨Ã¥¼¹ï­F­L-­L¨àªºµo¨|³y¦¨¥ô¦ó¼vÅT¡C ¦b¤@¶µ¥H¥À¤j¹«©Ò¶i¦æªº¥Í¨|¤O»P¦­´Á­F­Lµo¨|¼vÅT¬ã¨s¤¤¡A©óÀR¯ß§ë¤©remdesivir 10²@§J/¤½¤ç¡i¨ä¥D­n´`Àô¥NÁÂª«¡]®ÖäÃþ¦üª«¡^ªº¥þ¨­¼ÉÅS¶q¡]AUC¡^¬Û·í©ó®Ö­ã¾¯¶q©Ò¹F¨ì¤§¼ÉÅS¶qªº1.3­¿¡j¤§«á¡A´¿Æ[¹î¨ì¶ÀÅé¡B­F­LµÛ§É¤Î¦s¬¡­F­L´î¤Öªº²{¶H¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]À³Åv¿ÅªvÀøªº®Ä¯q»PÁý­÷¥À¨Åªº®Ä¯q¡AµM«á¨M©wÄ~Äò©Î°±¤î­÷¨Å¡C ¦b°Êª«¬ã¨s¡]¤j¹«¡^¤¤¡A´¿¦b§ë¤©remdesivir¤§¥À¹«©Ò­÷¨Åªº¥J¹«Åé¤ºÀË¥Xremdesivir¤Î¨ä¥NÁÂª«¡A³o¥i¯à¬Oremdesivir¥X²{©ó¥À¨Å¤¤©Ò­P¡C,IVD;,19mLª`®g¥Î¤ô,¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¹ï¦¨¤H»PÅé­«¤j©ó 40¤½¤çªº¨àµ£¡A²Ä1¤Ñªº§ëÃÄ(Remdesivir 200mg)À³¨Ï¥Î2¤ä¤p²~¡A¨ÃÀ³±N¨C¤ä¤p²~¤¤ªº20mL·»²G(¦@40mL)¥[¤J¥Í²z­¹ÆQ¤ô¤¤¡A¨ÏÁ`Åé¿n¹F¨ì100mL©Î250mL¡C¥H30-120¤ÀÄÁªº®É¶¡ÀR¯ß¿éª`¡C ¦Ü©ó²Ä2¤Ñ°_ªº§ëÃÄ(Remdesivir 100mg)¡A«hÀ³±N1¤ä¤p²~¤¤ªº20mL·»²G¥[¤J¥Í²z­¹ÆQ¤ô¤¤¡A¨ÏÁ`Åé¿n¹F¨ì100mL©Î250mL¡C¥H30-120¤ÀÄÁªº®É¶¡ÀR¯ß¿éª`¡C,1.±N19mLª`®g¥Î¤ô¥[¤J¤p²~¤¤¡A¥ß§Y¦A«×®¶·n30¬í¡CÀR¸m2-3¤ÀÄÁ¤§«á¡AÀ³½T»{¤p²~¤¤ªº·»²G¬O§_¼á²M(¿@«×¡G5mg/mL)¡C¦pªG¤p²~¤¤ªº¤º®eª«¥¼§¹¥þ·»¸Ñ¡AÀ³­«½Æ®¶·n¤p²~¡A¨Ï¤º®eª«¼á²M¡C 2.¿éª`§¹¦¨¤§«á¡A½Ð¥Î¦Ü¤Ö30²@¤Éªº0.9%¥Í²z­¹ÆQ¤ô¨R¬~¡C 3.¥Hª`®g¥Î¤ô½Õ»s¤§«á¡Aµ}ÄÀªºremdesivir·»²G¦b20-25¢Jªº·Å«×¤UÀ³©ó4¤p®É¤º¶i¦æ»s³Æ¡A¦b2-8¢Jªº·Å«×¤UÀ³©ó24¤p®É¤º¶i¦æ»s³Æ¡C 4.»s³Æ¦nªºµ}ÄÀ·»²G¦b«Ç·Å(20-25¢XC)¤U¥iºû«ù¦w©w4¤p®É¡A¦b2-8¢XCªº¦B½c¤¤¥iºû«ù24¤p®É¡C
EPOP5,Polymyxin B + Neomycin + Prednisolone,Poly-Pred oph susp 5mL,TOPH,,¾AÀ³¯g:Inflammatory ocular conditions: Management of corticosteroid-responsive inflammatory ocular conditions where bacterial infection or a risk of bacterial infection exists °Æ§@¥Î: Hypersensitivity: Hypersensitivity reaction Ophthalmic: Glaucoma¡A increased intraocular pressure¡A optic nerve damage (infrequent)¡A subcapsular posterior cataract ¸T§Ò:Hypersensitivity to neomycin¡A polymyxin B¡A prednisolone¡A or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis¡A vaccinia¡A varicella); mycobacterial ophthalmic infection; fungal diseases of ocular structures.,,15-25 C,Suspension: Eye drops 1 drop 3-4 hrly. The frequency may be increased in severe disease; frequency should decrease as signs and symptoms improve.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
HCVDA04,Viekirax + Exviera + Ribavirin (1a/24¶g),HCVDAA0004(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1a/24¶g,QANB,,,,,,,,,,,,,,,,,,,
LATH,Ketotifen,Athmin syrup 0.2mg/mL¡A 60mL,HIMM,Bronchial asthma¡A allergic bronchitis¡A prevention of asthma and hay fever symptoms¡A prevention and treatment of allergic rhinitis or allergic skin reactions.,Hypersensitivity to ketotifen products or benzoate compounds,Common Neurologic: Headache (10%-25%) Respiratory: Pharyngitis¡A Rhinitis (10%-25%) Other: Influenza,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Children 6 months to 3 years: 0.25 mL/kg BID. Children >3 years: 5 mL BID. Patients sensitive to sedation: Initial: half of the recommended dose once daily or in 2 divided doses for 5 days; and up to dose to target dose in 5 days.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,[¥é³æ]¥¼¸ü¬ÛÃö¸ê®Æ,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥¼¸ü¬ÛÃö¸ê®Æ,AC;AC15;PC;PO;WM;,,,,,
ECOLO5,Hydroquinone + Tretinoin + Dexamethasone,Color cream 5gm,TDER,Hyperpigmentation of skin,Hypersensitivity to hydroquinone or any component of the formulation.,Common Dermatologic: Burning sensation¡A Contact dermatitis¡A localized¡A Erythema,25¢J¥H¤UÀx¦s,Hyperpigmentation of skin apply 1-2 times at night,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human data suggest risk in 1st trimester,Hydroquinone: Limited Human Data - Probably Compatible. Tretinoin: Contraindicated - 1st Trimester. Dexamethasone: Compatible - Maternal Benefit >> Embryo¡VFetal Risk.,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Hydroquinone: No Human Data - Probably Compatible. Tretinoin: No Human Data - Probably Compatible. Dexamethasone: No Human Data - Probably Compatible.,EXT;,,,,,
OOKW,Omeprazole,OKWE 20mg,ALIM,Ulcer of duodenum. Gastroesophageal reflux disease. Gastric ulcer. Erosive esophagitis. Zollinger-Ellison Syndrome,Concomitant use of rilpivirine-containing products. Hypersensitivity to any component of the product or to substituted benzimidazoles; anaphylaxis and acute interstitial nephritis have been reported.,Common Dermatologic: Rash (2% ) Gastrointestinal: Abdominal pain (5% )¡A Constipation (2% )¡A Diarrhea (4% )¡A Flatulence (3% )¡A Nausea (4% )¡A Regurgitation¡A Acid (2% )¡A Vomiting (3% ) Neurologic: Asthenia (2% )¡A Dizziness (2% )¡A Headache (7% ) Respiratory: Upper respiratory infection (Adult¡A 2% ) Other: Fever (1 to less than 2 years¡A 33% ) Serious Dermatologic: Cutaneous lupus erythematosus¡A Erythema multiforme¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis Endocrine metabolic: Hypomagnesemia Gastrointestinal: Atrophic gastritis¡A Clostridium difficile diarrhea¡A Fundic gland polyposis of stomach¡A Pancreatitis Hematologic: Hemolytic anemia Hepatic: Hepatic encephalopathy¡A Hepatic necrosis¡A Liver failure Immunologic: Anaphylaxis Musculoskeletal: Fracture of bone¡A Hip fracture¡A Rhabdomyolysis Renal: Tubulointerstitial nephritis¡A acute Other: Angioedema,30¢J¥H¤UÁ×¥ú¡A¥»«~©È¼é¡A½Ð°È¥²±N²~»\ºò«Ê,Peptic or duodenal ulcer: adult¡A initial 20 mg QD for 2 weeks; if necessary¡A 20- 40mg QD for another 2 weeks Gastric ulcer & GERD: 20 mg QD for 4 weeks; if necessary¡A 20- 40mg QD for another 4 weeks Zollinger-Ellison syndrome: Initial¡A 60 mg QD; may increase up to 120 mg once daily; doses greater than 80 mg/day should be administered in divided doses¡A and the dose should be individualized for each patient.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¨x¥\¯à¤£¨Î±wªÌ¥ÍÅé¥i¥Î²v¤Î¦å¼ß¥b°I´Á¼W¥[¡A¨C¤Ñ¾¯¶q10-20 mg ¥i¯à§Y¤w¨¬°÷. [Micromedex 20201227] Hepatic impairment: maintenance of healing of erosive esophagitis: Reduce dose to 10 mg orally once daily.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest low risk,[¥é³æ]¥Ñ°õ¦æ¨}¦nªº¬y¯f¾Ç¬ã¨s«ü¥X¡AOmeprazole¹ïÃh¥¥©Î¹ï­L¨à/·s¥Í¨àªº°·±d¨S¦³¤£¨}¼vÅT. ¦]¦¹¦bÃh¥¥´Á¶¡¥i¥H¨Ï¥ÎOmeprazole.,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Omeprazole¥i¥Ñ¨Å¥Ä±Æ°£¡A¨ä¹ï¤p«Äªº¼vÅT¤£©ú.,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»¿õ¾¯À³¾ã²É¥H²GÅé§]ªA¡A¤£¥iÄZ¯}©ÎÀ£¯}¡C­Y»Ý©î½¦Ån½Ð¤Å±N½¦Ån¤¤ªº¤pÃÄ²y«r¸H©ÎÀ£¸H¡C
LCHH10,Chloral hydrate,Chloral hydrate 10%¡A 30mL (±M®×»s³y),CNEU,,¾AÀ³¯g: Short-term sedative and hypnotic (<2 weeks)¡A sedative/hypnotic prior to nonpainful therapeutic or diagnostic procedures (eg¡A EEG¡A CT scan¡A MRI¡A ophthalmic exam¡A dental procedure) °Æ§@¥Î: Gastric irritation¡A abdominal distention and flatulence¡A vertigo¡A ataxia¡A staggering gait¡A rashes¡A malaise¡A lightheadedness¡A headache¡A ketonuria¡A excitement¡A nightmares¡A delirium (especially in elderly)¡A eosinophilia¡A reduction in white blood cell count; dependence on prolonged use. ¸T§Ò: Hepatic or renal impairment¡A cardiac disease¡A hypersensitivity¡A porphyria¡A oesophagitis¡A gastritis. Pregnancy and lactation.,,,Chloral hydrate 10%= 100 mg/mL --Dosing: Adult Sedation¡A anxiety: Oral: 250 mg 3 times daily Hypnotic: Oral: 500-1000 mg 15-30 minutes before bedtime or 30 minutes prior to procedure¡A not to exceed 2000 mg per 24 hours --Dosing: Pediatric Hypnotic: Oral: 50 mg/kg/day in 1 or more divided doses; maximum single dose: 1000 mg Sedation or anxiety: Oral: 25 mg/kg/day in 1 or more divided doses; maximum single dose: 500 mg Procedural sedation: Oral: 25-50 mg/kg/dose¡A 30 minutes prior to procedure; may repeat in 30 minutes using half the dose,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
RIBMK,Bimekizumab,¸ÕPS0014-Bimekizumab 160mg/Pre-filled Syringe,HIMM,,,,,,,,,,,,,,SC;,,,,,
ESOJ,Sevoflurane,Sojourn Inhalation Liquid 250mL(­­³Â¾K¬ì),ZANE,Induction and maintenance of general anesthesia in adults and pediatric patients for inpatient and outpatient surgery.,Hypersensitivity to sevoflurane¡A other halogenated anesthetics¡A or any component of the formulation; known or suspected susceptibility to malignant hyperthermia.,>10%: Cardiovascular: Hypotension (4% to 11%; dose-dependent) Central nervous system: Agitation (7% to 15%) Gastrointestinal: Nausea (25%)¡A vomiting (18%) Respiratory: Cough (5% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2% to 6%)¡A bradycardia (5%)¡A hypertension (2%) Central nervous system: Drowsiness (9%)¡A shivering (6%)¡A dizziness (4%)¡A headache (1%)¡A hypothermia (1%)¡A myoclonus (1%)¡A delirium (emergence) Gastrointestinal: Sialorrhea (2% to 4%) Respiratory: Airway obstruction (8%)¡A laryngospasm (2% to 8%)¡A breath-holding (2% to 5%)¡A apnea (2%) Miscellaneous: Fever (1%),20-25¢XC,Individualized dosage. Adult Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide. Minimum Alveolar Concentration (MAC) values for surgical levels of anesthesia: (25 years) Sevoflurane in oxygen: 2.6%¡A Sevoflurane in 65% N2O/35% oxygen: 1.4% (40 years) Sevoflurane in oxygen: 2.1%¡A Sevoflurane in 65% N2O/35% oxygen: 1.1% (60 years) Sevoflurane in oxygen: 1.7%¡A Sevoflurane in 65% N2O/35% oxygen: 0.9% (80 years) Sevoflurane in oxygen: 1.4%¡A Sevoflurane in 65% N2O/35% oxygen: 0.7% Pediatric Anesthesia: Inhalation: Surgical levels of anesthesia are generally achieved with concentrations from 0.5% to 3% with or without the concomitant use of nitrous oxide. MAC values for surgical levels of anesthesia: (0 to 1 month old full-term neonates) Sevoflurane in oxygen: 3.3% (1 to <6 months) Sevoflurane in oxygen: 3% (6 months to <1 year) Sevoflurane in oxygen: 2.8%¡A Sevoflurane in 65% N2O/35% oxygen: 2% (1 to <3 years) Sevoflurane in oxygen: 2.8%¡A Sevoflurane in 60% N2O/40% oxygen: 2% (3-12 years) Sevoflurane in oxygen: 2.5%,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IH;,,,,,
OGXB,Empagliflozin + Linagliptin,Glyxambi 25/5mg,META,Type 2 diabetes mellitus,Severe renal impairment¡A dialysis¡A or end-stage renal disease. Hypersensitivity reaction to empagliflozin¡A linagliptin¡A or any of the excipients; anaphylaxis¡A angioedema¡A exfoliative skin conditions¡A urticaria¡A or bronchial hyperreactivity have occurred.,Common Renal: Urinary tract infectious disease (11.4% to 12.5% ) Respiratory: Nasopharyngitis (5.9% to 6.6% )¡A Upper respiratory infection (7% ) Serious Cardiovascular: Heart failure¡A Hypotension Endocrine metabolic: Diabetic ketoacidosis¡A Hypoglycemia (2.2% to 3.6% ) Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Musculoskeletal: Arthralgia Renal: Creatinine clearance-glomerular filtration abnormal¡A Decreased¡A Pyelonephritis¡A Sepsis due to urinary tract infection¡A Serum creatinine raised Reproductive: Necrotizing fasciitis¡A Perineum Other: Angioedema,30¢XC ¥H¤U,Initial empagliflozin 10 mg/linagliptin 5 mg orally once daily in the morning¡A may increase to empagliflozin 25 mg/linagliptin 5 mg once daily if tolerated.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,Empagliflozin: No Human Data-Animal Data Suggest Low Risk. Linagliptin: No Human Data-Animal Data Suggest Low Risk [¥é³æ]¥Ñ©óempagliflozinªº°Êª«¬ã¨s¸ê®ÆÅã¥Ü¦³¤£¨}µÇÅ¦¼vÅT¡A ¦]¦¹¤£«ØÄ³¦bÃh¥¥²Ä¤G¥¥´Á©M²Ä¤T¥¥´Á®É¨Ï¥ÎGLYXAMBI¡C ¦bÃh¥¥°ü¤k¨Ï¥ÎGLYXAMBI¡Blinagliptin©Îempagliflozinªº²{¦³¸ê®Æ·¥¤Ö¡A ¦]¦¹µLªk¾Ú¥H§P©wÃÄª«»P­«¤j¥ý¤Ñ¯Ê³´©M¬y²£­·ÀI¤§¶¡¬O§_¨ã¦³¬ÛÃö©Ê¡C Ãh¥¥´Á¶¡¿}§¿¯f±±¨î¤£¨Î¥i¯à¹ï¥ÀÅé©M­L¨à³y¦¨­·ÀI,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,Empagliflozin: No Human Data¡XPotential Toxicity. Linagliptin: No Human Data¡XProbably Compatible. [¥é³æ]Ãö©óGLYXAMBI©Î¨ä­Ó§O¦¨¤À¬O§_·|¶i¤J¤HÃþªº¨Å¥Ä¥H¤Î¨ä¹ï­÷¨ÅÀ¦¨à©Î¨Å¥Ä¥Í¦¨¦³¦ó¼vÅT¡A ¥Ø«e©|µL¬ÛÃö¸ê®Æ¡CEmpagliflozin©Mlinagliptin·|¤Àªc¨ì±Â¨Å¤¤¤j¹«ªº¨Å¥Ä¤º¡C ¥Ñ©ó¤HÃþªºµÇÅ¦¬O¦b¤l®c¤º¨ì¥X¥Í«á2¦~¤º³vº¥¦¨¼ô (¦¹®É¥i¯à¦]­÷¨Å¦Ó¼ÉÅS)¡A ¦]¦¹¤HÃþµÇÅ¦ªºµo¨|¥i¯à³B©ó­·ÀI¤§¤¤¡C¦]¬°GLYXAMBI¥i¯à¹ï±µ¨ü­÷¨ÅªºÀ¦¨à³y¦¨ÄY­«ªº¤£¨}¤ÏÀ³(¥]¬Aempagliflozin¥i¯à¼vÅT¥X¥Í«áªºµÇÅ¦µo¨|)¡A À³§iª¾¯f¤H¡A¤£«ØÄ³¦b­÷¨Å´Á¶¡¨Ï¥ÎGLYXAMBI¡C,AC;PC;PO;WM;,,,,,
OATMX,Atomoxetine,APO-Atomoxetine 18mg,CNEU,Attention deficit hyperactivity disorder,Do not administer atomoxetine during therapy with or within 2 weeks of discontinuing an MAOI; do not administer MAOI within 2 weeks of discontinuing atomoxetine. Hypersensitivity to atomoxetine or to other components of the product. Narrow angle glaucoma. Pheochromocytoma¡A current or history of. Severe cardiac or vascular disorders when at risk for deterioration with clinically important increase of blood pressure (eg¡A 15 to 20 mm Hg) or heart rate (eg¡A 20 beats per minute),Common: Increased heart rate (Adult¡A 10.2-22.4%; pediatric¡A 12.2-23.4%)¡A Weight decreased (Adult¡A 2%; pediatric¡A 3%)¡A Abdominal pain (Adult¡A 7%; pediatric¡A 18%)¡A Constipation (Adult¡A 8%; pediatric¡A 1-2%)¡A Decrease in appetite (Adult¡A 16%; pediatric¡A 16%)¡A Nausea (Adult¡A 26%; pediatric¡A 10%)¡A Vomiting (Adult¡A 4%; pediatric¡A 11%)¡A Xerostomia (Adult¡A 20%)¡A Dizziness (Adult¡A 8%; pediatric¡A 5%)¡A Headache (Pediatric¡A 19%)¡A Insomnia (Adult¡A 15%; pediatric¡A at least 2%)¡A Somnolence (Adult¡A 8%; pediatric¡A 11%)¡A Delay when starting to pass urine (Adult¡A 6%)¡A Dysmenorrhea (Adult¡A 3%)¡A Erectile dysfunction (Adult¡A 8%)¡A Fatigue (Adult¡A 10%; pediatric¡A 8%) Serious: Increased diastolic arterial pressure (Adult¡A 4.8-12.6%; pediatric¡A 9.3-21.5%)¡A Increased systolic arterial pressure (Adult¡A 4.2-12.4%; pediatric¡A 4.9-12.5%)¡A Myocardial infarction¡A Sudden cardiac death¡A Tachycardia (Adult¡A 1.5%; pediatric¡A 0.3%)¡A Injury of liver (Severe)¡A Liver failure¡A Cerebrovascular accident¡A Aggressive behavior¡A Hostile behavior¡A Mania¡A Psychotic disorder¡A Suicidal thoughts (Pediatric¡A 0.4%)¡A Priapism,25¢J¥H¤U°®ÀêÀô¹Ò,Acute treatment:6 years or older¡A up to 70 kg: Acute treatment: Initial¡A approximately 0.5 mg/kg orally daily; increase after a minimum of 3 days to a target dose of approximately 1.2 mg/kg daily¡A as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; maximum 1.4 mg/kg daily or 100 mg/day¡A whichever is less Acute treatment: 6 years or older¡A greater than 70 kg: Acute treatment: Initial¡A 40 mg orally daily; increase after a minimum of 3 days to a target dose of 80 mg daily as a single daily dose in the morning or in 2 divided doses in the morning and late afternoon/early evening; may increase to 100 mg/day after 2 to 4 weeks; maximum 100 mg daily. Maintenance / continuous treatment: 1.2¡ã1.8 mg/ kg/ day.,»Ý½Õ¾ã¾¯¶q,[¥é³æ]¤¤«×ªº¨x¥\¯à¤£¥þ¯f±w(Child-Pugh Class B)¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 50¢H¡C ±w¦³ÄY­«¨x¥\¯à¤£¥þ(Child-Pugh Class C)ªº¯f±w¡A°_©l¤Î¥Ø¼Ð¾¯¶qÀ³¬°¤@¯ë¾¯¶qªº 25¢H¡C,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,[¥é³æ] ¦bÃh¥¥¨ß¤lªº¾¹©x§Î¦¨´Á¶¡¡AÁý­¹¾¯¶q³Ì°ª¦Ü 100 mg/ kg/ day ªºAtomoxetine¡C¦b¤T½g¬ã¨s¤¤ªº¤@½g¡AÆ[¹î¨ì¬¡­L¼Æ´î¤Ö¡A¦­´Á¦A§l¦¬¼W¥[¡C¤£¥¿±`ÀV°Ê¯ß°_·½¤Î¯Ê¤ÖÂê°©¤U°Ê¯ßªºµo¥Í²vµy·L¼W¥[¡C³o¨Çµ²ªGµo²{©ó·|¤Þ°_»´·L¥ÀÅé¬r©Êªº¾¯¶q¡C ³o¨Çµ²ªGªºµL§@¥Î¾¯¶q¡]no-effect dose¡^¬° 30 mg/ kg/ day¡C¥Hmg/ m2­p¡A100 mg/ kg ªº¾¯¶q¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 23 ­¿¡A¨ß¤l¦å¤¤ªº Atomoxetine¿@«×¡]AUC¡^¦ô­p¬°±µ¨ü³Ì°ª¤HÅé¾¯¶qªº¤HÅé¤ºªº 3.3 ­¿¡]§Ö³t¥NÁÂªÌ¡^©Î 0.4 ­¿¡]½wºC¥NÁÂªÌ¡^¡C ±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î 10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨¤Î­÷¨Å´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J¤£¶W¹L¤j¬ù 50 mg/ kg/ day ªº atomoxetine¡]¥H mg/ m2­pºâ¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 6 ­¿¡^¡C ¦b¤G½g¬ã¨sªº¨ä¤¤¤@½g¡Aµo²{¤p¹«Åé­«¤Î¦s¬¡¼Æ´î¤Ö¡C¦b 25 mg/ kg¡]«D 13 mg/ kg¡^¡A¤]µo²{¨ì¤p¹«ªº¦s¬¡´î¤Öªº²{¶H¡C ¤@½g±q¥æ°t«e 2 ¶g¡]¥À¹«¡^©Î10 ¶g¡]¤½¹«¡^¡A¨ì¾¹©x§Î¦¨´Á¬°¤î¡A¦b¦Ñ¹«¶¼­¹¤¤¥[¤J Atomoxetine ªº¬ã¨s¤¤¡A40mg/ kg/ day¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº 5 ­¿¡^¡Aµo²{¨ì­L¹«Åé­«´î¤Ö¡]¶È¥À¹«¡^¤Î´Õ°©¤}¡]vertebral arch¡^¤£§¹¥þ¦¨°©ªºµo¥Í²v¼W¥[ªº²{¶H¡A¦¹²{¶H¨Ã¨S¦³¦b 20 mg/ kg/ day ¾¯¶q²Õ¤¤µo²{¡C ¦b¾¹©x§Î¦¨´Á¶¡¡A¥H 150 mg/ kg/ day ªº¾¯¶q¡]¥H mg/ m2­p¡A¬ù¬°³Ì°ª¤HÅé¾¯¶qªº17 ­¿¡^Áý­¹Ãh¥¥¥À¹«¡A­L¨à¨Ã¥¼¥X²{¥ô¦óªº°Æ§@¥Î¡C ¥Ø«e©|µLÃö©óÃh¥¥°ü¤k¤§¥R¤À¤Î§¹¾ãªº¹ï·Ó©Ê¬ã¨s¡C Ãh¥¥´Á¶¡¤£¥iªA¥Î Atomoxetine¡A°£«D®Ä¯q¶W¹L­L¨à¥i¯à²£¥Íªº­·ÀI©Ê¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]Atomoxetine ¤Î/ ©Î¨ä¥NÁÂª«·|¤Àªc¦Ü¦Ñ¹«ªº¨Å¥Ä¤¤¡C Atomoxetine ¬O§_·|¤Àªc¦Ü¤HÃþ¥À¨Å¤¤«h¥¼ª¾¡C ­÷¨Å¤¤ªº°ü¤k­YªA¥Î Atomoxetine ®É¡AÀ³¥[¥Hª`·N¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ½Ð¾ãÁû½¦Ån§]ªA¡C­Y¦³¿i¯»»Ý¨D½Ð¨Ï¥Î«e¦Û¦æ¿i¯»¨Ãª`·N¥»ÃÄ¯»¥½¨ã¦³²´³¡¨ë¿E©Ê¡C
IDUP,Diazepam,Diazepam(Dupin) inj 10mg/2mL,CNEU,Insomnia¡A anxiety¡A muscle spasm¡A status epilepticus.,Respiratory depression; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment.,Drowsiness & lightheadedness; confusion & ataxia; amnesia; dependence; paradoxical increase in aggression; muscle weakness; headache¡A vertigo¡A hypotension¡A salivation changes¡A GI disturbances¡A visual disturbances¡A dysarthria¡A tremor¡A changes in libido¡A incontinence¡A urinary retention; thrombophlebitis. Cardiovascular: Hypotension Dermatologic: Rash (3%¡A rectal gel ) Gastrointestinal: Diarrhea (4%¡A rectal gel ) Musculoskeletal: Muscle weakness Neurologic: Ataxia¡A Incoordination (3%¡A rectal gel )¡A Somnolence Psychiatric: Euphoria (3%¡A rectal gel ) Respiratory: Respiratory depression Other: Fatigue,30¢J¥H¤UÁ×¥úÁ×§K§N­á,Adults: Anxiety:1.Before surgery:5-10mg IM/IV. 2.Anxiety symptoms:2mg-10 mg IM/IV. If necessary¡A repeat 3-4 hours later. Alcohol withdrawal:10mg IM/IV. If necessary¡A 5-10mg every 3-4 hours. Amnestic:1.Cardioversion:5-15mg IV¡A 5-10 minutes before the procedure. 2. Endoscopy: IV: up to 20 mg before the procedure. IM:5-10mg 30 minutes before the procedure. Spasm:Initial dose:5-10mg IM/IV¡A If necessary¡A repeat every 10-15 minutes.maximum dose:30 mg. Skeletal muscle relaxation: Initial dose:5-10mg IM/IV¡A If necessary¡A repeat every 3-4 hours. Elderly or frail patients: Initial dose:2-5mg IM/IV¡A increase as needed and tolerable.IV: slowly Inject¡A at least 1 minute per 5mg(1mL) injection time. Children: Not recommended for newborns. Epilepsy and severe recurrent seizures: Infants over 30 days old to children under 5 years old: IV/IM:200-500mcg (0.2-0.5mg) every 2-5 minutes¡A maximum dose :5mg¡A if necessary¡A repeat every 2-4 hours. Children 5 years and over 5 years of age: IV/IM:1mg every 2-5 minutes¡A maximum dose:10mg. If necessary¡A repeat every 2-4 hours. Tonic spasms: Infants over 30 days to children under 5 years of age: IV/IM:1-2 mg¡A repeat every 3-4 hours as needed. Children 5 years and older: IV/IM:5-10 mg¡A repeat every 3-4 hours as needed.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human data suggest risk in 1st and 3 rd trimesters,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,IM;IVPUSH;,,,±Àª`³t²v< 5 mg/min,1.¥»ÃÄ¤£¥i»P¨ä¥¦·»²G¡BÀR¯ß¿éª`²G©Î¨ä¥LÃÄª«²V¦X©Îµ}ÄÀ¡A¦]¬°¦³¨ÏDiazepam ¨H¾ý¤§¥i¯à¡A¦Ó¥BDiazepam ·|³Q¿é²G³U¤Î¿é²GºÞ©Ò§lªþ¡A¦]¦¹¥»ÃÄ¤£©y§@ÀR¯ß¿éª`¡C 2.¦pªG¤£¯àª½±µÀR¯ßª`®g¡A¤]¥i½wºCª`¤J¿é²GºÞ¤º¡A¦ý­nºÉ¶q±µªñª`®gÂI¡]Insertion Point¡^¡C 3.ÀR¯ßª`®g®É¡AÀ³¤Å¨Ï¥Î¤â­I©Î¤âµÃ¤§¤pÀR¯ß¡A¦Ó¥BÁÙ­nÁ×§Kª`®g¨ì¦åºÞ¥~¡A¤]¤Å§@°Ê¯ßª`®g¡A¥H¨¾ÀR¯ß®ê¶ë¡BÀR¯ßª¢¡B§½³¡¨ë¿E¡B¸~µÈ¥H¤Î¦åºÞ·l¶Ë¡C,1. IM: inject deeply into muscle mass. 2. IV: inject slowly; do not administer faster than 5 mg/min. Do not use small veins for injection; if direct injection is not feasible¡A may inject through infusion tubing as close as possible to the vein insertion. 3. Do not mix or dilute with other solutions or drugs in syringe or infusion flask.
IPHE,Phenobarbital,Phenobital inj 100mg/1mL,CNEU,Seizures.,Hypersensitivity to phenobarbital¡A barbiturates or any component of the formulation; marked hepatic impairment; dyspnea or airway obstruction; porphyria (manifest and latent); intra-arterial administration¡A subcutaneous administration (not recommended); use in patients with a history of sedative/hypnotic addiction; nephritic patients (large doses).,Cardiovascular: Bradycardia¡A hypotension¡A syncope¡A thrombophlebitis (IV) Central nervous system: Agitation¡A anxiety¡A ataxia¡A central nervous system stimulation¡A central nervous system depression¡A confusion¡A dizziness¡A drowsiness¡A hallucination¡A hangover effect¡A headache¡A impaired judgement¡A insomnia¡A lethargy¡A nervousness¡A nightmares Dermatologic: Exfoliative dermatitis¡A skin rash¡A Stevens-Johnson syndrome Gastrointestinal: Constipation¡A nausea¡A vomiting Genitourinary: Oliguria Hematologic & oncologic: Agranulocytosis¡A thrombocytopenia¡A megaloblastic anemia Local: Pain at injection site Neuromuscular & skeletal: Hyperkinesia¡A laryngospasm Respiratory: Apnea (especially with rapid IV use)¡A hypoventilation¡A respiratory depression,25¢J¥H¤U,Adult dosing: 1-2 mL QD¡A 15-7 years :0-1.5mL ¡A 2-7 years :0.5-0.7mL¡A <2 years: 0.2-0.5mL¡A depending on the symptoms¡A it can be changed to 2~3 times a day.Can only be injected IM or SC¡A not IV.,»Ý½Õ¾ã¾¯¶q,Use is contraindicated in marked impairment.,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,ÃÄ«~¥é³æ:¤£¥i¨Ï¥Î¦bÃh¥¥¤Î­÷¨Å°ü¤k¡C,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,IM;IVD;,,¡iD10W¡j¥i¿ï ¡C¡iD5NS¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C¡iH/S¡j¥i¿ï ¡C¡iL/R¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,Avoid IV push.,(Children) Inject IV at a rate not to exceed 30 mg/min. (Adult) Inject IV at a rate not to exceed 60 mg/min.,IM: Inject deeply into a large muscle. Avoid injection into or near peripheral nerves due to the risk of permanent neurological deficit. IV: Inject slowly to avoid severe respiratory depression¡A apnea¡A laryngospasm¡A hypertension or vasodilation with fall in blood pressure.
OSTRM,Ivermectin,Stromectol 3mg,TDER,Scabies¡A Onchocerciasis¡A Intestinal strongyloidiasis.,Hypersensitivity to oral ivermectin or any other component of the product. Specific contraindications have not been determined for topical ivermectin.,Common Dermatologic: Pruritus (2.8% )¡A Urticaria (Oral¡A 0.9% ) Neurologic: Dizziness (2.8% ) Serious Immunologic: Mazzotti reaction Neurologic: Seizure,30¢J¥H¤U,Scabies: Oral: 200 mcg/kg as a single dose¡A dose could follow (3mg/TAB): 15-24kg:1TAB; 25-35kg: 2 TAB; 36-50kg:3 TAB; 51-65kg: 4TAB; 66-79kg: 5 TAB; >=80kg:200 mcg/kg. If the symptoms of infection are still present and the test is positive¡A Could be administered again after 8-15 days. Onchocerciasis: Oral: 200 mcg/kg as a single dose¡A dose could follow (3mg/TAB): 15-24kg:1 TAB; 25-35kg:2 TAB; 36-50kg:3 TAB; 51-65kg: 4 TAB; 66-79kg: 5 TAB; >=80kg:200 mcg/kg. Intestinal strongyloidiasis: Oral: 200 mcg/kg as a single dose¡A dose could follow (3mg/TAB): 15-24kg:1TAB ; 25-35kg:2 TAB; 36-50kg:3 TAB ; 51-65kg:4 TAB ; 66-79kg:5 TAB ; >=80kg:200 mcg/kg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ]¦]¥Ø«e©|¥¼¦³ivermectin¨Ï¥Î¦b¥¥°üªº¦w¥þ©Ê³ø§i¡A¥¥°üÀ³¤Å¨Ï¥Îivermectin¡C ¤À§O§ë¤©¤fªA¾¯¶q 0.4 ©M 10 ²@§J/¤½¤ç/¤Ñªº ivermectin¡A·|¾É­P¤p¹«©M¤j¹«ÃEµõ¡A §ë¤©¤fªA¾¯¶q 3 ²@§J/¤½¤ç/¤Ñªº ivermectin¡A·|¾É­P¨ß¤lÃEµõ©M«e¤ö¤ºÂ½¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]Ivermectin ·|±Æªn©ó¨Å¥Ä¤¤¡A¹ï·s¥Í¨à¤§¦w¥þ©Ê©|¥¼«Ø¥ß¡C¦b¤j¹«¡A±±¨î²Õªº¥®¹«¤Î¦b¤l®c¤º´¿±µ¨ü¼ÉÅSªº¥®¹«¡A »PªvÀø¹Lªº¥À¹«¶i¦æ¥æ¤e¹}¾i¡A¬ÒÆ[¹î¨ì­°§C¥®¹«¤§¦s¬¡²v¡CµM¦Ó¦b±±¨î²Õ¥®¹«¤Î¦b¤l®c¤º´¿±µ¨ü¼ÉÅSªº ¥®¹«¡A»P±±¨î²Õ¥À¹«¶i¦æ¥æ¤e¹}¾i¤U¡A«h¬Ò¥¼µo²{¥®¹«¤§¦s¬¡²v­°§C²{¶H¡C ¥u¦³¦bªvÀø¥À¿Ëªº®Ä¯q¶W¶VÁý­÷¥À¨Å¤§À¦¨à©Ò¥i¯à­±Á{¤§­·ÀIªº±¡ªp¤U¡A¤~¥i¹ï±Â¨Å¥À¿Ë§ë¤©¥»ÃÄ¡A ¥B·Ç³Æ¬°À¦¨àÁý­÷¥À¨Åªº¥À¿ËÀ³©µ«á¨ìÀ¦¨à¥X¥Í¦Ü¤Ö 1 ¶g«á¦A¶i¦æªvÀø¡C,AC;,,,,,
LSUT,Butamirate,Sutussi liquid 0.8mg/mL¡A 60mL,ERSP,Antitussive. Cough caused by cold¡A bronchitis¡A or asthmatic bronchitis.,Patients with Hypersensitivity or allergy to Butamirate,Allergic reactions¡A Skin rash¡A Nausea¡A Vertigo¡A Diarrhea¡A Dizziness.,25¢J¥H¤U¡A¤£»Ý¦B¦s¨ÃÁ×§K¶§¥úª½®g,Children: 5ml TID. Adult: 7.5ml TID-QID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥¦MÀIµ¥¯ÅB¡C³oªí¥Ü¦b°Êª«¨­¤W¶i¦æªº¥Í´Þ¸ÕÅç¤¤¡A¨Ã¥¼Åã¥Ü¯S§OÄY­«ªº¦MÀI¡C ¦ý¥Ø«e¬°¤î©|µL¥¥°ü¸ÕÅç³ø§iªºµoªí¡C¦]¦¹¡A¬°¤F¦w¥þ°_¨£¡AÃh¥¥ªì´Á3­Ó¤ë¤ºÀ³Á×§KªA¥Î¦¹¾¯¡F3­Ó¤ë¤§«á¤è¥iªA¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¯Ê¥FÃö©ó¥»ÃÄªº¥D¦¨¤À¬O§_·|±q¥ÀÅé¶i¤J¥À¨Å¤ºªº¸ê®Æ¡A¬°¤F¦w¥þ°_¨£¡A¥À¿Ë¦b­÷¨Å´Á¶¡±ýªA¥Î¥»ÃÄ¡AÀ³¯S§O¤p¤ß¡C,AC;AC15;PC;PO;WM;,,,,,
ONLD,Aluminum Hydroxide + Butinolin + Calcium carbonate,Nolidin 200/2/300mg,ALIM,Cramps and pain caused by hyperacidity¡A gastritis¡A duodenitis¡A gastric and duodenal ulcers,Hypersensitivity to any component of the formulation.,Frequency not defined. Gastrointestinal: Constipation¡A fecal discoloration (white speckles)¡A fecal impaction¡A nausea¡A stomach cramps¡A vomiting Endocrine & metabolic: Hypomagnesemia¡A hypophosphatemia,25¢J¥H¤UÀx¦s¡AÁ×§K¶§¥úª½®g,Nolidin 200/2/300mg: Aluminum Hydroxide 200mg + Butinolin 2mg + Calcium carbonate 300mg. usual dose: adult¡A 1 tab TID.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,Aluminum Hydroxide¡A Butinolin: ¨S¦³¸ê®Æ Calcium carbonate: Compatible. [¥é³æ]¨S¦³¬ÛÃö¬ö¸ü,Unknown ¨S¦³¸ê®Æ,Aluminum Hydroxide¡A Butinolin: ¨S¦³¸ê®Æ Calcium carbonate: Compatible. [¥é³æ]¨S¦³¬ÛÃö¬ö¸ü,AC;AC15;PC;PO;WM;,,,,,
ONES,Alogliptin,NESINA 25mg,META,Diabetes mellitus¡A type 2,History of serious hypersensitivity (eg¡A anaphylaxis¡A angioedema¡A severe cutaneous reactions) to alogliptin or any component of the formulation.,Common: Headache (4.3%)¡A Nasopharyngitis (4.8%)¡A Upper respiratory infection (4.5%) Serious: Congestive heart failure¡A Bullous pemphigoid¡A Stevens-Johnson syndrome¡A Pancreatitis¡A acute (0.2%)¡A Fulminant hepatic failure¡A Anaphylaxis¡A Hypersensitivity reaction¡A Arthralgia¡A Angioedema,25¢J¥H¤U,25 mg once daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
ERES,Cyclosporine,Restasis 0.05%¡A 0.4mL eye emulsion,TOPH,Keratoconjunctivitis sicca.,Active ocular infections. Hypersensitivity to cyclosporine or any of ingredient in the formulation of the product.,Common Ophthalmic: Blepharitis (Ophthalmic route 1% to 5% )¡A Burning sensation in eye (Ophthalmic route¡A 17% )¡A Conjunctival hyperemia (Ophthalmic route¡A 1% to 6% )¡A Eye irritation (Ophthalmic route¡A 1% to 5% )¡A Pain in eye (Ophthalmic route¡A emulsion 1% to 5% ; solution¡A 22% ) Serious Endocrine metabolic: Hyperkalemia¡A Hypomagnesemia Hepatic: Hepatotoxicity (7% or less ) Immunologic: Disease due to Polyomavirus Neurologic: Encephalopathy¡A Progressive multifocal leukoencephalopathy¡A Seizure (1% to 5% ) Renal: Hemolytic uremic syndrome¡A Nephrotoxicity (25% to 38% ) Other: Infectious disease,15¢J- 25¢J,Ophthalmic: Instill 1 drop in each eye twice daily (approximately 12 hours apart) Before use¡A turn the ampoule upside down several times to form a uniform white opaque emulsion¡A and then drop one drop in each eye¡A which can be combined with artificial liquid¡A but the use of two drugs should be separated by 15 minutes.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V probably compatible,Cyclosporine Ophthalmic: No Human Data¡XProbably Compatible [¥é³æ] RESTASISR©|¥¼©ó¥¥°ü¶i¦æ¥R¤À¥B¦³¨}¦n¹ï·Ó²Õ¤§Á{§É¬ã¨s¡C §½³¡²´¥ÎCyclosporine 0.05%²´¥Î¨Å¾¯¤£·|³y¦¨¥þ¨­©Ê§l¦¬¡A¥B¨Ï¥Î©ó¥¥°ü¤]¤£·|¹ï­L¨à³y¦¨¼vÅT¡C°Êª«¸ÕÅç¤¤¡A°ß¦³¦b°ª¾¯¶q¥ÀÅé¬r©Ê®ÉÅã¥Ü¦³¥Í´Þ¬r©Ê¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Cyclosporine Ophthalmic: No Human Data¡XProbably Compatible [¥é³æ] Cyclosporine ¤wª¾©ó¥þ¨­©Ê§ëÃÄ«á·|¤Àªc©ó¤HÃþ¨Å¥Ä¡A¦ý¥¼´¿¶i¦æ§½³¡ªvÀø¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Äªº¬ã¨s¡FÁöµM§½³¡§ë¤©RESTASISR²´¥Î¨Å¾¯«á¦å¤¤¿@«×°»´ú¤£¨ì¡A¦ý RESTASISR§ë¤©­÷¨Å°ü®ÉÀ³¼f·V¡C,OD;OL;OU;,,,,,¨C²~­­³æ¦¸¨Ï¥Î¡A¤p²~¤¤ªº¨Å¾¯¶·¦b¶}«Ê«á§Y¨èÂI©ó³æ²´©ÎÂù²´¡A³Ñ¾lÃÄ²G¶·©ó§ëÃÄ«á§Y¨è©ß±ó¡C¤£­nÅýÃÄ²~¦yºÝ±µÄ²¨ì²´²y©Î¥ô¦ó¨ä¥¦ªí­±¡A¥H§K¦Ã¬V¥»«~©Îµø¤O·l®`¡CRESTASISR¸T§Ò©ó¨ØÀ¹Áô§Î²´Ãèª¬ºA¤U§ëÃÄ¡A­Y¦³¨ØÀ¹Áô§Î²´Ãè¡A¶·¦b¥»«~§ëÃÄ«e¨ú¤UÁô§Î²´Ãè¡Aµ¥RESTASISR²´¥Î¨Å ¾¯§ëÃÄ«á15¤ÀÄÁ¡A¦A­«·sÀ¹¤WÁô§Î²´Ãè¡C
OCONT,Naltrexone + Bupropion,Contrave 8/90mg extended-release,META,An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g.¡A hypertension¡A type 2 diabetes mellitus¡A or dyslipidemia).,Uncontrolled hypertension. Seizure disorder or a history of seizures. Use of other bupropion-containing products (including¡A but not limited to¡A WELLBUTRIN¡A WELLBUTRIN SR¡A WELLBUTRIN XL¡A and APLENZIN). Bulimia or anorexia nervosa¡A which increase the risk for seizure. Chronic opioid or opiate agonist (e.g.¡A methadone) or partial agonists (e.g.¡A buprenorphine) use¡A or acute opiate withdrawal. Patients undergoing an abrupt discontinuation of alcohol¡A benzodiazepines¡A barbiturates¡A and antiepileptic drugs. Concomitant administration of monoamine oxidase inhibitors (MAOI). At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with CONTRAVE. There is an increased risk of hypertensive reactions when CONTRAVE is used concomitantly with MAOIs. Starting CONTRAVE in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated. Known allergy to bupropion¡A naltrexone or any other component of CONTRAVE. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported with bupropion. Pregnancy.,Common Gastrointestinal: Constipation (19.2% )¡A Diarrhea (7.1% )¡A Nausea (32.5% )¡A Vomiting (10.7% )¡A Xerostomia (8.1% ) Neurologic: Dizziness (9.9% )¡A Headache (17.6% )¡A Insomnia (9.2% ) Psychiatric: Anxiety (4.2% ) Serious Cardiovascular: Hypertension (3.2% )¡A Increased heart rate¡A Myocardial infarction (Less than 2% ) Dermatologic: Erythema multiforme (Rare )¡A Stevens-Johnson syndrome (Rare ) Endocrine metabolic: Hypoglycemia Gastrointestinal: Cholecystitis (Less than 2% )¡A Hematochezia (Less than 2% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis¡A Delayed hypersensitivity disorder Musculoskeletal: Intervertebral disc prolapse (Less than 2% ) Neurologic: Amnesia (Less than 2% )¡A Seizure (0.1% ) Ophthalmic: Angle-closure glaucoma Psychiatric: Depression (6.3% to 7.1% )¡A Mania¡A Psychiatric symptom¡A Suicidal thoughts (0.03% ) Renal: Infectious disorder of kidney (Less than 2% )¡A Serum creatinine raised (Less than 2% ) Respiratory: Pneumonia (Less than 2% ),30¢J¥H¤U,Extended-Release Tablets: Naltrexone 8mg + Bupropion 90mg. CONTRAVE dosing should be escalated according to the following schedule: Week 1: 1 tablet in the morning. Week 2: 1 tablet BID. Week 3: 2 tablets in the morning and 1 tablet in the evening. Week 4 - Onward: 2 tablets BID. A total daily dosage of two CONTRAVE 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ¸T¥Î¡A¤¤«×¨x¥\¯à¤£¥þ¤£«ØÄ³¨Ï¥Î,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,PREGNANCY RECOMMENDATION: BUPROPION: Human Data Suggest Risk NALTREXONE: Limited Human Data¡XAnimal Data Suggest Moderate Risk [¥é³æ]Åé­«´î»´¹ïÃh¥¥¯f¤H¨S¦³¯q³B¡A¥B¥i¯à¹ï­L¨à¦³®`¡C½T»{Ãh¥¥®É¡A½Ð¦VÃh¥¥¯f¤H§iª¾­L¨à©Ó¨üªº­·ÀI¨Ã°±¥ÎCONTRAVE¡C²{¦³ÃÄª«ºÊ´ú¸ê®Æ¥H¤Î¦bÃh¥¥¯f¤H¤¤¨Ï¥ÎCONTRAVE­Ó§O¦¨¤ÀªºÁ{§É¸ÕÅç©Ò±o¨ìªº¸ê®Æ¡A¥¼Åã¥Ü­«¤j¥X¥Í¯Ê³´¡B¬y²£©Î¤£¨}¥À¿Ë©Î­L¨àµ²ªGªºÃÄª«¬ÛÃö­·ÀI¡C Bupropion °w¹ï¦b²Ä¤@¥¥´Á¨ü¨ìbupropion¼ÉÅSªºÃh¥¥¯f¤H¶i¦æªº¬y¦æ¯f¾Ç¬ã¨s¡A¨ä¸ê®Æ¨Ã¥¼µo²{¾ãÅé¦Ó¨¥¥ý¤Ñ©Ê·î§Îªº­·ÀI¤W¤É¡]°Ñ¾\¼Æ¾Ú¸ê®Æ¡^¡C¦b¾¹©xµo¥Í´Á¶¡¹ïÃh¥¥¤j¹«¬I¥Î bupropion®É¡A¦b³Ì°ª¦Ü360 mg/¤é¤§³Ì¤j«ØÄ³¤HÅé¾¯¶q (MRHD) ªº¤j¬ù20­¿¾¯¶q¤U¡A¨ÃµL­L¹«µo¥Í·î§ÎªºÃÒ¾Ú¡C¦b¾¹©xµo¥Í´Á¶¡¹ïÃh¥¥¨ß°¦µ¹ÃÄ®É¡A¦b¬ù¨â­¿MRHD¤Î§ó°ªªº¾¯¶q¤U¡A´¿Æ[¹î¨ì­L¨ß·î§Îµo¥Í²v¥X²{«D¾¯¶q¬ÛÃö¤W¤É²{¶H¥H¤Î°©ÀfÅÜ²§¡C¦b5­¿MRHD¤Î§ó°ªªº¾¯¶q¤U¡A´¿Æ[¹î¨ì­L¨ßÅé­«´î¤Ö¡C Naltrexone ¦b²Ä¤@¥¥´Á¤¤¨ü¨ìnaltrexone¼ÉÅSªºÃh¥¥¯f¤Hªº¦³­­­Ó®×³ø§i¸ê®Æ¡A¨Ã«Dµo²{¾ãÅé¦Ó¨¥¥ý¤Ñ©Ê·î§Îªº­·ÀI¤W¤É¡C¬ã¨s¤wÅã¥Ü¦b¾¹©xµo¥Í´Á¶¡¨C¤é¸g¤fµ¹»Pnaltrexone¡A¤À§O¦b ? 15­¿©M ? 60 MRHD¡]32 mg/¤é¡^ªº¾¯¶q¤U¼W¥[¤F¤j¹«©M¨ß°¦¤¤¦­´Á­L¹«/¨ß¬y¥¢ªºµo¥Í²v¡C¦b³Ì°ª¤À§O¬°¬ù100©M200­¿MHRDªº¾¯¶q¤U¡A¦b¤j¹«©M¨ß°¦¤¤¨ÃµL­L¹«/¨ß·î§ÎªºÃÒ¾Ú¡C ¹ï©ó¾AÀ³¯g±Ú¸s¦Ó¨¥¡A­«¤j¥X¥Í¯Ê³´©M¬y²£ªº­I´º­·ÀI¦ô­p­È¤´ÄÝ¥¼ª¾¡C¦b¬ü°êÁ`¤H¤f·í¤¤¡A¦bÁ{§É¤WÃÒ¹ê¤§Ãh¥¥®×¨Ò¤¤­«¤j¥X¥Í¯Ê³´©M¬y²£ªº­I´º­·ÀI¦ô­p­È¤À§O¬°2-4% ©M15-20%¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,BREASTFEEDING RECOMMENDATION: BUPROPION: Limited Human Data¡XPotential Toxicity NALTREXONE: Limited Human Data¡XProbably Compatible [¥é³æ]¤wµoªíªº¤åÄm¸ê®Æ´¿«ü¥Xbupropion¤Î¨ä¥NÁÂ²£ª«·|¥X²{¦b¤HÃþ¨Å¥Ä¤¤¡C ¦bªc¨Å´Á¶¡¨Ï¥Îbupropionªº¤W¥««á³ø§iªº¦³­­¸ê®Æ¤¤¡A¨Ã¥¼µo²{­÷¨ÅÀ¦¨à¨­¤W¤£¨}¤ÏÀ³ªº©ú½T¬ÛÃö©Ê¡C Naltrexone¤Î¨ä¥D­n¥NÁÂ²£ª«6£]-naltrexol¡A¤]´¿¥X²{¦b¤HÃþ¨Å¥Ä¤¤¡C ¥Ø«e¨S¦³bupropion¡Bnaltrexone©Î¨ä¥NÁÂ²£ª«¹ï¨Å¥Ä¥Í¦¨³y¦¨¼vÅTªº¬ÛÃö¸ê®Æ¡C ­÷Áý¥À¨Å¦bµo¨|©M°·±d¤è­±±a¨Óªº®Ä¯q¡AÀ³»P¥À¿Ë¦bÁ{§É¤W¹ïCONTRAVEªº»Ý¨D¡A¥H¤ÎCONTRAVE©Î¥À¿Ëªº¬J¦³¯f¯g¹ï­÷¨ÅÀ¦¨à¥i¯à³y¦¨ªº¥ô¦ó¤£¨}¤ÏÀ³¤@¨Ö¦Ò¶q¡C,AC;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥é³æ«ØÄ³¥»ÃÄÀ³¾ãÁû§]ªA¡A¤Å­é¥b¡B©CÄZ©ÎÀ£¸H¡C 1. ½Ð´£¿ô¯f±wªñ¨â¶g¦³¨Ï¥ÎÃþ¾~¤ù¤îµhÃÄ©Î§ÜÆ{ÃÄª«½Ð¥D°Ê§iª¾Âå®v¡C 2. ¤£¥i·f°t°ª¯×À\ÂI¨Ö¥Î¡C
OBNG,·íÂk¡A¶ÀÍÁ¡A¬õ¯Ï¡A¤ÑªÇ¶À¡A¤H°Ñ¡A®ã­J¡A¶À³s¡A¥Ì¯ó,BNG-1 3gm/pack¡A 84pack/²°,HEMT,In combination with Aspirin to assist in improving activities of daily living for adult patients from 20 to under 65 years of age who have an ischemic stroke.,Pregnancy. Lactation. Patients under 20 years of age or above 65 years of age.,Constipation¡A diarrhea¡A upper abdominal pain¡A pyrexia¡A liver function test abnormal¡A allergic rhinitis¡A nasopharyngitis¡A upper respiratory tract infection¡A back pain¡A dizziness¡A headache¡A anxiety¡A haematuria¡A nocturia¡A cough.,25¢J¥H¤U,1 sachet TID for 4 weeks. Take with warm water¡A and take on an empty stomach (1 hour before meals or 2 hours after meals). BNG-1 and aspirin should be taken at least one hour apart.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ] ²Ä¤T´ÁÁ{§É¸ÕÅç±Æ°£¦³¤wª¾Á{§É­«¤j¯e¯f±wªÌ(¨Ò¦p:¨xµÇ©Ê¯e¯f)¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥»«~¹ï©óÃh¥¥°ü¤k¡B­÷¨Å°ü¤k¡A¦w¥þ©Ê¤Î¦³®ÄÃÒ¾Ú©|¥¼½T¥ß¡AÀ³Á×§K¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥»«~¹ï©óÃh¥¥°ü¤k¡B­÷¨Å°ü¤k¡A¦w¥þ©Ê¤Î¦³®ÄÃÒ¾Ú©|¥¼½T¥ß¡AÀ³Á×§K¨Ï¥Î¡C,AC;PO;,,,,,
ILUC3,Ranibizumab,Lucentis inj 10mg/mL¡A 0.165mL,TOPH,Diabetic macular edema: Treatment of diabetic macular edema (DME). Diabetic retinopathy: Treatment of diabetic retinopathy Macular degeneration: Treatment of neovascular (wet) age-related macular degeneration (AMD) Macular edema: Treatment of macular edema following retinal vein occlusion (RVO) Myopic choroidal neovascularization: Treatment of myopic choroidal neovascularization (mCNV).,Active or suspected ocular or periocular infections¡A active intraocular inflammation.,Nasopharyngitis¡A influenza; anemia; anxiety; headache¡A stroke; intraocular inflammation¡A vitritis¡A vitreous detachment¡A retinal hemorrhage¡A visual disturbance¡A eye pain¡A vitreous floaters¡A conjunctival hemorrhage¡A eye irritation¡A foreign body sensation in eyes¡A lacrimation increased¡A blepharitis¡A dry eye¡A ocular hyperemia¡A eye pruritus; retinal degeneration¡A retinal disorder¡A retinal detachment¡A retinal tear¡A detachment of retinal pigment epithelium¡A retinal pigment epithelium tear¡A visual acuity reduced¡A vitreous hemorrhage¡A vitreous disorder¡A uveitis¡A iritis¡A iridacyclitis¡A cataract¡A calaract subcapsular¡A posterior capsule opacification¡A punctuate keratitis¡A corneal abrasion¡A anterior chamber flare¡A vision blurred¡A inj site hemorrhage¡A eye hemorrhage¡A conjunctivitis¡A conjunctivitis allergic¡A eye discharge¡A photopsia¡A photophobia¡A ocular discomfort¡A eyelid edema¡A eyelid pain¡A conjunctival hyperemia; cough; nausea; allergic reactions; arthralgia; intraocular pressure increased. Common Ophthalmic: Cataract ( eovascular(wet) age-related macular degeneration 11% to 17%;macular edema following retinal vein occlusion¡A2%) ¡A conjunctival hemorrhage (neovascular (wet) age- related macular degeneration 64% to 74%; macular edema following retinal vein occlusion¡A 48%) ¡A Eye irritation (neovascular (wet) age- related macular degeneration 13% to 15% ; macular edema following retinal vein occlusion¡A7%) ¡A Foreign body sensation¡A in the eyes (neovascular (wet) age- related macular degeneration 13% to 16%; macular edema following retinal vein occlusion¡A 7% to 16%) ¡AInflammatory disorder of the eye (neovascular (wet) age- related macular degeneration 13% to 18% )¡A Pain in eye (neovascular (wet) age- related macular degeneration 26 % to 35% ; macular edema following retinal vein occlusion¡A 17% )¡A Raised intraocular pressure (neovascular (wet) age- related macular degeneration 17% to 24% ; macular edema following retinal vein occlusion¡A7% ) ¡AVisual disturbance (neovascular (wet) age- related macular degeneration 13% to 18% ; macular edema following retinal vein occlusion¡A5% )¡A Vitreous detachment (neovascular (wet) age- related macular degeneration 15% to 21% ; macular edema following retinal vein occlusion¡A4% ) ¡A Vitreous floaters (neovascular (wet) age- related macular degeneration19 % to 27% ; macular edema following retinal vein occlusion¡A 7 %),2-8¢JÁ×¥úÁ×§K§N­á,0.5mg via IVIA. The second injections into the same eyeball must be at least 4 weeks apart. The initial treatment may require 3 months or longer until no vision and/or anatomy in patient with wet type (Neovascular) of age-related macular degeneration (wAMD)¡A diabetic macular edema(DME)¡A retinal vein occlusion (RVO).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,¥é³æ¡G1.¹w­pÃh¥¥ªº°ü¤k¡G¨ã¥Í¨|¯à¤Oªº°ü¤k©óªvÀø´Á¶¡¤º¶·¨Ï¥Î¦³®ÄªºÁ×¥¥±¹¬I¡C ¹ï©ó·QÃh¥¥ªº°ü¤k¡A«ØÄ³©ó¬I¥´³Ì«á¤@¾¯ranibizumab¦Ü¤Ö¤T­Ó¤ë«á¤è¶i¦æÃh¥¥¡C 2.¥Ø«e©|µL¥¥°ü¨Ï¥Îranibizumab ªºÁ{§É¸ê®Æ¡C²´¤ºª`®granibizumab ªº¥þ¨­¼ÉÅS¶q¸û§C¡A¦ý¬O¥Ñ©óranibizumab ªº§@¥Î¾÷Âà¡A¥²¶·¦Ò¼{¨ä¼ç¦b³y¦¨­P·î­L©Ê ¤Î¹ï­L¨à/ ­F­Lµo¨|¤£¨}¼vÅTªº¥i¯à©Ê¡CÃh¥¥®É¤£«ØÄ³¨Ï¥Îranibizumab¡C RANIBIZUMAB OPHTHALMIC Selective Vascular Endothelial Growth Factor Antagonist PREGNANCY RECOMMENDATION: Limited Human Data¡XProbably Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,¥é³æ¡G¥Ø«e¥¼ª¾Lucentis ¬O§_·|¤Àªc©ó¤HÅé¨Å¥Ä¤¤¡C¬°¤F¤p¤ß°_¨£¡A°ü¤k¦b¨Ï¥ÎLucentis ªºªvÀø´Á¶¡¤£«ØÄ³Áý­÷¥À¨Å¡C RANIBIZUMAB OPHTHALMIC Selective Vascular Endothelial Growth Factor Antagonist BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,IVI;,,,,,1.Lucentis ¥²¶·¥Ñ¹ï¬Á¼þÅéª`®g¦³¸gÅç¤§¦X®æªº²´¬ìÂå¥Í¨Ó¨Ï¥Î¡C 2.«ØÄ³¾¯¶q¬°¤@¦¸¦b¬Á¼þÅé¤ºª`®g0.5 mgªºLucentis¡Cª`®g¦Ü¦P¤@­Ó²´²y¤ºªº¨â¦¸¾¯¶q¡A¦Ü¤Ö»Ý¶¡ ¹j4 ¶g¡C 3.´¿¸g¦³Lucentis »P¹p®g¥ú¾®Àøªk¦P®É¨Ï¥Îªº¸gÅç¡C¦b¦P¤@¤Ñ¬I¦æªvÀø®É¡AÀ³©ó¹p®g¥ú¾®Àøªk§¹¦¨«á¦Ü¤Ö30 ¤ÀÄÁ¦A¬I¥´Lucentis¡C
EALC754,Alcohol,75% Alcohol 4000mL/bottle,TDER,,,,25¢J¥H¤UÀx¦s,,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,,,,,,EXT;,,,,,
OXAR25,Rivaroxaban,Xarelto 2.5mg,HEMT,Cardiovascular event risk; Prophylaxis of Peripheral arterial occlusive disease and Coronary arteriosclerosis¡A In combination with aspirin.,Active pathological bleeding. Severe hypersensitivity reaction (eg¡A anaphylaxis) to rivaroxaban. Patients with severe hepatic impairment or with any degree of hepatic disease associated with coagulopathy. Patients with severe progressive bleeding (such as intracranial hemorrhage¡A gastrointestinal hemorrhage). PREGNANCY and BREASTFEEDING. Patients with CrCl <15 mL/min.,Common Hematologic: Hemorrhage (DVT prophylaxis following hip or knee replacement¡A 5.8%; treatment of DVT or pulmonary embolism¡A 28.3%; reduction in risk of recurrence of DVT or pulmonary embolism¡A 13.4% ; prophylaxis of VTE in acutely ill medical patients¡A 2.9% ) Serious Cardiovascular: Syncope (1.2% ) Gastrointestinal: Gastrointestinal hemorrhage (0.5% to 2% )¡A Upper gastrointestinal bleeding Hematologic: Hematoma¡A Epidural or spinal¡A Hemorrhage¡A Major (Stroke prevention in nonvalvular atrial fibrillation¡A 3.6%; DVT prophylaxis following hip or knee replacement¡A 0.3%; treatment of DVT or pulmonary embolism¡A 1%; reduction in risk of recurrence of DVT or pulmonary embolism¡A 0.4%; prophylaxis of VTE in acutely ill medical patients¡A 0.7% ) Immunologic: Angioedema Other: Drug withdrawal¡A Stroke and non-CNS embolism.,Àx¦s·Å«×¤£¥i¶W¹L 30¢J,Prophylaxis of CAD and PAD: 2.5mg BID combined with aspirin 100mg QD. This regimen should not be used when acute thrombosis happened.,»Ý½Õ¾ã¾¯¶q,¤Ö¼ÆÁ{§É¸ê®ÆÅã¥Ü¤¤«×¨x¥\¯à¤£¥þ¯f¤H (Child Pugh B) ªºÃÄ²z¬¡©ÊÅãµÛ¼W¥[¡C­««×¨x¥\¯à¤£¥þ¯f¤H (Child Pugh C) µLÁ{§É¸ê®Æ¥i¨Ñ°Ñ¦Ò¡C¿©±wÄY­«¨x¯f¥B»P¾®¦å²§±`¦³Ãö¦Ó·|¾É­PÁ{§É¬ÛÃö¥X¦å­·ÀIªº¯f¤H¡A¸T¤î¨Ï¥Î¥»«~¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]µL¥¥°ü¨Ï¥Î¥»«~ªº¦w¥þ©Ê»P¦³®Ä©Ê¸ê®Æ¥i¨Ñ°Ñ¦Ò¡C¦b°Êª«¸ÕÅç¤¤Åã¥Ü¥»«~¦³¥Í´Þ©Ê¬r©Ê¡C ¥Ñ©ó¼ç¦bªº¥ÀÅé¬r©Ê»P­P·î­L©Ê¥H¤Î¤º¦bªº¥X¦å­·ÀI¡C ¥[¤Wrivaroxaban¥i¬ï¹L­L½L¡AÃh¥¥°ü¤k¸T¤î¨Ï¥Î¥»«~¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]µL±Â¨Å°ü¤k¨Ï¥Î¥»«~ªº¦w¥þ©Ê»P¦³®Ä©Ê¸ê®Æ¥i¨Ñ°Ñ¦Ò¡C ¦b¦Ñ¹«¸ÕÅç¤¤Åã¥Ürivaroxaban¥i¤Àªc¦Ü¥À¨Å¤¤¡A¦]¦¹¶È¯à¦bÂ_¥¤«á¨Ï¥Î¥»«~,AC;AC15;PC;PO;WM;,,,,,
ORANC,Ranolazine,Rancad 500mg extended release,CAVS,Stable angina.,Concurrent use of CYP3A inducers¡A such as rifampin¡A rifabutin¡A rifapentine¡A phenobarbital¡A phenytoin¡A carbamazepine¡A and St John's wort. Concurrent use of strong CYP3A inhibitors such as ketoconazole¡A itraconazole¡A clarithromycin¡A nefazodone¡A nelfinavir¡A ritonavir¡A indinavir¡A and saquinavir. Hepatic cirrhosis,Common Gastrointestinal: Constipation (4.5% )¡A Nausea (4.4% ) Neurologic: Dizziness (6.2% )¡A Headache (5.5% ) Serious Cardiovascular: Prolonged QT interval¡A Vasovagal syncope (0.5% to 4% ),25¢XC¥H¤U,Oral: Initial: 500 mg twice daily; may increase to 1000 mg twice daily as needed (based on symptoms); maximum recommended dose: 1000 mg twice daily.,»Ý½Õ¾ã¾¯¶q,Ranolazine ¸T¥Î©ó¨xµw¤Æ¯f¤H¡C ¥H¨xµw¤Æ¯f¤H¬°¹ï¶Hªº¬ã¨s¤¤¡A»´«×¨x¥\¯à¤£¥þªº¯f¤H¡]Child-Pugh Ãþ§OA¡^¬Û¸û©ó¨x¥\¯à¥¿±`ªÌ¡ARanolazine ªº³Ì°ª¦å¤¤¿@«×¡]Cmax¡^·|¤W¤É30%¡A¦ý¤¤«×¨x¥\¯à¤£¥þªÌ¡]Child-Pugh Ãþ§OB¡^·|¤W¤É 80%¡CµM¦Ó¡A»´«×¤Î¤¤«×¨x¥\¯à¤£¥þ¯f¤HªºRanolazine ¦å¤¤¿@«×¤É´T¨Ã¤£¯à§¹¥þ»¡©ú³y¦¨QT ¶¡¶Z©µªø3 ­¿ªº­ì¦]¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,[¥é³æ]¨S¦³¥ô¦ó¥¥°ü¨Ï¥Î Ranolazine ªvÀø«áµo¥Í»PÃÄª«¬ÛÃöªº­·ÀI¼Æ¾Ú¡C ®Ú¾Ú¤j¹«©M¨ß¤lªº°Êª«¸ÕÅçµ²ªGÅã¥Ü¡A·í°Êª«ÃnÃÄ¶q¬°³Ì¤j«ØÄ³¤HÅé¾¯¶q(MRHD)ªº 4 ­¿®É¡AµLÃÒ¾ÚÅã¥Ü¹ï­L¨à³y¦¨·l®`¡C ¦b¬ü°êªºÁ`¤H¤f¤¤¡A­«¤j¥ý¤Ñ©Ê¯Ê³´©MÁ{§É½T¶E¬y²£ªº¹w´Á­I´º­·ÀI¾÷²v¤À§O¬° 2-4% ©M 15-20%¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ]¥Ø«e¨S¦³Ranolazine¤Àªc©ó¤HÃþ¨Å¥Ä¡B¼vÅT¥À¨ÅÁý¾iªºÀ¦¨à¡B©Î¼vÅT¨Å¥Ä¤Àªcªº¼Æ¾Ú¡C µM¦Ó¡ARanolazine·|¥X²{¦b±Â¨Å¤j¹«ªº¨Å¥Ä¤º¡C°£¦Ò¶q¥H¥À¨Å­÷¨|ªºµo¨|©M°·±d¯q³B¥~¡A¥À¿Ë¹ïRanolazineªºÁ{§É»Ý¨D¡A©Î¥ô¦ó¥i¯à¥X²{¦b±µ¨üRanolazine¥À¨ÅÁý¾i¤§À¦¨à©Î¥ÀÅé¼ç¦bªº¤£¨}¤ÏÀ³¥çÀ³¤@¨Ö¦Ò¶q¡C ¦¨¦~»Û©Ê¤j¹«±q§³®W²Ä6¤Ñ¨ì¥®Øæ¥X¥Í«á²Ä20¤Ñ¤fªAµ¹¤©Ranolazine¡C¦b¥ÀÅé§ë»P60mg/kg/day ªº¾¯¶q¤ô¥­¤U(®Ú¾ÚAUC±À©w¡A¬Û·í©óMRHD)¥¼Æ[¹î¨ì¹ï¥®Øæµo¨|¡B¦æ¬°©Î¥Í´Þ°Ñ¼Æªº¤£¨}¤ÏÀ³¡C ¦b¾É­P¥ÀÅé¬r©Êªº¾¯¶q¤U¡A·|¥X²{¶¯©Ê©M»Û©Ê¥®Øæ¦º¤`²v¼W¥[©MÅé­«´î»´¡A¥H¤Î»Û©Ê¥®Øæ¬¡°Ê¤O¼W¥[ªº±¡ªp¡C¥®Øæ¥i¯à³z¹L¥À¨Å±µ¨ü¤F¤Ö¶qªºRanolazine¡C,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¬°«ùÄò©ÊÃÄ®Ä¿õ¡A¤Å±N¦¹ÃÄ¿õ«r¸H¡AÀ£¸H¡A­é¥b©Î¿i¯»¡C
ORISD,Risperidone,Apa-Risdol 2mg,CNEU,Treatment of schizophrenia¡A including 1st episode psychoses¡A acute schizophrenic exacerbations¡A chronic schizophrenia¡A & other psychotic conditions. Alleviates affective symptoms (eg. depression¡A guilt feelings¡A anxiety) associated with schizophrenia. Long-term therapy for the prevention of relapse in chronic schizophrenia. Treatment of behavioral disturbances in patients with dementia. As adjunctive therapy to mood stabilizers or monotherapy in the treatment of manic episodes associated with bipolar disorder. Treatment of conduct & other disruptive behavioral disorders in children¡A adolescents & adults with subaverage intellectual functioning or mental retardation.,Hypersensitivity to any component of the formulation.,Common: insomnia¡A agitation¡A anxiety¡A headache. Less common: somnolence¡A fatigue¡A dizziness¡A impaired concentration¡A constipation¡A dyspepsia¡A nausea/vomiting¡A abdominal pain¡A blurred vision¡A priapism¡A erectile dysfunction¡A ejaculatory dysfunction¡A urinary incontinence¡A rhinitis¡A rash & other allergic reactions. Occasionally¡A orthostatic hypotension¡A reflex tachycardia or hypertension. Cardiovascular: Peripheral edema (adults¡A up to 3%; children¡A less than 5% .)¡A Tachycardia (oral¡A adults¡A up to 5%; children¡A up to 7% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% ) Dermatologic: Rash (oral¡A adults¡A 2% to 4%; children¡A up to 11% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% ) Endocrine metabolic: Hyperprolactinemia (oral¡A adults¡A less than 1%; children¡A 49% to 87% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Weight gain (oral¡A adults¡A up to 18%; children¡A up to 14%; intramuscular¡A schizophrenia¡A 4% to 5%; bipolar I disorder¡A 5% to 7% ) Gastrointestinal: Abdominal pain (oral¡A adults¡A 2% to 4%; children¡A 15% to 18% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Constipation (oral¡A adults¡A 5% to 9%; children¡A 21% ; intramuscular¡A schizophrenia¡A 5% to 7% )¡A Diarrhea (oral¡A adults¡A up to 6%; children¡A 7% to 8% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Excessive salivation (oral¡A adults¡A 1% to 4%; children¡A up to 22% ; intramuscular¡A schizophrenia¡A 1% to 4% )¡A Increased appetite (oral¡A children¡A 4 to 49% ; intramuscular¡A bipolar I disorder¡A 4% )¡A Indigestion (oral¡A adults¡A 4% to 10%; children¡A 5% to 16% ; intramuscular¡A schizophrenia¡A 6% )¡A Nausea (oral¡A adults¡A 4% to 9%; children¡A 8% to 16% ; intramuscular¡A schizophrenia¡A 3% to 4% )¡A Vomiting (oral¡A children¡A 10% to 12% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Xerostomia (oral¡A adults¡A up to 4%; children¡A up to 13% ; intramuscular¡A schizophrenia¡A 0% to 7%) Musculoskeletal: Pain¡A in Extremity (intramuscular¡A schizophrenia¡A 2% to 6% ) Neurologic: Akathisia (oral¡A adults¡A 5% to 9%; children¡A up to 10% ; intramuscular¡A schizophrenic adults¡A 4% to 11% )¡A Dizziness (oral¡A adults¡A 4% to 11%; children¡A 7% to 16% ; intramuscular¡A schizophrenia¡A 7% to 11%; bipolar I disorder¡A 3% )¡A Extrapyramidal disease (adults¡A 7% to 31% )¡A Headache (intramuscular¡A 15% to 21% )¡A Insomnia (oral¡A adults¡A less than 1%; children¡A less than 5% ; intramuscular¡A schizophrenia¡A less than 2%; bipolar I disorder¡A less than 4% )¡A Parkinsonism (oral¡A adults¡A 0.6% to 20%; children¡A 2% to 16% ; intramuscular¡A schizophrenia¡A 8% to 15%; bipolar I disorder¡A 15% )¡A Somnolence (oral¡A adults¡A 5% to 14%; children¡A 12% to 67% ; intramuscular¡A schizophrenia¡A 5% to 6%; bipolar I disorder¡A 7% )¡A Tremor (oral¡A adults¡A up to 5% to 6%; children¡A 10% to 12% ; intramuscular¡A schizophrenia¡A 0% to 3%; bipolar I disorder¡A 24% ),25¢J¥H¤U°®ÀêÁ×¥ú,Schizophrenia: Adults: Initial dose:2mg/day¡A in single-dose¡A or 2 divided doses. The dose can be increased to 4mg the next day. General dose:4-6mg /day. Dose exceeding 10 mg/day may cause extrapyramidal symptoms. maximum: 16mg/day. Children¡A 13-17 years old: Initial dose: 0.5mg QD¡A in the morning or afternoon. Increased by 0.5mg or 1mg daily adjust to 3mg/day. The adjustment interval cannot be less than 24 hours. Effective range:1-6mg/day. Children under 13 years old: lack of data. Elderly (65 years old and above):0.5mg BID¡A then increased by 0.5mg each dose twice a day to target dose 1-2 mg BID. Manic episodes of bipolar disorder: Adults: Initial dose:2mg or 3mg QD. Increase by 1mg/day if necessary. The adjustment interval cannot be less than 24 hours. Effective range:1-6mg/day. Children¡A 10-17 years old: Initial dose:0.5mg QD. If necessary¡A increase by 0.5mg/day or 1mg/day adjust to target dose 2.5mg/day. The adjustment interval cannot be less than 24 hours. Effective range:0.5-6mg. Children under 10 years old: lack of data. Agitation¡A aggressive behavior¡A or psychotic symptoms in patients with Alzheimer's disease: Initial dose:0.25mg BID¡A increased by 0.25mg each dose twice a day adjust to target dose 0.5-1 mg BID. Behavioral Disorders and Other Disruptive Behavior Disorders (5-18 years old): >=50kg:Initial dose:Initial dose:0.5mg/day¡A increased by 0.5mg/day every two days when necessary. Effective range:0.5-1.5mg. <50kg:Initial dose:Initial dose:0.25mg/day¡A increased by 0.25mg/day every two days when necessary. Effective range:0.25-0.75mg. Children under 5 years old: lack of data. Agitated symptoms in children and adolescents with autism¡A children(5-17 years old): <20kg:Initial dose:0.25mg/day(day1-day3)¡A 0.5mg/day(day4-day14). If necessary¡A increase by 0.25/day at more than two weeks adjustment interval. Effective range:0.5mg-1.5mg/day >=20kg:Initial dose:0.5mg/day(day1-day3)¡A 1mg/day(day4-day14). If necessary¡A increase by 0.5/day at more than two weeks adjustment interval. Effective range:1mg-2.5mg/day.The maximum dose for patients > 45 kg is 3.5 mg/day. Children under 5 years old: lack of data.,»Ý½Õ¾ã¾¯¶q,ÄY­«¨x¥\¯à¤£¥þ±wªÌ(Child Pugh 10 to 15): Initial¡A 0.5 mg orally twice daily; increase dose in increments of no more than 0.5 mg twice a day¡A with increases to dosages above 1.5 mg twice a day occurring at intervals of at least 1 week,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible ¡V maternal benefit >> embryo-fetal risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
IADD,Cr+Cu+Fe+Zn+Mn+Se+I+F+Mo,Addamel N inj 10mL/vial (¦¨¤H¥Î),NUTR,,,,,,,,,,,,,,,,,,,
IPEDI,Cu+Zn+Mn+Se+I+F,Peditrace inj 10mL/vial (¤p¨à¥Î),NUTR,,,,,As TPN material¡A for TPN Pediatric: 1mL/kg/day¡A Maximum dose: 15 mL. Each mL contains: Copper chloride dihydrate eq. to Copper 20 mcg Manganese chloride tetrahydrate eq. to Manganese 1 mcg Potassium iodide eq. to Iodine 1 mcg Sodium fluoride eq. to Fluoride 57 mcg Sodium selenite anhydrous eq. to Selenium 2 mcg Zinc chloride eq. to Zinc 250 mcg,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,IVA;,,,,,
ODIF5,Fluconazole,Diflucan 50mg,QANB,,¾AÀ³¯g: Dermatomycosis including tinea pedis¡A tinea corporis¡A tinea cruris¡A tinea versicolor and candidal infections. °Æ§@¥Î: Nausea¡A abdominal pain¡A diarrhoea; rash. ¸T§Ò: Patients with known hypersensitivity to fluconazole or to related azole compounds.,,«Ç·Å,Candidemia¡Adisseminated candidiasis & invasive candidias is 400mg daily followed by 200mg daily. Oropharyngeal candidiasis 50mg daily for 7-14 days. Vag candidiasis :150mg as a single dose. Cryptococcosis : Initially 400mg then 200mg daily for 6-8 weeks. Dermal infection (tinea corporis¡A cruris & dermal candidal infection)150mg once wkly or 50 mg daily 2-4wk¡A tinea pedis 150 mg once wkly or 50 mg daily for 2-6 wk; tinea versicolor 50mg once daily for 2-4 wk. Prevention of fungal infection in patients with AIDS 50 mg daily.,,,,ºÉ¶qÁ×§K,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,,,,,,
IAPCN,Penicillin G,Penicilina Atral inj 1 MIU/vial,QANB,,Bacterial endocarditis Adult: 1.2 g every 4 hr by slow inj or infusion¡A usually used with an aminoglycoside. Renal impairment: Dose adjustments may be necessary. Intrapartum prophylaxis against group B Streptoccocal infection in neonates Adult: Initially¡A 3 g via IV inj¡A followed by 1.5 g every 4 hr until delivery. Child: 150 mg/kg daily in 4 divided doses. Renal impairment: Dose adjustments may be necessary. Meningococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Pneumococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Susceptible infections Adult: 0.6-4.8 g/day in 2-4 divided doses via IM¡A slow IV inj or infusion¡A higher doses may be needed in more serious infections. IV doses >1.2 g should be given at a rate of not >300 mg/minute. Child: 1 mth-12 yr: 100 mg/kg daily in 4 divided doses. Infant 1-4 wk: 75 mg/kg daily in 3 divided doses. Premature infant and neonate up to 7 days old: 50 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary.,,«Ç·Å,Bacterial endocarditis Adult: 1.2 g every 4 hr by slow inj or infusion¡A usually used with an aminoglycoside. Renal impairment: Dose adjustments may be necessary. Intrapartum prophylaxis against group B Streptoccocal infection in neonates Adult: Initially¡A 3 g via IV inj¡A followed by 1.5 g every 4 hr until delivery. Child: 150 mg/kg daily in 4 divided doses. Renal impairment: Dose adjustments may be necessary. Meningococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Pneumococcal meningitis Adult: 2.4 g every 4 hr by slow inj or infusion. Up to 18 g/day in meningococcal meningitis. Administer high doses (>1.2 g) at a rate not >300 mg/minute to prevent CNS irritation and electrolyte imbalance. Child: 1 mth-12 yr: 180-300 mg/kg daily in 4-6 divided doses. Infant 1-4 wk: 150 mg/kg daily in 3 divided doses. Premature infant and neonate: 100 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary. Susceptible infections Adult: 0.6-4.8 g/day in 2-4 divided doses via IM¡A slow IV inj or infusion¡A higher doses may be needed in more serious infections. IV doses >1.2 g should be given at a rate of not >300 mg/minute. Child: 1 mth-12 yr: 100 mg/kg daily in 4 divided doses. Infant 1-4 wk: 75 mg/kg daily in 3 divided doses. Premature infant and neonate up to 7 days old: 50 mg/kg daily in 2 divided doses. Renal impairment: Dose adjustments may be necessary.,,,,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IV;,,,,,1. ª`®g«eÀË¬d¯f±w¬O§_¦³PCN¹L±Ó¥v¡C 2. ª`®g°ª¾¯¶q (¨C¤é¤j©ó1¤d¸U³æ¦ì) ®É¡AÀ³´îºCª`®g³t²v¨ÃºÊ´ú¹q¸Ñ½èª¬ºA¡C 3. Penicillin G sodium §t¶u¶q¡G1.68 mEq/100¸U³æ¦ì (¨C²~§t¦³5.04 mEq ¶u)¡C 4. (IV infusion) ¥H¾A·í¿éª`²Gµ}ÄÀ¦¨ 50¡A000-100¡A000 unit/mL¡A½wºCºwª`15 ~ 30¤ÀÄÁ¡C 5. º¯³zÀ£»P©PÃäÀR¯ßµ¹ÃÄ³Ì¤jµ}ÄÀ¿@«×¡G154000 units/mL in D/W¡A76000 units/mL in N/S¡A85000 units/mL in D5W¡C
OBOW,Picosulfate + MgO + Citric acid,Bowklean powder 16.2gm¡A 2pk/box,ALIM,Bowel cleansing prior to colonoscopy,Hypersensitivity to sodium picosulfate¡A magnesium oxide¡A anhydrous citric acid¡A or any component of the formulation; GI obstruction or ileus; bowel perforation; gastric retention; toxic colitis; toxic megacolon; severe renal impairment (CrCl <30 mL/minute).,>10%: Endocrine & metabolic: Hypermagnesemia (9% to 12%) Genitourinary: Decreased estimated GFR (eGFR; ?48 hours after colonoscopy: 10% to 29%) 1% to 10%: Central nervous system: Headache (2% to 3%) Endocrine & metabolic: Hypokalemia (5% to 7%)¡A hypochloremia (1% to 4%)¡A hyponatremia (1% to 4%) Gastrointestinal: Nausea (3%)¡A vomiting (1%) Renal: Increased serum creatinine (5%) <1% (Limited to important or life-threatening): Hypersensitivity reaction¡A ischemic colitis¡A seizure¡A ulcer (aphthoid ileal),25¢J¥H¤U,First sachet in 150 mL water¡A in the evening before the colonoscopy (5 PM-9 PM)¡A (After taking the medicine¡A replenish 250mL clear liquid drink at least 5 times before going to bed¡A and drink it within 5 hours). Followed by the second sachet in 150 mL water (5 oz) ~5 hours before the colonoscopy. (After taking the second dose ¡A replenish 250mL clear liquid drink at least 3 times ¡A and drink it before the colonoscopy 2 hours.),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«e¨ÃµL¥R¨¬¥B¹ï·Ó¨}¦nªº¤HÃþ¥¥°ü¸ÕÅç¡C¥Ñ©ó°Êª«¸ÕÅçµLªk§¹¥þ¹w´ú¤HÅéªº¤ÏÀ³¡A¦]¦¹¥²¶·¦b¦³©ú½T»Ý¨D®É¡A¤~¥i©óÃh¥¥´Á¶¡¨Ï¥Î Bowklean Powder¡C ¥¥°ü¡G°£«D½T¦³»Ý¨D¡A§_«hÃh¥¥´Á¶¡¤£¥i¨Ï¥Î Bowklean Powder,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥Ø«eÁÙ¤£²M·¡¥»«~¬O§_·|¤Àªc¦Ü¤HÃþªº¨Å¥Ä¤¤¡C¥Ñ©ó³\¦hÃÄª«³£·|¤Àªc¶i¤J¤H¨Å¡A¬°­÷¨Å¤¤ªº°ü¤k³B¤èBowklean Powder ®ÉÀ³¯S§O¤p¤ß¡C,PO;,,,,,
OREOS,Risedronic acid,Reosteo 150mg,META,Treatment of osteoporosis in postmenopausal women to increase bone mass & reduce incidence of fractures¡A including those of the hip & spine (vertebral compression fractures). Treatment of osteoporosis in men to increase bone mass.,Esophageal abnormalities (eg¡A stricture or achalasia) that delay esophageal emptying. Hypersensitivity to risedronate or any component of the product. Inability to sit or stand upright for at least 30 minutes. Hypocalcemia.,Common Dermatologic: Rash (osteoporosis¡A 7.9%; Paget disease¡A 11.5% ) Gastrointestinal: Abdominal pain (osteoporosis¡A 2.9% to 12.2% ; Paget disease¡A 11.5% )¡A Constipation (osteoporosis¡A 2.9% to 12.9% ; osteoporosis prevention¡A 6.5%; Paget disease¡A 6.6% )¡A Diarrhea (osteoporosis¡A 4.9% to 10.8% ; Paget disease¡A 19.7% )¡A Indigestion (3.9% to 10.8% )¡A Nausea (osteoporosis¡A 3.6% to 3.9% ; osteoporosis prevention¡A 7.3% to 13.2% ; Paget disease¡A 9.8% ) Musculoskeletal: Backache (adult¡A 5.9% to 28% ; pediatric¡A 17% ) Renal: Urinary tract infectious disease (11.1% ) Other: Influenza-like illness (up to 9.8% ) Serious Cardiovascular: Cardiac dysrhythmia (men¡A 2% )¡A Peripheral edema (8.2% ) Dermatologic: Hypersensitivity reaction Musculoskeletal: Arthralgia (osteoporosis¡A 6.8% to 24.7% ; osteoporosis prevention¡A 13.9%; Paget disease¡A 32.8% )¡A Bone pain (adult¡A 5.3%; acute phase reaction¡A 1.1% to 7.6%; pediatric¡A 10% )¡A Myalgia (1% to 6.7% ; osteoporosis prevention¡A 5.1% )¡A Osteonecrosis of jaw Ophthalmic: Iritis¡A Uveitis Renal: Nephrolithiasis (3% ) Reproductive: Benign prostatic hyperplasia (5% ),25¢J¥H¤U,150 mg TAB ORALLY taken once monthly or 35 mg TAB orally taken once weekly; take with 6 to 8 ounces of water at least 30 minutes prior to the first food or drink of the day.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥¼¦³¬ÛÃö¬ö¸ü,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¥¼¦³¬ÛÃö¬ö¸ü,AC;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄ¤£¥i§l§m¡B«r¸H¡BÀ£¸H¡B­é¥b©Î¿i¯»¡AÁ×§K¨ë¿E¤f«|³¡¡C
EFPX,Plectranthus amboinicus + Centella asiatica,Fespixon cream 1.25%¡A 15 gm,TDER,Diabetic foot ulcer.,Hypersensitive to the ingredients of the cream¡A including Plectranthus amboinicus¡A Centella asiatica¡A or excipients.,Cellulitis(6.6%)¡A Upper respiratory tract infection(4.9%)¡A Skin ulcer(11.5%)¡A Hypertension(2.5%)¡A Peripheral swelling(0.8%)¡A Staphylococcal infection(0.8%)¡A Would complication(0.8%)¡A weight increased(0.8%)¡A Hyperuricaemia(1.6%)¡A Dermatitis contact(0.8%)¡A Eczema(1.6%)¡A Erythema(0.8%)¡A Rash(0.8%).,25¢J«Ç·Å,Apply to the lesion twice a day by fully covering the ulcer. Cream 1.25% contains extracts of Plectranthus amboinicus(PA-F4)¡A 0.25% + Centella asiatica(S1)¡A 1%.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¤j¹«¤fªA­P·î­L©Ê¸ÕÅçÅã¥Ü¥»«~¤£¨ã¦³­P·î­L©Ê¡C µM¦Ó¡A¥Ø«e©|¥¼°w¹ïÃh¥¥©Î±Â¨Å°ü¤kµ¥¯S®í±Ú¸s¶i¦æ¬ã¨s¡A¤´¤£²M·¡¦b¥¥°ü¨Ï¥Î®É¬O§_·|³y¦¨­L¨à¶Ë®`¡A©ÎªÌ·|¼vÅT¥Í¨|¯à¤O¡C ¥u¦³¦b©ú½T»Ý­n®É¤~¥i¨Ñµ¹¥¥°ü¨Ï¥Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]©|¤£½T©wPA-F4©MS1¬O§_·|³Q¤Àªc¦Ü¤HÃþ¨Å¥Ä¡C ¥Ñ©ó³\¦hÃÄª«·|³Q¤Àªc¦Ü¨Å¥Ä¤¤¡A¦bµ¹±Â¨Åªº¥À¿Ë¨Ï¥Î¥»«~®ÉÀ³®æ¥~¤p¤ß¡C,EXT;,,,,,
OFLAT,Otilonium,Flatin 40mg,ALIM,Relief of abdominal pain due to irritable bowel syndrome.,Glaucoma. Hypersensitivity to Otilonium or any component of product.,Upper abdominal pain¡A dizziness¡A headache¡A dry mouth¡A nausea¡A tiredness¡A itching¡A erythema¡A urticaria¡A angioedema,25¢J¥H¤U,Oral¡A 40 mg BID-TID. Adult: Up to 120 mg daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]©|µL§¹¾ãªº¤HÅéÃh¥¥¤Î±Â¨Å°ü¤kªº¬ã¨s¸ÕÅç¸ê®Æ¡A©ó¦¹¨ä¶¡¤£«ØÄ³¨Ï¥Î¥»ÃÄª«¡C¦ý°Êª«¹êÅç¨ÃµL­P·î­L©Ê³ø§i¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]©|µL§¹¾ãªº¤HÅéÃh¥¥¤Î±Â¨Å°ü¤kªº¬ã¨s¸ÕÅç¸ê®Æ¡A©ó¦¹¨ä¶¡¤£«ØÄ³¨Ï¥Î¥»ÃÄª«¡C¦ý°Êª«¹êÅç¨ÃµL­P·î­L©Ê³ø§i¡C,AC;AC15;PC;PO;WM;,,,,,
OMEYD,Methylphenidate,Methydur 22mg sustained release,CNEU,,,,,,,,,,,,,,AC;AC15;PC;PO;WM;,,,,,
OCAR1,Propranolol,Pronolol 10mg,CAVS,Angina¡A arrhythmias (ventricular and supraventricular)¡A primary and renal hypertension¡A migraine¡A essential tremor¡A anxiety-induced tachycardia¡A adjunct in hyperthyroidism¡A pheochromocytoma.,History of bronchial asthma or bronchospasm¡A Cardiogenic shock¡A Decompensated heart failure¡A Second or third degree heart block (if no pacemaker is present)¡A Sick sinus syndrome (if no pacemaker is present)¡A Sinus bradycardia (if no pacemaker is present) [Micromdex] Blood pressure <50/30 mmHg¡A Hypersensitivity to propranolol hydrochloride or any component of the product¡A Pheochromocytoma¡A Premature infants with corrected age <5 weeks¡A Infants weighing <2 kg,Common: Diarrhea¡A Vomiting¡A Dizziness (Hypertension¡A 4-7% )¡A Sleep disorder¡A Fatigue (5-7% ) Serious: Bradyarrhythmia¡A Cardiogenic shock¡A Congestive heart failure¡A Heart block¡A Heart failure¡A Hypotension¡A Prolonged PR interval¡A Shortened QT interval¡A Erythroderma¡A Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Hypoglycemia¡A Anaphylaxis¡A Cerebrovascular accident¡A Bronchospasm¡A Withdrawal symptom,Àx¦s©óºò±K®e¾¹¡A25¢J¥H¤U°®ÀêÁ×¥ú,[Adult dosage] Angina pectoris: Initially 10-20 mg TID-QID¡A may titrate every 3-7 days gradually to 320 mg/day. Arrhythmia: 10-30mg TID-QID. Migraine prophylaxis: Initially 20mg QID; then up to 160-240 mg/day in divided doses. Hypertension: 120-240 mg/day¡A may increase to 640mg based on response and tolerability. Thyrotoxicosis: 10-40mg TID-QID. Pheochromocytoma: 20 mg before surgery¡A TID for 3 days¡A should be used in conjunction with an alpha-blocker. (Do not start using propranolol before the alpha-blocker has taken effect.) [Pediatric dosage] not yet established. Supraventricular tachycardia: 0.5 to 1 mg/kg/day in 3-4 divided doses.,»Ý½Õ¾ã¾¯¶q,¨x¥\¯à¤£¨}¡A¨Ï¥Î¥»ÃÄ»Ý¸û§C¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 2nd and 3 rd trimesters,[¥é³æ] ¥»ÃÄ¦bÅj¾¦°Êª«¤Î®a¨ß¥H°ª©ó¤H¥Î³Ì¤j¾¯¶q¼Æ­¿ªº¦UºØ¾¯¶q¤U¡A¬ã¨sÅã²{¥X­F­L¬r»P­L¨à¦A§l¦¬¡CÁöµM¦b¤HÅé¤§¬ã¨s©|¥¼°µ¹L¡A¦ý¬O¥¥°ü¨Ï¥Î®ÉÀ³´N¨ä¨Ï¥Î¤Wªº¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡C·s¥Í¨à¤§¤ß°Ê®}½w¡B§C¦å¿}¯g¤Î©I§l§í¨î¡A´N»{¬°»PÃh¥¥¨ä¤¤¨Ï¥Î¥»ÃÄªvÀø¦³Ãö¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,[¥é³æ] ¦³¤Ö¶q±Æªn©ó¨Å¥Ä¤¤¡A­÷¨Å°ü¨Ï¥Î®É¡AÀ³´N¨ä¨Ï¥Î¤W¤§¦MÀI»P®Ä¯q¥[¥H¦Ò¼{¡C,AC;AC15;PC;PO;WM;,,,,,
ISLQ,Insulin glargine + Lixisenatide,Soliqua inj 100 Unit/50mcg/mL 3mL Pen,META,Use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who have inadequate control with (1) metformin in combination with another oral antidiabetic agent or metformin in combination with basal insulin (daily dose <60 units)¡A (2) metformin in combination with a glucagon-like peptide-1 (GLP-1) receptor agonist or metformin in combination with another oral antidiabetic agent and a GLP-1 receptor agonist¡A or (3) basal insulin (daily dose less than 60 units) or lixisenatide.,History of serious hypersensitivity to insulin glargine¡A lixisenatide¡A or any component of the formulation; during episodes of hypoglycemia.,Common: Diarrhea (7%)¡A Nausea (10%)¡A Headache (5.4%)¡A Nasopharyngitis (7%)¡A Upper respiratory infection (5.5%) Serious: Hypoglycemia (17.8%)¡A Hypokalemia¡A Pancreatitis¡A Cholecystitis¡A Cholelithiasis¡A Disorder of gallbladder¡A Anaphylaxis¡A Hypersensitivity reaction¡A Acute injury of kidney¡A Angioedema,¥¼¶}«Ê¡G§NÂÃ(2-8¢XC)¡C¶}«Ê«á¡G¤£¥i§NÂÃ¡A«Ç·Å<25¢XC¥i«O¦s28¤Ñ¡F«Ç·Å<30¢XC¥i«O¦s14¤Ñ¡C,Administer once daily¡A injected within 1 hour before the same meal each day. Discontinue basal insulin or glucagon-like peptide-1 (GLP-1) receptor agonist therapy prior to initiation. Initial dose: (1) If no previous use of insulin: 10 units (10 units/5 mcg). (2) If using <20 units of **insulin glargine (100 units/ml)**: 10 units (10 units/5 mcg). (3) If using 20-30 units of **insulin glargine (100 units/ml)**: 20 units (20 units/10 mcg). Max: 40 units/day (insulin glargine 40 units + lixisenatide 20 mcg). **Note**: If a different basal insulin is used: - If the basal insulin is given twice daily or if daily insulin glargine (300 units/mL) is used¡A the previous total daily dose should be reduced by 20% as the starting dose for Soliqua. - For any other basal insulin¡A the calculation method is the same as for insulin glargine (100 units/mL).,»Ý½Õ¾ã¾¯¶q,[¥é³æ] ¨x¥\¯à¤£¥þ¯f¤H¡A¯Ø®q¯À»Ý¨D¶q¦³¥i¯à¦]¿}½è·s¥Í(gluconeogenesis)ªº¯à¤O¤U­°¤Î¯Ø®q¯À¥NÁÂ­°§C¦Ó´î¤Ö¡C¨x¥\¯à¤£¥þ¯f¤H¨Ï¥Î Soliqua ®É¡A¥i¯à»ÝÀWÁcºÊ´ú¦å¿}¨Ã½Õ¾ã¾¯¶q¡C,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest risk,Insulin glargine: Compatible; lixisenatide: No Human Data¡XAnimal Data Suggest Risk [¥é³æ] ©|µLSoliqua¡Binsulin glargine©Îlixisenatide ¦b¹ï·Ó©ÊÁ{§É¸ÕÅç¤¤¨Ï¥Î©óÃh¥¥°ü¤k¤§Á{§É¸ê®Æ¡C¹ï¤HÃþªº¼ç¦b­·ÀI©|¤£²M·¡¡C ¥Ø«e©|µLÃh¥¥°ü¤k¨Ï¥Îlixisenatideªº¨¬°÷¸ê®Æ¡C°Êª«¸ÕÅçªºµ²ªGÅã¥Ü¡Alixisenatide¨ã¦³¥Í´Þ¬r©Ê¡C Soliqua¤£À³¦bÃh¥¥´Á¶¡¨Ï¥Î¡C­Y¯f¤H·Q­nÃh¥¥©Î¤w¸gÃh¥¥¡AÀ³°±¥ÎSoliqua¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Insulin glargine: Compatible; lixisenatide: No Human Data¡XProbably Compatible [¥é³æ] Insulin glargine©Îlixisenatide¬O§_·|±q¤HÃþ¨Å¥Ä¤¤¤Àªc¤´¤£±o¦Óª¾¡C Soliqua¤£¥i¦b­÷¨Å´Á¶¡¨Ï¥Î¡C,SC;,,,,,1. ¥¼¶}«Ê®ÉÀ³§NÂÃ(2-8¢XC)¡A¤£¥i§N­á¡C¶}«Ê«á¡G¤£¥i§NÂÃ/§N­á¡A«Ç·Å<25¢XC¥i«O¦s28¤Ñ¡F«Ç·Å<30¢XC¥i«O¦s14¤Ñ¡C 2. SoliquaÀ³ª`®g©ó¸¡³¡¡B¤WÁu©Î¤j»Lªº¥Ö¤U¡C 3. ½Ð¤Åµ}ÄÀ¥»ÃÄ©Î±N¨ä»P¥ô¦ó¨ä¥L¯Ø®q¯ÀÃÄ²V¦X¡C 4. ¤£¥i¨Ï¥Îª`®g¾¹©â¨úSoliqua¹w¶ñª`®gµ§¥d§X¤º¤§ÃÄª«¡C
IFUL,Pegfilgrastim,Fulphila inj 6mg/0.6mL,HEMT,To decrease the incidence of infection¡A as manifested by febrile neutropenia¡A in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.,Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.,Common: Bone pain (31%)¡A Pain in limb (9%) Serious: Aortitis¡A Capillary leak syndrome¡A Acute myeloid leukemia¡A Leukocytosis (<1% )¡A Myelodysplastic syndrome¡A Rupture of spleen¡A Sickle cell anemia with crisis¡A Thrombocytopenia¡A Anaphylaxis¡A Glomerulonephritis¡A Acute respiratory distress syndrome,©ó²°¤ºÁ×¥ú§NÂÃ2-8¢J,Patients with cancer receiving myelosuppressive chemotherapy: 6 mg subQ once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy.,µL»Ý½Õ¾ã¾¯¶q,[¥é³æ]¥Ø«e©|µL¸ê°T¡C,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,[¥é³æ] ÁöµM¦bÃh¥¥°ü¤k¤¤¨Ï¥Îpegfilgrastimªº²{¦³¼Æ¾Ú¤£¨¬¥H½T©w¬O§_¦s¦b»P¥D­n¥ý¤Ñ©Ê²§±`¡A ¬y²£©Î¤£§Q©ó¥ÀÅé©Î­L¨à¬ÛÃöªºÃÄª«­·ÀI¡A¦ý¦³¤w¤½¥¬ªº¬ã¨sÅã¥ÜÃh¥¥°ü¤k±µÄ²filgrastimÃÄ«~ªº¼Æ¾Ú¡A ³o¨Ç¬ã¨s©|¥¼½T©wÃh¥¥´Á¶¡¨Ï¥ÎfilgrastimÃÄ«~»P¥D­n¥ý¤Ñ©Ê²§±`¡A¬y²£©Î¤£§Q©ó¥ÀÅé©Î­L¨à¤§ÃöÁp¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] ¨S¦³Ãö©ópegfilgrastim¦s¦b©ó¤H¨Å¤¤¡B¹ï­÷¨Å¨àµ£ªº¼vÅT©Î¹ï²£¨Å¶qªº¼vÅT¤§¼Æ¾Ú¡C ¨ä¥LfilgrastimÃÄ«~«Ü¤Ö³Q¤Àªc©ó¨Å¥Ä¤¤¤Î·s¥Í¨à¤£·|¤fªA§l¦¬filgrastimÃÄ«~¡C ©ó¦Ò¶q­÷¨Åªºµo¨|©M°·±d¯q³B®É¡A¥À¿Ë¹ïpegfilgrastimªºÁ{§É»Ý¨D¡Bpegfilgrastim©Î¼ç¦bªº¥ÀÅéª¬ªp¹ï­÷¨Å¨àµ£ªº¼ç¦b¤£§Q¼vÅTÀ³¤@¨Ö¦C¤J¦Ò¶q¡C,SC;,,,,,1. Á×§K®¶·n¡C¸m©ó«Ç·Å(¤£¶W¹L30¢J)¶W¹L48¤p®É«á»Ý¥á±ó¡CÁ×§K§N­á¡C 2. µ¹ÃÄ«eÀ³¥ØµøÀË¬dÁû²Éª«½è¤ÎÅÜ¦â¡C·íµo²{Áû²Éª«½è©ÎÅÜ¦â®É¡A½Ð¤Å¨Ï¥Î¡C 3. ³æ¦¸¨Ï¥Îªº¹w¥R¶ñ°wµ©ªº°wÀY»\§t¦³°®Àêªº¤ÑµM¾ó¥Ö(­l¥Í¦Û¨Å½¦)¡F¹ï¨Å½¦¹L±Óªº¤H¤£¥i¨Ï¥Î¥»²£«~¡C
IKET2BAD,Ketamine,Ketamine-hameln ´Ý¾l¾PÀì(±M®×) inj 500mg/10mL,ZANE,,,,,,,,,,,,,,IM;IV;IVPUSH;,,,,,
OMTD22,Methylphenidate,Methydur 22mg sustained release,CNEU,Treatment for Attention Deficit Hyperactivity Disorder (ADHD),Hypersensitivity to methylphenidate or other components of the product¡A Marked agitation¡A anxiety¡A and tension; may aggravate symptoms¡A Glaucoma¡A Motor tics¡A Concomitant use of MAOIs¡A or use within 14 days of MAOI discontinuation¡A Family history or diagnosis of Tourette syndrome¡A Fructose intolerance¡A glucose-galactose malabsorption¡A or sucrase-isomaltase insufficiency; contains sucrose.,Common: Tachycardia (4.8-7%)¡A Diaphoresis (Adult¡A 5.1%)¡A Weight decreased (2.4-12%)¡A Abdominal pain (Pediatric 4-15%)¡A Decrease in appetite (2-35%)¡A Loss of appetite (Adult 1.7% ; pediatric 3.1-9% or greater )¡A Nausea (2.4-12.8%)¡A Vomiting (1.7-9%)¡A Xerostomia (3-14%)¡A Dizziness (Adult 6.7%; pediatric 1.9-3%)¡A Headache (Adult 22.2% ; pediatric 2.4-19%)¡A Insomnia (2.8-41%)¡A Anxiety (Adult 8.2%)¡A Depression (Adult 1.7-3.9%)¡A Irritability (5.8-10%) Serious: Myocardial infarction¡A Raynaud's phenomenon¡A Sudden cardiac death¡A Decreased body growth¡A Gastrointestinal obstruction¡A With preexisting severe gastrointestinal narrowing and use of controlled-release formulations¡A Abnormal liver function¡A Cerebral artery occlusion¡A Cerebral hemorrhage¡A Cerebrovascular accident¡A Lowered convulsive threshold¡A Seizure¡A Blurred vision (>1.7-2%)¡A Aggressive behavior (1.7-2.4%)¡A Mania¡A Psychotic disorder¡A Priapism¡A Drug abuse¡A Substance dependence,25¢J¥H¤U°®Àê³B,Take once daily¡A within 20 minutes after breakfast¡A with water. Do not chew¡A split¡A or crush the capsules. For patients not previously taking Methylphenidate or other stimulants: 22mg/day. If the desired effect is not achieved: increase dose by 11mg every 7 days (max 44mg/day).,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Human data suggest risk in 3 rd trimester,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O] ¥»ÃÄ¬°ªø®Ä¿õ¡A½Ð¾ã²É§]ªA¡A¤£¥i­é¥b©Î¿i¯»¡C
RIHUM,Adalimumab/Placebo,¸ÕHumira-1311.30 (40 mg Adalimumab/Placebo),HIMM,,,,,,,,,,,,,,SC;,,,,,
OCELL,Mycophenolate mofetil,Cellcept 250mg,HIMM,Prophylaxis of acute organ rejection in patients receiving allogeneic renal¡A cardiac & hepatic transplants¡A concomitantly w/ cyclosporin & corticosteroids. Induction & maintenance treatment of lupus nephritis¡A concomitantly w/ corticosteroids.,Hypersensitivity to mycophenolate mofetil or mycophenolic acid (MPA).,Diarrhoea¡A dyspepsia¡A vomiting¡A elevated liver function test¡A acne¡A leucopenia¡A sepsis¡A certain infections; CV¡A metabolic¡A CNS & musculoskeletal events.,25¢J¥H¤U,Renal transplant 1 g BID. Cardiac & hepatic transplant 1.5 g BID. Lupus nephritis induction dose 0.75-1.5 g BID¡A maintenance dose 0.25-1 g BID.,»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,ºÉ¶qÁ×§K,Human (and animal) data suggest risk,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,¥é³æ«ØÄ³:¥¥°ü¸T¥Î,AC;AC15;PC;PO;WM;,,,,,[¿i¯»/ºÞÄéµù°O]¥»ÃÄÀ³¾ã²É§]ªA¡A ¤Á¤Å«rÄZ¡BÀ£¸H©Î¥´¶}½¦Ån¡C¥»ÃÄ¨ã­P·î­L©Ê¡A½Ðª`·N¬ÛÃö¼ÉÅS­·ÀI¡A¤×¨ä¬O°ü¤k¤Î¤p«Ä¡C
IFIB2,Sodium Tetradecyl Sulphate,Fibro-Vein inj 3%¡A 2mL (±M®×¶i¤f),ZOTH,For the treatment of uncomplicated primary varicose veins¡A recurrent or residual varicose veins following surgery¡A reticular veins¡A venules¡A and spider veins of the lower extremities that show simple dilation.,Hypersensitivity to sodium tetradecyl sulfate or to any component of the preparation and allergic conditions. Patients were unable to walk due to any cause¡A bedridden patients. Patients with a high risk of thrombosis e.g. patients with a congenital predisposition to blood clots or with multiple risk factors such as hormonal contraception or hormone replacement therapy¡A significant obesity¡A smoking¡A or extended periods of immobility. Recent acute superficial thrombophlebitis¡A deep vein thrombosis¡A or pulmonary embolism. Recent surgery. Varicosities caused by pelvic or abdominal tumors unless the tumor has been removed. Uncontrolled systemic disease such as diabetes mellitus¡A toxic hyperthyroidism¡A tuberculosis¡A asthma¡A neoplasm¡A sepsis¡A blood dyscrasias¡A and acute respiratory or skin diseases. Evolutive cancer. Significant valvular incompetence of the deep veins. Occlusive arterial disease. Huge superficial veins with wide open communications to deeper veins. Phlebitis migrans. Acute cellulitis. Acute infections. In addition when the sclerosant has been converted to foam: Known symptomatic patent foramen ovale (PFO).,Common Dermatologic: Injection site pain¡A Injection site ulcer¡A Injection site urticaria Gastrointestinal: Nausea¡A Vomiting Neurologic: Headache Serious Cardiovascular: Myocardial infarction Dermatologic: Skin necrosis¡A Tissue necrosis Hematologic: Arterial embolism¡A Deep venous thrombosis Immunologic: Allergic reaction¡A Anaphylaxis Neurologic: Cerebrovascular accident Respiratory: Pulmonary embolism,25¢J¥H¤UÁ×¥úÁ×§K§N­á,[Micromedex2021/07/29] Venous varices: Because hypersensitivities have occurred¡A a test dose of 0.5 mL followed by several hours of observation is recommended before larger doses are administered. 0.5 to 2 mL (preferably 1 mL Maximum) IV into the vein intended for sclerosis; the 1% solution is used most often¡A with the 3% solution being reserved for larger varicosities; Maximum single treatment 10 mL,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Safety for use in pregnancy has not been established. There are no or limited amount of data from the use of sodium tetradecyl sulfate in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Treatment should be postponed until after childbirth. Fibrovein should be used only when clearly needed for symptomatic relief and when the potential benefits outweigh the potential hazards to the fetus.,Unknown ¨S¦³¸ê®Æ,[¥é³æ] It is not known whether sodium tetradecyl sulfate is excreted in human milk. Caution should be exercised when used in nursing mothers. Fertility It is not known whether sodium tetradecyl sulfate affects fertility.,,,,,,Fibrovein is a single-use parenteral product. Once the container is opened¡A use immediately and discard any unused portion.
OCAPA,Nefopam,Capain 30mg,CNEU,Relief of pain,Patients with history of syncope. patients with myocardial infarction,Nausea¡A dizziness¡A drowsiness¡A dry mouth¡A insomnia¡A paraesthesia¡A Night sweats.,25¢J¥H¤UÁ×¥ú,30-60 mg 3 times daily.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Áö¦b°Êª«¸ÕÅç¥¼µo²{·î§Î­L¡A¦ý¥»¾¯¦p¨ä¥LÃÄ¤@¼Ë¡A©óû«®W«e¤T­Ó¤ë¤º¨Ï¥Î®É©yÂÔ·V.,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¤HÃþ­÷¨Å´Á¨Ï¥Î¥»©u¤§¸ê®Æ¯Ê¥F¡A ¬G¨Ï¥Î®É©y¤p¤ß¿Å¶q¨äÀuÂI¥H¤Î¹ï¥À¤l©Ò¥i¯à³y¦¨¤§·l®`.,AC;AC15;PC;PO;WM;,,,,,
LMOR,Morphine,Morphine Sulfate 2mg/mL¡A 60mL,CNEU,,¾AÀ³¯g: Relief of moderate to severe pain. °Æ§@¥Î: Nausea¡A vomiting¡A constipation¡A drowsiness¡A palpitations¡A headache¡A disorientation¡A vertigo¡A mood changes¡A decreased libido¡A ureteric spasm¡A urinary retention¡A rash¡A sweating¡A facial flushing¡A miosis. Cardiovascular: Peripheral edema (5% to 10% ) Dermatologic: Pruritus (up to 80% )¡A Rash (5% to 10% )¡A Sweating (5% to 10% ) Gastrointestinal: Abdominal pain (5% to 10% )¡A Constipation (> 10% )¡A Diarrhea (5% to 10% )¡A Loss of appetite (5% to 10% )¡A Nausea and vomiting (7% to 70% )¡A Xerostomia (5% to 10% ) Hepatic: Liver function tests abnormal (< 5% ) Musculoskeletal: Backache (5% to 10% ) Neurologic: Asthenia (5% to 10% )¡A Dizziness (6% )¡A Headache (>10% )¡A Insomnia (5% to 10% )¡A Lightheadedness¡A Paresthesia (5% to 10% )¡A Somnolence (> 10% ) Ophthalmic: Amblyopia (< 5% )¡A Miosis Psychiatric: Anxiety (6% )¡A Depression (5% to 10% ) Renal: Urinary retention (oral: < 5% ; epidural/intrathecal: 15% to 70% ) Other: Fever (5% to 10% )¡A Hiccoughs (< 5% ) ¸T§Ò: Respiratory depression¡A head injury¡A obstructive airways disease¡A paralytic ileus¡A GI obstruction¡A delayed gastric emptying¡A acute hepatic disease. Use within 2 weeks of MAOI therapy. Not recommended during pregnancy & in children < 3 years.,,«Ç·Å,10 to 20 mg every 4 hours as needed.,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ITDP4,Tdap-IPV,Boostrix-Polio (¥|¦X¤@¡A¬F©²´£¨Ñ),HIMM,,¾AÀ³¯g: For active immunisation against diphtheria¡A tetanus¡A pertussis and poliomyelitis in adults¡A adolescents and children aged 4 years and older as a booster following primary immunisation. Children 4-6 years of age should have already received four doses of DTPa and IPV or OPV. °Æ§@¥Î: Adolescents and Adults- Injection site pain¡A erythema and swelling¡A tiredness¡A headache¡A bodyache¡A chills¡A nausea¡A fever¡A arthralgia or joint swelling (?1/10) Diarrhoea¡A vomiting (<1/10 and ?1/100) Children 5 to 6 years old - Injection site pain and swelling; fatigue (?1/10) Injection site erythema and pruritus; fever ?38¢XC (<1/10 and ?1/100) Diarrhoea¡A vomiting (<1/100 and ?1/1¡A000) ¸T§Ò: Hypersensitivity. Acute illness eg febrile illness¡A encephalopathy of unknown origin w/in 7 days of previous pertussis vaccination. Pregnancy & lactation.,,2-8¢J,A single 0.5 mL dose¡A may be administered from the age of four years onwards.,,,,¤£¥i¨Ï¥Î,,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),,,,,,,
IVAXS,Purified Split Inactivated Influenza Virus,4»ù¦Û¶O¬y·P (VaxigripTetra)0.5mL/dose,HIMM,Active immunisation against influenza¡A Influenza Vaccine for children aged > or = 6 months and adult.,Hypersensitivity to the active substances¡A to any of the excipients listed in Description or to any component that may be present as traces such as eggs (ovalbumin¡A chicken proteins)¡A neomycin¡A formaldehyde and octoxinol-9.,Inj site soreness¡A fever¡A malaise¡A myalgia¡A headache¡A GI disturbances¡A lymphadenitis¡A oculorespiratory syndrome.,2-8¢XC.½Ð¤Å§N­á,IM¡A 0.5 mL¡A > or = 6 months (< 9 years who have not been vaccinated previously¡A the 2nd dose can be given after 4 weeks.),µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[¥é³æ]Ãh¥¥°ü¤k¬O¬y·P¨Öµo¯gªº°ª¦MÀIªÌ¡A¥]¬A¦­²£¡B¦í°|©M¦º¤`¡A©Ò¥HÃh¥¥°ü¤kÀ³¸Ó±µºØ¬y·P¬Ì­]¡C VaxigripTetra¥i¦bÃh¥¥ªº¥ô¦ó®É´Á±µºØ¡C ¬Û¸û©ó²Ä¤@¥¥´Á¡A¤£¬¡¤Æ¬y·P¬Ì­]ªº¦w¥þ©Ê¸ê®Æ§ó¦h¨Ó¦Û©ó²Ä¤G¥¥´Á¤Î²Ä¤T¥¥´Á±µºØ¡A²Ä¤@¥¥´Á±µºØªº¸ê®Æ¸û¤Ö¡C±q¥þ²y¨Ï¥Î¤£¬¡¤Æ¬y·P¬Ì­]¡]¥]¬AVaxigripTetra¤Î¤T»ù¤£¬¡¤Æ¬y·P¬Ì­]Vaxigrip¡^ªº¼Æ¾Ú¨Ó¬Ý¡A¤£¬¡¤Æ¬y·P¬Ì­]¹ï­L¨à¤Î¥ÀÅé¨ÃµL¥ô¦ó¤£¨}¼vÅT¡C ¦¹»P²Ä¤G¥¥´Á©Î²Ä¤T¥¥´ÁÃh¥¥°ü¤k±µºØVaxigripTetra¤ÎVaxigrip (VaxigripTetra±µºØ²Õ¦³230¦W¥¥°ü¤Î231¦W¬¡²£À¦¨à¡AVaxigrip±µºØ²Õ¦³116¦W¥¥°ü¤Î119¦W¬¡²£À¦¨à)ªº¤@¶µÁ{§É¸ÕÅç©ÒÆ[¹î¨ìªºµ²ªG¤@­P¡C ¥|­ÓÁ{§É¬ã¨s²Ä¤G¥¥´Á¤Î²Ä¤T¥¥´ÁªºÃh¥¥°ü¤k±µºØ¤T»ù¤£¬¡¤Æ¬y·P¬Ì­]Vaxigrip¡]¶W¹L5000­ÓÃh¥¥±µºØ¤Î¶W¹L5000­ÓÀ¦¨à°lÂÜ¦Ü²£«á¬ù6­Ó¤ë¡^ªº¸ê®Æ¤¤¡A­L¨à¡BÀ¦¨à¤Î¥À¿Ë¬Ò¨S¦³Åã¥Ü¥ô¦ó»P¬Ì­]¬ÛÃöªºÄY­«µ²ªG¡C ¦b«n«D¤Î¥§ªyº¸¶i¦æªºÁ{§É¬ã¨s¡A¤T»ù¤£¬¡¤Æ¬y·P¬Ì­]Vaxigrip²Õ»P¦w¼¢¾¯²Õ¦b­L¨à¡B·s¥Í¨à¡BÀ¦¨à¤Î¥À¿Ë¦w¥þ©Êµ²ªG¤è­±¡]¥]¬A¬y²£¡B¦º­L¡B¦­²£¤Î§C¥X¥ÍÅé­«¡^¡A¨â²Õ¶¡¨Ã¨S¦³ÅãµÛ®t²§¡C ¤@­Ó¦b°¨§Q(Mali)¶i¦æªºÁ{§É¬ã¨s¡AVaxigrip²Õ»P¹ï·Ó²Õ¡]¥|»ù¬y¦æ©Ê¸£¯áÅè½¤ª¢¬Ì­]¡^¦b¦­²£¡B¦º­L¤Î§C¥X¥ÍÅé­«/­L¨à¤p©ó§³®W¦~ÄÖªºµo¥Í²v¡A¨â²Õ¶¡¨Ã¨S¦³ÅãµÛ®t²§¡C ®Ú¾Ú¤@¶µ°Êª«¬ã¨sªºµ²ªGÅã¥Ü¡AVaxigripTetra¤£·|¹ïÃh¥¥¡B­F­L/­L¨àªºµo¨|¤Î¥X¥Í«áªº¦­´Áµo¨|¦³ª½±µ©Î¶¡±µªº¶Ë®`¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]VaxigripTetra¥i¦b±Â¨Å´Á¶¡¨Ï¥Î¡C,IM;SC;,,,,,1. ¥i¯à§t¦³·L¶qÂû³J¤º®eª«¡A¨Ò¦p§Z¥Õ³J¥Õ(ovalbumin)¥H¤Î¦b»sµ{¤¤¨Ï¥Îªº·sÅð¯À(neomycin)¡B¥ÒîÇ(formaldehyde)©M¨¯­f»E¾J9 (octoxynol-9). 2. µá¬y¹F¥|»ù¬y·P¬Ì­]¨C0.5²@¤É¤§¾¯¶q§t¦³¥H¤Uªº¬y·P¯f¬r®è*¡]¤£¬¡¤Æ¡Bµõ¸Ñ¡^¡G ¡P A/Victoria/2570/2019 (H1N1)pdm09 - like strain (A/Victoria/2570/2019¡A IVR-215)¡K15 micrograms HA** ¡P A/Darwin/9/2021 (H3N2) - like strain (A/Darwin/9/2021¡A IVR-228)¡K15 micrograms HA** ¡P B/Austria/1359417/2021 - like strain (B/Michigan/01/2021¡A wild type¡A)¡K15 micrograms HA** ¡P B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013¡A wild type)¡K15 micrograms HA**
OKIS0,Ribociclib,Kisqali 200mg 63#/²° (sample),RACA,Treatment of hormone receptor (HR)-positive¡A human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy.,Known hypersensitivity to Ribociclib succinate.,>10%: Cardiovascular: Peripheral edema (12%) Central nervous system: Fatigue (37%)¡A headache (22%)¡A insomnia (12%) Dermatologic: Alopecia (33%)¡A skin rash (17%)¡A pruritus (14%) Endocrine & metabolic: Decreased serum potassium (11%) Gastrointestinal: Nausea (52%)¡A diarrhea (35%)¡A vomiting (29%)¡A constipation (25%)¡A decreased appetite (19%)¡A stomatitis (12%)¡A abdominal pain (11%) Genitourinary: Urinary tract infection (11%) Hematologic & oncologic: Neutropenia (75%; grade 3: 50%; grade 4: 10%)¡A leukopenia (33%; grade 3: 20%; grade 4: 1%)¡A decreased platelet count (29%; grade 3: 1%)¡A anemia (18%; grade 4: <1%)¡A abnormal phosphorus levels (decreased; 13%; grade 3: 5%; grade 4: 1%)¡A lymphocytopenia (11%; grade 3: 6%; grade 4: 1%) Hepatic: Increased serum ALT (<46%)¡A increased serum AST (<44%)¡A increased serum bilirubin (18%) Neuromuscular & skeletal: Back pain (20%) Renal: Increased serum creatinine (20%) Respiratory: Dyspnea (12%) Miscellaneous: Fever (13%),30¢J¥H¤U,600 mg orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. KISQALI can be taken with or without food. Coadminister KISQALI with letrozole 2.5 mg taken once daily throughout the 28-day cycle. Patients should take their dose of KISQALI and letrozole at approximately the same time each day¡A preferably in themorning.  Recommended Dose Modification for Adverse Reactions: - Starting dose: 600 mg/day (three 200 mg tablets) - 1st dose reduction: 400 mg/day (two 200 mg tablets) - 2nd dose reduction: 200 mg/day (one 200 mg tablet) If further dose reduction below 200 mg/day is required¡A discontinue the treatment.,»Ý½Õ¾ã¾¯¶q,Moderate or severe impairment (Child-Pugh class B or C): Reduce initial dose to 400 mg/day.,»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,PO;,,,,,
LTRIL,Oxcarbazepine,Trileptal 60mg/mL¡A 100mL oral suspension,CNEU,Epilepsy: Partial & generalized tonic-clonic seizures.,Hypersensitivity.,Somnolence¡A headache¡A dizziness; diplopia; vomiting¡A nausea; fatigue. Hyponatremia; agitation¡A affect lability¡A confusional state¡A depression¡A apathy; ataxia¡A tremor¡A nystagmus¡A disturbance in attention¡A amnesia; blurred vision¡A visual disturbance; vertigo; diarrhea¡A abdominal pain¡A constipation; rash¡A alopecia¡A acne; asthenia. Children 1 mth to <4 yr: Ataxia¡A irritability¡A vomiting¡A lethargy¡A fatigue¡A nystagmus¡A tremor¡A decreased appetite & increased blood uric acid.,30¢J¥H¤U,Adult & elderly Mono or combine therapy: 600 mg/day (8-10 mg/kg/day) in 2 divided doses. Maintenance: 600 mg/day & 2400 mg/day. May be increased by a maximum of 600 mg/day increments at approximate weekly intervals. Maximum: 2400 mg/day over 48 hr in a controlled hospital setting. -Childn Mono-& adjunctive therapy: 8-10 mg/kg/day in 2 divided doses. Maintenance: 31-60 mg/kg/day for adjunctive therapy. May be increased by a maximum of 10 mg/kg/day increments at approximate weekly intervals from starting dose to maximum daily dose of 60 mg/kg/day. -Renal impairment CrCl <30 mL/min Start at 300 mg/day & increase slowly to achieve the desired clinical response.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
HCVDA10,Harvoni +/- Ribavirin (1¡B4¡B5¡B6/12¶g),HCVDAA0010(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 1¡B4¡B5¡B6/12¶g,QANB,,,,,,,,,,,,,,,,,,,
HCVDA11,Sovaldi + Ribavirin (2/12¶g),HCVDAA0011(C¨x¥þ¤fªA·sÃÄ°·«O­pµe) 2/12¶g,QANB,,,,,,,,,,,,,,,,,,,
EALM,Antazoline + Tetrahydrozoline + Chlorhexidine,Alminto eye drops 10mL,TOPH,Irritant conjunctivitis¡A allergic inflammatory conditions of the conjunctiva¡A particularly hay fever conjunctivitis & vernal conjunctivitis.,Narrow-angle glaucoma.,Mild burning sensation; Blurred vision,25¢J¥H¤UÁ×¥úÀx¦s,instill 1-2 drops 3 to 4 times daily into the eye.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,TETRAHYDROZOLINE OPHTHALMIC Sympathomimetic (£\-adrenergic) PREGNANCY RECOMMENDATION: No Human Data¡XProbably Compatible CHLORHEXIDINE Anti-infective PREGNANCY RECOMMENDATION: Compatible,Unknown ¨S¦³¸ê®Æ,TETRAHYDROZOLINE OPHTHALMIC Sympathomimetic (£\-adrenergic) BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible CHLORHEXIDINE Anti-infective BREASTFEEDING RECOMMENDATION: No Human Data¡XProbably Compatible,OD;OL;OU;,,,,,
ODOM,Domperidone,Domper 10mg,ALIM,Nausea and vomiting or GI motility disorder,Hypersensitivity to domperidone or any component of the formulation; prolactin-releasing pituitary tumor (prolactinoma); known existing prolongation of cardiac conduction intervals¡A particularly QT; significant electrolyte disturbances; underlying cardiac disease (eg¡A heart failure); moderate or severe hepatic impairment; patients with GI hemorrhage¡A mechanical obstruction¡A or perforation; concomitant use with potent CYP3A4 inhibitors such as azole antifungals (eg¡A ketoconazole)¡A macrolides (eg¡A erythromycin)¡A protease inhibitors¡A or nefazodone; concomitant use with QT-prolonging drugs,1% to 10%: Central nervous system: Headache¡A migraine Gastrointestinal: Xerostomia <1%¡A postmarketing¡A and/or case reports: Abdominal cramps¡A acid regurgitation¡A change in appetite¡A conjunctivitis¡A constipation¡A diarrhea¡A dizziness¡A dysuria¡A edema¡A extrapyramidal reaction (rare)¡A galactorrhea¡A gynecomastia¡A heartburn¡A hot flash¡A increased serum ALT¡A increased serum AST¡A increased serum cholesterol¡A increased serum prolactin¡A increased thirst¡A insomnia¡A irritability¡A leg cramps¡A lethargy¡A mastalgia¡A menstrual disease¡A nausea¡A nervousness¡A palpitations¡A pruritus¡A skin rash¡A stomatitis¡A torsades de pointes¡A urinary frequency¡A urticaria¡A weakness,25¢J¥H¤UÁ×¥ú,Adult & children > 12 years with > 35kg: 10mg each time¡A up to 3 times a day; Children < 12 years or > 12 years with < 35kg: 0.25mg/kg each time¡A up to 3 times a day.,»Ý½Õ¾ã¾¯¶q,Moderate to severe: Contraindicated.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ] Ãh¥¥°ü¤k¨Ï¥ÎDomperidoneªº¤W¥««á¸ê®Æ¦³­­¡C¹ï¦Ñ¹«¶i¦æ¬ã¨sµo²{¨Ï¥Î°ª¾¯¶q¡B¹ï¥ÀÅé¦³¬rªº¾¯¶q·|²£¥Í¥Í´Þ¬r©Ê¡C¥¼ª¾¹ï¤HÃþªº¼ç¦b¦MÀI©Ê¬°¦ó¡C ¦]¦¹¡AÃh¥¥´Á¶¡¨Ï¥ÎDomperidone¡A¶È­­©ó¦³¹w´ÁªvÀø®Ä¯qªº±¡§Î¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ¥»ÃÄ·|¤Àªc©ó±Â¨Å¤j¹«¤§¨Å¥Ä¤¤¡C­÷¨Å°ü¤k¨Å¥ÄªºDomperidone¿@«×¬°¬ÛÃö¦å¼ß¿@«×ªº10-50%¡A¥B¹w´Á¤£·|¶W¹L10ng/mL¡C¥H³Ì°ª«ØÄ³¾¯¶q§ë»P¡ADomperidone±Æ°£¨ì¤HÅé¨Å¥Ä¤¤ªºÁ`¶q¡A¤@¤Ñ§C©ó7ug¤£²M·¡³o¬O§_¹ï·s¥Í¨à¦³®`¡C ¦]¦¹¡A¦b¨Ï¥ÎDomperidone¤£«ØÄ³¿Ë¦Û­÷¨Å¡C,AC;AC15;PC;PO;WM;,,,,,
ICER,HPV type16/18 L1 protein,«O»_Cervarix (gsk) 0.5mL/dose,HIMM,Prevention of cervical cancer in females 10-25 years¡A by protecting against incident & persistent infections¡A cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) & cervical intraepithelial neoplasia (CIN)¡A CIN1 & pre-cancerous lesions (CIN2 & CIN3) caused by HPV Types 16 & 18.,Subjects with known hypersensitivity to any component of Cervarix.,Headache¡A GI disturbances¡A itch¡A rash¡A myalgia¡A arthralgia¡A inj site reactions¡A fatigue¡A fever.,2-8¢JÁ×¥úÁ×§K§N­á,IM¡A 0.5mL¡A > or = 15 years 3 doses at 0¡A 1¡A and 6 months. 9-14 years can take 3 doses at 0¡A 1¡A and 6 months or 2 doses at 0 and 6-12 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,[¥é³æ]Á{§É¸ÕÅç¡BÃh¥¥¸ê®Æ®w©M¬y¦æ¯f¾Ç¸ÕÅç¤¤¡A ¨ÃµLµo²{±µºØ·|¼W¥[·s¥Í¨à¥]¬A¥Í¨|¯Ê³´¦b¤ºªº¤£¥¿±`±¡ªp¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¥¼¦³Á{§É¬ã¨sµû¦ô¹ïÁý­÷¥À¨Å¤§À¦¨àªº¼vÅT¡A ¥u¦³¦b¼ç¦b®Ä¯q¶W¶V¥i¯à­±Á{¤§­·ÀI®É¤~¥i¨Ï¥Î¡C,IM;,,,,,1. ¨Ï¥Î«eÀ³¥ý¥R¤À·n¤Ã¡C 2. À³¥H¦Ù¦×ª`®gªº¤è¦¡¬I¥´©ó¤WÁu¤T¨¤¦Ù³¡¦ì¡C
IGAR,HPV type 6/11/16/18 L1 protein,Gardasil inj 0.5mL/dose (¦Û¶O),HIMM,,¾AÀ³¯g: Prevention of cervical cancer¡A genital warts & precancerous or dysplastic lesions eg¡A cervical adenocarcinoma in situ¡A cervical intraepithelial neoplasia (CIN) grades 2 & 3¡A vulvar intraepithelial neoplasia (VIN) grades 2 & 3¡A vag intraepithelial neoplasia grades 2 & 3 (VaIN)¡A cervical intraepithelial neoplasia grade 1 in girls & women 9-26 yr. °Æ§@¥Î: Injection site reactions¡A fever¡A nausea¡A dizziness. ¸T§Ò: Hypersensitivity.,,2-8¢J,0.5 mL IM in the deltoid region of the upper arm or in the higher anterolateral area of the thigh¡A according to the following schedule: 1st dose: At elected date; 2nd dose: 2 month after the 1st dose; 3rd dose: 6 month after the 1st dose. Girls between the ages of 9 and 13 can also take two doses of vaccination¡A the second dose should be given 6 to 12 months after the first dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V probably compatible,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;,,,,,1. ¨Ï¥Î«e½Ð¥R¤À·n¤Ã¡A¨Ï¬Ì­]«O«ùÄa¯B²Gªºª¬ºA¡C 2. Gardasil À³¥H¦Ù¦×ª`®gªº¤è¦¡¬I¥´©ó¤WÁuªº¤T¨¤¦Ù°Ï°ì¡A©Î¬O¤j»L«e¥~°¼°Ï°ì¸û°ªªº³¡¦ì¡C
IGAR9,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,(¤E»ù) Gardasil 9 inj 0.5mL/dose,HIMM,For 9 to 45 years old people to prevent diseases caused by human papillomavirus (HPV) (cervical cancer¡A genital warts & precancerous or dysplastic lesions) Precancerous lesions and cancers of the cervix¡A vulva¡A vagina and anus caused by HPV types 6¡A 11¡A 16¡A 18¡A 31¡A 33¡A 45¡A 52 and 58. Genital warts (condyloma acuminatum) caused by HPV types 6 and 11.,Hypersensitivity¡Ahypersensitivity to yeast.,Injection site reactions¡A fever¡A nausea¡A dizziness.,2-8¢JÁ×¥ú,IM¡A 0.5mL¡A in the deltoid region of the upper arm or in the higher anterolateral area of the thigh¡A 9-45 years 3 doses at 0¡A 2¡A and 6 months. 9-14 years can also take 2 doses at 0 and 6-12 months.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling.,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,Uknown ¨S¦³¸ê®Æ,[³X³æ]²{¦³ªº¤HÃþ¸ÕÅç¸ê®Æ¨Ã¥¼Åã¥Ü¦bÃh¥¥´Á¶¡¬I¥´GARDASIL 9·|¨Ïµo¥Í­«¤j¥X¥Í¯Ê³´»P ¬y²£ªº­·ÀI¦]¨Ï¥Î¬Ì­]¦Ó¤É°ª¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]²{¦³ªº¸ê®Æ¨Ã¤£¨¬¥Hµû¦ôGARDASIL 9¹ïÁý­÷¥À¨Å¤§À¦¨à©Î¹ï¨Å¥Ä¥Í¦¨/¤Àªc§@¥Îªº¼vÅT¡C À³±NÁý­÷¥À¨Å¹ïµo¨|¤Î°·±dªº®Ä¯q©M¥À¿Ë¹ïGARDASIL 9ªºÁ{§É»Ý¨D¡A¥H¤ÎGARDASIL 9©Î¥À¿Ë ªº°òÂ¦ª¬ºA¹ïÁý­÷¥À¨Å¤§¥®¨àªº¥ô¦ó¥i¯à¤£¨}¼vÅT©ñ¦b¤@°_¦Ò¼{¡C ´N¹w¨¾©Ê¬Ì­]¦Ó¨¥¡A¥À¿Ëªº°òÂ¦ª¬ºA«Y«ü¹ï¸Ó¬Ì­]©Ò­n¹w¨¾¤§¯e¯fªº©ö·P©Ê¡C,IM;,,,,,1. ¨Ï¥Î«e½Ð¥R¤À·n¤Ã¡A¨Ï¬Ì­]«O«ùÄa¯B²Gªºª¬ºA¡C 2. Gardasil 9 À³¥H¦Ù¦×ª`®gªº¤è¦¡¬I¥´©ó¤WÁuªº¤T¨¤¦Ù°Ï°ì¡A©Î¬O¤j»L«e¥~°¼°Ï°ì¸û°ªªº³¡¦ì¡C
IGAR9S,HPV type 6/11/16/18/31/33/45/52/58 L1 protein,(¤E»ù) Gardasil (­­±M®×­û¤u¥Î) 9 inj 0.5mL/dose,HIMM,,,,,,,,,,,,,,IM;,,,,,
IPED0,DTaP-IPV-HIB,Infanrix (¤­¦X¤@¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Active immunization of children from 2 months of age to 7 years against diphtheria¡A tetanus¡A pertussis¡A poliomyelitis & invasive Haemophilus influenzae type b disease.,Hypersensitivity to neomycin¡A streptomycin or polymyxin B. Postpone vaccination in acute febrile illness. Children > 7 yr¡A adults.,Redness¡A tenderness & swelling at inj site; fever¡A crying¡A drowsiness; decreased feeding¡A vomiting¡A irritability.,2-8¢JÁ×§K§N­á,IM¡A 0.5 mL¡A 4 doses at 2¡A 4¡A 6 and 18 months. Where more rapid protection is preferred¡A the first 3 doses may be administered at intervals of 4 weeks.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest low risk,DPT-5 No human data - animal data suggest low risk. IPV-Compatible HIB-Compatible [¥é³æ]µL¸ê®Æ¡C¤£À³¨Ï¥Î©ó¤p©ó¤»¶g©Îº¡¤C·³ªº«Äµ£©Î¦¨¤H¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,DPT-3 No human Data- Probably Compatible IPV- No Human Data¡XProbably Compatible HIB-Compatible [¥é³æ]µL¸ê®Æ¡C¤£À³¨Ï¥Î©ó¤p©ó¤»¶g©Îº¡¤C·³ªº«Äµ£©Î¦¨¤H¡C,IM;,,,,,1. ª`®g«eÀ³¥R¤À·n¤Ã¡C 2. À³¥H¦Ù¦×ª`®g¤è¦¡§ë¤©¡A³Ì¦nª`®g©ó¤j»L¤¤¬qªº«e¥~°¼ (ªÑ¥~°¼¦Ù) ©Î¤âÁuªº¤T¨¤¦Ù¡C¶W¹L¤@·³ªº«Äµ£¡A³Ì¦n¬Oª`®g¦b¤T¨¤¦Ù¡C
IMAXI,Cefepime,Maxipime inj 500mg,QANB,Treatment of resp tract & skin infections; UTI.,Hypersensitivity to cefepime¡A other cephalosporins¡A penicillins¡A other beta-lactam antibiotics¡A or any component of the formulation.,Anaphylaxis¡A rash¡A pruritus¡A urticaria; diarrhea¡A nausea¡A vomiting¡A oral moniliasis¡A colitis¡A (including pseudomembranous colitis)¡A taste perversion¡A constipation¡A abdominal pain¡A dyspepsia; vasodilation; dyspnea; headache¡A dizziness¡A paresthesia; fever¡A vaginitis¡A erythema¡A genital pruritus¡A chills & unspecified moniliasis. Local reactions eg phlebitis & inflammation at IV inj site & inflammation or pain at IM inj site; elevations in ALT¡A AST¡A alkaline phosphate¡A total bilirubin¡A eosinophilia¡A anemia¡A thrombocytopenia¡A prolonged prothrombin time¡A partial thromboplastin time & +ve Coombs' test w/o hemolysis; transient elevations of BUN &/or serum creatinine¡A & thrombocytopenia.,30¢J¥H¤UÁ×¥ú,Adults and children > 40 kg: 0.5-1 g IV/IM every 12 hours; 2 g IV q8-12h for serious infection. Children (2 months to 12 years) 50 mg/kg IV q8-12h; (1 month to 2 months) 30 mg/kg IV q8-12h. *****NEONATE ANTIBIOTICS DOSE***** Cefepime: mild to moderate infection: 30mg/kg Q12H Cefepime: pneumonia or meningitis (due to Pseudomonas aeruginosa or Enterobacter spp) Body weight <1kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50mg/kg Q12H  Age 15-28 day 50 mg/kg Q8H Body weight 1-2kg ge<=7day 50mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50 mg/kg Q8H Body weight >2kg Age<=7ayd 50 mg/kg Q12H  Age 8-14 day 50 mg/kg Q8H  Age 15-28 day 50mg/kg Q8H,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,Compatible ­÷¨Å®É¥i¨Ï¥Î,,IM;IVD;IVP;IVPUSH;,IM: 1.3 mL D/W¡A N/S¡AD5W¡A0.5% Lidocaine IV: 5mL D/W¡A N/S¡A D5W,¡iN/S¡j¥i¿ï ¡C¡iD5W¡j¥i¿ï ¡C,±Àª`®É¶¡¦Ü¤Ö3 ~ 5¤ÀÄÁ,«ØÄ³¥H30¤ÀÄÁ½wºCºwª`,1.¤Å»PaminoglycosideÃþ§Ü¥Í¯À²V¦X©Î¦P®Éª`®g 2.¤Å»Pvancomycin²V¦X 3.µ}ÄÀ«á¡A¦w©w©Ê(«Ç·Å24¤p®É; §NÂÃ7¤é) 4.¥»²£«~«ØÄ³¨Ï¥Î20.21©Î22¸¹°wÀY¶i¦æ½Õ°t¡AÁ×§K²£¥Í½¦¶ë­é¸¨±¡§Î.
OCOP,Clopidogrel + Acetylsalicylic acid,CoPlavix 75/100mg,HEMT,Prevention of atherothrombotic events in adult patients already taking both clopidogrel + aspirin. Fixed-dose combination for continuation of therapy in: Non-ST-segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) including patients undergoing stent placement following percutaneous coronary intervention; ST-segment elevation acute MI in medically-treated patients eligible for thrombolytic therapy.,Hypersensitivity to clopidogrel¡A aspirin or NSAIDs. Patients w/ syndrome of asthma¡A rhinitis & nasal polyps. Severe hepatic & renal impairment. Active pathological bleeding eg peptic ulcer or intracranial hemorrhage. Pregnancy (3rd trimester).,Dyspepsia¡A abdominal pain¡A diarrhea; bleeding¡A hematoma¡A epistaxis; esophagitis¡A esophageal ulceration¡A perforation; fixed eruption.,25¢J¥H¤U,75mg/100mg QD.,»Ý½Õ¾ã¾¯¶q,CoPlavix must not be used in patients with severe hepatic impairment. Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses.,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V probably compatible,ASPIRIN: Compatible (Low Dose); Human Data Suggest Risk in 1st and 3rd Trimesters (Full Dose) CLOPIDOGREL: Limited Human Data¡XProbably Compatible ÃÄ«~¥é³æ:Ãh¥¥«e6­Ó¤ë¤£À³¨Ï¥Î¡A³Ì«á3­Ó¤ë¸T¥Î¡C,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,ASPIRIN: Limited Human Data¡XPotential Toxicity CLOPIDOGREL: No Human Data¡XProbably Compatible,PC;PO;,,,,,
IZOL1,Goserelin,10.8mg ZOLADEX LA DEPOT (¤T­Ó¤ë),RACA,Treatment of prostate cancer. Treatment of breast cancer for premenopausal women.,Hypersensitivity to goserelin¡A gonadotropin releasing hormone (GnRH)¡A GnRH agonist analogues¡A or any component of the product. Pregnancy in females with endometriosis or endometrial thinning¡A as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation.,Common Cardiovascular: Peripheral edema (21% ) Dermatologic: Acne (42% )¡A Seborrhea (26% )¡A Sweating (1% to 45% ) Endocrine metabolic: Atrophy of breast (33% ) Neurologic: Headache (men¡A greater than 1% to less than 5%; women¡A 32% to 75% ) Psychiatric: Depression (men¡A greater than 1% to less than 5%; women¡A 54% )¡A Mood swings (60% ) Reproductive: Erectile dysfunction (18% )¡A Flushing (46% to 96% )¡A Reduced libido (47.7% to 61% )¡A Sexual dysfunction (21% )¡A Vaginitis (5% to 75% ) Other: Pain (8% to 17% ) Serious Cardiovascular: Cardiovascular event risk¡A Congestive heart failure (5% )¡A Hemorrhagic shock¡A Myocardial infarction (greater than 1% to less than 5% )¡A Prolonged QT interval Dermatologic: Injection site hemorrhage Endocrine metabolic: Diabetes mellitus (10.9% to 22.2% )¡A Pituitary apoplexy (rare )¡A Pituitary tumor (rare )¡A Tumor flare (23% ) Hematologic: Hemorrhage Immunologic: Anaphylaxis¡A Hypersensitivity reaction (1% or greater ) Neurologic: Cerebrovascular accident (greater than 1% to less than 5% ) Renal: Renal impairment (greater than 1% to less than 5% ) Respiratory: Chronic obstructive pulmonary disease (5% ) Other: Tumor flare (23% ),25¢J¥H¤U,10.8 mg SC every 12 weeks,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]¥Ñ©ó¦bÃh¥¥´Á¶¡¨Ï¥Î LHRH «P®Ä¾¯¡A²z½×¤W¦³³y¦¨¬y²£©Î­L¨à²§±`ªº­·ÀI¡A¦]¦¹Ãh¥¥´Á¶¡¤£À³¨Ï¥Î ZOLADEX LA 10.8 mg¡C ¥i¯àÃh¥¥ªº°ü¤k¦b¨Ï¥Î¥»«~«eÀ³¥J²ÓÀËÅç¡A±Æ°£¤wÃh¥¥ªº¥i¯à¡C ªvÀø´Á¶¡À³±Ä¨ú²üº¸»X¥H¥~¤§Á×¥¥¤èªk¡Aª½¨ì¤ë¸g«ì´_¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ]¤£«ØÄ³¦b­÷¨Å´Á¶¡¨Ï¥Î ZOLADEX LA 10.8mg¡C,SC;,,,,,
IPREC,Dexmedetomidine,Precedex inj 200mcg/2mL,ZANE,Sedation during surgery or procedure and during ICU care,Hypersensitivity to dexmedetomidine or any component of the formulation.,>10%:Hypotension (24% to 56%)¡A bradycardia (5% to 42%)¡A systolic hypertension (28%)¡A tachycardia (25%)¡A hypertension (diastolic; 12%)¡A hypertension (11%)¡A Agitation (5% to 14%)¡A Constipation (6% to 14%)¡A nausea (3% to 11%)¡A Respiratory depression (37%; placebo 32%) 1% to 10%: Atrial fibrillation (2% to 9%)¡A peripheral edema (3% to 7%)¡A hypovolemia (3%)¡A edema (2%)¡A Anxiety (5% to 9%)¡A Hypokalemia (9%)¡A hyperglycemia (7%)¡A hypoglycemia (5%)¡A increased thirst (2%)¡A hypocalcemia (1%)¡A hypomagnesemia (1%)¡A Xerostomia (3% to 4%)¡A Oliguria (2%)¡A Anemia (3%)¡A Acute renal failure (2% to 3%)¡A decreased urine output (1%)¡A Respiratory failure (2% to 10%)¡A adult respiratory distress syndrome (1% to 9%)¡A pleural effusion (2%)¡A wheezing (?1%)¡A Fever (5% to 7%)¡A withdrawal syndrome (ICU sedation; 3% to 5%) Postmarketing and/or case reports: Abdominal pain¡A acidosis¡A apnea¡A atrioventricular block¡A bronchospasm¡A cardiac arrhythmia¡A cardiac disease¡A chills¡A confusion¡A convulsions¡A decreased visual acuity¡A delirium¡A diaphoresis¡A diarrhea¡A dizziness¡A drug tolerance (use >24 hours)¡A dyspnea¡A extrasystoles¡A hallucination¡A headache¡A heart block¡A hemorrhage¡A hepatic insufficiency¡A hyperbilirubinemia¡A hypercapnia¡A hyperkalemia¡A hypernatremia¡A hyperpyrexia¡A hypoventilation¡A hypoxia¡A illusion¡A increased blood urea nitrogen¡A increased gamma-glutamyl transferase¡A increased serum alkaline phosphatase¡A increased serum ALT¡A increased serum AST¡A inversion T-wave on ECG¡A myocardial infarction¡A neuralgia¡A neuritis¡A pain¡A photopsia¡A polyuria¡A prolonged Q-T interval on ECG¡A pulmonary congestion¡A respiratory acidosis¡A rigors¡A seizure¡A sinoatrial arrest¡A speech disturbance¡A supraventricular tachycardia¡A tachyphylaxis (use >24 hours)¡A variable blood pressure¡A ventricular arrhythmia¡A ventricular tachycardia¡A visual disturbance¡A vomiting,«Ç·Å 20-25¢J,Precedex injection do not continue infusion for more than 24 hours. ICU sedation: IV: Initial: Loading infusion of 0.5-1 mcg/kg over 10 minutes¡A followed by a maintenance infusion of 0.2-0.7 mcg/kg/hour; adjust rate to desired level of sedation; titration no more frequently than every 30 minutes may reduce the incidence of hypotension. Procedural sedation: IV: Initial: Loading infusion of 0.5-1 mcg/kg (0.5 mcg/kg for less invasive procedures) over 10 minutes¡A followed by a maintenance infusion of 0.2-1 mcg/kg/hour¡A titrate to desired effect. Fiberoptic intubation (awake): IV: Initial: Loading infusion of 1 mcg/kg over 10 minutes¡A followed by a maintenance infusion of 0.7 mcg/kg/hour until endotracheal tube is secured.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,IVD;,,¡iD5W¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iL/R¡j¥i¿ï ¥é³æ«ØÄ³¡C¡iN/S¡j¥i¿ï ¥é³æ«ØÄ³¡C,,¨Ï¥ÎPrecedex¤§«e¡A¥²¶·¥H0.9%´â¤Æ¶u·»²Gµ}ÄÀ¦Ü©Ò»Ý­nªº¿@«×¡]4 mcg/mL¡^¡CµL½×¬O·Ç³Æªì©l¾¯¶q©Îºû«ù¾¯¶q¡A»s³Æ¿éª`·»²Gªº¤è¦¡³£¤@¼Ë¡A¥B§¡¶·ÄY¦uµLµß¾Þ§@¡C ·Ç³Æ¿éª`·»²G®É¡A©â¥X2 mL Precedex¡A¥[¤J48 mL 0.9%´â¤Æ¶u·»²G¤¤¨Ï¦¨¬°50 mL¡C»´·n²V¤Ã¡C,¨Ï¥Îª`®g»s¾¯«e¡A¦b·»²G»P®e¾¹³\¥iªºª¬ªp¤U¡A³£À³¥ØµøÀË¬d¬O§_¦³·L²Éª«½è¤ÎÅÜ¦â±¡§Î¡C
IXOL0,Omalizumab,Xolair inj 150mg/1.2mL (sample),ERSP,--Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. --Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.,Hypersensitivity reaction to omalizumab or any component of the formulation,°Æ§@¥Î: >10%: Central nervous system: Headache (6% to 12%) 1% to 10%: Cardiovascular: Peripheral edema (>2%) Central nervous system: Anxiety (>2%)¡A migraine (>2%) Dermatologic: Alopecia (>2%) Gastrointestinal: Toothache (>2%) Genitourinary: Urinary tract infection (>2%) Infection: Fungal infection (>2%) Local: Injection site reaction (3%) Neuromuscular & skeletal: Arthralgia (3%)¡A limb pain (>2%)¡A musculoskeletal pain (>2%)¡A myalgia (>2%) Respiratory: Nasopharyngitis (9%)¡A sinusitis (5%)¡A upper respiratory tract infection (3%)¡A asthma (>2%)¡A oropharyngeal pain (>2%)¡A sinus headache (>2%)¡A cough (2%)¡A viral upper respiratory tract infection (<2%) Miscellaneous: Fever (>2%) All indications: <1% (Limited to important or life-threatening): Alopecia¡A anaphylaxis¡A antibody development¡A arthritis¡A chest tightness¡A Churg-Strauss syndrome¡A lymphadenopathy¡A malignant neoplasm¡A pulmonary hypertension¡A syncope¡A thrombocytopenia¡A transient ischemic attacks,2-8¢JÁ×¥úÁ×§K§N­á,Allergic asthma: The appropriate dose and frequency of Xolair is determined by baseline IgE (IU/ml)¡A measured before the start of treatment¡A and body weight (kg). Prior to administration of the initial dose¡A patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements¡A 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration. Chronic spontaneous urticaria(CSU): Usual dose: 150 or 300 mg every 4 weeks. Dosing for this indication is not dependent on serum IgE (free or total) level or body weight.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,SC;,¨Ï¥Î©Òªþµ}ÄÀ·»²G,,,,1.¥»ÃÄ¶È¨Ñ³æ¦¸¨Ï¥Îªº¤p²~¡A°t»s«áÃÄ«~©ó2¢J¦Ü8¢J¥i©ñ¸m8 ¤p®É¡A©ó30¢J¤U¬°4 ¤p®É¡C 2.¥H°t³Æ¦³¤j¤º®|18 ¸¹°wÀY¡A¦Û¦wÞÀ¤¤©â1.4 ²@¤Éª`®g¥Î¤ô¡A¨Ãª`¤Jomalizumab ¤p²~¤¤¡C 3. ±N¤p²~«O«ùª½¥ß¡A¤£°±¦a±ÛÂàª½¥ß¤p²~¡]¤£¥i¤W¤U·n°Ê¡^¡A­á´¹°®¯»§¹¥þ·»¸Ñ¥i¯àªá¶O¶W¹L20 ¤ÀÄÁ¡C°t»s«áÃÄ«~¬°¼á²M©Î¨Ç³\¤£³z©ú·P¡C­Y¦³²§ª«§Y¤£¥i¨Ï¥Î¡C 4. ¥H 25 ¸¹°wÀY¶i¦æ¥Ö¤Uª`®g¡C±Æ°£®ðÅé¡B¤j®ðªw¤Î¦h¾lªº·»²G¡A¦¹ª`®g¤p²~§t1.2 ²@¤É¡]150 ²@§J¡^ªº³ß·ç¼Ö¡C¦]·»²G¸ûÖß¸Y¡Aª`®g»Ý5-10 ¬í¡C 5. ©ó¤âÁu©Î¤j»Lªº¤T¨¤¦Ù°Ï°ì¶i¦æ¥Ö¤Uª`®g¡AÁ×¶}ëC³Â¯l¯f¨_³B¡C
ODAK,Daclatasvir,Daklinza 60mg,QANB,Chronic hepatitis C: Treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection in combination with sofosbuvir¡A with or without ribavirin,Concurrent use of strong CYP3A inducers (eg¡A carbamazepine¡A phenytoin¡A rifampin¡A St John's wort). When used in combination with other agents (eg¡A ribavirin)¡A the contraindications to those agents also apply (refer to respective labeling information).,>10%: Central nervous system: Fatigue (14% to 15%)¡A headache (12% to 14%) Gastrointestinal: Nausea (8% to 15%) Hematologic & Oncologic: Anemia (20%) 1~10% Central nervous system: Drowsiness (5%)¡A insomnia (3%) Dermatologic: Skin rash (8%) Gastrointestinal: Diarrhea (3% to 5%)¡A increased serum lipase (>3x ULN¡A transient),30¢J¥H¤U,Not indicated as monotherapy. The American Association for the Study of Liver Diseases/Infectious Diseases Society of America guidelines for testing¡A managing¡A and treating hepatitis C no longer include daclatasvir as a component of recommended treatment regimens for hepatitis C virus infection (AASLD/IDSA 2020). (¥é³æ) 60 mg orally once daily with or without food in combination with other agents for chronic hepatitis C.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,No (limited) human data ¡V animal data suggest low risk,,No (Limited) Human Data ¡V Potential Toxicity(Mother) µL(«Ü¤Ö)¸ê®Æ ¡V Á×§K¨Ï¥Î(¥ÀÅé),¥H¤WÃh¥¥¤Î­÷¨Å¤À¯Å°Ñ¦Ò¸ê®Æ¨Ó·½¬°ÃÄ«~¥é³æ,AC;AC15;PC;PO;WM;,,,,,
OSEF,Ceftibuten,Seftem 100mg,QANB,,¾AÀ³¯g:Treatment of acute bacterial exacerbations of chronic bronchitis and acute bacterial otitis media. °Æ§@¥Î: Central nervous system: Headache (<3%)¡A dizziness (<1%) Gastrointestinal: Nausea (<4%)¡A diarrhea (3% to 4%)¡A dyspepsia (<2%)¡A loose stools (<2%)¡A abdominal pain (1% to 2%)¡A vomiting (1% to 2%) Hematologic & oncologic: Eosinophilia (3%)¡A decreased hemoglobin (1% to 2%)¡A change in platelet count (increase: <1%) Hepatic: Increased serum ALT (<1%)¡A increased serum bilirubin (<1%) Renal: Increased blood urea nitrogen (2% to 4%) <1%¡A postmarketing¡A and/or case reports: Agitation¡A anorexia¡A aphasia¡A candidiasis¡A constipation¡A dehydration¡A diaper rash¡A drowsiness¡A dysgeusia¡A dyspnea¡A dysuria¡A eructation¡A fatigue¡A fever¡A flatulence¡A hematuria¡A hyperkinesia¡A increased serum alkaline phosphatase¡A increased serum AST¡A increased serum creatinine¡A insomnia¡A irritability¡A jaundice¡A leukopenia¡A melena¡A nasal congestion¡A paresthesia¡A pruritus¡A pseudomembranous colitis¡A psychosis¡A rigors¡A serum sickness¡A skin rash¡A Stevens-Johnson syndrome¡A stridor¡A thrombocytopenia¡A toxic epidermal necrolysis¡A urticaria¡A vaginitis¡A xerostomia ¸T§Ò:Hypersensitivity to ceftibuten¡A other cephalosporins¡A or any component of the formulation.,,,Adult:200 mg twice daily Gonorrhea urethritis:100 mg 3 times daily Acute bacterial otitis media:Infants and Children 6 months to <12 years: Oral: 9 mg/kg/dose once daily (maximum dose: 400 mg/day) for 10 days; Children >=12 years and Adolescents: Oral: Refer to adult dosing.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¥i¯à¦w¥þ,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,,,,,,
ORIZ,Rizatriptan,Rizatan 5mg,CNEU,Acute treatment of migraine with or without aura,Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal's angina); history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; basilar or hemiplegic migraine; during or within 2 weeks of MAO inhibitors; during or within 24 hours of treatment with another 5-HT1 agonist¡A or an ergot-containing or ergot-type medication (eg¡A methysergide¡A dihydroergotamine),Cardiovascular: Chest pain (<3%)¡A flushing (>1%)¡A palpitations (>1%)¡A flushing Central nervous system: Dizziness (4% to 9%)¡A drowsiness (4% to 8%)¡A fatigue (adults: 4% to 7%; children: >1%)¡A paresthesia (3% to 4%)¡A pain (3%)¡A feeling of heaviness (<2%)¡A headache (<2%)¡A euphoria (>1%)¡A hypoesthesia (>1%) Gastrointestinal: Nausea (4% to 6%)¡A xerostomia (3%)¡A sore throat (<2%)¡A abdominal distress (children: >1%)¡A diarrhea (>1%)¡A vomiting (>1%) Neuromuscular & skeletal: Weakness (4% to 7%)¡A jaw pain (<2%)¡A jaw pressure (<2%)¡A jaw tightness (<2%)¡A neck pain (<2%)¡A neck pressure (<2%)¡A neck tightness (<2%)¡A tremor (>1%) Respiratory: Pharyngeal edema (<2%)¡A pressure on pharynx (<2%)¡A dyspnea (>1%),30¢J¥H¤U,Migraine¡A acute: Adult: 5-10 mg¡A repeat after 2 hours if significant relief is not attained; maximum: 30 mg/24 hours. Children 6-17 years old: < 40 kg¡A 5 mg; > 40 kg¡A 10 mg. Maximum: 1 dose/24 hour. Children with concomitant propranolol use: > 40 kg¡A 5 mg in a 24-hour period; < 40 kg¡A rizatriptan is not recommended.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,No (limited) human data ¡V animal data suggest moderate risk,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,,AC;AC15;PC;PO;WM;,,,,,
LPIR,Piracetam,Piracetam soln 200mg/mL¡A 200mL,CNEU,Treatment of cerebrovascular insufficiency & age-related cognitive impairment; adjunct in the treatment of myoclonus of cortical origin.,Severe renal impairment. Cerebral haemorrhage. Pregnancy and lactation.,Hyperkinesia¡A nervousness¡A depression¡A diarrhoea¡A rashes. CNS stimulation¡A sleep disturbances¡A dizziness¡A excitement¡A insomnia¡A somnolence¡A wt gain.,«Ç·Å,Oral Cognitive enhancer in cerebrocortical insufficiency Adult: 1.2~2.4 g daily. Up to 4.8 g daily may be used in severe cases. Adjunct in cortical myoclonus [Handbook of Pediatric Drug Therapy and Immunization. 3rd Edition(2020)] Children:40mg/kg/day divided Q8H Adult: 7.2 g daily in 2-3 divided doses¡A increased by 4.8 g/day every 3-4 days. Maximum dose: 24 g daily.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,AC;AC15;PC;PO;WM;,,,,,
OESM,Ulipristal,Esmya 5mg,HM,,¾AÀ³¯g:Pre-op or intermittent treatment of moderate to severe uterine fibroids in women of reproductive age. °Æ§@¥Î: >10%: Central nervous system: Headache (1% to 16%) Endocrine & metabolic: Hot flash (1% to 25%) 1% to 10%: Cardiovascular: Edema (<=1%)¡A hypotension (<=1%)¡A sinus bradycardia (<=1%) Central nervous system: Fatigue (<=4%)¡A vertigo (<=4%)¡A insomnia (<=2%)¡A dizziness (1%)¡A aggressive behavior (<=1%)¡A drowsiness (<=1%)¡A emotional lability (<=1%)¡A migraine (<=1%)¡A sleep disorder (<=1%) Dermatologic: Night sweats (<=2%)¡A acne vulgaris (<=1%)¡A alopecia (<=1%)¡A seborrhea (<=1%)¡A xeroderma (<=1%) Endocrine & metabolic: Hypercholesterolemia (3%)¡A hypertriglyceridemia (<=3%)¡A hypothyroidism (<=2%)¡A obesity (1%)¡A amenorrhea (<=1%)¡A increased gamma-glutamyl transferase (<=1%)¡A ovarian cyst (<=1%)¡A ovarian hyperstimulation (<=1%)¡A thyroid disease (<=1%) Gastrointestinal: Nausea (3%)¡A constipation (1%)¡A dyspepsia (<=1%)¡A upper abdominal pain (<=1%) Genitourinary: Mastalgia (2%)¡A pelvic pain (1% to 2%)¡A endometrial hyperplasia (<=2%)¡A genital bleeding (<=2%)¡A breast swelling (<=1%)¡A breast tenderness (<=1%)¡A genital discharge (<=1%)¡A uterine disease (<=1%)¡A uterine hemorrhage (<=1%)¡A vaginal dryness (<=1%)¡A vulvovaginal candidiasis (<=1%) Infection: Herpes virus infection (<=1%) Neuromuscular & skeletal: Arthralgia (2%)¡A muscle spasm (<=2%)¡A back pain (<=1%)¡A limb pain (<=1%) Respiratory: Dyspnea (<=1%)¡A epistaxis (<=1%)¡A pharyngitis (<=1%) Miscellaneous: Fever (<=1%) ¸T§Ò:Hypersensitivity to ulipristal or any component of the formulation; pregnancy; breast-feeding; genital bleeding of unknown etiology or for reasons other than uterine fibroids; cancer of the breast¡A cervix¡A uterus¡A or ovaries; continuous use longer than 3 months,,«Ç·Å,Adult 1 tab once daily for up to 3 mth. Start during the 1st wk of menstruation. If required¡A 3-mth treatment course can be repeated once. Start treatment at the earliest during 2nd menstruation after completing the initial course,,No dosage adjustment necessary in mild or moderate impairment; has not been studied in severe impairment (monitor closely if initiating therapy).,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,,Contraindicated ­÷¨Å´Á¨Ï¥Î¸T§Ò,,,,,,,
OUFR,Levetiracetam,UFree ER 500mg,CNEU,,¾AÀ³¯g:Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 12 years with epilepsy. °Æ§@¥Î: Most common: Somnolence¡A asthenia. Others: dizziness¡A convulsion¡A headache¡A hyperkinesia. ataxia¡A tremor¡A amnesia¡A agitation¡A aggression¡A anger¡A anxiety¡A confusion¡A depression¡A emotional instability¡A hallucination¡A hostility¡A insomnia¡A irritability¡A or nervousness¡A mental disorder¡A personality disorders¡A thinking abnormal¡A suicide¡A suicide attempt & suicidal ideation¡A GI disturbances¡A anorexia¡A vertigo¡A accidental injury¡A infection¡A cough increased¡A rash¡A alopecia¡A diplopia¡A decreased number of RBC¡A WBC &/or blood platelets. Gastrointestinal: Loss of appetite (partial onset seizures¡A adults¡A 3% ; pediatrics¡A 13% )¡A Vomiting (partial onset seizures¡A pediatrics¡A 15% ) Immunologic: Infectious disease (partial onset seizures¡A adults¡A 13% ) Neurologic: Asthenia (partial onset seizures¡A adults¡A 14.7% ; pediatrics¡A 8.9% )¡A Dizziness (5% to 9% )¡A Headache (partial onset seizures¡A adults¡A 14% )¡A Somnolence (8% to 45% ) Psychiatric: Abnormal behavior¡A Depression (3% to 5% )¡A Feeling nervous (partial onset seizures¡A adults¡A 4% ; pediatrics¡A 10% )¡A Hostile behavior (partial onset seizures¡A adults¡A 2% ; pediatrics¡A 12% )¡A Mood disorder¡A Mood swings (2% to 6% ) Respiratory: Cough (partial onset seizures¡A adults¡A 2% ; pediatrics¡A 11% )¡A Nasopharyngitis (7% to 14% )¡A Pharyngitis (6% to 10% )¡A Rhinitis (partial onset seizures¡A adults¡A 4% ; pediatrics¡A 13% ) Other: Fatigue (primary generalized tonic-clonic seizures¡A 10% )¡A Pain (partial onset seizures¡A adults¡A 7% ; pediatrics¡A 6% ) ¸T§Ò: Patients with hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients of Keppra.,,«Ç·Å,Monotherapy for partial seizures with or without secondary generalisation Adult: Recommended starting dose is 250 mg bid¡A increased to an initial therapeutic dose of 500 mg bid after 2 wk. May further increase by 250 mg bid every 2 wk depending upon response. Max: 1¡A500 mg bid.,µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,1) Micromedex Lactation Rating: Infant risk cannot be ruled out. a) Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. 2) Clinical Management a) Levetiracetam is detected in breastmilk¡A with a mean milk/maternal plasma ratio of approximately 1; adverse effects in the nursing infants were not reported. Based on limited data¡A maternal use of levetiracetam appears to be safe for the nursing infant. However¡A the manufacturer cautions that due to the potential for adverse reactions in nursing infants¡A either nursing or the drug should be discontinued.,,,,,,
ILEV1,Norepinephrine,Levophed Bitartrate inj 4mg/4mL,CAVS,,¾AÀ³¯g: Restoration of BP in acute hypotensive states. Adjunct in the treatment of cardiac arrest & profound hypotension. °Æ§@¥Î: Occasionally¡A bradycardia; anxiety¡A transient headache. Plasma vol depletion (prolonged administration). Respiratory difficulty¡A ischemic injury. ¸T§Ò: Patients who are hypotensive from blood vol deficits except as emergency measure until blood vol therapy can be completed. Cyclopropane & halothane anesth¡A mesenteric or peripheral vascular thrombosis.,,«Ç·Å,4 mL amp to 1000 mL of 5% dextrose soln. IV infusion¡A Adult: 8-12 mcg/min initially¡A adjusting rate to maintenance a systolic blood pressure = 80-100 mmHg¡A average maintenance dose: 2-4 mcg/min. Child: 2 mcg/m2/min (max. 6 mcg/m2/min).,,,,°£«DªvÀø¤W»Ý­n,,,No (Limited) Human Data - Potential Toxicity µL(«Ü¤Ö)¸ê®Æ - Á×§K¨Ï¥Î,,,,,,,1.¤£«ØÄ³¥ÎNS
OFZP,Flunitrazepam,Fluzepam 2mg,CNEU,,¾AÀ³¯g: Insomnia. °Æ§@¥Î: Drowsiness & lightheadedness the next day; confusion & ataxia; dependence. ¸T§Ò: Preexisting CNS depression or coma¡A resp depression¡A acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis¡A phobic or obsessional states; may precipitate suicide or aggressive behavior; not to be used alone to treat depression or anxiety associated with depression; glaucoma. Pregnancy¡A lactation. Neonates.,,«Ç·Å,Adult 0.5-1 mg at bedtime. Max: 2 mg/day. Elderly or debilitated patients Initially 0.5 mg at bedtime. Max: 1 mg/day.,,,,ºÉ¶qÁ×§K,,,Human Data Suggest Potential Toxicity,,,,,,,
EFUC2,Fusidic Acid,Fucidin cream 2%¡A 15gm,TDER,Skin infections caused by Staph¡A Strep & other organisms sensitive to fusidic acid.,Hypersensitivity to fusidic acid or any component of the formulation.,Angioedema¡A application site irritation¡A application site pain¡A conjunctivitis¡A dermatitis¡A erythema¡A hypersensitivity reaction¡A pruritus¡A skin blister¡A skin irritation¡A skin rash¡A urticaria.,30¢J¥H¤U,Apply BID-TID,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,,Unknown ¨S¦³¸ê®Æ,,EXT;,,,,,
IPNE,Pneumococcal Vaccine Polyvalent,Pneumovax 23 (¦Û¶O) 0.5mL/dose 23»ùªÍª¢¬Ì­],HIMM,Immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine,Hypersensitivity. Revaccination of adults with Pneumovax 23 is contraindicated except for those at highest risk of pneumococcal infections. Patients with Hodgkin's disease immunised < 7 to 10 days prior to or during immunosuppressive therapy & patients with Hodgkin's disease who have received extensive chemotherapy &/or nodal irradiation.,Local inj-site soreness¡A warmth¡A erythema & swelling. Fever¡A headache¡A malaise¡A rash¡A urticaria¡A arthritis¡A arthralgia.,2-8¢J,IM or SC¡A 0.5mL¡A > or = 2 years a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,[³X³æ]¥Ø«e¤£ª¾Ãh¥¥°ü¤k±µºØ«á¬O§_·|³y¦¨­L¨àªº¶Ë®`©Î¼vÅT¨ä¥Í¨|¤O¡A ¥u¦³¦b©ú½Tª¾¹D¥²¬I¥´ªº±¡ªp¤U¡A¥¥°ü¤~¯à¬I¥´¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¤£ª¾¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¦]¦¹±µºØ¤§±Â¨Å°ü¤k»Ýª`·N¡C,IM;,,,,,
IPNE0,Pneumococcal Vaccine Polyvalent,Pneumovax 23 (23»ùªÍª¢¡A¬F©²´£¨Ñ) 0.5mL/dose,HIMM,Immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine,Hypersensitivity. Revaccination of adults with Pneumovax 23 is contraindicated except for those at highest risk of pneumococcal infections. Patients with Hodgkin's disease immunised < 7 to 10 days prior to or during immunosuppressive therapy & patients with Hodgkin's disease who have received extensive chemotherapy &/or nodal irradiation.,Local inj-site soreness¡A warmth¡A erythema & swelling. Fever¡A headache¡A malaise¡A rash¡A urticaria¡A arthritis¡A arthralgia.,2-8¢J,IM or SC¡A 0.5mL¡A > or = 2 years a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Compatible,[³X³æ]¥Ø«e¤£ª¾Ãh¥¥°ü¤k±µºØ«á¬O§_·|³y¦¨­L¨àªº¶Ë®`©Î¼vÅT¨ä¥Í¨|¤O¡A ¥u¦³¦b©ú½Tª¾¹D¥²¬I¥´ªº±¡ªp¤U¡A¥¥°ü¤~¯à¬I¥´¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[³X³æ]¥Ø«e©|¤£ª¾¬O§_·|¤Àªc¦Ü¤HÃþ¨Å¥Ä¡A¦]¦¹±µºØ¤§±Â¨Å°ü¤k»Ýª`·N¡C,IM;,,,,,
IPR13,Pneumococcal Vaccine Polyvalent,Prevenar 0.5mL/dose (13»ùªÍª¢¬Ì­]),HIMM,Active immunisation of infants & toddlers against invasive disease caused by Strep pneumoniae serotypes (4¡A 6B¡A 9V¡A 14¡A 18C¡A 19F & 23F) at 2¡A 4¡A 6 & 12-15 months of age. Active immunisation of infants & toddlers < 2 years against otitis media caused by Strep pneumoniae serotypes (1¡A 2¡A 3¡A 4¡A 5¡A 6A¡A 7F¡A 9V¡A 14¡A 18C¡A 19A¡A 19F & 23F).,Hypersensitivity to any component of the formulation.,Decreased appetite¡A vomiting¡A diarrhoea¡A injection site reactions (e.g. erythema¡A induration/swelling¡A pain/tenderness)¡A tenderness interfering with movement¡A fever¡A irritability¡A drowsiness¡A restless sleep.,2-8¢JÁ×§K§N­á,IM¡A 0.5mL¡A children 2-6 months 3 doses primary immunization at intervals of 1 month (the 1st dose can be given at 6 weeks of age)¡A a booster dose at 12-15 months. 7-11 months 2 doses primary immunization at an interval of 1 month ¡A a booster dose at 12 months. 12-23 months 2 doses at intervals of 2 months. > or = 2 years a single dose.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer¡¦s labeling.,µL»Ý½Õ¾ã¾¯¶q,°£«DªvÀø¤W»Ý­n,Compatible,VACCINE¡A PNEUMOCOCCAL POLYVALENT: Compatible [¥é³æ]¥Ø«e¨ÃµL¥ô¦ó¹ï¥¥°ü±µºØªº¸ê®Æ¥i°Ñ¦Ò¡A¦]¦¹Ãh¥¥´Á¶¡À³Á×§K±µºØ¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,VACCINE¡A PNEUMOCOCCAL POLYVALENT: No Human Data¡XProbably Compatible [¥é³æ]¥Ø«e¨Ã¤£½Tª¾¬O§_·|¤Àªc¶i¤J¤HÃþ¨Å¥Ä¡C,IM;,,,,,1. À³¥H¦Ù¦×ª`®g¤è¦¡§ë¤©¡A³Ì¦nª`®g¦bÀ¦¨à¤j»L«e¥~°¼ªºªÑ¥~°¼¦Ù¡A©Î¬O¥®µ£¤WÁuªº¤T¨¤¦Ù¡C
IVAR,Varicella Virus Vaccine,Varivax 0.5mL/dose(¦Û¶O¤ôµk¬Ì­]),HIMM,Active immunisation against varicella of healthy infants from 12 months onwards¡A susceptible high-risk patients & their susceptible healthy close contacts.,Pregnancy. Acute febrile illness. Total lymphocyte count < 1200/mm3. Hypersensitivity to neomycin.,Common: Injection site disorder (19.3-32.5%)¡A Rash¡A Varicella-like (0.5-5.5%)¡A Fever (9.5-66.8%) Serious: Stevens-Johnson syndrome¡A Toxic epidermal necrolysis¡A Thrombocytopenic purpura¡A Anaphylaxis¡A Herpes zoster ophthalmicus¡A Encephalitis¡A Febrile seizure (Less than 0.1%),2-8¢JÁ×¥ú,SC¡A 0.5 mL¡A 12 months-12 years 2 doses administered 3 months apart. > or = 13 years 2 doses administered 4-8 weeks apart.,µL»Ý½Õ¾ã¾¯¶q,There are no dosage adjustments provided in the manufacturer's labeling,µL»Ý½Õ¾ã¾¯¶q,¤£¥i¨Ï¥Î,Contraindicated,[¥é³æ]¥Ø«e¥¼ª¾Ãh¥¥°ü¤k±µºØ¬O§_·|¹ï­L¨à³y¦¨¼vÅT¡A¦]¦¹Ãh¥¥°ü¤k¤£À³±µºØ¡A ¥BÀ³Á×§K©ó±µºØ«á¤T­Ó¤ë¤ºÃh¥¥¡C,Compatible ­÷¨Å®É¥i¨Ï¥Î,[¥é³æ]¥Ø«e©|¤£½Tª¾¬O§_·|¤Àªc¦Ü¨Å¥Ä¡A¥Ñ©ó¤wª¾¦³¨Ç¯f¬r·|¶i¤J¤HÃþ¨Å¥Ä¡A ¦]¦¹±µºØ¤§­÷¨Å°ü¤k¶·¯S§Oª`·N¡C,SC;,¨Ï¥Î¼t°Ó©Òªþµ}ÄÀ·»²G,,,,1. Varilrix»P§t¦³³Â¯l¦¨¤Àªº¬Ì­]À³¶¡¹j¦Ü¤Ö¤@­Ó¤ë¥H¤W¡C
ICISA,Cisatracurium,Cisatracurium inj 10mg/5mL,CNEU,,¾AÀ³¯g:Muscle relaxation during surgical procedures eg cardiac surgery¡A other procedures & in intensive care. Adjunct to general anesth or sedation in the ICU¡A to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation. °Æ§@¥Î:Bradycardia¡A hypotension. Rarely cutaneous flushing¡A bronchospasm¡A rash. ¸T§Ò:Hypersensitivity to cisatracurium besylate or any component of the formulation; use of the 10 mL multiple-dose vials in premature infants (formulation contains benzyl alcohol),,2-8¢XC,IV bolus Tracheal intubation Adult Initially 0.15 mg/kg over 5-10 sec. Maintenance: 0.03 mg/kg.(about 20 mins effic Childn 1 mth-12 yr Same as adult dose. Maintenance: 0.02 mg/kg. IV infusion Adult & childn 1 mth-12 yr Maintenance of neuromuscular block 3 mcg/kg/min to restore 89-99% T1 suppression then 1-2 mcg/kg/min to maintain block in this range.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,,[¥é³æ] ¥Í¨|¤O: ©|¥¼¶i¦æ¥Í¨|¤O¬ã¨s¡C Ãh¥¥: ¥u¦³¦bÃÄª«¹ï¥À¿Ë²£¥Íªº¹w´Á§Q¯q¤j©ó¹ï­L¨à³y¦¨ªº¼ç¦b¦MÀI®É¡A¥»²£«~¤~¥i¨Ï¥Î©óÃh¥¥´Á¶¡¡C ·î§Î: °Êª«¬ã¨s«ü¥X¡Acisatracurium ¹ï©ó­L¨àªºµo¨|¨S¦³¤£¨}¼vÅT¡C,Unknown ¨S¦³¸ê®Æ,[¥é³æ] ±Â¨Å: ¥Ø«e©|¥¼±oª¾ cisatracurium ©Î¨ä¥NÁÂª«¬O§_·|¤Àªc©ó¤HÃþ¨Å¥Ä¤¤¡C,IVD;IVP;IVPUSH;,,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,IVP¿éª`®É¶¡»Ý5-10sec (®ðºÞ¤º´¡ºÞ),IVDµ¹ÃÄ³t²v¬°0.03-0.6 mg/kg/hr (µ¹ÃÄ¿@«× 0.1-2 mg/mL) Maintenance infusion in ICU¡A 3 mcg/kg/min IV infusion (range of 0.5 to 10.2 mcg/kg/min due to interpatient variability).,1.¶È¨ÑÀR¯ßµ¹ÃÄ¡C 2.µ¹ÃÄ¿@«× 0.1-2 mg/mL¡C 3.¥»«~»Ý§NÂÃÁ×¥ú¶J¦s 4.¤£¥i»PÆP©Ê·»²G²V¦X 5.­­¨Ï¥Î¤H¤u©I§l¾¹ªvÀø¯f±w¨Ï¥Î
INF333,³t§J¥ñ 3HPµuµ{ªvÀø³B¤è,¼ç¥ñµ²®Ö·P¬V¤§ªvÀø (Treatment of LTBI),QANB,,,,,,,,,,,,,,,,,,,
IREB,Interferon beta-1a,Rebif inj 44mcg,HIMM,Multiple sclerosis.,Pregnancy¡A People currently with severe depression and / or suicidal tendency¡A Hypersensitivity to natural or recombinant interferon beta or any other component of the formulation.,>10%: Headache (58% to 70%)¡A fatigue (33% to 41%)¡A depression (18% to 25%)¡A pain (23%)¡A chills (19%)¡A dizziness (14%)¡A Nausea (23%)¡A abdominal pain (8% to 22%)¡A Urinary tract infection (17%)¡A Leukopenia (28% to 36%)¡A lymphadenopathy (11% to 12%)¡A Increased serum ALT (20% to 27%)¡A increased serum AST (10% to 17%)¡A Antibody development (neutralizing; significance not known; Rebif: 24% to 31%; Avonex: 5%)¡A Injection site reaction (3% to 92%)¡A Myalgia (25% to 29%)¡A back pain (23% to 25%)¡A weakness (24%)¡A skeletal pain (10% to 15%)¡A rigors (6% to 13%)¡A Visual disturbance (7% to 13%)¡A Flu-like symptoms (49% to 59%)¡A sinusitis (14%)¡A upper respiratory tract infection (14%)¡A Fever (20% to 28%) 1% to 10%: Chest pain (5% to 8%)¡A vasodilation (2%)¡A Hypertonia (6% to 7%)¡A migraine (5%)¡A ataxia (4% to 5%)¡A drowsiness (4% to 5%)¡A malaise (4% to 5%)¡A seizure (1% to 5%)¡A suicidal tendencies (4%) Dermatologic: Erythematous rash (5% to 7%)¡A maculopapular rash (4% to 5%)¡A alopecia (4%)¡A hyperhidrosis (4%)¡A urticaria¡A Thyroid disease (4% to 6%)¡A Xerostomia (1% to 5%)¡A toothache (3%)¡A Urinary frequency (2% to 7%)¡A urinary incontinence (2% to 4%)¡A urine abnormality (3%)¡A Thrombocytopenia (2% to 8%)¡A anemia (3% to 5%)¡A Hyperbilirubinemia (2% to 3%)¡A Infection (7%)¡A Pain at injection site (8%)¡A bruising at injection site (6%)¡A inflammation at injection site (6%)¡A tissue necrosis at injection site (1% to 3%)¡A Arthralgia (9%)¡A Eye disease (4%)¡A xerophthalmia (1% to 3%)¡A Bronchitis (8%),2-8¢JÁ×¥úÁ×§K§N­á,SC¡A initial: 8.8 mcg 3 times weekly on week 1-2.Titration: 22 mcg 3 times weekly on week 3-4.Target dose: 44 mcg 3 times weekly after week 5. target dose may be decreased to 22 mcg if necessary.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,No (limited) human data ¡V animal data suggest moderate risk,[¥é³æ]¼Æ¾Ú«ü¥X¡A©ó¨ü¥¥«e©Î§³®W²Ä¤@´Á®É¼ÉÅS©ó interferon beta¡A ¨äµo¥Í­«¤j¥ý¤Ñ©Ê²§±`ªº­·ÀI¨Ã¥¼¼W¥[¡C¦¬¶°¼Æ¾Ú®É interferon beta ©|ÄÝÃh¥¥´Á¶¡¤§¨Ï¥Î¸T§Ò¡A¦bÀË´ú¥X/©Î½T»{Ãh¥¥«á¥i¯à·|¤¤Â_ªvÀø¡A¦]¦¹µLªk½T©w¦b§³®W²Ä¤@´Áªº¼ÉÅS®É¶¡¡A¦Ó¼ÉÅS©ó§³®W²Ä¤G´Á¤Î²Ä¤T´Áªº¸gÅç«D±`¦³­­¡C ¨Ì¾Ú°Êª«¸ÕÅç¼Æ¾Ú¡A¦Ûµo©Ê¬y²£ªº­·ÀI¥i¯à·|¼W¥[¡C µM¦Ó¨Ì¾Ú¥Ø«e¥iÀò±oªº¼Æ¾Ú¡A©|µLªk¥R¤Àµû¦ô¼ÉÅS©óinterferon beta ªº¥¥°ü¨ä¦Ûµo©Ê¬y²£ªº­·ÀI¡A¦ý¥Ø«e¸Ó¼Æ¾Ú¨Ã¥¼Åã¥Ü¦³¼W¥[ªº­·ÀI¡C ¦p¦³Á{§É»Ý­n¡A¥i¥H¦bÃh¥¥´Á¶¡¦Ò¼{¨Ï¥Î Rebif¡C,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,[¥é³æ] Ãö©ó interferon beta-1a ¬O§_·|¤À§G¨ì¥À¨Å¤¤¡A¥Ø«e¥iÀò±oªº¸ê°T¦³­­¡C ­Y¤@¨Ö¦Ò¶qinterferon beta ªº¤Æ¾Ç/¥Í²z¾Ç¯S©Ê¡A«h¨Å¥Ä¤¤¤Àªcªº interferon beta-1a ¿@«×À³«Ü§C¡C ­÷¨Åªº®Ä¯q¤Î¥i¯à­·ÀIÀ³»P¯f¤H¹ï©ó interferon beta-1a ªvÀøªºÁ{§É»Ý¨D¤@¨Ö¦Ò¶q¡C,SC;,,,,,³æ¦¸¨Ï¥Î¡C¥u¦³¼á²M¦Ü¨Å¥Õ¦â·»²G¡BµLÁû²É¡BµL¥i¨£ÅÜ½è¸ñ¶Hªºª`®g²G¤~¥i¨Ï¥Î¡C
IFMR,Flomoxef,Flumarin inj 1gm,QANB,Flomoxef sodium susceptible strains of Staphylococcus sp.¡A Streptococcus sp.¡A Pneumococcus sp.¡A Neisseria gonorrhoeae¡A Moraxella (Branhamella) catarrhalis¡A Escherichia coli¡A Klebsiella sp.¡A Proteus sp.¡A Morganella morganii¡A Providencia sp.¡A Haemophilus influenzae¡A Peptostreptococcus sp.¡A Bacteroides sp.¡A Prevotella sp. (excluding Prevotella bivia),Patients with a history of shock following exposure to any of the ingredients in this product. RELATIVE CONTRAINDICATIONS: Patients with a history of hypersensitivity to any of the ingredients in this product or to other cephalosporin antibiotics Careful Administration: Patients with a history of hypersensitivity to penicillins. Patients with a personal or familial predisposition to allergic reactions such as bronchial asthma¡A rash and urticaria. Patients with severe renal dysfunction. Patients of poor oral ingestion¡A patients receiving parenteral feeding¡A or patients in poor general condition. Elderly patients.,Rash¡A Anemia (decreased RBC¡A decreased hemoglobin¡A decreased hematocrit)¡A eosinophilia¡A granulocytopenia¡A Increased SGOT(AST)¡A increased SGPT (ALT)¡A increased Al-P¡A increased gamma-GTP¡A Diarrhea.,25¢J¥H¤U,Adult: 1-4 g/day IV Q6H-Q12H in divided doses. Children: 60-150 mg/kg/day IV Q6H-Q8H in divided doses. Neonates and preterm infants: 20 mg/kg IV Q8H-Q12H within 3 days of birth¡A then Q6H-Q8H from the 4th day after birth (maximum dose: 150 mg/kg/day Q6H-Q8H),µL»Ý½Õ¾ã¾¯¶q,,»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Uknown ¨S¦³¸ê®Æ,[¥é³æ]Ãö©óÃh¥¥´Á§ë¤©ªº¦w¥þ©Ê©|¥¼½T¥ß¡A ¥¥°ü©Î¦³¥i¯àÃh¥¥ªº°ü¤H¡A¦bªvÀø¤W§PÂ_¨ä¦³¯q©Ê°ª©ó¦MÀI©Ê®É¤~¯à§ë»P,Unknown ¨S¦³¸ê®Æ,[¥é³æ]Ãö©óÃh¥¥´Á§ë¤©ªº¦w¥þ©Ê©|¥¼½T¥ß¡A ¥¥°ü©Î¦³¥i¯àÃh¥¥ªº°ü¤H¡A¦bªvÀø¤W§PÂ_¨ä¦³¯q©Ê°ª©ó¦MÀI©Ê®É¤~¯à§ë»P,IVD;IVPUSH;,1gªºvial¥]¸Ë¡A¥H4mL¥H¤Wªºª`®g¥Î¤ô¡A5%¸²µå¿}ª`®g²G¡A©Î¥Í²z­¹ÆQ¤ô¥[¤J«á·»¸Ñ.,¡iD5W¡j¥i¿ï ¡C¡iN/S¡j¥i¿ï ¡C,½wºCª`®g3¤ÀÄÁ,¥é³æµL«ØÄ³ºwª`®É¶¡¡A¦ý°Ê¤O¾Ç¸ê®Æ¬O±NÃÄª«¥H1¤p®ÉÂIºw¿éª`.,1. ½Õ°t«á«Ç·Å¥i«O¦s6¤p®É¡A§NÂÃ¥i«O¦s24¤p®É¡C 2. ¥é³æµLµ}ÄÀ«á¦w©w©Ê¸ê®Æ¡C2021/1/24¼t°Ó´£¨Ñ¦w©w©Ê¸ê®Æ¡A1gµ}ÄÀ©ó5%¸²µå¿}ª`®g²G©Î¥Í²z­¹ÆQ¤ô100mL©Î500mL¦bÄá¤ó25«×¥H¤U¥i¦³6¤p®É¦w©w¡A§NÂÃ¥i¦³24¤p®É¦w©w¡C 3. Á{§É¸ÕÅç¤¤ÀR¯ßª`®gflomoxef 1gµ¹ÃÄ®É¶¡¬°3¤ÀÄÁ¤º¡A½wºCª`®g¥i¯àÁ×§Kµ¹ÃÄ¤£¾A¡C
ECASI,Betamethasone + Lidocaine + Phenylephrine,Calmsit cream 15gm,ALIM,External hemorrhoids¡A hemorrhoid bleeding¡A hemorrhoid pain¡A anal fissure¡A perianal inflammation¡A anal itching¡A anal eczema¡A anal ulcer,Avoid contact with eyes or oral consumption.,Common Dermatologic: Burning sensation¡A Itching¡A Stinging of skin Serious Endocrine metabolic: Cushing's syndrome¡A Hyperglycemia¡A Hypothalamic-pituitary-adrenal axis dysfunction¡A Suppression. Immunologic: Anaphylaxis Dermatologic: Necrosis,25¢J¥H¤UÀx¦s,2-3 times daily. Calmsit 1 gm: Betamethasone 0.42mg + Lidocaine 25mg + Phenylephrine 1mg.,µL»Ý½Õ¾ã¾¯¶q,,µL»Ý½Õ¾ã¾¯¶q,¨S¦³¸ê®Æ,Human (and animal) data suggest risk,Phenylephrine (Sympathomimetic): Human Data Suggest Risk. Betamethasone: Compatible Lidocaine (Local Anesthetic/Cardiac): Compatible,No (Limited) Human Data - Probably Compatible µL(«Ü¤Ö)¸ê®Æ - ¥i¨Ï¥Î,Phenylephrine (Sympathomimetic): No Human Data - Probably Compatible. Betamethasone: No Human Data¡XProbably Compatible Lidocaine (Local Anesthetic/Cardiac): Limited Human Data¡XProbably Compatible,EXT;RECT;,,,,,
